PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Aamann, MD; Sorensen, MM; Hvitby, C; Berquist, BR; Muftuoglu, M; Tian, JY; de Souza-Pinto, NC; Scheibye-Knudsen, M; Wilson, DM; Stevnsner, T; Bohr, VA				Aamann, Maria D.; Sorensen, Martin M.; Hvitby, Christina; Berquist, Brian R.; Muftuoglu, Meltem; Tian, Jingyan; de Souza-Pinto, Nadja C.; Scheibye-Knudsen, Morten; Wilson, David M., III; Stevnsner, Tinna; Bohr, Vilhelm A.			Cockayne syndrome group B protein promotes mitochondrial DNA stability by supporting the DNA repair association with the mitochondrial membrane	FASEB JOURNAL			English	Article						base excision repair; BER; CSB; oxidative stress	BASE EXCISION-REPAIR; CELLULAR REPAIR; HELICASE DOMAIN; ATPASE DOMAIN; GENE-PRODUCT; DAMAGE; CSB; 8-OXOGUANINE; DEFICIENT; FORMAMIDOPYRIMIDINES	Cockayne syndrome (CS) is a human premature aging disorder associated with severe developmental deficiencies and neurodegeneration, and phenotypically it resembles some mitochondrial DNA (mtDNA) diseases. Most patients belong to complementation group B, and the CS group B (CSB) protein plays a role in genomic maintenance and transcriptome regulation. By immunocytochemistry, mitochondrial fractionation, and Western blotting, we demonstrate that CSB localizes to mitochondria in different types of cells, with increased mitochondrial distribution following menadione-induced oxidative stress. Moreover, our results suggest that CSB plays a significant role in mitochondrial base excision repair (BER) regulation. In particular, we find reduced 8-oxo-guanine, uracil, and 5-hydroxy-uracil BER incision activities in CSB-deficient cells compared to wild-type cells. This deficiency correlates with deficient association of the BER activities with the mitochondrial inner membrane, suggesting that CSB may participate in the anchoring of the DNA repair complex. Increased mutation frequency in mtDNA of CSB-deficient cells demonstrates functional significance of the presence of CSB in the mitochondria. The results in total suggest that CSB plays a direct role in mitochondrial BER by helping recruit, stabilize, and/or retain BER proteins in repair complexes associated with the inner mitochondrial membrane, perhaps providing a novel basis for understanding the complex phenotype of this debilitating disorder.-Aamann, M. D., Sorensen, M. M., Hvitby, C., Berquist, B. R., Muftuoglu, M., Tian, J., de Souza-Pinto, N. C., Scheibye-Knudsen, M., Wilson, D. M., III, Stevnsner, T., Bohr, V. A. Cockayne syndrome group B protein promotes mitochondrial DNA stability by supporting the DNA repair association with the mitochondrial membrane. FASEB J. 24, 2334-2346 (2010). www.fasebj.org	[Aamann, Maria D.; Sorensen, Martin M.; Berquist, Brian R.; Muftuoglu, Meltem; Tian, Jingyan; de Souza-Pinto, Nadja C.; Scheibye-Knudsen, Morten; Wilson, David M., III; Bohr, Vilhelm A.] NIA, Lab Mol Gerontol, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Aamann, Maria D.; Hvitby, Christina; Stevnsner, Tinna] Aarhus Univ, Danish Ctr Mol Gerontol, Aarhus, Denmark; [Aamann, Maria D.; Hvitby, Christina; Stevnsner, Tinna] Aarhus Univ, Dept Mol Biol, Danish Aging Res Ctr, DK-8000 Aarhus, Denmark	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University; Aarhus University	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, Intramural Res Program, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Muftuoglu, Meltem/AAG-5004-2019; Bohr, Vilhelm/AAP-5931-2020; Souza-Pinto, Nadja/T-3050-2019; Souza-Pinto, Nadja C./C-3462-2013; Wilson, David M/AAK-5409-2021	Muftuoglu, Meltem/0000-0001-5372-4780; Souza-Pinto, Nadja/0000-0003-4206-964X; Souza-Pinto, Nadja C./0000-0003-4206-964X; Wilson, David M/0000-0002-8945-0395; Stevnsner, Tinna/0000-0003-1007-0427; Scheibye-Knudsen, Morten/0000-0002-6637-1280	National Institute of Health, National Institute on Aging; Danish Research Council [271-08-0697]; Velux Foundation [24715]; European Commission [LSHM-CT-2004-512020]; Danish Cancer Society [DP05118]; Lundbeck Foundation [4-55951-95094019]; NATIONAL INSTITUTE ON AGING [ZIAAG000722, ZIAAG000733, ZIAAG000723, ZIAAG000751, ZIAAG000727] Funding Source: NIH RePORTER; Lundbeck Foundation [R5-2006-128] Funding Source: researchfish	National Institute of Health, National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Danish Research Council(Det Frie Forskningsrad (DFF)); Velux Foundation(Velux Fonden); European Commission(European CommissionEuropean Commission Joint Research Centre); Danish Cancer Society(Danish Cancer Society); Lundbeck Foundation(Lundbeckfonden); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Lundbeck Foundation(Lundbeckfonden)	Alfred May and Ulla Henriksen provided excellent technical assistance. The authors thank John Vissing (Department of Neurology, Rigshospitalet, Copenhagen, Denmark) and co-workers for providing human muscle mitochondria. This research was supported by the Intramural Research Program of the National Institute of Health, National Institute on Aging, the Danish Research Council (grant 271-08-0697), the Velux Foundation (grant 24715), the European Commission (LSHM-CT-2004-512020), the Danish Cancer Society (DP05118), and the Lundbeck Foundation (4-55951-95094019). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akbari M, 2007, NEUROSCIENCE, V145, P1201, DOI 10.1016/j.neuroscience.2006.10.010; ALBRING M, 1977, P NATL ACAD SCI USA, V74, P1348, DOI 10.1073/pnas.74.4.1348; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; Balajee AS, 2000, ONCOGENE, V19, P477, DOI 10.1038/sj.onc.1203372; Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200; Bogenhagen DF, 2003, MOL CELL PROTEOMICS, V2, P1205, DOI 10.1074/mcp.M300035-MCP200; de Souza-Pinto NC, 2008, DNA REPAIR, V7, P1098, DOI 10.1016/j.dnarep.2008.03.011; de Souza-Pinto NC, 2009, DNA REPAIR, V8, P704, DOI 10.1016/j.dnarep.2009.01.021; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302; DiMauro S, 2006, CURR OPIN RHEUMATOL, V18, P636, DOI 10.1097/01.bor.0000245729.17759.f2; Flohr C, 2003, NUCLEIC ACIDS RES, V31, P5332, DOI 10.1093/nar/gkg715; Frossi B, 2002, J CELL PHYSIOL, V193, P180, DOI 10.1002/jcp.10159; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; Griffiths LM, 2009, MOL CELL BIOL, V29, P794, DOI 10.1128/MCB.01357-08; Hu JP, 2005, J BIOL CHEM, V280, P40544, DOI 10.1074/jbc.M508772200; Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004; Lehmann AR, 2003, BIOCHIMIE, V85, P1101, DOI 10.1016/j.biochi.2003.09.010; Licht CL, 2003, AM J HUM GENET, V73, P1217, DOI 10.1086/380399; Liu MQ, 2000, J BIOL CHEM, V275, P29400, DOI 10.1074/jbc.M002173200; Loupatty FJ, 2007, AM J HUM GENET, V80, P195, DOI 10.1086/510725; Maynard S, 2009, CARCINOGENESIS, V30, P2, DOI 10.1093/carcin/bgn250; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; Mitra S, 2007, DNA REPAIR, V6, P461, DOI 10.1016/j.dnarep.2006.10.010; Muftuoglu M, 2002, GENE, V283, P27, DOI 10.1016/S0378-1119(01)00870-8; Muftuoglu M, 2009, J BIOL CHEM, V284, P9270, DOI 10.1074/jbc.M807006200; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Osenbroch PO, 2009, FEBS J, V276, P2811, DOI 10.1111/j.1742-4658.2009.07004.x; Osterod M, 2002, ONCOGENE, V21, P8232, DOI 10.1038/sj.onc.1206027; Rorbach J, 2008, NUCLEIC ACIDS RES, V36, P5787, DOI 10.1093/nar/gkn576; Scheibye-Knudsen M, 2009, EUR J APPL PHYSIOL, V105, P279, DOI 10.1007/s00421-008-0901-9; Selzer RR, 2002, NUCLEIC ACIDS RES, V30, P782, DOI 10.1093/nar/30.3.782; Shimomura Y, 2004, BIOCHEM BIOPH RES CO, V313, P381, DOI 10.1016/j.bbrc.2003.07.022; Stevnsner T, 2002, ONCOGENE, V21, P8675, DOI 10.1038/sj.onc.1205994; Stuart JA, 2005, NUCLEIC ACIDS RES, V33, P3722, DOI 10.1093/nar/gki683; Sunesen M, 2002, ONCOGENE, V21, P3571, DOI 10.1038/sj.onc.1205443; Thorslund T, 2005, MOL CELL BIOL, V25, P7625, DOI 10.1128/MCB.25.17.7625-7636.2005; Thorslund T, 2002, DNA REPAIR, V1, P261, DOI 10.1016/S1568-7864(02)00003-4; Trapp C, 2007, ONCOGENE, V26, P4044, DOI 10.1038/sj.onc.1210167; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Tuo JS, 2003, FASEB J, V17, P668, DOI 10.1096/fj.02-0851com; Tuo JS, 2002, J BIOL CHEM, V277, P30832, DOI 10.1074/jbc.M204814200; Tuo JS, 2002, DNA REPAIR, V1, P913, DOI 10.1016/S1568-7864(02)00116-7; van den Boom V, 2004, J CELL BIOL, V166, P27, DOI 10.1083/jcb.200401056; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; WALLACE DC, 1975, J CELL BIOL, V67, P174, DOI 10.1083/jcb.67.1.174; Wilson DM, 2007, DNA REPAIR, V6, P544, DOI 10.1016/j.dnarep.2006.10.017; Wong HK, 2007, NUCLEIC ACIDS RES, V35, P4103, DOI 10.1093/nar/gkm404; Wong HK, 2005, BIOCHEMISTRY-US, V44, P14335, DOI 10.1021/bi051161o	49	106	109	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2334	2346		10.1096/fj.09-147991	http://dx.doi.org/10.1096/fj.09-147991			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20181933	Green Published			2022-12-28	WOS:000279343600020
J	Hegge, S; Munter, S; Steinbuchel, M; Heiss, K; Engel, U; Matuschewski, K; Frischknecht, F				Hegge, Stephan; Muenter, Sylvia; Steinbuechel, Marion; Heiss, Kirsten; Engel, Ulrike; Matuschewski, Kai; Frischknecht, Friedrich			Multistep adhesion of Plasmodium sporozoites	FASEB JOURNAL			English	Article						flow chamber; malaria; TRAP; gliding motility	TRAP-LIKE PROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; GLIDING MOTILITY; MALARIA PARASITES; CIRCUMSPOROZOITE PROTEIN; ACTIN CYTOSKELETON; STATISTICS NOTES; INVASION; CELLS; MOSQUITO	Adhesion of eukaryotic cells is a complex process during which interactions between extracellular ligands and cellular receptors on the plasma membrane modulate the organization of the cytoskeleton. Pathogens particularly rely often on adhesion to tissues or host cells in order to establish an infection. Here, we examined the adhesion of Plasmodium sporozoites, the motile form of the malaria parasite transmitted by the mosquito, to flat surfaces. Experiments using total internal reflection fluorescence microscopy and analysis of sporozoites under flow revealed a stepwise and developmentally regulated adhesion process. The sporozoite-specific transmembrane proteins TRAP and S6 were found to be important for initial adhesion. The structurally related protein TLP appears to play a specific role in adhesion under static conditions, as tlp(-) sporozoites move 4 times less efficiently than wild-type sporozoites. This likely reflects the decreased intradermal sporozoite movement of sporozoites lacking TLP. Further, these three sporozoite surface proteins also act in concert with actin filaments to organize efficient adhesion of the sporozoite prior to initiating motility and host cell invasion.-Hegge, S., Munter, S., Steinbuchel, M., Heiss, K., Engel, U., Matuschewski, K., Frischknecht, F. Multistep adhesion of Plasmodium sporozoites. FASEB J. 24, 2222-2234 (2010). www.fasebj.org	[Hegge, Stephan; Muenter, Sylvia; Steinbuechel, Marion; Heiss, Kirsten; Matuschewski, Kai; Frischknecht, Friedrich] Heidelberg Univ, Dept Parasitol, Inst Hyg, Sch Med, D-69120 Heidelberg, Germany; [Engel, Ulrike] BioQuant, Nikon Imaging Ctr, Heidelberg, Germany; [Matuschewski, Kai] Max Planck Inst Infect Biol, Dept Parasitol, Berlin, Germany	Ruprecht Karls University Heidelberg; Nikon Corporation; Ruprecht Karls University Heidelberg; Max Planck Society	Frischknecht, F (corresponding author), Heidelberg Univ, Dept Parasitol, Inst Hyg, Sch Med, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	freddy.frischknecht@med.uni-heidelberg.de	Engel, Ulrike/E-5456-2014; Engel, Ulrike/AAO-7719-2020	Engel, Ulrike/0000-0002-6953-6845; Frischknecht, Friedrich/0000-0002-8332-6668; Matuschewski, Kai/0000-0001-6147-8591	Federal German Ministry for Education and Research (BMBF-BioFuture); German Research Foundation [DFG-SFB 544]; European Network of Excellence BioMalPar; University of Heidelberg Medical School; Cluster of Excellence CellNetworks	Federal German Ministry for Education and Research (BMBF-BioFuture)(Federal Ministry of Education & Research (BMBF)); German Research Foundation(German Research Foundation (DFG)); European Network of Excellence BioMalPar; University of Heidelberg Medical School; Cluster of Excellence CellNetworks	The authors thank Kai Uhrig for discussions and comments on the manuscript. The work was funded by grants from the Federal German Ministry for Education and Research (BMBF-BioFuture), the German Research Foundation (DFG-SFB 544), and the European Network of Excellence BioMalPar. The authors gratefully acknowledge support from the University of Heidelberg Medical School and the Cluster of Excellence CellNetworks. The authors thank Diana Schep-pan and Iris Arnold for mosquito infection, Jan-Peter Roderer for help with data analysis, and the Nikon Imaging Center at the University of Heidelberg for access to their microscopes. The authors declare no conflicts of interest.	Amino R, 2006, NAT MED, V12, P220, DOI 10.1038/nm1350; Amino R, 2005, CURR OPIN MICROBIOL, V8, P407, DOI 10.1016/j.mib.2005.06.019; Baum J, 2008, TRENDS PARASITOL, V24, P557, DOI 10.1016/j.pt.2008.08.006; Bland JM, 1998, BRIT MED J, V316, P129; Brennan JDG, 2000, P NATL ACAD SCI USA, V97, P13859, DOI 10.1073/pnas.250472597; BUBB MR, 1995, J BIOL CHEM, V270, P3463, DOI 10.1074/jbc.270.8.3463; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; Combe A, 2009, INT J PARASITOL, V39, P489, DOI 10.1016/j.ijpara.2008.10.004; Coppi A, 2005, J EXP MED, V201, P27, DOI 10.1084/jem.20040989; Coppi A, 2007, CELL HOST MICROBE, V2, P316, DOI 10.1016/j.chom.2007.10.002; Cowman AF, 2006, CELL, V124, P755, DOI 10.1016/j.cell.2006.02.006; Cramer LP, 1999, CURR BIOL, V9, P1095, DOI 10.1016/S0960-9822(99)80478-3; Frevert U, 2005, PLOS BIOL, V3, P1034, DOI 10.1371/journal.pbio.0030192; Frevert U, 2006, CELL MICROBIOL, V8, P1537, DOI 10.1111/j.1462-5822.2006.00777.x; Frischknecht F, 2004, CELL MICROBIOL, V6, P687, DOI 10.1111/j.1462-5822.2004.00395.x; Gantt S, 2000, INFECT IMMUN, V68, P3667, DOI 10.1128/IAI.68.6.3667-3673.2000; Ghosh AK, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000265; Hegge Stephan, 2009, Biotechnology Journal, V4, P903, DOI 10.1002/biot.200900007; Heintzelman MB, 2006, INT REV CYTOL, V251, P79, DOI 10.1016/S0074-7696(06)51003-4; Heiss K, 2008, EUKARYOT CELL, V7, P1062, DOI 10.1128/EC.00089-08; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; Kebaier C, 2010, INT J PARASITOL, V40, P25, DOI 10.1016/j.ijpara.2009.06.011; Kerry SM, 1998, BMJ-BRIT MED J, V316, P54, DOI 10.1136/bmj.316.7124.54; Lacroix C, 2008, TRENDS PARASITOL, V24, P431, DOI 10.1016/j.pt.2008.07.003; Matuschewski K, 2002, EMBO J, V21, P1597, DOI 10.1093/emboj/21.7.1597; Matuschewski K, 2006, CELL MICROBIOL, V8, P1547, DOI 10.1111/j.1462-5822.2006.00778.x; MILLER LH, 1979, J EXP MED, V149, P172, DOI 10.1084/jem.149.1.172; Mizuno Y, 2002, PARASITOL RES, V88, P844, DOI 10.1007/s00436-002-0666-8; Morahan BJ, 2009, TRENDS PARASITOL, V25, P77, DOI 10.1016/j.pt.2008.11.004; Moreira CK, 2008, CELL MICROBIOL, V10, P1505, DOI 10.1111/j.1462-5822.2008.01143.x; Munter S, 2009, CELL HOST MICROBE, V6, P551, DOI 10.1016/j.chom.2009.11.007; Natarajan R, 2001, CELL MICROBIOL, V3, P371, DOI 10.1046/j.1462-5822.2001.00117.x; Pinzon-Ortiz C, 2001, J BIOL CHEM, V276, P26784, DOI 10.1074/jbc.M104038200; Poupel O, 1999, MICROBES INFECT, V1, P653, DOI 10.1016/S1286-4579(99)80066-5; Pradel G, 2002, MOL MICROBIOL, V45, P637, DOI 10.1046/j.1365-2958.2002.03057.x; Rathore D, 2002, J BIOL CHEM, V277, P7092, DOI 10.1074/jbc.M106862200; Saito S, 1998, J BIOCHEM-TOKYO, V123, P571; Sherman IW, 2003, MICROBES INFECT, V5, P897, DOI 10.1016/S1286-4579(03)00162-X; SIMONETTI AB, 1993, J EUKARYOT MICROBIOL, V40, P569, DOI 10.1111/j.1550-7408.1993.tb06109.x; Sinden RE, 2005, MOLECULAR APPROACHES TO MALARIA, P169; Starnes GL, 2009, CELL HOST MICROBE, V5, P353, DOI 10.1016/j.chom.2009.03.005; Steinbuechel M, 2009, CELL MICROBIOL, V11, P279, DOI 10.1111/j.1462-5822.2008.01252.x; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; van Dijk MR, 2001, CELL, V104, P153, DOI 10.1016/S0092-8674(01)00199-4; VANDERBERG JP, 1974, J PROTOZOOL, V21, P527, DOI 10.1111/j.1550-7408.1974.tb03693.x; Vlachou D, 2004, CELL MICROBIOL, V6, P671, DOI 10.1111/j.1462-5822.2004.00394.x; Wetzel DM, 2003, MOL BIOL CELL, V14, P396, DOI 10.1091/mbc.E02-08-0458; Zaidel-Bar R, 2007, NAT CELL BIOL, V9, P858, DOI 10.1038/ncb0807-858	48	60	60	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2222	2234		10.1096/fj.09-148700	http://dx.doi.org/10.1096/fj.09-148700			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20159960				2022-12-28	WOS:000279343600009
J	Lainez, S; Valente, P; Ontoria-Oviedo, I; Estevez-Herrera, J; Camprubi-Robles, M; Ferrer-Montiel, A; Planells-Cases, R				Lainez, S.; Valente, P.; Ontoria-Oviedo, I.; Estevez-Herrera, J.; Camprubi-Robles, M.; Ferrer-Montiel, A.; Planells-Cases, R.			GABA(A) receptor associated protein (GABARAP) modulates TRPV1 expression and channel function and desensitization	FASEB JOURNAL			English	Article						pain; analgesia; nociceptor; cytoskeleton; tubulin; inflammation	ROOT GANGLION NEURONS; PLASMA-MEMBRANE; GABA(A)-RECEPTOR-ASSOCIATED PROTEIN; VANILLOID RECEPTOR-1; BINDING; KINASE; IDENTIFICATION; INTERACTS; PHOSPHORYLATION; MICROTUBULES	Transient receptor potential vanilloid (TRPV1) transduces noxious chemical and physical stimuli in high-threshold nociceptors. The pivotal role of TRPV1 in the physiopathology of pain transduction has thrust the identification and characterization of interacting partners that modulate its cellular function. Here, we report that TRPV1 associates with gamma-amino butyric acid A-type (GABA(A)) receptor associated protein (GABARAP) in HEK293 cells and in neurons from dorsal root ganglia coexpressing both proteins. At variance with controls, GABARAP augmented TRPV1 expression in cotransfected cells and stimulated surface receptor clustering. Functionally, GABARAP expression attenuated voltage and capsaicin sensitivity of TRPV1 in the presence of extracellular calcium. Furthermore, the presence of the anchor protein GABARAP notably lengthened the kinetics of vanilloid-induced tachyphylaxia. Notably, the presence of GABARAP selectively increased the interaction of tubulin with the C-terminal domain of TRPV1. Disruption of tubulin cytoskeleton with nocodazole reduced capsaicin-evoked currents in cells expressing TRPV1 and GABARAP, without affecting the kinetics of vanilloid- induced desensitization. Taken together, these findings indicate that GABARAP is an important component of the TRPV1 signaling complex that contributes to increase the channel expression, to traffic and cluster it on the plasma membrane, and to modulate its functional activity at the level of channel gating and desensitization.-Lainez, S., Valente, P., Ontoria-Oviedo, I., Estevez-Herrera, J., Camprub Robles, M., Ferrer-Montiel, A. Planells-Cases, R. GABA(A) receptor associated protein (GABARAP) modulates TRPV1 expression and channel function and desensitization. FASEB J. 24, 1958-1970 (2010). www.fasebj.org	[Lainez, S.; Ontoria-Oviedo, I.; Estevez-Herrera, J.; Planells-Cases, R.] Ctr Invest Principe Felipe, Valencia 46012, Spain	Prince Felipe Research Center	Planells-Cases, R (corresponding author), Ctr Invest Principe Felipe, Av Autopista Saler 16, Valencia 46012, Spain.	rplanells@cipf.es	Ferrer-Montiel, Antonio/C-3072-2015; Valente, Pierluigi/AAF-2802-2021; Ontoria-Oviedo, Imelda/W-1069-2018; Estevez Herrera, Judith/R-5333-2018	Ferrer-Montiel, Antonio/0000-0002-2973-6607; Ontoria-Oviedo, Imelda/0000-0002-2497-1325; Estevez Herrera, Judith/0000-0001-8130-2294	Ministerio de Ciencia e Innovacion (MICINN) [SAF2006-2580, SAF2007-63193, CSD2008-00005]; la Fundacio La Marato de TV3; la Fundacion Emilio Botin	Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); la Fundacio La Marato de TV3; la Fundacion Emilio Botin	This work was supported by grants from el Ministerio de Ciencia e Innovacion (MICINN; SAF2006-2580 to A.F.-M. and SAF2007-63193 to R.P.-C.); the Consolider-Ingenio 2010 (MICINN; CSD2008-00005 to A.F.-M and R.P.-C.), la Fundacio La Marato de TV3 (to A.F.-M and R.P.-C.), and la Fundacion Emilio Botin (to A.F.-M).	Alam J, 2010, REGUL PEPTIDES, V159, P78, DOI 10.1016/j.regpep.2009.09.002; Bavro VN, 2002, EMBO REP, V3, P183, DOI 10.1093/embo-reports/kvf026; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Cabedo H, 2004, J BIOL CHEM, V279, P33623, DOI 10.1074/jbc.M401962200; Camprubi-Robles M, 2009, FASEB J, V23, P3722, DOI 10.1096/fj.09-134346; Chen CG, 2006, J BIOL CHEM, V281, P7983, DOI 10.1074/jbc.M509805200; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Chen ZW, 2007, J NEUROCHEM, V100, P279, DOI 10.1111/j.1471-4159.2006.04206.x; Cook JL, 2008, CIRC RES, V102, P1539, DOI 10.1161/CIRCRESAHA.108.176594; Coyle JE, 2003, NEUROSCIENTIST, V9, P205, DOI 10.1177/1073858403009003013; Coyle JE, 2002, NEURON, V33, P63, DOI 10.1016/S0896-6273(01)00558-X; Docherty RJ, 1996, PFLUG ARCH EUR J PHY, V431, P828, DOI 10.1007/BF02332166; Gonzalez MI, 2007, J NEUROCHEM, V103, P1917, DOI 10.1111/j.1471-4159.2007.04881.x; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Goswami C, 2006, J NEUROCHEM, V96, P254, DOI 10.1111/j.1471-4159.2005.03551.x; Goswami C, 2004, J NEUROCHEM, V91, P1092, DOI 10.1111/j.1471-4159.2004.02795.x; Jung JY, 2004, J BIOL CHEM, V279, P7048, DOI 10.1074/jbc.M311448200; Kim AY, 2008, CELL, V133, P475, DOI 10.1016/j.cell.2008.02.053; Kittler JT, 2001, MOL CELL NEUROSCI, V18, P13, DOI 10.1006/mcne.2001.1005; Koplas PA, 1997, J NEUROSCI, V17, P3525; Leil TA, 2004, J NEUROSCI, V24, P11429, DOI 10.1523/JNEUROSCI.3355-04.2004; Lilja J, 2007, J NEUROSCI RES, V85, P1413, DOI 10.1002/jnr.21255; Lishko PV, 2007, NEURON, V54, P905, DOI 10.1016/j.neuron.2007.05.027; Mohapatra DP, 2005, J BIOL CHEM, V280, P13424, DOI 10.1074/jbc.M410917200; Mohrluder J, 2007, BIOCHEMISTRY-US, V46, P14537, DOI 10.1021/bi7018145; Molina ML, 2006, J BIOL CHEM, V281, P18837, DOI 10.1074/jbc.M600342200; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Planells-Cases R, 2005, PFLUG ARCH EUR J PHY, V451, P151, DOI 10.1007/s00424-005-1423-5; Reining SC, 2009, AM J PHYSIOL-RENAL, V296, pF1118, DOI 10.1152/ajprenal.90492.2008; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Stein AT, 2006, J GEN PHYSIOL, V128, P509, DOI 10.1085/jgp.200609576; Sun H, 2008, J PHYSIOL-LONDON, V586, P751, DOI 10.1113/jphysiol.2007.136440; Valente P, 2008, FASEB J, V22, P3298, DOI 10.1096/fj.08-107425; Vennekens R, 2008, CURR PHARM DESIGN, V14, P18; Voets T, 2004, NATURE, V430, P748, DOI 10.1038/nature02732; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Zhang XM, 2008, NEURON, V59, P450, DOI 10.1016/j.neuron.2008.05.015	39	57	57	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2010	24	6					1958	1970		10.1096/fj.09-151472	http://dx.doi.org/10.1096/fj.09-151472			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20179142				2022-12-28	WOS:000278200000030
J	Schue, M; Maurin, D; Dhouib, R; N'Goma, JCB; Delorme, V; Lambeau, G; Carriere, F; Canaan, S				Schue, Mathieu; Maurin, Damien; Dhouib, Rabeb; N'Goma, Jean-Claude Bakala; Delorme, Vincent; Lambeau, Gerard; Carriere, Frederic; Canaan, Stephane			Two cutinase-like proteins secreted by Mycobacterium tuberculosis show very different lipolytic activities reflecting their physiological function	FASEB JOURNAL			English	Article						lipase; phospholipase; cytotoxicity	FUSARIUM-SOLANI CUTINASE; ACETYLXYLAN ESTERASE; CATALYTIC SERINE; ENZYME; FAMILY; LIPASE; ACID; BIOSYNTHESIS; PURIFICATION; EVOLUTION	Cutinases are extracellular enzymes that are able to degrade cutin, a polyester protecting plant leaves and many kinds of lipids. Although cutinases are mainly found in phytopathogenic fungi or bacteria, 7 genes related to the cutinase family have been predicted in the genome of Mycobacterium tuberculosis. These genes may encode proteins that are involved in the complex lipid metabolism of the bacterium. Here, we report on the biochemical characterization of two secreted proteins of M. tuberculosis, Rv1984c and Rv3452, belonging to the cutinase family. Although their amino acid sequence shows 50% identity with that of the well-characterized cutinase from Fusarium solani pisi, and a high level of homology has been found to exist between these two enzymes, they show distinct substrate specificities. Rv1984c preferentially hydrolyzes medium-chain carboxylic esters and monoacylglycerols, whereas Rv3452 behaves like a phospholipase A(2), and it is able to induce macrophage lysis. The tetrahydrolipstatin inhibitor, a specific lipase inhibitor, abolishes the activity of both enzymes. Site-directed mutagenesis was performed to identify the catalytic triad of Rv1984c. Structural models for Rv1984c and Rv3452 were built, based on the crystal structure of F. solani cutinase, with a view to investigating the contribution of specific residues to the substrate specificity. Our findings open new prospects for investigating the physiological roles of cutinase-like proteins in the lipid metabolism and virulence of M. tuberculosis.-Schue, M., Maurin, D., Dhouib, R., Bakala N'Goma, J.-C., Delorme, V., Lambeau, G., Carriere, F., Canaan, S. Two cutinase-like proteins secreted by Mycobacterium tuberculosis show very different lipolytic activities reflecting their physiological function. FASEB J. 24, 1893-1903 (2010). www.fasebj.org	[Schue, Mathieu; Maurin, Damien; Dhouib, Rabeb; N'Goma, Jean-Claude Bakala; Delorme, Vincent; Carriere, Frederic; Canaan, Stephane] Aix Marseille Univ, CNRS, Enzymol Interfaciale & Physiol Lipolyse UPR 9025, F-13402 Marseille, France; [Lambeau, Gerard] Univ Nice Sophia Antipolis, CNRS, UMR 6097, Inst Pharmacol Mol & Cellulaire, Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Canaan, S (corresponding author), Aix Marseille Univ, CNRS, Enzymol Interfaciale & Physiol Lipolyse UPR 9025, 31 Chemin Joseph Aiguier, F-13402 Marseille, France.	stephane.canaan@ifr88.cnrs-mrs.fr	Carrière, Frédéric/E-8408-2010; Lambeau, Gerard/GRJ-5624-2022	Carrière, Frédéric/0000-0003-4848-9418; Lambeau, Gerard/0000-0002-9239-518X; Delorme, Vincent/0000-0001-5235-7069	Groupement d'Interet Public-Agence Nationale de la Recherche [06-JCJC-0067-01]; Centre National de la Recherche Scientifique	Groupement d'Interet Public-Agence Nationale de la Recherche(French National Research Agency (ANR)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS))	This work was funded by Groupement d'Interet Public-Agence Nationale de la Recherche grant 06-JCJC-0067-01 and by the Centre National de la Recherche Scientifique. The authors thank Pamela N'Guele for her help and Regine Lebrun (Institut de Microbiologie de la Mediterannee, Marseille, France) for conducting the proteomic analyses. The authors also thank Dr. M. Gilleron, Dr. E. Layre, and D. De-Paepe (Institut de Pharmacologie et de Biologie Structurale, Toulouse, France) for their technical assistance with the PIM hydrolysis. Finally, the authors thank Dr. Jessica Blanc for revising the English in this report.	Belbahri L, 2008, GENE, V408, P1, DOI 10.1016/j.gene.2007.10.019; BELFRAGE P, 1969, J LIPID RES, V10, P341; Bennett-Lovsey RM, 2008, PROTEINS, V70, P611, DOI 10.1002/prot.21688; Bhatt A, 2007, MOL MICROBIOL, V64, P1442, DOI 10.1111/j.1365-2958.2007.05761.x; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cotes K, 2008, APPL MICROBIOL BIOT, V78, P741, DOI 10.1007/s00253-008-1397-2; Cotes K, 2007, BIOCHEM J, V408, P417, DOI 10.1042/BJ20070745; Deb C, 2006, J BIOL CHEM, V281, P3866, DOI 10.1074/jbc.M505556200; DeLano W. L., 2002, PROTEIN-STRUCT FUNCT, V30, P442, DOI DOI 10.1234/12345678; Egmond MR, 2000, BIOCHIMIE, V82, P1015, DOI 10.1016/S0300-9084(00)01183-4; Ghosh D, 2001, J BIOL CHEM, V276, P11159, DOI 10.1074/jbc.M008831200; Goldman Robert C., 2007, Infectious Disorders - Drug Targets, V7, P73; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hakulinen N, 2000, J STRUCT BIOL, V132, P180, DOI 10.1006/jsbi.2000.4318; Karim EK, 2005, FEBS LETT, V579, P6067, DOI 10.1016/j.febslet.2005.09.072; Kolattukudy PE, 2001, ADV BIOCHEM ENG BIOT, V71, P1; Lau EY, 1999, BIOPHYS J, V77, P85, DOI 10.1016/S0006-3495(99)76874-8; Longhi S, 1999, BBA-MOL CELL BIOL L, V1441, P185, DOI 10.1016/S1388-1981(99)00159-6; Longhi S, 1996, PROTEINS, V26, P442, DOI [10.1002/(SICI)1097-0134(199612)26:4<442::AID-PROT5>3.3.CO;2-H, 10.1002/(SICI)1097-0134(199612)26:4&lt;442::AID-PROT5&gt;3.0.CO;2-D]; MANNESSE MLM, 1995, BIOCHEMISTRY-US, V34, P6400, DOI 10.1021/bi00019a020; MARTINEZ C, 1994, BIOCHEMISTRY-US, V33, P83, DOI 10.1021/bi00167a011; MARTINEZ C, 1992, NATURE, V356, P615, DOI 10.1038/356615a0; Masaki K, 2005, APPL ENVIRON MICROB, V71, P7548, DOI 10.1128/AEM.71.11.7548-7550.2005; Minnikin DE, 2002, CHEM BIOL, V9, P545, DOI 10.1016/S1074-5521(02)00142-4; Neyrolles O, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000043; Parker SK, 2007, J BACTERIOL, V189, P4153, DOI 10.1128/JB.01909-06; Parker SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004281; Petersen SB, 1998, J BIOTECHNOL, V66, P11, DOI 10.1016/S0168-1656(98)00153-9; Peyron P, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000204; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; Rouault M, 2007, BIOCHEMISTRY-US, V46, P1647, DOI 10.1021/bi062119b; Russell DG, 2007, NAT REV MICROBIOL, V5, P39, DOI 10.1038/nrmicro1538; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Sitkiewicz I, 2006, P NATL ACAD SCI USA, V103, P16009, DOI 10.1073/pnas.0607669103; Vincentelli R, 2004, PROTEIN SCI, V13, P2782, DOI 10.1110/ps.04806004; Waltermann M, 2005, J BACTERIOL, V187, P3607, DOI 10.1128/JB.187.11.3607-3619.2005; WEIBEL EK, 1987, J ANTIBIOT, V40, P1081, DOI 10.7164/antibiotics.40.1081; Weldingh K, 1998, INFECT IMMUN, V66, P3492, DOI 10.1128/IAI.66.8.3492-3500.1998; West NP, 2008, VACCINE, V26, P3853, DOI 10.1016/j.vaccine.2008.05.007; West NP, 2009, FASEB J, V23, P1694, DOI 10.1096/fj.08-114421; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Whitmore L, 2008, BIOPOLYMERS, V89, P392, DOI 10.1002/bip.20853	43	55	57	2	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1893	1903		10.1096/fj.09-144766	http://dx.doi.org/10.1096/fj.09-144766			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20103719				2022-12-28	WOS:000278200000024
J	Fasana, E; Fossati, M; Ruggiano, A; Brambillasca, S; Hoogenraad, CC; Navone, F; Francolini, M; Borgese, N				Fasana, Elisa; Fossati, Matteo; Ruggiano, Annamaria; Brambillasca, Silvia; Hoogenraad, Casper C.; Navone, Francesca; Francolini, Maura; Borgese, Nica			A VAPB mutant linked to amyotrophic lateral sclerosis generates a novel form of organized smooth endoplasmic reticulum	FASEB JOURNAL			English	Article						inclusion bodies; neurodegenerative diseases; post-translational insertion; tail-anchored membrane proteins	PROTEIN-ASSOCIATED PROTEIN; LIPID-BINDING PROTEINS; TAIL-ANCHORED PROTEINS; MOTOR-NEURON DISEASE; LOSS-OF-FUNCTION; MEMBRANE-PROTEIN; FFAT MOTIF; ER; MUTATION; TRANSPORT	VAPB (vesicle-associated membrane protein-associated protein B) is an endoplasmic reticulum (ER)-resident tail-anchored adaptor protein involved in lipid transport. A dominantly inherited mutant, P56S-VAPB, causes a familial form of amyotrophic lateral sclerosis (ALS) and forms poorly characterized inclusion bodies in cultured cells. To provide a cell biological basis for the understanding of mutant VAPB pathogenicity, we investigated its biogenesis and the inclusions that it generates. Translocation assays in cell-free systems and in cultured mammalian cells were used to investigate P56S-VAPB membrane insertion, and the inclusions were characterized by confocal imaging and electron microscopy. We found that mutant VAPB inserts post-translationally into ER membranes in a manner indistinguishable from the wild-type protein but that it rapidly clusters to form inclusions that remain continuous with the rest of the ER. Inclusions were induced by the mutant also when it was expressed at levels comparable to the endogenous wild-type protein. Ultrastructural analysis revealed that the inclusions represent a novel form of organized smooth ER (OSER) consisting in a limited number of parallel cisternae (usually 2 or 3) interleaved by a similar to 30 nm-thick electron-dense cytosolic layer. Our results demonstrate that the ALS-linked VAPB mutant causes dramatic ER restructuring that may underlie its pathogenicity in motoneurons.-Fasana, E., Fossati, M., Ruggiano, A., Brambillasca, S., Hoogenraad, C. C., Navone, F., Francolini, M., Borgese, N. A VAPB mutant linked to amyotrophic lateral sclerosis generates a novel form of organized smooth endoplasmic reticulum. FASEB J. 24, 1419-1430 (2010). www.fasebj.org	[Fasana, Elisa; Fossati, Matteo; Ruggiano, Annamaria; Brambillasca, Silvia; Navone, Francesca; Francolini, Maura; Borgese, Nica] Inst Neurosci, CNR, I-20129 Milan, Italy; [Fasana, Elisa; Fossati, Matteo; Ruggiano, Annamaria; Brambillasca, Silvia; Navone, Francesca; Francolini, Maura; Borgese, Nica] Univ Milan, Dept Pharmacol, Milan, Italy; [Hoogenraad, Casper C.] Erasmus MC, Dept Neurosci, Rotterdam, Netherlands; [Borgese, Nica] Univ Catanzaro, Dept Pharmacobiol Sci, Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Erasmus University Rotterdam; Erasmus MC; Magna Graecia University of Catanzaro	Borgese, N (corresponding author), Inst Neurosci, CNR, Via Vanvitelli 32, I-20129 Milan, Italy.	n.borgese@in.cnr.it	Borgese, Nica/GWZ-8895-2022; Fossati, Matteo/AAB-6081-2019; Hoogenraad, Casper/B-8866-2011; Fossati, Matteo/J-4131-2018	Borgese, Nica/0000-0002-7537-3974; Fossati, Matteo/0000-0002-9210-5242; Hoogenraad, Casper/0000-0002-2666-0758; Fossati, Matteo/0000-0002-9210-5242; Ruggiano, Annamaria/0000-0003-4514-7922; FRANCOLINI, MAURA/0000-0002-3126-1575	Telethon [GGP07010]; CAR-IPLO Foundation; University of Milan	Telethon(Fondazione Telethon); CAR-IPLO Foundation(Fondazione Cariplo); University of Milan	In addition to the people who kindly supplied reagents (listed in Materials and Methods and in Supplemental Table 2), the authors thank Paolo Ronchi for helpful discussions. Special thanks are extended to the Monzino Foundation (Milan, Italy), for its generous gift of the Zeiss LSM 510 Meta confocal microscope. This work was supported by Telethon (grant GGP07010) and by the CAR-IPLO Foundation. E. F. was a doctoral student supported by the University of Milan.	Amarilio R, 2005, J BIOL CHEM, V280, P5934, DOI 10.1074/jbc.M409566200; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BASSETTI M, 1995, ENDOCRINOLOGY, V136, P1168, DOI 10.1210/en.136.3.1168; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; BORGESE N, 2009, PROTEIN TRANSPORT EN, P91; Borgese N, 2007, CURR OPIN CELL BIOL, V19, P368, DOI 10.1016/j.ceb.2007.04.019; Borgese N, 2006, CURR OPIN CELL BIOL, V18, P358, DOI 10.1016/j.ceb.2006.06.008; Brambillasca S, 2005, EMBO J, V24, P2533, DOI 10.1038/sj.emboj.7600730; Brambillasca S, 2006, J CELL BIOL, V175, P767, DOI 10.1083/jcb.200608101; Colombo SF, 2009, J CELL SCI, V122, P2383, DOI 10.1242/jcs.049460; DESILVESTRIS M, 1995, FEBS LETT, V370, P69, DOI 10.1016/0014-5793(95)00797-D; Foster LJ, 2000, TRAFFIC, V1, P512, DOI 10.1034/j.1600-0854.2000.010609.x; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; Kagiwada S, 1998, J BACTERIOL, V180, P1700, DOI 10.1128/JB.180.7.1700-1708.1998; Kaiser SE, 2005, STRUCTURE, V13, P1035, DOI 10.1016/j.str.2005.04.010; Kanekura K, 2006, J BIOL CHEM, V281, P30223, DOI 10.1074/jbc.M605049200; Kawano M, 2006, J BIOL CHEM, V281, P30279, DOI 10.1074/jbc.M605032200; Kopito RR, 2000, EMBO REP, V1, P225, DOI 10.1093/embo-reports/kvd052; Lev S, 2008, TRENDS CELL BIOL, V18, P282, DOI 10.1016/j.tcb.2008.03.006; Loewen CJR, 2005, J BIOL CHEM, V280, P14097, DOI 10.1074/jbc.M500147200; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; Marques VD, 2006, MUSCLE NERVE, V34, P731, DOI 10.1002/mus.20657; Nishimura AL, 2004, AM J HUM GENET, V75, P822, DOI 10.1086/425287; Peretti D, 2008, MOL BIOL CELL, V19, P3871, DOI 10.1091/mbc.E08-05-0498; Powers ET, 2009, ANNU REV BIOCHEM, V78, P959, DOI 10.1146/annurev.biochem.052308.114844; Prosser DC, 2008, J CELL SCI, V121, P3052, DOI 10.1242/jcs.028696; Ratnaparkhi A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002334; Rocha N, 2009, J CELL BIOL, V185, P1209, DOI 10.1083/jcb.200811005; Ronchi P, 2008, J CELL BIOL, V181, P105, DOI 10.1083/jcb.200710093; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Saita S, 2009, J BIOL CHEM, V284, P13766, DOI 10.1074/jbc.M807938200; SKEHEL PA, 1995, SCIENCE, V269, P1580, DOI 10.1126/science.7667638; Snapp EL, 2003, J CELL BIOL, V163, P257, DOI 10.1083/jcb.200306020; Soussan L, 1999, J CELL BIOL, V146, P301, DOI 10.1083/jcb.146.2.301; Sprocati T, 2006, J CELL SCI, V119, P3249, DOI 10.1242/jcs.03058; Suzuki H, 2009, J NEUROCHEM, V108, P973, DOI [10.1111/j.1471-4159.2008.05857.x, 10.1111/j.0022-3042.2008.05857.x]; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Teuling E, 2007, J NEUROSCI, V27, P9801, DOI 10.1523/JNEUROSCI.2661-07.2007; Wakana Y, 2008, MOL BIOL CELL, V19, P1825, DOI 10.1091/mbc.E07-08-0781; Winklhofer KF, 2008, EMBO J, V27, P336, DOI 10.1038/sj.emboj.7601930	40	75	78	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2010	24	5					1419	1430		10.1096/fj.09-147850	http://dx.doi.org/10.1096/fj.09-147850			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20008544				2022-12-28	WOS:000277158900015
J	Hoashi, T; Sato, S; Yamaguchi, Y; Passeron, T; Tamaki, K; Hearing, VJ				Hoashi, Toshihiko; Sato, Shinichi; Yamaguchi, Yuji; Passeron, Thierry; Tamaki, Kunihiko; Hearing, Vincent J.			Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein	FASEB JOURNAL			English	Article						ectodomain shedding; glycosylation; phorbol ester	MALIGNANT-MELANOMA; DESMOPLASTIC MELANOMA; PRECURSOR PROTEIN; REPEAT DOMAIN; EXPRESSION; PMEL17; CLEAVAGE; OSTEOACTIVIN; ECTODOMAIN; MEMBRANE	Melanosomes are organelles specialized for the production of melanin pigment and are specifically produced by melanocytic cells. More than 150 pigmentation-related genes have been identified, including glycoprotein nonmetastatic melanoma protein b (GPNMB). A recent proteomics analysis revealed that GPNMB is localized in melanosomes, and GPNMB is a membrane-bound glycoprotein that shows high homology with a well-known melanosomal structural protein, Pmel17/gp100. In this study, we show that GPNMB is expressed in melanocytes of normal human skin, as well as in human melanoma cells. GPNMB is heavily glycosylated and is enriched in mature (stage III and IV) melanosomes in contrast to MART-1 and Pmel17, which are abundant in early (stage I and II) melanosomes. MART-1 and Pmel17 play critical roles in the maturation of early melanosomes; thus, we speculate that GPNMB might be important in the functions of late melanosomes, possibly their transport and/or transfer to keratinocytes. We also demonstrate that a secreted form of GPNMB is released by ectodomain shedding from the largely Golgi-modified form of GPNMB and that the PKC and Ca2+ intracellular signaling pathways regulate that shedding. We conclude that GPNMB is a melanosomal protein that is released by proteolytic ectodomain shedding and might be a useful and specific histological marker of melanocytic cells.-Hoashi, T., Sato, S., Yamaguchi, Y., Passeron, T., Tamaki, K., Hearing, V. J. Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein. FASEB J. 24, 1616-1629 (2010). www.fasebj.org	[Hoashi, Toshihiko; Yamaguchi, Yuji; Passeron, Thierry; Hearing, Vincent J.] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; [Hoashi, Toshihiko; Sato, Shinichi; Tamaki, Kunihiko] Univ Tokyo, Fac Med, Dept Dermatol, Tokyo 113, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Tokyo	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 2132, Bethesda, MD 20892 USA.	thoashi-tky@umin.ac.jp; hearingv@nih.gov	Yamaguchi, Yuji/X-6681-2019; Yamaguchi, Yuji/B-9312-2008	Passeron, Thierry/0000-0002-0797-6570; Yamaguchi, Yuji/0000-0003-4338-2662	Shiseido grant for science research; U.S. National Institutes of Health, National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIABC010785] Funding Source: NIH RePORTER	Shiseido grant for science research; U.S. National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors gratefully thank Dr. Michael S. Marks (University of Pennsylvania, Philadelphia, PA, USA) for kindly providing the Pmel17-i vector. This work was largely supported by a Shiseido grant for science research (T.H.) and in part by the Intramural Research Program of the U.S. National Institutes of Health, National Cancer Institute.	Abdelmagid SM, 2008, EXP CELL RES, V314, P2334, DOI 10.1016/j.yexcr.2008.02.006; Aisner DL, 2005, HUM PATHOL, V36, P1016, DOI 10.1016/j.humpath.2005.07.010; Anderson MG, 2002, NAT GENET, V30, P81, DOI 10.1038/ng794; Angles-Cano E, 2002, BIOL CHEM, V383, P93, DOI 10.1515/BC.2002.009; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; Basrur V, 2003, J PROTEOME RES, V2, P69, DOI 10.1021/pr025562r; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; Bosserhoff AK, 1997, CANCER RES, V57, P3149; Boyle JL, 2002, ARCH PATHOL LAB MED, V126, P816; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; Carlson JA, 2005, J AM ACAD DERMATOL, V52, P743, DOI 10.1016/j.jaad.2004.08.034; Chi A, 2006, J PROTEOME RES, V5, P3135, DOI 10.1021/pr060363j; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; Dlugosz A, 2002, J INVEST DERM SYMP P, V7, P17, DOI 10.1046/j.1523-1747.2002.19631.x; Dowdy JC, 1995, PHOTODERMATOL PHOTO, V11, P143, DOI 10.1111/j.1600-0781.1995.tb00156.x; Furochi H, 2007, FEBS LETT, V581, P5743, DOI 10.1016/j.febslet.2007.11.036; Harper DC, 2008, J BIOL CHEM, V283, P2307, DOI 10.1074/jbc.M708007200; Hoashi T, 2005, J BIOL CHEM, V280, P14006, DOI 10.1074/jbc.M413692200; Hoashi T, 2008, J DERMATOL, V35, P122, DOI 10.1111/j.1346-8138.2008.00427.x; Hoashi T, 2006, J BIOL CHEM, V281, P21198, DOI 10.1074/jbc.M601643200; Hoashi T, 2010, FASEB J, V24, P916, DOI 10.1096/fj.09-140921; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; ITO S, 1984, J CHROMATOGR, V311, P154, DOI 10.1016/S0378-4347(00)84702-7; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; Kummer MP, 2009, J BIOL CHEM, V284, P2296, DOI 10.1074/jbc.M808904200; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; KWON BS, 1987, MOL BIOL MED, V4, P339; KWON BS, 1995, NUCLEIC ACIDS RES, V23, P154, DOI 10.1093/nar/23.1.154; Lambert DW, 2008, FEBS LETT, V582, P385, DOI 10.1016/j.febslet.2007.11.085; Le Borgne R, 2001, J CELL SCI, V114, P2831; Loftus SK, 2009, PIGM CELL MELANOMA R, V22, P99, DOI 10.1111/j.1755-148X.2008.00518.x; MARESH GA, 1994, ARCH BIOCHEM BIOPHYS, V311, P95, DOI 10.1006/abbi.1994.1213; McGlinchey RP, 2009, P NATL ACAD SCI USA, V106, P13731, DOI 10.1073/pnas.0906509106; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Ogawa T, 2005, AM J PHYSIOL-CELL PH, V289, pC697, DOI 10.1152/ajpcell.00565.2004; Ohsie SJ, 2008, J CUTAN PATHOL, V35, P433, DOI 10.1111/j.1600-0560.2007.00891.x; ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Qian XZ, 2008, MOL ONCOL, V2, P81, DOI 10.1016/j.molonc.2008.02.002; Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809; Ripoll VM, 2007, J IMMUNOL, V178, P6557, DOI 10.4049/jimmunol.178.10.6557; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; Safadi FF, 2002, J CELL BIOCHEM, V84, P12, DOI 10.1002/jcb.1259; SCANU AM, 1995, BBA-LIPID LIPID MET, V1256, P1, DOI 10.1016/0005-2760(95)00012-2; SEIJI M, 1963, NATURE, V197, P1082, DOI 10.1038/1971082a0; Sheffield MV, 2002, AM J CLIN PATHOL, V118, P930, DOI 10.1092/AU8L65UJFQ75DVGC; Sheng MHC, 2008, FEBS LETT, V582, P1451, DOI 10.1016/j.febslet.2008.03.030; Shikano S, 2001, J BIOL CHEM, V276, P8125, DOI 10.1074/jbc.M008539200; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Slominski A, 2002, ARCH PATHOL LAB MED, V126, P775; Slominski A, 2001, ARCH PATHOL LAB MED, V125, P1295; Theos AC, 2006, DEV CELL, V10, P343, DOI 10.1016/j.devcel.2006.01.012; Theos AC, 2005, PIGM CELL RES, V18, P322, DOI 10.1111/j.1600-0749.2005.00269.x; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Tomihari M, 2009, EXP DERMATOL, V18, P586, DOI 10.1111/j.1600-0625.2008.00830.x; Truschel ST, 2009, TRAFFIC, V10, P1318, DOI 10.1111/j.1600-0854.2009.00955.x; Tse KF, 2006, CLIN CANCER RES, V12, P1373, DOI 10.1158/1078-0432.CCR-05-2018; Valencia JC, 2006, J CELL SCI, V119, P1080, DOI 10.1242/jcs.02804; Valencia JC, 2007, J BIOL CHEM, V282, P11266, DOI 10.1074/jbc.M608449200; VOGEL AM, 1988, CANCER RES, V48, P1286; Watabe H, 2004, J BIOL CHEM, V279, P7971, DOI 10.1074/jbc.M309714200; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Yamaguchi Y, 2009, BIOFACTORS, V35, P193, DOI 10.1002/biof.29; Yasumoto K, 2004, J BIOL CHEM, V279, P28330, DOI 10.1074/jbc.M401269200	74	76	86	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1616	1629		10.1096/fj.09-151019	http://dx.doi.org/10.1096/fj.09-151019			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20056711	Green Published			2022-12-28	WOS:000277158900033
J	Iturrioz, X; Alvear-Perez, R; De Mota, N; Franchet, C; Guillier, F; Leroux, V; Dabire, H; Le Jouan, M; Chabane, H; Gerbier, R; Bonnet, D; Berdeaux, A; Maigret, B; Galzi, JL; Hibert, M; Llorens-Cortes, C				Iturrioz, Xavier; Alvear-Perez, Rodrigo; De Mota, Nadia; Franchet, Christel; Guillier, Fabrice; Leroux, Vincent; Dabire, Hubert; Le Jouan, Melissande; Chabane, Hadjila; Gerbier, Romain; Bonnet, Dominique; Berdeaux, Alain; Maigret, Bernard; Galzi, Jean-Luc; Hibert, Marcel; Llorens-Cortes, Catherine			Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist	FASEB JOURNAL			English	Article							NITRIC-OXIDE; ENDOGENOUS LIGAND; BIASED AGONISM; BLOOD-PRESSURE; APJ RECEPTOR; CORECEPTOR; PEPTIDE; VASOPRESSIN; INHIBITION; IMMUNOREACTIVITY	Apelin plays a prominent role in body fluid and cardiovascular homeostasis. To explore further upstream the role played by this peptide, nonpeptidic agonists and antagonists of the apelin receptor are required. To identify such compounds that do not exist to date, we used an original fluorescence resonance energy transfer-based assay to screen a G-protein-coupled receptor-focused library of fluorescent compounds on the human EGFP-tagged apelin receptor. This led to isolated E339-3D6 that displayed a 90 nM affinity and behaved as a partial agonist with regard to cAMP production and as a full agonist with regard to apelin receptor internalization. Finally, E339-3D6 induced vasorelaxation of rat aorta precontracted with noradrenaline and potently inhibited systemic vasopressin release in water-deprived mice when intracerebroventricularly injected. This compound represents the first nonpeptidic agonist of the apelin receptor, the optimization of which will allow development of a new generation of vasodilator and aquaretic agents.-Iturrioz, X., Alvear-Perez, R., De Mota, N., Franchet, C., Guillier, F., Leroux, V., Dabire, H., Le Jouan, M., Chabane, H., Gerbier, R., Bonnet, D., Berdeaux, A., Maigret, B., Galzi J.-L., Hibert, M., Llorens-Cortes, C. Identification and pharmacological properties of E339-3D6, FASEB J. 24, 1506-1517 (2010). www.fasebj.org	[Iturrioz, Xavier; Alvear-Perez, Rodrigo; De Mota, Nadia; Le Jouan, Melissande; Gerbier, Romain; Llorens-Cortes, Catherine] Univ Paris 06, INSERM, U691, Coll France, F-75005 Paris, France; [Franchet, Christel; Guillier, Fabrice; Chabane, Hadjila; Bonnet, Dominique; Galzi, Jean-Luc; Hibert, Marcel] Univ Strasbourg 1, CNRS, Fac Pharm, UMR 7175,LC1, Illkirch Graffenstaden, France; [Franchet, Christel; Guillier, Fabrice; Chabane, Hadjila; Bonnet, Dominique; Galzi, Jean-Luc; Hibert, Marcel] Ecole Biotechnol, Illkirch Graffenstaden, France; [Leroux, Vincent; Maigret, Bernard] H Poincare Univ, Fac 7503, CNRS, Unite Mixte Rech,Orpailleur Grp,Lab Lorrain Rech, Nancy, France; [Dabire, Hubert; Berdeaux, Alain] Univ Paris, Fac Med, INSERM, U955, Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Llorens-Cortes, C (corresponding author), Univ Paris 06, INSERM, U691, Coll France, 11 Pl Marcelin Berthelot, F-75005 Paris, France.	c.llorens-cortes@college-de-france.fr	DABIRE, Hubert/G-5488-2018; Llorens-Cortes, Catherine/E-5839-2016; Bonnet, Dominique/N-7275-2014; Llorens-Cortès, catherine/AAL-3893-2021; Iturrioz, Xavier/AAS-3555-2020; GERBIER, Romain/ABF-2481-2020; ITURRIOZ, Xavier/Q-4406-2017	DABIRE, Hubert/0000-0002-5829-2718; Llorens-Cortes, Catherine/0000-0002-7667-0401; Bonnet, Dominique/0000-0002-8252-9199; Llorens-Cortès, catherine/0000-0002-7667-0401; Iturrioz, Xavier/0000-0001-7143-8323; ITURRIOZ, Xavier/0000-0001-7143-8323; DE MOTA, Nadia/0000-0003-3754-3722; Leroux, Vincent/0000-0002-4142-0883; Gerbier, Romain/0000-0003-4617-4850	Agence Nationale pour la Recherche Cardiovasculaire Obesite et Diabete [2005]; Societe Francaise d'Hypertension Arterielle; Ile de France Domaine d'Interet Majeur-Maladies Cardiovasculaires, Diabete et Obesite	Agence Nationale pour la Recherche Cardiovasculaire Obesite et Diabete(French National Research Agency (ANR)); Societe Francaise d'Hypertension Arterielle; Ile de France Domaine d'Interet Majeur-Maladies Cardiovasculaires, Diabete et Obesite	This work was supported by the Agence Nationale pour la Recherche Cardiovasculaire Obesite et Diabete 2005. X. I. was supported by a grant from the Societe Francaise d'Hypertension Arterielle. R. G. was supported by a grant from the Ile de France Domaine d'Interet Majeur-Maladies Cardiovasculaires, Diabete et Obesite. The authors declare no competing financial interests.	Ashley EA, 2005, CARDIOVASC RES, V65, P73, DOI 10.1016/j.cardiores.2004.08.018; Azizi M, 2008, J AM SOC NEPHROL, V19, P1015, DOI 10.1681/ASN.2007070816; BASCANDS JL, 1993, MOL PHARMACOL, V44, P818; Berry MF, 2004, CIRCULATION, V110, pII187, DOI 10.1161/01.CIR.0000138382.57325.5c; Bonnet D, 2006, BIOCONJUGATE CHEM, V17, P1618, DOI 10.1021/bc060140j; Brailoiu GC, 2002, NEUROSCI LETT, V327, P193, DOI 10.1016/S0304-3940(02)00411-1; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; CORTES CL, 2008, Patent No. 1903052; De Mota N, 2000, NEUROENDOCRINOLOGY, V72, P400, DOI 10.1159/000054609; De Mota N, 2004, P NATL ACAD SCI USA, V101, P10464, DOI 10.1073/pnas.0403518101; Drake MT, 2008, J BIOL CHEM, V283, P5669, DOI 10.1074/jbc.M708118200; Edinger AL, 1998, J VIROL, V72, P7934, DOI 10.1128/JVI.72.10.7934-7940.1998; Evans NA, 2001, J NEUROCHEM, V77, P476, DOI 10.1046/j.1471-4159.2001.00269.x; Fan XJ, 2003, BIOCHEMISTRY-US, V42, P10163, DOI 10.1021/bi030049s; Galandrin S, 2006, MOL PHARMACOL, V70, P1575, DOI 10.1124/mol.106.026716; GALZI JL, 2003, Patent No. 2003107004; GALZI JL, 1998, Patent No. 199855873; Habata Y, 1999, BBA-MOL CELL RES, V1452, P25, DOI 10.1016/S0167-4889(99)00114-7; Hibert M., 2006, Patent, Patent No. [WO 2006003329 A1, 2006003329]; HIBERT M, 2006, Patent No. 2006003330; Hus-Citharel A, 2008, KIDNEY INT, V74, P486, DOI 10.1038/ki.2008.199; Ilien B, 2003, J NEUROCHEM, V85, P768, DOI 10.1046/j.1471-4159.2003.01717.x; Ishida J, 2004, J BIOL CHEM, V279, P26274, DOI 10.1074/jbc.M404149200; Iturrioz X, 2000, BIOCHEMISTRY-US, V39, P3061, DOI 10.1021/bi9925726; Japp AG, 2008, BIOCHEM PHARMACOL, V75, P1882, DOI 10.1016/j.bcp.2007.12.015; Katugampola SD, 2002, CAN J PHYSIOL PHARM, V80, P369, DOI 10.1139/Y02-029; Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9; Kuba K, 2007, CIRC RES, V101, pE32, DOI 10.1161/CIRCRESAHA.107.158659; Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x; Lenkei Z, 2000, J HISTOCHEM CYTOCHEM, V48, P1553, DOI 10.1177/002215540004801112; MASRI B, 2004, FASEB J, V22, P22; Medhurst AD, 2003, J NEUROCHEM, V84, P1162, DOI 10.1046/j.1471-4159.2003.01587.x; Messari SE, 2004, J NEUROCHEM, V90, P1290, DOI 10.1111/j.1471-4159.2004.02591.x; Moon MJ, 2007, MOL CELL ENDOCRINOL, V277, P51, DOI 10.1016/j.mce.2007.07.008; O'Carroll AM, 2000, BBA-GENE STRUCT EXPR, V1492, P72, DOI 10.1016/S0167-4781(00)00072-5; O'Carroll AM, 2003, J NEUROENDOCRINOL, V15, P661, DOI 10.1046/j.1365-2826.2003.01044.x; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Puybasset L, 1996, CIRC RES, V79, P343, DOI 10.1161/01.RES.79.2.343; Reaux A, 2001, J NEUROCHEM, V77, P1085, DOI 10.1046/j.1471-4159.2001.00320.x; Reaux A, 2002, NEUROSCIENCE, V113, P653, DOI 10.1016/S0306-4522(02)00192-6; Reaux-Le Goazigo A, 2004, ENDOCRINOLOGY, V145, P4392, DOI 10.1210/en.2004-0384; Salcedo A, 2007, REGUL PEPTIDES, V144, P50, DOI 10.1016/j.regpep.2007.06.005; Scott IC, 2007, DEV CELL, V12, P403, DOI 10.1016/j.devcel.2007.01.012; Shukla AK, 2008, P NATL ACAD SCI USA, V105, P9988, DOI 10.1073/pnas.0804246105; Szokodi I, 2002, CIRC RES, V91, P434, DOI 10.1161/01.RES.0000033522.37861.69; Tatemoto K, 2001, REGUL PEPTIDES, V99, P87, DOI 10.1016/S0167-0115(01)00236-1; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Trochu JN, 1999, BRIT J PHARMACOL, V128, P69, DOI 10.1038/sj.bjp.0702797; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; Vollmer JY, 1999, J BIOL CHEM, V274, P37915, DOI 10.1074/jbc.274.53.37915; Zeng XXI, 2007, DEV CELL, V12, P391, DOI 10.1016/j.devcel.2007.01.011; Zhong JC, 2007, CARDIOVASC RES, V74, P388, DOI 10.1016/j.cardiores.2007.02.002; Zhou NM, 2003, VIROLOGY, V317, P84, DOI 10.1016/j.virol.2003.08.026; Zhou NM, 2003, VIROLOGY, V312, P196, DOI 10.1016/S0042-6822(03)00185-5	54	86	100	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1506	1517		10.1096/fj.09-140715	http://dx.doi.org/10.1096/fj.09-140715			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20040517	Green Submitted			2022-12-28	WOS:000277158900023
J	Yoo, SH				Yoo, Seung Hyun			Secretory granules in inositol 1,4,5-trisphosphate-dependent Ca2+ signaling in the cytoplasm of neuroendocrine cells	FASEB JOURNAL			English	Review						chromogranin A; chromogranin B; IP3 receptor/Ca2+ channel; chromaffin cell	ADRENAL CHROMAFFIN CELLS; INTRALUMINAL LOOP PEPTIDE; PH-DEPENDENT INTERACTION; CHROMOGRANIN-A FRAGMENT; CATECHOLAMINE STORAGE-VESICLES; PANCREATIC ACINAR-CELLS; RIBOSE-MEDIATED RELEASE; RECEPTOR/CA2+ CHANNEL; SECRETOGRANIN-II; ENDOPLASMIC-RETICULUM	Of all the intracellular organelles, secretory granules contain by far the highest calcium concentration; secretory granules of typical neuroendocrine chromaffin cells contain similar to 40 mM Ca2+ and occupy similar to 20% cell volume, accounting for > 60% of total cellular calcium. They also contain the majority of cellular inositol 1,4,5-trisphosphate receptors (IP(3)Rs) in addition to the presence of > 2 mM of chromogranins A and B that function as high-capacity, low-affinity Ca2+ storage proteins. Chromogranins A and B also interact with the IP3Rs and activate the IP3R/Ca2+ channels. In experiments with both neuroendocrine PC12 and nonneuroendocrine NIH3T3 cells, in which the number of secretory granules present was changed by either suppression or induction of secretory granule formation, secretory granules were demonstrated to account for > 70% of the IP3-induced Ca2+ releases in the cytoplasm. Moreover, the IP3 sensitivity of secretory granule IP3R/Ca2+ channels is at least similar to 6- to 7-fold more sensitive than those of the endoplasmic reticulum, thus enabling secretory granules to release Ca2+ ahead of the endoplasmic reticulum. Further, there is a direct correlation between the number of secretory granules and the IP3 sensitivity of cytoplasmic IP3R/Ca2+ channels and the increased ratio of IP3-induced cytoplasmic Ca2+ release, highlighting the importance of secretory granules in the IP3-dependent Ca2+ signaling. Given that secretory granules are present in all secretory cells, these results presage critical roles of secretory granules in the control of cytoplasmic Ca2+ concentrations in other secretory cells.-Yoo, S. H. Secretory granules in inositol 1,4,5-trisphosphate-dependent Ca2+ signaling in the cytoplasm of neuroendocrine cells. FASEB J. 24, 653-664 (2010). www.fasebj.org	Inha Univ, Dept Biochem, Sch Med, Inchon 400712, South Korea	Inha University	Yoo, SH (corresponding author), Inha Univ, Dept Biochem, Sch Med, Inchon 400712, South Korea.	shyoo@inha.ac.kr			U.S. National Institutes of Health; Creative Research Initiative program of the Republic of Korea	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Creative Research Initiative program of the Republic of Korea	The author thanks past collaborators and former and present members of the author's laboratory who have contributed to the development of the topic. Research covered in this review was funded by the U.S. National Institutes of Health in its early stage and by the Creative Research Initiative program of the Republic of Korea in its later stage.	AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Beuret N, 2004, J BIOL CHEM, V279, P20242, DOI 10.1074/jbc.M310613200; BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; Camacho M, 2008, J BIOL CHEM, V283, P22383, DOI 10.1074/jbc.M800552200; Choe CU, 2004, J BIOL CHEM, V279, P35551, DOI 10.1074/jbc.M311261200; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; Csordas G, 2006, J CELL BIOL, V174, P915, DOI 10.1083/jcb.200604016; DANIELS AJ, 1978, NEUROSCIENCE, V3, P573, DOI 10.1016/0306-4522(78)90022-2; Duchen MR, 2008, CELL CALCIUM, V44, P1, DOI 10.1016/j.ceca.2008.02.001; Egger M, 2007, FASEB J, V21, P2906, DOI 10.1096/fj.06-7440com; Fischer-Colbrie R, 2005, CURR PROTEIN PEPT SC, V6, P373, DOI 10.2174/1389203054546334; Foskett JK, 2007, PHYSIOL REV, V87, P593, DOI 10.1152/physrev.00035.2006; Garcia AG, 2006, PHYSIOL REV, V86, P1093, DOI 10.1152/physrev.00039.2005; Gerasimenko JV, 2006, J CELL SCI, V119, P226, DOI 10.1242/jcs.02721; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Gerber SH, 2008, SCIENCE, V321, P1507, DOI 10.1126/science.1163174; Giraudo CG, 2006, SCIENCE, V313, P676, DOI 10.1126/science.1129450; Gregorc V, 2007, CANCER-AM CANCER SOC, V110, P845, DOI 10.1002/cncr.22856; HAIGH JR, 1989, BIOCHEM J, V259, P485, DOI 10.1042/bj2590485; Haynes CL, 2006, BIOPHYS CHEM, V123, P20, DOI 10.1016/j.bpc.2006.04.005; Heidrich FM, 2008, CIRC RES, V102, P1230, DOI 10.1161/CIRCRESAHA.107.166033; Helle KB, 2000, ADV EXP MED BIOL, V482, P3; Huh YH, 2007, BIOCHEMISTRY-US, V46, P14032, DOI 10.1021/bi701364p; Huh YH, 2006, BIOCHEMISTRY-US, V45, P1362, DOI 10.1021/bi051837f; Huh YH, 2006, BIOCHEMISTRY-US, V45, P1212, DOI 10.1021/bi051594r; Huh YH, 2005, FEBS LETT, V579, P5145, DOI 10.1016/j.febslet.2005.08.025; Huh YH, 2005, FEBS LETT, V579, P2597, DOI 10.1016/j.febslet.2005.03.076; Huh YH, 2005, BIOCHEMISTRY-US, V44, P6122, DOI 10.1021/bi048070w; Huh YH, 2003, FEBS LETT, V555, P411, DOI 10.1016/S0014-5793(03)01273-0; Huh YH, 2003, J BIOL CHEM, V278, P40581, DOI 10.1074/jbc.M304942200; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; Jacob SN, 2005, J NEUROSCI, V25, P2853, DOI 10.1523/JNEUROSCI.4313-04.2005; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; KIRCHMAIR R, 1993, NEUROSCIENCE, V53, P359, DOI 10.1016/0306-4522(93)90200-Y; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Mahapatra NR, 2004, J BIOL CHEM, V279, P51107, DOI 10.1074/jbc.M408742200; Mahata SK, 2004, MOL PHARMACOL, V66, P1180, DOI 10.1124/mol.104.002139; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; Martens S, 2007, SCIENCE, V316, P1205, DOI 10.1126/science.1142614; MARUYAMA Y, 1994, CELL CALCIUM, V16, P419, DOI 10.1016/0143-4160(94)90035-3; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Menteyne A, 2006, CURR BIOL, V16, P1931, DOI 10.1016/j.cub.2006.07.070; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; Montero-Hadjadje M, 2008, ACTA PHYSIOL, V192, P309, DOI 10.1111/j.1748-1716.2007.01806.x; Montesinos MS, 2008, J NEUROSCI, V28, P3350, DOI 10.1523/JNEUROSCI.5292-07.2008; Mundorf ML, 2000, J BIOL CHEM, V275, P9136, DOI 10.1074/jbc.275.13.9136; Nguyen T, 1998, NATURE, V395, P908, DOI 10.1038/27686; NORDMANN JJ, 1984, J NEUROCHEM, V42, P434, DOI 10.1111/j.1471-4159.1984.tb02696.x; O'Connor DT, 2008, CIRCULATION, V118, P247, DOI 10.1161/CIRCULATIONAHA.107.709105; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; Petersen OH, 2008, ANNU REV PHYSIOL, V70, P273, DOI 10.1146/annurev.physiol.70.113006.100618; PHILLIPS JH, 1982, NEUROSCIENCE, V7, P1595, DOI 10.1016/0306-4522(82)90017-3; Plattner H, 1997, J CELL BIOL, V139, P1709, DOI 10.1083/jcb.139.7.1709; Prasad P, 2008, J IMMUNOL, V181, P5024, DOI 10.4049/jimmunol.181.7.5024; Quesada I, 2003, BIOPHYS J, V85, P963, DOI 10.1016/S0006-3495(03)74535-4; Quesada I, 2001, BIOPHYS J, V80, P2133, DOI 10.1016/S0006-3495(01)76186-3; Ravazzola M, 1996, P NATL ACAD SCI USA, V93, P2745, DOI 10.1073/pnas.93.7.2745; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Saegusa C, 2002, J BIOL CHEM, V277, P24499, DOI 10.1074/jbc.M202767200; SantoDomingo J, 2008, EUR J NEUROSCI, V28, P1265, DOI 10.1111/j.1460-9568.2008.06440.x; Scheenen WJJM, 1998, J BIOL CHEM, V273, P19002, DOI 10.1074/jbc.273.30.19002; Schrott-Fischer A, 2009, REGUL PEPTIDES, V152, P13, DOI 10.1016/j.regpep.2008.07.009; SPAT A, 1986, NATURE, V319, P514, DOI 10.1038/319514a0; Srivastava M, 1999, P NATL ACAD SCI USA, V96, P13783, DOI 10.1073/pnas.96.24.13783; Stridsberg M, 2008, REGUL PEPTIDES, V148, P95, DOI 10.1016/j.regpep.2008.03.007; TAGAYA M, 1995, J BIOL CHEM, V270, P15930, DOI 10.1074/jbc.270.27.15930; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Taupenot L, 2003, NEW ENGL J MED, V348, P1134, DOI 10.1056/NEJMra021405; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; Thrower EC, 2003, J BIOL CHEM, V278, P49699, DOI 10.1074/jbc.M309307200; Thrower EC, 2002, J BIOL CHEM, V277, P15801, DOI 10.1074/jbc.M110139200; Tota B, 2003, REGUL PEPTIDES, V114, P123, DOI 10.1016/S0167-0115(03)00112-5; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Wiederkehr A, 2008, CELL CALCIUM, V44, P64, DOI 10.1016/j.ceca.2007.11.004; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; Xie L, 2006, TRAFFIC, V7, P429, DOI 10.1111/j.1600-0854.2006.00401.x; Yoo SH, 2007, BIOCHEMISTRY-US, V46, P14663, DOI 10.1021/bi701339m; YOO SH, 1995, BIOCHEMISTRY-US, V34, P8680, DOI 10.1021/bi00027a017; Yoo SH, 2000, J BIOL CHEM, V275, P12553, DOI 10.1074/jbc.275.17.12553; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1990, BIOCHIM BIOPHYS ACTA, V1040, P66, DOI 10.1016/0167-4838(90)90146-7; YOO SH, 1994, J BIOL CHEM, V269, P12001; Yoo SH, 2005, BIOCHEMISTRY-US, V44, P9246, DOI 10.1021/bi047427t; Yoo SH, 2005, FEBS LETT, V579, P222, DOI 10.1016/j.febslet.2004.11.079; Yoo SH, 1996, J BIOL CHEM, V271, P17041, DOI 10.1074/jbc.271.29.17041; Yoo SH, 2001, J BIOL CHEM, V276, P45806, DOI 10.1074/jbc.M107532200; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1990, J BIOL CHEM, V265, P13446; YOO SH, 1994, FEBS LETT, V341, P28, DOI 10.1016/0014-5793(94)80234-3; Yoo SH, 2000, J BIOL CHEM, V275, P15067, DOI 10.1074/jbc.M909391199; Yoo SH, 2000, TRENDS NEUROSCI, V23, P424, DOI 10.1016/S0166-2236(00)01621-0; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023; Yoo SH, 1998, FEBS LETT, V427, P55, DOI 10.1016/S0014-5793(98)00393-7; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030; Yoo SH, 2000, J BIOL CHEM, V275, P30293, DOI 10.1074/jbc.M001204200; Yule DI, 1997, J BIOL CHEM, V272, P9093; Zhang KX, 2006, DIABETES OBES METAB, V8, P621, DOI 10.1111/j.1463-1326.2006.00575.x	110	40	40	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2010	24	3					653	664		10.1096/fj.09-132456	http://dx.doi.org/10.1096/fj.09-132456			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19837865	Green Published			2022-12-28	WOS:000274974600002
J	Bonde, S; Pedram, M; Stultz, R; Zavazava, N				Bonde, Sabrina; Pedram, Mehrdad; Stultz, Ryan; Zavazava, Nicholas			Cell fusion of bone marrow cells and somatic cell reprogramming by embryonic stem cells	FASEB JOURNAL			English	Article						cre/loxP; transdifferentiation; lacZ; beta-gal	ACUTE MYOCARDIAL-INFARCTION; IN-VIVO; PROGENITOR CELLS; EXPRESSION; TRANSPLANTATION; CARDIOMYOCYTES; HEPATOCYTES; ENGRAFTMENT; TOLERANCE; PHENOTYPE	Bone marrow transplantation is a curative treatment for many diseases, including leukemia, autoimmune diseases, and a number of immunodeficiencies. Recently, it was claimed that bone marrow cells transdifferentiate, a much desired property as bone marrow cells are abundant and therefore could be used in regenerative medicine to treat incurable chronic diseases. Using a Cre/loxP system, we studied cell fusion after bone marrow transplantation. Fused cells were chiefly Gr-1(+), a myeloid cell marker, and found predominantly in the bone marrow; in parenchymal tissues. Surprisingly, fused cells were most abundant in the kidney, Peyer's patches, and cardiac tissue. In contrast, after cell fusion with embryonic stem cells, bone marrow cells were reprogrammed into new tetraploid pluripotent stem cells that successfully differentiated into beating cardiomyocytes. Together, these data suggest that cell fusion is ubiquitous after cellular transplants and that the subsequent sharing of genetic material between the fusion partners affects cellular survival and function. Fusion between tumor cells and bone marrow cells could have consequences for tumor malignancy.-Bonde, S., Pedram, M., Stultz, R., Zavazava, N. Cell fusion of bone marrow cells and somatic cell reprogramming by embryonic stem cells. FASEB J. 24, 364-373 (2010). www.fasebj.org	[Bonde, Sabrina; Pedram, Mehrdad; Stultz, Ryan; Zavazava, Nicholas] Univ Iowa, Dept Vet Affairs Med Ctr, Iowa City, IA 52242 USA; [Stultz, Ryan] Univ Iowa, Iowa Biosci Advantage Program, Iowa City, IA 52242 USA; [Pedram, Mehrdad] Univ Tehran Med Sci, Dept Med Genet, Tehran, Iran; [Zavazava, Nicholas] Univ Iowa, Grad Program Immunol, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; Tehran University of Medical Sciences; University of Iowa	Zavazava, N (corresponding author), Univ Iowa, Dept Vet Affairs Med Ctr, 200 Hawkins Dr,C51-F, Iowa City, IA 52242 USA.	nicholas-zavazava@uiowa.edu	Pedram, Mehrdad/L-4072-2016	Pedram, Mehrdad/0000-0002-7348-3475	VA Merit Review award; National Institutes of Health/National Heart Lung and Blood Institute [R01 HLO73015]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073015] Funding Source: NIH RePORTER	VA Merit Review award(US Department of Veterans Affairs); National Institutes of Health/National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was made possible by a VA Merit Review award and by National Institutes of Health/National Heart Lung and Blood Institute grant R01 HLO73015. We thank the University of Iowa Gene Transfer Vector Core for providing the FIV vectors and Chantal Allamargot (University of Iowa Central Microscopy Research Facility) for technical assistance. We thank John Engelhardt (Department of Anatomy and Cell Biology, University of Iowa) for useful discussions.	Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Arai A, 1997, DEV DYNAM, V210, P344, DOI 10.1002/(SICI)1097-0177(199711)210:3<344::AID-AJA13>3.0.CO;2-A; Assmus B, 2006, NEW ENGL J MED, V355, P1222, DOI 10.1056/NEJMoa051779; Bailey AS, 2006, P NATL ACAD SCI USA, V103, P13156, DOI 10.1073/pnas.0604203103; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Bonde S, 2006, STEM CELLS, V24, P2192, DOI 10.1634/stemcells.2006-0022; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Fazel S, 2006, J CLIN INVEST, V116, P1865, DOI 10.1172/JCI27019; Hofmann M, 2005, CIRCULATION, V111, P2198, DOI 10.1161/01.CIR.0000163546.27639.AA; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kucia M, 2006, LEUKEMIA, V20, P857, DOI 10.1038/sj.leu.2404171; Kurtz J, 2004, BLOOD, V103, P4336, DOI 10.1182/blood-2003-08-2642; Laugwitz KL, 2005, NATURE, V433, P647, DOI 10.1038/nature03215; Lunde K, 2006, NEW ENGL J MED, V355, P1199, DOI 10.1056/NEJMoa055706; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schachinger V, 2006, NEW ENGL J MED, V355, P1210, DOI 10.1056/NEJMoa060186; Stein CS, 2001, MOL THER, V3, P850, DOI 10.1006/mthe.2001.0325; Strizzi Luigi, 2008, Breast Dis, V29, P91; Sykes M, 2001, IMMUNITY, V14, P417, DOI 10.1016/S1074-7613(01)00122-4; Takei S, 2005, CELL TRANSPLANT, V14, P701, DOI 10.3727/000000005783982693; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Terashima T, 2005, P NATL ACAD SCI USA, V102, P12525, DOI 10.1073/pnas.0505717102; Vallier L, 2009, STEM CELLS, V27, P2655, DOI 10.1002/stem.199; Vallier L, 2009, DEVELOPMENT, V136, P1339, DOI 10.1242/dev.033951; Ventura C, 2004, J BIOL CHEM, V279, P23574, DOI 10.1074/jbc.M401869200; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; WEKERLE T, 1999, NAT MED, V6, P464; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	35	16	16	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					364	373		10.1096/fj.09-137141	http://dx.doi.org/10.1096/fj.09-137141			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19762558	Green Published			2022-12-28	WOS:000274045000005
J	Jung, SK; Jeong, DG; Chung, SJ; Kim, JH; Park, BC; Tonks, NK; Ryu, SE; Kim, SJ				Jung, Suk-Kyeong; Jeong, Dae Gwin; Chung, Sang J.; Kim, Jae Hoon; Park, Byoung Chul; Tonks, Nicholas K.; Ryu, Seong Eon; Kim, Seung Jun			Crystal structure of ED-Eya2: insight into dual roles as a protein tyrosine phosphatase and a transcription factor	FASEB JOURNAL			English	Article						branchio-oto-renal syndrome; eyes absent phosphatase; halo-acid dehalogenase	EYES-ABSENT GENE; BRANCHIOOTORENAL SYNDROME; PHOSPHOSERINE PHOSPHATASE; HUMAN HOMOLOG; DROSOPHILA; MUTATIONS; EYA; COMPLEX; BOR; DEPHOSPHORYLATION	Eya proteins are transcription factors that play pivotal roles in organ formation during development by mediating interactions between Sine Oculis (SO) and Dachshund (DAC). Remarkably, the transcriptional activity of Eya proteins is regulated by a dephosphorylating activity within its Eya domain (ED). However, the molecular basis for the link between catalytic and transcriptional activities remains unclear. Here we report the first description of the crystal structure of the ED of human Eya2 (ED-Eya2), determined at 2.4-angstrom resolution. In stark contrast to other members of the haloacid dehalogenase (HAD) family to which ED-Eya2 belongs, the helix-bundle motif (HBM) is elongated along the back of the catalytic site. This not only results in a structure that accommodates large protein substrates but also positions the catalytic and the SO-interacting sites on opposite faces, which suggests that SO binding is not directly affected by catalytic function. Based on the observation that the DAC-binding site is located between the catalytic core and SO binding sites within ED-Eya2, we propose that catalytic activity can be translated to SO binding through DAC, which acts as a transcriptional switch. We also captured at two stages of reaction cycles-acyl-phosphate intermediate and transition state of hydrolysis step, which provided a detailed view of reaction mechanism. The ED-Eya2 structure defined here serves as a model for other members of the Eya family and provides a framework for understanding the role of Eya phosphatase mutations in disease.-Jung, S.-K., Jeong, D. G., Chung, S. J., Kim, J. H., Park, B. C., Tonks, N. K., Ryu, S. E., Kim, S. J.. Crystal structure of ED-Eya2: insight into dual roles as a protein tyrosine phosphatase and a transcription factor. FASEB J. 24, 560-569 (2010). www.fasebj.org	[Jung, Suk-Kyeong; Jeong, Dae Gwin; Park, Byoung Chul; Kim, Seung Jun] Korea Res Inst Biosci & Biotechnol, Med Prote Res Ctr, Taejon 305600, South Korea; [Chung, Sang J.] Korea Res Inst Biosci & Biotechnol, BioNanotechnol Res Ctr, Taejon 305600, South Korea; [Kim, Jae Hoon; Ryu, Seong Eon] Korea Res Inst Biosci & Biotechnol, System Prote Res Ctr, Taejon 305600, South Korea; [Kim, Jae Hoon] Jeju Natl Univ, Coll Appl Life Sci, Fac Biotechnol, Cheju, South Korea; [Tonks, Nicholas K.; Kim, Seung Jun] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Ryu, Seong Eon] Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Jeju National University; Cold Spring Harbor Laboratory; Hanyang University	Kim, SJ (corresponding author), Korea Res Inst Biosci & Biotechnol, Med Prote Res Ctr, 52 Eoeun Dong, Taejon 305600, South Korea.	ryuse@hanyang.ac.kr; ksj@kribb.re.kr	Kim, Seung Jun/N-5248-2019	Kim, Seung Jun/0000-0002-6913-6358	Korea Research Institute of Bioscience and Biotechnology Research Initiative Program	Korea Research Institute of Bioscience and Biotechnology Research Initiative Program	The authors thank the staff of Pohang Accelerator Laboratory 4A Macromolecular Crystallography Wiggler Beamline (Pohang, Korea) and SPring8 BL38B1 (Hyogo, Japan) for their help with data collection. This research was supported by a grant from the Korea Research Institute of Bioscience and Biotechnology Research Initiative Program.	Abdelhak S, 1997, NAT GENET, V15, P157, DOI 10.1038/ng0297-157; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Azuma N, 2000, HUM MOL GENET, V9, P363, DOI 10.1093/hmg/9.3.363; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bui QT, 2000, GENETICS, V155, P709; Burroughs AM, 2006, J MOL BIOL, V361, P1003, DOI 10.1016/j.jmb.2006.06.049; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; Epstein JA, 2003, NATURE, V426, P238, DOI 10.1038/426238a; Ghosh A, 2008, MOL CELL, V32, P478, DOI 10.1016/j.molcel.2008.09.021; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ikeda K, 2002, MOL CELL BIOL, V22, P6759, DOI 10.1128/MCB.22.19.6759-6766.2002; JEMC J, 2007, ANN REV BIOCH, V76; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krishnan N, 2009, J BIOL CHEM, V284, P16066, DOI 10.1074/jbc.C900032200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Lu ZB, 2005, BIOCHEMISTRY-US, V44, P8684, DOI 10.1021/bi050009j; Migliosi V, 2004, CLIN GENET, V66, P478, DOI 10.1111/j.1399-0004.2004.00318.x; Mutsuddi M, 2005, GENETICS, V170, P687, DOI 10.1534/genetics.104.039156; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ozaki H, 2002, J HUM GENET, V47, P107, DOI 10.1007/s100380200011; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Rayapureddi JP, 2006, FEBS LETT, V580, P3853, DOI 10.1016/j.febslet.2006.06.009; Rayapureddi JP, 2005, BIOCHEMISTRY-US, V44, P751, DOI 10.1021/bi0481794; Rayapureddi JP, 2003, NATURE, V426, P295, DOI 10.1038/nature02093; Rebay I, 2005, TRENDS GENET, V21, P163, DOI 10.1016/j.tig.2005.01.005; Ridder IS, 1999, J BIOL CHEM, V274, P30672, DOI 10.1074/jbc.274.43.30672; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; Vincent C, 1997, EUR J HUM GENET, V5, P242, DOI 10.1159/000484770; Wang H, 2005, J MOL BIOL, V348, P917, DOI 10.1016/j.jmb.2005.01.072; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3; Yin SY, 2007, NAT METHODS, V4, P466, DOI 10.1038/nmeth0607-466; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616	43	34	39	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					560	569		10.1096/fj.09-143891	http://dx.doi.org/10.1096/fj.09-143891			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19858093	Green Accepted, Green Published			2022-12-28	WOS:000274045000023
J	Zhang, SM; Sun, Y; Fan, R; Xu, QZ; Liu, XD; Zhang, XM; Wang, Y; Zhou, PK				Zhang, Shi-Meng; Sun, Yi; Fan, Rong; Xu, Qin-Zhi; Liu, Xiao-Dan; Zhang, Xiangming; Wang, Ya; Zhou, Ping-Kun			HIV-1 Tat regulates cyclin B1 by promoting both expression and degradation	FASEB JOURNAL			English	Article						apoptosis; ubiquitination	HUMAN-IMMUNODEFICIENCY-VIRUS; KINASE ACTIVATION; INDUCED APOPTOSIS; INFECTED PATIENTS; PROSTATE-CANCER; T-CELLS; PROTEIN; GENE; TYPE-1; LYMPHOCYTES	Cyclin B1, an important cell cycle regulator, was up-regulated in lymphocytes of human immunodeficiency virus (HIV)-infected patients. However, the mechanism of cyclin B1 up-regulation and the effects of the up-regulation on the host cells remain unclear. Here, we show that HIV-encoded Tat protein regulates cyclin B1 levels in two different ways: first, Tat stimulates the transcription of cyclin B1, which increases cyclin B1 levels and promotes the cells apoptosis; and second, Tat stimulates polyubiquitination-mediated degradation of cyclin B1 through binding to the N-terminal of cyclin B1 (aa 61-129) that is just downstream of the D box, which prevents excessive levels of cyclin B1 in the cells. These results suggest that Tat-regulating cyclin B1 affects the status of HIV: Tat stimulates cyclin B1 expression to slow down the host cell cycle progress and to promote the host cell apoptosis, which might facilitate HIV release; Tat stimulates cyclin B1 degradation to prevent overaccumulation of cyclin B1, which might facilitate HIV replication. Taken together, our results reveal for the first time how HIV-Tat regulates cyclin B1 and keeps its balance in the cells.-Zhang, S.-M., Sun, Y., Fan, R., Xu, Q.-Z., Liu, X.-D., Zhang, X., Wang, Y., Zhou, P.-K. HIV-1 Tat regulates cyclin B1 by promoting both expression and degradation. FASEB J. 24, 495-503 (2010). www.fasebj.org	[Zhang, Shi-Meng; Sun, Yi; Fan, Rong; Xu, Qin-Zhi; Liu, Xiao-Dan; Zhou, Ping-Kun] Beijing Inst Radiat Med, Dept Radiat Toxicol & Oncol, Beijing, Peoples R China; [Zhang, Shi-Meng; Zhang, Xiangming; Wang, Ya] Emory Univ, Sch Med, Dept Radiat Oncol, Winship Canc Inst, Atlanta, GA USA	Academy of Military Medical Sciences - China; Emory University	Wang, Y (corresponding author), 1365 Clifton Rd,C5090, Atlanta, GA 30322 USA.	yawang@radonc.emory.org; zhoupk@nic.bmi.ac.cn	Zhou, Ping-Kun/GSJ-3972-2022; Zhou, Ping-Kun/AAF-3536-2019	Zhou, Ping-Kun/0000-0001-7666-1209; 	National BioResource Project (NBRP), Ministry of Science and Technology (MOST), 973 Program [2007CB914603]; China National Natural Science Foundation (CNNSF) [30500267, 30400120]; Outstanding Youth Science Foundation, Natural Science Foundation of China (NFSC) [30825011]; International Atomic Energy Agency Coordinated Research [E3.30.22, 12510/R4]; United States (National Institutes of Health) [G-M080771]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER	National BioResource Project (NBRP), Ministry of Science and Technology (MOST), 973 Program(National Basic Research Program of ChinaMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); China National Natural Science Foundation (CNNSF)(National Natural Science Foundation of China (NSFC)); Outstanding Youth Science Foundation, Natural Science Foundation of China (NFSC)(National Natural Science Foundation of China (NSFC)); International Atomic Energy Agency Coordinated Research; United States (National Institutes of Health)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The authors thank Dr. Lung-Ji Chang (University of Florida, Gainesville, FL, USA), Junjie Qian (Beijing Insitute of Radiation Medicine, Beijing, China), Hui Zhang (Thomas Jefferson University, Philadelphia, PA, USA) and Karen S. Katula (University of North Carolina, Chapel Hill, NC, USA) for providing reagents. This work was supported by grants from China [National BioResource Project (NBRP), Ministry of Science and Technology (MOST), 973 Program 2007CB914603; China National Natural Science Foundation (CNNSF), grants 30500267 and 30400120; Outstanding Youth Science Foundation, Natural Science Foundation of China (NFSC), grant 30825011; International Atomic Energy Agency Coordinated Research Project E3.30.22, grant 12510/R4) and from the United States (National Institutes of Health, grant G-M080771).	Ambrosino C, 1997, J BIOL CHEM, V272, P14883, DOI 10.1074/jbc.272.23.14883; Apcher GS, 2003, FEBS LETT, V553, P200, DOI 10.1016/S0014-5793(03)01025-1; Badou A, 2000, J VIROL, V74, P10551, DOI 10.1128/JVI.74.22.10551-10562.2000; Bartz SR, 1999, J VIROL, V73, P1956, DOI 10.1128/JVI.73.3.1956-1963.1999; Borgne A, 2006, ONCOGENE, V25, P7361, DOI 10.1038/sj.onc.1209718; Cannavo G, 2001, BLOOD, V97, P1756, DOI 10.1182/blood.V97.6.1756; Cheng N, 2002, MOL CANCER RES, V1, P2; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Col E, 2005, EMBO J, V24, P2634, DOI 10.1038/sj.emboj.7600734; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; Ehret A, 2001, EUR J IMMUNOL, V31, P1790, DOI 10.1002/1521-4141(200106)31:6<1790::AID-IMMU1790>3.0.CO;2-G; Epie N, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-6; Galati D, 2003, J INFECT DIS, V188, P1483, DOI 10.1086/379249; Gavioli R, 2004, J IMMUNOL, V173, P3838, DOI 10.4049/jimmunol.173.6.3838; Gomez LA, 2007, MOL CANCER THER, V6, P1534, DOI 10.1158/1535-7163.MCT-06-0727; Gougeon ML, 2003, NAT REV IMMUNOL, V3, P392, DOI 10.1038/nri1087; Herbert M, 2003, NAT CELL BIOL, V5, P1023, DOI 10.1038/ncb1062; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; Huang XH, 2002, J MOL BIOL, V323, P771, DOI 10.1016/S0022-2836(02)00998-1; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Kawamoto H, 1997, AM J PATHOL, V150, P15; Kirkpatrick DS, 2006, NAT CELL BIOL, V8, P700, DOI 10.1038/ncb1436; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; Lindqvist A, 2007, PLOS BIOL, V5, P1127, DOI 10.1371/journal.pbio.0050123; Loregian A, 2003, FEBS LETT, V543, P61, DOI 10.1016/S0014-5793(03)00399-5; Macho A, 1999, ONCOGENE, V18, P7543, DOI 10.1038/sj.onc.1203095; Mahieux R, 2001, J VIROL, V75, P1736, DOI 10.1128/JVI.75.4.1736-1743.2001; Mashal RD, 1996, CANCER RES, V56, P4159; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Paiardini M, 2004, AIDS, V18, P393, DOI 10.1097/00002030-200402200-00004; Piedimonte G, 1999, AIDS, V13, P1159, DOI 10.1097/00002030-199907090-00003; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Porter LA, 2003, BLOOD, V101, P1928, DOI 10.1182/blood-2002-04-1103; Porter LA, 2000, BLOOD, V95, P2645; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; Sastry KJ, 1996, ONCOGENE, V13, P487; Seeger M, 1997, J BIOL CHEM, V272, P8145, DOI 10.1074/jbc.272.13.8145; Sun Y, 2006, INT J RADIAT ONCOL, V65, P842, DOI 10.1016/j.ijrobp.2006.02.040; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Zhang MJ, 2001, J BIOMED SCI, V8, P290, DOI 10.1159/000054045	42	12	12	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					495	503		10.1096/fj.09-143925	http://dx.doi.org/10.1096/fj.09-143925			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19825974	Green Published			2022-12-28	WOS:000274045000017
J	Lombardi, A; Bursomanno, S; Lopardo, T; Traini, R; Colombatti, M; Ippoliti, R; Flavell, DJ; Flavell, SU; Ceriotti, A; Fabbrini, MS				Lombardi, Alessio; Bursomanno, Sara; Lopardo, Teresa; Traini, Roberta; Colombatti, Marco; Ippoliti, Rodolfo; Flavell, David J.; Flavell, Sopsamorn U.; Ceriotti, Aldo; Fabbrini, Maria Serena			Pichia pastoris as a host for secretion of toxic saporin chimeras	FASEB JOURNAL			English	Article						plant ribosome-inactivating proteins; eukaryotic expression; codon usage; tumor-targeted therapy; human urokinase receptor	RIBOSOME-INACTIVATING PROTEINS; T-CELL IMMUNOTOXIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; AMINO-TERMINAL FRAGMENT; SAPONARIA-OFFICINALIS; EXPRESSION; ANTIBODY; INTERNALIZATION; RICIN; GENE	Most of the targeting moieties, such as antibody fragments or growth factor domains, used to construct targeted toxins for anticancer therapy derive from secretory proteins. These normally fold in the oxidative environment of the endoplasmic reticulum, and hence their folding in bacterial cells can be quite inefficient. For instance, only low amounts of properly folded antimetastatic chimera constituted by the amino-terminal fragment of human urokinase (ATF) fused to the plant ribosome-inactivating protein saporin could be recovered. ATF-saporin was instead secreted efficiently when expressed in eukaryotic cells protected from autointoxication with neutralizing anti-saporin antibodies. Pichia pastoris is a microbial eukaryotic host where these domains can fold into a transport-competent conformation and reach the extracellular medium. We show here that despite some host toxicity codon-usage optimization greatly increased the expression levels of active saporin but not those of an active-site mutant SAP-KQ in GS115 (his4) strain. The lack of any toxicity associated with expression of the latter confirmed that toxicity is due to saporin catalytic activity. Nevertheless, GS115 (his4) cells in flask culture secreted 3.5 mg/L of a histidine-tagged ATF-saporin chimera showing an IC50 of 6 x 10(-11) M against U937 cells, thus demonstrating the suitability of this expression platform for secretion of toxic saporin-based chimeras.-Lombardi, A., Bursomanno, S., Lopardo, T., Traini, R., Colombatti, M., Ippoliti, R., Flavell, D. J., Flavell, S. U., Ceriotti, A., Fabbrini, M. S. Pichia pastoris as a host for secretion of toxic saporin chimeras. FASEB J. 24, 253-265 (2010). www.fasebj.org	[Lombardi, Alessio; Bursomanno, Sara; Lopardo, Teresa; Traini, Roberta; Ceriotti, Aldo; Fabbrini, Maria Serena] CNR, IBBA, I-20133 Milan, Italy; [Colombatti, Marco] Univ Verona, Policlin GB Rossi, I-37100 Verona, Italy; [Ippoliti, Rodolfo] Univ Aquila, I-67100 Laquila, Italy; [Flavell, David J.; Flavell, Sopsamorn U.] Leukaemia Busters Clin Trials Support Unit, Southampton, Hants, England; [Flavell, David J.; Flavell, Sopsamorn U.] Southampton Gen Hosp, Simon Flavell Leukaemia Res Lab, Southampton SO9 4XY, Hants, England	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Biotecnologia Agraria (IBBA-CNR); University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of L'Aquila; University of Southampton	Fabbrini, MS (corresponding author), CNR, IBBA, Via Bassini 15, I-20133 Milan, Italy.	fabbrini@ibba.cnr.it	Ceriotti, Aldo/A-1448-2016; Flavell, David/AAQ-1916-2020; IPPOLITI, RODOLFO/C-3677-2011	Ceriotti, Aldo/0000-0002-8230-8863; IPPOLITI, RODOLFO/0000-0003-0652-3470	Leukaemia Busters; Ingenio (Regione Lombardia); Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Leukaemia Busters; Ingenio (Regione Lombardia)(Regione Lombardia); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Leukaemia Busters (www. leukaemiabusters.org.uk) as part of the Recombinant Immunotoxin Study Group coordinated by D.J.F. S. B. had a fellowship supported by Ingenio (Regione Lombardia). We thank Alessandro Pini (University of Siena, Siena, Italy) for providing pHEN1-containing scFv alpha PA63, and Pietro Della Cristina (University of Verona, Verona, Italy) and Richard Marshall (University of Warwick, Coventry, UK) for fruitful discussions. Financial contributions by AIRC Regionale Veneto and by Fondazione Cariverona (bando 2007) are gratefully acknowledged.	AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; Ass K, 2008, CANCER TREAT REV, V34, P122, DOI 10.1016/j.ctrv.2007.10.005; BENATTI L, 1989, EUR J BIOCHEM, V183, P465, DOI 10.1111/j.1432-1033.1989.tb14951.x; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; Cereghino JL, 2000, FEMS MICROBIOL REV, V24, P45, DOI 10.1111/j.1574-6976.2000.tb00532.x; CREGG JM, 1989, MOL CELL BIOL, V9, P1316, DOI 10.1128/MCB.9.3.1316; Day PJ, 1998, EUR J BIOCHEM, V258, P540, DOI 10.1046/j.1432-1327.1998.2580540.x; Doma MK, 2007, CELL, V131, P660, DOI 10.1016/j.cell.2007.10.041; Doma MK, 2006, NATURE, V440, P561, DOI 10.1038/nature04530; Emberson LM, 2005, J IMMUNOL METHODS, V305, P135, DOI 10.1016/j.jim.2005.04.005; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Fabbrini MS, 1997, FASEB J, V11, P1169, DOI 10.1096/fasebj.11.13.9367352; Fabbrini MS, 1997, BIOCHEM J, V322, P719, DOI 10.1042/bj3220719; Fabbrini MS, 2000, FASEB J, V14, P391, DOI 10.1096/fasebj.14.2.391; Flavell DJ, 2001, BRIT J CANCER, V84, P571, DOI 10.1054/bjoc.2000.1633; Flavell DJ, 1998, CANCER RES, V58, P5787; Frankel AE, 2000, CLIN CANCER RES, V6, P326; Ghosh P, 2006, BIOCHEM J, V400, P99, DOI 10.1042/BJ20060895; Gurkan C, 2005, MICROB CELL FACT, V4, P1, DOI 10.1186/1475-2859-4-33; Haraguchi Y, 2008, PLANT CELL PHYSIOL, V49, P314, DOI 10.1093/pcp/pcn005; Hartley MR, 2004, BBA-PROTEINS PROTEOM, V1701, P1, DOI 10.1016/j.bbapap.2004.06.004; Hohenblum H, 2004, BIOTECHNOL BIOENG, V85, P367, DOI 10.1002/bit.10904; Hong E, 1996, J CELL BIOL, V135, P623, DOI 10.1083/jcb.135.3.623; Ippoliti R, 2000, FASEB J, V14, P1335, DOI 10.1096/fj.14.10.1335; Liu YY, 2003, PROTEIN EXPRES PURIF, V30, P262, DOI 10.1016/S1046-5928(03)00129-3; Pastan I, 2006, NAT REV CANCER, V6, P559, DOI 10.1038/nrc1891; Peumans WJ, 2001, FASEB J, V15, P1493, DOI 10.1096/fj.00-0751rev; Piazza T, 2005, J CELL SCI, V118, P1515, DOI 10.1242/jcs.02280; Rajamohan F, 2000, PROTEIN EXPRES PURIF, V18, P193, DOI 10.1006/prep.1999.1181; Ramage JG, 2003, LEUKEMIA RES, V27, P79, DOI 10.1016/S0145-2126(02)00077-2; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; Santanche S, 1997, BIOCHEM BIOPH RES CO, V234, P129, DOI 10.1006/bbrc.1997.6597; Savino C, 2000, FEBS LETT, V470, P239, DOI 10.1016/S0014-5793(00)01325-9; Silacci M, 2005, PROTEOMICS, V5, P2340, DOI 10.1002/pmic.200401273; SREEKRISHNA K, 1993, INDUSTRIAL MICROORGANISMS: BASIC AND APPLIED MOLECULAR GENETICS, P119; Tolner B, 2006, NAT PROTOC, V1, P1213, DOI 10.1038/nprot.2006.127; Wang P, 2000, PROTEIN EXPRES PURIF, V20, P179, DOI 10.1006/prep.2000.1310; Woo JH, 2004, APPL ENVIRON MICROB, V70, P3370, DOI 10.1128/AEM.70.6.3370-3376.2004; Woo JH, 2002, PROTEIN EXPRES PURIF, V25, P270, DOI 10.1016/S1046-5928(02)00009-8; Woo JH, 2008, PROTEIN EXPRES PURIF, V58, P1, DOI 10.1016/j.pep.2007.11.006; Wu YH, 2004, J BIOL CHEM, V279, P19264, DOI 10.1074/jbc.M307049200; Yadava A, 2003, INFECT IMMUN, V71, P4961, DOI 10.1128/IAI.71.9.4961-4969.2003; Zarovni N, 2007, CANCER GENE THER, V14, P165, DOI 10.1038/sj.cgt.7700998; Zhao GX, 2006, PROTEIN EXPRES PURIF, V49, P71, DOI 10.1016/j.pep.2006.05.005	44	31	34	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					253	265		10.1096/fj.08-118042	http://dx.doi.org/10.1096/fj.08-118042			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19786581				2022-12-28	WOS:000273233600026
J	Yehuda-Shnaidman, E; Kalderon, B; Azazmeh, N; Bar-Tana, J				Yehuda-Shnaidman, Einav; Kalderon, Bella; Azazmeh, Narmen; Bar-Tana, Jacob			Gating of the mitochondrial permeability transition pore by thyroid hormone	FASEB JOURNAL			English	Article						Bcl2; IP3 receptor; PP2B; calcium; mitochondrial uncoupling; Jurkat; rat liver	INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; INTRACELLULAR CALCIUM MOBILIZATION; HYPOTHYROID RATS RESTORES; CYTOCHROME-C RELEASE; APOPTOTIC CELL-DEATH; ENDOPLASMIC-RETICULUM; PHYSIOLOGICAL SIGNIFICANCE; TRISPHOSPHATE RECEPTOR; LIVER-MITOCHONDRIA; OUTER-MEMBRANE	The calorigenic-thermogenic activity of thyroid hormone (T3) has long been ascribed to uncoupling of mitochondrial oxidative phosphorylation. However, the mode of action of T3 in promoting mitochondrial proton leak is still unresolved. Mitochondrial uncoupling by T3 is reported here to be transduced in vivo in rats and in cultured Jurkat cells by gating of the mitochondrial permeability transition pore (PTP). T3-induced PTP gating is shown here to be abrogated in inositol 1,4,5-trisphosphate (IP3) receptor 1 (IP(3)R1)(-/-) cells, indicating that the endoplasmic reticulum IP(3)R1 may serve as upstream target for the mitochondrial activity of T3. IP(3)R1 gating by T3 is due to its increased expression and truncation into channel-only peptides, resulting in IP3-independent Ca2+ efflux. Increased cytosolic Ca2+ results in activation of protein phosphatase 2B, dephosphorylation and depletion of mitochondrial Bcl2 (S70), and increase in mitochondrial free Bax leading to low-conductance PTP gating. The T3 transduction pathway integrates genomic and nongenomic activities of T3 in regulating mitochondrial energetics and may offer novel targets for thyromimetics designed to modulate energy expenditure.-Yehuda-Shnaidman, E., Kalderon, B., Azazmeh, N., Bar-Tana, J. Gating of the mitochondrial permeability transition pore by thyroid hormone. FASEB J. 24, 93-104 ( 2010). www.fasebj.org	[Yehuda-Shnaidman, Einav; Kalderon, Bella; Azazmeh, Narmen; Bar-Tana, Jacob] Hebrew Univ Jerusalem, Sch Med, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Bar-Tana, J (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel.	bartanaj@cc.huji.ac.il			Israeli Science Foundation	Israeli Science Foundation(Israel Science Foundation)	The kind generosity of Dr. A. R. Marks ( Columbia University, New York, NY, USA; IP3R <SUP>-/-</SUP> Jurkat cells) and Dr. A. Gross (Weizmann Institute of Science, Rehovot, Israel; rabbit anti-rat Bax antibody) is deeply acknowledged. We thank Dr. S. Collins for her support and V. Wong for excellent technical assistance. This work was supported by the Israeli Science Foundation.	Adachi M, 2004, AM J PHYSIOL-GASTR L, V287, pG695, DOI 10.1152/ajpgi.00415.2003; Assefa Z, 2004, J BIOL CHEM, V279, P43227, DOI 10.1074/jbc.M403872200; Belzacq AS, 2003, CANCER RES, V63, P541; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brustovetsky N, 2000, J NEUROSCI, V20, P103, DOI 10.1523/JNEUROSCI.20-01-00103.2000; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; Chavez E, 1998, BBA-MOL BASIS DIS, V1407, P243, DOI 10.1016/S0925-4439(98)00048-9; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 2000, CURR OPIN CELL BIOL, V12, P414, DOI 10.1016/S0955-0674(00)00110-1; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; D'Arezzo S, 2004, ENDOCRINOLOGY, V145, P5694, DOI 10.1210/en.2004-0890; DENG X, 2000, J NATL CANC I MONOGR, V28, P30; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Doran E, 2000, BIOCHEM J, V348, P343, DOI 10.1042/0264-6021:3480343; Erin N, 2003, NEUROSCIENCE, V117, P541, DOI 10.1016/S0306-4522(02)00933-8; EVERTS ME, 1986, AM J PHYSIOL, V251, pE258, DOI 10.1152/ajpendo.1986.251.3.E258; Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Grundler W, 2001, CYTOMETRY, V44, P45, DOI 10.1002/1097-0320(20010501)44:1<45::AID-CYTO1081>3.3.CO;2-P; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hajnoczky G, 2002, CELL CALCIUM, V32, P363, DOI 10.1016/S0143416002001872; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Harper ME, 2008, ANNU REV NUTR, V28, P13, DOI 10.1146/annurev.nutr.28.061807.155357; Harper ME, 2008, THYROID, V18, P145, DOI 10.1089/thy.2007.0250; HARPER ME, 1993, J BIOL CHEM, V268, P14850; Hausenloy D, 2004, CIRCULATION, V109, P1714, DOI 10.1161/01.CIR.0000126294.81407.7D; Hermesh O, 2000, BBA-BIOENERGETICS, V1457, P166, DOI 10.1016/S0005-2728(00)00097-9; HUMMERICH H, 1989, BIOCHEM J, V258, P363, DOI 10.1042/bj2580363; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Ishizuya-Oka A, 2007, DEV DYNAM, V236, P3358, DOI 10.1002/dvdy.21291; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; Jayaraman T, 2000, J BIOL CHEM, V275, P6417, DOI 10.1074/jbc.275.9.6417; Jorns A, 2002, DIABETOLOGIA, V45, P851, DOI 10.1007/s00125-002-0842-5; Joseph SK, 2007, APOPTOSIS, V12, P951, DOI 10.1007/s10495-007-0719-7; KALDERON B, 1995, ENDOCRINOLOGY, V136, P3552, DOI 10.1210/en.136.8.3552; Koshkin V, 2008, J BIOL CHEM, V283, P7936, DOI 10.1074/jbc.M705652200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Mihara S, 1999, J CLIN ENDOCR METAB, V84, P1378, DOI 10.1210/jc.84.4.1378; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Moro L, 2004, ENDOCRINOLOGY, V145, P5121, DOI 10.1210/en.2004-0909; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Novgorodov SA, 1996, J BIOENERG BIOMEMBR, V28, P139, DOI 10.1007/BF02110644; Ozawa T, 2006, INT J MOL MED, V18, P187; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Rolfe DFS, 1997, BIOSCIENCE REP, V17, P9, DOI 10.1023/A:1027327015957; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shi Y, 2003, BIOCHEM BIOPH RES CO, V305, P989, DOI 10.1016/S0006-291X(03)00871-4; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Short KR, 2001, AM J PHYSIOL-ENDOC M, V280, pE761, DOI 10.1152/ajpendo.2001.280.5.E761; Silva JE, 2006, PHYSIOL REV, V86, P435, DOI 10.1152/physrev.00009.2005; Smith MA, 1996, BRAIN RES, V717, P99, DOI 10.1016/0006-8993(95)01473-X; Szewczyk A, 2002, PHARMACOL REV, V54, P101, DOI 10.1124/pr.54.1.101; Szlufcik K, 2006, BIOL CELL, V98, P1, DOI 10.1042/BC20050031; Thrower EC, 2001, TRENDS PHARMACOL SCI, V22, P580, DOI 10.1016/S0165-6147(00)01809-5; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; Upadhyay G, 2004, HEPATOLOGY, V39, P1120, DOI 10.1002/hep.20085; Vacca RA, 2003, ENDOCRINOLOGY, V144, P3783, DOI 10.1210/en.2003-0310; Verbert L, 2008, BIOL CELL, V100, P39, DOI 10.1042/BC20070086; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Wojcikiewicz RJH, 1996, J BIOL CHEM, V271, P16652, DOI 10.1074/jbc.271.28.16652; Yamauchi M, 2008, MOL ENDOCRINOL, V22, P893, DOI 10.1210/me.2007-0249; Yehuda-Shnaidman E, 2005, ENDOCRINOLOGY, V146, P2462, DOI 10.1210/en.2004-1161; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	69	25	25	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					93	104		10.1096/fj.09-133538	http://dx.doi.org/10.1096/fj.09-133538			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19723706				2022-12-28	WOS:000273233600012
J	Miljkovic-Licina, M; Hammel, P; Garrido-Urbani, S; Bradfield, PF; Szepetowski, P; Imhof, BA				Miljkovic-Licina, Marijana; Hammel, Philippe; Garrido-Urbani, Sarah; Bradfield, Paul F.; Szepetowski, Pierre; Imhof, Beat A.			Sushi repeat protein X-linked 2, a novel mediator of angiogenesis	FASEB JOURNAL			English	Article						endothelial remodeling; migration; sprouting; uPAR	ENDOTHELIAL-CELL MIGRATION; ACTIVATOR RECEPTOR UPAR; FOCAL ADHESION KINASE; UROKINASE RECEPTOR; IN-VIVO; SRPX2; MORPHOGENESIS; DISORDERS; INTEGRIN; DISEASE	On appropriate stimuli, quiescent endothelial cells start to proliferate and form de novo blood vessels through angiogenesis. To further define molecular mechanisms accompanying the activation of endothelial cells during angiogenesis, we identified genes that were differentially regulated during this process using microarray analyses. In this work, we established a regulatory role for Sushi repeat protein X-linked 2 (Srpx2) in endothelial cell remodeling during angiogenesis. In particular, silencing of Srpx2 using small interfering RNAs (siRNAs) specifically attenuated endothelial cell migration and delayed angiogenic sprout formation. In vivo, Srpx2 expression was detected in de novo formation of blood vessels in angiogenic tissues by in situ mRNA hybridization and immunostaining. Pull-down experiments identified Srpx2 as a ligand for vascular uPAR, a key molecule involved in invasive migration of angiogenic endothelium. Immunostaining revealed coexpression of the Srpx2 and uPAR on vascular endothelium. These findings suggest that Srpx2 regulates endothelial cell migration and tube formation and provides a new target for modulating angiogenesis.-Miljkovic-Licina, M., Hammel, P., Garrido-Urbani, S., Bradfield, P. F., Szepetowski, P., Imhof, B. A. Sushi repeat protein Xlinked 2, a novel mediator, of angiogenesis. FASEB J. 23, 4105-4116 (2009). www.fasebj.org	[Miljkovic-Licina, Marijana; Hammel, Philippe; Garrido-Urbani, Sarah; Bradfield, Paul F.; Imhof, Beat A.] Univ Geneva, CMU, Dept Pathol & Immunol, CH-1211 Geneva 4, Switzerland; [Szepetowski, Pierre] Univ Mediterranee, INSERM, UMR 901, Marseille, France; [Szepetowski, Pierre] Univ Mediterranee, UMR 910, Marseille, France	University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Imhof, BA (corresponding author), Univ Geneva, CMU, Dept Pathol & Immunol, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland.	beat.imhof@unige.ch		Garrido-Urbani, Sarah/0000-0002-7309-0137; Miljkovic-Licina, Marijana/0000-0001-9023-2208; Hammel, Pascal/0000-0002-4630-4996				Adachi Y, 2001, J BIOL CHEM, V276, P47171, DOI 10.1074/jbc.M104334200; Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Ashraf S, 2008, CURR OPIN RHEUMATOL, V20, P573, DOI 10.1097/BOR.0b013e3283103d12; Aurrand-Lions M, 2004, J PATHOL, V203, P700, DOI 10.1002/path.1571; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Callebaut I, 2000, PROTEIN SCI, V9, P1382, DOI 10.1110/ps.9.7.1382; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cheresh DA, 2008, ONCOGENE, V27, P6285, DOI 10.1038/onc.2008.304; Cherqui S, 2007, MOL THER, V15, P1264, DOI 10.1038/sj.mt.6300183; Colman RW, 2006, CURR PHARM DESIGN, V12, P2599, DOI 10.2174/138161206777698710; Dominguez MG, 2007, P NATL ACAD SCI USA, V104, P3243, DOI 10.1073/pnas.0611510104; Egami K, 2006, J LEUKOCYTE BIOL, V79, P971, DOI 10.1189/jlb.0805448; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482; Goh PP, 2007, CURR CANCER DRUG TAR, V7, P743, DOI 10.2174/156800907783220462; HALLMANN R, 1995, DEV DYNAM, V202, P325, DOI 10.1002/aja.1002020402; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Horst AK, 2006, J CLIN INVEST, V116, P1596, DOI 10.1172/JCI24340; Hoshino M, 1996, DEVELOPMENT, V122, P589; Jones CA, 2007, CURR OPIN GENET DEV, V17, P332, DOI 10.1016/j.gde.2007.07.004; Kroon ME, 1999, AM J PATHOL, V154, P1731, DOI 10.1016/S0002-9440(10)65429-6; Kurosawa H, 1999, BLOOD, V93, P321, DOI 10.1182/blood.V93.1.321.401k05_321_332; Lakka SS, 2005, BRAIN PATHOL, V15, P327; Lamalice L, 2007, CIRC RES, V100, P782, DOI 10.1161/01.RES.0000259593.07661.1e; Larrivee B, 2009, CIRC RES, V104, P428, DOI 10.1161/CIRCRESAHA.108.188144; McMahon B, 2007, PATHOPHYSIOL HAEMO T, V36, P184, DOI 10.1159/000175156; Mellberg S, 2009, FASEB J, V23, P1490, DOI 10.1096/fj.08-123810; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; O'Leary JM, 2004, PROTEIN SCI, V13, P1238, DOI 10.1110/ps.03582704; Oh IY, 2007, BLOOD, V110, P3891, DOI 10.1182/blood-2006-10-048991; Oliveira-Ferrer L, 2004, CANCER RES, V64, P8932, DOI 10.1158/0008-5472.CAN-04-0505; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; Prager GW, 2004, CIRC RES, V94, P1562, DOI 10.1161/01.RES.0000131498.36194.6b; Reynolds LE, 2006, METH MOLEC MED, V120, P503; Roca C, 2007, GENE DEV, V21, P2511, DOI 10.1101/gad.1589207; Roll P, 2006, HUM MOL GENET, V15, P1195, DOI 10.1093/hmg/ddl035; Royer B, 2007, BMC GENET, V8, DOI 10.1186/1471-2156-8-72; Royer-Zemmour B, 2008, HUM MOL GENET, V17, P3617, DOI 10.1093/hmg/ddn256; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Schmidt M, 2007, DEVELOPMENT, V134, P2913, DOI 10.1242/dev.002576; Soares DC, 2005, PROTEIN ENG DES SEL, V18, P379, DOI 10.1093/protein/gzi039; Suchting S, 2006, EXP CELL RES, V312, P668, DOI 10.1016/j.yexcr.2005.11.009; Tammela T, 2008, NATURE, V454, P656, DOI 10.1038/nature07083; Tanaka K, 2009, INT J CANCER, V124, P1072, DOI 10.1002/ijc.24065; Tarui T, 2003, J BIOL CHEM, V278, P29863, DOI 10.1074/jbc.M304694200; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034	52	32	41	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4105	4116		10.1096/fj.09-135202	http://dx.doi.org/10.1096/fj.09-135202			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19667118				2022-12-28	WOS:000272193700007
J	Huttunen, HJ; Peach, C; Bhattacharyya, R; Barren, C; Pettingell, W; Hutter-Paier, B; Windisch, M; Berezovska, O; Kovacs, DM				Huttunen, Henri J.; Peach, Camilla; Bhattacharyya, Raja; Barren, Cory; Pettingell, Warren; Hutter-Paier, Birgit; Windisch, Manfred; Berezovska, Oksana; Kovacs, Dora M.			Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway	FASEB JOURNAL			English	Article						Alzheimer's disease; cholesterol; endoplasmic reticulum; lipid; protein maturation	ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM; BETA-PEPTIDE; QUALITY CONTROL; APP; CLEAVAGE; METABOLISM; GENERATION; CELLS; MODEL	Amyloid beta-peptide (A beta) has a central role in the pathogenesis of Alzheimer's disease (AD). Cellular cholesterol homeostasis regulates endoproteolytic generation of A beta from the amyloid precursor protein (APP). Previous studies have identified acylcoenzyme A: cholesterol acyltransferase (ACAT), an enzyme that regulates subcellular cholesterol distribution, as a potential therapeutic target for AD. Inhibition of ACAT activity decreases A beta generation in cell-and animal-based models of AD through an unknown mechanism. Here we show that ACAT inhibition retains a fraction of APP molecules in the early secretory pathway, limiting the availability of APP for secretase-mediated proteolytic processing. ACAT inhibitors delayed the trafficking of immature APP molecules from the endoplasmic reticulum (ER) as shown by metabolic labeling and live-cell imaging. This resulted in partial ER retention of APP and enhanced ER-associated degradation of APP by the proteasome, without activation of the unfolded protein response pathway. The ratio of mature APP to immature APP was reduced in brains of mice treated with ACAT inhibitors, and strongly correlated with reduced brain APP-C99 and cerebrospinal fluid A beta levels in individual animals. Our results identify a novel ACAT-dependent mechanism that regulates secretory trafficking of APP, likely contributing to decreased A beta generation in vivo.-Huttunen, H. J., Peach, C., Bhattacharyya, R., Barren, C., Pettingell, W., Hutter-Paier, B., Windisch, M., Berezovska, O., Kovacs, D. M. Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. FASEB J. 23, 3819-3828 (2009). www.fasebj.org	[Huttunen, Henri J.; Peach, Camilla; Bhattacharyya, Raja; Barren, Cory; Pettingell, Warren; Kovacs, Dora M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurobiol Dis Lab,Genet & Aging Res Unit, Charlestown, MA 02129 USA; [Huttunen, Henri J.; Peach, Camilla; Bhattacharyya, Raja; Barren, Cory; Pettingell, Warren; Berezovska, Oksana; Kovacs, Dora M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA; [Huttunen, Henri J.; Peach, Camilla; Bhattacharyya, Raja; Barren, Cory; Pettingell, Warren; Hutter-Paier, Birgit; Windisch, Manfred; Berezovska, Oksana; Kovacs, Dora M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; [Hutter-Paier, Birgit; Windisch, Manfred] Inst Expt Pharmacol, JSW Res Forsch Lab, Graz, Austria	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Kovacs, DM (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurobiol Dis Lab,Genet & Aging Res Unit, 114 16th St, Charlestown, MA 02129 USA.	dora_kovacs@hms.harvard.edu		Huttunen, Henri/0000-0002-9867-4438	Cure Alzheimer's Fund; U.S. National Institutes of Health [R01 NS45860]; Helsingin Sanomat Centennial Foundation; Maud Kuistila Foundation [CI-1011, CP-113,818]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045860] Funding Source: NIH RePORTER	Cure Alzheimer's Fund; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Helsingin Sanomat Centennial Foundation; Maud Kuistila Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by grants from the Cure Alzheimer's Fund (D. M. K.), the U.S. National Institutes of Health (R01 NS45860; D. M. K.), the Helsingin Sanomat Centennial Foundation (H.J.H.), and the Maud Kuistila Foundation (H.J.H.). CI-1011 and CP-113,818 were kind gifts from Lit-Fui Lau and James Harwood (Pfizer, Groton, CT, USA), respectively.	Alegret M, 2004, METHOD FIND EXP CLIN, V26, P563, DOI 10.1358/mf.2004.26.7.863738; Anelli T, 2008, EMBO J, V27, P315, DOI 10.1038/sj.emboj.7601974; Anliker B, 2006, NEURODEGENER DIS, V3, P239, DOI 10.1159/000095262; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Chen Q, 2002, J CELL BIOL, V158, P79, DOI 10.1083/jcb.200110151; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Forster ML, 2006, J CELL BIOL, V173, P853, DOI 10.1083/jcb.200602046; Fujimoto T, 2006, AUTOPHAGY, V2, P299, DOI 10.4161/auto.2904; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Grbovic OM, 2003, J BIOL CHEM, V278, P31261, DOI 10.1074/jbc.M304122200; Grimm MO, 2007, TRENDS MOL MED, V13, P337, DOI 10.1016/j.molmed.2007.06.004; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hare JF, 2001, BIOCHEM BIOPH RES CO, V281, P1298, DOI 10.1006/bbrc.2001.4507; Hirsch-Reinshagen V, 2007, CURR OPIN LIPIDOL, V18, P325, DOI 10.1097/MOL.0b013e32813aeabf; Hutter-Paier B, 2004, NEURON, V44, P227, DOI 10.1016/j.neuron.2004.08.043; Huttunen HJ, 2007, J BIOL CHEM, V282, P28285, DOI 10.1074/jbc.M702951200; Huttunen HJ, 2007, FEBS LETT, V581, P1688, DOI 10.1016/j.febslet.2007.03.056; Huttunen HJ, 2009, J MOL NEUROSCI, V37, P6, DOI 10.1007/s12031-008-9088-0; Kaether C, 2006, TRAFFIC, V7, P408, DOI 10.1111/j.1600-0854.2006.00396.x; Kouchi Z, 1999, BIOCHEM BIOPH RES CO, V254, P804, DOI 10.1006/bbrc.1998.9977; Kumar P, 2007, HUM MOL GENET, V16, P848, DOI 10.1093/hmg/ddm030; Lott IT, 2005, NEUROBIOL AGING, V26, P383, DOI 10.1016/j.neurobiolaging.2004.08.005; Maltese WA, 2001, J BIOL CHEM, V276, P20267, DOI 10.1074/jbc.M007238200; Matsui T, 2007, BRAIN RES, V1161, P116, DOI 10.1016/j.brainres.2007.05.050; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Paganetti P, 2005, J CELL BIOL, V168, P863, DOI 10.1083/jcb.200410047; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Ploegh HL, 2007, NATURE, V448, P435, DOI 10.1038/nature06004; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Rockenstein E, 2001, J NEUROSCI RES, V66, P573, DOI 10.1002/jnr.1247; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rovelet-Lecrux A, 2006, NAT GENET, V38, P24, DOI 10.1038/ng1718; Schmidt V, 2007, J BIOL CHEM, V282, P32956, DOI 10.1074/jbc.M705073200; Senechal Y, 2006, NEURODEGENER DIS, V3, P134, DOI 10.1159/000094772; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Theuns J, 2006, AM J HUM GENET, V78, P936, DOI 10.1086/504044; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Wolfe MS, 2007, J CELL SCI, V120, P3157, DOI 10.1242/jcs.03481; Wolozin B, 2004, NEURON, V41, P7, DOI 10.1016/S0896-6273(03)00840-7; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552; YEO KT, 1985, J BIOL CHEM, V260, P7896	50	42	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2009	23	11					3819	3828		10.1096/fj.09-134999	http://dx.doi.org/10.1096/fj.09-134999			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19625658	Green Published			2022-12-28	WOS:000271272500018
J	Xu, XR; Gammon, MD; Zeisel, SH; Bradshaw, PT; Wetmur, JG; Teitelbaum, SL; Neugut, AI; Santella, RM; Chen, J				Xu, Xinran; Gammon, Marilie D.; Zeisel, Steven H.; Bradshaw, Patrick T.; Wetmur, James G.; Teitelbaum, Susan L.; Neugut, Alfred I.; Santella, Regina M.; Chen, Jia			High intakes of choline and betaine reduce breast cancer mortality in a population-based study	FASEB JOURNAL			English	Article						risk; diet; BHMT; LIBCSP	ONE-CARBON METABOLISM; DNA METHYLATION; METHYLTRANSFERASE BHMT; LONG-ISLAND; RISK; HOMOCYSTEINE; DEFICIENCY; METHIONINE; NUTRIENTS; SURVIVAL	Choline and betaine provide methyl groups for one-carbon metabolism. Humans obtain these nutrients from a wide range of foods. Betaine can also be synthesized endogenously from its precursor, choline. Although animal studies have implied a causal relationship between choline deficiency and carcinogenesis, the role of these two nutrients in human carcinogenesis and tumor progression is not well understood. We investigated the associations of dietary intakes of choline and betaine and breast cancer risk and mortality in the population-based Long Island Breast Cancer Study Project. Among the 1508 case-group women, 308 (20.2%) deaths occurred, among whom 164 (53.2%) died of breast cancer by December 31, 2005. There was an indication that a higher intake of free choline was associated with reduced risk of breast cancer (P-trend=0.04). Higher intakes of betaine, phosphocholine, and free choline were associated with reduced all-cause as well as breast cancer-specific mortality in a dose-dependent fashion. We also explored associations of polymorphisms of three key choline-and betaine-metabolizing genes and breast cancer mortality. The betaine-homocysteine methyltransferase gene (BHMT) rs3733890 polymorphism was associated with reduced breast cancer-specific mortality (hazard ratio, 0.64; 95% confidence interval, 0.42-0.97). Our study supports the important roles of choline and betaine in breast carcinogenesis. It suggests that high intake of these nutrients may be a promising strategy to prevent the development of breast cancer and to reduce its mortality.-Xu, X., Gammon, M. D., Zeisal, S. H., Bradshaw, P. T., Wetmur, J. G., Teitelbaum, S. L., Neugut, A. I., Santella, R. M., Chen, J. High intakes of choline and betaine reduce breast cancer mortality in a population-based study. FASEB J. 23, 4022-4028 (2009). www.fasebj.org	[Xu, Xinran; Teitelbaum, Susan L.; Chen, Jia] Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA; [Wetmur, James G.] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; [Wetmur, James G.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA; [Chen, Jia] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; [Chen, Jia] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; [Gammon, Marilie D.; Bradshaw, Patrick T.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Zeisel, Steven H.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA; [Neugut, Alfred I.] Columbia Univ, Dept Epidemiol, New York, NY USA; [Neugut, Alfred I.] Columbia Univ, Dept Med, New York, NY USA; [Santella, Regina M.] Columbia Univ, Dept Environm Hlth Sci, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Columbia University; Columbia University; Columbia University	Chen, J (corresponding author), Mt Sinai Sch Med, Dept Community & Prevent Med, Box 1057,1 Gustave L Levy Pl, New York, NY 10029 USA.	jia.chen@mssm.edu	Bradshaw, Patrick/AAJ-7529-2021	Bradshaw, Patrick/0000-0001-7761-3129; Xu, Xinran/0000-0001-6435-8181	National Institutes of Health [CA109753, DK55865]; Department of Defense [BC031746]; National Cancer Institute; National Institutes of Environmental Health and Sciences [UO1CA/ES66572, UO1CA66572, P30ES009089, P30ES10126]; University of North Carolina Clinical Nutrition Research Unit [DK56350]; Department of Defense Breast Cancer Research Program [W81XWH-06-1-0298]; NATIONAL CANCER INSTITUTE [R01CA109753, U01CA066572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350, R01DK055865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089, P30ES010126] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Environmental Health and Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); University of North Carolina Clinical Nutrition Research Unit; Department of Defense Breast Cancer Research Program(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by grants from the National Institutes of Health (CA109753 to J. C. and DK55865 to S. H. Z.) and in part by grants from the Department of Defense (BC031746), National Cancer Institute, and the National Institutes of Environmental Health and Sciences (UO1CA/ES66572, UO1CA66572, P30ES009089, and P30ES10126), and by the University of North Carolina Clinical Nutrition Research Unit (DK56350). X. X. is a recipient of a Predoctoral Traineeship Award (W81XWH-06-1-0298) of the Department of Defense Breast Cancer Research Program.	Ackerstaff E, 2003, J CELL BIOCHEM, V90, P525, DOI 10.1002/jcb.10659; Baker JA, 2006, J NUTR, V136, P166, DOI 10.1093/jn/136.1.166; Chiuve SE, 2007, AM J CLIN NUTR, V86, P1073, DOI 10.1093/ajcn/86.4.1073; Cho EY, 2007, CANCER EPIDEM BIOMAR, V16, P2787, DOI 10.1158/1055-9965.EPI-07-0683; Cho E, 2007, JNCI-J NATL CANCER I, V99, P1224, DOI 10.1093/jnci/djm082; Cleveland RJ, 2007, CANCER EPIDEM BIOMAR, V16, P1803, DOI 10.1158/1055-9965.EPI-06-0889; DACOSTA KA, 1995, CARCINOGENESIS, V16, P327, DOI 10.1093/carcin/16.2.327; Dalmeijer GW, 2008, EUR J CLIN NUTR, V62, P386, DOI 10.1038/sj.ejcn.1602725; Gammon MD, 2002, BREAST CANCER RES TR, V74, P235, DOI 10.1023/A:1016387020854; Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P677; Ganmaa D, 2008, INT J CANCER, V122, P2071, DOI 10.1002/ijc.23336; Gaudet MM, 2004, CANCER EPIDEM BIOMAR, V13, P1485; GHOSHAL AK, 1984, CARCINOGENESIS, V5, P1367, DOI 10.1093/carcin/5.10.1367; Glunde K, 2006, PHARMACOGENOMICS, V7, P1109, DOI 10.2217/14622416.7.7.1109; Hosmer D. W., 1999, APPL SURVIVAL ANAL; HOSMER DW, 1989, APPL LOGISTIC REGRES; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kovacheva VP, 2009, FASEB J, V23, P1054, DOI 10.1096/fj.08-122168; Morin I, 2003, AM J MED GENET A, V119A, P172, DOI 10.1002/ajmg.a.20115; NEWBERNE PM, 1986, ANNU REV NUTR, V6, P407, DOI 10.1146/annurev.nu.06.070186.002203; ROGERS AE, 1990, CARCINOGENESIS, V11, P1491, DOI 10.1093/carcin/11.9.1491; Rothman K., 1998, MODERN EPIDEMIOLOGY; Schwahn BC, 2003, FASEB J, V17, P512, DOI 10.1096/fj.02-0456fje; Sohn KJ, 2009, INT J CANCER, V124, P1999, DOI 10.1002/ijc.24003; Tang NP, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.10.019; Tsujiuchi T, 1999, JPN J CANCER RES, V90, P909, DOI 10.1111/j.1349-7006.1999.tb00834.x; Ueland PM, 2005, CLIN CHEM LAB MED, V43, P1069, DOI 10.1515/CCLM.2005.187; WAINFAN E, 1990, CARCINOGENESIS, V11, P361, DOI 10.1093/carcin/11.3.361; Weisberg IS, 2003, ATHEROSCLEROSIS, V167, P205, DOI 10.1016/S0021-9150(03)00010-8; Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606; Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279; Yan PS, 2001, CANCER RES, V61, P8375; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Yates AA, 1998, J AM DIET ASSOC, V98, P699, DOI 10.1016/S0002-8223(98)00160-6; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; Zeisel SH, 2003, J NUTR, V133, P1302	36	70	71	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					4022	4028		10.1096/fj.09-136507	http://dx.doi.org/10.1096/fj.09-136507			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19635752	Green Submitted, Green Published			2022-12-28	WOS:000271272500037
J	Burke, SJ; Collier, JJ; Scott, DK				Burke, Susan J.; Collier, J. Jason; Scott, Donald K.			cAMP opposes the glucose-mediated induction of the L-PK gene by preventing the recruitment of a complex containing ChREBP, HNF4 alpha, and CBP	FASEB JOURNAL			English	Article						transcription; repression; promoter; signaling	PYRUVATE-KINASE GENE; ELEMENT-BINDING PROTEIN; PANCREATIC BETA-CELLS; FATTY-ACID SYNTHASE; TRANSCRIPTION FACTOR; CYCLIC-AMP; C-MYC; EXPRESSION; CREB; COACTIVATORS	Glucose-mediated activation of the L-type pyruvate kinase (L-PK) gene is repressed by cAMP, making this an excellent model for studying the mechanism by which these contrary signals regulate gene expression. Using the 832/13 rat insulinoma cell line, we demonstrate using RNA interference and chromatin immunoprecipitation that carbohydrate response element binding protein (ChREBP), hepatic nuclear factor 4 alpha (HNF4 alpha), and the coactivator CREB binding protein (CBP) are required for the glucose response of the L-PK gene and are recruited to the promoter by glucose. The cAMP agonist forskolin blocked the glucose-mediated induction of the L-PK gene in a PKA-dependent manner and blocked the recruitment of ChREBP, HNF4 alpha, and CBP to the L-PK promoter, while simultaneously recruiting CBP to the cAMP-inducible gene, nuclear receptor subfamily 4, group A, member 2 (NR4A2). Overexpression of CBP, but not ChREBP, reversed the cAMP repression of the L-PK gene. In addition, CBP augmented the glucose response of the L-PK promoter. We conclude that cAMP and glucose signaling converge on a complex containing ChREBP, HNF4 alpha, and CBP, and that cAMP acts by disrupting this transcriptional complex assembled by glucose-derived signals.-Burke, S. J., Collier, J. J., Scott, D. K. cAMP opposes the glucose-mediated induction of the L-PK gene by preventing the recruitment of a complex containing ChREBP, HNF4 alpha, and CBP. FASEB J. 23, 2855-2865 (2009). www.fasebj.org	[Scott, Donald K.] Univ Pittsburgh, Dept Med, Div Endocrinol, Pittsburgh, PA 15261 USA; [Collier, J. Jason] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC USA; [Collier, J. Jason] Duke Univ, Sarah W Stedman Nutr & Metab Ctr, Durham, NC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Duke University; Duke University	Scott, DK (corresponding author), Univ Pittsburgh, Dept Med, Div Endocrinol, E1147 BST,200 Lothrop St, Pittsburgh, PA 15261 USA.	dks23@pitt.edu	Collier, Susan J/N-1959-2017; Collier, James/N-1958-2017	Collier, Susan J/0000-0003-2571-4416; 				Adamson AW, 2006, BIOCHEM J, V399, P285, DOI 10.1042/BJ20060659; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; Billin AN, 1999, J BIOL CHEM, V274, P36344, DOI 10.1074/jbc.274.51.36344; Chan HM, 2001, J CELL SCI, V114, P2363; Collier JJ, 2007, AM J PHYSIOL-ENDOC M, V293, pE48, DOI 10.1152/ajpendo.00357.2006; Collier JJ, 2006, DIABETES, V55, P1398, DOI 10.2337/db05-1000; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; Davies MN, 2008, J BIOL CHEM, V283, P24029, DOI 10.1074/jbc.M801539200; Dentin R, 2004, J BIOL CHEM, V279, P20314, DOI 10.1074/jbc.M312475200; Geisberg JV, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh148; Gourdon L, 1999, FEBS LETT, V459, P9, DOI 10.1016/S0014-5793(99)01203-X; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; Herzig S, 2003, NATURE, V426, P190, DOI 10.1038/nature02110; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ishii S, 2004, P NATL ACAD SCI USA, V101, P15597, DOI 10.1073/pnas.0405238101; Jambal P, 2003, J BIOL CHEM, V278, P23055, DOI 10.1074/jbc.M212450200; Kawaguchi T, 2001, P NATL ACAD SCI USA, V98, P13710, DOI 10.1073/pnas.231370798; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Li MV, 2008, MOL ENDOCRINOL, V22, P1658, DOI 10.1210/me.2007-0560; Li MV, 2006, DIABETES, V55, P1179, DOI 10.2337/db05-0822; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; LIU ZR, 1993, J BIOL CHEM, V268, P12787; Luo GY, 2000, MOL ENDOCRINOL, V14, P114, DOI 10.1210/me.14.1.114; Ma L, 2005, J BIOL CHEM, V280, P12019, DOI 10.1074/jbc.M413063200; MARIE S, 1993, J BIOL CHEM, V268, P23881; Sakiyama H, 2008, J BIOL CHEM, V283, P24899, DOI 10.1074/jbc.M804308200; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Stoeckman AK, 2004, J BIOL CHEM, V279, P15662, DOI 10.1074/jbc.M311301200; TOMKINS GM, 1975, SCIENCE, V189, P760, DOI 10.1126/science.169570; Tsatsos NG, 2006, BIOCHEM BIOPH RES CO, V340, P449, DOI 10.1016/j.bbrc.2005.12.029; UHLER MD, 1986, J BIOL CHEM, V261, P5360; Wang HY, 2002, J BIOL CHEM, V277, P32746, DOI 10.1074/jbc.M201635200; Xavier GD, 2006, J LIPID RES, V47, P2482, DOI 10.1194/jlr.M600289-JLR200; Xu W, 2007, EMBO J, V26, P2890, DOI 10.1038/sj.emboj.7601734; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871	37	31	32	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2855	2865		10.1096/fj.08-126631	http://dx.doi.org/10.1096/fj.08-126631			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19406844				2022-12-28	WOS:000270241000008
J	Scaloni, F; Gianni, S; Federici, L; Falini, B; Brunori, M				Scaloni, Flavio; Gianni, Stefano; Federici, Luca; Falini, Brunangelo; Brunori, Maurizio			Folding mechanism of the C-terminal domain of nucleophosmin: residual structure in the denatured state and its pathophysiological significance	FASEB JOURNAL			English	Article						kinetics; acute myeloid leukemia; protein stability; Hammond effect; ground state effect	ACUTE MYELOID-LEUKEMIA; NUCLEAR EXPORT; ENERGY LANDSCAPE; UNFOLDED STATES; NPMC(+) AML; PROTEIN; INTERMEDIATE; TRANSITION; MUTANTS; CANCER	Nucleophosmin (NPM1) is a ubiquitously expressed protein and is one of the most abundant proteins found in the nucleolus. Naturally occurring mutations in the C-terminal domain of nucleophosmin (Cter-NPM1) are found in similar to 30% of patients with acute myeloid leukemia (AML). These mutations cause changes at the C terminus of NPM1 that lead to denaturation of the protein, a critical factor in determining aberrant translocation of NPM1 to the cytosol. Hence, this protein system represents an ideal candidate to investigate the relations between folding and unfolding and disease. Here we report the characterization of the folding and unfolding kinetics of Cter-NPM1. Data reveal that this small helical domain folds via a compact denatured state, displaying a malleable residual structure. Moreover, analysis of folding rate constants measured under different experimental conditions suggests that the existence of a preorganized structure in the denatured state accelerates folding, implying a native-like residual structure. Because a major feature of Cter-NPM1 mutants responsible for AML is a reduction in stability of the protein and thus prevalence of a denatured state even under physiological conditions, our findings may pave the way to further studies with the aim of designing chemicals capable of interacting with the "pathological" mutants to stabilize the native conformation.-Scaloni, F., Gianni, S., Federici, L., Falini, B., Brunori, M. Folding mechanism of the C-terminal domain of nucleophosmin: residual structure in the denatured state and its pathophysiological significance. FASEB J. 23, 2360-2365 (2009)	[Scaloni, Flavio; Gianni, Stefano; Brunori, Maurizio] Univ Roma La Sapienza, CNR, Dipartimento Sci Biochim A Rossi Fanelli, Ist Biol & Patol Mol, I-00185 Rome, Italy; [Scaloni, Flavio; Gianni, Stefano; Brunori, Maurizio] Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy; [Federici, Luca] Univ G dAnnunzio, Ctr Studi Invecchiamento, Chieti, Italy; [Federici, Luca] Univ G dAnnunzio, Dipartimento Sci Biomed, Chieti, Italy; [Falini, Brunangelo] Univ Perugia, Sez Ematol & Immunol, Dipartimento Med Clin & Sperimentale, I-06100 Perugia, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; University of Perugia	Brunori, M (corresponding author), Univ Roma La Sapienza, CNR, Dipartimento Sci Biochim A Rossi Fanelli, Ist Biol & Patol Mol, Ple A Moro 5, I-00185 Rome, Italy.	maurizio.brunori@uniroma1.it	gianni, stefano/C-8536-2009	FALINI, Brunangelo/0000-0002-7198-5965; Brunori, Maurizio/0000-0002-7795-1635; Gianni, Stefano/0000-0003-1653-1925	Associazione Italiana Ricerca sul Cancro	Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grants from the Associazione Italiana Ricerca sul Cancro to M. B and B. F.	BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; Cellmer T, 2007, J AM CHEM SOC, V129, P14564, DOI 10.1021/ja0761939; Dalby PA, 1998, BIOCHEMISTRY-US, V37, P4674, DOI 10.1021/bi972798d; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Falini B, 2007, BLOOD, V109, P874, DOI 10.1182/blood-2006-07-012252; Falini B, 2006, BLOOD, V108, P1999, DOI 10.1182/blood-2006-03-007013; Falini B, 2006, BLOOD, V107, P4514, DOI 10.1182/blood-2005-11-4745; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; Geierhaas CD, 2007, PROTEIN SCI, V16, P125, DOI 10.1110/ps.062383807; Gianni S, 2003, P NATL ACAD SCI USA, V100, P13286, DOI 10.1073/pnas.1835776100; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Grummitt Charles G, 2008, J Biol Chem, V283, P23326, DOI 10.1074/jbc.M801706200; HAMMOND GS, 1955, J AM CHEM SOC, V77, P334, DOI 10.1021/ja01607a027; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Krantz BA, 2002, J MOL BIOL, V324, P359, DOI 10.1016/S0022-2836(02)01029-X; Leung AKL, 2004, J CELL BIOL, V166, P787, DOI 10.1083/jcb.200405013; Lindberg MO, 2007, CURR OPIN STRUC BIOL, V17, P21, DOI 10.1016/j.sbi.2007.01.008; Lindberg MJ, 2005, P NATL ACAD SCI USA, V102, P9754, DOI 10.1073/pnas.0501957102; Luheshi LM, 2008, CURR OPIN CHEM BIOL, V12, P25, DOI 10.1016/j.cbpa.2008.02.011; Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07; McCarney ER, 2005, CRIT REV BIOCHEM MOL, V40, P181, DOI 10.1080/10409230591008143; Merchant KA, 2007, P NATL ACAD SCI USA, V104, P1528, DOI 10.1073/pnas.0607097104; Mittag T, 2007, CURR OPIN STRUC BIOL, V17, P3, DOI 10.1016/j.sbi.2007.01.009; Mok KH, 2007, NATURE, V447, P106, DOI 10.1038/nature05728; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Religa TL, 2005, NATURE, V437, P1053, DOI 10.1038/nature04054; Sanchez IE, 2003, J MOL BIOL, V327, P867, DOI 10.1016/S0022-2836(03)00171-2; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; Ternstrom T, 1999, P NATL ACAD SCI USA, V96, P14854, DOI 10.1073/pnas.96.26.14854; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; WANG DR, 1994, J BIOL CHEM, V269, P30994; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Yu Y, 2006, MOL CELL BIOL, V26, P3798, DOI 10.1128/MCB.26.10.3798-3809.2006; Zhang YP, 2004, CELL CYCLE, V3, P259	41	28	28	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2360	2365		10.1096/fj.08-128306	http://dx.doi.org/10.1096/fj.08-128306			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19289604				2022-12-28	WOS:000268836700004
J	Tamma, R; Colaianni, G; Camerino, C; Di Benedetto, A; Greco, G; Strippoli, M; Vergari, R; Grano, A; Mancini, L; Mori, G; Colucci, S; Grano, M; Zallone, A				Tamma, Roberto; Colaianni, Graziana; Camerino, Claudia; Di Benedetto, Adriana; Greco, Giovanni; Strippoli, Maurizio; Vergari, Rosaria; Grano, Antonella; Mancini, Lucia; Mori, Giorgio; Colucci, Silvia; Grano, Maria; Zallone, Alberta			Microgravity during spaceflight directly affects in vitro osteoclastogenesis and bone resorption	FASEB JOURNAL			English	Article						mechanical forces; osteoporosis; bone remodeling	MESENCHYMAL STEM-CELLS; MODELED MICROGRAVITY; SPACE-FLIGHT; INCREASES; DIFFERENTIATION; PROLIFERATION; ADIPOGENESIS; OSTEOBIOLOGY; STRAIN; LEVEL	During space flight, severe losses of bone mass are observed. Both bone formation and resorption are probably involved, but their relative importance remains unclear. The purpose of this research is to understand the role of osteoclasts and their precursors in microgravity-induced bone loss. Three experiments on isolated osteoclasts (OCs) and on their precursors, OSTEO, OCLAST, and PITS, were launched in the FOTON-M3 mission. The OSTEO experiment was conducted for 10 d in microgravity within bioreactors with a perfusion system, where the differentiation of precursors, cultured on a synthetic 3-dimensional bonelike biomaterial, skelite, toward mature OCs was assessed. In OCLAST and in PITS experiments, differentiated OCs were cultured on devitalized bovine bone slices for 4 d in microgravity. All of the experiments were replicated on ground in the same bioreactors, and OCLAST also had an inflight centrifuge as a control. Gene expression in microgravity, compared with ground controls, demonstrated a severalfold increase in genes involved in osteoclast maturation and activity. Increased bone resorption, proved by an increased amount of collagen telopeptides released VS ground and centrifuge control, was also found. These results indicate for the first time osteoclasts and their precursors as direct targets for microgravity and mechanical forces.-Tamma, R., Colaianni, G., Camerino, C., Di Benedetto, A., Greco, G., Strippoli, M., Vergari, R., Grano, A., Mancini, L., Mori, G., Colucci, S., Grano, M., Zallone, A. Microgravity during spaceflight directly affects in vitro osteoclastogenesis and bone resorption. FASEB J. 23, 2549-2554 (2009)	[Tamma, Roberto; Colaianni, Graziana; Camerino, Claudia; Di Benedetto, Adriana; Greco, Giovanni; Strippoli, Maurizio; Vergari, Rosaria; Grano, Antonella; Mancini, Lucia; Mori, Giorgio; Colucci, Silvia; Grano, Maria; Zallone, Alberta] Univ Bari, Sch Med, Dept Human Anat & Histol, I-70124 Bari, Italy	Universita degli Studi di Bari Aldo Moro	Zallone, A (corresponding author), Univ Bari, Sch Med, Dept Human Anat & Histol, Piazza G Cesare 11, I-70124 Bari, Italy.	a.zallone@anatomia.uniba.it	tamma, roberto/C-3679-2016; Mori, Giorgio/P-1370-2014	Mori, Giorgio/0000-0001-6731-0247; Camerino, Claudia/0000-0001-7217-9327; TAMMA, Roberto/0000-0003-4623-5406; Camerino, Giulia Maria/0000-0003-1410-6327; Colaianni, Graziana/0000-0001-8501-5399; Grano, Maria/0000-0002-7121-5899; Colucci, Silvia/0000-0001-9970-3539	Italian Space Agency (Osteporosis and Muscle Atrophy project); European Space Agency (European Research in Space and Terrestrial Osteoporosis, Microgravity Applied Project)	Italian Space Agency (Osteporosis and Muscle Atrophy project)(Agenzia Spaziale Italiana (ASI)); European Space Agency (European Research in Space and Terrestrial Osteoporosis, Microgravity Applied Project)(European Space Agency)	This work was supported by grants from the Italian Space Agency (Osteporosis and Muscle Atrophy project) and from the European Space Agency (European Research in Space and Terrestrial Osteoporosis, Microgravity Applied Project) to A.Z.	Basso N, 2005, BONE, V36, P173, DOI 10.1016/j.bone.2004.09.016; Caillot-Augusseau A, 2000, CLIN CHEM, V46, P1136; Dai ZQ, 2007, CELL PROLIFERAT, V40, P671, DOI 10.1111/j.1365-2184.2007.00461.x; Grano M, 2002, CALCIFIED TISSUE INT, V70, P176, DOI 10.1007/s00223-001-2034-6; Grigoriev A I, 1998, Aviakosm Ekolog Med, V32, P21; Hughes-Fulford M, 2001, J Gravit Physiol, V8, pP1; Hughes-Fulford M, 2006, J CELL BIOCHEM, V99, P435, DOI 10.1002/jcb.20883; Kumei Y, 2006, ANN NY ACAD SCI, V1090, P311, DOI 10.1196/annals.1378.034; LeBlanc A. D., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P33; Marie PJ, 2000, CALCIFIED TISSUE INT, V67, P2, DOI 10.1007/s00223001088; Meyers VE, 2005, J BONE MINER RES, V20, P1858, DOI 10.1359/JBMR.050611; Rucci N, 2002, J CELL BIOCHEM, V85, P167, DOI 10.1002/jcb.10120; Rucci N, 2007, J CELL BIOCHEM, V100, P464, DOI 10.1002/jcb.21059; Sibonga JD, 2007, BONE, V41, P973, DOI 10.1016/j.bone.2007.08.022; Vico L, 2001, CALCIFIED TISSUE INT, V68, P1, DOI 10.1007/BF02684996; Zayzafoon M, 2004, ENDOCRINOLOGY, V145, P2421, DOI 10.1210/en.2003-1156	16	92	107	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2549	2554		10.1096/fj.08-127951	http://dx.doi.org/10.1096/fj.08-127951			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19329761				2022-12-28	WOS:000268836700023
J	Meier, ID; Bernreuther, C; Tilling, T; Neidhardt, J; Wong, YW; Schulze, C; Streichert, T; Schachner, M				Meier, Ingo D.; Bernreuther, Christian; Tilling, Thomas; Neidhardt, John; Wong, Yong Wee; Schulze, Christian; Streichert, Thomas; Schachner, Melitta			Short DNA sequences inserted for gene targeting can accidentally interfere with off-target gene expression	FASEB JOURNAL			English	Article						loxP sites; conditional knockout mice; genomic positional effects	EXTRACELLULAR-MATRIX; REGULATORY ELEMENTS; TENASCIN-R; DISRUPTION; NCAM; MICE; INACTIVATION; MECHANISMS; DELETION; REVEALS	Targeting of genes in mice, a key approach to study development and disease, often leaves a neo cassette, loxP, or FRT sites inserted in the mouse genome. Insertion of neo can influence the expression of neighboring genes, but similar effects have not been reported for loxP sites. We therefore performed microarray analyses of mice in which the Ncam or the Tnr gene were targeted either by insertion of neo or loxP/FRT sites. In the case of Ncam, neo, but not loxP/FRT insertion, led to a 2-fold reduction in mRNA levels of 3 genes located at distances between 0.2 and 3.1 Mb from the target. In contrast, after introduction of loxP/FRT sites into introns of Tnr, we observed a 2.5- to 4-fold reduction in the transcript level of the Gas5 gene, 1.1 Mb away from Tnr, most probably due to disruption of a conserved regulatory element in Tnr. Insertion of short DNA sequences such as loxP/FRT can thus influence off-target mRNA levels if these sites are accidentally placed into regulatory elements. Our results imply that conditional knockout mice should be analyzed for genomic positional side effects that may influence the animals' phenotypes.-Meier, I. D., Bernreuther, C., Tilling, T., Neidhardt, J., Wong, Y. W., Schulze, C., Streichert, T., Schachner, M. Short DNA sequences inserted for gene targeting can accidentally interfere with off-target gene expression. FASEB J. 24, 1714-1724 (2010). www.fasebj.org	[Meier, Ingo D.; Bernreuther, Christian; Tilling, Thomas; Neidhardt, John; Wong, Yong Wee; Schulze, Christian; Schachner, Melitta] Univ Med Ctr Hamburg Eppendorf, Ctr Mol Neurobiol, Hamburg, Germany; [Bernreuther, Christian] Univ Med Ctr Hamburg Eppendorf, Inst Neuropathol, Hamburg, Germany; [Streichert, Thomas] Univ Med Ctr Hamburg Eppendorf, Inst Clin Chem, Hamburg, Germany; [Neidhardt, John] Univ Zurich, Inst Med Genet, Div Med Mol Genet & Gene Diagnost, CH-8603 Schwerzenbach, Switzerland; [Schachner, Melitta] Rutgers State Univ, WM Keck Ctr Collaborat Neurosci, Piscataway, NJ USA; [Schachner, Melitta] Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ USA; [Schachner, Melitta] Shantou Med Coll, Ctr Neurosci, Shantou, Peoples R China	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Zurich; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Schachner, M (corresponding author), Univ Klinikum Hamburg Eppendorf, Zentrum Mol Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.	melitta.schachner@zmnh.uni-hamburg.de	Neidhardt, John/J-4310-2017; Schulze, Christian/AGJ-7744-2022	Schulze, Christian/0000-0001-9442-7141; Neidhardt, John/0000-0002-9205-8394; Schulze, Christian/0000-0002-1442-1987	Alexander von Humboldt Foundation; German Federal Ministry for Research (Nationales Genomforschungsnetz); New Jersey Professorship of Spinal Cord Research	Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); German Federal Ministry for Research (Nationales Genomforschungsnetz); New Jersey Professorship of Spinal Cord Research	The authors thank Fabio Morellini and Edgar Kramer for helpful discussions and comments on the manuscript. The authors also thank Achim Dahlmann and Peggy Putthoff for expert technical assistance, Michael Bosl for blastocyst injection, Eva Kronberg for animal care, Kristin Reeck for help with microarray analysis, Sabine Wuttke for help with the design of Supplemental Fig. S2, and Kavita Praveen for proofreading of the manuscript. This work was supported by a research fellowship awarded by the Alexander von Humboldt Foundation (to Y.W.W.); the German Federal Ministry for Research (Nationales Genomforschungsnetz; NGFN2 to M. S.); and a New Jersey Professorship of Spinal Cord Research (to M. S.).	Branda CS, 2004, DEV CELL, V6, P7, DOI 10.1016/S1534-5807(03)00399-X; Bukalo O, 2004, J NEUROSCI, V24, P1565, DOI 10.1523/JNEUROSCI.3298-03.2004; Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Dityatev A, 2006, CELL TISSUE RES, V326, P647, DOI 10.1007/s00441-006-0217-1; FIERING S, 1993, P NATL ACAD SCI USA, V90, P8469, DOI 10.1073/pnas.90.18.8469; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Hinsby AM, 2004, FRONT BIOSCI-LANDMRK, V9, P2227, DOI 10.2741/1393; Hirose T, 2006, MOL CELL, V23, P673, DOI 10.1016/j.molcel.2006.07.011; Kaufman RM, 2001, BLOOD, V98, P65, DOI 10.1182/blood.V98.1.65; Kawaji H, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040022; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833; Lestrade L, 2006, NUCLEIC ACIDS RES, V34, pD158, DOI 10.1093/nar/gkj002; Lettice LA, 2003, HUM MOL GENET, V12, P1725, DOI 10.1093/hmg/ddg180; Maness PF, 2007, NAT NEUROSCI, V10, P19, DOI 10.1038/nn1827; MORGANTI MC, 1990, EXP NEUROL, V109, P98, DOI 10.1016/S0014-4886(05)80012-3; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; Pennacchio LA, 2001, NAT REV GENET, V2, P100, DOI 10.1038/35052548; Pesheva P, 2000, PROG NEUROBIOL, V61, P465, DOI 10.1016/S0301-0082(99)00061-1; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; Ren SY, 2002, DEV DYNAM, V225, P305, DOI 10.1002/dvdy.10171; Revell PA, 2005, J IMMUNOL, V174, P2124, DOI 10.4049/jimmunol.174.4.2124; RIJLI FM, 1994, DEV DYNAM, V201, P366, DOI 10.1002/aja.1002010408; Santini S, 2003, GENOME RES, V13, P1111, DOI 10.1101/gr.700503; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Smith CM, 1998, MOL CELL BIOL, V18, P6897, DOI 10.1128/MCB.18.12.6897; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Stork O, 2000, EUR J NEUROSCI, V12, P3291, DOI 10.1046/j.1460-9568.2000.00197.x; TORRES PM, 1997, LAB PROTOCOLS CONDIT; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; vanderNeut R, 1997, J NEUROSCI METH, V71, P19, DOI 10.1016/S0165-0270(96)00123-9; Weber P, 1999, J NEUROSCI, V19, P4245, DOI 10.1523/jneurosci.19-11-04245.1999; Ying SY, 2008, MOL BIOTECHNOL, V38, P257, DOI 10.1007/s12033-007-9013-8; Zekri L, 2005, MOL CELL BIOL, V25, P8703, DOI 10.1128/MCB.25.19.8703-8716.2005	40	57	68	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1714	1724		10.1096/fj.09-140749	http://dx.doi.org/10.1096/fj.09-140749			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20110269				2022-12-28	WOS:000278200000009
J	Choi, E; Abbott, GW				Choi, Eun; Abbott, Geoffrey W.			A shared mechanism for lipid- and beta-subunit-coordinated stabilization of the activated K+ channel voltage sensor	FASEB JOURNAL			English	Article						KCNQ1; KCNE3; MinK-related peptide; colonic epithelium; activation gating	KCNQ1 POTASSIUM CHANNEL; GASTRIC-ACID-SECRETION; MEMBRANE; PROTEINS; K(V)LQT1; PORE; CONDUCTANCE; FAMILY; KCNE1; FORM	The low-dielectric plasma membrane provides an energy barrier hindering transmembrane movement of charged particles. The positively charged, voltage-sensing fourth transmembrane domain (S4) of voltage-gated ion channels must surmount this energy barrier to initiate channel activation, typically necessitating both membrane depolarization and interaction with membrane lipid phospho-head groups (MLPHGs). In contrast, and despite containing S4, the KCNQ1 K+ channel alpha subunit exhibits predominantly constitutive activation when in complexes with transmembrane beta subunits, MinK-related peptide (MiRP) 1 (KCNE2) or MiRP2 (KCNE3). Here, using a 2-electrode voltage clamp and scanning mutagenesis of channels heterologously expressed in Xenopus laevis oocytes, we discovered that 2 of the 8 MiRP2 extracellular domain acidic residues (D54 and D55) are important for KCNQ1-MiRP2 constitutive activation. Double-mutant thermodynamic cycle analysis revealed energetic coupling of D54 and D55 to R237 in KCNQ1 S4 but not to 10 other native or introduced polar residues in KCNQ1 S4 and surrounding linkers. MiRP2-D54 and KCNQ1-R237 also similarly dictated susceptibility to the inhibitory effects of MLPHG hydrolysis, whereas other closely situated polar residues did not. Thus, by providing negative charge near the plasma membrane extracellular face, MiRP2 uses a lipomimetic mechanism to constitutively stabilize the activated KCNQ1 voltage sensor.-Choi, E., Abbott, G. W. A shared mechanism for lipid-and beta-subunit-coordinated stabilization of the activated K+ channel voltage sensor. FASEB J. 24, 1518-1524 (2010). www.fasebj.org	[Abbott, Geoffrey W.] Cornell Univ, Weill Med Coll, Greenberg Div Cardiol, Dept Med, New York, NY 10021 USA; [Choi, Eun; Abbott, Geoffrey W.] Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Cornell University; Cornell University	Abbott, GW (corresponding author), Cornell Univ, Weill Med Coll, Greenberg Div Cardiol, Dept Med, Starr 463,1300 York Ave, New York, NY 10021 USA.	gwa2001@med.cornell.edu		Abbott, Geoffrey/0000-0003-4552-496X	National Institutes of Health [R01 HL079275]; American Heart Association [0855756D]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079275] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors are grateful to Dr. Gianina Panaghie (Weill Medical College, Cornell University) for construction of mutant KCNQ1 cDNAs, and Kerry Purtell for expert technical assistance. G.W.A. is supported by the National Institutes of Health (R01 HL079275) and the American Heart Association (0855756D).	Angelo K, 2002, BIOPHYS J, V83, P1997, DOI 10.1016/S0006-3495(02)73961-1; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bleich M, 2000, PFLUG ARCH EUR J PHY, V440, P202, DOI 10.1007/s004240000257; Chang HR, 2008, J NEUROSCI, V28, P1546, DOI 10.1523/JNEUROSCI.3485-07.2008; Coll O, 2007, J LIPID RES, V48, P1924, DOI 10.1194/jlr.M700069-JLR200; Dedek K, 2001, PFLUG ARCH EUR J PHY, V442, P896, DOI 10.1007/s004240100609; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Grahammer F, 2001, GASTROENTEROLOGY, V120, P1363, DOI 10.1053/gast.2001.24053; Grunnet M, 2002, J PHYSIOL-LONDON, V542, P119, DOI 10.1113/jphysiol.2002.017301; Heitzmann D, 2004, J PHYSIOL-LONDON, V561, P547, DOI 10.1113/jphysiol.2004.075168; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Kang CB, 2008, BIOCHEMISTRY-US, V47, P7999, DOI 10.1021/bi800875q; Kosek M, 2003, B WORLD HEALTH ORGAN, V81, P197; Lambrecht NWG, 2005, PHYSIOL GENOMICS, V21, P81, DOI 10.1152/physiolgenomics.00212.2004; Long SB, 2007, NATURE, V450, P376, DOI 10.1038/nature06265; McCrossan ZA, 2004, NEUROPHARMACOLOGY, V47, P787, DOI 10.1016/j.neuropharm.2004.06.018; Melman YF, 2002, J BIOL CHEM, V277, P25187, DOI 10.1074/jbc.M200564200; Melman YF, 2004, NEURON, V42, P927, DOI 10.1016/j.neuron.2004.06.001; Melman YF, 2001, J BIOL CHEM, V276, P6439, DOI 10.1074/jbc.M010713200; Panaghie G, 2006, J PHYSIOL-LONDON, V570, P455, DOI 10.1113/jphysiol.2005.100644; Panaghie G, 2007, J GEN PHYSIOL, V129, P121, DOI 10.1085/jgp.200609612; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Ries L MD, 2008, SEER CANC STAT REV 1; Roepke TK, 2006, J BIOL CHEM, V281, P23740, DOI 10.1074/jbc.M604155200; Roepke TK, 2009, NAT MED, V15, P1186, DOI 10.1038/nm.2029; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Saslowsky DE, 2009, FASEB J, V23, P259, DOI 10.1096/fj.08-116467; Schroer TA, 2000, TRAFFIC, V1, P3, DOI 10.1034/j.1600-0854.2000.010102.x; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Xu YP, 2008, NATURE, V451, P826, DOI 10.1038/nature06618	32	13	13	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2010	24	5					1518	1524		10.1096/fj.09-145219	http://dx.doi.org/10.1096/fj.09-145219			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20040519	Green Published			2022-12-28	WOS:000277158900024
J	Fulcher, AJ; Roth, DM; Fatima, S; Alvisi, G; Jans, DA				Fulcher, Alex J.; Roth, Daniela M.; Fatima, Shadma; Alvisi, Gualtiero; Jans, David A.			The BRCA-1 binding protein BRAP2 is a novel, negative regulator of nuclear import of viral proteins, dependent on phosphorylation flanking the nuclear localization signal	FASEB JOURNAL			English	Article						SV40 large-tumor antigen; T-ag; cytomegalovirus processivity factor ppUL44; cytoplasmic retention factor; nuclear transport regulation; p53 tumor suppressor	NF-KAPPA-B; DYSPLASIA/AUTOSOMAL SEX REVERSAL; TRANSCRIPTION FACTOR PHO4; VIRUS MATRIX PROTEIN; SV40 T-ANTIGEN; TARGETING SIGNAL; CYTOPLASMIC RETENTION; SITE FLANKING; DNA-BINDING; TRANSPORT	This study describes for the first time the ability of the novel BRCA1-binding protein 2 (BRAP2) to inhibit the nuclear import of specific viral proteins dependent on phosphorylation. Ectopic expression of BRAP2 in transfected African green monkey kidney COS-7 cells was found to significantly reduce nuclear localization signal (NLS)-dependent nuclear accumulation of either simian virus SV40 large-tumor antigen (T-ag) or human cytomegalovirus DNA polymerase processivity factor ppUL44; this was also observed in HL-60 human promyelocytic leukemia cells on induction of BRAP2 expression by vitamin D3 treatment. BRAP2 inhibition of nuclear accumulation was dependent on phosphorylation sites flanking the respective NLSs, where substitution of the cyclin-dependent kinase site T124 of T-ag with Ala or Asp prevented or enhanced BRAP2 inhibition of nuclear import, respectively. Substitution of T427 within the NLS of ppUL44 gave similar results, whereas no effect of BRAP2 was observed on nuclear targeting of other viral proteins, such as herpes simplex virus-1 pUL30, which lacks a phosphorylation site near its NLS, and the human immunodeficiency virus-1 Tat protein. Pulldowns/AlphaScreen assays indicated direct, high-affinity binding of BRAP2(442-592) to T-ag(111-135), strictly dependent on negative charge at T124 and the NLS. All results are consistent with BRAP2 being a novel, phosphorylation-regulated negative regulator of nuclear import, with potential as an antiviral agent.-Fulcher, A. J., Roth, D. M., Fatima, S., Alvisi, G., and Jans, D. A. The BRCA-1 binding protein BRAP2 is a novel, negative regulator of nuclear import of viral proteins, dependent on phosphorylation flanking the nuclear localization signal. FASEB J. 24, 1454-1466 (2010). www.fasebj.org	[Fulcher, Alex J.; Roth, Daniela M.; Fatima, Shadma; Alvisi, Gualtiero; Jans, David A.] Monash Univ, Dept Biochem & Mol Biol, Nucl Signaling Lab, Clayton, Vic 3800, Australia; [Fatima, Shadma; Jans, David A.] Monash Univ, Australian Res Council, Ctr Excellence Biotechnol & Dev, Clayton, Vic 3800, Australia	Monash University; Monash University	Jans, DA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Nucl Signaling Lab, Wellington Rd, Clayton, Vic 3800, Australia.	david.jans@med.monash.edu.au	Fatima, Shadma/HCG-9539-2022; Alvisi, Gualtiero/F-9915-2012	Alvisi, Gualtiero/0000-0002-8177-3616; Fatima, Shadma/0000-0002-3583-1301; Jans, David/0000-0001-5115-4745	Australian National Health and Medical Research Council [334013, 491055]; Australian Research Council (ARC Centre of Excellence) [CE0348239]	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council (ARC Centre of Excellence)(Australian Research Council)	The authors acknowledge the support of the Australian National Health and Medical Research Council (fellowship 334013 and project grant 491055) and the Australian Research Council (ARC Centre of Excellence grant CE0348239), and thank Manisha Dias and Tracy Waterhouse for skilled technical assistance, and Stefan Huebner and Teodora Paicu for assistance with preliminary experiments.	Alvisi G, 2005, TRAFFIC, V6, P1002, DOI 10.1111/j.1600-0854.2005.00331.x; Alvisi G, 2008, BBA-PROTEINS PROTEOM, V1784, P213, DOI 10.1016/j.bbapap.2007.08.021; Alvisi G, 2007, BIOCHEMISTRY-US, V46, P9155, DOI 10.1021/bi7002394; Alvisi G, 2006, BIOCHEMISTRY-US, V45, P6866, DOI 10.1021/bi060086u; Argentaro A, 2003, J BIOL CHEM, V278, P33839, DOI 10.1074/jbc.M302078200; Asada M, 2004, MOL CELL BIOL, V24, P8236, DOI 10.1128/MCB.24.18.8236-8243.2004; Baliga BC, 2003, J BIOL CHEM, V278, P4899, DOI 10.1074/jbc.M211512200; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bird CH, 2001, MOL CELL BIOL, V21, P5396, DOI 10.1128/MCB.21.16.5396-5407.2001; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; Child ES, 2006, CELL CYCLE, V5, P1313, DOI 10.4161/cc.5.12.2863; Fridell RA, 1997, J CELL SCI, V110, P1325; Ghildyal R, 2005, BIOCHEMISTRY-US, V44, P12887, DOI 10.1021/bi050701e; Ghildyal R, 2009, J VIROL, V83, P5353, DOI 10.1128/JVI.02374-08; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Harley VR, 2003, P NATL ACAD SCI USA, V100, P7045, DOI 10.1073/pnas.1137864100; Harreman MT, 2004, J BIOL CHEM, V279, P20613, DOI 10.1074/jbc.M401720200; Hubner S, 2006, J CELL BIOCHEM, V98, P810, DOI 10.1002/jcb.20791; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kim IS, 2000, J BIOL CHEM, V275, P23139, DOI 10.1074/jbc.M909256199; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Mikenberg I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000589; Moseley GW, 2007, MOL BIOL CELL, V18, P3204, DOI 10.1091/mbc.E07-01-0030; Nakajima A, 2003, CANCER LETT, V201, P195, DOI 10.1016/S0304-3835(03)00443-9; Nakielny S, 1996, EXP CELL RES, V229, P261, DOI 10.1006/excr.1996.0369; Nguyen NL, 2008, J VIROL, V82, P5381, DOI 10.1128/JVI.02697-07; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Pei Y, 2008, VIRUS RES, V135, P107, DOI 10.1016/j.virusres.2008.02.012; Piller SC, 1999, J VIROL, V73, P4230, DOI 10.1128/JVI.73.5.4230-4238.1999; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Poon IH, 2005, CANCER RES, V65, P7059, DOI 10.1158/0008-5472.CAN-05-1370; Poon IKH, 2005, TRAFFIC, V6, P173, DOI 10.1111/j.1600-0854.2005.00268.x; Poon IKH, 2005, J VIROL, V79, P1339, DOI 10.1128/JVI.79.2.1339-1341.2005; Preiss S, 2001, J BIOL CHEM, V276, P27864, DOI 10.1074/jbc.M101278200; Pryor MJ, 2007, TRAFFIC, V8, P795, DOI 10.1111/j.1600-0854.2007.00579.x; RIHS HP, 1991, FEBS LETT, V291, P6, DOI 10.1016/0014-5793(91)81090-U; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Rodriguez-Vilarrupla A, 2002, FEBS LETT, V531, P319, DOI 10.1016/S0014-5793(02)03549-4; SCHEIDTMANN KH, 1984, J VIROL, V50, P1; Sim H, 2005, MOL ENDOCRINOL, V19, P1884, DOI 10.1210/me.2004-0334; Sunn KL, 2005, BIOCHEM J, V388, P509, DOI 10.1042/BJ20042040; Tago K, 2004, MOL CELL ENDOCRINOL, V213, P131, DOI 10.1016/j.mce.2003.10.057; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Trapani JA, 1998, CELL DEATH DIFFER, V5, P488, DOI 10.1038/sj.cdd.4400373; Truant R, 1999, MOL CELL BIOL, V19, P1210; Wagstaff KM, 2006, ANAL BIOCHEM, V348, P49, DOI 10.1016/j.ab.2005.10.029; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191	56	33	35	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1454	1466		10.1096/fj.09-136564	http://dx.doi.org/10.1096/fj.09-136564			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20040518	Green Submitted			2022-12-28	WOS:000277158900018
J	Liang, LM; Meng, ZH; Ye, FP; Yang, JK; Liu, SQ; Sun, YN; Guo, Y; Mi, QL; Huang, XW; Zou, CG; Rao, ZH; Lou, ZY; Zhang, KQ				Liang, Lianming; Meng, Zhaohui; Ye, Fengping; Yang, Jinkui; Liu, Shuqun; Sun, Yuna; Guo, Yu; Mi, Qili; Huang, Xiaowei; Zou, Chenggang; Rao, Zihe; Lou, Zhiyong; Zhang, Ke-Qin			The crystal structures of two cuticle-degrading proteases from nematophagous fungi and their contribution to infection against nematodes	FASEB JOURNAL			English	Article						Ver112; PL646; serine protease; nematocidal virulence	EXTRACELLULAR SERINE-PROTEASE; PAECILOMYCES-LILACINUS; MELOIDOGYNE-INCOGNITA; ARTHROBOTRYS-OLIGOSPORA; TRAPPING FUNGUS; PROTEINASE-K; LECANICILLIUM-PSALLIOTAE; CAENORHABDITIS-ELEGANS; NEMATOCIDAL ACTIVITY; BIOLOGICAL-ACTIVITY	Cuticle-degrading proteases are involved in the breakdown of cuticle/eggshells of nematodes or insects, a hard physical barrier against fungal infections. Understanding the 3-dimensional structures of these proteins can provide crucial information for improving the effectiveness of these fungi in biocontrol applications, e. g., by targeted protein engineering. However, the structures of these proteases remain unknown. Here, we report the structures of two cuticle-degrading proteases from two species of nematophagous fungi. The two structures were solved with X-ray crystallography to resolutions of 1.65 angstrom (Ver112) and 2.1 angstrom (PL646), respectively. Crystal structures of PL646 and Ver112 were found to be very similar to each other, and similar to that of proteinase K from another fungus Tritirachium album. Differences between the structures were found among residues of the substrate binding sites (S1 and S4). Experimental studies showed that the enzymes differed in hydrolytic activity to synthetic peptide substrates. Our analyses of the hydrophobic/hydrophilic and electrostatic features of these two proteins suggest that their surfaces likely play important roles during fungal infection against nematodes. The two crystal structures provide a solid basis for investigating the relationship between structure and function of cuticle-degrading proteases.-Liang, L., Lou, Z., Ye, F., Yang, J., Liu, S., Sun, Y., Guo, Y., Mi, Q., Huang, X., Zou, C., Meng, Z., Rao, Z., Zhang, K.-Q. The crystal structures of two cuticle-degrading proteases from nematophagous fungi and their contribution to infection against nematodes. FASEB J. 24, 1391-1400 (2010). www.fasebj.org	[Liang, Lianming; Meng, Zhaohui; Ye, Fengping; Yang, Jinkui; Liu, Shuqun; Mi, Qili; Huang, Xiaowei; Zou, Chenggang; Zhang, Ke-Qin] Yunnan Univ, Lab Conservat & Utilizat Bioresources, Kunming 650091, Peoples R China; [Liang, Lianming; Meng, Zhaohui; Ye, Fengping; Yang, Jinkui; Liu, Shuqun; Mi, Qili; Huang, Xiaowei; Zou, Chenggang; Zhang, Ke-Qin] Yunnan Univ, Minist Educ, Key Lab Microbial Resources, Kunming 650091, Peoples R China; [Meng, Zhaohui] Kunming Med Univ, Affiliated Hosp 1, Dept Cardiol, Mol Cardiol Lab, Kunming, Peoples R China; [Sun, Yuna; Guo, Yu; Rao, Zihe; Lou, Zhiyong] Tsinghua Univ, Tsinghua Nankai Inst Biophys Joint Res Grp Struct, Beijing 100084, Peoples R China	Yunnan University; Yunnan University; Kunming Medical University; Tsinghua University	Zhang, KQ (corresponding author), Yunnan Univ, Lab Conservat & Utilizat Bioresources, 2 N Cuihu Rd, Kunming 650091, Peoples R China.	louzy@xtal.tsinghua.edu.cn; kqzhang111@yahoo.com.cn	zhang, ke/AAH-8217-2019; Liang, Lian-Ming/AAL-3861-2021; Rao, Zihe/HCH-6944-2022	Yang, Jinkui/0000-0002-3106-2189	National Basic Research Program of China [2007CB411600]; National Natural Science Foundation of China [30630003, 30660107, 30960229, 30860011, 30860278, 30221003]; Department of Science and Technology of Yunnan Province [2007C007Z, 2006C0071M, 2007C0001R, 2009CI052]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Science and Technology of Yunnan Province	The authors are grateful to Prof. Jianping Xu (Department of Biology, McMaster University, Hamilton, ON, Canada), for valuable comments and critical discussion. This work was funded by the National Basic Research Program of China (2007CB411600), by projects from the National Natural Science Foundation of China (30630003, 30660107, 30960229, 30860011, 30860278, and 30221003), and the Department of Science and Technology of Yunnan Province (2007C007Z, 2006C0071M, 2007C0001R, and 2009CI052).	Agarwala S. P., 1999, Journal of Communicable Diseases, V31, P193; Ahman J, 2002, APPL ENVIRON MICROB, V68, P3408, DOI 10.1128/AEM.68.7.3408-3415.2002; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Basualdo JA, 2000, PARASITOL RES, V86, P854, DOI 10.1007/PL00008513; BETZEL C, 1988, EUR J BIOCHEM, V178, P155, DOI 10.1111/j.1432-1033.1988.tb14440.x; BETZEL C, 1990, PROTEIN ENG, V3, P161, DOI 10.1093/protein/3.3.161; Bidochka MJ, 2000, CAN J MICROBIOL, V46, P1138, DOI 10.1139/cjm-46-12-1138; BLAXTER ML, 1992, PARASITOL TODAY, V8, P243, DOI 10.1016/0169-4758(92)90126-M; BONANTS PJM, 1995, MICROBIOL-UK, V141, P775, DOI 10.1099/13500872-141-4-775; Brand D, 2004, APPL BIOCHEM BIOTECH, V118, P81, DOI 10.1385/ABAB:118:1-3:081; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CABANILLAS E, 1989, J NEMATOL, V21, P164; CABANILLAS E, 1989, J NEMATOL, V21, P115; Charnley AK, 2003, ADV BOT RES, V40, P241, DOI 10.1016/S0065-2296(05)40006-3; COX GN, 1981, J CELL BIOL, V90, P7, DOI 10.1083/jcb.90.1.7; DeLano W.L, PYMOL MOL GRAPHICS S; DELMAR EG, 1979, ANAL BIOCHEM, V99, P316, DOI 10.1016/S0003-2697(79)80013-5; Dong LQ, 2007, NEMATOLOGY, V9, P743, DOI 10.1163/156854107782024802; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gunasekera TS, 2000, CAN J MICROBIOL, V46, P775, DOI 10.1139/cjm-46-9-775; HIMMELHOCH S, 1978, EXP PARASITOL, V45, P208, DOI 10.1016/0014-4894(78)90061-9; Huang XW, 2004, RES MICROBIOL, V155, P811, DOI 10.1016/j.resmic.2004.07.003; JATALA P, 1980, J NEMATOL, V12, P226; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHI L, 1995, FEMS MICROBIOL LETT, V125, P211, DOI 10.1111/j.1574-6968.1995.tb07360.x; Kalele D N, 2007, Commun Agric Appl Biol Sci, V72, P209; Khan A, 2004, BIOL CONTROL, V31, P346, DOI 10.1016/j.biocontrol.2004.07.011; Khan A, 2003, PROTEIN EXPRES PURIF, V32, P210, DOI 10.1016/j.pep.2003.07.007; Khan A, 2003, FEMS MICROBIOL LETT, V227, P107, DOI 10.1016/S0378-1097(03)00654-2; Kiewnick S., 2004, Communications in Agricultural and Applied Biological Sciences, V69, P373; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li J, 2006, PROCESS BIOCHEM, V41, P925, DOI 10.1016/j.procbio.2005.10.006; Liu SQ, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-33; Lott Mary Elizabeth, 2007, J Drugs Dermatol, V6, P436; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Mendoza A., 2004, Communications in Agricultural and Applied Biological Sciences, V69, P365; Morton CO, 2003, MYCOL RES, V107, P38, DOI 10.1017/S0953756202007050; MURRELL KD, 1983, EXP PARASITOL, V55, P331, DOI 10.1016/0014-4894(83)90030-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park JO, 2004, LETT APPL MICROBIOL, V38, P271, DOI 10.1111/j.1472-765X.2004.01488.x; Pastor FJ, 2006, CLIN MICROBIOL INFEC, V12, P948, DOI 10.1111/j.1469-0691.2006.01481.x; Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716; Saberhagen C, 1997, CLIN INFECT DIS, V25, P1411, DOI 10.1086/516136; Sasser J. N., 1987, Vistas on Nematology: A Commemoration of the Twenty-fifth Anniversary of the Society of Nematologists, P7; SEGERS R, 1994, MICROBIOL-SGM, V140, P2715, DOI 10.1099/00221287-140-10-2715; Siddiqui ZA, 1996, BIORESOURCE TECHNOL, V58, P229, DOI 10.1016/S0960-8524(96)00122-8; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; STLEGER RJ, 1987, ARCH BIOCHEM BIOPHYS, V253, P221, DOI 10.1016/0003-9861(87)90655-2; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TUNLID A, 1991, APPL ENVIRON MICROB, V57, P2868, DOI 10.1128/AEM.57.10.2868-2872.1991; TUNLID A, 1994, MICROBIOL-UK, V140, P1687, DOI 10.1099/13500872-140-7-1687; Walter H.E., 1984, METHOD ENZYMAT AN, P270; WOLF WM, 1991, J BIOL CHEM, V266, P17695; Yang JK, 2007, APPL MICROBIOL BIOT, V75, P21, DOI 10.1007/s00253-007-0881-4; Yang JK, 2005, BIOTECHNOL LETT, V27, P1123, DOI 10.1007/s10529-005-8461-0; Ye FP, 2009, ACTA CRYSTALLOGR F, V65, P271, DOI 10.1107/S1744309109003595; Zhao ML, 2004, MYCOLOGIA, V96, P16, DOI 10.2307/3761982; [No title captured]	59	29	43	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1391	1400		10.1096/fj.09-136408	http://dx.doi.org/10.1096/fj.09-136408			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20007510				2022-12-28	WOS:000277158900012
J	van den Broek, NMA; Ciapaite, J; De Feyter, HMML; Houten, SM; Wanders, RJA; Jeneson, JAL; Nicolay, K; Prompers, JJ				van den Broek, N. M. A.; Ciapaite, J.; De Feyter, H. M. M. L.; Houten, S. M.; Wanders, R. J. A.; Jeneson, J. A. L.; Nicolay, K.; Prompers, J. J.			Increased mitochondrial content rescues in vivo muscle oxidative capacity in long-term high-fat-diet-fed rats	FASEB JOURNAL			English	Article						diabetes; insulin resistance; magnetic resonance spectroscopy; intramyocellular lipid; mitochondrial function	SATURATION-TRANSFER MEASUREMENTS; INTRAMYOCELLULAR LIPID-CONTENT; SKELETAL-MUSCLE; INSULIN-RESISTANCE; LIVER-MITOCHONDRIA; GENE-EXPRESSION; ACID OXIDATION; PHOSPHORYLATION; DEHYDROGENASE; DYSFUNCTION	Mitochondria are thought to play a crucial role in the etiology of muscle insulin resistance (IR). The aim of this study was to gain more insight into the timing and nature of mitochondrial adaptations during the development of high-fat-diet (HFD)-induced IR. Adult Wistar rats were fed HFD or normal chow for 2.5 and 25 wk. Intramyocellular lipids (IMCLs) were quantified in vivo using H-1 magnetic resonance spectroscopy (MRS). Muscle oxidative capacity was assessed in vivo using P-31 MRS and in vitro by measuring mitochondrial DNA copy number and oxygen consumption in isolated mitochondria. MRS in tibialis anterior muscle revealed 3.3-fold higher IMCL content and 1.2-fold increased oxidative capacity after 2.5 wk of HFD feeding. The latter result could be fully accounted for by increased mitochondrial content. After 25 wk of HFD, maximal ADP-stimulated oxygen consumption in isolated mitochondria oxidizing pyruvate plus malate remained unaffected, while IMCL and mitochondrial content had further increased compared to controls (5.1-fold and 1.4-fold, respectively). Interestingly, in vivo oxidative capacity at this time point was identical to controls. These results show that skeletal muscle in HFD-induced IR accompanied by IMCL accumulation requires a progressively larger mitochondrial pool size to maintain normal oxidative capacity in vivo.-Van den Broek, N. M. A., Ciapaite, J., De Feyter, H. M. M. L., Houten, S. M., Wanders, R. J. A., Jeneson, J. A. L., Nicolay, K., Prompers, J. J. Increased mitochondrial content rescues in vivo muscle oxidative capacity in long-term high-fat-diet-fed rats. FASEB J. 24, 1354-1364 (2010). www.fasebj.org	[van den Broek, N. M. A.; Ciapaite, J.; Jeneson, J. A. L.; Nicolay, K.; Prompers, J. J.] Eindhoven Univ Technol, Biomed NMR, Dept Biomed Engn, NL-5600 MB Eindhoven, Netherlands; [Ciapaite, J.; Jeneson, J. A. L.] Netherlands Consortium Syst Biol, Amsterdam, Netherlands; [De Feyter, H. M. M. L.] Yale Univ, Sch Med, Dept Diagnost Radiol, Magnet Resonance Res Ctr, New Haven, CT 06510 USA; [Houten, S. M.; Wanders, R. J. A.] Univ Amsterdam, Acad Med Ctr, Dept Pediat, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands; [Houten, S. M.; Wanders, R. J. A.] Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands	Eindhoven University of Technology; Yale University; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Prompers, JJ (corresponding author), Eindhoven Univ Technol, Biomed NMR, Dept Biomed Engn, NL B1-08,POB 513, NL-5600 MB Eindhoven, Netherlands.	j.j.prompers@tue.nl	De Feyter, Henk/B-8107-2008; Houten, Sander/Y-3599-2019; Nicolay, Klaas/F-4192-2010	De Feyter, Henk/0000-0001-6111-0316; Houten, Sander/0000-0002-6167-9147; Ciapaite, Jolita/0000-0001-8761-9233; Nicolay, Klaas/0000-0002-4179-616X; Prompers, Jeanine/0000-0002-4756-4474	Netherlands Consortium for Systems Biology (NCSB); Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research; Netherlands Organisation for Scientific Research (VIDI) [700.58.421, 016.086.336]	Netherlands Consortium for Systems Biology (NCSB); Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Netherlands Organisation for Scientific Research (VIDI)(Netherlands Organization for Scientific Research (NWO))	The authors thank J. W. Habets, L. B. P. Niesen, and R. A. M. Jonkers for technical assistance. The work of J. C. and J. A. L. J. is financed by the Netherlands Consortium for Systems Biology (NCSB), which is part of the Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research. J. J. P. and S. M. H. are supported by VIDI grants from the Netherlands Organisation for Scientific Research (VIDI grants 700.58.421 and 016.086.336, respectively).	Andrade FH, 2005, INVEST OPHTH VIS SCI, V46, P4541, DOI 10.1167/iovs.05-0809; Boden G, 2001, DIABETES, V50, P1612, DOI 10.2337/diabetes.50.7.1612; Bonnard C, 2008, J CLIN INVEST, V118, P789, DOI 10.1172/JCI32601; Boushel R, 2007, DIABETOLOGIA, V50, P790, DOI 10.1007/s00125-007-0594-3; BRASS EP, 1980, BIOCHEM J, V190, P495, DOI 10.1042/bj1900495; BRINDLE KM, 1989, BIOCHEMISTRY-US, V28, P4887, DOI 10.1021/bi00437a054; BRINDLE KM, 1987, BIOCHIM BIOPHYS ACTA, V928, P45, DOI 10.1016/0167-4889(87)90084-X; Chanseaume E, 2007, OBESITY, V15, P50, DOI 10.1038/oby.2007.511; Ciapaite J, 2007, BBA-MOL BASIS DIS, V1772, P307, DOI 10.1016/j.bbadis.2006.10.018; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; Costford SR, 2008, AM J PHYSIOL-ENDOC M, V295, pE1018, DOI 10.1152/ajpendo.00779.2007; De Feyter HM, 2008, EUR J ENDOCRINOL, V158, P643, DOI 10.1530/EJE-07-0756; De Feyter HM, 2008, FASEB J, V22, P3947, DOI 10.1096/fj.08-112318; De Feyter HMML, 2006, MAGN RESON MED, V56, P19, DOI 10.1002/mrm.20924; de Graaf RA, 1998, MAGNET RESON MED, V40, P690, DOI 10.1002/mrm.1910400508; Didier L, 2007, AM J PHYSIOL-ENDOC M, V293, pE1169, DOI 10.1152/ajpendo.00263.2007; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Garcia-Roves P, 2007, P NATL ACAD SCI USA, V104, P10709, DOI 10.1073/pnas.0704024104; Garwood M, 2001, J MAGN RESON, V153, P155, DOI 10.1006/jmre.2001.2340; Goodpaster BH, 2001, J CLIN ENDOCR METAB, V86, P5755, DOI 10.1210/jc.86.12.5755; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; Hancock CR, 2008, P NATL ACAD SCI USA, V105, P7815, DOI 10.1073/pnas.0802057105; Hoeks J, 2008, FEBS LETT, V582, P510, DOI 10.1016/j.febslet.2008.01.013; Iossa S, 2003, BRIT J NUTR, V90, P953, DOI 10.1079/BJN2003000968; KEMP GJ, 1994, MAGN RESON QUART, V10, P43; Kemp GJ, 2008, AM J PHYSIOL-ENDOC M, V294, pE640, DOI 10.1152/ajpendo.00797.2007; Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013; LAAKSO M, 1992, DIABETES, V41, P1076, DOI 10.2337/diabetes.41.9.1076; LERNER E, 1972, J BIOL CHEM, V247, P1513; LIN BJ, 2002, J MICROLITH MICROFAB, V1, P1; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; McAinch AJ, 2003, OBES RES, V11, P1471, DOI 10.1038/oby.2003.197; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morino K, 2006, DIABETES, V55, pS9, DOI 10.2337/db06-S002; MUNUJOS P, 1993, ANAL BIOCHEM, V212, P506, DOI 10.1006/abio.1993.1360; NEMETH PM, 1992, AM J PHYSIOL, V262, pC282, DOI 10.1152/ajpcell.1992.262.2.C282; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; QUISTORFF B, 1993, BIOCHEM J, V291, P681, DOI 10.1042/bj2910681; REICHERT M, 1978, ACTA BIOL MED GER, V37, P1167; Ritov VB, 2005, DIABETES, V54, P8, DOI 10.2337/diabetes.54.1.8; Sahlin K, 1978, Acta Physiol Scand Suppl, V455, P1; Short KR, 2004, NEW ENGL J MED, V350, P2419; Sinha R, 2002, DIABETES, V51, P1022, DOI 10.2337/diabetes.51.4.1022; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; SRERE PA, 1963, ACTA CHEM SCAND, V17, P129, DOI 10.3891/acta.chem.scand.17s-0129; Stump CS, 2003, P NATL ACAD SCI USA, V100, P7996, DOI 10.1073/pnas.1332551100; Szuhai K, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e13; Taylor D J, 1983, Mol Biol Med, V1, P77; Toledo FGS, 2007, DIABETES, V56, P2142, DOI 10.2337/db07-0141; Tran TT, 2003, CANCER EPIDEM BIOMAR, V12, P47; Turner N, 2008, TRENDS ENDOCRIN MET, V19, P324, DOI 10.1016/j.tem.2008.08.001; Turner N, 2007, DIABETES, V56, P2085, DOI 10.2337/db07-0093; van Hall G, 1999, P NUTR SOC, V58, P899, DOI 10.1017/S0029665199001202; van Loon LJC, 2004, AM J PHYSIOL-ENDOC M, V287, pE558, DOI 10.1152/ajpendo.00464.2003; Van Vlies N, 2005, BIOCHEM J, V387, P185, DOI 10.1042/BJ20041489; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; Vicini P, 2000, AM J PHYSIOL-CELL PH, V279, pC213, DOI 10.1152/ajpcell.2000.279.1.C213; Wagenmakers AJM, 2005, PLOS MED, V2, P839, DOI 10.1371/journal.pmed.0020289; Wanders RJA, 1999, J INHERIT METAB DIS, V22, P442, DOI 10.1023/A:1005504223140; Wang YF, 2005, AM J CLIN NUTR, V81, P555; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	63	41	42	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1354	1364		10.1096/fj.09-143842	http://dx.doi.org/10.1096/fj.09-143842			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20040520				2022-12-28	WOS:000277158900009
J	Zentilin, L; Puligadda, U; Lionetti, V; Zacchigna, S; Collesi, C; Pattarini, L; Ruozi, G; Camporesi, S; Sinagra, G; Pepe, M; Recchia, FA; Giacca, M				Zentilin, Lorena; Puligadda, Uday; Lionetti, Vincenzo; Zacchigna, Serena; Collesi, Chiara; Pattarini, Lucia; Ruozi, Giulia; Camporesi, Silvia; Sinagra, Gianfranco; Pepe, Martino; Recchia, Fabio A.; Giacca, Mauro			Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction	FASEB JOURNAL			English	Article						apoptosis; adeno-associated virus; angiogenesis; gene therapy; gene expression	ENDOTHELIAL GROWTH-FACTOR; SKELETAL-MUSCLE REGENERATION; IN-VIVO; STEM-CELLS; MOLECULAR-BASIS; ADULT-MOUSE; ANGIOGENESIS; MICE; EXPRESSION; RECEPTOR	Mounting evidence indicates that the function of members of the vascular endothelial growth factor (VEGF) family extends beyond blood vessel formation. Here, we show that the prolonged intramyocardial expression of VEGF-A165 and VEGF-B167 on adeno-associated virus-mediated gene delivery determined a marked improvement in cardiac function after myocardial infarction in rats, by promoting cardiac contractility, preserving viable cardiac tissue, and preventing remodeling of the left ventricle (LV) over time. Consistent with this functional outcome, animals treated with both factors showed diminished fibrosis and increased contractile myocardium, which were more pronounced after expression of the selective VEGF receptor-1 (VEGFR-1) ligand VEGF-B, in the absence of significant induction of angiogenesis. We found that cardiomyocytes expressed VEGFR-1, VEGFR-2, and neuropilin-1 and that, in particular, VEGFR-1 was specifically up-regulated in hypoxia and on exposure to oxidative stress. VEGF-B exerted powerful antiapoptotic effect in both cultured cardiomyocytes and after myocardial infarction in vivo. Finally, VEGFR-1 activation by VEGF-B was found to elicit a peculiar gene expression profile proper of the compensatory, hypertrophic response, consisting in activation of alpha MHC and repression of beta MHC and skeletal alpha-actin, and an increase in SERCA2a, RYR, PGC1 alpha, and cardiac natriuretic peptide transcripts, both in cultured cardiomyocytes and in infarcted hearts. The finding that VEGFR-1 activation by VEGF-B prevents loss of cardiac mass and promotes maintenance of cardiac contractility over time has obvious therapeutic implications.-Zentilin, L., Puligadda, U., Lionetti, V., Zacchigna, S., Collesi, C., Pattarini, L., Ruozi, G., Camporesi, S., Sinagra, G., Pepe, M., Recchia, F. A., Giacca, M. Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction. FASEB J. 24, 1467-1478 (2010). www.fasebj.org	[Zentilin, Lorena; Puligadda, Uday; Zacchigna, Serena; Collesi, Chiara; Pattarini, Lucia; Ruozi, Giulia; Camporesi, Silvia; Giacca, Mauro] ICGEB, Mol Med Lab, Trieste, Italy; [Lionetti, Vincenzo; Recchia, Fabio A.] Scuola Super Sant Anna, Sector Med, Pisa, Italy; [Sinagra, Gianfranco] Osped Cattinara, Azienda Osped Univ Osped Riuniti Trieste, SC Cardiol, Trieste, Italy; [Pepe, Martino; Recchia, Fabio A.] New York Med Coll, New York, NY USA; [Giacca, Mauro] Univ Trieste, Fac Med, Dept Biomed, Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB); Scuola Superiore Sant'Anna; New York Medical College; University of Trieste	Giacca, M (corresponding author), CGEB Trieste, Mol Med Lab, Padriciano 99, I-34012 Trieste, Italy.	giacca@icgeb.org	sinagra, gianfranco gs/P-7643-2014; Lionetti, Vincenzo/AAH-9503-2020; Recchia, Fabio/F-2315-2010; Sinagra, Gianfranco/AAE-3943-2020; Lionetti, Vincenzo/AAN-1994-2020; Giacca, Mauro/J-9287-2016; Collesi, Chiara/AAB-8979-2019; Lionetti, Vincenzo/G-9528-2014; ZACCHIGNA, SERENA/E-9496-2017	Lionetti, Vincenzo/0000-0002-0640-8651; Giacca, Mauro/0000-0003-2927-7225; SINAGRA, GIANFRANCO/0000-0003-2700-8478; ZACCHIGNA, SERENA/0000-0001-6705-3076; COLLESI, CHIARA/0000-0003-3909-422X	Fondazione CR Trieste, Trieste, Italy; Regione Friuli Venezia Giulia, Italy; World Anti-Doping Agency (WADA), Montreal, Canada	Fondazione CR Trieste, Trieste, Italy; Regione Friuli Venezia Giulia, Italy(Regione Friuli Venezia Giulia); World Anti-Doping Agency (WADA), Montreal, Canada	The authors are grateful to Marina Dapas and Michela Zotti for superb technical support in AAV production, to Mauro Sturnega for help in animal experimentation, and to Suzanne Kerbavcic for editorial assistance. This work was supported by a grant from the Fondazione CR Trieste, Trieste, Italy; by grants from the Regione Friuli Venezia Giulia, Italy; and by a grant from the World Anti-Doping Agency (WADA), Montreal, Canada. F. A. R. is an Established Investigator of the American Heart Association.	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Arsic N, 2004, MOL THER, V10, P844, DOI 10.1016/j.ymthe.2004.08.007; Arsic N, 2003, MOL THER, V7, P450, DOI 10.1016/S1525-0016(03)00034-0; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Bhardwaj S, 2003, HUM GENE THER, V14, P1451, DOI 10.1089/104303403769211664; BRENT GA, 1994, NEW ENGL J MED, V331, P847; Brusselmans K, 2005, J BIOL CHEM, V280, P3493, DOI 10.1074/jbc.M406613200; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Collesi C, 2008, J CELL BIOL, V183, P117, DOI 10.1083/jcb.200806091; Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667; DILLMANN W, 2009, HEART FAIL REV; Eble DM, 1998, AM J PHYSIOL-CELL PH, V274, pC1226, DOI 10.1152/ajpcell.1998.274.5.C1226; Favre D, 2001, MOL THER, V4, P559, DOI 10.1006/mthe.2001.0494; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrarini M, 2006, CIRC RES, V98, P954, DOI 10.1161/01.RES.0000217342.83731.89; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Germani A, 2003, AM J PATHOL, V163, P1417, DOI 10.1016/S0002-9440(10)63499-2; Hoshijima M, 2006, AM J PHYSIOL-HEART C, V290, pH1313, DOI 10.1152/ajpheart.00816.2005; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Karpanen T, 2008, CIRC RES, V103, P1018, DOI 10.1161/CIRCRESAHA.108.178459; Lahteenvuo JE, 2009, CIRCULATION, V119, P845, DOI 10.1161/CIRCULATIONAHA.108.816454; Lagercrantz J, 1998, BBA-GENE STRUCT EXPR, V1398, P157, DOI 10.1016/S0167-4781(98)00040-2; Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Li X, 2008, ARTERIOSCL THROM VAS, V28, P1614, DOI 10.1161/ATVBAHA.107.158725; Li Y, 2008, J CLIN INVEST, V118, P913, DOI 10.1172/JCI33673; Liu Q, 2003, GENE THER, V10, P935, DOI 10.1038/sj.gt.3302036; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Mayr-Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756-3282(01)00690-1; Messina S, 2007, FASEB J, V21, P3737, DOI 10.1096/fj.07-8459com; Mould AW, 2005, CIRC RES, V97, P60, DOI 10.1161/01.RES.0000182631.33638.77; Mueller C, 2008, GENE THER, V15, P858, DOI 10.1038/gt.2008.68; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; PARK JE, 1994, J BIOL CHEM, V269, P25646; PFEFFER MA, 1979, CIRC RES, V44, P503, DOI 10.1161/01.RES.44.4.503; Poesen K, 2008, J NEUROSCI, V28, P10451, DOI 10.1523/JNEUROSCI.1092-08.2008; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Rottbauer W, 2005, GENE DEV, V19, P1624, DOI 10.1101/gad.1319405; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785; Schaub MC, 1997, J MOL MED, V75, P901, DOI 10.1007/s001090050182; Silvestre JS, 2003, CIRC RES, V93, P114, DOI 10.1161/01.RES.0000081594.21764.44; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682; Tardiff JC, 2000, AM J PHYSIOL-HEART C, V278, pH412, DOI 10.1152/ajpheart.2000.278.2.H412; Tirziu D, 2007, J CLIN INVEST, V117, P3188, DOI 10.1172/JCI32024; Trivieri MG, 2006, P NATL ACAD SCI USA, V103, P6043, DOI 10.1073/pnas.0601072103; Ventura C, 2007, J BIOL CHEM, V282, P14243, DOI 10.1074/jbc.M609350200; Zacchigna S, 2008, J CLIN INVEST, V118, P2062, DOI 10.1172/JCI32832; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	54	123	135	2	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1467	1478		10.1096/fj.09-143180	http://dx.doi.org/10.1096/fj.09-143180			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20019242				2022-12-28	WOS:000277158900019
J	Espinoza, DO; Boros, LG; Crunkhorn, S; Gami, H; Patti, ME				Espinoza, Daniel O.; Boros, Laszlo G.; Crunkhorn, Sarah; Gami, Hiral; Patti, Mary-Elizabeth			Dual modulation of both lipid oxidation and synthesis by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha and-1 beta in cultured myotubes	FASEB JOURNAL			English	Article						metabolomics; fatty acid metabolism; lipid metabolism	HUMAN SKELETAL-MUSCLE; INDUCED INSULIN-RESISTANCE; SATURATED FATTY-ACIDS; ERR-ALPHA; CERAMIDE SYNTHESIS; ENERGY-METABOLISM; GENE-EXPRESSION; ADIPOSE-TISSUE; OBESE SUBJECTS; PGC-1-ALPHA	The peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family is a key regulator of mitochondrial function, and reduced mRNA expression may contribute to muscle lipid accumulation in obesity and type 2 diabetes. To characterize the effects of PGC-1 on lipid metabolism, we overexpressed PGC-1 alpha and PGC-1 beta in C2C12 myotubes using adenoviral vectors. Both PGC-1 alpha and -1 beta increased palmitate oxidation [31% (P<0.01) and 26% (P<0.05), respectively] despite reductions in cellular uptake [by 6% (P<0.05) and 21% (P<0.001)]. Moreover, PGC-1 alpha and -1 beta increased mRNA expression of genes regulating both lipid oxidation (e.g., CPT1b and ACADL/M) and synthesis (FAS, CS, ACC1/2, and DGAT1). To determine the net effect, we assessed lipid composition in PGC-1-expressing cells. Total lipid content decreased by 42% in palmitate-loaded serum-starved cells overexpressing PGC-1 alpha (P<0.05). In contrast, in serum-replete cells, total lipid content was not significantly altered, but fatty acids C14:0, C16:0, C18:0, and C18: 1 were increased 2- to 4-fold for PGC-1 alpha/beta (P<0.05). Stable isotope-based dynamic metabolic profiling in serum-replete cells labeled with C-13 substrates revealed both increased de novo fatty acid synthesis from glucose and increased fatty acid synthesis by chain elongation with either PGC-1 alpha or -1 beta expression. These results indicate that PGC-1 can promote both lipid oxidation and synthesis, with net balance determined by the nutrient/hormonal environment.-Espinoza, D. O., Boros, L. G., Crunkhorn, S., Gami, H., Patti, M.-E. Dual Modulation of both lipid oxidation and synthesis by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha and -1 beta in cultured myotubes. FASEB J. 24, 1003-1014 (2010). www.fasebj.org	[Espinoza, Daniel O.; Crunkhorn, Sarah; Gami, Hiral; Patti, Mary-Elizabeth] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; [Espinoza, Daniel O.; Crunkhorn, Sarah; Gami, Hiral; Patti, Mary-Elizabeth] Harvard Univ, Sch Med, Boston, MA USA; [Boros, Laszlo G.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; [Boros, Laszlo G.] SIDMAP LLC, Los Angeles, CA USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Patti, ME (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	mary.elizabeth.patti@joslin.harvard.edu			National Institute of Diabetes and Digestive and Kidney Diseases [DK062948]; Diabetes and Endocrinology Research Center [P30 DK36836]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062948, P30DK036836] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Diabetes and Endocrinology Research Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Bruce Spiegelman (Dana Farber Cancer Institute, Boston, MA, USA) for the gift of adenovirus constructs Ad-GFP, AdPGC-1 alpha, and AdPGC-1 beta and Drs. Masa Katic, Yuji Yamamoto, and Enxuan Jing (Joslin Diabetes Center, Boston, MA, USA) for selected primers. The authors appreciate the assistance of the Lipid Core, Mouse Metabolic Phenotyping Center, Vanderbilt University (Nashville, TN, USA). The authors gratefully acknowledge grant funding from the National Institute of Diabetes and Digestive and Kidney Diseases (DK062948) and the Diabetes and Endocrinology Research Center (P30 DK36836).	Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25; Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002; Arany Z, 2007, CELL METAB, V5, P35, DOI 10.1016/j.cmet.2006.12.003; BABSON AL, 1962, CLIN CHIM ACTA, V7, P800, DOI 10.1016/0009-8981(62)90062-1; Benton CR, 2008, J BIOL CHEM, V283, P4228, DOI 10.1074/jbc.M704332200; Bodennec J, 2000, J LIPID RES, V41, P1524; Calvo JA, 2008, J APPL PHYSIOL, V104, P1304, DOI 10.1152/japplphysiol.01231.2007; Crowder CM, 2009, SCIENCE, V324, P343, DOI 10.1126/science.1173278; Crunkhorn S, 2007, J BIOL CHEM, V282, P15439, DOI 10.1074/jbc.M611214200; Dufour CR, 2007, CELL METAB, V5, P345, DOI 10.1016/j.cmet.2007.03.007; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; Goodpaster BH, 2001, J CLIN ENDOCR METAB, V86, P5755, DOI 10.1210/jc.86.12.5755; Hammarstedt A, 2003, BIOCHEM BIOPH RES CO, V301, P578, DOI 10.1016/S0006-291X(03)00014-7; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Handschin C, 2007, J CLIN INVEST, V117, P3463, DOI 10.1172/JCI31785; Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200; Haus JM, 2009, DIABETES, V58, P337, DOI 10.2337/db08-1228; Holland WL, 2007, CELL METAB, V5, P167, DOI 10.1016/j.cmet.2007.01.002; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Jacob S, 1999, DIABETES, V48, P1113, DOI 10.2337/diabetes.48.5.1113; Jakobsson A, 2006, PROG LIPID RES, V45, P237, DOI 10.1016/j.plipres.2006.01.004; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Koves TR, 2005, J BIOL CHEM, V280, P33588, DOI 10.1074/jbc.M507621200; Larrouy D, 1999, INT J OBESITY, V23, P1327, DOI 10.1038/sj.ijo.0801106; Lelliott CJ, 2006, PLOS BIOL, V4, P2042, DOI 10.1371/journal.pbio.0040369; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Montell E, 2001, AM J PHYSIOL-ENDOC M, V280, pE229, DOI 10.1152/ajpendo.2001.280.2.E229; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Pewzner-Jung Y, 2006, J BIOL CHEM, V281, P25001, DOI 10.1074/jbc.R600010200; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Richardson DK, 2005, J BIOL CHEM, V280, P10290, DOI 10.1074/jbc.M408985200; Russell AP, 2005, FASEB J, V19, P986, DOI 10.1096/fj.04-3168fje; Savage DB, 2007, PHYSIOL REV, V87, P507, DOI 10.1152/physrev.00024.2006; Scarpulla RC, 2002, GENE, V286, P81, DOI 10.1016/S0378-1119(01)00809-5; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Semple RK, 2004, INT J OBESITY, V28, P176, DOI 10.1038/sj.ijo.0802482; Simoneau JA, 1997, J APPL PHYSIOL, V83, P166, DOI 10.1152/jappl.1997.83.1.166; SONODA J, P NATL ACAD SCI US, V104, P5223; Sparks LM, 2005, DIABETES, V54, P1926, DOI 10.2337/diabetes.54.7.1926; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Tortorella LL, 2002, AM J PHYSIOL-ENDOC M, V283, pE514, DOI 10.1152/ajpendo.00092.2002; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Vianna CR, 2006, CELL METAB, V4, P453, DOI 10.1016/j.cmet.2006.11.003; Wende AR, 2007, J BIOL CHEM, V282, P36642, DOI 10.1074/jbc.M707006200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yang G, 2009, AM J PHYSIOL-ENDOC M, V297, pE211, DOI 10.1152/ajpendo.91014.2008	55	45	46	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1003	1014		10.1096/fj.09-133728	http://dx.doi.org/10.1096/fj.09-133728			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19906680	Green Published			2022-12-28	WOS:000276462300008
J	Owczarek, S; Kiryushko, D; Larsen, MH; Kastrup, JS; Gajhede, M; Sandi, C; Berezin, V; Bock, E; Soroka, V				Owczarek, Sylwia; Kiryushko, Darya; Larsen, Marianne Hald; Kastrup, Jette Sandholm; Gajhede, Michael; Sandi, Carmen; Berezin, Vladimir; Bock, Elisabeth; Soroka, Vladislav			Neuroplastin-55 binds to and signals through the fibroblast growth factor receptor	FASEB JOURNAL			English	Article						hippocampal; cell adhesion molecule; mimetic peptide; synaptic plasticity	CELL-ADHESION MOLECULE; LONG-TERM POTENTIATION; IMMUNOGLOBULIN-SUPERFAMILY MEMBERS; SYNAPTIC GLYCOPROTEIN NEUROPLASTIN; SYNTHETIC PEPTIDE LIGAND; FGF-RECEPTOR; NEURITE OUTGROWTH; CRYSTAL-STRUCTURE; PRESYNAPTIC FUNCTION; HOMOPHILIC ADHESION	Neuroplastin (Np) is a glycoprotein belonging to the immunoglobulin superfamily of cell adhesion molecules (CAMs) and existing in two isoforms, Np55 and Np65, named according to their molecular weights. The extracellular part of Np65 contains three immunoglobulin (Ig)-like modules (Ig1, Ig2, and Ig3), whereas Np55 lacks the Ig1 module. Of these two isoforms, only Np65 is involved in homophilic interactions resulting in cell adhesion, whereas the role of Np55 is poorly understood. The present study reports for the first time the crystal structure of the ectodomain of Np55 at 1.95-angstrom resolution and demonstrates that Np55 binds to and activates the fibroblast growth factor receptor 1 (FGFR1). Furthermore, we identify a sequence motif in the Ig2 module of Np55 interacting with FGFR1 and show that a synthetic peptide encompassing this motif, termed narpin, binds to and activates FGFR1. We show that both Np55 and the narpin peptide induce neurite outgrowth through FGFR1 activation and that Np55 increases synaptic calcium concentration in an FGFR1-dependent manner. Moreover, we demonstrate that narpin has an antidepressive-like effect in rats subjected to the forced swim test, suggesting that Np55-induced signaling may be involved in synaptic plasticity in vivo. Owczarek, S., Kiryushko, D., Larsen, M. H., Kastrup, J. S., Gajhede, M., Sandi, C., Berezin, V., Bock, E., Soroka, V. Neuroplastin-55 binds to and signals through the fibroblast growth factor receptor. FASEB J. 24, 1139-1150 (2010). www.fasebj.org	[Owczarek, Sylwia] Univ Copenhagen, Panum Inst, Dept Neurosci & Pharmacol, Prot Lab, DK-2200 Copenhagen, Denmark; [Kastrup, Jette Sandholm; Gajhede, Michael] Univ Copenhagen, Fac Pharmaceut Sci, Dept Med Chem, DK-2200 Copenhagen, Denmark; [Larsen, Marianne Hald; Sandi, Carmen] Ecole Polytech Fed Lausanne, Brain Mind Inst, Lausanne, Switzerland; [Soroka, Vladislav] Enkam Pharmaceut AS, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Owczarek, S (corresponding author), Univ Copenhagen, Panum Inst, Dept Neurosci & Pharmacol, Prot Lab, Blegdamsvej 3C,Bldg 24-2, DK-2200 Copenhagen, Denmark.	sylwia@sund.ku.dk		Kastrup, Jette Sandholm/0000-0003-2654-1510; Gajhede, Michael/0000-0001-9864-2287; Sandi, Carmen/0000-0001-7713-8321	Seventh Framework Programme (FP7) [HEALTH-F2M-2007201600]; Swiss National Science Foundation [3100A0-108102]; Alfred Benzon Foundation (Denmark), Neurocluster; Copenhagen University; Lundbeck Foundation; Danish Research Councils	Seventh Framework Programme (FP7)(European Commission); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Alfred Benzon Foundation (Denmark), Neurocluster; Copenhagen University; Lundbeck Foundation(Lundbeckfonden); Danish Research Councils(Det Frie Forskningsrad (DFF))	The authors thank Gregoire Parchet and beamline scientists at the European Molecular Biology Laboratory (DESY, Hamburg, Germany) and ESRF (Grenoble, France) for skillful technical assistance. This study was supported by a Seventh Framework Programme (FP7) grant (HEALTH- F2M-2007201600; MemStick to C.S.), the Swiss National Science Foundation (3100A0-108102), the Alfred Benzon Foundation (Denmark), Neurocluster, Copenhagen University, the Lundbeck Foundation, and the Danish Research Councils.	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aonurm-Helm A, 2008, EUR J NEUROSCI, V28, P1618, DOI 10.1111/j.1460-9568.2008.06471.x; Archer FR, 1999, EUR J NEUROSCI, V11, P3565, DOI 10.1046/j.1460-9568.1999.00773.x; Belton RJ, 2008, J BIOL CHEM, V283, P17805, DOI 10.1074/jbc.M801876200; Bernstein HG, 2007, BRAIN RES, V1134, P107, DOI 10.1016/j.brainres.2006.11.090; Bukalo O, 2004, J NEUROSCI, V24, P1565, DOI 10.1523/JNEUROSCI.3298-03.2004; Cambon K, 2004, J NEUROSCI, V24, P4197, DOI 10.1523/JNEUROSCI.0436-04.2004; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Einat H, 2003, J NEUROSCI, V23, P7311; Empson RM, 2006, J NEUROCHEM, V99, P850, DOI 10.1111/j.1471-4159.2006.04123.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans SJ, 2004, P NATL ACAD SCI USA, V101, P15506, DOI 10.1073/pnas.0406788101; Garcia-Maya M, 2006, J CELL PHYSIOL, V206, P386, DOI 10.1002/jcp.20483; Hansen SM, 2008, CELL MOL LIFE SCI, V65, P3809, DOI 10.1007/s00018-008-8290-0; Jacobsen J, 2008, NEUROCHEM RES, V33, P2532, DOI 10.1007/s11064-008-9680-2; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kiryushko D, 2006, MOL BIOL CELL, V17, P2278, DOI 10.1091/mbc.E05-10-0987; Kiryushko D, 2003, J BIOL CHEM, V278, P12325, DOI 10.1074/jbc.M211628200; Kiselyov VV, 2006, PROTEIN SCI, V15, P2318, DOI 10.1110/ps.062206106; Kiselyov VV, 2003, STRUCTURE, V11, P691, DOI 10.1016/S0969-2126(03)00096-0; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Kulahin N, 2008, MOL CELL NEUROSCI, V37, P528, DOI 10.1016/j.mcn.2007.12.001; Langnaese K, 1998, FEBS LETT, V429, P284, DOI 10.1016/S0014-5793(98)00616-4; Langnaese K, 1997, J BIOL CHEM, V272, P821, DOI 10.1074/jbc.272.2.821; Laskowski RA, 2009, NUCLEIC ACIDS RES, V37, pD355, DOI 10.1093/nar/gkn860; LUTHL A, 1994, NATURE, V22, P777; Marzban H, 2003, J COMP NEUROL, V462, P286, DOI 10.1002/cne.10719; Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008; Neiiendam JL, 2004, J NEUROCHEM, V91, P920, DOI 10.1111/j.1471-4159.2004.02779.x; Olsen SK, 2004, P NATL ACAD SCI USA, V101, P935, DOI 10.1073/pnas.0307287101; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; PORSOLT RD, 1978, EUR J PHARMACOL, V47, P379, DOI 10.1016/0014-2999(78)90118-8; Porter NM, 1997, J NEUROSCI, V17, P5629; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; Reuss B, 2003, CELL TISSUE RES, V313, P139, DOI 10.1007/s00441-003-0756-7; Ronn LCB, 2000, J NEUROCHEM, V75, P665, DOI 10.1046/j.1471-4159.2000.0750665.x; Rosenthal R, 2001, FASEB J, V15, P970, DOI 10.1096/fj.00-0188com; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Smalla KH, 2000, P NATL ACAD SCI USA, V97, P4327, DOI 10.1073/pnas.080389297; Soroka V, 2003, STRUCTURE, V11, P1291, DOI 10.1016/j.str.2003.09.006; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; TSANG M, 2004, SCI STKE, V228, P17; Turner CA, 2008, BRAIN RES, V1224, P63, DOI 10.1016/j.brainres.2008.05.088; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yu XL, 2008, J BIOL CHEM, V283, P18056, DOI 10.1074/jbc.M802694200; Yurchenko V, 2006, IMMUNOLOGY, V117, P301, DOI 10.1111/j.1365-2567.2005.02316.x	54	41	43	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2010	24	4					1139	1150		10.1096/fj.09-140509	http://dx.doi.org/10.1096/fj.09-140509			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19952283				2022-12-28	WOS:000276462300021
J	Veitia, RA				Veitia, Reiner A.			A generalized model of gene dosage and dominant negative effects in macromolecular complexes	FASEB JOURNAL			English	Article						aneuploidy; haploinsufficiency; genetic synergy; nonallelic noncomplementation	SACCHAROMYCES-CEREVISIAE; YEAST; MUTATIONS; DUPLICABILITY; SENSITIVITY; EXPRESSION; POLYPLOIDY; LETHALITY; EVOLUTION; ETIOLOGY	Most genes and their corresponding products are supposed to be involved in genetic or biochemical interactions. A typical example is provided by macromolecular complexes, which may contain tens of proteins in defined stoichiometric proportions. Stoichiometric imbalances in such complexes can be a source of abnormal phenotypes. Comparable effects can also arise from negative dominance/transdominance, even though the underlying mechanisms are different. Here I propose a general yet simple biochemical model accounting for the effects of dosage changes and weak dominant/transdominant negative mutations in macromolecular complexes. The molecular alterations studied are predicted to lead to synergistic effects that can drive total multimer concentration and/or activity in a multiple heterozygote below a critical threshold required to ensure a normal phenotype, thus providing an explanation for the phenomenon of unlinked noncomplementation or nonallelic noncomplementation. The model also helps in understanding the basis of heterosis and the long-term consequences of gene dosage alterations and weak dominant/transdominant negative effects. Indeed, it can explain the observed extensive retention of paralogs in polyploids. Finally, because the effects of weak single-gene alterations can escape selection, they may accumulate in the population. This situation has important evolutionary consequences and may eventually lead to reproductive isolation and speciation.-Veitia, R. A. A generalized model of gene dosage and dominant negative effects in macromolecular complexes. FASEB J. 24, 994-1002 (2010). www.fasebj.org	[Veitia, Reiner A.] Inst Jacques Monod, Equipe Genet & Genom Dev Gonad, Ctr Natl Rech Sci, UMR 7592, F-75205 Paris 13, France; [Veitia, Reiner A.] Univ Paris 07, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Veitia, RA (corresponding author), Inst Jacques Monod, Equipe Genet & Genom Dev Gonad, Ctr Natl Rech Sci, UMR 7592, Batiment Buffon,15 Rue Helene Brion, F-75205 Paris 13, France.	reiner.veitia@inserm.fr			Centre National de la Recherche Scientifique; Universite Paris-Diderot; Association pour la Recherche sur le Cancer; Institut Universitaire de France	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Universite Paris-Diderot; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Institut Universitaire de France	The author thanks B. Benayoun, D. Lhote, A. Georges, Michael Freeling, Vidya Nanjundiah, and S. Bottani for reading and/or commenting on this article. The author thanks two anonymous referees for their very helpful comments. The research of R. A. V. is funded by the Centre National de la Recherche Scientifique, the Universite Paris-Diderot, the Association pour la Recherche sur le Cancer, and the Institut Universitaire de France.	Adams KL, 2003, P NATL ACAD SCI USA, V100, P4649, DOI 10.1073/pnas.0630618100; Bader GD, 2002, NAT BIOTECHNOL, V20, P991, DOI 10.1038/nbt1002-991; Birchler JA, 2001, DEV BIOL, V234, P275, DOI 10.1006/dbio.2001.0262; Boyer J, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r72; Bray D, 1997, P NATL ACAD SCI USA, V94, P13493, DOI 10.1073/pnas.94.25.13493; Brideau NJ, 2006, SCIENCE, V314, P1292, DOI 10.1126/science.1133953; Comai L, 2005, NAT REV GENET, V6, P836, DOI 10.1038/nrg1711; DOBZHANSKY T, 1946, GENETICS, V31, P269; Dobzhansky T., 1937; Ettwiller L, 2007, COMP FUNCT GENOM, DOI 10.1155/2007/58721; Finger FP, 2000, GENETICS, V156, P943; Gibson TJ, 1998, TRENDS GENET, V14, P46, DOI 10.1016/S0168-9525(97)01367-X; GOODMAN LA, 1960, J AM STAT ASSOC, V55, P708, DOI 10.2307/2281592; Grossniklaus U, 1996, J THEOR BIOL, V182, P299, DOI 10.1006/jtbi.1996.0167; GUARENTE L, 1993, TRENDS GENET, V9, P362, DOI 10.1016/0168-9525(93)90042-G; Haarer B, 2007, GENE DEV, V21, P148, DOI 10.1101/gad.1477507; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Jansen R, 2002, GENOME RES, V12, P37, DOI 10.1101/gr.205602; Kroll ES, 1996, GENETICS, V143, P95; Kuznetsov VA, 2002, GENETICS, V161, P1321; Lemos B, 2008, P NATL ACAD SCI USA, V105, P14471, DOI 10.1073/pnas.0805160105; Liang H, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040011; Measday V, 2005, P NATL ACAD SCI USA, V102, P13956, DOI 10.1073/pnas.0503504102; MENDEL G, 2004, VERH NATURFORSCH VER, V4, P3; NOVICK P, 1989, GENETICS, V121, P659; Papp B, 2003, NATURE, V424, P194, DOI 10.1038/nature01771; Phillips PC, 1998, GENETICS, V150, P449; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Reguly Teresa, 2006, J Biol, V5, P11, DOI 10.1186/jbiol36; Springer NM, 2007, GENOME RES, V17, P264, DOI 10.1101/gr.5347007; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Veitia RA, 2005, PLANT CELL, V17, P4, DOI 10.1105/tpc.104.170130; Veitia RA, 2004, GENETICS, V168, P569, DOI 10.1534/genetics.104.029785; Veitia RA, 2003, J THEOR BIOL, V220, P19, DOI 10.1006/jtbi.2003.3105; Veitia RA, 2002, BIOESSAYS, V24, P175, DOI 10.1002/bies.10023; Veitia RA, 2008, TRENDS GENET, V24, P390, DOI 10.1016/j.tig.2008.05.005; Veitia RA, 2007, PLANT CELL, V19, P3843, DOI 10.1105/tpc.107.055053; Veitia RA, 2009, J PATHOL, V218, P409, DOI 10.1002/path.2583; Yang J, 2003, P NATL ACAD SCI USA, V100, P15661, DOI 10.1073/pnas.2536672100; Yook KJ, 2001, GENETICS, V158, P209	40	39	39	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					994	1002		10.1096/fj.09-146969	http://dx.doi.org/10.1096/fj.09-146969			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	20007508				2022-12-28	WOS:000276462300007
J	Lakshmana, MK; Chung, JY; Wickramarachchi, S; Tak, E; Bianchi, E; Koo, EH; Kang, DE				Lakshmana, Madepalli K.; Chung, John Y.; Wickramarachchi, Supul; Tak, Eileen; Bianchi, Elisabetta; Koo, Edward H.; Kang, David E.			A fragment of the scaffolding protein RanBP9 is increased in Alzheimer's disease brains and strongly potentiates amyloid-beta peptide generation	FASEB JOURNAL			English	Article						APP; BACE1; LRP; LisH	PRECURSOR PROTEIN; CYTOPLASMIC DOMAIN; NUCLEAR-PROTEIN; RECEPTOR; PATHWAY; COMPLEX; LRP; IDENTIFICATION; DIMERIZATION; CONTRIBUTES	Increasing biochemical and genetic evidence indicates that the amyloid-beta ( A beta)peptide derived from amyloid precursor protein (APP) plays a central role in Alzheimer's disease ( AD) pathogenesis. We previously reported that RanBP9 promotes A beta generation by scaffolding APP/BACE1/LRP complexes together. Interestingly, the RanBP9-Delta 1/N60 ( residues 1-392) deletion mutant interacted much more strongly with APP/BACE1/LRP than full-length RanBP9. In this study, we found that RanBP9-N60, a processed form of RanBP9 virtually identical to the RanBP9-Delta 1/N60 mutant, was strongly increased in AD brains compared with controls. To evaluate the potential pathogenic consequences of this phenotype, we studied the differential biological properties of full-length RanBP9 vs. RanBP9-Delta 1/N60 in HEK293T and Neuro-2A cells. The RanBP9-Delta 1/N60 fragment, which lacks a nuclear localization signal, displayed enhanced cytoplasmic vs. nuclear localization and >3-fold enhanced stability than full-length RanBP9. Importantly, RanBP9-Delta 1/N60, which contains the LisH dimerization domain, retained the capacity to form self-interacting multimeric complexes and increased A beta generation by similar to 5-fold over vector controls, more potent than the similar to 3-fold increase seen by full-length RanBP9. Taken together, these data indicate that RanBP9-N60 may further drive the amyloid cascade in AD and that the proteolytic processing of RanBP9 may be an attractive therapeutic target.-Lakshmana, M. K., Chung, J. Y., Wickramarachchi, S., Tak, E., Bianchi, E., Koo, E. H., Kang, D. E. A fragment of the scaffolding protein RanBP9 is increased in Alzheimer's disease brains and strongly potentiates amyloid beta peptide generation. FASEB J. 24,119-127 ( 2010). www.fasebj.org	[Lakshmana, Madepalli K.; Chung, John Y.; Wickramarachchi, Supul; Tak, Eileen; Koo, Edward H.; Kang, David E.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Bianchi, Elisabetta] Inst Pasteur, Dept Immunol, Immunoregulat Lab, F-75724 Paris, France; [Kang, David E.] Seoul Natl Univ, Coll Med, World Class Univ Neurocyt Program, Seoul, South Korea	University of California System; University of California San Diego; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Seoul National University (SNU)	Kang, DE (corresponding author), Univ Calif San Diego, Dept Neurosci, Leichtag Biomed Res 3A17,9500 Gilman Dr, La Jolla, CA 92093 USA.	dekang@ucsd.edu	Kang, David E./E-5234-2012	Kang, David E./0000-0002-7132-821X	American Health Assistance Foundation [A2007-05]; Alzheimer's Association [NIRG-07-60584]; National Institute of Aging [AG 005131-24S1]; Korea Science and Engineering Foundation; NATIONAL INSTITUTE ON AGING [P50AG005131] Funding Source: NIH RePORTER	American Health Assistance Foundation(BrightFocus Foundation); Alzheimer's Association(Alzheimer's Association); National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Korea Science and Engineering Foundation(Korea Science and Engineering Foundation); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported in part by the American Health Assistance Foundation (A2007-05 to D. E. K.), the Alzheimer's Association (NIRG-07-60584, M. K. L.), the National Institute of Aging (AG 005131-24S1 to D. E. K.), and a World Class University grant from the Korea Science and Engineering Foundation ( to D. E. K.).	Bourne KZ, 2007, J NEUROSCI RES, V85, P1194, DOI 10.1002/jnr.21252; Bowman AL, 2008, MOL BIOL CELL, V19, P3782, DOI 10.1091/mbc.E08-03-0237; Dansereau DA, 2008, J CELL BIOL, V182, P963, DOI 10.1083/jcb.200711046; De Strooper B, 2000, J CELL SCI, V113, P1857; Denti S, 2004, J BIOL CHEM, V279, P13027, DOI 10.1074/jbc.M313515200; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; Gerlitz G, 2005, CELL CYCLE, V4, P1632, DOI 10.4161/cc.4.11.2151; Harper JA, 2003, CLIN GENET, V64, P461, DOI 10.1046/j.1399-0004.2003.00194.x; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hu XY, 2006, NAT NEUROSCI, V9, P1520, DOI 10.1038/nn1797; Kang DE, 2005, J BIOL CHEM, V280, P31537, DOI 10.1074/jbc.M500833200; Kobayashi N, 2007, GENE, V396, P236, DOI 10.1016/j.gene.2007.02.032; Lakshmana MK, 2009, J BIOL CHEM, V284, P11863, DOI 10.1074/jbc.M807345200; Lakshmana MK, 2008, J CELL MOL MED, V12, P2665, DOI 10.1111/j.1582-4934.2008.00320.x; Mateja A, 2006, J MOL BIOL, V357, P621, DOI 10.1016/j.jmb.2006.01.002; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Poirier MB, 2006, J MOL ENDOCRINOL, V36, P313, DOI 10.1677/jme.1.01891; Rao MA, 2002, J BIOL CHEM, V277, P48020, DOI 10.1074/jbc.M209741200; Repetto E, 2007, J BIOL CHEM, V282, P31504, DOI 10.1074/jbc.M704273200; Seebahn A, 2008, FEBS LETT, V582, P2453, DOI 10.1016/j.febslet.2008.06.010; Takeda T, 2003, AM J PHYSIOL-CELL PH, V284, pC1105, DOI 10.1152/ajpcell.00514.2002; Tamagno E, 2002, NEUROBIOL DIS, V10, P279, DOI 10.1006/nbdi.2002.0515; Tesco G, 2007, NEURON, V54, P721, DOI 10.1016/j.neuron.2007.05.012; Togashi H, 2006, J NEUROSCI, V26, P4961, DOI 10.1523/JNEUROSCI.0704-06.2006; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Umeda M, 2003, GENE, V303, P47, DOI 10.1016/S0378-1119(02)01153-8; Valiyaveettil M, 2008, J CELL BIOL, V182, P727, DOI 10.1083/jcb.200801133; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Yoon IS, 2007, FASEB J, V21, P2742, DOI 10.1096/fj.07-8114com; Yoon IS, 2005, J BIOL CHEM, V280, P20140, DOI 10.1074/jbc.M413729200; Zou YL, 2003, J BIOL CHEM, V278, P49573, DOI 10.1074/jbc.M307556200	32	52	53	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					119	127		10.1096/fj.09-136457	http://dx.doi.org/10.1096/fj.09-136457			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19729516	Green Published			2022-12-28	WOS:000273233600014
J	Lee, NY; Haney, JC; Sogani, J; Blobe, GC				Lee, Nam Y.; Haney, John C.; Sogani, Julie; Blobe, Gerard C.			Casein kinase 2 beta as a novel enhancer of activin-like receptor-1 signaling	FASEB JOURNAL			English	Article						TGF-beta superfamily signaling; endothelial cell biology; angiogenesis; bone morphogenetic protein; migration	GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; ENDOTHELIAL-CELL MIGRATION; SMAD1/5 PHOSPHORYLATION; REGULATORY SUBUNIT; INHIBITS MOS; I RECEPTORS; PROTEIN; ENDOGLIN; CK2	ALK-1 is a transforming growth factor beta (TGF-beta) superfamily receptor that is predominantly expressed in endothelial cells and is essential for angiogenesis, as demonstrated by the embryonic lethal phentoype when targeted for deletion in mice and its mutation in the human disease hereditary hemorrhagic telangiectasia. Although ALK-1 and the endothelial-specific TGF-beta superfamily coreceptor, endoglin, form a heteromeric complex and bind similar TGF-beta superfamily ligands, their signaling mechanisms remain poorly characterized. Here we report the identification of CK2 beta, the regulatory subunit of protein kinase CK2, as a novel enhancer of ALK-1 signaling. The cytoplasmic domain of ALK-1 specifically binds to CK2 beta in vitro and in vivo. NAAIRS mutagenesis studies define amino acid sequences 181-199 of CK2 beta and 207-212 of ALK-1 as the interaction domains, respectively. The ALK-1/CK2 beta interaction specifically enhanced Smad1/5/8 phosphorylation and ALK-1-mediated reporter activation in response to TGF-beta 1 and BMP-9 treatment. In a reciprocal manner, siRNA-mediated silencing of endogenous CK2 beta inhibited TGF-beta 1 and BMP-9-stimulated Smad1/5/8 phosphorylation and ALK-1-mediated reporter activation. Functionally, CK2 beta enhanced the ability of activated or ligand-stimulated ALK-1 to inhibit endothelial cell migration. Similarly, ALK-1 and CK2 beta antagonized endothelial tubule formation in Matrigel. These studies support CK2 beta as an important regulator of ALK-1 signaling and ALK-1-mediated functions in endothelial cells.-Lee, N. Y., Haney, J. C., Sogani, J., Blobe, G. C. Casein kinase 2 beta as a novel enhancer of activin-like receptor-1 signaling. FASEB J. 23, 3712-3721 (2009). www.fasebj.org	[Lee, Nam Y.; Sogani, Julie; Blobe, Gerard C.] Duke Univ, Dept Med, Durham, NC USA; [Haney, John C.] Duke Univ, Dept Surg, Durham, NC USA; [Blobe, Gerard C.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC USA	Duke University; Duke University; Duke University	Blobe, GC (corresponding author), Box 91004,Res Dr,B534 LSRC, Durham, NC 27708 USA.	gerard.blobe@duke.edu	Lee, Nam/H-3073-2016; Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901	National Institute of Health/National Cancer Institute [R01-CA105255, F32-CA124139, T32-CA093245]; NATIONAL CANCER INSTITUTE [R01CA105255, T32CA093245, F32CA124139] Funding Source: NIH RePORTER	National Institute of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were supported by National Institute of Health/National Cancer Institute grants R01-CA105255 (to G. C. B.), F32-CA124139 (to N.Y.L), and T32-CA093245 (to J.C.H.). The GST-CK2 beta expression vector was generously supplied by Dr. Jonathan Cooper (Fred Hutchinson Cancer Center, Seattle, WA, USA). Special thanks to Dr. Chandra Tucker and the Yeast Model Systems Genomics Group at Duke University for their assistance with the yeast 2-hybrid screen, and Dr. Kevin Peters (Procter & Gamble Pharmaceuticals) for the endothelial cell library.	Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bjorling-Poulsen M, 2005, ONCOGENE, V24, P6194, DOI 10.1038/sj.onc.1208762; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bolanos-Garcia VM, 2006, TRENDS BIOCHEM SCI, V31, P654, DOI 10.1016/j.tibs.2006.10.005; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Bren GD, 2000, J MOL BIOL, V297, P1245, DOI 10.1006/jmbi.2000.3630; Buchou T, 2003, MOL CELL BIOL, V23, P908, DOI 10.1128/MCB.23.3.908-915.2003; Carvalho RLC, 2007, J CELL SCI, V120, P4269, DOI 10.1242/jcs.013169; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; Daly AC, 2008, MOL CELL BIOL, V28, P6889, DOI 10.1128/MCB.01192-08; David L, 2007, J CELL PHYSIOL, V213, P484, DOI 10.1002/jcp.21126; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Kristensen LP, 2004, FEBS LETT, V569, P217, DOI 10.1016/j.febslet.2004.05.069; Kusk M, 1999, MOL CELL BIOCHEM, V191, P51, DOI 10.1023/A:1006840613986; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Lee NY, 2008, J BIOL CHEM, V283, P32527, DOI 10.1074/jbc.M803059200; Lee NY, 2007, J BIOL CHEM, V282, P21507, DOI 10.1074/jbc.M700176200; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Lieberman SL, 2004, DEV BIOL, V268, P271, DOI 10.1016/j.ydbio.2003.12.009; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; Liu IM, 2009, EMBO J, V28, P88, DOI 10.1038/emboj.2008.266; Lux A, 2005, J BIOL CHEM, V280, P8482, DOI 10.1074/jbc.M409197200; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Mo JY, 2002, J BIOL CHEM, V277, P50788, DOI 10.1074/jbc.M210376200; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Park SO, 2008, BLOOD, V111, P633, DOI 10.1182/blood-2007-08-107359; Sanz-Rodriguez F, 2004, J BIOL CHEM, V279, P32858, DOI 10.1074/jbc.M400843200; Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Urness LD, 2000, NAT GENET, V26, P328, DOI 10.1038/81634; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Ye L, 2008, MOL CANCER RES, V6, P1594, DOI 10.1158/1541-7786.MCR-08-0171	52	17	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3712	3721		10.1096/fj.09-131607	http://dx.doi.org/10.1096/fj.09-131607			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19592636	Green Published			2022-12-28	WOS:000271272500009
J	Sun, L; Guo, RF; Gao, HW; Sarma, JV; Zetoune, FS; Ward, PA				Sun, Lei; Guo, Ren-Feng; Gao, Hongwei; Sarma, J. Vidya; Zetoune, Firas S.; Ward, Peter A.			Attenuation of IgG immune complex-induced acute lung injury by silencing C5aR in lung epithelial cells	FASEB JOURNAL			English	Article						complement; siRNA; PMNs; inflammation	ANAPHYLATOXIN RECEPTOR C5AR; SMALL INTERFERING RNA; IN-VIVO; INFLAMMATORY REACTIONS; CHEMOKINE GENERATION; ENDOTHELIAL-CELLS; MESSENGER-RNA; GENE-TRANSFER; UP-REGULATION; RAT-LIVER	Acute lung injury (ALI) in mouse lung occurs after distal airway deposition of IgG immune complexes (IgGICs), resulting in a breakdown of the vascular-airway barrier, causing intrapulmonary edema, hemorrhage, and accumulation of neutrophils [polymorphonuclear leukocytes (PMNs)] in the alveolar compartment, these changes being complement (C5a) and C5a receptor (C5aR) dependent. In this ALI model, C5aR expression (protein) was found to occur on upper (bronchial) and lower (alveolar) airway epithelial cells. An adenovirus construct (siRNA) was used to silence mRNA for C5aR in the lung. Under such conditions, C5aR protein was markedly reduced on lung epithelial cells, resulting in much reduced leakage of albumin into the lung, diminished buildup of PMNs, and lower levels of proinflammatory mediators in bronchoalveolar lavage fluids. These studies indicate that bronchial and alveolar epithelial cell C5aR is up-regulated and greatly contributes to inflammation and injury in the lung. The use of siRNA administered into the airways avoids systemic suppression of C5aR, which might compromise innate immunity. It is possible that such an intervention might be employed in humans with ALI or acute respiratory distress syndrome as well as in upper-airway inflammatory diseases, such as chronic obstructive pulmonary disease and asthma, where there is evidence for complement activation and buildup of PMNs.-Sun, L., Guo, R.-F., Gao, H., Sarma, J. V., Zetoune, F. S., Ward, P. A. Attenuation of IgG immune complex-induced acute lung injury by silencing C5aR in lung epithelial cells. FASEB J. 23, 3808-3818 (2009). www.fasebj.org	[Sun, Lei; Guo, Ren-Feng; Gao, Hongwei; Sarma, J. Vidya; Zetoune, Firas S.; Ward, Peter A.] Univ Michigan, Dept Pathol, Sch Med, Ann Arbor, MI 48109 USA; [Guo, Ren-Feng] Hannover Med Sch, Dept Trauma Surg, D-3000 Hannover, Germany	University of Michigan System; University of Michigan; Hannover Medical School	Ward, PA (corresponding author), Univ Michigan, Dept Pathol, Sch Med, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu			U.S. National Institutes of Health [GM-61656, HL-31963]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061656] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work is supported by the U.S. National Institutes of Health (grants GM-61656 and HL-31963). The authors thank Niels C. Riedemann for his significant assistance with the adenoviral construct and its application to the animal model.	AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; Arts GJ, 2003, GENOME RES, V13, P2325, DOI 10.1101/gr.1332603; Arumugam TV, 2004, J HEPATOL, V40, P934, DOI 10.1016/j.jhep.2004.02.017; Boden D, 2004, MOL THER, V9, P396, DOI 10.1016/j.ymthe.2003.11.025; Bonniaud P, 2003, AM J RESP CRIT CARE, V168, P770, DOI 10.1164/rccm.200210-1254OC; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; BUCHNER RR, 1995, J IMMUNOL, V155, P308; CHENOWETH DE, 1978, P NATL ACAD SCI USA, V75, P3943, DOI 10.1073/pnas.75.8.3943; CHENOWETH DE, 1982, J EXP MED, V156, P68, DOI 10.1084/jem.156.1.68; Czermak BJ, 1999, AM J PATHOL, V154, P1513, DOI 10.1016/S0002-9440(10)65405-3; Czermak BJ, 1999, J IMMUNOL, V162, P2321; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Czermak BJ, 1998, J LEUKOCYTE BIOL, V64, P40, DOI 10.1002/jlb.64.1.40; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Fayyazi A, 2000, IMMUNOLOGY, V99, P38, DOI 10.1046/j.1365-2567.2000.00911.x; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; Gao HW, 2006, J IMMUNOL, V177, P612, DOI 10.4049/jimmunol.177.1.612; GASQUE P, 1995, J IMMUNOL, V155, P4882; Gasque P, 1997, AM J PATHOL, V150, P31; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; Guo RF, 2003, FASEB J, V17, P1889, DOI 10.1096/fj.03-0009fje; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; HUANG SA, 1995, J VIROL, V69, P2257, DOI 10.1128/JVI.69.4.2257-2263.1995; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang MS, 2002, FASEB J, V16, P1567, DOI 10.1096/fj.02-0209com; Hwang JI, 2004, P NATL ACAD SCI USA, V101, P488, DOI 10.1073/pnas.0307549100; Jagels MA, 2000, IMMUNOPHARMACOLOGY, V46, P209, DOI 10.1016/S0162-3109(99)00178-2; JOHNSON KJ, 1974, J CLIN INVEST, V54, P349, DOI 10.1172/JCI107770; Kaner RJ, 1999, AM J RESP CELL MOL, V20, P361, DOI 10.1165/ajrcmb.20.3.3398; Kay MA, 2003, NATURE, V424, P251, DOI 10.1038/424251b; Koleva M, 2002, GASTROENTEROLOGY, V122, P697, DOI 10.1053/gast.2002.31883; KURIMOTO Y, 1989, J EXP MED, V170, P467, DOI 10.1084/jem.170.2.467; MOLAD Y, 1994, BIOCHEM J, V299, P881, DOI 10.1042/bj2990881; Mulligan MS, 1997, J IMMUNOL, V158, P1857; MULLIGAN MS, 1995, J IMMUNOL, V154, P1350; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; Mulligan MS, 1996, J CLIN INVEST, V98, P503, DOI 10.1172/JCI118818; Naik N, 1997, J CELL SCI, V110, P2381; Riedemann NC, 2002, J CLIN INVEST, V110, P101, DOI 10.1172/JCI200215409; Riedemann NC, 2002, J IMMUNOL, V168, P1919, DOI 10.4049/jimmunol.168.4.1919; Rittirsch D, 2008, J IMMUNOL, V180, P7664, DOI 10.4049/jimmunol.180.11.7664; Schieferdecker HL, 1997, FEBS LETT, V406, P305, DOI 10.1016/S0014-5793(97)00292-5; Schlaf G, 1999, LAB INVEST, V79, P1287; Schomber T, 2004, BLOOD, V103, P4511, DOI 10.1182/blood-2003-07-2397; Shanley TP, 1997, J IMMUNOL, V158, P3439; Shushakova N, 2002, J CLIN INVEST, V110, P1823, DOI 10.1172/JCI200216577; SICILIANO SJ, 1990, J BIOL CHEM, V265, P19568; STRUNK RC, 1988, J CLIN INVEST, V81, P1419, DOI 10.1172/JCI113472; Suda T, 2003, J THORAC CARDIOV SUR, V126, P1155, DOI 10.1016/S0022-5223(03)00939-5; Sun L, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/28945; Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066; Vergunst CE, 2007, RHEUMATOLOGY, V46, P1773, DOI 10.1093/rheumatology/kem222; Wang Y, 2004, AM J PHYSIOL-LUNG C, V286, pL1188, DOI 10.1152/ajplung.00288.2003; Ward PA, 1996, AM J PATHOL, V149, P1079; WERFEL T, 1992, BLOOD, V79, P152, DOI 10.1182/blood.V79.1.152.bloodjournal791152; WETSEL RA, 1995, IMMUNOL LETT, V44, P183, DOI 10.1016/0165-2478(94)00212-A; Woodruff TM, 2008, ADV EXP MED BIOL, V632, P143, DOI 10.1007/978-0-387-78952-1_11; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Zahedi R, 2000, CLIN EXP IMMUNOL, V121, P226, DOI 10.1046/j.1365-2249.2000.01249.x; Zhao LJ, 2003, GENE, V316, P137, DOI 10.1016/S0378-1119(03)00750-9	65	39	42	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3808	3818		10.1096/fj.09-133694	http://dx.doi.org/10.1096/fj.09-133694			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19620403	Green Published, Green Submitted			2022-12-28	WOS:000271272500017
J	Huang, P; Zhao, XYS; Fields, M; Ransohoff, RM; Zhou, L				Huang, Ping; Zhao, Xinyu S.; Fields, Matthew; Ransohoff, Richard M.; Zhou, Lan			Imatinib attenuates skeletal muscle dystrophy in mdx mice	FASEB JOURNAL			English	Article						necrosis; inflammation; fibrosis; c-abl; TGF-beta; PDGF	DUCHENNE MUSCULAR-DYSTROPHY; MESSENGER-RNA EXPRESSION; GROWTH-FACTOR; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; INFLAMMATORY RESPONSE; KINASE INHIBITOR; LIVER FIBROSIS; IN-VITRO; MOUSE	Duchenne-Meryon muscular dystrophy (DMD) is the most common and lethal genetic muscle disease. Ameliorating muscle necrosis, inflammation, and fibrosis represents an important therapeutic approach for DMD. Imatinib, an antineoplastic agent, demonstrated antiinflammatory and antifibrotic effects in liver, kidney, lung, and skin of various animal models. This study tested antiinflammatory and antifibrotic effects of imatinib in mdx mice, a DMD mouse model. We treated mdx mice with intraperitoneal injections of imatinib at the peak of limb muscle inflammation and the onset of diaphragm fibrosis. Controls received PBS vehicle or were left untreated. Muscle necrosis, inflammation, fibrosis, and function were evaluated by measuring serum CK activity, endomysial CD45 immunoreactive inflammation area, endomysial collagen III deposition, and hind limb grip strength. Phosphorylation of the tyrosine kinase targets of imatinib was assessed by Western blot in diaphragm tissue and in primary cultures of peritoneal macrophages and skeletal muscle fibroblasts. Imatinib markedly reduced muscle necrosis, inflammation, and fibrosis, and significantly improved hind limb grip strength in mdx mice. Reduced clinical disease was accompanied by inhibition of c-abl and PDGFR phosphorylation and suppression of TNF-alpha and IL-1 beta expression. Imatinib therapy for DMD may hold promise for ameliorating muscle necrosis, inflammation, and fibrosis by inhibiting c-abl and PDGFR signaling pathways and downstream inflammatory cytokine and fibrotic gene expression.-Huang, P., Zhao, X. S., Fields, M., Ransohoff, R. M., Zhou, L. Imatinib attenuates skeletal muscle dystrophy in mdx mice. FASEB J. 23, 2539-2548 (2009)	[Zhou, Lan] Cleveland Clin, Dept Neurol, Neurol Inst,Dept Neurosci, Lerner Res Inst,Neuroinflammat Res Ctr, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Zhou, L (corresponding author), Cleveland Clin, Dept Neurol, Neurol Inst,Dept Neurosci, Lerner Res Inst,Neuroinflammat Res Ctr, 9500 Euclid Ave,S90, Cleveland, OH 44195 USA.	zhoul2@ccf.org			NIH [K08 NS049346, K24 NS51400]; MDA [91682]; The Frankino Charity Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS049346, K24NS051400] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MDA(Muscular Dystrophy Association); The Frankino Charity Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work is supported by NIH grants K08 NS049346 (L. Z.), and K24 NS51400 (R. M. R.), MDA ( award 91682) (L. Z.), and The Frankino Charity Foundation (L. Z.). We thank our statistician, Dr. Jianbo Li, for his assistance in statistical analysis.	Abdollahi A, 2005, J EXP MED, V201, P925, DOI 10.1084/jem.20041393; Andreetta F, 2006, J NEUROIMMUNOL, V175, P77, DOI 10.1016/j.jneuroim.2006.03.005; BERNASCONI P, 1995, J CLIN INVEST, V96, P1137, DOI 10.1172/JCI118101; Bonner JC, 2004, CYTOKINE GROWTH F R, V15, P255, DOI 10.1016/j.cytogfr.2004.03.006; Bueso-Ramos CE, 2004, CANCER-AM CANCER SOC, V101, P332, DOI 10.1002/cncr.20380; Cardona AE, 2008, BLOOD, V112, P256, DOI 10.1182/blood-2007-10-118497; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; Cohn RD, 2007, NAT MED, V13, P204, DOI 10.1038/nm1536; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; CULLEN MJ, 1988, ACTA NEUROPATHOL, V77, P69, DOI 10.1007/BF00688245; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Dewar AL, 2005, IMMUNOL CELL BIOL, V83, P48, DOI 10.1111/j.1440-1711.2004.01296.x; Distler JHW, 2007, ARTHRITIS RHEUM-US, V56, P311, DOI 10.1002/art.22314; Druker BJ, 2004, ADV CANCER RES, V91, P1, DOI 10.1016/S0065-230X(04)91001-9; DUPONTVERSTEEGDEN EE, 1992, MUSCLE NERVE, V15, P1105, DOI 10.1002/mus.880151008; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; Fadic R, 2006, J CELL MOL MED, V10, P758, DOI 10.1111/j.1582-4934.2006.tb00435.x; Gonzalo T, 2007, J PHARMACOL EXP THER, V321, P856, DOI 10.1124/jpet.106.114496; Gosselin LE, 2004, MUSCLE NERVE, V30, P645, DOI 10.1002/mus.20150; Grounds MD, 2004, FASEB J, V18, P676, DOI 10.1096/fj.03-1024com; Hodgetts S, 2006, NEUROMUSCULAR DISORD, V16, P591, DOI 10.1016/j.nmd.2006.06.011; HOPPE G, 1994, J CLIN INVEST, V94, P1506, DOI 10.1172/JCI117490; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Liu LP, 2006, J IMMUNOL, V176, P4399, DOI 10.4049/jimmunol.176.7.4399; Melone MAB, 2000, J CELL PHYSIOL, V185, P143, DOI 10.1002/1097-4652(200010)185:1<143::AID-JCP14>3.0.CO;2-U; Sadanaga A, 2005, ARTHRITIS RHEUM-US, V52, P3987, DOI 10.1002/art.21424; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; TIDBALL JG, 1992, EXP CELL RES, V203, P141, DOI 10.1016/0014-4827(92)90049-E; Wang SN, 2005, FASEB J, V19, P1, DOI 10.1096/fj.04-2370com; Wolf AM, 2005, P NATL ACAD SCI USA, V102, P13622, DOI 10.1073/pnas.0501758102; Yoshiji H, 2005, AM J PHYSIOL-GASTR L, V288, pG907, DOI 10.1152/ajpgi.00420.2004; Zhao YJ, 2003, J PATHOL, V201, P149, DOI 10.1002/path.1414; Zhou L, 2006, NEUROMUSCULAR DISORD, V16, P32, DOI 10.1016/j.nmd.2005.09.009; Zhou L, 2008, J NEUROL SCI, V264, P106, DOI 10.1016/j.jns.2007.08.029; Zoja C, 2006, KIDNEY INT, V70, P97, DOI 10.1038/sj.ki.5001528	37	77	83	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2539	2548		10.1096/fj.09-129833	http://dx.doi.org/10.1096/fj.09-129833			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19289603	Green Published			2022-12-28	WOS:000268836700022
J	James, SJ; Rose, S; Melnyk, S; Jernigan, S; Blossom, S; Pavliv, O; Gaylor, DW				James, S. Jill; Rose, Shannon; Melnyk, Stepan; Jernigan, Stefanie; Blossom, Sarah; Pavliv, Oleksandra; Gaylor, David W.			Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism	FASEB JOURNAL			English	Article						autistic disorder; oxidative stress; nitric oxide	COULOMETRIC ELECTROCHEMICAL DETECTION; INCREASED OXIDATIVE STRESS; NITRIC-OXIDE; PATHOPHYSIOLOGICAL MECHANISMS; NEURODEGENERATIVE DISEASES; SPECTRUM DISORDERS; NITROSATIVE STRESS; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; BIPOLAR DISORDER	Research into the metabolic phenotype of autism has been relatively unexplored despite the fact that metabolic abnormalities have been implicated in the pathophysiology of several other neurobehavioral disorders. Plasma biomarkers of oxidative stress have been reported in autistic children; however, intracellular redox status has not yet been evaluated. Lymphoblastoid cells (LCLs) derived from autistic children and unaffected controls were used to assess relative concentrations of reduced glutathione (GSH) and oxidized disulfide glutathione (GSSG) in cell extracts and isolated mitochondria as a measure of intracellular redox capacity. The results indicated that the GSH/GSSG redox ratio was decreased and percentage oxidized glutathione increased in both cytosol and mitochondria in the autism LCLs. Exposure to oxidative stress via the sulfhydryl reagent thimerosal resulted in a greater decrease in the GSH/GSSG ratio and increase in free radical generation in autism compared to control cells. Acute exposure to physiological levels of nitric oxide decreased mitochondrial membrane potential to a greater extent in the autism LCLs, although GSH/GSSG and ATP concentrations were similarly decreased in both cell lines. These results suggest that the autism LCLs exhibit a reduced glutathione reserve capacity in both cytosol and mitochondria that may compromise antioxidant defense and detoxification capacity under prooxidant conditions.-James, S. J., Rose, S., Melnyk, S., Jernigan, S., Blossom, S., Pavliv, O., Gaylor, D. W. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J. 23, 2374-2383 (2009)	[James, S. Jill; Rose, Shannon; Melnyk, Stepan; Jernigan, Stefanie; Blossom, Sarah; Pavliv, Oleksandra] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Res Inst, Dept Pediat, Little Rock, AR 72202 USA; [Gaylor, David W.] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Res Inst, Dept Biostat, Little Rock, AR 72202 USA	Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences	James, SJ (corresponding author), Univ Arkansas Med Sci, Arkansas Childrens Hosp, Res Inst, Dept Pediat, 1120 Marshall St,Slot 512-41 B, Little Rock, AR 72202 USA.	jamesjill@uams.edu	Blossom, Sarah/AAG-2852-2019	Blossom, Sarah/0000-0003-3110-4577; Rose, Shannon/0000-0003-0595-4367	National Institute of Child Health and Human Development [RO1 HD051873]; Safeminds, Inc.; Arkansas Biosciences Institute; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD051873] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Safeminds, Inc.; Arkansas Biosciences Institute; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank the many autism families that participated in the Autism Genetic Research Exchange program. This research was supported, in part, with funding from the National Institute of Child Health and Human Development (RO1 HD051873) to S.J.J., and by grants from Safeminds, Inc., and the Arkansas Biosciences Institute (S.J.J.).	Almeida A, 2002, J NEUROCHEM, V81, P207, DOI 10.1046/j.1471-4159.2002.00827.x; AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; Andreazza AC, 2008, J AFFECT DISORDERS, V111, P135, DOI 10.1016/j.jad.2008.04.013; Antunes F, 2007, ANTIOXID REDOX SIGN, V9, P1569, DOI 10.1089/ars.2007.1677; Aon MA, 2007, J BIOL CHEM, V282, P21889, DOI 10.1074/jbc.M702841200; Aw TY, 2003, NEWS PHYSIOL SCI, V18, P201, DOI 10.1152/nips.01448.2003; Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3; Baldelli S, 2008, INT J BIOCHEM CELL B, V40, P2660, DOI 10.1016/j.biocel.2008.05.013; Baskin DS, 2003, TOXICOL SCI, V74, P361, DOI 10.1093/toxsci/kfg126; Berendji D, 1999, FREE RADICAL BIO MED, V27, P773, DOI 10.1016/S0891-5849(99)00123-9; Berk M, 2008, BIOL PSYCHIAT, V64, P468, DOI 10.1016/j.biopsych.2008.04.022; Beversdorf DQ, 2007, J AUTISM DEV DISORD, V37, P1040, DOI 10.1007/s10803-006-0242-7; Biswas S, 2006, BIOCHEM PHARMACOL, V71, P551, DOI 10.1016/j.bcp.2005.10.044; Bolanos JP, 2008, BBA-BIOENERGETICS, V1777, P789, DOI 10.1016/j.bbabio.2008.04.011; Boso M, 2006, NEUROSCI LETT, V410, P169, DOI 10.1016/j.neulet.2006.08.092; Brorson JR, 1999, J NEUROSCI, V19, P147, DOI 10.1523/JNEUROSCI.19-01-00147.1999; Brorson JR, 1997, J NEUROCHEM, V68, P95; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Cao ZX, 2004, BIOCHEM BIOPH RES CO, V316, P1043, DOI 10.1016/j.bbrc.2004.02.156; Cecchi C, 1999, NEUROSCI LETT, V275, P152, DOI 10.1016/S0304-3940(99)00751-X; Chauhan A, 2004, LIFE SCI, V75, P2539, DOI 10.1016/j.lfs.2004.04.038; Chugani DC, 1999, PROG NEURO-PSYCHOPH, V23, P635, DOI 10.1016/S0278-5846(99)00022-6; COLEMAN M, 1985, J AUTISM DEV DISORD, V15, P1, DOI 10.1007/BF01837894; Correia C, 2006, J AUTISM DEV DISORD, V36, P1137, DOI 10.1007/s10803-006-0138-6; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; EKLOW L, 1981, FEBS LETT, V127, P125, DOI 10.1016/0014-5793(81)80357-2; Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004; Erusalimsky JD, 2007, ARTERIOSCL THROM VAS, V27, P2524, DOI 10.1161/ATVBAHA.107.151167; Filiano JJ, 2002, J CHILD NEUROL, V17, P435, DOI 10.1177/088307380201700607; Filipek PA, 2004, J AUTISM DEV DISORD, V34, P615, DOI 10.1007/s10803-004-5283-1; Filipek PA, 2003, ANN NEUROL, V53, P801, DOI 10.1002/ana.10596; Fratelli M, 2005, P NATL ACAD SCI USA, V102, P13998, DOI 10.1073/pnas.0504398102; Graf WD, 2000, J CHILD NEUROL, V15, P357, DOI 10.1177/088307380001500601; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Gysin R, 2007, P NATL ACAD SCI USA, V104, P16621, DOI 10.1073/pnas.0706778104; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; Hansen JM, 2006, ANNU REV PHARMACOL, V46, P215, DOI 10.1146/annurev.pharmtox.46.120604.141122; Husain M, 2008, J BIOL CHEM, V283, P7682, DOI 10.1074/jbc.M708845200; James SJ, 2006, AM J MED GENET B, V141B, P947, DOI 10.1002/ajmg.b.30366; James SJ, 2004, AM J CLIN NUTR, V80, P1611, DOI 10.1093/ajcn/80.6.1611; James SJ, 2005, NEUROTOXICOLOGY, V26, P1, DOI 10.1016/j.neuro.2004.07.012; Jones DP, 2006, ANTIOXID REDOX SIGN, V8, P1865, DOI 10.1089/ars.2006.8.1865; Jones DP, 2006, REJUV RES, V9, P169, DOI 10.1089/rej.2006.9.169; Keating DJ, 2008, J NEUROCHEM, V104, P298, DOI 10.1111/j.1471-4159.2007.04997.x; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Krey JF, 2007, CURR OPIN NEUROBIOL, V17, P112, DOI 10.1016/j.conb.2007.01.010; Kwon YW, 2003, BIOL CHEM, V384, P991, DOI 10.1515/BC.2003.111; LASZLO A, 1994, CLIN CHIM ACTA, V229, P205, DOI 10.1016/0009-8981(94)90243-7; Lenaz G, 1997, MOL CELL BIOCHEM, V174, P329, DOI 10.1023/A:1006854619336; Lenton KJ, 1999, ANAL BIOCHEM, V274, P125, DOI 10.1006/abio.1999.4258; Leuner K, 2007, J NEURAL TRANSM-SUPP, P207; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Li ZB, 2007, PLOS BIOL, V5, P212, DOI 10.1371/journal.pbio.0050035; Lombard J, 1998, MED HYPOTHESES, V50, P497, DOI 10.1016/S0306-9877(98)90270-5; Maes M, 2008, NEUROENDOCRINOL LETT, V29, P287; Makani S, 2002, GENES IMMUN, V3, P270, DOI 10.1038/sj.gene.6363854; Melnyk S, 1999, J NUTR BIOCHEM, V10, P490, DOI 10.1016/S0955-2863(99)00033-9; Melnyk S, 2000, CLIN CHEM, V46, P265; Ming X, 2005, PROSTAG LEUKOTR ESS, V73, P379, DOI 10.1016/j.plefa.2005.06.002; Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x; Ng F, 2008, INT J NEUROPSYCHOPH, V11, P851, DOI 10.1017/S1461145707008401; Noble M, 2003, ANN NY ACAD SCI, V991, P251; OLAFSDOTTIR K, 1988, BIOCHIM BIOPHYS ACTA, V964, P377, DOI 10.1016/0304-4165(88)90038-4; Oliveira G, 2005, DEV MED CHILD NEUROL, V47, P185, DOI 10.1017/S0012162205000332; Pani G, 2000, IUBMB LIFE, V49, P381; Paolicchi A, 2002, BIOCHEM PHARMACOL, V64, P1027, DOI 10.1016/S0006-2952(02)01173-5; Pardo CA, 2006, INT REV PSYCHIATR, V17, P485, DOI 10.1080/02646830500381930; Poling JS, 2006, J CHILD NEUROL, V21, P170, DOI 10.1177/08830738060210021401; Pons R, 2004, J PEDIATR-US, V144, P81, DOI 10.1016/j.jpeds.2003.10.023; Quintana A, 2007, P NATL ACAD SCI USA, V104, P14418, DOI 10.1073/pnas.0703126104; Quiroz JA, 2008, NEUROPSYCHOPHARMACOL, V33, P2551, DOI 10.1038/sj.npp.1301671; Rahman I, 2004, BIOCHEM PHARMACOL, V68, P1255, DOI 10.1016/j.bcp.2004.05.042; Rebrin I, 2008, ADV DRUG DELIVER REV, V60, P1545, DOI 10.1016/j.addr.2008.06.001; Rice Catherine, 2007, Morbidity and Mortality Weekly Report, V56, P12; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Serra JA, 2001, J NEURAL TRANSM, V108, P1135, DOI 10.1007/s007020170003; Sogut S, 2003, CLIN CHIM ACTA, V331, P111, DOI 10.1016/S0009-8981(03)00119-0; Takabayashi A, 2000, ANTIOXID REDOX SIGN, V2, P673, DOI 10.1089/ars.2000.2.4-673; Tsao CY, 2007, J CHILD NEUROL, V22, P1121, DOI 10.1177/0883073807306266; Weissman JR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003815; Wolin MS, 2005, AM J PHYSIOL-LUNG C, V289, pL159, DOI 10.1152/ajplung.00060.2005; Yao JK, 2006, DIS MARKERS, V22, P83, DOI 10.1155/2006/248387; Yorbik O, 2002, PROSTAG LEUKOTR ESS, V67, P341, DOI 10.1054/plef.2002.0439; Zoroglu SS, 2004, EUR ARCH PSY CLIN N, V254, P143, DOI 10.1007/s00406-004-0456-7; Zoroglu SS, 2003, CELL BIOCHEM FUNCT, V21, P55, DOI 10.1002/cbf.989	87	155	160	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2374	2383		10.1096/fj.08-128926	http://dx.doi.org/10.1096/fj.08-128926			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19307255	Green Published			2022-12-28	WOS:000268836700006
J	Ghafoori, P; Yoshimura, T; Turpie, B; Masli, S				Ghafoori, Paiman; Yoshimura, Takeru; Turpie, Bruce; Masli, Sharmila			Increased I kappa B alpha expression is essential for the tolerogenic property of TGF-beta-exposed APCs	FASEB JOURNAL			English	Article						monocytes; macrophages; antigen presentation; antigen processing; tolerance	ANTIGEN-PRESENTING CELLS; SITE-SPECIFIC PHOSPHORYLATION; CLONED MACROPHAGE HYBRIDOMAS; GROWTH-FACTOR-BETA; DENDRITIC CELLS; IMMUNE DEVIATION; FUNCTIONAL-ANALYSIS; NUCLEAR-LOCALIZATION; PROMOTING PROPERTIES; ENDOTHELIAL-CELLS	I kappa B alpha is an inhibitor of the transcriptional factor NF-kappa B, and it is an essential component of the signaling pathways that lead to expression of inflammatory molecules. These include cytokines and costimulatory molecules associated with antigen presentation in an inflammatory immune response. In this study, we report that antigen-presenting cells exposed to TGF-beta induce peripheral tolerance by increasing I kappa B alpha expression. Exposure of antigen presenting cells (APCs) to TGF-beta is known to impair their ability to secrete IL-12, and such impairment correlated with reduced NF-kappa B activity as indicated by significantly reduced nuclear levels of p50, an essential subunit of NF-kappa B for IL-12 transcription. Blockade of increased nuclear I kappa B alpha in APCs by expression of small interfering RNA molecules (siRNAs) targeting I kappa B alpha transcripts prevented IL-12 impairment and the decline in nuclear p50 levels. Furthermore, such I kappa B alpha blockade also interfered with the tolerogenic property of TGF-beta-exposed APCs. However, increased expression of I kappa B alpha in APCs, independent of TGF-beta exposure, reduced nuclear p50 levels and permitted tolerance induction by APCs. Thus, our findings attribute a direct and significant role to I kappa B alpha in the tolerogenic potential of APCs. Increased I kappa B alpha expression in APCs may therefore offer a therapeutic approach to achieve antigen-specific immuno-modulation.-Ghafoori, P., Yoshimura, T., Turpie, B., Masli, S. Increased I kappa B alpha expression is essential for the tolerogenic property of TGF-beta-exposed APCs. FASEB J. 23, 2226-2234 (2009)	[Ghafoori, Paiman; Yoshimura, Takeru; Turpie, Bruce; Masli, Sharmila] Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute	Masli, S (corresponding author), Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.	sharmila.masli@schepens.harvard.edu			U.S. National Institutes of Health [EY015472]; NATIONAL EYE INSTITUTE [R01EY015472] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This research was supported by U.S. National Institutes of Health grant EY015472.	ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chakrabarti S, 2007, J BIOL CHEM, V282, P18307, DOI 10.1074/jbc.M700211200; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Dabir P, 2008, CIRC RES, V102, P1558, DOI 10.1161/CIRCRESAHA.108.176990; Gao JX, 1999, IMMUNOLOGY, V98, P159; HARA Y, 1992, J IMMUNOL, V149, P1531; HARA Y, 1993, J IMMUNOL, V151, P5162; Hecker KH, 1999, IMMUNOLOGY, V96, P372; Hill JA, 2003, J IMMUNOL, V171, P691, DOI 10.4049/jimmunol.171.2.691; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; ISHIKURA H, 1989, J IMMUNOL, V143, P414; Jobin C, 1998, J IMMUNOL, V160, P410; Kezuka T, 2000, INVEST OPHTH VIS SCI, V41, P1410; KUCHROO VK, 1988, J IMMUNOL, V141, P10; Laderach D, 2003, J IMMUNOL, V171, P1750, DOI 10.4049/jimmunol.171.4.1750; Li GL, 2005, J IMMUNOL, V174, P4706, DOI 10.4049/jimmunol.174.8.4706; Liu HT, 2000, J IMMUNOL, V164, P4277, DOI 10.4049/jimmunol.164.8.4277; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; Masli S, 2006, INT IMMUNOL, V18, P689, DOI 10.1093/intimm/dxl006; Masli S, 2002, J IMMUNOL, V168, P2264, DOI 10.4049/jimmunol.168.5.2264; MASLI S, 2008, IMMUNOLOGY, DOI DOI 10.1111/J.1365-2567.2008.2933.X; McLaughlin JN, 2005, J BIOL CHEM, V280, P22172, DOI 10.1074/jbc.M500721200; Na SY, 1999, J BIOL CHEM, V274, P7674, DOI 10.1074/jbc.274.12.7674; Poligone B, 2002, J IMMUNOL, V168, P188, DOI 10.4049/jimmunol.168.1.188; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITT DA, 1995, J IMMUNOL, V154, P5114; Streilein JW, 2002, HUM IMMUNOL, V63, P435, DOI 10.1016/S0198-8859(02)00393-2; Takeuchi M, 1997, EUR J IMMUNOL, V27, P1648, DOI 10.1002/eji.1830270709; Takeuchi M, 1998, J IMMUNOL, V160, P1589; Taoufik Y, 2001, EUR J IMMUNOL, V31, P3228, DOI 10.1002/1521-4141(200111)31:11<3228::AID-IMMU3228>3.0.CO;2-7; Thommesen L, 2005, J BIOCHEM MOL BIOL, V38, P281; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; UCHIDA T, 1985, J IMMUNOL, V134, P772; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P1031, DOI 10.1002/eji.1830220423; Xu H, 2007, BIOCHEM BIOPH RES CO, V353, P812, DOI 10.1016/j.bbrc.2006.12.108; Yoshimura S, 2003, SCAND J IMMUNOL, V58, P165, DOI 10.1046/j.1365-3083.2003.01246.x; Yoshimura S, 2001, EUR J IMMUNOL, V31, P1883, DOI 10.1002/1521-4141(200106)31:6<1883::AID-IMMU1883>3.0.CO;2-V; Yoshimura S, 2001, INT IMMUNOL, V13, P675, DOI 10.1093/intimm/13.5.675; Zhang-Hoover J, 2004, J IMMUNOL, V172, P178, DOI 10.4049/jimmunol.172.1.178; Zhou LF, 2006, ACTA PHARMACOL SIN, V27, P609, DOI 10.1111/j.1745-7254.2006.00310.x	47	14	14	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2226	2234		10.1096/fj.08-124545	http://dx.doi.org/10.1096/fj.08-124545			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19237504	Green Published			2022-12-28	WOS:000268836500022
J	Lan, MS; Breslin, MB				Lan, Michael S.; Breslin, Mary B.			Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation	FASEB JOURNAL			English	Review						Ngn3; Mash 1; zinc-finger transcription factor; pancreatic endocrine pathway; sympatho-adrenal lineage development; developing neocortex	DEVELOPING NERVOUS-SYSTEM; MOUSE FETAL DEVELOPMENT; INSULINOMA-ASSOCIATED 1; CELL LUNG-CANCER; CAENORHABDITIS-ELEGANS; SONIC HEDGEHOG; MOTOR NEURONS; PROLINE-RICH; GENE INSM1; CYCLIN D1	Zinc-finger transcription factors are DNA-binding proteins that are implicated in many diverse biological functions. INSM1 (formerly IA-1) contains five zinc-finger motifs and functions as a transcription factor. INSM1 protein structure is highly conserved in homologues of different species. It is predominantly expressed in developing neuroendocrine tissues and the nervous system in mammals. INSM1 represents an important player in early embryonic neurogenesis. In pancreatic endocrine cell differentiation, Ngn3 first activates INSM1 and subsequently NeuroD/beta 2. Conversely, INSM1 exerts a feedback mechanism to suppress NeuroD/beta 2 and its own gene expression. INSM1 gene ablation in the mouse results in the impairment of pancreatic endocrine cell maturation. Further, deletion of INSM1 severely impairs catecholamine biosynthesis and secretion from the adrenal gland that results in early embryonic lethality. Genetically, INSM1 acts as a downstream factor of Mash 1 and Phox2b in the differentiation of the sympatho-adrenal lineage. In the developing neocortex, mouse embryos lacking INSM1 expression contain half the number of basal progenitors and show a reduction in cortical plate radial thickness. Cell signaling studies reveal that INSM1 contributes to the induction of cell cycle arrest/exit necessary to facilitate cellular differentiation. INSM1 is highly expressed in tumors of neuroendocrine origin. Hence, its promoter could serve as a tumor-specific promoter that drives a specific targeted cancer gene therapy for the treatment of neuroendocrine tumors. Taken together, all of these features of INSM1 strongly support its role as an important regulator during neuroendocrine differentiation.-Lan, M. S., Breslin, M. B. Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation. FASEB J. 23, 2024-2033 (2009)	[Lan, Michael S.; Breslin, Mary B.] Childrens Hosp, Res Inst Children, New Orleans, LA 70118 USA; [Lan, Michael S.; Breslin, Mary B.] Louisiana State Univ, Dept Pediat, Hlth Sci Ctr, New Orleans, LA USA; [Lan, Michael S.] Louisiana State Univ, Dept Genet, Hlth Sci Ctr, New Orleans, LA USA; [Breslin, Mary B.] Louisiana State Univ, Dept Biochem & Mol Biol, Hlth Sci Ctr, New Orleans, LA USA	Children's Hospital of New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Lan, MS (corresponding author), Childrens Hosp, Res Inst Children, 200 Henry Clay Ave,Res & Educ Bldg,Rm 2211, New Orleans, LA 70118 USA.	mlan@chnola-research.org	Lan, Michael/CAF-1839-2022		Research Institute for Children, Children's Hospital, New Orleans; Diana Helis Henry Medical Research Foundation; National Institute of Diabetes and Digestive and Kidney Diseases [DK-61436]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061436] Funding Source: NIH RePORTER	Research Institute for Children, Children's Hospital, New Orleans; Diana Helis Henry Medical Research Foundation; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by funds from the Research Institute for Children, Children's Hospital, New Orleans; a grant from the Diana Helis Henry Medical Research Foundation (to M. B. B.); and a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (DK-61436; to M. S. L.).	Breslin MB, 2007, FEBS LETT, V581, P949, DOI 10.1016/j.febslet.2007.01.087; Breslin MB, 2003, J BIOL CHEM, V278, P38991, DOI 10.1074/jbc.M306795200; Breslin MB, 2002, NUCLEIC ACIDS RES, V30, P1038, DOI 10.1093/nar/30.4.1038; Candal E, 2007, DEV BIOL, V309, P1, DOI 10.1016/j.ydbio.2007.04.038; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Castro DS, 2006, DEV CELL, V11, P831, DOI 10.1016/j.devcel.2006.10.006; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; De Smaele E, 2008, NEOPLASIA, V10, P89, DOI 10.1593/neo.07891; DESAI C, 1989, GENETICS, V121, P703; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; Duggan A, 2008, J COMP NEUROL, V507, P1497, DOI 10.1002/cne.21629; Farkas LM, 2008, NEURON, V60, P40, DOI 10.1016/j.neuron.2008.09.020; Ferretti E, 2005, TRENDS MOL MED, V11, P537, DOI 10.1016/j.molmed.2005.10.005; Gierl MS, 2006, GENE DEV, V20, P2465, DOI 10.1101/gad.381806; Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; Huber K, 2005, DEV BIOL, V279, P501, DOI 10.1016/j.ydbio.2005.01.007; Huber K, 2002, DEVELOPMENT, V129, P4729; JASANI B, 1979, BIOCHEM J, V181, P623, DOI 10.1042/bj1810623; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Kuzin A, 2005, DEV BIOL, V277, P347, DOI 10.1016/j.ydbio.2004.09.027; Kuzin A, 2007, DEV BIOL, V310, P35, DOI 10.1016/j.ydbio.2007.07.012; LAN MS, 1993, CANCER RES, V53, P4169; LANS MS, 1994, J BIOL CHEM, V269, P14170; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Leslie RDG, 1999, DIABETOLOGIA, V42, P3, DOI 10.1007/s001250051105; Li Q, 1997, BIOCHEM BIOPH RES CO, V236, P776, DOI 10.1006/bbrc.1997.7054; Liu WD, 2006, BIOCHEM J, V397, P169, DOI 10.1042/BJ20051669; Lukowski CM, 2006, GENE EXPR PATTERNS, V6, P711, DOI 10.1016/j.modgep.2005.12.008; Mellitzer G, 2006, EMBO J, V25, P1344, DOI 10.1038/sj.emboj.7601011; Moriguchi T, 2006, DEVELOPMENT, V133, P3871, DOI 10.1242/dev.02553; Murtaugh LC, 2003, P NATL ACAD SCI USA, V100, P14920, DOI 10.1073/pnas.2436557100; Nelson BR, 2007, DEV BIOL, V304, P479, DOI 10.1016/j.ydbio.2007.01.001; Parlier D, 2008, DEV DYNAM, V237, P2147, DOI 10.1002/dvdy.21621; Pedersen N, 2006, CANCER GENE THER, V13, P375, DOI 10.1038/sj.cgt.7700887; Pedersen N, 2003, CANCER RES, V63, P1943; Perier RC, 2000, NUCLEIC ACIDS RES, V28, P302, DOI 10.1093/nar/28.1.302; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Stivers C, 2000, MECH DEVELOP, V97, P205, DOI 10.1016/S0925-4773(00)00409-3; SUNDARESAN V, 1991, BRIT J CANCER, V64, P333, DOI 10.1038/bjc.1991.301; Taniwaki M, 2006, INT J ONCOL, V29, P567; TATEMOTO K, 1978, P NATL ACAD SCI USA, V75, P4115, DOI 10.1073/pnas.75.9.4115; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; Wang HW, 2008, J ENDOCRINOL, V198, P29, DOI 10.1677/JOE-08-0001; Wetmore C, 2003, CURR OPIN GENET DEV, V13, P34, DOI 10.1016/S0959-437X(03)00002-9; Wildner H, 2008, DEVELOPMENT, V135, P473, DOI 10.1242/dev.011783; Wu J, 2001, GENE DEV, V15, P789, DOI 10.1101/gad.857401; Xie JP, 2002, GENOMICS, V80, P54, DOI 10.1006/geno.2002.6800; Yu H, 2003, DEVELOPMENT, V130, P5217, DOI 10.1242/dev.00678; Zhang T, 2009, J BIOL CHEM, V284, P5574, DOI 10.1074/jbc.M808843200; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0; Zhu M, 2002, PANCREAS, V24, P139, DOI 10.1097/00006676-200203000-00004; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001; Zwicker J, 1999, ONCOGENE, V18, P19, DOI 10.1038/sj.onc.1202286	55	92	97	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2024	2033		10.1096/fj.08-125971	http://dx.doi.org/10.1096/fj.08-125971			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19246490	Green Published			2022-12-28	WOS:000268836500003
J	Sosne, G; Qiu, P; Goldstein, AL; Wheater, M				Sosne, Gabriel; Qiu, Ping; Goldstein, Allan L.; Wheater, Michelle			Biological activities of thymosin beta(4) defined by active sites in short peptide sequences	FASEB JOURNAL			English	Review						inflammation; apoptosis; wound healing; angiogenesis	ASPARTYL-LYSYL-PROLINE; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; INFLAMMATORY MEDIATORS; SEQUESTERING PEPTIDE; BETA-4; TETRAPEPTIDE; MIGRATION; SURVIVAL; GROWTH; CELLS	Thymosin beta(4), a small ubiquitous protein containing 43 aa, has structure/function activity via its actin-binding domain and numerous biological affects on cells. Since it is the major actin-sequestering molecule in eukaryotic cells and is found essentially in all cells and body fluids, thymosin beta(4) has the potential for significant roles in tissue development, maintenance, repair, and pathology. Several active sites with unique functions have been identified, including the amino-terminal site containing 4 aa (Ac-SDKP) that generally blocks inflammation and reduces fibrosis. Another active site at the amino terminus contains 15 aa, including Ac-SDKP, and promotes cell survival and blocks apoptosis, while a short sequence containing LKKTETQ, the central actin-binding domain (aa 17-23) plus 1 additional amino acid (Q), promotes angiogenesis, wound healing, and cell migration. Several additional biological activities have been identified but not yet localized in the molecule, including its antimicrobial activity, the induction of various genes (including laminin-5, MMPs, TGF beta, zyxin, terminal deoxynucleotidyl transferase, and angiogenesis-related proteins), and the ability to activate ILK/PINCH/Akt, and other signaling molecules important in both apoptosis and inflammatory pathways. This review details these important physiologically and pathologically active sites and their potential therapeutic uses.-Sosne, G., Qiu, P., Goldstein, A. L., Wheater. M. Biological activities of thymosin beta(4) defined by active sites in short peptide sequences. FASEB J. 24, 2144-2151 (2010). www.fasebj.org	[Sosne, Gabriel] Wayne State Univ, Sch Med, Dept Opthalmol & Anat Cell Biol, Detroit, MI 48201 USA; [Qiu, Ping; Goldstein, Allan L.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA; [Wheater, Michelle] Univ Detroit Mercy, Sch Dent, Detroit, MI 48221 USA	Wayne State University; George Washington University; University of Detroit Mercy	Sosne, G (corresponding author), Wayne State Univ, Sch Med, Dept Opthalmol & Anat Cell Biol, Scott Hall 8314,540 E Canfield, Detroit, MI 48201 USA.	gsosne@med.wayne.edu			Research to Prevent Blindness (New York, NY, USA); Sinai Guild (Detroit, MI, USA)	Research to Prevent Blindness (New York, NY, USA)(Research to Prevent Blindness (RPB)); Sinai Guild (Detroit, MI, USA)	G. S. is the recipient of a Physician Scientist Award from Research to Prevent Blindness (New York, NY, USA) and an unrestricted grant from The Sinai Guild (Detroit, MI, USA).	Azizi M, 1997, HYPERTENSION, V30, P1015, DOI 10.1161/01.HYP.30.5.1015; Badamchian M, 2003, INT IMMUNOPHARMACOL, V3, P1225, DOI 10.1016/S1567-5769(03)00024-9; Bednarek R, 2008, J BIOL CHEM, V283, P1534, DOI 10.1074/jbc.M707539200; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Bock-Marquette I, 2009, J MOL CELL CARDIOL, V46, P728, DOI 10.1016/j.yjmcc.2009.01.017; BONNET D, 1993, BLOOD, V82, P3307; BORDER BG, 1993, J NEUROCHEM, V61, P2104, DOI 10.1111/j.1471-4159.1993.tb07448.x; Brieger A, 2007, BIOCHEM BIOPH RES CO, V364, P731, DOI 10.1016/j.bbrc.2007.10.010; Cavasin MA, 2004, HYPERTENSION, V43, P1140, DOI 10.1161/01.HYP.0000126172.01673.84; Cavasin Maria A, 2006, Am J Cardiovasc Drugs, V6, P305, DOI 10.2165/00129784-200606050-00003; Cavasin MA, 2007, HYPERTENSION, V50, P130, DOI 10.1161/HYPERTENSIONAHA.106.084103; Cha HJ, 2003, J NATL CANCER I, V95, P1674, DOI 10.1093/jnci/djg100; Cingolani OH, 2004, HYPERTENSION, V43, P1067, DOI 10.1161/01.HYP.0000125013.22494.c5; Fan Y, 2009, DEV CELL, V16, P661, DOI 10.1016/j.devcel.2009.03.009; Girardi M, 2003, IMMUNOLOGY, V109, P1, DOI 10.1046/j.1365-2567.2003.01616.x; GOLDSTEI.AL, 1966, P NATL ACAD SCI USA, V56, P1010, DOI 10.1073/pnas.56.3.1010; Goldstein AL, 2005, TRENDS MOL MED, V11, P421, DOI 10.1016/j.molmed.2005.07.004; GRANT DS, 1995, J CELL SCI, V108, P3685; GUIGON M, 1990, EXP HEMATOL, V18, P1112; Hinkel R, 2008, CIRCULATION, V117, P2232, DOI 10.1161/CIRCULATIONAHA.107.758904; Ho JHC, 2008, BRIT J OPHTHALMOL, V92, P992, DOI 10.1136/bjo.2007.136747; Hofer S, 2009, CRIT CARE, V13, DOI 10.1186/cc7923; HU SK, 1981, MOL CELL BIOCHEM, V41, P49; Huang CM, 2006, PROTEOMICS, V6, P5805, DOI 10.1002/pmic.200600163; Huff T, 2004, J CELL SCI, V117, P5333, DOI 10.1242/jcs.01404; Ito M, 2009, BIOL PHARM BULL, V32, P1101, DOI 10.1248/bpb.32.1101; Kanasaki K, 2006, BIOCHEM BIOPH RES CO, V342, P758, DOI 10.1016/j.bbrc.2006.02.019; Kanasaki K, 2002, J AM SOC NEPHROL, V13, p86A; Kraehenbuehl TP, 2009, BIOMATERIALS, V30, P4318, DOI 10.1016/j.biomaterials.2009.04.057; Kupatt C, 2008, TRENDS CARDIOVAS MED, V18, P205, DOI 10.1016/j.tcm.2008.10.002; Lee HR, 2009, IMMUNOL LETT, V123, P72, DOI 10.1016/j.imlet.2009.02.008; Lee SJ, 2008, FEBS LETT, V582, P2161, DOI 10.1016/j.febslet.2008.03.058; Leeanansaksiri W, 2004, CHEM BIODIVERS, V1, P1091, DOI 10.1002/cbdv.200490081; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; Li XK, 2007, PROTEIN EXPRES PURIF, V56, P229, DOI 10.1016/j.pep.2007.08.011; Li Yan, 2008, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V22, P1306; Lin CX, 2008, AM J PHYSIOL-HEART C, V295, pH1253, DOI 10.1152/ajpheart.00481.2008; Malinda KM, 1999, J INVEST DERMATOL, V113, P364, DOI 10.1046/j.1523-1747.1999.00708.x; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; Mannherz HG, 2009, CELL MOTIL CYTOSKEL, V66, P839, DOI 10.1002/cm.20371; MOROIANU J, 1993, P NATL ACAD SCI USA, V90, P3815, DOI 10.1073/pnas.90.9.3815; PAZMINO NH, 1978, J EXP MED, V147, P708, DOI 10.1084/jem.147.3.708; Peng HM, 2001, HYPERTENSION, V37, P794, DOI 10.1161/01.HYP.37.2.794; Philp D, 2003, WOUND REPAIR REGEN, V11, P19, DOI 10.1046/j.1524-475X.2003.11105.x; Philp D, 2003, FASEB J, V17, P385, DOI 10.1096/fj.03-0244fje; Philp D, 2003, FASEB J, V17, P2103, DOI 10.1096/fj.03-0121fje; Philp D, 2006, J CELL PHYSIOL, V208, P195, DOI 10.1002/jcp.20650; Pokharel S, 2002, HYPERTENSION, V40, P155, DOI 10.1161/01.HYP.0000025880.56816.FA; Popoli P, 2007, ANN NY ACAD SCI, V1112, P219, DOI 10.1196/annals.1415.033; QUI P, 2007, J CELL PHYSL, V212, P165; SAFER D, 1991, J BIOL CHEM, V266, P4029; Sharma U, 2008, AM J PHYSIOL-HEART C, V294, pH1226, DOI 10.1152/ajpheart.00305.2007; Shibuya K, 2005, DIABETES, V54, P838, DOI 10.2337/diabetes.54.3.838; Smart N, 2007, NATURE, V445, P177, DOI 10.1038/nature05383; Sosne G, 2002, EXP EYE RES, V74, P293, DOI 10.1006/exer.2001.1125; Sosne G, 2004, INVEST OPHTH VIS SCI, V45, P1095, DOI 10.1167/iovs.03-1002; Sosne G, 2004, EXP CELL RES, V293, P175, DOI 10.1016/j.yexcr.2003.09.022; Sosne G, 2001, EXP EYE RES, V72, P605, DOI 10.1006/exer.2000.0985; Sosne G, 2007, ANN NY ACAD SCI, V1112, P114, DOI 10.1196/annals.1415.004; Sosne G, 2007, EXP EYE RES, V84, P663, DOI 10.1016/j.exer.2006.12.004; Vartiainen N, 1996, NEUROREPORT, V7, P1613, DOI 10.1097/00001756-199607080-00017; Volkov L, 1996, CELL IMMUNOL, V168, P302, DOI 10.1006/cimm.1996.0080; Wang DH, 2004, AM J PHYSIOL-HEART C, V287, pH2099, DOI 10.1152/ajpheart.00592.2004; Wyczolkowska J, 2007, PEPTIDES, V28, P752, DOI 10.1016/j.peptides.2007.01.004; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277; Yang F, 2004, HYPERTENSION, V43, P229, DOI 10.1161/01.HYP.0000107777.91185.89; Yang H, 2008, NEUROCHEM RES, V33, P2269, DOI 10.1007/s11064-008-9712-y; Young JD, 1999, NAT MED, V5, P1424; Zhang J, 2009, NEUROSCIENCE, V164, P1887, DOI 10.1016/j.neuroscience.2009.09.054	69	100	109	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2144	2151		10.1096/fj.09-142307	http://dx.doi.org/10.1096/fj.09-142307			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20179146				2022-12-28	WOS:000279343600002
J	Kroviarski, Y; Debbabi, M; Bachoual, R; Perianin, A; Gougerot-Pocidalo, MA; El-Benna, J; Dang, PMC				Kroviarski, Yolande; Debbabi, Maya; Bachoual, Rafik; Perianin, Axel; Gougerot-Pocidalo, Marie-Anne; El-Benna, Jamel; Dang, Pham My-Chan			Phosphorylation of NADPH oxidase activator 1 (NOXA1) on serine 282 by MAP kinases and on serine 172 by protein kinase C and protein kinase A prevents NOX1 hyperactivation	FASEB JOURNAL			English	Article						reactive oxygen species; innate immunity; inflammation	RESPIRATORY BURST OXIDASE; COLON EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; SUPEROXIDE-PRODUCTION; CYCLIC-AMP; NEUTROPHIL ACTIVATION; COMPONENT P47(PHOX); NAD(P)H OXIDASE-1; CYTOCHROME B(558); TISSUE EXPRESSION	NADPH oxidase activator 1 (NOXA1) together with NADPH oxidase organizer 1 (NOXO1) are key regulatory subunits of the NADPH oxidase NOX1. NOX1 is expressed mainly in colon epithelial cells and could be involved in mucosal innate immunity by producing reactive oxygen species (ROS). Contrary to its phagocyte counterpart NOX2, the mechanisms involved in NOX1 activation and regulation remain unclear. Here we report that NOX1 activity is regulated through MAP kinase (MAPK), protein kinase C (PKC), and protein kinase A (PKA)-dependent phosphorylation of NOXA1. We identified Ser-282 as target of MAPK and Ser-172 as target of PKC and PKA in vitro and in a transfected human embryonic kidney 293 (HEK293) cell model using site directed mutagenesis and phosphopeptide mapping analysis. In HEK293 cells, phosphorylation of these sites occurred at a basal level and down-regulated constitutive NOX1 activity. Indeed, S172A and S282A single mutants of NOXA1 significantly up-regulated constitutive NOX1-derived ROS production, and S172A/S282A double mutant further increased it, as compared to wild-type NOXA1. Furthermore, phosphorylation of NOXA1 on Ser-282 and Ser-172 decreased its binding to NOX1 and Rac1. These results demonstrated a critical role of NOXA1 phosphorylation on Ser-282 and Ser-172 in preventing NOX1 hyperactivation through the decrease of NOXA1 interaction to NOX1 and Rac1.-Kroviarski, Y., Debbabi, M., Bachoual, R., Perianin, A., Gougerot-Pocidalo, M.-A., El-Benna, J., Dang, P. M. Phosphorylation of NADPH oxidase activator 1 (NOXA1) on serine 282 by MAP kinases and on serine 172 by protein kinase C and protein kinase A prevents NOX1 hyperactivation. FASEB J. 24, 2077-2092 (2010). www.fasebj.org	[Dang, Pham My-Chan] Univ Paris 07, INSERM, U773, Ctr Rech Biomed Bichat Beaujon CRB3, F-75018 Paris, France; [Kroviarski, Yolande; Debbabi, Maya; Gougerot-Pocidalo, Marie-Anne; El-Benna, Jamel; Dang, Pham My-Chan] Univ Paris 07, Paris, France; [Kroviarski, Yolande; Gougerot-Pocidalo, Marie-Anne] CHU Xavier Bichat, AP HP, Ctr Invest Biomed Phenogen, Paris, France; [Perianin, Axel] CNRS, Inst Cochin, INSERM, U567,UMR 8104, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dang, PMC (corresponding author), Univ Paris 07, INSERM, U773, Ctr Rech Biomed Bichat Beaujon CRB3, 16 Rue Henri Huchard, F-75018 Paris, France.	my-chan.dang@inserm.fr		BACHOUAL, Rafik/0000-0003-2195-4068	French Research Ministry	French Research Ministry(Ministry of Research, France)	The authors thank Dr. Yun Soo Bae (Ewha Womans University, Seoul, Korea) for the PGEX-4T-1-NOX1(217-550) plasmid, Dr. Alan Hall (University College, London, UK) for the pGEX-4T-3-Rac1 plasmid, and Dr. Anne Brunet and Dr. Jacques Pouyssegur (Universite de Nice, CNRS UMR 6543, Nice, France) for the constitutively active MEK1-mutant plasmid. The authors are grateful to Dr. Tom Leto (NIH, Bethesda, MD, USA) for providing pcDNA3.1 plamids encoding NOX1, NOXO1, and NOXA1 and for comments on the manuscript. M. D. is a recipient of fellowships from the French Research Ministry.	Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Ago T, 2003, P NATL ACAD SCI USA, V100, P4474, DOI 10.1073/pnas.0735712100; Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Cheng GJ, 2005, GENE, V356, P118, DOI 10.1016/j.gene.2005.03.008; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Cheng G, 2006, J BIOL CHEM, V281, P17718, DOI 10.1074/jbc.M512751200; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Crawford MA, 2006, J IMMUNOL, V176, P7557, DOI 10.4049/jimmunol.176.12.7557; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; Dang PMC, 2003, BIOCHEMISTRY-US, V42, P4520, DOI 10.1021/bi0205754; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; GRISHAM MB, 1994, LANCET, V344, P859, DOI 10.1016/S0140-6736(94)92831-2; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Jacob C, 2004, BRIT J PHARMACOL, V143, P257, DOI 10.1038/sj.bjp.0705927; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kim JS, 2007, J BIOL CHEM, V282, P34787, DOI 10.1074/jbc.M704754200; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Kuwano Y, 2008, FREE RADICAL BIO MED, V45, P1642, DOI 10.1016/j.freeradbiomed.2008.08.033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P332, DOI 10.1016/j.freeradbiomed.2007.03.027; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; Lin P, 2005, J IMMUNOL, V174, P2981, DOI 10.4049/jimmunol.174.5.2981; Mizrahi A, 2006, J LEUKOCYTE BIOL, V79, P881, DOI 10.1189/jlb.1005553; Nakano Y, 2007, BIOCHEM J, V403, P97, DOI 10.1042/BJ20060819; Nauseef WM, 2008, J BIOL CHEM, V283, P16961, DOI 10.1074/jbc.R700045200; OTTONELLO L, 1995, BRIT J HAEMATOL, V91, P566, DOI 10.1111/j.1365-2141.1995.tb05348.x; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; Park HS, 2006, BIOCHEM BIOPH RES CO, V339, P985, DOI 10.1016/j.bbrc.2005.11.108; Raad H, 2009, FASEB J, V23, P1011, DOI 10.1096/fj.08-114553; Rokutan K, 2006, ANTIOXID REDOX SIGN, V8, P1573, DOI 10.1089/ars.2006.8.1573; Saha S, 2008, CAN J PHYSIOL PHARM, V86, P190, DOI 10.1139/Y08-012; SAVITHA G, 1993, CELL SIGNAL, V5, P107, DOI 10.1016/0898-6568(93)90063-R; Sheppard FR, 2005, J LEUKOCYTE BIOL, V78, P1025, DOI 10.1189/jlb.0804442; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ueyama T, 2006, MOL CELL BIOL, V26, P2160, DOI 10.1128/MCB.26.6.2160-2174.2006; Yasunari K, 2000, CIRCULATION, V101, P2302, DOI 10.1161/01.CIR.101.19.2302	54	50	50	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					2077	2092		10.1096/fj.09-147629	http://dx.doi.org/10.1096/fj.09-147629			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20110267				2022-12-28	WOS:000278200000041
J	Rana, S; Gupta, K; Gomez, J; Matsuyama, S; Chakrabarti, A; Agarwal, ML; Agarwal, A; Agarwal, MK; Wald, DN				Rana, Sonia; Gupta, Kalpana; Gomez, Jose; Matsuyama, Shigemi; Chakrabarti, Amitabha; Agarwal, Munna L.; Agarwal, Anju; Agarwal, Mukesh K.; Wald, David N.			Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells	FASEB JOURNAL			English	Article						cell death; drug development; signaling	P53 TUMOR-SUPPRESSOR; DNA-DAMAGE; WILD-TYPE; C-ABL; P73; EXPRESSION; INHIBITOR; GROWTH	The identification of agents that preferentially kill cancer cells while protecting normal cells offers the potential to overcome toxicities found in many existing chemotherapeutic agents. Because p53 is frequently inactivated in cancer, agents that preferentially kill p53-null cells and protect wild-type p53-expressing cells are highly desirable chemotherapeutic agents. By using pairs of isogenic colon cancer cell lines that differ only in p53 expression (RKO and HCT116), securinine was found to exhibit these properties. Securinine (30 mu M) induces apoptosis in 73% of p53-null HCT116 cells (LD50 17.5 mu M) as opposed to 17.6% of HCT116 parental cells (LD50 50 mu M) at 72 h after treatment. The mechanism of securinine-mediated death in p53-deficient cells involves the induction of the p53 family member, p73. Interestingly, the proapoptotic protein p73 is down-regulated in colon cancer cells expressing p53. This differential regulation of p73 in a p53-dependent fashion reveals a novel pathway for preferentially targeting cancer cells. In contrast to p53-deficient cells, cells expressing p53 are protected from cell death through the p53-mediated up-regulation of p21. These studies reveal a novel approach to specifically target colon cancer cells lacking p53 as well as identify a novel clinically relevant pathway to selectively induce p73 in p53-null cells.-Rana, S., Gupta, K., Gomez, J., Matsuyama, S., Chakrabarti, A., Agarwal, M. L., Agarwal, A., Agarwal, M. K., Wald, D. N. Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells. FASEB J. 24, 2126- 2134 (2010). www.fasebj.org	[Wald, David N.] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; [Gomez, Jose; Matsuyama, Shigemi] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; [Agarwal, Munna L.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; [Rana, Sonia; Chakrabarti, Amitabha; Agarwal, Anju; Agarwal, Mukesh K.] Invenio Therapeut, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; [Wald, David N.] Case Med Ctr, Cleveland, OH USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University	Wald, DN (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pathol, WRB3-530,2103 Cornell Rd, Cleveland, OH 44106 USA.	mukeshagarwal@inveniotherapeutics.com; dnw@case.edu						Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; Amin ARMR, 2007, CANCER RES, V67, P5617, DOI 10.1158/0008-5472.CAN-07-0655; BURAVTSEVA G R, 1958, Farmakol Toksikol, V21, P7; Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Copperman R, 1973, Pa Med, V76, P36; COPPERMAN R, 1974, JAMA-J AM MED ASSOC, V228, P288, DOI 10.1001/jama.1974.03230280016013; DeFrank JS, 1996, CANCER RES, V56, P5365; Dong NZ, 1999, ACTA PHARMACOL SIN, V20, P267; Duke J. A., 1985, REFERENCE PUBLICATIO, pS219; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; FAN SJ, 1995, CANCER RES, V55, P1649; Ferreira CG, 1999, ANN ONCOL, V10, P1011, DOI 10.1023/A:1008361818480; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gascoigne KE, 2009, J CELL SCI, V122, P2579, DOI 10.1242/jcs.039719; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Li Y, 2007, CELL DEATH DIFFER, V14, P2058, DOI 10.1038/sj.cdd.4402219; Lokshin M, 2005, COLD SH Q B, V70, P121, DOI 10.1101/sqb.2005.70.046; Lubick K, 2007, J LEUKOCYTE BIOL, V82, P1062, DOI 10.1189/jlb.0407255; Mueller S, 2000, CANCER RES, V60, P156; Raj K, 2001, NATURE, V412, P914, DOI 10.1038/35091082; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH ML, 1995, ONCOGENE, V10, P1053; Thottassery JV, 2006, MOL CANCER THER, V5, P400, DOI 10.1158/1535-7163.MCT-05-0409; Tomkova K, 2008, NEOPLASMA, V55, P177; Tsai-Turton M, 2007, TOXICOL SCI, V98, P216, DOI 10.1093/toxsci/kfm087; Yu T, 2006, DNA REPAIR, V5, P935, DOI 10.1016/j.dnarep.2006.05.040; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; ZHIVOTOSKY B, 2001, CURR PROTOC CELL BIO	32	34	35	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					2126	2134		10.1096/fj.09-148999	http://dx.doi.org/10.1096/fj.09-148999			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20133503				2022-12-28	WOS:000278200000045
J	Eliyahu, E; Shtraizent, N; Martinuzzi, K; Barritt, J; He, XX; Wei, H; Chaubal, S; Copperman, AB; Schuchman, EH				Eliyahu, Efrat; Shtraizent, Nataly; Martinuzzi, Kurt; Barritt, Jason; He, Xingxuan; Wei, Hong; Chaubal, Sanjeev; Copperman, Alan B.; Schuchman, Edward H.			Acid ceramidase improves the quality of oocytes and embryos and the outcome of in vitro fertilization	FASEB JOURNAL			English	Article						reproduction; apoptosis; ceramide	ENRICHED MEMBRANE DOMAINS; REPRODUCTIVE TECHNOLOGIES; APOPTOSIS; SPHINGOSINE; MATURATION; REGULATORS; CATTLE	A major challenge of assisted reproduction technologies (ARTs) is to mimic the natural environment required to sustain oocyte and embryo survival. Herein, we show that the ceramide-metabolizing enzyme, acid ceramidase (AC), is expressed in human cumulus cells and follicular fluid, essential components of this environment, and that the levels of this enzyme are positively correlated with the quality of human embryos formed in vitro. These observations led us to develop a new approach for oocyte and embryo culture that markedly improved the outcome of in vitro fertilization (IVF). The addition of recombinant AC (rAC) to human and mouse oocyte culture medium maintained their healthy morphology in vitro. Following fertilization, the number of mouse embryos formed in the presence of rAC also was improved (from similar to 40 to 88%), leading to similar to 5-fold more healthy births. To confirm these observations, immature bovine oocytes were matured in vitro and subjected to IVF in the presence of rAC. Significantly more high-grade blastocysts were formed, and the number of morphologically intact, hatched embryos was increased from similar to 24 to 70%. Overall, these data identify AC as an important component of the in vivo oocyte and embryo environment, and provide a novel technology for enhancing the outcome of assisted fertilization. Eliyahu, E., Shtraizent, N., Martinuzzi, K., Barritt, J., He, X., Wei, H., Chaubal, S., Copperman, A. B., Schuchman, E. H. Acid ceramidase improves the quality of oocytes and embryos and the outcome of in vitro fertilization. FASEB J. 24, 1229-1238 (2010). www.fasebj.org	[Eliyahu, Efrat; Shtraizent, Nataly; He, Xingxuan; Schuchman, Edward H.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA; [Martinuzzi, Kurt; Barritt, Jason; Copperman, Alan B.] Mt Sinai Sch Med, Dept Obstet Gynecol & Reprod Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Schuchman, EH (corresponding author), Mt Sinai Sch Med, Dept Genet & Genom Sci, 1425 Madison Ave,Rm 14-20A, New York, NY 10029 USA.	edward.schuchman@mssm.edu			U.S. National Institutes of Health [R01 DK 54830]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054830] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This research was supported, in part, by a grant from the U.S. National Institutes of Health to E. H. S. (R01 DK 54830). The authors also acknowledge the Mouse Genetics Shared Resource Facility at the Mount Sinai School of Medicine for assistance with the mouse surgeries. E. H. S., E. E., N.S. and X. H. are coinventors on a patent application describing the use of AC for cell survival.	Bartke N, 2009, J LIPID RES, V50, pS91, DOI 10.1194/jlr.R800080-JLR200; BENYOSEF D, 1995, MOL REPROD DEV, V42, P122, DOI 10.1002/mrd.1080420116; Caperton L, 2007, P NATL ACAD SCI USA, V104, P5085, DOI 10.1073/pnas.0611642104; Chaube SK, 2005, APOPTOSIS, V10, P863, DOI 10.1007/s10495-005-0367-8; De La Fuente R, 2006, DEV BIOL, V292, P1, DOI 10.1016/j.ydbio.2006.01.008; De Sutter P, 2003, FERTIL STERIL, V79, P1294, DOI 10.1016/S0015-0282(03)00264-4; Eliyahu E, 2007, FASEB J, V21, P1403, DOI 10.1096/fj.06-7016com; Ferlinz K, 2001, J BIOL CHEM, V276, P35352, DOI 10.1074/jbc.M103066200; Galli C, 2008, REPROD DOMEST ANIM, V43, P1, DOI 10.1111/j.1439-0531.2008.01136.x; Grassme H, 2007, PROG LIPID RES, V46, P161, DOI 10.1016/j.plipres.2007.03.002; Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007; He XX, 2003, J BIOL CHEM, V278, P32978, DOI 10.1074/jbc.M301936200; Kolialexi A, 2008, MASS SPECTROM REV, V27, P624, DOI 10.1002/mas.20181; Mao CG, 2008, BBA-MOL CELL BIOL L, V1781, P424, DOI 10.1016/j.bbalip.2008.06.002; Meng QG, 2007, ACTA VET HUNG, V55, P369, DOI 10.1556/AVet.55.2007.3.11; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Perez GI, 1999, MOL HUM REPROD, V5, P414, DOI 10.1093/molehr/5.5.414; Perez GI, 2005, FASEB J, V19, P860, DOI 10.1096/fj.04-2903fje; Pukazhenthi BS, 2004, REPROD FERT DEVELOP, V16, P33, DOI 10.1071/RD03076; Revelli A, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-40; Scherzer J, 2008, REPROD DOMEST ANIM, V43, P371, DOI 10.1111/j.1439-0531.2007.00921.x; Shtraizent N, 2008, J BIOL CHEM, V283, P11253, DOI 10.1074/jbc.M709166200; Swanson WR, 2006, THERIOGENOLOGY, V66, P49, DOI 10.1016/j.theriogenology.2006.03.024; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; WRIGHT JM, 1981, THERIOGENOLOGY, V15, P43, DOI 10.1016/S0093-691X(81)80017-9; Wright Victoria C, 2003, MMWR Surveill Summ, V52, P1; Wu J, 2000, FERTIL STERIL, V74, P1137, DOI 10.1016/S0015-0282(00)01597-1; Young LE, 1998, REV REPROD, V3, P155, DOI 10.1530/revreprod/3.3.155; Zhang Y, 2009, BBA-BIOMEMBRANES, V1788, P178, DOI 10.1016/j.bbamem.2008.07.030; Zheng P, 2007, ANIM REPROD SCI, V98, P56, DOI 10.1016/j.anireprosci.2006.10.005	30	22	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1229	1238		10.1096/fj.09-145508	http://dx.doi.org/10.1096/fj.09-145508			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	20007509	Green Published			2022-12-28	WOS:000276462300029
J	van Wijk, SJL; Timmers, HTM				van Wijk, Sjoerd J. L.; Timmers, H. T. Marc			The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins	FASEB JOURNAL			English	Review						ubiquitination; ubiquitin-protein ligases (E3); ubiquitin-like proteins; protein degradation; post-translational modification	POLYUBIQUITIN CHAINS; PROTEASOMAL DEGRADATION; STRUCTURAL BASIS; NONCOVALENT INTERACTION; ISG15 MODIFICATION; CRYSTAL-STRUCTURE; DNA-REPAIR; E1 ENZYMES; E3 LIGASE; COMPLEX	The family of ubiquitin-conjugating (E2) enzymes is characterized by the presence of a highly conserved ubiquitin-conjugating (UBC) domain. These domains accommodate the ATP-activated ubiquitin (Ub) or ubiquitin-like (UBL) protein via a covalently linked thioester onto its active-site residue. E2 enzymes act via selective protein-protein interactions with the E1 and E3 enzymes and connect activation to covalent modification. By doing so, E2s differentiate effects on downstream substrates, either with a single Ub/UBL molecule or as a chain. While E3s are involved in substrate selection, E2s are the main determinants for selection of the lysine to construct ubiquitin chains, which thereby directly control the cellular fate of the substrate. In humans, 35 active E2 enzymes have been identified so far, while other eukaryotic genomes harbor 16 to 35 E2 family members. Some E2s possess Nand/ or C-terminal extensions that mediate E2-specific processes. During the past two decades, strong support has led to the control of E2 enzymes in decisions concerning the life or death of a protein. Here, we summarize current knowledge and recent developments on E2 enzymes with respect to structural characteristics and functions. From this we propose a shelllike model to rationalize the selectivity of these key enzymes in directing Ub/UBL-conjugation pathways.Van Wijk, S. J. L., Timmers, H. T. M. The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins. FASEB J. 24, 981-993 (2010). www.fasebj.org	[van Wijk, Sjoerd J. L.; Timmers, H. T. Marc] Univ Med Ctr Utrecht, Div Biomed Genet, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Timmers, HTM (corresponding author), Univ Med Ctr Utrecht, Div Biomed Genet, Dept Physiol Chem, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	h.t.m.timmers@umcutrecht.nl	van Wijk, Sjoerd/AAL-6680-2021	van Wijk, Sjoerd/0000-0001-6532-7651				Andersen PL, 2005, J CELL BIOL, V170, P745, DOI 10.1083/jcb.200502113; Ardley HC, 2005, ESSAYS BIOCHEM, V41, P15, DOI 10.1042/EB0410015; Bartke T, 2004, MOL CELL, V14, P801, DOI 10.1016/j.molcel.2004.05.018; Berleth ES, 1996, BIOCHEMISTRY-US, V35, P1664, DOI 10.1021/bi952105y; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Brzovic PS, 2006, MOL CELL, V21, P873, DOI 10.1016/j.molcel.2006.02.008; Burroughs AM, 2008, J STRUCT BIOL, V162, P205, DOI 10.1016/j.jsb.2007.12.006; Chen B, 2006, P NATL ACAD SCI USA, V103, P341, DOI 10.1073/pnas.0506618103; Christensen DE, 2007, NAT STRUCT MOL BIOL, V14, P941, DOI 10.1038/nsmb1295; Coccetti P, 2008, CELL CYCLE, V7, P1391, DOI 10.4161/cc.7.10.5825; de Pril R, 2007, MOL CELL NEUROSCI, V34, P10, DOI 10.1016/j.mcn.2006.09.006; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Dikic I, 2009, NAT REV MOL CELL BIO, V10, P659, DOI 10.1038/nrm2767; Dominguez C, 2004, STRUCTURE, V12, P633, DOI 10.1016/j.str.2004.03.004; Durfee LA, 2008, J BIOL CHEM, V283, P23895, DOI 10.1074/jbc.M804069200; Dye BT, 2007, ANNU REV BIOPH BIOM, V36, P131, DOI 10.1146/annurev.biophys.36.040306.132820; Eddins MJ, 2006, NAT STRUCT MOL BIOL, V13, P915, DOI 10.1038/nsmb1148; Eletr ZM, 2007, J MOL BIOL, V369, P419, DOI 10.1016/j.jmb.2007.03.026; Eletr ZM, 2005, NAT STRUCT MOL BIOL, V12, P933, DOI 10.1038/nsmb984; Furukawa K, 2000, J BIOL CHEM, V275, P7462, DOI 10.1074/jbc.275.11.7462; Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Golebiowski F, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000282; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Hao YY, 2004, NAT CELL BIOL, V6, P849, DOI 10.1038/ncb1159; Hipp MS, 2005, MOL CELL BIOL, V25, P3483, DOI 10.1128/MCB.25.9.3483-3491.2005; Hochstrasser M, 2009, NATURE, V458, P422, DOI 10.1038/nature07958; Hoeller D, 2007, MOL CELL, V26, P891, DOI 10.1016/j.molcel.2007.05.014; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Huang DT, 2008, NAT STRUCT MOL BIOL, V15, P280, DOI 10.1038/nsmb.1387; Huang DT, 2007, NATURE, V445, P394, DOI 10.1038/nature05490; Huang DT, 2009, MOL CELL, V33, P483, DOI 10.1016/j.molcel.2009.01.011; Huang DT, 2005, MOL CELL, V17, P341, DOI 10.1016/j.molcel.2004.12.020; Huang DT, 2004, NAT STRUCT MOL BIOL, V11, P927, DOI 10.1038/nsmb826; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; Iyer LM, 2008, BIOL DIRECT, V3, DOI 10.1186/1745-6150-3-45; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kim HT, 2007, J BIOL CHEM, V282, P17375, DOI 10.1074/jbc.M609659200; Kim HT, 2009, EMBO J, V28, P1867, DOI 10.1038/emboj.2009.115; KLEMPERER NS, 1989, BIOCHEMISTRY-US, V28, P6035, DOI 10.1021/bi00440a047; Kloor M, 2002, BBA-GENE STRUCT EXPR, V1579, P219, DOI 10.1016/S0167-4781(02)00543-2; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Lee I, 2008, CELL, V134, P268, DOI 10.1016/j.cell.2008.05.046; Lesche R, 1997, MAMM GENOME, V8, P879, DOI 10.1007/s003359900604; Lewis MJ, 2006, J BIOMOL NMR, V34, P89, DOI 10.1007/s10858-005-5583-6; Li W, 2007, NATURE, V446, P333, DOI 10.1038/nature05542; Lin DH, 2002, J BIOL CHEM, V277, P21740, DOI 10.1074/jbc.M108418200; Lois LM, 2005, EMBO J, V24, P439, DOI 10.1038/sj.emboj.7600552; Love KR, 2007, NAT CHEM BIOL, V3, P697, DOI 10.1038/nchembio.2007.43; Makhnevych T, 2009, MOL CELL, V33, P124, DOI 10.1016/j.molcel.2008.12.025; Markson G, 2009, GENOME RES, V19, P1905, DOI 10.1101/gr.093963.109; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Michelle C, 2009, J MOL EVOL, V68, P616, DOI 10.1007/s00239-009-9225-6; Mohideen F, 2009, NAT STRUCT MOL BIOL, V16, P945, DOI 10.1038/nsmb.1648; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Pearce MJ, 2008, SCIENCE, V322, P1104, DOI 10.1126/science.1163885; Pichler A, 2005, NAT STRUCT MOL BIOL, V12, P264, DOI 10.1038/nsmb903; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; PITLUK ZW, 1995, MOL CELL BIOL, V15, P1210; Plafker SM, 2004, J CELL BIOL, V167, P649, DOI 10.1083/jcb.200406001; Pohl C, 2008, CELL, V132, P832, DOI 10.1016/j.cell.2008.01.012; Qian SB, 2006, NATURE, V440, P551, DOI 10.1038/nature04600; Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468; Ravid T, 2007, NAT CELL BIOL, V9, P422, DOI 10.1038/ncb1558; Remy I, 2004, MOL CELL BIOL, V24, P1493, DOI 10.1128/MCB.24.4.1493-1504.2004; Rossman TG, 2003, ONCOGENE, V22, P1817, DOI 10.1038/sj.onc.1206283; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; Sadowski M, 2007, BIOCHEM J, V405, P569, DOI 10.1042/BJ20061812; Saeki Y, 2009, EMBO J, V28, P359, DOI 10.1038/emboj.2008.305; Sakata E, 2007, NAT STRUCT MOL BIOL, V14, P167, DOI 10.1038/nsmb1191; Schulman BA, 2009, NAT REV MOL CELL BIO, V10, P319, DOI 10.1038/nrm2673; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; STAUB O, 2004, SCI STKE, pPE43; Striebel F, 2009, NAT STRUCT MOL BIOL, V16, P647, DOI 10.1038/nsmb.1597; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; Summers MK, 2008, MOL CELL, V31, P544, DOI 10.1016/j.molcel.2008.07.014; Takeuchi T, 2005, J BIOCHEM, V138, P711, DOI 10.1093/jb/mvi172; Takeuchi T, 2005, BIOCHEM BIOPH RES CO, V336, P9, DOI 10.1016/j.bbrc.2005.08.034; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; van Wijk SJL, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.55; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Walden H, 2003, MOL CELL, V12, P1427, DOI 10.1016/S1097-2765(03)00452-0; Wang JH, 2007, MOL CELL, V27, P228, DOI 10.1016/j.molcel.2007.05.023; Winkler GS, 2004, J MOL BIOL, V337, P157, DOI 10.1016/j.jmb.2004.01.031; Winn PJ, 2004, STRUCTURE, V12, P1563, DOI 10.1016/j.str.2004.06.017; Xu L, 2008, MOL BIOL CELL, V19, P5059, DOI 10.1091/mbc.E08-05-0473; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Xu Z, 2008, BMC STRUCT BIOL, V8, DOI 10.1186/1472-6807-8-26; Zhang MH, 2005, MOL CELL, V20, P525, DOI 10.1016/j.molcel.2005.09.023; Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; Zou WG, 2005, BIOCHEM BIOPH RES CO, V336, P61, DOI 10.1016/j.bbrc.2005.08.038	100	268	272	4	78	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					981	993		10.1096/fj.09-136259	http://dx.doi.org/10.1096/fj.09-136259			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19940261	Bronze			2022-12-28	WOS:000276462300006
J	Varani, K; Caramori, G; Vincenzi, F; Tosi, A; Barczyk, A; Contoli, M; Casolari, P; Triggiani, M; Hansel, T; Leung, E; MacLennan, S; Barnes, PJ; Chung, KF; Adcock, I; Papi, A; Borea, PA				Varani, Katia; Caramori, Gaetano; Vincenzi, Fabrizio; Tosi, Alice; Barczyk, Adam; Contoli, Marco; Casolari, Paolo; Triggiani, Massimo; Hansel, Trevor; Leung, Edward; MacLennan, Stephen; Barnes, Peter J.; Chung, Kian Fan; Adcock, Ian; Papi, Alberto; Borea, Pier Andrea			Oxidative/nitrosative stress selectively altered A(2B) adenosine receptors in chronic obstructive pulmonary disease	FASEB JOURNAL			English	Article						COPD; macrophages; proliferation; alveolar macrophages; proinflammatory cytokines; U937 cells	HISTONE DEACETYLASE; OXIDATIVE STRESS; AIRWAY INFLAMMATION; EXPRESSION; ASTHMA; BINDING	The primary aim of this study was to investigate adenosine receptors (ARs) in bronchoalveolar lavage (BAL) macrophages from patients with chronic obstructive pulmonary disease (COPD) and age-matched healthy smokers. A(2B)ARs were significantly decreased in BAL macrophages from patients with COPD when compared with healthy smokers. The effect of proinflammatory cytokines and oxidative/nitrosative stress on AR expression and function in U937 cells before and after PMA treatment was evaluated. IL-1 beta and TNF-alpha treatment up-regulated A(2A)- and A(3)ARs but not A(1)- or A(2B)ARs, whereas IL-6 did not modify AR expression. In contrast, oxidative/nitrosative stress selectively decreased A(2B)AR expression, which was associated with a reduction in the potency of the adenosine agonist 5'-N-ethylcarboxamideadenosine (NECA) to induce cAMP. Further, the ability of NECA to enhance cell proliferation was increased after oxidative/nitrosative stress. The specific involvement of A(2B)ARs was investigated by using potent and selective A(2B)AR antagonist and by A(2B)AR knockdown using siRNA and demonstrated responses similar to those obtained with oxidative/nitrosative stress. N-acetylcysteine (NAC), an antioxidant agent, counteracted the decrease in A(2B)AR expression, as well as the altered NECA effects on cAMP and cell proliferation. These findings highlight the central role of A(2B)ARs in alveolar macrophages, suggesting that their modulation could represent an innovative pharmacological strategy to manage COPD.-Varani, K., Caramori, G., Vincenzi, F., Tosi, A., Barczyk, A., Contoli, M., Casolari, P., Triggiani, M., Hansel, T., Leung, E., MacLennan, S., Barnes, P. J., Fan Chung, K., Adcock, I., Papi, A., Borea, P. A. Oxidative/nitrosative stress selectively altered A(2B) adenosine receptors in chronic obstructive pulmonary disease. FASEB J. 24, 1192-1204 (2010). www.fasebj.org	[Borea, Pier Andrea] Univ Ferrara, Dept Clin & Expt Med, Pharmacol Unit, Pharmacol Sect, I-44100 Ferrara, Italy; [Caramori, Gaetano; Contoli, Marco; Casolari, Paolo; Papi, Alberto] Univ Ferrara, Dept Clin & Expt Med, Resp Dis Sect, I-44100 Ferrara, Italy; [Barczyk, Adam] Slaskiej Akad Medycznej, Katedra & Klin Pneumonol, Katowice, Poland; [Leung, Edward; MacLennan, Stephen] King Pharmaceut, Cary, NC USA; [Triggiani, Massimo] Univ Naples Federico II, Div Clin Immunol & Allergy, Naples, Italy; [Hansel, Trevor; Barnes, Peter J.; Chung, Kian Fan; Adcock, Ian] Univ London Imperial Coll Sci Technol & Med, Airways Dis Sect, Natl Heart & Lung Inst, London SW7 2AZ, England	University of Ferrara; University of Ferrara; Pfizer; University of Naples Federico II; Imperial College London	Borea, PA (corresponding author), Univ Ferrara, Dept Clin & Expt Med, Pharmacol Unit, Pharmacol Sect, Via Fossato Mortara 17-19, I-44100 Ferrara, Italy.	bpa@unife.it	Contoli, Marco/K-3947-2018; Vincenzi, Fabrizio/E-7925-2013; Chung, Kian Fan/B-1872-2012; Adcock, Ian/L-3217-2019; Triggiani, Massimo/K-8271-2016; Caramori, Gaetano/AAS-8611-2020; Chung, Kian Fan/I-8456-2019; Papi, alberto/AAC-1888-2019; Barczyk, Adam/GYV-4487-2022	Contoli, Marco/0000-0002-2731-5809; Chung, Kian Fan/0000-0001-7101-1426; Triggiani, Massimo/0000-0001-7318-2093; Caramori, Gaetano/0000-0002-9807-327X; Chung, Kian Fan/0000-0001-7101-1426; Adcock, Ian/0000-0003-2101-8843; Barnes, Peter/0000-0002-5122-4018; Vincenzi, Fabrizio/0000-0002-5027-1699; Barczyk, Adam/0000-0002-6567-9208; PAPI, ALBERTO/0000-0002-6924-4500	GlaxoSmithKline (Brentford, UK); Wellcome Trust; Associazione per la Ricerca e la Cura dell'Asma (ARCA; Padova, Italy); King Pharmaceuticals (Cary, NC, USA)	GlaxoSmithKline (Brentford, UK)(GlaxoSmithKline); Wellcome Trust(Wellcome TrustEuropean Commission); Associazione per la Ricerca e la Cura dell'Asma (ARCA; Padova, Italy); King Pharmaceuticals (Cary, NC, USA)	This work was supported by GlaxoSmithKline (Brentford, UK), Wellcome Trust, Associazione per la Ricerca e la Cura dell'Asma (ARCA; Padova, Italy), and King Pharmaceuticals (Cary, NC, USA). None of authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript.	Adenuga D, 2009, AM J RESP CELL MOL, V40, P464, DOI 10.1165/rcmb.2008-0255OC; Anderson GP, 2003, TRENDS PHARMACOL SCI, V24, P71, DOI 10.1016/S0165-6147(02)00052-4; Barnes Peter J., 2005, Current Drug Targets - Inflammation and Allergy, V4, P675, DOI 10.2174/156801005774912833; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brozyna S, 2009, COPD, V6, P4, DOI 10.1080/15412550902724164; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Caramori G, 2005, CURR OPIN ALLERGY CL, V5, P77, DOI 10.1097/00130832-200502000-00014; Chung KF, 2006, EUR J PHARMACOL, V533, P110, DOI 10.1016/j.ejphar.2005.12.059; Cosio BG, 2004, J EXP MED, V200, P689, DOI 10.1084/jem.20040416; de Boer WI, 2000, J PATHOL, V190, P619, DOI 10.1002/(SICI)1096-9896(200004)190:5<619::AID-PATH555>3.0.CO;2-6; Di Stefano A, 2004, CLIN EXP ALLERGY, V34, P1156, DOI 10.1111/j.1365-2222.2004.02030.x; GESSI S, 2005, MOL PHARM, V67, P1; Global Initiative for Chronic Obstructive Lung Disease, 2001, NIH PUBL, V2701, P1; Ham J., 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P244, DOI 10.2174/187153008786848303; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; Khoa ND, 2001, J IMMUNOL, V167, P4026, DOI 10.4049/jimmunol.167.7.4026; Kolachala VL, 2008, BRIT J PHARMACOL, V155, P127, DOI 10.1038/bjp.2008.227; MacNee William, 2005, Proc Am Thorac Soc, V2, P50, DOI 10.1513/pats.200411-056SF; Martinet W, 2003, BIOTECHNOL LETT, V25, P1025, DOI 10.1023/A:1024157508492; Merighi S, 2005, J BIOL CHEM, V280, P19516, DOI 10.1074/jbc.M413772200; Morello S, 2006, J IMMUNOL, V177, P7173, DOI 10.4049/jimmunol.177.10.7173; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Ochs-Balcom HM, 2006, EUR J CLIN NUTR, V60, P991, DOI 10.1038/sj.ejcn.1602410; Papi A, 2000, AM J RESP CRIT CARE, V162, P1773, DOI 10.1164/ajrccm.162.5.9910112; Paschen W, 2001, J NEUROCHEM, V76, P1916, DOI 10.1046/j.1471-4159.2001.00206.x; Pinho RA, 2007, RESP MED, V101, P1830, DOI 10.1016/j.rmed.2007.02.004; Pluemsampant S, 2008, INT J CANCER, V122, P333, DOI 10.1002/ijc.23094; Psarras S, 2005, CURR PHARM DESIGN, V11, P2053, DOI 10.2174/1381612054065774; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Rabe KF, 2005, LANCET, V366, P563, DOI 10.1016/S0140-6736(05)67100-0; Ricciardolo FLM, 2005, J ALLERGY CLIN IMMUN, V116, P1028, DOI 10.1016/j.jaci.2005.06.034; Sun CX, 2006, J CLIN INVEST, V116, P2173, DOI 10.1172/JCI27303; Tomita K, 2002, AM J RESP CRIT CARE, V166, P724, DOI 10.1164/rccm.2104010; Varani K, 2000, MOL PHARMACOL, V57, P968; Varani K, 2006, AM J RESP CRIT CARE, V173, P398, DOI 10.1164/rccm.200506-869OC; Varani K, 2005, BIOCHEM PHARMACOL, V70, P1601, DOI 10.1016/j.bcp.2005.08.018; Varani K, 2003, FASEB J, V17, P2148, DOI 10.1096/fj.03-0079fje; Zhou Y, 2009, PHARMACOL THERAPEUT, V123, P105, DOI 10.1016/j.pharmthera.2009.04.003; Zhou Y, 2009, J IMMUNOL, V182, P8037, DOI 10.4049/jimmunol.0900515	44	15	17	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1192	1204		10.1096/fj.09-139485	http://dx.doi.org/10.1096/fj.09-139485			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	20008542				2022-12-28	WOS:000276462300026
J	Engel, T; Murphy, BM; Hatazaki, S; Jimenez-Mateos, EM; Concannon, CG; Woods, I; Prehn, JHM; Henshall, DC				Engel, Tobias; Murphy, Brona M.; Hatazaki, Seiji; Jimenez-Mateos, Eva M.; Concannon, Caoimhin G.; Woods, Ina; Prehn, Jochen H. M.; Henshall, David C.			Reduced hippocampal damage and epileptic seizures after status epilepticus in mice lacking proapoptotic Puma	FASEB JOURNAL			English	Article						apoptosis; Bcl-2; BH3-only protein; epileptogenesis; kainate; p53	TEMPORAL-LOBE EPILEPSY; TUMOR-SUPPRESSOR P53; BCL-2 FAMILY-MEMBERS; CELL-DEATH; INDUCED APOPTOSIS; NEURONAL DAMAGE; KAINIC ACID; PROTECTS NEURONS; BAX ACTIVATION; DNA-DAMAGE	The functional significance of neuronal death for pathogenesis of epilepsy and the underlying molecular mechanisms thereof remain incompletely understood. The p53 transcription factor has been implicated in seizure damage, but its target genes and the influence of cell death under its control on epilepsy development are unknown. In the present study, we report that status epilepticus (SE) triggered by intra-amygdala kainic acid in mice causes rapid p53 accumulation and subsequent hippocampal damage. Expression of p53-up-regulated mediator of apoptosis (Puma), a proapoptotic Bcl-2 homology domain 3-only protein under p53 control, was increased within a few hours of SE. Induction of Puma was blocked by pharmacologic inhibition of p53, and hippocampal damage was also reduced. Puma induction was also blocked in p53-deficient mice subject to SE. Compared to Puma-expressing mice, Puma-deficient mice had significantly smaller hippocampal lesions after SE. Long-term, continuous telemetric EEG monitoring revealed a similar to 60% reduction in the frequency of epileptic seizures in the Puma-deficient mice compared to Puma-expressing mice. These are the first data showing genetic deletion of a proapoptotic protein acting acutely to influence neuronal death subsequently alters the phenotype of epilepsy in the long-term, supporting the concept that apoptotic pathway activation is a trigger of epileptogenesis.-Engel, T., Murphy, B. M., Hatazaki, S., Jimenez-Mateos, E. M., Concannon, C. G., Woods, I., Prehn, J. H. M., Henshall, D. C. Reduced hippocampal damage and epileptic seizures after status epilepticus in mice lacking proapoptotic Puma. FASEB J. 24, 853-861 (2010). www.fasebj.org	[Engel, Tobias; Murphy, Brona M.; Hatazaki, Seiji; Jimenez-Mateos, Eva M.; Concannon, Caoimhin G.; Woods, Ina; Prehn, Jochen H. M.; Henshall, David C.] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland; [Hatazaki, Seiji] Mie Univ, Sch Med, Dept Neurosurg, Tsu, Mie 514, Japan	Royal College of Surgeons - Ireland; Mie University	Henshall, DC (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.	dhenshall@rcsi.ie	Prehn, Jochen HM/A-3928-2010; Concannon, Caoimhin/B-2075-2010; Jimenez-Mateos, Eva/AAG-8072-2019; Murphy, Brona/P-2544-2019; Murphy, Brona/D-4873-2012; Henshall, David/C-3364-2012	Prehn, Jochen HM/0000-0003-3479-7794; Murphy, Brona/0000-0002-6740-8858; Murphy, Brona/0000-0002-6740-8858; Jimenez-Mateos, Eva/0000-0001-6417-6580; Henshall, David/0000-0001-6237-9632; Engel, Tobias/0000-0001-9137-0637	Health Research Board Ireland [RP/2005/24, RP/2007/37, RP/2008/69, PD/2009/31]; Wellcome Trust [GR076576]; Science Foundation Ireland [08/IN1/B1875]; Marie Curie ToK [FP-14499]; Irish Research Council for Science Engineering and Technology	Health Research Board Ireland; Wellcome Trust(Wellcome TrustEuropean Commission); Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Marie Curie ToK(European Commission); Irish Research Council for Science Engineering and Technology(Irish Research Council for Science, Engineering and TechnologyCGIAR)	The authors thank Andreas Strasser (Walter and Eliza Hall Institute of Medical Research, Parkville, Australia) and Andreas Villunger (University of Innsbruck, Innsbruck, Austria) for providing Puma-deficient mice, and Genshin Mouri, Liam Tuffy and Clara Schindler for technical support. This work was supported by grants from Health Research Board Ireland (RP/2005/24, RP/2007/37, RP/2008/69, PD/2009/31), the Wellcome Trust (GR076576), Science Foundation Ireland (08/IN1/B1875), Marie Curie ToK FP-14499, and a fellowship (to T. E.) from the Irish Research Council for Science Engineering and Technology.	Akhtar RS, 2006, J NEUROSCI, V26, P7257, DOI 10.1523/JNEUROSCI.0196-06.2006; Andre V, 2000, EPILEPSY RES, V42, P7, DOI 10.1016/S0920-1211(00)00153-4; Andre V, 2000, NEUROSCIENCE, V99, P469, DOI 10.1016/S0306-4522(00)00209-8; Araki T, 2004, HIPPOCAMPUS, V14, P326, DOI 10.1002/hipo.10184; Bernasconi A, 2002, PROG BRAIN RES, V135, P297; Biagini G, 2008, J NEUROPATH EXP NEUR, V67, P687, DOI 10.1097/NEN.0b013e318181b8ae; Brandt C, 2003, NEUROSCIENCE, V118, P727, DOI 10.1016/S0306-4522(03)00027-7; Bumanglag AV, 2008, J COMP NEUROL, V510, P561, DOI 10.1002/cne.21801; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Concannon CG, 2008, J NEUROCHEM, V105, P891, DOI 10.1111/j.1471-4159.2007.05187.x; Cregan SP, 2004, J NEUROSCI, V24, P10003, DOI 10.1523/JNEUROSCI.2114-04.2004; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; DEGIORGIO CM, 1992, EPILEPSIA, V33, P23, DOI 10.1111/j.1528-1157.1992.tb02278.x; Djebaili M, 2002, NEUROSCI LETT, V327, P1, DOI 10.1016/S0304-3940(02)00137-4; Djebaili M, 2001, MOL BRAIN RES, V93, P190, DOI 10.1016/S0169-328X(01)00197-8; Dube C, 2006, BRAIN, V129, P911, DOI 10.1093/brain/awl018; Endo H, 2006, J NEUROSCI, V26, P7974, DOI 10.1523/JNEUROSCI.0897-06.2006; Engel Tobias, 2009, Int J Physiol Pathophysiol Pharmacol, V1, P97; Fujikawa TG, 2000, EPILEPSIA, V41, P981, DOI 10.1111/j.1528-1157.2000.tb00283.x; Gallenne T, 2009, J CELL BIOL, V185, P279, DOI 10.1083/jcb.200809153; Gomez-Lazaro M, 2005, EXP NEUROL, V196, P96, DOI 10.1016/j.expneurol.2005.07.011; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Jimenez-Mateos EM, 2008, NEUROBIOL DIS, V32, P442, DOI 10.1016/j.nbd.2008.08.008; Kienzler F, 2009, J COMP NEUROL, V515, P181, DOI 10.1002/cne.22059; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Li TF, 2008, J CLIN INVEST, V118, P571, DOI 10.1172/JCI33737; Liu W, 1999, MOL BRAIN RES, V63, P248, DOI 10.1016/S0169-328X(98)00285-X; Mikaeloff Y, 2006, EPILEPSY RES, V69, P67, DOI 10.1016/j.eplepsyres.2006.01.002; MIYASHITA T, 1995, CELL, V80, P293; Morrison RS, 1996, J NEUROSCI, V16, P1337; Mouri G, 2008, BRAIN RES, V1213, P140, DOI 10.1016/j.brainres.2008.03.061; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; Murphy B, 2007, AM J PATHOL, V171, P1258, DOI 10.2353/ajpath.2007.070269; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Narkilahti S, 2003, NEUROPHARMACOLOGY, V44, P1068, DOI 10.1016/S0028-3908(03)00115-1; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pitkanen A, 2007, EPILEPSIA, V48, P13, DOI 10.1111/j.1528-1167.2007.01063.x; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Raol YSH, 2003, ANN NEUROL, V53, P503, DOI 10.1002/ana.10490; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Sakhi S, 1997, EXP NEUROL, V145, P81, DOI 10.1006/exnr.1997.6451; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Schindler CK, 2006, J CEREBR BLOOD F MET, V26, P583, DOI 10.1038/sj.jcbfm.9600219; Sedarous M, 2003, J BIOL CHEM, V278, P26031, DOI 10.1074/jbc.M302833200; Shinoda S, 2004, J NEUROSCI RES, V76, P121, DOI 10.1002/jnr.20064; Sohn D, 2009, CELL DEATH DIFFER, V16, P869, DOI 10.1038/cdd.2009.17; Steckley D, 2007, J NEUROSCI, V27, P12989, DOI 10.1523/JNEUROSCI.3400-07.2007; Tan ZQ, 2002, BRAIN RES, V929, P129, DOI 10.1016/S0006-8993(01)03360-1; Tasch E, 1999, ANN NEUROL, V45, P568, DOI 10.1002/1531-8249(199905)45:5<568::AID-ANA4>3.0.CO;2-P; Tokita Y, 1996, EUR J NEUROSCI, V8, P69, DOI 10.1111/j.1460-9568.1996.tb01168.x; Uo T, 2007, J NEUROSCI, V27, P12198, DOI 10.1523/JNEUROSCI.3222-05.2007; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Xiang H, 1996, J NEUROSCI, V16, P6753; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	57	50	54	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					853	861		10.1096/fj.09-145870	http://dx.doi.org/10.1096/fj.09-145870			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19890018	Green Published			2022-12-28	WOS:000274974600021
J	Sallustio, F; De Benedictis, L; Castellano, G; Zaza, G; Loverre, A; Costantino, V; Grandaliano, G; Schena, FP				Sallustio, Fabio; De Benedictis, Luca; Castellano, Giuseppe; Zaza, Gianluigi; Loverre, Antonia; Costantino, Vincenzo; Grandaliano, Giuseppe; Schena, Francesco P.			TLR2 plays a role in the activation of human resident renal stem/progenitor cells	FASEB JOURNAL			English	Article						renal stem cell; chemokine receptor; complement; MCP-1	MESENCHYMAL STEM-CELLS; TOLL-LIKE RECEPTORS; PROGENITOR CELLS; KIDNEY REPAIR; REGENERATION; MOBILIZATION; COMPLEMENT; DANGER; ANGIOGENESIS; CONTRIBUTE	In the past few years, adult renal progenitor/stem cells (ARPCs) have been identified in human kidneys, and particularly in Bowman's capsule and proximal tubules. They may play an important role in the kidney regenerative processes and might prospectively be the ideal cell type for the treatment of both acute and chronic renal injury. In this study, microarray analysis identified 6 gene clusters that discriminated normal human glomerular and tubular ARPCs from renal proximal tubular epithelial cells and mesenchymal stem cells. The top-scored pathway in the ARPC gene expression profile contained growth factor receptors and immune system-related genes, including toll-like receptor 2 (TLR2). Stimulation of TLR2 by ligands that mime inflammatory mediators or damage associated molecular pattern molecules induced secretion of elevated amounts of monocyte chemoattractant protein-1 (MCP-1), IL-6, IL-8, and C3 via NF-kappa B activation. TLR2 stimulation also increased the ARPC proliferation rate, suggesting a role for TLR2 in ARPC activation via autocrine signaling. Moreover, TLR2 stimulation improved ARPC differentiation into renal epithelial cells and was responsible of ARPC branching morphogenesis and tubule-like structures formation. For the first time, this study provides a genomic characterization of renal multipotent progenitor cells and shows that TLR2 found on ARPCs might be responsible for their activation in the kidney, orchestrating the activation of crucial signaling networks necessary for renal repair.-Sallustio, F., De Benedictis, L., Castellano, G., Zaza, G., Loverre, A., Costantino, V., Grandaliano, G., Schena, F. P. TLR2 plays a role in the activation of human resident renal stem/progenitor cells. FASEB J. 24, 514-525 (2010). www.fasebj.org	[Sallustio, Fabio; De Benedictis, Luca; Castellano, Giuseppe; Zaza, Gianluigi; Loverre, Antonia; Costantino, Vincenzo; Grandaliano, Giuseppe; Schena, Francesco P.] Univ Bari, Nephrol Dialysis & Transplantat Unit, Dept Emergency & Organ Transplantat, I-70124 Bari, Italy	Universita degli Studi di Bari Aldo Moro	Schena, FP (corresponding author), Univ Bari, Nephrol Dialysis & Transplantat Unit, Dept Emergency & Organ Transplantat, Piazza G Cesare 11, I-70124 Bari, Italy.	fp.schena@nephro.uniba.it	Sallustio, Fabio/AFP-7212-2022; Grandaliano, Giuseppe/J-7822-2016; Castellano, Giuseppe/H-1626-2012; Sallustio, Fabio/D-2326-2011; Grandaliano, Giuseppe/G-2963-2012; Schena, Francesco P/K-6982-2016; Zaza, Gianluigi/K-3827-2018	Sallustio, Fabio/0000-0002-5132-6532; Grandaliano, Giuseppe/0000-0003-1213-2177; Castellano, Giuseppe/0000-0002-0153-3795; Sallustio, Fabio/0000-0002-5132-6532; Schena, Francesco P/0000-0001-7927-5207; Zaza, Gianluigi/0000-0002-6004-6196	Regione Puglia (Progetto strategico 2006) [PS 144/06]; Ministry of University and Research (MIUR) [PRIN 2005 069117]	Regione Puglia (Progetto strategico 2006); Ministry of University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR))	We thank Michele Battaglia (University of Bari) for harvesting the renal tissue, and Antonio Traficante (Di Venere Hospital, Bari, Italy). We thank Paola Romagnani (University of Florence, Florence, Italy) and Giovanni Camussi (University of Turin, Turin, Italy) for help in laboratory procedures. This study was supported by grants from Regione Puglia (Progetto strategico 2006 PS 144/06) and from the Ministry of University and Research (MIUR; PRIN 2005 069117).	Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Anders HJ, 2007, CURR OPIN NEPHROL HY, V16, P177, DOI 10.1097/MNH.0b013e32803fb767; Anders HJ, 2004, J AM SOC NEPHROL, V15, P854, DOI 10.1097/01.ASN.0000121781.89599.16; Belema-Bedada F, 2008, CELL STEM CELL, V2, P566, DOI 10.1016/j.stem.2008.03.003; Bonventre JV, 2003, J AM SOC NEPHROL, V14, pS55, DOI 10.1097/01.ASN.0000067652.51441.21; Bussolati B, 2005, AM J PATHOL, V166, P545, DOI 10.1016/S0002-9440(10)62276-6; Bussolati B, 2008, AM J NEPHROL, V28, P813, DOI 10.1159/000137681; Castellano G, 2005, J AM SOC NEPHROL, V16, P2003, DOI 10.1681/ASN.2002120972; Chen J, 2008, KIDNEY INT, V74, P879, DOI 10.1038/ki.2008.304; Cho HH, 2006, STEM CELLS, V24, P2744, DOI 10.1634/stemcells.2006-0189; Duffield JS, 2005, KIDNEY INT, V68, P1956, DOI 10.1111/j.1523-1755.2005.00629.x; Duffield JS, 2005, J CLIN INVEST, V115, P1743, DOI 10.1172/JCI22593; Fibbe WE, 2000, SEMIN HEMATOL, V37, P19, DOI 10.1016/S0037-1963(00)90085-4; Gupta S, 2002, KIDNEY INT, V62, P1285, DOI 10.1111/j.1523-1755.2002.kid569.x; HUMES HD, 1989, J CLIN INVEST, V84, P1757, DOI 10.1172/JCI114359; Humphreys B D, 2006, Minerva Urol Nefrol, V58, P329; Humphreys BD, 2008, CELL STEM CELL, V2, P284, DOI 10.1016/j.stem.2008.01.014; Kale S, 2003, J CLIN INVEST, V112, P42, DOI 10.1172/JCI200317856; Lang A, 2005, J AM SOC NEPHROL, V16, P383, DOI 10.1681/ASN.2004040276; LATERVEER L, 1995, BLOOD, V85, P2269, DOI 10.1182/blood.V85.8.2269.bloodjournal8582269; Leemans JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005704; Li M, 2008, NEPHROL DIAL TRANSPL, V23, P860, DOI 10.1093/ndt/gfm670; Little MH, 2006, J AM SOC NEPHROL, V17, P2390, DOI 10.1681/ASN.2006030218; Loverre A, 2008, TRANSPLANTATION, V85, P1112, DOI 10.1097/TP.0b013e31816a8891; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Morigi M, 2004, J AM SOC NEPHROL, V15, P1794, DOI 10.1097/01.ASN.0000128974.07460.34; Nam NH, 2006, MINI-REV MED CHEM, V6, P945, DOI 10.2174/138955706777934937; Nishida M, 2003, AM J KIDNEY DIS, V42, DOI 10.1053/S0272-6386(03)01021-7; Plotkin MD, 2006, AM J PHYSIOL-RENAL, V291, pF902, DOI 10.1152/ajprenal.00396.2005; Ratajczak J, 2004, BLOOD, V103, P2071, DOI 10.1182/blood-2003-06-2099; Reca R, 2007, STEM CELLS, V25, P3093, DOI 10.1634/stemcells.2007-0525; Ronconi E, 2009, J AM SOC NEPHROL, V20, P322, DOI 10.1681/ASN.2008070709; Sagrinati C, 2008, TRENDS MOL MED, V14, P277, DOI 10.1016/j.molmed.2008.05.005; Sagrinati C, 2006, J AM SOC NEPHROL, V17, P2443, DOI 10.1681/ASN.2006010089; SCHENA FP, 1998, KIDNEY INT S, V66, P11; Shigeoka AA, 2007, J IMMUNOL, V178, P6252, DOI 10.4049/jimmunol.178.10.6252; Stich S, 2008, EUR J CELL BIOL, V87, P365, DOI 10.1016/j.ejcb.2008.03.009; Tomchuck SL, 2008, STEM CELLS, V26, P99, DOI 10.1634/stemcells.2007-0563; Widera D, 2004, EUR J CELL BIOL, V83, P381, DOI 10.1078/0171-9335-00403; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277; Yokoo T, 2008, KIDNEY INT, V74, P847, DOI 10.1038/ki.2008.327	42	93	96	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					514	525		10.1096/fj.09-136481	http://dx.doi.org/10.1096/fj.09-136481			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19843711				2022-12-28	WOS:000274045000019
J	Xu, YZ; Zhang, ZY; Hu, J; Stillman, IE; Leopold, JA; Handy, DE; Loscalzo, J; Stanton, RC				Xu, Yizhen; Zhang, Zhaoyun; Hu, Ji; Stillman, Isaac E.; Leopold, Jane A.; Handy, Diane E.; Loscalzo, Joseph; Stanton, Robert C.			Glucose-6-phosphate dehydrogenase-deficient mice have increased renal oxidative stress and increased albuminuria	FASEB JOURNAL			English	Article						pentose phosphate pathway; inflammation; mouse kidney	CHRONIC KIDNEY-DISEASE; ENDOTHELIAL DYSFUNCTION; DIABETES-MELLITUS; OXIDANT STRESS; NITRIC-OXIDE; ENZYME; G6PD; MUTATION; GROWTH	Glucose-6-phosphate dehydrogenase (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway and the principal source of NADPH, a major cellular reductant, and is central to cell survival. Our previous work showed that diabetes and increased aldosterone are acquired forms of G6PD deficiency, leading to decreased G6PD activity and NADPH levels and damage to kidney tissue and endothelial cells. In this study, G6PD-deficient mice were studied to test the hypothesis that decreased G6PD activity per se can cause changes similar to those seen in the acquired conditions of G6PD deficiency. Results show that as compared with control mice, G6PD-deficient mice had increased oxidative stress, as manifested by decreased NADPH levels and decreased GSH levels, and increased markers of lipid peroxidation. G6PD-deficient mice had increased protein kinase C activity, increased nuclear factor-kappa B activity, and increased urinary albumin levels, all of which is similar to changes seen in diabetic mice. Changes persisted as the mice aged, as old G6PD-deficient mice (17-20 mo) had higher urine albumin levels and also had evidence for increased apoptosis in the renal cortex. These results show that decreased G6PD activity per se is sufficient to cause changes similar to those seen in diabetic mice.-Xu, Y., Zhang, Z., Hu, J., Stillman, I. E., Leopold, J. A., Handy, D. E., Loscalzo, J., Stanton, R. C. Glucose-6-phosphate dehydrogenase-deficient mice have increased renal oxidative stress and increased albuminuria. FASEB J. 24, 609-616 (2010). www.fasebj.org	[Xu, Yizhen; Zhang, Zhaoyun; Hu, Ji; Stanton, Robert C.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Brigham & Womens Hosp,Res Div, Boston, MA 02115 USA; [Leopold, Jane A.; Handy, Diane E.; Loscalzo, Joseph] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA; [Stillman, Isaac E.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; [Stillman, Isaac E.] Beth Israel Deaconess Med Ctr, Dept Med, Div Renal, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Stanton, RC (corresponding author), Joslin Diabet Ctr, Div Renal, 1 Joslin Pl, Boston, MA 02215 USA.	robert.stanton@joslin.harvard.edu	Loscalzo, Joseph/ABD-8980-2021; Stillman, Isaac E/ABC-7278-2020; Stanton, Robert C/AAG-7584-2020	Stanton, Robert C/0000-0002-3056-1277; Handy, Diane/0000-0002-4310-8527	National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01-DK54380]; NIH/National Heart, Lung, and Blood Institute [R37HL61795, R01-HL58796, P01-HL81587, K02 HL081110, U54-HL70819]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U54HL070819, P01HL081587, R37HL061795, R01HL058976, K02HL081110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054380] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant R01-DK54380 to R. C. S.; NIH/National Heart, Lung, and Blood Institute grants R37HL61795, R01-HL58796, and P01-HL81587 to J. L.; and grants K02 HL081110 and U54-HL70819 to J. A. L.	Ahmad FK, 2005, CURR DRUG TARGETS, V6, P487, DOI 10.2174/1389450054021990; Cachofeiro V, 2008, KIDNEY INT, V74, pS4, DOI 10.1038/ki.2008.516; Fornoni A, 2008, CURR DIABETES REV, V4, P10, DOI 10.2174/157339908783502361; Gaskin Robert St. C., 2001, Ethnicity and Disease, V11, P749; Ho HY, 2000, FREE RADICAL BIO MED, V29, P156, DOI 10.1016/S0891-5849(00)00331-2; Horton JD, 2002, BIOCHEM SOC T, V30, P1091, DOI 10.1042/bst0301091; KEHRER JP, 1994, FREE RADICAL BIO MED, V17, P65, DOI 10.1016/0891-5849(94)90008-6; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; LEE CY, 1980, MOL CELL BIOCHEM, V30, P143; Leopold JA, 2003, J BIOL CHEM, V278, P32100, DOI 10.1074/jbc.M301293200; Leopold JA, 2003, ARTERIOSCL THROM VAS, V23, P411, DOI 10.1161/01.ATV.0000056744.26901.BA; Leopold JA, 2001, FASEB J, V15, P1771, DOI 10.1096/fj.00-0893fje; Longo L, 2002, EMBO J, V21, P4229, DOI 10.1093/emboj/cdf426; Muller G, 2009, HORM METAB RES, V41, P152, DOI 10.1055/s-0028-1086023; Munro AW, 2007, BBA-GEN SUBJECTS, V1770, P345, DOI 10.1016/j.bbagen.2006.08.018; NIAZI GA, 1991, INT J HEMATOL, V54, P295; Nicol CJ, 2000, FASEB J, V14, P111, DOI 10.1096/fasebj.14.1.111; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; PANICH V, 1980, HUM GENET, V55, P123, DOI 10.1007/BF00329138; PRETSCH W, 1988, BIOCHEM GENET, V26, P89, DOI 10.1007/BF00555491; Rahangdale S, 2009, FRONT BIOSCI-LANDMRK, V14, P192, DOI 10.2741/3240; ROSENSTRAUS M, 1975, P NATL ACAD SCI USA, V72, P493, DOI 10.1073/pnas.72.2.493; Sanders S, 1997, MUTAT RES-FUND MOL M, V374, P79, DOI 10.1016/S0027-5107(96)00222-9; Solt LA, 2008, IMMUNOL RES, V42, P3, DOI 10.1007/s12026-008-8025-1; Suliman ME, 2008, CLIN J AM SOC NEPHRO, V3, P976, DOI 10.2215/CJN.03960907; SUZUKI Y, 1989, JPN J PHARMACOL, V51, P181, DOI 10.1254/jjp.51.181; Tian WN, 1998, J BIOL CHEM, V273, P10609, DOI 10.1074/jbc.273.17.10609; Tian WN, 1999, AM J PHYSIOL-CELL PH, V276, pC1121, DOI 10.1152/ajpcell.1999.276.5.C1121; Touyz RM, 2004, HYPERTENSION, V44, P248, DOI 10.1161/01.HYP.0000138070.47616.9d; Wan GH, 2002, ENDOCRINE, V19, P191, DOI 10.1385/ENDO:19:2:191; Xu YZ, 2005, AM J PHYSIOL-RENAL, V289, pF1040, DOI 10.1152/ajprenal.00076.2005; Zhang ZQ, 2000, J BIOL CHEM, V275, P40042, DOI 10.1074/jbc.M007505200	32	67	69	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					609	616		10.1096/fj.09-135731	http://dx.doi.org/10.1096/fj.09-135731			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19805580	Green Published			2022-12-28	WOS:000274045000028
J	Gruszka, A; de Marco, A				Gruszka, Alicja; de Marco, Ario			A (musical) note on protein purification	FASEB JOURNAL			English	Editorial Material									[de Marco, Ario] IFOM IEO Campus Oncogenom, Prot Chem Unit, Cogentech, I-20139 Milan, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO)	de Marco, A (corresponding author), IFOM IEO Campus Oncogenom, Prot Chem Unit, Cogentech, Via Adamello 16, I-20139 Milan, Italy.	ario.demarco@ifom-ieo-campus.it	Gruszka, Alicja M/O-5398-2019; de Marco, Ario/A-2760-2014	Gruszka, Alicja M/0000-0002-5359-0281; de Marco, Ario/0000-0001-7729-819X					0	0	0	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					6	6		10.1096/fj.10-0103ufm	http://dx.doi.org/10.1096/fj.10-0103ufm			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	20047895				2022-12-28	WOS:000273233600002
J	Massip, L; Garand, C; Paquet, ER; Cogger, VC; O'Reilly, JN; Tworek, L; Hatherell, A; Taylor, CG; Thorin, E; Zahradka, P; Le Couteur, DG; Lebel, M				Massip, Laurent; Garand, Chantal; Paquet, Eric R.; Cogger, Victoria C.; O'Reilly, Jennifer N.; Tworek, Leslee; Hatherell, Avril; Taylor, Carla G.; Thorin, Eric; Zahradka, Peter; Le Couteur, David G.; Lebel, Michel			Vitamin C restores healthy aging in a mouse model for Werner syndrome	FASEB JOURNAL			English	Article						ascorbate; metabolism; microarrays; liver; adipocyte; inflammation	GENE-EXPRESSION PROFILES; L-ASCORBIC-ACID; INSULIN-RESISTANCE; SYNDROME PROTEIN; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASE-1; DWARF MICE; LIFE-SPAN; KAPPA-B; CELLS	Werner syndrome (WS) is a premature aging disorder caused by mutations in a RecQ-like DNA helicase. Mice lacking the helicase domain of the WRN homologue exhibit many phenotypic features of WS, including a prooxidant status and a shorter mean life span compared to wild-type animals. Here, we show that Wrn mutant mice also develop premature liver sinusoidal endothelial defenestration along with inflammation and metabolic syndrome. Vitamin C supplementation rescued the shorter mean life span of Wrn mutant mice and reversed several age-related abnormalities in adipose tissues and liver endothelial defenestration, genomic integrity, and inflammatory status. At the molecular level, phosphorylation of age-related stress markers like Akt kinase-specific substrates and the transcription factor NF-kappa B, as well as protein kinase C delta and Hif-1 alpha transcription factor levels, which are increased in the liver of Wrn mutants, were normalized by vitamin C. Vitamin C also increased the transcriptional regulator of lipid metabolism PPAR alpha. Finally, microarray and gene set enrichment analyses on liver tissues revealed that vitamin C decreased genes normally up-regulated in human WS fibroblasts and cancers, and it increased genes involved in tissue injury response and adipocyte dedifferentiation in obese mice. Vitamin C did not have such effect on wild-type mice. These results indicate that vitamin C supplementation could be beneficial for patients with WS.-Massip, L., Garand, C., Paquet, E. R., Cogger, V. C., O'Reilly, J. N., Tworek, L., Hatherell, A., Taylor, C. G., Thorin, E., Zahradka, P., Le Couteur, D. G., Lebel, M. Vitamin C restores healthy aging in a mouse model for Werner syndrome. FASEB J. 24, 158-172 ( 2010). www.fasebj.org	[Massip, Laurent; Garand, Chantal; Paquet, Eric R.; Lebel, Michel] Univ Laval, Ctr Rech Cancerol, Hop Hotel Dieu, Quebec City, PQ, Canada; [Cogger, Victoria C.; O'Reilly, Jennifer N.; Le Couteur, David G.] Univ Sydney, Ctr Educ & Res Ageing, Sydney, NSW 2006, Australia; [Cogger, Victoria C.; O'Reilly, Jennifer N.; Le Couteur, David G.] Univ Sydney, ANZAC Res Inst, Sydney, NSW 2006, Australia; [Cogger, Victoria C.; O'Reilly, Jennifer N.; Le Couteur, David G.] Concord RG Hosp, Sydney, NSW, Australia; [Tworek, Leslee; Hatherell, Avril; Taylor, Carla G.; Zahradka, Peter] Univ Manitoba, Canadian Ctr Agri Food Res Hlth & Med, Winnipeg, MB, Canada; [Tworek, Leslee; Hatherell, Avril; Taylor, Carla G.; Zahradka, Peter] St Boniface Gen Hosp, Res Ctr, Winnipeg, MB, Canada; [Thorin, Eric] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada	Laval University; University of Sydney; University of Sydney; ANZAC Research Institute; Concord Repatriation General Hospital; University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; Universite de Montreal	Lebel, M (corresponding author), Hop HoDieu Quebec, Ctr Rech Cancerol, 9 McMahon St, Quebec City, PQ G1R 2J6, Canada.	michel.lebel@crhdq.ulaval.ca	Thorin, Eric/K-3978-2013; Research Institute, ANZAC/CAE-9030-2022	Thorin, Eric/0000-0001-5827-8935; Taylor, Carla G./0000-0003-3358-6418; Zahradka, Peter/0000-0002-7814-0658; Le Couteur, David/0000-0002-4227-5817; Garand, Chantal/0000-0003-0716-6487; Paquet, Eric/0000-0001-9194-1655	Canadian Institutes of Health Research; National Sciences and Engineering Research Council of Canada; The National Health and Medical Research Council of Australia; Aging and Alzheimers Research Foundation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); The National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Aging and Alzheimers Research Foundation	We thank Dr. O. Neyret-Djossou of the functional genomic platform of the Institut de Recherche Clinique de Montreal (Montreal, QC, Canada) for the microarray services. We are also grateful to M. Sild and A. Labbe for real-time RT-PCRs ( Centre de Recherche en Cancerologie de l'Universite Laval). This work was supported in part by grants from the Canadian Institutes of Health Research and from the National Sciences and Engineering Research Council of Canada to M. L. and from The National Health and Medical Research Council of Australia and from the Aging and Alzheimers Research Foundation ( a Division of the Medical Foundation of the University of Sydney) to D. G. L. M. L. is a senior scholar of the Fonds de la Recherche en Sante du Quebec.	Adler AS, 2007, GENE DEV, V21, P3244, DOI 10.1101/gad.1588507; Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Bokko PB, 2007, MOL BIOL CELL, V18, P1874, DOI 10.1091/mbc.E06-09-0881; BORGESE N, 1986, BIOCHEM J, V239, P393, DOI 10.1042/bj2390393; Chang S, 2004, NAT GENET, V36, P877, DOI 10.1038/ng1389; Cooper MP, 2000, GENE DEV, V14, P907; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; Cummins EP, 2005, PFLUG ARCH EUR J PHY, V450, P363, DOI 10.1007/s00424-005-1413-7; Davis T, 2005, J GERONTOL A-BIOL, V60, P1386, DOI 10.1093/gerona/60.11.1386; Deschenes F, 2005, HUM MOL GENET, V14, P3293, DOI 10.1093/hmg/ddi362; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; Flechner SM, 2004, AM J TRANSPLANT, V4, P1475, DOI 10.1111/j.1600-6143.2004.00526.x; Hilmer SN, 2005, HEPATOLOGY, V42, P1349, DOI 10.1002/hep.20937; Hoffmann R, 2002, GENOME RES, V12, P98, DOI 10.1101/gr.201501; Honjo S, 2008, J AM GERIATR SOC, V56, P173, DOI 10.1111/j.1532-5415.2007.01484.x; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Hsieh CC, 2006, FASEB J, V20, P259, DOI 10.1096/fj.05-4376com; Huang SR, 2006, HUM MUTAT, V27, P558, DOI 10.1002/humu.20337; Ichiba T, 2003, BLOOD, V102, P763, DOI 10.1182/blood-2002-09-2748; Kashino G, 2003, FREE RADICAL BIO MED, V35, P438, DOI 10.1016/S0891-5849(03)00326-5; Kipling D, 2004, SCIENCE, V305, P1426, DOI 10.1126/science.1102587; Kondo Y, 2006, P NATL ACAD SCI USA, V103, P5723, DOI 10.1073/pnas.0511225103; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kuo SM, 2004, J NUTR, V134, P2216; Kyng KJ, 2003, P NATL ACAD SCI USA, V100, P12259, DOI 10.1073/pnas.2130723100; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; Le Couteur DG, 2008, ANAT REC, V291, P672, DOI 10.1002/ar.20661; Lebel M, 2003, AM J PATHOL, V162, P1559, DOI 10.1016/S0002-9440(10)64290-3; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Linster CL, 2007, FEBS J, V274, P1, DOI 10.1111/j.1742-4658.2006.05607.x; Lloret A, 2008, FREE RADICAL BIO MED, V44, P495, DOI 10.1016/j.freeradbiomed.2007.10.046; Lombard DB, 2000, MOL CELL BIOL, V20, P3286, DOI 10.1128/MCB.20.9.3286-3291.2000; Maeda N, 2000, P NATL ACAD SCI USA, V97, P841, DOI 10.1073/pnas.97.2.841; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; MASSIE HR, 1984, GERONTOLOGY, V30, P370, DOI 10.1159/000212659; Massip L, 2006, EXP GERONTOL, V41, P157, DOI 10.1016/j.exger.2005.10.011; Masternak MM, 2007, PPAR RES, V2007, DOI 10.1155/2007/28436; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McLachlan JL, 2005, BBA-MOL BASIS DIS, V1741, P271, DOI 10.1016/j.bbadis.2005.03.007; Moore G, 2008, MECH AGEING DEV, V129, P201, DOI 10.1016/j.mad.2007.12.009; MORI S, 2001, INT J OBESITY, V25, P29229; Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371; Otsuka M, 1999, J NUTR SCI VITAMINOL, V45, P163, DOI 10.3177/jnsv.45.163; Ozgenc A, 2005, MUTAT RES-FUND MOL M, V577, P237, DOI 10.1016/j.mrfmmm.2005.03.020; Pagano G, 2005, FREE RADICAL RES, V39, P529, DOI 10.1080/10715760500092683; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; SALK D, 1982, HUM GENET, V62, P1, DOI 10.1007/BF00295598; Schumacher B, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000161; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shepard JL, 2005, P NATL ACAD SCI USA, V102, P13194, DOI 10.1073/pnas.0506583102; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swindell WR, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-353; Taylor CT, 2008, J PHYSIOL-LONDON, V586, P4055, DOI 10.1113/jphysiol.2008.157669; Villalba JM, 2000, ANTIOXID REDOX SIGN, V2, P213, DOI 10.1089/ars.2000.2.2-213; Wang CX, 2004, MECH AGEING DEV, V125, P629, DOI 10.1016/j.mad.2004.07.003; Warren A, 2005, EXP GERONTOL, V40, P807, DOI 10.1016/j.exger.2005.06.012; Wieland S, 2004, P NATL ACAD SCI USA, V101, P6669, DOI 10.1073/pnas.0401771101; Yamamoto H, 2007, CLIN CHIM ACTA, V379, P167, DOI 10.1016/j.cca.2007.01.009; Yokote K, 2008, J AM GERIATR SOC, V56, P1770, DOI 10.1111/j.1532-5415.2008.01817.x; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Yu DN, 2005, ANN NY ACAD SCI, V1059, P145, DOI 10.1196/annals.1339.047; Fokko ZA, 2007, BBA-MOL CELL BIOL L, V1771, P972, DOI 10.1016/j.bbalip.2007.04.021; Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470	69	75	75	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					158	172		10.1096/fj.09-137133	http://dx.doi.org/10.1096/fj.09-137133			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19741171	Green Accepted			2022-12-28	WOS:000273233600018
J	Held-Kuznetsov, V; Rotem, S; Assaraf, YG; Mor, A				Held-Kuznetsov, Viktoria; Rotem, Shahar; Assaraf, Yehuda G.; Mor, Amram			Host-defense peptide mimicry for novel antitumor agents	FASEB JOURNAL			English	Article						antimicrobial peptide; peptide-mimetic; drug design; monotherapy; combination therapy; multidrug resistance	ACYL-LYSINE OLIGOMERS; KILLS CANCER-CELLS; ANTIMICROBIAL PEPTIDES; MULTIDRUG-RESISTANCE; FOLATE HOMEOSTASIS; CARCINOMA CELLS; TUMOR-GROWTH; IN-VITRO; LINES; DEATH	Although evidence is accumulating for promising anticancer properties of host-defense peptides (HDPs), their potential therapeutic use suffers from limitations inherent to peptide pharmaceuticals, including poor bioavailability and potential toxicity. Therefore, we tested the hypothesis that HDP mimics might generate improved anticancer derivatives. Oligomers of acyl-lysyl (OAKs) varying with respect to charge, hydrophobicity, and backbone length were screened against prostate adenocarcinoma cell line TRAMP-C2 using the XTT assay. A promising 11-mer sequence, designated alpha(12)-3 beta(12), was further characterized in terms of selectivity (using human primary fibroblasts and malignant cells), mechanism of action and its relation to multidrug resistance (using 7 ABC multidrug efflux transporters), and antitumor efficacy (as assessed in C57BL/6J mice bearing TRAMP-C2 tumors). The OAK exerted rapid and selective cytotoxicity against malignant cells, apparently via an intracellular multitarget mode of action, thereby overcoming major modalities of chemoresistance. Both systemic and local administrations of alpha(12)-3 beta(12) to tumor-bearing mice significantly inhibited tumor progression and were associated with an improved toxicity profile when compared to doxorubicin. Moreover, a combination of alpha(12)-3 beta(12) with doxorubicin can lead to tumor eradication. Collectively, the current findings establish the potential of an HDP-mimetic approach for developing simplified yet robust antitumor agents that bear a key advantage of overcoming MDR phenomena. Held-Kuznetsov, V., Rotem, S., Assaraf, Y. G., Mor, A. Host-defense peptide mimicry for novel antitumor agents. FASEB J. 23, 4299-4307 (2009). www.fasebj.org	[Held-Kuznetsov, Viktoria; Rotem, Shahar; Mor, Amram] Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; [Assaraf, Yehuda G.] Technion Israel Inst Technol, Fred Wyszkowski Canc Res Lab, Fac Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology	Mor, A (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel.	amor@tx.technion.ac.il			Israel Science Foundation [283/08]; Fred Wyszkowski Cancer Research Fund	Israel Science Foundation(Israel Science Foundation); Fred Wyszkowski Cancer Research Fund	This research was supported by the Israel Science Foundation (grant 283/08 to A. M.) and by the Fred Wyszkowski Cancer Research Fund (research grant to Y. G. A.). The assistance of Mrs. Abigail Morgenstern and Dr. Mark Tendler in animal experiments is gratefully acknowledged. The OAK sequences described here have been submitted as part of a U. S. patent application.	Assaraf YG, 2006, DRUG RESIST UPDATE, V9, P227, DOI 10.1016/j.drup.2006.09.001; AZACHIRICA P, 1994, EUR J BIOCHEM, V224, P257; Borgnia MJ, 1996, J BIOL CHEM, V271, P3163, DOI 10.1074/jbc.271.6.3163; Bram EE, 2007, BIOCHEM PHARMACOL, V74, P41, DOI 10.1016/j.bcp.2007.03.028; Bullard KM, 2003, INT J CANCER, V107, P739, DOI 10.1002/ijc.11475; Chan SC, 1998, ANTICANCER RES, V18, P4467; Chang CC, 2006, CANCER CHEMOTH PHARM, V58, P640, DOI 10.1007/s00280-006-0214-9; Chen HM, 1997, BBA-GEN SUBJECTS, V1336, P171, DOI 10.1016/S0304-4165(97)00024-X; Chen JG, 2005, CANCER RES, V65, P4614, DOI 10.1158/0008-5472.CAN-04-2253; Chongsiriwatana NP, 2008, P NATL ACAD SCI USA, V105, P2794, DOI 10.1073/pnas.0708254105; Chuang CM, 2009, HUM GENE THER, V20, P303, DOI 10.1089/hum.2008.124; CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792; CRUCIANI RA, 1992, EUR J PHARM-MOLEC PH, V226, P287, DOI 10.1016/0922-4106(92)90045-W; Eliassen LT, 2006, INT J CANCER, V119, P493, DOI 10.1002/ijc.21886; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Epand RF, 2008, J MOL BIOL, V379, P38, DOI 10.1016/j.jmb.2008.03.047; Epand RM, 2008, J AM CHEM SOC, V130, P14346, DOI 10.1021/ja8062327; Foster BA, 1997, CANCER RES, V57, P3325; Fotin-Mleczek M, 2005, CURR PHARM DESIGN, V11, P3613, DOI 10.2174/138161205774580778; Gademann K, 2001, HELV CHIM ACTA, V84, P2924, DOI 10.1002/1522-2675(20011017)84:10<2924::AID-HLCA2924>3.3.CO;2-5; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Ghavami S, 2008, J CELL MOL MED, V12, P1005, DOI 10.1111/j.1582-4934.2008.00129.x; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267; Heerdt BG, 2003, CANCER RES, V63, P6311; Heerdt BG, 2005, CANCER RES, V65, P9861, DOI 10.1158/0008-5472.CAN-05-2444; Higgins CF, 2007, NATURE, V446, P749, DOI 10.1038/nature05630; Hooijberg JH, 2003, BIOCHEM PHARMACOL, V65, P765, DOI 10.1016/S0006-2952(02)01615-5; Hoskin DW, 2008, BBA-BIOMEMBRANES, V1778, P357, DOI 10.1016/j.bbamem.2007.11.008; Kanome T, 2007, ONCOGENE, V26, P5991, DOI 10.1038/sj.onc.1210423; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Krugliak M, 2000, ANTIMICROB AGENTS CH, V44, P2442, DOI 10.1128/AAC.44.9.2442-2451.2000; LINCKE CR, 1990, CANCER RES, V50, P1779; Liu SJ, 2008, HEPATOLOGY, V47, P1964, DOI 10.1002/hep.22240; Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217; Mader JS, 2005, MOL CANCER THER, V4, P612, DOI 10.1158/1535-7163.MCT-04-0077; Makovitzki A, 2009, CANCER RES, V69, P3458, DOI 10.1158/0008-5472.CAN-08-3021; Mowery BP, 2007, J AM CHEM SOC, V129, P15474, DOI 10.1021/ja077288d; Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010; OHSAKI Y, 1992, CANCER RES, V52, P3534; Papo N, 2004, CANCER RES, V64, P5779, DOI 10.1158/0008-5472.CAN-04-1438; Papo N, 2003, J BIOL CHEM, V278, P21018, DOI 10.1074/jbc.M211204200; Radzishevsky I, 2007, ANTIMICROB AGENTS CH, V51, P1753, DOI 10.1128/AAC.01288-06; Radzishevsky IS, 2008, CHEM BIOL, V15, P354, DOI 10.1016/j.chembiol.2008.03.006; Radzishevsky IS, 2007, NAT BIOTECHNOL, V25, P657, DOI 10.1038/nbt1309; Risso A, 2002, MOL CELL BIOL, V22, P1926, DOI 10.1128/MCB.22.6.1926-1935.2002; Rotem S, 2008, FASEB J, V22, P2652, DOI 10.1096/fj.07-105015; Rotem S, 2009, BBA-BIOMEMBRANES, V1788, P1582, DOI 10.1016/j.bbamem.2008.10.020; SHARMA SV, 1992, ONCOGENE, V7, P193; Shaw JE, 2008, J STRUCT BIOL, V162, P121, DOI 10.1016/j.jsb.2007.11.003; SOBALLE PW, 1995, INT J CANCER, V60, P280; Takeshima K, 2003, J BIOL CHEM, V278, P1310, DOI 10.1074/jbc.M208762200; Tew GN, 2002, P NATL ACAD SCI USA, V99, P5110, DOI 10.1073/pnas.082046199; Tyagi AK, 2002, CLIN CANCER RES, V8, P3512; UTSUGI T, 1991, CANCER RES, V51, P3062; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Wang C, 2009, J BIOL CHEM, V284, P3804, DOI 10.1074/jbc.M807191200; Wielinga PR, 2002, MOL PHARMACOL, V62, P1321, DOI 10.1124/mol.62.6.1321; Xu N, 2008, MOL CANCER THER, V7, P1588, DOI 10.1158/1535-7163.MCT-08-0010; Yang N, 2002, J PEPT RES, V60, P187, DOI 10.1034/j.1399-3011.2002.21008.x; YOGEESWARAN G, 1981, SCIENCE, V212, P1514, DOI 10.1126/science.7233237; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	62	15	16	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4299	4307		10.1096/fj.09-136358	http://dx.doi.org/10.1096/fj.09-136358			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19706728				2022-12-28	WOS:000272193700024
J	van Beek, EM; de Vries, TJ; Mulder, L; Schoenmaker, T; Hoeben, KA; Matozaki, T; Langenbach, GEJ; Kraal, G; Everts, V; van den Berg, TK				van Beek, Ellen M.; de Vries, Teun J.; Mulder, Lars; Schoenmaker, Ton; Hoeben, Kees A.; Matozaki, Takashi; Langenbach, Geerling E. J.; Kraal, Georg; Everts, Vincent; van den Berg, Timo K.			Inhibitory regulation of osteoclast bone resorption by signal regulatory protein alpha	FASEB JOURNAL			English	Article						immunoreceptor; actin ring; osteoclast function; osteoclastogenesis	TYROSINE-PHOSPHATASE SHP-1; IN-VITRO; C-SRC; RECEPTOR; SHPS-1; INTEGRIN; FUSION; LIGAND; CELLS; DIFFERENTIATION	Osteoclasts mediate bone resorption, which is critical for bone development, maintenance, and repair. Proper control of osteoclast development and function is important and deregulation of these processes may lead to bone disease, such as osteoporosis. Previous studies have shown that the cytosolic protein tyrosine phosphatase SHP-1 acts as a suppressor of osteoclast differentiation and function, but putative inhibitory receptors that mediate recruitment and activation of SHP-1 in osteoclasts have remained unknown. In the present study, we identify the SHP-1-recruiting inhibitory immunoreceptor signal regulatory protein (SIRP) alpha as a negative regulator of osteoclast activity. SIRP alpha is expressed by osteoclasts, and osteoclasts from mice lacking the SIRP alpha cytoplasmic tail and signaling capacity display enhanced bone resorption in vitro. Consequently, SIRP alpha-mutant mice have a significantly reduced cortical bone mass. Furthermore, osteoclasts from SIRP alpha-mutant mice show an enhanced formation of actin rings, known to be instrumental in bone resorption. SIRP alpha mutation did not significantly affect osteoclast formation, implying that the role of SIRP alpha was limited to the regulation of mature osteoclast function. This identifies SIRP alpha as a bona fide inhibitory receptor that regulates the bone-resorption activity and supports a concept in which osteoclast function is balanced by the signaling activities of activating and inhibitory immunoreceptors.-Van Beek, E. M., de Vries, T. J., Mulder, L., Schoenmaker, T., Hoeben, K. A., Matozaki, T., Langenbach, G. E. J., Kraal, G., Everts, V., van den Berg, T. K. Inhibitory regulation of osteoclast bone resorption by signal regulatory protein alpha. FASEB J. 23, 4081-4090 (2009). www.fasebj.org	[van den Berg, Timo K.] Univ Amsterdam, Acad Med Ctr, Sanquin Res & Landsteiner Lab, Phagocyte Lab, NL-1066 CX Amsterdam, Netherlands; [Hoeben, Kees A.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1066 CX Amsterdam, Netherlands; [de Vries, Teun J.; Schoenmaker, Ton; Everts, Vincent] Univ Amsterdam, MOVE Res Inst, Acad Ctr Dent Amsterdam, Dept Periodontol & Oral Cell Biol, NL-1066 CX Amsterdam, Netherlands; [Langenbach, Geerling E. J.] Univ Amsterdam, MOVE Res Inst, Acad Ctr Dent Amsterdam, Dept Funct Anat, NL-1066 CX Amsterdam, Netherlands; [Kraal, Georg] Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands; [Mulder, Lars] Eindhoven Univ Technol, Dept Biomed Engn, NL-5600 MB Eindhoven, Netherlands; [Matozaki, Takashi] Gunma Univ, Lab Biosignal Sci, Inst Mol & Cellular Regulat, Gunma, Japan	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Academic Center for Dentistry Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Academic Center for Dentistry Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Eindhoven University of Technology; Gunma University	van den Berg, TK (corresponding author), Univ Amsterdam, Acad Med Ctr, Sanquin Res & Landsteiner Lab, Phagocyte Lab, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	t.k.vandenberg@sanquin.nl	van den Berg, Timo K/AAC-2479-2022	Schoenmaker, Ton/0000-0001-6649-374X; de Vries, Teun/0000-0001-6464-5172				Adams S, 1998, J IMMUNOL, V161, P1853; Aoki K, 1999, BONE, V25, P261, DOI 10.1016/S8756-3282(99)00174-X; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; CHUANG W, 1990, DEV BIOL, V137, P219, DOI 10.1016/0012-1606(90)90249-I; Chung DH, 2003, J IMMUNOL, V171, P6541, DOI 10.4049/jimmunol.171.12.6541; de Vries HE, 2002, J IMMUNOL, V168, P5832, DOI 10.4049/jimmunol.168.11.5832; de Vries TJ, 2006, J CELL BIOCHEM, V98, P370, DOI 10.1002/jcb.20795; de Vries TJ, 2005, J CELL BIOCHEM, V94, P954, DOI 10.1002/jcb.20326; de Vries TJ, 1999, BRIT J CANCER, V80, P883, DOI 10.1038/sj.bjc.6690436; Everts V, 1999, FASEB J, V13, P1219, DOI 10.1096/fasebj.13.10.1219; Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Fukunaga A, 2004, J IMMUNOL, V172, P4091, DOI 10.4049/jimmunol.172.7.4091; Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200; Hatherley D, 2007, J BIOL CHEM, V282, P14567, DOI 10.1074/jbc.M611511200; Humphrey MB, 2006, J BONE MINER RES, V21, P237, DOI 10.1359/JBMR.051016; Humphrey MB, 2004, J BONE MINER RES, V19, P224, DOI 10.1359/JBMR.0301234; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Ishikawa-Sekigami T, 2006, BLOOD, V107, P341, DOI 10.1182/blood-2005-05-1896; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Johansson MK, 2007, BLOOD, V109, P5178, DOI 10.1182/blood-2006-12-061382; Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; LOWENTHAL JW, 1985, J IMMUNOL, V135, P3988; Lundberg P, 2007, BIOCHEM BIOPH RES CO, V352, P444, DOI 10.1016/j.bbrc.2006.11.057; Manolagas SC, 2000, J BONE MINER RES, V15, P1001, DOI 10.1359/jbmr.2000.15.6.1001; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; Mulder L, 2004, ACTA RADIOL, V45, P769, DOI 10.1080/02841850410008171; Nikolic T, 2003, INT IMMUNOL, V15, P515, DOI 10.1093/intimm/dxg050; Nordahl J, 1998, CALCIFIED TISSUE INT, V63, P401, DOI 10.1007/s002239900548; Perez-Amodio S, 2004, J BONE MINER RES, V19, P1722, DOI 10.1359/JBMR.040509; Saginario C, 1995, P NATL ACAD SCI USA, V92, P12210, DOI 10.1073/pnas.92.26.12210; Saginario C, 1998, MOL CELL BIOL, V18, P6213, DOI 10.1128/MCB.18.11.6213; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; TEITELBAUM SL, 1993, J BONE MINER RES, V8, pS523; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Umeda S, 1999, AM J PATHOL, V155, P223, DOI 10.1016/S0002-9440(10)65116-4; van den Berg TK, 2004, TRENDS IMMUNOL, V25, P11, DOI 10.1016/j.it.2003.11.006; van den Nieuwenhof IM, 2001, J CELL SCI, V114, P1321; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Yamao T, 2002, J BIOL CHEM, V277, P39833, DOI 10.1074/jbc.M203287200; Zenger S, 2007, BONE, V41, P820, DOI 10.1016/j.bone.2007.07.010; Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083	50	26	26	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4081	4090		10.1096/fj.09-131557	http://dx.doi.org/10.1096/fj.09-131557			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19667119				2022-12-28	WOS:000272193700005
J	Chen, ZJ; Kastaniotis, AJ; Miinalainen, IJ; Rajaram, V; Wierenga, RK; Hiltunen, JK				Chen, Zhijun; Kastaniotis, Alexander J.; Miinalainen, Ilkka J.; Rajaram, Venkatesan; Wierenga, Rik K.; Hiltunen, J. Kalervo			17 beta-Hydroxysteroid dehydrogenase type 8 and carbonyl reductase type 4 assemble as a ketoacyl reductase of human mitochondrial FAS	FASEB JOURNAL			English	Article						HsKAR; heterotetramer; lipids; fatty acid synthesis; metabolism	FATTY-ACID SYNTHESIS; 2-ENOYL THIOESTER REDUCTASE; CRYSTAL-STRUCTURE; 3-HYDROXYACYL-ACP DEHYDRATASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; KE 6; EXPRESSION; YEAST; CLONING	Mitochondrial fatty acid synthesis (FAS) generates the octanoyl-group that is required for the synthesis of lipoic acid and is linked to mitochondrial RNA metabolism. All of the human enzymes involved in mitochondrial FAS have been characterized except for beta-ketoacyl thioester reductase (HsKAR), which catalyzes the second step in the pathway. We report here the unexpected finding that a heterotetramer composed of human 17 beta-hydroxysteroid dehydrogenase type 8 (Hs17 beta-HSD8) and human carbonyl reductase type 4 (HsCBR4) forms the long-sought HsKAR. Both proteins share sequence similarities to the yeast 3-oxoacyl-(acyl carrier protein) reductase (Oar1p) and the bacterial FabG, although HsKAR is NADH dependent, whereas FabG and Oar1p are NADPH dependent. Hs17 beta-HSD8 and HsCBR4 show a strong genetic interaction in vivo in yeast, where, only if they are expressed together, they rescue the respiratory deficiency and restore the lipoic acid content of oar1 Delta cells. Moreover, these two proteins display a stable physical interaction and form an active heterotetramer. Both Hs17 beta-HSD8 and HsCBR4 are targeted to mitochondria in vivo in cultured HeLa cells. Notably, 17 beta-HSD8 was previously classified as a steroid-metabolizing enzyme, but our data suggest that 17 beta-HSD8 is primarily involved in mitochondrial FAS.-Chen, Z., Kastaniotis, A. J., Miinalainen, I. J., Rajaram, V., Wierenga R. K., Hiltunen, J. K. 17 beta-Hydroxysteroid dehydrogenase type 8 and carbonyl reductase type 4 assemble as a ketoacyl reductase of human mitochondrial FAS. FASEB J. 23, 3682-3691 (2009). www.fasebj.org	[Hiltunen, J. Kalervo] Univ Oulu, Bioctr Oulu, FI-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FI-90014 Oulu, Finland	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Hiltunen, JK (corresponding author), Univ Oulu, Bioctr Oulu, POB 3000, FI-90014 Oulu, Finland.	kalervo.hiltunen@oulu.fi	Chen, Zhijun/V-3228-2019	Miinalainen, Ilkka/0000-0002-3922-3442; Venkatesan, Rajaram/0000-0002-7257-1211; Hiltunen, Kalervo/0000-0002-3073-9602; Kastaniotis, Alexander/0000-0003-3624-9214	Sigrid Juselius Foundation; Academy of Finland; NordForsk [070010]	Sigrid Juselius Foundation(Sigrid Juselius Foundation); Academy of Finland(Academy of Finland); NordForsk	We thank Dr. Lloyd Ruddock (University of Oulu, Oulu, Finland) for the kind gift of E. coli expression strains and vectors, and Dr. Ulrich Bergmann for mass spectrometric work, as well as Tatu Haataja and Prasad Kasaragod for their help with enzymatic assays. We are grateful to Leena Ollitervo, Katri Nappa, and Johanna Moilanen for technical assistance and to Dr. Aner Gurvitz and Dr. Paivi Pirila for useful discussions. This work was supported by grants from the Sigrid Juselius Foundation, the Academy of Finland, and the NordForsk under the Nordic Centres of Excellence Program in Food, Nutrition, and Health, Project (070010) MitoHealth.	Ando A, 1996, GENOMICS, V35, P600, DOI 10.1006/geno.1996.0405; Autio KJ, 2008, FEBS LETT, V582, P729, DOI 10.1016/j.febslet.2008.01.051; Autio KJ, 2008, FASEB J, V22, P569, DOI 10.1096/fj.07-8986; AZIZ N, 1993, MOL CELL BIOL, V13, P1847, DOI 10.1128/MCB.13.3.1847; Aziz N, 1996, ENDOCRINOLOGY, V137, P5581, DOI 10.1210/en.137.12.5581; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; Chen ZJ, 2008, J MOL BIOL, V379, P830, DOI 10.1016/j.jmb.2008.04.041; Chen ZJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005589; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Endo S, 2008, BIOCHEM BIOPH RES CO, V377, P1326, DOI 10.1016/j.bbrc.2008.11.003; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; Feng DJ, 2009, J BIOL CHEM, V284, P11436, DOI 10.1074/jbc.M806991200; Fomitcheva J, 1998, J BIOL CHEM, V273, P22664, DOI 10.1074/jbc.273.35.22664; Hiltunen JK, 2009, J BIOL CHEM, V284, P9011, DOI 10.1074/jbc.R800068200; Joshi AK, 2003, J BIOL CHEM, V278, P33142, DOI 10.1074/jbc.M305459200; JOSHI AK, 1993, BIOCHEM J, V296, P143, DOI 10.1042/bj2960143; Kastaniotis AJ, 2004, MOL MICROBIOL, V53, P1407, DOI 10.1111/j.1365-2958.2004.04191.x; Koski MK, 2005, J MOL BIOL, V345, P1157, DOI 10.1016/j.jmb.2004.11.009; Kyuno J, 2008, MECH DEVELOP, V125, P571, DOI 10.1016/j.mod.2008.03.001; Maier T, 2008, SCIENCE, V321, P1315, DOI 10.1126/science.1161269; Matsunaga T, 2006, DRUG METAB PHARMACOK, V21, P1, DOI 10.2133/dmpk.21.1; MAXWELL MM, 1995, J BIOL CHEM, V270, P25213, DOI 10.1074/jbc.270.42.25213; Meier M, 2009, ANN NY ACAD SCI, V1155, P15, DOI 10.1111/j.1749-6632.2009.03702.x; Miinalainen IJ, 2003, J BIOL CHEM, V278, P20154, DOI 10.1074/jbc.M302851200; Moeller G, 2009, MOL CELL ENDOCRINOL, V301, P7, DOI 10.1016/j.mce.2008.10.040; Moon JY, 2006, HEART VESSELS, V21, P195, DOI 10.1007/s00380-005-0859-z; Mori M, 1998, BBA-MOL CELL RES, V1403, P12, DOI 10.1016/S0167-4889(98)00021-4; Ohno S, 2008, MOL CELL BIOCHEM, V309, P209, DOI 10.1007/s11010-007-9637-9; Pletnev VZ, 2005, J STEROID BIOCHEM, V94, P327, DOI 10.1016/j.jsbmb.2004.12.031; Price AC, 2001, BIOCHEMISTRY-US, V40, P12772, DOI 10.1021/bi010737g; Reinders J, 2007, MOL IMMUNOL, V44, P848, DOI 10.1016/j.molimm.2006.04.003; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; Schneider R, 1997, CURR GENET, V32, P384, DOI 10.1007/s002940050292; Schonauer MS, 2008, MOL CELL BIOL, V28, P6646, DOI 10.1128/MCB.01162-08; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Torkko JM, 2001, MOL CELL BIOL, V21, P6243, DOI 10.1128/MCB.21.18.6243-6253.2001; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; Witkowski A, 2007, J BIOL CHEM, V282, P14178, DOI 10.1074/jbc.M701486200; ZENSEN R, 1992, FEBS LETT, V310, P179, DOI 10.1016/0014-5793(92)81324-F; Zhang L, 2005, J BIOL CHEM, V280, P12422, DOI 10.1074/jbc.M413686200; Zhang L, 2003, J BIOL CHEM, V278, P40067, DOI 10.1074/jbc.M306121200; Zhang NS, 2003, GENE, V303, P121, DOI 10.1016/S0378-1119(02)01142-3; Zhang YM, 2008, NAT REV MICROBIOL, V6, P222, DOI 10.1038/nrmicro1839; Zhou LY, 2005, J MOL ENDOCRINOL, V35, P103, DOI 10.1677/jme.1.01801	46	39	45	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3682	3691		10.1096/fj.09-133587	http://dx.doi.org/10.1096/fj.09-133587			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19571038				2022-12-28	WOS:000271272500006
J	Manni, I; Artuso, S; Careccia, S; Rizzo, MG; Baserga, R; Piaggio, G; Sacchi, A				Manni, Isabella; Artuso, Simona; Careccia, Silvia; Rizzo, Maria Giulia; Baserga, Renato; Piaggio, Giulia; Sacchi, Ada			The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms	FASEB JOURNAL			English	Article						3 ' UTR; hematopoiesis; p53 family; small non-coding RNAs	MIR-17-92 CLUSTER; LUNG CANCERS; CYCLE ARREST; P53 HOMOLOG; EXPRESSION; DIFFERENTIATION; GENE; TRANSCRIPTION; DELTA-NP63-ALPHA; POLYCISTRON	MicroRNAs (miRs) are 21- to 23-nucleotide RNA molecules that regulate the stability or translational efficiency of target messenger RNAs of proteins involved in cell growth and apoptosis. miR-92 is part of the mir-17-92 cluster, which comprises members with an effect on cell proliferation. However, the role of miR-92 is unknown, and its targets have not been identified. Here, we describe a mechanism through which miR-92 contributes to regulate cell proliferation. Using a miR-92 synthetic double-strand oligonucleotide, we demonstrate that miR-92 increases 32D myeloid cell proliferation and 5-bromo-2-deoxyuridine (BrdU) incorporation and inhibits cell death. The effect is miR-92 specific since the miR-92 antagomir inhibits cell proliferation. Moreover, we show that miR-92 acts by modulating p63-isoform abundance through down-regulatation of endogenous Delta Np63 beta. Using luciferase reporters containing p63 3'UTR fragments with wild-type or mutant miR-92 complementary sites, we demonstrate that the wild-type 3'UTR is a direct target of miR-92. Finally, we observed that a miR-92-resistant Delta Np63 beta isoform (without 3'UTR) inhibits cell proliferation and parallels the effect of the antagomir. We conclude that one of the molecular mechanisms through which miR-92 increases cell proliferation is by negative regulation of an isoform of the cell-cycle regulator p63.-Manni, I., Artuso, S., Careccia, S., Rizzo, M. G., Baserga, R., Piaggio, G., Sacchi, A. The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J. 23, 3957-3966 (2009). www.fasebj.org	[Manni, Isabella; Artuso, Simona; Careccia, Silvia; Rizzo, Maria Giulia; Piaggio, Giulia; Sacchi, Ada] Ist Regina Elena, Dept Expt Oncol, I-00158 Rome, Italy; [Piaggio, Giulia] Ist Regina Elena, ROC, I-00158 Rome, Italy; [Baserga, Renato] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Jefferson University	Piaggio, G (corresponding author), Ist Regina Elena, Dept Expt Oncol, Via Messi DOro 156, I-00158 Rome, Italy.	piaggio@ifo.it	Careccia, Silvia/K-6475-2016; Rizzo, Maria Giulia/B-2107-2018; Manni, Isabella/ABH-6460-2020; Piaggio, Giulia/AAD-7336-2022; Piaggio, Giulia/J-7214-2018	Careccia, Silvia/0000-0001-7221-8170; Rizzo, Maria Giulia/0000-0002-5009-2412; Manni, Isabella/0000-0003-4823-0596; Piaggio, Giulia/0000-0003-2114-1892	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero della Salute; Istituto Superiore di Sanita (ISS) Alleanza Contro il Cancro (ACC) [ICS-120.4/RA00-90, R.F.02/184]	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero della Salute; Istituto Superiore di Sanita (ISS) Alleanza Contro il Cancro (ACC)	The authors thank Bert Vogelstein and Kenneth W. Kinzler (Johns Hopkins University, Baltimore, MD, USA) for generously providing Dicer-KO cells; Barry Trink (Johns Hopkins University), Giulia Fontemaggi (Istituto Regina Elena, Rome, Italy), and Fabio Martelli (Istituto Dermatopatico dell'Immacolata, Rome, Italy) for providing p63 expression vectors, oligonucleotides for p63 RTPCR, and pMir expression vector; Antonio Costanzo for interesting discussions on the manuscript; Silvia Bacchetti for editing the manuscript; Maria Pia Gentileschi for technical advice; and Vincenzo Giusti for computing assistance. G. P. is supported by grants from Associazione Italiana Ricerca sul Cancro (AIRC), Ministero della Salute, and Istituto Superiore di Sanita (ISS) Alleanza Contro il Cancro (ACC) (ICS-120.4/RA00-90; R.F.02/184). A. S. is supported by the ISS-Italia-USA program.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; ANDO K, 1995, ONCOGENE, V10, P751; ASKEW DS, 1991, ONCOGENE, V6, P1915; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Candi E, 2007, CELL CYCLE, V6, P274, DOI 10.4161/cc.6.3.3797; Carleton M, 2007, CELL CYCLE, V6, P2127, DOI 10.4161/cc.6.17.4641; Chen AL, 2008, BIOTECHNOL LETT, V30, P2045, DOI 10.1007/s10529-008-9800-8; Cloonan N, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-8-r127; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Gurtner A, 2003, MOL BIOL CELL, V14, P2706, DOI 10.1091/mbc.E02-09-0600; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Koralov SB, 2008, CELL, V132, P860, DOI 10.1016/j.cell.2008.02.020; Koster MI, 2006, CANCER RES, V66, P3981, DOI 10.1158/0008-5472.CAN-06-0027; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu Y, 2007, DEV BIOL, V310, P442, DOI 10.1016/j.ydbio.2007.08.007; Ma L, 2008, CELL CYCLE, V7, P570, DOI 10.4161/cc.7.5.5547; Matsubara H, 2007, ONCOGENE, V26, P6099, DOI 10.1038/sj.onc.1210425; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; NAGEL S, 2009, LEUKEMIA LYMPHOMA, V15, P1; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Patterson M K Jr, 1979, Methods Enzymol, V58, P141; Petitjean A, 2008, CARCINOGENESIS, V29, P273, DOI 10.1093/carcin/bgm258; Petrocca F, 2008, CANCER RES, V68, P8191, DOI 10.1158/0008-5472.CAN-08-1768; Pichiorri F, 2008, P NATL ACAD SCI USA, V105, P12885, DOI 10.1073/pnas.0806202105; Shi B, 2006, J CELL PHYSIOL, V207, P706, DOI 10.1002/jcp.20613; Testoni B, 2006, NUCLEIC ACIDS RES, V34, P928, DOI 10.1093/nar/gkj477; Truong AB, 2007, CELL CYCLE, V6, P295, DOI 10.4161/cc.6.3.3753; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Venturini L, 2007, BLOOD, V109, P4399, DOI 10.1182/blood-2006-09-045104; Wang L, 2008, MOL CELL BIOL, V28, P6262, DOI 10.1128/MCB.00923-08; Wu GJ, 2005, CANCER RES, V65, P758; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018; Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642; Yue JM, 2006, CANCER BIOL THER, V5, P573, DOI 10.4161/cbt.5.6.2872; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028	50	69	75	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3957	3966		10.1096/fj.09-131847	http://dx.doi.org/10.1096/fj.09-131847			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19608627	Bronze			2022-12-28	WOS:000271272500031
J	Oudhoff, MJ; Kroeze, KL; Nazmi, K; van den Keijbus, PAM; van't Hof, W; Fernandez-Borja, M; Hordijk, PL; Gibbs, S; Bolscher, JGM; Veerman, ECI				Oudhoff, Menno J.; Kroeze, Kim L.; Nazmi, Kamran; van den Keijbus, Petra A. M.; van't Hof, Wim; Fernandez-Borja, Mar; Hordijk, Peter L.; Gibbs, Susan; Bolscher, Jan G. M.; Veerman, Enno C. I.			Structure-activity analysis of histatin, a potent wound healing peptide from human saliva: cyclization of histatin potentiates molar activity 1000-fold	FASEB JOURNAL			English	Article						antimicrobial peptides; cell migration; cyclic peptide; domain mapping; reepithelialization	EPIDERMAL-GROWTH-FACTOR; ANTIMICROBIAL PEPTIDES; KERATINOCYTE MIGRATION; CYCLIC-PEPTIDES; TRANSACTIVATION; DEFENSINS; RECEPTOR; CYTOKINES; MUCOSAL; BINDING	Wounds in the mouth heal faster and with less scarification and inflammation than those in the skin. Saliva is thought to be essential for the superior oral wound healing, but the involved mechanism is still unclear. We have previously discovered that a human-specific peptide, histatin, might be implicated in the wound-healing properties of saliva. Here we report that histatin enhances reepithelialization in a human full-skin wound model closely resembling normal skin. The peptide does not stimulate proliferation but induces cell spreading and migration, two key initiating steps in reepithelialization. Activation of cells by histatin requires a G-protein-coupled receptor that activates the ERK1/2 pathway. Using a stepwise-truncation method, we determined the minimal domain (SHREFPFYGDYGS) of the 38-mer-parent peptide that is required for activity. Strikingly, N- to C-terminal cyclization of histatin-1 potentiates the molar activity similar to 1000-fold, indicating that the recognition of histatin by its cognate receptor requires a specific spatial conformation of the peptide. Our results emphasize the importance of histatin in human saliva for tissue protection and recovery and establish the experimental basis for the development of synthetic histatins as novel skin wound-healing agents.-Oudhoff, M. J., Kroeze, K. L., Nazmi, K., van den Keijbus, P. A. M., van 't Hof, W., Fernandez-Borja, M., Hordijk, P. L., Gibbs, S., Bolscher, J. G. M., Veerman, E. C. I. Structure-activity analysis of histatin, a potent wound healing peptide from human saliva: cyclization of histatin potentiates molar activity 1000-fold. FASEB J. 23, 3928-3935 (2009). www.fasebj.org	[Oudhoff, Menno J.; Nazmi, Kamran; van den Keijbus, Petra A. M.; van't Hof, Wim; Bolscher, Jan G. M.; Veerman, Enno C. I.] Univ Amsterdam, Dept Oral Biochem, Acad Ctr Dent Amsterdam, NL-1081 BT Amsterdam, Netherlands; [Oudhoff, Menno J.; Nazmi, Kamran; van den Keijbus, Petra A. M.; van't Hof, Wim; Bolscher, Jan G. M.; Veerman, Enno C. I.] Vrije Univ Amsterdam, NL-1081 BT Amsterdam, Netherlands; [Kroeze, Kim L.; Gibbs, Susan] Vrije Univ Amsterdam, Med Ctr, Dept Dermatol, Amsterdam, Netherlands; [Fernandez-Borja, Mar; Hordijk, Peter L.] Univ Amsterdam, Dept Mol Cell Biol, Sanquin Res & Landsteiner Lab, Acad Med Ctr, NL-1081 BT Amsterdam, Netherlands	Academic Center for Dentistry Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Oudhoff, MJ (corresponding author), Univ Amsterdam, Dept Oral Biochem, Acad Ctr Dent Amsterdam ACTA, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	mj.oudhoff@vumc.nl	Bolscher, Jan/ABF-6102-2021	Bolscher, Jan/0000-0001-5669-6164; Oudhoff, Menno/0000-0002-1180-8975; Hordijk, Peter/0000-0002-3348-078X	Skeletal Tissue Engineering Group Amsterdam (STEGA)	Skeletal Tissue Engineering Group Amsterdam (STEGA)	We thank Hakan Kalay (VU Medical Center, Amsterdam) for determining the mass of the peptides by mass spectrometry. E. C. I. V. gratefully acknowledges the support from the Skeletal Tissue Engineering Group Amsterdam (STEGA).	Aarbiou J, 2006, INFLAMM RES, V55, P119, DOI 10.1007/s00011-005-0062-9; ABRAMOFF MD, 2004, BIOPHOTON INT, V11, P26; Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x; BAUM BJ, 1976, ARCH BIOCHEM BIOPHYS, V177, P427, DOI 10.1016/0003-9861(76)90455-0; Breetveld M, 2006, J INVEST DERMATOL, V126, P1918, DOI 10.1038/sj.jid.5700330; Brennand DM, 1997, FEBS LETT, V413, P70, DOI 10.1016/S0014-5793(97)00885-5; Denny P, 2008, J PROTEOME RES, V7, P1994, DOI 10.1021/pr700764j; Engeland CG, 2006, ARCH SURG-CHICAGO, V141, P1193, DOI 10.1001/archsurg.141.12.1193; FISHER DA, 1990, ENDOCR REV, V11, P418, DOI 10.1210/edrv-11-3-418; Garcia AE, 2008, INFECT IMMUN, V76, P5883, DOI 10.1128/IAI.01100-08; Gibbs S, 2006, BRIT J DERMATOL, V155, P267, DOI 10.1111/j.1365-2133.2006.07266.x; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HUTSON JM, 1979, NATURE, V279, P793, DOI 10.1038/279793a0; JACKSON S, 1994, J AM CHEM SOC, V116, P3220, DOI 10.1021/ja00087a007; Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718; KIECOLTGLASER JK, 1995, LANCET, V346, P1194, DOI 10.1016/S0140-6736(95)92899-5; KONTUREK SJ, 1988, GASTROENTEROLOGY, V94, P1300, DOI 10.1016/0016-5085(88)90667-1; Lorenowicz MJ, 2007, AM J PHYSIOL-LUNG C, V293, pL1321, DOI 10.1152/ajplung.00443.2006; Mochon AB, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000190; MURPHY RA, 1980, J HISTOCHEM CYTOCHEM, V28, P890, DOI 10.1177/28.8.6969274; Niyonsaba F, 2007, J INVEST DERMATOL, V127, P594, DOI 10.1038/sj.jid.5700599; Occleston NL, 2008, DRUG DISCOV TODAY, V13, P973, DOI 10.1016/j.drudis.2008.08.009; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; Oudhoff MJ, 2008, FASEB J, V22, P3805, DOI 10.1096/fj.08-112003; PONEC M, 1981, J INVEST DERMATOL, V76, P211, DOI 10.1111/1523-1747.ep12525761; Ruissen ALA, 2002, PEPTIDES, V23, P1391, DOI 10.1016/S0196-9781(02)00076-1; Stawikowski M, 2006, TETRAHEDRON LETT, V47, P8587, DOI 10.1016/j.tetlet.2006.09.116; Sun X, 2009, FASEB J, V23; Szpaderska AM, 2003, J DENT RES, V82, P621, DOI 10.1177/154405910308200810; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Tjabringa GS, 2003, J IMMUNOL, V171, P6690, DOI 10.4049/jimmunol.171.12.6690; Tokumaru S, 2005, J IMMUNOL, V175, P4662, DOI 10.4049/jimmunol.175.7.4662; VanWetering S, 1997, J LEUKOCYTE BIOL, V62, P217, DOI 10.1002/jlb.62.2.217; Veerman ECI, 2007, J BIOL CHEM, V282, P18831, DOI 10.1074/jbc.M610555200; Vissink A, 2003, CRIT REV ORAL BIOL M, V14, P199, DOI 10.1177/154411130301400305; von Haussen J, 2008, LUNG CANCER, V59, P12, DOI 10.1016/j.lungcan.2007.07.014; Xu KP, 2007, INVEST OPHTH VIS SCI, V48, P636, DOI 10.1167/iovs.06-0203; Yokoyama F, 2004, BIOCHEMISTRY-US, V43, P13590, DOI 10.1021/bi049009u; Zhou NM, 2002, J BIOL CHEM, V277, P17476, DOI 10.1074/jbc.M202063200; Zlotnik A, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-12-243	40	69	75	3	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3928	3935		10.1096/fj.09-137588	http://dx.doi.org/10.1096/fj.09-137588			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19652025				2022-12-28	WOS:000271272500028
J	Chandrasekharan, BP; Kolachala, VL; Dalmasso, G; Merlin, D; Ravid, K; Sitaraman, SV; Srinivasan, S				Chandrasekharan, Bindu P.; Kolachala, Vasantha L.; Dalmasso, Guillaume; Merlin, Didier; Ravid, Katya; Sitaraman, Shanthi V.; Srinivasan, Shanthi			Adenosine 2B receptors (A(2B)AR) on enteric neurons regulate murine distal colonic motility	FASEB JOURNAL			English	Article						stool retention; stool frequency; nitric oxide	A2B; EXPRESSION; COLITIS; MOUSE; CELLS; RAT; INFLAMMATION; PROTECTS; TRANSIT	Delayed colonic emptying leading to constipation is a significant health concern. We investigated the role of adenosine 2B receptor (A(2B)AR) in modulating distal colonic motility using wild-type and A(2B)AR-knockout (A(2B)AR(-/-)) mice. Colon motility was assessed using stool characteristics and colonic transit. Distal colonic ganglia, isolated by laser capture microdissection, were tested for A(2B)AR expression by RTPCR. The distal colon contraction and relaxation responses were assessed by electrical field stimulation (EFS) in presence of A(2B)AR agonists, antagonists or inhibitors of nitric oxide (NO) and guanylate cyclase. Nitrite levels were measured in enteric neuronal cultures exposed to A(2B)AR agonists/antagonists. A(2B)AR(-/-) mice display increased stool retention, decreased stool frequency, delayed colonic emptyping, and decreased circular muscle relaxation. RT-PCR identified A(2B)AR expression in distal colonic ganglia. EFS studies revealed that enteric neuronal A(2B)AR is essential for distal colonic relaxation, and A(2B)AR antagonists can inhibit relaxation. Enteric neurons stimulated with A(2B)AR agonists produced more nitrite than cultures treated with antagonists. We demonstrate an essential role of A(2B)AR in regulating distal colon relaxation, as A(2B)AR activation is linked to NO signaling. Hence targeting the colonic A(2B)AR could represent a novel therapeutic strategy to treat constipation.-Chandrasekharan, B. P., Kolachala, V. L., Dalmasso, G., Merlin, D., Ravid, K., Sitaraman, S. V., Srinivasan, S. Adenosine 2B receptors (A(2B)AR) on enteric neurons regulate murine distal colonic motility. FASEB J. 23, 2727-2734 ( 2009)	[Chandrasekharan, Bindu P.; Kolachala, Vasantha L.; Dalmasso, Guillaume; Merlin, Didier; Sitaraman, Shanthi V.; Srinivasan, Shanthi] Emory Univ, Div Digest Dis, Atlanta, GA 30322 USA; [Ravid, Katya] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Ravid, Katya] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Emory University; Boston University; Boston University	Sitaraman, SV (corresponding author), Emory Univ, Div Digest Dis, Suite 246,Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	ssitar2@emory.edu; ssrini2@emory.edu	Dalmasso, Guillaume/N-2443-2018; Chandrasekharan, Bindu/CAA-0476-2022; chandrasekharan, bindu/AAU-5479-2021; Srinivasan, Shanthi/A-6133-2013	Dalmasso, Guillaume/0000-0002-3433-870X; Chandrasekharan, Bindu/0000-0003-2943-3902; Ravid, Katya/0000-0002-9918-3024	Crohn's and Colitis Foundation of America (CCFA); Ruth L. Kirstein National Research Service Award for Individual Postdoctoral Fellows [F32]; NIH [NIH-KO8 DK067045, RO3 DK078552, DK06411, RO1-DK-071594, HL 13262]; Digestive Diseases Research Center [DK064399]; Pax Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399, R03DK078552, K08DK067045, R01DK080684, R01DK071594] Funding Source: NIH RePORTER	Crohn's and Colitis Foundation of America (CCFA); Ruth L. Kirstein National Research Service Award for Individual Postdoctoral Fellows(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Digestive Diseases Research Center; Pax Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	B. C. and G. D. are supported by Crohn's and Colitis Foundation of America (CCFA) Research Fellowship Awards, and V. L. K. is supported by a Ruth L. Kirstein National Research Service Award for Individual Postdoctoral Fellows (F32). Authors are supported by the following NIH grants: NIH-KO8 DK067045 ( S. S.), RO3 DK078552 ( S. S.), DK06411 ( S. V. S.), RO1-DK-071594 ( D. M.), and a Digestive Diseases Research Center grant (DK064399). K. R., an established researcher with the American Heart Association, is supported by NIH HL 13262. The authors thank Pax Health ( New Haven, CT, USA), a division of Clinical Data, for supplying ATL-801. The authors thank Mr. Zinan Zhang for help with experiments related to whole-animal motility studies.	Anitha M, 2008, GASTROENTEROLOGY, V134, P1424, DOI 10.1053/j.gastro.2008.02.018; Anitha M, 2006, GASTROENTEROLOGY, V131, P1164, DOI 10.1053/j.gastro.2006.07.019; Bachmanov AA, 2002, BEHAV GENET, V32, P435, DOI 10.1023/A:1020884312053; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; Burnstock G, 2008, NEUROGASTROENT MOTIL, V20, P8, DOI 10.1111/j.1365-2982.2008.01107.x; Christofi FL, 2001, J COMP NEUROL, V439, P46, DOI 10.1002/cne.1334; Coates MD, 2006, NEUROGASTROENT MOTIL, V18, P464, DOI 10.1111/j.1365-2982.2006.00792.x; Compos-Neto A, 1998, J IMMUNOL, V160, P2037; de Lorijn F, 2005, GUT, V54, P1107, DOI 10.1136/gut.2004.051045; De Man JG, 2001, BRIT J PHARMACOL, V133, P695, DOI 10.1038/sj.bjp.0704115; Giaroni C, 2002, NEUROPHARMACOLOGY, V43, P1313, DOI 10.1016/S0028-3908(02)00294-0; Grenz A, 2008, PLOS MED, V5, P968, DOI 10.1371/journal.pmed.0050137; Kolachala V, 2005, CELL MOL LIFE SCI, V62, P2647, DOI 10.1007/s00018-005-5328-4; Kolachala V, 2005, J BIOL CHEM, V280, P4048, DOI 10.1074/jbc.M409577200; Kolachala VL, 2008, BRIT J PHARMACOL, V155, P127, DOI 10.1038/bjp.2008.227; Kolachala VL, 2008, GASTROENTEROLOGY, V135, P861, DOI 10.1053/j.gastro.2008.05.049; Mi T, 2008, J CLIN INVEST, V118, P1491, DOI 10.1172/JCI33467; MILLER MS, 1981, J PHARMACOL METHOD, V6, P211, DOI 10.1016/0160-5402(81)90110-8; Mizuta Y, 1999, AM J PHYSIOL-GASTR L, V277, pG275, DOI 10.1152/ajpgi.1999.277.2.G275; Nemeth ZH, 2005, J IMMUNOL, V175, P8260, DOI 10.4049/jimmunol.175.12.8260; RIVKEES SA, 1992, MOL ENDOCRINOL, V6, P1598, DOI 10.1210/me.6.10.1598; Toda N, 2005, PHARMACOL REV, V57, P315, DOI 10.1124/pr.57.3.4; Van Crombruggen K, 2007, NEUROPHARMACOLOGY, V53, P257, DOI 10.1016/j.neuropharm.2007.05.010; Van Crombruggen K, 2004, NEUROGASTROENT MOTIL, V16, P81; Xu Y, 2008, J BIOL CHEM, V283, P14213, DOI 10.1074/jbc.M708657200; Yaar R, 2005, J CELL PHYSIOL, V202, P9, DOI 10.1002/jcp.20138; Yang D, 2008, P NATL ACAD SCI USA, V105, P792, DOI 10.1073/pnas.0705563105; Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933; Zizzo MG, 2006, BRIT J PHARMACOL, V148, P956, DOI 10.1038/sj.bjp.0706808	29	34	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2727	2734		10.1096/fj.09-129544	http://dx.doi.org/10.1096/fj.09-129544			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19357134	Green Published			2022-12-28	WOS:000268836700040
J	Zhang, HM; Astrof, NS; Liu, JH; Wang, JH; Shimaoka, M				Zhang, Hongmin; Astrof, Nathan S.; Liu, Jin-Huan; Wang, Jia-Huai; Shimaoka, Motomu			Crystal structure of isoflurane bound to integrin LFA-1 supports a unified mechanism of volatile anesthetic action in the immune and central nervous systems	FASEB JOURNAL			English	Article						allosteric modulation; conformational change; ferritin; halogen bond; stereoisomer	I-DOMAIN; GABA(A) RECEPTOR; OPTICAL ISOMERS; SERUM-ALBUMIN; BINDING; INHIBITION; PROTEINS; INFLAMMATION; REFINEMENT; ACTIVATION	Volatile anesthetics (VAs), such as isoflurane, induce a general anesthetic state by binding to specific targets (i.e., ion channels) in the central nervous system (CNS). Simultaneously, VAs modulate immune functions, possibly via direct interaction with alternative targets on leukocytes. One such target, the integrin lymphocyte function-associated antigen-1 (LFA-1), has been shown previously to be inhibited by isoflurane. A better understanding of the mechanism by which isoflurane alters protein function requires the detailed information about the drug-protein interaction at an atomic level. Here, we describe the crystal structure of the LFA-1 ligand-binding domain (I domain) in complex with isoflurane at 1.6 angstrom. We discovered that isoflurane binds to an allosteric cavity previously implicated as critical for the transition of LFA-1 from the low-to the high-affinity state. The isoflurane binding site in the I domain involves an array of amphiphilic interactions, thereby resembling a "common anesthetic binding motif" previously predicted for authentic VA binding sites. These results suggest that the allosteric modulation of protein function by isoflurane, as demonstrated for the integrin LFA-1, might represent a unified mechanism shared by the interactions of volatile anesthetics with targets in the CNS.-Zhang, H., Astrof, N. S., Liu, J.-H., Wang, J.-H., Shimaoka, M. Crystal structure of isoflurane bound to integrin LFA-1 supports a unified mechanism of volatile anesthetic action in the immune and central nervous systems. FASEB J. 23, 2735-2740 ( 2009)	[Astrof, Nathan S.; Shimaoka, Motomu] Childrens Hosp, Immune Dis Inst, Program Cellular & Mol Med, Boston, MA 02115 USA; [Zhang, Hongmin; Liu, Jin-Huan; Wang, Jia-Huai] Dana Farber Canc Inst, Boston, MA 02115 USA; [Zhang, Hongmin; Liu, Jin-Huan; Wang, Jia-Huai] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Zhang, Hongmin; Liu, Jin-Huan; Wang, Jia-Huai] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Astrof, Nathan S.; Shimaoka, Motomu] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Shimaoka, M (corresponding author), Childrens Hosp, Immune Dis Inst, Program Cellular & Mol Med, 3 Blackfan Circle, Boston, MA 02115 USA.	shimaoka@idi.harvard.edu	Zhang, Hongmin/S-9953-2017; Zhang, Hongmin/C-4503-2009	Zhang, Hongmin/0000-0003-4356-3615; Zhang, Hongmin/0000-0001-6357-4106	National Institutes of Health, [AI063421, HL048675]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063421] Funding Source: NIH RePORTER	National Institutes of Health,(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Koichi Yuki and Sulpicio G. Soriano ( Children's Hospital Boston and Harvard Medical School, Boston, MA, USA) for providing reagents and advice. This work was supported by grants from the National Institutes of Health, AI063421 ( M. S.) and HL048675 ( M. S., J. H. W.).	Auffinger P, 2004, P NATL ACAD SCI USA, V101, P16789, DOI 10.1073/pnas.0407607101; Bertaccini EJ, 2007, ANESTH ANALG, V104, P318, DOI 10.1213/01.ane.0000253029.67331.8d; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; Chiang N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001879; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Dickinson R, 2000, ANESTHESIOLOGY, V93, P837, DOI 10.1097/00000542-200009000-00035; DUSTIN ML, 1999, GUIDEBOOK EXTRACELLU, P228; Eckenhoff RG, 1997, PHARMACOL REV, V49, P343; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; Franks NP, 1998, BIOPHYS J, V75, P2205, DOI 10.1016/S0006-3495(98)77664-7; FRANKS NP, 1991, SCIENCE, V254, P427, DOI 10.1126/science.1925602; HALL AC, 1994, BRIT J PHARMACOL, V112, P906, DOI 10.1111/j.1476-5381.1994.tb13166.x; Hayes JK, 2004, ANESTH ANALG, V98, P999, DOI 10.1213/01.ANE.0000104584.91385.1D; Hemmings HC, 2005, TRENDS PHARMACOL SCI, V26, P503, DOI 10.1016/j.tips.2005.08.006; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; Kortagere S, 2008, J MOL GRAPH MODEL, V27, P170, DOI 10.1016/j.jmgm.2008.04.001; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LIEN EJ, 1976, MOL PHARMACOL, V12, P598; Liu RY, 2005, FASEB J, V19, P567, DOI 10.1096/fj.04-3171com; McBride WT, 1996, ANAESTHESIA, V51, P465, DOI 10.1111/j.1365-2044.1996.tb07793.x; Mobert J, 1999, ANESTHESIOLOGY, V90, P1372, DOI 10.1097/00000542-199905000-00022; MOODY EJ, 1993, BRAIN RES, V615, P101, DOI 10.1016/0006-8993(93)91119-D; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PFEIFFER CC, 1956, SCIENCE, V124, P29, DOI 10.1126/science.124.3210.29; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QUINLAN JJ, 1995, ANESTHESIOLOGY, V83, P611, DOI 10.1097/00000542-199509000-00021; Shimaoka M, 2003, NAT REV DRUG DISCOV, V2, P703, DOI 10.1038/nrd1174; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Streiff JH, 2008, J CHEM INF MODEL, V48, P2066, DOI 10.1021/ci800206a; Xu Y, 1996, BIOPHYS J, V70, P532, DOI 10.1016/S0006-3495(96)79599-1; Yuki K, 2008, FASEB J, V22, P4109, DOI 10.1096/fj.08-113324	34	34	34	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2735	2740		10.1096/fj.09-129908	http://dx.doi.org/10.1096/fj.09-129908			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19332643	Green Published			2022-12-28	WOS:000268836700041
J	Strom, K; Gundersen, TE; Hansson, O; Lucas, S; Fernandez, C; Blomhoff, R; Holm, C				Strom, Kristoffer; Gundersen, Thomas E.; Hansson, Ola; Lucas, Stephanie; Fernandez, Celine; Blomhoff, Rune; Holm, Cecilia			Hormone-sensitive lipase (HSL) is also a retinyl ester hydrolase: evidence from mice lacking HSL	FASEB JOURNAL			English	Article						adipocyte differentiation; brown adipocyte; cAMP; retinoic acid	RECEPTOR COREPRESSOR RIP140; ADIPOSE-TISSUE; PPAR-GAMMA; ACID; EXPRESSION; DIFFERENTIATION; ADIPOCYTES; CELLS; WHITE; RETINOIDS	Here, we investigated the importance of hormone-sensitive lipase (HSL) as a retinyl ester hydrolase (REH). REH activity was measured in vitro using recombinant HSL and retinyl palmitate. The expression of retinoic acid (RA)-regulated genes and retinoid metabolites were measured in high-fat diet fed HSL-null mice using real-time quantitative PCR and triplestage liquid chromatography/tandem mass spectrometry, respectively. Age- and gender-matched wild-type littermates were used as controls. The REH activity of rat HSL was found to be higher than that against the hitherto best known HSL substrate, i.e., diacylglycerols. REH activity in white adipose tissue (WAT) of HSL-null mice was completely blunted and accompanied by increased levels of retinyl esters and decreased levels of retinol, retinaldehyde and all-trans RA. Accordingly, genes known to be positively regulated by RA were down-regulated in HSL-null mice, including pRb and RIP140, key factors promoting differentiation into the white over the brown adipocyte lineage. Dietary RA supplementation partly restored WAT mass and the expression of RA-regulated genes in WAT of HSL-null mice. These findings demonstrate the importance of HSL as an REH of adipose tissue and suggest that HSL via this action provides RA and other retinoids for signaling events that are crucial for adipocyte differentiation and lineage commitment.-Strom, K., Gundersen, T. E., Hansson, O., Lucas, S., Fernandez, C., Blomhoff, R., Holm, C. Hormone-sensitive lipase (HSL) is also a retinyl ester hydrolase: evidence from mice lacking HSL. FASEB J. 23, 2307-2316 (2009)	[Strom, Kristoffer] Lund Univ, Div Diabet Metab & Endocrinol, Dept Expt Med Sci, SE-22184 Lund, Sweden; [Gundersen, Thomas E.; Blomhoff, Rune] Univ Oslo, Dept Nutr, Fac Med, Oslo, Norway	Lund University; University of Oslo	Strom, K (corresponding author), Lund Univ, Div Diabet Metab & Endocrinol, Dept Expt Med Sci, BMC C11, SE-22184 Lund, Sweden.	kristoffer.strom@med.lu.se	Fernandez, Celine/ABH-9332-2020; Hansson, Ola/F-1793-2011	Fernandez, Celine/0000-0003-1290-4982; Hansson, Ola/0000-0002-7394-7639; LUCAS, Stephanie/0000-0001-7530-7486	Swedish Research Council [11284]; Juvenile Diabetes Foundation, USA; Knut and Alice Wallenberg Foundation, Sweden; Swedish Diabetes Association; Novo Nordisk; A. Pahlsson, Salubrin/Druvan; Torsten and Ragnar Soderberg; Cell Factory for Functional Genomics; Swedish Foundation for Strategic Research; Foundation of Tage Blucher for Medical Research; Swedish Research School of Genomics and Bioinformatics	Swedish Research Council(Swedish Research CouncilEuropean Commission); Juvenile Diabetes Foundation, USA; Knut and Alice Wallenberg Foundation, Sweden(Knut & Alice Wallenberg Foundation); Swedish Diabetes Association; Novo Nordisk(Novo Nordisk); A. Pahlsson, Salubrin/Druvan; Torsten and Ragnar Soderberg; Cell Factory for Functional Genomics; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Foundation of Tage Blucher for Medical Research; Swedish Research School of Genomics and Bioinformatics	We thank Birgitta Danielsson and Ann-Helen Thoren-Fischer for excellent technical assistance. Financial support was provided by the Swedish Research Council (project no. 11284 to C. H); a Center of Excellence grant from the Juvenile Diabetes Foundation, USA; the Knut and Alice Wallenberg Foundation, Sweden; and the Swedish Diabetes Association; as well as the following foundations: Novo Nordisk, A. Pahlsson, Salubrin/Druvan, and Torsten and Ragnar Soderberg. O.H. was supported by the Cell Factory for Functional Genomics, a program funded by the Swedish Foundation for Strategic Research, S. L was supported by the Foundation of Tage Blucher for Medical Research, and C. F. was supported by the Swedish Research School of Genomics and Bioinformatics.	AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; BLANER WS, 1994, J BIOL CHEM, V269, P16559; BLOMHOFF R, 1992, ANNU REV NUTR, V12, P37, DOI 10.1146/annurev.nu.12.070192.000345; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Chen QY, 2004, EXP CELL RES, V297, P68, DOI 10.1016/j.yexcr.2004.02.017; Contreras JA, 1998, PROTEIN EXPRES PURIF, V12, P93, DOI 10.1006/prep.1997.0821; Dani C, 1997, J CELL SCI, V110, P1279; Fernandez C, 2008, AM J PHYSIOL-ENDOC M, V295, pE820, DOI 10.1152/ajpendo.90206.2008; Gagnon I, 2002, BBA-PROTEIN STRUCT M, V1596, P156, DOI 10.1016/S0167-4838(02)00213-3; Gundersen TE, 2007, RAPID COMMUN MASS SP, V21, P1176, DOI 10.1002/rcm.2946; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; Hansen JB, 2004, P NATL ACAD SCI USA, V101, P4112, DOI 10.1073/pnas.0301964101; Hansson O, 2006, J PROTEOME RES, V5, P1701, DOI 10.1021/pr060101h; Harada K, 2003, AM J PHYSIOL-ENDOC M, V285, pE1182, DOI 10.1152/ajpendo.00259.2003; Holm C, 1999, METH MOL B, V109, P109; Holm C, 1999, METH MOL B, V109, P165; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; Imai T, 2004, P NATL ACAD SCI USA, V101, P4543, DOI 10.1073/pnas.0400356101; Kerley JS, 2001, BIOCHEM BIOPH RES CO, V285, P969, DOI 10.1006/bbrc.2001.5274; Leonardsson G, 2004, P NATL ACAD SCI USA, V101, P8437, DOI 10.1073/pnas.0401013101; Mic FA, 2002, DEVELOPMENT, V129, P2271; Mulder H, 2003, J BIOL CHEM, V278, P36380, DOI 10.1074/jbc.M213032200; MURRAY T, 1980, J SUPRAMOL STR CELL, V14, P255, DOI 10.1002/jss.400140214; Nedergaard J, 2005, BBA-MOL BASIS DIS, V1740, P293, DOI 10.1016/j.bbadis.2005.02.003; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; O'Byrne SM, 2005, J BIOL CHEM, V280, P35647, DOI 10.1074/jbc.M507924200; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; Park EY, 2005, CANCER RES, V65, P9923, DOI 10.1158/0008-5472.CAN-05-1604; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; RODBELL M, 1964, J BIOL CHEM, V239, P375; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; SAFONOVA I, 1994, MOL CELL ENDOCRINOL, V104, P201, DOI 10.1016/0303-7207(94)90123-6; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Strom K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001793; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; Wei SH, 1997, J BIOL CHEM, V272, P14159, DOI 10.1074/jbc.272.22.14159; Wongsiriroj N, 2008, J BIOL CHEM, V283, P13510, DOI 10.1074/jbc.M800777200; Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711; Yen CLE, 2005, J LIPID RES, V46, P1502, DOI 10.1194/jlr.M500036-JLR200; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747; Ziouzenkova O, 2007, NAT MED, V13, P695, DOI 10.1038/nm1587; ZOVICH DC, 1992, J BIOL CHEM, V267, P13884	44	65	67	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2307	2316		10.1096/fj.08-120923	http://dx.doi.org/10.1096/fj.08-120923			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19246492				2022-12-28	WOS:000268836500030
J	Bolego, C; Rossoni, G; Fadini, GP; Vegeto, E; Pinna, C; Albiero, M; Boscaro, E; Agostini, C; Avogaro, A; Gaion, RM; Cignarella, A				Bolego, Chiara; Rossoni, Giuseppe; Fadini, Gian Paolo; Vegeto, Elisabetta; Pinna, Christian; Albiero, Mattia; Boscaro, Elisa; Agostini, Carlo; Avogaro, Angelo; Gaion, Rosa Maria; Cignarella, Andrea			Selective estrogen receptor-alpha agonist provides widespread heart and vascular protection with enhanced endothelial progenitor cell mobilization in the absence of uterotrophic action	FASEB JOURNAL			English	Article						tissue selectivity; ischemia-reperfusion; endothelial function; pharmacology	ISCHEMIA-REPERFUSION INJURY; ER-ALPHA; MYOCARDIAL-INFARCTION; FEMALE RATS; IN-VIVO; BETA; MICE; ACTIVATION; GENE; ESTRADIOL	The beneficial effects of estrogens on the cardiovascular system are associated with adverse effects on reproductive tissues. On the basis of previous work indicating a major role for estrogen receptor (ER)-alpha in maintaining cardiovascular health, we evaluated the tissue selectivity of the ER alpha-selective agonist propyl pyrazole triol (PPT) compared with 17 beta-estradiol (E2) in vivo. Four weeks postovariectomy, equimolar doses of PPT and E2 were administered to rats in subcutaneous implants for 5 d. Both treatments restored rapid vasorelaxation of aortic tissue to estrogenic agents and prevented coronary hyperresponsiveness to angiotensin II in isolated heart preparations. Accordingly, multiple endpoints of myocardial ischemia-reperfusion injury exacerbated by ovariectomy returned to baseline following treatment. These protective effects were linked to increased in vivo levels of endothelial progenitor cells (EPCs). Human EPC function was enhanced in vitro after PPT treatment. In sharp contrast to E2, PPT treatment had no effect on uterine weight and histomorphology except for vessel density, and failed to up-regulate classic estrogen target genes. Dissection of the effects on vascular reactivity and uterine morphology was also observed following increased exposure to PPT at a higher dose for longer time. These data provide the first in vivo evidence for tissue-specific ER alpha activation. By conferring cardiovascular protection dissected from unwanted uterotrophic effects, ER alpha-selective agonists may represent a potential safer alternative to natural hormones.-Bolego, C., Rossoni, G., Fadini, G. P., Vegeto, E., Pinna, C., Albiero, M., Boscaro, E., Agostini, C., Avogaro, A., Gaion, R. M., Cignarella, A. Selective estrogen receptor-alpha agonist provides widespread heart and vascular protection with enhanced endothelial progenitor cell mobilization in the absence of uterotrophic action. FASEB J. 24, 2262-2272 (2010). www.fasebj.org	[Bolego, Chiara; Gaion, Rosa Maria; Cignarella, Andrea] Univ Padua, Dept Pharmacol & Anesthesiol, I-35131 Padua, Italy; [Rossoni, Giuseppe] Univ Milan, Dept Pharmacol Chemotherapy & Med Toxicol, Milan, Italy; [Vegeto, Elisabetta; Pinna, Christian] Univ Milan, Dept Pharmacol Sci, Milan, Italy; [Fadini, Gian Paolo; Albiero, Mattia; Boscaro, Elisa; Agostini, Carlo; Avogaro, Angelo] Padua Univ Hosp, Dept Clin & Expt Med, Padua, Italy	University of Padua; University of Milan; University of Milan; University of Padua; Azienda Ospedaliera - Universita di Padova	Bolego, C (corresponding author), Univ Padua, Dept Pharmacol & Anesthesiol, Largo Meneghetti 2, I-35131 Padua, Italy.	chiara.bolego@unipd.it	Albiero, Mattia/AAG-4257-2019; Fadini, Gian Paolo/M-4575-2019; Albiero, Mattia/J-4145-2012; Avogaro, Angelo/S-3808-2016; Agostini, Carlo/J-3103-2012	Albiero, Mattia/0000-0003-4142-9738; Fadini, Gian Paolo/0000-0002-6510-2097; Albiero, Mattia/0000-0003-4142-9738; Agostini, Carlo/0000-0001-7786-3574; AVOGARO, ANGELO/0000-0002-1177-0516; Cignarella, Andrea/0000-0002-4820-4876; VEGETO, ELISABETTA/0000-0003-4351-3650	Milan University; Padua University; Heart Repair consortium; Italian Ministry of University and Research [2006065483_003]	Milan University; Padua University; Heart Repair consortium; Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR))	This study was funded by grants from Milan University, Padua University, the Heart Repair consortium (http://www.heartrepair.eu), and the Italian Ministry of University and Research (PRIN grant 2006065483_003).	Ball LJ, 2009, MOL CELL ENDOCRINOL, V299, P204, DOI 10.1016/j.mce.2008.10.050; BERGMEYER HU, 1970, Z KLIN CHEM KLIN BIO, V8, P658; Bolego C, 2005, J PHARMACOL EXP THER, V313, P1203, DOI 10.1124/jpet.104.082867; Bolego C, 2006, ARTERIOSCL THROM VAS, V26, P2192, DOI 10.1161/01.ATV.0000242186.93243.25; Booth EA, 2005, AM J PHYSIOL-HEART C, V289, pH2039, DOI 10.1152/ajpheart.00479.2005; Brewer LD, 2009, J NEUROSCI, V29, P6058, DOI 10.1523/JNEUROSCI.5253-08.2009; Carthew P, 1999, TOXICOL SCI, V48, P197, DOI 10.1093/toxsci/48.2.197; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Dupont S, 2000, DEVELOPMENT, V127, P4277; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126/science.1103333; Fadini GP, 2006, DIABETOLOGIA, V49, P3075, DOI 10.1007/s00125-006-0401-6; Fadini GP, 2008, ATHEROSCLEROSIS, V197, P496, DOI 10.1016/j.atherosclerosis.2007.12.039; Fadini GP, 2008, ARTERIOSCL THROM VAS, V28, P997, DOI 10.1161/ATVBAHA.107.159558; Fadini GP, 2006, ARTERIOSCL THROM VAS, V26, P2140, DOI 10.1161/01.ATV.0000237750.44469.88; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Hamada H, 2006, CIRCULATION, V114, P2261, DOI 10.1161/CIRCULATIONAHA.106.631465; Harris HA, 2002, ENDOCRINOLOGY, V143, P4172, DOI 10.1210/en.2002-220403; Harris HA, 2007, MOL ENDOCRINOL, V21, P1, DOI 10.1210/me.2005-0459; HOHORST HJ, 1963, METHOD ENZYMAT AN, P215; Karas RH, 1999, P NATL ACAD SCI USA, V96, P15133, DOI 10.1073/pnas.96.26.15133; Karas RH, 2001, CIRC RES, V89, P534, DOI 10.1161/hh1801.097239; Kraichely DM, 2000, ENDOCRINOLOGY, V141, P3534, DOI 10.1210/en.141.10.3534; Le Saux M, 2006, J NEUROENDOCRINOL, V18, P25, DOI 10.1111/j.1365-2826.2005.01380.x; Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002-0206; Liu J, 2002, J BIOL CHEM, V277, P20927, DOI 10.1074/jbc.M110712200; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; Makela S, 1999, P NATL ACAD SCI USA, V96, P7077, DOI 10.1073/pnas.96.12.7077; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Morani A, 2006, P NATL ACAD SCI USA, V103, P7165, DOI 10.1073/pnas.0602194103; Novotny JL, 2009, ENDOCRINOLOGY, V150, P889, DOI 10.1210/en.2008-0708; O'Lone R, 2007, MOL ENDOCRINOL, V21, P1281, DOI 10.1210/me.2006-0497; Pare G, 2002, CIRC RES, V90, P1087, DOI 10.1161/01.RES.0000021114.92282.FA; Pelzer T, 2005, CARDIOVASC RES, V67, P604, DOI 10.1016/j.cardiores.2005.04.035; Pendaries C, 2002, P NATL ACAD SCI USA, V99, P2205, DOI 10.1073/pnas.042688499; Pinna C, 2008, HYPERTENSION, V51, P1210, DOI 10.1161/HYPERTENSIONAHA.107.106807; Rosenzweig A, 2005, NEW ENGL J MED, V353, P1055, DOI 10.1056/NEJMe058134; Rossoni G, 1998, J CARDIOVASC PHARM, V32, P260, DOI 10.1097/00005344-199808000-00013; Schrepfer S, 2006, MENOPAUSE, V13, P489, DOI 10.1097/01.gme.0000185941.63497.10; Schuit SCE, 2004, JAMA-J AM MED ASSOC, V291, P2969, DOI 10.1001/jama.291.24.2969; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; WATSON RE, 1986, BRAIN RES, V398, P157, DOI 10.1016/0006-8993(86)91261-8; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Xing DQ, 2009, ARTERIOSCL THROM VAS, V29, P289, DOI 10.1161/ATVBAHA.108.182279	43	25	32	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2010	24	7					2262	2272		10.1096/fj.09-139220	http://dx.doi.org/10.1096/fj.09-139220			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20203089	Green Submitted			2022-12-28	WOS:000279343600013
J	Lindberg, MJ; Popko-Scibor, AE; Hansson, ML; Wallberg, AE				Lindberg, Mikael J.; Popko-Scibor, Anita E.; Hansson, Magnus L.; Wallberg, Annika E.			SUMO modification regulates the transcriptional activity of MAML1	FASEB JOURNAL			English	Article						HDAC; coactivator; Notch	UBIQUITIN-LIKE PROTEIN; NEUROGENIC LOCUS MASTERMIND; COACTIVATOR MAML1; SUBNUCLEAR LOCALIZATION; DROSOPHILA MASTERMIND; COVALENT MODIFICATION; NOTCH COACTIVATOR; IN-VITRO; SUMOYLATION; ACTIVATION	The Mastermindlike ( MAML) family, comprising human MAML1, MAML2, and MAML3, are transcriptional regulators in Notch signaling. MAML proteins contain two consensus sites for SUMOylation at Lysine217 and Lysine299 that are conserved in humans, mice, and Xenopus. In this report, we show that MAML1 is SUMOylated at both sites. The E2-conjugating enzyme UBC9 is essential for MAML1 SUMOylation, and the E3 ligase PIAS1 stimulates this activity. Mutation of the lysines abolishes SUMOylation of MAML1 and strongly increases MAML1-activated transcription in cell culture assays. The protease SENP1 reverses SUMOylation of MAML1 and potentiates the transcription factor activity of MAML1. Furthermore, SUMOylation enhances MAML1 interaction with HDAC7, which decreases MAML1 transcriptional activity. Taken together, our data indicate that SUMOylation of MAML1 is a mechanism for repressing MAML1 activity by influencing its interaction with HDAC7.-Lindberg, M.J., Popko-Scibor, A.E., Hansson, M.L., Wallberg, A. E. SUMO modification regulates the transcriptional activity of MAML1. FASEB J. 24, 2396-2404 (2010). www.fasebj.org	[Lindberg, Mikael J.; Popko-Scibor, Anita E.; Hansson, Magnus L.; Wallberg, Annika E.] Karolinska Inst, Dept Biosci & Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet	Wallberg, AE (corresponding author), Karolinska Inst, Dept Biosci & Nutr, Halsovagen 7-9, S-14186 Huddinge, Sweden.	annika.wallberg@ki.se		Lindberg, Mikael/0000-0001-8595-8901	Swedish Research Council; Swedish Cancer Society; Swedish Children's Cancer Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Children's Cancer Foundation	The authors thank Dr. Frances Fuller-Pace (University of Dundee, Dundee, UK), Dr. Ron Hay (University of Dundee), Dr. Peter O'Hare (Marie Curie Research Institute, Osted, UK), Dr. Jorma Palvimo (University of Kuopio, Kuopio, Finland), Dr. Ed Seto (University of South Florida, Tampa, FL, USA), and Dr. Eric Jensen (University of Minnesota School of Dentistry, Minneapolis, MN, USA) for generously providing expression plasmids described in Materials and Methods. This work was supported by grants from the Swedish Research Council, the Swedish Cancer Society, and the Swedish Children's Cancer Foundation to A.E.W. M.J.L. was supported by a fellowship from the Swedish Children's Cancer Foundation and a grant from Alex and Eva Wallstrom foundation.	Alves-Guerra MC, 2007, CANCER RES, V67, P8690, DOI 10.1158/0008-5472.CAN-07-1720; Anckar J, 2007, BIOCHEM SOC T, V35, P1409, DOI 10.1042/BST0351409; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Fu CH, 2005, ONCOGENE, V24, P5401, DOI 10.1038/sj.onc.1208714; Gao CZ, 2008, MOL CELL BIOL, V28, P5658, DOI 10.1128/MCB.00874-08; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Gregoire S, 2006, J BIOL CHEM, V281, P4423, DOI 10.1074/jbc.M509471200; Hansson ML, 2009, NUCLEIC ACIDS RES, V37, P2996, DOI 10.1093/nar/gkp163; Hay RT, 2007, TRENDS CELL BIOL, V17, P370, DOI 10.1016/j.tcb.2007.08.002; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hofmann WA, 2009, J CELL BIOL, V186, P193, DOI 10.1083/jcb.200905016; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Jacobs AMF, 2007, ONCOGENE, V26, P5866, DOI 10.1038/sj.onc.1210387; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Ribeiro MSJ, 2007, BIOCHEM J, V404, P289, DOI 10.1042/BJ20061900; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kao HY, 2000, GENE DEV, V14, P55; Kitagawa M, 2001, MOL CELL BIOL, V21, P4337, DOI 10.1128/MCB.21.13.4337-4346.2001; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Meulmeester E, 2008, NATURE, V452, P709, DOI 10.1038/452709a; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Ribeiro MSJ, 2009, NUCLEIC ACIDS RES, V37, P6691, DOI 10.1093/nar/gkp724; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Shen HX, 2006, GENE DEV, V20, P675, DOI 10.1101/gad.1383706; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; Stankovic-Valentin N, 2007, MOL CELL BIOL, V27, P2661, DOI 10.1128/MCB.01098-06; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740; Vethantham V, 2008, GENE DEV, V22, P499, DOI 10.1101/gad.1628208; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu SY, 2009, EMBO J, V28, P1246, DOI 10.1038/emboj.2009.83; Yamaguchi T, 2005, MOL CELL BIOL, V25, P5171, DOI 10.1128/MCB.25.12.5171-5182.2005; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; YEDVOBNICK B, 1988, GENETICS, V118, P483; Yeh ETH, 2009, J BIOL CHEM, V284, P8223, DOI 10.1074/jbc.R800050200; Zhang XD, 2008, MOL CELL, V29, P729, DOI 10.1016/j.molcel.2008.01.013; Zhao J, 2007, CELL MOL LIFE SCI, V64, P3017, DOI 10.1007/s00018-007-7137-4; Zhao X, 2005, MOL CELL BIOL, V25, P8456, DOI 10.1128/MCB.25.19.8456-8464.2005; Zhao YT, 2007, J BIOL CHEM, V282, P11969, DOI 10.1074/jbc.M608974200	62	18	18	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2396	2404		10.1096/fj.09-149401	http://dx.doi.org/10.1096/fj.09-149401			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20203086				2022-12-28	WOS:000279343600026
J	Mendez, MG; Kojima, SI; Goldman, RD				Mendez, Melissa G.; Kojima, Shin-Ichiro; Goldman, Robert D.			Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition	FASEB JOURNAL			English	Article							INTERMEDIATE-FILAMENT NETWORKS; MICE LACKING VIMENTIN; IN-VIVO; MICROMECHANICAL PROPERTIES; DYNAMIC PROPERTIES; FOCAL ADHESIONS; SHEAR-STRESS; CANCER-CELLS; PHOSPHORYLATION; EXPRESSION	Vimentin is used widely as a marker of the epithelial to mesenchymal transitions (EMTs) that take place during embryogenesis and metastasis, yet the functional implications of the expression of this type III intermediate filament (IF) protein are poorly understood. Using form factor analysis and quantitative Western blotting of normal, metastatic, and vimentin-null cell lines, we show that the level of expression of vimentin IFs (VIFs) correlates with mesenchymal cell shape and motile behavior. The reorganization of VIFs caused by expressing a dominant-negative mutant or by silencing vimentin with shRNA (neither of which alter microtubule or microfilament assembly) causes mesenchymal cells to adopt epithelial shapes. Following the microinjection of vimentin or transfection with vimentin cDNA, epithelial cells rapidly adopt mesenchymal shapes coincident with VIF assembly. These shape transitions are accompanied by a loss of desmosomal contacts, an increase in cell motility, and a significant increase in focal adhesion dynamics. Our results demonstrate that VIFs play a predominant role in the changes in shape, adhesion, and motility that occur during the EMT.-Mendez, M. G., Kojima, S.-I., Goldman, R. D. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 24, 1838-1851 (2010). www.fasebj.org	[Mendez, Melissa G.; Kojima, Shin-Ichiro; Goldman, Robert D.] Northwestern Univ, Feinberg Sch Med, Evanston, IL USA; [Kojima, Shin-Ichiro] Gakushuin Univ, Fac Sci, Dept Life Sci, Tokyo 171, Japan	Northwestern University; Feinberg School of Medicine; Gakushuin University	Goldman, RD (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave,Ward 11-145, Chicago, IL 60611 USA.	r-goldman@northwestern.edu	Mendez, Melissa G/B-1357-2014	Mendez, Melissa G/0000-0002-3995-2469	U.S. National Institutes of Health [R37 GM36806-27]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036806] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work has been supported by a grant from the General Medical Sciences Institute of the U.S. National Institutes of Health (R37 GM36806-27). The authors also thank Brian Helfand, Ed Kuczmarski, Boris Grin, and Anne Goldman for helpful comments.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Barberis L, 2009, EUR J IMMUNOL, V39, P1136, DOI 10.1002/eji.200838884; Bhattacharya R, 2009, J CELL SCI, V122, P1390, DOI 10.1242/jcs.043042; Bindels S, 2006, ONCOGENE, V25, P4975, DOI 10.1038/sj.onc.1209511; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; Chang L, 2009, J CELL SCI, V122, P2914, DOI 10.1242/jcs.046789; Chou YH, 1996, J CELL SCI, V109, P817; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Correia I, 1999, J CELL BIOL, V146, P831, DOI 10.1083/jcb.146.4.831; Cross SE, 2007, NAT NANOTECHNOL, V2, P780, DOI 10.1038/nnano.2007.388; Davies PF, 1995, J BIOMECH, V28, P1553, DOI 10.1016/0021-9290(95)00102-6; Eckes B, 2000, J CELL SCI, V113, P2455; Flitney EW, 2009, FASEB J, V23, P2110, DOI 10.1096/fj.08-124453; FRANKE WW, 1983, P NATL ACAD SCI-BIOL, V80, P7113, DOI 10.1073/pnas.80.23.7113; Gilles C, 1999, J CELL SCI, V112, P4615; Godsel LM, 2005, J CELL BIOL, V171, P1045, DOI 10.1083/jcb.200510038; GOLDMAN RD, 1971, J CELL BIOL, V51, P752, DOI 10.1083/jcb.51.3.752; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; Goto H, 2002, GENES CELLS, V7, P91, DOI 10.1046/j.1356-9597.2001.00504.x; GREEN KJ, 1987, J CELL BIOL, V104, P1389, DOI 10.1083/jcb.104.5.1389; GYOEVA FK, 1991, NATURE, V353, P445, DOI 10.1038/353445a0; Hay ED, 2005, DEV DYNAM, V233, P706, DOI 10.1002/dvdy.20345; Helfand BT, 2002, J CELL BIOL, V157, P795, DOI 10.1083/jcb.200202027; Helfand BT, 2003, MOL BIOL CELL, V14, P5069, DOI 10.1091/mbc.E03-06-0376; Helmke BP, 2000, CIRC RES, V86, P745, DOI 10.1161/01.RES.86.7.745; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Janmey P A, 1998, Subcell Biochem, V31, P381; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Kojima SI, 2004, BIOTECHNIQUES, V36, P74, DOI 10.2144/04361ST02; Kreplak L, 2005, J MOL BIOL, V354, P569, DOI 10.1016/j.jmb.2005.09.092; Lang SH, 2002, PROSTATE, V52, P253, DOI 10.1002/pros.10088; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; Liao GJ, 1998, J BIOL CHEM, V273, P9797, DOI 10.1074/jbc.273.16.9797; Ma LL, 1999, J BIOL CHEM, V274, P19145, DOI 10.1074/jbc.274.27.19145; Molli PR, 2009, ONCOGENE, V28, P2545, DOI 10.1038/onc.2009.119; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Perlson E, 2006, J MOL BIOL, V364, P938, DOI 10.1016/j.jmb.2006.09.056; Phua DCY, 2009, MOL BIOL CELL, V20, P2841, DOI 10.1091/mbc.E08-02-0199; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; Santini D, 1996, J PATHOL, V179, P386, DOI 10.1002/(SICI)1096-9896(199608)179:4<386::AID-PATH631>3.0.CO;2-V; Schock F, 2002, ANNU REV CELL DEV BI, V18, P463, DOI 10.1146/annurev.cellbio.18.022602.131838; Sin WC, 1998, MOL CELL BIOL, V18, P6325, DOI 10.1128/MCB.18.11.6325; Sivaramakrishnan S, 2008, P NATL ACAD SCI USA, V105, P889, DOI 10.1073/pnas.0710728105; SOLL DR, 1988, J CELL BIOCHEM, V37, P177, DOI 10.1002/jcb.240370205; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P3692, DOI 10.1073/pnas.78.6.3692; Suresh S, 2007, ACTA BIOMATER, V3, P413, DOI 10.1016/j.actbio.2007.04.002; Tsuruta D, 2003, J CELL SCI, V116, P4977, DOI 10.1242/jcs.00823; Tzivion G, 2000, J BIOL CHEM, V275, P29772, DOI 10.1074/jbc.M001207200; Wei JC, 2008, ANTICANCER RES, V28, P327; WEINSTEIN DE, 1991, J CELL BIOL, V112, P1205, DOI 10.1083/jcb.112.6.1205; Windoffer R, 2006, J CELL BIOL, V173, P341, DOI 10.1083/jcb.200511124; Wolfenson H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004304; Woll S, 2005, EUR J CELL BIOL, V84, P311, DOI 10.1016/j.ejcb.2004.12.004; Yoon KH, 2001, J CELL BIOL, V153, P503, DOI 10.1083/jcb.153.3.503; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147; Zhang Q, 2009, CLIN CANCER RES, V15, P3557, DOI 10.1158/1078-0432.CCR-08-1656	61	603	627	0	96	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1838	1851		10.1096/fj.09-151639	http://dx.doi.org/10.1096/fj.09-151639			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20097873	Green Published			2022-12-28	WOS:000278200000020
J	Squillaro, T; Alessio, N; Cipollaro, M; Renieri, A; Giordano, A; Galderisi, U				Squillaro, Tiziana; Alessio, Nicola; Cipollaro, Marilena; Renieri, Alessandra; Giordano, Antonio; Galderisi, Umberto			Partial silencing of methyl cytosine protein binding 2 (MECP2) in mesenchymal stem cells induces senescence with an increase in damaged DNA	FASEB JOURNAL			English	Article						marrow stromal stem cells; differentiation; apoptosis; cell cycle; DNA repair	RETT-SYNDROME; STROMAL CELLS; REPAIR; MECHANISMS; OSTEOPENIA; APOPTOSIS; COMPLEX; GROWTH; CANCER; LINKS	DNA methylation is an epigenetic modification that occurs almost exclusively on CpG dinucleotides. MECP2 is a member of a family of proteins that preferentially bind to methylated CpGs. We analyzed the contribution of MECP2 to the physiology of mesenchymal stem cells (MSCs). Partial silencing of MECP2 in human MSCs induced a significant reduction of S-phase cells, along with an increase in G(1) cells. These changes were accompanied by a reduction of apoptosis, the triggering of senescence, a decrease in telomerase activity, and the down-regulation of genes involved in maintaining stem cell properties. Senescence appeared to rely on impairment of DNA damage repair and seemed to occur through RB- and P53-related pathways. The effects of MECP2 silencing could be related to the modification of the DNA methylation status. Our results indicate that the silencing of MECP2 induces an increase in methylated cytosines in the genome. Nevertheless, MECP2 partial silencing did not change the methylation of promoters, whose expression is affected by MECP2 down-regulation.-Squillaro, T., Alessio, N., Cipollaro, M., Renieri, A., Giordano, A., Galderisi, U. Partial silencing of methyl cytosine protein binding 2 (MECP2) in mesenchymal stem cells induces senescence with an increase in damaged DNA. FASEB J. 24, 1593-1603 (2010). www.fasebj.org	[Alessio, Nicola; Cipollaro, Marilena; Galderisi, Umberto] Univ Naples 2, Dept Expt Med, Biotechnol & Mol Biol Sect, I-80138 Naples, Italy; [Squillaro, Tiziana; Alessio, Nicola; Giordano, Antonio; Galderisi, Umberto] Temple Univ, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Philadelphia, PA 19122 USA; [Giordano, Antonio] Univ Siena, Dept Human Pathol & Oncol, Siena, Italy; [Squillaro, Tiziana; Renieri, Alessandra] Univ Siena, Dept Med Genet, Siena, Italy; [Giordano, Antonio] Human Hlth Fdn, Spoleto, Italy	Universita della Campania Vanvitelli; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena; University of Siena	Galderisi, U (corresponding author), Univ Naples 2, Dept Expt Med, Biotechnol & Mol Biol Sect, Via Costantinopoli 16, I-80138 Naples, Italy.	umberto.galderisi@unina2.it	Renieri, Alessandra/K-5950-2016; Alessio, Nicola/K-2119-2018; Giordano, Antonio/F-1927-2010	Renieri, Alessandra/0000-0002-0846-9220; Alessio, Nicola/0000-0002-5019-2130; Giordano, Antonio/0000-0002-5959-016X; GALDERISI, Umberto/0000-0003-0909-7403; Cipollaro, Marilena/0000-0003-4350-4324	Sbarro Health Research Organization funds	Sbarro Health Research Organization funds	This work was partially supported by Sbarro Health Research Organization funds to U.G. and A.G. The authors thank M.R. Cipollaro for technical assistance.	Ager S, 2006, J CHILD NEUROL, V21, P809, DOI 10.1177/08830738060210091501; Beyer Nardi N, 2006, HANDB EXP PHARM, V174, P249; Bienvenu T, 2006, NAT REV GENET, V7, P415, DOI 10.1038/nrg1878; Bindokas VP, 2003, J BIOL CHEM, V278, P9796, DOI 10.1074/jbc.M206913200; Budden SS, 2001, BRAIN DEV-JPN, V23, pS133, DOI 10.1016/S0387-7604(01)00338-2; Budden SS, 2003, J CHILD NEUROL, V18, P698, DOI 10.1177/08830738030180100401; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Collins AL, 2004, HUM MOL GENET, V13, P2679, DOI 10.1093/hmg/ddh282; Diggle CP, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng083; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Galderisi U, 2006, ONCOGENE, V25, P5250, DOI 10.1038/sj.onc.1209736; Galderisi U, 1999, J CELL BIOCHEM, V73, P97, DOI 10.1002/(SICI)1097-4644(19990401)73:1<97::AID-JCB11>3.0.CO;2-M; Galderisi U, 2009, STEM CELLS DEV, V18, P1033, DOI 10.1089/scd.2008.0324; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Giorgio M, 2007, NAT REV MOL CELL BIO, V8, p722A; Haas RH, 1997, J PEDIATR-US, V131, P771, DOI 10.1016/S0022-3476(97)70113-6; Harikrishnan KN, 2005, NAT GENET, V37, P254, DOI 10.1038/ng1516; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kholodenko BN, 2000, EUR J BIOCHEM, V267, P1583, DOI 10.1046/j.1432-1327.2000.01197.x; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Mikkers H, 2005, EMBO J, V24, P2715, DOI 10.1038/sj.emboj.7600749; Mnatzakanian GN, 2004, NAT GENET, V36, P339, DOI 10.1038/ng1327; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; MULLERSIEBURG CE, 1995, STEM CELLS, V13, P477, DOI 10.1002/stem.5530130505; Nan XS, 2007, P NATL ACAD SCI USA, V104, P2709, DOI 10.1073/pnas.0608056104; Napolitano MA, 2007, J CELL SCI, V120, P2904, DOI 10.1242/jcs.004002; Oberdoerffer P, 2007, NAT REV MOL CELL BIO, V8, P692, DOI 10.1038/nrm2238; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Ronen A, 2001, ENVIRON MOL MUTAGEN, V37, P241, DOI 10.1002/em.1033; Sambrook J., 2001, MOL CLONING LAB MANU; Sethe S, 2006, AGEING RES REV, V5, P91, DOI 10.1016/j.arr.2005.10.001; Sharpless NE, 2007, NAT REV MOL CELL BIO, V8, P703, DOI 10.1038/nrm2241; Singh J, 2008, NUCLEIC ACIDS RES, V36, P6035, DOI 10.1093/nar/gkn591; SQUILLARO T, 2008, ISSCR ANN M 2008 PHI, P80; Squillaro T, 2008, WHAT IS NEW EUROPE F; Squillaro T, 2008, J CELL BIOCHEM, V103, P1877, DOI 10.1002/jcb.21582; Suzuki M, 2006, ONCOGENE, V25, P2477, DOI 10.1038/sj.onc.1209272; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; von Zglinicki T, 2001, EXP GERONTOL, V36, P1049, DOI 10.1016/S0531-5565(01)00111-5; Weaving LS, 2005, J MED GENET, V42, P1, DOI 10.1136/jmg.2004.027730; Yasui DH, 2007, P NATL ACAD SCI USA, V104, P19416, DOI 10.1073/pnas.0707442104; Yu K, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000129; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zysman L, 2006, THESCIENTIFICWORLDJO, V6, P1619, DOI 10.1100/tsw.2006.266	53	33	36	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1593	1603		10.1096/fj.09-143057	http://dx.doi.org/10.1096/fj.09-143057			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20065105				2022-12-28	WOS:000277158900031
J	Kane, MA; Folias, AE; Wang, C; Napoli, JL				Kane, Maureen A.; Folias, Alexandra E.; Wang, Chao; Napoli, Joseph L.			Ethanol elevates physiological all-trans-retinoic acid levels in select loci through altering retinoid metabolism in multiple loci: a potential mechanism of ethanol toxicity	FASEB JOURNAL			English	Article						vitamin A; alcohol dehydrogenase; short-chain dehydrogenase; retinol dehydrogenase; fetal alcohol syndrome; hippocampus	RECEPTOR MESSENGER-RNA; FETAL ALCOHOL SYNDROME; VITAMIN-A; BINDING-PROTEIN; 13-CIS-RETINOIC ACID; HIPPOCAMPAL-NEURONS; MEMBRANE-RECEPTOR; NUCLEAR RECEPTORS; RAR-ALPHA; EXPOSURE	All-trans-retinoic acid (atRA) supports embryonic development, central nervous system function, and the immune response. atRA initiates neurogenesis and dendritic growth in the hippocampus and is required for spatial memory; superphysiological atRA inhibits neurogenesis, causes teratology and/or embryo toxicity, and alters cognitive function and behavior. Because abnormal atRA shares pathological conditions with alcoholism, inhibition of retinol (vitamin A) activation into atRA has been credited widely as a mechanism of ethanol toxicity. Here, we analyze the effects of ethanol on retinoid concentrations in vivo during normal vitamin A nutriture, using sensitive and analytically robust assays. Ethanol either increased or had no effect on atRA, regardless of changes in retinol and retinyl esters. Acute ethanol (3.5 g/kg) increased atRA in adult hippocampus (1.6-fold), liver (2.4-fold), and testis (1.5-fold). Feeding dams a liquid diet with 6.5% ethanol from embryonic day 13 (e13) to e19 increased atRA in fetal hippocampus (up to 20-fold) and cortex ( up to 50-fold), depending on blood alcohol content. One-month feeding of the 6.5% ethanol diet increased atRA in adult hippocampus (20-fold), cortex (2-fold), testis (2-fold), and serum (10-fold). Tissue-specific increases in retinoid dehydrogenase mRNAs and activities, extrahepatic retinol concentrations, and atRA catabolism combined to produce site-specific effects. Because a sustained increase in atRA has deleterious effects on the central nervous system and embryo development, these data suggest that superphysiological atRA contributes to ethanol pathological conditions, including cognitive dysfunction and fetal alcohol syndrome.-Kane, M. A., Folias, A. E., Wang, C., Napoli, J. L. Ethanol elevates physiological all- trans-retinoic acid levels in select loci through altering retinoid metabolism in multiple loci: a potential mechanism of ethanol toxicity. FASEB J. 24, 823-832 (2010). www.fasebj.org	[Kane, Maureen A.; Folias, Alexandra E.; Wang, Chao; Napoli, Joseph L.] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Napoli, JL (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 119 Morgan Hall,MC 3104, Berkeley, CA 94720 USA.	jna@berkeley.edu	Wang, Chao/A-4626-2016	Wang, Chao/0000-0003-0357-4096	U.S. National Institutes of Health (NIH) [AA17927, AG13566, DK061918]; NIH Kirschstein Individual Fellowship [DK066924]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061918, F32DK066924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA017927] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Kirschstein Individual Fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	The authors thank Na Chen for assistance with embryo dissections; Rob Griswold for assistance in refining the subcellular fractionation procedure; James Chithalen, Hua Tran, Susan Sparks, and Saverio Roberto for assistance with animal care; and Charles Krois for assistance with CrbpI preparation. This work was supported by U.S. National Institutes of Health (NIH) grants AA17927 and AG13566 (J.L.N.), NIH Kirschstein Individual Fellowship DK066924 (M. A. K.), and NIH predoctoral training grant DK061918 (A. E. F.).	Bagnardi V, 2001, ALCOHOL RES HEALTH, V25, P263; Barua AB, 1998, MOL BIOTECHNOL, V10, P167, DOI 10.1007/BF02760863; Berman RE, 2000, HIPPOCAMPUS, V10, P94, DOI 10.1002/(SICI)1098-1063(2000)10:1<94::AID-HIPO11>3.3.CO;2-K; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; Bouillet P, 1997, MECH DEVELOP, V63, P173, DOI 10.1016/S0925-4773(97)00039-7; Bremmer JD, 2008, PROG NEURO-PSYCHOPH, V32, P315, DOI 10.1016/j.pnpbp.2007.07.001; Calvert-Evers JL, 2003, MOL CELL BIOCHEM, V245, P23, DOI 10.1023/A:1022806129035; Chen N, 2008, J BIOL CHEM, V283, P20841, DOI 10.1074/jbc.M802314200; Chen N, 2008, FASEB J, V22, P236, DOI 10.1096/fj.07-8739com; Chen Y, 2009, MED ONCOL, V26, P463, DOI 10.1007/s12032-008-9147-y; Chiang MY, 1998, NEURON, V21, P1353, DOI 10.1016/S0896-6273(00)80654-6; Chung SSW, 2004, CYTOGENET GENOME RES, V105, P189, DOI 10.1159/000078189; Crandall J, 2004, P NATL ACAD SCI USA, V101, P5111, DOI 10.1073/pnas.0306336101; Deltour L, 1996, FASEB J, V10, P1050, DOI 10.1096/fasebj.10.9.8801166; DREOSTI IE, 1993, ANN NY ACAD SCI, V678, P193; Fields AL, 2007, J CELL BIOCHEM, V102, P886, DOI 10.1002/jcb.21530; FRANK O, 1976, J NUTR, V106, P606, DOI 10.1093/jn/106.5.606; FRIEDMAN H, 1989, ARCH BIOCHEM BIOPHYS, V269, P69, DOI 10.1016/0003-9861(89)90087-8; Grummer MA, 1995, ALCOHOL CLIN EXP RES, V19, P1376, DOI 10.1111/j.1530-0277.1995.tb00995.x; GRUMMER MA, 1993, ALCOHOL CLIN EXP RES, V17, P592, DOI 10.1111/j.1530-0277.1993.tb00805.x; Holson RR, 1997, NEUROTOXICOL TERATOL, V19, P335, DOI 10.1016/S0892-0362(97)00039-1; Holson RR, 1997, NEUROTOXICOL TERATOL, V19, P355, DOI 10.1016/S0892-0362(97)00041-X; HORST RL, 1995, BIOCHEMISTRY-US, V34, P1203, DOI 10.1021/bi00004a013; Kane MA, 2005, BIOCHEM J, V388, P363, DOI 10.1042/BJ20041867; Kane MA, 2008, ANAL BIOCHEM, V378, P71, DOI 10.1016/j.ab.2008.03.038; Kane MA, 2008, ANAL CHEM, V80, P1702, DOI 10.1021/ac702030f; Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244; KIM KH, 1990, MOL ENDOCRINOL, V4, P1679, DOI 10.1210/mend-4-11-1679; Leo MA, 1999, AM J CLIN NUTR, V69, P1071; Liu C, 2002, ALCOHOL CLIN EXP RES, V26, P1703, DOI 10.1097/01.ALC.0000037135.09289.69; Liu Y, 2008, J NEUROCHEM, V106, P1104, DOI 10.1111/j.1471-4159.2008.05445.x; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; Molotkov A, 2002, J BIOL CHEM, V277, P22553, DOI 10.1074/jbc.M201603200; Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; Noy N, 2007, BIOCHEMISTRY-US, V46, P13461, DOI 10.1021/bi7018699; Oscar-Berman M, 2003, ALCOHOL RES HEALTH, V27, P125; POSCH KC, 1992, J BIOL CHEM, V267, P19676; Redondo C, 2008, FASEB J, V22, P1043, DOI 10.1096/fj.07-8939com; SATO M, 1981, J NUTR, V111, P2015, DOI 10.1093/jn/111.11.2015; Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050; Shaw N, 2003, J BIOL CHEM, V278, P41589, DOI 10.1074/jbc.C300368200; Smith SM, 1997, ALCOHOL HEALTH RES W, V21, P287; Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167; Tzimas G, 1996, J NUTR, V126, P2159, DOI 10.1093/jn/126.9.2159; VORHEES CV, 1974, TERATOLOGY, V10, P269, DOI 10.1002/tera.1420100309; VORHEES CV, 1978, TERATOLOGY, V17, P271, DOI 10.1002/tera.1420170305; Wang XD, 2005, ALCOHOL, V35, P251, DOI 10.1016/j.alcohol.2005.04.006; Warren KR, 2001, ALCOHOL RES HEALTH, V25, P153; Zakhari S, 2006, ALCOHOL RES HEALTH, V29, P245	51	62	63	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2010	24	3					823	832		10.1096/fj.09-141572	http://dx.doi.org/10.1096/fj.09-141572			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19890016	Green Published			2022-12-28	WOS:000274974600018
J	Nabavi, S; Nazar, RN				Nabavi, Sadeq; Nazar, Ross N.			Fail-safe termination elements: a common feature of the eukaryotic genome?	FASEB JOURNAL			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL TERMINATION; MESSENGER-RNAS; POLYADENYLATION; INITIATION; POLY(A); GENES; SURVEILLANCE; DOWNSTREAM; EFFICIENCY	A recent scan of the human genome (1) identified similar to 11 million hairpins. Some have been linked to known sequences, such as viruses, transposable elements, and, more recently, regulating or microRNAs, but the significance, if any, of most sequences that can be predicted to form hairpins remains unknown. Here we show that hairpins that are cleaved by RNase III-like nucleases can induce termination, even with normally polyadenylated transcripts, and that a cleaved hairpin downstream of a normal termination signal can induce fail-safe termination. Because such cleavage sites appear common to intergenic regions, the results raise the possibility that similar fail-safe termination elements are widely distributed in the eukaryotic genome to prevent read-through transcription from disrupting downstream promoter elements or opposing transcription.-Nabavi, S., Nazar, R. N. Fail-safe termination elements: a common feature of the eukaryotic genome? FASEB J. 24, 684-688 (2010). www.fasebj.org	[Nabavi, Sadeq; Nazar, Ross N.] Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	University of Guelph	Nazar, RN (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada.	rnnazar@uoguelph.ca		Nabavi, Sadegh/0000-0002-3940-1210	Natural Sciences and Engineering Research Council of Canada	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	We are very grateful to Dr. D. Frendeway (Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA) for providing the Pac1 endonuclease used in this study. This study was supported by the Natural Sciences and Engineering Research Council of Canada.	Aranda A, 2001, MOL CELL, V7, P1003, DOI 10.1016/S1097-2765(01)00235-0; ASHFIELD R, 1991, EMBO J, V10, P4197, DOI 10.1002/j.1460-2075.1991.tb04998.x; BAKKEN A, 1982, P NATL ACAD SCI-BIOL, V79, P56, DOI 10.1073/pnas.79.1.56; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; Danin-Kreiselman M, 2003, MOL CELL, V11, P1279, DOI 10.1016/S1097-2765(03)00137-0; Dye MJ, 1999, MOL CELL, V3, P371, DOI 10.1016/S1097-2765(00)80464-5; El Hage A, 2008, GENE DEV, V22, P1069, DOI 10.1101/gad.463708; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; Ge DL, 2005, CURR BIOL, V15, P140, DOI 10.1016/j.cub.2004.12.001; Greger IH, 1998, EMBO J, V17, P4771, DOI 10.1093/emboj/17.16.4771; GRUMMT I, 1985, CELL, V43, P801, DOI 10.1016/0092-8674(85)90253-3; Hitchen J, 1997, J MOL BIOL, V274, P481, DOI 10.1006/jmbi.1997.1376; Huang YQ, 1996, MOL CELL BIOL, V16, P1534; HYMAN LE, 1993, MOL CELL BIOL, V13, P5159, DOI 10.1128/MCB.13.9.5159; Kawauchi J, 2008, GENE DEV, V22, P1082, DOI 10.1101/gad.463408; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; Lee A, 2005, MOL CELL, V19, P39, DOI 10.1016/j.molcel.2005.05.021; LOSSON R, 1983, CELL, V32, P371, DOI 10.1016/0092-8674(83)90456-7; MATHEWS DH, 2007, CURR PROTOC NUCL ACI, V11; Nabavi S, 2008, J BIOL CHEM, V283, P13601, DOI 10.1074/jbc.M710125200; Nazar RN, 2007, FASEB J, V21, pA1028; Rotondo G, 1996, NUCLEIC ACIDS RES, V24, P2377, DOI 10.1093/nar/24.12.2377; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; Shwed PS, 1999, NUCLEIC ACIDS RES, V27, P2883, DOI 10.1093/nar/27.14.2883; SOLLNERWEBB B, 1979, CELL, V18, P485, DOI 10.1016/0092-8674(79)90066-7; West S, 2006, RNA, V12, P655, DOI 10.1261/rna.2232406; Zer C, 2005, J BIOL CHEM, V280, P28997, DOI 10.1074/jbc.M505913200	28	2	2	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					684	688		10.1096/fj.09-142745	http://dx.doi.org/10.1096/fj.09-142745			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19841037				2022-12-28	WOS:000274974600004
J	Herron, TJ; Devaney, E; Mundada, L; Arden, E; Day, S; Guerrero-Serna, G; Turner, I; Westfall, M; Metzger, JM				Herron, Todd J.; Devaney, Eric; Mundada, Lakshmi; Arden, Erik; Day, Sharlene; Guerrero-Serna, Guadalupe; Turner, Immanuel; Westfall, Margaret; Metzger, Joseph M.			Ca2+-independent positive molecular inotropy for failing rabbit and human cardiac muscle by alpha-myosin motor gene transfer	FASEB JOURNAL			English	Article						cardiac gene transfer; ischemic heart failure; adenoviral gene transfer	CHAIN ISOFORM EXPRESSION; HUMAN HEART-FAILURE; HEAVY-CHAIN; VENTRICULAR MYOCARDIUM; FORCE DEVELOPMENT; RAT MYOCARDIUM; POWER OUTPUT; CROSSBRIDGE KINETICS; THIN FILAMENT; MYOCYTES	Current inotropic therapies used to increase cardiac contractility of the failing heart center on increasing the amount of calcium available for contraction, but their long-term use is associated with increased mortality due to fatal arrhythmias. Thus, there is a need to develop and explore novel inotropic therapies that can act via calcium-independent mechanisms. The purpose of this study was to determine whether fast alpha-myosin molecular motor gene transfer can confer calcium-independent positive inotropy in slow beta-myosin-dominant rabbit and human failing ventricular myocytes. To this end, we generated a recombinant adenovirus (AdMYH6) to deliver the full-length human alpha-myosin gene to adult rabbit and human cardiac myocytes in vitro. Fast alpha-myosin motor expression was determined by Western blotting and immunocytochemical analysis and confocal imaging. In experiments using electrically stimulated myocytes from ischemic failing hearts, AdMYH6 increased the contractile amplitude of failing human [23.9 +/- 7.8 nm (n = 10) vs. AdMYH6 amplitude 78.4 +/- 16.5 nm (n = 6)] and rabbit myocytes. The intracellular calcium transient amplitude was not altered. Control experiments included the use of a green fluorescent protein or a beta-myosin heavy chain adenovirus. Our data provide evidence for a novel form of calcium-independent positive inotropy in failing cardiac myocytes by fast alpha-myosin motor protein gene transfer.-Herron, T. J., Devaney, E., Mundada, L., Arden, E., Day, S., Guerrero-Serna, G., Turner, I., Westfall, M., Metzger, J. M. Ca2+-independent positive molecular inotropy for failing rabbit and human cardiac muscle by alpha-myosin motor gene transfer. FASEB J. 24, 415-424 (2010). www.fasebj.org	[Arden, Erik; Metzger, Joseph M.] Univ Minnesota, Sch Med, Dept Integrat Biol & Physiol, Minneapolis, MN 55455 USA; [Herron, Todd J.; Turner, Immanuel; Westfall, Margaret] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI USA; [Herron, Todd J.; Guerrero-Serna, Guadalupe] Univ Michigan, Sch Med, Ctr Arrhythmia Res, Ann Arbor, MI USA; [Devaney, Eric; Mundada, Lakshmi; Westfall, Margaret] Univ Michigan, Sch Med, Dept Cardiac Surg, Ann Arbor, MI USA; [Day, Sharlene] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA	University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Metzger, JM (corresponding author), Univ Minnesota, Sch Med, Dept Integrat Biol & Physiol, 6-125 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	metzgerj@umn.edu		Westfall, Margaret/0000-0001-9491-0125	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL080880] Funding Source: NIH RePORTER; NHLBI NIH HHS [L30 HL082192, F32 HL080880] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antoniades C, 2007, PHARMACOL THERAPEUT, V114, P184, DOI 10.1016/j.pharmthera.2007.01.008; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; Butter C, 2008, J AM COLL CARDIOL, V51, P1784, DOI 10.1016/j.jacc.2008.01.036; Cleland JGF, 2006, EUR J HEART FAIL, V8, P105, DOI 10.1016/j.ejheart.2005.12.003; Cohn JN, 1998, NEW ENGL J MED, V339, P1810, DOI 10.1056/NEJM199812173392503; Cross HR, 2003, AM J PHYSIOL-HEART C, V284, pH683, DOI 10.1152/ajpheart.00567.2002; Day SM, 2006, NAT MED, V12, P181, DOI 10.1038/nm1346; del Monte F, 1999, CIRCULATION, V100, P2308, DOI 10.1161/01.CIR.100.23.2308; del Monte F, 2002, CIRCULATION, V105, P904, DOI 10.1161/hc0802.105564; Fitzsimons DP, 1999, AM J PHYSIOL-HEART C, V276, pH1511; Fitzsimons DP, 1998, J PHYSIOL-LONDON, V513, P171, DOI 10.1111/j.1469-7793.1998.171by.x; GORZA L, 1984, CIRC RES, V54, P694, DOI 10.1161/01.RES.54.6.694; HARRIS DE, 1994, J MUSCLE RES CELL M, V15, P11, DOI 10.1007/BF00123828; Hasenfuss G, 2002, J MOL CELL CARDIOL, V34, P951, DOI 10.1006/jmcc.2002.2037; Herron TJ, 2002, CIRC RES, V90, P1150, DOI 10.1161/01.RES.0000022879.57270.11; Herron TJ, 2001, AM J PHYSIOL-HEART C, V281, pH1217, DOI 10.1152/ajpheart.2001.281.3.H1217; Herron TJ, 2007, CIRC RES, V100, P1182, DOI 10.1161/01.RES.0000264102.00706.4e; HOH JFY, 1978, J MOL CELL CARDIOL, V10, P1053, DOI 10.1016/0022-2828(78)90401-7; HOLUBARSCH C, 1985, CIRC RES, V56, P78, DOI 10.1161/01.RES.56.1.78; James J, 2005, CIRCULATION, V111, P2339, DOI 10.1161/01.CIR.0000164233.09448.B1; Korte FS, 2005, AM J PHYSIOL-HEART C, V289, pH801, DOI 10.1152/ajpheart.01227.2004; Krenz M, 2004, J AM COLL CARDIOL, V44, P2390, DOI 10.1016/j.jacc.2004.09.044; LITTEN RZ, 1985, CIRC RES, V57, P406, DOI 10.1161/01.RES.57.3.406; Locher MR, 2009, AM J PHYSIOL-HEART C, V297, pH247, DOI 10.1152/ajpheart.00922.2008; Lowes BD, 2002, NEW ENGL J MED, V346, P1357, DOI 10.1056/NEJMoa012630; Lowes BD, 1997, J CLIN INVEST, V100, P2315, DOI 10.1172/JCI119770; MAHAFFEY KW, 1995, CIRCULATION, V91, P794, DOI 10.1161/01.CIR.91.3.794; Marian AJ, 2005, CIRCULATION, V111, P2276, DOI 10.1161/01.CIR.0000167559.13502.9A; Maurice JP, 1999, AM J PHYSIOL-HEART C, V276, pH1853, DOI 10.1152/ajpheart.1999.276.6.H1853; McKinsey TA, 2005, J CLIN INVEST, V115, P538, DOI 10.1172/JCI200524144; MERCADIER JJ, 1981, CIRC RES, V49, P525, DOI 10.1161/01.RES.49.2.525; METZGER JM, 1995, BIOPHYS J, V68, P1430, DOI 10.1016/S0006-3495(95)80316-4; Metzger JM, 1999, CIRC RES, V84, P1310, DOI 10.1161/01.RES.84.11.1310; Michele DE, 2000, TRENDS CARDIOVAS MED, V10, P177, DOI 10.1016/S1050-1738(00)00067-0; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; Nakao K, 1997, J CLIN INVEST, V100, P2362, DOI 10.1172/JCI119776; Palmer S, 1998, CIRC RES, V83, P179, DOI 10.1161/01.RES.83.2.179; Perrone SV, 2005, INT J CARDIOL, V103, P248, DOI 10.1016/j.ijcard.2004.12.012; Rastogi S, 2005, HEART FAIL REV, V10, P157, DOI 10.1007/s10741-005-4643-z; Rundell VLM, 2004, AM J PHYSIOL-HEART C, V287, pH408, DOI 10.1152/ajpheart.00049.2004; Rundell VLM, 2005, AM J PHYSIOL-HEART C, V288, pH896, DOI 10.1152/ajpheart.00407.2004; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Schoffstall B, 2006, J PHYSIOL-LONDON, V577, P935, DOI 10.1113/jphysiol.2006.120105; Solaro RJ, 2009, IDRUGS, V12, P243; Sugiura S, 1998, CIRC RES, V82, P1029, DOI 10.1161/01.RES.82.10.1029; Suzuki T, 2009, CIRC-HEART FAIL, V2, P334, DOI 10.1161/CIRCHEARTFAILURE.108.802298; Tardiff JC, 2000, AM J PHYSIOL-HEART C, V278, pH412, DOI 10.1152/ajpheart.2000.278.2.H412; Teerlink JR, 2009, HEART FAIL REV, V14, P289, DOI 10.1007/s10741-009-9135-0; van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089	49	24	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					415	424		10.1096/fj.09-140566	http://dx.doi.org/10.1096/fj.09-140566			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19801488	Green Published			2022-12-28	WOS:000274045000010
J	Morales-Rios, E; de la Rosa-Morales, F; Mendoza-Hernandez, G; Rodriguez-Zavala, JS; Celis, H; Zarco-Zavala, M; Garcia-Trejo, JJ				Morales-Rios, Edgar; de la Rosa-Morales, Fernanda; Mendoza-Hernandez, Guillermo; Rodriguez-Zavala, Jose S.; Celis, Heliodoro; Zarco-Zavala, Mariel; Garcia-Trejo, Jose J.			A novel 11-kDa inhibitory subunit in the F1FO ATP synthase of Paracoccus denitrificans and related alpha-proteobacteria	FASEB JOURNAL			English	Article						inhibitor; F1FO ATPase; nanomotor; rhodobacteraceae	BLUE NATIVE ELECTROPHORESIS; OXIDATIVE-PHOSPHORYLATION; RHODOSPIRILLUM-RUBRUM; F1F0-ATP SYNTHASE; STRUCTURAL BASIS; EPSILON-SUBUNIT; PURIFICATION; PROTEIN; RESOLUTION; ROTATION	The F1FO and F-1-ATPase complexes of Paracoccus denitrificans were isolated for the first time by ion exchange, gel filtration, and density gradient centrifugation into functional native preparations. The liposome-reconstituted holoenzyme preserves its tight coupling between F-1 and F-O sectors, as evidenced by its high sensitivity to the FO inhibitors venturicidin and diciclohexylcarbodiimide. Comparison and N-terminal sequencing of the band profile in SDS-PAGE of the F-1 and F1FO preparations showed a novel 11-kDa protein in addition to the 5 canonical alpha, beta, gamma, delta, and epsilon subunits present in all known F-1-ATPase complexes. BN-PAGE followed by 2D-SDS-PAGE confirmed the presence of this 11-kDa protein bound to the native F1FO-ATP synthase of P. denitrificans, as it was observed after being isolated. The recombinant 11 kDa and epsilon subunits of P. denitrificans were cloned, overexpressed, isolated, and reconstituted in particulate F1FO and soluble F-1-ATPase complexes. The 11-kDa protein, but not the epsilon subunit, inhibited the F1FO and F-1-ATPase activities of P. denitrificans. The 11-kDa protein was also found in Rhodobacter sphaeroides associated to its native F1FO-ATPase. Taken together, the data unveil a novel inhibitory mechanism exerted by this 11-kDa protein on the F1FO-ATPase nanomotor of P. denitrificans and closely related alpha-proteobacteria.-Morales-Rios, E., de la Rosa-Morales, F., Mendoza-Hernandez, G., Rodriguez-Zavala, J. S., Celis, H., Zarco-Zavala, M., Garcia-Trejo, J. J. A novel 11-kDa inhibitory subunit in the F1FO ATP synthase of Paracoccus denitrificans and related alpha-proteobacteria. FASEB J. 24, 599-608 (2010). www.fasebj.org	[Morales-Rios, Edgar; Zarco-Zavala, Mariel; Garcia-Trejo, Jose J.] Univ Nacl Autonoma Mexico, Fac Chem, Dept Biol, Mexico City 04510, DF, Mexico; [Mendoza-Hernandez, Guillermo] Univ Nacl Autonoma Mexico, Dept Biochem, Fac Med, Mexico City 04510, DF, Mexico; [Celis, Heliodoro] Univ Nacl Autonoma Mexico, Cell Physiol Inst, Mexico City 04510, DF, Mexico; [de la Rosa-Morales, Fernanda; Rodriguez-Zavala, Jose S.] Natl Inst Cardiol, Dept Biochem, Mexico City, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; National Institute of Cardiology - Mexico	Garcia-Trejo, JJ (corresponding author), Univ Nacl Autonoma Mexico, Fac Quim, Dept Biol, Ciudad Univ,Edificio F,Lab 117, Mexico City 04510, DF, Mexico.	jjgartre@unam.mx	Rodriguez-Zavala, Jose S/AAI-3604-2020	Rodriguez-Zavala, Jose S/0000-0002-7094-5523; Morales-Rios, Edgar/0000-0003-1139-2292	National Research Council of Mexico [J34744-N, V43814-M]; UNAM	National Research Council of Mexico; UNAM(Universidad Nacional Autonoma de Mexico)	The experimental work of Alicia Castillo-Martinez and Fermin Pacheco-Moises in the initial part of this project is gratefully acknowledged. The excellent assistance of Paulina Cortes-Hernandez in the preparation of the polyclonal antibody against the 11-kDa subunit is acknowledged. Monoclonal antibodies against E. coli F1-ATPase subunits (subunit alpha) were kindly given by Prof. Roderick A. Capaldi (University of Oregon, Eugene, OR, USA). The supply of the PD1222 strain of P. denitrificans was provided by Juan Carlos Estrada-Mora (director of the Collection of Microbial Cultures, CIN-VESTAV-IPN, Mexico City, Mexico). This strain is also known as CDBB-B-912, according to the registration in the World Federation for Culture Collection. The collaborative efforts of Mario F. Fuentes-Iniestra [head librarian, Instituto Nacional de Cardiologia (INC), Mexico City, Mexico], in literature acquisition and submission of data are also acknowledged. The critical reading and excellent suggestions for the manuscript of Prof. Armando Gomez-Puyou are gratefully acknowledged. This work was supported by two consecutive research projects from the National Research Council of Mexico (CONACyT; projects J34744-N and V43814-M) and by a recent grant from UNAM under the program Direccion General de Asuntos del Personal Academico-Programa de Apoyo a Proyectos de Investigacion e Innovacion Technologica (DGAPA-PAPIIT) 2009, (project IN213809-3).	Aggeler R, 2002, J BIOL CHEM, V277, P33906, DOI 10.1074/jbc.M204538200; Bald D, 2001, J BIOL CHEM, V276, P39505, DOI 10.1074/jbc.C100436200; BERRY EA, 1985, J BIOL CHEM, V260, P2458; Brosche M, 1998, EUR J BIOCHEM, V255, P87, DOI 10.1046/j.1432-1327.1998.2550087.x; Cook GM, 2003, J BACTERIOL, V185, P4442, DOI 10.1128/JB.185.15.4442-4449.2003; Cortes-Hernandez P, 2007, J BIOL CHEM, V282, P1051, DOI 10.1074/jbc.M606828200; DEVRIES GE, 1989, ARCH MICROBIOL, V152, P52, DOI 10.1007/BF00447011; Enroth C, 2008, BBA-PROTEINS PROTEOM, V1784, P379, DOI 10.1016/j.bbapap.2007.11.005; Etzold C, 1997, EUR J BIOCHEM, V243, P336, DOI 10.1111/j.1432-1033.1997.0336a.x; FALK G, 1988, BIOCHEM J, V254, P109, DOI 10.1042/bj2540109; FALK G, 1985, BIOCHEM J, V228, P391, DOI 10.1042/bj2280391; Feniouk Boris A., 2008, V45, P279, DOI 10.1007/400_2007_043; Fiske CH, 1925, J BIOL CHEM, V66, P375; Garcia JJ, 1998, J BIOL CHEM, V273, P15940, DOI 10.1074/jbc.273.26.15940; Garcia-Trejo JJ, 2008, J BIOL PHYS, V34, P197, DOI 10.1007/s10867-008-9114-z; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; HARRIS DA, 1977, BIOCHIM BIOPHYS ACTA, V459, P546, DOI 10.1016/0005-2728(77)90053-6; Iino R, 2009, J BIOL CHEM, V284, P17457, DOI 10.1074/jbc.M109.003798; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JOHANSSON BC, 1975, FEBS LETT, V53, P221, DOI 10.1016/0014-5793(75)80024-X; JOHN P, 1975, NATURE, V254, P495, DOI 10.1038/254495a0; Keis S, 2006, J BACTERIOL, V188, P3796, DOI 10.1128/JB.00040-06; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Masaike T, 2006, BIOCHEM BIOPH RES CO, V342, P800, DOI 10.1016/j.bbrc.2006.02.017; Minauro-Sanmiguel F, 2005, P NATL ACAD SCI USA, V102, P12356, DOI 10.1073/pnas.0503893102; Minauro-Sanmiguel F, 2002, J BIOENERG BIOMEMBR, V34, P433, DOI 10.1023/A:1022514008462; MULLER H, 1982, EUR J BIOCHEM, V127, P559; NORLING B, 1988, BIOCHIM BIOPHYS ACTA, V935, P123, DOI 10.1016/0005-2728(88)90209-5; OHKUBO S, 1986, J BIOCHEM, V100, P1261, DOI 10.1093/oxfordjournals.jbchem.a121832; Ozaki Y, 2008, BIOCHEM BIOPH RES CO, V367, P663, DOI 10.1016/j.bbrc.2007.12.170; Pacheco-Moises F, 2002, J BIOENERG BIOMEMBR, V34, P269, DOI 10.1023/A:1020252401675; Pacheco-Moises F, 2000, EUR J BIOCHEM, V267, P993, DOI 10.1046/j.1432-1327.2000.01088.x; PENNOYER JD, 1988, BIOCHIM BIOPHYS ACTA, V935, P195, DOI 10.1016/0005-2728(88)90216-2; PEREZ JA, 1990, BIOCHEMISTRY-US, V29, P10503, DOI 10.1021/bi00498a013; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRINGLE MJ, 1985, BIOCHEMISTRY-US, V24, P7366, DOI 10.1021/bi00346a051; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SOSA A, 1995, ARCH BIOCHEM BIOPHYS, V316, P421, DOI 10.1006/abbi.1995.1056; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; Stocker A, 2007, STRUCTURE, V15, P904, DOI 10.1016/j.str.2007.06.009; TUENADEGOMEZPUYOU M, 1977, ARCH BIOCHEM BIOPHYS, V182, P82; WILLIAMS N, 1986, METHOD ENZYMOL, V126, P477; YAGI T, 1986, ARCH BIOCHEM BIOPHYS, V250, P302, DOI 10.1016/0003-9861(86)90731-9; Zharova TV, 2003, BIOCHEMISTRY-MOSCOW+, V68, P1101, DOI 10.1023/A:1026306611821	48	41	43	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					599	608		10.1096/fj.09-137356	http://dx.doi.org/10.1096/fj.09-137356			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19783785				2022-12-28	WOS:000274045000027
J	Obrdlik, A; Louvet, E; Kukalev, A; Naschekin, D; Kiseleva, E; Fahrenkrog, B; Percipalle, P				Obrdlik, Ales; Louvet, Emilie; Kukalev, Alexander; Naschekin, Dmitri; Kiseleva, Elena; Fahrenkrog, Birthe; Percipalle, Piergiorgio			Nuclear myosin 1 is in complex with mature rRNA transcripts and associates with the nuclear pore basket	FASEB JOURNAL			English	Article						preribosomal subunits; NPC; rRNA nuclear export	POLYMERASE-I TRANSCRIPTION; CHAIN-LIKE POLYPEPTIDE; GENE-EXPRESSION; EXPORT; SUBUNITS; ACTIN; NUP153; TRANSPORT; NUCLEOLUS; MESSENGER	In rRNA biogenesis, nuclear myosin 1 (NM1) and actin synergize to activate rRNA gene transcription. Evidence that actin is in preribosomal subunits and NM1 may control rRNA biogenesis post-transcriptionally prompted us to investigate whether NM1 associates with and accompanies rRNA to nuclear pores (NPC). Ultracentrifugation on HeLa nucleolar extracts showed RNA-dependent NM1 coelution with preribosomal subunits. In RNA immunoprecipitations (RIPs), NM1 coprecipitated with pre-rRNAs and 18S, 5.8S, and 28S rRNAs, but failed to precipitate 5S rRNA and 7SL RNA. In isolated nuclei and living HeLa cells, NM1 or actin inhibition and selective alterations in actin polymerization impaired 36S pre-rRNA processing. Immunoelectron microscopy (IEM) on sections of manually isolated Xenopus oocyte nuclei showed NM1 localization at the NPC basket. Field emission scanning IEM on isolated nuclear envelopes and intranuclear content confirmed basket localization and showed that NM1 decorates actin-rich pore-linked filaments. Finally, RIP and successive RIPs ( reRIPs) on cross-linked HeLa cells demonstrated that NM1, CRM1, and Nup153 precipitate same 18S and 28S rRNAs but not 5S rRNA. We conclude that NM1 facilitates maturation and accompanies export-competent preribosomal subunits to the NPC, thus modulating export.-Obrdlik, A., Louvet, E., Kukalev, A., Naschekin, D., Kiseleva, E., Fahrenkrog, B., Percipalle, P. Nuclear myosin 1 is in complex with mature rRNA transcripts and associates with the nuclear pore basket. FASEB J. 24, 146-157 ( 2010). www.fasebj.org	[Obrdlik, Ales; Louvet, Emilie; Kukalev, Alexander; Naschekin, Dmitri; Percipalle, Piergiorgio] Karolinska Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; [Kiseleva, Elena] Russian Acad Sci, Inst Cytol & Genet, Novosibirsk 630090, Russia; [Fahrenkrog, Birthe] Univ Basel, Biozentrum, Basel, Switzerland	Karolinska Institutet; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; University of Basel	Percipalle, P (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Box 285, SE-17177 Stockholm, Sweden.	piergiorgio.percipalle@ki.se	Fahrenkrog, Birthe/D-5840-2011	Nashchekin, Dmitry/0000-0001-7372-0752; Fahrenkrog, Birthe/0000-0003-4080-9413; Kiseleva, Elena/0000-0001-6949-182X; Obrdlik, Ales/0000-0001-8499-3879	Swedish Research Council (Vetenskapsradet); Fondation pour la Recherche Medicale; Wenner-Gren Foundation; Wellcome Trust; Russian Foundation for Basic Research; Russian Academy of Sciences Molecular and Cellular Biology (MCB RAS) program	Swedish Research Council (Vetenskapsradet)(Swedish Research Council); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Wenner-Gren Foundation; Wellcome Trust(Wellcome TrustEuropean Commission); Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); Russian Academy of Sciences Molecular and Cellular Biology (MCB RAS) program(Russian Academy of Sciences)	This work was supported by grants from the Swedish Research Council (Vetenskapsradet) to P. P. E. L. received postdoctoral fellowships from the Fondation pour la Recherche Medicale and the Wenner-Gren Foundation. E. K. was supported with grants from the Wellcome Trust, the Russian Foundation for Basic Research, and the Russian Academy of Sciences Molecular and Cellular Biology (MCB RAS) program.	Ball JR, 2004, RNA, V10, P19, DOI 10.1261/rna.5109104; BASCHONG W, 1990, J ELECTRON MICR TECH, V14, P313, DOI 10.1002/jemt.1060140405; BERRIOS M, 1986, J CELL BIOL, V103, P711, DOI 10.1083/jcb.103.3.711; BERRIOS M, 1991, P NATL ACAD SCI USA, V88, P219, DOI 10.1073/pnas.88.1.219; Cavellan E, 2006, J BIOL CHEM, V281, P16264, DOI 10.1074/jbc.M600233200; Cisterna B, 2006, FASEB J, V20, P1901, DOI 10.1096/fj.05-5278fje; Cisterna B, 2009, HISTOCHEM CELL BIOL, V131, P743, DOI 10.1007/s00418-009-0583-3; Fahrenkrog B, 2002, J STRUCT BIOL, V140, P254, DOI 10.1016/S1047-8477(02)00524-5; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Fomproix N, 2004, EXP CELL RES, V294, P140, DOI 10.1016/j.yexcr.2003.10.028; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; Granneman S, 2005, CURR OPIN CELL BIOL, V17, P281, DOI 10.1016/j.ceb.2005.04.001; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Hase ME, 2001, MOL BIOL CELL, V12, P2433, DOI 10.1091/mbc.12.8.2433; Hetzer MW, 2005, ANNU REV CELL DEV BI, V21, P347, DOI 10.1146/annurev.cellbio.21.090704.151152; Hofmann WA, 2006, BIOCHEM CELL BIOL, V84, P418, DOI 10.1139/O06-069; Hofmann WA, 2009, J CELL SCI, V122, P636, DOI 10.1242/jcs.030205; Holaska JM, 2007, BIOCHEMISTRY-US, V46, P8897, DOI 10.1021/bi602636m; Johnson AW, 2002, TRENDS BIOCHEM SCI, V27, P580, DOI 10.1016/S0968-0004(02)02208-9; Kahle M, 2007, HISTOCHEM CELL BIOL, V127, P139, DOI 10.1007/s00418-006-0231-0; Kiseleva E, 2004, J CELL SCI, V117, P2481, DOI 10.1242/jcs.01098; Louvet E, 2009, INT REV CEL MOL BIO, V272, P107, DOI 10.1016/S1937-6448(08)01603-1; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Obrdlik A, 2008, MOL CELL BIOL, V28, P6342, DOI 10.1128/MCB.00766-08; OCHS RL, 1985, CHROMOSOMA, V92, P330, DOI 10.1007/BF00327463; Oeffinger M, 2007, NAT METHODS, V4, P951, DOI 10.1038/NMETH1101; Orru S, 2007, MOL CELL PROTEOMICS, V6, P382, DOI 10.1074/mcp.M600156-MCP200; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; Pante N, 2000, J STRUCT BIOL, V129, P306, DOI 10.1006/jsbi.2000.4232; Paulillo SM, 2005, J MOL BIOL, V351, P784, DOI 10.1016/j.jmb.2005.06.034; Pederson T, 2000, J CELL BIOL, V148, P1091, DOI 10.1083/jcb.148.6.1091; Percipalle P, 2006, EMBO REP, V7, P525, DOI 10.1038/sj.embor.7400657; Percipalle P, 2009, CELL MOL LIFE SCI, V66, P2151, DOI 10.1007/s00018-009-0012-8; Philimonenko VV, 2004, NAT CELL BIOL, V6, P1165, DOI 10.1038/ncb1190; Politz JCR, 2003, MOL BIOL CELL, V14, P4805, DOI 10.1091/mbc.E03-06-0395; Rouquette J, 2005, EMBO J, V24, P2862, DOI 10.1038/sj.emboj.7600752; SCHINDLER M, 1986, J CELL BIOL, V102, P859, DOI 10.1083/jcb.102.3.859; Smythe C, 2000, EMBO J, V19, P3918, DOI 10.1093/emboj/19.15.3918; Soop T, 2005, MOL BIOL CELL, V16, P5610, DOI 10.1091/mbc.E05-08-0715; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Thomas F, 2003, J CELL SCI, V116, P2409, DOI 10.1242/jcs.00464; Trotta CR, 2003, EMBO J, V22, P2841, DOI 10.1093/emboj/cdg249; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; Wilson DN, 2005, CRIT REV BIOCHEM MOL, V40, P243, DOI 10.1080/10409230500256523; Yao W, 2007, MOL CELL, V26, P51, DOI 10.1016/j.molcel.2007.02.018; Zemp I, 2007, FEBS LETT, V581, P2783, DOI 10.1016/j.febslet.2007.05.013	47	31	33	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					146	157		10.1096/fj.09-135863	http://dx.doi.org/10.1096/fj.09-135863			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19729515				2022-12-28	WOS:000273233600017
J	Trotard, M; Lepere-Douard, C; Regeard, M; Piquet-Pellorce, C; Lavillette, D; Cosset, FL; Gripon, P; Le Seyec, J				Trotard, Maud; Lepere-Douard, Charlotte; Regeard, Morgane; Piquet-Pellorce, Claire; Lavillette, Dimitri; Cosset, Francois-Loic; Gripon, Philippe; Le Seyec, Jacques			Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening	FASEB JOURNAL			English	Article						hepacivirus; virus internalization; endocytosis; replicon; 1-phosphatidylinositol 4-kinase	CLATHRIN-MEDIATED ENDOCYTOSIS; DENSITY-LIPOPROTEIN RECEPTOR; PRIMARY HUMAN HEPATOCYTES; EFFICIENT REPLICATION; SCAVENGER RECEPTOR; PHOSPHATIDYLINOSITOL 4-KINASE; CELL-CULTURE; HOST-CELLS; IN-VITRO; INFECTION	The entry pathway of the hepatitis C virus (HCV), a major human pathogen, into the cell is incompletely defined. To better characterize this viral life cycle stage, we screened a small interfering RNA library dedicated to the membrane trafficking and remodeling with the infection model of Huh-7.5.1 cells by HCV pseudoparticles (HCVpp). Results showed that the down-regulation of different factors implied in clathrin-mediated endocytosis (CME) inhibits HCVpp cell infection. In addition, knockdown of the phosphatidylinositol 4-kinase type III-alpha (PI4KIII alpha) prevented infection by HCVpp or by cell-culture grown JFH-1-based HCV. Moreover, the replication activity of an HCV replicon was also affected by the PI4KIII alpha knockdown. Additional investigations on the different members of the PI4K family revealed that the presence of PI4KIII beta in the host cells influenced their susceptibility to HCVpp infection and their capacity to sustain the HCV replication. The PI4KIII involvement during the HCV life cycle seemed to occur by other ways than the control of the CME or of the membranous expression of HCV receptors. Finally, our library screening completed data on the CME-dependant entry route of HCV and identified 2 kinases, PI4KIII alpha and beta, as relevant potential therapeutic targets.-Trotard, M., Lepere-Douard, C., Regeard, M., Piquet-Pellorce, C., Lavillette, D., Cosset, F.-L., Gripon, P., Le Seyec, J. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. FASEB J. 23, 3780-3789 (2009). www.fasebj.org	[Le Seyec, Jacques] Univ Rennes 1, EA SERAIC 4427, Fac Pharm, IFR 140, F-35043 Rennes, France; [Lavillette, Dimitri; Cosset, Francois-Loic] Univ Lyon, UCB Lyon1, IFR 128, Lyon, France; [Trotard, Maud; Lepere-Douard, Charlotte; Regeard, Morgane; Gripon, Philippe; Le Seyec, Jacques] INSERM, U522, Rennes, France; [Lavillette, Dimitri; Cosset, Francois-Loic] INSERM, U758, F-69008 Lyon, France; [Lavillette, Dimitri; Cosset, Francois-Loic] Ecole Normale Super Lyon, F-69364 Lyon, France	Universite de Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Ecole Normale Superieure de Lyon (ENS de LYON)	Le Seyec, J (corresponding author), Univ Rennes 1, EA SERAIC 4427, Fac Pharm, IFR 140, Ave Prof Leon Bernard, F-35043 Rennes, France.	jacques.leseyec@univ-rennes1.fr	Le Seyec, Jacques/J-5680-2015; GRIPON, Philippe/J-6068-2015; PIQUET-PELLORCE, Claire SL/I-4195-2015; Cosset, François-Loïc/M-5862-2019; Le Seyec, Jacques/GLU-3933-2022	PIQUET-PELLORCE, Claire SL/0000-0003-3198-1975; Cosset, François-Loïc/0000-0001-8842-3726; Le Seyec, Jacques/0000-0002-1118-3311; Lavillette, Dimitri/0000-0002-4706-1519				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Ahn J, 2004, J BIOCHEM MOL BIOL, V37, P741; Balla A, 2006, TRENDS CELL BIOL, V16, P351, DOI 10.1016/j.tcb.2006.05.003; Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Berger KL, 2009, P NATL ACAD SCI USA, V106, P7577, DOI 10.1073/pnas.0902693106; Blanchard E, 2006, J VIROL, V80, P6964, DOI 10.1128/JVI.00024-06; Blight KJ, 2003, J VIROL, V77, P3181, DOI 10.1128/JVI.77.5.3181-3190.2003; Bruns JR, 2002, J BIOL CHEM, V277, P2012, DOI 10.1074/jbc.M108571200; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Cormier EG, 2004, P NATL ACAD SCI USA, V101, P7270, DOI 10.1073/pnas.0402253101; DAUTRYVARSAT A, 1986, BIOCHIMIE, V68, P375, DOI 10.1016/S0300-9084(86)80004-9; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Evans MJ, 2007, NATURE, V446, P801, DOI 10.1038/nature05654; Goff SP, 2008, CELL, V135, P417, DOI 10.1016/j.cell.2008.10.007; Grove J, 2007, J VIROL, V81, P3162, DOI 10.1128/JVI.02356-06; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kato T, 2003, GASTROENTEROLOGY, V125, P1808, DOI 10.1053/j.gastro.2003.09.023; Kolokoltsov AA, 2007, J VIROL, V81, P7786, DOI 10.1128/JVI.02780-06; Koutsoudakis G, 2007, J VIROL, V81, P588, DOI 10.1128/JVI.01534-06; Lavillette D, 2005, HEPATOLOGY, V41, P265, DOI 10.1002/hep.20542; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Liu SF, 2009, J VIROL, V83, P2011, DOI 10.1128/JVI.01888-08; Meertens L, 2008, J VIROL, V82, P3555, DOI 10.1128/JVI.01977-07; Meertens L, 2006, J VIROL, V80, P11571, DOI 10.1128/JVI.01717-06; Molina S, 2008, J VIROL, V82, P569, DOI 10.1128/JVI.01443-07; Molina S, 2007, J HEPATOL, V46, P411, DOI 10.1016/j.jhep.2006.09.024; NAGY K, 1983, INT J CANCER, V32, P321, DOI 10.1002/ijc.2910320310; Negre D, 2000, GENE THER, V7, P1613, DOI 10.1038/sj.gt.3301292; Perrais D, 2005, DEV CELL, V9, P581, DOI 10.1016/j.devcel.2005.10.002; Ploss A, 2009, NATURE, V457, P882, DOI 10.1038/nature07684; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Rumin S, 1999, J GEN VIROL, V80, P3007, DOI 10.1099/0022-1317-80-11-3007; Shears SB, 2001, CELL SIGNAL, V13, P151, DOI 10.1016/S0898-6568(01)00129-2; Sun XJ, 2005, VIROLOGY, V338, P53, DOI 10.1016/j.virol.2005.05.006; Tai AW, 2009, CELL HOST MICROBE, V5, P298, DOI 10.1016/j.chom.2009.02.001; Takeuchi T, 1999, GASTROENTEROLOGY, V116, P636, DOI 10.1016/S0016-5085(99)70185-X; Thomson BJ, 2005, CLIN MICROBIOL INFEC, V11, P86, DOI 10.1111/j.1469-0691.2004.01061.x; Tscherne DM, 2006, J VIROL, V80, P1734, DOI 10.1128/JVI.80.4.1734-1741.2006; Vaillancourt FH, 2009, VIROLOGY, V387, P5, DOI 10.1016/j.virol.2009.02.039; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P341; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; Zeisel MB, 2007, HEPATOLOGY, V46, P1722, DOI 10.1002/hep.21994; Zheng AH, 2007, J VIROL, V81, P12465, DOI 10.1128/JVI.01457-07; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102; Zoncu R, 2007, P NATL ACAD SCI USA, V104, P3793, DOI 10.1073/pnas.0611733104	48	114	117	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3780	3789		10.1096/fj.09-131920	http://dx.doi.org/10.1096/fj.09-131920			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19608626				2022-12-28	WOS:000271272500015
J	Shen, H; Kuo, CC; Chou, J; Delvolve, A; Jackson, SN; Post, J; Woods, AS; Hoffer, BJ; Wang, Y; Harvey, BK				Shen, Hui; Kuo, Chi-Chung; Chou, Jenny; Delvolve, Alice; Jackson, Shelley N.; Post, Jeremy; Woods, Amina S.; Hoffer, Barry J.; Wang, Yun; Harvey, Brandon K.			Astaxanthin reduces ischemic brain injury in adult rats	FASEB JOURNAL			English	Article						antioxidant; stroke; neuroprotection; apoptosis; glutamate	FOCAL CEREBRAL-ISCHEMIA; ALGA HAEMATOCOCCUS-PLUVIALIS; PENAEUS-MONODON FABRICIUS; NIVALIS BAUER WILLE; OXIDATIVE STRESS; RAINBOW-TROUT; DIETARY SUPPLEMENTATION; SYNTHETIC ASTAXANTHIN; ANTIOXIDANT ACTIVITY; ONCORHYNCHUS-MYKISS	Astaxanthin (ATX) is a dietary carotenoid of crustaceans and fish that contributes to their coloration. Dietary ATX is important for development and survival of salmonids and crustaceans and has been shown to reduce cardiac ischemic injury in rodents. The purpose of this study was to examine whether ATX can protect against ischemic injury in the mammalian brain. Adult rats were injected intracerebroventricularly with ATX or vehicle prior to a 60-min middle cerebral artery occlusion (MCAo). ATX was present in the infarction area at 70-75 min after onset of MCAo. Treatment with ATX, compared to vehicle, increased locomotor activity in stroke rats and reduced cerebral infarction at 2 d after MCAo. To evaluate the protective mechanisms of ATX against stroke, brain tissues were assayed for free radical damage, apoptosis, and excitoxicity. ATX antagonized ischemia-mediated loss of aconitase activity and reduced glutamate release, lipid peroxidation, translocation of cytochrome c, and TUNEL labeling in the ischemic cortex. ATX did not alter physiological parameters, such as body temperature, brain temperature, cerebral blood flow, blood gases, blood pressure, and pH. Collectively, our data suggest that ATX can reduce ischemia-related injury in brain tissue through the inhibition of oxidative stress, reduction of glutamate release, and antiapoptosis. ATX may be clinically useful for patients vulnerable or prone to ischemic events.-Shen, H., Kuo, C.-C., Chou, J., Delvolve, A., Jackson, S. N., Post, J., Woods, A. S., Hoffer, B. J., Wang, Y., Harvey, B. K. Astaxanthin reduces ischemic brain injury in adult rats. FASEB J. 23, 1958-1968 (2009)	[Shen, Hui; Kuo, Chi-Chung; Chou, Jenny; Delvolve, Alice; Jackson, Shelley N.; Post, Jeremy; Woods, Amina S.; Hoffer, Barry J.; Wang, Yun; Harvey, Brandon K.] NIDA, NIH, Intramural Res Program, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Harvey, BK (corresponding author), NIDA, NIH, Intramural Res Program, Ste 200,Rm 06A729,251 Bayview Blvd, Baltimore, MD 21224 USA.	bharvey@intra.nida.nih.gov	Harvey, Brandon Keith/AAY-4080-2021	Harvey, Brandon Keith/0000-0002-4036-1383	Intramural Research Program at the National Institute on Drug Abuse (USA); NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000461, ZIADA000443, Z01DA000461] Funding Source: NIH RePORTER	Intramural Research Program at the National Institute on Drug Abuse (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by the Intramural Research Program at the National Institute on Drug Abuse (USA). We thank Mr. Douglas Howard and Dr. Guann-Juh Chen for their technical assistance, Dr. Michael Tlusty for his photograph of the lobsters and his input on ATX in crustaceans, and Dr. Marc Halterman for his review and comments on the manuscript.	Amar EC, 2001, AQUAC RES, V32, P162, DOI 10.1046/j.1355-557x.2001.00051.x; Aoi W, 2003, ANTIOXID REDOX SIGN, V5, P139, DOI 10.1089/152308603321223630; Ascherio A, 1999, ANN INTERN MED, V130, P963, DOI 10.7326/0003-4819-130-12-199906150-00003; Bell JG, 2000, J NUTR, V130, P1800, DOI 10.1093/jn/130.7.1800; Bertram JS, 2005, BBA-MOL BASIS DIS, V1740, P170, DOI 10.1016/j.bbadis.2005.01.003; CAMERA E, 2009, EXP DERMATOL    0918; Chang CF, 2002, NEUROPHARMACOLOGY, V43, P418, DOI 10.1016/S0028-3908(02)00092-8; Chaumont D, 1995, J APPL PHYCOL, V7, P529, DOI 10.1007/BF00003939; Chen GJ, 2006, J NEUROSCI RES, V84, P1848, DOI 10.1002/jnr.21071; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; Chien YH, 2005, J EXP MAR BIOL ECOL, V318, P201, DOI 10.1016/j.jembe.2004.12.016; Chien YH, 2003, AQUACULTURE, V216, P177, DOI 10.1016/S0044-8486(02)00056-X; Clark WM, 2001, STROKE, V32, P1000, DOI 10.1161/01.STR.32.4.1000; Deng XL, 2001, MOL BRAIN RES, V93, P64, DOI 10.1016/S0169-328X(01)00184-X; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Flores M, 2007, AQUAC RES, V38, P740, DOI 10.1111/j.1365-2109.2007.01720.x; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; Gorton HL, 2003, PHOTOCHEM PHOTOBIOL, V77, P608, DOI 10.1562/0031-8655(2003)077<0608:URATSA>2.0.CO;2; Gorton HL, 2001, PHOTOCHEM PHOTOBIOL, V73, P611, DOI 10.1562/0031-8655(2001)073<0611:TLEACO>2.0.CO;2; Gross GJ, 2005, MOL CELL BIOCHEM, V272, P221, DOI 10.1007/s11010-005-7555-2; Gross GJ, 2004, LIFE SCI, V75, P215, DOI 10.1016/j.lfs.2003.12.006; Harvey BK, 2004, NEUROSCI LETT, V369, P138, DOI 10.1016/j.neulet.2004.07.086; Haskew-Layton RE, 2005, J BIOL CHEM, V280, P3548, DOI 10.1074/jbc.M409803200; Hirvonen T, 2000, STROKE, V31, P2301, DOI 10.1161/01.STR.31.10.2301; Hsiao G, 2004, IN VIVO, V18, P351; Hurtado O, 2003, FASEB J, V17, P2082, DOI 10.1096/fj.02-1086fje; Hussein G, 2005, BIOL PHARM BULL, V28, P47, DOI 10.1248/bpb.28.47; Imai H, 2001, STROKE, V32, P2149, DOI 10.1161/hs0901.095725; Jackson SN, 2007, J MASS SPECTROM, V42, P1093, DOI 10.1002/jms.1245; Khanna S, 2005, STROKE, V36, pE144, DOI 10.1161/01.STR.0000181082.70763.22; Kobayashi M, 2000, APPL MICROBIOL BIOT, V54, P550, DOI 10.1007/s002530000416; Lee SJ, 2003, MOL CELLS, V16, P97; Leinonen JS, 2000, STROKE, V31, P33, DOI 10.1161/01.STR.31.1.33; Lin SZ, 1996, STROKE, V27, P747, DOI 10.1161/01.STR.27.4.747; Liu XB, 2007, BIOCHEM BIOPH RES CO, V357, P187, DOI 10.1016/j.bbrc.2007.03.120; Lockwood SF, 2005, CARDIOVASC DRUG REV, V23, P199; Lyons NM, 2002, J DERMATOL SCI, V30, P73, DOI 10.1016/S0923-1811(02)00063-4; Mackensen GB, 2001, J NEUROSCI, V21, P4582, DOI 10.1523/JNEUROSCI.21-13-04582.2001; Mailly F, 1999, J NEUROCHEM, V73, P1181, DOI 10.1046/j.1471-4159.1999.0731181.x; Merchie G, 1998, AQUAC RES, V29, P579, DOI 10.1111/j.1365-2109.1998.tb01171.x; MIKI W, 1991, PURE APPL CHEM, V63, P141, DOI 10.1351/pac199163010141; Naguib YMA, 2000, J AGR FOOD CHEM, V48, P1150, DOI 10.1021/jf991106k; Nakajima Y, 2008, J PHARM PHARMACOL, V60, P1365, DOI 10.1211/jpp/60.10.0013; Nakano T, 1999, BBA-GEN SUBJECTS, V1426, P119, DOI 10.1016/S0304-4165(98)00145-7; NAKANO T, 1995, J AGR FOOD CHEM, V43, P1570, DOI 10.1021/jf00054a029; Namura S, 2001, STROKE, V32, P1906, DOI 10.1161/01.STR.32.8.1906; Page GI, 2005, COMP BIOCHEM PHYS B, V142, P398, DOI 10.1016/j.cbpb.2005.09.001; Pan CH, 2003, J EXP MAR BIOL ECOL, V297, P107, DOI 10.1016/j.jembe.2003.07.002; Pan CH, 2001, ZOOL STUD, V40, P371; Pangantihon-Kuhlmann MP, 1998, AQUAT LIVING RESOUR, V11, P403, DOI 10.1016/S0990-7440(99)80006-0; Shen H, 2005, STROKE, V36, P654, DOI 10.1161/01.STR.0000155747.15679.04; Shen H, 2009, J NEUROSCI RES, V87, P545, DOI 10.1002/jnr.21865; Spiller Gene A., 2003, Journal of Medicinal Food, V6, P51, DOI 10.1089/109662003765184741; Steinbrenner J, 2003, PLANT MOL BIOL, V52, P343, DOI 10.1023/A:1023948929665; Tomac AC, 2002, P NATL ACAD SCI USA, V99, P9521, DOI 10.1073/pnas.152535899; Tsai SK, 2007, J VASC SURG, V46, P346, DOI 10.1016/j.jvs.2007.04.044; Vine AL, 2005, MOL CARCINOGEN, V43, P75, DOI 10.1002/mc.20080; Wang HYJ, 2008, INT J MASS SPECTROM, V278, P143, DOI 10.1016/j.ijms.2008.04.005; Wang Y, 2003, J NEUROSCI, V23, P7958; Wang Y, 2005, EXP NEUROL, V193, P75, DOI 10.1016/j.expneurol.2004.12.014; Wang Y, 2001, STROKE, V32, P2170, DOI 10.1161/hs0901.095650; Wu TH, 2006, J AGR FOOD CHEM, V54, P2418, DOI 10.1021/jf052651q; Zhang WR, 2000, NEUROL RES, V22, P517	63	100	113	0	44	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1958	1968		10.1096/fj.08-123281	http://dx.doi.org/10.1096/fj.08-123281			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19218497	Green Published			2022-12-28	WOS:000266652400034
J	Lapucci, A; Lulli, M; Amedei, A; Papucci, L; Witort, E; Di Gesualdo, F; Bertolini, F; Brewer, G; Nicolin, A; Bevilacqua, A; Schiavone, N; Morello, D; Donnini, M; Capaccioli, S				Lapucci, Andrea; Lulli, Matteo; Amedei, Amedeo; Papucci, Laura; Witort, Ewa; Di Gesualdo, Federico; Bertolini, Francesco; Brewer, Gary; Nicolin, Angelo; Bevilacqua, Annamaria; Schiavone, Nicola; Morello, Dominique; Donnini, Martino; Capaccioli, Sergio			zeta-Crystallin is a bcl-2 mRNA binding protein involved in bcl-2 overexpression in T-cell acute lymphocytic leukemia	FASEB JOURNAL			English	Article						post-transcriptional control; cancer; ARE-binding protein	ACUTE LYMPHOBLASTIC-LEUKEMIA; GUINEA-PIG LENS; GENE-EXPRESSION; QUINONE REDUCTASE; UP-REGULATION; ELEMENT; IDENTIFICATION; APOPTOSIS; STABILIZATION; PURIFICATION	The human antiapoptotic bcl-2 gene has been discovered in t(14; 18) B-cell leukemias/lymphomas because of its overexpression caused at a transcriptional control level by the bcl-2/IgH fusion gene. We were the first to disclose the post-transcriptional control of bcl-2 expression mediated by interactions of an adenine + uracil (AU)-rich element (ARE) in the 3'-UTR of bcl-2 mRNA with AU-binding proteins (AUBPs). Here, we identify and characterize zeta-crystallin as a new bcl-2 AUBP, whose silencing or overexpression has impact on bcl-2 mRNA stability. An increased Bcl-2 level observed in normal phytohemagglutinin (PHA)-activated T lymphocytes, acute lymphatic leukemia (ALL) T-cell lines, and T cells of patients with leukemia in comparison with normal non-PHA-activated T lymphocytes was concomitant with an increase in zeta-crystallin level. The specific association of zeta-crystallin with the bcl-2 ARE was significantly enhanced in T cells of patients with ALL, which accounts for the higher stability of bcl-2 mRNA and suggests a possible contribution of zeta-crystallin to bcl-2 overexpression occurring in this leukemia.-Lapucci, A., Lulli, M., Amedei, A., Papucci, L., Witort, E., Di Gesualdo, F., Bertolini, F., Brewer, G., Nicolin, A., Bevilacqua, A., Schiavone, N., Morello, D., Donnini, M., Capaccioli, S. zeta-Crystallin is a bcl-2 mRNA binding protein involved in bcl-2 overexpression in T-cell acute lymphocytic leukemia. FASEB J. 24, 1852-1865 (2010). www.fasebj.org	[Lapucci, Andrea; Lulli, Matteo; Papucci, Laura; Witort, Ewa; Di Gesualdo, Federico; Schiavone, Nicola; Donnini, Martino; Capaccioli, Sergio] Univ Florence, Dept Expt Pathol & Oncol, I-50134 Florence, Italy; [Amedei, Amedeo] Univ Florence, Immunol Sect, Dept Internal Med, I-50134 Florence, Italy; [Lapucci, Andrea; Lulli, Matteo; Papucci, Laura; Witort, Ewa; Di Gesualdo, Federico; Donnini, Martino; Capaccioli, Sergio] Unit Ist Toscano Tumori, Florence, Italy; [Lapucci, Andrea; Lulli, Matteo; Amedei, Amedeo; Di Gesualdo, Federico; Brewer, Gary; Morello, Dominique; Donnini, Martino; Capaccioli, Sergio] Phoenix Stem Cell Fdn Human Life, Florence, Italy; [Bertolini, Francesco] European Inst Oncol, Div Clin Hematooncol, Milan, Italy; [Brewer, Gary] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08854 USA; [Nicolin, Angelo; Bevilacqua, Annamaria] Univ Milan, Dept Pharmacol, Milan, Italy; [Morello, Dominique] Univ Toulouse 3, Ctr Dev Biol, F-31062 Toulouse, France	University of Florence; University of Florence; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; IRCCS European Institute of Oncology (IEO); Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Milan; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Donnini, M (corresponding author), Univ Florence, Dept Expt Pathol & Oncol, Viale GB Morgagni 50, I-50134 Florence, Italy.	martinod@unifi.it; sergio@unifi.it	Bevilacqua, Annamaria/C-6357-2008; Amedei, Amedeo/G-5378-2011; Lapucci, Andrea/AAA-6645-2019; Lulli, Matteo/M-5377-2019; Lulli, Matteo/J-8623-2016; bertolini, francesco/AAC-9780-2019	Bevilacqua, Annamaria/0000-0002-3136-3424; Amedei, Amedeo/0000-0002-6797-9343; Lulli, Matteo/0000-0002-8528-4094; Lulli, Matteo/0000-0002-8528-4094; bertolini, francesco/0000-0001-5660-3255; LAPUCCI, Andrea/0000-0001-9613-7164; Papucci, Laura/0000-0002-8450-7428; Schiavone, Nicola/0000-0002-1592-4244	Programmi di Ricerca di Interesse Nazionale; Associazione Italiana per la Ricerca sul Cancro; Ente Cassa di Risparmio di Firenze; Fondazione Cassa di Risparmio di Lucca; U.S. National Institutes of Health [R01 CA052443]; NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER	Programmi di Ricerca di Interesse Nazionale; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Ente Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze); Fondazione Cassa di Risparmio di Lucca; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Professors Vieri Boddi and Riccardo Caldini for help with the statistical analysis, Dr. J. Samuel Zigler, Jr. (National Eye Institute, Bethesda, MD, USA) for the contribution of the anti-zeta-crystallin antibody, and Professor Mary Forrest and Dr. Carolyn Demsey for accurate editing of the article. This work was supported by grants from Programmi di Ricerca di Interesse Nazionale (to S. C. and A. N.), the Associazione Italiana per la Ricerca sul Cancro (to S. C.), the Ente Cassa di Risparmio di Firenze (to S. C.), the Fondazione Cassa di Risparmio di Lucca (to S. C.), and the U.S. National Institutes of Health (R01 CA052443 to G. B.).	Abraham RT, 2004, NAT REV IMMUNOL, V4, P301, DOI 10.1038/nri1330; Amedei A, 2001, EUR J IMMUNOL, V31, P1927, DOI 10.1002/1521-4141(200106)31:6<1927::AID-IMMU1927>3.0.CO;2-D; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Barata JT, 2001, BLOOD, V98, P1524, DOI 10.1182/blood.V98.5.1524; Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Bevilacqua A, 2003, J BIOL CHEM, V278, P23451, DOI 10.1074/jbc.M210620200; Bevilacqua A, 2007, MOL PHARMACOL, V71, P531, DOI 10.1124/mol.106.029041; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Borgmann A, 2003, BLOOD, V101, P3835, DOI 10.1182/blood.V101.10.3835; Bose SK, 2006, BIOCHEM J, V396, P99, DOI 10.1042/BJ20051548; Capaccioli S, 1996, ONCOGENE, V13, P105; CHESSELLS JM, BR J HAEMATOL, V102, P423; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cok SJ, 2004, J BIOL CHEM, V279, P8196, DOI 10.1074/jbc.M308475200; Donnini M, 2004, J BIOL CHEM, V279, P20154, DOI 10.1074/jbc.M314071200; Donnini M, 2001, BIOCHEM BIOPH RES CO, V287, P1063, DOI 10.1006/bbrc.2001.5700; DUHAIMAN AS, 1995, BIOCHEM BIOPH RES CO, V215, P632, DOI 10.1006/bbrc.1995.2511; Fernandez MR, 2007, CELL MOL LIFE SCI, V64, P1419, DOI 10.1007/s00018-007-7091-1; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Fujii Y, 2001, J BIOL CHEM, V276, P28134, DOI 10.1074/jbc.M102880200; GALA JL, 1994, ANN HEMATOL, V69, P17, DOI 10.1007/BF01757343; GARLAND D, 1991, ARCH BIOCHEM BIOPHYS, V285, P134, DOI 10.1016/0003-9861(91)90339-K; Gaynon PS, 1998, CANCER, V82, P1387, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1387::AID-CNCR24>3.0.CO;2-1; Ghisolfi L, 2009, J BIOL CHEM, V284, P20946, DOI 10.1074/jbc.M109.023721; GONZALEZ P, 1993, BIOCHEM BIOPH RES CO, V191, P902, DOI 10.1006/bbrc.1993.1302; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; Graux C, 2006, LEUKEMIA, V20, P1496, DOI 10.1038/sj.leu.2404302; Harrison Christine J, 2002, Rev Clin Exp Hematol, V6, P91, DOI 10.1046/j.1468-0734.2002.00069.x; HUANG QL, 1987, CURR EYE RES, V6, P725, DOI 10.3109/02713688709034836; Ibrahim H, 2008, KIDNEY INT, V73, P11, DOI 10.1038/sj.ki.5002581; Ishimaru D, 2009, MOL CANCER RES, V7, P1354, DOI 10.1158/1541-7786.MCR-08-0476; Karawajew L, 2000, BLOOD, V96, P297, DOI 10.1182/blood.V96.1.297.013k24_297_306; Kranthi BV, 2006, NUCLEIC ACIDS RES, V34, P4060, DOI 10.1093/nar/gkl577; Lapucci A, 2002, J BIOL CHEM, V277, P16139, DOI 10.1074/jbc.M201377200; Mano J, 2000, BBA-PROTEIN STRUCT M, V1480, P374, DOI 10.1016/S0167-4838(00)00073-X; Morelli S, 1997, P NATL ACAD SCI USA, V94, P8150, DOI 10.1073/pnas.94.15.8150; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Otake Y, 2007, BLOOD, V109, P3069, DOI 10.1182/blood-2006-08-043257; Porte S, 2009, CHEM-BIOL INTERACT, V178, P288, DOI 10.1016/j.cbi.2008.10.018; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; RAO PV, 1992, BIOCHIM BIOPHYS ACTA, V1117, P315; RAO PV, 1992, J BIOL CHEM, V267, P96; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; Robertson LE, 1996, LEUKEMIA, V10, P456; RODOKANAKI A, 1989, GENE, V78, P215, DOI 10.1016/0378-1119(89)90224-2; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Schroeder JM, 2003, AM J PHYSIOL-RENAL, V285, pF258, DOI 10.1152/ajprenal.00422.2002; Sengupta TK, 2004, J BIOL CHEM, V279, P10855, DOI 10.1074/jbc.M309111200; STEUBE KG, 1995, LEUKEMIA, V9, P1841; Tang A, 2001, J BIOL CHEM, V276, P21375, DOI 10.1074/jbc.M101941200; VALERIE I, 2008, IMMUNOL RES, V42, P84	54	17	18	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1852	1865		10.1096/fj.09-140459	http://dx.doi.org/10.1096/fj.09-140459			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20103721	Green Published, Green Submitted			2022-12-28	WOS:000278200000021
J	Moise, AR; Lobo, GP; Erokwu, B; Wilson, DL; Peck, D; Alvarez, S; Dominguez, M; Alvarez, R; Flask, CA; de Lera, AR; von Lintig, J; Palczewski, K				Moise, Alexander R.; Lobo, Glenn P.; Erokwu, Bernadette; Wilson, David L.; Peck, David; Alvarez, Susana; Dominguez, Marta; Alvarez, Rosana; Flask, Chris A.; de Lera, Angel R.; von Lintig, Johannes; Palczewski, Krzysztof			Increased adiposity in the retinol saturase-knockout mouse	FASEB JOURNAL			English	Article						retinoic acid; dihydroretinol; retinol-binding proteins; retinoic acid receptor	VITAMIN-A SUPPLEMENTATION; ACTIVATED RECEPTOR-GAMMA; PPAR-GAMMA; IN-VITRO; LEPTIN EXPRESSION; REGULATES OBESITY; GENE-EXPRESSION; ACID RECEPTOR; MAP KINASE; TISSUE	The enzyme retinol saturase (RetSat) catalyzes the saturation of all-trans-retinol to produce (R)-all-trans-13,14-dihydroretinol. As a peroxisome proliferator-activated receptor (PPAR) gamma target, RetSat was shown to be required for adipocyte differentiation in the 3T3-L1 cell culture model. To understand the mechanism involved in this putative proadipogenic effect of RetSat, we studied the consequences of ablating RetSat expression on retinoid metabolism and adipose tissue differentiation in RetSat-null mice. Here, we report that RetSat-null mice have normal levels of retinol and retinyl palmitate in liver, serum, and adipose tissue, but, in contrast to wild-type mice, are deficient in the production of all-trans-13,14-dihydroretinol from dietary vitamin A. Despite accumulating more fat, RetSat-null mice maintained on either low-fat or high-fat diets gain weight and have similar rates of food intake as age-and gender-matched wildtype control littermates. This increased adiposity of RetSat-null mice is associated with up-regulation of PPAR gamma, a key transcriptional regulator of adipogenesis, and also its downstream target, fatty acid-binding protein 4 (FABP4/aP2). On the basis of these results, we propose that dihydroretinoids produced by RetSat control physiological processes that influence PPAR gamma activity and regulate lipid accumulation in mice.-Moise, A. R., Lobo, G. P., Erokwu, B., Wilson, D. L., Peck, D., Alvarez, S., Dom nguez, M., Alvarez, R., Flask, C. A., de Lera, A. R., von Lintig, J., Palczewski, K. Increased adiposity in the retinol saturase-knockout mouse. FASEB J. 24, 1261-1270 (2010). www.fasebj.org	[Moise, Alexander R.; Lobo, Glenn P.; Peck, David; von Lintig, Johannes; Palczewski, Krzysztof] Case Western Reserve Univ, Dept Pharmacol, Case Sch Med, Cleveland, OH 44106 USA; [Erokwu, Bernadette; Wilson, David L.; Flask, Chris A.] Case Western Reserve Univ, Dept Radiol, Cleveland, OH 44106 USA; [Erokwu, Bernadette; Wilson, David L.; Flask, Chris A.] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA; [Alvarez, Susana; Dominguez, Marta; Alvarez, Rosana; de Lera, Angel R.] Univ Vigo, Fac Quim, Dept Quim Organ, Vigo 36310, Spain	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Universidade de Vigo	Moise, AR (corresponding author), Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA.	alexmoise@ku.edu	Moise, Alexander R/C-9498-2009; alvarez, susana/L-9941-2015; AR, Moise/P-2474-2019; Dominguez, Marta/AAA-2084-2019; Lobo, Glenn P./AAI-9736-2020; Rodríguez, Rosana Alvarez/AAA-1998-2019	Moise, Alexander R/0000-0003-2307-6035; alvarez, susana/0000-0003-2420-4721; AR, Moise/0000-0003-2307-6035; Rodríguez, Rosana Alvarez/0000-0001-5608-7561; Rodriguez de Lera, Angel/0000-0001-6896-9078; Flask, Chris/0000-0002-1066-333X; Wilson, David/0000-0001-9763-1463; Dominguez Seoane, Marta/0000-0003-4569-8011; von Lintig, Johannes/0000-0002-2079-2143	National Eye Institute (National Institutes of Health, Bethesda, MD, USA) [EY01730, EY019478, EY015399, EY08061, SAF 2007-63880-FEDER, PGIDIT07PXIBIB3174174PR]; NATIONAL EYE INSTITUTE [R01EY008061, R29EY008061, R01EY019478, P30EY001730, R03EY015399] Funding Source: NIH RePORTER	National Eye Institute (National Institutes of Health, Bethesda, MD, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The authors thank members of the K. P. and J.V. laboratories and Dr. Leslie Webster Jr. for critical reading of the manuscript. This research was supported in part by U.S. Public Health Service grants EY01730, EY019478, EY015399, and EY08061 from the National Eye Institute (National Institutes of Health, Bethesda, MD, USA) to K. P., and grants SAF 2007-63880-FEDER and PGIDIT07PXIBIB3174174PR to A. R. D. and R. A.	Amengual J, 2008, OBESITY, V16, P585, DOI 10.1038/oby.2007.104; Anghel SI, 2007, J BIOL CHEM, V282, P29946, DOI 10.1074/jbc.M702490200; Berry DC, 2009, MOL CELL BIOL, V29, P3286, DOI 10.1128/MCB.01742-08; Bonet ML, 2003, CELL MOL LIFE SCI, V60, P1311, DOI 10.1007/s00018-003-2290-x; Bost F, 2005, DIABETES, V54, P402, DOI 10.2337/diabetes.54.2.402; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Felipe F, 2005, BBA-MOL BASIS DIS, V1740, P258, DOI 10.1016/j.bbadis.2004.11.014; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Hessel S, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M706763200; Hollung K, 2004, J CELL BIOCHEM, V92, P307, DOI 10.1002/jcb.20047; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jeyakumar SM, 2008, BIOCHEM BIOPH RES CO, V370, P243, DOI 10.1016/j.bbrc.2008.03.073; Jeyakumar SM, 2006, OBESITY, V14, P52, DOI 10.1038/oby.2006.7; Johnson DH, 2008, J MAGN RESON IMAGING, V28, P915, DOI 10.1002/jmri.21481; Kane MA, 2005, BIOCHEM J, V388, P363, DOI 10.1042/BJ20041867; Kane MA, 2008, ANAL CHEM, V80, P1702, DOI 10.1021/ac702030f; KURIHARCUCH W, 1982, DIFFERENTIATION, V23, P164, DOI 10.1111/j.1432-0436.1982.tb01279.x; Lillie RD, 1976, HISTOPATHOLOGIC TECH, V4th; Lopez IP, 2004, BIOCHEM BIOPH RES CO, V318, P234, DOI 10.1016/j.bbrc.2004.04.018; Lopez IP, 2005, MOL CELL BIOCHEM, V275, P109, DOI 10.1007/s11010-005-1082-z; Mercader J, 2007, CELL PHYSIOL BIOCHEM, V20, P1061, DOI 10.1159/000110717; Mercader J, 2006, ENDOCRINOLOGY, V147, P5325, DOI 10.1210/en.2006-0760; Moise AR, 2008, J AM CHEM SOC, V130, P1154, DOI 10.1021/ja710487q; Moise AR, 2007, BIOCHEMISTRY-US, V46, P1811, DOI 10.1021/bi062147u; Moise AR, 2009, MOL PHARMACOL, V76, P1228, DOI 10.1124/mol.109.060038; Moise AR, 2005, J BIOL CHEM, V280, P27815, DOI 10.1074/jbc.M503520200; Moise AR, 2004, J BIOL CHEM, V279, P50230, DOI 10.1074/jbc.M409130200; MURRAY T, 1980, J SUPRAMOL STR CELL, V14, P255, DOI 10.1002/jss.400140214; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Ribot J, 2001, OBES RES, V9, P500, DOI 10.1038/oby.2001.65; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; SAFONOVA I, 1994, MOL CELL ENDOCRINOL, V104, P201, DOI 10.1016/0303-7207(94)90123-6; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; Schupp M, 2009, P NATL ACAD SCI USA, V106, P1105, DOI 10.1073/pnas.0812065106; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Shin DJ, 1997, J NUTR, V127, P1274, DOI 10.1093/jn/127.7.1274; Strom K, 2009, FASEB J, V23, P2307, DOI 10.1096/fj.08-120923; Trujillo ME, 2006, ENDOCR REV, V27, P798, DOI 10.1210/er.2006-0033; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; Xue JC, 1996, MOL CELL BIOL, V16, P1567; Yu HZ, 2008, MAGN RESON MED, V60, P1122, DOI 10.1002/mrm.21737; Zhang M, 2007, FASEB J, V21, P2886, DOI 10.1096/fj.06-7964com; Ziouzenkova O, 2008, FEBS LETT, V582, P32, DOI 10.1016/j.febslet.2007.11.081; Ziouzenkova O, 2007, NAT MED, V13, P695, DOI 10.1038/nm1587	46	40	42	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2010	24	4					1261	1270		10.1096/fj.09-147207	http://dx.doi.org/10.1096/fj.09-147207			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19940255	Green Published			2022-12-28	WOS:000276462300032
J	Tjellstrom, H; Hellgren, LI; Wieslander, A; Sandelius, AS				Tjellstrom, Henrik; Hellgren, Lars I.; Wieslander, Ake; Sandelius, Anna Stina			Lipid asymmetry in plant plasma membranes: phosphate deficiency-induced phospholipid replacement is restricted to the cytosolic leaflet	FASEB JOURNAL			English	Article						detergent-resistant membrane; digalactosyldiacyl-glycerol; liposome; raft; sterol derivative	DETERGENT-RESISTANT MEMBRANES; LATERAL PRESSURE PROFILE; BIOLOGICAL-MEMBRANES; SPHINGOLIPID CLASSES; CELL-MEMBRANES; RAFTS; ARABIDOPSIS; LEAVES; MODEL; BIOSYNTHESIS	As in other eukaryotes, plant plasma membranes contain sphingolipids, phospholipids, and free sterols. In addition, plant plasma membranes also contain sterol derivatives and usually <5 mol% of a galactolipid, digalactosyldiacylglycerol (DGDG). We earlier reported that compared to fully fertilized oats (Avena sativa), oats cultivated without phosphate replaced up to 70 mol% of the root plasma membrane phospholipids with DGDG. Here, we investigated the implications of a high DGDG content on membrane properties. The phospholipid-to-DGDG replacement almost exclusively occurred in the cytosolic leaflet, where DGDG constituted up to one-third of the lipids. In the apoplastic (exoplasmic) leaflet, as well as in rafts, phospholipids were not replaced by DGDG, but by acylated sterol glycosides. Liposome studies revealed that the chain ordering in free sterol/phospholipid mixtures clearly decreased when > 5mol% DGDG was included. As both the apoplastic plasma membrane leaflet (probably the major water permeability barrier) and rafts both contain only trace amounts of DGDG, we conclude that this lipid class is not compatible with membrane functions requiring a high degree of lipid order. By not replacing phospholipids site specifically with DGDG, negative functional effects of this lipid in the plasma membrane are avoided.-Tjellstrom, H., Hellgren, L. I., Wieslander, A., Sandelius, A. S. Lipid asymmetry in plant plasma membranes: phosphate deficiency-induced phospholipid replacement is restricted to the cytosolic leaflet. FASEB J. 24, 1128-1138 (2010). www.fasebj.org	[Tjellstrom, Henrik; Sandelius, Anna Stina] Univ Gothenburg, Dept Plant & Environmen Sci, SE-40530 Gothenburg, Sweden; [Hellgren, Lars I.] Tech Univ Denmark, Dept Syst Biol, DK-2800 Lyngby, Denmark; [Hellgren, Lars I.] Tech Univ Denmark, Ctr Adv Food Studies, DK-2800 Lyngby, Denmark; [Wieslander, Ake] Stockholm Univ, Dept Biochem & Biophys, Ctr Biomembrane Res, S-10691 Stockholm, Sweden	University of Gothenburg; Technical University of Denmark; Technical University of Denmark; Stockholm University	Tjellstrom, H (corresponding author), Univ Gothenburg, Dept Plant & Environmen Sci, POB 461, SE-40530 Gothenburg, Sweden.	henrik.tjellstrom@dpes.gu.se	Hellgren, Lars/B-5137-2010	Hellgren, Lars/0000-0001-9215-4880	Swedish Council for Forestry and Agricultural Research (FORMAS); The Royal Society of Arts and Sciences in Goteborg (KVVS); Carl Trygger's Science Foundation	Swedish Council for Forestry and Agricultural Research (FORMAS)(Swedish Research Council Formas); The Royal Society of Arts and Sciences in Goteborg (KVVS); Carl Trygger's Science Foundation	The authors thank Professors Maryse Block and Eric Marechal (CNRS, Grenoble, France), for generously supplying the DGDG primary antibody. The Centre for Cellular Imaging at the University of Gothenburg is acknowledged for the use of imaging equipment and for the support from the staff. Financial support was from the Swedish Council for Forestry and Agricultural Research (FORMAS), The Royal Society of Arts and Sciences in Goteborg (KVVS), and Carl Trygger's Science Foundation.	Andersson MX, 2005, J BIOL CHEM, V280, P27578, DOI 10.1074/jbc.M503273200; Andersson MX, 2003, FEBS LETT, V537, P128, DOI 10.1016/S0014-5793(03)00109-1; Bodennec J, 2000, METHOD ENZYMOL, V312, P101; Borner GHH, 2006, J CELL BIOL, V175, P571, DOI 10.1083/jcb.200607164; Borner GHH, 2005, PLANT PHYSIOL, V137, P104, DOI 10.1104/pp.104.053041; Bose R, 1998, J BIOL CHEM, V273, P28852, DOI 10.1074/jbc.273.44.28852; Brade L, 2000, GLYCOBIOLOGY, V10, P629, DOI 10.1093/glycob/10.6.629; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Cantor RS, 1999, BIOPHYS J, V76, P2625, DOI 10.1016/S0006-3495(99)77415-1; CARLSSON AS, 1994, PHYSIOL PLANTARUM, V91, P754, DOI 10.1111/j.1399-3054.1994.tb03016.x; Christie W.W, 2003, LIPID ANAL ISOLATION, V3rd; Contreras FX, 2003, J BIOL CHEM, V278, P37169, DOI 10.1074/jbc.M303206200; Devaux PF, 2006, CHEM PHYS LIPIDS, V141, P119, DOI 10.1016/j.chemphyslip.2006.02.007; Dormann P, 1999, SCIENCE, V284, P2181, DOI 10.1126/science.284.5423.2181; EFRATI H, 1986, ARCH BIOCHEM BIOPHYS, V248, P282, DOI 10.1016/0003-9861(86)90425-X; EGGER A, 1992, PHYSIOL PLANTARUM, V84, P121, DOI 10.1111/j.1399-3054.1992.tb08774.x; FREDRICKSON GH, 1989, PHYS FLUIDS A-FLUID, V1, P3, DOI 10.1063/1.857546; Hartel H, 2000, P NATL ACAD SCI USA, V97, P10649, DOI 10.1073/pnas.180320497; Hedfalk K, 2006, CURR OPIN STRUC BIOL, V16, P447, DOI 10.1016/j.sbi.2006.06.009; HEINZ E, 1975, Z PFLANZENPHYSIOL, V75, P78, DOI 10.1016/S0044-328X(75)80077-8; Hill WG, 1999, J GEN PHYSIOL, V114, P405, DOI 10.1085/jgp.114.3.405; HOEKSTRA D, 1992, BIOCHIM BIOPHYS ACTA, V1113, P227; Jouhet J, 2004, J CELL BIOL, V167, P863, DOI 10.1083/jcb.200407022; KADOWAKI H, 1983, J LIPID RES, V24, P1389; Kelly AA, 2003, PLANT CELL, V15, P2694, DOI 10.1105/tpc.016675; KLEINSCHMIDT MG, 1972, PLANT PHYSIOL, V49, P852, DOI 10.1104/pp.49.5.852; Krylov AV, 2001, J GEN PHYSIOL, V118, P333, DOI 10.1085/jgp.118.4.333; Larsson C., 1990, The plant plasma membrane., P1; Lefebvre B, 2007, PLANT PHYSIOL, V144, P402, DOI 10.1104/pp.106.094102; Lingwood D, 2007, NAT PROTOC, V2, P2159, DOI 10.1038/nprot.2007.294; Marechal E, 2002, EUKARYOT CELL, V1, P653, DOI 10.1128/EC.1.4.653-656.2002; Markham JE, 2006, J BIOL CHEM, V281, P22684, DOI 10.1074/jbc.M604050200; Marsh D, 2007, BIOPHYS J, V93, P3884, DOI 10.1529/biophysj.107.107938; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; Mongrand S, 2004, J BIOL CHEM, V279, P36277, DOI 10.1074/jbc.M403440200; Morel J, 2006, MOL CELL PROTEOMICS, V5, P1396, DOI 10.1074/mcp.M600044-MCP200; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nakamura Y, 2005, J BIOL CHEM, V280, P7469, DOI 10.1074/jbc.M408799200; NORBERG P, 1991, PLANT PHYSIOL, V96, P1136, DOI 10.1104/pp.96.4.1136; PALMGREN MG, 1990, PLANT PHYSIOL, V92, P871, DOI 10.1104/pp.92.4.871; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Raffaele S, 2009, PLANT CELL, V21, P1541, DOI 10.1105/tpc.108.064279; ROCHESTER CP, 1987, ARCH BIOCHEM BIOPHYS, V255, P385, DOI 10.1016/0003-9861(87)90406-1; Salaun C, 2004, TRAFFIC, V5, P255, DOI 10.1111/j.1600-0854.2004.0162.x; Shangguan T, 1998, BBA-BIOMEMBRANES, V1368, P171, DOI 10.1016/S0005-2736(97)00151-X; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons K, 2001, NAT REV MOL CELL BIO, V2, P216; SOMMARIN M, 1988, BIOCHIM BIOPHYS ACTA, V958, P268, DOI 10.1016/0005-2760(88)90185-3; Sperling P, 2005, PLANT PHYSIOL BIOCH, V43, P1031, DOI 10.1016/j.plaphy.2005.10.004; Sperling P, 2003, BBA-MOL CELL BIOL L, V1632, P1, DOI 10.1016/S1388-1981(03)00033-7; SUNAMOTO J, 1980, J BIOCHEM-TOKYO, V88, P1219, DOI 10.1093/oxfordjournals.jbchem.a133089; Takeda Y, 2001, BBA-BIOMEMBRANES, V1513, P38, DOI 10.1016/S0005-2736(01)00342-X; Templer RH, 1998, FARADAY DISCUSS, V111, P41; Tjellstrom H, 2008, PLANT CELL ENVIRON, V31, P1388, DOI 10.1111/j.1365-3040.2008.01851.x; TOLEDO MS, 1995, J MED VET MYCOL, V33, P247; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; Wikstrom M, 2009, J BIOL CHEM, V284, P954, DOI 10.1074/jbc.M804482200; XIANG TX, 1993, BIOPHYS J, V65, P1108, DOI 10.1016/S0006-3495(93)81156-1; YOSHIDA S, 1986, PLANT PHYSIOL, V82, P807, DOI 10.1104/pp.82.3.807	59	53	56	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2010	24	4					1128	1138		10.1096/fj.09-139410	http://dx.doi.org/10.1096/fj.09-139410			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19966136				2022-12-28	WOS:000276462300020
J	Chou, YH; Kuo, WL; Rosner, MR; Tang, WJ; Goldman, RD				Chou, Ying-Hao; Kuo, Wen-Liang; Rosner, Marsha Rich; Tang, Wei-Jen; Goldman, Robert D.			Structural changes in intermediate filament networks alter the activity of insulin-degrading enzyme	FASEB JOURNAL			English	Article						phosphorylation; metalloprotease; cytoskeleton	PHOSPHORYLATION SITES; PROGENITOR CELLS; NESTIN; VIMENTIN; PROTEINS; EXPRESSION; STEM; REORGANIZATION; DEGRADATION; RECOGNITION	The intermediate filament (IF) protein nestin coassembles with vimentin and promotes the disassembly of these copolymers when vimentin is hyperphosphorylated during mitosis. The aim of this study is to determine the function of these nonfilamentous particles by identifying their interacting partners. In this study, we report that these disassembled vimentin/nestin complexes interact with insulin degrading enzyme (IDE). Both vimentin and nestin interact with IDE in vitro, but vimentin binds IDE with a higher affinity than nestin. Although the interaction between vimentin and IDE is enhanced by vimentin phosphorylation at Ser-55, the interaction between nestin and IDE is phosphorylation independent. Further analyses show that phosphorylated vimentin plays the dominant role in targeting IDE to the vimentin/nestin particles in vivo, while the requirement for nestin is related to its ability to promote vimentin IF disassembly. The binding of IDE to either nestin or phosphorylated vimentin regulates IDE activity differently, depending on the substrate. The insulin degradation activity of IDE is suppressed similar to 50% by either nestin or phosphorylated vimentin, while the cleavage of bradykinin-mimetic peptide by IDE is increased 2- to 3-fold. Taken together, our data demonstrate that the nestin-mediated disassembly of vimentin IFs generates a structure capable of sequestering and modulating the activity of IDE.-Chou, Y.-H., Kuo, W.-L., Rich Rosner, M., Tang, W.-J., Goldman, R. D. Structural changes in intermediate filament networks alter the activity of insulin-degrading enzyme. FASEB J. 23, 3734-3742 (2009). www.fasebj.org	[Goldman, Robert D.] Northwestern Univ, Dept Cell & Mol Biol, Feinberg Sch Med, Chicago, IL 60611 USA; [Kuo, Wen-Liang] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; [Rosner, Marsha Rich; Tang, Wei-Jen] Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	Northwestern University; Feinberg School of Medicine; University of Chicago; University of Chicago	Goldman, RD (corresponding author), Northwestern Univ, Dept Cell & Mol Biol, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.	r-goldman@northwestern.edu		Tang, Wei-Jen/0000-0002-8267-8995	National Institute of General Medical Sciences; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081539] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr. Edward Kuczmarski and Dr. Stephen Adam for critically reading the manuscript and for suggestions. This research is supported by a grant from the National Institute of General Medical Sciences to R. D. G.	Bieberich E, 2003, J CELL BIOL, V162, P469, DOI 10.1083/jcb.200212067; Caulin C, 2000, J CELL BIOL, V149, P17, DOI 10.1083/jcb.149.1.17; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; Chesneau V, 2000, PROTEIN EXPRES PURIF, V19, P91, DOI 10.1006/prep.2000.1217; Chou YH, 1996, J CELL SCI, V109, P817; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; Chou YH, 2003, MOL BIOL CELL, V14, P1468, DOI 10.1091/mbc.E02-08-0545; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; Chou YH, 2007, EXP CELL RES, V313, P2236, DOI 10.1016/j.yexcr.2007.04.008; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; DAHLSTRAND J, 1992, J CELL SCI, V103, P589; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; Eckes B, 2000, J CELL SCI, V113, P2455; Eriksson JE, 2004, J CELL SCI, V117, P919, DOI 10.1242/jcs.00906; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Fawcett J, 2007, ARCH BIOCHEM BIOPHYS, V468, P128, DOI 10.1016/j.abb.2007.09.019; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; Helfand BT, 2005, TRENDS CELL BIOL, V15, P568, DOI 10.1016/j.tcb.2005.09.009; Inada H, 2001, J CELL BIOL, V155, P415, DOI 10.1083/jcb.200103078; Inagaki M, 1997, J BIOCHEM, V121, P407; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Johnson GD, 2000, ANAL BIOCHEM, V286, P112, DOI 10.1006/abio.2000.4772; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; JONES JCR, 1985, J CELL BIOL, V100, P93, DOI 10.1083/jcb.100.1.93; Kawaguchi A, 2001, MOL CELL NEUROSCI, V17, P259, DOI 10.1006/mcne.2000.0925; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Ku NO, 2002, P NATL ACAD SCI USA, V99, P4373, DOI 10.1073/pnas.072624299; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li QX, 2006, CELL, V127, P305, DOI 10.1016/j.cell.2006.08.046; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Malito E, 2008, CELL MOL LIFE SCI, V65, P2574, DOI 10.1007/s00018-008-8112-4; Malito E, 2008, BIOCHEMISTRY-US, V47, P12822, DOI 10.1021/bi801192h; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; Nieminen M, 2006, NAT CELL BIOL, V8, P156, DOI 10.1038/ncb1355; Omary MB, 2006, TRENDS BIOCHEM SCI, V31, P383, DOI 10.1016/j.tibs.2006.05.008; Omary MB, 2006, NATURE, V441, P296, DOI 10.1038/441296a; Perlson E, 2005, NEURON, V45, P715, DOI 10.1016/j.neuron.2005.01.023; Phua DCY, 2009, MOL BIOL CELL, V20, P2841, DOI 10.1091/mbc.E08-02-0199; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; Rutka JT, 1999, INT J DEV NEUROSCI, V17, P503, DOI 10.1016/S0736-5748(99)00049-0; Safavi A, 1996, BIOCHEMISTRY-US, V35, P14318, DOI 10.1021/bi960582q; Sahlgren CM, 2006, EMBO J, V25, P4808, DOI 10.1038/sj.emboj.7601366; Sahlgren CM, 2001, J BIOL CHEM, V276, P16456, DOI 10.1074/jbc.M009669200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEJERSEN T, 1993, J CELL SCI, V106, P1291; Shen YQ, 2006, NATURE, V443, P870, DOI 10.1038/nature05143; Song ES, 2005, J BIOL CHEM, V280, P17701, DOI 10.1074/jbc.M501896200; Sultana S, 1998, AM J PATHOL, V153, P1157, DOI 10.1016/S0002-9440(10)65660-X; Thomas SK, 2004, J BIOL CHEM, V279, P27994, DOI 10.1074/jbc.M312663200; TOHYAMA T, 1992, LAB INVEST, V66, P303; Tzivion G, 2000, J BIOL CHEM, V275, P29772, DOI 10.1074/jbc.M001207200; Wakamatsu Y, 2007, DEVELOPMENT, V134, P2425, DOI 10.1242/dev.02862; Weirich G, 2008, BIOL CHEM, V389, P1441, DOI 10.1515/BC.2008.157	56	14	14	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3734	3742		10.1096/fj.09-137455	http://dx.doi.org/10.1096/fj.09-137455			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19584300	Green Published, Bronze			2022-12-28	WOS:000271272500011
J	Michel, V; Bakovic, M				Michel, Vera; Bakovic, Marica			The solute carrier 44A1 is a mitochondrial protein and mediates choline transport	FASEB JOURNAL			English	Article							RAT-LIVER MITOCHONDRIA; FUNCTIONAL-CHARACTERIZATION; ESSENTIAL NUTRIENT; EXPRESSION; MEMBRANE; FAMILY; INHIBITORS; APOPTOSIS; NEURONS; HUMANS	Choline oxidation to betaine takes place in the mitochondria; however, a protein regulating mitochondrial choline transport was never identified. The purpose of this study was to analyze subcellular localization of the solute carrier 44A1 (SLC44A1), a plasma membrane choline transporter sensitive to inhibition by hemicholinium-3. We generated N- and C-terminal-SLC44A1- specific antibodies and analyzed localization of endogenous and overexpressed SLC44A1 in C2C12 mouse muscle cells, MCF7 human breast cancer cells, and mouse tissues using confocal microscopy, differential centrifugation, and Western blotting. We further performed choline uptake competition studies on isolated mitochondria using the specific inhibitor hemicholinium-3 and SLC44A1 antibodies, and analyzed mitochondria of FL83B hepatocytes after the targeted knock-down of SLC44A1 using siRNA technology. In addition, we analyzed SLC44A1 expression during choline deficiency. Localization studies revealed plasma membrane, cytosolic, microsomal, and mitochondrial localization of endogenous and His-tagged SLC44A1. Uptake studies in isolated mitochondria show an accumulation of H-3-choline, which is strongly inhibited by hemicholinium- 3 (60%), by an excess of unlabeled choline (97%), and by both SLC44A1 antibodies. SLC44A1 mRNA and protein expression were down-regulated during choline deficiency. These data clearly establish SLC44A1 as an important mediator of choline transport across both the plasma membrane and the mitochondrial membrane.-Michel, V., Bakovic, M. The solute carrier 44A1 is a mitochondrial protein and mediates choline transport. FASEB J. 23, 2749-2758 ( 2009)	[Michel, Vera; Bakovic, Marica] Univ Guelph, Dept Human Hlth & Nutr Sci, Guelph, ON N1G 2W1, Canada	University of Guelph	Michel, V (corresponding author), Univ Guelph, Dept Human Hlth & Nutr Sci, Anim Sci & Nutr Bldg,Rm 309, Guelph, ON N1G 2W1, Canada.	vmichel@uoguelph.ca			Ontario Graduate Scholarship in Science and Technology; Natural Sciences and Engineering Research Council of Canada	Ontario Graduate Scholarship in Science and Technology; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	This study was supported by an Ontario Graduate Scholarship in Science and Technology (to V. M.) and by an operating grant from the Natural Sciences and Engineering Research Council of Canada (to M. B.).	Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; Birbes H, 2002, ADV ENZYME REGUL, V42, P113, DOI 10.1016/S0065-2571(01)00026-7; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; DEVES R, 1979, BIOCHIM BIOPHYS ACTA, V557, P469, DOI 10.1016/0005-2736(79)90344-4; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fisher MC, 2001, TERATOLOGY, V64, P114, DOI 10.1002/tera.1053; Fujita T, 2006, NEUROSCI LETT, V393, P216, DOI 10.1016/j.neulet.2005.09.069; Fullerton MD, 2006, AM J PHYSIOL-CELL PH, V290, pC1230, DOI 10.1152/ajpcell.00255.2005; GRASSL SM, 1994, BBA-BIOMEMBRANES, V1194, P203, DOI 10.1016/0005-2736(94)90221-6; HAUBRICH DR, 1981, BIOCHEM PHARMACOL, V30, P2993, DOI 10.1016/0006-2952(81)90265-3; HOSTETLER KY, 1979, CANCER RES, V39, P2978; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Inazu M, 2005, J NEUROCHEM, V94, P1427, DOI 10.1111/j.1471-4159.2005.03299.x; Jin JK, 2006, NEUROSCI LETT, V407, P263, DOI 10.1016/j.neulet.2006.08.062; KAPLAN CP, 1993, FEBS LETT, V321, P24, DOI 10.1016/0014-5793(93)80613-Y; Kharbanda KK, 2007, J HEPATOL, V46, P314, DOI 10.1016/j.jhep.2006.08.024; Madesh M, 1998, BBA-LIPID LIPID MET, V1389, P206, DOI 10.1016/S0005-2760(97)00155-0; MCMURRAY WC, 1986, BIOCHEM CELL BIOL, V64, P1115, DOI 10.1139/o86-147; Mellott TJ, 2007, BRAIN RES, V1151, P1, DOI 10.1016/j.brainres.2007.03.004; Michel V, 2006, EXP BIOL MED, V231, P490; O'Regan S, 2000, P NATL ACAD SCI USA, V97, P1835, DOI 10.1073/pnas.030339697; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; PORTER RK, 1992, J BIOL CHEM, V267, P14637; PORTER RK, 1993, BIOCHIM BIOPHYS ACTA, V1141, P269, DOI 10.1016/0005-2728(93)90052-H; SIMON JR, 1976, J NEUROCHEM, V26, P909, DOI 10.1111/j.1471-4159.1976.tb06472.x; Spector D. L., 1998, CELLS LAB MANUAL; Stone SJ, 2000, J BIOL CHEM, V275, P34534, DOI 10.1074/jbc.M002865200; STREUMERSVOBODOVA Z, 1977, PHYSIOL BOHEMOSLOV, V26, P525; Traiffort E, 2005, J NEUROCHEM, V92, P1116, DOI 10.1111/j.1471-4159.2004.02962.x; Voelker DR, 2004, TOP CURR GENET, V8, P267; Wang T, 2007, ACTA BIOCH BIOPH SIN, V39, P668, DOI 10.1111/j.1745-7270.2007.00323.x; Wille S, 2001, J IMMUNOL, V167, P5795, DOI 10.4049/jimmunol.167.10.5795; Yuan ZF, 2004, GENE, V341, P305, DOI 10.1016/j.gene.2004.07.042; Zeisel S H, 1997, Adv Pediatr, V44, P263; Zeisel SH, 2000, NUTRITION, V16, P669, DOI 10.1016/S0899-9007(00)00349-X; Zeisel SH, 2005, AM J CLIN NUTR, V82, P719, DOI 10.1093/ajcn/82.4.719; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061; Zhu LJ, 2005, ANAL BIOCHEM, V345, P102, DOI 10.1016/j.ab.2005.07.028	40	46	53	8	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2749	2758		10.1096/fj.08-121491	http://dx.doi.org/10.1096/fj.08-121491			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19357133				2022-12-28	WOS:000268836700043
J	Strijbis, K; van Roermund, CWT; Hardy, GP; van den Burg, J; Bloem, K; de Haan, J; van Vlies, N; Wanders, RJA; Vaz, FM; Distel, B				Strijbis, Karin; van Roermund, Carlo W. T.; Hardy, Guy P.; van den Burg, Janny; Bloem, Karien; de Haan, Jolanda; van Vlies, Naomi; Wanders, Ronald J. A.; Vaz, Frederic M.; Distel, Ben			Identification and characterization of a complete carnitine biosynthesis pathway in Candida albicans	FASEB JOURNAL			English	Article						hydroxytrimethyllysine aldolase; threonine aldolase; nonfermentable carbon source; acetyl unit transport; carnitine acetyltransferase	EPSILON-N-TRIMETHYLLYSINE; THREONINE ALDOLASE; SERINE HYDROXYMETHYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; BIOCHEMICAL-CHARACTERIZATION; DEPENDENT TRANSPORT; CARBON-SOURCES; RAT-LIVER; GENE; METABOLISM	Carnitine is an essential metabolite that enables intracellular transport of fatty acids and acetyl units. Here we show that the yeast Candida albicans can synthesize carnitine de novo, and we identify the 4 genes of the pathway. Null mutants of orf19.4316 (trimethyllysine dioxygenase), orf19.6306 (trimethylaminobutyraldehyde dehydrogenase), and orf19.7131 (butyrobetaine dioxygenase) lacked their respective enzymatic activities and were unable to utilize fatty acids, acetate, or ethanol as a sole carbon source, in accordance with the strict requirement for carnitine-mediated transport under these growth conditions. The second enzyme of carnitine biosynthesis, hydroxytrimethyllysine aldolase, is encoded by orf19.6305, a member of the threonine aldolase (TA) family in C. albicans. A strain lacking orf19.6305 showed strongly reduced growth on fatty acids and was unable to utilize either acetate or ethanol, but TA activity was unaffected. Growth of the null mutants on nonfermentable carbon sources is restored only by carnitine biosynthesis intermediates after the predicted enzymatic block in the pathway, which provides independent evidence for a specific defect in carnitine biosynthesis for each of the mutants. In conclusion, we have genetically characterized a complete carnitine biosynthesis pathway in C. albicans and show that a TA family member is mainly involved in the aldolytic cleavage of hydroxytrimethyllysine in vivo.-Strijbis, K., van Roermund, C. W. T., Hardy, G. P., van den Burg, J., Bloem, K., de Haan, J., van Vlies, N., Wanders, R. J. A., Vaz, F. M., Distel, B. Identification and characterization of a complete carnitine biosynthesis pathway in Candida albicans. FASEB J. 23, 2349-2359 (2009)	[Strijbis, Karin; Hardy, Guy P.; van den Burg, Janny; Bloem, Karien; de Haan, Jolanda; Distel, Ben] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands; [van Roermund, Carlo W. T.; van Vlies, Naomi; Wanders, Ronald J. A.; Vaz, Frederic M.] Univ Amsterdam, Acad Med Ctr, Dept Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Distel, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	b.distel@amc.uva.nl		Strijbis, Karin/0000-0001-9167-7137; Vaz, Frederic/0000-0002-9048-1041				BALLEVRE O, 1991, AM J PHYSIOL, V261, pE748, DOI 10.1152/ajpendo.1991.261.6.E748; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; BREMER J, 1962, BIOCHIM BIOPHYS ACTA, V57, P327, DOI 10.1016/0006-3002(62)91126-5; Contestabile R, 2001, EUR J BIOCHEM, V268, P6508, DOI 10.1046/j.0014-2956.2001.02606.x; DAVIS AJ, 1994, J NUTR, V124, P1667, DOI 10.1093/jn/124.9.1667; DUNN WA, 1982, J BIOL CHEM, V257, P7948; Edgar AJ, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-32; Gola S, 2003, YEAST, V20, P1339, DOI 10.1002/yea.1044; HENDERSON LM, 1982, FED PROC, V41, P2843; HENDERSON LM, 1980, CARNITINE BIOSYNTHES, P35; HOCHALTER JB, 1976, BIOCHEM BIOPH RES CO, V70, P364, DOI 10.1016/0006-291X(76)91054-8; HULSE JD, 1978, J BIOL CHEM, V253, P1654; KAUFMAN RA, 1977, J BIOL CHEM, V252, P7437; McNeil JB, 2000, YEAST, V16, P167, DOI 10.1002/(SICI)1097-0061(20000130)16:2&lt;167::AID-YEA519&gt;3.0.CO;2-1; Monschau N, 1997, FEMS MICROBIOL LETT, V150, P55, DOI 10.1016/S0378-1097(97)00096-7; Noble SM, 2005, EUKARYOT CELL, V4, P298, DOI 10.1128/EC.4.2.298-309.2005; Ogawa A, 2000, BIOSCI BIOTECH BIOCH, V64, P1133, DOI 10.1271/bbb.64.1133; OGAWA H, 1981, J BIOCHEM, V90, P381, DOI 10.1093/oxfordjournals.jbchem.a133484; Ogawa H, 2000, INT J BIOCHEM CELL B, V32, P289, DOI 10.1016/S1357-2725(99)00113-2; PAIK WK, 1971, SCIENCE, V174, P114, DOI 10.1126/science.174.4005.114; Piraud M, 2003, RAPID COMMUN MASS SP, V17, P1297, DOI 10.1002/rcm.1054; PULLMAN ME, 1963, METHOD ENZYMOL, V6, P277, DOI 10.1016/0076-6879(63)06174-7; Ramon AM, 2003, EUKARYOT CELL, V2, P718, DOI 10.1128/EC.2.4.718-728.2003; REBOUCHE CJ, 1984, J CLIN INVEST, V73, P857, DOI 10.1172/JCI111281; REBOUCHE CJ, 1980, BIOCHIM BIOPHYS ACTA, V630, P22, DOI 10.1016/0304-4165(80)90133-6; REBOUCHE CJ, 1986, J NUTR, V116, P751; Schaub Y, 2006, J BASIC MICROB, V46, P416, DOI 10.1002/jobm.200510133; Staib P, 2001, INT J MED MICROBIOL, V291, P183, DOI 10.1078/1438-4221-00114; Steiber Alison, 2004, Molecular Aspects of Medicine, V25, P455, DOI 10.1016/j.mam.2004.06.006; Strijbis K, 2008, EUKARYOT CELL, V7, P610, DOI 10.1128/EC.00017-08; Swiegers JH, 2001, YEAST, V18, P585, DOI 10.1002/yea.712; TANPHAIC.V, 1973, J BIOL CHEM, V248, P2176; van Roermund CWT, 1999, EMBO J, V18, P5843, DOI 10.1093/emboj/18.21.5843; van Vlies N, 2006, ANAL BIOCHEM, V354, P132, DOI 10.1016/j.ab.2006.04.007; Vaz FM, 1998, BIOCHEM BIOPH RES CO, V250, P506, DOI 10.1006/bbrc.1998.9343; Vaz FM, 2000, J BIOL CHEM, V275, P7390, DOI 10.1074/jbc.275.10.7390; Vaz FM, 2002, BIOCHEM J, V361, P417, DOI 10.1042/0264-6021:3610417; Vaz FM, 2001, J BIOL CHEM, V276, P33512, DOI 10.1074/jbc.M105929200; Walther A, 2003, CURR GENET, V42, P339, DOI 10.1007/s00294-002-0349-0; Zhou H, 2008, MICROBIOL-SGM, V154, P500, DOI 10.1099/mic.0.2007/014555-0	41	28	33	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2349	2359		10.1096/fj.08-127985	http://dx.doi.org/10.1096/fj.08-127985			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19289605				2022-12-28	WOS:000268836700003
J	Jindal, R; Nahmias, Y; Tilles, AW; Berthiaume, F; Yarmush, ML				Jindal, Rohit; Nahmias, Yaakov; Tilles, Arno W.; Berthiaume, Francois; Yarmush, Martin L.			Amino acid-mediated heterotypic interaction governs performance of a hepatic tissue model	FASEB JOURNAL			English	Article						acute phase proteins; coculture; extracellular matrix; liver	EXTRACELLULAR-MATRIX; HEPATOCYTE FUNCTION; ENDOTHELIAL-CELLS; LIVER; RAT; CULTURE; COCULTURE; GEL; TRANSCRIPTION; METABOLISM	Tissue-engineered models that mimic in vivo tissue organization offer the potential of capturing complex signaling pathways in vitro. In the liver, hepatocytes and endothelial cells are closely associated but separated by the extracellular matrix of the space of Disse. This unique configuration was mimicked by embedding primary hepatocytes in collagen gel and overlaying the matrix with endothelial cells. We demonstrate that during the first few days of culture, the secretion of albumin and fibrinogen was 2-fold higher in cocultures compared to hepatocytes alone. Hepatocyte function in both cultures stabilized to a similar level during the second week, suggesting that endothelial cells can induce the early recovery of hepatocytes after isolation and seeding. Endothelial cell-conditioned medium reproduced the effect of coculture in a dose-dependent fashion, suggesting a role for endothelial cell-derived soluble factors. Endothelial cell-conditioned medium increased mRNA levels of various acute-phase proteins such as albumin, fibrinogen, transferrin, and alpha-macroglobulin in hepatocytes. Surprisingly, the effect of endothelial cell-conditioned medium was not mediated by growth factors or cytokines, or by secreted extracellular matrix, but by the release of the amino acid proline, which mediates endogenous collagen synthesis by hepatocytes. These findings suggest an important role for proline secretion by endothelial cells as a paracrine factor regulating hepatocyte function.-Jindal, R., Nahmias, Y., Tilles, A. W., Berthiaume, F., Yarmush, M. L. Amino acid-mediated heterotypic interaction governs performance of a hepatic tissue model. FASEB J. 23, 2288-2298 (2009)	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA USA; Shriners Hosp Children, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Yarmush, ML (corresponding author), 51 Blossom St, Boston, MA 02114 USA.	ireis@sbi.org	Nahmias, Yaakov/H-4725-2013; Berthiaume, Francois/ABD-2139-2020; Nahmias, Yaakov/AAM-3872-2020	Nahmias, Yaakov/0000-0002-6051-616X; Nahmias, Yaakov/0000-0002-6051-616X; Yarmush, Martin/0000-0003-4986-8444	NIH BioMEMS Resource Center [P41 EB-002503, RO1AI063795]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561, K01DK080241] Funding Source: NIH RePORTER	NIH BioMEMS Resource Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Chris Pohun Chen, Avrum Leeder, Luke Selby, and Carley Shulman for the isolation of cells from rat livers. We appreciate the help of Dr. David Yarmush in conducting collagen measurement studies. This work was supported by NIH BioMEMS Resource Center grant P41 EB-002503 and NIH grant RO1AI063795. Microscopic imaging studies were made possible by a core morphology facility, and gene expression measurements were carried out at the Genomic and Proteomic Facility at Boston's Shriners Burns Hospital.	Arai K, 2001, HEPATOLOGY, V34, P360, DOI 10.1053/jhep.2001.26515; Behnia K, 2000, TISSUE ENG, V6, P467, DOI 10.1089/107632700750022125; Berthiaume F, 1996, FASEB J, V10, P1471, DOI 10.1096/fasebj.10.13.8940293; Bhatia SN, 1998, J BIOMAT SCI-POLYM E, V9, P1137, DOI 10.1163/156856298X00695; Bhatia SN, 1999, FASEB J, V13, P1883, DOI 10.1096/fasebj.13.14.1883; BISSELL DM, 1987, J CLIN INVEST, V79, P801, DOI 10.1172/JCI112887; CARON JM, 1990, MOL CELL BIOL, V10, P1239, DOI 10.1128/MCB.10.3.1239; Davidson AJ, 2003, SCIENCE, V299, P835, DOI 10.1126/science.1082006; Deroanne CF, 2001, CARDIOVASC RES, V49, P647, DOI 10.1016/S0008-6363(00)00233-9; DUNN JCY, 1989, FASEB J, V3, P174, DOI 10.1096/fasebj.3.2.2914628; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; GOULET F, 1988, HEPATOLOGY, V8, P1010, DOI 10.1002/hep.1840080506; Harimoto M, 2002, J BIOMED MATER RES, V62, P464, DOI 10.1002/jbm.10228; HONDA H, 1995, BIOTECHNOL LETT, V17, P365, DOI 10.1007/BF00130791; Hui EE, 2007, P NATL ACAD SCI USA, V104, P5722, DOI 10.1073/pnas.0608660104; Ito A, 2004, TISSUE ENG, V10, P833, DOI 10.1089/1076327041348301; Khetani SR, 2004, HEPATOLOGY, V40, P545, DOI 10.1002/hep.20351; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; LEE J, 1993, FASEB J, V7, P586, DOI 10.1096/fasebj.7.6.8472895; LEE JW, 1992, BIOTECHNOL BIOENG, V40, P298, DOI 10.1002/bit.260400214; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MARTINEZHERNANDEZ A, 1995, FASEB J, V9, P1401, DOI 10.1096/fasebj.9.14.7589981; MORIN O, 1986, J CELL PHYSIOL, V129, P103, DOI 10.1002/jcp.1041290115; Nahmias Y, 2006, HEPATOLOGY, V43, P257, DOI 10.1002/hep.21016; Nahmias Y, 2007, ADV BIOCHEM ENG BIOT, V103, P309, DOI 10.1007/10_029; Peters K, 2002, MICROVASC RES, V64, P334, DOI 10.1006/mvre.2002.2438; Rajagopalan P, 2006, TISSUE ENG, V12, P1553, DOI 10.1089/ten.2006.12.1553; ROJKIND M, 1995, AM J PATHOL, V146, P1508; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; UITTO J, 1975, SCIENCE, V190, P1202, DOI 10.1126/science.1198105; Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437	32	36	37	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2288	2298		10.1096/fj.08-114934	http://dx.doi.org/10.1096/fj.08-114934			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19246486	Green Published			2022-12-28	WOS:000268836500028
J	Lee, HS; Kim, EY; Kim, KH; Moon, J; Park, KS; Kim, KS; Lee, KA				Lee, Hyun-Seo; Kim, Eun-Young; Kim, Kyeoung-Hwa; Moon, Jisook; Park, Kyung-Soon; Kim, Kwang-Soo; Lee, Kyung-Ah			Obox4 critically regulates cAMP-dependent meiotic arrest and MI-MII transition in oocytes	FASEB JOURNAL			English	Article						oocyte maturation; GV arrest; RNA interference; overexpression	MOUSE OOCYTES; FOLLICULAR DEVELOPMENT; TRANSCRIPTION FACTORS; SPINDLE CHECKPOINT; EMBRYO DEVELOPMENT; CELL-INTERACTIONS; GENE-EXPRESSION; HOMEOBOX GENES; GERM-CELLS; IN-VITRO	Extra follicular oocytes spontaneously resume meiosis in vitro, but the intact germinal vesicle (GV) is retained if the oocytes are cultured in medium containing phosphodiesterase (PDE) inhibitors or cAMP analogues. On the basis of our finding that Obox4 is prominently expressed in oocytes, the present study was conducted to determine the functional role of the homeodomain-containing factor Obox4 during in vitro oocyte maturation. After microinjection of Obox4 dsRNA into the cytoplasm of GV oocytes cultured in M16 medium, oocytes were arrested at metaphase I (MI, 77.7%) and metaphase II (MII, 22.3%). Surprisingly, however, 89% of Obox4 RNAi-treated oocytes resumed meiosis and developed to MI and MII when cultured in medium containing 0.2 mM 3-isobutyl-1-metyl-xanthine (IBMX), in which untreated oocytes maintain intact GVs. Spindles were aberrant, and chromosomes were severely aggregated with decreased MPF and MAP kinase activities in arrested MI oocytes after exposure to Obox4 RNAi. Oocytes overexpressing Obox4 retained intact GVs when cultured in M16 medium. Taken together, for the first time to our knowledge, these findings indicate that Obox4 plays a key role in the cAMP-dependent signaling cascades that maintain GV arrest. Oocytes not expressing Obox4 failed to maintain intact GVs in IBMX-supplemented medium, while GVs remained intact when oocytes were kept in plain medium and overexpressing Obox4, suggesting that Obox4 plays a critical role in cAMP-dependent cascade for maintaining intact GVs.-Lee, H.-S., Kim, E.-Y., Kim, K.-H., Moon, J., Park, K.-S., Kim, K.-S., Lee, K.-A. Obox4 critically regulates cAMP-dependent meiotic arrest and MI-MII transition in oocytes. FASEB J. 24, 2314-2324 (2010). www.fasebj.org	[Lee, Hyun-Seo; Kim, Eun-Young; Kim, Kyeoung-Hwa; Moon, Jisook; Park, Kyung-Soon; Lee, Kyung-Ah] CHA Univ, Dept Biomed Sci, Coll Life Sci, Seoul 135081, South Korea; [Moon, Jisook; Park, Kyung-Soon; Kim, Kwang-Soo; Lee, Kyung-Ah] CHA Univ, CHA Stem Cell Inst, Seoul 135081, South Korea; [Kim, Kwang-Soo] Harvard Univ, Sch Med, Mol Neurobiol Lab, McLean Hosp, Boston, MA USA	Pochon Cha University; Pochon Cha University; Harvard University; Harvard Medical School; McLean Hospital	Lee, KA (corresponding author), CHA Univ, Dept Biomed Sci, Coll Life Sci, 606-13 Yeoksam 1 Dong, Seoul 135081, South Korea.	leeka@ovary.co.kr			Ministry of Science and Technology, Republic of Korea [SC4021]	Ministry of Science and Technology, Republic of Korea(Ministry of Science & Technology (MOST), Republic of Korea)	This work was supported by a grant (SC4021) from the Stem Cell Research Center of the 21st Century Frontier Research Program, funded by the Ministry of Science and Technology, Republic of Korea.	Anger M, 2005, BIOL REPROD, V72, P188, DOI 10.1095/biolreprod.104.035451; Barnes FL, 2000, SEMIN REPROD MED, V18, P123, DOI 10.1055/s-2000-12551; Cao YK, 2005, REPRODUCTION, V130, P431, DOI 10.1530/rep.1.00391; CHO WK, 1974, J EXP ZOOL, V187, P383, DOI 10.1002/jez.1401870307; Conti M, 2002, MOL CELL ENDOCRINOL, V187, P153, DOI 10.1016/S0303-7207(01)00686-4; Conti M, 2002, BIOL REPROD, V67, P1653, DOI 10.1095/biolreprod.102.004952; FULKA J, 1993, MOL REPROD DEV, V34, P427, DOI 10.1002/mrd.1080340412; Fulka J, 2004, TRENDS BIOTECHNOL, V22, P279, DOI 10.1016/j.tibtech.2004.04.002; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Juengel JL, 2002, BIOL REPROD, V67, P1777, DOI 10.1095/biolreprod.102.007146; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Kezele P, 2002, FRONT BIOSCI-LANDMRK, V7, pD1990, DOI 10.2741/kezele; Kim KH, 2008, BIOL REPROD, V79, P1192, DOI 10.1095/biolreprod.108.068478; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; Ledan E, 2001, DEV BIOL, V232, P400, DOI 10.1006/dbio.2001.0188; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; Mannervik M, 1999, BIOESSAYS, V21, P267, DOI 10.1002/(SICI)1521-1878(199904)21:4<267::AID-BIES1>3.3.CO;2-3; Park CE, 2004, MOL REPROD DEV, V69, P365, DOI 10.1002/mrd.20179; PEDERSEN T, 1968, J REPROD FERTIL, V17, P555, DOI 10.1530/jrf.0.0170555; PETERS H, 1969, ACTA ENDOCRINOL-COP, V62, P98, DOI 10.1530/acta.0.0620098; Rajkovic A, 2004, SCIENCE, V305, P1157, DOI 10.1126/science.1099755; Rajkovic A, 2002, GENOMICS, V79, P711, DOI 10.1006/geno.2002.6759; SCHULTZ RM, 1977, P NATL ACAD SCI USA, V74, P538, DOI 10.1073/pnas.74.2.538; Svingen T, 2007, SEX DEV, V1, P12, DOI 10.1159/000096235; Svingen T, 2006, HEREDITY, V97, P88, DOI 10.1038/sj.hdy.6800847; Svoboda P, 2000, DEVELOPMENT, V127, P4147; THIBAULT C, 1977, J REPROD FERTIL, V51, P1; Thomas FH, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-19; Tsafriri A, 1996, DEV BIOL, V178, P393, DOI 10.1006/dbio.1996.0226; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016; Yoon SJ, 2006, FERTIL STERIL, V86, P1129, DOI 10.1016/j.fertnstert.2006.02.105; Yoon SJ, 2009, BIOL REPROD, V81, P497, DOI 10.1095/biolreprod.108.073759; Yoon SJ, 2005, FERTIL STERIL, V83, P1293, DOI 10.1016/j.fertnstert.2004.09.037	34	11	11	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2314	2324		10.1096/fj.09-147314	http://dx.doi.org/10.1096/fj.09-147314			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20154267				2022-12-28	WOS:000279343600018
J	Diavatopoulos, DA; Short, KR; Price, JT; Wilksch, JJ; Brown, LE; Briles, DE; Strugnell, RA; Wijburg, OL				Diavatopoulos, Dimitri A.; Short, Kirsty R.; Price, John T.; Wilksch, Jonathan J.; Brown, Lorena E.; Briles, David E.; Strugnell, Richard A.; Wijburg, Odilia L.			Influenza A virus facilitates Streptococcus pneumoniae transmission and disease	FASEB JOURNAL			English	Article						viral-bacterial interactions; pneumococcal disease; pandemic; respiratory infectious disease	NASOPHARYNGEAL COLONIZATION; PNEUMOCOCCAL PNEUMONIA; LETHAL SYNERGISM; INFECTION; MICE; SUSCEPTIBILITY; CHILDREN; ASSOCIATION; ANTIBODIES; RESOLUTION	Streptococcus pneumoniae (the pneumococcus) kills similar to 1.6 million people annually. Pneumococcal infections predominantly manifest as pneumonia, sepsis, meningitis, and otitis media. S. pneumoniae is also a member of the normal nasopharyngeal flora, colonizing up to 80% of children. Infection with influenza A virus (IAV) has been associated with both pneumococcal disease and transmission. However, to date no animal model has been available to investigate the role of IAV in the spread of S. pneumoniae. Here we investigate pneumococcal-influenza synergism with a particular focus on the role of IAV on pneumococcal transmission. Infant mice were colonized with S. pneumoniae and subsequently infected with IAV 3 d later. Using this novel model we show increased pneumococcal colonization and disease in the presence of IAV. Notably, in vivo imaging showed that IAV was essential for the transmission of S. pneumoniae from colonized ("index") mice to their naive cohoused littermates ("contacts"). Transmission occurred only when all mice were infected with IAV and was prevented when an IAV-neutralizing antibody was used to inhibit IAV replication in either index mice or contact mice. Together, these data provide novel insights into pneumococcal-influenza synergism and may indicate a previously unappreciated role of IAV in the spread of S. pneumoniae.-Diavatopoulos, D. A., Short, K. R., Price, J. T., Wilksch, J. J., Brown, L. E., Briles, D. E., Strugnell, R. A., Wijburg, O. L. Influenza A virus facilitates Streptococcus pneumoniae transmission and disease. FASEB J. 24, 1789-1798 (2010). www.fasebj.org	[Diavatopoulos, Dimitri A.; Short, Kirsty R.; Wilksch, Jonathan J.; Brown, Lorena E.; Strugnell, Richard A.; Wijburg, Odilia L.] Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic, Australia; [Price, John T.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Briles, David E.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Strugnell, Richard A.; Wijburg, Odilia L.] Univ Melbourne, Australian Bacterial Pathogenesis Program, Parkville, Vic 3052, Australia	University of Melbourne; Monash University; University of Alabama System; University of Alabama Birmingham; University of Melbourne	Diavatopoulos, DA (corresponding author), Radboud Univ Nijmegen, Med Ctr, Lab Pediat Infect Dis, Kapittelweg 29, NL-6525 EN Nijmegen, Netherlands.	d.diavatopoulos@cukz.umcn.nl	Diavatopoulos, Dimitri A/L-4269-2015	Diavatopoulos, Dimitri A/0000-0001-7065-7807; Short, Kirsty/0000-0003-4963-6184; Brown, Lorena/0000-0001-9342-909X; Price, John/0000-0002-8244-1023; Strugnell, Richard/0000-0003-0614-5641	National Health and Medical Research Council of Australia (NHMRC) [400011, 284214]	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia)	The authors thank Mrs. Emily Fairmaid (University of Melbourne, Melbourne, VIC, Australia) for assistance with the HI tests, Dr. Reinhold Bruckner (University of Kaiserslautern, Kaiserslautern, Germany) for the kind gift of the pPP2 plasmid, Dr. Vyvyan Salisbury (University of the West of England, Bristol, UK) for providing the pAL2 plasmid, and Prof. J. Paton and Dr. D. Ogunniyi (University of Adelaide, Adelaide, SA, Australia) for technical help and advice. This work was supported by the National Health and Medical Research Council of Australia (NHMRC) grants 400011 and 284214. O.L.W. is an NHMRC R. D. Wright Fellow.	Adegbola RA, 2001, PEDIATR INFECT DIS J, V20, P718, DOI 10.1097/00006454-200107000-00018; [Anonymous], 2003, Weekly Epidemiological Record, V78, P110; Baumann M, 2000, MACROMOL MATER ENG, V280, P1, DOI 10.1002/1439-2054(20000801)280:1<1::AID-MAME1>3.0.CO;2-U; Beard SJ, 2002, ANTIMICROB AGENTS CH, V46, P538, DOI 10.1128/AAC.46.2.538-542.2002; Briles DE, 2005, INFECT IMMUN, V73, P6945, DOI 10.1128/IAI.73.10.6945-6951.2005; BRILES DE, 1992, INFECT IMMUN, V60, P111, DOI 10.1128/IAI.60.1.111-116.1992; BROWN LE, 1990, ARCH VIROL, V114, P1, DOI 10.1007/BF01311008; Brundage JF, 2006, LANCET INFECT DIS, V6, P303, DOI 10.1016/S1473-3099(06)70466-2; Burghout P, 2007, J BACTERIOL, V189, P6540, DOI 10.1128/JB.00573-07; CONVERSE GM, 1977, J CLIN MICROBIOL, V5, P293; Didierlaurent A, 2008, J EXP MED, V205, P323, DOI 10.1084/jem.20070891; GRAY BM, 1980, J INFECT DIS, V142, P923, DOI 10.1093/infdis/142.6.923; GWALTNEY JM, 1975, J INFECT DIS, V132, P62, DOI 10.1093/infdis/132.1.62; Halfmann A, 2007, FEMS MICROBIOL LETT, V268, P217, DOI 10.1111/j.1574-6968.2006.00584.x; Holsapple MP, 2003, BIRTH DEFECTS RES B, V68, P321, DOI 10.1002/bdrb.10035; Jansen AGSC, 2008, EPIDEMIOL INFECT, V136, P1448, DOI 10.1017/S0950268807000271; Jones N, 1998, AIDS, V12, P2177, DOI 10.1097/00002030-199816000-00013; Joyce EA, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-404; Kadioglu A, 2008, NAT REV MICROBIOL, V6, P288, DOI 10.1038/nrmicro1871; Malley R, 1998, J INFECT DIS, V178, P878, DOI 10.1086/597600; McCullers JA, 2003, J INFECT DIS, V187, P1000, DOI 10.1086/368163; McCullers JA, 2002, J INFECT DIS, V186, P341, DOI 10.1086/341462; McCullers JA, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030028; McCullers JA, 2006, CLIN MICROBIOL REV, V19, P571, DOI 10.1128/CMR.00058-05; McNamee LA, 2006, INFECT IMMUN, V74, P6707, DOI 10.1128/IAI.00789-06; Mozdzanowska K, 2003, J VIROL, V77, P8322, DOI 10.1128/JVI.77.15.8322-8328.2003; NOVAK M, 1993, VACCINE, V11, P55, DOI 10.1016/0264-410X(93)90339-Y; O'Brien KL, 2000, CLIN INFECT DIS, V30, P784, DOI 10.1086/313772; ODIE EL, 1921, EPIDEMIC RESP DIS PN; OSLER W, 1901, PRINCIPLES PRACTICE; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; RYTEL MW, 1969, J GEN VIROL, V5, P429, DOI 10.1099/0022-1317-5-3-429; Sa-Leado R, 2008, J CLIN MICROBIOL, V46, P225, DOI 10.1128/JCM.01551-07; Sambrook J., 2001, MOL CLONING LAB MANU; SCHULMAN JL, 1962, NATURE, V195, P1129, DOI 10.1038/1951129a0; SCHULMAN JL, 1963, J EXP MED, V118, P257, DOI 10.1084/jem.118.2.257; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; Smith-Vaughan Heidi, 2008, BMC Res Notes, V1, P112, DOI 10.1186/1756-0500-1-112; Speshock JL, 2007, INFECT IMMUN, V75, P3102, DOI 10.1128/IAI.01943-06; Trappetti C, 2009, J INFECT DIS, V199, P1497, DOI 10.1086/598483; van der Sluijs KF, 2004, J IMMUNOL, V172, P7603, DOI 10.4049/jimmunol.172.12.7603; WADOWSKY RM, 1995, INFECT IMMUN, V63, P1153, DOI 10.1128/IAI.63.4.1153-1157.1995; Wu R, 2010, VET MICROBIOL, V142, P211, DOI 10.1016/j.vetmic.2009.09.068; Yagupsky P, 1998, J INFECT DIS, V177, P1003, DOI 10.1086/515239; Zhang Z, 2009, J CLIN INVEST, V119, P1899, DOI 10.1172/JCI36731	45	134	134	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1789	1798		10.1096/fj.09-146779	http://dx.doi.org/10.1096/fj.09-146779			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20097876				2022-12-28	WOS:000278200000016
J	Shumilina, E; Xuan, NT; Matzner, N; Bhandaru, M; Zemtsova, IM; Lang, F				Shumilina, Ekaterina; Xuan, Nguyen Thi; Matzner, Nicole; Bhandaru, Madhuri; Zemtsova, Irina M.; Lang, Florian			Regulation of calcium signaling in dendritic cells by 1,25-dihydroxyvitamin D-3	FASEB JOURNAL			English	Article						Na+/Ca2+ exchanger; CD86; lipopolysaccharide; 3 ',4 '-dichlorobenzamyl	VITAMIN-D-RECEPTOR; DEPENDENT NA+/CA2+ EXCHANGERS; NA/CA EXCHANGE; CO-STIMULATION; CA2+; MODULATION; PATHWAYS; ENTRY; 1-ALPHA,25-DIHYDROXYVITAMIN-D-3; ENCEPHALOMYELITIS	Dendritic cells (DCs) are antigen- presenting cells that provide a link between innate and adaptive immunity. Ca2+-dependent signaling plays a central regulatory role in DC responses to diverse antigens. DCs are a primary target of 1,25-dihydroxyvitamin D-3 [1,25(OH)(2)D-3], a secosteroid hormone, that, in addition to its well-established action on Ca2+ homeostasis, possesses immunomodulatory properties. Surprisingly, nothing is known about its effects on DC cytosolic Ca2+ activity. The present study explored whether 1,25(OH)(2)D-3 modifies the intracellular Ca2+ concentration ([Ca2+](i)) in DCs. Here we show that mouse DCs expressed K+-independent (NCX1-3) and K+-dependent (NCKX1, 3, 4, and 5) Na+/Ca2+ exchangers. Acute application of LPS (100 ng/ml) to DCs increased [Ca2+](i), an effect significantly blunted by prior incubation with 1,25(OH)(2)D-3. 1,25(OH)(2)D-3 increased the membrane abundance of the NCKX1 protein, up-regulated the K+- and Na+-dependent Ca2+ entry and enhanced the K+-dependent Na+/Ca2+ exchanger currents. The NCKX blocker 3',4'-dichlorobenzamyl (DBZ) reversed the inhibitory effect of 1,25(OH)(2)D-3 on the LPS-induced increase of [Ca2+](i). Expression of the costimulatory molecule CD86 was down-regulated by 1,25(OH)(2)D-3, an effect reversed by DBZ. In summary, 1,25(OH)(2)D-3 blunts the LPS-induced increase in [Ca2+](i) by stimulation of Na+/Ca2+ exchanger-dependent Ca2+ extrusion, an effect that contributes to 1,25(OH)(2)D-3-mediated immunosuppression. The results disclose completely novel mechanisms in the regulation of DC maturation and function.-Shumilina, E., Xuan, N. T., Matzner, N., Bhandaru, M., Zemtsova, I. M., Lang, F. Regulation of calcium signaling in dendritic cells by 1,25-dihydroxyvitamin D-3. FASEB J. 24, 1989-1996 (2010). www.fasebj.org	[Shumilina, Ekaterina; Xuan, Nguyen Thi; Matzner, Nicole; Bhandaru, Madhuri; Zemtsova, Irina M.; Lang, Florian] Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Lang, F (corresponding author), Univ Tubingen, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	florian.lang@uni-tuebingen.de		Xuan, Nguyen Thi/0000-0003-3494-5136	Deutsche Forschungsgemeinschaft [SFB 766, GRK 1302/1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors gratefully acknowledge the technical assistance of E. Faber and the meticulous preparation of the manuscript by Lejla Subasic and Tanja Loch. This work was supported by the Deutsche Forschungsgemeinschaft (SFB 766; GRK 1302/1).	Adorini L, 2004, J STEROID BIOCHEM, V89-90, P437, DOI 10.1016/j.jsbmb.2004.03.013; Aki D, 2008, GENES CELLS, V13, P199, DOI 10.1111/j.1365-2443.2007.01159.x; Aneiros E, 2005, J IMMUNOL, V174, P119, DOI 10.4049/jimmunol.174.1.119; BALASUBRAMANYAM M, 1994, J CLIN INVEST, V94, P2002, DOI 10.1172/JCI117553; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Barbet G, 2008, NAT IMMUNOL, V9, P1148, DOI 10.1038/ni.1648; BECKLUND BR, 2009, P NATL ACAD SCI US; Bellou A, 2005, CURR ALLERGY ASTHM R, V5, P149, DOI 10.1007/s11882-005-0089-6; Berridge MJ, 2006, CELL CALCIUM, V40, P405, DOI 10.1016/j.ceca.2006.09.002; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Canitano A, 2002, ANN NY ACAD SCI, V976, P394; Cantorna MT, 1999, J NUTR, V129, P1966, DOI 10.1093/jn/129.11.1966; Cantorna MT, 2004, AM J CLIN NUTR, V80, p1717S, DOI 10.1093/ajcn/80.6.1717S; Cantorna MT, 1996, P NATL ACAD SCI USA, V93, P7861, DOI 10.1073/pnas.93.15.7861; Choy EH, 2009, CLIN EXP RHEUMATOL, V27, P510; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; Connolly SF, 2007, IMMUNOL RES, V39, P115, DOI 10.1007/s12026-007-0076-1; Deluca HF, 2001, FASEB J, V15, P2579, DOI 10.1096/fj.01-0433rev; den Haan JMM, 2000, P NATL ACAD SCI USA, V97, P12950, DOI 10.1073/pnas.97.24.12950; Fritsche J, 2003, BLOOD, V102, P3314, DOI 10.1182/blood-2002-11-3521; Gauzzi MC, 2005, J IMMUNOL, V174, P270, DOI 10.4049/jimmunol.174.1.270; Griffin MD, 2007, ARCH BIOCHEM BIOPHYS, V460, P218, DOI 10.1016/j.abb.2007.01.034; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heine G, 2008, EUR J IMMUNOL, V38, P2210, DOI 10.1002/eji.200838216; Herchuelz A, 2007, ANN NY ACAD SCI, V1099, P456, DOI 10.1196/annals.1387.048; Herrmann TL, 2007, J LEUKOCYTE BIOL, V82, P686, DOI 10.1189/jlb.0107045; Hewison M, 2003, J IMMUNOL, V170, P5382, DOI 10.4049/jimmunol.170.11.5382; Hewison M, 2003, J BONE MINER RES, V18, P579, DOI 10.1359/jbmr.2003.18.3.579; Hsu SF, 2001, J IMMUNOL, V166, P6126, DOI 10.4049/jimmunol.166.10.6126; Imazeki I, 2006, BIOMED RES-TOKYO, V27, P1, DOI 10.2220/biomedres.27.1; Kimura M, 1999, AM J PHYSIOL-HEART C, V277, pH911, DOI 10.1152/ajpheart.1999.277.3.H911; Korhonen R, 2009, BASIC CLIN PHARMACOL, V104, P276, DOI 10.1111/j.1742-7843.2009.00375.x; Koski GK, 1999, J IMMUNOL, V163, P82; Lagana B, 2009, CLIN DRUG INVEST, V29, P185, DOI 10.2165/00044011-200929030-00005; Lambers TT, 2006, KIDNEY INT, V69, P650, DOI 10.1038/sj.ki.5000169; LEMIRE JM, 1991, J CLIN INVEST, V87, P1103, DOI 10.1172/JCI115072; Lyakh LA, 2005, J IMMUNOL, V174, P2061, DOI 10.4049/jimmunol.174.4.2061; Lytton J, 2007, BIOCHEM J, V406, P365, DOI 10.1042/BJ20070619; Matzner N, 2008, J IMMUNOL, V181, P6803, DOI 10.4049/jimmunol.181.10.6803; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Penna G, 2007, J IMMUNOL, V178, P145, DOI 10.4049/jimmunol.178.1.145; Ramasamy I, 2006, CLIN CHEM LAB MED, V44, P237, DOI 10.1515/CCLM.2006.046; Reppel M, 2007, ANN NY ACAD SCI, V1099, P361, DOI 10.1196/annals.1387.065; Rogister F, 2001, EUR J MED CHEM, V36, P597, DOI 10.1016/S0223-5234(01)01247-8; Rumpel E, 2000, BIOPHYS J, V79, P2975, DOI 10.1016/S0006-3495(00)76534-9; Schmitt R, 1999, AM J PHYSIOL-RENAL, V276, pF367, DOI 10.1152/ajprenal.1999.276.3.F367; Sipido KR, 2007, ANN NY ACAD SCI, V1099, P339, DOI 10.1196/annals.1387.066; Staiano RL, 2009, EUR J IMMUNOL, V39, P1405, DOI 10.1002/eji.200838792; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Szeles L, 2009, J IMMUNOL, V182, P2074, DOI 10.4049/jimmunol.0803345; Tintinger GR, 2004, BIOCHEM PHARMACOL, V67, P2263, DOI 10.1016/j.bcp.2004.02.029; van Etten E, 2005, J STEROID BIOCHEM, V97, P93, DOI 10.1016/j.jsbmb.2005.06.002; Venetucci LA, 2007, ANN NY ACAD SCI, V1099, P315, DOI 10.1196/annals.1387.033; Visser F, 2007, PHYSIOLOGY, V22, P185, DOI 10.1152/physiol.00001.2007; Visser F, 2007, J BIOL CHEM, V282, P4453, DOI 10.1074/jbc.M610582200; Vukcevic M, 2008, J BIOL CHEM, V283, P34913, DOI 10.1074/jbc.M804472200; Yamazaki S, 2009, J DERMATOL SCI, V54, P69, DOI 10.1016/j.jdermsci.2009.02.001; Yu SH, 2008, P NATL ACAD SCI USA, V105, P5207, DOI 10.1073/pnas.0711558105; Zehnder D, 1999, MOL CELL ENDOCRINOL, V151, P213, DOI 10.1016/S0303-7207(99)00039-8	60	25	26	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1989	1996		10.1096/fj.09-142265	http://dx.doi.org/10.1096/fj.09-142265			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20124438				2022-12-28	WOS:000278200000033
J	Sun, DW; Nakao, S; Xie, F; Zandi, S; Schering, A; Hafezi-Moghadam, A				Sun, Dawei; Nakao, Shintaro; Xie, Fang; Zandi, Souska; Schering, Alexander; Hafezi-Moghadam, Ali			Superior sensitivity of novel molecular imaging probe: simultaneously targeting two types of endothelial injury markers	FASEB JOURNAL			English	Article						early diagnosis; ocular inflammation; leukocyte-endothelial interaction; adhesion molecules	ENDOTOXIN-INDUCED UVEITIS; SELECTIN GLYCOPROTEIN LIGAND-1; ROLLING IN-VIVO; P-SELECTIN; UP-REGULATION; CELLS; ADHESION; ICAM-1; LFA-1; DISEASE	The need remains great for early diagnosis of diseases. The special structure of the eye provides a unique opportunity for noninvasive light-based imaging of fundus vasculature. To detect endothelial injury at the early and reversible stage of adhesion molecule up-regulation, we generated novel imaging agents that target two distinct types of endothelial molecules, a mediator of rolling, P-selectin, and one that mediates firm adhesion, ICAM-1. Interactions of these double-conjugated fluorescent microspheres (MSs) in retinal or choroidal microvasculature were visualized in live animals by scanning laser ophthalmoscopy. The new imaging agents showed significantly higher sensitivity for detection of endothelial injury than singly conjugated MSs (rPSGL-1- or alpha-ICAM-1-conjugated), both in terms of rolling (P<0.01) and firm adhesion (P<0.01). The rolling flux of alpha-ICAM-1-conjugated MSs did not differ in EIU animals, whereas double-conjugated MSs showed significantly higher rolling flux (P<0.01), revealing that ICAM-1 in vivo supports rolling, once MS interaction with the endothelium is initiated. Double-conjugated MSs specifically detected firmly adhering leukocytes (P<0.01), allowing in vivo quantification of immune response. Antiinflammatory treatment with dexamethasone led to reduced leukocyte accumulation (P<0.01) as well as MS interaction (P<0.01), which suggests that treatment success and resolution of inflammation is quantitatively reflected with this molecular imaging approach. This work introduces novel imaging agents for noninvasive detection of endothelial injury in vivo. Our approach may be developed further to diagnose human disease at a much earlier stage than currently possible.-Sun, D., Nakao, S., Xie, F., Zandi, S., Schering, A., Hafezi-Moghadam, A. Superior sensitivity of novel molecular imaging probe: simultaneously targeting two types of endothelial injury markers. FASEB J. 24, 1532-1540 (2010). www.fasebj.org	[Sun, Dawei; Nakao, Shintaro; Xie, Fang; Zandi, Souska; Schering, Alexander; Hafezi-Moghadam, Ali] Harvard Univ, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Sch Med,Angiogenesis Lab, Boston, MA 02114 USA; [Sun, Dawei] Harbin Med Coll, Dept Ophthalmol, Affiliated Hosp 2, Harbin, Peoples R China	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harbin Medical University	Hafezi-Moghadam, A (corresponding author), Harvard Univ, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Sch Med,Angiogenesis Lab, 325 Cambridge St,3rd Floor, Boston, MA 02114 USA.	ali_hafezi-moghadam@hms.harvard.edu		Hafezi-Moghadam, Ali/0000-0002-5336-0697; Zandi, Souska/0000-0001-9351-4278	U.S. National Institute of Health (NIH) [AI050775, HL086933]; Science and Technology project of Heilongjiang Province, China [GB06C40104]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050775] Funding Source: NIH RePORTER	U.S. National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Science and Technology project of Heilongjiang Province, China; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Recombinant PSGL-1 (Y's PSGL) was a generous gift of Y's Therapeutics, Inc. (San Bruno, CA, USA). The authors thank Mark I. Melhorn and Rebecca C. Garland for their help in the preparation of this manuscript. This work was supported by U.S. National Institute of Health (NIH) grants AI050775 (A.H.-M.) and HL086933 (Alan Cross, University of Maryland, College Park, MD, USA), the American Health Assistance Foundation (A.H.-M.), and a Science and Technology project of Heilongjiang Province, China (GB06C40104 to D. S.). The authors thank the Massachusetts Lions Eye Research Fund Inc., Research to Prevent Blindness, and the Marion W. and Edward F. Knight AMD Fund. Author contributions: A.H.-M. designed research; D.S., S.N., F.X., and S.Z. performed research; D.S., A.S., and A.H.-M. analyzed data; D. S. and A.H.-M. wrote the paper.	Becker MD, 2001, INVEST OPHTH VIS SCI, V42, P2563; BISCHOFF PM, 1995, RETINA-J RET VIT DIS, V15, P91, DOI 10.1097/00006982-199515020-00002; CRONSTEIN BN, 1992, P NATL ACAD SCI USA, V89, P9991, DOI 10.1073/pnas.89.21.9991; Devine L, 1996, IMMUNOLOGY, V88, P456, DOI 10.1046/j.1365-2567.1996.d01-666.x; Durrani OM, 2004, OPHTHALMOLOGICA, V218, P223, DOI 10.1159/000078612; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Hafezi-Moghadam A, 2007, FASEB J, V21, P464, DOI 10.1096/fj.06-6390com; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; Hirata Y, 2006, PROG RETIN EYE RES, V25, P129, DOI 10.1016/j.preteyeres.2005.08.001; Jin XH, 2006, INVEST OPHTH VIS SCI, V47, P2562, DOI 10.1167/iovs.05-1429; Kanagawa T, 1996, JPN J OPHTHALMOL, V40, P174; Khoobehi B, 1997, OPHTHALMIC SURG LAS, V28, P937; Laszik Z, 1996, BLOOD, V88, P3010, DOI 10.1182/blood.V88.8.3010.bloodjournal8883010; Miyahara S, 2008, FASEB J, V22, P1973, DOI 10.1096/fj.07-096891; Miyamoto K, 1996, INVEST OPHTH VIS SCI, V37, P2708; Moore KL, 1998, LEUKEMIA LYMPHOMA, V29, P1, DOI 10.3109/10428199809058377; Nakao S, 2007, AM J PATHOL, V171, P1058, DOI 10.2353/ajpath.2007.070172; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; ROSENBAUM JT, 1980, NATURE, V286, P611, DOI 10.1038/286611a0; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; Suzuma K, 1997, INVEST OPHTH VIS SCI, V38, P1610; Xu HP, 2003, INVEST OPHTH VIS SCI, V44, P226, DOI 10.1167/iovs.01-1202	23	25	25	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1532	1540		10.1096/fj.09-148981	http://dx.doi.org/10.1096/fj.09-148981			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20103715	Green Published			2022-12-28	WOS:000277158900026
J	Gosens, R; Baarsma, HA; Heijink, IH; Oenema, TA; Halayko, AJ; Meurs, H; Schmidt, M				Gosens, Reinoud; Baarsma, Hoeke A.; Heijink, Irene H.; Oenema, Tjitske A.; Halayko, Andrew J.; Meurs, Herman; Schmidt, Martina			De novo synthesis of beta-catenin via H-Ras and MEK regulates airway smooth muscle growth	FASEB JOURNAL			English	Article						GSK-3; airway remodeling; asthma; Wnt; proliferation	IDIOPATHIC PULMONARY-FIBROSIS; MAP KINASE ACTIVATION; CELL-PROLIFERATION; PATHWAY ACTIVATION; COLON-CANCER; WNT; EXPRESSION; CADHERIN; DISEASE; COMPLEX	beta-Catenin is a component of adherens junctions that also acts as a transcriptional coactivator when expressed in the nucleus. Growth factors are believed to regulate the nuclear expression of beta-catenin via inactivation of glycogen synthase kinase 3 (GSK-3) by phosphorylation, resulting in increased beta-catenin protein stability. Here, we report on a novel pathway that regulates the expression and nuclear presence of beta-catenin. In proliferating human airway smooth muscle cells, we observed increased expression of beta-catenin, which was required for proliferation. Interestingly, increased beta-catenin expression was accompanied by an increase in beta-catenin mRNA and was independent of beta-catenin liberation from the plasma membrane, suggesting a role for de novo synthesis. This was confirmed using actinomycin D and cycloheximide, which abrogated the induction and nuclear localization of beta-catenin protein. GSK-3 inhibition using SB216763 failed to regulate beta-catenin mRNA. However, expression of dominant negative H-Ras or pharmacological inhibition of MEK reduced serum and TGF-beta-induced beta-catenin mRNA and protein. Collectively, these data indicate that beta-catenin is an important signaling intermediate in airway smooth muscle growth and that its cellular accumulation and nuclear localization require de novo protein synthesis effected, in part, via H-Ras and MEK.-Gosens, R., Baarsma, H. A., Heijink, I. H., Oenema, T. A., Halayko, A. J., Meurs, H., Schmidt, M. De novo synthesis of beta-catenin via H-Ras and MEK regulates airway smooth muscle growth. FASEB J. 24, 757-768 (2010). www.fasebj.org	[Gosens, Reinoud; Baarsma, Hoeke A.; Oenema, Tjitske A.; Meurs, Herman; Schmidt, Martina] Univ Groningen, Dept Mol Pharmacol, NL-9713 AV Groningen, Netherlands; [Heijink, Irene H.] Univ Med Ctr Groningen, Dept Med Biol & Pathol, NL-9713 AV Groningen, Netherlands; [Halayko, Andrew J.] Univ Manitoba, Dept Physiol, Winnipeg, MB, Canada; [Halayko, Andrew J.] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada	University of Groningen; University of Groningen; University of Manitoba; University of Manitoba	Gosens, R (corresponding author), Univ Groningen, Dept Mol Pharmacol, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	r.gosens@rug.nl	Schmidt, Martina/C-5339-2018	Schmidt, Martina/0000-0003-3075-0630; Gosens, Reinoud/0000-0002-5595-152X; Halayko, Andrew/0000-0002-7865-4552; Baarsma, Hoeke/0000-0002-0792-0374	Dutch Organisation for Scientific Research (NWO) [916.86.036]; University of Groningen; The Netherlands Asthma Foundation [NAF 3.2.07.023]; Boehringer Ingelheim; Canada Research Chairs Program; Canadian Institutes of Health Research	Dutch Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); University of Groningen; The Netherlands Asthma Foundation; Boehringer Ingelheim(Boehringer Ingelheim); Canada Research Chairs Program(Canada Research Chairs); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by a Veni grant (916.86.036) from the Dutch Organisation for Scientific Research (NWO) to R. G. M. S. is the recipient of a Rosalind Franklin Fellowship from the University of Groningen. H. A. B. is supported by a grant from The Netherlands Asthma Foundation (NAF 3.2.07.023). T.A.O. is supported by a grant from Boehringer Ingelheim. A.J.H. is supported by the Canada Research Chairs Program and Canadian Institutes of Health Research. We are grateful to Dr. W. T. Gerthoffer (University of Nevada-Reno, Reno, NV, USA) for preparation of the hTERT cell lines used in the study. We thank Bart G. J. Dekkers for expert technical assistance.	Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; An SS, 2007, EUR RESPIR J, V29, P834, DOI 10.1183/09031936.00112606; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Blankesteijn WM, 2008, TRENDS PHARMACOL SCI, V29, P175, DOI 10.1016/j.tips.2008.01.003; Bowley E, 2007, J SURG RES, V138, P141, DOI 10.1016/j.jss.2006.07.026; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Chilosi M, 2003, AM J PATHOL, V162, P1495, DOI 10.1016/S0002-9440(10)64282-4; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; De Langhe SP, 2005, DEV BIOL, V277, P316, DOI 10.1016/j.ydbio.2004.09.023; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Douglas IS, 2006, AM J RESP CELL MOL, V34, P274, DOI 10.1165/rcmb.2005-0277OC; George SJ, 2006, ATHEROSCLEROSIS, V188, P1, DOI 10.1016/j.atherosclerosis.2005.12.017; George SJ, 2004, TRENDS CARDIOVAS MED, V14, P100, DOI 10.1016/j.tcm.2003.12.008; Gosens R, 2008, N-S ARCH PHARMACOL, V378, P185, DOI 10.1007/s00210-008-0269-8; Gosens R, 2007, AM J PHYSIOL-LUNG C, V293, pL1348, DOI 10.1152/ajplung.00346.2007; Gosens R, 2007, AM J PHYSIOL-LUNG C, V292, pL1163, DOI 10.1152/ajplung.00471.2006; Gosens R, 2006, AM J PHYSIOL-LUNG C, V291, pL523, DOI 10.1152/ajplung.00013.2006; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Hirst Stuart J, 2004, J Allergy Clin Immunol, V114, pS2, DOI 10.1016/j.jaci.2004.04.039; Howe LR, 1999, CANCER RES, V59, P1572; Hwang SG, 2005, FEBS LETT, V579, P4837, DOI 10.1016/j.febslet.2005.07.067; Iwano M, 2004, CURR OPIN NEPHROL HY, V13, P279, DOI 10.1097/00041552-200405000-00003; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; Jeon SH, 2007, J BIOL CHEM, V282, P14482, DOI 10.1074/jbc.M611129200; Kim D, 2007, ONCOGENE, V26, P4571, DOI 10.1038/sj.onc.1210230; Kim SE, 2007, CELL SIGNAL, V19, P1554, DOI 10.1016/j.cellsig.2007.02.003; Konigshoff M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002142; LE FN, 2005, FASEB J, V19, P144; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Marchetti A, 2008, CELL SIGNAL, V20, P2113, DOI 10.1016/j.cellsig.2008.08.002; Masckauchan T. Nestor H., 2005, Angiogenesis, V8, P43, DOI 10.1007/s10456-005-5612-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nunes RO, 2008, AM J PHYSIOL-LUNG C, V294, pL1110, DOI 10.1152/ajplung.00500.2007; Rahmani M, 2005, J BIOL CHEM, V280, P13019, DOI 10.1074/jbc.M411766200; Slater SC, 2004, ARTERIOSCL THROM VAS, V24, P1204, DOI 10.1161/01.ATV.0000130464.24599.e0; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thompson MD, 2007, HEPATOLOGY, V45, P1298, DOI 10.1002/hep.21651; Toualbi K, 2007, ONCOGENE, V26, P3492, DOI 10.1038/sj.onc.1210133; Tran T, 2007, AM J RESP CELL MOL, V37, P668, DOI 10.1165/rcmb.2007-0165OC; Tran T, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-117; Truant SC, 2008, J SURG RES, V150, P212, DOI 10.1016/j.jss.2007.12.800; Uglow EB, 2003, CIRC RES, V92, P1314, DOI 10.1161/01.RES.0000079027.44309.53; Wang Q, 2006, ONCOGENE, V25, P43, DOI 10.1038/sj.onc.1209004; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Wu BB, 2007, IMMUNITY, V26, P227, DOI 10.1016/j.immuni.2006.12.007; Zhang XB, 2001, CANCER RES, V61, P6050	47	37	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2010	24	3					757	768		10.1096/fj.09-136325	http://dx.doi.org/10.1096/fj.09-136325			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19906679				2022-12-28	WOS:000274974600012
J	Wen, JM; Jiang, XZ; Dai, YB; Zhang, YJ; Tang, YX; Sun, H; Mi, TJ; Phatarpekar, PV; Kellems, RE; Blackburn, MR; Xia, Y				Wen, Jiaming; Jiang, Xianzhen; Dai, Yingbo; Zhang, Yujin; Tang, Yuxin; Sun, Hong; Mi, Tiejuan; Phatarpekar, Prasad V.; Kellems, Rodney E.; Blackburn, Michael R.; Xia, Yang			Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A(2B) adenosine receptor signaling	FASEB JOURNAL			English	Article						adenosine deaminase-deficient mice; sickle cell disease; TGF-beta; signaling pathway	DEAMINASE-DEFICIENT MICE; CAVERNOSAL NERVE RESECTION; SICKLE-CELL-DISEASE; VENOOCCLUSIVE DYSFUNCTION; FIBROBLAST PROLIFERATION; PULMONARY-FIBROSIS; LUNG FIBROBLASTS; FIBROTIC PLAQUE; NITRIC-OXIDE; MOUSE MODEL	Priapism is a condition of persistent penile erection in the absence of sexual excitation. Of men with sickle cell disease (SCD), 40% display priapism. The disorder is a dangerous and urgent condition, given its association with penile fibrosis and eventual erectile dysfunction. Current strategies to prevent its progression are poor because of a lack of fundamental understanding of the molecular mechanisms for penile fibrosis in priapism. Here we demonstrate that increased adenosine is a novel causative factor contributing to penile fibrosis in two independent animal models of priapism, adenosine deaminase (ADA)-deficient mice and SCD transgenic mice. An important finding is that chronic reduction of adenosine by ADA enzyme therapy successfully attenuated penile fibrosis in both mouse models, indicating an essential role of increased adenosine in penile fibrosis and a novel therapeutic possibility for this serious complication. Subsequently, we identified that both mice models share a similar fibrotic gene expression profile in penile tissue (including procollagen I, TGF-beta(1) 1, and plasminogen activator inhibitor-1 mRNA), suggesting that they share similar signaling pathways for progression to penile fibrosis. Thus, in an effort to decipher specific cell types and underlying mechanism responsible for adenosine-mediated penile fibrosis, we purified corpus cavernosal fibroblast cells (CCFCs), the major cell type involved in this process, from wild-type mice. Quantitative RT-PCR showed that the major receptor expressed in these cells is the adenosine receptor A(2B)R. Based on this fact, we further purified CCFCs from A(2B)R-deficient mice and demonstrated that A(2B)R is essential for excess adenosine-mediated penile fibrosis. Finally, we revealed that TGF-beta functions downstream of the A(2B)R to increase CCFC collagen secretion and proliferation. Overall, our studies identify an essential role of increased adenosine in the pathogenesis of penile fibrosis via A(2B)R signaling and offer a potential target for prevention and treatment of penile fibrosis, a dangerous complication seen in priapism.-Wen, J., Jiang, X., Dai, Y., Zhang, Y., Tang, Y., Sun, H., Mi, T., Phatarpekar, P. V., Kellems, R. E., Blackburn, M. R., Xia, Y. Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A(2B) adenosine receptor signaling. FASEB J. 24, 740-749 (2010). www.fasebj.org	[Wen, Jiaming; Dai, Yingbo; Zhang, Yujin; Mi, Tiejuan; Phatarpekar, Prasad V.; Kellems, Rodney E.; Blackburn, Michael R.; Xia, Yang] Univ Texas Houston Med Sch, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Wen, Jiaming; Jiang, Xianzhen; Dai, Yingbo; Tang, Yuxin] Cent S Univ, Xiangya Hosp 3, Dept Urol, Changsha, Hunan, Peoples R China; [Sun, Hong] Cent S Univ, Xiangya Hosp 3, Dept Otorhinolaryngol, Changsha, Hunan, Peoples R China	University of Texas System; University of Texas Health Science Center Houston; Central South University; Central South University	Xia, Y (corresponding author), Univ Texas Houston Med Sch, Dept Biochem & Mol Biol, 6431 Fannin St,MSB 6-200, Houston, TX 77030 USA.	yang.xia@uth.tmc.edu	tang, yuxin/GZN-2336-2022	Blackburn, Michael/0000-0002-1394-9966	U.S. National Institute of Health [DK077748, DK083559, HL070952]; China Scholarship Council [2008637068]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK077748, R01DK083559] Funding Source: NIH RePORTER	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council(China Scholarship Council); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institute of Health grants DK077748 (to Y.X.), DK083559 (to Y. X), and HL070952 (to M. R. B.) and by China Scholarship Council 2008637068 (to J.W.).	Bivalacqua TJ, 2009, J SEX MED, V6, P2494, DOI 10.1111/j.1743-6109.2009.01359.x; Blackburn MR, 2000, J BIOL CHEM, V275, P32114, DOI 10.1074/jbc.M005153200; Blackburn MR, 2005, ADV IMMUNOL, V86, P1, DOI 10.1016/S0065-2776(04)86001-2; Blackburn MR, 1996, J BIOL CHEM, V271, P15203, DOI 10.1074/jbc.271.25.15203; Blackburn MR, 1998, J BIOL CHEM, V273, P5093, DOI 10.1074/jbc.273.9.5093; Booth C, 2007, CLIN IMMUNOL, V123, P139, DOI 10.1016/j.clim.2006.12.009; Bruno D, 2001, J UROLOGY, V166, P803, DOI 10.1016/S0022-5347(05)65841-7; Burnett AL, 2006, J UROLOGY, V175, pS25, DOI 10.1016/S0022-5347(05)00309-5; Burnett AL, 2003, INT J IMPOT RES, V15, pS80, DOI 10.1038/sj.ijir.3901077; Burnett AL, 2003, J UROLOGY, V170, P26, DOI 10.1097/01.ju.0000046303.22757.f2; Chan ESL, 2006, BRIT J PHARMACOL, V148, P1144, DOI 10.1038/sj.bjp.0706812; Chandrasekharan BP, 2009, FASEB J, V23, P2727, DOI 10.1096/fj.09-129544; Che J, 2007, MOL PHARMACOL, V72, P1626, DOI 10.1124/mol.107.038760; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chunn JL, 2006, AM J PHYSIOL-LUNG C, V290, pL579, DOI 10.1152/ajplung.00258.2005; Chunn JL, 2005, J IMMUNOL, V175, P1937, DOI 10.4049/jimmunol.175.3.1937; Chunn JL, 2001, J IMMUNOL, V167, P4676, DOI 10.4049/jimmunol.167.8.4676; Claudino MA, 2009, J SEX MED, V6, P2187, DOI 10.1111/j.1743-6109.2009.01337.x; Cronstein Bruce N, 2004, ScientificWorldJournal, V4, P1; Dai YB, 2009, J SEX MED, V6, P292, DOI 10.1111/j.1743-6109.2008.01187.x; Davila HH, 2004, BIOL REPROD, V71, P1568, DOI 10.1095/biolreprod.104.030833; de Andrade CR, 2001, J PERIODONTOL, V72, P1726, DOI 10.1902/jop.2001.72.12.1726; Diggs LW, 1934, SOUTH MED J, V27, P839; Eickelberg O, 2001, FASEB J, V15, P797, DOI 10.1096/fj.00-0233com; Ferrini MG, 2006, UROLOGY, V68, P429, DOI 10.1016/j.urology.2006.05.011; Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Hershfield MS, 2005, EUR J IMMUNOL, V35, P25, DOI 10.1002/eji.200425738; Konigshoff M, 2007, AM J RESP CELL MOL, V37, P640, DOI 10.1165/rcmb.2006-0379TR; Kovanecz I, 2008, INT J IMPOT RES, V20, P202, DOI 10.1038/sj.ijir.3901612; Kovanecz I, 2008, BJU INT, V101, P203, DOI 10.1111/j.1464-410X.2007.07223.x; Mi T, 2008, J CLIN INVEST, V118, P1491, DOI 10.1172/JCI33467; Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876; Paszty C, 1997, Curr Opin Hematol, V4, P88; Rachid D, 2009, UROLOGY, V74, P1054, DOI 10.1016/j.urology.2009.04.071; Ramirez A, 2007, AM J PHYSIOL-LUNG C, V293, pL972, DOI 10.1152/ajplung.00010.2007; Ryan TM, 1997, SCIENCE, V278, P873, DOI 10.1126/science.278.5339.873; Strutz F, 2001, KIDNEY INT, V59, P579, DOI 10.1046/j.1523-1755.2001.059002579.x; Van Der Horst C., 2003, Int. braz j urol., V29, P391, DOI 10.1590/S1677-55382003000500002; Vernet D, 2002, NITRIC OXIDE-BIOL CH, V7, P262, DOI 10.1016/S1089-8603(02)00124-6; Zhong HY, 2005, AM J RESP CELL MOL, V32, P2, DOI 10.1165/rcmb.2004-0103OC	41	60	62	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2010	24	3					740	749		10.1096/fj.09-144147	http://dx.doi.org/10.1096/fj.09-144147			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19858092	Green Published			2022-12-28	WOS:000274974600010
J	Trejo, HE; Lecuona, E; Grillo, D; Szleifer, I; Nekrasova, OE; Gelfand, VI; Sznajder, JI				Trejo, Humberto E.; Lecuona, Emilia; Grillo, Doris; Szleifer, Igal; Nekrasova, Oksana E.; Gelfand, Vladimir I.; Sznajder, Jacob I.			Role of kinesin light chain-2 of kinesin-1 in the traffic of Na,K-ATPase-containing vesicles in alveolar epithelial cells	FASEB JOURNAL			English	Article						intracellular traffic; molecular motors; sodium pump	MICROTUBULE-BASED MOTILITY; PROTEIN-COUPLED RECEPTOR; FAST AXONAL-TRANSPORT; PLASMA-MEMBRANE; NA+,K+-ATPASE ENDOCYTOSIS; MOLECULAR-MECHANISMS; MONOCLONAL-ANTIBODY; FLUORESCENT PROTEIN; PULMONARY-EDEMA; MOTOR PROTEINS	Recruitment of the Na,K-ATPase to the plasma membrane of alveolar epithelial cells results in increased active Na+ transport and fluid clearance in a process that requires an intact microtubule network. However, the microtubule motors involved in this process have not been identified. In the present report, we studied the role of kinesin-1, a plus-end microtubule molecular motor that has been implicated in the movement of organelles in the Na, K-ATPase traffic. We determined by confocal microscopy and biochemical assays that kinesin-1 and the Na, K-ATPase are present in the same membranous cellular compartment. Knockdown of kinesin-1 heavy chain (KHC) or the light chain-2 (KLC2), but not of the light chain-1 (KLC1), decreased the movement of Na, K-ATPase-containing vesicles when compared to sham siRNA-transfected cells (control group). Thus, a specific isoform of kinesin-1 is required for microtubule-dependent recruitment of Na, K-ATPase to the plasma membrane, which is of physiological significance-Trejo, H. E., Lecuona, E., Grillo, D., Szleifer, I., Nekrasova, O. E., Gelfand, V. I., Sznajder, J. I. Role of kinesin light chain-2 of kinesin-1 in the traffic of Na, K-ATPase-containing vesicles in alveolar epithelial cells. FASEB J. 24, 374-382 (2010). www.fasebj.org	[Trejo, Humberto E.; Lecuona, Emilia; Nekrasova, Oksana E.; Sznajder, Jacob I.] Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA; [Gelfand, Vladimir I.] Northwestern Univ, Feinberg Sch Med, Dept Mol & Cell Biol, Chicago, IL 60611 USA; [Grillo, Doris; Szleifer, Igal] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University	Sznajder, JI (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, 240 E Huron,McGaw M300, Chicago, IL 60611 USA.	j-sznajder@northwestern.edu	Gelfand, Vladimir I/D-2545-2013; Szleifer, Igal/B-6920-2009; Gelfand, Vladimir/M-1974-2019	Gelfand, Vladimir I/0000-0002-6361-2798; Gelfand, Vladimir/0000-0002-6361-2798; Trejo BIttar, Humberto/0000-0003-2701-6531	U.S. National Institutes of Health [HL-48129, HL-71643, GM-52111]; American Heart Association; National Science Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL071643, R01HL048129, R37HL048129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM052111, R01GM052111] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); National Science Foundation(National Science Foundation (NSF)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors acknowledge the valuable insights and comments to this manuscript of Lynn Welch. This work was supported in part by U.S. National Institutes of Health grants HL-48129, HL-71643, and GM-52111. H. T. is a recipient of an American Heart Association Postdoctoral Fellowship grant. D. G. is a recipient of a National Science Foundation Graduate Research Fellowship.	Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; BERTHIAUME Y, 1988, J APPL PHYSIOL, V65, P585, DOI 10.1152/jappl.1988.65.2.585; Bertorello AM, 2003, MOL BIOL CELL, V14, P1149, DOI 10.1091/mbc.E02-06-0367; Boldogh IR, 2007, TRENDS CELL BIOL, V17, P502, DOI 10.1016/j.tcb.2007.07.008; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; Brown CL, 2005, TRAFFIC, V6, P1114, DOI 10.1111/j.1600-0854.2005.00347.x; BROWN D, 1993, J CELL SCI, P49; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cai T, 2008, J CELL BIOL, V182, P1153, DOI 10.1083/jcb.200712022; Chen ZP, 2006, AM J RESP CELL MOL, V35, P127, DOI 10.1165/rcmb.2006-0044OC; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; Colin E, 2008, EMBO J, V27, P2124, DOI 10.1038/emboj.2008.133; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Feschenko MS, 1997, ANN NY ACAD SCI, V834, P479, DOI 10.1111/j.1749-6632.1997.tb52306.x; Frederick RL, 2007, TRAFFIC, V8, P1668, DOI 10.1111/j.1600-0854.2007.00644.x; Glater EE, 2006, J CELL BIOL, V173, P545, DOI 10.1083/jcb.200601067; Gyoeva FK, 2004, BIOCHEMISTRY-US, V43, P13525, DOI 10.1021/bi049288l; Gyoeva FK, 2000, J CELL SCI, V113, P2047; Helfand BT, 2003, MOL BIOL CELL, V14, P5069, DOI 10.1091/mbc.E03-06-0376; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; Junco A, 2001, BIOL REPROD, V64, P1320, DOI 10.1095/biolreprod64.5.1320; Khodjakov A, 1998, MOL BIOL CELL, V9, P333, DOI 10.1091/mbc.9.2.333; Kojima SI, 2004, BIOTECHNIQUES, V36, P74, DOI 10.2144/04361ST02; Lecuona E, 1999, CHEST, V116, p29S, DOI 10.1378/chest.116.suppl_1.29S; LECUONA E, 2009, J CELL SCI IN PRESS; Lecuona E, 2007, J BIOENERG BIOMEMBR, V39, P391, DOI 10.1007/s10863-007-9102-1; Lecuona E, 2009, AM J RESP CELL MOL, V41, P671, DOI 10.1165/rcmb.2008-0365OC; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; McCart AE, 2003, TRAFFIC, V4, P576, DOI 10.1034/j.1600-0854.2003.00113.x; MITCHISON TJ, 1986, J CELL SCI, P121; Morfini G, 2002, EMBO J, V21, P281, DOI 10.1093/emboj/21.3.281; Mutlu GM, 2005, AM J PHYSIOL-LUNG C, V289, pL685, DOI 10.1152/ajplung.00247.2005; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; Oatey PB, 1997, BIOCHEM J, V327, P637; Potokar M, 2005, BIOCHEM BIOPH RES CO, V329, P678, DOI 10.1016/j.bbrc.2005.02.030; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; Rose SD, 2003, J NEUROCHEM, V85, P287, DOI 10.1046/j.1471-4159.2003.01649.x; Saldias F, 1998, AM J PHYSIOL-LUNG C, V274, pL694, DOI 10.1152/ajplung.1998.274.5.L694; Saldias FJ, 1999, J APPL PHYSIOL, V87, P30, DOI 10.1152/jappl.1999.87.1.30; Sarkar S, 2006, TRAFFIC, V7, P1078, DOI 10.1111/j.1600-0854.2006.00447.x; Schepis A, 2007, CELL MICROBIOL, V9, P1960, DOI 10.1111/j.1462-5822.2007.00927.x; Schliwa M, 2003, NATURE, V422, P759, DOI 10.1038/nature01601; Schnapp BJ, 2003, J CELL SCI, V116, P2125, DOI 10.1242/jcs.00488; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; Semiz S, 2003, EMBO J, V22, P2387, DOI 10.1093/emboj/cdg237; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shoshani L, 2005, MOL BIOL CELL, V16, P1071, DOI 10.1091/mbc.E04-03-0267; Skou JC, 1998, BIOSCIENCE REP, V18, P155, DOI 10.1023/A:1020196612909; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; Teixeira VL, 2003, ANN NY ACAD SCI, V986, P587, DOI 10.1111/j.1749-6632.2003.tb07257.x; Tietz PS, 2006, BIOL CELL, V98, P43, DOI 10.1042/BC20040089; Tsai MY, 2000, MOL BIOL CELL, V11, P2161, DOI 10.1091/mbc.11.6.2161; Tuma MC, 1999, PIGM CELL RES, V12, P283, DOI 10.1111/j.1600-0749.1999.tb00762.x; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; Wozniak MJ, 2006, EMBO J, V25, P5457, DOI 10.1038/sj.emboj.7601427; Wubbolts R, 1999, J CELL SCI, V112, P785; Xie ZJ, 2003, ANN NY ACAD SCI, V986, P497, DOI 10.1111/j.1749-6632.2003.tb07234.x	63	16	16	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					374	382		10.1096/fj.09-137802	http://dx.doi.org/10.1096/fj.09-137802			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19773350	Green Published			2022-12-28	WOS:000274045000006
J	Laver, JR; Stevanin, TM; Messenger, SL; Lunn, AD; Lee, ME; Moir, JWB; Poole, RK; Read, RC				Laver, Jay R.; Stevanin, Tania M.; Messenger, Sarah L.; Lunn, Amy Dehn; Lee, Margaret E.; Moir, James W. B.; Poole, Robert K.; Read, Robert C.			Bacterial nitric oxide detoxification prevents host cell S-nitrosothiol formation: a novel mechanism of bacterial pathogenesis	FASEB JOURNAL			English	Article						S-nitrosylation; infection; macrophage; nitrosative stress	ENTERICA SEROVAR TYPHIMURIUM; COLI FLAVOHAEMOGLOBIN HMP; NEISSERIA-MENINGITIDIS; ESCHERICHIA-COLI; FLAVOHEMOGLOBIN HMP; NITROSATIVE STRESS; HUMAN MACROPHAGES; SALMONELLA FLAVOHEMOGLOBIN; SKELETAL-MUSCLE; REPRESSOR NSRR	S-nitrosylation is an important mediator of multiple nitric oxide-dependent biological processes, including eukaryotic cellular events such as macrophage apoptosis and proinflammatory signaling. Many pathogenic bacteria possess NO detoxification mechanisms, such as the nitric oxide reductase (NorB) of Neisseria meningitidis and the flavohemoglobins (Hmp) of Salmonella enterica and Escherichia coli, which serve to protect the microorganism from nitrosative stress within the intracellular environment. In this study, we demonstrate that expression of meningococcal NorB increases the rate at which low-molecular-weight S-nitrosothiol (SNO) decomposes in vitro. To determine whether this effect occurs in cells during infection by bacteria, we induced SNO formation in murine macrophages by activation with lipopolysaccharide and gamma-interferon and observed a reduced abundance of SNO during coincubation with N. meningitidis, S. enterica, or E. coli. In each case, this effect was shown to be dependent on bacterial NO detoxification genes, which act to prevent SNO formation through the removal of NO. This may represent a novel mechanism of host cell injury by bacteria.-Laver, J. R., Stevanin, T. M., Messenger, S. L., Dehn Lunn, A., Lee, M. E., Moir, J. W. B., Poole, R. K., Read, R. C. Bacterial nitric oxide detoxification prevents host cell S-nitrosothiol formation: a novel mechanism of bacterial pathogenesis. FASEB J. 24, 286-295 (2010). www.fasebj.org	[Laver, Jay R.; Stevanin, Tania M.; Messenger, Sarah L.; Lunn, Amy Dehn; Lee, Margaret E.; Read, Robert C.] Univ Sheffield, Dept Infect & Immun, Sheffield, S Yorkshire, England; [Poole, Robert K.] Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; [Moir, James W. B.] Univ York, Dept Biol, Heslington, England	University of Sheffield; University of Sheffield; University of York - UK	Laver, JR (corresponding author), Royal Hallamshire Hosp, Sch Med, Dept Infect & Immun, Beech Hill Rd, Sheffield, S Yorkshire, England.	j.r.laver@sheffield.ac.uk	Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Read, Robert/0000-0002-4297-6728; Moir, James/0000-0003-2972-5235	Wellcome Trust [069791]; Sheffield Hospitals Charitable Trust [7866]; Meningitis Research Foundation [0902.0]; Biotechnology and Biological Sciences Research Council [BB/F000952/1, BB/E015883/1] Funding Source: researchfish; BBSRC [BB/F000952/1, BB/E015883/1] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); Sheffield Hospitals Charitable Trust; Meningitis Research Foundation(Meningitis Research Foundation (MRF)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We acknowledge the assistance of Prof. Neil Hogg for advice on the measurement of SNO using the Sievers NOA and of Dr. Jonathan Shaw for advice in the preparation of this manuscript. This work has been supported by grants to R. C. R. from the Wellcome Trust (grant 069791) and the Sheffield Hospitals Charitable Trust (grant 7866). J. R. L. and R. C. R. are supported by the Meningitis Research Foundation (project 0902.0).	Anjum MF, 2002, J BACTERIOL, V184, P2987, DOI 10.1128/JB.184.11.2987-2993.2002; Bang IS, 2006, J BIOL CHEM, V281, P28039, DOI 10.1074/jbc.M605174200; Benhar M, 2008, SCIENCE, V320, P1050, DOI 10.1126/science.1158265; Bizzozero O, 2005, NEUROCHEM RES, V30, P139, DOI 10.1007/s11064-004-9695-2; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Broniowska KA, 2006, J BIOL CHEM, V281, P33835, DOI 10.1074/jbc.M603248200; Busch T, 2000, INTENS CARE MED, V26, P391, DOI 10.1007/s001340051172; Chen B, 1998, BIOPHYS J, V75, P745, DOI 10.1016/S0006-3495(98)77564-2; Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; Darton T, 2009, CLIN INFECT DIS, V48, P587, DOI 10.1086/596707; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; Fang JG, 2007, P NATL ACAD SCI USA, V104, P18742, DOI 10.1073/pnas.0705904104; Fang KZ, 1998, BIOCHEM BIOPH RES CO, V252, P535, DOI 10.1006/bbrc.1998.9688; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; Farres J, 2005, BIOCHEMISTRY-US, V44, P4125, DOI 10.1021/bi047389d; Forrester MT, 2006, ACS CHEM BIOL, V1, P355, DOI 10.1021/cb600244c; GERLACH H, 1994, LANCET, V343, P518, DOI 10.1016/S0140-6736(94)91465-6; Gilberthorpe NJ, 2007, MICROBIOL-SGM, V153, P1756, DOI 10.1099/mic.0.2006/003731-0; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; Hara MR, 2006, CELL MOL NEUROBIOL, V26, P527, DOI 10.1007/s10571-006-9011-6; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Hausladen A, 2001, P NATL ACAD SCI USA, V98, P10108, DOI 10.1073/pnas.181199698; Hernandez-Urzua E, 2003, J BIOL CHEM, V278, P34975, DOI 10.1074/jbc.M303629200; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Heurlier K, 2008, J BACTERIOL, V190, P2488, DOI 10.1128/JB.01869-07; Hoffmann J, 2003, FEBS LETT, V551, P153, DOI 10.1016/S0014-5793(03)00917-7; Iwakiri Y, 2006, P NATL ACAD SCI USA, V103, P19777, DOI 10.1073/pnas.0605907103; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; JAMES JH, 1990, METABOLISM, V39, P335, DOI 10.1016/0026-0495(90)90245-8; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kimberly B, 1996, AM J RESP CRIT CARE, V153, P829, DOI 10.1164/ajrccm.153.2.8564139; Lancaster JR, 2004, AM J PHYSIOL-LUNG C, V287, pL465, DOI 10.1152/ajplung.00151.2004; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Laver JR, 2008, METHOD ENZYMOL, V436, P113, DOI 10.1016/S0076-6879(08)36007-8; Li HF, 1999, AM J PHYSIOL-CELL PH, V276, pC803, DOI 10.1152/ajpcell.1999.276.4.C803; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li S, 2007, AM J PHYSIOL-CELL PH, V292, pC1263, DOI 10.1152/ajpcell.00382.2006; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Mannick JB, 2002, ARCH BIOCHEM BIOPHYS, V408, P1, DOI 10.1016/S0003-9861(02)00490-3; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; MCGUINNESS BT, 1991, LANCET, V337, P514, DOI 10.1016/0140-6736(91)91297-8; Membrillo-Hernandez J, 1998, MOL MICROBIOL, V29, P1101, DOI 10.1046/j.1365-2958.1998.01000.x; Miles AA, 1938, J HYG-CAMBRIDGE, V38, P732, DOI 10.1017/S002217240001158X; Padgett C. M., 1995, AM J PHYSIOL, V269, pC739; Paige JS, 2008, CHEM BIOL, V15, P1307, DOI 10.1016/j.chembiol.2008.10.013; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; POOLE RK, 1994, P ROY SOC B-BIOL SCI, V255, P251, DOI 10.1098/rspb.1994.0036; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; Que LG, 2009, AM J RESP CRIT CARE, V180, P226, DOI 10.1164/rccm.200901-0158OC; Rabkin SW, 2007, NITRIC OXIDE-BIOL CH, V16, P339, DOI 10.1016/j.niox.2006.10.007; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Rock JD, 2005, MOL MICROBIOL, V58, P800, DOI 10.1111/j.1365-2958.2005.04866.x; Rock JD, 2007, J BACTERIOL, V189, P1138, DOI 10.1128/JB.01368-06; Schonhoff CM, 2006, P NATL ACAD SCI USA, V103, P2404, DOI 10.1073/pnas.0507243103; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; Stevanin TM, 2007, GENE, V398, P62, DOI 10.1016/j.gene.2007.03.021; Stevanin TM, 2007, MICROBES INFECT, V9, P981, DOI 10.1016/j.micinf.2007.04.002; Stevanin TM, 2002, INFECT IMMUN, V70, P4399, DOI 10.1128/IAI.70.8.4399-4405.2002; Stevanin TM, 2005, INFECT IMMUN, V73, P3322, DOI 10.1128/IAI.73.6.3322-3329.2005; Stevanin TM, 2000, J BIOL CHEM, V275, P35868, DOI 10.1074/jbc.M002471200; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; Tunbridge AJ, 2006, INFECT IMMUN, V74, P729, DOI 10.1128/IAI.74.1.729-733.2006; Zhang YH, 2004, AM J PHYSIOL-LUNG C, V287, pL467, DOI 10.1152/ajplung.00350.2003; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	71	43	43	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2010	24	1					286	295		10.1096/fj.08-128330	http://dx.doi.org/10.1096/fj.08-128330			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19720623	Green Published			2022-12-28	WOS:000273233600029
J	Guignabert, C; Tu, L; Izikki, M; Dewachter, L; Zadigue, P; Humbert, M; Adnot, S; Fadel, E; Eddahibi, S				Guignabert, Christophe; Tu, Ly; Izikki, Mohamed; Dewachter, Laurence; Zadigue, Patricia; Humbert, Marc; Adnot, Serge; Fadel, Elie; Eddahibi, Saadia			Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22 alpha-targeted overexpression of the serotonin transporter	FASEB JOURNAL			English	Article						pulmonary vascular remodeling; serotonin pathway; NFAT/Kv1.5 axis; PDK inhibitor; Bcl-2/Bax ratio	SMOOTH-MUSCLE-CELLS; GATED K+ CURRENTS; ARTERIAL-HYPERTENSION; KINASE ACTIVATION; APOPTOSIS; CHANNELS; GENE; 5-HYDROXYTRYPTAMINE; EXPRESSION; PREVENTS	Voltage-gated potassium (Kv)1.5 is decreased in pulmonary arteries (PAs) of patients with idiopathic pulmonary arterial hypertension (IPAH) and in experimental models including mice with SM22 alpha-targeted overexpression of the serotonin transporter (5-HTT). The mechanisms underlying these abnormalities, however, remain unknown. Dichloroacetate (DCA) inhibits chronic hypoxia-or monocrotaline-induced PAH by inhibiting nuclear factor of activated T-cells (NFAT) c2 and increasing Kv1.5. Therefore, we hypothesized that DCA could regress established PAH in SM22-5-HTT+ mice. We evaluated pulmonary hemodynamics, vascular remodeling, NFATc2, and Kv1.5 protein in 20-wk-old SM22-5-HTT+ or wild-type mice treated for 1, 7, and 21 d with DCA, cyclosporine-A (NFAT inhibitor), or vehicle. DCA partially reversed PAH in SM22-5-HTT+ mice by decreasing proliferation and increasing apoptosis in muscularized PAs. Furthermore, serotonin (10(-8)-10(-6) M) dose-dependently increased PA-smooth muscle cell (PA-SMC) proliferation in culture (EC50 = 0.97 x 10(-7) M) and DCA (5 x 10(-4) M) vs. PBS markedly reduced the growth of PA-SMC from IPAH and control patients treated with the highest dose of serotonin by 50 and 30%, respectively. Finally, although serotonin induces NFATc2 activation in PA-SMCs, inhibition of NFATc2 alone with cyclosporine-A was not sufficient for reversing PAH in this model. Our results support the possibility that DCA may be an interesting agent for investigation in patients with PAH.-Guignabert, C., Tu, L., Izikki, M., Dewachter, L., Zadigue, P., Humbert, M., Adnot, S., Fadel, E., Eddahibi, S. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22 alpha-targeted overexpression of the serotonin transporter. FASEB J. 23, 4135-4147 (2009). www.fasebj.org	[Guignabert, Christophe; Tu, Ly; Izikki, Mohamed; Dewachter, Laurence; Humbert, Marc; Fadel, Elie; Eddahibi, Saadia] Univ Paris 11, Ctr Chirurg Marie Lannelongue, INSERM Unity Pulm Hypertens Pathophysiol & Innova, F-92350 Le Plessis Robinson, France; [Guignabert, Christophe; Tu, Ly; Izikki, Mohamed; Zadigue, Patricia; Adnot, Serge; Eddahibi, Saadia] Inst Mondor Rech Biomed, INSERM, U955, Creteil, France; [Fadel, Elie] Ctr Chirurg Marie Lannelongue, UPRES, EA2705, Le Plessis Robinson, France; [Humbert, Marc] Hop Antoine Beclere, INSERM, U764, AP HP, Clamart, France	Hopital Marie Lannelongue; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Marie Lannelongue; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Guignabert, C (corresponding author), Univ Paris 11, Ctr Chirurg Marie Lannelongue, INSERM Unity Pulm Hypertens Pathophysiol & Innova, 133 Ave Resistance, F-92350 Le Plessis Robinson, France.	christophe.guignabert@inserm.fr	GUIGNABERT, Christophe/G-3873-2013; Humbert, Marc/ABD-5112-2021; GUIGNABERT, Christophe/AGI-2488-2022; TU, Ly/G-4035-2013; TU, Ly/AAK-4996-2020	GUIGNABERT, Christophe/0000-0002-8545-4452; GUIGNABERT, Christophe/0000-0002-8545-4452; TU, Ly/0000-0003-2336-5099; TU, Ly/0000-0003-2336-5099; Humbert, Marc/0000-0003-0703-2892	French National Institute for Health and Medical Research (IN-SERM); Ministere de la Recherche	French National Institute for Health and Medical Research (IN-SERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France)	The authors thank Michel Hamon for helpful discussions. This research was supported by grants from the French National Institute for Health and Medical Research (IN-SERM), the Ministere de la Recherche.	Archer SL, 2008, AM J PHYSIOL-HEART C, V294, pH570, DOI 10.1152/ajpheart.01324.2007; Bonnet S, 2007, P NATL ACAD SCI USA, V104, P11418, DOI 10.1073/pnas.0610467104; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Bonnet S, 2006, CIRCULATION, V113, P2630, DOI 10.1161/CIRCULATIONAHA.105.609008; Bush E, 2004, P NATL ACAD SCI USA, V101, P2870, DOI 10.1073/pnas.0308723101; Cogolludo A, 2006, CIRC RES, V98, P931, DOI 10.1161/01.RES.0000216858.04599.e1; de Caestecker M, 2006, CIRC RES, V98, P1229, DOI 10.1161/01.RES.0000225927.04710.33; Eddahibi S, 2000, J CLIN INVEST, V105, P1555, DOI 10.1172/JCI8678; Eddahibi S, 2006, CIRCULATION, V113, P1857, DOI 10.1161/CIRCULATIONAHA.105.591321; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI12805; Evans AM, 1996, J PHYSIOL-LONDON, V496, P407, DOI 10.1113/jphysiol.1996.sp021694; Guignabert C, 2005, CIRCULATION, V111, P2812, DOI 10.1161/CIRCULATIONAHA.104.524926; Guignabert C, 2006, CIRC RES, V98, P1323, DOI 10.1161/01.RES.0000222546.45372.a0; Guilluy C, 2009, AM J RESP CRIT CARE, V179, P1151, DOI 10.1164/rccm.200805-691OC; Humbert M, 2004, J AM COLL CARDIOL, V43, p13S, DOI 10.1016/j.jacc.2004.02.029; Izikki M, 2009, J CLIN INVEST, V119, P512, DOI 10.1172/JCI35070; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Lee SL, 2001, AM J PHYSIOL-LUNG C, V281, pL646, DOI 10.1152/ajplung.2001.281.3.L646; Lee SL, 1998, FREE RADICAL BIO MED, V24, P855, DOI 10.1016/S0891-5849(97)00359-6; Lee SL, 1997, AM J PHYSIOL-CELL PH, V272, pC223, DOI 10.1152/ajpcell.1997.272.1.C223; Liu YL, 2004, CIRC RES, V95, P579, DOI 10.1161/01.RES.0000141428.53262.a4; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; MacLean MR, 2000, BRIT J PHARMACOL, V131, P161, DOI 10.1038/sj.bjp.0703570; Marcos E, 2003, AM J RESP CRIT CARE, V168, P487, DOI 10.1164/rccm.200210-1212OC; McMurtry MS, 2005, J CLIN INVEST, V115, P1479, DOI 10.1172/JCI23203; McMurtry MS, 2004, CIRC RES, V95, P830, DOI 10.1161/01.RES.0000145360.16770.9f; Merklinger SL, 2005, CIRCULATION, V112, P423, DOI 10.1161/CIRCULATIONAHA.105.540542; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Michelakis ED, 2002, CIRCULATION, V105, P244, DOI 10.1161/hc0202.101974; Michelakis ED, 2008, CIRCULATION, V118, P1486, DOI 10.1161/CIRCULATIONAHA.106.673988; Moudgil R, 2006, MICROCIRCULATION, V13, P615, DOI 10.1080/10739680600930222; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; POST JM, 1995, CIRC RES, V77, P131, DOI 10.1161/01.RES.77.1.131; Pozeg ZI, 2003, CIRCULATION, V107, P2037, DOI 10.1161/01.CIR.0000062688.76508.B3; Reeve HL, 2001, J APPL PHYSIOL, V90, P2249, DOI 10.1152/jappl.2001.90.6.2249; Remillard CV, 2007, AM J PHYSIOL-CELL PH, V292, pC1837, DOI 10.1152/ajpcell.00405.2006; Schermuly RT, 2005, J CLIN INVEST, V115, P2811, DOI 10.1172/JCI24838; Voelkel NF, 1998, CHEST, V114, p225S, DOI 10.1378/chest.114.3_Supplement.225S; Walczak-Drzewiecka A, 2008, J IMMUNOL, V181, P1665, DOI 10.4049/jimmunol.181.3.1665; Wong JYY, 2008, GYNECOL ONCOL, V109, P394, DOI 10.1016/j.ygyno.2008.01.038; Young KA, 2006, AM J PHYSIOL-LUNG C, V290, pL841, DOI 10.1152/ajplung.00158.2005; Yu Y, 2001, CIRCULATION, V104, P1557, DOI 10.1161/hc3801.095662; Yuan JXJ, 1998, CIRCULATION, V98, P1400, DOI 10.1161/01.CIR.98.14.1400; YUAN XJ, 1995, CIRC RES, V77, P370, DOI 10.1161/01.RES.77.2.370; Yuan XJ, 1998, LANCET, V351, P726, DOI 10.1016/S0140-6736(05)78495-6; ZHAI FG, 2009, CLIN EXP PHARM PHYSL	46	66	72	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4135	4147		10.1096/fj.09-131664	http://dx.doi.org/10.1096/fj.09-131664			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19679640				2022-12-28	WOS:000272193700010
J	Henes, J; Schmit, MA; Morote-Garcia, JC; Mirakaj, V; Kohler, D; Glover, L; Eldh, T; Walter, U; Karhausen, J; Colgan, SP; Rosenberger, P				Henes, Janek; Schmit, Marthe A.; Morote-Garcia, Julio C.; Mirakaj, Valbona; Koehler, David; Glover, Louise; Eldh, Therese; Walter, Ulrich; Karhausen, Joern; Colgan, Sean P.; Rosenberger, Peter			Inflammation-associated repression of vasodilator-stimulated phosphoprotein (VASP) reduces alveolar-capillary barrier function during acute lung injury	FASEB JOURNAL			English	Article						cytoskeleton; ALI; ventilator-induced lung injury; pulmonary inflammation; actin	GAP FORMATION; PERMEABILITY; ADENOSINE; HYPOXIA; KINASE; INCREASE; IDENTIFICATION; REGENERATION; ENDOTHELIUM; ACTIVATION	Acute lung injury (ALI) is an inflammatory disorder associated with reduced alveolar-capillary barrier function, increased pulmonary vascular permeability, and infiltration of leukocytes into the alveolar space. Pulmonary function might be compromised, its most severe form being the acute respiratory distress syndrome. A protein central to physiological barrier properties is vasodilator-stimulated phosphoprotein (VASP). Given the fact that VASP expression is reduced during periods of cellular hypoxia, we investigated the role of VASP during ALI. Initial studies revealed reduced VASP expressional levels through cytokines in vitro. Studies in the putative human VASP promoter identified NF-kappa B as a key regulator of VASP transcription. This VASP repression results in increased paracellular permeability and migration of neutrophils in vitro. In a model of LPS-induced ALI, VASP(-/-) mice demonstrated increased pulmonary damage compared with wild-type animals. These findings were confirmed in a second model of ventilator-induced lung injury. Studies employing bone marrow chimeric animals identified tissue-specific repression of VASP as the underlying cause of decreased barrier properties of the alveolar-capillary barrier during ALI. Taken together these studies identify tissue-specific VASP as a central protein in the control of the alveolar-capillary barrier properties during ALI.-Henes, J., Schmit, M. A., Morote-Garcia, J. C., Mirakaj, V., Kohler, D., Glover, L., Eldh, T., Walter, U., Karhausen, J., Colgan, S. P., Rosenberger, P. Inflammation-associated repression of vasodilator-stimulated phosphoprotein (VASP) reduces alveolar-capillary barrier function during acute lung injury. FASEB J. 23, 4244-4255 (2009). www.fasebj.org	[Henes, Janek; Schmit, Marthe A.; Morote-Garcia, Julio C.; Mirakaj, Valbona; Koehler, David; Karhausen, Joern; Rosenberger, Peter] Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, D-72076 Tubingen, Germany; [Eldh, Therese] Univ Tubingen Hosp, Dept Radiat Oncol, D-72076 Tubingen, Germany; [Schmit, Marthe A.] Univ Munich, Tieraerztl Fak, Munich, Germany; [Glover, Louise; Colgan, Sean P.] Univ Colorado, Hlth Sci Ctr, Mucosal Inflammat Program, Denver, CO USA; [Walter, Ulrich] Univ Wurzburg, Inst Clin Biochem & Pathobiochem, Wurzburg, Germany; [Walter, Ulrich] Univ Wurzburg, Div Lab Med, IKBZ, Wurzburg, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Munich; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Wurzburg; University of Wurzburg	Rosenberger, P (corresponding author), Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	peter.rosenberger@medizin.uni-tuebingen.de	Walter, ulrich/W-2478-2017; karhausen, jorn/X-8813-2019	Walter, ulrich/0000-0001-6784-2307; karhausen, jorn/0000-0002-4240-229X; Mirakaj, Valbona/0000-0002-6907-6455; Glover, Louise/0000-0001-9056-1810	Deutsche Forschungsgemeinschaft [DFG RO 3671/4-1]; Tuebingen University Fortuene [IZKF 1639-0]; European Society of Anesthesiology; Karl-Kuhn Foundation for Cardiovascular Research; Ministere de la Culture; de l'Enseignement Superieur et de la Recherche; Grand-Duche de Luxembourg; U. S. National Institutes of Health [NIH DK50189]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050189, R01DK050189, R29DK050189] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Tuebingen University Fortuene; European Society of Anesthesiology; Karl-Kuhn Foundation for Cardiovascular Research; Ministere de la Culture; de l'Enseignement Superieur et de la Recherche; Grand-Duche de Luxembourg; U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Marion Faigle and Stephanie Zug for help with immunhistochemistry and CHIP assay and Stefanie Laucher for help with the performance of animal experiments. This work was supported by a grant from the Deutsche Forschungsgemeinschaft (DFG RO 3671/4-1), a Tuebingen University Fortuene grant (IZKF 1639-0), a research grant of the European Society of Anesthesiology, and the Karl-Kuhn Foundation for Cardiovascular Research grant (all to P. R.); a grant from the Ministere de la Culture, de l'Enseignement Superieur et de la Recherche, Grand-Duche de Luxembourg to M. A. S; and a grant by the U. S. National Institutes of Health (NIH DK50189) to S. P. C. J. H., M. S., J. C. M.-G., V. M., D. K., and L. G. performed experiments and analyzed data.; T. E. performed bone marrow transplantation; U. W. designed research and helped with manuscript writing; J. K. designed research and analyzed data; and S. P. C. and P. R. designed research and wrote the manuscript.	Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115; Angelini DJ, 2006, AM J PHYSIOL-LUNG C, V291, pL1232, DOI 10.1152/ajplung.00109.2006; Barone G W, 1989, J Card Surg, V4, P140, DOI 10.1111/j.1540-8191.1989.tb00270.x; Belperio JA, 2002, J CLIN INVEST, V110, P1703, DOI 10.1172/JCI200215849; Benz PM, 2008, J CELL BIOL, V180, P205, DOI 10.1083/jcb.200709181; Bouvry D, 2006, AM J RESP CELL MOL, V35, P519, DOI 10.1165/rcmb.2005-0478OC; Chin AC, 2007, ANNU REV PATHOL-MECH, V2, P111, DOI 10.1146/annurev.pathol.2.010506.091944; Comerford KM, 2002, FASEB J, V16, P583, DOI 10.1096/fj.01-0739fje; Eckle T, 2008, AM J PHYSIOL-LUNG C, V295, pL718, DOI 10.1152/ajplung.90298.2008; Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203; Eckle T, 2007, J IMMUNOL, V178, P8127, DOI 10.4049/jimmunol.178.12.8127; FASANO A, 1995, J CLIN INVEST, V96, P710, DOI 10.1172/JCI118114; Furman C, 2007, J CELL BIOL, V179, P761, DOI 10.1083/jcb.200705002; GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; Hershberg RM, 1998, J CLIN INVEST, V102, P792, DOI 10.1172/JCI3201; Hohenstein B, 2005, J AM SOC NEPHROL, V16, P986, DOI 10.1681/ASN.2004070591; Holtzman MJ, 2002, PHYSIOL REV, V82, P19, DOI 10.1152/physrev.00020.2001; Kayyali US, 2002, J BIOL CHEM, V277, P42596, DOI 10.1074/jbc.M205863200; Khoury J, 2007, J CLIN INVEST, V117, P703, DOI 10.1172/JCI30049; Lawrence DW, 2002, AM J PHYSIOL-CELL PH, V282, pC1235, DOI 10.1152/ajpcell.00288.2001; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849, DOI 10.1164/ajrccm.159.6.9808136; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P571, DOI 10.1083/jcb.11.3.571; Minamino T, 2006, J CLIN INVEST, V116, P2316, DOI 10.1172/JCI29637; MIZUNOYAGYU Y, 1987, BIOCHEM PHARMACOL, V36, P3809; MOLITORIS BA, 1991, AM J PHYSIOL, V260, pF769; Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168; Price CJ, 2000, ARTERIOSCL THROM VAS, V20, P2051, DOI 10.1161/01.ATV.20.9.2051; Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004; Reutershan J, 2007, J IMMUNOL, V179, P1254, DOI 10.4049/jimmunol.179.2.1254; Rosenberger P, 2007, FASEB J, V21, P2613, DOI 10.1096/fj.06-8004com; Rosenberger P, 2009, NAT IMMUNOL, V10, P195, DOI 10.1038/ni.1683; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Schlegel N, 2008, AM J PHYSIOL-CELL PH, V294, pC178, DOI 10.1152/ajpcell.00273.2007; Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wojciak-Stothard B, 2006, AM J PHYSIOL-LUNG C, V290, pL1173, DOI 10.1152/ajplung.00309.2005; Wojciak-Stothard B, 2005, AM J PHYSIOL-LUNG C, V288, pL749, DOI 10.1152/ajplung.00361.2004; WU NZ, 1992, AM J PHYSIOL, V262, pH1238; Yamashita R, 2006, NUCLEIC ACIDS RES, V34, pD86, DOI 10.1093/nar/gkj129	44	34	36	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4244	4255		10.1096/fj.09-138693	http://dx.doi.org/10.1096/fj.09-138693			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19690214	Green Published			2022-12-28	WOS:000272193700019
J	Huang, SK; White, ES; Wettlaufer, SH; Grifka, H; Hogaboam, CM; Thannickal, VJ; Horowitz, JC; Peters-Golden, M				Huang, Steven K.; White, Eric S.; Wettlaufer, Scott H.; Grifka, Heather; Hogaboam, Cory M.; Thannickal, Victor J.; Horowitz, Jeffrey C.; Peters-Golden, Marc			Prostaglandin E-2 induces fibroblast apoptosis by modulating multiple survival pathways	FASEB JOURNAL			English	Article						PTEN; survivin; Fas; Akt; idiopathic pulmonary fibrosis	IDIOPATHIC PULMONARY-FIBROSIS; FIBROTIC LUNG FIBROBLASTS; GROWTH-FACTOR-BETA; INHIBITS FIBROBLAST; CELL-DEATH; E-PROSTANOID-2 RECEPTOR; CASPASE INHIBITORS; MESENCHYMAL CELLS; EPITHELIAL-CELLS; ACTIVATION	Although the lipid mediator prostaglandin E-2 (PGE(2)) exerts antifibrotic effects by inhibiting multiple fibroblast functions, its ability to regulate fibroblast survival is unknown. Here, we examined the effects of this prostanoid on apoptosis and apoptosis pathways in normal and fibrotic lung fibroblasts. As compared to medium alone, 24 h of treatment with PGE(2) increased apoptosis of normal lung fibroblasts in a dose-dependent manner (EC50 similar to 50 nM), as measured by annexin V staining, caspase 3 activity, cleavage of poly-ADP-ribose polymerase, and single-stranded DNA levels. PGE(2) also potentiated apoptosis elicited by Fas ligand plus cycloheximide. These proapoptotic actions were dependent on signaling through the EP2/EP4 receptors and by downstream activation of both caspases 8 and 9. Silencing and gene deletion of PTEN demonstrated that the effects of PGE(2) involved decreased activity of the prosurvival molecule Akt. PGE(2) also down-regulated expression of survivin, an inhibitor of apoptosis, and increased expression of Fas. Fibroblasts from patients with pulmonary fibrosis exhibited resistance to the apoptotic effects of PGE(2). These findings show for the first time that, in contrast to its effects on many other cell types, PGE(2) promotes apoptosis in lung fibroblasts through diverse pathways. They provide another dimension by which PGE(2) may inhibit, and perhaps even reverse, fibrogenesis in patients with interstitial lung disease.-Huang, S. K., White, E. S., Wettlaufer, S. H., Grifka, H., Hogaboam, C. M., Thannickal, V. J., Horowitz, J. C., Peters-Golden, M. Prostaglandin E-2 induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J. 23, 4317-4326 (2009). www.fasebj.org	[Huang, Steven K.; White, Eric S.; Wettlaufer, Scott H.; Grifka, Heather; Thannickal, Victor J.; Horowitz, Jeffrey C.; Peters-Golden, Marc] Univ Michigan, Div Pulm & Crit Care Med, Dept Internal Med, Sch Med, Ann Arbor, MI 48109 USA; [Hogaboam, Cory M.] Univ Michigan, Dept Pathol, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Peters-Golden, M (corresponding author), Univ Michigan, Div Pulm & Crit Care Med, Dept Internal Med, Sch Med, 6301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	petersm@umich.edu	Hogaboam, Cory M./AAI-1433-2021; Horowitz, Jeffrey/AAY-7238-2021; hogaboam, cory/M-3578-2014	Hogaboam, Cory M./0000-0003-3366-4850; Horowitz, Jeffrey/0000-0002-1505-2837; White, Eric/0000-0003-4060-8443	U.S. National Institutes of Health [P50 HL56402]; Parker B. Francis Fellowship; American Thoracic Society Fellows Career Development Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007749, P50HL056402, R01HL085083] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Parker B. Francis Fellowship; American Thoracic Society Fellows Career Development Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr. Rommel Sagana for providing assistance with the PTEN siRNA experiments. This work was supported by U.S. National Institutes of Health grant P50 HL56402 from the National Heart, Lung, and Blood Institute. S. K. H. was supported by a Parker B. Francis Fellowship and an American Thoracic Society Fellows Career Development Award.	Barbas-Filho JV, 2001, J CLIN PATHOL, V54, P132, DOI 10.1136/jcp.54.2.132; BITTERMAN PB, 1986, J CLIN INVEST, V77, P700, DOI 10.1172/JCI112364; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buhling F, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-37; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; CHAUNCEY JB, 1988, LAB INVEST, V58, P133; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; ELIAS JA, 1985, AM REV RESPIR DIS, V131, P94; Falleni M, 2003, J PATHOL, V200, P620, DOI 10.1002/path.1388; FINE A, 1989, J BIOL CHEM, V264, P16988; Hawcroft G, 2007, ONCOGENE, V26, P3006, DOI 10.1038/sj.onc.1210113; Hodges RJ, 2004, AM J PATHOL, V165, P1663, DOI 10.1016/S0002-9440(10)63423-2; Hogaboam CM, 2005, METH MOLEC MED, V117, P209; Horowitz JC, 2006, AM J PHYSIOL-LUNG C, V290, pL415, DOI 10.1152/ajplung.00276.2005; Horowitz JC, 2004, J BIOL CHEM, V279, P1359, DOI 10.1074/jbc.M306248200; Huang S, 2007, AM J PHYSIOL-LUNG C, V292, pL405, DOI 10.1152/ajplung.00232.2006; Huang SK, 2008, AM J RESP CRIT CARE, V177, P66, DOI 10.1164/rccm.200706-963OC; Jeong JC, 2009, NEUROCHEM RES, V34, P991, DOI 10.1007/s11064-008-9868-5; Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508; Kawasaki H, 1998, CANCER RES, V58, P5071; Keerthisingam CB, 2001, AM J PATHOL, V158, P1411, DOI 10.1016/S0002-9440(10)64092-8; Kohyama T, 2001, AM J PHYSIOL-LUNG C, V281, pL1257, DOI 10.1152/ajplung.2001.281.5.L1257; Kolodsick JE, 2003, AM J RESP CELL MOL, V29, P537, DOI 10.1165/rcmb.2002-0243OC; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Krysan K, 2004, FASEB J, V18, P205, DOI 10.1096/fj.03-0369fje; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Laurent Geoffrey J, 2008, Proc Am Thorac Soc, V5, P311, DOI 10.1513/pats.200710-159DR; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lin J, 2005, BIOCHEM PHARMACOL, V70, P658, DOI 10.1016/j.bcp.2005.05.028; LIPCHIK RJ, 1990, AM J PHYSIOL, V259, pL73, DOI 10.1152/ajplung.1990.259.2.L73; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Moodley YP, 2004, J PATHOL, V202, P486, DOI 10.1002/path.1531; Moore BB, 2000, J IMMUNOL, V165, P4032, DOI 10.4049/jimmunol.165.7.4032; Moore BB, 2005, J IMMUNOL, V174, P5644, DOI 10.4049/jimmunol.174.9.5644; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; Nishimura K, 2006, BIOSCI BIOTECH BIOCH, V70, P2145, DOI 10.1271/bbb.60106; Parcellier A, 2008, CELL SIGNAL, V20, P21, DOI 10.1016/j.cellsig.2007.07.010; Plataki M, 2005, CHEST, V127, P266, DOI 10.1378/chest.127.1.266; Porter BO, 1999, EUR J IMMUNOL, V29, P2360, DOI 10.1002/(SICI)1521-4141(199907)29:07<2360::AID-IMMU2360>3.0.CO;2-A; Rahimi RA, 2007, J CELL BIOCHEM, V102, P593, DOI 10.1002/jcb.21501; Rosner D, 2006, AM J PATHOL, V168, P2054, DOI 10.2353/ajpath.2006.050473; Sauerwald TM, 2003, BIOTECHNOL BIOENG, V81, P329, DOI 10.1002/bit.10473; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; Sheng HM, 1998, CANCER RES, V58, P362; Sugiura H, 2007, J CELL PHYSIOL, V210, P99, DOI 10.1002/jcp.20825; Sweeney EA, 1998, FEBS LETT, V425, P61, DOI 10.1016/S0014-5793(98)00198-7; Tessner TG, 2004, J CLIN INVEST, V114, P1676, DOI 10.1172/JCI200422218; Thannickal Victor J, 2006, Proc Am Thorac Soc, V3, P350, DOI 10.1513/pats.200601-001TK; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uhal BD, 1998, AM J PHYSIOL-LUNG C, V275, pL1192, DOI 10.1152/ajplung.1998.275.6.L1192; Weinlich R, 2008, CELL DEATH DIFFER, V15, P1901, DOI 10.1038/cdd.2008.128; White ES, 2006, AM J RESP CRIT CARE, V173, P112, DOI 10.1164/rccm.200507-1058OC; White ES, 2005, AM J RESP CELL MOL, V32, P135, DOI 10.1165/rcmb.2004-0126OC; WILBORN J, 1995, J CLIN INVEST, V95, P1861, DOI 10.1172/JCI117866; Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045	57	113	114	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4317	4326		10.1096/fj.08-128801	http://dx.doi.org/10.1096/fj.08-128801			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19671668	Green Published, Green Submitted			2022-12-28	WOS:000272193700026
J	Maruvada, R; Prasadarao, NV; Rubens, CE				Maruvada, Ravi; Prasadarao, Nemani V.; Rubens, C. E.			Acquisition of factor H by a novel surface protein on group B Streptococcus promotes complement degradation	FASEB JOURNAL			English	Article						streptococcal histidine triad protein; CRASP; protease treatment; LC-MS; pathogenecity islands; membrane attack complex	ESCHERICHIA-COLI K1; CAPSULAR POLYSACCHARIDE; BORRELIA-BURGDORFERI; SERUM RESISTANCE; IMMUNE EVASION; BINDING; IDENTIFICATION; REGULATORS; DISEASE; MECHANISMS	Binding of the host complement regulator, factor H (FH), by some pathogenic microbes constitutes an important virulence mechanism, whereby complement is broken down to help microbes survive in the host. Although it has been hypothesized for the past two decades that GBS type III binds FH via sialic acid present on its capsule, neither the binding of FH to GBS has been demonstrated nor the mechanism of interaction identified. We observed that FH bound to both wild-type and capsule or sialic acid-deficient GBS that were used as negative controls. Wild-type and acapsular GBS were incubated with serum or pure FH degraded almost 90% of C3b, suggesting that the GBS-bound FH maintained cofactor activity. In addition, dot-blot analysis showed similar to 5-10% of C5 and C9 formation, as compared to an Escherichia coli control, suggesting breakdown at the C3b level. Protease treatment of the bacteria completely abolished binding of FH. Using overlay assays and mass spectroscopic analysis, we identified the FH receptor as the streptococcal histidine triad (SHT) surface protein. The ability of binding FH to SHT was further confirmed by using recombinant SHT. This report describes the identification of the SHT as an FH-binding protein on the surface of GBS type III, revealing a novel mechanism by which the bacterium acquires FH to evade complement opsonization.-Maruvada, R., Prasadarao, N. V., Rubens, C. E. Acquisition of factor H by a novel surface protein on group B Streptococcus promotes complement degradation. FASEB J. 23, 3967-3977 (2009). www.fasebj.org	[Maruvada, Ravi] Johns Hopkins Sch Med, Div Infect Dis, Baltimore, MD 21205 USA; [Prasadarao, Nemani V.] Univ So Calif, Div Infect Dis, Childrens Hosp Los Angeles, Los Angeles, CA USA; [Prasadarao, Nemani V.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Rubens, C. E.] Univ Washington, Ctr Childhood Infect & Prematur Res, Seattle Childrens Hosp, Res Inst,Dept Pediat, Seattle, WA 98195 USA	Johns Hopkins University; Johns Hopkins Medicine; Children's Hospital Los Angeles; University of Southern California; University of Southern California; Seattle Children's Hospital; University of Washington; University of Washington Seattle	Maruvada, R (corresponding author), Johns Hopkins Sch Med, Div Infect Dis, 200 N Wolfe St, Baltimore, MD 21205 USA.	rmaruva1@jhmi.edu			NIH [AI22498, AI40567]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040567, R23AI022498, R01AI040567, R01AI022498] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by NIH grants AI22498 to C. E. R. and AI40567 to N. V. P. We thank Dr. Phil Gafken (Fred Hutchinson Cancer Research Institute, Seattle, WA, USA) for mass spectroscopy studies, and Dr. Hal Soucier (University of Southern California. Los Angeles, CA, USA) for flow cytometry studies. We thank Dr. Ravin Seepersaud and Donald Chaffin for technical advice. We thank Dr. Kellie Howard for careful review of the manuscript.	ABBAL M, 1991, COMPLEMENT INFLAMMAT, V8, P92, DOI 10.1159/000463185; Adamou JE, 2001, INFECT IMMUN, V69, P949, DOI 10.1128/IAI.69.2.949-958.2001; AHMED AEE, 1995, CLIN DIAGN LAB IMMUN, V2, P509, DOI 10.1128/CDLI.2.5.509-517.1995; Albanyan EA, 2000, INFECT IMMUN, V68, P2053, DOI 10.1128/IAI.68.4.2053-2060.2000; Alexander JJ, 2005, J AM SOC NEPHROL, V16, P52, DOI 10.1681/ASN.2004090778; ANTAL JM, 1992, INFECT IMMUN, V60, P1114, DOI 10.1128/IAI.60.3.1114-1121.1992; Areschoug T, 2002, J BIOL CHEM, V277, P12642, DOI 10.1074/jbc.M112072200; AVERY VM, 1993, J IMMUNOL, V151, P5545; Baker C., 1995, INFECT DIS FETUS NEW, V4th ed., P980; Beckmann C, 2002, INFECT IMMUN, V70, P2869, DOI 10.1128/IAI.70.6.2869-2876.2002; Bingen E, 1997, J CLIN MICROBIOL, V35, P2981, DOI 10.1128/JCM.35.11.2981-2982.1997; Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998; CAMPBELL JR, 1992, INFECT IMMUN, V60, P4558, DOI 10.1128/IAI.60.11.4558-4562.1992; Dave S, 2001, INFECT IMMUN, V69, P3435, DOI 10.1128/IAI.69.5.3435-3437.2001; EDWARDS MS, 1980, J EXP MED, V151, P1275, DOI 10.1084/jem.151.5.1275; EDWARDS MS, 1993, INFECT IMMUN, V61, P2866, DOI 10.1128/IAI.61.7.2866-2871.1993; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; HACKER J, 1990, MICROB PATHOGENESIS, V8, P213, DOI 10.1016/0882-4010(90)90048-U; Harris TO, 2003, J CLIN INVEST, V111, P61, DOI 10.1172/JCI200316270; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; Janulczyk R, 2000, J BIOL CHEM, V275, P37257, DOI 10.1074/jbc.M004572200; Jarva H, 2003, MOL IMMUNOL, V40, P95, DOI 10.1016/S0161-5890(03)00108-1; Johnsson E, 1998, J IMMUNOL, V161, P4894; Kotarsky H, 2001, MOL MICROBIOL, V41, P817, DOI 10.1046/j.1365-2958.2001.02496.x; Kotarsky H, 1998, J IMMUNOL, V160, P3349; Kraiczy P, 2002, WIEN KLIN WOCHENSCHR, V114, P568; Kraiczy P, 2001, EUR J IMMUNOL, V31, P1674, DOI 10.1002/1521-4141(200106)31:6&lt;1674::AID-IMMU1674&gt;3.0.CO;2-2; KRISTENSEN T, 1986, P NATL ACAD SCI USA, V83, P3963, DOI 10.1073/pnas.83.11.3963; MARQUES MB, 1992, INFECT IMMUN, V60, P3986, DOI 10.1128/IAI.60.10.3986-3993.1992; MARTIN TR, 1988, J INFECT DIS, V157, P91, DOI 10.1093/infdis/157.1.91; Maruvada R, 2008, IMMUNOLOGY, V124, P265, DOI 10.1111/j.1365-2567.2007.02764.x; McDowell JV, 2003, INFECT IMMUN, V71, P3597, DOI 10.1128/IAI.71.6.3597-3602.2003; MOORE MD, 1989, J BIOL CHEM, V264, P20576; Nizet V, 1999, STREPTOCOCCAL INFECTIONS, P180; Ogunniyi AD, 2009, FASEB J, V23, P731, DOI 10.1096/fj.08-119537; Pandiripally V, 2003, INFECT IMMUN, V71, P7119, DOI 10.1128/IAI.71.12.7119-7128.2003; Pandiripally V, 2002, INFECT IMMUN, V70, P6206, DOI 10.1128/IAI.70.11.6206-6214.2002; Perez-Caballero D, 2004, J IMMUNOL, V173, P6899, DOI 10.4049/jimmunol.173.11.6899; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; Ram S, 1999, MOL IMMUNOL, V36, P915, DOI 10.1016/S0161-5890(99)00114-5; RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593; Rooijakkers SHM, 2005, NAT IMMUNOL, V6, P920, DOI 10.1038/ni1235; RUBENS CE, 1993, MOL MICROBIOL, V8, P843, DOI 10.1111/j.1365-2958.1993.tb01631.x; Schlaf G, 2004, EUR J IMMUNOL, V34, P3257, DOI 10.1002/eji.200324806; Schuchat A, 1998, CLIN MICROBIOL REV, V11, P497, DOI 10.1128/CMR.11.3.497; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIM E, 1981, FEBS LETT, V132, P55, DOI 10.1016/0014-5793(81)80426-7; VIK DP, 1990, CURR TOP MICROBIOL, V153, P147; Vogel U, 1999, INFECT IMMUN, V67, P954, DOI 10.1128/IAI.67.2.954-957.1999; WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268; WESSELS MR, 1992, INFECT IMMUN, V60, P392, DOI 10.1128/IAI.60.2.392-400.1992; WEXLER DE, 1985, P NATL ACAD SCI USA, V82, P8144, DOI 10.1073/pnas.82.23.8144; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147; Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3; ZON LI, 1989, BIOTECHNIQUES, V7, P696	55	24	26	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3967	3977		10.1096/fj.09-138149	http://dx.doi.org/10.1096/fj.09-138149			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19608625	Green Published			2022-12-28	WOS:000271272500032
J	Messner, S; Schuermann, D; Altmeyer, M; Kassner, I; Schmidt, D; Schar, P; Muller, S; Hottiger, MO				Messner, Simon; Schuermann, David; Altmeyer, Matthias; Kassner, Ingrid; Schmidt, Darja; Schaer, Primo; Mueller, Stefan; Hottiger, Michael O.			Sumoylation of poly(ADP-ribose) polymerase 1 inhibits its acetylation and restrains transcriptional coactivator function	FASEB JOURNAL			English	Article						NAD; SUMO; hypoxia; PARP-1	NF-KAPPA-B; SUMO-2 TARGET PROTEINS; GENE-EXPRESSION; ADP-RIBOSYLATION; PHOSPHORYLATION; HYPOXIA; BINDING; IDENTIFICATION; REPRESSION; PARP-1	Poly(ADP-ribose) polymerase 1 (PARP1) is a chromatin-associated nuclear protein and functions as a molecular stress sensor. At the cellular level, PARP1 has been implicated in a wide range of processes, such as maintenance of genome stability, cell death, and transcription. PARP1 functions as a transcriptional coactivator of nuclear factor kappa B (NF-kappa B) and hypoxia inducible factor 1 (HIF1). In proteomic studies, PARP1 was found to be modified by small ubiquitin-like modifiers (SUMOs). Here, we characterize PARP1 as a substrate for modification by SUMO1 and SUMO3, both in vitro and in vivo. PARP1 is sumoylated at the single lysine residue K486 within its automodification domain. Interestingly, modification of PARP1 with SUMO does not affect its ADP-ribosylation activity but completely abrogates p300-mediated acetylation of PARP1, revealing an intriguing crosstalk of sumoylation and acetylation on PARP1. Genetic complementation of PARP1-depleted cells with wildtype and sumoylation-deficient PARP1 revealed that SUMO modification of PARP1 restrains its transcriptional coactivator function and subsequently reduces gene expression of distinct PARP1-regulated target genes. Messner, S., Schuermann, D., Altmeyer, M., Kassner, I., Schmidt, D., Schar, P., Muller, S., and Hottiger, M. O. Sumoylation of poly(ADP-ribose) polymerase 1 inhibits its acetylation and restrains transcriptional coactivator function. FASEB J. 23, 3978-3989 (2009). www.fasebj.org	[Messner, Simon; Altmeyer, Matthias; Kassner, Ingrid; Hottiger, Michael O.] Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland; [Messner, Simon; Altmeyer, Matthias; Kassner, Ingrid] Univ Zurich, Life Sci Zurich Grad Sch, Mol Life Sci Program, CH-8057 Zurich, Switzerland; [Schuermann, David; Schaer, Primo] Univ Basel, Inst Biochem & Genet, Dept Biomed, Basel, Switzerland; [Schmidt, Darja; Mueller, Stefan] Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	University of Zurich; University of Zurich; University of Basel; Max Planck Society	Hottiger, MO (corresponding author), Univ Zurich, Inst Vet Biochem & Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	hottiger@vetbio.uzh.ch	Schär, Primo/G-5967-2012; Hottiger, Michael O./J-7747-2013; Altmeyer, Matthias/AAE-8186-2019; Schuermann, David/AAC-4075-2019	Schär, Primo/0000-0003-1843-6147; Hottiger, Michael O./0000-0002-7323-2270; Altmeyer, Matthias/0000-0003-3780-1170; Schuermann, David/0000-0003-2904-1378; Muller, Stefan/0000-0002-8792-7700	Deutsche Forschungsgemeinschaft; Swiss National Science Foundation [31-109315.05, 31-122421/1]; Kanton of Zurich	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Kanton of Zurich	We are grateful to L. Sistonen and H. A. Blomster (University of Turku, Turku, Finland) for support and scientific insight. We thank G. Poirier and D. Gauvin (Laval University Medical Research Center, Laval University, Quebec, QC, Canada), D. Stiehl and R. Wenger (University of Zurich, Zurich, Switzerland), S. Pastorekova (Slovak Academy of Sciences, Bratislava, Slovak Republic), R. T. Hay (University of Dundee, Dundee, UK), and R. Niedenthal (Hannover Medical School, Hannover, Germany) for generously providing reagents. We are grateful to T. Valovka (University of Innsbruck, Innsbruck, Austria) and P. O. Hassa, M. Fey, and other members of the Institute of Veterinary Biochemistry and Molecular Biology (University of Zurich) for their critical and constructive comments on the manuscript. This work was supported in part by the Deutsche Forschungsgemeinschaft (to S. Muller), the Swiss National Science Foundation (grants 31-109315.05 and 31-122421/1 to M. O. H.), and the Kanton of Zurich (to M. O. H.).	Altmeyer M, 2009, NUCLEIC ACIDS RES, V37, P3723, DOI 10.1093/nar/gkp229; Ayaydin F, 2004, MOL BIOL CELL, V15, P5208, DOI 10.1091/mbc.E04-07-0589; Baba D, 2005, NATURE, V435, P979, DOI 10.1038/nature03634; Blomster HA, 2009, MOL CELL PROTEOMICS, V8, P1382, DOI 10.1074/mcp.M800551-MCP200; Buerki C, 2008, NUCLEIC ACIDS RES, V36, P1665, DOI 10.1093/nar/gkn003; Carbia-Nagashima A, 2007, CELL, V131, P309, DOI 10.1016/j.cell.2007.07.044; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Comerford KM, 2003, P NATL ACAD SCI USA, V100, P986, DOI 10.1073/pnas.0337412100; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dadke S, 2007, NAT CELL BIOL, V9, P80, DOI 10.1038/ncb1522; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; El-Andaloussi N, 2006, MOL CELL, V22, P51, DOI 10.1016/j.molcel.2006.02.013; Elser M, 2008, MOL CANCER RES, V6, P282, DOI 10.1158/1541-7786.MCR-07-0377; Fahrer J, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm944; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Gregoire S, 2006, J BIOL CHEM, V281, P4423, DOI 10.1074/jbc.M509471200; Haenni SS, 2008, INT J BIOCHEM CELL B, V40, P2274, DOI 10.1016/j.biocel.2008.03.008; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; Hassa PO, 2005, J BIOL CHEM, V280, P40450, DOI 10.1074/jbc.M507553200; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hassa PO, 2003, J BIOL CHEM, V278, P45145, DOI 10.1074/jbc.M307957200; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Hunter T, 2007, MOL CELL, V28, P730, DOI 10.1016/j.molcel.2007.11.019; Jian OY, 2009, MOL CELL, V34, P145, DOI 10.1016/j.molcel.2009.03.013; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kaluz S, 2009, BBA-REV CANCER, V1795, P162, DOI 10.1016/j.bbcan.2009.01.001; Kerscher O, 2007, EMBO REP, V8, P550, DOI 10.1038/sj.embor.7400980; Kim JH, 2009, BBA-MOL BASIS DIS, V1792, P155, DOI 10.1016/j.bbadis.2008.12.008; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Liu B, 2008, CURR OPIN CELL BIOL, V20, P288, DOI 10.1016/j.ceb.2008.03.014; Mukhopadhyay D, 2007, TRENDS BIOCHEM SCI, V32, P286, DOI 10.1016/j.tibs.2007.05.002; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Peinado H, 2008, CANCER RES, V68, P4541, DOI 10.1158/0008-5472.CAN-07-6345; Rosas-Acosta G, 2005, MOL CELL PROTEOMICS, V4, P56, DOI 10.1074/mcp.M400149-MCP200; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Shalizi A, 2006, SCIENCE, V311, P1012, DOI 10.1126/science.1122513; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Stankovic-Valentin N, 2007, MOL CELL BIOL, V27, P2661, DOI 10.1128/MCB.01098-06; Stielow B, 2008, MOL CELL, V29, P742, DOI 10.1016/j.molcel.2007.12.032; Takahashi H, 2005, J BIOL CHEM, V280, P5611, DOI 10.1074/jbc.M408130200; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tremblay AM, 2008, MOL ENDOCRINOL, V22, P570, DOI 10.1210/me.2007-0357; Vertegaal ACO, 2004, J BIOL CHEM, V279, P33791, DOI 10.1074/jbc.M404201200; Vertegaal ACO, 2006, MOL CELL PROTEOMICS, V5, P2298, DOI 10.1074/mcp.M600212-MCP200; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; ZHU S, 2009, CELL, V33, P570	52	57	59	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3978	3989		10.1096/fj.09-137695	http://dx.doi.org/10.1096/fj.09-137695			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19622798	Green Accepted			2022-12-28	WOS:000271272500033
J	Dodd, SL; Hain, B; Senf, SM; Judge, AR				Dodd, Stephen L.; Hain, Brian; Senf, Sarah M.; Judge, Andrew R.			Hsp27 inhibits IKK beta-induced NF-kappa B activity and skeletal muscle atrophy	FASEB JOURNAL			English	Article						MuRF1; atrogin-1/MAFbx; immobilization	HEAT-SHOCK PROTEINS; STRESS-PROTEINS; GENE-EXPRESSION; OXIDATIVE STRESS; DISUSE ATROPHY; KINASE IKK; ALPHA; DEGRADATION; ACTIVATION; RATS	Heat shock protein 25/27 (Hsp25/27) is a cytoprotective protein that is ubiquitously expressed in most cells, and is up-regulated in response to cellular stress. Previous work, in nonmuscle cells, has shown that Hsp27 inhibits TNF-alpha-induced NF-kappa B activation. During skeletal muscle disuse, Hsp25/27 levels are decreased and NF-kappa B activity increased, and this increase in NF-kappa B activity is required for disuse muscle atrophy. Therefore, the purpose of the current study was to determine whether electrotransfer of Hsp27 into the soleus muscle of rats, prior to skeletal muscle disuse, is sufficient to inhibit skeletal muscle disuse atrophy and NF-kappa B activation. The 35% disuse muscle-fiber atrophy observed in nontransfected fibers was attenuated by 50% in fibers transfected with Hsp27. Hsp27 also inhibited the disuse-induced increase in MuRF1 and atrogin-1 transcription by 82 and 40%, respectively. Furthermore, disuse- and IKK beta-induced NF-kappa B transactivation were abolished by Hsp27. In contrast, Hsp27 had no effect on Foxo transactivation. In conclusion, Hsp27 is a negative regulator of NF-kappa B in skeletal muscle, in vivo, and is sufficient to inhibit MuRF1 and atrogin-1 and attenuate skeletal muscle disuse atrophy.-Dodd, S. L., Hain, B., Senf, S. M., Judge, A. R. Hsp27 inhibits IKK beta-induced NF-kappa B activity and skeletal muscle atrophy. FASEB J. 23, 3415-3423 ( 2009). www.fasebj.org	[Dodd, Stephen L.; Hain, Brian; Senf, Sarah M.; Judge, Andrew R.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Judge, AR (corresponding author), Univ Florida, Dept Appl Physiol & Kinesiol, 25 Stadium Rd, Gainesville, FL 32611 USA.	ajudge@hhp.ufl.edu		Judge, Sarah/0000-0002-3974-0247	U. S. National Institutes of Health [R03AR056418]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR056418] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by U. S. National Institutes of Health grant R03AR056418 ( to A.R.J.).	Ahtikoski AM, 2003, ACTA PHYSIOL SCAND, V177, P473, DOI 10.1046/j.1365-201X.2003.01061.x; Alzghoul MB, 2004, FASEB J, V18, P221, DOI 10.1096/fj.03-0293fje; Arriaga MA, 1998, AM J OTOL, V19, P26; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; BOOTH FW, 1973, J APPL PHYSIOL, V34, P404, DOI 10.1152/jappl.1973.34.3.404; Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Dupont-Versteegden EE, 2004, MUSCLE NERVE, V29, P73, DOI 10.1002/mus.10511; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; Huey KA, 2008, EXP PHYSIOL, V93, P415, DOI 10.1113/expphysiol.2007.041228; Hunter RB, 2004, J CLIN INVEST, V114, P1504, DOI 10.1172/JCI200421696; Hunter RB, 2002, FASEB J, V16, P529, DOI 10.1096/fj.01-0866com; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; INAGUMA Y, 1993, J BIOCHEM-TOKYO, V114, P378, DOI 10.1093/oxfordjournals.jbchem.a124184; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Judge AR, 2007, AM J PHYSIOL-CELL PH, V292, pC372, DOI 10.1152/ajpcell.00293.2006; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Lawler JM, 2006, MUSCLE NERVE, V33, P200, DOI 10.1002/mus.20454; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liu YF, 2006, FRONT BIOSCI-LANDMRK, V11, P2802, DOI 10.2741/2011; LOCKE M, 1990, AM J PHYSIOL, V258, pC723, DOI 10.1152/ajpcell.1990.258.4.C723; Mitchell-Felton H, 1999, AM J PHYSIOL-CELL PH, V277, pC1269, DOI 10.1152/ajpcell.1999.277.6.C1269; Mounier N, 2002, CELL STRESS CHAPERON, V7, P167, DOI 10.1379/1466-1268(2002)007<0167:ACASHS>2.0.CO;2; Murlasits Z, 2006, EXP GERONTOL, V41, P398, DOI 10.1016/j.exger.2006.01.005; Naito H, 2000, J APPL PHYSIOL, V88, P359, DOI 10.1152/jappl.2000.88.1.359; Ousman SS, 2007, NATURE, V448, P474, DOI 10.1038/nature05935; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Park KJ, 2003, J BIOL CHEM, V278, P35272, DOI 10.1074/jbc.M305095200; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pittet JF, 2005, J IMMUNOL, V174, P384, DOI 10.4049/jimmunol.174.1.384; Qing GL, 2006, CELL RES, V16, P895, DOI 10.1038/sj.cr.7310109; Rana ZA, 2004, ACTA PHYSIOL SCAND, V181, P233, DOI 10.1111/j.1365-201X.2004.01282.x; SALO DC, 1991, FREE RADICAL BIO MED, V11, P239, DOI 10.1016/0891-5849(91)90119-N; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Selsby JT, 2007, J APPL PHYSIOL, V102, P1702, DOI 10.1152/japplphysiol.00722.2006; Selsby JT, 2005, AM J PHYSIOL-REG I, V289, pR134, DOI 10.1152/ajpregu.00497.2004; Senf SM, 2008, FASEB J, V22, P3836, DOI 10.1096/fj.08-110163; Stevenson EJ, 2003, J PHYSIOL-LONDON, V551, P33, DOI 10.1113/jphysiol.2003.044701; Storz P, 2005, MOL CELL BIOL, V25, P8520, DOI 10.1128/MCB.25.19.8520-8530.2005; Sur R, 2008, J INVEST DERMATOL, V128, P1116, DOI 10.1038/sj.jid.5701157; Vazeille E, 2008, AM J PHYSIOL-ENDOC M, V295, pE1181, DOI 10.1152/ajpendo.90532.2008; Venkatakrishnan CD, 2008, AM J PHYSIOL-HEART C, V294, pH1736, DOI 10.1152/ajpheart.91507.2007; Waddell DS, 2008, AM J PHYSIOL-ENDOC M, V295, pE785, DOI 10.1152/ajpendo.00646.2007; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063	46	61	62	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3415	3423		10.1096/fj.08-124602	http://dx.doi.org/10.1096/fj.08-124602			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19528257	Green Published			2022-12-28	WOS:000270354300019
J	Vandenburgh, H; Shansky, J; Benesch-Lee, F; Skelly, K; Spinazzola, JM; Saponjian, Y; Tseng, BS				Vandenburgh, Herman; Shansky, Janet; Benesch-Lee, Frank; Skelly, Kirsten; Spinazzola, Janelle M.; Saponjian, Yero; Tseng, Brian S.			Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts	FASEB JOURNAL			English	Article						tetanic force; glucocorticoids; mdx mouse; dietary supplements; cardiovascular drugs	DUCHENNE MUSCULAR-DYSTROPHY; THERAPEUTIC STRATEGIES; GLYCOPROTEIN COMPLEX; SKELETAL-MUSCLES; MDX MOUSE; MICE; STRENGTH; PREDNISOLONE; PROTEIN; TARGET	Identification of factors that improve muscle function in boys with Duchenne muscular dystrophy (DMD) could lead to an improved quality of life. To establish a functional in vitro assay for muscle strength, mdx murine myoblasts, the genetic homologue of DMD, were tissue engineered in 96-microwell plates into 3-dimensional muscle constructs with parallel arrays of striated muscle fibers. When electrically stimulated, they generated tetanic forces measured with an automated motion tracking system. Thirty-one compounds of interest as potential treatments for patients with DMD were tested at 3 to 6 concentrations. Eleven of the compounds (insulin-like growth factor-1, creatine, beta-hydroxy-beta-methylbutyrate, trichostatin A, lisinopril, and 6 from the glucocorticoid family) significantly increased tetanic force relative to placebo-treated controls. The glucocorticoids methylprednisolone, deflazacort, and prednisone increased tetanic forces at low doses (EC50 of 6, 19, and 56 nM, respectively), indicating a direct muscle mechanism by which they may be benefitting DMD patients. The tetanic force assay also identified beneficial compound interactions ( arginine plus deflazacort and prednisone plus creatine) as well as deleterious interactions ( prednisone plus creatine inhibited by pentoxifylline) of combinatorial therapies taken by some DMD patients. Since mdx muscle in vivo and DMD patients respond in a similar manner to many of these compounds, the in vitro assay will be a useful tool for the rapid identification of new potential treatments for muscle weakness in DMD and other muscle disorders.-Vandenburgh, H., Shansky, J., Benesch-Lee, F., Skelly, K., Spinazzola, J. M., Saponjian, Y., Tseng, B. S. Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts. FASEB J. 23, 3325-3334 ( 2009). www.fasebj.org	[Vandenburgh, Herman] Myomics Inc, Slater Biotechnol Ctr, Providence, RI 02906 USA; [Vandenburgh, Herman; Shansky, Janet] Miriam Hosp, Brown Med Sch, Dept Pathol, Providence, RI 02906 USA; [Saponjian, Yero; Tseng, Brian S.] Massachusetts Gen Hosp, Boston, MA 02114 USA	Brown University; Lifespan Health Rhode Island; Miriam Hospital; Harvard University; Massachusetts General Hospital	Vandenburgh, H (corresponding author), Myomics Inc, Slater Biotechnol Ctr, 5th Floor,4 Richmond Sq, Providence, RI 02906 USA.	hvandenburgh@myomics.com	Benesch-Lee, Frank/O-2482-2014	Benesch-Lee, Frank/0000-0002-4551-3163	Slater Technology Fund; National Institutes of Health [AG-029705, NS-059098, AR-052308]; National Science Foundation [0724445]; Hood, Sharp, and Jett Foundations; Charley's Fund; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR052308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R43NS059098, R44NS059098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R43AG029705] Funding Source: NIH RePORTER	Slater Technology Fund; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Hood, Sharp, and Jett Foundations; Charley's Fund; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr. Terry Partridge ( Children's National Medical Center, Washington, DC, USA) for providing the conditionally immortalized control and mdx skeletal muscle cells. This work was supported by the Slater Technology Fund; the National Institutes of Health (AG-029705, NS-059098, and AR-052308); the National Science Foundation ( award 0724445); the Hood, Sharp, and Jett Foundations; and Charley's Fund. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and not necessarily those of the granting agencies. H. V. and B. T. designed the experiments and wrote the paper; J.S., K. S., and J.M.S. performed the tissue engineering, compound screening, and force measurements; F.B.-L. developed the casting molds for the micropost plugs, wrote the LabView and MatLab software, and built the MAD device; and Y.S. performed histological analyses.	Acharyya S, 2005, CANCER CELL, V8, P421, DOI 10.1016/j.ccr.2005.10.004; Archer JD, 2006, FASEB J, V20, P738, DOI 10.1096/fj.05-4821fje; Asai A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000806; Bellinger AM, 2008, J CLIN INVEST, V118, P445, DOI 10.1172/JCI34006; Bonifati MD, 2000, MUSCLE NERVE, V23, P1344, DOI 10.1002/1097-4598(200009)23:9<1344::AID-MUS4>3.3.CO;2-6; Brunelli S, 2007, P NATL ACAD SCI USA, V104, P264, DOI 10.1073/pnas.0608277104; Catoire H, 2008, HUM MOL GENET, V17, P2108, DOI 10.1093/hmg/ddn109; Chamberlain J, 2006, DUCHENNE MUSCULAR DY; CHROMIAK JA, 1992, AM J PHYSIOL, V262, pC1471, DOI 10.1152/ajpcell.1992.262.6.C1471; Ciafaloni E, 2008, CURR TREAT OPTION N, V10, P86, DOI 10.1007/s11940-008-0010-4; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; Cohn RD, 2007, NAT MED, V13, P204, DOI 10.1038/nm1536; Courdier-Fruh I, 2002, NEUROMUSCULAR DISORD, V12, pS95, DOI 10.1016/S0960-8966(02)00089-5; Escolar D, 2008, NEUROMUSCULAR DISORD, V18, P824, DOI 10.1016/j.nmd.2008.06.345; Fisher I, 2005, FASEB J, V19, P834, DOI 10.1096/fj.04-2511fje; Franco-Obregon A, 2002, J PHYSIOL-LONDON, V539, P391, DOI 10.1113/jphysiol.2001.013043; Gaud A, 2004, NEUROMUSCULAR DISORD, V14, P365, DOI 10.1016/j.nmd.2004.02.011; Golumbek PT, 2007, NEUROMUSCULAR DISORD, V17, P376, DOI 10.1016/j.nmd.2007.02.005; Granchelli JA, 2000, NEUROMUSCULAR DISORD, V10, P235, DOI 10.1016/S0960-8966(99)00126-1; Grounds MD, 2008, CELL MOL LIFE SCI, V65, P1621, DOI 10.1007/s00018-008-7574-8; HUDECKI MS, 1993, RES COMMUN CHEM PATH, V79, P45; Johnson BD, 2005, P NATL ACAD SCI USA, V102, P4191, DOI 10.1073/pnas.0409695102; Khademhosseini A, 2006, P NATL ACAD SCI USA, V103, P2480, DOI 10.1073/pnas.0507681102; Khurana TS, 2003, NAT REV DRUG DISCOV, V2, P379, DOI 10.1038/nrd1085; Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03-0453com; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Leijendekker WJ, 1996, BRIT J PHARMACOL, V118, P611, DOI 10.1111/j.1476-5381.1996.tb15445.x; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; McClure WC, 2007, NEUROMUSCULAR DISORD, V17, P639, DOI 10.1016/j.nmd.2007.04.008; McNally EM, 2008, HEART, V94, P976, DOI 10.1136/hrt.2007.138461; METZINGER L, 1995, BRIT J PHARMACOL, V116, P2811, DOI 10.1111/j.1476-5381.1995.tb15930.x; Minetti GC, 2006, NAT MED, V12, P1147, DOI 10.1038/nm1479; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Ng R, 2008, AM J PHYSIOL-CELL PH, V295, pC146, DOI 10.1152/ajpcell.00017.2008; Nissen SL, 2003, J APPL PHYSIOL, V94, P651, DOI 10.1152/japplphysiol.00755.2002; Passaquin AC, 2002, NEUROMUSCULAR DISORD, V12, P174, DOI 10.1016/S0960-8966(01)00273-5; Payne ET, 2006, MUSCLE NERVE, V33, P66, DOI 10.1002/mus.20436; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Sampaolesi M, 2001, PFLUG ARCH EUR J PHY, V442, P161, DOI 10.1007/s004240100516; Schertzer JD, 2006, AM J PHYSIOL-ENDOC M, V291, pE499, DOI 10.1152/ajpendo.00101.2006; Siegel AL, 2009, NEUROMUSCULAR DISORD, V19, P131, DOI 10.1016/j.nmd.2008.10.006; Steen MS, 2009, MOL BIOL CELL, V20, P146, DOI 10.1091/mbc.E08-08-0811; Steffen LS, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-79; Sumukadas D, 2006, GERONTOLOGY, V52, P237, DOI 10.1159/000093656; Tanaka M, 2005, PLOS BIOL, V3, P764, DOI 10.1371/journal.pbio.0030128; Tarnopolsky MA, 2004, NEUROLOGY, V62, P1771, DOI 10.1212/01.WNL.0000125178.18862.9D; Terstappen GC, 2007, NAT REV DRUG DISCOV, V6, P891, DOI 10.1038/nrd2410; Tidball JG, 2004, PEDIATR RES, V56, P831, DOI 10.1203/01.PDR.0000145578.01985.D0; Vandenburgh H, 2008, MUSCLE NERVE, V37, P438, DOI 10.1002/mus.20931; VANDENBURGH HH, 1991, FASEB J, V5, P2860, DOI 10.1096/fasebj.5.13.1916108; Villalta SA, 2009, HUM MOL GENET, V18, P482, DOI 10.1093/hmg/ddn376; Welch EM, 2007, NATURE, V447, P87, DOI 10.1038/nature05756; Yeung EW, 2003, J PHYSIOL-LONDON, V552, P449, DOI 10.1113/jphysiol.2003.047373; Zhu CH, 2007, AGING CELL, V6, P515, DOI 10.1111/j.1474-9726.2007.00306.x	55	80	91	0	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3325	3334		10.1096/fj.09-134411	http://dx.doi.org/10.1096/fj.09-134411			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19487307	Green Published			2022-12-28	WOS:000270354300010
J	Cao, PR; Hanai, J; Tanksale, P; Imamura, S; Sukhatme, VP; Lecker, SH				Cao, Peirang; Hanai, Jun-ichi; Tanksale, Preeti; Imamura, Shintaro; Sukhatme, Vikas P.; Lecker, Stewart H.			Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect	FASEB JOURNAL			English	Article						atrophy; farnesylation	DEPENDENT CARDIAC-HYPERTROPHY; SKELETAL-MUSCLE; IGF-I; GENE-EXPRESSION; KINASE; MYOPATHY; PATHWAY; CELLS; INHIBITION; RHEB	Statins are widely used to treat hypercholesterolemia but can lead to a number of side effects in muscle, including rhabdomyolysis. Our recent findings implicated the induction of atrogin-1, a gene required for the development of muscle atrophy, in statin-induced muscle damage. Since statins inhibit many biochemical reactions besides cholesterol synthesis, we sought to define the statin-inhibited pathways responsible for atrogin-1 expression and muscle damage. We report here that lovastatin-induced atrogin-1 expression and muscle damage in cultured mouse myotubes and zebrafish can be prevented in the presence of geranylgeranol but not farnesol. Further, inhibitors of the transfer of geranylgeranyl isoprene units to protein targets cause statin muscle damage and atrogin-1 induction in cultured cells and in fish. These findings support the concept that dysfunction of small GTP-binding proteins lead to statin-induced muscle damage since these molecules require modification by geranylgeranyl moieties for their cellular localization and activity. Collectively, our animal and in vitro findings shed light on the molecular mechanism of statin-induced myopathy and suggest that atrogin-1 may be regulated by novel signaling pathways.-Cao, P., Hanai, J., Tanksale, P., Imamura, S., Sukhatme, V. P., Lecker, S. H. Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect. FASEB J. 23, 2844-2854 (2009). www.fasebj.org	[Cao, Peirang; Hanai, Jun-ichi; Tanksale, Preeti; Sukhatme, Vikas P.; Lecker, Stewart H.] Beth Israel Deaconess Med Ctr, Div Renal, Dept Med, Boston, MA 02215 USA; [Hanai, Jun-ichi; Sukhatme, Vikas P.] Beth Israel Deaconess Med Ctr, Div Interdisciplinary Med & Biotechnol, Dept Med, Boston, MA 02215 USA; [Imamura, Shintaro] Natl Res Inst Fisheries Sci, Food Technol & Biochem Div, Yokohama, Kanagawa, Japan	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Japan Fisheries Research & Education Agency (FRA)	Lecker, SH (corresponding author), Beth Israel Deaconess Med Ctr, Div Renal, Dept Med, DA517,330 Brookline Ave, Boston, MA 02215 USA.	slecker@bidmc.harvard.edu	cao, peirang/AAH-1746-2019; Sukhatme, Vikas/W-2776-2019	cao, peirang/0000-0003-4729-5478; 	U.S. National Institutes of Health [DK062307]; Beth Israel Deaconess Medical Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062307] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Beth Israel Deaconess Medical Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank members of the V.P.S. laboratory and the Alfred L. Goldberg laboratory (Harvard Medical School, Boston, MA, USA) for their useful discussions. We also thank Eriko Koshimizu and Nathaniel Doro for technical support. This work was supported by grants from the U.S. National Institutes of Health (DK062307) to S. H. L. and seed funds from Beth Israel Deaconess Medical Center to V.P.S.	Antons KA, 2006, AM J MED, V119, P400, DOI 10.1016/j.amjmed.2006.02.007; Attaix D, 2005, INT J BIOCHEM CELL B, V37, P1962, DOI 10.1016/j.biocel.2005.04.009; Baba TT, 2008, J MUSCLE RES CELL M, V29, P127, DOI 10.1007/s10974-008-9146-9; Baker SK, 2001, CLIN INVEST MED, V24, P258; Baker SK, 2005, MUSCLE NERVE, V31, P572, DOI 10.1002/mus.20291; Ballantyne CM, 2003, ARCH INTERN MED, V163, P553, DOI 10.1001/archinte.163.5.553; Bdolah Y, 2007, AM J PHYSIOL-REG I, V292, pR971, DOI 10.1152/ajpregu.00617.2006; Berthold HK, 2006, DRUG SAFETY, V29, P703, DOI 10.2165/00002018-200629080-00007; Birely J, 2005, DEV BIOL, V280, P162, DOI 10.1016/j.ydbio.2005.01.012; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Buerger C, 2006, BIOCHEM BIOPH RES CO, V344, P869, DOI 10.1016/j.bbrc.2006.03.220; Buettner C, 2008, PHARMACOGENOMICS, V9, P1133, DOI 10.2217/14622416.9.8.1133; Buettner C, 2008, J GEN INTERN MED, V23, P1182, DOI 10.1007/s11606-008-0636-7; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Crick DC, 1997, BIOCHEM BIOPH RES CO, V237, P483, DOI 10.1006/bbrc.1997.7145; CROW MT, 1986, DEV BIOL, V118, P333, DOI 10.1016/0012-1606(86)90002-3; Devoto SH, 1996, DEVELOPMENT, V122, P3371; Fernandez M, 2005, J MOL ENDOCRINOL, V34, P699, DOI 10.1677/jme.1.01703; Flint OP, 1997, TOXICOL APPL PHARM, V145, P91, DOI 10.1006/taap.1997.8131; Foley KA, 2004, AM J CARDIOL, V93, P193, DOI 10.1016/j.amjcard.2003.09.035; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Graham DJ, 2004, JAMA-J AM MED ASSOC, V292, P2585, DOI 10.1001/jama.292.21.2585; Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064; Hanai JI, 2007, J CLIN INVEST, V117, P3940, DOI 10.1172/JCI32741; Hattori M, 2003, J BIOCHEM, V134, P479, DOI 10.1093/jb/mvg180; Holstein SA, 2006, CANCER CHEMOTH PHARM, V57, P155, DOI 10.1007/s00280-005-0013-8; Ivorra' C, 2006, GENE DEV, V20, P307, DOI 10.1101/gad.349506; Kaufmann P, 2006, CELL MOL LIFE SCI, V63, P2415, DOI 10.1007/s00018-006-6235-z; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Lagirand-Cantaloube J, 2008, EMBO J, V27, P1266, DOI 10.1038/emboj.2008.52; Lamperti C, 2005, ARCH NEUROL-CHICAGO, V62, P1709, DOI 10.1001/archneur.62.11.1709; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Li HH, 2004, J CLIN INVEST, V114, P1058, DOI 10.1172/JCl200422220; Li HH, 2007, J CLIN INVEST, V117, P3211, DOI 10.1172/JCI31757; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; Marcoff L, 2007, J AM COLL CARDIOL, V49, P2231, DOI 10.1016/j.jacc.2007.02.049; Matzno S, 1997, J LIPID RES, V38, P1639; Maurer-Stroh S, 2007, PLOS COMPUT BIOL, V3, P634, DOI 10.1371/journal.pcbi.0030066; Mieulet V, 2007, AM J PHYSIOL-CELL PH, V293, pC712, DOI 10.1152/ajpcell.00499.2006; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; NAMBUDIRI AMD, 1980, J BIOL CHEM, V255, P5894; O'Meara JG, 2004, ARCH INTERN MED, V164, P1313, DOI 10.1001/archinte.164.12.1313; Okuno Y, 2002, BLOOD, V100, P4420, DOI 10.1182/blood-2002-03-0788; PAN HY, 1990, J CLIN PHARMACOL, V30, P1128, DOI 10.1002/j.1552-4604.1990.tb01856.x; Phillips PS, 2002, ANN INTERN MED, V137, P581, DOI 10.7326/0003-4819-137-7-200210010-00009; Pizon V, 2000, ONCOGENE, V19, P6074, DOI 10.1038/sj.onc.1203984; Ren ZB, 1997, BIOCHEM PHARMACOL, V54, P113, DOI 10.1016/S0006-2952(97)00151-2; Romano D, 2006, ENDOCRINOLOGY, V147, P6036, DOI 10.1210/en.2006-0325; Sakamoto K, 2007, FASEB J, V21, P4087, DOI 10.1096/fj.07-8713com; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Siddals KW, 2004, J BIOL CHEM, V279, P38353, DOI 10.1074/jbc.M404838200; Staffa JA, 2002, NEW ENGL J MED, V346, P539, DOI 10.1056/NEJM200202143460721; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Thompson PD, 2003, JAMA-J AM MED ASSOC, V289, P1681, DOI 10.1001/jama.289.13.1681; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; Tomasetti M, 1999, BIOFACTORS, V9, P231, DOI 10.1002/biof.5520090218; Ulucan C, 2007, AM J PHYSIOL-HEART C, V293, pH1662, DOI 10.1152/ajpheart.00159.2007; Urso ML, 2005, ARTERIOSCL THROM VAS, V25, P2560, DOI 10.1161/01.ATV.0000190608.28704.71; Van Kolen K, 2006, CELL SIGNAL, V18, P1169, DOI 10.1016/j.cellsig.2005.09.005; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Yang HM, 2005, J CELL BIOCHEM, V94, P1058, DOI 10.1002/jcb.20371	64	80	82	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2844	2854		10.1096/fj.08-128843	http://dx.doi.org/10.1096/fj.08-128843			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19406843	Green Published			2022-12-28	WOS:000270241000007
J	Zhou, HF; Chan, HW; Wickline, SA; Lanza, GM; Pham, CTN				Zhou, Hui-fang; Chan, Happy W.; Wickline, Samuel A.; Lanza, Gregory M.; Pham, Christine T. N.			alpha(v)beta(3)-Targeted nanotherapy suppresses inflammatory arthritis in mice	FASEB JOURNAL			English	Article						angiogenesis; K/BxN mouse model; perfluorocarbon nanoparticles; systemic drug delivery	COLLAGEN-INDUCED ARTHRITIS; VX-2 RABBIT TUMORS; RHEUMATOID-ARTHRITIS; MAGNETIC-RESONANCE; INTRAARTICULAR TREATMENT; ANGIOGENESIS; NANOPARTICLES; EFFICACY; BIOLOGICS; INHIBITOR	The purpose of this study was to assess whether an alternative treatment approach that targets angiogenesis, delivered through ligand-targeted nano-therapy, would ameliorate inflammatory arthritis. Arthritis was induced using the K/BxN mouse model of inflammatory arthritis. After arthritis was clearly established, mice received three consecutive daily doses of alpha(v)beta 3-targeted fumagillin nanoparticles. Control groups received no treatment or alpha(v)beta(3)-targeted nanoparticles without drugs. Disease score and paw thickness were measured daily. Mice that received alpha(v)beta(3)-targeted fumagillin nanoparticles showed a significantly lower disease activity score (mean score of 1.4 +/- 0.4; P<0.001) and change in ankle thickness (mean increase of 0.17 +/- 0.05 mm; P<0.001) 7 d after arthritis induction, whereas the group that received alpha(v)beta(3)-targeted nanoparticles without drugs exhibited a mean arthritic score of 9.0 +/- 0.3 and mean change in ankle thickness of 1.01 +/- 0.09 mm. Meanwhile, the group that received no treatment showed a mean arthritic score of 9.8 +/- 0.5 and mean change in ankle thickness of 1.05 +/- 0.10 mm. Synovial tissues from animals treated with targeted fumagillin nanoparticles also showed significant decrease in inflammation and angiogenesis and preserved proteoglycan integrity. Ligand-targeted nanotherapy to deliver antiangiogenic agents may represent an effective way to treat inflammatory arthritis.-Zhou, H.-F., Chan, H. W., Wickline, S. A., Lanza, G. M., Pham, C. T. N. alpha(v)beta(3)-Targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J. 23, 2978-2985 (2009). www.fasebj.org	[Zhou, Hui-fang; Pham, Christine T. N.] Washington Univ, Sch Med, Div Rheumatol, St Louis, MO USA; [Wickline, Samuel A.; Lanza, Gregory M.] Washington Univ, Sch Med, Div Cardiol, St Louis, MO USA; [Chan, Happy W.] Univ Calif Davis, Div Rheumatol, Sch Med, Davis, CA 95616 USA	Washington University (WUSTL); Washington University (WUSTL); University of California System; University of California Davis	Pham, CTN (corresponding author), 660 S Euclid Ave,Box 8045, St Louis, MO 63110 USA.	cpham@im.wustl.edu			National Institutes of Health [AR-056468, CA-119342, HL-78631]; NATIONAL CANCER INSTITUTE [U54CA119342] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056468] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by grants from the National Institutes of Health (AR-056468, CA-119342, and HL-78631). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. S. A. W. and G. M. L. are scientific cofounders of Kereos, Inc. and minority shareholders (<5%). We extend sincere appreciation to Ralph Fuhrhop for formulation chemistry. We thank Dr. Fei Shih (Washington University) for the generous gift of K/BxN serum.	Adkison AM, 2002, J CLIN INVEST, V109, P363, DOI 10.1172/JCI13462; Badger AM, 2001, ARTHRITIS RHEUM-US, V44, P128, DOI 10.1002/1529-0131(200101)44:1<128::AID-ANR17>3.0.CO;2-M; Bernier SG, 2004, P NATL ACAD SCI USA, V101, P10768, DOI 10.1073/pnas.0404105101; Bhargava P, 1999, CLIN CANCER RES, V5, P1989; Buch MH, 2007, RHEUMATOLOGY, V46, P1153, DOI 10.1093/rheumatology/kem075; Caruthers SD, 2006, INVEST RADIOL, V41, P305, DOI 10.1097/01.rli.0000199281.60135.6a; Ceponis A, 2001, ARTHRITIS RHEUM, V44, P1908; de Bandt M, 2000, ARTHRITIS RHEUM, V43, P2056; Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003; Gartlehner G, 2006, J RHEUMATOL, V33, P2398; Gerlag DM, 2001, ARTHRITIS RES, V3, P357, DOI 10.1186/ar327; Hannig G, 2007, ARTHRITIS RHEUM-US, V56, P850, DOI 10.1002/art.22402; Hu G, 2007, INT J CANCER, V120, P1951, DOI 10.1002/ijc.22581; Ji H, 2001, J EXP MED, V194, P321, DOI 10.1084/jem.194.3.321; KAUFMAN R, 1996, EMULSIONS EMULSION S, V132, P343; Koch AE, 2003, ANN RHEUM DIS, V62, P60, DOI 10.1136/ard.62.suppl_2.ii60; Kochansky J, 2004, APIDOLOGIE, V35, P301, DOI 10.1051/apido:2004017; Koning GA, 2006, ARTHRITIS RHEUM-US, V54, P1198, DOI 10.1002/art.21719; Krafft MP, 2001, ADV DRUG DELIVER REV, V47, P209, DOI 10.1016/S0169-409X(01)00107-7; Kudelka AP, 1998, NEW ENGL J MED, V338, P991, DOI 10.1056/NEJM199804023381412; Lainer DT, 2005, EXPERT OPIN INV DRUG, V14, P1, DOI 10.1517/13543784.14.1.1; Lainer-Carr D, 2007, NAT CLIN PRACT RHEUM, V3, P434, DOI 10.1038/ncprheum0559; Lanza GM, 2005, CURR TOP DEV BIOL, V70, P57, DOI 10.1016/S0070-2153(05)70003-X; Liggins RT, 2004, INFLAMM RES, V53, P363, DOI 10.1007/s00011-004-1273-1; Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324; Mandik-Nayak L, 2005, IMMUNOL RES, V32, P5, DOI 10.1385/IR:32:1-3:005; Nahar M, 2006, CRIT REV THER DRUG, V23, P259, DOI 10.1615/CritRevTherDrugCarrierSyst.v23.i4.10; Neubauer AM, 2007, J CARDIOVASC MAGN R, V9, P565, DOI 10.1080/10976640600945481; Offodile R, 1999, TUMORI, V85, P51, DOI 10.1177/030089169908500111; Riess JG, 2001, CHEM REV, V101, P2797, DOI 10.1021/cr970143c; Schmieder AH, 2005, MAGN RESON MED, V53, P621, DOI 10.1002/mrm.20391; Schmieder AH, 2008, FASEB J, V22, P4179, DOI 10.1096/fj.08-112060; Schnell MA, 2002, HUM GENE THER, V13, P155, DOI 10.1089/10430340152712700; Siddiqui MAA, 2007, CURR OPIN RHEUMATOL, V19, P308, DOI 10.1097/01.bor.0000265447.48722.04; Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756; Szekanecz Z, 2005, FRONT BIOSCI-LANDMRK, V10, P1739, DOI 10.2741/1657; Tarner IH, 2007, NAT CLIN PRACT RHEUM, V3, P336, DOI 10.1038/ncprheum0506; Tsai CY, 2007, ARTHRITIS RHEUM-US, V56, P544, DOI 10.1002/art.22401; VANLENT PLEM, 1993, RHEUMATOL INT, V13, P21, DOI 10.1007/BF00290330; Winter PM, 2008, FASEB J, V22, P2758, DOI 10.1096/fj.07-103929; Winter PM, 2006, ARTERIOSCL THROM VAS, V26, P2103, DOI 10.1161/01.ATV.0000235724.11299.76; Winter PM, 2003, CANCER RES, V63, P5838; Winter PM, 2003, CIRCULATION, V108, P2270, DOI 10.1161/01.CIR.0000093185.16083.95; YADAV JS, 2008, SYNTHESIS-STUTTGART, V9, P1460; Zink A, 2006, ARTHRITIS RHEUM-US, V54, P3399, DOI 10.1002/art.22193	45	67	68	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2978	2985		10.1096/fj.09-129874	http://dx.doi.org/10.1096/fj.09-129874			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19376816	Green Published			2022-12-28	WOS:000270241000020
J	Issuree, PDA; Pushparaj, PN; Pervaiz, S; Melendez, AJ				Issuree, Priya D. A.; Pushparaj, Peter N.; Pervaiz, Shazib; Melendez, Alirio J.			Resveratrol attenuates C5a-induced inflammatory responses in vitro and in vivo by inhibiting phospholipase D and sphingosine kinase activities	FASEB JOURNAL			English	Article						infl131ammation; neutrophil migration; oxidative burst; chemotaxis; ERK1/2; anaphylatoxin	ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; C5A DELAYS APOPTOSIS; FC-GAMMA-RI; NF-KAPPA-B; HUMAN-NEUTROPHILS; PHOSPHATIDIC-ACID; TNF-ALPHA; KEY ROLE; OXIDATIVE BURST	The anti-inflammatory activity of the phytoalexin resveratrol (RSV) was evaluated in C5 anaphylatoxin (C5a)-stimulated primary neutrophils and in a mouse model of acute peritonitis. Pretreatment of human and mouse neutrophils with RSV significantly blocked oxidative burst, leukocyte migration, degranulation, and inflammatory cytokine production. The anti-inflammatory activity of RSV was a function of inhibition of sphingosine kinase (SphK) activity (IC50 similar to 20 mu M) within 5 min of exposure, its membrane localization, and SphK1-mediated Ca2+ release. As an experimental control, the SphK1 pharmacological inhibitor N,N-dimethyl sphingosine (DMS) was used to compare the inhibitory effect of RSV. We also provide evidence that the SphK inhibitory effect of RSV was mediated via its ability to block phospholipase D (PLD) activity and membrane recruitment. Furthermore, RSV blocked ERK1/2 phosphorylation, which functioned independently of SphK1 in this study. To provide in vivo relevance to these data, C5a-induced model of acute peritonitis was established, and the effects of prior injection of RSV were investigated. Indeed, prior injection of RSV virtually completely attenuated the effects of C5a on vascular permeability, neutrophil migration, release of interleukin 1 beta, tumor necrosis factor alpha, interleukin 6, and the chemokine MIP-1 alpha. Taken together, these data demonstrate strong anti-inflammatory activity of RSV in vitro and in vivo and highlight SphK1 as a potential target of this remarkable phytoalexin. These data could have tremendous implications for the clinical use of RSV in inflammatory pathologies.-Issuree, P. D. A., Pushparaj, P. N., Pervaiz, S., Melendez, A. J. Resveratrol attenuates C5a-induced inflammatory responses in vitro and in vivo by inhibiting phospholipase D and sphingosine kinase activities. FASEB J. 23, 2412-2424 (2009)	[Issuree, Priya D. A.; Pushparaj, Peter N.; Pervaiz, Shazib; Melendez, Alirio J.] Natl Univ Singapore, Dept Physiol, Yong Loo Lin Sch Med, Singapore 117597, Singapore; [Pervaiz, Shazib; Melendez, Alirio J.] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117597, Singapore; [Pervaiz, Shazib] Natl Univ Singapore, Duke NUS Grad Med Sch, Singapore 117597, Singapore; [Pushparaj, Peter N.; Melendez, Alirio J.] Univ Glasgow, Glasgow Biomed Res Ctr, Glasgow, Lanark, Scotland; [Pervaiz, Shazib] Singapore Massachusetts Inst Technol, Singapore, Singapore	National University of Singapore; National University of Singapore; National University of Singapore; University of Glasgow; Massachusetts Institute of Technology (MIT); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore	Pervaiz, S (corresponding author), Natl Univ Singapore, Dept Physiol, Yong Loo Lin Sch Med, Singapore 117597, Singapore.	phssp@nus.edu.sg; a.melendez-romero@clinmed.gla.ac.uk	Pushparaj, Peter Natesan/H-9871-2012; Pervaiz, Shazib/C-4188-2015	Pushparaj, Peter Natesan/0000-0001-7574-1880; Issuree, Priya/0000-0002-8886-6436	National University of Singapore Academic Research Funds; Medical Research Council-UK [MRC G0700794]; National Medical Research Council and the Biomedical Research Council, Singapore; Medical Research Council [G0700794] Funding Source: researchfish	National University of Singapore Academic Research Funds(National University of Singapore); Medical Research Council-UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Medical Research Council and the Biomedical Research Council, Singapore(National Medical Research Council, Singapore); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	A. J. M. is supported by the National University of Singapore Academic Research Funds and Medical Research Council-UK, grant MRC G0700794. S. P. is supported by grants from the National Medical Research Council and the Biomedical Research Council, Singapore. P. D. A. I. performed most of the experiments and helped in the initial draft of the manuscript; P.N.P. performed Ca<SUP>2+</SUP> measurements and helped with the animal experiments and the initial draft of the manuscript; S. P. is a senior principal investigator and was involved in designing the study, analyzing the data, writing the final version of the manuscript, and funding support for the work; A. J. M. is a senior principal investigator and was involved in designing the study, setting up the in vivo model, analyzing the data, writing the manuscript, and funding support for the work.	Aggarwal BB, 2004, ANTICANCER RES, V24, P2783; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; Albert D, 2008, J LEUKOCYTE BIOL, V83, P1019, DOI 10.1189/jlb.0807531; Barthomeuf C, 2007, FREE RADICAL BIO MED, V42, P312, DOI 10.1016/j.freeradbiomed.2006.11.002; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; Baumruker T, 2005, IMMUNOL LETT, V96, P175, DOI 10.1016/j.imlet.2004.09.001; Blaukat A, 2001, BIOL CHEM, V382, P135, DOI 10.1515/BC.2001.020; Bohm M, 2002, DEUT MED WOCHENSCHR, V127, P2748, DOI 10.1055/s-2002-36275; Boncoeur E, 2008, INT J BIOCHEM CELL B, V40, P432, DOI 10.1016/j.biocel.2007.08.013; Brown KM, 2007, NAT CLIN PRACT NEPHR, V3, P277, DOI 10.1038/ncpneph0465; Chen XL, 2004, AM J PHYSIOL-HEART C, V287, pH1452, DOI 10.1152/ajpheart.01101.2003; Chiou WF, 2004, INT IMMUNOPHARMACOL, V4, P1329, DOI 10.1016/j.intimp.2004.05.017; Choi OH, 1996, NATURE, V380, P634; Clement MV, 1998, BLOOD, V92, P996; Crowell JA, 2004, TOXICOL SCI, V82, P614, DOI 10.1093/toxsci/kfh263; DAHINDEN CA, 1983, J CLIN INVEST, V72, P113, DOI 10.1172/JCI110948; Das Samarjit, 2007, Inflammation & Allergy Drug Targets, V6, P168, DOI 10.2174/187152807781696464; Dewas C, 2000, J IMMUNOL, V165, P5238, DOI 10.4049/jimmunol.165.9.5238; Drost EM, 2002, EUR J IMMUNOL, V32, P393, DOI 10.1002/1521-4141(200202)32:2<393::AID-IMMU393>3.0.CO;2-5; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Feng GJ, 1999, J IMMUNOL, V163, P6403; GERARD C, 1981, J IMMUNOL, V127, P1978; GOLDSTEI.IM, 1974, J IMMUNOL, V113, P1583; Gomez-Cambronero J, 2007, J LEUKOCYTE BIOL, V82, P272, DOI 10.1189/jlb.0107033; Goodridge HS, 2003, IMMUNOLOGY, V109, P415, DOI 10.1046/j.1365-2567.2003.01689.x; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Hannigan MO, 2001, J IMMUNOL, V167, P3953, DOI 10.4049/jimmunol.167.7.3953; Holme AL, 2007, J BIOENERG BIOMEMBR, V39, P59, DOI 10.1007/s10863-006-9053-y; HUGLI T E, 1981, Critical Reviews in Immunology, V1, P321; Ibrahim FBM, 2004, J BIOL CHEM, V279, P44802, DOI 10.1074/jbc.M403977200; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; KANAHO Y, 1991, FEBS LETT, V279, P249, DOI 10.1016/0014-5793(91)80160-5; Khanduja KL, 2004, J NUTR SCI VITAMINOL, V50, P61, DOI 10.3177/jnsv.50.61; Lai WQ, 2008, J IMMUNOL, V180, P4323, DOI 10.4049/jimmunol.180.6.4323; Lee C, 2004, J TRAUMA, V57, P955, DOI 10.1097/01.ta.0000149495.44582.76; Lee SC, 2006, PROTEOMICS, V6, P2386, DOI 10.1002/pmic.200500366; Lehman JA, 2001, AM J PHYSIOL-CELL PH, V280, pC183, DOI 10.1152/ajpcell.2001.280.1.C183; Liu K, 2008, J BIOL CHEM, V283, P9977, DOI 10.1074/jbc.M710257200; Mansfield PJ, 2002, BLOOD, V99, P1434, DOI 10.1182/blood.V99.4.1434; MARDER SR, 1985, J IMMUNOL, V134, P3325; Maupas-Schwalm F, 2004, FASEB J, V18, P1398, DOI 10.1096/fj.03-1123fje; Melendez A, 1998, CURR BIOL, V8, P210, DOI 10.1016/S0960-9822(98)70085-5; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Melendez AJ, 2001, BLOOD, V98, P3421, DOI 10.1182/blood.V98.12.3421; Melendez AJ, 2007, NAT MED, V13, P1375, DOI 10.1038/nm1654; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; N'Guessan PD, 2007, EUR RESPIR J, V30, P443, DOI 10.1183/09031936.00008707; Nagata T, 2001, BRIT J ANAESTH, V86, P853, DOI 10.1093/bja/86.6.853; Nishiuma T, 2008, AM J PHYSIOL-LUNG C, V294, pL1085, DOI 10.1152/ajplung.00445.2007; Perianayagam MC, 2002, KIDNEY INT, V61, P456, DOI 10.1046/j.1523-1755.2002.00139.x; Perianayagam MC, 2004, EUR J CLIN INVEST, V34, P50, DOI 10.1111/j.1365-2362.2004.01273.x; Pervaiz S, 2004, DRUG RESIST UPDATE, V7, P333, DOI 10.1016/j.drup.2004.11.001; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pilette C, 2002, J IMMUNOL, V168, P4103, DOI 10.4049/jimmunol.168.8.4103; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pushparaj PN, 2008, INT J BIOCHEM CELL B, V40, P1817, DOI 10.1016/j.biocel.2008.01.015; Riedemann NC, 2002, J IMMUNOL, V168, P1919, DOI 10.4049/jimmunol.168.4.1919; SACKS T, 1978, J CLIN INVEST, V61, P1161, DOI 10.1172/JCI109031; Schett G, 2000, ARTHRITIS RHEUM, V43, P2501, DOI 10.1002/1529-0131(200011)43:11<2501::AID-ANR18>3.0.CO;2-K; Sebai H, 2008, FREE RADICAL RES, V42, P913, DOI 10.1080/10715760802555577; Sethu S, 2008, J IMMUNOL, V180, P6027, DOI 10.4049/jimmunol.180.9.6027; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Szewczuk LM, 2004, J NAT PROD, V67, P1777, DOI 10.1021/np0498410; Tou JS, 2001, CELL SIGNAL, V13, P191, DOI 10.1016/S0898-6568(01)00137-1; Vlasenko LP, 2005, J IMMUNOL, V174, P6456, DOI 10.4049/jimmunol.174.10.6456; von Knethen A, 1999, J IMMUNOL, V163, P2858; Wu WC, 2004, MOL CELL BIOL, V24, P7359, DOI 10.1128/MCB.24.17.7359-7369.2004; Xythalis D, 2002, INFLAMMATION, V26, P83, DOI 10.1023/A:1014836211643; Zhi L, 2006, J CELL PHYSIOL, V208, P109, DOI 10.1002/jcp.20646	72	48	49	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2412	2424		10.1096/fj.09-130542	http://dx.doi.org/10.1096/fj.09-130542			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19346296	Bronze			2022-12-28	WOS:000268836700010
J	Krautz-Peterson, G; Ndegwa, D; Vasquez, K; Korideck, H; Zhang, J; Peterson, JD; Skelly, PJ				Krautz-Peterson, Greice; Ndegwa, David; Vasquez, Kristine; Korideck, Houari; Zhang, Jun; Peterson, Jeffrey D.; Skelly, Patrick J.			Imaging schistosomes in vivo	FASEB JOURNAL			English	Article						schistosomiasis; platyhelminth; parasite; fluorescence molecular tomography	TOXOPLASMA-GONDII; DRUG-RESISTANCE; MANSONI; PRAZIQUANTEL; MICE; INFECTION; MIGRATION; EXPRESSION; ARTEMETHER; VACCINES	Schistosomes are intravascular, parasitic helminths that cause a chronic, often debilitating disease afflicting over 200 million people in over 70 countries. Here we describe novel imaging methods that, for the first time, permit visualization of live schistosomes within their living hosts. The technology centers on fluorescent agent uptake and activation in the parasite's gut, and subsequent detection and signal quantitation using fluorescence molecular tomography (FMT). There is a strong positive correlation between the signal detected and parasite number. Schistosoma mansoni parasites of both sexes recovered from infected experimental animals exhibit vivid fluorescence throughout their intestines. Likewise, the remaining important human schistosome parasites, S. japonicum and S. hematobium, also exhibit gut fluorescence when recovered from infected animals. Imaging has been used to efficiently document the decline in parasite numbers in infected mice treated with the antischistosome drug praziquantel. This technology will provide a unique opportunity both to help rapidly identify much-needed, novel antischistosome therapies and to gain direct visual insight into the intravascular lives of the major schistosome parasites of humans.-Krautz-Peterson, G., Ndegwa, D., Vasquez, K., Korideck, H., Zhang, J., Peterson, J. D., Skelly, P. J. Imaging schistosomes in vivo. FASEB J. 23, 2673-2680 (2009)	[Krautz-Peterson, Greice; Ndegwa, David; Skelly, Patrick J.] Tufts Univ, Dept Biomed Sci, Cummings Sch Vet Med, Div Infect Dis,Mol Helminthol Lab, North Grafton, MA 01536 USA; [Vasquez, Kristine; Korideck, Houari; Zhang, Jun; Peterson, Jeffrey D.] VisEn Med Inc, Bedford, MA USA	Tufts University	Skelly, PJ (corresponding author), Tufts Univ, Dept Biomed Sci, Cummings Sch Vet Med, Div Infect Dis,Mol Helminthol Lab, 200 Westboro Rd, North Grafton, MA 01536 USA.	patrick.skelly@tufts.edu			Biomedical Research Institute (Rockville, MD, USA); National Institutes of Health-National Institute of Allergy and Infectious Diseases (NIH-NIAID) [N01-AI-30026, AI-056273]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030026, R01AI056273] Funding Source: NIH RePORTER	Biomedical Research Institute (Rockville, MD, USA); National Institutes of Health-National Institute of Allergy and Infectious Diseases (NIH-NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Schistosome-infected snails were provided by the Biomedical Research Institute (Rockville, MD, USA) through National Institutes of Health-National Institute of Allergy and Infectious Diseases (NIH-NIAID) contract N01-AI-30026. The work in P.J.S.'s laboratory is funded by NIH-NIAID grant AI-056273.	Abo-Madyan Ahmed A., 2004, Journal of the Egyptian Society of Parasitology, V34, P423; Albuquerque MCPA, 2005, PHARMAZIE, V60, P13; Alonso D, 2006, AM J TROP MED HYG, V74, P342, DOI 10.4269/ajtmh.2006.74.342; ARAUJO N, 1991, MEM I OSWALDO CRUZ, V86, P185, DOI 10.1590/S0074-02761991000600042; BALDE AM, 1989, PLANTA MED, P41, DOI 10.1055/s-2006-961821; Borrmann S, 2001, J INFECT DIS, V184, P1363, DOI 10.1086/324004; Botros S, 2004, AM J TROP MED HYG, V71, P206, DOI 10.4269/ajtmh.2004.71.206; Botros S, 2003, ANTIMICROB AGENTS CH, V47, P3853, DOI 10.1128/AAC.47.12.3853-3858.2003; Boyle JP, 2007, EXP PARASITOL, V116, P302, DOI 10.1016/j.exppara.2007.01.010; Brindley PJ, 2007, INT J PARASITOL, V37, P465, DOI 10.1016/j.ijpara.2006.12.012; CHANDIWANA SK, 1988, PARASITOLOGY, V97, P489, DOI 10.1017/S0031182000058893; Chatterjee S, 2002, TRENDS PARASITOL, V18, P295, DOI 10.1016/S1471-4922(02)02294-8; Cioli D, 2000, CURR OPIN INFECT DIS, V13, P659, DOI 10.1097/00001432-200012000-00014; CIOLI D, 1993, PARASITOL TODAY, V9, P162, DOI 10.1016/0169-4758(93)90138-6; Coles GC, 2002, TRENDS PARASITOL, V18, P294, DOI 10.1016/S1471-4922(02)02315-2; Cook RM, 2004, INFECT IMMUN, V72, P6112, DOI 10.1128/IAI.72.10.6112-6124.2004; Correnti JM, 2007, INT J PARASITOL, V37, P1107, DOI 10.1016/j.ijpara.2007.02.011; Corstjens PLAM, 2008, J CLIN MICROBIOL, V46, P171, DOI 10.1128/JCM.00877-07; CRABTREE JE, 1986, PARASITOLOGY, V92, P343, DOI 10.1017/S0031182000064118; DEAN DA, 1984, AM J TROP MED HYG, V33, P97, DOI 10.4269/ajtmh.1984.33.97; Despommier DD, 1994, PARASITIC DIS; DOVEY HF, 1985, MOL BIOCHEM PARASIT, V16, P185, DOI 10.1016/0166-6851(85)90086-6; El-Lakkany NM, 2004, INT J PARASITOL, V34, P1405, DOI 10.1016/j.ijpara.2004.08.012; Faust E. C., 1934, Puerto Rico Journal of Public Health, V10, P133; FLISSER A, 1989, PARASITE IMMUNOL, V11, P319, DOI 10.1111/j.1365-3024.1989.tb00670.x; Franke-Fayard B, 2006, NAT PROTOC, V1, P476, DOI 10.1038/nprot.2006.69; GONNERT R, 1977, Z PARASITENKD, V52, P129, DOI 10.1007/BF00389899; Graves EE, 2004, CURR MOL MED, V4, P419, DOI 10.2174/1566524043360555; Grimm J, 2005, P NATL ACAD SCI USA, V102, P14404, DOI 10.1073/pnas.0503920102; Hackett F, 1993, Methods Mol Biol, V21, P89; Hagan P, 2004, TRENDS PARASITOL, V20, P92, DOI 10.1016/j.pt.2003.11.010; Heussler V, 2006, TRENDS PARASITOL, V22, P192, DOI 10.1016/j.pt.2006.03.001; Heyers O, 2003, EXP PARASITOL, V105, P174, DOI 10.1016/j.exppara.2003.11.001; Hutchens M, 2007, CELL MICROBIOL, V9, P2315, DOI 10.1111/j.1462-5822.2007.00995.x; Katz N, 1989, Rev Soc Bras Med Trop, V22, P183, DOI 10.1590/S0037-86821989000400004; Kenworthy JD, 2003, VET PARASITOL, V113, P83, DOI 10.1016/S0304-4017(03)00036-0; Kines KJ, 2006, EXP PARASITOL, V112, P209, DOI 10.1016/j.exppara.2006.02.003; King CH, 2008, CHRONIC ILLN, V4, P65, DOI 10.1177/1742395307084407; Krautz-Peterson G, 2007, MOL BIOCHEM PARASIT, V153, P194, DOI 10.1016/j.molbiopara.2007.03.006; Liang You-Sheng, 2003, Southeast Asian Journal of Tropical Medicine and Public Health, V34, P274; Lu SH, 2006, PARASITOL INT, V55, P63, DOI 10.1016/j.parint.2005.10.001; Mahmoud MR, 2002, ARZNEIMITTEL-FORSCH, V52, P294; McManus DP, 2008, CLIN MICROBIOL REV, V21, P225, DOI 10.1128/CMR.00046-07; Midzi N, 2009, T ROY SOC TROP MED H, V103, P45, DOI 10.1016/j.trstmh.2008.08.018; MILLER P, 1978, PARASITOLOGY, V77, P281, DOI 10.1017/S0031182000050253; Montet X, 2005, CANCER RES, V65, P6330, DOI 10.1158/0008-5472.CAN-05-0382; Morales ME, 2007, FASEB J, V21, P3479, DOI 10.1096/fj.07-8726com; NDAMBA J, 1989, ACTA TROP, V46, P303, DOI 10.1016/0001-706X(89)90043-0; Ribeiro Fabio, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P231, DOI 10.1590/S0036-46652004000400010; Robijn MLM, 2008, T ROY SOC TROP MED H, V102, P79, DOI 10.1016/j.trstmh.2007.09.017; Saeij JPJ, 2005, INFECT IMMUN, V73, P695, DOI 10.1128/IAI.73.2.695-702.2005; STIREWALT M. A., 1959, ANN TROP MED AND PARASITOL, V53, P400; STIREWALT MA, 1974, EXP PARASITOL, V35, P1, DOI 10.1016/0014-4894(74)90002-2; Tort J, 1999, ADV PARASIT, V43, P161, DOI 10.1016/S0065-308X(08)60243-2; WARREN KS, 1982, IMMUNOL REV, V61, P189, DOI 10.1111/j.1600-065X.1982.tb00377.x; WHEATER PR, 1979, PARASITOLOGY, V79, P49, DOI 10.1017/S0031182000051970; WHO, 2002, PREVENTION CONTROL S; Wilson RA, 2006, MEM I OSWALDO CRUZ, V101, P13, DOI 10.1590/S0074-02762006000900004; WILSON RA, 1978, PARASITOLOGY, V77, P57, DOI 10.1017/S0031182000048721; Wippersteg V, 2002, INT J PARASITOL, V32, P1219, DOI 10.1016/S0020-7519(02)00092-9	60	18	18	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2673	2680		10.1096/fj.08-127738	http://dx.doi.org/10.1096/fj.08-127738			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19346298	Green Published			2022-12-28	WOS:000268836700035
J	Vizlin-Hodzic, D; Ryme, J; Simonsson, S; Simonsson, T				Vizlin-Hodzic, Dzeneta; Ryme, Jessica; Simonsson, Stina; Simonsson, Tomas			Developmental studies of Xenopus shelterin complexes: the message to reset telomere length is already present in the egg	FASEB JOURNAL			English	Article						telosome; differentiation; ES cell; iPS cell; quadruplex; cellular senescence	SINGLE-STRANDED-DNA; CELLULAR SENESCENCE; MAMMALIAN TELOMERES; CLONED CATTLE; STEM-CELLS; POT1; PROTEINS; TRF2; PROTECTION; REGULATOR	The 6-protein complex shelterin protects the telomeres of human chromosomes. The recent discovery that telomeres are important for epigenetic gene regulation and vertebrate embryonic development calls for the establishment of model organisms to study shelterin and telomere function under normal developmental conditions. Here, we report the sequences of the shelterin-encoding genes in Xenopus laevis and its close relation Xenopus tropicalis. In vitro expression and biochemical characterization of the Xenopus shelterin proteins TRF1, TRF2, POT1, TIN2, RAP1, TPP1, and the shelterin accessory factor PINX1 indicate that all main functions of their human orthologs are conserved in Xenopus. The X1TRF1 and XtTRF1 proteins bind double-stranded telomeric DNA sequence specifically and interact with X1TIN2 and XtTIN2, respectively. Similarly, the X1TRF2 and XtTRF2 proteins bind double-stranded telomeric DNA and interact with X1RAP1 and XtRAP1, respectively, whereas the X1POT1 and XtPOT1 proteins bind single-stranded telomeric DNA. Real-time PCR further reveals the gene expression profiles for telomerase and the shelterin genes during embryogenesis. Notably, the composition of shelterin and the formation of its subcomplexes appear to be temporally regulated during embryonic development. Moreover, unexpectedly high telomerase and shelterin gene expression during early embryogenesis may reflect a telomere length-resetting mechanism, similar to that reported for induced pluripotent stem cells and for animals cloned through somatic nuclear transfer.-Vizlin-Hodzic, D., Ryme, J., Simonsson, S., Simonsson, T. Developmental studies of Xenopus shelterin complexes: the message to reset telomere length is already present in the egg. FASEB J. 23, 2587-2594 ( 2009)	[Vizlin-Hodzic, Dzeneta; Ryme, Jessica; Simonsson, Stina; Simonsson, Tomas] Univ Gothenburg, Dept Biomed, Med Biochem & Cell Biol Div, SE-40530 Gothenburg, Sweden	University of Gothenburg	Simonsson, T (corresponding author), Univ Gothenburg, Dept Biomed, Med Biochem & Cell Biol Div, POB 440, SE-40530 Gothenburg, Sweden.	tomas.simonsson@gu.se	Simonsson, Stina/R-2699-2016	Simonsson, Stina/0000-0001-9020-3714	Wellcome Trust/Cancer Research UK Gurdon Institute; Swedish Research Council; Swedish Cancer Society; Assar Gabrielsson cancer research foundation; Johan Jansson foundation; Magn. Bergvall Research Foundation [x1TRF1 EU422974, x1TRF2 EU422975, x1POT1 EU422976, x1TIN2 EU422981, x1RAP1 EU422979, x1TPP1 AY673986, x1PINX1 EU520258, xtTRF1 EU422977, xtTRF2 EU422978, xtPOT1 AY535401, xtTIN2 EU422982, xtRAP1 EU422980, xtTPP1 AY673987, xtPINX1 EU520259]	Wellcome Trust/Cancer Research UK Gurdon Institute(Wellcome Trust); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Assar Gabrielsson cancer research foundation; Johan Jansson foundation; Magn. Bergvall Research Foundation	We thank John Gurdon and Nigel Garett at the Wellcome Trust/Cancer Research UK Gurdon Institute for embryo staging and X. laevis cDNA. This work was supported by the Swedish Research Council, the Swedish Cancer Society, the Assar Gabrielsson cancer research foundation, the Johan Jansson foundation, and the Magn. Bergvall Research Foundation. Nucleotide sequences have been deposited to GenBank under the following accession numbers: x1TRF1 EU422974, x1TRF2 EU422975, x1POT1 EU422976, x1TIN2 EU422981, x1RAP1 EU422979, x1TPP1 AY673986, x1PINX1 EU520258, xtTRF1 EU422977, xtTRF2 EU422978, xtPOT1 AY535401, xtTIN2 EU422982, xtRAP1 EU422980, xtTPP1 AY673987, and xtPINX1 EU520259.	Azzalin CM, 2007, NATURE, V448, P1001, DOI 10.1038/4481001a; Baumann P, 2002, MOL CELL BIOL, V22, P8079, DOI 10.1128/MCB.22.22.8079-8087.2002; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Betts DH, 2001, P NATL ACAD SCI USA, V98, P1077, DOI 10.1073/pnas.031559298; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blasco MA, 2007, NAT CHEM BIOL, V3, P640, DOI 10.1038/nchembio.2007.38; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; Chen LY, 2007, MOL CELL BIOL, V27, P5898, DOI 10.1128/MCB.00603-07; Chen Y, 2008, SCIENCE, V319, P1092, DOI 10.1126/science.1151804; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Court R, 2005, EMBO REP, V6, P39, DOI 10.1038/sj.embor.7400314; Crumet N, 2006, GENE, V369, P20, DOI 10.1016/j.gene.2005.10.006; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Faber J., 1994, NORMAL TABLE XENOPUS, P2; Finkel T, 2007, NATURE, V448, P767, DOI 10.1038/nature05985; Greider C W, 2000, Harvey Lect, V96, P33; Hanaoka S, 2001, J MOL BIOL, V312, P167, DOI 10.1006/jmbi.2001.4924; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446; Hockemeyer D, 2007, NAT STRUCT MOL BIOL, V14, P754, DOI 10.1038/nsmb1270; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; Houghtaling BR, 2004, CURR BIOL, V14, P1621, DOI 10.1016/j.cub.2004.08.052; Kim S, 2004, J BIOL CHEM, V279, P43799, DOI 10.1074/jbc.M408650200; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Kubista Mikael, 2006, Molecular Aspects of Medicine, V27, P95, DOI 10.1016/j.mam.2005.12.007; Lanza RP, 2000, SCIENCE, V288, P665, DOI 10.1126/science.288.5466.665; Lei M, 2004, NAT STRUCT MOL BIOL, V11, P1223, DOI 10.1038/nsmb867; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; Ly H, 2003, GENE DEV, V17, P1078, DOI 10.1101/gad.1060803; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Marion RM, 2009, CELL STEM CELL, V4, P141, DOI 10.1016/j.stem.2008.12.010; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; MCCLINTOCK B, 1938, GENETICS, V23, P403; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nishiyama A, 2006, EMBO J, V25, P575, DOI 10.1038/sj.emboj.7600964; O'Reilly Marc, 1999, Current Opinion in Structural Biology, V9, P56, DOI 10.1016/S0959-440X(99)80008-6; Schoeftner S, 2008, NAT CELL BIOL, V10, P228, DOI 10.1038/ncb1685; Simonsson T, 2003, TRENDS BIOCHEM SCI, V28, P632, DOI 10.1016/j.tibs.2003.10.005; Simonsson T, 2001, BIOL CHEM, V382, P621, DOI 10.1515/BC.2001.073; Sindelka R, 2008, NUCLEIC ACIDS RES, V36, P387, DOI 10.1093/nar/gkm1024; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Tian XC, 2000, NAT GENET, V26, P272, DOI 10.1038/81559; Wang F, 2007, NATURE, V445, P506, DOI 10.1038/nature05454; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; Xin HW, 2007, NATURE, V445, P559, DOI 10.1038/nature05469; Ye JZS, 2004, J BIOL CHEM, V279, P47264, DOI 10.1074/jbc.M409047200; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4	58	11	13	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2587	2594		10.1096/fj.09-129619	http://dx.doi.org/10.1096/fj.09-129619			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19329760				2022-12-28	WOS:000268836700027
J	Heeb, MJ; Prashun, D; Griffin, JH; Bouma, BN				Heeb, Mary J.; Prashun, Duane; Griffin, John H.; Bouma, Bonno N.			Plasma protein S contains zinc essential for efficient activated protein C-independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor	FASEB JOURNAL			English	Article; Proceedings Paper	21st Congress of the International-Society-on-Thrombosis-and-Haemostasis	JUL 06-12, 2007	Geneva, SWITZERLAND	Int Soc Thrombosis & Haemostasis		blood coagulation regulation; zinc metalloprotein; vitamin K-dependent protein	K-DEPENDENT PROTEIN; CRYSTAL-STRUCTURE; FACTOR-IX; FACTOR VA; DEFICIENCY; AFFINITY; GLOBULIN; COMPLEX; DOMAIN; CARBOXYPEPTIDASE	Protein S ( PS) is a cofactor for activated protein C (APC), which inactivates coagulation factors (F) Va and VIIIa. Deficiency of protein C or PS is associated with risk of thrombosis. We found that PS also has APC-independent anticoagulant activity (PS-direct) and directly inhibits thrombin generated by FXa/FVa (prothrombinase complex). Here we report that PS contains Zn(2+) that is required for PS-direct and that is lost during certain purification procedures. Immunoaffinity-purified PS contained 1.4 +/- 0.6 Zn(2+)/mol, whereas MonoQ-purified and commercial PS contained 0.15 +/- 0.15 Zn(2+)/mol. This may explain the controversy regarding the validity of PS-direct. Zn(2+) content correlated positively with PS-direct in prothrombinase assays and clotting assays, but APC-cofactor activity of PS was independent of Zn(2+) content. PS-direct and Zn(2+) were restored to inactive PS under mildly denaturing conditions. Conversely, o-phenanthroline reversibly impaired the PS-direct of active PS. Zn(2+)-containing PS bound FXa more efficiently (K(dapp) = 9.3 nM) than Zn(2+)-deficient PS (K(dapp) = 110 nM). PS bound TFPI efficiently, independently of Zn(2+) content (K(dapp) = 21 nM). Antibodies that block PS-direct preferentially recognized Zn(2+)-containing PS, suggesting conformation differences at or near the interface of 2 laminin G-like domains near the PS C terminus. Thus, Zn(2+) is required for PS-direct and efficient FXa binding and may play a role in stabilizing PS conformation.-Heeb, M. J., Prashun, D., Griffin, J. H., Bouma, B. N. Plasma protein S contains zinc essential for efficient activated protein C-independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor. FASEB J. 23, 2244-2253 (2009)	[Heeb, Mary J.; Griffin, John H.; Bouma, Bonno N.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; [Prashun, Duane] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; [Prashun, Duane] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Heeb, MJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM276,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	heeb@scripps.edu		Griffin, John/0000-0002-4302-2547	NHLBI NIH HHS [R01 HL021544, R01 HL070002, R01 HL088375, HL 0888375, HL70002, HL21544] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088375, R01HL021544, R01HL070002] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Avvakumov GV, 2002, J BIOL CHEM, V277, P45219, DOI 10.1074/jbc.M207762200; Bajaj SP, 2006, J BIOL CHEM, V281, P24873, DOI 10.1074/jbc.M509971200; BAJAJ SP, 1983, PREP BIOCHEM, V13, P191, DOI 10.1080/00327488308064248; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; GRINNELL BW, 1990, BLOOD, V76, P2546; Grishkovskaya I, 2000, EMBO J, V19, P504, DOI 10.1093/emboj/19.4.504; Hackeng TM, 2006, P NATL ACAD SCI USA, V103, P3106, DOI 10.1073/pnas.0504240103; HACKENG TM, 1994, J BIOL CHEM, V269, P21051; Heeb MJ, 2006, J THROMB HAEMOST, V4, P2215, DOI 10.1111/j.1538-7836.2006.02117.x; Heeb MJ, 2006, J THROMB HAEMOST, V4, P385, DOI 10.1111/j.1538-7836.2006.01743.x; Heeb MJ, 1999, J BIOL CHEM, V274, P36187, DOI 10.1074/jbc.274.51.36187; HEEB MJ, 1994, P NATL ACAD SCI USA, V91, P2728, DOI 10.1073/pnas.91.7.2728; Heeb MJ, 2004, J THROMB HAEMOST, V2, P1766, DOI 10.1111/j.1538-7836.2004.00901.x; Heeb MJ, 2002, BLOOD CELL MOL DIS, V29, P190, DOI 10.1006/bcmd.2002.0558; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; HEEB MJ, 2007, J THROMB HAEMOST S2, V5, pE0; Jensen AF, 2002, J BIOL INORG CHEM, V7, P490, DOI 10.1007/s00775-001-0324-0; Koenen RR, 2003, BLOOD, V102, P1686, DOI 10.1182/blood-2003-02-0620; MAHASANDANA C, 1990, LANCET, V335, P61, DOI 10.1016/0140-6736(90)90201-F; Mahmoodi BK, 2008, CIRCULATION, V118, P1659, DOI 10.1161/CIRCULATIONAHA.108.780759; Maret W, 2005, J TRACE ELEM MED BIO, V19, P7, DOI 10.1016/j.jtemb.2005.02.003; Marx PF, 2002, BIOCHEMISTRY-US, V41, P1211, DOI 10.1021/bi0115683; Passerini A, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-39; Petersen LC, 2000, PROTEIN SCI, V9, P859, DOI 10.1110/ps.9.5.859; Sasaki T, 2002, J BIOL CHEM, V277, P44164, DOI 10.1074/jbc.M207340200; SCHWARZ HP, 1984, BLOOD, V64, P1297; Sekiya F, 1996, J BIOL CHEM, V271, P8541, DOI 10.1074/jbc.271.15.8541; Sere KM, 2001, BIOCHEMISTRY-US, V40, P8852; Shikamoto Y, 2003, J BIOL CHEM, V278, P24090, DOI 10.1074/jbc.M300650200; Stenberg Y, 1998, EUR J BIOCHEM, V251, P558, DOI 10.1046/j.1432-1327.1998.2510558.x; Stenflo J, 2000, BBA-PROTEIN STRUCT M, V1477, P51, DOI 10.1016/S0167-4838(99)00262-9; STENFLO J, 1976, J BIOL CHEM, V251, P355; VALLEE BL, 1960, J BIOL CHEM, V235, P64; van Wijnen M, 1998, THROMB HAEMOSTASIS, V80, P930; van Wijnen M, 1998, BIOCHEM J, V330, P389; Villoutreix BO, 2001, PROTEINS, V43, P203, DOI 10.1002/1097-0134(20010501)43:2<203::AID-PROT1031>3.0.CO;2-W; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; Yegneswaran S, 2008, J BIOL CHEM, V283, P33046, DOI 10.1074/jbc.M806527200	38	27	27	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2009	23	7					2244	2253		10.1096/fj.08-123174	http://dx.doi.org/10.1096/fj.08-123174			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19244162	Green Published			2022-12-28	WOS:000268836500024
J	Mizuno, Y; Chang, H; Umeda, K; Niwa, A; Iwasa, T; Awaya, T; Fukada, S; Yamamoto, H; Yamanaka, S; Nakahata, T; Heike, T				Mizuno, Yuta; Chang, Hsi; Umeda, Katsutsugu; Niwa, Akira; Iwasa, Toru; Awaya, Tomonari; Fukada, So-ichiro; Yamamoto, Hiroshi; Yamanaka, Shinya; Nakahata, Tatsutoshi; Heike, Toshio			Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells	FASEB JOURNAL			English	Article						Duchenne muscular dystrophy; Pax7; long-term engraftment; no teratoma formation; high engraftment efficiency	BONE-MARROW; DYSTROPHIN EXPRESSION; SATELLITE CELLS; MOUSE; REGENERATION; FIBROBLASTS; PROGENITORS; CULTURE; MDX	Induced pluripotent stem (iPS) cells, which are a type of pluripotent stem cell generated from reprogrammed somatic cells, are expected to have potential for patient-oriented disease investigation, drug screening, toxicity tests, and transplantation therapies. Here, we demonstrated that murine iPS cells have the potential to develop in vitro into skeletal muscle stem/progenitor cells, which are almost equivalent to murine embryonic stem cells. Cells with strong in vitro myogenic potential effectively were enriched by fluorescence-activated cell sorting using the anti-satellite cell antibody SM/C-2.6. Furthermore, on transplantation into mdx mice, SM/C-2.6(+) cells exerted sustained myogenic lineage differentiation in injured muscles, while providing long-lived muscle stem cell support. Our data suggest that iPS cells have the potential to be used in clinical treatment of muscular dystrophies.-Mizuno, Y., Chang, H., Umeda, K., Niwa, A., Iwasa, T., Awaya, T., Fukada, S., Yamamoto, H., Yamanaka, S., Nakahata, T., Heike, T. Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells. FASEB J. 24, 2245-2253 (2010). www.fasebj.org	[Heike, Toshio] Kyoto Univ, Dept Pediat, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan; [Yamanaka, Shinya] Kyoto Univ, Dept Stem Cell Biol, Inst Frontier Med Sci, Kyoto 6068507, Japan; [Yamanaka, Shinya; Nakahata, Tatsutoshi] Kyoto Univ, Ctr iPS Cell Res & Applicat, Inst Integrated Cell Mat Sci, Kyoto 6068507, Japan; [Fukada, So-ichiro; Yamamoto, Hiroshi] Osaka Univ, Dept Immunol, Grad Sch Pharmaceut Sci, Osaka, Japan; [Yamanaka, Shinya] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama, Japan	Kyoto University; Kyoto University; Kyoto University; Osaka University; Japan Science & Technology Agency (JST)	Heike, T (corresponding author), Kyoto Univ, Dept Pediat, Grad Sch Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	heike@kuhp.kyoto-u.ac.jp	Fukada, So-ichiro/AAI-9151-2020; Awaya, Tomonari/O-2757-2015	Fukada, So-ichiro/0000-0003-4051-5108; Awaya, Tomonari/0000-0002-9004-3172	Japan Ministry of Education, Culture, Sports, Science, and Technology; Grants-in-Aid for Scientific Research [22249042] Funding Source: KAKEN	Japan Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by grants from the Japan Ministry of Education, Culture, Sports, Science, and Technology.	Aoi T, 2008, SCIENCE, V321, P699, DOI 10.1126/science.1154884; Baba S, 2007, STEM CELLS, V25, P1375, DOI 10.1634/stemcells.2006-0574; Barberi T, 2007, NAT MED, V13, P642, DOI 10.1038/nm1533; Bhagavati S, 2005, BIOCHEM BIOPH RES CO, V333, P644, DOI 10.1016/j.bbrc.2005.05.135; Buckingham M, 2007, ANNU REV CELL DEV BI, V23, P645, DOI 10.1146/annurev.cellbio.23.090506.123438; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Cerletti M, 2008, CELL, V134, P37, DOI 10.1016/j.cell.2008.05.049; Chang H, 2009, FASEB J, V23, P1907, DOI 10.1096/fj.08-123661; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Darabi R, 2008, NAT MED, V14, P134, DOI 10.1038/nm1705; Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542; Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364; Emery AEH, 2002, LANCET, V359, P687, DOI 10.1016/S0140-6736(02)07815-7; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fukada S, 2004, EXP CELL RES, V296, P245, DOI 10.1016/j.yexcr.2004.02.018; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hanna J, 2008, CELL, V133, P250, DOI 10.1016/j.cell.2008.03.028; Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092; Harris JB, 2003, TOXICON, V42, P933, DOI 10.1016/j.toxicon.2003.11.011; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Jejurikar SS, 2003, APOPTOSIS, V8, P573, DOI 10.1023/A:1026127307457; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; Meissner A, 2007, NAT BIOTECHNOL, V25, P1177, DOI 10.1038/nbt1335; Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758; Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374; Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; PARTRIDGE TA, 1991, MUSCLE NERVE, V14, P197, DOI 10.1002/mus.880140302; Peault B, 2007, MOL THER, V15, P867, DOI 10.1038/mt.sj.6300145; Pownall ME, 2002, ANNU REV CELL DEV BI, V18, P747, DOI 10.1146/annurev.cellbio.18.012502.105758; Sakurai H, 2008, STEM CELLS, V26, P1865, DOI 10.1634/stemcells.2008-0173; Sampaolesi M, 2006, NATURE, V444, P574, DOI 10.1038/nature05282; SMITH TH, 1993, DEVELOPMENT, V117, P1125; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Torrente Y, 2004, J CLIN INVEST, V114, P182, DOI 10.1172/JCI200420325; Tsuchiya A, 2007, STEM CELLS, V25, P895, DOI 10.1634/stemcells.2006-0558; WALLACE GQ, 2008, ANN REV PHYSL; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	45	119	135	2	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2245	2253		10.1096/fj.09-137174	http://dx.doi.org/10.1096/fj.09-137174			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20181939				2022-12-28	WOS:000279343600011
J	Chen, W; Jarzyna, PA; van Tilborg, GAF; Nguyen, VA; Cormode, DP; Klink, A; Griffioen, AW; Randolph, GJ; Fisher, EA; Mulder, WJM; Fayad, ZA				Chen, Wei; Jarzyna, Peter A.; van Tilborg, Geralda A. F.; Nguyen, Van Anh; Cormode, David P.; Klink, Ahmed; Griffioen, Arjan W.; Randolph, Gwendalyn J.; Fisher, Edward A.; Mulder, Willem J. M.; Fayad, Zahi A.			RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe	FASEB JOURNAL			English	Article						angiogenesis; optical imaging; magnetic resonance imaging	HIGH-RISK PLAQUE; CONTRAST AGENT; QUANTUM DOTS; ATHEROSCLEROTIC PLAQUES; CHOLESTERYL ESTERS; SELECTIVE UPTAKE; IN-VIVO; CANCER; ANGIOGENESIS; MACROPHAGES	High density lipoprotein (HDL), an endogenous nanoparticle, transports fat throughout the body and is capable of transferring cholesterol from atheroma in the vessel wall to the liver. In the present study, we utilized HDL as a multimodal nanoparticle platform for tumor targeting and imaging via nonspecific accumulation and specific binding to angiogenically activated blood vessels. We reconstituted HDL (rHDL) with amphiphilic gadolinium chelates and fluorescent dyes. To target angiogenic endothelial cells, rHDL was functionalized with alpha v beta 3-integrin-specific RGD peptides (rHDL-RGD). Nonspecific RAD peptides were conjugated to rHDL nanoparticles as a control (rHDL-RAD). It was observed in vitro that all 3 nanoparticles were phagocytosed by macrophages, while alpha v beta 3-integrin-specific rHDL-RGD nanoparticles were preferentially taken up by endothelial cells. The uptake of nanoparticles in mouse tumors was evaluated in vivo using near infrared (NIR) and MR imaging. All nanoparticles accumulated in tumors but with very different accumulation/binding kinetics as observed by NIR imaging. Moreover, confocal microscopy revealed rHDL-RGD to be associated with tumor endothelial cells, while rHDL and rHDL-RAD nanoparticles were mainly found in the interstitial space. This study demonstrates the ability to reroute HDL from its natural targets to tumor blood vessels and its potential for multimodal imaging of tumor-associated processes.-Chen, W., Jarzyna, P. A., van Tilborg, G. A. F., Nguyen, V. A., Cormode, D. P., Klink, A., Griffioen, A. W., Randolph, G. J., Fisher, E. A., Mulder, W. J. M., Fayad, Z. A. RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J. 24, 1689-1699 (2010). www.fasebj.org	[Chen, Wei; Jarzyna, Peter A.; Cormode, David P.; Klink, Ahmed; Mulder, Willem J. M.; Fayad, Zahi A.] Mt Sinai Sch Med, Translat & Mol Imaging Inst, Imaging Sci Labs, Dept Radiol, New York, NY 10029 USA; [Chen, Wei; Jarzyna, Peter A.; Cormode, David P.; Klink, Ahmed; Mulder, Willem J. M.; Fayad, Zahi A.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; [Nguyen, Van Anh; Randolph, Gwendalyn J.; Mulder, Willem J. M.] Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA; [Fayad, Zahi A.] Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA; [Fayad, Zahi A.] Mt Sinai Sch Med, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, New York, NY 10029 USA; [van Tilborg, Geralda A. F.] Univ Utrecht, Image Sci Inst, Utrecht, Netherlands; [Klink, Ahmed] Hop Europeen Georges Pompidou, AP HP, INSERM, Paris Cardiovasc Res Ctr, Paris, France; [Griffioen, Arjan W.] Maastricht Univ & Hosp, Res Inst Growth & Dev, Dept Pathol, Angiogenesis Lab, Maastricht, Netherlands; [Fisher, Edward A.] NYU, Sch Med, Ctr Prevent Cardiovasc Dis, Leon H Charney Div Cardiol, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Utrecht University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Maastricht University; Maastricht University Medical Centre (MUMC); New York University	Mulder, WJM (corresponding author), Mt Sinai Sch Med, Translat & Mol Imaging Inst, Imaging Sci Labs, Dept Radiol, Atran BM-24,Box 1234,1 Gustave L Levy Pl, New York, NY 10029 USA.	willem.mulder@mountsinai.org; zahi.fayad@mssm.edu	Mulder, Willem J.M./B-7232-2009; Fisher, Edward/ABE-7469-2020; van Tilborg, Geralda/H-1229-2011; Cormode, David/C-6440-2008; Fayad, Zahi/Z-3272-2019; Nguyen, Anh/C-5389-2013	Mulder, Willem J.M./0000-0001-8665-3878; Fayad, Zahi/0000-0002-3439-7347; Cormode, David/0000-0002-8391-9500; Fisher, Edward/0000-0001-9802-143X; Nguyen, Anh/0000-0001-6703-2291	U.S. National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute [R01 H-71021, R01 H-78667]; NIH/National Institute of Biomedical Imaging and Bioengineering [EB-009638]; NIH-National Cancer Institute [5R24 CA-095823-04, 1 S10 RR-09145-01]; National Science Foundation [DBI-9724504]; NATIONAL CANCER INSTITUTE [R24CA095823] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB009638] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/National Institute of Biomedical Imaging and Bioengineering(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIH-National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Science Foundation(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	Partial support was provided by U.S. National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute grants R01 H-71021 and R01 H-78667 and NIH/National Institute of Biomedical Imaging and Bioengineering grant EB-009638 (to Z.A.F.). We thank CSL Behring (Bern, Switzerland) for the kind gift of apoA-I. Confocal microscopy was performed at the Mount Sinai School of Medicine Microscopy Shared Resource Facility and supported by NIH-National Cancer Institute grant 5R24 CA-095823-04, National Science Foundation grant DBI-9724504, and NIH grant 1 S10 RR-09145-01.	BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brekke C, 2007, NMR BIOMED, V20, P77, DOI 10.1002/nbm.1077; Brundert M, 2006, J LIPID RES, V47, P2408, DOI 10.1194/jlr.M600136-JLR200; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen J, 2007, J AM CHEM SOC, V129, P5798, DOI 10.1021/ja069336k; Chen W, 2008, CONTRAST MEDIA MOL I, V3, P233, DOI 10.1002/cmmi.257; Conca P, 2008, NUTR METAB CARDIOVAS, V18, P329, DOI 10.1016/j.numecd.2007.11.001; Corbin IR, 2007, J BIOMED NANOTECHNOL, V3, P367, DOI 10.1166/jbn.2007.053; Cormode DP, 2008, NANO LETT, V8, P3715, DOI 10.1021/nl801958b; Cormode DP, 2008, SMALL, V4, P1437, DOI 10.1002/smll.200701285; De Grand AM, 2003, TECHNOL CANCER RES T, V2, P553, DOI 10.1177/153303460300200607; Florentin M, 2008, CURR OPIN CARDIOL, V23, P370, DOI 10.1097/HCO.0b013e3283043806; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Forrester JS, 2006, AM J CARDIOL, V98, P1542, DOI 10.1016/j.amjcard.2006.06.059; Frias JC, 2004, J AM CHEM SOC, V126, P16316, DOI 10.1021/ja044911a; Frias JC, 2006, NANO LETT, V6, P2220, DOI 10.1021/nl061498r; Fuster V, 2005, J AM COLL CARDIOL, V46, P937, DOI 10.1016/j.jacc.2005.03.074; Fuster V, 2005, J AM COLL CARDIOL, V46, P1209, DOI 10.1016/j.jacc.2005.03.075; Hu G, 2007, INT J CANCER, V120, P1951, DOI 10.1002/ijc.22581; Kim S, 2004, NAT BIOTECHNOL, V22, P93, DOI 10.1038/nbt920; Kok MB, 2009, MAGN RESON MED, V61, P1022, DOI 10.1002/mrm.21910; Kok RJ, 2002, BIOCONJUGATE CHEM, V13, P128, DOI 10.1021/bc015561+; Kontush A, 2006, NAT CLIN PRACT CARD, V3, P144, DOI 10.1038/ncpcardio0500; Koole R, 2008, BIOCONJUGATE CHEM, V19, P2471, DOI 10.1021/bc800368x; Lacko AG, 2007, EXPERT OPIN DRUG DEL, V4, P665, DOI 10.1517/17425247.4.6.665; Matveev S, 1999, J LIPID RES, V40, P1647; Modo M, 2005, MOL IMAGING, V4, P143; Mulder WJM, 2009, ANGIOGENESIS, V12, P17, DOI 10.1007/s10456-008-9124-2; Mulder WJM, 2006, NANO LETT, V6, P1, DOI 10.1021/nl051935m; Mulder WJM, 2005, FASEB J, V19, P2008, DOI 10.1096/fj.05-4145fje; Nakayama Akira, 2002, Mol Imaging, V1, P365, DOI 10.1162/153535002321093972; RINNINGER F, 1994, ATHEROSCLEROSIS, V105, P145, DOI 10.1016/0021-9150(94)90044-2; Shaish A, 2001, PATHOBIOLOGY, V69, P225, DOI 10.1159/000055947; Song LP, 2007, INT J NANOMED, V2, P767; Stefflova K, 2007, BIOCONJUGATE CHEM, V18, P379, DOI 10.1021/bc0602578; Strijkers GJ, 2009, MAGN RESON MED, V61, P1049, DOI 10.1002/mrm.21919; Tabet F, 2009, CLIN SCI, V116, P87, DOI 10.1042/CS20080106; Terreno E, 2006, MAGN RESON MED, V55, P491, DOI 10.1002/mrm.20793; van Tilborg GAF, 2008, NEOPLASIA, V10, P1459, DOI 10.1593/neo.08858; Williams KJ, 2007, CURR OPIN LIPIDOL, V18, P443, DOI 10.1097/MOL.0b013e32823bcb15; Winter PM, 2008, FASEB J, V22, P2758, DOI 10.1096/fj.07-103929; Zheng G, 2005, P NATL ACAD SCI USA, V102, P17757, DOI 10.1073/pnas.0508677102	42	92	95	1	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1689	1699		10.1096/fj.09-139865	http://dx.doi.org/10.1096/fj.09-139865			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20075195	Green Published			2022-12-28	WOS:000278200000007
J	Dainese, E; Angelucci, CB; Sabatucci, A; De Filippis, V; Mei, G; Maccarrone, M				Dainese, Enrico; Angelucci, Clotilde B.; Sabatucci, Annalaura; De Filippis, Vincenzo; Mei, Giampiero; Maccarrone, Mauro			A novel role for iron in modulating the activity and membrane-binding ability of a trimmed soybean lipoxygenase-1	FASEB JOURNAL			English	Article						limited proteolysis; metal substitution; enzyme activity; enzyme structure; pathogen infection	X-RAY-SCATTERING; CRYSTAL-STRUCTURE; TYROSINE-HYDROXYLASE; MANGANESE LIPOXYGENASE; ORGANELLE DEGRADATION; ANGSTROM RESOLUTION; HUMAN CERULOPLASMIN; NONHEME IRON; METAL-IONS; CALCIUM	Lipoxygenases (LOXs) are iron-containing enzymes that play critical roles in plants and animals. As yet, metal atom extraction, reconstitution, and substitution have not been successfully applied to soybean LOX-1 [Glycine max (L.) Merrill], a prototype member of the LOX family that is widely used in structural and kinetic studies. Here, tryptic digestion of native LOX-1, used as a control, allowed us to isolate the 60-kDa C-terminal region (termed miniLOX), that retains the catalytically active iron in a more accessible position. Then, iron was removed to obtain an unprecedented apo-miniLOX, which was reconstituted and substituted with different metal ions. These forms of miniLOX were characterized vs. native LOX-1 by kinetic analysis, near UV circular dichroism, steady-state fluorescence, and fluorescence resonance energy transfer. MiniLOX showed a 2-fold increase in the membrane-binding affinity compared with native LOX-1 and a remarkable 4-fold increase compared with apo-miniLOX (K(d) = 9.2 +/- 1.0, 17.9 +/- 2.0, and 45.4 +/- 4.3 mu M, respectively). Furthermore, miniLOX reconstituted with Fe(II) or Fe(III) partially recovered its membrane-binding ability (K(d) = 21.4 +/- 2.4 and 18.9 +/- 5.5 mu M, respectively), overall supporting a novel noncatalytic role for iron in the LOX family.-Dainese, E., Angelucci, C. B., Sabatucci, A., De Filippis, V., Mei, M., Maccarrone, M. A novel role for iron in modulating the activity and membrane-binding ability of a trimmed soybean lipoxygenase-1. FASEB J. 24, 1725-1736 (2010). www.fasebj.org	[Dainese, Enrico; Angelucci, Clotilde B.; Sabatucci, Annalaura; Maccarrone, Mauro] Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy; [De Filippis, Vincenzo] Univ Padua, Dept Pharmacol Sci, Padua, Italy; [Mei, Giampiero] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00173 Rome, Italy; [Maccarrone, Mauro] European Ctr Brain Res Santa Lucia Fdn, Rome, Italy	University of Teramo; University of Padua; University of Rome Tor Vergata	Dainese, E (corresponding author), Univ Teramo, Dept Biomed Sci, Piazzo Aldo Moro N 45, I-64100 Teramo, Italy.	edainese@unite.it; mmaccarrone@unite.it	Maccarrone, Mauro/K-5398-2012; SABATUCCI, Annalaura/E-9996-2013	Maccarrone, Mauro/0000-0002-3990-2963; Dainese, Enrico/0000-0001-7163-9344; SABATUCCI, Annalaura/0000-0002-8004-2547	University of Rome Tor Vergata, Rome, Italy; Ministero dell'Universita e della Ricerca [PRIN 2005]; Ministero della Salute (Progetto Ricerca Corrente) [IZS LT 08/07 RC]; Italian Space Agency (ASI); Fondazione TERCAS	University of Rome Tor Vergata, Rome, Italy; Ministero dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); Ministero della Salute (Progetto Ricerca Corrente)(Ministry of Health, Italy); Italian Space Agency (ASI)(Agenzia Spaziale Italiana (ASI)); Fondazione TERCAS(Fondazione CarifeFondazione Caritro)	The authors thank Professor Alessandro Finazzi-Agro (University of Rome Tor Vergata, Rome, Italy) for his continuing support. The kind assistance of Dr. Maria Luisa Salucci (University of L'Aquila, L'Aquila, Italy) in the preliminary experiments on apo-miniLOX isolation and that of Dr. Annamaria Draghi, Dr. Daniela Galla, and Dr. Paolo Di Muro (University of Padua, Padua, Italy) in CD and atomic absorption measurements, respectively, are gratefully acknowledged. This work was supported by Ministero dell'Universita e della Ricerca (PRIN 2005) and by Ministero della Salute (Progetto Ricerca Corrente, IZS LT 08/07 RC to E. D.), by the Italian Space Agency (ASI) (MoMa contract 2006), and by Fondazione TERCAS (project 2005-2008 to M. M.).	AULD DS, 1988, METHOD ENZYMOL, V158, P71, DOI 10.1016/0076-6879(88)58048-5; BABA A, 1989, J BIOL CHEM, V264, P15790; BLECHERT S, 1995, P NATL ACAD SCI USA, V92, P4099, DOI 10.1073/pnas.92.10.4099; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BOYINGTON JC, 1994, ANN NY ACAD SCI, V744, P310; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; BUBACCO L, 1992, BIOCHEMISTRY-US, V31, P9294, DOI 10.1021/bi00153a024; Carlile AJ, 2000, MOL PLANT MICROBE IN, V13, P538, DOI 10.1094/MPMI.2000.13.5.538; Challis GL, 2003, P NATL ACAD SCI USA, V100, P14555, DOI 10.1073/pnas.1934677100; Cristea M, 2005, ARCH BIOCHEM BIOPHYS, V434, P201, DOI 10.1016/j.abb.2004.10.026; Dainese E, 2005, J MOL BIOL, V349, P143, DOI 10.1016/j.jmb.2005.03.027; Decker H, 1998, J BIOL CHEM, V273, P25889, DOI 10.1074/jbc.273.40.25889; Di Venere A, 2003, J BIOL CHEM, V278, P18281, DOI 10.1074/jbc.M212122200; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; FINAZZIAGRO A, 1973, BIOCHIM BIOPHYS ACTA, V326, P462, DOI 10.1016/0005-2760(73)90146-X; Forneris F, 2008, SCIENCE, V321, P213, DOI 10.1126/science.1151118; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Grechkin A, 1998, PROG LIPID RES, V37, P317, DOI 10.1016/S0163-7827(98)00014-9; Grullich C, 2001, FEBS LETT, V489, P51, DOI 10.1016/S0014-5793(01)02080-4; HAAVIK J, 1992, EUR J BIOCHEM, V210, P23, DOI 10.1111/j.1432-1033.1992.tb17386.x; HAAVIK J, 1991, EUR J BIOCHEM, V199, P371, DOI 10.1111/j.1432-1033.1991.tb16133.x; Hammel M, 2004, J MOL BIOL, V343, P917, DOI 10.1016/j.jmb.2004.08.076; Hornsten L, 2002, EUR J BIOCHEM, V269, P2690, DOI 10.1046/j.1432-1033.2002.02936.x; Kariapper MST, 2001, BIOCHEM BIOPH RES CO, V284, P563, DOI 10.1006/bbrc.2001.5011; Kim ES, 2003, PLANT MOL BIOL, V52, P1203, DOI 10.1023/B:PLAN.0000004331.94803.b0; Knapp MJ, 2003, BIOCHEMISTRY-US, V42, P11466, DOI 10.1021/bi0300884; Knapp MJ, 2002, J AM CHEM SOC, V124, P3865, DOI 10.1021/ja012205t; Komoda T, 2004, BIOSCI BIOTECH BIOCH, V68, P903, DOI 10.1271/bbb.68.903; Kuhn H, 1999, ADV EXP MED BIOL, V447, P5; Kuhn H, 2005, BIOCHEM BIOPH RES CO, V338, P93, DOI 10.1016/j.bbrc.2005.08.238; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Maccarrone M, 1999, EUR J BIOCHEM, V265, P27, DOI 10.1046/j.1432-1327.1999.00630.x; Maccarrone M, 2001, CELL DEATH DIFFER, V8, P776, DOI 10.1038/sj.cdd.4400908; Maccarrone M, 2001, BIOCHEMISTRY-US, V40, P6819, DOI 10.1021/bi010187m; MARTINEZ A, 1993, BIOCHEMISTRY-US, V32, P6381, DOI 10.1021/bi00076a011; MATSUDA S, 1991, BIOCHIM BIOPHYS ACTA, V1084, P202; Mei G, 2008, BIOCHEMISTRY-US, V47, P9234, DOI 10.1021/bi800638v; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; MYERS JS, 1975, J BIOL CHEM, V250, P3785; Nillius D, 2008, FEBS LETT, V582, P749, DOI 10.1016/j.febslet.2008.01.056; Oldham ML, 2005, J BIOL CHEM, V280, P39545, DOI 10.1074/jbc.M506675200; Pande AH, 2005, BIOPHYS J, V88, P4084, DOI 10.1529/biophysj.104.056788; Qin S, 2004, J MOL BIOL, V344, P71, DOI 10.1016/j.jmb.2004.09.034; Radmark O, 2007, TRENDS BIOCHEM SCI, V32, P332, DOI 10.1016/j.tibs.2007.06.002; SALVATO B, 1989, BIOCHIM BIOPHYS ACTA, V998, P14, DOI 10.1016/0167-4838(89)90112-X; SCHILSTRA MJ, 1994, BIOCHEMISTRY-US, V33, P3974, DOI 10.1021/bi00179a025; SkrzypczakJankun E, 1996, ACTA CRYSTALLOGR D, V52, P959, DOI 10.1107/S0907444996005239; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; Solomon EI, 1997, CHEM BIOL, V4, P795, DOI 10.1016/S1074-5521(97)90113-7; Sreerama N, 2001, ANAL BIOCHEM, V299, P271, DOI 10.1006/abio.2001.5420; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; Taccone-Gallucci M, 2008, NEW ENGL J MED, V358, P746, DOI 10.1056/NEJMc073333; Tatulian SA, 1998, BIOCHEMISTRY-US, V37, P15481, DOI 10.1021/bi981062t; Timasheff S.N., 1989, PROTEIN STRUCTURE PR, P331; Titus GP, 2000, NAT STRUCT BIOL, V7, P542; Vachette P, 2002, J BIOL CHEM, V277, P40823, DOI 10.1074/jbc.M207188200; van der Donk WA, 2002, BIOCHEMISTRY-US, V41, P15451, DOI 10.1021/bi026938h; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; VANDERHEIJDT LM, 1995, EUR J BIOCHEM, V231, P186, DOI 10.1111/j.1432-1033.1995.tb20685.x; Vassiliev VB, 1997, J INORG BIOCHEM, V65, P167, DOI 10.1016/S0162-0134(96)00119-5; Walther M, 2004, J BIOL CHEM, V279, P3717, DOI 10.1074/jbc.M309564200; WATSON A, 1994, BIOCHEM J, V298, P377, DOI 10.1042/bj2980377; Welch KD, 2002, ARCH BIOCHEM BIOPHYS, V397, P360, DOI 10.1006/abbi.2001.2694; Xiao K, 2002, BIOL CONTROL, V23, P285, DOI 10.1006/bcon.2001.1015; Yamanaka K, 2005, MICROBIOL-SGM, V151, P2899, DOI 10.1099/mic.0.28139-0	68	21	22	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2010	24	6					1725	1736		10.1096/fj.09-141390	http://dx.doi.org/10.1096/fj.09-141390			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20081094	Green Submitted			2022-12-28	WOS:000278200000010
J	Ocampo, A; Zambrano, A; Barrientos, A				Ocampo, Alejandro; Zambrano, Andrea; Barrientos, Antoni			Suppression of polyglutamine-induced cytotoxicity in Saccharomyces cerevisiae by enhancement of mitochondrial biogenesis	FASEB JOURNAL			English	Article						mitochondrial metabolism; HAP4; yeast model	MUTANT HUNTINGTIN FRAGMENT; COMPLEX-II; IN-VITRO; PROTEIN-SYNTHESIS; MOUSE MODEL; YEAST; AGGREGATION; EXPRESSION; OVEREXPRESSION; TOXICITY	Alterations in mitochondrial metabolism have been associated with age-related neurodegenerative disorders. This is seen in diseases caused by misfolding of proteins with expanded polyglutamine (polyQ) tracts, such as Huntington's disease. Although evidence of mitochondrial impairment has been extensively documented in patients and disease models, the mechanisms involved and their relevance to the initiation of polyQ cytotoxicity and development of clinical manifestations remain controversial. We report that in yeast models of polyQ cytotoxicity, wild-type and mutant polyQ domains might associate early with the outer mitochondrial membrane. The association of mutant domains with mitochondrial membranes could contribute to induce significant changes in mitochondrial physiology, ultimately compromising the cell's ability to respire. The respiratory defect can be fully prevented by enhancing mitochondrial biogenesis by overexpression of Hap4p, the catalytic subunit of the transcriptional activator Hap2/3/4/5p complex, the master regulator of the expression of many nuclear genes encoding mitochondrial proteins in yeast. Protecting cellular respiratory capacity in this way ameliorates the effect of expanded polyQ on cellular fitness. We conclude that mitochondrial dysfunction is an important contributor to polyQ cytotoxicity. Our results suggest that therapeutic approaches enhancing mitochondrial biogenesis could reduce polyQ toxicity and delay the development of clinical symptoms in patients.-Ocampo, A., Zambrano, A., Barrientos, A. Suppression of polyglutamine-induced cytotoxicity in Saccharomyces cerevisiae by enhancement of mitochondrial biogenesis. FASEB J. 24, 1431-1441 (2010). www.fasebj.org	[Zambrano, Andrea; Barrientos, Antoni] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; [Ocampo, Alejandro; Barrientos, Antoni] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA	University of Miami; University of Miami	Barrientos, A (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, 1600 NW 10th Ave,RMSB 2067, Miami, FL 33136 USA.	abarrientos@med.miami.edu		Ocampo, Alejandro/0000-0002-3731-3647	Stanley Glaser Foundation	Stanley Glaser Foundation	The authors thank Prof. Susan Lindquist (Whitehead Institute for Biomedical Research, Cambridge, MA, USA) and Prof. Miriam L. Greenberg (Department of Biological Sciences, Wayne State University, Detroit, MI, USA) for providing reagents. The authors thank Dr. Flavia Fontanesi, Dr. Brant Watson, and Darryl Horn for critical reading of the manuscript. This research was supported by a Stanley Glaser Foundation grant (to A. B.).	Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Bauer PO, 2009, AUTOPHAGY, V5, P747, DOI 10.4161/auto.5.5.8704; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Benchoua A, 2006, MOL BIOL CELL, V17, P1652, DOI 10.1091/mbc.E05-07-0607; Bennett EJ, 2007, NATURE, V448, P704, DOI 10.1038/nature06022; Brouillet E, 2005, J NEUROCHEM, V95, P1521, DOI 10.1111/j.1471-4159.2005.03515.x; Choo YS, 2004, HUM MOL GENET, V13, P1407, DOI 10.1093/hmg/ddh162; Cui LB, 2006, CELL, V127, P59, DOI 10.1016/j.cell.2006.09.015; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Duennwald ML, 2006, P NATL ACAD SCI USA, V103, P11045, DOI 10.1073/pnas.0604547103; Duennwald ML, 2008, GENE DEV, V22, P3308, DOI 10.1101/gad.1673408; DuRose JB, 2009, MOL CELL BIOL, V29, P4295, DOI 10.1128/MCB.00260-09; Fontanesi F, 2008, HUM MOL GENET, V17, P775, DOI 10.1093/hmg/ddm349; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; Giorgini F, 2005, NAT GENET, V37, P526, DOI 10.1038/ng1542; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; HUNTER FE, 1967, METHOD ENZYMOL, V10, P689; Kaminosono S, 2008, J NEUROSCI, V28, P8747, DOI 10.1523/JNEUROSCI.0973-08.2008; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Landles C, 2004, EMBO REP, V5, P958, DOI 10.1038/sj.embor.7400250; Lascaris R, 2003, GENOME BIOL, V4; Ma LN, 2004, J BIOL CHEM, V279, P44394, DOI 10.1074/jbc.M405479200; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; MCKEE EE, 1984, J BIOL CHEM, V259, P9320; Meriin AB, 2003, MOL CELL BIOL, V23, P7554, DOI 10.1128/MCB.23.21.7554-7565.2003; Meriin AB, 2002, J CELL BIOL, V157, P997, DOI 10.1083/jcb.200112104; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; Nagai Y, 2007, NAT STRUCT MOL BIOL, V14, P332, DOI 10.1038/nsmb1215; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Panov AV, 2003, ARCH BIOCHEM BIOPHYS, V410, P1, DOI 10.1016/S0003-9861(02)00585-4; Ruan QM, 2004, HUM MOL GENET, V13, P669, DOI 10.1093/hmg/ddh082; Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shao J, 2007, HUM MOL GENET, V16, pR115, DOI 10.1093/hmg/ddm213; Slow EJ, 2003, HUM MOL GENET, V12, P1555, DOI 10.1093/hmg/ddg169; Sokolov S, 2006, BBA-BIOENERGETICS, V1757, P660, DOI 10.1016/j.bbabio.2006.05.004; Solans A, 2006, HUM MOL GENET, V15, P3063, DOI 10.1093/hmg/ddl248; Taherzadeh-Fard E, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-10; Trushina E, 2004, MOL CELL BIOL, V24, P8195, DOI 10.1128/MCB.24.18.8195-8209.2004; Vacher C, 2005, HUM MOL GENET, V14, P3425, DOI 10.1093/hmg/ddi372; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wang HM, 2009, HUM MOL GENET, V18, P737, DOI 10.1093/hmg/ddn404; Wellington CL, 2002, J NEUROSCI, V22, P7862; Willingham S, 2003, SCIENCE, V302, P1769, DOI 10.1126/science.1090389	50	39	39	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1431	1441		10.1096/fj.09-148601	http://dx.doi.org/10.1096/fj.09-148601			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20008543				2022-12-28	WOS:000277158900016
J	Zhang, ZY; Liew, CW; Handy, DE; Zhang, YY; Leopold, JA; Hu, J; Guo, LL; Kulkarni, RN; Loscalzo, J; Stanton, RC				Zhang, Zhaoyun; Liew, Chong Wee; Handy, Diane E.; Zhang, Yingyi; Leopold, Jane A.; Hu, Ji; Guo, Lili; Kulkarni, Rohit N.; Loscalzo, Joseph; Stanton, Robert C.			High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and beta-cell apoptosis	FASEB JOURNAL			English	Article						diabetes mellitus; islets; antioxidants; pentose phosphate pathway	ENZYME GENE-EXPRESSION; GLUTATHIONE-PEROXIDASE; PANCREATIC-ISLETS; INSULIN-RELEASE; OXIDANT STRESS; IN-VITRO; TOXICITY; 6-AMINONICOTINAMIDE; PROTECTION; MECHANISM	Patients with type 2 diabetes lose beta cells, but the underlying mechanisms are incompletely understood. Glucose-6-phosphate dehydrogenase (G6PD) is the principal source of the major intracellular reductant, NADPH, which is required by many enzymes, including enzymes of the antioxidant pathway. Previous work from our laboratory has shown that high glucose impairs G6PD activity in endothelial and kidney cells, which leads to decreased cell survival. Pancreatic beta cells are highly sensitive to increased ROS. This study aimed to determine whether G6PD and NADPH play central roles in beta-cell survival. Human and mouse islets, MIN6 cell line, and G6PD deficient mice were studied. High glucose inhibited G6PD expression and activity. Inhibition of G6PD with siRNA led to increased ROS and apoptosis, decreased proliferation, and impaired insulin secretion. High glucose decreased insulin secretion, which was improved by overexpressing G6PD. G6PD-deficient mice had smaller islets and impaired glucose tolerance compared with control mice, which suggests that G6PD deficiency per se leads to beta-cell dysfunction and death. G6PD plays an important role in beta-cell function and survival. High-glucose-mediated decrease in G6PD activity may provide a mechanistic explanation for the gradual loss of beta cells in patients with diabetes.-Zhang, Z., Liew, C. W., Handy, D. E., Zhang, Y., Leopold, J. A., Hu, J., Guo, L., Kulkarni, R. N., Loscalzo, J., Stanton, R. C. High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and beta-cell apoptosis. FASEB J. 24, 1497-1505 (2010). www.fasebj.org	[Zhang, Zhaoyun; Liew, Chong Wee; Hu, Ji; Guo, Lili; Kulkarni, Rohit N.; Stanton, Robert C.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA; [Handy, Diane E.; Zhang, Yingyi; Leopold, Jane A.; Loscalzo, Joseph] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, Boston, MA 02115 USA; [Zhang, Zhaoyun] Huashan Hosp, Dept Endocrinol & Metab, Shanghai, Peoples R China	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Fudan University	Stanton, RC (corresponding author), Joslin Diabet Ctr, Div Renal, 1 Joslin Pl, Boston, MA 02215 USA.	robert.stanton@joslin.harvard.edu	Stanton, Robert C/AAG-7584-2020; Loscalzo, Joseph/ABD-8980-2021	Stanton, Robert C/0000-0002-3056-1277; Liew, Chong Wee/0000-0001-9904-0958; Handy, Diane/0000-0002-4310-8527	U.S. National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01-DK54380]; NIH/National Heart, Lung, and Blood Institute (NHLBI) [HL 61795, N01 HV 28178, P01 HL 81857, U54 HL 070819, HL 089734]; NIH [RO1 DK 68721, RO1 DK 67536, T32DK007260]; Diabetes Endocrinology Research Center (DERC) [P30DK036836]; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL089734, R01HL061795, R01HL081857, R37HL061795, U54HL070819, P01HL081587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067536, R01DK054380, R01DK068721, T32DK007260, P30DK036836] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Diabetes Endocrinology Research Center (DERC); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dan Kawamori, Xiaodan Wang, Wan-Chun Li, Jiang Hu, and Hui Li for technical assistance. This work was supported by U.S. National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant R01-DK54380 to R.C.S.; NIH/National Heart, Lung, and Blood Institute (NHLBI) grants HL 61795, N01 HV 28178, P01 HL 81857, and U54 HL 070819 to J.A.L.; and NIH/NHLBI grant HL 089734 to D.E.H. with Jacob Joseph (Brigham and Women's Hospital, Boston, MA, USA). R.N.K. was supported by NIH grants RO1 DK 68721 and RO1 DK 67536; and C.L.W. is supported by NIH training grant T32DK007260. The Joslin Core Facilities were used for islet isolation and other measurements, which are funded by Diabetes Endocrinology Research Center (DERC) grant P30DK036836. The authors declare no conflicts of interests.	AMMON HPT, 1972, DIABETES, V21, P143, DOI 10.2337/diab.21.3.143; AMMON HPT, 1972, ENDOCRINOLOGY, V91, P33, DOI 10.1210/endo-91-1-33; AMMON HPT, 1973, BIOCHIM BIOPHYS ACTA, V297, P352, DOI 10.1016/0304-4165(73)90083-4; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Benhamou PY, 1998, DIABETOLOGIA, V41, P1093, DOI 10.1007/s001250051035; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Diaz-Flores M, 2006, LIFE SCI, V78, P2601, DOI 10.1016/j.lfs.2005.10.022; Eisenbarth GS, 2007, J CLIN ENDOCR METAB, V92, P2403, DOI 10.1210/jc.2007-0339; Forbes JM, 2008, DIABETES, V57, P1446, DOI 10.2337/db08-0057; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; Gupte RS, 2007, J CARD FAIL, V13, P497, DOI 10.1016/j.cardfail.2007.04.003; Harmon JS, 2005, J BIOL CHEM, V280, P11107, DOI 10.1074/jbc.M410345200; Iatropoulos MJ, 1996, EXP TOXICOL PATHOL, V48, P175, DOI 10.1016/S0940-2993(96)80039-X; Jain M, 2003, CIRC RES, V93, pE9, DOI 10.1161/01.RES.0000083489.83704.76; Kirkman HN, 1999, J BIOL CHEM, V274, P13908, DOI 10.1074/jbc.274.20.13908; Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5; Lenzen S, 2008, BIOCHEM SOC T, V36, P343, DOI 10.1042/BST0360343; Leopold JA, 2003, J BIOL CHEM, V278, P32100, DOI 10.1074/jbc.M301293200; Leopold JA, 2003, ARTERIOSCL THROM VAS, V23, P411, DOI 10.1161/01.ATV.0000056744.26901.BA; Lupi R, 2008, DIABETES METAB, V34, pS56, DOI 10.1016/S1262-3636(08)73396-2; Marchetti P, 2004, J CLIN ENDOCR METAB, V89, P5535, DOI 10.1210/jc.2004-0150; Maritim AC, 2003, J BIOCHEM MOL TOXIC, V17, P24, DOI 10.1002/jbt.10058; Martini G, 1996, BIOESSAYS, V18, P631, DOI 10.1002/bies.950180806; Matsui R, 2006, ARTERIOSCL THROM VAS, V26, P910, DOI 10.1161/01.ATV.0000205850.49390.3b; Mazumder Suparna, 2008, V414, P13; Moriscot C, 2003, DIABETES METAB, V29, P145, DOI 10.1016/S1262-3636(07)70021-6; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; Park J, 2006, DIABETES, V55, P2939, DOI 10.2337/db05-1570; PRETSCH W, 1988, BIOCHEM GENET, V26, P89, DOI 10.1007/BF00555491; Qiu LH, 2005, MOL CELL PROTEOMICS, V4, P1311, DOI 10.1074/mcp.M500016-MCP200; Robertson RP, 2007, CELL BIOCHEM BIOPHYS, V48, P139, DOI 10.1007/s12013-007-0026-5; Robertson RP, 2007, FEBS LETT, V581, P3743, DOI 10.1016/j.febslet.2007.03.087; Robertson RP, 2005, ANN NY ACAD SCI, V1043, P513, DOI 10.1196/annals.1333.058; Robertson RP, 2004, DIABETES, V53, pS119, DOI 10.2337/diabetes.53.2007.S119; Robertson RP, 2004, J BIOL CHEM, V279, P42351, DOI 10.1074/jbc.R400019200; Ronnebaum SM, 2006, J BIOL CHEM, V281, P30593, DOI 10.1074/jbc.M511908200; Sakuraba H, 2002, DIABETOLOGIA, V45, P85, DOI 10.1007/s125-002-8248-z; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; Sanders S, 1997, MUTAT RES-FUND MOL M, V374, P79, DOI 10.1016/S0027-5107(96)00222-9; Starborg M, 1996, J CELL SCI, V109, P143; Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P12363, DOI 10.1073/pnas.192445199; Tian WN, 1998, J BIOL CHEM, V273, P10609, DOI 10.1074/jbc.273.17.10609; Tian WN, 1999, AM J PHYSIOL-CELL PH, V276, pC1121, DOI 10.1152/ajpcell.1999.276.5.C1121; TIAN WN, 1994, J BIOL CHEM, V269, P14798; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; Tiedge M, 1998, DIABETES, V47, P1578, DOI 10.2337/diabetes.47.10.1578; Ursini MV, 1997, BIOCHEM J, V323, P801, DOI 10.1042/bj3230801; Wajchenberg BL, 2007, ENDOCR REV, V28, P187, DOI 10.1210/er.2006-0038; Xu YZ, 2005, AM J PHYSIOL-RENAL, V289, pF1040, DOI 10.1152/ajprenal.00076.2005; Zhang ZQ, 2000, J BIOL CHEM, V275, P40042, DOI 10.1074/jbc.M007505200	50	151	163	1	31	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1497	1505		10.1096/fj.09-136572	http://dx.doi.org/10.1096/fj.09-136572			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20032314	Green Published			2022-12-28	WOS:000277158900022
J	Morrison, JI; Borg, P; Simon, A				Morrison, Jamie I.; Borg, Paula; Simon, Andras			Plasticity and recovery of skeletal muscle satellite cells during limb regeneration	FASEB JOURNAL			English	Article						Pax7; blastema; salamander; reprogramming	SELF-RENEWAL; DEDIFFERENTIATION; EXPRESSION; ORIGIN	Salamander limb regeneration depends on local progenitors whose progeny are recruited to the new limb. We previously identified a Pax7(+) cell population in skeletal muscle whose progeny have the potential to contribute to the regenerating limb. However, the plasticity of individual Pax7(+) cells, as well as their recovery within the new limb, was unclear. Here, we show that Pax7(+) cells remain present after multiple rounds of limb amputation/regeneration. Pax7(+) cells are found exclusively within skeletal muscle in the regenerating limb and proliferate where the myofibers are growing. Pax7 is rapidly down-regulated in the blastema, and analyses of clonal derivatives show that Pax7(+) cell progeny are not restricted to skeletal muscle during limb regeneration. Our data suggest that the newt regeneration blastema is not entirely a composite of lineage-restricted progenitors. The results demonstrate that except for a transient and subsequently blunted increase, skeletal muscle satellite cells constitute a stable pool of reserve cells for multiple limb regeneration events.-Morrison, J. i., Borg, P., Simon, A. Plasticity and recovery of skeletal muscle satellite cells during limb regeneration. FASEB J. 24, 750-756 (2010). www.fasebj.org	[Morrison, Jamie I.; Borg, Paula; Simon, Andras] Karolinska Inst, Dept Cell & Mol Biol, Ctr Excellence Dev Biol Regenerat Med, S-17177 Stockholm, Sweden	Karolinska Institutet	Simon, A (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Ctr Excellence Dev Biol Regenerat Med, Eulersvag 3, S-17177 Stockholm, Sweden.	jamie.morrison@molbio.su.se; andras.simon@ki.se		Simon, Andras/0000-0002-1018-1891	Swedish Research Council; Swedish Foundation for Strategic Research; Karolinska Institute	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Karolinska Institute(Karolinska Institutet)	The authors thank members of the A. S. laboratory for discussions, E. Littson for help with the clonal isolations, Y. Kawakami for virus production, and M. Kirkham for help with adenovirus infections. This project was supported by grants from the Swedish Research Council, the Swedish Foundation for Strategic Research, and the Karolinska Institute to A. S.	Alvarado AS, 2006, NAT REV GENET, V7, P873, DOI 10.1038/nrg1923; Bauer S, 2005, J CELL BIOL, V171, P641, DOI 10.1083/jcb.200505072; Brockes JP, 2005, SCIENCE, V310, P1919, DOI 10.1126/science.1115200; Brockes JR, 2002, NAT REV MOL CELL BIO, V3, P566, DOI 10.1038/nrm881; Bryant SV, 2002, INT J DEV BIOL, V46, P887; CAMERON JA, 1986, NATURE, V321, P607, DOI 10.1038/321607a0; CARLSON B M, 1976, Folia Morphologica (Prague), V24, P359; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; DUNIS DA, 1977, DEV BIOL, V56, P97, DOI 10.1016/0012-1606(77)90157-9; Echeverri K, 2001, DEV BIOL, V236, P151, DOI 10.1006/dbio.2001.0312; Gardiner DM, 2005, REJUV RES, V8, P141, DOI 10.1089/rej.2005.8.141; Imokawa Y, 2004, INT J DEV BIOL, V48, P285, DOI 10.1387/ijdb.031787yi; Kawakami Y, 2006, GENE DEV, V20, P3232, DOI 10.1101/gad.1475106; Kragl M, 2009, NATURE, V460, P60, DOI 10.1038/nature08152; Kuang SH, 2007, CELL, V129, P999, DOI 10.1016/j.cell.2007.03.044; Kumar A, 2004, PLOS BIOL, V2, P1168, DOI 10.1371/journal.pbio.0020218; Kumar A, 2000, DEV BIOL, V218, P125, DOI 10.1006/dbio.1999.9569; Laube F, 2006, J CELL SCI, V119, P4719, DOI 10.1242/jcs.03252; Maki N, 2009, DEV DYNAM, V238, P1613, DOI 10.1002/dvdy.21959; Meeson AP, 2004, STEM CELLS, V22, P1305, DOI 10.1634/stemcells.2004-0077; Morrison JI, 2006, J CELL BIOL, V172, P433, DOI 10.1083/jcb.200509011; MUNEOKA K, 1986, DEV BIOL, V116, P256, DOI 10.1016/0012-1606(86)90062-X; NAMENWIRTH M, 1974, DEV BIOL, V41, P42, DOI 10.1016/0012-1606(74)90281-4; POPIELA H, 1976, J EXP ZOOL, V198, P57, DOI 10.1002/jez.1401980108; ROSENBLATT JD, 1995, DEV BIOL ANIM, V31, P773; Sacco A, 2008, NATURE, V456, P502, DOI 10.1038/nature07384; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Shinin V, 2006, NAT CELL BIOL, V8, P677, DOI 10.1038/ncb1425; Slack JMW, 2006, TRENDS CELL BIOL, V16, P273, DOI 10.1016/j.tcb.2006.04.007; Tanaka EM, 2003, CELL, V113, P559, DOI 10.1016/S0092-8674(03)00395-7; Tanaka KK, 2009, CELL STEM CELL, V4, P217, DOI 10.1016/j.stem.2009.01.016; Whited Jessica L, 2009, J Biol, V8, P5, DOI 10.1186/jbiol105	32	38	40	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					750	756		10.1096/fj.09-134825	http://dx.doi.org/10.1096/fj.09-134825			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19887652				2022-12-28	WOS:000274974600011
J	Zhu, ML; Kyprianou, N				Zhu, Meng-Lei; Kyprianou, Natasha			Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells	FASEB JOURNAL			English	Article						cytoskeleton reorganization; actin; talin; cofilin; metastasis; TGF-beta signaling	GROWTH-FACTOR-BETA; TUMOR PROGRESSION; TGF-BETA; NUCLEAR TRANSLOCATION; INDUCED APOPTOSIS; CATENIN; THERAPY; DEPRIVATION; ACTIVATION; PLASTICITY	Androgens are functionally required for the normal growth of the prostate gland and in prostate tumor development and progression. Epithelial-mesenchymal-transition (EMT) is an important process during normal development and in cancer cell metastasis induced by factors within the microenvironment, such as transforming growth factor-beta (TGF-beta). This study examined the ability of androgens to influence EMT of prostate cancer epithelial cells. The EMT pattern was evaluated on the basis of expression of the epithelial markers E-cadherin/beta-catenin, and the mesenchymal markers N-cadherin, as well as cytoskeleton reorganization in response to 5 alpha-dihydrotestosterone (DHT; 1 nM) and/or TGF-beta (5 ng/ml). Overexpressing and silencing approaches to regulate androgen receptor (AR) expression were conducted to determine the involvement of AR in EMT in the presence or absence of an AR antagonist. Our results demonstrate that androgens induce the EMT pattern in prostate tumor epithelial cell with Snail activation and lead to significant changes in prostate cancer cell migration and invasion potential. Expression levels of AR inversely correlated with androgen-mediated EMT in prostate tumor epithelial cells, pointing to a low AR content required for the EMT phenotype. These findings indicate the ability of androgens to induce EMT by potentially bypassing the functional involvement of TGF-beta, thus contributing to metastatic behavior of prostate cancer cells.-Zhum, M.-L., Kyprianou, N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J. 24, 769-777 (2010). www.fasebj.org	[Kyprianou, Natasha] Univ Kentucky, Med Ctr, Dept Toxicol, Coll Med, Lexington, KY 40536 USA; [Zhu, Meng-Lei; Kyprianou, Natasha] Univ Kentucky, Coll Med, Dept Urol Surg, Lexington, KY 40536 USA; [Kyprianou, Natasha] Univ Kentucky, Coll Med, Dept Mol Biochem, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Kyprianou, N (corresponding author), Univ Kentucky, Med Ctr, Dept Toxicol, Coll Med, Combs Res Bldg,Rm 306, Lexington, KY 40536 USA.	nkypr2@uky.edu			U.S. National Institutes of Health [R01 CA107575-06]; NATIONAL CANCER INSTITUTE [R01CA107575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK083761] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by a U.S. National Institutes of Health R01 CA107575-06 grant (N.K.). The authors acknowledge Dr. Donald Tindall (Mayo Clinic, Rochester, MN, USA) and Dr. Scott Dehm (University of Minnesota, Minneapolis, MN, USA) for the generous gift of the plasmid pCMV5-AR; Dr. Mary Vore (Department of Toxicology, University of Kentucky, Lexington, KY, USA) for useful advice; and Lorie Howard for assistance in the submission of the manuscript.	Alimirah F, 2006, FEBS LETT, V580, P2294, DOI 10.1016/j.febslet.2006.03.041; Balk Steven P, 2008, Nucl Recept Signal, V6, pe001, DOI 10.1621/nrs.06001; Boccon-Gibod L, 2007, BJU INT, V100, P738, DOI 10.1111/j.1464-410X.2007.07053.x; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Bruckheimer EM, 2001, ENDOCRINOLOGY, V142, P2419, DOI 10.1210/en.142.6.2419; Burnstein KL, 2005, J CELL BIOCHEM, V95, P657, DOI 10.1002/jcb.20460; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Cinar B, 2007, J BIOL CHEM, V282, P29584, DOI 10.1074/jbc.M703310200; Cronauer MV, 2005, INT J ONCOL, V26, P1033; De Marzo AM, 1998, J UROLOGY, V160, P2381, DOI 10.1016/S0022-5347(01)62196-7; Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Fuchs IB, 2002, ANTICANCER RES, V22, P3415; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; GLEAVE ME, 1993, CANCER RES, V53, P5300; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Guo YP, 1999, CANCER RES, V59, P1366; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; IMPERATOMCGINLEY J, 1985, ENDOCRINOLOGY, V116, P807, DOI 10.1210/endo-116-2-807; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kang HY, 2002, J BIOL CHEM, V277, P43749, DOI 10.1074/jbc.M205603200; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Lu-Yao GL, 2008, JAMA-J AM MED ASSOC, V300, P173, DOI 10.1001/jama.300.2.173; Makhsida N, 2005, J UROLOGY, V174, P827, DOI 10.1097/01.ju.0000169490.78443.59; Martinez HD, 2008, J BIOL CHEM, V283, P29938, DOI 10.1074/jbc.M800534200; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Meyer G, 2005, CELL MOL LIFE SCI, V62, P461, DOI 10.1007/s00018-004-4456-6; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12188, DOI 10.1073/pnas.0804701105; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943; SIITERI PK, 1974, J CLIN ENDOCR METAB, V38, P113, DOI 10.1210/jcem-38-1-113; Suzuki H, 2008, INT J CLIN ONCOL, V13, P401, DOI 10.1007/s10147-008-0830-y; Tahmatzopoulos A, 2005, ONCOGENE, V24, P5375, DOI 10.1038/sj.onc.1208684; Tanentzapf G, 2006, NAT CELL BIOL, V8, P601, DOI 10.1038/ncb1411; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Wang G, 2008, CANCER RES, V68, P9918, DOI 10.1158/0008-5472.CAN-08-1718; Warg X, 2007, J CELL BIOCHEM, V102, P571, DOI 10.1002/jcb.21491; Zhau HE, 2008, CLIN EXP METASTAS, V25, P601, DOI 10.1007/s10585-008-9183-1; Zhu ML, 2008, ENDOCR-RELAT CANCER, V15, P841, DOI 10.1677/ERC-08-0084	50	157	164	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					769	777		10.1096/fj.09-136994	http://dx.doi.org/10.1096/fj.09-136994			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19901020	Green Published			2022-12-28	WOS:000274974600013
J	Padua, MB; Kowalski, AA; Canas, MY; Hansen, PJ				Padua, Maria B.; Kowalski, Andres A.; Canas, Miryan Y.; Hansen, Peter J.			The molecular phylogeny of uterine serpins and its relationship to evolution of placentation	FASEB JOURNAL			English	Article						uterine milk proteins; SERPINA14; pregnancy; hinge region; positive selection	PROGESTERONE-INDUCED PROTEINS; CODON-SUBSTITUTION MODELS; OVINE; SUPERFAMILY; SECRETIONS; BINDING; UTEROFERRIN; DIVERGENCE; GENETICS; ACCURACY	Uterine serpins (USs), designated as SERPINA14, are expressed in the endometrium in response to progesterone. All species identified as having USs exhibit epitheliochorial placentation and are in the Ruminantia and Suidae orders of the Laurasiatheria superorder. The objective was to identify US genes in species within and outside Laurasiatheria and evaluate whether evolution of the US gene was associated with development of the epitheliochorial placenta. Through queries of nucleotide and genomic databases, known US genes were identified (caprine, bovine, porcine, water buffalo), and new US coding sequences were found in dolphins, horses, dogs, and cats. The cat sequence contained several stop codons. No sequence was found in completed genomic sequences for primates, rodents, rabbits, opossums, or duck-billed platypuses. Reverse transcription-polymerase chain reaction confirmed expression of the US gene in the uterus of pregnant horses and dogs. The ratio of nonsynonymous/synonymous substitutions suggests that the US gene evolved under positive selection. In conclusion, the US gene evolved within the Laurasiatheria superorder to play a role in pregnancy for species with epitheliochorial placentation and some but not all Laurasiatheria species that have a different form of placentation. The positive selection taking place in the gene suggests development of species-specific functions.-Padua, M. B., Kowalski, A. A., Canas, M. Y., Hansen, P. J. The molecular phylogeny of uterine serpins and its relationship to evolution of placentation. FASEB J. 24, 526-537 (2010). www.fasebj.org	[Padua, Maria B.; Hansen, Peter J.] Univ Florida, Dept Anim Sci, Gainesville, FL 32611 USA; [Kowalski, Andres A.; Canas, Miryan Y.] Univ Centroccidental Lisandro Alvarado, Lab Embriol & Endocrinol Mol, Barquisimeto, Edo Lara, Venezuela	State University System of Florida; University of Florida	Hansen, PJ (corresponding author), Univ Florida, Dept Anim Sci, POB 110910, Gainesville, FL 32611 USA.	pjhansen@ufl.edu	Hansen, Peter/AAI-4693-2021	Hansen, Peter/0000-0003-3061-9333				Anisimova M, 2001, MOL BIOL EVOL, V18, P1585, DOI 10.1093/oxfordjournals.molbev.a003945; Barbour KW, 2002, MOL BIOL EVOL, V19, P718, DOI 10.1093/oxfordjournals.molbev.a004130; BAUMBACH GA, 1986, J BIOL CHEM, V261, P2869; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bielawski JP, 2003, J STRUCT FUNCT GENOM, V3, P201, DOI DOI 10.1007/978-94-010-0263-9_20; BROWN AL, 1987, NATURE, V326, P12, DOI 10.1038/326012b0; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Goodwin RL, 1996, MOL BIOL EVOL, V13, P346, DOI 10.1093/oxfordjournals.molbev.a025594; HANSEN PJ, 1988, ARCH BIOCHEM BIOPHYS, V260, P208, DOI 10.1016/0003-9861(88)90442-0; HANSEN PJ, 1985, J REPROD FERTIL, V73, P411, DOI 10.1530/jrf.0.0730411; ING NH, 1989, J BIOL CHEM, V264, P3372; Irving JA, 2002, MOL BIOL EVOL, V19, P1881, DOI 10.1093/oxfordjournals.molbev.a004012; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Khatib H, 2007, J DAIRY SCI, V90, P2427, DOI 10.3168/jds.2006-722; Knight PG, 2006, REPRODUCTION, V132, P191, DOI 10.1530/rep.1.01074; Knox K, 2008, GENOME RES, V18, P695, DOI 10.1101/gr.071407.107; LEISER R, 1977, MICROSC RES TECHNIQ, V38, P76; LESLIE MV, 1991, STEROIDS, V56, P589, DOI 10.1016/0039-128X(91)90022-N; LESLIE MV, 1990, DOMEST ANIM ENDOCRIN, V7, P517, DOI 10.1016/0739-7240(90)90009-O; LIU WJ, 1995, ENDOCRINOLOGY, V136, P779, DOI 10.1210/en.136.2.779; Louis EJ, 2007, NATURE, V449, P673, DOI 10.1038/449673a; MALATHY PV, 1990, MOL ENDOCRINOL, V4, P428, DOI 10.1210/mend-4-3-428; Mathialagan N, 1996, P NATL ACAD SCI USA, V93, P13653, DOI 10.1073/pnas.93.24.13653; McFarlane JR, 1999, ENDOCRINOLOGY, V140, P4745, DOI 10.1210/en.140.10.4745; Mess A, 2007, COMP BIOCHEM PHYS A, V148, P769, DOI 10.1016/j.cbpa.2007.01.029; MOFFATT J, 1987, BIOL REPROD, V36, P419, DOI 10.1095/biolreprod36.2.419; Moffett A, 2006, NAT REV IMMUNOL, V6, P584, DOI 10.1038/nri1897; Murphy WJ, 2007, GENOME RES, V17, P413, DOI 10.1101/gr.5918807; Nishihara H, 2006, P NATL ACAD SCI USA, V103, P9929, DOI 10.1073/pnas.0603797103; Padua MB, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-5; Padua MB, 2005, MOL REPROD DEV, V71, P347, DOI 10.1002/mrd.20301; Peltier MR, 2000, J EXP ZOOL, V288, P165, DOI 10.1002/1097-010X(20000815)288:2&lt;165::AID-JEZ7&gt;3.0.CO;2-R; Peltier MR, 2000, BBA-PROTEIN STRUCT M, V1479, P37, DOI 10.1016/S0167-4838(00)00063-7; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sauk JJ, 2005, FRONT BIOSCI-LANDMRK, V10, P107, DOI 10.2741/1513; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Sheng SJ, 2006, J CELL PHYSIOL, V209, P631, DOI 10.1002/jcp.20786; Silverman GA, 2004, CELL MOL LIFE SCI, V61, P301, DOI 10.1007/s00018-003-3240-3; Steenbakkers PJM, 2008, MYCOL RES, V112, P999, DOI 10.1016/j.mycres.2008.01.021; Stern A, 2007, NUCLEIC ACIDS RES, V35, pW506, DOI 10.1093/nar/gkm382; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Tekin S, 2005, MOL REPROD DEV, V70, P262, DOI 10.1002/mrd.20206; Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176; Vogel P, 2005, PLACENTA, V26, P591, DOI 10.1016/j.placenta.2004.11.005; Whisstock JC, 2006, CURR OPIN STRUC BIOL, V16, P761, DOI 10.1016/j.sbi.2006.10.005; Whisstock JC, 2000, J MOL BIOL, V295, P651, DOI 10.1006/jmbi.1999.3375; Wong WSW, 2004, GENETICS, V168, P1041, DOI 10.1534/genetics.104.031153; Yang ZH, 2002, MOL BIOL EVOL, V19, P908, DOI 10.1093/oxfordjournals.molbev.a004148; Yang ZH, 2000, GENETICS, V155, P431; Yang ZH, 2007, MOL BIOL EVOL, V24, P1586, DOI 10.1093/molbev/msm088; Zhang JZ, 2005, MOL BIOL EVOL, V22, P2472, DOI 10.1093/molbev/msi237	55	14	14	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					526	537		10.1096/fj.09-138453	http://dx.doi.org/10.1096/fj.09-138453			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19825977				2022-12-28	WOS:000274045000020
J	Kang, HW; Walvick, R; Bogdanov, A				Kang, Hye-Won; Walvick, Ronn; Bogdanov, Alexei, Jr.			In vitro and In vivo imaging of antivasculogenesis induced by Noggin protein expression in human venous endothelial cells	FASEB JOURNAL			English	Article						HUVEC; BMP; MRI; PGC	BONE MORPHOGENETIC PROTEIN; SIGNAL-TRANSDUCTION; ADOPTIVE TRANSFER; STEM-CELLS; BMP; DIFFERENTIATION; ANGIOGENESIS; ADHESION; MICE	Noggin protein is a potent bone morphogenetic protein (BMP) antagonist capable of inhibiting vasculogenesis even in the presence of provasculogenic VEGF and FGF-2. We found that human umbilical vein endothelial cells (HUVECs) do not express Noggin in culture and used these cells for modeling of antivasculogenesis. We hypothesized that high-efficiency transduction of HUVECs with bicistronic lentiviral vector encoding Noggin and enhanced green fluorescent protein (EGFP) enables direct visualization of Noggin effects in homogenous primary cell populations in vitro and in vivo. By comparing HUVECs transduced with a control GFP and GFP/Noggin expression cassettes, we showed that constitutive and orthotopic Noggin protein expression did not influence cell proliferation, down-regulated BMP-2 expression, and showed no effect on BMP receptor transcripts. We demonstrated that in contrast to GFP-only control, Noggin expression in endothelial cells abrogated endothelial migration in response to monolayer injury, blocked endothelial transmigration, and caused abrogation of cord formation in vitro. Adding exogenous BMP-4 restored the formation of cords. Imaging experiments in vivo investigated vessel formation in Matrigel implants in athymic mice by utilizing GFP imaging or magnetic resonance imaging of perfusion in the implants. Both approaches demonstrated the lack of functional vessel formation after the adoptive transfer of GFP/Noggin-expressing human endothelial cells in mice.-Kang, H.-W., Walvick, R., Bogdanov, A. In vitro and in vivo imaging of antivasculogenesis induced by Noggin protein expression in human venous endothelial cells. FASEB J. 23, 4126-4134 (2009). www.fasebj.org	[Kang, Hye-Won; Bogdanov, Alexei, Jr.] Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA 01655 USA; [Walvick, Ronn] Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA	University of Massachusetts System; University of Massachusetts Worcester; Worcester Polytechnic Institute	Bogdanov, A (corresponding author), Univ Massachusetts, Sch Med, Dept Radiol, 55 Lake Ave N, Worcester, MA 01655 USA.	alexei.bogdanov@umassmed.edu	Bogdanov, Alexei A/K-4946-2017	Bogdanov, Alexei A/0000-0003-4806-5869	U. S. National Institutes of Health [RO1-EB000858]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG034901] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported in part by U. S. National Institutes of Health grant RO1-EB000858 (A. B.). The authors are grateful to Dr. Miguel Sena-Esteves (Department of Neurology, Massachusetts General Hospital, Boston, MA, USA) for providing hightiter lentiviral vectors, Dr. Marian Nakada (Centocor, Malvern, PA, USA) for supplying anti-human CD31 monoclonal antibody, and Bill Luscinskas (Brigham and Women's Hospital, Boston, MA, USA) for providing HUVECs.	Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Bogdanov AA, 2007, PHARM RES-DORDR, V24, P1186, DOI 10.1007/s11095-006-9219-7; Bonaguidi MA, 2008, J NEUROSCI, V28, P9194, DOI 10.1523/JNEUROSCI.3314-07.2008; Boyd NL, 2007, EXP BIOL MED, V232, P833; Bressan M, 2009, DEV BIOL, V326, P101, DOI 10.1016/j.ydbio.2008.10.045; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; Chang K, 2007, CIRCULATION, V116, P1258, DOI 10.1161/CIRCULATIONAHA.106.683227; Chiba S, 2008, STEM CELLS, V26, P2810, DOI 10.1634/stemcells.2008-0085; Dai JL, 2004, CANCER RES, V64, P994, DOI 10.1158/0008-5472.CAN-03-1382; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Hotfilder M, 1997, KLIN PADIATR, V209, P265, DOI 10.1055/s-2008-1043960; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Kang HW, 2002, BIOCONJUGATE CHEM, V13, P122, DOI 10.1021/bc0155521; Kang HW, 2006, LAB INVEST, V86, P599, DOI 10.1038/labinvest.3700421; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kelly MA, 2009, ARTERIOSCL THROM VAS, V29, P718, DOI 10.1161/ATVBAHA.109.184200; Kim YR, 2005, CANCER RES, V65, P9253, DOI 10.1158/0008-5472.CAN-03-2619; Kiyono M, 2003, MOL CELL BIOL, V23, P4627, DOI 10.1128/MCB.23.13.4627-4636.2003; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Lewin M, 1999, INT J CANCER, V83, P798, DOI 10.1002/(SICI)1097-0215(19991210)83:6<798::AID-IJC16>3.0.CO;2-W; Moser M, 2003, MOL CELL BIOL, V23, P5664, DOI 10.1128/MCB.23.16.5664-5679.2003; Nakada MT, 2000, J IMMUNOL, V164, P452, DOI 10.4049/jimmunol.164.1.452; Nimmagadda S, 2005, DEV BIOL, V280, P100, DOI 10.1016/j.ydbio.2005.01.005; Reese DE, 2004, DEV CELL, V6, P699, DOI 10.1016/S1534-5807(04)00127-3; Rosen V, 2006, ANN NY ACAD SCI, V1068, P19, DOI 10.1196/annals.1346.005; Sena-Esteves M, 2004, J VIROL METHODS, V122, P131, DOI 10.1016/j.jviromet.2004.08.017; Skovseth DK, 2002, AM J PATHOL, V160, P1629, DOI 10.1016/S0002-9440(10)61110-8; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Sucosky P, 2009, ARTERIOSCL THROM VAS, V29, P254, DOI 10.1161/ATVBAHA.108.176347	31	9	9	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4126	4134		10.1096/fj.08-127795	http://dx.doi.org/10.1096/fj.08-127795			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19692649	Green Published			2022-12-28	WOS:000272193700009
J	Xu, DS; Sharma, C; Hemler, ME				Xu, Daosong; Sharma, Chandan; Hemler, Martin E.			Tetraspanin12 regulates ADAM10-dependent cleavage of amyloid precursor protein	FASEB JOURNAL			English	Article						Alzheimer's disease; alpha-secretase; pericellular proteolysis	ALPHA-SECRETASE ADAM10; DISINTEGRIN-LIKE; CELL; INTEGRIN; ASSOCIATION; ACTIVATION; PALMITOYLATION; EXPRESSION; PROMOTES; CD81	Using mass spectrometry, we identified ADAM10 (a membrane-associated metalloproteinase) as a partner for TSPAN12, a tetraspanin protein. TSPAN12-ADAM10 interaction was confirmed by reciprocal coimmunoprecipitation in multiple tumor cell lines. TSPAN12, to a greater extent than other tetraspanins (CD81, CD151, CD9, and CD82), associated with ADAM10 but not with ADAM17. Overexpression of TSPAN12 enhanced ADAM10-dependent shedding of amyloid precursor protein (APP) in MCF7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines. Conversely, siRNA ablation of endogenous TSPAN12 markedly diminished APP proteolysis in both cell lines. Furthermore, TSPAN12 overexpression enhanced ADAM10 prodomain maturation, whereas TSPAN12 ablation diminished ADAM10 maturation. A palmitoylation-deficient TSPAN12 mutant failed to associate with ADAM10, inhibited ADAM10-dependent proteolysis of APP, and inhibited ADAM10 maturation, most likely by interfering with endogenous wild-type TSPAN12. In conclusion, TSPAN12 serves as a novel and robust partner for ADAM10 and promotes ADAM10 maturation, thereby facilitating ADAM10-dependent proteolysis of APP. This novel mode of regulating APP cleavage is of relevance to Alzheimer's disease therapy.-Xu, D., Sharma, C., Hemler, M. E. Tetraspanin12 regulates ADAM10-dependent cleavage of amyloid precursor protein. FASEB J. 23, 3674-3681 (2009). www.fasebj.org	[Hemler, Martin E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Hemler, ME (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.	martin_hemler@dfci.harvard.edu			National Institutes of Health [GM38903, CA102034]; NATIONAL CANCER INSTITUTE [R01CA102034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health grants GM38903 and CA102034 to M. E. H.	Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Anderegg U, 2009, J INVEST DERMATOL, V129, P1471, DOI 10.1038/jid.2008.323; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Arduise C, 2008, J IMMUNOL, V181, P7002, DOI 10.4049/jimmunol.181.10.7002; Berditchevski F, 2002, J BIOL CHEM, V277, P36991, DOI 10.1074/jbc.M205265200; Berditchevski F, 2007, TRAFFIC, V8, P89, DOI 10.1111/j.1600-0854.2006.00515.x; Camden JM, 2005, J BIOL CHEM, V280, P18696, DOI 10.1074/jbc.M500219200; Charrin S, 2002, FEBS LETT, V516, P139, DOI 10.1016/S0014-5793(02)02522-X; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Fahrenholz F, 2007, CURR ALZHEIMER RES, V4, P412, DOI 10.2174/156720507781788837; Fahrenholz F, 2006, NEURODEGENER DIS, V3, P255, DOI 10.1159/000095264; Gutwein P, 2005, CLIN CANCER RES, V11, P2492, DOI 10.1158/1078-0432.CCR-04-1688; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hemler ME, 2008, NAT REV DRUG DISCOV, V7, P747, DOI 10.1038/nrd2659; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Herlevsen M, 2003, J CELL SCI, V116, P4373, DOI 10.1242/jcs.00760; Imbimbo BP, 2008, CURR TOP MED CHEM, V8, P54, DOI 10.2174/156802608783334015; Kovalenko OV, 2004, BIOCHEM J, V377, P407, DOI 10.1042/BJ20031037; Kuhn S, 2007, MOL CANCER RES, V5, P553, DOI 10.1158/1541-7786.MCR-06-0384; LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168; Lafleur MA, 2009, MOL BIOL CELL, V20, P2030, DOI 10.1091/mbc.E08-11-1149; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Le Gall SM, 2009, MOL BIOL CELL, V20, P1785, DOI 10.1091/mbc.E08-11-1135; Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548; Ludwig A, 2005, COMB CHEM HIGH T SCR, V8, P161, DOI 10.2174/1386207053258488; Marcello E, 2007, J NEUROSCI, V27, P1682, DOI 10.1523/JNEUROSCI.3439-06.2007; Min GW, 2006, J CELL BIOL, V173, P975, DOI 10.1083/jcb.200602086; Moss ML, 2008, CURR PHARM BIOTECHNO, V9, P2, DOI 10.2174/138920108783497613; Moss ML, 2007, J BIOL CHEM, V282, P35712, DOI 10.1074/jbc.M703231200; Murai T, 2004, J BIOL CHEM, V279, P4541, DOI 10.1074/jbc.M307356200; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Rubinstein E, 2006, SEMIN CELL DEV BIOL, V17, P254, DOI 10.1016/j.semcdb.2006.02.012; Serru V, 2000, BBA-PROTEIN STRUCT M, V1478, P159, DOI 10.1016/S0167-4838(00)00022-4; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Shoham T, 2003, J IMMUNOL, V171, P4062, DOI 10.4049/jimmunol.171.8.4062; Stipp CS, 2003, J CELL BIOL, V163, P1167, DOI 10.1083/jcb.200309113; Stipp CS, 2001, J BIOL CHEM, V276, P4853, DOI 10.1074/jbc.M009859200; Stone AL, 1999, J PROTEIN CHEM, V18, P447, DOI 10.1023/A:1020692710029; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Vassar R, 2004, J MOL NEUROSCI, V23, P105, DOI 10.1385/JMN:23:1-2:105; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; Wolfe MS, 2007, J CELL SCI, V120, P3157, DOI 10.1242/jcs.03481; Xu DS, 2005, MOL CELL PROTEOMICS, V4, P1061, DOI 10.1074/mcp.M400207-MCP200; Yang XWH, 2008, CANCER RES, V68, P3204, DOI 10.1158/0008-5472.CAN-07-2949; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Zhang L, 2008, J BIOL CHEM, V283, P35507, DOI 10.1074/jbc.M806948200	50	100	105	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3674	3681		10.1096/fj.09-133462	http://dx.doi.org/10.1096/fj.09-133462			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19587294	Green Published			2022-12-28	WOS:000271272500005
J	Izzotti, A; Calin, GA; Steele, VE; Croce, CM; De Flora, S				Izzotti, Alberto; Calin, George A.; Steele, Vernon E.; Croce, Carlo M.; De Flora, Silvio			Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and light	FASEB JOURNAL			English	Article						lung cancer; molecular mechanisms	CANCER CHEMOPREVENTIVE AGENTS; GENE-EXPRESSION; RESPIRATORY-TRACT; MICE; MODULATION; TUMORS; RATS; TRANSCRIPTOME; POLYMORPHISM; APOPTOSIS	MicroRNAs provide a formidable tool not only in cancer research but also to investigate physiological mechanisms and to assess the effect of environmental exposures in healthy tissues. Collectively, cigarette smoke and sunlight have been estimated to account for 40% of all human cancers, and not only smoke but also, surprisingly, UV light induced genomic and postgenomic alterations in mouse lung. Here we evaluated by microarray the expression of 484 microRNAs in the lungs of CD-1 mice, including new-borns, postweanling males and females, and their dams, either untreated or exposed to environmental cigarette smoke and/or UV-containing light. The results obtained highlighted age-related variations in microRNA profiles, especially during the weanling period, due to perinatal stress and postnatal maturation of the lung. UV light alone did not affect pulmonary microRNAs, whereas smoke produced dramatic changes, mostly in the sense of down-regulation, reflecting both adaptive mechanisms and activation of pathways involved in the pathogenesis of pulmonary diseases. Both gender and age affected smoke-related microRNA dysregulation in mice. The data presented provide supporting evidence that microRNAs play a fundamental role in both physiological and pathological changes occurring in mouse lung.-Izzotti, A., Calin, G. A., Vernon E. St., Croce, G. M., De Flora, S. Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and light. FASEB J. 23, 3243-3250 ( 2009). www.fasebj.org	[Izzotti, Alberto; De Flora, Silvio] Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy; [Calin, George A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Steele, Vernon E.] NCI, Rockville, MD USA; [Croce, Carlo M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University of Genoa; University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	De Flora, S (corresponding author), Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italy.	sdf@unige.it	Calin, George/E-9390-2011; Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Calin, George/0000-0001-6704-5615; izzotti, alberto/0000-0002-8588-0347	National Cancer Institute [N01-CN 53301]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the National Cancer Institute ( contract N01-CN 53301).	Balansky RM, 2003, CARCINOGENESIS, V24, P1525, DOI 10.1093/carcin/bgg108; Balansky R, 2007, CARCINOGENESIS, V28, P2236, DOI 10.1093/carcin/bgm122; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bonner AE, 2004, ONCOGENE, V23, P1166, DOI 10.1038/sj.onc.1207234; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Couzin J, 2008, SCIENCE, V319, P1782, DOI 10.1126/science.319.5871.1782; D'Agostini F, 2005, MUTAT RES-FUND MOL M, V591, P173, DOI 10.1016/j.mrfmmm.2005.03.034; D'Agostini F, 2001, CARCINOGENESIS, V22, P375, DOI 10.1093/carcin/22.3.375; DAVIS WB, LUNG SCI FDN, P1821; De Flora S, 2003, CANCER RES, V63, P793; De Flora S, 2008, MUTAT RES-REV MUTAT, V659, P137, DOI 10.1016/j.mrrev.2007.11.004; De Flora S, 2007, CANCER RES, V67, P1001, DOI 10.1158/0008-5472.CAN-06-3882; DEFLORA S, 1989, CARCINOGENESIS, V10, P1089, DOI 10.1093/carcin/10.6.1089; Duan RH, 2007, HUM MOL GENET, V16, P1124, DOI 10.1093/hmg/ddm062; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; HIGGINSON J, 1979, JNCI-J NATL CANCER I, V63, P1291; Izzotti A, 2005, MUTAT RES-FUND MOL M, V591, P212, DOI 10.1016/j.mrfmmm.2005.03.032; Izzotti A, 2005, EUR J CANCER, V41, P1864, DOI 10.1016/j.ejca.2005.04.011; Izzotti A, 2004, CANCER RES, V64, P8566, DOI 10.1158/0008-5472.CAN-04-1420; Izzotti A, 2004, FASEB J, V18, P1559, DOI 10.1096/fj.04-1877fje; Izzotti A, 2003, MUTAT RES-REV MUTAT, V544, P441, DOI 10.1016/j.mrrev.2003.05.004; Izzotti A, 2007, CARCINOGENESIS, V28, P892, DOI 10.1093/carcin/bgl208; Izzotti A, 2009, FASEB J, V23, P806, DOI 10.1096/fj.08-121384; Jay C, 2007, DNA CELL BIOL, V26, P293, DOI 10.1089/dna.2006.0554; Kalscheuer S, 2008, CARCINOGENESIS, V29, P2394, DOI 10.1093/carcin/bgn209; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Liu X, 2009, CLIN CANCER RES, V15, P1177, DOI 10.1158/1078-0432.CCR-08-1355; Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104; Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106; Spira A, 2004, P NATL ACAD SCI USA, V101, P10143, DOI 10.1073/pnas.0401422101; Williams AE, 2008, CELL MOL LIFE SCI, V65, P545, DOI 10.1007/s00018-007-7355-9; Williams AE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-172; Yao RS, 2005, EXP LUNG RES, V31, P271, DOI 10.1080/0190214059090386	34	128	139	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3243	3250		10.1096/fj.09-135251	http://dx.doi.org/10.1096/fj.09-135251			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19465468	Green Published			2022-12-28	WOS:000270241000046
J	Kim, D; Kolch, W; Cho, KH				Kim, Dongsan; Kolch, Walter; Cho, Kwang-Hyun			Multiple roles of the NF-kappa B signaling pathway regulated by coupled negative feedback circuits	FASEB JOURNAL			English	Article						heterogeneity; oscillations; stochastic simulations; systems biology; mathematical model; design principle	GENE-EXPRESSION; PROTEIN EXPRESSION; TEMPORAL CONTROL; NOISE; OSCILLATIONS; CELLS; ACTIVATION; PHENOTYPES; EVOLUTION; NETWORKS	The NF-kappa B signaling pathway can perform multiple functional roles depending on specific cellular environments and cell types. Even in the same cell clones, the pathway can show different kinetic and phenotypic properties. It is believed that the complex networks controlling the NF-kappa B signaling pathway can generate these diverse and sometimes ambiguous phenomena. We noted, however, that the dynamics of NF-kappa B signaling pathway is highly stochastic and that the NF-kappa B signaling pathway contains multiple negative feedback circuits formed by I kappa B isoform proteins, I kappa B alpha and I kappa B epsilon in particular. Considering the topological similarity, their functional roles seem to be redundant, raising the question why different types of I kappa B isoforms need to exist. From extensive stochastic simulations of the NF-kappa B signaling pathway, we found that each I kappa B isoform actually conducts a different regulatory role through its own negative feedback. Specifically, our data suggest that I kappa B alpha controls the dynamic patterns of nuclear NF-kappa B, while I kappa B epsilon induces cellular heterogeneity of the NF-kappa B activities. These results may provide an answer to the question of how a single NF-kappa B signaling pathway can perform multiple biological functions even in the same clonal populations.-Kim, D., Kolch, W., Cho, K.-H. Multiple roles of the NF-kappa B signaling pathway regulated by coupled negative feedback circuits. FASEB J. 23, 2796-2802 (2009). www.fasebj.org	[Kim, Dongsan; Cho, Kwang-Hyun] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Taejon 305701, South Korea; [Kolch, Walter] Canc Res UK, Beatson Inst Canc Res, Glasgow, Lanark, Scotland; [Kolch, Walter] Univ Glasgow, Glasgow, Lanark, Scotland	Korea Advanced Institute of Science & Technology (KAIST); Beatson Institute; Cancer Research UK; University of Glasgow	Cho, KH (corresponding author), Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, 335 Gwahangno, Taejon 305701, South Korea.	ckh@kaist.ac.kr	Kolch, Walter/ABF-2102-2021; Cho, Kwang-Hyun/C-1684-2011; Admin, SBI/HGB-2738-2022	Kolch, Walter/0000-0001-5777-5016	Korea Science and Engineering Foundation (KOSEF); Korea Ministry of Education, Science, and Technology [M10503010001-07N030100112]; Nuclear Research [M20708000001-07B0800-00110]; 21C Frontier Microbial Genomics and Application Center [MG08-0205-4-0]; World Class University (WCU) [R32-2008-000-10218-0]; Cancer Research UK	Korea Science and Engineering Foundation (KOSEF)(Korea Science and Engineering Foundation); Korea Ministry of Education, Science, and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Nuclear Research; 21C Frontier Microbial Genomics and Application Center(Ministry of Education, Science & Technology (MEST), Republic of Korea); World Class University (WCU); Cancer Research UK(Cancer Research UK)	This work was supported by a Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea Ministry of Education, Science, and Technology through Systems Biology grant M10503010001-07N030100112, Nuclear Research grant M20708000001-07B0800-00110, 21C Frontier Microbial Genomics and Application Center Program grant MG08-0205-4-0, World Class University (WCU) grant R32-2008-000-10218-0, and Cancer Research UK.	Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Bar-Even A, 2006, NAT GENET, V38, P636, DOI 10.1038/ng1807; Blake WJ, 2006, MOL CELL, V24, P853, DOI 10.1016/j.molcel.2006.11.003; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Cai L, 2006, NATURE, V440, P358, DOI 10.1038/nature04599; Chang HH, 2008, NATURE, V453, P544, DOI 10.1038/nature06965; Cooper MD, 2006, CELL, V124, P815, DOI 10.1016/j.cell.2006.02.001; Doerre S, 2005, J IMMUNOL, V174, P983, DOI 10.4049/jimmunol.174.2.983; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gillespie DT, 2003, J CHEM PHYS, V119, P8229, DOI 10.1063/1.1613254; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hayot F, 2006, J THEOR BIOL, V240, P583, DOI 10.1016/j.jtbi.2005.10.018; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Jang YJ, 2003, CANCER LETT, V194, P107, DOI 10.1016/S0304-3835(02)00680-8; Kaern M, 2005, NAT REV GENET, V6, P451, DOI 10.1038/nrg1615; Kaufmann BB, 2007, CURR OPIN GENET DEV, V17, P107, DOI 10.1016/j.gde.2007.02.007; Kearns JD, 2006, J CELL BIOL, V173, P659, DOI 10.1083/jcb.200510155; Krishna S, 2006, P NATL ACAD SCI USA, V103, P10840, DOI 10.1073/pnas.0604085103; Lin SC, 1996, MOL CELL BIOL, V16, P4591; Lipniacki T, 2006, BIOPHYS J, V90, P725, DOI 10.1529/biophysj.104.056754; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Neildez-Nguyen TMA, 2008, DIFFERENTIATION, V76, P33, DOI 10.1111/j.1432-0436.2007.00219.x; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Newman JRS, 2006, NATURE, V441, P840, DOI 10.1038/nature04785; Notarangelo LD, 2006, J ALLERGY CLIN IMMUN, V117, P855, DOI 10.1016/j.jaci.2006.01.043; Pasparakis M, 2006, CELL DEATH DIFFER, V13, P861, DOI 10.1038/sj.cdd.4401870; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Raj A, 2006, PLOS BIOL, V4, P1707, DOI 10.1371/journal.pbio.0040309; Ramsey Stephen, 2005, Journal of Bioinformatics and Computational Biology, V3, P415, DOI 10.1142/S0219720005001132; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Sayers EW, 2009, NUCLEIC ACIDS RES, V37, pD5, DOI 10.1093/nar/gkp967; Sillitoe K, 2007, BIOCHEM SOC T, V35, P263, DOI 10.1042/BST0350263; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Subkhankulova T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-268; Thattai M, 2001, P NATL ACAD SCI USA, V98, P8614, DOI 10.1073/pnas.151588598; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tian B, 2005, J BIOL CHEM, V280, P17435, DOI 10.1074/jbc.M500437200; Wagner A, 1996, BIOL CYBERN, V74, P557, DOI 10.1007/BF00209427; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Wilkinso D.J., 2006, STOCHASTIC MODELLING; Yu J, 2006, SCIENCE, V311, P1600, DOI 10.1126/science.1119623	43	17	18	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2796	2802		10.1096/fj.09-130369	http://dx.doi.org/10.1096/fj.09-130369			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19417085				2022-12-28	WOS:000270241000002
J	Trottier, C; Colombo, M; Mann, KK; Miller, WH; Ward, BJ				Trottier, Claire; Colombo, Myrian; Mann, Koren K.; Miller, Wilson H., Jr.; Ward, Brian J.			Retinoids inhibit measles virus through a type I IFN-dependent bystander effect	FASEB JOURNAL			English	Article						Vitamin A; paramyxovirus; all-trans retinoic acid	ACID-INDUCED DIFFERENTIATION; VITAMIN-A SUPPLEMENTATION; V-PROTEIN; SIGNALING PATHWAY; STAT PROTEIN; C-PROTEIN; INTERFERON; EXPRESSION; INFECTION; CELLS	Measles-associated mortality can be decreased in response to treatment with vitamin A. Our goal was to understand the mechanism by which vitamin A and other retinoids reduce measles virus (MeV) replication in vitro. MeV is known to inhibit type I interferon (IFN) signaling, and retinoids are increasingly implicated in modulating innate immunity. Type I IFN blocking antibodies abrogated the inhibitory effects of all-trans retinoic acid ( ATRA) on MeV replication (EC50 of ATRA: 3.17x10(-8) M). IFN-stimulated genes (ISGs) are up-regulated by ATRA in MeV-infected U937 cell cultures starting at 12 h and reaching a plateau at 24 h postinfection when compared to either treatment or infection alone. We found that this increased gene expression occurs in uninfected cells by using a transwell system where the uninfected cells were separated from infected cells by a membrane with 0.02-mu M pores. Uninfected bystander cells from the ATRA-treated transwells did not support substantial viral replication when subsequently infected with MeV. In the absence of ATRA, the cells from the uninfected chamber did not up-regulate ISG expression and were not protected from subsequent challenge with virus. These results demonstrate that retinoids inhibit MeV replication by up-regulating elements of the innate immune response in uninfected bystander cells, making them refractory to productive infection during subsequent rounds of viral replication.-Trottier, C., Colombo, M., Mann, K. K., Miller, W. H., Jr., Ward, B. J. Retinoids inhibit measles virus through a type I IFN-dependent bystander effect. FASEB J. 23, 3203-3212 ( 2009). www.fasebj.org	[Trottier, Claire; Ward, Brian J.] McGill Univ, Ctr Hlth, Res Inst, Dept Infect Dis, Montreal, PQ, Canada; [Trottier, Claire; Colombo, Myrian; Mann, Koren K.; Miller, Wilson H., Jr.] McGill Univ, Lady Davis Inst Med Res, Segal Canc Ctr, SMBD Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada	McGill University; Lady Davis Institute; McGill University	Ward, BJ (corresponding author), Montreal Gen Hosp, Res Inst, L10-309,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	wmiller@ldi.jgh.mcgill.ca; brian.ward@mcgill.ca						Benn CS, 2005, BMJ-BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55; Bocher WO, 2008, LIVER INT, V28, P347, DOI 10.1111/j.1478-3231.2007.01666.x; Caignard G, 2007, VIROLOGY, V368, P351, DOI 10.1016/j.virol.2007.06.037; Centers for Disease Control and Prevention (CDC), 2007, MMWR Morb Mortal Wkly Rep, V56, P1237; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Chen QY, 2002, IMMUNOLOGY, V107, P199, DOI 10.1046/j.1365-2567.2002.01485.x; Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003; D'Souza RM, 2002, J TROP PEDIATRICS, V48, P323, DOI 10.1093/tropej/48.6.323; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Dimberg A, 2000, BLOOD, V96, P2870; ESOLEN LM, 1993, J INFECT DIS, V168, P47, DOI 10.1093/infdis/168.1.47; Fontana JM, 2008, VIROLOGY, V374, P71, DOI 10.1016/j.virol.2007.12.031; GHAZAL P, 1992, P NATL ACAD SCI USA, V89, P7630, DOI 10.1073/pnas.89.16.7630; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Gotoh B, 2002, REV MED VIROL, V12, P337, DOI 10.1002/rmv.357; Helin E, 1999, VIROLOGY, V253, P35, DOI 10.1006/viro.1998.9460; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Huiming YM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001479.pub3; Irlam JH, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003650.pub2; Isaacs CE, 1997, ANTIVIR RES, V33, P117, DOI 10.1016/S0166-3542(96)01009-1; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Long KZ, 2007, J INFECT DIS, V196, P978, DOI 10.1086/521195; Luo XM, 2006, EXP BIOL MED, V231, P619; Maciaszek JW, 1998, J VIROL, V72, P5862, DOI 10.1128/JVI.72.7.5862-5869.1998; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; MOSCA JD, 1986, MOL CELL BIOL, V6, P2279, DOI 10.1128/MCB.6.6.2279; Naniche D, 2000, J VIROL, V74, P7478, DOI 10.1128/JVI.74.16.7478-7484.2000; Ni J, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003700.pub2; Ohno S, 2004, J GEN VIROL, V85, P2991, DOI 10.1099/vir.0.80308-0; OLSON JA, 1994, NUTR REV, V52, P67, DOI 10.1111/j.1753-4887.1994.tb01389.x; ONG DE, 1993, J NUTR, V123, P351, DOI 10.1093/jn/123.suppl_2.351; Palosaari H, 2003, J VIROL, V77, P7635, DOI 10.1128/JVI.77.13.7635-7644.2003; Parisien JP, 2002, J VIROL, V76, P4190, DOI 10.1128/JVI.76.9.4190-4198.2002; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Percario ZA, 1999, CELL GROWTH DIFFER, V10, P263; Perry Robert T., 2004, Journal of Infectious Diseases, V189, pS4, DOI 10.1086/377712; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Rodeheffer C, 2007, J NUTR, V137, P1916, DOI 10.1093/jn/137.8.1916; RUSSELL JK, 1984, BIOCHEM BIOPH RES CO, V122, P851, DOI 10.1016/S0006-291X(84)80112-6; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Shaffer JA, 2003, VIROLOGY, V315, P389, DOI 10.1016/S0042-6822(03)00537-3; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Sommer A, 2008, J NUTR, V138, P1835, DOI 10.1093/jn/138.10.1835; Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167; Takeuchi K, 2003, FEBS LETT, V545, P177, DOI 10.1016/S0014-5793(03)00528-3; Trottier C, 2008, ANTIVIR RES, V80, P45, DOI 10.1016/j.antiviral.2008.04.003; TURPIN JA, 1992, J IMMUNOL, V148, P2539; Villamor E, 2000, J INFECT DIS, V182, pS122, DOI 10.1086/315921; *WHO, 2007, WKLY EPIDEMIOL REC, V82, P418; Witcher M, 2008, NUCLEIC ACIDS RES, V36, P435, DOI 10.1093/nar/gkm1058; Xiao WH, 1997, J BIOL CHEM, V272, P9742, DOI 10.1074/jbc.272.15.9742; YAMAMOTO N, 1979, NATURE, V278, P553, DOI 10.1038/278553a0; Yokota S, 2003, VIROLOGY, V306, P135, DOI 10.1016/S0042-6822(02)00026-0; 1987, WKLY EPIDEMIOL REC, V19, P133	57	47	48	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3203	3212		10.1096/fj.09-129288	http://dx.doi.org/10.1096/fj.09-129288			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19447880				2022-12-28	WOS:000270241000042
J	Ishizuya-Oka, A; Hasebe, T; Buchholz, DR; Kajita, M; Fu, LZ; Shi, YB				Ishizuya-Oka, Atsuko; Hasebe, Takashi; Buchholz, Daniel R.; Kajita, Mitsuko; Fu, Liezhen; Shi, Yun-Bo			Origin of the adult intestinal stem cells induced by thyroid hormone in Xenopus laevis	FASEB JOURNAL			English	Article						transgenic frog; organ culture; tissue recombination; gut remodeling; metamorphosis	MATRIX-METALLOPROTEINASE STROMELYSIN-3; ACID-BINDING PROTEIN; AMPHIBIAN METAMORPHOSIS; GENE-EXPRESSION; POSTEMBRYONIC DEVELOPMENT; EPITHELIAL DEVELOPMENT; EXTRACELLULAR-MATRIX; CONNECTIVE-TISSUE; TADPOLE INTESTINE; PROGENITOR CELLS	In the amphibian intestine during metamorphosis, de novo stem cells generate the adult epithelium analogous to the mammalian counterpart. Interestingly, to date the exact origin of these stem cells remains to be determined, making intestinal metamorphosis a unique model to study development of adult organ-specific stem cells. Here, to determine their origin, we made use of transgenic Xenopus tadpoles expressing green fluorescent protein (GFP) for recombinant organ cultures. The larval epithelium separated from the wild-type (Wt) or GFP transgenic (Tg) intestine before metamorphic climax was recombined with homologous and heterologous nonepithelial tissues and was cultivated in the presence of thyroid hormone, the causative agent of metamorphosis. In all kinds of recombinant intestine, adult progenitor cells expressing markers for intestinal stem cells such as sonic hedgehog became detectable and then differentiated into the adult epithelium expressing intestinal fatty acid binding-protein, a marker for absorptive cells. Notably, whenever the epithelium was derived from Tg intestine, both the adult progenitor/stem cells and their differentiated cells expressed GFP, whereas neither of them expressed GFP in the Wt-derived epithelium. Our results provide direct evidence that stem cells that generate the adult intestinal epithelium originate from the larval epithelium, through thyroid hormone-induced dedifferentiation.-Ishizuya-Oka, A., Hasebe, T., Buchholz, D. R., Kajita, M., Fu, L., Shi, Y.-B. The origin of the adult intestinal stem cells induced by thyroid hormone in Xenopus laevis. FASEB J. 23, 2568-2575 (2009)	[Ishizuya-Oka, Atsuko] Nippon Med Sch, Dept Biol, Nakahara Ku, Kanagawa 2210063, Japan; [Ishizuya-Oka, Atsuko; Kajita, Mitsuko] Nippon Med Sch, Inst Dev & Aging Sci, Kanagawa 2210063, Japan; [Buchholz, Daniel R.] Univ Cincinnati, Dept Biol Sci, Cincinnati, OH 45221 USA; [Fu, Liezhen; Shi, Yun-Bo] NICHHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	Nippon Medical School; Nippon Medical School; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Ishizuya-Oka, A (corresponding author), Nippon Med Sch, Dept Biol, Nakahara Ku, 2-297-2 Kosugi Cho, Kanagawa 2210063, Japan.	a-oka@nms.ac.jp		Shi, Yun-Bo/0000-0002-6330-0639; Hasebe, Takashi/0000-0001-7200-8173	Japan Society for the Promotion of Science [20570060]; National Institute of Child Health and Human Development, U.S. National Institutes of Health; Grants-in-Aid for Scientific Research [20570060] Funding Source: KAKEN; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008858] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008858] Funding Source: NIH RePORTER	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); National Institute of Child Health and Human Development, U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank Dr. Dave Turner (University of Michigan, Ann Arbor, MI, USA) and Dr. Gert Jan C. Veenstra (University of Nijmegen, Nijmegen, The Netherlands) for kind gifts of plasmids. This work was supported in part by the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (C) (grant 20570060 to A.I.-O.) and in part by the Intramural Research Program of the National Institute of Child Health and Human Development, U.S. National Institutes of Health (to Y.-B.S.).	Amano T, 1998, Wound Repair Regen, V6, P302, DOI 10.1046/j.1524-475X.1998.60406.x; Amano T, 1998, DEV GROWTH DIFFER, V40, P177; [Anonymous], 1977, INT REV CYTOL; Barbara PD, 2003, CELL MOL LIFE SCI, V60, P1322, DOI 10.1007/s00018-003-2289-3; BJERKNES M, 1981, AM J ANAT, V160, P77, DOI 10.1002/aja.1001600107; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Buchholz DR, 2007, DEV BIOL, V303, P576, DOI 10.1016/j.ydbio.2006.11.037; Buchholz DR, 2004, MOL CELL BIOL, V24, P9026, DOI 10.1128/MCB.24.20.9026-9037.2004; CHENG H, 1985, ANAT REC, V211, P420, DOI 10.1002/ar.1092110408; DODD MHI, 1977, PHYSL AMPHIBIA, V3, P467; Fu LZ, 2002, MOL REPROD DEV, V62, P470, DOI 10.1002/mrd.10137; Hasebe T, 2008, DEV DYNAM, V237, P3006, DOI 10.1002/dvdy.21698; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Ishizuya-Oka A, 1997, DEV BIOL, V192, P149, DOI 10.1006/dbio.1997.8749; Ishizuya-Oka A, 2000, J CELL BIOL, V150, P1177, DOI 10.1083/jcb.150.5.1177; Ishizuya-Oka A, 2003, J CELL SCI, V116, P3157, DOI 10.1242/jcs.00616; Ishizuya-Oka A, 2001, DIFFERENTIATION, V69, P27, DOI 10.1046/j.1432-0436.2001.690103.x; Ishizuya-Oka A, 2007, DEV DYNAM, V236, P3358, DOI 10.1002/dvdy.21291; IshizuyaOka A, 1996, CELL TISSUE RES, V286, P467, DOI 10.1007/s004410050716; ISHIZUYAOKA A, 1991, IN VITRO CELL DEV B, V27, P853; ISHIZUYAOKA A, 1992, ROUX ARCH DEV BIOL, V201, P322, DOI 10.1007/BF00592113; Kayahara T, 2003, FEBS LETT, V535, P131, DOI 10.1016/S0014-5793(02)03896-6; KIKUYAMA S, 1993, INT REV CYTOL, V145, P105, DOI 10.1016/S0074-7696(08)60426-X; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kroll KL, 1996, DEVELOPMENT, V122, P3173; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; MARSHALL JA, 1978, J ANAT, V126, P133; MARSHALL JA, 1978, J EXP ZOOL, V203, P31, DOI 10.1002/jez.1402030104; MCAVOY JW, 1977, J EXP ZOOL, V202, P129, DOI 10.1002/jez.1402020115; MCAVOY JW, 1978, J ANAT, V125, P155; Mills JC, 2001, P NATL ACAD SCI USA, V98, P12334, DOI 10.1073/pnas.231487198; Mukhi S, 2008, P NATL ACAD SCI USA, V105, P8962, DOI 10.1073/pnas.0803569105; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Offield MF, 2000, DEVELOPMENT, V127, P1789; Okamoto R, 2002, NAT MED, V8, P1011, DOI 10.1038/nm755; Potten CS, 1998, PHILOS T R SOC B, V353, P821, DOI 10.1098/rstb.1998.0246; Potten CS, 2003, DIFFERENTIATION, V71, P28, DOI 10.1046/j.1432-0436.2003.700603.x; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; Schreiber AM, 2005, P NATL ACAD SCI USA, V102, P3720, DOI 10.1073/pnas.0409868102; Shi Y.-B., 1999, AMPHIBIAN METAMORPHO; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; Shi YB, 1996, CURR TOP DEV BIOL, V32, P205, DOI 10.1016/S0070-2153(08)60429-9; SHI YB, 1993, J BIOL CHEM, V268, P20312; Shi YB, 2007, PHARMACOL THERAPEUT, V116, P391, DOI 10.1016/j.pharmthera.2007.07.005; Shimizu K, 2002, DEV GENES EVOL, V212, P357, DOI 10.1007/s00427-002-0250-3; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Su Y, 1997, J CELL BIOL, V139, P1533, DOI 10.1083/jcb.139.6.1533; Suzuki K, 2002, DEV GROWTH DIFFER, V44, P225; TATA JR, 1993, BIOESSAYS, V15, P239, DOI 10.1002/bies.950150404; Utoh R, 2003, DEV DYNAM, V227, P157, DOI 10.1002/dvdy.10302; YOSHIZATO K, 1989, INT REV CYTOL, V119, P97; Yoshizato K, 2007, INT REV CYTOL, V260, P213, DOI 10.1016/S0074-7696(06)60005-3	52	59	61	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2568	2575		10.1096/fj.08-128124	http://dx.doi.org/10.1096/fj.08-128124			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19299481	Green Published			2022-12-28	WOS:000268836700025
J	Lohner, S; Walev, I; Boukhallouk, F; Palmer, M; Bhakdi, S; Valeva, A				Loehner, Sabine; Walev, Iwan; Boukhallouk, Fatima; Palmer, Michael; Bhakdi, Sucharit; Valeva, Angela			Pore formation by Vibrio cholerae cytolysin follows the same archetypical mode as beta-barrel toxins from gram-positive organisms	FASEB JOURNAL			English	Article						prepore; assembly intermediate; membrane perforation; microbial pathogenicity	STAPHYLOCOCCAL ALPHA-HEMOLYSIN; CHOLESTEROL-DEPENDENT CYTOLYSIN; HEPTAMERIC TRANSMEMBRANE PORE; EL-TOR CYTOLYSIN; NUCLEOTIDE-SEQUENCE; INTERMEDIATE STAGES; GAMMA-HEMOLYSIN; FORMING TOXIN; MEMBRANE; INSERTION	Vibrio cholerae cytolysin (VCC) forms SDS- stable heptameric beta-barrel transmembrane pores in mammalian cell membranes. In contrast to structurally related pore formers of gram-positive organisms, no oligomeric prepore stage of assembly has been detected to date. In the present study, disulfide bonds were engineered to tie the pore-forming amino acid sequence to adjacent domains. In their nonreduced form, mutants were able to bind to rabbit erythrocytes and to native erythrocyte membranes suspended in PBS solution and form SDS-labile oligomers. These remained nonfunctional and represented the long-sought VCC prepores. Disulfide bond reduction in these oligomers released the pore-forming sequence from its locked position, and subsequent membrane insertion led to formation of SDS-stable pores and hemolysis. Addition of increasing amounts of an inactive mutant to wild-type toxin resulted in the formation of mixed oligomers with progressively reduced SDS stability on membranes. Membrane insertion of active monomers in these hybrid oligomers was still observed, but the functional pore diameter was reduced. These findings indicate that formation of an oligomeric prepore precedes membrane insertion of the pore-forming amino acid sequence and demonstrate that pore formation by VCC follows the same archetypical pathway as beta-barrel cytolysins of gram-positive organisms such as staphylococcal alpha-toxin.-Lohner, S., Walev, I., Boukhallouk, F., Palmer, M., Bhakdi, S., Valeva, A. Pore formation by Vibrio cholerae cytolysin follows the same archetypical mode as beta-barrel toxins from gram-positive organisms. FASEB J. 23, 2521-2528 (2009)	[Loehner, Sabine; Walev, Iwan; Boukhallouk, Fatima; Bhakdi, Sucharit; Valeva, Angela] Johannes Gutenberg Univ Mainz, Inst Med Microbiol & Hyg, D-55131 Mainz, Germany; [Palmer, Michael] Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada	Johannes Gutenberg University of Mainz; University of Waterloo	Bhakdi, S (corresponding author), Johannes Gutenberg Univ Mainz, Inst Med Microbiol & Hyg, Augustuspl, D-55131 Mainz, Germany.	sbhakdi@uni-mainz.de			Deutsche Forschungsgemeinschaft [SFB 490]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This study was supported by the Deutsche Forschungsgemeinschaft, grant SFB 490, Project D3.	Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; Cormack B., 2001, CURR PROTOC MOL BIOL; Furini S, 2008, BIOPHYS J, V95, P2265, DOI 10.1529/biophysj.107.127019; Gouaux E, 1997, PROTEIN SCI, V6, P2631; HIRONO I, 1993, MICROB PATHOGENESIS, V15, P269, DOI 10.1006/mpat.1993.1077; HIRONO I, 1991, MICROB PATHOGENESIS, V11, P189, DOI 10.1016/0882-4010(91)90049-G; Hotze EM, 2001, J BIOL CHEM, V276, P8261, DOI 10.1074/jbc.M009865200; Iacovache I, 2006, EMBO J, V25, P457, DOI 10.1038/sj.emboj.7600959; Kawate T, 2003, PROTEIN SCI, V12, P997, DOI 10.1110/ps.0231203; Montoya M, 2003, BBA-BIOMEMBRANES, V1609, P19, DOI 10.1016/S0005-2736(02)00663-6; Nagamune K, 1996, INFECT IMMUN, V64, P4655, DOI 10.1128/IAI.64.11.4655-4658.1996; Nagamune K, 1997, J BIOL CHEM, V272, P1338, DOI 10.1074/jbc.272.2.1338; Nguyen VT, 2002, MOL MICROBIOL, V45, P1485, DOI 10.1046/j.1365-2958.2002.03125.x; Olson R, 2005, J MOL BIOL, V350, P997, DOI 10.1016/j.jmb.2005.05.045; Olson R, 2003, PROTEIN SCI, V12, P379, DOI 10.1110/ps.0231703; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Shepard LA, 2000, BIOCHEMISTRY-US, V39, P10284, DOI 10.1021/bi000436r; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Valeva A, 2005, MOL MICROBIOL, V57, P124, DOI 10.1111/j.1365-2958.2005.04684.x; Valeva A, 2004, J BIOL CHEM, V279, P25143, DOI 10.1074/jbc.M313913200; Valeva A, 1997, BIOCHEMISTRY-US, V36, P13298, DOI 10.1021/bi971075r; Valeva A, 2001, J BIOL CHEM, V276, P14835, DOI 10.1074/jbc.M100301200; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; YAMAMOTO K, 1990, INFECT IMMUN, V58, P4106, DOI 10.1128/IAI.58.12.4106-4116.1990; YAMAMOTO K, 1990, INFECT IMMUN, V58, P2706, DOI 10.1128/IAI.58.8.2706-2709.1990; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375; ZITZER A, 1995, MED MICROBIOL IMMUN, V184, P37, DOI 10.1007/BF00216788; Zitzer A, 1997, EUR J BIOCHEM, V247, P209, DOI 10.1111/j.1432-1033.1997.00209.x; Zitzer A, 2000, BBA-BIOMEMBRANES, V1509, P264, DOI 10.1016/S0005-2736(00)00303-5; ZITZER AO, 1993, ZBL BAKT-INT J MED M, V279, P494, DOI 10.1016/S0934-8840(11)80421-4	32	18	18	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2521	2528		10.1096/fj.08-127688	http://dx.doi.org/10.1096/fj.08-127688			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19276173				2022-12-28	WOS:000268836700020
J	Planel, E; Bretteville, A; Liu, L; Virag, L; Du, AL; Yu, WH; Dickson, DW; Whittington, RA; Duff, KE				Planel, Emmanuel; Bretteville, Alexis; Liu, Li; Virag, Laszlo; Du, Angela L.; Yu, Wai Haung; Dickson, Dennis W.; Whittington, Robert A.; Duff, Karen E.			Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia	FASEB JOURNAL			English	Article						Alzheimer's disease; hypothermia; tau hyperphosphorylation; microtubules	GLYCOGEN-SYNTHASE KINASE-3-BETA; PAIRED HELICAL FILAMENTS; PROTEIN PHOSPHATASE 2A; ALZHEIMERS-DISEASE; TAU-PROTEIN; IN-VIVO; STABLE MICROTUBULES; P301L TAU; PHOSPHORYLATION; KINASE	Alzheimer's disease and other tauopathies are characterized by the presence of intracellular neurofibrillary tangles composed of hyperphosphorylated, insoluble tau. General anesthesia has been shown to be associated with increased risk of Alzheimer's disease, and we have previously demonstrated that anesthesia induces hypothermia, which leads to overt tau hyperphosphorylation in the brain of mice regardless of the anesthetic used. To investigate whether anesthesia enhances the long-term risk of developing pathological forms of tau, we exposed a mouse model with tauopathy to anesthesia and monitored the outcome at two time points-during anesthesia, or 1 wk after exposure. We found that exposure to isoflurane at clinically relevant doses led to increased levels of phospho-tau, increased insoluble, aggregated forms of tau, and detachment of tau from microtubules. Furthermore, levels of phospho-tau distributed in the neuropil, as well as in cell bodies increased. Interestingly, the level of insoluble tau was increased 1 wk following anesthesia, suggesting that anesthesia precipitates changes in the brain that provoke the later development of tauopathy. Overall, our results suggest that anesthesia-induced hypothermia could lead to an acceleration of tau pathology in vivo that could have significant clinical implications for patients with early stage, or overt neurofibrillary tangle pathology.-Planel, E., Bretteville, A., Liu, L., Virag, L., Du, A. L., Yu, W. Y., Dickson, D. W., Whittington, R. A., Duff, K. E. Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J. 23, 2595-2604 ( 2009)	[Planel, Emmanuel; Bretteville, Alexis; Liu, Li; Du, Angela L.; Yu, Wai Haung; Duff, Karen E.] Columbia Univ, Med Ctr, Dept Pathol, Taub Inst Alzheimers Dis Res, New York, NY 10032 USA; [Planel, Emmanuel] Univ Laval, Ctr Hosp Univ Quebec, Ctr Hosp Univ Laval, Quebec City, PQ, Canada; [Virag, Laszlo; Whittington, Robert A.] Columbia Univ, Med Ctr, Dept Anesthesiol, New York, NY 10032 USA; [Planel, Emmanuel; Duff, Karen E.] New York State Psychiat Inst & Hosp, Dept Integrat Neurosci, New York, NY 10032 USA; [Dickson, Dennis W.] Mayo Clin Jacksonville, Dept Pathol & Neurosci, Jacksonville, FL 32224 USA	Columbia University; Laval University; Columbia University; New York State Psychiatry Institute; Mayo Clinic	Duff, KE (corresponding author), Columbia Univ, Med Ctr, Dept Pathol, Taub Inst Alzheimers Dis Res, P&S Bldg 12-461,630 W 168th St, New York, NY 10032 USA.	ked2115@columbia.edu	Duff, Karen EK/C-2510-2009	Dickson, Dennis W/0000-0001-7189-7917; Yu, Wai Haung/0000-0001-7186-6731; Duff, Karen/0000-0002-6177-868X; Planel, Emmanuel/0000-0001-5128-0565	Institute for the Study of Aging/Alzheimer's Drug Discovery Foundation; National Institute of Neurological Disorders and Stroke [NS048447]; National Institute on Aging [AG017216]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS048447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017216] Funding Source: NIH RePORTER	Institute for the Study of Aging/Alzheimer's Drug Discovery Foundation; National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors are grateful to Dr. Jada Lewis ( Mayo Clinic, Jacksonville, FL, USA) for help with the motor function analysis. We thank Dr. Peter Davies (Albert Einstein College of Medicine, Bronx, NY, USA) for the generous gift of antibodies. We are also grateful to Helen Y. Figueroa and Mathieu Herman for technical help. This work was supported by an Institute for the Study of Aging/Alzheimer's Drug Discovery Foundation grant ( to E. P.), a National Institute of Neurological Disorders and Stroke grant (NS048447), and a National Institute on Aging grant (AG017216; to K. E. D.).	Ancelin ML, 2001, BRIT J PSYCHIAT, V178, P360, DOI 10.1192/bjp.178.4.360; Avila J, 2004, NAT MED, V10, P460, DOI 10.1038/nm0504-460; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; Bianchi SL, 2008, NEUROBIOL AGING, V29, P1002, DOI 10.1016/j.neurobiolaging.2007.02.009; BOHNEN N, 1994, INT J NEUROSCI, V77, P181, DOI 10.3109/00207459408986029; Bone I, 2000, ANAESTHESIA, V55, P592, DOI 10.1046/j.1365-2044.2000.01479-5.x; Bretteville A, 2008, J ALZHEIMERS DIS, V14, P431; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Eckenhoff RG, 2004, ANESTHESIOLOGY, V101, P703, DOI 10.1097/00000542-200409000-00019; ECKENHOFF RG, 2007, CELL SCI REV, V4, P78; Fujishiro H, 2008, ACTA NEUROPATHOL, V116, P17, DOI 10.1007/s00401-008-0383-1; Giannakopoulos P, 2003, NEUROLOGY, V60, P1495, DOI 10.1212/01.WNL.0000063311.58879.01; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GURLAND G, 1993, P NATL ACAD SCI USA, V90, P8827, DOI 10.1073/pnas.90.19.8827; Holtzmam A, 2000, MED HYPOTHESES, V55, P440, DOI 10.1054/mehy.2000.1085; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Johansson C, 1996, AGING CLIN EXP RES, V8, P189, DOI 10.1007/BF03339676; Kim D, 1999, BRAIN RES, V839, P253, DOI 10.1016/S0006-8993(99)01724-2; Ksiezak-Reding H, 2003, BBA-MOL BASIS DIS, V1639, P159, DOI 10.1016/j.bbadis.2003.09.001; LAMY C, 1989, NEUROPATH APPL NEURO, V15, P563, DOI 10.1111/j.1365-2990.1989.tb01255.x; Levy SF, 2005, J BIOL CHEM, V280, P13520, DOI 10.1074/jbc.M413490200; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; Merrick SE, 1997, J NEUROSCI, V17, P5726; Noble W, 2005, P NATL ACAD SCI USA, V102, P6990, DOI 10.1073/pnas.0500466102; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Planel E, 2002, DRUG DEVELOP RES, V56, P491, DOI 10.1002/ddr.10100; Planel E, 2001, J BIOL CHEM, V276, P34298, DOI 10.1074/jbc.M102780200; Planel E, 2004, J NEUROSCI, V24, P2401, DOI 10.1523/JNEUROSCI.5561-03.2004; Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007; Planel E, 2008, J NEUROSCI, V28, P12798, DOI 10.1523/JNEUROSCI.4101-08.2008; REES DI, 1985, TEX MED, V81, P45; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Ritchie K, 1997, Int Psychogeriatr, V9, P309, DOI 10.1017/S1041610297004468; Sahara N, 2002, J NEUROCHEM, V83, P1498, DOI 10.1046/j.1471-4159.2002.01241.x; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sessler DI, 2000, ANESTHESIOLOGY, V92, P578, DOI 10.1097/00000542-200002000-00042; Sironi JJ, 1998, FEBS LETT, V436, P471, DOI 10.1016/S0014-5793(98)01185-5; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; Tolivia J, 2006, ANAL QUANT CYTOL, V28, P43; TROJANOWSKI JQ, 1994, AM J PATHOL, V144, P449; Weaver CL, 2000, NEUROBIOL AGING, V21, P719, DOI 10.1016/S0197-4580(00)00157-3; Xie ZC, 2006, ANESTHESIOLOGY, V104, P988, DOI 10.1097/00000542-200605000-00015; Xie ZC, 2006, EXP GERONTOL, V41, P346, DOI 10.1016/j.exger.2006.01.014; Zhu XW, 2002, NEUROSIGNALS, V11, P270, DOI 10.1159/000067426	52	99	104	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2595	2604		10.1096/fj.08-122424	http://dx.doi.org/10.1096/fj.08-122424			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19279139	Green Published			2022-12-28	WOS:000268836700028
J	Trikalinos, TA				Trikalinos, Thomas A.			Does it mean anything if your own name is wrong in your published paper?	FASEB JOURNAL			English	Article						errors; errata; galley proofs; sloppiness	PROOFS	Journals instruct authors to proofread their accepted manuscripts before signing them off for publication and expect them to submit errata to correct any mistakes identified thereafter. Herein, I examine papers with obvious errors in the author name list. I queried PubMed for papers under common Greek forenames looking for citations where author surnames and forenames are swapped. I identified 113 such papers from 101 journals. Author names are corrected with errata only in 20, after a median of 6.5 mo. Time to name correction is shorter for journals with impact factor above the median (P=0.015). To further explore this suggested association of apparent author sloppiness with journal impact, I use as controls all errata published between 1996 and 2008 in 5 top-cited general medical journals ( New England Journal of Medicine, JAMA, The Lancet, Annals of Internal Medicine, and British Medical Journal); 3.4% of the latter contain name corrections (vs. 18.1% of all errata in the 101 journals during the same period, P<10(-6)). Egregious errors may be markers of cursory if any proofreading and, therefore, markers for additional unidentified inaccuracies. In addition, I wonder whether authors may be as reluctant to rectify other, nonobvious (yet potentially consequential) mistakes after a paper's publication. -Trikalinos, T. A. Does it mean anything if your own name is wrong in your published paper? FASEB J. 23, 2345-2348 (2009)	Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Clin Evidence Synth, Boston, MA 02111 USA	Tufts Medical Center	Trikalinos, TA (corresponding author), Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Clin Evidence Synth, 800 Washington St,Box 63, Boston, MA 02111 USA.	ttrikalin@mac.com						Janse MJ, 2002, CARDIOVASC RES, V55, P236, DOI 10.1016/S0008-6363(02)00485-6; Kalambokis G, 2005, DIGEST DIS SCI, V50, P1771, DOI 10.1007/s10620-005-2935-8; Kalambokis G, 2005, J GASTROEN HEPATOL, V20, P1075, DOI 10.1111/j.1440-1746.2005.03902.x; Lygidakis NJ, 2002, ANN SURG, V236, P806, DOI 10.1097/00000658-200212000-00013; MEZWA D, 1993, DIS COLON RECTUM, V36, P309, DOI 10.1007/BF02053520; Vassilis P, 2008, J STRENGTH COND RES, V22, P1222, DOI 10.1519/JSC.0b013e318173da21	6	6	7	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2009	23	8					2345	2348		10.1096/fj.09-130922	http://dx.doi.org/10.1096/fj.09-130922			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19289602				2022-12-28	WOS:000268836700002
J	Wang, XX; Wu, YT; Zhou, B				Wang, Xiaoxi; Wu, Yuantai; Zhou, Bing			Dietary zinc absorption is mediated by ZnT1 in Drosophila melanogaster	FASEB JOURNAL			English	Article						dZnT1, metallothionein; midgut constriction; basolateral membrane	TRANSCRIPTION FACTOR MTF-1; OF-INTIMACY ENCODES; MAMMALIAN ZINC; CONFERS RESISTANCE; FUNCTIONAL-CHARACTERIZATION; GONAD MORPHOGENESIS; COPPER HOMEOSTASIS; MENKES PROTEIN; TRANSPORTER; GENE	Zinc is an essential nutritional factor involved in many key biological processes. However, the physiological function of zinc transporters at the organismal level is not well characterized. Early embryonic lethality of Znt1 knockout mice precludes functional analysis of the role of ZnT1 in dietary zinc absorption. Here, we report the identification and characterization of the Drosophila ZnT1 orthologue, dZnT1, for its role in Drosophila dietary zinc absorption. In cell culture, dZnT1 promoted zinc transport to reduce cytoplasmic zinc levels. Ubiquitous RNA interference of dZnT1 in Drosophila resulted in developmental arrest under restriction of dietary zinc, while dZnT1-overexpressing flies exhibited hypersensitivity to zinc. dZnT1 was prominently expressed in restricted regions of the midgut and exhibited a distribution on the basolateral membrane of the enterocytes. Gut-specific silencing of dZnT1 was sufficient to evoke lethality under zinc scarcity. Human ZnT1, but not ZnT7 or ZnT4, could rescue the zinc-acquiring defects caused by dZnT1 silencing. Taken together, our results proved that dZnT1 is a key zinc transporter in dietary zinc absorption, functioning by pumping zinc out of the enterocytes across the basolateral membrane. This study will be helpful in understanding the fundamental process of acquiring dietary zinc in higher eukaryotes.-Wang, X., Wu, Y., Zhou, B. Dietary zinc absorption is mediated by ZnT1 in Drosophila melanogaster. FASEB J. 23, 2650-2661 (2009)	[Wang, Xiaoxi; Wu, Yuantai; Zhou, Bing] Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China	Tsinghua University	Zhou, B (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China.	zhoubing@mail.tsinghua.edu.cn	Wang, Xiaoxi/C-7178-2015	Wang, Xiaoxi/0000-0002-2232-8504	National Basic Research Program of China [2005CB522503]; National Scientific Foundation of China [30688001]	National Basic Research Program of China(National Basic Research Program of China); National Scientific Foundation of China(National Natural Science Foundation of China (NSFC))	We greatly appreciate the kind gifts of fly stocks from Dr. Walter Schaffner ( University of Zurich, Zurich, Switzerland) and Dr. Craig Montell ( Johns Hopkins University School of Medicine, Baltimore, MD, USA); Drosophila S2 cells and expression vector pPac5c-PL from Dr. Hong Luo (Tsinghua University, Beijing, China). We are also grateful to the Bloomington Stock Center, the Drosophila Genetic Resource Center at the Kyoto Institute of Technology, Flytrap, and the Vienna Drosophila RNAi Center for fly stocks. This work was supported by the National Basic Research Program of China (2005CB522503) and by the National Scientific Foundation of China (30688001). We thank Sumin Guo for assistance in Drosophila microinjection and Wen Lu for help in antibody preparation.	Aarskog NK, 2000, HUM GENET, V107, P494, DOI 10.1007/s004390000399; Andrews GK, 2004, GENESIS, V40, P74, DOI 10.1002/gene.20067; BAER MT, 1984, AM J CLIN NUTR, V39, P556, DOI 10.1093/ajcn/39.4.556; Balamurugan K, 2007, EMBO J, V26, P1035, DOI 10.1038/sj.emboj.7601543; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Brenner R, 1997, COMP BIOCHEM PHYS B, V118, P411, DOI 10.1016/S0305-0491(97)00167-3; BREWER GJ, 1990, J AM COLL NUTR, V9, P487, DOI 10.1080/07315724.1990.10720405; BRUGGER C, 1974, J INSECT PHYSIOL, V20, P121, DOI 10.1016/0022-1910(74)90128-0; Bruinsma JJ, 2002, DEV CELL, V2, P567, DOI 10.1016/S1534-5807(02)00151-X; Carstens J, 1997, CLIN CHEM, V43, P638; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Cousins RJ, 2006, J BIOL CHEM, V281, P24085, DOI 10.1074/jbc.R600011200; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P33474, DOI 10.1074/jbc.M305000200; DURLIAT M, 1995, BIOMETALS, V8, P339; Egli D, 2006, MOL CELL BIOL, V26, P2286, DOI 10.1128/MCB.26.6.2286-2296.2006; Egli D, 2003, EMBO J, V22, P100, DOI 10.1093/emboj/cdg012; Egli D, 2006, GENES CELLS, V11, P647, DOI 10.1111/j.1365-2443.2006.00971.x; Eide DJ, 2006, BBA-MOL CELL RES, V1763, P711, DOI 10.1016/j.bbamcr.2006.03.005; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Huang L, 2007, J BIOL CHEM, V282, P37053, DOI 10.1074/jbc.M706631200; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Inoue K, 2002, HUM MOL GENET, V11, P1775, DOI 10.1093/hmg/11.15.1775; JARIAL MS, 1987, TISSUE CELL, V19, P559, DOI 10.1016/0040-8166(87)90048-6; Kalidas S, 2002, NEURON, V33, P177, DOI 10.1016/S0896-6273(02)00560-3; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Kim AH, 2000, BRAIN RES, V886, P99, DOI 10.1016/S0006-8993(00)02944-9; King JC, 2000, J NUTR, V130, p1360S, DOI 10.1093/jn/130.5.1360S; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Kumanovics A, 2006, J BIOL CHEM, V281, P22566, DOI 10.1074/jbc.M604730200; Kury S, 2002, NAT GENET, V31, P239, DOI 10.1038/ng913; Lai EC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r42; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Liuzzi JP, 2004, ANNU REV NUTR, V24, P151, DOI 10.1146/annurev.nutr.24.012003.132402; Lutsenko S, 2007, PHYSIOL REV, V87, P1011, DOI 10.1152/physrev.00004.2006; MacDonald RS, 2000, J NUTR, V130, p1500S, DOI 10.1093/jn/130.5.1500S; Mathews WR, 2006, DEVELOPMENT, V133, P1143, DOI 10.1242/dev.02256; Mathews WR, 2005, J BIOL CHEM, V280, P787, DOI 10.1074/jbc.M411308200; McMahon RJ, 1998, P NATL ACAD SCI USA, V95, P4841, DOI 10.1073/pnas.95.9.4841; McNulty M, 2001, CELL TISSUE RES, V304, P383, DOI 10.1007/s004410100371; Mehta A, 2008, BIOCHEM SOC T, V36, P1313, DOI 10.1042/BST0361313; Michalczyk AA, 2002, BIOCHEM J, V364, P105, DOI 10.1042/bj3640105; Missirlis F, 2007, GENETICS, V177, P89, DOI 10.1534/genetics.107.075150; Monty JF, 2005, J NUTR, V135, P2762, DOI 10.1093/jn/135.12.2762; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Murgia C, 1999, AM J PHYSIOL-GASTR L, V277, pG1231, DOI 10.1152/ajpgi.1999.277.6.G1231; Naito Y, 2005, NUCLEIC ACIDS RES, V33, pW589, DOI 10.1093/nar/gki419; Norgate M, 2006, MOL BIOL CELL, V17, P475, DOI 10.1091/mbc.E05-06-0492; Nyasae L, 2007, AM J PHYSIOL-GASTR L, V292, pG1181, DOI 10.1152/ajpgi.00472.2006; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Pielage J, 2004, DEV BIOL, V275, P245, DOI 10.1016/j.ydbio.2004.07.039; Poulsen D. F., 1952, Experimental Cell Research New York Supplement, VNo. 2, P161; Sekler I, 2007, MOL MED, V13, P337, DOI 10.2119/2007-00037.Sekler; Selvaraj A, 2005, GENE DEV, V19, P891, DOI 10.1101/gad.1301805; Turski ML, 2007, J BIOL CHEM, V282, P24017, DOI 10.1074/jbc.M703792200; Valentine RA, 2007, J BIOL CHEM, V282, P14389, DOI 10.1074/jbc.M701752200; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Van Doren M, 2003, DEVELOPMENT, V130, P2355, DOI 10.1242/dev.00454; VANCAMPEN DR, 1965, J NUTR, V86, P120, DOI 10.1093/jn/86.2.120; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; Wang T, 2007, J CELL BIOL, V177, P305, DOI 10.1083/jcb.200610081; Yepiskoposyan H, 2006, NUCLEIC ACIDS RES, V34, P4866, DOI 10.1093/nar/gkl606; Yu YY, 2007, J HISTOCHEM CYTOCHEM, V55, P223, DOI 10.1369/jhc.6A7032.2006; Zhou H, 2003, J BIOL CHEM, V278, P48210, DOI 10.1074/jbc.M309820200	66	64	66	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2650	2661		10.1096/fj.08-126649	http://dx.doi.org/10.1096/fj.08-126649			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19325039				2022-12-28	WOS:000268836700033
J	Kienhofer, J; Haussler, DJF; Ruckelshausen, F; Muessig, E; Weber, K; Pimentel, D; Ullrich, V; Burkle, A; Bachschmid, MM				Kienhoefer, Joachim; Haeussler, Dagmar Johanna Franziska; Ruckelshausen, Florian; Muessig, Elisabeth; Weber, Klaus; Pimentel, David; Ullrich, Volker; Buerkle, Alexander; Bachschmid, Markus Michael			Association of mitochondrial antioxidant enzymes with mitochondrial DNA as integral nucleoid constituents	FASEB JOURNAL			English	Article						SOD2; nucleoid complex; aging; smooth muscle cell; TFAM; Pol gamma	TRANSCRIPTION-FACTOR-A; MANGANESE SUPEROXIDE-DISMUTASE; NITROCELLULOSE-FILTER BINDING; RAT-LIVER MITOCHONDRIA; ESCHERICHIA-COLI K-12; SMOOTH-MUSCLE-CELLS; OXIDATIVE STRESS; SACCHAROMYCES-CEREVISIAE; PROSTANOID SYNTHESIS; REDOX REGULATION	Mitochondrial DNA ( mtDNA) is organized in protein-DNA macrocomplexes called nucleoids. Average nucleoids contain 2-8 mtDNA molecules, which are organized by the histone-like mitochondrial transcription factor A. Besides well-characterized constituents, such as single-stranded binding protein or polymerase gamma (Pol gamma), various other proteins with ill-defined functions have been identified. We report for the first time that mammalian nucleoids contain essential enzymes of an integral antioxidant system. Intact nucleoids were isolated with sucrose density gradients from rat and bovine heart as well as human Jurkat cells. Manganese superoxide dismutase (SOD2) was detected by Western blot in the nucleoid fractions. DNA, mitochondrial glutathione peroxidase (GPx1), and Pol gamma were coimmunoprecipitated with SOD2 from nucleoid fractions, which suggests that an antioxidant system composed of SOD2 and GPx1 are integral constituents of nucleoids. Interestingly, in cultured bovine endothelial cells the association of SOD2 with mtDNA was absent. Using a sandwich filter-binding assay, direct association of SOD2 by salt-sensitive ionic forces with a chemically synthesized mtDNA fragment was demonstrated. Increasing salt concentrations during nucleoid isolation on sucrose density gradients disrupted the association of SOD2 with mitochondrial nucleoids. Our biochemical data reveal that nucleoids contain an integral antioxidant system that may protect mtDNA from superoxide-induced oxidative damage.-Kienhofer, J., Haussler, D. J. F., Ruckelshausen, F., Muessig, E., Weber, K., Pimentel, D., Ullrich, V., Burkle, A., Bachschmid, M. M. Association of mitochondrial antioxidant enzymes with mitochondrial DNA as integral nucleoid constituents. FASEB J. 23, 2034-2044 (2009)	[Haeussler, Dagmar Johanna Franziska; Bachschmid, Markus Michael] Boston Univ, Med Ctr, Vasc Biol Unit, Boston, MA 02118 USA; [Kienhoefer, Joachim; Ruckelshausen, Florian; Muessig, Elisabeth; Ullrich, Volker; Buerkle, Alexander] Univ Konstanz, Dept Biol, Constance, Germany; [Pimentel, David] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Myocardial Unit, Boston, MA 02118 USA; [Weber, Klaus] Herz Zentrum Bodensee, Kreuzlingen, Switzerland	Boston University; University of Konstanz; Boston University	Bachschmid, MM (corresponding author), Boston Univ, Med Ctr, Vasc Biol Unit, X726,650 Albany St, Boston, MA 02118 USA.	bach@bu.edu	Ruckelshausen, Florian/E-8194-2014; Weber, Klaus/P-8241-2019	Ruckelshausen, Florian/0000-0002-2942-606X; Weber, Klaus/0000-0002-2421-6178; Pimentel, David/0000-0002-0537-7195; Bachschmid, Markus Michael/0000-0002-0748-5528	Deutsche Forschungsgemeinschaft [BU 698/6-1]; Whitaker Cardiovascular Institute; NIH [R01 AG027080-04, P01 HL081738-03, K08HL071563]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL081587, K08HL071563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027080] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Whitaker Cardiovascular Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr. Elisa Ferrando-May for assistance with the confocal microscope, Dr. Rudolf J. Wiesner (University of Heidelberg, Heidelberg, Germany) for supplying the anti-TFAM antibody, Dr. W. Hofer for assisting with the MDH activity assays, Rebecca Zee and Alicia Evangelista for preparing the manuscript, and Dr. Richard A. Cohen for his support. This work was supported by grant BU 698/6-1 of the Deutsche Forschungsgemeinschaft (DFG). D. J. F. H. and M. M. B. were supported by the Whitaker Cardiovascular Institute and NIH grants R01 AG027080-04 and P01 HL081738-03. D. P. was supported by NIH grant K08HL071563.	Aime S, 2003, BIOCHEM BIOPH RES CO, V307, P962, DOI 10.1016/S0006-291X(03)01307-X; ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955; ANNEX BH, 1990, MOL CELL BIOL, V10, P5671, DOI 10.1128/MCB.10.11.5671; Bachschmid M, 2005, BIOCHEM BIOPH RES CO, V338, P536, DOI 10.1016/j.bbrc.2005.08.157; Ballinger SW, 2002, CIRCULATION, V106, P544, DOI 10.1161/01.CIR.0000023921.93743.89; Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960; Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200; Bogenhagen DF, 2003, MOL CELL PROTEOMICS, V2, P1205, DOI 10.1074/mcp.M300035-MCP200; Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7; Brown KA, 2007, ARTERIOSCL THROM VAS, V27, P1941, DOI 10.1161/ATVBAHA.107.146852; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Casteilla L, 2001, IUBMB LIFE, V52, P181, DOI 10.1080/15216540152845984; Chen XJ, 2005, SCIENCE, V307, P714, DOI 10.1126/science.1106391; Czerwinski JD, 2005, ANAL BIOCHEM, V336, P300, DOI 10.1016/j.ab.2004.10.029; Dinardo MM, 2003, BIOCHEM BIOPH RES CO, V301, P187, DOI 10.1016/S0006-291X(02)03008-5; Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; Faraci FM, 2004, ARTERIOSCL THROM VAS, V24, P1367, DOI 10.1161/01.ATV.0000133604.20182.cf; Finsterer J, 2006, NETH J MED, V64, P61; FISHER RP, 1992, J BIOL CHEM, V267, P3358; Frein D, 2005, BIOCHEM PHARMACOL, V70, P811, DOI 10.1016/j.bcp.2005.04.012; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; Garstka HL, 2003, NUCLEIC ACIDS RES, V31, P5039, DOI 10.1093/nar/gkg717; GARSTKA HL, 1994, BIOCHEM BIOPH RES CO, V200, P619, DOI 10.1006/bbrc.1994.1493; Gensler S, 2001, NUCLEIC ACIDS RES, V29, P3657, DOI 10.1093/nar/29.17.3657; Gouliaeva NA, 2006, BIOFIZIKA+, V51, P692; Grivennikova VG, 2006, BBA-BIOENERGETICS, V1757, P553, DOI 10.1016/j.bbabio.2006.03.013; He JY, 2007, J CELL BIOL, V176, P141, DOI 10.1083/jcb.200609158; Hobbs AEA, 2001, J CELL BIOL, V152, P401, DOI 10.1083/jcb.152.2.401; HOKE GD, 1990, ARCH BIOCHEM BIOPHYS, V282, P116, DOI 10.1016/0003-9861(90)90094-F; HOPKIN KA, 1992, J BIOL CHEM, V267, P24253; Ide T, 1999, CIRC RES, V85, P357, DOI 10.1161/01.RES.85.4.357; Jeng JY, 2008, J CELL BIOCHEM, V103, P347, DOI 10.1002/jcb.21625; Kang D, 2005, ANN NY ACAD SCI, V1042, P101, DOI 10.1196/annals.1338.010; Kang D, 2007, MITOCHONDRION, V7, P39, DOI 10.1016/j.mito.2006.11.017; Kanki T, 2004, ANN NY ACAD SCI, V1011, P61, DOI 10.1196/annals.1293.007; Kaufman BA, 2007, MOL BIOL CELL, V18, P3225, DOI 10.1091/mbc.E07-05-0404; KEELE BB, 1970, J BIOL CHEM, V245, P6176; Koga Y, 2006, NEUROLOGY, V66, P1766, DOI 10.1212/01.wnl.0000220197.36849.1e; Kondo-Okamoto N, 2003, J BIOL CHEM, V278, P48997, DOI 10.1074/jbc.M308436200; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Lee HC, 1997, J BIOMED SCI, V4, P319, DOI 10.1007/BF02258357; Lee HC, 2007, EXP BIOL MED, V232, P592; Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134; Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x; Leuner K, 2007, ANTIOXID REDOX SIGN, V9, P1659, DOI 10.1089/ars.2007.1763; Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523; Luscombe NM, 2002, J MOL BIOL, V320, P991, DOI 10.1016/S0022-2836(02)00571-5; Madamanchi NR, 2007, CIRC RES, V100, P460, DOI 10.1161/01.RES.0000258450.44413.96; Maniura-Weber K, 2004, NUCLEIC ACIDS RES, V32, P6015, DOI 10.1093/nar/gkh921; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; MIYAKAWA I, 1984, J CELL SCI, V66, P21; MIYAKAWA I, 1987, J CELL SCI, V88, P431; MIYAKAWA I, 1995, PLANT CELL PHYSIOL, V36, P1179; Miyakawa I, 1996, PLANT CELL PHYSIOL, V37, P816, DOI 10.1093/oxfordjournals.pcp.a029017; NASS MMK, 1969, SCIENCE, V165, P25, DOI 10.1126/science.165.3888.25; NASS MMK, 1965, EXP CELL RES, V37, P516, DOI 10.1016/0014-4827(65)90204-1; NEMETH PM, 1981, J PHYSIOL-LONDON, V311, P489, DOI 10.1113/jphysiol.1981.sp013600; OBERLEY LW, 1979, CANCER RES, V39, P1141; Osiewacz HD, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1275; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; PAVCO PA, 1985, J CELL BIOL, V100, P258, DOI 10.1083/jcb.100.1.258; RICHTER C, 1995, INT J BIOCHEM CELL B, V27, P647, DOI 10.1016/1357-2725(95)00025-K; Schapira AHV, 1998, BBA-BIOENERGETICS, V1366, P225, DOI 10.1016/S0005-2728(98)00115-7; Schildknecht S, 2005, BIOCHEM BIOPH RES CO, V327, P43, DOI 10.1016/j.bbrc.2004.11.132; Schildknecht S, 2008, FASEB J, V22, P215, DOI 10.1096/fj.06-8015com; Shadel GS, 2005, TRENDS BIOCHEM SCI, V30, P294, DOI 10.1016/j.tibs.2005.04.007; Shen EL, 2001, NUCLEIC ACIDS RES, V29, P2822, DOI 10.1093/nar/29.13.2822; Silva JP, 2002, BBA-BIOENERGETICS, V1555, P106, DOI 10.1016/S0005-2728(02)00263-3; SPAMER C, 1979, HISTOCHEMISTRY, V60, P9, DOI 10.1007/BF00495725; STEINMAN HM, 1994, J BIOL CHEM, V269, P28629; Trifunovic A, 2008, J INTERN MED, V263, P167, DOI 10.1111/j.1365-2796.2007.01905.x; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; van der Loo B, 2006, BIOCHEM BIOPH RES CO, V344, P972, DOI 10.1016/j.bbrc.2006.03.224; Van Houten B, 2006, DNA REPAIR, V5, P145, DOI 10.1016/j.dnarep.2005.03.002; VANTUYLE GC, 1985, J CELL BIOL, V100, P251, DOI 10.1083/jcb.100.1.251; VANTUYLE GC, 1979, J BIOL CHEM, V254, P6044; Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393; Wang YS, 2006, J BIOL CHEM, V281, P25791, DOI 10.1074/jbc.M604501200; Wei YH, 2001, CHINESE J PHYSIOL, V44, P1; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259	82	60	64	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2034	2044		10.1096/fj.08-113571	http://dx.doi.org/10.1096/fj.08-113571			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19228881	Green Submitted, Green Published			2022-12-28	WOS:000268836500004
J	Liu, YL; Ren, WY; Warburton, R; Toksoz, D; Fanburg, BL				Liu, Yinglin; Ren, Wenying; Warburton, Rod; Toksoz, Deniz; Fanburg, Barry L.			Serotonin induces Rho/ROCK-dependent activation of Smads 1/5/8 in pulmonary artery smooth muscle cells	FASEB JOURNAL			English	Article						5-HT; BMP receptor; pulmonary hypertension; RhoA; 5-HT1B receptor	BONE MORPHOGENETIC PROTEINS; II RECEPTOR; BETA RECEPTOR; HYPERTENSION; GROWTH; KINASE; TRANSACTIVATION; MITOGENESIS; EXPRESSION; MUTATIONS	Serotonin (5-HT) stimulates pulmonary artery smooth muscle cell proliferation and has been associated with pulmonary arterial hypertension (PAH). Bone morphogenetic protein receptor 2 (BMPR2) mutations similarly have been linked to PAH. However, possible crosstalk between 5-HT and BMPR signaling remains poorly characterized. We report here that 5-HT activates Smads 1/5/8 in bovine and human pulmonary artery smooth muscle cells (SMCs) and causes translocation of these Smads from cytoplasm to the nucleus. DN BMPR1A blocked 5-HT activation of Smads 1/5/8 by 5-HT and BMPR1A overexpression enhanced it. Activation of Smads by 5-HT occurred through the 5-HT 1B/1D receptor as it was blocked with the inhibitor GR 55562 but unaffected by inhibitors of the 5-HT transporter and a variety of 5-HT receptors. Activation of the Smads by 5-HT depended on Rho/Rho kinase signaling as it was blocked by Y27632, but unaffected by inhibitors of PI3K or MAPK. Transfection of cells with BMPR1A and ligation of the BMP receptor with BMP-2 also activated GTP-Rho A of these SMCs, while DN BMPR1A blocked the activation. 5-HT stimulated an increase in serine/threonine phosphorylation of BMPR1A, supporting the activation of BMPR1A by 5-HT in SMCs. Infusion of 5-HT into mice with miniosmotic infusion pumps caused activation of Smads 1/5/8 in lung tissue, demonstrating the effect in vivo. The studies support a unique concept that 5-HT trans-activates the serine kinase receptor, BMPR 1A, to activate Smads 1/5/8 via Rho and Rho kinase in pulmonary artery SMCs. Rho and Rho kinase also participate in the activation of Smads by BMP.-Liu, Y., Ren, W., Warburton, R., Toksoz, D., Fanburg, B. L. Serotonin induces Rho/ROCK-dependent activation of Smads 1/5/8 in pulmonary artery smooth muscle cells. FASEB J. 23, 2299-2306 (2009)	[Liu, Yinglin; Ren, Wenying; Warburton, Rod; Toksoz, Deniz; Fanburg, Barry L.] Tufts Med Ctr, Pulm Crit Care & Sleep Div, Tupper Res Inst, Boston, MA 02111 USA	Tufts Medical Center	Fanburg, BL (corresponding author), Tufts Med Ctr, Pulm Crit Care & Sleep Div, Tupper Res Inst, 750 Washington St,257, Boston, MA 02111 USA.	bfanburg@tuftsmedicalcenter.org						Adnot S, 2003, B ACAD NAT MED PARIS, V187, P1529, DOI 10.1016/S0001-4079(19)33889-0; ADNOT S, 2003, B ACAD NATL MED, V187, P1543; Atkinson C, 2002, CIRCULATION, V105, P1672, DOI 10.1161/01.CIR.0000012754.72951.3D; Day RM, 2006, BIOCHEM PHARMACOL, V71, P386, DOI 10.1016/j.bcp.2005.10.035; De Caestecker M, 2001, RESPIR RES, V2, P193; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Eguchi S, 2000, REGUL PEPTIDES, V91, P13, DOI 10.1016/S0167-0115(00)00126-9; Foletta VC, 2003, J CELL BIOL, V162, P1089, DOI 10.1083/jcb.200212060; Grewal JS, 1999, AM J PHYSIOL-RENAL, V276, pF922, DOI 10.1152/ajprenal.1999.276.6.F922; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; HERVE P, 1990, AM J MED, V89, P117, DOI 10.1016/0002-9343(90)90111-P; Jian B, 2002, AM J PATHOL, V161, P2111, DOI 10.1016/S0002-9440(10)64489-6; Kamaraju SK, 2005, J BIOL CHEM, V280, P1024, DOI 10.1074/jbc.M403960200; Kintscher U, 2002, CIRC RES, V91, pE35, DOI 10.1161/01.RES.0000046017.96083.34; LEE SL, 1991, CIRC RES, V68, P1362, DOI 10.1161/01.RES.68.5.1362; Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282, DOI 10.1152/ajplung.1999.277.2.L282; Liu Y, 2008, AM J PHYSIOL-LUNG C, V295, pL471, DOI 10.1152/ajplung.00071.2008; Liu YL, 2007, FASEB J, V21, P2725, DOI 10.1096/fj.06-8058com; Liu YL, 2006, AM J RESP CELL MOL, V34, P182, DOI 10.1165/rcmb.2005-0163OC; Liu YL, 2004, CIRC RES, V95, P579, DOI 10.1161/01.RES.0000141428.53262.a4; Long L, 2006, CIRC RES, V98, P818, DOI 10.1161/01.RES.0000215809.47923.fd; Morse JH, 2001, ANN MED, V33, P596, DOI 10.3109/07853890109002105; Nichol SM, 2005, J VASC SURG, V41, P672, DOI 10.1016/j.jvs.2005.01.007; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Rudarakanchana N, 2002, HUM MOL GENET, V11, P1517, DOI 10.1093/hmg/11.13.1517; SZTRYMF B, 2005, DIFFUSE LUNG DIS S1, V22, pS91; Theriault BL, 2007, CARCINOGENESIS, V28, P1153, DOI 10.1093/carcin/bgm015; Thomasson AL, 2001, TOPOI-INT REV PHILOS, V20, P149, DOI 10.1023/A:1017900607919; Thomson JR, 2000, J MED GENET, V37, P741, DOI 10.1136/jmg.37.10.741; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Voisin L, 2002, AM J PHYSIOL-CELL PH, V283, pC446, DOI 10.1152/ajpcell.00261.2001; Wen ZX, 2007, J CELL BIOL, V178, P107, DOI 10.1083/jcb.200703055; Yang CM, 2005, J CELL PHYSIOL, V203, P538, DOI 10.1002/jcp.20250; Yu PB, 2008, J BIOL CHEM, V283, P3877, DOI 10.1074/jbc.M706797200; Yu PB, 2005, J BIOL CHEM, V280, P24443, DOI 10.1074/jbc.M502825200	35	33	35	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2299	2306		10.1096/fj.08-127910	http://dx.doi.org/10.1096/fj.08-127910			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19244313				2022-12-28	WOS:000268836500029
J	Sztainberg, Y; Kuperman, Y; Issler, O; Gil, S; Vaughan, J; Rivier, J; Vale, W; Chen, A				Sztainberg, Yehezkel; Kuperman, Yael; Issler, Orna; Gil, Shosh; Vaughan, Joan; Rivier, Jean; Vale, Wylie; Chen, Alon			A novel corticotropin-releasing factor receptor splice variant exhibits dominant negative activity: a putative link to stress-induced heart disease	FASEB JOURNAL			English	Article						cardiovascular disease; urocortins; isoform; alternative splicing; ER retention	MESSENGER-RNA EXPRESSION; RAT CARDIOVASCULAR-SYSTEM; HORMONE-RECEPTOR; ENDOPLASMIC-RETICULUM; REPERFUSION INJURY; HIV-1 INFECTION; TYPE-2 RECEPTOR; SKELETAL-MUSCLE; CRF RECEPTORS; UROCORTIN-III	A growing body of experimental and clinical studies supports a strong association between psychological stress and cardiovascular disease. An important endogenous cardioprotective role in heart physiology has been attributed to corticotropin-releasing factor receptor type 2 beta(CRFR2 beta). Here, we report the isolation of cDNA from mouse (m) heart encoding a novel CRFR2 beta splice variant. Translation of this insertion variant (iv)-mCRFR2 beta isoform produces a 421-aa protein that includes a unique C-terminal cytoplasmic tail. Our functional analysis and cellular localization studies demonstrated that when coexpressed with wild-type mCRFR2 beta, iv-mCRFR2 beta significantly inhibited the wild-type mCRFR2 beta membrane expression and its functional signaling by ER-Golgi complex retention, suggesting a dose-dependent dominant negative effect. Interestingly, mice exposed to a 4-wk paradigm of chronic variable stress, a model of chronic psychological stress in humans, presented significantly lower levels of mCRFR2 beta and higher levels of iv-mCRFR2 beta mRNA expression in their hearts, compared to nonstressed control mice. The dominant-negative effect of iv-mCRFR2 beta and its up-regulation by psychological stress suggest a new form of regulation of the mCRFR2 beta cardioprotective effect and a potential role for this novel isoform in stress-induced heart disease.-Sztainberg, Y., Kuperman, Y., Issler, O., Gil, S., Vaughan, J., Rivier, J., Vale, W., Chen, A. A novel corticotropin-releasing factor receptor splice variant exhibits dominant negative activity: a putative link to stress-induced heart disease. FASEB J. 23, 2186-2196 (2009)	[Sztainberg, Yehezkel; Kuperman, Yael; Issler, Orna; Gil, Shosh; Chen, Alon] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; [Sztainberg, Yehezkel] Bar Ilan Univ, Leslie & Susan Gonda Goldschmied Multidisciplinar, Ramat Gan, Israel; [Vaughan, Joan; Rivier, Jean; Vale, Wylie] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA	Weizmann Institute of Science; Bar Ilan University; Salk Institute	Chen, A (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	alon.chen@weizmann.ac.il		Chen, Alon/0000-0003-3625-8233; Issler, Orna/0000-0003-1473-8295	NIDDK NIH HHS [5P01DK026741-29, P01 DK026741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410; Bale TL, 2000, NAT GENET, V24, P410, DOI 10.1038/74263; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Boonprasert P, 2008, INT J CARDIOL, V127, P307, DOI 10.1016/j.ijcard.2007.11.026; Bosma H, 1998, AM J PUBLIC HEALTH, V88, P68, DOI 10.2105/AJPH.88.1.68; Brar BK, 2000, J BIOL CHEM, V275, P8508, DOI 10.1074/jbc.275.12.8508; Brar BK, 2004, ENDOCRINOLOGY, V145, P24, DOI 10.1210/en.2003-0689; BRAR BK, 2002, ENCY HORMONES RELATE, P313; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; Charles Christopher J., 2004, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V2, P43, DOI 10.2174/1568016043477341; Chen A, 2005, MOL ENDOCRINOL, V19, P441, DOI 10.1210/me.2004-0300; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Coste SC, 2000, NAT GENET, V24, P403, DOI 10.1038/74255; Coste SC, 2001, ENDOCRINOLOGY, V142, P3537, DOI 10.1210/en.142.8.3537; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dimsdale JE, 2008, J AM COLL CARDIOL, V51, P1237, DOI 10.1016/j.jacc.2007.12.024; Dong CM, 2007, BBA-BIOMEMBRANES, V1768, P853, DOI 10.1016/j.bbamem.2006.09.008; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Edwards SW, 2000, TRENDS PHARMACOL SCI, V21, P304, DOI 10.1016/S0165-6147(00)01513-3; Grammatopoulos DK, 1999, MOL ENDOCRINOL, V13, P2189, DOI 10.1210/me.13.12.2189; Harada N, 2008, AM J PHYSIOL-ENDOC M, V294, pE61, DOI 10.1152/ajpendo.00358.2007; Hashimoto K, 2004, PEPTIDES, V25, P1711, DOI 10.1016/j.peptides.2004.05.024; Heldwein KA, 1996, ENDOCRINOLOGY, V137, P3631, DOI 10.1210/en.137.9.3631; Heldwein KA, 1997, MOL CELL ENDOCRINOL, V131, P167, DOI 10.1016/S0303-7207(97)00103-2; Hoare SRJ, 2005, PEPTIDES, V26, P457, DOI 10.1016/j.peptides.2004.10.019; Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936; Jasper JR, 1997, BRIT J PHARMACOL, V122, P126, DOI 10.1038/sj.bjp.0701336; Jiang Wei, 2008, Cleve Clin J Med, V75 Suppl 2, pS20; Kageyama K, 2000, ENDOCRINOLOGY, V141, P2285, DOI 10.1210/en.141.7.2285; Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; Kostich WA, 1998, MOL ENDOCRINOL, V12, P1077, DOI 10.1210/me.12.8.1077; Lewis K, 2001, P NATL ACAD SCI USA, V98, P7570, DOI 10.1073/pnas.121165198; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; LOVENBERG TW, 1995, ENDOCRINOLOGY, V136, P4139, DOI 10.1210/en.136.9.4139; Marchese A, 2008, ANNU REV PHARMACOL, V48, P601, DOI 10.1146/annurev.pharmtox.48.113006.094646; MINAKAMI R, 1993, BIOCHEM BIOPH RES CO, V194, P622, DOI 10.1006/bbrc.1993.1866; Minneman K P, 2001, Mol Interv, V1, P108; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Nazarloo HP, 2002, REGUL PEPTIDES, V105, P121, DOI 10.1016/S0167-0115(02)00006-X; Parkes DG, 1997, AM J PHYSIOL-HEART C, V272, pH2115, DOI 10.1152/ajpheart.1997.272.5.H2115; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P2969, DOI 10.1073/pnas.92.7.2969; Perrin MH, 1999, ANN NY ACAD SCI, V885, P312, DOI 10.1111/j.1749-6632.1999.tb08687.x; Pisarchik A, 2004, EUR J BIOCHEM, V271, P2821, DOI 10.1111/j.1432-1033.2004.04216.x; Pournajafi-Nazarloo H, 2007, NEUROENDOCRINOLOGY, V86, P17, DOI 10.1159/000103587; Rademaker MT, 2006, EUR HEART J, V27, P2088, DOI 10.1093/eurheartj/ehl138; Rademaker MT, 2005, CIRCULATION, V112, P3624, DOI 10.1161/CIRCULATIONAHA.105.561308; Rademaker MT, 2005, EUR HEART J, V26, P2055, DOI 10.1093/eurheartj/ehi351; Rademaker MT, 2002, J AM COLL CARDIOL, V40, P1495, DOI 10.1016/S0735-1097(02)02170-8; Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398; Rosengren A, 2004, LANCET, V364, P953, DOI 10.1016/S0140-6736(04)17019-0; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Shang LJL, 2007, CIRC RES, V101, P1146, DOI 10.1161/CIRCRESAHA.107.152918; Shioda T, 2001, J VIROL, V75, P3462, DOI 10.1128/JVI.75.7.3462-3468.2001; Slominski A, 2006, FRONT BIOSCI-LANDMRK, V11, P2230, DOI 10.2741/1966; STENZEL P, 1995, MOL ENDOCRINOL, V9, P637, DOI 10.1210/me.9.5.637; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Terui K, 2001, J ENDOCRINOL, V169, P177, DOI 10.1677/joe.0.1690177; Vale S, 2005, POSTGRAD MED J, V81, P429, DOI 10.1136/pgmj.2004.028977; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; VAUGHAN JM, 1989, METHODS ENZYMOL, V168, P588; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; Zmijewski MA, 2009, J CELL PHYSIOL, V218, P593, DOI 10.1002/jcp.21632	66	20	20	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2186	2196		10.1096/fj.08-128066	http://dx.doi.org/10.1096/fj.08-128066			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19246489	Green Published			2022-12-28	WOS:000268836500018
J	Berezniuk, I; Sironi, J; Callaway, MB; Castro, LM; Hirata, IY; Ferro, ES; Fricker, LD				Berezniuk, Iryna; Sironi, Juan; Callaway, Myrasol B.; Castro, Leandro M.; Hirata, Izaura Y.; Ferro, Emer S.; Fricker, Lloyd D.			CCP1/Nna1 functions in protein turnover in mouse brain: Implications for cell death in Purkinje cell degeneration mice	FASEB JOURNAL			English	Article						proteasome; carboxypeptidase; aminopeptidase; protein degradation; neurodegeneration	CEREBELLAR MUTANT MOUSE; PCD MUTANT; THIMET OLIGOPEPTIDASE; RETINAL DEGENERATION; MASS-SPECTROMETRY; WILD-TYPE; PEPTIDES; NNA1; NEUROPEPTIDOMICS; DEGRADATION	Purkinje cell degeneration (pcd) mice have a mutation within the gene encoding cytosolic carboxypeptidase 1 (CCP1/Nna1), which has homology to metallocarboxypeptidases. To assess the function of CCP1/Nna1, quantitative proteomics and peptidomics approaches were used to compare proteins and peptides in mutant and wild-type mice. Hundreds of peptides derived from cytosolic and mitochondrial proteins are greatly elevated in pcd mouse hypothalamus, amygdala, cortex, prefrontal cortex, and striatum. However, the major proteins detected on 2-D gel electrophoresis were present in mutant and wild-type mouse cortex and hypothalamus at comparable levels, and proteasome activity is normal in these brain regions of pcd mice, suggesting that the increase in cellular peptide levels in the pcd mice is due to reduced degradation of the peptides downstream of the proteasome. Both nondegenerating and degenerating regions of pcd mouse brain, but not wild-type mouse brain, show elevated autophagy, which can be triggered by a decrease in amino acid levels. Taken together with previous studies on CCP1/Nna1, these data suggest that CCP1/Nna1 plays a role in protein turnover by cleaving proteasome-generated peptides into amino acids and that decreased peptide turnover in the pcd mice leads to cell death.-Berezniuk, I., Sironi, J., Callaway, M. B., Castro, L. M., Hirata, I. Y., Ferro, E. S., Fricker, L. D. CCP1/Nna1 functions in protein turnover in mouse brain: Implications for cell death in Purkinje cell degeneration mice. FASEB J. 24, 1813-1823 (2010). www.fasebj.org	[Sironi, Juan; Callaway, Myrasol B.; Fricker, Lloyd D.] Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; [Berezniuk, Iryna; Fricker, Lloyd D.] Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; [Castro, Leandro M.; Ferro, Emer S.] Univ Sao Paulo, Dept Cell & Dev Biol, Sao Paulo, Brazil; [Hirata, Izaura Y.] Univ Fed Sao Paulo, Dept Biophys, Sao Paulo, Brazil	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP)	Fricker, LD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lloyd.fricker@einstein.yu.edu	Castro, Leandro/ABI-5520-2020; Castro, Leandro/O-6762-2019; Ferro, Emer S/D-3908-2012; Castro, Leandro M/E-5654-2014	Castro, Leandro/0000-0002-7156-2006; Castro, Leandro/0000-0002-7156-2006; Ferro, Emer S/0000-0003-1651-9192; 	National Institutes of Health [DK-51271, DA-04494]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [04/04933-2, 04/14846-0]; Financiadora de Estudos e Projetos [A-03/134]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico; Universidade de Campinas, Campinas, SP, Brazil; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Financiadora de Estudos e Projetos(Financiadora de Inovacao e Pesquisa (Finep)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Universidade de Campinas, Campinas, SP, Brazil; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported in part by National Institutes of Health grants DK-51271 and DA-04494 (to L. D. F.), and by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo 04/04933-2, 04/14846-0 and Financiadora de Estudos e Projetos A-03/134 (to E. S. F.). Thanks are also due to fellowships from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (E. S. F. and L. M. C.). Mass spectrometry was performed through the Rede de Proteoma do Estado de Sao Paulo in the Laboratorio Nacional de Luz Sincrotron (Campinas, SP, Brazil). We are thankful to Prof. Fabio Gozzo (Universidade de Campinas, Campinas, SP, Brazil) for his immeasurable support with mass spectrometry. Thanks are due to Julia Grushko and Jonathan Wardman for assistance with the handling of the pcd mice. Fluorescence microscopy was performed in the laboratory of Dr. Jonathan M. Backer (Department of Molecular Pharmacology), and confocal microscopy was performed in the Analytical Imaging Facility of the Albert Einstein College of Medicine.	Arolas JL, 2007, CURR PHARM DESIGN, V13, P349, DOI 10.2174/138161207780162980; Beninga J, 1998, J BIOL CHEM, V273, P18734, DOI 10.1074/jbc.273.30.18734; Berti DA, 2009, J BIOL CHEM, V284, P14105, DOI 10.1074/jbc.M807916200; Bett JS, 2006, HUM MOL GENET, V15, P33, DOI 10.1093/hmg/ddi423; BLANKS JC, 1982, J COMP NEUROL, V212, P231, DOI 10.1002/cne.902120303; BLANKS JC, 1992, EXP EYE RES, V54, P637, DOI 10.1016/0014-4835(92)90019-O; Chakrabarti L, 2008, VISION RES, V48, P1999, DOI 10.1016/j.visres.2008.05.026; Chakrabarti L, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-24; Chang A C, 1993, Chin J Physiol, V36, P141; Chang YY, 2009, BIOCHEM SOC T, V37, P232, DOI 10.1042/BST0370232; Che FY, 2007, J PROTEOME RES, V6, P4667, DOI 10.1021/pr060690r; Che FY, 2005, MOL CELL PROTEOMICS, V4, P1391, DOI 10.1074/mcp.T500010-MCP200; Che FY, 2005, J MASS SPECTROM, V40, P227, DOI 10.1002/jms.742; CONDORELLI DF, 1990, J NEUROSCI RES, V26, P251, DOI 10.1002/jnr.490260216; Cunha FM, 2008, J BIOL CHEM, V283, P24448, DOI 10.1074/jbc.M801252200; de la Vega MR, 2007, FASEB J, V21, P851, DOI 10.1096/fj.06-7330com; Fernandez-Gonzalez A, 2002, SCIENCE, V295, P1904, DOI 10.1126/science.1068912; Ford GD, 2008, BIOCHEM BIOPH RES CO, V377, P556, DOI 10.1016/j.bbrc.2008.10.033; Fricker LD, 2006, MASS SPECTROM REV, V25, P327, DOI 10.1002/mas.20079; Fricker LD, 2007, ENDOCRINOLOGY, V148, P4185, DOI 10.1210/en.2007-0123; Gass J, 2007, CELL MOL LIFE SCI, V64, P345, DOI 10.1007/s00018-006-6317-y; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Goldberg AL, 2002, MOL IMMUNOL, V39, P147, DOI 10.1016/S0161-5890(02)00098-6; Harris A, 2000, MOL CELL NEUROSCI, V16, P578, DOI 10.1006/mcne.2000.0900; Hepp R, 1999, GLIA, V27, P181, DOI 10.1002/(SICI)1098-1136(199908)27:2<181::AID-GLIA8>3.0.CO;2-9; Kalinina E, 2007, FASEB J, V21, P836, DOI 10.1096/fj.06-7329com; Kisselev AF, 2005, METHOD ENZYMOL, V398, P364, DOI 10.1016/S0076-6879(05)98030-0; Kwak MK, 2007, LIFE SCI, V80, P2411, DOI 10.1016/j.lfs.2007.04.014; Kyuhou S, 2006, NEUROSCI LETT, V396, P91, DOI 10.1016/j.neulet.2005.11.023; LANDIS SC, 1978, J COMP NEUROL, V177, P125, DOI 10.1002/cne.901770109; Lyons PJ, 2008, J BIOL CHEM, V283, P7054, DOI 10.1074/jbc.M707680200; MCBRIDE WJ, 1988, NEUROCHEM RES, V13, P121, DOI 10.1007/BF00973323; Morano C, 2008, ANAL CHEM, V80, P9298, DOI 10.1021/ac801654h; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; OGORMAN S, 1985, J COMP NEUROL, V234, P277, DOI 10.1002/cne.902340302; OKUBO A, 1995, JPN J OPHTHALMOL, V39, P152; Petiot A, 2002, CELL STRUCT FUNCT, V27, P431, DOI 10.1247/csf.27.431; Power JHT, 2008, ACTA NEUROPATHOL, V115, P611, DOI 10.1007/s00401-008-0373-3; Rong YQ, 2004, MOL BRAIN RES, V132, P128, DOI 10.1016/j.molbrainres.2004.10.015; Saric T, 2004, J BIOL CHEM, V279, P46723, DOI 10.1074/jbc.M406537200; Schiaffino S, 2008, AUTOPHAGY, V4, P727, DOI 10.4161/auto.6143; Svensson M, 2007, BIOCHEM SOC T, V35, P588, DOI 10.1042/BST0350588; Tonelli RR, 2004, CELL MICROBIOL, V6, P733, DOI 10.1111/j.1462-5822.2004.00397.x; Valero J, 2006, MOL CELL NEUROSCI, V33, P283, DOI 10.1016/j.mcn.2006.08.002; Wang TY, 2007, BRAIN RES, V1140, P26, DOI 10.1016/j.brainres.2006.07.065; Wang TY, 2006, MOL CELL NEUROSCI, V33, P200, DOI 10.1016/j.mcn.2006.07.009; Xiao R, 2005, MOL CELLS, V20, P219; Zhang RJ, 2002, ANAL CHEM, V74, P3662, DOI 10.1021/ac025614w; Zhang X, 2008, J NEUROCHEM, V107, P1596, DOI 10.1111/j.1471-4159.2008.05722.x	49	40	41	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1813	1823		10.1096/fj.09-147942	http://dx.doi.org/10.1096/fj.09-147942			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20061535	Green Published			2022-12-28	WOS:000278200000018
J	Jacob, A; Hack, B; Chiang, E; Garcia, JGN; Quigg, RJ; Alexander, JJ				Jacob, Alexander; Hack, Bradley; Chiang, Eddie; Garcia, Joe G. N.; Quigg, Richard J.; Alexander, Jessy J.			C5a alters blood-brain barrier integrity in experimental lupus	FASEB JOURNAL			English	Article						endothelium; complement system; systemic lupus erythematosus; neurodegeneration	CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE PRODUCTION; NEUROPSYCHIATRIC LUPUS; COMPLEMENT ACTIVATION; AUTOIMMUNE-DISEASE; CEREBROSPINAL-FLUID; GLUTAMATE-RECEPTOR; ENDOTHELIAL-CELLS; EMERGING CONCEPTS; VASCULAR INJURY	The blood-brain barrier (BBB) is a crucial anatomic location in the brain. Its dysfunction complicates many neurodegenerative diseases, from acute conditions, such as sepsis, to chronic diseases, such as systemic lupus erythematosus (SLE). Several studies suggest an altered BBB in lupus, but the underlying mechanism remains unknown. In the current study, we observed a definite loss of BBB integrity in MRL/MpJ-Tnfrsf6(lpr) (MRL/lpr) lupus mice by IgG infiltration into brain parenchyma. In line with this result, we examined the role of complement activation, a key event in this setting, in maintenance of BBB integrity. Complement activation generates C5a, a molecule with multiple functions. Because the expression of the C5a receptor (C5aR) is significantly increased in brain endothelial cells treated with lupus serum, the study focused on the role of C5a signaling through its G-protein-coupled receptor C5aR in brain endothelial cells, in a lupus setting. Reactive oxygen species production increased significantly in endothelial cells, in both primary cells and the bEnd3 cell line treated with lupus serum from MRL/lpr mice, compared with those treated with control serum from MRL+/+ mice. In addition, increased permeability monitored by changes in transendothelial electrical resistance, cytoskeletal remodeling caused by actin fiber rearrangement, and increased iNOS mRNA expression were observed in bEnd3 cells. These disruptive effects were alleviated by pretreating cells with a C5a receptor antagonist (C5aRant) or a C5a antibody. Furthermore, the structural integrity of the vasculature in MRL/lpr brain was maintained by C5aR inhibition. These results demonstrate the regulation of BBB integrity by the complement system in a neuroinflammatory setting. For the first time, a novel role of C5a in the maintenance of BBB integrity is identified and the potential of C5a/C5aR blockade highlighted as a promising therapeutic strategy in SLE and other neurodegenerative diseases.-Jacob, A., Hack, B., Chiang, E., Garcia, J. G. N., Quigg, R. J., Alexander, J. J. C5a alters blood-brain barrier integrity in experimental lupus. FASEB J. 24, 1682-1688 (2010). www.fasebj.org	[Jacob, Alexander; Hack, Bradley; Chiang, Eddie; Garcia, Joe G. N.; Quigg, Richard J.; Alexander, Jessy J.] Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Alexander, JJ (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC5100, Chicago, IL 60637 USA.	jalexand@medicine.bsd.uchicago.edu	Garcia, Joe GN/E-8862-2010; Alexander, Jessy/ABA-7664-2020		U.S. National Institutes of Health [R01DK055357, P01 HL58064]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL058064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055357] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grants R01DK055357 (to R.J.Q.) and P01 HL58064 (to J.G.N.G.).	Abbott NJ, 2003, LUPUS, V12, P908, DOI 10.1191/0961203303lu501oa; ABEL T, 1980, J RHEUMATOL, V7, P325; ABRAMSON S, 1987, J RHEUMATOL, V14, P43; Alexander JJ, 2007, EUR J IMMUNOL, V37, P1691, DOI 10.1002/eji.200636638; Alexander JJ, 2007, NEUROCHEM INT, V50, P5, DOI 10.1016/j.neuint.2006.08.005; Alexander JJ, 2005, J IMMUNOL, V175, P8312, DOI 10.4049/jimmunol.175.12.8312; Alexander JJ, 2005, NEUROCHEM INT, V47, P143, DOI 10.1016/j.neuint.2005.04.016; Alexander JJ, 2003, BBA-MOL BASIS DIS, V1639, P169, DOI 10.1016/j.bbadis.2003.09.005; Appenzeller S, 2005, ARTHRITIS RHEUM-US, V52, P2783, DOI 10.1002/art.21271; Arora V, 2004, MOL IMMUNOL, V41, P449, DOI 10.1016/j.molimm.2004.03.004; Ballok DA, 2004, HIPPOCAMPUS, V14, P649, DOI 10.1002/hipo.10205; Ballok DA, 2003, BEHAV BRAIN RES, V140, P119, DOI 10.1016/S0166-4328(02)00276-0; Ballok DA, 2007, BRAIN RES REV, V54, P67, DOI 10.1016/j.brainresrev.2006.12.003; Bao LH, 2005, EUR J IMMUNOL, V35, P2496, DOI 10.1002/eji.200526327; Barnum SR, 2002, IMMUNOL RES, V26, P7, DOI 10.1385/IR:26:1-3:007; Belmont HM, 1997, ARTHRITIS RHEUM, V40, P1810, DOI 10.1002/art.1780401013; BELMONT HM, 1986, ARTHRITIS RHEUM, V29, P1085, DOI 10.1002/art.1780290905; Borbiev T, 2004, AM J PHYSIOL-LUNG C, V287, pL911, DOI 10.1152/ajplung.00372.2003; BOUMPAS DT, 1995, ANN INTERN MED, V123, P42, DOI 10.7326/0003-4819-123-1-199507010-00007; BOUMPAS DT, 1995, ANN INTERN MED, V122, P940, DOI 10.7326/0003-4819-122-12-199506150-00009; Brey RL, 2002, NEUROLOGY, V58, P1214, DOI 10.1212/WNL.58.8.1214; Brey RL, 1997, ANN NY ACAD SCI, V823, P97, DOI 10.1111/j.1749-6632.1997.tb48382.x; Brown GC, 2006, BIOCHEM SOC T, V34, P953, DOI 10.1042/BST0340953; Brown RC, 2007, BRAIN RES, V1130, P17, DOI 10.1016/j.brainres.2006.10.083; Carroll MC, 1997, CURR OPIN IMMUNOL, V9, P64, DOI 10.1016/S0952-7915(97)80160-4; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; Carroll MC, 1998, NAT GENET, V19, P3, DOI 10.1038/ng0598-3; Coisne C, 2005, LAB INVEST, V85, P734, DOI 10.1038/labinvest.3700281; Daha MR, 2006, NEPHROL DIAL TRANSPL, V21, P3374, DOI 10.1093/ndt/gfl515; Davson H, 1995, PHYSL CSF BLOOD BRAI; Davson Hugh, 1993, INTRO BLOOD BRAIN BA; DeGiorgio LA, 2001, NAT MED, V7, P1189, DOI 10.1038/nm1101-1189; DENBURG JA, 1988, ISRAEL J MED SCI, V24, P754; Diamond B, 2006, ADV IMMUNOL, V89, P289, DOI 10.1016/S0065-2776(05)89007-8; Diamond B, 2003, ARTHRITIS RHEUM, V48, P2710, DOI 10.1002/art.11278; Dixon F J, 1978, Arthritis Rheum, V21, pS64, DOI 10.1002/art.1780210909; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Easton AS, 2002, BRAIN RES, V953, P157, DOI 10.1016/S0006-8993(02)03281-X; Farkas I, 2003, J IMMUNOL, V170, P5764, DOI 10.4049/jimmunol.170.11.5764; Farrell M, 1997, LUPUS, V6, P268, DOI 10.1177/096120339700600310; Flierl MA, 2009, CRIT CARE, V13, DOI 10.1186/cc7710; GOLOMBEK SJ, 1986, ARTHRITIS RHEUM, V29, P1090, DOI 10.1002/art.1780290906; Gotze O, 1976, Adv Immunol, V24, P1, DOI 10.1016/S0065-2776(08)60328-4; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Hahn BH, 2001, LUPUS, V10, P589, DOI 10.1191/096120301682430140; Hanly JG, 2006, J RHEUMATOL, V33, P1553; Hawlisch H, 2005, IMMUNITY, V22, P415, DOI 10.1016/j.immuni.2005.02.006; HESS DC, 1993, J RHEUMATOL, V20, P610; HOPKINS P, 1988, ARTHRITIS RHEUM, V31, P632, DOI 10.1002/art.1780310508; Hu TS, 2005, AM J PHYSIOL-RENAL, V289, pF816, DOI 10.1152/ajprenal.00024.2005; Huerta PT, 2006, P NATL ACAD SCI USA, V103, P678, DOI 10.1073/pnas.0510055103; HUGHES GRV, 1988, POSTGRAD MED J, V64, P517, DOI 10.1136/pgmj.64.753.517; James WG, 2006, CLIN EXP IMMUNOL, V144, P299, DOI 10.1111/j.1365-2249.2006.03056.x; Jongen PJH, 2000, ACTA NEUROL SCAND, V101, P116, DOI 10.1034/j.1600-0404.2000.101002116.x; Kowal C, 2006, P NATL ACAD SCI USA, V103, P19854, DOI 10.1073/pnas.0608397104; Lossinsky AS, 2004, HISTOL HISTOPATHOL, V19, P535, DOI 10.14670/HH-19.535; Ma XX, 2006, J NEUROIMMUNOL, V179, P26, DOI 10.1016/j.jneuroim.2006.06.023; Moller T, 1997, J NEUROSCI, V17, P615; Mukherjee P, 2001, J NEUROCHEM, V77, P43, DOI 10.1046/j.1471-4159.2001.00167.x; Muller-Eberhard H J, 1980, Adv Immunol, V29, P1, DOI 10.1016/S0065-2776(08)60042-5; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; Nishiura H, 2009, LAB INVEST, V89, P676, DOI 10.1038/labinvest.2009.27; Pytel P, 2009, CURR OPIN NEUROL, V22, P283, DOI 10.1097/WCO.0b013e32832b3101; QUIGG RJ, 1995, IMMUNOGENETICS, V42, P362, DOI 10.1007/BF00179397; Rice A, 2005, J MED CHEM, V48, P832, DOI 10.1021/jm040114b; Sakic B, 1996, BRAIN RES BULL, V41, P305, DOI 10.1016/S0361-9230(96)00190-6; Sayah S, 2003, MOL BRAIN RES, V112, P53, DOI 10.1016/S0169-328X(03)00046-9; Szechtman H, 1997, LUPUS, V6, P223, DOI 10.1177/096120339700600302; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; THEOFILOPOULOS AN, 1989, ADV IMMUNOL, V46, P61, DOI 10.1016/S0065-2776(08)60651-3; VOGELWEID CM, 1991, J NEUROIMMUNOL, V35, P89, DOI 10.1016/0165-5728(91)90164-3; WEINBERG JB, 1994, J EXP MED, V179, P651, DOI 10.1084/jem.179.2.651; Woodruff TM, 2006, FASEB J, V20, P1407, DOI 10.1096/fj.05-5814com	73	77	81	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1682	1688		10.1096/fj.09-138834	http://dx.doi.org/10.1096/fj.09-138834			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20065106	Green Published			2022-12-28	WOS:000278200000006
J	Toribio, RE; Brown, HA; Novince, CM; Marlow, B; Hernon, K; Lanigan, LG; Hildreth, BE; Werbeck, JL; Shu, ST; Lorch, G; Carlton, M; Foley, J; Boyaka, P; McCauley, LK; Rosol, TJ				Toribio, Ramiro E.; Brown, Holly A.; Novince, Chad M.; Marlow, Brandlyn; Hernon, Krista; Lanigan, Lisa G.; Hildreth, Blake E., III; Werbeck, Jillian L.; Shu, Sherry T.; Lorch, Gwendolen; Carlton, Michelle; Foley, John; Boyaka, Prosper; McCauley, Laurie K.; Rosol, Thomas J.			The midregion, nuclear localization sequence, and C terminus of PTHrP regulate skeletal development, hematopoiesis, and survival in mice	FASEB JOURNAL			English	Article						parathyroid; osteoblast; craniofacial; lethality	HORMONE-RELATED PROTEIN; PARATHYROID-HORMONE; PTH/PTHRP RECEPTOR; HUMORAL HYPERCALCEMIA; CALCIUM-TRANSPORT; TARGETING SIGNAL; LINK PROTEIN; CELL-DEATH; IN-VITRO; PEPTIDE	The functions of parathyroid hormone-related protein (PTHrP) on morphogenesis, cell proliferation, apoptosis, and calcium homeostasis have been attributed to its N terminus. Evidence suggests that many of these effects are not mediated by the N terminus but by the midregion, a nuclear localization sequence (NLS), and C terminus of the protein. A knock-in mouse lacking the midregion, NLS, and C terminus of PTHrP (Pthrp(Delta/Delta)) was developed. Pthrp(Delta/Delta) mice had craniofacial dysplasia, chondrodysplasia, and kyphosis, with most mice dying by d 5 of age. In bone, there were fewer chondrocytes and osteoblasts per area, bone mass was decreased, and the marrow was less cellular, with erythroid hypoplasia. Cellular proliferation was impaired, and apoptosis was increased. Runx2, Ocn, Sox9, Crtl1, beta-catenin, Runx1, ephrin B2, cyclin D1, and Gata1 were underexpressed while P16/Ink4a, P21, GSK-3 beta, Il-6, Ffg3, and Ihh were overexpressed. Mammary gland development was aberrant, and energy metabolism was deregulated. These results establish that the midregion, NLS, and C terminus of PTHrP are crucial for the commitment of osteogenic and hematopoietic precursors to their lineages, and for survival, and many of the effects of PTHrP on development are not mediated by its N terminus. The down-regulation of Runx1, Runx2, and Sox9 indicates that PTHrP is a modulator of transcriptional activation during stem cell commitment. Toribio, R. E., Brown, H. A., Novince, C. M., Marlow, B. Hernon, K., Lanigan, L. G., Hildreth III, B. E., Werbeck, J. L., Shu, S. T., Lorch, G., Carlton, M., Foley, J., Boyaka, P., McCauley, L. K., Rosol, T. J. The midregion, nuclear localization sequence, and C terminus of PTHrP regulate skeletal development, hematopoiesis, and survival in mice. FASEB J. 24, 1947-1957 (2010). www.fasebj.org	[Toribio, Ramiro E.; Brown, Holly A.; Marlow, Brandlyn; Hernon, Krista] Ohio State Univ, Dept Vet Clin Sci, Columbus, OH 43210 USA; [Lanigan, Lisa G.; Hildreth, Blake E., III; Werbeck, Jillian L.; Shu, Sherry T.; Lorch, Gwendolen; Boyaka, Prosper; Rosol, Thomas J.] Ohio State Univ, Dept Vet Biosci, Coll Vet Med, Columbus, OH 43210 USA; [Carlton, Michelle] Ohio State Univ, Wright Ctr Innovat Biomed Imaging, Columbus, OH 43210 USA; [Novince, Chad M.; McCauley, Laurie K.] Univ Michigan, Sch Med, Dept Periodont & Oral Med, Ann Arbor, MI USA; [McCauley, Laurie K.] Univ Michigan, Dept Psychol, Sch Med, Ann Arbor, MI USA; [Foley, John] Indiana Univ, Sch Med, Med Sci Program, Bloomington, IN 47405 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Indiana University System; Indiana University Bloomington	Toribio, RE (corresponding author), Ohio State Univ, Dept Vet Clin Sci, 601 Vernon Tharp St, Columbus, OH 43210 USA.	toribio.1@osu.edu	McCauley, Laurie/G-4041-2012; Rosol, Thomas/G-9585-2011; Toribio, Ramiro/H-7838-2013; Hildreth, Eason/W-8186-2019	Rosol, Thomas/0000-0003-3737-1190; Toribio, Ramiro/0000-0002-9063-540X; Hildreth, Eason/0000-0002-4631-1117; Boyaka, Prosper/0000-0001-6857-9088; Lanigan, Lisa/0000-0001-8969-7411	Ohio State University, Columbus, OH, USA; National Institutes of Health [K01 RR018924, S10 RR020888, DE014073, CA09390]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR020888, K01RR018924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [T32DE007057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014073] Funding Source: NIH RePORTER	Ohio State University, Columbus, OH, USA(Ohio State University); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors thank laboratory members for their support; Hui Wang and Gustavo Leone (Human Cancer Genetics Program, The Ohio State University, Columbus, OH, USA) for their assistance with embryonic stem cell work and for providing the EIIa-Cre mice; Sanjay Singh and Girish Rajgolikar for technical assistance; Jan Hu for consultation regarding tooth morphology; and Alan Flechtner and Florinda Jaynes for histological specimen processing. The pPNT plasmid was a kind gift from Dr. Michael Weinstein (Human Cancer Genetics Program, The Ohio State University). The authors thank Dr. T.J. Martin for the constructive comments on this manuscript. This study was possible with funding from the National Institutes of Health to R.E.T. (K01 RR018924; S10 RR020888) and L.K.M. (DE014073 and CA09390). The authors declare no competing financial interests.	Aarts MM, 1999, J BONE MINER RES, V14, P1493, DOI 10.1359/jbmr.1999.14.9.1493; Aarts MM, 2001, J BIOL CHEM, V276, P37934; Aarts MM, 1999, J BIOL CHEM, V274, P4832, DOI 10.1074/jbc.274.8.4832; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; BURTIS WJ, 1994, J CLIN ENDOCR METAB, V78, P317, DOI 10.1210/jc.78.2.317; BURTIS WJ, 1992, J CLIN ENDOCR METAB, V75, P1110, DOI 10.1210/jc.75.4.1110; CARE AD, 1990, EXP PHYSIOL, V75, P605, DOI 10.1113/expphysiol.1990.sp003437; Cebrian A, 2002, DIABETES, V51, P3003, DOI 10.2337/diabetes.51.10.3003; Chatterjee O, 2002, BRAIN RES, V930, P58, DOI 10.1016/S0006-8993(01)03407-2; Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690; de Gortazar AR, 2006, CALCIFIED TISSUE INT, V79, P360, DOI 10.1007/s00223-006-0099-y; De Miguel F, 2001, ENDOCRINOLOGY, V142, P4096, DOI 10.1210/en.142.9.4096; FENTON AJ, 1991, ENDOCRINOLOGY, V129, P3424, DOI 10.1210/endo-129-6-3424; Fuentes J, 2006, AM J PHYSIOL-REG I, V291, pR1499, DOI 10.1152/ajpregu.00892.2005; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Kou I, 2004, J BIOL CHEM, V279, P50942, DOI 10.1074/jbc.M406786200; Kovacs CS, 1996, P NATL ACAD SCI USA, V93, P15233, DOI 10.1073/pnas.93.26.15233; Kuznetsov SA, 2004, J CELL BIOL, V167, P1113, DOI 10.1083/jcb.200408079; Lam MHC, 2001, BIOCHEM BIOPH RES CO, V282, P629, DOI 10.1006/bbrc.2001.4607; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Lee K, 1996, ENDOCRINOLOGY, V137, P5109, DOI 10.1210/en.137.11.5109; LOPEZHILKER S, 1992, J LAB CLIN MED, V119, P738; MARTIN TJ, 1988, AUST NZ J MED, V18, P287, DOI 10.1111/j.1445-5994.1988.tb02039.x; Miao DS, 2008, P NATL ACAD SCI USA, V105, P20309, DOI 10.1073/pnas.0805690105; MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048; Onda K, 2006, J VET MED SCI, V68, P709, DOI 10.1292/jvms.68.709; Orloff JJ, 1996, ENDOCRINOLOGY, V137, P5376, DOI 10.1210/en.137.12.5376; Pache JC, 2006, ENDOCRINOLOGY, V147, P990, DOI 10.1210/en.2005-0663; Pannier S, 2009, BBA-MOL BASIS DIS, V1792, P140, DOI 10.1016/j.bbadis.2008.11.010; Philbrick WM, 1998, P NATL ACAD SCI USA, V95, P11846, DOI 10.1073/pnas.95.20.11846; Sawada Y, 2001, MOL CELL ENDOCRINOL, V182, P265, DOI 10.1016/S0303-7207(01)00482-8; Schipani Ernestina, 2003, Birth Defects Research, V69, P352, DOI 10.1002/bdrc.10028; SEITZ PK, 1995, MINER ELECTROL METAB, V21, P180; STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275; Su XH, 2009, EMBO J, V28, P1904, DOI 10.1038/emboj.2009.151; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; Uemura H, 1997, J ENDOCRINOL, V153, P445, DOI 10.1677/joe.0.1530445; Valin A, 2001, ENDOCRINOLOGY, V142, P2752, DOI 10.1210/en.142.7.2752; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; VanHouten JN, 2003, J CLIN INVEST, V112, P1429, DOI 10.1172/JCI200319504; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; Wu TL, 1996, J BIOL CHEM, V271, P24371, DOI 10.1074/jbc.271.40.24371; Wysolmerski JJ, 1998, ANNU REV PHYSIOL, V60, P431, DOI 10.1146/annurev.physiol.60.1.431; Wysolmerski JJ, 1998, DEVELOPMENT, V125, P1285; Wysolmerski JJ, 2001, J CLIN ENDOCR METAB, V86, P1788, DOI 10.1210/jc.86.4.1788	49	52	55	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1947	1957		10.1096/fj.09-147033	http://dx.doi.org/10.1096/fj.09-147033			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20145205	Green Published, Green Submitted			2022-12-28	WOS:000278200000029
J	Leitao, B; Jones, MC; Fusi, L; Higham, J; Lee, Y; Takano, M; Goto, T; Christian, M; Lam, EWF; Brosens, JJ				Leitao, Beatriz; Jones, Marius C.; Fusi, Luca; Higham, Jenny; Lee, Yun; Takano, Masashi; Goto, Tomoko; Christian, Mark; Lam, Eric W. -F.; Brosens, Jan J.			Silencing of the JNK pathway maintains progesterone receptor activity in decidualizing human endometrial stromal cells exposed to oxidative stress signals	FASEB JOURNAL			English	Article						sumoylation; MKP1; reactive oxygen species; pregnancy	ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; N-TERMINAL KINASE; SUMO MODIFICATIONS; INDUCED APOPTOSIS; CROSS-TALK; EXPRESSION; SUMOYLATION; DEATH; DIFFERENTIATION	Survival of the conceptus is dependent on continuous progesterone signaling in the maternal decidua but how this is achieved under conditions of oxidative stress that characterize early pregnancy is unknown. Using primary cultures, we show that modest levels of reactive oxygen species (ROS) increase sumoylation in human endometrial stromal cells (HESCs), leading to enhanced modification and transcriptional inhibition of the progesterone receptor (PR). The ability of ROS to induce a sustained hypersumoylation response, or interfere with PR activity, was lost upon differentiation of HESCs into decidual cells. Hypersumoylation in response to modest levels of ROS requires activation of the JNK pathway. Although ROS-dependent JNK signaling is disabled on decidualization, the cells continue to mount a transcriptional response, albeit distinct from that observed in undifferentiated HESCs. We further show that attenuated JNK signaling in decidual cells is a direct consequence of altered expression of key pathway modulators, including induction of MAP kinase phosphatase 1 (MKP1). Overexpression of MKP1 dampens JNK signaling, prevents hypersumoylation, and maintains PR activity in undifferentiated HESCs exposed to ROS. Thus, JNK silencing uncouples ROS signaling from the SUMO conjugation pathway and maintains progesterone responses and cellular homeostasis in decidual cells under oxidative stress conditions imposed by pregnancy.-Leitao, B., Jones, M. C., Fusi, L., Higham, J., Lee, Y. Takano, M., Goto, T., Christian, M., Lam, E. W.-F., Brosens, J. J. Silencing of the Jnk pathway maintains progesterone receptor activity in decidualizing human endometrial stromal cells exposed to oxidative stress signals. FASEB J. 24, 1541-1551 (2010). www.fasebj.org	[Leitao, Beatriz; Jones, Marius C.; Fusi, Luca; Higham, Jenny; Lee, Yun; Takano, Masashi; Goto, Tomoko; Christian, Mark; Brosens, Jan J.] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Hammersmith Hosp, London W12 0NN, England; [Lam, Eric W. -F.] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London W12 0NN, England	Imperial College London; Imperial College London	Brosens, JJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Hammersmith Campus,Du Canc Rd, London W12 0NN, England.	j.brosens@imperial.ac.uk	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Brosens, Jan/0000-0003-0116-9329; Christian, Mark/0000-0002-1616-4179	Wellcome Trust [084336]; Institute of Obstetrics and Gynaecology (IOG) Trust; National Institute for Health Research (NIHR) Biomedical Research Centre; Cancer Research UK [12011] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Institute of Obstetrics and Gynaecology (IOG) Trust; National Institute for Health Research (NIHR) Biomedical Research Centre(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK)	The authors are grateful to all the women who participated in this study. This work was supported by the Wellcome Trust (084336), the Institute of Obstetrics and Gynaecology (IOG) Trust, and the National Institute for Health Research (NIHR) Biomedical Research Centre funding scheme. The authors declare no conflicts of interest.	Abdel-Hafiz H, 2002, J BIOL CHEM, V277, P33950, DOI 10.1074/jbc.M204573200; Barthel A, 2005, BIOL CHEM, V386, P207, DOI 10.1515/BC.2005.026; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bergink S, 2009, NATURE, V458, P461, DOI 10.1038/nature07963; Bogoyevitch MA, 2006, BIOESSAYS, V28, P923, DOI 10.1002/bies.20458; Bossis G, 2006, MOL CELL, V21, P349, DOI 10.1016/j.molcel.2005.12.019; Brar AK, 2001, PHYSIOL GENOMICS, V7, P135, DOI 10.1152/physiolgenomics.00061.2001; Brosens JJ, 2006, J MOL ENDOCRINOL, V36, P389, DOI 10.1677/jme.1.02060; Brosens JJ, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.11.037; Brosens JJ, 1999, ENDOCRINOLOGY, V140, P4809, DOI 10.1210/en.140.10.4809; CHARLES CH, 1992, ONCOGENE, V7, P187; Christian M, 2002, MOL ENDOCRINOL, V16, P141, DOI 10.1210/me.16.1.141; Cloke B, 2008, ENDOCRINOLOGY, V149, P4462, DOI 10.1210/en.2008-0356; Critchley HOD, 2001, CLIN ENDOCRINOL, V55, P701, DOI 10.1046/j.1365-2265.2001.01432.x; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EMSLIE EA, 1994, HUM GENET, V93, P513; Gellersen B, 2003, J ENDOCRINOL, V178, P357, DOI 10.1677/joe.0.1780357; Gellersen B, 2007, SEMIN REPROD MED, V25, P445, DOI 10.1055/s-2007-991042; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; Golebiowski F, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000282; Holgado-Madruga M, 2003, MOL CELL BIOL, V23, P4471, DOI 10.1128/MCB.23.13.4471-4484.2003; Huang C, 2009, EMBO J, V28, P2748, DOI 10.1038/emboj.2009.210; Jauniaux E, 2000, AM J PATHOL, V157, P2111, DOI 10.1016/S0002-9440(10)64849-3; Jauniaux E, 2006, HUM REPROD UPDATE, V12, P747, DOI 10.1093/humupd/dml016; Jones MC, 2006, P NATL ACAD SCI USA, V103, P16272, DOI 10.1073/pnas.0603002103; Kajihara T, 2006, MOL ENDOCRINOL, V20, P2444, DOI 10.1210/me.2006-0118; Keyse SM, 2008, CANCER METAST REV, V27, P253, DOI 10.1007/s10555-008-9123-1; Kuwano Y, 2008, CELL CYCLE, V7, P2640, DOI 10.4161/cc.7.17.6534; Labied S, 2006, MOL ENDOCRINOL, V20, P35, DOI 10.1210/me.2005-0275; Lievre M, 2009, CONTRACEPTION, V80, P95, DOI 10.1016/j.contraception.2009.01.011; Lyst MJ, 2007, BIOCHEM SOC T, V35, P1389, DOI 10.1042/BST0351389; Manza LL, 2004, CHEM RES TOXICOL, V17, P1706, DOI 10.1021/tx049767l; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; Meinecke I, 2007, P NATL ACAD SCI USA, V104, P5073, DOI 10.1073/pnas.0608773104; Molton SA, 2003, ONCOGENE, V22, P4690, DOI 10.1038/sj.onc.1206692; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Poston L, 2006, LANCET, V367, P1145, DOI 10.1016/S0140-6736(06)68433-X; Qu J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001085; Sanchez-Perez I, 2002, MOL BIOL CELL, V13, P2933, DOI 10.1091/mbc.E02-01-0022; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takano M, 2007, MOL ENDOCRINOL, V21, P2334, DOI 10.1210/me.2007-0058; Tempe D, 2008, BIOCHEM SOC T, V36, P874, DOI 10.1042/BST0360874; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Venugopal SK, 2007, J BIOL CHEM, V282, P31900, DOI 10.1074/jbc.M703729200; Wang ZQ, 2006, CANCER RES, V66, P8870, DOI 10.1158/0008-5472.CAN-06-1280; Xie P, 2009, J BIOL CHEM, V284, P5488, DOI 10.1074/jbc.M806487200; Xu QH, 2004, FREE RADICAL BIO MED, V36, P985, DOI 10.1016/j.freeradbiomed.2004.01.009; Xu Z, 2008, FASEB J, V22, P127, DOI 10.1096/fj.06-7871com; YAN MH, 1994, NATURE, V372, P798; Yang JJ, 2002, BIOCHEM BIOPH RES CO, V297, P105, DOI 10.1016/S0006-291X(02)02123-X; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Zhao J, 2007, CELL MOL LIFE SCI, V64, P3017, DOI 10.1007/s00018-007-7137-4	53	67	68	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1541	1551		10.1096/fj.09-149153	http://dx.doi.org/10.1096/fj.09-149153			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20026682	hybrid, Green Published			2022-12-28	WOS:000277158900027
J	Barash, U; Cohen-Kaplan, V; Arvatz, G; Gingis-Velitski, S; Levy-Adam, F; Nativ, O; Shemesh, R; Ayalon-Sofer, M; Ilan, N; Vlodavsky, I				Barash, Uri; Cohen-Kaplan, Victoria; Arvatz, Gil; Gingis-Velitski, Svetlana; Levy-Adam, Flonia; Nativ, Ofer; Shemesh, Ronen; Ayalon-Sofer, Michal; Ilan, Neta; Vlodavsky, Israel			A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics	FASEB JOURNAL			English	Article						cell proliferation; colony formation; xenograft; Src; phosphorylation	EXTRACELLULAR-MATRIX; MAMMALIAN HEPARANASE; CANCER METASTASIS; FACTOR EXPRESSION; INHIBITOR PI-88; CELL-ADHESION; ANGIOGENESIS; PROTEIN; GROWTH; PHOSPHORYLATION	Heparanase is a mammalian endo-beta-D-glucuronidase that can cleave heparan sulfate side chains, an activity strongly implicated in tumor cell dissemination. The current study aimed to identify and characterize heparanase splice variants. LEADS, Compugen's alternative splicing modeling platform (Compugen, Tel Aviv, Israel), was used to search for splice variants in silico; tumor-derived cell lines (i.e., CAG myeloma) and tumor biopsies were utilized to validate T5 expression in vivo; signaling (i.e., Src phosphorylation) was evaluated following T5 gene silencing or overexpression and correlated with cell proliferation, colony formation, and tumor xenograft development. A novel spliced form of human heparanase, termed T5, was identified. In this splice variant, 144 bp of intron 5 are joined with exon 4, which results in a truncated, enzymatically inactive protein. T5 overexpression resulted in increased cell proliferation and larger colonies in soft agar, mediated by Src activation. Furthermore, T5 overexpression markedly enhanced tumor xenograft development. T5 expression is up-regulated in 75% of human renal cell carcinoma biopsies examined, which suggests that this splice variant is clinically relevant. Controls included cells overexpressing wild-type heparanase or an empty plasmid and normal-looking tissue adjacent the carcinoma lesion. T5 is a novel functional splice variant of human heparanase endowed with protumorigenic characteristics.-Barash, U., Cohen-Kaplan, V., Arvatz, G., Gingis-Velitski, S., Levy-Adam, F., Nativ, O., Shemesh, R., Ayalon-Sofer, M., Ilan, N., Vlodavsky, I. A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J. 24, 1239-1248 (2010). www.fasebj.org	[Barash, Uri; Cohen-Kaplan, Victoria; Arvatz, Gil; Gingis-Velitski, Svetlana; Levy-Adam, Flonia; Ilan, Neta; Vlodavsky, Israel] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; [Nativ, Ofer] Bnai Zion Med Ctr, Dept Urol, Haifa, Israel; [Shemesh, Ronen; Ayalon-Sofer, Michal] Compugen Ltd, Tel Aviv, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Bnai Zion Medical Center	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Fac Med, Canc & Vasc Biol Res Ctr, POB 9649, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il		Barash, Uri/0000-0003-1049-270X	Israel Science Foundation [549/06]; National Cancer Institute, U.S. National Institutes of Health [RO1-CA106456]; DKFZ-MOST; Technion; Israel Cancer Research Fund (ICRF); NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); National Cancer Institute, U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DKFZ-MOST; Technion; Israel Cancer Research Fund (ICRF); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the Israel Science Foundation (549/06); the National Cancer Institute, U.S. National Institutes of Health (RO1-CA106456); the DKFZ-MOST cooperation program in cancer research; the Technion Fine Postdoctoral Fellowship; and the Israel Cancer Research Fund (ICRF) Postdoctoral Fellowship. I. V. is a Research Professor of the ICRF.	Abboud-Jarrous G, 2005, J BIOL CHEM, V280, P13568, DOI 10.1074/jbc.M413370200; Abboud-Jarrous G, 2008, J BIOL CHEM, V283, P18167, DOI 10.1074/jbc.M801327200; Basche M, 2006, CLIN CANCER RES, V12, P5471, DOI 10.1158/1078-0432.CCR-05-2423; Ben-Zaken O, 2008, INT J BIOCHEM CELL B, V40, P530, DOI 10.1016/j.biocel.2007.09.003; Ben-Zaken O, 2007, BIOCHEM BIOPH RES CO, V361, P829, DOI 10.1016/j.bbrc.2007.06.188; Birzele F, 2008, NUCLEIC ACIDS RES, V36, P550, DOI 10.1093/nar/gkm1054; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Casu B, 2007, PATHOPHYSIOL HAEMO T, V36, P195, DOI 10.1159/000175157; Cohen E, 2005, FEBS LETT, V579, P2334, DOI 10.1016/j.febslet.2005.03.030; Cohen I, 2006, INT J CANCER, V118, P1609, DOI 10.1002/ijc.21552; Cohen-Kaplan V, 2008, CANCER RES, V68, P10077, DOI 10.1158/0008-5472.CAN-08-2910; Cooper TA, 2009, CELL, V136, P777, DOI 10.1016/j.cell.2009.02.011; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Doviner V, 2006, MODERN PATHOL, V19, P878, DOI 10.1038/modpathol.3800603; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Fairweather JK, 2008, BIOORGAN MED CHEM, V16, P699, DOI 10.1016/j.bmc.2007.10.044; Ferro V, 2004, MINI-REV MED CHEM, V4, P693, DOI 10.2174/1389557043403729; Ferro V, 2007, SEMIN THROMB HEMOST, V33, P557, DOI 10.1055/s-2007-982088; Fux L, 2009, TRENDS BIOCHEM SCI, V34, P511, DOI 10.1016/j.tibs.2009.06.005; Fux L, 2009, CANCER RES, V69, P1758, DOI 10.1158/0008-5472.CAN-08-1837; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P44084, DOI 10.1074/jbc.M402131200; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; Goldschmidt O, 2003, FASEB J, V17, P1015, DOI 10.1096/fj.02-0773com; Goldshmidt O, 2002, EXP CELL RES, V281, P50, DOI 10.1006/excr.2002.5651; Ilan N, 2006, INT J BIOCHEM CELL B, V38, P2018, DOI 10.1016/j.biocel.2006.06.004; Kelly T, 2003, CANCER RES, V63, P8749; Levy-Adam F, 2005, J BIOL CHEM, V280, P20457, DOI 10.1074/jbc.M414546200; Levy-Adam F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002319; Lewis KD, 2008, INVEST NEW DRUG, V26, P89, DOI 10.1007/s10637-007-9080-5; McKenzie EA, 2007, BRIT J PHARMACOL, V151, P1, DOI 10.1038/sj.bjp.0707182; Miao HQ, 2006, CURR MED CHEM, V13, P2101, DOI 10.2174/092986706777935230; Nadav L, 2006, CANCER RES, V66, P8608, DOI 10.1158/0008-5472.CAN-06-1301; Nadir Y, 2006, J THROMB HAEMOST, V4, P2443, DOI 10.1111/j.1538-7836.2006.02212.x; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; Nasser NJ, 2007, BIOCHEM BIOPH RES CO, V354, P33, DOI 10.1016/j.bbrc.2006.12.189; Nasser NJ, 2009, P NATL ACAD SCI USA, V106, P2253, DOI 10.1073/pnas.0812846106; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056; Simizu S, 2004, J BIOL CHEM, V279, P2697, DOI 10.1074/jbc.M300541200; Sorek R, 2004, GENOME RES, V14, P1617, DOI 10.1101/gr.2572604; Sorek R, 2003, NUCLEIC ACIDS RES, V31, P1067, DOI 10.1093/nar/gkg170; Sorek R, 2002, GENOME RES, V12, P1060, DOI 10.1101/gr.229302; Sotnikov I, 2004, J IMMUNOL, V172, P5185, DOI 10.4049/jimmunol.172.9.5185; Tazi J, 2009, BBA-MOL BASIS DIS, V1792, P14, DOI 10.1016/j.bbadis.2008.09.017; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; van Alphen RJ, 2009, BRIT J CANCER, V100, P228, DOI 10.1038/sj.bjc.6604801; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1983, CANCER RES, V43, P2704; Vlodavsky I, 2007, CURR PHARM DESIGN, V13, P2057; Vreys V, 2007, J CELL MOL MED, V11, P427, DOI 10.1111/j.1582-4934.2007.00039.x; Xie HQ, 2002, GENOMICS, V80, P326, DOI 10.1006/geno.2002.6841; Zcharia E, 2005, FASEB J, V19, P211, DOI 10.1096/fj.04-1970com; Zetser A, 2006, CANCER RES, V66, P1455, DOI 10.1158/0008-5472.CAN-05-1811; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068; Zetser A, 2003, CANCER RES, V63, P7733	56	36	40	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1239	1248		10.1096/fj.09-147074	http://dx.doi.org/10.1096/fj.09-147074			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	20007507	Green Published			2022-12-28	WOS:000276462300030
J	Moretti, A; Bellin, M; Jung, CB; Thies, TM; Takashima, Y; Bernshausen, A; Schiemann, M; Fischer, S; Moosmang, S; Smith, AG; Lam, JT; Laugwitz, KL				Moretti, Alessandra; Bellin, Milena; Jung, Christian B.; Thies, Tu-Mai; Takashima, Yasuhiro; Bernshausen, Alexandra; Schiemann, Matthias; Fischer, Stefanie; Moosmang, Sven; Smith, Austin G.; Lam, Jason T.; Laugwitz, Karl-Ludwig			Mouse and human induced pluripotent stem cells as a source for multipotent Isl1(+) cardiovascular progenitors	FASEB JOURNAL			English	Article						iPS cells; reprogramming; cardiac development; regenerative medicine	SMOOTH-MUSCLE; FIBROBLASTS; GENERATION; DIFFERENTIATION; EXPRESSION; INDUCTION; CARDIOMYOCYTE; LESSONS; MURINE	Ectopic expression of defined sets of genetic factors can reprogram somatic cells to create induced pluripotent stem (iPS) cells. The capacity to direct human iPS cells to specific differentiated lineages and to their progenitor populations can be used for disease modeling, drug discovery, and eventually autologous cell replacement therapies. During mouse cardiogenesis, the major lineages of the mature heart, cardiomyocytes, smooth muscle cells, and endothelial cells arise from a common, multipotent cardiovascular progenitor expressing the transcription factors Isl1 and Nkx2.5. Here we show, using genetic fate-mapping, that Isl1(+) multipotent cardiovascular progenitors can be generated from mouse iPS cells and spontaneously differentiate in all 3 cardiovascular lineages in vivo without teratoma. Moreover, we report the identification of human iPS-derived ISL1(+) progenitors with similar developmental potential. These results support the possibility to use patient-specific iPS-generated cardiovascular progenitors as a model to elucidate the pathogenesis of congenital and acquired forms of heart diseases.-Moretti, A., Bellin, M., Jung, C. B., Thies, T.-M., Takashima, Y., Bernshausen, A., Schiemann, M., Fischer, S., Moosmang, S., Smith, A. G., Lam, J. T., Laugwitz, K.-L. Mouse and human induced pluripotent stem cells as a source for multipotent Isl1(+) cardiovascular progenitors. FASEB J. 24, 700-711 (2010). www.fasebj.org	[Moretti, Alessandra; Bellin, Milena; Jung, Christian B.; Thies, Tu-Mai; Bernshausen, Alexandra; Lam, Jason T.; Laugwitz, Karl-Ludwig] Tech Univ Munich, Klinikum Rechts Isar, Dept Med, D-81675 Munich, Germany; [Moretti, Alessandra; Bellin, Milena; Jung, Christian B.; Thies, Tu-Mai; Bernshausen, Alexandra; Lam, Jason T.; Laugwitz, Karl-Ludwig] Tech Univ Munich, Deutsch Herzzentrum, Dept Med, D-81675 Munich, Germany; [Schiemann, Matthias] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany; [Fischer, Stefanie; Moosmang, Sven] Tech Univ Munich, Inst Pharmacol, D-81675 Munich, Germany; [Takashima, Yasuhiro; Smith, Austin G.] Univ Cambridge, Wellcome Trust Ctr Stem Cell Res, Cambridge, England	Technical University of Munich; German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; University of Cambridge	Lam, JT (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Med, Ismaninger Str 22, D-81675 Munich, Germany.	jtlam@med1.med.tum.de; klaugwitz@med1.med.tum.de	Moretti, Alessandra/O-9271-2015; Bellin, Milena/M-2311-2014	Moretti, Alessandra/0000-0001-5782-7832; Bellin, Milena/0000-0001-5380-6743; Smith, Austin/0000-0002-3029-4682	European Research Council [MEXT-23208]; German Research Foundation [La 1238 3-1/4-1]; German Ministry for Education and Research [01 GN 0826]; MRC [G0800784, G1001028, G9806702] Funding Source: UKRI; Medical Research Council [G0800784, G1001028, G9806702, G0800784B] Funding Source: researchfish	European Research Council(European Research Council (ERC)European Commission); German Research Foundation(German Research Foundation (DFG)); German Ministry for Education and Research(Federal Ministry of Education & Research (BMBF)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank Toshio Kitamura (University of Tokyo, Tokyo, Japan), Shinya Yamanaka (Kyoto University, Kyoto, Japan), and George Daley (Harvard Medical School, Boston, MA, USA) for providing viral vectors through Addgene. Some of the monoclonal antibodies were obtained from the Developmental Studies Hybridoma Bank, which was developed under the auspices of the National Institute Human Development and is maintained by the University of Iowa. The authors especially acknowledge K. Goetsch for her expertise in the FACS sorting analysis and M. Rudelius and D. Grewe for assistance in histology. This work was supported by a Marie Curie Excellence Team Grant from the European Research Council (MEXT-23208), the German Research Foundation (La 1238 3-1/4-1), and the German Ministry for Education and Research (01 GN 0826).	Aasen T, 2008, NAT BIOTECHNOL, V26, P1276, DOI 10.1038/nbt.1503; Bu L, 2009, NATURE, V460, P113, DOI 10.1038/nature08191; Cai CL, 2008, NATURE, V454, P104, DOI 10.1038/nature06969; Cai CL, 2003, DEV CELL, V5, P877, DOI 10.1016/S1534-5807(03)00363-0; Carey BW, 2009, P NATL ACAD SCI USA, V106, P157, DOI 10.1073/pnas.0811426106; Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799; Ebert AD, 2009, NATURE, V457, P277, DOI 10.1038/nature07677; Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092; Huangfu DW, 2008, NAT BIOTECHNOL, V26, P795, DOI 10.1038/nbt1418; Kanai-Azuma M, 2002, DEVELOPMENT, V129, P2367; Kattman SJ, 2006, DEV CELL, V11, P723, DOI 10.1016/j.devcel.2006.10.002; Kim JB, 2008, NATURE, V454, P646, DOI 10.1038/nature07061; Kim JB, 2009, CELL, V136, P411, DOI 10.1016/j.cell.2009.01.023; Kitajima S, 2000, DEVELOPMENT, V127, P3215; Laugwitz KL, 2008, DEVELOPMENT, V135, P193, DOI 10.1242/dev.001883; Laugwitz KL, 2005, NATURE, V433, P647, DOI 10.1038/nature03215; Leschik J, 2008, NAT PROTOC, V3, P1381, DOI 10.1038/nprot.2008.116; Li XJ, 2005, NAT BIOTECHNOL, V23, P215, DOI 10.1038/nbt1063; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Mauritz C, 2008, CIRCULATION, V118, P507, DOI 10.1161/CIRCULATIONAHA.108.778795; Moretti A, 2007, CELL MOL LIFE SCI, V64, P674, DOI 10.1007/s00018-007-6520-5; Moretti A, 2006, CELL, V127, P1151, DOI 10.1016/j.cell.2006.10.029; Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008; Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374; Narazaki G, 2008, CIRCULATION, V118, P498, DOI 10.1161/CIRCULATIONAHA.108.769562; Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; ORKIN SH, 1992, BLOOD, V80, P575; Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041; Passier R, 2008, NATURE, V453, P322, DOI 10.1038/nature07040; Rubart M, 2006, ANNU REV PHYSIOL, V68, P29, DOI 10.1146/annurev.physiol.68.040104.124530; SASAKI H, 1993, DEVELOPMENT, V118, P47; Schenke-Layland K, 2008, STEM CELLS, V26, P1537, DOI 10.1634/stemcells.2008-0033; Schwahn DJ, 2005, PIGM CELL RES, V18, P203, DOI 10.1111/j.1600-0749.2005.00229.x; Silva J, 2008, PLOS BIOL, V6, P2237, DOI 10.1371/journal.pbio.0060253; Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Srinivas S., 2001, BMC DEV BIOL, V1; Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494; Sun YF, 2007, DEV BIOL, V304, P286, DOI 10.1016/j.ydbio.2006.12.048; Takahashi K, 2007, NAT PROTOC, V2, P3081, DOI 10.1038/nprot.2007.418; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Wernig M, 2008, P NATL ACAD SCI USA, V105, P5856, DOI 10.1073/pnas.0801677105; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863; Wu SM, 2008, CELL, V132, P537, DOI 10.1016/j.cell.2008.02.002; Wu SM, 2006, CELL, V127, P1137, DOI 10.1016/j.cell.2006.10.028; Yang L, 2008, NATURE, V453, P524, DOI 10.1038/nature06894; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482; Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005	53	88	98	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					700	711		10.1096/fj.09-139477	http://dx.doi.org/10.1096/fj.09-139477			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19850773				2022-12-28	WOS:000274974600006
J	Minami, SS; Sung, YM; Dumanis, SB; Chi, SH; Burns, MP; Ann, EJ; Suzuki, T; Turner, RS; Park, HS; Pak, DTS; Rebeck, GW; Hoe, HS				Minami, S. Sakura; Sung, You Me; Dumanis, Sonya B.; Chi, Seong Hwan; Burns, Mark P.; Ann, Eun-Jung; Suzuki, Toshiharu; Turner, R. Scott; Park, Hee-Sae; Pak, Daniel T. S.; Rebeck, G. William; Hoe, Hyang-Sook			The cytoplasmic adaptor protein X11 alpha and extracellular matrix protein Reelin regulate ApoE receptor 2 trafficking and cell movement	FASEB JOURNAL			English	Article						Mint; wound healing; cell migration	AMYLOID PRECURSOR PROTEIN; DENSITY-LIPOPROTEIN RECEPTOR; APOLIPOPROTEIN-E RECEPTORS; NEURONAL MIGRATION; ALZHEIMERS-DISEASE; SYNAPTIC PLASTICITY; INTERACTION DOMAINS; BRAIN-DEVELOPMENT; TRANSGENIC MICE; FE65	The goal of this study was to determine the effect of X11 alpha on ApoE receptor 2 (ApoEr2) trafficking and the functional significance of this interaction on cell movement in MCF 10A epithelial cells. We found that X11 alpha increased surface levels of ApoEr2 by 64% compared to vector control, as determined by surface protein biotinylation. To examine the functional significance of this effect, we tested whether ApoEr2 played a novel role in cell movement in a wound-healing assay. We found that overexpression of ApoEr2 in MCF 10A cells increased cell migration velocity by 87% (P<0.01, n = 4) compared to GFP control. Cotransfection of X11 alpha had an additive effect on average velocity compared to ApoEr2 alone (13%; P<0.05, n = 4). In addition, we tested whether ApoEr2 ligands altered the effect of ApoEr2 on cell movement. We found that treatment with concentrated medium containing the extracellular matrix protein Reelin, but not control medium, further increased the velocity of ApoEr2-but not APP-transfected cells (20%; P<0.001, n = 4). Similarly, Reelin treatment increased cell velocity on the presence of ApoEr2 and X11 alpha (10%; P<0.05, n = 4). In the present study, we are the first to demonstrate that ApoEr2 regulates cell movement, and both X11 alpha and Reelin enhance this effect.-Minami, S. S., Sung, Y. M., Dumanis, S. B., Chi, S. H., Burns, M. P., Ann, E.-J., Suzuki, T., Turner, R. S., Park, H.-S., Pak, D. T. S., Rebeck, G. W., Hoe, H.- S. The cytoplasmic adaptor protein X11 alpha and extracellular matrix protein Reelin regulate ApoE receptor 2 trafficking and cell movement. FASEB J. 24, 58-69 ( 2010). www.fasebj.org	[Turner, R. Scott] Georgetown Univ, Dept Neurol, Med Ctr, Washington, DC 20057 USA; [Minami, S. Sakura; Dumanis, Sonya B.; Chi, Seong Hwan; Burns, Mark P.; Rebeck, G. William; Hoe, Hyang-Sook] Georgetown Univ, Dept Neurosci, Med Ctr, Washington, DC 20057 USA; [Sung, You Me] Georgetown Univ, Dept Oncol, Med Ctr, Washington, DC 20057 USA; [Pak, Daniel T. S.] Georgetown Univ, Dept Pharmacol, Med Ctr, Washington, DC 20057 USA; [Ann, Eun-Jung; Park, Hee-Sae] Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Kwangju, South Korea; [Suzuki, Toshiharu] Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Sapporo, Hokkaido, Japan	Georgetown University; Georgetown University; Georgetown University; Georgetown University; Chonnam National University; Hokkaido University	Hoe, HS (corresponding author), Georgetown Univ, Dept Neurol, Med Ctr, 4000 Reservoir Rd NW, Washington, DC 20057 USA.	hh69@georgetown.edu	Suzuki, Toshiharu/B-5342-2013; Rebeck, George William/J-2192-2012; Turner, Raymond Scott/G-2263-2011	Rebeck, George William/0000-0001-6276-248X; Turner, Raymond Scott/0000-0001-7534-2935; Dumanis, Sonya/0000-0002-3345-9497; Burns, Mark P/0000-0003-4750-2000	U. S. National Institutes of Health [AG032330, AG030060, AG026478, AG014473]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG030128, R01AG026478, R29AG014473, R03AG032330, R01AG014473, R03AG030060] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by U. S. National Institutes of Health grants AG032330 ( H. S. H.), AG030060 ( G. W. R.), AG026478 ( R. S. T.), and AG014473 ( G. W. R.). We thank Dr. Christopher Miller and Dr. Declan McLoughlin ( King's College London, London, UK) for X11 plasmid DNA, Dr. Joachim Herz ( University of Texas Southwestern Medical Center, Dallas, TX, USA) for ApoEr2 ( without exon19) plasmid DNA, and Dr. Andre Goffinet ( Catholic University of Leuven, Brussels, Belgium) and Dr. Suzanne Guenette ( Massachusetts General Hospital, Charlestown, MA, USA) for Dab1 and FE65 antibodies, respectively. We also thank Ji-yun Lee for her generous contribution toward the yeast 2-hybrid experiments.	Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Beffert U, 2005, NEURON, V47, P567, DOI 10.1016/j.neuron.2005.07.007; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chai XJ, 2009, J NEUROSCI, V29, P288, DOI 10.1523/JNEUROSCI.2934-08.2009; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Hack I, 2007, DEVELOPMENT, V134, P3883, DOI 10.1242/dev.005447; He XY, 2007, J NEUROSCI, V27, P4052, DOI 10.1523/JNEUROSCI.3993-06.2007; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Herz J, 2006, NAT REV NEUROSCI, V7, P850, DOI 10.1038/nrn2009; Herz J, 2009, CURR OPIN LIPIDOL, V20, P190, DOI 10.1097/MOL.0b013e32832d3a10; Hoe HS, 2005, MOL BRAIN RES, V137, P31, DOI 10.1016/j.molbrainres.2005.02.013; Hoe HS, 2008, J BIOL CHEM, V283, P6288, DOI 10.1074/jbc.M704140200; Hoe HS, 2006, J BIOL CHEM, V281, P35176, DOI 10.1074/jbc.M602162200; Hoe HS, 2006, J BIOL CHEM, V281, P24521, DOI 10.1074/jbc.M600728200; Lau KF, 2000, NEUROREPORT, V11, P3607, DOI 10.1097/00001756-200011090-00041; Lee JH, 2004, J BIOL CHEM, V279, P49099, DOI 10.1074/jbc.M405602200; Lee JH, 2003, J BIOL CHEM, V278, P47025, DOI 10.1074/jbc.M300503200; Mayer H, 2006, MOL CELL BIOL, V26, P19, DOI 10.1128/MCB.26.1.19-27.2006; Mueller HT, 2000, J BIOL CHEM, V275, P39302, DOI 10.1074/jbc.M008453200; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Parisiadou L, 2007, NEUROBIOL AGING, V28, P377, DOI 10.1016/j.neurobiolaging.2005.12.015; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; Perkinton MS, 2004, J BIOL CHEM, V279, P22084, DOI 10.1074/jbc.M311479200; Pramatarova A, 2008, MOL CELL NEUROSCI, V37, P178, DOI 10.1016/j.mcn.2007.09.008; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SOULE HD, 1990, CANCER RES, V50, P6075; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Vishnu S, 2006, DEV BIOL, V289, P296, DOI 10.1016/j.ydbio.2005.09.016; Young-Pearse TL, 2007, J NEUROSCI, V27, P14459, DOI 10.1523/JNEUROSCI.4701-07.2007	39	22	23	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					58	69		10.1096/fj.09-138123	http://dx.doi.org/10.1096/fj.09-138123			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19720620	Green Published			2022-12-28	WOS:000273233600009
J	Benton, G; Crooke, E; George, J				Benton, Gabriel; Crooke, Elliott; George, Jay			Laminin-1 induces E-cadherin expression in 3-dimensional cultured breast cancer cells by inhibiting DNA methyltransferase 1 and reversing promoter methylation status	FASEB JOURNAL			English	Article						extracellular matrix; epigenetic; metastasis; microenvironment; mesenchymal to epithelial reverting transition; MErT	MAMMARY EPITHELIAL-CELLS; RECONSTITUTED BASEMENT-MEMBRANE; ALUI RESTRICTION ENZYME; GENE-EXPRESSION; MESENCHYMAL TRANSITION; SIGNALING PATHWAYS; TUMOR PROGRESSION; CARCINOMA-CELLS; EXTRACELLULAR-MATRIX; TISSUE ARCHITECTURE	This study determines the role of laminin-1 in promoting metastatic colonization during breast cancer. For this purpose, human mammary epithelial cell lines representing normal (MCF-10A), adenocarcinoma (MCF-7), and malignant carcinoma (MDA-MB-231) were propagated in 3-dimensional cultures composed of laminin-1, collagen I, or mixtures of the two, and analyzed by Western blot, immunocytochemistry, semiquantitative reverse transcription polymerase chain reaction, and methylation-specific PCR. Here we demonstrate that laminin-1 decreases methylation of the E-cadherin promoter, resulting in increased mRNA and protein expression for malignant mammary epithelial cells. This decreased methylation is associated with dramatic changes in the cellular and structural morphology as well as a 70-fold decrease in DNA methyltransferase 1 (DNMT1) and a 6-fold decrease in cadherin 11 protein expression. To control for specificity of laminin-1 interactions, cells were also cultured on 2-dimensional plastic substrata and collagen I hydrogels for analysis, and the MCF-10A and MCF-7 were used as nonmalignant controls. Using a 3-dimensional model, we present evidence that laminin-1 is capable of inducing epigenetic change by inhibiting expression of DNMT1 and preventing methylation of the E-cadherin promoter, resulting in E-cadherin expression and the formation of cell-cell bonds in malignant carcinoma.-Benton, G., Crooke, E., George, J. Laminin-1 induces E-cadherin expression in 3-dimensional-cultured breast cancer cells by inhibiting DNA methyltransferase 1 and reversing promoter methylation status. FASEB J. 23, 3884-3895 (2009). www.fasebj.org	[Benton, Gabriel; Crooke, Elliott] Georgetown Univ, Washington, DC USA; [Benton, Gabriel; George, Jay] Trevigen Inc, Gaithersburg, MD USA	Georgetown University	Benton, G (corresponding author), 8405 Helgerman Ct, Gaithersburg, MD 20877 USA.	gjb2@georgetown.edu		Benton, Gabriel/0000-0003-4244-5764				Alpaugh ML, 1999, CANCER RES, V59, P5079; Ballestar E, 2005, BIOCHEM CELL BIOL, V83, P374, DOI 10.1139/o05-035; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849; Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016; Bissell MJ, 2003, BREAST CANCER RES, V5, P117, DOI 10.1186/bcr579; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Fan H, 2007, EUR J GASTROEN HEPAT, V19, P952, DOI 10.1097/MEG.0b013e3282c3a89e; FRIDMAN R, 1991, JNCI-J NATL CANCER I, V83, P769, DOI 10.1093/jnci/83.11.769; Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005; GRAFF JR, 1995, CANCER RES, V55, P5195; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hurtubise A, 2004, ANTI-CANCER DRUG, V15, P161, DOI 10.1097/01.cad.0000113334.52071.97; Imamichi Y, 2007, CELLS TISSUES ORGANS, V185, P180, DOI 10.1159/000101319; Ivascu A, 2007, INT J ONCOL, V31, P1403; Kanai Y, 2007, CARCINOGENESIS, V28, P2434, DOI 10.1093/carcin/bgm206; KANE RE, 1995, DRUG METAB DISPOS, V23, P303; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kleinman H K, 2001, Surg Oncol Clin N Am, V10, P329; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KOCAREK TA, 1993, MOL PHARMACOL, V43, P328; Koenig A, 2006, CANCER RES, V66, P4662, DOI 10.1158/0008-5472.CAN-05-2804; Le Beyec J, 2007, EXP CELL RES, V313, P3066, DOI 10.1016/j.yexcr.2007.04.022; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; Liu YQ, 2004, FASEB J, V18, P457, DOI 10.1096/fj.03-0948com; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Maniotis AJ, 2005, AM J PATHOL, V166, P1187, DOI 10.1016/S0002-9440(10)62338-3; McCabe MT, 2006, CANCER RES, V66, P385, DOI 10.1158/0008-5472.CAN-05-2020; Moiseeva EP, 2007, MOL CANCER THER, V6, P3071, DOI 10.1158/1535-7163.MCT-07-0117; MONAGHAN P, 1983, P NATL ACAD SCI-BIOL, V80, P3344, DOI 10.1073/pnas.80.11.3344; Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265; Nelson CM, 2008, J CELL BIOCHEM, V105, P25, DOI 10.1002/jcb.21821; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Olave IA, 2007, J BIOL CHEM, V282, P853, DOI 10.1074/jbc.M610404200; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008-5472.CAN-05-3071; PARRY G, 1987, J CELL BIOL, V105, P2043, DOI 10.1083/jcb.105.5.2043; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Pishvaian MJ, 1999, CANCER RES, V59, P947; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Rahnama F, 2009, ENDOCRINOLOGY, V150, P1466, DOI 10.1210/en.2008-1142; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rubin MA, 2001, HUM PATHOL, V32, P690, DOI 10.1053/hupa.2001.25902; Sandal T, 2007, AM J PATHOL, V170, P1739, DOI 10.2353/ajpath.2007.060922; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Schmelzle T, 2007, P NATL ACAD SCI USA, V104, P3787, DOI 10.1073/pnas.0700115104; SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302; SEELY KA, 1991, J CELL PHYSIOL, V146, P117, DOI 10.1002/jcp.1041460116; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; Thomlinson R H, 1977, J Clin Pathol Suppl (R Coll Pathol), V11, P105; Troyanovsky RB, 2003, MOL CELL BIOL, V23, P7965, DOI 10.1128/MCB.23.22.7965-7972.2003; Vincent-Salomon A, 2003, BREAST CANCER RES, V5, P101, DOI 10.1186/bcr578; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; WARBURTON MJ, 1982, J HISTOCHEM CYTOCHEM, V30, P667, DOI 10.1177/30.7.6179984; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Webber MM, 1997, CARCINOGENESIS, V18, P1225, DOI 10.1093/carcin/18.6.1225; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Wilsbacher Julie L, 2006, Cell Commun Signal, V4, P5, DOI 10.1186/1478-811X-4-5; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Yanagisawa M, 2006, J CELL BIOL, V174, P1087, DOI 10.1083/jcb.200605022; Yates CC, 2007, BRIT J CANCER, V96, P1246, DOI 10.1038/sj.bjc.6603700; Yates C, 2007, ADV CANCER RES, V97, P225, DOI 10.1016/S0065-230X(06)97010-9; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhou J, 2006, CANCER LETT, V237, P10, DOI 10.1016/j.canlet.2005.05.028	84	38	39	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3884	3895		10.1096/fj.08-128702	http://dx.doi.org/10.1096/fj.08-128702			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19635753				2022-12-28	WOS:000271272500024
J	Cheng, AG; Kim, HK; Burts, ML; Krausz, T; Schneewind, O; Missiakas, DM				Cheng, Alice G.; Kim, Hwan Keun; Burts, Monica L.; Krausz, Thomas; Schneewind, Olaf; Missiakas, Dominique M.			Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues	FASEB JOURNAL			English	Article						surface proteins; vaccine; protective immunity; sortase; envelope-associated proteins	BIOFILM FORMATION; SURFACE-PROTEINS; INTERCELLULAR-ADHESION; SORTASE; VIRULENCE; EXPRESSION; SEQUENCE; IMMUNITY; ANCHORS; TYPE-5	Staphylococcus aureus infections are associated with abscess formation and bacterial persistence; however, the genes that enable this lifestyle are not known. We show here that following intravenous infection of mice, S. aureus disseminates rapidly into organ tissues and elicits abscess lesions that develop over weeks but cannot be cleared by the host. Staphylococci grow as communities at the center of abscess lesions and are enclosed by pseudocapsules, separating the pathogen from immune cells. By testing insertional variants in genes for cell wall-anchored surface proteins, we are able to infer the stage at which these molecules function. Fibrinogen-binding proteins ClfA and ClfB are required during the early phase of staphylococcal dissemination. The heme scavenging factors IsdA and IsdB, as well as SdrD and protein A, are necessary for abscess formation. Envelope-associated proteins, Emp and Eap, are either required for abscess formation or contribute to persistence. Fluorescence microscopy revealed Eap deposition within the pseudocapsule, whereas Emp was localized within staphylococcal abscess communities. Antibodies directed against envelope-associated proteins generated vaccine protection against staphylococcal abscess formation. Thus, staphylococci employ envelope proteins at discrete stages of a developmental program that enables abscess formation and bacterial persistence in host tissues. Cheng, A. G., Kim, H. K., Burts, M. L., Krausz, T., Schneewind, O., Missiakas, D. M. Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J. 23, 3393-3404 ( 2009). www.fasebj.org	[Cheng, Alice G.; Kim, Hwan Keun; Burts, Monica L.; Schneewind, Olaf; Missiakas, Dominique M.] Univ Chicago, Dept Microbiol, Chicago, IL 60637 USA; [Krausz, Thomas] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Schneewind, O (corresponding author), Univ Chicago, Dept Microbiol, 920 E 58th St, Chicago, IL 60637 USA.	oschnee@bsd.uchicago.edu		Kim, Hwan Keun/0000-0003-2095-9705	National Institute of Allergy and Infectious Diseases, Infectious Diseases Branch [AI42797]; Novartis Vaccines and Diagnostics (Siena, Italy); Regional Center of Excellence in Biodefense and Emerging Infectious Diseases Consortium [1-U54-AI-057153]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052474, R01AI075258, U54AI057153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, Infectious Diseases Branch(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Novartis Vaccines and Diagnostics (Siena, Italy); Regional Center of Excellence in Biodefense and Emerging Infectious Diseases Consortium(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Qiti Guo for electron microscopy, Shirley Bond for light microscopy, Vytas Bindokas for fluorescence microscopy, and members of our laboratories, as well as Guido Grandi and Fabio Bagnoli (Novartis) for discussion. This work was supported, in part, by grants from the National Institute of Allergy and Infectious Diseases, Infectious Diseases Branch (AI42797 to O.S.) and by Novartis Vaccines and Diagnostics (Siena, Italy). A. G. C. was a trainee of the National Institutes of Health Medical Scientist Training Program at The University of Chicago (GM07281). O.S. and D. M. M. acknowledge membership within and support from the Region V ( Great Lakes) Regional Center of Excellence in Biodefense and Emerging Infectious Diseases Consortium (GLRCE, National Institute of Allergy and Infectious Diseases award 1-U54-AI-057153).	ALBUS A, 1991, INFECT IMMUN, V59, P1008, DOI 10.1128/IAI.59.3.1008-1014.1991; Baba T, 2008, J BACTERIOL, V190, P300, DOI 10.1128/JB.01000-07; Bae T, 2004, P NATL ACAD SCI USA, V101, P12312, DOI 10.1073/pnas.0404728101; Brady RA, 2008, FEMS IMMUNOL MED MIC, V52, P13, DOI 10.1111/j.1574-695X.2007.00357.x; Brady RA, 2006, INFECT IMMUN, V74, P3415, DOI 10.1128/IAI.00392-06; Cassat James E., 2007, V391, P127; Cramton SE, 1999, INFECT IMMUN, V67, P5427, DOI 10.1128/IAI.67.10.5427-5433.1999; Diep BA, 2006, LANCET, V367, P731, DOI 10.1016/S0140-6736(06)68231-7; Drenkard E, 2002, NATURE, V416, P740, DOI 10.1038/416740a; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; Gomez MI, 2004, NAT MED, V10, P842, DOI 10.1038/nm1079; Gorbach SL, 1995, J CLIN INVEST, V96, P2545, DOI 10.1172/JCI118316; Gotz F, 2002, MOL MICROBIOL, V43, P1367, DOI 10.1046/j.1365-2958.2002.02827.x; Hall-Stoodley L, 2004, NAT REV MICROBIOL, V2, P95, DOI 10.1038/nrmicro821; Hartleib J, 2000, BLOOD, V96, P2149; Heilmann C, 1996, MOL MICROBIOL, V20, P1083, DOI 10.1111/j.1365-2958.1996.tb02548.x; JENSEN KLAUS, 1958, ACTA PATHOL ET MICROBIOL SCAND, V44, P421; Jones C, 2005, CARBOHYD RES, V340, P1097, DOI 10.1016/j.carres.2005.02.001; Jonsson IM, 2002, J INFECT DIS, V185, P1417, DOI 10.1086/340503; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Kolter R, 2006, NATURE, V441, P300, DOI 10.1038/441300a; LAM GT, 1963, J BACTERIOL, V86, P87, DOI 10.1128/JB.86.1.87-91.1963; Lee LY, 2002, J CLIN INVEST, V110, P1461, DOI 10.1172/JC1200216318; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Mack D, 1996, J BACTERIOL, V178, P175, DOI 10.1128/jb.178.1.175-183.1996; Mazmanian SK, 2002, P NATL ACAD SCI USA, V99, P2293, DOI 10.1073/pnas.032523999; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; O'Riordan K, 2004, CLIN MICROBIOL REV, V17, P218, DOI 10.1128/CMR.17.1.218-234.2004; ROBEN PW, 1995, J IMMUNOL, V154, P6437; Rodig SJ, 2001, ARCH PATHOL LAB MED, V125, P1515; Russell DG, 2008, CELL HOST MICROBE, V3, P115, DOI 10.1016/j.chom.2008.02.008; Sau S, 1997, MICROBIOL-UK, V143, P2395, DOI 10.1099/00221287-143-7-2395; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1368, DOI 10.1056/NEJM198405243102107; Singh PK, 2002, NATURE, V417, P552, DOI 10.1038/417552a; Stranger-Jones YK, 2006, P NATL ACAD SCI USA, V103, P16942, DOI 10.1073/pnas.0606863103; Tzianabos AO, 1995, J CLIN INVEST, V96, P2727, DOI 10.1172/JCI118340; UHLEN M, 1984, J BIOL CHEM, V259, P1695; Vuong C, 2004, J BIOL CHEM, V279, P54881, DOI 10.1074/jbc.M411374200; Wallenfang T, 1980, Neurosurg Rev, V3, P101, DOI 10.1007/BF01644062; Weiss WJ, 2004, J ANTIMICROB CHEMOTH, V53, P480, DOI 10.1093/jac/dkh078; Xiong YQ, 2005, ANTIMICROB AGENTS CH, V49, P380, DOI 10.1128/AAC.49.1.380-387.2005	43	300	318	3	47	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3393	3404		10.1096/fj.09-135467	http://dx.doi.org/10.1096/fj.09-135467			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19525403	Green Published			2022-12-28	WOS:000270354300017
J	Lu, J; Zhang, SY; Chen, D; Wang, HB; Wu, WT; Wang, XT; Lei, YP; Wang, JC; Qian, J; Fan, WW; Hu, ZB; Jin, L; Shen, HB; Huang, W; Wei, QY; Lu, DR				Lu, Juan; Zhang, Shuyu; Chen, Dan; Wang, Huibo; Wu, Wenting; Wang, Xiaotian; Lei, Yunping; Wang, Jiucun; Qian, Ji; Fan, Weiwei; Hu, Zhibin; Jin, Li; Shen, Hongbing; Huang, Wei; Wei, Qingyi; Lu, Daru			Functional characterization of a promoter polymorphism in APE1/Ref-1 that contributes to reduced lung cancer susceptibility	FASEB JOURNAL			English	Article						association; Oct-1; binding affinity; lung carcinogenesis	BASE-EXCISION-REPAIR; SIGNALING PROTEIN APE1/REF-1; HOGG1 SER326CYS POLYMORPHISM; MULTIFUNCTIONAL DNA-REPAIR; TRANSCRIPTION FACTOR OCT-1; GENETIC POLYMORPHISMS; ENDONUCLEASE ACTIVITY; ENZYME HAP1; RISK; CELLS	Apurinic/apyrimidinic endonuclease 1/redox effector factor-1 (APE1/Ref-1) is a ubiquitous multifunctional protein that possesses both DNA-repair and redox regulatory activities. Although it was originally identified as a DNA-repair enzyme, accumulating evidence supports a role of APE1/Ref-1 in tumor development. To investigate association between APE1/Ref-1 polymorphisms and lung cancer risk in Chinese populations, we first genotyped three variants of APE1/Ref-1 and found a -141 T-to-G variant (rs1760944) in the promoter associated with decreased risk of lung cancer [ odds ratio ( OR) = 0.62 for GG; P = 0.043]. Similar results were obtained in a follow-up replication study. Combined data from the two studies comprising a total of 1072 lung cancer patients and 1064 cancer-free control participants generated a more significant association ( P = 0.002). We observed lower APE1/Ref-1 mRNA levels in the presence of the protective G allele in human peripheral blood mononuclear cells and normal lung tissues. The -141G-allele-promoter construct exhibited decreased luciferase reporter gene expression. Electrophoretic mobility shift assays and surface plasmon resonance analysis showed that the -141G allele impaired the binding affinity of some transcription factor, accounting for lower APE1/Ref-1-promoter activity. Supershift assays further revealed that the protein of interest was octamer-binding transcription factor-1 (Oct-1). Chromatin immunoprecipitation reconfirmed binding of Oct-1 to the APE1/Ref-1 -141-promoter region. We also found that Oct-1 conferred attenuated transactivation capacity toward the -141G variant by exogenously introducing Oct-1. These data indicate that genetic variations in APE1/Ref-1 may modify susceptibility to lung cancer and provide new insights into an unexpected effect of APE1/Ref-1 on lung carcinogenesis.-Lu, J., Zhang, S., Chen, D., Wang, H., Wu, W., Wang, X., Lei, Y., Wang, J., Qian, J., Fan, W., Hu, Z., Jin, L., Shen, H., Huang, W., Wei, Q., Lu, D. Functional characterization of a promoter polymorphism in APE1/Ref-1 that contributes to reduced lung cancer susceptibility. FASEB J. 23, 3459-3469 ( 2009). www.fasebj.org	[Lu, Juan; Zhang, Shuyu; Chen, Dan; Wang, Huibo; Wu, Wenting; Wang, Xiaotian; Lei, Yunping; Wang, Jiucun; Qian, Ji; Fan, Weiwei; Jin, Li; Lu, Daru] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China; [Lu, Juan; Zhang, Shuyu; Chen, Dan; Wang, Huibo; Wu, Wenting; Wang, Xiaotian; Lei, Yunping; Wang, Jiucun; Qian, Ji; Fan, Weiwei; Jin, Li; Lu, Daru] Fudan Univ, Sch Life Sci, Minist Educ, Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China; [Wang, Huibo] Harbin Med Coll, Clin Med Sch 1, Brain Tumor Res Ctr, Dept Neurol Surg, Harbin, Peoples R China; [Hu, Zhibin; Shen, Hongbing] Nanjing Med Univ, Canc Res Ctr, Dept Epidemiol & Biostat, Nanjing, Peoples R China; [Jin, Li; Huang, Wei] Chinese Natl Human Genome Ctr, Dept Genet, Shanghai, Peoples R China; [Wei, Qingyi] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	Fudan University; Fudan University; Harbin Medical University; Nanjing Medical University; University of Texas System; UTMD Anderson Cancer Center	Lu, DR (corresponding author), Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.	drlu@fudan.edu.cn	Jin, Li/M-5063-2019; Lei, Yunping/B-6322-2009; Wang, Jiucun/J-8744-2012; Jin, Li/C-1468-2009; wu, wenting/Q-4979-2016; Anthropology, MOE KeyLab Fudan/A-9454-2010; Frank, Viki/GXZ-9902-2022	Lei, Yunping/0000-0003-1504-0884; Wang, Jiucun/0000-0003-2765-0620; Jin, Li/0000-0002-4546-2415; wu, wenting/0000-0003-0982-771X; 	China National Key Basic Research Program [2002CB512902]; Shanghai Science and Technology Research Program [06DZ19501]; Shanghai Leading Academic Discipline Project [B111]; Shanghai Subject Chief Scientist for Public Health [08GWD07]; Shanghai Key Subject Project for Public Health [08GWZX0301]	China National Key Basic Research Program(National Basic Research Program of China); Shanghai Science and Technology Research Program; Shanghai Leading Academic Discipline Project(Shanghai Leading Academic Discipline Project); Shanghai Subject Chief Scientist for Public Health; Shanghai Key Subject Project for Public Health	We thank all of the patients and control participants for donating samples, as well as the laboratory members for their contribution toward this work. We are grateful to Dr. Pamela Mellon ( University of California, San Diego, CA, USA) for providing the pCRII-TOPO-Oct-1 expression vector. This work was supported partially by China National Key Basic Research Program grant 2002CB512902, Shanghai Science and Technology Research Program grant 06DZ19501, Shanghai Leading Academic Discipline Project B111, Shanghai Subject Chief Scientist for Public Health grant 08GWD07, and Shanghai Key Subject Project for Public Health grant 08GWZX0301.	Ando K, 2008, NUCLEIC ACIDS RES, V36, P4327, DOI 10.1093/nar/gkn416; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Bobola MS, 2005, CLIN CANCER RES, V11, P7405, DOI 10.1158/1078-0432.CCR-05-1068; Bowen AR, 2003, J INVEST DERMATOL, V120, P48, DOI 10.1046/j.1523-1747.2003.12010.x; Chiarini LB, 2000, CELL DEATH DIFFER, V7, P272, DOI 10.1038/sj.cdd.4400639; De Ruyck K, 2007, MUTAT RES-GEN TOX EN, V631, P101, DOI 10.1016/j.mrgentox.2007.03.010; El-Domyati M, 2009, J EUR ACAD DERMATOL, V23, P7, DOI 10.1111/j.1468-3083.2008.02937.x; Fishel ML, 2008, DNA REPAIR, V7, P177, DOI 10.1016/j.dnarep.2007.09.008; Herring CJ, 1999, BRIT J CANCER, V80, P940, DOI 10.1038/sj.bjc.6690447; Hu ZB, 2007, HUM MUTAT, V28, P431, DOI 10.1002/humu.20462; Hung RJ, 2005, AM J EPIDEMIOL, V162, P925, DOI 10.1093/aje/kwi318; Lau JP, 2004, BRIT J CANCER, V91, P1166, DOI 10.1038/sj.bjc.6602080; Le Marchand L, 2002, CANCER EPIDEM BIOMAR, V11, P409; Lee JM, 2001, INT J CANCER, V95, P240, DOI 10.1002/1097-0215(20010720)95:4<240::AID-IJC1041>3.0.CO;2-1; Lo YL, 2009, CANCER EPIDEM BIOMAR, V18, P223, DOI 10.1158/1055-9965.EPI-08-0749; Luo M, 2008, ANTIOXID REDOX SIGN, V10, P1853, DOI 10.1089/ars.2008.2120; Miller KL, 2006, CARCINOGENESIS, V27, P1670, DOI 10.1093/carcin/bgi376; Nelson HH, 2002, CANCER RES, V62, P152; ONO Y, 1994, MUTAT RES, V315, P55, DOI 10.1016/0921-8777(94)90028-0; Robertson KA, 1997, CELL GROWTH DIFFER, V8, P443; Shen M, 2005, INT J CANCER, V116, P768, DOI 10.1002/ijc.21117; Spitz MR, 2003, CANCER EPIDEM BIOMAR, V12, P689; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Sugimura H, 1999, CANCER EPIDEM BIOMAR, V8, P669; Tantin D, 2005, CANCER RES, V65, P10750, DOI 10.1158/0008-5472.CAN-05-2399; Tell G, 2005, ANTIOXID REDOX SIGN, V7, P367, DOI 10.1089/ars.2005.7.367; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; Wang NP, 2001, CIRC RES, V88, P1223, DOI 10.1161/hh1201.093162; Wiederhold L, 2004, MOL CELL, V15, P209, DOI 10.1016/j.molcel.2004.06.003; Wu XF, 2002, JNCI-J NATL CANCER I, V94, P681; Yang S, 2007, CARCINOGENESIS, V28, P2382, DOI 10.1093/carcin/bgm128; Zaky A, 2008, NUCLEIC ACIDS RES, V36, P1555, DOI 10.1093/nar/gkm1173; Zhang XM, 2005, CANCER RES, V65, P722; Zhao HC, 2000, CANCER RES, V60, P6276; Zhu YM, 2007, CARCINOGENESIS, V28, P698, DOI 10.1093/carcin/bgl201; Zienolddiny S, 2006, CARCINOGENESIS, V27, P560, DOI 10.1093/carcin/bgi232; Zou GM, 2008, MOL CANCER THER, V7, P2012, DOI 10.1158/1535-7163.MCT-08-0113	37	60	62	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3459	3469		10.1096/fj.09-136549	http://dx.doi.org/10.1096/fj.09-136549			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19541747				2022-12-28	WOS:000270354300023
J	Pearson, MS; Bethony, JM; Pickering, DA; de Oliveira, LM; Jariwala, A; Santiago, H; Miles, AP; Zhan, B; Jiang, DS; Ranjit, N; Mulvenna, J; Tribolet, L; Plieskatt, J; Smith, T; Bottazzi, ME; Jones, K; Keegan, B; Hotez, PJ; Loukas, A				Pearson, Mark S.; Bethony, Jeffrey M.; Pickering, Darren A.; de Oliveira, Luciana M.; Jariwala, Amar; Santiago, Helton; Miles, Aaron P.; Zhan, Bin; Jiang, Desheng; Ranjit, Najju; Mulvenna, Jason; Tribolet, Leon; Plieskatt, Jordan; Smith, Tracey; Bottazzi, Maria Elena; Jones, Kathryn; Keegan, Brian; Hotez, Peter J.; Loukas, Alex			An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection	FASEB JOURNAL			English	Article						vaccine; protease; hemoglobin; neglected tropical disease	TRANSMITTED HELMINTH INFECTIONS; D ASPARTIC PROTEASES; CATHEPSIN-D; HAEMONCHUS-CONTORTUS; ANCYLOSTOMA-CANINUM; FASCIOLA-HEPATICA; VACCINATION; VACCINES; PROTEINASES; LARVAE	Hookworms digest hemoglobin from erythrocytes via a proteolytic cascade that begins with the aspartic protease, APR-1. Ac-APR-1 from the dog hookworm, Ancylostoma caninum, protects dogs against hookworm infection via antibodies that neutralize enzymatic activity and interrupt blood-feeding. Toward developing a human hookworm vaccine, we expressed both wild-type (Na-APR-1(wt)) and mutant (Na-APR-1(mut)-mutagenesis of the catalytic aspartic acids) forms of Na-APR-1 from the human hookworm, Necator americanus. Refolded Na-APR-1(wt) was catalytically active, and Na-APR-1(mut) was catalytically inactive but still bound substrates. Vaccination of canines with Na-APR-1(mut) and heterologous challenge with A. caninum resulted in significantly reduced parasite egg burdens (P=0.034) and weight loss (P=0.022). Vaccinated dogs also had less gut pathology, fewer adult worms, and reduced blood loss compared to controls but these did not reach statistical significance. Vaccination with Na-APR-1mut induced antibodies that bound the native enzyme in the parasite gut and neutralized enzymatic activity of Na-APR-1(wt) and APR-1 orthologues from three other hookworm species that infect humans. IgG1 against Na-APR-1(mut) was the most prominently detected antibody in sera from people resident in high-transmission areas for N. americanus, indicating that natural boosting may occur in exposed humans. Na-APR-1(mut) is now a lead antigen for the development of an antihematophagy vaccine for human hookworm disease.-Pearson, M. S., Bethony, J. M., Pickering, D. A., de Oliveira, L. M., Jariwala, A., Santiago, H., Miles, A. P., Zhan, B., Jiang, D., Ranjit, N., Mulvenna, J., Tribolet, L., Plieskatt, J., Smith, T., Bottazzi, M. E., Jones, K., Keegan, B., Hotez, P. J., Loukas, A. An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection. FASEB J. 23, 3007-3019 (2009). www.fasebj.org	[Pearson, Mark S.; Pickering, Darren A.; Ranjit, Najju; Mulvenna, Jason; Tribolet, Leon; Loukas, Alex] Queensland Inst Med Res, Div Infect Dis, Brisbane, Qld 4006, Australia; [Pearson, Mark S.; Pickering, Darren A.; Ranjit, Najju; Mulvenna, Jason; Tribolet, Leon; Loukas, Alex] Australian Ctr Vaccine Dev, Brisbane, Qld 4006, Australia; [Bethony, Jeffrey M.; de Oliveira, Luciana M.; Jariwala, Amar; Santiago, Helton; Miles, Aaron P.; Zhan, Bin; Jiang, Desheng; Plieskatt, Jordan; Smith, Tracey; Bottazzi, Maria Elena; Jones, Kathryn; Keegan, Brian; Hotez, Peter J.] George Washington Univ, Med Ctr, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA	QIMR Berghofer Medical Research Institute; George Washington University	Loukas, A (corresponding author), Queensland Inst Med Res, Div Infect Dis, 300 Herston Rd, Brisbane, Qld 4006, Australia.	alex.loukas@qimr.edu.au	de Oliveira, Luciana/AAE-7182-2022; Pearson, Mark S/O-5636-2014; de Oliveira, Luciana M/I-8842-2012; Santiago, Helton/AAA-8558-2021; Loukas, Alex/B-7355-2014; Mulvenna, Jason/H-7110-2014; Santiago, Helton/F-8704-2012	de Oliveira, Luciana/0000-0002-3080-8604; Loukas, Alex/0000-0002-0896-8441; Mulvenna, Jason/0000-0003-3521-8061; Santiago, Helton/0000-0002-5695-8256; Hotez, Peter/0000-0001-8770-1042; Plieskatt, Jordan/0000-0002-2333-7234; Tribolet, Leon/0000-0002-2093-9678; Pearson, Mark/0000-0002-0002-1544; Wolf, Nathaniel/0000-0001-6567-2447; Bottazzi, Maria Elena/0000-0002-8429-0476	Bill and Melinda Gates Foundation; Albert B. Sabin Vaccine Institute; National Health and Medical Research Council of Australia (NHMRC); ARC/NHMRC Research Network for Parasitology; Australian Centre for Vaccine Development	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Albert B. Sabin Vaccine Institute; National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); ARC/NHMRC Research Network for Parasitology(Australian Research CouncilNational Health and Medical Research Council (NHMRC) of Australia); Australian Centre for Vaccine Development	We thank Drs. Jane Halpern, Philip Russell, and Ami Shah-Brown for helpful discussions and Mark J. Hoenerhoff for conducting the canine clinical pathology. This work was funded by a grant awarded from the Bill and Melinda Gates Foundation to the Albert B. Sabin Vaccine Institute and a grant from the National Health and Medical Research Council of Australia (NHMRC). A. L. is the recipient of an NHMRC senior research fellowship. J. B. is the recipient of travel awards from the ARC/NHMRC Research Network for Parasitology and the Australian Centre for Vaccine Development.	Albonico M, 2004, INT J PARASITOL, V34, P1205, DOI 10.1016/j.ijpara.2004.08.001; ALBONICO M, 1995, T ROY SOC TROP MED H, V89, P538, DOI 10.1016/0035-9203(95)90101-9; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Bethony J, 2005, FASEB J, V19, P1743, DOI 10.1096/fj.05-3936fje; Brooker S, 2007, T ROY SOC TROP MED H, V101, P146, DOI 10.1016/j.trstmh.2006.05.012; Brooker S, 2006, INT J PARASITOL, V36, P1143, DOI 10.1016/j.ijpara.2006.05.009; Dalton JP, 2003, INT J PARASITOL, V33, P1173, DOI 10.1016/S0020-7519(03)00171-1; de Silva NR, 2003, TRENDS PARASITOL, V19, P547, DOI 10.1016/j.pt.2003.10.002; Don TA, 2004, INT J PARASITOL, V34, P1029, DOI 10.1016/j.ijpara.2004.04.013; Don TA, 2008, INT J INFECT DIS, V12, pE39, DOI 10.1016/j.ijid.2007.10.007; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Fleming FM, 2006, TROP MED INT HEALTH, V11, P56, DOI 10.1111/j.1365-3156.2005.01541.x; Fujiwara RT, 2006, VACCINE, V24, P501, DOI 10.1016/j.vaccine.2005.07.091; Geldhof P, 2002, PARASITE IMMUNOL, V24, P263, DOI 10.1046/j.1365-3024.2002.00461.x; Hotez P.J., 2007, ANN NY ACAD SCI, V1136, P38; Hotez PJ, 2008, J CLIN INVEST, V118, P1311, DOI 10.1172/JCI34261; Hotez PJ, 2003, J PARASITOL, V89, P853, DOI 10.1645/GE-46R; HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5; Jacobson RH, 1998, REV SCI TECH OIE, V17, P469, DOI 10.20506/rst.17.2.1119; Knox DP, 2003, INT J PARASITOL, V33, P1129, DOI 10.1016/S0020-7519(03)00167-X; Krauer K, 2004, J GEN VIROL, V85, P165, DOI 10.1099/vir.0.19549-0; KREMER M, 2004, 112W10324 HARV U CTR; Leal AT, 2006, VET IMMUNOL IMMUNOP, V114, P341, DOI 10.1016/j.vetimm.2006.08.011; Loukas A, 2005, PLOS MED, V2, P1008, DOI 10.1371/journal.pmed.0020295; Loukas A, 2004, J INFECT DIS, V189, P1952, DOI 10.1086/386346; Loukas A, 2006, LANCET INFECT DIS, V6, P733, DOI 10.1016/S1473-3099(06)70630-2; McManus DP, 2008, CLIN MICROBIOL REV, V21, P225, DOI 10.1128/CMR.00046-07; Morales ME, 2008, MOL BIOCHEM PARASIT, V157, P160, DOI 10.1016/j.molbiopara.2007.10.009; Munn EA, 1997, INT J PARASITOL, V27, P359, DOI 10.1016/S0020-7519(97)00003-9; Piacenza L, 1997, J HELMINTHOL, V71, P333, DOI 10.1017/S0022149X00016151; Piacenza L, 1999, INFECT IMMUN, V67, P1954; Quinn CP, 2002, EMERG INFECT DIS, V8, P1103, DOI 10.3201/eid0810.020380; RANJIT N, 2009, J INFECT DIS; Redmond DL, 2004, VACCINE, V22, P4252, DOI 10.1016/j.vaccine.2004.04.028; Tarcha EJ, 2006, INFECT IMMUN, V74, P516, DOI 10.1128/IAI.74.1.516-527.2006; Verity CK, 2001, PARASITE IMMUNOL, V23, P153, DOI 10.1046/j.1365-3024.2001.00369.x; Vilanova M, 2004, IMMUNOLOGY, V111, P334, DOI 10.1111/j.1365-2567.2004.01819.x; Williamson AL, 2004, J BIOL CHEM, V279, P35950, DOI 10.1074/jbc.M405842200; Williamson AL, 2003, PARASITOLOGY, V126, P179, DOI 10.1017/S0031182002002706; Williamson AL, 2002, FASEB J, V16, P1458, DOI 10.1096/fj.02-0181fje; Xiao S, 2008, EXP PARASITOL, V118, P32, DOI 10.1016/j.exppara.2007.05.010; Yoshida Y., 1960, Japanese Journal of Parasitology, V9, P735	43	70	70	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3007	3019		10.1096/fj.09-131433	http://dx.doi.org/10.1096/fj.09-131433			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19380510	Green Published			2022-12-28	WOS:000270241000023
J	Wang, ZY; Ma, W; Chabot, JG; Quirion, R				Wang, Zhiyong; Ma, Weiya; Chabot, Jean-Guy; Quirion, Remi			Cell-type specific activation of p38 and ERK mediates calcitonin gene-related peptide involvement in tolerance to morphine-induced analgesia	FASEB JOURNAL			English	Article						neuropeptide; astrocyte; microglia; cytokine; kinase	PRIMARY SENSORY NEURONS; SPINAL NERVE LIGATION; PROTEIN-KINASE; NEUROPATHIC PAIN; PROINFLAMMATORY CYTOKINES; CENTRAL SENSITIZATION; MECHANICAL ALLODYNIA; SIGNAL-TRANSDUCTION; SUBSTANCE-P; EXPRESSION	Tolerance to morphine-induced analgesia is a well-established phenomenon, often limiting its usefulness in the long-term treatment of pain. The mechanisms underlying tolerance are not well understood. We previously suggested a possible role for spinal calcitonin gene-related peptide ( CGRP) in the development of tolerance to morphine-induced analgesia. In the present study, we demonstrate that CGRP is involved in morphine tolerance by differentially regulating the ERK-dependent up-regulation of IL-1 beta, TNF-alpha, and microsomal prostaglandin E synthase-1 (mPGES-1) in astrocytes and p38-dependent up-regulation of IL-6 in microglia in the rat spinal cord. A 7-d treatment with morphine induced tolerance to the antinociceptive effect and increased phosphorylated ERK localized in astrocytes and phosphorylated p38 enriched in microglia, both effects being inhibited by blocking CGRP receptors. Interestingly, the inhibition of the ERK pathway suppressed the development of tolerance and morphine-induced up-regulation of IL1 beta, TNF-alpha, and mPGES-1. Blockade of p38 activity also inhibited the development of tolerance and morphine-induced IL-6 up-regulation. Taken together, these data suggest that chronic morphine induces the synthesis of CGRP, which in turn acts on CGRP receptors located on astrocytes and microglia to stimulate ERK and p38, respectively, leading to increased synthesis and release of proinflammatory mediators resulting in tolerance to morphine-induced analgesia.-Wang, Z., Ma, W., Chabot, J.-G., Quirion, R. Cell-type specific activation of p38 and ERK mediates calcitonin gene-related peptide involvement in tolerance to morphine-induced analgesia. FASEB J. 23, 2576-2586 ( 2009)	[Wang, Zhiyong; Ma, Weiya; Chabot, Jean-Guy; Quirion, Remi] McGill Univ, Douglas Mental Hlth Univ Inst, Montreal, PQ H4H 1R3, Canada	McGill University	Quirion, R (corresponding author), McGill Univ, Douglas Mental Hlth Univ Inst, 6875 Blvd LaSalle, Montreal, PQ H4H 1R3, Canada.	remi.quirion@douglas.mcgill.ca			Canadian Institutes of Health	Canadian Institutes of Health(Canadian Institutes of Health Research (CIHR))	This study was supported by a grant from the Canadian Institutes of Health Research to R. Q.	Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Bird GC, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-31; Chen Y, 2008, J NEUROSCI, V28, P5836, DOI 10.1523/JNEUROSCI.4170-07.2008; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; CRIDLAND RA, 1988, NEUROPEPTIDES, V11, P23, DOI 10.1016/0143-4179(88)90024-8; Cui Y, 2006, BRAIN RES, V1069, P235, DOI 10.1016/j.brainres.2005.11.066; Cui Y, 2008, BRAIN BEHAV IMMUN, V22, P114, DOI 10.1016/j.bbi.2007.07.014; De Oliveira ACP, 2008, GLIA, V56, P844, DOI 10.1002/glia.20658; Doods H, 2000, BRIT J PHARMACOL, V129, P420, DOI 10.1038/sj.bjp.0703110; Doods H, 2007, TRENDS PHARMACOL SCI, V28, P580, DOI 10.1016/j.tips.2007.10.005; Fan XL, 2003, NEUROSCIENCE, V122, P997, DOI 10.1016/j.neuroscience.2003.08.062; Gardell LR, 2002, J NEUROSCI, V22, P6747; HAAS CA, 1991, EUR J NEUROSCI, V3, P708, DOI 10.1111/j.1460-9568.1991.tb00856.x; Ho TW, 2008, LANCET, V372, P2115, DOI 10.1016/S0140-6736(08)61626-8; HOKFELT T, 1992, ANN NY ACAD SCI, V657, P119; Houghton AK, 1999, PAIN, V82, P73, DOI 10.1016/S0304-3959(99)00034-2; Hutchinson MR, 2008, BRAIN BEHAV IMMUN, V22, P1178, DOI 10.1016/j.bbi.2008.05.004; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017; Ji RR, 2001, NEUROBIOL DIS, V8, P1, DOI 10.1006/nbdi.2000.0360; Johnston IN, 2004, J NEUROSCI, V24, P7353, DOI 10.1523/JNEUROSCI.1850-04.2004; KANGRGA I, 1990, NEUROSCI LETT, V108, P155, DOI 10.1016/0304-3940(90)90723-M; Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008; King T, 2005, NEUROSIGNALS, V14, P194, DOI 10.1159/000087658; LEGREVES P, 1985, EUR J PHARMACOL, V115, P309, DOI 10.1016/0014-2999(85)90706-X; Lofgren O, 1997, NEUROPEPTIDES, V31, P601, DOI 10.1016/S0143-4179(97)90006-8; Ma WY, 2001, EUR J NEUROSCI, V14, P1091, DOI 10.1046/j.0953-816x.2001.01731.x; MAO J, 1994, J NEUROSCI, V14, P2301; Mayer DJ, 1999, P NATL ACAD SCI USA, V96, P7731, DOI 10.1073/pnas.96.14.7731; MENARD DP, 1995, J PHARMACOL EXP THER, V273, P887; Menard DP, 1996, J NEUROSCI, V16, P2342; Olesen J, 2004, NEW ENGL J MED, V350, P1104, DOI 10.1056/NEJMoa030505; Parameswaran N, 2000, EUR J PHARMACOL, V389, P125, DOI 10.1016/S0014-2999(99)00874-2; Powell KJ, 1999, BRIT J PHARMACOL, V127, P631, DOI 10.1038/sj.bjp.0702587; Powell KJ, 2000, BRIT J PHARMACOL, V131, P875, DOI 10.1038/sj.bjp.0703655; Powell KJ, 2003, EUR J NEUROSCI, V18, P1572, DOI 10.1046/j.1460-9568.2003.02887.x; Poyner D, 1995, TRENDS PHARMACOL SCI, V16, P424, DOI 10.1016/S0165-6147(00)89093-8; Priller J, 1995, GLIA, V15, P447, DOI 10.1002/glia.440150408; Raghavendra V, 2004, NEUROPSYCHOPHARMACOL, V29, P327, DOI 10.1038/sj.npp.1300315; Raghavendra V, 2002, J NEUROSCI, V22, P9980, DOI 10.1523/jneurosci.22-22-09980.2002; REDDINGTON M, 1995, CAN J PHYSIOL PHARM, V73, P1047, DOI 10.1139/y95-148; ROSENFELD MG, 1984, SCIENCE, V225, P1315, DOI 10.1126/science.6089345; Ruda MA, 2000, SCIENCE, V289, P628, DOI 10.1126/science.289.5479.628; Russo SJ, 2007, NAT NEUROSCI, V10, P93, DOI 10.1038/nn1812; Schaible HG, 1996, PROG BRAIN RES, V113, P423, DOI 10.1016/S0079-6123(08)61102-4; Tepper SJ, 2008, HEADACHE, V48, P1259, DOI 10.1111/j.1526-4610.2008.01214.x; Trang T, 2002, BRIT J PHARMACOL, V136, P37, DOI 10.1038/sj.bjp.0704681; Tsuda M, 2004, GLIA, V45, P89, DOI 10.1002/glia.10308; VAN RD, 1997, NEUROSCI BIOBEHAV R, V21, P649; Wang ZY, 2006, NEUROPHARMACOLOGY, V51, P764, DOI 10.1016/j.neuropharm.2006.05.024; Watkins LR, 2007, BRAIN BEHAV IMMUN, V21, P131, DOI 10.1016/j.bbi.2006.10.011; Watkins LR, 2005, TRENDS NEUROSCI, V28, P661, DOI 10.1016/j.tins.2005.10.001; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Willis WD, 1997, J CLIN NEUROPHYSIOL, V14, P2, DOI 10.1097/00004691-199701000-00002; Wimalawansa SJ, 1996, ENDOCR REV, V17, P533, DOI 10.1210/er.17.5.533; Ye Z, 1999, NEUROSCIENCE, V92, P1389, DOI 10.1016/S0306-4522(99)00088-3; Yue X, 2008, EUR J PHARMACOL, V584, P272, DOI 10.1016/j.ejphar.2008.02.013; Zhuang ZY, 2005, PAIN, V114, P149, DOI 10.1016/j.pain.2004.12.022; Zhuang ZY, 2006, J NEUROSCI, V26, P3551, DOI 10.1523/JNEUROSCI.5290-05.2006	59	80	94	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2576	2586		10.1096/fj.08-128348	http://dx.doi.org/10.1096/fj.08-128348			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19299480				2022-12-28	WOS:000268836700026
J	Marazziti, D; Di Pietro, C; Golini, E; Mandillo, S; Matteoni, R; Tocchini-Valentini, GP				Marazziti, Daniela; Di Pietro, Chiara; Golini, Elisabetta; Mandillo, Silvia; Matteoni, Rafaele; Tocchini-Valentini, Glauco P.			Induction of macroautophagy by overexpression of the Parkinson's disease-associated GPR37 receptor	FASEB JOURNAL			English	Article						parkin; PAEL-R; endoplasmic reticulum stress; proteasome; GRP78; protein	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN RESPONSE; PAEL-R; GENE-EXPRESSION; AUTOPHAGY; SYSTEM; LC3; POLYGLUTAMINE; PROTEASOME; CELLS	The orphan G-protein-coupled receptor 37 (GPR37) is a substrate of parkin, and its insoluble aggregates accumulate in brain tissue samples of Parkinson's disease patients, including Lewy bodies and neurites. Parkin activates the clearance of the unfolded receptor, while the overexpression of GPR37, in the absence of parkin, can lead to unfolded protein-induced cell death. We found that overexpression of the human GPR37 receptor in HEK293 cells and consequent activation of an endoplasmic reticulum (ER) stress response had effects comparable to starvation, in inducing the cellular autophagic pathway. Treatment with specific modulators provided further evidence for the autophagic clearance of the overexpressed GPR37 protein, in detergent-soluble and -insoluble fractions, as confirmed by the conversion of the microtubule-associated protein 1, light chain 3 (LC3)-I marker to its LC3-II isoform. Furthermore, Gpr37-null mutant mice displayed consistent alterations of ER stress and autophagic pathway markers in brain tissue samples. These findings show that GPR37 overexpression per se can induce cellular autophagy, which may prevent the selective degeneration of GPR37-expressing neurons, as reported for Parkinson's and related neurodegenerative diseases.-Marazziti, D., Di Pietro, C., Golini, E., Mandillo, S., Matteoni, R., Tocchini-Valentini, G. P. Induction of macroautophagy by overexpression of the Parkinson's disease-associated GPR37 receptor. FASEB J. 23, 1978-1987 (2009)	[Marazziti, Daniela; Di Pietro, Chiara; Golini, Elisabetta; Mandillo, Silvia; Matteoni, Rafaele; Tocchini-Valentini, Glauco P.] CNR, Ist Biol Cellulare, I-00015 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR)	Tocchini-Valentini, GP (corresponding author), CNR, Ist Biol Cellulare, Campus A Buzzati Traverso,Via F Ramarini 32, I-00015 Rome, Italy.	gtocchini@ibc.cnr.it	Golini, Elisabetta/AAX-2849-2020; Daniela, Marazziti/AAC-1062-2022; Di Pietro, Chiara/AAA-7161-2021; Mandillo, Silvia/E-6503-2019; Mandillo, Silvia/AAW-1363-2020; , Elisabetta/D-9095-2015	Daniela, Marazziti/0000-0002-1582-9271; Mandillo, Silvia/0000-0002-4869-0974; MATTEONI, RAFAELE/0000-0002-0314-5948; , Elisabetta/0000-0002-9323-7124; DI PIETRO, CHIARA/0000-0002-2680-1821	Italian Ministry of Research	Italian Ministry of Research(Ministry of Education, Universities and Research (MIUR))	We are grateful to G. Di Segni for critical reading of the manuscript. We greatly thank Ryosuke Takahashi and Yuzuru Imai (RIKEN Brain Science Institute, Saitama, Japan) for the generous gift of the GPR37-specific antibody; V. Berno for help with the confocal microscopy; G. Di Franco, G. D' Erasmo, and A. Ventrera for excellent technical assistance; and A. Ferrara and T. Cuccurullo for secretarial work. This study was supported by Italian Ministry of Research grants (FIRB-G. Armenise Harvard Found. 2005, FIRB- Idee Progettuali 2005, PRIN-Cofin. 2007), and European Union Framework Programme 6 contracts (MUGEN, EURASNET, EUMODIC).	Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; Cantuti-Castelvetri I, 2007, NEUROBIOL DIS, V26, P606, DOI 10.1016/j.nbd.2007.02.009; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Fortun J, 2007, NEUROBIOL DIS, V25, P252, DOI 10.1016/j.nbd.2006.09.018; Garcia-Echeverria C, 2002, MINI-REV MED CHEM, V2, P247, DOI 10.2174/1389557023406142; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Imai Y, 2007, NEUROSCI RES, V59, P413, DOI 10.1016/j.neures.2007.08.005; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kitao Y, 2007, HUM MOL GENET, V16, P50, DOI 10.1093/hmg/ddl439; Ko HS, 2005, J NEUROSCI, V25, P7968, DOI 10.1523/JNEUROSCI.2172-05.2005; Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984; Kubota K, 2006, J NEUROCHEM, V97, P1259, DOI 10.1111/j.1471-4159.2006.03782.x; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81; Lu M, 2003, TRAFFIC, V4, P416, DOI 10.1034/j.1600-0854.2003.00097.x; Marazziti D., 2001, Current Genomics, V2, P253, DOI 10.2174/1389202013350850; Marazziti D, 2004, P NATL ACAD SCI USA, V101, P10189, DOI 10.1073/pnas.0403661101; Marazziti D, 1998, GENOMICS, V53, P315, DOI 10.1006/geno.1998.5433; Marino G, 2004, CELL MOL LIFE SCI, V61, P1439, DOI 10.1007/s00018-004-4012-4; Matsuda S, 2008, NEURON, V57, P730, DOI 10.1016/j.neuron.2008.02.012; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; Murakami T, 2004, ANN NEUROL, V55, P439, DOI 10.1002/ana.20064; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Oh YK, 2008, J NEUROCHEM, V104, P993, DOI 10.1111/j.1471-4159.2007.05053.x; Ostrowska H, 2000, INT J BIOCHEM CELL B, V32, P747, DOI 10.1016/S1357-2725(00)00021-2; Pattarini R, 2008, NEUROSCIENCE, V155, P1174, DOI 10.1016/j.neuroscience.2008.06.064; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Rezgaoui M, 2006, J CELL SCI, V119, P542, DOI 10.1242/jcs.02766; Rideout HJ, 2004, INT J BIOCHEM CELL B, V36, P2551, DOI 10.1016/j.biocel.2004.05.008; Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Uehara T, 2006, NATURE, V441, P513, DOI 10.1038/nature04782; Wang HY, 2007, NEUROTOXICOLOGY, V28, P979, DOI 10.1016/j.neuro.2007.02.013; Wang HQ, 2008, J NEUROCHEM, V107, P171, DOI 10.1111/j.1471-4159.2008.05607.x; Wang JY, 2008, NEUROCHEM INT, V52, P1037, DOI 10.1016/j.neuint.2007.10.017; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Wong ESP, 2008, HUM MOL GENET, V17, P2570, DOI 10.1093/hmg/ddn157; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Yorimitsu T, 2007, AUTOPHAGY, V3, P160, DOI 10.4161/auto.3653	47	34	39	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1978	1987		10.1096/fj.08-121210	http://dx.doi.org/10.1096/fj.08-121210			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19218498				2022-12-28	WOS:000266652400036
J	Konstantinidou, V; Covas, MI; Munoz-Aguayo, D; Khymenets, O; de la Torre, R; Saez, G; Tormos, MD; Toledo, E; Marti, A; Ruiz-Gutierrez, V; Mendez, MVR; Fito, M				Konstantinidou, Valentini; Covas, Maria-Isabel; Munoz-Aguayo, Daniel; Khymenets, Olha; de la Torre, Rafael; Saez, Guillermo; del Carmen Tormos, Maria; Toledo, Estefania; Marti, Amelia; Ruiz-Gutierrez, Valentina; Ruiz Mendez, Maria Victoria; Fito, Montserrat			In vivo nutrigenomic effects of virgin olive oil polyphenols within the frame of the Mediterranean diet: a randomized controlled trial	FASEB JOURNAL			English	Article						inflammation; oxidative stress; DNA damage; gene expression; IFN gamma	PHYSICAL-ACTIVITY QUESTIONNAIRE; RISK-FACTORS; HYPERCHOLESTEROLEMIC PATIENTS; INTERLEUKIN-7 RECEPTOR; GENE-EXPRESSION; DISEASE; INFLAMMATION; VALIDATION; ADHERENCE; TIME	The aim of the study was to assess whether benefits associated with the traditional Mediterranean diet (TMD) and virgin olive oil (VOO) consumption could be mediated through changes in the expression of atherosclerosis-related genes. A randomized, parallel, controlled clinical trial in healthy volunteers (n=90) aged 20 to 50 yr was performed. Three-month intervention groups were as follows: 1) TMD with VOO ( TMD+VOO), 2) TMD with washed virgin olive oil (TMD+WOO), and 3) control with participants' habitual diet. WOO was similar to VOO, but with a lower polyphenol content (55 vs. 328 mg/kg, respectively). TMD consumption decreased plasma oxidative and inflammatory status and the gene expression related with both inflammation [INF-gamma (INF gamma), Rho GTPase-activating protein15 (ARHGAP15), and interleukin-7 receptor (IL7R)] and oxidative stress [adrenergic beta(2)-receptor (ADRB2) and polymerase (DNA-directed) kappa (POLK)] in peripheral blood mononuclear cells. All effects, with the exception of the decrease in POLK expression, were particularly observed when VOO, rich in polyphenols, was present in the TMD dietary pattern. Our results indicate a significant role of olive oil polyphenols in the down-regulation of proatherogenic genes in the context of a TMD. In addition, the benefits associated with a TMD and olive oil polyphenol consumption on cardiovascular risk can be mediated through nutrigenomic effects.-Konstantinidou, V., Covas, M.-I., Munoz-Aguayo, D., Khymenets, O., de la Torre, R., Saez, G., del Carmen Tormos, M., Toledo, E., Marti, A., Ruiz-Gutierrez, V., Ruiz Mendez, M. V., Fito, M. In vivo nutrigenomic effects of virgin olive oil polyphenols within the frame of the Mediterranean diet: a randomized controlled trial. FASEB J. 24, 2546-2557 (2010). www.fasebj.org	[Konstantinidou, Valentini; Covas, Maria-Isabel; Munoz-Aguayo, Daniel; Fito, Montserrat] Hosp del Mar, IMIM, Cardiovasc Risk & Nutr Res Grp, Ctr Invest Biomed Eu Red Fisiopatol Obesidad & Nu, Barcelona, Spain; [Khymenets, Olha; de la Torre, Rafael] Hosp del Mar, IMIM, Human Pharmacol & Clin Neurosci Res Grp, Ctr Invest Biomed Eu Red Fisiopatol Obesidad & Nu, Barcelona, Spain; [Konstantinidou, Valentini] Pompeu Fabra Univ, Dept Ciencies Expt & Salut, PhD Program Biomed, Barcelona, Spain; [Saez, Guillermo; del Carmen Tormos, Maria] Univ Valencia, Dept Biochem & Mol Biol, Valencia, Spain; [Toledo, Estefania] Univ Navarra, Dept Prevent Med & Publ Hlth, Navarra, Spain; [Marti, Amelia] Univ Navarra, Dept Nutr Food Sci Physiol & Toxicol, Navarra, Spain; [Ruiz-Gutierrez, Valentina; Ruiz Mendez, Maria Victoria] Inst Grasa, Inst Nutr & Lipid Metab, Seville, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; University of Valencia; University of Navarra; University of Navarra; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de la Grasa (IG)	Covas, MI (corresponding author), Hosp del Mar, IMIM, Cardiovasc Risk & Nutr Res Grp, Ctr Invest Biomed Eu Red Fisiopatol Obesidad & Nu, PRBB,Carrer Dr Aiguader 88-08003, Barcelona, Spain.	mcovas@imim.es	Fito, Montserrat/C-1822-2012; Toledo, Estefania/H-6211-2014; Marti, Amelia/M-2709-2019; Martí, Amelia/H-1192-2017; de la Torre, Rafael/D-3561-2018; Khymenets, Olha/I-9752-2014; Ruiz-Méndez, M. Victoria/P-1627-2014	Fito, Montserrat/0000-0002-1817-483X; Toledo, Estefania/0000-0002-6263-4434; Marti, Amelia/0000-0001-9832-7981; Martí, Amelia/0000-0001-9832-7981; de la Torre, Rafael/0000-0002-6765-1866; Khymenets, Olha/0000-0002-8668-580X; Ruiz-Méndez, M. Victoria/0000-0003-0750-7915; Saez, Guillermo/0000-0002-8164-4048	Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional (FIS-FEDER) [PI041308]; Sistema National de Salud (SNS) [CP06/00100]; Instituto de Salud Carlos III; Greek State Scholarship Foundation (Athens, Greece); Generalitat of Catalunya [2005 SGR 00577]	Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional (FIS-FEDER); Sistema National de Salud (SNS); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Greek State Scholarship Foundation (Athens, Greece); Generalitat of Catalunya(Generalitat de Catalunya)	The CIBER de Fisiopatolog a de la Obesidad y Nutricion is an initiative of the Instituto de Salud Carlos III, Madrid, Spain. This work was supported by Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional (FIS-FEDER; PI041308), by Sistema National de Salud (SNS) contract Miguel Servet (CP06/00100) Instituto de Salud Carlos III, and by the Greek State Scholarship Foundation (Athens, Greece), and partially supported by the Generalitat of Catalunya (2005 SGR 00577). The authors declare no conflicting financial interests.	Acin S, 2006, J BIOCHEM, V140, P383, DOI 10.1093/jb/mvj166; Beauchamp GK, 2005, NATURE, V437, P45, DOI 10.1038/437045a; Benetou V, 2008, BRIT J CANCER, V99, P191, DOI 10.1038/sj.bjc.6604418; Bogani P, 2007, ATHEROSCLEROSIS, V190, P181, DOI 10.1016/j.atherosclerosis.2006.01.011; Choi HK, 2005, CURR OPIN RHEUMATOL, V17, P141, DOI 10.1097/01.cco.0000152664.87204.3c; Chrysohoou C, 2004, J AM COLL CARDIOL, V44, P152, DOI 10.1016/j.jacc.2004.03.039; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Coppack SW, 2001, P NUTR SOC, V60, P349, DOI 10.1079/PNS2001110; Covas MI, 2007, PHARMACOL RES, V55, P175, DOI 10.1016/j.phrs.2007.01.010; Covas MI, 2006, NUTR REV, V64, pS20, DOI 10.1111/j.1753-4887.2006.tb00260.x; Covas MI, 2006, ANN INTERN MED, V145, P333, DOI 10.7326/0003-4819-145-5-200609050-00006; Damas JK, 2003, CIRCULATION, V107, P2670, DOI 10.1161/01.CIR.0000070542.18001.87; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; ELOSUA R, 1994, AM J EPIDEMIOL, V139, P1197, DOI 10.1093/oxfordjournals.aje.a116966; Elosua R, 2000, MED SCI SPORT EXER, V32, P1431, DOI 10.1097/00005768-200008000-00011; Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440; Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004; Feldman I, 2008, P NATL ACAD SCI USA, V105, P4323, DOI 10.1073/pnas.0701722105; Fito M, 2008, EUR J CLIN NUTR, V62, P570, DOI 10.1038/sj.ejcn.1602724; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Ghittoni R, 2005, FASEB J, V19, P605, DOI 10.1096/fj.04-2702fje; Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104; Gregory SG, 2007, NAT GENET, V39, P1083, DOI 10.1038/ng2103; Hao JJ, 2010, J NUTR BIOCHEM, V21, P634, DOI 10.1016/j.jnutbio.2009.03.012; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Imadome K, 2008, CANCER BIOL THER, V7, P208, DOI 10.4161/cbt.7.2.5255; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; Khymenets O, 2005, ANAL BIOCHEM, V347, P156, DOI 10.1016/j.ab.2005.07.007; Khymenets O, 2008, CLIN BIOCHEM, V41, P1348, DOI 10.1016/j.clinbiochem.2008.08.064; Khymenets O, 2009, OMICS, V13, P7, DOI 10.1089/omi.2008.0079; Konstantinidou V, 2009, FOLIA BIOL-PRAGUE, V55, P85; Konstantinidou V, 2009, OMICS, V13, P431, DOI 10.1089/omi.2008.0085; Kunkel TA, 2003, DNA REPAIR, V2, P135, DOI 10.1016/S1568-7864(02)00224-0; Laufs U, 2002, CARDIOVASC RES, V53, P911, DOI 10.1016/S0008-6363(01)00540-5; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Llorente-Cortes V, 2010, ATHEROSCLEROSIS, V208, P442, DOI 10.1016/j.atherosclerosis.2009.08.004; Machowetz A, 2007, FASEB J, V21, P45, DOI 10.1096/fj.06-6328com; Martinez-Dominguez E, 2001, INFLAMM RES, V50, P102, DOI 10.1007/s000110050731; MARTINMORENO JM, 1993, INT J EPIDEMIOL, V22, P512, DOI 10.1093/ije/22.3.512; Menendez JA, 2006, EUR J CANCER, V42, P2425, DOI 10.1016/j.ejca.2005.10.016; Miro-Casas E, 2001, ANAL BIOCHEM, V294, P63, DOI 10.1006/abio.2001.5160; Mobini R, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-19; Pacheco YM, 2007, BRIT J NUTR, V98, P260, DOI 10.1017/S0007114507701666; Paniagua JA, 2007, DIABETES CARE, V30, P1717, DOI 10.2337/dc06-2220; Parikh P, 2005, J AM COLL CARDIOL, V45, P1379, DOI 10.1016/j.jacc.2004.11.068; Perez-Jimenez F, 2005, EUR J CLIN INVEST, V35, P421, DOI 10.1111/j.1365-2362.2005.01516.x; Philipson L. H., 2002, Journal of Allergy and Clinical Immunology, V110, pS313, DOI 10.1067/mai.2002.129702; Rough J, 2009, SURGERY, V145, P235, DOI 10.1016/j.surg.2008.09.013; Ruano J, 2005, J AM COLL CARDIOL, V46, P1864, DOI 10.1016/j.jacc.2005.06.078; Ruano J, 2007, AM J CLIN NUTR, V86, P341, DOI 10.1093/ajcn/86.2.341; Salas-Salvado J, 2008, ARCH INTERN MED, V168, P2449, DOI 10.1001/archinte.168.22.2449; Seoh ML, 2003, FEBS LETT, V539, P131, DOI 10.1016/S0014-5793(03)00213-8; Sofi F, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1344; Takahata Y, 2009, J CELL PHYSIOL, V218, P268, DOI 10.1002/jcp.21594; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Trichopoulou A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2337; Visioli F, 2005, EUR J NUTR, V44, P121, DOI 10.1007/s00394-004-0504-0; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; WOOLF SH, 1990, J CLIN EPIDEMIOL, V43, P891, DOI 10.1016/0895-4356(90)90073-X	60	200	205	1	69	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2546	2557		10.1096/fj.09-148452	http://dx.doi.org/10.1096/fj.09-148452			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20179144				2022-12-28	WOS:000279343600041
J	Palmer, CV; Bythell, JC; Willis, BL				Palmer, Caroline V.; Bythell, John C.; Willis, Bette L.			Levels of immunity parameters underpin bleaching and disease susceptibility of reef corals	FASEB JOURNAL			English	Article						melanin; phenoloxidase; fluorescent protein; climate change; reef resilience	GREAT-BARRIER-REEF; PROPHENOLOXIDASE-ACTIVATING SYSTEM; CAUSE OXIDATIVE STRESS; PHENOLOXIDASE ACTIVITY; SCLERACTINIAN CORAL; FLUORESCENT PROTEINS; SPATIAL VARIABILITY; MARINE ECOLOGY; CLIMATE-CHANGE; HOST PIGMENTS	Immunity is a key life history trait that may explain hierarchies in the susceptibility of corals to disease and thermal bleaching, two of the greatest current threats to coral health and the persistence of tropical reefs. Despite their ongoing and rapid global decline, there have been few investigations into the immunity mechanisms of reef-building corals. Variables commonly associated with invertebrate immunity, including the presence of melanin, size of melanin-containing granular cells, and phenoloxidase (PO) activity, as well as concentrations of fluorescent proteins (FPs), were investigated in hard (Scleractinia) and soft (Alcyonacea) corals spanning 10 families from the Great Barrier Reef. Detectable levels of these indicators were present in all corals investigated, although relative investment differed among coral taxa. Overall levels of investment were inversely correlated to thermal bleaching and disease susceptibility. In addition, PO activity, melanin-containing granular cell size, and FP concentration were each found to be significant predictors of susceptibility and thus may play key roles in coral immunity. Correlative evidence that taxonomic (family-level) variation in the levels of these constituent immunity parameters underpins susceptibility to both thermal bleaching and disease indicates that baseline immunity underlies the vulnerability of corals to these two threats. This reinforces the necessity of a holistic approach to understanding bleaching and disease in order to accurately determine the resilience of coral reefs.-Palmer, C. V., Bythell, J. C., Willis. B. L. Levels of immunity parameters underpin bleaching and disease susceptibility of reef corals. FASEB J. 24, 1935-1946 (2010). www.fasebj.org	[Palmer, Caroline V.; Willis, Bette L.] James Cook Univ, Sch Marine & Trop Biol, Townsville, Qld 4811, Australia; [Palmer, Caroline V.; Willis, Bette L.] James Cook Univ, Australian Res Council, Ctr Excellence Coral Reef Studies, Townsville, Qld 4811, Australia; [Palmer, Caroline V.; Bythell, John C.] Newcastle Univ, Sch Biol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	James Cook University; James Cook University; Newcastle University - UK	Palmer, CV (corresponding author), James Cook Univ, Sch Marine & Trop Biol, Townsville, Qld 4811, Australia.	caroline.palmer@jcu.edu.au	Bythell, John C/E-7962-2010; Bythell, John/ABE-6138-2021; Palmer, Caroline/B-6498-2011	Bythell, John C/0000-0003-2416-9786; Bythell, John/0000-0003-2416-9786; Palmer, Caroline/0000-0002-5903-995X	Natural Environmental Research Council UK; Australian Research Council; Natural Environment Research Council [NE/E006949/1] Funding Source: researchfish; NERC [NE/E006949/1] Funding Source: UKRI	Natural Environmental Research Council UK(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Australian Research Council(Australian Research Council); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	The authors thank David Abrego and Patricia Warner for assistance with sample collection, Sue Reilly and Karen Chong-Seng for assistance with histological processing, Laura D. Mydlarz for comments on manuscript drafts, and Scan Connolly for valuable suggestions. Research funding was provided by a Natural Environmental Research Council UK grant to J.B. and an Australian Research Council Discovery Project grant to B.W.	Abrego D, 2008, P ROY SOC B-BIOL SCI, V275, P2273, DOI 10.1098/rspb.2008.0180; Adamo SA, 2004, ANIM BEHAV, V68, P1443, DOI 10.1016/j.anbehav.2004.05.005; Adamo SA, 2004, J INSECT PHYSIOL, V50, P209, DOI 10.1016/j.jinsphys.2003.11.011; Alieva NO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002680; Armitage SAO, 2005, HEREDITY, V94, P650, DOI 10.1038/sj.hdy.6800675; Aronson RB, 2004, ECOLOGY, V85, P1876, DOI 10.1890/03-0108; Aronson RB, 2003, SCIENCE, V302, P1502; Asokan R, 1997, DEV COMP IMMUNOL, V21, P1, DOI 10.1016/S0145-305X(97)00004-9; Baird AH, 2002, MAR ECOL PROG SER, V237, P133, DOI 10.3354/meps237133; Baird AH, 2009, TRENDS ECOL EVOL, V24, P16, DOI 10.1016/j.tree.2008.09.005; Barnes AI, 2000, P ROY SOC B-BIOL SCI, V267, P177, DOI 10.1098/rspb.2000.0984; Bellwood DR, 2004, NATURE, V429, P827, DOI 10.1038/nature02691; Berkelmans R, 1999, CORAL REEFS, V18, P55, DOI 10.1007/s003380050154; Bou-Abdallah F, 2006, BBA-GEN SUBJECTS, V1760, P1690, DOI 10.1016/j.bbagen.2006.08.014; Brenner M, 2008, PHOTOCHEM PHOTOBIOL, V84, P539, DOI 10.1111/j.1751-1097.2007.00226.x; Brown BE, 2002, CORAL REEFS, V21, P119, DOI 10.1007/s00338-002-0215-z; Brown BE, 1997, CORAL REEFS, V16, pS129, DOI 10.1007/s003380050249; Brown BE, 2000, NATURE, V404, P142, DOI 10.1038/35004657; Bruno JF, 2003, ECOL LETT, V6, P1056, DOI 10.1046/j.1461-0248.2003.00544.x; Bruno JF, 2007, PLOS BIOL, V5, P1220, DOI 10.1371/journal.pbio.0050124; BULL AT, 1970, ARCH BIOCHEM BIOPHYS, V137, P345, DOI 10.1016/0003-9861(70)90448-0; Burkhart CG, 2005, INT J DERMATOL, V44, P340, DOI 10.1111/j.1365-4632.2004.02556.x; Butt D, 2008, DEV COMP IMMUNOL, V32, P299, DOI 10.1016/j.dci.2007.06.006; Bythell J.C., 1988, P535; Cerenius L, 2008, TRENDS IMMUNOL, V29, P263, DOI 10.1016/j.it.2008.02.009; Cooper Edwin L., 2008, V15, P1, DOI 10.1159/000135680; COOPER MD, 2002, INTERFACE INNATE ACQ; Costantini D, 2009, COMP BIOCHEM PHYS A, V153, P339, DOI 10.1016/j.cbpa.2009.03.010; Cox G, 2007, MICROSC RES TECHNIQ, V70, P243, DOI 10.1002/jemt.20410; Crabbe MJC, 2009, MAR ENVIRON RES, V67, P189, DOI 10.1016/j.marenvres.2009.01.003; Domart-Coulon IJ, 2006, CORAL REEFS, V25, P531, DOI 10.1007/s00338-006-0133-6; Dove S, 2006, LIMNOL OCEANOGR, V51, P1149, DOI 10.4319/lo.2006.51.2.1149; Dove S, 2004, MAR ECOL PROG SER, V272, P99, DOI 10.3354/meps272099; Dove SG, 2001, CORAL REEFS, V19, P197, DOI 10.1007/PL00006956; Dove SG, 2008, PLANT CELL ENVIRON, V31, P1523, DOI 10.1111/j.1365-3040.2008.01852.x; Fabricius K, 2005, MAR POLLUT BULL, V51, P384, DOI 10.1016/j.marpolbul.2004.10.041; Fitt WK, 2009, J EXP MAR BIOL ECOL, V373, P102, DOI 10.1016/j.jembe.2009.03.011; GATES RD, 1992, BIOL BULL, V182, P324, DOI 10.2307/1542252; Harvell C. D., 2007, OCEANOGRAPHY, V20, P58; Harvell CD, 1999, SCIENCE, V285, P1505, DOI 10.1126/science.285.5433.1505; Harvell CD, 2002, SCIENCE, V296, P2158, DOI 10.1126/science.1063699; Hawkridge JM, 2000, MAR BIOL, V137, P1, DOI 10.1007/s002270000324; HILDEMANN WH, 1977, IMMUNOGENETICS, V5, P193, DOI 10.1007/BF01570476; Hoegh-Guldberg O, 2007, SCIENCE, V318, P1737, DOI 10.1126/science.1152509; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; HOEGHGULDBERG O, 1989, J EXP MAR BIOL ECOL, V129, P279, DOI 10.1016/0022-0981(89)90109-3; Hosken DJ, 2001, CURR BIOL, V11, pR379, DOI 10.1016/S0960-9822(01)00211-1; HUGHES TP, 1994, SCIENCE, V265, P1547, DOI 10.1126/science.265.5178.1547; HUSTON MA, 1985, ANNU REV ECOL SYST, V16, P149, DOI 10.1146/annurev.es.16.110185.001053; Hutton DMC, 1996, BIOL BULL-US, V191, P441, DOI 10.2307/1543017; JACKSON JBC, 1979, BIOL SYSTEMATICS COL, P499; Jones RJ, 1998, PLANT CELL ENVIRON, V21, P1219, DOI 10.1046/j.1365-3040.1998.00345.x; Kelmanson IV, 2003, MOL BIOL EVOL, V20, P1125, DOI 10.1093/molbev/msg130; KramarskyWinter E, 1996, MAR ECOL PROG SER, V134, P179, DOI 10.3354/meps134179; Kvennefors ECE, 2008, DEV COMP IMMUNOL, V32, P1582, DOI 10.1016/j.dci.2008.05.010; Lang J.C., 1990, P209; Laufer Z, 2006, ANN BOT-LONDON, V98, P1035, DOI 10.1093/aob/mcl184; Lesser MP, 2006, ANNU REV PHYSIOL, V68, P253, DOI 10.1146/annurev.physiol.68.040104.110001; Lesser MP, 1996, LIMNOL OCEANOGR, V41, P271, DOI 10.4319/lo.1996.41.2.0271; Leutenegger A, 2007, J EXP MAR BIOL ECOL, V353, P221, DOI 10.1016/j.jembe.2007.09.013; Leuzinger S, 2003, OECOLOGIA, V136, P524, DOI 10.1007/s00442-003-1305-5; Loya Y, 2001, ECOL LETT, V4, P122, DOI 10.1046/j.1461-0248.2001.00203.x; Marshall PA, 2000, CORAL REEFS, V19, P155, DOI 10.1007/s003380000086; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Mayer AM, 2002, PHYTOCHEMISTRY, V60, P551, DOI 10.1016/S0031-9422(02)00171-1; Maynard JA, 2008, MAR BIOL, V155, P173, DOI 10.1007/s00227-008-1015-y; McClanahan TR, 2004, MAR BIOL, V144, P1239, DOI 10.1007/s00227-003-1271-9; McClanahan TR, 2004, MAR POLLUT BULL, V48, P327, DOI 10.1016/j.marpolbul.2003.08.024; Meredith P, 2006, SOFT MATTER, V2, P37, DOI 10.1039/b511922g; Meszaros A, 1999, J INVERTEBR PATHOL, V73, P321, DOI 10.1006/jipa.1999.4851; Metchnikoff E, 1892, LECONS PATHOLOGIE CO; Miller DJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r59; Mucklow PT, 2004, P ROY SOC B-BIOL SCI, V271, P1175, DOI 10.1098/rspb.2004.2707; Munoz P, 2006, FISH SHELLFISH IMMUN, V20, P12, DOI 10.1016/j.fsi.2005.02.002; MUSCATINE L, 1991, MAR ECOL PROG SER, V77, P233, DOI 10.3354/meps077233; Mydlarz LD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001811; Mydlarz LD, 2006, ANNU REV ECOL EVOL S, V37, P251, DOI 10.1146/annurev.ecolsys.37.091305.110103; Mydlarz LD, 2007, COMP BIOCHEM PHYS A, V146, P54, DOI 10.1016/j.cbpa.2006.09.005; Mydlarz LD, 2009, DIS AQUAT ORGAN, V87, P67, DOI 10.3354/dao02088; Nappi AJ, 2000, BIOESSAYS, V22, P469, DOI 10.1002/(SICI)1521-1878(200005)22:5<469::AID-BIES9>3.3.CO;2-W; Nappi AJ, 2005, INSECT BIOCHEM MOLEC, V35, P443, DOI 10.1016/j.ibmb.2005.01.014; Newton K, 2004, DEV COMP IMMUNOL, V28, P565, DOI 10.1016/j.dci.2003.10.004; Nishiyama Y, 2006, BBA-BIOENERGETICS, V1757, P742, DOI 10.1016/j.bbabio.2006.05.013; Nosanchuk JD, 2003, CELL MICROBIOL, V5, P203, DOI 10.1046/j.1462-5814.2003.00268.x; Olano CT, 2000, J INVERTEBR PATHOL, V76, P176, DOI 10.1006/jipa.2000.4974; Page CA, 2008, CORAL REEFS, V27, P257, DOI 10.1007/s00338-007-0317-8; Page C, 2006, DIS AQUAT ORGAN, V69, P41, DOI 10.3354/dao069041; Palmer CV, 2008, P ROY SOC B-BIOL SCI, V275, P2687, DOI 10.1098/rspb.2008.0335; Palmer CV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007298; Palmer CV, 2009, BIOL BULL-US, V216, P68, DOI 10.1086/BBLv216n1p68; Raymundo LJ, 2005, DIS AQUAT ORGAN, V64, P181, DOI 10.3354/dao064181; Rinkevich B, 2004, IMMUNOL REV, V198, P25, DOI 10.1111/j.0105-2896.2004.0114.x; Rinkevich B, 1996, MAR ECOL PROG SER, V143, P297, DOI 10.3354/meps143297; RINKEVICH B, 1996, INVERTEBRATE IMMUNOL; Roff G, 2006, CORAL REEFS, V25, P255, DOI 10.1007/s00338-006-0099-4; Rolff J, 2003, SCIENCE, V301, P472, DOI 10.1126/science.1080623; Rowley AF, 1996, MEDIAT INFLAMM, V5, P3, DOI 10.1155/S0962935196000014; Sadd BM, 2009, EVOL APPL, V2, P113, DOI 10.1111/j.1752-4571.2008.00057.x; Salih A., 2001, Photosynthesis Research, V69, P221; Salih A, 2000, NATURE, V408, P850, DOI 10.1038/35048564; Salih A, 1998, P AUSTR COR REEF SOC, P217; Sandland GJ, 2003, TRENDS PARASITOL, V19, P571, DOI 10.1016/j.pt.2003.10.006; Schwarzenbach GA, 2007, J EVOLUTION BIOL, V20, P2192, DOI 10.1111/j.1420-9101.2007.01430.x; Selig ER., 2006, ANALYZING RELATIONSH, P111; Sheldon BC, 1996, TRENDS ECOL EVOL, V11, P317, DOI 10.1016/0169-5347(96)10039-2; Shick JM, 2002, ANNU REV PHYSIOL, V64, P223, DOI 10.1146/annurev.physiol.64.081501.155802; Siva-Jothy MT, 2005, ADV INSECT PHYSIOL, V32, P1, DOI 10.1016/S0065-2806(05)32001-7; Smith-Keune C, 2008, MAR BIOTECHNOL, V10, P166, DOI 10.1007/s10126-007-9049-6; SODERHALL K, 1982, DEV COMP IMMUNOL, V6, P601; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; SOONG K, 1991, B MAR SCI, V49, P832; SOONG KY, 1992, BIOL BULL, V183, P418, DOI 10.2307/1542018; Stearns S.C., 1992, pi; Stearns S.C., 1993, EVOLUTION LIFE HIST; Stedman T.L., 2000, STEDMANS MED DICT, V27th ed.; Sugumaran H, 2002, PIGM CELL RES, V15, P2, DOI 10.1034/j.1600-0749.2002.00056.x; Thompson DM, 2009, P ROY SOC B-BIOL SCI, V276, P2893, DOI 10.1098/rspb.2009.0591; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Veron J.E.N., 2000, CORALS WORLD, V1-3; Ward JR, 2006, DIS AQUAT ORGAN, V69, P23, DOI 10.3354/dao069023; Weil E, 2009, DIS AQUAT ORGAN, V83, P195, DOI 10.3354/dao02011; Weis VM, 2008, J EXP BIOL, V211, P3059, DOI 10.1242/jeb.009597; Willis BL, 2004, CORAL HEALTH AND DISEASE, P69; Wilson K, 2001, ECOL LETT, V4, P637, DOI 10.1046/j.1461-0248.2001.00279.x; Wootton EC, 2003, FISH SHELLFISH IMMUN, V15, P249, DOI 10.1016/S1050-4648(02)00164-X; [No title captured]	126	98	100	1	96	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1935	1946		10.1096/fj.09-152447	http://dx.doi.org/10.1096/fj.09-152447			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20124432				2022-12-28	WOS:000278200000028
J	Hoashi, T; Tamaki, K; Hearing, VJ				Hoashi, Toshihiko; Tamaki, Kunihiko; Hearing, Vincent J.			The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding	FASEB JOURNAL			English	Article						melanosome; glycosylation; proprotein convertase	MATRIX PROTEIN PMEL17/GP100; MONOCLONAL-ANTIBODY; MELANOSOME BIOGENESIS; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; AMYLOID FORMATION; T-LYMPHOCYTES; SILVER LOCUS; CLEAVAGE; CELLS	Ectodomain shedding is a proteolytic mechanism by which a transmembrane protein is converted into a secreted form. Pmel17/gp100 is a melanocyte-specific membrane-bound glycoprotein that has amyloid characteristics and forms fibrillar structures in melanosomes after a complex sequence of post-translational processing and trafficking events, including cleavage by a furin-like proprotein convertase (PC). A secreted form of Pmel17 (termed sPmel17) was also thought to be released due to cleavage by a PC. We used multidisciplinary approaches to demonstrate that sPmel17 is released by ectodomain shedding at the juxtamembrane and/or intramembrane motif and to show that this is independent of cleavage by a PC. We further show that sPmel17 consists of 2 fragments linked by disulfide bonds and that the shedding is inhibited at low temperature but not by metalloproteinase inhibitors. Moreover, treatment with a phorbol ester or a calmodulin inhibitor induces Pmel17 shedding. We also refine the reactivity of HMB50 and NKI/beteb, 2 monoclonal antibodies commonly used as melanoma-specific markers. The fact that those antibodies require physically separated domains of Pmel17 sheds interesting light on its 3-dimensional conformation. We conclude that sPmel17 is released by regulated proteolytic ectodomain shedding.-Hoashi, T., Tamaki, K., Hearing, V. J. The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding. FASEB J. 24, 916-930 (2010). www.fasebj.org	[Hoashi, Toshihiko; Hearing, Vincent J.] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; [Hoashi, Toshihiko; Tamaki, Kunihiko] Univ Tokyo, Dept Dermatol, Fac Med, Tokyo 1138655, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Tokyo	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 2132, Bethesda, MD 20892 USA.	thoashi-tky@umin.ac.jp; hearingv@nih.gov			National Institutes of Health, National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIABC010785] Funding Source: NIH RePORTER	National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully thank Dr. Michael S. Marks (University of Pennsylvania, Philadelphia, PA, USA) for kindly providing the Pmel17-i, Pmel17-l, and Pmel17-s vectors; Dr. Richard N. Sifers (Baylor College of Medicine, Houston, TX, USA) for the kind gift of hATM-pcDNA3.1; Dr. Donald F. Steiner (University of Chicago, Chicago, IL, USA) for the kind gift of pCMV-furin; Dr. Susan H. Garfield and Dr. Stephen M. Wincovitch for expert advice on confocal microscopy; and Dr. Motozo Yamashita for useful suggestions. This research was supported, in part, by the Intramural Research Program of the National Institutes of Health, National Cancer Institute.	ADEMA GJ, 1994, J BIOL CHEM, V269, P20126; Adema GJ, 1996, BRIT J CANCER, V73, P1044, DOI 10.1038/bjc.1996.202; Angles-Cano E, 2002, BIOL CHEM, V383, P93, DOI 10.1515/BC.2002.009; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; Bosserhoff AK, 1997, CANCER RES, V57, P3149; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; Calvo PA, 1999, J BIOL CHEM, V274, P12780, DOI 10.1074/jbc.274.18.12780; Chiamenti AM, 1996, MELANOMA RES, V6, P291, DOI 10.1097/00008390-199608000-00003; de Vries TJ, 2001, J PATHOL, V193, P13; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; Dlugosz A, 2002, J INVEST DERM SYMP P, V7, P17, DOI 10.1046/j.1523-1747.2002.19631.x; Dowdy JC, 1995, PHOTODERMATOL PHOTO, V11, P143, DOI 10.1111/j.1600-0781.1995.tb00156.x; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; Elhabazi A, 2001, J IMMUNOL, V166, P4341, DOI 10.4049/jimmunol.166.7.4341; Fowler DM, 2006, PLOS BIOL, V4, P100, DOI 10.1371/journal.pbio.0040006; GOWN AM, 1986, AM J PATHOL, V123, P195; Harper DC, 2008, J BIOL CHEM, V283, P2307, DOI 10.1074/jbc.M708007200; Hearing VJ, 2005, J DERMATOL SCI, V37, P3, DOI 10.1016/j.jdermsci.2004.08.014; Hoashi T, 2005, J BIOL CHEM, V280, P14006, DOI 10.1074/jbc.M413692200; Hoashi T, 2006, J BIOL CHEM, V281, P21198, DOI 10.1074/jbc.M601643200; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; ITO S, 1984, J CHROMATOGR, V311, P154, DOI 10.1016/S0378-4347(00)84702-7; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; KAPUR RP, 1992, J HISTOCHEM CYTOCHEM, V40, P207, DOI 10.1177/40.2.1552165; Kuliawat R, 2009, EUR J CELL BIOL, V88, P653, DOI 10.1016/j.ejcb.2009.07.001; Kummer MP, 2009, J BIOL CHEM, V284, P2296, DOI 10.1074/jbc.M808904200; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; Lambert DW, 2008, FEBS LETT, V582, P385, DOI 10.1016/j.febslet.2007.11.085; Le Borgne R, 2001, J CELL SCI, V114, P2831; Lepage S, 2006, CANCER RES, V66, P2423, DOI 10.1158/0008-5472.CAN-05-2516; MARESH GA, 1994, ARCH BIOCHEM BIOPHYS, V311, P95, DOI 10.1006/abbi.1994.1213; MCGLINCHEY RP, 2009, P NATL ACAD SCI US; Miranda L, 1996, P NATL ACAD SCI USA, V93, P7695, DOI 10.1073/pnas.93.15.7695; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Nichols SE, 2003, J INVEST DERMATOL, V121, P821, DOI 10.1046/j.1523-1747.2003.12474.x; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809; Raposo G, 2007, NAT REV MOL CELL BIO, V8, P786, DOI 10.1038/nrm2258; Robila V, 2008, J IMMUNOL, V181, P7843, DOI 10.4049/jimmunol.181.11.7843; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; SCANU AM, 1995, BBA-LIPID LIPID MET, V1256, P1, DOI 10.1016/0005-2760(95)00012-2; SEIJI M, 1963, NATURE, V197, P1082, DOI 10.1038/1971082a0; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Solano F, 2000, PIGM CELL RES, V13, P118, DOI 10.1111/j.0893-5785.2000.130821.x; Swanson RA, 1996, DEV NEUROSCI-BASEL, V18, P515, DOI 10.1159/000111448; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Theos AC, 2006, DEV CELL, V10, P343, DOI 10.1016/j.devcel.2006.01.012; Theos AC, 2005, PIGM CELL RES, V18, P322, DOI 10.1111/j.1600-0749.2005.00269.x; Theos AC, 2006, MOL BIOL CELL, V17, P3598, DOI 10.1091/mbc.E06-01-0081; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; THOMSON W, 1989, J AM ACAD DERMATOL, V21, P1280, DOI 10.1016/S0190-9622(89)70344-3; Valencia JC, 2006, J CELL SCI, V119, P1080, DOI 10.1242/jcs.02804; Valencia JC, 2007, J BIOL CHEM, V282, P11266, DOI 10.1074/jbc.M608449200; VENNEGOOR C, 1988, AM J PATHOL, V130, P179; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; VOGEL AM, 1988, CANCER RES, V48, P1286; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Yasumoto K, 2004, J BIOL CHEM, V279, P28330, DOI 10.1074/jbc.M401269200	67	33	34	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					916	930		10.1096/fj.09-140921	http://dx.doi.org/10.1096/fj.09-140921			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19884326	Green Published			2022-12-28	WOS:000274974600027
J	Rampon, C; Bouzaffour, M; Ostuni, MA; Dufourcq, P; Girard, C; Freyssinet, JM; Lacapere, JJ; Schweizer-Groyer, G; Vriz, S				Rampon, Christine; Bouzaffour, Mohamed; Ostuni, Mariano A.; Dufourcq, Pascale; Girard, Christelle; Freyssinet, Jean Marie; Lacapere, Jean-Jacques; Schweizer-Groyer, Ghislaine; Vriz, Sophie			Translocator protein (18 kDa) is involved in primitive erythropoiesis in zebrafish	FASEB JOURNAL			English	Article						peripheral-type benzodiazepine receptor; hematopoiesis; transcription factor GATA-1	PERIPHERAL BENZODIAZEPINE-RECEPTOR; DIAZEPAM-BINDING INHIBITOR; CHOLESTEROL TRANSPORT; MITOCHONDRIAL-MEMBRANES; TRANSGENIC ZEBRAFISH; CELL-PROLIFERATION; ENDOGENOUS LIGANDS; DEATH RECEPTOR; HEMATOPOIESIS; EXPRESSION	The translocator protein (18 kDa) (TSPO), also known as peripheral-type benzodiazepine receptor, is directly or indirectly associated with many biological processes. Although extensively characterized, the specific function of TSPO during development remains unclear. It has been reported that TSPO is involved in a variety of mechanisms, including cell proliferation, apoptosis, regulation of mitochondrial functions, cholesterol transport and steroidogenesis, and porphyrin transport and heme synthesis. Although the literature has reported a murine knockout model, the experiment did not generate information because of early lethality. We then used the zebrafish model to address the function of tspo during development. Information about spatiotemporal expression showed that tspo has a maternal and a zygotic contribution which, during somatogenesis, seems to be erythroid restricted to the intermediate cell mass. Genetic and pharmacological approaches used to invalidate Tspo function resulted in embryos with specific erythropoietic cell depletion. Although unexpected, this lack of blood cells is independent of the Tspo cholesterol binding site and reveals a new in vivo key role for Tspo during erythropoiesis.-Rampon, C., Bouzaffour, M., Ostuni, M. A., Dufourcq, P., Girard, C., Freyssinet, J. M., Lacapere, J.-J., Schweizer-Groyer, G., Vriz, S. Translocator protein (18 kDa) is involved in primitive erythropoiesis in zebrafish. FASEB J. 23, 4181-4192 (2009). www.fasebj.org	[Rampon, Christine; Bouzaffour, Mohamed; Ostuni, Mariano A.; Dufourcq, Pascale; Lacapere, Jean-Jacques; Vriz, Sophie] Univ Paris 07, Paris, France; [Rampon, Christine; Bouzaffour, Mohamed; Dufourcq, Pascale; Freyssinet, Jean Marie; Vriz, Sophie] INSERM, U770, F-94275 Le Kremlin Bicetre, France; [Girard, Christelle; Schweizer-Groyer, Ghislaine] INSERM, U788, F-94275 Le Kremlin Bicetre, France; [Girard, Christelle; Schweizer-Groyer, Ghislaine] Univ Paris 11, Orsay, France; [Ostuni, Mariano A.; Lacapere, Jean-Jacques] CRB3, INSERM, U773, Paris, France	UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm)	Rampon, C (corresponding author), Coll France, CNRS, UMR 8542, 11 Pl Marcelin Berthelot, F-75231 Paris 05, France.	christine.rampon@college-de-france.fr	Freyssinet, Jean-Marie/G-2719-2013; girard, christelle/A-6564-2011; OSTUNI, Mariano/J-2930-2015	OSTUNI, Mariano/0000-0001-6769-3786; /0000-0002-9058-9378; rampon, christine/0000-0002-1444-3166; /0000-0003-2029-5750				Ach M, 2009, LEUKEMIA, V23, P712, DOI 10.1038/leu.2008.363; ALEXANDER BEE, 1992, BIOCHEM PHARMACOL, V44, P269, DOI 10.1016/0006-2952(92)90009-8; ALHO H, 1994, CELL GROWTH DIFFER, V5, P1005; Amatruda JF, 1999, DEV BIOL, V216, P1, DOI 10.1006/dbio.1999.9462; ANHOLT RRH, 1985, J PHARMACOL EXP THER, V233, P517; BERNASSAU JM, 1993, J MOL GRAPHICS, V11, P236, DOI 10.1016/0263-7855(93)80003-A; BRAESTRUP C, 1977, NATURE, V269, P702, DOI 10.1038/269702a0; Burgi B, 1999, J NEUROENDOCRINOL, V11, P85; CANAT X, 1993, LIFE SCI, V52, P107, DOI 10.1016/0024-3205(93)90293-C; Carradice D, 2008, BLOOD, V111, P3331, DOI 10.1182/blood-2007-10-052761; Davidson AJ, 2004, ONCOGENE, V23, P7233, DOI 10.1038/sj.onc.1207943; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; DOBLE A, 1985, EUR J PHARMACOL, V119, P153, DOI 10.1016/0014-2999(85)90291-2; Dooley K, 2000, CURR OPIN GENET DEV, V10, P252, DOI 10.1016/S0959-437X(00)00074-5; Dufourcq P, 2006, MOL CELL NEUROSCI, V33, P180, DOI 10.1016/j.mcn.2006.07.005; Dufourcq P, 2006, DEV GENES EVOL, V216, P635, DOI 10.1007/s00427-006-0066-7; FARGES R, 1994, MOL PHARMACOL, V46, P1160; Galiegue S, 1999, J BIOL CHEM, V274, P2938, DOI 10.1074/jbc.274.5.2938; Galloway JL, 2005, DEV CELL, V8, P109, DOI 10.1016/j.devcel.2004.12.001; GARNIER M, 1993, ENDOCRINOLOGY, V132, P444, DOI 10.1210/en.132.1.444; Gavish M, 1999, PHARMACOL REV, V51, P629; Golani I, 2001, BIOCHEMISTRY-US, V40, P10213, DOI 10.1021/bi010431+; GUIDOTTI A, 1983, P NATL ACAD SCI-BIOL, V80, P3531, DOI 10.1073/pnas.80.11.3531; Hardwick M, 1999, CANCER RES, V59, P831; Hauet T, 2002, TRANSPLANTATION, V74, P1507, DOI 10.1097/00007890-200212150-00006; Herbomel P, 1999, DEVELOPMENT, V126, P3735; Hsia N, 2005, EXP HEMATOL, V33, P1007, DOI 10.1016/j.exphem.2005.06.013; Hsu HJ, 2006, NATURE, V439, P480, DOI 10.1038/nature04436; Hsu HJ, 2003, DEVELOPMENT, V130, P2107, DOI 10.1242/dev.00427; Hsu Hwei-Jan, 2002, Gene Expression Patterns, V2, P219, DOI 10.1016/S1567-133X(02)00059-5; James ML, 2006, CURR MED CHEM, V13, P1991, DOI 10.2174/092986706777584979; Jamin N, 2005, MOL ENDOCRINOL, V19, P588, DOI 10.1210/me.2004-0308; Joseph-Liauzun E, 1998, J BIOL CHEM, V273, P2146, DOI 10.1074/jbc.273.4.2146; KRUEGER KE, 1990, J BIOL CHEM, V265, P15015; Kwan TT, 2006, EXP HEMATOL, V34, P27, DOI 10.1016/j.exphem.2005.09.017; Lacapere JJ, 2003, STEROIDS, V68, P569, DOI 10.1016/S0039-128X(03)00101-6; Lacapere JJ, 2001, BIOCHEM BIOPH RES CO, V284, P536, DOI 10.1006/bbrc.2001.4975; Lacor P, 1999, BRAIN RES, V815, P70, DOI 10.1016/S0006-8993(98)01105-6; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; LEFUR G, 1983, LIFE SCI, V32, P1839, DOI 10.1016/0024-3205(83)90062-0; Li H, 2001, MOL ENDOCRINOL, V15, P2211, DOI 10.1210/me.15.12.2211; Li H, 1998, ENDOCRINOLOGY, V139, P4991, DOI 10.1210/en.139.12.4991; Liao EC, 2002, DEVELOPMENT, V129, P649; Long QM, 2000, NAT CELL BIOL, V2, P549, DOI 10.1038/35019592; Maeda S, 1998, LIFE SCI, V63, P1423, DOI 10.1016/S0024-3205(98)00409-3; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MEYER UA, 1991, HARRISONS PRINCIPLES, P1829; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Nowak M, 2005, CELL DEATH DIFFER, V12, P52, DOI 10.1038/sj.cdd.4401519; OBEIRNE GB, 1990, EUR J BIOCHEM, V188, P131, DOI 10.1111/j.1432-1033.1990.tb15380.x; OKE BO, 1992, MOL CELL ENDOCRINOL, V87, pR1, DOI 10.1016/0303-7207(92)90248-5; OLSON JMM, 1988, EUR J PHARMACOL, V152, P47, DOI 10.1016/0014-2999(88)90834-5; Ostuni MA, 2004, AM J PHYSIOL-GASTR L, V286, pG1069, DOI 10.1152/ajpgi.00290.2003; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; Papadopoulos V, 2006, NEUROSCIENCE, V138, P749, DOI 10.1016/j.neuroscience.2005.05.063; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; Ransom DG, 1996, DEVELOPMENT, V123, P311; SNYDER SH, 1987, FASEB J, V1, P282, DOI 10.1096/fasebj.1.4.2820823; Traver D, 2003, NAT IMMUNOL, V4, P1238, DOI 10.1038/ni1007; Wang H, 1998, NAT GENET, V20, P239, DOI 10.1038/3041; Weinstein BM, 1996, DEVELOPMENT, V123, P303; Wendler G, 2003, BIOCHEM BIOPH RES CO, V311, P847, DOI 10.1016/j.bbrc.2003.10.070; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Wilms H, 2003, NEUROBIOL DIS, V14, P417, DOI 10.1016/j.nbd.2003.07.002; Yergeau DA, 2005, DEV BIOL, V283, P97, DOI 10.1016/j.ydbio.2005.04.006	66	28	28	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4181	4192		10.1096/fj.09-129262	http://dx.doi.org/10.1096/fj.09-129262			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19723704				2022-12-28	WOS:000272193700014
J	Conaway, HH; Persson, E; Halen, M; Granholm, S; Svensson, O; Pettersson, U; Lie, A; Lerner, UH				Conaway, H. Herschel; Persson, Emma; Halen, Marie; Granholm, Susanne; Svensson, Olle; Pettersson, Ulrika; Lie, Anita; Lerner, Ulf H.			Retinoids inhibit differentiation of hematopoetic osteoclast progenitors	FASEB JOURNAL			English	Article						osteoporosis; c-Fos; NFAT2; ATRA	BONE-MINERAL DENSITY; NF-KAPPA-B; VITAMIN-A; HYPERVITAMINOSIS-A; TRANSCRIPTION FACTORS; RECEPTOR ACTIVATOR; ACID; RISK; RESORPTION; PEPTIDE	Whether vitamin A promotes skeletal fragility, has no effect on fracture rate, or protects against bone loss is unclear. In the present study, effects of retinoids on osteoclast differentiation in cultured mouse bone marrow cells (BMCs), bone marrow macrophages (BMMs), spleen cells, and RAW264.7 cells were evaluated by analyzing osteoclast formation and expression of genes important in signal transduction and osteoclast function. All-trans-retinoic acid (ATRA) did not stimulate osteoclastogenesis in BMCs, but inhibited hormone and RANKL-induced gene expression and formation of osteoclasts. In BMMs, spleen cells, and RAW264.7 cells, osteoclast differentiation and formation stimulated by M-CSF/RANKL were inhibited (IC50 = 0.3 nM) by ATRA. The effect was exerted at an early step of RANKL-induced differentiation. ATRA also abolished increases of the transcription factors c-Fos and NFAT2 stimulated by RANKL and suppressed down-regulation of the antiosteoclastogenic transcription factor MafB. By comparing effects of several compounds structurally related to ATRA, as well as by using receptor antagonists, evaluation pointed to inhibition being mediated by RAR alpha, with no involvement of PPAR beta/delta. The results suggest that activation of RAR alpha by retinoids in myeloid hematopoietic precursor cells decreases osteoclast formation by altering expression of the transcription factors c-Fos, NFAT2, and MafB.-Conaway, H. H., Persson, E., Halen, M., Granholm, S., Svensson, O., Pettersson, U., Lie, A., Lerner, U. H. Retinoids inhibit differentiation of hematopoetic osteoclast progenitors. FASEB J. 23, 3526-3538 (2009). www.fasebj.org	[Persson, Emma; Halen, Marie; Granholm, Susanne; Lie, Anita; Lerner, Ulf H.] Umea Univ, Dept Oral Cell Biol, SE-90187 Umea, Sweden; [Svensson, Olle] Umea Univ, Dept Orthoped Surg, SE-90187 Umea, Sweden; [Pettersson, Ulrika] Umea Univ, Dept Clin Pharmacol, SE-90187 Umea, Sweden; [Conaway, H. Herschel] Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA	Umea University; Umea University; Umea University; University of Arkansas System; University of Arkansas Medical Sciences	Lerner, UH (corresponding author), Umea Univ, Dept Oral Cell Biol, SE-90187 Umea, Sweden.	lerner@odont.umu.se		Lerner, Ulf/0000-0002-3579-1960; Pettersson Kymmer, Ulrika/0000-0002-0557-9803	Swedish Science Council [07525]; Swedish Rheumatism Association; Royal 80 Year Foundation of King Gustav V; Faculty of Medicine at Umea University; County Council of Vasterbotten	Swedish Science Council; Swedish Rheumatism Association; Royal 80 Year Foundation of King Gustav V; Faculty of Medicine at Umea University; County Council of Vasterbotten	This project was supported by grants from the Swedish Science Council (project 07525), the Swedish Rheumatism Association, the Royal 80 Year Foundation of King Gustav V, the Faculty of Medicine at Umea University, and the County Council of Vasterbotten. We are grateful for the excellent drawing of the figures by Ingrid Bostrom. We gratefully thank Dr. Tim Arnett (University College London, London, UK) for providing ivory slices.	Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Berry DC, 2007, PPAR RES, V2007, DOI 10.1155/2007/73256; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Bocher V, 2002, ANN NY ACAD SCI, V967, P7; Caire-Juvera G, 2009, AM J CLIN NUTR, V89, P323, DOI 10.3945/ajcn.2008.26451; Conaway HH, 1997, J ENDOCRINOL, V155, P513, DOI 10.1677/joe.0.1550513; Feskanich D, 2002, JAMA-J AM MED ASSOC, V287, P47, DOI 10.1001/jama.287.1.47; FRANKEL TL, 1986, J NUTR, V116, P578, DOI 10.1093/jn/116.4.578; Granholm S, 2007, J ENDOCRINOL, V195, P415, DOI 10.1677/JOE-07-0338; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; HOUGH S, 1988, ENDOCRINOLOGY, V122, P2933, DOI 10.1210/endo-122-6-2933; Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657; Ishimi Y, 1999, J CLIN BIOCHEM NUTR, V27, P113; Johansson S, 2002, BONE, V31, P685, DOI 10.1016/S8756-3282(02)00910-9; Kaneko H, 2007, PROSTAG LEUKOTR ESS, V77, P181, DOI 10.1016/j.plefa.2007.09.002; Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007-0014; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood-2006-09-048249; Kneissel M, 2005, BONE, V36, P202, DOI 10.1016/j.bone.2004.11.006; Lerner UH, 2000, MATRIX BIOL, V19, P107, DOI 10.1016/S0945-053X(00)00052-4; Lerner UH, 2004, CRIT REV ORAL BIOL M, V15, P64, DOI 10.1177/154411130401500202; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Mano H, 2000, J BIOL CHEM, V275, P8126, DOI 10.1074/jbc.275.11.8126; Melhus H, 1998, ANN INTERN MED, V129, P770, DOI 10.7326/0003-4819-129-10-199811150-00003; Mic FA, 2003, P NATL ACAD SCI USA, V100, P7135, DOI 10.1073/pnas.1231422100; Michaelsson K, 2003, NEW ENGL J MED, V348, P287, DOI 10.1056/NEJMoa021171; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Nakashima T, 2008, ARCH BIOCHEM BIOPHYS, V473, P166, DOI 10.1016/j.abb.2008.04.004; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; OREFFO ROC, 1988, J BONE MINER RES, V3, P203; Persson E, 2005, BONE, V37, P513, DOI 10.1016/j.bone.2005.04.043; Promislow JHE, 2002, J BONE MINER RES, V17, P1349, DOI 10.1359/jbmr.2002.17.8.1349; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Ribaya-Mercado JD, 2007, NUTR REV, V65, P425, DOI 10.1111/j.1753-4887.2007.tb00268.x; SCHEVEN BAA, 1990, BONE, V11, P53, DOI 10.1016/8756-3282(90)90072-7; Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050; Takasu H, 2006, J CLIN INVEST, V116, P528, DOI 10.1172/JCI24742; Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672; Wang XX, 2002, J BONE MINER RES, V17, P91, DOI 10.1359/jbmr.2002.17.1.91; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Yang Ying, 2007, Einstein J Biol Med, V23, P2; Yonezawa T, 2007, BIOCHEM BIOPH RES CO, V355, P10, DOI 10.1016/j.bbrc.2006.12.237	45	40	41	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3526	3538		10.1096/fj.09-132548	http://dx.doi.org/10.1096/fj.09-132548			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19546303				2022-12-28	WOS:000270354300029
J	Hong, S; Derfoul, A; Pereira-Mouries, L; Hall, DJ				Hong, Sohee; Derfoul, Assia; Pereira-Mouries, Lucilia; Hall, David J.			A novel domain in histone deacetylase 1 and 2 mediates repression of cartilage-specific genes in human chondrocytes	FASEB JOURNAL			English	Article						osteoarthritis; transcription; collagen 2(alpha 1); chromatin	II COLLAGEN; ARTICULAR-CARTILAGE; TRANSCRIPTIONAL CONTROL; EXTRACELLULAR-MATRIX; INDUCED ARTHRITIS; HDAC INHIBITORS; TRICHOSTATIN-A; EXPRESSION; CANCER; CELLS	The role of histone deacetylase 1 and 2 (HDAC1 and HDAC2) in regulating cartilage-specific gene expression was explored in primary human chondrocytes. HDAC1 and HDAC2 protein levels were elevated in chondrocytes from osteoarthritic patients, consistent with a down-regulation of some cartilage marker genes. When expressed in these cells, HDAC1 and HDAC2 repressed aggrecan and collagen 2(alpha 1) expression but differed in their repression of collagen 9(alpha 1), collagen 11(alpha 1), dermatopontin, and cartilage oligomeric matrix protein (COMP). To identify the basis of these differences between HDAC1 and HDAC2, their carboxy-terminal domains (CTDs) were deleted, which led to proteins that retained enzymatic activity but were unable to repress cartilage gene expression. Further, exchange of the CTDs between HDAC1 and HDAC2 led to proteins that were enzymatically active but displayed altered target gene specificity, indicating that these CTDs can function independently of HDAC enzymatic activity, to target the HDACs to specific genes. The Snail transcription factor was identified as a mediator of HDAC1 and HDAC2 repression of the collagen 2(alpha 1) gene, via its interaction with the HDAC1 and 2 CTDs. The data indicate that the CTD serves a novel function within HDAC1 and HDAC2, to mediate repression of cartilage-specific gene expression in human chondrocytes.-Hong, S., Derfoul, A., Pereira-Mouries, L., Hall, D. J. A novel domain in histone deacetylase 1 and 2 mediates repression of cartilage-specific genes in human chondrocytes. FASEB J. 23, 3539-3552 (2009). www.fasebj.org	[Hong, Sohee; Derfoul, Assia; Pereira-Mouries, Lucilia; Hall, David J.] NIAMSD, Cartilage Mol Genet Grp, Cartilage Biol & Orthopaed Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Hall, DJ (corresponding author), 50 S Dr,Rm 1524, Bethesda, MD 20892 USA.	halld@mail.nih.gov		Pereira Mouries, Lucilia/0000-0001-5836-6011	National Institutes of Arthritis and Musculoskeletal and Skin Diseases within the National Institutes of Health; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041141, ZIAAR041141] Funding Source: NIH RePORTER	National Institutes of Arthritis and Musculoskeletal and Skin Diseases within the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank the National Disease Research Interchange (Philadelphia, PA, USA) for providing the human cartilage tissue samples. We also thank Dr. Ed Seto (Moffitt Cancer Center, Tampa, FL, USA) for the gift of the HDAC2 expression plasmid. The HDAC1 expression plasmid was provided by Origene Technologies (Rockville, MD, USA). This work was supported by the Intramural Research Program of the National Institutes of Arthritis and Musculoskeletal and Skin Diseases within the National Institutes of Health (Bethesda, MD, USA).	Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004; Chiba T, 2004, ONCOLOGY-BASEL, V66, P481, DOI 10.1159/000079503; Chung YL, 2003, MOL THER, V8, P707, DOI 10.1016/S1525-0016(03)00235-1; Cobaleda C, 2007, ANNU REV GENET, V41, P41, DOI 10.1146/annurev.genet.41.110306.130146; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; FRUTOS CA, 2007, DEV CELL, V13, P872; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Glaser KB, 2003, MOL CANCER THER, V2, P151; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Hasan S, 2002, J MOL MED, V80, P463, DOI 10.1007/s00109-002-0341-7; Huh YH, 2007, J BIOL CHEM, V282, P17123, DOI 10.1074/jbc.M700599200; Joseph J, 2004, ONCOGENE, V23, P6304, DOI 10.1038/sj.onc.1207852; Lallemand F, 1999, EXP CELL RES, V247, P432, DOI 10.1006/excr.1998.4370; Lefebvre Veronique, 2005, Birth Defects Research, V75, P200, DOI 10.1002/bdrc.20048; Lin HS, 2007, BRIT J PHARMACOL, V150, P862, DOI 10.1038/sj.bjp.0707165; Ma PP, 2008, DEV BIOL, V319, P110, DOI 10.1016/j.ydbio.2008.04.011; Martin I, 2001, OSTEOARTHR CARTILAGE, V9, P112, DOI 10.1053/joca.2000.0366; Matyas JR, 2002, ARTHRITIS RHEUM, V46, P1536, DOI 10.1002/art.10331; McKinsey TA, 2002, CURR OPIN CELL BIOL, V14, P763, DOI 10.1016/S0955-0674(02)00389-7; McLaughlin F, 2004, BIOCHEM PHARMACOL, V68, P1139, DOI 10.1016/j.bcp.2004.05.034; Nasu Y, 2008, OSTEOARTHR CARTILAGE, V16, P723, DOI 10.1016/j.joca.2007.10.014; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nishida K, 2004, ARTHRITIS RHEUM-US, V50, P3365, DOI 10.1002/art.20709; Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Poree B, 2008, J BIOL CHEM, V283, P4850, DOI 10.1074/jbc.M706387200; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Sakimura R, 2007, CLIN CANCER RES, V13, P275, DOI 10.1158/1078-0432.CCR-06-1696; Salminen H, 2001, ARTHRITIS RHEUM-US, V44, P947; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Seki K, 2003, J BIOL CHEM, V278, P41862, DOI 10.1074/jbc.M308336200; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Whetstine JR, 2005, MOL CELL, V18, P483, DOI 10.1016/j.molcel.2005.04.006; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Yagi R, 2005, J ORTHOP RES, V23, P1128, DOI 10.1016/j.orthres.2004.12.016; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Young DA, 2005, ARTHRITIS RES THER, V7, pR503, DOI 10.1186/ar1702; Young DA, 2005, FEBS J, V272, P1912, DOI 10.1111/j.1742-4658.2005.04622.x	42	79	84	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3539	3552		10.1096/fj.09-133215	http://dx.doi.org/10.1096/fj.09-133215			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19561124	Green Published			2022-12-28	WOS:000270354300030
J	Jansen, IDC; Mardones, P; Lecanda, F; de Vries, TJ; Recalde, S; Hoeben, KA; Schoenmaker, T; Ravesloot, JH; van Borren, MMGJ; van Eijden, TM; Bronckers, ALJJ; Kellokumpu, S; Medina, JF; Everts, V; Elferink, RPJO				Jansen, Ineke D. C.; Mardones, Pablo; Lecanda, Fernando; de Vries, Teun J.; Recalde, Sergio; Hoeben, Kees A.; Schoenmaker, Ton; Ravesloot, Jan-Hindrik; van Borren, Marcel M. G. J.; van Eijden, Theo M.; Bronckers, Antonius L. J. J.; Kellokumpu, Sakari; Medina, Juan F.; Everts, Vincent; Elferink, Ronald P. J. Oude			Ae2(a,b)-Deficient mice exhibit osteopetrosis of long bones but not of calvaria	FASEB JOURNAL			English	Article						osteoclast; osteoclastogenesis; skull; solute carriers; tibia	OSTEOCLAST PRECURSOR CELLS; ANION-EXCHANGER SLC4A2; AE2 CL-/HCO3-EXCHANGER; TARGETED DISRUPTION; MOLECULAR-CLONING; PH REGULATION; C-FMS; DEFICIENCY; RESORPTION; DIFFERENTIATION	Extracellular acidification by osteoclasts is essential to bone resorption. During proton pumping, intracellular pH (pH(i)) is thought to be kept at a near-neutral level by chloride/bicarbonate exchange. Here we show that the Na+-independent chloride/bicarbonate anion exchanger 2 (Ae2) is relevant for this process in the osteoclasts from the long bones of Ae2(a,b)(-/-) mice ( deficient in the main isoforms Ae2a, Ae2b(1), and Ae2b(2)). Although the long bones of these mice had normal numbers of multinucleated osteoclasts, these cells lacked a ruffled border and displayed impaired bone resorption activity, resulting in an osteopetrotic phenotype of long bones. Moreover, in vitro osteoclastogenesis assays using long-bone marrow cells from Ae2(a,b)(-/-) mice suggested a role for Ae2 in osteoclast formation, as fusion of preosteoclasts for the generation of active multinucleated osteoclasts was found to be slightly delayed. In contrast to the abnormalities observed in the long bones, the skull of Ae2(a,b)(-/-) mice showed no alterations, indicating that calvaria osteoclasts may display normal resorptive activity. Microfluorimetric analysis of osteoclasts from normal mice showed that, in addition to Ae2 activity, calvaria osteoclasts-but not long-bone osteoclasts-possess a sodium-dependent bicarbonate transporting activity. Possibly, this might compensate for the absence of Ae2 in calvaria osteoclasts of Ae2(a,b)(-/-) mice.-Jansen, I. D. C., Mardones, P., Lecanda, F., de Vries, T. J., Recalde, S., Hoeben, K. A., Schoenmaker, T., Ravesloot, J.-H., van Borren, M. M. G. J., van Eijden, T. M., Bronckers, A. L. J. J., Kellokumpu, S., Medina, J. F., Everts, V., Oude Elferink, R. P. J. Ae2(a,b)-deficient mice exhibit osteopetrosis of long bones but not of calvaria. FASEB J. 23, 3470-3481 ( 2009). www.fasebj.org	[Jansen, Ineke D. C.] Vrije Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Periodontol, Res Inst MOVE, NL-1081 BT Amsterdam, Netherlands; [Jansen, Ineke D. C.; de Vries, Teun J.; Schoenmaker, Ton; Everts, Vincent] Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Periodontol, Amsterdam, Netherlands; [Jansen, Ineke D. C.; de Vries, Teun J.; Schoenmaker, Ton; Bronckers, Antonius L. J. J.; Everts, Vincent] Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Oral Cell Biol, Amsterdam, Netherlands; [van Eijden, Theo M.] Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Funct Anat, Amsterdam, Netherlands; [Mardones, Pablo; Elferink, Ronald P. J. Oude] Univ Amsterdam, Acad Med Ctr, AMC Liver Ctr, NL-1105 AZ Amsterdam, Netherlands; [Hoeben, Kees A.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1105 AZ Amsterdam, Netherlands; [Ravesloot, Jan-Hindrik; van Borren, Marcel M. G. J.] Univ Amsterdam, Acad Med Ctr, Dept Physiol, NL-1105 AZ Amsterdam, Netherlands; [Lecanda, Fernando; Recalde, Sergio; Medina, Juan F.] Univ Navarra, Sch Med, E-31080 Pamplona, Spain; [Lecanda, Fernando; Recalde, Sergio; Medina, Juan F.] Univ Navarra, CIMA, E-31080 Pamplona, Spain; [Kellokumpu, Sakari] Univ Oulu, Dept Biochem, Oulu, Finland; [Medina, Juan F.] Univ Navarra, Div Gene Therapy & Hepatol, CIMA & Clin, E-31080 Pamplona, Spain; [Medina, Juan F.] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Pamplona, Spain	Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam; Academic Center for Dentistry Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Academic Center for Dentistry Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Academic Center for Dentistry Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Navarra; University of Navarra; Finland National Institute for Health & Welfare; University of Oulu; University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD	Jansen, IDC (corresponding author), Vrije Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Periodontol, Res Inst MOVE, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	ineke.jansen@vumc.nl	Mardones Hiche, Pablo/B-8544-2009; Recalde, Sergio/D-1815-2017; Mardones, Pablo/ABG-3418-2021	Recalde, Sergio/0000-0002-9328-9725; de Vries, Teun/0000-0001-6464-5172; Schoenmaker, Ton/0000-0001-6649-374X	Spanish Ministerio de Education y Ciencia [SAF2005-02468, SAF2006-07818]; Instituto de Salud Carlos III [FIS-01/0777]; NWO [912-02-073]; The Royal Academy of Sciences, KNAW; NIH [DE 13508-06]	Spanish Ministerio de Education y Ciencia(Spanish Government); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); NWO(Netherlands Organization for Scientific Research (NWO)); The Royal Academy of Sciences, KNAW; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr. P. Leenen ( Department of Immunology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands) for the ER-MP12 and ER-MP20 antibodies. This work was supported through the UTE for CIMA project; by grants awarded by the Spanish Ministerio de Education y Ciencia (SAF2005-02468 and SAF2006-07818) and Instituto de Salud Carlos III (FIS-01/0777 and Ciberehd) to J. F. M; and by three different grants from The Netherlands to R.P.J.O.E. (NWO, program 912-02-073), T. J. D. ( The Royal Academy of Sciences, KNAW), and A. L. J. J. B. (NIH; DE 13508-06). We thank E. Saez, S. Sarvide, A. Concepcion, C. Zandueta, and Dr. J. T. Salas for their valuable help.	Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; Aranda V, 2004, BIOCHEM BIOPH RES CO, V319, P1040, DOI 10.1016/j.bbrc.2004.05.080; Borthwick KJ, 2003, J MED GENET, V40, P115, DOI 10.1136/jmg.40.2.115; Bronckers ALJJ, 2009, J EXP ZOOL PART B, V312B, P375, DOI 10.1002/jez.b.21267; Creemers LB, 1997, BIOTECHNIQUES, V22, P656, DOI 10.2144/97224bm19; de Vries TJ, 2005, J CELL BIOCHEM, V94, P954, DOI 10.1002/jcb.20326; DEBRUIJN MFTR, 1994, EUR J IMMUNOL, V24, P2279, DOI 10.1002/eji.1830241003; Denker SP, 2002, CURR OPIN CELL BIOL, V14, P214, DOI 10.1016/S0955-0674(02)00304-6; El Zohairy AA, 2003, DENT MATER, V19, P575, DOI 10.1016/S0109-5641(02)00107-0; Everts V, 1999, FASEB J, V13, P1219, DOI 10.1096/fasebj.13.10.1219; Gawenis LR, 2004, J BIOL CHEM, V279, P30531, DOI 10.1074/jbc.M403779200; Helfrich MH, 2003, MICROSC RES TECHNIQ, V61, P514, DOI 10.1002/jemt.10375; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; Holappa K, 2001, J HISTOCHEM CYTOCHEM, V49, P259, DOI 10.1177/002215540104900213; Josephsen K, 2009, P NATL ACAD SCI USA, V106, P1638, DOI 10.1073/pnas.0811682106; Klein M, 2000, J GEN PHYSIOL, V115, P599, DOI 10.1085/jgp.115.5.599; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Kurschat CE, 2006, J BIOL CHEM, V281, P1885, DOI 10.1074/jbc.M509734200; Lecanda J, 2000, BIOCHEM BIOPH RES CO, V276, P117, DOI 10.1006/bbrc.2000.3439; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lyaruu DM, 2008, MATRIX BIOL, V27, P119, DOI 10.1016/j.matbio.2007.09.006; Medina JF, 2003, P NATL ACAD SCI USA, V100, P15847, DOI 10.1073/pnas.2536127100; Medina JF, 1997, GENOMICS, V39, P74, DOI 10.1006/geno.1996.4467; Medina JF, 2000, BIOCHEM BIOPH RES CO, V267, P228, DOI 10.1006/bbrc.1999.1951; Muller-Berger S, 2001, PFLUG ARCH EUR J PHY, V442, P718, DOI 10.1007/s004240100592; Perez-Amodio S, 2006, CALCIFIED TISSUE INT, V79, P245, DOI 10.1007/s00223-005-0289-z; RAVESLOOT JH, 1995, J GEN PHYSIOL, V105, P177, DOI 10.1085/jgp.105.2.177; Recalde S, 2006, AM J PATHOL, V169, P165, DOI 10.2353/ajpath.2006.051096; Romero MF, 2004, PFLUG ARCH EUR J PHY, V447, P495, DOI 10.1007/s00424-003-1180-2; Salas JT, 2008, GASTROENTEROLOGY, V134, P1482, DOI 10.1053/j.gastro.2008.02.020; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; Samuelson LC, 2003, ANNU REV PHYSIOL, V65, P383, DOI 10.1146/annurev.physiol.65.092101.142213; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Sterling D, 2002, J BIOL CHEM, V277, P25239, DOI 10.1074/jbc.M202562200; Taranta A, 2003, AM J PATHOL, V162, P57, DOI 10.1016/S0002-9440(10)63798-4; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; TETI A, 1989, J CLIN INVEST, V83, P227, DOI 10.1172/JCI113863; THESINGH CW, 1985, BONE, V6, P43, DOI 10.1016/8756-3282(85)90406-5; Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; Wang Z, 1996, J BIOL CHEM, V271, P7835, DOI 10.1074/jbc.271.13.7835; Wu J, 2008, P NATL ACAD SCI USA, V105, P16934, DOI 10.1073/pnas.0808763105; Yamane T, 1997, BLOOD, V90, P3516, DOI 10.1182/blood.V90.9.3516	48	52	52	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3470	3481		10.1096/fj.08-122598	http://dx.doi.org/10.1096/fj.08-122598			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19564250				2022-12-28	WOS:000270354300024
J	Bistulfi, G; Diegelman, P; Foster, BA; Kramer, DL; Porter, CW; Smiraglia, DJ				Bistulfi, G.; Diegelman, P.; Foster, B. A.; Kramer, D. L.; Porter, C. W.; Smiraglia, D. J.			Polyamine biosynthesis impacts cellular folate requirements necessary to maintain S-adenosylmethionine and nucleotide pools	FASEB JOURNAL			English	Article						one-carbon metabolism; prostate cancer	ORNITHINE-DECARBOXYLASE; MEMBRANE ANTIGEN; PROSTATE-CANCER; DIETARY-FOLATE; DNA METHYLATION; ANDROGEN-REGULATION; METABOLIC FLUX; FOLIC-ACID; DEFICIENCY; EXPRESSION	Folate (vitamin B9) is utilized for synthesis of both S-adenosylmethionine (AdoMet) and deoxythymidine monophosphate (dTMP), which are required for methylation reactions and DNA synthesis, respectively. Folate depletion leads to an imbalance in both AdoMet and nucleotide pools, causing epigenetic and genetic damage capable of initiating tumorigenesis. Polyamine biosynthesis also utilizes AdoMet, but polyamine pools are not reduced under a regimen of folate depletion. We hypothesized that high polyamine biosynthesis, due to the high demand on AdoMet pools, might be a factor in determining sensitivity to folate depletion. We found a significant correlation (P<0.001) between polyamine biosynthesis and the amount of folate required to sustain cell line proliferation. We manipulated polyamine biosynthesis by genetic and pharmacological intervention and mechanistically demonstrated that we could thereby alter AdoMet pools and increase or decrease demand on folate availability needed to sustain cellular proliferation. Furthermore, growing a panel of cell lines with 100 nM folate led to imbalanced nucleotide and AdoMet pools only in cells with endogenously high polyamine biosynthesis. These data demonstrate that polyamine biosynthesis is a critical factor in determining sensitivity to folate depletion and may be particularly important in the prostate, where biosynthesis of polyamines is characteristically high due to its secretory function.-Bistulfi, G., Diegelman, P., Foster, B. A., Kramer, D. L., Porter, C. W., Smiraglia, D. J. Polyamine biosynthesis impacts cellular folate requirements necessary to maintain S-adenosylmethionine and nucleotide pools. FASEB J. 23, 2888-2897 (2009). www.fasebj.org	[Bistulfi, G.; Smiraglia, D. J.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Smiraglia, DJ (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St,BLSC L3-314, Buffalo, NY 14263 USA.	dominic.smiraglia@rosewellpark.org	Smiraglia, Dominic/R-2069-2019	Smiraglia, Dominic/0000-0001-8852-1510	American Institute for Cancer Research Fellowship; American-Italian Cancer Foundation Fellowship; National Cancer Institute (NCI) [NCI R21 CA121216, NCI CA022153, NCI CA076428]; NCI Cancer Center [CA016056]; NATIONAL CANCER INSTITUTE [R21CA121216, R01CA076428, R21CA131646, P30CA016056, R01CA022153] Funding Source: NIH RePORTER	American Institute for Cancer Research Fellowship; American-Italian Cancer Foundation Fellowship; National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported in part by an American Institute for Cancer Research Fellowship (G.B.); an American-Italian Cancer Foundation Fellowship (G.B.); National Cancer Institute (NCI) grants NCI R21 CA121216 (G.B. and D.J.S.), NCI CA022153 (C.W P.), and NCI CA076428 (C.W.P.); and the NCI Cancer Center Support grant to the Roswell Park Cancer Institute (CA016056). We thank Dr. Sufrin (Roswell Park Cancer Institute, Buffalo, NY, USA), who kindly gave us purified dcAdoMet to use as an HPLC standard.	BLACKSHEAR PJ, 1989, MOL ENDOCRINOL, V3, P68, DOI 10.1210/mend-3-1-68; Bronder JL, 2003, J BIOL CHEM, V278, P48861, DOI 10.1074/jbc.M304844200; Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243; CHANDAR N, 1988, CARCINOGENESIS, V9, P259, DOI 10.1093/carcin/9.2.259; Chen Y, 2001, CANCER RES, V61, P6437; Cole BF, 2007, JAMA-J AM MED ASSOC, V297, P2351, DOI 10.1001/jama.297.21.2351; CROSS DR, 1993, CELL PROLIFERAT, V26, P327, DOI 10.1111/j.1365-2184.1993.tb00328.x; Crott JW, 2008, J NUTR BIOCHEM, V19, P328, DOI 10.1016/j.jnutbio.2007.05.003; Cyriac J, 2002, PROSTATE, V50, P252, DOI 10.1002/pros.10052; DANZIN C, 1990, BIOCHEM PHARMACOL, V40, P1499, DOI 10.1016/0006-2952(90)90446-R; Duthie SJ, 2000, NUTR CANCER, V37, P245, DOI 10.1207/S15327914NC372_18; Fair WR, 1997, PROSTATE, V32, P140; FJOSNE HE, 1992, PROSTATE, V21, P239, DOI 10.1002/pros.2990210307; FOGEL WA, 1980, ARCH IMMUNOL THER EX, V28, P907; Foster BA, 1997, CANCER RES, V57, P3325; Gangjee A, 2007, ANTI-CANCER AGENT ME, V7, P524, DOI 10.2174/187152007781668724; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; Ghosh A, 2004, J CELL BIOCHEM, V91, P528, DOI 10.1002/jcb.10661; Harrison GA, 1931, BIOCHEM J, V25, P1885, DOI 10.1042/bj0251885; HESTON WDW, 1991, CANCER SURV, V11, P217; HORNE DW, 1988, CLIN CHEM, V34, P2357; Hultdin J, 2005, INT J CANCER, V113, P819, DOI 10.1002/ijc.20646; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; ISRAELI RS, 1993, CANCER RES, V53, P227; James SJ, 1997, CARCINOGENESIS, V18, P287, DOI 10.1093/carcin/18.2.287; James SJ, 2003, J NUTR, V133, p3740S, DOI 10.1093/jn/133.11.3740S; JANNE OA, 1991, J STEROID BIOCHEM, V40, P307, DOI 10.1016/0960-0760(91)90196-C; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; Kee K, 2004, J BIOL CHEM, V279, P40076, DOI 10.1074/jbc.M406002200; Kee K, 2004, J BIOL CHEM, V279, P27050, DOI 10.1074/jbc.M403323200; Kim YI, 2006, GUT, V55, P1387, DOI 10.1136/gut.2006.095463; Kim YI, 1997, AM J CLIN NUTR, V65, P46, DOI 10.1093/ajcn/65.1.46; Kim YI, 1996, GUT, V39, P732, DOI 10.1136/gut.39.5.732; Kim YI, 2005, J NUTR, V135, P2703, DOI 10.1093/jn/135.11.2703; Knock E, 2006, CANCER RES, V66, P10349, DOI 10.1158/0008-5472.CAN-06-2477; KRAMER D, 1995, BIOCHEM PHARMACOL, V50, P1433, DOI 10.1016/0006-2952(95)02037-3; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; Kramer DL, 2008, J BIOL CHEM, V283, P4241, DOI 10.1074/jbc.M706806200; Kramer DL, 2001, CANCER RES, V61, P7754; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu H, 1997, CANCER RES, V57, P3629; Loenen WAM, 2006, BIOCHEM SOC T, V34, P330, DOI 10.1042/BST0340330; Mi Z, 1998, PROSTATE, V34, P51, DOI 10.1002/(SICI)1097-0045(19980101)34:1<51::AID-PROS7>3.0.CO;2-N; Mohan RR, 1999, CLIN CANCER RES, V5, P143; PEGG AE, 1970, BIOCHEM J, V117, P17, DOI 10.1042/bj1170017; Pelucchi C, 2005, CANCER EPIDEM BIOMAR, V14, P944, DOI 10.1158/1055-9965.EPI-04-0787; Pinto JT, 1996, CLIN CANCER RES, V2, P1445; Pogribny IP, 1997, CARCINOGENESIS, V18, P2071, DOI 10.1093/carcin/18.11.2071; Pogribny IP, 2004, MUTAT RES-FUND MOL M, V548, P53, DOI 10.1016/j.mrfmmm.2003.12.014; POGRIBNY IP, 1995, CANCER RES, V55, P1894; Rossi E, 2006, ANN EPIDEMIOL, V16, P206, DOI 10.1016/j.annepidem.2005.03.010; Silver DA, 1997, CLIN CANCER RES, V3, P81; Sohn KJ, 2003, CARCINOGENESIS, V24, P81, DOI 10.1093/carcin/24.1.81; Stempak JM, 2005, CARCINOGENESIS, V26, P981, DOI 10.1093/carcin/bgi037; Stevens VL, 2006, AM J EPIDEMIOL, V163, P989, DOI 10.1093/aje/kwj126; Sun DM, 2002, J NUTR, V132, P2632, DOI 10.1093/jn/132.9.2632; WILLIAMSASHMAN HG, 1979, PERSPECT BIOL MED, V22, P421; YARLETT N, 1988, MOL BIOCHEM PARASIT, V27, P1, DOI 10.1016/0166-6851(88)90019-9	59	46	49	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2888	2897		10.1096/fj.09-130708	http://dx.doi.org/10.1096/fj.09-130708			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19417083	Green Published			2022-12-28	WOS:000270241000012
J	Ghosh, AK; Bhattacharyya, S; Wei, J; Kim, S; Barak, Y; Mori, Y; Varga, J				Ghosh, Asish K.; Bhattacharyya, Swati; Wei, Jun; Kim, Suyeon; Barak, Yaacov; Mori, Yasuji; Varga, John			Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator	FASEB JOURNAL			English	Article						fibrosis; 15d-PGJ(2); type I collagen; fibroblast; acetyltransferase	GROWTH-FACTOR-BETA; NORMAL SKIN FIBROBLASTS; CREB-BINDING PROTEIN; SMOOTH-MUSCLE-CELLS; PPAR-GAMMA; GENE-EXPRESSION; I COLLAGEN; TGF-BETA; PROFIBROTIC RESPONSES; INTERFERON-GAMMA	Ligands of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) abrogate the stimulation of collagen gene transcription induced by transforming growth factor-beta (TGF-beta). Here, we delineate the mechanisms underlying this important novel physiological function for PPAR-gamma in connective tissue homeostasis. First, we demonstrated that antagonistic regulation of TGF-beta activity by PPAR-gamma ligands involves cellular PPAR-gamma, since 15-deoxy-Delta 12,14-prostaglandin J(2) (15d-PGJ(2)) failed to block TGF-beta-induced responses in either primary cultures of PPAR-gamma-null murine embryonic fibroblasts, or in normal human skin fibroblasts with RNAi-mediated knockdown of PPAR-gamma. Next, we examined the molecular basis underlying the abrogation of TGF-beta signaling by PPAR-gamma in normal human fibroblasts in culture. The results demonstrated that Smad-dependent transcriptional responses were blocked by PPAR-gamma without preventing Smad2/3 activation. In contrast, the interaction between activated Smad2/3 and the transcriptional coactivator and histone acetyltransferase p300 induced by TGF-beta, and the accumulation of p300 on consensus Smad-binding DNA sequences and histone H4 hyperacetylation at the COL1A2 locus, were all prevented by PPAR-gamma. Wild-type p300, but not a mutant form of p300 lacking functional histone acetyltransferase, was able to restore TGF-beta-induced stimulation of COL1A2 in the presence of PPAR-gamma ligands. Collectively, these results indicate that PPAR-gamma blocked Smad-mediated transcriptional responses by preventing p300 recruitment and histone H4 hyperacetylation, resulting in the inhibition of TGF-beta-induced collagen gene expression. Pharmacological activation of PPAR-gamma thus may represent a novel therapeutic approach to target p300-dependent TGF-beta profibrotic responses such as stimulation of collagen gene expression.-Ghosh, A. K., Bhattacharyya, S., Wei, J., Kim, S., Barak, Y., Mori, Y., and Varga, J. Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J. 23, 2968-2977 (2009). www.fasebj.org	[Ghosh, Asish K.] Northwestern Univ, Feinberg Cardiovasc Res Inst, Feinberg Sch Med, Chicago, IL 60611 USA; [Bhattacharyya, Swati; Wei, Jun; Mori, Yasuji; Varga, John] Northwestern Univ, Div Rheumatol, Feinberg Sch Med, Chicago, IL 60611 USA; [Kim, Suyeon; Barak, Yaacov] Jackson Lab, Bar Harbor, ME 04609 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Jackson Laboratory	Ghosh, AK (corresponding author), Northwestern Univ, Feinberg Cardiovasc Res Inst, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.	a-ghosh2@northwestern.edu; j-varga@northwestern.edu	Bhattacharyya, Swati/W-8145-2019; Wei, Jun/G-3295-2012; Varga, John/AAK-6472-2021; Wei, Jun/G-5854-2012		Scleroderma Foundation; National Institutes of Health [AR-49025]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049025] Funding Source: NIH RePORTER	Scleroderma Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We are grateful to Christopher K. Glass (University of California, San Diego, CA, USA) and Joan Boyes (Institute of Cancer Research, London, UK) for PPAR-gamma and p300 expression vectors. This work was supported by grants from the Scleroderma Foundation to A.K.G. and the National Institutes of Health (AR-49025) to J.V.	Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bhattacharyya S, 2005, ARTHRITIS RHEUM-US, V52, P1248, DOI 10.1002/art.20996; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Burgess HA, 2005, AM J PHYSIOL-LUNG C, V288, pL1146, DOI 10.1152/ajplung.00383.2004; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Farrajota K, 2005, ARTHRITIS RHEUM-US, V52, P94, DOI 10.1002/art.20714; Galli A, 2002, GASTROENTEROLOGY, V122, P1924, DOI 10.1053/gast.2002.33666; Gao DF, 2007, BIOCHEM PHARMACOL, V73, P185, DOI 10.1016/j.bcp.2006.09.019; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Genovese T, 2005, EUR RESPIR J, V25, P225, DOI 10.1183/09031936.05.00049704; Ghosh AK, 2004, ARTHRITIS RHEUM-US, V50, P1305, DOI 10.1002/art.20104; Ghosh AK, 2006, J CELL PHYSIOL, V207, P251, DOI 10.1002/jcp.20559; Ghosh AK, 2004, J BIOL CHEM, V279, P47455, DOI 10.1074/jbc.M403477200; Ghosh AK, 2002, EXP BIOL MED, V227, P301, DOI 10.1177/153537020222700502; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Ghosh AK, 2008, BIOCHEM BIOPH RES CO, V374, P231, DOI 10.1016/j.bbrc.2008.07.014; Ghosh AK, 2007, J CELL PHYSIOL, V213, P663, DOI 10.1002/jcp.21162; Gressner OA, 2008, J HEPATOL, V49, P758, DOI 10.1016/j.jhep.2008.03.029; Hayashi S, 2002, MECH DEVELOP, V119, pS97, DOI 10.1016/S0925-4773(03)00099-6; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 2006, RHEUMATOLOGY, V45, P157, DOI 10.1093/rheumatology/kei124; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200; Kon K, 2002, BIOCHEM BIOPH RES CO, V291, P55, DOI 10.1006/bbrc.2002.6385; Lakatos HF, 2007, PPAR RES, V2007, DOI 10.1155/2007/71323; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Li YJ, 2006, J AM SOC NEPHROL, V17, P54, DOI 10.1681/ASN.2005030257; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Ma LJ, 2001, KIDNEY INT, V59, P1899, DOI 10.1046/j.1523-1755.2001.0590051899.x; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; McCarthy KJ, 2000, KIDNEY INT, V58, P2341, DOI 10.1046/j.1523-1755.2000.00418.x; Mori Y, 2003, ARTHRITIS RHEUM-US, V48, P1964, DOI 10.1002/art.11157; Mori Y, 2000, EXP CELL RES, V258, P374, DOI 10.1006/excr.2000.4930; Panchapakesan U, 2005, AM J PHYSIOL-RENAL, V289, pF1153, DOI 10.1152/ajprenal.00097.2005; Ramirez F, 2006, MATRIX BIOL, V25, P365, DOI 10.1016/j.matbio.2006.05.002; Redondo S, 2005, DIABETES, V54, P811, DOI 10.2337/diabetes.54.3.811; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Ricote M, 2007, BBA-MOL CELL BIOL L, V1771, P926, DOI 10.1016/j.bbalip.2007.02.013; Ross S, 2006, EMBO J, V25, P4490, DOI 10.1038/sj.emboj.7601332; Ruiz E, 2007, J PHARMACOL EXP THER, V321, P431, DOI 10.1124/jpet.106.114934; Sertznig P, 2007, J CELL PHYSIOL, V212, P1, DOI 10.1002/jcp.20998; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; Takahashi N, 2002, J BIOL CHEM, V277, P16906, DOI 10.1074/jbc.M200585200; Teresi RE, 2006, INT J CANCER, V118, P2390, DOI 10.1002/ijc.21799; Varga J, 2008, CURR OPIN RHEUMATOL, V20, P720, DOI 10.1097/BOR.0b013e32830e48e8; Varga J, 2007, J CLIN INVEST, V117, P557, DOI 10.1172/JCI31139; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; White ES, 2006, AM J RESP CRIT CARE, V173, P112, DOI 10.1164/rccm.200507-1058OC; Wu MH, 2009, AM J PATHOL, V174, P519, DOI 10.2353/ajpath.2009.080574; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Xia H, 2008, J EXP MED, V205, P1659, DOI 10.1084/jem.20080001; Xu Y, 2007, J BIOL CHEM, V282, P26046, DOI 10.1074/jbc.M703652200; Yavrom S, 2005, J BIOL CHEM, V280, P40650, DOI 10.1074/jbc.M510094200; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhao CY, 2006, BIOCHEM BIOPH RES CO, V350, P385, DOI 10.1016/j.bbrc.2006.09.069; Zheng F, 2002, AM J PHYSIOL-RENAL, V282, pF639, DOI 10.1152/ajprenal.00189.2001	62	92	96	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2968	2977		10.1096/fj.08-128736	http://dx.doi.org/10.1096/fj.08-128736			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19395477	Green Published			2022-12-28	WOS:000270241000019
J	Mauro, TM; McCormick, JA; Wang, J; Boini, KM; Ray, L; Monks, B; Birnbaum, MJ; Lang, F; Pearce, D				Mauro, Theodora M.; McCormick, James A.; Wang, Jian; Boini, Krishna M.; Ray, Leena; Monks, Bobby; Birnbaum, Morris J.; Lang, Florian; Pearce, David			Akt2 and SGK3 are both determinants of postnatal hair follicle development	FASEB JOURNAL			English	Article						phosphatidylinositol-3-kinase; beta-catenin; Lef1; proliferation; baldness	GLUCOCORTICOID-INDUCIBLE KINASE-1; FORKHEAD TRANSCRIPTION FACTOR; TARGETED MICE LACKING; VITAMIN-D-RECEPTOR; PROTEIN-KINASE; BETA-CATENIN; GLUCOSE-HOMEOSTASIS; SGK1-KNOCKOUT MOUSE; GENE-EXPRESSION; STEM-CELLS	SGK3, which previously has been shown to play a key role in hair follicle development in mice, is a member of the AGC family of serine-threonine kinases. Mice lacking SGK3 have abnormal follicle cycling, which begins shortly after birth and ameliorates substantially with age. However, this developmental abnormality is not recapitulated in mice lacking closely related kinases Akt1, Akt2, or Akt3. To examine whether Akt2 interacts with SGK3 in postnatal hair development, we have generated and characterized Akt2/SGK3 double knockouts (DKOs). We find that the DKO mice have a defect in hair growth that is markedly worse than that of SGK3(-/-) mice and does not ameliorate with age. Morphologically, this defect is characterized by accelerated entry into catagen and through anagen, irregular hair follicle orientation, and increased expression of sebaceous glands. The defect is preceded by a profound failure to increase follicle matrix cell nuclear beta-catenin accumulation and proliferation at the onset of morphogenesis. Furthermore, in cultured keratinocytes, transfected Akt2 and SGK3 both stimulate transcription of a beta-catenin-LEF1-dependent reporter gene. Thus, SGK3 and Akt2 both appear to play important roles in postnatal hair follicle morphogenesis, likely because of their redundant regulation of beta-catenin-dependent transcriptional processes, which control hair follicle cell proliferation.-Mauro, T. M., McCormick, J. A., Wang, J., Boini, K. M., Ray, L., Monks, B., Birnbaum, M. J., Lang, F., and Pearce, D. Akt2 and SGK3 are both determinants of postnatal hair follicle development. FASEB J. 23, 3193-3202 (2009). www.fasebj.org	[McCormick, James A.; Wang, Jian; Ray, Leena; Pearce, David] Univ Calif San Francisco, Dept Med, San Francisco, CA 94107 USA; [Mauro, Theodora M.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [McCormick, James A.; Wang, Jian; Ray, Leena; Pearce, David] Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; [Mauro, Theodora M.] San Francisco Vet Hosp, Dept Dermatol, San Francisco, CA USA; [McCormick, James A.] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97201 USA; [McCormick, James A.; Boini, Krishna M.; Lang, Florian] Univ Tubingen, Dept Physiol, Tubingen, Germany; [Monks, Bobby; Birnbaum, Morris J.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Oregon Health & Science University; Eberhard Karls University of Tubingen; University of Pennsylvania	Pearce, D (corresponding author), Univ Calif San Francisco, Dept Med, Box 2140, San Francisco, CA 94107 USA.	dpearce@medsfgh.ucsf.edu	Boini, Krishna/H-3548-2011; McCormick, James A/A-9121-2010	McCormick, James/0000-0003-4000-6653; Birnbaum, Morris/0000-0001-9972-8680	U.S. National Institutes of Health (NIH) [T32DK007219, AR051930, DK-56886, DK56695]; Deutsche Forschungsgemeinschaft [La 315/4-6]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056695, R01DK056886, T32DK007219] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health (NIH) training grant T32DK007219 ( to J.A.M.), NIH grant AR051930 ( to T. M.), NIH grant DK-56886 ( to M. B.), Deutsche Forschungsgemeinschaft ( La 315/4-6) ( to F. L.), and NIH grant DK56695 ( to D. P.). We thank D. Kusewitt ( Ohio State University Mouse Phenotyping Service, Columbus, OH, USA) for multiple-tissue histological analysis, blood chemistry and cytokeratin immunostaining; Z. Huang and Melanie Hupe for technical assistance; L. Prentice for skin section preparation; and Louella Lee for assistance with preparation of the manuscript. We gratefully thank Rudy Grosschedl (Max Planck Institute of Immunobiology, Freiburg, Germany) for providing Lef1 reporter and expression vector.	Alonso L, 2005, J CELL BIOL, V170, P559, DOI 10.1083/jcb.200504131; Altomare DA, 1998, ONCOGENE, V16, P2407, DOI 10.1038/sj.onc.1201750; Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Bikle DD, 2006, J CELL PHYSIOL, V207, P340, DOI 10.1002/jcp.20578; Boini KM, 2006, DIABETES, V55, P2059, DOI 10.2337/db05-1038; Botchkarev VA, 2000, FASEB J, V14, P1931, DOI 10.1096/fj.99-0930com; Botchkarev VA, 2001, AM J PATHOL, V158, P1913, DOI 10.1016/S0002-9440(10)64659-7; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chen SY, 1997, J BIOL CHEM, V272, P14087, DOI 10.1074/jbc.272.22.14087; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Chen XL, 2003, J CELL SCI, V116, P3511, DOI 10.1242/jcs.00675; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cianferotti L, 2007, P NATL ACAD SCI USA, V104, P9428, DOI 10.1073/pnas.0702884104; Dai FY, 1999, GENOMICS, V62, P95, DOI 10.1006/geno.1999.5969; Dai FY, 2002, BIOCHEM BIOPH RES CO, V293, P1191, DOI 10.1016/S0006-291X(02)00349-2; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dummler B, 2006, MOL CELL BIOL, V26, P8042, DOI 10.1128/MCB.00722-06; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Edlund S, 2005, MOL CELL BIOL, V25, P1475, DOI 10.1128/MCB.25.4.1475-1488.2005; Fuchs E, 2001, DEV CELL, V1, P13, DOI 10.1016/S1534-5807(01)00022-3; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; Grahammer F, 2006, AM J PHYSIOL-REG I, V290, pR945, DOI 10.1152/ajpregu.00484.2005; Grahammer F, 2006, AM J PHYSIOL-GASTR L, V290, pG1114, DOI 10.1152/ajpgi.00231.2005; Guha U, 2004, AM J PATHOL, V165, P729, DOI 10.1016/S0002-9440(10)63336-6; Huang DY, 2004, J AM SOC NEPHROL, V15, P885, DOI 10.1097/01.ASN.0000120368.59693.A8; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobielak K, 2007, P NATL ACAD SCI USA, V104, P10063, DOI 10.1073/pnas.0703004104; Lang F, 2001, Sci STKE, V2001, pre17, DOI 10.1126/stke.2001.108.re17; Li X, 2004, GASTROENTEROLOGY, V126, P122, DOI 10.1053/j.gastro.2003.10.061; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Maupas-Schwalm F, 2005, CANCER RES, V65, P526; McCormick JA, 2004, MOL BIOL CELL, V15, P4278, DOI 10.1091/mbc.E04-01-0027; Muller D, 2007, DIABETOLOGIA, V50, P1239, DOI 10.1007/s00125-007-0671-7; Muller D, 2006, DIABETES, V55, P2835, DOI 10.2337/db06-0532; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; O'Shaughnessy RFL, 2007, CANCER RES, V67, P8207, DOI 10.1158/0008-5472.CAN-07-0755; Okada T, 2006, AM J PATHOL, V168, P1119, DOI 10.2353/ajpath.2006.050507; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; Pao AC, 2007, AM J PHYSIOL-RENAL, V292, pF1741, DOI 10.1152/ajprenal.00027.2007; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Plikus MV, 2008, NATURE, V451, P340, DOI 10.1038/nature06457; Sandu C, 2005, PFLUG ARCH EUR J PHY, V451, P437, DOI 10.1007/s00424-005-1474-7; Sharov AA, 2005, P NATL ACAD SCI USA, V102, P93, DOI 10.1073/pnas.0408455102; Strutz-Seebohm N, 2005, J PHYSIOL-LONDON, V565, P381, DOI 10.1113/jphysiol.2004.079582; Tian Q, 2005, CELL CYCLE, V4, P215; Tian Q, 2004, P NATL ACAD SCI USA, V101, P15370, DOI 10.1073/pnas.0406499101; Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864; Ullrich S, 2005, DIABETES, V54, P1090, DOI 10.2337/diabetes.54.4.1090; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; Wang J, 1999, J MOL BIOL, V286, P315, DOI 10.1006/jmbi.1998.2489; Wulff P, 2002, J CLIN INVEST, V110, P1263, DOI 10.1172/JCI200215696; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Yang ZZ, 2005, MOL CELL BIOL, V25, P10407, DOI 10.1128/MCB.25.23.10407-10418.2005; Yang ZZ, 2003, J BIOL CHEM, V278, P32124, DOI 10.1074/jbc.M302847200	63	16	18	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3193	3202		10.1096/fj.08-123729	http://dx.doi.org/10.1096/fj.08-123729			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19433625	Green Published			2022-12-28	WOS:000270241000041
J	Nakamaru, Y; Vuppusetty, C; Wada, H; Milne, JC; Ito, M; Rossios, C; Elliot, M; Hogg, J; Kharitonov, S; Goto, H; Bemis, JE; Elliott, P; Barnes, PJ; Ito, K				Nakamaru, Yuji; Vuppusetty, Chaitanya; Wada, Hiroo; Milne, Jill C.; Ito, Misako; Rossios, Christos; Elliot, Mark; Hogg, James; Kharitonov, Sergei; Goto, Hajime; Bemis, Jean E.; Elliott, Peter; Barnes, Peter J.; Ito, Kazuhiro			A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9	FASEB JOURNAL			English	Article						cigarette smoke; chronic obstructive pulmonary disease; COPD; oxidative stress; U937 cells	NF-KAPPA-B; OBSTRUCTIVE PULMONARY-DISEASE; SMALL-MOLECULE ACTIVATORS; OXIDATIVE STRESS; CIGARETTE-SMOKE; MATRIX-METALLOPROTEINASE-9 EXPRESSION; ALVEOLAR MACROPHAGES; LUNG-DISEASES; IN-VITRO; EMPHYSEMA	Inappropriate elevation of matrix metalloproteinase-9 (MMP9) is reported to be involved in the pathogenesis of chronic obstructive pulmonary disease (COPD). The object of this study was to identify the molecular mechanism underlying this increase of MMP9 expression, and here we show that oxidative stress-dependent reduction of a protein deacetylase, SIRT1, known as a putative antiaging enzyme, causes elevation of MMP9 expression. A sirtuin inhibitor, splitomycin, and SIRT1 knockdown by RNA interference led an increase in MMP9 expression in human monocytic U937 cells and in primary sputum macrophages, which was detected by RT-PCR, Western blot, activity assay, and zymography. In fact, the SIRT1 level was significantly decreased in peripheral lungs of patients with COPD, and this increase was inversely correlated with MMP9 expression and MMP9 promoter activation detected by a chromatin immunoprecipitation assay. H2O2 reduced SIRT1 expression and activity in U937 cells; furthermore, cigarette smoke exposure also caused reduction of SIRT1 expression in lung tissue of A/J mice, with concomitant elevation of MMP9. Intranasal treatment of a selective and novel SIRT1 small molecule activator, SRT2172, blocked the increase of MMP9 expression in the lung as well as pulmonary neutrophilia and the reduction in exercise tolerance. Thus, SIRT1 is a negative regulator of MMP9 expression, and SIRT1 activation is implicated as a novel therapeutic approach to treating chronic inflammatory diseases, in which MMP9 is abundant.-Nakamaru, Y., Vuppusetty, C., Wada, H., Milne, J. C., Ito, M., Rossios, C., Elliot, M., Hogg, J., Kharitonov, S., Goto, H., Bemis, J. E., Elliott, P., Barnes, P. J., Ito, K. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J. 23, 2810-2819 (2009). www.fasebj.org	[Nakamaru, Yuji; Vuppusetty, Chaitanya; Ito, Misako; Rossios, Christos; Kharitonov, Sergei; Barnes, Peter J.; Ito, Kazuhiro] Univ London Imperial Coll Sci Technol & Med, Airway Dis Sect, Natl Heart & Lung Inst, London SW3 6LY, England; [Wada, Hiroo; Goto, Hajime] Kyorin Univ, Dept Resp Med, Sch Med, Tokyo, Japan; [Milne, Jill C.; Bemis, Jean E.; Elliott, Peter] GSK Co, Sirtris, Cambridge, MA USA; [Elliot, Mark; Hogg, James] Univ British Columbia, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, St Pauls Hosp, Vancouver, BC V5Z 1M9, Canada	Imperial College London; Kyorin University; GlaxoSmithKline; St. Paul's Hospital; University of British Columbia; University of Saskatchewan	Ito, K (corresponding author), Univ London Imperial Coll Sci Technol & Med, Airway Dis Sect, Natl Heart & Lung Inst, London SW3 6LY, England.	k.ito@imperial.ac.uk	Nakamaru, Yuji/G-5441-2012; Wada, Hiroo/ABF-2531-2020; Ito, Kazuhiro/AAF-5994-2019	Rossios, Christos/0000-0003-3470-3233; Barnes, Peter/0000-0002-5122-4018	Clinical Research Committee (Royal Brompton Hospital); GlaxoSmithKline (GSK); Teijin Ltd.; Sirtris; GSK company; Canadian Institutes of Health Research [7246]	Clinical Research Committee (Royal Brompton Hospital); GlaxoSmithKline (GSK)(GlaxoSmithKline); Teijin Ltd.; Sirtris; GSK company; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by grants to K.I. and P.J.B. from the Clinical Research Committee (Royal Brompton Hospital), nonrestrictive funding from GlaxoSmithKline (GSK) and Teijin Ltd., and a project grant from Sirtris, a GSK company. W.M.E and J.C.H. were supported by Canadian Institutes of Health Research grant 7246. The authors declare that they have no competing interests. We are indebted to Sally Meah (National Heart and Lung Institute, London, UK) for assistance in collecting clinical samples and to Dr. Yuichi Kunori for assistance in preparation of the SIRT1 plasmid.	Antonicelli F, 2007, CURR TOP DEV BIOL, V79, P99, DOI 10.1016/S0070-2153(06)79005-6; Barnes Peter J, 2004, Proc Am Thorac Soc, V1, P264, DOI 10.1513/pats.200402-014MS; Barnes PJ, 2005, EUR RESPIR J, V25, P552, DOI 10.1183/09031936.05.00117504; Bernhard D, 2007, EXP GERONTOL, V42, P160, DOI 10.1016/j.exger.2006.09.016; Boschetto P, 2006, THORAX, V61, P1037, DOI 10.1136/thx.2006.058321; Brindicci C, 2005, EUR RESPIR J, V26, P52, DOI 10.1183/09031936.04.00125304; Chang YH, 2008, CLIN BIOCHEM, V41, P955, DOI 10.1016/j.clinbiochem.2008.04.012; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Deshmukh HS, 2008, AM J RESP CELL MOL, V38, P446, DOI 10.1165/rcmb.2006-0339OC; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Foronjy R, 2008, AM J PHYSIOL-LUNG C, V294, pL1149, DOI 10.1152/ajplung.00481.2007; Fortino V, 2007, TOXICOL LETT, V173, P73, DOI 10.1016/j.toxlet.2007.06.004; Furukawa A, 2007, CELL PHYSIOL BIOCHEM, V20, P45, DOI 10.1159/000104152; *GOLD, 2007, EX SUMM GLOB STRAT D; Habedank D, 1998, EUR J APPL PHYSIOL O, V77, P421, DOI 10.1007/s004210050354; Harman D, 2006, ANN NY ACAD SCI, V1067, P10, DOI 10.1196/annals.1354.003; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Ito I, 2005, AM J RESP CRIT CARE, V172, P1378, DOI 10.1164/rccm.200506-953OC; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027; Kolev K, 2003, THROMB HAEMOSTASIS, V90, P528, DOI 10.1160/TH03-02-0070; Kruszewski M, 2005, DNA REPAIR, V4, P1306, DOI 10.1016/j.dnarep.2005.06.013; Lelongt B, 2001, J EXP MED, V193, P793, DOI 10.1084/jem.193.7.793; Lombard DB, 2008, J INTERN MED, V263, P128, DOI 10.1111/j.1365-2796.2007.01902.x; Meyer KC, 1998, MECH AGEING DEV, V104, P169, DOI 10.1016/S0047-6374(98)00065-7; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Minematsu N, 2001, BIOCHEM BIOPH RES CO, V289, P116, DOI 10.1006/bbrc.2001.5936; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175, DOI 10.1164/ajrccm.162.3.2001063; Mostoslavsky R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; NEWBY AC, 1994, BASIC RES CARDIOL, V89, P59; Nikula KJ, 2000, CHEST, V117, p246S, DOI 10.1378/chest.117.5_suppl_1.246S-a; Ohbayashi H, 2002, CURR PROTEIN PEPT SC, V3, P409, DOI 10.2174/1389203023380549; OhIshi S, 1997, AM J RESP CRIT CARE, V156, P1579, DOI 10.1164/ajrccm.156.5.96-11035; Pageon H, 2007, EUR J DERMATOL, V17, P12; Patel BD, 2006, THORAX, V61, P568, DOI 10.1136/thx.2005.053827; Rajendrasozhan S, 2008, AM J RESP CRIT CARE, V177, P861, DOI 10.1164/rccm.200708-1269OC; Ram M, 2006, J CLIN IMMUNOL, V26, P299, DOI 10.1007/s10875-006-9022-6; Russell REK, 2002, AM J RESP CELL MOL, V26, P602, DOI 10.1165/ajrcmb.26.5.4685; Salvioli S, 2006, CURR PHARM DESIGN, V12, P3161, DOI 10.2174/138161206777947470; van Kempen LCL, 2002, CANCER CELL, V2, P251, DOI 10.1016/S1535-6108(02)00157-5; Wallace AM, 2008, COPD, V5, P13, DOI 10.1080/15412550701817789; Yang SR, 2007, AM J PHYSIOL-LUNG C, V292, pL567, DOI 10.1152/ajplung.00308.2006; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Yoon HK, 2007, ENVIRON HEALTH PERSP, V115, P1557, DOI 10.1289/ehp.10289	49	178	193	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2810	2819		10.1096/fj.08-125468	http://dx.doi.org/10.1096/fj.08-125468			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19376817				2022-12-28	WOS:000270241000004
J	Rogers, SC; Said, A; Corcuera, D; McLaughlin, D; Kell, P; Doctor, A				Rogers, Stephen C.; Said, Ahmed; Corcuera, Daniella; McLaughlin, Dylan; Kell, Pamela; Doctor, Allan			Hypoxia limits antioxidant capacity in red blood cells by altering glycolytic pathway dominance	FASEB JOURNAL			English	Article						band 3 protein; hemoglobin; glucose metabolism; thiol; reactive oxygen species; glycolysis	REDUCED PYRIDINE-NUCLEOTIDES; HUMAN-ERYTHROCYTES; NITRIC-OXIDE; MEMBRANE-PROTEIN; GLUTATHIONE TURNOVER; SUPEROXIDE ANIONS; FREE-RADICALS; IN-VITRO; OXYGEN; HEMOGLOBIN	The erythrocyte membrane is a newly appreciated platform for thiol-based circulatory signaling, and it requires robust free thiol maintenance. We sought to define physiological constraints on erythrocyte antioxidant defense. Hemoglobin (Hb) conformation gates glycolytic flux through the hexose monophosphate pathway (HMP), the sole source of nicotinamide adenine dinucleotide phosphate ( NADPH) in erythrocytes. We hypothesized elevated intraerythrocytic deoxyHb would limit resilience to oxidative stress. Human erythrocytes were subjected to controlled oxidant ( superoxide) loading following independent manipulation of oxygen tension, Hb conformation, and glycolytic pathway dominance. Sufficiency of antioxidant defense was determined by serial quantification of GSH, NADPH, NADH redox couples. Hypoxic erythrocytes demonstrated greater loss of reduction potential [Delta GSH E-hc (mV): 123.4 +/- 9.7 vs. 57.2 +/- 11.1] and reduced membrane thiol (47.7 +/- 5.7 vs. 20.1 +/- 4.3%) ( hypoxia vs. normoxia, respectively; P<0.01), a finding mimicked in normoxic erythrocytes after HMP blockade. Rebalancing HMP flux during hypoxia restored resilience to oxidative stress at all stages of the system. Cell-free studies assured oxidative loading was not altered by oxygen tension, heme ligation, or the inhibitors employed. These data indicate that Hb conformation controls coupled glucose and thiol metabolism in erythrocytes, and implicate hypoxemia in the pathobiology of erythrocyte-based vascular signaling.-Rogers, S. C., Said, A., Corcuera, D., McLaughlin, D., Kell, P., Doctor, A. Hypoxia limits antioxidant capacity in red blood cells by altering glycolytic pathway dominance. FASEB J. 23, 3159-3170 ( 2009). www.fasebj.org	[Rogers, Stephen C.; Said, Ahmed; Corcuera, Daniella; McLaughlin, Dylan; Kell, Pamela; Doctor, Allan] Washington Univ, Dept Pediat, St Louis, MO 63110 USA; [Doctor, Allan] Washington Univ, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Doctor, A (corresponding author), Washington Univ, Dept Pediat, McDonnell Pediat Res Bldg,Campus Box 8116,1 Child, St Louis, MO 63110 USA.	doctor@wustl.edu	Said, Ahmed/AAA-1152-2022	Said, Ahmed/0000-0002-1215-2664; Rogers, Stephen/0000-0003-1139-4730; Doctor, Allan/0000-0002-6096-6400	U.S. National Institutes of Health [1K08GM069977]; Children's Discovery Institute; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K08GM069977] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Discovery Institute; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We greatly appreciate the gift of KA from Dr. Keiji Hasumi, (Tokyo Noko University, Tokyo, Japan). We thank Dr. Alan Schwartz and Dr. Jonathan Gitlin for thoughtful comments. This work was supported by U.S. National Institutes of Health grant 1K08GM069977 and by an interdisciplinary research initiative from the Children's Discovery Institute ( both to A. D.).	Balagopalakrishna C, 1996, BIOCHEMISTRY-US, V35, P6393, DOI 10.1021/bi952875+; Barvitenko NN, 2005, CELL PHYSIOL BIOCHEM, V15, P1, DOI 10.1159/000083634; Baskurt OK, 1998, FREE RADICAL BIO MED, V24, P102, DOI 10.1016/S0891-5849(97)00169-X; Bennett-Guerrero E, 2007, P NATL ACAD SCI USA, V104, P17063, DOI 10.1073/pnas.0708160104; Bossi D, 1996, MOL ASPECTS MED, V17, P117, DOI 10.1016/0098-2997(96)88343-9; Buehler PW, 2005, ANTIOXID REDOX SIGN, V7, P1755, DOI 10.1089/ars.2005.7.1755; Buehler PW, 2004, ANTIOXID REDOX SIGN, V6, P1000, DOI 10.1089/ars.2004.6.1000; Campanella ME, 2008, BLOOD, V112, P3900, DOI 10.1182/blood-2008-03-146159; Campanella ME, 2005, P NATL ACAD SCI USA, V102, P2402, DOI 10.1073/pnas.0409741102; Chang SH, 2001, J BIOL CHEM, V276, P22223, DOI 10.1074/jbc.M100604200; Chu HY, 2008, BLOOD, V111, P932, DOI 10.1182/blood-2007-07-100180; Cimen MYB, 2008, CLIN CHIM ACTA, V390, P1, DOI 10.1016/j.cca.2007.12.025; CORBISIER P, 1987, ANAL BIOCHEM, V164, P240, DOI 10.1016/0003-2697(87)90392-7; Crimi E, 2007, FREE RADICAL RES, V41, P1364, DOI 10.1080/10715760701732830; Dietrich HH, 2000, AM J PHYSIOL-HEART C, V278, pH1294, DOI 10.1152/ajpheart.2000.278.4.H1294; Doctor A, 2005, P NATL ACAD SCI USA, V102, P5709, DOI 10.1073/pnas.0407490102; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; ENDO A, 1985, J ANTIBIOT, V38, P920, DOI 10.7164/antibiotics.38.920; FEIG SA, 1972, J CLIN INVEST, V51, P1547, DOI 10.1172/JCI106951; Forman HJ, 2004, AM J PHYSIOL-CELL PH, V287, pC246, DOI 10.1152/ajpcell.00516.2003; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; Gibson JS, 2000, J EXP BIOL, V203, P1395; Gonzalez C, 2002, RESP PHYSIOL NEUROBI, V132, P17, DOI 10.1016/S1569-9048(02)00047-2; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; GRIFFITH OW, 1981, J BIOL CHEM, V256, P4900; HAMASAKI N, 1970, J BIOCHEM-TOKYO, V68, P157, DOI 10.1093/oxfordjournals.jbchem.a129341; Kemp M, 2008, FREE RADICAL BIO MED, V44, P921, DOI 10.1016/j.freeradbiomed.2007.11.008; Kinoshita A, 2007, J BIOL CHEM, V282, P10731, DOI 10.1074/jbc.M610717200; KONDO T, 1989, METHOD ENZYMOL, V171, P217; Lang KS, 2005, CELL PHYSIOL BIOCHEM, V15, P195, DOI 10.1159/000086406; LOW PS, 1993, J BIOL CHEM, V268, P14627; LUNN G, 1979, BLOOD, V54, P238; LYNCH RE, 1978, J BIOL CHEM, V253, P4697; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Messana I, 1996, FEBS LETT, V390, P25, DOI 10.1016/0014-5793(96)00624-2; Messner KR, 2002, METHOD ENZYMOL, V349, P354, DOI 10.1016/S0076-6879(02)49351-2; Minetti M, 2007, CARDIOVASC RES, V75, P21, DOI 10.1016/j.cardiores.2007.03.007; Mingone CJ, 2006, AM J PHYSIOL-LUNG C, V290, pL549, DOI 10.1152/ajplung.00331.2005; MURPHY JR, 1960, J LAB CLIN MED, V55, P286; NIORT G, 1985, J STEROID BIOCHEM, V23, P657, DOI 10.1016/0022-4731(85)90018-4; Palmer LA, 2007, J CLIN INVEST, V117, P2592, DOI 10.1172/JCI29444; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; RAPOPORT I, 1976, BIOCHIM BIOPHYS ACTA, V428, P193, DOI 10.1016/0304-4165(76)90120-3; Richards RS, 1998, MED HYPOTHESES, V50, P363, DOI 10.1016/S0306-9877(98)90206-7; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Singel DJ, 2005, ANNU REV PHYSIOL, V67, P99, DOI 10.1146/annurev.physiol.67.060603.090918; Souza HP, 2002, AM J PHYSIOL-HEART C, V282, pH466, DOI 10.1152/ajpheart.00482.2001; Sun GY, 2008, J CHROMATOGR B, V867, P1, DOI 10.1016/j.jchromb.2008.02.014; UYESAKA N, 1992, BIORHEOLOGY, V29, P217; VALENTINE WN, 1985, ANN INTERN MED, V103, P245, DOI 10.7326/0003-4819-103-2-245; WAGNER TC, 1994, ANAL BIOCHEM, V222, P417, DOI 10.1006/abio.1994.1511; Wang X, 1999, CLIN HEMORHEOL MICRO, V21, P137; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9	53	65	69	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3159	3170		10.1096/fj.09-130666	http://dx.doi.org/10.1096/fj.09-130666			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19417084	Green Published			2022-12-28	WOS:000270241000038
J	Ueda, S; Kitazawa, S; Ishida, K; Nishikawa, Y; Matsui, M; Matsumoto, H; Aoki, T; Nozaki, S; Takeda, T; Tamori, Y; Aiba, A; Kahn, CR; Kataoka, T; Satoh, T				Ueda, Shuji; Kitazawa, Sohei; Ishida, Kota; Nishikawa, Yuki; Matsui, Megumi; Matsumoto, Hikaru; Aoki, Takuji; Nozaki, Shinsuke; Takeda, Tomoya; Tamori, Yoshikazu; Aiba, Atsu; Kahn, C. Ronald; Kataoka, Tohru; Satoh, Takaya			Crucial role of the small GTPase Rac1 in insulin-stimulated translocation of glucose transporter 4 to the mouse skeletal muscle sarcolemma	FASEB JOURNAL			English	Article						GLUT4; Akt; AS160; electron microscopy	LIVING MICE; T-TUBULES; GLUT4; GLUCOSE; CELLS; ACTIN; COMPARTMENTS; ACTIVATION; RESISTANCE; DISRUPTION	The Rho family GTPase Rac1 has been implicated in the regulation of glucose uptake in myoblast cell lines. However, no evidence for the role of Rac1 has been provided by a mouse model. The purpose of this study is to test the involvement of Rac1 in insulin action in mouse skeletal muscle. Intravenous administration of insulin indeed elicited Rac1 activation in gastrocnemius muscle, suggesting the involvement of Rac1 in this signaling pathway. We then examined whether insulin-stimulated translocation of the facilitative glucose transporter GLUT4 from its storage sites to the skeletal muscle sarcolemma depends on Rac1. We show that ectopic expression of constitutively activated Rac1, as well as intravenous administration of insulin, caused translocation of GLUT4 to the gastrocnemius muscle sarcolemma, as revealed by immunofluorescent staining of a transiently expressed exofacial epitope-tagged GLUT4 reporter. Of particular note, insulin-dependent, but not constitutively activated Rac1-induced, GLUT4 translocation was markedly suppressed in skeletal muscle-specific rac1-knockout mice compared to control mice. Immunogold electron microscopic analysis of endogenous GLUT4 gave similar results. Collectively, we propose a critical role of Rac1 in insulin-dependent GLUT4 translocation to the skeletal muscle sarcolemma, which has heretofore been predicted solely by cell culture studies.-Ueda, S., Kitazawa, S., Ishida, K., Nishikawa, Y., Matsui, M., Matsumoto, H., Aoki, T., Nozaki, S., Takeda, T., Tamori, Y., Aiba, A., Kahn, C. R., Kataoka, T., Satoh, T. Crucial role of the small GTPase Rac1 in insulin-stimulated translocation of glucose transporter 4 to the mouse skeletal muscle sarcolemma. FASEB J. 24, 2254-2261 (2010). www.fasebj.org	[Satoh, Takaya] Kobe Univ, Grad Sch Med, Dept Biochem & Mol Biol, Div Mol Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan; [Kitazawa, Sohei] Kobe Univ, Grad Sch Med, Dept Pathol, Div Mol Pathol, Kobe, Hyogo 6500017, Japan; [Tamori, Yoshikazu] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Diabet Metab & Endocrinol, Kobe, Hyogo 6500017, Japan; [Aiba, Atsu] Kobe Univ, Grad Sch Med, Dept Physiol & Cell Biol, Div Mol Genet, Kobe, Hyogo 6500017, Japan; [Kahn, C. Ronald] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA	Kobe University; Kobe University; Kobe University; Kobe University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Satoh, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Biochem & Mol Biol, Div Mol Biol,Chuo Ku, 5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	tkysato@med.kobe-u.ac.jp	Kahn, Ronald/AAY-2435-2021; Satoh, Takaya/K-2628-2014; Kitazawa, Sohei/E-5602-2010	Kahn, Ronald/0000-0002-7583-9228; Kitazawa, Sohei/0000-0002-7466-7356; Aiba, Atsu/0000-0002-8192-0778	Ministry of Education, Culture, Sports, Science, and Technology of Japan; Takeda Science Foundation	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF))	The authors are grateful to Jonathan Bogan (Yale University School of Medicine, New Haven, CT, USA), Harvey Lodish (Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA, USA), and Jun-ichi Miyazaki (Osaka University, Osaka, Japan) for plasmid DNAs. The authors also thank Masato Kasuga (International Medical Center of Japan) for critical reading of the manuscript and valuable suggestions and Nobuyuki Takenaka (Kobe University) for technical assistance. This investigation was supported by Grants-in-Aid for Scientific Research on Priority Areas (Systems Genomics and Life Surveyor), Scientific Research (B), the 21st Century COE Program (Center of Excellence for Signal Transduction Disease: Diabetes Mellitus as Model), and the Global COE Program (Global Center for Education and Research in Integrative Membrane Biology) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and by a grant from the Takeda Science Foundation.	Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867; Biddinger SB, 2006, ANNU REV PHYSIOL, V68, P123, DOI 10.1146/annurev.physiol.68.040104.124723; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bogan JS, 2001, MOL CELL BIOL, V21, P4785, DOI 10.1128/MCB.21.14.4785-4806.2001; Brozinick JT, 2004, J BIOL CHEM, V279, P40699, DOI 10.1074/jbc.M402697200; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Fazakerley DJ, 2009, J CELL SCI, V122, P727, DOI 10.1242/jcs.041178; Huang SH, 2007, CELL METAB, V5, P237, DOI 10.1016/j.cmet.2007.03.006; Ishikura S, 2008, ACTA PHYSIOL, V192, P61, DOI 10.1111/j.1748-1716.2007.01778.x; Jebailey L, 2004, MOL ENDOCRINOL, V18, P359, DOI 10.1210/me.2003-0294; JeBailey L, 2007, DIABETES, V56, P394, DOI 10.2337/db06-0823; Kassai H, 2008, EUR J NEUROSCI, V28, P257, DOI 10.1111/j.1460-9568.2008.06343.x; Khayat ZA, 2000, J CELL SCI, V113, P279; Kitazawa S, 2006, J STRUCT BIOL, V153, P64, DOI 10.1016/j.jsb.2005.09.010; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; Lauritzen HPMM, 2008, DIABETES, V57, P315, DOI 10.2337/db06-1578; Lauritzen HPMM, 2008, DIABETES, V57, P13, DOI 10.2337/db07-0516; Lauritzen HPMM, 2006, DIABETES, V55, P1300, DOI 10.2337/db05-1216; MARETTE A, 1992, DIABETES, V41, P1562, DOI 10.2337/diabetes.41.12.1562; Mayhew TM, 2004, HISTOCHEM CELL BIOL, V122, P171, DOI 10.1007/s00418-004-0685-x; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; Randhawa VK, 2008, J BIOL CHEM, V283, P27208, DOI 10.1074/jbc.M804282200; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Schertzer JD, 2009, ENDOCRINOLOGY, V150, P1935, DOI 10.1210/en.2008-1372; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Ueda S, 2008, BIOL CELL, V100, P645, DOI 10.1042/BC20070160; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693	29	88	90	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2254	2261		10.1096/fj.09-137380	http://dx.doi.org/10.1096/fj.09-137380			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20203090	Green Published			2022-12-28	WOS:000279343600012
J	Bilbo, SD; Tsang, V				Bilbo, Staci D.; Tsang, Verne			Enduring consequences of maternal obesity for brain inflammation and behavior of offspring	FASEB JOURNAL			English	Article						cytokines; hippocampus; cognition; microglia; perinatal programming	DIET-INDUCED OBESITY; FATTY-ACIDS; INSULIN-RESISTANCE; METABOLIC SYNDROME; DUAL ROLE; INTERLEUKIN-1; TRANS; CONSUMPTION; RESTRICTION; MICROGLIA	Obesity is well characterized as a systemic inflammatory condition, and is also associated with cognitive disruption, suggesting a link between the two. We assessed whether peripheral inflammation in maternal obesity may be transferred to the offspring brain, in particular, the hippocampus, and thereby result in cognitive dysfunction. Rat dams were fed a high-saturated-fat diet (SFD), a high-trans-fat diet (TFD), or a low-fat diet (LFD) for 4 wk prior to mating, and remained on the diet throughout pregnancy and lactation. SFD/TFD exposure significantly increased body weight in both dams and pups compared to controls. Microglial activation markers were increased in the hippocampus of SFD/TFD pups at birth. At weaning and in adulthood, proinflammatory cytokine expression was strikingly increased in the periphery and hippocampus following a bacterial challenge [lipo-polysaccharide (LPS)] in the SFD/TFD groups compared to controls. Microglial activation within the hippocampus was also increased basally in SFD rats, suggesting a chronic priming of the cells. Finally, there were marked changes in anxiety and spatial learning in SFD/TFD groups. These effects were all observed in adulthood, even after the pups were placed on standard chow at weaning, suggesting these outcomes were programmed early in life.-Bilbo, S. D., Tsang, V. Enduring consequences of maternal obesity for brain inflammation and behavior of offspring. FASEB J. 24, 2104-2115 (2010). www.fasebj.org	[Bilbo, Staci D.; Tsang, Verne] Duke Univ, Dept Psychol & Neurosci, Durham, NC 27708 USA	Duke University	Bilbo, SD (corresponding author), Duke Univ, Dept Psychol & Neurosci, 572 Res Dr,Box 91050,3016 GSRB 2, Durham, NC 27708 USA.	staci.bilbo@duke.edu	Bilbo, Staci D/L-5076-2016	Bilbo, Staci D/0000-0001-6736-7841; Bilbo, Staci/0000-0001-7395-5033				Armitage JA, 2004, J PHYSIOL-LONDON, V561, P355, DOI 10.1113/jphysiol.2004.072009; Bilbo SD, 2010, PSYCHONEUROENDOCRINO, V35, P369, DOI 10.1016/j.psyneuen.2009.07.014; Bland ST, 2010, BRAIN BEHAV IMMUN, V24, P329, DOI 10.1016/j.bbi.2009.09.012; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cedergren MI, 2004, OBSTET GYNECOL, V103, P219, DOI 10.1097/01.AOG.0000107291.46159.00; Chen H, 2008, ENDOCRINOLOGY, V149, P5348, DOI 10.1210/en.2008-0582; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Craig-Schmidt MC, 2001, LIPIDS, V36, P997, DOI 10.1007/s11745-001-0811-8; Cunningham C, 2005, J NEUROSCI, V25, P9275, DOI 10.1523/JNEUROSCI.2614-05.2005; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Das UN, 2001, NUTRITION, V17, P953, DOI 10.1016/S0899-9007(01)00672-4; de la Monte SM, 2009, BMB REP, V42, P475, DOI 10.5483/BMBRep.2009.42.8.475; Duffield JA, 2009, PEDIATR RES, V66, P59, DOI 10.1203/PDR.0b013e3181a7c121; Dunn GA, 2009, ENDOCRINOLOGY, V150, P4999, DOI 10.1210/en.2009-0500; Elias SL, 2001, AM J CLIN NUTR, V73, P807; Frank MG, 2007, BRAIN BEHAV IMMUN, V21, P47, DOI 10.1016/j.bbi.2006.03.005; Frank MG, 2006, NEUROBIOL AGING, V27, P717, DOI 10.1016/j.neurobiolaging.2005.03.013; Freeman DJ, 2010, SEMIN FETAL NEONAT M, V15, P113, DOI 10.1016/j.siny.2009.09.001; Goshen I, 2007, PSYCHONEUROENDOCRINO, V32, P1106, DOI 10.1016/j.psyneuen.2007.09.004; GRANDGIRARD A, 1994, LIPIDS, V29, P251, DOI 10.1007/BF02536329; Granholm AC, 2008, J ALZHEIMERS DIS, V14, P133; Grattan DR, 2008, ENDOCRINOLOGY, V149, P5345, DOI 10.1210/en.2008-1106; Greenwood CE, 2005, NEUROBIOL AGING, V26, pS42, DOI 10.1016/j.neurobiolaging.2005.08.017; Hayashi T, 2009, NEURON, V64, P213, DOI 10.1016/j.neuron.2009.08.017; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Lafrance V, 2010, BRAIN BEHAV IMMUN, V24, P358, DOI 10.1016/j.bbi.2009.11.003; Legendre A, 2007, AM J PHYSIOL-REG I, V293, pR1076, DOI 10.1152/ajpregu.00592.2006; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luvisetto S, 2008, NEUROSCIENCE, V155, P585, DOI 10.1016/j.neuroscience.2008.06.030; McAfoose J, 2009, NEUROSCI BIOBEHAV R, V33, P355, DOI 10.1016/j.neubiorev.2008.10.005; McGuire W, 2010, SEMIN FETAL NEONAT M, V15, P108, DOI 10.1016/j.siny.2009.09.005; McNaull BBA, 2010, GERONTOLOGY, V56, P3, DOI 10.1159/000237873; Milanski M, 2009, J NEUROSCI, V29, P359, DOI 10.1523/JNEUROSCI.2760-08.2009; Murray AJ, 2009, FASEB J, V23, P4353, DOI 10.1096/fj.09-139691; Padilla ND, 2003, IMMUNOLOGY, V109, P564, DOI 10.1046/j.1365-2567.2003.01681.x; Pasinetti GM, 2008, J NEUROCHEM, V106, P1503, DOI 10.1111/j.1471-4159.2008.05454.x; PETTERSEN J, 1988, LIPIDS, V23, P720, DOI 10.1007/BF02535675; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pinteaux E, 2007, J NEUROCHEM, V102, P826, DOI 10.1111/j.1471-4159.2007.04559.x; Ross FM, 2003, J NEUROIMMUNOL, V144, P61, DOI 10.1016/j.jneuroim.2003.08.030; Saberi M, 2009, CELL METAB, V10, P419, DOI 10.1016/j.cmet.2009.09.006; Schmatz M, 2010, J PERINATOL, V30, P441, DOI 10.1038/jp.2009.182; Shaftel SS, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-7; Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898; Simmons R, 2008, SEMIN PERINATOL, V32, P371, DOI 10.1053/j.semperi.2008.08.004; Souza CG, 2007, LIFE SCI, V81, P198, DOI 10.1016/j.lfs.2007.05.001; Spulber S, 2009, J NEUROIMMUNOL, V208, P46, DOI 10.1016/j.jneuroim.2009.01.010; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Suganami T, 2007, ARTERIOSCL THROM VAS, V27, P84, DOI 10.1161/01.ATV.0000251608.09329.9a; Tozuka Y, 2009, FASEB J, V23, P1920, DOI 10.1096/fj.08-124784; Tsukumo DML, 2007, DIABETES, V56, P1986, DOI 10.2337/db06-1595; White CL, 2009, NEUROBIOL DIS, V35, P3, DOI 10.1016/j.nbd.2009.04.002; Wolff RL, 2003, LIPIDS, V38, P1143, DOI 10.1007/s11745-003-1172-z; Woods LL, 2005, AM J PHYSIOL-REG I, V289, pR1131, DOI 10.1152/ajpregu.00037.2003	55	339	346	1	45	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					2104	2115		10.1096/fj.09-144014	http://dx.doi.org/10.1096/fj.09-144014			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20124437				2022-12-28	WOS:000278200000043
J	Marx, A; Nugoor, C; Panneerselvam, S; Mandelkow, E				Marx, A.; Nugoor, C.; Panneerselvam, S.; Mandelkow, E.			Structure and function of polarity-inducing kinase family MARK/Par-1 within the branch of AMPK/Snf1-related kinases	FASEB JOURNAL			English	Review						kinase structure; neurodegeneration; Alzheimer disease; UBA domain; KA1; autoinhibitory domain	UBIQUITIN-ASSOCIATED DOMAINS; ACTIVATED PROTEIN-KINASE; AMPK-RELATED KINASES; CRYSTAL-STRUCTURES; MAP KINASES; PHOSPHORYLATION; IDENTIFICATION; LOCALIZATION; RECOGNITION; BINDING	Kinases of the MARK/Par-1 family of S/T protein kinases are regulators of diverse cellular processes in Caenorhabditis elegans, Drosophila, yeast, and mammalian cells. They are involved in nematode embryogenesis, epithelial cell polarization, cell signaling, and neuronal differentiation. MARK phosphorylates microtubule-associated proteins such as tau and is a key regulator of microtubule-based intracellular transport. Hyperphosphorylation of tau causes defects in neuronal transport and may induce abnormal aggregation of tau in Alzheimer disease and other tauopathies. Recent high-resolution structure analysis of MARK fragments covering the kinase domain and accessory regulatory domains has revealed important details regarding the autoregulation of MARK, but their interpretation has remained controversial. Here we focus on the structural aspects of MARK activity and autoregulation. Comparison of the available MARK structures with related kinases of the AMPK family and with new structures of MARK isoforms (MARK2 and 3) reveals unexpected structural similarities between these kinases that may help to resolve the existing controversies.-Marx, A., Nugoor, C., Panneerselvam, S., Mandelkow, E. Structure and function of polarity-inducing kinase family MARK/Par-1 within the branch of AMPK/Snf1-related kinases. FASEB J. 24, 1637-1648 (2010). www.fasebj.org	[Marx, A.; Nugoor, C.; Panneerselvam, S.; Mandelkow, E.] DESY, Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society	Marx, A (corresponding author), DESY, Max Planck Unit Struct Mol Biol, Notkestr 85, D-22607 Hamburg, Germany.	marx@mpasmb.desy.de			Deutsche Forschungsgemeinschaft	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported in part by the Deutsche Forschungsgemeinschaft. The authors thank T. Timm and E.-M. Mandelkow for stimulating discussions throughout this work.	Al-Hakim AK, 2008, BIOCHEM J, V411, P249, DOI 10.1042/BJ20080067; Amodeo GA, 2007, NATURE, V449, P492, DOI 10.1038/nature06127; Bachmann M, 2004, J BIOL CHEM, V279, P48319, DOI 10.1074/jbc.M404440200; Beghini A, 2003, ONCOGENE, V22, P2581, DOI 10.1038/sj.onc.1206336; Beullens M, 2005, J BIOL CHEM, V280, P40003, DOI 10.1074/jbc.M507274200; Bright NJ, 2009, ACTA PHYSIOL, V196, P15, DOI 10.1111/j.1748-1716.2009.01971.x; Bryson K, 2005, NUCLEIC ACIDS RES, V33, pW36, DOI 10.1093/nar/gki410; Chen L, 2009, NATURE, V459, P1146, DOI 10.1038/nature08075; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; DeLano W, 2002, PYMOL 0 99; Dequiedt F, 2006, MOL CELL BIOL, V26, P7086, DOI 10.1128/MCB.00231-06; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Elbert M, 2005, MOL BIOL CELL, V16, P532, DOI 10.1091/mbc.E04-07-0549; Espinosa L, 1998, CYTOGENET CELL GENET, V81, P278, DOI 10.1159/000015046; Finn RD, 2008, NUCLEIC ACIDS RES, V36, pD281, DOI 10.1093/nar/gkm960; Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hulo N, 2008, NUCLEIC ACIDS RES, V36, pD245, DOI 10.1093/nar/gkm977; Hurov JB, 2004, CURR BIOL, V14, P736, DOI 10.1016/j.cub.2004.04.007; INGLIS JD, 1993, MAMM GENOME, V4, P401, DOI 10.1007/BF00360595; Jaleel M, 2006, BIOCHEM J, V394, P545, DOI 10.1042/BJ20051844; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kato T, 2001, NEOPLASIA, V3, P4, DOI 10.1038/sj.neo.7900132; Kemphues K, 2000, CELL, V101, P345, DOI 10.1016/S0092-8674(00)80844-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Lu HS, 2009, J BIOL CHEM, V284, P23024, DOI 10.1074/jbc.M109.001008; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Marx A, 2006, J BIOL CHEM, V281, P27586, DOI 10.1074/jbc.M604865200; Matenia D, 2005, MOL BIOL CELL, V16, P4410, DOI 10.1091/mbc.E05-01-0081; Matenia D, 2009, TRENDS BIOCHEM SCI, V34, P332, DOI 10.1016/j.tibs.2009.03.008; Mocanu MM, 2008, J NEUROSCI, V28, P737, DOI 10.1523/JNEUROSCI.2824-07.2008; Moroni RF, 2006, NEUROSCIENCE, V143, P83, DOI 10.1016/j.neuroscience.2006.07.052; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Muller J, 2003, EMBO J, V22, P4431, DOI 10.1093/emboj/cdg426; Murphy JM, 2007, P NATL ACAD SCI USA, V104, P14336, DOI 10.1073/pnas.0703012104; Nayak V, 2006, STRUCTURE, V14, P477, DOI 10.1016/j.str.2005.12.008; Nesic D, 2010, NAT STRUCT MOL BIOL, V17, P130, DOI 10.1038/nsmb.1705; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Panneerselvam S, 2006, STRUCTURE, V14, P173, DOI 10.1016/j.str.2005.09.022; Pellicena P, 2006, CURR OPIN STRUC BIOL, V16, P702, DOI 10.1016/j.sbi.2006.10.007; Raasi S, 2005, NAT STRUCT MOL BIOL, V12, P708, DOI 10.1038/nsmb962; Sapir T, 2008, J NEUROSCI, V28, P5710, DOI 10.1523/JNEUROSCI.0911-08.2008; Scholz R, 2009, J BIOL CHEM, V284, P27425, DOI 10.1074/jbc.M109.047670; Suzuki A, 2004, CURR BIOL, V14, P1425, DOI 10.1016/j.cub.2004.08.021; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Terabayashi T, 2008, BIOCHEM BIOPH RES CO, V375, P660, DOI 10.1016/j.bbrc.2008.08.098; Timm T, 2003, EMBO J, V22, P5090, DOI 10.1093/emboj/cdg447; Timm T, 2008, J BIOL CHEM, V283, P18873, DOI 10.1074/jbc.M706596200; Timm T, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S2-S9; Tochio N, 2006, PROTEIN SCI, V15, P2534, DOI 10.1110/ps.062391106; Townley R, 2007, SCIENCE, V315, P1726, DOI 10.1126/science.1137503; Uboha NV, 2007, J NEUROSCI, V27, P4413, DOI 10.1523/JNEUROSCI.0725-07.2007; Varadan R, 2005, MOL CELL, V18, P687, DOI 10.1016/j.molcel.2005.05.013; Watkins JL, 2008, P NATL ACAD SCI USA, V105, P18378, DOI 10.1073/pnas.0809661105; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Xiao B, 2007, NATURE, V449, P496, DOI 10.1038/nature06161; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	62	85	89	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1637	1648		10.1096/fj.09-148064	http://dx.doi.org/10.1096/fj.09-148064			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20071654				2022-12-28	WOS:000278200000002
J	Nehra, R; Riggins, RB; Shajahan, AN; Zwart, A; Crawford, AC; Clarke, R				Nehra, Ruchi; Riggins, Rebecca B.; Shajahan, Ayesha N.; Zwart, Alan; Crawford, Anatasha C.; Clarke, Robert			BCL2 and CASP8 regulation by NF-kappa B differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells	FASEB JOURNAL			English	Article						apoptosis; autophagy; breast neoplasms; RELA; selective estrogen receptor modulators; tamoxifen	CYTOCHROME-C RELEASE; ESTROGEN-RECEPTOR; ACQUIRED-RESISTANCE; THERAPY RESISTANCE; FACTOR-I; ACTIVATION; EXPRESSION; APOPTOSIS; AUTOPHAGY; MCF-7	Resistance to endocrine therapies remains a major problem in the management of estrogen receptor-alpha (ER)-positive breast cancer. We show that inhibition of NF-kappa B (p65/RELA), either by overexpression of a mutant I kappa B (I kappa BSR) or a small-molecule inhibitor of NF-kappa B (parthenolide; IC50=500 nM in tamoxifen-resistant cells), synergistically restores sensitivity to 4-hydroxytamoxifen (4HT) in resistant MCF7/RR and MCF7/LCC9 cells and further sensitizes MCF-7 and MCF7/LCC1 control cells to 4HT. These effects are independent of changes in either cell cycle distribution or in the level of autophagy measured by inhibition of p62/SQSTM1 expression and cleavage of LC3. NF-kappa B inhibition restores the ability of 4HT to decrease BCL2 expression, increase mitochondrial membrane permeability, and induce a caspase-dependent apoptotic cell death in resistant cells. Each of these effects is reversed by a caspase 8 (CASP8)-specific inhibitor that blocks enzyme-substrate binding. Thus, increased activation of NF-kappa B can alter sensitivity to tamoxifen by modulating CASP8 activity, with consequent effects on BCL2 expression, mitochondrial function, and apoptosis. These data provide significant new insights into how molecular signaling affects antiestrogen responsiveness and strongly suggest that a combination of parthenolide and tamoxifen may offer a novel therapeutic approach to the management of some ER-positive breast cancers.-Nehra, R., Riggins, R. B., Shajahan, A. N., Zwart, A., Crawford, A. C., Clarke, R. BCL2 and CASP8 regulation by NF-kappa B differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J. 24, 2040-2055 (2010). www.fasebj.org	[Nehra, Ruchi; Riggins, Rebecca B.; Shajahan, Ayesha N.; Zwart, Alan; Crawford, Anatasha C.; Clarke, Robert] Georgetown Univ, Dept Oncol, Sch Med, Washington, DC 20057 USA; [Nehra, Ruchi; Riggins, Rebecca B.; Shajahan, Ayesha N.; Zwart, Alan; Crawford, Anatasha C.; Clarke, Robert] Georgetown Univ, Lombardi Comprehens Canc Ctr, Sch Med, Washington, DC 20057 USA; [Clarke, Robert] Georgetown Univ, Dept Physiol & Biophys, Sch Med, Washington, DC 20057 USA	Georgetown University; Georgetown University; Georgetown University	Clarke, R (corresponding author), Georgetown Univ, Dept Oncol, Sch Med, Rm W405A Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	clarker@georgetown.edu	Riggins, Rebecca/GQH-4466-2022; Clarke, Robert/A-6485-2008	Clarke, Robert/0000-0002-9278-0854; Riggins, Rebecca/0000-0002-1555-4431; Shajahan-Haq, Ayesha/0000-0001-7616-320X; Zwart, Alan/0000-0001-6834-9290	U.S. Army [W81XWH-04-1-0378, W81XWH-04-1-0570]; U.S. Department of Health and Human Services, National Institutes of Health [R01-CA131465, R21-CA139246]; NATIONAL CANCER INSTITUTE [R01CA131465, R21CA139246] Funding Source: NIH RePORTER	U.S. Army(United States Department of DefenseUnited States Army); U.S. Department of Health and Human Services, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Department of Defense Awards W81XWH-04-1-0378 and W81XWH-04-1-0570 from the U.S. Army Medical Research and Materiel Command and R01-CA131465 and R21-CA139246 from the U.S. Department of Health and Human Services, National Institutes of Health. Technical services were provided by the Lombardi Comprehensive Cancer Center Flow Cytometry and Cell Sorting and Macromolecular Shared Resources. The authors thank Dr. Marty Mayo (University of Virginia, Charlottesville, VA, USA) for providing the empty pCMV4 and the S32/36A mutant pCMV4-FLAG I kappa B alpha (I kappa BSR) plasmids. The authors also thank Drs. Stephen Byers, Dean Rosenthal, Thomas G. Sherman, and Bassem R. Haddad for thoughtful comments in carrying out this research.	Bachleitner-Hofmann T, 2002, CLIN CANCER RES, V8, P3427; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; BRUNNER N, 1993, CANCER RES, V53, P3229; Brunner N, 1997, CANCER RES, V57, P3486; BRUNNER N, 1993, CANCER RES, V53, P283; BUTLER WB, 1992, CANCER RES, V52, P6164; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Clarke R, 2001, PHARMACOL REV, V53, P25; Clarke R, 2009, J STEROID BIOCHEM, V114, P8, DOI 10.1016/j.jsbmb.2008.12.023; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Crawford AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008604; Curry EA, 2004, INVEST NEW DRUG, V22, P299, DOI 10.1023/B:DRUG.0000026256.38560.be; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Drew PD, 1995, J INTERF CYTOK RES, V15, P1037, DOI 10.1089/jir.1995.15.1037; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Goonesinghe A, 2005, BIOCHEM J, V387, P109, DOI 10.1042/BJ20041389; Gu ZP, 2002, CANCER RES, V62, P3428; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Kim KY, 2008, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2008/01/002; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Kuske B, 2006, ENDOCR-RELAT CANCER, V13, P1121, DOI 10.1677/erc.1.01257; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lilling G, 2000, CANCER LETT, V161, P27, DOI 10.1016/S0304-3835(00)00579-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Nakshatri H, 2004, ONCOGENE, V23, P7330, DOI 10.1038/sj.onc.1207995; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Riggins RB, 2005, VITAM HORM, V71, P201, DOI 10.1016/S0083-6729(05)71007-4; Riggins RB, 2005, MOL CANCER THER, V4, P33; Romanelli S, 1998, CANCER CHEMOTH PHARM, V41, P385, DOI 10.1007/s002800050755; Samaddar JS, 2008, MOL CANCER THER, V7, P2977, DOI 10.1158/1535-7163.MCT-08-0447; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; TAYLOR IW, 1983, CANCER RES, V43, P4007; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Verma IM, 2004, ANN RHEUM DIS, V63, P57, DOI 10.1136/ard.2004.028266; Viatour P, 2003, LEUKEMIA, V17, P1349, DOI 10.1038/sj.leu.2402982; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wen J, 2002, J BIOL CHEM, V277, P38954, DOI 10.1074/jbc.M203842200; Zhou F, 2007, IET RADAR SONAR NAV, V1, P59, DOI 10.1049/iet-rsn:20060040	52	66	71	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					2040	2055		10.1096/fj.09-138305	http://dx.doi.org/10.1096/fj.09-138305			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20154269	Green Published			2022-12-28	WOS:000278200000038
J	Noorbakhsh, F; Ramachandran, R; Barsby, N; Ellestad, KK; LeBlanc, A; Dickie, P; Baker, G; Hollenberg, MD; Cohen, EA; Power, C				Noorbakhsh, Farshid; Ramachandran, Rithwik; Barsby, Nicola; Ellestad, Kristofor K.; LeBlanc, Andrea; Dickie, Peter; Baker, Glen; Hollenberg, Morley D.; Cohen, Eric A.; Power, Christopher			MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival	FASEB JOURNAL			English	Article						cell death; HIV encephalitis; caspases; microRNA; viral protein R	CENTRAL-NERVOUS-SYSTEM; AMINO-ACID OXIDASE; TRANSGENIC MICE; NEURONAL DEATH; D-SERINE; APOPTOSIS; EXPRESSION; VPR; ACTIVATION; TAT	MicroRNAs (miRNAs) are small noncoding RNA molecules, which are known to regulate gene expression in physiological and pathological conditions. miRNA profiling was performed using brain tissue from patients with HIV encephalitis (HIVE), a neuroinflammatory/degenerative disorder caused by HIV infection of the brain. Microarray analysis showed differential expression of multiple miRNAs in HIVE compared to control brains. Target prediction and gene ontology enrichment analysis disclosed targeting of several gene families/biological processes by differentially expressed miRNAs (DEMs), with cell death-related genes, including caspase-6, showing a bias toward down-regulated DEMs. Consistent with the miRNA data, HIVE brains exhibited higher levels of caspase-6 transcripts compared with control patients. Immunohistochemical analysis showed localization of the cleaved form of caspase-6 in astrocytes in HIVE brain sections. Exposure of cultured human primary astrocytes to HIV viral protein R (Vpr) induced p53 up-regulation, loss of mitochondrial membrane potential, and caspase-6 activation followed by cell injury. Transgenic mice, expressing Vpr in microglial cells, demonstrated astrocyte apoptosis in brain, which was associated with caspase-6 activation and neurobehavioral abnormalities. Overall, these data point to previously unrecognized alterations in miRNA profile in the brain during HIV infection, which contribute to cell death through dysregulation of cell death machinery.-Noorbakhsh, F., Ramachandran, R., Barsby, N., Ellestad, K. K., LeBlanc, A., Dickie, P., Baker, G., Hollenberg, M. D., Cohen, E. A., Power, C. MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival. FASEB J. 24, 1799-1812 (2010). www.fasebj.org	[Power, Christopher] Univ Alberta, Dept Med Neurol, Heritage Med Res Ctr 6 11, Edmonton, AB T6G 2S2, Canada; [Barsby, Nicola; Dickie, Peter] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2S2, Canada; [Baker, Glen; Power, Christopher] Univ Alberta, Dept Psychiat, Edmonton, AB T6G 2S2, Canada; [Ramachandran, Rithwik; Hollenberg, Morley D.] Univ Calgary, Dept Pharmacol & Expt Therapeut, Calgary, AB, Canada; [LeBlanc, Andrea] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; [Cohen, Eric A.] Univ Montreal, Inst Rech Clin Montreal, Montreal, PQ, Canada; [Cohen, Eric A.] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada	University of Alberta; University of Alberta; University of Alberta; University of Calgary; Lady Davis Institute; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal	Power, C (corresponding author), Univ Alberta, Dept Med Neurol, Heritage Med Res Ctr 6 11, Edmonton, AB T6G 2S2, Canada.	chris.power@ualberta.ca	Hollenberg, Morley/AFV-6966-2022; Ramachandran, Rithwik/N-7815-2015; Power, Christopher/C-7181-2013	Ramachandran, Rithwik/0000-0001-9557-9905; Power, Christopher/0000-0002-5131-9711	Canadian Institutes for Health Research (CIHR); Alberta Heritage Foundation for Medical Research (AHFMR)	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alberta Heritage Foundation for Medical Research (AHFMR)(Alberta Heritage Foundation for Medical Research)	The authors thank Leah DeBlock for assistance with manuscript preparation. The expert technical assistance of Gail Rauw is greatly appreciated. F.N. is supported by Canadian Institutes for Health Research (CIHR) and Alberta Heritage Foundation for Medical Research (AHFMR) fellowships. E. A. C., C. P., and G. B. hold Canada Research Chairs (Tier 1) in Retrovirology, Neurological Infection and Immunity, and Neurochemistry and Drug Development, respectively. C. P. is an AHFMR Senior Scholar. These studies were supported by the CIHR.	Al-Ani B, 1999, BRIT J PHARMACOL, V128, P1105, DOI 10.1038/sj.bjp.0702834; Albrecht S, 2007, AM J PATHOL, V170, P1200, DOI 10.2353/ajpath.2007.060974; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Andersen JL, 2005, CURR HIV RES, V3, P43, DOI 10.2174/1570162052772988; Bansal AK, 2000, BRAIN RES, V879, P42, DOI 10.1016/S0006-8993(00)02725-6; Berglund CMD, 2004, J NEUROSCI RES, V78, P580, DOI 10.1002/jnr.20273; BERRADA F, 1995, J VIROL, V69, P6770, DOI 10.1128/JVI.69.11.6770-6778.1995; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Cysique LA, 2009, NEUROPSYCHOL REV, V19, P169, DOI 10.1007/s11065-009-9092-3; Dickie P, 2004, VIROLOGY, V322, P69, DOI 10.1016/j.virol.2004.01.026; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; Garden GA, 2004, FASEB J, V18, P1141, DOI 10.1096/fj.04-1676fje; Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Grant SL, 2006, J CHROMATOGR B, V844, P278, DOI 10.1016/j.jchromb.2006.07.022; Gray F, 2001, CLIN NEUROPATHOL, V20, P146; Guo HS, 2004, AM J PATHOL, V165, P523, DOI 10.1016/S0002-9440(10)63317-2; Hayes DJ, 2009, BEHAV BRAIN RES, V197, P323, DOI 10.1016/j.bbr.2008.08.034; Hebert SS, 2009, TRENDS NEUROSCI, V32, P199, DOI 10.1016/j.tins.2008.12.003; Jones GJ, 2007, J NEUROSCI, V27, P3703, DOI 10.1523/JNEUROSCI.5522-06.2007; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Kim BO, 2003, AM J PATHOL, V162, P1693, DOI 10.1016/S0002-9440(10)64304-0; Kitayama H, 2008, J VIROL, V82, P2528, DOI 10.1128/JVI.02094-07; Klaiman G, 2008, MOL CELL PROTEOMICS, V7, P1541, DOI 10.1074/mcp.M800007-MCP200; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; Mattson MP, 2005, CELL DEATH DIFFER, V12, P893, DOI 10.1038/sj.cdd.4401577; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; Noorbakhsh F, 2005, J IMMUNOL, V174, P7320, DOI 10.4049/jimmunol.174.11.7320; Noorbakhsh F, 2009, TRENDS NEUROSCI, V32, P88, DOI 10.1016/j.tins.2008.10.003; Park HK, 2006, J BIOCHEM, V139, P295, DOI 10.1093/jb/mvj036; Pomerantz RJ, 2004, DNA CELL BIOL, V23, P227, DOI 10.1089/104454904773819815; Power C, 1998, J VIROL, V72, P9045, DOI 10.1128/JVI.72.11.9045-9053.1998; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Ransom B, 2003, TRENDS NEUROSCI, V26, P520, DOI 10.1016/j.tins.2003.08.006; Roberts ES, 2003, AM J PATHOL, V162, P2041, DOI 10.1016/S0002-9440(10)64336-2; Sabri F, 2003, BRAIN PATHOL, V13, P84, DOI 10.1111/j.1750-3639.2003.tb00009.x; Schmittgen TD, 2008, J CELL MOL MED, V12, P1811, DOI 10.1111/j.1582-4934.2008.00483.x; Shi B, 1996, J CLIN INVEST, V98, P1979, DOI 10.1172/JCI119002; Shi L, 2008, BRAIN RES, V1236, P185, DOI 10.1016/j.brainres.2008.07.085; Singh IN, 2004, J NEUROVIROL, V10, P141, DOI 10.1080/13550280490441103; Thompson KA, 2001, ANN NEUROL, V49, P745, DOI 10.1002/ana.1011; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; Urai Y, 2002, NEUROSCI LETT, V324, P101, DOI 10.1016/S0304-3940(02)00184-2; Wang T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002507; Warby SC, 2008, HUM MOL GENET, V17, P2390, DOI 10.1093/hmg/ddn139; Wesselingh SL, 2001, CURR OPIN NEUROL, V14, P375, DOI 10.1097/00019052-200106000-00018; Zhang N, 2000, J NEUROSURG, V93, P6, DOI 10.3171/jns.2000.93.supplement_3.0006; Zhou BY, 2004, MOL CELL NEUROSCI, V27, P296, DOI 10.1016/j.mcn.2004.07.003; Zhu Y, 2009, FASEB J, V23, P2928, DOI 10.1096/fj.08-128819	52	67	70	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1799	1812		10.1096/fj.09-147819	http://dx.doi.org/10.1096/fj.09-147819			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20097875				2022-12-28	WOS:000278200000017
J	Wang, FE; Zhang, CN; Maminishkis, A; Dong, LJ; Zhi, CN; Li, R; Zhao, J; Majerciak, V; Gaur, AB; Chen, S; Miller, SS				Wang, Fei E.; Zhang, Connie; Maminishkis, Arvydas; Dong, Lijin; Zhi, Connie; Li, Rong; Zhao, Jing; Majerciak, Vladimir; Gaur, Arti B.; Chen, Shan; Miller, Sheldon S.			MicroRNA-204/211 alters epithelial physiology	FASEB JOURNAL			English	Article						tumorigenesis; transepithelial resistance; membrane potential; tight junctions; claudins; retinal pigment epithelium	RETINAL-PIGMENT EPITHELIUM; CENTRAL-NERVOUS-SYSTEM; FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; FLUID TRANSPORT; MESENCHYMAL TRANSITION; GENE-EXPRESSION; MIR-200 FAMILY; CANCER-CELLS; MICRORNAS	MicroRNA (miRNA) expression in fetal human retinal pigment epithelium (hfRPE), retina, and choroid were pairwise compared to determine those miRNAs that are enriched by 10-fold or more in each tissue compared with both of its neighbors. miRs-184, 187, 200a/200b, 204/211, and 221/222 are enriched in hfRPE by 10- to 754-fold compared with neuroretina or choroid (P<0.05). Five of these miRNAs are enriched in RPE compared with 20 tissues throughout the body and are 10- to 20,000-fold more highly expressed (P<0.005). miR-204 and 211 are the most highly expressed in the RPE. In addition, expression of miR-204/211 is significantly lower in the NCI60 tumor cell line panel compared with that in 13 normal tissues, suggesting the progressive disruption of epithelial barriers and increased proliferation. We demonstrated that TGF-beta receptor 2 (TGF-beta R2) and SNAIL2 are direct targets of miR-204 and that a reduction in miR-204 expression leads to reduced expression of claudins 10, 16, and 19 (message/protein) consistent with our observation that anti-miR-204/211 decreased transepithelial resistance by 80% and reduced cell membrane voltage and conductance. The anti-miR-204-induced decrease in Kir7.1 protein levels suggests a signaling pathway that connects TGF-beta R2 and maintenance of potassium homeostasis. Overall, these data indicate a critical role for miR-204/211 in maintaining epithelial barrier function and cell physiology.-Wang, F. E., Zhang, C., Maminishkis, A., Dong, L., Zhi, C., Li, R., Zhao, J., Majerciak, V., Gaur, A. B., Chen, S., Miller, S. S. MicroRNA-204/211 alters epithelial physiology. FASEB J. 24, 1552-1571 (2010). www.fasebj.org	[Miller, Sheldon S.] NEI, NIH, Bethesda, MD 20892 USA; [Majerciak, Vladimir] NCI, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA; [Gaur, Arti B.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Lebanon, NH USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Dartmouth College; Norris Cotton Cancer Center	Miller, SS (corresponding author), NEI, NIH, 31 Ctr Dr,MSC 2510, Bethesda, MD 20892 USA.	millers@nei.nih.gov		Maminishkis, Arvydas/0000-0003-3345-3375; Majerciak, Vladimir/0000-0003-2907-4583	Intramural NIH HHS [Z01 EY000421-04] Funding Source: Medline; NATIONAL EYE INSTITUTE [ZIAEY000421, ZIAEY000419, ZICEY000458] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adijanto J, 2009, J GEN PHYSIOL, V133, P603, DOI 10.1085/jgp.200810169; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bak M, 2008, RNA, V14, P432, DOI 10.1261/rna.783108; Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905; Bellone RR, 2008, GENETICS, V179, P1861, DOI 10.1534/genetics.108.088807; Bharti K, 2008, DEVELOPMENT, V135, P1169, DOI 10.1242/dev.014142; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523; Carrozzino F, 2005, AM J PHYSIOL-CELL PH, V289, pC1002, DOI 10.1152/ajpcell.00175.2005; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Deo M, 2006, DEV DYNAM, V235, P2538, DOI 10.1002/dvdy.20847; Economopoulou M, 2009, INVEST OPHTH VIS SCI, V50, P1454, DOI 10.1167/iovs.08-2129; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; FISHER SK, 1982, J COMP NEUROL, V206, P131, DOI 10.1002/cne.902060204; GALLEMORE R, 1998, RETINAL PIGMENT EPIT; Garzon R, 2008, P NATL ACAD SCI USA, V105, P3945, DOI 10.1073/pnas.0800135105; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Harteneck C, 2007, BIOCHEM SOC T, V35, P91, DOI 10.1042/BST0350091; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hejtmancik JF, 2008, AM J HUM GENET, V82, P174, DOI 10.1016/j.ajhg.2007.08.002; Hou JH, 2008, J CLIN INVEST, V118, P619, DOI 10.1172/JCI33970; Hou JH, 2009, P NATL ACAD SCI USA, V106, P15350, DOI 10.1073/pnas.0907724106; HUGHES B, 1998, RETINAL PIGMENT EPIT; JOSEPH DP, 1991, J PHYSIOL-LONDON, V435, P439, DOI 10.1113/jphysiol.1991.sp018518; Kapsimali M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r173; Karali M, 2007, INVEST OPHTH VIS SCI, V48, P509, DOI 10.1167/iovs.06-0866; Klaassen I, 2009, EXP EYE RES, V89, P4, DOI 10.1016/j.exer.2009.01.006; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Levin MH, 2006, J MEMBRANE BIOL, V210, P105, DOI 10.1007/s00232-005-0849-1; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li R, 2007, INVEST OPHTH VIS SCI, V48, P5722, DOI 10.1167/iovs.07-0327; Li R, 2009, INVEST OPHTH VIS SCI, V50, P5988, DOI 10.1167/iovs.09-3591; Li R, 2009, AM J PHYSIOL-CELL PH, V297, pC1452, DOI 10.1152/ajpcell.00255.2009; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Makeyev EV, 2008, SCIENCE, V319, P1789, DOI 10.1126/science.1152326; Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622; Marchi N, 2003, J NEUROSCI, V23, P1949; Martinez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591; Mueller DW, 2009, BRIT J CANCER, V101, P551, DOI 10.1038/sj.bjc.6605204; Murisier F, 2006, HISTOL HISTOPATHOL, V21, P567, DOI 10.14670/HH-21.567; Nandrot EF, 2008, ADV EXP MED BIOL, V613, P369, DOI 10.1007/978-0-387-74904-4_43; Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Parry DA, 2009, AM J HUM GENET, V84, P683, DOI 10.1016/j.ajhg.2009.04.005; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Rahimi RA, 2007, J CELL BIOCHEM, V102, P593, DOI 10.1002/jcb.21501; Rizzolo LJ, 2007, INT REV CYTOL, V258, P195, DOI 10.1016/S0074-7696(07)58004-6; Ryan D, 2006, MOL VIS, V12, P1175; Saika S, 2004, LAB INVEST, V84, P1245, DOI 10.1038/labinvest.3700156; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225; Van Itallie CM, 2006, ANNU REV PHYSIOL, V68, P403, DOI 10.1146/annurev.physiol.68.040104.131404; Varallyay E, 2008, NAT PROTOC, V3, P190, DOI 10.1038/nprot.2007.528; Visone R, 2007, ENDOCR-RELAT CANCER, V14, P791, DOI 10.1677/ERC-07-0129; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu SP, 2009, CHINESE J STRUC CHEM, V28, P87; Yakmovych I, 2001, FASEB J, V15, P553; Yang DL, 2003, INVEST OPHTH VIS SCI, V44, P3178, DOI 10.1167/iovs.02-1189; Yang DL, 2008, EXP EYE RES, V87, P176, DOI 10.1016/j.exer.2008.05.010; Yu J, 2008, P NATL ACAD SCI USA, V105, P19300, DOI 10.1073/pnas.0803992105; Zhang W, 2008, BIOCHEM BIOPH RES CO, V377, P981, DOI 10.1016/j.bbrc.2008.10.110; Zhiqi S, 2004, MELANOMA RES, V14, P509, DOI 10.1097/00008390-200412000-00011	73	183	200	1	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1552	1571		10.1096/fj.08-125856	http://dx.doi.org/10.1096/fj.08-125856			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20056717	Green Published			2022-12-28	WOS:000277158900028
J	Adler, ED; Chen, VC; Bystrup, A; Kaplan, AD; Giovannone, S; Briley-Saebo, K; Young, W; Kattman, S; Mani, V; Laflamme, M; Zhu, WZ; Fayad, Z; Keller, G				Adler, Eric D.; Chen, Vincent C.; Bystrup, Anne; Kaplan, Aaron D.; Giovannone, Steven; Briley-Saebo, Karen; Young, Wilson; Kattman, Steve; Mani, Venkatesh; Laflamme, Michael; Zhu, Wei-Zhong; Fayad, Zahi; Keller, Gordon			The cardiomyocyte lineage is critical for optimization of stem cell therapy in a mouse model of myocardial infarction	FASEB JOURNAL			English	Article						cardiac regeneration; cadiomyopathy; embryonic stem cells	CARDIOVASCULAR PROGENITOR CELLS; MARROW-DERIVED ANGIOBLASTS; CARDIAC-FUNCTION; SMOOTH-MUSCLE; REPAIR; NEOVASCULARIZATION; HEARTS; MICE	We recently described a murine embryonic stem cell (ESC) line engineered to express the activated Notch 4 receptor in a tetracycline (doxcycline; Dox) regulated fashion (tet-notch4 ESCs). Notch 4 induction in Flk1(+) hematopoietic and vascular progenitors from this line respecified them to a cardiovascular fate. We reasoned that these cells would be ideal for evaluating the contribution of the cardiomyocyte and vascular lineages to the functional improvement noted following stem cell transplantation in infarcted hearts. Flk-1(+) Tet-notch4 cells from d 3 embryoid bodies exposed to doxycycline (Dox(+)) were compared to uninduced (Dox(+)) Flk-1(+) cells. Mice underwent transplantation of 5 x 10(5) Dox(+) cells, Dox(-) cells, or an equal volume of serum-free medium after surgically induced myocardial infarction. The mean ejection fraction was 59 +/- 15, 46 +/- 17, and 39 +/- 13% in the Dox(+), Dox(-), and serum-free medium groups, respectively (P<0.05 for the differences among all 3 groups). Immunohistochemistry of hearts injected with Dox(+) grafts expressed myocardial and vascular markers, whereas grafts of Dox(-) cells expressed primarily vascular markers. We conclude that cardiovascular progenitors are more effective than vascular progenitors in improving function after myocardial infarction. The transplantation of appropriate cell types is critical for maximizing the benefit of cardiovascular cell therapy.-Adler, E. D., Chen, V. C., Bystrup, A., Kaplan, A. D., Giovannone, S., Briley-Saebo, K., Young, W., Kattman, S., Mani, V., Laflamme, M., Zhu, W.-Z., Fayad, Z., Keller, G. The cardiomyocyte lineage is critical for optimization of stem cell therapy in a mouse model of myocardial infarction. FASEB J. 24, 1073-1081 (2010). www.fasebj.org	[Adler, Eric D.; Bystrup, Anne; Kaplan, Aaron D.; Briley-Saebo, Karen; Young, Wilson; Mani, Venkatesh; Fayad, Zahi] Mt Sinai Hosp, New York, NY 10029 USA; [Chen, Vincent C.] City Hope Hosp, Pasadena, CA USA; [Giovannone, Steven] New York Univ Hosp, New York, NY USA; [Kattman, Steve; Keller, Gordon] Univ Hlth Networks, Toronto, ON, Canada; [Laflamme, Michael; Zhu, Wei-Zhong] Univ Washington, Med Ctr, Seattle, WA 98195 USA	Icahn School of Medicine at Mount Sinai; New York University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Washington; University of Washington Seattle	Adler, ED (corresponding author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code UN-62, Portland, OR 97239 USA.	adler@ohsu.edu; gkeller@uhnresearch.ca	Zhu, Wei-Zhong/G-4919-2011; Fayad, Zahi/Z-3272-2019; Laflamme, Michael/AAV-6791-2021; Mani, Venkatesh/B-8939-2011	Fayad, Zahi/0000-0002-3439-7347; Laflamme, Michael/0000-0001-5908-880X; Mani, Venkatesh/0000-0002-0432-2918; Briley, Karen/0000-0001-5402-8779; Keller, Gordon/0000-0001-9309-9297	The Glorney Raisbeck Fellowship in Cardiovascular Disease; U.S. National Institutes of Health [R01 HL71800, RO1 HL48834, R01 HL071021, R01 HL078667]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078667, T32HL007824, R01HL071021, R01HL048834, R01HL071800] Funding Source: NIH RePORTER	The Glorney Raisbeck Fellowship in Cardiovascular Disease; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This investigation was partially supported by The Glorney Raisbeck Fellowship in Cardiovascular Disease (E.A.) and U.S. National Institutes of Health grants R01 HL71800 and RO1 HL48834 (G.K.) and R01 HL071021 and R01 HL078667 (Z.A.F.) The authors do not have any disclosures.	Abdel-Latif A, 2007, ARCH INTERN MED, V167, P989, DOI 10.1001/archinte.167.10.989; ADLER E, 2006, KEYST S MOL MECH CAR, P101; Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Albert J, 2003, ACTA ANAESTH SCAND, V47, P407, DOI 10.1034/j.1399-6576.2003.00059.x; Chaudhry HW, 2004, J BIOL CHEM, V279, P35858, DOI 10.1074/jbc.M404975200; Chen VC, 2008, NAT BIOTECHNOL, V26, P1169, DOI 10.1038/nbt.1497; Herreros J, 2003, EUR HEART J, V24, P2012, DOI 10.1016/j.ehj.2003.09.012; Heubach JF, 2004, J PHYSIOL-LONDON, V554, P659, DOI 10.1113/jphysiol.2003.055806; Houghton FD, 1999, DEV GENET, V24, P5, DOI 10.1002/(SICI)1520-6408(1999)24:1/2&lt;5::AID-DVG2&gt;3.0.CO;2-F; Itescu S, 2002, ANN HEMATOL, V81, pS21; Kattman SJ, 2006, DEV CELL, V11, P723, DOI 10.1016/j.devcel.2006.10.002; Kehat I, 2004, NAT BIOTECHNOL, V22, P1282, DOI 10.1038/nbt1014; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Kolossov E, 2006, J EXP MED, V203, P2315, DOI 10.1084/jem.20061469; Laflamme MA, 2007, NAT BIOTECHNOL, V25, P1015, DOI 10.1038/nbt1327; Levkau B, 2008, CIRCULATION, V117, P1583, DOI 10.1161/CIRCULATIONAHA.107.734160; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Moretti A, 2006, CELL, V127, P1151, DOI 10.1016/j.cell.2006.10.029; Mummery C L, 2006, Ned Tijdschr Geneeskd, V150, P943; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; O'Connell Timothy D, 2007, Methods Mol Biol, V357, P271; Orlic D, 2001, ANN NY ACAD SCI, V938, P221; Penn MS, 2002, PROG CARDIOVASC DIS, V45, P21, DOI 10.1053/pcad.2002.123466; Rubart M, 2006, ANN NY ACAD SCI, V1080, P34, DOI 10.1196/annals.1380.004; Smith RR, 2007, CIRCULATION, V115, P896, DOI 10.1161/CIRCULATIONAHA.106.655209; Taylor DA, 2001, CURR CONTR TRIALS C, V2, P208, DOI 10.1186/CVM-2-5-208; Valiunas V, 2004, J PHYSIOL-LONDON, V555, P617, DOI 10.1113/jphysiol.2003.058719; van Laake LW, 2007, STEM CELL RES, V1, P9, DOI 10.1016/j.scr.2007.06.001; Yang L, 2008, NATURE, V453, P524, DOI 10.1038/nature06894; Yuasa Shinsuke, 2008, Circ J, V72 Suppl A, pA49, DOI 10.1253/circj.CJ-08-0378	30	15	16	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2010	24	4					1073	1081		10.1096/fj.09-135426	http://dx.doi.org/10.1096/fj.09-135426			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19940262	Green Published			2022-12-28	WOS:000276462300015
J	Inoue, A; Aoki, F				Inoue, Azusa; Aoki, Fugaku			Role of the nucleoplasmin 2 C-terminal domain in the formation of nucleolus-like bodies in mouse oocytes	FASEB JOURNAL			English	Article						oogenesis; embryo; development; nucleogenesis	PREIMPLANTATION EMBRYOS; IMMUNOELECTRON MICROSCOPY; LOCALIZATION SIGNAL; COILED BODY; PROTEIN; NUCLEAR; CHROMATIN; GROWTH; TRANSCRIPTION; PHOSPHATASE	Nucleolus-like bodies (NLBs) are characteristic structures found in the germinal vesicles of mammalian oocytes. Although these structures are essential for embryonic development, their composition, precise function, and mechanism of formation have not been elucidated. Here, we used immunoblotting and EGFP fusion protein fluorescence to demonstrate that murine nucleoplasmin 2 (NPM2) is a component of mouse NLBs and that the targeting of NPM2 to NLBs is regulated by a lysine-rich, 16-aa C-terminal motif (K-rich motif). When the K-rich motif was fused to another nuclear protein, MafG, the resultant fusion protein accumulated in NLBs but not in the nucleoli of somatic cells, suggesting that the K-rich motif functions to target NPM2 specifically to NLBs. To investigate the role of the K-rich motif in NLB formation, we replaced the endogenous NPM2 in growing oocytes with a mutant NPM2 protein lacking the K-rich motif (NPM2(C16del)). Growing oocytes surrounded by granulosa layers were coinjected with NPM2C16del mRNA and with small-interfering RNA targeting NPM2 (siNpm2), which was used to degrade the endogenous NPM2 mRNA. After culture in vitro, the NLBs in the resulting full-grown oocytes were significantly smaller than those in control oocytes that had been coinjected with siNpm2 and NPM2 mRNA, indicating that the K-rich motif is necessary for NLB development. Together, these results suggest that NPM2 targeting of NLBs is regulated by the K-rich motif and is essential for the formation of NLBs.-Inoue, A., Aoki, F. Role of the nucleoplasmin 2 C-terminal domain in the formation of nucleolus-like bodies in mouse oocytes. FASEB J. 24, 485-494 (2010). www.fasebj.org	[Inoue, Azusa; Aoki, Fugaku] Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan	University of Tokyo	Aoki, F (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan.	aokif@k.u-tokyo.ac.jp	AOKI, FUGAKU/AAO-7617-2021					Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; BARAN V, 1995, MOL REPROD DEV, V40, P305, DOI 10.1002/mrd.1080400306; BIGGIOGERA M, 1990, DEVELOPMENT, V110, P1263; BIGGIOGERA M, 1994, EXP CELL RES, V213, P55, DOI 10.1006/excr.1994.1172; Borsuk E, 1996, MOL REPROD DEV, V43, P376, DOI 10.1002/(SICI)1098-2795(199603)43:3&lt;376::AID-MRD12&gt;3.0.CO;2-#; Bouniol-Baly C, 1999, BIOL REPROD, V60, P580, DOI 10.1095/biolreprod60.3.580; Burns KH, 2003, SCIENCE, V300, P633, DOI 10.1126/science.1081813; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; Cho HP, 2005, MOL CELL BIOL, V25, P4541, DOI 10.1128/MCB.25.11.4541-4551.2005; CHOUINARD LA, 1971, J CELL SCI, V9, P637; Dutta S, 2001, MOL CELL, V8, P841, DOI 10.1016/S1097-2765(01)00354-9; FERREIRA J, 1995, DEVELOPMENT, V121, P601; Flechon JE, 1998, ZYGOTE, V6, P183, DOI 10.1017/S0967199498000112; Frehlick LJ, 2007, BIOESSAYS, V29, P49, DOI 10.1002/bies.20512; GEUSKENS M, 1984, CELL DIFFER DEV, V14, P125, DOI 10.1016/0045-6039(84)90037-X; Hartshorne G M, 1997, Rev Reprod, V2, P94; Horke S, 2004, J BIOL CHEM, V279, P26563, DOI 10.1074/jbc.M401017200; Huang N, 2005, J BIOL CHEM, V280, P5496, DOI 10.1074/jbc.M407856200; KOPECNY V, 1995, MOL REPROD DEV, V41, P449, DOI 10.1002/mrd.1080410407; Kopecny V, 1996, REPROD NUTR DEV, V36, P667; LAWITTS JA, 1993, METHOD ENZYMOL, V225, P153; Lechertier T, 2007, J CELL SCI, V120, P265, DOI 10.1242/jcs.03345; Liu JY, 2006, FEBS LETT, V580, P1405, DOI 10.1016/j.febslet.2006.01.064; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Longo F, 2003, MOL REPROD DEV, V66, P279, DOI 10.1002/mrd.10354; MacArthur CA, 1997, GENOMICS, V42, P137, DOI 10.1006/geno.1997.4353; Maddox-Hyttel P, 2005, REPROD FERT DEVELOP, V17, P3, DOI 10.1071/RD04108; Nagahama M, 2004, MOL BIOL CELL, V15, P5712, DOI 10.1091/mbc.E04-08-0692; Ogushi S, 2008, SCIENCE, V319, P613, DOI 10.1126/science.1151276; Parfenov VN, 2003, J CELL BIOCHEM, V89, P720, DOI 10.1002/jcb.10545; Pesty A, 2007, MOL HUM REPROD, V13, P3, DOI 10.1093/molehr/gal089; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; QUINN P, 1984, AUST J BIOL SCI, V37, P147, DOI 10.1071/BI9840147; Rao MRKS, 2006, J MOL BIOL, V364, P637, DOI 10.1016/j.jmb.2006.09.007; Sheng Z, 2004, J BIOL CHEM, V279, P40153, DOI 10.1074/jbc.M400123200; Takagi M, 1999, J CELL SCI, V112, P2463; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; WANG DR, 1993, CELL MOL BIOL RES, V39, P33; Zatsepina O, 2003, DEV BIOL, V253, P66, DOI 10.1006/dbio.2002.0865; Zatsepina OV, 2000, DEV BIOL, V223, P354, DOI 10.1006/dbio.2000.9762	41	36	38	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					485	494		10.1096/fj.09-143370	http://dx.doi.org/10.1096/fj.09-143370			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19805576				2022-12-28	WOS:000274045000016
J	Gruber, F; Mayer, H; Lengauer, B; Mlitz, V; Sanders, JM; Kadl, A; Bilban, M; de Martin, R; Wagner, O; Kensler, TW; Yamamoto, M; Leitinger, N; Tschachler, E				Gruber, Florian; Mayer, Herbert; Lengauer, Barbara; Mlitz, Veronika; Sanders, John M.; Kadl, Alexandra; Bilban, Martin; de Martin, Rainer; Wagner, Oswald; Kensler, Thomas W.; Yamamoto, Masayuki; Leitinger, Norbert; Tschachler, Erwin			NF-E2-related factor 2 regulates the stress response to UVA-1-oxidized phospholipids in skin cells	FASEB JOURNAL			English	Article						lipid oxidation; antioxidant response; redox-sensitive transcription; long-wavelength ultraviolet; phototherapy	SYSTEMIC-LUPUS-ERYTHEMATOSUS; ARYL-HYDROCARBON RECEPTOR; NRF2 TRANSCRIPTION FACTOR; LIPID OXIDATION-PRODUCTS; ULTRAVIOLET-B RADIATION; LOW-DENSITY-LIPOPROTEIN; OXIDIZED PHOSPHOLIPIDS; HEME OXYGENASE-1; ANTIOXIDANT RESPONSE; SIGNALING PATHWAY	Long-wavelength ultraviolet (UVA-1) radiation causes oxidative stress that modifies cellular molecules. To defend themselves against noxious oxidation products, skin cells produce detoxifying enzymes and antioxidants. We have recently shown that UVA-1 oxidized the abundant membrane phospholipid 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC), which then induced the stress-response protein heme oxygenase 1 (HO-1) in dermal fibroblasts. Here we examined the effects of UVA-1- and UV-oxidized phospholipids on global gene expression in human dermal fibroblasts and keratinocytes. We identified a cluster of genes that were coinduced by UVA-1-oxidized PAPC and UVA-1 radiation. The cluster included HO-1, glutamate-cysteine ligase modifier subunit, aldo-keto reductases-1-C1 and -C2, and IL-8. These genes are members of the cellular stress response system termed "antioxidant response." Accordingly, the regulatory regions of all of these genes contain binding sites for NF-E2-related factor 2 (NRF2), a major regulator of the antioxidant response. Both UVA-1 irradiation and treatment with oxidized lipids led to increased nuclear accumulation and DNA binding of NRF2. Silencing and deficiency of NRF2 suppressed the antioxidant response. Taken together, our data show that UVA-1- mediated lipid oxidation induces expression of antioxidant response genes, which is dependent on the redox-regulated transcription factor NRF2. Our findings suggest a different view on UV-generated lipid mediators that were commonly regarded as detrimental.-Gruber, F., Mayer, H., Lengauer, B., Mlitz, V., Sanders, J. M., Kadl, A., Bilban, M., de Martin, R., Wagner, O., Kensler, T. W., Yamamoto, M., Leitinger, N., Tschachler, E. NF-E2-related factor 2 regulates the stress response to UVA1- oxidized phospholipids in skin cells. FASEB J. 24, 39-48 ( 2010). www.fasebj.org	[Gruber, Florian; Sanders, John M.; Kadl, Alexandra; Leitinger, Norbert] Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; [Gruber, Florian; Lengauer, Barbara; Mlitz, Veronika; Tschachler, Erwin] Med Univ Vienna, Dept Dermatol, Vienna, Austria; [Mayer, Herbert; de Martin, Rainer] Med Univ Vienna, Dept Vasc Biol & Thrombosis Res, Vienna, Austria; [Bilban, Martin; Wagner, Oswald] Med Univ Vienna, Dept Lab Med, Vienna, Austria; [Kensler, Thomas W.] Johns Hopkins Univ, Dept Environm Hlth Sci, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Yamamoto, Masayuki] Univ Tsukuba, Tsukuba, Ibaraki, Japan; [Tschachler, Erwin] Ctr Rech & Invest Epiderm & Sensorielles, Neuilly, France	University of Virginia; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Tsukuba	Leitinger, N (corresponding author), Univ Virginia, Cardiovasc Res Ctr, POB 801394, Charlottesville, VA 22908 USA.	nl2q@virginia.edu	Kensler, Thomas W/D-8686-2014; Yamamoto, Masayuki/A-4873-2010; Kadl, Alexandra/AAV-3395-2021	Kensler, Thomas W/0000-0002-6676-261X; Yamamoto, Masayuki/0000-0002-9073-9436; Gruber, Florian/0000-0003-1094-5641; Tschachler, Erwin/0000-0002-0248-1798; Bilban, Martin/0000-0001-7043-7142	NIH [R01 HL084422-01]; American Heart Association; Max Kade Postdoctoral Fellowship; NATIONAL CANCER INSTITUTE [R01CA094076] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084422] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Max Kade Postdoctoral Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Maria Buchberger-Mosser and Joanne Lannigan for their contributions. This work was supported in part by NIH grant R01 HL084422-01 and a grant in aid from the American Heart Association ( to N.L.). F. G. was supported in part by a Max Kade Postdoctoral Fellowship.	Aerts S, 2005, NUCLEIC ACIDS RES, V33, pW393, DOI 10.1093/nar/gki354; Aerts S, 2003, NUCLEIC ACIDS RES, V31, P1753, DOI 10.1093/nar/gkg268; Afaq F, 2001, J PHOTOCH PHOTOBIO B, V63, P61, DOI 10.1016/S1011-1344(01)00217-2; Alam J, 2000, J BIOL CHEM, V275, P27694; Balla J, 2007, ANTIOXID REDOX SIGN, V9, P2119, DOI 10.1089/ars.2007.1787; Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06; Birukova AA, 2007, MICROVASC RES, V73, P173, DOI 10.1016/j.mvr.2006.12.004; Bochkov VN, 2006, CIRC RES, V99, P900, DOI 10.1161/01.RES.0000245485.04489.ee; Bochkov VN, 2003, J MOL MED, V81, P613, DOI 10.1007/s00109-003-0467-2; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Burczynski ME, 2001, J BIOL CHEM, V276, P2890, DOI 10.1074/jbc.M006655200; Chang MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/jem.20031763; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dickinson DA, 2004, FREE RADICAL BIO MED, V37, P1152, DOI 10.1016/j.freeradbiomed.2004.06.011; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eicheler W, 1998, ARCH DERMATOL RES, V290, P126, DOI 10.1007/s004030050277; Fritsche E, 2007, P NATL ACAD SCI USA, V104, P8851, DOI 10.1073/pnas.0701764104; Frostegard J, 2005, ARTHRITIS RHEUM-US, V52, P192, DOI 10.1002/art.20780; Gao L, 2007, J BIOL CHEM, V282, P2529, DOI 10.1074/jbc.M607622200; Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101; Gargalovic PS, 2006, ARTERIOSCL THROM VAS, V26, P2490, DOI 10.1161/01.ATV.0000242903.41158.a1; Gargalovic PS, 2006, P NATL ACAD SCI USA, V103, P12741, DOI 10.1073/pnas.0605457103; George TC, 2006, J IMMUNOL METHODS, V311, P117, DOI 10.1016/j.jim.2006.01.018; George TC, 2004, CYTOM PART A, V59A, P237, DOI 10.1002/cyto.a.20048; Giudice A, 2006, BIOESSAYS, V28, P169, DOI 10.1002/bies.20359; Gruber F, 2007, J BIOL CHEM, V282, P16934, DOI 10.1074/jbc.M702523200; Hirota A, 2005, J INVEST DERMATOL, V124, P825, DOI 10.1111/j.0022-202X.2005.23670.x; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Hubatsch I, 2002, CHEM RES TOXICOL, V15, P1114, DOI 10.1021/tx020027r; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; Itoh K, 2004, MOL CELL BIOL, V24, P36, DOI 10.1128/MCB.24.1.36-45.2004; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kann S, 2005, TOXICOL SCI, V87, P365, DOI 10.1093/toxsci/kfi253; Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291; Keller UAD, 2006, MOL CELL BIOL, V26, P3773, DOI 10.1128/MCB.26.10.3773-3784.2006; Konger RL, 2008, PROSTAG OTH LIPID M, V87, P1, DOI 10.1016/j.prostaglandins.2008.04.002; Kvam E, 1999, FREE RADICAL BIO MED, V26, P511, DOI 10.1016/S0891-5849(98)00224-X; Kwak MK, 2004, MUTAT RES-FUND MOL M, V555, P133, DOI 10.1016/j.mrfmmm.2004.06.041; Lee S, 2009, J LIPID RES, V50, P265, DOI 10.1194/jlr.M800317-JLR200; Leitinger N, 2003, CURR OPIN LIPIDOL, V14, P421, DOI 10.1097/00041433-200310000-00002; Leitinger N, 1999, P NATL ACAD SCI USA, V96, P12010, DOI 10.1073/pnas.96.21.12010; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Li WG, 2009, MOL CARCINOGEN, V48, P91, DOI 10.1002/mc.20465; Lou H, 2006, MOL PHARMACOL, V69, P1662, DOI 10.1124/mol.105.019794; Ma Q, 2006, AM J PATHOL, V168, P1960, DOI 10.2353/ajpath.2006.051113; Mang R, 2005, PHOTODERMATOL PHOTO, V21, P103, DOI 10.1111/j.1600-0781.2005.00146.x; Marathe GK, 2005, J BIOL CHEM, V280, P35448, DOI 10.1074/jbc.M503811200; Mayer H, 2004, ARTERIOSCL THROM VAS, V24, P1192, DOI 10.1161/01.ATV.0000131263.06296.77; MCGRATH H, 1994, CLIN EXP RHEUMATOL, V12, P129; McMillan BJ, 2007, P NATL ACAD SCI USA, V104, P1412, DOI 10.1073/pnas.0607296104; Mildner M, 1999, PHOTOCHEM PHOTOBIOL, V70, P674, DOI 10.1562/0031-8655(1999)070<0674:UAURDR>2.3.CO;2; Moeller LC, 2005, J CLIN ENDOCR METAB, V90, P936, DOI 10.1210/jc.2004-1768; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; Osburn WO, 2008, MUTAT RES-REV MUTAT, V659, P31, DOI 10.1016/j.mrrev.2007.11.006; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Penning TM, 2007, ARCH BIOCHEM BIOPHYS, V464, P241, DOI 10.1016/j.abb.2007.04.024; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Reis A, 2005, BIOMED CHROMATOGR, V19, P129, DOI 10.1002/bmc.429; Shin S, 2007, MOL CELL BIOL, V27, P7188, DOI 10.1128/MCB.00915-07; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; Theilgaard-Monch K, 2004, J IMMUNOL, V172, P7684, DOI 10.4049/jimmunol.172.12.7684; Tyrrell RM, 2004, ANTIOXID REDOX SIGN, V6, P835, DOI 10.1089/1523086041798033; Valencia A, 2008, J INVEST DERMATOL, V128, P214, DOI 10.1038/sj.jid.5700960; VILE GF, 1995, FREE RADICAL BIO MED, V18, P721, DOI 10.1016/0891-5849(94)00192-M; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; Villacorta L, 2007, AM J PHYSIOL-HEART C, V293, pH770, DOI 10.1152/ajpheart.00261.2007; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Wondrak GT, 2007, CURR OPIN INVEST DR, V8, P390; Yeh M, 2004, J BIOL CHEM, V279, P30175, DOI 10.1074/jbc.M312198200; Yoh K, 2001, KIDNEY INT, V60, P1343, DOI 10.1046/j.1523-1755.2001.00939.x; Zhang XL, 2005, EUR J IMMUNOL, V35, P3258, DOI 10.1002/eji.200526116	74	65	68	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					39	48		10.1096/fj.09-133520	http://dx.doi.org/10.1096/fj.09-133520			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19720622	Green Published			2022-12-28	WOS:000273233600007
J	Huysseune, S; Kienlen-Campard, P; Hebert, S; Tasiaux, B; Leroy, K; Devuyst, O; Brion, JP; De Strooper, B; Octave, JN				Huysseune, Sandra; Kienlen-Campard, Pascal; Hebert, Sebastien; Tasiaux, Bernadette; Leroy, Karelle; Devuyst, Olivier; Brion, Jean-Pierre; De Strooper, Bart; Octave, Jean-Noel			Epigenetic control of aquaporin 1 expression by the amyloid precursor protein	FASEB JOURNAL			English	Article						AICD; Alzheimer's disease; gene expression; histone acetylation	DEPENDENT TRANSCRIPTIONAL CONTROL; HISTONE DEACETYLASE INHIBITORS; DEGRADING ENZYME NEPRILYSIN; GAMMA-SECRETASE COMPLEXES; GENE-EXPRESSION; INTRACELLULAR DOMAIN; CYTOSKELETAL DYNAMICS; MICE LACKING; PRESENILIN; APP	Cellular processing of the amyloid precursor protein (APP) has been extensively studied, but its precise function remains elusive. The intracellular domain of APP has been proposed to regulate expression of several genes by mechanisms that are largely unknown. We report that APP regulates expression of the aquaporin 1 (AQP1) gene in mouse embryonic fibroblasts and in transgenic mice. AQP1 mRNA and protein were down-regulated in fibroblasts lacking APP or presenilin 2 in which AQP1 expression was restored by stable expression of full-length APP or presenilin 2 but not by APP deleted from its carboxy-terminal domain. The transcriptional activity of the AQP1 gene promoter and the stability of AQP1 mRNA were identical in fibroblasts expressing or not expressing APP. Control of AQP1 expression by APP was sensitive to trichostatin A, an histone deacetylase inhibitor, and histone deacetylase activity coimmunoprecipitated with APP. Altogether, these data show that a presenilin-2-dependent gamma-secretase activity releases the intracellular domain of APP involved in the epigenetic control of AQP1 expression. Since AQP1 is found in astrocytes surrounding senile plaques, this epigenetic control of AQP1 expression could have important implications in Alzheimer disease.-Huysseune, S., Kienlen-Campard, P., Hebert, S., Tasiaux, B., Leroy, K., Devuyst, O., Brion, J.-P., De Strooper, B., Octave, J.-N. Epigenetic control of aquaporin 1 expression by the amyloid precursor protein. FASEB J. 23, 4158-4167 (2009). www.fasebj.org	[Huysseune, Sandra; Kienlen-Campard, Pascal; Tasiaux, Bernadette; Octave, Jean-Noel] Catholic Univ Louvain, Inst Neurosci, B-1200 Brussels, Belgium; [Hebert, Sebastien] CHU Quebec, Ctr Rech, Laurier, PQ, Canada; [Leroy, Karelle; Brion, Jean-Pierre] Univ Libre Bruxelles, Fac Med, Lab Histol Neuroanat & Neuropathol, Brussels, Belgium; [Devuyst, Olivier] Catholic Univ Louvain, Unite Nephrol, B-1200 Brussels, Belgium; [Hebert, Sebastien; De Strooper, Bart] Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium; [Hebert, Sebastien; De Strooper, Bart] VIB, Dept Mol & Dev Genet, Louvain, Belgium	Universite Catholique Louvain; Universite Libre de Bruxelles; Universite Catholique Louvain; KU Leuven; Flanders Institute for Biotechnology (VIB)	Octave, JN (corresponding author), Catholic Univ Louvain, Inst Neurosci, FARL 5410,Ave Hippocrate 54, B-1200 Brussels, Belgium.	jean-noel.octave@uclouvain.be	Brion, Jean-Pierre/C-6467-2009; de+Strooper, Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012	Brion, Jean-Pierre/0000-0002-1917-775X; De Strooper, Bart/0000-0001-5455-5819; Devuyst, Olivier/0000-0003-3744-4767; Leroy, Karelle/0000-0002-8661-5262; Hebert, Sebastien/0000-0002-0391-9325; Kienlen-Campard, Pascal/0000-0003-1086-2942	Belgian Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture; Belgian Fonds National pour la Recherche Scientifique, bourses du Patrimoine; Communaute Francaise de Belgique; Action de Recherche Concertees; Belgian Federal Science Policy Office [P6/43, P6/05]; Belgian Fonds de la Recherche Scientifique Medicale; Alzheimer Belgique; la Fondation pour la Recherche sur la Maladie d'Alzheimer/Stichting voor Alzheimer Onderzoek; Region Walonne; Fondation Alphonse Jean Forton; European Community [GA 201590]; Flemish government; KU Leuven; VIB	Belgian Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture(Fonds de la Recherche Scientifique - FNRS); Belgian Fonds National pour la Recherche Scientifique, bourses du Patrimoine(Fonds de la Recherche Scientifique - FNRS); Communaute Francaise de Belgique(Australian Research Council); Action de Recherche Concertees; Belgian Federal Science Policy Office(Belgian Federal Science Policy Office); Belgian Fonds de la Recherche Scientifique Medicale(Fonds de la Recherche Scientifique - FNRS); Alzheimer Belgique; la Fondation pour la Recherche sur la Maladie d'Alzheimer/Stichting voor Alzheimer Onderzoek; Region Walonne(Region Auvergne-Rhone-AlpesRegion Bourgogne-Franche-ComteRegion Hauts-de-FranceRegion Nouvelle-Aquitaine); Fondation Alphonse Jean Forton; European Community(European Commission); Flemish government(European Commission); KU Leuven(KU Leuven); VIB	We thank Huguette Debaix for technical assistance and Jean-Christophe Renauld and Laurent Knoops for assistance in designing the miccroarray experiments. We thank Belaid Sekkali for discussion in the field of epigenetics. We also thank Wim Annaert (KU Leuven and VIB, Leuven, Belgium) for providing PS2<SUP>-/-</SUP> rescue PS2 MEFs and Alan S. Verkman for providing the Aqp1 mouse. This work was supported by the Belgian Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture (to S. H.), the Belgian Fonds National pour la Recherche Scientifique, bourses du Patrimoine (to S. H), the Communaute Francaise de Belgique, the Action de Recherche Concertees, the Interuniversity Attraction Poles (IUAP) Program (P6/43, P6/05) of the Belgian Federal Science Policy Office, the Belgian Fonds de la Recherche Scientifique Medicale, Alzheimer Belgique, la Fondation pour la Recherche sur la Maladie d'Alzheimer/Stichting voor Alzheimer Onderzoek, the Programme d'excellence "Marshall" DIANE convention from the Region Walonne, the Fondation Alphonse & Jean Forton, and the European Network for the Study of Orphan Nephropathies (EUNEFRON) program of the European Community (FP7, GA#201590). Work in the laboratory of B. D. S. was supported by a Methusalem grant of the Flemish government and funding from the KU Leuven and VIB.	Alarcon R, 2005, J BIOL CHEM, V280, P30406, DOI 10.1074/jbc.M414686200; Annaert W, 1999, TRENDS NEUROSCI, V22, P439, DOI 10.1016/S0166-2236(99)01455-1; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Beel AJ, 2008, CELL MOL LIFE SCI, V65, P1311, DOI 10.1007/s00018-008-7462-2; Belyaev ND, 2009, EMBO REP, V10, P94, DOI 10.1038/embor.2008.222; Boassa D, 2006, J NEUROSCI, V26, P7811, DOI 10.1523/JNEUROSCI.0525-06.2006; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Carey N, 2006, CURR OPIN PHARMACOL, V6, P369, DOI 10.1016/j.coph.2006.03.010; Chen AC, 2007, NEURON, V53, P479, DOI 10.1016/j.neuron.2007.01.023; Clayton AL, 2006, MOL CELL, V23, P289, DOI 10.1016/j.molcel.2006.06.017; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Fass DM, 2003, J BIOL CHEM, V278, P43014, DOI 10.1074/jbc.M305905200; Fischer A, 2007, NATURE, V447, P178, DOI 10.1038/nature05772; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Heber S, 2000, J NEUROSCI, V20, P7951; Hebert SS, 2006, EMBO REP, V7, P739, DOI 10.1038/sj.embor.7400704; Hebert SS, 2004, NEUROBIOL DIS, V17, P260, DOI 10.1016/j.nbd.2004.08.002; Herms J, 2004, EMBO J, V23, P4106, DOI 10.1038/sj.emboj.7600390; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Huysseune S, 2007, BIOCHEM BIOPH RES CO, V361, P317, DOI 10.1016/j.bbrc.2007.06.186; Kajiwara Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005071; Kienlen-Campard P, 2008, J BIOL CHEM, V283, P7733, DOI 10.1074/jbc.M707142200; Kim D, 2008, NEURON, V60, P803, DOI 10.1016/j.neuron.2008.10.015; Kim HS, 2003, FASEB J, V17, P1951, DOI 10.1096/fj.03-0106fje; Kim JG, 2007, J BIOL CHEM, V282, P14923, DOI 10.1074/jbc.M701411200; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Makki MS, 2008, NUCLEIC ACIDS RES, V36, P4067, DOI 10.1093/nar/gkn356; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Misawa T, 2008, ACTA NEUROPATHOL, V116, P247, DOI 10.1007/s00401-008-0387-x; Muller T, 2008, PROG NEUROBIOL, V85, P393, DOI 10.1016/j.pneurobio.2008.05.002; Muller T, 2007, MOL BIOL CELL, V18, P201, DOI 10.1091/mbc.E06-04-0283; Oshio K, 2004, FASEB J, V18, P76, DOI 10.1096/fj.04-1711fje; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Perez E, 2007, BRAIN RES, V1128, P164, DOI 10.1016/j.brainres.2006.09.109; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662; Reinhard C, 2005, EMBO J, V24, P3996, DOI 10.1038/sj.emboj.7600860; SALMON P, 2007, CURR PROTOC HUM GENE, V54; Santos SF, 2009, J NEUROSCI, V29, P4708, DOI 10.1523/JNEUROSCI.4917-08.2009; Sato T, 2009, P NATL ACAD SCI USA, V106, P1421, DOI 10.1073/pnas.0812261106; Sato T, 2007, J BIOL CHEM, V282, P33985, DOI 10.1074/jbc.M705248200; Serneels L, 2005, P NATL ACAD SCI USA, V102, P1719, DOI 10.1073/pnas.0408901102; Serneels L, 2009, SCIENCE, V324, P639, DOI 10.1126/science.1171176; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Shirotani K, 2004, J BIOL CHEM, V279, P41340, DOI 10.1074/jbc.M405768200; Shirotani K, 2007, NEUROBIOL DIS, V27, P102, DOI 10.1016/j.nbd.2007.04.011; Sweatt JD, 2007, NATURE, V447, P151, DOI 10.1038/nature05716; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Verkman AS, 2005, J CELL SCI, V118, P3225, DOI 10.1242/jcs.02519; von Rotz RC, 2004, J CELL SCI, V117, P4435, DOI 10.1242/jcs.01323; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838	60	42	42	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4158	4167		10.1096/fj.09-140012	http://dx.doi.org/10.1096/fj.09-140012			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19687153				2022-12-28	WOS:000272193700012
J	Setsuie, R; Suzuki, M; Kabuta, T; Fujita, H; Miura, S; Ichihara, N; Yamada, D; Wang, YL; Ezaki, O; Suzuki, Y; Wada, K				Setsuie, Rieko; Suzuki, Mari; Kabuta, Tomohiro; Fujita, Hiromi; Miura, Shinji; Ichihara, Nobutsune; Yamada, Daisuke; Wang, Yu-Lai; Ezaki, Osamu; Suzuki, Yasuyuki; Wada, Keiji			Ubiquitin C-terminal hydrolase-L3-knockout mice are resistant to diet-induced obesity and show increased activation of AMP-activated protein kinase in skeletal muscle	FASEB JOURNAL			English	Article						energy balance; energy expenditure; deubiquitinating enzyme	ENERGY-EXPENDITURE; SIGNALING PATHWAYS; INSULIN-RESISTANCE; CELL APOPTOSIS; FAT; METABOLISM; GROWTH; FUEL; OVEREXPRESSION; DEGENERATION	Obesity results from the dysregulation of energy balance throughout the entire body. Although the ubiquitin system participates in many cellular processes, its contribution to the balance of energy in the body remains poorly understood. Here, we show that ubiquitin C-terminal hydrolase (UCH)-L3, one of the deubiquitinating enzymes, contributes to the regulation of metabolism. Uchl3(-/-) mice displayed a reduction of adipose tissue mass and were protected against high-fat diet (HFD)-induced obesity and insulin resistance. Uchl3(-/-) mice given both a normal chow and an HFD had an increased whole-body energy expenditure accounting for the reduction of adipose tissue mass. Activation of AMP-activated protein kinase (AMPK) in skeletal muscle has been reported to increase fatty acid beta-oxidation, leading to the elevation of the whole-body energy expenditure. Consistently, increased activation of AMPK and fatty acid beta-oxidation was observed in skeletal muscle of Uchl3(-/-) mice. Mouse embryonic fibroblasts derived from Uchl3(-/-) mice also showed increased activation of AMPK, indicating that UCH-L3 is involved in a cell-autonomous down-regulation of AMPK. These results suggest a role for UCH-L3 in the regulation of AMPK activity and whole-body energy metabolism.-Setsuie, R., Suzuki, M., Kabuta, T., Fujita, H., Miura, S., Ichihara, N., Yamada, D., Wang, Y.-L., Ezaki, O., Suzuki, Y., Wada, K. Ubiquitin C-terminal hydrolase-L3-knockout mice are resistant to diet-induced obesity and show increased activation of AMP-activated protein kinase in skeletal muscle. FASEB J. 23, 4148-4157 (2009). www.fasebj.org	[Setsuie, Rieko; Suzuki, Mari; Kabuta, Tomohiro; Fujita, Hiromi; Yamada, Daisuke; Wang, Yu-Lai; Suzuki, Yasuyuki; Wada, Keiji] Natl Ctr Neurol & Psychiat, Dept Degenerat Neurol Dis, Natl Inst Neurosci, Kodaira, Tokyo 1878502, Japan; [Miura, Shinji; Ezaki, Osamu] Natl Inst Hlth & Nutr, Nutr Sci Program, Tokyo 162, Japan; [Ichihara, Nobutsune] Azabu Univ, Sch Vet Med, Kanagawa, Japan; [Yamada, Daisuke; Wada, Keiji] Japan Sci & Technol Agcy, Saitama, Japan	National Center for Neurology & Psychiatry - Japan; National Institute of Health & Nutrition - Japan; Azabu University; Japan Science & Technology Agency (JST)	Wada, K (corresponding author), Natl Ctr Neurol & Psychiat, Dept Degenerat Neurol Dis, Natl Inst Neurosci, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878502, Japan.	wada@ncnp.go.jp	Miura, Shinji/K-6516-2013; Kabuta, Tomohiro/B-2948-2015	Miura, Shinji/0000-0001-8806-9763; Kabuta, Tomohiro/0000-0002-3058-2596; Yamada, Daisuke/0000-0002-6989-6736	National Institute of Biomedical Innovation of Japan; Ministry of Health, Labor, and Welfare of Japan; Ministry of Education, Culture, Sports, Science, and Technology of Japan	National Institute of Biomedical Innovation of Japan(National Institute of Biomedical Innovation); Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr. Shirley M. Tilghman (Princeton University, Princeton, NJ, USA) for providing the Uchl3<SUP>-/-</SUP> mice. We thank Mr. Miki Tadaishi (National Institute of Health and Nutrition, Tokyo, Japan) for his assistance with the measurement of fatty acid beta-oxidation. We thank Dr. Etsuko Wada (NCNP, Tokyo, Japan) and Ms. Mariko Yamamoto (NCNP) for their assistance with animal care, and Ms. Hisae Kikuchi (NCNP) for her assistance with histological studies. We thank Dr. Yukiko K. Hayashi (NCNP) for technical assistance and discussions concerning muscle analysis and Dr. Hirohiko Hohjoh (NCNP) for providing the homecage monitor. We thank Dr. Sachio Naito (High Energy Accelerator Research Organization, Tsukuba, Japan), Dr. Yoshitaka Nagai (NCNP), Dr. Hitoshi Osaka (Kanagawa Children's Medical Center, Kanagawa, Japan), Dr. Yukihiro Tsuchiya (NCNP), and Dr. Yusuke Tozuka (NCNP) for discussions and comments concerning manuscript preparation. This work was supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation of Japan and grants-in-aid for scientific research from the Ministry of Health, Labor, and Welfare of Japan and the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bezaire V, 2005, FASEB J, V19, P977, DOI 10.1096/fj.04-2765fje; Bray GA, 2000, NATURE, V404, P672, DOI 10.1038/35007544; Brown-Borg HM, 2009, MOL CELL ENDOCRINOL, V299, P64, DOI 10.1016/j.mce.2008.07.001; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Choi CS, 2007, P NATL ACAD SCI USA, V104, P16480, DOI 10.1073/pnas.0706794104; Choi CS, 2007, J CLIN INVEST, V117, P1995, DOI 10.1172/JCI13579; D'Eon TM, 2005, J BIOL CHEM, V280, P35983, DOI 10.1074/jbc.M507339200; de Lange P, 2007, FASEB J, V21, P3431, DOI 10.1096/fj.07-8527rev; Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017; Finn PF, 2006, NUTRITION, V22, P830, DOI 10.1016/j.nut.2006.04.008; Gan-Erdene T, 2003, J BIOL CHEM, V278, P28892, DOI 10.1074/jbc.M302890200; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hardie DG, 2006, PHYSIOLOGY, V21, P48, DOI 10.1152/physiol.00044.2005; Harper ME, 2008, ANNU REV NUTR, V28, P13, DOI 10.1146/annurev.nutr.28.061807.155357; Hemelaar J, 2004, MOL CELL BIOL, V24, P84, DOI 10.1128/MCB.24.1.84-95.2004; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kappeler L, 2009, ENDOCRINOLOGY, V150, P314, DOI 10.1210/en.2008-0981; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Koyama S, 2008, J MOL BIOL, V376, P1224, DOI 10.1016/j.jmb.2007.11.049; Kurihara LJ, 2000, MOL CELL BIOL, V20, P2498, DOI 10.1128/MCB.20.7.2498-2504.2000; Kwon J, 2004, AM J PATHOL, V165, P1367, DOI 10.1016/S0002-9440(10)63394-9; Kwon J, 2004, BIOL REPROD, V71, P515, DOI 10.1095/biolreprod.104.027565; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Long YC, 2008, AM J PHYSIOL-ENDOC M, V295, pE545, DOI 10.1152/ajpendo.90259.2008; Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044; Lucas A, 1998, J NUTR, V128, p401S, DOI 10.1093/jn/128.2.401S; Mayes J S, 2004, Obes Rev, V5, P197, DOI 10.1111/j.1467-789X.2004.00152.x; McInnes KJ, 2006, ENDOCRINOLOGY, V147, P5907, DOI 10.1210/en.2006-0879; Miura S, 2009, AM J PHYSIOL-ENDOC M, V296, pE47, DOI 10.1152/ajpendo.90690.2008; Molero JC, 2004, J CLIN INVEST, V114, P1326, DOI [10.1172/JCI200421480, 10.1172/JCI21480]; Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Nony P, 2003, ONCOGENE, V22, P9165, DOI 10.1038/sj.onc.1207179; OhkiHamazaki H, 1997, NATURE, V390, P165, DOI 10.1038/36568; Qi JZ, 2008, EMBO J, V27, P1537, DOI 10.1038/emboj.2008.92; Qi L, 2006, SCIENCE, V312, P1763, DOI 10.1126/science.1123374; Riant E, 2009, ENDOCRINOLOGY, V150, P2109, DOI 10.1210/en.2008-0971; Sano Y, 2006, AM J PATHOL, V169, P132, DOI 10.2353/ajpath.2006.060085; Semenova E, 2003, HUM MOL GENET, V12, P1301, DOI 10.1093/hmg/ddg140; Setsuie R, 2007, NEUROCHEM INT, V50, P119, DOI 10.1016/j.neuint.2006.07.015; Simpson ER, 2005, CELL METAB, V2, P346, DOI 10.1016/j.cmet.2005.11.010; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Steinberg GR, 2006, CELL METAB, V4, P465, DOI 10.1016/j.cmet.2006.11.005; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Watt MJ, 2006, NAT MED, V12, P541, DOI 10.1038/nm1383; Xu XS, 2008, MOL CELL, V30, P403, DOI 10.1016/j.molcel.2008.03.009; ZURLO F, 1990, J CLIN INVEST, V86, P1423, DOI 10.1172/JCI114857	53	17	17	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4148	4157		10.1096/fj.09-132217	http://dx.doi.org/10.1096/fj.09-132217			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19671667				2022-12-28	WOS:000272193700011
J	Deng, YR; Almsherqi, ZA; Shui, GH; Wenk, MR; Kohlwein, SD				Deng, Yuru; Almsherqi, Zakaria A.; Shui, Guanghou; Wenk, Markus R.; Kohlwein, Sepp D.			Docosapentaenoic acid (DPA) is a critical determinant of cubic membrane formation in amoeba Chaos mitochondria	FASEB JOURNAL			English	Article						very long-chain polyunsaturated fatty acid; omega-3 DPA; omega-6 DPA; lipid mass spectrometry	CORONARY SYNDROME PATIENTS; DOCOSAHEXAENOIC ACID; FATTY-ACIDS; CAROLINENSIS; BILAYERS; LIPIDS; DHA	Very long-chain polyunsaturated fatty acids (VLC-PUFAs), such as docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), have recently made it to the realm of "magical molecules" based on their multiple presumably beneficial effects in biological systems, making these PUFAs particularly interesting in biomedicine. Their specific biological functions, however, remain enigmatic. Here we provide evidence derived from studies in the amoeba Chaos that indicates a structural role for omega-6 DPA in cell membrane organization, which may help to explain the multiple diverse effects of VLC-PUFA in healthy and diseased states. Amoeba Chaos mitochondria undergo a remarkable and reversible morphological transition into cubic morphology on starvation. This morphological transition is reflected in major changes in fatty acid and lipid composition, as determined by gas liquid chromatography and mass spectrometry, in particular by a drastic increase in C22:5 modified phosphatidylcholine plasmalogen, phosphatidylethanolamine plasmalogen, and phosphatidylinositol species. Liposomes produced in vitro from lipids of starved amoeba cells show a high propensity to form hexagonal tubular and cubic morphologies. Addition of omega-6 DPA, but not of omega-3 DPA, to the cell culture also induced mitochondrial membrane transformation into cubic morphology in fed cells, demonstrating for the first time an important structural role of omega-6 DPA-containing lipids in cell membrane organization.-Deng, Y., Almsherqi, Z. A., Shui, G., Wenk, M. R., Kohlwein, S. D. Docosapentaenoic acid (DPA) is a critical determinant of cubic membrane formation in amoeba Chaos mitochondria. FASEB J. 23, 2866-2871 (2009). www.fasebj.org	[Deng, Yuru] Natl Univ Singapore, Dept Physiol, Yong Loo Lin Sch Med, Singapore 117597, Singapore; [Shui, Guanghou; Wenk, Markus R.] Natl Univ Singapore, Dept Biochem, Singapore 117597, Singapore; [Wenk, Markus R.] Natl Univ Singapore, Dept Biol Sci, Singapore 117597, Singapore; [Kohlwein, Sepp D.] Graz Univ, Inst Mol Biosci, Graz, Austria	National University of Singapore; National University of Singapore; National University of Singapore; University of Graz	Deng, YR (corresponding author), Natl Univ Singapore, Dept Physiol, Yong Loo Lin Sch Med, Singapore 117597, Singapore.	phsdy@nus.edu.sg	Wenk, Markus Rene/D-1441-2014	Shui, Guanghou/0000-0002-1621-9643; Kohlwein, Sepp Dieter/0000-0002-1030-0598	Austrian Science Fund FWF [Lipotox F3005]; National Research Foundation [2007-04]; Academic Research Fund [R-183-000-160-112]; Biomedical Research Council of Singapore [R-183-000211-305, R-185-000-065-305]; National Medical Research Council [R-183000-224-213, R-185-000-058-213]; Biomedical Research Council of Singapore; Austrian Science Fund (FWF) [F 3005] Funding Source: researchfish	Austrian Science Fund FWF(Austrian Science Fund (FWF)); National Research Foundation; Academic Research Fund(Ministry of Education, Singapore); Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR)); National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank Chwee Wah Low, Li Ling Olivia Tan, and Mei Yin Shoon for help with electron microscopy, liposome preparation, and amoeba cell culture. Support was provided by the Austrian Science Fund FWF (SFB project Lipotox F3005) to S. D. K.; the National Research Foundation under CRP award 2007-04, the Academic Research Fund (R-183-000-160-112), the Biomedical Research Council of Singapore (R-183-000211-305), and the National Medical Research Council (R-183000-224-213) to M. R. W; and the National Medical Research Council (R-185-000-058-213) and Biomedical Research Council of Singapore (R-185-000-065-305) to Y.D.	Almsherqi ZA, 2006, J CELL BIOL, V173, P839, DOI 10.1083/jcb.200603055; BIRCH EE, 1992, INVEST OPHTH VIS SCI, V33, P3242; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Block RC, 2008, ATHEROSCLEROSIS, V197, P821, DOI 10.1016/j.atherosclerosis.2007.07.042; Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591; DAS UN, 1994, PROSTAG LEUKOTR ESS, V51, P207, DOI 10.1016/0952-3278(94)90136-8; Deng YR, 1999, J STRUCT BIOL, V127, P231, DOI 10.1006/jsbi.1999.4147; Deng YR, 1998, PROTOPLASMA, V203, P16, DOI 10.1007/BF01280583; Eldho NV, 2003, J AM CHEM SOC, V125, P6409, DOI 10.1021/ja029029o; Epand RM, 1997, BIOCHEM SOC T, V25, P1073; Feller SE, 2008, CHEM PHYS LIPIDS, V153, P76, DOI 10.1016/j.chemphyslip.2008.02.013; Gawrisch K, 2008, CHEM PHYS LIPIDS, V153, P64, DOI 10.1016/j.chemphyslip.2008.02.016; Guan XL, 2006, FASEB J, V20, P1152, DOI 10.1096/fj.05-5362com; Harris WS, 2007, AM J CARDIOL, V99, P154, DOI 10.1016/j.amjcard.2006.08.013; Jump DB, 2008, CHEM PHYS LIPIDS, V153, P3, DOI 10.1016/j.chemphyslip.2008.02.007; KREMER JM, 1990, GERIATRICS, V45, P43; Larsson SC, 2004, AM J CLIN NUTR, V79, P935; Shui GH, 2007, J LIPID RES, V48, P1976, DOI 10.1194/jlr.M700060-JLR200; Siddiqui RA, 2008, CHEM PHYS LIPIDS, V153, P47, DOI 10.1016/j.chemphyslip.2008.02.009; Stillwell W, 2008, CHEM PHYS LIPIDS, V153, P1, DOI 10.1016/j.chemphyslip.2008.02.012; Tan Olivia Li Ling, 2005, Protistology, V4, P185; Tarahovsky YS, 2000, BIOPHYS J, V79, P3193, DOI 10.1016/S0006-3495(00)76552-0; Wassall SR, 2008, CHEM PHYS LIPIDS, V153, P57, DOI 10.1016/j.chemphyslip.2008.02.010; Wenk MR, 2003, METHOD ENZYMOL, V372, P248; Yokoyama A, 2000, INT ARCH ALLERGY IMM, V123, P327, DOI 10.1159/000053645	25	32	32	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2866	2871		10.1096/fj.09-130435	http://dx.doi.org/10.1096/fj.09-130435			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19406841				2022-12-28	WOS:000270241000009
J	Yu, KD; Di, GH; Fan, L; Wu, J; Hu, Z; Shen, ZZ; Huang, W; Shao, ZM				Yu, Ke-Da; Di, Gen-Hong; Fan, Lei; Wu, Jiong; Hu, Zhen; Shen, Zhen-Zhou; Huang, Wei; Shao, Zhi-Ming			A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer	FASEB JOURNAL			English	Article						risk pattern; AP-2; meta-analysis; functional verification	GLUTATHIONE-S-TRANSFERASE; T1 GENETIC POLYMORPHISMS; TRANSCRIPTION FACTOR; RISK; M1; ASSOCIATION; SUSCEPTIBILITY; METAANALYSIS; GENOTYPE; MODEL	Although a number of studies have been conducted to address the relation between a gene deletion polymorphism of glutathione S-transferase M1 (GSTM1) and breast cancer, no definite conclusion has been reached and no clear risk pattern has yet to emerge for GSTM1. We first conducted case-control studies that included 1920 subjects using a genotyping method allowing the definition of GSTM1-null (-/-), homozygous wild-type (+/+), and heterozygous (+/-) genotypes. The results show that GSTM1(-/-) confers an increased risk for breast cancer development compared with that in GSTM1-present individuals +/+ and +/-), which was subsequently confirmed by a meta-analysis of all of the 41 relevant studies (odds ratio: 1.10, P<0.001). Unexpectedly, we found that GSTM1(+/+) is also a risk genotype compared with GSTM1(+/-). Furthermore, we identified a functional polymorphism in the GSTM1 promoter region associated with breast cancer. The variant allele modifies DNA binding to the AP-2 alpha transcription factor, resulting in reduced promoter activity and mRNA expression. However, this low-activity allele is associated with reduced breast cancer risk. It seems that similar to 60-70% expression from one allele of GSTM1 could suffice for protection against breast cancer; null activity and over-activity of GSTM1 are both disadvantageous. These results indicate a U-shaped association of GSTM1 with breast cancer, which challenges the linear gene-dosage effect of GSTM1 that was previously proposed. We recommend that a more complicated role for GSTM1 should be considered in breast cancer risk prediction.-Yu, K. D., Di, G.-H., Fan, L., Wu, J., Hu, Z., Shen, Z.-Z., Huang, W., Shao, Z.-M. A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer. FASEB J. 23, 2274-2287 (2009)	[Yu, Ke-Da; Di, Gen-Hong; Fan, Lei; Wu, Jiong; Hu, Zhen; Shen, Zhen-Zhou; Shao, Zhi-Ming] Fudan Univ, Canc Hosp, Shanghai Med Coll, Inst Biomed Sci,Breast Canc Inst,Dept Oncol, Shanghai 200032, Peoples R China; [Huang, Wei] Chinese Natl Human Genome Ctr Shanghai, Shanghai, Peoples R China	Fudan University	Shao, ZM (corresponding author), Fudan Univ, Canc Hosp, Dept Breast Surg, Inst Canc,Breast Canc Inst, 399 Ling Ling Rd, Shanghai 200032, Peoples R China.	zhimingshao@yahoo.com		Di, Genhong/0000-0003-1171-7907	National Basic Research Program of China [2006CB910501]; National Natural Science Foundation of China [30371580, 30572109]; Shanghai Science and Technology Committee [06DJ14004, 06DZ19504]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee(Shanghai Science & Technology Committee)	This research was supported in part by grants from the National Basic Research Program of China (2006CB910501), National Natural Science Foundation of China (30371580 and 30572109), and the Shanghai Science and Technology Committee (06DJ14004 and 06DZ19504) We thank the women in the study for their willingness to cooperate. We also greatly appreciate Lei Wang (Pharmacology Research Center, Shanghai Medical College) for his excellent technical assistance in the chromatin immunoprecipitation assay.	AMBROSONE CB, 1995, CANCER RES, V55, P3483; Antoniou AC, 2003, GENET EPIDEMIOL, V25, P190, DOI 10.1002/gepi.10261; Bonetti M, 2000, STAT MED, V19, P2595, DOI 10.1002/1097-0258(20001015)19:19<2595::AID-SIM562>3.0.CO;2-M; Brasch-Andersen C, 2004, HUM MUTAT, V24, P208, DOI 10.1002/humu.20074; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; Chacko P, 2005, MUTAT RES-GEN TOX EN, V581, P153, DOI 10.1016/j.mrgentox.2004.11.018; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; Deng HW, 2001, GENETICS, V157, P885; Dunning AM, 1999, CANCER EPIDEM BIOMAR, V8, P843; Egan KM, 2004, CANCER EPIDEM BIOMAR, V13, P197, DOI 10.1158/1055-9965.EPI-03-0294; FRYER AA, 1993, BIOCHEM J, V295, P313, DOI 10.1042/bj2950313; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gyorffy B, 2004, J INVEST DERMATOL, V122, P644, DOI 10.1111/j.0022-202X.2004.22334.x; Harada S, 2001, BIOCHEM BIOPH RES CO, V281, P267, DOI 10.1006/bbrc.2001.4347; Helzlsouer KJ, 1998, J NATL CANCER I, V90, P512, DOI 10.1093/jnci/90.7.512; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jiang JG, 2000, BIOCHEM BIOPH RES CO, V272, P882, DOI 10.1006/bbrc.2000.2848; Li DQ, 2006, PROTEOMICS, V6, P3352, DOI 10.1002/pmic.200500617; Li WF, 2008, BREAST CANCER RES TR, V110, P99, DOI 10.1007/s10549-007-9708-3; Liu JB, 2007, J EUR ACAD DERMATOL, V21, P205, DOI 10.1111/j.1468-3083.2006.01899.x; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Mitrunen K, 2001, CANCER EPIDEM BIOMAR, V10, P229; Moshynska O, 2005, ONCOGENE, V24, P2042, DOI 10.1038/sj.onc.1208377; Moyer AM, 2007, CLIN CANCER RES, V13, P7207, DOI 10.1158/1078-0432.CCR-07-0635; Park SK, 2004, BREAST CANCER RES TR, V88, P55, DOI 10.1007/s10549-004-0745-x; Parl FF, 2005, CANCER LETT, V221, P123, DOI 10.1016/j.canlet.2004.06.016; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; Roodi N, 2004, CANCER RES, V64, P1233, DOI 10.1158/0008-5472.CAN-03-2861; Santen RJ, 2005, NEW ENGL J MED, V353, P275, DOI 10.1056/NEJMra035692; Sull JW, 2004, YONSEI MED J, V45, P683, DOI 10.3349/ymj.2004.45.4.683; Vogl FD, 2004, CANCER EPIDEM BIOMAR, V13, P1473; WIDERSTEN M, 1991, BIOCHEM J, V276, P519, DOI 10.1042/bj2760519; Wilson MH, 2000, FASEB J, V14, P791, DOI 10.1096/fasebj.14.5.791; Xiong P, 2001, CANCER RES, V61, P8465; Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yu KD, 2007, ANN SURG ONCOL, V14, P2502, DOI 10.1245/s10434-007-9436-2; Zhang XM, 2005, GASTROENTEROLOGY, V129, P565, DOI 10.1053/j.gastro.2005.05.003	39	44	47	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2274	2287		10.1096/fj.08-124073	http://dx.doi.org/10.1096/fj.08-124073			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19228880				2022-12-28	WOS:000268836500027
J	Sanchez-Zamora, Y; Terrazas, LI; Vilches-Flores, A; Leal, E; Juarez, I; Whitacre, C; Kithcart, A; Pruitt, J; Sielecki, T; Satoskar, AR; Rodriguez-Sosa, M				Sanchez-Zamora, Yuriko; Terrazas, Luis I.; Vilches-Flores, Alonso; Leal, Emmanuel; Juarez, Imelda; Whitacre, Caroline; Kithcart, Aaron; Pruitt, James; Sielecki, Thais; Satoskar, Abhay R.; Rodriguez-Sosa, Miriam			Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus	FASEB JOURNAL			English	Article						MIF; cytokines; type 2 diabetes	AUGSBURG CASE-COHORT; RHEUMATOID-ARTHRITIS; FACTOR MIF; GLUCOSE-METABOLISM; PROMOTER POLYMORPHISM; FACTOR GENE; CYTOKINE; MICE; DISEASE; ATHEROSCLEROSIS	Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine involved in the pathogenesis of a variety of autoimmune inflammatory diseases. Here, we investigated the role of MIF in the pathogenesis of non-insulin-dependent diabetes mellitus ( NIDDM) using MIF-/- mice and a mouse model of streptozotocin (STZ)-induced NIDDM. Following single injection of STZ, MIF-/- BALB/c mice showed a significant increase in blood glucose levels, developed polyuria, and succumbed to disease. In contrast, no such increase in blood glucose was observed in MIF-/- BALB/c mice treated with STZ. These mice produced significantly less inflammatory cytokines and resistin as compared with MIF-/- mice and failed to develop clinical disease. Finally, oral administration of a small-molecule MIF antagonist, CPSI-1306, to outbred ICR mice following induction of NIDDM significantly lowered blood glucose levels in the majority of animals, which was also associated with a significant reduction in the levels of the proinflammatory cytokines IL-6 and TNF-alpha in the sera. Taken together, these results demonstrate that MIF is involved in the pathogenesis of NIDDM and is a therapeutic target to treat this disease.-Sanchez- Zamora, Y., Terrazas, L.I., VilchesFlores, A., Leal, E., Juarez, I., Whitacre, C., Kithcart, A., Pruitt, J., Sielecki, T., Satoskar, A.R., Rodriguez-Sosa, M. Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. FASEB J. 24, 2583-2590 (2010). www.fasebj.org	[Satoskar, Abhay R.] Ohio State Univ, Med Ctr, Dept Pathol, Columbus, OH 43210 USA; [Sanchez-Zamora, Yuriko; Terrazas, Luis I.; Vilches-Flores, Alonso; Leal, Emmanuel; Juarez, Imelda; Whitacre, Caroline; Kithcart, Aaron; Rodriguez-Sosa, Miriam] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Sanchez-Zamora, Yuriko; Terrazas, Luis I.; Vilches-Flores, Alonso; Leal, Emmanuel; Juarez, Imelda; Rodriguez-Sosa, Miriam] Univ Nacl Autonoma Mexico, FES Iztacala, Unidad Biomed, Tlalnepantla 54090, Edo De Mexico, Mexico; [Pruitt, James; Sielecki, Thais] Cytokine PharmaSci, King Of Prussia, PA USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Universidad Nacional Autonoma de Mexico	Satoskar, AR (corresponding author), Ohio State Univ, Med Ctr, Dept Pathol, Columbus, OH 43210 USA.	satoskar.2@osu.edu; rodriguezm@campus.iztacala.unam.mx	Terrazas, Luis I/AAV-8858-2020; Vilches-Flores, Alonso/A-3225-2013; Satoskar, Abhay/AAB-7748-2019	Vilches-Flores, Alonso/0000-0001-6185-6257; Sanchez Zamora, Yuriko Itzel/0000-0002-0769-8523; Rodriguez-Sosa, Miriam/0000-0003-2911-9390; Terrazas, Luis I./0000-0003-1635-9467	Council of Science and Technology of Mexico (CONACYT) [49812-Q]; Programa de Apoyo a los Profesores de Carrera para la Formacion de Grupos de Investigacion (PAPCA)	Council of Science and Technology of Mexico (CONACYT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Programa de Apoyo a los Profesores de Carrera para la Formacion de Grupos de Investigacion (PAPCA)	This work was supported in part by grants from the Council of Science and Technology of Mexico (CONACYT) 49812-Q and Programa de Apoyo a los Profesores de Carrera para la Formacion de Grupos de Investigacion (PAPCA) Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autonoma de Mexico.	Adeghate E, 2004, CELL MOL LIFE SCI, V61, P2485, DOI 10.1007/s00018-004-4083-2; Alexandraki K, 2006, ANN NY ACAD SCI, V1084, P89, DOI 10.1196/annals.1372.039; Arner P, 2005, CURR MOL MED, V5, P333, DOI 10.2174/1566524053766022; Atsumi T, 2007, J IMMUNOL, V179, P5399, DOI 10.4049/jimmunol.179.8.5399; Ayoub S, 2008, NAT CLIN PRACT RHEUM, V4, P98, DOI 10.1038/ncprheum0701; Barnes KM, 2009, CURR PROTEIN PEPT SC, V10, P96, DOI 10.2174/138920309787315239; Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4; Baugh JA, 2002, GENES IMMUN, V3, P170, DOI 10.1038/sj.gene.6363867; Bojunga J, 2003, CYTOKINE, V21, P179, DOI 10.1016/S1043-4666(03)00076-0; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Burger-Kentischer A, 2002, CIRCULATION, V105, P1561, DOI 10.1161/01.CIR.0000012942.49244.82; Chen ZP, 2004, ARTERIOSCL THROM VAS, V24, P709, DOI 10.1161/01.ATV.0000119356.35748.9e; Crook M, 2004, DIABETIC MED, V21, P203, DOI 10.1046/j.1464-5491.2003.01030.x; Cvetkovic I, 2005, ENDOCRINOLOGY, V146, P2942, DOI 10.1210/en.2004-1393; de Jager W, 2007, ANN RHEUM DIS, V66, P589, DOI 10.1136/ard.2006.061853; de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720; Fain JN, 2006, VITAM HORM, V74, P443, DOI 10.1016/S0083-6729(06)74018-3; Goldstein BJ, 2002, AM J CARDIOL, V90, p3G; Hanifi-Moghaddam P, 2003, DIABETES, V52, P1137, DOI 10.2337/diabetes.52.5.1137; Hayashi K, 2006, BIOL PHARM BULL, V29, P1110, DOI 10.1248/bpb.29.1110; Herder C, 2008, DIABETOLOGIA, V51, P276, DOI 10.1007/s00125-007-0800-3; Herder C, 2006, DIABETES CARE, V29, P368, DOI 10.2337/diacare.29.02.06.dc05-1474; Herder C, 2008, ATHEROSCLEROSIS, V200, P380, DOI 10.1016/j.atherosclerosis.2007.12.025; Herder C, 2006, DIABETES, V55, P2340, DOI 10.2337/db05-1320; Hoi AY, 2006, J IMMUNOL, V177, P5687, DOI 10.4049/jimmunol.177.8.5687; Ito M, 2001, ENVIRON TOXICOL PHAR, V9, P71, DOI 10.1016/S1382-6689(00)00064-8; Ito M, 1999, BIOL PHARM BULL, V22, P988; Kochan Zdzislaw, 2003, Przegl Lek, V60, P40; Leech M, 1999, ARTHRITIS RHEUM, V42, P1601, DOI 10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B; McTernan PG, 2003, J CLIN ENDOCR METAB, V88, P6098, DOI 10.1210/jc.2003-030898; Mikulowska A, 1997, J IMMUNOL, V158, P5514; Mizue Y, 2005, P NATL ACAD SCI USA, V102, P14410, DOI 10.1073/pnas.0507189102; Mojiminiyi OA, 2007, SCAND J CLIN LAB INV, V67, P215, DOI 10.1080/00365510601032532; Morand EF, 2006, NAT REV DRUG DISCOV, V5, P399, DOI 10.1038/nrd2029; Morand EF, 2002, RHEUMATOLOGY, V41, P558, DOI 10.1093/rheumatology/41.5.558; Sakaue S, 2006, INT J OBESITY, V30, P238, DOI 10.1038/sj.ijo.0803148; Santos LL, 2009, CLIN CHIM ACTA, V399, P1, DOI 10.1016/j.cca.2008.09.014; Stosic-Grujicic S, 2008, J CELL PHYSIOL, V215, P665, DOI 10.1002/jcp.21346; Toso C, 2008, DIABETOLOGIA, V51, P1937, DOI 10.1007/s00125-008-1063-3; Vozarova B, 2002, DIABETOLOGIA, V45, P1739, DOI 10.1007/s00125-002-0896-4; Waeber G, 1997, P NATL ACAD SCI USA, V94, P4782, DOI 10.1073/pnas.94.9.4782; Waeber G, 1999, DIABETES-METAB RES, V15, P47, DOI 10.1002/(SICI)1520-7560(199901/02)15:1<47::AID-DMRR9>3.0.CO;2-J; Wang B, 2006, J IMMUNOL, V177, P5779, DOI 10.4049/jimmunol.177.9.5779	43	44	45	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2583	2590		10.1096/fj.09-147066	http://dx.doi.org/10.1096/fj.09-147066			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20203087				2022-12-28	WOS:000279343600045
J	Wang, HY; Moreau, F; Hirota, CL; MacNaughton, WK				Wang, Hongying; Moreau, France; Hirota, Christina L.; MacNaughton, Wallace K.			Proteinase-activated receptors induce interleukin-8 expression by intestinal epithelial cells through ERK/RSK90 activation and histone acetylation	FASEB JOURNAL			English	Article						inflammation; chemokine; epithelium; NF-kappa B; transcription	NF-KAPPA-B; INFLAMMATORY-BOWEL-DISEASE; NUCLEAR-LOCALIZATION; ULCERATIVE-COLITIS; OXIDATIVE STRESS; GENE-EXPRESSION; BETA-CATENIN; CANCER CELLS; PHOSPHORYLATION; MECHANISM	Proteinase-activated receptors (PARs) are involved in both inflammation and tumorigenesis in epithelial cells. Interleukin (IL)-8 is a potent chemoattractant and is also involved in angiogenesis. The molecular mechanism whereby PARs induce epithelial IL-8 expression is not known. In HT-29 colonic epithelial cells, PAR(1) or PAR(2) agonists stimulated the expression of IL-8 through a NF-kappa B-dependent pathway without inducing I kappa B degradation and disassociation of I kappa B from NF-kappa B. Further studies revealed that PAR activation induced the phosphorylation of p65 at Ser-276 in the nucleus, which increased the recruitment of histone acetyltransferase (HAT) p300 to p50. Inhibition of ERK activation completely blocked PAR-induced IL-8 expression, phosphorylation of p65 and HAT activity. We also demonstrated that RSK p90 was the downstream kinase that mediated ERK-induced nuclear p65 phosphorylation. In conclusion, activation of either PAR(1) or PAR(2) stimulated the transcriptional up-regulation of IL-8 in HT-29 colonic epithelial cells through a pathway that involved ERK/RSK p90, NF-kappa B phosphorylation, and HAT activity. These studies provide evidence of a new role for serine proteinases and PARs in the regulation of gene expression in colonic inflammation and tumorigenesis.-Wang, H., Moreau, F., Hirota, C. L., MacNaughton, W. K. Proteinase-activated receptors induce interleukin-8 expression by intestinal epithelial cells through ERK/RSK90 activation and histone acetylation. FASEB J. 24, 1971-1980 (2010). www.fasebj.org	[Moreau, France; Hirota, Christina L.; MacNaughton, Wallace K.] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB T2N 4N1, Canada; [Wang, Hongying; Moreau, France; Hirota, Christina L.; MacNaughton, Wallace K.] Univ Calgary, Inflammat Res Network, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	MacNaughton, WK (corresponding author), Univ Calgary, Dept Physiol & Pharmacol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	wmacnaug@ucalgary.ca	Hirota, Christina/AAS-8585-2020	Hirota, Christina/0000-0003-0799-2041; Wang, Hongying/0000-0001-8443-3839	Crohn's and Colitis Foundation of Canada (CCFC); CIHR; Canadian Association of Gastroenterology (CAG); CCFC; Abbott Laboratories	Crohn's and Colitis Foundation of Canada (CCFC); CIHR(Canadian Institutes of Health Research (CIHR)); Canadian Association of Gastroenterology (CAG); CCFC; Abbott Laboratories(Abbott Laboratories)	This work was supported by a grant from the Crohn's and Colitis Foundation of Canada (CCFC) to W.K.M. H.W. was the recipient of a postdoctoral award from the CIHR, the Canadian Association of Gastroenterology (CAG) and CCFC. C.L.H. was the recipient of a postdoctoral award from the CIHR, CAG and Abbott Laboratories. The authors gratefully acknowledge Dr. Andrew Keates (Beth Israel Deaconess Medical Center, Boston, MA, USA) and Dr. Joan Boyes (Leeds University, Leeds, UK) for providing the constructs for the IL-8 luciferase reporter and p300, respectively.	Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Asokananthan N, 2002, J IMMUNOL, V168, P3577, DOI 10.4049/jimmunol.168.7.3577; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brannigan AE, 2000, SHOCK, V13, P361, DOI 10.1097/00024382-200005000-00003; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chiu YC, 2008, MOL IMMUNOL, V45, P1587, DOI 10.1016/j.molimm.2007.10.004; Danese S, 2007, CURR MED CHEM, V14, P649, DOI 10.2174/092986707780059599; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; Grimm MC, 1996, GUT, V38, P90, DOI 10.1136/gut.38.1.90; Gunter MJ, 2006, CANCER EPIDEM BIOMAR, V15, P1126, DOI 10.1158/1055-9965.EPI-06-0042; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203; Hou L, 1998, IMMUNOLOGY, V94, P356, DOI 10.1046/j.1365-2567.1998.00528.x; IZZO RS, 1992, AM J GASTROENTEROL, V87, P1447; Jamaluddin M, 2007, CELL SIGNAL, V19, P1419, DOI 10.1016/j.cellsig.2007.01.020; Kefaloyianni E, 2006, CELL SIGNAL, V18, P2238, DOI 10.1016/j.cellsig.2006.05.004; Kim JA, 2003, INFLAMM BOWEL DIS, V9, P224, DOI 10.1097/00054725-200307000-00002; Koutroubakis IE, 2006, INFLAMM BOWEL DIS, V12, P515, DOI 10.1097/00054725-200606000-00012; LEBERRE N, 1995, J CLIN PATHOL, V48, P749, DOI 10.1136/jcp.48.8.749; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; MacNaughton WK, 2005, MEM I OSWALDO CRUZ, V100, P211, DOI 10.1590/S0074-02762005000900036; Mariadason JM, 2008, EPIGENETICS-US, V3, P28, DOI 10.4161/epi.3.1.5736; MAZZUCCHELLI L, 1994, AM J PATHOL, V144, P997; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; Nicholas C, 2007, J IMMUNOL, V179, P7121, DOI 10.4049/jimmunol.179.10.7121; Page K, 2005, AM J RESP CELL MOL, V32, P225, DOI 10.1165/rcmb.2004-0231OC; Rahman I, 2004, BIOCHEM PHARMACOL, V68, P1255, DOI 10.1016/j.bcp.2004.05.042; Rogler G, 1998, WORLD J SURG, V22, P382, DOI 10.1007/s002689900401; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; Tantivejkul K, 2005, J CELL BIOCHEM, V96, P641, DOI 10.1002/jcb.20533; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; Tomita K, 2003, BIOCHEM BIOPH RES CO, V301, P572, DOI 10.1016/S0006-291X(02)03029-2; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Vergnolle N, 2004, J CLIN INVEST, V114, P1444, DOI 10.1172/JCI200421689; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wang H, 2008, J BIOL CHEM, V283, P809, DOI 10.1074/jbc.M703021200; Wang HY, 2005, CANCER RES, V65, P8604, DOI 10.1158/0008-5472.CAN-05-1169; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zhang LP, 2005, ARTERIOSCL THROM VAS, V25, P1148, DOI 10.1161/01.ATV.0000164624.00099.e7; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200	48	33	33	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1971	1980		10.1096/fj.09-137646	http://dx.doi.org/10.1096/fj.09-137646			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20065107				2022-12-28	WOS:000278200000031
J	Ishimatsu-Tsuji, Y; Soma, T; Kishimoto, J				Ishimatsu-Tsuji, Yumiko; Soma, Tsutomu; Kishimoto, Jiro			Identification of novel hair-growth inducers by means of connectivity mapping	FASEB JOURNAL			English	Article						Cmap; microarray; hair follicle; cyclosporin; fluphenazine; iloprost	GENOMIC APPROACH; CYCLOSPORINE-A; STEM-CELLS; CYCLE; CANCER; GENES; INHIBITION; RESISTANCE; FOLLICLES; RAPAMYCIN	The aim of this study was to identify novel inducers of hair growth using gene expression profiling at various stages of hair-growth induction. First, we analyzed gene expression at the onset of hair growth in mice induced by cyclosporin A (CsA), a well-known hair-growth inducer, using DNA microarray analysis. The results unveiled genes involved in the step-by-step progression of hair growth, including increases in melanin biosynthesis and decreases in immune response at d 2 and the subsequent stimulation of cell proliferation at d 4, followed by the up-regulation of hair specific keratins at d 7 after CsA treatment. With the use of the connectivity map (Cmap), agents that had a similar "gene signature" to that of the profiles of CsA-treated mice were identified. Several agents, including CsA, were identified by the Cmap and were evaluated for hair induction activity in vivo. One of the proposed agents, fluphenazine (from the d 2 signature) actually induced hair growth in vivo (ED50: 2 mM for single application), and the subsequent application of 5 mM iloprost (from the d 4 signature) significantly enhanced the hair-growth effect of fluphenazine. From these results, Cmap analysis was proven to be a useful method that connects gene expression profiles of complicated biological processes, such as hair-growth induction, to effective agents.-Ishimatsu-Tsuji, Y., Soma, T., Kishimoto, J. Identification of novel hair-growth inducers by means of connectivity mapping. FASEB J. 24, 1489-1496 (2010). www.fasebj.org	[Kishimoto, Jiro] Shiseido Innovat Sci Res & Dev Ctr, Kanazawa Ku, Kanagawa 2368643, Japan	Shiseido Company, Limited	Kishimoto, J (corresponding author), Shiseido Innovat Sci Res & Dev Ctr, Kanazawa Ku, 2-12-1 Fukuura, Kanagawa 2368643, Japan.	jiro.kishimoto@to.shiseido.co.jp	KISHIMOTO, JIRO/AAD-7857-2019; Tsuji, Yumiko/AAV-9817-2020					Alonso L, 2006, J CELL SCI, V119, P391, DOI 10.1242/jcs02793; Botchkarev VA, 2003, J INVEST DERM SYMP P, V8, P46, DOI 10.1046/j.1523-1747.2003.12171.x; Christensen A V, 1985, Psychopharmacology Suppl, V2, P182; Gafter-Gvili A, 2003, AM J PHYSIOL-CELL PH, V284, pC1593, DOI 10.1152/ajpcell.00537.2002; Garman KS, 2008, P NATL ACAD SCI USA, V105, P19432, DOI 10.1073/pnas.0806674105; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; Hassane DC, 2008, BLOOD, V111, P5654, DOI 10.1182/blood-2007-11-126003; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Horsley V, 2008, CELL, V132, P299, DOI 10.1016/j.cell.2007.11.047; Ishimatsu-Tsuji Y, 2005, J INVEST DERMATOL, V125, P410, DOI 10.1111/j.0022-202X.2005.23825.x; IWABUCHI T, 1995, J DERMATOL SCI, V9, P64, DOI 10.1016/0923-1811(94)00351-E; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lin KK, 2004, P NATL ACAD SCI USA, V101, P15955, DOI 10.1073/pnas.0407114101; Mammucari C, 2005, DEV CELL, V8, P665, DOI 10.1016/j.devcel.2005.02.016; Michnick SW, 2006, NAT CHEM BIOL, V2, P663, DOI 10.1038/nchembio1206-663; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Olschewski H, 2002, NEW ENGL J MED, V347, P322, DOI 10.1056/NEJMoa020204; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PROZIALECK WC, 1982, J PHARMACOL EXP THER, V222, P509; Rendl M, 2005, PLOS BIOL, V3, P1910, DOI 10.1371/journal.pbio.0030331; Riedel RF, 2008, MOL CANCER THER, V7, P3141, DOI 10.1158/1535-7163.MCT-08-0642; Rosenbluth JM, 2008, MOL CELL BIOL, V28, P5951, DOI 10.1128/MCB.00305-08; Setlur SR, 2008, JNCI-J NATL CANCER I, V100, P815, DOI 10.1093/jnci/djn150; Wang SE, 2008, MOL CELL BIOL, V28, P5605, DOI 10.1128/MCB.00787-08; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; Zimmer M, 2008, MOL CELL, V32, P838, DOI 10.1016/j.molcel.2008.12.004	26	20	25	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1489	1496		10.1096/fj.09-145292	http://dx.doi.org/10.1096/fj.09-145292			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20026683				2022-12-28	WOS:000277158900021
J	Tamassia, N; Castellucci, M; Rossato, M; Gasperini, S; Bosisio, D; Giacomelli, M; Badolato, R; Cassatella, MA; Bazzoni, F				Tamassia, Nicola; Castellucci, Monica; Rossato, Marzia; Gasperini, Sara; Bosisio, Daniela; Giacomelli, Mauro; Badolato, Raffaele; Cassatella, Marco A.; Bazzoni, Flavia			Uncovering an IL-10-dependent NF-kappa B recruitment to the IL-1ra promoter that is impaired in STAT3 functionally defective patients	FASEB JOURNAL			English	Article						chromatin modification; inflammation; neutrophils; monocytes; transcription	INTERLEUKIN-1 RECEPTOR ANTAGONIST; HYPER-IGE SYNDROME; DNA-BINDING DOMAIN; GENE-EXPRESSION; HUMAN NEUTROPHILS; AUTOINFLAMMATORY DISEASE; HISTONE MODIFICATIONS; INTERFERON-GAMMA; HUMAN MONOCYTES; MOLECULAR-BASIS	The interleukin 1 receptor antagonist (IL-1ra) is an important negative regulator of the inflammatory response, whose genetic deficiency has been recently shown to cause a severe autoinflammatory syndrome in humans. In this study we characterized the molecular mechanisms whereby interleukin 10 (IL-10) potentiates IL-1ra transcription in LPS-stimulated monocytes and neutrophils. Using chromatin immunoprecipitation, we show that although NF-kappa Bp65 and NF-kappa Bp50 proteins accumulate into the nuclei and bind to the I kappa B alpha promoter during LPS stimulation, they are not recruited to the kappa B sites of the IL-1ra promoter. However, in response to LPS plus IL-10, which were found to induce chromatin acetylation, recruitment of both NF-kappa Bp65 and NF-kappa Bp50 to the IL-1ra promoter efficiently occurs in a STAT-3-dependent manner. Accordingly, in neutrophils from hyper-IgE syndrome patients, who carry a nonfunctional STAT3, IL-10 failed to promote NF-kappa Bp65 recruitment to the IL-1ra promoter and consequently to potentiate LPS-induced IL-1ra transcription. Altogether our findings uncover a novel mechanism whereby IL-10-activated STAT3 modulates IL-1ra transcription in LPS-treated phagocytes by making IL-1ra promoter accessible to readily available nuclear NF-kappa B.-Tamassia, N., Castellucci, M., Rossato, M., Gasperini, S., Bosisio, D., Giacomelli, M., Badolato, R., Cassatella, M. A., Bazzoni, F. Uncovering an IL-10-dependent NF-kappa B recruitment to the IL-1ra promoter that is impaired in STAT3 functionally defective patients. FASEB J. 24, 1365-1375 (2010). www.fasebj.org	[Tamassia, Nicola; Castellucci, Monica; Rossato, Marzia; Gasperini, Sara; Cassatella, Marco A.; Bazzoni, Flavia] Univ Verona, Div Gen Pathol, Dept Pathol, Verona, Italy; [Bosisio, Daniela] Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, Brescia, Italy; [Giacomelli, Mauro; Badolato, Raffaele] Univ Brescia, Inst Mol Med Angelo Nocivelli, Brescia, Italy; [Giacomelli, Mauro; Badolato, Raffaele] Univ Brescia, Dept Pediat, Brescia, Italy	University of Verona; University of Brescia; University of Brescia; University of Brescia	Bazzoni, F (corresponding author), Univ Verona, Div Gen Pathol, Dept Pathol, Str Grazie 8, Verona, Italy.	flavia.bazzoni@univr.it	Giacomelli, Mauro/AGX-9755-2022; Badolato, Raffaele/A-8081-2010; Bazzoni, Flavia/AAB-7674-2019; Tamassia, Nicola/J-8621-2016; Cassatella, M A/B-8037-2013; Rossato, Marzia/AAB-7827-2019	Badolato, Raffaele/0000-0001-7375-5410; Bazzoni, Flavia/0000-0001-6768-8012; Tamassia, Nicola/0000-0003-2990-3003; Cassatella, M A/0000-0001-7824-1806; Rossato, Marzia/0000-0002-6101-1550; BOSISIO, Daniela/0000-0001-6276-5365	Ministero dell'Istruzione, dell'Universita e della Ricerca [20083MNL5X_003, 2007ACZMMZ_005, 2007H9AWXY]; Fondazione Cariverona; Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 5839]; Fondazione Cariplo; EU [201461]; European Research Project on Rare Diseases (eRARE)	Ministero dell'Istruzione, dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); Fondazione Cariverona(Fondazione Cariverona); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Cariplo(Fondazione Cariplo); EU(European Commission); European Research Project on Rare Diseases (eRARE)	This work was supported by grants from Ministero dell'Istruzione, dell'Universita e della Ricerca (PRIN Anno 2006 prot. 20083MNL5X_003, 2007 prot. 2007ACZMMZ_005, and prot. 2007H9AWXY), the Fondazione Cariverona, the Associazione Italiana per la Ricerca sul Cancro (AIRC; IG 5839), the Fondazione Cariplo (Nobel project), EU grant FP7 HLH cure (project 201461), and the European Research Project on Rare Diseases (eRARE). We thank Dr. Rene de Waal Malefyt (Schering-Plough Biopharma, Palo Alto, CA, USA) for kindly providing recombinant human IL-10. The authors have no conflicting financial interests.	Aalfs JD, 2000, TRENDS BIOCHEM SCI, V25, P548, DOI 10.1016/S0968-0004(00)01689-3; Aksentijevich I, 2009, NEW ENGL J MED, V360, P2426, DOI 10.1056/NEJMoa0807865; Carl VS, 2004, J LEUKOCYTE BIOL, V76, P735, DOI 10.1189/jlb.1003526; Cassatella MA, 2005, EUR J IMMUNOL, V35, P1877, DOI 10.1002/eji.200526088; CASSATELLA MA, 1990, J BIOL CHEM, V265, P20241; CASSATELLA MA, 1994, J EXP MED, V179, P1695, DOI 10.1084/jem.179.5.1695; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; CONSTANTIN G, 1994, FEBS LETT, V350, P66, DOI 10.1016/0014-5793(94)00735-7; Crepaldi L, 2002, INT IMMUNOL, V14, P1145, DOI 10.1093/intimm/dxf079; Crepaldi L, 2001, J IMMUNOL, V167, P2312, DOI 10.4049/jimmunol.167.4.2312; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; Hagihara K, 2005, GENES CELLS, V10, P1051, DOI 10.1111/j.1365-2443.2005.00900.x; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; Heimall J, 2010, CLIN REV ALLERG IMMU, V38, P32, DOI 10.1007/s12016-009-8134-1; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; JENKINS JK, 1994, LYMPHOKINE CYTOK RES, V13, P47; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; McDonald PP, 1998, BIOCHEMISTRY-US, V37, P13165, DOI 10.1021/bi972539o; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Natoli G, 2006, FEBS LETT, V580, P2843, DOI 10.1016/j.febslet.2006.02.072; Paulson ML, 2008, CURR OPIN ALLERGY CL, V8, P527, DOI 10.1097/ACI.0b013e3283184210; Reddy S, 2009, NEW ENGL J MED, V360, P2438, DOI 10.1056/NEJMoa0809568; Rossato M, 2007, EUR J IMMUNOL, V37, P3176, DOI 10.1002/eji.200737625; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; SMITH MF, 1994, J IMMUNOL, V153, P3584; Smith MF, 1998, J BIOL CHEM, V273, P24272, DOI 10.1074/jbc.273.37.24272; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707; Yoshida Y, 2004, J BIOL CHEM, V279, P1768, DOI 10.1074/jbc.M311498200; Yu ZY, 2004, J AM SOC NEPHROL, V15, P585, DOI 10.1097/01.ASN.0000114556.19556.F9; Yu ZY, 2002, BIOCHEM J, V367, P97, DOI 10.1042/BJ20020588	39	33	35	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1365	1375		10.1096/fj.09-145573	http://dx.doi.org/10.1096/fj.09-145573			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20032313				2022-12-28	WOS:000277158900010
J	Abdo, H; Derkinderen, P; Gomes, P; Chevalier, J; Aubert, P; Masson, D; Galmiche, JP; Vanden Berghe, P; Neunlist, M; Lardeux, B				Abdo, Hind; Derkinderen, Pascal; Gomes, Priya; Chevalier, Julien; Aubert, Philippe; Masson, Damien; Galmiche, Jean-Paul; Vanden Berghe, Pieter; Neunlist, Michel; Lardeux, Bernard			Enteric glial cells protect neurons from oxidative stress in part via reduced glutathione	FASEB JOURNAL			English	Article						enteric nervous system; neuronal death; neuroprotection; active caspase 3	SLOW-TRANSIT CONSTIPATION; ADULT TRANSGENIC MICE; NERVOUS-SYSTEM; MYENTERIC NEURONS; ASTROCYTES; EXPRESSION; SURVIVAL; ABLATION; DISEASE; NEUROPATHOLOGY	Enteric glial cells (EGCs) are essential in the control of gastrointestinal functions. Although lesions of EGCs are associated with neuronal degeneration in animal models, their direct neuroprotective role remains unknown. Therefore, the aims of this study were to demonstrate the direct neuroprotective effects of EGCs and to identify putative glial mediators involved. First, viral targeted ablation of EGCs in primary cultures of enteric nervous system increased neuronal death both under basal conditions and in the presence of oxidative stress (dopamine, hydrogen peroxide). Second, direct or indirect coculture experiments of EGC lines with primary cultures of enteric nervous system or neuroblastoma cell lines (SH-SY5Y) prevented neurotoxic effects induced by oxidative stress (increased membrane permeability, release of neuronal specific enolase, caspase-3 immunoreactivity, changes in [Ca(2+)](i) response). Finally, combining pharmacological inhibition and mRNA silencing methods, we demonstrated that neuroprotective effects of EGCs were mediated in part by reduced glutathione but not by oxidized glutathione or by S-nitrosoglutathione. Our study identified the neuroprotective effects of EGCs via their release of reduced glutathione, extending their critical role in physiological contexts and in enteric neuropathies.-Abdo, H., Derkinderen, P., Gomes, P., Chevalier, J., Aubert, P., Masson, D., Galmiche, J.-P., Vanden Berghe, P., Neunlist, M., Lardeux, B. Enteric glial cells protect neurons from oxidative stress in part via reduced glutathione. FASEB J. 24, 1082-1094 (2010). www.fasebj.org	[Abdo, Hind; Derkinderen, Pascal; Chevalier, Julien; Aubert, Philippe; Masson, Damien; Galmiche, Jean-Paul; Neunlist, Michel; Lardeux, Bernard] INSERM, U913, F-44093 Nantes, France; [Abdo, Hind; Derkinderen, Pascal; Chevalier, Julien; Aubert, Philippe; Masson, Damien; Galmiche, Jean-Paul; Neunlist, Michel; Lardeux, Bernard] Univ Nantes, Fac Med, Nantes, France; [Abdo, Hind; Derkinderen, Pascal; Gomes, Priya; Chevalier, Julien; Aubert, Philippe; Masson, Damien; Galmiche, Jean-Paul; Neunlist, Michel; Lardeux, Bernard] CHU Nantes, Inst Malad Appareil Digestif, F-44035 Nantes 01, France; [Derkinderen, Pascal; Neunlist, Michel] CHU Nantes, Serv Neurol, F-44035 Nantes 01, France; [Gomes, Priya; Vanden Berghe, Pieter] Katholieke Univ Leuven, Ctr Gastroenterol Res, Leuven, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; KU Leuven	Lardeux, B (corresponding author), INSERM, U913, 1 Pl Alexis Ricordeau, F-44093 Nantes, France.	bernard.lardeux@univ-nantes.fr	Neunlist, Michel/K-2388-2015; Chevalier, Julien/K-2345-2015; Derkinderen, Pascal/K-2393-2015; Aubert, Philippe/K-2352-2015; Masson, Damien/K-2730-2015	Chevalier, Julien/0000-0002-7484-1457; Aubert, Philippe/0000-0001-7471-7694; Aubert, Philippe/0000-0002-3126-6202; Abdo, Hind/0000-0002-6910-9165; Vanden Berghe, Pieter/0000-0002-0009-2094	Centre National de la Recherche Scientifique (CNRS)	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS))	H. A. was supported by a grant from Inserm Pays de la Loire and SanTDige Foundation. M.N. and P.D. were supported by a contrat d'interface Inserm. B.L. is funded by the Centre National de la Recherche Scientifique (CNRS).	Anitha M, 2006, J CLIN INVEST, V116, P344, DOI 10.1172/JCI26295; Anitha M, 2006, GASTROENTEROLOGY, V131, P1164, DOI 10.1053/j.gastro.2006.07.019; Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825; Aube AC, 2006, GUT, V55, P630, DOI 10.1136/gut.2005.067595; Bassotti G, 2006, GUT, V55, P41, DOI 10.1136/gut.2005.073197; Bassotti G, 2005, J CLIN PATHOL, V58, P973, DOI 10.1136/jcp.2005.026112; Bassotti G, 2007, LAB INVEST, V87, P628, DOI 10.1038/labinvest.3700564; Bassotti G, 2006, HUM PATHOL, V37, P1252, DOI 10.1016/j.humpath.2006.04.027; Benarroch EE, 2007, NEUROLOGY, V69, P1953, DOI 10.1212/01.wnl.0000281999.56102.b5; Boulos S, 2006, BRAIN RES, V1102, P27, DOI 10.1016/j.brainres.2006.04.089; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Bush TG, 1998, CELL, V93, P189, DOI 10.1016/S0092-8674(00)81571-8; Chevalier J, 2008, J PHYSIOL-LONDON, V586, P1963, DOI 10.1113/jphysiol.2007.149815; Cornet A, 2001, P NATL ACAD SCI USA, V98, P13306, DOI 10.1073/pnas.231474098; Cui W, 2001, GLIA, V34, P272, DOI 10.1002/glia.1061; Desagher S, 1996, J NEUROSCI, V16, P2553; Diaz-Hernandez JI, 2005, J BIOL CHEM, V280, P38992, DOI 10.1074/jbc.M507065200; FERRI GL, 1982, NATURE, V297, P409, DOI 10.1038/297409a0; FRANK KB, 1984, J BIOL CHEM, V259, P1566; GABELLA G, 1981, NEUROSCIENCE, V6, P425, DOI 10.1016/0306-4522(81)90135-4; Gomes P, 2009, NEUROGASTROENT MOTIL, V21, P870, DOI 10.1111/j.1365-2982.2009.01302.x; Gulbransen BD, 2009, GASTROENTEROLOGY, V136, P1349, DOI 10.1053/j.gastro.2008.12.058; HEYMAN RA, 1989, P NATL ACAD SCI USA, V86, P2698, DOI 10.1073/pnas.86.8.2698; JESSEN KR, 1980, NATURE, V286, P736, DOI 10.1038/286736a0; Koch TR, 1997, NEUROSCI LETT, V235, P77, DOI 10.1016/S0304-3940(97)00726-X; Moriez R, 2009, BIOCHEM BIOPH RES CO, V382, P577, DOI 10.1016/j.bbrc.2009.03.073; Neunlist M, 2008, J INTERN MED, V263, P577, DOI 10.1111/j.1365-2796.2008.01963.x; Neunlist M, 2007, AM J PHYSIOL-GASTR L, V292, pG231, DOI 10.1152/ajpgi.00276.2005; Neunlist M, 2003, GUT, V52, P84, DOI 10.1136/gut.52.1.84; Ruhl A, 2001, NEUROGASTROENT MOTIL, V13, P95, DOI 10.1046/j.1365-2982.2001.00246.x; Savidge TC, 2007, LAB INVEST, V87, P731, DOI 10.1038/labinvest.3700600; Savidge TC, 2007, GASTROENTEROLOGY, V132, P1344, DOI 10.1053/j.gastro.2007.01.051; Schemann M, 2004, NEUROGASTROENT MOTIL, V16, P55, DOI 10.1111/j.1743-3150.2004.00476.x; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Selgrad M, 2009, GUT, V58, P25, DOI 10.1136/gut.2008.152512; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; von Boyen GBT, 2006, J NEUROENDOCRINOL, V18, P820, DOI 10.1111/j.1365-2826.2006.01478.x; Yang XG, 2000, BBA-GEN SUBJECTS, V1474, P390, DOI 10.1016/S0304-4165(00)00035-0; Zandecki M, 2006, NEUROGASTROENT MOTIL, V18, P307, DOI 10.1111/j.1365-2982.2005.00755.x	40	74	74	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2010	24	4					1082	1094		10.1096/fj.09-139519	http://dx.doi.org/10.1096/fj.09-139519			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19906678	Bronze			2022-12-28	WOS:000276462300016
J	Meng, Y; Eshghi, S; Li, YJ; Schmidt, R; Schaffer, DV; Healy, KE				Meng, Ying; Eshghi, Shawdee; Li, Ying J.; Schmidt, Ray; Schaffer, David V.; Healy, Kevin E.			Characterization of integrin engagement during defined human embryonic stem cell culture	FASEB JOURNAL			English	Article						extracellular matrix; Matrigel; peptide; microenvironment; biointerface; cell adhesion; feeder-free cell culture	LAMININ ALPHA-1 CHAIN; SELF-RENEWAL; UNDIFFERENTIATED GROWTH; VITRONECTIN RECEPTOR; SYNTHETIC PEPTIDES; HUMAN BLASTOCYSTS; IN-VITRO; G-DOMAIN; DIFFERENTIATION; ADHESION	Human embryonic stem (hES) cells are pluripotent, capable of differentiating into any cell type of the body, and therefore have the ability to provide insights into mechanisms of human development and disease, as well as to provide a potentially unlimited supply of cells for cell-based therapy and diagnostics. Knowledge of the adhesion receptors that hES cells employ to engage extracellular matrix (ECM) proteins is of basic biological interest and can enhance the design of cell culture and implantation systems to enable these biomedical applications. Although hES cells express a variety of cell surface receptors, little is known about which integrins are involved during subculture and passage. Matrigel is broadly used as a cell adhesive matrix for hES cell culture. Here, we sought to identify which integrins hES cells exploit for adhesion to Matrigel-coated surfaces in defined medium conditions. Using RT-PCR, flow cytometry, and fluorescence immunochemistry, we found that numerous integrins were expressed by H1 hES cells; however, antibody blocking assays indicated that only alpha(v)beta(3), alpha(6), beta(1), and alpha(2)beta(1) played a significant role in the initial adhesion of the hES cells to Matrigel in defined medium conditions. We subsequently identified a cohort of synthetic peptides that, when adsorbed to the culture surface, promoted H1 hES cell attachment and proliferation, as well as maintained a pluripotent phenotype. Peptides designed to engage with alpha(v)beta(3), alpha(6), beta(1), and alpha(2)beta(1) integrins and syndecan-1 were tested both individually and in various combinations. A combination of two integrin-engaging peptides (AG-10, C-16) and one syndecan-engaging peptide (AG-73) was sufficient to promote hES cell adhesion, maintenance, and proliferation. We propose that a specific integrin "fingerprint" is necessary for maintenance of hES cell self-renewal, and synthetic culture systems must capture this engagement profile for hES cells to remain undifferentiated.-Meng, Y., Eshghi, S., Li, Y. J., Schmidt, R., Schaffer, D. V., Healy, K. E. Characterization of integrin engagement during defined human embryonic stem cell culture. FASEB J. 24, 1056-1065 (2010). www.fasebj.org	[Schaffer, David V.; Healy, Kevin E.] Univ Calif Berkeley, Dept Mat Sci & Engn, Berkeley, CA 94720 USA; [Meng, Ying; Eshghi, Shawdee; Li, Ying J.; Schmidt, Ray; Schaffer, David V.; Healy, Kevin E.] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; [Eshghi, Shawdee; Schaffer, David V.] Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA; [Schaffer, David V.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Healy, KE (corresponding author), Univ Calif Berkeley, Dept Mat Sci & Engn, 370 Hearst Mem Min Bldg 1760, Berkeley, CA 94720 USA.	kehealy@berkeley.edu			University of California Discovery [bio06-10597]; U.S. National Institutes of Health; NIH [R21DE18044, R21DE018044, R01GM085754]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE018044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM085754] Funding Source: NIH RePORTER	University of California Discovery(University of California System); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by the University of California Discovery Grant program (bio06-10597) and Geron Corporation (Menlo Park, CA, USA), as well as by U.S. National Institutes of Health grants NIH R21DE18044, R21DE018044, and R01GM085754.The authors thank Elizabeth Irwin and Eric Jabart (University of California-Berkeley) for their critical reading of the manuscript.The authors thank Kiichiro Tomoda and Shinya Yamanaka (Gladstone Institute of Cardiovascular Disease, San Francisco, CA, USA) for the pluripotency and germ layer marker PCR primers and reaction conditions.Y.M., S.E., and Y.J.L.were responsible for collection and/or assembly of data, data analysis and interpretation, and manuscript writing.R.S.was responsible for collection and/or assembly of data, and manuscript writing. D.V.S.was responsible for conception and design, financial support, data analysis and interpretation, and manuscript writing.K.E.H.was responsible for conception and design, financial support, data analysis and interpretation, manuscript writing, and final approval of manuscript.	Adjaye J, 2005, STEM CELLS, V23, P1514, DOI 10.1634/stemcells.2005-0113; Beattie GM, 2005, STEM CELLS, V23, P489, DOI 10.1634/stemcells.2004-0279; Brandenberger R, 2004, NAT BIOTECHNOL, V22, P707, DOI 10.1038/nbt971; Chase LG, 2007, CURR OPIN CHEM BIOL, V11, P367, DOI 10.1016/j.cbpa.2007.06.421; Cheng LZ, 2003, STEM CELLS, V21, P131, DOI 10.1634/stemcells.21-2-131; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; Derda R, 2007, ACS CHEM BIOL, V2, P347, DOI 10.1021/cb700032u; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Fletcher JM, 2006, CLONING STEM CELLS, V8, P319, DOI 10.1089/clo.2006.8.319; Genbacev O, 2005, FERTIL STERIL, V83, P1517, DOI 10.1016/j.fertnstert.2005.01.086; Hansen KC, 2009, MOL CELL PROTEOMICS, V8, P1648, DOI 10.1074/mcp.M900039-MCP200; Hayashi Y, 2007, STEM CELLS, V25, P3005, DOI 10.1634/stemcells.2007-0103; HIERCK BP, 1993, CELL ADHES COMMUN, V1, P1; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hoffman MP, 2001, J BIOL CHEM, V276, P22077, DOI 10.1074/jbc.M100774200; HOGERVORST F, 1993, J CELL BIOL, V121, P179, DOI 10.1083/jcb.121.1.179; HORTON M, 1990, INT J EXP PATHOL, V71, P741; Ilic D, 1998, J CELL BIOL, V143, P547; Ingber DE, 2003, J CELL SCI, V116, P1397, DOI 10.1242/jcs.00360; KLEINMAN HK, 1979, J SUPRAMOL STR CELL, V11, P69, DOI 10.1002/jss.400110108; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; Leahy A, 1999, J EXP ZOOL, V284, P67, DOI 10.1002/(SICI)1097-010X(19990615)284:1&lt;67::AID-JEZ10&gt;3.0.CO;2-O; Li XJ, 2006, METH MOL B, V331, P169; Li Y, 2005, BIOTECHNOL BIOENG, V91, P688, DOI 10.1002/bit.20536; Li YJ, 2006, J BIOMED MATER RES A, V79A, P1, DOI 10.1002/jbm.a.30732; Liu YX, 2006, BIOCHEM BIOPH RES CO, V346, P131, DOI 10.1016/j.bbrc.2006.05.086; Ludwig TE, 2006, NAT BIOTECHNOL, V24, P185, DOI 10.1038/nbt1177; Ludwig TE, 2006, NAT METHODS, V3, P637, DOI 10.1038/NMETH902; Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181; Miura T, 2004, STEM CELLS DEV, V13, P694, DOI 10.1089/scd.2004.13.694; Nakahara H, 1996, J BIOL CHEM, V271, P27221, DOI 10.1074/jbc.271.44.27221; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Ponce ML, 2001, FASEB J, V15, P1389, DOI 10.1096/fj.00-0736com; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Rezania A, 1999, J ORTHOPAED RES, V17, P615, DOI 10.1002/jor.1100170423; Richards M, 2002, NAT BIOTECHNOL, V20, P933, DOI 10.1038/nbt726; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SMITH JW, 1990, J BIOL CHEM, V265, P2168; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; Tanentzapf G, 2007, NAT CELL BIOL, V9, P1413, DOI 10.1038/ncb1660; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Xiao L, 2006, STEM CELLS, V24, P1476, DOI 10.1634/stemcells.2005-0299; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Yao S, 2006, P NATL ACAD SCI USA, V103, P6907, DOI 10.1073/pnas.0602280103	50	84	90	0	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1056	1065		10.1096/fj.08-126821	http://dx.doi.org/10.1096/fj.08-126821			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19933311	Green Published			2022-12-28	WOS:000276462300013
J	Venturini, C; Beatson, SA; Djordjevic, SP; Walker, MJ				Venturini, Carola; Beatson, Scott A.; Djordjevic, Steven P.; Walker, Mark J.			Multiple antibiotic resistance gene recruitment onto the enterohemorrhagic Escherichia coli virulence plasmid	FASEB JOURNAL			English	Article						EHEC; enterohemolysin; Tn21	ANTIMICROBIAL RESISTANCE; STRAINS; REGION; SIMILARITY; INTEGRONS; ANIMALS; SITE; IDENTIFICATION; VISUALIZATION; TRANSPOSON	Enterohemorrhagic Escherichia coli (EHEC) strains are zoonotic pathogens responsible for a range of severe human disease. The repertoire of virulence determinants promoting EHEC disease is encoded on both the main chromosome and virulence plasmid. We examined a multiply antibiotic-resistant O26 EHEC strain for carriage of resistance genes on the virulence plasmid. The EHEC virulence plasmid containing a complex antibiotic-resistance gene locus, designated as pO26-CRL, was purified from EHEC O26:H- (patient with hemorrhagic colitis) and subjected to shotgun-sequencing and bioinformatic analysis. Determination of the 111,481-bp sequence of pO26-CRL revealed genes encoding a functional enterohemolysin operon (ehxCABD), STEC-specific extracellular serine protease (espP), putative EHEC adhesin (toxB), catalase/peroxidase (katP), and myristoyl transferase (msbB) involved in lipid A synthesis. A 22,609-bp Tn21 derivative is inserted within the conjugal transfer gene traC and encodes resistance to trimethoprim, streptomycin, sulfathiozole, kanamycin, neomycin, beta-lactams, and mercuric chloride. Plasmid pO26-CRL is nonconjugative but is mobilizable. This is the first report of an EHEC virulence plasmid containing a complex antibiotic resistance locus, and raises the concern that antibiotic use will coselect for virulence determinants, leading to increased disease potential in both commensal and pathogenic E. coli populations.-Venturini, C., Beatson, S. A., Djordjevic, S. P., Walker, M. J. Multiple antibiotic resistance gene recruitment onto the enterohemorrhagic Escherichia coli virulence plasmid. FASEB J. 24, 1160-1166 (2010). www.fasebj.org	[Venturini, Carola; Walker, Mark J.] Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; [Beatson, Scott A.; Walker, Mark J.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia; [Djordjevic, Steven P.] NSW Dept Primary Ind, Menangle, NSW, Australia; [Djordjevic, Steven P.] Univ Technol Sydney, Inst Biotechnol Infect Dis, Sydney, NSW 2007, Australia	University of Wollongong; University of Queensland; NSW Department of Primary Industries; University of Technology Sydney	Walker, MJ (corresponding author), Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia.	mwalker@uow.edu.au	Djordjevic, Steven/A-2024-2013; Venturini, Carola/G-6642-2018; Walker, Mark J./F-6940-2011; Beatson, Scott/B-6985-2013; djordjevic, steven/GNP-4000-2022	Djordjevic, Steven/0000-0001-9301-5372; Venturini, Carola/0000-0003-2370-8661; Beatson, Scott/0000-0002-1806-3283; djordjevic, steven/0000-0001-9301-5372; Walker, Mark/0000-0001-7423-2769	Australian Research Council (ARC) [LP0348851]; ARC Australian Research Fellowship [DP0881247]; New South Wales (NSW) Department of Primary Industries; University of Wollongong; Australian Genome Research Foundation	Australian Research Council (ARC)(Australian Research Council); ARC Australian Research Fellowship(Australian Research Council); New South Wales (NSW) Department of Primary Industries; University of Wollongong; Australian Genome Research Foundation	The authors acknowledge the financial support of the Australian Research Council (ARC) for provision of a Ph.D.scholarship (C.V.) and research support provided through the ARC Linkage system (LP0348851).S.A.B.is supported by an ARC Australian Research Fellowship (DP0881247).The authors also acknowledge the financial support of the New South Wales (NSW) Department of Primary Industries (S.P.D.) and the University of Wollongong (M.J.W.).The authors thank Dr.Karl Bettelheim [Microbiological Diagnostic Unit (MDU), University of Melbourne, Melbourne, VIC, Australia], for the provision of E.coli strain O6877.The MDU is supported by the Victorian Department of Human Services.The authors acknowledge the technical support provided by the Australian Genome Research Foundation and by Linda Falconer (NSW Department of Primary Industries).The authors also thank Lowan Turton for photographic images.	Aldick T, 2007, MICROBES INFECT, V9, P282, DOI 10.1016/j.micinf.2006.12.001; Appleman SS, 2009, CLIN PEDIATR, V48, P99, DOI 10.1177/0009922808321901; Arias CA, 2009, NEW ENGL J MED, V360, P439, DOI 10.1056/NEJMp0804651; Bettelheim KA, 2003, J MED MICROBIOL, V52, P155, DOI 10.1099/jmm.0.04903-0; Beutin L, 2004, J CLIN MICROBIOL, V42, P1099, DOI 10.1128/JCM.42.3.1099-1108.2004; Bielaszewska M, 2005, J CLIN MICROBIOL, V43, P4225, DOI 10.1128/JCM.43.8.4225-4228.2005; Brunder W, 1996, MICROBIOL-SGM, V142, P3305, DOI 10.1099/13500872-142-11-3305; Brunder W, 1997, MOL MICROBIOL, V24, P767, DOI 10.1046/j.1365-2958.1997.3871751.x; Carattoli A, 2009, ANTIMICROB AGENTS CH, V53, P2227, DOI 10.1128/AAC.01707-08; Carver TJ, 2005, BIOINFORMATICS, V21, P3422, DOI 10.1093/bioinformatics/bti553; d'Hauteville H, 2002, J IMMUNOL, V168, P5240, DOI 10.4049/jimmunol.168.10.5240; Djafari S, 1997, MOL MICROBIOL, V25, P771, DOI 10.1046/j.1365-2958.1997.5141874.x; *EASAC REP, 2007, TACKL ANT RES EUR; Fey PD, 2000, NEW ENGL J MED, V342, P1242, DOI 10.1056/NEJM200004273421703; FURUYA N, 1991, J BACTERIOL, V173, P6612, DOI 10.1128/jb.173.20.6612-6617.1991; Guerra B, 2006, J ANTIMICROB CHEMOTH, V57, P1210, DOI 10.1093/jac/dkl127; HALL RM, 1995, MOL MICROBIOL, V15, P593, DOI 10.1111/j.1365-2958.1995.tb02368.x; Jenkins C, 2008, J APPL MICROBIOL, V104, P14, DOI 10.1111/j.1365-2672.2007.03465.x; KARCH H, 1987, INFECT IMMUN, V55, P455, DOI 10.1128/IAI.55.2.455-461.1987; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kim SH, 2004, INFECT IMMUN, V72, P1174, DOI 10.1128/IAI.72.2.1174-1180.2004; KIM SR, 1993, J BACTERIOL, V175, P5035, DOI 10.1128/JB.175.16.5035-5042.1993; Levings RS, 2008, ANTIMICROB AGENTS CH, V52, P2529, DOI 10.1128/AAC.00189-08; Leyton DL, 2003, INFECT IMMUN, V71, P6307, DOI 10.1128/IAI.71.11.6307-6319.2003; Liebert CA, 1999, MICROBIOL MOL BIOL R, V63, P507, DOI 10.1128/MMBR.63.3.507-522.1999; Maidhof H, 2002, APPL ENVIRON MICROB, V68, P5834, DOI 10.1128/AEM.68.12.5834-5842.2002; Makino K, 1998, DNA Res, V5, P1, DOI 10.1093/dnares/5.1.1; Martinez JL, 2002, CLIN MICROBIOL REV, V15, P647, DOI 10.1128/CMR.15.4.647-679.2002; Miriagou V, 2005, ANTIMICROB AGENTS CH, V49, P3541, DOI 10.1128/AAC.49.8.3541-3543.2005; Newton HJ, 2009, EMERG INFECT DIS, V15, P372, DOI [10.3201/eid1502.080631, 10.3201/eid1503.080631]; Partridge SR, 2004, ANTIMICROB AGENTS CH, V48, P4250, DOI 10.1128/AAC.48.11.4250-4255.2004; Paton AW, 1998, J CLIN MICROBIOL, V36, P598, DOI 10.1128/JCM.36.2.598-602.1998; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schluter A, 2003, MICROBIOL-SGM, V149, P3139, DOI 10.1099/mic.0.26570-0; Schroeder CM, 2002, EMERG INFECT DIS, V8, P1409, DOI 10.3201/eid0812.0200770; Sherley M, 2004, MICROBIOL-SGM, V150, P1539, DOI 10.1099/mic.0.26773-0; Singer RS, 2003, LANCET INFECT DIS, V3, P47, DOI 10.1016/S1473-3099(03)00490-0; Singh R, 2005, J ANTIMICROB CHEMOTH, V56, P216, DOI 10.1093/jac/dki161; Sota M, 2007, J BACTERIOL, V189, P3091, DOI 10.1128/JB.01906-06; STOKES HW, 1989, MOL MICROBIOL, V3, P1669, DOI 10.1111/j.1365-2958.1989.tb00153.x; Stothard P, 2005, BIOINFORMATICS, V21, P537, DOI 10.1093/bioinformatics/bti054; Szczepanowski R, 2005, MICROBIOL-SGM, V151, P1095, DOI 10.1099/mic.0.27773-0; Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2; Tatsuno I, 2001, INFECT IMMUN, V69, P6660, DOI 10.1128/IAI.69.11.6660-6669.2001; Torres AG, 2005, INFECT IMMUN, V73, P18, DOI 10.1128/IAI.73.1.18-29.2005; Toukdarian A, 2004, PLASMID BIOLOGY, P259; Tozzi AE, 2003, EMERG INFECT DIS, V9, P106, DOI 10.3201/eid0901.020266; Tozzoli R, 2005, J CLIN MICROBIOL, V43, P4052, DOI 10.1128/JCM.43.8.4052-4056.2005; WALKER MJ, 1987, ARCH MICROBIOL, V146, P390, DOI 10.1007/BF00410941	50	62	64	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1160	1166		10.1096/fj.09-144972	http://dx.doi.org/10.1096/fj.09-144972			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19917674				2022-12-28	WOS:000276462300023
J	Wang, AX; Alimova, IN; Luo, PH; Jong, A; Triche, TJ; Wu, LT				Wang, Anxun; Alimova, Irina N.; Luo, Peihua; Jong, Ambrose; Triche, Timothy J.; Wu, Lingtao			Loss of CAK phosphorylation of RAR alpha mediates transcriptional control of retinoid-induced cancer cell differentiation	FASEB JOURNAL			English	Article						decreased CAK activity by RA; cell cycle G(1) exit; gene transcription; transcriptional repression	CDK-ACTIVATING KINASE; F9 CELLS; GRANULOCYTIC DIFFERENTIATION; SUBSTRATE-SPECIFICITY; MYELOID-LEUKEMIA; ACID RECEPTORS; G(1) ARREST; BINDING; EXPRESSION; TFIIH	Although the role of the classic retinoic acid (RA)-induced genomic pathway in cancer cell differentiation is well recognized, the underlying mechanisms remain to be dissected. Retinoic acid receptor alpha (RAR alpha) is a transcription factor activated by RA, and its serine 77 (RAR alpha S77) is the main residue phosphorylated by the cyclin-dependent kinase (CDK)-activating kinase (CAK) complex. We report here that in both human myeloid leukemia and mouse embryonic teratocarcinoma stem cells, either RA-suppressed CAK phosphorylation of RAR alpha or mutation of RAR alpha S77 to alanine (RAR alpha S77A)coordinates CAK-dependent G(1) arrest with cancer cell differentiation by transactivating RA-target genes. Both hypophosphorylated RAR alpha and RAR alpha S77A reduce binding to retinoic acid-responsive elements (RARE) in the promoters of RA-target genes while stimulating gene transcription. The enhanced transactivation and reduced RAR alpha-chromatin interaction are accompanied by RAR alpha dissociation from the transcriptional repressor N-CoR and are association with the coactivator NCoA-3. Such effects of decreased CAK phosphorylation of RAR alpha S77 on mediating RA-dependent transcriptional control of cancer cell differentiation are examined correspondingly in both RA-resistant myeloid leukemia and embryonic teratocarcinoma stem RAR alpha(-/-) cells. These studies demonstrate, for the first time, that RA couples G(1) arrest to transcriptional control of cancer cell differentiation by suppressing CAK phosphorylation of RAR alpha to release transcriptional repression.-Wang, A., Alimova, I. N., Luo, P. Jong, A., Triche, T. J., Wu, L. Loss of CAK phosphorylation of RAR alpha mediates transcriptional control of retinoid-induced cancer cell differentiation. FASEB J. 24, 833-843 (2010). www.fasebj.org	[Wu, Lingtao] Univ So Calif, Dept Pathol, Childrens Hosp Los Angeles, Keck Sch Med,Saban Res Inst, Los Angeles, CA 90027 USA; [Jong, Ambrose] Childrens Hosp Los Angeles, Saban Res Inst, Div Hematol & Oncol, Los Angeles, CA 90027 USA; [Jong, Ambrose; Triche, Timothy J.; Wu, Lingtao] Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California	Wu, LT (corresponding author), Univ So Calif, Dept Pathol, Childrens Hosp Los Angeles, Keck Sch Med,Saban Res Inst, MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	lingtaow@usc.edu			National Institutes of Health [R21 CA111440, R01 CA120512]; NATIONAL CANCER INSTITUTE [R21CA111440, R01CA120512] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Lorraine J. Gudas (Cornell University, Ithaca, NY, USA) for providing F9 RAR alpha<SUP>-/-</SUP> cells; and Dr. J. Song (University of California, Los Angeles, CA, USA) for providing beta RARE-TK-Luc plasmids. The authors acknowledge the Vector Core at Childrens Hospital Los Angeles (CHLA) and Roger Hollis for technical expertise in lentiviral-vector production. The authors thank Dr. Srinivas Somanchi for technical expertise in constructing lentiviral vector. This work was supported by grants from the National Institutes of Health (R21 CA111440 and R01 CA120512 to L. W.).	Arimura A, 2004, J BIOL CHEM, V279, P31105, DOI 10.1074/jbc.M404428200; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; Bruck N, 2009, EMBO J, V28, P34, DOI 10.1038/emboj.2008.256; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; Crowe David L, 2002, Cancer Cell Int, V2, P15, DOI 10.1186/1475-2867-2-15; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Epping MT, 2005, CELL, V122, P835, DOI 10.1016/j.cell.2005.07.003; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; He QJ, 2004, FASEB J, V18, P1734, DOI 10.1096/fj.04-2182fje; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; Keriel A, 2002, CELL, V109, P125, DOI 10.1016/S0092-8674(02)00692-X; Kinjo K, 2004, EXP HEMATOL, V32, P45, DOI 10.1016/j.exphem.2003.10.009; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Lamkin TJ, 2006, AM J HEMATOL, V81, P603, DOI 10.1002/ajh.20667; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Liao YP, 2004, J CELL SCI, V117, P2917, DOI 10.1242/jcs.01153; Losel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003; Luo PH, 2007, STEM CELLS, V25, P2628, DOI 10.1634/stemcells.2007-0264; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Montagne M, 2008, J MOL BIOL, V376, P141, DOI 10.1016/j.jmb.2007.11.062; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; ROBERTSON KA, 1992, BLOOD, V80, P1885; Rochette-Egly C, 2000, MOL ENDOCRINOL, V14, P1398, DOI 10.1210/me.14.9.1398; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Scita G, 1996, J BIOL CHEM, V271, P6502, DOI 10.1074/jbc.271.11.6502; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; Song J, 2004, J BIOL CHEM, V279, P24414, DOI 10.1074/jbc.M311406200; Soprano DR, 2004, ANNU REV NUTR, V24, P201, DOI 10.1146/annurev.nutr.24.012003.132407; SPEAR BT, 1995, SOMAT CELL MOLEC GEN, V21, P19, DOI 10.1007/BF02255819; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; Studzinski GP, 1999, INT REV CYTOL, V189, P1, DOI 10.1016/S0074-7696(08)61384-4; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Wang JG, 2006, FASEB J, V20, P2142, DOI 10.1096/fj.06-5900fje; Wang JW, 2002, J BIOL CHEM, V277, P43369, DOI 10.1074/jbc.M206792200; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; WEILERGUETTLER H, 1992, P NATL ACAD SCI USA, V89, P2155, DOI 10.1073/pnas.89.6.2155; Wu LT, 2001, MOL CELL BIOL, V21, P260, DOI 10.1128/MCB.21.1.260-270.2001; WU LT, 1994, ONCOGENE, V9, P2089; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Zanotto A, 2008, TOXICOL IN VITRO, V22, P1205, DOI 10.1016/j.tiv.2008.04.001; Zhang SN, 2004, CANCER RES, V64, P2977, DOI 10.1158/0008-5472.CAN-03-4018; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	55	21	23	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					833	843		10.1096/fj.09-142976	http://dx.doi.org/10.1096/fj.09-142976			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19917671	Green Published			2022-12-28	WOS:000274974600019
J	Gaspar, E; Hardenbicker, C; Bodo, E; Wenzel, B; Ramot, Y; Funk, W; Kromminga, A; Paus, R				Gaspar, Erzsebet; Hardenbicker, Celine; Bodo, Eniko; Wenzel, Bjoern; Ramot, Yuval; Funk, Wolfgang; Kromminga, Arno; Paus, Ralf			Thyrotropin releasing hormone (TRH): a new player in human hair-growth control	FASEB JOURNAL			English	Article						hair follicle; hair cycle regulation; cell cycle	PITUITARY-THYROID AXIS; CHECKPOINT KINASE CHK2; IN-VITRO; ATAXIA-TELANGIECTASIA; CUTANEOUS EXPRESSION; FOLLICLE REGRESSION; RANA-PIPIENS; HPA AXIS; SKIN; ACTIVATION	Thyrotropin-releasing hormone (TRH) is the most proximal component of the hypothalamic-pituitary-thyroid axis that regulates thyroid hormone synthesis. Since transcripts for members of this axis were detected in cultured normal human skin cells and since human hair follicles (HFs) respond to stimulation with thyrotropin, we now have studied whether human HF functions are also modulated by TRH. Here we report that the epithelium of normal human scalp HFs expresses not only TRH receptors (TRH-R) but also TRH itself at the gene and protein level. Stimulation of microdissected, organ-cultured HFs with TRH promotes hair-shaft elongation, prolongs the hair cycle growth phase (anagen), and antagonizes its termination by TGF-beta 2. It also increases proliferation and inhibits apoptosis of hair matrix keratinocytes. These TRH effects may be mediated in part by reducing the ATM/Atr-dependent phosphorylation of p53. By microarray analysis, several differentially up-or down-regulated TRH-target genes were detected (e. g., selected keratins). Thus, human scalp HFs are both a source and a target of TRH, which operates as a potent hair-growth stimulator. Human HFs provide an excellent discovery tool for identifying and dissecting nonclassical functions of TRH and TRH-mediated signaling in situ, which emerge as novel players in human epithelial biology.-Gaspar, E., Hardenbicker, C., Bodo, E., Wenzel, B., Ramot, Y., Funk, W., Kromminga, A., Paus, R. Thyrotropin releasing hormone (TRH): a new player in human hair-growth control. FASEB J. 24, 393-403 (2010). www.fasebj.org	[Gaspar, Erzsebet; Hardenbicker, Celine; Bodo, Eniko; Ramot, Yuval; Paus, Ralf] Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany; [Wenzel, Bjoern] Med Univ Lubeck, Dept Internal Med, D-23538 Lubeck, Germany; [Paus, Ralf] Univ Manchester, Sch Translat Med, Manchester, Lancs, England; [Bodo, Eniko] Coll Nyiregyhaza, Agr & Mol Res Inst, Nyiregyhaza, Hungary; [Ramot, Yuval] Hadassah Hebrew Univ, Med Ctr, Dept Dermatol, Jerusalem, Israel; [Funk, Wolfgang] Klin Dr Kozlowski, Munich, Germany; [Kromminga, Arno] Inst Immunol, Hamburg, Germany	University of Lubeck; University of Lubeck; University of Manchester; Hebrew University of Jerusalem; Hadassah University Medical Center	Paus, R (corresponding author), Med Univ Lubeck, Dept Dermatol, Univ Hosp Schleswig Holstein, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.	ralf.paus@uk-sh.de	Paus, Ralf/F-6243-2011; Paus, Ralf/B-5279-2015	Paus, Ralf/0000-0002-3492-9358	Deutsche Forschungsgemeinschaft (DFG); Minerva Research Followship	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Minerva Research Followship	We thank Dr. Burkhard Poeggeler for help throughout this study and gratefully acknowledge his expert advice. We also thank S. Grammerstorf and G. Scheel for excellent technical assistance and Dr. Ewan Langan for editing the manuscript. This study was supported in part by a grant from Deutsche Forschungsgemeinschaft (DFG) to R. P., as well as by a Minerva Research Followship to Y.R.	Bilek R, 2000, PHYSIOL RES, V49, pS19; Bodo E, 2005, AM J PATHOL, V166, P985, DOI 10.1016/S0002-9440(10)62320-6; BODO E, 2008, J INVEST DERMATOL, V89, P131; Bodo E, 2007, AM J PATHOL, V171, P1153, DOI 10.2353/ajpath.2007.061164; BOLAFFI JL, 1979, CELL TISSUE RES, V202, P505; Botchkarev VA, 2003, J INVEST DERMATOL, V120, P36, DOI 10.1046/j.1523-1747.2003.12002.x; BOWERS CY, 1971, BIOCHEM BIOPH RES CO, V45, P1033, DOI 10.1016/0006-291X(71)90441-4; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Castro CP, 1999, ENDOCRINOLOGY, V140, P690, DOI 10.1210/en.140.2.690; Chiamolera MI, 2009, ENDOCRINOLOGY, V150, P1091, DOI 10.1210/en.2008-1795; Ellerhorst JA, 2004, CLIN CANCER RES, V10, P5531, DOI 10.1158/1078-0432.CCR-03-0368; Foitzik K, 2006, AM J PATHOL, V168, P748, DOI 10.2353/ajpath.2006.050468; Foitzik K, 2000, FASEB J, V14, P752, DOI 10.1096/fasebj.14.5.752; Garcia SI, 2005, REGUL PEPTIDES, V128, P239, DOI 10.1016/j.regpep.2005.01.002; Hibino T, 2004, J DERMATOL SCI, V35, P9, DOI 10.1016/j.jdermsci.2003.12.003; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Ito N, 2005, FASEB J, V19, P1332, DOI 10.1096/fj.04-1968fje; Ito N, 2004, J INVEST DERMATOL, V122, P235, DOI 10.1046/j.1523-1747.2003.22145.x; JACKSON IMD, 1977, NATURE, V267, P853, DOI 10.1038/267853a0; JACKSON IMD, 1977, SCIENCE, V198, P414, DOI 10.1126/science.410104; JACKSON IMD, 1994, REGULATION THYROTROP; Kamath J, 2009, PHARMACOL THERAPEUT, V121, P20, DOI 10.1016/j.pharmthera.2008.09.004; Karisson-Rosenthal C, 2006, TRENDS CELL BIOL, V16, P285, DOI 10.1016/j.tcb.2006.04.002; KLOEPPER EJ, 2009, J EXP DERMATOL, DOI DOI 10.1111/J.1600-0625.2009.00939.X; Kobayashi H, 2005, FASEB J, V19, P1710, DOI 10.1096/fj.04-2293fje; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lechan RM, 2003, ENCY HORMONES, P510; LUO LG, 2007, ACTA BIOMED S, V1, P216; Luo LG, 2008, BIOCHEM BIOPH RES CO, V374, P69, DOI 10.1016/j.bbrc.2008.06.111; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Nikrodhanond AA, 2006, J BIOL CHEM, V281, P5000, DOI 10.1074/jbc.M511530200; Paus R, 2004, DIFFERENTIATION, V72, P489, DOI 10.1111/j.1432-0436.2004.07209004.x; Philpott M P, 1994, J Dermatol Sci, V7 Suppl, pS55, DOI 10.1016/0923-1811(94)90036-1; PHILPOTT MP, 1990, J CELL SCI, V97, P463; Pommier Y, 2005, CURR PHARM DESIGN, V11, P2855, DOI 10.2174/1381612054546716; Schneider MR, 2009, CURR BIOL, V19, pR132, DOI 10.1016/j.cub.2008.12.005; SEIBERG M, 1995, J INVEST DERMATOL, V104, P78, DOI 10.1111/1523-1747.ep12613555; SHAMBAUGH G, 1979, J CLIN ENDOCR METAB, V48, P483, DOI 10.1210/jcem-48-3-483; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2002, J INVEST DERMATOL, V119, P1449, DOI 10.1046/j.1523-1747.2002.19617.x; Slominski A, 2001, FASEB J, V15, P1678, DOI 10.1096/fj.00-0850rev; Slominski A, 2007, MOL CELL ENDOCRINOL, V265, P143, DOI 10.1016/j.mce.2006.12.012; Slominski AT, 1999, ANN NY ACAD SCI, V885, P287; Socci R, 1996, GEN PHYSIOL BIOPHYS, V15, P309; Soma T, 2002, J INVEST DERMATOL, V118, P993, DOI 10.1046/j.1523-1747.2002.01746.x; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Telek A, 2007, FASEB J, V21, P3534, DOI 10.1096/fj.06-7689com; van Beek N, 2008, J CLIN ENDOCR METAB, V93, P4381, DOI 10.1210/jc.2008-0283; Vaudry H, 1999, ANN NY ACAD SCI, V885, P41; WIBER JF, 1968, P SOC EXP BIOL MED, V127, P488; Wilber JF, 1998, THYROID, V8, P897, DOI 10.1089/thy.1998.8.897; Zhang ST, 2006, CELL CYCLE, V5, P2787, DOI 10.4161/cc.5.23.3523; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	55	58	63	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					393	403		10.1096/fj.08-126417	http://dx.doi.org/10.1096/fj.08-126417			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19825978				2022-12-28	WOS:000274045000008
J	Assuncao-Miranda, I; Amaral, FA; Bozza, FA; Fagundes, CT; Sousa, LP; Souza, DG; Pacheco, P; Barbosa-Lima, G; Gomes, RN; Bozza, PT; Da Poian, AT; Teixeira, MM; Bozza, MT				Assuncao-Miranda, Iranaia; Amaral, Flavio A.; Bozza, Fernando A.; Fagundes, Caio T.; Sousa, Lirlandia P.; Souza, Danielle G.; Pacheco, Patricia; Barbosa-Lima, Giselle; Gomes, Rachel N.; Bozza, Patricia T.; Da Poian, Andrea T.; Teixeira, Mauro M.; Bozza, Marcelo T.			Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection	FASEB JOURNAL			English	Article						MIF; cytokine; lipid droplets; inflammation; hemorrhagic fever; sepsis	FACTOR MIF; HEMORRHAGIC-FEVER; JAPANESE ENCEPHALITIS; CHEMOKINE RECEPTORS; DISEASE SEVERITY; INNATE IMMUNITY; REGULATORY ROLE; SHOCK-SYNDROME; SEPTIC SHOCK; SERUM-LEVELS	Dengue fever is an emerging viral disease transmitted by arthropods to humans in tropical countries. Dengue hemorrhagic fever (DHF) is escalating in frequency and mortality rates. Here we studied the involvement of macrophage migration inhibitory factor (MIF) in dengue virus (DENV) infection and its pathogenesis. Patients with DHF had elevated plasma concentrations of MIF. Both leukocytes from these patients and macrophages from healthy donors infected in vitro with DENV showed a substantial amount of MIF within lipid droplets. The secretion of MIF by macrophages and hepatocytes required a productive infection and occurred without an increase in gene transcription or cell death, thus indicating active secretion from preformed stocks. In vivo infection of wildtype and mif-deficient (Mif(-/-)) mice demonstrated a role of MIF in dengue pathogenesis. Clinical disease was less severe in Mif(-/-) mice, and they exhibited a significant delay in lethality, lower viremia, and lower viral load in the spleen than wild-type mice. This reduction in all parameters of severity on DENV infection in Mif(-/-) mice correlated with reduced proinflammatory cytokine concentrations. These results demonstrated the contribution of MIF to the pathogenesis of dengue and pointed to a possible beneficial role of neutralizing MIF as an adjunctive therapeutic approach to treat the severe forms of the disease.-Assuncao-Miranda, I., Amaral, F. A., Bozza, F. A., Fagundes, C. T., Sousa, L. P., Souza, D. G., Pacheco, P., Barbosa-Lima, G., Gomes, R. N., Bozza, P. T., Da Poian, A. T., Teixeira, M. M., Bozza, M. T. Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. FASEB J. 24, 218-228 (2010). www.fasebj.org	[Teixeira, Mauro M.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, BR-31270901 Belo Horizonte, MG, Brazil; [Assuncao-Miranda, Iranaia; Da Poian, Andrea T.] Univ Fed Rio de Janeiro, Programa Biol Estrutural, Inst Bioquim Med, Rio De Janeiro, Brazil; [Assuncao-Miranda, Iranaia; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941 Rio De Janeiro, Brazil; [Amaral, Flavio A.; Fagundes, Caio T.; Souza, Danielle G.] Univ Fed Minas Gerais, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil; [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Intens Care Unit, Rio De Janeiro, Brazil; [Pacheco, Patricia; Barbosa-Lima, Giselle; Gomes, Rachel N.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil	Universidade Federal de Minas Gerais; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal de Minas Gerais; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz	Teixeira, MM (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Ave Antonio Carlos,6627 Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.	mmtex@icb.ufmg.br; mtbozza@gmail.com	Da Poian, Andrea T./V-1699-2019; Bozza, Patricia T./AAE-2933-2021; Fagundes, Caio/AAK-9336-2020; souza, danielle/D-3378-2014; Teixeira, Mauro M/A-4587-2008; Amaral, Flávio Almeida/C-3768-2018; Bozza, Fernando A/A-2618-2013; Amaral, Flavio/D-5489-2014; Gomes, Rachel N/I-7643-2013; Bozza, Patricia T./AAM-4537-2021	Fagundes, Caio/0000-0002-6747-5233; Teixeira, Mauro M/0000-0002-6944-3008; Amaral, Flávio Almeida/0000-0002-1695-0612; Bozza, Fernando A/0000-0003-4878-0256; Amaral, Flavio/0000-0002-1695-0612; Bozza, Patricia T./0000-0001-8349-9529; Da Poian, Andrea/0000-0002-3969-704X; Bozza, Marcelo/0000-0003-3683-7550; Miranda, Iranaia/0000-0001-5684-4788	Conselho de Desenvolvimento Cientifico e Tecnologico (CNPq; Brazil); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ; Brazil); National Institute of Science and Technology in Dengue (INCT-Dengue; Brazil)	Conselho de Desenvolvimento Cientifico e Tecnologico (CNPq; Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ; Brazil)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); National Institute of Science and Technology in Dengue (INCT-Dengue; Brazil)	This work was supported by Conselho de Desenvolvimento Cientifico e Tecnologico (CNPq;Brazil), Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ; Brazil), and National Institute of Science and Technology in Dengue (INCT-Dengue; Brazil).	Amin MA, 2006, BLOOD, V107, P2252, DOI 10.1182/blood-2005-05-2011; Arjona A, 2007, J CLIN INVEST, V117, P3059, DOI 10.1172/JCI32218; Armstrong ME, 2008, J IMMUNOL, V180, P7125, DOI 10.4049/jimmunol.180.11.7125; Arndt U, 2002, J VIROL, V76, P9298, DOI 10.1128/JVI.76.18.9298-9306.2002; Assuncao-Miranda I, 2010, J MED VIROL, V82, P164, DOI 10.1002/jmv.21649; Atrasheuskaya A, 2003, FEMS IMMUNOL MED MIC, V35, P33, DOI 10.1111/j.1574-695X.2003.tb00646.x; Bacher M, 2002, VIROLOGY, V299, P32, DOI 10.1006/viro.2002.1464; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; Bosch I, 2002, J VIROL, V76, P5588, DOI 10.1128/JVI.76.11.5588-5597.2002; Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8; Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783; Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; BOZZA PT, 2009, BIOCHIM BIOPHYS ACTA, V1791, P40; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chen LC, 2006, AM J TROP MED HYG, V74, P142, DOI 10.4269/ajtmh.2006.74.142; Chen ST, 2008, NATURE, V453, P672, DOI 10.1038/nature07013; Chen YC, 2002, J VIROL, V76, P9877, DOI 10.1128/JVI.76.19.9877-9887.2002; El-Bacha T, 2007, BBA-MOL BASIS DIS, V1772, P1158, DOI 10.1016/j.bbadis.2007.08.003; Flieger O, 2003, FEBS LETT, V551, P78, DOI 10.1016/S0014-5793(03)00900-1; Flores M, 2008, FASEB J, V22, P3661, DOI 10.1096/fj.08-111666; Frascaroli G, 2009, J IMMUNOL, V182, P477, DOI 10.4049/jimmunol.182.1.477; Gibbons RV, 2002, BMJ-BRIT MED J, V324, P1563, DOI 10.1136/bmj.324.7353.1563; Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa; Guzman MG, 2008, T ROY SOC TROP MED H, V102, P522, DOI 10.1016/j.trstmh.2008.03.001; Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2; Higa LM, 2008, BBA-PROTEINS PROTEOM, V1784, P1607, DOI 10.1016/j.bbapap.2008.06.015; HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324; Kimura K, 2006, CLIN VACCINE IMMUNOL, V13, P415, DOI 10.1128/CVI.13.3.415-419.2006; Koebernick H, 2002, P NATL ACAD SCI USA, V99, P13681, DOI 10.1073/pnas.212488699; La Braga E, 2001, MEM I OSWALDO CRUZ, V96, P229, DOI 10.1590/S0074-02762001000200015; Leng L, 2005, CRIT CARE MED, V33, pS475, DOI 10.1097/01.CCM.0000191278.04636.D8; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200; Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144; Magalhaes ES, 2007, EUR J IMMUNOL, V37, P1097, DOI 10.1002/eji.200635968; Magalhaes ES, 2009, FASEB J, V23, P1262, DOI 10.1096/fj.08-124248; McDevitt MA, 2006, J EXP MED, V203, P1185, DOI 10.1084/jem.20052398; Merk M, 2009, J IMMUNOL, V182, P6896, DOI 10.4049/jimmunol.0803710; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Mizue Y, 2005, P NATL ACAD SCI USA, V102, P14410, DOI 10.1073/pnas.0507189102; Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498; Paiva CN, 2009, J LEUKOCYTE BIOL, V85, P855, DOI 10.1189/jlb.0108009; Pan American Health Organization, 2007, NUMB REP CAS DENG DE; Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; Souza DG, 2009, P NATL ACAD SCI USA, V106, P14138, DOI 10.1073/pnas.0906467106; Souza DG, 2002, AM J PATHOL, V160, P1755, DOI 10.1016/S0002-9440(10)61122-4; Sprong T, 2007, SHOCK, V27, P482, DOI 10.1097/01.shk.0000246898.65692.34; Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42, DOI 10.1055/s-0037-1612941; Suzuki T, 2000, BBA-GENE STRUCT EXPR, V1517, P100, DOI 10.1016/S0167-4781(00)00262-1; Umareddy I, 2008, J GEN VIROL, V89, P3052, DOI 10.1099/vir.0.2008/001594-0; *WHO, 2002, 117 WHO; Zhang Wei, 2002, Hepatobiliary Pancreat Dis Int, V1, P577	62	95	96	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					218	228		10.1096/fj.09-139469	http://dx.doi.org/10.1096/fj.09-139469			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19776337				2022-12-28	WOS:000273233600023
J	Ortiz-Masia, D; Hernandez, C; Quintana, E; Velazquez, M; Cebrian, S; Riano, A; Calatayud, S; Esplugues, JV; Barrachina, MD				Ortiz-Masia, Dolores; Hernandez, Carlos; Quintana, Elsa; Velazquez, Miriam; Cebrian, Sonia; Riano, Annia; Calatayud, Sara; Esplugues, Juan V.; Barrachina, Maria D.			iNOS-derived nitric oxide mediates the increase in TFF2 expression associated with gastric damage: role of HIF-1	FASEB JOURNAL			English	Article						NSAID gastropathy; macrophage activation; mucosal restitution; inducible nitric oxide synthase	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; EPITHELIAL-CELL MIGRATION; TREFOIL PEPTIDES; SYNTHASE; HIF-1-ALPHA; INHIBITION; ARGININE; OXYGEN; IMMUNOHISTOCHEMISTRY; PHOSPHORYLATION	Trefoil (TFF) peptides are involved in gastrointestinal mucosal restitution. An hypoxia inducible factor 1 (HIF-1)-dependent induction of TFF genes has been reported in gastric epithelial cells. Nitric oxide (NO) is associated with mucosal damage and modulates HIF-1 activity. The aim of the present study was to analyze the role of iNOS-derived NO in HIF-1 alpha stabilization and TFF gene expression in damaged gastric mucosa. Aspirin caused gastric injury that peaked 6 h after dosing and returned to normality at 24 h. iNOS mRNA expression occurs in the corpus in parallel with damage. Blockade of iNOS activity did not modify gastric lesions induced by aspirin but delayed mucosal healing. Aspirin induced HIF-1 alpha stabilization and TFF2 mRNA up-regulation in the mucosa, but these effects were diminished when iNOS activity was inhibited. Results obtained using a coculture setup showed that iNOS-derived NO from activated macrophages induced HIF-1 alpha stabilization, TFF gene expression, and accelerated wound healing in cultured epithelial cells. Finally, transient silencing of endogenous HIF-1 alpha in epithelial cells significantly undermined activated macrophage-induced TFF gene expression. Evidence suggests that the iNOS-derived NO associated with NSAID-induced gastric injury is implicated in mucosal restitution via the HIF-1-mediated induction of TFF genes.-Ortiz-Masia, D., Hernandez, C., Quintana, E., Velazquez, M., Cebrian, S., Riano, A., Calatayud, S., Esplugues, J. V., Barrachina, M. D. iNOS-derived nitric oxide mediates the increase in TFF2 expression associated with gastric damage: role of HIF-1. FASEB J. 24,136-145 (2010). www.fasebj.org	[Ortiz-Masia, Dolores; Velazquez, Miriam; Calatayud, Sara; Esplugues, Juan V.; Barrachina, Maria D.] Univ Valencia, Dept Pharmacol, Fac Med, Valencia 46010, Spain; [Ortiz-Masia, Dolores; Hernandez, Carlos; Quintana, Elsa; Velazquez, Miriam; Cebrian, Sonia; Riano, Annia; Calatayud, Sara; Esplugues, Juan V.; Barrachina, Maria D.] Univ Valencia, CIBERehd, Fac Med, Valencia 46010, Spain	University of Valencia; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Valencia	Barrachina, MD (corresponding author), Univ Valencia, Dept Pharmacol, Fac Med, Avda Blasco Ibanez 15-17, Valencia 46010, Spain.	dolores.barrachina@uv.es	Calatayud, Sara/ABB-9665-2021; Esplugues, Juan/ABC-1488-2021; Barrachina, Maria/ABB-9683-2021; SAEZ, CARLOS HERNANDEZ/M-3029-2014; ORTIZ-MASIA, MARIA DOLORES/M-1413-2017	Calatayud, Sara/0000-0001-9675-2423; SAEZ, CARLOS HERNANDEZ/0000-0001-8536-429X; ORTIZ-MASIA, MARIA DOLORES/0000-0002-7924-9962; Barrachina, Maria Dolores/0000-0002-4332-2929; Esplugues Mota, Juan Vicente/0000-0001-8205-021X	Ministerio de Educacion y Cultura [SAF2007064201]; Ministerio de Sanidad y Consumo [CIBER CD06/04/0071, PI081325]; Generalitat Valenciana [ACOMP07-297]	Ministerio de Educacion y Cultura(German Research Foundation (DFG)); Ministerio de Sanidad y Consumo(Instituto de Salud Carlos III); Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission)	The present study has been funded by grants SAF2007064201 from the Ministerio de Educacion y Cultura, CIBER CD06/04/0071 and PI081325 from the Ministerio de Sanidad y Consumo, and ACOMP07-297 from the Generalitat Valenciana.	Agani FH, 2002, AM J PHYSIOL-CELL PH, V283, pC178, DOI 10.1152/ajpcell.00381.2001; Akiba Y, 1998, J CLIN GASTROENTEROL, V27, pS64, DOI 10.1097/00004836-199800001-00011; Anand RJ, 2008, AM J PHYSIOL-GASTR L, V294, pG109, DOI 10.1152/ajpgi.00331.2007; Azarschab P, 2001, FEBS LETT, V488, P206, DOI 10.1016/S0014-5793(00)02422-4; Beck KF, 1999, J EXP BIOL, V202, P645; Boer R, 2000, MOL PHARMACOL, V58, P1026, DOI 10.1124/mol.58.5.1026; Bove PF, 2008, J BIOL CHEM, V283, P17919, DOI 10.1074/jbc.M709914200; Brune B, 2007, CARDIOVASC RES, V75, P275, DOI 10.1016/j.cardiores.2007.03.005; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; Calatayud S, 2001, MICROSC RES TECHNIQ, V53, P325, DOI 10.1002/jemt.1100; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; Dudar GK, 2008, AM J PHYSIOL-GASTR L, V295, pG374, DOI 10.1152/ajpgi.90325.2008; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Hayashi Y, 2005, MICROBIOL IMMUNOL, V49, P139, DOI 10.1111/j.1348-0421.2005.tb03713.x; Hernandez C, 2009, BRIT J PHARMACOL, V156, P262, DOI 10.1111/j.1476-5381.2008.00044.x; Hoffmann W, 2005, CELL MOL LIFE SCI, V62, P2932, DOI 10.1007/s00018-005-5481-9; Ito M, 2003, ALIMENT PHARM THER, V18, P90, DOI 10.1046/j.1365-2036.18.s1.10.x; Jimenez D, 2002, DIGEST DIS SCI, V47, P44, DOI 10.1023/A:1013203217788; Kato K, 1999, AM J PHYSIOL-GASTR L, V276, pG1105, DOI 10.1152/ajpgi.1999.276.5.G1105; KAUFFMAN GL, 1981, PROSTAGLANDINS, V21, P33, DOI 10.1016/0090-6980(81)90114-3; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Lando D, 2003, EUR J BIOCHEM, V270, P781, DOI 10.1046/j.1432-1033.2003.03445.x; Li F, 2007, MOL CELL, V26, P63, DOI 10.1016/j.molcel.2007.02.024; Longman RJ, 2000, GUT, V47, P792, DOI 10.1136/gut.47.6.792; Louis NA, 2006, J CELL BIOCHEM, V99, P1616, DOI 10.1002/jcb.20947; Ma L, 2000, AM J PHYSIOL-GASTR L, V279, pG341, DOI 10.1152/ajpgi.2000.279.2.G341; Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Mylonis I, 2006, J BIOL CHEM, V281, P33095, DOI 10.1074/jbc.M605058200; Nishida K, 1998, NITRIC OXIDE-BIOL CH, V2, P215, DOI 10.1006/niox.1998.0178; PLAYFORD RJ, 1995, GASTROENTEROLOGY, V108, P108, DOI 10.1016/0016-5085(95)90014-4; Quintana E, 2004, FASEB J, V18, P531, DOI 10.1096/fj.03-0596fje; Rhoads JM, 2008, J NUTR, V138, P1652, DOI 10.1093/jn/138.9.1652; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; Sands BE, 1996, ANNU REV PHYSIOL, V58, P253, DOI 10.1146/annurev.ph.58.030196.001345; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Souza MHLP, 2004, GUT, V53, P791, DOI 10.1136/gut.2002.012930; Takeuchi K, 1999, J PHYSIOLOGY-PARIS, V93, P423, DOI 10.1016/S0928-4257(99)00125-4; Tatemichi M, 2003, INT J EXP PATHOL, V84, P213, DOI 10.1111/j.1365-2613.2003.00357.x; Taupin D, 2003, NAT REV MOL CELL BIO, V4, P721, DOI 10.1038/nrm1203; Walker RA, 2006, HISTOPATHOLOGY, V49, P406, DOI 10.1111/j.1365-2559.2006.02514.x; WALLACE JL, 1993, CAN J PHYSIOL PHARM, V71, P98, DOI 10.1139/y93-014; Yasuhiro T, 1997, J PHYSIOLOGY-PARIS, V91, P131, DOI 10.1016/S0928-4257(97)89477-6; Yin JH, 2000, BIOCHEM BIOPH RES CO, V279, P30, DOI 10.1006/bbrc.2000.3896	47	19	20	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					136	145		10.1096/fj.09-137489	http://dx.doi.org/10.1096/fj.09-137489			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19741170				2022-12-28	WOS:000273233600016
J	Rivera-Meza, M; Quintanilla, ME; Tampier, L; Mura, CV; Sapag, A; Israel, Y				Rivera-Meza, Mario; Elena Quintanilla, Maria; Tampier, Lutske; Mura, Casilda V.; Sapag, Amalia; Israel, Yedy			Mechanism of protection against alcoholism by an alcohol dehydrogenase polymorphism: development of an animal model	FASEB JOURNAL			English	Article						ethanol; acetaldehyde; alcohol consumption; ADH1B*2; hormesis	SPONTANEOUSLY HYPERTENSIVE RAT; ALDEHYDE DEHYDROGENASE; ADH2-ASTERISK-2 ALLELE; GENETIC-POLYMORPHISM; HUMAN BETA-1-BETA-1; ETHANOL; LIVER; CONSUMPTION; METABOLISM; HORMESIS	Humans who carry a point mutation in the gene coding for alcohol dehydrogenase-1B (ADH1B*2; Arg47His) are markedly protected against alcoholism. Although this mutation results in a 100-fold increase in enzyme activity, it has not been reported to cause higher levels of acetaldehyde, a metabolite of ethanol known to deter alcohol intake. Hence, the mechanism by which this mutation confers protection against alcoholism is unknown. To study this protective effect, the wild-type rat cDNA encoding rADH-47Arg was mutated to encode rADH-47His, mimicking the human mutation. The mutated cDNA was incorporated into an adenoviral vector and administered to genetically selected alcohol-preferring rats. The V-max of rADH-47His was 6-fold higher (P<0.001) than that of the wild-type rADH-47Arg. Animals transduced with rAdh-47His showed a 90% (P<0.01) increase in liver ADH activity and a 50% reduction (P<0.001) in voluntary ethanol intake. In animals transduced with rAdh-47His, administration of ethanol (1g/kg) produced a short-lived increase of arterial blood acetaldehyde concentration to levels that were 3.5- to 5-fold greater than those in animals transduced with the wild-type rAdh-47Arg vector or with a noncoding vector. This brief increase (burst) in arterial acetaldehyde concentration after ethanol ingestion may constitute the mechanism by which humans carrying the ADH1B*2 allele are protected against alcoholism.-Rivera-Meza, M., Quintanilla, M. E., Tampier, L., Mura, C. V., Sapag, A., Israel, Y. Mechanism of protection against alcoholism by an alcohol dehydrogenase polymorphism: development of an animal model. FASEB J. 24, 266-274 (2010). www.fasebj.org	[Rivera-Meza, Mario; Sapag, Amalia; Israel, Yedy] Univ Chile, Lab Gene Therapy, Dept Pharmacol & Toxicol Chem, Fac Chem & Pharmaceut Sci, Santiago 8380492, Chile; [Elena Quintanilla, Maria; Tampier, Lutske; Israel, Yedy] Univ Chile, Fac Med, Dept Mol & Clin Pharmacol, Lab Pharmacogenet Alcoholism, Santiago 8380492, Chile; [Mura, Casilda V.; Israel, Yedy] Millennium Inst Cell Dynam & Biotechnol, Santiago, Chile	Universidad de Chile; Universidad de Chile	Israel, Y (corresponding author), Univ Chile, Lab Gene Therapy, Dept Pharmacol & Toxicol Chem, Fac Chem & Pharmaceut Sci, Olivos 1007, Santiago 8380492, Chile.	yisrael@uchile.cl	Sapag, Amalia/I-2574-2013	Sapag, Amalia/0000-0002-7029-2331; Quintanilla, Maria Elena/0000-0002-0278-3219; Israel, Yedy/0000-0003-3468-7966	U.S. National Institutes of Health [R01-AA 015421]; Millennium Scientific Initiative [ICM P05-001]; CONICYT-Chile; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA015421] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Millennium Scientific Initiative; CONICYT-Chile(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was supported by grants from the U.S. National Institutes of Health (R01-AA 015421) and the Millennium Scientific Initiative (ICM P05-001). M. R. held a doctoral fellowship from CONICYT-Chile. We thank Dr. Fernando Ezquer for pAAV-rADH-47Arg direction reversal, Juan Santibanez for skillful technical assistance, and Prof. Harold Kalant for his critical review of the manuscript.	Borras E, 2000, HEPATOLOGY, V31, P984, DOI 10.1053/he.2000.5978; Calabrese EJ, 2003, ANNU REV PHARMACOL, V43, P175, DOI 10.1146/annurev.pharmtox.43.100901.140223; Chambers GK, 2002, ALCOHOL CLIN EXP RES, V26, P949, DOI 10.1097/01.ALC.0000021145.47616.38; Chen CC, 1999, AM J HUM GENET, V65, P795, DOI 10.1086/302540; Chen YC, 2009, CHEM-BIOL INTERACT, V178, P2, DOI 10.1016/j.cbi.2008.10.029; Chen YJ, 2006, INT J CANCER, V119, P2827, DOI 10.1002/ijc.22199; CRABB DW, 1986, GENE, V48, P287, DOI 10.1016/0378-1119(86)90087-9; CRONHOLM T, 1985, BIOCHEM J, V229, P315, DOI 10.1042/bj2290315; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Duranceaux NCE, 2006, ALCOHOL CLIN EXP RES, V30, P1470, DOI 10.1111/j.1530-0277.2006.00178.x; Fechner H, 1999, GENE THER, V6, P1520, DOI 10.1038/sj.gt.3301030; Feinendegen LE, 2005, BRIT J RADIOL, V78, P3, DOI 10.1259/bjr/63353075; Garver E, 2001, J EXP MED, V194, P571, DOI 10.1084/jem.194.5.571; HARADA S, 1982, LANCET, V2, P827, DOI 10.1016/s0140-6736(82)92722-2; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Higuchi S, 1994, Alcohol Alcohol Suppl, V2, P29; Hilakivi L, 1984, Alcohol, V1, P71; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HURLEY NF, 1990, STRATIGRAPHIC TRAPS, V1, P1; HURLEY TD, 1990, J BIOL CHEM, V265, P16366; Kang MJ, 2008, FEBS J, V275, P5969, DOI 10.1111/j.1742-4658.2008.06725.x; Kim DJ, 2008, HUM MOL GENET, V17, P854, DOI 10.1093/hmg/ddm357; Le AD, 2001, ALCOHOL CLIN EXP RES, V25, P1613, DOI 10.1111/j.1530-0277.2001.tb02168.x; Lecky FE, 2002, CRIT CARE MED, V30, P981, DOI 10.1097/00003246-200205000-00005; Li N, 2007, DNA REPAIR, V6, P1297, DOI 10.1016/j.dnarep.2007.02.027; LI TK, 1995, CLIN NEUROSCI, V3, P182; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MARDONES J, 1983, NEUROBEH TOXICOL TER, V5, P171; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; MIZOI Y, 1983, PHARMACOL BIOCHEM BE, V18, P127, DOI 10.1016/0091-3057(83)90159-4; MIZOI Y, 1994, ALCOHOL ALCOHOLISM, V29, P707; Morral N, 1999, P NATL ACAD SCI USA, V96, P12816, DOI 10.1073/pnas.96.22.12816; Neumark YD, 1998, J STUD ALCOHOL, V59, P133, DOI 10.15288/jsa.1998.59.133; Neumark YD, 2004, ALCOHOL CLIN EXP RES, V28, P10, DOI 10.1097/01.ALC.0000108667.79219.4D; Ni L, 1997, J BIOL CHEM, V272, P18823, DOI 10.1074/jbc.272.30.18823; NUUTINEN HU, 1984, EUR J CLIN INVEST, V14, P306, DOI 10.1111/j.1365-2362.1984.tb01186.x; PARSONS PA, 1989, BIOL J LINN SOC, V37, P183, DOI 10.1111/j.1095-8312.1989.tb01900.x; Peng GS, 2007, PHARMACOGENET GENOM, V17, P845, DOI 10.1097/FPC.0b013e3282609e67; Quintanilla ME, 2006, ADDICT BIOL, V11, P310, DOI 10.1111/j.1369-1600.2006.00030.x; Quintanilla ME, 2007, AM J PHYSIOL-ENDOC M, V293, pE531, DOI 10.1152/ajpendo.00187.2007; RACHAMIN G, 1980, BIOCHEM J, V186, P483, DOI 10.1042/bj1860483; Rehm J, 2006, DRUG ALCOHOL REV, V25, P503, DOI 10.1080/09595230600944453; SCHMIDT W, 1987, BRIT J ADDICT, V82, P775; Schwartz DR, 2008, CURR OPIN PHARMACOL, V8, P160, DOI 10.1016/j.coph.2007.12.008; Simon FR, 2002, AM J PHYSIOL-GASTR L, V283, pG646, DOI 10.1152/ajpgi.00438.2001; STONE CL, 1993, J BIOL CHEM, V268, P892; Tampier L, 2008, ALCOHOL CLIN EXP RES, V32, P937, DOI 10.1111/j.1530-0277.2008.00658.x; THOMASSON HR, 1991, AM J HUM GENET, V48, P677; Toietta G, 2005, P NATL ACAD SCI USA, V102, P3930, DOI 10.1073/pnas.0500930102; TU GC, 1995, BEHAV GENET, V25, P59, DOI 10.1007/BF02197242; WAHID S, 1981, BIOCHEM PHARMACOL, V30, P1277, DOI 10.1016/0006-2952(81)90309-9; Wall TL, 2005, J ABNORM PSYCHOL, V114, P456, DOI 10.1037/0021-843X.114.3.456; WHO, 2007, WHO TECH REP SER, V935, P1; Yamada K, 2006, ANAL BIOCHEM, V352, P282, DOI 10.1016/j.ab.2006.02.017; Yang HY, 2007, CELL, V130, P1095, DOI 10.1016/j.cell.2007.07.035; Yokoyama A, 2001, CARCINOGENESIS, V22, P433, DOI 10.1093/carcin/22.3.433; Zintzaras E, 2006, HEPATOLOGY, V43, P352, DOI 10.1002/hep.21023	57	34	35	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					266	274		10.1096/fj.09-132563	http://dx.doi.org/10.1096/fj.09-132563			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19710201	Green Published			2022-12-28	WOS:000273233600027
J	Greco, S; De Simone, M; Colussi, C; Zaccagnini, G; Fasanaro, P; Pescatori, M; Cardani, R; Perbellini, R; Isaia, E; Sale, P; Meola, G; Capogrossi, MC; Gaetano, C; Martelli, F				Greco, Simona; De Simone, Marco; Colussi, Claudia; Zaccagnini, Germana; Fasanaro, Pasquale; Pescatori, Mario; Cardani, Rosanna; Perbellini, Riccardo; Isaia, Eleonora; Sale, Patrizio; Meola, Giovanni; Capogrossi, Maurizio C.; Gaetano, Carlo; Martelli, Fabio			Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia	FASEB JOURNAL			English	Article						tissue degeneration; inflammation; myogenic differentiation; therapy	TARGETS; MICRORNA-206; EXPRESSION; P66(SHCA); REVEALS; LIFE	The aim of this work was to identify micro-RNAs ( miRNAs) involved in the pathological pathways activated in skeletal muscle damage and regeneration by both dystrophin absence and acute ischemia. Eleven miRNAs were deregulated both in MDX mice and in Duchenne muscular dystrophy patients (DMD signature). Therapeutic interventions ameliorating the mdx-phenotype rescued DMD-signature alterations. The significance of DMD-signature changes was characterized using a damage/regeneration mouse model of hind-limb ischemia and newborn mice. According to their expression, DMD-signature miRNAs were divided into 3 classes. 1) Regeneration miRNAs, miR-31, miR-34c, miR-206, miR-335, miR-449, and miR-494, which were induced in MDX mice and in DMD patients, but also in newborn mice and in newly formed myofibers during postischemic regeneration. Notably, miR-206, miR-34c, and miR-335 were up-regulated following myoblast differentiation in vitro. 2) Degenerative-miRNAs, miR-1, miR-29c, and miR-135a, that were down-modulated in MDX mice, in DMD patients, in the degenerative phase of the ischemia response, and in newborn mice. Their down-modulation was linked to myofiber loss and fibrosis. 3) Inflammatory miRNAs, miR-222 and miR-223, which were expressed in damaged muscle areas, and their expression correlated with the presence of infiltrating inflammatory cells. These findings show an important role of miRNAs in physiopathological pathways regulating muscle response to damage and regeneration.-Greco, S., De Simone, M., Colussi, C., Zaccagnini, G., Fasanaro, P., Pescatori, M., Cardani, R., Perbellini, R., Isaia, E., Sale, P., Meola, G., Capogrossi, M. C., Gaetano, C., Martelli, F. Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J. 23, 3335-3346 ( 2009). www.fasebj.org	[Martelli, Fabio] IRCCS, Ist Dermopat Immacolata, Lab Patol Vasc, Rome, Italy; [Greco, Simona; Perbellini, Riccardo; Isaia, Eleonora; Meola, Giovanni] Policlin San Donato, IRCCS, Milan, Italy; [De Simone, Marco; Colussi, Claudia] IRCCS, Ctr Cardiol Monzino, Milan, Italy; [Sale, Patrizio] San Raffaele Pisana IRCCS, Rome, Italy; [Pescatori, Mario] Erasmus MC, Rotterdam, Netherlands; [Cardani, Rosanna; Perbellini, Riccardo; Meola, Giovanni] Univ Milan, Milan, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Policlinico San Donato; IRCCS Centro Cardiologico Monzino; IRCCS San Raffaele Pisana; Erasmus University Rotterdam; Erasmus MC; University of Milan	Martelli, F (corresponding author), IRCCS, Ist Dermopat Immacolata, Lab Patol Vasc, Rome, Italy.	f.martelli@idi.it	greco, simona/J-5374-2016; Sale, Patrizio/J-3276-2019; Meola, Giovanni/K-4775-2016; Sale, Patrizio/K-8757-2016; cardani, rosanna/ABH-6525-2020; Martelli, Fabio/AAL-3788-2020; greco, simona/AAD-3211-2021; Colussi, Claudia/H-8609-2019; perbellini, riccardo/AAB-3814-2019; Zaccagnini, Germana/J-7722-2016; Gaetano, Carlo/P-9997-2019	greco, simona/0000-0002-0275-7221; Sale, Patrizio/0000-0002-4850-3673; Meola, Giovanni/0000-0001-6396-717X; Sale, Patrizio/0000-0002-4850-3673; cardani, rosanna/0000-0001-8858-4327; Martelli, Fabio/0000-0002-8624-7738; greco, simona/0000-0002-0275-7221; Zaccagnini, Germana/0000-0002-9441-4735; Gaetano, Carlo/0000-0002-5238-1832; Colussi, Claudia/0000-0002-7727-8911	Ministero della Salute [RC07/08-1.3, ISS-Monz.-526D721, RF07Onc-26/1, RF06-Conv.74.1, RF07-637147]; Association Francaise contre les Myopathies (AMF); Programmi di Ricerca di Rilevante Interesse Nazionale (PRIN); School of Endocrinology, Catholic University, Rome	Ministero della Salute(Ministry of Health, Italy); Association Francaise contre les Myopathies (AMF)(Association Francaise contre les Myopathies); Programmi di Ricerca di Rilevante Interesse Nazionale (PRIN)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); School of Endocrinology, Catholic University, Rome	The authors thank Prof. E. Ricci ( Catholic University, Rome, Italy) for the kind gift of RNA samples from DMD and BMD patients. This work was partly supported by Ministero della Salute (RC07/08-1.3, ISS-Monz.-526D721, RF07Onc-26/1, RF06-Conv.74.1, RF07-637147), Association Francaise contre les Myopathies (AMF), and Programmi di Ricerca di Rilevante Interesse Nazionale (PRIN) 2006. C. C. is a Ph.D. student at the School of Endocrinology, Catholic University, Rome.	Banks GB, 2008, CURR TOP DEV BIOL, V84, P431, DOI 10.1016/S0070-2153(08)00609-1; BARTONDAVIS ER, 2008, J CLIN INVEST, V104, P367; Callis TE, 2008, EXP BIOL MED, V233, P131, DOI 10.3181/0709-MR-237; Cardani R, 2004, EUR J HISTOCHEM, V48, P437; Chimenti C, 2005, CHEST, V128, P2876, DOI 10.1378/chest.128.4.2876; Colussi C, 2009, FASEB J, V23, P2131, DOI 10.1096/fj.08-115618; Colussi C, 2008, P NATL ACAD SCI USA, V105, P19183, DOI 10.1073/pnas.0805514105; Eisenberg I, 2007, P NATL ACAD SCI USA, V104, P17016, DOI 10.1073/pnas.0708115104; Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Flynt AS, 2008, NAT REV GENET, V9, P831, DOI 10.1038/nrg2455; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607; Lall S, 2006, CURR BIOL, V16, P460, DOI 10.1016/j.cub.2006.01.050; Latronico MVG, 2007, CIRC RES, V101, P1225, DOI 10.1161/CIRCRESAHA.107.163147; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McCarthy JJ, 2007, AM J PHYSIOL-CELL PH, V293, pC451, DOI 10.1152/ajpcell.00077.2007; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Minetti GC, 2006, NAT MED, V12, P1147, DOI 10.1038/nm1479; Naguibneva I, 2006, NAT CELL BIOL, V8, P278, DOI 10.1038/ncb1373; Pescatori M, 2007, FASEB J, V21, P1210, DOI 10.1096/fj.06-7285com; ROSENBLATT JD, 1995, IN VITRO CELL DEV-AN, V31, P773; Thum T, 2008, CARDIOVASC RES, V79, P562, DOI 10.1093/cvr/cvn137; Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156; van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105; van Rooij E, 2008, TRENDS GENET, V24, P159, DOI 10.1016/j.tig.2008.01.007; Watchko JF, 2002, J APPL PHYSIOL, V93, P407, DOI 10.1152/japplphysiol.01242.2001; Wells D J, 2005, Acta Myol, V24, P172; Wong CF, 2008, J BIOL CHEM, V283, P9836, DOI 10.1074/jbc.M709614200; Yuasa K, 2008, CELL STRUCT FUNCT, V33, P163, DOI 10.1247/csf.08022; Zaccagnini G, 2005, J BIOL CHEM, V280, P14790, DOI 10.1074/jbc.M414644200; Zaccagnini G, 2004, CIRCULATION, V109, P2917, DOI 10.1161/01.CIR.0000129309.58874.0F; Zaccagnini G, 2007, J BIOL CHEM, V282, P31453, DOI 10.1074/jbc.M702511200	33	197	214	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3335	3346		10.1096/fj.08-128579	http://dx.doi.org/10.1096/fj.08-128579			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19528256				2022-12-28	WOS:000270354300011
J	Scott, RC; Rosano, JM; Ivanov, Z; Wang, B; Chong, PLG; Issekutz, AC; Crabbe, DL; Kiani, MF				Scott, Robert C.; Rosano, Jenna M.; Ivanov, Zhanna; Wang, Bin; Chong, Parkson Lee-Gau; Issekutz, Andrew C.; Crabbe, Deborah L.; Kiani, Mohammad F.			Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function	FASEB JOURNAL			English	Article						adhesion molecules; liposomes; microenvironment; targeted drug delivery	ENDOTHELIAL GROWTH-FACTOR; STEM-CELL TRANSPLANTATION; P-SELECTIN; THERAPEUTIC ANGIOGENESIS; MYOCARDIAL-INFARCTION; DRUG CARRIERS; DELIVERY; ISCHEMIA; REPAIR; GENE	Recent attempts at rebuilding the myocardium using stem cells have yielded disappointing results. The lack of a supporting vasculature may, in part, explain these disappointing findings. However, concerns over possible side effects have hampered attempts at revascularizing the infarcted myocardium using systemic delivery of proangiogenic compounds. In this study, we develop the technology to enhance the morphology and function of postinfarct neovasculature. Previously, we have shown that the up-regulated expression of endothelial cell adhesion molecules in the myocardial infarction (MI) region provides a potential avenue for selectively targeting drugs to infarcted tissue. After treatment with anti-P-selectin-conjugated liposomes containing vascular endothelial growth factor ( VEGF), changes in cardiac function and vasculature post-MI were quantified in a rat MI model. Targeted delivery of VEGF to post-MI tissue resulted in significant increase in fractional shortening and improved systolic function. These functional improvements were accompanied by a 21% increase in the number of anatomical vessels and a 74% increase in the number of perfused vessels in the MI region of treated animals. No significant improvements in cardiac function were observed in untreated, systemic VEGF-treated, nontargeted liposome-treated, or blank immunoliposome-treated animals. Targeted delivery of low doses of proangiogenic compounds to post-MI tissue results in significant improvements in cardiac function and vascular structure.-Scott, R. C., Rosano, J. M., Ivanov, Z., Wang, B., Lee-Gau Chong, P., Issekutz, I. C., Crabbe, D. L., Kiani, M. F. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J. 23, 3361-3367 ( 2009). www.fasebj.org	[Scott, Robert C.; Rosano, Jenna M.; Ivanov, Zhanna; Kiani, Mohammad F.] Temple Univ, Dept Mech Engn, Philadelphia, PA 19122 USA; [Kiani, Mohammad F.] Temple Univ, Dept Radiat Oncol, Philadelphia, PA 19122 USA; [Wang, Bin] Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; [Chong, Parkson Lee-Gau] Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19122 USA; [Crabbe, Deborah L.] Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19122 USA; [Issekutz, Andrew C.] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University System of Georgia; Augusta University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Dalhousie University	Kiani, MF (corresponding author), Temple Univ, Dept Mech Engn, 1947 N 12th St, Philadelphia, PA 19122 USA.	mkiani@temple.edu	Chong, Parkson Lee-Gau/I-3297-2019	Crabbe, Deborah/0000-0003-0061-3985	The American Heart Association; Pennsylvania Department of Health; Nanotechnology Institiute	The American Heart Association(American Heart Association); Pennsylvania Department of Health; Nanotechnology Institiute	This work was supported by grants from The American Heart Association, the Pennsylvania Department of Health, and the Nanotechnology Institiute. The human VEGF<INF>165A</INF> was generously provided by Genentech, Inc. ( San Francisco, CA, USA).	Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chien K, 2006, SCIENTIST, V20, P34; Chukwuemeka AO, 2005, ANN THORAC SURG, V79, P204, DOI 10.1016/j.athoracsur.2004.06.105; Ehrhardt C, 2004, ADV DRUG DELIVER REV, V56, P527, DOI 10.1016/j.addr.2003.10.029; Epstein SE, 2001, CIRCULATION, V104, P115, DOI 10.1161/01.CIR.104.1.115; Fenton BM, 1999, BRIT J CANCER, V79, P464, DOI 10.1038/sj.bjc.6690072; Freedman SB, 2002, ANN INTERN MED, V136, P54, DOI 10.7326/0003-4819-136-1-200201010-00011; Freedman SB, 2001, J MOL CELL CARDIOL, V33, P379, DOI 10.1006/jmcc.2000.1329; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Hiasa K, 2004, BASIC RES CARDIOL, V99, P165, DOI 10.1007/s00395-004-0456-9; Hughes GC, 2004, ANN THORAC SURG, V77, P812, DOI 10.1016/j.athoracsur.2003.09.060; Inoue M, 1998, CIRCULATION, V98, P2108, DOI 10.1161/01.CIR.98.20.2108; Jaakkola K, 2000, J AM COLL CARDIOL, V36, P122, DOI 10.1016/S0735-1097(00)00706-3; KIRBY C, 1984, BIO-TECHNOL, V2, P979, DOI 10.1038/nbt1184-979; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; Lee RJ, 2000, CIRCULATION, V102, P898; LITWIN SE, 1994, CIRCULATION, V89, P345, DOI 10.1161/01.CIR.89.1.345; Lopez JJ, 1998, CARDIOVASC RES, V40, P272, DOI 10.1016/S0008-6363(98)00136-9; Matsumoto R, 2005, ARTERIOSCL THROM VAS, V25, P1168, DOI 10.1161/01.ATV.0000165696.25680.ce; Misao Y, 2006, CARDIOVASC RES, V71, P455, DOI 10.1016/j.cardiores.2006.05.002; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Palazzo AJ, 1998, AM J PHYSIOL-HEART C, V275, pH1865, DOI 10.1152/ajpheart.1998.275.5.H1865; PATILLO CB, 2007, THESIS TEMPLE U PHIL; Payne TR, 2007, J AM COLL CARDIOL, V50, P1677, DOI 10.1016/j.jacc.2007.04.100; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104; Saxena A, 2008, CIRCULATION, V117, P2224, DOI 10.1161/CIRCULATIONAHA.107.694992; Schwarz ER, 2000, J AM COLL CARDIOL, V35, P1323, DOI 10.1016/S0735-1097(00)00522-2; Scott RC, 2008, EXPERT OPIN DRUG DEL, V5, P459, DOI 10.1517/17425247.5.4.459 ; Scott RC, 2007, BIOTECHNOL BIOENG, V96, P795, DOI 10.1002/bit.21233; Ulbrich H, 2003, TRENDS PHARMACOL SCI, V24, P640, DOI 10.1016/j.tips.2003.10.004; Vertesaljai M, 2008, HEART FAIL REV, V13, P227, DOI 10.1007/s10741-007-9047-9; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; Walter UM, 1997, HYBRIDOMA, V16, P249, DOI 10.1089/hyb.1997.16.249; Wang B, 2005, AM J PHYSIOL-HEART C, V289, pH108, DOI 10.1152/ajpheart.00001.2005; WANG B, 2007, THESIS TEMPLE U PHIL; Wang B, 2008, ADV EXP MED BIOL, V614, P333, DOI 10.1007/978-0-387-74911-2_37; Wang B, 2007, AM J PHYSIOL-HEART C, V293, pH3732, DOI 10.1152/ajpheart.00735.2007; Wollert KC, 2008, CURR OPIN PHARMACOL, V8, P202, DOI 10.1016/j.coph.2007.12.011; Yoshioka T, 2005, STEM CELLS, V23, P355, DOI 10.1634/stemcells.2004-0200	41	99	109	2	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3361	3367		10.1096/fj.08-127373	http://dx.doi.org/10.1096/fj.08-127373			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19535683				2022-12-28	WOS:000270354300013
J	Margarit, I; Bonacci, S; Pietrocola, G; Rindi, S; Ghezzo, C; Bombaci, M; Nardi-Dei, V; Grifantini, R; Speziale, P; Grandi, G				Margarit, Immaculada; Bonacci, Stefano; Pietrocola, Giampiero; Rindi, Simonetta; Ghezzo, Claudia; Bombaci, Mauro; Nardi-Dei, Vincenzo; Grifantini, Renata; Speziale, Pietro; Grandi, Guido			Capturing host-pathogen interactions by protein microarrays: identification of novel streptococcal proteins binding to human fibronectin, fibrinogen, and C4BP	FASEB JOURNAL			English	Article						GBS; GAS; virulence factors	GROUP-B STREPTOCOCCUS; COMPLETE GENOME SEQUENCE; PILUS-LIKE STRUCTURES; COMPLEMENT REGULATORS; SURFACE-PROTEINS; C5A PEPTIDASE; PYOGENES; VACCINE; ADHERENCE; PURIFICATION	Microbial pathogen entry and survival in the host is mediated by a network of molecular interactions between the two partners, which has been the subject of many research efforts. A complex picture is emerging in which host-pathogen crosstalk involves a high number of proteins, often with redundant functions. In the present study, we investigated the potential of protein microarrays to simultaneously scan interactions between surface proteins from two main human streptococcal pathogens, Streptococcus pyogenes and Streptococcus agalactiae, and three human ligands, fibronectin, fibrinogen, and C4 binding protein, known to play an important role in streptococcal pathogenesis. By using this technology, we confirmed interactions described in the literature and detected a novel set of streptococcal proteins with binding capacities for the human ligands. The observations were validated by Western blot and ELISA techniques. Three of the newly identified proteins were isoforms of a group B streptococcus-secreted component named Fib and displayed differential binding capacities for fibronectin, fibrinogen, and C4BP. The protein regions involved in the interaction with each ligand were identified by constructing fragments of one of the Fib variants. The approach proved valuable for the acquisition of novel insights into the complex network of protein-protein interactions occurring during microbial infection.-Margarit, I., Bonacci, S., Pietrocola, G., Rindi, S., Ghezzo, C., Bombaci, M., Nardi-Dei, V., Grifantini, R., Speziale, P., Grandi, G. Capturing host-pathogen interactions by protein microarrays: identification of novel streptococcal proteins binding to human fibronectin, fibrinogen and C4BP. FASEB J. 23, 3100-3112 ( 2009). www.fasebj.org	[Margarit, Immaculada; Bonacci, Stefano; Ghezzo, Claudia; Nardi-Dei, Vincenzo; Grandi, Guido] Novartis Vaccines & Diagnost, Siena, Italy; [Pietrocola, Giampiero; Rindi, Simonetta; Speziale, Pietro] Univ Pavia, Dept Biochem, I-27100 Pavia, Italy; [Bombaci, Mauro] Ist Nazl Genet Mol, Milan, Italy; [Grifantini, Renata] Externautics, Siena, Italy	Novartis; University of Pavia	Margarit, I (corresponding author), Novartis Vaccines, Res Ctr, Via Fiorentina 1, I-53100 Siena, Italy.	margarit_y_ros@novartis.com	Bombaci, Mauro/K-6106-2016; Renata, Grifantini/AAB-9969-2022; Bonacci, Stefano/ABI-5676-2020	Bombaci, Mauro/0000-0002-9887-4165; Renata, Grifantini/0000-0003-0024-3355; Grandi, Guido/0000-0001-9724-2185; PIETROCOLA, GIAMPIERO/0000-0002-7069-8155				AKESSON P, 1994, BIOCHEM J, V300, P877, DOI 10.1042/bj3000877; Bacarese-Hamilton T, 2004, J APPL MICROBIOL, V96, P10, DOI 10.1046/j.1365-2672.2003.02111.x; Beckmann C, 2002, INFECT IMMUN, V70, P2869, DOI 10.1128/IAI.70.6.2869-2876.2002; Berggard K, 2001, MOL MICROBIOL, V42, P539, DOI 10.1046/j.1365-2958.2001.02664.x; Bisno AL, 2003, LANCET INFECT DIS, V3, P191, DOI 10.1016/S1473-3099(03)00576-0; BORSI L, 1986, ANAL BIOCHEM, V155, P335, DOI 10.1016/0003-2697(86)90443-4; Brochet M, 2006, MICROBES INFECT, V8, P1227, DOI 10.1016/j.micinf.2005.11.010; Cai HY, 2005, J CLIN MICROBIOL, V43, P3427, DOI 10.1128/JCM.43.7.3427-3430.2005; Carlsson F, 2005, MOL MICROBIOL, V56, P28, DOI 10.1111/j.1365-2958.2005.04527.x; Chavakis T, 2005, THROMB HAEMOSTASIS, V94, P278, DOI 10.1160/TH05-05-0306; Chen CS, 2008, NAT METHODS, V5, P69, DOI 10.1038/NMETH1148; Cheng Q, 2002, INFECT IMMUN, V70, P2408, DOI 10.1128/IAI.70.5.2408-2413.2002; Courtney HS, 1999, MOL MICROBIOL, V32, P89, DOI 10.1046/j.1365-2958.1999.01328.x; COURTNEY HS, 1994, INFECT IMMUN, V62, P3937, DOI 10.1128/IAI.62.9.3937-3946.1994; Cue D, 2001, MICROB PATHOGENESIS, V31, P231, DOI 10.1006/mpat.2001.0467; Cue D, 1998, INFECT IMMUN, V66, P4593, DOI 10.1128/IAI.66.10.4593-4601.1998; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Dale JB, 2008, ADV EXP MED BIOL, V609, P53, DOI 10.1007/978-0-387-73960-1_5; Davies DH, 2005, P NATL ACAD SCI USA, V102, P547, DOI 10.1073/pnas.0408782102; Doran KS, 2004, MOL MICROBIOL, V54, P23, DOI 10.1111/j.1365-2958.2004.04266.x; Edwards RJ, 2005, J INFECT DIS, V192, P783, DOI 10.1086/432485; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Gutekunst H, 2004, INFECT IMMUN, V72, P3495, DOI 10.1128/IAI.72.6.3495-3504.2004; HANSKI E, 1992, P NATL ACAD SCI USA, V89, P6172, DOI 10.1073/pnas.89.13.6172; Hanski E, 1996, ADV EXP MED BIOL, V408, P141; Harris JW, 1998, HDB MATH COMPUTATION, P824; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; Johri AK, 2007, INFECT IMMUN, V75, P1473, DOI 10.1128/IAI.00638-06; Johri AK, 2006, NAT REV MICROBIOL, V4, P932, DOI 10.1038/nrmicro1552; Katerov V, 1998, MICROBIOL-UK, V144, P119, DOI 10.1099/00221287-144-1-119; Korf U, 2005, EXPERT REV PROTEOMIC, V2, P13, DOI 10.1586/14789450.2.1.13; Kwinn LA, 2007, FUTURE MICROBIOL, V2, P75, DOI 10.2217/17460913.2.1.75; Lauer P, 2005, SCIENCE, V309, P105, DOI 10.1126/science.1111563; Lee LYL, 2004, J BIOL CHEM, V279, P50710, DOI 10.1074/jbc.M408570200; Li B, 2005, INFECT IMMUN, V73, P3734, DOI 10.1128/IAI.73.6.3734-3739.2005; Liden A, 2008, J BIOL CHEM, V283, P1234, DOI 10.1074/jbc.M704827200; Lindahl G, 2005, CLIN MICROBIOL REV, V18, P102, DOI 10.1128/CMR.18.1.102-127.2005; Lindahl G, 2000, CURR OPIN IMMUNOL, V12, P44, DOI 10.1016/S0952-7915(99)00049-7; MacBeath G, 2000, SCIENCE, V289, P1760; Maione D, 2005, SCIENCE, V309, P148, DOI 10.1126/science.1109869; Manetti AGO, 2007, MOL MICROBIOL, V64, P968, DOI 10.1111/j.1365-2958.2007.05704.x; Marraffini LA, 2006, MICROBIOL MOL BIOL R, V70, P192, DOI 10.1128/MMBR.70.1.192-221.2006; Meenan NAG, 2007, J BIOL CHEM, V282, P25893, DOI 10.1074/jbc.M703063200; Mora M, 2005, P NATL ACAD SCI USA, V102, P15641, DOI 10.1073/pnas.0507808102; NOEL GJ, 1991, PEDIATR RES, V30, P118, DOI 10.1203/00006450-199107000-00023; Panizzi P, 2006, J BIOL CHEM, V281, P1179, DOI 10.1074/jbc.M507956200; Perez-Caballero D, 2004, J IMMUNOL, V173, P6899, DOI 10.4049/jimmunol.173.11.6899; Persson Jenny, 2006, PLoS Pathogens, V2, DOI 10.1371/journal.ppat.0020047; Rivera J, 2007, THROMB HAEMOSTASIS, V98, P503, DOI 10.1160/TH07-03-0233; Rodriguez-Ortega MJ, 2006, NAT BIOTECHNOL, V24, P191, DOI 10.1038/nbt1179; Rosini R, 2006, MOL MICROBIOL, V61, P126, DOI 10.1111/j.1365-2958.2006.05225.x; RUBENS CE, 1992, INFECT IMMUN, V60, P5157, DOI 10.1128/IAI.60.12.5157-5163.1992; Sandin C, 2006, MOL MICROBIOL, V59, P20, DOI 10.1111/j.1365-2958.2005.04913.x; Santi I, 2007, MOL MICROBIOL, V63, P754, DOI 10.1111/j.1365-2958.2006.05555.x; SCHMIDT KH, 1993, FEMS IMMUNOL MED MIC, V7, P135; Schubert A, 2002, MOL MICROBIOL, V46, P557, DOI 10.1046/j.1365-2958.2002.03177.x; Schuchat A, 1999, LANCET, V353, P51, DOI 10.1016/S0140-6736(98)07128-1; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V154, P15, DOI 10.1111/j.1432-1033.1986.tb09353.x; Sobke ACS, 2006, FASEB J, V20, P2621, DOI 10.1096/fj.06-5764fje; Speziale P, 2008, NAT PROTOC, V3, P525, DOI 10.1038/nprot.2008.12; Steller S, 2005, PROTEOMICS, V5, P2048, DOI 10.1002/pmic.200401097; TALAY SR, 1992, INFECT IMMUN, V60, P3837, DOI 10.1128/IAI.60.9.3837-3844.1992; Terao Y, 2002, J BIOL CHEM, V277, P47428, DOI 10.1074/jbc.M209133200; Terao Y, 2001, MOL MICROBIOL, V42, P75, DOI 10.1046/j.1365-2958.2001.02579.x; Tettelin H, 2005, P NATL ACAD SCI USA, V102, P13950, DOI 10.1073/pnas.0506758102; Tettelin H, 2002, P NATL ACAD SCI USA, V99, P12391, DOI 10.1073/pnas.182380799; WESTERLUND B, 1993, MOL MICROBIOL, V9, P687, DOI 10.1111/j.1365-2958.1993.tb01729.x; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083; Zhu H, 2006, P NATL ACAD SCI USA, V103, P4011, DOI 10.1073/pnas.0510921103; Zhu H, 2003, ANNU REV BIOCHEM, V72, P783, DOI 10.1146/annurev.biochem.72.121801.161511	71	43	43	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3100	3112		10.1096/fj.09-131458	http://dx.doi.org/10.1096/fj.09-131458			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19417080				2022-12-28	WOS:000270241000032
J	Dumont, M; Wille, E; Stack, C; Calingasan, NY; Beal, MF; Lin, MT				Dumont, Magali; Wille, Elizabeth; Stack, Cliona; Calingasan, Noel Y.; Beal, M. Flint; Lin, Michael T.			Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						Tg19959 mice; antioxidant; behavior; amyloid; synaptophysin	BETA-PEPTIDE; MITOCHONDRIAL DYSFUNCTION; COGNITIVE IMPAIRMENT; HYDROGEN-PEROXIDE; TGCRND8 MICE; IN-VIVO; DAMAGE; MECHANISM; AMYLOIDOGENESIS; EXPRESSION	In Alzheimer's disease (AD), oxidative stress is present early and contributes to disease pathogenesis. We previously reported that in Tg19959 transgenic AD mice, partial deficiency of the mitochondrial antioxidant enzyme manganese superoxide dismutase (MnSOD) exacerbated amyloid pathology. We therefore asked whether MnSOD overexpression would prove beneficial against AD pathogenesis, by studying the offspring of Tg19959 mice crossed with MnSOD-overexpressing mice. At 4 mo of age, there was a 2- to 3-fold increase in MnSOD protein levels in Tg19959-MnSOD mice compared to Tg19959 littermates. Tg19959-MnSOD mice also had a 50% increase in catalase protein levels, a 50% decrease in levels of oxidized protein, and a 33% reduction in cortical plaque burden compared to Tg19959 littermates. Spatial memory was impaired and synaptophysin levels were decreased in Tg19959 mice compared to wild-type littermates, but memory and synaptophysin levels were restored to wild-type levels in Tg19959-MnSOD littermates. These benefits occurred without changes in sodium dodecyl sulfate-soluble or formic acid-soluble A beta pools or A beta oligomers in Tg19959-MnSOD mice compared to Tg19959 littermates. These data demonstrate that facilitation of the mitochondrial antioxidant response improves resistance to A beta, slows plaque formation or increases plaque degradation, and markedly attenuates the phenotype in a transgenic AD mouse model.-Dumont, M., Wille, E., Stack, C., Calingasan, N. Y., Beal, M. F., Lin, M. T. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J. 23, 2459-2466 (2009)	[Dumont, Magali; Wille, Elizabeth; Stack, Cliona; Calingasan, Noel Y.; Beal, M. Flint; Lin, Michael T.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA	Cornell University	Lin, MT (corresponding author), Weill Cornell Med Coll, Dept Neurol & Neurosci, 525 E 68th St,A501, New York, NY 10065 USA.	mtl2002@med.cornell.edu		DUMONT, MAGALI/0000-0001-9990-6512	U.S. National Institutes of Health [AG20729]; NATIONAL INSTITUTE ON AGING [R01AG020729] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Charles Epstein (University of California, San Francisco, CA, USA) for providing MnSOD-overexpressing mice, and Anatoly Starkov, Davide Tampelini, Gunnar Gouras, and Yoon Kim for providing important scientific inputs to the manuscript. This research project was supported by U.S. National Institutes of Health grant AG20729.	BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; Bellucci A, 2006, NEUROBIOL DIS, V23, P260, DOI 10.1016/j.nbd.2006.03.012; Bieschke J, 2005, BIOCHEMISTRY-US, V44, P4977, DOI 10.1021/bi0501030; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Daumas S, 2008, LEARN MEMORY, V15, P625, DOI 10.1101/lm.990208; De Felice FG, 2007, J BIOL CHEM, V282, P11590, DOI 10.1074/jbc.M607483200; Dudal S, 2004, NEUROBIOL AGING, V25, P861, DOI 10.1016/j.neurobiolaging.2003.08.008; Dumont M, 2009, J NEUROCHEM, V109, P502, DOI 10.1111/j.1471-4159.2009.05970.x; Esposito L, 2006, J NEUROSCI, V26, P5167, DOI 10.1523/JNEUROSCI.0482-06.2006; Hartman RE, 2006, NEUROBIOL DIS, V24, P506, DOI 10.1016/j.nbd.2006.08.006; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Hyde LA, 2005, BEHAV BRAIN RES, V160, P344, DOI 10.1016/j.bbr.2004.12.017; Jucker M, 2008, NEURON, V59, P8, DOI 10.1016/j.neuron.2008.06.014; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Keller JN, 2005, NEUROLOGY, V64, P1152, DOI 10.1212/01.WNL.0000156156.13641.BA; Keller JN, 1998, J NEUROSCI, V18, P687; Li F, 2004, J NEUROCHEM, V89, P1308, DOI 10.1111/j.1471-4159.2004.02455.x; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Liu L, 2008, J MOL BIOL, V377, P1236, DOI 10.1016/j.jmb.2008.01.057; Lovasic L, 2005, GENES BRAIN BEHAV, V4, P197, DOI 10.1111/j.1601-183X.2004.00104.x; Melov S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000536; Morelra PI, 2008, FREE RADICAL BIO MED, V44, P1493, DOI 10.1016/j.freeradbiomed.2008.01.002; Murray IVJ, 2007, J BIOL CHEM, V282, P9335, DOI 10.1074/jbc.M608589200; Nunomura A, 2007, CURR MED CHEM, V14, P2968, DOI 10.2174/092986707782794078; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Pappolla MA, 1998, AM J PATHOL, V152, P871; Raineri I, 2001, FREE RADICAL BIO MED, V31, P1018, DOI 10.1016/S0891-5849(01)00686-4; Ringman JM, 2008, NEUROLOGY, V71, P85, DOI 10.1212/01.wnl.0000303973.71803.81; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Siedlak SL, 2009, FREE RADICAL RES, V43, P156, DOI 10.1080/10715760802644694; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; Sung S, 2003, FASEB J, V17, P323, DOI 10.1096/fj.03-0961fje; Tabner BJ, 2005, J BIOL CHEM, V280, P35789, DOI 10.1074/jbc.C500238200; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Tamagno E, 2005, J NEUROCHEM, V92, P628, DOI 10.1111/j.1471-4159.2004.02895.x; Tamagno E, 2002, NEUROBIOL DIS, V10, P279, DOI 10.1006/nbdi.2002.0515; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Varadarajan S, 1999, BRAIN RES BULL, V50, P133, DOI 10.1016/S0361-9230(99)00093-3; Yatin SM, 1999, NEUROCHEM RES, V24, P427, DOI 10.1023/A:1020997903147; Yoshiike Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003235	44	173	175	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2459	2466		10.1096/fj.09-132928	http://dx.doi.org/10.1096/fj.09-132928			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19346295	Green Published			2022-12-28	WOS:000268836700014
J	Fu, Q; Yu, X; Callaway, CW; Lane, RH; McKnight, RA				Fu, Qi; Yu, Xing; Callaway, Christopher W.; Lane, Robert H.; McKnight, Robert A.			Epigenetics: intrauterine growth retardation (IUGR) modifies the histone code along the rat hepatic IGF-1 gene	FASEB JOURNAL			English	Article						chromatin; DNA methylation; Barker hypothesis; chromatin immunoprecipitation; insulin resistance	FACTOR-I GENE; RNA-POLYMERASE-II; MESSENGER RIBONUCLEIC-ACIDS; TRANSCRIPTION START SITES; BIRTH-WEIGHT; UTEROPLACENTAL INSUFFICIENCY; LYSINE-4 METHYLATION; INSULIN-RESISTANCE; GESTATIONAL-AGE; EXTRAHEPATIC TISSUES	Intrauterine growth restriction ( IUGR) decreases serum insulin growth factor-1 (IGF-1) levels. IGF-1 is an epigenetically regulated gene that has two promoters, alternative exon 5 splicing, and multiple termination sites. The regulation of gene expression involves the whole gene, as evidenced by the aforementioned IGF-1 paradigm. We hypothesized that IUGR in the rat would affect hepatic IGF-1 expression and alter the epigenetic characteristics of the IGF-1 gene along its length. IUGR was induced through a bilateral uterine artery ligation of the pregnant rat, a well-characterized model of IUGR. Pups from anesthesia and sham-operated dams were used as controls. Real-time RTPCR and ELISA was used to measure expression at day of life (DOL) 0 and 21. Bisulfite sequencing and chromatin immunoprecipitation (ChIP) quantified IGF-1 epigenetic characteristics. A nontranscribed intergenic control was used for ChIP studies. IUGR decreased hepatic and serum IGF-1. Concurrently, IUGR modified epigenetic characteristics, particularly the histone code, along the length of the hepatic IGF-1 gene. Many changes persisted postnatally, and the postnatal effect of IUGR on the histone code was gender-specific. We conclude that IUGR modifies epigenetic characteristics of the rat hepatic IGF-1 gene along the length of the whole gene.-Fu, Q., Yu, X., Callaway, C. W., Lane, R. H., McKnight, R. A. Epigenetics: intrauterine growth retardation (IUGR) modifies the histone code along the rat hepatic IGF-1 gene. FASEB J. 23, 2438-2449 (2009)	[Fu, Qi; Yu, Xing; Callaway, Christopher W.; Lane, Robert H.; McKnight, Robert A.] Univ Utah, Sch Med, Dept Pediat, Div Neonatol, Salt Lake City, UT 84158 USA	Utah System of Higher Education; University of Utah	Lane, RH (corresponding author), Univ Utah, Sch Med, Dept Pediat, Div Neonatol, POB 581289, Salt Lake City, UT 84158 USA.	robert.lane@hsc.utah.edu		Callaway, Christopher/0000-0003-2072-0972	U.S. National Institutes of Health [HD41075]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041075] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The project was funded by the U.S. National Institutes of Health, grant HD41075. We thank the Division of Neonatology and the Developmental Origins of Health Laboratories at the University of Utah for their support and guidance.	ADAMO M, 1989, ENDOCRINOLOGY, V124, P2737, DOI 10.1210/endo-124-6-2737; Adamo ML, 2006, ENDOCRINOLOGY, V147, P2944, DOI 10.1210/en.2005-0742; ADAMO ML, 1991, MOL ENDOCRINOL, V5, P1677, DOI 10.1210/mend-5-11-1677; Ahmad K, 2002, CELL, V111, P281, DOI 10.1016/S0092-8674(02)01081-4; Alisi A, 2003, LIVER INT, V23, P179, DOI 10.1034/j.1600-0676.2003.00829.x; ASHTON IK, 1985, ACTA ENDOCRINOL-COP, V110, P558, DOI 10.1530/acta.0.1100558; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BASCRGA M, 2005, AM J PHYSIOL, V289, pR1348; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P7873, DOI 10.1093/nar/14.20.7873; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; BUTLER AA, 1994, MOL CELL ENDOCRINOL, V101, P321, DOI 10.1016/0303-7207(94)90249-6; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; CHEW SL, 1995, ENDOCRINOLOGY, V136, P1939, DOI 10.1210/en.136.5.1939; Dehe PM, 2006, J BIOL CHEM, V281, P35404, DOI 10.1074/jbc.M603099200; Demeny MA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000316; El Khattabi I, 2003, AM J PHYSIOL-ENDOC M, V285, pE991, DOI 10.1152/ajpendo.00037.2003; Fatemi M, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni180; Fattal-Valevski A, 2005, J PEDIATR ENDOCR MET, V18, P671; Flanagan DE, 2000, AM J PHYSIOL-ENDOC M, V278, pE700, DOI 10.1152/ajpendo.2000.278.4.E700; FOYT HL, 1992, MOL ENDOCRINOL, V6, P1881, DOI 10.1210/me.6.11.1881; Frusca T, 1997, EARLY HUM DEV, V48, P177, DOI 10.1016/S0378-3782(96)01854-3; Fu Q, 2004, PHYSIOL GENOMICS, V20, P108, DOI 10.1152/physiolgenomics.00175.2004; Fu Q, 2006, FASEB J, V20, P2127, DOI 10.1096/fj.06-6179fje; Gerber M, 2003, J BIOL CHEM, V278, P26303, DOI 10.1074/jbc.R300014200; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; GULER HP, 1987, NEW ENGL J MED, V317, P137, DOI 10.1056/NEJM198707163170303; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Hardy S, 2002, J BIOL CHEM, V277, P32875, DOI 10.1074/jbc.M205860200; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Huang HS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000809; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Isaksson OGP, 2001, HORM RES, V55, P18, DOI 10.1159/000063468; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Ke X, 2006, PHYSIOL GENOMICS, V25, P16, DOI 10.1152/physiolgenomics.00093.2005; Ke XR, 2005, AM J PHYSIOL-REG I, V288, pR1038, DOI 10.1152/ajpregu.00701.2004; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Lan F, 2007, NATURE, V448, P718, DOI 10.1038/nature06034; LASSARRE C, 1991, PEDIATR RES, V29, P219, DOI 10.1203/00006450-199103000-00001; LEROITH D, 1989, J MOL NEUROSCI, V1, P3, DOI 10.1007/BF02896850; Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; LOWE WL, 1988, MOL ENDOCRINOL, V2, P528, DOI 10.1210/mend-2-6-528; Martin DGE, 2006, MOL CELL BIOL, V26, P7871, DOI 10.1128/MCB.00573-06; McNairn AJ, 2003, BIOESSAYS, V25, P647, DOI 10.1002/bies.10305; Mi J, 2000, ANN INTERN MED, V132, P253, DOI 10.7326/0003-4819-132-4-200002150-00002; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Ozkan H, 1999, BIOL NEONATE, V76, P274, DOI 10.1159/000014169; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Radunovic N, 2000, J CLIN ENDOCR METAB, V85, P85, DOI 10.1210/jc.85.1.85; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Richards EJ, 2002, CURR BIOL, V12, pR694, DOI 10.1016/S0960-9822(02)01208-3; ROBERTS CT, 1987, MOL ENDOCRINOL, V1, P243, DOI 10.1210/mend-1-3-243; ROBERTS CT, 1987, BIOCHEM BIOPH RES CO, V146, P1154, DOI 10.1016/0006-291X(87)90768-6; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; SHIMATSU A, 1987, NUCLEIC ACIDS RES, V15, P7196, DOI 10.1093/nar/15.17.7196; SHIMATSU A, 1987, J BIOL CHEM, V262, P7894; SIEGFRIED JM, 1992, P NATL ACAD SCI USA, V89, P8107, DOI 10.1073/pnas.89.17.8107; SIMMONS JG, 1993, GROWTH FACTORS, V9, P205, DOI 10.3109/08977199309010833; Simmons RA, 2001, DIABETES, V50, P2279, DOI 10.2337/diabetes.50.10.2279; Sims RJ, 2006, GENE DEV, V20, P2779, DOI 10.1101/gad.1468206; Syddall HE, 2005, AM J EPIDEMIOL, V161, P1074, DOI 10.1093/aje/kwi137; Tenhola S, 2005, EUR J ENDOCRINOL, V152, P335, DOI 10.1530/eje.1.01869; TOBIN G, 1990, MOL ENDOCRINOL, V4, P1914, DOI 10.1210/mend-4-12-1914; Tresaugues L, 2006, J MOL BIOL, V359, P1170, DOI 10.1016/j.jmb.2006.04.050; Tsirka AE, 2001, J ENDOCRINOL, V169, P373, DOI 10.1677/joe.0.1690373; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; Verkauskiene R, 2005, J CLIN ENDOCR METAB, V90, P5672, DOI 10.1210/jc.2005-0423; VILEISIS RA, 1986, PEDIATR RES, V20, P126, DOI 10.1203/00006450-198602000-00006; Witlin AG, 1997, ANNU REV MED, V48, P115; Woelfle J, 2003, J BIOL CHEM, V278, P22696, DOI 10.1074/jbc.M301362200; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; Woods KA, 2000, J CLIN ENDOCR METAB, V85, P1407, DOI 10.1210/jc.85.4.1407; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Yarbrough DE, 1998, DIABETES CARE, V21, P1652, DOI 10.2337/diacare.21.10.1652; Zhang JH, 1997, ENDOCRINOLOGY, V138, P3112, DOI 10.1210/en.138.8.3112; Zimmermann P, 1997, ULTRASOUND OBST GYN, V9, P330, DOI 10.1046/j.1469-0705.1997.09050330.x; 2002, AM J PHYSL, V283, pR281	81	139	149	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2438	2449		10.1096/fj.08-124768	http://dx.doi.org/10.1096/fj.08-124768			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19364764	Green Published			2022-12-28	WOS:000268836700012
J	Lie, PPY; Mruk, DD; Lee, WM; Cheng, CY				Lie, Pearl P. Y.; Mruk, Dolores D.; Lee, Will M.; Cheng, C. Yan			Epidermal growth factor receptor pathway substrate 8 (Eps8) is a novel regulator of cell adhesion and the blood-testis barrier integrity in the seminiferous epithelium	FASEB JOURNAL			English	Article						spermatogenesis; Sertoli cells; germ cells; actin; actin dynamics	SERTOLI-CELL; ECTOPLASMIC SPECIALIZATION; RAT TESTIS; JUNCTION DYNAMICS; ADHERENS JUNCTIONS; TISSUE INHIBITOR; KINASE PATHWAY; MOUSE TESTES; IN-VIVO; SPERMATOGENESIS	In the seminiferous epithelium, Eps8 is localized to actin-based cell junctions at the blood-testis barrier (BTB) and the apical ectoplasmic specialization (ES) in stage V-VI tubules but is considerably diminished in stage VIII tubules. Eps8 down-regulation coincides with the time of BTB restructuring and apical ES disassembly, implicating the role of Eps8 in cell adhesion. Its involvement in Sertoli-germ cell adhesion was substantiated in studies using an in vivo animal model by treating rats with 1-(2,4-dichlorobenzy)-1H-indazole-3-carbohydrazide (adjudin) to induce anchoring junction restructuring, during which Eps8 disappeared at the apical ES before germ cell departure. In Sertoli cell cultures with established permeability barrier mimicking the BTB in vivo, the knockdown of Eps8 by RNAi led to F-actin disorganization and the mislocalization of the tight junction proteins occludin and ZO-1, suggesting the function of Eps8 in maintaining BTB integrity. In vivo knockdown of Eps8 in the testis caused germ cell sloughing and BTB damage, concomitant with occludin mislocalization, further validating that Eps8 is a novel regulator of cell adhesion and BTB integrity in the seminiferous epithelium.-Lie, P. P. Y., Mruk, D. D., Lee, W. M., Cheng, C. Y. Epidermal growth factor receptor pathway substrate 8 ( Eps8) is a novel regulator of cell adhesion and the blood-testis barrier integrity in the seminiferous epithelium. FASEB J. 23, 2555-2567 (2009)	[Cheng, C. Yan] Populat Council, Ctr Biomed Res, Mary M Wohlford Lab Male Contracept Res, New York, NY 10065 USA; [Lee, Will M.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China	Population Council; University of Hong Kong	Cheng, CY (corresponding author), Populat Council, Ctr Biomed Res, Mary M Wohlford Lab Male Contracept Res, 1230 York Ave, New York, NY 10065 USA.	y-cheng@popcbr.rockefeller.edu	Lee, Will M/D-2357-2009	Cheng, C Yan/0000-0003-3117-3791	NIH (NICHD) [R01HD056034, R03HD051512]; Hong Kong Research Grants Council [HKU7599/06M]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD056034] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD051512] Funding Source: NIH RePORTER	NIH (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Hong Kong Research Grants Council(Hong Kong Research Grants Council); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by NIH grants (NICHD, R01HD056034, R03HD051512 to C.Y.C.) and a Hong Kong Research Grants Council grant (HKU7599/06M to W. M. L.).	Aravindan GR, 1996, J CELL PHYSIOL, V168, P123; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Carlier MF, 2007, J BIOL CHEM, V282, P23005, DOI 10.1074/jbc.R700020200; CHENG CY, 1986, ENDOCRINOLOGY, V118, P480, DOI 10.1210/endo-118-2-480; Cheng CY, 2001, BIOL REPROD, V65, P449, DOI 10.1095/biolreprod65.2.449; Chung NPY, 2001, BIOL REPROD, V65, P1340, DOI 10.1095/biolreprod65.5.1340; CLERMONT Y, 1972, PHYSIOL REV, V52, P198, DOI 10.1152/physrev.1972.52.1.198; D'Souza R, 2009, ENDOCRINOLOGY, V150, P1861, DOI 10.1210/en.2008-1232; de Kretser D.M., 1988, P837; DeMali KA, 2003, J CELL SCI, V116, P2389, DOI 10.1242/jcs.00605; Di Fiore PP, 2002, INT J BIOCHEM CELL B, V34, P1178, DOI 10.1016/S1357-2725(02)00064-X; Disanza A, 2004, NAT CELL BIOL, V6, P1180, DOI 10.1038/ncb1199; Disanza A, 2006, NAT CELL BIOL, V8, P1337, DOI 10.1038/ncb1502; Galdieri M, 1981, J ANDROL, V5, P249; Guttman JA, 2000, J CELL SCI, V113, P2167; Higgs HN, 2004, NAT CELL BIOL, V6, P1147, DOI 10.1038/ncb1204-1147; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Lanzetti L, 2007, CURR OPIN CELL BIOL, V19, P453, DOI 10.1016/j.ceb.2007.04.017; Lee NPY, 2004, J ANDROL, V25, P200; Li R, 2008, NAT REV MOL CELL BIO, V9, P860, DOI 10.1038/nrm2522; Lui WY, 2003, ENDOCRINOLOGY, V144, P1139, DOI 10.1210/en.2002-0211; Lui WY, 2003, BBA-MOL CELL RES, V1593, P121, DOI 10.1016/S0167-4889(02)00348-8; Maa MC, 2007, J BIOL CHEM, V282, P19399, DOI 10.1074/jbc.M610280200; MacCalman CD, 1997, ENDOCRINOLOGY, V138, P41, DOI 10.1210/en.138.1.41; Meng J, 2005, P NATL ACAD SCI USA, V102, P16696, DOI 10.1073/pnas.0506084102; Miller MG, 1999, BIOL REPROD, V60, P1047, DOI 10.1095/biolreprod60.4.1047; Mruk DD, 2004, ENDOCR REV, V25, P747, DOI 10.1210/er.2003-0022; Mruk DD, 2003, J ANDROL, V24, P510; Mruk DD, 2008, PHARMACOL REV, V60, P146, DOI 10.1124/pr.107.07105; Offenhauser N, 2004, MOL BIOL CELL, V15, P91, DOI 10.1091/mbc.E03-06-0427; ORTH JM, 1982, ANAT REC, V203, P485, DOI 10.1002/ar.1092030408; PARVINEN M, 1982, ENDOCR REV, V3, P404, DOI 10.1210/edrv-3-4-404; PELLETIER RM, 1992, MICROSC RES TECHNIQ, V20, P3, DOI 10.1002/jemt.1070200104; PINEAU C, 1993, J ANDROL, V14, P87; POLLARD TD, 1999, GUIDEBOOK CYTOSKELET, P3; RUSSELL LD, 1988, BIOL REPROD, V39, P105, DOI 10.1095/biolreprod39.1.105; RUSSELL LD, 1987, GAMETE RES, V17, P43, DOI 10.1002/mrd.1120170106; RUSSELL LD, 1989, TISSUE CELL, V21, P361, DOI 10.1016/0040-8166(89)90051-7; Scita G, 2001, J CELL BIOL, V154, P1031, DOI 10.1083/jcb.200103146; Siu MKY, 2005, J BIOL CHEM, V280, P25029, DOI 10.1074/jbc.M501049200; Siu MKY, 2003, ENDOCRINOLOGY, V144, P371, DOI 10.1210/en.2002-220786; Toyama Yoshiro, 2003, Anatomical Science International, V78, P1, DOI 10.1046/j.0022-7722.2003.00034.x; Vaid KS, 2007, BIOL REPROD, V77, P1037, DOI 10.1095/biolreprod.107.063735; Velichkova M, 2002, CELL MOTIL CYTOSKEL, V51, P147, DOI 10.1002/cm.10025; Vogl AW, 2008, ADV EXP MED BIOL, V636, P186, DOI 10.1007/978-0-387-09597-4_11; Vogl AW, 2000, ARCH HISTOL CYTOL, V63, P1, DOI 10.1679/aohc.63.1; Vogl AW, 1993, SERTOLI CELL, P39; Wang RS, 2006, ENDOCRINOLOGY, V147, P5624, DOI 10.1210/en.2006-0138; Wiebe JP, 2000, J ANDROL, V21, P625; WIEBE JP, 1989, CONTRACEPTION, V39, P447, DOI 10.1016/0010-7824(89)90122-4; WIEBE JP, 1984, LIFE SCI, V34, P1747, DOI 10.1016/0024-3205(84)90574-5; Wong CH, 2005, ENDOCRINOLOGY, V146, P1893, DOI 10.1210/en.2004-1464; Wong EWP, 2008, BBA-BIOMEMBRANES, V1778, P692, DOI 10.1016/j.bbamem.2007.11.006; Xia WL, 2009, DEV BIOL, V327, P48, DOI 10.1016/j.ydbio.2008.11.028; Yan HHN, 2008, P NATL ACAD SCI USA, V105, P8950, DOI 10.1073/pnas.0711264105; Yan HHN, 2008, FASEB J, V22, P1945, DOI 10.1096/fj.06-070342; Yan HHN, 2007, BIOESSAYS, V29, P36, DOI 10.1002/bies.20513; Yan HHN, 2006, J BIOL CHEM, V281, P17286, DOI 10.1074/jbc.M513218200	59	112	117	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2555	2567		10.1096/fj.06-070573	http://dx.doi.org/10.1096/fj.06-070573			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19293393	Green Published			2022-12-28	WOS:000268836700024
J	Schroeder, MA; Atherton, HJ; Ball, DR; Cole, MA; Heather, LC; Griffin, JL; Clarke, K; Radda, GK; Tyler, DJ				Schroeder, Marie A.; Atherton, Helen J.; Ball, Daniel R.; Cole, Mark A.; Heather, Lisa C.; Griffin, Julian L.; Clarke, Kieran; Radda, George K.; Tyler, Damian J.			Real-time assessment of Krebs cycle metabolism using hyperpolarized C-13 magnetic resonance spectroscopy	FASEB JOURNAL			English	Article						dynamic nuclear polarization; ischemia; pyruvate dehydrogenase; TCA cycle	ACETYL-COENZYME-A; RAT-HEART; PYRUVATE-DEHYDROGENASE; ENERGY-METABOLISM; FAILING HEART; KETONE-BODIES; FATTY-ACIDS; NMR; OXIDATION; ENZYME	The Krebs cycle plays a fundamental role in cardiac energy production and is often implicated in the energetic imbalance characteristic of heart disease. In this study, we measured Krebs cycle flux in real time in perfused rat hearts using hyperpolarized magnetic resonance spectroscopy (MRS). [2-C-13] Pyruvate was hyperpolarized and infused into isolated perfused hearts in both healthy and postischemic metabolic states. We followed the enzymatic conversion of pyruvate to lactate, acetylcarnitine, citrate, and glutamate with 1 s temporal resolution. The appearance of C-13-labeled glutamate was delayed compared with that of other metabolites, indicating that Krebs cycle flux can be measured directly. The production of C-13-labeled citrate and glutamate was decreased postischemia, as opposed to lactate, which was significantly elevated. These results showed that the control and fluxes of the Krebs cycle in heart disease can be studied using hyperpolarized [2-C-13]pyruvate.-Schroeder, M. A., Atherton, H. J., Ball, D. R., Cole, M. A., Heather, L. C., Griffin, J. L., Clarke, K., Radda, G. K. Tyler, D. J. Real-time assessment of Krebs cycle metabolism using hyperpolarized C-13 magnetic resonance spectroscopy. FASEB J. 23, 2529-2538 (2009)	[Schroeder, Marie A.; Atherton, Helen J.; Ball, Daniel R.; Cole, Mark A.; Heather, Lisa C.; Clarke, Kieran; Radda, George K.; Tyler, Damian J.] Univ Oxford, Cardiac Metab Res Grp, Dept Physiol Anat & Genet, Oxford OX1 3PT, England; [Griffin, Julian L.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Oxford; University of Cambridge	Tyler, DJ (corresponding author), Univ Oxford, Cardiac Metab Res Grp, Dept Physiol Anat & Genet, Sherrington Bldg,Pk Rd, Oxford OX1 3PT, England.	damian.tyler@dpag.ox.ac.uk	Tyler, Damian/E-6296-2011	Tyler, Damian/0000-0002-0780-8905; Heather, Lisa/0000-0002-7246-1338; Cole, Mark/0000-0002-0727-7833	Newton Abraham Scholarship Foundation; NIH [1-F31-EB006692-01A1]; Medical Research Council (MRC) [G0601490]; British Heart Foundation (BHF) [PG/07/070/23365]; GE-Healthcare and Oxford Instruments Molecular Biotools; MRC [G0601490] Funding Source: UKRI; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [F31EB006692] Funding Source: NIH RePORTER; British Heart Foundation [PS/02/002/14893, RG/07/004/22659] Funding Source: researchfish; Medical Research Council [G0601490] Funding Source: researchfish	Newton Abraham Scholarship Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation (BHF)(British Heart Foundation); GE-Healthcare and Oxford Instruments Molecular Biotools; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors acknowledge previous work from scientists at Imagnia AB (Malmo, Sweden), which aided peak assignment in this study. We also thank Dr. Matthew Merritt and Professor Craig Malloy for helpful discussions regarding perfused heart techniques. M. S. gratefully acknowledges the Newton Abraham Scholarship Foundation for her D. Phil. studentship, and NIH grant 1-F31-EB006692-01A1. This work was funded by research grants from the Medical Research Council (MRC grant G0601490) and the British Heart Foundation (BHF grant PG/07/070/23365) and through equipment support from GE-Healthcare and Oxford Instruments Molecular Biotools.	Ardenkjaer-Larsen JH, 2003, P NATL ACAD SCI USA, V100, P10158, DOI 10.1073/pnas.1733835100; Atherton HJ, 2006, PHYSIOL GENOMICS, V27, P178, DOI 10.1152/physiolgenomics.00060.2006; BAILEY IA, 1981, FEBS LETT, V123, P315, DOI 10.1016/0014-5793(81)80317-1; BRINDLE KM, 1986, EUR J BIOCHEM, V158, P299, DOI 10.1111/j.1432-1033.1986.tb09751.x; Chen AP, 2007, MAGN RESON MED, V58, P1099, DOI 10.1002/mrm.21256; CLARKE K, 1993, NMR BIOMED, V6, P278, DOI 10.1002/nbm.1940060407; CLARKE K, 1987, J MOL CELL CARDIOL, V19, P1153, DOI 10.1016/S0022-2828(87)80525-4; CROSS HR, 1995, J MOL CELL CARDIOL, V27, P1369, DOI 10.1006/jmcc.1995.0130; Day SE, 2007, NAT MED, V13, P1382, DOI 10.1038/nm1650; DENNIS SC, 1991, J MOL CELL CARDIOL, V23, P1077, DOI 10.1016/0022-2828(91)91642-5; DEVILLALOBOS DH, 1995, LANCET, V345, P1552; Gallagher FA, 2008, NATURE, V453, P940, DOI 10.1038/nature07017; GARLAND PB, 1963, NATURE, V200, P169, DOI 10.1038/200169a0; Golman K, 2006, CANCER RES, V66, P10855, DOI 10.1158/0008-5472.CAN-06-2564; Golman K, 2006, P NATL ACAD SCI USA, V103, P11270, DOI 10.1073/pnas.0601319103; Jensen P.R., 2008, P INT SOC MAGN RES M; KERBEY AL, 1976, BIOCHEM J, V154, P327, DOI 10.1042/bj1540327; KURHANEWICZ J, 1995, UROLOGY, V45, P459, DOI 10.1016/S0090-4295(99)80016-8; LAUGHLIN MR, 1994, AM J PHYSIOL, V267, pH217, DOI 10.1152/ajpheart.1994.267.1.H217; Lopaschuk GD, 1997, CIRCULATION, V95, P313; Lydell CP, 2002, CARDIOVASC RES, V53, P841, DOI 10.1016/S0008-6363(01)00560-0; LYSIAK W, 1986, J BIOL CHEM, V261, P3698; MALLOY CR, 1990, BIOCHEMISTRY-US, V29, P6756, DOI 10.1021/bi00481a002; MALLOY CR, 1987, FEBS LETT, V212, P58, DOI 10.1016/0014-5793(87)81556-9; Merritt ME, 2007, P NATL ACAD SCI USA, V104, P19773, DOI 10.1073/pnas.0706235104; MOREADITH RW, 1984, J BIOL CHEM, V259, P6215; Naressi A, 2001, COMPUT BIOL MED, V31, P269, DOI 10.1016/S0010-4825(01)00006-3; NEELY JR, 1984, CIRC RES, V55, P816, DOI 10.1161/01.RES.55.6.816; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; Opie L.H., 2004, HEART PHYSL CELL CIR, DOI 10.1161/01.CIR.0000143724.99618.; Opie LH, 1998, HEART PHYSL CELL CIR; RANDLE PJ, 1963, LANCET, V1, P785; RENSTROM B, 1990, AM J PHYSIOL, V259, pH317, DOI 10.1152/ajpheart.1990.259.2.H317; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; Schroeder MA, 2008, P NATL ACAD SCI USA, V105, P12051, DOI 10.1073/pnas.0805953105; Sorokina N, 2007, CIRCULATION, V115, P2033, DOI 10.1161/CIRCULATIONAHA.106.668665; Stanley WC, 2005, PHYSIOL REV, V85, P1093, DOI 10.1152/physrev.00006.2004; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; TAEGTMEYER H, 1978, CIRC RES, V43, P808, DOI 10.1161/01.RES.43.5.808; Tyler DJ, 2008, APPL MAGN RESON, V34, P523, DOI 10.1007/s00723-008-0115-7	40	167	167	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2529	2538		10.1096/fj.09-129171	http://dx.doi.org/10.1096/fj.09-129171			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19329759	Green Published			2022-12-28	WOS:000268836700021
J	Tan, KM; Duquette, M; Joachimiak, A; Lawler, J				Tan, Kemin; Duquette, Mark; Joachimiak, Andrzej; Lawler, Jack			The crystal structure of the signature domain of cartilage oligomeric matrix protein: implications for collagen, glycosaminoglycan and integrin binding	FASEB JOURNAL			English	Article						thrombospondins; pseudoachondroplasia; multiple epiphyseal dysplasia	MULTIPLE EPIPHYSEAL DYSPLASIA; EXTRACELLULAR-MATRIX; CELL-DEATH; LIGAND RECOGNITION; COMP MUTATIONS; IX COLLAGEN; A-DOMAIN; PSEUDOACHONDROPLASIA; CALCIUM; THROMBOSPONDIN-1	Cartilage oligomeric matrix protein (COMP), or thrombospondin-5 (TSP-5), is a secreted glycoprotein that is important for growth plate organization and function. Mutations in COMP cause two skeletal dysplasias, pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (EDM1). In this study, we determined the structure of a recombinant protein that contains the last epidermal growth factor repeat, the type 3 repeats and the C-terminal domain (CTD) of COMP to 3.15-angstrom resolution limit by X-ray crystallography. The CTD is a beta-sandwich that is composed of 15 antiparallel beta-strands, and the type 3 repeats are a contiguous series of calcium binding sites that associate with the CTD at multiple points. The crystal packing reveals an exposed potential metal-ion-dependent adhesion site (MIDAS) on one edge of the beta-sandwich that is common to all TSPs and may serve as a binding site for collagens and other ligands. Disease-causing mutations in COMP disrupt calcium binding, disulfide bond formation, intramolecular interactions, or sites for potential ligand binding. The structure presented here and its unique molecular packing in the crystal identify potential interactive sites for glycosaminoglycans, integrins, and collagens, which are key to cartilage structure and function.-Tan, K., Duquette, M., Joachimiak, A., Lawler, J. The crystal structure of the signature domain of cartilage oligomeric matrix protein: implications for collagen, glycosaminoglycan and integrin binding. FASEB J. 23, 2490-2501 (2009)	[Duquette, Mark; Lawler, Jack] Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA; [Tan, Kemin; Joachimiak, Andrzej] Argonne Natl Lab, Midwest Ctr Struct Genom & Struct Biol Ctr, Biosci Div, Argonne, IL 60439 USA	Harvard University; Beth Israel Deaconess Medical Center; United States Department of Energy (DOE); Argonne National Laboratory	Lawler, J (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, 330 Brookline Ave,EC CLS 503, Boston, MA 02215 USA.	jlawler@bidmc.harvard.edu	Lawler, Jack/AAJ-1379-2020		National Institutes of Health [HL49081]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049081] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Jacqui Hecht and Dr. Karen Posey for insightful comments and suggestions, and Sami Lawler and Raji Bhat for expert assistance in the preparation of the manuscript. This work was funded by grant HL49081 from the National Institutes of Health. The coordinates and structural factors of E4T3C5 structure have been deposited in the PDB databank under the access code of 3FBY.	Adams JC, 2004, INT J BIOCHEM CELL B, V36, P1102, DOI 10.1016/j.biocel.2004.01.022; Adams JC, 2003, J MOL BIOL, V328, P479, DOI 10.1016/S0022-2836(03)00248-1; Adams JC, 2008, J CELL SCI, V121, P784, DOI 10.1242/jcs.021006; Arnaout MA, 2007, CURR OPIN CELL BIOL, V19, P495, DOI 10.1016/j.ceb.2007.08.002; Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S0955-0674(02)00371-X; Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Budde B, 2005, MOL CELL BIOL, V25, P10465, DOI 10.1128/MCB.25.23.10465-10478.2005; Carlson CB, 2008, J BIOL CHEM, V283, P27089, DOI 10.1074/jbc.M803842200; Carlson CB, 2005, NAT STRUCT MOL BIOL, V12, P910, DOI 10.1038/nsmb997; Chen FH, 2007, J BIOL CHEM, V282, P24591, DOI 10.1074/jbc.M611390200; Chen FH, 2005, J BIOL CHEM, V280, P32655, DOI 10.1074/jbc.M504778200; Chen TLL, 2008, J CELL BIOCHEM, V103, P778, DOI 10.1002/jcb.21445; Di Cesare PE, 2002, MATRIX BIOL, V21, P461, DOI 10.1016/S0945-053X(02)00015-X; Dinser R, 2002, J CLIN INVEST, V110, P505, DOI 10.1172/JCI200214386; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Giannoni P, 2003, BIORHEOLOGY, V40, P101; Halasz K, 2007, J BIOL CHEM, V282, P31166, DOI 10.1074/jbc.M705735200; Hecht JT, 2005, MATRIX BIOL, V23, P525, DOI 10.1016/j.matbio.2004.09.006; Hecht JT, 2004, J ORTHOP RES, V22, P759, DOI 10.1016/j.orthres.2003.11.010; Hecht JT, 1998, MATRIX BIOL, V17, P625, DOI 10.1016/S0945-053X(98)90113-5; Hecht JT, 2001, MATRIX BIOL, V20, P251, DOI 10.1016/S0945-053X(01)00136-6; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kawaji H, 2002, SKELETAL RADIOL, V31, P730, DOI 10.1007/s00256-002-0553-5; Kawaji H, 2002, GENOME RES, V12, P367, DOI 10.1101/gr.193702; Kennedy J, 2005, EUR J HUM GENET, V13, P547, DOI 10.1038/sj.ejhg.5201374; Kipnes J, 2003, OSTEOARTHR CARTILAGE, V11, P442, DOI 10.1016/S1063-4584(03)00055-4; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P6367, DOI 10.1073/pnas.0401506101; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618; Mann HH, 2004, J BIOL CHEM, V279, P25294, DOI 10.1074/jbc.M403778200; Merritt TM, 2007, AM J PATHOL, V170, P293, DOI 10.2353/ajpath.2007.060530; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; Pihlajamaa T, 2004, J BIOL CHEM, V279, P24265, DOI 10.1074/jbc.M402865200; Pirog-Garcia KA, 2007, HUM MOL GENET, V16, P2072, DOI 10.1093/hmg/ddm155; Posey KL, 2008, AM J PATHOL, V172, P1664, DOI 10.2353/ajpath.2008.071094; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Rudenko G, 2001, TRENDS BIOCHEM SCI, V26, P363, DOI 10.1016/S0968-0004(01)01832-1; Schmitz M, 2006, J BIOL CHEM, V281, P32587, DOI 10.1074/jbc.M601976200; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Song G, 2005, P NATL ACAD SCI USA, V102, P3366, DOI 10.1073/pnas.0500200102; Springer TA, 2008, J CELL BIOL, V182, P791, DOI 10.1083/jcb.200801146; STANESCU R, 1993, AM J MED GENET, V45, P501, DOI 10.1002/ajmg.1320450420; Takagi J, 2007, CURR OPIN CELL BIOL, V19, P557, DOI 10.1016/j.ceb.2007.09.002; Tan K, 2008, J BIOL CHEM, V283, P3932, DOI 10.1074/jbc.M705203200; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Valdramidou D, 2008, J BIOL CHEM, V283, P32704, DOI 10.1074/jbc.M802066200; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2; Weirich C, 2007, MATRIX BIOL, V26, P314, DOI 10.1016/j.matbio.2007.01.004; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xu K, 2007, J BIOL CHEM, V282, P11347, DOI 10.1074/jbc.M608744200	57	51	55	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2490	2501		10.1096/fj.08-128090	http://dx.doi.org/10.1096/fj.08-128090			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19276170	Green Published			2022-12-28	WOS:000268836700017
J	Yende, S; Angus, DC; Kong, L; Kellum, JA; Weissfeld, L; Ferrell, R; Finegold, D; Carter, M; Leng, L; Peng, ZY; Bucala, R				Yende, Sachin; Angus, Derek C.; Kong, Lan; Kellum, John A.; Weissfeld, Lisa; Ferrell, Robert; Finegold, David; Carter, Melinda; Leng, Lin; Peng, Zhi-Yong; Bucala, Richard			The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia	FASEB JOURNAL			English	Article						cytokines; innate immunity; sepsis; TNF	FACTOR MIF GENE; SEPTIC SHOCK; RHEUMATOID-ARTHRITIS; CRITICAL MEDIATOR; SEPSIS; SEVERITY; ASSOCIATION; INFECTIONS; PREDICTION; CYTOKINE	The cytokine, macrophage migration inhibitory factor (MIF), is encoded in a functionally polymorphic locus and subjects with high-expression MIF alleles are at an increased risk of inflammatory disease. Severe sepsis is the leading cause of death in intensive care units, and the prevailing hypothesis is that an excessive innate response contributes to its pathogenesis. To assess if MIF alleles influence the clinical course of infection, we conducted a case-control study to assess susceptibility and a parallel inception cohort study of community-acquired pneumonia (CAP) to assess risk of severe sepsis and 90-d mortality. Two distinct polymorphisms in the MIF promoter were analyzed: a G/C transition at -173 and a CATT repeat at -794. The frequency of both polymorphisms was similar in the CAP cohort (n = 1739) and controls (n = 639); however, the 90-d mortality was lower for the high-expression C allele (P=0.003). This association remained significant after adjusting for demographics, comorbid conditions, and disease severity score [hazard ratio=0.64 (0.44-0.91), P=0.01]. The hazard ratio was similar in different geographic subcohorts, and the association remained significant after adjusting for false discovery. These data indicate that polymorphisms associated with higher MIF expression may have a beneficial effect in community-acquired pneumonia.-Yende, S., Angus, D. C., Kong, L., Kellum, J. A., Weissfeld, L., Ferrell, R., Finegold, D., Carter, M., Leng, L., Peng, Z.-Y., Bucala, R. The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. FASEB J. 23, 2403-2411 (2009)	[Yende, Sachin; Angus, Derek C.; Kong, Lan; Kellum, John A.; Weissfeld, Lisa; Carter, Melinda; Peng, Zhi-Yong] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness Lab, Pittsburgh, PA 15261 USA; [Kong, Lan; Weissfeld, Lisa] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Ferrell, Robert; Finegold, David] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA; [Leng, Lin; Bucala, Richard] Yale Univ, Sch Med, Dept Pathol & Med, New Haven, CT USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yale University	Angus, DC (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness Lab, 614 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	angusdc@upmc.edu	Kellum, John/AAP-3072-2020; Angus, Derek C/E-9671-2012; Kellum, John A/HCH-2944-2022	Kellum, John/0000-0003-1995-2653; Kellum, John A/0000-0003-1995-2653; Finegold, David/0000-0001-9901-2578; Leng, Lin/0000-0002-0605-358X	NIH [NIGMS R01 GM61992, NIAID R01 AI042310, NO1 AI50031]; GlaxoSmithKline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042310, N01AI050031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061992] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are indebted to the nurses, respiratory therapists, phlebotomists, physicians, and other health care professionals who participated in GenIMS, as well as the patients and their families who supported this trial. A complete list of GenIMS investigators is available online (http://www.ccm.upmc.edu/genims_investigators). GenIMS was funded by NIH grants NIGMS R01 GM61992, NIAID R01 AI042310, and NO1 AI50031, with additional support from GlaxoSmithKline for enrollment and clinical data collection, Diagnostic Products Corporation for the cytokine assays, and an internal seed grant from the Department of Critical Care Medicine at the University of Pittsburgh. Yale University (R.B.) has applied for a patent describing the diagnostic value of MIF genotype. No other potential conflicts of interest were identified on behalf of the GenIMS investigators.	Baugh JA, 2002, GENES IMMUN, V3, P170, DOI 10.1038/sj.gene.6363867; Beishuizen A, 2001, J CLIN ENDOCR METAB, V86, P2811, DOI 10.1210/jc.86.6.2811; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Calandra T, 1998, P NATL ACAD SCI USA, V95, P11383, DOI 10.1073/pnas.95.19.11383; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christ-Crain M, 2004, LANCET, V363, P600, DOI 10.1016/S0140-6736(04)15591-8; Cohen J, 2001, CRIT CARE MED, V29, P880, DOI 10.1097/00003246-200104000-00039; Donn R, 2004, ARTHRITIS RHEUM-US, V50, P1604, DOI 10.1002/art.20178; Donn R, 2002, ARTHRITIS RHEUM-US, V46, P2402, DOI 10.1002/art.10492; Donn RP, 2001, ARTHRITIS RHEUM-US, V44, P1782, DOI 10.1002/1529-0131(200108)44:8<1782::AID-ART314>3.0.CO;2-#; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Gallagher PM, 2003, THORAX, V58, P154, DOI 10.1136/thorax.58.2.154; Gando S, 2001, INTENS CARE MED, V27, P1187, DOI 10.1007/s001340000818; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Holmes CL, 2003, CHEST, V124, P1103, DOI 10.1378/chest.124.3.1103; Honma N, 2000, IMMUNOLOGY, V100, P84, DOI 10.1046/j.1365-2567.2000.00011.x; Joshi N, 1999, NEW ENGL J MED, V341, P1906, DOI 10.1056/NEJM199912163412507; Kellum JA, 2007, ARCH INTERN MED, V167, P1655, DOI 10.1001/archinte.167.15.1655; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Koebernick H, 2002, P NATL ACAD SCI USA, V99, P13681, DOI 10.1073/pnas.212488699; Lehmann LE, 2001, INTENS CARE MED, V27, P1412, DOI 10.1007/s001340101022; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Metersky ML, 2004, AM J RESP CRIT CARE, V169, P342, DOI 10.1164/rccm.200309-1248OC; Meyer-Siegler KL, 2007, GENES IMMUN, V8, P646, DOI 10.1038/sj.gene.6364427; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Morand EF, 2002, RHEUMATOLOGY, V41, P558, DOI 10.1093/rheumatology/41.5.558; Pollak N, 2005, INFECT IMMUN, V73, P6488, DOI 10.1128/IAI.73.10.6488-6492.2005; Radstake TRDJ, 2005, ARTHRITIS RHEUM, V52, P3020, DOI 10.1002/art.21285; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001; Waterer GW, 2001, AM J RESP CRIT CARE, V163, P1599, DOI 10.1164/ajrccm.163.7.2011088; Zhong XB, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni123	41	72	75	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2403	2411		10.1096/fj.09-129445	http://dx.doi.org/10.1096/fj.09-129445			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19346297	Green Published			2022-12-28	WOS:000268836700009
J	Sudo, R; Chung, S; Zervantonakis, IK; Vickerman, V; Toshimitsu, Y; Griffith, LG; Kamm, RD				Sudo, Ryo; Chung, Seok; Zervantonakis, Ioannis K.; Vickerman, Vernella; Toshimitsu, Yasuko; Griffith, Linda G.; Kamm, Roger D.			Transport-mediated angiogenesis in 3D epithelial coculture	FASEB JOURNAL			English	Article						microfluidics; vascularization; tissue engineering	CELL-CELL INTERACTIONS; IN-VITRO; MICROFLUIDIC PLATFORM; LIVER-REGENERATION; ENDOTHELIAL-CELLS; PERFUSION-CULTURE; TISSUE; HEPATOCYTES; MORPHOGENESIS; TECHNOLOGIES	Increasing interest has focused on capturing the complexity of tissues and organs in vitro as models of human pathophysiological processes. In particular, a need exists for a model that can investigate the interactions in three dimensions (3D) between epithelial tissues and a microvascular network since vascularization is vital for reconstructing functional tissues in vitro. Here, we implement a microfluidic platform to analyze angiogenesis in 3D cultures of rat primary hepatocytes and rat/human microvascular endothelial cells (rMVECs/hMVECs). Liver and vascular cells were cultured on each sidewall of a collagen gel scaffold between two microfluidic channels under static or flow conditions. Morphogenesis of 3D hepatocyte cultures was found to depend on diffusion and convection across the nascent tissue. Furthermore, rMVECs formed 3D capillary-like structures that extended across an intervening gel to the hepatocyte tissues in hepatocyter-MVEC coculture while they formed 2D sheet-like structures in rMVEC monoculture. In addition, diffusion of fluorescent dextran across the gel scaffold was analyzed, demonstrating that secreted proteins from the hepatocytes and MVECs can be exchanged across the gel scaffold by diffusional transport. The experimental approach described here is useful more generally for investigating microvascular networks within 3D engineered tissues with multiple cell types in vitro.-Sudo, R., Chung, S., Zervantonakis, I. K., Vickerman, V., Toshimitsu, Y., Griffith, L. G., Kamm, R. D. Transport-mediated angiogenesis in 3D epithelial coculture. FASEB J. 23, 2155-2164 (2009)	[Sudo, Ryo; Chung, Seok; Toshimitsu, Yasuko; Griffith, Linda G.; Kamm, Roger D.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA; [Zervantonakis, Ioannis K.; Griffith, Linda G.; Kamm, Roger D.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA; [Vickerman, Vernella] MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Kamm, RD (corresponding author), MIT, Dept Biol Engn, 77 Massachusetts Ave,NE47-321, Cambridge, MA 02139 USA.	rdkamm@mit.edu	Sudo, Ryo/D-2319-2010; Zervantonakis, Ioannis/C-2890-2011; Kamm, Roger D/I-7630-2012; Zervantonakis, Ioannis/ADS-2519-2022; Zervantonakis, Ioannis/N-9717-2019; Chung, Seok/B-1501-2015	Zervantonakis, Ioannis/0000-0003-2386-9553; Zervantonakis, Ioannis/0000-0003-2386-9553; Zervantonakis, Ioannis/0000-0003-2386-9553; Sudo, Ryo/0000-0002-1053-9662; /0000-0002-7232-304X; Griffith, Linda/0000-0002-1801-5548	National Institute of Biomedical Imaging and Bioengineering [EB003805]; Draper Laboratories Inc [DL-H-550151]; Singapore-MIT Alliance for Research and Technology; Japan Society for the Promotion of Science; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB003805] Funding Source: NIH RePORTER	National Institute of Biomedical Imaging and Bioengineering(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); Draper Laboratories Inc; Singapore-MIT Alliance for Research and Technology; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We thank Jose Antonio Sanz-Hererrea for analyzing the diffusion experiments; Chen-rei Wan and Nathan Hammond for critical reading of the manuscript; and Laura Vineyard, Romie Littrell, and Ta- Chun Hang for technical assistance. We also appreciate helpful discussions with Carlos Semino at the Massachusetts Institute of Technology (MIT) and Donna Stolz at the University of Pittsburgh. This research is supported by the National Institute of Biomedical Imaging and Bioengineering (EB003805), Draper Laboratories Inc. (UR&D project DL-H-550151), Singapore-MIT Alliance for Research and Technology, and Japan Society for the Promotion of Science postdoctoral fellowships for research abroad ( R. S.).	Bhatia SN, 1999, FASEB J, V13, P1883, DOI 10.1096/fasebj.13.14.1883; Block GD, 1996, J CELL BIOL, V132, P1133, DOI 10.1083/jcb.132.6.1133; CHARY SR, 1989, P NATL ACAD SCI USA, V86, P5385, DOI 10.1073/pnas.86.14.5385; Chung S, 2009, LAB CHIP, V9, P269, DOI 10.1039/b807585a; Davis GE, 2002, ANAT RECORD, V268, P252, DOI 10.1002/ar.10159; Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858; Griffith LG, 2002, SCIENCE, V295, P1009, DOI 10.1126/science.1069210; Helm CLE, 2005, P NATL ACAD SCI USA, V102, P15779, DOI 10.1073/pnas.0503681102; Hui EE, 2007, P NATL ACAD SCI USA, V104, P5722, DOI 10.1073/pnas.0608660104; Hwa AJ, 2007, FASEB J, V21, P2564, DOI 10.1096/fj.06-7473com; Jain RK, 2005, NAT BIOTECHNOL, V23, P821, DOI 10.1038/nbt0705-821; Khademhosseini A, 2006, P NATL ACAD SCI USA, V103, P2480, DOI 10.1073/pnas.0507681102; Kim L, 2007, LAB CHIP, V7, P681, DOI 10.1039/b704602b; Lauffenburger DA, 2001, P NATL ACAD SCI USA, V98, P4282, DOI 10.1073/pnas.081083698; Levenberg S, 2005, NAT BIOTECHNOL, V23, P879, DOI 10.1038/nbt1109; MARTINEZHERNANDEZ A, 1995, FASEB J, V9, P1401, DOI 10.1096/fasebj.9.14.7589981; Michalopoulos GK, 2005, ADV BIOCHEM ENG BIOT, V93, P101, DOI 10.1007/b99968; Nahmias Y, 2007, ADV BIOCHEM ENG BIOT, V103, P309, DOI 10.1007/10_029; Nahmias Y, 2006, TISSUE ENG, V12, P1627, DOI 10.1089/ten.2006.12.1627; Nerem RM, 2006, TISSUE ENG, V12, P1143, DOI 10.1089/ten.2006.12.1143; Ross MA, 2001, HEPATOLOGY, V34, P1135, DOI 10.1053/jhep.2001.29624; Sudo R, 2005, FASEB J, V19, P1695, DOI 10.1096/fj.04-3269fje; Toh YC, 2007, LAB CHIP, V7, P302, DOI 10.1039/b614872g; Vailhe B, 2001, LAB INVEST, V81, P439, DOI 10.1038/labinvest.3780252; Vickerman V, 2008, LAB CHIP, V8, P1468, DOI 10.1039/b802395f; Walker GM, 2004, LAB CHIP, V4, P91, DOI 10.1039/b311214d; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Yamamura N, 2007, TISSUE ENG, V13, P1443, DOI 10.1089/ten.2006.0333	28	143	149	2	94	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2155	2164		10.1096/fj.08-122820	http://dx.doi.org/10.1096/fj.08-122820			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19246488	Green Published			2022-12-28	WOS:000268836500015
J	Dai, W; Kamei, H; Zhao, Y; Ding, J; Du, Z; Duan, CM				Dai, Wei; Kamei, Hiroyasu; Zhao, Yang; Ding, Jun; Du, Zhou; Duan, Cunming			Duplicated zebrafish insulin-like growth factor binding protein-5 genes with split functional domains: evidence for evolutionarily conserved IGF binding, nuclear localization, and transactivation activity	FASEB JOURNAL			English	Article						IGFBP; IGF-independent action; gene expression; subfunctionalization	AMINO-ACIDS; FACTOR-I; HEPARIN-BINDING; IGFBP-5; ROLES; DIVERGENCE; TRANSPORT	Insulin-like growth factor binding protein (IGFBP)-5 is a secreted protein that binds to IGF and modulates IGF actions. IGFBP-5 is also found in the nucleus of mammalian cells and has transactivation activity. The structural basis of this transactivation activity and its role in mediating IGF-independent actions are not clear. Here we report that there are 2 igfbp-5 genes in zebrafish and other teleost fish. In zebrafish, igfbp-5a and -5b are expressed in spatially restricted, mostly nonoverlapping domains during early development. The IGF binding site is conserved in both zebrafish IGFBP-5s, and they are both secreted and capable of IGF binding. Both proteins contain a consensus bipartite nuclear localization signal and were found in the nucleus when introduced into cultured cells. Although zebrafish IGFBP-5b possesses transactivation activity, zebrafish IGFBP-5a lacks this activity. Mutational analysis demonstrated that 2 unique amino acids in positions 22 and 56 of IGFBP-5a are responsible for its lack of transactivation activity. These findings suggest that the duplicated zebrafish IGFBP-5s have evolved divergent regulatory mechanisms and distinct biological properties by partitioning of ancestral structural domains and provide new evidence for a conserved role of the IGF binding, nuclear localization, and transactivation domain of this multifunctional IGFBP.-Dai, W., Kamei, H., Zhao, Y., Ding, J., Du, Z., Duan, C. Duplicated zebrafish insulin-like growth factor binding protein-5 genes with split functional domains: evidence for evolutionarily conserved IGF binding, nuclear localization, and transactivation activity. FASEB J. 24, 2020-2029 (2010). www.fasebj.org	[Dai, Wei; Kamei, Hiroyasu; Zhao, Yang; Ding, Jun; Du, Zhou; Duan, Cunming] Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Duan, CM (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.	cduan@umich.edu		KAMEI, HIROYASU/0000-0001-7123-040X; Dai, Wei/0000-0001-6069-9616	U.S. National Institutes of Health [2RO1HL60679]; National Science Foundation [IOB 0110864]; Japan Society for the Promotion of Science; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060679] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank John Allard for critical reading of this manuscript. This study was supported by U.S. National Institutes of Health grant 2RO1HL60679 and National Science Foundation research grant IOB 0110864 to C. D. H. K. is supported in part by a postdoctoral fellowship from the Japan Society for the Promotion of Science.	Abrass CK, 1997, AM J PHYSIOL-RENAL, V273, pF899, DOI 10.1152/ajprenal.1997.273.6.F899; Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; Arai T, 1996, J BIOL CHEM, V271, P6099, DOI 10.1074/jbc.271.11.6099; Beattie J, 2006, BIOCHEM J, V395, P1, DOI 10.1042/BJ20060086; Berfield AK, 2000, KIDNEY INT, V57, P1991, DOI 10.1046/j.1523-1755.2000.00049.x; Chothia C, 2003, SCIENCE, V300, P1701, DOI 10.1126/science.1085371; Duan CM, 2005, GEN COMP ENDOCR, V142, P44, DOI 10.1016/j.ygcen.2004.12.022; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Firth SM, 2001, ENDOCRINOLOGY, V142, P2147, DOI 10.1210/en.142.5.2147; Force A, 1999, GENETICS, V151, P1531; Hsieh T, 2003, J BIOL CHEM, V278, P42886, DOI 10.1074/jbc.M303835200; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Kamei H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003091; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kleinjan DA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040029; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Li WL, 1997, ENDOCRINOLOGY, V138, P1763, DOI 10.1210/en.138.4.1763; Li Y, 2005, J BIOL CHEM, V280, P3613, DOI 10.1074/jbc.M411479200; Maures T, 2002, ENDOCRINOLOGY, V143, P1858, DOI 10.1210/en.143.5.1858; McClintock JM, 2002, DEVELOPMENT, V129, P2339; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Ning Y, 2007, ENDOCRINOLOGY, V148, P2138, DOI 10.1210/en.2006-0041; Parker A, 1998, MOL BIOL CELL, V9, P2383, DOI 10.1091/mbc.9.9.2383; Postlethwait J, 2004, TRENDS GENET, V20, P481, DOI 10.1016/j.tig.2004.08.001; Ren HX, 2008, J CELL BIOL, V182, P979, DOI 10.1083/jcb.200712110; Rozen F, 1997, J NATL CANCER I, V89, P652, DOI 10.1093/jnci/89.9.652; Salih DAM, 2004, P NATL ACAD SCI USA, V101, P4314, DOI 10.1073/pnas.0400230101; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schlueter PJ, 2006, FASEB J, V20, P1230, DOI 10.1096/fj.05-3882fje; Shimizu M, 2000, GEN COMP ENDOCR, V119, P26, DOI 10.1006/gcen.2000.7498; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Tripathi G, 2009, FASEB J, V23, P2616, DOI 10.1096/fj.08-114124; Wang XL, 2009, AM J PHYSIOL-REG I, V296, pR1348, DOI 10.1152/ajpregu.90969.2008; Wood AW, 2005, INT REV CYTOL, V243, P215, DOI 10.1016/S0074-7696(05)43004-1; Xu QJ, 2004, CIRC RES, V94, pE46, DOI 10.1161/01.RES.0000124761.62846.DF; Zhao Y, 2006, J BIOL CHEM, V281, P14184, DOI 10.1074/jbc.M506941200; Zhou JF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003926; Zou SM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007026	42	39	40	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					2020	2029		10.1096/fj.09-149435	http://dx.doi.org/10.1096/fj.09-149435			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20081093	Green Published, Green Submitted			2022-12-28	WOS:000278200000036
J	Otero-Gonzalez, AJ; Magalhaes, BS; Garcia-Villarino, M; Lopez-Abarrategui, C; Sousa, DA; Dias, SC; Franco, OL				Jesus Otero-Gonzalez, Anselmo; Magalhaes, Beatriz Simas; Garcia-Villarino, Monica; Lopez-Abarrategui, Carlos; Sousa, Daniel Amaro; Dias, Simoni Campos; Franco, Octavio Luiz			Antimicrobial peptides from marine invertebrates as a new frontier for microbial infection control	FASEB JOURNAL			English	Review						innate immunity; peptide structure and function; unusual properties	HORSESHOE-CRAB HEMOCYTES; HOST-DEFENSE PEPTIDES; ANTIBACTERIAL PEPTIDE; INNATE IMMUNITY; BIG DEFENSIN; MOLECULAR CHARACTERIZATION; LITOPENAEUS-VANNAMEI; GRANULAR HEMOCYTES; SOLITARY TUNICATE; TACHYPLESIN-I	Antimicrobial peptides are widely expressed in organisms and have been linked to innate and acquired immunities in vertebrates. These compounds are constitutively expressed and rapidly induced at different cellular levels to interact directly with infectious agents and/or modulate immunoreactions involved in defense against pathogenic microorganisms. In invertebrates, antimicrobial peptides represent the major humoral defense system against infection, showing a diverse spectrum of action mechanisms, most of them related to plasma membrane disturbance and lethal alteration of microbial integrity. Marine invertebrates are widespread, extremely diverse, and constantly under an enormous microbial challenge from the ocean environment, itself altered by anthropic influences derived from industrialization and transportation. Consequently, this study reexamines the peptides isolated over the past 2 decades from different origins, bringing phyla not previously reviewed up to date. Moreover, a promising novel use of antimicrobial peptides as effective drugs in human and veterinary medicine could be based on their unusual properties and synergic counterparts as immune response humoral effectors, in addition to their direct microbicidal activity. This has been seen in many other marine proteins that are sufficiently immunogenic to humans, not necessarily in terms of antibody generation but as inflammation promoters and recruitment agents or immune enhancers.-Otero-Gonzalez, A. J., Magalhaes, B. S., Garcia-Villarino, M., Lopez-Abarrategui, C., Sousa, D. A., Dias, S. C., Franco, O. L. Antimicrobial peptides from marine invertebrates as a new frontier for microbial infection control. FASEB J. 24, 1320-1334 (2010). www.fasebj.org	[Magalhaes, Beatriz Simas; Sousa, Daniel Amaro; Dias, Simoni Campos; Franco, Octavio Luiz] Univ Catolica Brasilia, Ctr Anal Prote & Bioquim, BR-70790160 Brasilia, DF, Brazil; [Jesus Otero-Gonzalez, Anselmo; Garcia-Villarino, Monica; Lopez-Abarrategui, Carlos] Univ La Habana, Ctr Estudios Prot, Havana, Cuba; [Franco, Octavio Luiz] Univ Fed Juiz de Fora, Juiz De Fora, Brazil	Universidade Catolica de Brasilia; Universidad de la Habana; Universidade Federal de Juiz de Fora	Franco, OL (corresponding author), Univ Catolica Brasilia, Ctr Anal Prote & Bioquim, Campus 2,SGAN Quadra 916,Modulo B,Av W5 Norte, BR-70790160 Brasilia, DF, Brazil.	ocfranco@pos.ucb.br	Sousa, Daniel/HHS-6778-2022; Franco, Octavio L/T-3020-2017	Franco, Octavio/0000-0001-9546-0525	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Ministerio de Education Superior de Cuba (MES); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Universidade Catolica de Brasilia (UCB); Fundacao de Amparo e Pesquisa de Minas Gerais (FAPEMIG); Fundacao de Amparo a Pesquisa do Distrito Federal (FAPDF)	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Ministerio de Education Superior de Cuba (MES); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Universidade Catolica de Brasilia (UCB)(UCB Pharma SA); Fundacao de Amparo e Pesquisa de Minas Gerais (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); Fundacao de Amparo a Pesquisa do Distrito Federal (FAPDF)(Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF))	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Ministerio de Education Superior de Cuba (MES), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Universidade Catolica de Brasilia (UCB), Fundacao de Amparo e Pesquisa de Minas Gerais (FAPEMIG), and Fundacao de Amparo a Pesquisa do Distrito Federal (FAPDF) supported this work.	Altincicek B, 2007, FRONT ZOOL, V4, DOI 10.1186/1742-9994-4-18; Anderson RS, 2001, AQUAT LIVING RESOUR, V14, P343, DOI 10.1016/S0990-7440(01)01143-3; ARENAS A, 2006, ELECTRON J BIOTECHN, V9, DOI DOI 10.4067/S0717-34582006000200008; Azam F, 2007, NAT REV MICROBIOL, V5, P782, DOI 10.1038/nrmicro1747; AZUMI K, 1990, BIOCHEMISTRY-US, V29, P159, DOI 10.1021/bi00453a021; AZUMI K, 1990, EXPERIENTIA, V46, P1020, DOI 10.1007/BF01940661; Bartlett TC, 2002, MAR BIOTECHNOL, V4, P278, DOI 10.1007/s10126-002-0020-2; Battison AL, 2008, FISH SHELLFISH IMMUN, V25, P181, DOI 10.1016/j.fsi.2008.04.005; Beauregard KA, 2001, ADV EXP MED BIOL, V484, P55; Bewley CA, 1996, J AM CHEM SOC, V118, P4314, DOI 10.1021/ja953628w; Cai MM, 2008, COMP BIOCHEM PHYS B, V151, P110, DOI 10.1016/j.cbpb.2008.06.004; Capon RJ, 2002, J NAT PROD, V65, P358, DOI 10.1021/np010329d; Charlet M, 1996, J BIOL CHEM, V271, P21808, DOI 10.1074/jbc.271.36.21808; Chiou PP, 2006, DEV COMP IMMUNOL, V30, P797, DOI 10.1016/j.dci.2005.10.011; Christie AE, 2007, MOL IMMUNOL, V44, P3333, DOI 10.1016/j.molimm.2007.02.028; Cirioni O, 2007, ANTIMICROB AGENTS CH, V51, P2005, DOI 10.1128/AAC.01576-06; Clark DP, 1998, J ORG CHEM, V63, P8757, DOI 10.1021/jo980758p; Colwell R, 2001, HYDROBIOLOGIA, V460, P141, DOI 10.1023/A:1013111016642; Cooper EL, 2003, INTEGR COMP BIOL, V43, P278, DOI 10.1093/icb/43.2.278; Craig AG, 1999, EUR J BIOCHEM, V264, P271, DOI 10.1046/j.1432-1327.1999.00624.x; Cuesta A, 2008, MOL IMMUNOL, V45, P2333, DOI 10.1016/j.molimm.2007.11.007; Cuthbertson BJ, 2004, BIOCHEM J, V381, P79, DOI 10.1042/BJ20040330; Cuthbertson BJ, 2008, DEV COMP IMMUNOL, V32, P167, DOI 10.1016/j.dci.2007.06.009; Destoumieux D, 1999, EUR J BIOCHEM, V266, P335, DOI 10.1046/j.1432-1327.1999.00855.x; Destoumieux-Garzon D, 2001, J BIOL CHEM, V276, P47070, DOI 10.1074/jbc.M103817200; DRISCOLL PC, 1989, BIOCHEMISTRY-US, V28, P2178, DOI 10.1021/bi00431a032; Easton DM, 2009, TRENDS BIOTECHNOL, V27, P582, DOI 10.1016/j.tibtech.2009.07.004; EDWIN L, 1992, SCAND J IMMUNOL, V35, P247; Fedders H, 2008, BIOCHEM J, V416, P65, DOI 10.1042/BJ20080398; Fedders H, 2008, DEV COMP IMMUNOL, V32, P286, DOI 10.1016/j.dci.2007.06.003; Fritz JH, 2004, VACCINE, V22, P3274, DOI 10.1016/j.vaccine.2004.03.007; Fujitani N, 2002, J BIOL CHEM, V277, P23651, DOI 10.1074/jbc.M111120200; Fujitani N, 2007, J PEPT SCI, V13, P269, DOI 10.1002/psc.846; Gestal C, 2007, GENE, V406, P134, DOI 10.1016/j.gene.2007.07.030; Gonzalez M, 2007, DEV COMP IMMUNOL, V31, P332, DOI 10.1016/j.dci.2006.07.006; GULAVITA NK, 1992, J ORG CHEM, V57, P1767, DOI 10.1021/jo00032a031; Hancock REW, 2006, IMMUNOBIOLOGY, V211, P315, DOI 10.1016/j.imbio.2005.10.017; Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267; Hirakura Y, 2002, BBA-BIOMEMBRANES, V1562, P32, DOI 10.1016/S0005-2736(02)00358-9; Hisaeda H, 2004, NAT MED, V10, P29, DOI 10.1038/nm975; Hoskin DW, 2008, BBA-BIOMEMBRANES, V1778, P357, DOI 10.1016/j.bbamem.2007.11.008; Huang WS, 2006, J EXP MAR BIOL ECOL, V339, P37, DOI 10.1016/j.jembe.2006.06.029; Iijima R, 2003, DEV COMP IMMUNOL, V27, P305, DOI 10.1016/S0145-305X(02)00105-2; Iwanaga S, 1998, J BIOCHEM, V123, P1; Jang WS, 2005, PEPTIDES, V26, P2360, DOI 10.1016/j.peptides.2005.05.004; Jiravanichpaisal P, 2007, DEV COMP IMMUNOL, V31, P441, DOI 10.1016/j.dci.2006.08.002; Jung S, 2009, J BIOL CHEM, V284, P1896, DOI 10.1074/jbc.M804713200; Kang YS, 2006, DEV COMP IMMUNOL, V30, P1119, DOI 10.1016/j.dci.2006.03.005; KATO Y, 1988, J ORG CHEM, V53, P3930, DOI 10.1021/jo00252a009; Keller M, 2009, EMERG INFECT DIS, V15, P689, DOI 10.3201/eid1505.081114; Khoo L, 1999, MAR BIOTECHNOL, V1, P44, DOI 10.1007/PL00011750; Kouno T, 2008, BIOCHEMISTRY-US, V47, P10611, DOI 10.1021/bi800957n; KUBOTA Y, 1985, COMP BIOCHEM PHYS C, V82, P345, DOI 10.1016/0742-8413(85)90173-2; Laederach A, 2002, BIOCHEMISTRY-US, V41, P12359, DOI 10.1021/bi026185z; Lai YP, 2009, TRENDS IMMUNOL, V30, P131, DOI 10.1016/j.it.2008.12.003; Lee IH, 1997, COMP BIOCHEM PHYS B, V118, P515, DOI 10.1016/S0305-0491(97)00109-0; Lee IH, 1997, FEBS LETT, V400, P158, DOI 10.1016/S0014-5793(96)01374-9; Lee IH, 2001, J PEPT RES, V58, P445; Lee IH, 2001, BBA-GEN SUBJECTS, V1527, P141, DOI 10.1016/S0304-4165(01)00156-8; Lee SY, 2003, J BIOL CHEM, V278, P7927, DOI 10.1074/jbc.M209239200; Li CH, 2010, MOL BIOL REP, V37, P1451, DOI 10.1007/s11033-009-9534-2; Li C, 2008, DEV COMP IMMUNOL, V32, P1430, DOI 10.1016/j.dci.2008.06.013; LI HY, 1995, J MED CHEM, V38, P338, DOI 10.1021/jm00002a015; MATSUNAGA S, 1989, J AM CHEM SOC, V111, P2582, DOI 10.1021/ja00189a035; Matsuzaki K, 2009, BBA-BIOMEMBRANES, V1788, P1687, DOI 10.1016/j.bbamem.2008.09.013; Menzel LP, 2002, DEV COMP IMMUNOL, V26, P505, DOI 10.1016/S0145-305X(02)00010-1; Mitta G, 2000, J CELL SCI, V113, P2759; Mitta G, 1999, J CELL SCI, V112, P4233; Mitta G, 1999, EUR J BIOCHEM, V265, P71, DOI 10.1046/j.1432-1327.1999.00654.x; Mitta G, 2000, DEV COMP IMMUNOL, V24, P381, DOI 10.1016/S0145-305X(99)00084-1; Mitta G, 2000, FEBS LETT, V486, P185, DOI 10.1016/S0014-5793(00)02192-X; MIYATA T, 1989, J BIOCHEM, V106, P663, DOI 10.1093/oxfordjournals.jbchem.a122913; MUTA T, 1987, J BIOCHEM-TOKYO, V101, P1321, DOI 10.1093/oxfordjournals.jbchem.a121999; Mydlarz LD, 2006, ANNU REV ECOL EVOL S, V37, P251, DOI 10.1146/annurev.ecolsys.37.091305.110103; Oppenheim JJ, 2003, ANN RHEUM DIS, V62, P17, DOI 10.1136/ard.62.suppl_2.ii17; Ovchinnikova TV, 2008, BIOPOLYMERS, V89, P455, DOI 10.1002/bip.20865; Ovchinnikova TV, 2007, BIOCHEM BIOPH RES CO, V360, P156, DOI 10.1016/j.bbrc.2007.06.029; Ovchinnikova TV, 2006, BIOCHEM BIOPH RES CO, V348, P514, DOI 10.1016/j.bbrc.2006.07.078; Ovchinnikova TV, 2004, FEBS LETT, V577, P209, DOI 10.1016/j.febslet.2004.10.012; Pan WD, 2004, J BIOCHEM, V135, P297, DOI 10.1093/jb/mvh036; Pereira HA, 2006, CURR PHARM BIOTECHNO, V7, P229; Powers JPS, 2005, BIOCHEMISTRY-US, V44, P15504, DOI 10.1021/bi051302m; REICHARDT W, 1995, HELGOLANDER MEERESUN, V49, P135, DOI 10.1007/BF02368344; Relf JM, 1999, EUR J BIOCHEM, V264, P350, DOI 10.1046/j.1432-1327.1999.00607.x; Rinkevich B, 1999, J BIOTECHNOL, V70, P133, DOI 10.1016/S0168-1656(99)00067-X; RYU G, 1994, TETRAHEDRON, V50, P13409, DOI 10.1016/S0040-4020(01)89347-9; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; Schnapp D, 1996, EUR J BIOCHEM, V240, P532, DOI 10.1111/j.1432-1033.1996.0532h.x; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; Seo JK, 2005, BIOCHEM BIOPH RES CO, V338, P1998, DOI 10.1016/j.bbrc.2005.11.013; Sher D, 2005, J BIOL CHEM, V280, P22847, DOI 10.1074/jbc.M503242200; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; Shockey JE, 2009, DEV COMP IMMUNOL, V33, P668, DOI 10.1016/j.dci.2008.11.010; SONG YL, 1993, B I ZOOL ACAD SINICA, V32, P217; Sperstad SV, 2009, MOL IMMUNOL, V46, P2604, DOI 10.1016/j.molimm.2009.05.002; Stensvag K, 2008, DEV COMP IMMUNOL, V32, P275, DOI 10.1016/j.dci.2007.06.002; Tasiemski A, 2004, J BIOL CHEM, V279, P30973, DOI 10.1074/jbc.M312156200; Tasiemski A, 2007, DEV COMP IMMUNOL, V31, P749, DOI 10.1016/j.dci.2006.11.003; Tassanakajon Anchalee, 2008, P221; Taylor SW, 2000, J BIOL CHEM, V275, P38417, DOI 10.1074/jbc.M006762200; Tejuca M, 1996, BIOCHEMISTRY-US, V35, P14947, DOI 10.1021/bi960787z; Tincu JA, 2003, J BIOL CHEM, V278, P13546, DOI 10.1074/jbc.M211332200; Vallespi MG, 2003, INT IMMUNOPHARMACOL, V3, P247, DOI 10.1016/S1567-5769(02)00277-1; Wang GS, 2009, NUCLEIC ACIDS RES, V37, pD933, DOI 10.1093/nar/gkn823; YAMAZAKI M, 1990, DEV COMP IMMUNOL, V14, P379, DOI 10.1016/0145-305X(90)90030-I; YANG H, 2001, ANTIMICROB AGENTS CH, V45, P1558; Yang YS, 2000, BIOCHEMISTRY-US, V39, P14436, DOI 10.1021/bi0011835; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2; Yedery RD, 2009, ACTA BIOCHIM POL, V56, P71; Yeung SYM, 2005, J NEUROSCI, V25, P8735, DOI 10.1523/JNEUROSCI.2119-05.2005; ZABRISKIE TM, 1986, J AM CHEM SOC, V108, P3123, DOI 10.1021/ja00271a062; Zhang LJ, 2001, J BIOL CHEM, V276, P35714, DOI 10.1074/jbc.M104925200; Zhao JM, 2007, MOL IMMUNOL, V44, P360, DOI 10.1016/j.molimm.2006.02.025; Zou GZ, 2007, J BIOL CHEM, V282, P19653, DOI 10.1074/jbc.M611003200	114	132	144	7	79	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1320	1334		10.1096/fj.09-143388	http://dx.doi.org/10.1096/fj.09-143388			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20065108				2022-12-28	WOS:000277158900005
J	Bocedi, A; Dawood, KF; Fabrini, R; Federici, G; Gradoni, L; Pedersen, JZ; Ricci, G				Bocedi, Alessio; Dawood, Kutayba F.; Fabrini, Raffaele; Federici, Giorgio; Gradoni, Luigi; Pedersen, Jens Z.; Ricci, Giorgio			Trypanothione efficiently intercepts nitric oxide as a harmless iron complex in trypanosomatid parasites	FASEB JOURNAL			English	Article						Leishmania infantum; Trypanosoma brucei; dinitrosyl-iron complex; trypanothione reductase	GLUTATHIONE TRANSFERASE SUPERFAMILY; IN-VIVO; S-TRANSFERASE; LEISHMANIA-DONOVANI; NO-CARRIERS; REDUCTASE; ENZYME; METABOLISM; STORAGE; INACTIVATION	Trypanosomatids are protozoan organisms that cause serious diseases, including African sleeping sickness, Chagas' disease, and leishmaniasis, affecting about 30 million people in the world. These parasites contain the unusual dithiol trypanothione [T(SH)(2)] instead of glutathione (GSH) as the main intracellular reductant, and they have replaced the otherwise ubiquitous GSH/glutathione reductase redox couple with a T(SH) 2/trypanothione reductase (TR) system. The reason for the existence of T(SH) 2 in parasitic organisms has remained an enigma. Here, we show that T(SH) 2 is able to intercept nitric oxide and labile iron and form a dinitrosyl-iron complex with at least 600 times higher affinity than GSH. Accumulation of the paramagnetic dinitrosyl-trypanothionyl iron complex in vivo was observed in Trypanosoma brucei and Leishmania infantum exposed to nitric oxide. While the analogous dinitrosyl-diglutathionyl iron complex formed in mammalian cells is a potent irreversible inhibitor of glutathione reductase (IC50 = 4 mu M), the T(SH) 2 complex does not inactivate TR even at millimolar levels. The peculiar capacity of T(SH) 2 to sequester NO and iron in a harmless stable complex could explain the predominance of this thiol in parasites regularly exposed to NO.-Bocedi, A., Dawood, K. F., Fabrini, R., Federici, G., Gradoni, L., Pedersen, J. Z., Ricci, G. Trypanothione efficiently intercepts nitric oxide as a harmless iron complex in trypanosomatid parasites. FASEB J. 24, 1035-1042 (2010). www.fasebj.org	[Dawood, Kutayba F.; Fabrini, Raffaele; Ricci, Giorgio] Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; [Bocedi, Alessio] Univ Rome Roma Tre, Dept Biol, Rome, Italy; [Pedersen, Jens Z.] Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; [Federici, Giorgio] Childrens Hosp, Ist Ricovero & Cura Carattere Sci Bambin Gesu, Rome, Italy; [Gradoni, Luigi] Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, I-00161 Rome, Italy	University of Rome Tor Vergata; Roma Tre University; University of Rome Tor Vergata; IRCCS Bambino Gesu; Istituto Superiore di Sanita (ISS)	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, Via Ric Sci 1, I-00133 Rome, Italy.	riccig@uniroma2.it	Dawood, Kutayba/E-1505-2019; Gradoni, Luigi/C-4962-2016	Dawood, Kutayba/0000-0002-0762-9632; Ricci, Giorgio/0000-0002-7108-2846	Italian Ministry for Education; University and Research; General Management for International Research	Italian Ministry for Education(Ministry of Education, Universities and Research (MIUR)); University and Research; General Management for International Research	The authors thank Paolo Ascenzi for helpful discussion. J.Z.P. was supported by the Italian Ministry for Education, University and Research, General Management for International Research.	Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; Ariyanayagam MR, 2003, J BIOL CHEM, V278, P27612, DOI 10.1074/jbc.M302750200; Ascenzi P, 2003, IUBMB LIFE, V55, P573, DOI 10.1080/15216540310001639265; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; Bocedi A, 2004, BIOCHEM BIOPH RES CO, V315, P710, DOI 10.1016/j.bbrc.2004.01.113; Cesareo E, 2005, J BIOL CHEM, V280, P42172, DOI 10.1074/jbc.M507916200; CUNNINGHAM ML, 1995, EUR J BIOCHEM, V230, P460, DOI 10.1111/j.1432-1033.1995.tb20583.x; De Maria F, 2003, J BIOL CHEM, V278, P42283, DOI 10.1074/jbc.M305568200; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V70, P82; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; Giorgio S, 1998, INFECT IMMUN, V66, P807, DOI 10.1128/IAI.66.2.807-814.1998; Keese MA, 1997, BIOCHEM PHARMACOL, V54, P1307, DOI 10.1016/S0006-2952(97)00348-1; Krauth-Siegel RL, 2008, BBA-GEN SUBJECTS, V1780, P1236, DOI 10.1016/j.bbagen.2008.03.006; KRAUTHSIEGEL RL, 1987, EUR J BIOCHEM, V164, P123, DOI 10.1111/j.1432-1033.1987.tb11002.x; Lo Bello M, 2001, J BIOL CHEM, V276, P42138; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Marquis JF, 2007, TRENDS MICROBIOL, V15, P93, DOI 10.1016/j.tim.2007.01.001; MOUTIEZ M, 1994, CHEM PHARM BULL, V42, P2641; Pedersen JZ, 2007, J BIOL CHEM, V282, P6364, DOI 10.1074/jbc.M609905200; Rauhala Pekka, 2005, Toxicol Appl Pharmacol, V207, P91, DOI 10.1016/j.taap.2005.02.028; Richardson DR, 2008, BBA-GEN SUBJECTS, V1780, P638, DOI 10.1016/j.bbagen.2007.12.009; Salvati L, 2001, BBA-PROTEIN STRUCT M, V1545, P357, DOI 10.1016/S0167-4838(00)00297-1; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; Stella L, 2007, J BIOL CHEM, V282, P6372, DOI 10.1074/jbc.M609906200; Steverding D, 1998, PARASITOL RES, V84, P59, DOI 10.1007/s004360050357; Timoshin AA, 2007, NITRIC OXIDE-BIOL CH, V16, P286, DOI 10.1016/j.niox.2006.09.005; Toledo JC, 2008, J BIOL CHEM, V283, P28926, DOI 10.1074/jbc.M707862200; Tovar J, 1998, P NATL ACAD SCI USA, V95, P5311, DOI 10.1073/pnas.95.9.5311; Turella P, 2003, J BIOL CHEM, V278, P42294, DOI 10.1074/jbc.M305569200; Ueno T, 2000, JPN J PHARMACOL, V82, P95, DOI 10.1254/jjp.82.95; Vickers TJ, 2004, J BIOL CHEM, V279, P49003, DOI 10.1074/jbc.M407958200; Vickers TJ, 2004, J BIOL CHEM, V279, P27246, DOI 10.1074/jbc.M311039200; Vogt RN, 2003, BIOCHEM J, V371, P49, DOI 10.1042/BJ20021649; Wong ILK, 2006, MOL BIOCHEM PARASIT, V150, P278, DOI 10.1016/j.molbiopara.2006.08.014	35	48	48	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1035	1042		10.1096/fj.09-146407	http://dx.doi.org/10.1096/fj.09-146407			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19952282	Bronze			2022-12-28	WOS:000276462300011
J	Na, N; Chandel, NS; Litvan, J; Ridge, KM				Na, Ni; Chandel, Navdeep S.; Litvan, Juan; Ridge, Karen M.			Mitochondrial reactive oxygen species are required for hypoxia-induced degradation of keratin intermediate filaments	FASEB JOURNAL			English	Article						alveolar epithelial cells; superoxide dismutase; lung	EPIDERMOLYSIS-BULLOSA SIMPLEX; DESMIN CYTOSKELETON; NAD(P)H OXIDASE; PROTEIN-KINASE; PHOSPHORYLATION; ARCHITECTURE; REORGANIZATION; NA,K-ATPASE; ACTIVATION; MECHANISMS	Hypoxia can cause stress and structural changes to the epithelial cytoskeleton. The intermediate filament (IF) network is known to reorganize in response to stress. We examined whether rats exposed to hypoxia had altered keratin IF expression in their alveolar epithelial type II (ATII) cells. There was a significant decrease in keratin protein levels in hypoxic ATII cells compared with those in ATII cells isolated from normoxic rats. To define the mechanisms regulating this process we studied changes to the keratin IF network in A549 cells (an alveolar epithelial cell line) exposed to 1.5% oxygen. We observed a time-dependent disassembly-degradation of keratin 8 and 18 proteins, which was associated with an increase in reactive oxygen species (ROS). Hypoxia-treated A549 cells deficient in mitochondrial DNA or A549 cells treated with a small interfering RNA against the Rieske iron-sulfur protein of mitochondrial complex III did not have increased levels of ROS nor was the keratin IF network disassembled and degraded. The superoxide dismutase (SOD)/catalase mimetic (EUK-134) prevented the hypoxia-mediated keratin IF degradation as did the overexpression of SOD1 but not of SOD2. Accordingly, we provide evidence that hypoxia promotes the disassembly and degradation of the keratin IF network via mitochondrial complex III-generated reactive oxygen species.-Na, N., Chandel, N. S., Litvan, J., Ridge, K. M. Mitochondrial reactive oxygen species are required for hypoxia-induced degradation of keratin intermediate filaments. FASEB J. 24, 799-809 (2010). www.fasebj.org	[Na, Ni; Chandel, Navdeep S.; Litvan, Juan; Ridge, Karen M.] Northwestern Univ, Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA; [Chandel, Navdeep S.; Ridge, Karen M.] Northwestern Univ, Sch Med, Dept Mol Cell Biol, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Ridge, KM (corresponding author), Northwestern Univ, Sch Med, Div Pulm & Crit Care Med, 240 E Huron,McGaw 2328, Chicago, IL 60611 USA.	kridge@northwestern.edu			NHLBI NIH HHS [R01 HL079190] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079190] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beil M, 2003, NAT CELL BIOL, V5, P803, DOI 10.1038/ncb1037; Bell EL, 2005, MITOCHONDRION, V5, P322, DOI 10.1016/j.mito.2005.06.005; Bieberich E, 2003, J CELL BIOL, V162, P469, DOI 10.1083/jcb.200212067; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Budinger GRS, 2006, P NATL ACAD SCI USA, V103, P4604, DOI 10.1073/pnas.0507604103; Budinger GRS, 1996, AM J PHYSIOL-LUNG C, V270, pL44, DOI 10.1152/ajplung.1996.270.1.L44; Budinger GRS, 1998, J BIOL CHEM, V273, P3320, DOI 10.1074/jbc.273.6.3320; Capetanaki Y, 2002, TRENDS CARDIOVAS MED, V12, P339, DOI 10.1016/S1050-1738(02)00184-6; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chandel NS, 2000, J APPL PHYSIOL, V88, P1880, DOI 10.1152/jappl.2000.88.5.1880; Chou YH, 2000, J CELL BIOL, V150, pF101, DOI 10.1083/jcb.150.3.F101; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Emerling BM, 2005, MOL CELL BIOL, V25, P4853, DOI 10.1128/MCB.25.12.4853-4862.2005; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Galarneau L, 2007, EXP CELL RES, V313, P179, DOI 10.1016/j.yexcr.2006.10.007; Gilbert S, 2008, APOPTOSIS, V13, P1479, DOI 10.1007/s10495-008-0274-x; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; He T, 2002, J BIOL CHEM, V277, P10767, DOI 10.1074/jbc.M111436200; Heberlein W, 2000, AM J PHYSIOL-LUNG C, V278, pL640, DOI 10.1152/ajplung.2000.278.4.L640; Herrmann H, 2007, NAT REV MOL CELL BIO, V8, P562, DOI 10.1038/nrm2197; Jaitovich A, 2008, J BIOL CHEM, V283, P25348, DOI 10.1074/jbc.M801635200; Killilea DW, 2000, AM J PHYSIOL-LUNG C, V279, pL408, DOI 10.1152/ajplung.2000.279.2.L408; Kim S, 2007, GENE DEV, V21, P1581, DOI 10.1101/gad.1552107; Ku NO, 1999, AM J PHYSIOL-GASTR L, V277, pG1108, DOI 10.1152/ajpgi.1999.277.6.G1108; Ku NO, 2002, J BIOL CHEM, V277, P10775, DOI 10.1074/jbc.M107623200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Linden M, 2001, J BIOENERG BIOMEMBR, V33, P333, DOI 10.1023/A:1010611408007; Litvan J, 2006, J BIOL CHEM, V281, P19892, DOI 10.1074/jbc.M602064200; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Milner DJ, 2000, J CELL BIOL, V150, P1283, DOI 10.1083/jcb.150.6.1283; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Morley SM, 2003, BRIT J DERMATOL, V149, P46, DOI 10.1046/j.1365-2133.2003.05493.x; Parinandi NL, 2003, AM J PHYSIOL-LUNG C, V284, pL26, DOI 10.1152/ajplung.00123.2002; Paulin D, 2004, EXP CELL RES, V301, P1, DOI 10.1016/j.yexcr.2004.08.004; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; Ridge KM, 2005, J BIOL CHEM, V280, P30400, DOI 10.1074/jbc.M504239200; Sahlgren CM, 2006, EMBO J, V25, P4808, DOI 10.1038/sj.emboj.7601366; Sahlgren CM, 2003, MOL CELL BIOL, V23, P5090, DOI 10.1128/MCB.23.14.5090-5106.2003; Sanders KA, 2002, J APPL PHYSIOL, V93, P1357, DOI 10.1152/japplphysiol.00564.2001; Schweizer J, 2006, J CELL BIOL, V174, P169, DOI 10.1083/jcb.200603161; Sivaramakrishnan S, 2008, P NATL ACAD SCI USA, V105, P889, DOI 10.1073/pnas.0710728105; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Uttam J, 1996, P NATL ACAD SCI USA, V93, P9079, DOI 10.1073/pnas.93.17.9079; Wagner OI, 2003, J NEUROSCI, V23, P9046; Wang HL, 2007, J IMMUNOL, V179, P1834, DOI 10.4049/jimmunol.179.3.1834; Waypa GB, 2001, CIRC RES, V88, P1259, DOI 10.1161/hh1201.091960; Waypa GB, 2002, CIRC RES, V91, P719, DOI 10.1161/01.RES.0000036751.04896.F1; Weissmann Norbert, 2006, Novartis Found Symp, V272, P196; Wolin MS, 2005, AM J PHYSIOL-LUNG C, V289, pL159, DOI 10.1152/ajplung.00060.2005; Wong P, 2003, J CELL BIOL, V163, P327, DOI 10.1083/jcb.200305032; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147	59	26	26	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					799	809		10.1096/fj.08-128967	http://dx.doi.org/10.1096/fj.08-128967			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19897662	Green Published			2022-12-28	WOS:000274974600016
J	Chakrabarty, P; Jansen-West, K; Beccard, A; Ceballos-Diaz, C; Levites, Y; Verbeeck, C; Zubair, AC; Dickson, D; Golde, TE; Das, P				Chakrabarty, Paramita; Jansen-West, Karen; Beccard, Amanda; Ceballos-Diaz, Carolina; Levites, Yona; Verbeeck, Christophe; Zubair, Abba C.; Dickson, Dennis; Golde, Todd E.; Das, Pritam			Massive gliosis induced by interleukin-6 suppresses A beta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition	FASEB JOURNAL			English	Article						Alzheimer's disease; neuroinflammation; APP; recombinant adeno-associated virus	ALZHEIMERS-DISEASE PATIENTS; MOUSE MODEL; PLAQUE-FORMATION; TRANSGENIC MICE; MICROGLIA; ACTIVATION; CLEARANCE; PATHOLOGY; CYTOKINE; GENE	Proinflammatory stimuli, after amyloid beta (A beta) deposition, have been hypothesized to create a self-reinforcing positive feedback loop that increases amyloidogenic processing of the A beta precursor protein (APP), promoting further A beta accumulation and neuroinflammation in Alzheimer's disease (AD). Interleukin-6 (IL-6), a proinflammatory cytokine, has been shown to be increased in AD patients implying a pathological interaction. To assess the effects of IL-6 on A beta deposition and APP processing in vivo, we overexpressed murine IL-6 (mIL-6) in the brains of APP transgenic TgCRND8 and TG2576 mice. mIL-6 expression resulted in extensive gliosis and concurrently attenuated A beta deposition in TgCRND8 mouse brains. This was accompanied by up-regulation of glial phagocytic markers in vivo and resulted in enhanced microglia-mediated phagocytosis of A beta aggregates in vitro. Further, mIL-6-induced neuroinflammation had no effect on APP processing in TgCRND8 and had no effect on APP processing or steady-state levels of A beta in young Tg2576 mice. These results indicate that mIL-6-mediated reactive gliosis may be beneficial early in the disease process by potentially enhancing A beta plaque clearance rather than mediating a neurotoxic feedback loop that exacerbates amyloid pathology. This is the first study that methodically dissects the contribution of mIL-6 with regard to its potential role in modulating A beta deposition in vivo.-Chakrabarty, P., Jansen-West, K., Beccard, A., Ceballos-Diaz, C., Levites, Y., Verbeeck, C., Zubair, A. C., Dickson, D., Golde, T. E., Das, P. Massive gliosis induced by interleukin-6 suppresses A beta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 24, 548-559 (2010). www.fasebj.org	[Chakrabarty, Paramita; Jansen-West, Karen; Beccard, Amanda; Ceballos-Diaz, Carolina; Levites, Yona; Verbeeck, Christophe; Dickson, Dennis; Golde, Todd E.; Das, Pritam] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; [Zubair, Abba C.] Mayo Clin, Dept Lab Med & Pathol, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic	Das, P (corresponding author), Mayo Clin, Dept Neurosci, 4500 San Pablo Rd,457 Birdsall Bldg, Jacksonville, FL 32224 USA.	das.pritam@mayo.edu		Dickson, Dennis W/0000-0001-7189-7917	Mayo Clinic; National Institutes of Health/National Institute on Aging [RO1AG18454, RO1AG29886, P01AG25531, P01AG71216]; American Health Assistance Foundation [AHAF3J]; Robert H. and Clarice Smith Foundation; NATIONAL INSTITUTE ON AGING [R01AG029886, P01AG025531, R01AG018454] Funding Source: NIH RePORTER	Mayo Clinic; National Institutes of Health/National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Health Assistance Foundation(BrightFocus Foundation); Robert H. and Clarice Smith Foundation; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Monica Castanedes-Casey, V. A. Phillips, and Linda Rousseau for assistance with tissue processing and immunohistochemical analyses; Sunita Malik for help with FACS recording; and Faith Conkle, Deborah Maloy, and the Mayo Clinic Veterinary Medicine staff for animal maintenance. This work was supported by the Mayo Clinic (to T. G.), the National Institutes of Health/National Institute on Aging (grants RO1AG18454, RO1AG29886, and P01AG25531 to T. G. and P01AG71216 to D. D.), the American Health Assistance Foundation (grant AHAF3J to P. D.), and the Robert H. and Clarice Smith Foundation postdoctoral fellowship (to P. C.).	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Baranowska-Bik A, 2008, NEUROENDOCRINOL LETT, V29, P75; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Boissonneault V, 2009, BRAIN, V132, P1078, DOI 10.1093/brain/awn331; Bolmont T, 2008, J NEUROSCI, V28, P4283, DOI 10.1523/JNEUROSCI.4814-07.2008; Cho HJ, 2007, GLIA, V55, P253, DOI 10.1002/glia.20451; Dickson DW, 1999, AM J PATHOL, V154, P1627, DOI 10.1016/S0002-9440(10)65416-8; Ehlers MRW, 2000, MICROBES INFECT, V2, P289, DOI 10.1016/S1286-4579(00)00299-9; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245; Fiala M, 2005, J ALZHEIMERS DIS, V7, P221, DOI 10.3233/jad-2005-7304; Galimberti D, 2008, J NEUROL, V255, P539, DOI 10.1007/s00415-008-0737-6; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Ge YW, 2002, ANN NY ACAD SCI, V973, P463, DOI 10.1111/j.1749-6632.2002.tb04684.x; Giri RK, 2003, J IMMUNOL, V170, P5281, DOI 10.4049/jimmunol.170.10.5281; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Heneka MT, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-22; HUELL M, 1995, ACTA NEUROPATHOL, V89, P544; Jimenez S, 2008, J NEUROSCI, V28, P11650, DOI 10.1523/JNEUROSCI.3024-08.2008; Kim JS, 2008, J NEUROSCI, V28, P6030, DOI 10.1523/JNEUROSCI.0891-08.2008; Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004; Lahiri DK, 2003, J ALZHEIMERS DIS, V5, P81, DOI 10.3233/JAD-2003-5203; Licastro F, 2000, J NEUROIMMUNOL, V103, P97, DOI 10.1016/S0165-5728(99)00226-X; Licastro F, 2003, NEUROBIOL AGING, V24, P921, DOI 10.1016/S0197-4580(03)00013-7; Maier M, 2008, J NEUROSCI, V28, P6333, DOI 10.1523/JNEUROSCI.0829-08.2008; Malm TM, 2005, NEUROBIOL DIS, V18, P134, DOI 10.1016/j.nbd.2004.09.009; Mandrekar S, 2009, J NEUROSCI, V29, P4252, DOI 10.1523/JNEUROSCI.5572-08.2009; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; PERLMUTTER LS, 1990, NEUROSCI LETT, V119, P32, DOI 10.1016/0304-3940(90)90748-X; Ravaglia G, 2006, EXP GERONTOL, V41, P85, DOI 10.1016/j.exger.2005.10.005; Richard KL, 2008, J NEUROSCI, V28, P5784, DOI 10.1523/JNEUROSCI.1146-08.2008; Ringheim GE, 1998, MOL BRAIN RES, V55, P35, DOI 10.1016/S0169-328X(97)00356-2; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; Sastre M, 2006, INT J DEV NEUROSCI, V24, P167, DOI 10.1016/j.ijdevneu.2005.11.014; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Shaftel SS, 2007, J CLIN INVEST, V117, P1595, DOI 10.1172/JCI31450; Shibata N, 2002, AM J MED GENET, V114, P436, DOI 10.1002/ajmg.10417; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Sokolova A, 2009, BRAIN PATHOL, V19, P392, DOI 10.1111/j.1750-3639.2008.00188.x; Stalder M, 1999, AM J PATHOL, V154, P1673, DOI 10.1016/S0002-9440(10)65423-5; STRAUSS S, 1992, LAB INVEST, V66, P223; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Wyss-Coray T, 2002, P NATL ACAD SCI USA, V99, P10837, DOI 10.1073/pnas.162350199; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010	50	235	247	2	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					548	559		10.1096/fj.09-141754	http://dx.doi.org/10.1096/fj.09-141754			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19825975	Green Published			2022-12-28	WOS:000274045000022
J	Chen, Z; Li, ZZ; Wei, B; Yin, WX; Xu, T; Kotlikoff, MI; Ji, GJ				Chen, Zheng; Li, Zhengzheng; Wei, Bin; Yin, Wenxuan; Xu, Tao; Kotlikoff, Michael I.; Ji, Guangju			FKBP12.6-knockout mice display hyperinsulinemia and resistance to high-fat diet-induced hyperglycemia	FASEB JOURNAL			English	Article						pancreatic islets; diabetes; Ca2+; insulin secretion	PANCREATIC BETA-CELLS; INSULIN-SECRETION; RYANODINE RECEPTORS; SIGNALING SYSTEM; SMOOTH-MUSCLE; CA2+ RELEASE; CHANNEL	FK506 binding protein 12.6 kDa (FKBP12.6), a protein that regulates ryanodine Ca2+ release channels, may act as an important regulator of insulin secretion. In this study, the role of FKBP12.6 in the control of insulin secretion and blood glucose is clarified using FKBP12.6(-/-) mice. FKBP12.6(-/-) mice showed significant fed hyperinsulinemia but exhibited normoglycemia, fasting normoinsulinemia, and normal body weight compared with wild-type (WT) littermate control mice. Deletion of FKBP12.6 resulted in enhanced glucose-stimulated insulin secretion (GSIS) both in vivo and in vitro, a result that is due to enhanced glucose-induced islet Ca2+ elevation. After a high-fat dietary challenge (HF diet) for 3 mo, FKBP12.6(-/-) mice displayed higher body weight, hyperinsulinemia, and lower fed blood glucose concentrations compared with WT mice. FKBP12.6(-/-) mice displayed hyperinsulinemia, and resistance to HF diet-induced hyperglycemia, suggesting that FKBP12.6 plays an important role in insulin secretion and blood glucose control, and raising the possibility that it may be a potential therapeutic target for the treatment of type 2 diabetes.-Chen, Z., Li, Z., Wei, B., Yin, W., Xu, T., Kotlikoff, M. I., Ji, G. FKBP12.6-knockout mice display hyperinsulinemia and resistance to high-fat diet-induced hyperglycemia. FASEB J. 24, 357-363 (2010). www.fasebj.org	[Chen, Zheng; Li, Zhengzheng; Wei, Bin; Yin, Wenxuan; Xu, Tao; Ji, Guangju] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; [Kotlikoff, Michael I.; Ji, Guangju] Cornell Univ, Coll Vet Med, Ithaca, NY 14853 USA	Chinese Academy of Sciences; Institute of Biophysics, CAS; Cornell University	Ji, GJ (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	mik7@cornell.edu; gj28@ibp.ac.cn	Wei, Bin/M-2017-2014; Li, Zhengzheng/N-1415-2013; chen, zheng/J-4600-2014	chen, zheng/0000-0003-2161-6106; , zheng/0000-0001-7129-6644; Ji, Guangju/0000-0001-8626-3490	National Basic Research Program of China [007CB512100]; U.S. National Institutes of Health [HL45239, DK65992]; Chinese Academy of Sciences [KSCX2-YW-R-50]; National Foundation of Science and Technology [30770520, 2009CB918701]; 863 research program [2006AA02A106]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065992] Funding Source: NIH RePORTER	National Basic Research Program of China(National Basic Research Program of China); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chinese Academy of Sciences(Chinese Academy of Sciences); National Foundation of Science and Technology; 863 research program; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the National Basic Research Program of China (007CB512100 to G.J.), the U.S. National Institutes of Health (HL45239 and DK65992 to M. K.), the Knowledge Innovation Program of the Chinese Academy of Sciences (KSCX2-YW-R-50 to G.J.), the National Foundation of Science and Technology (30770520 and 2009CB918701); and the 863 research program (2006AA02A106).	Almind K, 2004, DIABETES, V53, P3274, DOI 10.2337/diabetes.53.12.3274; Biddinger SB, 2005, DIABETES, V54, P1314, DOI 10.2337/diabetes.54.5.1314; Bruton JD, 2002, FASEB J, V16, P301, DOI 10.1096/fj.02-0481fje; Chen LY, 2003, DIABETES, V52, P1723, DOI 10.2337/diabetes.52.7.1723; Empson RM, 1997, J BIOL CHEM, V272, P20967, DOI 10.1074/jbc.272.34.20967; Gamberucci A, 1999, FEBS LETT, V446, P309, DOI 10.1016/S0014-5793(99)00220-3; Heit JJ, 2006, ANNU REV CELL DEV BI, V22, P311, DOI 10.1146/annurev.cellbio.22.010305.104425; Henquin JC, 2002, DIABETES, V51, pS60, DOI 10.2337/diabetes.51.2007.S60; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; Islam MS, 2002, DIABETES, V51, P1299, DOI 10.2337/diabetes.51.5.1299; Ji GJ, 2006, J GEN PHYSIOL, V127, P225, DOI 10.1085/jgp.200509422; Ji GJ, 2004, J GEN PHYSIOL, V123, P377, DOI 10.1085/jgp.200308999; Johnson JD, 2004, FASEB J, V18, P878, DOI 10.1096/fj.03-1280fje; Kang LJ, 2006, CELL METAB, V3, P463, DOI 10.1016/j.cmet.2006.04.012; Noguchi N, 1997, J BIOL CHEM, V272, P3133, DOI 10.1074/jbc.272.6.3133; Noguchi N, 2008, BIOCHEM BIOPH RES CO, V371, P735, DOI 10.1016/j.bbrc.2008.04.142; Okamoto H, 1999, MOL CELL BIOCHEM, V193, P115, DOI 10.1023/A:1006980630912; Wehrens XHT, 2003, CELL, V113, P829, DOI 10.1016/S0092-8674(03)00434-3; Xin HB, 2002, NATURE, V416, P334, DOI 10.1038/416334a	19	14	17	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					357	363		10.1096/fj.09-138446	http://dx.doi.org/10.1096/fj.09-138446			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19805579	Green Published			2022-12-28	WOS:000274045000004
J	Seo, M; Lee, WH; Suk, K				Seo, Minchul; Lee, Won-Ha; Suk, Kyoungho			Identification of novel cell migration-promoting genes by a functional genetic screen	FASEB JOURNAL			English	Article						chchd2; hyaluronic acid-binding protein 1; NIH3T3 mouse fibroblast cells; retroviral cDNA library	ACID-BINDING-PROTEIN; SPLICING FACTOR SF2; IN-VIVO SELECTION; ENDOTHELIAL-CELLS; P-32 PROTEIN; EXPRESSION; ACTIN; HYALURONAN; KINASE; GROWTH	Here we describe the identification of novel cell migration-promoting genes based on an unbiased functional genetic screen in cultured cells. After the introduction of the retroviral mouse brain cDNA library into NIH3T3 mouse fibroblast cells, migration-promoted cells were selected by a 3-dimensional migration assay using cell culture inserts. After 5 rounds of enrichment, cDNAs were retrieved from the cells with a selected phenotype. Cell migration-promoting activity was confirmed by independent migration assays for the retrieved cDNAs, among which further investigation was focused on coiled-coil-helix-coiled-coil-helix domain-containing protein 2 (chchd2). Whereas overexpression of chchd2 promoted cell migration, knockdown of endogenous chchd2 expression reduced cell migration. Chchd2-induced cell migration was associated with augmented formation of actin stress fibers and focal adhesion, which was mediated through Akt, RhoA/ROCK, and Jnk pathways. CHCHD2 protein directly interacted with hyaluronic acid-binding protein 1 (HABP1) that possessed migration-suppressing activity. Intracellular localization and further functional studies suggested that CHCHD2 and HABP1 may mutually regulate each other to balance cell migration. Thus, chchd2 is a novel cell migration determinant identified by an in vitro functional genetic selection strategy. The selection method can also be useful for the isolation of genes that give other phenotypes of interest.-Seo, M., Lee, W.-H., Suk, K. Identification of novel cell migration-promoting genes by a functional genetic screen. FASEB J. 24, 464-478 (2010). www.fasebj.org	[Seo, Minchul; Suk, Kyoungho] Kyungpook Natl Univ, Brain Sci & Engn Inst, Sch Med, Dept Pharmacol,CMRI, Taegu 700422, South Korea; [Seo, Minchul; Lee, Won-Ha] Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Dept Genet Engn, Taegu 700422, South Korea	Kyungpook National University; Kyungpook National University	Suk, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	ksuk@knu.ac.kr			Korean government (Ministry of Education, Science, and Technology) [2009-0078941, 200804090, KRF-2006-005-J04202]	Korean government (Ministry of Education, Science, and Technology)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	We thank Dr. Frederick P. Roth at Harvard Medical School for critical reading of the manuscript. This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korean government (Ministry of Education, Science, and Technology; 2009-0078941) and by the Bio R&D program through KOSEF funded by the Ministry of Education, Science, and Technology (200804090). K. S. is a recipient of a Korea Research Foundation grant funded by the Korean government (Basic Research Promotion Fund; KRF-2006-005-J04202).	Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Barthe P, 1999, J BIOMOL NMR, V15, P271, DOI 10.1023/A:1008336418418; Barthe P, 2000, PROTEIN SCI, V9, P942, DOI 10.1110/ps.9.5.942; Bassi R, 2008, J NEURO-ONCOL, V87, P23, DOI 10.1007/s11060-007-9488-y; Benink HA, 2005, J CELL BIOL, V168, P429, DOI 10.1083/jcb.200411109; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Charpentier AH, 2000, CANCER RES, V60, P5977; Chen XY, 2009, PHARMACOLOGY, V83, P67, DOI 10.1159/000178814; Chhabra ES, 2007, NAT CELL BIOL, V9, P1110, DOI 10.1038/ncb1007-1110; Chilov D, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng115; Chowdhury AR, 2008, EXP CELL RES, V314, P651, DOI 10.1016/j.yexcr.2007.10.033; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; Deb TB, 1996, J BIOL CHEM, V271, P2206, DOI 10.1074/jbc.271.4.2206; Dedio J, 1998, J IMMUNOL, V160, P3534; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; Demene H, 2002, J BIOMOL NMR, V22, P47, DOI 10.1023/A:1013821123201; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Fogal V, 2008, CANCER RES, V68, P7210, DOI 10.1158/0008-5472.CAN-07-6752; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Franz CM, 2002, DEV CELL, V2, P153, DOI 10.1016/S1534-5807(02)00120-X; Ghebrehiwet B, 1998, IMMUNOBIOLOGY, V199, P225, DOI 10.1016/S0171-2985(98)80029-6; Ghosh I, 2004, MOL CELL BIOCHEM, V267, P133, DOI 10.1023/B:MCBI.0000049362.04033.ea; Ghosh I, 2002, J REPROD IMMUNOL, V53, P45, DOI 10.1016/S0165-0378(01)00095-X; Giannone G, 2004, CELL, V116, P431, DOI 10.1016/S0092-8674(04)00058-3; Giretti MS, 2008, STEROIDS, V73, P895, DOI 10.1016/j.steroids.2008.01.011; Goulimari P, 2005, J BIOL CHEM, V280, P42242, DOI 10.1074/jbc.M508690200; Gumireddy K, 2007, P NATL ACAD SCI USA, V104, P6696, DOI 10.1073/pnas.0701145104; GUPTA S, 1991, EUR J CELL BIOL, V56, P58; GUPTA S, 1991, EXP CELL RES, V195, P386, DOI 10.1016/0014-4827(91)90388-B; HARADA K, 2000, NUCL ACIDS S SER, V44, P269; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang Z, 2008, CELL SIGNAL, V20, P2002, DOI 10.1016/j.cellsig.2008.07.014; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; Jin C, 1997, CURR GENET, V31, P228, DOI 10.1007/s002940050199; Katsumi A, 2005, J BIOL CHEM, V280, P16546, DOI 10.1074/jbc.C400455200; Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324; Kim S, 2007, J NEUROCHEM, V103, P2640, DOI 10.1111/j.1471-4159.2007.04995.x; Kito H, 2000, J APPL PHYSIOL, V89, P2391, DOI 10.1152/jappl.2000.89.6.2391; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; Komarov AP, 2008, P NATL ACAD SCI USA, V105, P14453, DOI 10.1073/pnas.0807549105; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Kurokawa K, 2005, MOL BIOL CELL, V16, P4294, DOI 10.1091/mbc.E04-12-1076; Lee J, 2007, MOL CELL PROTEOMICS, V6, P669, DOI 10.1074/mcp.M600218-MCP200; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Li CC, 2007, MOL BIOL CELL, V18, P4420, DOI 10.1091/mbc.E07-02-0149; Lim BL, 1996, J BIOL CHEM, V271, P26739, DOI 10.1074/jbc.271.43.26739; Madani A, 1996, BLOOD, V87, P1923; Majumdar M, 2002, BIOCHEM BIOPH RES CO, V291, P829, DOI 10.1006/bbrc.2002.6491; Mallick J, 2005, EXP CELL RES, V309, P250, DOI 10.1016/j.yexcr.2005.05.025; Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677; Meenakshi J, 2003, BIOCHEM BIOPH RES CO, V300, P686, DOI 10.1016/S0006-291X(02)02788-2; Mejillano MR, 2004, CELL, V118, P363, DOI 10.1016/j.cell.2004.07.019; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Mummert ME, 2003, MOL CANCER THER, V2, P295; Ohtsu H, 2005, ARTERIOSCL THROM VAS, V25, P1831, DOI 10.1161/01.ATV.0000175749.41799.9b; Ozawa T, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni032; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Ranganathan S, 1995, CELL MOL BIOL RES, V41, P467; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rout UK, 1997, CELL CALCIUM, V22, P463, DOI 10.1016/S0143-4160(97)90074-9; Sabe H, 2003, J BIOCHEM, V134, P485, DOI 10.1093/jb/mvg181; Santra S, 2001, J BIOMED OPT, V6, P160, DOI 10.1117/1.1353590; Schauble S, 2007, J BIOL CHEM, V282, P14952, DOI 10.1074/jbc.M609221200; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Sengupta A, 2004, BIOCHEM J, V380, P837, DOI 10.1042/BJ20040264; Seo MC, 2008, J NEUROSCI RES, V86, P1087, DOI 10.1002/jnr.21552; Shmueli O, 2003, CR BIOL, V326, P1067, DOI 10.1016/j.crvi.2003.09.012; Soltys BJ, 2000, HISTOCHEM CELL BIOL, V114, P245; Stitz J, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni039; Suzuki H, 2007, NEUROSCI LETT, V421, P152, DOI 10.1016/j.neulet.2007.03.077; Swift S, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1017cs31; Toole BP, 2002, AM J PATHOL, V161, P745, DOI 10.1016/S0002-9440(10)64232-0; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Uchida C, 2008, CELL BIOL INT, V32, P769, DOI 10.1016/j.cellbi.2008.03.005; Vicente-Manzanares M, 2005, J CELL SCI, V118, DOI 10.1242/jcs.02662; Watanabe S, 2006, ONCOGENE, V25, P2697, DOI 10.1038/sj.onc.1209307; Westerman BA, 2004, GENOMICS, V83, P1094, DOI 10.1016/j.ygeno.2003.12.006; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Wiesner C, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf079; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Yanai I, 2005, BIOINFORMATICS, V21, P650, DOI 10.1093/bioinformatics/bti042; YOKOTA T, 1985, P NATL ACAD SCI USA, V82, P68, DOI 10.1073/pnas.82.1.68; Zhang WW, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000248	93	42	47	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					464	478		10.1096/fj.09-137562	http://dx.doi.org/10.1096/fj.09-137562			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19812375				2022-12-28	WOS:000274045000014
J	Macambira, SG; Vasconcelos, JF; Costa, CRS; Klein, W; Lima, RS; Guimaraes, P; Vidal, DTA; Mendez, LC; Ribeiro-dos-Santos, R; Soares, MBP				Macambira, Simone G.; Vasconcelos, Juliana F.; Costa, Claudio R. S.; Klein, Wilfried; Lima, Ricardo S.; Guimaraes, Patricia; Vidal, Daniel T. A.; Mendez, Lucas C.; Ribeiro-dos-Santos, Ricardo; Soares, Milena B. P.			Granulocyte colony-stimulating factor treatment in chronic Chagas disease: preservation and improvement of cardiac structure and function	FASEB JOURNAL			English	Article						chagasic cardiomyopathy; inflammation; arrhythmias; treadmill performance	BONE-MARROW-CELLS; ACUTE MYOCARDIAL-INFARCTION; G-CSF; HEART; REPAIR; MICE; TRANSPLANTATION; MOBILIZATION; RECRUITMENT; EXPRESSION	This study investigates the effects of granulocyte colony-stimulating factor (G-CSF) therapy in experimental chronic chagasic cardiomyopathy. Chagas disease is one of the leading causes of heart failure in Latin America and remains without an effective treatment other than cardiac transplantation. C57BL/6 mice were infected with 10(3) trypomastigotes of Trypanosoma cruzi, and chronic chagasic mice were treated with G-CSF or saline (control). Evaluations following treatment were functional, immunological, and histopathological. Comparing hearts of G-CSF-treated mice showed reduced inflammation and fibrosis compared to saline-treated chagasic mice. G-CSF treatment did not alter the parasite load but caused an increase in the number of apoptotic inflammatory cells in the heart. Cardiac conductance disturbances in all infected animals improved or remained stable due to the G-CSF treatment, whereas all of the saline-treated mice deteriorated. The distance run on a treadmill and the exercise time were significantly greater in G-CSF-treated mice when compared to chagasic controls, as well as oxygen consumption ((V) over dotO(2)), carbon dioxide production ((V) over dotCO(2)), and respiratory exchange ration (RER) during exercise. Administration of G-CSF in experimental cardiac ischemia had beneficial effects on cardiac structure, which were well correlated with improvements in cardiac function and whole animal performance.-Macambira, S. G., Vasconcelos, J. F., Costa, C. R. S., Klein, W., Lima, R. S., Guimaraes, P., Vidal, D. T. A., Mendez, L. C., Ribeiro-dos-Santos, R., Soares, M. B. P. Granulocyte colony-stimulating factor treatment in chronic Chagas disease: preservation and improvement of cardiac structure and function. FASEB J. 23, 3843-3850 (2009). www.fasebj.org	[Macambira, Simone G.; Vasconcelos, Juliana F.; Costa, Claudio R. S.; Lima, Ricardo S.; Guimaraes, Patricia; Vidal, Daniel T. A.; Mendez, Lucas C.; Ribeiro-dos-Santos, Ricardo; Soares, Milena B. P.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, BR-40296710 Salvador, BA, Brazil; [Macambira, Simone G.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941 Rio De Janeiro, Brazil; [Klein, Wilfried] Univ Fed Bahia, Inst Biol, Salvador, BA, Brazil; [Ribeiro-dos-Santos, Ricardo; Soares, Milena B. P.] Hosp Sao Rafael, Salvador, BA, Brazil	Fundacao Oswaldo Cruz; Universidade Federal do Rio de Janeiro; Universidade Federal da Bahia	Soares, MBP (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, 121 Rua Waldemar Falcao, BR-40296710 Salvador, BA, Brazil.	milena@bahia.fiocruz.br	Soares, Milena B. P./O-3771-2018; Klein, Wilfried/A-2228-2008; Vasconcelos, Juliana/AAN-5274-2021; Fisiologia comparada, Inct/I-2427-2013; Oliveira, Claudia DL/G-8618-2011	Klein, Wilfried/0000-0001-6099-6178; Vasconcelos, Juliana/0000-0003-4553-0315; Santana de Lima, Ricardo/0000-0002-1279-3445; Soares, Milena/0000-0001-7549-2992; Mendez, Lucas C./0000-0002-0440-3320	Brazilian Ministry of Science and Technology [Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)]; Financiadora de Estudos e Projetos (FINEP); Fiocruz, and Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)	Brazilian Ministry of Science and Technology [Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)](Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Financiadora de Estudos e Projetos (FINEP)(Financiadora de Inovacao e Pesquisa (Finep)); Fiocruz, and Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)	This work was supported by grants from the Brazilian Ministry of Science and Technology [Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)], Financiadora de Estudos e Projetos (FINEP), Fiocruz, and Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB).	Adesse D, 2008, MICROBES INFECT, V10, P21, DOI 10.1016/j.micinf.2007.09.017; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; Brunner S, 2008, EXP HEMATOL, V36, P695, DOI 10.1016/j.exphem.2008.01.011; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; Deindl E, 2006, FASEB J, V20, P956, DOI 10.1096/fj.05-4763fje; FEDERICI EE, 1964, AM J TROP MED HYG, V13, P272, DOI 10.4269/ajtmh.1964.13.272; Fujita J, 2007, STEM CELLS, V25, P2750, DOI 10.1634/stemcells.2007-0275; Fukuhara S, 2004, CELL TRANSPLANT, V13, P741, DOI 10.3727/000000004783983486; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; Iwanaga K, 2004, BIOCHEM BIOPH RES CO, V325, P1353, DOI 10.1016/j.bbrc.2004.10.149; JONES EM, 1993, AM J TROP MED HYG, V48, P348, DOI 10.4269/ajtmh.1993.48.348; Kanellakis P, 2006, CARDIOVASC RES, V70, P117, DOI 10.1016/j.cardiores.2006.01.005; Kuhlmann MT, 2006, J EXP MED, V203, P87, DOI 10.1084/jem.20051151; Kuwabara M, 2007, FEBS LETT, V581, P4821, DOI 10.1016/j.febslet.2007.09.007; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Leon JS, 2001, INFECT IMMUN, V69, P5643, DOI 10.1128/IAI.69.9.5643-5649.2001; Li YW, 2006, LAB INVEST, V86, P32, DOI 10.1038/labinvest.3700367; Mieno S, 2006, CIRCULATION, V114, pI186, DOI 10.1161/CIRCULATIONAHA.105.001610; Muller P, 2002, CIRCULATION, V106, P31, DOI 10.1161/01.CIR.0000022405.68464.CA; Okada H, 2008, J CELL MOL MED, V12, P1272, DOI 10.1111/j.1582-4934.2008.00294.x; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Palomino SAP, 2000, ANN TROP MED PARASIT, V94, P571, DOI 10.1080/00034983.2000.11813580; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Pontes-de-Carvalho L, 2002, J AUTOIMMUN, V18, P131, DOI 10.1006/jaut.2001.0574; Rocha NN, 2006, PARASITOLOGY, V133, P729, DOI 10.1017/S0031182006001193; Rutella S, 2002, BLOOD, V100, P2562, DOI 10.1182/blood-2001-12-0291; Rutella S, 2001, EXP HEMATOL, V29, P401, DOI 10.1016/S0301-472X(01)00617-8; Soares MBP, 2004, AM J PATHOL, V164, P441, DOI 10.1016/S0002-9440(10)63134-3; Soares MBP, 2001, AN ACAD BRAS CIENC, V73, P547, DOI 10.1590/S0001-37652001000400008; Soares MBP, 2001, AM J PATHOL, V159, P703, DOI 10.1016/S0002-9440(10)61741-5; Soares MBP, 2007, REGEN MED, V2, P257, DOI 10.2217/17460751.2.3.257; Sugano Y, 2005, CARDIOVASC RES, V65, P446, DOI 10.1016/j.cardiores.2004.10.008; Tanaka J, 2002, INT J HEMATOL, V75, P489, DOI 10.1007/BF02982111; Vandervelde S, 2005, J MOL CELL CARDIOL, V39, P363, DOI 10.1016/j.yjmcc.2005.05.012; Wojakowski W, 2004, CIRCULATION, V110, P3213, DOI 10.1161/01.CIR.0000147609.39780.02	37	22	24	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3843	3850		10.1096/fj.09-137869	http://dx.doi.org/10.1096/fj.09-137869			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19608624	Green Published			2022-12-28	WOS:000271272500020
J	Sexton, A; Harman, S; Shattock, RJ; Ma, JKC				Sexton, Amy; Harman, Sarah; Shattock, Robin J.; Ma, Julian K. -C.			Design, expression, and characterization of a multivalent, combination HIV microbicide	FASEB JOURNAL			English	Article						b12; cyanovirin-N; fusion protein; transgenic plants; plant biotechnology	CYANOVIRIN-N; IMMUNODEFICIENCY-VIRUS; MONOCLONAL-ANTIBODY; GLYCOPROTEIN GP120; TRANSMISSION; BINDING; PROTEIN; EPITOPE; PANEL; AIDS	Many promising microbicide candidates are proteins or peptides, including neutralizing monoclonal antibodies (mAbs). Here, the expression of the HIV-neutralizing mAb b12 in transgenic plants is described. The plant-derived mAb b12 was shown to have gp120 binding activity and HIV-neutralizing activity in vitro. However, it is likely that a protein-based microbicide will need to comprise a combination of two or more products, in order to provide long-lasting and cross-clade protection. Building on the expression of mAb b12 and to address the need for a combinational agent, the expression of a fusion protein of mAb b12 with cyanovirin-N, another protein microbicide, has been explored. This fusion protein molecule is predicted to have four binding sites for HIV gp120 with two different specificities. The fusion protein was assembled and expressed in planta, and functionality was confirmed by gp120 binding and HIV neutralization in vitro. Each moiety of the fusion protein retained its binding ability to gp120. In addition, this fusion protein demonstrated increased anti-HIV potency compared to b12 or CV-N alone. This fusion protein addresses the requirement to combine microbicide products, and the production in plants is a step toward resolving the issues of manufacturing scalability and cost for developing countries. Sexton, A., Harman, S., Shattock, R. J., Ma, J. K.-C. Design, expression, and characterization of a multivalent, combination HIV microbicide. FASEB J. 23, 3590-3600 (2009). www.fasebj.org	[Sexton, Amy; Harman, Sarah; Shattock, Robin J.; Ma, Julian K. -C.] Univ London, St Georges Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England	St Georges University London; University of London	Ma, JKC (corresponding author), Univ London, St Georges Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England.	jma@sgul.ac.uk		Ma, Julian/0000-0003-0767-0042; Harman, Sarah/0000-0001-6443-0614	EU; UK Medical Research Council; EMPRO	EU(European Commission); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EMPRO	We are grateful to Dr. Dennis Burton (The Scripps Research Institute, La Jolla, CA, USA) for providing the mAb b12 clone, and to Biosyn Inc. (Baton Rouge, LA, USA) for their collaborative efforts and provision of the CV-N N30Q/P51G DNA template and the rabbit anti-CV-N polyclonal antisera. We also thank the National Cancer Institute (Rockville, MD, USA) for additional rabbit anti-CV-N polyclonal antisera. We thank Dr. Susan Zolla Pazner (New York University Langone Medical Center, New York, NY, USA) for the D30 mAb. We acknowledge the Centralised Facility for AIDS Reagents (Potters Bar, UK), supported by the EU program EVA/MRC and the UK Medical Research Council, for the provision of recombinant gp120. This work was supported by EMPRO (EU framework 6).	Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004; Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521, DOI 10.1128/AAC.41.7.1521; Bublil EM, 2006, FASEB J, V20, P1762, DOI 10.1096/fj.05-5509rev; Buffa V, 2009, J GEN VIROL, V90, P234, DOI 10.1099/vir.0.004358-0; Chargelegue D, 2005, INFECT IMMUN, V73, P5915, DOI 10.1128/IAI.73.9.5915-5922.2005; Esser MT, 1999, J VIROL, V73, P4360, DOI 10.1128/JVI.73.5.4360-4371.1999; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Hu QX, 2007, VIROLOGY, V368, P145, DOI 10.1016/j.virol.2007.06.029; MA JKC, 1995, SCIENCE, V268, P716, DOI 10.1126/science.7732380; Miranda LR, 2007, J IMMUNOL, V178, P7132, DOI 10.4049/jimmunol.178.11.7132; MONTEFIORI D, 2004, CURRENT PROTOCOLS IM; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; Moulard M, 2002, P NATL ACAD SCI USA, V99, P6913, DOI 10.1073/pnas.102562599; Nuttall J, 2002, EUR J BIOCHEM, V269, P6042, DOI 10.1046/j.1432-1033.2002.03302.x; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Rademacher T, 2008, PLANT BIOTECHNOL J, V6, P189, DOI 10.1111/j.1467-7652.2007.00306.x; Ramessar K, 2008, P NATL ACAD SCI USA, V105, P3727, DOI 10.1073/pnas.0708841104; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; Sambrook J., 2001, MOL CLONING LAB MANU, V3rd ed.; Sexton A, 2006, FASEB J, V20, P356, DOI 10.1096/fj.05-4742fje; Shattock R, 2004, LANCET, V363, P1002, DOI 10.1016/S0140-6736(04)15876-5; Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729; Tsai CC, 2003, AIDS RES HUM RETROV, V19, P535, DOI 10.1089/088922203322230897; Tsai CC, 2004, AIDS RES HUM RETROV, V20, P11, DOI 10.1089/088922204322749459; TSUJI T, 1981, BIOCHEM J, V195, P691, DOI 10.1042/bj1950691; Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833; Vitale A, 1999, PLANT CELL, V11, P615, DOI 10.1105/tpc.11.4.615; Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580	28	42	44	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3590	3600		10.1096/fj.09-131995	http://dx.doi.org/10.1096/fj.09-131995			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19470798				2022-12-28	WOS:000270354300035
J	Kim, SM; Power, A; Brown, TM; Constance, CM; Coon, SL; Nishimura, T; Hirai, H; Cai, T; Eisner, C; Weaver, DR; Piggins, HD; Klein, DC; Schnermann, J; Notkins, AL				Kim, Soo Mi; Power, Andrea; Brown, Timothy M.; Constance, Cara M.; Coon, Steven L.; Nishimura, Takuya; Hirai, Hiroki; Cai, Tao; Eisner, Christoph; Weaver, David R.; Piggins, Hugh D.; Klein, David C.; Schnermann, Juergen; Notkins, Abner L.			Deletion of the secretory vesicle proteins IA-2 and IA-2 beta disrupts circadian rhythms of cardiovascular and physical activity	FASEB JOURNAL			English	Article						blood pressure; heart rate; temperature; diabetes; behavior	TYROSINE-PHOSPHATASE; SUPRACHIASMATIC NUCLEI; TRANSMEMBRANE PROTEIN; TARGETED DISRUPTION; CLOCK; MAINTENANCE; AUTOANTIGEN; PACEMAKER; GENES; ROLES	Targeted deletion of IA-2 and IA-2 beta, major autoantigens in type 1 diabetes and transmembrane secretory vesicle proteins, results in impaired secretion of hormones and neurotransmitters. In the present study, we evaluated the effect of these deletions on daily rhythms in blood pressure, heart rate, core body temperature, and spontaneous physical and neuronal activity. We found that deletion of both IA-2 and IA-2 beta profoundly disrupts the usual diurnal variation of each of these parameters, whereas the deletion of either IA-2 or IA-2 beta alone did not produce a major change. In situ hybridization revealed that IA-2 and IA-2 beta transcripts are highly but nonrhythmically expressed in the suprachiasmatic nuclei, the site of the brain's master circadian oscillator. Electrophysiological studies on tissue slices from the suprachiasmatic nuclei showed that disruption of both IA-2 and IA-2 beta results in significant alterations in neuronal firing. From these studies, we concluded that deletion of IA-2 and IA-2 beta, structural proteins of secretory vesicles and modulators of neuroendocrine secretion, has a profound effect on the circadian system.-Kim, S. M., Power, A., Brown, T. M., Constance, C. M., Coon, S. L., Nishimura, T., Hirai, H., Cai, T., Eisner, C., Weaver, D. R., Piggins, H. D., Klein, D. C., Schnermann, J., Notkins, A. L. Deletion of the secretory vesicle proteins IA-2 and IA-2 beta disrupts circadian rhythms of cardiovascular and physical activity. FASEB J. 23, 3226-3232 ( 2009). www.fasebj.org	[Nishimura, Takuya; Hirai, Hiroki; Cai, Tao; Notkins, Abner L.] Natl Inst Dent & Craniofacial Res, Expt Med Sect, NIH, Bethesda, MD 20892 USA; [Kim, Soo Mi; Eisner, Christoph; Schnermann, Juergen] NIDDK, Kidney Dis Branch, Bethesda, MD USA; [Coon, Steven L.; Klein, David C.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Neuroendocrinol, Program Dev Endocrinol & Genet, Bethesda, MD USA; [Power, Andrea; Brown, Timothy M.; Piggins, Hugh D.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Constance, Cara M.] Coll Holy Cross, Dept Biol, Worcester, MA 01610 USA; [Weaver, David R.] Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Manchester; College of the Holy Cross; University of Massachusetts System; University of Massachusetts Worcester	Notkins, AL (corresponding author), Natl Inst Dent & Craniofacial Res, Expt Med Sect, NIH, 30 Convent Dr, Bethesda, MD 20892 USA.	anotkins@mail.nih.gov	cai, tao/C-5060-2011; Brown, Timothy/A-3018-2011	Piggins, Hugh/0000-0003-2555-9858; Cai, Tao/0000-0002-2877-8637; Brown, Timothy/0000-0002-5625-4750; Weaver, David/0000-0001-7941-6719; Klein, David/0000-0002-1792-5806	National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Dental and Craniofacial Research; Eunice Kennedy Shriver National Institute of Child Health and Human Development; NIH [NS056125]; Biotechnology and Biological Sciences Research Council (UK); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008836, ZIAHD008838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK043410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS056125] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Biotechnology and Biological Sciences Research Council (UK)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the intramural research programs of the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Dental and Craniofacial Research, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, and by project grants from the Biotechnology and Biological Sciences Research Council (UK) to H. D. P. and NIH grant NS056125 to D. R. W. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors declare no conflicts of interest.	Albus H, 2002, CURR BIOL, V12, P1130, DOI 10.1016/S0960-9822(02)00923-5; [Anonymous], 1991, SUPRACHIASMATIC NUCL; Aton SJ, 2005, NAT NEUROSCI, V8, P476, DOI 10.1038/nn1419; Bae K, 2001, NEURON, V30, P525, DOI 10.1016/S0896-6273(01)00302-6; Bae K, 2007, J BIOL RHYTHM, V22, P85, DOI 10.1177/0748730406296718; Brown TM, 2007, J NEUROPHYSIOL, V97, P2553, DOI 10.1152/jn.01206.2006; Brown TM, 2007, PROG NEUROBIOL, V82, P229, DOI 10.1016/j.pneurobio.2007.05.002; Brown TM, 2006, J NEUROSCI METH, V156, P173, DOI 10.1016/j.jneumeth.2006.02.024; Brown TM, 2005, J NEUROSCI, V25, P11155, DOI 10.1523/JNEUROSCI.3821-05.2005; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; DeBruyne JP, 2007, NAT NEUROSCI, V10, P543, DOI 10.1038/nn1884; Dunlap J.C., 2004, CHRONOBIOLOGY BIOL T; Harashima S, 2005, P NATL ACAD SCI USA, V102, P8704, DOI 10.1073/pnas.0408887102; Hughes AT, 2004, J NEUROSCI, V24, P3522, DOI 10.1523/JNEUROSCI.5345-03.2004; Kim SM, 2006, AM J PHYSIOL-RENAL, V290, pF1016, DOI 10.1152/ajprenal.00367.2005; Kubosaki A, 2006, ENDOCRINOLOGY, V147, P811, DOI 10.1210/en.2005-0638; Kubosaki A, 2005, DIABETES, V54, pS46, DOI 10.2337/diabetes.54.suppl_2.S46; Kubosaki A, 2004, DIABETES, V53, P1684, DOI 10.2337/diabetes.53.7.1684; Lan MS, 1996, P NATL ACAD SCI USA, V93, P6367, DOI 10.1073/pnas.93.13.6367; Lu J, 1996, P NATL ACAD SCI USA, V93, P2307, DOI 10.1073/pnas.93.6.2307; Mahapatra NR, 2005, J CLIN INVEST, V115, P1942, DOI 10.1172/JCI24354; Maywood ES, 2006, CURR BIOL, V16, P599, DOI 10.1016/j.cub.2006.02.023; Nishimura T, 2009, NEUROSCIENCE, V159, P427, DOI 10.1016/j.neuroscience.2009.01.022; Notkins AL, 2001, J CLIN INVEST, V108, P1247, DOI 10.1172/JCI200114257; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Saeki K, 2002, DIABETES, V51, P1842, DOI 10.2337/diabetes.51.6.1842; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4	30	21	23	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3226	3232		10.1096/fj.09-132019	http://dx.doi.org/10.1096/fj.09-132019			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19433624	Green Published			2022-12-28	WOS:000270241000044
J	Paulhe, F; Wehrle-Haller, M; Jacquier, MC; Imhof, BA; Tabone-Eglinger, S; Wehrle-Haller, B				Paulhe, Frederique; Wehrle-Haller, Monique; Jacquier, Marie-Claude; Imhof, Beat A.; Tabone-Eglinger, Severine; Wehrle-Haller, Bernhard			Dimerization of Kit-ligand and efficient cell-surface presentation requires a conserved Ser-Gly-Gly-Tyr motif in its transmembrane domain	FASEB JOURNAL			English	Article						bimolecular fluorescence complementation; growth factors; intracellular transport; c-Kit; evolution; Flt3-L	C-KIT; STEEL FACTOR; FLUORESCENCE COMPLEMENTATION; INFLUENZA HEMAGGLUTININ; MELANOCYTE DEVELOPMENT; ENDOPLASMIC-RETICULUM; PROTEIN INTERACTIONS; CYTOPLASMIC DOMAIN; STRUCTURAL BASIS; POINT MUTATIONS	Kit-ligand (Kitl), also known as stem cell factor, is a membrane-anchored, noncovalently bound dimer signaling via the c-kit receptor tyrosine kinase, required for migration, survival, and proliferation of hematopoietic stem and germ cells, melanocytes, and mastocytes. Despite its fundamental role in morphogenesis and stem cell biology, the mechanisms that regulate Kitl dimerization are not well understood. By employing cell-permeable cross-linker and quantitative bimolecular fluorescence complementation of wildtype and truncated forms of Kitl, we determined that Kitl dimerization is initiated in the endoplasmic reticulum and mediated to similar levels by the transmembrane and the extracellular growth factor domain. Further biochemical and mutational analysis revealed a conserved Ser-Gly-Gly-Tyr-containing motif that is required for transmembrane domain dimerization and efficient cell-surface expression of Kitl. A novel intracellular capture assay with the Kitl transmembrane domain as bait revealed specific interactions with Kitl, but not with unrelated transmembrane proteins. During evolution, the transmembrane dimerization motif appeared in Kitl at the transition from teleosts to tetrapods, which correlates with the emergence of Kitl as a supporter of stem cell populations. Thus, transmembrane-mediated association of membrane-anchored growth factors consists of a novel mechanism to improve paracrine signaling and morphogenesis.-Paulhe, F., Wehrle-Haller, M., Jacquier, M.-C., Imhof, B. A., Tabone-Eglinger, S., Wehrle-Haller, B. Dimerization of Kit-ligand and efficient cell-surface presentation requires a conserved Ser-Gly-Gly-Tyr motif in its transmembrane domain. FASEB J. 23, 3037-3048 ( 2009). www.fasebj.org	[Paulhe, Frederique; Wehrle-Haller, Monique; Jacquier, Marie-Claude; Tabone-Eglinger, Severine; Wehrle-Haller, Bernhard] Univ Geneva, Dept Cellular Physiol & Metab, Ctr Med Univ Geneva, Geneva, Switzerland; [Imhof, Beat A.] Univ Geneva, Dept Pathol & Immunol, Ctr Med Univ Geneva, Geneva, Switzerland; [Tabone-Eglinger, Severine] Univ Lyon 1, Ctr Leon Berard, INSERM, Cytokine & Canc Grp,U590, F-69365 Lyon, France	University of Geneva; University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard	Wehrle-Haller, B (corresponding author), Ctr Med Univ Geneva, Dept Cellular Physiol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	bernhard.wehrle-haller@unige.ch		TABONE-eglinger, Severine/0000-0003-4247-1321	Swiss National Science Foundation [3100A0-103805]; Nevus Outreach; CONTICANET of the University of Lyon (Lyon, France)	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Nevus Outreach; CONTICANET of the University of Lyon (Lyon, France)	We thank Drs. Pierre Cosson ( Centre Medical Universitaire, Geneva, Switzerland) and Roger Tsien ( University of California, San Diego, CA, USA) for reagents, and Drs. Jim Weston, Benoit Gauthier, and Jean-Yves Blay for helpful discussions and critical reading of the manuscript. We are grateful to the support by the Swiss National Science Foundation (3100A0-103805) and Nevus Outreach. S.T.-E. is the recipient of a fellowship from the CONTICANET of the University of Lyon ( Lyon, France).	Aridor M, 2007, ADV DRUG DELIVER REV, V59, P759, DOI 10.1016/j.addr.2007.06.002; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; BRANNAN CI, 1992, GENE DEV, V6, P1832, DOI 10.1101/gad.6.10.1832; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; Cordes FS, 2002, J MOL BIOL, V323, P951, DOI 10.1016/S0022-2836(02)01006-9; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Goldman DC, 2006, BLOOD, V107, P3114, DOI 10.1182/blood-2005-09-3930; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hsu YR, 1997, J BIOL CHEM, V272, P6406, DOI 10.1074/jbc.272.10.6406; Hu CD, 2003, NAT BIOTECHNOL, V21, P539, DOI 10.1038/nbt816; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Hultman KA, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030017; Jiang XL, 2000, EMBO J, V19, P3192, DOI 10.1093/emboj/19.13.3192; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; Kunisada T, 1998, J EXP MED, V187, P1565, DOI 10.1084/jem.187.10.1565; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Liu HL, 2007, EMBO J, V26, P891, DOI 10.1038/sj.emboj.7601545; LU HS, 1995, BIOCHEM J, V305, P563, DOI 10.1042/bj3050563; Nyfeler B, 2007, BIOCHEM SOC T, V35, P970, DOI 10.1042/BST0350970; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; Parichy DM, 1999, DEVELOPMENT, V126, P3425; Paulhe F, 2004, J BIOL CHEM, V279, P55545, DOI 10.1074/jbc.M407813200; Rajaraman S, 2002, GENETICS, V162, P331; Rajaraman S, 2002, GENETICS, V162, P341; Rickert M, 2005, SCIENCE, V308, P1477, DOI 10.1126/science.1109745; RODEWALD HR, 1995, IMMUNITY, V3, P313, DOI 10.1016/1074-7613(95)90116-7; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; Savvides SN, 2000, NAT STRUCT BIOL, V7, P486; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schneider D, 2004, J MOL BIOL, V343, P799, DOI 10.1016/j.jmb.2004.08.083; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; Tajima Y, 1998, J EXP MED, V187, P1451, DOI 10.1084/jem.187.9.1451; Tajima Y, 1998, P NATL ACAD SCI USA, V95, P11903, DOI 10.1073/pnas.95.20.11903; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; Unterreitmeier S, 2007, J MOL BIOL, V374, P705, DOI 10.1016/j.jmb.2007.09.056; Wang XQ, 2005, SCIENCE, V310, P1159, DOI 10.1126/science.1117893; Waskow C, 2007, BLOOD, V109, P5363, DOI 10.1182/blood-2006-08-039131; Wehrle-Haller B, 1999, DEV BIOL, V210, P71, DOI 10.1006/dbio.1999.9260; Wehrle-Haller B, 2003, PIGM CELL RES, V16, P287, DOI 10.1034/j.1600-0749.2003.00055.x; Wehrle-Haller B, 2001, DEV BIOL, V232, P471, DOI 10.1006/dbio.2001.0167; Wehrle-Haller B, 2001, J BIOL CHEM, V276, P12667, DOI 10.1074/jbc.M008357200; WEHRLEHALLER B, 1995, DEVELOPMENT, V121, P731; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779; Yin H, 2007, SCIENCE, V315, P1817, DOI 10.1126/science.1136782; Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568; Yuzawa S, 2007, CELL, V130, P323, DOI 10.1016/j.cell.2007.05.055; Zama AM, 2005, BIOL REPROD, V73, P639, DOI 10.1095/biolreprod.105.042846; Zhang ZT, 2000, P NATL ACAD SCI USA, V97, P7732, DOI 10.1073/pnas.97.14.7732	53	13	13	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3037	3048		10.1096/fj.09-129577	http://dx.doi.org/10.1096/fj.09-129577			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19386768				2022-12-28	WOS:000270241000026
J	Jaeger, MA; Sonnemann, KJ; Fitzsimons, DP; Prins, KW; Ervasti, JM				Jaeger, Michele A.; Sonnemann, Kevin J.; Fitzsimons, Daniel P.; Prins, Kurt W.; Ervasti, James M.			Context-dependent functional substitution of alpha-skeletal actin by gamma-cytoplasmic actin	FASEB JOURNAL			English	Article						isoforms; isoform substitution; myofibril; sarcomere; thin filament; nemaline myopathy	CARDIAC ACTIN; BETA-ACTIN; MDX MICE; MUSCLE; DYSTROPHIN; ISOFORMS; EXPRESSION; SARCOLEMMA; OVEREXPRESSION; IDENTIFICATION	We generated transgenic mice that over-expressed gamma-(cyto) actin 2000-fold above wild-type levels in skeletal muscle. gamma-(cyto) actin comprised 40% of total actin in transgenic skeletal muscle, with a concomitant 40% decrease in alpha-actin. Surprisingly, transgenic muscle was histologically and ultrastructurally identical to wild-type muscle despite near-stoichiometric incorporation of gamma-(cyto) actin into sarcomeric thin filaments. Furthermore, several parameters of muscle physiological performance in the transgenic animals were not different from wild type. Given these surprising results, we tested whether overexpression of gamma-(cyto) actin could rescue the early postnatal lethality in alpha-(sk) actin-null mice (Acta1(-/-)). By quantitative Western blot analysis, we found total actin levels were decreased by 35% in Acta1(-/-) muscle. Although transgenic overexpression of gamma-(cyto) actin on the Acta1(-/-) background restored total actin levels to wild type, resulting in thin filaments composed of 60% gamma-cyto actin and a 40% mixture of cardiac and vascular actin, the life span of transgenic Acta1(-/-) mice was not extended. These results indicate that sarcomeric thin filaments can accommodate substantial incorporation of gamma-(cyto) actin without functional consequences, yet gamma-(cyto) actin cannot fully substitute for alpha-(sk) actin.-Jaeger, M. A., Sonnemann, K. J., Fitzsimons, D. P., Prins, K. W., Ervasti, J. M. Context-dependent functional substitution of alpha-skeletal actin by gamma-cytoplasmic actin. FASEB J. 23, 2205-2214 (2009)	[Jaeger, Michele A.; Sonnemann, Kevin J.; Prins, Kurt W.; Ervasti, James M.] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; [Fitzsimons, Daniel P.] Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Wisconsin System; University of Wisconsin Madison	Ervasti, JM (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	jervasti@umn.edu	Ervasti, James/AAZ-4786-2020	Prins, Kurt/0000-0002-0364-6742	American Heart Association Predoctoral Fellowships; NIH [AR049899]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049899] Funding Source: NIH RePORTER	American Heart Association Predoctoral Fellowships(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Dr. Nigel Laing and Dr. Kristen Nowak ( University of Western Australia, Perth, Australia) for generously providing Acta1<SUP>+/-</SUP> mice and for sharing their data prior to publication, and Dr. Richard L. Moss for helpful comments and suggestions. This study was supported by American Heart Association Predoctoral Fellowships to M.A.J and K.J.S., and NIH grant AR049899 to J.M.E.	BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; Barton ER, 2006, AM J PHYSIOL-CELL PH, V290, pC411, DOI 10.1152/ajpcell.00192.2005; BEALL CJ, 1989, GENE DEV, V3, P131, DOI 10.1101/gad.3.2.131; BRAVO R, 1981, CELL, V25, P195, DOI 10.1016/0092-8674(81)90244-0; CARLSON CG, 1990, MUSCLE NERVE, V13, P480, DOI 10.1002/mus.880130603; CRAIG SW, 1983, CELL MOTIL CYTOSKEL, V3, P449, DOI 10.1002/cm.970030513; Crawford K, 2002, MOL CELL BIOL, V22, P5887, DOI 10.1128/MCB.22.16.5887-5896.2002; DENOFRIO D, 1989, J CELL BIOL, V109, P191, DOI 10.1083/jcb.109.1.191; ERBA HP, 1988, MOL CELL BIOL, V8, P1775, DOI 10.1128/MCB.8.4.1775; FIRTEL RA, 1981, CELL, V24, P6, DOI 10.1016/0092-8674(81)90494-3; Fyrberg EA, 1998, BIOCHEM GENET, V36, P271, DOI 10.1023/A:1018785127079; GORDON DJ, 1977, J BIOL CHEM, V252, P8300; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; Hack AA, 2000, J CELL SCI, V113, P2535; Hanft LM, 2006, P NATL ACAD SCI USA, V103, P5385, DOI 10.1073/pnas.0600980103; HEWETT TE, 1994, CIRC RES, V74, P740, DOI 10.1161/01.RES.74.4.740; Kumar A, 2004, TRANSGENIC RES, V13, P531, DOI 10.1007/s11248-004-2823-6; Kumar A, 1997, P NATL ACAD SCI USA, V94, P4406, DOI 10.1073/pnas.94.9.4406; Lloyd CM, 2004, EXP CELL RES, V297, P82, DOI 10.1016/j.yexcr.2004.02.012; Marco-Ferreres R, 2005, BIOCHEM J, V386, P145, DOI 10.1042/BJ20041240; Martiny AC, 2002, WA SCI TECHNOL, V2, P283, DOI 10.2166/ws.2002.0114; MCHUGH KM, 1991, DEV BIOL, V148, P442, DOI 10.1016/0012-1606(91)90263-3; MCKENNA N, 1985, J CELL BIOL, V100, P292, DOI 10.1083/jcb.100.1.292; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; MOSSAKOWSKA M, 1985, EUR J BIOCHEM, V153, P373, DOI 10.1111/j.1432-1033.1985.tb09313.x; NOWAK K, 2007, NEUROMUSCUL DISORD, V17; Nowak KJ, 2007, ANN NEUROL, V61, P175, DOI 10.1002/ana.21035; OTEY CA, 1988, CELL MOTIL CYTOSKEL, V9, P337, DOI 10.1002/cm.970090406; OTEY CA, 1987, J CELL BIOCHEM, V34, P113, DOI 10.1002/jcb.240340205; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; PARDO JV, 1983, CELL, V32, P1093, DOI 10.1016/0092-8674(83)90293-3; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PROCHNIEWICZ E, 1980, EUR J BIOCHEM, V106, P305; Prochniewicz E, 1999, BIOCHEMISTRY-US, V38, P14860, DOI 10.1021/bi991343g; Renley BA, 1998, CELL MOTIL CYTOSKEL, V41, P264, DOI 10.1002/(SICI)1097-0169(1998)41:3<264::AID-CM7>3.3.CO;2-Q; RUBENSTEIN PA, 1990, BIOESSAYS, V12, P309, DOI 10.1002/bies.950120702; Rybakova IN, 2000, J CELL BIOL, V150, P1209, DOI 10.1083/jcb.150.5.1209; SCHEVZOV G, 1992, J CELL BIOL, V117, P775, DOI 10.1083/jcb.117.4.775; Sonnemann KJ, 2006, DEV CELL, V11, P387, DOI 10.1016/j.devcel.2006.07.001; Suzuki H, 1998, TISSUE CELL, V30, P274, DOI 10.1016/S0040-8166(98)80076-1; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; vonArx P, 1995, J CELL BIOL, V131, P1759, DOI 10.1083/jcb.131.6.1759	42	27	28	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2205	2214		10.1096/fj.09-129783	http://dx.doi.org/10.1096/fj.09-129783			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19279140	Green Published			2022-12-28	WOS:000268836500020
J	Li, YZ; Wray, R; Eaton, C; Blount, P				Li, Yuezhou; Wray, Robin; Eaton, Christina; Blount, Paul			An open-pore structure of the mechanosensitive channel MscL derived by determining transmembrane domain interactions upon gating	FASEB JOURNAL			English	Article						electrostatic repulsion; mechanosensation; MTS reagents; disulfide trapping; osmotic regulation	MECHANISM; TENSION; PROTEIN	Mechanosensation, the ability to detect mechanical forces, underlies the senses of hearing, balance, touch, and pain, as well as renal and cardiovascular regulation. Although the sensors are thought to be channels, relatively little is known about eukaryotic mechanosensitive channels or their molecular mechanisms. Thus, because of its tractable nature, a bacterial mechanosensitive channel that serves as an in vivo osmotic "emergency release valve," MscL, has become a paradigm of how a mechanosensitive channel can sense and respond to membrane tension. Here, we have determined the structural rearrangements and interactions between transmembrane domains of MscL that occur upon gating. We utilize an electrostatic repulsion test: If two residues approach upon gating we predicted that substituting like-charges at those sites would inhibit gating. The in vivo growth and viability and in vitro vesicular flux and electrophysiological data all support the hypothesis that residues G26 and I92 directly interact upon gating. The resulting model predicted other interacting residues. One of these sets, V23 and I96, was confirmed to truly interact upon gating by disulfide trapping as well as the electrostatic repulsion test. Together, the data strongly suggest a model for structural transitions and residue-residue proximities that occur upon MscL gating.-Li, Y., Wray, R., Eaton, C., Blount, P. An open-pore structure of the mechanosensitive channel MscL derived by determining transmembrane domain interactions upon gating. FASEB J. 23, 2197-2204 (2009)	[Li, Yuezhou; Wray, Robin; Eaton, Christina; Blount, Paul] Univ Texas SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Blount, P (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	paul.blount@utsouthwestern.edu			Welch Foundation [I-1420]; National Institutes of Health [GM61028]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061028] Funding Source: NIH RePORTER	Welch Foundation(The Welch Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Adam Wallenfang for his technical support, Dr. Ian Booth for helpful discussions, and Drs. Irene Iscla, and Limin Yang for helpful discussions and critical reading of the manuscript. The work was supported by grant I-1420 from the Welch Foundation and grant GM61028 from the National Institutes of Health.	Bartlett JL, 2006, BIOPHYS J, V91, P3684, DOI 10.1529/biophysj.106.088062; Bartlett JL, 2004, P NATL ACAD SCI USA, V101, P10161, DOI 10.1073/pnas.0402040101; Batiza AF, 2002, P NATL ACAD SCI USA, V99, P5643, DOI 10.1073/pnas.082092599; Betanzos M, 2002, NAT STRUCT BIOL, V9, P704, DOI 10.1038/nsb828; Blount P, 1999, Methods Enzymol, V294, P458; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; Blount P, 2007, CURR TOP MEMBR, V58, P201, DOI 10.1016/S1063-5823(06)58008-1; Blount Paul, 2008, V1, P71; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; Iscla I, 2004, BIOPHYS J, V87, P3172, DOI 10.1529/biophysj.104.049833; Iscla I, 2008, BIOPHYS J, V95, P2283, DOI 10.1529/biophysj.107.127423; Iscla I, 2007, BIOPHYS J, V92, P1224, DOI 10.1529/biophysj.106.090316; Kocer A, 2005, SCIENCE, V309, P755, DOI 10.1126/science.1114760; Levin G, 2004, BIOPHYS J, V86, P2862, DOI 10.1016/S0006-3495(04)74338-6; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; Li YZ, 2004, MOL MICROBIOL, V53, P485, DOI 10.1111/j.1365-2958.2004.04150.x; Moe P, 2005, BIOCHEMISTRY-US, V44, P12239, DOI 10.1021/bi0509649; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Powl AM, 2008, BIOCHEMISTRY-US, V47, P4317, DOI 10.1021/bi702409t; Steinbacher S, 2007, CURR TOP MEMBR, V58, P1, DOI 10.1016/S1063-5823(06)58001-9; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; Yoshimura K, 2001, BIOPHYS J, V80, P2198, DOI 10.1016/S0006-3495(01)76192-9	25	23	24	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2197	2204		10.1096/fj.09-129296	http://dx.doi.org/10.1096/fj.09-129296			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19261722	Green Published			2022-12-28	WOS:000268836500019
J	Oh, JE; Bae, GU; Yang, YJ; Yi, MJ; Lee, HJ; Kim, BG; Krauss, RS; Kang, JS				Oh, Ji-Eun; Bae, Gyu-Un; Yang, Youn-Joo; Yi, Min-Jeong; Lee, Hye-Jin; Kim, Bok-Geon; Krauss, Robert S.; Kang, Jong-Sun			Cdo promotes neuronal differentiation via activation of the p38 mitogen-activated protein kinase pathway	FASEB JOURNAL			English	Article						Cdc42; myogenic differentiation; tissue-specific basic helix-loop-helix transcription factors; Bnip-2; JLP; neurogenin1	EMBRYONAL CARCINOMA-CELLS; NEURITE OUTGROWTH; PC12 CELLS; MYOGENIC DIFFERENTIATION; P38-ALPHA/BETA MAPK; SURFACE PROTEIN; BHLH FACTORS; N-CADHERIN; EXPRESSION; CDC42	Neural basic helix-loop-helix transcription factors (bHLHs) control many aspects of neurogenesis, such as proliferation, fate determination, and differentiation. We have previously shown that the promyogenic cell surface receptor Cdo modulates the Cdc42 and p38 mitogen-activated protein kinase ( MAPK) pathways via a direct association with two scaffold-type proteins, JLP and Bnip-2, to regulate activities of myogenic bHLH factors and myogenic differentiation. We report here that Cdo uses similar regulatory mechanisms to promote neuronal differentiation. Expression of JLP, a scaffold protein for p38MAPK, and Bnip-2, a regulator of Cdc42, is increased during differentiation of C17.2 neural precursor cells and P19 embryonal carcinoma cells. These molecules regulate Cdc42 and p38MAPK activities, which increase in a Cdo-dependent manner during neuronal differentiation of C17.2 cells and retinoic acid-treated P19 cells. Furthermore, enhancement or reduction of Cdc42 and p38MAPK activities enhances or reduces, respectively, neuronal differentiation of these cell lines. Cdc42 and p38MAPK activities also promote heterodimerization of neurogenin1 and E47, suggesting that one way they promote neurogenesis is via regulation of neural bHLH factor activities. These results imply that a conserved intracellular signaling mechanism initiated by Cdo regulates the activities of tissue-specific bHLH factors and therefore functions as a key regulator of differentiation of several different cell lineages.-Oh, J.-E., Bae, G.-U., Yang, Y.-J., Yi, M.-J., Lee, H.-J., Kim, B.-G., Krauss, R. S., Kang, J.-S. Cdo promotes neuronal differentiation via activation of the p38 mitogen-activated protein kinase pathway. FASEB J. 23, 2088-2099 (2009)	[Oh, Ji-Eun; Bae, Gyu-Un; Yang, Youn-Joo; Yi, Min-Jeong; Lee, Hye-Jin; Kim, Bok-Geon; Kang, Jong-Sun] Sungkyunkwan Univ, Dept Mol Cell Biol, Samsung Biomed Res Inst, Sch Med, Suwon 440746, South Korea; [Bae, Gyu-Un; Krauss, Robert S.] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY USA	Sungkyunkwan University (SKKU); Icahn School of Medicine at Mount Sinai	Kang, JS (corresponding author), Sungkyunkwan Univ, Dept Mol Cell Biol, Samsung Biomed Res Inst, Sch Med, Suwon 440746, South Korea.	jskang@med.skku.ac.kr			Korean government [KRF-2008-313-C00260]; U.S. National Institutes of Health [AR46207]; March of Dimes; T.J. Martell Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046207] Funding Source: NIH RePORTER	Korean government(Korean Government); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); March of Dimes(March of Dimes); T.J. Martell Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Drs. Ruth Simon and Domenico Totorella for critical reading of the manuscript and Andrew Chan (Mount Sinai School of Medicine, New York, NY, USA) for the Cdc42V12 expression vector. This work was supported by a Korea Research Foundation grant funded by the Korean government (KRF-2008-313-C00260) to J.S.K. and by grants from the U.S. National Institutes of Health (AR46207), the March of Dimes, and the T.J. Martell Foundation to R. S. K.	Aoki K, 2004, J BIOL CHEM, V279, P713, DOI 10.1074/jbc.M306382200; BAIN G, 1994, BIOCHEM BIOPH RES CO, V200, P1252, DOI 10.1006/bbrc.1994.1585; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; BIXBY JL, 1990, J CELL BIOL, V110, P1253, DOI 10.1083/jcb.110.4.1253; Cappello S, 2006, NAT NEUROSCI, V9, P1099, DOI 10.1038/nn1744; Cole F, 2004, DEV CELL, V7, P843, DOI 10.1016/j.devcel.2004.10.009; Faigle R, 2004, MOL CELL BIOL, V24, P280, DOI 10.1128/MCB.24.1.280-293.2004; Farah MH, 2000, DEVELOPMENT, V127, P693; Gao X, 2001, BIOCHEM BIOPH RES CO, V284, P1098, DOI 10.1006/bbrc.2001.5089; Garvalov BK, 2007, J NEUROSCI, V27, P13117, DOI 10.1523/JNEUROSCI.3322-07.2007; Ge WH, 2006, P NATL ACAD SCI USA, V103, P1319, DOI 10.1073/pnas.0510419103; Iwasaki S, 1996, J BIOL CHEM, V271, P17360, DOI 10.1074/jbc.271.29.17360; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jones NM, 2004, J NEUROCHEM, V89, P157, DOI 10.1111/j.1471-4159.2004.02324.x; Kang JS, 2008, J CELL BIOL, V182, P497, DOI 10.1083/jcb.200801119; Kang JS, 1998, J CELL BIOL, V143, P403, DOI 10.1083/jcb.143.2.403; Kang JS, 2003, P NATL ACAD SCI USA, V100, P3989, DOI 10.1073/pnas.0736565100; Kang JS, 2004, J CELL BIOL, V167, P493, DOI 10.1083/jcb.200405039; Krauss RS, 2005, J CELL SCI, V118, P2355, DOI 10.1242/jcs.02397; Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528; Low BC, 1999, J BIOL CHEM, V274, P33123, DOI 10.1074/jbc.274.46.33123; Low BC, 2000, J BIOL CHEM, V275, P37742, DOI 10.1074/jbc.M004897200; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Mulieri PJ, 2000, DEV DYNAM, V219, P40, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1032>3.0.CO;2-M; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Pachernik J, 2005, PHYSIOL RES, V54, P115, DOI 10.33549/physiolres.930526; Redies C, 2000, PROG NEUROBIOL, V61, P611, DOI 10.1016/S0301-0082(99)00070-2; Rosario M, 2007, J CELL BIOL, V178, P503, DOI 10.1083/jcb.200609146; Takaesu G, 2006, J CELL BIOL, V175, P383, DOI 10.1083/jcb.200608031; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Yanagisawa M, 2001, GENES CELLS, V6, P1091, DOI 10.1046/j.1365-2443.2001.00483.x; Zhang W, 2006, MOL CELL BIOL, V26, P3764, DOI 10.1128/MCB.26.10.3764-3772.2006; Zhang W, 2006, DEV CELL, V10, P657, DOI 10.1016/j.devcel.2006.04.005	39	38	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2088	2099		10.1096/fj.08-119255	http://dx.doi.org/10.1096/fj.08-119255			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19244314	Green Published			2022-12-28	WOS:000268836500009
J	Briguori, C; Testa, U; Riccioni, R; Colombo, A; Petrucci, E; Condorelli, G; Mariani, G; D'Andrea, D; De Micco, F; Rivera, NV; Puca, AA; Peschle, C; Condorelli, G				Briguori, Carlo; Testa, Ugo; Riccioni, Roberta; Colombo, Antonio; Petrucci, Eleonora; Condorelli, Gerolama; Mariani, Gualtiero; D'Andrea, Davide; De Micco, Francesca; Rivera, Natalia V.; Puca, Annibale Alessandro; Peschle, Cesare; Condorelli, Gianluigi			Correlations between progression of coronary artery disease and circulating endothelial progenitor cells	FASEB JOURNAL			English	Article						endothelium; prognosis	PERIPHERAL-BLOOD; CD34(+) CELLS; EXPRESSION; EVENTS; NUMBER; ATHEROSCLEROSIS; ANGIOGENESIS; MODERATE; THERAPY	The pathophysiology of coronary artery disease (CAD) progression is not well understood. Endothelial progenitor cells (EPCs) may have an important role. In the present observational cohort study we assessed the number of circulating EPCs in 136 patients undergoing elective percutaneous coronary intervention and who had at least one major epicardial vessel with a nonsignificant stenosis [<50% diameter stenosis (DS)], and the relationship between plasma EPC levels and the 24-mo progression of the nonsignificant coronary artery lesion. The following cell populations were analyzed: CD34(+), CD133(+), CD34(+)/KDR+, CD34(+)/VE cadherin(+), and endothelial cell colony-forming units (CFU-ECs). Progression was defined as a >15% DS increase of the objective vessel at follow-up. At 24 mo, 57 patients (42%) experienced significant progression. Independent predictors of disease progression were LDL cholesterol > 100 mg/dl (OR=1.03; 95% CI 1.01-1.04; P=0.001), low plasma levels of CFU-ECs (OR=3.99; 95% CI 1.54-10.37; P=0.005), and male sex (OR=3.42; 95% CI 1.15-10.22; P=0.027). Circulating levels of EPCs are significantly lower in patients with angiographic CAD progression.-Briguori, C., Testa, U., Riccioni, R., Colombo, A., Petrucci, E., Condorelli, G., Mariani, G., D'Andrea, D., De Micco, F., Rivera, N. V., Puca, A. A., Peschle, C., Condorelli, G. Correlations between progression of coronary artery disease and circulating endothelial progenitor cells, FASEB J. 24, 1981-1988 (2010). www.fasebj.org	[Briguori, Carlo; D'Andrea, Davide; De Micco, Francesca] Clin Mediterranea, Lab Intervent Cardiol, I-80121 Naples, Italy; [Briguori, Carlo; D'Andrea, Davide; De Micco, Francesca] Clin Mediterranea, Dept Cardiol, I-80121 Naples, Italy; [Briguori, Carlo; Colombo, Antonio] Vita & Salute Univ, Hosp San Raffaele, Lab Intervent Cardiol, Sch Med, Milan, Italy; [Testa, Ugo; Riccioni, Roberta; Petrucci, Eleonora; Mariani, Gualtiero] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Condorelli, Gerolama] Univ Naples Federico II, Dept Biol Cellular & Mol Pathol, Naples, Italy; [Rivera, Natalia V.; Puca, Annibale Alessandro; Peschle, Cesare; Condorelli, Gianluigi] Ist Ricovero &Cura Carattere Sci Multimed, Milan, Italy; [Rivera, Natalia V.; Puca, Annibale Alessandro; Condorelli, Gianluigi] CNR, Inst Biomed Technol, Milan, Italy	Mediterranean Clinic; Mediterranean Clinic; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Istituto Superiore di Sanita (ISS); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Briguori, C (corresponding author), Clin Mediterranea, Lab Intervent Cardiol, Via Orazio 2, I-80121 Naples, Italy.	carlobriguori@clinicamediterranea.it	Rivera, Natalia/S-4231-2016; Colombo, Antonio/N-2960-2015; Testa, Ugo/J-6472-2016; PETRUCCI, ELEONORA/J-8778-2016; Puca, Annibale Alessandro/K-2099-2018; riccioni, roberta/AAC-5636-2021; Condorelli, Gerolama/AAC-3472-2022; Condorelli, Gianluigi/Q-6736-2017	Rivera, Natalia/0000-0002-1298-1243; Colombo, Antonio/0000-0002-2940-2455; Testa, Ugo/0000-0001-7900-8942; PETRUCCI, ELEONORA/0000-0001-6459-490X; riccioni, roberta/0000-0002-5766-7717; Condorelli, Gerolama/0000-0003-0177-8829; Condorelli, Gianluigi/0000-0003-0481-6843	Italian Ministry of University and Research (FIRB); Ministry of Health	Italian Ministry of University and Research (FIRB)(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Ministry of Health	This work is funded by grants from the Italian Ministry of University and Research (FIRB) and the Ministry of Health.	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Azen SP, 1996, CIRCULATION, V93, P34, DOI 10.1161/01.CIR.93.1.34; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; Eizawa T, 2004, HEART, V90, P685, DOI 10.1136/hrt.2002.008144; Fadini GP, 2007, EXP HEMATOL, V35, P1479, DOI 10.1016/j.exphem.2007.07.013; Fadini GP, 2006, EUR HEART J, V27, P2247, DOI 10.1093/eurheartj/ehl198; Fujiyama S, 2003, CIRC RES, V93, P980, DOI 10.1161/01.RES.0000099245.08637.CE; Gehling UM, 2000, BLOOD, V95, P3106; George J, 2004, EUR HEART J, V25, P1003, DOI 10.1016/j.ehj.2004.03.026; Griese DP, 2003, CIRCULATION, V108, P2710, DOI 10.1161/01.CIR.0000096490.16596.A6; Gulati R, 2003, CIRC RES, V93, P1023, DOI 10.1161/01.RES.0000105569.77539.21; Guven H, 2006, J AM COLL CARDIOL, V48, P1579, DOI 10.1016/j.jacc.2006.04.101; Hill JM, 2005, J AM COLL CARDIOL, V46, P1643, DOI 10.1016/j.jacc.2005.01.067; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Hur J, 2004, ARTERIOSCL THROM VAS, V24, P288, DOI 10.1161/01.ATV.0000114236.77009.06; Ito H, 1999, CANCER RES, V59, P5875; Lambiase PD, 2004, CIRCULATION, V109, P2986, DOI 10.1161/01.CIR.0000130639.97284.EC; LICHTLEN PR, 1992, CIRCULATION, V86, P828, DOI 10.1161/01.CIR.86.3.828; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Massa M, 2005, BLOOD, V105, P199, DOI 10.1182/blood-2004-05-1831; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; Nowak G, 2004, CIRCULATION, V110, P3699, DOI 10.1161/01.CIR.0000143626.16576.51; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; REIBER JHC, 1989, EUR HEART J, V10, P54, DOI 10.1093/eurheartj/10.suppl_F.54; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sandri M, 2005, CIRCULATION, V111, P3391, DOI 10.1161/CIRCULATIONAHA.104.527135; Schmidt-Lucke C, 2005, CIRCULATION, V111, P2981, DOI 10.1161/CIRCULATIONAHA.104.504340; SCHOENFELD DA, 1982, BIOMETRICS, V38, P163, DOI 10.2307/2530299; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Strehlow K, 2003, CIRCULATION, V107, P3059, DOI 10.1161/01.CIR.0000077911.81151.30; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Vasa M, 2001, CIRCULATION, V103, P2885, DOI 10.1161/hc2401.092816; Venneri MA, 2007, BLOOD, V109, P5276, DOI 10.1182/blood-2006-10-053504; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; Werner N, 2005, NEW ENGL J MED, V353, P999, DOI 10.1056/NEJMoa043814; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Yokoya K, 1999, CIRCULATION, V100, P903, DOI 10.1161/01.CIR.100.9.903	42	73	80	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1981	1988		10.1096/fj.09-138198	http://dx.doi.org/10.1096/fj.09-138198			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20056714				2022-12-28	WOS:000278200000032
J	Hu, YS; Xu, P; Pigino, G; Brady, ST; Larson, J; Lazarov, O				Hu, Yuan-Shih; Xu, Peng; Pigino, Gustavo; Brady, Scott T.; Larson, John; Lazarov, Orly			Complex environment experience rescues impaired neurogenesis, enhances synaptic plasticity, and attenuates neuropathology in familial Alzheimer's disease-linked APPswe/PS1 Delta E9 mice	FASEB JOURNAL			English	Article						neural stem cells; oligomeric beta-amyloid; tau; long-term potentiation; axonal transport; kinesin	LONG-TERM POTENTIATION; AMYLOID-BETA-PROTEIN; ADULT HIPPOCAMPAL NEUROGENESIS; FAST AXONAL-TRANSPORT; ENRICHMENT IMPROVES COGNITION; TRANSGENIC MOUSE MODEL; RAT DENTATE GYRUS; SPATIAL MEMORY; CELL-PROLIFERATION; PHYSICAL-ACTIVITY	Experience in complex environments induces numerous forms of brain plasticity, improving structure and function. It has been long debated whether brain plasticity can be induced under neuropathological conditions, such as Alzheimer's disease (AD), to an extent that would reduce neuropathology, rescue brain structure, and restore its function. Here we show that experience in a complex environment rescues a significant impairment of hippocampal neurogenesis in transgenic mice harboring familial AD-linked mutant APPswe/PS1 Delta E9. Proliferation of hippocampal cells is enhanced significantly after enrichment, and these proliferating cells mature to become new neurons and glia. Enhanced neurogenesis was accompanied by a significant reduction in levels of hyperphosphorylated tau and oligomeric A beta, the precursors of AD hallmarks, in the hippocampus and cortex of enriched mice. Interestingly, enhanced expression of the neuronal anterograde motor kinesin-1 was observed, suggesting enhanced axonal transport in hippocampal and cortical neurons after enrichment. Examination of synaptic physiology revealed that environmental experience significantly enhanced hippocampal long-term potentiation, without notable alterations in basal synaptic transmission. This study suggests that environmental modulation can rescue the impaired phenotype of the Alzheimer's brain and that induction of brain plasticity may represent therapeutic and preventive avenues in AD.-Y.-S. Hu, P. Xu, G. Pigino, S. T. Brady, J. Larson, O. Lazarov. Complex environment experience rescues impaired neurogenesis, enhances synaptic plasticity, and attenuates neuropathology in familial Alzheimer's disease-linked APPswe/PS1 Delta E9 mice. FASEB J. 24, 1667-1681 (2010). www.fasebj.org	[Hu, Yuan-Shih; Pigino, Gustavo; Brady, Scott T.; Lazarov, Orly] Univ Illinois, Coll Med, Dept Anat & Cell Biol, Chicago, IL 60612 USA; [Xu, Peng; Larson, John] Univ Illinois, Coll Med, Dept Psychiat, Inst Psychiat, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lazarov, O (corresponding author), Univ Illinois, Coll Med, Dept Anat & Cell Biol, 808 S Wood St,M-C 512, Chicago, IL 60612 USA.	olazarov@uic.edu	Lazarov, Orly/F-9406-2015; Hu, Jennifer Yuan-Shih/AAL-5876-2020; Pigino, Gustavo/L-7002-2019	Lazarov, Orly/0000-0002-5887-948X	Alzheimer's Association; Illinois Department of Public Health Alzheimer's Disease Research Fund; NATIONAL INSTITUTE ON AGING [R01AG033570] Funding Source: NIH RePORTER	Alzheimer's Association(Alzheimer's Association); Illinois Department of Public Health Alzheimer's Disease Research Fund; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Fan-Lu Kung (School of Pharmacy, National Taiwan University, Taipei, Taiwan) for reviewing the manuscript. This study was supported by the Alzheimer's Association Young Investigator Award (O.L.) and the Illinois Department of Public Health Alzheimer's Disease Research Fund award (O.L and J.L.). The authors thank Dr. Sangram S. Sisodia (University of Chicago, Chicago, IL, USA) for providing the transgenic animals and APP369 antibodies.	Adlard PA, 2005, J NEUROSCI, V25, P4217, DOI 10.1523/JNEUROSCI.0496-05.2005; Aimone JB, 2006, NAT NEUROSCI, V9, P723, DOI 10.1038/nn1707; Ambree O, 2006, AM J PATHOL, V169, P544, DOI 10.2353/ajpath.2006.051107; ANTONIAN E, 1987, BRAIN RES, V400, P403, DOI 10.1016/0006-8993(87)90643-3; Arendash GW, 2004, NEUROREPORT, V15, P1751, DOI 10.1097/01.wnr.0000137183.68847.4e; Arendash GW, 2001, DNA CELL BIOL, V20, P737, DOI 10.1089/10445490152717604; BENNETT EL, 1964, SCIENCE, V146, P610, DOI 10.1126/science.146.3644.610; Billings LM, 2007, J NEUROSCI, V27, P751, DOI 10.1523/JNEUROSCI.4800-06.2007; BRAAK H, 1985, ACTA NEUROPATHOL, V68, P325, DOI 10.1007/BF00690836; Braak H, 1996, ACTA NEUROL SCAND, V93, P3; Catlow BJ, 2009, BRAIN RES, V1256, P173, DOI 10.1016/j.brainres.2008.12.028; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; Choi SH, 2008, NEURON, V59, P568, DOI 10.1016/j.neuron.2008.07.033; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Costa DA, 2007, NEUROBIOL AGING, V28, P831, DOI 10.1016/j.neurobiolaging.2006.04.009; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; DEMARS M, 2010, J NEUROSCI IN PRESS; Dewachter I, 2002, J NEUROSCI, V22, P3445; Dineley KT, 2002, J BIOL CHEM, V277, P22768, DOI 10.1074/jbc.M200164200; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Dong H, 2004, NEUROSCIENCE, V127, P601, DOI 10.1016/j.neuroscience.2004.05.040; Donovan MH, 2006, J COMP NEUROL, V495, P70, DOI 10.1002/cne.20840; Duffy SN, 2001, LEARN MEMORY, V8, P26, DOI 10.1101/lm.36301; Ermini FV, 2008, AM J PATHOL, V172, P1520, DOI 10.2353/ajpath.2008.060520; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Farmer J, 2004, NEUROSCIENCE, V124, P71, DOI 10.1016/j.neuroscience.2003.09.029; FORDYCE DE, 1993, BRAIN RES, V619, P111, DOI 10.1016/0006-8993(93)91602-O; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; Frick KM, 2003, LEARN MEMORY, V10, P187, DOI 10.1101/lm.50703; GomezIsla T, 1996, J NEUROSCI, V16, P4491; Gordon MN, 2001, NEUROBIOL AGING, V22, P377, DOI 10.1016/S0197-4580(00)00249-9; GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; HAMMERSCHLAG R, 1992, MOL NEUROBIOL, V6, P191, DOI 10.1007/BF02780552; Hartman RE, 2005, J NEUROSCI, V25, P6213, DOI 10.1523/JNEUROSCI.0664-05.2005; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Herring A, 2009, EXP NEUROL, V216, P184, DOI 10.1016/j.expneurol.2008.11.027; HOLLOWAY RALPH L., 1966, BRAIN RES, V2, P393, DOI 10.1016/0006-8993(66)90009-6; Jankowsky JL, 2005, J NEUROSCI, V25, P5217, DOI 10.1523/JNEUROSCI.5080-04.2005; Jankowsky JL, 2003, J NEUROPATH EXP NEUR, V62, P1220, DOI 10.1093/jnen/62.12.1220; Jankowsky JL, 2001, BIOMOL ENG, V17, P157, DOI 10.1016/S1389-0344(01)00067-3; Janus C, 2000, NEUROBIOL AGING, V21, P541, DOI 10.1016/S0197-4580(00)00107-X; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 1998, CURR BIOL, V8, P939, DOI 10.1016/S0960-9822(07)00377-6; Kramar EA, 2004, J NEUROSCI, V24, P5151, DOI 10.1523/JNEUROSCI.0800-04.2004; LaPointe NE, 2009, J NEUROSCI RES, V87, P440, DOI 10.1002/jnr.21850; Larson J, 1999, BRAIN RES, V840, P23, DOI 10.1016/S0006-8993(99)01698-4; Lazarov O, 2006, J NEUROSCI, V26, P429, DOI 10.1523/JNEUROSCI.3961-05.2006; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; LAZAROV O, 2007, RES PROGR ALZHEIMERS, V3, P303; Lazarov O, 2007, J NEUROSCI, V27, P7011, DOI 10.1523/JNEUROSCI.4272-06.2007; Lazarov O, 2010, EXP NEUROL, V223, P267, DOI 10.1016/j.expneurol.2009.08.009; Lee VMY, 2006, J ALZHEIMERS DIS, V9, P257; Li SM, 2009, NEURON, V62, P788, DOI 10.1016/j.neuron.2009.05.012; Mirochnic S, 2009, HIPPOCAMPUS, V19, P1008, DOI 10.1002/hipo.20560; Moreno H, 2009, P NATL ACAD SCI USA, V106, P5901, DOI 10.1073/pnas.0900944106; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Niidome T, 2008, NEUROREPORT, V19, P1361, DOI 10.1097/WNR.0b013e32830e6dd6; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; PACTEAU C, 1989, BEHAV BRAIN RES, V34, P79, DOI 10.1016/S0166-4328(89)80092-0; Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135; Peterson DA, 1999, METHODS, V18, P493, DOI 10.1006/meth.1999.0818; Pigino G, 2003, J NEUROSCI, V23, P4499; Pigino G, 2009, P NATL ACAD SCI USA, V106, P5907, DOI 10.1073/pnas.0901229106; Pigino G, 2001, J NEUROSCI, V21, P834, DOI 10.1523/JNEUROSCI.21-03-00834.2001; Platel JC, 2009, GLIA, V57, P66, DOI 10.1002/glia.20735; Porayette P, 2009, J BIOL CHEM, V284, P23806, DOI 10.1074/jbc.M109.026328; Puolivali J, 2002, NEUROBIOL DIS, V9, P339, DOI 10.1006/nbdi.2002.0481; Renner M.J., 1987, ENRICHED IMPOVERISHE; Rodriguez JJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002935; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; ROSENZWEIG MR, 1964, J COMP PHYSIOL PSYCH, V57, P438, DOI 10.1037/h0046387; Saura CA, 2005, J NEUROSCI, V25, P6755, DOI 10.1523/JNEUROSCI.1247-05.2005; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Snyder JS, 2001, J NEUROPHYSIOL, V85, P2423, DOI 10.1152/jn.2001.85.6.2423; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; Taniuchi N, 2007, NEUROREPORT, V18, P1801, DOI 10.1097/WNR.0b013e3282f1c9e9; Thal DR, 2000, EXP NEUROL, V163, P98, DOI 10.1006/exnr.2000.7380; Townsend M, 2006, J PHYSIOL-LONDON, V572, P477, DOI 10.1113/jphysiol.2005.103754; Trinchese F, 2004, ANN NEUROL, V55, P801, DOI 10.1002/ana.20101; TURNER AM, 1985, BRAIN RES, V329, P195, DOI 10.1016/0006-8993(85)90525-6; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Verret L, 2007, J NEUROSCI, V27, P6771, DOI 10.1523/JNEUROSCI.5564-06.2007; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wen PH, 2002, NEUROBIOL DIS, V10, P8, DOI 10.1006/nbdi.2002.0490; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WEST RW, 1972, BEHAV BIOL, V7, P279, DOI 10.1016/S0091-6773(72)80207-4; Wolf SA, 2006, BIOL PSYCHIAT, V60, P1314, DOI 10.1016/j.biopsych.2006.04.004; Zhang C, 2007, EXP NEUROL, V204, P77, DOI 10.1016/j.expneurol.2006.09.018; Zhao B, 2008, PANMINERVA MED, V50, P55	99	134	140	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1667	1681		10.1096/fj.09-136945	http://dx.doi.org/10.1096/fj.09-136945			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20086049	Green Published			2022-12-28	WOS:000278200000005
J	Ramot, Y; Biro, T; Tiede, S; Toth, BI; Langan, EA; Sugawara, K; Foitzik, K; Ingber, A; Goffin, V; Langbein, L; Paus, R				Ramot, Yuval; Biro, Tamas; Tiede, Stephan; Toth, Balazs I.; Langan, Ewan A.; Sugawara, Koji; Foitzik, Kerstin; Ingber, Arieh; Goffin, Vincent; Langbein, Lutz; Paus, Ralf			Prolactin-a novel neuroendocrine regulator of human keratin expression in situ	FASEB JOURNAL			English	Article						human hair follicle; stem cells; keratinocytes; gene regulation; prolactin receptor antagonist	HUMAN HAIR FOLLICLE; CORTICOTROPIN-RELEASING HORMONE; EPITHELIAL STEM-CELLS; TERMINAL DIFFERENTIATION; THYROID-HORMONES; GENE-EXPRESSION; ROOT SHEATH; HUMAN SKIN; HPA AXIS; RECEPTOR	The controls of human keratin expression in situ remain to be fully elucidated. Here, we have investigated the effects of the neurohormone prolactin ( PRL) on keratin expression in a physiologically and clinically relevant test system: organ-cultured normal human hair follicles (HFs). Not only do HFs express a wide range of keratins, but they are also a source and target of PRL. Microarray analysis revealed that PRL differentially regulated a defined subset of keratins and keratin-associated proteins. Quantitative immunohistomorphometry and quantitative PCR confirmed that PRL up-regulated expression of keratins K5 and K14 and the epithelial stem cell-associated keratins K15 and K19 in organ-cultured HFs and/or isolated HF keratinocytes. PRL also up-regulated K15 promoter activity and K15 protein expression in situ, whereas it inhibited K6 and K31 expression. These regulatory effects were reversed by a pure competitive PRL receptor antagonist. Antagonist alone also modulated keratin expression, suggesting that "tonic stimulation" by endogenous PRL is required for normal expression levels of selected keratins. Therefore, our study identifies PRL as a major, clinically relevant, novel neuroendocrine regulator of both human keratin expression and human epithelial stem cell biology in situ.-Ramot, Y., Biro, T., Tiede, S. Toth, B. I., Langan, E. A., Sugawara, K., Foitzik, K., Ingber, A., Goffin, V., Langbein, L., Paus, R. Prolactin-a novel neuroendocrine regulator of human keratin expression in situ. FASEB J. 24, 1768-1779 (2010). www.fasebj.org	[Ramot, Yuval; Tiede, Stephan; Sugawara, Koji; Paus, Ralf] Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany; [Ramot, Yuval; Ingber, Arieh] Hadassah Hebrew Univ, Med Ctr, Dept Dermatol, Jerusalem, Israel; [Biro, Tamas; Toth, Balazs I.] Univ Debrecen, Med & Hlth Sci Ctr, Res Ctr Mol Med, Dept Physiol, H-4012 Debrecen, Hungary; [Langan, Ewan A.; Paus, Ralf] Univ Manchester, Sch Translat Med, Manchester, Lancs, England; [Foitzik, Kerstin] Childrens Hosp Wilhelmstift, Dept Dermatol, Hamburg, Germany; [Goffin, Vincent] INSERM, Res Ctr Growth & Signaling, U845, Paris, France; [Goffin, Vincent] Univ Paris 05, Fac Med, Paris, France; [Langbein, Lutz] German Canc Res Ctr, D-6900 Heidelberg, Germany	University of Lubeck; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Debrecen; University of Manchester; University of Hamburg; University Medical Center Hamburg-Eppendorf; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Helmholtz Association; German Cancer Research Center (DKFZ)	Paus, R (corresponding author), Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany.	ralf.paus@uk-sh.de	Tóth, Balázs István/K-1214-2013; Paus, Ralf/F-6243-2011; GOFFIN, Vincent/G-3322-2013; Paus, Ralf/B-5279-2015	Tóth, Balázs István/0000-0002-4103-4333; GOFFIN, Vincent/0000-0002-8021-3086; Paus, Ralf/0000-0002-3492-9358; Tiede, Stephan/0000-0002-6045-3736; Sugawara, Koji/0000-0003-1662-3272	Minerva Fellowship; German Federal Ministry of Education and Research [01GN0517]; Deutsche Forschungsgemeinschaft; Manchester National Health Research System Biomedical Research Center; Wilhelm Sander Stiftung [2007.133.1]	Minerva Fellowship; German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Manchester National Health Research System Biomedical Research Center; Wilhelm Sander Stiftung	The excellent technical assistance of Astrid Becker and Nadine Dorwald for these studies is gratefully acknowledged. The authors also thank Sophie Bernichtein for her help with PRLR antagonist preparation. This study was supported in part by a Minerva Fellowship (for Y.R.) and by grants from the German Federal Ministry of Education and Research (01GN0517), the Deutsche Forschungsgemeinschaft, the Manchester National Health Research System Biomedical Research Center (to R. P.), and the Wilhelm Sander Stiftung (2007.133.1 to L. L.).	Arin MJ, 2009, HUM GENET, V125, P355, DOI 10.1007/s00439-009-0646-5; Bernichtein S, 2003, J BIOL CHEM, V278, P35988, DOI 10.1074/jbc.M305687200; BLUM I, 1980, NEW ENGL J MED, V303, P1418; Bodo E, 2007, FASEB J, V21, P3346, DOI 10.1096/fj.07-8628com; Bodo E, 2009, J INVEST DERMATOL, V129, P1126, DOI 10.1038/jid.2008.361; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; Bowden PE, 2009, EXP DERMATOL, V18, P650, DOI 10.1111/j.1600-0625.2008.00820.x; Cai J, 2009, DEV BIOL, V326, P420, DOI 10.1016/j.ydbio.2008.11.021; Chahal J, 2008, PITUITARY, V11, P141, DOI 10.1007/s11102-008-0107-5; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Cotsarelis G, 2006, J INVEST DERMATOL, V126, P1459, DOI 10.1038/sj.jid.5700376; Craven AJ, 2001, ENDOCRINOLOGY, V142, P2533, DOI 10.1210/en.142.6.2533; DICKS P, 1994, J ENDOCRINOL, V143, P441, DOI 10.1677/joe.0.1430441; DUNCAN MJ, 1984, J EXP ZOOL, V230, P97, DOI 10.1002/jez.1402300113; FABRE N, 1993, CLIN NEUROPHARMACOL, V16, P266, DOI 10.1097/00002826-199306000-00012; Foitzik K, 2006, AM J PATHOL, V168, P748, DOI 10.2353/ajpath.2006.050468; Foitzik K, 2003, AM J PATHOL, V162, P1611, DOI 10.1016/S0002-9440(10)64295-2; Foitzik K, 2009, J INVEST DERMATOL, V129, P1071, DOI 10.1038/jid.2008.348; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; Gadd SL, 2006, MOL ENDOCRINOL, V20, P2734, DOI 10.1210/me.2006-0114; GASPAR E, 2009, FASEB J, DOI DOI 10.1096/FJ.08-126417V1; Goffin V, 2005, ENDOCR REV, V26, P400, DOI 10.1210/er.2004-0016; Goffin V, 2002, ANNU REV PHYSIOL, V64, P47, DOI 10.1146/annurev.physiol.64.081501.131049; Goffin V, 2006, NAT CLIN PRACT ENDOC, V2, P571, DOI 10.1038/ncpendmet0270; Goldhar AS, 2005, MOL CELL ENDOCRINOL, V232, P9, DOI 10.1016/j.mce.2005.01.005; Gootwine E, 2004, ANIM REPROD SCI, V82-3, P551, DOI 10.1016/j.anireprosci.2004.04.008; Gu LH, 2007, CURR OPIN CELL BIOL, V19, P13, DOI 10.1016/j.ceb.2006.12.007; Havlickova B, 2009, J INVEST DERMATOL, V129, P972, DOI 10.1038/jid.2008.315; HU L, 1994, J BIOL CHEM, V269, P183; IBRAHEEM M, 1994, J ANAT, V185, P135; Ichikawa E, 1997, ARCH DERMATOL RES, V289, P519, DOI 10.1007/s004030050233; Ito N, 2005, FASEB J, V19, P1332, DOI 10.1096/fj.04-1968fje; Jave-Suarez LF, 2004, J INVEST DERMATOL, V122, P555, DOI 10.1111/j.0022-202X.2004.22336.x; Kallergi G, 2007, MOL MED, V13, P79, DOI 10.2119/2006-00083.Kallergi; Kauser S, 2004, J INVEST DERMATOL, V123, P184, DOI 10.1111/j.0022-202X.2004.22724.x; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Kloepper JE, 2008, EXP DERMATOL, V17, P592, DOI 10.1111/j.1600-0625.2008.00720.x; Langan EA, 2010, J INVEST DERMATOL, V130, P886, DOI 10.1038/jid.2009.340; Langbein L, 2005, INT REV CYTOL, V243, P1, DOI 10.1016/S0074-7696(05)43001-6; Langbein L, 2005, J INVEST DERMATOL, V125, P428, DOI 10.1111/j.0022-202X.2005.23860.x; Langbein L, 1999, J BIOL CHEM, V274, P19874, DOI 10.1074/jbc.274.28.19874; Langbein L, 2006, J INVEST DERMATOL, V126, P2377, DOI 10.1038/sj.jid.5700494; Larouche D, 2008, FASEB J, V22, P1404, DOI 10.1096/fj.07-8109com; Limat A, 2003, J AM ACAD DERMATOL, V48, P207, DOI 10.1067/mjd.2003.69; LIMAT A, 1989, J INVEST DERMATOL, V92, P758, DOI 10.1111/1523-1747.ep12722530; LIMAT A, 1986, J INVEST DERMATOL, V87, P485, DOI 10.1111/1523-1747.ep12455548; LUPULESCU A, 1985, J NATL CANCER I, V74, P1335; Lyle S, 1998, J CELL SCI, V111, P3179; Ma L, 2003, DEVELOPMENT, V130, P379, DOI 10.1242/dev.00201; Ma SH, 1997, GENE EXPRESSION, V6, P361; MARTINET L, 1984, J ENDOCRINOL, V103, P9, DOI 10.1677/joe.0.1030009; Michalczyk A, 2001, DIFFERENTIATION, V67, P41, DOI 10.1046/j.1432-0436.2001.067001041.x; Michel M, 1996, J CELL SCI, V109, P1017; Moll R, 2008, HISTOCHEM CELL BIOL, V129, P705, DOI 10.1007/s00418-008-0435-6; Nixon AJ, 2002, J ENDOCRINOL, V172, P605, DOI 10.1677/joe.0.1720605; Ohnemus U, 2006, ENDOCR REV, V27, P677, DOI 10.1210/er.2006-0020; Ormandy CJ, 2003, RECENT PROG HORM RES, V58, P297, DOI 10.1210/rp.58.1.297; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Paus R, 2008, MOL CELL ENDOCRINOL, V288, P38, DOI 10.1016/j.mce.2008.02.023; Pearson AJ, 1996, J ENDOCRINOL, V148, P157, DOI 10.1677/joe.0.1480157; PHILPOTT MP, 1990, J CELL SCI, V97, P463; Radoja N, 2004, MOL CELL BIOL, V24, P3168, DOI 10.1128/MCB.24.8.3168-3179.2004; Ramot Y, 2009, BRIT J DERMATOL, V161, P933, DOI 10.1111/j.1365-2133.2009.09294.x; Ramot Y, 2009, BIOESSAYS, V31, P389, DOI 10.1002/bies.200800121; SCHMIDT JB, 1994, SKIN PHARMACOL, V7, P61; Schneider MR, 2009, CURR BIOL, V19, pR132, DOI 10.1016/j.cub.2008.12.005; SCHOFIELD JK, 1995, HISTOPATHOLOGY, V26, P153, DOI 10.1111/j.1365-2559.1995.tb00645.x; Schweizer J, 2007, EXP CELL RES, V313, P2010, DOI 10.1016/j.yexcr.2007.02.032; Schweizer J, 2006, J CELL BIOL, V174, P169, DOI 10.1083/jcb.200603161; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 2003, Minerva Endocrinol, V28, P135; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2001, FASEB J, V15, P1678, DOI 10.1096/fj.00-0850rev; Slominski A, 2007, MOL CELL ENDOCRINOL, V265, P143, DOI 10.1016/j.mce.2006.12.012; Slominski A, 2006, FRONT BIOSCI-LANDMRK, V11, P2230, DOI 10.2741/1966; Soares Michael J, 2004, Reprod Biol Endocrinol, V2, P51, DOI 10.1186/1477-7827-2-51; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; THEWES M, 1991, ARCH DERMATOL RES, V283, P465, DOI 10.1007/BF00371784; Tiede S, 2009, STEM CELLS, V27, P2793, DOI 10.1002/stem.213; Tiede S, 2009, J INVEST DERMATOL, V129, P2711, DOI 10.1038/jid.2009.148; Tkatchenko AV, 2001, DEVELOPMENT, V128, P1547; van Beek N, 2008, J CLIN ENDOCR METAB, V93, P4381, DOI 10.1210/jc.2008-0283; Weatherhead S, 2007, BRIT MED J, V334, P1218, DOI 10.1136/bmj.39202.518484.80; Xue ML, 2008, J INVEST DERMATOL, V128, P2676, DOI 10.1038/jid.2008.136; Zouboulis CC, 2000, HORM RES, V54, P230, DOI 10.1159/000053265; Zouboulis Christos C, 2004, Hormones (Athens), V3, P9	87	50	53	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1768	1779		10.1096/fj.09-146415	http://dx.doi.org/10.1096/fj.09-146415			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20103718				2022-12-28	WOS:000278200000014
J	Kajava, AV; Baxa, U; Steven, AC				Kajava, Andrey V.; Baxa, Ulrich; Steven, Alasdair C.			beta arcades: recurring motifs in naturally occurring and disease-related amyloid fibrils	FASEB JOURNAL			English	Review						amyloidogenicity; polymorphism; prion; misfolding; structural motif	SOLID-STATE NMR; PAIRED HELICAL FILAMENTS; URE2P PRION FILAMENTS; PROTEIN AGGREGATION; STRUCTURAL MODELS; EXPERIMENTAL CONSTRAINTS; SOLENOID PROTEINS; SHEET STRUCTURE; 3D STRUCTURE; IN-VITRO	Amyloid fibrils are filamentous protein aggregates that accumulate in diseases such as Alzheimer's or type II diabetes. The amyloid-forming protein is disease specific. Amyloids may also be formed in vitro from many other proteins, after first denaturing them. Unlike the diverse native folds of these proteins, their amyloids are fundamentally similar in being rigid, smooth-sided, and cross-beta-structured, that is, with beta strands running perpendicular to the fibril axis. In the absence of high-resolution fibril structures, increasingly credible models are being derived by integrating data from a crossfire of experimental techniques. Most current models of disease-related amyloids invoke "beta arcades," columnar structures produced by in-register stacking of "beta arches." A beta arch is a strand-turn-strand motif in which the two beta strands interact via their side chains, not via the polypeptide backbone as in a conventional beta hairpin. Crystal structures of beta-solenoids, a class of proteins with amyloid-like properties, offer insight into the beta-arc turns found in beta arches. General conformational and thermodynamic considerations suggest that complexes of 2 or more beta arches may nucleate amyloid fibrillogenesis in vivo. The apparent prevalence of beta arches and their components have implications for identifying amyloidogenic sequences, elucidating fibril polymorphisms, predicting the locations and conformations of beta arcs within amyloid fibrils, and refining existing fibril models.-Kajava, A. V., Baxa, U., Steven, A. C. beta arcades: recurring motifs in naturally occurring and disease-related amyloid fibrils. FASEB J. 24, 1311-1319 (2010). www.fasebj.org	[Baxa, Ulrich; Steven, Alasdair C.] NIAMSD, Struct Biol Lab, NIH, Bethesda, MD 20892 USA; [Kajava, Andrey V.] Univ Montpellier 1, CNRS, Ctr Rech Biochim & Macromol, Montpellier, France; [Kajava, Andrey V.] Univ Montpellier 2, CNRS, Ctr Rech Biochim & Macromol, Montpellier, France	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Steven, AC (corresponding author), NIAMSD, Struct Biol Lab, NIH, Bldg 50,Room 1517,MSC 8025, Bethesda, MD 20892 USA.	andrey.kajava@crbm.cnrs.fr; stevena@mail.nih.gov	Kajava, Andrey V/E-1107-2014	Kajava, Andrey V/0000-0002-2342-6886; Baxa, Ulrich/0000-0002-7263-5078	National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health, Bethesda, MD, USA; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041157] Funding Source: NIH RePORTER	National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health, Bethesda, MD, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Drs. Oleg Borisov and Christian Ligoure for discussion and suggestions. This work was supported in part by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health, Bethesda, MD, USA.	Antzutkin ON, 2000, P NATL ACAD SCI USA, V97, P13045, DOI 10.1073/pnas.230315097; Badger J, 2005, PROTEINS, V60, P787, DOI 10.1002/prot.20541; Baxa U, 2005, J STRUCT BIOL, V150, P170, DOI 10.1016/j.jsb.2005.02.007; Baxa U, 2003, J BIOL CHEM, V278, P43717, DOI 10.1074/jbc.M306004200; Baxa U, 2002, P NATL ACAD SCI USA, V99, P5253, DOI 10.1073/pnas.082097899; Baxa U, 2006, ADV PROTEIN CHEM, V73, P125, DOI 10.1016/S0065-3233(06)73005-4; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; Brachmann A, 2005, EMBO J, V24, P3082, DOI 10.1038/sj.emboj.7600772; Chang HY, 2008, P NATL ACAD SCI USA, V105, P13345, DOI 10.1073/pnas.0802215105; Chien P, 2004, ANNU REV BIOCHEM, V73, P617, DOI 10.1146/annurev.biochem.72.121801.161837; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Colby R.H., 2003, POLYM PHYS; CRICK FHC, 1955, NATURE, V176, P780, DOI 10.1038/176780a0; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; Diaz-Avalos R, 2005, P NATL ACAD SCI USA, V102, P10165, DOI 10.1073/pnas.0504599102; Dodatko T, 2004, BIOCHEMISTRY-US, V43, P10628, DOI 10.1021/bi049071r; EFIMOV AV, 1987, FEBS LETT, V224, P372, DOI 10.1016/0014-5793(87)80487-8; EISENBERG D, 1989, CHEM SCRIPTA, V29A, P217; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; Esteras-Chopo A, 2005, P NATL ACAD SCI USA, V102, P16672, DOI 10.1073/pnas.0505905102; Ferguson N, 2006, P NATL ACAD SCI USA, V103, P16248, DOI 10.1073/pnas.0607815103; Frieden C, 2007, PROTEIN SCI, V16, P2334, DOI 10.1110/ps.073164107; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Grant MA, 2007, P NATL ACAD SCI USA, V104, P16522, DOI 10.1073/pnas.0705197104; Guo Z, 2008, PROTEIN SCI, V17, P1617, DOI 10.1110/ps.036368.108; Hennetin J, 2006, J MOL BIOL, V358, P1094, DOI 10.1016/j.jmb.2006.02.039; Iengar P, 2006, STRUCTURE, V14, P529, DOI 10.1016/j.str.2005.11.021; Inouye H, 2006, ADV PROTEIN CHEM, V73, P181, DOI 10.1016/S0065-3233(06)73006-6; Iwata K, 2006, P NATL ACAD SCI USA, V103, P18119, DOI 10.1073/pnas.0607180103; Jeganathan S, 2008, BIOCHEMISTRY-US, V47, P10526, DOI 10.1021/bi800783d; Jimenez JL, 2002, P NATL ACAD SCI USA, V99, P9196, DOI 10.1073/pnas.142459399; Kajava AV, 2006, ADV PROTEIN CHEM, V73, P55, DOI 10.1016/S0065-3233(06)73003-0; Kajava AV, 1999, ACTA CRYSTALLOGR D, V55, P436, DOI 10.1107/S0907444998012438; Kajava AV, 2005, J MOL BIOL, V348, P247, DOI 10.1016/j.jmb.2005.02.029; Kajava AV, 2004, P NATL ACAD SCI USA, V101, P7885, DOI 10.1073/pnas.0402427101; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; Krishnan R, 2005, NATURE, V435, P765, DOI 10.1038/nature03679; Lashuel HA, 2006, Q REV BIOPHYS, V39, P167, DOI 10.1017/S0033583506004422; Liou YC, 2000, NATURE, V406, P322, DOI 10.1038/35018604; Luca S, 2007, BIOCHEMISTRY-US, V46, P13505, DOI 10.1021/bi701427q; Luhrs T, 2005, P NATL ACAD SCI USA, V102, P17342, DOI 10.1073/pnas.0506723102; Ma BY, 2002, P NATL ACAD SCI USA, V99, P14126, DOI 10.1073/pnas.212206899; Margittai M, 2004, P NATL ACAD SCI USA, V101, P10278, DOI 10.1073/pnas.0401911101; Margittai M, 2008, Q REV BIOPHYS, V41, P265, DOI 10.1017/S0033583508004733; Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680; Nelson R, 2006, ADV PROTEIN CHEM, V73, P235, DOI 10.1016/S0065-3233(06)73008-X; Pepys MB, 2006, ANNU REV MED, V57, P223, DOI 10.1146/annurev.med.57.121304.131243; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Petkova AT, 2006, BIOCHEMISTRY-US, V45, P498, DOI 10.1021/bi051952q; Ritter C, 2005, NATURE, V435, P844, DOI 10.1038/nature03793; Sachse C, 2008, P NATL ACAD SCI USA, V105, P7462, DOI 10.1073/pnas.0712290105; Sanders A, 2004, J MOL BIOL, V336, P165, DOI 10.1016/j.jmb.2003.12.011; SARAIVA MJM, 1995, HUM MUTAT, V5, P191; Saveanu L, 2002, MOL IMMUNOL, V39, P203, DOI 10.1016/S0161-5890(02)00102-5; Sawaya MR, 2007, NATURE, V447, P453, DOI 10.1038/nature05695; Sharma D, 2005, PROTEINS, V61, P398, DOI 10.1002/prot.20602; Shewmaker F, 2006, P NATL ACAD SCI USA, V103, P19754, DOI 10.1073/pnas.0609638103; Sikorski P, 2005, BIOMACROMOLECULES, V6, P425, DOI 10.1021/bm0494388; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Thakur AK, 2002, P NATL ACAD SCI USA, V99, P17014, DOI 10.1073/pnas.252523899; Tsai HH, 2006, STRUCTURE, V14, P1059, DOI 10.1016/j.str.2006.03.015; Tycko R, 2009, BIOCHEMISTRY-US, V48, P6072, DOI 10.1021/bi9002666; Wang JM, 2005, STRUCTURE, V13, P1279, DOI 10.1016/j.str.2005.06.010; Wasmer C, 2008, SCIENCE, V319, P1523, DOI 10.1126/science.1151839; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P2843, DOI 10.1073/pnas.87.7.2843; Wiltzius JJW, 2008, PROTEIN SCI, V17, P1467, DOI 10.1110/ps.036509.108; Zhou HX, 2004, ACCOUNTS CHEM RES, V37, P123, DOI 10.1021/ar0302282	70	96	98	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1311	1319		10.1096/fj.09-145979	http://dx.doi.org/10.1096/fj.09-145979			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20032312	Green Published			2022-12-28	WOS:000277158900004
J	Agassandian, M; Chen, BB; Schuster, CC; Houtman, JCD; Mallampalli, RK				Agassandian, Marianna; Chen, Bill B.; Schuster, Christopher C.; Houtman, Jon C. D.; Mallampalli, Rama K.			14-3-3 zeta escorts CCT alpha for calcium-activated nuclear import in lung epithelia	FASEB JOURNAL			English	Article						membrane; homeostasis; lipid	CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; GLYCOPROTEIN IB-ALPHA; SURFACTANT-PROTEIN-D; PHOSPHATIDYLCHOLINE SYNTHESIS; PSEUDOMONAS-AERUGINOSA; REGULATORY ENZYME; STRUCTURAL BASIS; BINDING-SITE; LOCALIZATION; PHOSPHORYLATION	Integrity of animal biomembranes is critical to preserve normal cellular functions and viability. Phosphatidylcholine, an indispensible membrane component, requires the enzyme CCT alpha for its biosynthesis. Nuclear expression of CCT alpha is needed for expansion of the nuclear membrane network, but mechanisms for CCT alpha nuclear import are unknown. Herein, we show that in epithelia, extracellular Ca2+ triggers CCT alpha cytoplasmic-nuclear translocation. CCT alpha nuclear import was associated with binding to 14-3-3 zeta, a key regulator of protein trafficking. 14-3-3 zeta was both sufficient and required for CCT alpha nuclear import. Helix G within the 14-3-3 zeta binding groove interacts with a putative molecular signature within the CCT alpha carboxyl-terminal phosphoserine motif (residues 328-343). 14-3-3 zeta was critically involved in preserving phosphatidylcholine synthesis and cell viability in a model of Pseudomonas aeruginosa infection where Ca2+ concentrations increase within epithelia. Thus, 14-3-3 zeta controls CCT alpha nuclear import in response to calcium signals, thereby regulating mammalian phospholipid synthesis. Agassandian, M., Chen, B. B., Schuster, C. C., Houtman, J. C. D., Mallampalli, R. K. 14-3-3 zeta escorts CCT alpha for calcium-activated nuclear import in lung epithelia. FASEB J. 24, 1271-1283 (2010). www.fasebj.org	[Agassandian, Marianna; Chen, Bill B.; Schuster, Christopher C.; Mallampalli, Rama K.] Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Mallampalli, Rama K.] Univ Iowa, Dept Biochem, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Houtman, Jon C. D.] Univ Iowa, Dept Microbiol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Mallampalli, Rama K.] Univ Iowa, Dept Vet Affairs Med Ctr, Roy J & Lucille A Carver Coll Med, Iowa City, IA USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Mallampalli, RK (corresponding author), Univ Pittsburgh, Pulm Allergy & Crit Care Div, Dept Internal Med, NW628 Montefiore,3459 5th Ave, Pittsburgh, PA 15213 USA.	mallampallirk@upmc.edu		Houtman, Jon/0000-0002-5307-9854	U.S. Department of Veteran's Affairs; U.S National Institutes of Health [R01 HL097376, R01 HL081784, R01 HL068135]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL098174, R01HL081784, R01HL068135, R01HL097376] Funding Source: NIH RePORTER	U.S. Department of Veteran's Affairs(US Department of Veterans Affairs); U.S National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by a Merit Review Award from the U.S. Department of Veteran's Affairs, and U.S National Institutes of Health R01 grants HL097376, HL081784, and HL068135 (to R. K. M).	Agassandian M, 2005, J BIOL CHEM, V280, P21577, DOI 10.1074/jbc.M412409200; Agassandian M, 2007, BIOCHEM J, V403, P409, DOI 10.1042/BJ20061364; Athwal GS, 1998, PLANT CELL PHYSIOL, V39, P1065, DOI 10.1093/oxfordjournals.pcp.a029303; Beguin P, 2006, J MOL BIOL, V355, P34, DOI 10.1016/j.jmb.2005.10.013; Berchtold CM, 2007, MOL CELL BIOL, V27, P497, DOI 10.1128/MCB.01772-06; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Chan HC, 2000, BIOCHEM BIOPH RES CO, V270, P581, DOI 10.1006/bbrc.2000.2454; Chen BB, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M706472200; Chen BB, 2009, MOL CELL BIOL, V29, P3062, DOI 10.1128/MCB.01824-08; Cooley J, 2008, J LEUKOCYTE BIOL, V83, P946, DOI 10.1189/jlb.1007684; CORNELL RB, 1995, BIOCHEM J, V310, P699, DOI 10.1042/bj3100699; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; DeLong CJ, 2000, J BIOL CHEM, V275, P32325, DOI 10.1074/jbc.M004644200; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Faul C, 2005, J CELL BIOL, V169, P415, DOI 10.1083/jcb.200411169; Frick M, 2004, AM J PHYSIOL-LUNG C, V286, pL210, DOI 10.1152/ajplung.00332.2003; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Ganguly S, 2005, P NATL ACAD SCI USA, V102, P1222, DOI 10.1073/pnas.0406871102; Gehrig K, 2008, MOL BIOL CELL, V19, P237, DOI 10.1091/mbc.E07-02-0179; Gu MY, 1998, J BIOL CHEM, V273, P33465, DOI 10.1074/jbc.273.50.33465; Henriksson ML, 2002, EUR J BIOCHEM, V269, P4921, DOI 10.1046/j.1432-1033.2002.03191.x; Hirche TO, 2004, J BIOL CHEM, V279, P27688, DOI 10.1074/jbc.M402936200; Jackowski S, 2005, J BIOL CHEM, V280, P853, DOI 10.1074/jbc.R400031200; Jacob T, 2002, INFECT IMMUN, V70, P6399, DOI 10.1128/IAI.70.11.6399-6408.2002; Li PP, 2007, J VIROL, V81, P6099, DOI 10.1128/JVI.02195-06; Mangin P, 2004, BLOOD, V104, P420, DOI 10.1182/blood-2003-08-2881; McCoy DM, 2006, AM J RESP CELL MOL, V35, P394, DOI 10.1165/rcmb.2005-0401OC; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Neuweiler H, 2004, CURR PHARM BIOTECHNO, V5, P285, DOI 10.2174/1389201043376896; Obsilova V, 2005, BIOCHEMISTRY-US, V44, P11608, DOI 10.1021/bi050618r; Paroni G, 2008, MOL BIOL CELL, V19, P655, DOI 10.1091/mbc.E07-06-0623; Qi WQ, 2005, INT J CANCER, V113, P359, DOI 10.1002/ijc.20492; Ridsdale R, 2001, J BIOL CHEM, V276, P49148, DOI 10.1074/jbc.M103566200; Shen YH, 2003, MOL BIOL CELL, V14, P4721, DOI 10.1091/mbc.E02-12-0821; Srinivasan M, 2007, J IMMUNOL, V179, P3734, DOI 10.4049/jimmunol.179.6.3734; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; WANG YL, 1993, J BIOL CHEM, V268, P5899; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang XW, 2006, P NATL ACAD SCI USA, V103, P17237, DOI 10.1073/pnas.0605779103; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zhou J, 2006, GENE THER, V13, P974, DOI 10.1038/sj.gt.3302746; Zhou JM, 2003, J BIOL CHEM, V278, P37032, DOI 10.1074/jbc.M304316200	44	17	17	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1271	1283		10.1096/fj.09-136044	http://dx.doi.org/10.1096/fj.09-136044			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	20007511	Green Published			2022-12-28	WOS:000276462300033
J	Kurotani, A; Takagi, T; Toyama, M; Shirouzu, M; Yokoyama, S; Fukami, Y; Tokmakov, AA				Kurotani, Atsushi; Takagi, Tetsuo; Toyama, Mitsutoshi; Shirouzu, Mikako; Yokoyama, Shigeyuki; Fukami, Yasuo; Tokmakov, Alexander A.			Comprehensive bioinformatics analysis of cell-free protein synthesis: identification of multiple protein properties that correlate with successful expression	FASEB JOURNAL			English	Article						recombinant proteins; heterologous expression; rationalization; physicochemical protein properties; structural protein properties	STRUCTURAL GENOMICS; ESCHERICHIA-COLI; PROPENSITY; PREDICTION; SYSTEMS; CRYSTALLIZATION; OVEREXPRESSION; PURIFICATION; SEQUENCES; ELEGANS	High-throughput cell-free protein synthesis is being used increasingly in structural/functional genomics projects. However, the factors determining expression success are poorly understood. Here, we evaluated the expression of 3066 human proteins and their domains in a bacterial cell-free system and analyzed the correlation of protein expression with 39 physicochemical and structural properties of proteins. As a result of the bioinformatics analysis performed, we determined the 18 most influential features that affect protein amenability to cell-free expression. They include protein length; hydrophobicity; pI; content of charged, nonpolar, and aromatic residues;, cysteine content; solvent accessibility; presence of coiled coil; content of intrinsically disordered and structured (alpha-helix and beta-sheet) sequence; number of disulfide bonds and functional domains; presence of transmembrane regions; PEST motifs; and signaling sequences. This study represents the first comprehensive bioinformatics analysis of heterologous protein synthesis in a cell-free system. The rules and correlations revealed here provide a plethora of important insights into rationalization of cell-free protein production and can be of practical use for protein engineering with the aim of increasing expression success.-Kurotani, A., Takagi, T., Toyama, M., Shirouzu, M., Yokoyama, S., Fukami, Y., Tokmakov, A. A. Comprehensive bioinformatics analysis of cell- free protein synthesis: identification of multiple protein properties that correlate with successful expression. FASEB J. 24, 1095-1104 (2010). www.fasebj.org	[Kurotani, Atsushi; Takagi, Tetsuo; Toyama, Mitsutoshi; Shirouzu, Mikako; Yokoyama, Shigeyuki; Tokmakov, Alexander A.] RIKEN Syst & Struct Biol Ctr, Yokohama, Kanagawa, Japan; [Kurotani, Atsushi] Plant Sci Ctr, Yokohama, Kanagawa, Japan; [Yokoyama, Shigeyuki] Univ Tokyo, Grad Sch Sci, Tokyo 113, Japan; [Fukami, Yasuo; Tokmakov, Alexander A.] Kobe Univ, Grad Sch Sci, Nada, Japan; [Fukami, Yasuo; Tokmakov, Alexander A.] Kobe Univ, Res Ctr Environm Genom, Nada, Japan	RIKEN; University of Tokyo; Kobe University; Kobe University	Tokmakov, AA (corresponding author), Kobe Univ, Res Ctr Environm Genom, Nada Ku, Rokko Dai 1-1, Kobe, Hyogo 6578501, Japan.	tokmak@phoenix.kobe-u.ac.jp	Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; 	RIKEN Structural Genomics/Proteomics; Ministry of Education, Culture, Sports, Science and Technology of Japan	RIKEN Structural Genomics/Proteomics; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by the RIKEN Structural Genomics/Proteomics Initiative, the National Project on Protein Structural and Functional Analyses, Ministry of Education, Culture, Sports, Science and Technology of Japan.	Bertone P, 2001, NUCLEIC ACIDS RES, V29, P2884, DOI 10.1093/nar/29.13.2884; Braun P, 2002, P NATL ACAD SCI USA, V99, P2654, DOI 10.1073/pnas.042684199; Busso Didier, 2004, Journal of Structural and Functional Genomics, V5, P69, DOI 10.1023/B:JSFG.0000029197.44728.c5; Cheng JL, 2006, PROTEINS, V62, P617, DOI 10.1002/prot.20787; Chikayama E, 2004, BIOINFORMATICS, V20, P2836, DOI 10.1093/bioinformatics/bth276; Davis GD, 1999, BIOTECHNOL BIOENG, V65, P382, DOI 10.1002/(SICI)1097-0290(19991120)65:4<382::AID-BIT2>3.3.CO;2-9; Ding HT, 2002, ACTA CRYSTALLOGR D, V58, P2102, DOI 10.1107/S0907444902016359; Dyson MR, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-32; Ferre F, 2005, NUCLEIC ACIDS RES, V33, pW230, DOI 10.1093/nar/gki412; Finley JB, 2004, PROTEIN EXPRES PURIF, V34, P49, DOI 10.1016/j.pep.2003.11.026; Goerke AR, 2009, BIOTECHNOL BIOENG, V102, P400, DOI 10.1002/bit.22070; Goh CS, 2004, J MOL BIOL, V336, P115, DOI 10.1016/j.jmb.2003.11.053; Idicula-Thomas S, 2005, PROTEIN SCI, V14, P582, DOI 10.1110/ps.041009005; Idicula-Thomas S, 2006, BIOINFORMATICS, V22, P278, DOI 10.1093/bioinformatics/bti810; Idicula-Thomas Susan, 2007, In Silico Biology, V7, P225; Ishihara G, 2005, PROTEIN EXPRES PURIF, V41, P27, DOI 10.1016/j.pep.2005.01.013; Kantardjieff KA, 2004, BIOINFORMATICS, V20, P2162, DOI 10.1093/bioinformatics/bth066; Katzen F, 2005, TRENDS BIOTECHNOL, V23, P150, DOI 10.1016/j.tibtech.2005.01.003; KIGAWA T, 1991, J BIOCHEM-TOKYO, V110, P166, DOI 10.1093/oxfordjournals.jbchem.a123551; Kigawa T, 1999, FEBS LETT, V442, P15, DOI 10.1016/S0014-5793(98)01620-2; Kigawa Takanori, 2004, Journal of Structural and Functional Genomics, V5, P63, DOI 10.1023/B:JSFG.0000029204.57846.7d; Koschorreck M, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-49; KUDLICKI W, 1992, ANAL BIOCHEM, V206, P389, DOI 10.1016/0003-2697(92)90383-I; Linding R, 2003, STRUCTURE, V11, P1453, DOI 10.1016/j.str.2003.10.002; Luan CH, 2004, GENOME RES, V14, P2102, DOI 10.1101/gr.2520504; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Marsden Russell L., 2008, V426, P3, DOI 10.1007/978-1-60327-058-8_1; Niwa T, 2009, P NATL ACAD SCI USA, V106, P4201, DOI 10.1073/pnas.0811922106; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Spirin AS, 2004, TRENDS BIOTECHNOL, V22, P538, DOI 10.1016/j.tibtech.2004.08.012; Suyama M, 2003, BIOINFORMATICS, V19, P673, DOI 10.1093/bioinformatics/btg031; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; Xie JM, 2005, METHODS, V36, P227, DOI 10.1016/j.ymeth.2005.04.010; Yabuki Takashi, 2007, Journal of Structural and Functional Genomics, V8, P173, DOI 10.1007/s10969-007-9038-z; Yokoyama S, 2003, CURR OPIN CHEM BIOL, V7, P39, DOI 10.1016/S1367-5931(02)00019-4; Yokoyama S, 2000, NAT STRUCT BIOL, V7, P943, DOI 10.1038/80712	37	18	18	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1095	1104		10.1096/fj.09-139527	http://dx.doi.org/10.1096/fj.09-139527			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19940260				2022-12-28	WOS:000276462300017
J	Himes, RW; Smith, CW				Himes, Ryan W.; Smith, C. Wayne			Tlr2 is critical for diet-induced metabolic syndrome in a murine model	FASEB JOURNAL			English	Article						adipose tissue; hepatic steatosis; insulin resistance; obesity	TOLL-LIKE RECEPTOR-2; INDUCED INSULIN-RESISTANCE; CHAIN FATTY-ACIDS; ADIPOSE-TISSUE; INDUCED OBESITY; CD36; MICE; MACROPHAGE; ACCUMULATION; INFLAMMATION	Obesity and its associated comorbidities, termed metabolic syndrome, are increasingly prevalent, and they pose a serious threat to the health of individuals and populations. Gene-environment interactions have been scrutinized since the kinetics of the increased prevalence of obesity would argue against a purely genetic etiology. Toll-like receptors (TLRs), widely expressed and highly conserved transmembrane receptors, are at the intersection of diet and metabolism, and may therefore be important determinants of weight gain and its sequellae. We sought specifically to determine the role of Tlr2 in the development of obesity and metabolic syndrome utilizing two dietary models that approximate contemporary diet compositions. Using C57BL/6 Hsd mice (wild type, WT) and mice with a targeted mutation in Tlr2 (Tlr2(-/-)), we showed that mice lacking TLR2 are substantially protected from diet-induced adiposity, insulin resistance, hypercholesterolemia, and hepatic steatosis. In adipose tissue, Tlr2 deletion was associated with attenuation of adipocyte hypertrophy, as well as diminished macrophage infiltration and inflammatory cytokine expression.-Himes, R. W., Smith, C. W. Tlr2 is critical for diet-induced metabolic syndrome in a murine model. FASEB J. 24, 731-739 (2010). www.fasebj.org	[Himes, Ryan W.] Texas Childrens Hosp, Sect Pediat Gastroenterol, Texas Childrens Feigin Ctr, Baylor Coll Med,Dept Pediat, Houston, TX 77030 USA; [Himes, Ryan W.] Texas Childrens Hosp, Baylor Coll Med, Gastroenterol Sect, Houston, TX 77030 USA; [Smith, C. Wayne] Texas Childrens Hosp, Baylor Coll Med, Sect Leukocyte Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Himes, RW (corresponding author), Texas Childrens Hosp, Sect Pediat Gastroenterol, Texas Childrens Feigin Ctr, Baylor Coll Med,Dept Pediat, 1102 Bates St,Rm 860B, Houston, TX 77030 USA.	himes@bcm.tmc.edu		Himes, Ryan/0000-0002-0116-2613	National Institutes of Health (NIH) [T32 DK 07644, R01 DK078847]; U.S. Department of Agriculture [ARS 6250-51000-04601A]; Texas Medical Center Digestive Disease Center [P30 DK56338]; Baylor College of Medicine Diabetes and Endocrinology Research Center [DK-079638]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079638, P30DK056338, R01DK078847] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Agriculture(United States Department of Agriculture (USDA)); Texas Medical Center Digestive Disease Center; Baylor College of Medicine Diabetes and Endocrinology Research Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health (NIH) institutional research training grant T32 DK 07644, U.S. Department of Agriculture grant ARS 6250-51000-04601A, and NIH grant R01 DK078847. We are grateful for the expert assistance provided by the Mouse Metabolic Research Unit at the Children's Nutrition Research Center, the Texas Medical Center Digestive Disease Center (NIH/National Institute of Diabetes and Digestive and Kidney Diseases Center grant P30 DK56338) and the Baylor College of Medicine Diabetes and Endocrinology Research Center (DK-079638).	ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Air EL, 2007, DIABETES CARE, V30, P3131, DOI 10.2337/dc06-1537; Arch JRS, 2006, INT J OBESITY, V30, P1322, DOI 10.1038/sj.ijo.0803280; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; Brake DK, 2006, AM J PHYSIOL-CELL PH, V291, pC1232, DOI 10.1152/ajpcell.00008.2006; Caricilli AM, 2008, J ENDOCRINOL, V199, P399, DOI 10.1677/JOE-08-0354; Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200; Clarke SD, 2001, AM J PHYSIOL-GASTR L, V281, pG865, DOI 10.1152/ajpgi.2001.281.4.G865; Coburn CT, 2001, J MOL NEUROSCI, V16, P117, DOI 10.1385/JMN:16:2-3:117; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Fox J, 2007, MOUSE BIOMEDICAL RES, DOI DOI 10.1016/B978-012369454-6/50094-7; Goudriaan JR, 2003, J LIPID RES, V44, P2270, DOI 10.1194/jlr.M300143-JLR200; Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404; Hajri T, 2002, J CLIN INVEST, V109, P1381, DOI [10.1172/JCI200214596, 10.1172/JCI0214596]; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Howard V., 1998, UNBIASED STEREOLOGY; Lee JY, 2004, J BIOL CHEM, V279, P16971, DOI 10.1074/jbc.M312990200; Liu X, 2008, ATHEROSCLEROSIS, V196, P146, DOI 10.1016/j.atherosclerosis.2007.03.025; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Parekh S, 2007, GASTROENTEROLOGY, V132, P2191, DOI 10.1053/j.gastro.2007.03.055; Robker RL, 2004, OBES RES, V12, P936, DOI 10.1038/oby.2004.114; Senn JJ, 2006, J BIOL CHEM, V281, P26865, DOI 10.1074/jbc.M513304200; Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3; Stuart LM, 2005, J CELL BIOL, V170, P477, DOI 10.1083/jcb.200501113; Triantafilou M, 2006, J BIOL CHEM, V281, P31002, DOI 10.1074/jbc.M602794200; Tsukumo DML, 2007, DIABETES, V56, P1986, DOI 10.2337/db06-1595; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wu HZ, 2007, CIRCULATION, V115, P1029, DOI 10.1161/CIRCULATIONAHA.106.638379; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Zhou J, 2008, GASTROENTEROLOGY, V134, P556, DOI 10.1053/j.gastro.2007.11.037	36	141	150	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					731	739		10.1096/fj.09-141929	http://dx.doi.org/10.1096/fj.09-141929			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19841034	Green Published			2022-12-28	WOS:000274974600009
J	Perla-Kajan, J; Jakubowski, H				Perla-Kajan, Joanna; Jakubowski, Hieronim			Paraoxonase 1 protects against protein N-homocysteinylation in humans	FASEB JOURNAL			English	Article						cystathionine; beta-synthase deficiency; enzymatic activities of high-density lipoprotein; homocysteine-thiolactonase; protein modification by homocysteine-thiolactone	CYSTATHIONINE BETA-SYNTHASE; THIOLACTONASE ACTIVITY; METHYLENETETRAHYDROFOLATE REDUCTASE; PATHOLOGICAL CONSEQUENCES; POSSIBLE MECHANISM; MOLECULAR-BASIS; PON1; TOXICITY; GENE; ATHEROSCLEROSIS	Genetic or nutritional disorders in homocysteine (Hcy) or folate metabolism elevate plasma Hcy-thiolactone and lead to vascular and/or brain pathologies. Hcy-thiolactone has the ability to form isopeptide bonds with protein lysine residues, which generates N-Hcy-protein with autoimmunogenic and prothrombotic properties. Paraoxonase (PON1), carried on high-density lipoproteins (HDLs) in the blood, hydrolyzes Hcy-thiolactone and protects against the accumulation of N-Hcy-protein in vitro. To determine its role in vivo, we studied how natural variation in Hcy-thiolactonase activity of PON1 affects plasma N-Hcy-protein levels in cystathionine beta-synthase-deficient patients (n = 28). We found that plasma N-Hcy-protein was negatively correlated with serum Hcy-thiolactonase activity (r = -0.43, P = 0.01), i.e., the higher the Hcy-thiolactonase activity, the lower N-Hcy protein levels. This relation was faithfully replicated in vitro in experiments with radiolabeled Hcy-thiolactone. We also found that enzymatic activities of the PON1 protein measured with artificial substrates correlated less strongly (r = -0.36, P = 0.025 for paraoxonase activity) or did not correlate at all (phenylacetate hydrolase and TBLase activities) with plasma N-Hcy protein. These findings provide evidence that the Hcy-thiolactonase activity of PON1 is a determinant of plasma N-Hcy-protein levels and that Hcy-thiolactonase/PON1 protects proteins against N-homocysteinylation in vivo, a novel mechanism likely to contribute to atheroprotective roles of HDL in humans.-Perla-Kajan, J., Jakubowski, H. Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J. 24, 931-936 (2010). www.fasebj.org	[Perla-Kajan, Joanna; Jakubowski, Hieronim] UMDNJ, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, Newark, NJ 07101 USA; [Perla-Kajan, Joanna; Jakubowski, Hieronim] Univ Life Sci, Dept Biochem & Biotechnol, Poznan, Poland; [Jakubowski, Hieronim] Polish Acad Sci, Inst Bioorgan Chem, Poznan, Poland	Rutgers State University New Brunswick; Rutgers State University Medical Center; Poznan University of Life Sciences; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Jakubowski, H (corresponding author), UMDNJ, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, 225 Warren St, Newark, NJ 07101 USA.	jakubows@umdnj.edu	Perla-Kajan, Joanna/F-2965-2010; Jakubowski, Hieronim/AAA-6834-2019; Jakubowski, Hieronim/A-2510-2017	Perla-Kajan, Joanna/0000-0002-0791-5057; Jakubowski, Hieronim/0000-0001-5845-4409	American Heart Association [0855919D]; Ministry of Science and Higher Education, Warsaw, Poland [NN 401 230634, N401 065 32/1504, POIG.01.03.01-00-097/08]	American Heart Association(American Heart Association); Ministry of Science and Higher Education, Warsaw, Poland(Ministry of Science and Higher Education, Poland)	This work was supported in part by grants from the American Heart Association (0855919D) and the Ministry of Science and Higher Education, Warsaw, Poland (NN 401 230634, N401 065 32/1504, POIG.01.03.01-00-097/08).	Bhattacharyya T, 2008, JAMA-J AM MED ASSOC, V299, P1265, DOI 10.1001/jama.299.11.1265; Camps J, 2009, CRIT REV CL LAB SCI, V46, P83, DOI 10.1080/10408360802610878; Chwatko G, 2005, ANAL BIOCHEM, V337, P271, DOI 10.1016/j.ab.2004.11.035; Chwatko G, 2007, FASEB J, V21, P1707, DOI 10.1096/fj.06-7435com; Connelly PW, 2005, FREE RADICAL BIO MED, V38, P164, DOI 10.1016/j.freeradbiomed.2004.10.010; de las Casas CM, 2003, BIRTH DEFECTS RES A, V67, P35, DOI 10.1002/bdra.10014; Domagala TB, 2006, CELL MOL BIOL, V52, P4, DOI 10.1170/T727; Endo N, 2006, BRIT J NUTR, V95, P1088, DOI 10.1079/BJN20061764; Glowacki R, 2004, J BIOL CHEM, V279, P10864, DOI 10.1074/jbc.M313268200; Gu WJ, 2008, ADV THER, V25, P914, DOI 10.1007/s12325-008-0097-8; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; JAKUBOWSKI H, 1993, FEBS LETT, V317, P237, DOI 10.1016/0014-5793(93)81283-6; Jakubowski H, 2000, J BIOL CHEM, V275, P3957, DOI 10.1074/jbc.275.6.3957; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 2005, CLIN CHEM LAB MED, V43, P1011, DOI 10.1515/CCLM.2005.177; Jakubowski H, 2004, CELL MOL LIFE SCI, V61, P470, DOI 10.1007/s00018-003-3204-7; Jakubowski H, 2008, J PHYSIOL PHARMACOL, V59, P155; Jakubowski H, 2001, FEBS LETT, V491, P35, DOI 10.1016/S0014-5793(01)02143-3; Jakubowski H, 2001, BIOMED PHARMACOTHER, V55, P443, DOI 10.1016/S0753-3322(01)00085-3; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; Jakubowski H, 2000, J NUTR, V130, p377S, DOI 10.1093/jn/130.2.377S; Jakubowski H, 2008, ANAL BIOCHEM, V380, P257, DOI 10.1016/j.ab.2008.05.049; Jakubowski H, 2007, CLIN CHEM LAB MED, V45, P1704, DOI 10.1515/CCLM.2007.338; Jakubowski H, 2007, ANAL BIOCHEM, V370, P124, DOI 10.1016/j.ab.2007.05.030; Jakubowski H, 2006, J NUTR, V136, p1741S, DOI 10.1093/jn/136.6.1741S; Jakubowski H, 2008, FASEB J, V22, P4071, DOI 10.1096/fj.08-112086; Jakubowski H, 2009, FASEB J, V23, P1721, DOI 10.1096/fj.08-127548; Jarvik GP, 2000, ARTERIOSCL THROM VAS, V20, P2441, DOI 10.1161/01.ATV.20.11.2441; Kosaka T, 2005, CLIN CHIM ACTA, V359, P156, DOI 10.1016/j.cccn.2005.03.046; Lacinski M, 2004, CELL MOL BIOL, V50, P885; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; Mackness Michael I, 2004, Am J Cardiovasc Drugs, V4, P211, DOI 10.2165/00129784-200404040-00002; Marathe GK, 2003, J BIOL CHEM, V278, P3937, DOI 10.1074/jbc.M211126200; MUDD SH, 2001, METABOLIC MOL BASES, V2, P2007; Perla-Kajan J, 2007, AMINO ACIDS, V32, P561, DOI 10.1007/s00726-006-0432-9; Perla-Kajan J, 2008, BIOMED PHARMACOTHER, V62, P473, DOI 10.1016/j.biopha.2008.04.001; Perla-Kajan J, 2007, BIOCHEMISTRY-US, V46, P6225, DOI 10.1021/bi602463m; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Teiber JF, 2004, J LIPID RES, V45, P2260, DOI 10.1194/jlr.M400213-JLR200; Yang X, 2006, CLIN CHIM ACTA, V364, P230, DOI 10.1016/j.cccn.2005.07.007; Yap S, 2001, ARTERIOSCL THROM VAS, V21, P2080, DOI 10.1161/hq1201.100225	42	67	70	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					931	936		10.1096/fj.09-144410	http://dx.doi.org/10.1096/fj.09-144410			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19880629				2022-12-28	WOS:000274974600028
J	Skaper, SD; Debetto, P; Giusti, P				Skaper, Stephen D.; Debetto, Patrizia; Giusti, Pietro			The P2X(7) purinergic receptor: from physiology to neurological disorders	FASEB JOURNAL			English	Review						ATP; neurodegeneration; microglia; inflammation; cytokines; chronic pain; depression	NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; MICROGLIAL CELLS; EXTRACELLULAR ATP; SPINAL-CORD; INTERLEUKIN-1-BETA RELEASE; PORE FORMATION; CYTOKINE PRODUCTION; SIGNALING PATHWAYS; TREATMENT RESPONSE	Purine nucleotides are well established as extracellular signaling molecules. P2X receptors are ATP-gated cation channels that mediate fast excitatory transmission in diverse regions of the brain and spinal cord. Several P2X receptor subtypes, including P2X(7), have the unusual property of changing their ion selectivity during prolonged exposure to ATP, which results in progressive dilation of the channel pore and the development of permeability to molecules as large as 900 Da. The P2X(7) receptor was originally described in cells of hematopoietic origin, including macrophages, microglia, and certain lymphocytes, and mediates the influx of Ca2+ and Na+ ions, as well as the release of proinflammatory cytokines. P2X(7) receptors may affect neuronal cell death through their ability to regulate the processing and release of interleukin-1 beta, a key mediator in neurodegeneration, chronic inflammation, and chronic pain. Activation of P2X(7) receptors provides an inflammatory stimulus, and P2X(7) receptor-deficient mice have substantially attenuated inflammatory responses, including models of neuropathic and chronic inflammatory pain. Moreover, P2X(7) receptor activity, by regulating the release of proinflammatory cytokines, may be involved in the pathophysiology of depression. The P2X(7) receptor may thus represent a critical communication link between the nervous and immune systems, while providing a target for therapeutic exploitation. This review discusses the current biology and cellular signaling pathways of P2X(7) receptor function, as well as insights into the role for this receptor in neurological/psychiatric diseases, outstanding questions, and the therapeutic potential of P2X(7) receptor antagonism.-Skaper, S. D., Debetto, P., Giusti, P. The P2X(7) purinergic receptor: from physiology to neurological disorders. FASEB J. 24, 337-345 (2010). www.fasebj.org	[Skaper, Stephen D.; Debetto, Patrizia; Giusti, Pietro] Univ Padua, Dept Pharmacol & Anesthesiol, I-35131 Padua, Italy	University of Padua	Skaper, SD (corresponding author), Univ Padua, Dept Pharmacol & Anesthesiol, Largo E Meneghetti 2, I-35131 Padua, Italy.	stephen.skaper@unipd.it		GIUSTi, Pietro/0000-0001-9352-4046				Adinolfi E, 2003, J BIOL CHEM, V278, P37344, DOI 10.1074/jbc.M301508200; Aga M, 2004, AM J PHYSIOL-CELL PH, V286, pC923, DOI 10.1152/ajpcell.00417.2003; Aga M, 2002, J LEUKOCYTE BIOL, V72, P222; Alesci S, 2005, J CLIN ENDOCR METAB, V90, P2522, DOI 10.1210/jc.2004-1667; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Anderson CM, 2006, TRENDS NEUROSCI, V29, P257, DOI 10.1016/j.tins.2006.03.003; Anisman H, 2005, CURR PHARM DESIGN, V11, P963, DOI 10.2174/1381612053381701; Barden N, 2006, AM J MED GENET B, V141B, P374, DOI 10.1002/ajmg.b.30303; Basso AM, 2009, BEHAV BRAIN RES, V198, P83, DOI 10.1016/j.bbr.2008.10.018; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bernardino L, 2008, J NEUROCHEM, V106, P271, DOI 10.1111/j.1471-4159.2008.05387.x; Broom DC, 2008, J PHARMACOL EXP THER, V327, P620, DOI 10.1124/jpet.108.141853; Brustolim D, 2006, INT IMMUNOPHARMACOL, V6, P903, DOI 10.1016/j.intimp.2005.12.007; Burnstock G, 2004, CURR TOP MED CHEM, V4, P793, DOI 10.2174/1568026043451014; Burnstock G, 1996, CURR OPIN NEUROBIOL, V6, P526, DOI 10.1016/S0959-4388(96)80060-2; Carroll WA, 2007, BIOORG MED CHEM LETT, V17, P4044, DOI 10.1016/j.bmcl.2007.04.075; Chakfe Y, 2002, J NEUROSCI, V22, P3061, DOI 10.1523/JNEUROSCI.22-08-03061.2002; Cheewatrakoolpong B, 2005, BIOCHEM BIOPH RES CO, V332, P17, DOI 10.1016/j.bbrc.2005.04.087; Chen Y, 2008, P NATL ACAD SCI USA, V105, P16773, DOI 10.1073/pnas.0801793105; Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Costigan M, 2000, J PAIN, V1, P35, DOI 10.1054/jpai.2000.9818; Dell'Antonio G, 2002, NEUROSCI LETT, V327, P87, DOI 10.1016/S0304-3940(02)00385-3; Denlinger LC, 2005, J IMMUNOL, V174, P4424, DOI 10.4049/jimmunol.174.7.4424; Deuchars SA, 2001, J NEUROSCI, V21, P7143, DOI 10.1523/JNEUROSCI.21-18-07143.2001; Di Virgilio F, 2003, BRIT J PHARMACOL, V140, P441, DOI 10.1038/sj.bjp.0705469; Donnelly-Roberts DL, 2009, NEUROPHARMACOLOGY, V56, P223, DOI 10.1016/j.neuropharm.2008.06.012; Donnelly-Roberts DL, 2004, J PHARMACOL EXP THER, V308, P1053, DOI 10.1124/jpet.103.059600; DONNELLYROBERTS DL, 2007, EUR J PHARMACOL, V447, P247; Dubyak GR, 2007, MOL PHARMACOL, V72, P1402, DOI 10.1124/mol.107.042077; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Egan TM, 2006, PFLUG ARCH EUR J PHY, V452, P501, DOI 10.1007/s00424-006-0078-1; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1996, J IMMUNOL, V156, P1531; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Ferrari D, 1997, J IMMUNOL, V159, P1451; Fields RD, 2006, NAT REV NEUROSCI, V7, P423, DOI 10.1038/nrn1928; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; Franke H, 2004, J NEUROPATH EXP NEUR, V63, P686, DOI 10.1093/jnen/63.7.686; Furber M, 2007, J MED CHEM, V50, P5882, DOI 10.1021/jm700949w; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; Guo C, 2007, MOL PHARMACOL, V72, P1447, DOI 10.1124/mol.107.035980; Hejjas K, 2009, AM J MED GENET B, V150B, P295, DOI 10.1002/ajmg.b.30799; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Honore P, 2006, J PHARMACOL EXP THER, V319, P1376, DOI 10.1124/jpet.106.111559; Honore P, 2009, BEHAV BRAIN RES, V204, P77, DOI 10.1016/j.bbr.2009.05.018; Humphreys BD, 1998, J LEUKOCYTE BIOL, V64, P265, DOI 10.1002/jlb.64.2.265; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; James G, 2002, EUR J PHARMACOL, V447, P247, DOI 10.1016/S0014-2999(02)01756-9; Keane RW, 2006, J NEUROTRAUM, V23, P335, DOI 10.1089/neu.2006.23.335; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Kim M, 2001, J BIOL CHEM, V276, P23262, DOI 10.1074/jbc.M102253200; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Korcok J, 2004, J BONE MINER RES, V19, P642, DOI 10.1359/JBMR.040108; Kraus MR, 2002, ALIMENT PHARM THER, V16, P1091, DOI 10.1046/j.1365-2036.2002.01265.x; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Lanquillon S, 2000, NEUROPSYCHOPHARMACOL, V22, P370, DOI 10.1016/S0893-133X(99)00134-7; Larson SJ, 2001, BRAIN BEHAV IMMUN, V15, P371, DOI 10.1006/brbi.2001.0643; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lucae S, 2006, HUM MOL GENET, V15, P2438, DOI 10.1093/hmg/ddl166; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Maes M, 2001, HUM PSYCHOPHARM CLIN, V16, P95, DOI 10.1002/hup.191; McGaraughty S, 2007, NEUROSCIENCE, V146, P1817, DOI 10.1016/j.neuroscience.2007.03.035; Merriman GH, 2005, BIOORG MED CHEM LETT, V15, P435, DOI 10.1016/j.bmcl.2004.10.052; MILLIGAN ED, 2003, SEM PAIN MED, V1, P171, DOI DOI 10.1016/S1537-5897(03)00044-2); Monif M, 2009, J NEUROSCI, V29, P3781, DOI 10.1523/JNEUROSCI.5512-08.2009; Narcisse L, 2005, GLIA, V49, P245, DOI 10.1002/glia.20110; Nelson DW, 2008, J MED CHEM, V51, P3030, DOI 10.1021/jm701516f; Nelson DW, 2006, J MED CHEM, V49, P3659, DOI 10.1021/jm051202e; Nicke A, 2008, BIOCHEM BIOPH RES CO, V377, P803, DOI 10.1016/j.bbrc.2008.10.042; Nieber K, 1999, PROG BRAIN RES, V120, P287; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Palomino-Doza J, 2008, HYPERTENSION, V52, P980, DOI 10.1161/HYPERTENSIONAHA.108.113282; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Pfeiffer ZA, 2004, J LEUKOCYTE BIOL, V75, P1173, DOI 10.1189/jlb.1203648; Pollak Y, 2002, INT J NEUROPSYCHOPH, V5, P389, DOI 10.1017/S1461145702003152; Potucek YD, 2006, NEUROCHEM INT, V49, P204, DOI 10.1016/j.neuint.2006.04.005; Raghavendra V., 2003, ADV MOL CEL, V31, P951, DOI 10.1016/S1569-2558(03)31042-2; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Ralevic V, 2003, DRUG NEWS PERSPECT, V16, P133, DOI 10.1358/dnp.2003.16.3.876886; Raouf R, 2007, NEUROPHARMACOLOGY, V53, P496, DOI 10.1016/j.neuropharm.2007.06.010; SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x; Sikora A, 1999, J IMMUNOL, V163, P558; Sim JA, 2004, J NEUROSCI, V24, P6307, DOI 10.1523/JNEUROSCI.1469-04.2004; Simen BB, 2006, BIOL PSYCHIAT, V59, P775, DOI 10.1016/j.biopsych.2005.10.013; Skaper SD, 2006, GLIA, V54, P234, DOI 10.1002/glia.20379; SMITH RS, 1991, MED HYPOTHESES, V35, P298, DOI 10.1016/0306-9877(91)90272-Z; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Sommer C, 1999, NEUROSCI LETT, V270, P25, DOI 10.1016/S0304-3940(99)00450-4; Sperlagh B, 2006, PROG NEUROBIOL, V78, P327, DOI 10.1016/j.pneurobio.2006.03.007; STEINER J, 2006, J PSYCHIATR RES, V42, P151; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Touzani O, 2002, J NEUROSCI, V22, P38, DOI 10.1523/JNEUROSCI.22-01-00038.2002; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Tuglu C, 2003, PSYCHOPHARMACOLOGY, V170, P429, DOI 10.1007/s00213-003-1566-z; Verderio C, 2001, J IMMUNOL, V166, P6383, DOI 10.4049/jimmunol.166.10.6383; Volonte C, 2003, CNS NEUROL DISORD-DR, V2, P403, DOI 10.2174/1568007033482643; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Werry EL, 2006, J NEUROCHEM, V99, P924, DOI 10.1111/j.1471-4159.2006.04133.x; Wichers M, 2002, INT J NEUROPSYCHOPH, V5, P375, DOI 10.1017/S1461145702003103; Wiley JS, 2003, J BIOL CHEM, V278, P17108, DOI 10.1074/jbc.M212759200; Wilson HL, 2002, J BIOL CHEM, V277, P34017, DOI 10.1074/jbc.M205120200; Witting A, 2006, P NATL ACAD SCI USA, V103, P6362, DOI 10.1073/pnas.0510418103; Xia ZL, 1996, IMMUNOPHARMACOLOGY, V34, P27, DOI 10.1016/0162-3109(96)00111-7; Yiangou Y, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-12; Yirmiya R, 2001, NEUROPSYCHOPHARMACOL, V24, P531, DOI 10.1016/S0893-133X(00)00226-8; Zhang XF, 2005, BRAIN RES, V1052, P63, DOI 10.1016/j.brainres.2005.06.022	113	284	320	1	51	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					337	345		10.1096/fj.09-138883	http://dx.doi.org/10.1096/fj.09-138883			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19812374				2022-12-28	WOS:000274045000002
J	Kasinathan, RS; Goronga, T; Messerli, SM; Webb, TR; Greenberg, RM				Kasinathan, Ravi S.; Goronga, Tinopiwa; Messerli, Shanta M.; Webb, Thomas R.; Greenberg, Robert M.			Modulation of a Schistosoma mansoni multidrug transporter by the antischistosomal drug praziquantel	FASEB JOURNAL			English	Article						verapamil; drug resistance; efflux transporter	GATED CA2+ CHANNELS; P-GLYCOPROTEIN; EXCRETORY SYSTEM; ABC TRANSPORTERS; IVERMECTIN RESISTANCE; HAEMONCHUS-CONTORTUS; MOLECULAR-BASIS; BINDING; MECHANISMS; SELECTION	P-glycoprotein (Pgp) is an ATP-dependent efflux pump involved in transport of xenobiotics from cells that, when overexpressed, can mediate multidrug resistance in mammalian cells. Pgp may be a candidate target for new anthelmintics, as it plays critical roles in normal cell physiology, in removal of drugs from cells, and potentially in the development of drug resistance. Schistosomes are parasitic flatworms that cause schistosomiasis, which affects hundreds of millions of people worldwide. Here, we express SMDR2, a Pgp homologue from Schistosoma mansoni ( Platyhelminthes), in Chinese hamster ovary (CHO) cells and use fluorescence-based assays to examine the functional and pharmacological properties of this transporter. Membrane vesicles from stably transfected CHO cells expressing recombinant SMDR2 show significant increases in rhodamine transport and ATP hydrolysis compared with those from control cells or cells transfected with empty vector. SMDR2-mediated transport is inhibited by the Pgp modulators verapamil (IC50 = 12.1 mu M) and nifedipine, and also by praziquantel, the current drug of choice against schisotosomiasis (IC50 = 17.4 mu M). Efflux measurements of a fluorescent analog of praziquantel indicate that it is also a substrate for SMDR2. The interaction of praziquantel with SMDR2 may offer new strategies for potentiating the action of praziquantel and possibly overcoming drug resistance.-Kasinathan, R. S., Goronga, T., Messerli, S. M., Webb, T. R., Greenberg, R. M. Modulation of a Schistosoma mansoni multidrug transporter by the antischistosomal drug praziquantel. FASEB J. 24, 128-135 ( 2010). www.fasebj.org	[Kasinathan, Ravi S.; Greenberg, Robert M.] Univ Penn, Dept Pathobiol, Sch Vet Med, Philadelphia, PA 19104 USA; [Goronga, Tinopiwa; Webb, Thomas R.] St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA; [Messerli, Shanta M.] Marine Biol Lab, Woods Hole, MA 02543 USA	University of Pennsylvania; St Jude Children's Research Hospital; Marine Biological Laboratory - Woods Hole	Greenberg, RM (corresponding author), Univ Penn, Dept Pathobiol, Sch Vet Med, 3800 Spruce St, Philadelphia, PA 19104 USA.	rgree@vet.upenn.edu	Kasinathan, Ravi/B-7657-2013		National Institutres of Health (NIH) [R01 AI-40522, R01 AI-73660, P41 RR-001395]; NIH/National Science Foundation Woods Hole Center for Oceans and Human Health [WHOI-A100354/A100360]; American Lebanese Syrian Associated Charities, St. Jude Children's Research Hospital; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073660, R01AI040522, R21AI082390] Funding Source: NIH RePORTER	National Institutres of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Science Foundation Woods Hole Center for Oceans and Human Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lebanese Syrian Associated Charities, St. Jude Children's Research Hospital(American Lebanese Syrian Associated Charities (ALSAC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank William Morgan, Christina Evola, and Jessica Roberts-Misterly for excellent technical assistance. We also thank Fred Lewis and the National Institute of Allergy and Infectious Diseases Schistosome Resource Center for supplying the schistosome life cycle. Flow cytometry experiments were performed at the Flow Cytometry Core Facility at the University of Pennsylvania School of Veterinary Medicine. This work was supported by National Institutres of Health (NIH) grants R01 AI-40522 and R01 AI-73660 (to R. M. G.). R. M. G. and S. M. M. were also supported in part by NIH/National Science Foundation Woods Hole Center for Oceans and Human Health grant WHOI-A100354/A100360. Support was also received from the NIH Biocurrents Research Center at the Marine Biological Laboratory (P41 RR-001395). This work was also supported in part by the American Lebanese Syrian Associated Charities, St. Jude Children's Research Hospital.	Aller SG, 2009, SCIENCE, V323, P1718, DOI 10.1126/science.1168750; Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; ANDREWS P, 1985, PHARMACOL THERAPEUT, V29, P129, DOI 10.1016/0163-7258(85)90020-8; Angelucci F, 2007, PARASITOLOGY, V134, P1215, DOI 10.1017/S0031182007002600; Aragon AD, 2009, MOL BIOCHEM PARASIT, V164, P57, DOI 10.1016/j.molbiopara.2008.11.007; Blackhall WJ, 2008, VET PARASITOL, V152, P101, DOI 10.1016/j.vetpar.2007.12.001; Bonn D, 2004, LANCET INFECT DIS, V4, P190, DOI 10.1016/S1473-3099(04)00986-7; BOSCH IB, 1994, MOL BIOCHEM PARASIT, V65, P351, DOI 10.1016/0166-6851(94)90085-X; Bourguinat C, 2008, MOL BIOCHEM PARASIT, V158, P101, DOI 10.1016/j.molbiopara.2007.11.017; Chitsulo L, 2004, NAT REV MICROBIOL, V2, P12, DOI 10.1038/nrmicro801; Day TA, 2006, PARASITIC FLATWORMS: MOLECULAR BIOLOGY, BIOCHEMISTRY, IMMUNOLOGY AND PHYSIOLOGY, P256, DOI 10.1079/9780851990279.0256; DAY TA, 1992, PARASITOL TODAY, V8, P342, DOI 10.1016/0169-4758(92)90070-I; Doenhoff MJ, 2008, CURR OPIN INFECT DIS, V21, P659, DOI 10.1097/QCO.0b013e328318978f; Engels D, 2002, ACTA TROP, V82, P139, DOI 10.1016/S0001-706X(02)00045-1; Gnanasekar M, 2009, ANTIMICROB AGENTS CH, V53, P1054, DOI 10.1128/AAC.01222-08; Greenberg RM, 2005, PARASITOLOGY, V131, pS97, DOI 10.1017/S0031182005008346; Greenway GM, 2005, CHEM WORLD-UK, V2, P9; Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3; Hayeshi R, 2006, EUR J PHARM SCI, V29, P70, DOI 10.1016/j.ejps.2006.05.009; Jeziorski MC, 2000, J EXP BIOL, V203, P841; Jeziorski MC, 2006, INT J PARASITOL, V36, P625, DOI 10.1016/j.ijpara.2006.02.002; Jones PM, 2005, INT J PARASITOL, V35, P555, DOI 10.1016/j.ijpara.2005.01.012; Kerboeuf D, 2003, INT J ANTIMICROB AG, V22, P332, DOI 10.1016/S0924-8579(03)00221-8; Kohler S, 2003, BIOTECHNOL BIOENG, V81, P507, DOI 10.1002/bit.10488; Kusel JR, 2006, MEM I OSWALDO CRUZ, V101, P293, DOI 10.1590/S0074-02762006000900046; Kusell JR, 2009, TRENDS PARASITOL, V25, P353, DOI 10.1016/j.pt.2009.05.003; Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411; Lespine A, 2008, TRENDS PARASITOL, V24, P293, DOI 10.1016/j.pt.2008.03.011; Messerli SM, 2009, MOL BIOCHEM PARASIT, V167, P54, DOI 10.1016/j.molbiopara.2009.04.007; Oliveira FA, 2006, PARASITOLOGY, V132, P321, DOI 10.1017/S0031182005009169; Paulsen IT, 2003, CURR OPIN MICROBIOL, V6, P446, DOI 10.1016/j.mib.2003.08.005; Pica-Mattoccia L, 2008, EXP PARASITOL, V119, P332, DOI 10.1016/j.exppara.2008.03.012; Redman CA, 1996, PARASITOL TODAY, V12, P14, DOI 10.1016/0169-4758(96)80640-5; Sangster NC, 1999, EXP PARASITOL, V91, P250, DOI 10.1006/expr.1998.4373; Sato H, 2004, PARASITOLOGY, V128, P43, DOI 10.1017/S0031182003004177; Sato H, 2002, PARASITOLOGY, V125, P527, DOI 10.1017/S0031182002002536; Seeger MA, 2009, BBA-PROTEINS PROTEOM, V1794, P725, DOI 10.1016/j.bbapap.2008.12.004; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Shapiro AB, 1998, ACTA PHYSIOL SCAND, V163, P227; Tallima H, 2007, INT J ANTIMICROB AG, V29, P570, DOI 10.1016/j.ijantimicag.2006.12.018; Valderramos SG, 2006, TRENDS PHARMACOL SCI, V27, P594, DOI 10.1016/j.tips.2006.09.005; Walter M., 2003, US Patent, Patent No. [6,514,963 B2, 6514963]; Xu M, 1998, MOL BIOCHEM PARASIT, V91, P327, DOI 10.1016/S0166-6851(97)00215-6; Zhou SF, 2008, CURR MED CHEM, V15, P1981, DOI 10.2174/092986708785132870	44	27	29	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					128	135		10.1096/fj.09-137091	http://dx.doi.org/10.1096/fj.09-137091			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19726755	Green Published			2022-12-28	WOS:000273233600015
J	Kupershmidt, L; Weinreb, O; Amit, T; Mandel, S; Carri, MT; Youdim, MBH				Kupershmidt, Lana; Weinreb, Orly; Amit, Tamar; Mandel, Silvia; Carri, Maria Teresa; Youdim, Moussa B. H.			Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis	FASEB JOURNAL			English	Article						motor neurodegenerative diseases; hypoxia-inducible factor; differentiation; G93A-SOD1 ALS mouse model	HYPOXIA-INDUCIBLE FACTOR; MONOAMINE-OXIDASE INHIBITION; SPINAL-CORD INJURY; PROTEIN-KINASE-C; NEURODEGENERATIVE DISEASES; GROWTH-FACTOR; IN-VIVO; SUPEROXIDE-DISMUTASE; NEUROTROPHIC FACTOR; PARKINSONS-DISEASE	Novel therapeutic approaches for the treatment of neurodegenerative disorders comprise drug candidates designed specifically to act on multiple central nervous system targets. We have recently synthesized multifunctional, nontoxic, brain-permeable iron-chelating drugs, M30 and HLA20, possessing the N-propargylamine neuroprotective moiety of rasagiline (Azilect) and the iron-chelating moiety of VK28. The present study demonstrates that M30 and HLA20 possess a wide range of pharmacological activities in mouse NSC-34 motor neuron cells, including neuroprotective effects against hydrogen peroxide-and 3-morpholinosydnonimine-induced neurotoxicity, induction of differentiation, and up-regulation of hypoxia-inducible factor (HIF)-1 alpha and HIF-target genes (enolase1 and vascular endothelial growth factor)(+) Both compounds induced NSC-34 neuritogenesis, accompanied by a marked increase in the expression of brain-derived neurotrophic factor and growth-associated protein-43, which was inhibited by PD98059 and GF109203X, indicating the involvement of mitogen-activated protein kinase and protein kinase C pathways. A major finding was the ability of M30 to significantly extend the survival of G93A-SOD1 amyotrophic lateral sclerosis mice and delay the onset of the disease. These properties of the novel multimodal iron-chelating drugs possessing neuroprotective/neuritogenic activities may offer future therapeutic possibilities for motor neurodegenerative diseases.-Kupershmidt, L., Weinreb, O., Amit, T., Mandel, S., Carri, M. T., Youdim, M. B. H. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 23, 3766-3779 (2009). www.fasebj.org	[Kupershmidt, Lana; Weinreb, Orly; Amit, Tamar; Mandel, Silvia; Youdim, Moussa B. H.] Technion Israel Inst Technol, Fac Med, Dept Pharmacol, Rappaport Family Res Inst, IL-31096 Haifa, Israel; [Carri, Maria Teresa] Fdn Santa Lucia, IRCCS, Neurochem Lab, Rome, Italy; [Carri, Maria Teresa] Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; IRCCS Santa Lucia; University of Rome Tor Vergata	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Pharmacol, Rappaport Family Res Inst, POB 9697, IL-31096 Haifa, Israel.	youdim@tx.technion.ac.il	Carri, Maria Teresa/K-5480-2016	Carri, Maria Teresa/0000-0002-1789-1546	The Israeli ALS Research Association (Haifa, Israel); Technion-Research and Development and Rappaport Family Research Institute, Technion-Israel Institute of Technology (Haifa, Israel)	The Israeli ALS Research Association (Haifa, Israel); Technion-Research and Development and Rappaport Family Research Institute, Technion-Israel Institute of Technology (Haifa, Israel)	The authors thank the personnel from Tor Vergata University, Rome, Italy, for generously providing the NSC-34 cell line and wt/G93A-SOD1 plasmids, and for their excellent assistance and kind advice. The authors gratefully acknowledged the support of The Israeli ALS Research Association (Haifa, Israel) and the Technion-Research and Development and Rappaport Family Research Institute, Technion-Israel Institute of Technology (Haifa, Israel).	Alexander GM, 2004, MOL BRAIN RES, V130, P7, DOI 10.1016/j.molbrainres.2004.07.002; Almli LM, 2001, DEV BRAIN RES, V132, P121, DOI 10.1016/S0165-3806(01)00302-9; Amit T, 2008, FASEB J, V22, P1296, DOI 10.1096/fj.07-8627rev; Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Avramovich-Tirosh Y, 2007, J NEUROCHEM, V100, P490, DOI 10.1111/j.1471-4159.2006.04258.x; Azzouz M, 2004, NATURE, V429, P413, DOI 10.1038/nature02544; Bar Am O, 2004, NEUROSCI LETT, V355, P169, DOI 10.1016/j.neulet.2003.10.067; Bar-Am O, 2004, J NEUROCHEM, V89, P1119, DOI 10.1111/j.1471-4159.2004.02425.x; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BelAiba RS, 2007, MOL BIOL CELL, V18, P4691, DOI 10.1091/mbc.E07-04-0391; Bendotti C, 2004, TRENDS MOL MED, V10, P393, DOI 10.1016/j.molmed.2004.06.009; Blancher C, 2001, CANCER RES, V61, P7349; Brand KA, 1997, FASEB J, V11, P388, DOI 10.1096/fasebj.11.5.9141507; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; Buck CR, 2000, J COMP NEUROL, V416, P309, DOI 10.1002/(SICI)1096-9861(20000117)416:3<309::AID-CNE3>3.0.CO;2-U; Burdo JR, 2003, BIOMETALS, V16, P63, DOI 10.1023/A:1020718718550; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Cassina P, 2002, J NEUROSCI RES, V67, P21, DOI 10.1002/jnr.10107; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; COMBS DJ, 1987, STROKE, V18, P503, DOI 10.1161/01.STR.18.2.503; Cookson MR, 1998, J NEUROCHEM, V70, P501; Cozzolino M, 2008, ANTIOXID REDOX SIGN, V10, P405, DOI 10.1089/ars.2007.1760; Danzeisen R, 2006, J BIOL INORG CHEM, V11, P489, DOI 10.1007/s00775-006-0099-4; DURHAM HD, 1993, NEUROTOXICOLOGY, V14, P387; Feng HL, 2008, NEUROSCIENCE, V155, P567, DOI 10.1016/j.neuroscience.2008.06.040; Forde JE, 2007, CELL MOL LIFE SCI, V64, P1930, DOI 10.1007/s00018-007-7045-7; Gaeta A, 2005, BRIT J PHARMACOL, V146, P1041, DOI 10.1038/sj.bjp.0706416; Gakh O, 2006, HUM MOL GENET, V15, P467, DOI 10.1093/hmg/ddi461; Gal S, 2005, J NEUROCHEM, V95, P79, DOI 10.1111/j.1471-4159.2005.03341.x; Garbuzova-Davis S, 2003, J HEMATOTH STEM CELL, V12, P255, DOI 10.1089/152581603322022990; Harley A, 1993, Brain Res, V627, P349; Heiman-Patterson TD, 2005, J NEUROL SCI, V236, P1, DOI 10.1016/j.jns.2005.02.006; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Ikeda O, 2002, J NEUROPATH EXP NEUR, V61, P142, DOI 10.1093/jnen/61.2.142; Imon Y, 1995, J NEUROL SCI, V134, P27, DOI 10.1016/0022-510X(95)00205-G; Jellinger KA, 1999, DRUG AGING, V14, P115, DOI 10.2165/00002512-199914020-00004; Jeong SY, 2009, J NEUROSCI, V29, P570, DOI 10.1523/JNEUROSCI.5443-08.2009; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; KASARSKIS EJ, 1995, J NEUROL SCI, V130, P203, DOI 10.1016/0022-510X(95)00037-3; Kulp KS, 1996, EXP CELL RES, V229, P60, DOI 10.1006/excr.1996.0343; Kyosseva SV, 2004, INT REV NEUROBIOL, V59, P201; Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211; Lindsay RM, 1996, PHILOS T ROY SOC B, V351, P365, DOI 10.1098/rstb.1996.0030; Ludolph Albert C, 2007, Amyotroph Lateral Scler, V8, P217, DOI 10.1080/17482960701292837; Martin LJ, 2007, REV NEUROSCIENCE, V18, P115; Matusica D, 2008, J NEUROSCI RES, V86, P553, DOI 10.1002/jnr.21507; Mizuno Y, 2006, ACTA NEUROPATHOL, V112, P597, DOI 10.1007/s00401-006-0122-4; Moreau C, 2006, J NEUROL NEUROSUR PS, V77, P255, DOI 10.1136/jnnp.2005.070904; Namiki J, 2000, J NEUROTRAUM, V17, P1219, DOI 10.1089/neu.2000.17.1219; Nurtjahja-Tjendraputra E, 2007, BLOOD, V109, P4045, DOI 10.1182/blood-2006-10-047753; OBA H, 1993, RADIOLOGY, V189, P843, DOI 10.1148/radiology.189.3.8234713; Pantopoulos K, 2004, ANN NY ACAD SCI, V1012, P1, DOI 10.1196/annals.1306.001; Qin DX, 2006, NEUROSCI LETT, V410, P222, DOI 10.1016/j.neulet.2006.10.006; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 2000, ADV EXP MED BIOL, V475, P123; Shoham S, 2000, CELL MOL BIOL, V46, P743; Siddiq A, 2005, J BIOL CHEM, V280, P41732, DOI 10.1074/jbc.M504963200; Singh AT, 2003, J BONE MINER RES, V18, P1453, DOI 10.1359/jbmr.2003.18.8.1453; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; TAKEDA E, 1981, LIFE SCI, V28, P1007, DOI 10.1016/0024-3205(81)90746-3; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; Tolosa L, 2009, NEUROSCIENCE, V158, P1348, DOI 10.1016/j.neuroscience.2008.10.060; Van Den Bosch L, 2004, NEUROBIOL DIS, V17, P21, DOI 10.1016/j.nbd.2004.06.004; Weinreb O, 2004, FASEB J, V18, P1471, DOI 10.1096/fj.04-1916fje; Whitnall Megan, 2006, Semin Pediatr Neurol, V13, P186, DOI 10.1016/j.spen.2006.08.008; Wiener CM, 1996, BIOCHEM BIOPH RES CO, V225, P485, DOI 10.1006/bbrc.1996.1199; Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537; Zheng H, 2005, J NEUROCHEM, V95, P68, DOI 10.1111/j.1471-4159.2005.03340.x; Zheng HL, 2005, BIOORGAN MED CHEM, V13, P773, DOI 10.1016/j.bmc.2004.10.037; Zhu W, 2007, FASEB J, V21, P3835, DOI 10.1096/fj.07-8386com	71	100	102	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3766	3779		10.1096/fj.09-130047	http://dx.doi.org/10.1096/fj.09-130047			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19638399				2022-12-28	WOS:000271272500014
J	Erdelyi, K; Bai, P; Kovacs, I; Szabo, E; Mocsar, G; Kakuk, A; Szabo, C; Gergely, P; Virag, L				Erdelyi, Katalin; Bai, Peter; Kovacs, Istvan; Szabo, Eva; Mocsar, Gabor; Kakuk, Annamaria; Szabo, Csaba; Gergely, Pal; Virag, Laszlo			Dual role of poly(ADP-ribose) glycohydrolase in the regulation of cell death in oxidatively stressed A549 cells	FASEB JOURNAL			English	Article						DNA damage; gene silencing; apoptosis; necrosis; hydrogen peroxide; apoptosis-inducing factor	APOPTOSIS-INDUCING FACTOR; DNA-DAMAGE; POLYMERASE INHIBITORS; NEURONAL DEATH; INTACT-CELLS; PROTECTS; METABOLISM; DEPLETION; ISOFORMS; NECROSIS	Activation of poly(ADP-ribose) polymerase-1 (PARP1) has been shown to mediate cell death induced by genotoxic stimuli. The role of poly(ADP-ribose) glycohydrolase (PARG), the enzyme responsible for polymer degradation, has been largely unexplored in the regulation of cell death. Using lentiviral gene silencing we generated A549 lung adenocarcinoma cell lines with stably suppressed PARG and PARP1 expression (shPARG and shPARP1 cell lines, respectively) and determined parameters of apoptotic and necrotic cell death following hydrogen peroxide exposure. shPARG cells accumulated large amounts of poly-(ADP-ribosyl)ated proteins and exhibited reduced PARP activation. Hydrogen peroxide-induced cell death is regulated by PARG in a dual fashion. Whereas the shPARG cell line (similarly to shPARP1 cells) was resistant to the necrotic effect of high concentrations of hydrogen peroxide, these cells exhibited stronger apoptotic response. Both shPARP1 and especially shPARG cells displayed a delayed repair of DNA breaks and exhibited reduced clonogenic survival following hydrogen peroxide treatment. Translocation of apoptosis-inducing factor could not be observed, but cells could be saved by methyl pyruvate and alpha-ketoglutarate, indicating that energy failure may mediate cytotoxicity in our model. These data indicate that PARG is a survival factor at mild oxidative damage but contributes to the apoptosis-necrosis switch in severely damaged cells.-Erdelyi, K., Bai, P., Kovacs, I., Szabo, E., Mocsar, G., Kakuk, A., Szabo, C., Gergely, P., Virag, L. Dual role of poly(ADP-ribose) glycohydrolase in the regulation of cell death in oxidatively stressed A549 cells. FASEB J. 23, 3553-3563 (2009). www.fasebj.org	[Erdelyi, Katalin; Bai, Peter; Kovacs, Istvan; Kakuk, Annamaria; Gergely, Pal; Virag, Laszlo] Univ Debrecen, Med & Hlth Sci Ctr, Dept Med Chem, H-4032 Debrecen, Hungary; [Szabo, Eva] Univ Debrecen, Med & Hlth Sci Ctr, Dept Dermatol, H-4032 Debrecen, Hungary; [Mocsar, Gabor] Univ Debrecen, Med & Hlth Sci Ctr, Dept Biophys & Cell Biol, H-4032 Debrecen, Hungary; [Erdelyi, Katalin; Mocsar, Gabor; Gergely, Pal; Virag, Laszlo] Hungarian Acad Sci, Res Ctr Mol Med, Cell Biol & Signaling Res Grp, Debrecen, Hungary; [Szabo, Csaba] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX USA	University of Debrecen; University of Debrecen; University of Debrecen; Hungarian Academy of Sciences; University of Texas System; University of Texas Medical Branch Galveston	Virag, L (corresponding author), Univ Debrecen, Med & Hlth Sci Ctr, Dept Med Chem, Elettudomanyi Epulet 3-311,Nagyerdei Krt 98, H-4032 Debrecen, Hungary.	lvirag@dote.hu	Virag, Laszlo/E-6124-2010; Szabo, Csaba/ABG-2644-2021; Szabo, Eva/B-8574-2011; Bai, Peter/C-8005-2014; Gergely, Pál/A-5547-2008; Szabo, Csaba/D-1882-2013	Virag, Laszlo/0000-0002-7099-6718	Hungarian Ministry of Health [12/2006]; Hungarian National Science Research Fund [OTKA K60780, K75864, K60620, NNF 78498, K77600]; University of Debrecen Medical and Health Science Center [Mec-1/2008]; U. S. National Institutes of Health [NIH R01 GM060915]; Hungarian Academy of Sciences; Istvan Szechenyi Fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060915] Funding Source: NIH RePORTER	Hungarian Ministry of Health; Hungarian National Science Research Fund(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); University of Debrecen Medical and Health Science Center; U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hungarian Academy of Sciences(Hungarian Academy of Sciences); Istvan Szechenyi Fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the Hungarian Ministry of Health (12/2006), the Hungarian National Science Research Fund (OTKA K60780, K75864, K60620, NNF 78498, K77600), the University of Debrecen Medical and Health Science Center (Mec-1/2008), and the U. S. National Institutes of Health (NIH R01 GM060915). E.S. and P. B. were supported by a Bolyai Fellowship from the Hungarian Academy of Sciences. L. V. was supported by an Istvan Szechenyi Fellowship. We thank Krisztian Csomos for his help with the lentiviral system. The excellent technical assistance of Ms. Erzsebet Herbaly is greatly appreciated.	Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Bai P, 2001, FREE RADICAL BIO MED, V31, P1616, DOI 10.1016/S0891-5849(01)00756-0; Blenn C, 2006, BIOCHEM J, V396, P419, DOI 10.1042/BJ20051696; Bonicalzi ME, 2005, CELL MOL LIFE SCI, V62, P739, DOI 10.1007/s00018-004-4505-1; BURKLE A, 1993, CARCINOGENESIS, V14, P559, DOI 10.1093/carcin/14.4.559; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Cohausz O, 2008, CELL MOL LIFE SCI, V65, P644, DOI 10.1007/s00018-008-7516-5; Cortes U, 2004, MOL CELL BIOL, V24, P7163, DOI 10.1128/MCB.24.16.7163-7178.2004; Diaz-Hernandez JI, 2007, CELL DEATH DIFFER, V14, P1211, DOI 10.1038/sj.cdd.4402117; Diefenbach J, 2005, CELL MOL LIFE SCI, V62, P721, DOI 10.1007/s00018-004-4503-3; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Erdelyi K, 2005, MOL PHARMACOL, V68, P895, DOI 10.1124/mol.105.012518; Falsig J, 2004, EUR J PHARMACOL, V497, P7, DOI 10.1016/j.ejphar.2004.06.042; Fisher AEO, 2007, MOL CELL BIOL, V27, P5597, DOI 10.1128/MCB.02248-06; Gagne JP, 2008, NUCLEIC ACIDS RES, V36, P6959, DOI 10.1093/nar/gkn771; Gagne JP, 2006, CURR OPIN CELL BIOL, V18, P145, DOI 10.1016/j.ceb.2006.02.013; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Haince JF, 2006, BBA-MOL CELL RES, V1763, P226, DOI 10.1016/j.bbamcr.2005.11.015; Hanai S, 2004, P NATL ACAD SCI USA, V101, P82, DOI 10.1073/pnas.2237114100; Hegedus C, 2008, FEBS LETT, V582, P1672, DOI 10.1016/j.febslet.2008.04.023; Huang Q, 2009, CELL DEATH DIFFER, V16, P264, DOI 10.1038/cdd.2008.151; Jo CH, 2008, CELL TISSUE RES, V334, P423, DOI 10.1007/s00441-008-0696-3; Keil C, 2006, J BIOL CHEM, V281, P34394, DOI 10.1074/jbc.M606470200; Koh DW, 2004, P NATL ACAD SCI USA, V101, P17699, DOI 10.1073/pnas.0406182101; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lontay B, 2005, CELL SIGNAL, V17, P1265, DOI 10.1016/j.cellsig.2005.01.008; Meyer RG, 2007, EXP CELL RES, V313, P2920, DOI 10.1016/j.yexcr.2007.03.043; Meyer-Ficca ML, 2004, EXP CELL RES, V297, P521, DOI 10.1016/j.yexcr.2004.03.050; Moroni F, 2001, CELL DEATH DIFFER, V8, P921, DOI 10.1038/sj.cdd.4400884; Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272; Nanavaty UB, 2002, EXP LUNG RES, V28, P591, DOI 10.1080/01902140260426715; Niere M, 2008, MOL CELL BIOL, V28, P814, DOI 10.1128/MCB.01766-07; Oka S, 2006, J BIOL CHEM, V281, P705, DOI 10.1074/jbc.M510290200; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Scovassi AI, 2004, FASEB J, V18, P1487, DOI 10.1096/fj.04-1841rev; Tentori L, 2001, CELL DEATH DIFFER, V8, P817, DOI 10.1038/sj.cdd.4400863; Virag L, 1998, J IMMUNOL, V161, P3753; Virag L, 1998, IMMUNOLOGY, V94, P345, DOI 10.1046/j.1365-2567.1998.00534.x; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wong HR, 1998, AM J PHYSIOL-LUNG C, V275, pL836, DOI 10.1152/ajplung.1998.275.4.L836; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	44	85	91	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3553	3563		10.1096/fj.09-133264	http://dx.doi.org/10.1096/fj.09-133264			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19571039	Green Published			2022-12-28	WOS:000270354300031
J	Freude, S; Hettich, MM; Schumann, C; Stohr, O; Koch, L; Kohler, C; Udelhoven, M; Leeser, U; Muller, M; Kubota, N; Kadowaki, T; Krone, W; Schroder, H; Bruning, JC; Schubert, M				Freude, Susanna; Hettich, Moritz M.; Schumann, Christina; Stoehr, Oliver; Koch, Linda; Koehler, Christoph; Udelhoven, Michael; Leeser, Uschi; Mueller, Marita; Kubota, Naoto; Kadowaki, Takashi; Krone, Wilhelm; Schroeder, Hannsjoerg; Bruening, Jens C.; Schubert, Markus			Neuronal IGF-1 resistance reduces A beta accumulation and protects against premature death in a model of Alzheimer's disease	FASEB JOURNAL			English	Article						beta-amyloid; longevity; insulin receptor substrate; brain; Tg2576 mice	AMYLOID PRECURSOR PROTEIN; TYPE-2 DIABETES-MELLITUS; GROWTH-FACTOR EXPRESSION; INSULIN-RECEPTOR; LIFE-SPAN; SECRETASE CLEAVAGE; IMPAIRED INSULIN; PLAQUE-FORMATION; BRAIN INSULIN; RAT-BRAIN	Alzheimer's disease ( AD) is characterized by progressive neurodegeneration leading to loss of cognitive abilities and ultimately to death. Postmortem investigations revealed decreased expression of cerebral insulin-like growth factor (IGF)-1 receptor (IGF-1R) and insulin receptor substrate (IRS) proteins in patients with AD. To elucidate the role of insulin/IGF-1 signaling in AD, we crossed mice expressing the Swedish mutation of amyloid precursor protein (APP(SW), Tg2576 mice) as a model for AD with mice deficient for either IRS-2, neuronal IGF-1R (nIGF-1R(-/-)), or neuronal insulin receptor (nIR(-/-)), and analyzed survival, glucose, and APP metabolism. In the present study, we show that IRS-2 deficiency in Tg2576 mice completely reverses premature mortality in Tg2576 females and delays beta-amyloid (A beta) accumulation. Analysis of APP metabolism suggested that delayed A beta accumulation resulted from decreased APP processing. To delineate the upstream signal responsible for IRS-2-mediated disease protection, we analyzed mice with nIGF-1R or nIR deficiency predominantly in the hippocampus. Interestingly, both male and female nIGF1R(-/-) Tg2576 mice were protected from premature death in the presence of decreased A beta accumulation specifically in the hippocampus formation. However, neuronal IR deletion had no influence on lethality of Tg2576 mice. Thus, impaired IGF-1/IRS-2 signaling prevents premature death and delays amyloid accumulation in amodel of AD.-Freude, S., Hettich, M. M., Schumann, C., Stohr, O., Koch, L., Kohler, C., Udelhoven, M., Leeser, U., Muller, M., Kubota, N., Kadowaki, T., Krone, W., Schroder, H., Bruning, J. C., Schubert, M. Neuronal IGF-1 resistance reduces A beta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J. 23, 3315-3324 ( 2009). www.fasebj.org	[Freude, Susanna; Hettich, Moritz M.; Schumann, Christina; Stoehr, Oliver; Udelhoven, Michael; Leeser, Uschi; Mueller, Marita; Krone, Wilhelm; Bruening, Jens C.; Schubert, Markus] Univ Cologne, Dept Internal Med 2, D-50937 Cologne, Germany; [Freude, Susanna; Hettich, Moritz M.; Schumann, Christina; Stoehr, Oliver; Koch, Linda; Udelhoven, Michael; Leeser, Uschi; Mueller, Marita; Krone, Wilhelm; Bruening, Jens C.; Schubert, Markus] Univ Cologne, Ctr Mol Med Cologne, D-50937 Cologne, Germany; [Freude, Susanna; Hettich, Moritz M.; Stoehr, Oliver; Koch, Linda; Udelhoven, Michael; Leeser, Uschi; Mueller, Marita; Krone, Wilhelm; Bruening, Jens C.; Schubert, Markus] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, D-50937 Cologne, Germany; [Koch, Linda; Bruening, Jens C.] Univ Cologne, Inst Genet, Dept Mouse Genet & Metab, D-50937 Cologne, Germany; [Koehler, Christoph; Schroeder, Hannsjoerg] Univ Cologne, Dept Anat 2, D-50937 Cologne, Germany; [Kubota, Naoto; Kadowaki, Takashi] Univ Tokyo, Grad Sch Med, Dept Metab Dis, Tokyo, Japan; [Bruening, Jens C.] Max Planck Inst Biol Ageing, Cologne, Germany	University of Cologne; University of Cologne; University of Cologne; University of Cologne; University of Cologne; University of Tokyo; Max Planck Society	Schubert, M (corresponding author), Univ Cologne, Dept Internal Med 2, Kerpener Str 62,LFI 4-061, D-50937 Cologne, Germany.	markus.schubert@uni-koeln.de	Kubota, Naoto/N-7892-2015; Schubert, Markus/F-5150-2010	Koch, Linda/0000-0002-2943-1993	Fritz-Thyssen Foundation [10.06.2.209]; Alzheimer Forschungs-Initiative [08813]; Deutsche Forschungsgemeinschaft [Br-1492-7]; Fritz-Thyssen Foundation	Fritz-Thyssen Foundation; Alzheimer Forschungs-Initiative; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Fritz-Thyssen Foundation	This work was supported by the Fritz-Thyssen Foundation (AZ 10.06.2.209) and Alzheimer Forschungs-Initiative e. V. ( 08813) to M. S. and by funds to J.C.B. by the Deutsche Forschungsgemeinschaft (Br-1492-7) and the Fritz-Thyssen Foundation. We gratefully thank Prof. R. Wiesner and Prof. C. Niessen for helpful discussions on the data and the manuscript.	Adlerz L, 2007, J BIOL CHEM, V282, P10203, DOI 10.1074/jbc.M611183200; BASKIN DG, 1986, J NEUROSCI METH, V16, P119, DOI 10.1016/0165-0270(86)90044-0; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Carlson GA, 1997, HUM MOL GENET, V6, P1951, DOI 10.1093/hmg/6.11.1951; Cohen E, 2006, SCIENCE, V313, P1604, DOI 10.1126/science.1124646; Cole AR, 2007, NEUROSCI BIOBEHAV R, V31, P1046, DOI 10.1016/j.neubiorev.2007.04.004; Costantini C, 2006, EMBO J, V25, P1997, DOI 10.1038/sj.emboj.7601062; Cukierman-Yaffe T, 2009, DIABETES CARE, V32, P221, DOI 10.2337/dc08-1153; de la Monte SM, 2006, J ALZHEIMERS DIS, V10, P89; Doria A, 2008, CELL METAB, V8, P186, DOI 10.1016/j.cmet.2008.08.006; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Finch CE, 2001, ANNU REV GENOM HUM G, V2, P435, DOI 10.1146/annurev.genom.2.1.435; Frolich L, 1999, ANN NY ACAD SCI, V893, P290, DOI 10.1111/j.1749-6632.1999.tb07839.x; Frolich L, 1998, J NEURAL TRANSM, V105, P423, DOI 10.1007/s007020050068; Haan MN, 2006, NAT CLIN PRACT NEURO, V2, P159, DOI 10.1038/ncpneuro0124; HILL JM, 1986, NEUROSCIENCE, V17, P1127, DOI 10.1016/0306-4522(86)90082-5; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kappeler L, 2008, PLOS BIOL, V6, P2144, DOI 10.1371/journal.pbio.0060254; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lovestone S, 1999, NEUROLOGY, V53, P1907, DOI 10.1212/WNL.53.9.1907; Luchsinger JA, 2004, NEUROLOGY, V63, P1187, DOI 10.1212/01.WNL.0000140292.04932.87; Matsubara E, 2003, J NEUROCHEM, V85, P1101, DOI 10.1046/j.1471-4159.2003.01654.x; McConlogue L, 2007, J BIOL CHEM, V282, P26326, DOI 10.1074/jbc.M611687200; Meilandt WJ, 2009, J NEUROSCI, V29, P1977, DOI 10.1523/JNEUROSCI.2984-08.2009; Moloney AM, 2010, NEUROBIOL AGING, V31, P224, DOI 10.1016/j.neurobiolaging.2008.04.002; Nathan C, 2005, J EXP MED, V202, P1163, DOI 10.1084/jem.20051529; Niedernhofer LJ, 2006, NATURE, V444, P1038, DOI 10.1038/nature05456; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Pitcher H, 2006, LANCET NEUROL, V5, P388, DOI 10.1016/S1474-4422(06)70434-3; Puglielli L, 2003, J BIOL CHEM, V278, P19777, DOI 10.1074/jbc.M300466200; Puglielli L, 2008, NEUROBIOL AGING, V29, P795, DOI 10.1016/j.neurobiolaging.2007.01.010; Reger MA, 2008, NEUROLOGY, V70, P440, DOI 10.1212/01.WNL.0000265401.62434.36; Rivera EJ, 2005, J ALZHEIMERS DIS, V8, P247; Ronnemaa E, 2008, NEUROLOGY, V71, P1065, DOI 10.1212/01.wnl.0000310646.32212.3a; Schulingkamp RJ, 2000, NEUROSCI BIOBEHAV R, V24, P855, DOI 10.1016/S0149-7634(00)00040-3; Seibler J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng012; Selman C, 2008, FASEB J, V22, P807, DOI 10.1096/fj.07-9261com; Stachelscheid H, 2008, EMBO J, V27, P2091, DOI 10.1038/emboj.2008.141; Steen E, 2005, J ALZHEIMERS DIS, V7, P63, DOI 10.3233/jad-2005-7107; Stein TD, 2002, J NEUROSCI, V22, P7380; Stewart R, 1999, DIABETIC MED, V16, P93, DOI 10.1046/j.1464-5491.1999.00027.x; Taguchi A, 2007, SCIENCE, V317, P369, DOI 10.1126/science.1142179; Tschanz JT, 2004, NEUROLOGY, V62, P1156, DOI 10.1212/01.WNL.0000118210.12660.C2; UNGER J, 1989, NEUROSCIENCE, V31, P143, DOI 10.1016/0306-4522(89)90036-5; Van Houten M, 1983, Adv Metab Disord, V10, P269; VANHOUTEN M, 1979, NATURE, V282, P623, DOI 10.1038/282623a0; Vardy ERLC, 2007, J ALZHEIMERS DIS, V12, P285; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WADSWORTH WG, 1989, DEV BIOL, V132, P167, DOI 10.1016/0012-1606(89)90214-5; WERTHER GA, 1987, ENDOCRINOLOGY, V121, P1562, DOI 10.1210/endo-121-4-1562; WHITMER RA, 2006, ALZHEIMERS DEMENT, V2, pS149; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; Zhao LX, 2004, J NEUROSCI, V24, P11120, DOI 10.1523/JNEUROSCI.2860-04.2004	61	158	162	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3315	3324		10.1096/fj.09-132043	http://dx.doi.org/10.1096/fj.09-132043			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19487308				2022-12-28	WOS:000270354300009
J	Reytor, E; Perez-Miguelsanz, J; Alvarez, L; Perez-Sala, D; Pajares, MA				Reytor, Edel; Perez-Miguelsanz, Juliana; Alvarez, Luis; Perez-Sala, Dolores; Pajares, Maria A.			Conformational signals in the C-terminal domain of methionine adenosyltransferase I/III determine its nucleocytoplasmic distribution	FASEB JOURNAL			English	Article						S-adenosylmethionine synthetase; epigenetic modifications; structural determinants of localization; tissular expression; nuclear methylation	S-ADENOSYLMETHIONINE SYNTHETASE; NUCLEAR-LOCALIZATION SIGNAL; RAT-LIVER; DIFFERENTIAL EXPRESSION; BINDING-SITE; DNA-BINDING; CELLS; ADENOSYLHOMOCYSTEINE; IDENTIFICATION; IMPORTIN	The methyl donor S-adenosylmethionine is synthesized in mammalian cytosol by three isoenzymes. Methionine adenosyltransferase II is ubiquitously expressed, whereas isoenzymes I (homotetramer) and III ( homodimer) are considered the hepatic enzymes. In this work, we identified methionine adenosyltransferase I/III in most rat tissues, both in the cytoplasm and the nucleus. Nuclear localization was the preferred distribution observed in extrahepatic tissues, where the protein colocalizes with nuclear matrix markers. A battery of mutants used in several cell lines to decipher the determinants involved in methionine adenosyltransferase subcellular localization demonstrated, by confocal microscopy and subcellular fractionation, the presence of two partially overlapping areas at the C-terminal end of the protein involved both in cytoplasmic retention and nuclear localization. Immunoprecipitation of coexpressed FLAG and EGFP fusions and gel-filtration chromatography allowed detection of tetramers and monomers in nuclear fractions that also exhibited S-adenosylmethionine synthesis. Neither nuclear localization nor matrix binding required activity, as demonstrated with the inactive F251D mutant. Nuclear accumulation of the active enzyme only correlated with histone H3K27 trimethylation among the epigenetic modifications evaluated, therefore pointing to the necessity of methionine adenosyltransferase I/III to guarantee the supply of S-adenosylmethionine for specific methylations. However, nuclear monomers may exhibit additional roles.-Reytor, E., Perez-Miguelsanz, J., Alvarez, L., Perez-Sala, D., Pajares, M. A. Conformational signals in the C-terminal domain of methionine adenosyltransferase I/III determine its nucleocytoplasmic distribution. FASEB J. 23, 3347-3360 ( 2009). www.fasebj.org	[Reytor, Edel; Pajares, Maria A.] UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; [Perez-Miguelsanz, Juliana] Univ Complutense Madrid, Dept Anat & Embriol Humana 1, Madrid, Spain; [Alvarez, Luis] Hosp Univ La Paz, Unidad Invest, Madrid, Spain; [Perez-Sala, Dolores] CSIC, Ctr Invest Biol, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Complutense University of Madrid; Hospital Universitario La Paz; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Pajares, MA (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	mapajares@iib.uam.es	Perez-Sala, Dolores/L-5969-2014; Pérez-Miguelsanz, María Juliana/H-1038-2017; Pajares, Maria Angeles/I-5952-2012	Perez-Sala, Dolores/0000-0003-0600-665X; Pajares, Maria Angeles/0000-0002-4714-9051; Perez-Miguelsanz, Juliana/0000-0001-8926-5248	Red de Centros de Metabolismo y Nutricion (RCMN) [C03/08, PI05/0563]; Consejo Superior de Investigaciones Cientificas (CSIC); Ministerio de Educacion y Ciencia [BMC2002-0243, BFU2005-00050, SAF2006-03489]; Instituto de Salud Carlos III [RCMN C03/08, RD07/0064/0007]	Red de Centros de Metabolismo y Nutricion (RCMN); Consejo Superior de Investigaciones Cientificas (CSIC); Ministerio de Educacion y Ciencia(Spanish Government); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission)	E. R. was a fellow of Red de Centros de Metabolismo y Nutricion (RCMN) C03/08, PI05/0563, and the I3P Program of the Consejo Superior de Investigaciones Cientificas (CSIC). The authors thank Dr. E. Sanchez-Gongora and Dr. C. D. Perez Ortega for preliminary experiments, Dr. Yuri Lazebnik ( Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA) for providing the multiple EGFP vectors, Dr. Juan E. Feliu ( Hospital Vall d'Hebron, Barcelona, Spain) for primary hepatocyte preparations, Dr. G. Varela-Moreiras and T. Partearroyo for their help in DNA methylation assays, and Dr. J. P. Garcia Ruiz for critical reading of the manuscript. This work was supported by grants of the Ministerio de Educacion y Ciencia (BMC2002-0243 and BFU2005-00050 to M. A. P.; SAF2006-03489 to D. P. S.) and the Instituto de Salud Carlos III ( RCMN C03/08 to M. A. P.; RD07/0064/0007 to D. P. S.).	ALVAREZ L, 1994, BIOCHEM J, V301, P557, DOI 10.1042/bj3010557; ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Avila MA, 1997, HEPATOLOGY, V25, P391; Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337; Cai JX, 1998, CANCER RES, V58, P1444; Cai JX, 1996, HEPATOLOGY, V24, P1090; Cansizoglu AE, 2007, NAT STRUCT MOL BIOL, V14, P452, DOI 10.1038/nsmb1229; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Chamberlin ME, 1996, J CLIN INVEST, V98, P1021, DOI 10.1172/JCI118862; Chen MH, 2005, J BIOL CHEM, V280, P10599, DOI 10.1074/jbc.M413194200; Cheng H, 1997, EXP NEUROL, V145, P580, DOI 10.1006/exnr.1997.6466; CHIANG PK, 1977, J BIOL CHEM, V252, P4506; CHRISTMAN JK, 1980, J CELL BIOL, V86, P366, DOI 10.1083/jcb.86.2.366; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; CORRALES F, 1991, HEPATOLOGY, V14, P528, DOI 10.1002/hep.1840140320; CORRALES F, 1992, HEPATOLOGY, V16, P1022, DOI 10.1002/hep.1840160427; Delgado M, 2008, CELL MOL LIFE SCI, V65, P2080, DOI 10.1007/s00018-008-8201-4; Dolnick BJ, 2003, CANCER BIOL THER, V2, P364, DOI 10.4161/cbt.2.4.424; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; FELIU JE, 1976, P NATL ACAD SCI USA, V73, P2762, DOI 10.1073/pnas.73.8.2762; Fontecave M, 2001, CURR OPIN CHEM BIOL, V5, P506, DOI 10.1016/S1367-5931(00)00237-4; Frago LM, 1998, FEBS LETT, V426, P305, DOI 10.1016/S0014-5793(98)00360-3; Friedrich B, 2006, MOL CELL BIOL, V26, P8697, DOI 10.1128/MCB.00708-06; Gil B, 1997, ENDOCRINOLOGY, V138, P1251, DOI 10.1210/en.138.3.1251; Gil B, 1996, HEPATOLOGY, V24, P876; Gonzalez B, 2000, J MOL BIOL, V300, P363, DOI 10.1006/jmbi.2000.3858; Graham DE, 2000, J BIOL CHEM, V275, P4055, DOI 10.1074/jbc.275.6.4055; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Horne DW, 1997, ARCH BIOCHEM BIOPHYS, V343, P201, DOI 10.1006/abbi.1997.0167; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Jungermann K, 1996, ANNU REV NUTR, V16, P179, DOI 10.1146/annurev.nu.16.070196.001143; Kahle J, 2005, MOL CELL BIOL, V25, P5339, DOI 10.1128/MCB.25.13.5339-5354.2005; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; Kramer A, 2007, J BIOL CHEM, V282, P31437, DOI 10.1074/jbc.M703720200; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Lu KK, 2003, FASEB J, V17, pA56, DOI 10.1096/fj.01-0752fje; Lu SC, 2000, AM J PHYSIOL-GASTR L, V279, pG178, DOI 10.1152/ajpgi.2000.279.1.G178; Lu SC, 2001, P NATL ACAD SCI USA, V98, P5560, DOI 10.1073/pnas.091016398; Majerciak V, 2006, J BIOL CHEM, V281, P28365, DOI 10.1074/jbc.M603095200; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; Mingorance J, 1996, BIOCHEM J, V315, P761, DOI 10.1042/bj3150761; PAJARES MA, 1994, BIOCHEM J, V303, P949, DOI 10.1042/bj3030949; Polizotto RS, 2001, J CELL BIOL, V154, P951, DOI 10.1083/jcb.200104078; Radomski N, 1999, MOL BIOL CELL, V10, P4283, DOI 10.1091/mbc.10.12.4283; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rodriguez M, 2006, J MOL BIOL, V360, P548, DOI 10.1016/j.jmb.2006.05.048; Sanchez-Perez GF, 2004, J MOL BIOL, V335, P693, DOI 10.1016/j.jmb.2003.11.022; Sanchez-Perez GF, 2003, J BIOL CHEM, V278, P7285, DOI 10.1074/jbc.M210177200; SanchezGongora E, 1996, BIOCHEM J, V319, P767, DOI 10.1042/bj3190767; Sessler RJ, 2005, MOL CELL, V18, P343, DOI 10.1016/j.molcel.2005.03.026; SHIVAPURKAR N, 1983, CARCINOGENESIS, V4, P1051, DOI 10.1093/carcin/4.8.1051; Turpin P, 1999, FEBS LETT, V452, P82, DOI 10.1016/S0014-5793(99)00533-5; Van Lanen SG, 2003, J BIOL CHEM, V278, P10491, DOI 10.1074/jbc.M207727200; Zhou WY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003390; ZhuO J, 2005, J BIOL CHEM, V280, P16038, DOI 10.1074/jbc.M500054200	59	62	63	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3347	3360		10.1096/fj.09-130187	http://dx.doi.org/10.1096/fj.09-130187			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19497982	Green Submitted			2022-12-28	WOS:000270354300012
J	Salmon, AB; Perez, VI; Bokov, A; Jernigan, A; Kim, G; Zhao, H; Levine, RL; Richardson, A				Salmon, Adam B.; Perez, Viviana I.; Bokov, Alex; Jernigan, Amanda; Kim, Geumsoo; Zhao, Hang; Levine, Rodney L.; Richardson, Arlan			Lack of methionine sulfoxide reductase A in mice increases sensitivity to oxidative stress but does not diminish life span	FASEB JOURNAL			English	Article						longevity; free radical; stress resistance; aging; antioxidant	FIBROBLAST CELL-LINES; ANTIOXIDANT ENZYMES; MULTIPLE FORMS; KNOCKOUT MOUSE; DWARF MICE; RESISTANCE; MSRA; DAMAGE; GENE; OVEREXPRESSION	Methionine sulfoxide reductase A (MsrA) repairs oxidized methionine residues within proteins and may also function as a general antioxidant. Previous reports have suggested that modulation of MsrA in mice and mammalian cell culture can affect the accumulation of oxidized proteins and may regulate resistance to oxidative stress. Thus, under the oxidative stress theory of aging, these results would predict that MsrA regulates the aging process in mammals. We show here that MsrA(-/-) mice are more susceptible to oxidative stress induced by paraquat. Skin-derived fibroblasts do not express MsrA, but fibroblasts cultured from MsrA(-/-) mice were, nevertheless, also more susceptible to killing by various oxidative stresses. In contrast to previous reports, we find no evidence for neuromuscular dysfunction in MsrA(-/-) mice in either young adult or in older animals. Most important, we found no difference between MsrA(-/-) and control mice in either their median or maximum life span. Thus, our results show that MsrA regulates sensitivity to oxidative stress in mice but has no effect on aging, as determined by life span.-Salmon, A. B., Perez, V. I., Bokov, A., Jernigan, A., Kim, G., Zhao, H., Levine, R. L., Richardson, A. Lack of methionine sulfoxide reductase A in mice increases sensitivity to oxidative stress but does not diminish life span. FASEB J. 23, 3601-3608 (2009). www.fasebj.org	[Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA; [Kim, Geumsoo; Zhao, Hang; Levine, Rodney L.] NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; [Richardson, Arlan] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Richardson, A (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA.	richardsona@uthscsa.edu	Levine, Rodney L/D-9885-2011; Zhao, Hang/A-2558-2012		National Institutes of Health (NIH) [T32 AG021890-05, R37AG026557]; San Antonio Nathan Shock Center for Excellence in the Basic Biology of Aging; National Heart, Lung, and Blood Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG026557, T32AG021890] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); San Antonio Nathan Shock Center for Excellence in the Basic Biology of Aging; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Jay Cox, Marian Sabia, and Quy Fung for assistance in animal care. We also thank Dr. James Harper for statistical analysis assistance and intellectual discourse. This study was supported by National Institutes of Health (NIH) training grant T32 AG021890-05 (A. B. S.), NIH MERIT grant R37AG026557 (A. R.), the San Antonio Nathan Shock Center for Excellence in the Basic Biology of Aging (A.R.), and the Intramural Research Program of the National Heart, Lung, and Blood Institute (G.K., H.Z., and R.L.L.).	Bokov A, 2004, MECH AGEING DEV, V125, P811, DOI 10.1016/j.mad.2004.07.009; BUS JS, 1976, TOXICOL APPL PHARM, V35, P501, DOI 10.1016/0041-008X(76)90073-9; Cocheme HM, 2008, J BIOL CHEM, V283, P1786, DOI 10.1074/jbc.M708597200; Erickson JR, 2008, CELL, V133, P462, DOI 10.1016/j.cell.2008.02.048; Fomenko DE, 2009, J BIOL CHEM, V284, P5986, DOI 10.1074/jbc.M805770200; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Harper JM, 2007, AGING CELL, V6, P1, DOI 10.1111/j.1474-9726.2006.00255.x; Harper JM, 2006, MECH AGEING DEV, V127, P687, DOI 10.1016/j.mad.2006.04.002; Hauck SJ, 2002, HORM METAB RES, V34, P481, DOI 10.1055/s-2002-34787; Kantorow M, 2004, P NATL ACAD SCI USA, V101, P9654, DOI 10.1073/pnas.0403532101; Khor HK, 2004, J BIOL CHEM, V279, P19486, DOI 10.1074/jbc.M310045200; Koc A, 2004, P NATL ACAD SCI USA, V101, P7999, DOI 10.1073/pnas.0307929101; Lee JW, 2006, EXP EYE RES, V82, P816, DOI 10.1016/j.exer.2005.10.003; Leiser SF, 2006, MECH AGEING DEV, V127, P821, DOI 10.1016/j.mad.2006.08.003; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Luo S, 2009, FASEB J, V23, P464, DOI 10.1096/fj.08-118414; Marchetti MA, 2006, EXP EYE RES, V83, P1281, DOI 10.1016/j.exer.2006.07.005; Miskin R, 1997, J GERONTOL A-BIOL, V52, pB118, DOI 10.1093/gerona/52A.2.B118; Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; MOSKOVITZ J, 1995, J BACTERIOL, V177, P502, DOI 10.1128/jb.177.3.502-507.1995; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; Murakami S, 2003, FASEB J, V17, P1565, DOI 10.1096/fj.02-1092fje; Oien DB, 2008, FREE RADICAL BIO MED, V45, P193, DOI 10.1016/j.freeradbiomed.2008.04.003; Pal R, 2007, EXP BRAIN RES, V180, P765, DOI 10.1007/s00221-007-0903-6; Perez VI, 2009, AGING CELL, V8, P73, DOI 10.1111/j.1474-9726.2008.00449.x; Picot CR, 2005, FREE RADICAL BIO MED, V39, P1332, DOI 10.1016/j.freeradbiomed.2005.06.017; Pletcher SD, 2000, J GERONTOL A-BIOL, V55, pB381, DOI 10.1093/gerona/55.8.B381; Prentice HM, 2008, BIOCHEM BIOPH RES CO, V366, P775, DOI 10.1016/j.bbrc.2007.12.043; Priest NK, 2002, EVOLUTION, V56, P927, DOI 10.1111/j.0014-3820.2002.tb01405.x; Ran Q, 2007, J GERONTOL A-BIOL, V62, P932, DOI 10.1093/gerona/62.9.932; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199; Salmon AB, 2005, AM J PHYSIOL-ENDOC M, V289, pE23, DOI 10.1152/ajpendo.00575.2004; Salmon AB, 2008, J GERONTOL A-BIOL, V63, P232, DOI 10.1093/gerona/63.3.232; Shahbazian MD, 2002, NEURON, V35, P243, DOI 10.1016/S0896-6273(02)00768-7; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Stadtman ER, 2005, BBA-PROTEINS PROTEOM, V1703, P135, DOI 10.1016/j.bbapap.2004.08.010; Stadtman ER, 2002, MOL CELL BIOCHEM, V234, P3, DOI 10.1023/A:1015916831583; Tirosh O, 2005, MECH AGEING DEV, V126, P1262, DOI 10.1016/j.mad.2005.07.003; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Wang CX, 2004, MECH AGEING DEV, V125, P629, DOI 10.1016/j.mad.2004.07.003; YUAN R, 2008, LONGITUDINAL ANAL LI	44	103	104	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3601	3608		10.1096/fj.08-127415	http://dx.doi.org/10.1096/fj.08-127415			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19487311	Green Published			2022-12-28	WOS:000270354300036
J	Jung-Hynes, B; Ahmad, N				Jung-Hynes, Brittney; Ahmad, Nihal			SIRT1 controls circadian clock circuitry and promotes cell survival: a connection with age-related neoplasms	FASEB JOURNAL			English	Article						sirtuins; melatonin; cancer; HDACs	GENE-EXPRESSION; CANCER; MELATONIN; GROWTH; SUPPRESSION; DEACETYLASE; PATHWAYS; TRANSCRIPTION; MECHANISMS; RESISTANCE	Aging is believed to be a primary risk factor for cancer. Interestingly, the sirtuin family of class III histone deacetylases (HDACs) has been implicated in the regulation of longevity and may be a lost link between aging and cancer. SIRT1, a nicotinamide adenine dinucleotide (NAD(+))-dependent sirtuin, has been shown to promote cell survival by inhibiting apoptosis or cellular senescence in mammalian cells. Recent studies have provided a link between the cellular metabolic function of SIRT1 and the circadian rhythm (controlled by a clock machinery), which, if deregulated, may lead to an increased risk for some cancers. Interestingly, the loss of the pineal hormone melatonin, a known regulator of circadian rhythm, has been shown to cause deregulation in the circadian rhythm machinery and an increase in susceptibility to cancer. On the basis of scientific evidence, we propose a hypothesis that SIRT1 inhibition will impart an anti-proliferative response in age-related cancers via resynchronization of deregulated core clock circuitry at the cellular level. If this hypothesis is found valid, it may ultimately lead to the development of novel approaches toward management of age-related malignancies and possibly other diseases.-Jung-Hynes, B., Ahmad, N. SIRT1 controls circadian clock circuitry and promotes cell survival: a connection with age-related neoplasms. FASEB J. 23, 2803-2809 (2009). www.fasebj.org	[Jung-Hynes, Brittney; Ahmad, Nihal] Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA; [Jung-Hynes, Brittney; Ahmad, Nihal] Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53706 USA; [Ahmad, Nihal] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ahmad, N (corresponding author), Univ Wisconsin, Dept Dermatol, 1300 Univ Ave,MSC 423, Madison, WI 53706 USA.	nahmad@wisc.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887	NIEHS NIH HHS [T32ES00715-30] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Asher G, 2008, CELL, V134, P317, DOI 10.1016/j.cell.2008.06.050; Balducci L, 2005, NAT REV CANCER, V5, P655, DOI 10.1038/nrc1675; Balducci Lodovico, 2005, J Oncol Manag, V14, P47; Belden WJ, 2008, CELL, V134, P212, DOI 10.1016/j.cell.2008.07.010; Blask David E., 2002, Current Topics in Medicinal Chemistry, V2, P113, DOI 10.2174/1568026023394407; Carreca I, 2005, CANCER TREAT REV, V31, P380, DOI 10.1016/j.ctrv.2005.04.012; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chu F, 2005, CANCER RES, V65, P10183, DOI 10.1158/0008-5472.CAN-05-2002; Dai Y, 2007, MOL ENDOCRINOL, V21, P1807, DOI 10.1210/me.2006-0467; Doi M, 2006, CELL, V125, P497, DOI 10.1016/j.cell.2006.03.033; Ershler William B, 2003, J Support Oncol, V1, P5; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Fraga MF, 2007, ANN NY ACAD SCI, V1100, P60, DOI 10.1196/annals.1395.005; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Gutierrez-Cuesta J, 2008, J PINEAL RES, V45, P497, DOI 10.1111/j.1600-079X.2008.00626.x; Hunt T, 2007, CELL, V129, P461, DOI 10.1016/j.cell.2007.04.015; Imbesi M, 2009, J PINEAL RES, V46, P87, DOI 10.1111/j.1600-079X.2008.00634.x; Jung B, 2006, CANCER RES, V66, P9789, DOI 10.1158/0008-5472.CAN-06-1776; Jung-Hynes B, 2009, J BIOL CHEM, V284, P3823, DOI 10.1074/jbc.M807869200; Jung-Hynes B, 2009, CELL CYCLE, V8, P1478, DOI 10.4161/cc.8.10.8408; Karasek M, 2007, J PHYSIOL PHARMACOL, V58, P105; Kim EJ, 2007, MOL CELL, V28, P277, DOI 10.1016/j.molcel.2007.08.030; Kojima K, 2008, BIOCHEM BIOPH RES CO, V373, P423, DOI 10.1016/j.bbrc.2008.06.045; Kondratov RV, 2007, COLD SPRING HARB SYM, V72, P477, DOI 10.1101/sqb.2007.72.050; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Longo VD, 2006, CELL, V126, P257, DOI 10.1016/j.cell.2006.07.002; Marmorstein R, 2004, BIOCHEM SOC T, V32, P904, DOI 10.1042/BST0320904; Miller BH, 2007, P NATL ACAD SCI USA, V104, P3342, DOI 10.1073/pnas.0611724104; Murakami S, 1996, GENETICS, V143, P1207; Nakahata Y, 2008, CELL, V134, P329, DOI 10.1016/j.cell.2008.07.002; Nakahata Y, 2009, SCIENCE, V324, P654, DOI 10.1126/science.1170803; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Porcu M, 2005, TRENDS PHARMACOL SCI, V26, P94, DOI 10.1016/j.tips.2004.12.009; Ramsey KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641; Reiter Russel J., 2007, Critical Reviews in Oncogenesis, V13, P303; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; Rouyer F, 1997, EMBO J, V16, P3944, DOI 10.1093/emboj/16.13.3944; Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006; Srinivasan V, 2008, INTEGR CANCER THER, V7, P189, DOI 10.1177/1534735408322846; Taylor DM, 2008, CELL MOL LIFE SCI, V65, P4000, DOI 10.1007/s00018-008-8357-y; Torres-Farfan C, 2006, ENDOCRINOLOGY, V147, P4618, DOI 10.1210/en.2006-0628; Torres-Farfan C, 2006, J PINEAL RES, V40, P64, DOI 10.1111/j.1600-079X.2005.00279.x; Vanfleteren JR, 1999, NEUROBIOL AGING, V20, P487, DOI 10.1016/S0197-4580(99)00087-1; Wang C, 2005, J PHARMACOL SCI, V97, P494, DOI 10.1254/jphs.FPJ04055X; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wood PA, 2008, MOL CANCER RES, V6, P1786, DOI 10.1158/1541-7786.MCR-08-0196; Yang XM, 2009, J BIOCHEM, V145, P289, DOI 10.1093/jb/mvn167; You SJ, 2005, BREAST CANCER RES TR, V91, P47, DOI 10.1007/s10549-004-6603-z; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118; Zheng X, 2007, P NATL ACAD SCI USA, V104, P15899, DOI 10.1073/pnas.0701599104	53	41	42	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2803	2809		10.1096/fj.09-129148	http://dx.doi.org/10.1096/fj.09-129148			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19439501	Green Published			2022-12-28	WOS:000270241000003
J	Moreau, A; Hill, M; Thebault, P; Deschamps, JY; Chiffoleau, E; Chauveau, C; Moullier, P; Anegon, I; Alliot-Licht, B; Cuturi, MC				Moreau, A.; Hill, M.; Thebault, P.; Deschamps, J. Y.; Chiffoleau, E.; Chauveau, C.; Moullier, P.; Anegon, I.; Alliot-Licht, B.; Cuturi, M. C.			Tolerogenic dendritic cells actively inhibit T cells through heme oxygenase-1 in rodents and in nonhuman primates	FASEB JOURNAL			English	Article						immune tolerance; cell therapy; macaque	ANTIGEN-PRESENTING CELLS; ALLOGRAFT SURVIVAL; TOLERANCE; MONOXIDE; MATURATION; IMMATURE; PROLIFERATION; EXPRESSION; TRANSPLANTATION; SUPPRESSION	Clinical translation of dendritic cell (DC)-based cell therapy requires preclinical studies in nonhuman primates (NHPs). The aim of this work was to establish the in vitro conditions for generation of NHP tolerogenic DCs (Tol-DCs), as well as to analyze the molecular mechanisms by which these cells could control an immune response. Two populations of NHP bone marrow-derived DCs (BMDCs) were obtained: adherent and nonadherent. Although both populations displayed a quite similar phenotype, they were very different functionally. We characterized the adherent BMDCs as Tol-DCs that were poor stimulators of T cells and actively inhibited T-cell proliferation, whereas the nonadherent population displayed immunogenic properties in vitro. Interestingly, the anti-inflammatory and immunosuppressive enzyme heme oxygenase-1 (HO-1) was up-regulated in Tol-DCs, compared to the immunogenic BMDCs. We demonstrated that HO-1 mediates the immunosuppressive properties of Tol-DCs in vitro ( in NHPs and rats) and that HO-1 is involved in the in vivo tolerogenic effect of Tol-DCs in a rat model of allotransplantation. In conclusion, here we characterized the in vitro generation of NHP Tol-DCs. Furthermore, we showed for the first time that HO-1 plays a role in the active inhibition of T-cell responses by rat and NHP Tol-DCs.-Moreau, A., Hill, M., Thebault, P., Deschamps, J. Y., Chiffoleau, E., Chauveau, C., Moullier, P., Anegon, I., Alliot-Licht, B., Cuturi M. C. Tolerogenic dendritic cells actively inhibit T cells through heme oxygenase-1 in rodents and in nonhuman primates. FASEB J. 23, 3070-3077 ( 2009). www.fasebj.org	[Hill, M.; Thebault, P.; Chiffoleau, E.; Chauveau, C.; Anegon, I.; Alliot-Licht, B.; Cuturi, M. C.] CHU Hotel Dieu, INSERM, U643, F-44093 Nantes 01, France; [Moreau, A.; Moullier, P.] CHU Hotel Dieu, INSERM, U649, F-44093 Nantes 01, France; [Hill, M.; Thebault, P.; Chiffoleau, E.; Chauveau, C.; Anegon, I.; Alliot-Licht, B.; Cuturi, M. C.] CHU Nantes, Inst Transplantat & Rech Transplantat, F-44035 Nantes 01, France; [Hill, M.; Thebault, P.; Chiffoleau, E.; Chauveau, C.; Anegon, I.; Alliot-Licht, B.; Cuturi, M. C.] Univ Nantes, Fac Med, Nantes, France; [Deschamps, J. Y.] Ecole Natl Vet Nantes, Serv Urgence, Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Nantes Universite; Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique	Cuturi, MC (corresponding author), CHU Hotel Dieu, INSERM, U643, 30 Bd Jean Monnet, F-44093 Nantes 01, France.	maria-cristina.cuturi@univ-nantes.fr	Moreau, Aurelie/J-4139-2017; Anegon, Ignacio/I-7498-2018; Chiffoleau, Elise/N-2982-2018; Anegon, Ignacio/I-7760-2018	Moreau, Aurelie/0000-0002-8519-2632; Chiffoleau, Elise/0000-0001-6167-682X; Hill, Marcelo/0000-0002-1589-0320				Akamatsu Y, 2004, FASEB J, V18, P771, DOI 10.1096/fj.03-0921fje; Beriou G, 2005, TRANSPLANTATION, V79, P969, DOI 10.1097/01.TP.0000158277.50073.35; Braudeau C, 2004, GENE THER, V11, P701, DOI 10.1038/sj.gt.3302208; Chabannes D, 2007, BLOOD, V110, P3691, DOI 10.1182/blood-2007-02-075481; Chauveau C, 2005, BLOOD, V106, P1694, DOI 10.1182/blood-2005-02-0494; Chitta S, 2008, IMMUNOL LETT, V116, P41, DOI 10.1016/j.imlet.2007.11.013; Choi BM, 2005, BIOCHEM BIOPH RES CO, V327, P1066, DOI 10.1016/j.bbrc.2004.12.106; Chora AA, 2007, J CLIN INVEST, V117, P438, DOI 10.1172/JCI28844; George JF, 2008, AM J PATHOL, V173, P154, DOI 10.2353/ajpath.2008.070963; Griffith LM, 2005, BIOL BLOOD MARROW TR, V11, P862, DOI 10.1016/j.bbmt.2005.07.009; Haga Y, 1996, BBA-MOL BASIS DIS, V1317, P65, DOI 10.1016/0925-4439(96)00039-7; Hill M, 2005, FASEB J, V19, P1957, DOI 10.1096/fj.05-3875com; Kapturczak MH, 2004, AM J PATHOL, V165, P1045, DOI 10.1016/S0002-9440(10)63365-2; Kotsch K, 2007, ANTIOXID REDOX SIGN, V9, P2049, DOI 10.1089/ars.2007.1801; Lee DY, 2006, AM J TRANSPLANT, V6, P1820, DOI 10.1111/j.1600-6143.2006.01414.x; Listopad J, 2007, EXP DERMATOL, V16, P661, DOI 10.1111/j.1600-0625.2007.00581.x; Lutz MB, 2000, EUR J IMMUNOL, V30, P1813, DOI 10.1002/1521-4141(200007)30:7<1813::AID-IMMU1813>3.0.CO;2-8; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Mashreghi MF, 2008, J IMMUNOL, V180, P7919, DOI 10.4049/jimmunol.180.12.7919; Moreau A, 2008, TRANSPLANTATION, V85, P1351, DOI 10.1097/TP.0b013e31816f22d6; Morelli AE, 2007, NAT REV IMMUNOL, V7, P610, DOI 10.1038/nri2132; Pae HO, 2004, J IMMUNOL, V172, P4744, DOI 10.4049/jimmunol.172.8.4744; Peche H, 2005, AM J TRANSPLANT, V5, P255, DOI 10.1111/j.1600-6143.2004.00683.x; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; ROSENBERG DW, 1989, PHARMACOLOGY, V39, P224, DOI 10.1159/000138601; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; Song RP, 2004, J IMMUNOL, V172, P1220, DOI 10.4049/jimmunol.172.2.1220; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Taille C, 2004, J BIOL CHEM, V279, P28681, DOI 10.1074/jbc.M310661200; Yamashita K, 2004, FASEB J, V18, P765, DOI 10.1096/fj.03-0839fje; Yamashita K, 2006, FASEB J, V20, P776, DOI 10.1096/fj.05-4791fje; Zelenay S, 2007, INT IMMUNOL, V19, P11, DOI 10.1093/intimm/dxl116	32	74	77	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2009	23	9					3070	3077		10.1096/fj.08-128173	http://dx.doi.org/10.1096/fj.08-128173			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19420134				2022-12-28	WOS:000270241000029
J	Wolf, SA; Steiner, B; Wengner, A; Lipp, M; Kammertoens, T; Kempermann, G				Wolf, Susanne A.; Steiner, Barbara; Wengner, Antje; Lipp, Martin; Kammertoens, Thomas; Kempermann, Gerd			Adaptive peripheral immune response increases proliferation of neural precursor cells in the adult hippocampus	FASEB JOURNAL			English	Article						CD4; glucocorticoids; rheumatoid arthritis	ADJUVANT-INDUCED ARTHRITIS; PITUITARY-ADRENAL AXIS; DENTATE GYRUS; ENVIRONMENTAL ENRICHMENT; PURKINJE NEURONS; RAT HIPPOCAMPUS; CHRONIC INFLAMMATION; NERVOUS-SYSTEM; NEUROGENESIS; STRESS	To understand the link between peripheral immune activation and neuronal precursor biology, we investigated the effect of T-cell activation on adult hippocampal neurogenesis in female C57B1/6 mice. A peripheral adaptive immune response triggered by adjuvant-induced rheumatoid arthritis (2 mu g/mu l methylated BSA) or staphylococcus enterotoxin B (EC50 of 0.25 mu g/ml per 20 g body weight) was associated with a transient increase in hippocampal precursor cell proliferation and neurogenesis as assessed by immunohistochemistry and confocal microscopy. Both treatments were paralleled by an increase in corticosterone levels in the hippocampus 1- to 2-fold over the physiological amount measured by quantitative radioimmunoassay. In contrast, intraperitoneal administration of the innate immune response activator lipopolysaccaride (EC50 of 0.5 mu g/ml per 20 g body weight) led to a chronic 5-fold increase of hippocampal glucocorticoid levels and a decrease of adult neurogenesis. In vitro exposure of murine neuronal progenitor cells to corticosterone triggered either cell death at high (1.5 nM) or proliferation at low ( 0.25 nM) concentrations. This effect could be blocked using a viral vector system expressing a transdomain of the glucocorticoid receptor. We suggest an evolutionary relevant communication route for the brain to respond to environmental stressors like inflammation mediated by glucocorticoid levels in the hippocampus.-Wolf, S. A., Steiner, B., Wengner, A., Lipp, M., Kammertoens, T., Kempermann, G. Adaptive peripheral immune response increases proliferation of neural precursor cells in the adult hippocampus. FASEB J. 23, 3121-3128 (2009). www.fasebj.org	[Wolf, Susanne A.; Steiner, Barbara; Kempermann, Gerd] Max Delbruck Ctr Mol Med, Neuronal Stem Cells Res Grp, Berlin, Germany; [Wengner, Antje; Lipp, Martin] Max Delbruck Ctr Mol Med, Mol Tumor Genet Res Grp, Berlin, Germany; [Kammertoens, Thomas] Max Delbruck Ctr Mol Med, Mol Immunol & Genetherapy Res Grp, Berlin, Germany; [Wolf, Susanne A.] Stanford Univ, Inst Biol Sci, Inst Neurosurg, Stanford, CA 94305 USA; [Steiner, Barbara; Kempermann, Gerd] Charite, Volkswagenstiftung Res Grp, Dept Expt Neurol, Berlin, Germany; [Kammertoens, Thomas] Charite, Inst Immunol, Berlin, Germany; [Steiner, Barbara] Charite, Dept Neurol, D-13353 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Stanford University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Volkswagen; Volkswagen Germany; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kempermann, G (corresponding author), CRTD DFG, Ctr Regenerat Therapies Dresden, Tatzberg 47-49, D-01307 Dresden, Germany.	gerd.kempermann@crt-dresden.de	Wolf, Susanne/A-1907-2011; Kempermann, Gerd/F-5416-2010; Wolf, Susanne/AAA-6598-2022	Kempermann, Gerd/0000-0002-5304-4061; Lipp, Martin/0000-0002-0087-2672; Steiner, Barbara/0000-0003-2106-4532; Wolf, Susanne/0000-0003-0922-8418; Kammertoens, Thomas/0000-0003-3309-5141	VolkswagenStiftung	VolkswagenStiftung(Volkswagen)	thank Ruth Zarmstorff for excellent technical assistance. We thank Ariel Achtmann for help in getting the AIA experiments started and Josef Kohrle for the corticosterone measurements. Many thanks to Robert Sapolsky ( Stanford University, Stanford, CA, USA), for providing us with the vector and essential information on glucocorticoid biology, and to Polly Matzinger, for reading and commenting on the manuscript. This work was supported by VolkswagenStiftung. B. S. is a Rahel Hirsch fellow of the Charite, University Medicine Berlin.	ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Babu H, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000388; Brunson KL, 2005, HIPPOCAMPUS, V15, P491, DOI 10.1002/hipo.20074; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Cameron H, 1996, J COMP NEUROL, V369, P56, DOI 10.1002/(SICI)1096-9861(19960520)369:1<56::AID-CNE4>3.0.CO;2-J; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; COOKE TD, 1972, ARTHRITIS RHEUM, V15, P327, DOI 10.1002/art.1780150402; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; de Kloet ER, 2008, NEUROCHEM RES, V33, P637, DOI 10.1007/s11064-007-9520-9; DEKLOET ER, 1993, J STEROID BIOCHEM, V47, P183; DEKLOET ER, 1988, PROG BRAIN RES, V73, P101; Droste SK, 2003, ENDOCRINOLOGY, V144, P3012, DOI 10.1210/en.2003-0097; Duric V, 2006, J PAIN, V7, P544, DOI 10.1016/j.jpain.2006.01.458; Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Ekstrand J, 2008, NEUROSCI LETT, V442, P203, DOI 10.1016/j.neulet.2008.06.085; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fediuc S, 2006, J APPL PHYSIOL, V100, P1867, DOI 10.1152/japplphysiol.01416.2005; Ferguson D, 2008, HIPPOCAMPUS, V18, P1103, DOI 10.1002/hipo.20467; FLEISCHER B, 1994, APMIS, V102, P3, DOI 10.1111/j.1699-0463.1994.tb04839.x; Garcia A, 2004, AGING CELL, V3, P363, DOI 10.1111/j.1474-9728.2004.00130.x; Gass P, 2000, EMBO REP, V1, P447, DOI 10.1093/embo-reports/kvd088; Gould E, 1999, BIOL PSYCHIAT, V46, P1472, DOI 10.1016/S0006-3223(99)00247-4; Heine VM, 2004, NEUROBIOL AGING, V25, P361, DOI 10.1016/S0197-4580(03)00090-3; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Ho DY, 1997, SCI AM, V276, P116, DOI 10.1038/scientificamerican0697-116; Johansson CB, 2008, NAT CELL BIOL, V10, P575, DOI 10.1038/ncb1720; Kaufer D, 2004, NAT NEUROSCI, V7, P947, DOI 10.1038/nn1296; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 2002, J NEUROSCI, V22, P635, DOI 10.1523/JNEUROSCI.22-03-00635.2002; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Kempermann G, 2008, CURR OPIN PSYCHIATR, V21, P290, DOI 10.1097/YCO.0b013e3282fad375; Kronenberg G, 2003, J COMP NEUROL, V467, P455, DOI 10.1002/cne.10945; Kusnecov AW, 2005, CURR PHARM DESIGN, V11, P1039, DOI 10.2174/1381612053381602; Mirescu C, 2006, HIPPOCAMPUS, V16, P233, DOI 10.1002/hipo.20155; Moncek F, 2004, J NEUROENDOCRINOL, V16, P423, DOI 10.1111/j.1365-2826.2004.01173.x; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Neves G, 2008, NAT REV NEUROSCI, V9, P65, DOI 10.1038/nrn2303; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Reagan LP, 1997, J CHEM NEUROANAT, V13, P149, DOI 10.1016/S0891-0618(97)00031-8; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; SARLIS NJ, 1992, ENDOCRINOLOGY, V130, P1775, DOI 10.1210/en.130.4.1775; SHORS TJ, 1989, SCIENCE, V244, P224, DOI 10.1126/science.2704997; Shurin G, 1997, NEUROENDOCRINOLOGY, V65, P18, DOI 10.1159/000127161; Simon J, 2001, J AUTOIMMUN, V17, P127, DOI 10.1006/jaut.2001.0534; SLOVITER RS, 1989, SCIENCE, V243, P535, DOI 10.1126/science.2911756; Toni N, 2008, NAT NEUROSCI, V11, P901, DOI 10.1038/nn.2156; VAHER P, 1994, ANN NY ACAD SCI, V746, P405; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; VANBEUSEKOM HJ, 1981, SCAND J RHEUMATOL, P37; VANEEKELEN JAM, 1988, J NEUROSCI RES, V21, P88, DOI 10.1002/jnr.490210113; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Windle RJ, 2001, J NEUROENDOCRINOL, V13, P905, DOI 10.1046/j.1365-2826.2001.00715.x; Wiskott L, 2006, HIPPOCAMPUS, V16, P329, DOI 10.1002/hipo.20167; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629; Ziv Y, 2008, BRAIN BEHAV IMMUN, V22, P167, DOI 10.1016/j.bbi.2007.08.006	58	61	63	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3121	3128		10.1096/fj.08-113944	http://dx.doi.org/10.1096/fj.08-113944			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19433626				2022-12-28	WOS:000270241000034
J	Potier, M; Gonzalez, JC; Motiani, RK; Abdullaev, IF; Bisaillon, JM; Singer, HA; Trebak, M				Potier, Marie; Gonzalez, Jose C.; Motiani, Rajender K.; Abdullaev, Iskandar F.; Bisaillon, Jonathan M.; Singer, Harold A.; Trebak, Mohamed			Evidence for STIM1-and Orai1-dependent store-operated calcium influx through I-CRAC in vascular smooth muscle cells: role in proliferation and migration	FASEB JOURNAL			English	Article						Ca2+ release-activated Ca2+ channels; store-operated Ca2+ entry channels; TRPC channels; phenotypic modulation	CAPACITATIVE CA2+ ENTRY; CHANNELS; ACTIVATION; DEPLETION; ORAI1; INHIBITION; CURRENTS; TRPC1; TRANSCRIPTION; POTENTIATION	The identity of store-operated calcium (Ca2+) entry (SOCE) channels in vascular smooth muscle cells (VSMCs) remains a highly contentious issue. Whereas previous studies have suggested that SOCE in VSMCs is mediated by the nonselective transient receptor potential canonical (TRPC) 1 protein, the identification of STIM1 and Orai1 as essential components of I-CRAC, a highly Ca2+-selective SOCE current in leukocytes, has challenged that view. Here we show that cultured proliferative migratory VSMCs isolated from rat aorta (called "synthetic") display SOCE with classic features, namely inhibition by 2-aminoethoxydiphenyl borate, ML-9, and low concentrations of lanthanides. On store depletion, synthetic VSMCs and A7r5 cells display currents with characteristics of I-CRAC. Protein knockdown of either STIM1 or Orai1 in synthetic VSMCs greatly reduced SOCE, whereas Orai2, Orai3, TRPC1, TRPC4, and TRPC6 knockdown had no effect. Orai1 knockdown reduced I-CRAC in synthetic VSMCs and A7r5 cells. Synthetic VSMCs showed up-regulated STIM1/Orai1 proteins and SOCE compared with quiescent freshly isolated VSMC. Knockdown of STIM1 and Orai1 inhibited synthetic VSMC proliferation and migration, whereas STIM2, Orai2, and Orai3 knockdown had no effect. To our knowledge, these results are the first to show I-CRAC in VSMCs and resolve a long-standing controversy by identifying CRAC as the elusive VSMC SOCE channel important for proliferation and migration.-Potier, M., Gonzalez, J. C., Motiani, R. K., Abdullaev, I. F., Bisaillon, J. M., Singer, H. A., and Trebak, M. Evidence for STIM1- and Orai1-dependent store-operated calcium influx through I-CRAC in vascular smooth muscle cells: role in proliferation and migration. FASEB J. 23, 2425-2437 (2009)	[Potier, Marie; Gonzalez, Jose C.; Motiani, Rajender K.; Abdullaev, Iskandar F.; Bisaillon, Jonathan M.; Singer, Harold A.; Trebak, Mohamed] Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA	Albany Medical College	Trebak, M (corresponding author), Albany Med Coll, Ctr Cardiovasc Sci, MC8,47 New Scotland Ave, Albany, NY 12208 USA.	trebakm@mail.amc.edu	Abdullaev, Iskandar/AAH-2478-2021; Potier-Cartereau, marie/AAC-4510-2022; Trebak, Mohamed/E-7405-2014	Potier-Cartereau, marie/0000-0002-1361-3397; Potier, Marie-Claude/0000-0003-2462-7150	NIH [K22ES014729]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092510, R01HL049426, R01HL097111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES014729] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by an NIH early career grant (K22ES014729) to M. T. We gratefully acknowledge Dr. Wayne DeHaven (National Institute of Environmental Health Sciences, NIH) for helpful advice on the patch-clamp recordings and Wendy Hobb for administrative assistance.	Abdullaev IF, 2008, CIRC RES, V103, P1289, DOI 10.1161/01.RES.0000338496.95579.56; Albert AP, 2007, J PHYSIOL-LONDON, V583, P25, DOI 10.1113/jphysiol.2007.137802; Albert AP, 2002, J PHYSIOL-LONDON, V538, P717, DOI 10.1113/jphysiol.2001.013101; Aubart FC, 2009, MOL THER, V17, P455, DOI 10.1038/mt.2008.291; Bakowski D, 2002, CELL CALCIUM, V32, P379, DOI 10.1016/S0143416002001914; Bergdahl A, 2005, AM J PHYSIOL-CELL PH, V288, pC872, DOI 10.1152/ajpcell.00334.2004; Berra-Romani R, 2008, AM J PHYSIOL-CELL PH, V295, pC779, DOI 10.1152/ajpcell.00173.2008; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; Brueggemann LI, 2006, J PHARMACOL EXP THER, V317, P488, DOI 10.1124/jpet.105.095067; Brueggemann LI, 2005, BIOCHEM J, V388, P237, DOI 10.1042/BJ20041360; CASTEELS R, 1981, J PHYSIOL-LONDON, V317, P263, DOI 10.1113/jphysiol.1981.sp013824; Csutora P, 2008, J BIOL CHEM, V283, P14524, DOI 10.1074/jbc.M709575200; DeHaven WI, 2007, J BIOL CHEM, V282, P17548, DOI 10.1074/jbc.M611374200; Dietrich A, 2007, PFLUG ARCH EUR J PHY, V455, P465, DOI 10.1007/s00424-007-0314-3; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Flemming R, 2003, BRIT J PHARMACOL, V139, P955, DOI 10.1038/sj.bjp.0705327; Giachini FRC, 2009, HYPERTENSION, V53, P409, DOI 10.1161/HYPERTENSIONAHA.108.124404; Golovina VA, 2001, AM J PHYSIOL-HEART C, V280, pH746, DOI 10.1152/ajpheart.2001.280.2.H746; Guo RW, 2009, CARDIOVASC RES, V81, P660, DOI 10.1093/cvr/cvn338; Gwack Y, 2007, CELL CALCIUM, V42, P145, DOI 10.1016/j.ceca.2007.03.007; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; House SJ, 2008, PFLUG ARCH EUR J PHY, V456, P769, DOI 10.1007/s00424-008-0491-8; House SJ, 2007, AM J PHYSIOL-CELL PH, V292, pC2276, DOI 10.1152/ajpcell.00606.2006; Kunichika N, 2004, AM J PHYSIOL-LUNG C, V287, pL962, DOI 10.1152/ajplung.00452.2003; Li J, 2008, CIRC RES, V103, pE97, DOI 10.1161/CIRCRESAHA.108.182931; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; McDaniel SS, 2001, AM J PHYSIOL-LUNG C, V280, pL870, DOI 10.1152/ajplung.2001.280.5.L870; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Ng LC, 2001, CIRC RES, V89, P923, DOI 10.1161/hh2201.100315; NILIUS B, 2004, SCI STKE, pPE36; Owens Gary K, 2007, Novartis Found Symp, V283, P174; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peel SE, 2008, AM J RESP CELL MOL, V38, P744, DOI 10.1165/rcmb.2007-0395OC; Peel SE, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-119; Peinelt C, 2008, J PHYSIOL-LONDON, V586, P3061, DOI 10.1113/jphysiol.2008.151365; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Potier M, 2008, PFLUG ARCH EUR J PHY, V457, P405, DOI 10.1007/s00424-008-0533-2; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Smyth JT, 2008, J CELL SCI, V121, P762, DOI 10.1242/jcs.023903; Sweeney M, 2002, AM J PHYSIOL-LUNG C, V283, pL144, DOI 10.1152/ajplung.00412.2001; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Trepakova ES, 2001, J BIOL CHEM, V276, P7782, DOI 10.1074/jbc.M010104200; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Wamhoff BR, 2006, CIRC RES, V98, P868, DOI 10.1161/01.RES.0000216596.73005.3c; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; Zarayskiy V, 2007, CHANNELS, V1, P246, DOI 10.4161/chan.4835; ZARAYSKIY VV, 2008, BIOPHYS J S, V94; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209	52	216	228	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2425	2437		10.1096/fj.09-131128	http://dx.doi.org/10.1096/fj.09-131128			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19364762	Green Published			2022-12-28	WOS:000268836700011
J	Schilling, D; Gehrmann, M; Steinem, C; De Maio, A; Pockley, AG; Abend, M; Molls, M; Multhoff, G				Schilling, Daniela; Gehrmann, Mathias; Steinem, Claudia; De Maio, Antonio; Pockley, Alan G.; Abend, Michael; Molls, Michael; Multhoff, Gabriele			Binding of heat shock protein 70 to extracellular phosphatidylserine promotes killing of normoxic and hypoxic tumor cells	FASEB JOURNAL			English	Article						nonapoptotic tumor cell death; stress proteins; ionizing radiation; cancer therapy	HEAT-SHOCK PROTEINS; NATURAL-KILLER-CELLS; IMMUNE-RESPONSE; MOLECULAR CHAPERONES; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; STRESS-PROTEINS; IN-VITRO; HSP70; CANCER	Hypoxia is well known to limit curability of tumors by ionizing radiation. Here, we show that hypoxia treatment of tumor cells causes coexpression of heat shock protein 70 (Hsp70) and phosphatidylserine ( PS) on the cell surface. Colocalization of Hsp70 and PS, as determined by confocal microscopy, also occurs when exogenous FITC-labeled Hsp70 protein is added to normoxic and hypoxic tumor cells. Moreover, the interaction of Hsp70 with PS was demonstrated in artificial unilamellar phosphatidylcholine/phosphatidylserine (PC/PS) liposomes at the physiological ratio of 8/2. Indeed, the Hsp70-liposome interaction gradually increased with elevating PS molar ratios (8/(2) under bar >= 7/3<5/5<4/6<3/7<(2) under bar /8). In contrast, only a weak Hsp70 interaction was detected in phosphatidylcholine/phosphatidylglycerol (PC/PG) liposomes, thus demonstrating that the interaction was not a charge-related effect. The interaction of Hsp70 with surface PS significantly reduces clonogenic cell survival in normoxic (EC50 of Hsp70 = 85 mu g/ml) and hypoxic (EC50 of Hsp70 = 55 mu g/ml) tumor cells. The radiationinduced tumor cell killing was significantly enhanced by the addition of Hsp70 protein (50 mu g/ml). Since apoptosis was not significantly enhanced in normoxic and hypoxic tumor cells by the addition of Hsp70, we hypothesize that the Hsp70 protein-induced reduction in clonogenic cell survival might be through necrosis rather than apoptosis.-Schilling, D., Gehrmann, M., Steinem, C., De Maio, A., Pockley, A. G., Abend, M., Molls, M., Multhoff, G. Binding of heat shock protein 70 to extracellular phosphatidylserine promotes killing of normoxic and hypoxic tumor cells. FASEB J. 23, 2467-2477 (2009)	[Schilling, Daniela; Gehrmann, Mathias; Molls, Michael; Multhoff, Gabriele] Tech Univ Munich, Klinikum Rechts Isar, Dept Radiat Oncol, D-81675 Munich, Germany; [Schilling, Daniela; Gehrmann, Mathias; Molls, Michael; Multhoff, Gabriele] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Inst Pathol, Munich, Germany; [Steinem, Claudia] Univ Gottingen, Inst Organ & Biomol Chem, Gottingen, Germany; [De Maio, Antonio] Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA; [Pockley, Alan G.] Univ Sheffield, Sch Med & Biomed Sci, Sheffield, S Yorkshire, England; [Abend, Michael] Fed Armed Forces Med Acad, Inst Radiobiol, Munich, Germany	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Gottingen; University of California System; University of California San Diego; University of Sheffield	Multhoff, G (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Radiat Oncol, Ismaningerstr 22, D-81675 Munich, Germany.	gabriele.multhoff@lrz.tu-muenchen.de	Pockley, Alan G/I-4704-2015; Steinem, Claudia/O-4801-2019; Steinem, Claudia/K-7534-2018	Pockley, Alan G/0000-0001-9593-6431; Steinem, Claudia/0000-0001-8778-9283; Multhoff, Gabriele/0000-0002-2616-3137	Deutsche Forschungsgemeinschaft (DFG) [MU1238 7/2]; Bundesministerium fur Forschung und Technologie (BMBF BioChance plus) [0313686A]; European Union [Transnet 512253, Stemdiagnostics LSHB CT 2007 037703, Cardiorisk 211404]; U.S. National Institutes of Health (NIH) [GM 050878]; Multimmune GmbH; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050878] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Bundesministerium fur Forschung und Technologie (BMBF BioChance plus)(Federal Ministry of Education & Research (BMBF)); European Union(European Commission); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Multimmune GmbH; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by grants from the Deutsche Forschungsgemeinschaft (DFG MU1238 7/2 to G. M.), the Bundesministerium fur Forschung und Technologie (BMBF BioChance plus, 0313686A to G. M.), the European Union (Transnet 512253; Stemdiagnostics LSHB CT 2007 037703; Cardiorisk 211404 to G. M.), the U.S. National Institutes of Health (NIH GM 050878 to A. D.), and Multimmune GmbH.	Arispe N, 2004, FASEB J, V18, P1636, DOI 10.1096/fj.04-2088com; Arispe N, 2002, CELL STRESS CHAPERON, V7, P330, DOI 10.1379/1466-1268(2002)007<0330:LIDTCA>2.0.CO;2; Asano K, 2004, J EXP MED, V200, P459, DOI 10.1084/jem.20040342; Asea A, 2001, INT J HYPERTHER, V17, P347, DOI 10.1080/02656730110053146; Barreto A, 2003, CELL IMMUNOL, V222, P97, DOI 10.1016/S0008-8749(03)00115-1; BENJAMIN IJ, 1990, P NATL ACAD SCI USA, V87, P6263, DOI 10.1073/pnas.87.16.6263; Broquet AH, 2003, J BIOL CHEM, V278, P21601, DOI 10.1074/jbc.M302326200; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Camphausen K, 2007, CLIN CANCER RES, V13, P4326, DOI 10.1158/1078-0432.CCR-07-0632; Campisi J, 2003, CELL STRESS CHAPERON, V8, P272, DOI 10.1379/1466-1268(2003)008<0272:SEHIAF>2.0.CO;2; De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382-199901000-00001; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; Fischer K, 2006, BLOOD, V108, P4094, DOI 10.1182/blood-2006-03-011742; Fouchaq B, 1999, EUR J BIOCHEM, V259, P379, DOI 10.1046/j.1432-1327.1999.00053.x; Gehrmann M, 2005, CELL DEATH DIFFER, V12, P38, DOI 10.1038/sj.cdd.4401510; GIACCIA AJ, 1992, INT J RADIAT ONCOL, V23, P891, DOI 10.1016/0360-3016(92)90667-7; GRAY LH, 1953, BRIT J RADIOL, V26, P638, DOI 10.1259/0007-1285-26-312-638; GRENMAN R, 1989, INT J CANCER, V44, P131, DOI 10.1002/ijc.2910440123; Guzhova I, 2001, BRAIN RES, V914, P66, DOI 10.1016/S0006-8993(01)02774-3; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Herrig A, 2006, BIOCHEMISTRY-US, V45, P13025, DOI 10.1021/bi061064a; HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Moseley P, 2000, IMMUNOPHARMACOLOGY, V48, P299, DOI 10.1016/S0162-3109(00)00227-7; Multhoff G, 1997, J IMMUNOL, V158, P4341; MULTHOFF G, 1995, INT J CANCER, V61, P272, DOI 10.1002/ijc.2910610222; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Pomorski T, 2004, J CELL SCI, V117, P805, DOI 10.1242/jcs.01055; PRICE BD, 1992, CANCER RES, V52, P3814; Ran S, 2002, INT J RADIAT ONCOL, V54, P1479, DOI 10.1016/S0360-3016(02)03928-7; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Schmitt E, 2007, J LEUKOCYTE BIOL, V81, P15, DOI 10.1189/jlb.0306167; Sovik A, 2007, INT J RADIAT ONCOL, V68, P1496, DOI 10.1016/j.ijrobp.2007.04.027; SRIVASTAVA PK, 1994, EXPERIENTIA, V50, P1054, DOI 10.1007/BF01923461; Terui K, 2004, BIOCHEM J, V380, P203, DOI 10.1042/BJ20031891; Tesniere A, 2008, CELL DEATH DIFFER, V15, P3, DOI 10.1038/sj.cdd.4402269; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P350; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; Vega VL, 2008, J IMMUNOL, V180, P4299, DOI 10.4049/jimmunol.180.6.4299; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Walton M, 1997, NEUROREPORT, V8, P3871, DOI 10.1097/00001756-199712220-00007; Wang MH, 2004, BRIT J CANCER, V90, P926, DOI 10.1038/sj.bjc.6601583	43	80	82	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2467	2477		10.1096/fj.08-125229	http://dx.doi.org/10.1096/fj.08-125229			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19289606	Green Published			2022-12-28	WOS:000268836700015
J	Saless, N; Litscher, SJ; Franco, GEL; Houlihan, MJ; Sudhakaran, S; Raheem, KA; O'Neil, TK; Vanderby, R; Demant, P; Blank, RD				Saless, Neema; Litscher, Suzanne J.; Franco, Gloria E. Lopez; Houlihan, Meghan J.; Sudhakaran, Shaan; Raheem, Khalid Abdul; O'Neil, Tyriina K.; Vanderby, Ray; Demant, Peter; Blank, Robert D.			Quantitative trait loci for biomechanical performance and femoral geometry in an intercross of recombinant congenic mice: restriction of the Bmd7 candidate interval	FASEB JOURNAL			English	Article						osteoporosis; Wnt; modeling and remodeling; linkage; endothelin	RECEPTOR-RELATED PROTEIN-5; BONE-MINERAL DENSITY; HETEROGENEOUS MOUSE-POPULATION; MECHANICAL-PROPERTIES; GENETIC DISSECTION; INBRED STRAINS; UTAH PARADIGM; MASS; STRENGTH; LRP5	Despite steady progress in identifying quantitative trait loci (QTLs) for bone phenotypes, relatively little progress has been made in moving from QTLs to identifying the relevant gene. We exploited the genetic structure of recombinant congenic mouse strains by performing a reciprocal intercross of the strains HcB-8 and HcB-23, phenotyped for body size, femoral biomechanical performance, and femoral diaphyseal geometry and mapped with R/qtl and QTL Cartographer. Significant QTLs are present on chromosomes 1, 2, 3, 4, 6, and 10. We found significant sex x QTL and cross-direction x QTL interactions. The chromosome 4 QTL affects multiple femoral anatomic features and biomechanical properties. The known segregating segment of chromosome 4 contains only 18 genes, among which Ece1, encoding endothelin-converting enzyme 1, stands out as a candidate. Endothelin signaling has been shown to promote the growth of osteoblastic metastases and to potentiate signaling via the Wnt pathway. The colocalizing chromosome 4 QTL Bmd7 (for bone mineral density 7) increases responsiveness to mechanical loading. By exploiting the short informative segment of chromosome 4 and the known biology, we propose that Ece1 is the gene responsible for Bmd7 and that it acts by increasing responsiveness to mechanical loading through modulation of Wnt signaling. Saless, N., Litscher, S. J., Lopez Franco, G. E., Houlihan, M. J., Sudhakaran, S., Raheem, K. A., O'Neil, T. K., Vanderby, R., Demant, P., Blank, R. D. Quantitative trait loci for biomechanical performance and femoral geometry in an intercross of recombinant congenic mice: restriction of the Bmd7 candidate interval. FASEB J. 23, 2142-2154 (2009)	[Saless, Neema; Litscher, Suzanne J.; Franco, Gloria E. Lopez; Houlihan, Meghan J.; Sudhakaran, Shaan; Raheem, Khalid Abdul; O'Neil, Tyriina K.; Vanderby, Ray; Blank, Robert D.] Univ Wisconsin, Madison, WI USA; [Demant, Peter] Roswell Pk Canc Inst, Buffalo, NY 14263 USA; [Blank, Robert D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; Roswell Park Cancer Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	Blank, RD (corresponding author), H4-556 CSC 5148,600 Highland Ave, Madison, WI 53705 USA.	rdb@medicine.wisc.edu	Blank, Robert D./V-5995-2019	Blank, Robert D./0000-0003-2950-1944	Office of Research and Development, Biomedical Laboratory Research and Development Service, Department of Veterans Affairs	Office of Research and Development, Biomedical Laboratory Research and Development Service, Department of Veterans Affairs(US Department of Veterans Affairs)	We thank Anath Shalev, Marc Drezner, Theresa Guise, and Charles Turner for helpful discussions. This material is based on work supported by the Office of Research and Development, Biomedical Laboratory Research and Development Service, Department of Veterans Affairs, and performed in the Geriatrics Research, Education, and Clinical Center at the William S. Middleton Memorial Veterans Hospital. This report is Madison GRECC manuscript 2008-13.	Balemans W, 2005, BONE, V36, P943, DOI 10.1016/j.bone.2005.02.019; Basten C, 1994, 5 WORLD C GEN APPL L, V22, P65; BASTEN CJ, 1999, QTL CARTOGRAPHER; Beamer WG, 2007, J BONE MINER RES, V22, P1187, DOI 10.1359/JBMR.070419; Beamer WG, 1996, BONE, V18, P397, DOI 10.1016/8756-3282(96)00047-6; Beamer WG, 2001, J BONE MINER RES, V16, P1195, DOI 10.1359/jbmr.2001.16.7.1195; Blank RD, 2003, CONNECT TISSUE RES, V44, P134, DOI 10.1080/03008200390223918; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Broman KW, 2003, BIOINFORMATICS, V19, P889, DOI 10.1093/bioinformatics/btg112; CARTER TC, 1951, J GENET, V50, P307, DOI 10.1007/BF02996226; CHURCHILL GA, 1994, GENETICS, V138, P963; Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006-0346; Clouthier DE, 1998, DEVELOPMENT, V125, P813; Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008-5472.CAN-07-6541; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; Edderkaoui B, 2007, BONE, V41, P340, DOI 10.1016/j.bone.2007.05.013; Edderkaoui B, 2007, GENOME RES, V17, P577, DOI 10.1101/gr.6009507; Eppig JT, 2007, NUCLEIC ACIDS RES, V35, pD630, DOI 10.1093/nar/gkl940; Ferrari SL, 2004, AM J HUM GENET, V74, P866, DOI 10.1086/420771; Franco GEL, 2004, J CLIN DENSITOM, V7, P326; Frost HM, 2001, ANAT RECORD, V262, P398, DOI 10.1002/ar.1049; Frost HM, 2000, J BONE MINER METAB, V18, P305, DOI 10.1007/s007740070001; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; HALEY CS, 1992, HEREDITY, V69, P315, DOI 10.1038/hdy.1992.131; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Ishimori N, 2008, J BONE MINER RES, V23, P1529, DOI 10.1359/JBMR.080414; Jepsen KJ, 2007, MAMM GENOME, V18, P492, DOI 10.1007/s00335-007-9017-5; Jepsen KJ, 2003, MAMM GENOME, V14, P97, DOI 10.1007/s00335-002-3045-y; JIANG CJ, 1995, GENETICS, V140, P1111; Judex S, 2002, FASEB J, V16, P1280, DOI 10.1096/fj.01-0913fje; Kesavan C, 2006, BONE, V39, P634, DOI 10.1016/j.bone.2006.03.005; Kiel DP, 2007, BONE, V40, P587, DOI 10.1016/j.bone.2006.09.029; Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985; Klein RF, 2002, J BONE MINER RES, V17, P1752, DOI 10.1359/jbmr.2002.17.10.1752; Koller DL, 2003, J BONE MINER RES, V18, P1758, DOI 10.1359/jbmr.2003.18.10.1758; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1989, GENETICS, V121, P185; Leppanen OV, 2008, J BIOMECH, V41, P1623, DOI 10.1016/j.jbiomech.2008.03.017; Li CY, 2005, J BONE MINER RES, V20, P2150, DOI 10.1359/JBMR.050819; Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216; Lindenau S, 2006, GENE, V373, P109, DOI 10.1016/j.gene.2006.01.024; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Masinde GL, 2002, CALCIFIED TISSUE INT, V71, P421, DOI 10.1007/s00223-001-1113-z; Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311; Orwoll ES, 2001, J BONE MINER RES, V16, P1962, DOI 10.1359/jbmr.2001.16.11.1962; Price C, 2005, J BONE MINER RES, V20, P1983, DOI 10.1359/JBMR.050707; Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200; Robling AG, 2002, FASEB J, V16, P324, DOI 10.1096/fj.02-0393fje; Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200; Shultz KL, 2003, J BONE MINER RES, V18, P175, DOI 10.1359/jbmr.2003.18.2.175; Stassen APM, 1996, MAMM GENOME, V7, P55, DOI 10.1007/s003359900013; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; TORRANCE AG, 1994, CALCIFIED TISSUE INT, V54, P241, DOI 10.1007/BF00301686; Turner CH, 2001, J BONE MINER RES, V16, P206, DOI 10.1359/jbmr.2001.16.2.206; Turner CH, 2003, CALCIFIED TISSUE INT, V73, P297, DOI 10.1007/s00223-002-1062-1; Volkman SK, 2004, J BONE MINER RES, V19, P1497, DOI 10.1359/JBMR.040506; Volkman SK, 2003, J BONE MINER RES, V18, P1497, DOI 10.1359/jbmr.2003.18.8.1497; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; Yershov Y, 2001, J BONE MINER RES, V16, P992, DOI 10.1359/jbmr.2001.16.6.992; ZENG ZB, 1994, GENETICS, V136, P1457	64	22	22	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2142	2154		10.1096/fj.08-118679	http://dx.doi.org/10.1096/fj.08-118679			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19261723				2022-12-28	WOS:000268836500014
J	Fei, Z; Liu, Y; Yan, Z; Fan, DM; Alexander, A; Yang, JH				Fei, Zhou; Liu, Yang; Yan, Zhen; Fan, Daiming; Alexander, Alice; Yang, Jing-Hua			Targeting viral dsRNA for antiviral prophylaxis	FASEB JOURNAL			English	Article						apoptosis; double-stranded RNA; pathogen-associated molecular pattern	DOUBLE-STRANDED-RNA; PROTEIN-SYNTHESIS; RIG-I; ACTIVATION; PKR; INHIBITION; EXPRESSION; INTERFERENCE; PARTICLES; INFECTION	Double-stranded (ds)RNA in the infected cells is a trait shared by most if not all viruses. While humans have developed variable immune responses, viruses have also developed countermeasures to defeat dsRNA-induced antiviral strategies. Thus, we proposed a broad antiviral strategy to antagonize the countermeasures of viruses and bypass the dsRNA-induced signals that are readily defeated by viruses. By rewiring the dsRNA-binding proteins in the dsRNA complex and reconnecting them to apoptosis signaling, we created several dsRNA-dependent caspase recruiters, termed dsCAREs, to bypass dsRNA-induced antiviral signals that would otherwise be targeted by viruses. Adenovirus and vesicular stomatitis virus, representing viruses of the dsDNA and negative-stranded RNA viral groups, were used to infect HEK293 cells. The dsCARE chimera was added in medium to evaluate its antiviral activity. The truncated dsCAREs were used as controls. We demonstrate that dsCARE suppresses viral infection starting at 0.1 mu g/ml and reaches the peak at 2 mu g/ml. The EC(50) was similar to 0.2 mu g/ml. However, it had an undetectable effect on uninfected cells. Further data show that both dsRNA binding and apoptosis activation of dsCARE are essential for its antiviral activity. We conclude that dsRNA is a practical virus-associated molecular pattern that can be targeted for broad and rapid antiviral prophylaxis.-Fei, Z., Liu, Y., Yan, Z., Fan, D., Alexander, A., Yang, J.-H. Targeting viral dsRNA for antiviral prophylaxis. FASEB J. 25, 1767-1774 (2011). www.fasebj.org	[Fei, Zhou; Liu, Yang; Alexander, Alice; Yang, Jing-Hua] Boston Univ, Dept Surg, Sch Med, Boston Vet Affairs Healthcare Syst, Boston, MA 02130 USA; [Fan, Daiming] Xijing Hosp, Dept Gastroenterol, Xian, Peoples R China; [Fei, Zhou] Xijing Hosp, Dept Neurosurg, Xian, Peoples R China; [Yan, Zhen] Xijing Hosp, Dept Pharmacol, Xian, Peoples R China	Boston University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Yang, JH (corresponding author), Boston Univ, Dept Surg, Sch Med, Boston Vet Affairs Healthcare Syst, 150 S Huntington Ave, Boston, MA 02130 USA.	jyang@bu.edu			National Institutes of Health [R01-GM-060426, K02-AI-060701]; National Science Foundation of China (NSFC) [30928031, 81071369]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI060701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060426] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by grants from the National Institutes of Health (R01-GM-060426 and K02-AI-060701) and the National Science Foundation of China (NSFC; 30928031 and 81071369) to J.-H.Y. and a visiting scholarship from NSFC to Z.F. It is the result of work supported with resources and the use of facilities at Boston Veterans Affairs Medical Center, Boston, MA, USA. The authors declare that they have no competing financial interests.	Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bowie AG, 2007, TRENDS IMMUNOL, V28, P147, DOI 10.1016/j.it.2007.02.002; Childs KS, 2009, J VIROL, V83, P1465, DOI 10.1128/JVI.01768-08; DACQUISTO F, 2001, SCI STKE, pRE1; Dalton KP, 2001, VIROLOGY, V279, P414, DOI 10.1006/viro.2000.0736; Embury J, 2001, DIABETES, V50, P1706, DOI 10.2337/diabetes.50.8.1706; Feng ZD, 2007, J VIROL, V81, P182, DOI 10.1128/JVI.01006-06; Fujita T, 2007, BIOCHIMIE, V89, P754, DOI 10.1016/j.biochi.2007.01.013; Gainey MD, 2008, J VIROL, V82, P828, DOI 10.1128/JVI.02023-07; Gupta V, 2003, VIROLOGY, V315, P283, DOI 10.1016/S0042-6822(03)00589-0; Ho A, 2001, CANCER RES, V61, P474; Kiyosawa H, 2003, GENOME RES, V13, P1324, DOI 10.1101/gr.982903; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; LEE JY, 1994, VIROLOGY, V200, P307, DOI 10.1006/viro.1994.1192; Li SD, 2006, VIROLOGY, V349, P13, DOI 10.1016/j.virol.2006.01.005; LIBONATI M, 1980, MOL CELL BIOCHEM, V31, P147; MARAN A, 1988, VIROLOGY, V164, P106, DOI 10.1016/0042-6822(88)90625-3; Nie YZ, 2007, J VIROL, V81, P917, DOI 10.1128/JVI.01527-06; Nie YZ, 2005, MOL CELL BIOL, V25, P6956, DOI 10.1128/MCB.25.16.6956-6963.2005; RIDER TH, 2006, Patent No. 7125839; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Schroder M, 2005, TRENDS IMMUNOL, V26, P462, DOI 10.1016/j.it.2005.07.002; Sioud M, 2007, ADV DRUG DELIVER REV, V59, P153, DOI 10.1016/j.addr.2007.03.006; STOLLAR BD, 1970, VIROLOGY, V42, P276, DOI 10.1016/0042-6822(70)90270-9; Strong JE, 2008, P NATL ACAD SCI USA, V105, P17982, DOI 10.1073/pnas.0809698105; TWU JS, 1988, P NATL ACAD SCI USA, V85, P252, DOI 10.1073/pnas.85.1.252; Weber F, 2004, VIRAL IMMUNOL, V17, P498, DOI 10.1089/vim.2004.17.498; Weber F, 2006, J VIROL, V80, P5059, DOI 10.1128/JVI.80.10.5059-5064.2006; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; Yount JS, 2006, J IMMUNOL, V177, P4503, DOI 10.4049/jimmunol.177.7.4503; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265	31	7	8	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1767	1774		10.1096/fj.09-144915	http://dx.doi.org/10.1096/fj.09-144915			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	19880628	Green Published			2022-12-28	WOS:000290023800032
J	Huang, MC; Patel, K; Taub, DD; Longo, DL; Goetzl, EJ				Huang, Mei-Chuan; Patel, Kalpesh; Taub, Dennis D.; Longo, Dan L.; Goetzl, Edward J.			Human CD4(-)8(-) T cells are a distinctive immunoregulatory subset	FASEB JOURNAL			English	Article						cytokines; autoimmunity; immunosenescence	MIGRATION INHIBITORY FACTOR; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; SYSTEMIC-LUPUS-ERYTHEMATOSUS; LYMPHOCYTE APOPTOSIS; IN-VITRO; MICE; ACTIVATION; RECEPTOR; ALPHA; EXPRESS	Human CD4(-)8(-) T cells are a minor subset quantitatively but potentially important in immunity because they are predominantly distributed at body surfaces, and their number and activities increase in autoimmune diseases and decrease with aging. Distinguishing characteristics of CD4(-)8(-) T cells are found to include a unique profile of cytokines, including Serpin E1, which is not generated by other T cells, MIF, and TGF-beta. At 2-5% of the total in mixtures with CD4 + CD8 T cells, CD4(-)8(-) T cells enhance the generation of IFN-gamma and IL-17 by up to 12- and 5-fold, respectively, without contributing either cytokine or affecting cytokine production by NK/NKT cells. CD4(-)8(-) T cell-derived MIF is their major enhancer and TGF beta their principal inhibitor of CD4 and CD8 T cell cytokine production. Decreases in CD4(-)8(-) T cell effects may diminish protective immunity in aging, whereas increases may augment the severity of autoimmune diseases.-Huang, M.-C., Patel, K., Taub, D. D., Longo, D. L., Goetzl, E.J. Human CD4(-)8(-) T cells are a distinctive immunoregulatory subset. FASEB J. 24, 2558-2566 (2010). www.fasebj.org	[Goetzl, Edward J.] Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA; [Huang, Mei-Chuan; Goetzl, Edward J.] Univ Calif San Francisco, Dept Microbiol Immunol, San Francisco, CA 94143 USA; [Patel, Kalpesh; Taub, Dennis D.; Longo, Dan L.] NIA, NIH, Baltimore, MD 21224 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Med, Room UB8B,UC Box 0711,533 Parnassus & 4th Ave, San Francisco, CA 94143 USA.	edward.goetzl@ucsf.edu	Longo, Dan L./F-6022-2011; Patel, Kalpesh/G-6685-2012	Patel, Kalpesh/0000-0002-2952-6773	Kenneth Rainin Foundation; U.S. National Institutes of Health [HL31809]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000104] Funding Source: NIH RePORTER	Kenneth Rainin Foundation; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by a grant from the Kenneth Rainin Foundation and by U.S. National Institutes of Health RO-1 grant HL31809. The authors are grateful to Judith H. Goetzl for preparation of the figures and tables. The authors declare no conflicts of interest. Authors' contributions: D.D.T., D.L.L., and E.J.G. designed research; M.-C.H., K.P., and E.J.G. performed research and analyzed data; E.J.G., M.-C.H., and D.L.L. wrote the paper.	Anand A, 2002, LUPUS, V11, P493, DOI 10.1191/0961203302lu235oa; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bernhagen J, 1996, J EXP MED, V183, P277, DOI 10.1084/jem.183.1.277; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Chen M, 2006, LETT MATH PHYS, V75, P1, DOI 10.1007/s11005-005-0041-7; Cowley SC, 2005, J EXP MED, V202, P309, DOI 10.1084/jem.20050569; Crispin JC, 2008, J IMMUNOL, V181, P8761, DOI 10.4049/jimmunol.181.12.8761; Dixit VD, 2007, J CLIN INVEST, V117, P2778, DOI 10.1172/JCI30248; Gore Y, 2008, J BIOL CHEM, V283, P2784, DOI 10.1074/jbc.M703265200; Haque MA, 1998, IMMUNOLOGY, V94, P536; Hernandez-Pigeon H, 2007, J BIOL CHEM, V282, P8157, DOI 10.1074/jbc.M607436200; Kowalewska Anita, 2006, Pol Arch Med Wewn, V115, P197; KOYAMADA N, 1993, CELL IMMUNOL, V149, P107, DOI 10.1006/cimm.1993.1140; LANIER LL, 1986, J EXP MED, V164, P339, DOI 10.1084/jem.164.1.339; Larson DF, 2006, CRIT CARE, V10, DOI 10.1186/cc4899; Liao H, 2007, FASEB J, V21, P935, DOI 10.1096/fj.06-6285com; LONDEI M, 1989, P NATL ACAD SCI USA, V86, P8502, DOI 10.1073/pnas.86.21.8502; Makino Y, 2002, CLIN IMMUNOL, V102, P302, DOI 10.1006/clim.2001.5178; MATTEI M, 1994, INT J IMMUNOPHARMACO, V16, P651, DOI 10.1016/0192-0561(94)90138-4; Metz CN, 1997, ADV IMMUNOL, V66, P197, DOI 10.1016/S0065-2776(08)60598-2; Mizue Y, 2005, P NATL ACAD SCI USA, V102, P14410, DOI 10.1073/pnas.0507189102; Ngiam N, 2007, AM J PHYSIOL-LUNG C, V293, pL1089, DOI 10.1152/ajplung.00265.2007; PAWANKAR R, 1993, ALLERGY, V48, P99, DOI 10.1111/j.1398-9995.1993.tb00693.x; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; Renckens R, 2006, J IMMUNOL, V177, P8171, DOI 10.4049/jimmunol.177.11.8171; Sejima T, 2005, J IMMUNOL, V174, P8135, DOI 10.4049/jimmunol.174.12.8135; Sneller MC, 1997, BLOOD, V89, P1341, DOI 10.1182/blood.V89.4.1341; Straus SE, 1999, ANN INTERN MED, V130, P591, DOI 10.7326/0003-4819-130-7-199904060-00020; Taub DD, 1996, J IMMUNOL, V156, P2095; THOMSSEN H, 1995, IMMUNOLOGY, V85, P33; Wadgaonkar R, 2008, J CELL BIOCHEM, V105, P1279, DOI 10.1002/jcb.21928; Zhang XH, 2002, J EXP MED, V195, P283, DOI 10.1084/jem.20011267	32	10	10	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2010	24	7					2558	2566		10.1096/fj.09-153148	http://dx.doi.org/10.1096/fj.09-153148			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20154266	Green Published			2022-12-28	WOS:000279343600042
J	Lin, ZC; Zhao, Y; Chung, CY; Zhou, YH; Xiong, NA; Glatt, CE; Isacson, O				Lin, Zhicheng; Zhao, Ying; Chung, Chee Yeun; Zhou, Yanhong; Xiong, Nian; Glatt, Charles E.; Isacson, Ole			High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life	FASEB JOURNAL			English	Article						human; promoter haplotypes; evolution; signaling cascades; transcription	DOPAMINE TRANSPORTER; TRANSCRIPTION FACTOR; IN-VIVO; EXPRESSION; PROMOTER; PATHWAY; VMAT2; RAT; SCHIZOPHRENIA; HAPLOTYPES	SLC18A2 encodes the vesicular monoamine transporter 2 protein that regulates neurotransmission and reduces cytosolic toxicity of monoamines. Deletion of this gene causes lethality in mice, and DNA sequence variation in this gene is associated with alcoholism and Parkinson's disease, among other disorders. The Caucasian SLC18A2 promoter has at least 20 haplotypes (A-T), with A representing two-thirds of 1460 chromosomes. It is not known why A is selected in the human lineage. To understand the selection, here we took a functional approach by investigating the regulations of 4 representative haplotypes (A, C, G, and T) by 17 agents. We show that 76.5% of the agents were able to regulate A but only 11.8-23.5% of them regulated the 3 other infrequent ones, observing a positive correlation between haplotype frequency and regulatability. Pathway and molecular analyses revealed five signaling hubs that regulate the four haplotypes differentially, probably through targeting the polymorphic core promoter region. These findings suggest that greater diversity of transcriptional regulations is the driving force for the haplotype selection in SLC18A2.-Lin, Z., Zhao, Y., Chung, C. Y., Zhou, Y., Xiong, N., Glatt, C. E., Isacson, O. High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life. FASEB J. 24, 2191-2200 (2010). www.fasebj.org	[Lin, Zhicheng; Zhao, Ying; Zhou, Yanhong; Xiong, Nian] McLean Hosp, Div Alcohol & Drug Abuse, Belmont, MA 02478 USA; [Chung, Chee Yeun; Isacson, Ole] McLean Hosp, Ctr Neuroregenerat Res, Belmont, MA 02478 USA; [Lin, Zhicheng; Zhao, Ying; Zhou, Yanhong; Xiong, Nian] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Chung, Chee Yeun; Isacson, Ole] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Glatt, Charles E.] Cornell Univ, Dept Psychiat, Weill Med Coll, New York, NY 10021 USA	Harvard University; McLean Hospital; Harvard University; McLean Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Cornell University	Lin, ZC (corresponding author), McLean Hosp, Div Alcohol & Drug Abuse, 115 Mill St, Belmont, MA 02478 USA.	zhicheng_lin@hms.harvard.edu		Isacson, Ole/0000-0001-8091-8302	U.S. National Institutes of Health [P50-NS039793, P01-ES016732, R01-DA021409]; Michael J. Fox Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES016732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS039793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA021409] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Michael J. Fox Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was funded by grants from the U.S. National Institutes of Health (P50-NS039793 to O.I., P01-ES016732 to C. E. G., and R01-DA021409 to Z.L.) and by a Michael J. Fox Foundation Award (to Z.L.).	Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Ekins S, 2007, METH MOL B, V356, P319; Gainetdinov RR, 1998, J NEUROCHEM, V70, P1973; Glatt CE, 2006, HUM MOL GENET, V15, P299, DOI 10.1093/hmg/ddi445; GUILLOT T, 2006, 82416BB27 SOC NEUR; Guillot TS, 2008, NEUROPEPTIDES, V42, P423, DOI 10.1016/j.npep.2008.04.003; Hall FS, 2003, NEUROPSYCHOPHARMACOL, V28, P620, DOI 10.1038/sj.npp.1300070; Kalueff AV, 2007, TRENDS PHARMACOL SCI, V28, P122, DOI 10.1016/j.tips.2007.01.002; Lebrand C, 1998, J COMP NEUROL, V401, P506; LIN Z, 2003, INFO ORG DESIGN SER, V3, P1; Lin ZC, 2005, HUM MOL GENET, V14, P1393, DOI 10.1093/hmg/ddi148; Lin ZC, 1999, MOL PHARMACOL, V56, P434, DOI 10.1124/mol.56.2.434; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mosharov EV, 2009, NEURON, V62, P218, DOI 10.1016/j.neuron.2009.01.033; Nikoshkov A, 2008, P NATL ACAD SCI USA, V105, P786, DOI 10.1073/pnas.0710902105; PETER D, 1995, J NEUROSCI, V15, P6179; Pfeffer M, 2009, J NEUROSCI, V29, P6114, DOI 10.1523/JNEUROSCI.0275-09.2009; Pothos EN, 2000, J NEUROSCI, V20, P7297; Ramagopalan SV, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000369; Rehavi M, 2002, EUR NEUROPSYCHOPHARM, V12, P261, DOI 10.1016/S0924-977X(02)00021-4; Ren XP, 2009, CIRCULATION, V119, P2357, DOI 10.1161/CIRCULATIONAHA.108.814145; Richardson JR, 2004, TOXICOL LETT, V148, P29, DOI 10.1016/j.toxlet.2003.12.006; Rusnak M, 2001, BRAIN RES, V899, P20, DOI 10.1016/S0006-8993(01)02126-6; Schwab SG, 2005, NEUROPSYCHOPHARMACOL, V30, P2263, DOI 10.1038/sj.npp.1300809; Schwarz J, 2006, FASEB J, V20, P935, DOI 10.1096/fj.05-5497com; Takahashi N, 1997, P NATL ACAD SCI USA, V94, P9938, DOI 10.1073/pnas.94.18.9938; Talkowski ME, 2008, HUM MOL GENET, V17, P747, DOI 10.1093/hmg/ddm347; Taylor SF, 2000, NEUROPSYCHOPHARMACOL, V23, P667, DOI 10.1016/S0893-133X(00)00165-2; Towers E, 2009, NUCLEIC ACIDS RES, V37, P3044, DOI 10.1093/nar/gkp175; Tseng PC, 2008, BIOCHEM PHARMACOL, V76, P1121, DOI 10.1016/j.bcp.2008.08.023; Wang GY, 2006, FASEB J, V20, P2639, DOI 10.1096/fj.06-6315fje; Watson F, 2001, J BIOL CHEM, V276, P7661, DOI 10.1074/jbc.M006697200; Yu MJ, 2009, P NATL ACAD SCI USA, V106, P2441, DOI 10.1073/pnas.0813002106; Zanotto E, 2007, NUCLEIC ACIDS RES, V35, P664, DOI 10.1093/nar/gkl1037; Zubieta JK, 2001, BIOL PSYCHIAT, V49, P110, DOI 10.1016/S0006-3223(00)00981-1; Zucker M, 2002, EUR NEUROPSYCHOPHARM, V12, P343, DOI 10.1016/S0924-977X(02)00041-X	36	16	16	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2191	2200		10.1096/fj.09-140368	http://dx.doi.org/10.1096/fj.09-140368			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20181938	Green Published			2022-12-28	WOS:000279343600006
J	Leibowitch, J; Mathez, D; de Truchis, P; Perronne, C; Melchior, JC				Leibowitch, Jacques; Mathez, Dominique; de Truchis, Pierre; Perronne, Christian; Melchior, Jean-Claude			Short cycles of antiretroviral drugs provide intermittent yet effective therapy: a pilot study in 48 patients with chronic HIV infection	FASEB JOURNAL			English	Article						intermittent HIV treatment; HIV genotype; cost of treatment; observance; antiviral regimen	STRUCTURED TREATMENT INTERRUPTION; ADHERENCE; PROTEASE; RNA; TOXICITY; REGIMEN; TRIAL	The present study evaluated the efficacy of intermittent antiviral treatment administered to HIV-infected patients under stepwise reductions in weekly medication. Forty-eight patients were invited to reduce their antiviral medication to 5 consecutive days per week; after control over HIV activity was ascertained, antiviral drugs were cut to 4 consecutive days per week. Of the 48, 39 then reduced medicines further to 3 d, and 12 of those eventually undertook a 2 d/wk schedule. Clinical and immunological status and plasma HIV load were repeatedly monitored. HIV was unremittingly maintained below detection levels in all patients under either 5- or 4-d/wk treatment regimens, for a mean 56 +/- 40 wk/patient (5-d regimen) and 84 +/- 46 wk/patient (4-d regimen). Of the 39 patients under 3-d regimens, 35 maintained optimal control over HIV activity for a mean 50 +/- 32 wk, as did 10 of the 12 under 2-d regimens, for 24 +/- 10.5 wk. Summing up treatment <= 5 d/wk, plasma HIV remained below detection levels for a cumulative 8895 wk (170 patient-yr). No major HIV-related clinical event was reported. and CD4(+) T-cell counts and percentages readily increased over the last value noted under the 7-d treatment course. Viral failure was documented in 6 of the 48 patients: 4 under a 3-d/wk regimen, 2 under a 2-d/wk regimen. All 6 patients had their treatment swiftly set back to a 7-d/wk regimen, resulting in rapid control over HIV replication. In summary, intermittent antiretroviral regimens optimally suppressed HIV in patients taking antiviral medicines 5 and 4 d/wk, as well as in a substantial proportion of patients under 3- or 2-d/wk antiviral regimens, reducing both expenses and, possibly, drug toxicity. Controlled prospective clinical trials are warranted before considering short weekly cycles of antiretroviral medicines an alternative in the management of chronically HIV-infected patients.-Leibowitch, J., Mathez, D., de Truchis, P., Perronne, C., Melchior, J. C. Short cycles of antiretroviral drugs provide intermittent yet effective therapy: a pilot study in 48 patients with chronic HIV infection. FASEB J. 24, 1649-1655 (2010). www.fasebj.org	[Leibowitch, Jacques; Mathez, Dominique] Hop Raymond Poincare, AP HP, Immunol & Virol Unit, F-92380 Garches, France; [de Truchis, Pierre; Perronne, Christian] Hop Raymond Poincare, AP HP, Clin Infect Dis Unit, F-92380 Garches, France; [Melchior, Jean-Claude] Hop Raymond Poincare, AP HP, Dept Internal Med & Infect Dis, Clin Nutr & Infect Dis Unit, F-92380 Garches, France; [Leibowitch, Jacques; Perronne, Christian; Melchior, Jean-Claude] Univ & Med Sch, Versailles, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP	Leibowitch, J (corresponding author), Hop Raymond Poincare, AP HP, Immunol & Virol Unit, 104 Bd Raymond Poincare, F-92380 Garches, France.	jacques.leibowitch@rpc.aphp.fr						Ananworanich J, 2003, AIDS, V17, pF33, DOI 10.1097/00002030-200310170-00001; Ananworanich J, 2003, CLIN INFECT DIS, V37, P723, DOI 10.1086/376989; Ananworanich J, 2008, J ANTIMICROB CHEMOTH, V61, P1340, DOI 10.1093/jac/dkn097; Bangsberg DR, 2006, AIDS, V20, P223, DOI 10.1097/01.aids.0000199825.34241.49; Bangsberg DR, 2004, J INFECT DIS, V190, P162, DOI 10.1086/420790; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Cardiello PG, 2005, CLIN INFECT DIS, V40, P594, DOI 10.1086/427695; Cohen CJ, 2007, HIV CLIN TRIALS, V8, P19, DOI 10.1310/hct0801-19; Dybul M, 2004, J INFECT DIS, V189, P1974, DOI 10.1086/386344; Dybul M, 2001, P NATL ACAD SCI USA, V98, P15161, DOI 10.1073/pnas.261568398; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Ferry JA, 2009, MODERN PATHOL, V22, P618, DOI 10.1038/modpathol.2009.36; Fischer M, 2004, J INFECT DIS, V190, P1979, DOI 10.1086/425983; Fischer M, 2003, AIDS, V17, P195, DOI 10.1097/00002030-200301240-00009; Hirschel B, 2009, AIDS, V23, P757, DOI 10.1097/QAD.0b013e328321b791; Ho JE, 2009, HEART, V95, P1193, DOI 10.1136/hrt.2008.161463; Magalhaes MG, 2007, J AM DENT ASSOC, V138, P1468, DOI 10.14219/jada.archive.2007.0083; Marsden MD, 2009, J ANTIMICROB CHEMOTH, V63, P7, DOI 10.1093/jac/dkn455; Martin M, 2008, AIDS RES HUM RETROV, V24, P1263, DOI 10.1089/aid.2008.0141; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Strenger V, 2009, CLIN INFECT DIS, V48, P91, DOI 10.1086/595004; Vergis EN, 2001, INT J STD AIDS, V12, P463, DOI 10.1258/0956462011923507; 2009, TREATMENTUPDATE, V21, P7	23	8	8	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1649	1655		10.1096/fj.09-148676	http://dx.doi.org/10.1096/fj.09-148676			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20103716				2022-12-28	WOS:000278200000003
J	Kojic, N; Chung, E; Kho, AT; Park, JA; Huang, A; So, PTC; Tschumperlin, DJ				Kojic, Nikola; Chung, Euiheon; Kho, Alvin T.; Park, Jin-Ah; Huang, Austin; So, Peter T. C.; Tschumperlin, Daniel J.			An EGFR autocrine loop encodes a slow-reacting but dominant mode of mechanotransduction in a polarized epithelium	FASEB JOURNAL			English	Article						airway epithelium; mechanical stress; lateral intercellular space	EPIDERMAL-GROWTH-FACTOR; LATERAL INTERCELLULAR SPACES; C-ERBB RECEPTORS; DIFFERENTIAL REGULATION; SIGNAL-TRANSDUCTION; MECHANICAL-STRESS; GENE-EXPRESSION; SHEAR-STRESS; KINASE; ACTIVATION	The mechanical landscape in biological systems can be complex and dynamic, with contrasting sustained and fluctuating loads regularly superposed within the same tissue. How resident cells discriminate between these scenarios to respond accordingly remains largely unknown. Here, we show that a step increase in compressive stress of physiological magnitude shrinks the lateral intercellular space between bronchial epithelial cells, but does so with strikingly slow exponential kinetics (time constant similar to 110 s). We confirm that epidermal growth factor (EGF)-family ligands are constitutively shed into the intercellular space and demonstrate that a step increase in compressive stress enhances EGF receptor (EGFR) phosphorylation with magnitude and onset kinetics closely matching those predicted by constant-rate ligand shedding in a slowly shrinking intercellular geometry. Despite the modest degree and slow nature of EGFR activation evoked by compressive stress, we find that the majority of transcriptomic responses to sustained mechanical loading require ongoing activity of this autocrine loop, indicating a dominant role for mechanotransduction through autocrine EGFR signaling in this context. A slow deformation response to a step increase in loading, accompanied by synchronous increases in ligand concentration and EGFR activation, provides one means for cells to mount a selective and context-appropriate response to a sustained change in mechanical environment.-Kojic, N., Chung, E., Kho, A. T., Park, J.-A., Huang, A., So, P. T. C., Tschumperlin, D. J. An EGFR autocrine loop encodes a slow-reacting but dominant mode of mechanotransduction in a polarized epithelium. FASEB J. 24, 1604-1615 (2010). www.fasebj.org	[Park, Jin-Ah; Tschumperlin, Daniel J.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Kojic, Nikola; Chung, Euiheon; Kho, Alvin T.; Huang, Austin] Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Cambridge, MA USA; [Chung, Euiheon] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; [Kho, Alvin T.] Childrens Hosp, Informat Program, Boston, MA 02115 USA; [So, Peter T. C.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Massachusetts Institute of Technology (MIT)	Tschumperlin, DJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.	dtschump@hsph.harvard.edu	Chung, Euiheon/A-1801-2009	Chung, Euiheon/0000-0002-3326-6927	National Institutes of Health (NIH) [HL082856, HL88028, NS040828]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K25HL091124, R01HL088028, R01HL082856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS040828, P01NS040828] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank J. Drazen, J. Fredberg, and D. Lauffen-burger for helpful discussions. This work was funded by National Institutes of Health (NIH) grants HL082856 and HL88028, and A.T.K. is funded by NIH NS040828.	AIDA S, 1994, RESPIRATION, V61, P161; Amishima M, 1998, AM J RESP CRIT CARE, V157, P1907, DOI 10.1164/ajrccm.157.6.9609040; Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Ateshian GA, 2004, J BIOMECH, V37, P391, DOI 10.1016/S0021-9290(03)00252-5; Blagoev B, 2004, NAT BIOTECHNOL, V22, P1139, DOI 10.1038/nbt1005; Button B, 2007, J PHYSIOL-LONDON, V580, P577, DOI 10.1113/jphysiol.2006.126086; Chachisvilis M, 2006, P NATL ACAD SCI USA, V103, P15463, DOI 10.1073/pnas.0607224103; Christensen JG, 2005, MOL CANCER THER, V4, P938, DOI 10.1158/1535-7163.MCT-04-0208; Chu EK, 2005, AM J RESP CELL MOL, V32, P373, DOI 10.1165/rcmb.2004-0266OC; Chu EK, 2006, AM J RESP CELL MOL, V35, P628, DOI 10.1165/rcmb.2006-0040OC; Coughlin MF, 1996, J APPL PHYSIOL, V80, P1880, DOI 10.1152/jappl.1996.80.6.1880; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; FERRIOLA PC, 1992, J CELL PHYSIOL, V152, P302, DOI 10.1002/jcp.1041520211; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; GUNST SJ, 1988, J APPL PHYSIOL, V64, P2522, DOI 10.1152/jappl.1988.64.6.2522; Hamilton LM, 2003, CLIN EXP ALLERGY, V33, P233, DOI 10.1046/j.1365-2222.2003.01593.x; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Haslett JN, 2003, NEUROGENETICS, V4, P163, DOI 10.1007/s10048-003-0148-x; Hollander M., 2014, NONPARAMETRIC STAT M, V3rd ed.; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Keyse SM, 2008, CANCER METAST REV, V27, P253, DOI 10.1007/s10555-008-9123-1; Kikuchi T, 2004, AM J PHYSIOL-LUNG C, V287, pL119, DOI 10.1152/ajplung.00365.2003; Kojic N, 2008, OPT EXPRESS, V16, P12403, DOI 10.1364/OE.16.012403; Kojic N, 2006, BIOPHYS J, V90, P4261, DOI 10.1529/biophysj.105.078345; Kovbasnjuk ON, 2000, J MEMBRANE BIOL, V175, P9, DOI 10.1007/s002320001050; LAI WM, 1991, J BIOMECH ENG-T ASME, V113, P245, DOI 10.1115/1.2894880; Lauffenburger DA, 1998, P NATL ACAD SCI USA, V95, P15368, DOI 10.1073/pnas.95.26.15368; Lehoux S, 2003, J BIOMECH, V36, P631, DOI 10.1016/S0021-9290(02)00441-4; Lehoux S, 2005, CIRCULATION, V111, P643, DOI 10.1161/01.CIR.0000154548.16191.2F; Lenormand G, 2004, J R SOC INTERFACE, V1, P91, DOI 10.1098/rsif.2004.0010; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maly IV, 2004, ANN BIOMED ENG, V32, P1319, DOI 10.1114/B:ABME.0000042221.61633.23; Matthews BD, 2006, J CELL SCI, V119, P508, DOI 10.1242/jcs.02760; Miettinen PJ, 1997, DEV BIOL, V186, P224, DOI 10.1006/dbio.1997.8593; MOW VC, 1980, J BIOMECH ENG-T ASME, V102, P73, DOI 10.1115/1.3138202; Nielsen UB, 2003, P NATL ACAD SCI USA, V100, P9330, DOI 10.1073/pnas.1633513100; Ofek G, 2009, BIOPHYS J, V97, P1873, DOI 10.1016/j.bpj.2009.07.050; Okamoto M, 2002, BBA-GENE STRUCT EXPR, V1574, P24, DOI 10.1016/S0167-4781(01)00345-1; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Park JA, 2009, AM J RESP CELL MOL, V41, P459, DOI 10.1165/rcmb.2008-0195OC; Peyton SR, 2008, BIOMATERIALS, V29, P2597, DOI 10.1016/j.biomaterials.2008.02.005; Polosa R, 2002, J ALLERGY CLIN IMMUN, V109, P75, DOI 10.1067/mai.2002.120274; Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Resat H, 2003, BIOPHYS J, V85, P730, DOI 10.1016/S0006-3495(03)74516-0; Ressler B, 2000, AM J PHYSIOL-LUNG C, V278, pL1264, DOI 10.1152/ajplung.2000.278.6.L1264; Reynolds AR, 2003, NAT CELL BIOL, V5, P447, DOI 10.1038/ncb981; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Sasagawa S, 2005, NAT CELL BIOL, V7, P365, DOI 10.1038/ncb1233; Sawada Y, 2006, CELL, V127, P1015, DOI 10.1016/j.cell.2006.09.044; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Sheu MT, 2001, BIOMATERIALS, V22, P1713, DOI 10.1016/S0142-9612(00)00315-X; Sorby M, 1996, J BIOL CHEM, V271, P10963; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; SPRING KR, 1978, SCIENCE, V200, P54, DOI 10.1126/science.635571; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Takeyama K, 2001, AM J RESP CRIT CARE, V163, P511, DOI 10.1164/ajrccm.163.2.2001038; Tarran R, 2006, ANNU REV PHYSIOL, V68, P543, DOI 10.1146/annurev.physiol.68.072304.112754; Tarran R, 2005, J BIOL CHEM, V280, P35751, DOI 10.1074/jbc.M505832200; Tschumperlin DJ, 2006, ANNU REV PHYSIOL, V68, P563, DOI 10.1146/annurev.physiol.68.072304.113102; Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543; Tschumperlin DJ, 2003, AM J RESP CELL MOL, V28, P142, DOI 10.1165/rcmb.2002-0121OC; Tschumperlin DJ, 2002, AM J PHYSIOL-LUNG C, V282, pL904, DOI 10.1152/ajplung.00270.2001; Tyner JW, 2006, J CLIN INVEST, V116, P309, DOI 10.1172/JCI25167; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Vinante F, 1999, BLOOD, V94, P3169, DOI 10.1182/blood.V94.9.3169.421k30_3169_3177; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Wang YX, 2005, NATURE, V434, P1040, DOI 10.1038/nature03469; Wiggs BR, 1997, J APPL PHYSIOL, V83, P1814, DOI 10.1152/jappl.1997.83.6.1814; Wiley HS, 2003, TRENDS CELL BIOL, V13, P43; Xia P, 1998, BIOPHYS J, V74, P3302, DOI 10.1016/S0006-3495(98)78037-3; Yoshida T, 2006, ONCOGENE, V25, P6056, DOI 10.1038/sj.onc.1209635; Yoshioka J, 2005, P NATL ACAD SCI USA, V102, P10622, DOI 10.1073/pnas.0501198102; Zhao Q, 2002, P NATL ACAD SCI USA, V99, P5704, DOI 10.1073/pnas.082092399; Zhen GH, 2007, AM J RESP CELL MOL, V36, P244, DOI 10.1165/rcmb.2006-0180OC	83	17	19	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1604	1615		10.1096/fj.09-145367	http://dx.doi.org/10.1096/fj.09-145367			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20056713	Bronze, Green Published			2022-12-28	WOS:000277158900032
J	Noti, M; Corazza, N; Tuffin, G; Schoonjans, K; Brunner, T				Noti, Mario; Corazza, Nadia; Tuffin, Gerald; Schoonjans, Kristina; Brunner, Thomas			Lipopolysaccharide induces intestinal glucocorticoid synthesis in a TNF alpha-dependent manner	FASEB JOURNAL			English	Article						inflammatory bowel disease; tumor necrosis factor alpha; intestinal epithelial cells; macrophages; TNF receptors	TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTOR-4; FACTOR-KAPPA-B; MOLECULAR-MECHANISMS; EPITHELIAL BARRIER; MICE; ENTEROCYTES; REPRESSION; PROTECTION; APOPTOSIS	Stringent control of immune responses in the intestinal mucosa is critical for the maintenance of immune homeostasis and prevention of tissue damage, such as observed during inflammatory bowel disease. Intestinal epithelial cells, primarily thought to form a simple physical barrier, critically regulate intestinal immune cell functions by producing immunoregulatory glucocorticoids on T-cell activation. In this study we investigated whether stimulation of cells of the innate immune system results in the induction of intestinal glucocorticoids synthesis and what role TNF-alpha plays in this process. Stimulation of the innate immune system with lipopolysaccharide (LPS) led to an up-regulation of colonic steroidogenic enzymes and the induction of intestinal glucocorticoid synthesis. The observed induction was dependent on macrophage effector functions, as depletion of macrophages using clodronate-containing liposomes, but not absence of T and B cells, inhibited intestinal glucocorticoid synthesis. LPS-induced glucocorticoid synthesis was critically dependent on TNF-alpha as it was significantly decreased in TNF-alpha -deficient animals. Both TNF receptor-1 and -2 were found to be equally involved in LPS- and T-cell-induced intestinal GC synthesis. These results describe a novel and critical role of TNF-alpha in immune cell-induced intestinal glucocorticoid synthesis.-Noti, M., Corazza, N., Tuffin, G., Schoonjans, K., Brunner, T. Lipopolysaccharide induces intestinal glucocorticoid synthesis in a TNF alpha-dependent manner. FASEB J. 24, 1340-1346 (2010). www.fasebj.org	[Noti, Mario; Corazza, Nadia; Brunner, Thomas] Univ Bern, Inst Pathol, Div Expt Pathol, CH-3010 Bern, Switzerland; [Tuffin, Gerald] Univ Appl Sci NW Switzerland, Sch Life Sci, Muttenz, Switzerland; [Schoonjans, Kristina] Ecole Polytech Fed Lausanne, Lab Integrat Syst & Physiol, Lausanne, Switzerland	University of Bern; FHNW University of Applied Sciences & Arts Northwestern Switzerland; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Brunner, T (corresponding author), Univ Bern, Inst Pathol, Div Expt Pathol, Murtenstr 31, CH-3010 Bern, Switzerland.	tbrunner@pathology.unibe.ch	Noti, Mario/I-6581-2019	Noti, Mario/0000-0001-9386-1245; Schoonjans, Kristina/0000-0003-1247-4265	Crohn's and Colitis Foundation of America; Swiss National Science Foundation; Oncosuisse	Crohn's and Colitis Foundation of America; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Oncosuisse	The authors thank the T. B. and K. S. lab for technical help. The authors further thank Christoph Mueller (University of Bern, Bern, Switzerland) for providing RAG2<SUP>-/-</SUP>, TNF-alpha<SUP>-/-</SUP>, TNFR1<SUP>-/-</SUP>, and TNFR2<SUP>-/-</SUP> animals and Manfred Kopf (Eidgenossische Technische Hochschule Zurich, Zurich, Switzerland) for the IL-6<SUP>-/-</SUP> mice. This work was supported by grants from the Crohn's and Colitis Foundation of America, the Swiss National Science Foundation, and Oncosuisse to T. B. The authors declare no conflicts of interest.	Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Artis D, 2008, NAT REV IMMUNOL, V8, P411, DOI 10.1038/nri2316; Bohan A, 2003, J BIOL CHEM, V278, P36688, DOI 10.1074/jbc.M304011200; Boirivant M, 2008, MUCOSAL IMMUNOL, V1, pS47, DOI 10.1038/mi.2008.52; Boivin MA, 2007, AM J PHYSIOL-GASTR L, V292, pG590, DOI 10.1152/ajpgi.00252.2006; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Cario E, 2008, CURR OPIN GASTROEN, V24, P725, DOI 10.1097/MOG.0b013e32830c4341; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cima I, 2004, J EXP MED, V200, P1635, DOI 10.1084/jem.20031958; CLAASSEN I, 1990, J IMMUNOL METHODS, V134, P153, DOI 10.1016/0022-1759(90)90376-7; Corazza N, 1999, J EXP MED, V190, P1479, DOI 10.1084/jem.190.10.1479; Coste A, 2007, P NATL ACAD SCI USA, V104, P13098, DOI 10.1073/pnas.0702440104; Davies E, 2003, CLIN EXP PHARMACOL P, V30, P437, DOI 10.1046/j.1440-1681.2003.03867.x; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Fries Walter, 2008, Int J Med Sci, V5, P169; GALANOS C, 1993, IMMUNOBIOLOGY, V187, P346, DOI 10.1016/S0171-2985(11)80349-9; Gitter AH, 2000, FASEB J, V14, P1749, DOI 10.1096/fj.99-0898com; Herold MJ, 2006, CELL MOL LIFE SCI, V63, P60, DOI 10.1007/s00018-005-5390-y; JACOB CO, 1988, NATURE, V331, P356, DOI 10.1038/331356a0; Kassiotis G, 2001, J EXP MED, V193, P427, DOI 10.1084/jem.193.4.427; Kontoyiannis D, 2000, EUR J IMMUNOL, V30, P2038, DOI 10.1002/1521-4141(200007)30:7<2038::AID-IMMU2038>3.0.CO;2-K; Lee J, 2008, SEMIN IMMUNOPATHOL, V30, P3, DOI 10.1007/s00281-007-0099-7; Marini M, 2003, P NATL ACAD SCI USA, V100, P8366, DOI 10.1073/pnas.1432897100; Matsuguchi T, 2000, J IMMUNOL, V165, P5767, DOI 10.4049/jimmunol.165.10.5767; McGuckin MA, 2009, INFLAMM BOWEL DIS, V15, P100, DOI 10.1002/ibd.20539; Mueller M, 2006, J EXP MED, V203, P2057, DOI 10.1084/jem.20060357; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Muller CA, 2005, CELL MOL LIFE SCI, V62, P1297, DOI 10.1007/s00018-005-5034-2; Ortega-Cava CF, 2003, J IMMUNOL, V170, P3977, DOI 10.4049/jimmunol.170.8.3977; Otte JM, 2004, GASTROENTEROLOGY, V126, P1054, DOI 10.1053/j.gastro.2004.01.007; Riccardi C, 2002, PHARMACOL RES, V45, P361, DOI 10.1006/phrs.2002.0969; Rutgeerts P, 2009, GASTROENTEROLOGY, V136, P1182, DOI 10.1053/j.gastro.2009.02.001; Salzman NH, 2007, SEMIN IMMUNOL, V19, P70, DOI 10.1016/j.smim.2007.04.002; Sapolsky RM, 2000, NEUROBIOL DIS, V7, P540, DOI 10.1006/nbdi.2000.0350; Schaaf MJM, 2002, J STEROID BIOCHEM, V83, P37, DOI 10.1016/S0960-0760(02)00263-7; Schenk M, 2007, SEMIN IMMUNOL, V19, P84, DOI 10.1016/j.smim.2006.09.002; Song HL, 2005, WORLD J GASTROENTERO, V11, P3701, DOI 10.3748/wjg.v11.i24.3701; VANROOIJEN N, 1992, RES IMMUNOL, V143, P215; Wilson NS, 2009, NAT IMMUNOL, V10, P348, DOI 10.1038/ni.1714; Xu B, 2009, MOL CELL BIOL, V29, P1719, DOI 10.1128/MCB.01010-08; Yamada Y, 1998, HEPATOLOGY, V28, P959, DOI 10.1002/hep.510280410	42	33	33	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1340	1346		10.1096/fj.09-140913	http://dx.doi.org/10.1096/fj.09-140913			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20056718	Green Submitted			2022-12-28	WOS:000277158900007
J	Murikinati, S; Juttler, E; Keinert, T; Ridder, DA; Muhammad, S; Waibler, Z; Ledent, C; Zimmer, A; Kalinke, U; Schwaninger, M				Murikinati, Sasidhar; Juettler, Eric; Keinert, Timo; Ridder, Dirk A.; Muhammad, Sajjad; Waibler, Zoe; Ledent, Catherine; Zimmer, Andreas; Kalinke, Ulrich; Schwaninger, Markus			Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment	FASEB JOURNAL			English	Article						stroke; chemotaxis; p38; bone marrow transplantation	ADHESION MOLECULE-1 ANTIBODY; CB2 RECEPTOR; BRAIN-DAMAGE; ISCHEMIC/REPERFUSION INJURY; ARTERY OCCLUSION; VIRUS-INFECTION; CELL-DAMAGE; MOUSE MODEL; STROKE; MICE	Activation of the cannabinoid 2 receptor (CB2) reduces ischemic injury in several organs. However, the mechanisms underlying this protective action are unclear. In a mouse model of ischemic stroke, we show that the CB2 agonist JWH-133 (1 mg . kg(-1) . d(-1)) decreases the infarct size measured 3 d after onset of ischemia. The neuroprotective effect of JWH-133 was lost in CB2-deficient mice, confirming the specificity of JWH-133. Analysis of bone marrow chimeric mice revealed that bone marrow-derived cells mediate the CB2 effect on ischemic brain injury. CB2 activation reduced the number of neutrophils in the ischemic brain as shown by FACS analysis and by measuring the levels of the neutrophil marker enzyme myeloperoxidase. Indeed, we found in vitro that CB2 activation inhibits adherence of neutrophils to brain endothelial cells. JWH-133 (1 mu M) also interfered with the migration of neutrophils induced by the endogenous chemokine CXCL2 (30 ng/ml) through activation of the MAP kinase p38. This effect on neutrophils is likely responsible for the neuroprotection mediated by JWH-133 because JWH-133 was no longer protective when neutrophils were depleted. In conclusion, our data demonstrate that by activating p38 in neutrophils, CB2 agonists inhibit neutrophil recruitment to the brain and protect against ischemic brain injury.-Murikinati, S., Juttler, E., Keinert, T., Ridder, D. A., Muhammad, S., Waibler, Z., Ledent, C., Zimmer, A., Kalinke, U., Schwaninger, M. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J. 24, 788-798 (2010). www.fasebj.org	[Murikinati, Sasidhar; Ridder, Dirk A.; Muhammad, Sajjad; Schwaninger, Markus] Heidelberg Univ, Dept Pharmacol, D-69120 Heidelberg, Germany; [Juettler, Eric; Keinert, Timo] Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany; [Waibler, Zoe] Paul Ehrlich Inst, Jr Res Grp, D-6070 Langen, Germany; [Ledent, Catherine] Inst Rech Interdisciplinaire Biol Humaine & Mol, Brussels, Belgium; [Zimmer, Andreas] Univ Bonn, Inst Mol Psychiat, D-5300 Bonn, Germany; [Kalinke, Ulrich] Ctr Expt & Clin Infect Res, Inst Expt Infect Res, Hannover, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Paul Ehrlich Institute; University of Bonn	Schwaninger, M (corresponding author), Heidelberg Univ, Dept Pharmacol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.	markus.schwaninger@pharma.uni-heidelberg.de	Zimmer, Andreas/B-8357-2009	Kalinke, Ulrich/0000-0003-0503-9564; Muhammad, Sajjad/0000-0002-6734-7979	European Union's Seventh Framework Programme [FP7/2007-2013, 201024, 202213]; Deutsche Forschungsgemeinschaft (DFG) [791]	European Union's Seventh Framework Programme; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The authors thank Christina Stannek and Nadine Gehrig for expert technical assistance. The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreements 201024 and 202213 (European Stroke Network). S. M. was supported by a scholarship of the Deutsche Forschungsgemeinschaft (DFG) graduate college 791. Twincore, Centre for Experimental and Clinical Infection Research, is a joint venture between Helmholtz Centre for Infection Research (HZI; Braunschweig, Germany) and Hannover Medical School (MHH; Hannover, Germany).	Akk AM, 2008, J IMMUNOL, V180, P3535, DOI 10.4049/jimmunol.180.5.3535; Andrew DP, 1998, EUR J IMMUNOL, V28, P1959, DOI 10.1002/(SICI)1521-4141(199806)28:06<1959::AID-IMMU1959>3.0.CO;2-4; Arumugam TV, 2004, AM J PHYSIOL-HEART C, V287, pH2555, DOI 10.1152/ajpheart.00588.2004; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Batkai S, 2007, FASEB J, V21, P1788, DOI 10.1096/fj.06-7451com; Berger C, 2004, J NEUROCHEM, V88, P1159, DOI 10.1046/j.1471-4159.2003.02244.x; Blazquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02-0795fje; Brown AJ, 2007, BRIT J PHARMACOL, V152, P567, DOI 10.1038/sj.bjp.0707481; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Chamorro A, 2007, STROKE, V38, P1097, DOI 10.1161/01.STR.0000258346.68966.9d; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; Dawson Deborah A., 1996, Keio Journal of Medicine, V45, P248; Defer N, 2009, FASEB J, V23, P2120, DOI 10.1096/fj.09-129478; Docagne F, 2007, MOL CELL NEUROSCI, V34, P551, DOI 10.1016/j.mcn.2006.12.005; Eljaschewitsch E, 2006, NEURON, V49, P67, DOI 10.1016/j.neuron.2005.11.027; Emerich DF, 2002, EXP NEUROL, V173, P168, DOI 10.1006/exnr.2001.7835; Fernandez-Lopez D, 2006, PEDIATR RES, V60, P169, DOI 10.1203/01.pdr.0000228839.00122.6c; Frangogiannis NG, 2007, THROMB HAEMOSTASIS, V97, P738, DOI 10.1160/TH07-01-0022; Furuya K, 2001, STROKE, V32, P2665, DOI 10.1161/hs3211.098535; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; Graff G, 1998, J PHARMACOL TOXICOL, V39, P169, DOI 10.1016/S1056-8719(98)00023-9; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; Heit B, 2008, NAT IMMUNOL, V9, P743, DOI 10.1038/ni.1623; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Hillard CJ, 2008, CURR PHARM DESIGN, V14, P2347, DOI 10.2174/138161208785740054; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968-0896(99)00219-9; Johns DG, 2007, BRIT J PHARMACOL, V152, P825, DOI 10.1038/sj.bjp.0707419; Juttler E, 2004, NEUROPHARMACOLOGY, V47, P580, DOI 10.1016/j.neuropharm.2004.05.009; Kataoka H, 2004, J CEREBR BLOOD F MET, V24, P668, DOI 10.1097/01.WCB.0000117812.35136.5B; Katzan IL, 2003, NEUROLOGY, V60, P620, DOI 10.1212/01.WNL.0000046586.38284.60; Khan AI, 2005, MICROCIRCULATION, V12, P421, DOI 10.1080/10739680590960368; Kim K, 2006, EUR J PHARMACOL, V542, P100, DOI 10.1016/j.ejphar.2006.05.025; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Liu QR, 2009, GENES BRAIN BEHAV, V8, P519, DOI 10.1111/j.1601-183X.2009.00498.x; Maresz K, 2007, NAT MED, V13, P492, DOI 10.1038/nm1561; Markt P, 2009, J MED CHEM, V52, P369, DOI 10.1021/jm801044g; McColl BW, 2007, J NEUROSCI, V27, P4403, DOI 10.1523/JNEUROSCI.5376-06.2007; Mestre L, 2006, BIOCHEM PHARMACOL, V72, P869, DOI 10.1016/j.bcp.2006.06.037; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Miller AM, 2008, BRIT J PHARMACOL, V153, P299, DOI 10.1038/sj.bjp.0707523; Montecucco F, 2009, J MOL CELL CARDIOL, V46, P612, DOI 10.1016/j.yjmcc.2008.12.014; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Muthian S, 2004, NEUROSCIENCE, V129, P743, DOI 10.1016/j.neuroscience.2004.08.044; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Onaivi ES, 2006, ANN NY ACAD SCI, V1074, P514, DOI 10.1196/annals.1369.052; Pacher P, 2008, BRIT J PHARMACOL, V153, P252, DOI 10.1038/sj.bjp.0707582; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1523/JNEUROSCI.4540-04.2005; Ridder DA, 2009, BRAIN RES, V1272, P3, DOI 10.1016/j.brainres.2009.03.046; Schabitz WR, 2002, STROKE, V33, P2112, DOI 10.1161/01.STR.0000023491.63693.18; Stella N, 2004, GLIA, V48, P267, DOI 10.1002/glia.20084; Tschop J, 2009, J IMMUNOL, V183, P499, DOI 10.4049/jimmunol.0900203; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; Villa P, 2007, MOL MED, V13, P125, DOI 10.2119/2007-00008.Villa; Viscomi MT, 2009, J NEUROSCI, V29, P4564, DOI 10.1523/JNEUROSCI.0786-09.2009; Weston RM, 2007, J CEREBR BLOOD F MET, V27, P100, DOI 10.1038/sj.jcbfm.9600324; Yamamoto W, 2008, EUR J PHARMACOL, V583, P56, DOI 10.1016/j.ejphar.2008.01.010; Zhang M, 2008, NEUROSCIENCE, V152, P753, DOI 10.1016/j.neuroscience.2008.01.022; Zhang M, 2007, J CEREBR BLOOD F MET, V27, P1387, DOI 10.1038/sj.jcbfm.9600447; Zhang M, 2009, MICROVASC RES, V78, P86, DOI 10.1016/j.mvr.2009.03.005; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438	64	141	144	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					788	798		10.1096/fj.09-141275	http://dx.doi.org/10.1096/fj.09-141275			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19884325				2022-12-28	WOS:000274974600015
J	Georges, AB; Benayoun, BA; Caburet, S; Veitia, RA				Georges, Adrien B.; Benayoun, Berenice A.; Caburet, Sandrine; Veitia, Reiner A.			Generic binding sites, generic DNA-binding domains: where does specific promoter recognition come from?	FASEB JOURNAL			English	Review						cooperativity; promoter; specificity; synergy; transcription	FORKHEAD TRANSCRIPTION FACTOR; RESPONSE ELEMENTS; POSTTRANSLATIONAL MODIFICATION; ESTROGEN-RECEPTOR; CRYSTAL-STRUCTURE; THYROID-HORMONE; DIRECT REPEATS; RETINOIC ACID; HOMEOBOX GENE; EXPRESSION	A transcription reaction relies on the specific recognition of cis-regulatory regions containing short DNA motifs. Such sequences are bound by transcription factors (TFs) involved in the recruitment, direct or not, of the transcriptional machinery. A eukaryotic genome can contain tens of genes encoding TFs that recognize very similar consensus DNA target sequences. In this review, we explore in a simple way how TFs coexpressed in the same cells and recognizing generic consensus sites with generic DNA-binding domains can achieve a specific modulation of target gene expression. We dissect the strategy followed by eukaryotes, which involves the formation of complex nucleoprotein structures involving many TFs and their cognate binding sites. This multiplicity of actors increases the effective length of the target DNA recognized by the TFs and might help paralogous TFs establish specific interactions. From this perspective, eukaryotic gene regulation implies the cooperation of several TFs, which is also the basis of information integration. Such cooperative TFs are likely to form a combinatorial partner code whose ultimate molecular hallmark is the assembly of enhanceosome-like structures ensuring the formation of an activation surface that is complementary to other coactivators and to the transcriptional machinery itself.-Georges, A. B., Benayoun, B. A., Caburet, S., Veitia, R. A. Generic binding sites, generic DNA-binding domains: where does specific promoter recognition come from? FASEB J. 24, 346-356 (2010). www.fasebj.org	[Veitia, Reiner A.] Inst Jacques Monod, Equipe Genet & Genom Dev Gonad, CNRS, UMR 7592, F-75205 Paris 13, France; [Georges, Adrien B.] Ecole Normale Super, F-75231 Paris, France; [Georges, Adrien B.; Benayoun, Berenice A.; Caburet, Sandrine; Veitia, Reiner A.] Univ Paris 07, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); UDICE-French Research Universities; Universite Paris Cite	Veitia, RA (corresponding author), Inst Jacques Monod, Equipe Genet & Genom Dev Gonad, CNRS, UMR 7592, Batiment Buffon,15 Rue Helene Brion, F-75205 Paris 13, France.	reiner.veitia@inserm.fr	Caburet, Sandrine/AAH-3435-2019; Benayoun, Bérénice A./K-7048-2012; Georges, Adrien/ABD-6348-2021	Benayoun, Bérénice A./0000-0002-7401-4777; Georges, Adrien/0000-0003-4208-2393; Caburet, Sandrine/0000-0002-7404-8213	Association pour la Recherche contre le Cancer; University Paris Diderot-Paris7; Centre National de la Recherche Scientifique; Institut National de la Sante et de la Recherche Medicale; Institut Universitaire de France; Ecole Normale Superieure de Paris; AMN/Universite Paris Diderot-Paris VII	Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); University Paris Diderot-Paris7; Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut Universitaire de France; Ecole Normale Superieure de Paris; AMN/Universite Paris Diderot-Paris VII	We gratefully thank two anonymous referees for their most helpful comments on a previous version of this manuscript. Work in R.A.V.'s laboratory is supported by the Association pour la Recherche contre le Cancer, the University Paris Diderot-Paris7, the Centre National de la Recherche Scientifique, and the Institut National de la Sante et de la Recherche Medicale. R.A.V. is member of and supported by the Institut Universitaire de France. A. B. G. is funded by Ecole Normale Superieure de Paris. B.A.B. is funded by an AMN/Universite Paris Diderot-Paris VII fellowship.	Benayoun BA, 2008, HUM MOL GENET, V17, P3118, DOI 10.1093/hmg/ddn209; Benayoun BA, 2009, TRENDS CELL BIOL, V19, P189, DOI 10.1016/j.tcb.2009.02.003; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Bilu Y, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-12-r103; Blount AL, 2009, J BIOL CHEM, V284, P7631, DOI 10.1074/jbc.M806676200; Brent MM, 2008, STRUCTURE, V16, P1407, DOI 10.1016/j.str.2008.06.013; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Casamassimi A, 2007, BIOCHIMIE, V89, P1439, DOI 10.1016/j.biochi.2007.08.002; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; Courey AJ, 2001, CURR BIOL, V11, pR250, DOI 10.1016/S0960-9822(01)00130-0; Draganescu A, 1998, J MOL BIOL, V276, P529, DOI 10.1006/jmbi.1997.1567; Ellsworth BS, 2003, MOL CELL ENDOCRINOL, V206, P93, DOI 10.1016/S0303-7207(03)00235-1; Feledy JA, 1999, NUCLEIC ACIDS RES, V27, P764, DOI 10.1093/nar/27.3.764; Foucher I, 2003, DEVELOPMENT, V130, P1867, DOI 10.1242/dev.00414; Foucher I, 2002, DEVELOPMENT, V129, P4065; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Gibson G, 1996, THEOR POPUL BIOL, V49, P58, DOI 10.1006/tpbi.1996.0003; Goff DJ, 1997, DEVELOPMENT, V124, P627; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hager GL, 2000, BIOCHEM SOC T, V28, P405, DOI 10.1042/0300-5127:0280405; Hatta M, 2007, J BIOL CHEM, V282, P35583, DOI 10.1074/jbc.M704735200; HERBOMEL P, 1990, New Biologist, V2, P1063; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Hueber SD, 2008, BIOESSAYS, V30, P965, DOI 10.1002/bies.20823; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Joshi R, 2007, CELL, V131, P530, DOI 10.1016/j.cell.2007.09.024; Kaestner KH, 2000, GENE DEV, V14, P142; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; Knosp WM, 2007, J BIOL CHEM, V282, P6843, DOI 10.1074/jbc.M610775200; Lammens T, 2009, TRENDS CELL BIOL, V19, P111, DOI 10.1016/j.tcb.2009.01.002; Lee CS, 2005, NATURE, V435, P944, DOI 10.1038/nature03649; Lehmann OJ, 2003, TRENDS GENET, V19, P339, DOI 10.1016/S0168-9525(03)00111-2; LEWIN B, 2000, GENES, V7, P634; Little TH, 2006, MOL ENDOCRINOL, V20, P831, DOI 10.1210/me.2005-0384; MARGALIT Y, 1993, NUCLEIC ACIDS RES, V21, P4915, DOI 10.1093/nar/21.21.4915; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Mohn F, 2009, TRENDS GENET, V25, P129, DOI 10.1016/j.tig.2008.12.005; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nirula A, 1997, J BIOL CHEM, V272, P7736, DOI 10.1074/jbc.272.12.7736; Nishio SI, 2008, MOL ENDOCRINOL, V22, P23, DOI 10.1210/me.2007-0170; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Pohl BS, 2004, DEV GENES EVOL, V214, P200, DOI 10.1007/s00427-004-0391-7; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rao E, 2001, HUM MOL GENET, V10, P3083, DOI 10.1093/hmg/10.26.3083; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; Salih DAM, 2008, CURR OPIN CELL BIOL, V20, P126, DOI 10.1016/j.ceb.2008.02.005; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Trindade M, 1999, DEV BIOL, V216, P442, DOI 10.1006/dbio.1999.9507; Tsai KL, 2007, NUCLEIC ACIDS RES, V35, P6984, DOI 10.1093/nar/gkm703; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; van der Vos KE, 2008, ONCOGENE, V27, P2289, DOI 10.1038/onc.2008.22; Veitia RA, 2006, BIOESSAYS, V28, P282, DOI 10.1002/bies.20377; Veitia RA, 2003, BIOL REV, V78, P149, DOI 10.1017/S1464793102006036; Venugopalan SR, 2008, HUM MOL GENET, V17, P3643, DOI 10.1093/hmg/ddn258; Wang B, 2003, J BIOL CHEM, V278, P24259, DOI 10.1074/jbc.M207174200; Wang LH, 2002, P NATL ACAD SCI USA, V99, P12721, DOI 10.1073/pnas.202461199; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Zeng J, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1117	66	63	64	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					346	356		10.1096/fj.09-142117	http://dx.doi.org/10.1096/fj.09-142117			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19762556				2022-12-28	WOS:000274045000003
J	Jin, HW; Chemaly, ER; Lee, A; Kho, C; Hadri, L; Hajjar, RJ; Akar, FG				Jin, Hongwei; Chemaly, Elie R.; Lee, Ahyoung; Kho, Changwon; Hadri, Lahouaria; Hajjar, Roger J.; Akar, Fadi G.			Mechanoelectrical remodeling and arrhythmias during progression of hypertrophy	FASEB JOURNAL			English	Article						heart failure; pressure overload hypertrophy; connexin; conduction	ECHOCARDIOGRAPHIC-ASSESSMENT; CONNEXIN43 EXPRESSION; CARDIAC-HYPERTROPHY; HEART-FAILURE; GENE-TRANSFER; MECHANISMS; ARRHYTHMOGENESIS; MICE	Despite a clear association between left ventricular (LV) mechanical dysfunction in end-stage heart failure and the incidence of arrhythmias, the majority of sudden cardiac deaths occur at earlier stages of disease development. The mechanisms by which structural, mechanical, and molecular alterations predispose to arrhythmias at the tissue level before the onset of LV dysfunction remain unclear. In a rat model of pressure overload hypertrophy (PoH) produced by ascending aortic banding, we correlated mechanical and structural changes measured in vivo with key electrophysiological changes measured ex vivo in the same animals. We found that action potential prolongation, a hallmark of electrical remodeling at the tissue level, is highly correlated with changes in LV wall thickness but not mechanical function. In contrast, conduction delays are not predicted by either mechanical or structural changes during disease development. Moreover, disrupted Cx43 phosphorylation at intermediate (increased) and late (decreased) stages of PoH are associated with moderate and severe conduction delays, respectively. Interestingly, the level of interaction between Cx43 and the cytoskeletal protein ZO-1 is exclusively decreased at the late stage of PoH. Closely coupled action potentials consistent with afterdepolarization-mediated triggered beats were readily observed in 6 of 15 PoH hearts but never in controls. Similarly, PoH (8/15) but not control hearts exhibited sustained episodes of ventricular tachycardia after rapid stimulation. The initiation and early maintenance of arrhythmias in PoH were formed by rapid and highly uniform activation wave-fronts emanating from sites distal to the former site of stimulation. In conclusion, repolarization but not conduction delays are predicted by structural remodeling in PoH. Cx43 phosphorylation is disrupted at intermediate (increased) and late (decreased) stages, which are associated with conduction delays. Dephosphorylation of Cx43 is associated with loss of interaction with ZO-1 and severe conduction delays. Remodeling at all stages of PoH predisposes to triggers and focal arrhythmias.-Jin, H., Chemaly, E. R., Lee, A., Kho, C., Hadri, L., Hajjar, R. J., Akar, F. G. Mechanoelectrical remodeling and arrhythmias during progression of hypertrophy. FASEB J. 24, 451-463 (2010). www.fasebj.org	[Akar, Fadi G.] Mt Sinai Sch Med, Inst Computat Med, Div Cardiol, Cardiovasc Res Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Akar, FG (corresponding author), Mt Sinai Sch Med, Inst Computat Med, Div Cardiol, Cardiovasc Res Ctr, 1 Gustave L Levy Pl, New York, NY 10029 USA.	fadi.akar@mssm.edu	Hadri, Lahouaria/AAP-6415-2020	Hadri, Lahouaria/0000-0001-8108-7993	National Institutes of Health [HL-091923, HL-080498]; American Heart Association [0830126N]; Irma T. Hirschl and Monique Weill Caullier Trusts; Celladon Corporation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091923, K01HL103176, R01HL080498, T32HL007824] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Irma T. Hirschl and Monique Weill Caullier Trusts; Celladon Corporation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by grants from the National Institutes of Health (HL-091923; to F. G. A.), the American Heart Association (0830126N; to F. G. A.), the Irma T. Hirschl and Monique Weill Caullier Trusts (to F. G. A.), Celladon Corporation (to F. G. A.), and the National Institutes of Health (HL-080498; to R.J.H.). F. G. A. is on the Scientific Advisory Board of Celladon Corporation.	Akar FG, 2007, AM J PHYSIOL-HEART C, V293, pH1223, DOI 10.1152/ajpheart.00079.2007; Akar FG, 2004, CIRC RES, V95, P717, DOI 10.1161/01.RES.0000144125.61927.1c; Akar FG, 2005, J CLIN INVEST, V115, P3527, DOI 10.1172/JCI25371; Danik SB, 2008, FASEB J, V22, P1204, DOI 10.1096/fj.07-8974com; Del Monte F, 2002, PHYSIOL GENOMICS, V9, P49, DOI 10.1152/physiolgenomics.00035.2001; Eloff BC, 2001, CARDIOVASC RES, V51, P681, DOI 10.1016/S0008-6363(01)00341-8; Escudero Eduardo Manuel, 2004, Eur J Echocardiogr, V5, P169, DOI 10.1016/j.euje.2003.11.004; Gutstein DE, 2001, CIRC RES, V88, P333, DOI 10.1161/01.RES.88.3.333; Hall DG, 2000, PEDIATR RES, V48, P36, DOI 10.1203/00006450-200007000-00009; Henkens IR, 2007, AM J PHYSIOL-HEART C, V293, pH1300, DOI 10.1152/ajpheart.01359.2006; Jalife J, 1999, J CARDIOVASC ELECTR, V10, P1649, DOI 10.1111/j.1540-8167.1999.tb00230.x; Jin HW, 2008, CIRCULATION, V118, pS531; Kang YJ, 2006, TOXICOL PATHOL, V34, P58, DOI 10.1080/01926230500419421; Kontogeorgis A, 2008, AM J PHYSIOL-HEART C, V295, pH1905, DOI 10.1152/ajpheart.590.2008; Kostin S, 2004, CARDIOVASC RES, V62, P426, DOI 10.1016/j.cardiores.2003.12.010; Lyon AR, 2008, CIRCULATION, V118, pS528; Marionneau C, 2008, CIRC RES, V102, P1406, DOI 10.1161/CIRCRESAHA.107.170050; Morley GE, 2000, J CARDIOVASC ELECTR, V11, P375, DOI 10.1111/j.1540-8167.2000.tb01811.x; Peters NS, 1996, CLIN SCI, V90, P447, DOI 10.1042/cs0900447; Peters NS, 1997, CIRCULATION, V95, P988; Poelzing S, 2004, AM J PHYSIOL-HEART C, V286, pH2001, DOI 10.1152/ajpheart.00987.2003; POGWIZD SM, 1995, CIRCULATION, V92, P1034, DOI 10.1161/01.CIR.92.4.1034; Qu JX, 2009, CIRC RES, V104, P365, DOI 10.1161/CIRCRESAHA.108.184044; QUAN WL, 1990, CIRC RES, V66, P367, DOI 10.1161/01.RES.66.2.367; Reisner Y, 2009, J CELL MOL MED, V13, P562, DOI 10.1111/j.1582-4934.2008.00361.x; Roepke TK, 2008, FASEB J, V22, P3648, DOI 10.1096/fj.08-110171; Saffitz JE, 1999, CARDIOVASC RES, V42, P309, DOI 10.1016/S0008-6363(99)00023-1; Salemi VMC, 2004, ARTIF ORGANS, V28, P332, DOI 10.1111/j.1525-1594.2004.47350.x; SCOTT BD, 1993, AM HEART J, V125, P1047, DOI 10.1016/0002-8703(93)90113-N; Stein AB, 2007, BASIC RES CARDIOL, V102, P28, DOI 10.1007/s00395-006-0627-y; Wickenden AD, 1998, CARDIOVASC RES, V37, P312, DOI 10.1016/S0008-6363(97)00256-3; Yan GX, 2001, AM J PHYSIOL-HEART C, V281, pH1968, DOI 10.1152/ajpheart.2001.281.5.H1968	32	36	37	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					451	463		10.1096/fj.09-136622	http://dx.doi.org/10.1096/fj.09-136622			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19825979	Green Published			2022-12-28	WOS:000274045000013
J	Mehedint, MG; Niculescu, MD; Craciunescu, CN; Zeisel, SH				Mehedint, Mihai G.; Niculescu, Mihai D.; Craciunescu, Corneliu N.; Zeisel, Steven H.			Choline deficiency alters global histone methylation and epigenetic marking at the Re1 site of the calbindin 1 gene	FASEB JOURNAL			English	Article						G9a; hippocampus; REST/NRSF; progenitors	NEURAL-TUBE DEFECTS; EMBRYONIC-DEVELOPMENT ALTERS; PROGENITOR-CELL MITOSIS; LYSINE-9 METHYLATION; S-ADENOSYLMETHIONINE; AVAILABILITY ALTERS; DNA METHYLATION; PRECURSOR CELLS; H3 LYSINE-9; STEM	Maternal choline availability is essential for fetal neurogenesis. Choline deprivation ( CD) causes hypomethylation of specific CpG islands in genes controlling cell cycling in fetal hippocampus. We now report that, in C57BL/6 mice, CD during gestational days 12-17 also altered methylation of the histone H3 in E17 fetal hippocampi. In the ventricular and subventricular zones, monomethyl-lysine 9 of H3 (H3K9me1) was decreased by 25% (P<0.01), and in the pyramidal layer, dimethyl-lysine 9 of H3 (H3K9me2) was decreased by 37% (P<0.05). These changes were region specific and were not observed in whole-brain preparations. Also, the same effects of CD on H3 methylation were observed in E14 neural progenitor cells (NPCs) in culture. Changes in G9a histone methyltransferase might mediate altered H3K9me2,1. Gene expression of G9a was decreased by 80% in CD NPCs (P<0.001). In CD, H3 was hypomethylated upstream of the RE1 binding site in the calbindin 1 promoter, and 1 CpG site within the calbindin 1 promoter was hypermethylated. REST binding to RE1 (recruits G9a) was decreased by 45% (P<0.01) in CD. These changes resulted in increased expression of calbindin 1 in CD (260%; P<0.05). Thus, CD modulates histone methylation in NPCs, and this could underlie the observed changes in neurogenesis.-Mehedint, M. G., Niculescu, M. D., Craciunescu, C. N., Zeisel, S. H. Choline deficiency alters global histone methylation and epigenetic marking at the Re1 site of the calbindin 1 gene. FASEB J. 24, 184-195 ( 2010). www.fasebj.org	Univ N Carolina Chapel Hill, Sch Publ Hlth, Dept Nutr, Nutr Res Inst Kannapolis, Kannapolis, NC USA; Univ N Carolina Chapel Hill, Sch Med, Kannapolis, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Zeisel, SH (corresponding author), UNC Nutr Res Inst Kannapolis, 500 Laureate Way, Kannapolis, NC 28081 USA.	steven_zeisel@unc.edu	Ariel, Pablo/AGJ-4118-2022		National Institutes of Health [AG-09525, DK-55865, DK-56350]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055865, P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grants from the National Institutes of Health (AG-09525, DK-55865). Support for this work was also provided by grants from the National Institutes of Health to the Clinical Nutrition Research Unit (DK-56350). We thank Dr. Robert Bagnell, Jr., Professor and Director of the Microscopy Service Laboratory, UNC Department of Pathology, for assistance.	Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 2005, DEV BRAIN RES, V159, P149, DOI 10.1016/j.devbrainres.2005.07.002; Albright CD, 2003, NUTR NEUROSCI, V6, P129, DOI 10.1080/1028415031000084418; Albright CD, 1996, FASEB J, V10, P510, DOI 10.1096/fasebj.10.4.8647350; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; ALTMAN J, 1990, J COMP NEUROL, V301, P325, DOI 10.1002/cne.903010302; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Ballas N, 2005, CURR OPIN NEUROBIOL, V15, P500, DOI 10.1016/j.conb.2005.08.015; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Blom HJ, 2006, NAT REV NEUROSCI, V7, P724, DOI 10.1038/nrn1986; Chin HG, 2007, NUCLEIC ACIDS RES, V35, P7313, DOI 10.1093/nar/gkm726; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Craciunescu CN, 2003, J NUTR, V133, P3614, DOI 10.1093/jn/133.11.3614; Cremisi F, 2003, CURR OPIN NEUROBIOL, V13, P26, DOI 10.1016/S0959-4388(03)00005-9; Esteve PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fisher MC, 2002, FASEB J, V16, P619, DOI 10.1096/fj.01-0564fje; Fisher MC, 2001, TERATOLOGY, V64, P114, DOI 10.1002/tera.1053; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Giegerich R, 1996, Proc Int Conf Intell Syst Mol Biol, V4, P68; Greenway DJ, 2007, STEM CELLS, V25, P354, DOI 10.1634/stemcells.2006-0207; Guan ZH, 2002, CELL, V111, P483, DOI 10.1016/S0092-8674(02)01074-7; Hsieh J, 2004, CURR OPIN GENET DEV, V14, P461, DOI 10.1016/j.gde.2004.07.006; Jacobowitz D.M, 1998, CHEMOARCHITECTONIC A; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jensen LJ, 2007, FASEB J, V21, pA519; Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853; Kovacheva VP, 2007, J BIOL CHEM, V282, P31777, DOI 10.1074/jbc.M705539200; Kuwabara T, 2004, CELL, V116, P779, DOI 10.1016/S0092-8674(04)00248-X; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Levenson JM, 2005, NAT REV NEUROSCI, V6, P108, DOI 10.1038/nrn1604; Levenson JM, 2004, J BIOL CHEM, V279, P40545, DOI 10.1074/jbc.M402229200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma DK, 2008, STEM CELLS, V26, P2131, DOI 10.1634/stemcells.2008-0388; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3053, DOI 10.1097/00001756-199709290-00010; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1999, DEV BRAIN RES, V118, P51, DOI 10.1016/S0165-3806(99)00105-4; Meck WH, 1997, NEUROREPORT, V8, P2831, DOI 10.1097/00001756-199709080-00005; Meck WH, 2003, NEUROSCI BIOBEHAV R, V27, P385, DOI 10.1016/S0149-7634(03)00069-1; Mutskov VJ, 2002, GENE DEV, V16, P1540, DOI 10.1101/gad.988502; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Niculescu MD, 2006, FASEB J, V20, P43, DOI 10.1096/fj.05-4707com; Niculescu MD, 2005, MOL BRAIN RES, V134, P309, DOI 10.1016/j.molbrainres.2004.11.001; Ooi L, 2007, NAT REV GENET, V8, P544, DOI 10.1038/nrg2100; Ozarda Ilcol Y, 2002, Arch Physiol Biochem, V110, P393; Park JJ, 1996, J NEUROBIOL, V30, P315, DOI 10.1002/(SICI)1097-4695(199607)30:3<315::AID-NEU1>3.0.CO;2-7; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Roopra A, 2004, MOL CELL, V14, P727, DOI 10.1016/j.molcel.2004.05.026; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Shaw GM, 2004, AM J EPIDEMIOL, V160, P102, DOI 10.1093/aje/kwh187; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; SHIVAPURKAR N, 1983, CARCINOGENESIS, V4, P1051, DOI 10.1093/carcin/4.8.1051; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wachs FP, 2003, LAB INVEST, V83, P949, DOI 10.1097/01.LAB.0000075556.74231.A5; Williams CL, 1998, BRAIN RES, V794, P225, DOI 10.1016/S0006-8993(98)00229-7; Wu Yuanyuan, 2008, V438, P39, DOI 10.1007/978-1-59745-133-8_5; Xiao B, 2003, NATURE, V421, P652, DOI 10.1038/nature01378; ZEISEL SH, 1989, BIOCHEM J, V259, P725, DOI 10.1042/bj2590725; Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhu XN, 2004, DEV BRAIN RES, V149, P121, DOI 10.1016/j.devbrainres.2004.01.004	76	111	116	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					184	195		10.1096/fj.09-140145	http://dx.doi.org/10.1096/fj.09-140145			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19752176	Green Published			2022-12-28	WOS:000273233600020
J	Kumar, A; Hoffman, TA; DeRicco, J; Naqvi, A; Jain, MK; Irani, K				Kumar, Ajay; Hoffman, Timothy A.; DeRicco, Jeremy; Naqvi, Asma; Jain, Mukesh K.; Irani, Kaikobad			Transcriptional repression of Kruppel like factor-2 by the adaptor protein p66shc	FASEB JOURNAL			English	Article						KLF2; MEF2A; reactive oxygen species; ShcA; thrombomodulin; endothelial	ENHANCER FACTOR 2A; OXIDATIVE STRESS; GENE-EXPRESSION; CELL APOPTOSIS; LIFE-SPAN; MEF2; KLF2; INHIBITION; REGULATOR; DIFFERENTIATION	The adaptor protein p66shc promotes cellular oxidative stress and apoptosis. Here, we demonstrate a novel mechanistic relationship between p66shc and the kruppel like factor-2 (KLF2) transcription factor and show that this relationship has biological relevance to p66shc-regulated cellular oxidant level, as well as KLF2-induced target gene expression. Genetic knockout of p66shc in mouse embryonic fibroblasts (MEFs) stimulates activity of the core KLF2 promoter and increases KLF2 mRNA and protein expression. Similarly, shRNA-induced knockdown of p66shc increases KLF2-promoter activity in HeLa cells. The increase in KLF2-promoter activity in p66shc-knockout MEFs is dependent on a myocyte enhancing factor-2A (MEF2A)-binding sequence in the core KLF2 promoter. Short-hairpin RNA-induced knockdown of p66shc in endothelial cells also stimulates KLF2 mRNA and protein expression, as well as expression of the endothelial KLF2 target gene thrombomodulin. MEF2A protein and mRNA are more abundant in p66shc-knockout MEFs, resulting in greater occupancy of the KLF2 promoter by MEF2A. In endothelial cells, the increase in KLF2 and thrombomodulin protein by shRNA-induced decrease in p66shc expression is partly abrogated by knockdown of MEF2A. Finally, knockdown of KLF2 abolishes the decrease in the cellular reactive oxygen species hydrogen peroxide observed with knockdown of p66shc, and KLF2 overexpression suppresses cellular hydrogen peroxide levels, independent of p66shc expression. These findings illustrate a novel mechanism by which p66shc promotes cellular oxidative stress, through suppression of MEF2A expression and consequent repression of KLF2 transcription.-Kumar, A., Hoffman, T. A., DeRicco, J., Naqvi, A., Jain, M. K., Irani, K. Transcriptional repression of Kruppel like factor-2 by the adaptor protein p66shc. FASEB J. 23, 4344-4352 (2009). www.fasebj.org	[Kumar, Ajay; Hoffman, Timothy A.; DeRicco, Jeremy; Naqvi, Asma; Irani, Kaikobad] Univ Pittsburgh, Med Ctr, Cardiovasc Inst, Pittsburgh, PA 15213 USA; [Jain, Mukesh K.] Case Western Reserve Univ, Sch Med, Case Cardiovasc Res Inst, Cleveland, OH USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Case Western Reserve University	Kumar, A (corresponding author), Univ Pittsburgh, Med Ctr, Cardiovasc Inst, 623S Scaife Hall,200 Lothrop St, Pittsburgh, PA 15213 USA.	kumara@upmc.edu; iranik@upmc.edu		Irani, Kaikobad/0000-0001-9194-7387	National Institutes of Health [R01 HL094959, R01 HL070929, P01 HL065608]; American Heart association [BGIA 0865419D]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL065608, R01HL070929, R01HL076754, R01HL094959] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank T. Finkel (National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA) for the gift of the p66<SUP>-/-</SUP> and WT MEFs, A. Hoffmann and D. Baltimore (California Institute of Technology, Pasadena, CA, USA) for the p65 and p50-null MEFs, and Huck Hui Ng (Genome Institute of Singapore, Singapore) for the KLF2 antibody. This work was supported by National Institutes of Health grants R01 HL094959, R01 HL070929, and P01 HL065608 (KI), and an American Heart association BGIA 0865419D (AK).	ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Bhattacharya R, 2005, J BIOL CHEM, V280, P28848, DOI 10.1074/jbc.C500200200; Bieker JJ, 1996, DNA CELL BIOL, V15, P347, DOI 10.1089/dna.1996.15.347; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; Dekker RJ, 2006, BLOOD, V107, P4354, DOI 10.1182/blood-2005-08-3465; Flavell SW, 2006, SCIENCE, V311, P1008, DOI 10.1126/science.1122511; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; GOLDSTONE SD, 1995, BBA-GENE STRUCT EXPR, V1263, P114, DOI 10.1016/0167-4781(95)00088-X; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Jackson JG, 2000, CLIN CANCER RES, V6, P1135; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Khanday FA, 2006, J CELL BIOL, V172, P817, DOI 10.1083/jcb.200506001; Kumar A, 2005, MOL CELL BIOL, V25, P5893, DOI 10.1128/MCB.25.14.5893-5903.2005; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Lin Q, 1998, DEVELOPMENT, V125, P4565; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lin ZY, 2005, CIRC RES, V96, pE48, DOI 10.1161/01.RES.0000159707.05637.a1; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Menini S, 2006, DIABETES, V55, P1642, DOI 10.2337/db05-1477; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Napoli C, 2003, P NATL ACAD SCI USA, V100, P2112, DOI 10.1073/pnas.0336359100; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Orsini F, 2004, J BIOL CHEM, V279, P25689, DOI 10.1074/jbc.M401844200; Pacini S, 2004, MOL CELL BIOL, V24, P1747, DOI 10.1128/MCB.24.4.1747-1757.2004; Parmar KM, 2006, J CLIN INVEST, V116, P49, DOI 10.1172/JCI24787; Pellegrini M, 2007, CELL DEATH DIFFER, V14, P338, DOI 10.1038/sj.cdd.4401997; PERKINS AC, 1995, NATURE, V375, P318; Ramachandran B, 2008, J BIOL CHEM, V283, P11935, DOI 10.1074/jbc.M707389200; Ramachandran B, 2008, J BIOL CHEM, V283, P10318, DOI 10.1074/jbc.M707623200; Sen-Banerjee S, 2005, CIRCULATION, V112, P720, DOI 10.1161/CIRCULATIONAHA.104.525774; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; Veeramani S, 2005, ONCOGENE, V24, P7203, DOI 10.1038/sj.onc.1208852; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Yamamori T, 2005, J MOL CELL CARDIOL, V39, P992, DOI 10.1016/j.yjmcc.2005.09.003; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790	46	21	21	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4344	4352		10.1096/fj.09-138743	http://dx.doi.org/10.1096/fj.09-138743			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19696221	Green Published			2022-12-28	WOS:000272193700029
J	Camprubi-Robles, M; Planells-Cases, R; Ferrer-Montiel, A				Camprubi-Robles, M.; Planells-Cases, R.; Ferrer-Montiel, A.			Differential contribution of SNARE-dependent exocytosis to inflammatory potentiation of TRPV1 in nociceptors	FASEB JOURNAL			English	Article						proalgesic agents; pain; analgesia; receptor; protein kinase C; CGRP	PROTEIN-KINASE-C; VANILLOID RECEPTOR TRPV1; NERVE GROWTH-FACTOR; SENSORY NEURONS; THERMAL HYPERALGESIA; DRG NEURONS; REGULATED EXOCYTOSIS; ACTIVATED CURRENTS; HEAT HYPERALGESIA; TYROSINE KINASE	Potentiation of the pain-integrator ion channel transient receptor potential vanilloid type 1 (TRPV1) underlies thermal hyperalgesia mediated by a variety of proinflammatory factors. Two complementary mechanisms of TRPV1 inflammatory sensitization have been proposed, namely a decrease of its activation threshold and an increment of its surface expression in nociceptors. Here we investigated the involvement of regulated exocytosis to the inflammatory sensitization of TRPV1 in rat neonatal dorsal root ganglion neurons by proalgesic agents. The contribution of soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE)-dependent exocytosis was evaluated using a small peptide patterned after the synaptosomal-associated protein of 25 kDa (SNAP-25) protein that acts as a specific and potent inhibitor of neuronal exocytosis. We found that TRPV1 sensitization mediated by nerve growth factor, ATP, and IGF-I was accompanied by a higher channel expression in the neuronal plasma membrane, which was prevented by blockade of regulated exocytosis. In contrast, TRPV1 sensitization caused by bradykinin, IL-1 beta, and artemin was insensitive to inhibition of SNARE-dependent vesicular fusion and was not due to an increase in TRPV1 surface expression. Therefore, it appears that some, but not all, proinflammatory agents sensitize rat nociceptors by promoting the recruitment of TRPV1 channels to the neuronal surface. These findings support the tenet that SNARE complex-mediated exocytosis of TRPV1 may be a valid therapeutic target to treat inflammatory pain.-Camprubi-Robles, M., Planells-Cases, R., Ferrer-Montiel, A. Differential contribution of SNARE-dependent exocytosis to inflammatory potentiation of TRPV1 in nociceptors. FASEB J. 23, 3722-3733 (2009). www.fasebj.org	[Camprubi-Robles, M.; Ferrer-Montiel, A.] Univ Miguel Hernandez, Inst Biol Mol & Celular, Alicante 03202, Spain; [Planells-Cases, R.] Ctr Invest Principe Felipe, Valencia, Spain	Universidad Miguel Hernandez de Elche; Prince Felipe Research Center	Ferrer-Montiel, A (corresponding author), Univ Miguel Hernandez, Inst Biol Mol & Celular, Av Univ S-N, Alicante 03202, Spain.	aferrer@umh.es	Ferrer-Montiel, Antonio/C-3072-2015	Ferrer-Montiel, Antonio/0000-0002-2973-6607	el Ministerio de Ciencia e Innovacion (MICINN) [SAF2006-2580, SAF2007-63193]; Consolider-Ingenio [CSD2008-00005]; la Fundacio la Marato de TV3; la Generalitat Valenciana; Fondo Social Europeo	el Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Consolider-Ingenio(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); la Fundacio la Marato de TV3; la Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)); Fondo Social Europeo(European Social Fund (ESF)European Commission)	This work was supported by grants from el Ministerio de Ciencia e Innovacion (MICINN) (SAF2006-2580 to A.F.-M. and SAF2007-63193 to R.P.-C.); Consolider-Ingenio 2010 ( MICINN, CSD2008-00005 to A.F.-M and R.P.-C.); and la Fundacio la Marato de TV3 ( to A.F.-M. and R.P.-C.). M.C.-R. is a fellowship recipient from la Generalitat Valenciana, and R. P. C. is a recipient of the Fondo Social Europeo. A.F.-M. and M.C.-R. are inventors of compound DD04107 and have filed a patent application.	Blanes-Mira C, 2002, Int J Cosmet Sci, V24, P303, DOI 10.1046/j.1467-2494.2002.00153.x; Blanes-Mira C, 2004, J NEUROCHEM, V88, P124, DOI 10.1046/j.1471-4159.2003.02133.x; Bonnington JK, 2003, J PHYSIOL-LONDON, V551, P433, DOI 10.1113/jphysiol.2003.039990; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Elitt CM, 2006, J NEUROSCI, V26, P8578, DOI 10.1523/JNEUROSCI.2185-06.2006; Fischbach T, 2007, J NEUROPHYSIOL, V98, P929, DOI 10.1152/jn.01096.2006; Garcia-Martinez C, 2002, P NATL ACAD SCI USA, V99, P2374, DOI 10.1073/pnas.022285899; Garcia-Sanz N, 2007, J NEUROSCI, V27, P11641, DOI 10.1523/JNEUROSCI.2457-07.2007; Huang JJ, 2006, SEMIN CELL DEV BIOL, V17, P638, DOI 10.1016/j.semcdb.2006.11.002; Huang JH, 2006, CURR NEUROPHARMACOL, V4, P197, DOI 10.2174/157015906778019554; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; Jin XC, 2004, AM J PHYSIOL-CELL PH, V287, pC558, DOI 10.1152/ajpcell.00113.2004; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Kawanishi M, 2000, J BIOL CHEM, V275, P8240, DOI 10.1074/jbc.275.11.8240; Klionsky L, 2006, J PHARMACOL EXP THER, V319, P192, DOI 10.1124/jpet.106.108092; Lakshmi S, 2005, CELL MOL NEUROBIOL, V25, P819, DOI 10.1007/s10571-005-4936-8; Lee SY, 2005, ARCH PHARM RES, V28, P405, DOI 10.1007/BF02977669; LEWIN GR, 1992, EUR J NEUROSCI, V4, P700, DOI 10.1111/j.1460-9568.1992.tb00179.x; Luo WQ, 2007, NEURON, V54, P739, DOI 10.1016/j.neuron.2007.04.027; Maione S, 2007, BRIT J PHARMACOL, V150, P766, DOI 10.1038/sj.bjp.0707145; Malin SA, 2008, PAIN, V138, P484, DOI 10.1016/j.pain.2008.01.026; Malin SA, 2006, J NEUROSCI, V26, P8588, DOI 10.1523/JNEUROSCI.1726-06.2006; Mandadi S, 2004, CELL CALCIUM, V35, P471, DOI 10.1016/j.ceca.2003.11.003; Matta JA, 2007, J PHYSIOL-LONDON, V578, P397, DOI 10.1113/jphysiol.2006.121988; Meng JH, 2007, J CELL SCI, V120, P2864, DOI 10.1242/jcs.012211; Messeguer A, 2006, CURR NEUROPHARMACOL, V4, P1, DOI 10.2174/157015906775202995; Mohapatra DP, 2003, J BIOL CHEM, V278, P50080, DOI 10.1074/jbc.M306619200; MOLLIVER DC, 1995, J COMP NEUROL, V361, P404, DOI 10.1002/cne.903610305; Molliver DC, 1997, NEURON, V19, P849, DOI 10.1016/S0896-6273(00)80966-6; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; Moriyama T, 2003, J NEUROSCI, V23, P6058, DOI 10.1523/JNEUROSCI.23-14-06058.2003; O'Dell DK, 2007, BIOORGAN MED CHEM, V15, P6164, DOI 10.1016/j.bmc.2007.06.032; Obreja O, 2002, FASEB J, V16, P1497, DOI 10.1096/fj.02-0101com; Planells-Cases R, 2005, PFLUG ARCH EUR J PHY, V451, P151, DOI 10.1007/s00424-005-1423-5; Robbins J, 2006, J NEUROSCI, V26, P7950, DOI 10.1523/JNEUROSCI.2138-06.2006; Sugiura T, 2002, J NEUROPHYSIOL, V88, P544, DOI 10.1152/jn.2002.88.1.544; Szallasi A, 2007, NAT REV DRUG DISCOV, V6, P357, DOI 10.1038/nrd2280; Valente P, 2008, FASEB J, V22, P3298, DOI 10.1096/fj.08-107425; Van Buren JJ, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-17; Zhang XM, 2005, EMBO J, V24, P4211, DOI 10.1038/sj.emboj.7600893; Zhang XM, 2008, NEURON, V59, P450, DOI 10.1016/j.neuron.2008.05.015; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	45	77	79	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3722	3733		10.1096/fj.09-134346	http://dx.doi.org/10.1096/fj.09-134346			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19584302				2022-12-28	WOS:000271272500010
J	Wu, JB; Chen, K; Li, YM; Lau, YFC; Shih, JC				Wu, Jason B.; Chen, Kevin; Li, Yunmin; Lau, Yun-Fai Chris; Shih, Jean C.			Regulation of monoamine oxidase A by the SRY gene on the Y chromosome	FASEB JOURNAL			English	Article						sex-determining region Y gene; transcriptional activation; sexual dimorphism; X chromosome gene; promoter regulation; Sp1 coactivation	DEFICIT HYPERACTIVITY DISORDER; TRANSCRIPTION FACTOR SP1; OBSESSIVE-COMPULSIVE DISORDER; SEX-DIFFERENCES; HUMAN BRAIN; B GENES; MAO-A; EMBRYONIC-DEVELOPMENT; ASSOCIATION ANALYSIS; SEROTONIN SYNTHESIS	Monoamine oxidase A (MAO A), encoded by the X chromosome, catalyzes the oxidative deamination of monoamine neurotransmitters, such as serotonin, and plays a critically important role in brain development and functions. Abnormal MAO A activity has been implicated in several neuropsychiatric disorders, such as depression, autism, and attention deficit hyperactivity disorder, which show sexual dimorphism. However, the molecular basis for these disease processes is unclear. Recently, we found that MAO A was a putative target gene directly regulated by a transcription factor encoded by the sex-determining region Y (SRY) gene located on the Y chromosome. We demonstrated that SRY activates both MAO A-promoter and catalytic activities in a human male neuroblastoma BE(2) C cell line. A functional SRY-binding site in the MAO A core promoter was identified and validated by electrophoretic mobility shift and chromatin immunoprecipitation (ChIP) analyses. Coimmunoprecipitation and ChIP assays showed that SRY and Sp1 form a transcriptional complex and synergistically activate MAO A transcription. This is the first study demonstrating that the Y-encoded transcription factor SRY is capable of regulating an X-located gene, suggesting a novel molecular mechanism for sexual dimorphism in neural development, brain functions, and initiation/progression of neural disorders associated with MAO A dysfunction.-Wu, J. B., Chen, K., Li, Y., Lau, Y.-F. C., Shih, J. C. Regulation of monoamine oxidase A by the SRY gene on the Y chromosome. FASEB J. 23, 4029-4038 (2009). www.fasebj.org	[Wu, Jason B.; Chen, Kevin; Shih, Jean C.] Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA; [Shih, Jean C.] Univ So Calif, Dept Cell & Neurobiol, Keck Sch Med, Los Angeles, CA 90089 USA; [Li, Yunmin; Lau, Yun-Fai Chris] Univ Calif San Francisco, Dept Med, Vet Affairs Med Ctr, San Francisco, CA USA	University of Southern California; University of Southern California; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Shih, JC (corresponding author), Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, 1985 Zonal Ave,PSC 518, Los Angeles, CA 90089 USA.	jcshih@usc.edu	Wu, Jason Boyang/I-5780-2013; Chen, Kevin/GYU-8963-2022; Lau, Yun-Fai C/E-4465-2014	Lau, Yun-Fai C/0000-0002-9119-7050	National Institute of Mental Health [R01MH67968, R01MH39085]; Boyd and Elsie Welin Professorship; U. S. Department of Defense; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067968, R01MH039085] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000865] Funding Source: NIH RePORTER	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Boyd and Elsie Welin Professorship; U. S. Department of Defense(United States Department of Defense); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by National Institute of Mental Health grants R01MH67968 and R01MH39085 and the Boyd and Elsie Welin Professorship to J. C. S., and by a concept grant from the U. S. Department of Defense Autism Research Program to Y.-F. C. L. Y.-F. C. L. is a Research Career Scientist of the Department of Veterans Affairs. The authors thank Dr. Hans Rotheneder (Department of Medical Biochemistry and Molecular Biology, Medical University of Vienna, Vienna, Austria) for providing HA-Sp1 expression construct. The authors are also grateful to Dr. Marco Bortolato for critical reading of the manuscript.	Alonso-Nanclares L, 2008, P NATL ACAD SCI USA, V105, P14615, DOI 10.1073/pnas.0803652105; Arnold AP, 2004, ENDOCRINOLOGY, V145, P1057, DOI 10.1210/en.2003-1491; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; Baron-Cohen S, 2005, SCIENCE, V310, P819, DOI 10.1126/science.1115455; Bortolato M, 2008, ADV DRUG DELIVER REV, V60, P1527, DOI 10.1016/j.addr.2008.06.002; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; Chan Wai-Yee, 2002, Current Molecular Medicine (Hilversum), V2, P25, DOI 10.2174/1566524023363095; Chen K, 2005, J BIOL CHEM, V280, P11552, DOI 10.1074/jbc.M410033200; Chen K, 2004, NEUROTOXICOLOGY, V25, P31, DOI 10.1016/S0161-813X(03)00113-X; Chugani DC, 1998, SYNAPSE, V28, P33, DOI 10.1002/(SICI)1098-2396(199801)28:1<33::AID-SYN5>3.0.CO;2-D; Cohen IL, 2003, CLIN GENET, V64, P190, DOI 10.1034/j.1399-0004.2003.00115.x; Cosgrove KP, 2007, BIOL PSYCHIAT, V62, P847, DOI 10.1016/j.biopsych.2007.03.001; Das M, 2006, AM J MED GENET B, V141B, P637, DOI 10.1002/ajmg.b.30385; Davis LK, 2008, AM J MED GENET B, V147B, P1145, DOI 10.1002/ajmg.b.30738; Dennis C, 2004, NATURE, V427, P390, DOI 10.1038/427390a; Dewing P, 2006, CURR BIOL, V16, P415, DOI 10.1016/j.cub.2006.01.017; Domschke K, 2005, AM J MED GENET B, V134B, P110, DOI 10.1002/ajmg.b.30158; Dulcan M, 1997, J AM ACAD CHILD PSY, V36, pS85, DOI 10.1097/00004583-199710001-00007; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; Guan L, 2009, MOL PSYCHIATR, V14, P546, DOI 10.1038/sj.mp.4002139; Harley VR, 2003, ENDOCR REV, V24, P466, DOI 10.1210/er.2002-0025; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Hranilovic D, 2008, COLLEGIUM ANTROPOL, V32, P75; Jaisoorya TS, 2009, COMPR PSYCHIAT, V50, P70, DOI 10.1016/j.comppsych.2008.05.003; Jiang HB, 2006, J BIOL CHEM, V281, P8591, DOI 10.1074/jbc.M510926200; Jiang SD, 2001, AM J MED GENET, V105, P783, DOI 10.1002/ajmg.10098; Jonsson EG, 2003, SCHIZOPHR RES, V61, P31, DOI 10.1016/S0920-9964(02)00224-4; Jungert K, 2007, CANCER RES, V67, P1563, DOI 10.1158/0008-5472.CAN-06-1670; Kim Y, 2006, DEV DYNAM, V235, P2292, DOI 10.1002/dvdy.20894; Knickmeyer RC, 2006, EARLY HUM DEV, V82, P755, DOI 10.1016/j.earlhumdev.2006.09.014; Knickmeyer RC, 2006, J CHILD NEUROL, V21, P825, DOI 10.1177/08830738060210101601; LAN NC, 1989, GENOMICS, V4, P552, DOI 10.1016/0888-7543(89)90279-6; Lau YFC, 2009, BIRTH DEFECTS RES C, V87, P114, DOI 10.1002/bdrc.20144; Lawson DC, 2003, AM J MED GENET B, V116B, P84, DOI 10.1002/ajmg.b.10002; Lee TL, 2006, GENOMICS, V88, P18, DOI 10.1016/j.ygeno.2006.03.008; Li YM, 2006, MOL CELL ENDOCRINOL, V257-8, P35, DOI 10.1016/j.mce.2006.06.008; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Mayer A, 1998, NEUROGENETICS, V1, P281, DOI 10.1007/s100480050042; Mill J, 2007, MOL PSYCHIATR, V12, P799, DOI 10.1038/sj.mp.4001992; Nishizawa S, 1997, P NATL ACAD SCI USA, V94, P5308, DOI 10.1073/pnas.94.10.5308; Nordquist N, 2006, BIOCHEM BIOPH RES CO, V348, P763, DOI 10.1016/j.bbrc.2006.07.131; Oh H, 2005, BIOL REPROD, V72, P407, DOI 10.1095/biolreprod.104.034447; OSRAN H, 1993, AM J PSYCHIAT, V150, P806; Ou XM, 2006, J BIOL CHEM, V281, P21512, DOI 10.1074/jbc.M600250200; Ozcan ME, 2003, EUR ARCH PSY CLIN N, V253, P193, DOI 10.1007/s00406-003-0424-7; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Pinsonneault JK, 2006, HUM MOL GENET, V15, P2636, DOI 10.1093/hmg/ddl192; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; Pooley EC, 2007, MOL PSYCHIATR, V12, P556, DOI 10.1038/sj.mp.4001951; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; Ren B, 2004, METHOD ENZYMOL, V376, P304; Rommelse NNJ, 2008, AM J MED GENET B, V147B, P1524, DOI 10.1002/ajmg.b.30845; Salahpour A, 2007, BIOL PSYCHIAT, V61, P65, DOI 10.1016/j.biopsych.2006.03.020; Scott AL, 2008, NEUROREPORT, V19, P739, DOI 10.1097/WNR.0b013e3282fd6e88; Shih JC, 1995, PROG BRAIN RES, V106, P49; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Spring S, 2007, NEUROIMAGE, V35, P1424, DOI 10.1016/j.neuroimage.2007.02.023; Strom AC, 1996, NUCLEIC ACIDS RES, V24, P1981, DOI 10.1093/nar/24.11.1981; Sumner BEH, 1997, NEUROSCI LETT, V234, P7, DOI 10.1016/S0304-3940(97)00651-4; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tadic A, 2003, AM J MED GENET B, V117B, P1, DOI 10.1002/ajmg.b.10013; Taketo T, 2005, DEV DYNAM, V233, P612, DOI 10.1002/dvdy.20352; Thevenet L, 2004, EMBO J, V23, P3336, DOI 10.1038/sj.emboj.7600352; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Wilhelm D, 2007, PHYSIOL REV, V87, P1, DOI 10.1152/physrev.00009.2006; Williams JG, 2008, J AUTISM DEV DISORD, V38, P1731, DOI 10.1007/s10803-008-0558-6; Wilson CA, 2007, REPRODUCTION, V133, P331, DOI 10.1530/REP-06-0078; Wright SL, 2009, DEPRESS ANXIETY, V26, P182, DOI 10.1002/da.20502; Wu JB, 2009, J BIOL CHEM, V284, P16723, DOI 10.1074/jbc.M901779200; Yoo HJ, 2009, NEUROSCI RES, V63, P172, DOI 10.1016/j.neures.2008.11.007; Zhao CT, 2005, DEV GROWTH DIFFER, V47, P201; ZHU QS, 1994, J NEUROSCI, V14, P7393; ZHU QS, 1992, J NEUROSCI, V12, P4437	78	87	90	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					4029	4038		10.1096/fj.09-139097	http://dx.doi.org/10.1096/fj.09-139097			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19661285	Green Published			2022-12-28	WOS:000271272500038
J	Mader, I; Wabitsch, M; Debatin, KM; Fischer-Posovszky, P; Fulda, S				Mader, Isabelle; Wabitsch, Martin; Debatin, Klaus-Michael; Fischer-Posovszky, Pamela; Fulda, Simone			Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis	FASEB JOURNAL			English	Article						cell death; preadipocytes; death receptor	DEATH-RECEPTOR; GLIOBLASTOMA CELLS; ADIPOSE-TISSUE; MODULATION; ADIPOCYTES; INSULIN; INHIBITION; EXPRESSION; OBESITY; SIRT1	The phytochemical resveratrol has recently gained attention for its protection against metabolic disease and for extension of life span, which have been linked to its metabolic effects and SIRT1 activation in fat cells. However, little is known about the effect of resveratrol on fat cell apoptosis. Here, we identify a novel, SIRT1-independent mechanism by which resveratrol regulates fat cell numbers. We demonstrate for the first time that resveratrol enhances TNF-related apoptosis-inducing ligand (TRAIL)-or CD95-induced apoptosis of human preadipocytes in a highly synergistic manner (EC50 at 72 h: resveratrol, > 300 mu M; TRAIL, > 100 ng/ml; combination: 30 mu M resveratrol and 10 ng/ml TRAIL, combination index 0.4). Similar results in primary human preadipocytes prepared from subcutaneous white adipose tissue and mature human adipocytes underline the relevance to human physiology. Mechanistic studies reveal that resveratrol inhibits PI3K-driven phosphorylation of Akt, leading to increased Bax activation, loss of mitochondrial membrane potential, cytochrome c release, and caspase-dependent apoptosis. The synergistic interaction of resveratrol and TRAIL depends on the intrinsic apoptosis pathway and caspases, since Bcl-2 overexpression and the caspase inhibitor zVAD.fmk inhibit apoptosis, whereas knockdown of SIRT1 by RNA interference has no effect. The discovery of this novel activity of resveratrol significantly advances the knowledge of fat tissue regulation by resveratrol and has important implications for its use in metabolic and age-related diseases.-Mader, I., Wabitsch, M., Debatin, K.-M., Fischer-Posovszky, P., Fulda, S. Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. FASEB J. 24, 1997-2009 (2010). www.fasebj.org	[Wabitsch, Martin; Fischer-Posovszky, Pamela] Univ Childrens Hosp, Div Pediat Endocrinol & Diabetol, D-89075 Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fischer-Posovszky, P (corresponding author), Univ Childrens Hosp, Div Pediat Endocrinol & Diabetol, Eythstr 24, D-89075 Ulm, Germany.	pamela.fischer@uniklinik-ulm.de; simone.fulda@uniklinik-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417; Fischer-Posovszky, Pamela/0000-0003-3402-9840	Deutsche Forschungsgemeinschaft [WA 1096/3-2]; Deutsche Krebshilfe; Wilhelm-Sander-Stiftung; Novartis Stiftung fur Therapeutische Forschung [IAP6/18]; Baden-Wuerttemberg Ministry of Science, Research and Arts; European Social Fund; University of Ulm; European Community	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); Wilhelm-Sander-Stiftung; Novartis Stiftung fur Therapeutische Forschung; Baden-Wuerttemberg Ministry of Science, Research and Arts; European Social Fund(European Social Fund (ESF)); University of Ulm; European Community(European Commission)	This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft (WA 1096/3-2) to M. W. and the Deutsche Krebshilfe, Wilhelm-Sander-Stiftung, Novartis Stiftung fur Therapeutische Forschung, IAP6/18 and the European Community (ApopTrain, APO-SYS) to S.F. P.F.P. is funded by a Margarete von Wrangell scholarship financed by the Baden-Wuerttemberg Ministry of Science, Research and Arts, the European Social Fund, and the University of Ulm.	Alcain FJ, 2009, EXPERT OPIN THER PAT, V19, P403, DOI 10.1517/13543770902762893; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Ashkenazi A, 2008, CYTOKINE GROWTH F R, V19, P325, DOI 10.1016/j.cytogfr.2008.04.001; Backesjo CM, 2009, CELLS TISSUES ORGANS, V189, P93, DOI 10.1159/000151744; Bai L, 2008, MOL CELL BIOCHEM, V307, P129, DOI 10.1007/s11010-007-9592-5; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Boocock DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1246, DOI 10.1158/1055-9965.EPI-07-0022; Choi JW, 2004, ANN CLIN LAB SCI, V34, P400; Chou TC, 1991, SYNERGISM ANTAGONISM, P61; Delmas D, 2004, ONCOGENE, V23, P8979, DOI 10.1038/sj.onc.1208086; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Falschlehner C, 2009, IMMUNOLOGY, V127, P145, DOI 10.1111/j.1365-2567.2009.03058.x; Fischer-Posovszky P, 2007, HORM METAB RES, V39, P314, DOI 10.1055/s-2007-976539; Fischer-Posovszky P, 2004, ENDOCRINOLOGY, V145, P1849, DOI 10.1210/en.2003-0985; Floyd ZE, 2008, METABOLISM, V57, pS32, DOI 10.1016/j.metabol.2008.04.006; Fulda S, 2004, ONCOGENE, V23, P6702, DOI 10.1038/sj.onc.1207630; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2005, EUR J CANCER, V41, P786, DOI 10.1016/j.ejca.2004.12.020; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Fulda S, 2006, CANCER DETECT PREV, V30, P217, DOI 10.1016/j.cdp.2006.03.007; Gill C, 2007, PROSTATE, V67, P1641, DOI 10.1002/pros.20653; Gonzales AM, 2008, NUTR METAB, V5, DOI 10.1186/1743-7075-5-17; Gross K, 2009, AM J PHYSIOL-GASTR L, V296, pG1012, DOI 10.1152/ajpgi.90351.2008; Guicciardi ME, 2009, FASEB J, V23, P1625, DOI 10.1096/fj.08-111005; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Hambrock A, 2007, J BIOL CHEM, V282, P3347, DOI 10.1074/jbc.M608216200; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Ivanov VN, 2008, EXP CELL RES, V314, P1163, DOI 10.1016/j.yexcr.2007.12.012; Kohlhaas SL, 2007, J BIOL CHEM, V282, P12831, DOI 10.1074/jbc.M700438200; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; La Ferla-Bruhl K, 2007, ONCOGENE, V26, P571, DOI 10.1038/sj.onc.1209841; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lin HY, 2006, FASEB J, V20, P1742, DOI 10.1096/fj.06-5743fje; Lockshin RA, 2007, J CELL MOL MED, V11, P1214, DOI 10.1111/j.1582-4934.2007.00150.x; Martin ASG, 2006, AM J CLIN NUTR, V83, p461S, DOI 10.1093/ajcn/83.2.461s; Opel D, 2008, CANCER RES, V68, P6271, DOI 10.1158/0008-5472.CAN-07-6769; Parcellier A, 2008, CELL SIGNAL, V20, P21, DOI 10.1016/j.cellsig.2007.07.010; Park HJ, 2008, J MED FOOD, V11, P773, DOI 10.1089/jmf.2008.0077; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Poirier P, 2006, ARTERIOSCL THROM VAS, V26, P968, DOI 10.1161/01.ATV.0000216787.85457.f3; Prins JB, 1997, CLIN SCI, V92, P3, DOI 10.1042/cs0920003; Rayalam S, 2008, PHYTOTHER RES, V22, P1367, DOI 10.1002/ptr.2503; Rayalam S, 2007, J NUTR, V137, P2668, DOI 10.1093/jn/137.12.2668; Shankar Sharmila, 2007, J Mol Signal, V2, P7, DOI 10.1186/1750-2187-2-7; Shankar S, 2007, MOL CELL BIOCHEM, V304, P273, DOI 10.1007/s11010-007-9510-x; Sorisky A, 2000, INT J OBESITY, V24, pS3, DOI 10.1038/sj.ijo.0801491; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; SZKUDELSKA K, 2009, EUR J CLIN INVEST; Szkudelska K, 2009, J STEROID BIOCHEM, V113, P17, DOI 10.1016/j.jsbmb.2008.11.001; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Vogler M, 2008, CANCER RES, V68, P7956, DOI 10.1158/0008-5472.CAN-08-1296; Wabitsch M, 2001, INT J OBESITY, V25, P8, DOI 10.1038/sj.ijo.0801520; Wabitsch M, 2000, HORM METAB RES, V32, P555, DOI 10.1055/s-2007-978685; Warne JP, 2003, J ENDOCRINOL, V177, P351, DOI 10.1677/joe.0.1770351; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yang JY, 2008, LIFE SCI, V82, P1032, DOI 10.1016/j.lfs.2008.03.003	64	66	69	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1997	2009		10.1096/fj.09-142943	http://dx.doi.org/10.1096/fj.09-142943			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20097879				2022-12-28	WOS:000278200000034
J	Sutton, GM; Begriche, K; Kumar, KG; Gimble, JM; Perez-Tilve, D; Nogueiras, R; McMillan, RP; Hulver, MW; Tschop, MH; Butler, AA				Sutton, Gregory M.; Begriche, Karima; Kumar, K. Ganesh; Gimble, Jeffrey M.; Perez-Tilve, Diego; Nogueiras, Ruben; McMillan, Ryan P.; Hulver, Matthew W.; Tschoep, Matthias H.; Butler, Andrew A.			Central nervous system melanocortin-3 receptors are required for synchronizing metabolism during entrainment to restricted feeding during the light cycle	FASEB JOURNAL			English	Article						hypothalamus; circadian biology; liver metabolism; glucose; ketones	AGOUTI-RELATED PROTEIN; NEURONAL ACTIVATION; BRAIN; OBESITY; CLOCK; FOOD; HYPOTHALAMUS; PATHOGENESIS; MECHANISMS; RHYTHMS	Melanocortin-3 receptors (Mc3rs) in the central nervous system are involved in expression of anticipatory rhythms and synchronizing clocks maintaining circadian rhythms during restricted feeding (RF) [mice housed under a 12-h light-dark cycle with lights on between zeitgeber time (ZT) 0 to ZT12 fed 60% of normal calories between ZT7 and ZT11]. Because the systems governing circadian rhythms are important for adaptation to RF, we investigated whether Mc3rs are required for metabolic adaption to RF. Mc3r(-/-) mice subjected to RF exhibited normal weight loss; however, they developed hyper-insulinemia, glucose intolerance, increased expression of lipogenic genes, and increased ketogenesis relative to controls. Rhythmic expression of transcription factors regulating liver clock activity and energy metabolism (Bmal1, Rev-erb alpha, Pgc1, Foxo1, Hnf4 alpha, and Pck1) was severely compromised in Mc3r(-/-) mice during RF. Inhibition of neural melanocortin receptors by agouti-related peptide also attenuated rhythmicity in the hepatic expression of these genes during RF. Collectively, these data suggest that neural Mc3rs are important for adapting metabolism and maintaining rhythms of liver metabolism during periods when feeding is restricted to the light cycle.-Sutton, G. M., Begriche, K., Kumar, K. G., Gimble, J. M., Perez-Tilve, D., Nogueiras, R., McMillan, R. P., Hulver, M. W., Tschop, M. H., Butler, A. A. Central nervous system melanocortin-3 receptors are required for synchronizing metabolism during entrainment to restricted feeding during the light cycle. FASEB J. 24, 862-872 (2010). www.fasebj.org	[Begriche, Karima; Kumar, K. Ganesh; Butler, Andrew A.] Scripps Res Inst, Dept Metab & Aging, Jupiter, FL 33458 USA; [Sutton, Gregory M.; Begriche, Karima; Kumar, K. Ganesh; Butler, Andrew A.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Neuropeptides Lab, Baton Rouge, LA USA; [Gimble, Jeffrey M.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Stem Cell Biol Lab, Baton Rouge, LA USA; [Gimble, Jeffrey M.; Butler, Andrew A.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Clin Nutr Res Unit, Baton Rouge, LA USA; [Perez-Tilve, Diego; Nogueiras, Ruben; Tschoep, Matthias H.] German Inst Human Nutr Potsdam Rehbrucke, Dept Pharmacol, Nuthetal, Germany; [Nogueiras, Ruben; Tschoep, Matthias H.] Univ Cincinnati, Obes Res Ctr, Dept Psychiat, Cincinnati, OH USA; [McMillan, Ryan P.; Hulver, Matthew W.] Virginia Polytech & State Univ, Dept Human Nutr Food & Exercise, Blacksburg, VA USA	Scripps Research Institute; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); University System of Ohio; University of Cincinnati; Virginia Polytechnic Institute & State University	Butler, AA (corresponding author), Scripps Res Inst, Dept Metab & Aging, 130 Scripps Way, Jupiter, FL 33458 USA.	abutler@scripps.edu	Tschoep, Matthias H/I-5443-2014; Nogueiras, Ruben/AAS-9427-2021; Begriche, Karima/Y-9444-2019	Nogueiras, Ruben/0000-0002-9976-9930; Tschoep, Matthias/0000-0002-4744-371X; Begriche, Karima/0000-0002-6378-3861; Butler, Andrew/0000-0001-7196-0170; Perez-Tilve, Diego/0000-0002-0351-4133	National Institutes of Health [DK073189]; Pennington Biomedical Research Foundation; National Institute of Diabetes and Digestive and Kidney Diseases [1P30 DK072476]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073189, P30DK072476] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennington Biomedical Research Foundation; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr. Jennifer Rood, Dr. Robert Koza, Dr. Jose Galgani, Brian Goh, Emily Meyer, Armand Centanni, and Xiying Wu for technical assistance. We thank Dr. H. Henry Dong (Rangos Research Center, Children's Hospital of Pittsburgh, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA) for providing the Foxo1 antibody. Funding for this work was provided by the National Institutes of Health (DK073189 to A. A. B.). A. A. B. and J.M.G. acknowledge the support of the Pennington Biomedical Research Foundation and Clinical Nutrition Research Unit Center grant, "Nutritional Programming: Environmental and Molecular Interactions" (1P30 DK072476), sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases. The authors declare that they have no competing interests.	Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; Butler AA, 2006, PEPTIDES, V27, P281, DOI 10.1016/j.peptides.2005.02.029; Caspi L, 2007, CELL METAB, V6, P99, DOI 10.1016/j.cmet.2007.07.005; Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254; Cone RD, 2005, NAT NEUROSCI, V8, P571, DOI 10.1038/nn1455; Cone RD, 2006, ENDOCR REV, V27, P736, DOI 10.1210/er.2006-0034; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Davidson AJ, 2006, AM J PHYSIOL-REG I, V290, pR1524, DOI 10.1152/ajpregu.00073.2006; Dudley CA, 2003, SCIENCE, V301, P379, DOI 10.1126/science.1082795; Duez H, 2008, FEBS LETT, V582, P19, DOI 10.1016/j.febslet.2007.08.032; Garfield AS, 2009, TRENDS ENDOCRIN MET, V20, P203, DOI 10.1016/j.tem.2009.02.002; Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200; Green CB, 2008, CELL, V134, P728, DOI 10.1016/j.cell.2008.08.022; Gross DN, 2008, ONCOGENE, V27, P2320, DOI 10.1038/onc.2008.25; Guo HN, 2005, P NATL ACAD SCI USA, V102, P3111, DOI 10.1073/pnas.0409734102; Gupta RK, 2004, TRENDS MOL MED, V10, P521, DOI 10.1016/j.molmed.2004.09.004; Gutierrez-Juarez R, 2004, J BIOL CHEM, V279, P49704, DOI 10.1074/jbc.M408665200; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Johnstone LE, 2006, CELL METAB, V4, P313, DOI 10.1016/j.cmet.2006.08.003; Konner AC, 2007, CELL METAB, V5, P438, DOI 10.1016/j.cmet.2007.05.004; Kornmann B, 2007, COLD SPRING HARB SYM, V72, P319, DOI 10.1101/sqb.2007.72.041; Lam TKT, 2007, NAT MED, V13, P171, DOI 10.1038/nm1540; Lamia KA, 2008, P NATL ACAD SCI USA, V105, P15172, DOI 10.1073/pnas.0806717105; Levin BE, 2007, CELL METAB, V6, P252, DOI 10.1016/j.cmet.2007.09.005; Liu C, 2007, NATURE, V447, P477, DOI 10.1038/nature05767; MacNeil DJ, 2002, EUR J PHARMACOL, V450, P91, DOI 10.1016/S0014-2999(02)01989-1; Mistlberger Ralph E, 2009, J Circadian Rhythms, V7, P3, DOI 10.1186/1740-3391-7-3; Myers MG, 2008, ANNU REV PHYSIOL, V70, P537, DOI 10.1146/annurev.physiol.70.113006.100707; Nogueiras R, 2007, J CLIN INVEST, V117, P3475, DOI 10.1172/JCI31743; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; Obici S, 2009, ENDOCRINOLOGY, V150, P2512, DOI 10.1210/en.2009-0409; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Parton LE, 2007, NATURE, V449, P228, DOI 10.1038/nature06098; Pendergast JS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004860; Perlemuter G, 2007, NAT CLIN PRACT ENDOC, V3, P458, DOI 10.1038/ncpendmet0505; Peschke E, 2008, J PINEAL RES, V44, P26, DOI 10.1111/j.1600-079X.2007.00519.x; Petersen KF, 2007, P NATL ACAD SCI USA, V104, P12587, DOI 10.1073/pnas.0705408104; Pocai A, 2005, CELL METAB, V1, P53, DOI 10.1016/j.cmet.2004.11.001; Pocai A, 2005, NATURE, V434, P1026, DOI 10.1038/nature03439; Qu S, 2006, ENDOCRINOLOGY, V147, P5641, DOI 10.1210/en.2006-0541; Ramsey KM, 2009, P NATL ACAD SCI USA, V106, P4069, DOI 10.1073/pnas.0901304106; Robinson SW, 2000, ANNU REV GENET, V34, P687, DOI 10.1146/annurev.genet.34.1.687; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; Rossi M, 1998, ENDOCRINOLOGY, V139, P4428, DOI 10.1210/en.139.10.4428; Singru PS, 2007, ENDOCRINOLOGY, V148, P638, DOI 10.1210/en.2006-1233; Small CJ, 2001, DIABETES, V50, P248, DOI 10.2337/diabetes.50.2.248; Staels B, 2006, NAT MED, V12, P54, DOI 10.1038/nm0106-54; Stephan FK, 2002, J BIOL RHYTHM, V17, P284, DOI 10.1177/074873002129002591; Storch KF, 2009, P NATL ACAD SCI USA, V106, P6808, DOI 10.1073/pnas.0902063106; Sutton GM, 2006, ENDOCRINOLOGY, V147, P2183, DOI 10.1210/en.2005-1209; Sutton GM, 2008, J NEUROSCI, V28, P12946, DOI 10.1523/JNEUROSCI.3615-08.2008; Wijnen H, 2009, SCIENCE, V324, P598, DOI 10.1126/science.1174132; Zhou L, 2007, CELL METAB, V6, P398, DOI 10.1016/j.cmet.2007.10.008	53	39	39	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					862	872		10.1096/fj.09-142000	http://dx.doi.org/10.1096/fj.09-142000			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19837866	Bronze, Green Published			2022-12-28	WOS:000274974600022
J	Al-Ansary, D; Bogeski, I; Disteldorf, BMJ; Becherer, U; Niemeyer, BA				Al-Ansary, Dalia; Bogeski, Ivan; Disteldorf, Barbara M. J.; Becherer, Ute; Niemeyer, Barbara A.			ATP modulates Ca2+ uptake by TRPV6 and is counteracted by isoform-specific phosphorylation	FASEB JOURNAL			English	Article						Ca2+ homeostasis; PKC beta II; TRP channels; ATP regulation; allele-specific selection; polymorphism	PROTEIN-KINASE-C; ANKYRIN REPEAT DOMAIN; EPITHELIAL CA2+; CHANNEL ACTIVITY; CALCIUM-CHANNEL; CAT-LIKE; INHIBITION; EXPRESSION; INACTIVATION; TRANSPORTERS	Ca2+ homeostasis requires balanced uptake and extrusion, and dysregulation leads to disease. TRPV6 channels are homeostasis regulators, are up-regulated in certain cancers, and show an unusual allelespecific evolution in humans. To understand how Ca2+ uptake can be adapted to changes in metabolic status, we investigate regulation of Ca2+-influx by ATP and phosphorylation. We show that ATP binds to TRPV6, reduces whole-cell current increments, and prevents channel rundown with an EC50 of 380 mu M. By using both biochemical binding studies and patch-clamp analyses of wild-type and mutant channels, we have mapped one relevant site for regulation by ATP to residues within the ankyrin repeat domain (ARD) and identify an additional C-terminal binding region. Stimulation of PKC largely prevented the effects of ATP. This regulation requires PKC beta II and defined phosphorylation sites within the ARD and the C-terminus. Both regulatory sites act synergistically to constitute a novel mechanism by which ATP stabilizes channel activity and acts as a metabolic switch for Ca2+ influx. Decreases in ATP concentration or activation of PKC beta II disable regulation of the channels by ATP, rendering them more susceptible to inactivation and rundown and preventing Ca2+ overload.-Al-Ansary, D., Bogeski, I., Disteldorf, B. M. J., Becherer, U., Niemeyer, B. A. ATP modulates Ca2+ uptake by TRPV6 and is counteracted by isoform-specific phosphorylation. FASEB J. 24, 425-435 (2010). www.fasebj.org	[Al-Ansary, Dalia; Bogeski, Ivan; Disteldorf, Barbara M. J.; Niemeyer, Barbara A.] Univ Saarland, Dept Biophys, D-66421 Homburg, Germany; [Becherer, Ute] Univ Saarland, Dept Physiol, D-66421 Homburg, Germany; [Al-Ansary, Dalia; Niemeyer, Barbara A.] Univ Saarland, Dept Pharmacol & Toxicol, D-66421 Homburg, Germany	Saarland University; Saarland University; Saarland University	Niemeyer, BA (corresponding author), Univ Saarland, Dept Biophys, Kirrberger Str,Geb 58, D-66421 Homburg, Germany.	barbara.niemeyer@uks.eu	Niemeyer, Barbara A./AAL-8972-2021; Becherer, Ute/AGW-2576-2022; Bogeski, Ivan/ABA-2141-2021; Becherer, Ute/F-6711-2010	Bogeski, Ivan/0000-0001-9879-7174; Becherer, Ute/0000-0001-6005-7517; Alansary, Dalia/0000-0002-7541-6057; Niemeyer, Barbara A./0000-0002-6963-0575	Deutsche Forschungsgemeinschaft (DFG) [NI 671, GK 1326]; HOMFOR	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); HOMFOR	We especially thank Dr. Veit Flockerzi and Dr. Ulrich Wissenbach (University of Saarland, Homburg, Germany) for the stable TRPV6 cell lines, for antibodies against TRPV6 and the HIS tag, and, together with Dr. Hoth, for discussions and critical reading of the manuscript. We also thank Dr. Yusuf Hannun (Medical University of South Carolina, Charleston, SC, USA) and Dr. Peter Lipp (University of Saarland) for kindly providing us with the cDNA for GFP-PKC<INF>beta II</INF> and GFP-PKC<INF>alpha</INF>; Dr. Marcel Meissner (University of Saarland) for fusion proteins of mTRPV6; Heidi Lohr, Anja Ludes, and Bettina Strauss for cell culture work; and members of the labs for critical input. This work was supported, in part, by the Deutsche Forschungsgemeinschaft (DFG; NI 671 to B.N.) and HOMFOR (B.N.). D.A.-A. is a member of the DFG-sponsored graduate program GK 1326.	Abdalla I, 1998, UROLOGY, V51, P300, DOI 10.1016/S0090-4295(97)00617-1; Akey JM, 2006, HUM MOL GENET, V15, P2106, DOI 10.1093/hmg/ddl134; Bodding M, 2002, J BIOL CHEM, V277, P36656, DOI 10.1074/jbc.M202822200; Cha SK, 2008, AM J PHYSIOL-RENAL, V294, pF1212, DOI 10.1152/ajprenal.00007.2008; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Craig TJ, 2008, J GEN PHYSIOL, V132, P131, DOI 10.1085/jgp.200709874; Derler I, 2006, J PHYSIOL-LONDON, V577, P31, DOI 10.1113/jphysiol.2006.118661; Dhar-Chowdhury P, 2007, CELL MOL LIFE SCI, V64, P3069, DOI 10.1007/s00018-007-7332-3; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Fixemer T, 2003, ONCOGENE, V22, P7858, DOI 10.1038/sj.onc.1206895; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guerini D, 2005, CELL CALCIUM, V38, P281, DOI 10.1016/j.ceca.2005.06.032; Guerini D, 1998, CELL TISSUE RES, V292, P191, DOI 10.1007/s004410051050; Hilgemann DW, 1997, ANNU REV PHYSIOL, V59, P193, DOI 10.1146/annurev.physiol.59.1.193; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hughes DA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001686; Jin XS, 2006, J BIOL CHEM, V281, P25006, DOI 10.1074/jbc.C600153200; Kameyama M, 1998, PFLUG ARCH EUR J PHY, V435, P344, DOI 10.1007/s004240050521; Lee J, 2005, J GEN PHYSIOL, V126, P439, DOI 10.1085/jgp.200509314; Lishko PV, 2007, NEURON, V54, P905, DOI 10.1016/j.neuron.2007.05.027; Moiseenkova-Bell VY, 2008, P NATL ACAD SCI USA, V105, P7451, DOI 10.1073/pnas.0711835105; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Nilius B, 2002, J BIOL CHEM, V277, P30852, DOI 10.1074/jbc.M202418200; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; OKASHIRO T, 1992, EXP PHYSIOL, V77, P719, DOI 10.1113/expphysiol.1992.sp003638; Phelps CB, 2008, BIOCHEMISTRY-US, V47, P2476, DOI 10.1021/bi702109w; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; Romani AMP, 2000, FRONT BIOSCI, V5, pD720, DOI 10.2741/Romani; ROMANIN C, 1991, PFLUG ARCH EUR J PHY, V418, P86, DOI 10.1007/BF00370456; Schwoebel ED, 2002, J CELL BIOL, V157, P963, DOI 10.1083/jcb.200111077; Suzuki Y, 2008, ANNU REV PHYSIOL, V70, P257, DOI 10.1146/annurev.physiol.69.031905.161003; Takahashi M, 2007, P NATL ACAD SCI USA, V104, P5800, DOI 10.1073/pnas.0700979104; Thyagarajan B, 2008, J BIOL CHEM, V283, P14980, DOI 10.1074/jbc.M704224200; van de Graaf SFJ, 2007, REV PHYSIOL BIOCH P, V158, P77, DOI 10.1007/11220060607; van de Graaf SFJ, 2008, J BIOL CHEM, V283, P4077, DOI 10.1074/jbc.M706959200; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200; Zhang XD, 2008, J GEN PHYSIOL, V132, P421, DOI 10.1085/jgp.200810023	42	20	20	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					425	435		10.1096/fj.09-141481	http://dx.doi.org/10.1096/fj.09-141481			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19805577	Green Accepted			2022-12-28	WOS:000274045000011
J	Bui, C; Ouzzine, M; Talhaoui, I; Sharp, S; Prydz, K; Coughtrie, MWH; Fournel-Gigleux, S				Bui, Catherine; Ouzzine, Mohamed; Talhaoui, Ibtissam; Sharp, Sheila; Prydz, Kristian; Coughtrie, Michael W. H.; Fournel-Gigleux, Sylvie			Epigenetics: methylation-associated repression of heparan sulfate 3-O-sulfotransferase gene expression contributes to the invasive phenotype of H-EMC-SS chondrosarcoma cells	FASEB JOURNAL			English	Article						tumor pathogenesis; proteoglycan synthesis; epigenetic regulation; glycosyltransferase	PROTEIN LINKAGE REGION; CANINE KIDNEY-CELLS; MOLECULAR-CLONING; CANCER-CELLS; GLYCOSAMINOGLYCAN BIOSYNTHESIS; PROTEOGLYCAN SYNTHESIS; HUMAN BREAST; GROWTH; EXT1; FIBROBLASTS	Heparan sulfate proteoglycans (HSPGs), strategically located at the cell-tissue-organ interface, regulate major biological processes, including cell proliferation, migration, and adhesion. These vital functions are compromised in tumors, due, in part, to alterations in heparan sulfate (HS) expression and structure. How these modifications occur is largely unknown. Here, we investigated whether epigenetic abnormalities involving aberrant DNA methylation affect HS biosynthetic enzymes in cancer cells. Analysis of the methylation status of glycosyltransferase and sulfotransferase genes in H-HEMC-SS chondrosarcoma cells showed a typical hypermethylation profile of 3-OST sulfotransferase genes. Exposure of chondrosarcoma cells to 5-aza-2'-deoxycytidine (5-Aza-dc), a DNA-methyltransferase inhibitor, up-regulated expression of 3-OST1, 3-OST2, and 3-OST3A mRNAs, indicating that aberrant methylation affects transcription of these genes. Furthermore, HS expression was restored on 5-Aza-dc treatment or reintroduction of 3-OST expression, as shown by indirect immunofluorescence microscopy and/or analysis of HS chains by anion-exchange and gel-filtration chromatography. Notably, 5-Aza-dc treatment of HEMC cells or expression of 3-OST3A cDNA reduced their proliferative and invading properties and augmented adhesion of chondrosarcoma cells. These results provide the first evidence for specific epigenetic regulation of 3-OST genes resulting in altered HSPG sulfation and point to a defect of HS-3-O-sulfation as a factor in cancer progression.-Bui, C., Ouzzine, M., Talhaoui, I., Sharp, S., Prydz, K., Coughtrie, M. W. H., Fournel-Gigleux, S. Epigenetics: methylation-associated repression of heparan sulfate 3-O-sulfotransferase gene expression contributes to the invasive phenotype of H-EMC-SS chondrosarcoma cells. FASEB J. 24, 436-450 (2010). www.fasebj.org	[Bui, Catherine; Ouzzine, Mohamed; Talhaoui, Ibtissam; Fournel-Gigleux, Sylvie] Univ Nancy 1, CNRS, UMR 7561, Fac Med, F-54505 Vandoeuvre Les Nancy, France; [Sharp, Sheila; Coughtrie, Michael W. H.] Univ Dundee, Ninewells Hosp & Med Sch, Div Med Sci, Dundee DD1 9SY, Scotland; [Prydz, Kristian] Univ Oslo, Dept Mol Biosci, Oslo, Norway	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; University of Dundee; University of Oslo	Fournel-Gigleux, S (corresponding author), Univ Nancy 1, CNRS, UMR 7561, Fac Med, BP 184, F-54505 Vandoeuvre Les Nancy, France.	sfg@medecine.uhp-nancy.fr	Ouzzine, Mohamed/G-4368-2013; Coughtrie, Michael/C-3855-2009	Coughtrie, Michael/0000-0003-1989-1416; OUZZINE, Mohamed/0000-0003-0058-4950	Institut National de la Sante et de la Recherche Medicale (INSERM)-University of Dundee International Collaboration Contract (C2I); Agence Nationale de la Recherche [ANR-08-PCVI-0023-01]; Ligue Regionale contre le Cancer; Royal Society International Joint Grant; Region Lorraine; Stevenson Exchange Scholarship	Institut National de la Sante et de la Recherche Medicale (INSERM)-University of Dundee International Collaboration Contract (C2I)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Agence Nationale de la Recherche(French National Research Agency (ANR)); Ligue Regionale contre le Cancer(Ligue nationale contre le cancer); Royal Society International Joint Grant; Region Lorraine(Region Grand-Est); Stevenson Exchange Scholarship	This work was supported by an Institut National de la Sante et de la Recherche Medicale (INSERM)-University of Dundee International Collaboration Contract (C2I), the Agence Nationale de la Recherche (GAG Network ANR-08-PCVI-0023-01), the Ligue Regionale contre le Cancer, a Royal Society International Joint Grant (to M. W. H. C., and S. F.-G.), and the Region Lorraine. C. B. was the recipient of a Stevenson Exchange Scholarship. We are grateful to Theodora Tucker (University of Dundee, Dundee, UK) for her expertise and assistance with the indirect immunofluorescence microscopy studies, to Dr. Celine Pourreyron (University of Dundee, Dundee, UK) for her helpful advice regarding the cell migration assays, and Sandrine Gulberti for critical reading of the manuscript. Dr. Narayanan Venkatesan (McGill University, Montreal, Quebec) is gratefully acknowledged for his help in performing statistical analysis and for critical reading of the manuscript.	Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Barre L, 2006, FASEB J, V20, P1692, DOI 10.1096/fj.05-5073fje; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817; Busse M, 2007, J BIOL CHEM, V282, P32802, DOI 10.1074/jbc.M703560200; Chandrasekaran EV, 2006, CARBOHYD RES, V341, P983, DOI 10.1016/j.carres.2006.02.017; Chow WA, 2007, CURR OPIN ONCOL, V19, P371, DOI 10.1097/CCO.0b013e32812143d9; Clark SJ, 2006, NAT PROTOC, V1, P2353, DOI 10.1038/nprot.2006.324; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Dick G, 2008, GLYCOBIOLOGY, V18, P53, DOI 10.1093/glycob/cwm121; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Gronbaek K, 2007, APMIS, V115, P1039, DOI 10.1111/j.1600-0463.2007.apm_636.xml.x; Gulberti S, 2005, J BIOL CHEM, V280, P1417, DOI 10.1074/jbc.M411552200; Gulberti S, 2003, J BIOL CHEM, V278, P32219, DOI 10.1074/jbc.M207899200; HajMohammadi S, 2003, J CLIN INVEST, V111, P989, DOI 10.1172/JCI200315809; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Kadenhe-Chiweshe A, 2008, MOL CANCER RES, V6, P1, DOI 10.1158/1541-7786.MCR-07-0101; Kamimura K, 2004, J CELL BIOL, V166, P1069, DOI 10.1083/jcb.200403077; Kaminski A, 2006, INT J MOL MED, V18, P941; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Lai JP, 2004, GASTROENTEROLOGY, V126, P231, DOI 10.1053/j.gastro.2003.09.043; Leteux C, 2001, J BIOL CHEM, V276, P12539, DOI 10.1074/jbc.M010291200; Li JS, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-14; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Mahalingam Y, 2007, J BIOL CHEM, V282, P3221, DOI 10.1074/jbc.M604938200; Mani K, 2004, GLYCOBIOLOGY, V14, P599, DOI 10.1093/glycob/cwh067; McCormick C, 1999, MOL MED TODAY, V5, P481, DOI 10.1016/S1357-4310(99)01593-2; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146; Mochizuki H, 2008, J BIOL CHEM, V283, P31237, DOI 10.1074/jbc.M801586200; Ouzzine M, 1999, FEBS LETT, V454, P187, DOI 10.1016/S0014-5793(99)00797-8; Petitou M, 2003, BIOCHIMIE, V85, P83, DOI 10.1016/S0300-9084(03)00078-6; Prydz K, 2000, J CELL SCI, V113, P193; QUENTIN E, 1990, P NATL ACAD SCI USA, V87, P1342, DOI 10.1073/pnas.87.4.1342; Ropero S, 2004, HUM MOL GENET, V13, P2753, DOI 10.1093/hmg/ddh298; Sanderson RD, 2005, J CELL BIOCHEM, V96, P897, DOI 10.1002/jcb.20602; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Stickens D, 2005, DEVELOPMENT, V132, P5055, DOI 10.1242/dev.02088; Su G, 2007, J BIOL CHEM, V282, P14906, DOI 10.1074/jbc.M611739200; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Svennevig K, 2006, DIABETOLOGIA, V49, P2214, DOI 10.1007/s00125-006-0330-4; Tsuchiya T, 2005, CANCER GENET CYTOGEN, V158, P148, DOI 10.1016/j.cancergencyto.2004.08.031; Tveit H, 2005, J BIOL CHEM, V280, P29596, DOI 10.1074/jbc.M503691200; Urbaniak MD, 2006, BIOORG MED CHEM LETT, V16, P5744, DOI 10.1016/j.bmcl.2006.08.091; Uzan B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004734; Valster A, 2005, METHODS, V37, P208, DOI 10.1016/j.ymeth.2005.08.001; Vanpouille C, 2007, J BIOL CHEM, V282, P24416, DOI 10.1074/jbc.M701835200; Venkatesan N, 2004, P NATL ACAD SCI USA, V101, P18087, DOI 10.1073/pnas.0404504102; Venkatesan N, 2009, FASEB J, V23, P813, DOI 10.1096/fj.08-118166; Vucic EA, 2008, PHARMACOGENOMICS, V9, P215, DOI 10.2217/14622416.9.2.215; Vuong TT, 2006, GLYCOBIOLOGY, V16, P326, DOI 10.1093/glycob/cwj075; Weissmann G, 2008, FASEB J, V22, P4033, DOI 10.1096/fj.08-1201ufm; Xu D, 2005, BIOCHEM J, V385, P451, DOI 10.1042/BJ20040908; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279; Yang Y, 2007, J BIOL CHEM, V282, P13326, DOI 10.1074/jbc.M611259200; Ye S, 2001, BIOCHEMISTRY-US, V40, P14429, DOI 10.1021/bi011000u	61	51	51	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					436	450		10.1096/fj.09-136291	http://dx.doi.org/10.1096/fj.09-136291			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19812376	Green Submitted			2022-12-28	WOS:000274045000012
J	Heinick, A; Urban, K; Roth, S; Spies, D; Nunes, F; Phanstiel, O; Liebau, E; Luersen, K				Heinick, Alexander; Urban, Katja; Roth, Stefan; Spies, Danica; Nunes, Frank; Phanstiel, Otto, IV; Liebau, Eva; Lueersen, Kai			Caenorhabditis elegans P-5B-type ATPase CATP-5 operates in polyamine transport and is crucial for norspermidine-mediated suppression of RNA interference	FASEB JOURNAL			English	Article						S-adenosylmethionine decarboxylase; body size; life span; ornithine decarboxylase; spermidine	ORNITHINE-DECARBOXYLASE GENE; PROTEIN-KINASE; C-ELEGANS; CLONING; SPERMIDINE; MECHANISM; CELLS	Physiological polyamines are required in various biological processes. In the current study, we used norspermidine, a structural analog of the natural polyamine spermidine, to investigate polyamine uptake in the model organism Caenorhabditis elegans. Norspermidine was found to have two remarkable effects: it is toxic for the nematode, without affecting its food, Escherichia coli; and it hampers RNA interference. By characterizing a norspermidine-resistant C. elegans mutant strain that has been isolated in a genetic screen, we demonstrate that both effects, as well as the uptake of a fluorescent polyamine-conjugate, depend on the transporter protein CATP-5, a novel P-5B-type ATPase. To our knowledge, CATP-5 represents the first P-5-type ATPase that is associated with the plasma membrane, being expressed in the apical membrane of intestinal cells and the excretory cell. Moreover, genetic interaction studies using C. elegans polyamine synthesis mutants indicate that CATP-5 has a function redundant to polyamine synthesis and link reduced polyamine levels to retarded postembryonic development, reduced brood size, shortened life span, and small body size. We suggest that CATP-5 represents a crucial component of the pharmacologically important polyamine transport system, the molecular nature of which has not been identified so far in metazoa.-Heinick, A., Urban, K., Roth, S., Spies, D., Nunes, F., Phanstiel IV, O., Liebau, E., Luersen, K. Caenorhabditis elegans P-5B-type ATPase CATP-5 operates in polyamine transport and is crucial for norspermidine-mediated suppression of RNA interference. FASEB J. 24, 206-217 (2010). www.fasebj.org	[Heinick, Alexander; Urban, Katja; Roth, Stefan; Spies, Danica; Liebau, Eva; Lueersen, Kai] Univ Munster, Inst Anim Physiol, D-48143 Munster, Germany; [Nunes, Frank] Univ Munster, Inst Pharmacol & Toxicol, D-48143 Munster, Germany; [Phanstiel, Otto, IV] Univ Cent Florida, Coll Med, Dept Med Educ, Orlando, FL 32816 USA	University of Munster; University of Munster; State University System of Florida; University of Central Florida	Luersen, K (corresponding author), Univ Munster, Inst Anim Physiol, Hindenburgpl 55, D-48143 Munster, Germany.	kai.luersen@uni-muenster.de		Heinick, Alexander/0000-0002-3770-105X	U. S. National Institutes of Health National Center for Research Resources; National Bioresource Project, Tokyo Women's Medical University School of Medicine; Deutsche Forschungsgemeinschaft [733/6]	U. S. National Institutes of Health National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Bioresource Project, Tokyo Women's Medical University School of Medicine(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	Some C. elegans strains were obtained from the Caenorhabditis Genetics Center at the University of Minnesota ( Minneapolis, MN, USA), which is funded by the U. S. National Institutes of Health National Center for Research Resources and by the National Bioresource Project, Tokyo Women's Medical University School of Medicine. This work was supported by Deutsche Forschungsgemeinschaft ( DFG; grant Lu 733/6) and is part of A. H.'s doctoral study at the Faculty of Biology, University of Muenster.	Belting M, 2003, J BIOL CHEM, V278, P47181, DOI 10.1074/jbc.M308325200; BRENNER S, 1974, GENETICS, V77, P71; Childs AC, 2003, CELL MOL LIFE SCI, V60, P1394, DOI 10.1007/s00018-003-2332-4; Corsi AK, 2006, ANAL BIOCHEM, V359, P1, DOI 10.1016/j.ab.2006.07.033; Cronin SR, 2002, J CELL BIOL, V157, P1017, DOI 10.1083/jcb.200203052; Habtemichael N, 2002, GENE, V283, P271, DOI 10.1016/S0378-1119(01)00881-2; Hamamichi S, 2008, P NATL ACAD SCI USA, V105, P728, DOI 10.1073/pnas.0711018105; Hasne MP, 2005, J BIOL CHEM, V280, P15188, DOI 10.1074/jbc.M411331200; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; Higashi K, 2008, J BIOL CHEM, V283, P32989, DOI 10.1074/jbc.M806027200; Igarashi K, 1999, BIOCHEM J, V344, P633, DOI 10.1042/0264-6021:3440633; Jakobsen MK, 2005, GENE DEV, V19, P2757, DOI 10.1101/gad.357305; Jones AK, 2005, NAT REV DRUG DISCOV, V4, P321, DOI 10.1038/nrd1692; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KAKINUMA Y, 1995, BIOCHEM BIOPH RES CO, V216, P985, DOI 10.1006/bbrc.1995.2717; Kamath RS, 2003, METHODS, V30, P313, DOI 10.1016/S1046-2023(03)00050-1; Kaouass M, 1997, MOL CELL BIOL, V17, P2994, DOI 10.1128/MCB.17.6.2994; KOUMOTO Y, 1990, CHEM PHARM BULL, V38, P1648; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; Macrae M, 1998, BIOCHEM J, V333, P309, DOI 10.1042/bj3330309; MACRAE M, 1995, GENETICS, V140, P517; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Moller AB, 2008, MOL PHYLOGENET EVOL, V46, P619, DOI 10.1016/j.ympev.2007.10.023; Morck C, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-39; Nishimura K, 2002, GENES CELLS, V7, P41, DOI 10.1046/j.1356-9597.2001.00494.x; Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001; Phanstiel O IV, 2007, AMINO ACIDS, V33, P305, DOI 10.1007/s00726-007-0527-y; Pollard KJ, 1999, EMBO J, V18, P5622, DOI 10.1093/emboj/18.20.5622; Porat Z, 2005, CELL MOL LIFE SCI, V62, P3106, DOI 10.1007/s00018-005-5341-7; PRAKASH NJ, 1988, ANTICANCER RES, V8, P563; Ramirez A, 2006, NAT GENET, V38, P1184, DOI 10.1038/ng1884; Romero-Calderon R, 2006, BIOCHEM J, V393, P583, DOI 10.1042/BJ20050981; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; Seiler N, 2003, CURR DRUG TARGETS, V4, P565, DOI 10.2174/1389450033490876; Soulet D, 2004, J BIOL CHEM, V279, P49355, DOI 10.1074/jbc.M401287200; Tsen C, 2008, J MED CHEM, V51, P324, DOI 10.1021/jm701198s; Uemura T, 2007, J BIOL CHEM, V282, P7733, DOI 10.1074/jbc.M611105200; Wang CJ, 2003, J MED CHEM, V46, P2663, DOI 10.1021/jm030028w; WATANABE S, 1991, J BIOL CHEM, V266, P20803; Whangbo JS, 2008, TRENDS GENET, V24, P297, DOI 10.1016/j.tig.2008.03.007; Wicks SR, 2001, NAT GENET, V28, P160, DOI 10.1038/88878	42	29	35	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					206	217		10.1096/fj.09-135889	http://dx.doi.org/10.1096/fj.09-135889			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19762559	Green Published, Bronze			2022-12-28	WOS:000273233600022
J	Kumar, AHS; Metharom, P; Schmeckpeper, J; Weiss, S; Martin, K; Caplice, NM				Kumar, Arun H. S.; Metharom, Pat; Schmeckpeper, Jeff; Weiss, Sharon; Martin, Kenneth; Caplice, Noel M.			Bone marrow-derived CX(3)CR1 progenitors contribute to neointimal smooth muscle cells via fractalkine CX(3)CR1 interaction	FASEB JOURNAL			English	Article						chemokine; neointima; vascular remodeling; myeloid; wire injury; monocytes	RECEPTOR CX(3)CR1; TARGETED DELETION; BLOOD; ATHEROSCLEROSIS; RECRUITMENT; DIFFERENTIATION; EXPRESSION; MONOCYTES; MACROPHAGES; HYPERPLASIA	Smooth muscle cells play a major role in numerous vascular diseases that contribute to remodeling, repair after injury, and arteriogenesis, and the source of these cells is thought to lie within the vessel wall and the circulating blood. Currently, the precise origin and mechanism of differentiation of extravascular smooth muscle progenitor cells (SPCs) is unclear. We show here that the CX(3)CR1 mononuclear cell population of murine bone marrow provides a source of SPCs that contributes to smooth muscle cells within the neointimal plaque after vascular injury. Moreover, CX(3)CR1-fractalkine (FKN) interaction in vivo is essential for smooth muscle cell differentiation of bone marrow-derived progenitor cells at the vessel wall level. Functional competence of bone marrow-derived CX(3)CR1 positive cells to interact with FKN is also crucial in part for neointima formation following vascular injury. Finally, in a pure preparation of bone marrow-derived CX(3)CR1 positive cells, we show that in vitro smooth muscle cell differentiation increases markedly in the presence of FKN. Our data highlight a novel functional relationship between the myeloid and vascular systems and in the context of vascular injury and repair underscores a key chemokine-receptor pathway that may regulate cell fate when smooth muscle cell differentiation is required.-Kumar, A. H. S., Metharom, P., Schmeckpeper, J., Weiss, S., Martin, K., Caplice, N. M. Bone marrow-derived CX(3)CR1 progenitors contribute to neointimal smooth muscle cells via fractalkine CX(3)CR1 interaction. FASEB J. 24, 81-92 (2010). www.fasebj.org	[Kumar, Arun H. S.; Metharom, Pat; Schmeckpeper, Jeff; Weiss, Sharon; Martin, Kenneth; Caplice, Noel M.] Natl Univ Ireland Univ Coll Cork, Biosci Inst, CRVB, Cork, Ireland	University College Cork	Caplice, NM (corresponding author), Natl Univ Ireland Univ Coll Cork, Biosci Inst, CRVB, Room 2-39, Cork, Ireland.	n.caplice@ucc.ie	Kumar, Arun/C-9149-2009	Kumar, Arun/0000-0001-8422-0219; Weiss, Sharon/0000-0002-0981-6917; Caplice, Noel/0000-0001-5445-1016	Science Foundation Ireland; Health Research Board, Ireland	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board, Ireland	We thank Barbara Rejman-Bochenek for technical assistance with the murine studies and Mary DeVoe for reviewing the manuscript. This work was supported by grants from Science Foundation Ireland and the Health Research Board, Ireland. The authors declare no conflicts of interest.	Adams LD, 2006, ARTERIOSCL THROM VAS, V26, P319, DOI 10.1161/01.ATV.0000196647.45718.d6; Agrotis A, 2004, J BIOL CHEM, V279, P42221, DOI 10.1074/jbc.M408121200; An GY, 2008, CIRCULATION, V117, P3227, DOI 10.1161/CIRCULATIONAHA.108.771048; Arakawa E, 2000, FEBS LETT, V481, P193, DOI 10.1016/S0014-5793(00)01995-5; Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883; Barlic J, 2007, J BIOL CHEM, V282, P19167, DOI 10.1074/jbc.M701642200; Bentzon JF, 2007, CIRCULATION, V116, P2053, DOI 10.1161/CIRCULATIONAHA.107.722355; Cambien B, 2001, BLOOD, V97, P2031, DOI 10.1182/blood.V97.7.2031; Caplice NM, 2003, P NATL ACAD SCI USA, V100, P4754, DOI 10.1073/pnas.0730743100; Civelek M, 2002, J APPL PHYSIOL, V93, P1907, DOI 10.1152/japplphysiol.00988.2001; Clarke MCH, 2006, NAT MED, V12, P1075, DOI 10.1038/nm1459; Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42; Diez M, 2007, CARDIOVASC RES, V76, P517, DOI 10.1016/j.cardiores.2007.08.007; Fogg DK, 2006, SCIENCE, V311, P83, DOI 10.1126/science.1117729; GALMICHE MC, 1993, BLOOD, V82, P66, DOI 10.1182/blood.V82.1.66.bloodjournal82166; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Hu YH, 2004, J CLIN INVEST, V113, P1258, DOI 10.1172/JCI200419628; Hu YH, 2002, CIRC RES, V91, pE13, DOI 10.1161/01.RES.0000037090.34760.EE; Hu YH, 2002, CIRCULATION, V106, P1834, DOI 10.1161/01.CIR.0000031333.86845.DD; Hungerford JE, 1996, DEV BIOL, V178, P375, DOI 10.1006/dbio.1996.0225; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; Jacobsen JCB, 2007, AM J PHYSIOL-HEART C, V293, pH229, DOI 10.1152/ajpheart.00727.2006; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kashiwakura Y, 2003, CIRCULATION, V107, P2078, DOI 10.1161/01.CIR.0000070082.64414.B5; Komatsu R, 1998, CIRCULATION, V98, P224, DOI 10.1161/01.CIR.98.3.224; Lee SJ, 2006, AM J PHYSIOL-HEART C, V291, pH2836, DOI 10.1152/ajpheart.00113.2006; Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555; Liu P, 2008, ARTERIOSCL THROM VAS, V28, P243, DOI 10.1161/ATVBAHA.107.158675; Liu P, 2006, ARTERIOSCL THROM VAS, V26, P2056, DOI 10.1161/01.ATV.0000234947.47788.8c; Lucas AD, 2003, CIRCULATION, V108, P2498, DOI 10.1161/01.CIR.0000097119.57756.EF; Metharom P, 2008, ATHEROSCLEROSIS, V198, P29, DOI 10.1016/j.atherosclerosis.2007.09.020; Nemenoff RA, 2008, CIRC RES, V102, P1036, DOI 10.1161/CIRCRESAHA.107.169896; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Passman JN, 2008, P NATL ACAD SCI USA, V105, P9349, DOI 10.1073/pnas.0711382105; PELED A, 1991, BLOOD, V78, P304; Pugsley MK, 2000, J PHARMACOL TOX MET, V44, P333, DOI 10.1016/S1056-8719(00)00125-8; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; Schach C, 2008, EXP LUNG RES, V34, P195, DOI 10.1080/01902140801925471; Schulz C, 2007, CIRCULATION, V116, P764, DOI 10.1161/CIRCULATIONAHA.107.695189; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; Simper D, 2002, CIRCULATION, V106, P1199, DOI 10.1161/01.CIR.0000031525.61826.A8; Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549; Tousoulis D, 1999, CARDIOVASC DRUG THER, V13, P295, DOI 10.1023/A:1007747114386; Zernecke A, 2005, CIRC RES, V96, P784, DOI 10.1161/01.RES.0000162100.52009.38; Zhou H, 2008, BIOCHEM BIOPH RES CO, V369, P213, DOI 10.1016/j.bbrc.2007.12.194; Zoll J, 2008, CARDIOVASC RES, V77, P471, DOI 10.1093/cvr/cvm034; ZON LI, 2001, HEMATOPOIESIS DEV AP	47	40	40	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					81	92		10.1096/fj.09-132225	http://dx.doi.org/10.1096/fj.09-132225			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19745110				2022-12-28	WOS:000273233600011
J	He, L; Kim, JA; Whistler, JL				He, Li; Kim, Joseph A.; Whistler, Jennifer L.			Biomarkers of morphine tolerance and dependence are prevented by morphine-induced endocytosis of a mutant mu-opioid receptor	FASEB JOURNAL			English	Article						adenylyl cyclase; c-fos; glucocorticoid receptor; NMDA receptor; trafficking	INDUCED DOWN-REGULATION; VENTRAL TEGMENTAL AREA; NMDA RECEPTORS; GLUCOCORTICOID-RECEPTORS; OPIATE WITHDRAWAL; RAT-BRAIN; C-FOS; REDUCES TOLERANCE; NUCLEUS-ACCUMBENS; INDUCED ANALGESIA	Growing evidence shows that trafficking of the mu-opioid receptor (MOR) is a critical process in functional recovery from desensitization following activation and plays important roles in morphine tolerance and dependence largely because of the failure of morphine to promote such trafficking. However, morphine tolerance and dependence are believed to be mediated by multiple mechanisms, including well-documented biochemical changes in cAMP activity, N-methyl-D-aspartate receptors (NMDARs), glucocorticoid receptors (GRs), and c-fos. Here, we assess the consequences of promoting morphine-induced endocytosis on these biochemical changes utilizing a knock-in mouse model, RMOR, in which MORs undergo morphine-induced endocytosis. Chronic morphine treatment of wild-type (WT) mice promoted superactivation of adenylyl cyclase, alterations in NMDARs, and up-regulation of GR and c-fos in distinct brain regions. Notably, none of these biochemical changes occurred in the RMOR-knock-in mice. Together, these data demonstrate that morphine tolerance and dependence are mediated by multiple biochemical mechanisms and that MOR endocytosis plays a critical role in each of these mechanisms.-He, L., Kim, J. A., Whistler, J. L. Biomarkers of morphine tolerance and dependence are prevented by morphine-induced endocytosis of a mutant mu-opioid receptor. FASEB J. 23, 4327-4334 (2009). www.fasebj.org	[Whistler, Jennifer L.] Univ Calif San Francisco, Ernest Gallo Clin, Dept Neurol, Emeryville, CA 94608 USA; Univ Calif San Francisco, Res Ctr, Dept Neurol, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco	Whistler, JL (corresponding author), Univ Calif San Francisco, Ernest Gallo Clin, Dept Neurol, 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.	jwhistler@gallo.ucsf.edu			National Institute on Drug Abuse [R01 DA015232, DA19958]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015232, R01DA019958] Funding Source: NIH RePORTER	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Drs. Anuradha Madhavan, Dawn Thompson, and Johan Enquist for critical reading of the manuscript. We thank Stacy Taylor and Madeline Ferwerda for maintenance and genotyping of the mouse colony. This work was supported by National Institute on Drug Abuse grant R01 DA015232 and DA19958 to J.L.W., and funds were provided by the state of California for medical research on alcohol and substance abuse through the University of California- San Francisco to J.L.W.	AvidorReiss T, 1996, J BIOL CHEM, V271, P21309, DOI 10.1074/jbc.271.35.21309; Bajo M, 2006, J NEUROSCI RES, V83, P532, DOI 10.1002/jnr.20756; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; David V, 2008, NEUROPSYCHOPHARMACOL, V33, P1746, DOI 10.1038/sj.npp.1301529; de Kloet ER, 2008, EUR J PHARMACOL, V585, P473, DOI 10.1016/j.ejphar.2008.03.011; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Erdtmann-Vourliotis M, 1999, MOL BRAIN RES, V72, P1, DOI 10.1016/S0169-328X(99)00184-9; Erdtmann-Vourliotis M, 1998, MOL BRAIN RES, V61, P51, DOI 10.1016/S0169-328X(98)00197-1; Ferguson SM, 2004, NEUROPSYCHOPHARMACOL, V29, P1664, DOI 10.1038/sj.npp.1300465; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Fitzgerald LW, 1996, J NEUROSCI, V16, P274; Grecksch G, 2006, PSYCHOPHARMACOLOGY, V186, P177, DOI 10.1007/s00213-006-0365-8; He L, 2005, CURR BIOL, V15, P1028, DOI 10.1016/j.cub.2005.04.052; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Inoue M, 2003, J NEUROSCI, V23, P6529; IZENWASSER S, 1993, J PHARMACOL EXP THER, V267, P145; Keith DE, 1998, MOL PHARMACOL, V53, P377, DOI 10.1124/mol.53.3.377; Kim JA, 2008, CURR BIOL, V18, P129, DOI 10.1016/j.cub.2007.12.057; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Kolber BJ, 2008, STRESS, V11, P321, DOI 10.1080/10253890701821081; Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012; KOOB GF, 1992, TRENDS NEUROSCI, V15, P186, DOI 10.1016/0166-2236(92)90171-4; Lim G, 2005, ANESTHESIOLOGY, V102, P832, DOI 10.1097/00000542-200504000-00020; Lim G, 2005, PAIN, V114, P81, DOI 10.1016/j.pain.2004.11.019; Lim GW, 2005, J NEUROSCI, V25, P11145, DOI 10.1523/JNEUROSCI.3768-05.2005; LIU JL, 1994, P NATL ACAD SCI USA, V91, P8537, DOI 10.1073/pnas.91.18.8537; Mao JR, 2002, J NEUROSCI, V22, P8312; Marinelli M, 1998, P NATL ACAD SCI USA, V95, P7742, DOI 10.1073/pnas.95.13.7742; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; Nye HE, 1996, MOL PHARMACOL, V49, P636; Pasternak GW, 2007, J CLIN INVEST, V117, P3185, DOI 10.1172/JCI34035; Pawar M, 2007, EUR J PHARMACOL, V563, P92, DOI 10.1016/j.ejphar.2007.01.059; RASMUSSEN K, 1990, J NEUROSCI, V10, P2308; Resink A, 1996, J NEUROCHEM, V66, P369; RESINK A, 1995, EUR J NEUROSCI, V7, P1700, DOI 10.1111/j.1460-9568.1995.tb00691.x; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Thomson F, 2008, NEUROCHEM RES, V33, P691, DOI 10.1007/s11064-007-9518-3; Trafton JA, 2000, J NEUROSCI, V20, P8578; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; Trujillo KA, 2000, PSYCHOPHARMACOLOGY, V151, P121, DOI 10.1007/s002130000416; WANG YH, 1995, J NEUROCHEM, V65, P176; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Williams JT, 2001, PHYSIOL REV, V81, P299, DOI 10.1152/physrev.2001.81.1.299; Yang Y, 2004, J NEUROSCI, V24, P2412, DOI 10.1523/JNEUROSCI.5544-03.2004; Zeng JS, 2006, J NEUROSCI, V26, P12033, DOI 10.1523/JNEUROSCI.2530-06.2006; Zollner C, 2008, J CLIN INVEST, V118, P1065, DOI 10.1172/JCI25911	50	32	32	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4327	4334		10.1096/fj.09-133223	http://dx.doi.org/10.1096/fj.09-133223			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19679639	Green Published			2022-12-28	WOS:000272193700027
J	Beurrier, C; Lopez, S; Revy, D; Selvam, C; Goudet, C; Lherondel, M; Gubellini, P; Kerkerian-LeGoff, L; Acher, F; Pin, JP; Amalric, M				Beurrier, Corinne; Lopez, Sebastien; Revy, Delphine; Selvam, Chelliah; Goudet, Cyril; Lherondel, Morgane; Gubellini, Paolo; Kerkerian-LeGoff, Lydia; Acher, Francine; Pin, Jean-Philippe; Amalric, Marianne			Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism	FASEB JOURNAL			English	Article						orthosteric ligands; 6-hydroxydopamine; GABA-A receptor; globus pallidus; mice; rats	DECARBOXYLASE MESSENGER-RNA; REACTION-TIME PERFORMANCE; RAT GLOBUS-PALLIDUS; BASAL-GANGLIA; SYNAPTIC-TRANSMISSION; ALLEVIATES AKINESIA; FUNCTIONAL-ANATOMY; ACTIVATION; NUCLEUS; DISEASE	Developing nondopaminergic palliative treatments for Parkinson's disease represents a major challenge to avoid the debilitating side effects produced by L-DOPA therapy. Increasing interest is addressed to the selective targeting of group III metabotropic glutamate (mGlu) receptors that inhibit transmitter release at presumably overactive synapses in the basal ganglia. Here we characterize the functional action of a new orthosteric group III mGlu agonist, LSP1-2111, with a preferential affinity for mGlu4 receptor. In mouse brain slices, LSP1-2111 inhibits striatopallidal GABAergic transmission by selectively activating the mGlu4 receptor but has no effect at a synapse modulated solely by the mGlu7 and mGlu8 receptors. Intrapallidal LSP1-2111 infusion reverses the akinesia produced by nigrostriatal dopamine depletion in a reaction time task, whereas an mGlu8-receptor agonist has no effect. Finally, systemic administration of LSP1-2111 counteracts haloperidol-induced catalepsy, opening promising perspectives for the development of antiparkinsonian therapeutic strategies focused on orthosteric mGlu4-receptor agonists.-Beurrier, C., Lopez, S., Revy, D., Selvam, C., Goudet, C., Lherondel, M., Gubellini, P., Kerkerian-LeGoff, L., Acher, F., Pin, J.-P., Amalric, M. Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J. 23, 3619-3628 (2009). www.fasebj.org	[Lopez, Sebastien; Lherondel, Morgane; Amalric, Marianne] Univ Aix Marseille 1, CNRS, UMR 6155, Lab Neurobiol Cognit, F-13331 Marseille 3, France; [Beurrier, Corinne; Revy, Delphine; Gubellini, Paolo; Kerkerian-LeGoff, Lydia] Univ Aix Marseille 2, CNRS, UMR 6216, Inst Biol Dev Marseille Luminy, Marseille, France; [Selvam, Chelliah; Acher, Francine] Univ Paris 05, CNRS, UMR 8601, Chim & Biochim Pharmacol & Toxicol Lab, Paris, France; [Goudet, Cyril; Pin, Jean-Philippe] Univ Montpellier 1, INSERM, CNRS,U661, Inst Genom Fonct,UMR 5203, Montpellier, France; [Goudet, Cyril; Pin, Jean-Philippe] Univ Montpellier 2, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier	Amalric, M (corresponding author), Univ Aix Marseille 1, CNRS, UMR 6155, Lab Neurobiol Cognit, Case C,3 Pl Victor Hugo, F-13331 Marseille 3, France.	marianne.amalric@univ-provence.fr	Goudet, Cyril/AAE-3415-2020; Pin, Jean-Philippe/Y-6668-2019	Goudet, Cyril/0000-0002-8255-3535; Pin, Jean-Philippe/0000-0002-1423-345X; Kerkerian-Le Goff, Lydia/0000-0002-7951-3479; Amalric, Marianne/0000-0002-9915-6763; SELVAM, CHELLIAH/0000-0003-1394-9349	Centre National de la Recherche Scientifique (CNRS); Universitede Provence; Universite de la Mediterranee; Fondation de France; French Ministry of Education and Research [ACI 04 2 91]; National Research Agency [ANR-05-NEUR-021]; Ministry of Education and Research and Fondation France Parkinson	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Universitede Provence; Universite de la Mediterranee; Fondation de France(Fondation de France); French Ministry of Education and Research; National Research Agency(French National Research Agency (ANR)); Ministry of Education and Research and Fondation France Parkinson	This research was supported by the Centre National de la Recherche Scientifique (CNRS), Universitede Provence, Universite de la Mediterranee, and research grants of the Fondation de France, the French Ministry of Education and Research (ACI 04 2 91), and the National Research Agency (ANR-05-NEUR-021). S. L. was supported by a grant from the Ministry of Education and Research and Fondation France Parkinson. We thank for their technical expertise: D. Rigault, I. Lemasson (LSP1-2111 synthesis), N. Oueslati (pharmacological characterization), D. Diabira, J.-L. Gaiarsa (hippocampus slice recordings), and N. Turle-Lorenzo (surgery and histology). We also thank D. Hampson (University of Toronto, Toronto, ON, Canada) for the generous gift of mice lacking mGlu4 receptor.	Acher F., 2007, Patent Application, Patent No. [WO2007052169, 2007052169, W02007052169]; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; AMALRIC M, 1989, BRAIN RES, V483, P389, DOI 10.1016/0006-8993(89)90186-8; AMALRIC M, 1987, J NEUROSCI, V7, P2129; AMALRIC M, 1995, EUR J NEUROSCI, V7, P972, DOI 10.1111/j.1460-9568.1995.tb01085.x; Ayala JE, 2008, NEUROPHARMACOLOGY, V54, P804, DOI 10.1016/j.neuropharm.2007.12.009; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; Battaglia G, 2006, J NEUROSCI, V26, P7222, DOI 10.1523/JNEUROSCI.1595-06.2006; Brabet I, 1998, NEUROPHARMACOLOGY, V37, P1043, DOI 10.1016/S0028-3908(98)00091-4; Bradley SR, 1999, J COMP NEUROL, V407, P33; Breysse N, 2003, J NEUROSCI, V23, P8302; Chesselet MF, 1996, TRENDS NEUROSCI, V19, P417; Corti C, 2002, NEUROSCIENCE, V110, P403, DOI 10.1016/S0306-4522(01)00591-7; Frauli M, 2007, MOL PHARMACOL, V71, P704, DOI 10.1124/mol.106.030254; Gauntlett-Gilbert J, 1998, NEUROSCI BIOBEHAV R, V22, P865, DOI 10.1016/S0149-7634(98)00014-1; Gomeza J, 1996, MOL PHARMACOL, V50, P923; Goudet C, 2004, P NATL ACAD SCI USA, V101, P378, DOI 10.1073/pnas.0304699101; Kearney JAF, 2000, NEUROSCIENCE, V95, P409; KINCAID AE, 1992, NEUROSCIENCE, V51, P705, DOI 10.1016/0306-4522(92)90309-P; Konieczny J, 2007, NEUROSCIENCE, V145, P611, DOI 10.1016/j.neuroscience.2006.12.006; Kosinski CM, 1999, J COMP NEUROL, V415, P266; Levy R, 1997, NEUROSCIENCE, V76, P335, DOI 10.1016/S0306-4522(96)00409-5; Lopez S, 2007, J NEUROSCI, V27, P6701, DOI 10.1523/JNEUROSCI.0299-07.2007; MacInnes N, 2004, BRIT J PHARMACOL, V141, P15, DOI 10.1038/sj.bjp.0705566; MANEUF YP, 1994, EXP NEUROL, V125, P65, DOI 10.1006/exnr.1994.1007; Marino MJ, 2003, P NATL ACAD SCI USA, V100, P13668, DOI 10.1073/pnas.1835724100; Matsui T, 2003, NEUROSCIENCE, V122, P727, DOI 10.1016/j.neuroscience.2003.08.032; MATSUMURA M, 1995, NEUROSCIENCE, V65, P59, DOI 10.1016/0306-4522(94)00484-M; Nielsen KM, 2003, SYNAPSE, V49, P246, DOI 10.1002/syn.10234; Niswender CM, 2008, MOL PHARMACOL, V74, P1345, DOI 10.1124/mol.108.049551; Obeso JA, 2006, EXP NEUROL, V202, P1, DOI 10.1016/j.expneurol.2006.07.004; OSSOWSKA K, 1984, PHARMACOL BIOCHEM BE, V21, P825, DOI 10.1016/S0091-3057(84)80060-X; Oueslati A, 2005, EUR J NEUROSCI, V22, P2765, DOI 10.1111/j.1460-9568.2005.04498.x; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V5th Edn, DOI 10.1016/c2009-0-63235-9; Pekhletski R, 1996, J NEUROSCI, V16, P6364; Scheel-Kruger J, 1984, Adv Neurol, V40, P85; Schmid S, 2006, NEUROPHARMACOLOGY, V50, P154, DOI 10.1016/j.neuropharm.2005.08.002; Selvam C, 2007, J MED CHEM, V50, P4656, DOI 10.1021/jm070400y; Sibille P, 2007, J MED CHEM, V50, P3585, DOI 10.1021/jm070262c; SOGHOMONIAN JJ, 1994, J NEUROSCI, V14, P6256; SOGHOMONIAN JJ, 1992, SYNAPSE, V11, P124, DOI 10.1002/syn.890110205; TREMBLAY L, 1989, BRAIN RES, V498, P17, DOI 10.1016/0006-8993(89)90395-8; Triballeau N, 2005, J MED CHEM, V48, P2534, DOI 10.1021/jm049092j; Valenti O, 2003, J NEUROSCI, V23, P7218, DOI 10.1523/JNEUROSCI.23-18-07218.2003; Wittmann M, 2002, J PHARMACOL EXP THER, V302, P433, DOI 10.1124/jpet.102.033266; Zhang CX, 2000, EXP NEUROL, V165, P278, DOI 10.1006/exnr.2000.7452	46	96	97	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3619	3628		10.1096/fj.09-131789	http://dx.doi.org/10.1096/fj.09-131789			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19525404				2022-12-28	WOS:000270354300038
J	Faille, D; Combes, V; Mitchell, AJ; Fontaine, A; Juhan-Vague, I; Alessi, MC; Chimini, G; Fusai, T; Grau, GE				Faille, Dorothee; Combes, Valery; Mitchell, Andrew J.; Fontaine, Albin; Juhan-Vague, Irene; Alessi, Marie-Christine; Chimini, Giovanna; Fusai, Thierry; Grau, Georges E.			Platelet microparticles: a new player in malaria parasite cytoadherence to human brain endothelium	FASEB JOURNAL			English	Article						vesiculation; internalization; antigen transfer; microvessels; pathogenesis; neuroinflammation	FALCIPARUM-INFECTED ERYTHROCYTES; PLASMODIUM-FALCIPARUM; CEREBRAL MALARIA; ACTIVATED PLATELETS; CHONDROITIN SULFATE; PATHOGENESIS; RECEPTOR; CELLS; MODULATION; ADHERENCE	Cerebral malaria ( CM) is characterized by accumulation of circulating cells within brain microvessels, among which platelets play an important role. In vitro, platelets modulate the cytoadherence of Plasmodium falciparum-parasitized red blood cells (PRBCs) to brain endothelial cells. Here we show for the first time that platelet microparticles (PMPs) are able to bind to PRBCs, thereby transferring platelet antigens to the PRBC surface. This binding is largely specific to PRBCs, because PMPs show little adherence to normal red blood cells. PMP adherence is also dependent on the P. falciparum erythrocyte membrane protein 1 variant expressed by PRBCs. PMP binding to PRBCs decreases after neutralization of PRBC surface proteins by trypsin or after treatment of PMPs with a mAb to platelet-endothelial cell adhesion molecule-1 (CD31) and glycoprotein IV (CD36). Furthermore, PMP uptake is a dynamic process that can be achieved by human brain endothelial cells (HBECs), inducing changes in the endothelial phenotype. Lastly, PMPs dramatically increase PRBC cytoadherence to HBECs. In conclusion, our study identifies several mechanisms by which PMPs may participate in CM pathogenesis while interacting with both PRBCs and HBECs. PMPs thereby provide a novel target for antagonizing interactions between vascular cells that promote microvascular sludging and blood brain barrier alteration during CM.-Faille, D., Combes, V., Mitchell, A. J., Fontaine, A., Juhan-Vague, I., Alessi, M.-C., Chimini, G., Fusa, T., Grau, G. E. Platelet microparticles: a new player in malaria parasite cytoadherence to human brain endothelium. FASEB J. 23, 3449-3458 ( 2009). www.fasebj.org	[Grau, Georges E.] Univ Sydney, Fac Med, Dept Pathol, Camperdown, NSW 2042, Australia; [Faille, Dorothee; Fontaine, Albin; Fusai, Thierry] Inst Trop Med, Serv Sante Armees, Unite Rech Biol & Epidemiol Parasitaires, Marseille, France; [Mitchell, Andrew J.; Chimini, Giovanna] Fac Sci, CNRS, UMR6102, Ctr Immunol Marseille Luminy,INSERM,U631, Marseille, France; [Juhan-Vague, Irene; Alessi, Marie-Christine] Aix Marseille Univ, Fac Med, INSERM, U626, Marseille, France	University of Sydney; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Grau, GE (corresponding author), Univ Sydney, Fac Med, Dept Pathol, Med Fdn Bldg K25,Rm 208,92-94 Parramatta Rd, Camperdown, NSW 2042, Australia.	ggrau@med.usyd.edu.au	Mitchell, Alex J/P-5671-2015; ALESSI, Marie-christine/AAK-3582-2020; Fontaine, Albin/K-4345-2019; Grau, Georges/AGR-7139-2022; Faille, Dorothée/AFO-5088-2022; Mitchell, Andrew/C-2714-2009	Mitchell, Alex J/0000-0001-6014-598X; ALESSI, Marie-christine/0000-0003-3927-5792; Fontaine, Albin/0000-0001-6869-6516; Grau, Georges/0000-0002-0442-0462; Faille, Dorothée/0000-0003-4414-739X; Mitchell, Andrew/0000-0003-4454-853X; Combes, Valery/0000-0003-2178-3596	National Health and Medical Research Council of Australia [464893]; Australian Research Council [DP0774425]; European Union-Health and Medical Research Council of Australia [512101]; Rebecca Cooper Foundation; University of Sydney	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); European Union-Health and Medical Research Council of Australia; Rebecca Cooper Foundation; University of Sydney(University of Sydney)	The authors are indebted to the Plate-forme d'Imagerie Commune Scientifique de Luminy for expert technical assistance. This work was supported by grants from the National Health and Medical Research Council of Australia (NHMRC project grant 464893; http://www.nhmrc.gov.au), the Australian Research Council ( ARC Discovery Project DP0774425; http://www.arc.gov.au), the European Union-Health and Medical Research Council of Australia (EU-NHMRC project grant 512101; http://europa.eu), the Rebecca Cooper Foundation (http://www.cooperfoundation.org.au), and the University of Sydney major equipment grant scheme (http://www.usyd.edu.au). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barry OP, 1998, J CLIN INVEST, V102, P136, DOI 10.1172/JCI2592; Birts CN, 2008, J BIOL CHEM, V283, P5034, DOI 10.1074/jbc.M708844200; BJERKNES R, 1984, BLUT, V49, P315, DOI 10.1007/BF00320205; CARLSON J, 1994, BLOOD, V84, P3909, DOI 10.1182/blood.V84.11.3909.bloodjournal84113909; Chotivanich K, 2004, J INFECT DIS, V189, P1052, DOI 10.1086/381900; Combes V, 2005, AM J PATHOL, V166, P295, DOI 10.1016/S0002-9440(10)62253-5; Combes V, 2004, JAMA-J AM MED ASSOC, V291, P2542, DOI 10.1001/jama.291.21.2542-b; del Conde I, 2005, BLOOD, V106, P1604, DOI 10.1182/blood-2004-03-1095; Diamant M, 2004, EUR J CLIN INVEST, V34, P392, DOI 10.1111/j.1365-2362.2004.01355.x; DOROVINIZIS K, 1991, LAB INVEST, V64, P425; FAJARDO LF, 1973, NATURE, V243, P298, DOI 10.1038/243298a0; Fernandez V, 1998, INFECT IMMUN, V66, P2969, DOI 10.1128/IAI.66.6.2969-2975.1998; Flaumenhaft R, 2006, BLOOD CELL MOL DIS, V36, P182, DOI 10.1016/j.bcmd.2005.12.019; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; GRAU GE, 1991, EUR J IMMUNOL, V21, P2265, DOI 10.1002/eji.1830210939; Grau GE, 2003, J INFECT DIS, V187, P461, DOI 10.1086/367960; GRAU GE, 1993, EUR CYTOKINE NETW, V4, P415; Ho M, 1999, AM J PHYSIOL-CELL PH, V276, pC1231, DOI 10.1152/ajpcell.1999.276.6.C1231; Hugel B, 2005, PHYSIOLOGY, V20, P22, DOI 10.1152/physiol.00029.2004; Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1; Idro R, 2005, LANCET NEUROL, V4, P827, DOI 10.1016/S1474-4422(05)70247-7; JENSEN JB, 1978, AM J TROP MED HYG, V27, P1274, DOI 10.4269/ajtmh.1978.27.1274; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; McMorran BJ, 2009, SCIENCE, V323, P797, DOI 10.1126/science.1166296; Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4; Nomura S, 2001, ATHEROSCLEROSIS, V158, P277, DOI 10.1016/S0021-9150(01)00433-6; Nomura S, 2007, THROMB HAEMOSTASIS, V98, P1143, DOI 10.1160/TH07-03-0217; Pain A, 2001, P NATL ACAD SCI USA, V98, P1805, DOI 10.1073/pnas.98.4.1805; PATNAIK JK, 1994, AM J TROP MED HYG, V51, P642, DOI 10.4269/ajtmh.1994.51.642; Piguet PF, 2002, APOPTOSIS, V7, P91, DOI 10.1023/A:1014341611412; PORTA J, 1993, CLIN NEUROPATHOL, V12, P142; PRADHAN D, 1994, MOL MEMBR BIOL, V11, P181, DOI 10.3109/09687689409162237; RINGWALD P, 1993, INFECT IMMUN, V61, P5198, DOI 10.1128/IAI.61.12.5198-5204.1993; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; ROWE A, 1995, INFECT IMMUN, V63, P2323, DOI 10.1128/IAI.63.6.2323-2326.1995; Salanova B, 2007, J BIOL CHEM, V282, P27960, DOI 10.1074/jbc.M704039200; Setty BNY, 2008, BLOOD, V111, P905, DOI 10.1182/blood-2007-07-099465; Silamut K, 1999, AM J PATHOL, V155, P395, DOI 10.1016/S0002-9440(10)65136-X; Sinauridze EI, 2007, THROMB HAEMOSTASIS, V97, P425, DOI 10.1160/TH06-06-0313; STEINER M, 1987, BIOCHIM BIOPHYS ACTA, V931, P286, DOI 10.1016/0167-4889(87)90218-7; Sun G, 2003, INFECT IMMUN, V71, P6553, DOI 10.1128/IAI.71.11.6553-6561.2003; Tocchetti EV, 2001, THROMB RES, V103, P47, DOI 10.1016/S0049-3848(01)00263-8; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Treutiger CJ, 1997, NAT MED, V3, P1405, DOI 10.1038/nm1297-1405; van der Heyde HC, 2005, BLOOD, V105, P1956, DOI 10.1182/blood-2004-06-2206; von zur Muhlen C, 2008, J CLIN INVEST, V118, P1198, DOI 10.1172/JCI33314; Wassmer SC, 2008, J INFECT DIS, V197, P72, DOI 10.1086/523761; Wassmer SC, 2006, INFECT IMMUN, V74, P645, DOI 10.1128/IAI.74.1.645-653.2006; Wassmer SC, 2004, J INFECT DIS, V189, P180, DOI 10.1086/380761; Yipp BG, 2003, BLOOD, V101, P331, DOI 10.1182/blood-2002-06-1725	53	86	87	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3449	3458		10.1096/fj.09-135822	http://dx.doi.org/10.1096/fj.09-135822			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19535685				2022-12-28	WOS:000270354300022
J	Martellini, JA; Cole, AL; Venkataraman, N; Quinn, GA; Svoboda, P; Gangrade, BK; Pohl, J; Sorensen, OE; Cole, AM				Martellini, Julie A.; Cole, Amy L.; Venkataraman, Nitya; Quinn, Gerry A.; Svoboda, Pavel; Gangrade, Bhushan K.; Pohl, Jan; Sorensen, Ole E.; Cole, Alexander M.			Cationic polypeptides contribute to the anti-HIV-1 activity of human seminal plasma	FASEB JOURNAL			English	Article						antigens; epitopes; AIDS; reproductive immunology; viral; antimicrobial	IMMUNODEFICIENCY-VIRUS TYPE-1; POLYACRYLAMIDE-GEL ELECTROPHORESIS; PROSTATE-SPECIFIC ANTIGEN; SPERM MOTILITY INHIBITOR; ANTIMICROBIAL PEPTIDES; SEMENOGELIN-I; ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; PROTEIN; LACTOFERRIN	Mucosal surfaces of the reproductive tract as well as their secretions have important roles in preventing sexual transmission of HIV-1. In the current study, the majority of the intrinsic anti-HIV-1 activity of human seminal plasma (SP) was determined to reside in the cationic polypeptide fraction. Antiviral assays utilizing luciferase reporter cells and lymphocytic cells revealed the ability of whole SP to prevent HIV-1 infection, even when SP was diluted 3200-fold. Subsequent fractionation by continuous flow acid-urea (AU)-PAGE and antiviral testing revealed that cationic polypeptides within SP were responsible for the majority of anti-HIV-1 activity. A proteomic approach was utilized to resolve and identify 52 individual cationic polypeptides that contribute to the aggregate anti-HIV-1 activity of SP. One peptide fragment of semenogelin I, termed SG-1, was purified from SP by a multistep chromatographic approach, protein sequenced, and determined to exhibit anti-HIV-1 activity against HIV-1. Anti-HIV-1 activity was transient, as whole SP incubated for prolonged time intervals exhibited a proportional decrease in anti-HIV-1 activity that was directly attributed to the degradation of semenogelin I peptides. Collectively, these results indicate that the cationic polypeptide fraction of SP is active against HIV-1, and that semenogelin-derived peptides contribute to the intrinsic anti-HIV-1 activity of SP.-Martellini, J. A., Cole, A. C., Venkataraman, N., Quinn, G. A., Svoboda, P., Gangrade, B. K., Pohl, J., Sorensen, O. E., Cole, A. M. Cationic polypeptides contribute to the anti-HIV-1 activity of human seminal plasma. FASEB J. 23, 3609-3618 (2009). www.fasebj.org	[Martellini, Julie A.; Cole, Amy L.; Venkataraman, Nitya; Quinn, Gerry A.; Cole, Alexander M.] Univ Cent Florida, Burnett Sch Biomed Sci, Biomol Sci Ctr, Dept Mol Biol & Microbiol, Orlando, FL 32816 USA; [Svoboda, Pavel; Pohl, Jan] Ctr Dis Control & Prevent, Div Safety Res, Biotechnol Core Facil Branch, Atlanta, GA USA; [Gangrade, Bhushan K.] Ctr Reprod Med, Orlando, FL USA; [Sorensen, Ole E.] Lund Univ, Dept Clin Sci, Div Infect Med, Lund, Sweden	State University System of Florida; University of Central Florida; Centers for Disease Control & Prevention - USA; Lund University	Cole, AM (corresponding author), 4000 Cent Florida Blvd,Bldg 20,Rm 236, Orlando, FL 32816 USA.	ole_e.sorensen@med.lu.se; acole@mail.ucf.edu		Sorensen, Ole E./0000-0001-8681-6921	NIAID NIH HHS [R01 AI052017-08, R01 AI052017-09, R01 AI052017-06, R01 AI052017-07, R01 AI052017, R01 AI052017-10] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052017] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Autiero M, 1997, EUR J BIOCHEM, V245, P208, DOI 10.1111/j.1432-1033.1997.00208.x; Berkhout B, 2004, BIOMETALS, V17, P291, DOI 10.1023/B:BIOM.0000027707.82911.be; BJORCK L, 1990, MOL MICROBIOL, V4, P1439, DOI 10.1111/j.1365-2958.1990.tb02054.x; Bourgeon F, 2004, BIOL REPROD, V70, P768, DOI 10.1095/biolreprod.103.022533; Brillard-Bourdet M, 2002, EUR J BIOCHEM, V269, P390, DOI 10.1046/j.0014-2956.2001.02667.x; CHRISTOPHERHENN.J, 2008, ANIM HEALTH RES REV, P1; Cole AM, 2003, CURR PHARM DESIGN, V9, P1463, DOI 10.2174/1381612033454667; Cole AM, 2002, J IMMUNOL, V169, P6985, DOI 10.4049/jimmunol.169.12.6985; Cole AL, 2006, J IMMUNOL, V176, P6900, DOI 10.4049/jimmunol.176.11.6900; Com E, 2003, BIOL REPROD, V68, P95, DOI 10.1095/biolreprod.102.005389; da Costa AO, 1999, BIOCELL, V23, P65; Edstrom AML, 2008, J IMMUNOL, V181, P3413, DOI 10.4049/jimmunol.181.5.3413; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ganz T, 2004, J LEUKOCYTE BIOL, V75, P34, DOI 10.1189/jlb.0403150; Ganz T, 1997, SEMIN HEMATOL, V34, P343; Groot F, 2005, J VIROL, V79, P3009, DOI 10.1128/JVI.79.5.3009-3015.2005; HARWIG SSL, 1993, ANAL BIOCHEM, V208, P382, DOI 10.1006/abio.1993.1065; Jonsson M, 2006, CELL MOL LIFE SCI, V63, P2886, DOI 10.1007/s00018-006-6287-0; Klotman ME, 2006, NAT REV IMMUNOL, V6, P447, DOI 10.1038/nri1860; Lehrer RI, 2002, CURR OPIN HEMATOL, V9, P18, DOI 10.1097/00062752-200201000-00004; LILJA H, 1990, ANDROLOGIA, V22, P132; LILJA H, 1985, FEBS LETT, V182, P181, DOI 10.1016/0014-5793(85)81179-0; LILJA H, 1993, WORLD J UROL, V11, P188; Malm J, 2000, INFECT IMMUN, V68, P4297, DOI 10.1128/IAI.68.7.4297-4302.2000; Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014; Robert M, 1997, BIOCHEMISTRY-US, V36, P3811, DOI 10.1021/bi9626158; Robert M, 1999, CELL MOL LIFE SCI, V55, P944, DOI 10.1007/s000180050346; ROBERT M, 1995, HUM REPROD, V10, P2192, DOI 10.1093/oxfordjournals.humrep.a136267; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shukeir N, 2003, CANCER RES, V63, P2072; Swart PJ, 1998, ADV EXP MED BIOL, V443, P205; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Udby L, 2005, BIOCHEM BIOPH RES CO, V333, P555, DOI 10.1016/j.bbrc.2005.05.139; van der Strate BWA, 2001, ANTIVIR RES, V52, P225, DOI 10.1016/S0166-3542(01)00195-4; Venkataraman N, 2005, J IMMUNOL, V175, P7560, DOI 10.4049/jimmunol.175.11.7560; Vray B, 2002, CELL MOL LIFE SCI, V59, P1503, DOI 10.1007/s00018-002-8525-4; Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411; Zhao H, 2008, PEPTIDES, V29, P505, DOI 10.1016/j.peptides.2008.01.009	38	59	63	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3609	3618		10.1096/fj.09-131961	http://dx.doi.org/10.1096/fj.09-131961			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19487309	Green Published, Green Submitted			2022-12-28	WOS:000270354300037
J	Defer, N; Wan, JH; Souktani, R; Escoubet, B; Perier, M; Caramelle, P; Manin, S; Deveaux, V; Bourin, MC; Zimmer, A; Lotersztajn, S; Pecker, F; Pavoine, C				Defer, Nicole; Wan, Jinghong; Souktani, Richard; Escoubet, Brigitte; Perier, Magali; Caramelle, Philippe; Manin, Sylvie; Deveaux, Vanessa; Bourin, Marie-Claude; Zimmer, Andreas; Lotersztajn, Sophie; Pecker, Francoise; Pavoine, Catherine			The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy	FASEB JOURNAL			English	Article						in vivo; remodeling; apoptosis; heart failure; signaling; fibrosis	ISCHEMIA-REPERFUSION INJURY; NECROSIS-FACTOR-ALPHA; INFARCT SIZE; TNF-ALPHA; MYOCARDIAL-INFARCTION; HEART-FAILURE; CB2 RECEPTOR; ENDOCANNABINOIDS; MICE; RATS	Post-myocardial infarction (MI) heart failure is a major public health problem in Western countries and results from ischemia/reperfusion (IR)-induced cell death, remodeling, and contractile dysfunction. Ex vivo studies have demonstrated the cardioprotective anti-inflammatory effect of the cannabinoid type 2 (CB2) receptor agonists within hours after IR. Herein, we evaluated the in vivo effect of CB2 receptors on IR-induced cell death, fibrosis, and cardiac dysfunction and investigated the target role of cardiac myocytes and fibroblasts. The infarct size was increased 24 h after IR in CB2(-/-) vs. wild-type (WT) hearts and decreased when WT hearts were injected with the CB2 agonist JWH133 (3 mg/kg) at reperfusion. Compared with WT hearts, CB2(-/-) hearts showed widespread injury 3 d after IR, with enhanced apoptosis and remodeling affecting the remote myocardium. Finally, CB2(-/-) hearts exhibited exacerbated fibrosis, associated with left ventricular dysfunction 4 wk after IR, whereas their WT counterparts recovered normal function. Cardiac myocytes and fibroblasts isolated from CB2(-/-) hearts displayed a higher H2O2-induced death than WT cells, whereas 1 mu M JWH133 triggered survival effects. Furthermore, H2O2-induced myofibroblast activation was increased in CB2(-/-) fibroblasts but decreased in 1 mu M JWH133-treated WT fibroblasts, compared with that in WT cells. Therefore, CB2 receptor activation may protect against post-IR heart failure through direct inhibition of cardiac myocyte and fibroblast death and prevention of myofibroblast activation.-Defer, N., Wan, J., Souktani, R., Escoubet, B., Perier, M., Caramelle, P., Manin, S., Deveaux, V., Bourin, M.-C., Zimmer, A., Lotersztajn, S., Pecker, F., Pavoine, C. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J. 23, 2120-2130 (2009)	[Defer, Nicole; Wan, Jinghong; Perier, Magali; Caramelle, Philippe; Manin, Sylvie; Deveaux, Vanessa; Bourin, Marie-Claude; Lotersztajn, Sophie; Pecker, Francoise; Pavoine, Catherine] Hop Henri Mondor, INSERM, U955, IMRB, F-94010 Creteil, France; [Defer, Nicole; Wan, Jinghong; Souktani, Richard; Perier, Magali; Caramelle, Philippe; Manin, Sylvie; Deveaux, Vanessa; Bourin, Marie-Claude; Lotersztajn, Sophie; Pecker, Francoise; Pavoine, Catherine] Univ Paris 12, Fac Med, UMR S 955, Creteil, France; [Souktani, Richard] IFR10 IM3, Creteil, France; [Escoubet, Brigitte] Univ Paris 07, INSERM, Assistance Publ Hop Paris, Hop Bichat,UFR Med,U872, Paris, France; [Zimmer, Andreas] Univ Bonn, Inst Mol Psychiat, D-5300 Bonn, Germany; [Pecker, Francoise] Grp Hosp Henri Mondor Albert Chenevier, Assistance Publ Hop Paris, Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; University of Bonn; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Pavoine, C (corresponding author), Hop Henri Mondor, INSERM, U955, IMRB, F-94010 Creteil, France.	catherine.pavoine@inserm.fr	Pavoine, Catherine/N-4405-2018; Lotersztajn, Sophie/K-9160-2017; Zimmer, Andreas/B-8357-2009	Pavoine, Catherine/0000-0002-0598-5545; lotersztajn, Sophie/0000-0002-0053-7807	INSERM; Universite Paris-Val de Marne; Assistance Publique des Hopitaux de Paris; Agence Nationale de la Recherche [R06403JS]	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Paris-Val de Marne; Assistance Publique des Hopitaux de Paris; Agence Nationale de la Recherche(French National Research Agency (ANR))	We thank A. Berdeaux for helpful discussions and M. Muffat-Joly for hemodynamic measurements that were performed at the Comite d'Etudes sur les Formations d'Ingenieurs-Institut Federatif de Recherche 2 ( Paris). This work was supported by INSERM, by the Universite Paris-Val de Marne, by the Assistance Publique des Hopitaux de Paris ( as a contrat d'interface to F. P.), and by a grant (R06403JS) from the Agence Nationale de la Recherche. J.W. was supported by a fellowship ( R06403JS, canna licoca) from the Agence Nationale de la Recherche.	Ait-Mamar B, 2005, J BIOL CHEM, V280, P18881, DOI 10.1074/jbc.M410305200; Batkai S, 2007, AM J PHYSIOL-HEART C, V293, pH909, DOI 10.1152/ajpheart.00373.2007; Batkai S, 2007, AM J PHYSIOL-HEART C, V293, pH1689, DOI 10.1152/ajpheart.00538.2007; Beggah AT, 2002, P NATL ACAD SCI USA, V99, P7160, DOI 10.1073/pnas.102673599; Billet S, 2007, J CLIN INVEST, V117, P1914, DOI 10.1172/JCI28764; Bourraindeloup M, 2004, CIRCULATION, V110, P2003, DOI 10.1161/01.CIR.0000143630.14515.7C; BRAUNWALD E, 1991, AM J CARDIOL, V68, pD1; Buckley NE, 2008, BRIT J PHARMACOL, V153, P309, DOI 10.1038/sj.bjp.0707527; Bujak M, 2007, CIRCULATION, V116, P2127, DOI 10.1161/CIRCULATIONAHA.107.704197; Cailleret M, 2004, CIRCULATION, V109, P406, DOI 10.1161/01.CIR.0000109499.00587.FF; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P9977, DOI 10.1073/pnas.161120198; Defer N, 2007, J BIOL CHEM, V282, P35564, DOI 10.1074/jbc.M704003200; Di Filippo C, 2004, J LEUKOCYTE BIOL, V75, P453, DOI 10.1189/jlb.0703303; Donath S, 2006, CIRCULATION, V113, P1203, DOI 10.1161/CIRCULATIONAHA.105.576785; Duffy D, 2007, TRENDS CARDIOVAS MED, V17, P35, DOI 10.1016/j.tcm.2006.11.003; Duran WN, 2008, AM J PHYSIOL-HEART C, V295, pH2221, DOI 10.1152/ajpheart.01050.2008; Frangogiannis NG, 2008, PHARMACOL RES, V58, P88, DOI 10.1016/j.phrs.2008.06.007; Frangogiannis NG, 2007, CIRCULATION, V115, P584, DOI 10.1161/CIRCULATIONAHA.106.646091; Gao X, 2008, AM J PHYSIOL-HEART C, V295, pH2242, DOI 10.1152/ajpheart.00587.2008; Gaskari SA, 2005, BRIT J PHARMACOL, V146, P315, DOI 10.1038/sj.bjp.0706331; Gottlieb RA, 1999, ANN NY ACAD SCI, V874, P412, DOI 10.1111/j.1749-6632.1999.tb09255.x; Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968-0896(99)00219-9; Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008-0150; Ikeuchi M, 2004, CARDIOVASC RES, V64, P526, DOI 10.1016/j.cardiores.2004.07.017; Joyeux M, 2002, CARDIOVASC RES, V55, P619, DOI 10.1016/S0008-6363(02)00268-7; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Lagneux C, 2001, BRIT J PHARMACOL, V132, P793, DOI 10.1038/sj.bjp.0703902; Lepicier P, 2007, LIFE SCI, V81, P1373, DOI 10.1016/j.lfs.2007.08.042; Lepicier P, 2006, J PHARMACOL SCI, V102, P155, DOI 10.1254/jphs.CRJ06011X; Liu J, 2003, J BIOL CHEM, V278, P45034, DOI 10.1074/jbc.M306062200; Liu J, 2000, BIOCHEM J, V346, P835, DOI 10.1042/0264-6021:3460835; Lotersztajn S, 2008, BRIT J PHARMACOL, V153, P286, DOI 10.1038/sj.bjp.0707511; Mach F, 2008, BRIT J PHARMACOL, V153, P290, DOI 10.1038/sj.bjp.0707517; Mallat A, 2008, AM J PHYSIOL-GASTR L, V294, pG9, DOI 10.1152/ajpgi.00467.2007; Mann DL, 2004, CIRCULATION, V109, P1594, DOI 10.1161/01.CIR.0000124490.27666.B2; Mann DL, 2003, ANNU REV PHYSIOL, V65, P81, DOI 10.1146/annurev.physiol.65.092101.142249; Mukhopadhyay P, 2007, J AM COLL CARDIOL, V50, P528, DOI 10.1016/j.jacc.2007.03.057; Pacher P, 2008, BRIT J PHARMACOL, V153, P252, DOI 10.1038/sj.bjp.0707582; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Pertwee RG, 2002, PROSTAG LEUKOTR ESS, V66, P101, DOI 10.1054/plef.2001.0341; Rajesh M, 2007, AM J PHYSIOL-HEART C, V293, pH2210, DOI 10.1152/ajpheart.00688.2007; Randall MD, 2004, BRIT J PHARMACOL, V142, P20, DOI 10.1038/sj.bjp.0705725; Sambrano GR, 2002, NATURE, V420, P712, DOI 10.1038/nature01306; Sarkar S, 2004, AM J PHYSIOL-HEART C, V287, pH107, DOI 10.1152/ajpheart.00763.2003; Shivakumar K, 2008, AM J PHYSIOL-HEART C, V294, pH2653, DOI 10.1152/ajpheart.91443.2007; Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389; Teixeira-Clerc F, 2006, NAT MED, V12, P671, DOI 10.1038/nm1421; Wagner JA, 2001, J AM COLL CARDIOL, V38, P2048, DOI 10.1016/S0735-1097(01)01671-0; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yellon DM, 2007, NEW ENGL J MED, V357, P1121, DOI 10.1056/NEJMra071667	50	93	113	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2120	2130		10.1096/fj.09-129478	http://dx.doi.org/10.1096/fj.09-129478			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19246487				2022-12-28	WOS:000268836500012
J	Kleinau, G; Haas, AK; Neumann, S; Worth, CL; Hoyer, I; Furkert, J; Rutz, C; Gershengorn, MC; Schulein, R; Krause, G				Kleinau, Gunnar; Haas, Ann-Karin; Neumann, Susanne; Worth, Catherine L.; Hoyer, Inna; Furkert, Jens; Rutz, Claudia; Gershengorn, Marvin C.; Schuelein, Ralf; Krause, Gerd			Signaling-sensitive amino acids surround the allosteric ligand binding site of the thyrotropin receptor	FASEB JOURNAL			English	Article						allosteric small molecules; glycoprotein hormone receptors; constitutively activating mutations; activation mechanisms	PROTEIN-COUPLED RECEPTORS; STIMULATING-HORMONE-RECEPTOR; TSH RECEPTOR; CONSTITUTIVE ACTIVITY; TRANSMEMBRANE DOMAIN; CRYSTAL-STRUCTURES; MUTATIONS; GPCR; PATHOPHYSIOLOGY; ACTIVATION	The thyrotropin receptor [thyroid-stimulating hormone receptor (TSHR)], a G-protein-coupled receptor (GPCR), is endogenously activated by thyrotropin, which binds to the extracellular region of the receptor. We previously identified a low-molecular-weight (LMW) agonist of the TSHR and predicted its allosteric binding pocket within the receptor's transmembrane domain. Because binding of the LMW agonist probably disrupts interactions or leads to formation of new interactions among amino acid residues surrounding the pocket, we tested whether mutation of residues at these positions would lead to constitutive signaling activity. Guided by molecular modeling, we performed site-directed mutagenesis of 24 amino acids in this spatial region, followed by functional characterization of the mutant receptors in terms of expression and signaling, measured as cAMP accumulation. We found that mutations V421I, Y466A, T501A, L587V, M637C, M637W, S641A, Y643F, L645V, and Y667A located in several helices exhibit constitutive activity. Of note is mutation M637W at position 6.48 in transmembrane helix 6, which has a significant effect on the interaction of the receptor with the LMW agonist. In summary, we found that a high proportion of residues in several helices surrounding the allosteric binding site of LMW ligands in the TSHR when mutated lead to constitutively active receptors. Our findings of signaling-sensitive residues in this region of the transmembrane bundle may be of general importance as this domain appears to be evolutionarily retained among GPCRs.-Kleinau, G., Haas, A.-K., Neumann, S., Worth, C. L., Hoyer, I., Furkert, J., Rutz, Gershengorn, M. C., Schulein, R., Krause, G. Signaling-sensitive amino acids surround the allosteric ligand binding site of the thyrotropin receptor. FASEB J. 24, 2347-2354 (2010). www.fasebj.org	[Kleinau, Gunnar; Haas, Ann-Karin; Worth, Catherine L.; Hoyer, Inna; Furkert, Jens; Rutz, Claudia; Schuelein, Ralf; Krause, Gerd] Leibniz Inst Mol Pharmacol, D-13125 Berlin, Germany; [Neumann, Susanne; Gershengorn, Marvin C.] NIDDK, NIH, Clin Endocrinol Branch, Bethesda, MD USA	Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Krause, G (corresponding author), Leibniz Inst Mol Pharmacol, Robert Rossle Str 10, D-13125 Berlin, Germany.	gkrause@fmp-berlin.de	Kleinau, Gunnar/GPX-6330-2022	Worth, Catherine/0000-0002-1796-9606	Deutsche Forschungsgemeinschaft [KR1273/4-1]; National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK011006] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Elena Eliseeva for her excellent technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (KR1273/4-1) and by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.	Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Deflorian F, 2008, PROTEINS, V71, P783, DOI 10.1002/prot.21763; Gozu HI, 2006, EUR J ENDOCRINOL, V155, P535, DOI 10.1530/eje.1.02253; Hanson MA, 2009, STRUCTURE, V17, P8, DOI 10.1016/j.str.2008.12.003; Heitman LH, 2008, MED RES REV, V28, P975, DOI 10.1002/med.20129; Holst B, 2004, J BIOL CHEM, V279, P53806, DOI 10.1074/jbc.M407676200; Jaschke H, 2006, J BIOL CHEM, V281, P9841, DOI 10.1074/jbc.C600014200; Kleinau G, 2008, CELL MOL LIFE SCI, V65, P3664, DOI 10.1007/s00018-008-8450-2; Kleinau G, 2008, FASEB J, V22, P2798, DOI 10.1096/fj.07-104711; Kleinau G, 2007, MOL ENDOCRINOL, V21, P574, DOI 10.1210/me.2006-0309; Kleinau G, 2007, J BIOL CHEM, V282, P518, DOI 10.1074/jbc.M606176200; Kleinau G, 2009, ENDOCR REV, V30, P133, DOI 10.1210/er.2008-0044; Kobilka B, 2008, TRENDS PHARMACOL SCI, V29, P79, DOI 10.1016/j.tips.2007.11.009; Kobilka BK, 2007, TRENDS PHARMACOL SCI, V28, P397, DOI 10.1016/j.tips.2007.06.003; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; Kosugi S, 1996, ENDOCR J, V43, P595, DOI 10.1507/endocrj.43.595; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lodowski DT, 2009, PHOTOCHEM PHOTOBIOL, V85, P425, DOI 10.1111/j.1751-1097.2008.00516.x; Moore S, 2006, J MED CHEM, V49, P3888, DOI 10.1021/jm060247s; Neumann S, 2009, P NATL ACAD SCI USA, V106, P12471, DOI 10.1073/pnas.0904506106; Neumann S, 2008, ENDOCRINOLOGY, V149, P5945, DOI 10.1210/en.2008-0836; Park JH, 2008, NATURE, V454, P183, DOI 10.1038/nature07063; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Rodien P, 2003, ANN ENDOCRINOL-PARIS, V64, P12; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Schoneberg T, 2004, PHARMACOL THERAPEUT, V104, P173, DOI 10.1016/j.pharmthera.2004.08.008; Schwartz TW, 2006, ANNU REV PHARMACOL, V46, P481, DOI 10.1146/annurev.pharmtox.46.120604.141218; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; SMITH BJ, 1993, APPL BIOCHEM BIOTECH, V41, P189, DOI 10.1007/BF02916422; Sum CS, 2009, J BIOL CHEM, V284, P3529, DOI 10.1074/jbc.M806987200; Surgand JS, 2006, PROTEINS, V62, P509, DOI 10.1002/prot.20768; Szkudlinski MW, 2002, PHYSIOL REV, V82, P473, DOI 10.1152/physrev.00031.2001; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006	36	34	36	3	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2347	2354		10.1096/fj.09-149146	http://dx.doi.org/10.1096/fj.09-149146			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20179143	Green Published			2022-12-28	WOS:000279343600021
J	Lu, ZJ; Kipnis, J				Lu, Zhenjie; Kipnis, Jonathan			Thrombospondin 1-a key astrocyte-derived neurogenic factor	FASEB JOURNAL			English	Article						neural progenitor cells; adult neurogenesis; oligodendrogenesis; extracellular matrix proteins	OLIGODENDROCYTE PRECURSOR CELLS; GLIA-LIKE CELLS; NEURONAL MIGRATION; ADULT NEUROGENESIS; NEURITE OUTGROWTH; DENTATE GYRUS; SPINAL-CORD; STEM-CELLS; NOTCH; DIFFERENTIATION	Thrombospondin 1 (TSP1), an oligomeric matrix protein, is known for its antiangiogenic activity. Recently, TSP1 has been shown to regulate synaptogenesis in the developing brain. In this study, we examine another role of TSP1 in the CNS, namely, in proliferation and differentiation of neural progenitor cells (NPCs). We found that adult mice deficient in TSP1 exhibit reduced proliferation of NPCs in vivo [13,330 +/- 826 vs. 4914 +/- 455 (mean +/- SE wt vs. TSP1(-/-)); P<0.001, Student's t test] and impaired neuronal differentiation (1382 +/- 83 vs. 879 +/- 79; P<0.001). In vitro, NPC obtained from adult TSP1(-/-) mice display decreased proliferation in BrdU assay (48 +/- 8 vs. 24 +/- 3.5%; P<0.01) and decreased neuronal fate commitment (8 +/- 0.85 vs. 4.6 +/- 0.5%; P<0.05) in contrast to wild-type NPCs. Both proliferation and neuronal differentiation deficits are remediable in vitro by exogenous TSP1. Notably, conditioned medium from TSP1(-/-) astrocytes, unlike that from control astrocytes, fails to promote neurogenesis in wild-type NPCs, suggesting that TSP1 is one of the key molecules responsible for astrocyte-induced neurogenesis. Our data demonstrate that TSP1 is a critical participant in maintenance of the adult NPC pool and in neuronal differentiation.-Lu, Z., Kipnis, J. Thrombospondin 1-a key astrocyte-derived neurogenic factor. FASEB J. 24, 1925-1934 (2010). www.fasebj.org	[Lu, Zhenjie; Kipnis, Jonathan] Univ Virginia, Dept Neurosci, Charlottesville, VA 22908 USA	University of Virginia	Kipnis, J (corresponding author), Univ Virginia, Dept Neurosci, Charlottesville, VA 22908 USA.	kipnis@virginia.edu	Kipnis, Jonathan/AGG-9735-2022	Kipnis, Jonathan/0000-0002-3714-517X	University of Washington, Seattle, WA, USA; National Institute of Child Health and Human Development [R21HD056293-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD056293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG034113] Funding Source: NIH RePORTER	University of Washington, Seattle, WA, USA(University of Washington); National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Noel Derecki for assistance with FACS acquisition and data processing. Special thanks are extended to Dr. Bettina Winckler (Department of Neuroscience, University of Virginia) and Dr. Benjamin Purow (Department of Neurology, University of Virginia) for their critical reading and discussion of the manuscript. The authors thank Shirley Smith for editing the manuscript. Dr. Paul Bornstein (University of Washington, Seattle, WA, USA) has kindly Foundation grant and, in part, by National Institute of Child Health and Human Development award R21HD056293-01 (to J.K.).	Adams J, 2004, INT J BIOCHEM CELL B, V36, P960, DOI 10.1016/j.biocel.2004.02.009; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Asakura K, 1996, J NEUROIMMUNOL, V65, P11, DOI 10.1016/0165-5728(95)00175-1; Baracskay KL, 2007, GLIA, V55, P1001, DOI 10.1002/glia.20519; Barkho BZ, 2006, STEM CELLS DEV, V15, P407, DOI 10.1089/scd.2006.15.407; Blake SM, 2008, EMBO J, V27, P3069, DOI 10.1038/emboj.2008.223; Bornstein P, 2004, INT J BIOCHEM CELL B, V36, P1115, DOI 10.1016/j.biocel.2004.01.012; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Breunig JJ, 2007, P NATL ACAD SCI USA, V104, P20558, DOI 10.1073/pnas.0710156104; Caceres M, 2007, CEREB CORTEX, V17, P2312, DOI 10.1093/cercor/bhl140; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Cordle J, 2008, NAT STRUCT MOL BIOL, V15, P849, DOI 10.1038/nsmb.1457; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Faivre-Sarrailh C, 2000, J CELL BIOL, V149, P491, DOI 10.1083/jcb.149.2.491; Genoud S, 2002, J CELL BIOL, V158, P709, DOI 10.1083/jcb.200202002; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Hashimoto-Torii K, 2008, NEURON, V60, P273, DOI 10.1016/j.neuron.2008.09.026; Hu QD, 2003, CELL, V115, P163, DOI 10.1016/S0092-8674(03)00810-9; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; Kippin TE, 2005, GENE DEV, V19, P756, DOI 10.1101/gad.1272305; Kyriakides TR, 2003, BLOOD, V101, P3915, DOI 10.1182/blood.V101.10.3915; Leuner B, 2004, J NEUROSCI, V24, P7477, DOI 10.1523/JNEUROSCI.0204-04.2004; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Liour SS, 2003, GLIA, V42, P109, DOI 10.1002/glia.10202; Lu L, 2008, STEM CELLS, V26, P580, DOI 10.1634/stemcells.2007-0106; Medrano S, 2009, NEUROBIOL AGING, V30, P483, DOI 10.1016/j.neurobiolaging.2007.07.016; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Murata T, 2006, J NEUROSCI, V26, P12397, DOI 10.1523/JNEUROSCI.3981-06.2006; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; OSHEA KS, 1991, NEURON, V7, P231, DOI 10.1016/0896-6273(91)90261-W; OSTERHOUT DJ, 1992, DEV BIOL, V150, P256, DOI 10.1016/0012-1606(92)90240-H; Panchision DM, 2007, STEM CELLS, V25, P1560, DOI 10.1634/stemcells.2006-0260; Park HC, 2003, DEVELOPMENT, V130, P3747, DOI 10.1242/dev.00576; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Stidworthy MF, 2004, BRAIN, V127, P1928, DOI 10.1093/brain/awh217; Talbott JF, 2005, EXP NEUROL, V192, P11, DOI 10.1016/j.expneurol.2004.05.038; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	40	83	83	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1925	1934		10.1096/fj.09-150573	http://dx.doi.org/10.1096/fj.09-150573			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20124433	Green Published			2022-12-28	WOS:000278200000027
J	Sarig, H; Livne, L; Held-Kuznetsov, V; Zaknoon, F; Ivankin, A; Gidalevitz, D; Mor, A				Sarig, Hadar; Livne, Liran; Held-Kuznetsov, Victoria; Zaknoon, Fadia; Ivankin, Andrey; Gidalevitz, David; Mor, Amram			A miniature mimic of host defense peptides with systemic antibacterial efficacy	FASEB JOURNAL			English	Article						antimicrobial peptide; chemical mimicry; drug design; drug resistance; mechanism of action	ACYL-LYSINE OLIGOMERS; DE-NOVO DESIGN; RESISTANT STAPHYLOCOCCUS-AUREUS; X-RAY-DIFFRACTION; IN-VIVO ACTIVITY; ANTIMICROBIAL PEPTIDES; AMINO-ACIDS; BACTERIAL-MEMBRANES; LIPID MONOLAYERS; DERIVATIVES	Oligomers of acylated lysines (OAKs) are synthetic mimics of host defense peptides (HDPs) with promising antimicrobial properties. Here we challenged the OAK concept for its ability to generate both systemically efficient and economically viable lead compounds for fighting multidrug-resistant bacteria. We describe the design and characterization of a miniature OAK composed of only 3 lysyls and 2 acyls (designated C12(omega 7)K-beta(12)) that preferentially targets gram-positive species by a bacteriostatic mode of action. To gain insight into the mechanism of action, we examined the interaction of OAK with various potential targets, including phospholipid bilayers, using surface plasmon resonance, and Langmuir monolayers, using insertion assays, epifluorescence microscopy, and grazing incidence X-ray diffraction, in a complementary manner. Collectively, the data support the notion that C12(omega 7)K-beta(12) damages the plasma-membrane architecture similarly to HDPs, that is, following a near-classic 2-step interaction including high-affinity electrostatic adhesion and a subsequent shallow insertion that was limited to the phospholipid head group region. Notably, preliminary acute toxicity and efficacy studies performed with mouse models of infection have consolidated the potential of OAK for treating bacterial infections, including systemic treatments of methicillin-resistant Staphylococcus aureus. Such simple yet robust chemicals might be useful for various antibacterial applications while circumventing potential adverse effects associated with cytolytic compounds.-Sarig, H., Livne, L., Held-Kuznetsov, V., Zaknoon, F., Ivankin, A., Gidalevitz, D., Mor, A. A miniature mimic of host defense peptides with systemic antibacterial efficacy. FASEB J. 24, 1904-1913 (2010). www.fasebj.org	[Sarig, Hadar; Livne, Liran; Held-Kuznetsov, Victoria; Zaknoon, Fadia; Mor, Amram] Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-3200 Haifa, Israel; [Ivankin, Andrey; Gidalevitz, David] IIT, Ctr Mol Study Condensed Soft Matter, Chicago, IL 60616 USA; [Ivankin, Andrey; Gidalevitz, David] IIT, Div Phys, Dept Biol Chem & Phys Sci, Chicago, IL 60616 USA	Technion Israel Institute of Technology; Illinois Institute of Technology; Illinois Institute of Technology	Mor, A (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-3200 Haifa, Israel.	amor@tx.technion.ac.il	Gidalevitz, David/D-6717-2012		Israel Science Foundation [283/08]; U.S. National Institutes of Health [R01 AI073892]; Division Of Chemistry [0822838] Funding Source: National Science Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073892] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Division Of Chemistry(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was supported by Israel Science Foundation grant 283/08 (A. M.) and U.S. National Institutes of Health grant R01 AI073892 (D. G.). The authors are indebted to Binhua Lin and Mati Meron for their help with X-ray measurements at APS. The OAK sequences described here have been submitted as part of a U.S. patent application.	Avrahami D, 2001, BIOCHEMISTRY-US, V40, P12591, DOI 10.1021/bi0105330; BERGE B, 1994, PHYS REV LETT, V73, P1652, DOI 10.1103/PhysRevLett.73.1652; Brockman H, 1999, CURR OPIN STRUC BIOL, V9, P438, DOI 10.1016/S0959-440X(99)80061-X; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Cherkasov A, 2009, ACS CHEM BIOL, V4, P65, DOI 10.1021/cb800240j; Choi S, 2009, P NATL ACAD SCI USA, V106, P6968, DOI 10.1073/pnas.0811818106; Chongsiriwatana NP, 2008, P NATL ACAD SCI USA, V105, P2794, DOI 10.1073/pnas.0708254105; Dhople V, 2006, BBA-BIOMEMBRANES, V1758, P1499, DOI 10.1016/j.bbamem.2006.07.007; Epand RF, 2009, BIOPHYS J, V97, P2250, DOI 10.1016/j.bpj.2009.08.006; Epand RF, 2001, EUR J BIOCHEM, V268, P703, DOI 10.1046/j.1432-1327.2001.01922.x; Epand RM, 2008, J AM CHEM SOC, V130, P14346, DOI 10.1021/ja8062327; Epand RM, 2009, BBA-BIOMEMBRANES, V1788, P289, DOI 10.1016/j.bbamem.2008.08.023; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Gaidukov L, 2003, BIOCHEMISTRY-US, V42, P12866, DOI 10.1021/bi034514x; Gidalevitz D, 2003, P NATL ACAD SCI USA, V100, P6302, DOI 10.1073/pnas.0934731100; Gottler LM, 2008, CHEMBIOCHEM, V9, P370, DOI 10.1002/cbic.200700643; Gottler LM, 2009, BBA-BIOMEMBRANES, V1788, P1680, DOI 10.1016/j.bbamem.2008.10.009; Hale JD, 2007, EXPERT REV ANTI-INFE, V5, P951, DOI 10.1586/14787210.5.6.951; Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267; Ilker MF, 2004, J AM CHEM SOC, V126, P15870, DOI 10.1021/ja045664d; Ishitsuka Y, 2006, J AM CHEM SOC, V128, P13123, DOI 10.1021/ja061186q; Javadpour MM, 1997, BIOCHEMISTRY-US, V36, P9540, DOI 10.1021/bi961644f; Jean-Francois F, 2008, BIOCHEMISTRY-US, V47, P6394, DOI 10.1021/bi800448h; Kamysz W, 2007, ANTIMICROB AGENTS CH, V51, P354, DOI 10.1128/AAC.00344-06; Kuroda K, 2005, J AM CHEM SOC, V127, P4128, DOI 10.1021/ja044205+; Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145; Liu DH, 2001, J AM CHEM SOC, V123, P7553, DOI 10.1021/ja0107475; Lohner K, 1999, BBA-BIOMEMBRANES, V1462, P141, DOI 10.1016/S0005-2736(99)00204-7; Maget-Dana R, 1999, BBA-BIOMEMBRANES, V1462, P109, DOI 10.1016/S0005-2736(99)00203-5; Makovitzki A, 2006, P NATL ACAD SCI USA, V103, P15997, DOI 10.1073/pnas.0606129103; Mangili A, 2005, CLIN INFECT DIS, V40, P1058, DOI 10.1086/428616; MIDOUX P, 1995, BBA-BIOMEMBRANES, V1239, P249, DOI 10.1016/0005-2736(95)00163-W; Mygind PH, 2005, NATURE, V437, P975, DOI 10.1038/nature04051; Navon-Venezia S, 2002, ANTIMICROB AGENTS CH, V46, P689, DOI 10.1128/AAC.46.3.689-694.2002; Neville F, 2006, BIOPHYS J, V90, P1275, DOI 10.1529/biophysj.105.067595; Neville F, 2008, SOFT MATTER, V4, P1665, DOI 10.1039/b718295c; Patch JA, 2003, J AM CHEM SOC, V125, P12092, DOI 10.1021/ja037320d; Porter EA, 2000, NATURE, V404, P565, DOI 10.1038/35007145; Radzishevsky I, 2007, ANTIMICROB AGENTS CH, V51, P1753, DOI 10.1128/AAC.01288-06; Radzishevsky IS, 2008, CHEM BIOL, V15, P354, DOI 10.1016/j.chembiol.2008.03.006; Radzishevsky IS, 2007, NAT BIOTECHNOL, V25, P657, DOI 10.1038/nbt1309; Rotem S., 2008, BIOCHIM BIOPHYS ACTA, V1788, P1582; Rotem S, 2008, FASEB J, V22, P2652, DOI 10.1096/fj.07-105015; Rotem S, 2006, ANTIMICROB AGENTS CH, V50, P2666, DOI 10.1128/AAC.00030-06; Sarig H, 2008, ANTIMICROB AGENTS CH, V52, P4308, DOI 10.1128/AAC.00656-08; Savage PB, 2002, FEMS MICROBIOL LETT, V217, P1; Scott RW, 2008, CURR OPIN BIOTECH, V19, P620, DOI 10.1016/j.copbio.2008.10.013; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Steenbergen JN, 2005, J ANTIMICROB CHEMOTH, V55, P283, DOI 10.1093/jac/dkh546; Tew GN, 2002, P NATL ACAD SCI USA, V99, P5110, DOI 10.1073/pnas.082046199; Thennarasu S, 2005, BBA-BIOMEMBRANES, V1711, P49, DOI 10.1016/j.bbamem.2005.02.010; VAN BF, 2008, TRENDS PHARMACOL SCI, V29, P124; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zetola N, 2005, LANCET INFECT DIS, V5, P275, DOI 10.1016/S1473-3099(05)70112-2	55	37	38	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1904	1913		10.1096/fj.09-149427	http://dx.doi.org/10.1096/fj.09-149427			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20124435	Green Published			2022-12-28	WOS:000278200000025
J	Gleissman, H; Yang, R; Martinod, K; Lindskog, M; Serhan, CN; Johnsen, JI; Kogner, P				Gleissman, Helena; Yang, Rong; Martinod, Kimberly; Lindskog, Magnus; Serhan, Charles N.; Johnsen, John Inge; Kogner, Per			Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates	FASEB JOURNAL			English	Article						neuroblastoma; docosanoids; lipidomics; omega-3 fatty acids; cancer	N-3 FATTY-ACIDS; CANCER-CELL-GROWTH; IN-VIVO; COLON-CANCER; OXIDATIVE STRESS; LIPID MEDIATORS; TRANSGENIC MICE; RESOLVIN D1; APOPTOSIS; NEUROBLASTOMA	Docosahexaenoic acid (DHA) protects neural cells from stress-induced apoptosis. On the contrary, DHA exerts anticancer effects, and we have shown that DHA induces apoptosis in neuroblastoma, an embryonal tumor of the sympathetic nervous system. We now investigate the DHA metabolome in neuroblastoma using a targeted lipidomic approach in order to elucidate the mechanisms behind the DHA-induced cytotoxicity. LC-MS/MS analysis was used to identify DHA-derived lipid mediators in neuroblastoma cells. Presence of the 15-lipoxygenase enzyme was investigated using immunoblotting, and cytotoxic potency of DHA and DHA-derived compounds was compared using the MTT cell viability assay. Neuroblastoma cells metabolized DHA to 17-hydroxydocosahexaenoic acid (17-HDHA) via 17-hydroperoxydocosahexaenoic acid (17-HpDHA) through 15-lipoxygenase and autoxidation. In contrast to normal neural cells, neuroblastoma cells did not produce the anti-inflammatory and protective lipid mediators, resolvins and protectins. 17-HpDHA had significant cytotoxic potency, with an IC(50) of 3-6 mu M at 72 h, compared to 12-15 mu M for DHA. alpha-Tocopherol protected cells from 17-HpDHA-induced cytotoxicity. DHA inhibited secretion of prostaglandin-E(2) and augmented the cytotoxic potency of the cyclooxygenase-2-inhibitor celecoxib. The cytotoxic effect of DHA in neuroblastoma is mediated through production of hydroperoxy fatty acids that accumulate to toxic intracellular levels with restricted production of its products, resolvins and protectins.-Gleissman, H., Yang, R., Martinod, K., Lindskog, M., Serhan, C. N., Johnsen, J. I., Kogner, P. Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J. 24, 906-915 (2010). www.fasebj.org	[Gleissman, Helena; Lindskog, Magnus; Johnsen, John Inge; Kogner, Per] Astrid Lindgren Childrens Hosp, Childhood Canc Res Unit, Dept Woman & Child Hlth, Karolinska Inst, S-17176 Stockholm, Sweden; [Yang, Rong; Martinod, Kimberly; Serhan, Charles N.] Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; [Yang, Rong; Martinod, Kimberly; Serhan, Charles N.] Harvard Univ, Sch Med, Boston, MA USA	Karolinska Institutet; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Gleissman, H (corresponding author), Astrid Lindgren Childrens Hosp, Childhood Canc Res Unit, Dept Woman & Child Hlth, Karolinska Inst, Q6-05, S-17176 Stockholm, Sweden.	helena.gleissman@ki.se	Yang, Rong/ABA-7587-2021; Martinod, Kimberly/K-4742-2019	Martinod, Kimberly/0000-0002-1026-6107; Johnsen, John Inge/0000-0003-1277-812X; Yang, Rong/0000-0001-8837-0089; Kogner, Per/0000-0002-2202-9694	Swedish Childhood Cancer Foundation; Swedish Research Council; Swedish Cancer Society; Cystic Fibrosis Foundation; Erik and Edith Fernstrom's Foundation for Medical Research; U.S. National Institutes of Health [GM38765, DK074448, P50-DE016191]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R01GM038765, R29GM038765] Funding Source: NIH RePORTER	Swedish Childhood Cancer Foundation(European Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); Erik and Edith Fernstrom's Foundation for Medical Research; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Prof. Mats Hamberg (Karolinska Institutet, Stockholm, Sweden) for critical scientific input and help with the steric analyses and Prof. Hans-Erik Claesson (Karolinska Institutet, Stockholm, Sweden) for kindly providing the 15-LOX type 1 antibody. This project was supported by the Swedish Childhood Cancer Foundation, the Swedish Research Council, the Swedish Cancer Society, the Cystic Fibrosis Foundation, Erik and Edith Fernstrom's Foundation for Medical Research, and U.S. National Institutes of Health grants GM38765, DK074448, and P50-DE016191 (C.N.S.). The authors also thank P. Pillai, S. Oh, S. Krishnamoorthy, A. Recchiuti, and L. Elfman for excellent technical assistance.	Akbar M, 2002, J NEUROCHEM, V82, P655, DOI 10.1046/j.1471-4159.2002.01015.x; Baryawno N, 2008, NEURO-ONCOLOGY, V10, P661, DOI 10.1215/15228517-2008-035; Bazan NG, 2005, MOL NEUROBIOL, V32, P89, DOI 10.1385/MN:32:1:089; Berquin IM, 2008, CANCER LETT, V269, P363, DOI 10.1016/j.canlet.2008.03.044; Brown MD, 2006, BRIT J CANCER, V94, P842, DOI 10.1038/sj.bjc.6603030; Calder PC, 2007, PROSTAG LEUKOTR ESS, V77, P327, DOI 10.1016/j.plefa.2007.10.015; Crean C, 2009, CHEM-EUR J, V15, P10634, DOI 10.1002/chem.200900500; Dommels YEM, 2003, CARCINOGENESIS, V24, P385, DOI 10.1093/carcin/24.3.385; Girotti AW, 1998, J LIPID RES, V39, P1529; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Hanebutt FL, 2008, CLIN NUTR, V27, P685, DOI 10.1016/j.clnu.2008.05.010; Hong S, 2007, J AM SOC MASS SPECTR, V18, P128, DOI 10.1016/j.jasms.2006.09.002; Hossain Z, 2009, NUTR CANCER, V61, P123, DOI 10.1080/01635580802395725; Jahn U, 2008, ANGEW CHEM INT EDIT, V47, P5894, DOI 10.1002/anie.200705122; Jia Q, 2008, CANCER RES, V68, P3985, DOI 10.1158/0008-5472.CAN-07-6251; Johnsen JI, 2004, CANCER RES, V64, P7210, DOI 10.1158/0008-5472.CAN-04-1795; Johnsen J, 2009, APOPTOSIS, V14, P424, DOI 10.1007/s10495-009-0325-y; Jones GR, 2008, J ANAL TOXICOL, V32, P183, DOI 10.1093/jat/32.2.183; Khan NA, 2006, J LIPID RES, V47, P2306, DOI 10.1194/jlr.M600269-JLR200; Kokoglu E, 1998, Cancer Biochem Biophys, V16, P301; Koletzko B, 2007, BRIT J NUTR, V98, P873, DOI 10.1017/S0007114507764747; Krishnamoorthy Sriram, 2008, V49, P145, DOI 10.1007/978-1-4020-8831-5_6; Larsson SC, 2004, AM J CLIN NUTR, V79, P935; LEPAGE G, 1986, J LIPID RES, V27, P114; Lindskog M, 2006, INT J CANCER, V118, P2584, DOI 10.1002/ijc.21555; Liu XB, 2008, J CLIN BIOCHEM NUTR, V43, P26, DOI 10.3164/jcbn.2008040; Lu Y, 2008, MOL CANCER THER, V7, P3203, DOI 10.1158/1535-7163.MCT-08-0494; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Martin DD, 1996, LIPIDS, V31, P1283, DOI 10.1007/BF02587914; Moyad MA, 2005, UROL ONCOL-SEMIN ORI, V23, P36, DOI 10.1016/j.urolonc.2005.03.001; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Mukutmoni-Norris M, 2000, CANCER LETT, V150, P101, DOI 10.1016/S0304-3835(99)00380-8; Piomelli D, 2007, NAT REV NEUROSCI, V8, P743, DOI 10.1038/nrn2233; Ponthan F, 2007, CLIN CANCER RES, V13, P1036, DOI 10.1158/1078-0432.CCR-06-1908; Reynolds LM, 2001, NEUROSCI LETT, V309, P193, DOI 10.1016/S0304-3940(01)02071-7; Rose DP, 1999, INT J ONCOL, V15, P1011; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI 10.1146/annurev.pathmechdis.3.121806.151409; Serhan CN, 2006, AAPS J, V8, pE284; Serhan CN, 2004, LIPIDS, V39, P1125, DOI 10.1007/s11745-004-1339-7; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serini S, 2008, APOPTOSIS, V13, P1172, DOI 10.1007/s10495-008-0246-1; Siddiqui RA, 2008, CHEM PHYS LIPIDS, V153, P47, DOI 10.1016/j.chemphyslip.2008.02.009; Sun H, 2008, CANCER RES, V68, P2912, DOI 10.1158/0008-5472.CAN-07-2305; Sun YP, 2007, J BIOL CHEM, V282, P9323, DOI 10.1074/jbc.M609212200; Sveinbjornsson B, 2008, FASEB J, V22, P3525, DOI 10.1096/fj.07-103457; Swamy MV, 2004, MOL CANCER THER, V3, P215; Wang MT, 2007, CANCER METAST REV, V26, P525, DOI 10.1007/s10555-007-9096-5; Wolk A, 2006, JAMA-J AM MED ASSOC, V296, P1371, DOI 10.1001/jama.296.11.1371; Xia SH, 2006, P NATL ACAD SCI USA, V103, P12499, DOI 10.1073/pnas.0605394103; Yin HY, 2005, J BIOL CHEM, V280, P26600, DOI 10.1074/jbc.M503088200	52	74	78	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2010	24	3					906	915		10.1096/fj.09-137919	http://dx.doi.org/10.1096/fj.09-137919			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19890019	Green Published			2022-12-28	WOS:000274974600026
J	Wang, DY; Stewart, AK; Zhuang, LH; Zhu, YX; Wang, YD; Shi, CX; Keating, A; Slutsky, A; Zhang, HB; Wen, XY				Wang, Dingyan; Stewart, A. Keith; Zhuang, Lihua; Zhu, Yuanxiao; Wang, Youdong; Shi, Changxin; Keating, Armand; Slutsky, Arthur; Zhang, Haibo; Wen, Xiao-Yan			Enhanced adaptive immunity in mice lacking the immunoinhibitory adaptor Hacs1	FASEB JOURNAL			English	Article						adaptor protein; B cells; gene targeting; dendritic cells; SAM domain; immune regulation	PROTEIN-TYROSINE-PHOSPHATASE; TUMOR-SUPPRESSOR GENE; AUTOIMMUNE-DISEASE; CELL-DEVELOPMENT; DEFICIENT MICE; ACTIVATION; EXPRESSION; RECEPTOR; LYN; RESPONSES	Hacs1, a SH3 and SAM domain-containing adaptor protein, is up-regulated by IL-4 in activated B cells and strongly expressed in dendritic cells. To elucidate the function of Hacs1 in immune regulation, we generated Hacs1(-/-) mice by deletion of the SH3 and SAM domains. Hacs1(-/-) mice were viable and fertile and had normal bone marrow B-cell development and normal splenic T-and B-cell populations. However, adult Hacs1(-/-) mice had increased peritoneal B1a cells (IgM(+)CD5(+)). On immunization with T-cell-independent antigen TNP-Ficoll, Hacs1(-/-) mice had increased production of anti-TNP IgM and IgG3. Purified splenic B cells from Hacs1(-/-) mice showed increased cell proliferation on BCR (B-cell receptor) stimulation. We further demonstrate that the Hacs1(-/-) B cells had increased global tyrosine phosphorylation, including tyrosine kinases Lyn and Akt. Both T-helper type 1 (Th1) and T-helper type 2 (Th2) humoral responses were enhanced in Hacs1(-/-) mice. In vitro bone marrow-derived Hacs1(-/-) dendritic cells showed increased IL-12 production on stimulation with ovalbumin (OVA). This study suggests that Hacs1 is an immunoinhibitory adaptor that might be a useful target for immune suppression therapy.-Wang, D., Stewart, A. K., Zhuang, L., Zhu, Y., Wang, Y., Shi, C., Keating, A., Slutsky, A., Zhang, H., Wen, X.-Y. Enhanced adaptive immunity in mice lacking the immunoinhibitory adaptor Hacs1. FASEB J. 24, 947-956 (2010). www.fasebj.org	[Wang, Dingyan; Wang, Youdong; Slutsky, Arthur; Zhang, Haibo; Wen, Xiao-Yan] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Wang, Dingyan; Wang, Youdong; Slutsky, Arthur; Zhang, Haibo; Wen, Xiao-Yan] Univ Toronto, Dept Med, Toronto, ON, Canada; [Wang, Dingyan; Zhuang, Lihua; Keating, Armand; Wen, Xiao-Yan] Princess Margaret Hosp, Dept Med Oncol & Hematol, Univ Hlth Network, Toronto, ON M4X 1K9, Canada; [Stewart, A. Keith; Zhu, Yuanxiao; Shi, Changxin] Mayo Clin, Div Hematol Oncol, Scottsdale, AZ USA; [Wen, Xiao-Yan] Tianjin Med Univ, Tianjin Inst Urol, Sch Med 2, Tianjin, Peoples R China	University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Mayo Clinic; Mayo Clinic Phoenix; Tianjin Medical University	Wen, XY (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, 30 Bond St,Queen Wing,Rm 8-019, Toronto, ON M5B 1W8, Canada.	x.wen@utoronto.ca	Slutsky, Arthur/M-3325-2019	Wen, Xiao-Yan/0000-0001-6728-0025				Beer S, 2005, MOL CELL BIOL, V25, P9646, DOI 10.1128/MCB.25.21.9646-9660.2005; Beer S, 2001, BBA-GENE STRUCT EXPR, V1520, P89, DOI 10.1016/S0167-4781(01)00242-1; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Bondada S, 2000, CURR TOP MICROBIOL, V252, P141; Claudio J, 2001, ONCOGENE, V20, P5373, DOI 10.1038/sj.onc.1204698; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; Fagarasan S, 2000, SCIENCE, V290, P89, DOI 10.1126/science.290.5489.89; Flynn DC, 2001, ONCOGENE, V20, P6270, DOI 10.1038/sj.onc.1204769; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Nakamura A, 2004, NAT IMMUNOL, V5, P623, DOI 10.1038/ni1074; O'Keefe TL, 1999, J EXP MED, V189, P1307, DOI 10.1084/jem.189.8.1307; Obermaier Bianca, 2003, Biol Proced Online, V5, P197, DOI 10.1251/bpo62; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Pan C, 1999, IMMUNITY, V11, P495, DOI 10.1016/S1074-7613(00)80124-7; Pao LI, 2007, IMMUNITY, V27, P35, DOI 10.1016/j.immuni.2007.04.016; Pawson T, 2007, CURR OPIN CELL BIOL, V19, P112, DOI 10.1016/j.ceb.2007.02.013; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Rimkus C, 2006, BRIT J CANCER, V95, P1419, DOI 10.1038/sj.bjc.6603452; Sen G, 1999, EUR J IMMUNOL, V29, P3319; Takai T, 2001, IMMUNOL REV, V181, P215, DOI 10.1034/j.1600-065X.2001.1810118.x; Uchida T, 2001, BIOCHEM BIOPH RES CO, V288, P137, DOI 10.1006/bbrc.2001.5722; Ujike A, 2002, NAT IMMUNOL, V3, P542, DOI 10.1038/ni801; Underhill DM, 2007, TRENDS IMMUNOL, V28, P66, DOI 10.1016/j.it.2006.12.004; Wang DY, 2008, TRANSGENIC RES, V17, P193, DOI 10.1007/s11248-007-9140-9; Xu YK, 2005, IMMUNITY, V22, P9, DOI 10.1016/j.immuni.2004.12.004; Zeller C, 2003, ONCOGENE, V22, P2972, DOI 10.1038/sj.onc.1206474; Zhu YX, 2004, J EXP MED, V200, P737, DOI 10.1084/jem.20031816	29	21	22	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					947	956		10.1096/fj.09-140806	http://dx.doi.org/10.1096/fj.09-140806			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19923443				2022-12-28	WOS:000274974600030
J	Orriss, GL; Patel, TR; Sorensen, J; Stetefeld, J				Orriss, George L.; Patel, Trushar R.; Sorensen, John; Stetefeld, Joerg			Absence of a catalytic water confers resistance to the neurotoxin gabaculine	FASEB JOURNAL			English	Article						drug resistance; microevolution; integrated approach; protein X-ray crystallography; chlorophyll biosynthesis	GLUTAMATE 1-SEMIALDEHYDE AMINOTRANSFERASE; ASPARTATE-AMINOTRANSFERASE; SEMIALDEHYDE AMINOTRANSFERASE; CRYSTAL-STRUCTURE; ENZYMES; PROTEINS; SITE; 2,1-AMINOMUTASE; SYNECHOCOCCUS; PURIFICATION	Gabaculine is a potent inhibitor of the vitamin B6-dependent key enzyme in chlorophyll biosynthesis, glutamate-1-semialdehyde aminomutase (GSAM). The inhibition effect is caused by an enzymatic deprotonation of the neurotoxin and requires the aldimine (PLP) form of the cofactor at the active site. In this study, we show that a single-point mutation confers resistance to gabaculine. A combined functional and structural analysis of wild-type GSAM in complex with gabaculine and the GSAM(M248I) form allowed us to decipher in atomic detail the molecular basis of this unique resistance. Interestingly, the gabaculine tolerance is caused by the absence of an essential water molecule that has a dual functional role. It serves as a nucleophilic shuttle for the hydroxyl anion along the reaction pathway and holds active-site Lys273 in a catalytically competent conformation. The single-point mutant is not able to fix this catalytic water between the beta-branched side chain of Ile248 and Lys273. As a consequence, the mutant enzyme is trapped in a gabaculine-insensitive but still enzymatically active amine (PMP) form.-Orriss, G. L., Patel, T. R., Sorensen, J., Stetefeld, J. Absence of a catalytic water confers resistance to the neurotoxin gabaculine. FASEB J. 24, 404-414 (2010). www.fasebj.org	[Orriss, George L.; Patel, Trushar R.; Sorensen, John; Stetefeld, Joerg] Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada	University of Manitoba	Stetefeld, J (corresponding author), Univ Manitoba, Dept Chem, 144 Dysart Rd, Winnipeg, MB R3T 2N2, Canada.	stetefel@cc.manitoba.ca	Patel, Trushar R./AAB-6250-2020; Patel, Trushar R/F-2776-2011; Stetefeld, Joerg/H-7630-2017	Patel, Trushar R./0000-0003-0627-2923; Patel, Trushar R/0000-0003-0627-2923; Stetefeld, Joerg/0000-0003-1478-3248	Natural Science and Engineering Council of Canada	Natural Science and Engineering Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC))	We thank Dr. Suat Oezbek for helpful discussions and critical reading of the manuscript and Clemens Schulze-Briese (Swiss Light Source, Villigen, Switzerland) for assistance during data collection. This work was supported by the Natural Science and Engineering Council of Canada. J.S. is a Canada Research Chair in Structural Biology.	ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; Amadasi A, 2007, CURR MED CHEM, V14, P1291, DOI 10.2174/092986707780597899; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ball P, 2008, CHEM REV, V108, P74, DOI 10.1021/cr068037a; BROOKS B, 1983, P NATL ACAD SCI-BIOL, V80, P6571, DOI 10.1073/pnas.80.21.6571; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Budisa N, 1998, EUR J BIOCHEM, V253, P1, DOI 10.1046/j.1432-1327.1998.2530001.x; Budisa N, 1998, P NATL ACAD SCI USA, V95, P455, DOI 10.1073/pnas.95.2.455; Contestabile R, 2000, J BIOL CHEM, V275, P3879, DOI 10.1074/jbc.275.6.3879; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; Eads JC, 1999, BIOCHEMISTRY-US, V38, P9840, DOI 10.1021/bi990018q; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GOLDBERG JM, 1991, BIOCHEMISTRY-US, V30, P305, DOI 10.1021/bi00215a041; GRIMM B, 1989, CARLSBERG RES COMMUN, V54, P67, DOI 10.1007/BF02907586; GRIMM B, 1991, J BIOL CHEM, V266, P12495; Hennig M, 1997, P NATL ACAD SCI USA, V94, P4866, DOI 10.1073/pnas.94.10.4866; HOFRICHTER J, 1976, ANNU REV BIOPHYS BIO, V5, P511, DOI 10.1146/annurev.bb.05.060176.002455; INOUE K, 1991, J BIOCHEM, V109, P570, DOI 10.1093/oxfordjournals.jbchem.a123421; JORDAN PM, 1973, J BIOL CHEM, V248, P1019; KANNANGARA CG, 1988, TRENDS BIOCHEM SCI, V13, P139; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; Krauss M, 2001, J PHYS CHEM B, V105, P8040, DOI 10.1021/jp012099h; Lazaridis T, 1999, PROTEINS, V35, P133, DOI 10.1002/(SICI)1097-0134(19990501)35:2<133::AID-PROT1>3.0.CO;2-N; Leslie AGW, 1994, MOSFLM USERS GUIDE; Mascarenhas JB, 2003, EMBO J, V22, P529, DOI 10.1093/emboj/cdg041; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; MURAKAMI K, 1993, APPL ENVIRON MICROB, V59, P347, DOI 10.1128/AEM.59.1.347-350.1993; Ozbek S, 2005, ACTA CRYSTALLOGR D, V61, P477, DOI 10.1107/S0907444905001204; PAULING L, 1948, NATURE, V161, P707, DOI 10.1038/161707a0; Piquemal JP, 2003, J COMPUT CHEM, V24, P1963, DOI 10.1002/jcc.10354; PUGH CE, 1991, ANAL BIOCHEM, V198, P43, DOI 10.1016/0003-2697(91)90503-L; RANDO RR, 1977, J AM CHEM SOC, V99, P5141, DOI 10.1021/ja00457a039; RANDO RR, 1977, BIOCHEMISTRY-US, V16, P4604, DOI 10.1021/bi00640a012; Schulze JO, 2006, J MOL BIOL, V358, P1212, DOI 10.1016/j.jmb.2006.02.064; SMITH MA, 1992, BIOCHEMISTRY-US, V31, P4122, DOI 10.1021/bi00131a031; SMITH MA, 1992, BIOCHEMISTRY-US, V31, P11249, DOI 10.1021/bi00160a041; SOPER TS, 1982, J BIOL CHEM, V257, P3930; Stetefeld J, 2006, P NATL ACAD SCI USA, V103, P13688, DOI 10.1073/pnas.0600306103; TYACKE RJ, 1993, BIOCHEM J, V293, P697, DOI 10.1042/bj2930697	39	10	10	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					404	414		10.1096/fj.09-138297	http://dx.doi.org/10.1096/fj.09-138297			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19786580				2022-12-28	WOS:000274045000009
J	Schneider, DJ; Lindsay, JC; Zhou, Y; Molina, JG; Blackburn, MR				Schneider, Daniel J.; Lindsay, Janci C.; Zhou, Yang; Molina, Jose G.; Blackburn, Michael R.			Adenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease	FASEB JOURNAL			English	Article						neutrophil; macrophage; emphysema; pulmonary fibrosis	BRONCHOALVEOLAR LAVAGE FLUID; SMOKE-INDUCED EMPHYSEMA; CELL-MIGRATION; AIRWAY DISEASE; MICE LACKING; INFLAMMATION; RECEPTOR; EXPRESSION; CD44; LUNG	Chronic obstructive pulmonary disease (COPD) is a major health concern. Adenosine, a signaling molecule generated in response to cell stress, contributes to the pathogenesis of COPD. An established model of adenosine-mediated lung injury is the adenosine deaminase-deficient (Ada(-/-)) mouse. Osteopontin (OPN) is a chemokine that is produced following injury and is implicated in a variety of human pathologies, but its expression and role in the pathogenesis of COPD have not been examined. To investigate the role of OPN in a model of COPD, Ada(-/-) double-knockout mice were generated, and inflammation and air-space enlargement endpoints were examined. Results demonstrate that Ada(-/-) mice exhibit OPN-dependent neutrophilia, alveolar air-space enlargement, and increases in mediators of air-space enlargement. Furthermore, we demonstrate that patients with COPD have increased OPN expression within distal airways in association with clinical airway obstruction. These results suggest that OPN represents a novel biomarker and therapeutic target for patients with COPD.-Schneider, D. J., Lindsay, J. C., Zhou, Y., Molina, J. G., Blackburn, M. R. Adenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease. FASEB J. 24, 70-80 ( 2010). www.fasebj.org	[Schneider, Daniel J.; Lindsay, Janci C.; Zhou, Yang; Molina, Jose G.; Blackburn, Michael R.] Univ Texas Houston Med Sch, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Blackburn, MR (corresponding author), Univ Texas Houston Med Sch, Dept Biochem & Mol Biol, 6431 Fannin Blvd, Houston, TX 77030 USA.	michael.r.blackburn@uth.tmc.edu	ZHou, Yang/D-3320-2012	Blackburn, Michael/0000-0002-1394-9966	U. S. National Institutes of Health [AI-43572, HL-70952, HL-095403]; National Center for Research Resources [TL1RR024147]; NATIONAL CENTER FOR RESEARCH RESOURCES [TL1RR024147] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL095403, R01HL070952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043572] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Amir Mohsenin, Richard Johnston, and Sandeep Agarwal for comments on the manuscript. This work was supported by U. S. National Institutes of Health grants AI-43572, HL-70952, and HL-095403 awarded to M. R. B. D. J. S. was funded by award TL1RR024147 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. The authors declare no conflicting financial interests.	Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Banerjee SK, 2002, AM J PHYSIOL-LUNG C, V282, pL169, DOI 10.1152/ajplung.00243.2001; Berman JS, 2004, AM J PHYSIOL-LUNG C, V286, pL1311, DOI 10.1152/ajplung.00394.2003; Betsuyaku T, 1999, AM J RESP CRIT CARE, V159, P1985, DOI 10.1164/ajrccm.159.6.9809043; Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; Blackburn MR, 2003, TRENDS PHARMACOL SCI, V24, P66, DOI 10.1016/S0165-6147(02)00045-7; Chakraborty G, 2008, J CELL MOL MED, V12, P2305, DOI 10.1111/j.1582-4934.2008.00263.x; Chunn JL, 2005, J IMMUNOL, V175, P1937, DOI 10.4049/jimmunol.175.3.1937; Churg A, 2007, THORAX, V62, P706, DOI 10.1136/thx.2006.068353; Demedts IK, 2006, THORAX, V61, P196, DOI 10.1136/thx.2005.042432; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Desai B, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-18; DRIVER AG, 1993, AM REV RESPIR DIS, V148, P91, DOI 10.1164/ajrccm/148.1.91; Eckle T, 2007, CIRCULATION, V115, P1581, DOI 10.1161/CIRCULATIONAHA.106.669697; Fitzgerald MF, 2007, DRUG DISCOV TODAY, V12, P479, DOI 10.1016/j.drudis.2007.04.005; Fozard JR, 1999, PULM PHARMACOL THER, V12, P111, DOI 10.1006/pupt.1999.0191; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Frey AB, 2007, HISTOPATHOLOGY, V50, P720, DOI 10.1111/j.1365-2559.2007.02675.x; Hasko G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Horowitz JC, 2008, AM J RESP CELL MOL, V38, P78, DOI 10.1165/rcmb.2007-0174OC; HUNNINGHAKE GW, 1983, AM REV RESPIR DIS, V128, P833; Huszar E, 2002, EUR RESPIR J, V20, P1393, DOI 10.1183/09031936.02.00005002; Jeffery PK, 1999, CLIN EXP ALLERGY, V29, P14, DOI 10.1046/j.1365-2222.1999.00004.x-i2; Kalla RV, 2009, PURINERG SIGNAL, V5, P21, DOI 10.1007/s11302-008-9119-x; Katagiri YU, 1999, CANCER RES, V59, P219; Keane MP, 2002, J IMMUNOL, V169, P6515, DOI 10.4049/jimmunol.169.11.6515; Koh A, 2007, IMMUNOLOGY, V122, P466, DOI 10.1111/j.1365-2567.2007.02682.x; Kohan M, 2007, CLIN EXP ALLERGY, V37, P1444, DOI 10.1111/j.1365-2222.2007.02801.x; Kolachala VL, 2008, GASTROENTEROLOGY, V135, P861, DOI 10.1053/j.gastro.2008.05.049; Kung Hsiang-Ching, 2008, Natl Vital Stat Rep, V56, P1; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; Lenga Y, 2008, CIRC RES, V102, P319, DOI 10.1161/CIRCRESAHA.107.160408; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Liaw L, 1998, J CLIN INVEST, V101, P1468; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma B, 2006, J CLIN INVEST, V116, P1274, DOI 10.1172/JCI26372; Marcondes MCG, 2008, CELL IMMUNOL, V254, P56, DOI 10.1016/j.cellimm.2008.06.012; Nomiyama T, 2007, J CLIN INVEST, V117, P2877, DOI 10.1172/JCI31986; O'Regan AW, 1999, J IMMUNOL, V162, P1024; Ophascharoensuk V, 1999, KIDNEY INT, V56, P571, DOI 10.1046/j.1523-1755.1999.00580.x; Pardo A, 2005, PLOS MED, V2, P891, DOI 10.1371/journal.pmed.0020251; Pauwels RA, 2004, LANCET, V364, P613, DOI 10.1016/S0140-6736(04)16855-4; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Rangaswami H, 2007, ONCOL REP, V18, P909; Senger DR, 1996, BBA-MOL CELL RES, V1314, P13, DOI 10.1016/S0167-4889(96)00067-5; Simoes DCM, 2009, AM J RESP CRIT CARE, V179, P894, DOI 10.1164/rccm.200807-1081OC; Sun CX, 2006, J CLIN INVEST, V116, P2173, DOI 10.1172/JCI27303; Sun CX, 2005, J CLIN INVEST, V115, P35, DOI 10.1172/JCI200522656; Svetlecic J, 2005, EXP MOL PATHOL, V79, P198, DOI 10.1016/j.yexmp.2005.08.008; Takahashi F, 2004, LUNG, V182, P173; Takahashi F, 2001, AM J RESP CELL MOL, V24, P264, DOI 10.1165/ajrcmb.24.3.4293; Trueblood NA, 2001, CIRC RES, V88, P1080, DOI 10.1161/hh1001.090842; Weber Georg F., 1996, Cytokine and Growth Factor Reviews, V7, P241, DOI 10.1016/S1359-6101(96)00030-5; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Woodruff PG, 2005, AM J RESP CRIT CARE, V172, P1383, DOI 10.1164/rccm.200505-686OC; Xanthou G, 2007, NAT MED, V13, P570, DOI 10.1038/nm1580; Young HWJ, 2004, J IMMUNOL, V173, P1380, DOI 10.4049/jimmunol.173.2.1380; Zohar R, 2000, J CELL PHYSIOL, V184, P118, DOI 10.1002/(SICI)1097-4652(200007)184:1<118::AID-JCP13>3.3.CO;2-P	60	37	40	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					70	80		10.1096/fj.09-140772	http://dx.doi.org/10.1096/fj.09-140772			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19720619	Green Published			2022-12-28	WOS:000273233600010
J	Ayroldi, E; Riccardi, C				Ayroldi, Emira; Riccardi, Carlo			Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action	FASEB JOURNAL			English	Review						immunomodulation; proliferation; apoptosis; protein-protein interaction	INDUCED THYMOCYTE APOPTOSIS; PROTECTS T-LYMPHOCYTES; MOLECULAR-MECHANISMS; TRANSCRIPTION FACTORS; DENDRITIC CELLS; TRANSGENIC MICE; KAPPA-B; ANTIINFLAMMATORY ACTIONS; ERYTHROID PROGENITORS; SIGNALING PATHWAYS	Glucocorticoids (GCs) represent the mainstay of current anti-inflammatory and immunosuppressive strategies, mediating effects that mostly result in transcriptional regulation of glucocorticoid receptor target genes. A variety of actions are tied together in the response to GC treatment. Dissecting the beneficial from the detrimental actions in GC therapy is a major challenge in basic research, raising the critical issue of whether a single target gene or gene family might eventually be linked to a specific GC function. Glucocorticoid-induced leucine zipper (GILZ) was originally discovered in studies aimed at characterizing genes targeted by dexamethasone. The first suggestion that GILZ plays an important role in GC immunomodulation came from observations of GILZ up-regulation by GCs, mainly in lymphoid organs, and inhibition of anti-CD3-induced activation and apoptosis. The identification of GILZ interaction with and inhibition of NF-kappa B provided a first molecular mechanistic basis for explaining GILZ effects on T cells. Subsequently, other GILZ targets have been identified, including AP-1, Raf-1, and Ras, all involved in GC effects. The finding that GILZ silencing abrogates the antiproliferative activity of dexamethasone and reduces GC inhibition of cytokine-induced COX-2 expression clearly gained GILZ a distinguished reputation within the critical mediators of GC effects. The multiple functions of GILZ and their potential biological relevance are here reviewed.-Ayroldi, E., Riccardi, C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J. 23, 3649-3658 (2009). www.fasebj.org	[Ayroldi, Emira; Riccardi, Carlo] Univ Perugia, Pharmacol Sect, Dept Clin & Expt Med, I-06122 Perugia, Italy	University of Perugia	Ayroldi, E (corresponding author), Univ Perugia, Pharmacol Sect, Dept Clin & Expt Med, Via Giochetto, I-06122 Perugia, Italy.	ayroldi@unipg.it; riccardi@unipg.it	Riccardi, Carlo/N-4610-2014	Riccardi, Carlo/0000-0001-9257-3997; Ayroldi, Emira/0000-0002-9073-7297	Associazione Italiana per la Ricerca sul Cancro, Milan, Italy; network Fondo per gli Investimenti della Ricerca di Base	Associazione Italiana per la Ricerca sul Cancro, Milan, Italy(Fondazione AIRC per la ricerca sul cancro); network Fondo per gli Investimenti della Ricerca di Base	This study was supported by the Associazione Italiana per la Ricerca sul Cancro, Milan, Italy, and by the network Fondo per gli Investimenti della Ricerca di Base grant, protocol RBPR05NWWC "CHEM-PROFARMA-NET" (Italy).	Abraham SM, 2006, J EXP MED, V203, P1883, DOI 10.1084/jem.20060336; Adcock IM, 2008, CHEST, V134, P394, DOI 10.1378/chest.08-0440; Almawi WY, 2002, HEMATOL ONCOL, V20, P17, DOI 10.1002/hon.684; Ash DM, 2007, MECH DEVELOP, V124, P559, DOI 10.1016/j.mod.2007.05.003; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Asselin-Labat ML, 2005, MOL ENDOCRINOL, V19, P1752, DOI 10.1210/me.2004-0206; Asselin-Labat ML, 2004, BLOOD, V104, P215, DOI 10.1182/blood-2003-12-4295; Ayroldi E, 2002, MOL CELL BIOL, V22, P7929, DOI 10.1128/MCB.22.22.7929-7941.2002; Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; Ayroldi E, 2007, J CLIN INVEST, V117, P1605, DOI 10.1172/JCI30724; Bai Xiang-jun, 2007, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V19, P7; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; BERESFORD JN, 1992, J CELL SCI, V102, P341; Berki T, 2002, INT IMMUNOL, V14, P463, DOI 10.1093/intimm/14.5.463; Berrebi D, 2003, BLOOD, V101, P729, DOI 10.1182/blood-2002-02-0538; Bianchini R, 2006, J PHARMACOL EXP THER, V319, P887, DOI 10.1124/jpet.106.108480; Blake JA, 2003, NUCLEIC ACIDS RES, V31, P193, DOI 10.1093/nar/gkg047; Bruscoli S, 2006, EUR J PHARMACOL, V529, P63, DOI 10.1016/j.ejphar.2005.10.053; Cannarile L, 2006, BLOOD, V107, P1039, DOI 10.1182/blood-2005-05-2183; Cannarile L, 2001, CELL DEATH DIFFER, V8, P201, DOI 10.1038/sj.cdd.4400798; Cannarile L, 2009, GASTROENTEROLOGY, V136, P530, DOI 10.1053/j.gastro.2008.09.024; Chen WW, 2006, MOL ENDOCRINOL, V20, P560, DOI 10.1210/me.2005-0318; Cifone MG, 1999, BLOOD, V93, P2282, DOI 10.1182/blood.V93.7.2282.407a23_2282_2296; Cinque B, 2008, INT J IMMUNOPATH PH, V21, P539, DOI 10.1177/039463200802100307; Clark AR, 2007, MOL CELL ENDOCRINOL, V275, P79, DOI 10.1016/j.mce.2007.04.013; Cohen N, 2006, BLOOD, V107, P2037, DOI 10.1182/blood-2005-07-2760; CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; Davies L, 2008, MOL ENDOCRINOL, V22, P1331, DOI 10.1210/me.2007-0360; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; Delfino DV, 2006, INT IMMUNOPHARMACOL, V6, P1126, DOI 10.1016/j.intimp.2006.02.001; Delfino DV, 2004, BLOOD, V104, P4134, DOI 10.1182/blood-2004-03-0920; Di Marco B, 2007, NUCLEIC ACIDS RES, V35, P517, DOI 10.1093/nar/gkl1080; Eddleston J, 2007, J ALLERGY CLIN IMMUN, V119, P115, DOI 10.1016/j.jaci.2006.08.027; Elenkov IJ, 2004, ANN NY ACAD SCI, V1024, P138, DOI 10.1196/annals.1321.010; Ellestad LE, 2009, J MOL ENDOCRINOL, V42, P171, DOI 10.1677/JME-08-0066; Falkenstein E, 2000, EUR J CLIN INVEST, V30, P51, DOI 10.1046/j.1365-2362.2000.0300s3051.x; Fiol DF, 2005, P NATL ACAD SCI USA, V102, P927, DOI 10.1073/pnas.0408956102; Fiol DF, 2007, FEBS J, V274, P109, DOI 10.1111/j.1742-4658.2006.05569.x; Gleissner CA, 2007, EUR J IMMUNOL, V37, P177, DOI 10.1002/eji.200636498; Glynne R, 2000, IMMUNOL REV, V176, P216; Godot V, 2006, ALLERGY, V61, P886, DOI 10.1111/j.1398-9995.2006.01065.x; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; GOULDING NJ, 1992, IMMUNOL TODAY, V13, P295, DOI 10.1016/0167-5699(92)90040-E; Gross KL, 2009, MOL CELL ENDOCRINOL, V300, P7, DOI 10.1016/j.mce.2008.10.001; Gupta V, 2007, INVEST OPHTH VIS SCI, V48, P1724, DOI 10.1167/iovs.06-0889; Hamdi H, 2007, HEPATOLOGY, V46, P1986, DOI 10.1002/hep.21880; Hamdi H, 2007, BLOOD, V110, P211, DOI 10.1182/blood-2006-10-052506; HOFFMAN GS, 1993, ANN ALLERGY, V70, P263; Hu XY, 2003, J IMMUNOL, V170, P4833, DOI 10.4049/jimmunol.170.9.4833; Iakoucheva LM, 2004, NUCLEIC ACIDS RES, V32, P1037, DOI 10.1093/nar/gkh253; Ingram WJ, 2002, ONCOGENE, V21, P8196, DOI 10.1038/sj.onc.1205975; Kaur M, 2008, MOL PHARMACOL, V73, P203, DOI 10.1124/mol.107.040121; Kofler R, 2000, HISTOCHEM CELL BIOL, V114, P1; Kolbus A, 2003, BLOOD, V102, P3136, DOI 10.1182/blood-2003-03-0923; Kumar R, 2005, J STEROID BIOCHEM, V94, P383, DOI 10.1016/j.jsbmb.2004.12.046; Lepine S, 2005, CRIT REV IMMUNOL, V25, P263, DOI 10.1615/CritRevImmunol.v25.i4.20; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; Marchetti MC, 2003, BLOOD, V101, P585, DOI 10.1182/blood-2002-06-1779; MIGLIORATI G, 1994, IMMUNOLOGY, V81, P21; Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200; Muller OG, 2003, J AM SOC NEPHROL, V14, P1107, DOI 10.1097/01.ASN.0000061777.67332.77; Norman M, 2002, CURR OPIN PHARMACOL, V2, P723, DOI 10.1016/S1471-4892(02)00232-1; Payne D N, 2001, Paediatr Respir Rev, V2, P145, DOI 10.1053/prrv.2000.0122; Perez SA, 2005, BLOOD, V106, P158, DOI 10.1182/blood-2004-08-3232; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Riccardi C, 2000, THERAPIE, V55, P165; Robert-Nicoud M, 2001, P NATL ACAD SCI USA, V98, P2712, DOI 10.1073/pnas.051603198; Rook GAW, 1999, BEST PRACT RES CL EN, V13, P567, DOI 10.1053/beem.1999.0044; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Shi XM, 2007, PPAR RES, V2007, DOI 10.1155/2007/92501; Shi XM, 2003, EMBO REP, V4, P374, DOI 10.1038/sj.embor.embor805; Simons SS, 2008, BIOESSAYS, V30, P744, DOI 10.1002/bies.20792; Soundararajan R, 2005, J BIOL CHEM, V280, P39970, DOI 10.1074/jbc.M508658200; Soundararajan R, 2007, J BIOL CHEM, V282, P36303, DOI 10.1074/jbc.M707287200; Thompson EB, 2008, ACTA BIOCH BIOPH SIN, V40, P595, DOI 10.1111/j.1745-7270.2008.00433.x; Tynan SH, 2004, J STEROID BIOCHEM, V91, P225, DOI 10.1016/j.jsbmb.2004.05.002; Van den Heuvel MM, 1999, CLIN EXP IMMUNOL, V115, P577; van der Laan S, 2008, J NEUROCHEM, V106, P2515, DOI 10.1111/j.1471-4159.2008.05575.x; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; Wang JC, 2004, P NATL ACAD SCI USA, V101, P15603, DOI 10.1073/pnas.0407008101; Wiper-Bergeron N, 2007, P NATL ACAD SCI USA, V104, P2703, DOI 10.1073/pnas.0607378104; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang NL, 2008, J CELL BIOCHEM, V103, P1760, DOI 10.1002/jcb.21562; Zhang WX, 2008, J BIOL CHEM, V283, P4723, DOI 10.1074/jbc.M704147200; Zhao BH, 2006, REPRODUCTION, V131, P561, DOI 10.1530/rep.1.00874	87	239	248	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2009	23	11					3649	3658		10.1096/fj.09-134684	http://dx.doi.org/10.1096/fj.09-134684			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19567371	Bronze			2022-12-28	WOS:000271272500003
J	Cormet-Boyaka, E; Hong, JS; Berdiev, BK; Fortenberry, JA; Rennolds, J; Clancy, JP; Benos, DJ; Boyaka, PN; Sorscher, EJ				Cormet-Boyaka, Estelle; Hong, Jeong S.; Berdiev, Bakhram K.; Fortenberry, James A.; Rennolds, Jessica; Clancy, J. P.; Benos, Dale J.; Boyaka, Prosper N.; Sorscher, Eric J.			A truncated CFTR protein rescues endogenous Delta F508-CFTR and corrects chloride transport in mice	FASEB JOURNAL			English	Article						cystic fibrosis; in vivo rescue; processing; transcomplementation	TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS MUTATION; ENDOPLASMIC-RETICULUM; EPITHELIAL-CELLS; AIRWAY EPITHELIA; PLASMA-MEMBRANE; LOW-TEMPERATURE; GENE-THERAPY; CHANNELS; PROTEASOME	Cystic fibrosis (CF) is most frequently associated with deletion of phenylalanine at position 508 (Delta F508) in the CF transmembrane conductance regulator (CFTR) protein. The Delta F508-CFTR mutant protein exhibits a folding defect that affects its processing and impairs chloride-channel function. This study aimed to determine whether CFTR fragments approximately half the size of wild-type CFTR and complementary to the portion of CFTR bearing the mutation can specifically rescue the processing of endogenous Delta F508-CFTR in vivo. cDNA encoding CFTR fragments were delivered to human airway epithelial cells and mice harboring endogenous Delta F508-CFTR. Delivery of small CFTR fragments, which do not act as chloride channels by themselves, rescue Delta F508-CFTR. Therefore, we can speculate that the presence of the CFTR fragment, which does not harbor a mutation, might facilitate intermolecular interactions. The rescue of CFTR was evident by the restoration of chloride transport in human CFBE41o- bronchial epithelial cells expressing Delta F508-CFTR in vitro. More important, nasal administration of an adenovirus expressing a complementary CFTR fragment restored some degree of CFTR activity in the nasal airways of Delta F508 homozygous mice in vivo. These findings identify complementary protein fragments as a viable in vivo approach for correcting disease-causing misfolding of plasma membrane proteins.-Cormet-Boyaka, E., Hong, J. S., Berdiev, B. K., Fortenberry, J. A., Rennolds, J., Clancy, J. P., Benos, D. J., Boyaka, P. N., Sorscher, E. J. A truncated CFTR protein rescues endogenous Delta F508-CFTR and corrects chloride transport in mice. FASEB J. 23, 3743-3751 (2009). www.fasebj.org	[Cormet-Boyaka, Estelle; Rennolds, Jessica] Ohio State Univ, Div Pulm Crit Care & Sleep Med, Columbus, OH 43201 USA; [Boyaka, Prosper N.] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43201 USA; [Hong, Jeong S.; Berdiev, Bakhram K.] Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; [Fortenberry, James A.; Sorscher, Eric J.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA; [Clancy, J. P.] Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA; [Benos, Dale J.] Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Cormet-Boyaka, E (corresponding author), Ohio State Univ, Div Pulm Crit Care & Sleep Med, Columbus, OH 43201 USA.	estelle.boyaka@osumc.edu	Cormet-Boyaka, Estelle/H-5624-2011	Sorscher, Eric J./0000-0001-9341-3354; Boyaka, Prosper/0000-0001-6857-9088	Cystic Fibrosis Foundation; U.S. National Institutes of Health [DK37206]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206, R56DK037206] Funding Source: NIH RePORTER	Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by a research grant and a pilot and feasibility grant awarded by the Cystic Fibrosis Foundation (to E.C.-B.), and U.S. National Institutes of Health grant DK37206 (to D.J.B.).	Alberti S, 2004, MOL BIOL CELL, V15, P4003, DOI 10.1091/mbc.E04-04-0293; Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; Baker JMR, 2007, NAT STRUCT MOL BIOL, V14, P738, DOI 10.1038/nsmb1278; Bebok Z, 2005, J PHYSIOL-LONDON, V569, P601, DOI 10.1113/jphysiol.2005.096669; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; Cebotaru L, 2008, J BIOL CHEM, V283, P21926, DOI 10.1074/jbc.M709156200; Clarke LL, 2004, AM J PHYSIOL-CELL PH, V287, pC192, DOI 10.1152/ajpcell.00337.2003; Cormet-Boyaka E, 2004, P NATL ACAD SCI USA, V101, P8221, DOI 10.1073/pnas.0400459101; Cui LY, 2007, J MOL BIOL, V365, P981, DOI 10.1016/j.jmb.2006.10.086; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; Dorin JR, 1996, GENE THER, V3, P797; Du K, 2005, NAT STRUCT MOL BIOL, V12, P17, DOI 10.1038/nsmb882; Flotte TR, 2001, CHEST, V120, p124S, DOI 10.1378/chest.120.3_suppl.124S; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; Heda GD, 2000, BIOCHEM BIOPH RES CO, V271, P659, DOI 10.1006/bbrc.2000.2684; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; KETNER G, 2006, ADENOVIRUS METHODS P, V1, P19; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; Ma TH, 2002, J BIOL CHEM, V277, P37235, DOI 10.1074/jbc.M205932200; Mazzei Mauro, 2003, Farmaco (Lausanne), V58, P961, DOI 10.1016/S0014-827X(03)00155-1; Mense M, 2006, EMBO J, V25, P4728, DOI 10.1038/sj.emboj.7601373; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Owsianik G, 2003, FEBS LETT, V554, P173, DOI 10.1016/S0014-5793(03)01162-1; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; Powe AC, 2002, J PHYSIOL-LONDON, V539, P333, DOI 10.1113/jphysiol.2001.013162; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; Rennolds J, 2008, BIOCHEM BIOPH RES CO, V366, P1025, DOI 10.1016/j.bbrc.2007.12.065; Rennolds J, 2008, J BIOL CHEM, V283, P833, DOI 10.1074/jbc.M706504200; Salinas DB, 2004, AM J PHYSIOL-LUNG C, V287, pL936, DOI 10.1152/ajplung.00354.2003; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Scaria A, 1998, J VIROL, V72, P7302, DOI 10.1128/JVI.72.9.7302-7309.1998; Serohijos AWR, 2008, P NATL ACAD SCI USA, V105, P3256, DOI 10.1073/pnas.0800254105; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; Swiatecka-Urban A, 2005, J BIOL CHEM, V280, P36762, DOI 10.1074/jbc.M508944200; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; Wang F, 2000, J PHYSIOL-LONDON, V524, P637, DOI 10.1111/j.1469-7793.2000.00637.x; Wang W, 2005, J GEN PHYSIOL, V125, P127, DOI 10.1085/jgp.200409115; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Zabner J, 1996, J VIROL, V70, P6994, DOI 10.1128/JVI.70.10.6994-7003.1996; Zsembery A, 2004, J BIOL CHEM, V279, P10720, DOI 10.1074/jbc.M313391200	45	10	10	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2009	23	11					3743	3751		10.1096/fj.08-127878	http://dx.doi.org/10.1096/fj.08-127878			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19620404	Green Published			2022-12-28	WOS:000271272500012
J	Elmasri, H; Karaaslan, C; Teper, Y; Ghelfi, E; Weng, MQ; Ince, TA; Kozakewich, H; Bischoff, J; Cataltepe, S				Elmasri, Harun; Karaaslan, Cagatay; Teper, Yaroslav; Ghelfi, Elisa; Weng, MeiQian; Ince, Tan A.; Kozakewich, Harry; Bischoff, Joyce; Cataltepe, Sule			Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; infantile hemangioma; microvessel; placenta	ACTIVATED RECEPTOR-GAMMA; GROWTH-FACTOR; PHENOTYPIC HETEROGENEITY; INSULIN-RESISTANCE; GENE-EXPRESSION; ADIPOSE-TISSUE; BABOON MODEL; MICE LACKING; IN-VITRO; AP2	Fatty acid binding protein 4 (FABP4) plays an important role in maintaining glucose and lipid homeostasis. FABP4 has been primarily regarded as an adipocyte-and macrophage-specific protein, but recent studies suggest that it may be more widely expressed. We found strong FABP4 expression in the endothelial cells (ECs) of capillaries and small veins in several mouse and human tissues, including the heart and kidney. FABP4 was also detected in the ECs of mature human placental vessels and infantile hemangiomas, the most common tumor of infancy and ECs. In most of these cases, FABP4 was detected in both the nucleus and cytoplasm. FABP4 mRNA and protein levels were significantly induced in cultured ECs by VEGF-A and bFGF treatment. The effect of VEGF-A on FABP4 expression was inhibited by chemical inhibition or short-hairpin (sh) RNA-mediated knockdown of VEGF-receptor-2 (R2), whereas the VEGFR1 agonists, placental growth factors 1 and 2, had no effect on FABP4 expression. Knockdown of FABP4 in ECs significantly reduced proliferation both under baseline conditions and in response to VEGF and bFGF. Thus, FABP4 emerged as a novel target of the VEGF/VEGFR2 pathway and a positive regulator of cell proliferation in ECs.-Elmasri, H., Karaaslan, C., Teper, Y., Ghelfi, E., Weng, M., Ince, T. A., Kozakewich, H., Bischoff, J., Cataltepe, S. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J. 23, 3865-3873 (2009). www.fasebj.org	[Elmasri, Harun; Karaaslan, Cagatay; Teper, Yaroslav; Ghelfi, Elisa; Weng, MeiQian; Cataltepe, Sule] Brigham & Womens Hosp, Div Newborn Med, Boston, MA 02115 USA; [Ince, Tan A.] Brigham & Womens Hosp, Div Womens & Perinatal Pathol, Dept Pathol, Boston, MA 02115 USA; [Ince, Tan A.] Harvard Univ, Sch Med, Boston, MA USA; [Kozakewich, Harry] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; [Bischoff, Joyce] Childrens Hosp, Dept Vasc Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Cataltepe, S (corresponding author), Brigham & Womens Hosp, Div Newborn Med, Thorn 1019,75 Francis St, Boston, MA 02115 USA.	scataltepe@partners.org	KARAASLAN, Cagatay/AAA-1621-2021; BISCHOFF, JOYCE/K-3354-2019	KARAASLAN, Cagatay/0000-0003-4857-0857; BISCHOFF, JOYCE/0000-0002-6367-1974; Ince, Tan/0000-0003-0315-6425	Peabody Foundation, Inc.; U.S. National Institutes of Health [5T32 HD007466-12]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007466] Funding Source: NIH RePORTER	Peabody Foundation, Inc.; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This study was supported in part by the Peabody Foundation, Inc. (S. C.) and U.S. National Institutes of Health grant 5T32 HD007466-12 (Y.T.). We are grateful to Dr. Gokhan Hotamisligil (Harvard School of Public Health, Boston, MA, USA) for the FABP4<SUP>-/-</SUP> mice and valuable discussions, and Drs. Patricia D'Amore and Stella Kourembanas for critical review of the manuscript. We also thank Drs. Alessia Di Nardo and Mustafa Sahin for the shRNA protocol. We are grateful to Marcia Filip, RN (Center for Clinical Investigation, Brigham and Women's Hospital, Boston, MA, USA), for her help with umbilical cord collection.	Adida A, 2006, BBA-MOL CELL BIOL L, V1761, P172, DOI 10.1016/j.bbalip.2006.02.006; Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a; Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae; Aljada A, 2008, ANGIOGENESIS, V11, P361, DOI 10.1007/s10456-008-9118-0; Altiok O, 2006, AM J RESP CRIT CARE, V173, P318, DOI 10.1164/rccm.200503-425OC; Arai Y, 2005, J NEUROSCI, V25, P9752, DOI 10.1523/JNEUROSCI.2512-05.2005; Autiero M, 2003, J THROMB HAEMOST, V1, P1356, DOI 10.1046/j.1538-7836.2003.00263.x; Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH547, DOI 10.1152/ajpheart.00616.2005; Barlow C, 1997, NUCLEIC ACIDS RES, V25, P2543, DOI 10.1093/nar/25.12.2543; Barnes CM, 2005, P NATL ACAD SCI USA, V102, P19097, DOI 10.1073/pnas.0509579102; Biron-Shental T, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.03.066; Bischoff J, 2009, J CRANIOFAC SURG, V20, P695, DOI 10.1097/SCS.0b013e318193d6ac; Boord JB, 2002, ARTERIOSCL THROM VAS, V22, P1686, DOI 10.1161/01.ATV.0000033090.81345.E6; Calicchio ML, 2009, AM J PATHOL, V174, P1638, DOI 10.2353/ajpath.2009.080517; Cao HM, 2008, CELL, V134, P933, DOI 10.1016/j.cell.2008.07.048; Charan NB, 1997, J APPL PHYSIOL, V82, P284, DOI 10.1152/jappl.1997.82.1.284; Ferrell Robert E., 2008, Lymphatic Research and Biology, V6, P69, DOI 10.1089/lrb.2007.1022; FISHMAN SJ, 1993, PEDIATR CLIN N AM, V40, P1177; Fu YC, 2000, J LIPID RES, V41, P2017; Furuhashi M, 2007, NATURE, V447, P959, DOI 10.1038/nature05844; Goto Y, 2006, CANCER RES, V66, P4443, DOI 10.1158/0008-5472.CAN-05-2505; Haunerland NH, 2004, PROG LIPID RES, V43, P328, DOI 10.1016/j.plipres.2004.05.001; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Hertzel AV, 2000, TRENDS ENDOCRIN MET, V11, P175; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jinnin M, 2008, NAT MED, V14, P1236, DOI 10.1038/nm.1877; Kraling BM, 1998, IN VITRO CELL DEV-AN, V34, P308; Kusakari Y, 2006, MOL CELL BIOCHEM, V284, P183, DOI 10.1007/s11010-005-9048-8; Lee MYK, 2007, ARTERIOSCL THROM VAS, V27, P2443, DOI 10.1161/ATVBAHA.107.141705; Linton MF, 2003, INT J OBESITY, V27, pS35, DOI 10.1038/sj.ijo.0802498; Maeda K, 2005, CELL METAB, V1, P107, DOI 10.1016/j.cmet.2004.12.008; Maharaj ASR, 2007, MICROVASC RES, V74, P100, DOI 10.1016/j.mvr.2007.03.004; Makowski L, 2005, CURR OPIN LIPIDOL, V16, P543, DOI 10.1097/01.mol.0000180166.08196.07; Makowski L, 2005, J BIOL CHEM, V280, P12888, DOI 10.1074/jbc.M413788200; Makowski L, 2004, J NUTR, V134, p2464S, DOI 10.1093/jn/134.9.2464S; Makowski L, 2001, NAT MED, V7, P699, DOI 10.1038/89076; Masouye I, 1997, CIRC RES, V81, P297, DOI 10.1161/01.RES.81.3.297; Matsumoto T, 2006, J ATHEROSCLER THROMB, V13, P130, DOI 10.5551/jat.13.130; Mostoslavsky G, 2005, MOL THER, V11, P932, DOI 10.1016/j.ymthe.2005.01.005; Piqueras L, 2007, ARTERIOSCL THROM VAS, V27, P63, DOI 10.1161/01.ATV.0000250972.83623.61; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Shum BOV, 2006, J CLIN INVEST, V116, P2183, DOI 10.1172/JCI24767; Slipicevic A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-276; SPIEGELMAN BM, 1980, J BIOL CHEM, V255, P8811; Stenmark KR, 2005, ANNU REV PHYSIOL, V67, P623, DOI 10.1146/annurev.physiol.67.040403.102229; Strawn LM, 1996, CANCER RES, V56, P3540; Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002; Uysal KT, 2000, ENDOCRINOLOGY, V141, P3388, DOI 10.1210/en.141.9.3388; VanGuilder HD, 2008, BIOTECHNIQUES, V44, P619, DOI 10.2144/000112776; WATANABE K, 1993, J PATHOL, V170, P59, DOI 10.1002/path.1711700110; Whittles CE, 2002, MICROCIRCULATION, V9, P513, DOI 10.1038/sj.mn.7800164; Wolfrum C, 2007, CELL MOL LIFE SCI, V64, P2465, DOI 10.1007/s00018-007-7279-4; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Yasumatsu R, 2006, AM J PHYSIOL-LUNG C, V291, pL619, DOI 10.1152/ajplung.00507.2005; Zimmerman AW, 2002, CELL MOL LIFE SCI, V59, P1096, DOI 10.1007/s00018-002-8490-y	58	217	229	2	40	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3865	3873		10.1096/fj.09-134882	http://dx.doi.org/10.1096/fj.09-134882			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19625659	Green Published			2022-12-28	WOS:000271272500022
J	Sorice, M; Matarrese, P; Tinari, A; Giammarioli, AM; Garofalo, T; Manganelli, V; Ciarlo, L; Gambardella, L; Maccari, G; Botta, M; Misasi, R; Malorni, W				Sorice, Maurizio; Matarrese, Paola; Tinari, Antonella; Giammarioli, Anna Maria; Garofalo, Tina; Manganelli, Valeria; Ciarlo, Laura; Gambardella, Lucrezia; Maccari, Giorgio; Botta, Maurizio; Misasi, Roberta; Malorni, Walter			Raft component GD3 associates with tubulin following CD95/Fas ligation	FASEB JOURNAL			English	Article						apoptosis; mitochondria; ganglioside; cytoskeleton	MITOCHONDRIAL PERMEABILITY TRANSITION; LIPID RAFTS; PERIPHERAL-BLOOD; APOPTOSIS; GANGLIOSIDE; CELLS; MICRODOMAINS; LYMPHOCYTES; HYPERPOLARIZATION; MICROTUBULES	In a previous investigation, we demonstrated that after CD95/Fas triggering, raft-associated GD3 ganglioside, normally localized at the plasma membrane of T cells, can be detected in mitochondria, where they contribute to apoptogenic events. Here, we show the association of the glycosphingolipid GD3 with microtubular cytoskeleton at very early time points following Fas ligation. This was assessed by different methodological approaches, including fluorescence resonance energy transfer, immunoelectron microscopy, and coimmunoprecipitation. Furthermore, docking analysis also showed that GD3 has a high affinity for the pore formed by 4 tubulin heterodimers ( type I pore), thus suggesting a possible direct interaction between tubulin and GD3. Finally, time-course analyses indicated that the relocalization of GD3 to the mitochondria was time related with the alterations of the mitochondrial membrane potential. Hence, microtubules could act as tracks for ganglioside redistribution following apoptotic stimulation, possibly contributing to the mitochondrial alterations leading to cell death.-Sorice, M., Matarrese, P., Tinari, A., Giammarioli, A. M., Garofalo, T., Manganelli, V., Ciarlo, L., Gambardella, L., Maccari, G., Botta, M., Misasi, R., Malorni, W. Raft component GD3 associates with tubulin following CD95/Fas ligation. FASEB J. 23, 3298-3308 ( 2009). www.fasebj.org	[Matarrese, Paola; Giammarioli, Anna Maria; Ciarlo, Laura; Gambardella, Lucrezia; Malorni, Walter] Ist Super Sanita, Dept Drug Res & Evaluat, Sect Cell Aging & Degenerat, I-00161 Rome, Italy; [Sorice, Maurizio; Garofalo, Tina; Manganelli, Valeria; Misasi, Roberta] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy; [Sorice, Maurizio; Garofalo, Tina] Sapienza Univ, Lab Expt Med & Environm Pathol, Rieti, Italy; [Tinari, Antonella] Ist Super Sanita, Dept Technol & Hlth, Sect Ultrastruct Infect Pathol, I-00161 Rome, Italy; [Maccari, Giorgio; Botta, Maurizio] Univ Siena, Dept Chem Technol Drugs, I-53100 Siena, Italy	Istituto Superiore di Sanita (ISS); Sapienza University Rome; Sapienza University Rome; Istituto Superiore di Sanita (ISS); University of Siena	Malorni, W (corresponding author), Ist Super Sanita, Dept Drug Res & Evaluat, Sect Cell Aging & Degenerat, Viale Regina Elena 299, I-00161 Rome, Italy.	malorni@iss.it	Sousa, Maria/HCI-9642-2022; Matarrese, Paola/A-4369-2014; Malorni, Walter/G-5874-2016; TINARI, ANTONELLA/F-2109-2015; Giammarioli, Anna Maria/AAY-7686-2020; Sorice, Maurizio/Q-5079-2019	Maccari, Giorgio/0000-0002-9552-5680; Garofalo, Tina/0000-0003-0645-2510; matarrese, paola/0000-0001-5477-3752; ciarlo, laura/0000-0002-6923-314X; malorni, walter/0000-0002-1223-7000; Sorice, Maurizio/0000-0003-3534-1502	Telethon and Ministero della Sanita; Sapienza University (Ateneo)	Telethon and Ministero della Sanita(Fondazione Telethon); Sapienza University (Ateneo)	The authors are indebted to Roberta Terlizzi and Zaira Maroccia for their technical assistance in the editing of the work. This work was partially supported by grants from Telethon and Ministero della Sanita to W. M. and from Sapienza University (Ateneo) to M. S.	Ardail D, 2003, BIOCHEM J, V371, P1013, DOI 10.1042/BJ20021834; Baas PW, 2005, TRENDS CELL BIOL, V15, P518, DOI 10.1016/j.tcb.2005.08.004; Balasubramanian N, 2007, NAT CELL BIOL, V9, P1381, DOI 10.1038/ncb1657; Banki K, 1999, J IMMUNOL, V162, P1466; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Bottegoni G, 2006, BIOINFORMATICS, V22, pE58, DOI 10.1093/bioinformatics/btl212; BURNS RG, 1991, CELL MOTIL CYTOSKEL, V20, P181, DOI 10.1002/cm.970200302; Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438; Cheng J, 2004, MOL PHARMACEUT, V1, P183, DOI 10.1021/mp049966y; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; Garofalo T, 2005, CELL DEATH DIFFER, V12, P1378, DOI 10.1038/sj.cdd.4401672; Garofalo T, 2003, J BIOL CHEM, V278, P8309, DOI 10.1074/jbc.M207618200; Garofalo T, 2002, J BIOL CHEM, V277, P11233, DOI 10.1074/jbc.M109601200; Garofaloa T, 2007, FEBS LETT, V581, P3899, DOI 10.1016/j.febslet.2007.07.020; Giammarioli AM, 2001, FEBS LETT, V506, P45, DOI 10.1016/S0014-5793(01)02776-4; Higuchi Y, 2005, FEBS LETT, V579, P3009, DOI 10.1016/j.febslet.2005.04.054; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; KIGUCHI K, 1990, J BIOCHEM-TOKYO, V107, P8, DOI 10.1093/oxfordjournals.jbchem.a123016; Kuypers FA, 1996, BLOOD, V87, P1179, DOI 10.1182/blood.V87.3.1179.bloodjournal8731179; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Maestrelli F, 2005, INT J PHARMACEUT, V298, P55, DOI 10.1016/j.ijpharm.2005.03.033; Malorni W, 2007, APOPTOSIS, V12, P941, DOI 10.1007/s10495-007-0757-1; Matarrese P, 2005, J BIOL CHEM, V280, P6969, DOI 10.1074/jbc.M409752200; Matarrese P, 2007, J BIOL CHEM, V282, P9029, DOI 10.1074/jbc.M607614200; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Patra SK, 2008, BBA-REV CANCER, V1785, P182, DOI 10.1016/j.bbcan.2007.11.002; Pizzo P, 2003, CURR OPIN IMMUNOL, V15, P255, DOI 10.1016/S0952-7915(03)00038-4; Riemann D, 2005, BIOCHEM BIOPH RES CO, V331, P1408, DOI 10.1016/j.bbrc.2005.04.061; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; SVENNERHOLM L, 1995, BIOCHIM BIOPHYS ACTA, V617, P97; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; YUASA H, 1990, TISSUE ANTIGENS, V36, P47, DOI 10.1111/j.1399-0039.1990.tb01799.x; Zamzami N, 2001, METHOD CELL BIOL, V65, P147, DOI 10.1016/S0091-679X(01)65009-X; Zurgil N, 2000, BIOCHEM BIOPH RES CO, V268, P155, DOI 10.1006/bbrc.1999.1934	46	32	33	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3298	3308		10.1096/fj.08-128140	http://dx.doi.org/10.1096/fj.08-128140			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19509307				2022-12-28	WOS:000270354300007
J	Tocchini-Valentini, GP; Tocchini-Valentini, MA; Schlessinger, D				Tocchini-Valentini, Glauco P.; Tocchini-Valentini, Marta A.; Schlessinger, David			How to build a kangaroo the way a kangaroo builds itself	FASEB JOURNAL			English	Editorial Material									[Tocchini-Valentini, Glauco P.] CNR, Ist Biol Cellulare, I-00015 Rome, Italy; [Schlessinger, David] NIA, Genet Lab, Baltimore, MD 21224 USA	Consiglio Nazionale delle Ricerche (CNR); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Tocchini-Valentini, GP (corresponding author), CNR, Ist Biol Cellulare, I-00015 Rome, Italy.				NATIONAL INSTITUTE ON AGING [ZIAAG000676] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BRENNER S, 1975, COMMUNICATION; Calvino Italo, 1974, INVISIBLE CITIES, P76; CHAITIN GJ, 1999, UNKNOWABLE, P122; Godel K, 1983, PHILOS MATH SELECTED, V2; Isalan M, 2009, NATURE, V458, P969, DOI 10.1038/458969a; LEIBNIZ GW, 1695, COMMUNICATION   0930; Lewis D., 1986, PLURALITY WORLDS; Nurse P, 2008, NATURE, V454, P424, DOI 10.1038/454424a; Tegmark M, 2004, SCI ULTIMATE REALITY; VONNEUMANN J, 1966, THEORY SELF REPROD A	10	0	0	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2009	23	10					3257	3259		10.1096/fj.09-1002	http://dx.doi.org/10.1096/fj.09-1002			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19797299				2022-12-28	WOS:000270354300002
J	Aubry, S; Burlina, F; Dupont, E; Delaroche, D; Joliot, A; Lavielle, S; Chassaing, G; Sagan, S				Aubry, Soline; Burlina, Fabienne; Dupont, Edmond; Delaroche, Diane; Joliot, Alain; Lavielle, Solange; Chassaing, Gerard; Sagan, Sandrine			Cell-surface thiols affect cell entry of disulfide-conjugated peptides	FASEB JOURNAL			English	Article						CPP; redox potential; MALDI-TOF MS	TOF MASS-SPECTROMETRY; PENETRATING PEPTIDES; DEPENDENT TRANSLOCATION; DRUG-DELIVERY; IN-VIVO; INHIBITION; PROTEIN; MEMBRANE; BONDS; QUANTIFICATION	Cell-penetrating peptides (CPPs) can cross the cell membrane and are widely used to deliver bioactive cargoes inside cells. The cargo and the CPP are often conjugated through a disulfide bridge with the common acceptation that this linker is stable in the extracellular biological medium and should not perturb the internalization process. However, with the use of thiol-specific reagents combined with mass spectrometry (as a quantitative method to measure intracellular concentrations of peptides) and confocal microscopy (as a qualitative method to visualize internalized peptides) analyses, we could show that, depending on the peptide sequence, thiol/disulfide exchange reactions could happen at the cell surface. These exchange reactions lead to the reduction of disulfide conjugates. In addition, it was observed that not only disulfide-but also thiol-containing peptides could cross-react with cell-surface thiols. The peptides cross-linked by thiol-containing membrane proteins were either trapped in the membrane or further internalized. Therefore, a new route of cellular uptake was unveiled that is not restricted to CPPs: a protein kinase C peptide inhibitor that is not cell permeant could cross cell membranes when an activated cysteine (with a 3-nitro-2-pyridinesulfenyl moiety) was introduced in its sequence.-Aubry, S., Burlina, F., Dupont, E., Delaroche, D., Joliot, A., Lavielle, S., Chassaing, G., Sagan, S. Cell-surface thiols affect cell entry of disulfide-conjugated peptides. FASEB J. 23, 2956-2967 (2009). www.fasebj.org	[Aubry, Soline; Burlina, Fabienne; Delaroche, Diane; Lavielle, Solange; Chassaing, Gerard; Sagan, Sandrine] Univ Paris 06, UMR 7613, F-75005 Paris, France; [Dupont, Edmond; Joliot, Alain] Ecole Normale Super, CNRS, UMR 8542, Paris, France; [Aubry, Soline; Burlina, Fabienne; Delaroche, Diane; Lavielle, Solange; Chassaing, Gerard; Sagan, Sandrine] CNRS, UMR 7613, Paris, France	UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS)	Sagan, S (corresponding author), Univ Paris 06, UMR 7613, Case Courier 182,4 Pl Jussieu, F-75005 Paris, France.	sandrine.sagan@upmc.fr	S, SAGAN/I-8132-2013; s, s/HIK-1178-2022; s, s/GYR-2278-2022; s, s/GVS-3323-2022; s, s/HHD-0404-2022; QI, DANDAN/GVR-9324-2022; SAGAN, Sandrine/AAA-8537-2022	S, SAGAN/0000-0003-0083-4411; Burlina, Fabienne/0000-0002-6042-680X	Agence Nationale pour la Recherche [ANR-06-PCVI-9187]; FRM	Agence Nationale pour la Recherche(French National Research Agency (ANR)); FRM(Fondation pour la Recherche Medicale)	We are grateful to Dr. Gerard Bolbach, Gilles Clodic, and Thierry Blasco from the Mass Spectrometry and Proteomic Plateform, Universite Pierre et Marie Curie, for fruitful discussion. We also thank Dr. Yves Jacquot and Vanessa Point for their assistance in peptide synthesis. This study was supported by Agence Nationale pour la Recherche (project ANR-06-PCVI-9187, ProbDom) and a grant from FRM (S.A.).	Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Astriab-Fisher A, 2000, BIOCHEM PHARMACOL, V60, P83, DOI 10.1016/S0006-2952(00)00310-5; Boon JM, 2003, J AM CHEM SOC, V125, P8195, DOI 10.1021/ja029670q; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Boutorine AS, 1990, BIOCONJUGATE CHEM, V1, P350, DOI 10.1021/bc00005a009; BOUTORINE AS, 1993, BIOCHIMIE, V75, P35, DOI 10.1016/0300-9084(93)90022-K; Burlina F, 2005, ANGEW CHEM INT EDIT, V44, P4244, DOI 10.1002/anie.200500477; Burlina F, 2006, NAT PROTOC, V1, P200, DOI 10.1038/nprot.2006.30; BUTTERS TD, 1980, J CELL SCI, V44, P33; CAPOZZI G, 1980, J CHEM SOC PERK T 2, P68, DOI 10.1039/p29800000068; Chaloin L, 1998, BIOCHEM BIOPH RES CO, V243, P601, DOI 10.1006/bbrc.1997.8050; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Cline DJ, 2004, ANAL BIOCHEM, V335, P168, DOI 10.1016/j.ab.2004.07.015; COLLINS DS, 1991, J IMMUNOL, V147, P4054; Delaroche D, 2007, ANAL CHEM, V79, P1932, DOI 10.1021/ac061108l; Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005; Dom G, 2003, NUCLEIC ACIDS RES, V31, P556, DOI 10.1093/nar/gkg160; Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x; Dupont E, 2007, J BIOL CHEM, V282, P8994, DOI 10.1074/jbc.M609246200; FEENER EP, 1990, J BIOL CHEM, V265, P18780; Fischer R, 2002, BBA-BIOMEMBRANES, V1564, P365, DOI 10.1016/S0005-2736(02)00471-6; Fretz MM, 2007, BIOCHEM J, V403, P335, DOI 10.1042/BJ20061808; Fujimoto K, 2000, CANCER LETT, V159, P151, DOI 10.1016/S0304-3835(00)00536-X; GRINNEL F, 1979, ARCH BIOCHEM BIOPHYS, V153, P193; Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4; Henriques ST, 2008, J PEPT SCI, V14, P482, DOI 10.1002/psc.1003; Jiang XM, 1999, J BIOL CHEM, V274, P2416, DOI 10.1074/jbc.274.4.2416; Jones AT, 2008, INT J PHARMACEUT, V354, P34, DOI 10.1016/j.ijpharm.2007.10.046; Kamp D, 2001, BIOCHEMISTRY-US, V40, P9438, DOI 10.1021/bi0107492; KICHLER A, 1995, BIOCHEM BIOPH RES CO, V209, P444, DOI 10.1006/bbrc.1995.1522; LAURIAULT VVM, 1991, MOL PHARMACOL, V40, P125; Loretz B, 2007, BIOCONJUGATE CHEM, V18, P1028, DOI 10.1021/bc0603079; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MAY JM, 1985, J BIOL CHEM, V260, P462; MCABEE DD, 1982, BIOCHEM J, V208, P473, DOI 10.1042/bj2080473; OBERHAUSER B, 1992, NUCLEIC ACIDS RES, V20, P533, DOI 10.1093/nar/20.3.533; Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8; Plummer JS, 1999, BIOORG MED CHEM LETT, V9, P835, DOI 10.1016/S0960-894X(99)00096-7; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; RAVENSCROFT M, 1982, J CHEM SOC PERK T 2, P1569, DOI 10.1039/p29820001569; RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; Sahaf B, 2005, ARCH BIOCHEM BIOPHYS, V434, P26, DOI 10.1016/j.abb.2004.11.015; Saito G, 2003, ADV DRUG DELIVER REV, V55, P199, DOI 10.1016/S0169-409X(02)00179-5; Schwertassek U, 2007, EMBO J, V26, P3086, DOI 10.1038/sj.emboj.7601746; Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036; THEODORE L, 1995, J NEUROSCI, V15, P7158; Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5; TURNER JJ, 2006, HDB CELL PENETRATING, P313; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; Weller K, 2005, BIOCHEMISTRY-US, V44, P15799, DOI 10.1021/bi051535d; Yang J, 2006, P NATL ACAD SCI USA, V103, P13872, DOI 10.1073/pnas.0601455103	53	118	121	0	37	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2956	2967		10.1096/fj.08-127563	http://dx.doi.org/10.1096/fj.08-127563			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19403512				2022-12-28	WOS:000270241000018
J	Cho, HJ; Son, SM; Jin, SM; Hong, HS; Shin, DH; Kim, SJ; Huh, K; Mook-Jung, I				Cho, H. J.; Son, S. M.; Jin, S. M.; Hong, H. S.; Shin, D. H.; Kim, S. J.; Huh, K.; Mook-Jung, I.			RAGE regulates BACE1 and A beta generation via NFAT1 activation in Alzheimer's disease animal model	FASEB JOURNAL			English	Article						Tg2576; plaques; intracellular calcium; secretase; AGE; SH-SY5Y	GLYCATION END-PRODUCTS; AMYLOID PRECURSOR PROTEIN; CELL-SURFACE RECEPTOR; SECRETASE ACTIVITY; SOLUBLE RECEPTOR; GAMMA-SECRETASE; OXIDATIVE STRESS; NUCLEAR-FACTOR; MOUSE-BRAIN; EXPRESSION	The receptor for advanced glycation end products (RAGE) is a multiligand cell surface receptor, and amyloid beta peptide (A beta) is one of the ligands for RAGE. Because RAGE is a transporter of A beta from the blood to the brain, RAGE is believed to play an important role in Alzheimer's disease (AD) pathogenesis. In the present study, the role of RAGE in A beta production was examined in the brain tissue of an AD animal model, Tg2576 mice, as well as cultured cells. Because beta-site APP-cleaving enzyme 1 (BACE1), an essential protease for A beta production, is up-regulated in cells overexpressing RAGE and in RAGE-injected brains of Tg2576 mice, the molecular mechanisms underlying RAGE, BACE1 expression, and A beta production were examined. Because RAGE stimulates intracellular calcium, nuclear factor of activated T-cells 1 (NFAT1) was examined. NFAT1 was activated following RAGE-induced BACE1 expression followed by A beta generation. Injection of soluble RAGE (sRAGE), which acts as a competitor with full-length RAGE (fRAGE), into aged Tg2576 mouse brains reduced the levels of plaques, A beta, BACE1, and the active form of NFAT1 compared with fRAGE-injected Tg2576 mice. Taken together, RAGE stimulates functional BACE1 expression through NFAT1 activation, resulting in more A beta production and deposition in the brain.-Cho, H. J., Son, S. M., Jin, S. M., Hong, H. S., Shin, D. H., Kim, S. J., Huh, K., Mook-Jung, I. RAGE regulates BACE1 and A beta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J. 23, 2639-2649 ( 2009)	[Cho, H. J.; Son, S. M.; Jin, S. M.; Hong, H. S.; Mook-Jung, I.] Seoul Natl Univ, Coll Med, Dept Biochem & Biomed Sci, Seoul 110799, South Korea; [Shin, D. H.; Kim, S. J.] Seoul Natl Univ, Coll Med, Dept Physiol, Seoul 110799, South Korea; [Huh, K.; Mook-Jung, I.] Seoul Natl Univ, Coll Med, Hypoxia Dis Inst, Seoul 110799, South Korea; [Huh, K.] Ajou Univ, Sch Med, Grad Program Neurosci, Suwon 441749, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Ajou University	Mook-Jung, I (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Biomed Sci, 28 Yungun Dong, Seoul 110799, South Korea.	inhee@snu.ac.kr	Kim, Sung Joon/H-1825-2012; Mook, Inhee/J-2754-2012	Kim, Sung-Joon/0000-0002-0289-121X	21C Frontier Functional Proteomics Project [FPR08K1301-02210]; New Drug Target Discovery Project [08N4800-09610]; Aging and Apoptosis Research Center Program Project [R112002-097-08001]; Korean Research Foundation [KRF-2007-355-C00040]	21C Frontier Functional Proteomics Project(Ministry of Education, Science & Technology (MEST), Republic of Korea); New Drug Target Discovery Project; Aging and Apoptosis Research Center Program Project; Korean Research Foundation(National Research Foundation of Korea)	This work was supported by grants from the 21C Frontier Functional Proteomics Project (FPR08K1301-02210), the New Drug Target Discovery Project (08N4800-09610), the Aging and Apoptosis Research Center Program Project (R112002-097-08001), and the World Class University-Neurocytomics Program project to I. M.-J. and the Korean Research Foundation (MOEHRD; KRF-2007-355-C00040) to H.J.C.	BACHMAN DL, 1993, NEUROLOGY, V43, P515, DOI 10.1212/WNL.43.3_Part_1.515; Boo JH, 2008, BIOCHEM BIOPH RES CO, V372, P913, DOI 10.1016/j.bbrc.2008.05.153; Bourne KZ, 2007, J NEUROSCI RES, V85, P1194, DOI 10.1002/jnr.21252; Cho HJ, 2008, AGING CELL, V7, P137, DOI 10.1111/j.1474-9726.2007.00360.x; Cho HJ, 2007, GLIA, V55, P253, DOI 10.1002/glia.20451; Collison KS, 2002, J LEUKOCYTE BIOL, V71, P433; Costantini C, 2006, EMBO J, V25, P1997, DOI 10.1038/sj.emboj.7601062; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; Emanuele E, 2005, ARCH NEUROL-CHICAGO, V62, P1734, DOI 10.1001/archneur.62.11.1734; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; Gibson GE, 1999, ANN NY ACAD SCI, V893, P79, DOI 10.1111/j.1749-6632.1999.tb07819.x; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hanford LE, 2004, J BIOL CHEM, V279, P50019, DOI 10.1074/jbc.M409782200; Heine RJ, 2002, DIABETOLOGIA, V45, P461, DOI 10.1007/s00125-001-0726-0; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Jin SM, 2008, CELL DEATH DIFFER, V15, P1375, DOI 10.1038/cdd.2008.49; Jin SM, 2007, CELL DEATH DIFFER, V14, P189, DOI 10.1038/sj.cdd.4402003; JOHNSTON JA, 1994, FEBS LETT, V354, P274, DOI 10.1016/0014-5793(94)01137-0; Kume S, 2005, J BONE MINER RES, V20, P1647, DOI 10.1359/JBMR.050514; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Lee M, 2006, MOL CELLS, V22, P1; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Malherbe P, 1999, MOL BRAIN RES, V71, P159, DOI 10.1016/S0169-328X(99)00174-6; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Petrova R, 2002, J MOL CELL CARDIOL, V34, P1425, DOI 10.1006/jmcc.2002.2084; Plyte S, 2001, J BIOL CHEM, V276, P14350, DOI 10.1074/jbc.M007854200; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; Sato Takashi, 2006, Am J Alzheimers Dis Other Demen, V21, P197; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; Simm A, 2004, EXP GERONTOL, V39, P407, DOI 10.1016/j.exger.2003.12.006; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Takeuchi M, 2003, J NEUROPATH EXP NEUR, V62, P486, DOI 10.1093/jnen/62.5.486; Takeuchi M, 2008, CURR PHARM DESIGN, V14, P973, DOI 10.2174/138161208784139693; Takeuchi M, 2004, CURR ALZHEIMER RES, V1, P39, DOI 10.2174/1567205043480582; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; Tyler SJ, 2002, BIOCHEM BIOPH RES CO, V299, P373, DOI 10.1016/S0006-291X(02)02635-9; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yan SD, 2000, BBA-MOL BASIS DIS, V1502, P145, DOI 10.1016/S0925-4439(00)00041-7; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zlokovic BV, 2008, NEUROTHERAPEUTICS, V5, P409, DOI 10.1016/j.nurt.2008.05.011	52	94	99	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2639	2649		10.1096/fj.08-126383	http://dx.doi.org/10.1096/fj.08-126383			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19332646				2022-12-28	WOS:000268836700032
J	Pollock, S; Antrobus, R; Newton, L; Kampa, B; Rossa, J; Latham, S; Nichita, NB; Dwek, RA; Zitzmann, N				Pollock, Stephanie; Antrobus, Robin; Newton, Laura; Kampa, Bettina; Rossa, Jan; Latham, Sally; Nichita, Norica Branza; Dwek, Raymond A.; Zitzmann, Nicole			Uptake and trafficking of liposomes to the endoplasmic reticulum	FASEB JOURNAL			English	Article						drug delivery; lipid trafficking; imaging tool; purification tool	HEPATITIS-C VIRUS; N-BUTYL-DEOXYNOJIRIMYCIN; PLASMA-MEMBRANE; BUTYLDEOXYNOJIRIMYCIN; CHOLESTEROL; INFECTION; MACROPHAGES; COMBINATION; ENDOSOMES; PATHWAY	Liposomes are vesicular structures consisting of an aqueous core surrounded by a lipid bilayer. Apart from the cytosol and lysosomes, no other intracellular compartment has been successfully targeted using liposomal delivery. Here, we report the development of liposomes capable of specific targeting to the endoplasmic reticulum (ER) and associated membranes. Using competition and inhibitor assays along with confocal microscopy, we have determined that ER liposomes utilize scavenger and low-density lipoprotein receptors for endocytosis and enter cells through a caveolin- and microtubule-dependent mechanism. They traffic intact to the ER, where fusion with the ER membrane occurs after 22-25 min, which was confirmed by fluorescence-dequenching assays. Once inside the ER, tagged lipids intercalate with the ER membrane and are subsequently incorporated into ER-assembling entities, such as the ER-budding viruses hepatitis C virus (HCV) and bovine viral diarrhea virus (BVDV), lipid droplets, and secreted lipoproteins. ER liposomes are superior to cytosolic liposome formulations for the intracellular delivery of aqueous cargo, such as HIV-1 antivirals, and are especially suited for the prolonged delivery of lipids and lipophilic drugs into human cells.-Pollock, S., Antrobus, R., Newton, L., Kampa, B., Rossa, J., Latham, S., Branza Nichita, N., Dwek, R. A., Zitzmann, N. Uptake and trafficking of liposomes to the endoplasmic reticulum. FASEB J. 24, 1866-1878 (2010). www.fasebj.org	[Pollock, Stephanie; Antrobus, Robin; Newton, Laura; Kampa, Bettina; Rossa, Jan; Latham, Sally; Dwek, Raymond A.; Zitzmann, Nicole] Univ Oxford, Oxford Antiviral Drug Discovery Unit, Dept Biochem, Oxford OX1 3QU, England; [Nichita, Norica Branza] Romanian Univ, Inst Biochem, Bucharest, Romania	University of Oxford; Romanian Academy of Sciences; Institute of Biochemistry, Bucharest; University of Bucharest	Zitzmann, N (corresponding author), Univ Oxford, Oxford Antiviral Drug Discovery Unit, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	nicole.zitzmann@bioch.ox.ac.uk		Newton, Laura/0000-0002-5328-8314	Oxford Glycobiology Endowment; Canadian Institutes of Health Research; United Therapeutics Corp.; IDEI [84]	Oxford Glycobiology Endowment; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); United Therapeutics Corp.; IDEI	The authors thank Takaji Wakita (Tokyo Metropolitan Institute for Neuroscience, Tokyo, Japan), Jens Bukh (U. S. National Institutes of Health, Bethesda, MD, USA), Charles M. Rice (The Rockefeller University, New York, NY, USA) and Ralf Bartenschlager (University of Heidelberg, Heidelberg, Germany) for reagents. This work is funded by the Oxford Glycobiology Endowment, by the Canadian Institutes of Health Research (to S. P.), and by a Blue Skies research grant from United Therapeutics Corp., of which R. A. D is a director and member of the scientific board. N. Z. is a senior research fellow of Linacre College, Oxford. N. B. N. was financially supported by IDEI grant ID_84 [Consiliului National al Cercetarii Stiintifice din Invatamantul Superior (CNCSIS)].	BLOCK TM, 1994, P NATL ACAD SCI USA, V91, P2235, DOI 10.1073/pnas.91.6.2235; Campbell SM, 2002, AIDS, V16, P2253, DOI 10.1097/00002030-200211220-00004; Chapel C, 2007, J GEN VIROL, V88, P1133, DOI 10.1099/vir.0.82465-0; FISCHER P, 1995, J VIROL, V69, P5791, DOI 10.1128/JVI.69.9.5791-5797.1995; FISCHL MA, 1994, J ACQ IMMUN DEF SYND, V7, P139; Fujinaga Y, 2003, MOL BIOL CELL, V14, P4783, DOI 10.1091/mbc.E03-06-0354; Guyader M, 2002, J VIROL, V76, P10356, DOI 10.1128/JVI.76.20.10356-10364.2002; Huth US, 2006, J CONTROL RELEASE, V110, P490, DOI 10.1016/j.jconrel.2005.10.018; KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H; Macovei A, 2010, J VIROL, V84, P243, DOI 10.1128/JVI.01207-09; Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912; Miller JL, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040017; Molina S, 2007, J HEPATOL, V46, P411, DOI 10.1016/j.jhep.2006.09.024; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; Pagler TA, 2006, J BIOL CHEM, V281, P11193, DOI 10.1074/jbc.M510261200; Pollock S, 2008, AIDS, V22, P1961, DOI 10.1097/QAD.0b013e32830efd96; Schwendener RA, 2007, ADV EXP MED BIOL, V620, P117; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Steinmann E, 2007, HEPATOLOGY, V46, P330, DOI 10.1002/hep.21686; SWIFT LL, 1995, J LIPID RES, V36, P395; TIERNEY M, 1995, J ACQ IMMUN DEF SYND, V10, P549, DOI 10.1097/00042560-199510050-00008; Torchilin VP, 1993, J LIPOSOME RES, V3, P201, DOI DOI 10.3109/08982109309148213]; Woodhouse SD, 2008, ANTIMICROB AGENTS CH, V52, P1820, DOI 10.1128/AAC.01181-07	25	61	72	0	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1866	1878		10.1096/fj.09-145755	http://dx.doi.org/10.1096/fj.09-145755			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20097877				2022-12-28	WOS:000278200000022
J	Fainaru, O; Almog, N; Yung, CW; Nakai, K; Montoya-Zavala, M; Abdollahi, A; D'Amato, R; Ingber, DE				Fainaru, Ofer; Almog, Nava; Yung, Chong Wing; Nakai, Kei; Montoya-Zavala, Martin; Abdollahi, Amir; D'Amato, Robert; Ingber, Donald E.			Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells	FASEB JOURNAL			English	Article						immune cells; vasculogenesis	DIFFERENTIATION; PRECURSORS; DEPLETION	Dendritic cells (DCs)-immunomodulatory cells that initiate adaptive immune responses-have recently been shown to exert proangiogenic effects when infiltrating the tumor microenvironment. As tumors that escape immune surveillance inhibit DC maturation, we explored whether maturation status determines their ability to promote angiogenesis and whether angiogenesis depends on the presence of DCs. Using mouse xenograft models of human tumors, we show that fast-growing "angiogenic" tumors are infiltrated by a more immature DC population than respective dormant avascular tumors. Accordingly, supplementation of immature DCs, but not mature DCs, enhanced tumor growth. When DCs were mixed with Matrigel and injected subcutaneously into mice, only immature DCs promoted the ingrowth of patent blood vessels. Notably, depletion of DCs in a transgenic mouse model that allows for their conditional ablation completely abrogated basic fibroblast growth factor-induced angiogenesis in Matrigel plugs, and significantly inhibited tumor growth in these mice. Because immature DCs actively promote angiogenesis and tumor growth, whereas DC maturation or ablation suppresses this response, we conclude that angiogenesis is dependent on the presence of immature DCs. Thus, cancer immunotherapies that promote DC maturation may act by both augmenting the host immune response to the tumor and by suppressing tumor angiogenesis.-Fainaru, O., Almog, N., Yung, C. W., Nakai, K., Montoya-Zavala, M., Abollahi, A., D'Amato, R., Ingber, D. E. Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB J. 24, 1411-1418 (2010). www.fasebj.org	[Ingber, Donald E.] Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Program, Boston, MA 02115 USA; [Fainaru, Ofer; Yung, Chong Wing; Montoya-Zavala, Martin; D'Amato, Robert; Ingber, Donald E.] Childrens Hosp, Dept Surg, Boston, MA 02115 USA; [Fainaru, Ofer; Yung, Chong Wing; Montoya-Zavala, Martin] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Ingber, Donald E.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Nakai, Kei; D'Amato, Robert] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA; [Montoya-Zavala, Martin; Ingber, Donald E.] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA; [Ingber, Donald E.] Harvard Univ, Harvard Sch Engn & Appl Sci, Boston, MA 02115 USA; [Almog, Nava; Abdollahi, Amir] Tufts Univ, Sch Med, Caritas St Elizabeths Med Ctr, Ctr Canc Syst Biol, Boston, MA 02111 USA; [Abdollahi, Amir] Heidelberg Univ, Dept Radiat Oncol, Sch Med, Heidelberg, Germany; [Abdollahi, Amir] German Canc Res Ctr, D-6900 Heidelberg, Germany	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard University; St. Elizabeth's Medical Center; Tufts University; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Ingber, DE (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Program, 300 Longwood Ave, Boston, MA 02115 USA.	donald.ingber@childrens.harvard.edu	Ingber, Donald E/AAC-5894-2019		Fulbright and Rothschild Foundations; European Molecular Biology Organization (EMBO); German Research Council [DFG-SPP1190]; National Aeronautics and Space Administration Specialized Center of Research (NSCOR) [NNJ04HJ12G]; U.S. Department of Defense [W81XWH-04-1-0316]; U.S. National Institutes of Health [P01 CA045548]; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER	Fulbright and Rothschild Foundations; European Molecular Biology Organization (EMBO)(European Molecular Biology Organization (EMBO)); German Research Council(German Research Foundation (DFG)); National Aeronautics and Space Administration Specialized Center of Research (NSCOR); U.S. Department of Defense(United States Department of Defense); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is dedicated to Dr. Judah Folkman, who helped launch and guide this effort. The authors also thank Lauren Bazinet for her expert technical assistance, and Kristin Johnson and Clare Lamont for photography and graphic art. This research was supported by the Fulbright and Rothschild Foundations and the European Molecular Biology Organization (EMBO) Fellowship (O.F.); German Research Council Priority Research Program Tumor-Vessel Interface (DFG-SPP1190) and National Aeronautics and Space Administration Specialized Center of Research (NSCOR) NNJ04HJ12G (A. A.); and U.S. Department of Defense Breast Cancer Innovator award W81XWH-04-1-0316 and U.S. National Institutes of Health award P01 CA045548 (D. I.).	Adini A, 2009, J IMMUNOL METHODS, V342, P78, DOI 10.1016/j.jim.2008.11.016; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bennett CL, 2007, TRENDS IMMUNOL, V28, P525, DOI 10.1016/j.it.2007.08.011; Carmi Y, 2009, J IMMUNOL, V183, P4705, DOI 10.4049/jimmunol.0901511; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Conejo-Garcia JR, 2004, NAT MED, V10, P950, DOI 10.1038/nm1097; Coukos G, 2005, BRIT J CANCER, V92, P1182, DOI 10.1038/sj.bjc.6602476; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; De Palma M, 2006, BBA-REV CANCER, V1766, P159, DOI 10.1016/j.bbcan.2006.06.003; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Fainaru O, 2008, FASEB J, V22, P522, DOI 10.1096/fj.07-9034com; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; Gabrilovich D, 2004, NAT REV IMMUNOL, V4, P941, DOI 10.1038/nri1498; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Huarte E, 2008, CANCER RES, V68, P7684, DOI 10.1158/0008-5472.CAN-08-1167; Jinushi M, 2007, CLIN CANCER RES, V13, P3762, DOI 10.1158/1078-0432.CCR-07-0880; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Lutz MB, 2000, EUR J IMMUNOL, V30, P1813, DOI 10.1002/1521-4141(200007)30:7<1813::AID-IMMU1813>3.0.CO;2-8; Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x; Melief CJM, 2008, IMMUNITY, V29, P372, DOI 10.1016/j.immuni.2008.08.004; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Nakai K, 2008, INVEST OPHTH VIS SCI, V49, P3666, DOI 10.1167/iovs.07-1640; NAUMOV GN, J NATL CANC I, V98, P316; PASSANITI A, 1992, LAB INVEST, V67, P519; Plaks V, 2008, J CLIN INVEST, V118, P3954, DOI 10.1172/JCI36682; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040	29	77	81	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1411	1418		10.1096/fj.09-147025	http://dx.doi.org/10.1096/fj.09-147025			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20008545	Green Published			2022-12-28	WOS:000277158900014
J	Glitsch, MD				Glitsch, Maike D.			Activation of native TRPC3 cation channels by phospholipase D	FASEB JOURNAL			English	Article						slow EPSC; mGluR; Rho GTPase; Purkinje cell; dendritic tree development	METABOTROPIC GLUTAMATE-RECEPTOR; PROTEIN-KINASE-C; CEREBELLAR PURKINJE-CELLS; NEURITE OUTGROWTH; PLASMA-MEMBRANE; DIACYLGLYCEROL; RELEASE; LOCALIZATION; MECHANISMS; EXPRESSION	In the mammalian nervous system, stimulation of G-protein-coupled type I glutamate receptors triggers various forms of neuronal plasticity, including cerebellar long-term depression and hippocampal long-term potentiation. Activation of these receptors in the cerebellum also leads to a slow excitatory postsynaptic current mediated by nonselective TRPC3 cation channels. How TRPC3 channels are opened is unknown, although it is widely thought that channel gating requires phospholipase C activation. Using the patch-clamp technique and immunohistochemistry in rat cerebellar slices, we show that metabotropic glutamate receptors activate TRPC3 channels through the small GTP-binding protein Rho and subsequent phospholipase D stimulation. TRPC3 channel gating is independent of phospholipase C activity. These results reveal a new mechanism for the gating of the ubiquitous TRPC3 channel and identify a key role for phospholipase D in the generation of the slow excitatory postsynaptic current in cerebellar Purkinje cells.-Glitsch, M. D. Activation of native TRPC3 cation channels by phospholipase D. FASEB J. 24, 318-325 (2010). www.fasebj.org	Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3RH, England	University of Oxford	Glitsch, MD (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Sherrington Bldg,Parks Rd, Oxford OX1 3RH, England.	maike.glitsch@dpag.ox.ac.uk		Glitsch, Maike/0000-0003-0723-3117				Adachi N, 2008, J BIOL CHEM, V283, P19854, DOI 10.1074/jbc.M801492200; Albert AP, 2006, J PHYSIOL-LONDON, V571, P361, DOI 10.1113/jphysiol.2005.102780; Albert AP, 2005, J PHYSIOL-LONDON, V566, P769, DOI 10.1113/jphysiol.2005.090852; Albert AP, 2003, J PHYSIOL-LONDON, V549, P143, DOI 10.1113/jphysiol.2002.038190; ALGER BE, 1995, TRENDS NEUROSCI, V18, P333, DOI 10.1016/0166-2236(95)93923-L; Becker EBE, 2009, P NATL ACAD SCI USA, V106, P6706, DOI 10.1073/pnas.0810599106; BOSS V, 1992, J NEUROCHEM, V59, P2340; Canepari M, 2001, J PHYSIOL-LONDON, V533, P765, DOI 10.1111/j.1469-7793.2001.00765.x; De Curtis I, 2008, DEV NEUROSCI-BASEL, V30, P47, DOI 10.1159/000109851; Delmas P, 2004, TRENDS NEUROSCI, V27, P41, DOI 10.1016/j.tins.2003.10.013; Glitsch MD, 2001, PFLUG ARCH EUR J PHY, V442, P404, DOI 10.1007/s004240100559; Hartmann J, 2005, CELL CALCIUM, V37, P459, DOI 10.1016/j.ceca.2005.01.014; Hartmann J, 2009, ACTA PHYSIOL, V195, P79, DOI 10.1111/j.1748-1716.2008.01923.x; Hartmann J, 2008, NEURON, V59, P392, DOI 10.1016/j.neuron.2008.06.009; Hashimotodani Y, 2007, CURR OPIN NEUROBIOL, V17, P360, DOI 10.1016/j.conb.2007.03.012; Hirono M, 1998, BIOCHEM BIOPH RES CO, V251, P753, DOI 10.1006/bbrc.1998.9465; Huang WC, 2007, CELL CALCIUM, V42, P1, DOI 10.1016/j.ceca.2006.11.002; Jenkins GM, 2005, CELL MOL LIFE SCI, V62, P2305, DOI 10.1007/s00018-005-5195-z; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kano M, 2008, PHILOS T R SOC B, V363, P2173, DOI 10.1098/rstb.2008.2270; Kim M, 2010, ACTA HISTOCHEM, V112, P81, DOI 10.1016/j.acthis.2008.09.004; Kim SJ, 2003, NATURE, V426, P285, DOI 10.1038/nature02162; Koh CG, 2006, NEUROSIGNALS, V15, P228, DOI 10.1159/000101527; Kwan HY, 2009, EUR J PHARMACOL, V602, P181, DOI 10.1016/j.ejphar.2008.10.054; Lee MY, 2000, BRAIN RES, V864, P52, DOI 10.1016/S0006-8993(00)02134-X; Lessard CB, 2005, CELL SIGNAL, V17, P437, DOI 10.1016/j.cellsig.2004.09.005; LLANO I, 1991, NEURON, V6, P565, DOI 10.1016/0896-6273(91)90059-9; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; MARTY A, 1995, CURR OPIN NEUROBIOL, V5, P335, DOI 10.1016/0959-4388(95)80046-8; Oh DY, 2007, J CELL BIOCHEM, V101, P221, DOI 10.1002/jcb.21166; Okamoto Y, 2007, CHEM BIODIVERS, V4, P1842, DOI 10.1002/cbdv.200790155; Olenik C, 1997, MOL BRAIN RES, V52, P263, DOI 10.1016/S0169-328X(97)00270-2; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; PellegriniGiampietro DE, 1996, BRIT J PHARMACOL, V118, P1035, DOI 10.1111/j.1476-5381.1996.tb15503.x; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; Ralevic V, 1998, PHARMACOL REV, V50, P413; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; RAYMOND SH, 1998, FEBS LETT, V422, P333; Safo PK, 2006, CEREBELLUM, V5, P134, DOI 10.1080/14734220600791477; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Smyth JT, 2006, J BIOL CHEM, V281, P11712, DOI 10.1074/jbc.M510541200; Soboloff J., 2007, V179, P575; Sugiyama T, 1999, BIOCHEM BIOPH RES CO, V265, P473, DOI 10.1006/bbrc.1999.1628; Tai YL, 2009, PFLUG ARCH EUR J PHY, V458, P283, DOI 10.1007/s00424-008-0618-y; Talavera K, 2008, TRENDS NEUROSCI, V31, P287, DOI 10.1016/j.tins.2008.03.002; Trebak M, 2005, MOL PHARMACOL, V67, P558, DOI 10.1124/mol.104.007252; Trebak M, 2003, CELL CALCIUM, V33, P451, DOI 10.1016/S0143-4160(03)00056-3; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Wang J, 2009, PROSTAG OTH LIPID M, V89, P112, DOI 10.1016/j.prostaglandins.2008.12.002; Weernink PAO, 2007, N-S ARCH PHARMACOL, V374, P399, DOI 10.1007/s00210-007-0131-4; Witte H, 2008, CURR OPIN NEUROBIOL, V18, P479, DOI 10.1016/j.conb.2008.09.019; Yamamoto S, 2007, BBA-MOL BASIS DIS, V1772, P958, DOI 10.1016/j.bbadis.2007.03.006; Yoon MS, 2006, BIOCHEM BIOPH RES CO, V347, P594, DOI 10.1016/j.bbrc.2006.06.111; Yoon MS, 2005, BIOCHEM BIOPH RES CO, V329, P804, DOI 10.1016/j.bbrc.2005.02.087; Zhang Y, 2005, J NEUROSCI, V25, P1797, DOI 10.1523/jneurosci.4850-04.2005; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	57	27	27	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					318	325		10.1096/fj.09-134973	http://dx.doi.org/10.1096/fj.09-134973			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19741172				2022-12-28	WOS:000273233600032
J	Quinn, JMW; Tam, S; Sims, NA; Saleh, H; McGregor, NE; Poulton, IJ; Scott, JW; Gillespie, MT; Kemp, BE; van Denderen, BJW				Quinn, Julian M. W.; Tam, Shanna; Sims, Natalie A.; Saleh, Hasnawati; McGregor, Narelle E.; Poulton, Ingrid J.; Scott, John W.; Gillespie, Matthew T.; Kemp, Bruce E.; van Denderen, B. J. W.			Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function	FASEB JOURNAL			English	Article						osteolysis; AMPK; AICA-riboside; osteoblast; knockout mouse	ADENOSINE-REGULATING AGENT; ISOLATED RAT HEPATOCYTES; AICA-RIBOSIDE; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE; MYOCARDIAL-INFARCTION; CONTROLLED-TRIAL; MINERAL DENSITY; SKELETAL-MUSCLE; FOOD-INTAKE; CELL-LINE	Since AMP-activated protein kinase (AMPK) plays important roles in modulating metabolism in response to diet and exercise, both of which influence bone mass, we examined the influence of AMPK on bone mass in mice. AMPK is an alpha beta gamma heterotrimer where the beta subunit anchors the alpha catalytic and gamma regulatory subunits. Germline deletion of either AMPK beta 1 or beta 2 subunit isoforms resulted in reduced trabecular bone density and mass, but without effects on osteoclast (OC) or osteoblast (OB) numbers, as compared to wild-type littermate controls. We tested whether activating AMPK in vivo would enhance bone density but found AICA-riboside treatment caused a profound loss of trabecular bone volume (49.5%) and density and associated increased OC numbers. Consistent with this, AICA-riboside strongly stimulated OC differentiation in vitro, in an adenosine kinase-dependent manner. OCs and macrophages (unlike OBs) lacked AMPK beta 2 subunit expression, and when generated from AMPK beta 1(-/-) mice displayed no detectable AMPK activity. Nevertheless, AICA-riboside was equally effective at stimulating OC differentiation from wildtype or beta 1(-/-) progenitors, indicating that AMPK is not essential for OC differentiation or the stimulatory action of AICA-riboside. These results show that AMPK is required to maintain normal bone density, but not through bone cell differentiation, and does not mediate powerful osteolytic effects of AICA-riboside.-Quinn, J. M. W., Tam, S., Sims, N. A., Saleh, H., McGregor, N. E., Poulton, I. J., Scott, J. W., Gillespie, M. T., Kemp, B. E., van Denderen, B. J. W. Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function. FASEB J. 24, 275-285 (2010). www.fasebj.org	[Tam, Shanna; Sims, Natalie A.; Saleh, Hasnawati; McGregor, Narelle E.; Poulton, Ingrid J.; Scott, John W.; Gillespie, Matthew T.; Kemp, Bruce E.; van Denderen, B. J. W.] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; [Quinn, Julian M. W.; Saleh, Hasnawati; Gillespie, Matthew T.] Monash Med Ctr, Prince Henrys Inst, Clayton, Vic 3168, Australia; [Quinn, Julian M. W.; Tam, Shanna; Sims, Natalie A.; Kemp, Bruce E.; van Denderen, B. J. W.] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic 3010, Australia	St. Vincent's Institute of Medical Research; Monash University; Prince Henry's Institute of Medical Research; St Vincent's Hospital Melbourne; University of Melbourne	van Denderen, BJW (corresponding author), St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.	bvandenderen@svi.edu.au	Scott, John W/AAA-2676-2021; van Denderen, Bryce/AAW-5454-2021; Kemp, Bruce/G-9602-2019; Sims, Natalie Ann/A-7192-2012; Kemp, Bruce E/L-2633-2014; Scott, John W/P-1170-2018	Scott, John W/0000-0002-1896-9798; Kemp, Bruce/0000-0001-6735-5082; Sims, Natalie Ann/0000-0003-1421-8468; Kemp, Bruce E/0000-0001-6735-5082; Scott, John W/0000-0002-1896-9798; Gillespie, Matthew/0000-0001-6543-8909	National Health and Medical Research Council (NHMRC)	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by National Health and Medical Research Council (NHMRC) grants; N. A. S. and B. E. K. are NHMRC Fellows.	Allan EH, 2003, J CELL BIOCHEM, V90, P158, DOI 10.1002/jcb.10614; Baron R, 2006, CURR TOP DEV BIOL, V76, P103, DOI 10.1016/S0070-2153(06)76004-5; Boyle JG, 2008, J BIOL CHEM, V283, P11210, DOI 10.1074/jbc.M710048200; Brown D, 1996, J EXP BIOL, V199, P2345; Campas C, 2003, BLOOD, V101, P3674, DOI 10.1182/blood-2002-07-2339; Carey AL, 2006, DIABETES, V55, P2688, DOI 10.2337/db05-1404; Chen ZP, 1999, FEBS LETT, V460, P343, DOI 10.1016/S0014-5793(99)01371-X; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DIXON R, 1991, J CLIN PHARMACOL, V31, P342, DOI 10.1002/j.1552-4604.1991.tb03715.x; Drew BG, 2008, EXPERT OPIN PHARMACO, V9, P2137, DOI [10.1517/14656566.9.12.2137, 10.1517/14656566.9.12.2137 ]; Elefteriou F, 2004, P NATL ACAD SCI USA, V101, P3258, DOI 10.1073/pnas.0308744101; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Gao S, 2007, P NATL ACAD SCI USA, V104, P17358, DOI 10.1073/pnas.0708385104; Glintborg D, 2008, J CLIN ENDOCR METAB, V93, P1696, DOI 10.1210/jc.2007-2249; Grey A, 2007, J CLIN ENDOCR METAB, V92, P1305, DOI 10.1210/jc.2006-2646; Guigas B, 2007, BIOCHEM J, V404, P499, DOI 10.1042/BJ20070105; Gutierrez GE, 2008, J BONE MINER RES, V23, P1722, DOI 10.1359/JBMR.080603; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Herman S, 2008, TRENDS MOL MED, V14, P245, DOI 10.1016/j.molmed.2008.04.001; Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Iseli TJ, 2005, J BIOL CHEM, V280, P13395, DOI 10.1074/jbc.M412993200; Jorgensen SB, 2007, AM J PHYSIOL-ENDOC M, V292, pE331, DOI 10.1152/ajpendo.00243.2006; Kanazawa I, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-51; Karsenty G, 2006, CELL METAB, V4, P341, DOI 10.1016/j.cmet.2006.10.008; Leboy PS, 2006, ANN NY ACAD SCI, V1068, P14, DOI 10.1196/annals.1346.003; Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047; Longnus SL, 2003, AM J PHYSIOL-REG I, V284, pR936, DOI 10.1152/ajpregu.00319.2002; Mangano DT, 2006, J AM COLL CARDIOL, V48, P206, DOI 10.1016/j.jacc.2006.04.044; Mangano DT, 1997, JAMA-J AM MED ASSOC, V277, P325, DOI 10.1001/jama.277.4.325; Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004; Meier C, 2008, ARCH INTERN MED, V168, P820, DOI 10.1001/archinte.168.8.820; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051; Nath N, 2005, J IMMUNOL, V175, P566, DOI 10.4049/jimmunol.175.1.566; Price JT, 2005, CANCER RES, V65, P4929, DOI 10.1158/0008-5472.CAN-04-4458; Quinn JMW, 1999, BONE, V25, P1, DOI 10.1016/S8756-3282(99)00094-0; Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787; Quinn JMW, 2002, BONE, V30, P164, DOI 10.1016/S8756-3282(01)00654-8; Quinn JMW, 2008, J IMMUNOL, V181, P5720, DOI 10.4049/jimmunol.181.8.5720; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Scott JW, 2009, FRONT BIOSCI-LANDMRK, V14, P596, DOI 10.2741/3266; Scott JW, 2008, CHEM BIOL, V15, P1220, DOI 10.1016/j.chembiol.2008.10.005; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Seibel MJ, 2002, CURR OPIN CLIN NUTR, V5, P525, DOI 10.1097/00075197-200209000-00011; Shang J, 2004, J BIOL CHEM, V279, P12076, DOI 10.1074/jbc.M400431200; Sims NA, 2006, AM J PHYSIOL-ENDOC M, V290, pE456, DOI 10.1152/ajpendo.00311.2005; Sims NA, 2003, J CLIN INVEST, V111, P1319, DOI 10.1172/JCI200317246; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Steinberg GR, 2006, CELL METAB, V4, P465, DOI 10.1016/j.cmet.2006.11.005; Sun W, 2006, CIRCULATION, V114, P2655, DOI 10.1161/CIRCULATIONAHA.106.630194; VINCENT MF, 1991, DIABETES, V40, P1259, DOI 10.2337/diabetes.40.10.1259; VINCENT MF, 1992, BIOCHEM J, V281, P267, DOI 10.1042/bj2810267; Walker EC, 2008, J BONE MINER RES, V23, P2025, DOI 10.1359/JBMR.080706; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; ZIMMERMAN TP, 1978, BIOCHEM PHARMACOL, V27, P709, DOI 10.1016/0006-2952(78)90508-7	58	43	49	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					275	285		10.1096/fj.09-137158	http://dx.doi.org/10.1096/fj.09-137158			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19723702	Green Published			2022-12-28	WOS:000273233600028
J	Okamura, E; Matsuzaki, H; Campbell, AD; Engel, JD; Fukamizu, A; Tanimoto, K				Okamura, Eiichi; Matsuzaki, Hitomi; Campbell, Andrew D.; Engel, James Douglas; Fukamizu, Akiyoshi; Tanimoto, Keiji			All of the human beta-type globin genes compete for LCR enhancer activity in embryonic erythroid cells of yeast artificial chromosome transgenic mice	FASEB JOURNAL			English	Article						hemoglobin; gene switching; chromosome conformation capture; 3C	LOCUS-CONTROL REGION; INTERGENIC TRANSCRIPTION; DEVELOPMENTAL REGULATION; HYPERSENSITIVE SITES; GAMMA-GLOBIN; EXPRESSION; DISTANCE; DIFFERENTIATION; ELEMENTS; LINKING	In primitive erythroid cells of human beta-globin locus transgenic mice (TgM), the locus control region (LCR)-proximal epsilon- and gamma-globin genes are transcribed, whereas the distal delta- and beta-globin genes are silent. It is generally accepted that the beta-globin gene is competitively suppressed by gamma-globin gene expression at this developmental stage. Previously, however, we observed that epsilon-globin gene expression was severely attenuated when its distance from the LCR was extended, implying that beta-globin gene might also be silenced because of its great distance from the LCR. Here, to clarify the beta-globin gene silencing mechanism, we established TgM lines carrying either gamma- or epsilon- plus gamma-globin promoter deletions, without significantly altering the distance between the beta-globin gene and the LCR. Precocious expression of delta- and beta-globin genes was observed in primitive erythroid cells of mutant, but not wild-type TgM, which was most evident when both the epsilon and gamma promoters were deleted. Thus, we clearly demonstrated that the repression of the delta- and beta-globin genes in primitive erythroid cells is dominated by competitive silencing by the epsilon- and gamma-globin gene promoters, and that epsilon- and the other beta-like globin genes might be activated by two distinct mechanisms by the LCR.-Okamura, E., Matsuzaki, H., Campbell, A. D., Engel, J. D., Fukamizu, A., Tanimoto, K. All of the human beta-type globin genes compete for LCR enhancer activity in embryonic erythroid cells of yeast artificial chromosome transgenic mice. FASEB J. 23, 4335-4343 (2009). www.fasebj.org	[Okamura, Eiichi; Matsuzaki, Hitomi; Fukamizu, Akiyoshi; Tanimoto, Keiji] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058577, Japan; [Campbell, Andrew D.; Engel, James Douglas] Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Tsukuba; University of Michigan System; University of Michigan	Tanimoto, K (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, Tennoudai 1-1-1, Tsukuba, Ibaraki 3058577, Japan.	keiji@tara.tsukuba.ac.jp	Tanimoto, Keiji/B-2600-2014; fukamizu, akiyoshi/J-5350-2012; Campbell, Andrew/AAX-8590-2020	fukamizu, akiyoshi/0000-0002-8786-6020; Campbell, Andrew/0000-0002-8829-0043; Okamura, Eiichi/0000-0002-1713-9290; Tanimoto, Keiji/0000-0003-1971-6546; Matsuzaki, Hitomi/0000-0002-8890-5933	U.S. National Institutes of Health [HL24415]; Ministry of Education, Culture, Sports, Science and Technology of Japan; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024415] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	thank Y. Tanimoto for technical assistance in generating TgM. This work was partially supported by research grants from the U.S. National Institutes of Health (HL24415 to J. D. E.) and the Ministry of Education, Culture, Sports, Science and Technology of Japan, Grant-in-Aid for Scientific Research (A) and for Young Scientists (S) (to K. T.).	Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; CLOUSTON W M, 1988, Genomics, V2, P240, DOI 10.1016/0888-7543(88)90008-0; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Dillon N, 1997, MOL CELL, V1, P131, DOI 10.1016/S1097-2765(00)80014-3; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; GAENSLER KML, 1993, P NATL ACAD SCI USA, V90, P11381, DOI 10.1073/pnas.90.23.11381; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; Hardison R, 1998, J EXP BIOL, V201, P1099; Hu X, 2007, BLOOD, V109, P2210, DOI 10.1182/blood-2006-06-029868; Kingsley PD, 2006, BLOOD, V107, P1665, DOI 10.1182/blood-2005-08-3097; Li QL, 2002, BLOOD, V100, P3077, DOI 10.1182/blood-2002-04-1104; Palstra RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/ng1244; Plant KE, 2001, MOL CELL BIOL, V21, P6507, DOI 10.1128/MCB.21.19.6507-6514.2001; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; Shimotsuma M, 2007, MOL CELL BIOL, V27, P5664, DOI 10.1128/MCB.00602-07; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS; Stamatoyannopoulos G, 2005, EXP HEMATOL, V33, P259, DOI 10.1016/j.exphem.2004.11.007; Tanimoto K, 2000, GENE DEV, V14, P2778, DOI 10.1101/gad.822500; Tanimoto K, 1999, NUCLEIC ACIDS RES, V27, P3130, DOI 10.1093/nar/27.15.3130; Tanimoto K, 2003, MOL CELL BIOL, V23, P8946, DOI 10.1128/MCB.23.24.8946-8952.2003; Tanimoto K, 1999, NATURE, V398, P344, DOI 10.1038/18698; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; TUAN D, 1992, P NATL ACAD SCI USA, V89, P11219, DOI 10.1073/pnas.89.23.11219; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; Yu M, 2006, MOL CELL BIOL, V26, P4775, DOI 10.1128/MCB.00406-06; Yu RN, 1998, NAT GENET, V20, P353, DOI 10.1038/3822; Zhu XG, 2007, NUCLEIC ACIDS RES, V35, P5532, DOI 10.1093/nar/gkm595	35	5	5	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4335	4343		10.1096/fj.09-137778	http://dx.doi.org/10.1096/fj.09-137778			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19690216	Green Published, Green Submitted			2022-12-28	WOS:000272193700028
J	Liu, N; Wang, GY; Lee, KC; Guan, Y; Chen, HL; Cai, ZW				Liu, Ning; Wang, Genyan; Lee, Kim Chung; Guan, Yi; Chen, Honglin; Cai, Zongwei			Mutations in influenza virus replication and transcription: detection of amino acid substitutions in hemagglutinin of an avian influenza virus (H1N1)	FASEB JOURNAL			English	Article						polymorphism of viral antigen; mass spectrometric sequencing; infection; receptor; mutation; replication and transcription	ANTIGENIC DRIFT; A VIRUSES; IDENTIFICATION; EVOLUTION; SEQUENCE; GENE	Influenza A viruses are RNA viruses that contain negative-sense, single-stranded, and segmented RNA genome, which depends on virally encoded RNA-dependent RNA polymerase and cellular DNA-dependent RNA polymerase for replication of viral genome and transcription of viral mRNA, respectively. Hemagglutinin ( HA), one of the major surface proteins of the influenza virus, is responsible for virus attachment to the receptor of host cells to initiate an infection. Amino acid ( AA) substitutions in HA may cause changes in virus antigenicity and even receptor specificity. To detect the AA substitutions within HA at protein level, nanoelectrospray-MS/MS was used to analyze tryptic digestion of HA antigen directly purified from virus particles of an avian influenza virus, A/WDK/JX/12416/2005 (H1N1), of which the HA gene was sequenced as a reference. The comparison of the sequences obtained from analysis of viral genome and peptide found seven variations between HA gene and protein, namely E103K, R130K, T169I, I338V, N387S, S398I/L, and I399S in HA. Because influenza virus uses different polymerase machineries for replication and transcription, these substitutions could be introduced in the viral genome through replication process but not in viral mRNA in the transcription. The results, for the first time, provided experimental evidence showing differences in AA sequence obtained from direct analysis of viral protein derived from viral genome.-Liu, N., Wang, G., Lee, K. C., Guan, Y., Chen, H., Cai, Z. Mutations in influenza virus replication and transcription: detection of amino acid substitutions in hemagglutinin of an avian influenza virus ( H1N1). FASEB J. 23, 3377-3382 ( 2009). www.fasebj.org	[Guan, Yi; Chen, Honglin] Univ Hong Kong, Dept Microbiol, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China; [Guan, Yi; Chen, Honglin] Univ Hong Kong, Res Ctr Infect & Immunol, Hong Kong, Hong Kong, Peoples R China; [Liu, Ning; Lee, Kim Chung; Cai, Zongwei] Hong Kong Baptist Univ, Dept Chem, Hong Kong, Hong Kong, Peoples R China; [Liu, Ning] Jilin Univ, Changchun 130023, Peoples R China; [Wang, Genyan; Guan, Yi; Chen, Honglin] Shantou Univ, Int Inst Infect & Immun, Shantou, Peoples R China	University of Hong Kong; University of Hong Kong; Hong Kong Baptist University; Jilin University; Shantou University	Chen, HL (corresponding author), Univ Hong Kong, Dept Microbiol, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.	hlchen@hkucc.hku.hk; zwcai@hkbu.edu.hk	Chen, Honglin/C-4224-2009; Cai, Zongwei/ABD-4001-2020	Chen, Honglin/0000-0001-5108-8338; Cai, Zongwei/0000-0002-8724-7684; Liu, Ning/0000-0002-7925-8535; Guan, Yi/0000-0001-6057-9243	Research Grants Council of the Hong Kong SAR [HKU 7500/06M, HKU 7488/05M]; Area of Excellence Scheme of the University [AoE/M-12/06]; research fund for the control of infectious diseases, Hong Kong SAR; Li Ka Shing Foundation; Hong Kong Baptist University [FRG/07-08/II-21]	Research Grants Council of the Hong Kong SAR(Hong Kong Research Grants Council); Area of Excellence Scheme of the University; research fund for the control of infectious diseases, Hong Kong SAR; Li Ka Shing Foundation; Hong Kong Baptist University	This work was supported by the Research Grants Council of the Hong Kong SAR (HKU 7500/06M and HKU 7488/05M); the Area of Excellence Scheme of the University Grants Committee (AoE/M-12/06); the research fund for the control of infectious diseases, Hong Kong SAR; the Li Ka Shing Foundation; and a faculty research grant from Hong Kong Baptist University (FRG/07-08/II-21).	Carr MJ, 2008, J VIROL METHODS, V153, P257, DOI 10.1016/j.jviromet.2008.07.011; Ha Y, 2003, VIROLOGY, V309, P209, DOI 10.1016/S0042-6822(03)00068-0; Hoffmann E, 2001, ARCH VIROL, V146, P2275, DOI 10.1007/s007050170002; KINNUNEN L, 1992, RES VIROLOGY, V143, P11, DOI 10.1016/S0923-2516(06)80071-3; Liu N, 2009, J AM SOC MASS SPECTR, V20, P312, DOI 10.1016/j.jasms.2008.10.010; Liu N, 2009, TALANTA, V78, P1492, DOI 10.1016/j.talanta.2009.01.057; McDonald NJ, 2007, J GEN VIROL, V88, P3209, DOI 10.1099/vir.0.83184-0; Obenauer JC, 2006, SCIENCE, V311, P1576, DOI 10.1126/science.1121586; ROCHA E, 1991, J VIROL, V65, P2340, DOI 10.1128/JVI.65.5.2340-2350.1991; Rudneva IA, 2005, J GEN VIROL, V86, P2831, DOI 10.1099/vir.0.81185-0; SLEIGH MJ, 1981, J VIROL, V37, P845, DOI 10.1128/JVI.37.3.845-853.1981; WHITE JM, 1997, STRUCTURAL BIOL VIRU, P80	12	10	12	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3377	3382		10.1096/fj.09-134072	http://dx.doi.org/10.1096/fj.09-134072			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19553505				2022-12-28	WOS:000270354300015
J	van Miltenburg, MHAM; Lalai, R; de Bont, H; van Waaij, E; Beggs, H; Danen, EHJ; van de Water, B				van Miltenburg, Martine H. A. M.; Lalai, Reshma; de Bont, Hans; van Waaij, Eveline; Beggs, Hilary; Danen, Erik H. J.; van de Water, Bob			Complete focal adhesion kinase deficiency in the mammary gland causes ductal dilation and aberrant branching morphogenesis through defects in Rho kinase-dependent cell contractility	FASEB JOURNAL			English	Article						adhesion signaling; lactation; myoepithelial cells; luminal epithelial cells	GENE-EXPRESSION; BETA-1-INTEGRIN; DIFFERENTIATION; INTEGRIN; TISSUE; FAK; ORGANIZATION; REGULATOR; DELETION; POLARITY	The adult, virgin mammary gland is a highly organized branched ductal network comprising two major cell types: myoepithelial and luminal epithelial cells. To study the role and mechanism of focal adhesion kinase (FAK)-mediated signaling in mammary gland development and differentiation, we used a conditional Fak-knockout mammary epithelial cell (MEC) transplantation model. Conditional Cre recombinase (Cre)-mediated Fak deletion in primary cultured MECs isolated from FAK(lox/lox)/Rosa26Cre-ERT2 donor mice caused loss of FAK in all mammary cells. Transplantation of Fak-knockout MECs in a cleared mammary fat pad of immunedeficient recipient mice resulted in development of new but dilated virgin ducts with a disrupted myoepithelial and luminal epithelial cell multilayer and aberrant ductal morphogenesis during pregnancy. In the absence of FAK, MECs spread poorly, showed enhanced Rho kinase (ROCK)-mediated cytoskeletal contractility, and failed to respond to receptor-mediated cytoskeletal remodeling. Likewise, FAK deficiency fully inhibited branching morphogenesis of mammary gland organoids in a ROCK-dependent manner. Altogether these data suggest a model in which FAK coordinates contractile forces in MECs to maintain the bilayered cellular organization of myoepithelial and luminal epithelial cells in ducts, thus allowing proper mammary gland development and function.-Van Miltenburg, M. H. A. M., Lalai, R., de Bont, H., van Waaij, E., Beggs, H., Danen, E. H. J., van de Water, B. Complete focal adhesion kinase deficiency in the mammary gland causes ductal dilation and aberrant branching morphogenesis through defects in ROCK-dependent cell contractility. FASEB J. 23, 3482-3493 ( 2009). www.fasebj.org	[van Miltenburg, Martine H. A. M.; Lalai, Reshma; de Bont, Hans; van Waaij, Eveline; Danen, Erik H. J.; van de Water, Bob] Leiden Univ, LACDR, Div Toxicol, NL-2300 RA Leiden, Netherlands; [Beggs, Hilary] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA	Leiden University; Leiden University - Excl LUMC; University of California System; University of California San Francisco	van de Water, B (corresponding author), Leiden Univ, LACDR, Div Toxicol, Einsteinweg 55,POB 9502, NL-2300 RA Leiden, Netherlands.	water_b@lacdr.leidenuniv.nl		danen, erik/0000-0002-0491-6345	Dutch Cancer Society [KWF-UL 2006-3538, UL 2007-3860]; European Union FP7 Health [201862]; Netherlands Organisation for Scientific Research [911-02-022]; Netherlands Toxicogenomics Center	Dutch Cancer Society(KWF Kankerbestrijding); European Union FP7 Health; Netherlands Organisation for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Netherlands Toxicogenomics Center	We thank Sjef Verbeek ( Leiden University Medical Center, Leiden, The Netherlands) for Rosa26Cre-ERT2 mice, Jos Jonkers ( The Netherlands Cancer Institute, Amsterdum, The Netherlands) for Rag2<SUP>-/-</SUP>gamma c<SUP>-/-</SUP> mice, and Daniel Streblow ( Oregon Health and Science University, Portland, OR, USA) for adenoviral HA-tagged FAK. We thank Marjo de Graauw and Leo Price for suggestions and critical reading of the manuscript and the members of the Division of Toxicology of the Leiden/Amsterdam Center for Drug Research for valuable discussion and support. This work was supported by grants from the Dutch Cancer Society (KWF-UL 2006-3538 and UL 2007-3860), European Union FP7 Health ( grant 201862; Metafight project), the Netherlands Organisation for Scientific Research ( grant 911-02-022), and the Netherlands Toxicogenomics Center.	Akhtar N, 2006, J CELL BIOL, V173, P781, DOI 10.1083/jcb.200601059; Beggs HE, 2003, NEURON, V40, P501, DOI 10.1016/S0896-6273(03)00666-4; Bissell MJ, 2003, BREAST CANCER RES, V5, P117, DOI 10.1186/bcr579; Braren R, 2006, J CELL BIOL, V172, P151, DOI 10.1083/jcb.200506184; Chen BH, 2002, J BIOL CHEM, V277, P33857, DOI 10.1074/jbc.M204429200; Danen EHJ, 2003, J PATHOL, V201, P632, DOI 10.1002/path.1472; de Graauw M, 2005, J BIOL CHEM, V280, P29885, DOI 10.1074/jbc.M412708200; DEUGNIER MA, 1995, DEV DYNAM, V204, P107, DOI 10.1002/aja.1002040202; Ewald AJ, 2008, DEV CELL, V14, P570, DOI 10.1016/j.devcel.2008.03.003; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; ILLC D, 1995, NATURE, V377, P539; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Li N, 2005, EMBO J, V24, P1942, DOI 10.1038/sj.emboj.7600674; Lollivier V, 2006, J PHYSIOL-LONDON, V570, P125, DOI 10.1113/jphysiol.2005.097816; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Nagy T, 2007, J BIOL CHEM, V282, P31766, DOI 10.1074/jbc.M705403200; Naylor MJ, 2005, J CELL BIOL, V171, P717, DOI 10.1083/jcb.200503144; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Ren XD, 2000, J CELL SCI, V113, P3673; Rico B, 2004, NAT NEUROSCI, V7, P1059, DOI 10.1038/nn1317; Schober M, 2007, J CELL BIOL, V176, P667, DOI 10.1083/jcb.200608010; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; Taddei I, 2008, NAT CELL BIOL, V10, P716, DOI 10.1038/ncb1734; Tilghman RW, 2008, SEMIN CANCER BIOL, V18, P45, DOI 10.1016/j.semcancer.2007.08.002; Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Yano H, 2004, J CELL BIOL, V166, P283, DOI 10.1083/jcb.200312013; Yu W, 2005, MOL BIOL CELL, V16, P433, DOI 10.1091/mbc.e04-05-0435	31	24	24	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3482	3493		10.1096/fj.08-123398	http://dx.doi.org/10.1096/fj.08-123398			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19584305				2022-12-28	WOS:000270354300025
J	Chang, YC; Kao, WC; Wang, WY; Wang, WY; Yang, RB; Peck, K				Chang, Yi-Chung; Kao, Wei-Chen; Wang, Wei-Ya; Wang, Wan-Yi; Yang, Ruey-Bing; Peck, Konan			Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses	FASEB JOURNAL			English	Article						aptamer microarray; microbial infection; IP-SELEX	GINGIVALIS LIPOPOLYSACCHARIDE; PORPHYROMONAS-GINGIVALIS; CELL MATURATION; KAPPA-B; RNA; ACTIVATION; PROTEIN; APTAMERS; LIGANDS; MICE	Toll-like receptors (TLRs) play important roles in the immune responses against invading microorganisms. Development of TLR antagonists is recognized as a promising direction in suppressing the associated inflammatory reactions of the TLRs. Aptamers are single-stranded RNA or DNA molecules isolated through an in vitro selection process. Using a novel molecular evolution strategy that combines immuno-precipitation (IP) with systematic evolution of ligands by exponential enrichment (SELEX), we developed an IP-SELEX selection method to facilitate the screening of high-affinity aptamers for the Toll-like receptor 2 (TLR2). Also, human TLR2 functional aptamers were identified and characterized using NF-kappa B reporter assays. Among the functional aptamers, the most effective, AP177, with a dissociation constant of 73 pM, was characterized with TLR2-expressing cells challenged with bacterial cells and purified ligands. The aptamer could effectively antagonize TLR2, significantly inhibit NF-kappa B activity, and suppress the secretion of the cytokines by >80%. In addition, the precise region within the functional aptamer that specifically bound TLR2 was resolved using aptamer microarray analysis. The results of functional assays showed that AP177 acted as a TLR2 antagonist and may hold therapeutic potential in the treatment of diseases related to dysregulated TLR2 immune responses.-Chang, Y.-C., Kao, W.-C., Wang, W.-Y., Wang, W.-Y., Yang, R.-B., Peck, K. Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses. FASEB J. 23, 3078-3088 ( 2009). www.fasebj.org	[Chang, Yi-Chung; Kao, Wei-Chen; Wang, Wei-Ya; Wang, Wan-Yi; Yang, Ruey-Bing; Peck, Konan] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Chang, Yi-Chung; Peck, Konan] Natl Taiwan Univ, Dept Microbiol, Taipei 10764, Taiwan	Academia Sinica - Taiwan; National Taiwan University	Peck, K (corresponding author), Acad Sinica, Inst Biomed Sci, 128,Sec 2,Acad Rd, Taipei 115, Taiwan.	konan@ibms.sinica.edu.tw	Yang, Ruey-Bing/O-1494-2018; Wang, Pa-Chun/AAD-4094-2019	Yang, Ruey-Bing/0000-0003-3017-3714; 	National Science Council [NSC-96-2628-B-001-024-MY3]; Department of Health, and Academia Sinica, Taipei, Taiwan, ROC	National Science Council(Ministry of Science and Technology, Taiwan); Department of Health, and Academia Sinica, Taipei, Taiwan, ROC	This work was supported by the National Science Council (NSC-96-2628-B-001-024-MY3), the NRPGM grant from the Department of Health, and Academia Sinica, Taipei, Taiwan, ROC. The authors declare no competing financial interests.	Abrahams VM, 2004, J IMMUNOL, V173, P4286, DOI 10.4049/jimmunol.173.7.4286; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Asagiri M, 2008, SCIENCE, V319, P624, DOI 10.1126/science.1150110; Barrat FJ, 2005, J EXP MED, V202, P1131, DOI 10.1084/jem.20050914; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Bourquin C, 2008, J IMMUNOL, V181, P2990, DOI 10.4049/jimmunol.181.5.2990; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987; Burdelya LG, 2008, SCIENCE, V320, P226, DOI 10.1126/science.1154986; Cerchia L, 2005, PLOS BIOL, V3, P697, DOI 10.1371/journal.pbio.0030123; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Hamdy S, 2008, VACCINE, V26, P5046, DOI 10.1016/j.vaccine.2008.07.035; Hayashi EA, 2005, J IMMUNOL, V174, P6639, DOI 10.4049/jimmunol.174.11.6639; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; HAYLETT DG, 2003, TXB RECEPTOR PHARM, P153; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hertz CJ, 2001, J IMMUNOL, V166, P2444, DOI 10.4049/jimmunol.166.4.2444; Huang YH, 2006, ENDOCRINOLOGY, V147, P4792, DOI 10.1210/en.2005-1476; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; Katilius E, 2007, NUCLEIC ACIDS RES, V35, P7626, DOI 10.1093/nar/gkm922; Kido J, 2003, J PERIODONTAL RES, V38, P557, DOI 10.1034/j.1600-0765.2003.00691.x; Koch TH, 2004, J MOL BIOL, V336, P1159, DOI 10.1016/j.jmb.2004.01.001; Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102; Liu X, 2008, ATHEROSCLEROSIS, V196, P146, DOI 10.1016/j.atherosclerosis.2007.03.025; Mathews DH, 2004, P NATL ACAD SCI USA, V101, P7287, DOI 10.1073/pnas.0401799101; McNamara JO, 2008, J CLIN INVEST, V118, P376, DOI 10.1172/JCI33365; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Meng GX, 2004, J CLIN INVEST, V113, P1473, DOI 10.1172/JCI200420762; Mi J, 2006, NUCLEIC ACIDS RES, V34, P3577, DOI 10.1093/nar/gkl482; Mullick AE, 2005, J CLIN INVEST, V115, P3149, DOI 10.1172/JCI25482; Nemoto E, 2006, J DENT RES, V85, P733, DOI 10.1177/154405910608500809; Nishikawa F, 2003, NUCLEIC ACIDS RES, V31, P1935, DOI 10.1093/nar/gkg291; Okusawa T, 2004, INFECT IMMUN, V72, P1657, DOI 10.1128/IAI.72.3.1657-1665.2004; Quesniaux VJ, 2004, J IMMUNOL, V172, P4425, DOI 10.4049/jimmunol.172.7.4425; Rodriguez D, 2003, J IMMUNOL, V171, P1001, DOI 10.4049/jimmunol.171.2.1001; Rusconi CP, 2004, NAT BIOTECHNOL, V22, P1423, DOI 10.1038/nbt1023; Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421; Shangguan D, 2006, P NATL ACAD SCI USA, V103, P11838, DOI 10.1073/pnas.0602615103; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Triantafilou M, 2006, J BIOL CHEM, V281, P31002, DOI 10.1074/jbc.M602794200; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Yadav M, 2006, BLOOD, V108, P3168, DOI 10.1182/blood-2006-05-024406; Zhang D, 2008, INNATE IMMUN-LONDON, V14, P99, DOI 10.1177/1753425907088244; Zhou QD, 2007, J IMMUNOL, V179, P7777, DOI 10.4049/jimmunol.179.11.7777	49	49	53	3	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3078	3088		10.1096/fj.09-129312	http://dx.doi.org/10.1096/fj.09-129312			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19406842				2022-12-28	WOS:000270241000030
J	Alard, JE; Dueymes, M; Mageed, RA; Saraux, A; Youinou, P; Jamin, C				Alard, Jean-Eric; Dueymes, Maryvonne; Mageed, Rizgar A.; Saraux, Alain; Youinou, Pierre; Jamin, Christophe			Mitochondrial heat shock protein (HSP) 70 synergizes with HSP60 in transducing endothelial cell apoptosis induced by anti-HSP60 autoantibody	FASEB JOURNAL			English	Article						antibodies; stress; endothelium; vasculitis; cell surface interaction; CCR5	SYSTEMIC-LUPUS-ERYTHEMATOSUS; TOLL-LIKE RECEPTOR-4; INNATE IMMUNE CELLS; EXTRACELLULAR HSP70; CHEMOKINE RECEPTORS; SIGNALING PATHWAY; MONONUCLEAR-CELLS; STRESS-PROTEINS; ANTIBODIES; BINDING	Heat shock protein (HSP) 60, up-regulated by endothelial cells (ECs) to resist stress, is the target of a subgroup of apoptosis-inducing anti-EC autoantibodies (Abs) in human vasculitides. Given that HSP60 is not a transmembrane protein, the mechanism by which these auto-Abs induces apoptosis is unclear. EC membrane proteins were analyzed using bidimensional electrophoresis and Far Western blot, and the HSP60 receptor was identified by mass spectrometry. Heat stress-dependent synthesis of HSP60 and receptor was examined by semiquantitative RT-PCR, and expression was examined by flow cytometry and indirect immunofluorescence. Interaction was demonstrated by coimmunoprecipitations. Lipid rafts were purified to evaluate specific localization, and the apoptotic response was investigated by blocking monoclonal Ab. Mitochondrial HSP70 (mtHSP70) was identified as an HSP60 receptor. Stress was required for ECs to up-regulate mRNA and express mtHSP70 on their surface. HSP60 and mtHSP70 colocalized and interacted within lipid rafts. They were associated with chemokine CC motif receptor 5 (CCR5), also induced at the mRNA and protein levels in stressed ECs. CCR5 was involved in the anti-HSP60-triggered apoptosis of ECs. These results provide new insights into the mechanism by which anti-EC auto-Abs from vasculitides induce apoptosis of ECs.-Alard, J.-E., Dueymes, M., Mageed, R. A., Saraux, A., Youinou, P., Jamin, C. Mitochondrial heat shock protein (HSP) 70 synergizes with HSP60 in transducing endothelial cell apoptosis induced by anti-HSP60 autoantibody. FASEB J. 23, 2772-2779 ( 2009)	[Alard, Jean-Eric; Dueymes, Maryvonne; Saraux, Alain; Youinou, Pierre; Jamin, Christophe] Univ Brest, EA Immunol & Pathol 2216, IFR ScInBioS 148, Brest, France; [Alard, Jean-Eric; Dueymes, Maryvonne; Saraux, Alain; Youinou, Pierre; Jamin, Christophe] Hop Morvan, CHU Brest, Brest, France; [Mageed, Rizgar A.] Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, Bone & Joint Res Unit, London, England	Universite de Bretagne Occidentale; CHU Brest; Universite de Bretagne Occidentale; University of London; Queen Mary University London	Youinou, P (corresponding author), Brest Univ, Med Sch Hosp, Immunol Lab, 5 Av Foch,BP 824, F-29609 Brest, France.	youinou@univ-brest.fr	Dueymes, maryvonne/GMW-7826-2022		Conseil Regional de Bretagne	Conseil Regional de Bretagne(Region Bretagne)	This work was supported by a grant from the Conseil Regional de Bretagne. We gratefully thank the maternity staff at Clinique Pasteur and Clinique de Keraudren for their help with umbilical cord collecting over the years. We also appreciate the secretarial assistance of Simone Forest and Cindy Sene.	Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Arispe N, 2004, FASEB J, V18, P1636, DOI 10.1096/fj.04-2088com; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Bordron A, 1998, J CLIN INVEST, V101, P2029, DOI 10.1172/JCI2261; Broquet AH, 2003, J BIOL CHEM, V278, P21601, DOI 10.1074/jbc.M302326200; Bulut Y, 2002, J IMMUNOL, V168, P1435, DOI 10.4049/jimmunol.168.3.1435; Calderwood SK, 2007, ANN NY ACAD SCI, V1113, P28, DOI 10.1196/annals.1391.019; DCRUZ DP, 1991, CLIN EXP IMMUNOL, V85, P254; Delneste Y, 2002, IMMUNITY, V17, P353, DOI 10.1016/S1074-7613(02)00388-6; DELPAPA N, 1992, CLIN IMMUNOL IMMUNOP, V63, P267, DOI 10.1016/0090-1229(92)90232-D; Dieude M, 2004, ARTHRITIS RHEUM-US, V50, P3221, DOI 10.1002/art.20564; Dugue C, 2004, INFECT IMMUN, V72, P301, DOI 10.1128/IAI.72.1.301-309.2004; Evdonin AL, 2006, EUR J CELL BIOL, V85, P443, DOI 10.1016/j.ejcb.2006.02.008; Fan J, 2003, J CLIN INVEST, V112, P1234, DOI 10.1172/JCI200318696; Fujieda M, 1997, CLIN EXP IMMUNOL, V107, P120, DOI 10.1046/j.1365-2249.1997.d01-894.x; Gehrmann M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001925; GILLARD BK, 1991, EXP CELL RES, V192, P433, DOI 10.1016/0014-4827(91)90062-Y; Gross C, 2003, BIOL CHEM, V384, P267, DOI 10.1515/BC.2003.030; Habich C, 2007, CELL MOL LIFE SCI, V64, P742, DOI 10.1007/s00018-007-6413-7; Habich C, 2002, J IMMUNOL, V168, P569, DOI 10.4049/jimmunol.168.2.569; Hillyer P, 2003, CLIN EXP IMMUNOL, V134, P431, DOI 10.1111/j.1365-2249.2003.02323.x; Huang MB, 2001, J ACQ IMMUN DEF SYND, V27, P213; Jamin C, 2005, ARTHRITIS RHEUM-US, V52, P4028, DOI 10.1002/art.21401; Kampinga HH, 2009, CELL STRESS CHAPERON, V14, P105, DOI 10.1007/s12192-008-0068-7; Kanda T, 2004, J NEUROSCI RES, V78, P141, DOI 10.1002/jnr.20228; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Meroni P, 2005, TRENDS IMMUNOL, V26, P275, DOI 10.1016/j.it.2005.03.006; Moroi Y, 2000, P NATL ACAD SCI USA, V97, P3485, DOI 10.1073/pnas.070550797; Nguyen DH, 2002, BLOOD, V99, P4298, DOI 10.1182/blood-2001-11-0087; Niu PY, 2006, CELL STRESS CHAPERON, V11, P162, DOI 10.1379/CSC-175R.1; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; PENNING CA, 1984, CLIN EXP IMMUNOL, V57, P548; Pockley AG, 2008, TRENDS BIOCHEM SCI, V33, P71, DOI 10.1016/j.tibs.2007.10.005; Salojin KV, 1997, AM J MED, V102, P178; Salojin KV, 1996, CLIN EXP RHEUMATOL, V14, P163; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; Sprenger RR, 2006, BIOCHEM J, V400, P401, DOI 10.1042/BJ20060355; Theriault JR, 2005, FEBS LETT, V579, P1951, DOI 10.1016/j.febslet.2005.02.046; Triantafilou M, 2002, J CELL SCI, V115, P2603; Tripathy NK, 2001, J RHEUMATOL, V28, P805; Tsan MF, 2004, AM J PHYSIOL-CELL PH, V286, pC739, DOI 10.1152/ajpcell.00364.2003; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Wagner M, 1999, AM J PHYSIOL-LUNG C, V277, pL1026, DOI 10.1152/ajplung.1999.277.5.L1026; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; Wang YF, 2001, IMMUNITY, V15, P971, DOI 10.1016/S1074-7613(01)00242-4; Whittall T, 2006, EUR J IMMUNOL, V36, P2304, DOI 10.1002/eji.200635953; Worda M, 2003, ARTHRITIS RHEUM-US, V48, P2605, DOI 10.1002/art.11179; YOUINOU P, 1995, IMMUNOL TODAY, V16, P363, DOI 10.1016/0167-5699(95)80001-8	52	16	16	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2772	2779		10.1096/fj.08-128785	http://dx.doi.org/10.1096/fj.08-128785			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19346294				2022-12-28	WOS:000268836700045
J	Johnston, RK; Balasubramanian, S; Kasiganesan, H; Baicu, CF; Zile, MR; Kuppuswamy, D				Johnston, Rebecca K.; Balasubramanian, Sundaravadivel; Kasiganesan, Harinath; Baicu, Catalin F.; Zile, Michael R.; Kuppuswamy, Dhandapani			beta(3) Integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy	FASEB JOURNAL			English	Article						NF-kappa B; cIAP1; pressure overload	NF-KAPPA-B; RAT VENTRICULAR MYOCYTES; FOCAL COMPLEX-FORMATION; CARDIAC-MUSCLE-CELLS; HEART-FAILURE; DILATED CARDIOMYOPATHY; PRESSURE-OVERLOAD; E3 LIGASES; IN-VIVO; C-SRC	Identifying the molecular mechanisms activated in compensatory hypertrophy and absent during decompensation will provide molecular targets for prevention of heart failure. We have previously shown enhanced ubiquitination (Ub) during the early growth period of pressure overload (PO) hypertrophy near intercalated discs of cardiomyocytes, where integrins are important for mechanotransduction. In this study, we tested the role of integrins upstream of Ub, whether enhanced Ub contributes to survival signaling in early PO, and if loss of this mechanism could lead to decreased ventricular function. The study used a beta(3) integrin (-/-) mouse and a wild-type mouse as a control for in vivo PO by transverse aortic constriction (TAC) and for cultured cardiomyocytes in vitro, stimulated with the integrin-activating peptide RGD. We demonstrate beta(3) integrin mediates transient Ub of targeted proteins during PO hypertrophy, which is necessary for cardiomyocyte survival and to maintain ventricular function. Prosurvival signaling proceeds by initiation of NF-kappa B transcription of the E3 ligase, cIAP1. In PO beta(-/-)(3) mice, absence of this mechanism correlates with increased TUNEL staining and decreased ventricular mass and function by 4 wk. This is the first study to show that a beta(3) integrin/Ub/NF-kappa B pathway contributes to compensatory hypertrophic growth.-Johnston, R. K., Balasubramanian, S., Kasiganesan, H., Baicu, C. F., Zile, M. R., Kuppuswamy, D. beta(3) Integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy. FASEB J. 23, 2759-2771 ( 2009)	[Johnston, Rebecca K.; Balasubramanian, Sundaravadivel; Kasiganesan, Harinath; Baicu, Catalin F.; Zile, Michael R.; Kuppuswamy, Dhandapani] Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, Charleston, SC 29425 USA; [Zile, Michael R.; Kuppuswamy, Dhandapani] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Kuppuswamy, D (corresponding author), Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, 114 Doughty St, Charleston, SC 29425 USA.	kuppusd@musc.edu		Zile, Michael/0000-0001-7076-221X	National Institutes of Health (NIH) [HL-48788, RO1 HL-092124, T32HL07260]; American Heart Association predoctoral fellowship [0615468U]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092124, P01HL048788, T32HL007260] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association predoctoral fellowship(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by National Institutes of Health (NIH) grant PPG HL-48788, by a Merit Award from the Research Service of the Department of Veterans Affairs, by NIH grant RO1 HL-092124 ( to D. K.), by American Heart Association predoctoral fellowship 0615468U ( to R. K. J.), and by NIH predoctoral fellowship NIH T32HL07260 ( to R. K. J.). We thank An Van Laer for proficiency with the TAC model. We also thank Dr. Robin Muise-Helmericks, Dr. Amy Bradshaw, and Phillip Moschella for thoughtful comments and useful discussions, and Dr. Francis G. Spinale for help with the measurement of myocyte cross-sectional area.	Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174; Balasubramanian S, 2003, J BIOL CHEM, V278, P42214, DOI 10.1074/jbc.M303428200; Balasubramanian S, 2006, J MOL CELL CARDIOL, V41, P669, DOI 10.1016/j.yjmcc.2006.04.022; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Birks EJ, 2008, CARDIOVASC RES, V79, P472, DOI 10.1093/cvr/cvn083; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cheng G, 2008, AM J PHYSIOL-HEART C, V294, pH2231, DOI 10.1152/ajpheart.91515.2007; Courter DL, 2005, J BIOL CHEM, V280, P12145, DOI 10.1074/jbc.M412555200; DeGroff CG, 2000, PEDIATR CARDIOL, V21, P439, DOI 10.1007/s002460010104; Depre C, 2006, CIRCULATION, V114, P1821, DOI 10.1161/CIRCULATIONAHA.106.637827; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Ha TZ, 2005, FREE RADICAL BIO MED, V39, P1570, DOI 10.1016/j.freeradbiomed.2005.08.002; Hedhli N, 2005, CARDIOVASC RES, V68, P186, DOI 10.1016/j.cardiores.2005.06.025; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Iijima Y, 2002, J BIOL CHEM, V277, P23065, DOI 10.1074/jbc.M200328200; KENT RL, 1989, AM J PHYSIOL, V257, pH1717, DOI 10.1152/ajpheart.1989.257.5.H1717; Kostin S, 2003, CIRC RES, V92, P715, DOI 10.1161/01.RES.0000067471.95890.5C; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; Laser M, 2000, J BIOL CHEM, V275, P35624, DOI 10.1074/jbc.M006124200; Lemler MS, 2000, AM J PHYSIOL-HEART C, V279, pH1365; Li HH, 2007, J CLIN INVEST, V117, P3211, DOI 10.1172/JCI31757; Li YH, 2004, AM J PHYSIOL-HEART C, V287, pH1712, DOI 10.1152/ajpheart.00124.2004; Lindsey ML, 2006, PROTEOMICS, V6, P2225, DOI 10.1002/pmic.200500013; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Ogawa E, 2000, J MOL CELL CARDIOL, V32, P765, DOI 10.1006/jmcc.2000.1119; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Ren J, 2007, J MOL CELL CARDIOL, V42, P367, DOI 10.1016/j.yjmcc.2006.11.002; Ross RS, 1998, CIRC RES, V82, P1160, DOI 10.1161/01.RES.82.11.1160; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Sambrano GR, 2002, NATURE, V420, P712, DOI 10.1038/nature01306; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Sarkar S, 2004, J BIOL CHEM, V279, P52630, DOI 10.1074/jbc.M402037200; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Spinale FG, 1998, CIRC RES, V82, P482, DOI 10.1161/01.RES.82.4.482; Spruill LS, 2008, J MOL CELL CARDIOL, V44, P69, DOI 10.1016/j.yjmcc.2007.10.011; Toruner M, 2006, J BIOL CHEM, V281, P8686, DOI 10.1074/jbc.M512178200; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Tsukamoto O, 2006, BIOCHEM BIOPH RES CO, V340, P1125, DOI 10.1016/j.bbrc.2005.12.120; Tuxworth WJ, 2004, BIOCHEM J, V378, P73, DOI 10.1042/BJ20031027; Lipinski KV, 2006, CIRC RES, V98, P1490, DOI 10.1161/01.RES.0000229267.77982.0d; Weekes J, 2003, PROTEOMICS, V3, P208, DOI 10.1002/pmic.200390029; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664; Willey CD, 2003, J MOL CELL CARDIOL, V35, P671, DOI 10.1016/S0022-2828(03)00112-3; Willey CD, 2008, INT J BIOL SCI, V4, P184; Xi YT, 2006, EUR J HEART FAIL, V8, P16, DOI 10.1016/j.ejheart.2005.05.014; Zhang RQ, 2001, BIOCHEMISTRY-US, V40, P14898, DOI 10.1021/bi0107445	49	40	44	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2759	2771		10.1096/fj.08-127480	http://dx.doi.org/10.1096/fj.08-127480			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19364763	Green Published			2022-12-28	WOS:000268836700044
J	Kalantari, P; Narayan, V; Henderson, AJ; Prabhu, KS				Kalantari, Parisa; Narayan, Vivek; Henderson, Andrew J.; Prabhu, K. Sandeep			15-Deoxy-Delta(12,14)-prostaglandin J(2) inhibits HIV-1 transactivating protein, Tat, through covalent modification	FASEB JOURNAL			English	Article						alkylation; cysteine thiols; arachidonic acid metabolite; cyclopentenone prostaglandins	HUMAN-IMMUNODEFICIENCY-VIRUS; CHROMATIN-REMODELING COMPLEX; LONG TERMINAL REPEAT; METAL-LINKED DIMER; CYCLOPENTENONE PROSTAGLANDINS; KAPPA-B; TRANSCRIPTIONAL INITIATION; DNA-BINDING; PPAR-GAMMA; REPLICATION	Controlling the HIV/AIDS epidemic remains a major challenge, with approximately 5 million new HIV infections annually. Cyclopentenone prostaglandins (CyPG), such as 15-deoxy-Delta(12,14)-PGJ(2) (15d-PGJ(2)), are arachidonic acid-derived endogenous electrophiles that possess anti-HIV activity by an unknown mechanism. Given that the reactive alpha,beta-unsaturated ketone in the cyclopentenone ring of 15d-PGJ(2) covalently modifies key Cys thiols in select proteins, we hypothesized that 15d-PGJ(2) inhibits HIV transcription and replication by targeting Cys thiols in HIV-1 Tat. Tat is a potent transactivator of viral gene expression required for HIV transcriptional elongation and replication. Our studies indicate that 15d-PGJ(2) treatment of cells inhibits Tat-dependent transcription and replication of HIV-1, while 9,10-dihydro-15d-PGJ(2), PGE(2), PGF(2 alpha), or PGD(2) that lack the reactive alpha,beta-unsaturated ketone were ineffective. The inhibition of Tat activity by 15d-PGJ(2) was dose-dependent, with an IC50 of 1.2 mu M and independent of NF-kappa B pathway. Furthermore, using a biotinylated derivative of 15d-PGJ(2), we demonstrate that 15d-PGJ(2) modifies free Cys-thiols in Tat to form covalent Michael adducts and that the interaction was further increased on reduction of Tat. 15d-PGJ(2)-modified Tat was unable to transactivate the HIV long terminal repeat in U937 human macrophages. These data demonstrate that Tat acts as a molecular target of CyPG leading to the inhibition of transcription and also suggest a novel therapeutic approach to complement current antiretroviral strategies for HIV/AIDS.-Kalantari, P., Narayan, V., Henderson, A. J., Prabhu, K. S. 15-Deoxy-Delta(12,14)-prostaglandin J(2) inhibits HIV-1 transactivating protein, Tat, through covalent modification. FASEB J. 23, 2366-2373 (2009)	[Kalantari, Parisa; Narayan, Vivek; Prabhu, K. Sandeep] Penn State Univ, Ctr Mol Immunol & Infect Dis, University Pk, PA 16802 USA; [Kalantari, Parisa; Narayan, Vivek; Prabhu, K. Sandeep] Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; [Henderson, Andrew J.] Boston Univ, Sch Med, Dept Med, Ctr HIV AIDS Care & Res, Boston, MA 02118 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Boston University	Prabhu, KS (corresponding author), Penn State Univ, Ctr Mol Immunol & Infect Dis, 115 Henning Bldg, University Pk, PA 16802 USA.	ksp4@psu.edu		PRABHU, NARAYAN/0000-0002-8359-2587; Narayan, Vivek/0000-0002-3232-7898; Henderson, Andrew/0000-0002-9299-5302	NIH	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	These studies were supported, in part, by Public Health Service grants from the NIH to A. J. H. and K. S. P. and an intramural seed grant from the College of Agricultural Sciences, Pennsylvania State University, to K. S. P. The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: monoclonal antibody to HIV-1 Tat (NT3 2D1.1; catalog no. 4138) from Dr. Jonathan Karn; pHis-Tat from Drs. Abhay Patki and M. M. Lederman, courtesy of the UK National Institute for Biological Standards and Control (NIBSC) Centralized Facility for AIDS Reagents. We are grateful to Dr. Kalipada Pahan (Rush University, Chicago, IL, USA) for providing the iNOS promoter-Luc construct. We also thank Professor C. Channa Reddy for his invaluable suggestions.	Agbottah E, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-48; AMICI C, 1991, J GEN VIROL, V72, P1877, DOI 10.1099/0022-1317-72-8-1877; Buzek J, 2002, NUCLEIC ACIDS RES, V30, P2340, DOI 10.1093/nar/30.11.2340; Emiliani S, 1996, P NATL ACAD SCI USA, V93, P6377, DOI 10.1073/pnas.93.13.6377; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRANKEL AD, 1988, P NATL ACAD SCI USA, V85, P6297, DOI 10.1073/pnas.85.17.6297; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Hayes MM, 2002, J BIOL CHEM, V277, P16913, DOI 10.1074/jbc.M200875200; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; HUGHESFULFORD M, 1992, ANTIMICROB AGENTS CH, V36, P2253, DOI 10.1128/AAC.36.10.2253; Ishihara Shunji, 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P379, DOI 10.2174/1568011043352902; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Kirsch T, 1996, PROTEIN EXPRES PURIF, V8, P75, DOI 10.1006/prep.1996.0076; KOKEN SEC, 1994, J BIOL CHEM, V269, P8366; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; Lima RG, 2006, AIDS RES HUM RETROV, V22, P763, DOI 10.1089/aid.2006.22.763; Mahmoudi T, 2006, J BIOL CHEM, V281, P19960, DOI 10.1074/jbc.M603336200; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MASTROMARINO P, 1993, ANTIVIR RES, V20, P209, DOI 10.1016/0166-3542(93)90021-A; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; Pande V, 2005, BIOORG MED CHEM LETT, V15, P4057, DOI 10.1016/j.bmcl.2005.06.025; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Patki AH, 1996, CELL IMMUNOL, V169, P40, DOI 10.1006/cimm.1996.0088; Perez-Sala D, 2003, J BIOL CHEM, V278, P51251, DOI 10.1074/jbc.M309409200; PICA F, 1993, ANTIVIR RES, V20, P193, DOI 10.1016/0166-3542(93)90020-J; Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665; Rajakariar R, 2007, P NATL ACAD SCI USA, V104, P20979, DOI 10.1073/pnas.0707394104; Rohr O, 2003, J LEUKOCYTE BIOL, V74, P736, DOI 10.1189/jlb.0403180; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rozera C, 1996, J CLIN INVEST, V97, P1795, DOI 10.1172/JCI118609; SANTORO MG, 1982, J GEN VIROL, V63, P435, DOI 10.1099/0022-1317-63-2-435; SANTORO MG, 1983, PROSTAGLANDINS, V25, P353, DOI 10.1016/0090-6980(83)90038-2; SANTORO MG, 1980, SCIENCE, V209, P1032, DOI 10.1126/science.6157190; Shibata T, 2003, J BIOL CHEM, V278, P26046, DOI 10.1074/jbc.M303690200; Stamatakis K, 2006, J AM SOC NEPHROL, V17, P89, DOI 10.1681/ASN.2005030329; Strandell A, 2000, HUM REPROD, V15, P14; Wada M, 2007, J BIOL CHEM, V282, P22254, DOI 10.1074/jbc.M703169200; Watson WH, 2003, J BIOL CHEM, V278, P33408, DOI 10.1074/jbc.M211107200; Williams SA, 2006, EMBO J, V25, P139, DOI 10.1038/sj.emboj.7600900	46	29	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2366	2373		10.1096/fj.08-124982	http://dx.doi.org/10.1096/fj.08-124982			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19299483	Green Published			2022-12-28	WOS:000268836700005
J	Dressel, R; Nolte, J; Elsner, L; Novota, P; Guan, KM; Streckfuss-Bomeke, K; Hasenfuss, G; Jaenisch, R; Engel, W				Dressel, Ralf; Nolte, Jessica; Elsner, Leslie; Novota, Peter; Guan, Kaomei; Streckfuss-Boemeke, Katrin; Hasenfuss, Gerd; Jaenisch, Rudolf; Engel, Wolfgang			Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells	FASEB JOURNAL			English	Article						multipotent adult germ-line stem cells; embryonic stem cells; teratomas; cellular cytotoxicity; NK receptor ligands	DNAM-1 CD226; GENERATION; IDENTIFICATION; RECOGNITION; FIBROBLASTS; LYMPHOCYTES; EXPRESSION; LIGANDS; DEFECT; LYSIS	Multipotent adult germ-line stem cells (maGSCs) and induced pluripotent stem cells (iPSCs) could be used to generate autologous cells for therapeutic purposes, which are expected to be tolerated by the recipient. However, effects of the immune system on these cells have not been investigated. We have compared the susceptibility of maGSC lines to IL-2-activated natural killer (NK) cells with embryonic stem cell (ESC) lines, iPSCs, and F9 teratocarcinoma cells. The killing of pluripotent cell lines by syngeneic, allogeneic, and xenogeneic killer cells ranged between 48 and 265% in chromium release assays when compared to YAC-1 cells, which served as highly susceptible reference cells. With the exception of 2 maGSC lines, they expressed ligands for the activating NK receptor NKG2D that belong to the RAE-1 family, and killing could be inhibited by soluble NKG2D, demonstrating a functional role of these molecules. Furthermore, ligands of the activating receptor DNAM-1 were frequently expressed. The susceptibility to NK cells might constitute a common feature of pluripotent cells. It could result in rejection after transplantation, as suggested by a reduced teratoma growth after NK cell activation in vivo, but it might also offer a strategy to deplete contaminating pluripotent cells before grafting of differentiated cells.-Dressel, R., Nolte, J., Elsner, L., Novota, P., Guan, K., Streckfuss-Bomeke, K., Hasenfuss, G., Jaenisch, R., Engel, W. Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells. FASEB J. 24, 2164-2177 (2010). www.fasebj.org	[Dressel, Ralf; Elsner, Leslie; Novota, Peter] Univ Gottingen, Dept Cellular & Mol Immunol, D-37073 Gottingen, Germany; [Nolte, Jessica; Engel, Wolfgang] Univ Gottingen, Inst Human Genet, D-37073 Gottingen, Germany; [Guan, Kaomei; Streckfuss-Boemeke, Katrin; Hasenfuss, Gerd] Univ Gottingen, Dept Cardiol & Pneumol, D-37073 Gottingen, Germany; [Jaenisch, Rudolf] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Jaenisch, Rudolf] MIT, Dept Biol, Cambridge, MA USA	University of Gottingen; University of Gottingen; University of Gottingen; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Dressel, R (corresponding author), Univ Gottingen, Dept Cellular & Mol Immunol, Humboldtallee 34, D-37073 Gottingen, Germany.	rdresse@gwdg.de	Dressel, Ralf/R-7065-2016	Dressel, Ralf/0000-0002-1651-1214	EU [MRTN-CT-2004-512253 (TRANS-NET)]; German Federal Ministry for Research and Technology (BMBF) [01GN0819, 01GN0601, 01GN0822]; Deutsche Forschungsgemeinschaft (DFG) [SSP 1356 (EN 84/22-1), FOR 1041 (EN 84/23-1), KFO155]	EU(European Commission); German Federal Ministry for Research and Technology (BMBF)(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The authors thank Dr. L. Walter, German Primate Center, Gottingen, for help on real-time PCR experiments. The technical assistance of J. Ulrich, B. Kaltwasser, L. Piontek, and A. Cierpka, is gratefully acknowledged. This work was supported by EU grant MRTN-CT-2004-512253 (TRANS-NET) and German Federal Ministry for Research and Technology (BMBF) grant 01GN0819 to R. D.; Deutsche Forschungsgemeinschaft (DFG) grants SSP 1356 (EN 84/22-1) and FOR 1041 (EN 84/23-1) to W. E.; DFG grant KFO155 to W. E., K. G., and G. H.; BMBF grant 01GN0601 to G. H., and BMBF grant 01GN0822 to K. G. and G. H.	Abdullah Z, 2007, J IMMUNOL, V178, P3390, DOI 10.4049/jimmunol.178.6.3390; ARTZT K, 1973, P NATL ACAD SCI USA, V70, P2988, DOI 10.1073/pnas.70.10.2988; Balaji KN, 2002, J EXP MED, V196, P493, DOI 10.1084/jem.20011836; Biassoni R, 1999, EUR J IMMUNOL, V29, P1014, DOI 10.1002/(SICI)1521-4141(199903)29:03<1014::AID-IMMU1014>3.0.CO;2-O; Bonde S, 2006, STEM CELLS, V24, P2192, DOI 10.1634/stemcells.2006-0022; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Byrne JA, 2008, HUM MOL GENET, V17, pR37, DOI 10.1093/hmg/ddn053; Castriconi R, 2009, J IMMUNOL, V182, P3530, DOI 10.4049/jimmunol.0802845; Cheng J, 2004, GENESIS, V39, P100, DOI 10.1002/gene.20031; Chowdhury D, 2008, ANNU REV IMMUNOL, V26, P389, DOI 10.1146/annurev.immunol.26.021607.090404; Conrad S, 2008, NATURE, V456, P344, DOI 10.1038/nature07404; Daley GQ, 2008, CELL, V132, P544, DOI 10.1016/j.cell.2008.02.009; Dressel R, 2004, J BIOL CHEM, V279, P20200, DOI 10.1074/jbc.M313108200; Dressel R, 2009, BIOL DIRECT, V4, DOI 10.1186/1745-6150-4-31; Dressel R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002622; Frenzel LP, 2009, STEM CELLS, V27, P307, DOI 10.1634/stemcells.2008-0528; Glaser T, 2008, STEM CELLS, V26, P2434, DOI 10.1634/stemcells.2008-0163; Guan K, 2006, NATURE, V440, P1199, DOI 10.1038/nature04697; Guan K, 2007, CIRC RES, V100, P1615, DOI 10.1161/01.RES.0000269182.22798.d9; Guan K, 2009, NAT PROTOC, V4, P143, DOI 10.1038/nprot.2008.242; HABU S, 1981, J IMMUNOL, V127, P34; Hayakawa Y, 2006, SEMIN IMMUNOL, V18, P176, DOI 10.1016/j.smim.2006.03.005; Kanatsu-Shinohara M, 2004, CELL, V119, P1001, DOI 10.1016/j.cell.2004.11.011; Karre K, 2008, NAT IMMUNOL, V9, P477, DOI 10.1038/ni0508-477; Koch CA, 2008, STEM CELLS, V26, P89, DOI 10.1634/stemcells.2007-0151; Kossack N, 2009, STEM CELLS, V27, P138, DOI 10.1634/stemcells.2008-0439; Maier LM, 2008, J IMMUNOL, V181, P7073, DOI 10.4049/jimmunol.181.10.7073; MATHEW PA, 1993, J IMMUNOL, V151, P5328; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; Meissner A, 2007, NAT BIOTECHNOL, V25, P1177, DOI 10.1038/nbt1335; Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nayernia K, 2004, HUM MOL GENET, V13, P1451, DOI 10.1093/hmg/ddh166; Nomura M, 1996, J BIOCHEM-TOKYO, V120, P987; Radosavljevic M, 2003, IMMUNOGENETICS, V55, P1, DOI 10.1007/s00251-003-0546-0; Raulet DH, 2006, SEMIN IMMUNOL, V18, P145, DOI 10.1016/j.smim.2006.03.003; Rideout WM, 2002, CELL, V109, P17, DOI 10.1016/S0092-8674(02)00681-5; Saric T, 2008, CELLS TISSUES ORGANS, V188, P78, DOI 10.1159/000118784; Seandel M, 2007, NATURE, V449, P346, DOI 10.1038/nature06129; Streckfuss-Bomeke K, 2009, STEM CELL RES, V2, P139, DOI 10.1016/j.scr.2008.09.001; Tahara-Hanaoka S, 2005, BIOCHEM BIOPH RES CO, V329, P996, DOI 10.1016/j.bbrc.2005.02.067; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zechner U, 2009, MOL HUM REPROD, V15, P345, DOI 10.1093/molehr/gap023; Zovoilis A, 2008, MOL HUM REPROD, V14, P521, DOI 10.1093/molehr/gan044	46	71	73	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2164	2177		10.1096/fj.09-134957	http://dx.doi.org/10.1096/fj.09-134957			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20145206				2022-12-28	WOS:000279343600004
J	Feng, JAQ; Guo, FJ; Jiang, BC; Zhang, Y; Frenkel, S; Wang, DW; Tang, W; Xie, YX; Liu, CJ				Feng, Jian Q.; Guo, Feng-Jin; Jiang, Bai-Chun; Zhang, Yan; Frenkel, Sally; Wang, Da-Wei; Tang, Wei; Xie, Yixia; Liu, Chuan-Ju			Granulin epithelin precursor: a bone morphogenic protein 2-inducible growth factor that activates Erk1/2 signaling and JunB transcription factor in chondrogenesis	FASEB JOURNAL			English	Article						GEP; BMP-2; chondrocyte; differentiation	OLIGOMERIC MATRIX PROTEIN; MULTIPLE EPIPHYSEAL DYSPLASIA; MESENCHYMAL STEM-CELL; IN-VITRO; GENE-EXPRESSION; FACTOR-BETA; GRANULIN/EPITHELIN PRECURSOR; CHONDROCYTE PROLIFERATION; FRONTOTEMPORAL DEMENTIA; FACTOR PCDGF	Granulin epithelin precursor (GEP) has been implicated in development, tissue regeneration, tumorigenesis, and inflammation. Herein we report that GEP stimulates chondrocyte differentiation from mesenchymal stem cells in vitro and endochondral ossification ex vivo, and GEP-knockdown mice display skeleton defects. Similar to bone morphogenic protein (BMP) 2, application of the recombinant GEP accelerates rabbit cartilage repair in vivo. GEP is a key downstream molecule of BMP2, and it is required for BMP2-mediated chondrocyte differentiation. We also show that GEP activates chondrocyte differentiation through Erk1/2 signaling and that JunB transcription factor is one of key downstream molecules of GEP in chondrocyte differentiation. Collectively, these findings reveal a novel critical role of GEP growth factor in chondrocyte differentiation and the molecular events both in vivo and in vitro.-Feng, J. Q., Guo, F.-J., Jiang, B.-C., Zhang, Y., Frenkel, S., Wang, D.-W., Tang, W., Xie, Y., Liu, C.-J. Granulin epithelin precursor: a bone morphogenic protein 2-inducible growth factor that activates Erk1/2 signaling and JunB transcription factor in chondrogenesis. FASEB J. 24, 1879-1892 (2010). www.fasebj.org	[Guo, Feng-Jin; Zhang, Yan; Frenkel, Sally; Wang, Da-Wei; Tang, Wei; Liu, Chuan-Ju] NYU, Sch Med, Dept Orthopaed Surg, New York, NY 10003 USA; [Frenkel, Sally; Liu, Chuan-Ju] NYU, Sch Med, Dept Cell Biol, New York, NY 10003 USA; [Feng, Jian Q.; Jiang, Bai-Chun; Xie, Yixia] Texas A&M Univ Syst, Hlth Sci Ctr, Baylor Coll Dent, Dept Biomed Sci, Dallas, TX USA	New York University; New York University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Liu, CJ (corresponding author), NYU, Sch Med, Dept Orthopaed Surg, 301 E 17th St, New York, NY 10003 USA.	chuanju.liu@med.nyu.edu	Liu, Chuan-ju/AAT-8165-2021; Tang, Wei/A-6254-2016	Tang, Wei/0000-0002-4573-3502; Wang, Dawei/0000-0002-6151-5839; Frenkel, Sally/0000-0001-9450-1946; liu, chuanju/0000-0002-7181-8032	U.S. NIH [AR053210, AR050620, AG029388, DE018486, AR51587]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051587, K01AR053210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE018486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG029388] Funding Source: NIH RePORTER	U.S. NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was aided by U.S. NIH research grants AR053210, AR050620, and AG029388 (to C. J. L.) and DE018486 and AR51587 (to J. Q. F).	ANAKWE OO, 1990, BIOL REPROD, V42, P317, DOI 10.1095/biolreprod42.2.317; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Attur M. G., 2002, Current Issues in Molecular Biology, V4, P129; Austin CP, 2004, NAT GENET, V36, P921, DOI 10.1038/ng0904-921; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; Bai XH, 2009, MOL CELL BIOL, V29, P4201, DOI 10.1128/MCB.00056-09; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Barreda DR, 2004, DEV COMP IMMUNOL, V28, P727, DOI 10.1016/j.dci.2003.11.005; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; Bhandari V, 1996, BIOCHEM J, V319, P441, DOI 10.1042/bj3190441; BRIGGS MD, 1993, GENOMICS, V18, P656, DOI 10.1016/S0888-7543(05)80369-6; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; Colnot C, 2005, J CELL BIOCHEM, V95, P688, DOI 10.1002/jcb.20449; Coumoul X, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni100; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Davidson B, 2004, CANCER-AM CANCER SOC, V100, P2139, DOI 10.1002/cncr.20219; Di Cesare PE, 2006, J ORTHOP RES, V24, P1118, DOI 10.1002/jor.20143; Franz-Odendaal TA, 2006, DEV DYNAM, V235, P1244, DOI 10.1002/dvdy.20718; Gass J, 2006, HUM MOL GENET, V15, P2988, DOI 10.1093/hmg/ddl241; Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652; Gonzalez EM, 2003, J BIOL CHEM, V278, P38113, DOI 10.1074/jbc.C300310200; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; He ZH, 2002, CANCER RES, V62, P5590; HECHT JT, 1993, GENOMICS, V18, P661, DOI 10.1016/S0888-7543(05)80370-2; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; Hoque M, 2005, J BIOL CHEM, V280, P13648, DOI 10.1074/jbc.M409575200; Hoque M, 2003, MOL CELL BIOL, V23, P1688, DOI 10.1128/MCB.23.5.1688-1702.2003; Hrabal R, 1996, NAT STRUCT BIOL, V3, P747, DOI 10.1038/nsb0996-747; Ijiri K, 2005, J BIOL CHEM, V280, P38544, DOI 10.1074/jbc.M504202200; Indrawattana N, 2004, BIOCHEM BIOPH RES CO, V320, P914, DOI 10.1016/j.bbrc.2004.06.029; Johnson KA, 2008, AM J PATHOL, V172, P440, DOI 10.2353/ajpath.2008.070753; Jones MB, 2003, GYNECOL ONCOL, V88, pS136, DOI 10.1006/gyno.2002.6704; Justen H P, 2000, Mol Cell Biol Res Commun, V3, P165, DOI 10.1006/mcbr.2000.0211; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; Koseki T, 2002, CELL SIGNAL, V14, P31, DOI 10.1016/S0898-6568(01)00221-2; Kvist AJ, 2006, J BIOL CHEM, V281, P33127, DOI 10.1074/jbc.M607892200; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; Liu CJ, 2006, FASEB J, V20, P988, DOI 10.1096/fj.05-3877fje; Liu CJ, 2004, J BIOL CHEM, V279, P47081, DOI 10.1074/jbc.M405288200; Locklin RM, 2001, J BONE MINER RES, V16, P2192, DOI 10.1359/jbmr.2001.16.12.2192; Lu RQ, 2000, P NATL ACAD SCI USA, V97, P3993, DOI 10.1073/pnas.97.8.3993; Meirelles LD, 2003, BRIT J HAEMATOL, V123, P702, DOI 10.1046/j.1365-2141.2003.04669.x; Nicole S, 2000, NAT GENET, V26, P480, DOI 10.1038/82638; Olney RC, 2004, BIOCHEM BIOPH RES CO, V317, P1171, DOI 10.1016/j.bbrc.2004.03.170; Ong CHP, 2003, HISTOL HISTOPATHOL, V18, P1275, DOI 10.14670/HH-18.1275; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Pei M, 2002, BIOCHEM BIOPH RES CO, V294, P149, DOI 10.1016/S0006-291X(02)00439-4; Rowland LP, 2006, ANN NEUROL, V60, P275, DOI 10.1002/ana.20962; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Sun XJ, 2004, AM J RESP CELL MOL, V30, P510, DOI 10.1165/rcmb.2003-0266OC; Susic S, 1997, CLIN GENET, V51, P219; Suzuki M, 2002, MOL GENET METAB, V75, P31, DOI 10.1006/mgme.2001.3274; Thornburg NJ, 2004, J VIROL, V78, P12848, DOI 10.1128/JVI.78.23.12848-12856.2004; Tuan RS, 2003, J BONE JOINT SURG AM, V85A, P137, DOI 10.2106/00004623-200300002-00019; VANDERKRAAN PM, 1990, J EXP PATHOL, V71, P19; Veilleux N, 2005, OSTEOARTHR CARTILAGE, V13, P278, DOI 10.1016/j.joca.2004.12.013; Wang WG, 2003, CLIN CANCER RES, V9, P2221; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Xu K, 2007, J BIOL CHEM, V282, P11347, DOI 10.1074/jbc.M608744200; Xu SQ, 1998, J BIOL CHEM, V273, P20078, DOI 10.1074/jbc.273.32.20078; Xu XL, 1999, DEV BIOL, V208, P293, DOI 10.1006/dbio.1999.9227; Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Zanocco-Marani T, 1999, CANCER RES, V59, P5331; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zhang HD, 1998, P NATL ACAD SCI USA, V95, P14202, DOI 10.1073/pnas.95.24.14202; Zhang Y, 2008, CELL DEATH DIFFER, V15, P1760, DOI 10.1038/cdd.2008.112; ZHOU J, 1993, J BIOL CHEM, V268, P10863; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	76	90	96	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1879	1892		10.1096/fj.09-144659	http://dx.doi.org/10.1096/fj.09-144659			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20124436	Green Published			2022-12-28	WOS:000278200000023
J	Grossmann, C; Wuttke, M; Ruhs, S; Seiferth, A; Mildenberger, S; Rabe, S; Schwerdt, G; Gekle, M				Grossmann, Claudia; Wuttke, Martin; Ruhs, Stefanie; Seiferth, Anja; Mildenberger, Sigrid; Rabe, Sindy; Schwerdt, Gerald; Gekle, Michael			Mineralocorticoid receptor inhibits CREB signaling by calcineurin activation	FASEB JOURNAL			English	Article						aldosterone; steroid hormone; cAMP; glucose-6-phosphate dehydrogenase; vascular smooth muscle cells	GROWTH-FACTOR RECEPTOR; GENE-EXPRESSION; TRANSDUCTION PATHWAYS; ESTROGEN-RECEPTOR; EPITHELIAL-CELLS; IN-VITRO; ALDOSTERONE; CAMP; TRANSCRIPTION; BLOCKER	We investigated the interaction of MR with cAMP-response element binding protein (CREB) and provide a mechanistic explanation and insights into the cellular relevance. MR -> CREB crosstalk was assessed in vascular smooth muscle cells and heterologous expression systems. Experiments were designed in a way that only one variable changed at a time and the respective vehicles served as controls. MR, but not GR, activation (aldosterone or hydrocortisone, IC50, similar to 0.3 nM) inhibits CREB transcriptional activity induced by stimulation of beta 1/2-adrenoceptors and adenylyl cyclase or addition of membrane-permeable cAMP up to 70% within 2 h after addition. The MR DNA-binding domain is not required for this inhibition. cAMP formation is virtually unchanged, whereas MR exerts a robust inhibition of CREBS133 phosphorylation via calcineurin/PP2B activation without changes in PP2B-A alpha or beta expression. In parallel, the PP2B-sensitive NFaT-pathway is activated. The inhibitory crosstalk attenuates CREB-induced glucose-6-phosphate dehydrogenase expression. Overall, transcriptional relevant MR -> CREB crosstalk occurs at the level of CREB phosphorylation by enhanced calcineurin activity, enables GRE-independent genomic signaling of MR, and is of potential pathophysiological relevance.-Grossmann, C., Wuttke, M., Ruhs, S., Seiferth, A., Mildenberger, S., Rabe, S., Schwerdt, G., Gekle, M. Mineralocorticoid receptor inhibits CREB signaling by calcineurin activation. FASEB J. 24, 2010-2019 (2010). www.fasebj.org	[Grossmann, Claudia; Wuttke, Martin; Ruhs, Stefanie; Seiferth, Anja; Mildenberger, Sigrid; Rabe, Sindy; Schwerdt, Gerald; Gekle, Michael] Univ Halle Wittenberg, Julius Bernstein Inst Physiol, D-06112 Halle, Saale, Germany	Martin Luther University Halle Wittenberg	Gekle, M (corresponding author), Univ Halle Wittenberg, Julius Bernstein Inst Physiol, Magdeburger Str 6, D-06112 Halle, Saale, Germany.	michael.gekle@medizin.uni-halle.de			Deutsche Forschungsgemeinschaft, DFG [Ge 905/8-1, 13-1]; Medical School, Universitat Halle-Wittenberg	Deutsche Forschungsgemeinschaft, DFG(German Research Foundation (DFG)); Medical School, Universitat Halle-Wittenberg	This study was supported by the Deutsche Forschungsgemeinschaft, DFG (grants Ge 905/8-1 and 13-1) and the WilhelmRoux program of the Medical School, Universitat Halle-Wittenberg. The authors declare no conflicts of interest.	AHMAD M, 1995, STEROIDS, V60, P147, DOI 10.1016/0039-128X(94)00019-9; Alzamora R, 2000, HYPERTENSION, V35, P1099, DOI 10.1161/01.HYP.35.5.1099; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Callera GE, 2005, HYPERTENSION, V46, P1032, DOI 10.1161/01.HYP.0000176588.51027.35; Callera GE, 2005, HYPERTENSION, V45, P773, DOI 10.1161/01.HYP.0000154365.30593.d3; Christ M, 1999, CIRCULATION, V99, P1485, DOI 10.1161/01.CIR.99.11.1485; Christ M, 2005, MOL CELL ENDOCRINOL, V231, P23, DOI 10.1016/j.mce.2004.12.004; Colella M, 2008, P NATL ACAD SCI USA, V105, P2859, DOI 10.1073/pnas.0712316105; Edwards DP, 2005, ANNU REV PHYSIOL, V67, P335, DOI 10.1146/annurev.physiol.67.040403.120151; Esposito C, 2000, KIDNEY INT, V58, P123, DOI 10.1046/j.1523-1755.2000.00147.x; Fuse H, 2000, MOL ENDOCRINOL, V14, P889, DOI 10.1210/me.14.6.889; Gekle M, 2002, AM J PHYSIOL-RENAL, V282, pF669, DOI 10.1152/ajprenal.00159.2001; Gekle M, 1996, P NATL ACAD SCI USA, V93, P10500, DOI 10.1073/pnas.93.19.10500; Gekle M, 2007, PFLUG ARCH EUR J PHY, V454, P403, DOI 10.1007/s00424-007-0211-9; Gonzalez-Nunez D, 2004, AM J PHYSIOL-RENAL, V286, pF936, DOI 10.1152/ajprenal.00070.2003; Goto J, 2009, AM J PHYSIOL-ENDOC M, V296, pE904, DOI 10.1152/ajpendo.90840.2008; Grossmann C, 2005, MOL ENDOCRINOL, V19, P1697, DOI 10.1210/me.2004-0469; Grossmann C, 2004, AM J PHYSIOL-RENAL, V286, pF1226, DOI 10.1152/ajprenal.00378.2003; Grossmann C, 2008, STEROIDS, V73, P973, DOI 10.1016/j.steroids.2007.12.008; Hallhuber M, 2006, CIRC RES, V99, P626, DOI 10.1161/01.RES.0000243208.59795.d8; Haseroth K, 1999, BIOCHEM BIOPH RES CO, V266, P257, DOI 10.1006/bbrc.1999.1771; Jaffe IZ, 2005, CIRC RES, V96, P643, DOI 10.1161/01.RES.0000159937.05502.d1; JAZAYERI A, 1989, J STEROID BIOCHEM, V33, P987, DOI 10.1016/0022-4731(89)90250-1; Klar J, 2004, AM J PHYSIOL-RENAL, V286, pF349, DOI 10.1152/ajprenal.00411.2002; Krug AW, 2003, J BIOL CHEM, V278, P43060, DOI 10.1074/jbc.M308134200; Leopold JA, 2000, AM J PHYSIOL-HEART C, V279, pH2477, DOI 10.1152/ajpheart.2000.279.5.H2477; Leopold JA, 2007, NAT MED, V13, P189, DOI 10.1038/nm1545; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; Lim-Tio SS, 1998, ENDOCRINOLOGY, V139, P1653, DOI 10.1210/en.139.4.1653; Liu XQ, 2004, AM J PHYSIOL-CELL PH, V286, pC1089, DOI 10.1152/ajpcell.00461.2003; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Mano A, 2004, CIRCULATION, V110, P317, DOI 10.1161/01.CIR.0000135599.33787.CA; Massaad C, 1999, MOL ENDOCRINOL, V13, P57, DOI 10.1210/me.13.1.57; NORDEEN SK, 1994, ENDOCRINOLOGY, V134, P1723, DOI 10.1210/en.134.4.1723; Ouvrard-Pascaud A, 2005, CIRCULATION, V111, P3025, DOI 10.1161/CIRCULATIONAHA.104.503706; Ouvrard-Pascaud A, 2004, AM J PHYSIOL-RENAL, V286, pF180, DOI 10.1152/ajprenal.00301.2002; Pascual-Le Tallec L, 2005, MOL ENDOCRINOL, V19, P2211, DOI 10.1210/me.2005-0089; Pedram A, 2008, ENDOCRINOLOGY, V149, P3361, DOI 10.1210/en.2008-0133; Pfau A, 2007, MOL CELL ENDOCRINOL, V264, P35, DOI 10.1016/j.mce.2006.10.002; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Rochette-Egly C, 2005, J BIOL CHEM, V280, P32565, DOI 10.1074/jbc.R500008200; Rogatsky I, 1998, J BIOL CHEM, V273, P14315, DOI 10.1074/jbc.273.23.14315; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; Savoia C, 2008, HYPERTENSION, V51, P432, DOI 10.1161/HYPERTENSIONAHA.107.103267; Savoia C, 2006, HYPERTENSION, V48, P271, DOI 10.1161/01.HYP.0000230234.84356.36; Sheader EA, 2002, J ENDOCRINOL, V175, P343, DOI 10.1677/joe.0.1750343; Someren JS, 1999, BIOCHEM BIOPH RES CO, V260, P619, DOI 10.1006/bbrc.1999.0800; Swaney JS, 2005, P NATL ACAD SCI USA, V102, P437, DOI 10.1073/pnas.0408704102; Takeda Y, 2002, CIRCULATION, V105, P677, DOI 10.1161/hc0602.104675; Thomas W, 2007, BIOCHEM SOC T, V35, P1049, DOI 10.1042/BST0351049; Tumlin JA, 1997, J CLIN INVEST, V99, P1217, DOI 10.1172/JCI119278; Vesey DA, 2002, KIDNEY INT, V62, P31, DOI 10.1046/j.1523-1755.2002.00401.x; Wohlfarth V, 2003, KIDNEY INT, V63, pS103, DOI 10.1046/j.1523-1755.63.s84.13.x; Zacchigna L, 2006, CELL, V124, P929, DOI 10.1016/j.cell.2005.12.035; Zhou ZH, 2001, AM J PHYSIOL-CELL PH, V281, pC1118, DOI 10.1152/ajpcell.2001.281.4.C1118; Ziera T, 2009, FASEB J, V23, P3936, DOI 10.1096/fj.09-134759; ZIYADEH FN, 1990, AM J PHYSIOL, V259, pF704, DOI 10.1152/ajprenal.1990.259.4.F704	59	23	23	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					2010	2019		10.1096/fj.09-146985	http://dx.doi.org/10.1096/fj.09-146985			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20103717				2022-12-28	WOS:000278200000035
J	Mounien, L; Marty, N; Tarussio, D; Metref, S; Genoux, D; Preitner, F; Foretz, M; Thorens, B				Mounien, Lourdes; Marty, Nell; Tarussio, David; Metref, Salima; Genoux, David; Preitner, Frederic; Foretz, Marc; Thorens, Bernard			Glut2-dependent glucose-sensing controls thermoregulation by enhancing the leptin sensitivity of NPY and POMC neurons	FASEB JOURNAL			English	Article						thermomodulation; glucose detection; central nervous system; glucose transporter; melanocortin pathway	BROWN ADIPOSE-TISSUE; BACTERIAL ARTIFICIAL CHROMOSOME; NUCLEUS-TRACTUS-SOLITARIUS; ADULT-RAT BRAIN; ARCUATE NUCLEUS; GLUCOSE-TRANSPORTER-2 GLUT2; ADAPTIVE THERMOGENESIS; HYPOTHALAMIC NEURONS; MEDIATE INHIBITION; ESCHERICHIA-COLI	The physiological contribution of glucose in thermoregulation is not completely established nor whether this control may involve a regulation of the melanocortin pathway. Here, we assessed thermoregulation and leptin sensitivity of hypothalamic arcuate neurons in mice with inactivation of glucose transporter type 2 (Glut2)-dependent glucose sensing. Mice with inactivation of Glut2-dependent glucose sensors are cold intolerant and show increased susceptibility to food deprivation-induced torpor and abnormal hypothermic response to intracerebroventricular administration of 2-deoxy-D-glucose compared to control mice. This is associated with a defect in regulated expression of brown adipose tissue uncoupling protein I and iodothyronine deiodinase II and with a decreased leptin sensitivity of neuropeptide Y (NPY) and proopiomelanocortin (POMC) neurons, as observed during the unfed-to-refed transition or following i.p. leptin injection. Sites of central Glut-2 expression were identified by a genetic tagging approach and revealed that glucose-sensitive neurons were present in the lateral hypothalamus, the dorsal vagal complex, and the basal medulla but not in the arcuate nucleus. NPY and POMC neurons were, however, connected to nerve terminals from Glut2-expressing neurons. Thus, our data suggest that glucose controls thermoregulation and the leptin sensitivity of NPY and POMC neurons through activation of Glut2-dependent glucose-sensing neurons located outside of the arcuate nucleus.-Mounien, L., Marty, N., Tarussio, D., Metref, S., Genoux, D., Preitner, F., Foretz, M., Thorens, B. Glut2-dependent glucose-sensing controls thermoregulation by enhancing the leptin sensitivity of NPY and POMC neurons. FASEB J. 24, 1747-1758 (2010). www.fasebj.org	[Mounien, Lourdes; Marty, Nell; Tarussio, David; Metref, Salima; Genoux, David; Preitner, Frederic; Foretz, Marc; Thorens, Bernard] Univ Lausanne, Dept Physiol, CH-1015 Lausanne, Switzerland; [Mounien, Lourdes; Marty, Nell; Tarussio, David; Metref, Salima; Genoux, David; Preitner, Frederic; Foretz, Marc; Thorens, Bernard] Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland; [Genoux, David] Ecole Polytech Fed Lausanne, Brain Mind Inst, Lab Computat Neurosci, Lausanne, Switzerland; [Foretz, Marc] Univ Paris 05, CNRS, INSERM,Dept Endocrinol Metab & Canc, Inst Cochin,U567,UMR8104, F-75270 Paris, France	University of Lausanne; University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Thorens, B (corresponding author), Univ Lausanne, Dept Physiol, Genopode Bldg, CH-1015 Lausanne, Switzerland.	bernard.thorens@unil.ch	FORETZ, Marc/O-7334-2017	FORETZ, Marc/0000-0001-7017-9032; Mounien, Lourdes/0000-0002-9221-5783	Swiss National Science Foundation [3100A0-113525]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	The authors gratefully acknowledge expert technical assistance from Martine Emery, Joel Gyger, Magali Joffraud, and Isabelle Bady, and also thank Dr. F. Jeanrenaud for critical reading of the manuscript. This work was supported by grants to B. T. from the Swiss National Science Foundation (3100A0-113525) and the National Competence Center Frontiers in Genetics from the Swiss National Science Foundation.	ADACHI A, 1984, NEUROSCI LETT, V46, P215, DOI 10.1016/0304-3940(84)90444-0; ANAND BK, 1964, AM J PHYSIOL, V207, P1146, DOI 10.1152/ajplegacy.1964.207.5.1146; Arluison M, 2004, J CHEM NEUROANAT, V28, P117, DOI 10.1016/j.jchemneu.2004.05.009; Arluison M, 2004, J CHEM NEUROANAT, V28, P137, DOI 10.1016/j.jchemneu.2004.06.002; Bady I, 2006, DIABETES, V55, P988, DOI 10.2337/diabetes.55.04.06.db05-1386; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Briski KP, 2001, NEUROSCI LETT, V306, P141, DOI 10.1016/S0304-3940(01)01826-2; Burdakov D, 2006, NEURON, V50, P711, DOI 10.1016/j.neuron.2006.04.032; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cano G, 2003, J COMP NEUROL, V460, P303, DOI 10.1002/cne.10643; Casper KB, 2006, MOL CELL NEUROSCI, V31, P676, DOI 10.1016/j.mcn.2005.12.006; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Dallaporta M, 1999, NEUROREPORT, V10, P2657, DOI 10.1097/00001756-199908200-00040; DiMicco JA, 2007, AM J PHYSIOL-REG I, V292, pR47, DOI 10.1152/ajpregu.00498.2006; Dunn-Meynell AA, 1998, BRAIN RES, V814, P41, DOI 10.1016/S0006-8993(98)00956-1; Dunn-Meynell AA, 2002, DIABETES, V51, P2056, DOI 10.2337/diabetes.51.7.2056; EGAWA M, 1989, AM J PHYSIOL, V257, pR1386, DOI 10.1152/ajpregu.1989.257.6.R1386; Fioramonti X, 2004, DIABETES, V53, P2767, DOI 10.2337/diabetes.53.11.2767; Fraley GS, 2003, ENDOCRINOLOGY, V144, P75, DOI 10.1210/en.2002-220659; FREINKEL N, 1972, NEW ENGL J MED, V287, P841, DOI 10.1056/NEJM197210262871702; Gao Q, 2004, P NATL ACAD SCI USA, V101, P4661, DOI 10.1073/pnas.0303992101; Gavrilova O, 1999, P NATL ACAD SCI USA, V96, P14623, DOI 10.1073/pnas.96.25.14623; Gong SC, 2007, J NEUROSCI, V27, P9817, DOI 10.1523/JNEUROSCI.2707-07.2007; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; Hausberg M, 2002, DIABETES, V51, P2434, DOI 10.2337/diabetes.51.8.2434; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kievit P, 2006, CELL METAB, V4, P123, DOI 10.1016/j.cmet.2006.06.010; Lee EC, 2001, GENOMICS, V73, P56, DOI 10.1006/geno.2000.6451; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Marty N, 2005, J CLIN INVEST, V115, P3545, DOI 10.1172/JCI26309; Marty N, 2006, DIABETES, V55, pS108, DOI 10.2337/db06-S014; Marty N, 2007, PHYSIOLOGY, V22, P241, DOI 10.1152/physiol.00010.2007; Miki T, 2001, NAT NEUROSCI, V4, P507, DOI 10.1038/87455; MIZUNO Y, 1984, BRAIN RES, V307, P109, DOI 10.1016/0006-8993(84)90466-9; MOBBS CV, 2004, PHYSIOL BEHAV, V19, P2; Morrison SF, 2008, EXP PHYSIOL, V93, P773, DOI 10.1113/expphysiol.2007.041848; Parton LE, 2007, NATURE, V449, P228, DOI 10.1038/nature06098; RITTER S, 1994, BRAIN RES, V641, P111, DOI 10.1016/0006-8993(94)91822-8; Ritter S, 2000, BRAIN RES, V856, P37, DOI 10.1016/S0006-8993(99)02327-6; Routh VH, 2002, PHYSIOL BEHAV, V76, P403, DOI 10.1016/S0031-9384(02)00761-8; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Silver IA, 1998, J NEUROPHYSIOL, V79, P1733, DOI 10.1152/jn.1998.79.4.1733; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; STE ML, 2000, P NATL ACAD SCI USA, V97, P12339; Thorens B, 2000, J BIOL CHEM, V275, P23751, DOI 10.1074/jbc.M002908200; Thorens B, 2001, MOL MEMBR BIOL, V18, P265, DOI 10.1080/09687680110100995; Voss-Andreae A, 2007, ENDOCRINOLOGY, V148, P1550, DOI 10.1210/en.2006-1389; Wang R, 2004, DIABETES, V53, P1959, DOI 10.2337/diabetes.53.8.1959; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Yang XJ, 2004, DIABETES, V53, P67, DOI 10.2337/diabetes.53.1.67; Yasuda T, 2004, EXP BIOL MED, V229, P235, DOI 10.1177/153537020422900303; YETTEFTI K, 1995, J AUTONOM NERV SYST, V51, P191, DOI 10.1016/0165-1838(94)00130-C	54	55	56	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2010	24	6					1747	1758		10.1096/fj.09-144923	http://dx.doi.org/10.1096/fj.09-144923			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20097878				2022-12-28	WOS:000278200000012
J	Oishi, Y; Manabe, I; Imai, Y; Hara, K; Horikoshi, M; Fujiu, K; Tanaka, T; Aizawa, T; Kadowaki, T; Nagai, R				Oishi, Yumiko; Manabe, Ichiro; Imai, Yasushi; Hara, Kazuo; Horikoshi, Momoko; Fujiu, Katsuhito; Tanaka, Toshihiro; Aizawa, Tadanori; Kadowaki, Takashi; Nagai, Ryozo			Regulatory polymorphism in transcription factor KLF5 at the MEF2 element alters the response to angiotensin II and is associated with human hypertension	FASEB JOURNAL			English	Article						p38 MAP kinase; reactive oxygen species	SMOOTH-MUSCLE-CELLS; ACTIVATED PROTEIN-KINASE; ARTERY-DISEASE; P38 MAPK; EXPRESSION; DIFFERENTIATION; GENE; RESTENOSIS; COMPONENT; PATHWAYS	Kruppel-like factor 5 (KLF5) is a zinc-finger-type transcription factor that mediates the tissue remodeling in cardiovascular diseases, such as atherosclerosis, restenosis, and cardiac hypertrophy. Our previous studies have shown that KLF5 is induced by angiotensin II (AII), although the precise molecular mechanism is not yet known. Here we analyzed regulatory single nucleotide polymorphisms (SNPs) within the KLF5 locus to identify clinically relevant signaling pathways linking AII and KLF5. One SNP was located at -1282 bp and was associated with an increased risk of hypertension: subjects with the A/A and A/G genotypes at -1282 were at significantly higher risk for hypertension than those with the G/G genotype. Interestingly, a reporter construct corresponding to the -1282G genotype showed much weaker responses to AII than a construct corresponding to -1282A. Electrophoretic mobility shift, chromatin immunoprecipitation, and reporter assays collectively showed that the -1282 SNP is located within a functional myocyte enhancer factor 2 (MEF2) binding site, and that the -1282G genotype disrupts the site and reduces the AII responsiveness of the promoter. Moreover, MEF2 activation via reactive oxygen species and p38 mitogen-activated protein kinase induced KLF5 expression in response to AII, and KLF5 and MEF2 were coexpressed in coronary atherosclerotic plaques. These results suggest that a novel signaling and transcription network involving MEF2A and KLF5 plays an important role in the pathogenesis of cardiovascular diseases such as hypertension.-Oishi, Y., Manabe, I., Imai, Y., Hara, K., Horikoshi, M., Fujiu, K., Tanaka, T., Aizawa, T., Kadowaki, T., Nagai, R. Regulatory polymorphism in transcription factor KLF5 at the MEF2 element alters the response to angiotensin II and is associated with human hypertension. FASEB J. 24, 1780-1788 (2010). www.fasebj.org	[Manabe, Ichiro] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo, Japan; [Oishi, Yumiko; Fujiu, Katsuhito; Nagai, Ryozo] Univ Tokyo, Translat Syst Biol & Med Initiat, Tokyo, Japan; [Manabe, Ichiro; Nagai, Ryozo] Univ Tokyo, Global Ctr Educ & Res Chem Biol, Tokyo, Japan; [Hara, Kazuo; Horikoshi, Momoko; Kadowaki, Takashi] Univ Tokyo, Grad Sch Med, Dept Metab Dis, Tokyo, Japan; [Manabe, Ichiro] Japan Sci & Technol Agcy, PRESTO, Saitama, Japan; [Tanaka, Toshihiro] RIKEN, Ctr Genom Med, Lab Cardiovasc Dis, Yokohama, Kanagawa, Japan; [Aizawa, Tadanori] Cardiovasc Inst, Dept Cardiol, Tokyo, Japan; [Nagai, Ryozo] Tokyo Univ Hosp, Translat Res Ctr, Tokyo 113, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); RIKEN; University of Tokyo	Manabe, I (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo, Japan.	manabe-tky@umin.ac.jp; nagai-tky@umin.ac.jp	Tanaka, Toshihiro/J-9310-2014; Manabe, Ichiro/E-1529-2014; Horikoshi, Momoko/AAF-9034-2019; Manabe, Ichiro/AAE-5105-2021	Tanaka, Toshihiro/0000-0001-6201-9784; 	Ministry of Education, Culture, Sports, Science and Technology, Japan; National Institute of Biomedical Innovation, Japan; Japan Science and Technology Agency; Japan Science and Technology Institute; NOVARTIS Foundation; Kato Memorial Bioscience Foundation; Takeda Science Foundation; Cell Science Research Foundation; Tokyo Biochemical Research Foundation	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Institute of Biomedical Innovation, Japan(National Institute of Biomedical Innovation); Japan Science and Technology Agency(Japan Science & Technology Agency (JST)); Japan Science and Technology Institute; NOVARTIS Foundation(Novartis); Kato Memorial Bioscience Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Cell Science Research Foundation(Cell Science Research Foundation, Japan); Tokyo Biochemical Research Foundation	This study was supported in part by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan (to R.N., I. M., and Y.O.), a research grant from the National Institute of Biomedical Innovation, Japan, and Special Coordination Funds for Promoting Science and Technology from the Japan Science and Technology Agency (to R.N.), and research grants from Japan Science and Technology Institute, NOVARTIS Foundation for the Promotion of Science, Kato Memorial Bioscience Foundation, Takeda Science Foundation, Cell Science Research Foundation, and Tokyo Biochemical Research Foundation (to I. M.). The authors declare no conflicts of interest. The authors gratefully acknowledge Noriko Yamanaka, Michiko Hayashi, Yuka Tani, Eriko Magoshi, Xiao Yingda, and Yuko Mouri for their excellent technical assistance.	Agarwal A, 2005, TRENDS ENDOCRIN MET, V16, P127, DOI 10.1016/j.tem.2005.02.009; Atkins GB, 2007, CIRC RES, V100, P1686, DOI 10.1161/01.RES.0000267856.00713.0a; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Chalmers J, 1999, J HYPERTENS, V17, P151; Clempus RE, 2006, CARDIOVASC RES, V71, P216, DOI 10.1016/j.cardiores.2006.02.033; Deaton RA, 2005, J BIOL CHEM, V280, P31172, DOI 10.1074/jbc.M504774200; Firulli AB, 1996, CIRC RES, V78, P196, DOI 10.1161/01.RES.78.2.196; Fujiu K, 2005, CIRC RES, V97, P1132, DOI 10.1161/01.RES.0000190613.22565.13; Gregoire S, 2006, J BIOL CHEM, V281, P4423, DOI 10.1074/jbc.M509471200; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; Hoshino Y, 2000, CIRCULATION, V102, P2528, DOI 10.1161/01.CIR.102.20.2528; Katoh Y, 1998, J BIOL CHEM, V273, P1511, DOI 10.1074/jbc.273.3.1511; Kawai-Kowase K, 1999, CIRC RES, V85, P787, DOI 10.1161/01.RES.85.9.787; Kearney M, 1997, CIRCULATION, V95, P1998, DOI 10.1161/01.CIR.95.8.1998; Kumar A, 2005, MOL CELL BIOL, V25, P5893, DOI 10.1128/MCB.25.14.5893-5903.2005; Kumar A, 2009, FASEB J, V23, P4344, DOI 10.1096/fj.09-138743; Lieb W, 2008, CIRCULATION, V117, P185, DOI 10.1161/CIRCULATIONAHA.107.728485; Lin Q, 1998, DEVELOPMENT, V125, P4565; Manabe I, 2001, CIRC RES, V88, P1127, DOI 10.1161/hh1101.091339; Manabe I, 2001, J CLIN INVEST, V107, P823, DOI 10.1172/JCI11385; Manabe Ichiro, 2003, Curr Atheroscler Rep, V5, P214, DOI 10.1007/s11883-003-0027-9; Mehta PK, 2007, AM J PHYSIOL-CELL PH, V292, pC82, DOI 10.1152/ajpcell.00287.2006; Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005; Oparil S, 2003, ANN INTERN MED, V139, P761, DOI 10.7326/0003-4819-139-9-200311040-00011; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Parmar KM, 2006, J CLIN INVEST, V116, P49, DOI 10.1172/JCI24787; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367; Prokunina Ludmila, 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404007690; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Suzuki E, 2004, CIRC RES, V95, P42, DOI 10.1161/01.RES.0000134631.75684.4A; Suzuki E, 2002, CIRC RES, V90, P1004, DOI 10.1161/01.RES.0000017629.70769.CC; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Wang LJ, 2003, SCIENCE, V302, P1578, DOI 10.1126/science.1088477	35	27	28	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1780	1788		10.1096/fj.09-146589	http://dx.doi.org/10.1096/fj.09-146589			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20086047				2022-12-28	WOS:000278200000015
J	Jang, YC; Lustgarten, MS; Liu, YH; Muller, FL; Bhattacharya, A; Liang, HY; Salmon, AB; Brooks, SV; Larkin, L; Hayworth, CR; Richardson, A; Van Remmen, H				Jang, Youngmok C.; Lustgarten, Michael S.; Liu, Yuhong; Muller, Florian L.; Bhattacharya, Arunabh; Liang, Hanyu; Salmon, Adam B.; Brooks, Susan V.; Larkin, Lisa; Hayworth, Christopher R.; Richardson, Arlan; Van Remmen, Holly			Increased superoxide in vivo accelerates age-associated muscle atrophy through mitochondrial dysfunction and neuromuscular junction degeneration	FASEB JOURNAL			English	Article						apoptosis; oxidative stress; sarcopenia	SKELETAL-MUSCLE; OXIDATIVE STRESS; MOTOR-NEURONS; MYONUCLEAR NUMBER; MOUSE HINDLIMB; FIBER TYPES; CELL-DEATH; DENERVATION; APOPTOSIS; MICE	Oxidative stress has been implicated in the etiology of age-related muscle loss (sarcopenia). However, the underlying mechanisms by which oxidative stress contributes to sarcopenia have not been thoroughly investigated. To directly examine the role of chronic oxidative stress in vivo, we used a mouse model that lacks the antioxidant enzyme CuZnSOD (Sod1). Sod1(-/-) mice are characterized by high levels of oxidative damage and an acceleration of sarcopenia. In the present study, we demonstrate that muscle atrophy in Sod1(-/-) mice is accompanied by a progressive decline in mitochondrial bioenergetic function and an elevation of mitochondrial generation of reactive oxygen species. In addition, Sod1(-/-) muscle exhibits a more rapid induction of mitochondrial-mediated apoptosis and loss of myonuclei. Furthermore, aged Sod1(-/-) mice show a striking increase in muscle mitochondrial content near the neuromuscular junctions (NMJs). Despite the increase in content, the function of mitochondria is significantly impaired, with increased denervated NMJs and fragmentation of acetylcholine receptors. As a consequence, contractile force in aged Sod1(-/-) muscles is greatly diminished. Collectively, we show that Sod1(-/-) mice display characteristics of normal aging muscle in an accelerated manner and propose that the superoxide-induced NMJ degeneration and mitochondrial dysfunction are potential mechanisms of sarcopenia.-Jang, Y. C., Lustgarten, M. S., Liu, Y., Muller, F. L., Bhattacharya, A., Liang, H., Salmon, A. B., Brooks, S. V., Larkin, L., Hayworth, C. R., Richardson, A., and Van Remmen, H. Increased superoxide in vivo accelerates age-associated muscle atrophy through mitochondrial dysfunction and neuromuscular junction degeneration. FASEB J. 24, 1376-1390 (2010). www.fasebj.org	[Jang, Youngmok C.; Liu, Yuhong; Muller, Florian L.; Bhattacharya, Arunabh; Liang, Hanyu; Salmon, Adam B.; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA; [Lustgarten, Michael S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA; [Jang, Youngmok C.; Lustgarten, Michael S.; Liu, Yuhong; Muller, Florian L.; Bhattacharya, Arunabh; Liang, Hanyu; Salmon, Adam B.; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA; [Brooks, Susan V.; Larkin, Lisa] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Hayworth, Christopher R.] Univ Texas Austin, Neurobiol Sect, Austin, TX 78712 USA; [Hayworth, Christopher R.] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA; [Richardson, Arlan; Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Michigan System; University of Michigan; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Van Remmen, H (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA.	vanremmen@uthscsa.edu		Brooks, Susan/0000-0003-1954-967X; Muller, Florian/0000-0001-7568-2948	American Federation for Aging Research [P01AG020591]; NATIONAL INSTITUTE ON AGING [P01AG020591] Funding Source: NIH RePORTER	American Federation for Aging Research; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Drs. Charles Epstein (University of California, San Francisco, CA, USA) and Ting Ting Huang (Stanford University, Palo Alto, CA, USA) for providing Sod1-null breeders, Corinne Price for proofreading our manuscript, and Drs. Asish Chaudhuri, Anson Pierce, James Lechleiter, Walter Ward, and Victoria Frohlich for their input and technical assistance. This work was supported by P01AG020591 (to H. V. R., A. R., S. V. B., L. L.), and a Julie Martin Mid-Career grant from the American Federation for Aging Research (to H. V. R.).	Adhihetty PJ, 2007, J APPL PHYSIOL, V102, P1143, DOI 10.1152/japplphysiol.00768.2006; Allen DL, 1999, MUSCLE NERVE, V22, P1350, DOI 10.1002/(SICI)1097-4598(199910)22:10<1350::AID-MUS3>3.0.CO;2-8; Anderson R, 2009, BBA-GEN SUBJECTS, V1790, P1059, DOI 10.1016/j.bbagen.2009.04.005; BaliceGordon RJ, 1997, MUSCLE NERVE, pS83; Bhattacharya A, 2009, J BIOL CHEM, V284, P46, DOI 10.1074/jbc.M806311200; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; Brack AS, 2005, J CELL SCI, V118, P4813, DOI 10.1242/jcs.02602; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; BROOKS SV, 1994, MED SCI SPORT EXER, V26, P432; Bruusgaard JC, 2006, J APPL PHYSIOL, V100, P2024, DOI 10.1152/japplphysiol.00913.2005; Bruusgaard JC, 2008, J CLIN INVEST, V118, P1450, DOI 10.1172/JCI34022; BURKHOLDER TJ, 1994, J MORPHOL, V221, P177, DOI 10.1002/jmor.1052210207; Cederna PS, 2001, J GERONTOL A-BIOL, V56, pB254, DOI 10.1093/gerona/56.6.B254; Chen F, 2007, NEURON, V55, P247, DOI 10.1016/j.neuron.2007.06.031; Choksi KB, 2008, FREE RADICAL BIO MED, V45, P826, DOI 10.1016/j.freeradbiomed.2008.06.006; Cohen TJ, 2009, FASEB J, V23, P99, DOI 10.1096/fj.08-115931; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Csukly K, 2006, J PHYSIOL-LONDON, V574, P319, DOI 10.1113/jphysiol.2006.109702; Dirks AJ, 2004, FREE RADICAL BIO MED, V36, P27, DOI 10.1016/j.freeradbiomed.2003.10.003; Dobrowolny G, 2008, CELL METAB, V8, P425, DOI 10.1016/j.cmet.2008.09.002; Dupont-Versteegden EE, 2005, EXP GERONTOL, V40, P473, DOI 10.1016/j.exger.2005.04.003; Dupuis L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005390; Elchuri S, 2005, ONCOGENE, V24, P367, DOI 10.1038/sj.onc.1208207; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Figueiredo PA, 2009, J GERONTOL A-BIOL, V64, P21, DOI 10.1093/gerona/gln048; Flood DG, 1999, AM J PATHOL, V155, P663, DOI 10.1016/S0002-9440(10)65162-0; Giniatullin AR, 2006, J NEUROCHEM, V98, P1789, DOI 10.1111/j.1471-4159.2006.03997.x; Giorgi C, 2008, CURR MOL MED, V8, P119; Grady RM, 2005, P NATL ACAD SCI USA, V102, P4359, DOI 10.1073/pnas.0500711102; Jejurikar SS, 2002, PLAST RECONSTR SURG, V110, P160, DOI 10.1097/00006534-200207000-00027; Kagan VE, 2004, FREE RADICAL BIO MED, V37, P1963, DOI 10.1016/j.freeradbiomed.2004.08.016; Kostrominova TY, 2007, CELL TISSUE RES, V327, P595, DOI 10.1007/s00441-006-0297-y; Lee HC, 2005, INT J BIOCHEM CELL B, V37, P822, DOI 10.1016/j.biocel.2004.09.010; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC806, DOI 10.1152/ajpcell.00129.2003; Lyons CN, 2006, J GERONTOL A-BIOL, V61, P3, DOI 10.1093/gerona/61.1.3; Lysakowski A, 1999, J COMP NEUROL, V403, P378, DOI 10.1002/(SICI)1096-9861(19990118)403:3<378::AID-CNE7>3.0.CO;2-X; Mansouri A, 2006, MECH AGEING DEV, V127, P298, DOI 10.1016/j.mad.2005.11.004; Moylan JS, 2007, MUSCLE NERVE, V35, P411, DOI 10.1002/mus.20743; Muller F, 2005, FREE RADICAL BIO MED, V39, pS127; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Muller FL, 2007, AM J PHYSIOL-REG I, V293, pR1159, DOI 10.1152/ajpregu.00767.2006; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Pagliari LJ, 2005, P NATL ACAD SCI USA, V102, P17975, DOI 10.1073/pnas.0506712102; Potthoff MJ, 2007, CURR OPIN RHEUMATOL, V19, P542, DOI 10.1097/BOR.0b013e3282efb761; Powers SK, 2008, PHYSIOL REV, V88, P1243, DOI 10.1152/physrev.00031.2007; Saelim N, 2007, APOPTOSIS, V12, P1781, DOI 10.1007/s10495-007-0109-1; Schaefer AM, 2005, J COMP NEUROL, V490, P209, DOI 10.1002/cne.20620; Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009; Shefner JM, 1999, NEUROLOGY, V53, P1239, DOI 10.1212/WNL.53.6.1239; Siu PM, 2005, AM J PHYSIOL-REG I, V289, pR1015, DOI 10.1152/ajpregu.00198.2005; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Terman A, 2006, ANTIOXID REDOX SIGN, V8, P197, DOI 10.1089/ars.2006.8.197; Terman A, 2006, CHEM-BIOL INTERACT, V163, P29, DOI 10.1016/j.cbi.2006.04.013; Wada KI, 2003, JPN J PHYSIOL, V53, P145; Wada KI, 2002, AM J PHYSIOL-CELL PH, V283, pC484, DOI 10.1152/ajpcell.00025.2002; Wenz T, 2009, P NATL ACAD SCI USA, V106, P20405, DOI 10.1073/pnas.0911570106	58	198	203	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1376	1390		10.1096/fj.09-146308	http://dx.doi.org/10.1096/fj.09-146308			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20040516	Green Submitted, Green Published			2022-12-28	WOS:000277158900011
J	Wirth, EK; Conrad, M; Winterer, J; Wozny, C; Carlson, BA; Roth, S; Schmitz, D; Bornkamm, GW; Coppola, V; Tessarollo, L; Schomburg, L; Kohrle, J; Hatfield, DL; Schweizer, U				Wirth, Eva K.; Conrad, Marcus; Winterer, Jochen; Wozny, Christian; Carlson, Bradley A.; Roth, Stephan; Schmitz, Dietmar; Bornkamm, Georg W.; Coppola, Vincenzo; Tessarollo, Lino; Schomburg, Lutz; Koehrle, Josef; Hatfield, Dolph L.; Schweizer, Ulrich			Neuronal selenoprotein expression is required for interneuron development and prevents seizures and neurodegeneration	FASEB JOURNAL			English	Article						selenium; parvalbumin; excitability; schizophrenia; gamma oscillation	APOLIPOPROTEIN-E RECEPTOR-2; NEUROLOGICAL DYSFUNCTION; SELENIUM DEFICIENCY; BRAIN-DEVELOPMENT; TARGET TISSUES; MICE; MOUSE; GENE; SURVIVAL; SELENOCYSTEINE	Cerebral selenium (Se) deficiency is associated with neurological phenotypes including seizures and ataxia. We wanted to define whether neurons require selenoprotein expression and which selenoproteins are most important, and explore the possible pathomechanism. Therefore, we abrogated the expression of all selenoproteins in neurons by genetic inactivation of the tRNA[Ser](Sec) gene. Cerebral expression of selenoproteins was significantly diminished in the mutants, and histological analysis revealed progressive neurodegeneration. Developing interneurons failed to specifically express parvalbumin (PV) in the mutants. Electrophysiological recordings, before overt cell death, showed normal excitatory transmission, but revealed spontaneous epileptiform activity consistent with seizures in the mutants. In developing cortical neuron cultures, the number of PV+ neurons was reduced on combined Se and vitamin E deprivation, while other markers, such as calretinin (CR) and GAD67, remained unaffected. Because of the synergism between Se and vitamin E, we analyzed mice lacking neuronal expression of the Se-dependent enzyme glutathione peroxidase 4 (GPx4). Although the number of CR+ interneurons remained normal in Gpx4-mutant mice, the number of PV+ interneurons was reduced. Since these mice similarly exhibit seizures and ataxia, we conclude that GPx4 is a selenoenzyme modulating interneuron function and PV expression. Cerebral SE deficiency may thus act via reduced GPx4 expression.-Wirth, E. K., Conrad, M., Winterer, J., Wozny, C., Carlson, B. A., Roth, S., Schmitz, D., Bornkamm, G. W., Coppola, V., Tessarollo, L., Schomburg, L., Kohrle, J., Hatfield, D. L., Schweizer, U. Neuronal selenoprotein expression is required for interneuron development and prevents seizures and neurodegeneration. FASEB J. 24, 844-852 (2010). www.fasebj.org	[Schomburg, Lutz; Koehrle, Josef; Schweizer, Ulrich] Charite, Inst Expt Endocrinol, D-13353 Berlin, Germany; [Winterer, Jochen; Wozny, Christian; Schmitz, Dietmar] Charite, Neurosci Res Ctr, D-13353 Berlin, Germany; [Conrad, Marcus; Bornkamm, Georg W.] Helmholtz Zentrum Munchen, Inst Clin Mol Biol & Tumour Genet, Munich, Germany; [Carlson, Bradley A.; Hatfield, Dolph L.] NCI, Mol Biol Selenium Sect, Lab Canc Prevent, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; [Coppola, Vincenzo; Tessarollo, Lino] NCI, Neural Dev Grp, Mouse Canc Genet Program, Frederick, MD 21701 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schweizer, U (corresponding author), Charite, Inst Expt Endocrinol, Augustenburger Pl 1, D-13353 Berlin, Germany.	ulrich.schweizer@charite.de	Köhrle, Josef/AAH-6438-2020; Schomburg, Lutz/D-8096-2013; Wozny, Christian/A-1498-2015; Conrad, Marcus/E-8792-2015; Schweizer, Ulrich/E-8105-2013; Coppola, Vincenzo/D-5352-2014; Coppola, Vincenzo/E-2917-2011	Köhrle, Josef/0000-0002-9187-9078; Schomburg, Lutz/0000-0001-9445-1555; Wozny, Christian/0000-0003-4220-2033; Conrad, Marcus/0000-0003-1140-5612; Coppola, Vincenzo/0000-0001-6163-1779; Coppola, Vincenzo/0000-0001-6163-1779; Schweizer, Ulrich/0000-0003-1380-4780; Schmitz, Dietmar/0000-0003-2741-5241; Wirth, Eva Katrin/0000-0002-0491-9941	Deutsche Forschungsgemeinschaft [Scho849/2-2, SFB 665/A7, Ko922/11-1]; Charite Universitatsmedizin Berlin; U.S. National Institutes of Health; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC005317] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Charite Universitatsmedizin Berlin; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Claudia Iserhot, who performed initial physiological studies. SiJie Zhang performed some of the neuron cultures. CamK-Cre mice were generously provided by Gunther Schutz (Deutsches Krebsforschungszentrum, Heidelberg, Germany). The authors gratefully acknowledge the technical assistance of Vartiter Seher, Anita Kinne, Silke Kappler, Antje Kretschmer, and Heidi Forster. Dorette Freyer (Experimental Neurology, Charite Universitatsmedizin Berlin), initially helped with primary neuron culture. Funding for this study was provided by Deutsche Forschungsgemeinschaft Scho849/2-2, SFB 665/A7, Ko922/11-1, and Charite Universitatsmedizin Berlin and in part by the Intramural Research Program of the U.S. National Institutes of Health, National Cancer Institute, Center for Cancer Research.	Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; Behrens MM, 2007, SCIENCE, V318, P1645, DOI 10.1126/science.1148045; Blauwkamp MN, 2008, BMC NEPHROL, V9, DOI 10.1186/1471-2369-9-7; Breustedt J, 2003, P NATL ACAD SCI USA, V100, P12450, DOI 10.1073/pnas.2035117100; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; Burk RF, 2007, J NEUROSCI, V27, P6207, DOI 10.1523/JNEUROSCI.1153-07.2007; Burk RF, 2005, ANNU REV NUTR, V25, P215, DOI 10.1146/annurev.nutr.24.012003.132120; Butt SJB, 2008, NEURON, V59, P722, DOI 10.1016/j.neuron.2008.07.031; Carlson BA, 2009, BIOCHEM J, V418, P61, DOI 10.1042/BJ20081304; Casanova E, 2001, GENESIS, V31, P37, DOI 10.1002/gene.1078; Coppola V, 2004, DEVELOPMENT, V131, P5185, DOI 10.1242/dev.01383; Fisahn A, 1998, NATURE, V394, P186, DOI 10.1038/28179; Gilbert ME, 2007, ENDOCRINOLOGY, V148, P92, DOI 10.1210/en.2006-0164; Gysin R, 2007, P NATL ACAD SCI USA, V104, P16621, DOI 10.1073/pnas.0706778104; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Hill KE, 2004, J NUTR, V134, P157, DOI 10.1093/jn/134.1.157; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; KAUFMAN LM, 1983, SCIENCE, V220, P1394, DOI 10.1126/science.6857258; Kinney JW, 2006, J NEUROSCI, V26, P1604, DOI 10.1523/JNEUROSCI.4722-05.2006; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Kumaraswamy E, 2003, MOL CELL BIOL, V23, P1477, DOI 10.1128/MCB.23.5.1477-1488.2003; Lewis DA, 2005, NAT REV NEUROSCI, V6, P312, DOI 10.1038/nrn1648; Olson GE, 2007, J BIOL CHEM, V282, P12290, DOI 10.1074/jbc.M611403200; Prozorovski T, 2008, NAT CELL BIOL, V10, P385, DOI 10.1038/ncb1700; RAMAEKERS VT, 1994, NEUROPEDIATRICS, V25, P217, DOI 10.1055/s-2008-1073025; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Scharpf M, 2007, J NEURAL TRANSM, V114, P877, DOI 10.1007/s00702-006-0617-0; Schomburg L, 2003, BIOCHEM J, V370, P397, DOI 10.1042/BJ20021853; SCHWARZ K, 1957, NUTRITION, V15, P255; Schweizer U, 2004, BIOCHEM J, V378, P21, DOI 10.1042/BJ20031795; Schweizer U, 2004, BRAIN RES REV, V45, P164, DOI 10.1016/j.brainresrev.2004.03.004; Schweizer U, 2005, BIOCHEM J, V386, P221, DOI 10.1042/BJ20041973; Schweizer U, 2004, J NUTR, V134, P707, DOI 10.1093/jn/134.4.707; Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005; Smith J, 2000, P NATL ACAD SCI USA, V97, P10032, DOI 10.1073/pnas.170209797; Soerensen J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001813; Valentine WM, 2008, J NEUROPATH EXP NEUR, V67, P68, DOI 10.1097/NEN.0b013e318160f347; Wallis K, 2008, J NEUROSCI, V28, P1904, DOI 10.1523/JNEUROSCI.5163-07.2008; WEBER GF, 1991, LANCET, V337, P1443, DOI 10.1016/0140-6736(91)93130-2; Wirth EK, 2009, J NEUROSCI, V29, P9439, DOI 10.1523/JNEUROSCI.6055-08.2009; Wonders CP, 2006, NAT REV NEUROSCI, V7, P687, DOI 10.1038/nrn1954; Yan J, 1998, J NEUROSCI, V18, P8682; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6; Zhang Y, 2008, J BIOL CHEM, V283, P2427, DOI 10.1074/jbc.M707951200	46	154	156	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					844	852		10.1096/fj.09-143974	http://dx.doi.org/10.1096/fj.09-143974			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19890015	Green Published			2022-12-28	WOS:000274974600020
J	Fossati, S; Cam, J; Meyerson, J; Mezhericher, E; Romero, IA; Couraud, PO; Weksler, BB; Ghiso, J; Rostagno, A				Fossati, S.; Cam, J.; Meyerson, J.; Mezhericher, E.; Romero, I. A.; Couraud, P. O.; Weksler, B. B.; Ghiso, J.; Rostagno, A.			Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-beta variants in cells composing the cerebral vessel walls	FASEB JOURNAL			English	Article						cerebral amyloid angiopathy; Alzheimer's disease; endothelial cells; smooth muscle cells; oligomerization	ALZHEIMERS-DISEASE; MUTANT PEPTIDES; DUTCH; HEREDITARY; HEMORRHAGE; PROTEIN; MODEL; DYSFUNCTION; EXPRESSION; ANGIOPATHY	Cerebral amyloid angiopathy (CAA) is an age-associated condition and a common finding in Alzheimer's disease in which amyloid-beta (A beta) vascular deposits are featured in > 80% of the cases. Familial A beta variants bearing substitutions at positions 21-23 are primarily associated with CAA, although they manifest with strikingly different clinical phenotypes: cerebral hemorrhage or dementia. The recently reported Piedmont L34V A beta mutant, located outside the hot spot 21-23, shows a similar hemorrhagic phenotype, albeit less aggressive than the widely studied Dutch E22Q variant. We monitored the apoptotic events occurring after stimulation of human brain microvascular endothelial and smooth muscle cells with nonfibrillar structures of both variants and wild-type A beta 40. Induction of analogous caspase-mediated mitochondrial pathways was elicited by all peptides, although within different time frames and intensity. Activated pathways were susceptible to pharmacological modulation either through direct inhibition of mitochondrial cytochrome c release or by the action of pan- and pathway-specific caspase inhibitors, giving a clear indication of the independent or synergistic engagement of both extrinsic and intrinsic mechanisms. Structural analyses of the A beta peptides showed that apoptosis preceded fibril formation, correlating with the presence of oligomers and/or protofibrils. The data support the notion that rare genetic mutations constitute unique paradigms to understand the molecular pathogenesis of CAA.-Fossati, S., Cam, J., Meyerson, J., Mezhericher, E., Romero, I. A., Couraud, P. O., Weksler, B. B., Ghiso, J., Rostagno, A. Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-beta variants in cells composing the cerebral vessel walls. FASEB J. 24, 229-241 (2010). www.fasebj.org	[Fossati, S.; Cam, J.; Meyerson, J.; Mezhericher, E.; Ghiso, J.; Rostagno, A.] New York Univ, Sch Med, Dept Pathol, New York, NY 10016 USA; [Ghiso, J.] New York Univ, Sch Med, Dept Psychiat, New York, NY 10016 USA; [Romero, I. A.] Open Univ, Dept Life Sci, Milton Keynes MK7 6AA, Bucks, England; [Couraud, P. O.] Univ Paris 05, Inst Cochin, Paris, France; [Weksler, B. B.] Cornell Univ, Div Hematol & Med Oncol, Weill Med Coll, New York, NY 10021 USA	New York University; New York University; Open University - UK; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Cornell University	Rostagno, A (corresponding author), New York Univ, Sch Med, Dept Pathol, 550 1st Ave TH-435, New York, NY 10016 USA.	agueda.rostagno@nyumc.org	Cam, Jorge Lora/U-4759-2018	Cam, Jorge Lora/0000-0001-8856-1053; Rostagno, Agueda/0000-0002-6817-2074; Fossati, Silvia/0000-0002-2047-222X; Romero, Ignacio/0000-0002-0322-9180	U. S. National Institutes of Health [NS-051715, AG-30539]; Alzheimer's Association; American Heart Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG030539, P30AG008051] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alzheimer's Association(Alzheimer's Association); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was partially funded by U. S. National Institutes of Health grants NS-051715 and AG-30539, the Alzheimer's Association, and the American Heart Association.	CAM J, 2006, ALZHEIMERS DIS NEW A, P397; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Cribbs DH, 2004, AM J PATHOL, V165, P353, DOI 10.1016/S0002-9440(10)63302-0; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; Dobson CM, 2001, BIOCHEM SOC SYMP, V68, P1; Folin M, 2006, INT J MOL MED, V17, P431; Frangione B, 2001, AMYLOID, V8, P36; GALLAGHER SR, 1995, CURRENT PROTOCOLS PR; Grant MA, 2007, P NATL ACAD SCI USA, V104, P16522, DOI 10.1073/pnas.0705197104; Hames BD., 1990, GEL ELECTROPHORESIS, P1; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417; Krone MG, 2008, J MOL BIOL, V381, P221, DOI 10.1016/j.jmb.2008.05.069; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Maat-Schieman M, 2005, NEUROPATHOLOGY, V25, P288, DOI 10.1111/j.1440-1789.2005.00631.x; Maat-Schieman MLC, 2000, ACTA NEUROPATHOL, V99, P409, DOI 10.1007/s004010051143; Matsui T, 2006, J NEUROPATH EXP NEUR, V65, P508, DOI 10.1097/01.jnen.0000229238.05748.12; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Murakami K, 2003, J BIOL CHEM, V278, P46179, DOI 10.1074/jbc.M301874200; Obici L, 2005, ANN NEUROL, V58, P639, DOI 10.1002/ana.20571; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Revesz T, 2009, ACTA NEUROPATHOL, V118, P115, DOI 10.1007/s00401-009-0501-8; Rostagno A, 2005, CELL MOL LIFE SCI, V62, P1814, DOI 10.1007/s00018-005-5092-5; Sajan Farrah D, 2007, Am J Alzheimers Dis Other Demen, V22, P319, DOI 10.1177/1533317507302447; Solito R, 2009, EXP CELL RES, V315, P385, DOI 10.1016/j.yexcr.2008.11.002; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; Takuma K, 2005, J PHARMACOL SCI, V97, P312, DOI 10.1254/jphs.CPJ04006X; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Viana RJS, 2009, CELL MOL LIFE SCI, V66, P1094, DOI 10.1007/s00018-009-8746-x; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x; Wang X, 2008, J NEUROSCI, V28, P9473, DOI 10.1523/JNEUROSCI.1867-08.2008; Weksler BB, 2005, FASEB J, V19, P1872, DOI 10.1096/fj.04-3458fje; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; Xu J, 2001, J CEREBR BLOOD F MET, V21, P702, DOI 10.1097/00004647-200106000-00008; Zhang-Nunes SX, 2006, BRAIN PATHOL, V16, P30, DOI 10.1111/j.1750-3639.2006.tb00559.x; Zheng J, 2007, BIOPHYS J, V93, P3046, DOI 10.1529/biophysj.107.110700	40	57	67	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					229	241		10.1096/fj.09-139584	http://dx.doi.org/10.1096/fj.09-139584			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19770225	Green Published			2022-12-28	WOS:000273233600024
J	Kaur, M; Saxena, A; Rai, A; Bhatnagar, R				Kaur, Manpreet; Saxena, Ankur; Rai, Anant; Bhatnagar, Rakesh			Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice	FASEB JOURNAL			English	Article						encephalitis; intramuscular administration; rabies virus neutralizing antibodies; survival; prophylactic; therapeutic	MHC CLASS-I; CYTOTOXIC T-LYMPHOCYTES; B SURFACE-ANTIGEN; GENE-GUN; VIRUS; IMMUNOGENICITY; IMMUNIZATION; INJECTION; RESPONSES; IMMUNITY	The worldwide incidence of rabies and the inability of currently used vaccination strategies to provide highly potent and cost-effective therapy indicate the need for an improved rabies vaccine. Thus, DNA vaccine based on lysosome-targeted glycoprotein of the rabies virus was evaluated in BALB/c mice. It imparted partial protection (60%) against challenge with 20 LD50 of the challenge virus standard (CVS) strain of rabies virus. To improve the outcome of vaccination, to ultimately enhance the immune response, we investigated different routes for DNA vaccine delivery, varied doses of DNA, and the influence of adjuvant supplementation. The highest immune response pertaining to IgG antibody titer, with a predominantly IgG1/IgG2a subclass distribution, effective cellular immunity, and a high level of rabies virus neutralizing antibodies (RVNAs) was attained by the optimized DNA vaccine formulation comprising intramuscular administration of 100 mu g of DNA vaccine supplemented with Emulsigen (R)-D. In preexposure prophylaxis, a 3-dose regimen of this formulation generated a high RVNA titer (32 IU/ml) and conferred complete protection against challenge with 20 LD50 of CVS. For postexposure efficacy analysis, rabies was experimentally induced with 50 LD50 of CVS. Subsequent therapy with 5 doses of the formulation completely prevented rabies in BALB/c mice, which maintained protective RVNA titers of 4 IU/ml. The World Health Organization recommended rabies protective titer threshold is 0.5 IU/ml. Thus, this optimized DNA vaccine formulation provides an avenue for preventing and controlling rabies.-Kaur, M., Saxena, A., Rai, A., and Bhatnagar, R. Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice. FASEB J. 24, 173-183 ( 2010). www.fasebj.org	[Kaur, Manpreet; Bhatnagar, Rakesh] Jawaharlal Nehru Univ, Lab Mol Biol & Genet Engn, Sch Biotechnol, New Delhi 110067, Delhi, India; [Saxena, Ankur; Rai, Anant] Indian Vet Res Inst, Natl Biotechnol Ctr, Izatnagar 243122, Uttar Pradesh, India	Jawaharlal Nehru University, New Delhi; Indian Council of Agricultural Research (ICAR); ICAR - Indian Veterinary Research Institute	Bhatnagar, R (corresponding author), Jawaharlal Nehru Univ, Lab Mol Biol & Genet Engn, Sch Biotechnol, New Delhi 110067, Delhi, India.	rakbhat01@yahoo.com	Rai, Anant/AAJ-9011-2020	Rai, Anant/0000-0003-3225-215X	Department of Biotechnology, Government of India; Council of Scientific and Industrial Research, Government of India	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); Council of Scientific and Industrial Research, Government of India(Council of Scientific & Industrial Research (CSIR) - India)	We thank Dr. V. Srinivasan ( Indian Immunological Ltd., Hyderabad, India) for providing inactivated PV viral antigen and rabies reference antiserum. We also thank Anuj Kumar Sharma ( School of Biotechnology, Jawaharlal Nehru University) for critical suggestions in manuscript preparation. This study was supported by a grant from the Department of Biotechnology, Government of India. M. K is the recipient of a Senior Research Fellowship from the Council of Scientific and Industrial Research, Government of India. The results published in this work are covered under Indian Patent 1449/DEL/2008, filed June 17, 2008, and PCT/IN2008/000578/5598, filed September 9, 2008.	Alves AMB, 1998, VACCINE, V16, P9, DOI 10.1016/S0264-410X(97)00147-3; [Anonymous], 2007, Wkly Epidemiol Rec, V82, P425; Bahloul C, 2006, VACCINE, V24, P1063, DOI 10.1016/j.vaccine.2005.09.016; Bahloul C, 2003, VACCINE, V22, P177, DOI 10.1016/S0264-410X(03)00568-1; Beran J, 2005, VACCINE, V23, P3902, DOI 10.1016/j.vaccine.2005.03.007; Chow YH, 1997, J VIROL, V71, P169, DOI 10.1128/JVI.71.1.169-178.1997; CONN A, 2726 BIOR LAB; Conry RM, 2002, CLIN CANCER RES, V8, P2782; Corr M, 1999, J IMMUNOL, V163, P4721; Dileo J, 2003, HUM GENE THER, V14, P79, DOI 10.1089/10430340360464732; Dobano C, 2007, IMMUNOL LETT, V111, P92, DOI 10.1016/j.imlet.2007.05.007; Dodet B, 2007, VACCINE, V25, P4123, DOI 10.1016/j.vaccine.2007.03.002; FELGNER P L, 1990, Advanced Drug Delivery Reviews, V5, P163, DOI 10.1016/0169-409X(90)90015-K; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; Fischer L, 2003, VACCINE, V21, P4593, DOI 10.1016/S0264-410X(03)00504-8; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; Greenland JR, 2007, VACCINE, V25, P3731, DOI 10.1016/j.vaccine.2007.01.120; Hanly W. Carey, 1995, ILAR J, V37, P93; Haynes JR, 2004, EXPERT OPIN BIOL TH, V4, P889, DOI 10.1517/14712598.4.6.889; Ito K, 2003, MOL IMMUNOL, V39, P847, DOI 10.1016/S0161-5890(03)00024-5; Kaur M, 2009, VACCINE, V27, P2128, DOI 10.1016/j.vaccine.2009.01.128; KIM N, 2006, CLIN MOL ALLERGY, V4, P1; Kirman JR, 2003, CURR OPIN IMMUNOL, V15, P471, DOI 10.1016/S0952-7915(03)00068-2; Klinman DM, 1997, J IMMUNOL, V158, P3635; Li WR, 2006, ACTA VIROL, V50, P251; LIN BC, 2006, 221228 AASV; Lin CC, 2004, MOL THER, V10, P290, DOI 10.1016/j.ymthe.2004.05.015; Lodmell DL, 1998, VACCINE, V16, P115, DOI 10.1016/S0264-410X(97)88325-9; Lodmell DL, 2003, VACCINE, V21, P3998, DOI 10.1016/S0264-410X(03)00297-4; Osorio JE, 1999, VACCINE, V17, P1109, DOI 10.1016/S0264-410X(98)00328-4; Patial S, 2007, VACCINE, V25, P4020, DOI 10.1016/j.vaccine.2007.02.051; Pavlenko M, 2004, BRIT J CANCER, V91, P688, DOI 10.1038/sj.bjc.6602019; Perrin P, 1999, VACCINE, V18, P479, DOI 10.1016/S0264-410X(99)00247-9; Schunk MK, 2005, ILAR J, V46, P241, DOI 10.1093/ilar.46.3.241; Smith J. S., 1996, P181; TESORO CE, 2006, DEV BIOL BASEL, V125, P221; Cruz ET, 2008, VACCINE, V26, P6936, DOI 10.1016/j.vaccine.2008.09.083; Timmerman JM, 2002, CANCER RES, V62, P5845; Torres CAT, 1997, J IMMUNOL, V158, P4529; Trimble C, 2003, VACCINE, V21, P4036, DOI 10.1016/S0264-410X(03)00275-5; TURING T, 1999, CURR OPIN MOL THER, V1, P216; Ulmer JB, 1999, VACCINE, V18, P18, DOI 10.1016/S0264-410X(99)00151-6; Ulmer JB, 1996, IMMUNOLOGY, V89, P59, DOI 10.1046/j.1365-2567.1996.d01-718.x; van Rooij EMA, 2002, J VIROL, V76, P10540, DOI 10.1128/JVI.76.20.10540-10545.2002; Vandermeer J, 2004, FOREST ECOL MANAG, V199, P125, DOI 10.1016/j.foreco.2004.05.033; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105	48	21	25	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					173	183		10.1096/fj.09-138644	http://dx.doi.org/10.1096/fj.09-138644			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19741168				2022-12-28	WOS:000273233600019
J	Wu, XA; Ye, S; Guo, SY; Yan, WP; Bartlam, M; Rao, ZH				Wu, Xiaoai; Ye, Sheng; Guo, Shuyuan; Yan, Wupeng; Bartlam, Mark; Rao, Zihe			Structural basis for a reciprocating mechanism of negative cooperativity in dimeric phosphagen kinase activity	FASEB JOURNAL			English	Article						crystal structure; arginine kinase; creatine kinase; energy metabolism	MUSCLE CREATINE-KINASE; PROTEIN-PROTEIN INTERFACES; STATE ANALOG COMPLEX; ARGININE KINASE; CRYSTAL-STRUCTURE; INDUCED FIT; EVOLUTION; SUBUNITS; SYSTEMS	Phosphagen kinase (PK) family members catalyze the reversible phosphoryl transfer between phosphagen and ADP to reserve or release energy in cell energy metabolism. The structures of classic quaternary complexes of dimeric creatine kinase (CK) revealed asymmetric ligand binding states of two protomers, but the significance and mechanism remain unclear. To understand this negative cooperativity further, we determined the first structure of dimeric arginine kinase (dAK), another PK family member, at 1.75 angstrom, as well as the structure of its ternary complex with AMPPNP and arginine. Further structural analysis shows that the ligand-free protomer in a ligand-bound dimer opens more widely than the protomers in a ligand-free dimer, which leads to three different states of a dAK protomer. The unexpected allostery of the ligand-free protomer in a ligand-bound dimer should be relayed from the ligand-binding-induced allostery of its adjacent protomer. Mutations that weaken the inter-protomer connections dramatically reduced the catalytic activities of dAK, indicating the importance of the allosteric propagation mediated by the homodimer interface. These results suggest a reciprocating mechanism of dimeric PK, which is shared by other ATP related oligomeric enzymes, e. g., ATP synthase.-Wu, X., Ye, S., Guo, S., Yan, W., Bartlam, M., Rao, Z. Structural basis for a reciprocating mechanism of negative cooperativity in dimeric phosphagen kinase activity. FASEB J. 24, 242-252 ( 2010). www.fasebj.org	[Wu, Xiaoai; Yan, Wupeng; Rao, Zihe] Tsinghua Univ, Struct Biol Lab, Sch Med, Beijing 100084, Peoples R China; [Ye, Sheng] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY USA; [Ye, Sheng] Howard Hughes Med Inst, New York, NY USA; [Guo, Shuyuan] Beijing Inst Technol, Sch Life Sci & Technol, Beijing 100081, Peoples R China; [Bartlam, Mark; Rao, Zihe] Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China; [Bartlam, Mark; Rao, Zihe] Nankai Univ, Tianjin Key Lab Prot Sci, Tianjin 300071, Peoples R China; [Rao, Zihe] Chinese Acad Sci, Inst Biophys, Natl Lab Macromol, Beijing 100080, Peoples R China	Tsinghua University; Columbia University; Howard Hughes Medical Institute; Beijing Institute of Technology; Nankai University; Nankai University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Rao, ZH (corresponding author), Tsinghua Univ, Struct Biol Lab, Sch Med, Life Sci Bldg, Beijing 100084, Peoples R China.	raozh@xtal.tsinghua.edu.cn	Rao, Zihe/HCH-6944-2022	Bartlam, Mark/0000-0001-5173-5080	Ministry of Science and Technology [2007CB914300]; Ministry of Science, the Technology International Cooperation Project [2006DFB32420]; Natural Science Foundation of China [30221003]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Ministry of Science, the Technology International Cooperation Project; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Prof. Xicheng Wang (Tsinghua University, Beijing, China) for providing the cDNA of sea cucumber dAK; John Schwanof, Randy Abramowitz, and Dr. Seetharaman Jayaraman for help with synchrotron data collection; and Prof. Bingbin Yu and Jiangang Chen for assistance with catalytic assays. We also thank Prof. Wayne A. Hendrickson (Columbia University, New York, NY, USA) for his kind supervision of the cooperation work in his lab. We are grateful to Dr. Luet Lok Wong (Department of Chemistry, University of Oxford, Oxford, UK) and Dr. K. Christopher Min ( Department of Neurology, Columbia University) for valuable comments and critical discussion. This work was supported by the Ministry of Science and Technology 973 Project ( grant no. 2007CB914300), the Ministry of Science, the Technology International Cooperation Project ( grant 2006DFB32420), and the Natural Science Foundation of China ( grant 30221003). The coordinates and structure factors for SeMet dAK ( PDB accession code 3JU5) and the ternary dAK-AMPPNP-Arg complex ( PDB code 3JU6) have been deposited in the Protein Data Bank.	Aksenov MY, 1997, EXP NEUROL, V146, P458, DOI 10.1006/exnr.1997.6550; Apple FS, 1999, CORONARY ARTERY DIS, V10, P75, DOI 10.1097/00019501-199903000-00003; Bong SM, 2008, FEBS LETT, V582, P3959, DOI 10.1016/j.febslet.2008.10.039; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Brunger AT, 2007, NAT PROTOC, V2, P2728, DOI 10.1038/nprot.2007.406; Ellington WR, 2001, ANNU REV PHYSIOL, V63, P289, DOI 10.1146/annurev.physiol.63.1.289; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P13861, DOI 10.1021/bi026655p; Larsen TA, 1998, STRUCT FOLD DES, V6, P421, DOI 10.1016/S0969-2126(98)00044-6; Laskowski RA, 1997, TRENDS BIOCHEM SCI, V22, P488, DOI 10.1016/S0968-0004(97)01140-7; Masaike T, 2008, NAT STRUCT MOL BIOL, V15, P1326, DOI 10.1038/nsmb.1510; McCoy AJ, 2007, ACTA CRYSTALLOGR D, V63, P32, DOI 10.1107/S0907444906045975; Morrison J. F., 1973, ENZYMES, V8, P457, DOI 10.1016/S1874-6047; NEWSHOLME EA, 1978, BIOCHEM J, V172, P533, DOI 10.1042/bj1720533; Ohren JF, 2007, ACTA CRYSTALLOGR D, V63, P381, DOI 10.1107/S0907444906056204; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ozawa E, 1999, MOL CELL BIOCHEM, V190, P143, DOI 10.1023/A:1006974613418; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PRICE NC, 1976, BIOCHIM BIOPHYS ACTA, V445, P364, DOI 10.1016/0005-2744(76)90090-5; Rao JK, 1998, FEBS LETT, V439, P133; Rodier F, 2005, PROTEINS, V60, P36, DOI 10.1002/prot.20478; Schiffenbauer YS, 1996, AM J PHYSIOL-CELL PH, V270, pC160, DOI 10.1152/ajpcell.1996.270.1.C160; Schneider TR, 2000, ACTA CRYSTALLOGR D, V56, P714, DOI 10.1107/S0907444900003723; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Simanshu DK, 2005, J MOL BIOL, V352, P876, DOI 10.1016/j.jmb.2005.07.069; Suzuki T, 1999, BIOCHEM J, V340, P671, DOI 10.1042/0264-6021:3400671; Suzuki T, 2009, COMP BIOCHEM PHYS B, V152, P60, DOI 10.1016/j.cbpb.2008.09.087; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Uda K, 2004, PROTEIN J, V23, P53, DOI 10.1023/B:JOPC.0000016258.55991.8a; Uda K, 2006, COMP BIOCHEM PHYS D, V1, P209, DOI 10.1016/j.cbd.2005.10.007; Watts D.C., 1975, Symposia Zool Soc Lond, VNo. 36, P105; WATTS DC, 1971, BIOCH EVOLUTION ORIG, P150; Yamaguchi H, 2001, MOL CELL, V7, P1047, DOI 10.1016/S1097-2765(01)00256-8; Yousef MS, 2003, PROTEIN SCI, V12, P103, DOI 10.1110/ps.0226303; Yu Z, 2002, PROTEIN PEPTIDE LETT, V9, P545; Zhou GF, 1998, P NATL ACAD SCI USA, V95, P8449, DOI 10.1073/pnas.95.15.8449; Zhou GF, 2000, BIOPHYS J, V78, P1541, DOI 10.1016/S0006-3495(00)76706-3	38	27	27	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2010	24	1					242	252		10.1096/fj.09-140194	http://dx.doi.org/10.1096/fj.09-140194			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19783784				2022-12-28	WOS:000273233600025
J	Bangham, A				Bangham, Alec			The physical chemistry of self/non-self: jigsaws, transplants and fetuses	FASEB JOURNAL			English	Editorial Material									Great Shelford, Cambridge CB2 5EG, England		Bangham, A (corresponding author), Great Shelford, 17 High Green, Cambridge CB2 5EG, England.	alecbangham@wwr.co.uk						Abramson HA, 1942, ELECTROPHORESIS PROT; Bangham AD, 2008, J LIPOSOME RES, V18, P91, DOI [10.1080/08982100801894034, 10.1080/08982100801894034 ]; BANGHAM AD, 1959, BIOCHEM J, V72, P486, DOI 10.1042/bj0720486; BANGHAM AD, 1983, BIOL CELL, V47, P1; BANGHAM AD, 1958, BIOCHEM J, V69, P12, DOI 10.1042/bj0690012; Bangham AD, 2001, J LIPOSOME RES, V11, P265; BANGHAM DH, 1949, FUEL 28, V10, P31; Calne Roy, 1998, ULTIMATE GIFT STORY; Fehr T, 2008, TRANSPL INT, V21, P1118, DOI 10.1111/j.1432-2277.2008.00783.x; Kawai T, 2008, NEW ENGL J MED, V358, P353, DOI 10.1056/NEJMoa071074; Lasic DD, 1995, STEALTH LIPOSOMES; Penn DJ, 2007, J R SOC INTERFACE, V4, P331, DOI 10.1098/rsif.2006.0182; SINGH PB, 1987, NATURE, V327, P161, DOI 10.1038/327161a0; Smith D, 2005, MASS SPECTROM REV, V24, P661, DOI 10.1002/mas.20033	14	1	1	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2009	23	11					3644	3646		10.1096/fj.09-1102ufm	http://dx.doi.org/10.1096/fj.09-1102ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19875638				2022-12-28	WOS:000271272500002
J	Lee, MH; Koria, P; Qu, J; Andreadis, ST				Lee, Meng-Horng; Koria, Piyush; Qu, Jun; Andreadis, Stelios T.			JNK phosphorylates beta-catenin and regulates adherens junctions	FASEB JOURNAL			English	Article						cell adhesion; E-cadherin; epithelial development; cell invasion; SP600125; okadaic acid	N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; PROTEIN; MORPHOGENESIS; LOCALIZATION; ACTIVATION; EXPRESSION; ADHESION; PATHWAY; TARGET	The c-Jun amino-terminal kinase (JNK) is an important player in inflammation, proliferation, and apoptosis. More recently, JNK was found to regulate cell migration by phosphorylating paxillin. Here, we report a novel role of JNK in cell adhesion. Specifically, we provide evidence that JNK binds to E-cadherin/beta-catenin complex and phosphorylates beta-catenin at serine 37 and threonine 41, the sites also phosphorylated by GSK-3 beta. Inhibition of JNK kinase activity using dominant-negative constructs reduces phosphorylation of beta-catenin and promotes localization of E-cadherin/beta-catenin complex to cell-cell contact sites. Conversely, activation of JNK induces beta-catenin phosphorylation and disruption of cell contacts, which are prevented by JNK siRNA. We propose that JNK binds to beta-catenin and regulates formation of adherens junctions, ultimately controlling cell-to-cell adhesion.-Lee, M.-H., Koria, P., Qu, J., Andreadis, S. T. JNK phosphorylates beta-catenin and regulates adherens junctions. FASEB J. 23, 3874-3883 (2009). www.fasebj.org	[Lee, Meng-Horng; Koria, Piyush; Andreadis, Stelios T.] SUNY Buffalo, Bioengn Lab, Dept Chem & Biol Engn, Amherst, NY 14260 USA; [Qu, Jun] SUNY Buffalo, Dept Pharmaceut Sci, Amherst, NY 14260 USA; [Qu, Jun; Andreadis, Stelios T.] SUNY Buffalo, Ctr Excellence Bioinformat & Life Sci, Amherst, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Andreadis, ST (corresponding author), SUNY Buffalo, Bioengn Lab, Dept Chem & Biol Engn, 908 Furnas Hall, Amherst, NY 14260 USA.	sandread@buffalo.edu			National Institutes of Health (NIH) [R01 EB 000876-01]; National Science Foundation [BES-0354626]; National Center for Research Resources, NIH [S10-RR14592, S10-RR021221]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR021221, S10RR014592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000876] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); National Center for Research Resources, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work was supported by grants from the National Institutes of Health (NIH; R01 EB 000876-01) and the National Science Foundation (BES-0354626) to S. T. A. We thank the Pharmaceutical Sciences Instrumentation Facility at the University at Buffalo (UB) for the use of the liquid chromatography/mass spectrometry systems. The MS instruments were obtained from shared instrumentation grants S10-RR14592 and S10-RR021221 from the National Center for Research Resources, NIH. We also thank Dr. Wade J. Sigurdson (Confocal Microscopy and Flow Cytometry Facility, UB) for his help with confocal microscopy.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Altan ZM, 2004, BIOCHEM BIOPH RES CO, V322, P56, DOI 10.1016/j.bbrc.2004.07.079; Avdi NJ, 2002, J BIOL CHEM, V277, P40687, DOI 10.1074/jbc.M204455200; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Dietrich C, 2002, BIOCHEM BIOPH RES CO, V292, P195, DOI 10.1006/bbrc.2002.6625; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Iordanov Mihail S., 2000, Molecular Cell Biology Research Communications, V4, P122, DOI 10.1006/mcbr.2000.0266; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Koria P, 2006, J INVEST DERMATOL, V126, P1834, DOI 10.1038/sj.jid.5700325; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Liao GH, 2006, P NATL ACAD SCI USA, V103, P16313, DOI 10.1073/pnas.0602557103; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Liu JY, 2008, CARDIOVASC RES, V79, P24, DOI 10.1093/cvr/cvn059; Qu J, 2005, RAPID COMMUN MASS SP, V19, P2857, DOI 10.1002/rcm.2138; Ramet M, 2002, DEV BIOL, V241, P145, DOI 10.1006/dbio.2001.0502; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; Sadot E, 2002, J CELL SCI, V115, P2771; Serres M, 1997, EXP CELL RES, V231, P163, DOI 10.1006/excr.1996.3443; Sharma M, 2006, J BIOL CHEM, V281, P17140, DOI 10.1074/jbc.M513027200; Shintani Y, 2006, MOL BIOL CELL, V17, P2963, DOI 10.1091/mbc.E05-12-1123; Steen H, 2006, MOL CELL PROTEOMICS, V5, P172, DOI 10.1074/mcp.M500135-MCP200; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Thyssen G, 2006, MOL CELL BIOL, V26, P8857, DOI 10.1128/MCB.01031-06; Tian J, 2009, GENE THER, V16, P874, DOI 10.1038/gt.2009.46; Tian J, 2008, MOL THER, V16, P1146, DOI 10.1038/mt.2008.79; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200	39	83	85	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3874	3883		10.1096/fj.08-117804	http://dx.doi.org/10.1096/fj.08-117804			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19667122	Green Published			2022-12-28	WOS:000271272500023
J	Zhang, L; Li, L; Liu, H; Borowitz, JL; Isom, GE				Zhang, Lu; Li, Li; Liu, Han; Borowitz, Joseph L.; Isom, Gary E.			BNIP3 mediates cell death by different pathways following localization to endoplasmic reticulum and mitochondrion	FASEB JOURNAL			English	Article						apoptosis; Bcl-2; calcium; thapsagargin	PERMEABILITY TRANSITION PORE; PROTEIN BNIP3; UP-REGULATION; TRANSMEMBRANE DOMAIN; INDUCED APOPTOSIS; BH3 DOMAIN; CA2+; BCL-2; BAX; CALCIUM	BNIP3 (Bcl-2/adenovirus E1B 19-kDa interacting protein 3) is a BH3-only proapoptotic member of the Bcl-2 family. Because the interaction of Bcl-2 proteins with intracellular Ca2+ stores has been linked to apoptosis, the role of Ca2+ transfer between endoplasmic reticulum ( ER) and mitochondria in BNIP3-mediated cell death was determined in a rat dopaminergic neuronal cell line, Mes 23.5. BNIP3 mutants were constructed to target either ER or mitochondria. Localization of BNIP3 to the ER membrane facilitated release of Ca2+ and subsequently increased uptake of Ca2+ into mitochondria. Excessive accumulation of mitochondrial Ca2+ decreased mitochondrial membrane potential (Delta Psi(m)), resulting in execution of a caspase-independent cell death. Reduction of ER Ca2+ induced by ER-targeted BNIP3 and the subsequent cell death was blocked by the antiapoptotic protein, Bcl-2. On the other hand, mitochondria-targeted BNIP3 initiated apoptosis by a Ca2+-independent mechanism by inducing mitochondrial pore transition and dissipation of Delta Psi(m). The disruption of Delta Psi(m) and cell death was not blocked by Bcl-2 overexpression. These findings show that BNIP3 undergoes a dual subcellular localization and initiates different cell death signaling events in the ER and mitochondria. Bcl-2 counters the BNIP3-initiated mobilization of ER Ca2+ depletion to reduce the level of apoptosis.-Zhang, L., Li, L., Liu, H., Borowitz, J. L., Isom, G. E. BNIP3 mediates cell death by different pathways following localization to endoplasmic reticulum and mitochondrion. FASEB J. 23, 3405-3414 ( 2009). www.fasebj.org	[Zhang, Lu; Li, Li; Liu, Han; Borowitz, Joseph L.; Isom, Gary E.] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Isom, GE (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA.	geisom@purdue.edu			U. S. National Institutes of Health [ES04140]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004140] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by a grant from the U. S. National Institutes of Health (ES04140). The authors thank Andrew D. Monnot ( School of Health Science, Purdue University) for technical assistance in conducting the confocal microscopy and image analysis.	Bocharov EV, 2007, J BIOL CHEM, V282, P16256, DOI 10.1074/jbc.M701745200; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Degterev A, 2008, NAT REV MOL CELL BIO, V9, P378, DOI 10.1038/nrm2393; Frazier DP, 2006, ANTIOXID REDOX SIGN, V8, P1625, DOI 10.1089/ars.2006.8.1625; Gustavsson N, 2006, BIOCHEM BIOPH RES CO, V340, P1119, DOI 10.1016/j.bbrc.2005.12.119; Handrick R, 2005, BIOCHEM PHARMACOL, V70, P837, DOI 10.1016/j.bcp.2005.06.021; Hanson CJ, 2008, CELL CALCIUM, V44, P243, DOI 10.1016/j.ceca.2007.11.014; Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036; Juhaszova M, 2008, ANN NY ACAD SCI, V1123, P197, DOI 10.1196/annals.1420.023; Kalamvoki M, 2007, J VIROL, V81, P6316, DOI 10.1128/JVI.00311-07; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kim R, 2005, ONCOL REP, V14, P595; Kolar SSN, 2007, CANCER RES, V67, P5561, DOI 10.1158/0008-5472.CAN-06-4716; Kubl DA, 2007, BIOCHEM J, V405, P407, DOI 10.1042/BJ20070319; LE WD, 1995, BRAIN RES, V686, P49, DOI 10.1016/0006-8993(95)00450-5; Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Orlandi F, 2007, CLIN CANCER RES, V13, P6195, DOI 10.1158/1078-0432.CCR-07-0258; PARIKH HN, 1995, SYNAPSE, V21, P278, DOI 10.1002/syn.890210304; Pinton P, 2006, CELL DEATH DIFFER, V13, P1409, DOI 10.1038/sj.cdd.4401960; Pizzo P, 2007, TRENDS CELL BIOL, V17, P511, DOI 10.1016/j.tcb.2007.07.011; Prabhakaran K, 2007, NEUROSCIENCE, V150, P159, DOI 10.1016/j.neuroscience.2007.07.033; Prabhakaran K, 2005, J PHARMACOL EXP THER, V314, P1338, DOI 10.1124/jpet.105.088625; Putney JW, 2005, J CELL BIOL, V169, P381, DOI 10.1083/jcb.200503161; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rong YP, 2008, MOL CELL, V31, P255, DOI 10.1016/j.molcel.2008.06.014; Schmidt-Kastner R, 2004, BRAIN RES, V1001, P133, DOI 10.1016/j.brainres.2003.11.065; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Tan EY, 2007, CLIN CANCER RES, V13, P467, DOI 10.1158/1078-0432.CCR-06-1466; Toda T, 2007, AM J PHYSIOL-HEART C, V293, pH3517, DOI 10.1152/ajpheart.00483.2006; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Wang WP, 2006, J BIOL CHEM, V281, P19676, DOI 10.1074/jbc.M602802200; Webster KA, 2005, J MOL CELL CARDIOL, V38, P35, DOI 10.1016/j.yjmcc.2004.11.007; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Zhang L, 2007, FREE RADICAL BIO MED, V43, P117, DOI 10.1016/j.freeradbiomed.2007.04.005; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	40	43	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3405	3414		10.1096/fj.08-124354	http://dx.doi.org/10.1096/fj.08-124354			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19535684	Green Published			2022-12-28	WOS:000270354300018
J	Zhang, XF; Kazerounian, S; Duquette, M; Perruzzi, C; Nagy, JA; Dvorak, HF; Parangi, S; Lawler, J				Zhang, Xuefeng; Kazerounian, Shideh; Duquette, Mark; Perruzzi, Carole; Nagy, Janice A.; Dvorak, Harold F.; Parangi, Sareh; Lawler, Jack			Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level	FASEB JOURNAL			English	Article						KDR; angiogenesis; integrin; CD36; VEGFR2	NITRIC-OXIDE; TUMOR-GROWTH; TYPE-1 REPEATS; DEFICIENT MICE; ANGIOGENESIS; CELLS; INHIBITION; PROTEINS; VEGF; BINDING	Vascular endothelial growth factor ( VEGF) is a well-established stimulator of vascular permeability and angiogenesis, whereas thrombospondin-1 (TSP-1) is a potent angiogenic inhibitor. In this study, we have found that the TSP-1 receptors CD36 and beta 1 integrin associate with the VEGF receptor 2 (VEGFR2). The coclustering of receptors that regulate angiogenesis may provide the endothelial cell with a platform for integration of positive and negative signals in the plane of the membrane. Thus, this complex may represent a molecular switch that regulates angiogenesis and determines endothelial cell behavior. In this context, physiological levels of TSP-1 appear to support VEGFR2 function on both the cellular and tissue level, because phosphorylation of VEGFR2 and vascular permeability in response to VEGF are decreased in TSP-1-null mice and isolated endothelial cells. A therapeutic agent based on the antiangiogenic domain of TSP-1, designated 3TSR ( for three TSP-1 type 1 repeats), has significant antiangiogenic and antitumor efficacy. Systemic treatment of wild-type mice with 3TSR significantly decreased VEGF-induced permeability. Consistent with this result, VEGF-stimulated phosphorylation of VEGFR2 was also significantly decreased in lung extracts from 3TSR-treated mice. Moreover, 3TSR significantly decreased VEGF-stimulated VEGFR2 phosphorylation in human dermal microvascular endothelial cells in culture. Taken together, the results indicate that TSP-1 and 3TSR modulate the function of VEGFR2.-Zhang, X., Kazerounian, S., Duquette, M., Perruzzi, C., Nagy, J. A., Dvorak, H. J., Parangi, S., and Lawler, J. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J. 23, 3368-3376 ( 2009). www.fasebj.org	[Zhang, Xuefeng; Kazerounian, Shideh; Duquette, Mark; Perruzzi, Carole; Nagy, Janice A.; Dvorak, Harold F.; Lawler, Jack] Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA; [Zhang, Xuefeng; Kazerounian, Shideh; Duquette, Mark; Perruzzi, Carole; Nagy, Janice A.; Dvorak, Harold F.; Parangi, Sareh; Lawler, Jack] Harvard Univ, Sch Med, Boston, MA USA; [Parangi, Sareh] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Lawler, J (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, 330 Brookline Ave,EC-CLS-503, Boston, MA 02215 USA.	jlawler@bidmc.harvard.edu	Lawler, Jack/AAJ-1379-2020		NIH [CA92644, CA130895]; NATIONAL CANCER INSTITUTE [P01CA092644, K08CA088965, R01CA130895] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Richard O. Hynes ( Massachusetts Institute of Technology, Cambridge, MA, USA) for antibodies of beta 1 integrin and Sami Lawler and Raji Bhat for help in preparing the manuscript. This work was supported by NIH grants CA92644 and CA130895.	Agah A, 2002, AM J PATHOL, V161, P831, DOI 10.1016/S0002-9440(10)64243-5; Bauer PM, 2005, P NATL ACAD SCI USA, V102, P204, DOI 10.1073/pnas.0406092102; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Dawson DW, 1999, MOL PHARMACOL, V55, P332, DOI 10.1124/mol.55.2.332; Ebbinghaus S, 2007, CLIN CANCER RES, V13, P6689, DOI 10.1158/1078-0432.CCR-07-1477; Geretti E, 2008, ANGIOGENESIS, V11, P31, DOI 10.1007/s10456-008-9097-1; Greenaway J, 2007, J CELL PHYSIOL, V210, P807, DOI 10.1002/jcp.20904; Gupta K, 1999, Angiogenesis, V3, P147, DOI 10.1023/A:1009018702832; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Hoffman R, 2004, MED HYPOTHESES, V63, P675, DOI 10.1016/j.mehy.2004.01.038; Huang HH, 2004, MOL CANCER RES, V2, P541; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Isenberg JS, 2008, CELL MOL LIFE SCI, V65, P728, DOI 10.1007/s00018-007-7488-x; Isenberg JS, 2007, J BIOL CHEM, V282, P15404, DOI 10.1074/jbc.M701638200; Isenberg JS, 2009, NAT REV CANCER, V9, P182, DOI 10.1038/nrc2561; Isenberg JS, 2005, P NATL ACAD SCI USA, V102, P13141, DOI 10.1073/pnas.0502977102; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kazerounian S, 2008, CELL MOL LIFE SCI, V65, P700, DOI 10.1007/s00018-007-7486-z; Kowanetz M, 2006, CLIN CANCER RES, V12, P5018, DOI 10.1158/1078-0432.CCR-06-1520; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; Lawler J, 2001, AM J PATHOL, V159, P1949, DOI 10.1016/S0002-9440(10)63042-8; Ling Y, 2007, BIOCHEM BIOPH RES CO, V361, P79, DOI 10.1016/j.bbrc.2007.06.155; Margosio B, 2008, INT J BIOCHEM CELL B, V40, P700, DOI 10.1016/j.biocel.2007.10.002; Markovic SN, 2007, AM J CLIN ONCOL-CANC, V30, P303, DOI 10.1097/01.coc.0000256104.80089.35; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Miao WM, 2001, CANCER RES, V61, P7830; Miao WM, 2001, BLOOD, V97, P1689, DOI 10.1182/blood.V97.6.1689; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; Nagy Peter D., 2008, V451, P55, DOI 10.1007/978-1-59745-102-4_4; Primo L, 2005, FASEB J, V19, P1713, DOI 10.1096/fj.05-3697fje; Reiher FK, 2002, INT J CANCER, V98, P682, DOI 10.1002/ijc.10247; Ren B, 2009, CANCER RES, V69, P3856, DOI 10.1158/0008-5472.CAN-08-2940; Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Scheef EA, 2007, MOL VIS, V13, P1483; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Shaked Y, 2005, CANCER CELL, V7, P101, DOI 10.1016/j.ccr.2004.11.023; Short SM, 2005, J CELL BIOL, V168, P643, DOI 10.1083/jcb.200407060; Stipp CS, 2001, J BIOL CHEM, V276, P4853, DOI 10.1074/jbc.M009859200; Sun JF, 2009, AM J PHYSIOL-HEART C, V296, pH1344, DOI 10.1152/ajpheart.01246.2008; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; Wang YJ, 2005, J CELL PHYSIOL, V204, P352, DOI 10.1002/jcp.20290; Yano K, 2003, J INVEST DERMATOL, V120, P14, DOI 10.1046/j.1523-1747.2003.12045.x; Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317; Yee KO, 2009, BREAST CANCER RES TR, V114, P85, DOI 10.1007/s10549-008-9992-6; Zhang XF, 2007, MICROVASC RES, V74, P90, DOI 10.1016/j.mvr.2007.04.007	48	87	89	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3368	3376		10.1096/fj.09-131649	http://dx.doi.org/10.1096/fj.09-131649			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19528255	Green Published			2022-12-28	WOS:000270354300014
J	Jia, Y; Warin, R; Yu, XB; Epstein, R; Noguchi, CT				Jia, Yi; Warin, Renaud; Yu, Xiaobing; Epstein, Reed; Noguchi, Constance Tom			Erythropoietin signaling promotes transplanted progenitor cell survival	FASEB JOURNAL			English	Article						myoblast; dystrophin; transplantation; receptor; EpoR	DUCHENNE MUSCULAR-DYSTROPHY; HEMATOPOIETIC STEM-CELLS; RECEPTOR GENE; PROLIFERATION; ACTIVATION; DIFFERENTIATION; ENGRAFTMENT; TRANSGENES; EXPRESSION; EXPANSION	We examine the potential for erythropoietin signaling to promote donor cell survival in a model of myoblast transplantation. Expression of a truncated erythropoietin receptor in hematopoietic stem cells has been shown to promote selective engraftment in mice. We previously demonstrated expression of endogenous erythropoietin receptor on murine myoblasts, and erythropoietin treatment can stimulate myoblast proliferation and delay differentiation. Here, we report that enhanced erythropoietin receptor expression, as well as exogenous erythropoietin treatment in myoblasts, provided a survival advantage and protection against apoptosis under serum-starvation conditions. When cultured in differentiation medium, expression of the myogenic regulatory proteins shifted toward early differentiation with increased erythropoietin receptor. Expression of early myogenic differentiation proteins Myf-5 and MyoD increased, while later stage protein myogenin decreased. Transplantation of C2C12 myoblasts overexpressing truncated erythropoietin receptor showed more transplanted cell incorporation into muscle fibers in muscular dystrophy mdx mice. These cells also restored dystrophin protein expression in mdx mice at 6 wk after cell treatment that was further increased with exogenous erythropoietin administration. In summary, enhanced erythropoietin receptor expression promotes transplanted cell survival in a mouse model for myoblast transplantation and provides dystrophin expression in mice with muscular dystrophy.-Jia, Y., Warin, R., Yu, X., Epstein, R., Noguchi, C. T. Erythropoietin signaling promotes transplanted progenitor cell survival. FASEB J. 23, 3089-3099 ( 2009). www.fasebj.org	[Jia, Yi; Warin, Renaud; Yu, Xiaobing; Epstein, Reed; Noguchi, Constance Tom] NIDDK, Mol Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Noguchi, CT (corresponding author), NIDDK, Mol Med Branch, NIH, Bldg 10,Rm 9N319,MSC-1822,10 Ctr Dr, Bethesda, MD 20892 USA.	cnoguchi@helix.nih.gov			National Institute of Diabetes and Digestive and Kidney Diseases; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK025103, ZIADK025021, Z01DK025103] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Mingfeng Zhao for technical assistance in vector construction and Brenda Klaunberg for her expertise in animal imaging. Funding was provided by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases.	Arcasoy MO, 1999, EXP HEMATOL, V27, P63, DOI 10.1016/S0301-472X(98)00003-4; Arcasoy MO, 2008, BRIT J HAEMATOL, V141, P14, DOI 10.1111/j.1365-2141.2008.07014.x; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cerletti M, 2008, CELL, V134, P37, DOI 10.1016/j.cell.2008.05.049; Chen J, 2008, J CLIN INVEST, V118, P526, DOI [10.1172/JC133813, 10.1172/JCI33813]; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; Cossu G, 2007, TRENDS MOL MED, V13, P520, DOI 10.1016/j.molmed.2007.10.003; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; Darabi R, 2008, NAT MED, V14, P134, DOI 10.1038/nm1705; Gensch N, 2008, DEVELOPMENT, V135, P1597, DOI 10.1242/dev.019331; Iwahori A, 2004, DEV BIOL, V270, P525, DOI 10.1016/j.ydbio.2004.03.012; Judge LM, 2006, J CELL SCI, V119, P1537, DOI 10.1242/jcs.02857; Kirby S, 2000, BLOOD, V95, P3710; Kirby SL, 1996, P NATL ACAD SCI USA, V93, P9402, DOI 10.1073/pnas.93.18.9402; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Meyer L, 2007, BLOOD, V109, P5215, DOI 10.1182/blood-2006-10-055350; Miller RG, 1997, MUSCLE NERVE, V20, P469, DOI 10.1002/(SICI)1097-4598(199704)20:4<469::AID-MUS10>3.3.CO;2-1; Nagashima T, 2004, J GENE MED, V6, P22, DOI 10.1002/jgm.467; Ogilvie M, 2000, J BIOL CHEM, V275, P39754, DOI 10.1074/jbc.M004999200; Partridge T, 2002, NEUROMUSCULAR DISORD, V12, pS3, DOI 10.1016/S0960-8966(02)00076-7; Peault B, 2007, MOL THER, V15, P867, DOI 10.1038/mt.sj.6300145; Pelletier S, 2006, MOL CELL BIOL, V26, P8527, DOI 10.1128/MCB.01035-06; Sacco A, 2008, NATURE, V456, P502, DOI 10.1038/nature07384; Sasaki R, 2003, INTERNAL MED, V42, P142, DOI 10.2169/internalmedicine.42.142; Shimizu R, 1999, EXP HEMATOL, V27, P229, DOI 10.1016/S0301-472X(98)00048-4; Urao N, 2006, CIRC RES, V98, P1405, DOI 10.1161/01.RES.0000224117.59417.f3; Urbinati F, 2005, HUM GENE THER, V16, P594, DOI 10.1089/hum.2005.16.594; Westenbrink BD, 2007, EUR HEART J, V28, P2018, DOI 10.1093/eurheartj/ehm177; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; Yu XB, 2003, MOL THER, V7, P827, DOI 10.1016/S1525-0016(03)00104-7; Yu XB, 2001, BLOOD, V98, P475, DOI 10.1182/blood.V98.2.475; Zhao W, 2006, BLOOD, V107, P907, DOI 10.1182/blood-2005-06-2516	33	21	23	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3089	3099		10.1096/fj.09-130237	http://dx.doi.org/10.1096/fj.09-130237			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19417086	Green Published			2022-12-28	WOS:000270241000031
J	Klover, P; Chen, WP; Zhu, BM; Hennighausen, L				Klover, Peter; Chen, Weiping; Zhu, Bing-Mei; Hennighausen, Lothar			Skeletal muscle growth and fiber composition in mice are regulated through the transcription factors STAT5a/b: linking growth hormone to the androgen receptor	FASEB JOURNAL			English	Article						chromatin immunoprecipitation; microarray	FACTOR-I; GENE-EXPRESSION; EXERCISE; SPECIFICATION; METABOLISM; RESISTANCE; PATHWAY; ALPHA; IGF-1; MASS	In skeletal muscle, STAT5a/b transcription factors are critical for normal postnatal growth, whole-animal glucose homeostasis, and local IGF-1 production. These observations have led us to hypothesize that STAT5a/b are critical for maintenance of normal muscle mass and function. To investigate this, mice with a skeletal muscle-specific deletion of the Stat5a/b genes (Stat5MKO) were used. Stat5MKO mice displayed reduced muscle mass, altered fiber-type distribution and reduced activity. On a molecular level, gene expression in skeletal muscle of Stat5MKO and control mice was analyzed by microarrays and real-time PCR, both in the presence and absence of growth hormone (GH) stimulation. Expression of several genes involved in muscle growth and fiber type were significantly changed. Specifically, in the quadriceps, a muscle almost exclusively composed of type II fibers, the absence of STAT5a/b led to increased expression of several genes associated with type I fibers and the de novo appearance of type I fibers. In addition, it is shown here that expression of the androgen receptor gene (Ar) is controlled by GH through STAT5a/b. The link between STAT5a/b and Ar gene is likely through direct transcriptional regulation, as chromatin immunoprecipitaion of the Ar promoter region in C2C12 myoblasts was accomplished by antibodies against STAT5a. These experiments demonstrate an important role for STAT5a/b in skeletal muscle physiology, and they provide a direct link to androgen signaling.-Klover, P., Chen, W., Zhu, B.-M., Hennighausen, L. Skeletal muscle growth and fiber composition in mice are regulated through the transcription factors STAT5a/b: linking growth hormone to the androgen receptor. FASEB J. 23, 3140-3148 (2009). www.fasebj.org	[Klover, Peter; Chen, Weiping; Zhu, Bing-Mei; Hennighausen, Lothar] NIDDK, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Klover, P (corresponding author), NIDDK, NIH, 9000 Rockville Pike,Bldg 8,Rm 107, Bethesda, MD 20892 USA.	kloverp@niddk.nih.gov	Chen, Weiping/C-9550-2011	Hennighausen, Lothar/0000-0001-8319-9841	NIH; NIDDK; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000, ZIADK061005, Z01DK061005, Z01DK061000] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank George Poy (NIDDK Genomics Core Laboratory, Bethesda, MD, USA) for assistance with the microarrays. We also thank Dr. Oksana Gavrilova and William Jou ( NIDDK Mouse Metabolism Core Laboratory) for conducting the locomotor activity and respiration experiments. Thanks to Dr. Richard Moriggl ( Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria) for providing the construct for the constitutively active STAT5a mutant. Finally, thanks to Alexandra Dr. McPherron and Dr. Kathleen Savage for technical expertise in muscle-fiber staining. This work was funded by the intramural program of NIH, NIDDK.	Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Baker PE, 2006, NEUROGENETICS, V7, P81, DOI 10.1007/s10048-006-0031-7; Ben-Dov I, 2003, CLIN ENDOCRINOL, V59, P763, DOI 10.1046/j.1365-2265.2003.01920.x; Clark RP, 2006, HORM RES, V66, P26, DOI 10.1159/000096620; Consitt LA, 2008, MED SCI SPORT EXER, V40, P1031, DOI 10.1249/MSS.0b013e3181690760; Davey HW, 2001, ENDOCRINOLOGY, V142, P3836, DOI 10.1210/en.142.9.3836; DRENTH JPH, 1995, J APPL PHYSIOL, V79, P1497, DOI 10.1152/jappl.1995.79.5.1497; Fernandez AM, 2002, J CLIN INVEST, V109, P347, DOI 10.1172/JCI200213503; Garcia-Fernandez M, 2008, ENDOCRINOLOGY, V149, P2433, DOI 10.1210/en.2007-1190; Gotherstrom G, 2005, CLIN ENDOCRINOL, V62, P105, DOI 10.1111/j.1365-2265.2004.02181.x; Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200; Herbst KL, 2004, CURR OPIN CLIN NUTR, V7, P271, DOI 10.1097/00075197-200405000-00006; Izumiya Y, 2008, CELL METAB, V7, P159, DOI 10.1016/j.cmet.2007.11.003; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Kitamura T, 2007, J CLIN INVEST, V117, P2477, DOI 10.1172/JCI32054; Klover P, 2007, ENDOCRINOLOGY, V148, P1489, DOI 10.1210/en.2006-1431; Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MacLean HE, 2008, FASEB J, V22, P2676, DOI 10.1096/fj.08-105726; Moriggl R, 2005, CANCER CELL, V7, P87, DOI 10.1016/j.ccr.2004.12.010; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Tallquist MD, 2000, DEVELOPMENT, V127, P5059; Tan SH, 2008, CANCER RES, V68, P236, DOI 10.1158/0008-5472.CAN-07-2972; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Zierath JR, 2004, PLOS BIOL, V2, P1523, DOI 10.1371/journal.pbio.0020348	26	45	46	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2009	23	9					3140	3148		10.1096/fj.08-128215	http://dx.doi.org/10.1096/fj.08-128215			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19417088	Green Published			2022-12-28	WOS:000270241000036
J	Faghiri, Z; Skelly, PJ				Faghiri, Zahra; Skelly, Patrick J.			The role of tegumental aquaporin from the human parasitic worm, Schistosoma mansoni, in osmoregulation and drug uptake	FASEB JOURNAL			English	Article						platyhelminth; RNAi; metabolite transport; antimonial; tegument	AMINO-ACID-TRANSPORT; GLUCOSE-TRANSPORTER; SURFACE; PROTEINS; PHOSPHOFRUCTOKINASE; ANTIMONIALS; SUPPRESSION; INHIBITION; APPEARANCE; EXPRESSION	Schistosomes are parasitic platyhelminths that constitute an important public health problem globally. Infection is characterized by the presence of adult worms within the vasculature of their hosts, where they can reside for many years. The worms are covered by an unusual dual lipid bilayer through which they import nutrients. How the parasites import other vital molecules, such as water, is not known. Recent proteomic analysis of the schistosome tegumental membranes revealed the presence of an aquaporin homologue at the host-interactive surface whose cDNA we have cloned and characterized. The cDNA encodes a predicted 304-aa protein (SmAQP) that is found largely in the parasite tegument by immunolocalization and is most highly expressed in the intravascular life stages. Treatment of parasites with short interfering RNAs targeting the SmAQP gene results in potent (>90%) suppression. These suppressed parasites resist swelling when placed in hypotonic medium, unlike their control counterparts, which rapidly double in volume. In addition, SmAQP-suppressed parasites, unlike controls, resist shrinkage when incubated in hyperosmotic solution. While suppressed parasites exhibit lower viability in culture relative to controls and exhibit a stunted appearance following prolonged suppression, they are nonetheless more resistant to killing by the drug potassium antimonyl tartrate (PAT). This is likely because SmAQP acts as a conduit for this drug, as is the case for aquaporins in other systems. These experiments reveal a heretofore unrecognized role of the schistosome tegument in controlling water and drug movement into the parasites and highlight the importance of the tegument in parasite osmoregulation and drug uptake.-Faghiri, Z., Skelly, P. J. The role of tegumental aquaporin from the human parasitic worm, Schistosoma mansoni, in osmoregulation and drug uptake. FASEB J. 23, 2780-2789 ( 2009)	[Faghiri, Zahra; Skelly, Patrick J.] Tufts Univ, Cummings Sch Vet Med, Mol Helminthol Lab, Div Infect Dis,Dept Biomed Sci, Grafton, MA USA	Tufts University	Skelly, PJ (corresponding author), Tufts Univ, Cummings Sch Vet Med, Dept Biomed Sci, 200 Westboro Rd, North Grafton, MA 01536 USA.	patrick.skelly@tufts.edu			NIH-NIAID [N01-AI-30026, AI-056273]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056273, R01AI030026] Funding Source: NIH RePORTER	NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Dr. Greice Krautz-Peterson and Dr. Chuck Shoemaker for helpful comments and David Ndegwa for technical assistance. Schistosome-infected snails were provided by the Biomedical Research Institute through National Institutes of Health-National Institute of Allergy and Infectious Diseases (NIH-NIAID) contract N01-AI-30026. This work was supported by NIH-NIAID grant AI-056273.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bienert GP, 2008, TRENDS BIOCHEM SCI, V33, P20, DOI 10.1016/j.tibs.2007.10.004; Braschi S, 2006, PROTEOMICS, V6, P1471, DOI 10.1002/pmic.200500368; Braschi S, 2006, MOL CELL PROTEOMICS, V5, P347, DOI 10.1074/mcp.M500287-MCP200; BUEDING E, 1957, BRIT J PHARM CHEMOTH, V12, P159, DOI 10.1111/j.1476-5381.1957.tb00114.x; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Correnti JA, 2005, MOL BIOCHEM PARASIT, V143, P209, DOI 10.1016/j.molbiopara.2005.06.007; Ghaleb H A, 1979, J Egypt Med Assoc, V62, P1; Gonen T, 2006, Q REV BIOPHYS, V39, P361, DOI 10.1017/S0033583506004458; Gourbal B, 2004, J BIOL CHEM, V279, P31010, DOI 10.1074/jbc.M403959200; Hackett F, 1993, Methods Mol Biol, V21, P89; HOCKLEY D J, 1973, International Journal for Parasitology, V3, P13, DOI 10.1016/0020-7519(73)90004-0; Jiang JW, 1996, EXP PARASITOL, V82, P201, DOI 10.1006/expr.1996.0025; JONES JT, 1988, MOL BIOCHEM PARASIT, V30, P35, DOI 10.1016/0166-6851(88)90130-2; King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4; King CH, 2008, CHRONIC ILLN, V4, P65, DOI 10.1177/1742395307084407; Koukounari A, 2007, J INFECT DIS, V196, P659, DOI 10.1086/520515; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krautz-Peterson G, 2007, J BIOL CHEM, V282, P21767, DOI 10.1074/jbc.M703512200; Kuntz AN, 2007, PLOS MED, V4, P1071, DOI 10.1371/journal.pmed.0040206; Liu ZJ, 2002, P NATL ACAD SCI USA, V99, P6053, DOI 10.1073/pnas.092131899; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; MCLAREN DJ, 1977, NATURE, V269, P147, DOI 10.1038/269147a0; MORRIS GP, 1968, J PARASITOL, V54, P15, DOI 10.2307/3276867; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; RODRIGUEZMOLINA R, 1950, AM J TROP MED, V30, P881; Sanders OI, 1997, J BACTERIOL, V179, P3365, DOI 10.1128/jb.179.10.3365-3367.1997; Skelly PJ, 2006, ADV PARASIT, V63, P185, DOI 10.1016/S0065-308X(06)63003-0; Skelly PJ, 1996, P NATL ACAD SCI USA, V93, P3642, DOI 10.1073/pnas.93.8.3642; SKELLY PJ, 1994, J BIOL CHEM, V269, P4247; Skelly PJ, 2003, INT J PARASITOL, V33, P363, DOI 10.1016/S0020-7519(03)00030-4; Skelly PJ, 2001, PARASITOLOGY, V123, P277, DOI 10.1017/S0031182001008484; SMITH JH, 1969, AM J TROP MED HYG, V18, P28, DOI 10.4269/ajtmh.1969.18.28; Su JGJ, 1996, MOL BIOCHEM PARASIT, V81, P171, DOI 10.1016/0166-6851(96)02702-8; Threadgold L. T., 1984, Biology of the integument. 1. Invertebrates, P132; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; Tsukaguchi H, 1999, AM J PHYSIOL-RENAL, V277, pF685, DOI 10.1152/ajprenal.1999.277.5.F685; WILSON RA, 1974, PARASITOLOGY, V68, P239, DOI 10.1017/S0031182000045765; ZHONG C, 1995, PARASITOLOGY, V110, P383, DOI 10.1017/S0031182000064726	40	74	80	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2780	2789		10.1096/fj.09-130757	http://dx.doi.org/10.1096/fj.09-130757			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19364765	Green Published			2022-12-28	WOS:000268836700046
J	Nagaoka, K; Aoki, F; Hayashi, M; Muroi, Y; Sakurai, T; Itoh, K; Ikawa, M; Okabe, M; Imakawa, K; Sakai, S				Nagaoka, Kentaro; Aoki, Fugaku; Hayashi, Mizuna; Muroi, Yoshikage; Sakurai, Toshihiro; Itoh, Kikuji; Ikawa, Masahito; Okabe, Masaru; Imakawa, Kazuhiko; Sakai, Senkiti			L-Amino acid oxidase plays a crucial role in host defense in the mammary glands	FASEB JOURNAL			English	Article						antibacterial; milk; H2O2; mastitis	CELL-DEATH; MASTITIS; MILK; EXPRESSION; INFECTION; VENOM; EVOLUTION; ACHACIN; CLONING	The innate immune system plays an important role in protecting organs that are continuous with the outer surface of the body from bacterial infection. The antibacterial factors involved in this system have been sought in exocrine glands, particularly in the mammary glands. Because milk produced in the mammary glands is enriched in various nutrients, supporting the proliferation of bacteria, mammary glands appear to be at the greatest risk of bacterial infection and proliferation. Here, we show that mouse milk contains L-amino acid oxidase (LAO), a lactating mammary gland-specific protein that displays antibacterial activity in vitro through the production of hydrogen peroxide from free amino acids. We produced LAO-disrupted mouse lines to define the physiological properties and importance of the protein in vivo. The LAO-knockout mice were healthy and had normal mammary gland development; however, the antibacterial activity normally observed in milk from wild-type mice was absent from the milk of knockout mice. The content of free amino acids targeted by LAO was very low in wild-type milk, whereas these amino acids were abundant in LAO-knockout milk. Knockout mice exhibited weak resistance to an intramammary bacterial challenge compared to their wild-type counterparts. Further, preadministration of wild-type milk whey reduced the severity of bacterial infection in LAO-knockout mice. These results demonstrate that milk LAO protects the mammary gland against bacterial infection, and this antibacterial effect may be due to the generation of hydrogen peroxide by using free amino acids abundantly present in milk. Nagaoka, K., Aoki, F., Hayashi, M., Muroi, Y., Sakurai, T., Itoh, K., Ikawa, M., Okabe, M., Imakawa, K., Sakai, S. L-Amino acid oxidase plays a crucial role in host defense in the mammary glands. FASEB J. 23, 2514-2520 (2009)	[Nagaoka, Kentaro] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Anim Breeding, Bunkyo Ku, Tokyo 1138657, Japan; [Itoh, Kikuji] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Publ Hlth, Tokyo 1138657, Japan; [Aoki, Fugaku] Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba, Japan; [Ikawa, Masahito; Okabe, Masaru] Osaka Univ, Genome Informat Res Ctr, Osaka, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Osaka University	Nagaoka, K (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Lab Anim Breeding, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	akenaga@mail.ecc.u-tokyo.ac.jp	Nagaoka, Kentaro/C-2019-2013; Imakawa, Kazuhiko/AAD-3211-2022; ikawa, masahito/A-5315-2009; AOKI, FUGAKU/AAO-7617-2021; Okabe, Masaru/B-6917-2015	Nagaoka, Kentaro/0000-0003-1038-1380; ikawa, masahito/0000-0001-9859-6217; Okabe, Masaru/0000-0002-0803-9044	Japan Society for the Promotion of Science	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank Dr. Li Jun You for technical support in determining the milk amino acid content, Dr. Joel Richter for his critical reading of the manuscript, Kimiko Tachikawa for animal care, and Akiko Kawai and Masato Tanaka for technical assistance with gene disruption. This work was supported by a grant-in-aid for scientific research from the Japan Society for the Promotion of Science.	Ande SR, 2006, APOPTOSIS, V11, P1439, DOI 10.1007/s10495-006-7959-9; Barbosa-Cesnik C, 2003, JAMA-J AM MED ASSOC, V289, P1609, DOI 10.1001/jama.289.13.1609; Bernt K, 2001, ADV EXP MED BIOL, V501, P11; Bradley AJ, 2002, VET J, V164, P116, DOI 10.1053/tvjl.2002.0724; Brouillette E, 2004, VET MICROBIOL, V101, P253, DOI 10.1016/j.vetmic.2004.04.008; COUDERT M, 1975, ARCH MICROBIOL, V102, P151, DOI 10.1007/BF00428360; DETILLEUX JC, 1995, VET IMMUNOL IMMUNOP, V44, P251, DOI 10.1016/0165-2427(94)05302-9; Du XY, 2002, TOXICON, V40, P659, DOI 10.1016/S0041-0101(02)00102-2; DUERRE JA, 1975, J BACTERIOL, V121, P656, DOI 10.1128/JB.121.2.656-663.1975; Ehara T, 2002, FEBS LETT, V531, P509, DOI 10.1016/S0014-5793(02)03608-6; EVANS M, 1995, BREASTFEED REV, V3, P65; Foxman B, 2002, AM J EPIDEMIOL, V155, P103, DOI 10.1093/aje/155.2.103; Kanzawa N, 2004, ARCH BIOCHEM BIOPHYS, V422, P103, DOI 10.1016/j.abb.2003.12.007; Kerr DE, 2001, NAT BIOTECHNOL, V19, P66, DOI 10.1038/83540; MAGA EA, 1994, TRANSGENIC RES, V3, P36, DOI 10.1007/BF01976025; MARSHALL BR, 1975, JAMA-J AM MED ASSOC, V233, P1377, DOI 10.1001/jama.233.13.1377; NIEDERMANN DM, 1990, J BIOL CHEM, V265, P17246; Osterman K L, 2000, J Hum Lact, V16, P297, DOI 10.1177/089033440001600405; Paape M, 2002, J MAMMARY GLAND BIOL, V7, P109, DOI 10.1023/A:1020343717817; RASSIN DK, 1978, EARLY HUM DEV, V2, P1, DOI 10.1016/0378-3782(78)90048-8; Samel M, 2006, BBA-PROTEINS PROTEOM, V1764, P707, DOI 10.1016/j.bbapap.2006.01.021; Semba RD, 2000, ANN NY ACAD SCI, V918, P156; SKARNES RC, 1970, NATURE, V225, P1072, DOI 10.1038/2251072a0; Sordillo LM, 2002, J MAMMARY GLAND BIOL, V7, P135, DOI 10.1023/A:1020347818725; Sun YP, 2002, J BIOL CHEM, V277, P19080, DOI 10.1074/jbc.M200936200; Tonismagi K, 2006, TOXICON, V48, P227, DOI 10.1016/j.toxicon.2006.05.004; VALLON O, 1993, EUR J BIOCHEM, V215, P351, DOI 10.1111/j.1432-1033.1993.tb18041.x; van Berkel PHC, 2002, NAT BIOTECHNOL, V20, P484, DOI 10.1038/nbt0502-484; Vorbach C, 2006, BIOESSAYS, V28, P606, DOI 10.1002/bies.20423; Wall RJ, 2005, NAT BIOTECHNOL, V23, P445, DOI 10.1038/nbt1078; Yang HC, 2005, J EXP BIOL, V208, P3609, DOI 10.1242/jeb.01795; Yarus S, 1996, P NATL ACAD SCI USA, V93, P14118, DOI 10.1073/pnas.93.24.14118; Zhang YJ, 2003, BIOCHEM BIOPH RES CO, V309, P598, DOI 10.1016/j.bbrc.2003.08.044	34	32	34	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2514	2520		10.1096/fj.08-126466	http://dx.doi.org/10.1096/fj.08-126466			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19276171				2022-12-28	WOS:000268836700019
J	Wang, NZ; Gates, KL; Trejo, H; Favoreto, S; Schleimer, RP; Sznajder, JI; Beitel, GJ; Sporn, PHS				Wang, Naizhen; Gates, Khalilah L.; Trejo, Humberto; Favoreto, Silvio, Jr.; Schleimer, Robert P.; Sznajder, Jacob I.; Beitel, Greg J.; Sporn, Peter H. S.			Elevated CO2 selectively inhibits interleukin-6 and tumor necrosis factor expression and decreases phagocytosis in the macrophage	FASEB JOURNAL			English	Article						monocytes; lipopolysaccharide; cytokines; phagocytosis; lung	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; CARBON-DIOXIDE AVOIDANCE; INDUCED LUNG INJURY; TOLL-LIKE RECEPTORS; HYPERCAPNIC ACIDOSIS; FACTOR-ALPHA; ALVEOLAR MACROPHAGES; HOST-DEFENSE; TNF-ALPHA	Elevated blood and tissue CO2, or hypercapnia, is common in severe lung disease. Patients with hypercapnia often develop lung infections and have an increased risk of death following pneumonia. To explore whether hypercapnia interferes with host defense, we studied the effects of elevated P-CO2 on macrophage innate immune responses. In differentiated human THP-1 macrophages and human and mouse alveolar macrophages stimulated with lipopolysaccharide (LPS) and other Toll-like receptor ligands, hypercapnia inhibited expression of tumor necrosis factor and interleukin (IL)-6, nuclear factor (NF)-kappa B-dependent cytokines critical for antimicrobial host defense. Inhibition of IL-6 expression by hypercapnia was concentration dependent, rapid, reversible, and independent of extracellular and intracellular acidosis. In contrast, hypercapnia did not down-regulate IL-10 or interferon-beta, which do not require NF-kappa B. Notably, hypercapnia did not affect LPS-induced degradation of I kappa B alpha, nuclear translocation of RelA/p65, or activation of mitogen-activated protein kinases, but it did block IL-6 promoter-driven luciferase activity in mouse RAW 264.7 macrophages. Elevated P-CO2 also decreased phagocytosis of opsonized polystyrene beads and heat-killed bacteria in THP-1 and human alveolar macrophages. By interfering with essential innate immune functions in the macrophage, hypercapnia may cause a previously unrecognized defect in resistance to pulmonary infection in patients with advanced lung disease.-Wang, N., Gates, K. L., Trejo, H., Favoreto, Jr., S., Schleimer, R. P., Sznajder, J. I., Beitel, G. J., Sporn, P. H. S. Elevated CO2 selectively inhibits interleukin-6 and tumor necrosis factor expression and decreases phagocytosis in the macrophage. FASEB J. 24, 2178-2190 (2010). www.fasebj.org	[Wang, Naizhen; Gates, Khalilah L.; Trejo, Humberto; Sznajder, Jacob I.; Sporn, Peter H. S.] Northwestern Univ, Div Pulm & Crit Care Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Favoreto, Silvio, Jr.; Schleimer, Robert P.] Northwestern Univ, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; [Beitel, Greg J.] Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL USA; [Sporn, Peter H. S.] Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Sporn, PHS (corresponding author), Northwestern Univ, Div Pulm & Crit Care Med, Feinberg Sch Med, 240 E Huron St,McGaw M-300, Chicago, IL 60611 USA.	p-sporn@northwestern.edu		Sporn, Peter/0000-0002-1006-9437	National Institutes of Health [HL068546, HL078860, HL085534, HL072891]; American Heart Association [0855686G]; Department of Veterans Affairs; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025741] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068546, R01HL085534, R01HL072891, R37HL068546, R01HL078860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Y. Gruenbaum, R. M. Pope, A. Kato, P. J. Bryce, and S. C. Shin for helpful discussions, and Aisha Nair for technical assistance. This work was supported by grants from the National Institutes of Health (HL068546 and HL078860 to R. P. S., HL085534 to J. I. S., and HL072891 to P. H. S. S.), the American Heart Association (grant-in-aid 0855686G to G. J. B.), and the Department of Veterans Affairs (Merit Review to P. H. S. S.).	Abolhassani M, 2009, AM J PHYSIOL-LUNG C, V296, pL657, DOI 10.1152/ajplung.90460.2008; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Belkin RA, 2006, AM J RESP CRIT CARE, V173, P659, DOI 10.1164/rccm.200410-1369OC; Bigatello L M, 2001, Curr Opin Crit Care, V7, P34, DOI 10.1097/00075198-200102000-00006; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Bondeson J, 1999, J IMMUNOL, V162, P2939; Bretscher AJ, 2008, P NATL ACAD SCI USA, V105, P8044, DOI 10.1073/pnas.0707607105; Briva A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001238; Broccard AF, 2001, AM J RESP CRIT CARE, V164, P802, DOI 10.1164/ajrccm.164.5.2007060; BURET A, 1994, INFECT IMMUN, V62, P5335, DOI 10.1128/IAI.62.12.5335-5343.1994; Chonghaile MN, 2008, ANESTHESIOLOGY, V109, P837, DOI 10.1097/ALN.0b013e3181895fb7; Chonghaile MN, 2008, CRIT CARE MED, V36, P3135, DOI 10.1097/CCM.0b013e31818f0d13; Costello R, 1997, AM J MED, V102, P239, DOI 10.1016/S0002-9343(97)00017-X; D'Addario M, 2000, J MOL BIOL, V298, P765, DOI 10.1006/jmbi.2000.3717; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Fischler W, 2007, NATURE, V448, P1054, DOI 10.1038/nature06101; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; Georganas C, 2000, J IMMUNOL, V165, P7199, DOI 10.4049/jimmunol.165.12.7199; Goel A, 2003, J GEN INTERN MED, V18, P824, DOI 10.1046/j.1525-1497.2003.20615.x; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Groenewegen KH, 2003, CHEST, V124, P459, DOI 10.1378/chest.124.2.459; Hallem EA, 2008, P NATL ACAD SCI USA, V105, P8038, DOI 10.1073/pnas.0707469105; Harrison RE, 2002, BIOCHEM CELL BIOL, V80, P509, DOI 10.1139/O02-142; Helenius IT, 2009, P NATL ACAD SCI USA, V106, P18710, DOI 10.1073/pnas.0905925106; Iregui MG, 2001, SEMIN RESP CRIT CARE, V22, P317, DOI 10.1055/s-2001-15788; Jones WD, 2007, NATURE, V445, P86, DOI 10.1038/nature05466; Kim HY, 2002, INFECT IMMUN, V70, P4132, DOI 10.1128/IAI.70.8.4132-4141.2002; Laffey JG, 2004, AM J RESP CRIT CARE, V169, P46, DOI 10.1164/rccm.200205-394OC; Laichalk LL, 1996, INFECT IMMUN, V64, P5211, DOI 10.1128/IAI.64.12.5211-5218.1996; Lang CJ, 2005, AM J PHYSIOL-LUNG C, V289, pL96, DOI 10.1152/ajplung.00394.2004; Lee JH, 2003, AM J RESP CRIT CARE, V168, P1462, DOI 10.1164/rccm.200302-303OC; Lu H, 2005, MOL BIOL CELL, V16, P4954, DOI 10.1091/mbc.E05-05-0426; Lu YC, 2009, J IMMUNOL, V182, P7212, DOI 10.4049/jimmunol.0802971; MARTINU T, 2003, CAN RESPIR J, V10, P301; Mehrad B, 1999, J IMMUNOL, V162, P1633; MOSER KM, 1973, JAMA-J AM MED ASSOC, V255, P705; MULLEN PG, 1995, J SURG RES, V58, P124, DOI 10.1006/jsre.1995.1020; *NAT HEART LUNG BL, 2007, MORB MORT 2007 CHART; O'Croinin DF, 2008, CRIT CARE MED, V36, P2128, DOI 10.1097/CCM.0b013e31817d1b59; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; O'Reilly PJ, 2003, AM J RESP CELL MOL, V28, P443, DOI 10.1165/rcmb.2002-0153OC; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Rai S, 2004, PEDIATR RES, V55, P42, DOI 10.1203/01.PDR.0000098502.72182.55; Roilides E, 1998, INFECT IMMUN, V66, P5999, DOI 10.1128/IAI.66.12.5999-6003.1998; Rutault K, 2001, J BIOL CHEM, V276, P6666, DOI 10.1074/jbc.M005486200; Scott CC, 2005, J CELL BIOL, V169, P139, DOI 10.1083/jcb.200412162; Sethi Sanjay, 2004, Proc Am Thorac Soc, V1, P109, DOI 10.1513/pats.2306029; Sharabi K, 2009, P NATL ACAD SCI USA, V106, P4024, DOI 10.1073/pnas.0900309106; Shirai R, 1997, CLIN EXP IMMUNOL, V109, P73, DOI 10.1046/j.1365-2249.1997.4211317.x; Siddiqui AA, 2006, INFECT IMMUN, V74, P5302, DOI 10.1128/IAI.00661-06; Sin DD, 2005, AM J MED, V118, P145, DOI 10.1016/j.amjmed.2004.10.014; Sinclair SE, 2002, AM J RESP CRIT CARE, V166, P403, DOI 10.1164/rccm.200112-117OC; Son YH, 2008, J CARDIOVASC PHARM, V51, P71, DOI 10.1097/FJC.0b013e31815bd23d; Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094; Standiford TJ, 1999, HUM GENE THER, V10, P899, DOI 10.1089/10430349950018300; Suzuki E, 2006, BIOMED PHARMACOTHER, V60, P578, DOI 10.1016/j.biopha.2006.07.089; Takashiba S, 1999, INFECT IMMUN, V67, P5573, DOI 10.1128/IAI.67.11.5573-5578.1999; Takeshita K, 2003, AM J RESP CELL MOL, V29, P124, DOI 10.1165/rcmb.2002-0126OC; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Vadasz I, 2008, J CLIN INVEST, V118, P752, DOI 10.1172/JCI29723; West MA, 1996, J SURG RES, V63, P269, DOI 10.1006/jsre.1996.0259; Williams DM, 1998, INFECT IMMUN, V66, P4564; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wu Q, 2007, MICROBES INFECT, V9, P78, DOI 10.1016/j.micinf.2006.10.012; Zarember KA, 2002, J IMMUNOL, V168, P554, DOI 10.4049/jimmunol.168.2.554; Zhu S, 2000, AM J PHYSIOL-LUNG C, V278, pL1025, DOI 10.1152/ajplung.2000.278.5.L1025	67	86	89	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2010	24	7					2178	2190		10.1096/fj.09-136895	http://dx.doi.org/10.1096/fj.09-136895			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20181940	Green Published			2022-12-28	WOS:000279343600005
J	Kueng, HJ; Manta, C; Haiderer, D; Leb, VM; Schmetterer, KG; Neunkirchner, A; Byrne, RA; Scheinecker, C; Steinberger, P; Seed, B; Pickl, WF				Kueng, Hans J.; Manta, Calin; Haiderer, Daniela; Leb, Victoria M.; Schmetterer, Klaus G.; Neunkirchner, Alina; Byrne, Ruth A.; Scheinecker, Clemens; Steinberger, Peter; Seed, Brian; Pickl, Winfried F.			Fluorosomes: a convenient new reagent to detect and block multivalent and complex receptor-ligand interactions	FASEB JOURNAL			English	Article						lipid rafts; viral pseudotyping; glycosyl phosphalidyl inositol anchored proteins; flow cytometry; fluorescent proteins	T-CELL-ACTIVATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; LIPID RAFTS; COSTIMULATORY MOLECULES; INTERLEUKIN-2 RECEPTORS; DENDRITIC CELLS; VIRUS; PROTEIN; EXPRESSION; ANTIGEN	We describe for the first time fluorescent virus-like particles decorated with biologically active mono-and multisubunit immune receptors of choice and the basic application of such fluorosomes (FSs) to visualize and target immune receptor-ligand interactions. For that purpose, human embryonic kidney (HEK)-293 cells were stably transfected with Moloney murine leukemia virus (MoMLV) matrix protein (MA) GFP fusion constructs. To produce FSs, interleukins (ILs), IL-receptors (IL-Rs), and costimulatory molecules were fused to the glycosyl phosphatidyl inositol anchor acceptor sequence of CD16b and coexpressed along with MoMLV group-specific antigen-polymerase (gag-pol) in MA::GFP(+) HEK-293 cells. We show that IL-2 decorated but not control-decorated FSs specifically identify normal and malignant IL-2 receptor-positive (IL-2R(+)) lymphocytes by flow cytometry. In addition to cytokines and costimulatory molecules, FSs were also successfully decorated with the heterotrimeric IL-2Rs, allowing identification of IL-2(+) target cells. Specificity of binding was proven by complete inhibition with nonlabeled, soluble ligands. Moreover, IL-2R FSs efficiently neutralized soluble IL-2 and thus induced unresponsiveness of T cells receiving full activation stimuli via T-cell antigen receptor and CD28. FSs are technically simple, multivalent tools for assessing and blocking mono-and multisubunit immune receptor-ligand interactions with natural constituents in a plasma membrane context.-Kueng, H. J., Manta, C., Haiderer, D., Leb, V. M., Schmetterer, K. G., Neunkirchner, A., Byrne, R. A., Scheinecker, C., Steinberger, P., Seed, B., Pickl, W. F. Fluorosomes: a convenient new reagent to detect and block multivalent and complex receptor-ligand interactions. FASEB J. 24, 1572-1582 (2010). www.fasebj.org	[Kueng, Hans J.; Manta, Calin; Haiderer, Daniela; Leb, Victoria M.; Schmetterer, Klaus G.; Neunkirchner, Alina; Steinberger, Peter; Pickl, Winfried F.] Med Univ Vienna, Inst Immunol, Ctr Physiol Pathophysiol & Immunol, A-1090 Vienna, Austria; [Byrne, Ruth A.; Scheinecker, Clemens] Med Univ Vienna, Gen Hosp Vienna, Div Rheumatol, A-1090 Vienna, Austria; [Leb, Victoria M.; Neunkirchner, Alina; Pickl, Winfried F.] Christian Doppler Lab Immunomodulat, Vienna, Austria; [Seed, Brian] Harvard Univ, Sch Med, Ctr Computat & Integrat Biol, Boston, MA USA	Medical University of Vienna; Medical University of Vienna; Harvard University; Harvard Medical School	Pickl, WF (corresponding author), Med Univ Vienna, Inst Immunol, Ctr Physiol Pathophysiol & Immunol, Borschkegasse 8A, A-1090 Vienna, Austria.	winfried.pickl@meduniwien.ac.at	Pickl, Winfried F/E-5682-2011	Reichl, Victoria/0000-0001-7546-3438; Pickl, Winfried F./0000-0003-0430-4952; Schmetterer, Klaus/0000-0001-9328-4871; Steinberger, Peter/0000-0001-6848-4097	Austrian Science Foundation [SFB F1816-B13]; Osterreichische Forschungsforderungsgesellschaft [812079]; Biomay (Vienna, Austria); Christian Doppler Society; U.S. National Institutes of Health	Austrian Science Foundation(Austrian Science Fund (FWF)); Osterreichische Forschungsforderungsgesellschaft; Biomay (Vienna, Austria); Christian Doppler Society; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Dr. Otto Majdic (Institute of Immunology, Medical University of Vienna, Vienna, Austria) for providing mAbs. This work was supported by the Austrian Science Foundation (grant SFB F1816-B13); the Osterreichische Forschungsforderungsgesellschaft (grant 812079); Biomay (Vienna, Austria); and the Christian Doppler Society. B.S. was supported by grants from the U.S. National Institutes of Health.	ARMITAGE RJ, 1986, CLIN EXP IMMUNOL, V63, P298; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Coffin J, 1997, RETROVIRUSES; Derdak SV, 2006, P NATL ACAD SCI USA, V103, P13144, DOI 10.1073/pnas.0602283103; Driesen J, 2008, IMMUNOBIOLOGY, V213, P849, DOI 10.1016/j.imbio.2008.07.026; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; HARELBELLAN A, 1989, J IMMUNOL METHODS, V119, P127, DOI 10.1016/0022-1759(89)90389-X; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HOSHINO S, 1990, BLOOD, V76, P767; JADUS MR, 1992, IMMUNOL LETT, V34, P127, DOI 10.1016/0165-2478(92)90238-J; Jaffe ES, 2001, WHO CLASSIFICATION T; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Klingen Y, 2008, J VIROL, V82, P237, DOI 10.1128/JVI.01342-07; Kueng HJ, 2007, J VIROL, V81, P8666, DOI 10.1128/JVI.00682-07; Lanza F, 1997, LEUKEMIA, V11, P1700, DOI 10.1038/sj.leu.2400794; Larson DR, 2005, P NATL ACAD SCI USA, V102, P15453, DOI 10.1073/pnas.0504812102; Leb VM, 2008, J ALLERGY CLIN IMMUN, V121, P64, DOI 10.1016/j.jaci.2007.10.006; Leb VM, 2009, J ALLERGY CLIN IMMUN, V124, P121, DOI 10.1016/j.jaci.2009.04.008; Mire-Sluis A.R., 1998, CYTOKINES; Montillo M, 2005, HAEMATOLOGICA, V90, P391; MOSMANN TR, 1986, P NATL ACAD SCI USA, V83, P5654, DOI 10.1073/pnas.83.15.5654; Noisakran S, 2008, J GEN VIROL, V89, P2492, DOI 10.1099/vir.0.83620-0; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536; Pfistershammer K, 2006, EUR J IMMUNOL, V36, P1104, DOI 10.1002/eji.200535344; Pickl WF, 2001, J VIROL, V75, P7175, DOI 10.1128/JVI.75.15.7175-7183.2001; PURE E, 1981, J IMMUNOL, V127, P1953; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; Stauber RH, 1999, BIOCHEM BIOPH RES CO, V258, P695, DOI 10.1006/bbrc.1999.0511; SWAIN SL, 1982, IMMUNOL REV, V63, P111, DOI 10.1111/j.1600-065X.1982.tb00413.x; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; von Bergwelt-Baildon MS, 2006, BLOOD, V108, P228, DOI 10.1182/blood-2005-08-3507; WALDMANN TA, 1986, SCIENCE, V232, P727, DOI 10.1126/science.3008337; Warrington KH, 2004, J VIROL, V78, P6595, DOI 10.1128/JVI.78.12.6595-6609.2004; WATSON J, 1979, J EXP MED, V150, P1510, DOI 10.1084/jem.150.6.1510; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; Yu F, 2001, J VIROL, V75, P2753, DOI 10.1128/JVI.75.6.2753-2764.2001; ZOLA H, 2007, LEUCOCYTE STROMAL CE	48	16	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1572	1582		10.1096/fj.09-137281	http://dx.doi.org/10.1096/fj.09-137281			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20056716	Green Published			2022-12-28	WOS:000277158900029
J	Poeggeler, B; Knuever, J; Gaspar, E; Biro, T; Klinger, M; Bodo, E; Wiesner, RJ; Wenzel, BE; Paus, R				Poeggeler, Burkhard; Knuever, Jana; Gaspar, Erzsebet; Biro, Tamas; Klinger, Matthias; Bodo, Eniko; Wiesner, Rudolf J.; Wenzel, Bjoern E.; Paus, Ralf			Thyrotropin powers human mitochondria	FASEB JOURNAL			English	Article						aging; hypothalamic-pituitary-thyroid axis; mitochondrial energy metabolism; oxygen utilization; skin	CORTICOTROPIN-RELEASING HORMONE; HAIR-FOLLICLES; COMPLEX-I; TRANSCRIPTIONAL CONTROL; ENERGY-METABOLISM; GENE-EXPRESSION; HPA AXIS; BIOGENESIS; ANTIOXIDANT; APOPTOSIS	Here we demonstrate that the neuropeptide hormone thyrotropin (TSH), which controls thyroid hormone production, exerts a major nonclassical function in mitochondrial biology. Based on transcriptional, ultrastructural, immunohistochemical, and biochemical evidence, TSH up-regulates mitochondrial biogenesis and consequently activity in organ-cultured normal human epidermis in situ. Mitochondrial activity was assessed by measuring 2 key components of the respiratory chain. The abundance of mitochondria was assessed employing 2 independent morphological techniques: counting their numbers in human epidermis by high-magnification light microscopy of skin sections immunostained for mitochondria-selective cytochromec-oxidase subunit 1 (MTCO1) and transmission electron microscopy (TEM). Treatment with 10 mU/ml of TSH for 6 d strongly up-regulates the number of light-microscopically visualized, MTCO1-demarcated mitochondria. On the ultrastructural level, TEM confirms that TSH indeed stimulates mitochondrial proliferation and biogenesis in the perinuclear region of human skin epidermal keratinocytes. On the transcriptional level, TSH up-regulates MTCO1 mRNA (quantitative RT-PCR) and significantly enhances complex I and IV (cytochrome-c-oxidase) activity. This study pioneers the concept that mitochondrial energy metabolism and biogenesis in a normal, prototypic human epithelial tissue underlies potent neuroendocrine controls and introduces human skin organ culture as a clinically relevant tool for further exploring this novel research frontier in the control of mitochondrial biology.-Poeggeler, B., Knuever, J., Gaspar, E., Biro, T., Klinger, M., Bodo, E., Wiesner, R. J., Wenzel, B. E., Paus, R. Thyrotropin powers human mitochondria. FASEB J. 24, 1525-1531 (2010). www.fasebj.org	[Poeggeler, Burkhard; Knuever, Jana; Gaspar, Erzsebet; Bodo, Eniko; Paus, Ralf] Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany; [Klinger, Matthias] Univ Lubeck, Dept Anat, D-23538 Lubeck, Germany; [Wenzel, Bjoern E.] Univ Lubeck, Dept Med 1, D-23538 Lubeck, Germany; [Biro, Tamas] Univ Debrecen, Dept Physiol, Debrecen, Hungary; [Biro, Tamas] Abiol Ltd, Debrecen, Hungary; [Bodo, Eniko] Coll Nyiregyhaza, Agr & Mol Res Inst, Nyiregyhaza, Hungary; [Wiesner, Rudolf J.] Univ Cologne, Dept Vegetat Physiol, Cologne, Germany; [Wiesner, Rudolf J.] Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany; [Wiesner, Rudolf J.] CMMC, Cologne, Germany; [Paus, Ralf] Univ Manchester, Sch Translat Med, Manchester, Lancs, England	University of Lubeck; University of Lubeck; University of Lubeck; University of Debrecen; University of Cologne; University of Cologne; University of Cologne; University of Manchester	Paus, R (corresponding author), Univ Lubeck, Dept Dermatol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	ralf.paus@uk-sh.de	Paus, Ralf/F-6243-2011; Paus, Ralf/B-5279-2015	Paus, Ralf/0000-0002-3492-9358	Manchester National Institute for Health Research (NIHR) Biomedical Research Center	Manchester National Institute for Health Research (NIHR) Biomedical Research Center(National Institute for Health Research (NIHR))	The excellent technical assistance of Gabriele Scheel, Antje Winter-Keil, Astrid Becker, and Silvia Grammerstorf-Rosche (University of Lubeck), as well as the generous contribution of human scalp skin samples by our collaborating surgeons, Dr. Wolfgang Funk (Klinik Dr. Kozlowski & Dr. Dr. Med. Funk, Munich, Germany) and Dr. Yoram Levy (Atrium Klinik GmbH & Co. KG, Holzkirchen, Germany) are most gratefully acknowledged. The authors are most grateful to PD Dr. T. Hellwig-Burgel (Department of Physiology, University of Lubeck) for his collaboration in generating the first pilot data on the TSH modulation of epidermal oxygen consumption, and also thank Prof. Dr. Saleh Ibrahim (University of Lubeck) for his expert advice and editing of the manuscript. This study was supported in part by a grant from the Manchester National Institute for Health Research (NIHR) Biomedical Research Center to R. P.	Anisimov VN, 2006, BBA-BIOENERGETICS, V1757, P573, DOI 10.1016/j.bbabio.2006.03.012; Bahi L, 2005, J CELL PHYSIOL, V203, P589, DOI 10.1002/jcp.20273; Blatt T, 2005, BIOFACTORS, V25, P179, DOI 10.1002/biof.5520250121; BODO E, 2010, ENDOCRINOLO IN PRESS; Bodo E, 2009, J INVEST DERMATOL, V129, P1126, DOI 10.1038/jid.2008.361; BRAVERMANN LE, 2005, THYROID FUNDAMENTAL, P300; Cianfarani F, 2010, J INVEST DERMATOL, V130, P93, DOI 10.1038/jid.2009.180; Dabbeni-Sala F, 2001, FASEB J, V15, P164, DOI 10.1096/fj.00-0129com; DAVAN CM, 2009, NAT REV ENDOCRINOL, V5, P211; Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028; Fernandez-Vizarra E, 2008, CURR GENET, V54, P13, DOI 10.1007/s00294-008-0194-x; Finley LWS, 2009, AGEING RES REV, V8, P173, DOI 10.1016/j.arr.2009.03.003; Foitzik K, 2006, AM J PATHOL, V168, P748, DOI 10.2353/ajpath.2006.050468; Franko A, 2008, MOL CELL BIOL, V28, P2446, DOI 10.1128/MCB.00980-07; Gaspar E, 2010, FASEB J, V24, P393, DOI 10.1096/fj.08-126417; Goffart S, 2003, EXP PHYSIOL, V88, P33, DOI 10.1113/eph8802500; Havlickova B, 2009, J INVEST DERMATOL, V129, P972, DOI 10.1038/jid.2008.315; Hock MB, 2009, ANNU REV PHYSIOL, V71, P177, DOI 10.1146/annurev.physiol.010908.163119; Ito N, 2005, FASEB J, V19, P1332, DOI 10.1096/fj.04-1968fje; Kramer J, 2005, ANAT EMBRYOL, V210, P175, DOI 10.1007/s00429-005-0020-x; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; LIMAT A, 1994, CELL TISSUE RES, V275, P169, DOI 10.1007/BF00305384; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lopez-Lluch G, 2008, EXP GERONTOL, V43, P813, DOI 10.1016/j.exger.2008.06.014; Lu ZF, 2007, EXP DERMATOL, V16, P37, DOI 10.1111/j.1600-0625.2006.00510.x; Mabalirajan U, 2008, J IMMUNOL, V181, P3540, DOI 10.4049/jimmunol.181.5.3540; Markham A, 2004, EUR J NEUROSCI, V20, P1189, DOI 10.1111/j.1460-9568.2004.03578.x; Mazzio EA, 2004, BIOCHEM PHARMACOL, V67, P1167, DOI 10.1016/j.bcp.2003.11.016; Moreno M, 2008, THYROID, V18, P239, DOI 10.1089/thy.2007.0248; Paquet P, 2007, INT J MOL MED, V19, P3; Peeters RP, 2006, EUR J ENDOCRINOL, V155, P655, DOI 10.1530/eje.1.02279; Poeggeler B, 2005, J NEUROCHEM, V95, P962, DOI 10.1111/j.1471-4159.2005.03425.x; Poeggeler B, 2010, EXP DERMATOL, V19, P12, DOI 10.1111/j.1600-0625.2009.00930.x; Ruiz-Romero C, 2009, MOL BIOSYST, V5, P1130, DOI 10.1039/b906296n; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007; Scheller K, 2003, EXP PHYSIOL, V88, P129, DOI 10.1113/eph8802507; Sheehan TE, 2004, AM J PHYSIOL-ENDOC M, V286, pE968, DOI 10.1152/ajpendo.00478.2003; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 2002, J INVEST DERMATOL, V119, P1449, DOI 10.1046/j.1523-1747.2002.19617.x; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2007, MOL CELL ENDOCRINOL, V265, P143, DOI 10.1016/j.mce.2006.12.012; Slominski A, 2006, FRONT BIOSCI-LANDMRK, V11, P2230, DOI 10.2741/1966; Stark HJ, 1999, J INVEST DERMATOL, V112, P681, DOI 10.1046/j.1523-1747.1999.00573.x; STENN KS, 1989, J INVEST DERMATOL, V93, P287, DOI 10.1111/1523-1747.ep12277593; Tiede S, 2009, J INVEST DERMATOL, V129, P2711, DOI 10.1038/jid.2009.148; Ventura-Clapier R, 2008, CARDIOVASC RES, V79, P208, DOI 10.1093/cvr/cvn098; Wallace DC, 2009, GENE DEV, V23, P1714, DOI 10.1101/gad.1784909; Weitzel JM, 2003, EXP PHYSIOL, V88, P121, DOI 10.1113/eph8802506; Wiedemann FR, 2006, INT J BIOCHEM CELL B, V38, P610, DOI 10.1016/j.biocel.2005.10.024	50	28	28	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1525	1531		10.1096/fj.09-147728	http://dx.doi.org/10.1096/fj.09-147728			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20075194				2022-12-28	WOS:000277158900025
J	Tatsioni, A; Vavva, E; Ioannidis, JPA				Tatsioni, Athina; Vavva, Effie; Ioannidis, John P. A.			Sources of funding for Nobel Prize-winning work: public or private?	FASEB JOURNAL			English	Article						financial support; research; science; high impact; sponsor	RADIOLOGY; HEALTH; IMPACT	Funding is important for scientists' work and may contribute to exceptional research outcomes. We analyzed the funding sources reported in the landmark scientific papers of Nobel Prize winners. Between 2000 and 2008, 70 Nobel laureates won recognition in medicine, physics, and chemistry. Sixty five (70%) of the 93 selected papers related to the Nobel-awarded work reported some funding source including U. S. government sources in 53 (82%), non-U.S. government sources in 19 (29%), and nongovernment sources in 33 (51%). A substantial portion of this exceptional work was unfunded. We contacted Nobel laureates whose landmark papers reported no funding. Thirteen Nobel laureates responded and offered their insights about the funding process and difficulties inherent in funding. Overall, very diverse sources amounting to a total of 64 different listed sponsors supported Nobel-related work. A few public institutions, in particular the U. S. National Institutes of Health (with n=26 funded papers) and the National Science Foundation (with n=17 papers), stood out for their successful record for funding exceptional research. However, Nobel-level work arose even from completely unfunded research, especially when institutions offered a protected environment for dedicated scientists.-Tatsioni, A., Vavva, E., Ioannidis, J.P.A. Sources of funding for Nobel Prize-winning work: public or private? FASEB J. 24, 1335-1339 (2010). www.fasebj.org	[Tatsioni, Athina; Vavva, Effie; Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece; [Tatsioni, Athina; Ioannidis, John P. A.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; [Tatsioni, Athina; Ioannidis, John P. A.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA; [Ioannidis, John P. A.] Fdn Res & Technol Hellas, Biomed Res Inst, Ioannina, Greece	University of Ioannina; Tufts University; Tufts Medical Center; Foundation for Research & Technology - Hellas (FORTH)	Tatsioni, A (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece.	atatsioni@gmail.com; jioannid@cc.uoi.gr	Ioannidis, John P. A./G-9836-2011; Tatsioni, Athina/AAQ-5413-2020					ABRIKOSOV AA, 1961, SOV PHYS JETP-USSR, V12, P1243; ABRIKOSOV AA, 1957, SOV PHYS JETP-USSR, V5, P1174; Berg JM, 2008, SCIENCE, V319, P900, DOI 10.1126/science.319.5865.900d; Capecchi MR, 2008, SCIENCE, V319, P900; Dorsey ER, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007015; Itagaki MW, 2008, RADIOLOGY, V247, P213, DOI 10.1148/radiol.2471070745; JAMIESON PW, 1992, ANN NEUROL, V32, P87, DOI 10.1002/ana.410320114; KOBAYASHI M, 1973, PROG THEOR PHYS, V49, P652, DOI 10.1143/PTP.49.652; LEGGETT AJ, 1975, REV MOD PHYS, V47, P331, DOI 10.1103/RevModPhys.47.331; Lewison G, 2001, GUT, V49, P295, DOI 10.1136/gut.49.2.295; Lyubarova R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006425; MANSFIELD P, 1977, J PHYS C SOLID STATE, V10, pL55, DOI 10.1088/0022-3719/10/3/004; MARSHALL B, 1983, LANCET, V1, P1273; MARSHALL BJ, 1984, LANCET, V1, P1311; Moses H, 2005, JAMA-J AM MED ASSOC, V294, P1333, DOI 10.1001/jama.294.11.1333; MUSSURAKIS S, 1994, AM J ROENTGENOL, V163, P973, DOI 10.2214/ajr.163.4.8092046; National Institute for Health and Clinical Excellence, 2008, SOC VAL JUDGM PRINC SOC VAL JUDGM PRINC, P1; ROBERTS K, 1981, ECONOMETRICA, V49, P1261, DOI 10.2307/1912754; Salter AJ, 2001, RES POLICY, V30, P509, DOI 10.1016/S0048-7333(00)00091-3; WARREN JR, 1983, LANCET, V1, P1273; Weissman JS, 1999, JAMA-J AM MED ASSOC, V281, P1093, DOI 10.1001/jama.281.12.1093	21	18	19	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1335	1339		10.1096/fj.09-148239	http://dx.doi.org/10.1096/fj.09-148239			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20056712				2022-12-28	WOS:000277158900006
J	Li, FQ; Tian, F; Wang, L; Williamson, IK; Sharifi, BG; Shah, PK				Li, Fuqiang; Tian, Fang; Wang, Lai; Williamson, Ian K.; Sharifi, Behrooz G.; Shah, Prediman K.			Pleiotrophin (PTN) is expressed in vascularized human atherosclerotic plaques: IFN-gamma/JAK/STAT1 signaling is critical for the expression of PTN in macrophages	FASEB JOURNAL			English	Article						plaque angiogenesis; neovascularization; vasculogenic mimicry	AFFIN REGULATORY PEPTIDE; GROWTH-FACTOR PLEIOTROPHIN; HUMAN CORONARY-ARTERIES; HUMAN PROSTATE-CANCER; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; INTERFERON-GAMMA; GENE-EXPRESSION; VASCULOGENIC MIMICRY; UP-REGULATION	Neovascularization is critical to destabilization of atheroma. We previously reported that the angiogenic growth factor pleiotrophin (PTN) coaxes monocytes to assume the phenotype of functional endothelial cells in vitro and in vivo. In this study we show that PTN expression is colocalized with capillaries of human atherosclerotic plaques. Among the various reagents that are critical to the pathogenesis of atherosclerosis, interferon (IFN)-gamma was found to markedly induce PTN mRNA expression in a dose-dependent manner in macrophages. Mechanistic studies revealed that the Janus kinase inhibitors, WHI-P154 and ATA, efficiently blocked STAT1 phosphorylation in a concentration-and time-dependent manner. Notably, the level of phosphorylated STAT1 was found to correlate directly with the PTN mRNA levels. In addition, STAT1/STAT3/p44/42 signaling molecules were found to be phosphorylated by IFN-gamma in macrophages, and they were translocated into the nucleus. Further, PTN promoter analysis showed that a gamma-activated sequence (GAS) located at -2086 to -2078 bp is essential for IFN-gamma-regulated promoter activity. Moreover, electrophoretic mobility shift, supershift, and chromatin immunoprecipitation analyses revealed that both STAT1 and STAT3 bind to the GAS at the chromatin level in the IFN-gamma stimulated cells. Finally, to test whether the combined effect of STAT1/STAT3/p44/42 signaling is required for the expression of PTN in macrophages, gene knockdowns of these transcription factors were performed using siRNA. Cells lacking STAT1, but not STAT3 or p42, have markedly reduced PTN mRNA levels. These data suggest that PTN expression in the human plaques may be in part regulated by IFN-gamma and that PTN is involved in the adaptive immunity.-Li, F., Tian, F., Wang, L., Williamson, I. K., Sharifi, B. G., Shah, P. K. Pleiotrophin (PTN) is expressed in vascularized human atherosclerotic plaques: IFN-gamma/JAK/STAT1 signaling is critical for the expression of PTN in macrophages FASEB J.24, 810-822 (2010). www.fasebj.org	[Li, Fuqiang; Tian, Fang; Wang, Lai; Williamson, Ian K.; Sharifi, Behrooz G.; Shah, Prediman K.] Cedars Sinai Med Ctr, Div Cardiol, Atherosclerosis Res Ctr, Burns & Allen Res Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center	Sharifi, BG (corresponding author), Cedars Sinai Med Ctr, Div Cardiol, Atherosclerosis Res Ctr, Burns & Allen Res Inst, Davis Bldg 1016,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	sharifi@cshs.org			U.S. National Institutes of Health [RO1 HL050566, RO1 HL090653]; Spielberg Research Fund; Heart Foundation; Corday Foundation; Feintech Foundation; Shapell and Guerin Foundation; United Hostesses; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090653, R01HL050566, R01HL104068] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spielberg Research Fund; Heart Foundation; Corday Foundation; Feintech Foundation; Shapell and Guerin Foundation; United Hostesses; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the U.S. National Institutes of Health (grants RO1 HL050566 and RO1 HL090653), the Spielberg Research Fund, the Heart Foundation, the Corday Foundation, the Feintech Foundation, the Shapell and Guerin Foundation, and United Hostesses.	Achour A., 2001, Cellular and Molecular Biology Online Papers, V47, pOL73; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; BARGER AC, 1990, AM J CARDIOL, V66, P41; Buono C, 2003, ARTERIOSCL THROM VAS, V23, P454, DOI 10.1161/01.ATV.0000059419.11002.6E; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Chen HM, 2007, BLOOD, V110, P287, DOI 10.1182/blood-2006-08-042374; Chen HM, 2009, BLOOD, V113, P1992, DOI 10.1182/blood-2008-02-133751; Chen HW, 2004, HEART, V90, P927, DOI 10.1136/hrt.2002.006734; Chen HX, 2005, J BIOL CHEM, V280, P19373, DOI 10.1074/jbc.M413528200; Christman KL, 2005, BIOMATERIALS, V26, P1139, DOI 10.1016/j.biomaterials.2004.04.025; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Boer OJ, 1999, CARDIOVASC RES, V41, P443, DOI 10.1016/S0008-6363(98)00255-7; Dineen SP, 2008, CANCER RES, V68, P4340, DOI 10.1158/0008-5472.CAN-07-6705; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; GENG YJ, 1995, ARTERIOSCL THROM VAS, V15, P1995, DOI 10.1161/01.ATV.15.11.1995; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220; Harvey EJ, 2005, CARDIOVASC RES, V67, P11, DOI 10.1016/j.cardiores.2005.04.019; Hatziapostolou M, 2005, PROSTATE, V65, P151, DOI 10.1002/pros.20270; Heil M, 2002, AM J PHYSIOL-HEART C, V283, pH2411, DOI 10.1152/ajpheart.01098.2001; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Kano A, 2003, J EXP MED, V198, P1517, DOI 10.1084/jem.20030077; LI YS, 1992, BIOCHEM BIOPH RES CO, V184, P427, DOI 10.1016/0006-291X(92)91211-8; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; Moreno PR, 2004, CIRCULATION, V110, P2032, DOI 10.1161/01.CIR.0000143233.87854.23; Moulton KS, 2003, P NATL ACAD SCI USA, V100, P4736, DOI 10.1073/pnas.0730843100; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Niu J, 2008, J BIOL CHEM, V283, P14542, DOI 10.1074/jbc.M802139200; OBRIEN ER, 1994, AM J PATHOL, V145, P883; Polytarchou C, 2005, J BIOL CHEM, V280, P40428, DOI 10.1074/jbc.M505120200; Pufe T, 2003, ARTHRITIS RHEUM, V48, P660, DOI 10.1002/art.10839; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Qin MH, 2003, ARTERIOSCL THROM VAS, V23, P425, DOI 10.1161/01.ATV.0000059303.94760.5C; RIEGEL AT, 1994, BREAST CANCER RES TR, V31, P309; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; Sharifi BG, 2006, ARTERIOSCL THROM VAS, V26, P1273, DOI 10.1161/01.ATV.0000222017.05085.8e; STEMME S, 1995, P NATL ACAD SCI USA, V92, P3893, DOI 10.1073/pnas.92.9.3893; TAKEDA A, 1995, NEUROSCIENCE, V68, P57, DOI 10.1016/0306-4522(95)00110-5; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Vacherot F, 1999, PROSTATE, V38, P126, DOI 10.1002/(SICI)1097-0045(19990201)38:2<126::AID-PROS6>3.0.CO;2-C; Virmani R, 2005, ARTERIOSCL THROM VAS, V25, P2054, DOI 10.1161/01.ATV.0000178991.71605.18; Wallner K, 1999, CIRCULATION, V99, P1284, DOI 10.1161/01.CIR.99.10.1284; Weber D, 2000, CANCER RES, V60, P5284; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Whitman SC, 2000, AM J PATHOL, V157, P1819, DOI 10.1016/S0002-9440(10)64820-1; Yeh HJ, 1998, J NEUROSCI, V18, P3699	50	14	16	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					810	822		10.1096/fj.09-140780	http://dx.doi.org/10.1096/fj.09-140780			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19917672	Green Published, Bronze			2022-12-28	WOS:000274974600017
J	Vasilaki, E; Papadimitriou, E; Tajadura, V; Ridley, AJ; Stournaras, C; Kardassis, D				Vasilaki, Eleftheria; Papadimitriou, Elsa; Tajadura, Virginia; Ridley, Anne J.; Stournaras, Christos; Kardassis, Dimitris			Transcriptional regulation of the small GTPase RhoB gene by TGF beta-induced signaling pathways	FASEB JOURNAL			English	Article						ERK; Smad; cell migration; HaCaT; DU145; NF-Y	GROWTH-FACTOR-BETA; FUNCTIONAL INTERACTIONS; UP-REGULATION; CELLS; BINDING; PROTEIN; CANCER; ACTIVATION; EXPRESSION; MECHANISM	The purpose of the present study was to investigate the mechanism of transcriptional induction of the small GTPase RhoB gene by the transforming growth factor beta (TGF beta) signaling pathway and the role of this regulation in TGF beta-induced cell migration. To achieve our goals, we utilized a combination of siRNA-mediated gene silencing, adenovirus-mediated gene transfer receptor and MAPK inhibition, transactivation assays, and DNA-protein interaction assays in human HaCaT keratinocytes. We found that the RhoB gene is a direct transcriptional target of TGF beta. We show that TGF beta activates an early MEK/ERK pathway and that this activation is required for the recruitment of Smad3 to a novel, nonclassical, Smad binding element in the proximal RhoB promoter, in a p53-dependent manner. This element is overlapping with a CCAAT box that constitutively binds nuclear factor Y. Mutagenesis of this site abolished the Smad-mediated transactivation of the RhoB promoter. Finally, silencing of RhoB gene expression via siRNA or utilization of a dominant negative form of RhoB significantly inhibited TGF beta-induced migration of HaCaT keratinocytes and DU145 prostate cancer cells. Our findings establish RhoB as a direct transcriptional target of TGF beta in human keratinocytes and identify an important role of RhoB in TGF beta-induced cell migration.-Vasilaki, E., Papadimitriou, E., Tajadura, V., Ridley, A. J., Stournaras, C., Kardassis, D. Transcriptional regulation of the small GTPase RhoB gene by TGF beta-induced signaling pathways. FASEB J. 24, 891-905 (2010). www.fasebj.org	[Vasilaki, Eleftheria; Papadimitriou, Elsa; Stournaras, Christos; Kardassis, Dimitris] Univ Crete, Dept Biochem, Sch Med, GR-71003 Iraklion, Greece; [Vasilaki, Eleftheria; Kardassis, Dimitris] Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion, Greece; [Tajadura, Virginia; Ridley, Anne J.] Kings Coll London, Randall Div Cell & Mol Biophys, London WC2R 2LS, England	University of Crete; Foundation for Research & Technology - Hellas (FORTH); University of London; King's College London	Kardassis, D (corresponding author), Univ Crete, Dept Biochem, Sch Med, GR-71003 Iraklion, Greece.	kardasis@imbb.forth.gr	Vasilaki, Eleftheria/AAY-6392-2020	Ridley, Anne/0000-0001-8186-5708	Greek General Secretariat for Research and Technology [PENED-03 EDelta688]; Cancer Research U.K.; FEBS short-term fellowship; Fundacion Ramon Areces, Spain	Greek General Secretariat for Research and Technology(Greek Ministry of Development-GSRT); Cancer Research U.K.(Cancer Research UK); FEBS short-term fellowship; Fundacion Ramon Areces, Spain	The authors thank Dr. Roberto Mantovani (Department of Genetics and Biology of Microorganisms, University of Milan, Milan, Italy) for the NF-Yexpression vectors, Dr. Aris Moustakas (Ludwig Institute for Cancer Research, Uppsala, Sweden) for recombinant adenoviruses and for useful comments on this manuscript, Dr. Aris Eliopoulos (University of Crete Medical School, Heraklion, Greece) for materials, Dr. Francisco Vega for advice, and all members of the D. K., C. S., and A.J.R. laboratories for helpful discussions. This research was supported by grants from the Greek General Secretariat for Research and Technology (PENED-03 E Delta 688) to C. S. and D. K. and from Cancer Research U.K. (V. T. and A. J. R.). E. V. was supported by a FEBS short-term fellowship; V. T. was supported by a postdoctoral fellowship from the Fundacion Ramon Areces, Spain.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Alabert C, 2006, ONCOGENE, V25, P3387, DOI 10.1038/sj.onc.1209385; Cordenonsi M, 2007, SCIENCE, V315, P840, DOI 10.1126/science.1135961; Coyle B, 2003, J BIOL CHEM, V278, P5920, DOI 10.1074/jbc.M211300200; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Dupont S, 2004, CANCER LETT, V213, P129, DOI 10.1016/j.canlet.2004.06.008; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Fong YC, 2009, LUNG CANCER, V64, P13, DOI 10.1016/j.lungcan.2008.07.010; Fritz G, 2001, NUCLEIC ACIDS RES, V29, P792, DOI 10.1093/nar/29.3.792; Guzman-Ayala M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004268; Heinke J, 2007, CARDIOVASC RES, V76, P390, DOI 10.1016/j.cardiores.2007.08.003; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Huang M, 2006, HISTOL HISTOPATHOL, V21, P213, DOI 10.14670/HH-21.213; Hutchison N, 2009, CELL SIGNAL, V21, P1522, DOI 10.1016/j.cellsig.2009.05.012; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kuo YC, 2009, INT J CANCER, V124, P2568, DOI 10.1002/ijc.24263; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Moustakas A, 2008, FEBS LETT, V582, P2051, DOI 10.1016/j.febslet.2008.03.027; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Pannu J, 2007, J BIOL CHEM, V282, P10405, DOI 10.1074/jbc.M611742200; Piek E, 1999, J CELL SCI, V112, P4557; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Prokova V, 2005, NUCLEIC ACIDS RES, V33, P3708, DOI 10.1093/nar/gki679; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; TEN DP, 2004, TRENDS BIOCHEM SCI, V29, P265; Thymiakou E, 2007, BIOCHEMISTRY-US, V46, P11473, DOI 10.1021/bi700994m; Vardouli L, 2005, J BIOL CHEM, V280, P11448, DOI 10.1074/jbc.M402651200; Vardouli L, 2008, FEBS J, V275, P4074, DOI 10.1111/j.1742-4658.2008.06549.x; Vasilaki E, 2009, BIOCHEMISTRY-US, V48, P8366, DOI 10.1021/bi9005489; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Wheeler AP, 2007, EXP CELL RES, V313, P3505, DOI 10.1016/j.yexcr.2007.07.014; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Xiao YQ, 2009, INVEST OPHTH VIS SCI, V50, P1698, DOI 10.1167/iovs.08-1675; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	52	42	42	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					891	905		10.1096/fj.09-134742	http://dx.doi.org/10.1096/fj.09-134742			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19890017				2022-12-28	WOS:000274974600025
J	Lonn, M; Mehlig, K; Bengtsson, C; Lissner, L				Lonn, Malin; Mehlig, Kirsten; Bengtsson, Calle; Lissner, Lauren			Adipocyte size predicts incidence of type 2 diabetes in women	FASEB JOURNAL			English	Article						obesity; prospective study; anthropometry; abdominal; heredity	ADIPOSE-TISSUE CELLULARITY; FAT-CELL SIZE; PROSPECTIVE POPULATION; INSULIN SENSITIVITY; GOTEBORG 1974-1975; WEIGHT-REDUCTION; BODY-COMPOSITION; OBESITY; RISK; MELLITUS	Enlarged subcutaneous abdominal adipocytes have been shown to predict incidence of type 2 diabetes (T2D) in the Pima population of Arizona (USA). We investigated the role of subcutaneous abdominal adipocyte size (AAS), as well as femoral adipocyte size (FAS), as predictors of T2D in a population-based Swedish cohort. In 1974-1975, a sample of 1302 middle-aged women underwent a health examination, including anthropometry and evaluation of parental medical history. In addition, body composition (total body potassium and total body water), AAS and FAS (adipose tissue needle biopsy) were assessed in a sub-sample of 245 women. Incidence of T2D was followed until 2001, with 36 cases eligible for inclusion in this analysis. Women developing T2D had larger AAS at baseline vs. women remaining healthy (age/heredity-adjusted hazard ratio for increase of AAS by 1 SD [AAS-HR] 1.91; P<0.001). Further adjustment for both body fat percentage and waist-to-height ratio (WHtR) indicated a robust association. For FAS, the corresponding associations were consistently weaker. WHtR retained a strong predictive association independent of AAS and FAS (WHtR-HR 2.6 and 2.7, respectively; P<0.001). To conclude, in addition to the amount and distribution of body fat in women, subcutaneous adipocyte size, particularly in the abdominal region, predicts incidence of T2D in later life.-Lonn, M., Mehlig, K., Bengtsson, C., Lissner, L. Adipocyte size predicts incidence of type 2 diabetes in women. FASEB J. 24, 326-331 (2010). www.fasebj.org	[Lonn, Malin] Univ Gothenburg, Dept Clin Chem, Gothenburg, Sweden; [Lonn, Malin] Univ Gothenburg, Wallenberg Lab, Gothenburg, Sweden; [Mehlig, Kirsten; Bengtsson, Calle; Lissner, Lauren] Univ Gothenburg, Sahlgrenska Acad, Publ Hlth Epidemiol Unit, Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg	Lonn, M (corresponding author), Sahlgrens Univ Hosp, Dept Clin Chem, Bruna Straket 16, SE-41345 Gothenburg, Sweden.	malin.lonn@medic.gu.se	Mehlig, Kirsten/AAT-3468-2020		FAS Center EpiLife; FAS project WISH	FAS Center EpiLife; FAS project WISH	The authors thank professors Cecilia Bjorkelund, Leif Lapidus, and Lena Carlsson for valuable discussions. This work was supported by FAS Center EpiLife and FAS project WISH.	BENGTSSON C, 1978, SCAND J SOC MED, V6, P49, DOI 10.1177/140349487800600201; BENGTSSON C, 1973, ACTA MED SCAND, P311; Bjorkelund C, 2005, DIABETES CARE, V28, P2739, DOI 10.2337/diacare.28.11.2739; Bjorkelund C, 1996, INT J OBESITY, V20, P213; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; DeFronzo RA, 2004, INT J CLIN PRACT, V58, P9, DOI 10.1111/j.1368-504X.2004.00389.x; EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304; GOLDRICK RB, 1967, AM J PHYSIOL, V212, P777, DOI 10.1152/ajplegacy.1967.212.4.777; HIRSCH J, 1964, J CLIN INVEST, V43, P1776, DOI 10.1172/JCI105052; Hsieh SD, 2003, INT J OBESITY, V27, P610, DOI 10.1038/sj.ijo.0802259; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; Janssen I, 2008, ARCH INTERN MED, V168, P1568, DOI 10.1001/archinte.168.14.1568; Jernas M, 2006, FASEB J, V20, P1540, DOI 10.1096/fj.05-5678fje; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; KROTKIEWSKI M, 1977, INT J OBESITY, V1, P395; Lofgren P, 2005, DIABETOLOGIA, V48, P2334, DOI 10.1007/s00125-005-1961-6; LUNDGREN H, 1989, INT J OBESITY, V13, P413; Lundgren M, 2007, DIABETOLOGIA, V50, P625, DOI 10.1007/s00125-006-0572-1; Lundgren M, 2004, J CLIN ENDOCR METAB, V89, P2989, DOI 10.1210/jc.2003-031157; Maffeis C, 2007, J PEDIATR-US, V151, P647, DOI 10.1016/j.jpeds.2007.04.053; McLaugblin T, 2007, DIABETOLOGIA, V50, P1707, DOI 10.1007/s00125-007-0708-y; MOMBELLI G, 2009, METAB SYNDR RELAT DI; NOPPA H, 1980, INT J OBESITY, V4, P253; NOPPA H, 1979, ACTA MED SCAND, V206, P501; NOPPA H, 1979, AM J CLIN NUTR, V32, P1388, DOI 10.1093/ajcn/32.7.1388; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; Olshansky SJ, 2005, NEW ENGL J MED, V352, P1138, DOI 10.1056/NEJMsr043743; Pasarica M, 2009, DIABETES CARE, V32, P900, DOI 10.2337/dc08-2240; Ridderstrale M, 2009, MOL CELL ENDOCRINOL, V297, P10, DOI 10.1016/j.mce.2008.10.002; SALANS LB, 1968, J CLIN INVEST, V47, P153, DOI 10.1172/JCI105705; SALANS LB, 1971, J CLIN INVEST, V50, P1399, DOI 10.1172/JCI106623; Shadid S, 2003, DIABETES CARE, V26, P3148, DOI 10.2337/diacare.26.11.3148; SJOSTROM L, 1971, J LIPID RES, V12, P521; Skurk T, 2007, J CLIN ENDOCR METAB, V92, P1023, DOI 10.1210/jc.2006-1055; SMITH U, 1970, Biochimica et Biophysica Acta, V218, P417, DOI 10.1016/0005-2760(70)90004-4; SMITH U, 1971, J LIPID RES, V12, P65; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; SVENDSEN OL, 1995, METABOLISM, V44, P369, DOI 10.1016/0026-0495(95)90168-X; Wei M, 1997, OBES RES, V5, P16, DOI 10.1002/j.1550-8528.1997.tb00278.x; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Weyer C, 2000, DIABETOLOGIA, V43, P1498, DOI 10.1007/s001250051560; World Health Organization, 1985, WHO TECHN REP SER, V727	43	136	137	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					326	331		10.1096/fj.09-133058	http://dx.doi.org/10.1096/fj.09-133058			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19741173				2022-12-28	WOS:000273233600033
J	Senkal, CE; Ponnusamy, S; Bielawski, J; Hannun, YA; Ogretmen, B				Senkal, Can E.; Ponnusamy, Suriyan; Bielawski, Jacek; Hannun, Yusuf A.; Ogretmen, Besim			Antiapoptotic roles of ceramide-synthase-6-generated C-16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways	FASEB JOURNAL			English	Article						sphingolipid; cell death; head and neck cancer; unfolded protein response	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; LONGEVITY ASSURANCE GENE-1; SQUAMOUS-CELL CARCINOMAS; HUMAN HEAD; CERAMIDE SYNTHASE; INDUCED APOPTOSIS; FAMILY-MEMBERS; DEATH PROGRAM; CANCER CELLS	Emerging results suggest that ceramides with different fatty acid chain lengths might play distinct functions in the regulation of tumor growth and therapy. Here we report that de novo-generated C-18- and C-16-ceramides by ceramide synthases 1 and 6 (CerS1 and CerS6) play opposing proapoptotic and prosurvival roles, respectively, in human head and neck squamous cell carcinomas (HNSCCs). Unexpectedly, knockdown of CerS6/C-16-ceramide using small interfering RNA induced endoplasmic reticulum (ER)-stress-mediated apoptosis. Reconstitution of C-16-ceramide generation by induced expression of wild-type CerS6, but not its catalytically inactive mutant, protected cells from cell death induced by knockdown of CerS6. Moreover, using molecular tools coupled with analysis of sphingolipid metabolism showed that generation of C-16-ceramide, and not dihydro-C-16-ceramide, by induced expression of CerS6 rescued cells from ER stress and apoptosis. Mechanistically, regulation of ER-stress-induced apoptosis by CerS6/C-16-ceramide was linked to the activation of a specific arm, ATF6/CHOP, of the unfolded protein response pathway. Notably, while expression of CerS1/C-18-ceramide inhibited HNSCC xenograft growth, CerS6/C-16-ceramide significantly protected ER stress, leading to enhanced tumor development and growth in vivo, consistent with their pro-and antiapoptotic roles, respectively. Thus, these data reveal an unexpected and novel prosurvival role of CerS6/C-16-ceramide involved in the protection against ER-stress-induced apoptosis and induction of HNSCC tumor growth.-Senkal, C. E., Ponnusamy, S., Bielawski, J., Hannun, Y. A., Ogretmen, B. Antiapoptotic roles of ceramide-synthase-6-generated C-16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J. 24, 296-308 (2010). www.fasebj.org	[Ogretmen, Besim] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Ogretmen, B (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, 86 Jonathan Lucas St,Rm 512A, Charleston, SC 29425 USA.	ogretmen@musc.edu			National Institutes of Health [C06 RR-015455, CA-88932, DE-016572, CA-97132]; NATIONAL CANCER INSTITUTE [P01CA097132, R01CA088932] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE016572] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr. Jennifer Schnellmann for critically reviewing the manuscript and the members of the B. O. laboratory for helpful discussions. The Flow Cytometry and Cell Sorting, and Lipidomics Core Laboratories are located in a facility constructed with support from the National Institutes of Health (C06 RR-015455). This work was supported by National Institutes of Health grants CA-88932, DE-016572, and CA-97132.	Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Contreras JL, 2003, TRANSPLANT INT, V16, P537, DOI 10.1007/s00147-003-0619-x; Culmsee Carsten, 2006, Current Alzheimer Research, V3, P269, DOI 10.2174/156720506778249461; Davenport EL, 2007, BLOOD, V110, P2641, DOI 10.1182/blood-2006-11-053728; Deng XZ, 2008, SCIENCE, V322, P110, DOI 10.1126/science.1158111; Deniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Guillas I, 2003, J BIOL CHEM, V278, P37083, DOI 10.1074/jbc.M307554200; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Hamanaka RB, 2009, ONCOGENE, V28, P910, DOI 10.1038/onc.2008.428; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Kadara H, 2007, CANCER BIOL THER, V6, P705, DOI 10.4161/cbt.6.5.3963; Kageyama-Yahara N, 2006, BIOCHEM J, V398, P585, DOI 10.1042/BJ20060697; Karahatay S, 2007, CANCER LETT, V256, P101, DOI 10.1016/j.canlet.2007.06.003; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; Lahiri S, 2005, J BIOL CHEM, V280, P33735, DOI 10.1074/jbc.M506485200; Laviad EL, 2008, J BIOL CHEM, V283, P5677, DOI 10.1074/jbc.M707386200; Lee AS, 2006, CANCER BIOL THER, V5, P721, DOI 10.4161/cbt.5.7.3120; Lei XY, 2008, J BIOL CHEM, V283, P34819, DOI 10.1074/jbc.M807409200; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Mehta S, 2000, CANCER CHEMOTH PHARM, V46, P85, DOI 10.1007/s002800000140; Menuz V, 2009, SCIENCE, V324, P381, DOI 10.1126/science.1168532; Min JX, 2007, MOL CANCER RES, V5, P801, DOI 10.1158/1541-7786.MCR-07-0100; Mizutani Y, 2005, BIOCHEM J, V390, P263, DOI 10.1042/BJ20050291; Mousley CJ, 2008, MOL BIOL CELL, V19, P4785, DOI 10.1091/mbc.E08-04-0426; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292; Oakes SA, 2006, CURR MOL MED, V6, P99, DOI 10.2174/156652406775574587; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Park MA, 2008, CANCER BIOL THER, V7, P1648, DOI 10.4161/cbt.7.10.6623; Rabik CA, 2008, J PHARMACOL EXP THER, V327, P442, DOI 10.1124/jpet.108.141291; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Schiffmann S, 2009, CARCINOGENESIS, V30, P745, DOI 10.1093/carcin/bgp061; Senkal CE, 2007, MOL CANCER THER, V6, P712, DOI 10.1158/1535-7163.MCT-06-0558; Senkal CE, 2006, J PHARMACOL EXP THER, V317, P1188, DOI 10.1124/jpet.106.101949; Spassieva S, 2006, J BIOL CHEM, V281, P33931, DOI 10.1074/jbc.M608092200; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang Y, 2000, J BIOL CHEM, V275, P27013; White-Gilbertson S, 2009, ONCOGENE, V28, P1132, DOI 10.1038/onc.2008.468; Whitney ML, 2009, BIOCHEM BIOPH RES CO, V379, P451, DOI 10.1016/j.bbrc.2008.12.079; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	51	189	190	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2010	24	1					296	308		10.1096/fj.09-135087	http://dx.doi.org/10.1096/fj.09-135087			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19723703	Green Published			2022-12-28	WOS:000273233600030
J	Zhao-Shea, R; Cohen, BN; Just, H; McClure-Begley, T; Whiteaker, P; Grady, SR; Salminen, O; Gardner, PD; Lester, HA; Tapper, AR				Zhao-Shea, Rubing; Cohen, Bruce N.; Just, Herwig; McClure-Begley, Tristan; Whiteaker, Paul; Grady, Sharon R.; Salminen, Outi; Gardner, Paul D.; Lester, Henry A.; Tapper, Andrew R.			Dopamine D-2-receptor activation elicits akinesia, rigidity, catalepsy, and tremor in mice expressing hypersensitive alpha 4 nicotinic receptors via a cholinergic-dependent mechanism	FASEB JOURNAL			English	Article						acetylcholine; striatum; nicotine; parkinsonian; interneuron	TONICALLY-ACTIVE NEURONS; ACETYLCHOLINE-RECEPTORS; PARKINSONS-DISEASE; AUTORECEPTOR FUNCTION; NUCLEUS-ACCUMBENS; STRIATAL FUNCTION; CALCIUM CURRENTS; FOS EXPRESSION; MOUSE STRIATUM; BRAIN-AREAS	Recent studies suggest that high-affinity neuronal nicotinic acetylcholine receptors (nAChRs) containing alpha 4 and beta 2 subunits (alpha 4 beta 2*) functionally interact with G-protein-coupled dopamine (DA) D-2 receptors in basal ganglia. We hypothesized that if a functional interaction between these receptors exists, then mice expressing an M2 point mutation (Leu9'Ala) rendering alpha 4 nAChRs hypersensitive to ACh may exhibit altered sensitivity to a D-2-receptor agonist. When challenged with the D2R agonist, quinpirole (0.5-10 mg/kg), Leu9'Ala mice, but not wild-type (WT) littermates, developed severe, reversible motor impairment characterized by rigidity, catalepsy, akinesia, and tremor. While striatal DA tissue content, baseline release, and quinpirole-induced DA depletion did not differ between Leu9' Ala and WT mice, quinpirole dramatically increased activity of cholinergic striatal interneurons only in mutant animals, as measured by increased c-Fos expression in choline acetyltransferase (ChAT)-positive interneurons. Highlighting the importance of the cholinergic system in this mouse model, inhibiting the effects of ACh by blocking muscarinic receptors, or by selectively activating hypersensitive nAChRs with nicotine, rescued motor symptoms. This novel mouse model mimics the imbalance between striatal DA/ACh function associated with severe motor impairment in disorders such as Parkinson's disease, and the data suggest that a D2R-alpha 4*-nAChR functional interaction regulates cholinergic interneuron activity.-Zhao-Shea, R., Cohen, B. N., Just, H., McClure-Begley, T., Whiteaker, P., Grady, S. R., Salminen, O., Gardner, P. D., Lester, H. A., Tapper, A. R. Dopamine D-2-receptor activation elicits akinesia, rigidity, catalepsy, and tremor in mice expressing hypersensitive alpha 4 nicotinic receptors via a cholinergic-dependent mechanism. FASEB J. 24, 49-57 (2010). www.fasebj.org	[Zhao-Shea, Rubing; Gardner, Paul D.; Tapper, Andrew R.] Univ Massachusetts, Sch Med, Brudnick Neuropsychiat Res Inst, Dept Psychiat, Worcester, MA 01604 USA; [Cohen, Bruce N.; Just, Herwig; Lester, Henry A.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [McClure-Begley, Tristan; Grady, Sharon R.] Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA; [Whiteaker, Paul] St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Salminen, Outi] Univ Helsinki, Dept Pharm, Div Pharmacol & Toxicol, Helsinki, Finland	University of Massachusetts System; University of Massachusetts Worcester; California Institute of Technology; University of Colorado System; University of Colorado Boulder; Barrow Neurological Institute; St. Joseph's Hospital and Medical Center; University of Helsinki	Tapper, AR (corresponding author), Univ Massachusetts, Sch Med, Brudnick Neuropsychiat Res Inst, Dept Psychiat, 303 Belmont St, Worcester, MA 01604 USA.	andrew.tapper@umassmed.edu		Salminen, Outi/0000-0003-0427-858X	National Institute of Neurological Disorders and Stroke [NS059586]; National Institute on Drug Abuse [DA017279, DA12242]; National Institute on Aging [AG033954]; NIH [DA015663]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG033954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA017279, R01DA012242, P30DA015663] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Ms. Marjo Vaha for excellent technical assistance and Dr. T. Petteri Piepponen for advice with the microdialysis experiments. This work was supported in part by the National Institute of Neurological Disorders and Stroke (NS059586), the National Institute on Drug Abuse (DA017279 and DA12242), and the National Institute on Aging (AG033954). Production of mice in Boulder was supported by NIH animal resources grant DA015663.	Agnati LF, 2003, PHARMACOL REV, V55, P509, DOI 10.1124/pr.55.3.2; Alcantara AA, 2003, BRAIN RES, V986, P22, DOI 10.1016/S0006-8993(03)03165-2; AOSAKI T, 1994, SCIENCE, V265, P412, DOI 10.1126/science.8023166; Calabresi P, 2000, TRENDS NEUROSCI, V23, P120, DOI 10.1016/S0166-2236(99)01501-5; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; COWARD DM, 1977, ARZNEIMITTEL-FORSCH, V27-2, P2326; de Rover M, 2002, EUR J NEUROSCI, V16, P2279, DOI 10.1046/j.1460-9568.2002.02289.x; DeBoer P, 1996, EUR J PHARMACOL, V317, P257, DOI 10.1016/S0014-2999(96)00761-3; Ding J, 2006, NAT NEUROSCI, V9, P832, DOI 10.1038/nn1700; Fonck C, 2005, J NEUROSCI, V25, P11396, DOI 10.1523/JNEUROSCI.3597-05.2005; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Goldberg JA, 2005, J NEUROSCI, V25, P10230, DOI 10.1523/JNEUROSCI.2734-05.2005; Gotti C, 2006, NEUROBIOL DIS, V23, P481, DOI 10.1016/j.nbd.2006.04.005; GRADY S, 1992, J NEUROCHEM, V59, P848, DOI 10.1111/j.1471-4159.1992.tb08322.x; Grady SR, 2007, BIOCHEM PHARMACOL, V74, P1235, DOI 10.1016/j.bcp.2007.07.032; GRADY SR, 1994, J NEUROCHEM, V62, P1390, DOI 10.1046/j.1471-4159.1994.62041390.x; HAIKALA H, 1987, J NEUROCHEM, V49, P1033, DOI 10.1111/j.1471-4159.1987.tb09991.x; JANSSEN PAJ, 1965, ARZNEI-FORSCHUNG, V15, P104; Jones S, 1999, TRENDS NEUROSCI, V22, P555, DOI 10.1016/S0166-2236(99)01471-X; Koos T, 2002, J NEUROSCI, V22, P529, DOI 10.1523/JNEUROSCI.22-02-00529.2002; Lester HA, 2003, CURR OPIN DRUG DISC, V6, P633; Lindner MD, 1996, BRAIN RES BULL, V39, P367, DOI 10.1016/0361-9230(96)00027-5; Lindstrom J, 1996, PROG BRAIN RES, V109, P125; MACKENZIE RG, 1989, EUR J PHARMACOL, V168, P43, DOI 10.1016/0014-2999(89)90631-6; Mercuri NB, 1997, NEUROSCIENCE, V79, P323; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Miwa H, 2009, PARKINSONISM RELAT D, V15, P30, DOI 10.1016/j.parkreldis.2008.02.008; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; Pisani A, 2006, NEUROBIOL DIS, V24, P318, DOI 10.1016/j.nbd.2006.07.006; Pisani A, 2001, PROG NEURO-PSYCHOPH, V25, P211, DOI 10.1016/S0278-5846(00)00153-6; Pisani A, 2007, TRENDS NEUROSCI, V30, P545, DOI 10.1016/j.tins.2007.07.008; Quarta D, 2007, NEUROPSYCHOPHARMACOL, V32, P35, DOI 10.1038/sj.npp.1301103; Quik M, 2003, MOL PHARMACOL, V63, P1169, DOI 10.1124/mol.63.5.1169; Raz A, 1996, J NEUROPHYSIOL, V76, P2083, DOI 10.1152/jn.1996.76.3.2083; Rice ME, 2004, NAT NEUROSCI, V7, P583, DOI 10.1038/nn1244; Salminen O, 1999, J NEUROSCI, V19, P8145; Salminen O, 2004, MOL PHARMACOL, V65, P1526, DOI 10.1124/mol.65.6.1526; Salminen O, 1996, PHARMACOL BIOCHEM BE, V54, P241, DOI 10.1016/0091-3057(95)02132-9; Savitt JM, 2006, J CLIN INVEST, V116, P1744, DOI 10.1172/JCI29178; Singh N, 2007, PROG NEUROBIOL, V81, P29, DOI 10.1016/j.pneurobio.2006.11.009; Sotnikova TD, 2005, PLOS BIOL, V3, P1488, DOI 10.1371/journal.pbio.0030271; Sullivan MA, 2008, J NEUROSCI, V28, P8682, DOI 10.1523/JNEUROSCI.2411-08.2008; Tammimaki A, 2006, EUR J PHARMACOL, V531, P118, DOI 10.1016/j.ejphar.2005.12.027; Tapper AR, 2006, CELL BIOLOGY OF ADDICTION, P179; Tapper AR, 2004, SCIENCE, V306, P1029, DOI 10.1126/science.1099420; Tepper JM, 1997, J NEUROSCI, V17, P2519; Tepper JM, 2004, CURR OPIN NEUROBIOL, V14, P685, DOI 10.1016/j.conb.2004.10.003; Whiteaker P, 2000, BRIT J PHARMACOL, V131, P729, DOI 10.1038/sj.bjp.0703616; Wilson CJ, 2005, NEURON, V45, P575, DOI 10.1016/j.neuron.2004.12.053; Wirtshafter D, 2004, EUR J PHARMACOL, V488, P85, DOI 10.1016/j.ejphar.2004.02.025; Yan Z, 1997, J NEUROPHYSIOL, V77, P1003, DOI 10.1152/jn.1997.77.2.1003; Zhang H, 2004, NAT NEUROSCI, V7, P581, DOI 10.1038/nn1243; Zhou FM, 2003, NEUROSCIENTIST, V9, P23, DOI 10.1177/1073858402239588; Zhou FM, 2001, NAT NEUROSCI, V4, P1224, DOI 10.1038/nn769	54	10	10	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2010	24	1					49	57		10.1096/fj.09-137034	http://dx.doi.org/10.1096/fj.09-137034			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19720621	Green Published			2022-12-28	WOS:000273233600008
J	Eble, JA; Niland, S; Bracht, T; Mormann, M; Peter-Katalinic, J; Pohlentz, G; Stetefeld, J				Eble, Johannes A.; Niland, Stephan; Bracht, Thilo; Mormann, Michael; Peter-Katalinic, Jasna; Pohlentz, Gottfried; Stetefeld, Joerg			The alpha 2 beta 1 integrin-specific antagonist rhodocetin is a cruciform, heterotetrameric molecule	FASEB JOURNAL			English	Article						C-type lectin-like protein; integrin; snake venom; Calloselasma rhodostoma	IB-BINDING PROTEIN; MALAYAN PIT VIPER; CRYSTAL-STRUCTURE; FLAVOCETIN-A; VENOM; INHIBITOR; DOMAIN; POTENT; RECEPTORS; REVEALS	The integrin alpha 2 beta 1 plays an important role in various pathophysiological processes, such as thrombosis, wound healing, inflammation, and metastasis. Rhodocetin, a constituent of the venom of the hemorrhagic Malayan pit viper (Calloselasma rhodostoma), is a specific alpha 2 beta 1 integrin antagonist. To understand its molecular mode of action, its structure was studied by crystallography. Its quaternary structure in solution was also analyzed biochemically. Two novel subunits of rhodocetin were sequenced by mass spectrometry. Their integrin binding was measured by protein interaction ELISAs. Rhodocetin is a C-type lectinlike protein (CLP) consisting of four homologous, yet distinct, subunits, alpha, beta, gamma, and delta, the latter two of which have been unknown to date. With their CLP folds and loop-swapping motifs, the subunits alpha, beta and gamma, delta form two heterodimeric pairs. Uniquely, they arrange orthogonally and shape a cruciform molecule. Bearing a single unpaired cysteine residue, rhodocetin can only form covalent supramolecular complexes with a maximum aggregation number of 2, unlike many heterodimeric CLPs. Being the first heterotetrameric CLP to be crystallized, rhodocetin provides not only the prototypic molecular structure for heterotetrameric CLPs, but also a lead structure for pharmaceutical alpha 2 beta 1 integrin antagonists.-Eble, J. A., Niland, S., Bracht, T., Mormann, M., Peter-Katalinic, J., Pohlentz, G., Stetefeld, J. The alpha 2 beta 1 integrin-specific antagonist rhodocetin is a cruciform, heterotetrameric molecule. FASEB J. 23, 2917-2927 (2009). www.fasebj.org	[Eble, Johannes A.; Niland, Stephan; Bracht, Thilo] Frankfurt Univ Hosp, Ctr Mol Med, Dept Vasc Matrix Biol, Excellence Cluster Cardiopulm Syst, D-60590 Frankfurt, Germany; [Mormann, Michael; Peter-Katalinic, Jasna; Pohlentz, Gottfried] Univ Munster, Inst Med Phys & Biophys, Munster, Germany; [Stetefeld, Joerg] Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada; [Stetefeld, Joerg] Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada	Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Munster; University of Manitoba; University of Manitoba	Eble, JA (corresponding author), Frankfurt Univ Hosp, Ctr Mol Med, Dept Vasc Matrix Biol, Excellence Cluster Cardiopulm Syst, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	eble@med.uni-frankfurt.de	Stetefeld, Joerg/H-7630-2017; Mormann, Michael/T-4860-2017; Bracht, Thilo/H-7258-2019	Stetefeld, Joerg/0000-0003-1478-3248; Mormann, Michael/0000-0002-7428-7329; Bracht, Thilo/0000-0002-1194-6614	Deutsche Forschungsgemeinschaft (DFG) [Eb177/5-1, STB492/Z2]; Canada Research Chair program	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Canada Research Chair program(Canada Research Chairs)	This work was financially supported by the Deutsche Forschungsgemeinschaft (DFG; grants Eb177/5-1 to J.A.E. and STB492/Z2 to J.P.K. and M.M.). J.S. is funded by the Canada Research Chair program.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arocas V, 1996, BIOCHEMISTRY-US, V35, P9083, DOI 10.1021/bi960043l; ATODA H, 1994, EUR J BIOCHEM, V224, P703, DOI 10.1111/j.1432-1033.1994.t01-1-00703.x; ATODA H, 1991, J BIOL CHEM, V266, P14903; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Batuwangala T, 2004, ACTA CRYSTALLOGR D, V60, P46, DOI 10.1107/S0907444903021620; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Curley GP, 1999, CELL MOL LIFE SCI, V56, P427, DOI 10.1007/s000180050443; Eble JA, 2003, BIOCHEM J, V376, P77, DOI 10.1042/BJ20030373; Eble JA, 2002, MATRIX BIOL, V21, P547, DOI 10.1016/S0945-053X(02)00068-9; Eble JA, 2001, J BIOL CHEM, V276, P12274, DOI 10.1074/jbc.M009338200; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Fox JW, 2005, TOXICON, V45, P969, DOI 10.1016/j.toxicon.2005.02.012; Fukuda K, 2000, BIOCHEMISTRY-US, V39, P1915, DOI 10.1021/bi992134z; Fukuda K, 2005, NAT STRUCT MOL BIOL, V12, P152, DOI 10.1038/nsmb892; Horii K, 2004, J MOL BIOL, V341, P519, DOI 10.1016/j.jmb.2004.06.036; Horii K, 2003, BIOCHEMISTRY-US, V42, P12497, DOI 10.1021/bi034890h; Huang KF, 2004, BIOCHEM J, V378, P399, DOI 10.1042/BJ20031507; Kong CG, 2001, J PROTEIN CHEM, V20, P383, DOI 10.1023/A:1012280720595; Kowalska MA, 1998, THROMB HAEMOSTASIS, V79, P609; Leslie AGW, 1994, MOSFLM USERS GUIDE; Lu QM, 2005, TOXICON, V45, P1089, DOI 10.1016/j.toxicon.2005.02.022; Maita N, 2003, J BIOL CHEM, V278, P37777, DOI 10.1074/jbc.M305566200; Marcinkiewicz C, 2000, BIOCHEMISTRY-US, V39, P9859, DOI 10.1021/bi000428a; Matsui T, 2005, TOXICON, V45, P1075, DOI 10.1016/j.toxicon.2005.02.023; Mizuno H, 2001, P NATL ACAD SCI USA, V98, P7230, DOI 10.1073/pnas.131179698; Morita T, 2005, TOXICON, V45, P1099, DOI 10.1016/j.toxicon.2005.02.021; Mormann M, 2008, ANAL BIOANAL CHEM, V392, P831, DOI 10.1007/s00216-008-2258-7; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; Paaventhan P, 2005, PROTEIN SCI, V14, P169, DOI 10.1110/ps.04945605; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Rosenow Felix, 2008, Neoplasia, V10, P168, DOI 10.1593/neo.07898; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shin Y, 2000, THROMB RES, V99, P239, DOI 10.1016/S0049-3848(00)00234-6; Wang RH, 1999, BIOCHEMISTRY-US, V38, P7584, DOI 10.1021/bi982132z; Wang WJ, 2003, THROMB HAEMOSTASIS, V90, P465, DOI 10.1160/TH03-02-0072; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x; Zutter MM, 2007, IMMUNOBIOLOGY, V212, P343, DOI 10.1016/j.imbio.2006.11.013	41	24	28	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2917	2927		10.1096/fj.08-126763	http://dx.doi.org/10.1096/fj.08-126763			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19369383				2022-12-28	WOS:000270241000015
J	Geng, L; Rachakonda, G; Morre, DJ; Morre, DM; Crooks, PA; Sonar, VN; Roti, JLR; Rogers, BE; Greco, S; Ye, F; Salleng, KJ; Sasi, S; Freeman, ML; Sekhar, KR				Geng, Ling; Rachakonda, Girish; Morre, D. James; Morre, Dorothy M.; Crooks, Peter A.; Sonar, Vijayakumar N.; Roti, Joseph L. Roti; Rogers, Buck E.; Greco, Suellen; Ye, Fei; Salleng, Kenneth J.; Sasi, Soumya; Freeman, Michael L.; Sekhar, Konjeti R.			Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature	FASEB JOURNAL			English	Article						angiogenesis; (Z)-(+/-)-2-(1-benzylindol-3-ylmethylene)-1-azabicyclo[2.2.2]octan-3-ol	MICROVESSEL DENSITY; IONIZING-RADIATION; PLASMA-MEMBRANE; S6 KINASE; ANGIOGENESIS; GROWTH; CANCER; THERAPY; OXIDASE; PROTEIN	There is a need for novel strategies that target tumor vasculature, specifically those that synergize with cytotoxic therapy, in order to overcome resistance that can develop with current therapeutics. A chemistry-driven drug discovery screen was employed to identify novel compounds that inhibit endothelial cell tubule formation. Cell-based phenotypic screening revealed that noncytotoxic concentrations of (Z)-(+/-)-2-(1-benzenesulfonylindol-3-ylmethylene)-1-azabicyclo[2. 2.2]octan-3-ol (analog I) and (Z)-(+/-)- 2-(1-benzylindol-3-ylmethylene)-1-azabicyclo[2.2.2]octan-3-ol (analog II) inhibited endothelial cell migration and the ability to form capillary-like structures in Matrigel by >= 70%. The ability to undergo neoangiogenesis, as measured in a window-chamber model, was also inhibited by 70%. Screening of biochemical pathways revealed that analog II inhibited the enzyme ENOX1 (EC50 = 10 mu M). Retroviral-mediated shRNA suppression of endothelial ENOX1 expression inhibited cell migration and tubule formation, recapitulating the effects observed with the small-molecule analogs. Genetic or chemical suppression of ENOX1 significantly increased radiation-mediated Caspase3-activated apoptosis, coincident with suppression of p70S6K1 phosphorylation. Administration of analog II prior to fractionated X-irradiation significantly diminished the number and density of tumor microvessels, as well as delayed syngeneic and xenograft tumor growth compared to results obtained with radiation alone. Analysis of necropsies suggests that the analog was well tolerated. These results suggest that targeting ENOX1 activity represents a novel therapeutic strategy for enhancing the radiation response of tumors.-Geng, L., Rachakonda, G., Morre, D. J., Morre, D. M., Crooks, P. A., Sonar, V. N., Roti Roti, J. L., Rogers, B. E., Greco, S., Ye, F., Salleng, K. J., Sasi, S., Freeman, M. L., Sekhar, K. R. Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature. FASEB J. 23, 2986-2995 (2009). www.fasebj.org	[Freeman, Michael L.] Vanderbilt Univ, Sch Med, TVC Radiat Oncol B902, Dept Radiat Oncol,Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Ye, Fei] Vanderbilt Univ, Sch Med, Dept Biostat, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Morre, D. James] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; [Morre, Dorothy M.] Purdue Univ, Dept Foods & Nutr, W Lafayette, IN 47907 USA; [Crooks, Peter A.; Sonar, Vijayakumar N.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA; [Roti, Joseph L. Roti; Rogers, Buck E.] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO USA; [Greco, Suellen] Washington Univ, Sch Med, Div Comparat Med, St Louis, MO USA	Vanderbilt University; Vanderbilt University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Kentucky; Washington University (WUSTL); Washington University (WUSTL)	Freeman, ML (corresponding author), Vanderbilt Univ, Sch Med, TVC Radiat Oncol B902, Dept Radiat Oncol,Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	michael.freeman@vanderbilt.edu; raja.konjeti@vanderbilt.edu		Freeman, Michael/0000-0003-1881-366X; Konjeti, Sekhar/0000-0003-2930-0739	U.S. National Institutes of Health/National Cancer Institute [PO1 CA104457]; Vanderbilt-Ingram Cancer Center [P30 CA68485]; NATIONAL CANCER INSTITUTE [P30CA068485, P01CA104457, R01CA140409] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Vanderbilt-Ingram Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by U.S. National Institutes of Health/National Cancer Institute grant PO1 CA104457 and Vanderbilt-Ingram Cancer Center grant P30 CA68485.	Al-Ghananeem AM, 2007, CANCER CHEMOTH PHARM, V60, P915, DOI 10.1007/s00280-007-0425-8; BRIGHTMAN AO, 1992, BIOCHIM BIOPHYS ACTA, V1105, P109, DOI 10.1016/0005-2736(92)90168-L; Brown M, 2003, CANCER BIOL THER, V2, P477, DOI 10.4161/cbt.2.5.450; Buck E, 2006, MOL CANCER THER, V5, P2676, DOI 10.1158/1535-7163.MCT-06-0166; Duda DG, 2007, J CLIN ONCOL, V25, P4033, DOI 10.1200/JCO.2007.11.3985; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Edwards E, 2002, CANCER RES, V62, P4671; Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524; Folkman J, 2006, EXP CELL RES, V312, P594, DOI 10.1016/j.yexcr.2005.11.015; Gangadhar NM, 2007, CURR OPIN CHEM BIOL, V11, P83, DOI 10.1016/j.cbpa.2006.11.033; Geng L, 2001, CANCER RES, V61, P2413; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Hull MA, 2003, CANCER TREAT REV, V29, P309, DOI 10.1016/S0305-7372(03)00014-8; Jones MK, 1999, NAT MED, V5, P1418; Lee S, 2009, J LIPID RES, V50, P265, DOI 10.1194/jlr.M800317-JLR200; Li CY, 2000, JNCI-J NATL CANCER I, V92, P143, DOI 10.1093/jnci/92.2.143; Liu SC, 2008, BIOCHEM BIOPH RES CO, V365, P672, DOI 10.1016/j.bbrc.2007.11.025; Mauceri HJ, 1998, NATURE, V394, P287, DOI 10.1038/28412; Mobius C, 2007, EJSO-EUR J SURG ONC, V33, P1025, DOI 10.1016/j.ejso.2007.02.020; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Morre DJ, 2004, METHOD ENZYMOL, V378, P179; MORRE DJ, 1999, PLASMA MEMBRANE REDO, P121; Morre DM, 2000, J EXP BIOL, V203, P1513; Ogawa K, 2007, CANCER RES, V67, P4016, DOI 10.1158/0008-5472.CAN-06-4498; Osusky Katherine L., 2004, Angiogenesis, V7, P225, DOI 10.1007/s10456-004-3149-y; Pearce HR, 2003, J GASTROEN HEPATOL, V18, P1180, DOI 10.1046/j.1440-1746.2003.03152.x; Poon RTP, 2002, J CLIN ONCOL, V20, P1775, DOI 10.1200/JCO.2002.07.089; Rozic JG, 2001, INT J CANCER, V93, P497, DOI 10.1002/ijc.1376; Scarlett DJG, 2005, BBA-BIOENERGETICS, V1708, P108, DOI 10.1016/j.bbabio.2005.03.006; Sekhar KR, 2007, CANCER RES, V67, P695, DOI 10.1158/0008-5472.CAN-06-3212; Sekhar KR, 2003, CANCER RES, V63, P5636; Sessa C, 2008, NAT CLIN PRACT ONCOL, V5, P378, DOI 10.1038/ncponc1150; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Shinohara ET, 2005, ONCOGENE, V24, P5414, DOI 10.1038/sj.onc.1208715; Shinohara ET, 2005, CANCER RES, V65, P4987, DOI 10.1158/0008-5472.CAN-04-4250; Sonar VN, 2007, BIOORG MED CHEM LETT, V17, P6821, DOI 10.1016/j.bmcl.2007.10.035; Wang HM, 2005, WORLD J GASTROENTERO, V11, P340, DOI 10.3748/wjg.v11.i3.340; Wild R, 2000, MICROVASC RES, V59, P368, DOI 10.1006/mvre.1999.2233; Yagiz K, 2006, J NUTR BIOCHEM, V17, P750, DOI 10.1016/j.jnutbio.2005.12.006; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Yazlovitskaya EM, 2008, CELL DEATH DIFFER, V15, P1641, DOI 10.1038/cdd.2008.93; Zhang P, 2006, ONCOGENE, V25, P7758, DOI 10.1038/sj.onc.1209744	42	14	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2986	2995		10.1096/fj.09-130005	http://dx.doi.org/10.1096/fj.09-130005			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19395476	Green Published			2022-12-28	WOS:000270241000021
J	Glover, DJ; Ng, SM; Mechler, A; Martin, LL; Jans, DA				Glover, Dominic J.; Ng, Su May; Mechler, Adam; Martin, Lisandra L.; Jans, David A.			Multifunctional protein nanocarriers for targeted nuclear gene delivery in nondividing cells	FASEB JOURNAL			English	Article						atomic force microscopy; nanoparticles; nonviral vector; nuclear import; subcellular transport	DNA UPTAKE; MECHANISM; PROTAMINE; TRANSCRIPTION; RECOGNITION; EXPRESSION; IMPORTIN; BINDING; DOMAIN	Compartmentalization within eukaryotic cells hinders the efficient delivery of therapeutic agents to the cell nucleus. Here we describe novel multifunctional DNA carriers (MDCs) that self-assemble with DNA to form structured nanoparticles that possess virus-like functions for cellular trafficking. MDCs contain, in fusion, the DNA-compacting sperm chromatin component protamine, alpha-melanocyte-stimulating hormone for cell-targeted internalization, the endosome-translocation domain of diphtheria toxin, and an optimized nuclear localization sequence to confer recognition by the nuclear import machinery. The structure of the MDC-DNA particles was examined using atomic force microscopy, and the functionality of each domain assessed using in vitro techniques, including a reconstituted nuclear transport assay in semi-intact cells relying on the use of quantitative confocal laser scanning microscopy. The nanoparticles were internalized in cell-specific fashion and subsequently exited the endosome into the cytoplasm. Notably, the nanoparticles interact with cellular nuclear transport proteins as shown in direct binding assays and are actively trafficked into the cell nucleus of nondividing cells, resulting in 3- to 4-fold higher reporter gene expression in growth-arrested human embryonic kidney cells, as well as lower cytotoxicity, than lipid and polyethyleneimine vectors. The importance of each functional domain was examined by comparing MDCs with different domain compositions as controls, as well as using antibodies to block particular pathways. MDCs that utilize cellular signaling pathways have enormous potential to safely and efficiently deliver therapeutic transgenes into the nucleus of nondividing cells.-Glover, D. J., Ng, S. M., Mechler, A., Martin, L. L., Jans, D. A. Multifunctional protein nanocarriers for targeted nuclear gene delivery in nondividing cells. FASEB J. 23, 2996-3006 (2009). www.fasebj.org	[Glover, Dominic J.; Jans, David A.] Monash Univ, Nucl Signaling Lab, Dept Biochem & Mol Biol, Monash, Vic 3800, Australia; [Ng, Su May; Mechler, Adam; Martin, Lisandra L.] Monash Univ, Dept Chem, Monash, Vic 3800, Australia; [Jans, David A.] ARC Ctr Excellence Biotechnol & Dev, Canberra, ACT, Australia	Monash University; Monash University	Jans, DA (corresponding author), Monash Univ, Nucl Signaling Lab, Dept Biochem & Mol Biol, POB 13D, Monash, Vic 3800, Australia.	david.jans@med.monash.edu.au	Martin, Lisandra L/E-4482-2010; Mechler, Adam/C-5777-2009; Glover, Dominic/C-3333-2018	Martin, Lisandra L/0000-0003-0486-5813; Mechler, Adam/0000-0002-6428-6760; Glover, Dominic/0000-0002-6819-4089; Jans, David/0000-0001-5115-4745	National Health and Medical Research Council [384109, 284205]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	The authors thank Ian McKinnon, School of Chemistry, Monash University, for assistance with zeta-potential and dynamic light-scattering experiments. The authors acknowledge the support of the National Health and Medical Research Council (fellowship no. 384109 and project grant no. 284205). The authors declare no competing financial interests.	Akhlynina TV, 1997, J BIOL CHEM, V272, P20328, DOI 10.1074/jbc.272.33.20328; Allen MJ, 1997, NUCLEIC ACIDS RES, V25, P2221, DOI 10.1093/nar/25.11.2221; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brewer LR, 1999, SCIENCE, V286, P120, DOI 10.1126/science.286.5437.120; Chan CK, 2000, GENE THER, V7, P1690, DOI 10.1038/sj.gt.3301275; Chan CK, 1998, GENE THER, V5, P1204, DOI 10.1038/sj.gt.3300708; Fasbender A, 1997, GENE THER, V4, P1173, DOI 10.1038/sj.gt.3300524; Glover DJ, 2005, NAT REV GENET, V6, P299, DOI 10.1038/nrg1577; Goncalves E, 2005, BIOCHEMISTRY-US, V44, P2692, DOI 10.1021/bi048046i; Grosse S, 2006, J GENE MED, V8, P845, DOI 10.1002/jgm.915; Hearps AC, 2006, BIOCHEM J, V398, P475, DOI 10.1042/BJ20060466; Hou X, 2007, FEBS J, V274, P1637, DOI 10.1111/j.1742-4658.2007.05712.x; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; Mastrobattista E, 2006, NAT REV DRUG DISCOV, V5, P115, DOI 10.1038/nrd1960; Masuda T, 2005, FEBS LETT, V579, P2143, DOI 10.1016/j.febslet.2005.02.071; McNulty DE, 2003, PROTEIN EXPRES PURIF, V27, P365, DOI 10.1016/S1046-5928(02)00610-1; Montagner C, 2007, BIOCHEMISTRY-US, V46, P1878, DOI 10.1021/bi602381z; Mudrak O, 2005, J CELL SCI, V118, P4541, DOI 10.1242/jcs.02581; Newton RA, 2005, PEPTIDES, V26, P1818, DOI 10.1016/j.peptides.2004.11.031; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253; Rosenkranz AA, 2003, FASEB J, V17, P1121, DOI 10.1096/fj.02-0888fje; Salazar-Onfray F, 2002, BRIT J CANCER, V87, P414, DOI 10.1038/sj.bjc.6600441; Salem AK, 2003, NAT MATER, V2, P668, DOI 10.1038/nmat974; Salman H, 2001, P NATL ACAD SCI USA, V98, P7247, DOI 10.1073/pnas.121067698; Vilfan ID, 2004, J BIOL CHEM, V279, P20088, DOI 10.1074/jbc.M312777200; Wagstaff KM, 2005, J FLUORESC, V15, P469, DOI 10.1007/s10895-005-2819-5; Wagstaff KM, 2007, MOL THER, V15, P721, DOI 10.1038/sj.mt.6300093; Wolff C, 2004, BBA-BIOMEMBRANES, V1661, P166, DOI 10.1016/j.bbamem.2004.01.001	29	18	21	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2996	3006		10.1096/fj.09-131425	http://dx.doi.org/10.1096/fj.09-131425			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19395475				2022-12-28	WOS:000270241000022
J	Spruill, LS; McDermott, PJ				Spruill, Laura S.; McDermott, Paul J.			Role of the 5 '-untranslated region in regulating translational efficiency of specific mRNAs in adult cardiocytes	FASEB JOURNAL			English	Article						cardiac hypertrophy; protein biosynthesis; polyribosomes; peptide chain initiation	ELECTRICALLY STIMULATED CONTRACTION; GLYCOGEN-SYNTHASE KINASE-3-BETA; PROTEIN-SYNTHESIS; CARDIAC-HYPERTROPHY; FELINE CARDIOCYTES; SYNTHESIS RATES; IN-VITRO; INITIATION; EXPRESSION; GROWTH	It has been hypothesized that translational efficiency is determined by the amount of secondary structure in the 5'-untranslated region (5'-UTR) of mRNA. Here, we examined whether specific 5'-UTRs with excessive secondary structure selectively regulate translational efficiency in adult cardiocytes. Recombinant adenoviruses were generated to express reporter mRNAs consisting of the 5'-UTR derived from c-jun or ornithine decarboxylase (ODC) fused to beta-galactosidase (beta Gal) coding sequence. Each adenovirus expressed GFP mRNA as a control for 5'-UTRs with minimal secondary structure. Subsequently, cardiocytes were electrically stimulated to contract at 1 Hz to accelerate protein synthesis as compared to quiescent controls. Translational efficiency was calculated by measuring protein expression as a function of mRNA levels. Translational efficiency of c-jun/beta Gal mRNA increased significantly by 3.7-fold in contracting vs. quiescent cardiocytes, but ODC/beta Gal mRNA was unchanged. Contraction increased c-jun/beta Gal mRNA levels in polyribosomes by 2.3-fold, which indicates that translational efficiency was enhanced by mobilization. A short, unstructured 5'-UTR was sufficient for efficient translation of beta Gal mRNA in quiescent and contracting cardiocytes. GFP mRNA produced similar results. These studies demonstrate that the 5'-UTR functions as a determinant of translational efficiency of specific mRNAs, such as c-jun, that regulate growth of the adult cardiocyte.-Spruill, L. S., McDermott, P. J. Role of the 5'-untranslated region in regulating translational efficiency of specific mRNAs in adult cardiocytes. FASEB J. 23, 2879-2887 (2009). www.fasebj.org	[Spruill, Laura S.; McDermott, Paul J.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Charleston, SC 29403 USA; [McDermott, Paul J.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	McDermott, PJ (corresponding author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Rm 303,Strom Thurmond Biomed Res Bldg,114 Doughty, Charleston, SC 29403 USA.	mcdermp@musc.edu			National Institutes of Health [PO1 HL-48788]; Research and Development Service, Department of Veterans Affairs; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research and Development Service, Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Daisy Dominick, Shaun Wahl, Harinath Kasiganesan, and Gina Keller for their excellent technical assistance. This work was supported by the National Institutes of Health (grant PO1 HL-48788) and by the Research and Development Service, Department of Veterans Affairs (Merit Review Award).	Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Colomer JM, 2003, MOL ENDOCRINOL, V17, P183, DOI 10.1210/me.2002-0350; Davuluri RV, 2000, GENOME RES, V10, P1807, DOI 10.1101/gr.GR-1460R; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gupta MP, 2007, J MOL CELL CARDIOL, V43, P388, DOI 10.1016/j.yjmcc.2007.07.045; Hannan RD, 2003, CLIN EXP PHARMACOL P, V30, P517, DOI 10.1046/j.1440-1681.2003.03873.x; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Heineke J, 2006, NAT REV MOL CELL BIO, V7, P589, DOI 10.1038/nrm1983; Hirotani S, 2007, CIRC RES, V101, P1164, DOI 10.1161/CIRCRESAHA.107.160614; IVESTER CT, 1995, J BIOL CHEM, V270, P21950, DOI 10.1074/jbc.270.37.21950; IVESTER CT, 1993, AM J PHYSIOL, V265, pH666; KATO S, 1995, AM J PHYSIOL-HEART C, V268, pH2495; Kozak M, 2005, GENE, V361, P13, DOI 10.1016/j.gene.2005.06.037; Lindsey ML, 2006, PROTEOMICS, V6, P2225, DOI 10.1002/pmic.200500013; LODISH HF, 1976, ANNU REV BIOCHEM, V45, P39, DOI 10.1146/annurev.bi.45.070176.000351; Makhlouf AA, 1998, AM J PHYSIOL-HEART C, V274, pH2133, DOI 10.1152/ajpheart.1998.274.6.H2133; Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; Mathonnet G, 2007, SCIENCE, V317, P1764, DOI 10.1126/science.1146067; Michael A, 2004, J BIOL CHEM, V279, P21383, DOI 10.1074/jbc.M401413200; Misquitta CM, 2001, MOL CELL BIOCHEM, V224, P53, DOI 10.1023/A:1011982932645; Morgan HE, 1997, MOL CELL BIOCHEM, V176, P145, DOI 10.1023/A:1006855818855; Nagatomo Y, 1999, AM J PHYSIOL-HEART C, V277, pH2176; Pegg AE, 2006, J BIOL CHEM, V281, P14529, DOI 10.1074/jbc.R500031200; Pesole G, 2001, GENE, V276, P73, DOI 10.1016/S0378-1119(01)00674-6; Pyronnet S, 2005, CELL MOL LIFE SCI, V62, P1267, DOI 10.1007/s00018-005-5020-8; Qin XL, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r63; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Saghir AN, 2001, BIOCHEM J, V356, P557, DOI 10.1042/0264-6021:3560557; Schluter KD, 1998, J MOL CELL CARDIOL, V30, P763, DOI 10.1006/jmcc.1998.0640; Spruill LS, 2006, FASEB J, V20, P2133, DOI 10.1096/fj.06-6245fje; Standart N, 2007, GENE DEV, V21, P1975, DOI 10.1101/gad.1591507; Swynghedauw B, 2006, J EXP BIOL, V209, P2320, DOI 10.1242/jeb.02084; Tuxworth WJ, 2004, BIOCHEM J, V378, P73, DOI 10.1042/BJ20031027; Tuxworth WJ, 1999, AM J PHYSIOL-HEART C, V277, pH1273, DOI 10.1152/ajpheart.1999.277.4.H1273; Van Rooij E, 2007, J CLIN INVEST, V117, P2369, DOI 10.1172/JCI33099; Wada H, 1996, AM J PHYSIOL-HEART C, V271, pH29, DOI 10.1152/ajpheart.1996.271.1.H29; Wada H, 1996, J BIOL CHEM, V271, P8359, DOI 10.1074/jbc.271.14.8359; Wiesner RJ, 1997, CIRCULATION, V95, P1253; Xu XD, 2005, CELL, V120, P59, DOI 10.1016/j.cell.2004.11.036; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	43	7	7	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2879	2887		10.1096/fj.08-128447	http://dx.doi.org/10.1096/fj.08-128447			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19417087	Green Published			2022-12-28	WOS:000270241000011
J	Toyoda, Y; Sakurai, A; Mitani, Y; Nakashima, M; Yoshiura, K; Nakagawa, H; Sakai, Y; Ota, I; Lezhava, A; Hayashizaki, Y; Niikawa, N; Ishikawa, T				Toyoda, Yu; Sakurai, Aki; Mitani, Yasumasa; Nakashima, Masahiro; Yoshiura, Koh-ichiro; Nakagawa, Hiroshi; Sakai, Yasuo; Ota, Ikuko; Lezhava, Alexander; Hayashizaki, Yoshihide; Niikawa, Norio; Ishikawa, Toshihisa			Earwax, osmidrosis, and breast cancer: why does one SNP (538G > A) in the human ABC transporter ABCC11 gene determine earwax type?	FASEB JOURNAL			English	Article						endoplasmic reticulum-associated degradation; genetic polymorphism; N-linked glycosylation; protein instability	BINDING CASSETTE TRANSPORTER; TRANSMEMBRANE CONDUCTANCE REGULATOR; SMART AMPLIFICATION PROCESS; ER-ASSOCIATED DEGRADATION; N-LINKED GLYCANS; QUALITY-CONTROL; ENDOPLASMIC-RETICULUM; CYSTIC-FIBROSIS; COMPETITIVE PROBE; EFFLUX PUMP	One single-nucleotide polymorphism (SNP), 538G>A (Gly180Arg), in the ABCC11 gene determines the type of earwax. The G/G and G/A genotypes correspond to the wet type of earwax, whereas A/A corresponds to the dry type. Wide ethnic differences exist in the frequencies of those alleles, reflecting global migratory waves of the ancestors of humankind. We herein provide the evidence that this genetic polymorphism has an effect on the N-linked glycosylation of ABCC11, intracellular sorting, and proteasomal degradation of the variant protein. Immunohistochemical studies with cerumen gland-containing tissue specimens revealed that the ABCC11 WT protein was localized in intracellular granules and large vacuoles, as well as at the luminal membrane of secretory cells in the cerumen gland, whereas granular or vacuolar localization was not detected for the SNP (Arg180) variant. This SNP variant lacking N-linked glycosylation is recognized as a misfolded protein in the endoplasmic reticulum and readily undergoes ubiquitination and proteasomal degradation, which determines the dry type of earwax as a mendelian trait with a recessive phenotype. For rapid genetic diagnosis of axillary osmidrosis and potential risk of breast cancer, we developed specific primers for the SmartAmp method that enabled us to clinically genotype the ABCC11 gene within 30 min.-Toyoda, Y., Sakurai, A., Mitani, Y., Nakashima, M., Yoshiura, K., Nakagawa, H., Sakai, Y., Ota, I., Lezhava, A., Hayashizaki, Y., Niikawa, N., Ishikawa, T. Earwax, osmidrosis, and breast cancer: why does one SNP (538G>A) in the human ABC transporter ABCC11 gene determine earwax type? FASEB J. 23, 2001-2013 (2009)	[Toyoda, Yu; Sakurai, Aki; Nakagawa, Hiroshi; Ishikawa, Toshihisa] Tokyo Inst Technol, Dept Biomol Engn, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; [Sakurai, Aki; Mitani, Yasumasa; Ota, Ikuko; Lezhava, Alexander; Hayashizaki, Yoshihide; Ishikawa, Toshihisa] RIKEN Yokohama Inst, OSC, Yokohama, Kanagawa, Japan; [Mitani, Yasumasa] KK DNAFORM, Yokohama, Kanagawa, Japan; [Nakashima, Masahiro] Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Tissue & Histopathol Sect, Nagasaki 852, Japan; [Yoshiura, Koh-ichiro; Niikawa, Norio] Nagasaki Univ, Grad Sch Biomed Sci, Dept Human Genet, Nagasaki 852, Japan; [Sakai, Yasuo] Fujita Hlth Univ, Dept Plast & Reconstruct Surg, Toyoake, Aichi, Japan; [Ota, Ikuko] Yokohama City Univ, Grad Sch Med, Dept Surg Gastroenterol, Yokohama, Kanagawa 232, Japan; [Niikawa, Norio] Hlth Sci Univ Hokkaido, Res Inst Personalized Hlth Sci, Sapporo, Hokkaido, Japan	Tokyo Institute of Technology; RIKEN; Nagasaki University; Nagasaki University; Fujita Health University; Yokohama City University; Health Sciences University of Hokkaido	Ishikawa, T (corresponding author), Tokyo Inst Technol, Dept Biomol Engn, Grad Sch Biosci & Biotechnol, Midori Ku, 4259-B-60 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	tishikaw@bio.titech.ac.jp	Toyoda, Yu/S-9802-2019; Hayashizaki, Yoshihide/N-6590-2015	Toyoda, Yu/0000-0002-7411-0531; 	JST Solution Oriented Research for Science and Technology (SORST); Scientific Research on Priority [18059027]; Ministry of Education, Culture, Sports, Science and Technology (MEXT)	JST Solution Oriented Research for Science and Technology (SORST); Scientific Research on Priority; Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by the Japan Science and Technology Agency (JST) research project, " Development of the world's fastest SNP detection system," to T. I.; by Grant-in-Aid for Scientific Research (A) 18201041 to T.I.; in part by a JST Solution Oriented Research for Science and Technology (SORST) grant to N. N.; by Japanese Society for the Promotion of Science (JSPS) Grant-in-Aid for Exploratory Research 19659136 to T. I.; by Grant-in-Aid for Young Scientists (B) 19791361 to H. N.; by Grant-in-Aid for Scientific Research on Priority Areas 18059027 to K. Y.; and by a Ministry of Education, Culture, Sports, Science and Technology (MEXT) research grant	Bera TK, 2001, MOL MED, V7, P509, DOI 10.1007/BF03401856; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Bortfeld M, 2006, NEUROSCIENCE, V137, P1247, DOI 10.1016/j.neuroscience.2005.10.025; BROOKSBANK BW, 1970, EXPERIENTIA, V26, P1012, DOI 10.1007/BF02114166; Chen ZS, 2005, MOL PHARMACOL, V67, P545, DOI 10.1124/mol.104.007138; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Furukawa T, 2009, PHARM RES-DORDR, V26, P469, DOI 10.1007/s11095-008-9752-7; Gesase AP, 2003, HISTOL HISTOPATHOL, V18, P597, DOI 10.14670/HH-18.597; Guo YP, 2003, J BIOL CHEM, V278, P29509, DOI 10.1074/jbc.M304059200; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; ING R, 1973, LANCET, V1, P41; Ishikawa T., 2003, NATURE ENCY HUMAN GE, V4, P154; JULESZ M, 1968, ACTA MED HUNG, V25, P273; Kawai Y, 2008, BIOLOGICALS, V36, P234, DOI 10.1016/j.biologicals.2008.01.003; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; Kruh GD, 2007, PFLUG ARCH EUR J PHY, V453, P675, DOI 10.1007/s00424-006-0114-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABOWS JN, 1979, STEROIDS, V34, P249, DOI 10.1016/0039-128X(79)90077-1; Mitani Y, 2007, NAT METHODS, V4, P257, DOI 10.1038/NMETH1007; Miura K, 2007, HUM GENET, V121, P631, DOI 10.1007/s00439-007-0356-9; Mochizuki K, 2007, AM J PHYSIOL-GASTR L, V292, pG818, DOI 10.1152/ajpgi.00415.2006; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Nakagawa H, 2008, BIOCHEM J, V411, P623, DOI 10.1042/BJ20071229; Nakashima M, 2002, PATHOL RES PRACT, V198, P717, DOI 10.1078/0344-0338-00326; Nakatsukasa K, 2008, CELL, V132, P101, DOI 10.1016/j.cell.2007.11.023; Ono N, 2007, BIOCHEM J, V406, P31, DOI 10.1042/BJ20070292; PETRAKIS NL, 1971, SCIENCE, V173, P347, DOI 10.1126/science.173.3994.347; PETRAKIS NL, 1983, AM J PHYS ANTHROPOL, V62, P115, DOI 10.1002/ajpa.1330620115; Qu BH, 1997, J BIOL CHEM, V272, P15739, DOI 10.1074/jbc.272.25.15739; Riordan JR, 2005, ANNU REV PHYSIOL, V67, P701, DOI 10.1146/annurev.physiol.67.032003.154107; SHEHADEH NH, 1963, J INVEST DERMATOL, V40, P61, DOI 10.1038/jid.1963.10; Shimizu H, 2003, GENE, V310, P17, DOI 10.1016/S0378-1119(03)00504-3; SHUGYO Y, 1988, AM J ANAT, V181, P377, DOI 10.1002/aja.1001810405; Skach WR, 2006, CELL, V127, P673, DOI 10.1016/j.cell.2006.11.002; Tammur J, 2001, GENE, V273, P89, DOI 10.1016/S0378-1119(01)00572-8; Tamura Ai, 2006, J Exp Ther Oncol, V6, P1; Tamura A, 2007, CANCER SCI, V98, P231, DOI 10.1111/j.1349-7006.2006.00371.x; Toyoda Y, 2008, XENOBIOTICA, V38, P833, DOI [10.1080/00498250701883514, 10.1080/00498250701883514 ]; Wakabayashi K, 2007, J BIOL CHEM, V282, P27841, DOI 10.1074/jbc.C700133200; Wakabayashi K, 2006, J EXP THER ONCOL, V5, P205; Wakabayashi-Nakao K, 2009, ADV DRUG DELIVER REV, V61, P66, DOI 10.1016/j.addr.2008.08.008; Wang XD, 2006, CELL, V127, P803, DOI 10.1016/j.cell.2006.09.043; Watanabe J, 2007, BIOTECHNIQUES, V43, P479, DOI 10.2144/000112563; Yabuuchi H, 2001, BIOCHEM BIOPH RES CO, V288, P933, DOI 10.1006/bbrc.2001.5865; Yamaguchi-Kabata Y, 2008, AM J HUM GENET, V83, P445, DOI 10.1016/j.ajhg.2008.08.019; Yoo WM, 2006, J PLAST RECONSTR AES, V59, P978, DOI 10.1016/j.bjps.2005.12.046; Yoshiura K, 2006, NAT GENET, V38, P324, DOI 10.1038/ng1733; Younger JM, 2006, CELL, V126, P571, DOI 10.1016/j.cell.2006.06.041	50	67	75	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					2001	2013		10.1096/fj.09-129098	http://dx.doi.org/10.1096/fj.09-129098			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19383836				2022-12-28	WOS:000266652400038
J	Oussedik, K; Francois, JC; Halby, L; Senamaud-Beaufort, C; Toutirais, G; Dallavalle, S; Pommier, Y; Pisano, C; Arimondo, PB				Oussedik, Kahina; Francois, Jean-Christophe; Halby, Ludovic; Senamaud-Beaufort, Catherine; Toutirais, Geraldine; Dallavalle, Sabrina; Pommier, Yves; Pisano, Claudio; Arimondo, Paola B.			Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins	FASEB JOURNAL			English	Article						DNA regulation; specific DNA cleavage; topoisomerase I poisons; triplex-forming oligonucleotides; anticancer agents	TRIPLEX-FORMING OLIGONUCLEOTIDES; GROWTH-FACTOR RECEPTOR; C-MYC GENE; TOPOISOMERASE-I; PROSTATE-CANCER; DNA CLEAVAGE; CELL-LINES; INSULIN; DERIVATIVES; INHIBITION	We and others have clearly demonstrated that a topoisomerase I (Top1) inhibitor, such as camptothecin (CPT), coupled to a triplex-forming oligonucleotide (TFO) through a suitable linker can be used to cause site-specific cleavage of the targeted DNA sequence in in vitro models. Here we evaluated whether these molecular tools induce sequence-specific DNA damage in a genome context. We targeted the insulin-like growth factor (IGF)-I axis and in particular promoter 1 of IGF-I and intron 2 of type 1 insulin-like growth factor receptor (IGF-IR) in cancer cells. The IGF axis molecules represent important targets for anticancer strategies, because of their central role in oncogenic maintenance and metastasis processes. We chemically attached 2 CPT derivatives to 2 TFOs. Both conjugates efficiently blocked gene expression in cells, reducing the quantity of mRNA transcribed by 70-80%, as measured by quantitative RT-PCR. We confirmed that the inhibitory mechanism of these TFO conjugates was mediated by Top1-induced cleavage through the use of RNA interference experiments and a camptothecin-resistant cell line. In addition, induction of phospho-H2AX foci supports the DNA-damaging activity of TFO-CPT conjugates at specific sites. The evaluated conjugates induce a specific DNA damage at the target gene mediated by Top1.-Oussedik, K., Francois, J.-C., Halby, L., Senamaud-Beaufort, C., Toutirais, G., Dallavalle, S., Pommier, Y., Pisano, C., Arimondo, P. B. Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins. FASEB J. 24, 2235-2244 (2010). www.fasebj.org	[Oussedik, Kahina; Francois, Jean-Christophe; Halby, Ludovic; Senamaud-Beaufort, Catherine; Toutirais, Geraldine; Arimondo, Paola B.] Museum Natl Hist Nat, F-75231 Paris, France; [Oussedik, Kahina; Francois, Jean-Christophe; Halby, Ludovic; Senamaud-Beaufort, Catherine; Toutirais, Geraldine; Arimondo, Paola B.] INSERM, U565, Paris, France; [Oussedik, Kahina] Univ Paris 06, Paris, France; [Dallavalle, Sabrina] Univ Milan, Dipartimento Sci Mol Agroalimentari, Milan, Italy; [Pommier, Yves] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Pisano, Claudio] Sigma Tau Pharmaceut Co, Pomezia, Italy	Museum National d'Histoire Naturelle (MNHN); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Milan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Leadiant Biosciences	Arimondo, PB (corresponding author), CNRS, UMR7196, 43 Rue Cuvier, F-75231 Paris 05, France.	arimondo@mnhn.fr	Arimondo, Paola B/R-9095-2017; Dallavalle, Sabrina/AGY-7086-2022; FRANCOIS, Jean-Christophe/O-1659-2018	Arimondo, Paola B/0000-0001-5175-4396; FRANCOIS, Jean-Christophe/0000-0003-4480-1822; pisano, claudio/0000-0001-8624-2980; Dallavalle, Sabrina/0000-0002-8813-8922; Halby, Ludovic/0000-0002-7988-7542	Ligue Nationale Contre le Cancer; Sigma Tau; Center for Cancer Research, National Cancer Institute, U.S. National Institutes of Health; Assocation pour la Recherche sur les Tumeurs de la Prostate; Association pour la Recherche sur le Cancer; NATIONAL CANCER INSTITUTE [ZIABC006150, ZIABC006161] Funding Source: NIH RePORTER	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Sigma Tau; Center for Cancer Research, National Cancer Institute, U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Assocation pour la Recherche sur les Tumeurs de la Prostate; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Tiphanie Durfort and Frederic Chapuis for technical help, Dr. Jean-Louis Mergny and Lucio Merlini for suggestions and useful discussions, Dr. P. Rotwein (Oregon Health and Science University, Portland, OR, USA) for providing IGF-I plasmids, Christophe Chamot for help with the fluorescence microscopy, and Dr F. Morel (Service de Cytogenetique Cytologie et Biologie de la Reproduction, Center Hospitalier Universitaire Morvan, Brest, France) for providing IGF-IR probes. This work was supported by grants from Ligue Nationale Contre le Cancer; a Sigma Tau collaboration grant; a Center for Cancer Research, National Cancer Institute, U. S. National Institutes of Health grant to Y.P.; and fellowships to K.O. from Assocation pour la Recherche sur les Tumeurs de la Prostate and Association pour la Recherche sur le Cancer.	Alexia C, 2004, BIOCHEM PHARMACOL, V68, P1003, DOI 10.1016/j.bcp.2004.05.029; Arianayagam M, 2007, AUST FAM PHYSICIAN, V36, P737; Arimondo PB, 2006, MOL CELL BIOL, V26, P324, DOI 10.1128/MCB.26.1.324-333.2006; Arimondo PB, 2005, BIOCHEMISTRY-US, V44, P4171, DOI 10.1021/bi048031k; Arimondo PB, 2002, J BIOL CHEM, V277, P3132, DOI 10.1074/jbc.M110181200; Arimondo PB, 2001, ANGEW CHEM INT EDIT, V40, P3045, DOI 10.1002/1521-3773(20010817)40:16<3045::AID-ANIE3045>3.0.CO;2-A; Baserga R, 2005, EXPERT OPIN THER TAR, V9, P753, DOI 10.1517/14728222.9.4.753; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Carbone GM, 2004, NUCLEIC ACIDS RES, V32, P2396, DOI 10.1093/nar/gkh527; Ciampolillo A, 2007, CURR PHARM DESIGN, V13, P729, DOI 10.2174/138161207780249209; Dallavalle S, 2001, J MED CHEM, V44, P3264, DOI 10.1021/jm0108092; Davies M, 2006, INT J COLORECTAL DIS, V21, P201, DOI 10.1007/s00384-005-0776-8; Dong AQ, 2008, ACTA BIOCH BIOPH SIN, V40, P497, DOI 10.1111/j.1745-7270.2008.00429.x; Francois JC, 2000, METHOD ENZYMOL, V313, P74; Guo N, 2003, GROWTH HORM IGF RES, V13, P44, DOI 10.1016/S1096-6374(02)00121-1; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; Hamel Y, 1999, BIOCHEM J, V339, P547, DOI 10.1042/0264-6021:3390547; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hofmann F, 2005, DRUG DISCOV TODAY, V10, P1041, DOI 10.1016/S1359-6446(05)03512-9; Karamouzis MV, 2006, TRENDS MOL MED, V12, P595, DOI 10.1016/j.molmed.2006.10.003; Kawada M, 2006, CANCER RES, V66, P4419, DOI 10.1158/0008-5472.CAN-05-4239; Koster DA, 2007, NATURE, V448, P213, DOI 10.1038/nature05938; Lacoste J, 1997, NUCLEIC ACIDS RES, V25, P1991, DOI 10.1093/nar/25.10.1991; Lacroix L, 1999, BIOCHEMISTRY-US, V38, P1893, DOI 10.1021/bi982290q; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; Lee YJ, 2007, LUNG CANCER, V55, P279, DOI 10.1016/j.lungcan.2006.10.020; LeRoith D, 2004, CANCER CELL, V5, P201, DOI 10.1016/S1535-6108(04)00054-6; Liao YD, 2005, HUM PATHOL, V36, P1186, DOI 10.1016/j.humpath.2005.07.023; Macris MA, 2003, J BIOL CHEM, V278, P3357, DOI 10.1074/jbc.M206542200; Marchand C, 2006, MOL CANCER THER, V5, P287, DOI 10.1158/1535-7163.MCT-05-0456; Matteucci M, 1997, J AM CHEM SOC, V119, P6939, DOI 10.1021/ja9702475; Meinbach DS, 2006, UROL ONCOL-SEMIN ORI, V24, P294, DOI 10.1016/j.urolonc.2005.12.004; Mignet N, 2000, NUCLEIC ACIDS RES, V28, P3134, DOI 10.1093/nar/28.16.3134; Monti S, 2007, CURR PHARM DESIGN, V13, P719, DOI 10.2174/138161207780249128; Napoli S, 2006, NUCLEIC ACIDS RES, V34, P734, DOI 10.1093/nar/gkj473; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Rao VA, 2007, CANCER RES, V67, P9971, DOI 10.1158/0008-5472.CAN-07-0804; Resnik JL, 1998, CANCER RES, V58, P1159; Riedemann J, 2006, ENDOCR-RELAT CANCER, V13, pS33, DOI 10.1677/erc.1.01280; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sordet O, 2004, J BIOL CHEM, V279, P50499, DOI 10.1074/jbc.M410277200; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stierle V, 2008, MOL PHARMACOL, V73, P1568, DOI 10.1124/mol.107.042010; Tao Y, 2007, NAT CLIN PRACT ONCOL, V4, P591, DOI 10.1038/ncponc0934; Trojan J, 2007, NEUROSCIENCE, V145, P795, DOI 10.1016/j.neuroscience.2007.01.021; Urasaki Y, 2001, CANCER RES, V61, P1964; Vasquez KM, 2000, SCIENCE, V290, P530, DOI 10.1126/science.290.5491.530; Vekhoff P, 2009, BIOCONJUGATE CHEM, V20, P666, DOI 10.1021/bc800494y; Yee D, 2007, Br J Cancer, V96 Suppl, pR7; Yuen JSP, 2008, EXPERT OPIN THER TAR, V12, P589, DOI 10.1517/14728222.12.5.589 	52	15	15	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2235	2244		10.1096/fj.09-132324	http://dx.doi.org/10.1096/fj.09-132324			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20179147	Green Published			2022-12-28	WOS:000279343600010
J	Ge, Z; Li, WJ; Wang, N; Liu, C; Zhu, QJ; Bjorkholm, M; Gruber, A; Xu, DW				Ge, Zheng; Li, Wenjuan; Wang, Na; Liu, Cheng; Zhu, Qingjun; Bjorkholm, Magnus; Gruber, Astrid; Xu, Dawei			Chromatin remodeling: recruitment of histone demethylase RBP2 by Mad1 for transcriptional repression of a Myc target gene, telomerase reverse transcriptase	FASEB JOURNAL			English	Article						HDM; MYC/MAX/MAD; hTERT; differentiation; E-box; immortalization	HTERT GENE; C-MYC; HUMAN CANCER; HUMAN-CELLS; DEACETYLASE INHIBITOR; MOLECULAR-MECHANISMS; DNA METHYLATION; HL60 CELLS; EXPRESSION; PROMOTER	The Myc/Max/Mad network transcription factors are known to govern target gene expression through recruiting histone acetyltransferases or deacetylases. In the present study, we show that Mad1 recruits the histone demethylase RBP2 to the Myc target telomerase reverse transcriptase (hTERT) gene promoter to repress transcription. With differentiation of leukemic HL60 cells, Mad1 and RBP2 were both up-regulated, interacted, and cooccupied the hTERT promoter accompanied by histone H3-K4 demethylation. In immortalized p493-6 B cells, shutting down c-Myc led to the accumulation of Mad1 and RBP2 at hTERT promoter and diminished hTERT mRNA expression. When RBP2 was depleted, hTERT expression was significantly enhanced, coupled with dissociation of RBP2 with and increased H3-K4 methylation at the hTERT promoter in p493-6 cells. Moreover, RBP2 and Mad1 were present on the hTERT promoter in human fibroblasts having a silent hTERT gene, and RBP2 depletion resulted in gene derepression. Taken together, Mad1 recruits RBP2 to the hTERT promoter that, in turn, demethylates H3-K4, thereby contributing to a stable repression of the hTERT gene in normal or differentiated malignant cells. Our findings reveal a novel mechanism through which the Myc/Max/Mad network proteins control their target gene transcription and provide insights into mechanisms underlying telomerase silencing and activation.-Ge, Z., Li, W., Wang, N., Liu, C., Zhu, Q., Bjorkholm, M., Gruber, A., Xu, D. Chromatin remodeling: recruitment of histone demethylase RBP2 by Mad1 for transcriptional repression of a Myc target gene, telomerase reverse transcriptase. FASEB J. 24, 579-586 (2010). www.fasebj.org	[Ge, Zheng; Li, Wenjuan; Wang, Na; Liu, Cheng; Zhu, Qingjun; Bjorkholm, Magnus; Gruber, Astrid; Xu, Dawei] Karolinska Univ Hosp Solna, Ctr Hematol, Dept Med, Stockholm, Sweden; [Ge, Zheng; Li, Wenjuan; Wang, Na; Liu, Cheng; Zhu, Qingjun; Bjorkholm, Magnus; Gruber, Astrid; Xu, Dawei] Karolinska Inst, Stockholm, Sweden; [Li, Wenjuan] Shandong Univ, Sch Med, Dept Microbiol, Jinan 250100, Peoples R China; [Zhu, Qingjun] Shandong Univ Tradit Chinese Med, Coll Basic Med Sci, Jinan, Peoples R China	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Shandong University; Shandong University of Traditional Chinese Medicine	Xu, DW (corresponding author), Karolinska Univ Hosp, CMM, L8 00, S-17176 Stockholm, Sweden.	dawei.xu@ki.se		Xu, Dawei/0000-0003-3141-4524	Swedish Cancer Society; Swedish Research Council; Cancer Society in Stockholm; Swedish Society of Medicine; Sven & Ebba-Christina Hagbergs Foundation; Karolinska Institute	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancer Society in Stockholm; Swedish Society of Medicine; Sven & Ebba-Christina Hagbergs Foundation; Karolinska Institute(Karolinska Institutet)	We thank Margareta Andersson and Yiteng Xu for technical assistance, Dr. D. Eick (GSF Research Centre, Munich, Germany) for the p493-6 cell line, Dr. S. Kyo ( Kanazawa University, Kanazawa, Japan) for the hTERT reporter plasmids, and Drs. P. A. Cloos and K. Helin ( University of Copenhagen, Copenhagen, Denmark) for the RBP2 plasmids. This work was supported by the grants from the Swedish Cancer Society, the Swedish Research Council, the Cancer Society in Stockholm, the Swedish Society of Medicine, the Sven & Ebba-Christina Hagbergs Foundation, and the Karolinska Institute.	Atkinson SP, 2005, CANCER RES, V65, P7585, DOI 10.1158/0008-5472.CAN-05-1715; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Blackburn EH, 2006, NAT MED, V12, P1133, DOI 10.1038/nm1006-1133; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Cassar L, 2009, FASEB J, V23, P1880, DOI 10.1096/fj.08-119529; Cerezo A, 2002, J CELL SCI, V115, P1305; Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003; Cole MD, 2006, SEMIN CANCER BIOL, V16, P241, DOI 10.1016/j.semcancer.2006.08.003; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Ge Z, 2006, MOL CELL BIOL, V26, P230, DOI 10.1128/MCB.26.1.230-237.2006; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Guilleret I, 2003, EXP CELL RES, V289, P326, DOI 10.1016/S0014-4827(03)00281-7; Guilleret I, 2002, INT J CANCER, V101, P335, DOI 10.1002/ijc.10593; Gunes C, 2000, CANCER RES, V60, P2116; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085; Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462; Jalink M, 2007, BIOCHEM BIOPH RES CO, V353, P999, DOI 10.1016/j.bbrc.2006.12.149; Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Kumakura S, 2005, CANCER RES, V65, P2778, DOI 10.1158/0008-5472.CAN-04-1819; Lai SR, 2005, FRONT BIOSCI-LANDMRK, V10, P1779, DOI 10.2741/1661; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Liu C, 2007, CANCER RES, V67, P2626, DOI 10.1158/0008-5472.CAN-06-4126; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Schlosser I, 2005, ONCOGENE, V24, P520, DOI 10.1038/sj.onc.1208198; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Secombe J, 2007, CELL CYCLE, V6, P1324, DOI 10.4161/cc.6.11.4269; Secombe J, 2007, GENE DEV, V21, P537, DOI 10.1101/gad.1523007; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Wang SW, 2003, J BIOL CHEM, V278, P18842, DOI 10.1074/jbc.M209544200; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Wooten-Blanks LG, 2007, FASEB J, V21, P3386, DOI 10.1096/fj.07-8621com; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Xu D, 1996, LEUKEMIA, V10, P1354; Xu D, 1999, BRIT J CANCER, V80, P1156, DOI 10.1038/sj.bjc.6690480; Xu DK, 2008, J BIOL CHEM, V283, P23567, DOI 10.1074/jbc.M800790200; Xu DW, 1998, BRIT J HAEMATOL, V102, P1367, DOI 10.1046/j.1365-2141.1998.00969.x; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396	54	42	43	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					579	586		10.1096/fj.09-140087	http://dx.doi.org/10.1096/fj.09-140087			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19762557				2022-12-28	WOS:000274045000025
J	Park, SK; Link, CD; Johnson, TE				Park, Sang-Kyu; Link, Christopher D.; Johnson, Thomas E.			Life-span extension by dietary restriction is mediated by NLP-7 signaling and coelomocyte endocytosis in C. elegans	FASEB JOURNAL			English	Article						CUP-4; longevity; regulation of aging; signal transduction; modulation of aging	NEMATODE CAENORHABDITIS-ELEGANS; DECREASES FOOD-INTAKE; OXIDATIVE STRESS; CALORIC RESTRICTION; ENHANCES LONGEVITY; GENE FAMILIES; CHOLECYSTOKININ; AUTOPHAGY; DROSOPHILA; NUTRITION	Recent studies have shown that the rate of aging can be modulated by diverse interventions. Dietary restriction is the most widely used intervention to promote longevity; however, the mechanisms underlying the effect of dietary restriction remain elusive. In a previous study, we identified two novel genes, nlp-7 and cup-4, required for normal longevity in Caenorhabditis elegans. nlp-7 is one of a set of neuropeptide-like protein genes; cup-4 encodes an ion-channel involved in endocytosis by coelomocytes. Here, we assess whether nlp-7 and cup-4 mediate longevity increases by dietary restriction. RNAi of nlp-7 or cup-4 significantly reduces the life span of the eat-2 mutant, a genetic model of dietary restriction, but has no effect on the life span of long-lived mutants resulting from reduced insulin/IGF-1 signaling or dysfunction of the mitochondrial electron transport chain. The life-span extension observed in wild-type N2 worms by dietary restriction using bacterial dilution is prevented significantly in nlp-7 and cup-4 mutants. RNAi knockdown of genes encoding candidate receptors of NLP-7 and genes involved in endocytosis by coelomocytes also specifically shorten the life span of the eat-2 mutant. We conclude that two novel pathways, NLP-7 signaling and endocytosis by coelomocytes, are required for life extension under dietary restriction in C. elegans.-Park, S.-K., Link, C. D., Johnson, T. E. Life-span extension by dietary restriction is mediated by NLP-7 signaling and coelomocyte endocytosis in C. elegans. FASEB J. 24, 383-392 (2010). www.fasebj.org	[Park, Sang-Kyu; Link, Christopher D.; Johnson, Thomas E.] Univ Colorado, Inst Behav Genet, Boulder, CO 80303 USA	University of Colorado System; University of Colorado Boulder	Park, SK (corresponding author), Univ Colorado, Inst Behav Genet, Box 447, Boulder, CO 80303 USA.	sangkyu@colorado.edu		/0000-0001-7147-8237	U.S. National Institute on Aging [AG016219]; NATIONAL INSTITUTE ON AGING [R01AG016219, R01AG012423] Funding Source: NIH RePORTER	U.S. National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank the members of the T.E.J. and C. D. L. laboratories for helpful discussion. We also thank Shohei Mitani (Tokyo Women's Medical University, Tokyo, Japan) for providing strains of nlp-7 deletion mutants. This research was supported by the U.S. National Institute on Aging ( grant AG016219).	An JH, 2003, GENE DEV, V17, P1882, DOI 10.1101/gad.1107803; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; Chapman T, 1996, P ROY SOC B-BIOL SCI, V263, P755, DOI 10.1098/rspb.1996.0113; Chen D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000486; CHIPPINDALE AK, 1993, J EVOLUTION BIOL, V6, P171, DOI 10.1046/j.1420-9101.1993.6020171.x; Chowdhury P, 2001, ANN CLIN LAB SCI, V31, P376; Clerc P, 2007, ENDOCRINOLOGY, V148, P1039, DOI 10.1210/en.2006-1064; Cypser JR, 2006, EXP GERONTOL, V41, P935, DOI 10.1016/j.exger.2006.09.004; Donovan MJ, 2007, PHYSIOL BEHAV, V92, P969, DOI 10.1016/j.physbeh.2007.07.003; GIBBS J, 1973, J COMP PHYSIOL PSYCH, V84, P488, DOI 10.1037/h0034870; Greener T, 2001, NAT CELL BIOL, V3, P215, DOI 10.1038/35055137; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; Hansen M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040024; Hars ES, 2007, AUTOPHAGY, V3, P93, DOI 10.4161/auto.3636; Hersh BM, 2002, P NATL ACAD SCI USA, V99, P4355, DOI 10.1073/pnas.062065399; HOSONO R, 1989, EXP GERONTOL, V24, P251, DOI 10.1016/0531-5565(89)90016-8; Houthoofd K, 2003, EXP GERONTOL, V38, P947, DOI 10.1016/S0531-5565(03)00161-X; Husson SJ, 2006, J NEUROCHEM, V98, P1999, DOI 10.1111/j.1471-4159.2006.04014.x; Janssen T, 2008, ENDOCRINOLOGY, V149, P2826, DOI 10.1210/en.2007-1772; Johnson TE, 1990, GENETIC EFFECTS AGIN, V2, P101; Juhasz G, 2007, GENE DEV, V21, P3061, DOI 10.1101/gad.1600707; Kaeberlein TL, 2006, AGING CELL, V5, P487, DOI 10.1111/j.1474-9726.2006.00238.x; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; KISSILEFF HR, 1981, AM J CLIN NUTR, V34, P154, DOI 10.1093/ajcn/34.2.154; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lee GD, 2006, AGING CELL, V5, P515, DOI 10.1111/j.1474-9726.2006.00241.x; Li C, 2005, PARASITOLOGY, V131, pS109, DOI 10.1017/S0031182005009376; Link CD, 1999, CELL STRESS CHAPERON, V4, P235, DOI 10.1379/1466-1268(1999)004<0235:DOOSRI>2.3.CO;2; Lo CM, 2008, AM J PHYSIOL-REG I, V294, pR803, DOI 10.1152/ajpregu.00682.2007; MANGO SE, 1994, DEVELOPMENT, V120, P3019; MCCAY CM, 1989, NUTRITION, V5, P155; Mckay RM, 2007, EMBO REP, V8, P1183, DOI 10.1038/sj.embor.7401086; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Moran TH, 2000, NUTRITION, V16, P858, DOI 10.1016/S0899-9007(00)00419-6; Nathoo AN, 2001, P NATL ACAD SCI USA, V98, P14000, DOI 10.1073/pnas.241231298; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; Park SK, 2009, AGING CELL, V8, P258, DOI 10.1111/j.1474-9726.2009.00473.x; Patton A, 2005, CURR BIOL, V15, P1045, DOI 10.1016/j.cub.2005.04.057; Simonsen A, 2008, AUTOPHAGY, V4, P176, DOI 10.4161/auto.5269; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Steinkraus KA, 2008, AGING CELL, V7, P394, DOI 10.1111/j.1474-9726.2008.00385.x; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Szewczyk NJ, 2006, J EXP BIOL, V209, P4129, DOI 10.1242/jeb.02492	48	36	51	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2010	24	2					383	392		10.1096/fj.09-142984	http://dx.doi.org/10.1096/fj.09-142984			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19783783	Green Published			2022-12-28	WOS:000274045000007
J	Belsham, DD; Fick, LJ; Dalvi, PS; Centeno, ML; Chalmers, JA; Lee, PKP; Wang, YY; Drucker, DJ; Koletar, MM				Belsham, Denise D.; Fick, Laura J.; Dalvi, Prasad S.; Centeno, Maria-Luisa; Chalmers, Jennifer A.; Lee, Paul K. P.; Wang, Yangyang; Drucker, Daniel J.; Koletar, Margaret M.			Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons	FASEB JOURNAL			English	Article						adult neuronal cell lines; neuroendocrinology; proglucagon; signal transduction	TRANSGENIC MICE; CELL-LINES; NESTIN EXPRESSION; PROGENITOR CELLS; GENE-EXPRESSION; NERVOUS-SYSTEM; RAT; BRAIN; PROLIFERATION; RECEPTOR	The distinct lack of cell lines derived from the adult brain is evident. Ciliary neurotrophic factor (CNTF) triggers neurogenesis in primary culture from adult mouse hypothalamus, as detected by bromodeoxyuridine and Ki67 immunostaining. Using SV-40 T-antigen, we immortalized dividing neurons and generated clonal cell lines expressing neuropeptides and receptors involved in neuroendocrine function. We hypothesized that proglucagon-derived peptides may be the mechanistic downstream effectors of CNTF due to documented neuroprotective and proliferative effects. Indeed, proglucagon gene expression was induced by CNTF, and exposure of primary cells to glucagon-like peptide-1 receptor (GLP-1) agonist, exendin-4, induced cell proliferation. Intracerebroventricular injection of CNTF into adult mice caused increased expression of proglucagon peptide in the hypothalamus. Using a specific GLP-1-receptor antagonist, we found that neurogenesis was significantly attenuated and primary culture from GLP-1-receptor-knockout mice lacked CNTF-mediated neuronal proliferation, thus linking the induction of neurogenesis in the hypothalamus to GLP-1-receptor signaling.-Belsham, D. D., Fick, L. J., Dalvi, P. S., Centeno, M.-L., Chalmers, J. A., Lee, P. K. P., Wang, Y., Drucker, D. J., Koletar, M. M. Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis allowing immortalization of adult murine hypothalamic neurons. FASEB J. 23, 4256-4265 (2009). www.fasebj.org	[Belsham, Denise D.; Fick, Laura J.; Dalvi, Prasad S.; Centeno, Maria-Luisa; Chalmers, Jennifer A.; Lee, Paul K. P.; Wang, Yangyang; Koletar, Margaret M.] Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; [Belsham, Denise D.] Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON M5S 1A8, Canada; [Belsham, Denise D.; Drucker, Daniel J.] Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; [Koletar, Margaret M.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A8, Canada; [Belsham, Denise D.] Toronto Gen Hosp, Res Inst, Univ Hlth Network, Div Cellular & Mol Biol, Toronto, ON, Canada; [Drucker, Daniel J.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Belsham, DD (corresponding author), Univ Toronto, Dept Physiol, Med Sci Bldg 3247A,1 Kings Coll Cir, Toronto, ON M5S 1A8, Canada.	d.belsham@utoronto.ca	Drucker, Daniel J/A-4092-2010; Dalvi, Prasad/F-1866-2015; Wang, Yangyang/GXH-5679-2022		Canadian Institutes for Health Research; Natural Sciences and Engineering Research Council; Canada Foundation for Innovation; Canada Research Chairs Program; Ontario Graduate Studentship; Banting and Best Diabetes Centre Studentships	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Canada Research Chairs Program(Canada Research Chairs); Ontario Graduate Studentship; Banting and Best Diabetes Centre Studentships	We thank Dr. Bernardo Yusta and members of the Belsham Lab for critical reading of the manuscript. We acknowledge funding from Canadian Institutes for Health Research, Natural Sciences and Engineering Research Council, Canada Foundation for Innovation, and the Canada Research Chairs Program to D. D. B. L. J. F. was supported by an Ontario Graduate Studentship. L. J. F. and P. S. D. both held Banting and Best Diabetes Centre Studentships.	Alvarez E, 1996, J NEUROCHEM, V66, P920; BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; Belsham DD, 2004, ENDOCRINOLOGY, V145, P393, DOI 10.1210/en.2003-0946; Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; CEPKO CL, 1989, ANNU REV NEUROSCI, V12, P47, DOI 10.1146/annurev.ne.12.030189.000403; Cheng H, 2008, ENDOCRINOLOGY, V149, P703, DOI 10.1210/en.2007-0772; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Cui H, 2006, FASEB J, V20, P2654, DOI 10.1096/fj.06-5989fje; DEVITRY F, 1974, P NATL ACAD SCI USA, V71, P3575; DRUCKER DJ, 1988, J BIOL CHEM, V263, P13475; Drucker DJ, 2003, MOL ENDOCRINOL, V17, P161, DOI 10.1210/me.2002-0306; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911; During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Everitt B J, 1990, Acta Neurochir Suppl (Wien), V47, P1; Fain JN, 2006, VITAM HORM, V74, P443, DOI 10.1016/S0083-6729(06)74018-3; Farilla L, 2003, ENDOCRINOLOGY, V144, P5149, DOI 10.1210/en.2003-0323; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HEINRICH G, 1984, J BIOL CHEM, V259, P4082; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kokoeva MV, 2007, J COMP NEUROL, V505, P209, DOI 10.1002/cne.21492; Kokoeva MV, 2005, SCIENCE, V310, P679, DOI 10.1126/science.1115360; LEE YC, 1990, ENDOCRINOLOGY, V127, P2217, DOI 10.1210/endo-127-5-2217; Li Y, 1999, BRAIN RES, V838, P1, DOI 10.1016/S0006-8993(99)01502-4; Lotz B, 1996, NEUROLOGY, V46, P1244; LUI EY, 1990, ENDOCRINOLOGY, V126, P110, DOI 10.1210/endo-126-1-110; Luque RM, 2007, ENDOCRINOLOGY, V148, P4601, DOI 10.1210/en.2007-0500; Markakis EA, 2004, J NEUROSCI, V24, P2886, DOI 10.1523/JNEUROSCI.4161-03.2004; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Ning K, 2006, EMBO J, V25, P2377, DOI 10.1038/sj.emboj.7601118; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611; Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481; Piessevaux J, 2006, J BIOL CHEM, V281, P32953, DOI 10.1074/jbc.M600776200; ROSENFELD MG, 1988, ANNU REV NEUROSCI, V11, P353, DOI 10.1146/annurev.neuro.11.1.353; SCHMECHEL DE, 1980, BRAIN RES, V190, P195, DOI 10.1016/0006-8993(80)91169-5; Scrocchi LA, 1998, DIABETES, V47, P632, DOI 10.2337/diabetes.47.4.632; SENDTNER M, 1991, J CELL SCI, P103; Sleeman M W, 2000, Pharm Acta Helv, V74, P265, DOI 10.1016/S0031-6865(99)00050-3; Velazquez E, 2003, EUR J BIOCHEM, V270, P3001, DOI 10.1046/j.1432-1033.2003.03677.x; Wauman J, 2008, MOL ENDOCRINOL, V22, P965, DOI 10.1210/me.2007-0414; Wiese C, 2004, CELL MOL LIFE SCI, V61, P2510, DOI 10.1007/s00018-004-4144-6; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	49	80	81	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2009	23	12					4256	4265		10.1096/fj.09-133454	http://dx.doi.org/10.1096/fj.09-133454			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19703933				2022-12-28	WOS:000272193700020
J	Chandrasekaran, S; Peterson, RE; Mani, SK; Addy, B; Buchholz, AL; Xu, L; Thiyagarajan, T; Kasiganesan, H; Kern, CB; Menick, DR				Chandrasekaran, Sangeetha; Peterson, Richard E.; Mani, Santhosh K.; Addy, Benjamin; Buchholz, Avery L.; Xu, Lin; Thiyagarajan, Thirumagal; Kasiganesan, Harinath; Kern, Christine B.; Menick, Donald R.			Histone deacetylases facilitate sodium/calcium exchanger up-regulation in adult cardiomyocytes	FASEB JOURNAL			English	Article						Nkx2.5; acetylation; cardiac hypertrophy; p300; transcriptional regulation	RABBIT VENTRICULAR MYOCYTES; CARDIAC-SPECIFIC EXPRESSION; SERUM RESPONSE FACTOR; NA+-CA2+ EXCHANGER; GENE-EXPRESSION; IN-VIVO; MUSCLE DIFFERENTIATION; TRANSCRIPTION FACTOR; NUCLEAR EXPORT; TRICHOSTATIN-A	It is becoming increasingly evident that histone deacetylases (HDACs) have a prominent role in the alteration of gene expression during the growth remodeling process of cardiac hypertrophy. HDACs are generally viewed as corepressors of gene expression. However, we demonstrate that class I and class II HDACs play an important role in the basal expression and up-regulation of the sodium calcium exchanger (Ncx1) gene in adult cardiomyocytes. Treatment with the HDAC inhibitor trichostatin A (TSA) prevented the pressure-overload-stimulated up-regulation of Ncx1 expression. Overexpression of HDAC5 resulted in the dose-dependent up-regulation of basal and alpha-adrenergic stimulated Ncx1 expression. We show that Nkx2.5 recruits HDAC5 to the Ncx1 promoter, where HDAC5 complexes with HDAC1. Nkx2.5 also interacts with transcriptional activator p300, which is recruited to the Ncx1 promoter. We demonstrate that when Nkx2.5 is acetylated, it is found associated with HDAC5, whereas deacetylated Nkx2.5 is in complex with p300. Notably, TSA treatment prevents p300 from being recruited to the endogenous Ncx1 promoter, resulting in the repression of Ncx1 expression. We propose a novel model for Ncx1 regulation in which deacetylation of Nkx2.5 is required for the recruitment of p300 and results in up-regulation of exchanger expression.-Chandrasekaran, S., Peterson, R. E., Mani, S. K., Addy, B., Buchholz, A. L., Xu, L., Thiyagarajan, T., Kasiganesan, H., Kern, C. B., Menick, D. R. Histone deacetylases facilitate sodium/calcium exchanger up-regulation in adult cardiomyocytes. FASEB J. 23, 3851-3864 (2009). www.fasebj.org	[Chandrasekaran, Sangeetha; Peterson, Richard E.; Mani, Santhosh K.; Addy, Benjamin; Buchholz, Avery L.; Xu, Lin; Thiyagarajan, Thirumagal; Kasiganesan, Harinath; Kern, Christine B.; Menick, Donald R.] Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, Charleston, SC 29425 USA	Medical University of South Carolina	Menick, DR (corresponding author), Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, 114 Doughty St,Box 250773, Charleston, SC 29425 USA.	menickd@musc.edu			NIH [R01 HL066223, P01 HL48788, RR016434, T32HL07260, RR16434]; American Heart Association [0765236]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016434] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788, R01HL066223, T32HL007260] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Eric Olson (University of Texas Southwestern Medical Center, Dallas, TX, USA) for his suggestions and gift of the S259/498A HDAC5 and wild-type HDAC5 adenovirus. We also thank Ludivine Renaud for technical assistance. This work was supported, in part, by NIH grants R01 HL066223 and P01 HL48788 (project 3) to D. R. M. and American Heart Association grant 0765236 and NIH grant RR016434 to C. B. K. R. E. P was supported by NIH postdoctoral fellowship T32HL07260, and L. X. was supported in part by NIH grant RR16434.	Antos CL, 2003, J BIOL CHEM, V278, P28930, DOI 10.1074/jbc.M303113200; Backs J, 2006, CIRC RES, V98, P15, DOI 10.1161/01.RES.0000197782.21444.8f; Chang S, 2005, J BIOL CHEM, V280, P796, DOI 10.1074/jbc.M409053200; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Cho YS, 2005, GENOMICS, V86, P606, DOI 10.1016/j.ygeno.2005.07.007; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Gallo P, 2008, CARDIOVASC RES, V80, P416, DOI 10.1093/cvr/cvn215; Golden KL, 2001, AM J PHYSIOL-HEART C, V280, pH1376, DOI 10.1152/ajpheart.2001.280.3.H1376; Golden KL, 2000, J MOL CELL CARDIOL, V32, P611, DOI 10.1006/jmcc.2000.1104; Harrison BC, 2006, MOL CELL BIOL, V26, P3875, DOI 10.1128/MCB.26.10.3875-3888.2006; Hasenfuss G, 1999, CIRCULATION, V99, P641, DOI 10.1161/01.CIR.99.5.641; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Kee HJ, 2006, CIRCULATION, V113, P51, DOI 10.1161/CIRCULATIONAHA.105.559724; KENT RL, 1989, AM J PHYSIOL, V257, pH1717, DOI 10.1152/ajpheart.1989.257.5.H1717; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Kong YL, 2006, CIRCULATION, V113, P2579, DOI 10.1161/CIRCULATIONAHA.106.625467; Li T, 2007, J MOL BIOL, V370, P976, DOI 10.1016/j.jmb.2007.05.033; Litwin SE, 1997, CIRC RES, V81, P1083; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2005, J CLIN INVEST, V115, P538, DOI 10.1172/JCI200524144; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; McKinsey TA, 2002, CURR OPIN CELL BIOL, V14, P763, DOI 10.1016/S0955-0674(02)00389-7; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; McKinsey Timothy A, 2004, Novartis Found Symp, V259, P132; Menick DR, 2007, ANN NY ACAD SCI, V1099, P195, DOI 10.1196/annals.1387.058; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Morisco C, 2001, J MOL CELL CARDIOL, V33, P561, DOI 10.1006/jmcc.2000.1332; Muller JG, 2002, J MOL CELL CARDIOL, V34, P807, DOI 10.1006/jmcc.2002.2019; Muller JG, 2002, CIRC RES, V90, P158, DOI 10.1161/hh0202.103231; Nusinzon I, 2006, MOL CELL BIOL, V26, P3106, DOI 10.1128/MCB.26.8.3106-3113.2006; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Place RF, 2005, BIOCHEM PHARMACOL, V70, P394, DOI 10.1016/j.bcp.2005.04.030; Pogwizd SM, 2001, CIRC RES, V88, P1159, DOI 10.1161/hh1101.091193; Pogwizd SM, 1999, CIRC RES, V85, P1009; Qiu Y, 2006, MOL CELL, V22, P669, DOI 10.1016/j.molcel.2006.04.019; Quivy V, 2004, BIOCHEM PHARMACOL, V68, P1221, DOI 10.1016/j.bcp.2004.05.039; Ranu HK, 2002, J MOL CELL CARDIOL, V34, P389, DOI 10.1006/jmcc.2001.1521; Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662; Roten L, 2000, J MOL CELL CARDIOL, V32, P109, DOI 10.1006/jmcc.1999.1052; Schillinger W, 2000, CIRC RES, V87, P581, DOI 10.1161/01.RES.87.7.581; Song K, 2006, CELL, V125, P453, DOI 10.1016/j.cell.2006.02.048; Sun JM, 2002, J BIOL CHEM, V277, P35783, DOI 10.1074/jbc.C200378200; Walkinshaw DR, 2008, J CELL BIOCHEM, V104, P1541, DOI 10.1002/jcb.21746; Wang A, 2002, SCIENCE, V298, P1412, DOI 10.1126/science.1077790; Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1; Weisser-Thomas J, 2005, J CARD FAIL, V11, P380, DOI 10.1016/j.cardfail.2005.01.004; Wu X, 2006, J CLIN INVEST, V116, P675, DOI 10.1172/JCI27374; Xu L, 2005, J MOL CELL CARDIOL, V38, P735, DOI 10.1016/j.yjmcc.2005.03.002; Xu L, 2006, J BIOL CHEM, V281, P34430, DOI 10.1074/jbc.M607446200; Xu Q, 2002, MOL BIOL CELL, V13, P1940, DOI 10.1091/mbc.02-02-0016; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang CL, 2002, MOL CELL BIOL, V22, P7302, DOI 10.1128/MCB.22.20.7302-7312.2002; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002; Zupkovitz G, 2006, MOL CELL BIOL, V26, P7913, DOI 10.1128/MCB.01220-06	63	38	40	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3851	3864		10.1096/fj.09-132415	http://dx.doi.org/10.1096/fj.09-132415			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19638401	Green Published			2022-12-28	WOS:000271272500021
J	Joshi, MB; Kyriakakis, E; Pfaff, D; Rupp, K; Philippova, M; Erne, P; Resink, TJ				Joshi, Manjunath B.; Kyriakakis, Emmanouil; Pfaff, Dennis; Rupp, Katharina; Philippova, Maria; Erne, Paul; Resink, Therese J.			Extracellular cadherin repeat domains EC1 and EC5 of T-cadherin are essential for its ability to stimulate angiogenic behavior of endothelial cells	FASEB JOURNAL			English	Article						deletion mutant; lentivirus vector; signaling; proliferation; adhesion; migration	ADHESION MOLECULE; GENE-THERAPY; N-CADHERIN; HEPATOCELLULAR-CARCINOMA; TUMOR ANGIOGENESIS; HUMAN VASCULATURE; EXPRESSION; GROWTH; CANCER; PROTEINS	T-cadherin (T-cad) promotes survival, proliferation, and migration of endothelial cells and induces angiogenesis. We aimed to identify domains of T-cad functionally relevant to its effects on endothelial cell behavior. To specifically target the functional properties of the 5 cadherin repeat domains (EC1-EC5) of T-cad, endothelial cells were transduced with lentivectors containing specific T-cad-domain-deletion mutant constructs (Delta I, Delta II, Delta III, Delta IV, Delta V). Empty (E) lentivector-transduced cells served as control. Similarly to overexpression of native T-cad, cells expressing Delta II, Delta III, or Delta IV displayed elevated levels of p-Akt and p-GSK3 beta and increased proliferation rates (for Delta II, Delta III) vs. E. Delta I- and Delta V-transduced cells exhibited reduced levels of p-Akt and p-GSK3 beta and retarded growth rates vs. E. Stimulatory effects of native T-cad overexpression on Akt and GSK3 beta phosphorylation were dose dependently inhibited by coexpression of Delta I or Delta V. Subsequent functional analyses compared only Delta I-, Delta II-, and Delta V-mutant constructs with E as a negative control. Unlike Delta II cells, Delta I and Delta V cells failed to exhibit homophilic ligation and deadhesion responses on a substratum of T-cad protein. In the wound assay, migration was increased for Delta II cells but impaired for Delta I and Delta V cells. In endothelial cell-spheroid assay, angiogenic sprouting was augmented for Delta II cells but inhibited for Delta I and Delta V cells. We conclude that EC1 and EC5 domains of T-cad are essential for its proangiogenic effects. Delta I and Delta V constructs may serve as dominant-negative mutants and as potential tools targeting excessive angiogenesis.-Joshi, M. B., Kyriakakis, E., Pfaff, D., Rupp, K., Philippova, M., Erne, P., Resink, T. J. Extracellular cadherin repeat domains EC1 and EC5 of T-cadherin are essential for its ability to stimulate angiogenic behavior of endothelial cells. FASEB J. 23, 4011-4021 (2009). www.fasebj.org	[Joshi, Manjunath B.; Kyriakakis, Emmanouil; Pfaff, Dennis; Rupp, Katharina; Philippova, Maria; Resink, Therese J.] Univ Basel Hosp, Dept Biomed, Lab Signal Transduct, CH-4031 Basel, Switzerland; [Erne, Paul] Kantonsspital Luzern, Div Cardiol, Luzern, Switzerland	University of Basel; Lucerne Cantonal Hospital	Resink, TJ (corresponding author), Univ Basel Hosp, Dept Biomed, Lab Signal Transduct, ZLF 316,Hebelstr 20, CH-4031 Basel, Switzerland.	therese-j.resink@unibas.ch	Kyriakakis, Emmanouil/AAS-5754-2021; Joshi, Manjunath B/G-2052-2012; Filippova, Maria/GXH-7313-2022	Joshi, Manjunath/0000-0002-1310-5480; Filippova, Maria/0000-0003-3124-3155; Kyriakakis, Emmanouil/0000-0002-6796-0431	Swiss National Science Foundation [310000-118468/1]; Herzkreislauf Stiftung; Novartis Foundation for Medical Biological Research	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Herzkreislauf Stiftung; Novartis Foundation for Medical Biological Research(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors thank Dr. Danila Ivanov and Ms. Vanya Morf (Department of Biomedicine, Basel University Hospital, Basel, Switzerland) for their initial planning and construction of mutant plasmids. The authors are supported by the Swiss National Science Foundation (grant 310000-118468/1), the Herzkreislauf Stiftung, and the Novartis Foundation for Medical Biological Research.	Adachi Y, 2006, VIRCHOWS ARCH, V448, P311, DOI 10.1007/s00428-005-0098-9; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Ahn A, 2008, CARDIOL REV, V16, P219, DOI 10.1097/CRD.0b013e3181620e50; Alajati A, 2008, NAT METHODS, V5, P439, DOI [10.1038/nmeth.1198, 10.1038/NMETH.1198]; Bai S, 2007, J BIOL CHEM, V282, P27171, DOI 10.1074/jbc.M700691200; Cao Y, 2008, ADV CANCER RES, V100, P113, DOI 10.1016/S0065-230X(08)00004-3; Dames Sonja A, 2008, J Biol Chem, V283, P23485, DOI 10.1074/jbc.M708335200; Ferreri DM, 2008, CELL COMMUN ADHES, V15, P333, DOI 10.1080/15419060802440377; Ghosh S, 2007, FEBS LETT, V581, P4523, DOI 10.1016/j.febslet.2007.08.038; Griffioen AW, 2008, CANCER IMMUNOL IMMUN, V57, P1553, DOI 10.1007/s00262-008-0524-3; Hebbard LW, 2008, CANCER RES, V68, P1407, DOI 10.1158/0008-5472.CAN-07-2953; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hicklin DJ, 2001, DRUG DISCOV TODAY, V6, P517, DOI 10.1016/S1359-6446(01)01759-7; Igarashi T, 2003, GENE THER, V10, P219, DOI 10.1038/sj.gt.3301878; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Ivanov D, 2004, CARDIOVASC RES, V64, P132, DOI 10.1016/j.cardiores.2004.06.010; Ivanov D, 2004, EXP CELL RES, V293, P207, DOI 10.1016/j.yexcr.2003.09.030; Ivanov D, 2001, HISTOCHEM CELL BIOL, V115, P231; Joshi MB, 2007, FASEB J, V21, P3083, DOI 10.1096/fj.06-7723com; Joshi MB, 2008, BIOCHEM J, V416, P271, DOI 10.1042/BJ20080765; Joshi MB, 2005, FASEB J, V19, P1737, DOI 10.1096/fj.05-3834fje; Koga M, 2008, BIOCHEM BIOPH RES CO, V365, P279, DOI 10.1016/j.bbrc.2007.10.182; Korff T, 1999, J CELL SCI, V112, P3249; Kudrjashova E, 2002, HISTOCHEM CELL BIOL, V118, P281, DOI 10.1007/s00418-002-0463-6; Kuzmenko YS, 1998, BIOCHEM BIOPH RES CO, V246, P489, DOI 10.1006/bbrc.1998.8645; Machein MR, 1999, HUM GENE THER, V10, P1117, DOI 10.1089/10430349950018111; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Norvell SM, 1998, J CELL SCI, V111, P1305; Pan JP, 2008, CANCER IMMUNOL IMMUN, V57, P1105, DOI 10.1007/s00262-008-0452-2; Pepper MS, 1997, ARTERIOSCL THROM VAS, V17, P605, DOI 10.1161/01.ATV.17.4.605; Persano L, 2007, MOL ASPECTS MED, V28, P87, DOI 10.1016/j.mam.2006.12.005; Pfeifer A, 2000, P NATL ACAD SCI USA, V97, P12227, DOI 10.1073/pnas.220399597; Phelps EA, 2009, REGEN MED, V4, P65, DOI 10.2217/17460751.4.1.65; Philippova M, 2005, FASEB J, V19, P588, DOI 10.1096/fj.04-2430fje; Philippova M, 2008, MOL CELL BIOL, V28, P4004, DOI 10.1128/MCB.00157-08; Philippova M, 2006, ARTERIOSCL THROM VAS, V26, P2222, DOI 10.1161/01.ATV.0000238356.20565.92; Philippova M, 2009, CELL SIGNAL, V21, P1035, DOI 10.1016/j.cellsig.2009.01.035; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; Riou P, 2006, FASEB J, V20, P2291, DOI 10.1096/fj.06-6085com; Rissanen TT, 2007, MOL THER, V15, P1233, DOI 10.1038/sj.mt.6300175; Rudd PM, 1997, CRIT REV BIOCHEM MOL, V32, P1, DOI 10.3109/10409239709085144; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; Simons M, 2003, NAT REV DRUG DISCOV, V2, P863, DOI 10.1038/nrd1226; TANDLE A, 2004, J TRANSL MED, V3, P2; Troxell ML, 1999, AM J PHYSIOL-CELL PH, V276, pC404, DOI 10.1152/ajpcell.1999.276.2.C404; Wyder L, 2000, CANCER RES, V60, P4682; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200; Youssoufian H, 2007, CLIN CANCER RES, V13, p5544S, DOI 10.1158/1078-0432.CCR-07-1107; Zanetta L, 2005, THROMB HAEMOSTASIS, V93, P1041, DOI 10.1160/TH04-10-0680; Zhang HT, 2003, MOL BIOTECHNOL, V25, P185, DOI 10.1385/MB:25:2:185; Zhao HB, 2008, J CELL BIOCHEM, V104, P162, DOI 10.1002/jcb.21608; Zhao YY, 2008, FEBS J, V275, P1939, DOI 10.1111/j.1742-4658.2008.06346.x	52	8	10	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					4011	4021		10.1096/fj.09-133611	http://dx.doi.org/10.1096/fj.09-133611			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19638398				2022-12-28	WOS:000271272500036
J	Lu, J; Zhong, LW; Lonn, ME; Burk, RF; Hill, KE; Holmgren, A				Lu, Jun; Zhong, Liangwei; Lonn, Maria Elisabet; Burk, Raymond F.; Hill, Kristina E.; Holmgren, Arne			Penultimate selenocysteine residue replaced by cysteine in thioredoxin reductase from selenium-deficient rat liver	FASEB JOURNAL			English	Article						selenoprotein; UGA codon; glutaredoxin	MAMMALIAN THIOREDOXIN; ESCHERICHIA-COLI; CANCER-THERAPY; ACTIVE-SITE; AMINO-ACID; KAPPA-B; GLUTAREDOXIN; GENE; RNA; UGA	Selenium is an essential micronutrient for humans and animals, and its deficiency can predispose to the development of pathological conditions. This study evaluates the effect of selenium deficiency on the thioredoxin system, consisting of NADPH, selenoprotein thioredoxin reductase (TrxR), and thioredoxin (Trx); and the glutathione system, including NADPH, glutathione reductase, glutathione, and glutaredoxin coupled with selenoprotein glutathione peroxidase (GPx). We particularly investigate whether inactive truncated TrxR is present under selenium-starvation conditions due to reading of the UGA codon as stop. Feeding rats a selenium-deficient diet resulted in a large decrease in activity of TrxR and GPx in rat liver but not in the levels of Trx1 and Grx1. However, selenium deficiency induced mitochondrial Grx2 10-fold and markedly changed the expression of some flavoproteins that are involved in the cellular folate, glucose, and lipid metabolism. Liver TrxR mRNA was nearly unchanged, but no truncated enzyme was found. Instead, a low-activity form of TrxR with a cysteine substituted for the penultimate selenocysteine in the C-terminal active site was identified in selenium-deficient rat liver. These results show a novel mechanism for decoding the UGA stop codon, inserting cysteine to make a full-length enzyme that may be required for selenium assimilation.-Lu, J., Zhong, L., Lonn, M. E., Burk, R. F., Hill, K. E., Holmgren, A. Penultimate selenocysteine residue replaced by cysteine in thioredoxin reductase from selenium-deficient rat liver. FASEB J. 23, 2394-2402 (2009)	[Lu, Jun; Zhong, Liangwei; Lonn, Maria Elisabet; Holmgren, Arne] Karolinska Inst, Dept Med Biochem & Biophys, Div Biochem, SE-17177 Stockholm, Sweden; [Burk, Raymond F.; Hill, Kristina E.] Vanderbilt Univ, Sch Med, Div Gastroenterol, Dept Med, Nashville, TN 37212 USA; [Burk, Raymond F.; Hill, Kristina E.] Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37212 USA	Karolinska Institutet; Vanderbilt University; Vanderbilt University	Lu, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Biochem, SE-17177 Stockholm, Sweden.	jun.lu@ki.se; arne.holmgren@ki.se	Lu, Jun/E-9701-2017	Lu, Jun/0000-0002-1699-8835	Swedish Cancer Society [961]; Swedish Research Council [3529]; U.S. National Institutes of Health [ES02497]; Swedish Hagelen Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002497, R37ES002497] Funding Source: NIH RePORTER	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swedish Hagelen Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr. Elias Arner and Mr. Qing Cheng (Department of Medical Biochemistry and Biophysics, Karolinska Institute) for kindly providing PAO Sepharose beads; R. Eliasson for the preparation of anti-rat TrxR antibodies; and Amy K. Motley and Marjan Hessam Amiri for technical assistance. This work was supported by the Swedish Cancer Society (grant 961), the Swedish Research Council (grant 3529), the U.S. National Institutes of Health (grant ES02497), and the K.A. Wallenberg foundation. L.Z. was supported in part by a fellowship from the Swedish Hagelen Foundation.	Anestal K, 2003, J BIOL CHEM, V278, P15966, DOI 10.1074/jbc.M210733200; Arner ESJ, 2006, SEMIN CANCER BIOL, V16, P420, DOI 10.1016/j.semcancer.2006.10.009; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; BARON C, 1990, NUCLEIC ACIDS RES, V18, P6761, DOI 10.1093/nar/18.23.6761; Berggren MM, 1999, BIOCHEM PHARMACOL, V57, P187, DOI 10.1016/S0006-2952(98)00283-4; Bergman T, 2001, ANAL BIOCHEM, V290, P74, DOI 10.1006/abio.2000.4922; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Burk RF, 2008, FREE RADICAL BIO MED, V44, P1617, DOI 10.1016/j.freeradbiomed.2008.01.016; BURK RF, 1987, METHOD ENZYMOL, V143, P307; Castellano S, 2005, P NATL ACAD SCI USA, V102, P16188, DOI 10.1073/pnas.0505146102; Cheng Q, 2006, NAT PROTOC, V1, P604, DOI 10.1038/nprot.2006.87; Chew EH, 2008, FASEB J, V22, P2072, DOI 10.1096/fj.07-101477; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; FENG YX, 1990, P NATL ACAD SCI USA, V87, P8860, DOI 10.1073/pnas.87.22.8860; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; HILL KE, 1992, BIOCHEM BIOPH RES CO, V185, P260, DOI 10.1016/S0006-291X(05)80984-2; Hill KE, 1997, BIOCHEM BIOPH RES CO, V234, P293, DOI 10.1006/bbrc.1997.6618; HILL KE, 1991, J BIOL CHEM, V266, P10050; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Jakupoglu C, 2005, MOL CELL BIOL, V25, P1980, DOI 10.1128/MCB.25.5.1980-1988.2005; Johansson L, 2004, NAT METHODS, V1, P61, DOI 10.1038/NMETH707; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Lacey BM, 2006, BIOCHEM BIOPH RES CO, V346, P629, DOI 10.1016/j.bbrc.2006.05.095; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Lillig CH, 2004, P NATL ACAD SCI USA, V101, P13227, DOI 10.1073/pnas.0401896101; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Lu J, 2006, CANCER RES, V66, P4410, DOI 10.1158/0008-5472.CAN-05-3310; Lu J, 2009, J BIOL CHEM, V284, P723, DOI 10.1074/jbc.R800045200; Lu J, 2007, P NATL ACAD SCI USA, V104, P12288, DOI 10.1073/pnas.0701549104; Lundberg M, 2004, BIOCHEM BIOPH RES CO, V319, P801, DOI 10.1016/j.bbrc.2004.04.199; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MEYER F, 1991, P NATL ACAD SCI USA, V88, P3758, DOI 10.1073/pnas.88.9.3758; Mostert V, 2003, FEBS LETT, V541, P85, DOI 10.1016/S0014-5793(03)00309-0; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Novoselov SV, 2005, ONCOGENE, V24, P8003, DOI 10.1038/sj.onc.1208940; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; Prabhu KS, 2002, BIOCHEM J, V366, P203, DOI 10.1042/BJ20020256; Primiano T, 1998, CARCINOGENESIS, V19, P999, DOI 10.1093/carcin/19.6.999; REITER R, 1983, BIOCHEM PHARMACOL, V32, P3063, DOI 10.1016/0006-2952(83)90250-2; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Savonet V, 1997, ANAL BIOCHEM, V247, P165, DOI 10.1006/abio.1997.2055; Shalini S, 2007, BIOMETALS, V20, P49, DOI 10.1007/s10534-006-9014-2; Suh JR, 2001, ANNU REV NUTR, V21, P255, DOI 10.1146/annurev.nutr.21.1.255; Suzuki T, 2008, J BIOL CHEM, V283, P2021, DOI 10.1074/jbc.M708352200; Takahata M, 2008, J BIOCHEM, V143, P467, DOI 10.1093/jb/mvm247; URBAN C, 1995, NUCLEIC ACIDS RES, V23, P4591, DOI 10.1093/nar/23.22.4591; Urig S, 2006, SEMIN CANCER BIOL, V16, P452, DOI 10.1016/j.semcancer.2006.09.004; Papp LV, 2007, ANTIOXID REDOX SIGN, V9, P775, DOI 10.1089/ars.2007.1528; YANG JG, 1989, J NUTR, V119, P1010, DOI 10.1093/jn/119.7.1010; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	63	50	50	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2009	23	8					2394	2402		10.1096/fj.08-127662	http://dx.doi.org/10.1096/fj.08-127662			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19351701	Green Published			2022-12-28	WOS:000268836700008
J	Middeldorp, J; Kamphuis, W; Sluijs, JA; Achoui, D; Leenaars, CHC; Feenstra, MGP; van Tijn, P; Fischer, DF; Berkers, C; Ovaa, H; Quinlan, RA; Hol, EM				Middeldorp, Jinte; Kamphuis, Willem; Sluijs, Jacqueline A.; Achoui, Dalila; Leenaars, Cathalijn H. C.; Feenstra, Matthijs G. P.; van Tijn, Paula; Fischer, David F.; Berkers, Celia; Ovaa, Huib; Quinlan, Roy A.; Hol, Elly M.			Intermediate filament transcription in astrocytes is repressed by proteasome inhibition	FASEB JOURNAL			English	Article						glial fibrillary acidic protein; astrogliosis; protein degradation; neurodegenerative diseases	FIBRILLARY ACIDIC PROTEIN; AGE-RELATED-CHANGES; REACTIVE ASTROCYTES; MESSENGER-RNA; NEURODEGENERATIVE DISORDERS; DEPENDENT PROTEOLYSIS; ALZHEIMERS-DISEASE; GENE-EXPRESSION; MICE DEFICIENT; UBIQUITIN	Increased expression of the astrocytic intermediate filament protein glial fibrillary acidic protein (GFAP) is a characteristic of astrogliosis. This process occurs in the brain during aging and neurodegeneration and coincides with impairment of the ubiquitin proteasome system. Inhibition of the proteasome impairs protein degradation; therefore, we hypothesized that the increase in GFAP may be the result of impaired proteasomal activity in astrocytes. We investigated the effect of proteasome inhibitors on GFAP expression and other intermediate filament proteins in human astrocytoma cells and in a rat brain model for astrogliosis. Extensive quantitative RT-PCR, immunocytochemistry, and Western blot analysis resulted unexpectedly in a strong decrease of GFAP mRNA to <4% of control levels [Control (DMSO) 100 +/- 19.2%; proteasome inhibitor (epoxomicin) 3.5 +/- 1.3%, n = 8; P<0.001] and a loss of GFAP protein in astrocytes in vitro. We show that the proteasome alters GFAP promoter activity, possibly mediated by transcription factors as demonstrated by a GFAP promoter-luciferase assay and RT2 Profiler PCR array for human transcription factors. Most important, we demonstrate that proteasome inhibitors also reduce GFAP and vimentin expression in a rat model for induced astrogliosis in vivo. Therefore, proteasome inhibitors could serve as a potential therapy to modulate astrogliosis associated with CNS injuries and disease.-Middeldorp, J., Kamphuis, W., Sluijs, J. A., Achoui, D., Leenaars, C. H. C., Feenstra, M. G. P., van Tijn, P., Fischer, D. F., Berkers, C., Ovaa, H., Quinlan, R. A., Hol, E. M. Intermediate filament transcription in astrocytes is repressed by proteasome inhibition. FASEB J. 23, 2710-2726 (2009)	[Middeldorp, Jinte; Kamphuis, Willem; Sluijs, Jacqueline A.; Achoui, Dalila; Leenaars, Cathalijn H. C.; Feenstra, Matthijs G. P.; van Tijn, Paula; Hol, Elly M.] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Dept Astrocyte Biol & Neurodegenerat, NL-1105 BA Amsterdam, Netherlands; [Fischer, David F.] BioFocus DPI, Leiden, Netherlands; [Berkers, Celia; Ovaa, Huib] Netherlands Canc Inst, Div Cellular Biochem, Tumor Biol & Immunol, NL-1066 CX Amsterdam, Netherlands; [Quinlan, Roy A.] Univ Durham, Sch Biol & Biomed Sci, Durham, England	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Netherlands Cancer Institute; Durham University	Hol, EM (corresponding author), Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Dept Astrocyte Biol & Neurodegenerat, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.	e.hol@nin.knaw.nl	Middeldorp, Jinte/M-2352-2016; Quinlan, Roy/A-1348-2012; , Jinte/AHA-6575-2022; Hol, Elly/J-2025-2019; van Tijn, Paula/E-4866-2012; Berkers, Celia/I-3848-2016; Leenaars, Cathalijn/P-7211-2015; Hol, Elly M/F-1891-2013; ovaa, huib/M-2334-2016	Middeldorp, Jinte/0000-0002-9198-8020; Quinlan, Roy/0000-0003-0644-4123; , Jinte/0000-0002-9198-8020; Hol, Elly/0000-0001-5604-2603; Leenaars, Cathalijn/0000-0002-8212-7632; Hol, Elly M/0000-0001-5604-2603; ovaa, huib/0000-0002-0068-054X; Berkers, Celia/0000-0003-0746-8565; Fischer, David/0000-0002-6690-0197	Hersenstichting Nederland [13F05.08]; Internationale Stichting Alzheimer Onderzoek [04511]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS042803] Funding Source: NIH RePORTER	Hersenstichting Nederland; Internationale Stichting Alzheimer Onderzoek; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This research was supported by the Hersenstichting Nederland (13F05.08 to E. M. H.) and the Internationale Stichting Alzheimer Onderzoek (04511 to E. M. H.). We thank J. Rutka ( University of Toronto, Toronto, ON, Canada) for the U343 glioblastoma cells; B. de Leeuw (Erasmus University Medical Center, Rotterdam, The Netherlands) for kindly providing us with U251 and SNB19 glioblastoma cells; O. Meijer ( Leiden University Medical Center, Leiden, The Netherlands) for the Renilla construct; and M. Brenner ( University of Alabama at Birmingham, Birmingham, AL, USA) for the pGfa2-luciferase construct. We thank Lourens Nonkes, Laura Koster, and Rick Wassing for their technical assistance during cell culture, flow cytometric analysis, and animal surgery, respectively.	Auld KL, 2006, MOL CELL, V21, P861, DOI 10.1016/j.molcel.2006.02.020; Bae MH, 2002, BBA-MOL CELL RES, V1592, P163, DOI 10.1016/S0167-4889(02)00310-5; Beck H, 2008, AM J PATHOL, V173, P77, DOI 10.2353/ajpath.2008.070648; BENVENISTE H, 1987, ACTA NEUROPATHOL, V74, P234, DOI 10.1007/BF00688186; Berkers CR, 2007, MOL PHARM, V4, P739, DOI 10.1021/mp0700256; BESNARD F, 1991, J BIOL CHEM, V266, P18877; Bhat KP, 2008, MOL IMMUNOL, V45, P2214, DOI 10.1016/j.molimm.2007.12.001; Blechingberg J, 2007, GLIA, V55, P497, DOI 10.1002/glia.20475; BORRETT D, 1985, BRAIN, V108, P367, DOI 10.1093/brain/108.2.367; Bush KT, 1997, J BIOL CHEM, V272, P9086; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; CHIU FC, 1984, J NEUROCHEM, V42, P166, DOI 10.1111/j.1471-4159.1984.tb09713.x; Choi KS, 2007, FEBS LETT, V581, P4691, DOI 10.1016/j.febslet.2007.08.065; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cotrina ML, 2002, J NEUROSCI RES, V67, P1; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; de Vrij FMS, 2004, PROG NEUROBIOL, V74, P249, DOI 10.1016/j.pneurobio.2004.10.001; Dembla-Rajpal N, 2004, BBA-GENE STRUCT EXPR, V1680, P34, DOI 10.1016/j.bbaexp.2004.08.008; Deroo BJ, 2002, J BIOL CHEM, V277, P20120, DOI 10.1074/jbc.C200173200; Desjardins S, 1997, NEUROBIOL AGING, V18, P37, DOI 10.1016/S0197-4580(96)00206-0; Dijk F, 2004, INVEST OPHTH VIS SCI, V45, P330, DOI 10.1167/iovs.03-0285; Ding QX, 2006, FASEB J, V20, P1055, DOI 10.1096/fj.05-5495com; Ding QX, 2005, J NEUROSCI, V25, P9171, DOI 10.1523/JNEUROSCI.3040-05.2005; Ding QX, 2001, J NEUROCHEM, V77, P1010, DOI 10.1046/j.1471-4159.2001.00302.x; DUCKETT S, 1992, PEDIATR NEUROSURG, V18, P134, DOI 10.1159/000120652; Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7; Fernandez S, 2008, BBA-MOL CELL RES, V1783, P803, DOI 10.1016/j.bbamcr.2007.10.020; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; Gadea A, 2008, J NEUROSCI, V28, P2394, DOI 10.1523/JNEUROSCI.5652-07.2008; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Glenn RJ, 2004, INT J ANTIMICROB AG, V24, P286, DOI 10.1016/j.ijantimicag.2004.02.023; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; GOSS JR, 1991, NEUROBIOL AGING, V12, P165, DOI 10.1016/0197-4580(91)90056-P; Hattori T, 2003, ONCOGENE, V22, P1273, DOI 10.1038/sj.onc.1206204; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hol EM, 2003, MOL PSYCHIATR, V8, P786, DOI 10.1038/sj.mp.4001379; Ingelsson M, 2004, NEUROLOGY, V62, P925, DOI 10.1212/01.WNL.0000115115.98960.37; James AB, 2006, J NEUROSCI, V26, P1624, DOI 10.1523/JNEUROSCI.4199-05.2006; Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200; Josefsberg LBY, 2000, BIOL REPROD, V62, P1270, DOI 10.1095/biolreprod62.5.1270; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Kashon ML, 2004, J ALZHEIMERS DIS, V6, P595; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; Koues OI, 2008, MOL CELL BIOL, V28, P5837, DOI 10.1128/MCB.00535-08; Kubicek GJ, 2009, INT J RADIAT ONCOL, V74, P433, DOI 10.1016/j.ijrobp.2008.08.050; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Larsson A, 2004, NEUROCHEM RES, V29, P2069, DOI 10.1007/s11064-004-6880-2; Lassot I, 2007, MOL CELL, V25, P369, DOI 10.1016/j.molcel.2006.12.020; Layfield R, 2005, ESSAYS BIOCHEM, V41, P157, DOI 10.1042/EB0410157; Lee DY, 2005, CELL, V123, P423, DOI 10.1016/j.cell.2005.08.015; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; Li R, 2005, ANN NEUROL, V57, P310, DOI 10.1002/ana.20406; Lim JH, 2004, BIOCHEM BIOPH RES CO, V318, P868, DOI 10.1016/j.bbrc.2004.04.103; Lindsten K, 2002, J CELL BIOL, V157, P417, DOI 10.1083/jcb.200111034; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; MACK KJ, 1994, MOL BRAIN RES, V23, P73, DOI 10.1016/0169-328X(94)90213-5; Mayer RJ, 1996, ADV EXP MED BIOL, V389, P261; McNaught KSP, 2004, ANN NEUROL, V56, P149, DOI 10.1002/ana.20186; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Miyajima M, 1996, J NEUROSCI RES, V46, P108, DOI 10.1002/(SICI)1097-4547(19961001)46:1<108::AID-JNR13>3.0.CO;2-1; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; NICHOLS NR, 1993, NEUROBIOL AGING, V14, P421, DOI 10.1016/0197-4580(93)90100-P; Nielsen AL, 2002, J BIOL CHEM, V277, P29983, DOI 10.1074/jbc.M112121200; Olanow CW, 2006, MOVEMENT DISORD, V21, P1806, DOI 10.1002/mds.21013; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Perng MD, 2008, MOL BIOL CELL, V19, P4521, DOI 10.1091/mbc.E08-03-0284; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Pihlaja R, 2008, GLIA, V56, P154, DOI 10.1002/glia.20599; Porchet R, 2003, PROTEOMICS, V3, P1476, DOI 10.1002/pmic.200300456; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; Quinlan RA, 2007, EXP CELL RES, V313, P2077, DOI 10.1016/j.yexcr.2007.04.004; Rattan SIS, 1996, EXP GERONTOL, V31, P33, DOI 10.1016/0531-5565(95)02022-5; Riol H, 1997, J NEUROSCI RES, V48, P53; Roelofs RF, 2005, GLIA, V52, P289, DOI 10.1002/glia.20243; Rutka JT, 1999, INT J DEV NEUROSCI, V17, P503, DOI 10.1016/S0736-5748(99)00049-0; Sabbatini A, 1999, MECH AGEING DEV, V108, P165, DOI 10.1016/S0047-6374(99)00008-1; Sakurai K, 2008, J NEUROSCI, V28, P4604, DOI 10.1523/JNEUROSCI.5074-07.2008; Salon ML, 2000, J NEUROSCI RES, V62, P302, DOI 10.1002/1097-4547(20001015)62:2<302::AID-JNR15>3.0.CO;2-L; San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479; SHUAIB A, 1990, NEUROSCI LETT, V112, P149, DOI 10.1016/0304-3940(90)90194-E; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Sprangers R, 2008, BIOCHEMISTRY-US, V47, P6727, DOI 10.1021/bi8005913; Tang GM, 2006, J BIOL CHEM, V281, P38634, DOI 10.1074/jbc.M604942200; Thal DR, 2000, ACTA NEUROPATHOL, V100, P608, DOI 10.1007/s004010000242; van der Meulen JAJ, 2007, CEREB CORTEX, V17, P1444, DOI 10.1093/cercor/bhl057; van Tijn P, 2007, J CELL SCI, V120, P1615, DOI 10.1242/jcs.03438; Vesce S, 2007, INT REV NEUROBIOL, V82, P57, DOI 10.1016/S0074-7742(07)82003-4; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Yoshida T, 1996, NEUROSCI LETT, V215, P107, DOI 10.1016/0304-3940(96)12966-9; Zhu Q, 2007, ONCOGENE, V26, P4199, DOI 10.1038/sj.onc.1210191; Zimmermann J, 2000, ONCOGENE, V19, P2913, DOI 10.1038/sj.onc.1203606	98	32	32	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2710	2726		10.1096/fj.08-127696	http://dx.doi.org/10.1096/fj.08-127696			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19332645	Green Published			2022-12-28	WOS:000268836700039
J	Urich, D; Soberanes, S; Burgess, Z; Chiarella, SE; Ghio, AJ; Ridge, KM; Kamp, DW; Chandel, NS; Mutlu, GM; Budinger, GRS				Urich, Daniela; Soberanes, Saul; Burgess, Zach; Chiarella, Sergio E.; Ghio, Andrew J.; Ridge, Karen M.; Kamp, David W.; Chandel, Navdeep S.; Mutlu, Goekhan M.; Budinger, G. R. Scott			Proapoptotic Noxa is required for particulate matter-induced cell death and lung inflammation	FASEB JOURNAL			English	Article						apoptosis; oxidant; bax; air pollution	LONG-TERM EXPOSURE; AIR-POLLUTION; APOPTOSIS; MORTALITY; PARTICLES; BCL-2; EXPRESSION; TRANSPORT; SCIENCE; PATHWAY	Elevated ambient levels of particulate matter air pollution are associated with excess daily mortality, largely attributable to increased rates of cardiovascular events. We have previously reported that particulate matter induces p53-dependent apoptosis in primary human alveolar epithelial cells. Activation of the intrinsic apoptotic pathway by p53 often requires the transcription of the proapoptotic Bcl-2 proteins Noxa, Puma, or both. In this study, we exposed alveolar epithelial cells in culture and mice to fine particulate matter <2.5 mu m in diameter (PM2.5) collected from the ambient air in Washington, D. C. Exposure to PM2.5 induced apoptosis in primary alveolar epithelial cells from wild-type but not Noxa(-/-) mice. Twenty-four hours after the intratracheal instillation of PM2.5, wildtype mice showed increased apoptosis in the lung and increased levels of mRNA encoding Noxa but not Puma. These changes were associated with increased permeability of the alveolar-capillary membrane and inflammation. All of these findings were absent or attenuated in Noxa(-/-) animals. We conclude that PM2.5-induced cell death requires Noxa both in vitro and in vivo and that Noxa-dependent cell death might contribute to PM-induced alveolar epithelial dysfunction and the resulting inflammatory response.-Urich, D., Soberanes, S., Burgess, Z., Chiarella, S. E., Ghio, A. J., Ridge, K. M., Kamp, D. W., Chandel, N. S., Mutlu, G. M., Budinger, G. R. S. Proapoptotic Noxa is required for particulate matter-induced cell death and lung inflammation. FASEB J. 23, 2055-2064 (2009)	[Urich, Daniela; Soberanes, Saul; Burgess, Zach; Chiarella, Sergio E.; Ridge, Karen M.; Kamp, David W.; Chandel, Navdeep S.; Mutlu, Goekhan M.; Budinger, G. R. Scott] Northwestern Univ, Div Pulm & Crit Care Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Ghio, Andrew J.] US EPA, Res Triangle Pk, NC 27711 USA	Northwestern University; Feinberg School of Medicine; United States Environmental Protection Agency	Budinger, GRS (corresponding author), Northwestern Univ, Div Pulm & Crit Care Med, Feinberg Sch Med, 240 E Huron,McGaw Pavil M300, Chicago, IL 60611 USA.	s-buding@northwestern.edu	Mutlu, Gokhan/HIR-2545-2022	Chiarella, Sergio/0000-0002-0445-4929	NIH [HL071643, GM060472, HL067835, ES015024, ES013995]; The American Lung Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL071643, K08HL067835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013995, R01ES015024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060472] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); The American Lung Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Jacob Sznajder and Dr. David Green for their advice during the performance of these experiments and preparation of the manuscript. This work was supported by NIH grants HL071643, GM060472, HL067835, ES015024, and ES013995, and by The American Lung Association.	ABBEY DE, 1991, ENVIRON HEALTH PERSP, V94, P43, DOI 10.2307/3431291; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Brunelle JK, 2007, MOL CELL BIOL, V27, P1222, DOI 10.1128/MCB.01535-06; Budinger GRS, 2006, P NATL ACAD SCI USA, V103, P4604, DOI 10.1073/pnas.0507604103; Budinger GRS, 2002, J BIOL CHEM, V277, P15654, DOI 10.1074/jbc.M109317200; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Churg A, 2000, ULTRASTRUCT PATHOL, V24, P353; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dominici F, 2003, ENVIRON HEALTH PERSP, V111, P39, DOI 10.1289/ehp.5181; Downs SH, 2007, NEW ENGL J MED, V357, P2338, DOI 10.1056/NEJMoa073625; Hiura TS, 2000, J IMMUNOL, V165, P2703, DOI 10.4049/jimmunol.165.5.2703; Hudson LG, 2007, MOL CARCINOGEN, V46, P257, DOI 10.1002/mc.20257; Huggins FE, 2000, J HAZARD MATER, V74, P1, DOI 10.1016/S0304-3894(99)00195-8; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Katsouyanni K, 2001, EPIDEMIOLOGY, V12, P521, DOI 10.1097/00001648-200109000-00011; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Matute-Bello G, 2004, CLIN DIAGN LAB IMMUN, V11, P358, DOI 10.1128/CDLI.11.2.358-361.2004; Matute-Bello G, 2003, CRIT CARE, V7, P355, DOI 10.1186/cc1861; Matute-Bello G, 2001, AM J PHYSIOL-LUNG C, V281, pL328, DOI 10.1152/ajplung.2001.281.2.L328; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Miller KA, 2007, NEW ENGL J MED, V356, P447, DOI 10.1056/NEJMoa054409; Mutlu GM, 2004, CIRC RES, V94, P1091, DOI 10.1161/01.RES.0000125623.56442.20; Mutlu GM, 2007, J CLIN INVEST, V117, P2952, DOI 10.1172/JCI30639; Mutlu GM, 2006, AM J RESP CELL MOL, V34, P670, DOI 10.1165/rcmb.2005-0329OC; Naik E, 2007, J CELL BIOL, V176, P415, DOI 10.1083/jcb.200608070; Nemmar A, 2003, AM J RESP CRIT CARE, V168, P1366, DOI 10.1164/rccm.200306-801OC; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PINKERTON KE, 1986, LAB INVEST, V55, P688; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Ridge KM, 1997, AM J PHYSIOL-LUNG C, V273, pL246, DOI 10.1152/ajplung.1997.273.1.L246; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Soberanes S, 2006, AM J RESP CRIT CARE, V174, P1229, DOI 10.1164/rccm.200602-203OC; Upadhyay D, 2003, AM J RESP CELL MOL, V29, P180, DOI 10.1165/rcmb.2002-0269OC; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang HL, 2007, J IMMUNOL, V179, P1834, DOI 10.4049/jimmunol.179.3.1834; Wellenius GA, 2005, STROKE, V36, P2549, DOI 10.1161/01.STR.0000189687.78760.47; Wellenius GA, 2005, AM J EPIDEMIOL, V161, P1030, DOI 10.1093/aje/kwi135; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Zhang GH, 1997, BIOTECHNIQUES, V23, P525, DOI 10.2144/97233pf01; Zhao Y, 2009, AM J RESP CELL MOL, V40, P19, DOI 10.1165/rcmb.2008-0105OC	44	28	31	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2055	2064		10.1096/fj.08-114546	http://dx.doi.org/10.1096/fj.08-114546			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19237507	Green Published			2022-12-28	WOS:000268836500006
J	Teng, ACT; Adamo, K; Tesson, F; Stewart, AFR				Teng, Allen C. T.; Adamo, Kristi; Tesson, Frederique; Stewart, Alexandre F. R.			Functional characterization of a promoter polymorphism that drives ACSL5 gene expression in skeletal muscle and associates with diet-induced weight loss	FASEB JOURNAL			English	Article						fatty acid; genetics; MyoD; obesity	TRANSCRIPTION FACTORS; FTO GENE; OBESITY; MYOGENESIS; COFACTOR; MYOD	Diet-induced weight loss is affected by a wide range of factors, including genetic variation. Identifying functional polymorphisms will help to elucidate mechanisms that account for variation in dietary metabolism. Previously, we reported a strong association between a common single nucleotide polymorphism (SNP) rs2419621 (C>T) in the promoter of acyl-CoA synthetase long chain 5 (ACSL5), rapid weight loss in obese Caucasian females, and elevated ACSL5 mRNA levels in skeletal muscle biopsies. Here, we showed by electrophoretic mobility shift assay (EMSA) that the T allele creates a functional cis-regulatory E-box element (CANNTG) that is recognized by the myogenic regulatory factor MyoD. The T allele promoted MyoD-dependent activation of a 1089-base pair ACSL5 promoter fragment in nonmuscle CV1 cells. Differentiation of skeletal myoblasts significantly elevated expression of the ACSL5 promoter. The T allele sustained promoter activity 48 h after differentiation, whereas the C allele showed a significant decline. These results reveal a mechanism for elevated transcription of ACSL5 in skeletal muscle of carriers of the rs2419621(T) allele, associated with more rapid diet-induced weight loss. Natural selection favoring promoter polymorphisms that reduced expression of catabolic genes in skeletal muscle likely accounts for the resistance of obese individuals to dietary intervention.-Teng, A. C., Adamo, K., Tesson, F., Stewart, A. F. R. Functional characterization of a promoter polymorphism that drives ACSL5 gene expression in skeletal muscle and associates with diet-induced weight loss. FASEB J. 23, 1705-1709 (2009)	[Adamo, Kristi; Tesson, Frederique] Univ Ottawa, Inst Heart, Lab Genet Cardiac Dis, Ottawa, ON K1Y 4W7, Canada; [Teng, Allen C. T.; Tesson, Frederique; Stewart, Alexandre F. R.] Univ Ottawa, Fac Med, Program Human & Mol Genet, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4W7, Canada; [Teng, Allen C. T.; Adamo, Kristi; Tesson, Frederique; Stewart, Alexandre F. R.] John & Jennifer Ruddy Canadian Cardiovasc Genet C, Ottawa, ON, Canada; [Adamo, Kristi] Childrens Hosp Eastern Ontario, Res Inst, Healthy Act Living & Obes Res Grp, Chalmers Res Grp, Ottawa, ON K1H 8L1, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario	Tesson, F (corresponding author), Univ Ottawa, Inst Heart, Lab Genet Cardiac Dis, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.	ftesson@ottawaheart.ca; astewart@ottawaheart.ca	Stewart, Alexandre F.R./A-5677-2011; Tesson, Frederique/A-3218-2013	Stewart, Alexandre/0000-0003-2673-9164; Adamo, Kristi/0000-0001-7925-1889	Canadian Institutes of Health Research (CIHR)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	We thank N. Mikhael and M. Belanger for plasmid construction. A.F.R.S. and F.T. are funded by the Canadian Institutes of Health Research (CIHR). We also thank Dr. S. Dandona for reviewing the manuscript.	Adamo KB, 2007, OBESITY, V15, P1068, DOI 10.1038/oby.2007.630; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Cecil JE, 2008, NEW ENGL J MED, V359, P2558, DOI 10.1056/NEJMoa0803839; Chen HH, 2004, GENESIS, V39, P273, DOI 10.1002/gene.20055; Dodou E, 2003, MECH DEVELOP, V120, P1021, DOI 10.1016/S0925-4773(03)00178-3; Donoviel DB, 1996, MOL CELL BIOL, V16, P1649; Haupt A, 2008, OBESITY, V16, P1969, DOI 10.1038/oby.2008.283; Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; Mashek DG, 2006, J BIOL CHEM, V281, P945, DOI 10.1074/jbc.M507646200; Mashek DG, 2006, J LIPID RES, V47, P2004, DOI 10.1194/jlr.M600150-JLR200; Muller TD, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-85; Poirier P, 2006, ARTERIOSCL THROM VAS, V26, P968, DOI 10.1161/01.ATV.0000216787.85457.f3; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SKERJANC IS, 1994, DEV BIOL, V163, P125, DOI 10.1006/dbio.1994.1128; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WILLIG TN, 1993, DEV MED CHILD NEUROL, V35, P1074, DOI 10.1111/j.1469-8749.1993.tb07925.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Yamashita Y, 2000, ONCOGENE, V19, P5919, DOI 10.1038/sj.onc.1203981; Zhou Y, 2007, ARTERIOSCL THROM VAS, V27, P2198, DOI 10.1161/ATVBAHA.107.148429; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	22	19	21	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1705	1709		10.1096/fj.08-120998	http://dx.doi.org/10.1096/fj.08-120998			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19218499	Green Accepted			2022-12-28	WOS:000266652400010
J	Kara, FM; Chitu, V; Sloane, J; Axelrod, M; Fredholm, BB; Stanley, ER; Cronstein, BN				Kara, Firas M.; Chitu, Violeta; Sloane, Jennifer; Axelrod, Matthew; Fredholm, Bertil B.; Stanley, E. Richard; Cronstein, Bruce N.			Adenosine A(1) receptors (A(1)Rs) play a critical role in osteoclast formation and function	FASEB JOURNAL			English	Article						P1 receptors; osteoporosis	NF-KAPPA-B; SMOOTH-MUSCLE-CELLS; DEFECTIVE INTERLEUKIN-1; BONE-RESORPTION; ION CHANNELS; K+ CHANNELS; RELEASE; ACTIVATION; DIFFERENTIATION; PRECURSORS	Adenosine regulates a wide variety of physiological processes via interaction with one or more G-protein-coupled receptors (A(1)R, A(2A)R, A(2B)R, and A(3)R). Because A(1)R occupancy promotes fusion of human monocytes to form giant cells in vitro, we determined whether A(1)R occupancy similarly promotes osteoclast function and formation. Bone marrow cells (BMCs) were harvested from C57Bl/6 female mice or A(1)R-knockout mice and their wild-type (WT) littermates and differentiated into osteoclasts in the presence of colony stimulating factor-1 and receptor activator of NF-kappa B ligand in the presence or absence of the A(1)R antagonist 1,3-dipropyl-8-cyclopentyl xanthine (DPCPX). Osteoclast morphology was analyzed in tartrate-resistant acid phosphatase or F-actin-stained samples, and bone resorption was evaluated by toluidine blue staining of dentin. BMCs from A(1)R-knockout mice form fewer osteoclasts than BMCs from WT mice, and the A(1)R antagonist DPCPX inhibits osteoclast formation (IC50 = 1 nM), with altered morphology and reduced ability to resorb bone. A(1)R blockade increased ubiquitination and degradation of TRAF6 in RAW264.7 cells induced to differentiate into osteoclasts. These studies suggest a critical role for adenosine in bone homeostasis via interaction with adenosine A(1)R and further suggest that A(1)R may be a novel pharmacologic target to prevent the bone loss associated with inflammatory diseases and menopause.-Kara, F. M., Chitu, V., Sloane, J., Axelrod, M., Fredholm, B. B., Stanley, R., Cronstein, B. N. Adenosine A(1) receptors (A(1)Rs) play a critical role in osteoclast formation and function. FASEB J. 24, 2325-2333 (2010). www.fasebj.org	[Kara, Firas M.; Sloane, Jennifer; Axelrod, Matthew; Cronstein, Bruce N.] NYU, Sch Med, Div Clin Pharmacol, Dept Med, New York, NY 10016 USA; [Chitu, Violeta; Stanley, E. Richard] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10467 USA; [Fredholm, Bertil B.] Karolinska Inst, Dept Physiol, S-10401 Stockholm, Sweden; [Fredholm, Bertil B.] Karolinska Inst, Dept Pharmacol, S-10401 Stockholm, Sweden	New York University; Yeshiva University; Albert Einstein College of Medicine; Karolinska Institutet; Karolinska Institutet	Cronstein, BN (corresponding author), NYU, Sch Med, Div Clin Pharmacol, Dept Med, 550 1st Ave,NBV16N1, New York, NY 10016 USA.	cronsb01@med.nyu.edu	Cronstein, Bruce N/D-4678-2011; Stanley, Evan R/J-9154-2013	Cronstein, Bruce N/0000-0002-4295-7383; Stanley, Evan R/0000-0002-2910-2065; Chitu, Violeta/0000-0001-6641-1564	U.S. National Institutes of Health [AR54897, AR41911, AA13336, RO1 CA25604, K01 AR054486-02]; NYU-HHC Clinical and Translational Science Institute [UL1RR029893]; New York Community Trust; Albert Einstein College of Medicine Cancer Center [P30 CA13330]; Kaplan Cancer Center of New York University School of Medicine; NATIONAL CANCER INSTITUTE [R37CA026504, P30CA013330, R01CA032551] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR054486, R01AR041911, R01AR054897, P30AR046121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013336] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NYU-HHC Clinical and Translational Science Institute; New York Community Trust; Albert Einstein College of Medicine Cancer Center; Kaplan Cancer Center of New York University School of Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	The authors thank Dr. Kevin McHugh (Beth Israel Deaconess Medical Center, Boston, MA, USA) for providing the RAW264.7 cell line. This work was supported by grants from the U.S. National Institutes of Health (AR54897, AR41911, and AA13336 to B.N.C.; RO1 CA25604 to E. R. S.; and K01 AR054486-02 to V. C.), the NYU-HHC Clinical and Translational Science Institute (UL1RR029893), a New York Community Trust blood diseases grant (V. C.), the Albert Einstein College of Medicine Cancer Center (P30 CA13330; to E. R. S.), and the Kaplan Cancer Center of New York University School of Medicine. In addition, the Musculoskeletal Repair and Regeneration Core Center at the Hospital for Special Surgery (AR046121) provided technical assistance. B.N.C. holds or has filed applications for patents on the use of adenosine A<INF>2A</INF>R agonists to promote wound healing and use of A<INF>2A</INF>R antagonists to inhibit fibrosis; use of adenosine A<INF>1</INF>R antagonists to treat osteoporosis and other diseases of bone; use of adenosine A<INF>1</INF>R and A<INF>2B</INF>R antagonists to treat fatty liver; and use of adenosine A<INF>2A</INF>R agonists to prevent prosthesis loosening. Consultancies (within past 2 yr): King Pharmaceutical (licensee of patents on wound healing and fibrosis above), CanFite Biopharmaceuticals, Savient Pharmaceuticals, Bristol-Myers Squibb, Roche Pharmaceuticals, Cellzome, Tap (Takeda) Pharmaceuticals, Prometheus Laboratories, Regeneron (Westat, DSMB), Sepracor, Amgen, Endocyte, Protalex, Allos, Inc., Combinatorx, Kyowa Hakka. Honoraria/speaker bureaus: Tap (Takeda) Pharmaceuticals. Stock: CanFite Biopharmaceuticals, received for membership on Scientific Advisory Board.	AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Baron R, 1995, ACTA ORTHOP SCAND, V66, P66, DOI 10.3109/17453679509157650; BERNE RM, 1985, ACTA MED SCAND, P9; Blay J, 1997, CANCER RES, V57, P2602; BORST MM, 1991, CIRC RES, V68, P797, DOI 10.1161/01.RES.68.3.797; Bosche LI, 2003, J PHYSIOL-LONDON, V550, P707, DOI 10.1113/jphysiol.2003.041962; Brubaker KD, 1999, J BONE MINER RES, V14, P1861, DOI 10.1359/jbmr.1999.14.11.1861; CHAMBERS TJ, 1993, P NATL ACAD SCI USA, V90, P5578, DOI 10.1073/pnas.90.12.5578; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; Chitu V, 2005, MOL BIOL CELL, V16, P2947, DOI 10.1091/mbc.e04-10-0914; DART C, 1993, J PHYSIOL-LONDON, V471, P767, DOI 10.1113/jphysiol.1993.sp019927; DEUSSEN A, 1986, PFLUG ARCH EUR J PHY, V406, P608, DOI 10.1007/BF00584028; DUNWIDDIE TV, 1989, J PHARMACOL EXP THER, V249, P31; Evans BAJ, 2006, J BONE MINER RES, V21, P228, DOI 10.1359/JBMR.051021; Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194; Finkelstein JS, 2000, CECIL TXB MED, P1366; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Fredholm BB, 2000, N-S ARCH PHARMACOL, V362, P364, DOI 10.1007/s002100000313; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Fu Y, 2006, CIRC RES, V98, P659, DOI 10.1161/01.RES.0000207497.50477.60; Galvin RJS, 1999, BIOCHEM BIOPH RES CO, V265, P233, DOI 10.1006/bbrc.1999.1632; Granholm S, 2007, J ENDOCRINOL, V195, P415, DOI 10.1677/JOE-07-0338; Heymann D, 1998, CYTOKINE, V10, P155, DOI 10.1006/cyto.1997.0277; Johansson B, 2001, P NATL ACAD SCI USA, V98, P9407, DOI 10.1073/pnas.161292398; Jones SJ, 1997, BONE, V21, P393, DOI 10.1016/S8756-3282(97)00174-9; Kara FM, 2010, ARTHRITIS RHEUM-US, V62, P534, DOI 10.1002/art.27219; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Khoa ND, 2006, MOL PHARMACOL, V69, P1311, DOI 10.1124/mol.105.016857; Khoa ND, 2003, J IMMUNOL, V171, P3991, DOI 10.4049/jimmunol.171.8.3991; Khoa ND, 2001, J IMMUNOL, V167, P4026, DOI 10.4049/jimmunol.167.7.4026; Kim EY, 1997, AM J PHYSIOL-HEART C, V272, pH325, DOI 10.1152/ajpheart.1997.272.1.H325; Komarova SV, 2003, CALCIFIED TISSUE INT, V73, P265, DOI 10.1007/s00223-002-1051-4; Komarova SV, 2001, CURR PHARM DESIGN, V7, P637, DOI 10.2174/1381612013397799; LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817; Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006-291X(03)00695-8; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; Liu AMF, 2004, J BIOL CHEM, V279, P53196, DOI 10.1074/jbc.M410196200; LOHSE MJ, 1987, N-S ARCH PHARMACOL, V336, P204, DOI 10.1007/BF00165806; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; MADARA JL, 1993, J CLIN INVEST, V91, P2320, DOI 10.1172/JCI116462; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; MEININGER CJ, 1988, AM J PHYSIOL, V255, pH554, DOI 10.1152/ajpheart.1988.255.3.H554; Merrill JT, 1997, ARTHRITIS RHEUM, V40, P1308, DOI 10.1002/1529-0131(199707)40:7<1308::AID-ART16>3.0.CO;2-M; MOONGA BS, 1992, J ENDOCRINOL, V132, P241, DOI 10.1677/joe.0.1320241; Morabito L, 1998, J CLIN INVEST, V101, P295, DOI 10.1172/JCI1554; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; Peng Z, 2009, J CLIN INVEST, V119, P582, DOI 10.1172/JCI37409; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04-06-0522; Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takagi H, 1996, INVEST OPHTH VIS SCI, V37, P1311; TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; TUCKER AL, 1993, CARDIOVASC RES, V27, P62, DOI 10.1093/cvr/27.1.62; VAANANEN HK, 1995, J CELL SCI, V108, P2729; Wani MR, 1999, ENDOCRINOLOGY, V140, P1927, DOI 10.1210/en.140.4.1927; Weidema AF, 2000, BONE, V27, P5, DOI 10.1016/S8756-3282(00)00287-8; Weidema AF, 1997, J PHYSIOL-LONDON, V503, P303, DOI 10.1111/j.1469-7793.1997.303bh.x; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yang M, 2001, J IMMUNOL, V166, P6885, DOI 10.4049/jimmunol.166.11.6885; Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756-3282(99)00121-0; Ye RD, 2001, J LEUKOCYTE BIOL, V70, P839	66	62	64	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2325	2333		10.1096/fj.09-147447	http://dx.doi.org/10.1096/fj.09-147447			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20181934	Green Published			2022-12-28	WOS:000279343600019
J	Rom, S; Rom, I; Passiatore, G; Pacifici, M; Radhakrishnan, S; Del Valle, L; Pina-Oviedo, S; Khalili, K; Eletto, D; Peruzzi, F				Rom, Slava; Rom, Inna; Passiatore, Giovanni; Pacifici, Marco; Radhakrishnan, Sujatha; Del Valle, Luis; Pina-Oviedo, Sergio; Khalili, Kamel; Eletto, Davide; Peruzzi, Francesca			CCL8/MCP-2 is a target for mir-146a in HIV-1-infected human microglial cells	FASEB JOURNAL			English	Article						microRNA; chronic inflammation; brain	CELLULAR MICRORNA MIR-146A; NORMAL IMMUNE FUNCTION; KAPPA-B; CHEMOATTRACTANT PROTEIN-1; HUMAN NEURONS; HUMAN CANCERS; HUMAN BRAIN; HIV-1 TAT; EXPRESSION; DISEASE	MicroRNA-mediated regulation of gene expression appears to be involved in a variety of cellular processes, including development, differentiation, proliferation, and apoptosis. Mir-146a is thought to be involved in the regulation of the innate immune response, and its expression is increased in tissues associated with chronic inflammation. Among the predicted gene targets for mir-146a, the chemokine CCL8/MCP-2 is a ligand for the CCR5 chemokine receptor and a potent inhibitor of CD4/CCR5-mediated HIV-1 entry and replication. In the present study, we have analyzed changes in the expression of mir-146a in primary human fetal microglial cells upon infection with HIV-1 and found increased expression of mir-146a. We further show that CCL8/MCP-2 is a target for mir-146a in HIV-1 infected microglia, as overexpression of mir-146a prevented HIV-induced secretion of MCP-2 chemokine. The clinical relevance of our findings was evaluated in HIV-encephalitis (HIVE) brain samples in which decreased levels of MCP-2 and increased levels of mir-146a were observed, suggesting a role for mir-146a in the maintenance of HIV-mediated chronic inflammation of the brain.-Rom, S., Rom, I., Passiatore, G., Pacifici, M., Radhakrishnan, S., Del Valle, L., Pina-Oviedo, S., Khalili, K., Eletto, D., Peruzzi, F. CCL8/MCP-2 is a target for mir-146a in HIV-1 infected human microglial cells. FASEB J. 24, 2292-2300 (2010). www.fasebj.org	[Rom, Slava; Rom, Inna; Passiatore, Giovanni; Pacifici, Marco; Radhakrishnan, Sujatha; Del Valle, Luis; Pina-Oviedo, Sergio; Khalili, Kamel; Peruzzi, Francesca] Temple Univ, Sch Med, Dept Neurosci, Philadelphia, PA 19122 USA; [Rom, Slava; Rom, Inna; Passiatore, Giovanni; Pacifici, Marco; Radhakrishnan, Sujatha; Del Valle, Luis; Pina-Oviedo, Sergio; Khalili, Kamel; Peruzzi, Francesca] Temple Univ, Sch Med, Ctr Neurovirol, Philadelphia, PA 19122 USA; [Eletto, Davide] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Eletto, Davide] Univ Penn, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Peruzzi, F (corresponding author), Temple Univ, Sch Med, Dept Neurosci, 1900 N 12th St, Philadelphia, PA 19122 USA.	fperuzzi@temple.edu	Del Valle, Luis/J-4085-2015; Oviedo, Sergio Pina/AAV-8814-2021; Rom, Slava/AAF-6872-2020; Peruzzi, Francesca/M-9804-2014	Del Valle, Luis/0000-0003-3894-9206; Rom, Slava/0000-0002-1050-1955	NIH [MH071162, MH079751];  [P01 NS30916]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH079751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030916] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Martyn White for editorial assistance. The work was supported by NIH grants MH071162 and MH079751, awarded to F. P. The parts of this work related to HIV-1 infection and immunohistochemistry were partially supported by grant P01 NS30916, awarded to L. D. V., S. A., and K. K. The authors thank Susan Morgello (Director of the Manhattan Brain Bank at Mt. Sinai School of Medicine, New York, NY, USA) for providing HIVE clinical samples.	Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bagasra O, 2004, J MOL HISTOL, V35, P545; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; Borgmann Kathleen, 2005, Methods Mol Biol, V304, P49; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cameron JE, 2008, J VIROL, V82, P1946, DOI 10.1128/JVI.02136-07; Care A, 2007, NAT MED, V13, P613, DOI 10.1038/nm1582; Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692; Coughlan CM, 2000, NEUROSCIENCE, V97, P591, DOI 10.1016/S0306-4522(00)00024-5; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; D'Aversa TG, 2005, J NEUROSCI RES, V81, P436, DOI 10.1002/jnr.20486; DECOCK B, 1990, BIOCHEM BIOPH RES CO, V167, P904, DOI 10.1016/0006-291X(90)90609-Q; Del Valle L, 2006, FRONT BIOSCI-LANDMRK, V11, P718, DOI 10.2741/1830; Dollard SC, 1995, NEUROPATH APPL NEURO, V21, P518, DOI 10.1111/j.1365-2990.1995.tb01098.x; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Eisenberg I, 2007, P NATL ACAD SCI USA, V104, P17016, DOI 10.1073/pnas.0708115104; Eletto D, 2008, J CELL PHYSIOL, V216, P764, DOI 10.1002/jcp.21452; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; Gu L, 1999, Chem Immunol, V72, P7, DOI 10.1159/000058723; Hansen T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000873; Hariharan M, 2005, BIOCHEM BIOPH RES CO, V337, P1214, DOI 10.1016/j.bbrc.2005.09.183; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hou J, 2009, J IMMUNOL, V183, P2150, DOI 10.4049/jimmunol.0900707; Huppi K, 2007, SEMIN CANCER BIOL, V17, P65, DOI 10.1016/j.semcancer.2006.10.004; Ikeda S, 2007, PHYSIOL GENOMICS, V31, P367, DOI 10.1152/physiolgenomics.00144.2007; Ke XS, 2003, CURR OPIN CHEM BIOL, V7, P516, DOI 10.1016/S1367-5931(03)00075-9; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lukiw WJ, 2008, J BIOL CHEM, V283, P31315, DOI 10.1074/jbc.M805371200; McManus C, 1998, J NEUROIMMUNOL, V86, P20, DOI 10.1016/S0165-5728(98)00002-2; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; Motsch N, 2007, RNA BIOL, V4, P131, DOI 10.4161/rna.4.3.5206; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; Proost P, 1996, J LEUKOCYTE BIOL, V59, P67, DOI 10.1002/jlb.59.1.67; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Sonkoly E, 2008, SEMIN CANCER BIOL, V18, P131, DOI 10.1016/j.semcancer.2008.01.005; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; van der Meer P, 2000, EXP MOL PATHOL, V69, P192, DOI 10.1006/exmp.2000.2336; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; Wang JB, 2006, J NEUROVIROL, V12, P472, DOI 10.1080/13550280601039659; Williams AE, 2008, BIOCHEM SOC T, V36, P1211, DOI 10.1042/BST0361211; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Xiao CC, 2009, CELL, V136, P26, DOI 10.1016/j.cell.2008.12.027; Yang OO, 2002, J INFECT DIS, V185, P1174, DOI 10.1086/339678; Zink MC, 2001, J INFECT DIS, V184, P1015, DOI 10.1086/323478	52	94	97	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2010	24	7					2292	2300		10.1096/fj.09-143503	http://dx.doi.org/10.1096/fj.09-143503			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20181935	Green Published			2022-12-28	WOS:000279343600016
J	Berry, A; Matthews, L; Jangani, M; Plumb, J; Farrow, S; Buchan, N; Wilson, PA; Singh, D; Ray, DW; Donn, RP				Berry, A.; Matthews, L.; Jangani, M.; Plumb, J.; Farrow, S.; Buchan, N.; Wilson, P. A.; Singh, D.; Ray, D. W.; Donn, R. P.			Interferon-inducible factor 16 is a novel modulator of glucocorticoid action	FASEB JOURNAL			English	Article						IFI16; steroid sensitivity; nuclear receptor; inflammation	NF-KAPPA-B; RECEPTOR FUNCTION; DOCKING PROTEIN; UP-REGULATION; GENE; EXPRESSION; SENSITIVITY; TRANSCRIPTION; IFI16; INHIBITION	Previously, we used cDNA expression profiling to identify genes associated with glucocorticoid (Gc) sensitivity. We now identify which of these directly influence Gc action. Interferon-inducible protein 16 (IFI16), bone morphogenetic protein receptor type II (BMPRII), and regulator of G-protein signaling 14 (RGS14) increased Gc transactivation, whereas sialyltransferase 4B (SIAT4B) had a negative effect. Amyloid beta (A4) precursor-protein binding, family B, member 1 (APBB1/Fe65) and neural cell expressed developmentally down-regulated 9 (NEDD9) were without effect. Only IFI16 potentiated Gc repression of NF-kappa B. In addition, IFI16 affected basal expression, and Gc induction of endogenous target genes. IFI16 did not affect glucocorticoid receptor (GR) expression, ligand-dependent repression of GR expression, or the ligand-dependent induction of GR phosphorylation on Ser-211 or Ser-203. Coimmunoprecipitation revealed an interaction, suggesting that IFI16 modulation of GR function is mediated by protein crosstalk. Transfection analysis with GR mutants showed that the ligand-binding domain of GR binds IFI16 and is the target domain for IFI16 regulation. Analysis of human lung sections identified colocalization of GR and IFI16, suggesting a physiologically relevant interaction. We demonstrate that IFI16 is a novel modulator of GR function and show the importance of analyzing variation in Gc sensitivity in humans, using appropriate technology, to drive discovery.-Berry, A., Matthews, L. Jangani, M., Plumb, J., Farrow, S., Buchan, N., Wilson, P. A., Singh, D., Ray, D., W., Donn, R. P. Interferon-inducible factor 16 is a novel modulator of glucocorticoid action. FASEB J. 24, 1700-1713 (2010). www.fasebj.org	[Berry, A.; Jangani, M.; Donn, R. P.] Univ Manchester, Arthrit Res Campaign Epidemiol Unit, Manchester M13 9PT, Lancs, England; [Berry, A.; Matthews, L.] Univ Manchester, Endocrine Sci Res Grp, Manchester Acad Hlth Sci Ctr, Manchester M13 9PT, Lancs, England; [Plumb, J.; Singh, D.] Univ Manchester, S Manchester Univ Hosp Trust, NW Reg Lung Ctr, Manchester M13 9PT, Lancs, England; [Farrow, S.; Buchan, N.; Wilson, P. A.] GlaxoSmithKline Medicines Res Ctr, Stevenage, Herts, England	University of Manchester; University of Manchester; University of Manchester; GlaxoSmithKline	Donn, RP (corresponding author), Univ Manchester, Arthrit Res Campaign Epidemiol Unit, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	david.w.ray@manchester.ac.uk; rachelle.donn@manchester.ac.uk		Ray, David/0000-0002-4739-6773; Donn, Rachelle/0000-0001-6976-9828; Plumb, Jonathan/0000-0002-7877-8053	Biotechnology and Biological Sciences Research Council; Wellcome Trust; University of Manchester; Arthritis Research Campaign [17552]; Medical Research Council; Manchester University; Manchester Academic Health Sciences Centre; National Institute for Health Research Manchester Biomedical Research Centre	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome Trust); University of Manchester; Arthritis Research Campaign(Versus Arthritis); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Manchester University; Manchester Academic Health Sciences Centre; National Institute for Health Research Manchester Biomedical Research Centre(National Institute for Health Research (NIHR))	The authors are grateful for help from Ros Cutts, Peter Woollard, and Ian Keddie. The authors also acknowledge Dr. Jorge Iniguez-Lluhi (University of Michigan Medical School, Ann Arbor, MI, USA) for the kind donation of plasmid and give special thanks to Robert Fernandez (University of Manchester Bioimaging Facility). Bioimaging Facility microscopes used in this study were purchased with grants from the Biotechnology and Biological Sciences Research Council, Wellcome Trust, and University of Manchester Strategic Fund. This work was funded by the Arthritis Research Campaign (grant code 17552) and the Medical Research Council and by a Manchester University Ph.D. studentship award. The Arthritis Research Campaign Epidemiology Unit and Endocrine Research Group Laboratories are supported by the Manchester Academic Health Sciences Centre and by the National Institute for Health Research Manchester Biomedical Research Centre. The authors report no conflicts of interest.	Adcock Ian M, 2005, Proc Am Thorac Soc, V2, P313, DOI 10.1513/pats.200504-035SR; Adcock IM, 1996, AM J RESP CRIT CARE, V154, P771, DOI 10.1164/ajrccm.154.3.8810618; Adcock IM, 2001, IMMUNOL CELL BIOL, V79, P376, DOI 10.1046/j.1440-1711.2001.01025.x; Aksentijevich I, 1997, CELL, V90, P797; Alimirah F, 2006, FEBS LETT, V580, P1659, DOI 10.1016/j.febslet.2006.02.015; Alimirah F, 2007, MOL CANCER RES, V5, P251, DOI 10.1158/1541-7786.MCR-06-0269; ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; Bao JY, 2007, MOL CELL BIOL, V27, P1321, DOI 10.1128/MCB.01280-06; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Cerami EG, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-497; Chriguer RS, 2005, J CLIN ENDOCR METAB, V90, P5978, DOI 10.1210/jc.2005-0067; Donn R, 2007, FASEB J, V21, P402, DOI 10.1096/fj.06-7236com; Doucas V, 2000, P NATL ACAD SCI USA, V97, P11893, DOI 10.1073/pnas.220413297; Fan BJ, 2008, INVEST OPHTH VIS SCI, V49, P1886, DOI 10.1167/iovs.07-0414; Fiorentino L, 2002, J BIOL CHEM, V277, P35333, DOI 10.1074/jbc.M200446200; Franchimont D, 1999, DIGEST DIS SCI, V44, P1208, DOI 10.1023/A:1026644711530; Gariglio M, 2002, J INTERF CYTOK RES, V22, P815, DOI 10.1089/107999002320271413; Gugliesi F, 2005, J LEUKOCYTE BIOL, V77, P820, DOI 10.1189/jlb.0904507; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Huizenga NATM, 1998, J CLIN ENDOCR METAB, V83, P47, DOI 10.1210/jc.83.1.47; Ismaili N, 2005, J BIOL CHEM, V280, P11120, DOI 10.1074/jbc.M500059200; Ismaili N, 2004, ANN NY ACAD SCI, V1024, P86, DOI 10.1196/annals.1321.007; Johnstone RW, 1998, BIOCHEMISTRY-US, V37, P11924, DOI 10.1021/bi981069a; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Kimkong I, 2009, LUPUS, V18, P1066, DOI 10.1177/0961203309106699; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Kino T, 2001, J ENDOCRINOL, V169, P437, DOI 10.1677/joe.0.1690437; Kudrin A, 2006, J BIOL CHEM, V281, P29641, DOI 10.1074/jbc.M601103200; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Law SF, 1996, MOL CELL BIOL, V16, P3327; Lee EJ, 2008, BMB REP, V41, P41, DOI 10.5483/BMBRep.2008.41.1.041; Ma XY, 2003, J BIOL CHEM, V278, P23008, DOI 10.1074/jbc.M302105200; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Mayburd AL, 2006, CLIN CANCER RES, V12, P1820, DOI 10.1158/1078-0432.CCR-05-2149; Min W, 1996, MOL CELL BIOL, V16, P359; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sierra DA, 2002, GENOMICS, V79, P177, DOI 10.1006/geno.2002.6693; Slatore CG, 2009, AM J MED, V122, P472, DOI 10.1016/j.amjmed.2008.09.048; Stevens A, 2004, J CLIN ENDOCR METAB, V89, P892, DOI 10.1210/jc.2003-031235; Stevens A, 2003, MOL ENDOCRINOL, V17, P845, DOI 10.1210/me.2002-0320; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; Szatmary Z, 2004, J BIOL CHEM, V279, P43708, DOI 10.1074/jbc.M406568200; TRAPANI JA, 1994, IMMUNOGENETICS, V40, P415; van der Strate BWA, 2006, AM J RESP CRIT CARE, V173, P751, DOI 10.1164/rccm.200504-594OC; van Rossum EFC, 2004, J CLIN ENDOCR METAB, V89, P4004, DOI 10.1210/jc.2003-031422; van Rossum EFC, 2004, RECENT PROG HORM RES, V59, P333, DOI 10.1210/rp.59.1.333; Vermeer H, 2003, J CLIN ENDOCR METAB, V88, P277, DOI 10.1210/jc.2002-020354; Waters CE, 2004, J ENDOCRINOL, V183, P375, DOI 10.1677/joe.1.05804; Yasukawa Z, 2005, GLYCOBIOLOGY, V15, P827, DOI 10.1093/glycob/cwi068	51	13	14	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1700	1713		10.1096/fj.09-139998	http://dx.doi.org/10.1096/fj.09-139998			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20086048	Green Published, hybrid			2022-12-28	WOS:000278200000008
J	Kostiuk, MA; Keller, BO; Berthiaume, LG				Kostiuk, Morris A.; Keller, Bernd O.; Berthiaume, Luc G.			Palmitoylation of ketogenic enzyme HMGCS2 enhances its interaction with PPAR alpha and transcription at the Hmgcs2 PPRE	FASEB JOURNAL			English	Article						HMG-CoA synthase 2; ketone bodies; mitochondria	PROLIFERATOR-ACTIVATED RECEPTORS; MITOCHONDRIAL 3-HYDROXY-3-METHYLGLUTARYL-COA SYNTHASE; SITE FATTY ACYLATION; PROTEIN PALMITOYLATION; DIABETIC-KETOACIDOSIS; MAMMALIAN-CELLS; ACID; METABOLISM; COA; LOCALIZATION	Excessive liver production of ketone bodies is one of many metabolic complications that can arise from diabetes, and in severe untreated cases, it can result in ketoacidosis, coma, and death. Mitochondrial HMG-CoA synthase (HMGCS2), the rate-limiting enzyme in ketogenesis, has been shown to interact with PPAR alpha and act as a coactivator to up-regulate transcription from the PPRE of its own gene. Although protein palmitoylation is typically a cytosolic process that promotes membrane association, we recently identified 21 palmitoylated proteins in rat liver mitochondria, including HMGCS2. Herein, our data support a mechanism whereby palmitate is first added onto HMGCS2 active site Cys166 and then transacylated to Cys305. Palmitoylation promotes the HMGCS2/PPAR alpha interaction, resulting in transcriptional activation from the Hmgcs2 PPRE. These results, together with the fact that 8 of the 21 palmitoylated mitochondrial proteins that we previously identified have nuclear receptor interacting motifs, demonstrate a novel-and perhaps ubiquitous-role for palmitoylation as a modulator of transcription.-Kostiuk, M. A., Keller, B. O., Berthiaume, L. G. Palmitoylation of ketogenic enzyme HMGCS2 enhances its interaction with PPAR alpha and transcription at the Hmgcs2 PPRE. FASEB J. 24, 1914-1924 (2010). www.fasebj.org	[Kostiuk, Morris A.; Berthiaume, Luc G.] Univ Alberta, Dept Cell Biol, Fac Med & Dent, Edmonton, AB T6G 2H7, Canada; [Keller, Bernd O.] Univ British Columbia, Dept Pathol & Lab Med, Child & Family Res Inst, Vancouver, BC V5Z 1M9, Canada	University of Alberta; Child & Family Research Institute; University of British Columbia	Berthiaume, LG (corresponding author), Univ Alberta, Dept Cell Biol, Fac Med & Dent, 5-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	luc.berthiaume@ualberta.ca		Berthiaume, Luc/0000-0003-0926-059X; Keller, Bernd/0000-0002-6154-5173	Canadian Institutes of Health Research [MOP 81248]; Heart and Stroke Foundation; Province of Alberta graduate scholarship; University of British Columbia's Child and Family Research Institute; Canada Foundation for Innovation; Michael Smith Foundation for Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation(Heart & Stroke Foundation of Canada); Province of Alberta graduate scholarship; University of British Columbia's Child and Family Research Institute; Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research)	This work was funded by Canadian Institutes of Health Research grant MOP 81248 and a Heart and Stroke Foundation grant to L.G.B. M.A.K. held a Province of Alberta graduate scholarship. The authors thank Megan C. Yap for technical assistance. B.O.K. thanks the University of British Columbia's Child and Family Research Institute for an Establishment Award. The authors thank Sheila Innis, Roger Dyer, Jurgen Kast, Jason Rogalski, and Suzanne Perry (University of British Columbia) for access to and help with the mass spectrometric equipment, which is funded through grants from the Canada Foundation for Innovation and the Michael Smith Foundation for Health Research.	BERTHIAUME L, 1994, J BIOL CHEM, V269, P6498; BERTHIAUME L, 1995, METHOD ENZYMOL, V250, P454; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Bizzozero OA, 2001, BBA-PROTEIN STRUCT M, V1545, P278, DOI 10.1016/S0167-4838(00)00291-0; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Casteels K, 2003, REV ENDOCR METAB DIS, V4, P159, DOI 10.1023/A:1022942120000; Corvi MM, 2001, J BIOL CHEM, V276, P45704, DOI 10.1074/jbc.M102766200; Cullingford TE, 2004, PROSTAG LEUKOTR ESS, V70, P253, DOI 10.1016/j.plefa.2003.09.008; Dai YQ, 1999, ANAL CHEM, V71, P1087, DOI 10.1021/ac980684h; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Drisdel RC, 2004, BIOTECHNIQUES, V36, P276, DOI 10.2144/04362RR02; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Eledrisi MS, 2006, AM J MED SCI, V331, P243, DOI 10.1097/00000441-200605000-00002; Fukao T, 2004, PROSTAG LEUKOTR ESS, V70, P243, DOI 10.1016/j.plefa.2003.11.001; Gurevich I, 2007, TOXICOL APPL PHARM, V223, P288, DOI 10.1016/j.taap.2007.05.019; Hegardt FG, 1999, BIOCHEM J, V338, P569, DOI 10.1042/0264-6021:3380569; ISOLA LM, 1995, P NATL ACAD SCI USA, V92, P9866, DOI 10.1073/pnas.92.21.9866; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Kang RJ, 2008, NATURE, V456, P904, DOI 10.1038/nature07605; Kostiuk MA, 2008, FASEB J, V22, P721, DOI 10.1096/fj.07-9199com; Kyrou I, 2006, ANN NY ACAD SCI, V1083, P77, DOI 10.1196/annals.1367.008; Linder ME, 2007, NAT REV MOL CELL BIO, V8, P74, DOI 10.1038/nrm2084; LOWE DM, 1985, BIOCHEM J, V232, P37, DOI 10.1042/bj2320037; LOWE DM, 1985, BIOCHEM J, V227, P591, DOI 10.1042/bj2270591; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Martin BR, 2009, NAT METHODS, V6, P135, DOI [10.1038/NMETH.1293, 10.1038/nmeth.1293]; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Meertens LM, 1998, EMBO J, V17, P6972, DOI 10.1093/emboj/17.23.6972; MIZIORKO HM, 1977, J BIOL CHEM, V252, P1414; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SERRA D, 1993, ARCH BIOCHEM BIOPHYS, V307, P40, DOI 10.1006/abbi.1993.1557; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Soltys BJ, 1996, EXP CELL RES, V222, P16, DOI 10.1006/excr.1996.0003; STUCKI JW, 1989, J BIOL CHEM, V264, P6376; VALERA A, 1994, J BIOL CHEM, V269, P6267; Wolfsdorf J, 2007, PEDIATR DIABETES, V8, P28, DOI 10.1111/j.1399-5448.2007.00224.x; Yang JY, 2005, BIOCHEMISTRY-US, V44, P11903, DOI 10.1021/bi0508082; Yang W, 2010, MOL CELL PROTEOMICS, V9, P54, DOI 10.1074/mcp.M800448-MCP200; Yu ST, 2007, BBA-MOL CELL BIOL L, V1771, P936, DOI 10.1016/j.bbalip.2007.01.008; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X	44	51	54	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2010	24	6					1914	1924		10.1096/fj.09-149765	http://dx.doi.org/10.1096/fj.09-149765			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20124434	Green Published			2022-12-28	WOS:000278200000026
J	Mouillet, JF; Chu, TJ; Nelson, DM; Mishima, T; Sadovsky, Y				Mouillet, Jean-Francois; Chu, Tianjiao; Nelson, D. Michael; Mishima, Takuya; Sadovsky, Yoel			MiR-205 silences MED1 in hypoxic primary human trophoblasts	FASEB JOURNAL			English	Article						placenta; hypoxia; microRNA; 3 '-UTR	RECEPTOR-BINDING PROTEIN; TERM HUMAN TROPHOBLASTS; MICRORNA EXPRESSION; GENE-EXPRESSION; IN-VITRO; HUMAN CYTOTROPHOBLAST; EMBRYONIC-DEVELOPMENT; MEDIATOR COMPLEX; MESSENGER-RNAS; DIFFERENTIATION	Acting through degradation of target mRNA or inhibition of translation, microRNAs (miRNAs) regulate development, differentiation, and cellular response to diverse cues. We analyzed changes in miRNA expression in human placental trophoblasts exposed to hypoxia, which may result from hypoperfusion and placental injury. Using an miRNA microarray screen, confirmed by Northern blot analysis, we defined a set of seven miRNAs (miR-93, miR-205, miR-224, miR-335, miR-424, miR-451, and miR-491) that are differentially regulated in primary trophoblasts exposed to hypoxia. We combined in silico prediction of miRNA targets with gene expression profiling data to identify a series of potential targets for the miRNAs, which were further analyzed using luciferase reporter assays. Among experimentally confirmed targets, we found that the transcriptional coactivator MED1, which plays an important role in placental development, is a target for miR-205. Using gain- and loss-of-function assays, we confirmed that miR-205 interacts with a specific target in the 3'-UTR sequence of MED1 and silences MED1 expression in human trophoblasts exposed to hypoxia, suggesting that miR-205 plays a role in trophoblast injury.-Mouillet, J.-F., Chu, T., Nelson, D. M., Mishima, T., Sadovsky, Y. MiR-205 silences MED1 in hypoxic primary human trophoblasts. FASEB J. 24, 2030-2039 (2010). www.fasebj.org	[Mouillet, Jean-Francois; Chu, Tianjiao; Mishima, Takuya; Sadovsky, Yoel] Univ Pittsburgh, Magee Womens Res Inst, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA; [Sadovsky, Yoel] Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA 15213 USA; [Nelson, D. Michael] Washington Univ, Dept Obstet & Gynecol, St Louis, MO USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL)	Sadovsky, Y (corresponding author), Univ Pittsburgh, Magee Womens Res Inst, Dept Obstet Gynecol & Reprod Sci, 204 Craft Ave, Pittsburgh, PA 15213 USA.	ysadovsky@mwri.magee.edu	Mishima, Takuya/G-1671-2011		National Institutes of Health [R01-HD29190, R21-HD053878, R01-HD45675]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029190, R01HD045675, R21HD053878] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The authors thank Dr. C. H. Graham (Queen's University, Kingston, ON, Canada) for the HTR-8/SVneo cells. The authors also thank Magdalena Jennings and Elena Sadovsky for technical assistance and Lori Rideout for assistance during preparation of the manuscript. The project was supported by grants from the National Institutes of Health (R01-HD29190 to D.M.N; R21-HD053878 and R01-HD45675 to Y.S).	Alsat E, 1996, J CELL PHYSIOL, V168, P346, DOI 10.1002/(SICI)1097-4652(199608)168:2<346::AID-JCP13>3.0.CO;2-1; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Anteby EY, 2005, EUR J OBSTET GYN R B, V119, P27, DOI 10.1016/j.ejogrb.2004.05.014; ARNHOLDT H, 1991, VIRCHOWS ARCH B, V60, P365, DOI 10.1007/BF02899568; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Behm-Ansmant I, 2006, COLD SPRING HARB SYM, V71, P523, DOI 10.1101/sqb.2006.71.013; Belakavadi M, 2006, REV PHYSIOL BIOCH P, V156, P23, DOI 10.1007/s10254-005-0002-7; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benyo DF, 1997, J CLIN ENDOCR METAB, V82, P1582, DOI 10.1210/jc.82.5.1582; Bissonauth V, 2006, DEVELOPMENT, V133, P3429, DOI 10.1242/dev.02526; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Camps C, 2008, CLIN CANCER RES, V14, P1340, DOI 10.1158/1078-0432.CCR-07-1755; Cartwright JE, 2007, ADV EXP MED BIOL, V618, P113; Chakrabarty A, 2007, P NATL ACAD SCI USA, V104, P15144, DOI 10.1073/pnas.0705917104; Chang TC, 2007, ANNU REV GENOM HUM G, V8, P215, DOI 10.1146/annurev.genom.8.080706.092351; Chen B, 2006, J BIOL CHEM, V281, P2764, DOI 10.1074/jbc.M507330200; Chendrimada TP, 2007, NATURE, V447, P823, DOI 10.1038/nature05841; Chiu J, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh172; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crawford SE, 2002, J BIOL CHEM, V277, P3585, DOI 10.1074/jbc.M107995200; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Crosby ME, 2009, CANCER RES, V69, P1221, DOI 10.1158/0008-5472.CAN-08-2516; Dijckmeester WA, 2009, J GASTROINTEST SURG, V13, P846, DOI 10.1007/s11605-009-0799-5; Donker RB, 2007, MOL HUM REPROD, V13, P273, DOI 10.1093/molehr/gam006; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Eulalio A, 2007, GENE DEV, V21, P2558, DOI 10.1101/gad.443107; Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200; Feber A, 2008, J THORAC CARDIOV SUR, V135, P255, DOI 10.1016/j.jtcvs.2007.08.055; FOX H, 1970, AM J OBSTET GYNECOL, V107, P1058, DOI 10.1016/0002-9378(70)90629-0; Frade R, 2000, CANCER RES, V60, P6585; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Genbacev O, 1997, SCIENCE, V277, P1669, DOI 10.1126/science.277.5332.1669; Genbacev O, 1996, J CLIN INVEST, V97, P540, DOI 10.1172/JCI118447; Giannakakis A, 2008, CANCER BIOL THER, V7, P255, DOI 10.4161/cbt.7.2.5297; Gordon DF, 2006, MOL ENDOCRINOL, V20, P1073, DOI 10.1210/me.2005-0115; Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019; GRAHAM CH, 1993, EXP CELL RES, V206, P204, DOI 10.1006/excr.1993.1139; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Guimbellot JS, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-15; Guller S, 2008, LAB INVEST, V88, P1057, DOI 10.1038/labinvest.2008.74; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Huang JC, 2007, NAT METHODS, V4, P1045, DOI 10.1038/nmeth1130; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Iorio MV, 2009, CANCER RES, V69, P2195, DOI 10.1158/0008-5472.CAN-08-2920; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Ito S, 2006, CLIN NEPHROL, V66, P160; Ivan M, 2008, J CELL MOL MED, V12, P1426, DOI 10.1111/j.1582-4934.2008.00398.x; Jauniaux E, 2001, AM J OBSTET GYNECOL, V184, P998, DOI 10.1067/mob.2001.111935; Kingdom JCP, 1997, PLACENTA, V18, P613, DOI 10.1016/S0143-4004(97)90000-X; Kingdom JCP, 1999, ADV EXP MED BIOL, V474, P259; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; Kulshreshtha R, 2008, CELL DEATH DIFFER, V15, P667, DOI 10.1038/sj.cdd.4402310; Kulshreshtha R, 2007, CELL CYCLE, V6, P1426; Lai EC, 2005, CURR BIOL, V15, pR458, DOI 10.1016/j.cub.2005.06.015; Landles C, 2003, MOL ENDOCRINOL, V17, P2418, DOI 10.1210/me.2003-0097; Latronico MVG, 2009, J CARDIOVASC ELECTR, V20, P230, DOI 10.1111/j.1540-8167.2008.01357.x; Lebanony D, 2009, J CLIN ONCOL, V27, P2030, DOI 10.1200/JCO.2008.19.4134; Levy R, 2000, AM J PHYSIOL-CELL PH, V278, pC982, DOI 10.1152/ajpcell.2000.278.5.C982; Li H, 2008, J BIOL CHEM, V283, P13077, DOI 10.1074/jbc.M800604200; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Massabbal E, 2005, MOL REPROD DEV, V71, P299, DOI 10.1002/mrd.20272; Mishima Y, 2006, CURR BIOL, V16, P2135, DOI 10.1016/j.cub.2006.08.086; Nelson DM, 1999, AM J OBSTET GYNECOL, V180, P896, DOI 10.1016/S0002-9378(99)70661-7; Pandey AK, 2009, CELL PHYSIOL BIOCHEM, V23, P221, DOI 10.1159/000218169; Pinheiro J., 2019, NLME LINEAR NONLINEA; Pinheiro J.C., 2000, MIXED EFFECTS MODELS, DOI [10.1007/0-387-22747-4_1, DOI 10.1007/B98882]; Pulkkinen K, 2008, FEBS LETT, V582, P2397, DOI 10.1016/j.febslet.2008.05.048; R Core Team, 2020, R LANG ENV STAT COMP; Reed SE, 2006, J VIROL METHODS, V138, P85, DOI 10.1016/j.jviromet.2006.07.024; RODESCH F, 1992, OBSTET GYNECOL, V80, P283; Roh CR, 2005, PLACENTA, V26, P319, DOI 10.1016/j.placenta.2004.06.013; Ryan D, 2006, MOL VIS, V12, P1175; Schaiff WT, 2005, J CLIN ENDOCR METAB, V90, P4267, DOI 10.1210/jc.2004-2265; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954; Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354; Soleymanlou N, 2005, J CLIN ENDOCR METAB, V90, P4299, DOI 10.1210/jc.2005-0078; Song HS, 2009, BIOCHEM BIOPH RES CO, V388, P400, DOI 10.1016/j.bbrc.2009.08.020; Stumpf M, 2006, P NATL ACAD SCI USA, V103, P18504, DOI 10.1073/pnas.0604494103; Udayakumar TS, 2006, J BIOL CHEM, V281, P14691, DOI 10.1074/jbc.M600163200; Wada O, 2004, ONCOGENE, V23, P6000, DOI 10.1038/sj.onc.1207786; Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Yu J, 2008, P NATL ACAD SCI USA, V105, P19300, DOI 10.1073/pnas.0803992105; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200	92	97	105	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					2030	2039		10.1096/fj.09-149724	http://dx.doi.org/10.1096/fj.09-149724			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20065103	Green Published			2022-12-28	WOS:000278200000037
J	de Marco, MDF; Alejo, A; Hudson, P; Damon, IK; Alcami, A				del Mar Fernandez de Marco, Maria; Alejo, Ali; Hudson, Paul; Damon, Inger K.; Alcami, Antonio			The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon	FASEB JOURNAL			English	Article						immune modulation; cytokine; infection; smallpox; vaccine	VACCINIA VIRUS; IMMUNE EVASION; ALPHA/BETA INTERFERON; POXVIRUS INFECTION; ANTIVIRAL ACTIVITY; HUMAN-COMPLEMENT; III INTERFERONS; BINDING-PROTEIN; HOST RESPONSE; RECEPTOR	Variola virus (VARV) caused smallpox, one of the most devastating human diseases and the first to be eradicated, but its deliberate release represents a dangerous threat. Virulent orthopoxviruses infecting humans, such as monkeypox virus (MPXV), could fill the niche left by smallpox eradication and the cessation of vaccination. However, immunomodulatory activities and virulence determinants of VARV and MPXV remain largely unexplored. We report the molecular characterization of the VARV- and MPXV-secreted type I interferon-binding proteins, which interact with the cell surface after secretion and prevent type I interferon responses. The proteins expressed in the baculovirus system have been purified, and their interferon-binding properties characterized by surface plasmon resonance. The ability of these proteins to inhibit a broad range of interferons was investigated to identify potential adaptation to the human immune system. Furthermore, we demonstrate by Western blot and activity assays the expression of the type I interferon inhibitor during VARV and MPXV infections. These findings are relevant for the design of new vaccines and therapeutics to smallpox and emergent virulent orthopoxviruses because the type I interferon-binding protein is a major virulence factor in animal models, vaccination with this protein induces protective immunity, and its neutralization prevents disease progression.-Fernandez de Marco, M. M., Alejo, A., Hudson, P., Damon, I. K., Alcami, A. The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon. FASEB J. 24, 1479-1488 (2010). www.fasebj.org	[del Mar Fernandez de Marco, Maria; Alcami, Antonio] Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; [Alejo, Ali] Inst Nacl Invest & Tecnol Agr & Alimentaria, Ctr Invest Sanidad Anim, Madrid, Spain; [Hudson, Paul; Damon, Inger K.] Ctr Dis Control & Prevent, Atlanta, GA USA; [Alcami, Antonio] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Instituto Nacional Investigacion Tecnologia Agraria Alimentaria (INIA); Centers for Disease Control & Prevention - USA; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Alcami, A (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, C Nicolas Cabrera,1 Campus Canto Blanco, E-28049 Madrid, Spain.	aalcami@cbm.uam.es	Alejo, Ali/AAF-1477-2020; Alcami, Antonio/F-8512-2015	Alejo, Ali/0000-0002-1613-6063; Alcami, Antonio/0000-0002-3333-6016	Wellcome Trust; European Union; Spanish Ministry of Science and Innovation; MRC [G9800943] Funding Source: UKRI; Medical Research Council [G9800943] Funding Source: researchfish	Wellcome Trust(Wellcome Trust); European Union(European Commission); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank R. Martin for excellent technical assistance and Sylvia Gutierrez Erlandsson for help with microscopy. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This work was funded by the Wellcome Trust and the European Union. A. Alejo was supported by a Ramon y Cajal contract (Spanish Ministry of Science and Innovation). This article is dedicated to the memory of Riccardo Wittek.	Alcami A, 1996, COMP IMMUNOL MICROB, V19, P305, DOI 10.1016/0147-9571(96)00013-6; Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; Alcami A, 2000, J VIROL, V74, P11230, DOI 10.1128/JVI.74.23.11230-11239.2000; Alejo A, 2006, P NATL ACAD SCI USA, V103, P5995, DOI 10.1073/pnas.0510462103; Ank N, 2008, J IMMUNOL, V180, P2474, DOI 10.4049/jimmunol.180.4.2474; Bartlett NW, 2005, J GEN VIROL, V86, P1589, DOI 10.1099/vir.0.80904-0; Biron CA, 1998, SEMIN IMMUNOL, V10, P383, DOI 10.1006/smim.1998.0138; Brunetti CR, 2003, P NATL ACAD SCI USA, V100, P4831, DOI 10.1073/pnas.0737244100; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; COLAMONICI OR, 1995, J BIOL CHEM, V270, P15974, DOI 10.1074/jbc.270.27.15974; DAVIES MV, 1992, J VIROL, V66, P1943, DOI 10.1128/JVI.66.4.1943-1950.1992; Deonarain R, 2000, J VIROL, V74, P3404, DOI 10.1128/JVI.74.7.3404-3409.2000; Di Giulio DB, 2004, LANCET INFECT DIS, V4, P15, DOI 10.1016/S1473-3099(03)00856-9; Dunlop LR, 2003, MICROBES INFECT, V5, P1049, DOI 10.1016/S1286-4579(03)00194-1; Earl PL, 2008, P NATL ACAD SCI USA, V105, P10889, DOI 10.1073/pnas.0804985105; Earl PL, 2004, NATURE, V428, P182, DOI 10.1038/nature02331; Esteban DJ, 2004, J GEN VIROL, V85, P1291, DOI 10.1099/vir.0.79902-0; Huang JY, 2007, P NATL ACAD SCI USA, V104, P9822, DOI 10.1073/pnas.0610352104; Jacobs BL, 2009, ANTIVIR RES, V84, P1, DOI 10.1016/j.antiviral.2009.06.006; Kim M, 2004, J BIOL CHEM, V279, P25838, DOI 10.1074/jbc.M400343200; Mann BA, 2008, J INTERF CYTOK RES, V28, P367, DOI 10.1089/jir.2007.0113; Mordstein M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000151; Nalca A, 2005, CLIN INFECT DIS, V41, P1765, DOI 10.1086/498155; Randall RE, 2008, J GEN VIROL, V89, P1, DOI 10.1099/vir.0.83391-0; Rosengard AM, 2002, P NATL ACAD SCI USA, V99, P8808, DOI 10.1073/pnas.112220499; Rubins KH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002628; Rubins KH, 2004, P NATL ACAD SCI USA, V101, P15190, DOI 10.1073/pnas.0405759101; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Shchelkunov SN, 2001, FEBS LETT, V509, P66, DOI 10.1016/S0014-5793(01)03144-1; SMITH GL, 1991, J GEN VIROL, V72, P511, DOI 10.1099/0022-1317-72-3-511; Smith GL, 2002, NAT REV IMMUNOL, V2, P521, DOI 10.1038/nri845; Smith VP, 2002, J VIROL, V76, P1124, DOI 10.1128/JVI.76.3.1124-1134.2002; Stanford MM, 2007, IMMUNOL CELL BIOL, V85, P93, DOI 10.1038/sj.icb.7100033; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; Takaoka A, 2006, CELL MICROBIOL, V8, P907, DOI 10.1111/j.1462-5822.2006.00716.x; Trindade GDS, 2007, J CLIN MICROBIOL, V45, P1370, DOI 10.1128/JCM.00920-06; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; Verardi PH, 2001, J VIROL, V75, P11, DOI 10.1128/JVI.75.1.11-18.2001; Waibler Z, 2009, J VIROL, V83, P1563, DOI 10.1128/JVI.01617-08; Weaver JR, 2008, IMMUNOL REV, V225, P96, DOI 10.1111/j.1600-065X.2008.00691.x; Xu RH, 2008, J EXP MED, V205, P981, DOI 10.1084/jem.20071854; Yadav VN, 2008, J VIROL, V82, P3283, DOI 10.1128/JVI.01935-07; Zhou ZL, 2007, J VIROL, V81, P7749, DOI 10.1128/JVI.02438-06	45	21	21	3	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1479	1488		10.1096/fj.09-144733	http://dx.doi.org/10.1096/fj.09-144733			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20019241	Green Published, hybrid			2022-12-28	WOS:000277158900020
J	Jeong, BS; Hu, WW; Belyi, V; Rabadan, R; Levine, AJ				Jeong, Byeong-Seon; Hu, Wenwei; Belyi, Vladimir; Rabadan, Raul; Levine, Arnold J.			Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis	FASEB JOURNAL			English	Article						single nucleotide polymorphism; transcription regulation	SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR-SUPPRESSOR PATHWAY; WILD-TYPE P53; CANCER; MDM2; CELL; SUSCEPTIBILITY; HAPLOTYPES; VARIANTS; GROWTH	Human populations contain a functional coding polymorphism (codon 72) in the p53 gene. To explore whether this polymorphism alters the transcriptional pattern of p53-regulated genes, the human isogenic cell lines harboring p53 with either the proline or arginine at codon 72 were employed to activate p53-mediated transcription. Thirty-four p53-regulated genes were assayed for their increased levels of mRNA using quantitative real-time PCR. The largest difference between p53-arginine and p53-proline was found with the PERP gene involved in cell-cell adhesion and apoptosis. The most common set of genes that are transcribed better by the p53-arginine protein than the p53-proline protein was found in the apoptotic function (DR-4, NOXA, PUMA, and PIG-3). LIF, a cytokine that is required for optimal reproductive function, was produced at 2 x higher levels by the p53-arginine than the p53-proline allele. The genes that induced their mRNAs at the highest levels compared to the baseline tended to be synthesized better by the p53-arginine protein than the p53-proline protein. These molecular studies may help to explain the complicated associations observed between this polymorphism and the incidence of some cancers, the longevity of some populations, and the fecundity of different groups.-Jeong, B.-S., Hu, W., Belyi, V., Rabadan, R., Levine, A. J. Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB J. 24, 1347-1353 (2010). www.fasebj.org	[Levine, Arnold J.] Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA; [Jeong, Byeong-Seon; Hu, Wenwei; Levine, Arnold J.] Univ Med & Dent New Jersey, Canc Inst New Jersey, New Brunswick, NJ USA; [Rabadan, Raul] Columbia Univ, Coll Phys & Surg, Dept Biomed Informat, New York, NY USA	Institute for Advanced Study - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Columbia University	Levine, AJ (corresponding author), Inst Adv Study, Sch Nat Sci, Einstein Dr, Princeton, NJ 08540 USA.	alevine@ias.edu	Rabadan, Raul/AAZ-7367-2020	Rabadan, Raul/0000-0001-7946-9255				Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Attardi LD, 2000, GENE DEV, V14, P704; Batchelor E, 2008, MOL CELL, V30, P277, DOI 10.1016/j.molcel.2008.03.016; BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879; BIRGANDER R, 1995, CARCINOGENESIS, V16, P2233, DOI 10.1093/carcin/16.9.2233; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Granja F, 2004, CANCER LETT, V210, P151, DOI 10.1016/j.canlet.2004.01.016; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hu WW, 2008, CELL CYCLE, V7, P848, DOI 10.4161/cc.7.7.5658; Hu WW, 2007, NATURE, V450, P721, DOI 10.1038/nature05993; Hu WW, 2007, CANCER RES, V67, P2757, DOI 10.1158/0008-5472.CAN-06-2656; Ihrie RA, 2005, CELL CYCLE, V4, P873, DOI 10.4161/cc.4.7.1836; Kang HJ, 2009, P NATL ACAD SCI USA, V106, P9761, DOI 10.1073/pnas.0904280106; Karlan BY, 2003, GYNECOL ONCOL, V88, pS11, DOI 10.1006/gyno.2002.6675; Kay C, 2006, REPROD BIOMED ONLINE, V13, P492, DOI 10.1016/S1472-6483(10)60635-9; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Murphy ME, 2006, CELL DEATH DIFFER, V13, P916, DOI 10.1038/sj.cdd.4401907; Orsted DD, 2007, J EXP MED, V204, P1295, DOI 10.1084/jem.20062476; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; Salvioli S, 2005, CELL CYCLE, V4, P1264, DOI 10.4161/cc.4.9.1978; Shi H, 2009, AM J HUM GENET, V84, P534, DOI 10.1016/j.ajhg.2009.03.009; Sjalander A, 1996, CARCINOGENESIS, V17, P1313, DOI 10.1093/carcin/17.6.1313; Strong LC, 2003, GYNECOL ONCOL, V88, pS4, DOI 10.1006/gyno.2002.6673; Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428; van Heemst D, 2005, EXP GERONTOL, V40, P11, DOI 10.1016/j.exger.2004.10.001; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WESTON A, 1994, CARCINOGENESIS, V15, P583, DOI 10.1093/carcin/15.4.583; Wu XF, 2002, JNCI-J NATL CANCER I, V94, P681; Yu X, 2006, CANCER RES, V66, P4795, DOI 10.1158/0008-5472.CAN-05-4579; Yu X, 2009, FEBS J, V276, P2201, DOI 10.1111/j.1742-4658.2009.06949.x; Zhang XM, 2006, HUM MUTAT, V27, P110, DOI 10.1002/humu.20277	44	49	50	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1347	1353		10.1096/fj.09-146001	http://dx.doi.org/10.1096/fj.09-146001			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20019240				2022-12-28	WOS:000277158900008
J	Huppert, J; Closhen, D; Croxford, A; White, R; Kulig, P; Pietrowski, E; Bechmann, I; Becher, B; Luhmann, HJ; Waisman, A; Kuhlmann, CRW				Huppert, Jula; Closhen, Dorothea; Croxford, Andrew; White, Robin; Kulig, Paulina; Pietrowski, Eweline; Bechmann, Ingo; Becher, Burkhard; Luhmann, Heiko J.; Waisman, Ari; Kuhlmann, Christoph R. W.			Cellular mechanisms of IL-17-induced blood-brain barrier disruption	FASEB JOURNAL			English	Article						multiple sclerosis; neuroinflammation; reactive oxygen species	CENTRAL-NERVOUS-SYSTEM; LIGHT-CHAIN KINASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MICROVESSEL ENDOTHELIAL-CELLS; MULTIPLE-SCLEROSIS LESIONS; SPHINGOSINE 1-PHOSPHATE; MEDICAL PROGRESS; FREE-RADICALS; T-CELL; IL-17	Recently T-helper 17 (Th17) cells were demonstrated to disrupt the blood-brain barrier (BBB) by the action of IL-17A. The aim of the present study was to examine the mechanisms that underlie IL-17A-induced BBB breakdown. Barrier integrity was analyzed in the murine brain endothelial cell line bEnd. 3 by measuring the electrical resistance values using electrical call impedance sensing technology. Furthermore, in-cell Western blots, fluorescence imaging, and monocyte adhesion and transendothelial migration assays were performed. Experimental autoimmune encephalomyelitis (EAE) was induced in C57BL/6 mice. IL-17A induced NADPH oxidase-or xanthine oxidase-dependent reactive oxygen species (ROS) production. The resulting oxidative stress activated the endothelial contractile machinery, which was accompanied by a down-regulation of the tight junction molecule occludin. Blocking either ROS formation or myosin light chain phosphorylation or applying IL-17A-neutralizing antibodies prevented IL-17A-induced BBB disruption. Treatment of mice with EAE using ML-7, an inhibitor of the myosin light chain kinase, resulted in less BBB disruption at the spinal cord and less infiltration of lymphocytes via the BBB and subsequently reduced the clinical characteristics of EAE. These observations indicate that IL-17A accounts for a crucial step in the development of EAE by impairing the integrity of the BBB, involving augmented production of ROS.-Huppert, J., Closhen, D., Croxford, A., White, R., Kulig, P., Pietrowski, E., Bechmann, I., Becher, B., Luhmann, H. J., Waisman, A., Kuhlmann, C. R. W. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J. 24, 1023-1034 (2010). www.fasebj.org	[Kuhlmann, Christoph R. W.] Johannes Gutenberg Univ Mainz, Inst Physiol & Pathophysiol, Univ Med Ctr, D-55131 Mainz, Germany; [Huppert, Jula; Croxford, Andrew; Waisman, Ari; Kuhlmann, Christoph R. W.] Johannes Gutenberg Univ Mainz, Dept Med 1, D-55131 Mainz, Germany; [Kulig, Paulina; Becher, Burkhard] Univ Zurich Hosp, Dept Pathol, Inst Expt Immunol, CH-8091 Zurich, Switzerland; [Bechmann, Ingo] Univ Leipzig, Inst Anat, Leipzig, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Zurich; University Zurich Hospital; Leipzig University	Kuhlmann, CRW (corresponding author), Johannes Gutenberg Univ Mainz, Inst Physiol & Pathophysiol, Univ Med Ctr, Duesbergweg 6, D-55131 Mainz, Germany.	waisman@uni-mainz.de; kuhlma@uni-mainz.de	Becher, Burkhard/ABE-4225-2020; Waisman, Ari/C-7383-2015; Luhmann, Heiko J./N-8797-2019	Becher, Burkhard/0000-0002-1541-7867; Waisman, Ari/0000-0003-4304-8234; Luhmann, Heiko J./0000-0002-7934-8661	Interdisziplinarer Forschungsschwerpunkt Neurowissenschaften; Hertie Foundation; Deutsche Forschungsgemeinschaft [SFB TR52/C2]	Interdisziplinarer Forschungsschwerpunkt Neurowissenschaften; Hertie Foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the Interdisziplinarer Forschungsschwerpunkt Neurowissenschaften at the University of Mainz (C.R.W.K., H.L., and A.W.), by the Hertie Foundation (C.R.W.K.and A.W.), by Deutsche Forschungsgemeinschaft grant SFB TR52/C2 (A.W.), and by funds from the Boehringer Ingelheim Stiftung (A.W.).Parts of this work represent partial fulfillment of the requirements for the Ph.D.thesis of J.H.	Afonso PV, 2007, J IMMUNOL, V179, P2576, DOI 10.4049/jimmunol.179.4.2576; Benton RL, 2008, J CEREBR BLOOD F MET, V28, P1771, DOI 10.1038/jcbfm.2008.76; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Brown RC, 2007, BRAIN RES, V1130, P17, DOI 10.1016/j.brainres.2006.10.083; Cayrol R, 2008, NAT IMMUNOL, V9, P137, DOI 10.1038/ni1551; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; Floris S, 2004, BRAIN, V127, P616, DOI 10.1093/brain/awh068; Frohman EM, 2006, NEW ENGL J MED, V354, P942, DOI 10.1056/NEJMra052130; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Haak S, 2009, J CLIN INVEST, V119, P61, DOI 10.1172/JCI35997; Haorah J, 2005, ALCOHOL CLIN EXP RES, V29, P999, DOI 10.1097/01.ALC.0000166944.79914.0A; Haorah J, 2008, GLIA, V56, P78, DOI 10.1002/glia.20596; Hofstetter HH, 2005, CELL IMMUNOL, V237, P123, DOI 10.1016/j.cellimm.2005.11.002; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Koch M, 2006, J NEUROL, V253, P483, DOI 10.1007/s00415-005-0037-3; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Kuhlmann CRW, 2007, J NEUROCHEM, V102, P501, DOI 10.1111/j.1471-4159.2007.04506.x; Kuhlmann CRW, 2009, STROKE, V40, P1458, DOI 10.1161/STROKEAHA.108.535930; Lagrange P, 1999, FREE RADICAL BIO MED, V27, P667, DOI 10.1016/S0891-5849(99)00112-4; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lubberts E, 2001, J IMMUNOL, V167, P1004, DOI 10.4049/jimmunol.167.2.1004; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; Minagar A, 2003, MULT SCLER J, V9, P540, DOI 10.1191/1352458503ms965oa; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; Prat A, 2002, ARCH NEUROL-CHICAGO, V59, P391, DOI 10.1001/archneur.59.3.391; Reijerkerk A, 2006, FASEB J, V20, P2550, DOI 10.1096/fj.06-6099fje; Rohn TA, 2006, EUR J IMMUNOL, V36, P2857, DOI 10.1002/eji.200636658; ROUVIER E, 1993, J IMMUNOL, V150, P5445; Schreibelt G, 2008, FREE RADICAL BIO MED, V45, P256, DOI 10.1016/j.freeradbiomed.2008.03.024; Schreibelt G, 2007, FASEB J, V21, P3666, DOI 10.1096/fj.07-8329com; Schreibelt G, 2006, J IMMUNOL, V177, P2630, DOI 10.4049/jimmunol.177.4.2630; STEFFEN BJ, 1994, AM J PATHOL, V145, P189; Tzartos JS, 2008, AM J PATHOL, V172, P146, DOI 10.2353/ajpath.2008.070690; Uyttenhove C, 2006, EUR J IMMUNOL, V36, P2868, DOI 10.1002/eji.200636662; van Horssen J, 2008, FREE RADICAL BIO MED, V45, P1729, DOI 10.1016/j.freeradbiomed.2008.09.023; Verin AD, 2000, J CELL BIOCHEM, V79, P113, DOI 10.1002/1097-4644(2000)79:1<113::AID-JCB110>3.0.CO;2-9; Volk T, 2000, MOL CELL BIOCHEM, V206, P105, DOI 10.1023/A:1007059616914; Wong CK, 2000, LUPUS, V9, P589, DOI 10.1191/096120300678828703; Wong D, 2007, J NEUROIMMUNOL, V184, P136, DOI 10.1016/j.jneuroim.2006.12.003; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404	41	310	323	3	58	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1023	1034		10.1096/fj.09-141978	http://dx.doi.org/10.1096/fj.09-141978			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19940258				2022-12-28	WOS:000276462300010
J	Pulkkinen, V; Bruce, S; Rintahaka, J; Hodgson, U; Laitinen, T; Alenius, H; Kinnula, VL; Myllarniemi, M; Matikainen, S; Kere, J				Pulkkinen, Ville; Bruce, Sara; Rintahaka, Johanna; Hodgson, Ulla; Laitinen, Tarja; Alenius, Harri; Kinnula, Vuokko L.; Myllarniemi, Marjukka; Matikainen, Sampsa; Kere, Juha			ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses	FASEB JOURNAL			English	Article						immunology; interferon; interstitial lung disease; virus	NF-KAPPA-B; EPITHELIAL-CELLS; EXPRESSION; RECOGNITION; INTERFERON; RNA; PHAGOCYTOSIS; ANTIBODIES; VIRUSES; PATHWAY	Viral infections and abnormal host response are thought to cause epithelial injury in idiopathic pulmonary fibrosis (IPF). To understand IPF pathogenesis, we have used overexpression cell models and expression microarrays to discover genes networked with ELMO domain containing 2 (ELMOD2) gene genetically implicated in IPF. The identified pathways were confirmed in vitro, and ELMOD2 protein expression was characterized in tissue samples. Here 303 genes were significantly altered after ELMOD2 transfection of human alveolar epithelial A549 cell line. The enriched pathways were interferon induction, viral response, antigen processing and presentation, and I-/nuclear factor-kappa B signaling. ELMOD2 showed immunoreactivity in macrophages and type II alveolar epithelial cells in normal human lung. In A549 cells, forced expression of ELMOD2 increased type I and type III interferon mRNA expression, and ELMOD2- specific siRNA molecules inhibited expression of these antiviral cytokines in response to Toll- like receptor three (TLR3) activation. In human macrophages silencing of ELMOD2 inhibited TLR3-dependent expression of type I and type III interferon genes. Influenza A virus infection decreased ELMOD2 mRNA expression in A549 cells and macrophages suggesting negative regulation in viral infections. In summary, our results show that TLR3 pathway is dependent on ELMOD2.-Pulkkinen, V., Bruce, S., Rintahaka, J., Hodgson, U., Laitinen, T., Alenius, H., Kinnula, V. L., Myllarniemi, M., Matikainen, S., Kere, J. ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses. FASEB J. 24, 1167-1177 (2010). www.fasebj.org	[Pulkkinen, Ville; Kere, Juha] Univ Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland; [Hodgson, Ulla; Kinnula, Vuokko L.; Myllarniemi, Marjukka] Univ Helsinki, Dept Med, FIN-00014 Helsinki, Finland; Univ Helsinki, Div Pulm Med, FIN-00014 Helsinki, Finland; [Pulkkinen, Ville; Kere, Juha] Folkhalsan Inst Genet, Helsinki, Finland; [Bruce, Sara; Kere, Juha] Karolinska Inst, Dept Biosci & Nutr Novum, Huddinge, Sweden; [Bruce, Sara; Kere, Juha] Karolinska Inst, Clin Res Ctr, Huddinge, Sweden; [Alenius, Harri; Matikainen, Sampsa] Finnish Inst Occupat Hlth, Unit Excellence Immunotoxicol, Helsinki, Finland; [Hodgson, Ulla; Laitinen, Tarja; Kinnula, Vuokko L.; Myllarniemi, Marjukka] Univ Helsinki, Cent Hosp, Div Pulm Med, Helsinki, Finland; [Laitinen, Tarja] Univ Helsinki, Cent Hosp, Res Unit Pulm Dis, Helsinki, Finland; [Laitinen, Tarja] Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Karolinska Institutet; Karolinska Institutet; Finnish Institute of Occupational Health; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	Pulkkinen, V (corresponding author), Univ Helsinki, Dept Med Genet, POB 63, FIN-00014 Helsinki, Finland.	ville.pulkkinen@helsinki.fi	Kere, Juha/AAX-9117-2021; Kere, Juha/A-9179-2008; Matikainen, Sampsa/AAH-8654-2021	Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271; Alenius, Harri/0000-0003-0106-8923; Myllarniemi, L Marjukka/0000-0001-9343-0867	Academy of Finland; Sigrid Juselius Foundation; Jalkanen Foundation; Finnish Anti-Tuberculosis Association Foundation; Swedish Research Council and Heart and Lung Foundation (Sweden); Helsinki University Central Hospital (HUSEVO); Jalmari and Rauha Ahokas Foundation; Finnish Medical Foundation	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Jalkanen Foundation; Finnish Anti-Tuberculosis Association Foundation; Swedish Research Council and Heart and Lung Foundation (Sweden)(Swedish Research Council); Helsinki University Central Hospital (HUSEVO); Jalmari and Rauha Ahokas Foundation; Finnish Medical Foundation	The authors thank Riitta Kankanen, Tiina Marjomaa, and the personnel at the Karolinska Institutes Bioinformatics and Expression Analysis Core Facility for their skillful laboratory work. Professor Ilkka Julkunen (National Institute for Health and Welfare, Helsinki, Finland) is acknowledged for providing the anti-MxA antibodies and Dr. Kaisa Salmenkivi (University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland) for providing normal lung tissue for immunohistochemical stainings. This study has been supported by the Academy of Finland, Sigrid Juselius Foundation, Sirpa and Markku Jalkanen Foundation, Finnish Anti-Tuberculosis Association Foundation, Swedish Research Council and Heart and Lung Foundation (Sweden), Helsinki University Central Hospital (HUSEVO), Jalmari and Rauha Ahokas Foundation, and Finnish Medical Foundation.	AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; *AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00; American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002, AM J RESP CRIT CARE, V165, P277, DOI [DOI 10.1164/AJRCCM.165.2.ATS01, 10.1164/ajrccm.165.2.ats01]; Bowzard JB, 2007, J BIOL CHEM, V282, P17568, DOI 10.1074/jbc.M701347200; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Cote JF, 2007, TRENDS CELL BIOL, V17, P383, DOI 10.1016/j.tcb.2007.05.001; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; DeBakker CD, 2004, CURR BIOL, V14, P2208, DOI 10.1016/j.cub.2004.12.029; EGAN JJ, 1995, THORAX, V50, P1234, DOI 10.1136/thx.50.12.1234; Ferrari F, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-446; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Haller O, 2007, MICROBES INFECT, V9, P1636, DOI 10.1016/j.micinf.2007.09.010; Hodgson U, 2006, AM J HUM GENET, V79, P149, DOI 10.1086/504639; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kawai T, 2007, J BIOCHEM, V141, P137, DOI 10.1093/jb/mvm032; LUNG ML, 1985, LANCET, V1, P889; MANIKA K, 2007, DIFFUSE LUNG DIS, V24, P134; Marshall RP, 2000, THORAX, V55, P143, DOI 10.1136/thorax.55.2.143; Matikainen S, 2006, J VIROL, V80, P3515, DOI 10.1128/JVI.80.7.3515-3522.2006; Meliconi R, 1996, THORAX, V51, P315, DOI 10.1136/thx.51.3.315; Miettinen M, 2001, GENES IMMUN, V2, P349, DOI 10.1038/sj.gene.6363791; Myllarniemi M, 2008, J PATHOL, V214, P456, DOI 10.1002/path.2300; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Rintahaka J, 2008, J IMMUNOL, V180, P1749, DOI 10.4049/jimmunol.180.3.1749; RONNI T, 1993, J IMMUNOL, V150, P1715; Selman Moises, 2006, Proc Am Thorac Soc, V3, P364, DOI 10.1513/pats.200601-003TK; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Stewart JP, 1999, AM J RESP CRIT CARE, V159, P1336, DOI 10.1164/ajrccm.159.4.9807077; Tang YW, 2003, J CLIN MICROBIOL, V41, P2633, DOI 10.1128/JCM.41.6.2633-2640.2003; Tissari J, 2005, J IMMUNOL, V174, P4289, DOI 10.4049/jimmunol.174.7.4289; UEDA T, 1992, AM REV RESPIR DIS, V146, P266, DOI 10.1164/ajrccm/146.1.266; Vannella KM, 2008, FIBROGENESIS TISSUE, V1, DOI 10.1186/1755-1536-1-2; Vendelin J, 2006, HUM MOL GENET, V15, P2923, DOI 10.1093/hmg/ddl234; Yonemaru M, 1997, EUR RESPIR J, V10, P2040, DOI 10.1183/09031936.97.10092040	38	46	49	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1167	1177		10.1096/fj.09-138545	http://dx.doi.org/10.1096/fj.09-138545			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19966137				2022-12-28	WOS:000276462300024
J	Han, JY; Liu, GQ; Profirovic, J; Niu, JX; Voyno-Yasenetskaya, T				Han, Jingyan; Liu, Guoquan; Profirovic, Jasmina; Niu, Jiaxin; Voyno-Yasenetskaya, Tatyana			Zyxin is involved in thrombin signaling via interaction with PAR-1 receptor	FASEB JOURNAL			English	Article						endothelium; G-protein-coupled receptors; actin cytoskeleton; heterotrimeric G proteins	SERUM RESPONSE FACTOR; STIMULATED PHOSPHOPROTEIN FAMILY; HUMAN ENDOTHELIAL-CELLS; STRESS FIBER FORMATION; ACTIN-POLYMERIZATION; FOCAL ADHESIONS; CYTOSKELETAL REORGANIZATION; PROTEIN; ACTIVATION; G-ALPHA(12)	Protease-activated receptor 1 (PAR-1) mediates thrombin signaling in human endothelial cells. As a G-protein-coupled receptor, PAR-1 transmits thrombin signal through activation of the heterotrimeric G proteins, Gi, Gq, and G12/13. In this study, we demonstrated that zyxin, a LIM-domain-containing protein, is involved in thrombin-mediated actin cytoskeleton remodeling and serum response element (SRE)dependent gene transcription. We determined that zyxin binds to the C-terminal domain of PAR-1, providing a possible mechanism of involvement of zyxin as a signal transducer in PAR-1 signaling. Data showing that disruption of PAR-1-zyxin interaction inhibited thrombin-induced stress fiber formation and SRE activation supports this hypothesis. Similarly, depletion of zyxin using siRNA inhibited thrombin-induced actin stress fiber formation and SRE-dependent gene transcription. In addition, depletion of zyxin resulted in delay of endothelial barrier restoration after thrombin treatment. Notably, down-regulation of zyxin did not affect thrombin-induced activation of RhoA or Gi, Gq, and G12/13 heterotrimeric G proteins, implicating a novel signaling pathway regulated by PAR-1 that is not mediated by G-proteins. The observation that zyxin targets VASP, a partner of zyxin in regulation of actin assembly and dynamics, to focal adhesions and along stress fibers on thrombin stimulation suggests that zyxin may participate in thrombin-induced cytoskeletal remodeling through recruitment of VASP. In summary, this study establishes a crucial role of zyxin in thrombin signaling in endothelial cells and provides evidence for a novel PAR-1 signaling pathway mediated by zyxin.-Han, J., Liu, G., Profirovic, J., Niu, J., Voyno-Yasenetskaya, T. Zyxin is involved in thrombin signaling via interaction with PAR-1 receptor. FASEB J. 23, 4193-4206 (2009). www.fasebj.org	[Han, Jingyan; Liu, Guoquan; Profirovic, Jasmina; Niu, Jiaxin; Voyno-Yasenetskaya, Tatyana] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; [Voyno-Yasenetskaya, Tatyana] Univ Illinois, Ctr Lung & Vasc Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Voyno-Yasenetskaya, T (corresponding author), Univ Illinois, Dept Pharmacol MC 868, 909 S Wolcott Ave, Chicago, IL 60612 USA.	tvy@uic.edu			National Institutes of Health [GM56159, P01 HL60678]; American Heart Association [0710113Z]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056159, R55GM056159] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by National Institutes of Health grants GM56159 and P01 HL60678 and by American Heart Association predoctoral fellowship 0710113Z to J. H.	Andreeva AV, 2005, J BIOL CHEM, V280, P30376, DOI 10.1074/jbc.M502844200; Baumer Y, 2008, HISTOCHEM CELL BIOL, V129, P765, DOI 10.1007/s00418-008-0422-y; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Fradelizi J, 2001, NAT CELL BIOL, V3, P699, DOI 10.1038/35087009; GARCIA JGN, 1995, J INVEST MED, V43, P117; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Gorovoy M, 2005, J BIOL CHEM, V280, P26533, DOI 10.1074/jbc.M502921200; Grosse R, 2003, EMBO J, V22, P3050, DOI 10.1093/emboj/cdg287; Han YH, 2002, J BIOL CHEM, V277, P49877, DOI 10.1074/jbc.M209107200; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirata H, 2008, J CELL SCI, V121, P2795, DOI 10.1242/jcs.030320; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hobert O, 1996, ONCOGENE, V12, P1577; Hoffman LM, 2006, J CELL BIOL, V172, P771, DOI 10.1083/jcb.200512115; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; KATADA T, 1984, J BIOL CHEM, V259, P3578; Kato T, 2005, J CLIN INVEST, V115, P2716, DOI 10.1172/JCI24280; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Lele TP, 2006, J CELL PHYSIOL, V207, P187, DOI 10.1002/jcp.20550; Li B, 2001, J BIOL CHEM, V276, P33328, DOI 10.1074/jbc.M100789200; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; Mahajan VB, 2000, P NATL ACAD SCI USA, V97, P12062, DOI 10.1073/pnas.97.22.12062; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; McLaughlin JN, 2005, J BIOL CHEM, V280, P25048, DOI 10.1074/jbc.M414090200; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Narayanan S, 1999, ANN CLIN LAB SCI, V29, P275; Nix DA, 2001, J BIOL CHEM, V276, P34759, DOI 10.1074/jbc.M102820200; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Pai KS, 2001, J BIOL CHEM, V276, P32642, DOI 10.1074/jbc.M104212200; Posern G, 2002, MOL BIOL CELL, V13, P4167, DOI 10.1091/mbc.02-05-0068; Rahman A, 2002, CIRC RES, V91, P398, DOI 10.1161/01.RES.0000033520.95242.A2; Rajagopal K, 2005, J CLIN INVEST, V115, P2971, DOI 10.1172/JCI26950; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Schaphorst KL, 1997, AM J RESP CELL MOL, V17, P443, DOI 10.1165/ajrcmb.17.4.2502; Schmeichel KL, 1998, BIOCHEM J, V331, P885, DOI 10.1042/bj3310885; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; Vaiskunaite R, 2001, J BIOL CHEM, V276, P46088, DOI 10.1074/jbc.M108711200; Vanhauwe JF, 2002, J BIOL CHEM, V277, P34143, DOI 10.1074/jbc.M204477200; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Waschke J, 2004, AM J PHYSIOL-HEART C, V286, pH394, DOI 10.1152/ajpheart.00221.2003; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Xu J, 2004, J BIOL CHEM, V279, P10459, DOI 10.1074/jbc.M311891200; Yi JS, 2002, J BIOL CHEM, V277, P9580, DOI 10.1074/jbc.M106922200; Yi JS, 1998, GENOMICS, V49, P314, DOI 10.1006/geno.1998.5248; Yoshigi M, 2005, J CELL BIOL, V171, P209, DOI 10.1083/jcb.200505018; Zhai PY, 2005, J CLIN INVEST, V115, P3045, DOI 10.1172/JCI25330	60	17	17	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4193	4206		10.1096/fj.09-131862	http://dx.doi.org/10.1096/fj.09-131862			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19690217	Green Published			2022-12-28	WOS:000272193700015
J	Romano, SA; Cordeiro, Y; Lima, LMTR; Lopes, MH; Silva, JL; Foguel, D; Linden, R				Romano, Sebastian A.; Cordeiro, Yraima; Lima, Luis Mauricio T. R.; Lopes, Marilene H.; Silva, Jerson L.; Foguel, Debora; Linden, Rafael			Reciprocal remodeling upon binding of the prion protein to its signaling partner hop/STI1	FASEB JOURNAL			English	Article						GPI-anchored proteins; multiprotein complexes; structural modifications; trophic signals; SAXS	STRESS-INDUCIBLE PROTEIN-1; SMALL-ANGLE SCATTERING; CO-CHAPERONE HOP; CELLULAR PRION; TETRATRICOPEPTIDE REPEAT; MOLECULAR CHAPERONE; X-RAY; DOMAIN; COMPLEXES; HSP90	The glycosylphosphatidylinositol (GPI)anchored prion protein (PrPC), usually associated with neurodegenerative diseases, modulates various cellular responses and may scaffold multiprotein cell surface signaling complexes. Engagement of PrPC with the secret-able cochaperone hop/STI1 induces neurotrophic transmembrane signals through unknown molecular mechanisms. We addressed whether interaction of PrPC and hop/STI1 entails structural rearrangements relevant for signaling. Using recombinant wild-type and mutant mouse proteins and binding peptides, we measured circular dichroism (CD), fluorescence spectroscopy, and small angle X-ray scattering (SAXS). PrPC: hop/STI1 interaction triggers loss of PrP helical structures, involving at least a perturbation of the PrP143-153 alpha-helix, but no secondary structural modification of hop/STI1 was detected. Novel SAXS models revealed a significant C-terminal compaction of hop/STI1 when bound to PrP. Differing from a recent dimeric model of human hop/STI1, both size-exclusion chromatography and SAXS data support a monomeric form of free murine hop/STI1. Changes in the PrP143-153 alpha-helix may engage the transmembrane signaling proteins laminin receptor precursor and neural cell adhesion molecule, both of which bind that domain of PrPC, and further ligands may be engaged by the tertiary structural changes of hop/STI1. These reciprocal structural modifications indicate a versatile mechanism for signaling mediated by PrPC: hop/STI1 interaction, consistent with the hypothesis of PrPC-dependent multiprotein signaling complexes.-Romano, S. A., Cordeiro, Y., Lima, L. M. T. R., Lopes, M. H., Silva, J. L., Foguel, D., Linden, R. Reciprocal remodeling upon binding of the prion protein to its signaling partner hop/STI1. FASEB J. 23, 4308-4316 (2009). www.fasebj.org	[Romano, Sebastian A.; Linden, Rafael] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941 Rio De Janeiro, Brazil; [Cordeiro, Yraima; Lima, Luis Mauricio T. R.] Univ Fed Rio de Janeiro, Fac Farm, BR-21941 Rio De Janeiro, Brazil; [Silva, Jerson L.; Foguel, Debora] Univ Fed Rio de Janeiro, Inst Bioquim Med, BR-21941 Rio De Janeiro, Brazil; [Lopes, Marilene H.] Ludwig Inst Canc Res, Sao Paulo, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Ludwig Institute for Cancer Research	Linden, R (corresponding author), UFRJ, CCS, Inst Biofis, Bloco G,Cidade Univ, BR-21941902 Rio De Janeiro, RJ, Brazil.	rlinden@biof.ufrj.br	SILVA, JERSON Lima/GRF-1442-2022; Neurociencia, Inct/I-1011-2013; Cordeiro, Yraima/J-7619-2012; Lopes, Marilene/GLV-4734-2022; Lima, Luis Mauricio/AAL-2098-2021; Silva, Jerson/J-8984-2014; Linden, Rafael/F-2275-2011	SILVA, JERSON Lima/0000-0001-9523-9441; Cordeiro, Yraima/0000-0003-4278-212X; Lopes, Marilene/0000-0003-2496-0674; Silva, Jerson/0000-0001-9523-9441; Linden, Rafael/0000-0003-3287-336X; Foguel, Debora/0000-0001-7312-7115; Romano, Sebastian/0000-0002-1430-4633; TR Lima, Luis Mauricio/0000-0001-6020-0504	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [472741/2007-1, 486489/2006-0, 420036/2005-9, 410554/2006-5, 151567/2004-2, 480986/2004-5, 420015/2005-1, 472174/2007-0, IMBEBB 42.0120/2005-0]; Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro Carlos Chagas Filho (FAPERJ) [APQ1-E-26/170.406/2006]; Brazilian Synchrotron Light Laboratory [D11A-SAS1 7690/08]; FAPESP [03/13189-2]	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro Carlos Chagas Filho (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Brazilian Synchrotron Light Laboratory; FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	We thank Dr. Tomas S. Plivelic, Dr. Fernando Q. Reis, and Dr. Lucas Sanfelici for excellent technical assistance with the LNLS beamline and Talita M. Oliveira for assistance on purification of STI1. This research was supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq 472741/2007-1, 486489/2006-0, 420036/2005-9, 410554/2006-5, 151567/2004-2, 480986/2004-5, 420015/2005-1, 472174/2007-0; IMBEBB 42.0120/2005-0); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro Carlos Chagas Filho (FAPERJ APQ1-E-26/170.406/2006, PRONEX and CNE Programs); Brazilian Synchrotron Light Laboratory (LNLS; D11A-SAS1 7690/08); and FAPESP 03/13189-2.	Americo TA, 2007, BIOCHEM BIOPH RES CO, V358, P620, DOI 10.1016/j.bbrc.2007.04.202; ARRUDACARVALHO M, 2007, BIOCHEM BIOPH RES CO, V358, P620; Baumann F, 2007, EMBO J, V26, P538, DOI 10.1038/sj.emboj.7601510; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bray D, 2004, ANNU REV BIOPH BIOM, V33, P53, DOI 10.1146/annurev.biophys.33.110502.132703; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Caetano FA, 2008, J NEUROSCI, V28, P6691, DOI 10.1523/JNEUROSCI.1701-08.2008; Carrigan PE, 2004, J BIOL CHEM, V279, P16185, DOI 10.1074/jbc.M314130200; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Christen B, 2009, J MOL BIOL, V389, P833, DOI 10.1016/j.jmb.2009.04.040; Collins SJ, 2004, LANCET, V363, P51, DOI 10.1016/S0140-6736(03)15171-9; Cordeiro Y, 2004, J BIOL CHEM, V279, P5346, DOI 10.1074/jbc.M312262200; Erlich RB, 2007, GLIA, V55, P1690, DOI 10.1002/glia.20579; Eustace BK, 2004, CELL CYCLE, V3, P1098; Flom G, 2007, BIOCHEM J, V404, P159, DOI 10.1042/BJ20070084; Glatter O., 1982, SMALL ANGLE XRAY SCA, P119; Golbik R, 1998, J MOL BIOL, V276, P505, DOI 10.1006/jmbi.1997.1538; Gomes AMO, 2003, BIOCHEMISTRY-US, V42, P5540, DOI 10.1021/bi027207k; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Lee KS, 2003, REV MED VIROL, V13, P399, DOI 10.1002/rmv.408; Li AM, 2007, EMBO J, V26, P548, DOI 10.1038/sj.emboj.7601507; Lima LMTR, 2004, J BIOL CHEM, V279, P47968, DOI 10.1074/jbc.M407696200; Linden R, 2008, PHYSIOL REV, V88, P673, DOI 10.1152/physrev.00007.2007; Lopes MH, 2005, J NEUROSCI, V25, P11330, DOI 10.1523/JNEUROSCI.2313-05.2005; Lu BY, 2001, EUR J BIOCHEM, V268, P3767, DOI 10.1046/j.1432-1327.2001.02283.x; Mallucci GR, 2002, EMBO J, V21, P202, DOI 10.1093/emboj/21.3.202; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Matozo HC, 2007, BIOPHYS J, V92, P4424, DOI 10.1529/biophysj.106.094961; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; Odunuga OO, 2004, BIOESSAYS, V26, P1058, DOI 10.1002/bies.20107; Onuoha SC, 2008, J MOL BIOL, V379, P732, DOI 10.1016/j.jmb.2008.02.013; Petoukhov MV, 2007, CURR OPIN STRUC BIOL, V17, P562, DOI 10.1016/j.sbi.2007.06.009; Petoukhov MV, 2005, BIOPHYS J, V89, P1237, DOI 10.1529/biophysj.105.064154; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Remenyi A, 2006, CURR OPIN STRUC BIOL, V16, P676, DOI 10.1016/j.sbi.2006.10.008; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; Santuccione A, 2005, J CELL BIOL, V169, P341, DOI 10.1083/jcb.200409127; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Lima LMTR, 2006, BIOCHEMISTRY-US, V45, P9180, DOI 10.1021/bi060532d; van der Spuy J, 2001, PROTEIN EXPRES PURIF, V21, P462, DOI 10.1006/prep.2001.1399; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Whitty A, 2008, NAT CHEM BIOL, V4, P435, DOI 10.1038/nchembio0808-435; WU S, 2007, NUCLEIC ACIDS RES, V35, P3357; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325	52	19	19	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4308	4316		10.1096/fj.09-138974	http://dx.doi.org/10.1096/fj.09-138974			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19703931				2022-12-28	WOS:000272193700025
J	Wartosch, L; Fuhrmann, JC; Schweizer, M; Stauber, T; Jentsch, TJ				Wartosch, Lena; Fuhrmann, Jens C.; Schweizer, Michaela; Stauber, Tobias; Jentsch, Thomas J.			Lysosomal degradation of endocytosed proteins depends on the chloride transport protein ClC-7	FASEB JOURNAL			English	Article						neurodegeneration; neuronal ceroid lipofuscinosis; NCL; lysosomal storage disease	AUTOSOMAL RECESSIVE OSTEOPETROSIS; DENTS-DISEASE; STORAGE DISEASE; LATE ENDOSOMES; BETA-SUBUNIT; PROTON PUMP; CHANNEL; DISRUPTION; PATHWAY; MOUSE	Mutations in either ClC-7, a late endosomal/lysosomal member of the CLC family of chloride channels and transporters, or in its beta-subunit Ostm1 cause osteopetrosis and lysosomal storage disease in mice and humans. The severe phenotype of mice globally deleted for ClC-7 or Ostm1 and the absence of storage material in cultured cells hampered investigations of the mechanism leading to lysosomal pathology in the absence of functional ClC-7/Ostm1 transporters. Tissue-specific ClC-7-knockout mice now reveal that accumulation of storage material occurs cell-autonomously in neurons or renal proximal tubular cells lacking ClC-7. Almost all ClC-7-deficient neurons die. The activation of glia is restricted to brain regions where ClC-7 has been inactivated. The effect of ClC-7 disruption on lysosomal function was investigated in renal proximal tubular cells, which display high endocytotic activity. Pulse-chase endocytosis experiments in vivo with mice carrying chimeric deletion of ClC-7 in proximal tubules allowed a direct comparison of the handling of endocytosed protein between cells expressing or lacking ClC-7. Whereas protein was endocytosed similarly in cells of either genotype, its half-life increased significantly in ClC-7-deficient cells. These experiments demonstrate that lysosomal pathology is a cell-autonomous consequence of ClC-7 disruption and that ClC-7 is important for lysosomal protein degradation.-Wartosch, L., Fuhrmann, J. C., Schweizer, M., Stauber, T., Jentsch, T. J. Lysosomal degradation of endocytosed proteins depends on the chloride transport protein ClC-7. FASEB J. 23, 4056-4068 (2009). www.fasebj.org	[Wartosch, Lena; Fuhrmann, Jens C.; Stauber, Tobias; Jentsch, Thomas J.] Leibniz Inst Mol Pharmacol, FMP, D-13125 Berlin, Germany; [Wartosch, Lena; Fuhrmann, Jens C.; Stauber, Tobias; Jentsch, Thomas J.] Max Delbruck Ctr Mol Med, MDC, Berlin, Germany; [Wartosch, Lena] Free Univ Berlin, D-1000 Berlin, Germany; [Schweizer, Michaela] Univ Hamburg, Zentrum Mol Neurobiol ZMNH, Hamburg, Germany	Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; University of Hamburg	Jentsch, TJ (corresponding author), Leibniz Inst Mol Pharmacol, FMP, Robert Rossle Str 10, D-13125 Berlin, Germany.	jentsch@fmp-berlin.de	Stauber, Tobias/E-4005-2010	Stauber, Tobias/0000-0003-0727-6109; Jentsch, Thomas/0000-0002-3509-2553; Fuhrmann, Jens/0000-0001-5730-381X	Deutsche Forschungsgemeinschaft; European Union (Euregene); Boehringer Ingelheim fellowship	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Union (Euregene)(European Commission); Boehringer Ingelheim fellowship(Boehringer Ingelheim)	We thank the following colleagues for generously making material available: Takuji Iwasato and Shigeyoshi Itohara (Brain Science Institute, RIKEN, Saitama, Japan) for EMX1-cre mice, Thomas Willnow (MDC, Berlin, Germany) for ApoE-cre mice, and Jean Gruenberg (University of Geneva, Geneva, Switzerland) for the LBPA antibody. We thank Sebastian Bachmann for helpful discussions; Irm Hermans-Borgmeyer and Tina Koppelmann for help in generating Clcn7lox/lox mice; Nicole Kronke, Patrick Seidler, and Stephanie Wernick for technical assistance; York Rudhard for EMX1-Z/AP reporter staining; and Gunter Delling for help with X-ray analysis. This work was supported by grants of the Deutsche Forschungsgemeinschaft and the European Union (Euregene) to T. J. J. and a Boehringer Ingelheim fellowship to L. W.	Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014-5793(95)01298-2; Chalhoub N, 2003, NAT MED, V9, P399, DOI 10.1038/nm842; Christensen EI, 2002, NAT REV MOL CELL BIO, V3, P258, DOI 10.1038/nrm778; Cigic B, 1999, EUR J BIOCHEM, V264, P944, DOI 10.1046/j.1432-1327.1999.00697.x; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; Cooper JD, 2006, BBA-MOL BASIS DIS, V1762, P873, DOI 10.1016/j.bbadis.2006.08.002; De Angeli A, 2006, NATURE, V442, P939, DOI 10.1038/nature05013; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; Faundez Victor, 2004, Sci STKE, V2004, pre8, DOI 10.1126/stke.2332004re8; Frattini A, 2003, J BONE MINER RES, V18, P1740, DOI 10.1359/jbmr.2003.18.10.1740; GIESELMANN V, 1995, BBA-MOL BASIS DIS, V1270, P103, DOI 10.1016/0925-4439(94)00075-2; Graves AR, 2008, NATURE, V453, P788, DOI 10.1038/nature06907; Gunther W, 2003, PFLUG ARCH EUR J PHY, V445, P456, DOI 10.1007/s00424-002-0950-6; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Hara-Chikuma M, 2005, J BIOL CHEM, V280, P1241, DOI 10.1074/jbc.M407030200; Iwasato T, 2000, NATURE, V406, P726, DOI 10.1038/35021059; Jentsch TJ, 2007, J PHYSIOL-LONDON, V578, P633, DOI 10.1113/jphysiol.2006.124719; Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535; Leheste JR, 2002, FASEB J, V16, P247, DOI 10.1096/fj.02-0578fje; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Luzio JP, 2007, BIOCHEM SOC T, V35, P1088, DOI 10.1042/BST0351088; Maranda B, 2001, J BIOL CHEM, V276, P18540, DOI 10.1074/jbc.M011577200; Maritzen T, 2008, J NEUROSCI, V28, P10587, DOI 10.1523/JNEUROSCI.3750-08.2008; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Nielsen R, 2007, P NATL ACAD SCI USA, V104, P5407, DOI 10.1073/pnas.0700330104; Pangrazio A, 2006, J BONE MINER RES, V21, P1098, DOI 10.1359/JBMR.060403; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; Poet M, 2006, P NATL ACAD SCI USA, V103, P13854, DOI 10.1073/pnas.0606137103; Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823; Saito M, 2007, J BIOL CHEM, V282, P27327, DOI 10.1074/jbc.M702557200; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Suzuki T, 2006, J CELL PHYSIOL, V206, P792, DOI 10.1002/jcp.20516; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Wang SS, 2000, HUM MOL GENET, V9, P2937, DOI 10.1093/hmg/9.20.2937; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619	45	53	56	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4056	4068		10.1096/fj.09-130880	http://dx.doi.org/10.1096/fj.09-130880			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19661288				2022-12-28	WOS:000272193700003
J	Figueroa-Romero, C; Iniguez-Lluhi, JA; Stadler, J; Chang, CR; Arnoult, D; Keller, PJ; Hong, Y; Blackstone, C; Feldman, EL				Figueroa-Romero, Claudia; Iniguez-Lluhi, Jorge A.; Stadler, Julia; Chang, Chuang-Rung; Arnoult, Damien; Keller, Peter J.; Hong, Yu; Blackstone, Craig; Feldman, Eva L.			SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle	FASEB JOURNAL			English	Article						Ubc9; small ubiquitin-like modifier; post-translational modification	DYNAMIN-RELATED PROTEIN; SUMO E3 LIGASE; COATED VESICLE FORMATION; DOMINANT OPTIC ATROPHY; MAMMALIAN-CELLS; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTORS; OUTER-MEMBRANE; GTPASE DRP1; MORPHOLOGY	Dynamin-related protein (Drp) 1 is a key regulator of mitochondrial fission and is composed of GTP-binding, Middle, insert B, and C-terminal GTPase effector (GED) domains. Drp1 associates with mitochondrial fission sites and promotes membrane constriction through its intrinsic GTPase activity. The mechanisms that regulate Drp1 activity remain poorly understood but are likely to involve reversible post-translational modifications, such as conjugation of small ubiquitin-like modifier (SUMO) proteins. Through a detailed analysis, we find that Drp1 interacts with the SUMO-conjugating enzyme Ubc9 via multiple regions and demonstrate that Drp1 is a direct target of SUMO modification by all three SUMO isoforms. While Drp1 does not harbor consensus SUMOylation sequences, our analysis identified2 clusters of lysine residues within the B domain that serve as noncanonical conjugation sites. Although initial analysis indicates that mitochondrial recruitment of ectopically expressed Drp1 in response to staurosporine is unaffected by loss of SUMOylation, we find that Drp1 SUMOylation is enhanced in the context of the K38A mutation. This dominant-negative mutant, which is deficient in GTP binding and hydrolysis, does not associate with mitochondria and prevents normal mitochondrial fission. This finding suggests that SUMOylation of Drp1 is linked to its activity cycle and is influenced by Drp1 localization.-Figueroa-Romero, C., Iniguez-Lluhi, J. A., Stadler, J., Chang, C.-R., Arnoult, D., Keller, P. J., Hong, Y., Blackstone, C., Feldman, E. L. SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle. FASEB J. 23, 3917-3927 (2009). www.fasebj.org	[Figueroa-Romero, Claudia; Keller, Peter J.; Hong, Yu; Feldman, Eva L.] Univ Michigan, Dept Neurol, Sch Med, Ann Arbor, MI 48109 USA; [Iniguez-Lluhi, Jorge A.] Univ Michigan, Dept Pharmacol, Sch Med, Ann Arbor, MI 48109 USA; [Stadler, Julia; Chang, Chuang-Rung; Blackstone, Craig] Natl Inst Neurol Disorders & Stroke, Cellular Neurol Unit, Neurogenet Branch, NIH, Bethesda, MD USA; [Arnoult, Damien] INSERM, U542, Villejuif, France; [Arnoult, Damien] Univ Paris 11, Hop Paul Brousse, Villejuif, France	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, Sch Med, 5017 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	efeldman@umich.edu	Chang, Chuang-Rung/C-1815-2012; Arnoult, Damien/R-2032-2018	Chang, Chuang-Rung/0000-0002-6124-5429; Feldman, Eva/0000-0002-9162-2694; Figueroa-Romero, Claudia/0000-0001-7546-4190; Iniguez-Lluhi, Jorge/0000-0001-7010-089X	U. S. Public Health Service [DK61656]; Program for Neurology Research and Discovery; A. Alfred Taubman Medical Research Institute; U. S. National Institutes of Health (NIH) [NIHU01 DK076160]; Intramural Research Program of the National Institute of Neurological Disorders and Stroke (NINDS); Agence Nationale de La Recherche sur le SIDA; Fondation pour La Recherche Medicale; Ligue contre le Cancer; Universite Paris Sud; National Institute of Diabetes and Digestive and Kidney Diseases [NIH5P60 DK20572]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK076160, P60DK020572, R56DK061656, R01DK061656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003025] Funding Source: NIH RePORTER	U. S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Program for Neurology Research and Discovery; A. Alfred Taubman Medical Research Institute; U. S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of the National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Agence Nationale de La Recherche sur le SIDA(ANRSFrench National Research Agency (ANR)); Fondation pour La Recherche Medicale(Fondation pour la Recherche Medicale); Ligue contre le Cancer(Ligue nationale contre le cancer); Universite Paris Sud; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by U. S. Public Health Service grant DK61656 (J. A. I.), the Program for Neurology Research and Discovery, the A. Alfred Taubman Medical Research Institute, U. S. National Institutes of Health (NIH) grant NIHU01 DK076160 (C. F.-R., E. L. F., Y. H., P. J. K.), and in part by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke (NINDS), NIH (J. S., C.-R. C., C. B.) as well as the Agence Nationale de La Recherche sur le SIDA, Fondation pour La Recherche Medicale, the Ligue contre le Cancer, and the Universite Paris Sud (D. A.). This work utilized the sequencing core of the Michigan Diabetes Research and Training Center, funded by National Institute of Diabetes and Digestive and Kidney Diseases grant NIH5P60 DK20572. The authors also thank J. Nagle and D. Kauffman (NINDS DNA Sequencing Facility) for DNA sequencing.	Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Arnoult D, 2005, CURR BIOL, V15, P2112, DOI 10.1016/j.cub.2005.10.041; Arnoult D, 2005, J BIOL CHEM, V280, P35742, DOI 10.1074/jbc.M505970200; Baloh RH, 2008, NEUROSCIENTIST, V14, P12, DOI 10.1177/1073858407307354; Benson MD, 2007, P NATL ACAD SCI USA, V104, P1805, DOI 10.1073/pnas.0606702104; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; Braschi E, 2009, EMBO REP, V10, P748, DOI 10.1038/embor.2009.86; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Cereghetti GM, 2008, P NATL ACAD SCI USA, V105, P15803, DOI 10.1073/pnas.0808249105; Cerveny KL, 2007, TRENDS CELL BIOL, V17, P563, DOI 10.1016/j.tcb.2007.08.006; Chan DC, 2007, NEW ENGL J MED, V356, P1707, DOI 10.1056/NEJMp078040; Chang CR, 2007, J BIOL CHEM, V282, P21583, DOI 10.1074/jbc.C700083200; Chen HC, 2006, CURR OPIN CELL BIOL, V18, P453, DOI 10.1016/j.ceb.2006.06.004; Cho DH, 2009, SCIENCE, V324, P102, DOI 10.1126/science.1171091; Chun TH, 2003, CIRC RES, V92, P1201, DOI 10.1161/01.RES.0000076893.70898.36; Chupreta S, 2005, MOL CELL BIOL, V25, P4272, DOI 10.1128/MCB.25.10.4272-4282.2005; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Dorval V, 2007, BBA-MOL CELL RES, V1773, P694, DOI 10.1016/j.bbamcr.2007.03.017; Etxebarria A, 2009, J BIOL CHEM, V284, P4200, DOI 10.1074/jbc.M808050200; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; Ghafourifar P, 2008, FRONT BIOSCI-LANDMRK, V13, P3116, DOI 10.2741/2913; Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200; Han XJ, 2008, J CELL BIOL, V182, P573, DOI 10.1083/jcb.200802164; Harder Z, 2004, CURR BIOL, V14, P340, DOI 10.1016/j.cub.2004.02.004; Ingerman E, 2005, J CELL BIOL, V170, P1021, DOI 10.1083/jcb.200506078; Ivanov AV, 2007, MOL CELL, V28, P823, DOI 10.1016/j.molcel.2007.11.012; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Kamimoto T, 1998, J BIOL CHEM, V273, P1044, DOI 10.1074/jbc.273.2.1044; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Leinninger GM, 2006, NEUROBIOL DIS, V23, P11, DOI 10.1016/j.nbd.2006.01.017; Li MY, 2005, J MOL MED, V83, P504, DOI 10.1007/s00109-005-0645-5; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Matic I, 2008, MOL CELL PROTEOMICS, V7, P132, DOI 10.1074/mcp.M700173-MCP200; Men XL, 2009, INT J BIOCHEM CELL B, V41, P879, DOI 10.1016/j.biocel.2008.08.031; Mishra RK, 2004, J BIOL CHEM, V279, P31445, DOI 10.1074/jbc.M402911200; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; MUKHERJEE S, 2009, J BIOL CHEM; Nakamura N, 2006, EMBO REP, V7, P1019, DOI 10.1038/sj.embor.7400790; Niemann HH, 2001, EMBO J, V20, P5813, DOI 10.1093/emboj/20.21.5813; Owerbach D, 2005, BIOCHEM BIOPH RES CO, V337, P517, DOI 10.1016/j.bbrc.2005.09.090; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pitts KR, 1999, MOL BIOL CELL, V10, P4403, DOI 10.1091/mbc.10.12.4403; Pountney DL, 2008, ACTA NEUROPATHOL, V116, P603, DOI 10.1007/s00401-008-0437-4; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Santel A, 2003, J CELL SCI, V116, P2763, DOI 10.1242/jcs.00479; Santel A, 2008, IUBMB LIFE, V60, P448, DOI 10.1002/iub.71; Schrader M, 2006, BBA-MOL CELL RES, V1763, P531, DOI 10.1016/j.bbamcr.2006.01.004; Shin HW, 1997, J BIOCHEM-TOKYO, V122, P525; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Su HL, 2002, GENE, V296, P65, DOI 10.1016/S0378-1119(02)00843-0; Subramaniam S, 2009, SCIENCE, V324, P1327, DOI 10.1126/science.1172871; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Ulrich HD, 2005, TRENDS CELL BIOL, V15, P525, DOI 10.1016/j.tcb.2005.08.002; Ulrich HD, 2008, MOL CELL, V32, P301, DOI 10.1016/j.molcel.2008.10.010; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang XL, 2008, AM J PATHOL, V173, P470, DOI 10.2353/ajpath.2008.071208; Wasiak S, 2007, J CELL BIOL, V177, P439, DOI 10.1083/jcb.200610042; Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436; Wells RC, 2007, J BIOL CHEM, V282, P33769, DOI 10.1074/jbc.M700807200; Yang YF, 2008, P NATL ACAD SCI USA, V105, P7070, DOI 10.1073/pnas.0711845105; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yoon Y, 2001, MOL BIOL CELL, V12, P2894, DOI 10.1091/mbc.12.9.2894; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; Yu TZ, 2008, CARDIOVASC RES, V79, P341, DOI 10.1093/cvr/cvn104; Zeviani M, 2007, CURR OPIN NEUROL, V20, P564, DOI 10.1097/WCO.0b013e3282ef58cd; Zhang FP, 2008, MOL CELL BIOL, V28, P5381, DOI 10.1128/MCB.00651-08; Zhu PP, 2004, J BIOL CHEM, V279, P35967, DOI 10.1074/jbc.M404105200; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341; Zunino R, 2007, J CELL SCI, V120, P1178, DOI 10.1242/jcs.03418; Zunino R, 2009, J BIOL CHEM, V284, P17783, DOI 10.1074/jbc.M901902200	83	140	146	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2009	23	11					3917	3927		10.1096/fj.09-136630	http://dx.doi.org/10.1096/fj.09-136630			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19638400	Green Published, Green Submitted			2022-12-28	WOS:000271272500027
J	Jean-Francois, F; Desbat, B; Dufourc, EJ				Jean-Francois, Frantz; Desbat, Bernard; Dufourc, Erick J.			Selectivity of cateslytin for fungi: the role of acidic lipid-ergosterol membrane fluidity in antimicrobial action	FASEB JOURNAL			English	Article						cholesterol; domains; NMR; infrared	AMYLOID-BETA-PEPTIDE; SOLID-STATE H-2-NMR; PHOSPHOLIPID-BILAYER; BACTERIAL-MEMBRANES; MAGNETIC-RESONANCE; ORDER PARAMETERS; CHOLESTEROL; STEROLS; DOMAINS; MODE	The specificity of the stress-produced antimicrobial peptide cateslytin to fungi membranes has been investigated using complex membrane models made of zwitterionic and negatively charged lipids, cholesterol, or ergosterol. Noninvasive solid-state NMR of deuterated neutral and negatively charged lipids, together with IR spectroscopy, afforded following both changes in membrane fluidity and in peptide secondary structure. Cateslytin, by adopting an aggregated antiparallel beta-sheeted structure at membrane interfaces, induces a fluid/rigid membrane separation on ergosterol-containing models only. This effect is accounted for by a 2-fold electronic interaction: attractive dipole-dipole between basic arginine residues and negatively charged lipid head groups, and attractive cation-pi between arginine and the conjugated pi electrons of the ergosterol fused-ring system. This complex leads to fluid/thinner membranes that laterally separate out from rigid/thicker membranes that are not bound by cateslytin. The boundary defects occurring between domains span several angstroms, as probed by NMR of perdeuterated lipids, and are proposed to trigger peptide permeation through membranes. The intrinsic greater membrane fluidity of ergosterol/acidic lipid components in fungi is shown to be one of the key factors for specific cateslytin biological action.-Jean-Francois, F., Desbat, B., Dufourc, E. J. Selectivity of cateslytin for fungi: the role of acidic lipid-ergosterol membrane fluidity in antimicrobial action. FASEB J. 23, 3692-3701 (2009). www.fasebj.org	[Jean-Francois, Frantz; Desbat, Bernard; Dufourc, Erick J.] Univ Bordeaux 1, CNRS, ENITAB, IECB,UMR 5248, Pessac, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite de Bordeaux	Dufourc, EJ (corresponding author), Univ Bordeaux, UMR CBMN 5248, CNRS, ENITAB,IECB, 2 Rue Robert Escarpit, F-33607 Pessac, France.	jean-francois@magnet.fsu.edu; e.dufourc@iecb.u-bordeaux.fr	DUFOURC, Erick Joel/AAA-4992-2020; Jean-Francois, Frantz/AAH-9429-2019	DUFOURC, Erick Joel/0000-0002-8221-9326; 	Aquitaine government; CNRS; Ministry of Research	Aquitaine government; CNRS(Centre National de la Recherche Scientifique (CNRS)); Ministry of Research(Ministry of Research and Technology of the Republic of Indonesia (RISTEK))	We are grateful to Dr. Thierry Buffeteau (UMR ISM 5255, Bordeaux) for the use of the ATR holder. We thank the Aquitaine government, CNRS, and the Ministry of Research for equipment and funding.	Alarcon JM, 2006, PEPTIDES, V27, P95, DOI 10.1016/j.peptides.2005.07.004; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Arnt L, 2006, J PHYS CHEM B, V110, P3527, DOI 10.1021/jp054339p; Arouri A, 2009, BBA-BIOMEMBRANES, V1788, P650, DOI 10.1016/j.bbamem.2008.11.022; Beck JG, 2007, FASEB J, V21, P1714, DOI 10.1096/fj.06-7809com; BLOOM M, 1981, CHEM PHYS LETT, V80, P198, DOI 10.1016/0009-2614(81)80089-9; Bonev B, 2001, PHYS CHEM CHEM PHYS, V3, P2904, DOI 10.1039/b103352m; Briolat J, 2005, CELL MOL LIFE SCI, V62, P377, DOI 10.1007/s00018-004-4461-9; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Buchoux S, 2008, BIOPHYS J, V95, P3840, DOI 10.1529/biophysj.107.128322; Castano S, 2005, BBA-BIOMEMBRANES, V1715, P81, DOI 10.1016/j.bbamem.2005.07.008; CORNELL BA, 1982, BIOCHIM BIOPHYS ACTA, V689, P337, DOI 10.1016/0005-2736(82)90267-X; Davis JH, 2009, BIOPHYS J, V96, P521, DOI 10.1016/j.bpj.2008.09.042; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; DOULIEZ JP, 1995, J CHIM PHYS PCB, V92, P1721, DOI 10.1051/jcp/1995921721; Douliez JP, 1996, J PHYS CHEM-US, V100, P18450, DOI 10.1021/jp961220v; DOULIEZ JP, 1995, BIOPHYS J, V68, P1727, DOI 10.1016/S0006-3495(95)80350-4; Dufourc E.J., 2006, CHEM BIOL, P113, DOI [10.1002/9780470319253.ch8, DOI 10.1002/9780470319253.CH8]; Dufourc Erick J, 2008, J Chem Biol, V1, P63, DOI 10.1007/s12154-008-0010-6; Epand RF, 2008, J MOL BIOL, V379, P38, DOI 10.1016/j.jmb.2008.03.047; Epand RF, 2006, BBA-BIOMEMBRANES, V1758, P1343, DOI 10.1016/j.bbamem.2006.01.018; Epand RM, 2008, J AM CHEM SOC, V130, P14346, DOI 10.1021/ja8062327; Epand RM, 2009, BBA-BIOMEMBRANES, V1788, P289, DOI 10.1016/j.bbamem.2008.08.023; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; FABIAN H, 2002, HDB VIBRATIONAL SPEC, V5, P3399; Garnier-Lhomme M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004255; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Hsueh YW, 2005, BIOPHYS J, V88, P1799, DOI 10.1529/biophysj.104.051375; Jean-Francois F, 2008, BIOCHEMISTRY-US, V47, P6394, DOI 10.1021/bi800448h; Jean-Francois F, 2007, EUR BIOPHYS J BIOPHY, V36, P1019, DOI 10.1007/s00249-007-0169-8; Jean-Francois F, 2008, BIOPHYS J, V95, P5748, DOI 10.1529/biophysj.108.136655; Khemtemourian L, 2006, ANAL CHEM, V78, P5348, DOI 10.1021/ac060207w; LEONARD A, 1991, BIOCHIMIE, V73, P1295, DOI 10.1016/0300-9084(91)90092-F; Lindblom G, 2009, BBA-BIOMEMBRANES, V1788, P234, DOI 10.1016/j.bbamem.2008.08.016; Loffler J, 2000, FEMS MICROBIOL LETT, V185, P59, DOI 10.1016/S0378-1097(00)00071-9; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; Mason AJ, 2007, BIOPHYS J, V93, P4289, DOI 10.1529/biophysj.107.116681; Matsumoto K, 2006, MOL MICROBIOL, V61, P1110, DOI 10.1111/j.1365-2958.2006.05317.x; Matsuzaki K, 1998, BBA-REV BIOMEMBRANES, V1376, P391, DOI 10.1016/S0304-4157(98)00014-8; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033; Olofsson A, 2007, J MOL BIOL, V374, P186, DOI 10.1016/j.jmb.2007.08.064; Perron GG, 2006, P ROY SOC B-BIOL SCI, V273, P251, DOI 10.1098/rspb.2005.3301; Peschel A, 2002, TRENDS MICROBIOL, V10, P179, DOI 10.1016/S0966-842X(02)02333-8; POTT T, 1995, BIOPHYS J, V68, P965, DOI 10.1016/S0006-3495(95)80272-9; Samuelsen O, 2005, FEBS LETT, V579, P3421, DOI 10.1016/j.febslet.2005.05.017; SCHINDLER H, 1975, BIOCHEMISTRY-US, V14, P2283, DOI 10.1021/bi00682a001; SEELIG J, 1977, Q REV BIOPHYS, V10, P353, DOI 10.1017/S0033583500002948; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Terzi E, 1997, BIOCHEMISTRY-US, V36, P14845, DOI 10.1021/bi971843e; Wong PT, 2009, J MOL BIOL, V386, P81, DOI 10.1016/j.jmb.2008.11.060; Xiong YQ, 2005, ANTIMICROB AGENTS CH, V49, P3114, DOI 10.1128/AAC.49.8.3114-3121.2005; Zandomeneghi G, 2004, PROTEIN SCI, V13, P3314, DOI 10.1110/ps.041024904; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	56	16	16	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3692	3701		10.1096/fj.09-135574	http://dx.doi.org/10.1096/fj.09-135574			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19571037				2022-12-28	WOS:000271272500007
J	Ziera, T; Irlbacher, H; Fromm, A; Latouche, C; Krug, SM; Fromm, M; Jaisser, F; Borden, SA				Ziera, Tim; Irlbacher, Horst; Fromm, Anja; Latouche, Celine; Krug, Susanne M.; Fromm, Michael; Jaisser, Frederic; Borden, Steffen A.			Cnksr3 is a direct mineralocorticoid receptor target gene and plays a key role in the regulation of the epithelial sodium channel	FASEB JOURNAL			English	Article						aldosterone; chromatin imunoprecipition; ERK/MAPK signaling; reporter gene assays; site-directed mutagenesis	ALDOSTERONE-INDUCED GENE; GLUCOCORTICOID-RECEPTOR; SCAFFOLD PROTEIN; COLLECTING DUCT; RAF ACTIVATION; RABBIT NEPHRON; NA+ TRANSPORT; EXPRESSION; CELLS; BINDING	Aldosterone is the principal hormonal regulator of sodium homeostasis in vertebrates. It exerts its actions through the mineralocorticoid receptor (MR) that regulates the transcription of specific target genes. In recent years, a number of MR target genes have been identified that are involved in the regulation of the epithelial sodium channel (ENaC), a key modulator of renal sodium absorption. Here we report the identification of cnksr3 as a direct MR target gene that is up-regulated in response to physiological concentrations of aldosterone. The cnksr3 promoter exhibits two functional aldosterone-responsive regions, which were bound by the MR as assessed by chromatin immunoprecipitation (ChIP). In vivo, CNKSR3 was highly expressed in the renal cortical collecting duct (CCD), the prime target segment of aldosterone-regulated sodium retention in the kidney. CCD cell lines stably over-expressing or silencing CNKSR3 were electrophysiologically analyzed and show that CNKSR3 expression correlated with and is required for ENaC-mediated transepithelial sodium transport. In parallel, CNKSR3 expression led to decreased MEK phosphorylation. We conclude that CNKSR3, a homologue of scaffold proteins involved in MAPK pathway regulation, is a direct target of MR and is required for the maintenance of transepithelial sodium transport in the kidney.-Ziera, T., Irlbacher, H., Fromm, A., Latouche, C., Krug, S. M., Fromm, M., Jaisser, F., Borden, S. A. Cnksr3 is a direct mineralocorticoid receptor target gene and plays a key role in the regulation of the epithelial sodium channel. FASEB J. 23, 3936-3946 (2009). www.fasebj.org	[Ziera, Tim; Irlbacher, Horst; Borden, Steffen A.] Bayer Schering Pharma AG, Therapeut Res Womens Hlth, D-13353 Berlin, Germany; [Fromm, Anja; Krug, Susanne M.; Fromm, Michael] Free Univ Berlin, Inst Clin Physiol, Charite, D-1000 Berlin, Germany; [Fromm, Anja; Krug, Susanne M.; Fromm, Michael] Humboldt Univ, Berlin, Germany; [Latouche, Celine; Jaisser, Frederic] Univ Paris 06, INSERM, U872, Ctr Rech Cordeliers,Team 1, Paris, France	Bayer AG; Bayer Healthcare Pharmaceuticals; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Borden, SA (corresponding author), Bayer Schering Pharma AG, Therapeut Res Womens Hlth, Mullerstr 178, D-13353 Berlin, Germany.	steffen.borden@bayerhealthcare.com	Latouche, Celine/C-4998-2013; Krug, Susanne M/AAY-6221-2020; Jaisser, Frederic/P-4287-2017; Fromm, Michael/K-6203-2013	Krug, Susanne M/0000-0002-1293-2484; Jaisser, Frederic/0000-0001-9051-1901; Fromm, Michael/0000-0003-4497-7983; Fromm, Anja/0000-0003-4091-9612	Societe Francaise de Nephrologie; Leducq Fondation	Societe Francaise de Nephrologie; Leducq Fondation	We thank N. Farman for microdissecting nephron segments from mouse kidneys, F. Prinz for lentivirus production, and D. Henderson for critical reading of the manuscript. Funding for INSERM U872 Team 1 was from the Societe Francaise de Nephrologie and the the Leducq Fondation (Transatlantic Network of Excellence in Cardiovascular Disease).	Afhuppe W, 2009, J STEROID BIOCHEM, V113, P105, DOI 10.1016/j.jsbmb.2008.11.015; Bhalla V, 2006, AM J PHYSIOL-RENAL, V291, pF714, DOI 10.1152/ajprenal.00061.2006; Bolton EC, 2007, GENE DEV, V21, P2005, DOI 10.1101/gad.1564207; Boulkroun S, 2002, J BIOL CHEM, V277, P31506, DOI 10.1074/jbc.M200272200; Brennan FE, 2006, ENDOCRINOLOGY, V147, P2809, DOI 10.1210/en.2005-1481; Casar B, 2009, MOL CELL BIOL, V29, P1338, DOI 10.1128/MCB.01359-08; Claperon A, 2007, ONCOGENE, V26, P3143, DOI 10.1038/sj.onc.1210408; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; Fakitsas P, 2007, J AM SOC NEPHROL, V18, P1084, DOI 10.1681/ASN.2006080902; FARMAN N, 1983, AM J PHYSIOL, V244, pF325, DOI 10.1152/ajprenal.1983.244.3.F325; FARMAN N, 1982, AM J PHYSIOL, V242, pF69, DOI 10.1152/ajprenal.1982.242.1.F69; FROMM M, 1993, AM J PHYSIOL, V264, pE68, DOI 10.1152/ajpendo.1993.264.1.E68; FUHRMANN U, 1995, CONTRACEPTION, V51, P45, DOI 10.1016/0010-7824(94)00003-F; Gomez-Sanchez CE, 2006, ENDOCRINOLOGY, V147, P1343, DOI 10.1210/en.2005-0860; Itani OA, 2002, AM J PHYSIOL-ENDOC M, V283, pE971, DOI 10.1152/ajpendo.00021.2002; Jaffe AB, 2005, CURR BIOL, V15, P405, DOI 10.1016/j.cub.2004.12.082; Jaffe AB, 2004, MOL CELL BIOL, V24, P1736, DOI 10.1128/MCB.24.4.1736-1746.2004; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; KROZOWSKI ZS, 1983, P NATL ACAD SCI-BIOL, V80, P6056, DOI 10.1073/pnas.80.19.6056; Lanigan TM, 2003, FASEB J, V17, P2048, DOI 10.1096/fj.02-1096com; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Muller OG, 2003, J AM SOC NEPHROL, V14, P1107, DOI 10.1097/01.ASN.0000061777.67332.77; Muller O, 2007, GENOMICS, V89, P370, DOI 10.1016/j.ygeno.2006.11.001; Nakhoul NL, 1998, AM J PHYSIOL-RENAL, V275, pF998, DOI 10.1152/ajprenal.1998.275.6.F998; Naray-Fejes-Toth A, 2004, P NATL ACAD SCI USA, V101, P17434, DOI 10.1073/pnas.0408146101; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Naray-Fejes-Toth A, 2000, KIDNEY INT, V57, P1290, DOI 10.1046/j.1523-1755.2000.00964.x; Naray-Fejes-Toth A, 2008, AM J PHYSIOL-RENAL, V295, pF18, DOI 10.1152/ajprenal.00573.2007; NARAYFEJESTOTH A, 1994, AM J PHYSIOL, V266, pF76, DOI 10.1152/ajprenal.1994.266.1.F76; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Oakley RH, 1997, ENDOCRINOLOGY, V138, P5028, DOI 10.1210/en.138.11.5028; Ouvrard-Pascaud A, 2005, CIRCULATION, V111, P3025, DOI 10.1161/CIRCULATIONAHA.104.503706; Pearce D, 2003, VITAM HORM, V66, P29, DOI 10.1016/S0083-6729(03)01002-1; Robert-Nicoud M, 2001, P NATL ACAD SCI USA, V98, P2712, DOI 10.1073/pnas.051603198; Rocheleau CE, 2005, P NATL ACAD SCI USA, V102, P11757, DOI 10.1073/pnas.0500937102; RUPPRECHT R, 1993, EUR J PHARM-MOLEC PH, V247, P145, DOI 10.1016/0922-4106(93)90072-H; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; So AYL, 2007, PLOS GENET, V3, P927, DOI 10.1371/journal.pgen.0030094; Soundararajan R, 2005, J BIOL CHEM, V280, P39970, DOI 10.1074/jbc.M508658200; Soundararajan R, 2009, P NATL ACAD SCI USA, V106, P7804, DOI 10.1073/pnas.0809892106; Spindler B, 1997, PFLUG ARCH EUR J PHY, V434, P323, DOI 10.1007/s004240050403; Staub O, 2005, J AM SOC NEPHROL, V16, P3167, DOI 10.1681/ASN.2005050454; Tanaka K, 2007, HEART VESSELS, V22, P254, DOI 10.1007/s00380-006-0968-3; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Tian LJ, 2001, J PHYSIOL-LONDON, V537, P57, DOI 10.1111/j.1469-7793.2001.0057k.x; Verrey F, 2008, KIDNEY INT, V73, P691, DOI 10.1038/sj.ki.5002737; Viengchareun Say, 2007, Nucl Recept Signal, V5, pe012, DOI 10.1621/nrs.05012; Wang JC, 2004, P NATL ACAD SCI USA, V101, P15603, DOI 10.1073/pnas.0407008101; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Wielputz MO, 2007, J BIOL CHEM, V282, P28264, DOI 10.1074/jbc.M702168200; Wulff P, 2002, J CLIN INVEST, V110, P1263, DOI 10.1172/JCI200215696; Zentner MD, 1998, J BIOL CHEM, V273, P30770, DOI 10.1074/jbc.273.46.30770; Ziogas A, 2005, J BIOL CHEM, V280, P24205, DOI 10.1074/jbc.M413327200	53	45	48	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3936	3946		10.1096/fj.09-134759	http://dx.doi.org/10.1096/fj.09-134759			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19567370				2022-12-28	WOS:000271272500029
J	Baglioni, S; Francalanci, M; Squecco, R; Lombardi, A; Cantini, G; Angeli, R; Gelmini, S; Guasti, D; Benvenuti, S; Annunziato, F; Bani, D; Liotta, F; Francini, F; Perigli, G; Serio, M; Luconi, M				Baglioni, Silvana; Francalanci, Michela; Squecco, Roberta; Lombardi, Adriana; Cantini, Giulia; Angeli, Roberta; Gelmini, Stefania; Guasti, Daniele; Benvenuti, Susanna; Annunziato, Francesco; Bani, Daniele; Liotta, Francesco; Francini, Fabio; Perigli, Giuliano; Serio, Mario; Luconi, Michaela			Characterization of human adult stem-cell populations isolated from visceral and subcutaneous adipose tissue	FASEB JOURNAL			English	Article						multipotential differentiation; immunophenotyping; mesenchymal stromal cells; ASCs	BONE-MARROW; IN-VITRO; STROMAL CELLS; ELECTROPHYSIOLOGICAL PROPERTIES; ENDOTHELIAL-CELLS; TEMPORAL-CHANGES; OBESE SUBJECTS; SELF-RENEWAL; DIFFERENTIATION; EXPRESSION	Adipose tissue is a dynamic endocrine organ with a central role in metabolism regulation. Functional differences in adipose tissue seem associated with the regional distribution of fat depots, in particular in subcutaneous and visceral omental pads. Here, we report for the first time the isolation of human adipose-derived adult stem cells from visceral omental and subcutaneous fat (V-ASCs and S-ASCs, respectively) from the same subject. Immunophenotyping shows that plastic culturing selects homogeneous cell populations of V-ASCs and S-ASCs from the corresponding stromal vascular fractions (SVFs), sharing typical markers of mesenchymal stem cells. Electron microscopy and electrophysiological and real-time RTPCR analyses confirm the mesenchymal stem nature of both V-ASCs and S-ASCs, while no significant differences in a limited pattern of cytokine/chemokine expression can be detected. Similar to S-ASCs, V-ASCs can differentiate in vitro toward adipogenic, osteogenic, chondrogenic, muscular, and neuronal lineages, as demonstrated by histochemical, immunofluorescence, real-time RT-PCR, and electrophysiological analyses, suggesting the multipotency of such adult stem cells. Our data demonstrate that both visceral and subcutaneous adipose tissues are a source of pluripotent stem cells with multigermline potential. However, the visceral rather than the subcutaneous ASC could represent a more appropriate in vitro cell model for investigating the molecular mechanisms implicated in the pathophysiology of metabolic disorders such as obesity.-Baglioni, S., Francalanci, M., Squecco, R., Lombardi, A., Cantini, G., Angeli, R., Gelmini, S., Guasti, D., Benvenuti, S., Annunziato, F., Bani, D., Liotta, F., Francini, F., Perigli, G., Serio, M., Luconi, M. Characterization of human adult stem-cell populations isolated from visceral and subcutaneous adipose tissue. FASEB J. 23, 3494-3505 (2009). www.fasebj.org	[Baglioni, Silvana; Francalanci, Michela; Lombardi, Adriana; Cantini, Giulia; Gelmini, Stefania; Benvenuti, Susanna; Serio, Mario; Luconi, Michaela] Univ Florence, Dept Clin Physiopathol, Endocrinol Unit, I-50139 Florence, Italy; [Angeli, Roberta; Annunziato, Francesco; Liotta, Francesco] Univ Florence, Dept Internal Med, Ctr Res Transfer High Educ & Technol DENOTHE, I-50139 Florence, Italy; [Squecco, Roberta; Francini, Fabio] Univ Florence, Sch Med, Dept Physiol Sci, I-50139 Florence, Italy; [Guasti, Daniele; Bani, Daniele] Univ Florence, Sch Med, Dept Anat Histol & Forens Med, I-50139 Florence, Italy; [Perigli, Giuliano] Univ Florence, Sch Med, Dept Gen Surg, I-50139 Florence, Italy	University of Florence; University of Florence; University of Florence; University of Florence; University of Florence	Luconi, M (corresponding author), Univ Florence, Dept Clin Physiopathol, Endocrinol Unit, Viale Pieraccini 6, I-50139 Florence, Italy.	m.luconi@dfc.unifi.it	Squecco, Roberta/K-8961-2019; Luconi, Michaela/W-9522-2019; GELMINI, STEFANIA/K-8387-2018; Annunziato, Francesco/C-1155-2013; Cantini, Giulia/K-7626-2016	Luconi, Michaela/0000-0001-5186-064X; GELMINI, STEFANIA/0000-0002-4718-0833; DANIELE, GUASTI/0000-0002-2856-6829; Bani, Daniele/0000-0001-6302-901X; CANTINI, GIULIA/0000-0002-9159-9199; Annunziato, Francesco/0000-0001-8798-7589; francini, fabio/0000-0002-9255-1824	University of Florence; Tuscany Regional Study on Rosiglitazone (TRESOR)	University of Florence; Tuscany Regional Study on Rosiglitazone (TRESOR)	We thank Dr. B. Mazzinghi (University of Florence) and Dr. A. Morelli (University of Florence) for kindly providing MAP2 and desmin primers, respectively. We are indebted to Dr. F. Nuti (University of Florence) for providing anti-gamma-enolase antibody and to Dr. S. Frontera (University of Florence) for cell karyotyping. We thank Dr. G. Luciani (University of Florence) for technical assistance in electrophysiological experiments. This study has been supported by the Tuscany Regional Study on Rosiglitazone (TRESOR) project.	Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Astori G, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-55; Bai XW, 2007, AM J PHYSIOL-CELL PH, V293, pC1539, DOI 10.1152/ajpcell.00089.2007; Barzilai N, 1999, DIABETES, V48, P94, DOI 10.2337/diabetes.48.1.94; Benvenuti S, 2006, EXP CELL RES, V312, P2592, DOI 10.1016/j.yexcr.2006.04.016; Boquest AC, 2006, STEM CELL REV, V2, P319, DOI 10.1007/BF02698059; Boushell LW, 2008, ARCH ORAL BIOL, V53, P109, DOI 10.1016/j.archoralbio.2007.09.012; De Ugarte DA, 2003, IMMUNOL LETT, V89, P267, DOI 10.1016/S0165-2478(03)00108-1; Despres JP, 2006, ANN MED, V38, P52, DOI 10.1080/07853890500383895; Fonseca-Alaniz MH, 2007, J PEDIAT-BRAZIL, V83, pS192, DOI [10.1590/S0021-75572007000700011, 10.2223/JPED.1709]; Formigli L, 2005, AM J PHYSIOL-CELL PH, V288, pC795, DOI 10.1152/ajpcell.00345.2004; FUJIOKA S, 1991, INT J OBESITY, V15, P853; Gronthos S, 2001, J CELL PHYSIOL, V189, P54, DOI 10.1002/jcp.1138; Halvorsen YDC, 2001, METABOLISM, V50, P407, DOI 10.1053/meta.2001.21690; Hauner H, 1988, Horm Metab Res Suppl, V19, P35; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kilroy GE, 2007, J CELL PHYSIOL, V212, P702, DOI 10.1002/jcp.21068; Kim DH, 2005, CYTOKINE, V31, P119, DOI 10.1016/j.cyto.2005.04.004; Krampera M, 2003, BLOOD, V101, P3722, DOI 10.1182/blood-2002-07-2104; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; Liu TM, 2007, STEM CELLS, V25, P750, DOI 10.1634/stemcells.2006-0394; Lombardi A, 2008, ARTERIOSCL THROM VAS, V28, P718, DOI 10.1161/ATVBAHA.107.160713; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Mantovani G, 2009, DIABETES, V58, P620, DOI 10.2337/db08-0585; McIntosh K, 2006, STEM CELLS, V24, P1246, DOI 10.1634/stemcells.2005-0235; Mitchell JB, 2006, STEM CELLS, V24, P376, DOI 10.1634/stemcells.2005-0234; Mizuno H, 2002, PLAST RECONSTR SURG, V109, P199, DOI 10.1097/00006534-200201000-00030; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Noel D, 2008, EXP CELL RES, V314, P1575, DOI 10.1016/j.yexcr.2007.12.022; Pan GJ, 2006, FASEB J, V20, P1730, DOI 10.1096/fj.05-5543fje; Park KS, 2007, STEM CELLS, V25, P2044, DOI 10.1634/stemcells.2006-0735; Pasquinelli G, 2007, ULTRASTRUCT PATHOL, V31, P23, DOI 10.1080/01913120601169477; Pei DQ, 2009, J BIOL CHEM, V284, P3365, DOI 10.1074/jbc.R800063200; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Pou KM, 2007, CIRCULATION, V116, P1234, DOI 10.1161/CIRCULATIONAHA.107.710509; Puissant N, 2005, BRIT J HAEMATOL, V129, P118, DOI 10.1111/j.1365-2141.2005.05409.x; Sartiani L, 2007, STEM CELLS, V25, P1136, DOI 10.1634/stemcells.2006-0466; Scriba D, 2000, EUR J ENDOCRINOL, V143, P439, DOI 10.1530/eje.0.1430439; Sengenes C, 2005, J CELL PHYSIOL, V205, P114, DOI 10.1002/jcp.20381; Sengenes C, 2007, STEM CELLS, V25, P2269, DOI 10.1634/stemcells.2007-0180; Sumanasinghe RD, 2009, J CELL PHYSIOL, V219, P77, DOI 10.1002/jcp.21653; Tchkonia T, 2002, AM J PHYSIOL-REG I, V282, pR1286, DOI 10.1152/ajpregu.00653.2001; Tchkonia T, 2007, AM J PHYSIOL-ENDOC M, V292, pE298, DOI 10.1152/ajpendo.00202.2006; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; Tricarico C, 1999, INT J BIOL MARKER, V14, P247, DOI 10.1177/172460089901400409; van Harmelen V, 2004, METABOLISM, V53, P632, DOI 10.1016/j.metabol.2003.11.012; von Eyben FE, 2003, INT J OBESITY, V27, P941, DOI 10.1038/sj.ijo.0802309; Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003; Wang K, 2005, STEM CELLS, V23, P1526, DOI 10.1634/stemcells.2004-0299; Zannettino ACW, 2008, J CELL PHYSIOL, V214, P413, DOI 10.1002/jcp.21210; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	52	146	156	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3494	3505		10.1096/fj.08-126946	http://dx.doi.org/10.1096/fj.08-126946			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19584303	Green Submitted			2022-12-28	WOS:000270354300026
J	Benedict, C; Scheller, J; Rose-John, S; Born, J; Marshall, L				Benedict, Christian; Scheller, Juergen; Rose-John, Stefan; Born, Jan; Marshall, Lisa			Enhancing influence of intranasal interleukin-6 on slow-wave activity and memory consolidation during sleep	FASEB JOURNAL			English	Article						neuromodulation; cytokine; cognition; electroencephalogram power	DECLARATIVE MEMORY; EMOTIONAL MEMORY; DEFICIENT MICE; BRAIN; IL-6; OSCILLATIONS; AMYGDALA; RATS; HIPPOCAMPUS; EXPRESSION	The cytokine IL-6 has been considered to exert neuromodulating influences on the brain, with promoting influences on sleep. Sleep enhances the consolidation of memories, and, in particular, late nocturnal sleep also represents a period of enhanced IL-6 signaling, due to a distinctly enhanced availability of soluble IL-6 receptors during this period, enabling trans-signaling of IL-6 to neurons. Thus, a contribution of IL-6 to sleep-dependent memory consolidation is hypothesized. To test this hypothesis, we compared effects of intranasally administered IL-6 (vs. placebo) on sleep-dependent consolidation of declarative (neutral and emotional texts, 2-dimensional object location) and procedural (finger sequence tapping) memories in 17 healthy young men. IL-6 distinctly improved the sleep-related consolidation of emotional text material (P<0.03), which benefits mostly from sleep in the second night-half, in which rapid eye movement sleep (REM) dominates the non-REM-REM sleep cycle. During this second night-half, the amount of electroencephalogram slow-wave activity (0.5-4 Hz) distinctly increased after IL-6 (P<0.01). Other types of memory were not affected. The ability of IL-6 to enhance sleep-associated emotional memory consolidation highlights an example of a functional interaction between the central nervous and immune system.-Benedict, C., Scheller, J., Rose-John, S., Born, J., Marshall, L. Enhancing influence of intranasal interleukin-6 on slow-wave activity and memory consolidation during sleep. FASEB J. 23, 3629-3636 (2009). www.fasebj.org	[Benedict, Christian; Born, Jan; Marshall, Lisa] Med Univ Lubeck, Dept Neuroendocrinol, D-23538 Lubeck, Germany; [Scheller, Juergen; Rose-John, Stefan] Univ Kiel, Dept Biochem, Kiel, Germany	University of Lubeck; University of Kiel	Marshall, L (corresponding author), Med Univ Lubeck, Dept Neuroendocrinol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	marshall@kfg.uni-luebeck.de	Born, Jan/K-2596-2016; Benedict, Christian/K-2190-2017; Rose-John, Stefan/A-7998-2010; Scheller, Jürgen/K-5290-2015	Born, Jan/0000-0002-1847-6248; Benedict, Christian/0000-0002-8911-4068; Rose-John, Stefan/0000-0002-7519-3279; , Lisa/0000-0002-3976-1822	Deutsche Forschungsgemeinschaft [SFB 654]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We are grateful to N. Jakob, V. Ulrich, C. Otten, I. von Lutzau, H. Ruf, M. Rohwer, and A. Otterbein for their expert and invaluable laboratory work and to M. Molle for support with EEG data analyses. The study was funded by a grant from the Deutsche Forschungsgemeinschaft (SFB 654: Plasticity and Sleep). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All authors had full access to all data in the study and take responsibility for the integrity and accuracy of the data analysis.	Aschenbrenner S., 2000, REGENSBURGER WORTFLU; Babiloni C, 2009, HUM BRAIN MAPP, V30, P2077, DOI 10.1002/hbm.20648; Baier PC, 2009, BEHAV BRAIN RES, V200, P192, DOI 10.1016/j.bbr.2009.01.013; Balschun D, 2004, FASEB J, V18, P1788, DOI 10.1096/fj.04-1625fje; Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849; Born J, 1997, J IMMUNOL, V158, P4454; Born J, 2006, NEUROSCIENTIST, V12, P410, DOI 10.1177/1073858406292647; Braida D, 2004, BEHAV BRAIN RES, V153, P423, DOI 10.1016/j.bbr.2003.12.018; CHRISTENSEN PR, 1958, WORD FLUENCY FORM A; de Quervain DJF, 2000, NAT NEUROSCI, V3, P313, DOI 10.1038/73873; Denecke H, 2002, PHARMACOL BIOCHEM BE, V73, P593, DOI 10.1016/S0091-3057(02)00823-7; Dimitrov S, 2006, FASEB J, V20, P2174, DOI 10.1096/fj.06-5754fje; Fischer S, 2002, P NATL ACAD SCI USA, V99, P11987, DOI 10.1073/pnas.182178199; Gais S, 2002, J NEUROSCI, V22, P6830; Gais S, 2006, LEARN MEMORY, V13, P259, DOI 10.1101/lm.132106; Guan ZW, 2005, BRAIN BEHAV IMMUN, V19, P526, DOI 10.1016/j.bbi.2005.01.005; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; Juttler E, 2002, NEUROSCIENTIST, V8, P268, DOI 10.1177/1073858402008003012; Krueger JM, 2003, ANN NY ACAD SCI, V992, P9, DOI 10.1111/j.1749-6632.2003.tb03133.x; LEMAY LG, 1990, AM J PHYSIOL, V258, pR798, DOI 10.1152/ajpregu.1990.258.3.R798; Luterman JD, 2000, ARCH NEUROL-CHICAGO, V57, P1153, DOI 10.1001/archneur.57.8.1153; MacLean, 1992, J Sleep Res, V1, P35; Maquet P, 2001, SCIENCE, V294, P1048, DOI 10.1126/science.1062856; Marshall L, 2002, INT REV NEUROBIOL, V52, P93; Marshall L, 2006, NATURE, V444, P610, DOI 10.1038/nature05278; Marshall U, 2007, TRENDS COGN SCI, V11, P442, DOI 10.1016/j.tics.2007.09.001; Marsland AL, 2006, PSYCHOSOM MED, V68, P895, DOI 10.1097/01.psy.0000238451.22174.92; McGaugh JL, 2004, ANNU REV NEUROSCI, V27, P1, DOI 10.1146/annurev.neuro.27.070203.144157; Molle M, 2004, P NATL ACAD SCI USA, V101, P13963, DOI 10.1073/pnas.0402820101; Mullington J, 2000, AM J PHYSIOL-REG I, V278, pR947, DOI 10.1152/ajpregu.2000.278.4.R947; Pare D, 2002, TRENDS COGN SCI, V6, P306, DOI 10.1016/S1364-6613(02)01924-1; Payne JD, 2008, PSYCHOL SCI, V19, P781, DOI 10.1111/j.1467-9280.2008.02157.x; Plihal W, 1999, PSYCHOPHYSIOLOGY, V36, P571, DOI 10.1111/1469-8986.3650571; Rasch B, 2007, CURR OPIN NEUROBIOL, V17, P698, DOI 10.1016/j.conb.2007.11.007; Rasch B, 2007, SCIENCE, V315, P1426, DOI 10.1126/science.1138581; Rechtschaffen A., 1968, BRAIN INFORM SERVICE; Rose-John S, 2003, ACTA BIOCHIM POL, V50, P603; Sallmann S, 2000, J NEUROSCI, V20, P8637; Scheller J, 2006, MED MICROBIOL IMMUN, V195, P173, DOI 10.1007/s00430-006-0019-9; SCHOBITZ B, 1995, FASEB J, V9, P659, DOI 10.1096/fasebj.9.8.7768358; Schurer-Necker E., 1994, GEDACHTNIS EMOTION Z; Seres J, 2004, NEUROIMMUNOMODULAT, V11, P316, DOI 10.1159/000079412; Sommer T, 2005, LEARN MEMORY, V12, P343, DOI 10.1101/lm.90405; Spath-Schwalbe E, 1998, J CLIN ENDOCR METAB, V83, P1573, DOI 10.1210/jc.83.5.1573; Tancredi V, 2000, J NEUROCHEM, V75, P634, DOI 10.1046/j.1471-4159.2000.0750634.x; Vgontzas AN, 2005, NEUROIMMUNOMODULAT, V12, P131, DOI 10.1159/000084844; Wagner U, 2001, LEARN MEMORY, V8, P112, DOI 10.1101/lm.36801; Wagner U, 2005, BIOL PSYCHIAT, V58, P885, DOI 10.1016/j.biopsych.2005.05.008; Walker MP, 2002, NEURON, V35, P205, DOI 10.1016/S0896-6273(02)00746-8	49	58	61	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3629	3636		10.1096/fj.08-122853	http://dx.doi.org/10.1096/fj.08-122853			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19546306				2022-12-28	WOS:000270354300039
J	Liu, H; Wang, P; Song, WH; Sun, XL				Liu, Heng; Wang, Pin; Song, Weihong; Sun, Xiulian			Degradation of regulator of calcineurin 1 (RCAN1) is mediated by both chaperone-mediated autophagy and ubiquitin proteasome pathways	FASEB JOURNAL			English	Article						Alzheimer; Down syndrome; DSCR1	SYNDROME CRITICAL REGION; AMYLOID PROTEIN-PRECURSOR; APOPTOTIC CELL-DEATH; ALZHEIMERS-DISEASE; DOWN-SYNDROME; NEURODEGENERATIVE DISEASES; INTERACTING PROTEIN-1; ALPHA-SYNUCLEIN; DSCR1 ADAPT78; IN-VITRO	Regulator of calcineurin 1 (RCAN1), a gene identified from the critical region of Down syndrome, has been implied in pathogenesis of Alzheimer's disease ( AD). RCAN1 expression was shown to be increased in AD brains; however, the mechanism of RCAN1 gene regulation is not well defined. The present study was designed to investigate the molecular mechanism of RCAN1 protein degradation. In addition to being degraded through the ubiquitin proteasome pathway, we found that lysosomal inhibition markedly increased RCAN1 protein expression in a time- and dosage-dependent manner. Inhibition of macroautophagy reduced RCAN1 expression, indicating that RCAN1 degradation is not through a macroautophagy pathway. However, disruption of chaperone-mediated autophagy (CMA) increased RCAN1 expression. Two CMA recognition motifs were indentified in RCAN1 protein to mediate its degradation through a CMA-lysosome pathway. A promoter assay further demonstrated that inhibition of RCAN1 degradation in cells reduced calcineurin-NFAT activity. Dysfunctions of ubiquitin-proteasome and autophagy-lysosome pathways have been implicated in neurodegenerative diseases. Therefore, elucidation of RCAN1 degradation by a ubiquitin proteasome pathway and CMA-lysosome pathway in the present study may greatly advance our understanding of AD pathogenesis.-Liu, H., Wang, P., Song, W., Sun, X. Degradation of regulator of calcineurin 1 ( RCAN1) is mediated by both chaperone-mediated autophagy and ubiquitin proteasome pathways. FASEB J. 23, 3383-3392 ( 2009). www.fasebj.org	[Song, Weihong] Univ British Columbia, Dept Psychiat, Townsend Family Labs, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; [Liu, Heng; Wang, Pin; Sun, Xiulian] Shandong Univ, Qilu Hosp, Jinan 250100, Shandong, Peoples R China	University of British Columbia; Shandong University	Song, WH (corresponding author), Univ British Columbia, Dept Psychiat, Townsend Family Labs, Brain Res Ctr, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	weihong@exchange.ubc.ca; xiulians@gmail.com	Song, Weihong/O-7623-2017	Song, Weihong/0000-0001-9928-889X	National Natural Science Foundation of China [NSFC 30771075]; Taishan Scholarship; Canadian Institutes of Health Research (CIHR); Jack Brown and Family Alzheimer's Research Foundation; Michael Smith Foundation for Health Research (MSFHR); Canada Research Chair in Alzheimer's Disease	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholarship; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Jack Brown and Family Alzheimer's Research Foundation; Michael Smith Foundation for Health Research (MSFHR)(Michael Smith Foundation for Health Research); Canada Research Chair in Alzheimer's Disease(Canada Research Chairs)	This work was supported by the National Natural Science Foundation of China (NSFC 30771075) and a Taishan Scholarship ( to X. S.), the Canadian Institutes of Health Research (CIHR), the Jack Brown and Family Alzheimer's Research Foundation, and the Michael Smith Foundation for Health Research (MSFHR) ( to W. S.). W. S. is the holder of the Canada Research Chair in Alzheimer's Disease.	Abbasi S, 2006, J BIOL CHEM, V281, P7717, DOI 10.1074/jbc.M510775200; Abbasi S, 2005, J BIOL CHEM, V280, P36737, DOI 10.1074/jbc.M506493200; Arron JR, 2006, NATURE, V441, P595, DOI 10.1038/nature04678; Asada S, 2008, INT J MOL MED, V22, P95; Berger Z, 2006, HUM MOL GENET, V15, P433, DOI 10.1093/hmg/ddi458; Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; Chan B, 2005, P NATL ACAD SCI USA, V102, P13075, DOI 10.1073/pnas.0503846102; Chang KT, 2003, P NATL ACAD SCI USA, V100, P15794, DOI 10.1073/pnas.2536696100; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Crystal AS, 2004, BIOCHEMISTRY-US, V43, P3555, DOI 10.1021/bi0361214; Cuervo AM, 2000, J BIOL CHEM, V275, P31505, DOI 10.1074/jbc.M002102200; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; David DC, 2002, J NEUROCHEM, V83, P176, DOI 10.1046/j.1471-4159.2002.01137.x; Davies KJA, 2007, FASEB J, V21, P3023, DOI 10.1096/fj.06-7246com; Dice JF, 2007, AUTOPHAGY, V3, P295, DOI 10.4161/auto.4144; DICE JF, 1986, J BIOL CHEM, V261, P6853; Dunys J, 2006, BIOCHEM J, V394, P501, DOI 10.1042/BJ20051197; Eckert A, 2003, ANN NY ACAD SCI, V1010, P604, DOI 10.1196/annals.1299.113; Ermak G, 2001, J BIOL CHEM, V276, P38787, DOI 10.1074/jbc.M102829200; Finn PE, 2005, AUTOPHAGY, V1, P141, DOI 10.4161/auto.1.3.2000; Finn PF, 2006, NUTRITION, V22, P830, DOI 10.1016/j.nut.2006.04.008; Fraser PE, 1998, NEUROBIOL AGING, V19, pS19, DOI 10.1016/S0197-4580(98)00029-3; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; Gandhi S, 2005, HUM MOL GENET, V14, P2749, DOI 10.1093/hmg/ddi308; Gyure KA, 2001, ARCH PATHOL LAB MED, V125, P489; Hampton T, 2005, JAMA-J AM MED ASSOC, V293, P284, DOI 10.1001/jama.293.3.284; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Harris CD, 2007, FEBS J, V274, P1715, DOI 10.1111/j.1742-4658.2007.05717.x; He GQ, 2007, J NEUROCHEM, V101, P982, DOI 10.1111/j.1471-4159.2007.04449.x; He GQ, 2006, J NEUROCHEM, V99, P1403, DOI 10.1111/j.1471-4159.2006.04184.x; Hilioti Z, 2004, GENE DEV, V18, P35, DOI 10.1101/gad.1159204; Honda T, 1999, J NEUROCHEM, V72, P255, DOI 10.1046/j.1471-4159.1999.0720255.x; Iwata A, 2005, P NATL ACAD SCI USA, V102, P13135, DOI 10.1073/pnas.0505801102; JACOBS PA, 1959, LANCET, V1, P710; Kaushik S, 2008, MOL BIOL CELL, V19, P2179, DOI 10.1091/mbc.E07-11-1155; Keck S, 2003, J NEUROCHEM, V85, P115, DOI 10.1046/j.1471-4159.2003.01642.x; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kluetzman KS, 2005, BIOCHEM BIOPH RES CO, V337, P595, DOI 10.1016/j.bbrc.2005.09.069; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; LEJEUNE J., 1959, BULL ACAD NATL MED [PARIS], V143, P256; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Liu SC, 2008, EUR J NEUROSCI, V28, P1980, DOI 10.1111/j.1460-9568.2008.06497.x; Ma H, 2004, J NEUROCHEM, V88, P1485, DOI 10.1046/j.1471-4159.2003.02294.x; Majeski AE, 2004, INT J BIOCHEM CELL B, V36, P2435, DOI 10.1016/j.biocel.2004.02.013; Massey AC, 2006, P NATL ACAD SCI USA, V103, P5805, DOI 10.1073/pnas.0507436103; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Nixon RA, 2006, TRENDS NEUROSCI, V29, P528, DOI 10.1016/j.tins.2006.07.003; Nunan J, 2003, J NEUROSCI RES, V74, P378, DOI 10.1002/jnr.10646; Nunan J, 2001, EUR J BIOCHEM, V268, P5329, DOI 10.1046/j.0014-2956.2001.02465.x; Qing H, 2004, FASEB J, V18, P1571, DOI 10.1096/fj.04-1994fje; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Rothermel BA, 2003, TRENDS CARDIOVAS MED, V13, P15, DOI 10.1016/S1050-1738(02)00188-3; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Seo SR, 2008, FEBS LETT, V582, P1889, DOI 10.1016/j.febslet.2008.04.059; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Skovronsky DM, 2000, BIOCHEMISTRY-US, V39, P810, DOI 10.1021/bi991728z; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Stathatos N, 2005, J CLIN ENDOCR METAB, V90, P5432, DOI 10.1210/jc.2005-0963; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Sun XL, 2006, FASEB J, V20, P1369, DOI 10.1096/FJ.05-5632COM; Sun XL, 2006, FASEB J, V20, P1361, DOI 10.1096/fj.05-5628com; Sun XL, 2005, FASEB J, V19, P739, DOI 10.1096/fj.04-3426com; TAYLOR JM, 1973, DRUG METAB DISPOS, V1, P84; van Rooij E, 2004, CIRC RES, V94, pE18, DOI 10.1161/01.RES.0000118597.54416.00; Vega RB, 2002, J BIOL CHEM, V277, P30401, DOI 10.1074/jbc.M200123200; Vogiatzi T, 2008, J BIOL CHEM, V283, P23542, DOI 10.1074/jbc.M801992200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765; Zhou WH, 2006, MOL CELL BIOL, V26, P3353, DOI 10.1128/MCB.26.9.3353-3364.2006	76	96	98	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3383	3392		10.1096/fj.09-134296	http://dx.doi.org/10.1096/fj.09-134296			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19509306				2022-12-28	WOS:000270354300016
J	Duka, T; Duka, V; Joyce, JN; Sidhu, A				Duka, Tetyana; Duka, Valeriy; Joyce, Jeffrey N.; Sidhu, Anita			alpha-Synuclein contributes to GSK-3 beta-catalyzed Tau phosphorylation in Parkinson's disease models	FASEB JOURNAL			English	Article						synucleopathies; tauopathies; neurodegeneration; Alzheimer's disease	GLYCOGEN-SYNTHASE KINASE-3-BETA; LEWY BODY PATHOLOGY; ALZHEIMERS-DISEASE; DOPAMINE TRANSPORTER; POSITIVE STRUCTURES; TRANSGENIC MICE; BODIES; LITHIUM; NEURONS; PROTEIN	We have shown in the parkinsonism-inducing neurotoxin MPP+/MPTP model that alpha-Synuclein (alpha-Syn), a presynaptic protein causal in Parkinson's disease (PD), contributes to hyperphosphorylation of Tau (p-Tau), a protein normally linked to tauopathies, such as Alzheimer's disease (AD). Here, we investigated the kinase involved and show that the Tau-specific kinase, glycogen synthase kinase 3 beta (GSK-3 beta), is robustly activated in various MPP+/MPTP models of Parkinsonism (SH-SY5Y cotransfected cells, mesencephalic neurons, transgenic mice overexpressing alpha-Syn, and postmortem striatum of PD patients). The activation of GSK-3 beta was absolutely dependent on the presence of alpha-Syn, as indexed by the absence of p-GSK-3 beta in cells lacking alpha-Syn and in alpha-Syn KO mice. MPP+ treatment induced translocation and accumulation of p-GSK-3 beta in nuclei of SH-SY5Y cells and mesencephalic neurons. Through coimmunoprecipitation (co-IP), we found that alpha-Syn, pSer396/404-Tau, and p-GSK-3 beta exist as a heterotrimeric complex in SH-SY5Y cells. GSK-3 beta inhibitors (lithium and TDZD-8) protected against MPP+-induced events in SH-SY5Y cells, preventing cell death and p-GSK-3 beta formation, by reversing increases in alpha-Syn accumulation and p-Tau formation. These data unveil a previously unappreciated role of alpha-Syn in the induction of p-GSK-3 beta, and demonstrate the importance of this kinase in the genesis and maintenance of neurodegenerative changes associated with PD.-Duka, T., Duka, V., Joyce, J. N., Sidhu, A. alpha-Synuclein contributes to GSK-3 beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J. 23, 2820-2830 (2009). www.fasebj.org	[Duka, Tetyana; Duka, Valeriy; Sidhu, Anita] Georgetown Univ, Dept Biochem Mol & Cellular Biol, Washington, DC USA; [Joyce, Jeffrey N.] Maricopa Integrated Hlth Syst, Dept Res, Phoenix, AZ USA	Georgetown University; Maricopa County General Hospital	Sidhu, A (corresponding author), Lab Mol Neurochem, Res Bldg,Rm W222,3970 Reservoir Rd NW, Washington, DC 20007 USA.	sidhua@georgetown.edu		Joyce, Jeffrey/0000-0002-0131-0946	National Institute of Aging [R01AG028108]; National Institutes of Neurological Disorders and Stroke [R01NS45326]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028108] Funding Source: NIH RePORTER	National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institutes of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We are grateful to Dr. P. Davies (Albert Einstein College of Medicine, Bronx, NY, USA) for providing the antibodies PHF-1 and CP13 against Tau phosphorylated at Ser-396/404 and Ser-202. We thank Dr. John L. Goudreau (Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, USA) for providing the striata from MPTP-treated alpha-Syn-knockout mice. We also thank Dr. Milan Rusnak for isolation of mesencephalic primary neurons. This work was supported in part by grants from the National Institute of Aging, R01AG028108, and National Institutes of Neurological Disorders and Stroke, R01NS45326, to A.S.	Agarwal-Mawal A, 2003, J BIOL CHEM, V278, P12722, DOI 10.1074/jbc.M211491200; Arai Y, 2001, BRAIN RES, V888, P287, DOI 10.1016/S0006-8993(00)03082-1; Arima K, 1999, BRAIN RES, V843, P53, DOI 10.1016/S0006-8993(99)01848-X; Bedford L, 2008, BBA-MOL BASIS DIS, V1782, P683, DOI 10.1016/j.bbadis.2008.10.009; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Caccamo A, 2007, AM J PATHOL, V170, P1669, DOI 10.2353/ajpath.2007.061178; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cole AR, 2004, J BIOL CHEM, V279, P50176, DOI 10.1074/jbc.C400412200; Dickson DW, 1999, BRAIN PATHOL, V9, P657; Drolet RE, 2004, NEUROTOXICOLOGY, V25, P761, DOI 10.1016/j.neuro.2004.05.002; Duka T, 2006, FASEB J, V20, P2302, DOI 10.1096/fj.06-6092com; Duka T, 2006, NEUROTOX RES, V10, P1, DOI 10.1007/BF03033329; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Frasier M, 2005, EXP NEUROL, V192, P274, DOI 10.1016/j.expneurol.2004.07.016; Frasier M, 2004, EXP NEUROL, V187, P235, DOI 10.1016/j.expneurol.2004.02.008; Geddes JW, 2005, EXP NEUROL, V192, P244, DOI 10.1016/j.expneurol.2004.12.002; Goers J, 2003, BIOCHEMISTRY-US, V42, P8465, DOI 10.1021/bi0341152; Gomez-Ramos A, 2004, BRAIN RES, V1007, P57, DOI 10.1016/j.brainres.2004.01.071; Habas A, 2006, J NEUROCHEM, V96, P335, DOI 10.1111/j.1471-4159.2005.03543.x; Hamilton RL, 2000, BRAIN PATHOL, V10, P378; Hanger DP, 2009, TRENDS MOL MED, V15, P112, DOI 10.1016/j.molmed.2009.01.003; Hernandez F, 2002, J NEUROCHEM, V83, P1529, DOI 10.1046/j.1471-4159.2002.01269.x; Hetman M, 2000, J NEUROSCI, V20, P2567; Hishikawa N, 2003, NEUROPATH APPL NEURO, V29, P280, DOI 10.1046/j.1365-2990.2003.00470.x; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; Ishizawa T, 2003, J NEUROPATH EXP NEUR, V62, P389, DOI 10.1093/jnen/62.4.389; Jeannotte AM, 2007, EUR J NEUROSCI, V26, P1509, DOI 10.1111/j.1460-9568.2007.05757.x; Joyce JN, 2003, EXP NEUROL, V184, P393, DOI 10.1016/S0014-4886(03)00353-4; Joyce JN, 2002, BRAIN RES, V955, P138, DOI 10.1016/S0006-8993(02)03396-6; Kawakami F, 2008, J BIOCHEM, V143, P359, DOI 10.1093/jb/mvm228; Kim JE, 2007, J CLIN NEUROL, V3, P9, DOI 10.3988/jcn.2007.3.1.9; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Kotzbauer PT, 2001, J MOL NEUROSCI, V17, P225, DOI 10.1385/JMN:17:2:225; Kozikowski AP, 2006, CHEMMEDCHEM, V1, P256, DOI 10.1002/cmdc.200500039; Kwok JBJ, 2005, ANN NEUROL, V58, P829, DOI 10.1002/ana.20691; Li BL, 2004, TRANSGENIC RES, V13, P385, DOI 10.1023/B:TRAG.0000040039.44899.6f; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; Lippa Sara M, 2005, Am J Alzheimers Dis Other Demen, V20, P315, DOI 10.1177/153331750502000506; Lochhead PA, 2006, MOL CELL, V24, P627, DOI 10.1016/j.molcel.2006.10.009; Loo DT, 1998, METHOD CELL BIOL, V57, P251; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Luna-Munoz J, 2005, J ALZHEIMERS DIS, V8, P29; Martinez A, 2008, J ALZHEIMERS DIS, V15, P181; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Muntane G, 2008, NEUROSCIENCE, V152, P913, DOI 10.1016/j.neuroscience.2008.01.030; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Popescu A, 2004, ARCH NEUROL-CHICAGO, V61, P1915, DOI 10.1001/archneur.61.12.1915; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Trembath Y, 2003, ACTA NEUROPATHOL, V105, P484, DOI 10.1007/s00401-003-0670-9; Vadivelan S, 2009, EUR J MED CHEM, V44, P2361, DOI 10.1016/j.ejmech.2008.08.012; Wang WY, 2007, NEUROPHARMACOLOGY, V52, P1678, DOI 10.1016/j.neuropharm.2007.03.017; Wersinger C, 2005, BIOCHEMISTRY-US, V44, P13612, DOI 10.1021/bi050402p; Wersinger C, 2003, FASEB J, V17, P2151, DOI 10.1096/fj.03-0152fje	59	191	196	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2820	2830		10.1096/fj.08-120410	http://dx.doi.org/10.1096/fj.08-120410			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19369384	Green Published			2022-12-28	WOS:000270241000005
J	Ruggiero, T; Trabucchi, M; De Santa, F; Zupo, S; Harfe, BD; McManus, MT; Rosenfeld, MG; Briata, P; Gherzi, R				Ruggiero, Tina; Trabucchi, Michele; De Santa, Francesca; Zupo, Simona; Harfe, Brian D.; McManus, Michael T.; Rosenfeld, M. Geoff; Briata, Paola; Gherzi, Roberto			LPS induces KH-type splicing regulatory protein-dependent processing of microRNA-155 precursors in macrophages	FASEB JOURNAL			English	Article						RNA-binding protein; post-transcriptional regulation of gene expression; inflammation	AU-RICH ELEMENT; POSTTRANSCRIPTIONAL REGULATION; SIGNALING PATHWAYS; INNATE IMMUNITY; RNA; EXPRESSION; KSRP; INFLAMMATION; MECHANISMS; STABILITY	The importance of post-transcriptional mechanisms for the regulation of the homoeostasis of the immune system and the response to challenge by microorganisms is becoming increasingly appreciated. We investigated the contribution of microRNAs (miRNAs) to macrophage activation induced by lipopolysaccharide (LPS). We first observed that Dicer knockout in bone marrow-derived macrophages (BMDMs) increases the LPS-induced expression of some inflammation mediators. miRNA microarray analysis in BMDMs revealed that LPS significantly induces the expression of a single miRNA, miR-155, and this induction depends on enhanced miR-155 maturation from its precursors. The single-strand RNA-binding protein KH-type splicing regulatory protein (KSRP) binds to the terminal loop of miR-155 precursors and promotes their maturation. Both inhibition of miR-155 and KSRP knockdown enhance the LPS-induced expression of select inflammation mediators, and the effect of KSRP knockdown is reverted by mature miR-155. Our studies unveil the existence of an LPS-dependent post-transcriptional regulation of miR-155 biogenesis. Once induced, miR-155 finely tunes the expression of select inflammation mediators in response to LPS.-Ruggiero, T., Trabucchi, M., De Santa, F., Zupo, S., Harfe, B. D., McManus, M. T., Rosenfeld, M. G., Briata, P., Gherzi, R. LPS induces KH- type splicing regulatory protein-dependent processing of microRNA-155 precursors in macrophages. FASEB J. 23, 2898-2908 (2009). www.fasebj.org	[Ruggiero, Tina] Ctr Biotecnol Avanzate, RNA Technol Lab, Genoa, Italy; [Trabucchi, Michele; Rosenfeld, M. Geoff] Univ Calif San Diego, Howard Hughes Med Inst, Dept Med, La Jolla, CA 92093 USA; [De Santa, Francesca] European Inst Oncol, Dept Expt Oncol, Milan, Italy; [Zupo, Simona; Briata, Paola; Gherzi, Roberto] Ist Nazl Ric Canc, I-16132 Genoa, Italy; [Harfe, Brian D.] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA; [McManus, Michael T.] Univ Calif San Francisco, Dept Microbiol & Immunol, UCSF Diabet Ctr, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; IRCCS European Institute of Oncology (IEO); University of Genoa; IRCCS AOU San Martino IST; State University System of Florida; University of Florida; University of California System; University of California San Francisco	Briata, P (corresponding author), Natl Canc Inst IST, Gene Express Regulat Lab, Largo R Benzi 10, I-16132 Genoa, Italy.	paola.briata@istge.it; rgherzi@ucsd.edu	Trabucchi, Michele/O-1755-2018; De Santa, Francesca/A-2954-2014; mcmanus, michael/AAB-1239-2020; Briata, Paola/AAC-6039-2020; DE SANTA, FRANCESCA/AAX-5810-2020; Gherzi, Roberto/AAA-7256-2020; Zupo, Simona/AAC-2757-2020	De Santa, Francesca/0000-0002-0034-5450; mcmanus, michael/0000-0003-3013-6569; Briata, Paola/0000-0003-3470-0454; DE SANTA, FRANCESCA/0000-0002-0034-5450; Gherzi, Roberto/0000-0001-8654-0611; Zupo, Simona/0000-0001-6837-5763; Trabucchi, Michele/0000-0001-6885-5628	Centro Biotecnologie Avanzate fellowship; Italian Telethon Foundation fellowship; CIPE; Associazione Italiana per la Ricerca sul Cancro; Italian Istituto Superiore di Sanita (ISS) [527B/2B/6]; ISS [526D/39]	Centro Biotecnologie Avanzate fellowship; Italian Telethon Foundation fellowship(Fondazione Telethon); CIPE; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Italian Istituto Superiore di Sanita (ISS); ISS	We are indebted to Dr. Gioacchino Natoli [European Institute of Oncology/FIRC Institute of Molecular Oncology Foundation (IEO/IFOM), Milan, Italy] and Dr. Antonio De Flora (University of Genova, Genoa, Italy) for helpful discussions and comments; Dr. G. Corte [Istituto Nazionale per la Ricerca sul Cancro (IST), Milan, Italy] for helpful discussions and for sharing lab facilities; and Dr. D. Shaffer (Bar Harbor BioTechnology, Trenton, ME, USA) for GPR analysis. T. R. is the recipient of a Centro Biotecnologie Avanzate fellowship [Interministerial Committee for Economic Planning (CIPE) 2007]. M. T. is the recipient of an Italian Telethon Foundation fellowship. The work of R. G. has been supported, in part, by CIPE 2007 (Regione Liguria), Associazione Italiana per la Ricerca sul Cancro, and the Italian Istituto Superiore di Sanita (ISS) (527B/2B/6). The work of P.B. has been supported, in part, by a grant from ISS (526D/39).	Akilesh S, 2003, GENOME RES, V13, P1719, DOI 10.1101/gr.533003; Akira S, 2006, CURR TOP MICROBIOL, V311, P1; Allam R, 2008, CURR OPIN RHEUMATOL, V20, P538, DOI 10.1097/BOR.0b013e3283025ed4; Anderson P, 2004, J LEUKOCYTE BIOL, V76, P42, DOI 10.1189/jlb.1103536; Banerjee A, 2007, IMMUNOL CELL BIOL, V85, P420, DOI 10.1038/sj.icb.7100098; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Briata P, 2005, MOL CELL, V20, P891, DOI 10.1016/j.molcel.2005.10.021; Ceppi M, 2009, P NATL ACAD SCI USA, V106, P2735, DOI 10.1073/pnas.0811073106; Chen CY, 2000, GENE DEV, V14, P1236; De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Fujihara M, 2003, PHARMACOL THERAPEUT, V100, P171, DOI 10.1016/j.pharmthera.2003.08.003; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Gherzi R, 2007, PLOS BIOL, V5, P82, DOI 10.1371/journal.pbio.0050005; Hao SL, 2009, NAT IMMUNOL, V10, P281, DOI 10.1038/ni.1699; Harfe BD, 2005, P NATL ACAD SCI USA, V102, P10898, DOI 10.1073/pnas.0504834102; Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527; Hong JA, 2004, J IMMUNOL, V172, P5870, DOI 10.4049/jimmunol.172.10.5870; Hume David A, 2007, Novartis Found Symp, V281, P2; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Kluiver J, 2007, ONCOGENE, V26, P3769, DOI 10.1038/sj.onc.1210147; Linker K, 2005, NUCLEIC ACIDS RES, V33, P4813, DOI 10.1093/nar/gki797; Lu F, 2008, J VIROL, V82, P10436, DOI 10.1128/JVI.00752-08; O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; Obernosterer G, 2006, RNA, V12, P1161, DOI 10.1261/rna.2322506; Papadimitraki ED, 2007, J AUTOIMMUN, V29, P310, DOI 10.1016/j.jaut.2007.09.001; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sharif O, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-1; Sheedy FJ, 2008, ANN RHEUM DIS, V67, P50, DOI 10.1136/ard.2008.100289; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Winzen R, 2007, MOL CELL BIOL, V27, P8388, DOI 10.1128/MCB.01493-07	41	169	181	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2898	2908		10.1096/fj.09-131342	http://dx.doi.org/10.1096/fj.09-131342			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19423639				2022-12-28	WOS:000270241000013
J	Lobo, GP; Hessel, S; Eichinger, A; Noy, N; Moise, AR; Wyss, A; Palczewski, K; von Lintig, J				Lobo, Glenn P.; Hessel, Susanne; Eichinger, Anne; Noy, Noa; Moise, Alexander R.; Wyss, Adrian; Palczewski, Krzysztof; von Lintig, Johannes			ISX is a retinoic acid-sensitive gatekeeper that controls intestinal beta,beta-carotene absorption and vitamin A production	FASEB JOURNAL			English	Article						carotenoids; retinoids; nuclear receptors; scavenger receptors	BETA-CAROTENE 15,15'-MONOOXYGENASE; RECEPTOR CLASS-B; I SR-BI; SCAVENGER RECEPTOR; CHOLESTEROL ABSORPTION; DIETARY-CHOLESTEROL; METABOLISM; EXPRESSION; TRANSPORT; ACYLTRANSFERASE	The uptake of dietary lipids from the small intestine is a complex process that depends on the activities of specific membrane receptors with yet unknown regulatory mechanisms. Using both mouse models and human cell lines, we show here that intestinal lipid absorption by the scavenger receptor class B type 1 (SR-BI) is subject to control by retinoid signaling. Retinoic acid via retinoic acid receptors induced expression of the intestinal transcription factor ISX. ISX then repressed the expression of SR-B1 and the carotenoid-15,15'-oxygenase Bcmo1. BCMO1 acts downstream of SR-BI and converts absorbed beta,beta-carotene to the retinoic acid precursor, retinaldehyde. Using BCMO1-knockout mice, we demonstrated increased intestinal SR-BI expression and systemic beta,beta-carotene accumulation. SR-BI-dependent accumulation of beta,beta-carotene was prevented by dietary retinoids that induced ISX expression. Thus, our study revealed a diet-responsive regulatory network that controls beta,beta-carotene absorption and vitamin A production by negative feedback regulation. The role of SR-BI in the intestinal absorption of other dietary lipids, including cholesterol, fatty acids, and tocopherols, implicates retinoid signaling in the regulation of lipid absorption more generally and has clinical implications for diseases associated with dyslipidemia.-Lobo, G. P., Hessel, S., Eichinger, A., Noy, N., Moise, A. R., Wyss, A., Palczewski, K., von Lintig, J. ISX is a retinoic acid-sensitive gatekeeper that controls intestinal beta,beta-carotene absorption and vitamin A production. FASEB J. 24, 1656-1666 (2010). www.fasebj.org	[Lobo, Glenn P.; Hessel, Susanne; Noy, Noa; Moise, Alexander R.; Palczewski, Krzysztof; von Lintig, Johannes] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44160 USA; [Eichinger, Anne; Wyss, Adrian] DSM Nutr Prod Ltd, R&D Human Nutr & Hlth, Basel, Switzerland	Case Western Reserve University; DSM NV	von Lintig, J (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol W333, 10900 Euclid Ave, Cleveland, OH 44160 USA.	johannes.vonlintig@case.edu	Moise, Alexander R/C-9498-2009; Lobo, Glenn P./AAI-9736-2020; AR, Moise/P-2474-2019	Moise, Alexander R/0000-0003-2307-6035; AR, Moise/0000-0003-2307-6035; von Lintig, Johannes/0000-0002-2079-2143	U.S. National Institutes of Health [EY019641, EY009339]; NATIONAL EYE INSTITUTE [R01EY020551, R01EY019641, R01EY009339] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The authors thank Dr. Elwin Morgan (Case Western Reserve University) and Dr. Kristi Bennett (Cleveland Clinic Foundation, Cleveland, OH, USA) for their technical advice in the ChIP assay. This work was supported by U.S. National Institutes of Health grants EY019641 to J.V.L. and EY009339 to K. P.	Bachmann H, 2002, J NUTR, V132, P3616, DOI 10.1093/jn/132.12.3616; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Bietrix F, 2006, J BIOL CHEM, V281, P7214, DOI 10.1074/jbc.M508868200; Borel P, 1998, J LIPID RES, V39, P2250; Boulanger A, 2003, FASEB J, V17, P1304, DOI 10.1096/fj.02-0690fje; Cai SF, 2001, J LIPID RES, V42, P902; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Choi MY, 2006, DEVELOPMENT, V133, P4119, DOI 10.1242/dev.02537; During A, 2007, J LIPID RES, V48, P2283, DOI 10.1194/jlr.M700263-JLR200; During A, 2005, J NUTR, V135, P2305, DOI 10.1093/jn/135.10.2305; Ferrucci L, 2009, AM J HUM GENET, V84, P123, DOI 10.1016/j.ajhg.2008.12.019; Gong XM, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-7; Hauser H, 1998, BIOCHEMISTRY-US, V37, P17843, DOI 10.1021/bi982404y; Hessel S, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M706763200; Kawada T, 1996, INT J OBESITY, V20, pS52; Kiefer C, 2002, P NATL ACAD SCI USA, V99, P10581, DOI 10.1073/pnas.162182899; Leung WH, 2008, FASEB J, V22; Liu LM, 2005, J BIOL CHEM, V280, P40226, DOI 10.1074/jbc.M509643200; Mardones P, 2001, J LIPID RES, V42, P170; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; MCNAMARA DJ, 1987, J CLIN INVEST, V79, P1729, DOI 10.1172/JCI113013; O'Byrne SM, 2005, J BIOL CHEM, V280, P35647, DOI 10.1074/jbc.M507924200; Paik J, 2004, J NUTR, V134, p276S, DOI 10.1093/jn/134.1.276S; Reboul E, 2006, J BIOL CHEM, V281, P4739, DOI 10.1074/jbc.M509042200; Ribot J, 2001, OBES RES, V9, P500, DOI 10.1038/oby.2001.65; Rosenblum SB, 1998, J MED CHEM, V41, P973, DOI 10.1021/jm970701f; Sehayek E, 1998, J LIPID RES, V39, P2415; Seino Y, 2008, J BIOL CHEM, V283, P4905, DOI 10.1074/jbc.M707928200; Takitani K, 2006, EUR J NUTR, V45, P320, DOI 10.1007/s00394-006-0601-3; van Bennekum A, 2005, BIOCHEMISTRY-US, V44, P4517, DOI 10.1021/bi0484320; Vaughan LA, 1997, J AM DIET ASSOC, V97, P1275, DOI 10.1016/S0002-8223(97)00305-2; von Lintig J, 2005, BBA-MOL BASIS DIS, V1740, P122, DOI 10.1016/j.bbadis.2004.11.010; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Voolstra O, 2006, BIOCHEMISTRY-US, V45, P13429, DOI 10.1021/bi060701u; Voshol PJ, 2001, BIOCHEM J, V356, P317, DOI 10.1042/0264-6021:3560317; Wang DQH, 2007, ANNU REV PHYSIOL, V69, P221, DOI 10.1146/annurev.physiol.69.031905.160725; Wang L, 2008, AM J CLIN NUTR, V88, P747, DOI 10.1093/ajcn/88.3.747; Webb NR, 1997, J LIPID RES, V38, P1490; WOLFE WS, 1988, J AM DIET ASSOC, V88, P822	39	154	160	2	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1656	1666		10.1096/fj.09-150995	http://dx.doi.org/10.1096/fj.09-150995			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20061533	Green Published			2022-12-28	WOS:000278200000004
J	Wang, JY; Ma, H; Tong, C; Zhang, HY; Lawlis, GB; Li, YD; Zang, MW; Ren, J; Nijland, MJ; Ford, SP; Nathanielsz, PW; Li, J				Wang, Jingying; Ma, Heng; Tong, Chao; Zhang, Hanying; Lawlis, Gavin B.; Li, Yuanda; Zang, Mengwei; Ren, Jun; Nijland, Mark J.; Ford, Stephen P.; Nathanielsz, Peter W.; Li, Ji			Overnutrition and maternal obesity in sheep pregnancy alter the JNK-IRS-1 signaling cascades and cardiac function in the fetal heart	FASEB JOURNAL			English	Article						cardiac dysfunction; signaling transduction; insulin resistance	ACTIVATED PROTEIN-KINASE; MYOCARDIAL SUBSTRATE METABOLISM; INSULIN-RESISTANCE; OXIDATIVE STRESS; SKELETAL-MUSCLE; PREPREGNANCY WEIGHT; RISK; PATHWAY; AKT; JNK	Maternal obesity in pregnancy predisposes offspring to insulin resistance and associated cardiovascular disease. Here, we used a well-established sheep model to investigate the effects of maternal obesity on cardiac functions. Multiparous ewes were assigned to a control (CON) diet [100% of National Research Council (NRC) recommendations] or an obesogenic (OB) diet (150% of NRC recommendations) from 60 d before conception to necropsy on d 135 of pregnancy. Fetal blood glucose and insulin were increased (P<0.01, n = 8) in OB (35.09 +/- 2.03 mg/dl and 3.40 +/- 1.43 mu U/ml, respectively) vs. CON ewes (23.80 +/- 1.38 mg/dl and 0.769 +/- 0.256 mu U/ml). Phosphorylation of AMP-activated protein kinase (AMPK), a cardioprotective signaling pathway, was reduced (P<0.05), while the stress signaling pathway, p38 MAPK, was up-regulated (P<0.05) in OB maternal and fetal hearts. Phosphorylation of c-Jun Nterminal kinase (JNK) and insulin receptor substrate-1 (IRS-1) at Ser-307 were increased (P<0.05) in OB fetal heart associated with lower downstream PI3K-Akt activity (P<0.05), indicating impaired cardiac insulin signaling. Although OB fetal hearts exhibited a normal contractile function vs. CON fetal hearts during basal perfusion, they developed an impaired heart-rate-left-ventricular- developed pressure product in response to high workload stress. Taken together, fetuses of OB mothers demonstrate alterations in cardiac PI3K-Akt, AMPK, and JNK-IRS-1 signaling pathways that would predispose them to insulin resistance and cardiac dysfunction.- Wang, J., Ma, H., Tong, C., Zhang, H., Lawlis, G. B., Li, Y., Zang, M., Ren, J., Nijland, M. J., Ford, S. P., Nathanielsz, P. W., Li, J. Overnutrition and maternal obesity in sheep pregnancy alter the JNK-IRS-1 signaling cascades and cardiac function in the fetal heart. FASEB J. 24, 2066-2076 (2010). www.fasebj.org	[Wang, Jingying; Tong, Chao; Li, Ji] SUNY Buffalo, Dept Pharmacol & Toxicol, Sch Med & Biomed Sci, Buffalo, NY 14214 USA; [Wang, Jingying; Ma, Heng; Tong, Chao; Zhang, Hanying; Lawlis, Gavin B.; Li, Yuanda; Ren, Jun; Li, Ji] Univ Wyoming, Div Pharmaceut Sci, Laramie, WY 82071 USA; [Ford, Stephen P.] Univ Wyoming, Dept Anim Sci, Laramie, WY 82071 USA; [Zang, Mengwei] Boston Univ, Sch Med, Boston, MA 02118 USA; [Nijland, Mark J.; Nathanielsz, Peter W.] Univ Texas Hlth Sci Ctr San Antonio, Ctr Pregnancy & Newborn Res, Dept Obstet & Gynecol, San Antonio, TX 78229 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Wyoming; University of Wyoming; Boston University; University of Texas System; University of Texas Health San Antonio	Li, J (corresponding author), SUNY Buffalo, Dept Pharmacol & Toxicol, Sch Med & Biomed Sci, Buffalo, NY 14214 USA.	jli23@buffalo.edu	Tong, Chao/AAM-2225-2020; Wang, Jingying/G-5568-2012; Ren, Jun/ACG-5366-2022	Tong, Chao/0000-0003-0828-2674; Wang, Jingying/0000-0001-8692-6928; Ren, Jun/0000-0002-0275-0783; Nijland, Mark/0000-0003-0998-8804; Nathanielsz, Peter/0000-0001-8410-6280; Zang, Mengwei/0000-0002-2502-2586	U.S. National Institute on Aging (NIA)/National Institutes of Health (NIH) [R03AG028163]; American Federation for Aging Research [08007]; NIH University of Wyoming Northern Rockies Regional Idea Network of Biomedical Research Excellence (INBRE) [5P20RR016474]; National Center for Research Resources [1UL1RR025014-01]; NIH INBRE [P20 RR16474-04]; American Diabetes Association [7-08-RA-130]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021350] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025014, P20RR016474] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG028163] Funding Source: NIH RePORTER	U.S. National Institute on Aging (NIA)/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Federation for Aging Research; NIH University of Wyoming Northern Rockies Regional Idea Network of Biomedical Research Excellence (INBRE); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH INBRE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by U.S. National Institute on Aging (NIA)/National Institutes of Health (NIH) grant R03AG028163 (J.L.), American Federation for Aging Research grant 08007 (J.L.), NIH University of Wyoming Northern Rockies Regional Idea Network of Biomedical Research Excellence (INBRE) pilot grant 5P20RR016474 (J.L.), National Center for Research Resources pilot grant 1UL1RR025014-01 (J.L.), NIH INBRE program project P20 RR16474-04 (S.P.F.), and American Diabetes Association grant 7-08-RA-130 (J.R.).	Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Barker DJP, 2002, TRENDS ENDOCRIN MET, V13, P364, DOI 10.1016/S1043-2760(02)00689-6; Bennett BL, 2003, CURR OPIN PHARMACOL, V3, P420, DOI 10.1016/S1471-4892(03)00068-7; Calvert JW, 2009, EXP PHYSIOL, V94, P805, DOI 10.1113/expphysiol.2009.047183; Chen A, 2009, EPIDEMIOLOGY, V20, P74, DOI 10.1097/EDE.0b013e3181878645; Cnattingius S, 1998, NEW ENGL J MED, V338, P147, DOI 10.1056/NEJM199801153380302; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Corrigan N, 2009, BIRTH DEFECTS RES A, V85, P523, DOI 10.1002/bdra.20567; Dyck JRB, 1999, EUR J BIOCHEM, V262, P184, DOI 10.1046/j.1432-1327.1999.00371.x; Ehrenberg HM, 2002, AM J OBSTET GYNECOL, V187, P1189, DOI 10.1067/mob.2002.127125; Ford SP, 2009, AM J PHYSIOL-REG I, V297, pR835, DOI 10.1152/ajpregu.00072.2009; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI21625, 10.1172/JCI20042162S]; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Hintz KK, 2003, INT J OBESITY, V27, P1196, DOI 10.1038/sj.ijo.0802389; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hull HR, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.10.796; Kaneto H, 2005, J MOL MED, V83, P429, DOI 10.1007/s00109-005-0640-x; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245; Kristensen J, 2005, BJOG-INT J OBSTET GY, V112, P403, DOI 10.1111/j.1471-0528.2005.00437.x; Li J, 2005, CIRC RES, V97, P872, DOI 10.1161/01.RES.0000187458.77026.10; Li J, 2004, AM J PHYSIOL-ENDOC M, V287, pE834, DOI 10.1152/ajpendo.00234.2004; Li J, 2003, FREE RADICAL BIO MED, V35, P292, DOI 10.1016/S0891-5849(03)00308-3; LOPASCHUK GD, 1991, AM J PHYSIOL, V261, pH1698, DOI 10.1152/ajpheart.1991.261.6.H1698; Ma H, 2009, J AM COLL CARDIOL, V54, P2187, DOI 10.1016/j.jacc.2009.04.100; Mighty Hugh E, 2007, Curr Diab Rep, V7, P289, DOI 10.1007/s11892-007-0046-y; Miller EJ, 2008, NATURE, V451, P578, DOI 10.1038/nature06504; Napoli C, 1997, J CLIN INVEST, V100, P2680, DOI 10.1172/JCI119813; Napoli C, 1999, LANCET, V354, P1234, DOI 10.1016/S0140-6736(99)02131-5; Nohr EA, 2007, OBSTET GYNECOL, V110, P1083, DOI 10.1097/01.AOG.0000286760.46679.f8; Okamoto F, 1998, JPN CIRC J, V62, P499, DOI 10.1253/jcj.62.499; OPIE LH, 1968, AM HEART J, V76, P685, DOI 10.1016/0002-8703(68)90168-3; Palinski W, 2009, J CARDIOVASC TRANSL, V2, P277, DOI 10.1007/s12265-009-9108-7; Peterson LR, 2006, CURR HYPERTENS REP, V8, P451, DOI 10.1007/s11906-006-0022-y; Peterson LR, 2004, CIRCULATION, V109, P2191, DOI 10.1161/01.CIR.0000127959.28627.F8; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; Reece EA, 2008, AM J OBSTET GYNECOL, V198, P23, DOI 10.1016/j.ajog.2007.06.076; RODRIGUES B, 1992, CARDIOVASC RES, V26, P913, DOI 10.1093/cvr/26.10.913; SANSON DW, 1993, J ANIM SCI, V71, P1112, DOI 10.2527/1993.7151112x; Schmatz M, 2010, J PERINATOL, V30, P441, DOI 10.1038/jp.2009.182; Shiojima I, 2002, J BIOL CHEM, V277, P37670, DOI 10.1074/jbc.M204572200; Skalicky J, 2008, CLIN CHEM LAB MED, V46, P499, DOI 10.1515/CCLM.2008.096; Sobngwi E, 2003, LANCET, V361, P1861, DOI 10.1016/S0140-6736(03)13505-2; Srinivasan M, 2006, AM J PHYSIOL-ENDOC M, V290, pE129, DOI 10.1152/ajpendo.00248.2005; Stanley WC, 2005, PHYSIOL REV, V85, P1093, DOI 10.1152/physrev.00006.2004; Steinberg GR, 2007, CELL CYCLE, V6, P888, DOI 10.4161/cc.6.8.4135; Steinberg GR, 2006, CELL METAB, V4, P465, DOI 10.1016/j.cmet.2006.11.005; Taylor PD, 2007, EXP PHYSIOL, V92, P287, DOI 10.1113/expphysiol.2005.032854; Tong J, 2008, J ANIM SCI, V86, P1296, DOI 10.2527/jas.2007-0794; Trovato GM, 2001, DIABETES NUTR METAB, V14, P325; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wang MY, 2005, AM J PHYSIOL-ENDOC M, V288, pE216, DOI 10.1152/ajpendo.00004.2004; Watanabe K, 1998, JPN CIRC J, V62, P541, DOI 10.1253/jcj.62.541; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; Woods LL, 2000, CURR OPIN NEPHROL HY, V9, P419, DOI 10.1097/00041552-200007000-00014; Young LH, 2005, TRENDS CARDIOVAS MED, V15, P110, DOI 10.1016/j.tcm.2005.04.005; Yu Ye-Rong, 2003, Zhonghua Yi Xue Za Zhi, V83, P1467; Zhao P, 2009, BIOCHEM PHARMACOL, V77, P1002, DOI 10.1016/j.bcp.2008.11.018; Zhu MJ, 2008, J PHYSIOL-LONDON, V586, P2651, DOI 10.1113/jphysiol.2007.149633	60	81	88	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					2066	2076		10.1096/fj.09-142315	http://dx.doi.org/10.1096/fj.09-142315			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20110268	Green Published			2022-12-28	WOS:000278200000040
J	Cai, X; Conley, SM; Nash, Z; Fliesler, SJ; Cooper, MJ; Naash, MI				Cai, Xue; Conley, Shannon M.; Nash, Zack; Fliesler, Steven J.; Cooper, Mark J.; Naash, Muna I.			Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa	FASEB JOURNAL			English	Article						gene replacement therapy; retinal degeneration slow protein; mouse opsin promoter	OUTER SEGMENT MORPHOGENESIS; DEGENERATION SLOW RDS; RETINAL DEGENERATION; TRANSGENIC MICE; ROD PHOTORECEPTORS; IN-VIVO; REPLACEMENT THERAPY; R172W MUTATION; DISK MEMBRANE; MUTANT MICE	The purpose of the present study was to test the therapeutic efficiency and safety of compacted-DNA nanoparticle-mediated gene delivery into the sub-retinal space of a juvenile mouse model of retinitis pigmentosa. Nanoparticles containing the mouse opsin promoter and wild-type mouse Rds gene were injected subretinally into mice carrying a haploinsufficiency mutation in the retinal degeneration slow (rds(+/-)) gene at postnatal day (P) 5 and 22. Control mice were either injected with saline, injected with uncompacted naked plasmid DNA carrying the Rds gene, or remained untreated. Rds mRNA levels peaked at postinjection day 2 to 7 (PI-2 to PI-7) for P5 injections, stabilized at levels 2-fold higher than in uninjected controls for both P5 and P22 injections, and remained elevated at the latest time point examined (PI-120). Rod function (measured by electroretinography) showed modest but statistically significant improvement compared with controls after both P5 and P22 injections. Cone function in nanoparticle-injected eyes reached wild-type levels for both ages of injections, indicating full prevention of cone degeneration. Ultrastructural examination at PI-120 revealed significant improvement in outer segment structures in P5 nanoparticle-injected eyes, while P22 injection had a modest structural improvement. There was no evidence of macrophage activation or induction of IL-6 or TNF-alpha mRNA in P5 or P22 nanoparticle-dosed eyes at either PI-2 or PI-30. Thus, compacted-DNA nanoparticles can efficiently and safely drive gene expression in both mitotic and postmitotic photoreceptors and retard degeneration in this model. These findings, using a clinically relevant treatment paradigm, illustrate the potential for application of nanoparticle-based gene replacement therapy for treatment of human retinal degenerations.-Cai, X., Conley, S. M., Nash, Z., Fliesler, S. J., Cooper, M. J., Naash, M. I. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J. 24, 1178-1191 (2010). www.fasebj.org	[Cai, Xue; Conley, Shannon M.; Nash, Zack; Naash, Muna I.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; [Fliesler, Steven J.] Vet Adm Western New York Healthcare Syst, Res Serv, Buffalo, NY USA; [Fliesler, Steven J.] SUNY Buffalo, Dept Ophthalmol, Ross Eye Inst, Buffalo, NY 14260 USA; [Fliesler, Steven J.] SUNY Buffalo, Dept Biochem, Buffalo, NY 14260 USA; [Cooper, Mark J.] Copernicus Therapeut Inc, Cleveland, OH USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Naash, MI (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, 940 Stanton L Young Blvd,BMSB 781, Oklahoma City, OK 73104 USA.	muna-naash@ouhsc.edu	Fliesler, Steven J./AAE-9243-2020	Fliesler, Steven/0000-0002-2557-142X	National Institutes of Health [EY-010609, EY-018656, EY-007361]; Foundation Fighting Blindness, Baltimore; Oklahoma Center for the Advancement of Science and Technology (OCAST), Oklahoma City, OK, USA; NATIONAL EYE INSTITUTE [R01EY010609, R01EY018656, R55EY010609, R56EY010609, R01EY007361] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation Fighting Blindness, Baltimore; Oklahoma Center for the Advancement of Science and Technology (OCAST), Oklahoma City, OK, USA; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The authors thank Barbara Nagel for excellent EM and Lauren Brush for visual behavior studies. The authors also thank Rasha Makkia and Ehsan Nour- Mohammadi for excellent technical assistance. Drs. Robert Barlow and Yumiko Umino provided assistance with the visual behavior testing, and Dr. Michelle Callegan generously shared positive control specimens. This work was supported by National Institutes of Health grants EY-010609 and EY-018656 (to M.I.N.) and EY-007361 (to S.J.F.); the Foundation Fighting Blindness, Baltimore, MD, USA (to M.I.N.); Oklahoma Center for the Advancement of Science and Technology (OCAST), Oklahoma City, OK, USA (to M.I.N.); a vision COBRE (to M.I.N.); and an unrestricted grant from Research to Prevent Blindness (to S.J.F.). M.I.N. and S.J.F. are recipients of the Research to Prevent Blindness James S. Adams Scholar Award and Senior Scientific Investigator Award, respectively. M.J.C. is an employee of Copernicus Therapeutics and owns stock in the company.	Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068; Bainbridge JWB, 2001, GENE THER, V8, P1665, DOI 10.1038/sj.gt.3301574; Cai X, 2008, VISION RES, V48, P319, DOI 10.1016/j.visres.2007.07.012; Cai X, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005290; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Chang GQ, 1997, MICROSC RES TECHNIQ, V36, P123, DOI 10.1002/(SICI)1097-0029(19970115)36:2<123::AID-JEMT5>3.0.CO;2-Q; Cheng T, 1997, J NEUROSCI, V17, P8118, DOI 10.1523/jneurosci.17-21-08118.1997; Conley S, 2007, INVEST OPHTH VIS SCI, V48, P5397, DOI 10.1167/iovs.07-0663; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; Davies M, 2006, MOL VIS, V12, P467; Davila I, 2007, J INVEST ALLERG CLIN, V17, P9; Ding XQ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007410; Ding XQ, 2004, HUM MOL GENET, V13, P2075, DOI 10.1093/hmg/ddh211; Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038; Farjo R, 2006, J CELL BIOL, V173, P59, DOI 10.1083/jcb.200509036; Farjo R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000038; Farjo R, 2007, J COMP NEUROL, V504, P619, DOI 10.1002/cne.21476; Farjo R, 2006, OPHTHALMIC GENET, V27, P117, DOI 10.1080/13816810600976806; Fink TL, 2006, GENE THER, V13, P1048, DOI 10.1038/sj.gt.3302761; Glushakova LG, 2006, MOL VIS, V12, P298; HAWKINS RK, 1985, EXP EYE RES, V41, P701, DOI 10.1016/0014-4835(85)90179-4; Kalloniatis Michael, 2004, Clin Exp Optom, V87, P65; Kedzierski W, 2001, P NATL ACAD SCI USA, V98, P7718, DOI 10.1073/pnas.141124198; Keen TJ, 1996, HUM MUTAT, V8, P297; Kohl S, 1998, ACTA ANAT, V162, P75; Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117; Le YZ, 2006, MOL VIS, V12, P389; Lee ES, 2006, INVEST OPHTH VIS SCI, V47, P2150, DOI 10.1167/iovs.05-0919; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Li CB, 2001, OPTOMETRY VISION SCI, V78, P425, DOI 10.1097/00006324-200106000-00015; Liu G, 2003, J BIOL CHEM, V278, P32578, DOI 10.1074/jbc.M305776200; MA JS, 1995, GENOMICS, V28, P212, DOI 10.1006/geno.1995.1133; Nour M, 2004, INVEST OPHTH VIS SCI, V45, P2514, DOI 10.1167/iovs.04-0065; Nour M, 2003, INVEST OPHTH VIS SCI, V44, P4505, DOI 10.1167/iovs.03-0453; Nour M, 2008, ADV EXP MED BIOL, V613, P129, DOI 10.1007/978-0-387-74904-4_14; Pang JJ, 2006, MOL VIS, V12, P756; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; Quiambao AB, 1997, VISUAL NEUROSCI, V14, P617, DOI 10.1017/S095252380001258X; Sarra GM, 2001, HUM MOL GENET, V10, P2353, DOI 10.1093/hmg/10.21.2353; Schlichtenbrede FC, 2003, J GENE MED, V5, P757, DOI 10.1002/jgm.401; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; Tan E, 2001, INVEST OPHTH VIS SCI, V42, P589; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; WELEBER R, 1999, DIGIT J OPTHALMOL, V5; Ziady AG, 2003, MOL THER, V8, P948, DOI 10.1016/j.ymthe.2003.09.002	47	95	109	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1178	1191		10.1096/fj.09-139147	http://dx.doi.org/10.1096/fj.09-139147			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19952284	Green Published			2022-12-28	WOS:000276462300025
J	Bruyere, F; Noel, A				Bruyere, Francoise; Noel, Agnes			Lymphangiogenesis: in vitro and in vivo models	FASEB JOURNAL			English	Review						lymphatic endothelial cell; lymphedema; metastatic dissemination; graft rejection	LYMPHATIC ENDOTHELIAL-CELLS; GROWTH-FACTOR-C; VEGF-C; NODE METASTASIS; INTERSTITIAL FLOW; TUMOR LYMPHANGIOGENESIS; FACTOR RECEPTOR-3; THORACIC-DUCT; GENE-THERAPY; INTRATUMORAL LYMPHANGIOGENESIS	Lymphangiogenesis, the formation of new lymphatic vessels from preexisting ones, is an important biological process associated with diverse pathologies, such as metastatic dissemination and graft rejection. In addition, lymphatic hypoplasia characterizes lymphedema, usually a progressive and lifelong condition for which no curative treatment exists. Much progress has been made in recent years in identifying molecules specifically expressed on lymphatic vessels and in the setting up of in vitro and in vivo models of lymphangiogenesis. These new tools rapidly provided an abundance of information on the mechanisms underlying lymphatic development and the progression of diseases associated with lymphatic dysfunction. In this review, we describe the common in vitro and in vivo models of lymphangiogenesis that have proven suitable for investigating lymphatic biology and the interactions occurring between lymphatic vessels and other cells, such as immune cells and cancer cells. Their rationales and limitations are discussed and illustrated by the most informative findings obtained with them.-Bruyere, F., Noel, A. Lymphangiogenesis: in vitro and in vivo models. FASEB J. 24, 8 - 21 (2010). www.fasebj.org	[Noel, Agnes] Univ Liege, Lab Tumor & Dev Biol, GIGA Canc, CHU Sart Tilman B23, B-4000 Liege, Belgium	University of Liege	Noel, A (corresponding author), Univ Liege, Lab Tumor & Dev Biol, GIGA Canc, CHU Sart Tilman B23, Ave Hop 3, B-4000 Liege, Belgium.	agnes.noel@ulg.ac.be		Noel, Agnes/0000-0002-7670-6179	European Union [FP7-2007-2011, 20179]; Fonds National de la Recherche Scientifique (FNRS; Belgium); Federation Belge contre le Cancer, the Fonds Speciaux de la Recherche (University of Liege); Centre Anticancereux res l'Universite de Liege,the Fonds Leon Fredericq (University of Liege); Region Wallonne; Interuniversity Attraction Poles Program-Belgian Science; Interuniversity Attraction Poles Program-Belgian Science Policy (Brussels, Belgium); Televie-FNRS	European Union(European Commission); Fonds National de la Recherche Scientifique (FNRS; Belgium)(Fonds de la Recherche Scientifique - FNRS); Federation Belge contre le Cancer, the Fonds Speciaux de la Recherche (University of Liege)(University of Liege); Centre Anticancereux res l'Universite de Liege,the Fonds Leon Fredericq (University of Liege)(University of Liege); Region Wallonne; Interuniversity Attraction Poles Program-Belgian Science(Belgian Federal Science Policy Office); Interuniversity Attraction Poles Program-Belgian Science Policy (Brussels, Belgium)(Belgian Federal Science Policy Office); Televie-FNRS(Fonds de la Recherche Scientifique - FNRS)	This work was supported by grants from the European Union Framework Program Projects (FP7-2007-2011 Microenvimet no. 20179), the Fonds National de la Recherche Scientifique (FNRS; Belgium), the Federation Belge contre le Cancer, the Fonds Speciaux de la Recherche (University of Liege), the Centre Anticancereux res l'Universite de Liege, the Fonds Leon Fredericq (University of Liege), the Direction Generale des Technologies, de la Recherche et de l'Energie (DGTRE) from the Region Wallonne, and the Interuniversity Attraction Poles Program-Belgian Science Policy (Brussels, Belgium). F. B. is the recipient of a Televie-FNRS grant.	Achen MG, 2008, ANN NY ACAD SCI, V1131, P225, DOI 10.1196/annals.1413.020; Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Alajati A, 2008, NAT METHODS, V5, P439, DOI [10.1038/nmeth.1198, 10.1038/NMETH.1198]; Amatschek S, 2007, BLOOD, V109, P4777, DOI 10.1182/blood-2006-10-053280; Ando T., 2005, Lymphatic Research and Biology, V3, P105, DOI 10.1089/lrb.2005.3.105; Ayadi A, 2001, EMBO J, V20, P5139, DOI 10.1093/emboj/20.18.5139; Baluk P, 2005, J CLIN INVEST, V115, P247, DOI 10.1172/JCI200522037; Baluk P, 2008, ANN NY ACAD SCI, V1131, P1, DOI 10.1196/annals.1413.001; Banziger-Tobler NE, 2008, AM J PATHOL, V173, P586, DOI 10.2353/ajpath.2008.080060; Berndt Sarah, 2008, P305, DOI 10.1007/978-0-387-69057-5_16; Bhang SH, 2009, ACS NANO, V3, P1389, DOI 10.1021/nn900138d; Bielenberg DR, 2008, NAT METHODS, V5, P384, DOI 10.1038/nmeth0508-384; Boardman KC, 2003, CIRC RES, V92, P801, DOI 10.1161/01.RES.0000065621.69843.49; BOARDMAN KC, 2001, BIOENG C, V50, P671; Bock F, 2008, GRAEF ARCH CLIN EXP, V246, P115, DOI 10.1007/s00417-007-0683-5; BOLLINGER A, 1981, CIRCULATION, V64, P1195, DOI 10.1161/01.CIR.64.6.1195; Brambilla L, 2006, J DERMATOL, V33, P451, DOI 10.1111/j.1346-8138.2006.00108.x; BRUYERE F, 2008, NAT PROTOC, DOI DOI 10.1038/NPROT.2008.86; Bruyere F, 2008, NAT METHODS, V5, P431, DOI [10.1038/nmeth.1205, 10.1038/NMETH.1205]; Buttler K, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-43; Cao RH, 2004, CANCER CELL, V6, P333, DOI 10.1016/j.ccr.2004.08.034; Cao RH, 2006, BLOOD, V107, P3531, DOI 10.1182/blood-2005-06-2538; Chang LK, 2004, P NATL ACAD SCI USA, V101, P11658, DOI 10.1073/pnas.0404272101; Chen SY, 2007, J HUAZHONG U SCI-MED, V27, P733, DOI 10.1007/s11596-007-0630-z; Chrobak KM, 2006, MICROVASC RES, V71, P185, DOI 10.1016/j.mvr.2006.02.005; Crnic I, 2004, CANCER RES, V64, P8630, DOI 10.1158/0008-5472.CAN-04-2523; Cueni LN, 2006, J INVEST DERMATOL, V126, P2167, DOI 10.1038/sj.jid.5700464; Cueni LN, 2009, EXP CELL RES, V315, P1715, DOI 10.1016/j.yexcr.2009.02.021; CUNNINGHAM DM, 1978, SURG GYNECOL OBSTET, V147, P877; Cursiefen C, 2006, CORNEA, V25, P443, DOI 10.1097/01.ico.0000183485.85636.ff; Cursiefen C, 2003, CORNEA, V22, P273, DOI 10.1097/00003226-200304000-00021; Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465; DALE MM, 1960, BRIT J EXP PATHOL, V41, P86; DALE MM, 1961, BRIT J EXP PATHOL, V42, P297; DAVISON PM, 1980, J INVEST DERMATOL, V75, P316, DOI 10.1111/1523-1747.ep12530941; Dellinger MT, 2007, DEV DYNAM, V236, P2346, DOI 10.1002/dvdy.21208; DJONEIDI M, 1991, MICROCIRC ENDOTH LYM, V7, P161; Ezaki T, 2006, ANAT EMBRYOL, V211, P379, DOI 10.1007/s00429-006-0091-3; Fruman DA, 2000, NAT GENET, V26, P379, DOI 10.1038/81715; Fu KD, 1998, PLAST RECONSTR SURG, V101, P134, DOI 10.1097/00006534-199801000-00022; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Gashev AA, 2002, J PHYSIOL-LONDON, V540, P1023, DOI 10.1113/jphysiol.2002.016642; Gasheva OY, 2007, MICROCIRCULATION, V14, P827, DOI 10.1080/10739680701444065; Giese C, 2006, ARTIF ORGANS, V30, P803, DOI 10.1111/j.1525-1594.2006.00303.x; GNEPP DR, 1985, IN VITRO CELL DEV B, V21, P200, DOI 10.1007/BF02620930; Greco KV, 2006, EUR J PHARMACOL, V551, P131, DOI 10.1016/j.ejphar.2006.08.090; Groger M, 2007, J INVEST DERMATOL, V127, P2893, DOI 10.1038/sj.jid.5701031; Groger M, 2004, J IMMUNOL, V173, P7161, DOI 10.4049/jimmunol.173.12.7161; Groot ACGD, 2004, DEV DYNAM, V230, P378, DOI 10.1002/dvdy.20054; Halin C, 2007, BLOOD, V110, P3158, DOI 10.1182/blood-2007-01-066811; Halin C, 2008, METHOD ENZYMOL, V445, P1, DOI 10.1016/S0076-6879(08)03001-2; Hama Y, 2007, J INVEST DERMATOL, V127, P2351, DOI 10.1038/sj.jid.5700892; Hama Y, 2007, BREAST CANCER RES TR, V103, P23, DOI 10.1007/s10549-006-9347-0; Harvey NL, 2005, NAT GENET, V37, P1072, DOI 10.1038/ng1642; Hayes H, 2003, Lymphat Res Biol, V1, P101, DOI 10.1089/153968503321642606; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; HEATH TJ, 1984, RES VET SCI, V37, P66, DOI 10.1016/S0034-5288(18)31930-1; Helm CLE, 2007, BIOTECHNOL BIOENG, V96, P167, DOI 10.1002/bit.21185; Helm CLE, 2005, P NATL ACAD SCI USA, V102, P15779, DOI 10.1073/pnas.0503681102; Henno A, 2009, BRIT J DERMATOL, V160, P581, DOI 10.1111/j.1365-2133.2008.08889.x; Herborn CU, 2002, AM J ROENTGENOL, V179, P1567, DOI 10.2214/ajr.179.6.1791567; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; Hoffmann F, 2001, GRAEF ARCH CLIN EXP, V239, P850, DOI 10.1007/s00417-001-0384-4; Holopainen T, 2009, CANCER RES, V69, P4656, DOI 10.1158/0008-5472.CAN-08-4654; Hong YK, 2004, NAT GENET, V36, P683, DOI 10.1038/ng1383; Hong YK, 2004, FASEB J, V18, P1111, DOI 10.1096/fj.03-1179fje; Hong YK, 2002, DEV DYNAM, V225, P351, DOI 10.1002/dvdy.10163; Hos D, 2008, EXP EYE RES, V87, P427, DOI 10.1016/j.exer.2008.07.013; Hosaka K, 2003, AM J PHYSIOL-HEART C, V284, pH2015, DOI 10.1152/ajpheart.00763.2002; Hosking B, 2007, BIOESSAYS, V29, P1192, DOI 10.1002/bies.20672; Hu Xueqing, 2006, Lymphatic Research and Biology, V4, P191, DOI 10.1089/lrb.2006.4403; HUANG G-K, 1983, Microsurgery, V4, P236; Huang XZ, 2000, MOL CELL BIOL, V20, P5208, DOI 10.1128/MCB.20.14.5208-5215.2000; Ikomi F, 2006, MICROCIRCULATION, V13, P365, DOI 10.1080/10739680600745810; Isaka N, 2004, CANCER RES, V64, P4400, DOI 10.1158/0008-5472.CAN-04-0752; Isogai S, 2009, ANAT SCI INT, V84, P102, DOI 10.1007/s12565-009-0024-3; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Jiang Dongling, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P483; Johnson LA, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702889200; Johnson LA, 2006, J EXP MED, V203, P2763, DOI 10.1084/jem.20051759; Kajiya K, 2008, FASEB J, V22, P530, DOI 10.1096/fj.07-8873com; Kajiya K, 2006, AM J PATHOL, V169, P1496, DOI 10.2353/ajpath.2006.060197; Kajiya K, 2009, J INVEST DERMATOL, V129, P1292, DOI 10.1038/jid.2008.351; Kalin RE, 2009, BLOOD, V114, P1110, DOI 10.1182/blood-2009-03-211771; KANTER MA, 1990, PLAST RECONSTR SURG, V85, P573, DOI 10.1097/00006534-199004000-00012; Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Karlsen TV, 2006, J PHYSIOL-LONDON, V574, P583, DOI 10.1113/jphysiol.2006.108308; Karpanen T, 2001, CANCER RES, V61, P1786; Karpanen T, 2008, ANNU REV PATHOL-MECH, V3, P367, DOI 10.1146/annurev.pathol.3.121806.151515; Karpanen T, 2006, AM J PATHOL, V169, P708, DOI 10.2353/ajpath.2006.051200; Kawai Yoshiko, 2008, Lymphatic Research and Biology, V6, P15, DOI 10.1089/lrb.2007.1019; Kawakami M, 2005, SURG TODAY, V35, P131, DOI 10.1007/s00595-004-2896-0; Kerjaschki D, 2004, J AM SOC NEPHROL, V15, P603, DOI 10.1097/01.ASN.0000113316.52371.2E; KOCH M, 2009, J PATHOL IN PRESS; Kono T, 2006, ARTERIOSCL THROM VAS, V26, P2070, DOI 10.1161/01.ATV.0000225770.57219.b0; Kopfstein L, 2007, AM J PATHOL, V170, P1348, DOI 10.2353/ajpath.2007.060835; Koyama H, 2008, AM J PATHOL, V172, P179, DOI 10.2353/ajpath.2008.070360; Kren A, 2007, EMBO J, V26, P2832, DOI 10.1038/sj.emboj.7601738; Kreuger J, 2006, ARTERIOSCL THROM VAS, V26, P1073, DOI 10.1161/01.ATV.0000217610.58032.b7; Kriederman B, 2002, LYMPHOLOGY, V35, P23; Kriederman BM, 2003, HUM MOL GENET, V12, P1179, DOI 10.1093/hmg/ddg123; Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797; Krishnan J, 2003, CANCER RES, V63, P713; Kuchler AM, 2006, CURR BIOL, V16, P1244, DOI 10.1016/j.cub.2006.05.026; Kuhnert F, 2005, DEV BIOL, V283, P140, DOI 10.1016/j.ydbio.2005.04.003; Kunstfeld R, 2004, BLOOD, V104, P1048, DOI 10.1182/blood-2003-08-2964; LEAK LV, 1994, IN VITRO CELL DEV-AN, V30A, P512, DOI 10.1007/BF02631324; Lee-Donaldson L, 1999, LYMPHOLOGY, V32, P111; Leu AJ, 2000, CANCER RES, V60, P4324; Liersch R, 2006, BLOOD, V107, P1214, DOI 10.1182/blood-2005-08-3400; Loughnan MS, 1996, AUST NZ J OPHTHALMOL, V24, P289, DOI 10.1111/j.1442-9071.1996.tb01596.x; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Mancardi S, 2003, IMMUNOLOGY, V108, P523, DOI 10.1046/j.1365-2567.2003.01613.x; Mancardi S, 1999, EXP CELL RES, V246, P368, DOI 10.1006/excr.1998.4270; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Maruyama K, 2005, J CLIN INVEST, V115, P2363, DOI 10.1172/JCI23874; Matsui J, 2008, CLIN CANCER RES, V14, P5459, DOI 10.1158/1078-0432.CCR-07-5270; Matsuo M, 2006, CELL TISSUE RES, V326, P749, DOI 10.1007/s00441-006-0229-x; Mattila MMT, 2002, INT J CANCER, V98, P946, DOI 10.1002/ijc.10283; Mizuno R, 2003, MICROCIRCULATION, V10, P127, DOI 10.1038/sj.mn.7800181; Mizuno Risuke, 2005, Lymphatic Research and Biology, V3, P127, DOI 10.1089/lrb.2005.3.127; Morisada T, 2005, BLOOD, V105, P4649, DOI 10.1182/blood-2004-08-3382; MUMPRECHT V, 2009, J CELL MOL MED; Muthuchamy M, 2008, ANN NY ACAD SCI, V1131, P89, DOI 10.1196/annals.1413.008; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Nakamura ES, 2004, CANCER SCI, V95, P25, DOI 10.1111/j.1349-7006.2004.tb03166.x; Nelson CM, 2006, CURR OPIN BIOTECH, V17, P518, DOI 10.1016/j.copbio.2006.08.011; Ng CP, 2004, MICROVASC RES, V68, P258, DOI 10.1016/j.mvr.2004.08.002; NICOSIA RF, 1987, IN VITRO CELL DEV B, V23, P167; Nisato RE, 2004, AM J PATHOL, V165, P11, DOI 10.1016/S0002-9440(10)63271-3; Ny A, 2006, EXP CELL RES, V312, P684, DOI 10.1016/j.yexcr.2005.10.018; Ny A, 2005, NAT MED, V11, P998, DOI 10.1038/nm1285; Ny A, 2008, BLOOD, V112, P1740, DOI 10.1182/blood-2007-08-106302; Okamoto N, 2007, J CLIN INVEST, V117, P997, DOI 10.1172/JCI30379; Okazaki T, 2009, AM J PATHOL, V174, P2388, DOI 10.2353/ajpath.2009.080949; Ono N, 2005, AM J PHYSIOL-HEART C, V289, pH1676, DOI 10.1152/ajpheart.01084.2004; Ota H, 2007, FEBS LETT, V581, P5220, DOI 10.1016/j.febslet.2007.10.009; Paavonen K, 2000, AM J PATHOL, V156, P1499, DOI 10.1016/S0002-9440(10)65021-3; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Pan Da, 2006, Lymphatic Research and Biology, V4, P211, DOI 10.1089/lrb.2006.4405; Papoutsi M, 2001, DEV DYNAM, V222, P238, DOI 10.1002/dvdy.1187; Papoutsi M, 2001, MICROSC RES TECHNIQ, V55, P100, DOI 10.1002/jemt.1161; Papoutsi M, 2000, HISTOCHEM CELL BIOL, V114, P373; Parsons-Wingerter P, 2006, ANAT REC PART A, V288A, P233, DOI 10.1002/ar.a.20309; Pedica F, 2008, VIRCHOWS ARCH, V452, P57, DOI 10.1007/s00428-007-0540-2; PEPPER MS, 1994, EXP CELL RES, V210, P298, DOI 10.1006/excr.1994.1042; Petrova TV, 2004, NAT MED, V10, P974, DOI 10.1038/nm1094; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Podgrabinska S, 2002, P NATL ACAD SCI USA, V99, P16069, DOI 10.1073/pnas.242401399; Radhakrisihnan K, 2008, ANN NY ACAD SCI, V1131, P155, DOI 10.1196/annals.1413.015; Rutkowski JM, 2006, AM J PHYSIOL-HEART C, V291, pH1402, DOI 10.1152/ajpheart.00038.2006; Rutkowski JM, 2006, MICROVASC RES, V72, P161, DOI 10.1016/j.mvr.2006.05.009; Saaristo A, 2002, J EXP MED, V196, P719, DOI 10.1084/jem.20020587; Saaristo A, 2006, AM J PATHOL, V169, P1080, DOI 10.2353/ajpath.2006.051251; Sabin FR, 1902, AM J ANAT, V1, P367, DOI 10.1002/aja.1000010310; SAITO N, 2009, PIGMENT CELL MELANOM; Saito Y, 2008, ONCOGENE, V27, P1821, DOI 10.1038/sj.onc.1210824; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Shao XJ, 2008, LYMPHOLOGY, V41, P64; Shibata MA, 2008, CANCER GENE THER, V15, P776, DOI 10.1038/cgt.2008.43; Shin WS, 2008, ANN NY ACAD SCI, V1131, P50, DOI 10.1196/annals.1413.005; Short RF, 2007, PEDIATR RADIOL, V37, P530, DOI 10.1007/s00247-007-0427-z; Sironi M, 2006, CELL TISSUE RES, V325, P91, DOI 10.1007/s00441-006-0171-y; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Slavin SA, 1999, ANN SURG, V229, P421, DOI 10.1097/00000658-199903000-00017; Sleeman JP, 2009, INT J CANCER, V125, P2747, DOI 10.1002/ijc.24702; Song M, 2007, BIOCHEM BIOPH RES CO, V357, P924, DOI 10.1016/j.bbrc.2007.04.033; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Streilein JW, 1996, INVEST OPHTH VIS SCI, V37, P413; Suematsu S, 2004, NAT BIOTECHNOL, V22, P1539, DOI 10.1038/nbt1039; Swartz MA, 1999, J BIOMECH, V32, P1297, DOI 10.1016/S0021-9290(99)00125-6; Szuba A, 2002, FASEB J, V16, P1985, DOI 10.1096/fj.02-0401fje; Tabibiazar R, 2006, PLOS MED, V3, P1114, DOI 10.1371/journal.pmed.0030254; Tan YZ, 1998, JPN J PHYSIOL, V48, P133, DOI 10.2170/jjphysiol.48.133; Uzarski J, 2008, AM J PHYSIOL-HEART C, V294, pH1326, DOI 10.1152/ajpheart.00900.2007; Wang HW, 2004, NAT GENET, V36, P687, DOI 10.1038/ng1384; Weninger W, 1999, LAB INVEST, V79, P243; Whitehurst Brandt, 2006, Lymphatic Research and Biology, V4, P119, DOI 10.1089/lrb.2006.4.119; Wick N, 2007, PHYSIOL GENOMICS, V28, P179, DOI 10.1152/physiolgenomics.00037.2006; Wiegand S, 2008, VIRCHOWS ARCH, V453, P1, DOI 10.1007/s00428-008-0611-z; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Yamaguchi T, 2008, FEBS J, V275, P1988, DOI 10.1111/j.1742-4658.2008.06353.x; Yamashita JK, 2007, TRENDS CARDIOVAS MED, V17, P59, DOI 10.1016/j.tcm.2007.01.001; Yanai Y, 2001, J EXP CLIN CANC RES, V20, P419; Yaniv K, 2006, NAT MED, V12, P711, DOI 10.1038/nm1427; Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694; Yong Carolyn, 2005, Lymphatic Research and Biology, V3, P183, DOI 10.1089/lrb.2005.3.183; Yoon Y, 2003, J CLIN INVEST, V111, P717, DOI 10.1172/JCI200315830; Yuan L, 2002, DEVELOPMENT, V129, P4797	194	70	70	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					8	21		10.1096/fj.09-132852	http://dx.doi.org/10.1096/fj.09-132852			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19726757	Green Submitted			2022-12-28	WOS:000273233600004
J	Flores-Valdez, MA; Morris, RP; Laval, F; Daffe, M; Schoolnik, GK				Alberto Flores-Valdez, Mario; Morris, Rowan P.; Laval, Francoise; Daffe, Mamadou; Schoolnik, Gary K.			Mycobacterium tuberculosis modulates its cell surface via an oligopeptide permease (Opp) transport system	FASEB JOURNAL			English	Article						lipid virulence factors; cell wall modulation; chronic infection; surface interaction	ALTERNATIVE SIGMA-FACTOR; STREPTOMYCES-COELICOLOR; MYCOLIC ACIDS; STREPTOCOCCUS-PNEUMONIAE; STRINGENT RESPONSE; BINDING-PROTEIN; AERIAL MYCELIUM; MUTANT LACKING; GENE-CLUSTER; BOVIS BCG	Bacterial species utilize a vast repertoire of surface structures to interact with their surroundings and employ a number of strategies to reconfigure the cellular envelope according to specific stimuli. Gram-positive bacteria, exemplified by Streptomyces and Bacillus species, control production of some exposed molecules by importing oligopeptide signals via permeases (Opp). Such oligopeptides modulate intracellular signaling pathways. In this work, we functionally characterized an Opp of the human pathogen Mycobacterium tuberculosis (Mtb) and propose its reannotation. Using genome-wide transcriptional profiling, we found that Opp was required to modulate (fold-change ranging from -3.5 to 2.0) the expression of several genes, most of them encoding surface-exposed molecules. These included the virulence-associated lipids mycolic acids and phthiocerol dimycocerosates (PDIMs) as well as PE-family proteins. By thin-layer chromatography and MALDI-TOF-MS we confirmed changes in the lipid profile, including an altered accumulation of triacylglycerides and an affected ratio of mycolic acids to PDIMs. An Opp loss of function mutant showed no in vitro growth defect, but had diminished burden during chronic infection and produced a slightly delayed time to death of animals when compared to WT Mtb infection.-Flores-Valdez, M. A., Morris, R. P., Laval, F., Daffe, M., Schoolnik, G. K. Mycobacterium tuberculosis modulates its cell surface via an oligopeptide permease (Opp) transport system. FASEB J. 23, 4091-4104 (2009). www.fasebj.org	[Alberto Flores-Valdez, Mario; Schoolnik, Gary K.] Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA; [Morris, Rowan P.] Novartis Pharma AG, Novartis Inst Biomed Res, Nat Prod Unit, Basel, Switzerland; [Laval, Francoise; Daffe, Mamadou] CNRS, Inst Pharmacol & Biol Struct, Dept Mecanismes Mol Infect Mycobacteriennes, Toulouse, France; [Laval, Francoise; Daffe, Mamadou] Univ Toulouse 3, F-31062 Toulouse, France	Stanford University; Novartis; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Flores-Valdez, MA (corresponding author), Ctr Invest & Asistencia Tecnol & Diseno Estado Ja, Normalistas 800, Guadalajara 44270, Jalisco, Mexico.	floresv@ciatej.net.mx	Flores-Valdez, Mario Alberto/D-4139-2018; Morris, Rowan/HGU-9105-2022; LAUZERAL-VIZCAINO, Françoise/W-8898-2019	Flores-Valdez, Mario Alberto/0000-0002-4125-1370; LAUZERAL-VIZCAINO, Françoise/0000-0002-9741-3252	NIH [N01-AI30036]; Stanford University School of Medicine	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stanford University School of Medicine	The support of NIH contract N01-AI30036 is gratefully acknowledged. Within this group, our especial appreciation to Dr. Gyanu Lamichhane, who designed animal infection experiments, Dr. Paul Converse for his advice and data analysis, and Scott Nolan for superior technical assistance. The authors thank Dr. Jeannette Barba for her assistance in exporting microarray data to GEO and ArrayExpress. M. A. F. V. was a recipient of the Stanford University School of Medicine Dean's Fellowship.	Agarwal N, 2007, INFECT IMMUN, V75, P452, DOI 10.1128/IAI.01395-06; Ando M, 2003, INFECT IMMUN, V71, P7170, DOI 10.1128/IAI.71.12.7170-7172.2003; ASHBRIDGE KR, 1990, J IMMUNOL, V144, P3137; Bardarov S, 2002, MICROBIOL-SGM, V148, P3007, DOI 10.1099/00221287-148-10-3007; Barry Clifton E., 2007, Infectious Disorders - Drug Targets, V7, P182; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Borezee E, 2000, INFECT IMMUN, V68, P7069, DOI 10.1128/IAI.68.12.7069-7077.2000; Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6; Calamita H, 2005, CELL MICROBIOL, V7, P233, DOI 10.1111/j.1462-5822.2004.00454.x; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; Chater KF, 2003, MOL MICROBIOL, V48, P9, DOI 10.1046/j.1365-2958.2003.03476.x; Chen P, 2000, INFECT IMMUN, V68, P5575, DOI 10.1128/IAI.68.10.5575-5580.2000; Cirillo SLG, 2009, INFECT IMMUN, V77, P2557, DOI 10.1128/IAI.01481-08; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; CUNDELL DR, 1995, INFECT IMMUN, V63, P2493, DOI 10.1128/IAI.63.7.2493-2498.1995; Dainese E, 2006, INFECT IMMUN, V74, P2457, DOI 10.1128/IAI.74.4.2457-2461.2006; Daniel J, 2004, J BACTERIOL, V186, P5017, DOI 10.1128/jb.186.15.5017-5030.2004; Dubey VS, 2002, MOL MICROBIOL, V45, P1451, DOI 10.1046/j.1365-2958.2002.03119.x; Dubnau E, 2000, MOL MICROBIOL, V36, P630, DOI 10.1046/j.1365-2958.2000.01882.x; ENGELBRE.HL, 1972, J BACTERIOL, V11, P33; Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002; Garton NJ, 2008, PLOS MED, V5, P634, DOI 10.1371/journal.pmed.0050075; Ghosh J, 2009, P NATL ACAD SCI USA, V106, P10781, DOI 10.1073/pnas.0904104106; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Gominet M, 2001, MOL MICROBIOL, V40, P963, DOI 10.1046/j.1365-2958.2001.02440.x; Green RM, 2000, INFECT IMMUN, V68, P429, DOI 10.1128/IAI.68.2.429-436.2000; Guilhot C, 2008, HDB TUBERCULOSIS MOL, V1, P21; Hahn MY, 2005, J BACTERIOL, V187, P7062, DOI 10.1128/JB.187.20.7062-7071.2005; Jackson M, 2007, TUBERCULOSIS, V87, P78, DOI 10.1016/j.tube.2006.05.003; Kaushal D, 2002, P NATL ACAD SCI USA, V99, P8330, DOI 10.1073/pnas.102055799; Kerr AR, 2004, INFECT IMMUN, V72, P3902, DOI 10.1128/IAI.72.7.3902-3906.2004; LAMB JR, 1988, EUR J IMMUNOL, V18, P973, DOI 10.1002/eji.1830180623; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; Lazazzera BA, 1997, CELL, V89, P917, DOI 10.1016/S0092-8674(00)80277-9; Lazazzera BA, 2001, PEPTIDES, V22, P1519, DOI 10.1016/S0196-9781(01)00488-0; Leonard BAB, 1996, P NATL ACAD SCI USA, V93, P260, DOI 10.1073/pnas.93.1.260; Lorenzana LM, 2004, J BACTERIOL, V186, P3431, DOI 10.1128/JB.186.11.3431-3438.2004; Manca C, 1999, J IMMUNOL, V162, P6740; Marrakchi H, 2008, MYCOBACTERIAL CELL ENVELOPE, P41; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Morris RP, 2005, P NATL ACAD SCI USA, V102, P12200, DOI 10.1073/pnas.0505446102; Munoz-Elias EJ, 2006, CELL MICROBIOL, V8, P10, DOI 10.1111/j.1462-5822.2005.00648.x; Nodwell JR, 1996, MOL MICROBIOL, V22, P881, DOI 10.1046/j.1365-2958.1996.01540.x; Nodwell JR, 1998, J BACTERIOL, V180, P1334, DOI 10.1128/JB.180.5.1334-1337.1998; OCHI K, 1987, J BACTERIOL, V169, P3608, DOI 10.1128/jb.169.8.3608-3616.1987; OCHI K, 1981, J BIOL CHEM, V256, P6866; Pandey AK, 2008, P NATL ACAD SCI USA, V105, P4376, DOI 10.1073/pnas.0711159105; Park HD, 2003, MOL MICROBIOL, V48, P833, DOI 10.1046/j.1365-2958.2003.03474.x; Perego M, 1996, P NATL ACAD SCI USA, V93, P1549, DOI 10.1073/pnas.93.4.1549; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; Pethe K, 2001, NATURE, V412, P190, DOI 10.1038/35084083; Piette A, 2005, J PROTEOME RES, V4, P1699, DOI 10.1021/pr050155b; Pope MK, 1996, MOL MICROBIOL, V19, P747, DOI 10.1046/j.1365-2958.1996.414933.x; Rachman H, 2006, INFECT IMMUN, V74, P1233, DOI 10.1128/IAI.74.2.1233-1242.2006; Raman S, 2004, J BACTERIOL, V186, P6605, DOI 10.1128/JB.186.19.6605-6616.2004; Rao V, 2006, J CLIN INVEST, V116, P1660, DOI 10.1172/JCI27335; Samen U, 2004, J BACTERIOL, V186, P1398, DOI 10.1128/JB.186.5.1398-1408.2004; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846; Schwartz D, 2004, APPL ENVIRON MICROB, V70, P7093, DOI 10.1128/AEM.70.12.7093-7102.2004; Slamti L, 2002, EMBO J, V21, P4550, DOI 10.1093/emboj/cdf450; Smirnova GV, 2005, BIOCHEMISTRY-MOSCOW+, V70, P1199, DOI 10.1007/s10541-005-0248-3; Solomon JM, 1996, GENE DEV, V10, P2014, DOI 10.1101/gad.10.16.2014; SORENSEN AL, 1995, INFECT IMMUN, V63, P1710; Stewart GR, 2005, PLOS PATHOG, V1, P269, DOI 10.1371/journal.ppat.0010033; Steyn AJC, 2002, P NATL ACAD SCI USA, V99, P3147, DOI 10.1073/pnas.052705399; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; Sun RG, 2004, MOL MICROBIOL, V52, P25, DOI 10.1111/j.1365-2958.2003.03958.x; Trivedi OA, 2005, MOL CELL, V17, P631, DOI 10.1016/j.molcel.2005.02.009; Ventura M, 2007, MICROBIOL MOL BIOL R, V71, P495, DOI 10.1128/MMBR.00005-07; Wang CH, 2005, INFECT IMMUN, V73, P2881, DOI 10.1128/IAI.73.5.2881-2890.2005; Zvi A, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-18	77	32	33	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4091	4104		10.1096/fj.09-132407	http://dx.doi.org/10.1096/fj.09-132407			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19671666	Green Published			2022-12-28	WOS:000272193700006
J	Murray, AJ; Knight, NS; Cochlin, LE; McAleese, S; Deacon, RMJ; Rawlins, JNP; Clarke, K				Murray, Andrew J.; Knight, Nicholas S.; Cochlin, Lowri E.; McAleese, Sara; Deacon, Robert M. J.; Rawlins, J. Nicholas P.; Clarke, Kieran			Deterioration of physical performance and cognitive function in rats with short-term high-fat feeding	FASEB JOURNAL			English	Article						exercise; cognition; nutrition; mitochondria; metabolism	ACTIVATED-RECEPTOR-ALPHA; MITOCHONDRIAL UNCOUPLING PROTEINS; INDUCED CARDIAC-HYPERTROPHY; DECREASED EFFICIENCY; ENDURANCE EXERCISE; MUSCLE GLYCOGEN; ACIDS; DIET; METABOLISM; EXPRESSION	Efficiency, defined as the amount of work produced for a given amount of oxygen consumed, is a key determinant of endurance capacity, and can be altered by metabolic substrate supply, in that fatty acid oxidation is less efficient than glucose oxidation. It is unclear, however, whether consumption of a high-fat diet would be detrimental or beneficial for endurance capacity, due to purported glycogen-sparing properties. In addition, a high-fat diet over several months leads to cognitive impairment. Here, we tested the hypothesis that short-term ingestion of a high-fat diet (55% kcal from fat) would impair exercise capacity and cognitive function in rats, compared with a control chow diet (7.5% kcal from fat) via mitochondrial uncoupling and energy deprivation. We found that rats ran 35% less far on a treadmill and showed cognitive impairment in a maze test with 9 d of high-fat feeding, with respiratory uncoupling in skeletal muscle mitochondria, associated with increased uncoupling protein (UCP3) levels. Our results suggest that high-fat feeding, even over short periods of time, alters skeletal muscle UCP3 expression, affecting energy production and physical performance. Optimization of nutrition to maximize the efficiency of mitochondrial ATP production could improve energetics in athletes and patients with metabolic abnormalities.-Murray, A. J., Knight, N. S., Cochlin, L. E., McAleese, S., Deacon, R. M. J., Rawlins, J. N. P., Clarke, K. Deterioration of physical performance and cognitive function in rats with short-term high-fat feeding. FASEB J. 23, 4353-4360 (2009). www.fasebj.org	[Murray, Andrew J.; Knight, Nicholas S.; Cochlin, Lowri E.; McAleese, Sara; Clarke, Kieran] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England; [Deacon, Robert M. J.; Rawlins, J. Nicholas P.] Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England	University of Oxford; University of Oxford	Murray, AJ (corresponding author), Univ Cambridge, Dept Physiol Dev & Neurosci, Downing St, Cambridge CB2 3EG, England.	ajm267@cam.ac.uk	Murray, Andrew/B-3130-2010	Murray, Andrew/0000-0002-0929-9315	Wellcome Trust; British Heart Foundation [RG/02/009/13631]; British Heart Foundation [RG/07/004/22659, PS/02/002/14893] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); British Heart Foundation(British Heart Foundation); British Heart Foundation(British Heart Foundation)	We thank Emma Carter for her invaluable technical assistance and Dr. Charles L. Hoppel and his research group for their generous help in teaching us their mitochondrial isolation and respiration protocols. We thank Stefan Alexson (Karolinska Institutet, Stockholm, Sweden) for his generous gift of the MTE-1 antibody. S. M. thanks the Wellcome Trust for her Undergraduate Vacation Studentship. This study was supported by the British Heart Foundation (grant RG/02/009/13631).	AMIEL SA, 1995, P NUTR SOC, V54, P151, DOI 10.1079/PNS19950044; Boehm EA, 2001, AM J PHYSIOL-HEART C, V280, pH977, DOI 10.1152/ajpheart.2001.280.3.H977; Boudina S, 2007, DIABETES, V56, P2457, DOI 10.2337/db07-0481; Erlenbusch M, 2005, INT J SPORT NUTR EXE, V15, P1, DOI 10.1123/ijsnem.15.1.1; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Gilde AJ, 2003, ACTA PHYSIOL SCAND, V178, P425, DOI 10.1046/j.1365-201X.2003.01161.x; Gilde AJ, 2003, CIRC RES, V92, P518, DOI 10.1161/01.RES.0000060700.55247.7C; Greenwood CE, 2005, NEUROBIOL AGING, V26, pS42, DOI 10.1016/j.neurobiolaging.2005.08.017; Hart G, 2003, EXP PHYSIOL, V88, P639, DOI 10.1113/eph8802619; Helge JW, 1996, J PHYSIOL-LONDON, V492, P293, DOI 10.1113/jphysiol.1996.sp021309; Helge JW, 2001, J PHYSIOL-LONDON, V537, P1009, DOI 10.1113/jphysiol.2001.012933; Helge JW, 1998, J APPL PHYSIOL, V85, P1342, DOI 10.1152/jappl.1998.85.4.1342; HERMANSE.L, 1967, ACTA PHYSIOL SCAND, V71, P129, DOI 10.1111/j.1748-1716.1967.tb03719.x; HICKSON RC, 1979, AM J PHYSIOL, V236, pH268, DOI 10.1152/ajpheart.1979.236.2.H268; HINKLE PC, 1991, BIOCHEMISTRY-US, V30, P3576, DOI 10.1021/bi00228a031; How O. -J., 2007, Archives of Physiology and Biochemistry, V113, P211, DOI 10.1080/13813450701783281; HULTMAN E, 1967, ACTA MED SCAND, V182, P109; HULTMAN E, 1967, SCAND J CLIN LAB INV, VS 19, P11; Joyner MJ, 2008, J PHYSIOL-LONDON, V586, P35, DOI 10.1113/jphysiol.2007.143834; Kalmijn S, 1997, AM J EPIDEMIOL, V145, P33, DOI 10.1093/oxfordjournals.aje.a009029; Kalmijn S, 2004, NEUROLOGY, V62, P275, DOI 10.1212/01.WNL.0000103860.75218.A5; Kerner J, 2001, AM J PHYSIOL-ENDOC M, V281, pE1054; King KL, 2007, J LIPID RES, V48, P1511, DOI 10.1194/jlr.M600364-JLR200; MILLER WC, 1984, J APPL PHYSIOL, V56, P78, DOI 10.1152/jappl.1984.56.1.78; Mogensen M, 2006, J PHYSIOL-LONDON, V571, P669, DOI 10.1113/jphysiol.2005.101691; Murray AJ, 2005, DIABETES, V54, P3496, DOI 10.2337/diabetes.54.12.3496; Murray AJ, 2008, J MOL CELL CARDIOL, V44, P694, DOI 10.1016/j.yjmcc.2008.01.008; Priego T, 2008, OBESITY, V16, P819, DOI 10.1038/oby.2007.117; Roriz JS, 2009, BBA-MOL BASIS DIS, V1792, P432, DOI 10.1016/j.bbadis.2008.12.003; Sienkiewicz ZJ, 2000, BIOELECTROMAGNETICS, V21, P151, DOI 10.1002/(SICI)1521-186X(200004)21:3<151::AID-BEM1>3.0.CO;2-Q; SIMI B, 1991, J APPL PHYSIOL, V71, P197, DOI 10.1152/jappl.1991.71.1.197; Stavinoha MA, 2004, AM J PHYSIOL-ENDOC M, V287, pE888, DOI 10.1152/ajpendo.00190.2004; Winocur G, 2005, NEUROBIOL AGING, V26, pS46, DOI 10.1016/j.neurobiolaging.2005.09.003; WISNESKI JA, 1987, J CLIN INVEST, V79, P359, DOI 10.1172/JCI112820; Young ME, 2001, FASEB J, V15, P833, DOI 10.1096/fj.00-0351com; Zackova M, 2003, J BIOL CHEM, V278, P20761, DOI 10.1074/jbc.M212850200	36	108	109	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4353	4360		10.1096/fj.09-139691	http://dx.doi.org/10.1096/fj.09-139691			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19667117				2022-12-28	WOS:000272193700030
J	Lazrak, A; Iles, KE; Liu, G; Noah, DL; Noah, JW; Matalon, S				Lazrak, Ahmed; Iles, Karen E.; Liu, Gang; Noah, Diana L.; Noah, James W.; Matalon, Sadis			Influenza virus M2 protein inhibits epithelial sodium channels by increasing reactive oxygen species	FASEB JOURNAL			English	Article						single channels; proteasome; Xenopus oocytes; protein kinase C; human airway cells	WNK1 ACTIVATES SGK1; M-2 ION-CHANNEL; NA+ CHANNEL; A VIRUS; BIOPHYSICAL PROPERTIES; MOLECULAR CHARACTERIZATION; FLUID TRANSPORT; KINASE-C; II CELLS; AMILORIDE	The mechanisms by which replicating influenza viruses decrease the expression and function of amiloride-sensitive epithelial sodium channels (ENaCs) have not been elucidated. We show that expression of M2, a transmembrane influenza protein, decreases ENaC membrane levels and amiloride-sensitive currents in both Xenopus oocytes, injected with human alpha-, beta-, and gamma-ENaCs, and human airway cells (H441 and A549), which express native ENaCs. Deletion of a 10-aa region within the M2 C terminus prevented 70% of this effect. The M2 ENaC down-regulation occurred at normal pH and was prevented by MG-132, a proteasome and lysosome inhibitor. M2 had no effect on Liddle ENaCs, which have decreased affinity for Nedd4-2. H441 and A549 cells transfected with M2 showed higher levels of reactive oxygen species, as shown by the activation of redox-sensitive dyes. Pretreatment with glutathione ester, which increases intracellular reduced thiol concentrations, or protein kinase C (PKC) inhibitors prevented the deleterious effects of M2 on ENaCs. The data suggest that M2 protein increases steady-state concentrations of reactive oxygen intermediates that simulate PKC and decrease ENaCs by enhancing endocytosis and its subsequent destruction by the proteasome. These novel findings suggest a mechanism for the influenza-induced rhinorrhea and life-threatening alveolar edema in humans.-Lazrak, A., Iles, K. E., Liu, G. Noah, D. L., Noah, J. W., Matalon, S. Influenza virus M2 protein inhibits epithelial sodium channels by increasing reactive oxygen species. FASEB J. 23, 3829-3842 (2009). www.fasebj.org	[Lazrak, Ahmed; Iles, Karen E.; Matalon, Sadis] Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL USA; [Lazrak, Ahmed; Iles, Karen E.; Liu, Gang; Noah, Diana L.; Noah, James W.; Matalon, Sadis] Univ Alabama Birmingham, Pulm Injury & Repair Ctr, Birmingham, AL USA; [Iles, Karen E.; Matalon, Sadis] Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL USA; [Liu, Gang] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA; [Liu, Gang] Univ Alabama Birmingham, Sch Publ Hlth, Dept Med, Birmingham, AL 35294 USA; [Noah, Diana L.; Noah, James W.] So Res Inst, Birmingham, AL 35255 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Matalon, S (corresponding author), 901 19th St S,224 BMR2, Birmingham, AL 35205 USA.	sadis@uab.edu		, Gang/0000-0002-6999-7633; Lazrak, Ahmed/0000-0002-4127-1937; Liu, Gang/0000-0003-2615-131X	U.S. National Institutes of Health [HL031197, 5U01ES015676, 1U54ES017218, AI071393, 5P30DK072482]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031197, R37HL031197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES015676, U54ES017218] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr. Peter Snyder (University of Iowa, Iowa City, IA, USA) for the gift of ENaC Liddle mutants, Dr. Honglong Ji for useful comments and generating some of the preliminary data, and Teri Potter for editorial assistance. This work was supported by U.S. National Institutes of Health grants HL031197, 5U01ES015676, and 1U54ES017218 to S. M.; AI071393 to J.W.N.; and 5P30DK072482 to G. L.	Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Awayda MS, 1996, J GEN PHYSIOL, V108, P49, DOI 10.1085/jgp.108.1.49; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chen L, 2004, AM J PHYSIOL-RENAL, V286, pF1202, DOI 10.1152/ajprenal.00352.2003; Chen XJ, 2004, AM J PHYSIOL-LUNG C, V287, pL366, DOI 10.1152/ajplung.00011.2004; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; DuVall MD, 1998, AM J PHYSIOL-CELL PH, V274, pC1417, DOI 10.1152/ajpcell.1998.274.5.C1417; Frank J, 2003, J BIOL CHEM, V278, P43939, DOI 10.1074/jbc.M304882200; Guo Y, 1998, AM J PHYSIOL-LUNG C, V274, pL369, DOI 10.1152/ajplung.1998.274.3.L369; Henkel JR, 1999, J BIOL CHEM, V274, P9854, DOI 10.1074/jbc.274.14.9854; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hoffmann HH, 2008, ANTIVIR RES, V80, P124, DOI 10.1016/j.antiviral.2008.05.008; Ilyinskii PO, 2007, CELL CYCLE, V6, P2043, DOI 10.4161/cc.6.16.4564; Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646; Ji HL, 2006, J BIOL CHEM, V281, P8233, DOI 10.1074/jbc.M512293200; Ji HL, 2009, AM J PHYSIOL-LUNG C, V296, pL372, DOI 10.1152/ajplung.90437.2008; Johnson MD, 2006, P NATL ACAD SCI USA, V103, P4964, DOI 10.1073/pnas.0600855103; Johnson MD, 2002, P NATL ACAD SCI USA, V99, P1966, DOI 10.1073/pnas.042689399; Knight KK, 2006, P NATL ACAD SCI USA, V103, P2805, DOI 10.1073/pnas.0511184103; Kunzelmann K, 2000, P NATL ACAD SCI USA, V97, P10282, DOI 10.1073/pnas.160041997; Kunzelmann K, 2004, J BIOL CHEM, V279, P48760, DOI 10.1074/jbc.M409747200; Lazrak A, 2000, AM J PHYSIOL-CELL PH, V279, pC762, DOI 10.1152/ajpcell.2000.279.3.C762; Lazrak A, 2003, AM J PHYSIOL-LUNG C, V285, pL443, DOI 10.1152/ajplung.00412.2002; Lazrak A, 2000, AM J PHYSIOL-LUNG C, V278, pL848, DOI 10.1152/ajplung.2000.278.4.L848; LAZRAK A, 2009, AM J RESP CELL MOL B; Leduc-Nadeau A, 2007, AM J PHYSIOL-CELL PH, V292, pC1132, DOI 10.1152/ajpcell.00136.2006; Leser GP, 2005, VIROLOGY, V342, P215, DOI 10.1016/j.virol.2005.09.049; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; Malik B, 2006, AM J PHYSIOL-RENAL, V290, pF1285, DOI 10.1152/ajprenal.00432.2005; Matalon S, 2003, AM J PHYSIOL-LUNG C, V285, pL1184, DOI 10.1152/ajplung.00281.2003; Matalon S, 1999, ANNU REV PHYSIOL, V61, P627, DOI 10.1146/annurev.physiol.61.1.627; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250; Mould JA, 2000, J BIOL CHEM, V275, P8592, DOI 10.1074/jbc.275.12.8592; Nayak DP, 2004, VIRUS RES, V106, P147, DOI 10.1016/j.virusres.2004.08.012; Neumann G, 2000, EMBO J, V19, P6751, DOI 10.1093/emboj/19.24.6751; Noah DL, 2003, VIROLOGY, V307, P386, DOI 10.1016/S0042-6822(02)00127-7; Palmer-Densmore M, 2002, J GEN PHYSIOL, V120, P897, DOI 10.1085/jgp.20028608; Pinto LH, 2007, MOL BIOSYST, V3, P18, DOI 10.1039/b611613m; Pinto LH, 2006, J BIOL CHEM, V281, P8997, DOI 10.1074/jbc.R500020200; Shimbo K, 1996, BIOPHYS J, V70, P1335, DOI 10.1016/S0006-3495(96)79690-X; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Smondyrev AM, 2002, BIOPHYS J, V83, P1987, DOI 10.1016/S0006-3495(02)73960-X; Snyder PM, 2005, ENDOCRINOLOGY, V146, P5079, DOI 10.1210/en.2005-0894; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Song WF, 2009, J BIOL CHEM, V284, P7294, DOI 10.1074/jbc.M806816200; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; Staub O, 1996, STRUCTURE, V4, P495, DOI 10.1016/S0969-2126(96)00054-8; Stockando JD, 2000, J BIOL CHEM, V275, P25760, DOI 10.1074/jbc.M003615200; Tobler K, 1999, J VIROL, V73, P9695, DOI 10.1128/JVI.73.12.9695-9701.1999; Venkataraman P, 2005, J BIOL CHEM, V280, P21463, DOI 10.1074/jbc.M412406200; Wang HC, 2000, J BIOL CHEM, V275, P8600, DOI 10.1074/jbc.275.12.8600; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035; Wolk KE, 2008, AM J RESP CRIT CARE, V178, P969, DOI 10.1164/rccm.200803-455OC; Xu BE, 2005, J BIOL CHEM, V280, P34218, DOI 10.1074/jbc.M505735200; Xu BE, 2005, P NATL ACAD SCI USA, V102, P10315, DOI 10.1073/pnas.0504422102; YUE G, 1995, P NATL ACAD SCI USA, V92, P8418, DOI 10.1073/pnas.92.18.8418	62	67	70	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3829	3842		10.1096/fj.09-135590	http://dx.doi.org/10.1096/fj.09-135590			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19596899	Green Published			2022-12-28	WOS:000271272500019
J	O'Boyle, G; Mellor, P; Kirby, JA; Ali, S				O'Boyle, Graeme; Mellor, Paul; Kirby, John A.; Ali, Simi			Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12	FASEB JOURNAL			English	Article						chemokine; glycosaminoglycan; G-protein-coupled receptors; integrin adhesion; receptor desensitization	CHEMOKINE-MEDIATED INFLAMMATION; BREAST-CANCER METASTASIS; GLYCOSAMINOGLYCAN-BINDING; RHEUMATOID-ARTHRITIS; RECEPTOR; CXCR4; CHEMOATTRACTANT; INHIBITION; CELLS; CC	Interaction between chemokines and heparan sulfate (HS) is essential for leukocyte recruitment during inflammation. Previous studies have shown that a non-HS-binding mutant form of the inflammatory chemokine CCL7 can block inflammation produced by wild-type chemokines. This study examined the anti-inflammatory mechanism of a non-HS-binding mutant of the homeostatic chemokine CXCL12. Initial experiments demonstrated that mutant CXCL12 was an effective CXCR4 agonist. However, this mutant chemokine failed to promote transendothelial migration in vitro and inhibited the haptotactic response to wild-type CCL7, CXCL12, and CXCL8, and naturally occurring chemoattractants in synovial fluid from the rheumatoid synovium, including CCL2, CCL7, and CXCL8. Notably, intravenous administration of mutant CXCL12 also inhibited the recruitment of leukocytes to murine air pouches filled with wild-type CXCL12. Following intravenous administration, wild-type CXCL12 was cleared from the circulation rapidly, while the mutant chemokine persisted for >24 h. Chronic exposure to mutant CXCL12 in the circulation reduced leukocyte-surface expression of CXCR4, reduced the chemotactic response of these cells to CXCL12, and inhibited normal chemokine-mediated induction of adhesion between the alpha 4 beta 1 integrin, VLA-4, and VCAM-1. These data demonstrate that systemic administration of non-HS-binding variants of CXCL12 can mediate a powerful anti-inflammatory effect through chemokine receptor desensitization.-O'Boyle, G., Mellor, P., Kirby, J. A., Ali, S. Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12. FASEB J. 23, 3906-3916 (2009). www.fasebj.org	[O'Boyle, Graeme; Mellor, Paul; Kirby, John A.; Ali, Simi] Univ Newcastle, Appl Immunobiol & Transplantat Res Grp, Inst Cellular Med, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Kirby, JA (corresponding author), Univ Newcastle, Appl Immunobiol & Transplantat Res Grp, Inst Cellular Med, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	j.a.kirby@ncl.ac.uk		Kirby, John/0000-0003-2543-4131; O'Boyle, Graeme/0000-0002-0472-8061	Wellcome Trust [078892]; Roche Organ Transplantation Research Fund [884289934]	Wellcome Trust(Wellcome TrustEuropean Commission); Roche Organ Transplantation Research Fund	The authors thank J. D. Issacs (University of Newcastle) for assistance with the synovial fluid study; Drs. H. Walden, C. Wilson, M. Baker, and M. Kirkley for technical support; and the Wellcome Trust (grant 078892) and the Roche Organ Transplantation Research Fund (grant 884289934) for financial support.	Al-Hamidi A, 2008, MOL IMMUNOL, V45, P4000, DOI 10.1016/j.molimm.2008.06.011; Ali S, 2005, J IMMUNOL, V175, P1257, DOI 10.4049/jimmunol.175.2.1257; Ali S, 2002, GLYCOBIOLOGY, V12, P535, DOI 10.1093/glycob/cwf069; Ali S, 2007, MOL IMMUNOL, V44, P1477, DOI 10.1016/j.molimm.2006.08.011; AlMughales J, 1996, CLIN EXP IMMUNOL, V106, P230, DOI 10.1046/j.1365-2249.1996.d01-836.x; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Bursill CA, 2009, GENE THER, V16, P93, DOI 10.1038/gt.2008.141; Chigaev A, 2007, J IMMUNOL, V178, P6828, DOI 10.4049/jimmunol.178.11.6828; Colville-Nash Paul, 2003, Methods Mol Biol, V225, P181; Comerford L, 2005, IMMUNOL LETT, V96, P163, DOI 10.1016/j.imlet.2004.08.018; Culley FJ, 2003, EUR J IMMUNOL, V33, P1302, DOI 10.1002/eji.200323509; Dowsland MH, 2003, CURR MED CHEM, V10, P579, DOI 10.2174/0929867033457944; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Fricker SP, 2008, EXPERT OPIN INV DRUG, V17, P1749, DOI 10.1517/13543784.17.11.1749 ; Glynn PC, 2001, EUR RESPIR J, V18, P522, DOI 10.1183/09031936.01.00057901; Gouwy M, 2008, MOL PHARMACOL, V74, P485, DOI 10.1124/mol.108.045146; Hardy LA, 2004, LAB INVEST, V84, P81, DOI 10.1038/labinvest.3700007; Harvey JR, 2007, CLIN CANCER RES, V13, P1562, DOI 10.1158/1078-0432.CCR-06-1987; Hecht I, 2003, INT IMMUNOL, V15, P29, DOI 10.1093/intimm/dxg002; Iwamoto T, 2008, FEBS J, V275, P4448, DOI 10.1111/j.1742-4658.2008.06580.x; Johnson Z, 2004, J IMMUNOL, V173, P5776, DOI 10.4049/jimmunol.173.9.5776; Johnson Z, 2004, BIOCHEM SOC T, V32, P366, DOI 10.1042/BST0320366; Konstandin MH, 2006, J IMMUNOL METHODS, V310, P67, DOI 10.1016/j.jim.2005.12.005; Laguri C, 2008, CARBOHYD RES, V343, P2018, DOI 10.1016/j.carres.2008.01.047; Lenoir M, 2004, J IMMUNOL, V172, P7136, DOI 10.4049/jimmunol.172.11.7136; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Misra P, 2008, J NUCL MED, V49, P963, DOI 10.2967/jnumed.107.050054; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; O'Boyle G, 2007, MOL IMMUNOL, V44, P1944, DOI 10.1016/j.molimm.2006.09.033; Potzinger H, 2006, BIOCHEM SOC T, V34, P435, DOI 10.1042/BST0340435; Proudfoot AEI, 2006, BIOCHEM SOC T, V34, P422, DOI 10.1042/BST0340422; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Proudfoot AEI, 2008, ARTHRITIS RHEUM, V58, P1889, DOI 10.1002/art.23590; Rueda P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002543; Shen HM, 2001, J IMMUNOL, V166, P5027, DOI 10.4049/jimmunol.166.8.5027; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; SIN YM, 1986, ANN RHEUM DIS, V45, P873, DOI 10.1136/ard.45.10.873; Sweeney EA, 2002, BLOOD, V99, P44, DOI 10.1182/blood.V99.1.44; Van Coillie E, 1999, CYTOKINE GROWTH F R, V10, P61, DOI 10.1016/S1359-6101(99)00005-2; Venkatesan S, 2003, MOL BIOL CELL, V14, P3305, DOI 10.1091/mbc.e02-11-0714	41	39	39	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3906	3916		10.1096/fj.09-134643	http://dx.doi.org/10.1096/fj.09-134643			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19667120	Green Published			2022-12-28	WOS:000271272500026
J	Kaafarani, I; Fernandez-Sauze, S; Berenguer, C; Chinot, O; Delfino, C; Dussert, C; Metellus, P; Boudouresque, F; Mabrouk, K; Grisoli, F; Figarella-Branger, D; Martin, PM; Ouafik, L				Kaafarani, Itidal; Fernandez-Sauze, Samantha; Berenguer, Caroline; Chinot, Olivier; Delfino, Christine; Dussert, Christophe; Metellus, Philippe; Boudouresque, Francoise; Mabrouk, Kamel; Grisoli, Francois; Figarella-Branger, Dominique; Martin, Pierre-Marie; Ouafik, L'Houcine			Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice	FASEB JOURNAL			English	Article						CLR/RAMP2; CLR/RAMP3; endothelial cells; pericytes; proangiogenic cells	PANCREATIC-CANCER; CELL-LINES; IN-VIVO; HUMAN CARCINOGENESIS; STEM-CELLS; PEPTIDE; EXPRESSION; ABNORMALITIES; PERICYTES; INVASION	Adrenomedullin ( AM) is a multifunctional peptide vasodilator that transduces its effects through calcitonin receptor-like receptor/receptor activity modifying protein-2 and -3 (CLR/RAMP2 and CLR/RAMP3). Previously, we reported on the development of an anti-AM antibody that potently inhibits tumor cell proliferation in vitro and tumor growth in vivo. Here, we report the effect of anti-AM receptor antibodies (alpha AMRs) on angiogenesis and tumor growth. We demonstrate that alpha AMRs decrease in a dose-dependent manner the growth of U87 glioblastoma cells and HT-29 colorectal cancer cells, but not A549 lung cancer cells, in vitro. In vivo, AM in Matrigel plugs induces angiogenesis by promoting recruitment of endothelial cells, pericytes, myeloid precursor cells, and macrophages and by promoting channel formation. Remarkably, systemic administration of alpha AMRs every 3 d markedly reduced neovascularization of Matrigel plugs in a dose-dependent fashion, as demonstrated by reduced numbers of the recruited cells and vessel structures. Several human tumor xenografts in athymic mice were used to examine the effect of alpha AMR treatment on tumor angiogenesis and growth. alpha AMR treatment significantly suppressed the growth of glioblastoma, lung, and colon tumors. Histological examination of alpha AMR-treated tumors showed evidence of disruption of tumor vascularity with decreased microvessel density, depletion of endothelial and pericyte cells, and increased tumor cell apoptosis. These findings support the conclusion that alpha AMR treatment inhibits tumor growth by suppression of angiogenesis and tumor growth and suggest that AMRs may be useful therapeutic targets.-Kaafarani, I., Fernandez-Sauze, S., Berenguer, C., Chinot, O., Delfino, C., Dussert, C., Metellus, P., Boudouresque, F., Mabrouk, K., Grisoli, F., Figarella-Branger, D., Martin, P.-M., Ouafik, L. H. Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice FASEB J. 23, 3424-3435 ( 2009). www.fasebj.org	[Ouafik, L'Houcine] Fac Med Nord, INSERM, UMR 911, CRO2, F-13916 Marseille 20, France; [Kaafarani, Itidal; Fernandez-Sauze, Samantha; Berenguer, Caroline; Chinot, Olivier; Delfino, Christine; Dussert, Christophe; Metellus, Philippe; Boudouresque, Francoise; Martin, Pierre-Marie; Ouafik, L'Houcine] Aix Marseille Univ, Fac Med, Secteur Nord, Expt Cancerol Lab, Marseille, France; [Martin, Pierre-Marie; Ouafik, L'Houcine] AP HM, Lab Transfert Oncol Biol, Marseille, France; [Mabrouk, Kamel] Aix Marseille Univ, Fac St Jerome, Equipe Chim Radicalaire Organ & Polymere Special, Lab Chim Provence,CNRS,UMR 6264, Marseille, France; [Grisoli, Francois] Hop La Timone, AP HM, Serv Neurochirurg, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Ouafik, L (corresponding author), Fac Med Nord, INSERM, UMR 911, CRO2, Bd Pierre Dramard, F-13916 Marseille 20, France.	lhoucine.ouafik@univmed.fr	CHINOT, Olivier/M-9196-2018	CHINOT, Olivier/0000-0001-6317-9691; Ouafik, L'Houcine/0000-0002-4848-1232	INSERM; AP-HM; Institut National du Cancer (INCa) [RS019]	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); AP-HM; Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France)	This study was supported by grants from INSERM, AP-HM, and Institut National du Cancer (INCa) ( grant RS019). The Association pour la Recherche contre le Cancer ( ARC) supported I. K., and the Association for Research on Brain Tumors ( ARTC Sud) supported the postdoctoral fellowship of S.F.-S. We thank V. Gagna for excellent secretarial assistance and M. Cayol for skillful technical assistance in animal handling.	Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; Cuttitta F, 2002, MICROSC RES TECHNIQ, V57, P110, DOI 10.1002/jemt.10059; De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871; Drew E, 2002, EXP HEMATOL, V30, P1211, DOI 10.1016/S0301-472X(02)00890-1; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Fernandez-Sauze S, 2004, INT J CANCER, V108, P797, DOI 10.1002/ijc.11663; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Fritz-Six KL, 2008, J CLIN INVEST, V118, P40, DOI 10.1172/JCI33302; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6; Ichikawa-Shindo Y, 2008, J CLIN INVEST, V118, P29, DOI 10.1172/JCI33022; Ishikawa T, 2003, ONCOGENE, V22, P1238, DOI 10.1038/sj.onc.1206207; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kapas S, 1995, BIOCHEM BIOPH RES CO, V217, P832, DOI 10.1006/bbrc.1995.2847; KAPAS S, 1995, J BIOL CHEM, V270, P25344, DOI 10.1074/jbc.270.43.25344; Keleg S, 2007, INT J CANCER, V121, P21, DOI 10.1002/ijc.22596; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Lopez J, 2002, INT REV CYTOL, V221, P1; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Moody TW, 1997, PEPTIDES, V18, P1111, DOI 10.1016/S0196-9781(97)00179-4; Neri D, 2005, NAT REV CANCER, V5, P436, DOI 10.1038/nrc1627; Nikitenko LL, 2006, BRIT J CANCER, V94, P1, DOI 10.1038/sj.bjc.6602832; NJUKI F, 1993, CLIN SCI, V85, P385, DOI 10.1042/cs0850385; Ouafik L, 2002, AM J PATHOL, V160, P1279, DOI 10.1016/S0002-9440(10)62555-2; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Ramachandran V, 2007, CANCER RES, V67, P2666, DOI 10.1158/0008-5472.CAN-06-3362; Rocchi P, 2001, CANCER RES, V61, P1196; Shindo T, 2001, CIRCULATION, V104, P1964, DOI 10.1161/hc4101.097111; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Zudaire E, 2006, AM J PATHOL, V168, P280, DOI 10.2353/ajpath.2006.050291	35	55	61	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3424	3435		10.1096/fj.08-127852	http://dx.doi.org/10.1096/fj.08-127852			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19546305				2022-12-28	WOS:000270354300020
J	McLeod, J; Curtis, N; Lewis, HD; Good, MA; Fagan, MJ; Genever, PG				McLeod, Jane; Curtis, Neil; Lewis, Huw D.; Good, Mark A.; Fagan, Michael J.; Genever, Paul G.			gamma-Secretase-dependent cleavage of amyloid precursor protein regulates osteoblast behavior	FASEB JOURNAL			English	Article						Alzheimer's disease; mesenchymal stem cell	MESENCHYMAL STEM-CELLS; RECEPTOR-RELATED PROTEIN; SMOOTH-MUSCLE-CELLS; ALZHEIMERS-DISEASE; TRANSGENIC MICE; INTRACELLULAR DOMAIN; BETA-PROTEIN; A-BETA; BASEMENT-MEMBRANE; BONE HOMEOSTASIS	gamma-Secretase cleaves amyloid precursor protein (APP) to generate amyloid-beta (A beta) peptides, which aggregate in the brain in Alzheimer's disease (AD). gamma-Secretase also cleaves molecules that regulate osteoblast activity, such as Notch and ephrinB2. However, the role of APP in bone is unknown. In this study, the expression, cleavage, and function of APP were investigated during osteogenesis in vitro and in vivo. Expression of all gamma-secretase subunits was confirmed in human primary osteoprogenitors cells, and a significant increase in enzyme activity was observed during osteogenic differentiation using a specific fluorimetric assay. Application of selective inhibitors confirmed gamma-secretase-dependent cleavage of APP within osteogenic cells, and secretion of A beta by mature osteoblasts was demonstrated with the use of a chemiluminescent immunoassay. Osteoprogenitors showed a selective and significant increase in adhesion to extracellular matrices containing aged A beta plaques compared with nonaged A beta peptide controls. A beta on the endosteal and periosteal surfaces of adult rat ulnae were identified by immunohistochemistry. MicroCT analysis of vertebrae from an AD mouse model, Tg2576, identified a decrease in bone volume, surface area, and thickness compared with wild-type controls. These findings indicate that APP functions as a novel regulator of osteoblast activity and suggest that the mechanisms underlying the pathogenesis of AD may also influence bone.-McLeod, J., Curtis, N., Lewis, H. D., Good, M. A., Fagan, M. J., Genever, P. G. gamma-Secretase-dependent cleavage of amyloid precursor protein regulates osteoblast behavior. FASEB J. 23, 2942- 2955 (2009). www.fasebj.org	[Genever, Paul G.] Univ York, Dept Biol, Area 9, York YO10 5YW, N Yorkshire, England; [Curtis, Neil; Fagan, Michael J.] Univ Hull, Dept Engn, Kingston Upon Hull HU6 7RX, N Humberside, England; [Lewis, Huw D.] Merck Sharp & Dohme Res Labs, Dept Mol & Cellular Neurosci, Harlow, Essex, England; [Good, Mark A.] Cardiff Univ, Sch Psychol, Cardiff, S Glam, Wales	University of York - UK; University of Hull; Merck & Company; Cardiff University	Genever, PG (corresponding author), Univ York, Dept Biol, Area 9, York YO10 5YW, N Yorkshire, England.	pg5@york.ac.uk		Genever, Paul/0000-0002-5730-8976	Medical Research Council [G9724886] Funding Source: Medline; MRC [G9724886] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adriani W, 2006, BEHAV PHARMACOL, V17, P525, DOI 10.1097/00008877-200609000-00019; Assis-Nascimento P, 2007, NEUROCHEM RES, V32, P1476, DOI 10.1007/s11064-007-9335-8; Best JD, 2005, J PHARMACOL EXP THER, V313, P902, DOI 10.1124/jpet.104.081174; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CHEN M, 1991, NEUROSCI LETT, V125, P223, DOI 10.1016/0304-3940(91)90034-Q; Churcher I, 2003, J MED CHEM, V46, P2275, DOI 10.1021/jm034058a; Churcher I, 2003, BIOORG MED CHEM LETT, V13, P179, DOI 10.1016/S0960-894X(02)00909-5; Compagni A, 2003, DEV CELL, V5, P217, DOI 10.1016/S1534-5807(03)00198-9; Coulson EJ, 1997, BRAIN RES, V770, P72, DOI 10.1016/S0006-8993(97)00757-9; Culvenor JG, 2000, EXP CELL RES, V255, P192, DOI 10.1006/excr.1999.4791; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712; Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22-5-849; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Frackowiak J, 2003, J NEUROPATH EXP NEUR, V62, P685, DOI 10.1093/jnen/62.6.685; Gillian AM, 1997, J NEUROSCI RES, V49, P154, DOI 10.1002/(SICI)1097-4547(19970715)49:2<154::AID-JNR4>3.0.CO;2-8; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716; Ho LB, 1996, J BIOL CHEM, V271, P30929, DOI 10.1074/jbc.271.48.30929; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Kim HS, 2003, FASEB J, V17, P1951, DOI 10.1096/fj.03-0106fje; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KNOPS J, 1992, J BIOL CHEM, V267, P16022; KOO EH, 1994, J BIOL CHEM, V269, P17386; KRAMER RH, 1984, JNCI-J NATL CANCER I, V72, P889; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; MELTON LJ, 1994, J AM GERIATR SOC, V42, P614, DOI 10.1111/j.1532-5415.1994.tb06859.x; Moir Robert D., 2005, Current Alzheimer Research, V2, P269, DOI 10.2174/1567205053585918; Mok SS, 2006, J NEUROCHEM, V96, P53, DOI 10.1111/j.1471-4159.2005.03539.x; Nguyen V, 2006, BRAIN RES, V1086, P76, DOI 10.1016/j.brainres.2006.02.122; Ognibene E, 2005, BEHAV BRAIN RES, V156, P225, DOI 10.1016/j.bbr.2004.05.028; Owens AP, 2003, BIOORG MED CHEM LETT, V13, P4143, DOI 10.1016/j.bmcl.2003.07.031; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1991, EUR J PHARM-MOLEC PH, V207, P367, DOI 10.1016/0922-4106(91)90014-9; Postuma RB, 2000, J NEUROCHEM, V74, P1122; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Roth AD, 2005, BIOL RES, V38, P381, DOI 10.4067/S0716-97602005000400011; Rozmahel R, 2002, NEUROBIOL AGING, V23, P187, DOI 10.1016/S0197-4580(01)00267-6; Sato Y, 1998, BONE, V23, P555, DOI 10.1016/S8756-3282(98)00134-3; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003-0463; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; Selkoe DJ, 2008, BEHAV BRAIN RES, V192, P106, DOI 10.1016/j.bbr.2008.02.016; Serneels L, 2005, P NATL ACAD SCI USA, V102, P1719, DOI 10.1073/pnas.0408901102; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Shindo K, 2003, EXP CELL RES, V290, P370, DOI 10.1016/S0014-4827(03)00349-5; Tropel P, 2004, EXP CELL RES, V295, P395, DOI 10.1016/j.yexcr.2003.12.030; TSUZUKI K, 1994, BRAIN RES, V659, P213, DOI 10.1016/0006-8993(94)90881-8; von Rotz RC, 2004, J CELL SCI, V117, P4435, DOI 10.1242/jcs.01323; Vujovic S, 2007, CELL PROLIFERAT, V40, P185, DOI 10.1111/j.1365-2184.2007.00426.x; Weller I, 2004, ANN EPIDEMIOL, V14, P319, DOI 10.1016/j.annepidem.2003.08.005; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012	65	9	9	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2942	2955		10.1096/fj.08-121657	http://dx.doi.org/10.1096/fj.08-121657			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19376818				2022-12-28	WOS:000270241000017
J	Nishijo, K; Hosoyama, T; Bjornson, CRR; Schaffer, BS; Prajapati, SI; Bahadur, AN; Hansen, MS; Blandford, MC; McCleish, AT; Rubin, BP; Epstein, JA; Rando, TA; Capecchi, MR; Keller, C				Nishijo, Koichi; Hosoyama, Tohru; Bjornson, Christopher R. R.; Schaffer, Beverly S.; Prajapati, Suresh I.; Bahadur, Ali N.; Hansen, Mark S.; Blandford, Mary C.; McCleish, Amanda T.; Rubin, Brian P.; Epstein, Jonathan A.; Rando, Thomas A.; Capecchi, Mario R.; Keller, Charles			Biomarker system for studying muscle, stem cells, and cancer in vivo	FASEB JOURNAL			English	Article						optical imaging; reporter gene; satellite cell	SECRETED ALKALINE-PHOSPHATASE; RED FLUORESCENT PROTEIN; GENE-EXPRESSION; SATELLITE CELLS; ALVEOLAR RHABDOMYOSARCOMA; LIVING SUBJECTS; TUMOR-GROWTH; MOUSE; REPORTER; CRE	Bioluminescent reporter genes are sensitive in situ tools for following disease progression in preclinical models, albeit they are subject to scattering and absorption in deep tissues. We have generated a bicistronic Cre/LoxP reporter mouse line that pairs the expression of firefly luciferase with quantifiable expression of a human placental alkaline phosphatase that is secreted into the serum (SeAP). With the use of this dual-modality bioreporter with a novel, inducible Pax7-CreER line for tracking muscle satellite cells, we demonstrate the longitudinal kinetics of muscle stem cell turnover, accounting for a doubling of the signal from satellite cell and progeny every 3.93 wk in the transition from adolescence to early adulthood. We also show that this dual-modality bioreporter can be incorporated in preclinical cancer models, whereby SeAP activity is reflective of tumor burden. Thus, this dual bioreporter permits both spatial localization and accurate quantification of biological processes in vivo even when the tissue of interest is deep within the animal.-Nishijo, K., Hosoyama, T., Bjornson, C. R. R., Schaffer, B. S., Prajapati, S. I., Bahadur, A. N., Hansen, M. S., Blandford, M. C., McCleish, A. T., Rubin, B. P., Epstein, J. A., Rando, T. A., Capecchi, M. R., Keller, C. Biomarker system for studying muscle, stem cells, and cancer in vivo. FASEB J. 23, 2681-2690 ( 2009)	[Nishijo, Koichi; Hosoyama, Tohru; Schaffer, Beverly S.; Prajapati, Suresh I.; Bahadur, Ali N.; McCleish, Amanda T.; Keller, Charles] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Nishijo, Koichi; Hosoyama, Tohru; Schaffer, Beverly S.; Prajapati, Suresh I.; Bahadur, Ali N.; McCleish, Amanda T.; Keller, Charles] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Nishijo, Koichi; Hosoyama, Tohru; Schaffer, Beverly S.; Prajapati, Suresh I.; Bahadur, Ali N.; McCleish, Amanda T.; Keller, Charles] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA; [Bjornson, Christopher R. R.; Rando, Thomas A.] Stanford Univ, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA; [Hansen, Mark S.; Blandford, Mary C.; Capecchi, Mario R.] Univ Utah, Dept Human Genet, Salt Lake City, UT USA; [Rubin, Brian P.] Cleveland Clin, Dept Anat Pathol, Taussig Canc Ctr, Cleveland, OH 44106 USA; [Rubin, Brian P.] Cleveland Clin, Dept Mol Genet, Taussig Canc Ctr, Cleveland, OH 44106 USA; [Rubin, Brian P.] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44106 USA; [Epstein, Jonathan A.] Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Stanford University; Utah System of Higher Education; University of Utah; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Pennsylvania	Keller, C (corresponding author), 8403 Floyd Curl Dr,MC-7784, San Antonio, TX 78229 USA.	kellerc2@uthscsa.edu	Hosoyama, Tohru/ABA-2797-2021	Rando, Thomas/0000-0001-5843-8564; Hosoyama, Tohru/0000-0002-1825-6923; Keller, Charles/0000-0003-2505-7487	National Institute of General Medical Sciences; NIGMS [GM-07717, GM-60655]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T34GM007717, R25GM060655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG023806] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	An application of this reporter system for discovery of spontaneous biomarkers is being patented by University of Texas Health Science Center, San Antonio, and has been licensed for commercial distribution by Numira Biosciences (www.numirabio.com), of which C. K. is a cofounder. Numira Biosciences provided partial funding for these studies. A. T. M. was supported by National Institute of General Medical Sciences grants NIGMS MARC-U*STAR GM-07717 and NIGMS MBRS-RISE GM-60655.	ALLEN RE, 1991, J CELL PHYSIOL, V149, P525, DOI 10.1002/jcp.1041490323; Bao R, 2000, GYNECOL ONCOL, V78, P373, DOI 10.1006/gyno.2000.5925; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; BISCHOFF R, 1986, DEV BIOL, V115, P129, DOI 10.1016/0012-1606(86)90234-4; Brown CB, 2005, GENESIS, V41, P202, DOI 10.1002/gene.20116; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chaudhuri TR, 2003, TECHNOL CANCER RES T, V2, P171, DOI 10.1177/153303460300200214; DEGREGORIO MW, 1989, CANCER CHEMOTH PHARM, V23, P68; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2005, CANCER RES, V65, P7530, DOI 10.1158/0008-5472.CAN-05-0477; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; LIEN EA, 1989, CANCER RES, V49, P2175; Louie AY, 2000, NAT BIOTECHNOL, V18, P321, DOI 10.1038/73780; Luche H, 2007, EUR J IMMUNOL, V37, P43, DOI 10.1002/eji.200636745; Lyons SK, 2003, CANCER RES, V63, P7042; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; Nilsson EE, 2002, CANCER CHEMOTH PHARM, V49, P93, DOI 10.1007/s00280-001-0396-0; O'Neal WK, 2000, MOL THER, V2, P640, DOI 10.1006/mthe.2000.0198; Oumard A, 2000, MOL CELL BIOL, V20, P2755, DOI 10.1128/MCB.20.8.2755-2759.2000; Ray P, 2004, CANCER RES, V64, P1323, DOI 10.1158/0008-5472.CAN-03-1816; Rodriguez CI, 2000, NAT GENET, V25, P139, DOI 10.1038/75973; ROSENBLATT JD, 1995, IN VITRO CELL DEV-AN, V31, P773; Sacco A, 2008, NATURE, V456, P502, DOI 10.1038/nature07384; Safran Michal, 2003, Mol Imaging, V2, P297, DOI 10.1162/153535003322750637; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Stoller JZ, 2008, GENESIS, V46, P200, DOI 10.1002/dvg.20384; Tang SHE, 2002, GENESIS, V32, P199, DOI 10.1002/gene.10030; Tannous BA, 2005, MOL THER, V11, P435, DOI 10.1016/j.ymthe.2004.10.016; Uhrbom L, 2004, NAT MED, V10, P1257, DOI 10.1038/nm1120; Vintersten K, 2004, GENESIS, V40, P241, DOI 10.1002/gene.20095; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	35	104	109	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2009	23	8					2681	2690		10.1096/fj.08-128116	http://dx.doi.org/10.1096/fj.08-128116			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19332644	Green Published			2022-12-28	WOS:000268836700036
J	Band, M; Joel, A; Hernandez, A; Avivi, A				Band, Mark; Joel, Alma; Hernandez, Alvaro; Avivi, Aaron			Hypoxia-induced BNIP3 expression and mitophagy: in vivo comparison of the rat and the hypoxia-tolerant mole rat, Spalax ehrenbergi	FASEB JOURNAL			English	Article						cancer; apoptosis/autophagy; splice variant; subterranean habitat	MYOCARDIAL ISCHEMIA/REPERFUSION INJURY; CARDIAC MYOCYTE DEATH; CELL-DEATH; ERYTHROPOIETIN RECEPTOR; PROTEIN BNIP3; BH3 DOMAIN; MITOCHONDRIAL; GENE; SURVIVAL; PATHWAY	The blind subterranean mole rat of the Spalax ehrenbergi superspecies is an excellent animal model for hypoxic tolerance. Unique physiological, functional, and gene structure changes allow Spalax species to survive lower oxygen levels than most terrestrial animals. BNIP3, an HIF-1 dependent hypoxia-response gene, has a proapoptotic function; however, expression is suppressed in many types of cancers. Under hypoxic conditions, BNIP3 also functions as a mediator of mitochondrial autophagy, a survival adaptation to control ROS production and DNA damage. Using real-time PCR and Western blotting, we investigated the impact of hypoxia on BNIP3 expression and mitophagy, in the skeletal muscle and heart, of the Rattus and two Spalax species. BNIP3 transcript, as well as protein levels, increased to significantly higher levels under hypoxia in Rattus tissues, with smaller changes in Spalax. Mitophagy was correlated with BNIP3 expression in the heart with an inverse correlation to hypoxia tolerance. A dense network of vessels in Spalax muscle may offer protection from physiological hypoxia, while the response in Rattus reflects the increase of hypoxic stress. In Spalax tissues, as in many cancers, BNIP3 expression and mitophagy are significantly less affected by hypoxia. Similar mechanisms, beneficial to organisms adapted to stressful environments, may also confer malignant cells with survival features. Understanding the molecular basis of such adaptations may enhance development of new therapeutic modalities.-Band, M., Joel, A., Hernandez, A., Avivi, A. Hypoxiainduced BNIP3 expression and mitophagy: in vivo comparison of the rat and the hypoxia-tolerant mole rat, Spalax ehrenbergi. FASEB J. 23, 2327-2335 (2009)	[Joel, Alma; Avivi, Aaron] Univ Haifa, Inst Evolut, IL-31905 Haifa, Israel; [Band, Mark; Hernandez, Alvaro] Univ Illinois, WM Keck Ctr Comparat & Funct Genom, Urbana, IL 61801 USA	University of Haifa; University of Illinois System; University of Illinois Urbana-Champaign	Avivi, A (corresponding author), Univ Haifa, Inst Evolut, IL-31905 Haifa, Israel.	markband@illinois.edu; aaron@research.haifa.ac.il			United States-Israel Binational Science Foundation (BSF) [2005346]	United States-Israel Binational Science Foundation (BSF)(US-Israel Binational Science Foundation)	This work was supported by the United States-Israel Binational Science Foundation (BSF), grant 2005346.	ARIELI R, 1981, PHYSIOL ZOOL, V54, P14, DOI 10.1086/physzool.54.1.30155800; ARIELI R, 1991, COMP BIOCHEM PHYS A, V100, P543, DOI 10.1016/0300-9629(91)90367-L; ARIELI R, 1984, EXPERIENTIA, V40, P512, DOI 10.1007/BF01952413; ARIELI R, 1986, EXPERIENTIA, V42, P441, DOI 10.1007/BF02118650; Ashur-Fabian C, 2004, P NATL ACAD SCI USA, V101, P12236, DOI 10.1073/pnas.0404998101; Avivi A, 2007, ONCOGENE, V26, P2507, DOI 10.1038/sj.onc.1210045; Avivi A, 2005, FASEB J, V19, P1314, DOI 10.1096/fj.04-3414fje; Avivi A, 1999, FEBS LETT, V452, P133, DOI 10.1016/S0014-5793(99)00584-0; Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278; Baetz D, 2005, CIRCULATION, V112, P3777, DOI 10.1161/CIRCULATIONAHA.105.573899; Band M, 2008, FASEB J, V22, P105, DOI 10.1096/fj.07-8892com; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Crow MT, 2002, CIRC RES, V91, P183, DOI 10.1161/01.RES.0000030195.38795.CF; Gerlach F, 2006, ISR J ECOL EVOL, V52, P389, DOI 10.1560/IJEE_52_3-4_389; Graham RA, 2004, J EXP BIOL, V207, P3189, DOI 10.1242/jeb.01109; GURNETT AM, 1984, J PROTEIN CHEM, V3, P445, DOI 10.1007/BF01025063; Hamacher-Brady A, 2007, CELL DEATH DIFFER, V14, P146, DOI 10.1038/sj.cdd.4401936; Hamacher-Brady A, 2006, CARDIOVASC DRUG THER, V20, P445, DOI 10.1007/s10557-006-0583-7; Hankeln T, 2005, J INORG BIOCHEM, V99, P110, DOI 10.1016/j.jinorgbio.2004.11.009; Jubb AM, 2004, J CLIN PATHOL, V57, P504, DOI 10.1136/jcp.2003.012963; Jubb AM, 2003, J PATHOL, V200, P577, DOI 10.1002/path.1371; Kim JY, 2002, ARCH BIOCHEM BIOPHYS, V398, P147, DOI 10.1006/abbi.2001.2673; KLEINSCHMIDT T, 1984, H-S Z PHYSIOL CHEM, V365, P531, DOI 10.1515/bchm2.1984.365.1.531; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Magnusson KP, 1998, ONCOGENE, V17, P2333, DOI 10.1038/sj.onc.1202149; Mellor HR, 2007, CANCER METAST REV, V26, P553, DOI 10.1007/s10555-007-9080-0; Murai M, 2005, BRIT J CANCER, V92, P1165, DOI 10.1038/sj.bjc.6602422; Murai M, 2005, CLIN CANCER RES, V11, P1021; Nevo, 1999, MOSAIC EVOLUTION SUB; NEVO E, 1989, HEREDITY, V62, P85, DOI 10.1038/hdy.1989.11; NEVO E., 2001, ADAPTIVE RAD BLIND S; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Ravid O, 2007, P NATL ACAD SCI USA, V104, P14360, DOI 10.1073/pnas.0706777104; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Shams I, 2005, FASEB J, V19, P1749, DOI 10.1096/fj.05-3975fje; Shams I, 2005, COMP BIOCHEM PHYS A, V142, P376, DOI 10.1016/j.cbpa.2005.09.003; Shams I, 2004, P NATL ACAD SCI USA, V101, P9698, DOI 10.1073/pnas.0403540101; Shams Imad, 2005, FASEB J, V19, P307; Singer D, 1999, COMP BIOCHEM PHYS A, V123, P221, DOI 10.1016/S1095-6433(99)00057-4; Sowter HM, 2003, J PATHOL, V201, P573, DOI 10.1002/path.1486; Sowter HM, 2001, CANCER RES, V61, P6669; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Webster KA, 2005, J MOL CELL CARDIOL, V38, P35, DOI 10.1016/j.yjmcc.2004.11.007; Widmer HR, 1997, P NATL ACAD SCI USA, V94, P2062, DOI 10.1073/pnas.94.5.2062; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yurkova N, 2008, CIRC RES, V102, P472, DOI 10.1161/CIRCRESAHA.107.164731; ZHANG H, 2008, J BIOL CHEM	48	72	80	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2327	2335		10.1096/fj.08-122978	http://dx.doi.org/10.1096/fj.08-122978			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19255257				2022-12-28	WOS:000268836500032
J	Tang-Schomer, MD; Patel, AR; Baas, PW; Smith, DH				Tang-Schomer, Min D.; Patel, Ankur R.; Baas, Peter W.; Smith, Douglas H.			Mechanical breaking of microtubules in axons during dynamic stretch injury underlies delayed elasticity, microtubule disassembly, and axon degeneration	FASEB JOURNAL			English	Article						traumatic brain injury; traumatic axonal injury; taxol; micropattern	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; SODIUM-CHANNELS; BETA-APP; CYTOSKELETAL; ELONGATION; GROWTH; TETRODOTOXIN; ACCUMULATION	Little is known about which components of the axonal cytoskeleton might break during rapid mechanical deformation, such as occurs in traumatic brain injury. Here, we micropatterned neuronal cell cultures on silicone membranes to induce dynamic stretch exclusively of axon fascicles. After stretch, undulating distortions formed along the axons that gradually relaxed back to a straight orientation, demonstrating a delayed elastic response. Subsequently, swellings developed, leading to degeneration of almost all axons by 24 h. Stabilizing the microtubules with taxol maintained the undulating geometry after injury but greatly reduced axon degeneration. Conversely, destabilizing microtubules with nocodazole prevented undulations but greatly increased the rate of axon loss. Ultrastructural analyses of axons postinjury revealed immediate breakage and buckling of microtubules in axon undulations and progressive loss of microtubules. Collectively, these data suggest that dynamic stretch of axons induces direct mechanical failure at specific points along microtubules. This microtubule disorganization impedes normal relaxation of the axons, resulting in undulations. However, this physical damage also triggers progressive disassembly of the microtubules around the breakage points. While the disintegration of microtubules allows delayed recovery of the "normal" straight axon morphology, it comes at a great cost by interrupting axonal transport, leading to axonal swelling and degeneration.-Tang-Schomer, M. D., Patel, A. R,, Baas, P. W., Smith, D. H. Mechanical breaking of microtubules in axons during dynamic stretch injury underlies delayed elasticity, microtubule disassembly, and axon degeneration. FASEB J. 24, 1401-1410 (2010). www.fasebj.org	[Tang-Schomer, Min D.; Patel, Ankur R.; Smith, Douglas H.] Univ Penn, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Tang-Schomer, Min D.; Patel, Ankur R.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Baas, Peter W.] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Drexel University	Smith, DH (corresponding author), 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	Tang-Schomer, Min/AAD-9501-2020; smith, douglas/A-1321-2007; Tang-Schomer, Min/C-1967-2013	Tang-Schomer, Min/0000-0001-7585-3890; 	NIH [NS-056202, NS-038104, NS-048949]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048949, P01NS056202, R01NS038104] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Tracy Yuen, Catherine von Reyn, and Matthew Weingard from the Center for Brain Injury and Repair, University of Pennsylvania, for technical assistance; Ray Meade from the Biomedical Imaging Core, University of Pennsylvania, for electron microscopic assistance; and Dr. David Meaney from the Department of Bioengineering, University of Pennsylvania, for insightful discussions. This work is supported by NIH grants NS-056202, NS-038104, and NS-048949 (to D. H. S.).	ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; AHMAD FJ, 1993, J NEUROSCI, V13, P856; BAAS PW, 1993, J NEUROSCI, V13, P2177; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Dimitrov A, 2008, SCIENCE, V322, P1353, DOI 10.1126/science.1165401; DRECHSEL DN, 1994, CURR BIOL, V4, P1053, DOI 10.1016/S0960-9822(00)00243-8; DYE RB, 1993, J BIOL CHEM, V268, P6847; Erturk A, 2007, J NEUROSCI, V27, P9169, DOI 10.1523/JNEUROSCI.0612-07.2007; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Hammarlund M, 2007, J CELL BIOL, V176, P269, DOI 10.1083/jcb.200611117; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Jordan MA, 1998, METHOD ENZYMOL, V298, P252, DOI 10.1016/S0076-6879(98)98024-7; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; MCINTOSH JR, 1984, NATURE, V312, P196, DOI 10.1038/312196b0; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MICKEY B, 1995, J CELL BIOL, V130, P909, DOI 10.1083/jcb.130.4.909; Myers KA, 2007, J CELL BIOL, V178, P1081, DOI 10.1083/jcb.200702074; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; Tang MD, 2003, J AM CHEM SOC, V125, P12988, DOI 10.1021/ja037677h; VanBuren V, 2005, BIOPHYS J, V89, P2911, DOI 10.1529/biophysj.105.060913; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; ZHENG J, 1991, J NEUROSCI, V11, P1117	43	238	245	2	44	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1401	1410		10.1096/fj.09-142844	http://dx.doi.org/10.1096/fj.09-142844			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20019243	Green Published			2022-12-28	WOS:000277158900013
J	Morgan, EA; Schneider, JG; Baroni, TE; Ulckan, O; Heller, E; Hurchla, MA; Deng, HJ; Floyd, D; Berdy, A; Prior, JL; Piwnica-Worms, D; Teitelbaum, SL; Ross, FP; Weilbaecher, KN				Morgan, Elizabeth A.; Schneider, Jochen G.; Baroni, Timothy E.; Ulckan, Oezge; Heller, Emanuela; Hurchla, Michelle A.; Deng, Hongju; Floyd, Desiree; Berdy, Andrew; Prior, Julie L.; Piwnica-Worms, David; Teitelbaum, Steven L.; Ross, F. Patrick; Weilbaecher, Katherine N.			Dissection of platelet and myeloid cell defects by conditional targeting of the beta 3-integrin subunit	FASEB JOURNAL			English	Article						Pf4-Cre; LysM-Cre; conditional knockout	ENDOTHELIAL GROWTH-FACTOR; INTEGRIN-LINKED KINASE; MARROW-DERIVED CELLS; BETA(3)-INTEGRIN-DEFICIENT MICE; PATHOLOGICAL ANGIOGENESIS; ALPHA-V-BETA-3 INTEGRIN; BETA(3) INTEGRIN; BONE-RESORPTION; GLIOMA GROWTH; TUMOR-GROWTH	The purpose of this work was to determine platelet and myeloid cell-specific requirements for beta 3-containing integrins in hemostasis, bone resorption, and tumor growth. LoxP-flanked mice were generated to study the conditional deletion of beta 3-integrin in platelets [knockout in platelets (KOP)] and myeloid cells [knockout in myeloid (KOM)]. Using the beta 3KOP and beta 3KOM strains of mice, we studied the role of beta 3-integrin in hemostasis, bone resorption, and subcutaneous tumor growth. Tissue-specific deletion of platelet beta 3-integrins in beta 3KOP mice did not affect bone mass but resulted in a severe bleeding phenotype. No growth difference of tumor xenografts or in neoangiogenesis were found in beta 3KOP mice, in contrast to the defects observed in germline beta 3(-/-) mice. Conditional deletion of myeloid beta 3-integrins in beta 3KOM mice resulted in osteopetrosis but had no effect on hemostasis or mortality. Tumor growth in beta 3KOM mice was increased and accompanied by decreased macrophage infiltration, without increase in blood vessel number. Platelet beta 3-integrin deficiency was sufficient to disrupt hemostasis but had no effect on bone mass or tumor growth. Myeloid-specific beta 3-integrin deletion was sufficient to perturb bone mass and enhance tumor growth due to reduced macrophage infiltration in the tumors. These results suggest that beta 3-integrins have cell-specific roles in complex biological processes.-Morgan, E. A., Schneider, J. G., Baroni, T. E., Uluckan, O., Heller, E., Hurchla, M. A., Deng, H., Floyd, D., Berdy, A., Prior, J. L., Piwnica-Worms, D., Teitelbaum, S. L., Ross, F. P., Weilbaecher, K. N. Dissection of platelet and myeloid cell defects by conditional targeting of the beta 3-integrin subunit. FASEB J. 24, 1117-1127 (2010). www.fasebj.org	[Morgan, Elizabeth A.; Schneider, Jochen G.; Baroni, Timothy E.; Ulckan, Oezge; Heller, Emanuela; Hurchla, Michelle A.; Deng, Hongju; Floyd, Desiree; Berdy, Andrew; Weilbaecher, Katherine N.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Prior, Julie L.; Piwnica-Worms, David] Washington Univ, Sch Med, Mol Imaging Ctr, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA; [Teitelbaum, Steven L.; Ross, F. Patrick] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; [Schneider, Jochen G.] Univ Wurzburg, Dept Clin Biochem & Pathobiochem, Wurzburg, Germany	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Wurzburg	Weilbaecher, KN (corresponding author), Washington Univ, Sch Med, Div Oncol, Dept Med & Cell Biol & Physiol, 660 S Euclid Ave,POB 8069, St Louis, MO 63110 USA.	kweilbae@dom.wustl.edu	Uluckan, Ozge/H-6912-2015	Uluckan, Ozge/0000-0001-9468-1211; Morgan, Elizabeth/0000-0001-5880-9337; Teitelbaum, Steven/0000-0002-4054-6679	NATIONAL CANCER INSTITUTE [R56CA097250, P50CA094056, R01CA097250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032788, R01AR046523, R01AR046852, P30AR057235, R37AR046523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA097250, P50 CA94056, P50 CA094056, R56 CA097250] Funding Source: Medline; NIAMS NIH HHS [R01 AR046852, AR032788, R01 AR046523, R37 AR046523, AR046852, AR046523, R01 AR032788, P30 AR057235] Funding Source: Medline; NIDDK NIH HHS [P30 DK52574, DK56341, P30 DK056341-09, P30 DK056341, P30 DK052574] Funding Source: Medline; NIGMS NIH HHS [T32 GM007200, T32 GM7200] Funding Source: Medline; PHS HHS [NIHR0152152] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bakewell SJ, 2003, P NATL ACAD SCI USA, V100, P14205, DOI 10.1073/pnas.2234372100; BEER J, 1989, J BIOL CHEM, V264, P17564; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Castro CHM, 2003, CELL COMMUN ADHES, V10, P445, DOI 10.1080/15419060390267700; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; DEJANA E, 1979, THROMB RES, V15, P199, DOI 10.1016/0049-3848(79)90065-3; Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924; Feng WY, 2008, J CELL BIOL, V183, P1145, DOI 10.1083/jcb.200802179; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; Friedrich EB, 2004, MOL CELL BIOL, V24, P8134, DOI 10.1128/MCB.24.18.8134-8144.2004; Galarneau H, 2007, CANCER RES, V67, P8874, DOI 10.1158/0008-5472.CAN-07-0177; Graubert TA, 1998, NUCLEIC ACIDS RES, V26, P2849, DOI 10.1093/nar/26.12.2849; Guerrero CA, 2000, P NATL ACAD SCI USA, V97, P14644, DOI 10.1073/pnas.250299897; Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108; HILLIARD TJ, 1990, J BONE MINER RES, V5, P1217; Hirbe AC, 2007, BLOOD, V109, P3424, DOI 10.1182/blood-2006-09-048686; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Italiano JE, 2008, BLOOD, V111, P1227, DOI 10.1182/blood-2007-09-113837; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Kanamori M, 2006, J BIOL CHEM, V281, P37256, DOI 10.1074/jbc.M605344200; Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Mahabeleshwar GH, 2006, J EXP MED, V203, P2495, DOI 10.1084/jem.20060807; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; Rafii DC, 2008, ARTERIOSCL THROM VAS, V28, P217, DOI 10.1161/ATVBAHA.107.151159; Ren J, 2007, J MOL CELL CARDIOL, V42, P367, DOI 10.1016/j.yjmcc.2006.11.002; Reynolds AR, 2004, CANCER RES, V64, P8643, DOI 10.1158/0008-5472.CAN-04-2760; Reynolds LE, 2005, NAT MED, V11, P167, DOI 10.1038/nm1165; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Robinson SD, 2004, ARTERIOSCL THROM VAS, V24, P2108, DOI 10.1161/01.ATV.0000143857.27408.de; Rosen HN, 2000, CALCIFIED TISSUE INT, V66, P100, DOI 10.1007/PL00005830; ROSS FP, 1993, J BIOL CHEM, V268, P9901; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Schaffner A, 2005, J LEUKOCYTE BIOL, V78, P202, DOI 10.1189/jlb.0105024; Schneider JG, 2007, ARTERIOSCL THROM VAS, V27, P2699, DOI 10.1161/ATVBAHA.107.153650; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Srivatsa SS, 1997, CARDIOVASC RES, V36, P408, DOI 10.1016/S0008-6363(97)00184-3; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; Taverna D, 2004, P NATL ACAD SCI USA, V101, P763, DOI 10.1073/pnas.0307289101; Tiedt R, 2007, BLOOD, V109, P1503, DOI 10.1182/blood-2006-04-020362; Tucker KL, 2008, BLOOD, V112, P4523, DOI 10.1182/blood-2008-03-148502; Uluckan O, 2008, J CELL BIOCHEM, V104, P1311, DOI 10.1002/jcb.21709; Weerasinghe D, 1998, J CELL BIOL, V142, P595, DOI 10.1083/jcb.142.2.595; Ye M, 2003, IMMUNITY, V19, P689, DOI 10.1016/S1074-7613(03)00299-1	50	38	38	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1117	1127		10.1096/fj.09-138420	http://dx.doi.org/10.1096/fj.09-138420			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19933310	Green Published			2022-12-28	WOS:000276462300019
J	Verkaar, F; Blankesteijn, WM; Smits, JFM; Zaman, GJR				Verkaar, Folkert; Blankesteijn, W. Matthijs; Smits, Jos F. M.; Zaman, Guido J. R.			beta-Galactosidase enzyme fragment complementation for the measurement of Wnt/beta-catenin signaling	FASEB JOURNAL			English	Article						AEB-071; GSK3; PKC; sotrastaurin; Wnt-3a; Wnt-5a	WNT PATHWAY; PROTEIN; ASSAY; INHIBITOR; LITHIUM; IDENTIFICATION; MECHANISM	Wnt/beta-catenin signaling is an important regulator of cell polarity, proliferation, and stem cell maintenance during development and adulthood. Wnt proteins induce the nuclear accumulation of beta-catenin, which regulates the expression of Wnt-responsive genes through association with TCF/LEF transcription factors. Aberrant Wnt/beta-catenin signaling has been implicated in a plethora of pathologies and, most notably, underlies initiation and expansion of several cancers. Here, we apply enzyme fragment complementation to measure the nuclear accumulation of beta-catenin. beta-catenin was tagged with a peptide fragment of beta-galactosidase and transfected into cells expressing a corresponding deletion mutant of the enzyme exclusively in the nucleus. Stimulation of the cells with recombinant Wnt-3a restored beta-galactosidase activity in a dose-dependent manner with nanomolar potency. Using the assay, we confirmed that Wnt-5a represses beta-catenin-driven reporter gene activity downstream of nuclear entry of beta-catenin. In addition, we tested a library of >2000 synthetic chemical compounds for their ability to induce beta-catenin nuclear accumulation. The immunosuppressive protein kinase C inhibitor sotrastaurin (AEB-071) was identified as an activator of Wnt/beta-catenin signaling at micromolar concentrations. It was confirmed that the compound stabilizes endogenous beta-catenin protein and can induce TCF/LEF-dependent gene transcription. Subsequent biochemical profiling of >200 kinases revealed both isoforms of glycogen synthase kinase 3, as previously unappreciated targets of sotrastaurin. We show that the beta-catenin nuclear accumulation assay contributes to our knowledge of molecular interactions within the Wnt/beta-catenin pathway and can be used to find new therapeutics targeting Wnt/beta-catenin signaling.-Verkaar, F., Blankesteijn, W. M., Smits, J. F. M., Zaman, G. J. R. beta-Galactosidase enzyme fragment complementation for the measurement of Wnt/beta-catenin signaling. FASEB J. 24, 1205-1217 (2010). www.fasebj.org	[Verkaar, Folkert; Zaman, Guido J. R.] Schering Plough Res Inst, NL-5340 BH Oss, Netherlands; [Verkaar, Folkert; Blankesteijn, W. Matthijs; Smits, Jos F. M.] Maastricht Univ, Dept Pharmacol & Toxicol, Cardiovasc Res Inst, Maastricht, Netherlands	Merck & Company; Maastricht University	Zaman, GJR (corresponding author), Schering Plough Res Inst, POB 20, NL-5340 BH Oss, Netherlands.	guido.zaman@spcorp.com			Netherlands BSIK	Netherlands BSIK(Ministry of Economic Affairs, Netherlands)	The authors thank Els van Doornmalen for assistance with high-content image analysis, and Martine Prinsen, Duby Ballak, Lonneke Voorneveld, and Bridget Bulwer for technical assistance. The authors thank Ruben Smeets, Martin Smit, and Jac Wijkmans for critical reading of the manuscript. Prof. Dr. Randall Moon (University of Washington, Seattle, WA, USA), Prof. Dr. Yasuhiro Minami (Kobe University, Kobe, Japan), and Dr. Jan Kitajewski (Columbia University, New York, NY, USA) are acknowledged for providing plasmids. This research is supported by The Netherlands BSIK program (to F. V., W. M. B., and J.F.M.S.).	Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Baron R, 2006, CURR TOP DEV BIOL, V76, P103, DOI 10.1016/S0070-2153(06)76004-5; Binnerts ME, 2007, P NATL ACAD SCI USA, V104, P14700, DOI 10.1073/pnas.0702305104; Borchert KM, 2005, ASSAY DRUG DEV TECHN, V3, P133, DOI 10.1089/adt.2005.3.133; Borchert KM, 2006, METHOD ENZYMOL, V414, P140; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cohen Y, 1998, MED ONCOL, V15, P32, DOI 10.1007/BF02787342; Crisman TJ, 2007, J CHEM INF MODEL, V47, P1319, DOI 10.1021/ci6005504; Cywin CL, 2007, BIOORG MED CHEM LETT, V17, P225, DOI 10.1016/j.bmcl.2006.09.056; DU SJ, 1995, MOL CELL BIOL, V15, P2625; FLEMING PE, 2005, Patent No. 2005066139; Gould TD, 2003, PHARMACOL RES, V48, P49, DOI 10.1016/S0143-6618(03)00096-3; Hannoush RN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003498; Horecka J, 2006, BIOTECHNIQUES, V40, P381, DOI 10.2144/000112119; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Knight ZA, 2005, CHEM BIOL, V12, P621, DOI 10.1016/j.chembiol.2005.04.011; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Loomans EEMG, 2003, ASSAY DRUG DEV TECHN, V1, P445, DOI 10.1089/154065803322163759; Merani S, 2009, TRANSPLANTATION, V87, P59, DOI 10.1097/TP.0b013e31819198b4; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morrell NT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002930; Naik S, 2007, P NATL ACAD SCI USA, V104, P17465, DOI 10.1073/pnas.0704465104; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Skvara H, 2008, J CLIN INVEST, V118, P3151, DOI 10.1172/JCI35636; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Van der Lee MMC, 2008, J BIOMOL SCREEN, V13, P986, DOI 10.1177/1087057108326144; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Verkaar F, 2009, CELL SIGNAL, V21, P22, DOI 10.1016/j.cellsig.2008.09.008; Wehrman TS, 2005, NAT METHODS, V2, P521, DOI 10.1038/NMETH771; Yokoyama Noriko, 2007, J Mol Signal, V2, P11, DOI 10.1186/1750-2187-2-11; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zhu PJ, 2008, COMB CHEM HIGH T SCR, V11, P545, DOI 10.2174/138620708785204045	40	17	18	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1205	1217		10.1096/fj.09-141671	http://dx.doi.org/10.1096/fj.09-141671			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19940259	Green Submitted			2022-12-28	WOS:000276462300027
J	Drake, PMW; Barbi, T; Drever, MR; van Dolleweerd, CJ; Porter, AJR; Ma, JKC				Drake, Pascal M. W.; Barbi, Tommaso; Drever, Matthew R.; van Dolleweerd, Craig J.; Porter, Andrew J. R.; Ma, Julian K. -C.			Generation of transgenic plants expressing antibodies to the environmental pollutant microcystin-LR	FASEB JOURNAL			English	Article						phytoremediation; rhizosecretion	CYANOBACTERIAL HEPATOTOXINS; PHAGE DISPLAY; PROTEIN; GROWTH; TRANSFORMATION; TOXICITY; GENES	We describe the engineering, regeneration, and characterization of transgenic tobacco plants expressing a recombinant antibody specific to microcystin-LR (MC-LR), the environmental toxin pollutant produced by species of cyanobacteria. The antibody was created by a genetic fusion of the antigen-binding regions of the microcystin-specific single-chain antibody, 3A8, with constant regions from the murine IgG1 kappa, Guy's 13. IgG transgenes were controlled by a leader peptide that targets the transgene products to the secretory pathway and also allows for rhizosecretion. The antibody, extracted from the leaves or rhizosecreted into hydroponic medium by transgenic plants, was shown to have functional binding to MC-LR. Antibody yields in transgenic plant leaves reached a maximum of 64 mu g/g leaf fresh weight (0.6% total soluble protein), and the rate of antibody rhizosecretion reached a maximum of 5 mu g/g root dry weight/24 h. Rhizosecreted antibody bound to MC-LR in hydroponic medium, and transgenic plants grew more efficiently on medium containing MC-LR compared to wild-type controls. This proof of concept paves the way for applications to produce diagnostic antibodies to microcystin-LR, remove it from the environment by phytoremediation, or enhance yields in crops exposed to MC-LR.-Drake, P. M. W., Barbi, T., Drever, M. R., van Dolleweerd, C. J., Porter, A. J. R., Ma, J. K.-C. Generation of transgenic plants expressing antibodies to the environmental pollutant microcystin-LR. FASEB J. 24, 882-890 (2010). www.fasebj.org	[Drake, Pascal M. W.] St Georges Univ London, Mol Immunol Unit, Ctr Infect, Dept Cellular & Mol Med,Jenner Wing, London SW17 0RF, England; [Drever, Matthew R.; Porter, Andrew J. R.] Univ Aberdeen, Dept Mol & Cell Biol, Foresterhill Sch Med Sci, Aberdeen, Scotland	St Georges University London; University of London; University College London; University of Aberdeen	Drake, PMW (corresponding author), St Georges Univ London, Mol Immunol Unit, Ctr Infect, Dept Cellular & Mol Med,Jenner Wing, Room 2-148,Floor 2, London SW17 0RF, England.	pdrake@sgul.ac.uk		Drake, Pascal/0000-0002-6181-0600; Ma, Julian/0000-0003-0767-0042; van Dolleweerd, Craig/0000-0002-1380-6930	Sir Joseph Hotung; St. George's University of London/Royal Holloway University of London	Sir Joseph Hotung; St. George's University of London/Royal Holloway University of London	We are grateful to Mark Smedley (John Innes Institute, Norwich, UK) for supplying the pGreen vector. We also thank Sir Joseph Hotung for funding P. M. W. D. and J. K.-C. M. T. B. is funded by a joint St. George's University of London/Royal Holloway University of London Ph.D. studentship.	Borisjuk NV, 1999, NAT BIOTECHNOL, V17, P466, DOI 10.1038/8643; CANGELOSI GA, 1991, METHOD ENZYMOL, V204, P384; DENEVE M, 1993, TRANSGENIC RES, V2, P227, DOI 10.1007/BF01977353; Drake PMW, 2009, FASEB J, V23, P3581, DOI 10.1096/fj.09-131771; Drake PMW, 2002, FASEB J, V16, P1855, DOI 10.1096/fj.02-0148com; Drake PMW, 2003, PLANT MOL BIOL, V52, P233, DOI 10.1023/A:1023909331482; Giritch A, 2006, P NATL ACAD SCI USA, V103, P14701, DOI 10.1073/pnas.0606631103; HAMVAS MM, 2003, AQUAT TOXICOL, V62, P1; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Harada Ken-Ichi, 1996, Natural Toxins, V4, P277; Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kurki-Helasmo K, 1998, TOXICON, V36, P1921, DOI 10.1016/S0041-0101(98)00114-7; MA JKC, 1995, SCIENCE, V268, P716, DOI 10.1126/science.7732380; MA JKC, 1994, EUR J IMMUNOL, V24, P131, DOI 10.1002/eji.1830240120; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; Majsterek I, 2004, COMP BIOCHEM PHYS C, V139, P175, DOI 10.1016/j.cca.2004.10.007; McElhiney J, 2000, FEMS MICROBIOL LETT, V193, P83; McElhiney J, 2005, TOXICOL APPL PHARM, V203, P219, DOI 10.1016/j.taap.2004.06.002; McElhiney J, 2002, APPL ENVIRON MICROB, V68, P5288, DOI 10.1128/AEM.68.11.5288-5295.2002; McElhiney J, 2001, TOXICON, V39, P1411, DOI 10.1016/S0041-0101(01)00100-3; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; OWEN M, 1992, BIO-TECHNOL, V10, P790, DOI 10.1038/nbt0792-790; Pouria S, 1998, LANCET, V352, P21, DOI 10.1016/S0140-6736(97)12285-1; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; Schultz PG, 2002, NATURE, V418, P485, DOI 10.1038/418485a; Ueno Y, 1996, CARCINOGENESIS, V17, P1317, DOI 10.1093/carcin/17.6.1317; Villani ME, 2009, PLANT BIOTECHNOL J, V7, P59, DOI 10.1111/j.1467-7652.2008.00371.x; Weiss Y, 2006, NAT BIOTECHNOL, V24, P713, DOI 10.1038/nbt1213; Wojcik T, 2008, CURR MED CHEM, V15, P1606, DOI 10.2174/092986708784911533	31	10	10	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					882	890		10.1096/fj.09-140848	http://dx.doi.org/10.1096/fj.09-140848			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19841035				2022-12-28	WOS:000274974600024
J	Minhas, N; Xue, ML; Fukudome, K; Jackson, CJ				Minhas, Nikita; Xue, Meilang; Fukudome, Kenji; Jackson, Christopher J.			Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function	FASEB JOURNAL			English	Article						endothelial cells; smooth muscle cells; sepsis; permeability; barrier integrity	SEVERE SEPSIS; HUMAN KERATINOCYTES; HEALING PHENOTYPE; TYROSINE KINASE; TIE2 RECEPTOR; SEPTIC SHOCK; IN-VITRO; ANGIOGENESIS; CELLS; IDENTIFICATION	Activated protein C (APC) is an anticoagulant, approved as a treatment for severe sepsis, that can prevent apoptosis, inflammation, and vascular leakage. The aim of this study was to investigate whether APC protects endothelial barrier function through the angiopoietin (Ang)/Tie2 axis. APC significantly up-regulated gene and protein expression of Tie2 and Ang1 in a dose (0.01-10 mu g/ml)- and time (0.5-24h)-dependent manner in human umbilical vein endothelial cells (HUVECs). Interestingly, it markedly inhibited Ang2 with an IC50 of similar to 0.1 mu g/ml. HUVEC permeability, measured using Evans blue dye transfer, was significantly reduced in the presence of APC, and, in concordance, the tight junction associated protein zona occludens (ZO)-1 was up-regulated and localized peripherally around cells, compared with controls. Smooth muscle cell migration toward APC-stimulated HUVECs was elevated compared with un-stimulated cells. Blocking antibodies and small interfering (si) RNA treatment, compared with isotype (IgG) or scrambled siRNA controls, showed that APC requires 3 receptors, the endothelial protein C receptor, protease-activated receptor 1, and Tie2 to perform all these barrier stabilization functions. In summary, this study demonstrates that APC has novel effects on the Ang/Tie2 axis, which enhance endothelial barrier function and are likely to contribute to its therapeutic effect in sepsis and other diseases associated with vascular leakage.-Minhas, N., Xue, M., Fukudome, K., Jackson, C. J. Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB J. 24, 873-881 (2010). www.fasebj.org	[Minhas, Nikita; Xue, Meilang; Jackson, Christopher J.] Univ Sydney, Royal N Shore Hosp, Sutton Arthrit Res Labs, Inst Bone & Joint Res,Kolling Inst, St Leonards, NSW 2065, Australia; [Fukudome, Kenji] Saga Med Sch, Dept Immunol, Saga, Japan	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; Saga University	Jackson, CJ (corresponding author), Univ Sydney, Royal N Shore Hosp, Sutton Arthrit Res Labs, Inst Bone & Joint Res,Kolling Inst, Level 10,Kolling Bldg, St Leonards, NSW 2065, Australia.	cjackson@med.usyd.edu.au		Xue, Meilang/0000-0002-8563-7216; Jackson, Christopher/0000-0002-9234-9116	National Health and Medical Research Council of Australia; Rebecca Cooper Medical Research Foundation; Northern Sydney Area Health Service	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Rebecca Cooper Medical Research Foundation; Northern Sydney Area Health Service	We thank the Royal North Shore Hospital Maternity Unit for providing umbilical cords. Funding was provided by the National Health and Medical Research Council of Australia, the Rebecca Cooper Medical Research Foundation, and the Northern Sydney Area Health Service.	ANDERSON JM, 1989, J CELL BIOL, V109, P1047, DOI 10.1083/jcb.109.3.1047; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; Bae JS, 2007, P NATL ACAD SCI USA, V104, P2867, DOI 10.1073/pnas.0611493104; Baker WF, 1999, SEMIN THROMB HEMOST, V25, P387, DOI 10.1055/s-2007-994942; Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bohlin Kath, 1996, Methods in Cell Science, V18, P329, DOI 10.1007/BF00127910; Chen JX, 2008, ARTERIOSCL THROM VAS, V28, P1606, DOI 10.1161/ATVBAHA.108.169235; Childs EW, 2008, AM J PHYSIOL-HEART C, V294, pH2285, DOI 10.1152/ajpheart.01361.2007; Crowley SR, 1996, HEART LUNG, V25, P124, DOI 10.1016/S0147-9563(96)80114-2; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; FIJNVANDRAAT K, 1995, THROMB HAEMOSTASIS, V73, P15; Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Ganter MT, 2008, ANN SURG, V247, P320, DOI 10.1097/SLA.0b013e318162d616; Griffin JH, 2002, SEMIN HEMATOL, V39, P197, DOI 10.1053/shem.2002.34093; Harfouche R, 2003, FASEB J, V17, P1523, DOI 10.1096/fj.02-0698fje; Harfouche R, 2006, AM J PHYSIOL-HEART C, V291, pH1635, DOI 10.1152/ajpheart.01318.2005; Hughes DP, 2003, CIRC RES, V92, P630, DOI 10.1161/01.RES.0000063422.38690.DC; Iivanainen E, 2003, FASEB J, V17, P1609, DOI 10.1096/fj.02-0939com; Jackson C, 2008, EXPERT OPIN BIOL TH, V8, P1109, DOI 10.1517/14712598.8.8.1109 ; Jackson CJ, 2005, WOUND REPAIR REGEN, V13, P284, DOI 10.1111/j.1067-1927.2005.00130311.x; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Lay AJ, 2007, BLOOD, V109, P1984, DOI 10.1182/blood-2006-07-037945; Li X, 2008, BLOOD, V111, P3489, DOI 10.1182/blood-2007-05-092148; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Murakami K, 1997, AM J PHYSIOL-LUNG C, V272, pL197, DOI 10.1152/ajplung.1997.272.2.L197; Orfanos SE, 2007, CRIT CARE MED, V35, P199, DOI 10.1097/01.CCM.0000251640.77679.D7; Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046; PATTERSON CE, 1992, J APPL PHYSIOL, V72, P865, DOI 10.1152/jappl.1992.72.3.865; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Uchiba M, 2004, CIRC RES, V95, P34, DOI 10.1161/01.RES.0000133680.87668.FA; Wada H, 2005, BLOOD COAGUL FIBRIN, V16, P17, DOI 10.1097/00001721-200501000-00003; Wang YL, 2007, EYE, V21, P1501, DOI 10.1038/sj.eye.6702716; Whitmont K, 2008, ARCH DERMATOL, V144, P1479, DOI 10.1001/archderm.144.11.1479; Witzenbichler B, 2005, CIRCULATION, V111, P97, DOI 10.1161/01.CIR.0000151287.08202.8E; Xue ML, 2009, J CELL MOL MED, V13, P749, DOI 10.1111/j.1582-4934.2008.00359.x; Xue ML, 2005, J INVEST DERMATOL, V125, P1279, DOI 10.1111/j.0022-202X.2005.23952.x; Xue ML, 2004, EXP CELL RES, V299, P119, DOI 10.1016/j.yexcr.2004.05.015; Yuan HT, 2009, MOL CELL BIOL, V29, P2011, DOI 10.1128/MCB.01472-08	44	68	69	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					873	881		10.1096/fj.09-134445	http://dx.doi.org/10.1096/fj.09-134445			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19858095				2022-12-28	WOS:000274974600023
J	Delanote, V; Vanloo, B; Catillon, M; Friederich, E; Vandekerckhove, J; Gettemans, J				Delanote, Veerle; Vanloo, Berlinda; Catillon, Marie; Friederich, Evelyne; Vandekerckhove, Joel; Gettemans, Jan			An alpaca single-domain antibody blocks filopodia formation by obstructing L-plastin-mediated F-actin bundling	FASEB JOURNAL			English	Article						immunomodulation; cytoskeleton; fimbrin; cancer cell; invasion	CANCER-CELL MIGRATION; COLON-CANCER; T-PLASTIN; PROTEIN; INVASION; EXPRESSION; COMPLEX; FASCIN; GENE; FIMBRIN	L-plastin, a conserved modular F-actin bundling protein, is ectopically expressed in tumor cells and contributes to cell malignancy and invasion. The underlying molecular mechanisms involved remain unclear, in part, because specific inhibitors of L-plastin are lacking. We used recombinant alpaca-derived L-plastin single-domain antibodies (nanobodies) as effector of L-plastin function in cells. Key findings were compared with L-plastin down-regulation by RNAi. We show that nanobodies strongly interact with L-plastin by targeting discrete conformational epitopes with nanomolar affinity. A nanobody that selectively interacts with the tandem ABDs in L-plastin completely inhibits F-actin bundling at equimolar ratios, in contrast to a control green fluorescent protein (GFP) nanobody. This "knockout" nanobody inhibits filopodia formation, motility, and invasion when expressed in PC-3 cells. L-plastin RNA interference showed no significant effect on filopodial integrity and only marginally restrained the motile properties of cells. L-plastin nanobodies uniquely expose a fundamental role for this protein in filopodia formation and cell migration. Therefore, these molecules represent a potent instrument to ablate functions of structural proteins without manipulating gene expression. In addition, we show that they can be instrumental in uncovering new functions of proteins that remain obscured by RNAi.-Delanote, V., Vanloo, B., Catillon, M., Friederich, E., Vandekerckhove, J., Gettemans, J. An alpaca singledomain antibody blocks filopodia formation by obstructing L-plastin-mediated F-actin bundling. FASEB J. 24, 105-118(2010). www.fasebj.org	[Delanote, Veerle; Vanloo, Berlinda; Vandekerckhove, Joel; Gettemans, Jan] Univ Ghent, Dept Biochem, Fac Med & Hlth Sci, B-9000 Ghent, Belgium; [Catillon, Marie; Friederich, Evelyne] Univ Luxembourg, Fac Sci Technol & Commun, Life Sci Res Unit, Luxembourg, Luxembourg; [Delanote, Veerle; Vanloo, Berlinda; Vandekerckhove, Joel; Gettemans, Jan] VIB, Dept Med Prot Res, Ghent, Belgium	Ghent University; University of Luxembourg; Flanders Institute for Biotechnology (VIB)	Gettemans, J (corresponding author), Univ Ghent, Dept Biochem, Fac Med & Hlth Sci, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium.	jan.gettemans@ugent.be			Fund for Scientific Research-Flanders (FWO-Vlaanderen); Stichting tegen Kanker; Vlaamse Liga tegen Kanker; Ghent University (GOA); Human Frontier Science Program (HFSP); Interuniversity Attraction Poles [IUAP06]; Stichting Emmanuel van der Schueren	Fund for Scientific Research-Flanders (FWO-Vlaanderen)(FWO); Stichting tegen Kanker; Vlaamse Liga tegen Kanker; Ghent University (GOA)(Ghent University); Human Frontier Science Program (HFSP)(Human Frontier Science Program); Interuniversity Attraction Poles(Belgian Federal Science Policy Office); Stichting Emmanuel van der Schueren	This work was supported by the Fund for Scientific Research-Flanders (FWO-Vlaanderen), the Stichting tegen Kanker, the Vlaamse Liga tegen Kanker, the Concerted Actions Programme of Ghent University (GOA), the Human Frontier Science Program (HFSP) and the Interuniversity Attraction Poles (IUAP06). V. D. is supported by the Vlaamse Liga tegen Kanker through a grant of the Stichting Emmanuel van der Schueren. The authors thank Dr. A. Lambrechts for help with microscopy. The authors also thank Dr. Ariane De Ganck and Dr. Katrien Van Impe for their contributions to this work.	Adams JC, 2000, J CELL BIOL, V150, P807, DOI 10.1083/jcb.150.4.807; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brieher WM, 2004, J CELL BIOL, V165, P233, DOI 10.1083/jcb.200311040; Cao T, 2005, ANN CLIN LAB SCI, V35, P227; Condeelis J, 2005, ANNU REV CELL DEV BI, V21, P695, DOI 10.1146/annurev.cellbio.21.122303.120306; Correia I, 1999, J CELL BIOL, V146, P831, DOI 10.1083/jcb.146.4.831; DEARRUDA MV, 1990, J CELL BIOL, V111, P1069, DOI 10.1083/jcb.111.3.1069; Delanote V, 2005, TRAFFIC, V6, P335, DOI 10.1111/j.1600-0854.2005.00276.x; Delanote V, 2005, ACTA PHARMACOL SIN, V26, P769, DOI 10.1111/j.1745-7254.2005.00145.x; Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602; Evans JG, 2003, J CELL BIOL, V161, P697, DOI 10.1083/jcb.200212037; Faix J, 2006, CURR OPIN CELL BIOL, V18, P18, DOI 10.1016/j.ceb.2005.11.002; Faix J, 2009, INT J BIOCHEM CELL B, V41, P1656, DOI 10.1016/j.biocel.2009.02.012; Foran E, 2006, INT J CANCER, V118, P2098, DOI 10.1002/ijc.21593; Galkin VE, 2008, P NATL ACAD SCI USA, V105, P1494, DOI 10.1073/pnas.0708667105; Giganti A, 2005, J CELL SCI, V118, P1255, DOI 10.1242/jcs.01698; GLENNEY JR, 1981, J BIOL CHEM, V256, P9283; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Hara T, 2007, MOL CELL PROTEOMICS, V6, P479, DOI 10.1074/mcp.M600129-MCP200; Howl J, 2007, BIOCHEM SOC T, V35, P767, DOI 10.1042/BST0350767; Janji B, 2006, J CELL SCI, V119, P1947, DOI 10.1242/jcs.02874; Kaufmann U, 2000, J CELL SCI, V113, P4121; Klemke M, 2007, INT J CANCER, V120, P2590, DOI 10.1002/ijc.22589; Korotkov KV, 2009, STRUCTURE, V17, P255, DOI 10.1016/j.str.2008.11.011; LICHTLEN P, 2002, TARGETS, V1, P37; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; NAMBA Y, 1992, J BIOCHEM-TOKYO, V112, P503, DOI 10.1093/oxfordjournals.jbchem.a123929; Otsuka M, 2001, BIOCHEM BIOPH RES CO, V289, P876, DOI 10.1006/bbrc.2001.6047; PACAUD M, 1993, BIOCHEMISTRY-US, V32, P3448, DOI 10.1021/bi00064a031; PARK TS, 1994, CANCER RES, V54, P1775; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Rothbauer U, 2006, NAT METHODS, V3, P887, DOI 10.1038/NMETH953; Rutka JT, 2008, NEOPLASIA, V10, P149, DOI 10.1593/neo.07909; Shinomiya H, 2007, BIOPHYS CHEM, V131, P36, DOI 10.1016/j.bpc.2007.09.001; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Thompson CC, 2007, GUT, V56, P95, DOI 10.1136/gut.2005.083691; Towbin H, 1992, Biotechnology, V24, P145; van den Abbeele A, 2007, CANCER LETT, V255, P57, DOI 10.1016/j.canlet.2007.03.023; Vignjevic D, 2008, SEMIN CANCER BIOL, V18, P12, DOI 10.1016/j.semcancer.2007.08.001; Vignjevic D, 2007, CANCER RES, V67, P6844, DOI 10.1158/0008-5472.CAN-07-0929; Vignjevic D, 2006, J CELL BIOL, V174, P863, DOI 10.1083/jcb.200603013; Visintin M, 2008, J BIOTECHNOL, V135, P1, DOI 10.1016/j.jbiotec.2008.02.012; Wang W, 2006, J CELL BIOL, V173, P395, DOI 10.1083/jcb.200510115; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Zheng JP, 1999, AM J PATHOL, V155, P115, DOI 10.1016/S0002-9440(10)65106-1; Zheng JP, 1997, AM J PATHOL, V150, P2009	47	44	48	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					105	118		10.1096/fj.09-134304	http://dx.doi.org/10.1096/fj.09-134304			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19726756				2022-12-28	WOS:000273233600013
J	Xie, YY; Zhou, CJ; Zhou, ZR; Hong, J; Che, MX; Fu, QS; Song, AX; Lin, DH; Hu, HY				Xie, Yuan-Yuan; Zhou, Chen-Jie; Zhou, Zi-Ren; Hong, Jing; Che, Mei-Xia; Fu, Qing-Shan; Song, Ai-Xin; Lin, Dong-Hai; Hu, Hong-Yu			Interaction with synphilin-1 promotes inclusion formation of alpha-synuclein: mechanistic insights and pathological implication	FASEB JOURNAL			English	Article						coiled coil; solution structure; Parkinson's disease; Lewy body; dimerization; N-terminal stretch	PARKINSONS-DISEASE; LEWY BODIES; NEUROBLASTOMA-CELLS; AGGRESOME FORMATION; CHEMICAL-SHIFT; WILD-TYPE; PROTEIN; AGGREGATION; NMR; MUTATION	alpha-Synuclein (alpha-Syn) is the major component of Lewy bodies (LBs) deposited in the brains of patients with Parkinson's disease. Synphilin-1 (Sph1) is a novel alpha-Syn-interacting protein also present in the LBs. However, the roles of alpha-Syn-Sph1 interaction in LB formation and in the related pathogenesis are still unclear. We have studied the interaction between alpha-Syn and Sph1 by biochemical and structural approaches and found that the central coiled-coil domain of Sph1 specifically interacts with the N-terminal stretch of alpha-Syn. When overexpressed in HEK 293T cells, Sph1 forms inclusions together with alpha-Syn, but the Sph1positive inclusions cannot recruit the N-terminally truncated alpha-Syn. The central portion of Sph1 can also recruit alpha-Syn and induce inclusion formation through its coiled-coil domain. These observations demonstrate that the alpha-Syn-Sph1 interaction significantly promotes the formation of cytoplasmic alpha-Syn inclusions, which may have implications for LB formation in neural cells. We have also elucidated solution structure of the coiled-coil domain of Sph1 and its interaction with the N-terminal peptide of alpha-Syn. The specific interaction between alpha-Syn and Sph1 provides mechanistic insights into the inclusion-body formation in cells and pathological implication in Parkinson's disease. Xie, Y.-Y., Zhou, C.-J., Zhou, Z.-R., Hong, J., Che, M.-X., Fu, Q.-S., Song, A.-X., Lin, D.-H., and Hu, H.-Y. Interaction with synphilin-1 promotes inclusion formation of alpha-synuclein: mechanistic insights and pathological implication. FASEB J. 24, 196-205 (2010). www.fasebj.org	[Xie, Yuan-Yuan; Zhou, Chen-Jie; Zhou, Zi-Ren; Che, Mei-Xia; Fu, Qing-Shan; Song, Ai-Xin; Hu, Hong-Yu] Chinese Acad Sci, State Key Lab Mol Biol, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; [Hong, Jing; Lin, Dong-Hai] Shanghai Inst Biol Sci, Inst Mat Med, Shanghai, Peoples R China; [Xie, Yuan-Yuan; Zhou, Zi-Ren; Hong, Jing; Che, Mei-Xia; Fu, Qing-Shan] Chinese Acad Sci, Grad Sch, Beijing, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Hu, HY (corresponding author), Chinese Acad Sci, State Key Lab Mol Biol, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	hyhu@sibs.ac.cn	Che, Meixia/Q-2119-2019; Hu, Hong-Yu/AAQ-2633-2020; Xie, Yuanyuan/F-1974-2017; Chou, Steven Ziren/M-1995-2014; Fu, Qingshan/E-1405-2015; Fu, Qingshan/E-8083-2015	Che, Meixia/0000-0002-4515-1414; Fu, Qingshan/0000-0002-7445-2355; 	National Basic Research Program of China [2006CB910305, 2006CB806508]; National Natural Science Foundation of China [30570377, 30600103, 30870485]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The authors thank Dr. C. W. Jin and Ms. F. Yang ( Beijing NMR Center, Peking University, Beijing, China) for providing the NMR facilities and technical assistance. We thank Drs. L. N. Ji, J. W. Zhou, and X. Y. Luo for valuable discussions, and Mr. T. Y. Zhang, Mr. M. Xu, and Mr. H. C. Gao for technical help. We also thank Dr. M. M. Mouradian ( National Institutes of Health, Bethesda, MD, USA) for providing the synphilin-1 cDNA. This work was supported by grants from the National Basic Research Program of China (2006CB910305, 2006CB806508), and the National Natural Science Foundation of China (30570377, 30600103, 30870485). The coordinates and structure factors for the coiled-coil domain (Sph1CC) and the alpha-Syn12 peptide bound with Sph1M have been deposited in the Protein Data Bank with accession codes 2KES and 2JN5, respectively.	Bao WJ, 2006, PROTEIN EXPRES PURIF, V47, P599, DOI 10.1016/j.pep.2005.11.021; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Du HN, 2003, BIOCHEMISTRY-US, V42, P8870, DOI 10.1021/bi034028+; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Eyal A, 2006, P NATL ACAD SCI USA, V103, P5917, DOI 10.1073/pnas.0509707103; Gao YG, 2006, STRUCTURE, V14, P1755, DOI 10.1016/j.str.2006.09.014; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Goddard T. D., 2004, SPARKY, V3; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Hasegawa T, 2004, BRAIN RES, V1013, P51, DOI 10.1016/j.brainres.2004.04.018; Ito T, 2003, J BIOL CHEM, V278, P29106, DOI 10.1074/jbc.M302763200; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kawamata H, 2001, J NEUROCHEM, V77, P929, DOI 10.1046/j.1471-4159.2001.00301.x; KINCAID RL, 1982, J BIOL CHEM, V257, P638; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krenz A, 2009, J NEUROCHEM, V108, P139, DOI 10.1111/j.1471-4159.2008.05755.x; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee G, 2002, J NEUROCHEM, V83, P346, DOI 10.1046/j.1471-4159.2002.01136.x; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; Megy S, 2005, J BIOL CHEM, V280, P29107, DOI 10.1074/jbc.M501628200; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Nagano Y, 2003, J BIOL CHEM, V278, P51504, DOI 10.1074/jbc.M306347200; Neystat M, 2002, NEUROSCI LETT, V325, P119, DOI 10.1016/S0304-3940(02)00253-7; O'Farrell C, 2002, NEUROSCI LETT, V322, P9, DOI 10.1016/S0304-3940(02)00068-X; O'Farrell C, 2001, MOL BRAIN RES, V97, P94, DOI 10.1016/S0169-328X(01)00292-3; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Parry DAD, 2008, J STRUCT BIOL, V163, P258, DOI 10.1016/j.jsb.2008.01.016; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ribeiro CS, 2002, J BIOL CHEM, V277, P23927, DOI 10.1074/jbc.M201115200; Rieping W, 2007, BIOINFORMATICS, V23, P381, DOI 10.1093/bioinformatics/btl589; Ryo A, 2006, J BIOL CHEM, V281, P4117, DOI 10.1074/jbc.M507026200; Shults CW, 2006, P NATL ACAD SCI USA, V103, P1661, DOI 10.1073/pnas.0509567103; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Sung JY, 2001, J BIOL CHEM, V276, P27441, DOI 10.1074/jbc.M101318200; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; WISHART DS, 1994, J BIOMOL NMR, V4, P171; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141; Zaarur N, 2008, J BIOL CHEM, V283, P27575, DOI 10.1074/jbc.M802216200; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154; Zhou ZR, 2008, PROTEIN SCI, V17, P1805, DOI 10.1110/ps.036384.108	49	27	30	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					196	205		10.1096/fj.09-133082	http://dx.doi.org/10.1096/fj.09-133082			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19762560	Bronze			2022-12-28	WOS:000273233600021
J	Hayer, S; Pundt, N; Peters, MA; Wunrau, C; Kuhnel, I; Neugebauer, K; Strietholt, S; Zwerina, J; Korb, A; Penninger, J; Joosten, LAB; Gay, S; Ruckle, T; Schett, G; Pap, T				Hayer, Silvia; Pundt, Noreen; Peters, Marvin A.; Wunrau, Christina; Kuehnel, Inga; Neugebauer, Katja; Strietholt, Simon; Zwerina, Jochen; Korb, Adelheid; Penninger, Josef; Joosten, Leo A. B.; Gay, Steffen; Rueckle, Thomas; Schett, Georg; Pap, Thomas			PI3K gamma regulates cartilage damage in chronic inflammatory arthritis	FASEB JOURNAL			English	Article						inflammation; rheumatoid arthritis; synovial fibroblast; chondrocytes; signaling	PHOSPHOINOSITIDE 3-KINASE GAMMA; FIBROBLAST-LIKE SYNOVIOCYTES; MATRIX METALLOPROTEINASES; RHEUMATOID-ARTHRITIS; EMBRYONIC LETHALITY; NEUTRAL PROTEASES; MODEL; DEGRADATION; INHIBITION; EXPRESSION	The gamma isoform of phosphoinositide 3-kinase (PI3K gamma) has been viewed as restricted to leukocytes mediating the regulation of chemokine-induced migration and recruitment of neutrophils, monocytes, and macrophages. In line with the observation that PI3K gamma-deficient mice display defects in adaptive immunity, inhibition of PI3K gamma reduces synovial inflammation in the collagen-induced arthritis mouse model of inflammatory arthritis [rheumatoid arthritis (RA)], which has been attributed to reduced influx of inflammatory cells. Challenging the concept of leukocyte-restricted PI3K gamma function, we report here a novel, nonredundant function of PI3K gamma as an important regulator of fibroblast-induced cartilage destruction during chronic destructive arthritis. We show that in human tumor necrosis factor transgenic mice, the loss of PI3K gamma leads to a milder inflammatory arthritis. Interestingly, PI3K gamma deficiency does not alter the recruitment of inflammatory cells, but significantly reduces cartilage damage through reduced expression of matrix metalloproteinases in fibroblasts and chondrocytes. In vitro analyses demonstrate that the decreased invasiveness of fibroblasts is mediated by reduced phosphorylation of Akt and extracellular signal-regulated kinase. Using a PI3K gamma specific inhibitor, these data are confirmed in human synovial fibroblasts from patients with RA who exhibit a disease-specific up-regulation of PI3K gamma. Our data indicate that in addition to mediating the recruitment of inflammatory cells, PI3K gamma is an important regulator of fibroblast-mediated joint destruction in RA and suggest that specific inhibitors of PI3K gamma will interfere with the activation of RA synovial fibroblasts and reduce cartilage destruction in RA.-Hayer, S., Pundt, N., Peters, M. A., Wunrau, C., Kuhnel, I., Neugebauer, K., Strietholt, S., Zwerina, J., Korb, A., Penninger, J., Joosten, L. A. B., Gay, S., Ruckle, T., Schett, G., Pap, T. Phosphatidylinositol 3-kinase-gamma regulates cartilage damage in chronic inflammatory arthritis. FASEB J. 23, 4288-4298 (2009). www.fasebj.org	[Zwerina, Jochen; Schett, Georg] Univ Erlangen Nurnberg, Dept Internal Med 3, D-91054 Erlangen, Germany; [Hayer, Silvia] Med Univ Vienna, Dept Internal Med 3, Div Rheumatol, Vienna, Austria; [Pundt, Noreen; Peters, Marvin A.; Wunrau, Christina; Kuehnel, Inga; Neugebauer, Katja; Strietholt, Simon; Pap, Thomas] Univ Hosp Muenster, Div Mol Med Musculoskeletal Tissue, Munster, Germany; [Korb, Adelheid] Univ Hosp Muenster, Dept Internal Med Nephrol & Rheumatol, Munster, Germany; [Penninger, Josef] Austrian Acad Sci, Inst Mol Biotechnol, A-1010 Vienna, Austria; [Joosten, Leo A. B.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Gay, Steffen] Univ Zurich Hosp, Ctr Expt Rheumatol, CH-8091 Zurich, Switzerland; [Rueckle, Thomas] Merck Serono Int, Operat Excellence, Geneva, Switzerland	University of Erlangen Nuremberg; Medical University of Vienna; University of Munster; University of Munster; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Radboud University Nijmegen; University of Zurich; University Zurich Hospital; Merck KGaA; EMD Serono Inc.	Schett, G (corresponding author), Univ Erlangen Nurnberg, Dept Internal Med 3, Krankenhausstr 12, D-91054 Erlangen, Germany.	georg.schett@uk-erlangen.de	Penninger, Josef M/I-6860-2013; Joosten, Leo AB/H-3138-2015	Penninger, Josef M/0000-0002-8194-3777; Joosten, Leo AB/0000-0001-6166-9830	Austrian Science Fund START prize; Deutsche Forschungegemeinschaft [SFB492, SFB 643]; Forschergruppe [661]; Interdisciplinary Center for Clinical Research Erlangen; European Union	Austrian Science Fund START prize(Austrian Science Fund (FWF)); Deutsche Forschungegemeinschaft(German Research Foundation (DFG)); Forschergruppe; Interdisciplinary Center for Clinical Research Erlangen; European Union(European Commission)	We thank Birgit Niederreiter, Carl-Walter Steiner, Karolina v. Dalwigk, Love Amoyo, Margareta Tryniecki, Borna Truckenbrod, and Vera Eckervogt for excellent technical assistance. We further thank George Kollias (Alexander Fleming Biomedical Sciences Research Centre, Vari, Greece), who originally generated the Tg197 hTNFtg mice, for kindly providing these mice. We also thank Montserrat Camps and Christian Rommel (Merck Serono, Geneva, Switzerland) for the scientific discussions, Tzventanka Bondeva and Reinhard Wetzker (Institute of Molecular Cell Biology, University of Jena, Jena, Germany) for kindly providing an antibody against PI3K gamma, and Jennifer Gerding for carefully reading the manuscript. This work was supported by an Austrian Science Fund START prize (G. S.), the Deutsche Forschungegemeinschaft through its SFB492 (T. P.), SFB 643 (G. S.), Forschergruppe 661 (G. S.), the Interdisciplinary Center for Clinical Research Erlangen (G. S.), and the European Union projects MASTERSWITCH (S. H., G. S.), ADIPOA (G. S.), and KINACEPT (G. S.).	Barber DF, 2005, NAT MED, V11, P933, DOI 10.1038/nm1291; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bi L, 2002, MAMM GENOME, V13, P169, DOI 10.1007/s00335-001-2123-x; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Cawson T, 1998, MOL MED TODAY, V4, P130, DOI 10.1016/S1357-4310(97)01192-1; Del Prete A, 2004, EMBO J, V23, P3505, DOI 10.1038/sj.emboj.7600361; Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538; Endo D, 2009, INT ARCH ALLERGY IMM, V149, P66, DOI 10.1159/000211375; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; Hayer S, 2007, ARTHRITIS RHEUM-US, V56, P79, DOI 10.1002/art.22313; Heller R, 2008, CARDIOVASC RES, V80, P96, DOI 10.1093/cvr/cvn159; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kong D, 2008, CANCER SCI, V99, P1734, DOI 10.1111/j.1349-7006.2008.00891.x; Lehmann K, 2009, BIOCHEM J, V419, P603, DOI 10.1042/BJ20081268; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Ludwig T, 2002, AM J PHYSIOL-RENAL, V283, pF319, DOI 10.1152/ajprenal.00327.2001; Muller-Ladner U, 1997, Curr Opin Rheumatol, V9, P213; Noss EH, 2008, IMMUNOL REV, V223, P252, DOI 10.1111/j.1600-065X.2008.00648.x; ORONSKY AL, 1976, ARCH BIOCHEM BIOPHYS, V176, P539, DOI 10.1016/0003-9861(76)90197-1; Otero M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2292; Pap T, 2000, ARTHRITIS RHEUM, V43, P1226, DOI 10.1002/1529-0131(200006)43:6<1226::AID-ANR5>3.0.CO;2-4; Pap T, 2000, ARTHRITIS RES, V2, P361, DOI 10.1186/ar113; Pomel V, 2006, J MED CHEM, V49, P3857, DOI 10.1021/jm0601598; Puri KD, 2005, BLOOD, V106, P150, DOI 10.1182/blood-2005-01-0023; Randis TM, 2008, EUR J IMMUNOL, V38, P1215, DOI 10.1002/eji.200838266; Rannou FO, 2006, JOINT BONE SPINE, V73, P29, DOI 10.1016/j.jbspin.2004.12.013; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Schett G, 2009, J BONE MINER RES, V24, P1142, DOI 10.1359/jbmr.090533; Sweeney SE, 2004, INT J BIOCHEM CELL B, V36, P372, DOI 10.1016/S1357-2725(03)00259-0; Szekanecz Z, 2006, CURR DRUG TARGETS, V7, P91, DOI 10.2174/138945006775270231; Tolboom TCA, 2002, ANN RHEUM DIS, V61, P975, DOI 10.1136/ard.61.11.975; UITTO VJ, 1980, EUR J BIOCHEM, V105, P409, DOI 10.1111/j.1432-1033.1980.tb04515.x; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wang ZL, 2009, BIOCHEM BIOPH RES CO, V386, P569, DOI 10.1016/j.bbrc.2009.06.060	41	53	70	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4288	4298		10.1096/fj.09-135160	http://dx.doi.org/10.1096/fj.09-135160			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19734303				2022-12-28	WOS:000272193700023
J	Welsh, M; Saunders, PTK; Atanassova, N; Sharpe, RM; Smith, LB				Welsh, Michelle; Saunders, Philippa T. K.; Atanassova, Nina; Sharpe, Richard M.; Smith, Lee B.			Androgen action via testicular peritubular myoid cells is essential for male fertility	FASEB JOURNAL			English	Article						spermatogenesis; stromal-epithelial interactions; testosterone; steroid receptors	FOLLICLE-STIMULATING-HORMONE; SEMINIFEROUS TUBULE FLUID; MALE-MICE LACKING; SERTOLI-CELL; POSTNATAL-DEVELOPMENT; SELECTIVE KNOCKOUT; GENE-EXPRESSION; GERM-CELLS; RECEPTOR; RAT	Androgens are essential for normal spermatogenesis and male fertility, but how androgens exert this effect remains uncertain. Androgen receptors (ARs) are expressed in several testicular cell types, but continuing uncertainty exists over which cell type mediates androgen control of spermatogenesis. Androgen signaling via Sertoli cells (SCs) is essential for complete spermatogenesis, but the role for androgen signaling via peritubular myoid (PTM) cells is contentious. To address this controversy, we generated PTM-specific AR-knockout (PTM-ARKO) mice in which gross reproductive development was normal, but all PTM-ARKO males were azoospermic and infertile. Testis weight was reduced beyond puberty, and in adulthood there was an 86% reduction in germ cells, compared with wild-type littermates. These changes were not explained by any deficits in testosterone, luteinizing hormone, or follicle-stimulating hormone concentrations. SC function was impaired in PTM-ARKO males, indicated by reduced seminiferous tubule fluid production and reduced expression of some androgen-dependent SC genes. Androgen action via PTM cells is therefore essential for normal testis function, spermatogenesis, and fertility in males. This study also provides the first direct evidence for the importance of androgen-driven stromal-epithelial interactions underpinning the regulation of spermatogenesis; PTM-ARKO mice will enable identification of the new molecular pathways involved.-Welsh, M., Saunders, P. T. K., Atanassova, N., Sharpe, R. M., Smith, L. B. Androgen action via testicular peritubular myoid cells is essential for male fertility. FASEB J. 23, 4218-4230 (2009). www.fasebj.org	[Welsh, Michelle; Saunders, Philippa T. K.; Sharpe, Richard M.; Smith, Lee B.] Queens Med Res Inst, MRC, Human Reprod Sci Unit, Ctr Reprod Biol, Edinburgh EH16 4TJ, Midlothian, Scotland; [Atanassova, Nina] Bulgarian Acad Sci, Inst Expt Morphol & Anthropol Museum, Sofia, Bulgaria	University of Edinburgh; Bulgarian Academy of Sciences	Smith, LB (corresponding author), Queens Med Res Inst, MRC, Human Reprod Sci Unit, Ctr Reprod Biol, Edinburgh EH16 4TJ, Midlothian, Scotland.	l.smith@hrsu.mrc.ac.uk	Smith, Lee B/J-4861-2013; welsh, michelle/G-2261-2010; Sharpe, Richard M/D-2725-2013; Atanassova, Nina/AAH-2722-2021; Saunders, Philippa TK/C-7489-2013	Sharpe, Richard M/0000-0003-1686-8085; Atanassova, Nina/0000-0002-9032-3588; Saunders, Philippa TK/0000-0001-9051-9380; Smith, Lee/0000-0002-4103-3074	UK Medical Research Council [WBS U.1276.00.002.0003.01]; MRC [MC_U127684422, MC_U127685844, MC_U127685841] Funding Source: UKRI; Medical Research Council [MC_U127685841, MC_U127684422, MC_U127685844] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We are grateful to Karel De Gendt and Guido Verhoeven (Catholic University of Leuven, Leuven, Belgium) for providing the AR<SUP>flox</SUP> mice, The Jackson Laboratory (Bar Harbor, ME, USA) for SM22-Cre mice, and Michael Kotlikoff (Cornell University, Ithaca, NY, USA) for smMHC-Cre mice. We thank the UK Medical Research Council for funding (WBS U.1276.00.002.0003.01). We also thank Ian Swanston, Mark Fisken, Lindsey Moffat, Lindsay Rutherford, Nancy Nelson, and the members of the histology department for technical assistance.	Andersson AM, 2008, INT J ANDROL, V31, P74, DOI 10.1111/j.1365-2605.2007.00853.x; Baker PJ, 2003, ENDOCRINOLOGY, V144, P138, DOI 10.1210/en.2002-220637; Baker PJ, 2001, REPRODUCTION, V122, P227, DOI 10.1530/rep.0.1220227; Chang CS, 2004, P NATL ACAD SCI USA, V101, P6876, DOI 10.1073/pnas.0307306101; CORKER CS, 1978, J STEROID BIOCHEM, V9, P373, DOI 10.1016/0022-4731(78)90634-9; CUNHA GR, 1976, INT REV CYTOL, V47, P137, DOI 10.1016/S0074-7696(08)60088-1; Cunha GR, 2004, ARCH HISTOL CYTOL, V67, P417, DOI 10.1679/aohc.67.417; De Gendt K, 2004, P NATL ACAD SCI USA, V101, P1327, DOI 10.1073/pnas.0308114100; De Gendt K, 2005, ENDOCRINOLOGY, V146, P4117, DOI 10.1210/en.2005-0300; DEFRANCA LR, 1994, ANAT REC, V240, P225; Denolet E, 2006, MOL ENDOCRINOL, V20, P321, DOI 10.1210/me.2005-0113; FARR CH, 1980, J REPROD FERTIL, V58, P37, DOI 10.1530/jrf.0.0580037; Fisher JS, 2003, HUM REPROD, V18, P1383, DOI 10.1093/humrep/deg273; Franca LR, 2000, BIOL REPROD, V63, P1403, DOI 10.1095/biolreprod63.5.1403; Frutkin AD, 2006, J MOL CELL CARDIOL, V41, P724, DOI 10.1016/j.yjmcc.2006.06.067; Holtwick R, 2002, P NATL ACAD SCI USA, V99, P7142, DOI 10.1073/pnas.102650499; Jeanes A, 2005, REPRODUCTION, V130, P509, DOI 10.1530/rep.1.00718; JEGOU B, 1983, INT J ANDROL, V6, P249, DOI 10.1111/j.1365-2605.1983.tb00539.x; Johnston DS, 2001, ENDOCRINOLOGY, V142, P2405, DOI 10.1210/en.142.6.2405; Johnston H, 2004, ENDOCRINOLOGY, V145, P318, DOI 10.1210/en.2003-1055; KOTITE NJ, 1978, BIOL REPROD, V18, P65, DOI 10.1095/biolreprod18.1.65; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; McLachlan RI, 2002, RECENT PROG HORM RES, V57, P149, DOI 10.1210/rp.57.1.149; McNeilly JR, 2000, ENDOCRINOLOGY, V141, P4284, DOI 10.1210/en.141.11.4284; Meistrich ML, 2003, J ANDROL, V24, P135; ODONNELL L, 1994, ENDOCRINOLOGY, V135, P2608, DOI 10.1210/en.135.6.2608; Patek CE, 2005, TRANSGENIC RES, V14, P691, DOI 10.1007/s11248-005-7216-y; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; RICHARDSON LL, 1995, BIOL REPROD, V52, P320, DOI 10.1095/biolreprod52.2.320; Romano F, 2005, CONTRACEPTION, V72, P294, DOI 10.1016/j.contraception.2005.03.009; RUSSELL LD, 1989, AM J ANAT, V184, P179, DOI 10.1002/aja.1001840302; Sharpe Richard M., 1994, P1363; SHARPE RM, 1994, J REPROD FERTIL, V101, P193, DOI 10.1530/jrf.0.1010193; SHARPE RM, 2004, SERTOLI CELL BIOL, P199; SKINNER MK, 1985, J CELL BIOL, V100, P1941, DOI 10.1083/jcb.100.6.1941; SKINNER MK, 1985, P NATL ACAD SCI USA, V82, P114, DOI 10.1073/pnas.82.1.114; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Tan KAL, 2005, ENDOCRINOLOGY, V146, P2674, DOI 10.1210/en.2004-1630; Verhoeven G, 2000, ANDROLOGIA, V32, P42; Wang GS, 2009, J ANDROL, V30, P338, DOI 10.2164/jandrol.108.006890; Wang RS, 2006, ENDOCRINOLOGY, V147, P5624, DOI 10.1210/en.2006-0138; Welsh M, 2006, ENDOCRINOLOGY, V147, P4820, DOI 10.1210/en.2006-0149; Welsh M, 2009, ENDOCRINOLOGY, V150, P2472, DOI 10.1210/en.2008-0529; Xin HB, 2002, PHYSIOL GENOMICS, V10, P211, DOI 10.1152/physiolgenomics.00054.2002; Zhang CX, 2006, P NATL ACAD SCI USA, V103, P17718, DOI 10.1073/pnas.0608556103	45	164	172	1	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4218	4230		10.1096/fj.09-138347	http://dx.doi.org/10.1096/fj.09-138347			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19692648	Green Published			2022-12-28	WOS:000272193700017
J	Zheng, W; Xin, N; Chi, ZH; Zhao, BL; Zhang, J; Li, JY; Wang, ZY				Zheng, Wei; Xin, Na; Chi, Zhi-Hong; Zhao, Bo-Lu; Zhang, Jie; Li, Jia-Yi; Wang, Zhan-You			Divalent metal transporter 1 is involved in amyloid precursor protein processing and A beta generation	FASEB JOURNAL			English	Article						beta-amyloid peptide; RNA interference; APP/PS1 transgenic mouse; Alzheimer's disease; divalent cation transporter 1	IRON-RESPONSIVE ELEMENT; ALZHEIMERS-DISEASE; MESSENGER-RNA; 5'-UNTRANSLATED REGION; TRANSGENIC MICE; UP-REGULATION; BELGRADE RAT; EXPRESSION; COPPER; CELLS	The amyloid-beta precursor protein (APP) and its pathogenic byproduct beta-amyloid peptide (A beta) play central roles in the pathogenesis of Alzheimer's disease (AD). Reduction in levels of the potentially toxic A beta is one of the most important therapeutic goals in AD. Recent studies have shown that bivalent metals such as iron, copper, and zinc are involved in APP expression, A beta deposition, and senile plaque formation in the AD brain. However, the underlying mechanisms involved in abnormal homeostasis of bivalent metals in AD brain remain unclear. In the present study, we found that two isoforms of the divalent metal transporter 1 (DMT1), DMT1-IRE, and DMT1-nonIRE, were colocalized with A beta in the plaques of postmortem AD brain. Using the APP/PS1 transgenic mouse model, we found that the levels of both DMT1-IRE and DMT1-nonIRE were significantly increased in the cortex and hippocampus compared with wild type-control. We further verified the proposed mechanisms by which DMT1 might be involved in APP processing and A beta secretion by using the SH-SY5Y cell line stably overexpressing human APP Swedish mutation (APPsw) as a cell model. We found that overexpression of APPsw resulted in increased expression levels of both DMT1-IRE and DMT1-nonIRE in SH-SY5Y cells. Interestingly, silencing of endogenous DMT1 by RNA interference, which reduced bivalent ion influx, led to reductions of APP expression and A beta secretion. These findings suggest both that DMT1 plays a critical role in ion-mediated neuropathogenesis in AD and that pharmacological blockage of DMT1 may provide novel therapeutic strategies against AD.-Zheng, W., Xin, N., Chi, Z.-H., Zhao, B.-L., Zhang, J., Li, J.-Y., Wang, Z.-Y. Divalent metal transporter 1 (DMT1) is involved in amyloid precursor protein processing and A beta generation. FASEB J. 23, 4207-4217 (2009). www.fasebj.org	[Zheng, Wei; Xin, Na; Chi, Zhi-Hong; Wang, Zhan-You] China Med Univ, Lab Cell Engn & Cell Therapy, Minist Publ Hlth China, Key Lab Cell Biol, Shenyang 110001, Peoples R China; [Zhao, Bo-Lu; Zhang, Jie] Acad Sinica, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing 100080, Peoples R China; [Li, Jia-Yi] Lund Univ, Dept Expt Med Sci, S-22100 Lund, Sweden	China Medical University; Chinese Academy of Sciences; Institute of Biophysics, CAS; Lund University	Wang, ZY (corresponding author), China Med Univ, Lab Cell Engn & Cell Therapy, Minist Publ Hlth China, Key Lab Cell Biol, Shenyang 110001, Peoples R China.	zhanyouw@hotmail.com	Zhang, Jie/A-5426-2010	Wang, Zhan-You/0000-0003-0807-9916; Li, Jia-Yi/0000-0002-7770-7376	Natural Science Foundation of China [30770680]; Program for New Century Excellent Talents in University [NCET-04-0288]; China Postdoctoral Science Foundation [2005037008]; Specialized Research Fund for the Doctoral Program of Higher Education [SRFDP-20060159001]; National Grand Fundamental Research 973 Program of China [2006CB500700]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); National Grand Fundamental Research 973 Program of China(National Basic Research Program of China)	We are grateful to Dr. Rong Liu for statistical analysis. The study was supported by the Natural Science Foundation of China (30770680), the Program for New Century Excellent Talents in University (NCET-04-0288), the China Postdoctoral Science Foundation (2005037008), the Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP-20060159001), and the National Grand Fundamental Research 973 Program of China (2006CB500700).	Andrews NC, 1999, INT J BIOCHEM CELL B, V31, P991, DOI 10.1016/S1357-2725(99)00065-5; Aracena P, 2006, BIOL RES, V39, P157, DOI 10.4067/S0716-97602006000100017; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Atwood CS, 1999, MET IONS BIOL SYST, V36, P309; Bandyopadhyay S, 2006, J NEURAL TRANSM-SUPP, P237; Bandyopadhyay S, 2006, J NEUROSCI RES, V84, P106, DOI 10.1002/jnr.20864; Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200; Burdo JR, 2004, J CEREBR BLOOD F MET, V24, P67, DOI 10.1097/01.WCB.0000095800.98378.03; Burdo JR, 2001, J NEUROSCI RES, V66, P1198, DOI 10.1002/jnr.1256.abs; Burdo JR, 1999, NEUROSCIENCE, V93, P1189, DOI 10.1016/S0306-4522(99)00207-9; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Ci WM, 2003, CELL CALCIUM, V33, P257, DOI 10.1016/S0143-4160(02)00240-3; Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351; Conrad ME, 2000, AM J PHYSIOL-GASTR L, V279, pG767, DOI 10.1152/ajpgi.2000.279.4.G767; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P277; Devirgiliis C, 2007, MUTAT RES-FUND MOL M, V622, P84, DOI 10.1016/j.mrfmmm.2007.01.013; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Erikson KM, 2006, NEUROTOXICOLOGY, V27, P125, DOI 10.1016/j.neuro.2005.07.003; Falangola MF, 2005, NEUROCHEM RES, V30, P201, DOI 10.1007/s11064-004-2442-x; Finefrock AE, 2003, J AM GERIATR SOC, V51, P1143, DOI 10.1046/j.1532-5415.2003.51368.x; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Huang E, 2006, EXP BRAIN RES, V170, P376, DOI 10.1007/s00221-005-0220-x; Huang XD, 2004, J BIOL INORG CHEM, V9, P954, DOI 10.1007/s00775-004-0602-8; Hubert N, 2002, P NATL ACAD SCI USA, V99, P12345, DOI 10.1073/pnas.192423399; Jamieson SE, 2005, NEUROSCI LETT, V374, P124, DOI 10.1016/j.neulet.2004.10.038; Jankowsky JL, 2001, BIOMOL ENG, V17, P157, DOI 10.1016/S1389-0344(01)00067-3; Ke Y, 2005, NEUROBIOL AGING, V26, P739, DOI 10.1016/j.neurobiolaging.2004.06.002; Ke Y, 2007, PROG NEUROBIOL, V83, P149, DOI 10.1016/j.pneurobio.2007.07.009; Knutson M, 2004, J NEUROSCI RES, V76, P633, DOI 10.1002/jnr.20113; Lee JY, 2004, NEUROBIOL AGING, V25, P1315, DOI 10.1016/j.neurobiolaging.2004.01.005; Lee PL, 1998, BLOOD CELL MOL DIS, V24, P199, DOI 10.1006/bcmd.1998.0186; Li HY, 2003, BIOCHEM J, V372, P757, DOI 10.1042/BJ20030075; Liu GJ, 2006, J STRUCT BIOL, V155, P45, DOI 10.1016/j.jsb.2005.12.011; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Mackenzie B, 2007, BIOCHEM J, V403, P59, DOI 10.1042/BJ20061290; Macreadie IG, 2008, EUR BIOPHYS J BIOPHY, V37, P295, DOI 10.1007/s00249-007-0235-2; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; Miller LM, 2006, J STRUCT BIOL, V155, P30, DOI 10.1016/j.jsb.2005.09.004; Nevo Y, 2004, J BIOL CHEM, V279, P53056, DOI 10.1074/jbc.M408398200; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Paradkar PN, 2006, J NEUROCHEM, V96, P1768, DOI 10.1111/j.1471-4159.2006.03702.x; Phinney AL, 2003, P NATL ACAD SCI USA, V100, P14193, DOI 10.1073/pnas.2332851100; Rogers JT, 2008, BIOCHEM SOC T, V36, P1282, DOI 10.1042/BST0361282; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Saavedra L, 2007, J BIOL CHEM, V282, P35722, DOI 10.1074/jbc.M701823200; Salazar J, 2008, P NATL ACAD SCI USA, V105, P18578, DOI 10.1073/pnas.0804373105; Tabner BJ, 2005, J BIOL CHEM, V280, P35789, DOI 10.1074/jbc.C500238200; Tandy S, 2000, J BIOL CHEM, V275, P1023, DOI 10.1074/jbc.275.2.1023; Venti A, 2004, ANN NY ACAD SCI, V1035, P34, DOI 10.1196/annals.1332.003; Wang XC, 2005, AM J PHYSIOL-LUNG C, V289, pL24, DOI 10.1152/ajplung.00428.2003; Wardrop SL, 2000, EUR J BIOCHEM, V267, P6586, DOI 10.1046/j.1432-1327.2000.01752.x; Xu HM, 2008, NEUROCHEM INT, V52, P1044, DOI 10.1016/j.neuint.2007.10.019; Zhang J, 2006, NEUROSCIENCE, V143, P63, DOI 10.1016/j.neuroscience.2006.07.023; Zhang J, 2006, FASEB J, V20, P1212, DOI 10.1096/fj.05-5214fje; Zhang LH, 2008, BRAIN RES BULL, V77, P55, DOI 10.1016/j.brainresbull.2008.03.014; Zhang LH, 2010, NEUROBIOL AGING, V31, P74, DOI 10.1016/j.neurobiolaging.2008.02.018; ZHANG S, 2008, NEUROBIOL AGING, V32, pS12	60	73	80	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4207	4217		10.1096/fj.09-135749	http://dx.doi.org/10.1096/fj.09-135749			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19679638				2022-12-28	WOS:000272193700016
J	Miyoshi, K; Kasahara, K; Miyazaki, I; Shimizu, S; Taniguchi, M; Matsuzaki, S; Tohyama, M; Asanuma, M				Miyoshi, Ko; Kasahara, Kyosuke; Miyazaki, Ikuko; Shimizu, Shoko; Taniguchi, Manabu; Matsuzaki, Shinsuke; Tohyama, Masaya; Asanuma, Masato			Pericentrin, a centrosomal protein related to microcephalic primordial dwarfism, is required for olfactory cilia assembly in mice	FASEB JOURNAL			English	Article						kendrin; ciliogenesis; olfaction	POLYCYSTIC KIDNEY-DISEASE; CG-NAP; INTRAFLAGELLAR TRANSPORT; ADENYLYL-CYCLASE; SHARES HOMOLOGY; GENE; DISRUPTION; COMPLEX; MOUSE; ORGANIZATION	The Drosophila pericentrin-like protein has been shown to be essential for the formation of the sensory cilia of chemosensory and mechanosensory neurons by mutant analysis in flies, while the in vivo function of pericentrin, a well-studied mammalian centrosomal protein related to microcephalic primordial dwarfism, has been unclear. To determine whether pericentrin is required for ciliogenesis in mammals, we generated and analyzed mice with a hypomorphic mutation of Pcnt encoding the mouse pericentrin. Immunofluorescence analysis demonstrated that olfactory cilia of chemosensory neurons in the nasal olfactory epithelium were malformed in the homozygous mutant mice. On the other hand, the assembly of motile and primary cilia of non-neuronal epithelial cells and the formation of sperm flagella were not affected in the Pcnt-mutant mice. The defective assembly of olfactory cilia in the mutant was apparent from birth. The mutant animals displayed reduced olfactory performance in agreement with the compromised assembly of olfactory cilia. Our findings suggest that pericentrin is essential for the assembly of chemosensory cilia of olfactory receptor neurons, but it is not globally required for cilia formation in mammals.-Miyoshi, K., Kasahara, K., Miyazaki, I., Shimizu, S., Taniguchi, M., Matsuzaki, S., Tohyama, M., Asanuma, M. Pericentrin, a centrosomal protein related to microcephalic primordial dwarfism, is required for olfactory cilia assembly in mice. FASEB J. 23, 3289-3297 ( 2009). www.fasebj.org	[Miyoshi, Ko; Kasahara, Kyosuke; Miyazaki, Ikuko; Asanuma, Masato] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Brain Sci, Okayama 7008558, Japan; [Shimizu, Shoko; Taniguchi, Manabu; Matsuzaki, Shinsuke; Tohyama, Masaya] Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Osaka, Japan; [Matsuzaki, Shinsuke; Tohyama, Masaya] Osaka Univ, Grad Sch Med, Osaka Hamamatsu Joint Res Ctr Child Mental Dev, Osaka, Japan	Okayama University; Osaka University; Osaka University	Miyoshi, K (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Brain Sci, 2-5-1 Shikatacho, Okayama 7008558, Japan.	miyoshi@cc.okayama-u.ac.jp			Grants-in-Aid for Scientific Research [19591355]	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Grants-in-Aid for Scientific Research (Kakenhi; grant 19591355).	Araki K, 1999, CELL MOL BIOL, V45, P737; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; Cano DA, 2004, DEVELOPMENT, V131, P3457, DOI 10.1242/dev.01189; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; Flory MR, 2000, P NATL ACAD SCI USA, V97, P5919, DOI 10.1073/pnas.97.11.5919; Flory MR, 2003, GENOMICS, V82, P401, DOI 10.1016/S0888-7543(03)00119-8; Gillingham AK, 2000, EMBO REP, V1, P524; Griffith E, 2008, NAT GENET, V40, P232, DOI 10.1038/ng.2007.80; Jurczyk A, 2004, J CELL BIOL, V166, P637, DOI 10.1083/jcb.200405023; Kawaguchi S, 2004, MOL BIOL CELL, V15, P37, DOI 10.1091/mbc.E03-03-0191; Kim J, 2008, HUM MOL GENET, V17, P3796, DOI 10.1093/hmg/ddn277; Kubo A, 2003, J CELL SCI, V116, P919, DOI 10.1242/jcs.00282; Kulaga HM, 2004, NAT GENET, V36, P994, DOI 10.1038/ng1418; Liu QQ, 2001, J CELL SCI, V114, P797; Marshall WF, 2008, J CELL BIOL, V180, P17, DOI 10.1083/jcb.200710085; Martinez-Campos M, 2004, J CELL BIOL, V165, P673, DOI 10.1083/jcb.200402130; Miura K, 2006, BIOCHEM BIOPH RES CO, V341, P132, DOI 10.1016/j.bbrc.2005.12.151; Miyoshi K, 2006, BIOCHEM BIOPH RES CO, V351, P745, DOI 10.1016/j.bbrc.2006.10.101; Miyoshi K, 2006, DEV GENES EVOL, V216, P537, DOI 10.1007/s00427-006-0065-8; MOYER JH, 1994, SCIENCE, V264, P1329, DOI 10.1126/science.8191288; Mykytyn K, 2004, P NATL ACAD SCI USA, V101, P8664, DOI 10.1073/pnas.0402354101; Nachury MV, 2007, CELL, V129, P1201, DOI 10.1016/j.cell.2007.03.053; Nishimura DY, 2004, P NATL ACAD SCI USA, V101, P16588, DOI 10.1073/pnas.0405496101; Pan JM, 2005, LAB INVEST, V85, P452, DOI 10.1038/labinvest.3700253; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Rauch A, 2008, SCIENCE, V319, P816, DOI 10.1126/science.1151174; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Ross AJ, 2005, NAT GENET, V37, P1135, DOI 10.1038/ng1644; Takahashi M, 2002, MOL BIOL CELL, V13, P3235, DOI 10.1091/mbc.E02-02-0112; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Taniwaki T, 2005, DEV GROWTH DIFFER, V47, P163; Taulman PD, 2001, MOL BIOL CELL, V12, P589, DOI 10.1091/mbc.12.3.589; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X; Yamamura K, 2008, CANCER SCI, V99, P1, DOI 10.1111/j.1349-7006.2007.00611.x; Zhang QH, 2005, LAB INVEST, V85, P45, DOI 10.1038/labinvest.3700207; Zimmerman WC, 2004, MOL BIOL CELL, V15, P3642, DOI 10.1091/mbc.E03-11-0796	39	33	34	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3289	3297		10.1096/fj.08-124420	http://dx.doi.org/10.1096/fj.08-124420			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19470799				2022-12-28	WOS:000270354300006
J	Vojtova-Vodolanova, J; Basler, M; Osicka, R; Knapp, O; Maier, E; Cerny, J; Benada, O; Benz, R; Sebo, P				Vojtova-Vodolanova, Jana; Basler, Marek; Osicka, Radim; Knapp, Oliver; Maier, Elke; Cerny, Jan; Benada, Oldrich; Benz, Roland; Sebo, Peter			Oligomerization is involved in pore formation by Bordetella adenylate cyclase toxin	FASEB JOURNAL			English	Article						blue native electrophoresis; planar lipid bilayer membranes; pore-forming activity; pulldown; repeats in toxin	BLUE NATIVE ELECTROPHORESIS; CELL-INVASIVE ACTIVITY; MEMBRANE TRANSLOCATION; HEMOLYTIC ACTIVITIES; ESCHERICHIA-COLI; PERTUSSIS TOXIN; SHEEP ERYTHROCYTES; FATTY-ACYLATION; DENDRITIC CELLS; TARGET-CELLS	The Bordetella adenylate cyclase-hemolysin (CyaA, ACT, or AC-Hly) is a multifunctional toxin. Simultaneously with promoting calcium ion entry, CyaA delivers into host cells an adenylate cyclase enzyme (AC) and permeabilizes cell membrane by forming small cation-selective pores. Indirect evidence suggested that these two activities were accomplished by different membrane-inserted CyaA conformers, one acting as an AC-delivering monomer and the other as an uncharacterized poreforming oligomer. We tested this model by directly detecting toxin oligomers in cell membrane and by assessing oligomerization of specific mutants with altered poreforming properties. CyaA oligomers were revealed in sheep erythrocyte membranes by immunogold labeling and directly demonstrated by pulldown of membrane-inserted CyaA together with biotinylated CyaA-AC(-) toxoid. Membrane oligomers of CyaA could also be resolved by nondenaturing electrophoresis of mild detergent extracts of erythrocytes. Furthermore, CyaA mutants exhibiting enhanced (E581K) or reduced (E570K + E581P) specific hemolytic and pore-forming activity were found to exhibit also a correspondingly enhanced or reduced propensity to form oligomers in erythrocyte membranes. On the other hand, processed CyaA, with the AC domain cleaved off by erythrocyte proteases, was detected only in a monomeric form excluded from the oligomers of unprocessed CyaA. These results provide the first direct evidence that oligomerization is involved in formation of CyaA pores in target membranes and that translocation of the AC domain across cell membrane may be accomplished by monomeric CyaA.-Vojtova-Vodolanova, J., Basler, M., Osicka, R., Knapp, O., Maier, E., Cerny, J., Benada, O., Benz, R., Sebo, P. Oligomerization is involved in pore formation by Bordetella adenylate cyclase toxin. FASEB J. 23, 2831-2843 (2009). www.fasebj.org	[Vojtova-Vodolanova, Jana; Basler, Marek; Osicka, Radim; Benada, Oldrich; Sebo, Peter] Acad Sci Czech Republic, Inst Microbiol, CAS, CZ-14220 Prague 4, Czech Republic; [Knapp, Oliver; Maier, Elke; Benz, Roland] Univ Wurzburg, Lehrstuhl Biotechnol, Theodor Boveri Inst, Biozentrum, Wurzburg, Germany; [Cerny, Jan] Charles Univ Prague, Dept Cell Biol, Fac Sci, Prague, Czech Republic	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of Wurzburg; Charles University Prague	Vojtova-Vodolanova, J (corresponding author), Acad Sci Czech Republic, Inst Microbiol, CAS, Videnska 1083, CZ-14220 Prague 4, Czech Republic.	sebo@biomed.cas.cz	SEBO, Peter/F-7423-2011; Basler, Marek/A-3559-2012; Vojtova, Jana/G-6520-2019; Cerny, Jan/C-1887-2012; Osicka, Radim/H-6776-2014; SEBO, Peter/N-2043-2019; Benada, Oldřich/H-2437-2014	SEBO, Peter/0000-0002-9755-7715; Basler, Marek/0000-0001-5414-2088; Vojtova, Jana/0000-0003-0174-9331; Cerny, Jan/0000-0002-5624-2215; Osicka, Radim/0000-0003-2626-5456; SEBO, Peter/0000-0002-9755-7715; Benada, Oldřich/0000-0002-4592-6216; Benz, Roland/0000-0002-9510-9265	EU 6th FP [LSHB-CT-2003-503582 THERAVAC]; Deutsche Forschungsgemeinschaft SFB 487 [A5]; Institutional Research Concept [AVOZ50200510]; Academy of Sciences [IAA50020091h]; Ministry of Education, Youth and Sports of the Czech Republic [1M0506];  [MSM0021620858]	EU 6th FP(European Commission); Deutsche Forschungsgemeinschaft SFB 487(German Research Foundation (DFG)); Institutional Research Concept; Academy of Sciences(Egyptian Academy of Scientific Research & Technology (ASRT)); Ministry of Education, Youth and Sports of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); 	The generous gift of monoclonal antibodies by Erik L. Hewlett (University of Virginia School of Medicine, Charlottesville, VA, USA) and protein A-gold by Jan Slot (University Medical Center, Utrecht, The Netherlands), as well as insightful advice of P. Hozak on pair correlation function analysis, are gratefully acknowledged. This work was supported by EU 6th FP contract LSHB-CT-2003-503582 THERAVAC; Deutsche Forschungsgemeinschaft SFB 487 project A5; Institutional Research Concept AVOZ50200510; Academy of Sciences grant IAA50020091h; and grant MSM0021620858 and Center of Molecular Immunology grant 1M0506 from the Ministry of Education, Youth and Sports of the Czech Republic.	Bagley KC, 2002, J LEUKOCYTE BIOL, V72, P962; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; Basar T, 1999, J BIOL CHEM, V274, P10777, DOI 10.1074/jbc.274.16.10777; Basler M, 2006, INFECT IMMUN, V74, P2207, DOI 10.1128/IAI.74.4.2207-2214.2006; Basler M, 2007, J BIOL CHEM, V282, P12419, DOI 10.1074/jbc.M611226200; Bejerano M, 1999, MOL MICROBIOL, V31, P381, DOI 10.1046/j.1365-2958.1999.01183.x; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1994, J BIOL CHEM, V269, P27231; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; Fiser R, 2007, J BIOL CHEM, V282, P2808, DOI 10.1074/jbc.M609979200; FRIEDMAN RL, 1987, INFECT IMMUN, V55, P135, DOI 10.1128/IAI.55.1.135-140.1987; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GOODWIN MS, 1990, INFECT IMMUN, V58, P3445, DOI 10.1128/IAI.58.10.3445-3447.1990; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; Gray M, 1998, J BIOL CHEM, V273, P18260, DOI 10.1074/jbc.273.29.18260; Gray MC, 2004, MOL MICROBIOL, V53, P1709, DOI 10.1111/j.1365-2958.2004.04227.x; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; GROSS MK, 1992, P NATL ACAD SCI USA, V89, P4898, DOI 10.1073/pnas.89.11.4898; Guermonprez P, 1999, J IMMUNOL, V162, P1910; Guermonprez P, 2001, J EXP MED, V193, P1035, DOI 10.1084/jem.193.9.1035; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HACKETT M, 1995, J BIOL CHEM, V270, P20250, DOI 10.1074/jbc.270.35.20250; HAINFELD JF, 1987, SCIENCE, V236, P450, DOI 10.1126/science.3563522; Heuberger EHML, 2002, J MOL BIOL, V317, P591, DOI 10.1006/jmbi.2002.5416; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; Horiuchi M, 2001, P NATL ACAD SCI USA, V98, P1448, DOI 10.1073/pnas.041329498; IWAKI M, 1995, MOL MICROBIOL, V17, P1015, DOI 10.1111/j.1365-2958.1995.mmi_17061015.x; Iwaki M, 2000, INFECT IMMUN, V68, P3727, DOI 10.1128/IAI.68.6.3727-3730.2000; Kang DS, 2004, J BIOL CHEM, V279, P22102, DOI 10.1074/jbc.M402572200; Kang DS, 2005, MOL PHARMACOL, V67, P309, DOI 10.1124/mol.104.002840; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; KHELEF N, 1992, MICROB PATHOGENESIS, V12, P227, DOI 10.1016/0882-4010(92)90057-U; KHELEF N, 1993, INFECT IMMUN, V61, P4064, DOI 10.1128/IAI.61.10.4064-4071.1993; Ladant D, 1999, TRENDS MICROBIOL, V7, P172, DOI 10.1016/S0966-842X(99)01468-7; LADANT D, 1988, J BIOL CHEM, V263, P2612; Lee SJ, 2005, ARCH BIOCHEM BIOPHYS, V438, P80, DOI 10.1016/j.abb.2005.04.001; Lee SJ, 1999, INFECT IMMUN, V67, P2090, DOI 10.1128/IAI.67.5.2090-2095.1999; Masin J, 2004, BBA-BIOMEMBRANES, V1660, P144, DOI 10.1016/j.bbamem.2003.11.008; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Osickova A, 1999, J BIOL CHEM, V274, P37644; PEARSON RD, 1987, J IMMUNOL, V139, P2749; Philimonenko VV, 2001, EXP CELL RES, V264, P201, DOI 10.1006/excr.2001.5150; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROGEL A, 1991, J BIOL CHEM, V266, P3154; Roos N., 1990, CRYOPREPARATION THIN; ROSE T, 1995, J BIOL CHEM, V270, P26370, DOI 10.1074/jbc.270.44.26370; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schlecht G, 2004, J IMMUNOL, V173, P6089, DOI 10.4049/jimmunol.173.10.6089; Skinner JA, 2004, J IMMUNOL, V173, P1934, DOI 10.4049/jimmunol.173.3.1934; SLOT JW, 1989, AM J ANAT, V185, P271, DOI 10.1002/aja.1001850220; SZABO G, 1994, J BIOL CHEM, V269, P22496; Vojtova J, 2006, MICROSC RES TECHNIQ, V69, P119, DOI 10.1002/jemt.20277; Weingart CL, 2000, INFECT IMMUN, V68, P7152, DOI 10.1128/IAI.68.12.7152-7155.2000; WEISS AA, 1984, J INFECT DIS, V150, P219, DOI 10.1093/infdis/150.2.219	61	45	46	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2009	23	9					2831	2843		10.1096/fj.09-131250	http://dx.doi.org/10.1096/fj.09-131250			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19417082				2022-12-28	WOS:000270241000006
J	Zhu, Y; Vergote, D; Pardo, C; Noorbakhsh, F; McArthur, JC; Hollenberg, MD; Overall, CM; Power, C				Zhu, Yu; Vergote, David; Pardo, Carlos; Noorbakhsh, Farshid; McArthur, Justin C.; Hollenberg, Morley D.; Overall, Christopher M.; Power, Christopher			CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy	FASEB JOURNAL			English	Article						HIV; FIV; neuroinflammation; CXCL12	HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; HIV-INFECTION; FACTOR-I; MOLECULAR-MECHANISMS; ALZHEIMERS-DISEASE; TYPE-1 INFECTION; DEMENTIA; EXPRESSION; RECEPTOR	Previous studies have implicated CXCL12 in the neuropathogenesis of HIV infection. Proteolysis of CXCL12 generates a neurotoxic molecule, CXCL12(5-67), which engages and activates CXCR3, in addition to exhibiting increased expression in the brains of patients with HIV-associated dementia (HAD). Herein, we investigated CXCR3-mediated neuronal injury, particularly, its contribution to autophagy suppression and the concomitant effects of antiretroviral therapy using human brain samples and models of HIV neuropathogenesis. Neurons in the brains of HAD patients and feline immunodeficiency virus (FIV)-infected animals, as well as cultured human neurons, expressed CXCR3, which was modulated in a ligand-specific manner. Exposure of human neurons to CXCL12(5-67) caused a reduction in the autophagy-associated molecule LC3 (P<0.05) and neuronal survival (P<0.05), which recapitulated findings in FIV- and HIV-infected brains (P<0.05). Oral didanosine (ddI) treatment of FIV- infected animals reduced neurobehavioral abnormalities in conjunction with diminished plasma viral load ( P<0.05). F4/80 transcript abundance and CXCL12(5-67) immunoreactivity were reduced with restored neuronal LC3 expression in the brains of FIV-infected animals after ddI treatment (P<0.05). ddI treatment also prevented microglial activation and depletion of synaptic proteins in the cortex of FIV- infected animals (P<0.05). These findings indicate that the beneficial effects of ddI might be a consequence of a reduced systemic viral burden and concurrent leukocyte activation, leading to diminished neuroinflammation with preservation of neuronal autophagy by regulating CXCR3 activation.-Zhu, Y., Vergote, D., Pardo, C., Noorbakhsh, F., McArthur, J. C., Hollenberg, M. D., Overall, C. M., Power, C. CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy. FASEB J. 23, 2928-2941 (2009). www.fasebj.org	[Zhu, Yu; Vergote, David; Noorbakhsh, Farshid; Power, Christopher] Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; [Pardo, Carlos; McArthur, Justin C.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA; [Hollenberg, Morley D.] Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB, Canada; [Overall, Christopher M.] Univ British Columbia, Dept Oral Biol & Med Sci, Ctr Blood Res, Vancouver, BC V5Z 1M9, Canada; [Overall, Christopher M.] Univ British Columbia, Dept Biochem & Mol Biol, Ctr Blood Res, Vancouver, BC V5Z 1M9, Canada	University of Alberta; Johns Hopkins University; University of Calgary; University of British Columbia; University of British Columbia	Power, C (corresponding author), Univ Alberta, Dept Med Neurol, 6-11 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	chris.power@ualberta.ca	Hollenberg, Morley/AFV-6966-2022; Pardo, Carlos A./A-5192-2008; Power, Christopher/C-7181-2013	Pardo, Carlos A./0000-0002-4128-5335; Power, Christopher/0000-0002-5131-9711; Vergote, David/0000-0002-1298-3783	Toupin Chair fellowship; CIHR; Alberta Heritage Foundation for Medical Research fellowships; U.S. National Institutes of Health-National Institute of Mental Health; NATIONAL INSTITUTE ON DRUG ABUSE [K08DA016160] Funding Source: NIH RePORTER	Toupin Chair fellowship; CIHR(Canadian Institutes of Health Research (CIHR)); Alberta Heritage Foundation for Medical Research fellowships; U.S. National Institutes of Health-National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank Leah DeBlock for assistance with manuscript preparation. Y.Z. was a Canadian Institutes for Health Research (CIHR) fellow. D.V. was supported by a Toupin Chair fellowship. F.N. is supported by CIHR and Alberta Heritage Foundation for Medical Research fellowships. C.M.O. and C.P. hold Canada Research Chairs (tier 1) in metalloproteinases and systems biology and neurological infection and immunity, respectively. C.P. is an Alberta Heritage Foundation for Medical Research senior scholar. These studies were supported by the U.S. National Institutes of Health-National Institute of Mental Health and CIHR.	Adle-Biassette H, 1999, NEUROPATH APPL NEURO, V25, P123; Aksoy MO, 2006, AM J PHYSIOL-LUNG C, V290, pL909, DOI 10.1152/ajplung.00430.2005; Alirezaei M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002906; Anthony IC, 2008, INT REV PSYCHIATR, V20, P15, DOI 10.1080/09540260701862037; Antinori A, 2005, CLIN INFECT DIS, V41, P1787, DOI 10.1086/498310; Bellizzi MJ, 2006, J NEUROIMMUNE PHARM, V1, P20, DOI 10.1007/s11481-005-9006-y; Boisse L, 2008, NEUROL CLIN, V26, P799, DOI 10.1016/j.ncl.2008.04.002; Boven LA, 1999, FEMS IMMUNOL MED MIC, V26, P243, DOI 10.1111/j.1574-695X.1999.tb01395.x; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; Conant K, 1999, ANN NEUROL, V46, P391, DOI 10.1002/1531-8249(199909)46:3<391::AID-ANA15>3.0.CO;2-0; Datta D, 2006, CANCER RES, V66, P9509, DOI 10.1158/0008-5472.CAN-05-4345; Ehlert JE, 2004, J IMMUNOL, V173, P6234, DOI 10.4049/jimmunol.173.10.6234; Elder JH, 2008, VET IMMUNOL IMMUNOP, V123, P3, DOI 10.1016/j.vetimm.2008.01.007; Everall IP, 1999, BRAIN PATHOL, V9, P209; EVERALL IP, 1994, ACTA NEUROPATHOL, V88, P538; Fehder W P, 2001, Semin Clin Neuropsychiatry, V6, P229; Feldman ED, 2006, ANN SURG ONCOL, V13, P125, DOI 10.1245/ASO.2006.03.038; Fletcher NF, 2008, VET IMMUNOL IMMUNOP, V123, P134, DOI 10.1016/j.vetimm.2008.01.028; Garg H, 2004, VIROLOGY, V321, P274, DOI 10.1016/j.virol.2004.01.006; Garin A, 2003, J IMMUNOL, V171, P5305, DOI 10.4049/jimmunol.171.10.5305; Gupta SK, 1999, J LEUKOCYTE BIOL, V66, P135, DOI 10.1002/jlb.66.1.135; HARTMANN K, 1992, VET IMMUNOL IMMUNOP, V35, P167, DOI 10.1016/0165-2427(92)90129-E; Hult B, 2008, INT REV PSYCHIATR, V20, P3, DOI 10.1080/09540260701862086; JANSSEN RS, 1992, NEUROLOGY, V42, P1472, DOI 10.1212/WNL.42.8.1472; Johnston JB, 2000, J VIROL, V74, P7211, DOI 10.1128/JVI.74.16.7211-7220.2000; Jones G, 2006, NEUROBIOL DIS, V21, P1, DOI 10.1016/j.nbd.2005.07.018; Kaul M, 2006, CURR HIV RES, V4, P307, DOI 10.2174/157016206777709384; Kennedy JM, 2004, AIDS, V18, P1241, DOI 10.1097/00002030-200406180-00002; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; KOENIG RE, 1986, LANCET, V2, P627; Langford D, 2006, J NEUROVIROL, V12, P100, DOI 10.1080/13550280600713932; Lasagni L, 2003, J EXP MED, V197, P1537, DOI 10.1084/jem.20021897; Letendre Scott, 2008, Top HIV Med, V16, P15; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Levine B, 2006, J CLIN INVEST, V116, P2078, DOI 10.1172/JCI29447; Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Muller T, 2008, PROG NEUROBIOL, V85, P393, DOI 10.1016/j.pneurobio.2008.05.002; Noorbakhsh F, 2006, J EXP MED, V203, P425, DOI 10.1084/jem.20052148; Noorbakhsh F, 2005, J IMMUNOL, V174, P7320, DOI 10.4049/jimmunol.174.11.7320; Noorbakhsh F, 2009, TRENDS NEUROSCI, V32, P88, DOI 10.1016/j.tins.2008.10.003; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Ohtani Y, 1998, NEUROSCI LETT, V249, P163, DOI 10.1016/S0304-3940(98)00425-X; Power C, 1998, J VIROL, V72, P9109, DOI 10.1128/JVI.72.11.9109-9115.1998; Power C, 2004, J NEUROVIROL, V10, P113, DOI 10.1080/13550280490270815; Price RW, 2008, J INFECT DIS, V197, pS294, DOI 10.1086/533419; Richardson J, 1999, J VIROL, V73, P3661, DOI 10.1128/JVI.73.5.3661-3671.1999; Rock RB, 2006, J NEUROIMMUNE PHARM, V1, P117, DOI 10.1007/s11481-006-9012-8; Roth JS, 1999, DRUG METAB DISPOS, V27, P1128; Rumbaugh JA, 2006, CURR PHARM DESIGN, V12, P1023, DOI 10.2174/138161206776055877; Ryan LA, 2002, CELL MOL BIOL, V48, P137; Sacktor N, 2002, J NEUROVIROL, V8, P115, DOI 10.1080/13550280290101094; Sarkar S, 2008, MOL BIOSYST, V4, P895, DOI 10.1039/b804606a; St Hillaire C, 2005, J NEUROVIROL, V11, P535, DOI 10.1080/13550280500385203; Tang GM, 2008, HUM MOL GENET, V17, P1540, DOI 10.1093/hmg/ddn042; Ventruti A, 2007, CURR NEUROL NEUROSCI, V7, P443, DOI 10.1007/s11910-007-0068-5; Vergote D, 2006, P NATL ACAD SCI USA, V103, P19182, DOI 10.1073/pnas.0604678103; Wynn HE, 2002, CNS DRUGS, V16, P595, DOI 10.2165/00023210-200216090-00002; Yang DS, 2008, AM J PATHOL, V173, P665, DOI 10.2353/ajpath.2008.071176; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127; Zhou DJ, 2008, AIDS, V22, P695, DOI 10.1097/QAD.0b013e3282f4a836; Zink MC, 2006, CURR HIV RES, V4, P293	64	34	35	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2928	2941		10.1096/fj.08-128819	http://dx.doi.org/10.1096/fj.08-128819			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19380511	Green Published			2022-12-28	WOS:000270241000016
J	Xu, RJ; Sun, W; Jin, JF; Obeid, LM; Mao, CG				Xu, Ruijuan; Sun, Wei; Jin, Junfei; Obeid, Lina M.; Mao, Cungui			Role of alkaline ceramidases in the generation of sphingosine and its phosphate in erythrocytes	FASEB JOURNAL			English	Article						ceramide; erythroid cells; S1P; and S1P lyase	MOLECULAR-CLONING; NEUTRAL CERAMIDASE; ACID CERAMIDASE; FARBER-DISEASE; SPHINGOSINE-1-PHOSPHATE LYASE; FUNCTIONAL-CHARACTERIZATION; CELLS; GENE; SPHINGOMYELINASE; DIFFERENTIATION	Plasma sphingosine-1-phosphate (S1P) has been suggested to mainly originate from erythrocytes; however, within the erythrocyte, how sphingosine (SPH) generation-the precursor to S1P-is controlled is unknown. SPH is only generated from the hydrolysis of ceramides via ceramidases. Five human ceramidases have been identified: 1 acid, 1 neutral, and 3 alkaline ceramidases (ACER1, ACER2, and ACER3). Here, we demonstrate that only alkaline ceramidase activity is expressed in erythrocytes and that it is instrumental for SPH generation. Erythrocytes have alkaline but not acid or neutral ceramidase activity on D-e-C-18:1-ceramide, a common substrate of ceramidases. Not only alkaline ceramidase activity but also the generation of SPH and S1P are increased during erythroid differentiation in K562 erythroleukemic cells. Such SPH and S1P increases were inhibited by the alkaline ceramidase inhibitor D-e-MAPP, suggesting that alkaline ceramidases have a role in the generation of SPH and S1P in erythroid cells. Alkaline ceramidase activity is highly expressed in mouse erythrocytes, and intravenous administration of D-e-MAPP decreased both SPH and S1P in erythrocytes and plasma. Collectively, these results suggest that alkaline ceramidase activity is important for the generation of SPH, the S1P precursor in erythrocytes.-Xu, R., Sun, W., Jin, J., Obeid, L. M., Mao, C. Role of alkaline ceramidases in the generation of sphingosine and its phosphate in erythrocytes. FASEB J. 24, 2507-2515 (2010). www.fasebj.org	[Mao, Cungui] Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA; [Obeid, Lina M.; Mao, Cungui] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Obeid, Lina M.] Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Mao, CG (corresponding author), Med Univ S Carolina, Dept Med, Div Gen Internal Med, 114 Doughty St,Rm 646,STB,POB 250779, Charleston, SC 29425 USA.	maoc@musc.edu	xu, rui/GRX-5734-2022	obeid, lina/0000-0002-0734-0847; Jin, Junfei/0000-0002-9237-9024	U.S. National Institutes of Health [R01CA104834, P20RR017677, GM062887]; Veterans Affairs merit award; NATIONAL CANCER INSTITUTE [R01CA104834] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs merit award(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by U.S. National Institutes of Health grants R01CA104834 (C.M.), P20RR017677 (C.M.), and GM062887 (L.M.O.), and a Veterans Affairs merit award (L.M.O.). The authors thank Dr. Jennifer Schnellmann for English proofreading and editing of the manuscript.	Bandhuvula P, 2007, J LIPID RES, V48, P2769, DOI 10.1194/jlr.D700010-JLR200; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Burek C, 2001, ONCOGENE, V20, P6493, DOI 10.1038/sj.onc.1204841; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; English D, 2001, CARDIOVASC RES, V49, P588, DOI 10.1016/S0008-6363(00)00230-3; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; Hanel P, 2007, FASEB J, V21, P1202, DOI 10.1096/fj.06-7433com; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; Hu W, 2010, J BIOL CHEM, V285, P7964, DOI 10.1074/jbc.M109.063586; Hwang YH, 2005, BIOCHEM BIOPH RES CO, V331, P37, DOI 10.1016/j.bbrc.2005.03.134; Ito K, 2007, BIOCHEM BIOPH RES CO, V357, P212, DOI 10.1016/j.bbrc.2007.03.123; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kono M, 2006, J BIOL CHEM, V281, P7324, DOI 10.1074/jbc.M508382200; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; LUISIDELUCA C, 1984, J CLIN INVEST, V74, P821, DOI 10.1172/JCI111498; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Mao CG, 2003, J BIOL CHEM, V278, P31184, DOI 10.1074/jbc.M303875200; MOMOI T, 1982, BIOCHEM J, V205, P419, DOI 10.1042/bj2050419; Monick MM, 2004, J IMMUNOL, V173, P123, DOI 10.4049/jimmunol.173.1.123; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Obeid L.M., 2001, J BIOL CHEM, V16, P16; Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221; Pyne S, 2004, SEMIN CELL DEV BIOL, V15, P491, DOI 10.1016/j.semcdb.2004.05.007; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; Sun W, 2008, J INVEST DERMATOL, V128, P389, DOI 10.1038/sj.jid.5701025; Sun W, 2010, J BIOL CHEM, V285, P8995, DOI 10.1074/jbc.M109.069203; Sun W, 2009, FASEB J, V23, P656, DOI 10.1096/fj.08-115634; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Van Veldhoven PP, 2000, BBA-MOL CELL BIOL L, V1487, P128, DOI 10.1016/S1388-1981(00)00079-2; Xu RJ, 2006, FASEB J, V20, P1813, DOI 10.1096/fj.05-5689com; Zhou JH, 1998, BIOCHEM BIOPH RES CO, V242, P502, DOI 10.1006/bbrc.1997.7993	39	34	34	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2507	2515		10.1096/fj.09-153635	http://dx.doi.org/10.1096/fj.09-153635			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20207939	Green Published			2022-12-28	WOS:000279343600037
J	Leibiger, B; Moede, T; Uhles, S; Barker, CJ; Creveaux, M; Domin, J; Berggren, PO; Leibiger, IB				Leibiger, Barbara; Moede, Tilo; Uhles, Sabine; Barker, Christopher J.; Creveaux, Marion; Domin, Jan; Berggren, Per-Olof; Leibiger, Ingo B.			Insulin-feedback via PI3K-C2 alpha activated PKB alpha/Akt1 is required for glucose-stimulated insulin secretion	FASEB JOURNAL			English	Article						insulin signaling; diabetes mellitus; fluorescence microscopy; biosensors	II PHOSPHOINOSITIDE 3-KINASE; PROTEIN-KINASE B; PHOSPHATIDYLINOSITOL 3-KINASE; C2 DOMAIN; GENE-TRANSCRIPTION; ALPHA-ISOFORM; CDNA CLONING; RECEPTOR; LOCALIZATION; GLUCOKINASE	Phosphatidylinositide 3-kinases (PI3Ks) play central roles in insulin signal transduction. While the contribution of class Ia PI3K members has been extensively studied, the role of class II members remains poorly understood. The diverse actions of class II PI3K-C2 alpha have been attributed to its lipid product PI(3) P. By applying pharmacological inhibitors, transient overexpression and small-interfering RNA-based knockdown of PI3K and PKB/Akt isoforms, together with PI-lipid profiling and live-cell confocal and total internal reflection fluorescence microscopy, we now demonstrate that in response to insulin, PI3K-C2 alpha generates PI(3,4) P-2, which allows the selective activation of PKB alpha/Akt1. Knockdown of PI3K-C2 alpha expression and subsequent reduction of PKB alpha/Akt1 activity in the pancreatic beta-cell impaired glucose-stimulated insulin release, at least in part, due to reduced glucokinase expression and increased AS160 activity. Hence, our results identify signal transduction via PI3K-C2 alpha as a novel pathway whereby insulin activates PKB/Akt and thus discloses PI3K-C2 alpha as a potential drugable target in type 2 diabetes. The high degree of codistribution of PI3K-C2 alpha and PKB alpha/Akt1 with insulin receptor B type, but not A type, in the same plasma membrane microdomains lends further support to the concept that selectivity in insulin signaling is achieved by the spatial segregation of signaling events.-Leibiger, B., Moede, T., Uhles, S., Barker, C. J., Creveaux, M., Domin, J., Berggren, P.-O., Leibiger, I. B. Insulin-feedback via PI3K-C2 alpha activated PKB alpha/Akt1 is required for glucose-stimulated insulin secretion. FASEB J. 24, 1824-1837 (2010). www.fasebj.org	[Leibiger, Barbara; Moede, Tilo; Uhles, Sabine; Barker, Christopher J.; Creveaux, Marion; Berggren, Per-Olof; Leibiger, Ingo B.] Karolinska Inst, Rolf Luft Res Ctr Diabet & Endocrinol, SE-17176 Stockholm, Sweden; [Domin, Jan] Univ London Imperial Coll Sci Technol & Med, Fac Med, Renal Sect, London, England	Karolinska Institutet; Imperial College London	Berggren, PO (corresponding author), Karolinska Inst, Rolf Luft Res Ctr Diabet & Endocrinol, L1 03, SE-17176 Stockholm, Sweden.	per-olof.berggren@ki.se; ingo.leibiger@ki.se		Berggren, Per-Olof/0000-0001-8991-413X; Uhles, Sabine/0000-0002-2836-8726; Moede, Tilo/0000-0002-2045-9244	Karolinska Institutet; Swedish Diabetes Association; Swedish Research Council; Novo Nordisk Foundation, Eurodia [FP6-518153]; Berth von Kantzow Foundation; Juvenile Diabetes Research Foundation; Family Erling-Persson Foundation; MRC [G0500936] Funding Source: UKRI; Medical Research Council [G0500936] Funding Source: researchfish	Karolinska Institutet(Karolinska Institutet); Swedish Diabetes Association; Swedish Research Council(Swedish Research CouncilEuropean Commission); Novo Nordisk Foundation, Eurodia(Novo Nordisk Foundation); Berth von Kantzow Foundation; Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); Family Erling-Persson Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank F. Saupe for technical assistance, and Dr. Dario R. Alessi (MRC Protein Phosphorylation Unit, University of Dundee, Dundee, UK), Dr. Harald A. Stenmark (Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway), Dr. Boudewijn M. T. Burgering (University Medical Center Utrecht, Utrecht, The Netherlands), Dr. Roger Y. Tsien (University of California-San Diego, La Jolla, CA, USA), Dr. Anders Tengholm (Uppsala University Biomedical Centre, Uppsala, Sweden), Dr. Georges Bismuth (Institut Cochin, Universite Paris Decartes, Paris, France), and Dr. Morris J. Birnbaum (Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, PA, USA) for sharing expression constructs. This work was supported by funds from Karolinska Institutet and by grants from the Swedish Diabetes Association, the Swedish Research Council, the Novo Nordisk Foundation, Eurodia (FP6-518153), the Berth von Kantzow Foundation, the Juvenile Diabetes Research Foundation, and the Family Erling-Persson Foundation. P.-O.B. is cofounder of BioCrine AB. B. L., I. B. L., and C. J. B. are consultants to BioCrine AB.	Arcaro A, 2000, MOL CELL BIOL, V20, P3817, DOI 10.1128/MCB.20.11.3817-3830.2000; Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; Barker CJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE1113, DOI 10.1152/ajpendo.00088.2002; Bouzakri K, 2008, DIABETES, V57, P1195, DOI 10.2337/db07-1469; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; Brown RA, 1997, BIOCHEM BIOPH RES CO, V233, P537, DOI 10.1006/bbrc.1997.6495; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; Elghazi L, 2006, INT J BIOCHEM CELL B, V38, P157, DOI 10.1016/j.biocel.2005.08.017; Fabre S, 2005, J IMMUNOL, V174, P4161, DOI 10.4049/jimmunol.174.7.4161; Falasca M, 2007, J BIOL CHEM, V282, P28226, DOI 10.1074/jbc.M704357200; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Hirsch E, 2007, J ENDOCRINOL, V194, P243, DOI 10.1677/JOE-07-0097; Ho LKF, 1997, BIOCHEM BIOPH RES CO, V235, P130, DOI 10.1006/bbrc.1997.6747; KARPOVA T, 2006, CURR PROTOC CYTOM, V12; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohler M, 2003, DIABETES, V52, P2943, DOI 10.2337/diabetes.52.12.2943; Krook A, 1997, J BIOL CHEM, V272, P30208, DOI 10.1074/jbc.272.48.30208; Leibiger B, 1998, P NATL ACAD SCI USA, V95, P9307, DOI 10.1073/pnas.95.16.9307; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; LEIBIGER IB, 1994, FEBS LETT, V337, P161, DOI 10.1016/0014-5793(94)80265-3; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Leibiger IB, 2008, ANNU REV NUTR, V28, P233, DOI 10.1146/annurev.nutr.28.061807.155530; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Maffucci T, 2003, EMBO J, V22, P4178, DOI 10.1093/emboj/cdg402; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; Meunier FA, 2005, MOL BIOL CELL, V16, P4841, DOI 10.1091/mbc.E05-02-0171; Misawa H, 1998, BIOCHEM BIOPH RES CO, V244, P531, DOI 10.1006/bbrc.1998.8294; Ono F, 1998, J BIOL CHEM, V273, P7731, DOI 10.1074/jbc.273.13.7731; Rozycka M, 1998, GENOMICS, V54, P569, DOI 10.1006/geno.1998.5621; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Soos MA, 2001, ARCH BIOCHEM BIOPHYS, V396, P244, DOI 10.1006/abbi.2001.2587; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; Tengholm A, 2002, CURR BIOL, V12, P1871, DOI 10.1016/S0960-9822(02)01223-X; Uhles S, 2003, J CELL BIOL, V163, P1327, DOI 10.1083/jcb.200306093; Uhles S, 2007, FASEB J, V21, P1609, DOI 10.1096/fj.06-7589com; Urso B, 1999, FEBS LETT, V460, P423, DOI 10.1016/S0014-5793(99)01388-5; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; Xavier GD, 2000, J BIOL CHEM, V275, P36269, DOI 10.1074/jbc.M006597200; Yu J, 2007, MOL ENDOCRINOL, V21, P2775, DOI 10.1210/me.2006-0473	58	88	93	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1824	1837		10.1096/fj.09-148072	http://dx.doi.org/10.1096/fj.09-148072			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20061534				2022-12-28	WOS:000278200000019
J	Tian, MZ; Schiemann, WP				Tian, Maozhen; Schiemann, William P.			PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis	FASEB JOURNAL			English	Article						angiogenesis; metastasis; prostaglandins; signal transduction	GROWTH-FACTOR-BETA; BREAST-CANCER PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; SKIN TUMOR-DEVELOPMENT; KAPPA-B ACTIVATION; PROSTAGLANDIN E-2; CYCLIC-AMP; CYCLOOXYGENASE-2 INDUCTION; APOPTOSIS PROTEIN; MOUSE SKIN	The molecular mechanisms that enable cyclooxygenase-2 (COX-2) and its mediator prostaglandin E2 (PGE2) to inhibit transforming growth factor-beta (TGF-beta) signaling during mammary tumorigenesis remain unknown. We show here that TGF-beta selectively stimulated the expression of the PGE2 receptor EP2, which increased normal and malignant mammary epithelial cell (MEC) invasion, anchorage-independent growth, and resistance to TGF-beta-induced cytostasis. Mechanistically, elevated EP2 expression in normal MECs inhibited the coupling of TGF-beta to Smad2/3 activation and plasminogen activator inhibitor-1 (PAI1) expression, while EP2 deficiency in these same MECs augmented Smad2/3 activation and PAI expression stimulated by TGF-beta. Along these lines, engineering malignant MECs to lack EP2 expression prevented their growth in soft agar, restored their cytostatic response to TGF-beta, decreased their invasiveness in response to TGF-beta, and potentiated their activation of Smad2/3 and expression of PAI stimulated by TGF-beta. More important, we show that COX-2 or EP2 deficiency both significantly decreased the growth, angiogenesis, and pulmonary metastasis of mammary tumors produced in mice. Collectively, this investigation establishes EP2 as a potent mediator of the anti-TGF-beta activities elicited by COX-2/PGE2 in normal and malignant MECs. Our findings also suggest that pharmacological targeting of EP2 receptors may provide new inroads to antagonize the oncogenic activities of TGF-beta during mammary tumorigenesis.-Tian, M., Schiemann, W. P. PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. FASEB J. 24, 1105-1116 (2010). www. fasebj. org	[Tian, Maozhen; Schiemann, William P.] Univ Colorado Denver, Dept Pharmacol, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Schiemann, WP (corresponding author), Univ Colorado Denver, Dept Pharmacol, MS-8303,Anschutz Med Campus,RC1 S Tower,Rm L18-61, Aurora, CO 80045 USA.	bill.schiemann@ucdenver.edu	tian, maozhen/F-5457-2010		National Institutes of Health [CA-114039, CA-129359]; NATIONAL CANCER INSTITUTE [R01CA114039, R01CA129359] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Paul Jedlicka for pathology help and assistance. The authors also thank the members of the W. P. S. laboratory for critical comments and reading of the manuscript. W.P.S. was supported by grants from the National Institutes of Health (CA-114039 and CA-129359).	Ansari KM, 2007, CARCINOGENESIS, V28, P2063, DOI 10.1093/carcin/bgm011; Banu SK, 2009, MOL ENDOCRINOL, V23, P1291, DOI 10.1210/me.2009-0017; Boniface K, 2009, J EXP MED, V206, P535, DOI 10.1084/jem.20082293; Bradbury DA, 2003, J BIOL CHEM, V278, P49954, DOI 10.1074/jbc.M307964200; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chang SH, 2005, PROSTAG OTH LIPID M, V76, P48, DOI 10.1016/j.prostaglandins.2004.12.001; Chang SH, 2005, CANCER RES, V65, P4496, DOI 10.1158/0008-5472.CAN-05-0129; Chell S, 2006, BBA-REV CANCER, V1766, P104, DOI 10.1016/j.bbcan.2006.05.002; Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581; Chun KS, 2007, CANCER RES, V67, P2015, DOI 10.1158/0008-5472.CAN-06-3617; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; Desai S, 2000, MOL PHARMACOL, V58, P1279, DOI 10.1124/mol.58.6.1279; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Eibl G, 2003, BIOCHEM BIOPH RES CO, V306, P887, DOI 10.1016/S0006-291X(03)01079-9; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Galliher AJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1524; Galliher-Beckley AJ, 2008, CARCINOGENESIS, V29, P244, DOI 10.1093/carcin/bgm245; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; Howe LR, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1678; Kamiyama M, 2006, ONCOGENE, V25, P7019, DOI 10.1038/sj.onc.1209694; Kuo KT, 2009, ANN SURG ONCOL, V16, P352, DOI 10.1245/s10434-008-0242-2; Lee BPL, 2009, INT IMMUNOPHARMACOL, V9, P534, DOI 10.1016/j.intimp.2009.01.023; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; Mazhar D, 2006, BRIT J CANCER, V94, P346, DOI 10.1038/sj.bjc.6602942; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nam JS, 2008, CANCER RES, V68, P3835, DOI 10.1158/0008-5472.CAN-08-0215; Neil JR, 2008, CARCINOGENESIS, V29, P2227, DOI 10.1093/carcin/bgn202; Neil JR, 2008, CANCER RES, V68, P1462, DOI 10.1158/0008-5472.CAN-07-3094; Neil JR, 2009, J BIOL CHEM, V284, P21209, DOI 10.1074/jbc.M109.018374; Nishigaki N, 1996, MOL PHARMACOL, V50, P1031; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Schiemann BJ, 2003, MOL BIOL CELL, V14, P3977, DOI 10.1091/mbc.E03-01-0001; Schiemann WP, 1999, BLOOD, V94, P2854, DOI 10.1182/blood.V94.8.2854.420k07_2854_2861; Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200; Shao JY, 2003, CANCER RES, V63, P5218; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Singh B, 2007, ONCOGENE, V26, P3789, DOI 10.1038/sj.onc.1210154; Singh-Ranger G, 2008, BREAST CANCER RES TR, V109, P189, DOI 10.1007/s10549-007-9641-5; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Subbaramaiah K, 2008, J BIOL CHEM, V283, P3433, DOI 10.1074/jbc.M705409200; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Sung YM, 2006, ONCOGENE, V25, P5507, DOI 10.1038/sj.onc.1209538; Sung YM, 2005, CANCER RES, V65, P9304, DOI 10.1158/0008-5472.CAN-05-1015; Tian MZ, 2009, TRANSL ONCOL, V2, P174, DOI 10.1593/tlo.09145; Tian M, 2009, FUTURE ONCOL, V5, P259, DOI 10.2217/14796694.5.2.259; Wang XY, 2007, MOL CARCINOGEN, V46, P912, DOI 10.1002/mc.20320; Wilkins-Port CE, 2007, CELLS TISSUES ORGANS, V185, P116, DOI 10.1159/000101312; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Yang L, 2003, J CLIN INVEST, V111, P727, DOI 10.1172/JCI200316492	54	47	50	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1105	1116		10.1096/fj.09-141341	http://dx.doi.org/10.1096/fj.09-141341			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19897661	Green Published			2022-12-28	WOS:000276462300018
J	Grundtman, C; Bruton, J; Yamada, T; Ostberg, T; Pisetsky, DS; Harris, HE; Andersson, U; Lundberg, IE; Westerblad, H				Grundtman, Cecilia; Bruton, Joseph; Yamada, Takashi; Ostberg, Therese; Pisetsky, David S.; Harris, Helena Erlandsson; Andersson, Ulf; Lundberg, Ingrid E.; Westerblad, Hakan			Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies	FASEB JOURNAL			English	Article						MHC class 1; muscle weakness; Ca2+; cytokines; muscle fatigue	GROUP BOX CHROMOSOMAL-PROTEIN-1; MHC CLASS-I; RHEUMATOID-ARTHRITIS; INCREASED-EXPRESSION; ANTIGEN-EXPRESSION; POLYMYOSITIS; DERMATOMYOSITIS; MEDIATOR; TISSUE; ACTIVATION	Idiopathic inflammatory myopathies (IIMs) are heterogeneous rheumatic disorders of unknown cause characterized by muscle weakness, inflammatory cell infiltrates, and major histocompatibility complex (MHC) class I expression on muscle fibers. The nonhistone nuclear protein alarmin high-mobility group box 1 protein (HMGB1) has been detected extranuclearly in muscle biopsies from patients with IIMs. We hypothesize that HMGB1 has a central role in the cause of muscle weakness, particularly in the early phases of IIMs. Experiments were performed on skeletal muscle fibers isolated from adult mice, which were exposed to recombinant interferon (IFN)-gamma or HMGB1. The myoplasmic free [Ca2+] was measured. Stimulation with IFN-gamma resulted in increased HMGB1 expression in muscle nuclei and the myoplasm. Exposure to HMGB1 induced a reversible up-regulation of MHC class I in the muscle fibers. However, HMGB1 exposure caused an irreversible decrease in Ca2+ release from the sarcoplasmic reticulum during fatigue, induced by repeated tetanic contractions. HMGB1 and MHC class I were frequently colocalized in the myoplasm of muscle fibers in muscle biopsies from patients with early IIMs. However, HMGB1-expressing fibers outnumbered fibers expressing MHC class I. Our data indicate that HMGB1 could be an early inducer of skeletal muscle dysfunction in IIMs.-Grundtman, C., Bruton, J., Yamada, T., Ostberg, T., Pisetsky, D. S., Harris, H. E., Andersson, U., Lundberg, I. E., Westerblad, H. Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J. 24, 570-578 (2010). www.fasebj.org	[Grundtman, Cecilia; Ostberg, Therese; Harris, Helena Erlandsson; Lundberg, Ingrid E.] Karolinska Univ Hosp Solna, Dept Med, Rheumatol Unit, Stockholm, Sweden; [Ostberg, Therese; Andersson, Ulf] Karolinska Univ Hosp Solna, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Bruton, Joseph; Yamada, Takashi; Westerblad, Hakan] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden; [Pisetsky, David S.] Duke Univ, Med Ctr, Div Rheumatol & Immunol, Durham, NC USA; [Pisetsky, David S.] Durham Vet Adm Hosp, Med Res Serv, Durham, NC USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Duke University	Grundtman, C (corresponding author), Innsbruck Med Univ, Lab Autoimmun, Div Expt Pathophysiol & Immunol, Schopfstr 41, A-6020 Innsbruck, Austria.	cecilia.grundtman@i-med.ac.at	Yamada, Takashi/U-8443-2019; Yamada, Takashi/AAZ-6212-2021; Andersson, Ulf/ABD-5162-2021	Yamada, Takashi/0000-0003-1797-3880; Yamada, Takashi/0000-0003-1797-3880; Andersson, Ulf/0000-0003-0316-3860; Bruton, Joseph/0000-0002-6985-099X; Lundberg, Ingrid/0000-0002-6068-9212; Westerblad, Hakan/0000-0002-8180-3029	Myositis Association; Swedish Research Council; Stockholm County Council; Karolinska Institutet; Swedish Rheumatism Association; King Gustaf V 80 Year Foundation; Freemason Lodge Barnhuset, Stockholm; European Union [LSH-018661]; Lupus Research Institute; Veterans Affairs Merit Review; Michele Foundation	Myositis Association; Swedish Research Council(Swedish Research CouncilEuropean Commission); Stockholm County Council(Stockholm County Council); Karolinska Institutet(Karolinska Institutet); Swedish Rheumatism Association; King Gustaf V 80 Year Foundation; Freemason Lodge Barnhuset, Stockholm; European Union(European Commission); Lupus Research Institute; Veterans Affairs Merit Review(US Department of Veterans Affairs); Michele Foundation	This study was supported by grants from the Myositis Association; the Swedish Research Council; the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and the Karolinska Institutet; the Swedish Rheumatism Association; the King Gustaf V 80 Year Foundation; Funds at the Karolinska Institutet; Freemason Lodge Barnhuset, Stockholm; the European Union Sixth Framework Programme (project AutoCure; LSH-018661); the Lupus Research Institute; Veterans Affairs Merit Review; and the Michele Foundation. The authors thank Associate Professor Inger Nennesmo for the histopathology evaluation of the muscle biopsies.	af Klint E, 2005, ARTHRITIS RHEUM-US, V52, P3880, DOI 10.1002/art.21488; Allen DG, 2008, J APPL PHYSIOL, V104, P296, DOI 10.1152/japplphysiol.00908.2007; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Andrade FH, 1998, J PHYSIOL-LONDON, V509, P565, DOI 10.1111/j.1469-7793.1998.565bn.x; Andrassy M, 2008, CIRCULATION, V117, P3216, DOI 10.1161/CIRCULATIONAHA.108.769331; ARAHATA K, 1984, ANN NEUROL, V16, P193, DOI 10.1002/ana.410160206; Aydin J, 2009, HUM MOL GENET, V18, P278, DOI 10.1093/hmg/ddn355; BOHAN A, 1975, NEW ENGL J MED, V292, P403, DOI 10.1056/NEJM197502202920807; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; Campana L, 2008, CURR OPIN IMMUNOL, V20, P518, DOI 10.1016/j.coi.2008.04.012; Cea G, 2002, BRAIN, V125, P1635, DOI 10.1093/brain/awf163; De Mori R, 2007, ARTERIOSCL THROM VAS, V27, P2377, DOI 10.1161/ATVBAHA.107.153429; Dorph C, 2001, J RHEUMATOL, V28, P1591; Ek M, 2006, ARTHRITIS RHEUM, V54, P2289, DOI 10.1002/art.21969; EMSLIESMITH AM, 1989, HUM PATHOL, V20, P224, DOI 10.1016/0046-8177(89)90128-7; ENGEL AG, 1990, RES P ARNMD, V68, P141; Englund P, 2002, ARTHRITIS RHEUM, V46, P1044, DOI 10.1002/art.10140; Englund P, 2001, AM J PATHOL, V159, P1263, DOI 10.1016/S0002-9440(10)62513-8; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; Grundtman C, 2008, ARTHRITIS RHEUM, V58, P3224, DOI 10.1002/art.23884; Grundtman C, 2007, ARTHRITIS RHEUM, V56, P674, DOI 10.1002/art.22388; Hamada T, 2008, ARTHRITIS RHEUM-US, V58, P2675, DOI 10.1002/art.23729; HOHLFELD R, 1991, NEUROLOGY, V41, P2015, DOI 10.1212/WNL.41.12.2015-c; ISENBERG DA, 1986, CLIN EXP IMMUNOL, V63, P450; Jiang W, 2008, ANN RHEUM DIS, V67, P727, DOI 10.1136/ard.2007.074484; Kokkola R, 2002, ARTHRITIS RHEUM, V46, P2598, DOI 10.1002/art.10540; Levy RM, 2007, AM J PHYSIOL-REG I, V293, pR1538, DOI 10.1152/ajpregu.00272.2007; Liu YW, 1997, AM J PHYSIOL-CELL PH, V273, pC1915, DOI 10.1152/ajpcell.1997.273.6.C1915; Lundberg I, 1997, ARTHRITIS RHEUM, V40, P865, DOI 10.1002/art.1780400514; Martins AS, 2008, J PHYSIOL-LONDON, V586, P197, DOI 10.1113/jphysiol.2007.146571; Nagaraju K, 2005, ARTHRITIS RHEUM, V52, P1824, DOI 10.1002/art.21103; Nagaraju K, 1998, CLIN EXP IMMUNOL, V113, P407; Nagaraju K, 1999, CLIN IMMUNOL, V92, P161, DOI 10.1006/clim.1999.4743; Nyberg P, 2000, J RHEUMATOL, V27, P940; Olsen NJ, 1997, ARTHRIT CARE RES, V10, P200, DOI 10.1002/art.1790100308; PEDROL E, 1995, CLIN NEUROPATHOL, V14, P179; Peltz ED, 2009, SHOCK, V32, P17, DOI 10.1097/SHK.0b013e3181997173; Plomgaard P, 2005, EXERC IMMUNOL REV, V11, P53; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; Popovic K, 2005, ARTHRITIS RHEUM, V52, P3639, DOI 10.1002/art.21398; Porto A, 2006, FASEB J, V20, P2565, DOI 10.1096/fj.06-5867fje; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Reid MB, 2001, J APPL PHYSIOL, V90, P724, DOI 10.1152/jappl.2001.90.2.724; Salomonsson S, 2009, MUSCLE NERVE, V39, P674, DOI 10.1002/mus.21129; Sundberg E, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2387; Taniguchi N, 2003, ARTHRITIS RHEUM, V48, P971, DOI 10.1002/art.10859; Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457; Tzeng HP, 2008, AM J PHYSIOL-HEART C, V294, pH1490, DOI 10.1152/ajpheart.00910.2007; Ulfgren AK, 2004, ARTHRITIS RHEUM, V50, P1586, DOI 10.1002/art.20220; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248	50	61	62	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					570	578		10.1096/fj.09-144782	http://dx.doi.org/10.1096/fj.09-144782			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19837864				2022-12-28	WOS:000274045000024
J	Varani, K; Vincenzi, F; Tosi, A; Gessi, S; Casetta, I; Granieri, G; Fazio, P; Leung, E; MacLennan, S; Granieri, E; Borea, PA				Varani, Katia; Vincenzi, Fabrizio; Tosi, Alice; Gessi, Stefania; Casetta, Ilaria; Granieri, Gino; Fazio, Patrik; Leung, Edward; MacLennan, Stephen; Granieri, Enrico; Borea, Pier Andrea			A(2A) adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease	FASEB JOURNAL			English	Article						D-2 dopamine receptors; human putamen; human lymphocytes and neutrophils	PERIPHERAL-BLOOD CELLS; INFLAMMATORY CYTOKINES; BINDING; EXPRESSION; CAFFEINE; DOPAMINE; ISTRADEFYLLINE; ASSOCIATION; ANTAGONISTS; MEMBRANE	The antagonistic interaction between adenosine and dopamine receptors could have important pathophysiological and therapeutic implications in Parkinson's disease (PD). The primary aim of this study was to investigate the expression, affinity, and density of A(1), A(2A), A(2B), and A(3) adenosine receptors (ARs) and D-2 dopamine receptors (D(2)Rs) in PD. An increase in A(2A)AR density in putamen was found. The presence and functionality of ARs in human lymphocyte and neutrophil membranes from patients with PD revealed a specific A(2A)AR alteration compared with healthy subjects. A statistically significant linear correlation among the A(2A)AR density, functionality, or tumor necrosis factor-alpha (TNF-alpha) levels and Unified Parkinson's Disease Rating Scale (UPDRS) motor score was reported. Adenosine concentration and TNF-alpha levels were increased in plasma of patients with PD. In rat adrenal pheochromocytoma (PC12) cells, a widely useful model, adenosine antagonists decreased dopamine uptake, and an opposite effect was mediated by A(2A) agonists. This is the first report showing the presence of an A(2A)AR alteration in putamen in PD that mirrors a similar up-regulation in human peripheral blood cells. Moreover, the correlation found between A(2A)AR density or A(2A) agonist potency and UPDRS motor score highlights the central role of A(2A)ARs in the pharmacological treatment of PD.-Varani, K., Vincenzi, F., Tosi, A., Gessi, S., Casetta, I., Granieri, G., Fazio, P., Leung, E., MacLennan, S., Granieri, E., Borea, P. A. A(2A) adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. FASEB J. 24, 587-598 (2010). www.fasebj.org	[Borea, Pier Andrea] Univ Ferrara, Dept Clin & Expt Med, Pharmacol Unit, Pharmacol Sect, I-44100 Ferrara, Italy; [Granieri, Gino] Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy; [Casetta, Ilaria; Fazio, Patrik; Granieri, Enrico] Univ Hosp Ferrara, Neurol Clin, Ferrara, Italy; [Leung, Edward; MacLennan, Stephen] King Pharmaceut Inc, Res & Dev, Cary, NC USA	University of Ferrara; University of Ferrara; University of Ferrara; Arcispedale Sant'Anna; Pfizer	Borea, PA (corresponding author), Univ Ferrara, Dept Clin & Expt Med, Pharmacol Unit, Pharmacol Sect, Via Fossato Mortara 17-19, I-44100 Ferrara, Italy.	bpa@unife.it	Gessi, Stefania/AAS-3844-2020; Vincenzi, Fabrizio/E-7925-2013; Casetta, Ilaria/K-5289-2016	Casetta, Ilaria/0000-0003-4099-8875; Granieri, Enrico/0000-0003-4038-3192; Vincenzi, Fabrizio/0000-0002-5027-1699; Fazio, Patrik/0000-0002-1863-1922; Gessi, Stefania/0000-0002-2197-5611	King Pharmaceuticals; Cassa di Risparmio di Ferrara (Ferrara, Italy)	King Pharmaceuticals; Cassa di Risparmio di Ferrara (Ferrara, Italy)	This study was supported by King Pharmaceuticals and Cassa di Risparmio di Ferrara (Ferrara, Italy).	Boison D, 2008, CURR OPIN PHARMACOL, V8, P2, DOI 10.1016/j.coph.2007.09.002; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODDE OE, 1987, TRENDS PHARMACOL SCI, V8, P403, DOI 10.1016/0165-6147(87)90108-8; Burnstock G, 2008, NAT REV DRUG DISCOV, V7, P575, DOI 10.1038/nrd2605; Calon F, 2004, BRAIN, V127, P1075, DOI 10.1093/brain/awh128; Capecchi PL, 2005, J CARD FAIL, V11, P67, DOI 10.1016/j.cardfail.2004.04.005; CAPECCHI PL, 2005, J CARD FAIL, V67, pA2; Cieslak M, 2008, PURINERG SIGNAL, V4, P305, DOI 10.1007/s11302-008-9100-8; Daly JW, 2007, CELL MOL LIFE SCI, V64, P2153, DOI 10.1007/s00018-007-7051-9; Fahn S., 1987, RECENT DEV PARKINSON, P153; Ferre S, 2008, CURR PHARM DESIGN, V14, P1468, DOI 10.2174/138161208784480108; Forrest CM, 2005, CLIN EXP RHEUMATOL, V23, P89; Fredholm BB, 2007, PROG NEUROBIOL, V83, P263, DOI 10.1016/j.pneurobio.2007.07.005; Fuxe K, 2007, MOVEMENT DISORD, V22, P1990, DOI 10.1002/mds.21440; Gartlon J, 2006, TOXICOL IN VITRO, V20, P1569, DOI 10.1016/j.tiv.2006.07.009; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; Gessi S, 2004, CLIN CANCER RES, V10, P5895, DOI 10.1158/1078-0432.CCR-1134-03; GESSI S, 2005, MOL PHARM, V67, P1; Golembiowska K, 2008, PHARMACOL REP, V60, P319; Hashimoto W, 2005, LIFE SCI, V76, P1603, DOI 10.1016/j.lfs.2004.08.029; Hasko G, 2008, J LEUKOCYTE BIOL, V83, P447, DOI 10.1189/jlb.0607359; HAUSER RA, 2007, MOV DIS, V3, P359; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; HUTCHISON KA, 1990, BIOCHEMISTRY-US, V29, P5138, DOI 10.1021/bi00473a020; Jankovic J, 2008, ANN NEUROL, V63, P267, DOI 10.1002/ana.21348; Jenner P, 2005, EXPERT OPIN INV DRUG, V14, P729, DOI 10.1517/13543784.14.6.729; KADOWAKI K, 1990, NEUROENDOCRINOLOGY, V52, P256, DOI 10.1159/000125595; Khoa ND, 2006, MOL PHARMACOL, V69, P1311, DOI 10.1124/mol.105.016857; Khoa ND, 2001, J IMMUNOL, V167, P4026, DOI 10.4049/jimmunol.167.7.4026; MARTINEZMIR MI, 1991, NEUROSCIENCE, V42, P697, DOI 10.1016/0306-4522(91)90038-P; Merighi S, 2002, J INVEST DERMATOL, V119, P923, DOI 10.1046/j.1523-1747.2002.00111.x; Morello S, 2006, J IMMUNOL, V177, P7173, DOI 10.4049/jimmunol.177.10.7173; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nagatsu T, 2006, CELL MOL NEUROBIOL, V26, P781, DOI 10.1007/s10571-006-9061-9; NQUYEN DK, 2003, J IMMUNOL, V171, P3991; Orr CF, 2002, PROG NEUROBIOL, V68, P325, DOI 10.1016/S0301-0082(02)00127-2; Pahwa Rajesh, 2006, J Am Med Dir Assoc, V7, P4; Pearson T, 2001, J NEUROSCI, V21, P2298, DOI 10.1523/JNEUROSCI.21-07-02298.2001; Petzer JP, 2009, NEUROTHERAPEUTICS, V6, P141, DOI 10.1016/j.nurt.2008.10.035; Pinna A, 2007, SYNAPSE, V61, P606, DOI 10.1002/syn.20410; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; Saint-Hilaire Marie-Helene, 2008, Med Health R I, V91, P136; Schwarzschild MA, 2006, TRENDS NEUROSCI, V29, P647, DOI 10.1016/j.tins.2006.09.004; Stoessl AJ, 2008, EXPERT OPIN THER TAR, V12, P425, DOI [10.1517/14728222.12.4.425 , 10.1517/14728222.12.4.425]; TRAMPUS M, 1991, EUR J PHARMACOL, V194, P17, DOI 10.1016/0014-2999(91)90118-A; vanderPloeg I, 1996, N-S ARCH PHARMACOL, V353, P250, DOI 10.1007/BF00168626; Varani K, 2000, MOL PHARMACOL, V57, P968; Varani K, 2003, FASEB J, V17, P2148, DOI 10.1096/fj.03-0079fje; Whitton PS, 2007, BRIT J PHARMACOL, V150, P963, DOI 10.1038/sj.bjp.0707167	49	92	97	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					587	598		10.1096/fj.09-141044	http://dx.doi.org/10.1096/fj.09-141044			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19776336				2022-12-28	WOS:000274045000026
J	Allington, TM; Galliher-Beckley, AJ; Schiemann, WP				Allington, Tressa M.; Galliher-Beckley, Amy J.; Schiemann, William P.			Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors	FASEB JOURNAL			English	Article						EMT; matrix metalloproteinases; organotypic cultures; Imatinib; signal transduction	EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER CELLS; PHASE-II TRIAL; MATRIX-METALLOPROTEINASE INHIBITORS; IMATINIB MESYLATE; TGF-BETA; C-ABL; TYROSINE KINASE; PROSTATE-CANCER; BIOCHEMICAL RELAPSE	Transforming growth factor-beta (TGF-beta) is a ubiquitous cytokine with dual roles in tumor suppression and promotion, and these dichotomous functions have frustrated the development of therapies targeting oncogenic signaling by TGF-beta. In comparison, Abl is well established as an initiator of hematopoietic cancers; however, a clear role for Abl in regulating solid tumor development remains elusive. Here, we investigated the role of Abl in TGF-beta-mediated epithelial-mesenchymal transition (EMT) in normal and metastatic mammary epithelial cells (MECs). In doing so, we identified Abl as an essential regulator of MEC morphology and showed that Abl inactivation was sufficient to induce phenotypic and transcriptional EMT in normal MECs. Increasing Abl activity in metastatic MECs resulted in their complete morphological reversion, restored their cytostatic response to TGF-beta, and blocked their secretion of matrix metalloproteinases induced by TGF-beta. Constitutively active Abl expression blocked TGF-beta-responsive mammary tumor growth in mice, while Imatinib therapy afforded no clinical benefit in mice bearing mammary tumors. Collectively, this investigation establishes Abl as a potent mediator of MEC identity, and as a suppressor of oncogenic TGF-beta signaling during mammary tumorigenesis. Notably, our findings strongly caution against the use of pharmacological Abl antagonists in the treatment of developing and progressing mammary tumors.-Allington, T. M., Galliher-Beckley, A. J., Schiemann, W. P. Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. FASEB J. 23, 4231-4243 (2009). www.fasebj.org	[Allington, Tressa M.; Galliher-Beckley, Amy J.; Schiemann, William P.] Univ Colorado Denver, Dept Pharmacol, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Schiemann, WP (corresponding author), Univ Colorado Denver, Dept Pharmacol, MS-8303,Anschutz Med Campus,RC1 S Tower,Rm L18-61, Aurora, CO 80045 USA.	bill.schiemann@ucdenver.edu			National Institutes of Health [CA129359]; Komen Foundation [BCTR0706967]; Department of Defense Predoctoral Training Fellowship [BC083323]; NATIONAL CANCER INSTITUTE [R01CA129359] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Komen Foundation(Susan G. Komen Breast Cancer Foundation); Department of Defense Predoctoral Training Fellowship(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Tony Hunter (Salk Institute, La Jolla, CA, USA) for providing wild-type, kinase-dead, and constitutively-active murine c-Abl (type IV) constructs. We also thank members of the W. P. S. laboratory for critical comments and reading of the manuscript. Research support was provided in part by the National Institutes of Health (CA129359) and the Komen Foundation (BCTR0706967) to W. P. S., and by the Department of Defense Predoctoral Training Fellowship (BC083323) to T. M. A.	ALBINI A, 1987, CANCER RES, V47, P3239; Bajaj GK, 2007, UROLOGY, V69, P526, DOI 10.1016/j.urology.2006.12.006; Benson JR, 2004, LANCET ONCOL, V5, P229, DOI 10.1016/S1470-2045(04)01426-3; Bhattacharyya S, 2009, ONCOGENE, V28, P1285, DOI 10.1038/onc.2008.479; Bissell MJ, 2005, COLD SH Q B, V70, P343, DOI 10.1101/sqb.2005.70.013; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544; Chen J, 2006, CANCER LETT, V233, P328, DOI 10.1016/j.canlet.2005.03.027; Chew HK, 2008, CLIN BREAST CANCER, V8, P511, DOI 10.3816/CBC.2008.n.062; Cristofanilli M, 2008, ANN ONCOL, V19, P1713, DOI 10.1093/annonc/mdn352; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Dumont N, 2000, BREAST CANCER RES, V2, P125, DOI 10.1186/bcr44; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; Erler JT, 2009, CLIN EXP METASTAS, V26, P35, DOI 10.1007/s10585-008-9209-8; Frasca F, 2001, ONCOGENE, V20, P3845, DOI 10.1038/sj.onc.1204531; Galliher-Beckley AJ, 2008, CARCINOGENESIS, V29, P244, DOI 10.1093/carcin/bgm245; Gharibo M, 2008, PANCREAS, V36, P341, DOI 10.1097/MPA.0b013e31815d50f9; Hamer G, 2001, ONCOGENE, V20, P4298, DOI 10.1038/sj.onc.1204568; Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Kominsky SL, 2008, CLIN EXP METASTAS, V25, P865, DOI 10.1007/s10585-008-9202-2; Kumar S, 2009, CANCER METAST REV, V28, P113, DOI 10.1007/s10555-008-9173-4; Lee YH, 2008, CARCINOGENESIS, V29, P2243, DOI 10.1093/carcin/bgn199; Lemaitre Vincent, 2006, Birth Defects Research, V78, P1, DOI 10.1002/bdrc.20065; Li LS, 2008, J BIOL CHEM, V283, P21394, DOI 10.1074/jbc.M709954200; Lin AM, 2007, CLIN GENITOURIN CANC, V5, P323, DOI 10.3816/CGC.2007.n.011; Lin AM, 2006, BJU INT, V98, P763, DOI 10.1111/j.1464-410X.2006.06396.x; Lin J, 2008, ONCOGENE, V27, P4385, DOI 10.1038/onc.2008.86; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; Modi S, 2005, BREAST CANCER RES TR, V90, P157, DOI 10.1007/s10549-004-3974-0; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Neil JR, 2008, CANCER RES, V68, P1462, DOI 10.1158/0008-5472.CAN-07-3094; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Ongkeko WM, 2006, LARYNGOSCOPE, V116, P1390, DOI 10.1097/01.mlg.0000225941.60901.0f; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Przybylo JA, 2007, INT J BIOCHEM CELL B, V39, P1082, DOI 10.1016/j.biocel.2007.03.002; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Radisky Derek C, 2008, Proc Am Thorac Soc, V5, P316, DOI 10.1513/pats.200711-166DR; Schiemann BJ, 2003, MOL BIOL CELL, V14, P3977, DOI 10.1091/mbc.E03-01-0001; Schiemann WP, 2007, EXPERT REV ANTICANC, V7, P609, DOI 10.1586/14737140.7.5.609; Schiemann WP, 2002, J BIOL CHEM, V277, P27367, DOI 10.1074/jbc.M200148200; Sinpitaksakul SN, 2008, BIOCHEM BIOPH RES CO, V371, P713, DOI 10.1016/j.bbrc.2008.04.128; Sirvent A, 2007, ONCOGENE, V26, P7313, DOI 10.1038/sj.onc.1210543; Skiles JW, 2004, CURR MED CHEM, V11, P2911, DOI 10.2174/0929867043364018; Skiles JW, 2001, CURR MED CHEM, V8, P425, DOI 10.2174/0929867013373417; Soverini S, 2008, EXPERT REV ANTICANC, V8, P853, DOI 10.1586/14737140.8.6.853; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Tian M, 2009, FUTURE ONCOL, V5, P259, DOI 10.2217/14796694.5.2.259; Wagner MW, 2008, J BIOL CHEM, V283, P21382, DOI 10.1074/jbc.M709953200; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wakefield LM, 2001, J MAMMARY GLAND BIOL, V6, P67, DOI 10.1023/A:1009568532177; Wang JYJ, 2006, NAT CELL BIOL, V8, P785, DOI 10.1038/ncb0806-785; Wang SN, 2005, FASEB J, V19, P1, DOI 10.1096/fj.04-2370com; Wilkes MC, 2006, J BIOL CHEM, V281, P27846, DOI 10.1074/jbc.M603721200; Woodring PJ, 2004, J CELL BIOL, V165, P493, DOI 10.1083/jcb.200312171; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yan CH, 2007, J CELL PHYSIOL, V211, P19, DOI 10.1002/jcp.20948; Zandy NL, 2008, CELL CYCLE, V7, P444, DOI 10.4161/cc.7.4.5452	68	48	51	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4231	4243		10.1096/fj.09-138412	http://dx.doi.org/10.1096/fj.09-138412			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19690215	Green Published			2022-12-28	WOS:000272193700018
J	Everitt, AB; Seymour, VAL; Curmi, J; Laver, DR; Gage, PW; Tierney, ML				Everitt, Andrea B.; Seymour, Victoria A. L.; Curmi, John; Laver, Derek R.; Gage, Peter W.; Tierney, M. Louise			Protein interactions involving the gamma 2 large cytoplasmic loop of GABA(A) receptors modulate conductance	FASEB JOURNAL			English	Article						single-channel conductance; diazepam; MA helix; competitor peptide	CULTURED HIPPOCAMPAL-NEURONS; SINGLE-CHANNEL CONDUCTANCE; NICOTINIC ACETYLCHOLINE-RECEPTORS; ACID TYPE-A; AMINOBUTYRIC-ACID; CHLORIDE CHANNELS; CROSS-TALK; GATED CHANNELS; SUBUNIT; GABARAP	Native GABA(A) channels display a single-channel conductance ranging between similar to 10 and 90 pS. Diazepam increases the conductance of some of these native channels but never those of recombinant receptors, unless they are coexpressed with GABARAP. This trafficking protein clusters recombinant receptors in the membrane, suggesting that high-conductance channels arise from receptors that are at locally high concentrations. The amphipathic (MA) helix that is present in the large cytoplasmic loop of every subunit of all ligand-gated ion channels mediates protein-protein interactions. Here we report that when applied to inside-out patches, a peptide mimicking the MA helix of the gamma 2 subunit (gamma(381-403)) of the GABA(A) receptor abrogates the potentiating effect of diazepam on both endogenous receptors and recombinant GABA(A) receptors coexpressed with GABARAP, by substantially reducing their conductance. The protein interaction disrupted by the peptide did not involve GABARAP, because a shorter peptide (gamma(386-403)) known to compete with the gamma 2-GABARAP interaction did not affect the conductance of recombinant alpha beta gamma receptors coexpressed with GABARAP. The requirement for receptor clustering and the fact that the gamma 2 MA helix is able to self-associate support a mechanism whereby adjacent GABA(A) receptors interact via their gamma 2-subunit MA helices, altering ion permeation through each channel. Alteration of ion-channel function arising from dynamic interactions between ion channels of the same family has not been reported previously and highlights a novel way in which inhibitory neurotransmission in the brain may be differentially modulated.-Everitt, A. B., Seymour, V. A. L., Curmi, J., Laver, D. R., Gage, P. W., Tierney, M. L. Protein interactions involving the gamma 2 large cytoplasmic loop of GABAA receptors modulate conductance. FASEB J. 23, 4361-4369 (2009). www.fasebj.org	[Tierney, M. Louise] Australian Natl Univ, Div Mol Biosci, John Curtin Sch Med Res, Struct Biol Programme, Canberra, ACT 0200, Australia; [Laver, Derek R.] Univ Newcastle, Sch Biomed Sci, Newcastle, NSW 2308, Australia; [Laver, Derek R.] Hunter Med Res Inst, Newcastle, NSW, Australia	Australian National University; John Curtin School of Medical Research; University of Newcastle; Hunter Medical Research Institute; University of Newcastle	Tierney, ML (corresponding author), Australian Natl Univ, Div Mol Biosci, John Curtin Sch Med Res, Struct Biol Programme, Bldg 54,Garran Rd, Canberra, ACT 0200, Australia.	louise.tierney@anu.edu.au			National Health and Medical Research Council [418027]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	The authors acknowledge the foresight and contribution made by the late Peter W. Gage. We thank P.J. Milburn and S. M. Howitt for comments on the manuscript. This work was supported by a National Health and Medical Research Council grant to M. L. T. and D. R. L. (418027).	ANGELOTTI TP, 1993, J NEUROSCI, V13, P1429; Boue-Grabot E, 2004, J BIOL CHEM, V279, P52517, DOI 10.1074/jbc.M410223200; Boue-Grabot E, 2004, J BIOL CHEM, V279, P6967, DOI 10.1074/jbc.M307772200; Boue-Grabot E, 2003, J NEUROSCI, V23, P1246, DOI 10.1523/JNEUROSCI.23-04-01246.2003; Carland JE, 2009, J BIOL CHEM, V284, P2023, DOI 10.1074/jbc.M806618200; Castillo M, 2005, J BIOL CHEM, V280, P27062, DOI 10.1074/jbc.M503746200; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Christie SB, 2006, MOL CELL NEUROSCI, V31, P1, DOI 10.1016/j.mcn.2005.08.014; Christie SB, 2002, J NEUROSCI, V22, P684, DOI 10.1523/JNEUROSCI.22-03-00684.2002; CURMI JP, 1993, J MEMBRANE BIOL, V136, P273; Eghbali M, 2000, MOL PHARMACOL, V58, P463, DOI 10.1124/mol.58.3.463; Eghbali M, 2003, EUR J PHARMACOL, V468, P75, DOI 10.1016/S0014-2999(03)01641-8; Eghbali M, 1997, NATURE, V388, P71, DOI 10.1038/40404; Everitt AB, 2004, J BIOL CHEM, V279, P21701, DOI 10.1074/jbc.M312806200; FATIMASHAD K, 1992, P ROY SOC B-BIOL SCI, V250, P99, DOI 10.1098/rspb.1992.0136; GAGE PW, 1994, P ROY SOC B-BIOL SCI, V255, P167, DOI 10.1098/rspb.1994.0024; Gaul S, 2007, J STEROID BIOCHEM, V104, P35, DOI 10.1016/j.jsbmb.2006.09.042; Glykys J, 2008, J NEUROSCI, V28, P1421, DOI 10.1523/JNEUROSCI.4751-07.2008; GRAY R, 1985, J NEUROPHYSIOL, V54, P134, DOI 10.1152/jn.1985.54.1.134; Guyon A, 1999, J PHYSIOL-LONDON, V516, P719, DOI 10.1111/j.1469-7793.1999.0719u.x; Hales TG, 2006, J BIOL CHEM, V281, P8062, DOI 10.1074/jbc.M513222200; Higgins MK, 2002, EMBO J, V21, P2087, DOI 10.1093/emboj/21.9.2087; HORN R, 1987, BIOPHYS J, V51, P255, DOI 10.1016/S0006-3495(87)83331-3; Kawaguchi SY, 2007, J NEUROSCI, V27, P6788, DOI 10.1523/JNEUROSCI.1981-07.2007; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; Khakh BS, 2000, NATURE, V406, P405, DOI 10.1038/35019066; Kobertz WR, 2000, BIOCHEMISTRY-US, V39, P10347, DOI 10.1021/bi001292j; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Luu T, 2005, J MEMBRANE BIOL, V205, P17, DOI 10.1007/s00232-005-0759-2; Luu T, 2006, J BIOL CHEM, V281, P35699, DOI 10.1074/jbc.M605590200; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Marsden KC, 2007, J NEUROSCI, V27, P14326, DOI 10.1523/JNEUROSCI.4433-07.2007; Nusser Z, 1998, J NEUROSCI, V18, P1693; Nymann-Andersen J, 2002, J NEUROCHEM, V80, P815, DOI 10.1046/j.0022-3042.2002.00762.x; Nymann-Andersen J, 2002, J NEUROCHEM, V83, P1164, DOI 10.1046/j.1471-4159.2002.01222.x; ROGERS CJ, 1994, J PHYSIOL-LONDON, V475, P69, DOI 10.1113/jphysiol.1994.sp020050; Sato C, 2001, NATURE, V409, P1047, DOI 10.1038/35059098; Seymour VAL, 2009, J MEMBRANE BIOL, V227, P111, DOI 10.1007/s00232-008-9150-4; SIGEL E, 1988, J NEUROSCI, V8, P289; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; Tierney ML, 2008, INT J BIOCHEM CELL B, V40, P968, DOI 10.1016/j.biocel.2007.10.029; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264	44	16	16	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2009	23	12					4361	4369		10.1096/fj.09-137042	http://dx.doi.org/10.1096/fj.09-137042			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19703932	Green Published			2022-12-28	WOS:000272193700031
J	Sundaram, S; Roy, SK; Ambati, BK; Kompella, UB				Sundaram, Sneha; Roy, Shyamal K.; Ambati, Balamurali K.; Kompella, Uday B.			Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium	FASEB JOURNAL			English	Article						deslorelin; transferrin; anti-VEGF intraceptor; prostate cancer; gene therapy; poly-L-lactide-co-glycolide	GONADOTROPIN-RELEASING-HORMONE; HUMAN PROSTATE CANCERS; TRANSFERRIN-RECEPTOR; DRUG-DELIVERY; LHRH-RECEPTOR; BREAST-CANCER; GROWTH-FACTOR; IN-VITRO; EXPRESSION; TRANSPORT	The objective of this study was to determine whether surface-modified nanoparticles enhance permeability across nasal mucosa, while retaining the effectiveness of the payload. The uptake and permeability of polystyrene nanoparticles (PS-NPs; Fluo-Spheres) was evaluated across the various regions of the bovine nasal epithelia following conjugation with deslorelin and transferrin. Uptake and transport of PS-NPs, deslorelin-PS-NPs, and transferrin-PS-NPs exhibited regional differences in the order: inferior turbinate posterior (ITP) > medium turbinate posterior (MTP) > medium turbinate anterior (MTA). Uptake and transport also exhibited directionality and temperature dependence in these tissues. Further, uptake as well as transport of functionalized nanoparticles could be inhibited by excess free functionalizing ligand. Confocal microscopy indicated the presence of functionalized nanoparticles in respiratory epithelial cells, as well as other cell types of the nasal tissue. We chose the ITP region for further studies with deslorelin or transferrin-conjugated poly-L-lactide-co-glycolide nanoparticles (PLGA-NPs) encapsulating an anti-VEGF intraceptor (Flt23k) plasmid. Transport of the nanoparticles, as well as the plasmid from the nanoparticles, exhibited the following order: transferrin-PLGA-NPs > deslorelin-PLGA-NPs > PLGA-NPs >> plasmid. The ability of the nanoparticles transported across the nasal tissue to retain the effectiveness of the Flt23k plasmid was evaluated by measuring transfection efficiency (percentage of cells expressing GFP) and VEGF inhibition in LNCaP and PC-3 prostate cancer cells. Transfection efficiencies and VEGF inhibition in LNCaP and PC-3 cells exhibited the following trend: transferrin-PLGA-NPs >= deslorelin-PLGA-NPs > PLGA-NPs >> plasmid. Further, functionalized nanoparticles exhibited transfection efficiencies and VEGF inhibition significantly superior compared with the routinely used transfecting agent, lipofectamine. Formulating plasmids into nanoparticulate delivery systems enhances the transnasal delivery and gene therapy at remote target cancer cells, which can be further enhanced by nanoparticle functionalization with deslorelin or transferrin.-Sundaram, S., Roy, S. K., Ambati, B. K., Kompella, U. B. Surface functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. FASEB J. 23, 3752-3765 (2009). www.fasebj.org	[Sundaram, Sneha; Kompella, Uday B.] Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE USA; [Roy, Shyamal K.] Univ Nebraska, Med Ctr, Dept Obstet & Gynecol, Omaha, NE USA; [Roy, Shyamal K.] Univ Nebraska, Med Ctr, Dept Cellular & Integrat Physiol, Omaha, NE USA; [Sundaram, Sneha; Kompella, Uday B.] Univ Colorado Denver, Dept Pharmaceut Sci, Denver, CO USA; [Ambati, Balamurali K.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Utah System of Higher Education; University of Utah	Kompella, UB (corresponding author), Univ Colorado Denver, Dept Pharmaceut Sci, 12700 E 19th Ave, Aurora, CO 80045 USA.	uday.kompella@ucdenver.edu	Sundaram, Sneha/G-4607-2012; Kompella, U/C-9789-2011		U.S. National Institutes of Health [DK064172, EY013842]; Unviersity of Nebraska Medical Center (UNMC) Bukey Fellowship; American Heart Association; NATIONAL EYE INSTITUTE [R03EY013842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064172] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Unviersity of Nebraska Medical Center (UNMC) Bukey Fellowship; American Heart Association(American Heart Association); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by U.S. National Institutes of Health grants DK064172 and EY013842. S. S. was supported by a Unviersity of Nebraska Medical Center (UNMC) Bukey Fellowship and a Predoctoral Fellowship from the American Heart Association. We thank Prof. Ming-Fong Lin (Department of Biochemistry and Molecular Biology, UNMC) for kindly providing us with the prostate cancer cell lines used in this study. We thank Janice Taylor of the Confocal Laser Scanning Microscopy Core Facility at UNMC, which is supported by the Nebraska Research Initiative, for providing assistance with confocal microscopy. We thank Tom Bargar of the Electron Microscopy Facility for his assistance in obtaining nanoparticle images. We thank the Flow Cytometry Core Facility for assistance in FACS analysis for nanoparticle uptake.	Apel A, 2009, EXP CELL RES, V315, P498, DOI 10.1016/j.yexcr.2008.11.013; Bandi N, 2002, EUR J PHARMACOL, V437, P9, DOI 10.1016/S0014-2999(02)01267-0; BERGER H, 1991, REGUL PEPTIDES, V33, P299, DOI 10.1016/0167-0115(91)90232-6; Brooking J, 2001, J DRUG TARGET, V9, P267, DOI 10.3109/10611860108997935; Grundker C, 2002, EUR J ENDOCRINOL, V146, P1, DOI 10.1530/eje.0.1460001; Halmos G, 2000, J UROLOGY, V163, P623, DOI 10.1016/S0022-5347(05)67947-5; HAZUM E, 1980, P NATL ACAD SCI-BIOL, V77, P6692, DOI 10.1073/pnas.77.11.6692; Illum L, 2003, J CONTROL RELEASE, V87, P187, DOI 10.1016/S0168-3659(02)00363-2; Kang SW, 2008, BIOMATERIALS, V29, P1109, DOI 10.1016/j.biomaterials.2007.11.004; KEER HN, 1990, J UROLOGY, V143, P381, DOI 10.1016/S0022-5347(17)39970-6; Koushik K, 2004, PHARM RES-DORDR, V21, P1034, DOI 10.1023/B:PHAM.0000029294.70707.74; Koushik KN, 2004, J PHARM PHARMACOL, V56, P861, DOI 10.1211/0022357023646; Li HY, 2002, TRENDS PHARMACOL SCI, V23, P206, DOI 10.1016/S0165-6147(02)01989-2; Li HY, 2002, MED RES REV, V22, P225, DOI 10.1002/med.10008; Millar RP, 2005, ANIM REPROD SCI, V88, P5, DOI 10.1016/j.anireprosci.2005.05.032; Mo Y, 2007, MOL VIS, V13, P746; *MOL PROB INV DET, 2004, WORK FLUOSPHERES FLU; Prost AC, 1998, INT J ONCOL, V13, P871; Qian ZM, 2002, PHARMACOL REV, V54, P561, DOI 10.1124/pr.54.4.561; Relf M, 1997, CANCER RES, V57, P963; Schmidt MC, 2000, J PHARM SCI, V89, P396, DOI 10.1002/(SICI)1520-6017(200003)89:3<396::AID-JPS10>3.0.CO;2-F; SHINDELMAN JE, 1981, INT J CANCER, V27, P329, DOI 10.1002/ijc.2910270311; Singh N, 2005, INVEST OPHTH VIS SCI, V46, P1647, DOI 10.1167/iovs.04-1172; Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185; Straub B, 2001, CLIN CANCER RES, V7, P2340; SUNDARAM S, 2004, AM PHARM REV, V7, P130; Sundaram S, 2009, PEPTIDES, V30, P351, DOI 10.1016/j.peptides.2008.10.005; Widera A, 2003, ADV DRUG DELIVER REV, V55, P1439, DOI 10.1016/j.addr.2003.07.004; Widera A, 2003, PHARMACEUT RES, V20, P1231, DOI 10.1023/A:1025005232421; Wirsig-Wiechmann Celeste R., 2001, Keio Journal of Medicine, V50, P81, DOI 10.2302/kjm.50.81; YlaHerttuala S, 1997, CURR OPIN LIPIDOL, V8, P72	31	29	32	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3752	3765		10.1096/fj.09-129825	http://dx.doi.org/10.1096/fj.09-129825			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19608628	Green Published			2022-12-28	WOS:000271272500013
J	Elimova, E; Kisilevsky, R; Ancsin, JB				Elimova, Elena; Kisilevsky, Robert; Ancsin, John B.			Heparan sulfate promotes the aggregation of HDL-associated serum amyloid A: evidence for a proamyloidogenic histidine molecular switch	FASEB JOURNAL			English	Article						lipoprotein; amyloidosis; remodeling; acidic-pH binding site	HIGH-DENSITY-LIPOPROTEIN; GROWTH-FACTOR-BINDING; APOLIPOPROTEIN-E; AA-AMYLOIDOSIS; PRION PROTEIN; IN-VITRO; MACROPHAGE CHOLESTEROL; PERITONEAL-MACROPHAGES; ALZHEIMERS-DISEASE; ACUTE-INFLAMMATION	During inflammatory diseases, serum amyloid A (SAA), an acute-phase apolipoprotein of HDL, can assemble into tissue deposits called AA amyloids. The mechanism and physiological factors promoting amyloidosis are largely unknown but likely involve heparan sulfate (HS), a glycosaminoglycan colocalized with all types of amyloids. In this study, we explored HDL-SAA: HS interactions using in vitro and cell culture assays to identify HS-binding domains that promote the conversion of native SAA into AA amyloid. HS causes the remodeling of HDL-SAA at mildly acidic pH, producing SAA-rich aggregates. A sequence motif in SAA responsible for this conversion was identified that contains a pH-sensitive heparin/HS-binding site, functions as a ligand for a cell surface receptor, and acts as a structural focal point for SAA aggregation. Synthetic peptides corresponding to this region promoted the deposition of AA amyloid in a monocyte culture model for AA amyloidogenesis. The effects were peptide sequence specific and reliant on the protonation of H36. We conclude that a highly conserved motif required for SAA binding to macrophages can, under acidic pH conditions and in an HS-dependent manner, also act as a molecular switch, directing SAA misfolding into AA amyloid. Similar histidine-dependent HS-binding sites are also found in other amyloidogenic polypeptides.-Elimova, E., Kisilevsky, R., Ancsin, J. B. Heparan sulfate promotes the aggregation of HDL-associated serum amyloid A: evidence for a proamyloidogenic histidine molecular switch. FASEB J. 23, 3436-3448 ( 2009). www.fasebj.org	[Kisilevsky, Robert; Ancsin, John B.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada; [Elimova, Elena; Kisilevsky, Robert; Ancsin, John B.] Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; [Kisilevsky, Robert] Kingston Gen Hosp, Syl & Molly Apps Res Ctr, Kingston, ON K7L 2V7, Canada	McMaster University; Queens University - Canada; Queens University - Canada; Queens University - Canada	Ancsin, JB (corresponding author), Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada.	3jba1@queensu.ca			Canadian Institutes of Health Research [MOP-3153]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The authors thank Elizabeth Hearn for her able technical support. This work was supported by grant MOP-3153 ( R. K.) from the Canadian Institutes of Health Research.	Ancsin JB, 1999, J BIOL CHEM, V274, P7172, DOI 10.1074/jbc.274.11.7172; Ancsin JB, 2003, AMYLOID, V10, P67, DOI 10.3109/13506120309041728; AXELRAD MA, 1982, LAB INVEST, V47, P139; Bellotti V, 2008, CURR OPIN STRUC BIOL, V18, P771, DOI 10.1016/j.sbi.2008.10.001; BENDITT EP, 1971, FEBS LETT, V19, P169, DOI 10.1016/0014-5793(71)80506-9; BENDITT EP, 1977, P NATL ACAD SCI USA, V74, P4025, DOI 10.1073/pnas.74.9.4025; Benjwal S, 2005, BIOCHEMISTRY-US, V44, P10218, DOI 10.1021/bi050781m; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; Cai L, 2005, J BIOL CHEM, V280, P2954, DOI 10.1074/jbc.M411555200; Caldwell EEO, 1996, INT J BIOCHEM CELL B, V28, P203, DOI 10.1016/1357-2725(95)00123-9; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carneiro FA, 2003, J BIOL CHEM, V278, P13789, DOI 10.1074/jbc.M210615200; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CEVC G, 1990, BIOCHIM BIOPHYS ACTA, V1031, P311, DOI 10.1016/0304-4157(90)90015-5; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; Creighton T. E., 1993, PROTEINS STRUCTURE M; Dember LM, 2007, NEW ENGL J MED, V356, P2349, DOI 10.1056/NEJMoa065644; Dong J, 2001, BIOCHEMISTRY-US, V40, P2826, DOI 10.1021/bi002417n; Elimova E, 2004, FASEB J, V18, P1749, DOI 10.1096/fj.03-1436fje; ERICSSON LH, 1987, FEBS LETT, V218, P11, DOI 10.1016/0014-5793(87)81008-6; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; GEISOW MJ, 1984, EXP CELL RES, V150, P36, DOI 10.1016/0014-4827(84)90699-2; Goerges AL, 2003, J BIOL CHEM, V278, P19518, DOI 10.1074/jbc.M211208200; GOLDSMITH MR, 1979, ANAL BIOCHEM, V99, P33, DOI 10.1016/0003-2697(79)90041-1; Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8; Hallgren J, 2004, J IMMUNOL, V173, P1868, DOI 10.4049/jimmunol.173.3.1868; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hayat S, 2000, SCAND J IMMUNOL, V51, P141; Hondal RJ, 2001, J BIOL CHEM, V276, P15823, DOI 10.1074/jbc.M010405200; Hull RL, 2007, AM J PHYSIOL-CELL PH, V293, pC1586, DOI 10.1152/ajpcell.00208.2007; Inoue S, 1996, LAB INVEST, V74, P1081; Inoue S, 1996, LAB INVEST, V74, P670; Inoue S, 2002, AMYLOID, V9, P115, DOI 10.3109/13506120208995244; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jayaraman S, 2006, BIOCHEMISTRY-US, V45, P4620, DOI 10.1021/bi0524565; Kinkley SM, 2006, AMYLOID, V13, P123, DOI 10.1080/13506120600877201; KISILEVSKY R, 1983, LAB INVEST, V48, P53; Kisilevsky R, 2004, J MOL NEUROSCI, V24, P167, DOI 10.1385/JMN:24:1:167; Kisilevsky R, 2004, AM J PATHOL, V164, P2127, DOI 10.1016/S0002-9440(10)63771-6; Kisilevsky R, 2003, J LIPID RES, V44, P2257, DOI 10.1194/jlr.M300133-JLR200; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; KISILEVSKY R, 1992, LAB INVEST, V66, P778; KISILEVSKY R, 1994, AMYLOID, V1, P174, DOI 10.3109/13506129409148449; Kisilevsky R, 2000, J STRUCT BIOL, V130, P99, DOI 10.1006/jsbi.2000.4222; Kisilevsky R, 2007, AMYLOID, V14, P21, DOI 10.1080/13506120601116419; Kluve-Beckerman B, 2001, SCAND J IMMUNOL, V53, P393, DOI 10.1046/j.1365-3083.2001.00879.x; Kuang ZH, 2006, J MOL BIOL, V364, P690, DOI 10.1016/j.jmb.2006.09.006; LENDRUM AC, 1972, J CLIN PATHOL, V25, P373, DOI 10.1136/jcp.25.5.373; LEVIN M, 1973, J EXP MED, V138, P373, DOI 10.1084/jem.138.2.373; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Li JP, 2005, P NATL ACAD SCI USA, V102, P6473, DOI 10.1073/pnas.0502287102; Libeu CP, 2001, J BIOL CHEM, V276, P39138, DOI 10.1074/jbc.M104746200; Mahley RW, 1999, J LIPID RES, V40, P1; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; Miles E W, 1977, Methods Enzymol, V47, P431; Miller GJ, 2001, J BIOL CHEM, V276, P28829, DOI 10.1074/jbc.M102561200; Mulgrew-Nesbitt A, 2006, BBA-MOL CELL BIOL L, V1761, P812, DOI 10.1016/j.bbalip.2006.07.002; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; Ohashi K, 2002, NEPHRON, V90, P158, DOI 10.1159/000049037; Park K, 2001, J BIOL CHEM, V276, P16611, DOI 10.1074/jbc.M008423200; Pepys MB, 2006, ANNU REV MED, V57, P223, DOI 10.1146/annurev.med.57.121304.131243; PRECIADOPATT L, 1994, EUR J BIOCHEM, V223, P35, DOI 10.1111/j.1432-1033.1994.tb18963.x; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; Rai SS, 1998, J BIOL CHEM, V273, P31131, DOI 10.1074/jbc.273.47.31131; Ratnaswamy G, 1999, CHEM BIOL, V6, P293, DOI 10.1016/S1074-5521(99)80075-1; Rocken C, 1997, AMYLOID, V4, P259, DOI 10.3109/13506129709003837; Sebollela A, 2005, J BIOL CHEM, V280, P31949, DOI 10.1074/jbc.M505314200; SMITH PK, 1980, ANAL BIOCHEM, V109, P466, DOI 10.1016/0003-2697(80)90679-X; SNOW AD, 1987, LAB INVEST, V56, P665; SNOW AD, 1991, J HISTOCHEM CYTOCHEM, V39, P1321, DOI 10.1177/39.10.1940305; SNOW AD, 1985, LAB INVEST, V53, P37; SOBEL M, 1992, J BIOL CHEM, V267, P8857; Stevens FJ, 2000, CELL MOL LIFE SCI, V57, P441, DOI 10.1007/PL00000706; Stickens D, 2005, DEVELOPMENT, V132, P5055, DOI 10.1242/dev.02088; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Suk JY, 2006, BIOCHEMISTRY-US, V45, P2234, DOI 10.1021/bi0519295; Tam SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003867; Tam SP, 2005, J LIPID RES, V46, P2091, DOI 10.1194/jlr.M500191-JLR200; Tam SP, 2002, J LIPID RES, V43, P1410, DOI 10.1194/jlr.M100388-JLR200; TAPE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P295, DOI 10.1016/0005-2760(90)90030-2; Tojo K, 2005, AMYLOID, V12, P103, DOI 10.1080/13506120500107097; UHLAR CM, 1994, GENOMICS, V19, P228, DOI 10.1006/geno.1994.1052; van de Weert M, 2004, PHARM RES-DORDR, V21, P2354, DOI 10.1007/s11095-004-7689-z; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; WESTERMARK GT, 1992, BIOCHEM BIOPH RES CO, V182, P27, DOI 10.1016/S0006-291X(05)80107-X; Westermark P, 2005, FEBS J, V272, P5942, DOI 10.1111/j.1742-4658.2005.05024.x; Yamaguchi I, 2003, KIDNEY INT, V64, P1080, DOI 10.1046/j.1523-1755.2003.00167.x; Yan SD, 2000, NAT MED, V6, P643, DOI 10.1038/76216; ZOU S, 1992, COMP BIOCHEM PHYS B, V103, P889, DOI 10.1016/0305-0491(92)90210-I	93	45	46	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3436	3448		10.1096/fj.09-134981	http://dx.doi.org/10.1096/fj.09-134981			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19549924				2022-12-28	WOS:000270354300021
J	Perrot, R; Julien, JP				Perrot, Rodolphe; Julien, Jean-Pierre			Real-time imaging reveals defects of fast axonal transport induced by disorganization of intermediate filaments	FASEB JOURNAL			English	Article						lysosomes; mitochondria; neurofilament; peripherin	AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE; MARIE-TOOTH-DISEASE; KINESIN HEAVY-CHAIN; MITOCHONDRIAL ALTERATIONS; NEUROFILAMENT PROTEIN; ALZHEIMERS-DISEASE; IN-VIVO; PERIPHERIN; DEATH	Intermediate filament ( IF) abnormalities frequently appear in neurodegenerative disorders, but how they may contribute to neuronal dysfunction remains unclear. Here, we examined the effects of IF disorganization on the fast axonal transport using time-lapse microscopy. We studied the axonal transport of mitochondria and lysosomes in cultured primary dorsal root ganglion (DRG) neurons derived from mice deficient for neurofilament light (NFL-/-), mice overexpressing peripherin (Per), and mice double transgenic Per; NFL-/-. Unexpectedly, a net retrograde transport of mitochondria was detected in Per; NFL-/- neurons, opposite to the net anterograde transport of these organelles observed in wild-type (Wt), NFL-/-, and Per neurons. A detailed analysis of the kinetic properties of mitochondrial movements revealed an increased frequency of retrograde movements and an increase of their velocity in Per; NFL-/- neurons compared to Wt, NFL-/-, and Per neurons. We also noticed that the depletion of axonal neurofilaments (NFs) in NFL-/- and Per; NFL-/- neurons induced longer and more persistent movements of mitochondria and lysosomes in both directions, which suggests that the NF network hampers the traffic of these organelles. The finding that an upregulation of peripherin in context of NFL deficiency can provoke a net retrograde transport of mitochondria is a phenomenon that may contribute to pathogenic changes in some neurodegenerative disorders with IF protein accumulations.-Perrot, R., Julien, J.-P. Realtime imaging reveals defects of fast axonal transport induced by disorganization of intermediate filaments. FASEB J. 23, 3213-3225 ( 2009). www.fasebj.org	[Perrot, Rodolphe; Julien, Jean-Pierre] Univ Laval, Dept Anat & Physiol, Ctr Hosp Univ Quebec, Ctr Rech, Quebec City, PQ G1V 4G2, Canada	Laval University	Julien, JP (corresponding author), Univ Laval, Dept Anat & Physiol, Ctr Hosp Univ Quebec, Ctr Rech, Pavillon CHUL,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	jean-pierre.julien@crchul.ulaval.ca			Canadian Institute of Health and Research (CIHR)	Canadian Institute of Health and Research (CIHR)(Canadian Institutes of Health Research (CIHR))	We thank R. Paradis and R. Lariviere for technical assistance. We are grateful to M. Simard and M.-C. Richer of the Research Center of Centre Hospitalier de l'Universite Laval for technical assistance with animals. This work was supported by the Canadian Institute of Health and Research (CIHR). J.-P.J. holds a Canada Research Chair in neurodegeneration. R. P. is the recipient of the Tim E. Noel Fellowship (ALS Society of Canada).	Amiri M, 2008, DEV NEUROBIOL, V68, P1348, DOI 10.1002/dneu.20668; Baloh RH, 2007, J NEUROSCI, V27, P422, DOI 10.1523/JNEUROSCI.4798-06.2007; Beaulieu JM, 1999, J CELL BIOL, V147, P531, DOI 10.1083/jcb.147.3.531; Beaulieu JM, 2000, J NEUROSCI, V20, P5321, DOI 10.1523/JNEUROSCI.20-14-05321.2000; BERGERON C, 1994, J NEUROPATH EXP NEUR, V53, P221, DOI 10.1097/00005072-199405000-00002; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Brown A, 2003, J CELL BIOL, V160, P817, DOI 10.1083/jcb.200212017; Brownlees J, 2002, HUM MOL GENET, V11, P2837, DOI 10.1093/hmg/11.23.2837; Cairns NJ, 2004, AM J PATHOL, V164, P2153, DOI 10.1016/S0002-9440(10)63773-X; Chevalier-Larsen E, 2006, BBA-MOL BASIS DIS, V1762, P1094, DOI 10.1016/j.bbadis.2006.04.002; Cho KI, 2007, TRAFFIC, V8, P1722, DOI 10.1111/j.1600-0854.2007.00647.x; CORBO M, 1992, J NEUROPATH EXP NEUR, V51, P531, DOI 10.1097/00005072-199209000-00008; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; De Vos KJ, 2005, CURR BIOL, V15, P678, DOI 10.1016/j.cub.2005.02.064; De Vos KJ, 2008, ANNU REV NEUROSCI, V31, P151, DOI 10.1146/annurev.neuro.31.061307.090711; De Vos KJ, 2007, HUM MOL GENET, V16, P2720, DOI 10.1093/hmg/ddm226; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Fischer LR, 2007, NEURODEGENER DIS, V4, P431, DOI 10.1159/000107704; Fransson A, 2006, BIOCHEM BIOPH RES CO, V344, P500, DOI 10.1016/j.bbrc.2006.03.163; Glater EE, 2006, J CELL BIOL, V173, P545, DOI 10.1083/jcb.200601067; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P461, DOI 10.1097/00005072-198409000-00001; ISHII T, 1979, ACTA NEUROPATHOL, V48, P105, DOI 10.1007/BF00691151; Jimenez-Mateos EM, 2006, BIOCHEM J, V397, P53, DOI 10.1042/BJ20060205; Julien JP, 1998, PROG NUCLEIC ACID RE, V61, P1, DOI 10.1016/S0079-6603(08)60823-5; Lecomte MJ, 1998, J NEUROCHEM, V70, P971; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; MIGHELI A, 1993, LAB INVEST, V68, P185; Millecamps S, 2007, J NEUROSCI, V27, P4947, DOI 10.1523/JNEUROSCI.5299-06.2007; Millecamps S, 2006, J NEUROCHEM, V98, P926, DOI 10.1111/j.1471-4159.2006.03932.x; Miller KE, 2006, J CELL BIOL, V173, P373, DOI 10.1083/jcb.200510097; MORRIS RL, 1993, J CELL SCI, V104, P917; MORRIS RL, 1995, J CELL BIOL, V131, P1315, DOI 10.1083/jcb.131.5.1315; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; PEIFFER J, 1977, ACTA NEUROPATHOL, V40, P213, DOI 10.1007/BF00691956; Perrot R, 2008, MOL NEUROBIOL, V38, P27, DOI 10.1007/s12035-008-8033-0; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Robertson J, 2001, J CELL BIOL, V155, P217, DOI 10.1083/jcb.200107058; Rouleau GA, 1996, ANN NEUROL, V39, P128, DOI 10.1002/ana.410390119; Rui YF, 2006, J NEUROSCI, V26, P10480, DOI 10.1523/JNEUROSCI.3231-06.2006; Sasaki S, 2007, ACTA NEUROPATHOL, V114, P633, DOI 10.1007/s00401-007-0299-1; Sasaki S, 2007, J NEUROPATH EXP NEUR, V66, P10, DOI 10.1097/nen.0b013e31802c396b; Stagi M, 2005, J NEUROSCI, V25, P352, DOI 10.1523/JNEUROSCI.3887-04.2005; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Sterneck E, 1996, J NEUROCHEM, V67, P1365; StraubeWest K, 1996, J CELL SCI, V109, P2319; Takeuchi H, 2005, J BIOL CHEM, V280, P10444, DOI 10.1074/jbc.M413863200; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; Trimmer PA, 2005, ANTIOXID REDOX SIGN, V7, P1101, DOI 10.1089/ars.2005.7.1101; Trinczek B, 1999, J CELL SCI, V112, P2355; Trushina E, 2004, MOL CELL BIOL, V24, P8195, DOI 10.1128/MCB.24.18.8195-8209.2004; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Wagner OI, 2003, J NEUROSCI, V23, P9046; Wong NKY, 2000, J NEUROPATH EXP NEUR, V59, P972, DOI 10.1093/jnen/59.11.972; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654	55	36	36	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3213	3225		10.1096/fj.09-129585	http://dx.doi.org/10.1096/fj.09-129585			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19451279				2022-12-28	WOS:000270241000043
J	Zingaretti, MC; Crosta, F; Vitali, A; Guerrieri, M; Frontini, A; Cannon, B; Nedergaard, J; Cinti, S				Zingaretti, Maria Cristina; Crosta, Francesca; Vitali, Alessandra; Guerrieri, Mario; Frontini, Andrea; Cannon, Barbara; Nedergaard, Jan; Cinti, Saverio			The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue	FASEB JOURNAL			English	Article						uncoupling protein; obesity; sympathetic nervous system; tyrosine hydroxylase immunoreactivity; capillaries; precursor cells	THERMOGENESIS; PROPRANOLOL	Classically, adult humans have been considered not to possess active brown adipose tissue ( BAT). However, positron-emission-tomography has shown fluorodeoxyglucose uptake that is distributed in such a way (e.g., in the neck) that it would seem to be BAT. Until now this has not been supported by direct evidence that these areas truly represented BAT, that is, the presence of the BAT-unique uncoupling protein-1 (UCP1). Samples of adipose tissue from the neck of 35 patients undergoing surgery for thyroid diseases were obtained and analyzed. In 1/3 of the subjects ( the younger and leaner), distinct islands composed of UCP1 immunoreactive brown adipocytes could clearly be discerned, accounting for up to 1/3 of all adipocytes. The brown-adipose islands were richly sympathetically innervated ( indicating acute central control); adjacent white adipose areas were not. The capillary density was high, implying a high capacity for oxygen delivery. Cells with features of brown adipocyte precursors were found in pericapillary areas. These data demonstrate that human adults indeed possess BAT and thus imply possibilities of future therapeutic strategies for the treatment of obesity, including maintenance of brown adipocytes and stimulation of the growth of preexisting brown precursors.-Zingaretti, M. C., Crosta, F., Vitali, A., Guerrieri, M., Frontini, A., Cannon, B., Nedergaard, J., Cinti, S. The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue. FASEB J. 23, 3113-3120 ( 2009). www.fasebj.org	[Zingaretti, Maria Cristina; Vitali, Alessandra; Frontini, Andrea; Cinti, Saverio] Univ Ancona, Osped Riuniti Ancona, Dept Mol Pathol & Innovat Therapies, Politecn Marche,Fac Med, IT-60020 Ancona, Italy; [Crosta, Francesca; Guerrieri, Mario] Univ Ancona, Osped Riuniti Ancona, Clin Chirurg Gen & Metodol Chirurg, Politecn Marche, IT-60020 Ancona, Italy; [Cannon, Barbara; Nedergaard, Jan] Stockholm Univ, Dept Physiol, Wenner Gren Inst, Arrhenius Labs F3, S-10691 Stockholm, Sweden	Marche Polytechnic University; Marche Polytechnic University; Stockholm University	Cinti, S (corresponding author), Univ Ancona, Osped Riuniti Ancona, Dept Mol Pathol & Innovat Therapies, Politecn Marche,Fac Med, Via Tronto 10 A, IT-60020 Ancona, Italy.	cinti@univpm.it	Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010; Frontini, A/AAB-8767-2021; Cannon, Barbara/B-3089-2016	Cannon, Barbara/0000-0001-6594-2363; Nedergaard, Jan/0000-0003-2070-1587; CINTI, Saverio/0000-0003-0362-5017; Frontini, Andrea/0000-0002-7381-4107	EU [COFIN 2007 BBR57M_005]; Swedish Research Council.	EU(European Commission); Swedish Research Council.(Swedish Research CouncilEuropean Commission)	This study was supported by EU grant COFIN 2007 BBR57M_005 and the Swedish Research Council.	AHERNE W, 1966, J PATHOL BACTERIOL, V91, P223, DOI 10.1002/path.1700910126; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Christensen CR, 2006, CLIN NUCL MED, V31, P193, DOI 10.1097/01.rlu.0000204199.33136.05; Cinti S, 1995, ITALIAN JOURNAL OF ANATOMY AND EMBRYOLOGY, VOL 100 - SUPPLEMENT N.1 - 1995, P75; Cinti S, 1999, ADIPOSE ORGAN; Feldmann HM, 2009, CELL METAB, V9, P203, DOI 10.1016/j.cmet.2008.12.014; Frontini A, 2007, J HISTOCHEM CYTOCHEM, V55, P183, DOI 10.1369/jhc.6A7013.2006; Gelfand MJ, 2004, PEDIATR RADIOL, V34, P577, DOI 10.1007/s00247-003-1136-x; Lean M. E. J., 1986, BROWN ADIPOSE TISSUE, P339; LEAN MEJ, 1989, P NUTR SOC, V48, P243, DOI 10.1079/PNS19890036; Murano I, 2009, J ANAT, V214, P171, DOI 10.1111/j.1469-7580.2008.01001.x; Nedergaard J, 2001, BBA-BIOENERGETICS, V1504, P82, DOI 10.1016/S0005-2728(00)00247-4; Nedergaard J, 2007, AM J PHYSIOL-ENDOC M, V293, pE444, DOI 10.1152/ajpendo.00691.2006; Okuyama C, 2003, J NUCL MED, V44, P1421; Parysow O, 2007, CLIN NUCL MED, V32, P351, DOI 10.1097/01.rlu.0000259570.69163.04; Soderlund V, 2007, EUR J NUCL MED MOL I, V34, P1018, DOI 10.1007/s00259-006-0318-9	16	556	572	1	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3113	3120		10.1096/fj.09-133546	http://dx.doi.org/10.1096/fj.09-133546			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19417078				2022-12-28	WOS:000270241000033
J	Huang, K; Sanders, S; Singaraja, R; Orban, P; Cijsouw, T; Arstikaitis, P; Yanai, A; Hayden, MR; El-Husseini, A				Huang, Kun; Sanders, Shaun; Singaraja, Roshni; Orban, Paul; Cijsouw, Tony; Arstikaitis, Pamela; Yanai, Anat; Hayden, Michael R.; El-Husseini, Alaa			Neuronal palmitoyl acyl transferases exhibit distinct substrate specificity	FASEB JOURNAL			English	Article						acyl-biotin exchange; DHHC proteins; HIP14; HIP14L; huntingtin; SNAP25	HUNTINGTIN-INTERACTING PROTEIN-14; GABA(A) RECEPTORS; TRAFFICKING; DOMAIN; YEAST; IDENTIFICATION; EXPRESSION; SUBUNIT; PSD-95; HIP14	Palmitoylation, a post-translational modification of cysteine residues with the lipid palmitate, has recently emerged as an important mechanism for regulating protein trafficking and function. With the identification of 23 DHHC mammalian palmitoyl acyl transferases (PATs), a key question was the nature of substrate-enzyme specificity for these PATs. Using the acyl-biotin exchange palmitoylation assay, we compared the substrate specificity of four neuronal PATs, namely DHHC-3, DHHC-8, HIP14L (DHHC-13), and HIP14 (DHHC-17). Exogenous expression of enzymes and substrates in COS cells reveals that HIP14L and HIP14 modulate huntingtin palmitoylation, DHHC-8 modulates paralemmin-1 palmitoylation, and DHHC-3 shows the least substrate specificity. These in vitro data were validated by lentiviral siRNA- mediated knockdown of endogenous HIP14 and DHHC-3 in cultured rat cortical neurons. PATs require the presence of palmitoylated cysteines in order to interact with their substrates. To understand the elements that influence enzyme/substrate specificity further, we fused the HIP14 ankryin repeat domain to the N terminus of DHHC-3, which is not a PAT for huntingtin. This modification enabled DHHC-3 to behave similarly to HIP14 by modulating palmitoylation and trafficking of huntingtin. Taken together, this study indicates that individual PATs have specific substrate preference, determined by regulatory domains outside the DHHC domain of the enzymes.-Huang, K., Sanders, S., Singaraja, R., Orban, P., Cijsouw, T., Arstikaitis, P., Yanai, A., Hayden, M. R., El-Husseini, A. Neuronal palmitoyl acyl transferases exhibit distinct substrate specificity. FASEB J. 23, 2605-2615 ( 2009)	[Huang, Kun; Sanders, Shaun; Singaraja, Roshni; Orban, Paul; Yanai, Anat; Hayden, Michael R.] Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; [Arstikaitis, Pamela; El-Husseini, Alaa] Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 4H4, Canada; [Cijsouw, Tony] Vrije Univ Amsterdam, Dept Funct Genom, Ctr Neurogenom & Cognit Res, Amsterdam, Netherlands; [Hayden, Michael R.] British Columbia Childrens Hosp, Children & Family Res Inst, Vancouver, BC V6H 3V4, Canada	University of British Columbia; University of British Columbia; Vrije Universiteit Amsterdam; BC Childrens Hospital; University of British Columbia	Hayden, MR (corresponding author), Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada.	mrh@cmmt.ubc.ca	Hayden, Michael R/D-8581-2011; Cijsouw, Anthony/B-8309-2008	Hayden, Michael R/0000-0001-5159-1419; Cijsouw, Anthony/0000-0002-3670-7863; Yanai, Anat/0000-0002-0792-6901; Singaraja, Roshni/0000-0002-3418-3867	Canadian Institutes for Health Research (CIHR); Michael Smith Foundation for Health Research (MSFHR); High Q Foundation; MSFHR senior scholar; Heart and Stroke Foundation; Huntington Society of Canada; U. S. National Institutes of Health	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research (MSFHR)(Michael Smith Foundation for Health Research); High Q Foundation; MSFHR senior scholar(Michael Smith Foundation for Health Research); Heart and Stroke Foundation(Heart & Stroke Foundation of Canada); Huntington Society of Canada; U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This manuscript is dedicated to the memory of our dear colleague and mentor Dr. Alaa El-Hussseini, who tragically died during the completion of the work for this manuscript. We thank Esther Yu for her excellent technical assistance. This work was supported by grants to A. E. H. from the Canadian Institutes for Health Research (CIHR), the Michael Smith Foundation for Health Research (MSFHR), and the High Q Foundation. A. E. H. was an MSFHR senior scholar. M. R. H. is Canada Research Chair in Human Genetics and Molecular Medicine and is supported by CIHR, MSFHR, the High Q Foundation, the Heart and Stroke Foundation, the Huntington Society of Canada, and the U. S. National Institutes of Health.	Arstikaitis P, 2008, MOL BIOL CELL, V19, P2026, DOI 10.1091/mbc.E07-08-0802; Drisdel RC, 2004, J NEUROSCI, V24, P10502, DOI 10.1523/JNEUROSCI.3315-04.2004; Drisdel RC, 2004, BIOTECHNIQUES, V36, P276, DOI 10.2144/04362RR02; Drisdel RC, 2006, METHODS, V40, P127, DOI 10.1016/j.ymeth.2006.04.015; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; Fang C, 2006, J NEUROSCI, V26, P12758, DOI 10.1523/JNEUROSCI.4214-06.2006; Faul T, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-35; Fernandez-Hernando C, 2006, J CELL BIOL, V174, P369, DOI 10.1083/jcb.200601051; Fukata M, 2004, NEURON, V44, P987, DOI 10.1016/j.neuron.2004.12.005; Hayashi T, 2005, NEURON, V47, P709, DOI 10.1016/j.neuron.2005.06.035; Huang K, 2005, CURR OPIN NEUROBIOL, V15, P527, DOI 10.1016/j.conb.2005.08.001; Huang K, 2004, NEURON, V44, P977, DOI 10.1016/j.neuron.2004.11.027; Kang RJ, 2004, J BIOL CHEM, V279, P50524, DOI 10.1074/jbc.M404981200; Keller CA, 2004, J NEUROSCI, V24, P5881, DOI 10.1523/JNEUROSCI.1037-04.2004; Lam KKY, 2006, J CELL BIOL, V174, P19, DOI 10.1083/jcb.200602049; Linder ME, 2007, NAT REV MOL CELL BIO, V8, P74, DOI 10.1038/nrm2084; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mukai J, 2004, NAT GENET, V36, P725, DOI 10.1038/ng1375; Ohno Y, 2006, BBA-MOL CELL BIOL L, V1761, P474, DOI 10.1016/j.bbalip.2006.03.010; Ohyama T, 2007, J CELL BIOL, V179, P1481, DOI 10.1083/jcb.200710061; Resh MD, 2006, METHODS, V40, P191, DOI 10.1016/j.ymeth.2006.04.013; RESH MD, 2006, SCI STKE, pRE14, DOI DOI 10.1126/STKE.3592006RE14; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Roth AF, 2006, CELL, V125, P1003, DOI 10.1016/j.cell.2006.03.042; Santamaria J, 2009, J NEUROSCI RES, V87, P532, DOI 10.1002/jnr.21866; Singaraja RR, 2002, HUM MOL GENET, V11, P2815, DOI 10.1093/hmg/11.23.2815; Stowers RS, 2007, J NEUROSCI, V27, P12874, DOI 10.1523/JNEUROSCI.2464-07.2007; Swarthout JT, 2005, J BIOL CHEM, V280, P31141, DOI 10.1074/jbc.M504113200; Tsutsumi R, 2008, PFLUG ARCH EUR J PHY, V456, P1199, DOI 10.1007/s00424-008-0465-x; Tsutsumi R, 2009, MOL CELL BIOL, V29, P435, DOI 10.1128/MCB.01144-08; Uemura T, 2002, BIOCHEM BIOPH RES CO, V296, P492, DOI 10.1016/S0006-291X(02)00900-2; Yanai A, 2006, NAT NEUROSCI, V9, P824, DOI 10.1038/nn1702; Zhao LH, 2002, J BIOL CHEM, V277, P49352, DOI 10.1074/jbc.M209760200	36	119	125	4	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2605	2615		10.1096/fj.08-127399	http://dx.doi.org/10.1096/fj.08-127399			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19299482	Green Published			2022-12-28	WOS:000268836700029
J	Nguyen, HG; Makitalo, M; Yang, D; Chinnappan, D; Hilaire, CS; Ravid, K				Nguyen, Hao G.; Makitalo, Maria; Yang, Dan; Chinnappan, Dharmaraj; Hilaire, Cynthia St.; Ravid, Katya			Deregulated Aurora-B induced tetraploidy promotes tumorigenesis	FASEB JOURNAL			English	Article						polyploidy; cancer; cell cycle; premature chromatid separation	PREMATURE CHROMATID SEPARATION; MOSAIC VARIEGATED ANEUPLOIDY; MAMMARY EPITHELIAL-CELLS; MITOTIC-SPINDLE CHECKPOINT; GENOMIC INSTABILITY; GROWTH-FACTOR; CHROMOSOMAL INSTABILITY; CANCER; POLYPLOIDY; ANAPHASE	High expression of Aurora-B has been observed in various cancers, and inhibition of this kinase has been shown to halt cellular proliferation. However, the mechanism of effect of Aurora-B on cellular transformation has not been fully explored. Here, we show that overexpression of Aurora-B in murine epithelial cells promotes generation of tetraploids. In search of a related mechanism, spectral karyotyping was carried out, showing premature chromatid separation (PCS). Of interest, PCS is a hallmark of Robert's syndrome, which also involves cellular polyploidy and aneuploidy. Sorted tetraploid Aurora-B-overexpressing cells promoted significant mammary epithelial cancers when injected into nude mice, as compared to injection of nonfractionated cells, suggesting that tetraploidy is an important mediator of Aurora-B-induced tumorigenesis. Comparative chromosome hybridization performed on DNA derived from tetraploid cell-induced tumors indicates amplifications and deletions of regions throughout the genome, which include tumor-promoting or tumor-suppressing genes, respectively. Thus, sustained expression of Aurora-B induces tetraploidy, which, in turn, facilitates genomic instability and tumor development in a xenograft model.-Nguyen, H. G., Makitalo, M., Yang, D., Chinnappan, D., St. Hilaire, C., Ravid, K. Deregulated Aurora-B induced tetraploidy promotes tumorigenesis. FASEB J. 23, 2741-2748 ( 2009)	[Ravid, Katya] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Ravid, K (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.	kravid@bu.edu	St. Hilaire, Cynthia/R-8205-2017; St. Hilaire, Cynthia/I-4713-2014	St. Hilaire, Cynthia/0000-0003-1871-6915; Nguyen, Hao/0000-0001-8275-5375; Ravid, Katya/0000-0002-9918-3024	National Cancer Institute seed funds to Boston University School of Medicine Cancer Center	National Cancer Institute seed funds to Boston University School of Medicine Cancer Center	This work was supported by National Cancer Institute seed funds to Boston University School of Medicine Cancer Center.	COLTRERA MD, 1995, CANCER RES, V55, P2703; Dai J, 2006, DEV CELL, V11, P741, DOI 10.1016/j.devcel.2006.09.018; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Dikovskaya D, 2007, J CELL BIOL, V176, P183, DOI 10.1083/jcb.200610099; Duesberg P, 2006, CONTRIB MICROBIOL, V13, P16, DOI 10.1159/000092963; Egler RA, 2005, ONCOGENE, V24, P8038, DOI 10.1038/sj.onc.1208821; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Furuta J, 2006, CANCER RES, V66, P6080, DOI 10.1158/0008-5472.CAN-06-0157; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; GERMAN J, 1979, CLIN GENET, V16, P441; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Gimenez-Abian JF, 2004, CURR BIOL, V14, P1187, DOI 10.1016/j.cub.2004.06.052; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jeon S, 2005, J NEUROCHEM, V95, P1608, DOI 10.1111/j.1471-4159.2005.03505.x; Kaitna S, 2002, CURR BIOL, V12, P798, DOI 10.1016/S0960-9822(02)00820-5; Kajii T, 1998, AM J MED GENET, V78, P245, DOI 10.1002/(SICI)1096-8628(19980707)78:3<245::AID-AJMG7>3.0.CO;2-O; Kajii T, 2001, AM J MED GENET, V104, P57, DOI 10.1002/ajmg.1580; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Kienitz A, 2005, ONCOGENE, V24, P4301, DOI 10.1038/sj.onc.1208589; Kimmins S, 2007, MOL ENDOCRINOL, V21, P726, DOI 10.1210/me.2006-0332; Klominek J, 1998, CLIN EXP METASTAS, V16, P529, DOI 10.1023/A:1006542301794; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Knippschild U, 2005, ONKOLOGIE, V28, P508, DOI 10.1159/000087137; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li YJ, 2007, P NATL ACAD SCI USA, V104, P3490, DOI 10.1073/pnas.0610163104; Margolis RL, 2005, CANCER CELL, V8, P353, DOI 10.1016/j.ccr.2005.10.017; Matsuura S, 2000, AM J HUM GENET, V67, P483, DOI 10.1086/303022; Matsuura S, 2006, AM J MED GENET A, V140A, P358, DOI 10.1002/ajmg.a.31069; Mazzoni E, 2003, MOL CANCER RES, V1, P776; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Minoshima Y, 2005, MOL CELL BIOL, V25, P10315, DOI 10.1128/MCB.25.23.10315-10328.2005; Nguyen HG, 2006, J CELL PHYSIOL, V208, P12, DOI 10.1002/jcp.20565; Nguyen HG, 2005, MOL CELL BIOL, V25, P4977, DOI 10.1128/MCB.25.12.4977-4992.2005; Olaharski AJ, 2006, CARCINOGENESIS, V27, P337, DOI 10.1093/carcin/bgi218; Orr B, 2007, MOL BIOL CELL, V18, P850, DOI 10.1091/mbc.E06-07-0587; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Ravid K, 2002, J CELL PHYSIOL, V190, P7, DOI 10.1002/jcp.10035; Resnick TD, 2006, DEV CELL, V11, P57, DOI 10.1016/j.devcel.2006.04.021; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wang XX, 2005, EXP CELL RES, V310, P1, DOI 10.1016/j.yexcr.2005.07.018; Zhang Y, 2004, BLOOD, V103, P3717, DOI 10.1182/blood-2003-09-3365; Zimmet J, 2000, EXP HEMATOL, V28, P3, DOI 10.1016/S0301-472X(99)00124-1	53	75	76	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2741	2748		10.1096/fj.09-130963	http://dx.doi.org/10.1096/fj.09-130963			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19332642	Green Published			2022-12-28	WOS:000268836700042
J	Tripathi, G; Salih, DAM; Drozd, AC; Cosgrove, RA; Cobb, LJ; Pell, JM				Tripathi, Gyanendra; Salih, Dervis A. M.; Drozd, Anja C.; Cosgrove, Ruth A.; Cobb, Laura J.; Pell, Jennifer M.			IGF-independent effects of insulin-like growth factor binding protein-5 (Igfbp5) in vivo	FASEB JOURNAL			English	Article						muscle; transgenic	BREAST-CANCER CELLS; TRANSGENIC MICE; TERMINAL DOMAINS; PROSTATE-CANCER; SMOOTH-MUSCLE; AMINO-ACIDS; RECEPTOR; INSULIN-LIKE-GROWTH-FACTOR-BINDING-PROTEIN-5; DIFFERENTIATION; EXPRESSION	IGF activity is regulated tightly by a family of IGF binding proteins (IGFBPs). IGFBP-5 is the most conserved of these and is up-regulated significantly during differentiation of several key lineages and in some cancers. The function of IGFBP-5 in these physiological and pathological situations is unclear, however, several IGFBP-5 sequence motifs and studies in vitro suggest IGF-independent actions. Therefore, we aimed to compare the phenotypes of mice overexpressing wild-type Igfbp5 or an N-terminal mutant Igfbp5 with negligible IGF binding affinity. Both significantly inhibited growth, even at low expression levels. Even though wild-type IGFBP-5 severely disrupted the IGF axis, we found no evidence for interaction of mutant IGFBP-5 with the IGF system. Further, overexpression of wildtype IGFBP-5 rescued the lethal phenotype induced by "excess" IGF-II in type 2 receptor-null mice; mutant IGFBP-5 overexpression could not. Therefore, wildtype IGFBP-5 provides a very effective mechanism for the inhibition of IGF activity and a powerful in vivo mechanism to inhibit IGF activity in pathologies such as cancer. This study is also the first to suggest significant IGF-independent actions for IGFBP-5 during development.-Tripathi, G., Salih, D. A. M., Drozd, A. C., Cosgrove, R. A., Cobb, L. J., Pell, J. M. IGF-independent effects of insulin-like growth factor binding protein-5 ( Igfbp5) in vivo. FASEB J. 23, 2616-2626 ( 2009)	[Tripathi, Gyanendra; Salih, Dervis A. M.; Drozd, Anja C.; Cosgrove, Ruth A.; Cobb, Laura J.; Pell, Jennifer M.] Babraham Inst, Mol Signalling Lab, Cambridge CB22 3AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Pell, JM (corresponding author), Babraham Inst, Mol Signalling Lab, Cambridge CB22 3AT, England.	jenny.pell@bbsrc.ac.uk	Tripathi, Gyanendra/C-8832-2011	Tripathi, Gyanendra/0000-0001-6889-706X; Salih, Dervis/0000-0001-7651-8998	Biotechnology and Biological Sciences Research Council via a competitive strategic grant to The Babraham Institute [202/S15716]	Biotechnology and Biological Sciences Research Council via a competitive strategic grant to The Babraham Institute(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors thank The Babraham Institute Gene Targeting Facility/Small Animal Barrier Unit, Simon Walker from the Imaging Facility, and Anne Segonds-Pichon from Babraham Bioinformatics for their expert skills. This work was funded by the Biotechnology and Biological Sciences Research Council via a competitive strategic grant to The Babraham Institute and a responsive mode grant (202/S15716) to J.M.P.	Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; Andress DL, 1998, AM J PHYSIOL-ENDOC M, V274, pE744, DOI 10.1152/ajpendo.1998.274.4.E744; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Baxter RC, 2002, J CLIN ENDOCR METAB, V87, P271, DOI 10.1210/jc.87.1.271; Butt AJ, 2003, J BIOL CHEM, V278, P29676, DOI 10.1074/jbc.M301965200; Chan JM, 2002, J NATL CANCER I, V94, P1099; Clemmons D. R., 1995, Progress in Growth Factor Research, V6, P357, DOI 10.1016/0955-2235(95)00013-5; Cobb LJ, 2004, J CELL SCI, V117, P1737, DOI 10.1242/jcs.01028; Fernandez AM, 2002, J CLIN INVEST, V109, P347, DOI 10.1172/JCI200213503; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; GREEN BN, 1994, ENDOCRINOLOGY, V134, P954, DOI 10.1210/en.134.2.954; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; Ishibashi J, 2005, J CELL BIOL, V171, P471, DOI 10.1083/jcb.200502101; James PL, 1996, J CELL BIOL, V133, P683, DOI 10.1083/jcb.133.3.683; Kawarabayashi T, 1996, NEUROBIOL AGING, V17, P215, DOI 10.1016/0197-4580(95)02061-6; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Kuemmerle JF, 2002, J BIOL CHEM, V277, P20563, DOI 10.1074/jbc.M200885200; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Leu JI, 2003, MOL CELL BIOL, V23, P1251, DOI 10.1128/MCB.23.4.1251-1259.2003; Li XQ, 2007, CANCER SCI, V98, P1592, DOI 10.1111/j.1349-7006.2007.00565.x; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; Marshman E, 2003, J CELL SCI, V116, P675, DOI 10.1242/jcs.00263; Miyake H, 2000, CANCER RES, V60, P3058; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; Modric T, 2001, ENDOCRINOLOGY, V142, P1958, DOI 10.1210/en.142.5.1958; Ning Y, 2007, ENDOCRINOLOGY, V148, P2138, DOI 10.1210/en.2006-0041; Ning Y, 2006, MOL ENDOCRINOL, V20, P2173, DOI 10.1210/me.2005-0196; Parker A, 1996, J BIOL CHEM, V271, P13523, DOI 10.1074/jbc.271.23.13523; Perks CM, 2002, BIOCHEM BIOPH RES CO, V294, P995, DOI 10.1016/S0006-291X(02)00570-3; Perks CM, 2000, J CELL BIOCHEM, V80, P248; Salih DAM, 2004, P NATL ACAD SCI USA, V101, P4314, DOI 10.1073/pnas.0400230101; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2007, MOL ENDOCRINOL, V21, P2378, DOI 10.1210/me.2006-0558; Shand JH, 2003, J BIOL CHEM, V278, P17859, DOI 10.1074/jbc.M300526200; Silha JV, 2006, ENDOCRINOLOGY, V147, P2112, DOI 10.1210/en.2005-1270; Silha JV, 2005, ENDOCRINOLOGY, V146, P1523, DOI 10.1210/en.2004-0905; Sorrell AM, 2006, J BIOL CHEM, V281, P10883, DOI 10.1074/jbc.M508505200; Stolf BS, 2003, CANCER LETT, V191, P193, DOI 10.1016/S0304-3835(02)00679-1; Tanno B, 2005, CELL DEATH DIFFER, V12, P213, DOI 10.1038/sj.cdd.4401546; Tonner E, 2002, DEVELOPMENT, V129, P4547; Tsibris JCM, 2002, FERTIL STERIL, V78, P114, DOI 10.1016/S0015-0282(02)03191-6; Wilson EM, 2004, MOL BIOL CELL, V15, P497, DOI 10.1091/mbc.E03-05-0351; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Xu QJ, 2004, CIRC RES, V94, pE46, DOI 10.1161/01.RES.0000124761.62846.DF; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yin P, 2004, J BIOL CHEM, V279, P32660, DOI 10.1074/jbc.M401378200; Zeslawski W, 2001, EMBO J, V20, P3638, DOI 10.1093/emboj/20.14.3638; Zhao Y, 2006, J BIOL CHEM, V281, P14184, DOI 10.1074/jbc.M506941200	50	55	56	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2616	2626		10.1096/fj.08-114124	http://dx.doi.org/10.1096/fj.08-114124			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19332648				2022-12-28	WOS:000268836700030
J	Fischer, S; Nishio, M; Peters, SC; Tschernatsch, M; Walberer, M; Weidemann, S; Heidenreich, R; Couraud, PO; Weksler, BB; Romero, IA; Gerriets, T; Preissner, KT				Fischer, Silvia; Nishio, Miwako; Peters, Saskia C.; Tschernatsch, Marlene; Walberer, Maureen; Weidemann, Susanne; Heidenreich, Regina; Couraud, Pierre O.; Weksler, Babette B.; Romero, Ignacio A.; Gerriets, Tibo; Preissner, Klaus T.			Signaling mechanism of extracellular RNA in endothelial cells	FASEB JOURNAL			English	Article						VEGF-receptor; neuropilin-1	GROWTH-FACTOR EXPRESSION; MAP KINASE PATHWAY; VASCULAR-PERMEABILITY; RECEPTOR; BRAIN; ANGIOGENESIS; VEGF; NEUROPILIN-1; BINDING; SERUM	Extracellular RNA has been shown to induce vascular endothelial growth factor (VEGF)-dependent hyperpermeability in vivo as well as in vitro. Studies were performed to investigate the mechanism of these effects. For permeability studies primary cultures of porcine brain-derived microvascular endothelial cells (BMECs) and for all other analytical studies the human brain endothelial cell line HCMEC/D3 or human umbilical vein endothelial cells (HUVECs) were used. RNA, but not DNA, initiated signaling events by binding of VEGF to neuropilin-1, followed by VEGF-R2 phosphorylation, activation of phospholipase C ( PLC), and intracellular release of Ca2+. Activation of these pathways by RNA also resulted in the release of von Willebrand Factor from Weibel-Palade bodies. Pretreatment of cells with heparinase totally abrogated the RNA-induced permeability changes, whereas RNA together with VEGF completely restored VEGF-R2-mediated hyperpermeability. Although poly: IC increased the interleukin-6 release via activation of toll-like receptor-3 (TLR-3), permeability changes mediated by poly: IC or RNA remained unchanged after blocking TLR-3 or NF-kB activation. These results indicate that extracellular RNA serves an important cofactor function to engage VEGF for VEGF-R2-dependent signal transduction, reminiscent of the coreceptor mechanism mediated by proteoglycans, which might be of relevance for the mobilization and cellular activities of RNA-binding cytokines in general.-Fischer, S., Nishio, M., Peters, S. C., Tschernatsch, M., Walberer, M., Weidemann, S., Heidenreich, R., Couraud, P. O., Weksler, B. B., Romero, I. A., Gerriets, T., Preissner, K. T. Signaling mechanism of extracellular RNA in endothelial cells. FASEB J. 23, 2100-2109 (2007)	[Fischer, Silvia; Nishio, Miwako; Preissner, Klaus T.] Univ Giessen, Sch Med, Dept Biochem, D-35392 Giessen, Germany; [Peters, Saskia C.] Univ Giessen, Sch Med, Dept Anim Welf & Ethol, D-35392 Giessen, Germany; [Tschernatsch, Marlene; Gerriets, Tibo] Univ Giessen, Sch Med, Dept Expt Neurol, D-35392 Giessen, Germany; [Walberer, Maureen] Univ Cologne, Dept Neurol, Cologne, Germany; [Weidemann, Susanne; Heidenreich, Regina] Univ Tubingen, Dept Dermatol, Tubingen, Germany; [Couraud, Pierre O.] Univ Paris 05, Inst Cochin, Paris, France; [Weksler, Babette B.] Weill Cornell Med Coll, New York, NY USA; [Romero, Ignacio A.] Open Univ, Milton Keynes MK7 6AA, Bucks, England	Justus Liebig University Giessen; Justus Liebig University Giessen; Justus Liebig University Giessen; University of Cologne; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Cornell University; Open University - UK	Preissner, KT (corresponding author), Univ Giessen, Sch Med, Dept Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	klaus.t.preissner@biochemie.med.uni-giessen.de	Fischer, Silvia/ABG-3104-2021	Romero, Ignacio/0000-0002-0322-9180	Deutsche Forschungsgemeinschaft (Bonn, Germany) [SFB 547, SFB 685, SPP 1190]; Deutsche Krebshilfe [107128]	Deutsche Forschungsgemeinschaft (Bonn, Germany)(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank Barbel Fuhler and Ute Niebergall for their skilful technical assistance and Prof. Martin Rocken (University of Tubingen, Tubingen, Germany) for his kind cooperation. Studies were generously supported by grants (SFB 547, SFB 685, SPP 1190) from the Deutsche Forschungsgemeinschaft (Bonn, Germany) and the Deutsche Krebshilfe (107128).	ABBOTT NJ, 1991, CEREBROVAS BRAIN MET, V3, P39; Abid MR, 2004, J BIOL CHEM, V279, P44030, DOI 10.1074/jbc.M408285200; BAETHMAN A, 1978, NEUROSURG REV, V1, P85; Becker PM, 2005, CIRC RES, V96, P1257, DOI 10.1161/01.RES.0000171756.13554.49; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Blagoveshchenskaya AD, 2002, MOL BIOL CELL, V13, P1582, DOI 10.1091/mbc.01-09-0462; Chen XQ, 2000, CLIN CANCER RES, V6, P3823; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; DOUKAS J, 1994, AM J PATHOL, V145, P137; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fischer S, 2005, EUR J CELL BIOL, V84, P687, DOI 10.1016/j.ejcb.2005.03.002; Fischer S, 2007, BLOOD, V110, P2457, DOI 10.1182/blood-2006-08-040691; Fong TAT, 1999, CANCER RES, V59, P99; Garcia-Olmo DC, 2004, HISTOL HISTOPATHOL, V19, P575, DOI 10.14670/HH-19.575; Goldman CK, 1997, NEUROSURGERY, V40, P1269, DOI 10.1097/00006123-199706000-00029; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Imaizumi T, 2007, GLYCOBIOLOGY, V17, p12C, DOI 10.1093/glycob/cwm045; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kannemeier C, 2007, P NATL ACAD SCI USA, V104, P6388, DOI 10.1073/pnas.0608647104; Kopreski MS, 1999, CLIN CANCER RES, V5, P1961; Lake AC, 2006, J BIOL CHEM, V281, P37844, DOI 10.1074/jbc.M600686200; LEVINE JD, 1982, BLOOD, V60, P531; Liu XG, 2008, BLOOD, V112, P4961, DOI 10.1182/blood-2008-03-144022; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; Matsushita K, 2005, BLOOD, V105, P207, DOI 10.1182/blood-2004-04-1519; Nakazawa F, 2005, BIOCHEM J, V385, P831, DOI 10.1042/BJ20041021; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; REDDI KK, 1976, P NATL ACAD SCI USA, V73, P2308, DOI 10.1073/pnas.73.7.2308; Robinson CJ, 2006, J BIOL CHEM, V281, P1731, DOI 10.1074/jbc.M510760200; Robinson CJ, 2001, J CELL SCI, V114, P853; Rouet V, 2005, J BIOL CHEM, V280, P32792, DOI 10.1074/jbc.M504492200; SAMPAOLO S, 1991, ACTA NEUROPATHOL, V82, P107, DOI 10.1007/BF00293952; Schoch HJ, 2002, BRAIN, V125, P2549, DOI 10.1093/brain/awf257; Senger DR, 1996, AM J PATHOL, V149, P293; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; VRIES CD, 1992, SCIENCE, V255, P989; Weksler BB, 2005, FASEB J, V19, P1872, DOI 10.1096/fj.04-3458fje; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; WIECZOREK AJ, 1985, P NATL ACAD SCI USA, V82, P3455, DOI 10.1073/pnas.82.10.3455; Winston WM, 2007, P NATL ACAD SCI USA, V104, P10565, DOI 10.1073/pnas.0611282104; YANG J, 1994, J IMMUNOL, V152, P361	54	47	49	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2100	2109		10.1096/fj.08-121608	http://dx.doi.org/10.1096/fj.08-121608			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19246491				2022-12-28	WOS:000268836500010
J	Mounier, R; Lantier, L; Leclerc, J; Sotiropoulos, A; Pende, M; Daegelen, D; Sakamoto, K; Foretz, M; Viollet, B				Mounier, Remi; Lantier, Louise; Leclerc, Jocelyne; Sotiropoulos, Athanassia; Pende, Mario; Daegelen, Dominique; Sakamoto, Kei; Foretz, Marc; Viollet, Benoit			Important role for AMPK alpha 1 in limiting skeletal muscle cell hypertrophy	FASEB JOURNAL			English	Article						muscle functional overload; protein synthesis; mTOR-S6K signaling	ACTIVATED PROTEIN-KINASE; MAMMALIAN TARGET; GLUCOSE-UPTAKE; AMPK; EXERCISE; GROWTH; EXPRESSION; RAPAMYCIN; PHOSPHORYLATION; CONTRACTION	Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis through the suppression of the mammalian target of rapamycin complex 1 (mTORC1), a critical regulator of muscle growth. The purpose of this investigation was to determine the role of the AMPK alpha 1 catalytic subunit on muscle cell size control and adaptation to muscle hypertrophy. We found that AMPK alpha 1(-/-) primary cultured myotubes and myofibers exhibit larger cell size compared with control cells in response to chronic Akt activation. We next subjected the plantaris muscle of AMPK alpha 1(-/-) and control mice to mechanical overloading to induce muscle hypertrophy. We observed significant elevations of AMPK alpha 1 activity in the control muscle at days 7 and 21 after the overload. Overloading-induced muscle hypertrophy was significantly accelerated in AMPK alpha 1(-/-) mice than in control mice [+32 vs. +53% at day 7 and +57 vs. +76% at day 21 in control AMPK alpha 1(-/-) mice, respectively]. This enhanced growth of AMPK alpha 1-deficient muscle was accompanied by increased phosphorylation of mTOR signaling downstream targets and decreased phosphorylation of eukaryotic elongation factor 2. These results demonstrate that AMPK alpha 1 plays an important role in limiting skeletal muscle overgrowth during hypertrophy through inhibition of the mTOR-signaling pathway. Mounier, R., Louise Lantier, Leclerc, J., Sotiropoulos, A., Pende, M., Daegelen, D., Sakamoto, K., Foretz, M., Viollet, B. Important role for AMPK alpha 1 in limiting skeletal muscle cell hypertrophy. FASEB J. 23, 2264-2273 (2009)	[Viollet, Benoit] Univ Paris 05, INSERM U567, Inst Cochin, Dept Endocrinol Metab & Canc,CNRS,UMR 8104, F-75014 Paris, France; [Pende, Mario] INSERM, U845, Paris, France; [Pende, Mario] Univ Paris 05, UMRS 845, F-75014 Paris, France; [Sakamoto, Kei] Univ Dundee, Med Res Council, Prot Phosphorylat Unit, Coll Life Sci, Dundee, Scotland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Dundee	Viollet, B (corresponding author), Univ Paris 05, INSERM U567, Inst Cochin, Dept Endocrinol Metab & Canc,CNRS,UMR 8104, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	benoit.viollet@inserm.fr	FORETZ, Marc/O-7334-2017; Viollet, Benoit/N-2397-2019; sakamoto, kei/C-8806-2019; Pende, Mario/AFR-1348-2022; Sotiropoulos, Athanassia/P-4269-2017; Viollet, Benoit/O-6927-2017	FORETZ, Marc/0000-0001-7017-9032; Viollet, Benoit/0000-0002-0121-0224; sakamoto, kei/0000-0001-8839-5980; Pende, Mario/0000-0002-7864-8937; Viollet, Benoit/0000-0002-0121-0224; Sotiropoulos, Athanassia/0000-0002-7265-1473	European Union [LSHM-CT-2004-005272]; Agence Nationale de la Recherche (ANR); Association Francaise contre les Myopathies (AFM); UK Medical Research Council; Diabetes UK; AstraZeneca; Boehringer-Ingelheim; GlaxoSmithKline; Merck; Merck KGaA; Pfizer; MRC [MC_U127088492] Funding Source: UKRI; Medical Research Council [MC_U127088492] Funding Source: researchfish	European Union(European Commission); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); Association Francaise contre les Myopathies (AFM)(Association Francaise contre les Myopathies); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Diabetes UK(Diabetes UK); AstraZeneca(AstraZeneca); Boehringer-Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Merck KGaA; Pfizer(Pfizer); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the European Union FP6 program (EXGENESIS Integrated Project LSHM-CT-2004-005272), Agence Nationale de la Recherche (ANR) and Association Francaise contre les Myopathies (AFM). K. S. is supported by the UK Medical Research Council and Diabetes UK and by the companies AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Merck KGaA, and Pfizer. We gratefully acknowledge Charlotte Lahoute and Veronique Fauveau. We thank Grahame Hardie (University of Dundee, Dundee, UK) for providing AMPK alpha 1 and -alpha 2 antibodies.	Aguilar V, 2007, CELL METAB, V5, P476, DOI 10.1016/j.cmet.2007.05.006; Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Bolster DR, 2003, J PHYSIOL-LONDON, V553, P213, DOI 10.1113/jphysiol.2003.047019; CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x; Chan AYM, 2004, J BIOL CHEM, V279, P32771, DOI 10.1074/jbc.M403528200; Durante PE, 2002, AM J PHYSIOL-ENDOC M, V283, pE178, DOI 10.1152/ajpendo.00404.2001; Fujii N, 2000, BIOCHEM BIOPH RES CO, V273, P1150, DOI 10.1006/bbrc.2000.3073; Fulco M, 2008, CELL CYCLE, V7, P3669, DOI 10.4161/cc.7.23.7164; Gordon SE, 2008, EXERC SPORT SCI REV, V36, P179, DOI 10.1097/JES.0b013e3181877e13; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hardie DG, 2006, PHYSIOLOGY, V21, P48, DOI 10.1152/physiol.00044.2005; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jensen TE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002102; Jorgensen SB, 2005, FASEB J, V19, P1146, DOI 10.1096/fj.04-3144fje; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; Jorgensen SB, 2004, DIABETES, V53, P3074, DOI 10.2337/diabetes.53.12.3074; Jorgensen SB, 2007, AM J PHYSIOL-ENDOC M, V292, pE331, DOI 10.1152/ajpendo.00243.2006; Jorgensen SB, 2008, FRONT BIOSCI-LANDMRK, V13, P5589; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Koh HJ, 2006, MOL CELL BIOL, V26, P8217, DOI 10.1128/MCB.00979-06; Kumar A, 2008, MOL CELL BIOL, V28, P61, DOI 10.1128/MCB.01405-07; Le Grand F, 2007, CURR OPIN CELL BIOL, V19, P628, DOI 10.1016/j.ceb.2007.09.012; Le Grand F, 2007, DEVELOPMENT, V134, P3953, DOI 10.1242/dev.005934; Lee-Young RS, 2008, MED SCI SPORT EXER, V40, P1490, DOI 10.1249/MSS.0b013e318173a037; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Mcgee SL, 2008, J PHYSIOL-LONDON, V586, P1731, DOI 10.1113/jphysiol.2007.143685; Nader GA, 2002, CLIN ORTHOP RELAT R, pS178, DOI 10.1097/01.blo.0000031979.92980.2e; Nielsen JN, 2003, J APPL PHYSIOL, V94, P631, DOI 10.1152/japplphysiol.00642.2002; Ohanna M, 2005, NAT CELL BIOL, V7, P286, DOI 10.1038/ncb1231; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Reznick RM, 2007, CELL METAB, V5, P151, DOI 10.1016/j.cmet.2007.01.008; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Sakamoto K, 2006, AM J PHYSIOL-ENDOC M, V290, pE780, DOI 10.1152/ajpendo.00443.2005; Sakamoto K, 2004, AM J PHYSIOL-ENDOC M, V287, pE310, DOI 10.1152/ajpendo.00074.2004; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sanders MJ, 2007, J BIOL CHEM, V282, P32539, DOI 10.1074/jbc.M706543200; Stephens TJ, 2002, AM J PHYSIOL-ENDOC M, V282, pE688, DOI 10.1152/ajpendo.00101.2001; Thomson DM, 2006, J PHYSIOL-LONDON, V574, P291, DOI 10.1113/jphysiol.2006.107490; Thomson DM, 2005, J APPL PHYSIOL, V98, P557, DOI 10.1152/japplphysiol.00811.2004; Toyoda T, 2006, AM J PHYSIOL-ENDOC M, V290, pE583, DOI 10.1152/ajpendo.00395.2005; TSIKA RW, 1995, AM J PHYSIOL-CELL PH, V269, pC665, DOI 10.1152/ajpcell.1995.269.3.C665; Viollet B, 2007, DIABETES METAB, V33, P395, DOI 10.1016/j.diabet.2007.10.004; Wojtaszewski JFP, 2000, J PHYSIOL-LONDON, V528, P221, DOI 10.1111/j.1469-7793.2000.t01-1-00221.x; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yu M, 2003, J PHYSIOL-LONDON, V546, P327, DOI 10.1113/jphysiol.2002.034223	49	87	90	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2264	2273		10.1096/fj.08-119057	http://dx.doi.org/10.1096/fj.08-119057			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19237506	Green Submitted			2022-12-28	WOS:000268836500026
J	Dainese, M; Quarta, M; Lyfenko, AD; Paolini, C; Canato, M; Reggiani, C; Dirksen, RT; Protasi, F				Dainese, Marco; Quarta, Marco; Lyfenko, Alla D.; Paolini, Cecilia; Canato, Marta; Reggiani, Carlo; Dirksen, Robert T.; Protasi, Feliciano			Anesthetic- and heat-induced sudden death in calsequestrin-1-knockout mice	FASEB JOURNAL			English	Article						excitation-contraction coupling; environmental heat stroke; malignant hyperthermia; muscle disease; ryanodine receptor	CENTRAL CORE DISEASE; POLYMORPHIC VENTRICULAR-TACHYCARDIA; EXERCISE-INDUCED RHABDOMYOLYSIS; MUSCLE RYANODINE RECEPTOR; TWITCH SKELETAL-MUSCLE; AMINO-ACID-SEQUENCE; MALIGNANT-HYPERTHERMIA; SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; CARDIAC CALSEQUESTRIN	Calsequestrin-1 (CASQ1) is a moderate-affinity, high-capacity Ca2+-binding protein in the sarcoplasmic reticulum (SR) terminal cisternae of skeletal muscle. CASQ1 functions as both a Ca2+-binding protein and a luminal regulator of ryanodine receptor (RYR1)-mediated Ca2+ release. Mice lacking skeletal CASQ1 are viable but exhibit reduced levels of releasable Ca2+ and altered contractile properties. Here we report that CASQ1-null mice exhibit increased spontaneous mortality and susceptibility to heat- and anesthetic-induced sudden death. Exposure of CASQ1-null mice to either 2% halothane or heat stress triggers lethal episodes characterized by whole-body contractures, elevated core temperature, and severe rhabdomyolysis, which are prevented by prior dantrolene administration. The characteristics of these events are remarkably similar to analogous episodes observed in humans with malignant hyperthermia (MH) and animal models of MH and environmental heat stroke (EHS). In vitro studies indicate that CASQ1-null muscle exhibits increased contractile sensitivity to temperature and caffeine, temperature-dependent increases in resting Ca2+, and an increase in the magnitude of depolarization-induced Ca2+ release. These results demonstrate that CASQ1 deficiency alters proper control of RYR1 function and suggest CASQ1 as a potential candidate gene for linkage analysis in families with MH/EHS where mutations in the RYR1 gene are excluded.-Dainese, M., Quarta, M., Lyfenko, A. D., Paolini, C., Canato, M., Reggiani, C., Dirksen, R. T., Protasi, F. Anesthetic- and heat-induced sudden death in calsequestrin-1-knockout mice. FASEB J. 23, 1710-1720 (2009)	[Dainese, Marco; Paolini, Cecilia; Protasi, Feliciano] Univ G DAnnunzio, Dept Basic & Appl Med Sci, Ctr Sci Invecchiamento, Interuniv Inst Myol, I-66013 Chieti, Italy; [Quarta, Marco; Canato, Marta] Univ Padua, Dept Anat & Physiol, Interuniv Inst Myol, Padua, Italy; [Lyfenko, Alla D.; Reggiani, Carlo; Dirksen, Robert T.] Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	G d'Annunzio University of Chieti-Pescara; University of Padua; University of Rochester	Protasi, F (corresponding author), Univ G DAnnunzio, Dept Basic & Appl Med Sci, Ctr Sci Invecchiamento, Interuniv Inst Myol, I-66013 Chieti, Italy.	fprotasi@unich.it	Paolini, Cecilia/AAI-4444-2021		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044657, P01AR052354, R29AR044657] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR044657, AR44657, P01 AR052354, P01 AR052354-030004, 5P01AR052354, R01 AR044657-11, R29 AR044657] Funding Source: Medline; Telethon [GGP08153] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Telethon(Fondazione Telethon)		Avila G, 2001, J GEN PHYSIOL, V118, P277, DOI 10.1085/jgp.118.3.277; Avila G, 2005, CELL CALCIUM, V38, P35, DOI 10.1016/j.ceca.2005.05.001; Beard NA, 2002, BIOPHYS J, V82, P310, DOI 10.1016/S0006-3495(02)75396-4; Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089; BOURDON L, 1995, MED HYPOTHESES, V45, P268, DOI 10.1016/0306-9877(95)90116-7; Brandom B., 2002, ANESTHESIOLOGY, V96, pA1199, DOI [10.1097/00000542-200209002-01199, DOI 10.1097/00000542-200209002-01199]; Burkman JM, 2007, ANESTHESIOLOGY, V106, P901, DOI 10.1097/01.anes.0000265148.86566.68; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1197; Chelu MG, 2006, FASEB J, V20, P329, DOI 10.1096/fj.05-4497fje; DAMIANI E, 1990, J MUSCLE RES CELL M, V11, P522, DOI 10.1007/BF01745219; Davis M, 2002, BRIT J ANAESTH, V88, P508, DOI 10.1093/bja/88.4.508; Defranchi E, 2005, MICROSC RES TECHNIQ, V67, P27, DOI 10.1002/jemt.20177; Denborough M, 1998, LANCET, V352, P1131, DOI 10.1016/S0140-6736(98)03078-5; Dirksen RT, 2004, BIOPHYS J, V87, P3193, DOI 10.1529/biophysj.104.049447; Durham WJ, 2008, CELL, V133, P53, DOI 10.1016/j.cell.2008.02.042; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; Fryer MW, 1996, J PHYSIOL-LONDON, V493, P357, DOI 10.1113/jphysiol.1996.sp021388; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; Galli L, 2006, HUM MUTAT, V27, DOI 10.1002/humu.9442; Grogan H, 2002, BRIT J ANAESTH, V88, P700, DOI 10.1093/bja/88.5.700; GROUP TEM, 1984, BR J ANAESTHESIA, V56, P1267; Hausfater P, 2005, CRIT CARE, V9, P23, DOI 10.1186/cc2939; HOPKINS PM, 1991, LANCET, V338, P1491, DOI 10.1016/0140-6736(91)92304-K; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; Knollmann BC, 2006, J CLIN INVEST, V116, P2510, DOI 10.1172/JCI29128; Lahat H, 2001, AM J HUM GENET, V69, P1378, DOI 10.1086/324565; Lyfenko AD, 2004, BIOCHEM BIOPH RES CO, V322, P1256, DOI 10.1016/j.bbrc.2004.08.031; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; Migita T, 2007, J ANESTH, V21, P285, DOI 10.1007/s00540-006-0495-5; Monnier N, 1997, AM J HUM GENET, V60, P1316, DOI 10.1086/515454; Muldoon S, 2004, EXERC SPORT SCI REV, V32, P174; MURPHY RM, 2008, J PHYSL, V587, P443; ORDING H, 1985, ACTA ANAESTH SCAND, V29, P698, DOI 10.1111/j.1399-6576.1985.tb02283.x; PAMUKCOGLU T, 1988, AM J FOREN MED PATH, V9, P161, DOI 10.1097/00000433-198806000-00015; Paolini C, 2007, J PHYSIOL-LONDON, V583, P767, DOI 10.1113/jphysiol.2007.138024; Priori SG, 2001, CIRCULATION, V103, P196; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; RIOS E, 1991, J MUSCLE RES CELL M, V12, P127, DOI 10.1007/BF01774031; Rizzi N, 2008, CIRC RES, V103, P298, DOI 10.1161/CIRCRESAHA.108.171660; Robinson R, 2006, HUM MUTAT, V27, P977, DOI 10.1002/humu.20356; Rosenberg H, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-21; Royer L, 2008, J PHYSIOL-LONDON, V586, P4609, DOI 10.1113/jphysiol.2008.157990; Ryan JF, 1997, J CLIN ANESTH, V9, P66, DOI 10.1016/S0952-8180(96)00207-3; SACCHETTO R, 1993, J MUSCLE RES CELL M, V14, P646, DOI 10.1007/BF00141561; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SIDMAN RD, 1995, ACAD EMERG MED, V2, P315, DOI 10.1111/j.1553-2712.1995.tb03229.x; STRAZIS KP, 1993, ANESTH ANALG, V77, P297, DOI 10.1213/00000539-199377020-00014; Terentyev D, 2003, P NATL ACAD SCI USA, V100, P11759, DOI 10.1073/pnas.1932318100; Tobin JR, 2001, JAMA-J AM MED ASSOC, V286, P168, DOI 10.1001/jama.286.2.168; Treves S, 2005, NEUROMUSCULAR DISORD, V15, P577, DOI 10.1016/j.nmd.2005.06.008; Wang Y, 2006, J BIOL CHEM, V281, P15572, DOI 10.1074/jbc.M600090200; Wappler F, 2001, ANESTHESIOLOGY, V94, P95, DOI 10.1097/00000542-200101000-00019; WEDEL DJ, 1995, MAYO CLIN PROC, V70, P241, DOI 10.4065/70.3.241; Wei L, 2006, BIOPHYS J, V91, P1288, DOI 10.1529/biophysj.106.082610; Weiss RG, 2004, AM J PHYSIOL-CELL PH, V287, pC1094, DOI 10.1152/ajpcell.00173.2004; Wyndham C H, 1977, Ann N Y Acad Sci, V301, P128, DOI 10.1111/j.1749-6632.1977.tb38192.x; Yang TZ, 2006, ANESTHESIOLOGY, V105, P1164, DOI 10.1097/00000542-200612000-00016; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	62	83	83	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1710	1720		10.1096/fj.08-121335	http://dx.doi.org/10.1096/fj.08-121335			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19237502	Green Published			2022-12-28	WOS:000266652400011
J	Grosse, SM; Tagalakis, AD; Mustapa, MFM; Elbs, M; Meng, QH; Mohammadi, A; Tabor, AB; Hailes, HC; Hart, SL				Grosse, Stephanie M.; Tagalakis, Aristides D.; Mustapa, M. Firouz Mohd; Elbs, Martin; Meng, Qing-Hai; Mohammadi, Atefeh; Tabor, Alethea B.; Hailes, Helen C.; Hart, Stephen L.			Tumor-specific gene transfer with receptor-mediated nanocomplexes modified by polyethylene glycol shielding and endosomally cleavable lipid and peptide linkers	FASEB JOURNAL			English	Article						integrin-targeting peptides; PEGylated lipids; cleavable linkers; systemic delivery; nonviral vectors; gene expression	SYNTHETIC VECTOR SYSTEM; AIRWAY EPITHELIAL-CELLS; DELIVERY VECTOR; VASCULAR CELLS; PHAGE DISPLAY; IN-VITRO; INTEGRIN; BINDING; PEG; DNA	Synthetic nanoparticle formulations have the potential for tumor-targeted gene delivery. Receptor-targeted nanocomplex (RTN) formulations comprise mixtures of cationic liposomes and targeting peptides that self-assemble on mixing with nucleic acids. RTN formulations were prepared containing different polyethylene glycol (PEG)ylated lipids with esterase-cleavable linkers (e. g., ME42) to promote intracellular PEG detachment and nanoparticle disassembly. In addition, integrin-targeting peptides (peptide ME27) were tested with endosomal furin-and cathepsin B-cleavable peptide linkers located between the integrin-binding ligand and the K-16 nucleic acid-binding domain to promote intracellular disengagement from the receptor. ME42/ME27 RTNs formed stable particles of <200 nm in isotonic salt buffers, compared with 4-mu m particles formed by un-PEGylated RTNs. Transfection efficiency by PEG-modified, cleavable RTNs improved similar to 2-fold in 4 different cell lines, with 80% efficiency in murine neuroblastoma cells. In an in vivo model of neuroblastoma, ME42/ME27 RTNs delivering luciferase genes were tumor specific, with little expression in other organs tested. PEGylation of the RTNs enhanced luciferase transfection 5-fold over non-PEG formulations, whereas the cleavability of the peptide ME27 enhanced transfection 4-fold over that of RTNs with noncleavable peptides. Cleavability of the lipid for in vivo transfections had no effect. PEGylated, cleavable RTN formulations offer prospects for tumor-specific therapeutic gene transfer.-Grosse, S. M., Tagalakis, A. D., Firouz Mohd Mustapa, M., Elbs, M., Meng, Q.-H., Mohammadi, A., Tabor, A. B., Hailes, H. C., Hart, S. L. Tumor-specific gene transfer with receptor-mediated nanocomplexes modified by polyethylene glycol shielding and endosomally cleavable lipid and peptide linkers. FASEB J. 24, 2301-2313 (2010). www.fasebj.org	[Grosse, Stephanie M.; Tagalakis, Aristides D.; Meng, Qing-Hai; Hart, Stephen L.] UCL, Mol Immunol Unit, Inst Child Hlth, London, England; [Mustapa, M. Firouz Mohd; Elbs, Martin; Mohammadi, Atefeh; Tabor, Alethea B.; Hailes, Helen C.] UCL, Dept Chem, London, England; [Hart, Stephen L.] Genex Biosyst Ltd, London, England	University of London; University College London; University of London; University College London	Hart, SL (corresponding author), UCL Inst Child Hlth, Wolfson Ctr Gene Therapy Childhood Dis, 30 Guilford St, London WC1N 1EH, England.	shart@ich.ucl.ac.uk	Hart, Stephen L/C-1615-2008; Tagalakis, Aristides/E-8883-2011	Hart, Stephen L/0000-0001-8254-376X; Hailes, Helen/0000-0001-5574-4742	Biotechnology and Biological Sciences Research Council; Biotechnology and Biological Sciences Research Council [BBS/B/03645] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors thank Jo Sinclair [University College London (UCL) Institute of Child Health, London, UK] for her help in flow cytometry analysis and Dyanne Rampling (UCL Institute of Child Health, London, UK) for technical assistance in tumor paraffin sections. This work was funded by the Biotechnology and Biological Sciences Research Council.	ALLEN TM, 1994, TRENDS PHARMACOL SCI, V15, P215, DOI 10.1016/0165-6147(94)90314-X; Band AM, 2001, FEBS LETT, V505, P118, DOI 10.1016/S0014-5793(01)02798-3; Barker SE, 2007, BRIT J CANCER, V97, P210, DOI 10.1038/sj.bjc.6603857; Chonn A, 1998, ADV DRUG DELIVER REV, V30, P73, DOI 10.1016/S0169-409X(97)00108-7; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Cunningham S, 2002, J GENE MED, V4, P438, DOI 10.1002/jgm.270; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Ebert DH, 2002, J BIOL CHEM, V277, P24609, DOI 10.1074/jbc.M201107200; Erbacher P, 1996, EXP CELL RES, V225, P186, DOI 10.1006/excr.1996.0169; GU ML, 1995, FEBS LETT, V365, P95, DOI 10.1016/0014-5793(95)00447-H; Hart S, 1999, EXP NEPHROL, V7, P193; Hart SL, 1997, GENE THER, V4, P1225, DOI 10.1038/sj.gt.3300513; Hart SL, 1998, HUM GENE THER, V9, P575, DOI 10.1089/hum.1998.9.4-575; Hurley CA, 2004, J ORG CHEM, V69, P980, DOI 10.1021/jo035422g; Hurley CA, 2008, ORG BIOMOL CHEM, V6, P2554, DOI 10.1039/b719702k; Irvine SA, 2008, MOL THER, V16, P508, DOI 10.1038/sj.mt.6300381; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; Jenkins RG, 2003, GENE THER, V10, P1026, DOI 10.1038/sj.gt.3301963; Jenkins RG, 2000, GENE THER, V7, P393, DOI 10.1038/sj.gt.3301095; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; Lee M, 2005, PHARM RES-DORDR, V22, P1, DOI 10.1007/s11095-004-9003-5; Meng QH, 2004, J GENE MED, V6, P210, DOI 10.1002/jgm.483; Meng QH, 2006, HUM GENE THER, V17, P717, DOI 10.1089/hum.2006.17.717; Mustapa MFM, 2007, BIOCHEMISTRY-US, V46, P12930, DOI 10.1021/bi701014y; Mustapa MFM, 2009, BIOCONJUGATE CHEM, V20, P518, DOI 10.1021/bc800450r; Ogris M, 2001, AAPS PHARMSCI, V3, part. no.; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; Parkes R, 2002, J GENE MED, V4, P292, DOI 10.1002/jgm.265; Pilkington-Miksa MA, 2008, EUR J ORG CHEM, V2008, P2900, DOI 10.1002/ejoc.200701188; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; Rao GA, 2008, J DRUG TARGET, V16, P79, DOI 10.1080/10611860701733328 ; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Semple SC, 1998, ADV DRUG DELIVER REV, V32, P3, DOI 10.1016/S0169-409X(97)00128-2; Siapati KE, 2003, BRIT J CANCER, V88, P1641, DOI 10.1038/sj.bjc.6600928; Tagalakis AD, 2008, MOL THER, V16, P907, DOI 10.1038/mt.2008.38; Torchilin VP, 2007, PHARM RES-DORDR, V24, P1, DOI 10.1007/s11095-006-9132-0; Uduehi A, 2003, BIOTECHNOL APPL BIOC, V38, P201, DOI 10.1042/BA20030062; White RE, 2003, J GENE MED, V5, P883, DOI 10.1002/jgm.420; Wong JB, 2008, MOL BIOSYST, V4, P532, DOI 10.1039/b719782a; Workman P, 1998, BRIT J CANCER, V77, P1; Writer M, 2006, J LIPOSOME RES, V16, P373, DOI 10.1080/08982100600992500; Writer MJ, 2004, J DRUG TARGET, V12, P185, DOI 10.1080/10611860410001724459; Yu W, 2004, GENE THER, V11, P1434, DOI 10.1038/sj.gt.3302304	44	49	54	2	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2301	2313		10.1096/fj.09-144220	http://dx.doi.org/10.1096/fj.09-144220			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20203088				2022-12-28	WOS:000279343600017
J	Yoshida, T; Zhang, HF; Iwase, T; Shen, JK; Semenza, GL; Campochiaro, PA				Yoshida, Tsunehiko; Zhang, Huafeng; Iwase, Takeshi; Shen, Jikui; Semenza, Gregg L.; Campochiaro, Peter A.			Digoxin inhibits retinal ischemia-induced HIF-1 alpha expression and ocular neovascularization	FASEB JOURNAL			English	Article						age-related macular degeneration; angiogenesis; cardiac glycosides; diabetic retinopathy	ENDOTHELIAL GROWTH-FACTOR; SUPPRESSES CHOROIDAL NEOVASCULARIZATION; HYPOXIA-INDUCIBLE FACTOR-1; KINASE INHIBITOR; PROLIFERATIVE RETINOPATHY; MACULAR DEGENERATION; DIABETIC-RETINOPATHY; IN-VIVO; VEGF; ANGIOGENESIS	Digoxin and other cardiac glycosides inhibit hypoxia-inducible factor-1 (HIF-1) transcriptional activity in cultured cells and suppress tumor xenograft growth. We tested the hypothesis that digoxin reduces HIF-1 levels in ischemic tissue in vivo and suppresses neovascularization. Well-established murine models of ocular neovascularization were used to test our hypothesis. In mice with ischemic retinopathy, intraocular or intraperitoneal injection of digoxin markedly reduced retinal levels of HIF-1 alpha protein and mRNAs encoding multiple hypoxia-regulated proangiogenic proteins and their receptors. Daily intraperitoneal injection of 2 mg/kg starting at postnatal day (P) 12 or a single intravitreous injection of 100 ng of digoxin at P12 reduced retinal neovascularization by >70% at P17. Digoxin also reduced the number of CXCR4(+) cells and F4/80(+) macrophages in ischemic retina and significantly reduced choroidal neovascularization at Bruch's membrane rupture sites. Digoxin suppresses retinal and choroidal neovascularization by reducing HIF-1 alpha levels, which blocks several proangiogenic pathways. Since digoxin suppresses multiple pathways in addition to VEGF signaling, it may provide advantages over specific VEGF antagonists for treatment of patients with retinal and choroidal diseases complicated by neovascularization and/or excessive vascular permeability. It may also be useful for treatment of neovascular diseases in other tissues.-Yoshida, T., Zhang, H., Iwase, T., Shen, J., Semenza, G. L., Campochiaro, P. A. Digoxin inhibits retinal ischemia-induced HIF-1 alpha expression and ocular neovascularization. FASEB J. 24, 1759-1767 (2010). www.fasebj.org	[Yoshida, Tsunehiko; Iwase, Takeshi; Shen, Jikui; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; [Yoshida, Tsunehiko; Iwase, Takeshi; Shen, Jikui; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; [Zhang, Huafeng; Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn, Baltimore, MD 21205 USA; [Zhang, Huafeng; Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Campochiaro, PA (corresponding author), Wilmer Eye Inst, 719 Maumenee,600 N Wolfe St, Baltimore, MD 21287 USA.	gsemenza@jhmi.edu; pcampo@jhmi.edu	Zhang, Huafeng/A-7188-2012; Iwase, Takeshi/H-8110-2015		U.S. National Institutes of Health/National Eye Institute [EY012609]; Johns Hopkins Institute for Cell Engineering; NATIONAL EYE INSTITUTE [R01EY012609] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Johns Hopkins Institute for Cell Engineering; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by U.S. National Institutes of Health/National Eye Institute grant EY012609 (P.A.C.) and the Johns Hopkins Institute for Cell Engineering (G.L.S.) G.L.S. is the C. Michael Armstrong Professor of Johns Hopkins University. P.A.C. is the George and Dolores Eccles Professor of Ophthalmology and Neuroscience.	AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; Boyer DS, 2009, INVEST OPHTHALMOL VI; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655; Butler JM, 2005, J CLIN INVEST, V115, P86, DOI 10.1172/JCI200522869; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; COUSINS SW, 2009, INVEST OPHTHALMOL VI; Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698; Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426; Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607; Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.3.CO;2-Z; Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128; Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588; Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338; Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2001; Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114; Morita M, 2003, EMBO J, V22, P1134, DOI 10.1093/emboj/cdg117; Okamoto N, 1997, AM J PATHOL, V151, P281; Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje; Oshima Y, 2004, J CELL PHYSIOL, V199, P412, DOI 10.1002/jcp.10442; Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744; Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6; Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182; Patel TH, 2005, CARDIOVASC RES, V68, P144, DOI 10.1016/j.cardiores.2005.05.002; Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2; Seo MS, 2000, AM J PATHOL, V157, P995, DOI 10.1016/S0002-9440(10)64612-3; Shen JK, 2007, INVEST OPHTH VIS SCI, V48, P4335, DOI 10.1167/iovs.07-0113; Silva RLE, 2007, FASEB J, V21, P3219, DOI 10.1096/fj.06-7359com; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436; Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773; Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105	46	91	105	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1759	1767		10.1096/fj.09-145664	http://dx.doi.org/10.1096/fj.09-145664			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20065104	Green Published			2022-12-28	WOS:000278200000013
J	Xu, HW; Wu, ZY; Fang, F; Guo, L; Chen, D; Chen, JX; Stern, D; Taylor, GA; Jiang, H; Yan, SS				Xu, Hongwei; Wu, Zhi-Ying; Fang, Fang; Guo, Lan; Chen, Doris; Chen, John Xi; Stern, David; Taylor, Gregory A.; Jiang, Hong; Yan, Shirley ShiDu			Genetic deficiency of Irgm1 (LRG-47) suppresses induction of experimental autoimmune encephalomyelitis by promoting apoptosis of activated CD4(+) T cells	FASEB JOURNAL			English	Article						IFN-gamma-mediated apoptosis; EAE/MS; animal model	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; INTERFERON-GAMMA; MYCOBACTERIAL INFECTION; INTRACELLULAR PATHOGENS; MULTIPLE-SCLEROSIS; MICE DEFICIENT; P47 GTPASES; SURVIVAL; IMMUNITY	The immunity-related GTPase Irgm1, also called LRG-47, is known to regulate host resistance to intracellular pathogens through multiple mechanisms that include controlling the survival of T lymphocytes. Here, we address whether Irgm1 also plays a role in the pathogenesis of experimental autoimmune encephalitis (EAE). We find that Irgm1/LRG-47 is a significant factor in the progression of EAE and multiple sclerosis (MS). Expression of Irgm1 was robustly elevated in MS-affected lesions and in the central nervous system (CNS) of myelin basic protein (MBP)-induced EAE mice, especially in cells of lymphoid and mononuclear phagocyte origin. Homozygous Irgm1 null mice were resistant to MBP-induced EAE, and CD4(+) T cells in spleen and CNS of these mice displayed decreased proliferative capacity, increased apoptosis, and up-regulated interferon (IFN)-gamma induction. Therefore, Irgm1-induced survival of autoreactive CD4(+) T cells contributes significantly to the pathogenesis of EAE. Blockade of Irgm1 may be a potential therapeutic strategy for halting multiple sclerosis.-Xu, H., Wu, Z.-Y., Fang, F., Guo, L., Chen, D., Chen, J. X., Stern, D., Taylor, G. A., Jiang, H., Yan, S. S. Genetic deficiency of Irgm1 (LRG-47) suppresses induction of experimental autoimmune encephalomyelitis by promoting apoptosis of activated CD4(+) T cells. FASEB J. 24, 1583-1592 (2010). www.fasebj.org	[Xu, Hongwei; Wu, Zhi-Ying; Fang, Fang; Guo, Lan; Chen, Doris; Yan, Shirley ShiDu] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Xu, Hongwei; Wu, Zhi-Ying; Fang, Fang; Guo, Lan; Chen, Doris; Yan, Shirley ShiDu] Columbia Univ, Dept Surg, New York, NY 10032 USA; [Jiang, Hong] Columbia Univ, Dept Med, Taub Inst Res Alzheimers Dis & Aging, Coll Phys & Surg, New York, NY 10032 USA; [Xu, Hongwei] Harbin Med Coll, Dept Immunol, Harbin, Peoples R China; [Chen, John Xi] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; [Stern, David] Univ Cincinnati, Dept Hlth Affairs, Cincinnati, OH USA; [Taylor, Gregory A.] Duke Univ, Med Ctr, Dept Med, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; [Taylor, Gregory A.] Duke Univ, Med Ctr, Dept Immunol, Div Geriatr, Durham, NC 27710 USA; [Taylor, Gregory A.] Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC 27710 USA; [Taylor, Gregory A.] Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC USA; [Wu, Zhi-Ying] Fudan Univ, State Key Lab Med Neurobiol, Shanghai Med Coll, Inst Neurol,Huashan Hosp, Shanghai 200433, Peoples R China; [Wu, Zhi-Ying] Fudan Univ, Dept Neurol, Shanghai 200433, Peoples R China	Columbia University; Columbia University; Columbia University; Harbin Medical University; Memorial Sloan Kettering Cancer Center; University System of Ohio; University of Cincinnati; Duke University; Duke University; Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Fudan University; Fudan University	Yan, SS (corresponding author), Columbia Univ, Dept Pathol, 650 W 168th St, New York, NY 10032 USA.	sdy1@columbia.edu	Xu, Hongwei/S-3865-2018	Xu, Hongwei/0000-0001-5763-3894	National Institute of Neurological Disorders and Stroke grant [NINDS 042855]; U. S. National Institutes of Health [AI-57831]; Veterans Affairs Merit Review; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057831] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs Merit Review(US Department of Veterans Affairs); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	These studies were supported by National Institute of Neurological Disorders and Stroke grant NINDS 042855. The authors thank A. P. Hays ( Department of Pathology, Columbia University) for providing human MS samples and suggestions. G. T. is supported by U. S. National Institutes of Health grant AI-57831 and a Veterans Affairs Merit Review grant.	Arancio O, 2004, EMBO J, V23, P4096, DOI 10.1038/sj.emboj.7600415; Butcher BA, 2005, INFECT IMMUN, V73, P3278, DOI 10.1128/IAI.73.6.3278-3286.2005; Chu CQ, 2000, J EXP MED, V192, P123, DOI 10.1084/jem.192.1.123; Collazo CM, 2001, J EXP MED, V194, P181, DOI 10.1084/jem.194.2.181; Dalton DK, 2000, J EXP MED, V192, P117, DOI 10.1084/jem.192.1.117; DU Y.S., 1997, P NATL ACAD SCI USA, V94, P5296; Feng CG, 2008, NAT IMMUNOL, V9, P1279, DOI 10.1038/ni.1653; Feng CG, 2008, CELL STEM CELL, V2, P83, DOI 10.1016/j.stem.2007.10.007; Feng CG, 2004, J IMMUNOL, V172, P1163, DOI 10.4049/jimmunol.172.2.1163; Ferber IA, 1996, J IMMUNOL, V156, P5; Gold R, 1997, TRENDS NEUROSCI, V20, P399, DOI 10.1016/S0166-2236(97)01079-5; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Hohlfeld R, 2001, CURR OPIN NEUROL, V14, P299, DOI 10.1097/00019052-200106000-00006; Hur EM, 2007, NAT IMMUNOL, V8, P74, DOI 10.1038/ni1415; Krakowski M, 1996, EUR J IMMUNOL, V26, P1641, DOI 10.1002/eji.1830260735; MacMicking JD, 2003, SCIENCE, V302, P654, DOI 10.1126/science.1088063; MacMicking JD, 2004, TRENDS IMMUNOL, V25, P601, DOI 10.1016/j.it.2004.08.010; Mahoney JA, 2005, CURR OPIN IMMUNOL, V17, P583, DOI 10.1016/j.coi.2005.09.018; Mao PZ, 2010, BBA-MOL BASIS DIS, V1802, P66, DOI 10.1016/j.bbadis.2009.07.002; O'Connor RA, 2005, J AUTOIMMUN, V24, P93, DOI 10.1016/j.jaut.2005.01.005; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; Refaeli Y, 2002, J EXP MED, V196, P999, DOI 10.1084/JEM.20020666; Santiago HC, 2005, J IMMUNOL, V175, P8165, DOI 10.4049/jimmunol.175.12.8165; Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577; Sospedra M, 2005, ANNU REV IMMUNOL, V23, P683, DOI 10.1146/annurev.immunol.23.021704.115707; Stromnes IM, 2007, NAT IMMUNOL, V8, P19, DOI 10.1038/ni0107-19; TABI Z, 1994, EUR J IMMUNOL, V24, P2609, DOI 10.1002/eji.1830241107; Taylor GA, 2004, NAT REV IMMUNOL, V4, P100, DOI 10.1038/nri1270; Taylor GA, 1996, J BIOL CHEM, V271, P20399, DOI 10.1074/jbc.271.34.20399; Todaro M, 2004, J CLIN IMMUNOL, V24, P1, DOI 10.1023/B:JOCI.0000018057.89066.c6; Yan SS, 2003, NAT MED, V9, P287, DOI 10.1038/nm831; ZAMVIL S, 1985, NATURE, V317, P355, DOI 10.1038/317355a0; Zhang HFM, 2003, J BIOL CHEM, V278, P33011, DOI 10.1074/jbc.M305352200	33	28	30	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2010	24	5					1583	1592		10.1096/fj.09-137323	http://dx.doi.org/10.1096/fj.09-137323			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20056715	Bronze, Green Published			2022-12-28	WOS:000277158900030
J	Czyzyk, TA; Nogueiras, R; Lockwood, JF; McKinzie, JH; Coskun, T; Pintar, JE; Hammond, C; Tschop, MH; Statnick, MA				Czyzyk, Traci A.; Nogueiras, Ruben; Lockwood, John F.; McKinzie, Jamie H.; Coskun, Tamer; Pintar, John E.; Hammond, Craig; Tschop, Matthias H.; Statnick, Michael A.			kappa-Opioid receptors control the metabolic response to a high-energy diet in mice	FASEB JOURNAL			English	Article						malonyl CoA; corticosterone; hepatocytes; energy expenditure; nonexercise activity thermogenesis	INDUCED OBESITY; MESSENGER-RNA; FOOD-INTAKE; PARAVENTRICULAR NUCLEUS; PREFRONTAL CORTEX; DEFICIENT MICE; MOUSE-BRAIN; MALONYL-COA; DYNORPHIN; RAT	General opioid receptor antagonists reduce food intake and body weight in rodents, but the contributions of specific receptor subtypes are unknown. We examined whether genetic deletion of the kappa-opioid receptor (KOR) in mice alters metabolic physiology. KOR-knockout (KO) and wild-type (WT) mice were fed a high-energy diet (HED) for 16 wk. KO mice had 28% lower body weight and 45% lower fat mass when compared to WT mice fed an HED. No differences in caloric intake were found. An HED reduced energy expenditure in WT mice, but not in KO mice. KOR deficiency led to an attenuation of triglyceride synthesis in the liver. Malonyl CoA levels were also reduced in response to an HED, thereby promoting hepatic beta-oxidation. Glycemic control was also found to be improved in KO mice. These data suggest a key role for KORs in the central nervous system regulation of the metabolic adaptation to an HED, as we were unable to detect expression of KOR in liver, white adipose tissue, or skeletal muscle in WT mice. This study provides the first evidence that KORs play an essential physiological role in the control of hepatic lipid metabolism, and KOR activation is a permissive signal toward fat storage.-Czyzyk, T. A., Nogueiras, R., Lockwood, J. F., McKinzie, J. H., Coskun, T., Pintar, J. E., Hammond, C., Tschop, M. H., Statnick, M. A. kappa-Opioid receptors control the metabolic response to a high-energy diet in mice. FASEB J. 24, 1151-1159 (2010). www.fasebj.org	[Czyzyk, Traci A.] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA; [Nogueiras, Ruben; Tschop, Matthias H.] Univ Cincinnati, Dept Med, Div Endocrinol, Metab Dis Inst, Cincinnati, OH 45221 USA; [Pintar, John E.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA; [Nogueiras, Ruben] Univ Santiago de Compostela, Dept Physiol, Inst Invest Sanitaria, Santiago De Compostela, Spain	Eli Lilly; University System of Ohio; University of Cincinnati; Rutgers State University New Brunswick; Rutgers State University Medical Center; Universidade de Santiago de Compostela	Czyzyk, TA (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, DC 0403,355 E Merrill St, Indianapolis, IN 46285 USA.	czyzyk-morgantr@lilly.com; m.statnick@lilly.com	Nogueiras, Ruben/AAS-9427-2021; Coskun, Tamer/AAR-8422-2021; Tschoep, Matthias H/I-5443-2014	Nogueiras, Ruben/0000-0002-9976-9930; Tschoep, Matthias/0000-0002-4744-371X; Czyzyk, Traci/0000-0002-3888-8338	National Institutes of Health [NIDDK59630, NIDDK69987, NIDDK56863]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Aaron Showalter, Jim Baker, and Kelly Credile for their outstanding technical support and helpful advice. The authors also thank David Peake, Lawrence Goodwin, Thomas Seng, David Yurek, Rita Davidson, and MingShang Kuo for development of LC-MS/MS methods for malonyl CoA measurements. Research at the University of Cincinnati was funded by National Institutes of Health grants NIDDK59630, NIDDK69987, and NIDDK56863 (to M.H.T.). Portions of this work were presented in abstract form for the 2009 Keystone Symposia, Obesity: Novel Aspects of the Regulation of Body Weight (Banff, AB, Canada).	Ansonoff MA, 2006, J PHARMACOL EXP THER, V318, P641, DOI 10.1124/jpet.106.101998; Bodnar RJ, 2004, PEPTIDES, V25, P697, DOI 10.1016/j.peptides.2004.01.006; Brugman S, 2002, ENDOCRINOLOGY, V143, P4265, DOI 10.1210/en.2002-220230; Chang GQ, 2007, AM J PHYSIOL-ENDOC M, V292, pE561, DOI 10.1152/ajpendo.00087.2006; Chefer VI, 2005, J NEUROSCI, V25, P5029, DOI 10.1523/JNEUROSCI.0854-05.2005; Chien D, 2000, AM J PHYSIOL-ENDOC M, V279, pE259, DOI 10.1152/ajpendo.2000.279.2.E259; Chou TC, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-19-j0003.2001; Cooke D, 2006, NAT REV DRUG DISCOV, V5, P919, DOI 10.1038/nrd2136; CZYZYK TA, 1999, 29 ANN SOC NEUR M, V25, P179; DEPAOLI AM, 1994, MOL CELL NEUROSCI, V5, P327, DOI 10.1006/mcne.1994.1039; DICHIARA G, 1988, J PHARMACOL EXP THER, V244, P1067; FLATT JP, 1993, ANN NY ACAD SCI, V683, P122; KAPAS S, 1995, J ENDOCRINOL, V144, P503, DOI 10.1677/joe.0.1440503; Kieffer BL, 2002, PROG NEUROBIOL, V66, P285, DOI 10.1016/S0301-0082(02)00008-4; KOCH JE, 1995, NEUROSCIENCE, V66, P951, DOI 10.1016/0306-4522(95)00001-Y; Kokkotou E, 2005, AM J PHYSIOL-REG I, V289, pR117, DOI 10.1152/ajpregu.00861.2004; Lean MEJ, 2000, P NUTR SOC, V59, P331, DOI 10.1017/S0029665100000379; LEVINE AS, 1991, BRAIN RES, V566, P193, DOI 10.1016/0006-8993(91)91698-Z; MANSOUR A, 1994, MOL CELL NEUROSCI, V5, P124, DOI 10.1006/mcne.1994.1015; Maolood N, 2008, NEUROSCIENCE, V154, P1121, DOI 10.1016/j.neuroscience.2008.04.011; Margolis EB, 2006, P NATL ACAD SCI USA, V103, P2938, DOI 10.1073/pnas.0511159103; Minkler PE, 2006, ANAL BIOCHEM, V352, P24, DOI 10.1016/j.ab.2006.02.015; MORLEY JE, 1983, PEPTIDES, V4, P797, DOI 10.1016/0196-9781(83)90069-4; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Pfluger PT, 2008, AM J PHYSIOL-GASTR L, V294, pG610, DOI 10.1152/ajpgi.00321.2007; Roy S, 1998, MOL BRAIN RES, V56, P281, DOI 10.1016/S0169-328X(98)00051-5; Ruderman NB, 2003, ENDOCRINOLOGY, V144, P5166, DOI 10.1210/en.2003-0849; SAHR AE, 2008, AM J PHYSIOL, V295, pR468; Sainsbury A, 2007, MOL ENDOCRINOL, V21, P1722, DOI 10.1210/me.2006-0367; SHAW WN, 1993, PHARMACOL BIOCHEM BE, V46, P653, DOI 10.1016/0091-3057(93)90557-A; SHAW WN, 1991, INT J OBESITY, V15, P387; Shuster SJ, 2000, NEUROSCIENCE, V96, P373, DOI 10.1016/S0306-4522(99)00472-8; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Smith MJ, 2001, BRAIN RES, V898, P162, DOI 10.1016/S0006-8993(01)02154-0; Statnick MA, 2003, AM J PHYSIOL-REG I, V284, pR1399, DOI 10.1152/ajpregu.00632.2002; Svingos AL, 2002, BRAIN RES, V946, P262, DOI 10.1016/S0006-8993(02)02894-9; Svingos AL, 1999, J NEUROSCI, V19, P1804; Tabarin A, 2005, DIABETES, V54, P3510, DOI 10.2337/diabetes.54.12.3510; Tataranni PA, 1996, AM J PHYSIOL-ENDOC M, V271, pE317, DOI 10.1152/ajpendo.1996.271.2.E317; Welch CC, 1996, BRAIN RES, V721, P126, DOI 10.1016/0006-8993(96)00151-5; Wittmann W, 2009, NEUROPSYCHOPHARMACOL, V34, P775, DOI 10.1038/npp.2008.142; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; Zuberi AR, 2008, EUR J PHARMACOL, V585, P14, DOI 10.1016/j.ejphar.2008.01.047	44	63	64	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2010	24	4					1151	1159		10.1096/fj.09-143610	http://dx.doi.org/10.1096/fj.09-143610			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19917675	Green Published			2022-12-28	WOS:000276462300022
J	Favier, B; LeMaoult, J; Lesport, E; Carosella, ED				Favier, Benoit; LeMaoult, Joel; Lesport, Emilie; Carosella, Edgardo D.			ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse	FASEB JOURNAL			English	Article						cytoskeleton; inhibitory receptor; immunological synapse	NATURAL-KILLER-CELLS; ALDRICH-SYNDROME PROTEIN; IMMUNOLOGICAL SYNAPSE; HLA-G; TRANSCRIPT-2 ILT2; IMMUNE SYNAPSES; DENDRITIC CELLS; INNATE IMMUNITY; T-CELLS; CYTOTOXICITY	Natural killer (NK) cells play a crucial role in the antitumoral responses through cytolytic function and cytokine production. Expression of HLA-G at the surface of tumoral cells confers a protection against NK-cell cytolysis through its interaction with the ILT2 inhibitory receptor. Even though the role of this interaction on the inhibition of NK-cell cytotoxicity is well established, its effect on the molecular events occurring at the NK/target-cell synapse is not well characterized. We found that the interaction of the inhibitory receptor ILT2 with HLA-G inhibited the polarization of NK-cell lytic granules and the microtubule organizing center (MTOC) as well as the accumulation of filamentous actin (F-actin) at the area of contact. However, it did not affect the recruitment of the activatory receptor CD2 at the NK/target-cell interface. Even though CD2 was accumulated to the NK-cell synapse, the interaction of ILT2 with HLA-G efficiently inhibited intracellular calcium mobilization and IFN-gamma polarized production of NK cells. These results indicate that while the ILT2/HLA-G interaction leads to the inhibition of NK-cell functions, it displays differential effects on cytoskeleton reorganization and CD2 localization at the NK-cell synapse.-Favier, B., LeMaoult, J., Lesport, E., Carosella, E. D. ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell-activating synapse. FASEB J. 24, 689-699 (2010). www.fasebj.org	[Favier, Benoit; LeMaoult, Joel; Lesport, Emilie; Carosella, Edgardo D.] Hop St Louis, CEA, Serv Rech Hematoimmunol I2BM, Inst Univ Hematol, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; CEA; UDICE-French Research Universities; Universite Paris Cite	Favier, B (corresponding author), Hop St Louis, CEA, Serv Rech Hematoimmunol I2BM, Inst Univ Hematol, 1 Ave Claude Vellefaux, F-75010 Paris, France.	benoit.favier@cea.fr	LeMaoult, Joel/E-9583-2011; FAVIER, Benoit/W-7379-2019	Lesport, Emilie/0000-0001-8078-2361; LeMaoult, Joel/0000-0002-4513-9482	Comissariat a l'Energie Atomique (CEA); Ile France	Comissariat a l'Energie Atomique (CEA)(French Atomic Energy Commission); Ile France	This work was supported by the Comissariat a l'Energie Atomique (CEA) and Ile France. We thank N. Setterblad and the Service Commun d'Imagerie Cellulaire et Moleculaire for their help. We also thank Sylvie Sousa for technical assistance.	Badour K, 2003, IMMUNITY, V18, P141, DOI 10.1016/S1074-7613(02)00516-2; Bryceson YT, 2006, BLOOD, V107, P159, DOI 10.1182/blood-2005-04-1351; Bryceson YT, 2005, J EXP MED, V202, P1001, DOI 10.1084/jem.20051143; Butler B, 2008, NAT IMMUNOL, V9, P887, DOI 10.1038/ni.1630; Caraux A, 2006, BLOOD, V107, P994, DOI 10.1182/blood-2005-06-2428; Carlin LM, 2001, J EXP MED, V194, P1507, DOI 10.1084/jem.194.10.1507; Carosella ED, 2008, BLOOD, V111, P4862, DOI 10.1182/blood-2007-12-127662; Davis Daniel M., 2000, Science Progress, V83, P303; Davis DM, 1999, P NATL ACAD SCI USA, V96, P15062, DOI 10.1073/pnas.96.26.15062; Davis DM, 2004, TRENDS IMMUNOL, V25, P323, DOI 10.1016/j.it.2004.03.007; Davis DM, 2002, TRENDS IMMUNOL, V23, P356, DOI 10.1016/S1471-4906(02)02243-3; Degli-Esposti MA, 2005, NAT REV IMMUNOL, V5, P112, DOI 10.1038/nri1549; Dietrich J, 2001, J IMMUNOL, V166, P2514, DOI 10.4049/jimmunol.166.4.2514; Espagnolle N, 2007, INT IMMUNOL, V19, P239, DOI 10.1093/intimm/dxl141; Favier B, 2007, TISSUE ANTIGENS, V69, P150, DOI 10.1111/j.1399-0039.2006.763_6.x; Favier B, 2007, TISSUE ANTIGENS, V69, P207, DOI 10.1111/j.1399-0039.2006.00757.x; Gismondi A, 2000, J IMMUNOL, V164, P2272, DOI 10.4049/jimmunol.164.5.2272; Graham DB, 2006, J IMMUNOL, V177, P2349, DOI 10.4049/jimmunol.177.4.2349; Hamerman JA, 2005, CURR OPIN IMMUNOL, V17, P29, DOI 10.1016/j.coi.2004.11.001; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Le Gal FA, 1999, INT IMMUNOL, V11, P1351, DOI 10.1093/intimm/11.8.1351; LeMaoult J, 2005, FASEB J, V19, P662, DOI 10.1096/fj.04-1617fje; Malorni W, 2003, J IMMUNOL, V171, P4195, DOI 10.4049/jimmunol.171.8.4195; Menier C, 2002, INT J CANCER, V100, P63, DOI 10.1002/ijc.10460; Moretta L, 2006, IMMUNOL REV, V214, P219, DOI 10.1111/j.1600-065X.2006.00450.x; Orange JS, 2008, NAT REV IMMUNOL, V8, P713, DOI 10.1038/nri2381; Orange JS, 2003, P NATL ACAD SCI USA, V100, P14151, DOI 10.1073/pnas.1835830100; Orange JS, 2002, P NATL ACAD SCI USA, V99, P11351, DOI 10.1073/pnas.162376099; Riteau B, 2001, J IMMUNOL, V166, P5018, DOI 10.4049/jimmunol.166.8.5018; Rouas-Freiss N, 2007, SEMIN CANCER BIOL, V17, P413, DOI 10.1016/j.semcancer.2007.07.003; RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P11520, DOI 10.1073/pnas.94.21.11520; Schleinitz N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003278; Shiroishi M, 2003, P NATL ACAD SCI USA, V100, P8856, DOI 10.1073/pnas.1431057100; Stebbins CC, 2003, MOL CELL BIOL, V23, P6291, DOI 10.1128/MCB.23.17.6291-6299.2003; Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071; Stinchcombe JC, 2003, SEMIN IMMUNOL, V15, P301, DOI 10.1016/j.smim.2003.09.003; Tassi I, 2005, J IMMUNOL, V175, P749, DOI 10.4049/jimmunol.175.2.749; Tassi I, 2006, IMMUNOL REV, V214, P92, DOI 10.1111/j.1600-065X.2006.00463.x; Trotta R, 2007, J EXP MED, V204, P2397, DOI 10.1084/jem.20070419; VELY F, 2005, SCI STKE, pCM7; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Vyas YM, 2001, J IMMUNOL, V167, P4358, DOI 10.4049/jimmunol.167.8.4358; Walzer T, 2005, BLOOD, V106, P2252, DOI 10.1182/blood-2005-03-1154; Wulfing C, 2003, P NATL ACAD SCI USA, V100, P7767, DOI 10.1073/pnas.1336920100	44	85	96	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2010	24	3					689	699		10.1096/fj.09-135194	http://dx.doi.org/10.1096/fj.09-135194			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19841038				2022-12-28	WOS:000274974600005
J	Tolu, S; Avale, ME; Nakatani, H; Pons, S; Parnaudeau, S; Tronche, F; Vogt, A; Monyer, H; Vogel, R; de Chaumont, F; Olivo-Marin, JC; Changeux, JP; Maskos, U				Tolu, Stefania; Avale, M. Elena; Nakatani, Hiroko; Pons, Stephanie; Parnaudeau, Sebastien; Tronche, Francois; Vogt, Angelika; Monyer, Hannah; Vogel, Roland; de Chaumont, Fabrice; Olivo-Marin, Jean-Christophe; Changeux, Jean-Pierre; Maskos, Uwe			A versatile system for the neuronal subtype specific expression of lentiviral vectors	FASEB JOURNAL			English	Article						ventral tegmental area; VTA; eGFP; stereotactic injection; cell-type specific reexpression; Cre/loxP recombination system	SITE-SPECIFIC RECOMBINATION; ENHANCED TRANSGENE EXPRESSION; VENTRAL TEGMENTAL AREA; CENTRAL-NERVOUS-SYSTEM; MEDIATED GENE-TRANSFER; IN-VIVO; TRANSDUCTION PATTERNS; DNA RECOMBINATION; MOUSE-BRAIN; MICE	Lentiviral expression vectors are powerful tools for gene therapy and long-term gene expression/repression in the mammalian brain. However, no specificity of transduction has been reported so far in the central nervous system. Here we have developed a novel system to achieve a neuronal subtype specific expression in either dopaminergic (DA) or GABAergic neurons. We employed a delivery strategy by which the transgene is not expressed until its activation by Cre recombinase. We successfully tested the system in vitro and then used this novel lentivector, containing loxP sites, in 2 different transgenic mouse lines expressing Cre either in DA or in GABAergic neurons. In both lines the reporter gene was detected exclusively in Cre-positive cells, demonstrating that with this experimental approach we were able to achieve completely specific expression of transgenes delivered by lentiviral vectors. This universal system can be applied to all neural subtypes making use of the growing number of specific Cre driver lines.-Tolu, S., Avale, M. E., Nakatani, H., Pons, S., Parnaudeau, S., Tronche, F., Vogt, A., Monyer, H., Vogel, R., de Chaumont, F., Olivo-Marin, J.-C., Changeux, J.-P., Maskos, U. A versatile system for the neuronal subtype specific expression of lentiviral vectors. FASEB J. 24, 723-730 (2010). www.fasebj.org	[Tolu, Stefania; Avale, M. Elena; Nakatani, Hiroko; Pons, Stephanie; Changeux, Jean-Pierre; Maskos, Uwe] Inst Pasteur, CNRS, Unite Neurobiol Integrat Syst Cholinerg, URA 2182, F-75724 Paris 15, France; [Parnaudeau, Sebastien; Tronche, Francois] UPMC, CNRS, Coll France, UMR7224, Paris, France; [Vogt, Angelika; Monyer, Hannah] Interdisciplinary Ctr Neurosci, Dept Clin Neurobiol, Heidelberg, Germany; [Vogel, Roland] Hop La Pitie Salpetriere, CNRS, UMR 7225, Paris, France; [Vogel, Roland] Hop La Pitie Salpetriere, INSERM, UMRS 975, Equipe Biotechnol & Biotherapie, Paris, France; [de Chaumont, Fabrice; Olivo-Marin, Jean-Christophe] Inst Pasteur, CNRS, Unite Anal Images Quantitat, URA 2582, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; Sorbonne Universite; Ruprecht Karls University Heidelberg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Maskos, U (corresponding author), Inst Pasteur, CNRS, Unite Neurobiol Integrat Syst Cholinerg, URA 2182, 25 Rue Dr Roux, F-75724 Paris 15, France.	umaskos@pasteur.fr	TRONCHE, François/F-3895-2011; Olivo-Marin, Jean-Christophe/K-4428-2015	Olivo-Marin, Jean-Christophe/0000-0001-6796-0696; Tolu, Stefania/0000-0002-0928-5810; Avale, Maria Elena/0000-0002-0251-0093; de Chaumont, Fabrice/0000-0001-7613-7204	Agence Nationale pour la Recherche; Institut Pasteur; College de France; Centre National de la Recherche Scientifique CNRS [URA 2182]; Association de Recherche sur le Cancer (ARC); Institut National du Cancer (INCa); Mission Interministerielle de Lutte contre la Drogue et la Toxicomanie (MILDT); Fondation pour la Recherche Medicale (FRM); European Commission; ANR-Neuro-GRADA; EU-STREP-PheCOMP; MILDT; Region of Sardinia; Fondation pour la Recherche Medicale FRM	Agence Nationale pour la Recherche(French National Research Agency (ANR)); Institut Pasteur(European Commission); College de France; Centre National de la Recherche Scientifique CNRS(Centre National de la Recherche Scientifique (CNRS)); Association de Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Mission Interministerielle de Lutte contre la Drogue et la Toxicomanie (MILDT); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); European Commission(European CommissionEuropean Commission Joint Research Centre); ANR-Neuro-GRADA(French National Research Agency (ANR)); EU-STREP-PheCOMP; MILDT; Region of Sardinia(Regione Sardegna); Fondation pour la Recherche Medicale FRM(Fondation pour la Recherche Medicale)	This work was supported by grants from the Agence Nationale pour la Recherche (ANR Neuroscience, Neurologie et Psychiatrie 2005), Institut Pasteur, the College de France, the Centre National de la Recherche Scientifique CNRS URA 2182, the Association de Recherche sur le Cancer (ARC), the Institut National du Cancer (INCa), Mission Interministerielle de Lutte contre la Drogue et la Toxicomanie (MILDT), the Fondation pour la Recherche Medicale (FRM), and European Commission contracts NIDE and Nicotine and Aging to U. M. and J.-P. C. F. T. was supported by ANR-Neuro-GRADA, EU-STREP-PheCOMP, and MILDT grants. MENRT and College de France supported S. P. S. T. acknowledges the support of the Region of Sardinia and Fondation pour la Recherche Medicale FRM.	Baekelandt V, 2002, HUM GENE THER, V13, P841, DOI 10.1089/10430340252899019; Blomer U, 1997, J VIROL, V71, P6641; CARLSSON A, 1993, ADV NEUROL, V60, P1; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Colin A, 2009, GLIA, V57, P667, DOI 10.1002/glia.20795; CUNNINGHAM MG, 1993, J NEUROSCI METH, V47, P105, DOI 10.1016/0165-0270(93)90026-N; Deglon N, 2000, HUM GENE THER, V11, P179, DOI 10.1089/10430340050016256; Dittgen T, 2004, P NATL ACAD SCI USA, V101, P18206, DOI 10.1073/pnas.0407976101; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Fuchs EC, 2001, P NATL ACAD SCI USA, V98, P3571, DOI 10.1073/pnas.051631898; Galimi F, 2002, CURR TOP MICROBIOL, V261, P245; Goldman-Rakic P S, 1998, Adv Pharmacol, V42, P707; GOSLIN K, 1989, J CELL BIOL, V108, P1507, DOI 10.1083/jcb.108.4.1507; Ikawa M, 2003, MOL THER, V8, P666, DOI 10.1016/S1525-0016(03)00240-5; Jakobsson J, 2006, MOL THER, V13, P484, DOI 10.1016/j.ymthe.2005.11.012; Jakobsson J, 2003, J NEUROSCI RES, V73, P876, DOI 10.1002/jnr.10719; Kaczmarczyk SJ, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.12.e56; Kafri T, 1999, J VIROL, V73, P576, DOI 10.1128/JVI.73.1.576-584.1999; Kellendonk C, 1999, J MOL BIOL, V285, P175, DOI 10.1006/jmbi.1998.2307; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209; Maskos U, 2005, NATURE, V436, P103, DOI 10.1038/nature03694; Mitrophanous KA, 1999, GENE THER, V6, P1808, DOI 10.1038/sj.gt.3301023; Nair-Roberts RG, 2008, NEUROSCIENCE, V152, P1024, DOI 10.1016/j.neuroscience.2008.01.046; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; OADES RD, 1987, BRAIN RES REV, V12, P117, DOI 10.1016/0165-0173(87)90011-7; Olivo-Marin JC, 2002, PATTERN RECOGN, V35, P1989, DOI 10.1016/S0031-3203(01)00127-3; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; Paxinos G., 2001, MOUSE BRAIN STEREOTA; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Sirven A, 2001, MOL THER, V3, P438, DOI 10.1006/mthe.2001.0282; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; SWANSON LW, 1982, BRAIN RES BULL, V9, P321, DOI 10.1016/0361-9230(82)90145-9; Turiault M, 2007, FEBS J, V274, P3568, DOI 10.1111/j.1742-4658.2007.05886.x; Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637; Watson DJ, 2002, MOL THER, V5, P528, DOI 10.1006/mthe.2002.0584; Wong LF, 2004, MOL THER, V9, P101, DOI 10.1016/j.ymthe.2003.09.017; Wong LF, 2006, HUM GENE THER, V17, P1, DOI 10.1089/hum.2006.17.1; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	45	26	26	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					723	730		10.1096/fj.09-139790	http://dx.doi.org/10.1096/fj.09-139790			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19858094				2022-12-28	WOS:000274974600008
J	Lefebvre, JS; Marleau, S; Milot, V; Levesque, T; Picard, S; Flamand, N; Borgeat, P				Lefebvre, Julie S.; Marleau, Sylvie; Milot, Valerie; Levesque, Tania; Picard, Serge; Flamand, Nicolas; Borgeat, Pierre			Toll-like receptor ligands induce polymorphonuclear leukocyte migration: key roles for leukotriene B-4 and platelet-activating factor	FASEB JOURNAL			English	Article						inflammation; lipid mediators; transendothelial migration; mouse air-pouch model; endothelial cells	HUMAN-ENDOTHELIAL-CELLS; CYTOSOLIC PHOSPHOLIPASE A(2); HUMAN NEUTROPHILS; INNATE IMMUNE; LUNG INJURY; BIOSYNTHESIS; INHIBITION; INVOLVEMENT; INTERLEUKIN-8; RECRUITMENT	Activation of toll-like receptors (TLRs) and polymorphonuclear leukocyte (PMN) accumulation at infection sites are critical events of host defense. The involvement of leukotriene (LT) B-4 and platelet-activating factor (PAF) in TLR ligand-induced activation of inflammatory cell functions is essentially unknown. Using an in vitro model of human PMN migration through human endothelial cell monolayers, we demonstrate that prototypic ligands of TLR1/2, 2/6, 3, 4, 5, and 7/8 promote PMN migration, an effect markedly inhibited by 3 LTB4 receptor antagonists (70-80% inhibition at 100 nM compared to vehicle-treated cells), 3 PAF receptor antagonists (20-50% inhibition at 10 nM), 3 LT biosynthesis inhibitors (75-85% inhibition at 100 nM), and 1 cytosolic phospholipase A(2)alpha (cPLA(2)alpha) inhibitor (90% inhibition at 1 mu M). Accordingly, selected TLR ligands caused Ser-505- phosphorylation of cPLA(2)alpha and measurable LTB4 and PAF biosynthesis in the transmigration assay. As negative controls, interleukin-8- and formyl-methionylleucyl-phenylalanine-elicited migration in vitro was not inhibited either by an LTB4 receptor antagonist or by the cPLA(2)alpha inhibitor. Finally, LTB4 and PAF receptor antagonists inhibited (up to similar to 65% at optimal doses) TLR ligand-induced PMN infiltration in the mouse air-pouch model. These studies unravel the critical involvement of de novo LTB4 and PAF biosynthesis in PMN migration elicited by TLR ligands.-Lefebvre, J. S., Marleau, S., Milot, V., Levesque, T., Picard, S., Flamand, N., Borgeat, P. Toll-like receptor ligands induce polymorphonuclear leukocyte migration: key roles for leukotriene B-4 and platelet-activating factor. FASEB J. 24, 637-647 (2010). www.fasebj.org	[Lefebvre, Julie S.; Milot, Valerie; Levesque, Tania; Picard, Serge; Borgeat, Pierre] Ctr Hosp Univ Quebec, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1V 4G2, Canada; [Lefebvre, Julie S.; Milot, Valerie; Levesque, Tania; Picard, Serge; Flamand, Nicolas; Borgeat, Pierre] Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada; [Marleau, Sylvie] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada; [Flamand, Nicolas] Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Quebec City, PQ, Canada	Laval University; Laval University; Universite de Montreal; Laval University	Borgeat, P (corresponding author), Ctr Hosp Univ Quebec, Ctr Rech Rhumatol & Immunol, 2705 Laurier Blvd,Rm T1-49, Quebec City, PQ G1V 4G2, Canada.	pierre.borgeat@crchul.ulaval.ca	Flamand, Nicolas/H-5823-2019	Flamand, Nicolas/0000-0001-5944-7200	Canadian Institute for Health Research; Canadian Arthritis Network	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Arthritis Network	This work was supported by the Canadian Institute for Health Research (P. B. and S. M.). J.S.L. received a fellowship from the Canadian Institute for Health Research, and V. M. received a fellowship from the Canadian Arthritis Network. The authors thank Maurice Dufour and Isabelle Dubuc for technical assistance.	Abdollahi-Roodsaz S, 2007, ARTHRITIS RHEUM, V56, P2957, DOI 10.1002/art.22848; Andonegui G, 2003, J CLIN INVEST, V111, P1011, DOI 10.1172/JCI200316510; Andonegui G, 2002, J IMMUNOL, V169, P2111, DOI 10.4049/jimmunol.169.4.2111; Aomatsu K, 2008, IMMUNOLOGY, V123, P171, DOI 10.1111/j.1365-2567.2007.02684.x; BANNATYNE RM, 1977, J INFECT DIS, V136, P469, DOI 10.1093/infdis/136.4.469; Belanger C, 2008, IMMUNOLOGY, V124, P295, DOI 10.1111/j.1365-2567.2007.02767.x; Benjamim CF, 2005, J IMMUNOL, V174, P1616, DOI 10.4049/jimmunol.174.3.1616; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; Cepinskas G, 1999, J CELL SCI, V112, P1937; Chen M, 2006, J EXP MED, V203, P837, DOI 10.1084/jem.20052371; Chen NN, 2001, J NEUROIMMUNOL, V120, P94, DOI 10.1016/S0165-5728(01)00415-5; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x; Fasano MB, 1998, CLIN IMMUNOL IMMUNOP, V87, P304, DOI 10.1006/clin.1998.4545; Flamand N, 2004, BRIT J PHARMACOL, V141, P552, DOI 10.1038/sj.bjp.0705654; Flamand N, 2002, MOL PHARMACOL, V62, P250, DOI 10.1124/mol.62.2.250; FONTEH AN, 1993, J IMMUNOL, V151, P339; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Gautam N, 1998, BRIT J PHARMACOL, V125, P1109, DOI 10.1038/sj.bjp.0702186; Ghosh M, 2006, PROG LIPID RES, V45, P487, DOI 10.1016/j.plipres.2006.05.003; Hattermann K, 2007, FASEB J, V21, P1575, DOI 10.1096/fj.06-7457com; Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078; HOPKINS NK, 1984, BIOCHIM BIOPHYS ACTA, V805, P30, DOI 10.1016/0167-4889(84)90033-8; Kim ND, 2006, J EXP MED, V203, P829, DOI 10.1084/jem.20052349; Krishnan J, 2007, EXP MOL MED, V39, P421, DOI 10.1038/emm.2007.47; Krump E, 1997, J EXP MED, V186, P1401, DOI 10.1084/jem.186.8.1401; Kurose I, 1997, AM J PHYSIOL-HEART C, V272, pH2976, DOI 10.1152/ajpheart.1997.272.6.H2976; Kurt-Jones EA, 2002, BLOOD, V100, P1860, DOI 10.1182/blood.V100.5.1860.h81702001860_1860_1868; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; LIN AH, 1982, J CLIN INVEST, V70, P1058, DOI 10.1172/JCI110693; MACLOUF J, 1989, BLOOD, V74, P703; MCDONALD PP, 1993, J IMMUNOL, V151, P6399; MCDONALD PP, 1994, BRIT J PHARMACOL, V111, P852, DOI 10.1111/j.1476-5381.1994.tb14816.x; MOILANEN E, 1993, INFLAMMATION, V17, P705, DOI 10.1007/BF00920475; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; Nagase T, 2003, AM J PHYSIOL-LUNG C, V284, pL720, DOI 10.1152/ajplung.00396.2002; Nohgawa M, 1997, J LEUKOCYTE BIOL, V62, P203, DOI 10.1002/jlb.62.2.203; Opitz B, 2007, THROMB HAEMOSTASIS, V98, P319, DOI 10.1160/TH06-12-0694; PALMBLAD J, 1994, J IMMUNOL, V152, P262; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Sabroe I, 2005, CLIN INFECT DIS, V41, pS421, DOI 10.1086/431992; SALARI H, 1985, INFLAMMATION, V9, P127, DOI 10.1007/BF00917585; Scott MJ, 2004, CLIN DIAGN LAB IMMUN, V11, P936, DOI 10.1128/CDLI.11.5.936-941.2004; Sheahan T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000240; SILVESTRO L, 1994, SEMIN THROMB HEMOST, V20, P214, DOI 10.1055/s-2007-1001905; SURETTE ME, 1993, J EXP MED, V178, P1347, DOI 10.1084/jem.178.4.1347; TAKAHASHI M, 1995, CARDIOVASC RES, V29, P670; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Wagner H, 2006, ADV IMMUNOL, V91, P159, DOI 10.1016/S0065-2776(06)91004-9; Wilde I, 2007, MED MICROBIOL IMMUN, V196, P61, DOI 10.1007/s00430-006-0027-9; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529	54	26	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					637	647		10.1096/fj.09-135624	http://dx.doi.org/10.1096/fj.09-135624			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19843712				2022-12-28	WOS:000274045000031
J	Zwaenepoel, K; Goris, J; Erneux, C; Parker, PJ; Janssens, V				Zwaenepoel, Karen; Goris, Jozef; Erneux, Christophe; Parker, Peter J.; Janssens, Veerle			Protein phosphatase 2A PR130/B ''alpha 1 subunit binds to the SH2 domain-containing inositol polyphosphate 5-phosphatase 2 and prevents epidermal growth factor (EGF)-induced EGF receptor degradation sustaining EGF-mediated signaling	FASEB JOURNAL			English	Article						receptor tyrosine kinase; c-Cbl; Akt/protein kinase B; extracellular signal-regulated kinase	PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; DOWN-REGULATION; TYROSINE PHOSPHORYLATION; REGULATORY SUBUNIT; LIPID PHOSPHATASE; B''/PR72 SUBUNIT; GENE IEX-1; IN-VIVO; SHIP2; IDENTIFICATION	To elucidate novel cell biological functions of specific protein phosphatase 2A (PP2A) holoenzymes, we identified and biochemically characterized a complex between the Src homology 2 (SH2) domain-containing inositol polyphosphate 5-phosphatase 2 (SHIP2) and a PP2A holoenzyme comprising PR130/B ''alpha 1 as a regulatory subunit (PP2A(T130)) in several mammalian cell lines. PR130/B ''alpha 1 and SHIP2 partially colocalize in untreated HeLa cells, and both translocate to the cell membrane on epidermal growth factor (EGF) stimulation. Concomitantly, a transient EGF-dependent interaction of PR130/B ''alpha 1 with the EGF receptor (EGFR) was observed, whereas the SHIP2-PR130 interaction remained constitutive. As previously reported for SHIP2, RNA interference-mediated knockdown of PR130 in COS-7 cells resulted in increased EGF-induced proteasome-dependent EGFR degradation, and an increased interaction of EGFR with the E3 ligase c-Cbl. In concordance with faster EGFR clearance or desensitization, intrinsic EGFR kinase activity (phospho-Tyr-1068) and downstream protein kinase B and extracellular signal-regulated kinase/mitogen-activated protein kinase pathways were more rapidly inactivated in PR130-knockdown cells. Notably, these effects could be rescued by reintroduction of RNA interference-resistant Myc-PR130, excluding any off-target effect. These data highlight a novel biological role of the PP2A(T130) holoenzyme in EGF signaling through interaction with EGFR and the phosphatidylinositol (3,4,5)-trisphosphate 5-phosphatase SHIP2. This interaction may be of clinical relevance as dysfunction of EGF-mediated signaling has been linked to various human cancers.-Zwaenepoel, K., Goris, J., Erneux, C., Parker, P. J., Janssens, V. Protein phosphatase 2A PR130/B ''alpha 1 subunit binds to the SH2 domain-containing inositol polyphosphate 5-phosphatase 2 and prevents epidermal growth factor (EGF)-induced EGF receptor degradation sustaining EGF-mediated signaling. FASEB J. 24, 538-547 (2010). www.fasebj.org	[Zwaenepoel, Karen; Goris, Jozef; Janssens, Veerle] Katholieke Univ Leuven, Fac Med, Dept Mol Cell Biol, Prot Phosphorylat & Prote Lab, Louvain, Belgium; [Erneux, Christophe] Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, Brussels, Belgium; [Parker, Peter J.] London Res Inst Canc Res UK, Prot Phosphorylat Lab, London, England; [Parker, Peter J.] Kings Coll London, Div Canc Studies, London WC2R 2LS, England	KU Leuven; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of London; Institute of Cancer Research - UK; University of London; King's College London	Janssens, V (corresponding author), Gasthuisberg O&NI, Fac Med, Dept Mol Cell Biol, Prot Phosphorylat & Prote Lab, Herestr 49,Box 901, B-3000 Louvain, Belgium.	veerle.janssens@med.kuleuven.be	Janssens, Veerle/I-7059-2016; Parker, Peter j/D-5192-2013	Janssens, Veerle/0000-0002-6772-8448; parker, peter/0000-0002-6218-2933	Geconcerteerde OnderzoeksActies of the Flemish government; Interuniversitary Attraction Poles of the Belgian Science Policy [P6/28]; National Fund for scientific research; Fonds voor Wetenschappelijk Onderzoek-Vlaanderen	Geconcerteerde OnderzoeksActies of the Flemish government; Interuniversitary Attraction Poles of the Belgian Science Policy; National Fund for scientific research; Fonds voor Wetenschappelijk Onderzoek-Vlaanderen(FWO)	We acknowledge the Cell Imaging Core (Katholieke Universiteit Leuven) for the use of microscope facilities, Dr. S. Dilworth (Imperial College, London, UK) for providing antibodies, and Dr. N. Totty (Protein Analysis Laboratory, London Research Institute-Cancer Research UK, London, UK) for mass spectroscopic analyses. This work was supported by grants from the Geconcerteerde OnderzoeksActies of the Flemish government (to V.J. and J.G.), the Interuniversitary Attraction Poles of the Belgian Science Policy P6/28 (to J.G. and C. E.), the National Fund for scientific research (to C. E.), and the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen (to V.J. and J.G.).	Ahn JH, 2007, P NATL ACAD SCI USA, V104, P9876, DOI 10.1073/pnas.0703589104; Artemenko Y, 2007, J CELL PHYSIOL, V211, P598, DOI 10.1002/jcp.20965; Brehme M, 2009, P NATL ACAD SCI USA, V106, P7414, DOI 10.1073/pnas.0900653106; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; Creyghton MP, 2006, P NATL ACAD SCI USA, V103, P5397, DOI 10.1073/pnas.0507237103; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Daub H, 2008, MOL CELL, V31, P438, DOI 10.1016/j.molcel.2008.07.007; Davis AJ, 2008, J BIOL CHEM, V283, P16104, DOI 10.1074/jbc.M710313200; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Grempler R, 2007, FEBS LETT, V581, P5885, DOI 10.1016/j.febslet.2007.11.066; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HERNANDEZSOTOMAYOR SMT, 1991, J BIOL CHEM, V266, P21281; Huang SL, 2004, J BIOL CHEM, V279, P36490, DOI 10.1074/jbc.M401208200; Hudelist G, 2006, PROTEOMICS, V6, P1989, DOI 10.1002/pmic.200500129; Ishihara H, 1999, BIOCHEM BIOPH RES CO, V260, P265, DOI 10.1006/bbrc.1999.0888; Janssens V, 2003, J BIOL CHEM, V278, P10697, DOI 10.1074/jbc.M211717200; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Koch A, 2005, ONCOGENE, V24, P3436, DOI 10.1038/sj.onc.1208558; Kono Y, 2002, GENES CELLS, V7, P821, DOI 10.1046/j.1365-2443.2002.00562.x; Kuo YC, 2008, J BIOL CHEM, V283, P1882, DOI 10.1074/jbc.M709585200; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Lubert EJ, 2001, J BIOL CHEM, V276, P38582, DOI 10.1074/jbc.M106906200; Magenta A, 2008, MOL CELL BIOL, V28, P873, DOI 10.1128/MCB.00480-07; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; Mertins P, 2008, MOL CELL PROTEOMICS, V7, P1763, DOI 10.1074/mcp.M800196-MCP200; Miyabayashi T, 2007, P NATL ACAD SCI USA, V104, P5668, DOI 10.1073/pnas.0701331104; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Paternotte N, 2005, FEBS J, V272, P6052, DOI 10.1111/j.1742-4658.2005.04996.x; Pesesse X, 1998, FEBS LETT, V437, P301, DOI 10.1016/S0014-5793(98)01255-1; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Pesesse X, 2001, J BIOL CHEM, V276, P28348, DOI 10.1074/jbc.M103537200; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; Prasad NK, 2008, CARCINOGENESIS, V29, P25, DOI 10.1093/carcin/bgm213; Prasad NK, 2005, J BIOL CHEM, V280, P13129, DOI 10.1074/jbc.M410289200; Raaijmakers JH, 2007, CELL SIGNAL, V19, P1249, DOI 10.1016/j.cellsig.2006.12.015; Rocher G, 2007, J BIOL CHEM, V282, P5468, DOI 10.1074/jbc.M609712200; Roepstorff K, 2008, HISTOCHEM CELL BIOL, V129, P563, DOI 10.1007/s00418-008-0401-3; Salomon AR, 2003, P NATL ACAD SCI USA, V100, P443, DOI 10.1073/pnas.2436191100; Schiebel K, 2000, CYTOGENET CELL GENET, V91, P224, DOI 10.1159/000056849; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stevens I, 2003, EUR J BIOCHEM, V270, P376, DOI 10.1046/j.1432-1033.2003.03398.x; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Van Kanegan MJ, 2005, J BIOL CHEM, V280, P36029, DOI 10.1074/jbc.M506986200; Vandenbroere I, 2003, BIOCHEM BIOPH RES CO, V300, P494, DOI 10.1016/S0006-291X(02)02894-2; Wang YJ, 2004, J IMMUNOL, V173, P6820, DOI 10.4049/jimmunol.173.11.6820; WELSH JB, 1991, J CELL BIOL, V114, P533, DOI 10.1083/jcb.114.3.533; Xie JW, 2008, FEBS LETT, V582, P3011, DOI 10.1016/j.febslet.2008.07.048; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang J, 2007, CELL SIGNAL, V19, P2194, DOI 10.1016/j.cellsig.2007.06.022; Zhuang GL, 2007, J BIOL CHEM, V282, P2683, DOI 10.1074/jbc.M608509200; Zwaenepoel K, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-393	55	38	40	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					538	547		10.1096/fj.09-140228	http://dx.doi.org/10.1096/fj.09-140228			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19825976				2022-12-28	WOS:000274045000021
J	El Firar, A; Voisin, T; Rouyer-Fessard, C; Ostuni, MA; Couvineau, A; Laburthe, M				El Firar, Aadil; Voisin, Thierry; Rouyer-Fessard, Christiane; Ostuni, Mariano A.; Couvineau, Alain; Laburthe, Marc			Discovery of a functional immunoreceptor tyrosine-based switch motif in a 7-transmembrane-spanning receptor: role in the orexin receptor OX1R-driven apoptosis	FASEB JOURNAL			English	Article						neuropeptide; G protein-coupled receptor; tyrosine-based motifs; protein tyrosine phosphatase; SHP-2	PROTEIN-COUPLED-RECEPTOR; SRC HOMOLOGY-2 DOMAINS; CRYSTAL-STRUCTURE; INHIBITORY RECEPTORS; PHOSPHATASE SH-PTP1; CELL-PROLIFERATION; PERIPHERAL-TISSUES; SH2 DOMAINS; ACTIVATION; SHP-2	The orexin neuropeptides promote robust apoptosis in cancer cells. We have recently shown that the 7-transmembrane-spanning orexin receptor OX1R mediates apoptosis through an original mechanism. OX1R is equipped with a tyrosine-based inhibitory motif ITIM, which is tyrosine-phosphorylated on receptor activation, allowing the recruitment and activation of the tyrosine phosphatase SHP-2, leading to apoptosis. We show here that another motif, immunoreceptor tyrosine-based switch motif (ITSM), is present in OX1R and is mandatory for OX1R-mediated apoptosis. This conclusion is based on the following observations: 1) a canonical ITSM sequence is present in the first intracellular loop of OX1R; 2) mutation of Y-83 to F within ITSM abolished OX1R-mediated apoptosis but did not alter orexin-induced inositol phosphate formation or calcium transient via coupling of OX1R to G(q) protein; 3) mutation of Y-83 to F further abolished orexin-induced tyrosine phosphorylation in ITSM and subsequent recruitment of SHP-2 by the receptor. Finally, we developed a structural model of OX1R showing that the spatial localization of phosphotyrosines in ITSM and ITIM in OX1R is compatible with their interaction with the two SH2 domains of SHP-2. These data represent the first evidence for a functional role of an ITSM in a 7-transmembrane-spanning receptor.-El Firar, A., Voisin, T., Rouyer-Fessard, C., Ostuni, M. A., Couvineau, A., Laburthe, M. Discovery of a functional immunoreceptor tyrosine-based switch motif in a 7-transmembrane-spanning receptor: role in the orexin receptor OX1R-driven apoptosis. FASEB J. 23, 4069-4080 (2009). www.fasebj.org	[Voisin, Thierry] INSERM, U773, CRB3, F-75018 Paris, France; Univ Paris 07, UMR S773, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Voisin, T (corresponding author), INSERM, U773, CRB3, F-75018 Paris, France.	thierry.voisin@inserm.fr; marc.laburthe@inserm.fr	couvineau, alain/G-3641-2013; couvineau, alain/T-3466-2019; voisin, thierry/R-1241-2017; LABURTHE, Marc/C-1875-2012; OSTUNI, Mariano/J-2930-2015	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168; voisin, thierry/0000-0002-4320-5183; OSTUNI, Mariano/0000-0001-6769-3786	Ministere de la Recherche et de l'Enseignement Superieur; Universite Paris-Sud 11	Ministere de la Recherche et de l'Enseignement Superieur; Universite Paris-Sud 11	A. E. F. is supported by Ministere de la Recherche et de l'Enseignement Superieur and Universite Paris-Sud 11. We thank N. Rivard (University of Sherbrooke, Sherbrooke, QC, Canada) for supplying us with the SHP-1 and SHP-2 dominant-negative constructions.	Barrow AD, 2006, EUR J IMMUNOL, V36, P1646, DOI 10.1002/eji.200636195; Boutrel B, 2005, P NATL ACAD SCI USA, V102, P19168, DOI 10.1073/pnas.0507480102; Boutrel B, 2008, PHYSIOL BEHAV, V93, P947, DOI 10.1016/j.physbeh.2007.11.022; Bruhns P, 1999, J IMMUNOL, V162, P3168; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Chemnitz JM, 2004, J IMMUNOL, V173, P945, DOI 10.4049/jimmunol.173.2.945; Chen LW, 2006, MOL PHARMACOL, V70, P562, DOI 10.1124/mol.106.025536; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; Daeron M, 2008, IMMUNOL REV, V224, P11, DOI 10.1111/j.1600-065X.2008.00666.x; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Duchene J, 2002, J BIOL CHEM, V277, P40375, DOI 10.1074/jbc.M202744200; Duchesne C, 2003, J BIOL CHEM, V278, P14274, DOI 10.1074/jbc.M300425200; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Eissmann P, 2005, BLOOD, V105, P4722, DOI 10.1182/blood-2004-09-3796; Ferjoux G, 2003, MOL BIOL CELL, V14, P3911, DOI 10.1091/mbc.E03-02-0069; Gentili C, 2006, J ENDOCRINOL, V188, P69, DOI 10.1677/joe.1.06397; Gether U, 2002, PHARMACOL TOXICOL, V91, P304, DOI 10.1034/j.1600-0773.2002.910607.x; Harris GC, 2006, TRENDS NEUROSCI, V29, P571, DOI 10.1016/j.tins.2006.08.002; Heinonen MV, 2008, ACTA PHYSIOL, V192, P471, DOI 10.1111/j.1748-1716.2008.01836.x; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Imhof D, 2006, J BIOL CHEM, V281, P20271, DOI 10.1074/jbc.M601047200; Kukkonen JP, 2001, NEUROREPORT, V12, P2017, DOI 10.1097/00001756-200107030-00046; Kumaresan PR, 2002, MOL IMMUNOL, V39, P1, DOI 10.1016/S0161-5890(02)00094-9; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; Magga J, 2006, BIOCHEM PHARMACOL, V71, P827, DOI 10.1016/j.bcp.2005.12.021; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nishino S, 2007, SLEEP MED, V8, P373, DOI 10.1016/j.sleep.2007.03.008; Ostrakhovitch EA, 2006, BIOCHEM CELL BIOL, V84, P832, DOI 10.1139/O06-191; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Rouet-Benzineb P, 2004, J BIOL CHEM, V279, P45875, DOI 10.1074/jbc.M404136200; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Shlapatska LM, 2001, J IMMUNOL, V166, P5480, DOI 10.4049/jimmunol.166.9.5480; Sidorenko SP, 2003, NAT IMMUNOL, V4, P19, DOI 10.1038/ni0103-19; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Vatinel S, 2006, BBA-MOL CELL RES, V1763, P1098, DOI 10.1016/j.bbamcr.2006.07.003; Voisin T, 2003, CELL MOL LIFE SCI, V60, P72, DOI 10.1007/s000180300005; Voisin T, 2008, FASEB J, V22, P1993, DOI 10.1096/fj.07-098723; Voisin T, 2006, ENDOCRINOLOGY, V147, P4977, DOI 10.1210/en.2006-0201; Williams Rhiannan H., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000823; Zhu Y, 2003, J PHARMACOL SCI, V92, P259	45	36	44	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4069	4080		10.1096/fj.09-131367	http://dx.doi.org/10.1096/fj.09-131367			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19661287				2022-12-28	WOS:000272193700004
J	Rhodes, LE; Gledhill, K; Masoodi, M; Haylett, AK; Brownrigg, M; Thody, AJ; Tobin, DJ; Nicolaou, A				Rhodes, Lesley E.; Gledhill, Karl; Masoodi, Mojgan; Haylett, Ann K.; Brownrigg, Margaret; Thody, Anthony J.; Tobin, Desmond J.; Nicolaou, Anna			The sunburn response in human skin is characterized by sequential eicosanoid profiles that may mediate its early and late phases	FASEB JOURNAL			English	Article						hydroxyeicosatetraenoic acids; prostaglandins; cyclooxygenase; lipoxygenase; leukocytes	ULTRAVIOLET-B-IRRADIATION; TANDEM MASS-SPECTROMETRY; HYDROXY-FATTY-ACIDS; ARACHIDONIC-ACID; 12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; CHEMOTACTIC ACTIVITY; HUMAN KERATINOCYTES; LIPIDOMIC ANALYSIS; ATOPIC-DERMATITIS; COX-2 EXPRESSION	Sunburn is a commonly occurring acute inflammatory process, with dermal vasodilatation and leukocyte infiltration as central features. Ultraviolet (UV) B-induced hydrolysis of membrane phospholipids releases polyunsaturated fatty acids, and their subsequent metabolism by cyclooxygenases (COXs) and lipoxygenases (LOXs) may produce potent eicosanoid mediators modulating different stages of the inflammation. Our objective was to identify candidate eicosanoids formed during the sunburn reaction in relation to its clinical and histological course. We exposed skin of healthy humans (n=32) to UVB and, for 72 h, examined expression of proinflammatory and anti-inflammatory eicosanoids using LC/ESI-MS/MS, and examined immunohistochemical expression of COX-2, 12-LOX, 15-LOX, and leukocyte markers, while quantifying clinical erythema. We show that vasodilatory prostaglandins (PGs) PGE(2), PGF(2 alpha), and PGE(3) accompany the erythema in the first 24-48 h, associated with increased COX-2 expression at 24 h. Novel, potent leukocyte chemoattractants 11-, 12-, and 8-monohydroxy-eicosatetraenoic acid (HETE) are elevated from 4 to 72 h, in association with peak dermal neutrophil influx at 24 h, and increased dermal CD(3+) lymphocytes and 12- and 15-LOX expression from 24 to 72 h. Anti-inflammatory metabolite 15-HETE shows later expression, peaking at 72 h. Sunburn is characterized by overlapping sequential profiles of increases in COX products followed by LOX products that may regulate subsequent events and ultimately its resolution.-Rhodes, L. E., Gledhill, K., Masoodi, M., Haylett, A. K., Brownrigg, M., Thody, A. J., Tobin, D. J., Nicolaou, A. The sunburn response in human skin is characterized by sequential eicosanoid profiles that may mediate its early and late phases. FASEB J. 23, 3947-3956 (2009). www.fasebj.org	[Rhodes, Lesley E.; Haylett, Ann K.; Brownrigg, Margaret] Univ Manchester, Photobiol Unit, Salford Royal NHS Fdn Hosp, Manchester Acad Hlth Sci Ctr,Sch Translat Med, Manchester M6 8HD, Lancs, England; [Gledhill, Karl; Tobin, Desmond J.; Nicolaou, Anna] Univ Bradford, Ctr Skin Sci, Sch Life Sci, Bradford BD7 1DP, W Yorkshire, England; [Masoodi, Mojgan; Nicolaou, Anna] Univ Bradford, Sch Pharm, Bradford BD7 1DP, W Yorkshire, England; [Thody, Anthony J.] Newcastle Univ, Sch Clin & Lab Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Salford Royal NHS Foundation Trust; Salford Royal Hospital; University of Manchester; University of Bradford; University of Bradford; Newcastle University - UK	Rhodes, LE (corresponding author), Univ Manchester, Photobiol Unit, Salford Royal NHS Fdn Hosp, Manchester Acad Hlth Sci Ctr,Sch Translat Med, Manchester M6 8HD, Lancs, England.	lesley.e.rhodes@manchester.ac.uk	Gledhill, Karl/H-8935-2012; Nicolaou, Anna/D-4025-2018; Rhodes, Lesley E/H-5324-2015; MASOODI, MOJGAN/P-1499-2019; MASOODI, MOJGAN/B-8814-2012; Tobin, Desmond/A-5228-2009	Nicolaou, Anna/0000-0002-1314-413X; Rhodes, Lesley E/0000-0002-9107-6654; MASOODI, MOJGAN/0000-0001-9840-1731; Haylett, Ann/0000-0001-6625-7640; Tobin, Desmond/0000-0003-4566-9392	Wellcome Trust [WT077714]; National Institute for Health Research Manchester Biomedical Research Centre	Wellcome Trust(Wellcome TrustEuropean Commission); National Institute for Health Research Manchester Biomedical Research Centre(National Institute for Health Research (NIHR))	The authors acknowledge The Wellcome Trust, project WT077714, for funding this research. The Dermatological Sciences Research Group is supported by the National Institute for Health Research Manchester Biomedical Research Centre. The authors thank Andrew Healey (University of Bradford Analytical Centre) for technical support.	BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; Bagga D, 2003, P NATL ACAD SCI USA, V100, P1751, DOI 10.1073/pnas.0334211100; BARR RM, 1984, BRIT J DERMATOL, V111, P23, DOI 10.1111/j.1365-2133.1984.tb04012.x; BLACK AK, 1978, BRIT J CLIN PHARMACO, V5, P431, DOI 10.1111/j.1365-2125.1978.tb01650.x; BLACK AK, 1985, BRIT J CLIN PHARMACO, V20, P185, DOI 10.1111/j.1365-2125.1985.tb05059.x; BLACK AK, 1980, BRIT J CLIN PHARMACO, V10, P453, DOI 10.1111/j.1365-2125.1980.tb01788.x; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; BURRALL BA, 1985, BIOCHEM BIOPH RES CO, V133, P208, DOI 10.1016/0006-291X(85)91862-5; CAMP RDR, 1983, BRIT J PHARMACOL, V80, P497, DOI 10.1111/j.1476-5381.1983.tb10721.x; Capdevila JH, 2000, J LIPID RES, V41, P163; CRUNKHORN P, 1971, BRIT J PHARMACOL, V41, P49, DOI 10.1111/j.1476-5381.1971.tb09934.x; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; Di Nuzzo S, 1998, J INVEST DERMATOL, V110, P978, DOI 10.1046/j.1523-1747.1998.00220.x; DOWD PM, 1985, J INVEST DERMATOL, V84, P537, DOI 10.1111/1523-1747.ep12273537; Gewirtz AT, 2002, J IMMUNOL, V168, P5260, DOI 10.4049/jimmunol.168.10.5260; GOETZL EJ, 1980, IMMUNOLOGY, V39, P491; Grundmann JU, 2004, SKIN PHARMACOL PHYS, V17, P37, DOI 10.1159/000074061; GSCHWENDT M, 1986, CARCINOGENESIS, V7, P449, DOI 10.1093/carcin/7.3.449; HAMMARSTROM S, 1979, J INVEST DERMATOL, V73, P180, DOI 10.1111/1523-1747.ep12581645; HAWK JLM, 1988, BRIT J DERMATOL, V118, P27, DOI 10.1111/j.1365-2133.1988.tb01746.x; HEDQVIST P, 1977, ANNU REV PHARMACOL, V17, P259, DOI 10.1146/annurev.pa.17.040177.001355; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P251; KRAGBALLE K, 1987, DERMATOLOGICA, V174, P209, DOI 10.1159/000249181; Kuhn H, 2006, PROG LIPID RES, V45, P334, DOI 10.1016/j.plipres.2006.02.003; LANDS WEM, 1992, FASEB J, V6, P2530, DOI 10.1096/fasebj.6.8.1592205; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Masoodi M, 2008, RAPID COMMUN MASS SP, V22, P75, DOI 10.1002/rcm.3331; Masoodi M, 2006, RAPID COMMUN MASS SP, V20, P3023, DOI 10.1002/rcm.2697; Profita M, 2002, J PHARMACOL EXP THER, V300, P868, DOI 10.1124/jpet.300.3.868; RAUD J, 1988, P NATL ACAD SCI USA, V85, P2315, DOI 10.1073/pnas.85.7.2315; Rhodes LE, 2001, J INVEST DERMATOL, V117, P880, DOI 10.1046/j.0022-202x.2001.01514.x; RHODES LE, 1995, J INVEST DERMATOL, V105, P532, DOI 10.1111/1523-1747.ep12323389; Rhodes LE, 2003, CARCINOGENESIS, V24, P919, DOI 10.1093/carcin/bgg038; RHODES LE, 1994, J INVEST DERMATOL, V103, P151, DOI 10.1111/1523-1747.ep12392604; RIEGER G, 1987, J INVEST DERMATOL, V89, P339; RUZICKA T, 1986, PHOTODERMATOLOGY, V3, P306; RUZICKA T, 1986, J INVEST DERMATOL, V86, P105, DOI 10.1111/1523-1747.ep12284061; RUZICKA T, 1983, J INVEST DERMATOL, V81, P300, DOI 10.1111/1523-1747.ep12519287; Serhan CN, 2003, J IMMUNOL, V171, P6856, DOI 10.4049/jimmunol.171.12.6856; Strickland I, 1997, J INVEST DERMATOL, V108, P763, DOI 10.1111/1523-1747.ep12292156; Teunissen MBM, 2002, J IMMUNOL, V168, P3732, DOI 10.4049/jimmunol.168.8.3732; Vachier I, 2002, BIOCHEM BIOPH RES CO, V290, P219, DOI 10.1006/bbrc.2001.6155; VANDERHOEK JY, 1980, J BIOL CHEM, V255, P64; WARREN JB, 1994, FASEB J, V8, P247, DOI 10.1096/fasebj.8.2.7509761; Yoo H, 2008, FEBS LETT, V582, P3249, DOI 10.1016/j.febslet.2008.08.017; ZIBOH VA, 1992, SEMIN DERMATOL, V11, P114	46	93	95	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2009	23	11					3947	3956		10.1096/fj.09-136077	http://dx.doi.org/10.1096/fj.09-136077			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19584301	Green Published			2022-12-28	WOS:000271272500030
J	Banks, G; Kemenes, I; Schofield, M; O'Shea, M; Korneev, SA				Banks, Gareth; Kemenes, Ildiko; Schofield, Michael; O'Shea, Michael; Korneev, Sergei A.			Acetylcholine binding protein of mollusks is unlikely to act as a regulator of cholinergic neurotransmission at neurite-neurite synaptic sites in vivo	FASEB JOURNAL			English	Article						nonsynaptic signaling; glial cells; snail	CENTRAL-NERVOUS-SYSTEM; SNAIL LYMNAEA-STAGNALIS; CRYSTAL-STRUCTURE; RELEASE; NEURONS; ACHBP; INNERVATION; RECEPTORS; REVEALS; COMPLEX	A population of glial cells in the central nervous system of the gastropod mollusk Lymnaea stagnalis produces a soluble protein that specifically binds acetylcholine. This protein is named the acetylcholine binding protein (AChBP). Experiments performed in vitro indicated that AChBP inactivates released acetylcholine at cholinergic synapses. On the basis of these observations, a similar in vivo role for AChBP was hypothesized. To fulfill this function, AChBP-expressing glia ought to be located in close proximity to cholinergic synapses in vivo. To examine this, we have analyzed the cellular and subcellular expression of AChBP in the intact CNS. Using a variety of molecular techniques, we demonstrate here that AChBP expression is confined to a subpopulation of glial cells located within the peripheral zone of each of the ganglia constituting the CNS. This zone contains the cell bodies of neurons, but few synapses. Conversely, glial cells that do not express the AChBP are predominantly located in the synapse-rich central neuropile zone but are rare in the cell body zone. Thus, our findings are not compatible with the previous conclusions drawn from in vitro studies and suggest that AChBP functions in vivo as a regulator of nonsynaptic cholinergic transmission.-Banks, G., Kemenes, I., Schofield, M., O'Shea, M., Korneev, S. A. Acetylcholine binding protein of mollusks is unlikely to act as a regulator of cholinergic neurotransmission at neurite-neurite synaptic sites in vivo. FASEB J. 23, 3030-3036 (2009). www.fasebj.org	[Banks, Gareth; Kemenes, Ildiko; Schofield, Michael; O'Shea, Michael; Korneev, Sergei A.] Univ Sussex, Sussex Ctr Neurosci, De Biol & Environm Sci, Sch Life Sci, Brighton BN1 9QG, E Sussex, England	University of Sussex	Korneev, SA (corresponding author), Univ Sussex, Sussex Ctr Neurosci, De Biol & Environm Sci, Sch Life Sci, Brighton BN1 9QG, E Sussex, England.	s.korneev@sussex.ac.uk		Kemenes, Ildiko/0000-0002-8722-8766; Banks, Gareth/0000-0002-8647-667X	UK Biotechnology and Biological Sciences Research Council (BBSRC)	UK Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by a grant from the UK Biotechnology and Biological Sciences Research Council (BBSRC).	BOCHAROVA LS, 1976, BRAIN RES, V101, P185, DOI 10.1016/0006-8993(76)90262-6; Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; BUMA P, 1986, NEUROSCIENCE, V17, P867, DOI 10.1016/0306-4522(86)90051-5; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; CHASE R, 1992, J COMP NEUROL, V318, P93, DOI 10.1002/cne.903180107; ELEKES K, 1993, J NEUROCYTOL, V22, P1, DOI 10.1007/BF01183971; ELLIOTT CJH, 1992, PHILOS T ROY SOC B, V336, P167, DOI 10.1098/rstb.1992.0054; Granvogl B, 2007, PROTEOMICS, V7, P642, DOI 10.1002/pmic.200600607; KERKHOVEN RM, 1991, BRAIN RES, V565, P8, DOI 10.1016/0006-8993(91)91730-O; Korneev SA, 1998, J NEUROBIOL, V35, P65, DOI 10.1002/(SICI)1097-4695(199804)35:1<65::AID-NEU6>3.0.CO;2-9; Magoski NS, 1997, J NEUROBIOL, V33, P247, DOI 10.1002/(SICI)1097-4695(199709)33:3<247::AID-NEU4>3.3.CO;2-F; Nagy T, 2000, J NEUROCYTOL, V29, P43, DOI 10.1023/A:1007112130414; SCHMIDT ED, 1987, NEUROSCIENCE, V20, P247, DOI 10.1016/0306-4522(87)90017-0; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Smit AB, 2006, J MOL NEUROSCI, V30, P9, DOI 10.1385/JMN:30:1:9; van Nierop P, 2006, J BIOL CHEM, V281, P1680, DOI 10.1074/jbc.M508571200; VIZI ES, 1983, NEUROSCIENCE, V10, P967, DOI 10.1016/0306-4522(83)90234-8; Vulfius CA, 2005, NEUROSCI LETT, V373, P232, DOI 10.1016/j.neulet.2004.10.010; VULFIUS EA, 1967, NATURE, V216, P400, DOI 10.1038/216400a0	21	8	8	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3030	3036		10.1096/fj.08-117135	http://dx.doi.org/10.1096/fj.08-117135			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19395478				2022-12-28	WOS:000270241000025
J	Gomes, I; Grushko, JS; Golebiewska, U; Hoogendoorn, S; Gupta, A; Heimann, AS; Ferro, ES; Scarlata, S; Fricker, LD; Devi, LA				Gomes, Ivone; Grushko, Julia S.; Golebiewska, Urszula; Hoogendoorn, Sascha; Gupta, Achla; Heimann, Andrea S.; Ferro, Emer S.; Scarlata, Suzanne; Fricker, Lloyd D.; Devi, Lakshmi A.			Novel endogenous peptide agonists of cannabinoid receptors	FASEB JOURNAL			English	Article						G-protein-coupled receptors; pain; analgesia; drug abuse	INCREASES INTRACELLULAR CALCIUM; CPE(FAT/FAT) MOUSE HYPOTHALAMUS; DIAZEPAM BINDING INHIBITOR; STABLE ISOTOPIC TAGS; FUNCTIONAL-CHARACTERIZATION; QUANTITATIVE PEPTIDOMICS; NEURITE OUTGROWTH; AT(4) RECEPTOR; CB2 RECEPTORS; RAT-BRAIN	Hemopressin (Hp), a 9-residue alpha-hemoglobin-derived peptide, was previously reported to function as a CB1 cannabinoid receptor antagonist (1). In this study, we report that mass spectrometry (MS) data from peptidomics analyses of mouse brain extracts identified N-terminally extended forms of Hp containing either three (RVD-Hp alpha) or two (VD-Hp alpha) additional amino acids, as well as a beta-hemoglobinderived peptide with sequence similarity to that of hemopressin (VD-Hp beta). Characterization of the alpha-hemoglobin-derived peptides using binding and functional assays shows that in contrast to Hp, which functions as a CB1 cannabinoid receptor antagonist, both RVD-Hp alpha and VD-Hp alpha function as agonists. Studies examining the increase in the phosphorylation of ERK1/2 levels or release of intracellular Ca2+ indicate that these peptides activate a signal transduction pathway distinct from that activated by the endo-cannabinoid, 2-arachidonoylglycerol, or the classic CB1 agonist, Hu-210. This finding suggests an additional mode of regulation of endogenous cannabinoid receptor activity. Taken together, these results suggest that the CB1 receptor is involved in the integration of signals from both lipid-and peptide-derived signaling molecules.-Gomes, I., Grushko, J. S., Golebiewska, U., Hoogendoorn, S., Gupta, A., Heimann, A. S., Ferro, E. S., Scarlata, S., Fricker, L. D., Devi, L. A. Novel endogenous peptide agonists of cannabinoid receptors. FASEB J. 23, 3020-3029 (2009). www.fasebj.org	[Gomes, Ivone; Hoogendoorn, Sascha; Gupta, Achla; Devi, Lakshmi A.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA; [Grushko, Julia S.; Fricker, Lloyd D.] Albert Einstein Coll Med, Dept Mol Pharmacol, New York, NY USA; [Golebiewska, Urszula; Scarlata, Suzanne] SUNY Stony Brook, Dept Physiol & Biophys, Med Ctr, New York, NY USA; [Heimann, Andrea S.] Proteimax Biotechnol Ltd, Cotia, Brazil; [Ferro, Emer S.] Univ Sao Paulo, Dept Cell Biol & Dev, Inst Biomed Sci, Sao Paulo, Brazil	Icahn School of Medicine at Mount Sinai; Yeshiva University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Universidade de Sao Paulo	Devi, LA (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, 1 Gustave L Levy Pl,Box 1603, New York, NY 10029 USA.	lakshmi.devi@mssm.edu	Ferro, Emer S/D-3908-2012; Devi P, Lakshmi/GXM-5982-2022	Ferro, Emer S/0000-0003-1651-9192; Devi P, Lakshmi/0000-0001-9274-4776; Hoogendoorn, Sascha/0000-0002-1155-8697	NIH [DA019521, GM05313, GM071558, DA04494, DK51271]; Zwanenberg Foundation Fellowship; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [04/04933-2, 04/14258-0]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM071558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA019521, R01DA004494] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Zwanenberg Foundation Fellowship; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by NIH grants (DA019521 to L.A.D., GM05313 to S. S., GM071558 to L.A.D. and S.S., and DA04494 and DK51271 to L.D.F.), by a Zwanenberg Foundation Fellowship (to S.H.), by the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Grants 04/04933-2 to E.S.F. and 04/14258-0 to A.S.H.), and by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (E.S.F.). Mass spectrometry was performed through Rede de Proteoma do Estado de Sao Paulo in the Laboratorio Nacional de Luz Sincrotron, Campinas, Sao Paulo, Brazil. We thank Dr. K. Mackie (Indiana University, Bloomington, IN, USA) for the plasmid cDNAs for CB1 cannabinoid and CB2 cannabinoid receptors and for GPR55. We also thank Emeline Maillet and Robert Margolskee for help with analysis using the FLEX Station.	Badamchian M, 2007, ANN NY ACAD SCI, V1112, P458, DOI 10.1196/annals.1415.046; Battista Natalia, 2006, Ital J Biochem, V55, P283; Bazinet RP, 2005, NEUROCHEM RES, V30, P597, DOI 10.1007/s11064-005-2746-5; Begg M, 2005, PHARMACOL THERAPEUT, V106, P133, DOI 10.1016/j.pharmthera.2004.11.005; Bhaskaran M, 2005, BIOCHEM BIOPH RES CO, V333, P1348, DOI 10.1016/j.bbrc.2005.06.042; Boyd ST, 2006, PHARMACOTHERAPY, V26, p218S, DOI 10.1592/phco.26.12part2.218S; BRANTL V, 1986, EUR J PHARMACOL, V125, P309, DOI 10.1016/0014-2999(86)90044-0; Che FY, 2007, J PROTEOME RES, V6, P4667, DOI 10.1021/pr060690r; Che FY, 2006, J MOL NEUROSCI, V28, P265, DOI 10.1385/JMN:28:3:265; Che FY, 2005, MOL CELL PROTEOMICS, V4, P1391, DOI 10.1074/mcp.T500010-MCP200; Che FY, 2005, J MASS SPECTROM, V40, P227, DOI 10.1002/jms.742; Che FY, 2005, J MASS SPECTROM, V40, P238, DOI 10.1002/jms.743; Che FY, 2005, J BIOL CHEM, V280, P4451, DOI 10.1074/jbc.M411178200; COSTA E, 1991, LIFE SCI, V49, P325, DOI 10.1016/0024-3205(91)90440-M; Coutts AA, 2001, J NEUROSCI, V21, P2425; Dassen H, 2008, HUM REPROD, V23, P635, DOI 10.1093/humrep/dem430; Decaillot FM, 2006, J MOL NEUROSCI, V28, P277, DOI 10.1385/JMN:28:3:277; Di Marzo V, 2007, CURR OPIN LIPIDOL, V18, P129, DOI 10.1097/MOL.0b013e32803dbdec; Drake MT, 2008, J BIOL CHEM, V283, P5669, DOI 10.1074/jbc.M708118200; Ferro ES, 2004, PROTEIN PEPTIDE LETT, V11, P415, DOI 10.2174/0929866043406706; Fricker LD, 2006, MASS SPECTROM REV, V25, P327, DOI 10.1002/mas.20079; Fricker LD, 2007, ENDOCRINOLOGY, V148, P4185, DOI 10.1210/en.2007-0123; FUKUI K, 1983, NEUROPHARMACOLOGY, V22, P191, DOI 10.1016/0028-3908(83)90008-4; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Goldstein AL, 2005, TRENDS MOL MED, V11, P421, DOI 10.1016/j.molmed.2005.07.004; Gomes I, 2003, METH MOLEC MED, V84, P157; Goumon Y, 2004, J BIOL CHEM, V279, P13054, DOI 10.1074/jbc.M308533200; He JCJ, 2005, J BIOL CHEM, V280, P33426, DOI 10.1074/jbc.M502812200; Heimann AS, 2007, P NATL ACAD SCI USA, V104, P20588, DOI 10.1073/pnas.0706980105; Howlett AC, 2000, CHEM PHYS LIPIDS, V108, P53, DOI 10.1016/S0009-3084(00)00187-0; Hsieh C, 1999, J NEUROCHEM, V73, P493, DOI 10.1046/j.1471-4159.1999.0730493.x; Iversen L, 2002, CURR OPIN PHARMACOL, V2, P50, DOI 10.1016/S1471-4892(01)00120-5; Jordan JD, 2005, J BIOL CHEM, V280, P11413, DOI 10.1074/jbc.M411521200; Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105; Lauckner JE, 2005, P NATL ACAD SCI USA, V102, P19144, DOI 10.1073/pnas.0509588102; Lee J, 2003, J PHARMACOL EXP THER, V305, P205, DOI 10.1124/jpet.102.045492; LIEBMANN C, 1997, EUR J PHARMACOL, V166, P523; Lim J, 2006, J NEUROCHEM, V96, P1169, DOI 10.1111/j.1471-4159.2005.03614.x; Liu LM, 1999, P NATL ACAD SCI USA, V96, P6643, DOI 10.1073/pnas.96.12.6643; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MILLINGTON WR, 1991, J NEUROCHEM, V57, P775, DOI 10.1111/j.1471-4159.1991.tb08219.x; Moeller I, 1997, J NEUROCHEM, V68, P2530; Mukai H, 2008, J BIOL CHEM, V283, P30596, DOI 10.1074/jbc.M803913200; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Newton DA, 2006, J BIOL CHEM, V281, P5668, DOI 10.1074/jbc.M509314200; Nishi H, 2008, J AM SOC NEPHROL, V19, P1500, DOI 10.1681/ASN.2007101085; Ojika K, 2000, PROG NEUROBIOL, V60, P37, DOI 10.1016/S0301-0082(99)00021-0; Pan H, 2005, BIOCHEMISTRY-US, V44, P4939, DOI 10.1021/bi047852m; Pan H, 2006, J NEUROCHEM, V98, P1763, DOI 10.1111/j.1471-4159.2006.04067.x; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Pertwee RG, 2002, PROSTAG LEUKOTR ESS, V66, P101, DOI 10.1054/plef.2001.0341; Richter F, 2009, J COMP NEUROL, V515, P538, DOI 10.1002/cne.22062; Skold K, 2007, PROTEOMICS, V7, P4445, DOI 10.1002/pmic.200700142; SLOBODYANSKY E, 1989, J NEUROCHEM, V53, P1276, DOI 10.1111/j.1471-4159.1989.tb07425.x; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; Wride MA, 2003, MOL VIS, V9, P360; Zhang J, 2003, EUR J NEUROSCI, V17, P2750, DOI 10.1046/j.1460-9568.2003.02704.x	57	113	126	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3020	3029		10.1096/fj.09-132142	http://dx.doi.org/10.1096/fj.09-132142			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19380512	Green Published			2022-12-28	WOS:000270241000024
J	Sorg, H; Krueger, C; Schulz, T; Menger, MD; Schmitz, F; Vollmar, B				Sorg, Heiko; Krueger, Christian; Schulz, Torsten; Menger, Michael D.; Schmitz, Frank; Vollmar, Brigitte			Effects of erythropoietin in skin wound healing are dose related	FASEB JOURNAL			English	Article						microcirculation; cell migration; apoptosis; angiogenesis; epithelialization; pericytes	MICE OVEREXPRESSING ERYTHROPOIETIN; MYOCARDIAL-INFARCTION; STIMULATES ANGIOGENESIS; IMPROVES ANGIOGENESIS; GRANULATION-TISSUE; DARBEPOETIN-ALPHA; APOPTOSIS; INJURY; INFLAMMATION; PROTECTS	The hematopoietic growth factor erythropoietin (EPO) attracts attention due to its all-tissue-protective pleiotropic properties. We studied the effect of EPO on dermal regeneration using intravital microscopy in a model of full dermal thickness wounds in the skin-fold chamber of hairless mice. Animals received repetitive low doses or high doses of EPO (RLD-EPO or RHD-EPO) or a single high dose of EPO (SHD-EPO). SHD-EPO accelerated wound epithelialization, reduced wound cellularity, and induced maturation of newly formed microvascular networks. In contrast, RHD-EPO impaired the healing process, as indicated by delayed epithelialization, high wound cellularity, and lack of maturation of microvascular networks. Also, RHD-EPO caused an excessive erythrocyte mass and rheological malfunction, further deteriorating vessel and tissue maturation. Moreover, RHD-EPO altered fibroblast and keratinocyte migration in vitro, while both cell types exposed to RLD-EPO, and, in particular, to SHD-EPO showed accelerated wound scratch closure. In summary, our data show that a single application of a high dose of EPO accelerates and improves skin wound healing.-Sorg, H., Krueger, C., Schulz, T., Menger, M. D., Schmitz, F., Vollmar, B. Effects of erythropoietin in skin wound healing are dose related. FASEB J. 23, 3049-3058 ( 2009). www.fasebj.org	[Sorg, Heiko; Krueger, Christian; Schulz, Torsten; Vollmar, Brigitte] Univ Rostock, Inst Expt Surg, D-18055 Rostock, Germany; [Menger, Michael D.] Univ Saarland, Inst Clin & Expt Surg, D-6650 Homburg, Germany; [Schmitz, Frank] Univ Saarland, Inst Anat, D-6650 Homburg, Germany	University of Rostock; Saarland University; Saarland University	Vollmar, B (corresponding author), Univ Rostock, Inst Expt Surg, Schillingallee 69A, D-18055 Rostock, Germany.	brigitte.vollmar@med.uni-rostock.de		Sorg, Heiko/0000-0001-6827-0857	Deutsche Forschungsgemeinschaft; Bonn-Bad Godesberg [Vo 450/10-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bonn-Bad Godesberg	We thank Berit Blendow, Doris Butzlaff, Dorothea Frenz, and Maren Nerowski ( Institute for Experimental Surgery, University of Rostock) for excellent technical assistance; Karin Gerber and Kathrin Sievert-Kuchenmeister ( Institute for Experimental Surgery, University of Rostock) for help with the animal care; Christina Marx ( Institute for Clinical and Experimental Surgery, University of Saarland) for assistance in sample preparation for transmission electron microscopy; Gerlinde Kuhnreich ( Institute for Anatomy, University of Saarland) for making ultrathin sections; and Marika Fleischer ( Language Center, University of Rostock) for critical editing of the manuscript. This work was supported by a grant from the Deutsche Forschungsgemeinschaft, Bonn-Bad Godesberg (Vo 450/10-1). We declare no conflicts of interest.	Arcasoy MO, 2008, BRIT J HAEMATOL, V141, P14, DOI 10.1111/j.1365-2141.2008.07014.x; Ashley RA, 2002, PEDIATR RES, V51, P472, DOI 10.1203/00006450-200204000-00012; Au K, 2007, PLAST RECONSTR SURG, V120, P91, DOI 10.1097/01.prs.0000263363.28474.e9; Ben-Dor I, 2007, CARDIOVASC DRUG THER, V21, P339, DOI 10.1007/s10557-007-6049-8; Blann AD, 2001, THROMB RES, V101, P321, DOI 10.1016/S0049-3848(00)00419-9; Bor-Kucukatay M, 2000, BRIT J HAEMATOL, V110, P82, DOI 10.1046/j.1365-2141.2000.02150.x; Bordel R, 2005, CELL TISSUE RES, V320, P427, DOI 10.1007/s00441-005-1078-8; Buemi M, 2004, SHOCK, V22, P169, DOI 10.1097/01.shk.0000133591.47776.bd; Chernyavsky AI, 2007, EXP CELL RES, V313, P3542, DOI 10.1016/j.yexcr.2007.07.011; Clark RAF, 2007, J INVEST DERMATOL, V127, P1018, DOI 10.1038/sj.jid.5700715; Contaldo C, 2007, AM J PHYSIOL-HEART C, V293, pH274, DOI 10.1152/ajpheart.01031.2006; Desmouliere A, 1997, INT J BIOCHEM CELL B, V29, P19, DOI 10.1016/S1357-2725(96)00117-3; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; DYSON M, 1992, J INVEST DERMATOL, V99, P729, DOI 10.1111/1523-1747.ep12614460; Eming SA, 2007, J INVEST DERMATOL, V127, P514, DOI 10.1038/sj.jid.5700701; Fisher JW, 2003, EXP BIOL MED, V228, P1; Furlani D, 2008, TRANSPL P, V40, P962, DOI 10.1016/j.transproceed.2008.03.033; Galeano M, 2006, CRIT CARE MED, V34, P1139, DOI 10.1097/01.CCM.0000206468.18653.EC; Galeano M, 2004, DIABETES, V53, P2509, DOI 10.2337/diabetes.53.9.2509; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Greenhalgh DG, 1998, INT J BIOCHEM CELL B, V30, P1019, DOI 10.1016/S1357-2725(98)00058-2; Haroon ZSA, 2003, AM J PATHOL, V163, P993, DOI 10.1016/S0002-9440(10)63459-1; Heeschen C, 2003, BLOOD, V102, P1340, DOI 10.1182/blood-2003-01-0223; Heinicke K, 2006, AM J PHYSIOL-REG I, V291, pR947, DOI 10.1152/ajpregu.00152.2006; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hosokawa R, 2005, J INVEST DERMATOL, V125, P1302, DOI 10.1111/j.0022-202X.2005.23963.x; Imamura R, 2008, CELL TRANSPLANT, V17, P135, DOI 10.3727/000000008783907044; Jelkmann W, 2004, ANN HEMATOL, V83, P673, DOI 10.1007/s00277-004-0911-6; Jelkmann W, 2004, INTERNAL MED, V43, P649, DOI 10.2169/internalmedicine.43.649; Kwaan HC, 2003, SEMIN THROMB HEMOST, V29, P451; Le Minh K, 2007, AM J PATHOL, V170, P1954, DOI 10.2353/ajpath.2007.061056; Lindenblatt N, 2007, ARTERIOSCL THROM VAS, V27, P1191, DOI 10.1161/ATVBAHA.107.141580; Lipsic E, 2004, J CARDIOVASC PHARM, V44, P473, DOI 10.1097/01.fjc.0000140209.04675.c3; Lipsic E, 2008, EUR J HEART FAIL, V10, P22, DOI 10.1016/j.ejheart.2007.10.008; Luster AD, 1998, P ASSOC AM PHYSICIAN, V110, P183; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Moon C, 2006, CARDIOVASC DRUG THER, V20, P245, DOI 10.1007/s10557-006-0080-z; Muller-Ehmsen J, 2006, AM J PHYSIOL-HEART C, V290, pH331, DOI 10.1152/ajpheart.01269.2004; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; Park SH, 2007, J AM SOC NEPHROL, V18, P1497, DOI 10.1681/ASN.2005080866; Quaschning T, 2002, FASEB J, V16, P259, DOI 10.1096/fj.02-0296fje; Ribatti D, 2003, EUR J CLIN INVEST, V33, P891, DOI 10.1046/j.1365-2362.2003.01245.x; Rico RM, 2002, J SURG RES, V102, P193, DOI 10.1006/jsre.2001.6316; ROGER SD, 1993, CLIN NEPHROL, V39, P103; Savino R, 2004, CELL DEATH DIFFER, V11, pS2, DOI 10.1038/sj.cdd.4401469; Sayan H, 2006, J INVEST SURG, V19, P163, DOI 10.1080/08941930600674694; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Sorg H, 2007, J ANAT, V211, P810, DOI 10.1111/j.1469-7580.2007.00822.x; Spiess BD, 1998, J THORAC CARDIOV SUR, V116, P460, DOI 10.1016/S0022-5223(98)70012-1; STAIANOCOICO L, 2000, OSTOMY WOUND MANAG S, V46, P85; Taylor JE, 1996, INT ANGIOL, V15, P33; Tobu M, 2004, CLIN APPL THROMB-HEM, V10, P225, DOI 10.1177/107602960401000304; Tredget EE, 1997, SURG CLIN N AM, V77, P701, DOI 10.1016/S0039-6109(05)70576-4; Vajkoczy Peter, 1999, Neoplasia (New York), V1, P31, DOI 10.1038/sj.neo.7900006; Vesey DA, 2004, NEPHROL DIAL TRANSPL, V19, P348, DOI 10.1093/ndt/gfg547; Wassermann RJ, 1998, J SURG RES, V75, P74, DOI 10.1006/jsre.1998.5267; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wiessner C, 2001, J CEREBR BLOOD F MET, V21, P857, DOI 10.1097/00004647-200107000-00011; Yamasaki K, 1998, J CLIN INVEST, V101, P967, DOI 10.1172/JCI2067	60	60	62	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3049	3058		10.1096/fj.08-109991	http://dx.doi.org/10.1096/fj.08-109991			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19403513				2022-12-28	WOS:000270241000027
J	Leyris, JP; Gondeau, C; Charnet, A; Delattre, C; Rousset, M; Cens, T; Charnet, P				Leyris, J. -P.; Gondeau, C.; Charnet, A.; Delattre, C.; Rousset, M.; Cens, T.; Charnet, P.			RGK GTPase-dependent Ca(V)2.1 Ca2+ channel inhibition is independent of Ca-V beta-subunit-induced current potentiation	FASEB JOURNAL			English	Article						Gem; Rem; Rem2; Xenopus oocytes; GK domain	CALCIUM-CHANNEL; MOLECULAR DETERMINANTS; BINDING PROTEINS; ALPHA-SUBUNIT; KINASE DOMAIN; VOLTAGE; REM; CALMODULIN; EXPRESSION; COMPLEX	RGK (Rad-Gem-Rem) GTPases have been described as potent negative regulators of the Ca2+ influx via high-threshold voltage-activated Ca2+ channels. Recent work, mostly performed on Ca(V)1.2 Ca2+ channels, has highlighted the crucial role played by the channel auxiliary Ca-V beta subunits and identified several GTPase and beta-subunit protein domains involved in this regulation. We now extend these conclusions by producing the first complete characterization of the effects of Gem, Rem, and Rem2 on the neuronal Ca(V)2.1 Ca2+ channels expressed with Ca-V beta(1) or Ca-V beta(2) subunits. Current inhibition is limited to a decrease in amplitude with no modification in the voltage dependence or kinetics of the current. We demonstrate that this inhibition can occur for Ca-V beta constructs with impaired capacity to induce current potentiation, but that it is lost for Ca-V beta constructs deleted for their beta-interaction domain. The RGK C-terminal last similar to 80 amino acids are sufficient to allow potent current inhibition and in vivo beta-subunit/Gem interaction. Interestingly, although Gem and Gem carboxy-terminus induce a completely different pattern of beta-subunit cellular localization, they both potently inhibit CaV2.1 channels. These data therefore set the status of neuronal Ca(V)2.1 Ca2+ channel inhibition by RGK GTPases, emphasizing the role of short amino acid sequences of both proteins in beta-subunit binding and channel inhibition and revealing a new mechanism for channel inhibition.-Leyris, J.-P., Gondeau, C., Charnet, A., Delattre, C., Rousset, M., Cens, T., Charnet, P. RGK GTPase-dependent Ca(V)2.1 Ca2+ channel inhibition is independent of Ca-V beta-subunit-induced current potentiation. FASEB J. 23, 2627-2638 (2009)	[Charnet, P.] Univ Montpellier 1 & 2, CNRS, CRBM, UMR 5237, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Charnet, P (corresponding author), Univ Montpellier 1 & 2, CNRS, CRBM, UMR 5237, 1919 Rte Mende, F-34293 Montpellier, France.	pierre.charnet@crbm.cnrs.fr	Cens, Thierry/M-3337-2017	Cens, Thierry/0000-0002-4109-2779; Rousset, Matthieu/0000-0003-2064-2791; Charnet, Pierre/0000-0003-4692-528X	CNRS; INSERM; Association pour la Recherche contre le Cancer; Fondation pour la Recherche sur le Cerveau; Fondation Simone et Cino del Duca; Agence Nationale de la Recherche	CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Fondation pour la Recherche sur le Cerveau; Fondation Simone et Cino del Duca; Agence Nationale de la Recherche(French National Research Agency (ANR))	The authors thank Dr. D. Fesquet, P. Fort, and M. C. Morris (CRBM, Montpellier, France) and Dr. I. A. Lefevre (SanofiAventis, Montpellier, France) for helpful discussions and proofreading of the manuscript; J.-M. Donnay and J.-C. Mazure for oocyte preparation; and CNRS, INSERM, Association pour la Recherche contre le Cancer, Fondation pour la Recherche sur le Cerveau, Fondation Simone et Cino del Duca, and Agence Nationale de la Recherche for financial support.	Altier C, 2002, J BIOL CHEM, V277, P33598, DOI 10.1074/jbc.M202476200; Beguin P, 2005, J CELL SCI, V118, P1923, DOI 10.1242/jcs.02321; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Beguin P, 2007, J BIOL CHEM, V282, P11509, DOI 10.1074/jbc.M606423200; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; BOURINET E, 1992, FEBS LETT, V299, P5, DOI 10.1016/0014-5793(92)80087-W; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Catterall WA, 2005, PHARMACOL REV, V57, P411, DOI 10.1124/pr.57.4.5; Cens T, 2005, MOL B INT U, P95; Cens T, 1998, J BIOL CHEM, V273, P18308, DOI 10.1074/jbc.273.29.18308; Cens T, 1998, PFLUG ARCH EUR J PHY, V435, P865, DOI 10.1007/s004240050595; Cens T, 1999, J BIOL CHEM, V274, P5483, DOI 10.1074/jbc.274.9.5483; Chen HM, 2005, J NEUROSCI, V25, P9762, DOI 10.1523/JNEUROSCI.3111-05.2005; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; Correll RN, 2008, CELL SIGNAL, V20, P292, DOI 10.1016/j.cellsig.2007.10.028; Correll RN, 2007, J BIOL CHEM, V282, P28431, DOI 10.1074/jbc.M706176200; Crump SM, 2006, AM J PHYSIOL-HEART C, V291, pH1959, DOI 10.1152/ajpheart.00956.2005; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Finlin BS, 2006, J BIOL CHEM, V281, P23557, DOI 10.1074/jbc.M604867200; Finlin BS, 2005, J BIOL CHEM, V280, P41864, DOI 10.1074/jbc.M414261200; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; Fischer R, 1996, J BIOL CHEM, V271, P25067, DOI 10.1074/jbc.271.41.25067; Flynn R, 2008, BIOCHEM BIOPH RES CO, V368, P827, DOI 10.1016/j.bbrc.2008.02.020; Gao TY, 2001, J BIOL CHEM, V276, P21089, DOI 10.1074/jbc.M008000200; Gerster U, 1999, J PHYSIOL-LONDON, V517, P353, DOI 10.1111/j.1469-7793.1999.0353t.x; Hanlon MR, 1999, FEBS LETT, V445, P366, DOI 10.1016/S0014-5793(99)00156-8; Hibino H, 2003, P NATL ACAD SCI USA, V100, P307, DOI 10.1073/pnas.0136791100; Hulme JT, 2006, J PHYSIOL-LONDON, V576, P87, DOI 10.1113/jphysiol.2006.111799; Iftinca M, 2007, NAT NEUROSCI, V10, P854, DOI 10.1038/nn1921; Kiyonaka S, 2007, NAT NEUROSCI, V10, P691, DOI 10.1038/nn1904; Kobayashi T, 2007, BIOCHEM BIOPH RES CO, V360, P679, DOI 10.1016/j.bbrc.2007.06.112; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Leone A, 2001, ONCOGENE, V20, P3217, DOI 10.1038/sj.onc.1204420; Mahalakshmi RN, 2007, TRAFFIC, V8, P1150, DOI 10.1111/j.1600-0854.2007.00598.x; McGee AW, 2004, NEURON, V42, P89, DOI 10.1016/S0896-6273(04)00149-7; Murata M, 2004, CIRC RES, V95, P398, DOI 10.1161/01.RES.0000138449.85324.c5; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; Paradis S, 2007, NEURON, V53, P217, DOI 10.1016/j.neuron.2006.12.012; Piccoli G, 2004, J NEUROSCI, V24, P10918, DOI 10.1523/JNEUROSCI.4020-04.2004; Restituito S, 2000, J NEUROSCI, V20, P9046; Sasaki T, 2005, J BIOL CHEM, V280, P9308, DOI 10.1074/jbc.M413773200; Seu L, 2006, J GEN PHYSIOL, V128, P605, DOI 10.1085/jgp.200609631; Splingard A, 2007, J BIOL CHEM, V282, P1905, DOI 10.1074/jbc.M604363200; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; Takahashi SX, 2005, J GEN PHYSIOL, V126, P365, DOI 10.1085/jgp.200509354; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; Ward Y, 2004, MOL CELL BIOL, V24, P651, DOI 10.1128/MCB.24.2.651-661.2004; WEI XY, 1994, J BIOL CHEM, V269, P1635; Yang T, 2007, NAT CHEM BIOL, V3, P795, DOI 10.1038/nchembio.2007.42; Yu K, 2008, J NEUROSCI, V28, P5660, DOI 10.1523/JNEUROSCI.0065-08.2008	54	20	20	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2627	2638		10.1096/fj.08-122135	http://dx.doi.org/10.1096/fj.08-122135			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19332647				2022-12-28	WOS:000268836700031
J	Nilsson, KE; Andren, M; de Stahl, TD; Kleinau, S				Nilsson, Kajsa E.; Andren, Maria; de Stahl, Teresita Diaz; Kleinau, Sandra			Enhanced susceptibility to low-dose collagen-induced arthritis in CR1/2-deficient female mice-possible role of estrogen on CR1 expression	FASEB JOURNAL			English	Article						complement receptor; B cells; knockout mice; autoimmunity	SYSTEMIC-LUPUS-ERYTHEMATOSUS; SOLUBLE COMPLEMENT RECEPTOR; B-CELL ACTIVATION; T-DEPENDENT ANTIGEN; FC-GAMMA-RIIB; II COLLAGEN; DBA/1 MICE; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; INDUCED SUPPRESSION	The influence of complement receptor 1 and 2 (CR1/2) was investigated on the susceptibility to low-dose collagen-induced arthritis (CIA) in wild-type (WT) and CR1/2-deficient DBA/1 mice. Significantly enhanced CIA was observed in female CR1/2-deficient mice compared with WT female mice, while male mutant and WT mice showed similar arthritis development. The enhanced CIA was accompanied with higher complement levels and a prolonged IgM anti-collagen type II response. When investigating whether estrogen contributed to the different arthritis susceptibility, we found that ovariectomy rendered WT females more sensitive to low-dose CIA and to the same extent as CR1/2-deficient females, while CR1/2-deficient mice were unaffected by ovariectomy. Notably, the ovariectomized WT mice displayed reduced CR1(+) B220(+) B-cell numbers and CR1 expression compared with sham-operated WT mice, suggesting a stimulatory effect of estrogen on CR1. In accordance, a significant correlation was observed between reduced CR1 expression in B cells and increased age in healthy female blood donors but not in male donors. Our findings demonstrate an important role of CR1/2 in suppressing CIA in female mice under low-antigen conditions. The data suggest that estrogen promote CR1 expression in B cells. These findings provide insight to the increased frequency of rheumatoid arthritis in postmenopausal women.-Nilsson, K. E., Andren, M., Diaz de Stahl, T., Kleinau, S. Enhanced susceptibility to low-dose collagen-induced arthritis in CR1/2-deficient female mice-possible role of estrogen on CR1 expression. FASEB J. 23, 2450-2458 (2009)	[Nilsson, Kajsa E.; Andren, Maria; Kleinau, Sandra] Uppsala Univ, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden; [de Stahl, Teresita Diaz] Uppsala Univ, Dept Genet & Pathol, SE-75124 Uppsala, Sweden	Uppsala University; Uppsala University	Kleinau, S (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Box 596, SE-75124 Uppsala, Sweden.	sandra.kleinau@icm.uu.se	Kleinau, Sandra/C-9545-2013	Kleinau, Sandra/0000-0002-9729-2286; Diaz de Stahl, Teresita/0000-0001-5933-6623	Swedish Research Council; Swedish Rheumatism Association; King Gustaf V's 80-years foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Rheumatism Association; King Gustaf V's 80-years foundation	We thank Birgitta Heyman and Sofia Magnusson for critical reading of the manuscript and Dr. Inga Hansson for technical assistance. This work was supported by the Swedish Research Council, the Swedish Rheumatism Association, and the King Gustaf V's 80-years foundation.	Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; Andren M, 2005, EUR J IMMUNOL, V35, P3020, DOI 10.1002/eji.200526291; Applequist SE, 2000, J IMMUNOL, V165, P2398, DOI 10.4049/jimmunol.165.5.2398; ATKINSON JP, 1989, CLIN EXP RHEUMATOL, V7, pS95; Chakravarty L, 2002, INT IMMUNOL, V14, P139, DOI 10.1093/intimm/14.2.139; CORVETTA A, 1991, J RHEUMATOL, V18, P1021; COURTENAY JS, 1980, NATURE, V283, P666, DOI 10.1038/283666a0; CREAMER P, 1994, BRIT J RHEUMATOL, V33, P583; Croix DA, 1996, J EXP MED, V183, P1857, DOI 10.1084/jem.183.4.1857; de Stahl TD, 2003, J EXP MED, V197, P1183, DOI 10.1084/jem.20022232; Del Nagro CJ, 2005, J IMMUNOL, V175, P5379, DOI 10.4049/jimmunol.175.8.5379; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Dreja H, 2000, ARTHRITIS RHEUM-US, V43, P1698, DOI 10.1002/1529-0131(200008)43:8<1698::AID-ANR5>3.0.CO;2-8; Erdei A, 2003, CURR PHARM DESIGN, V9, P1849, DOI 10.2174/1381612033454351; ERICKSON RP, 1964, J IMMUNOL, V92, P611; Goodfellow RM, 2000, CLIN EXP IMMUNOL, V119, P210, DOI 10.1046/j.1365-2249.2000.01129.x; Grimaldi CM, 2006, CURR OPIN RHEUMATOL, V18, P456, DOI 10.1097/01.bor.0000240354.37927.dd; Grimaldi CM, 2005, MOL IMMUNOL, V42, P811, DOI 10.1016/j.molimm.2004.05.014; Grimaldi CM, 2002, J CLIN INVEST, V109, P1625, DOI 10.1172/JCI200214873; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; Hietala MA, 2002, J IMMUNOL, V169, P454, DOI 10.4049/jimmunol.169.1.454; HOLMDAHL R, 1985, CLIN EXP IMMUNOL, V62, P639; Jansson L, 1998, INFLAMM RES, V47, P290, DOI 10.1007/s000110050332; JANSSON L, 1992, CLIN EXP IMMUNOL, V89, P446; JANSSON L, 1990, J AUTOIMMUN, V3, P257, DOI 10.1016/0896-8411(90)90145-I; Jansson L, 2001, ARTHRITIS RHEUM, V44, P2168, DOI 10.1002/1529-0131(200109)44:9<2168::AID-ART370>3.0.CO;2-2; Jozsi M, 2002, J IMMUNOL, V168, P2782, DOI 10.4049/jimmunol.168.6.2782; KERWAR SS, 1983, ARTHRITIS RHEUM, V26, P1120, DOI 10.1002/art.1780260910; KERWAR SS, 1982, J IMMUNOPHARMACOL, V3, P323, DOI 10.3109/08923978109031065; KINOSHITA T, 1988, J IMMUNOL, V140, P3066; Kuhn KA, 2008, MOL IMMUNOL, V45, P2808, DOI 10.1016/j.molimm.2008.01.036; KUMAR A, 1994, IMMUNOBIOLOGY, V191, P9, DOI 10.1016/S0171-2985(11)80264-0; KURTZ CB, 1990, J IMMUNOL, V144, P3581; Linton SM, 1999, MOL IMMUNOL, V36, P905, DOI 10.1016/S0161-5890(99)00113-3; Magnusson SE, 2008, CLIN IMMUNOL, V127, P225, DOI 10.1016/j.clim.2008.02.002; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; MOLINA H, 1994, J IMMUNOL, V153, P789; Mongini PKA, 1997, J IMMUNOL, V159, P3782; MUNSON LG, 1995, CLIN IMMUNOL IMMUNOP, V75, P20, DOI 10.1006/clin.1995.1047; Nandakumar KS, 2003, EUR J IMMUNOL, V33, P2269, DOI 10.1002/eji.200323810; Olsen Nancy J, 2002, J Gend Specif Med, V5, P28; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; Prodeus AP, 1998, IMMUNITY, V9, P721, DOI 10.1016/S1074-7613(00)80669-X; Renaudineau Y, 2005, AUTOIMMUNITY, V38, P11, DOI 10.1080/08916930400022574; Sakiniene E, 1999, SCAND J IMMUNOL, V50, P250; SEKI N, 1988, J IMMUNOL, V140, P1477; STUART JM, 1983, J EXP MED, V158, P378, DOI 10.1084/jem.158.2.378; Svensson L, 1998, CLIN EXP IMMUNOL, V111, P521; Takahashi K, 1997, J IMMUNOL, V159, P1557; Walport MJ, 2002, ARTHRITIS RES THER, V4, pS279, DOI 10.1186/ar586; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; Wang Y, 2000, J IMMUNOL, V164, P4340, DOI 10.4049/jimmunol.164.8.4340; WATSON WC, 1985, J EXP MED, V162, P1878, DOI 10.1084/jem.162.6.1878; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; WILSON JG, 1986, ARTHRITIS RHEUM, V29, P739, DOI 10.1002/art.1780290606; WOOLEY PH, 1981, J EXP MED, V154, P688, DOI 10.1084/jem.154.3.688	58	12	13	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2450	2458		10.1096/fj.08-125849	http://dx.doi.org/10.1096/fj.08-125849			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19351702				2022-12-28	WOS:000268836700013
J	Waak, J; Weber, SS; Waldenmaier, A; Gorner, K; Alunni-Fabbroni, M; Schell, H; Vogt-Weisenhorn, D; Pham, TT; Reumers, V; Baekelandt, V; Wurst, W; Kahle, PJ				Waak, Jens; Weber, Stephanie S.; Waldenmaier, Andrea; Goerner, Karin; Alunni-Fabbroni, Marianna; Schell, Heinrich; Vogt-Weisenhorn, Daniela; Pham, Thu-Trang; Reumers, Veerle; Baekelandt, Veerle; Wurst, Wolfgang; Kahle, Philipp J.			Regulation of astrocyte inflammatory responses by the Parkinson's disease-associated gene DJ-1	FASEB JOURNAL			English	Article						nitric oxide synthase; mitogen-activated protein kinase; Toll-like receptor signaling; neuroinflammation; lipopolysaccharide	OXIDATIVE STRESS; DJ-1-DEFICIENT MICE; PROTEIN STABILITY; NITRIC-OXIDE; IN-VIVO; EXPRESSION; MUTATIONS; LIPOPOLYSACCHARIDE; NEUROPROTECTION; LOCALIZATION	The Parkinson's disease (PD)-associated gene DJ-1 mediates direct neuroprotection. The up-regulation of DJ-1 in reactive astrocytes also suggests a role in glia. Here we show that DJ-1 regulates proinflammatory responses in mouse astrocyte-rich primary cultures. When treated with a Toll-like receptor 4 agonist, the bacterial endotoxin lipopolysaccharide (LPS), Dj-1-knockout astrocytes generated >10 times more nitric oxide (NO) than littermate controls. Lentiviral reintroduction of DJ-1 restored the NO response to LPS. The enhanced NO production in Dj-1(-/-) astrocytes was mediated by a signaling pathway involving reactive oxygen species leading to specific hyperinduction of type II NO synthase [inducible NO synthase ( iNOS)]. These effects coincided with significantly increased phosphorylation of p38 mitogen-activated protein kinase (MAPK), and p38(MAPK) inhibition suppressed NO production and iNOS mRNA and protein induction. Dj-1(-/-) astrocytes also induced the proinflammatory mediators cyclooxygenase-2 and interleukin-6 significantly more strongly, but not nerve growth factor. Finally, primary neuron cultures grown on Dj-1(-/-) astrocytes became apoptotic in response to LPS in an iNOS-dependent manner, directly demonstrating the neurotoxic potential of astrocytic DJ-1 deficiency. These findings identify DJ-1 as a regulator of proinflammatory responses and suggest that loss of DJ-1 contributes to PD pathogenesis by deregulation of astrocytic neuroinflammatory damage.-Waak, J., Weber, S. S., Waldenmaier, A., Gorner, K., Alunni-Fabbroni, M., Schell, H., Vogt-Weisenhorn, D., Pham, T.-T., Reumers, V., Baekelandt, V., Wurst, W., Kahle, P. J. Regulation of astrocyte inflammatory responses by the Parkinson's disease-associated gene DJ-1. FASEB J. 23, 2478-2489 (2009)	[Kahle, Philipp J.] Univ Clin Tubingen, Hertie Inst Clin Brain Res, Lab Funct Neurogenet, Dept Neurodegenerat, D-72076 Tubingen, Germany; [Waldenmaier, Andrea; Goerner, Karin; Alunni-Fabbroni, Marianna] BBD, Advalytix Prod, Olympus Life Sci Res Europe, Munich, Germany; [Vogt-Weisenhorn, Daniela; Pham, Thu-Trang; Wurst, Wolfgang] Helmholtz Ctr Munich, Inst Dev Genet, Neuherberg, Germany; [Reumers, Veerle; Baekelandt, Veerle] Katholieke Univ Leuven, Div Mol Med, Dept Mol & Cellular Med, Lab Neurobiol & Gene Therapy, Leuven, Belgium	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Olympus Corporation; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; KU Leuven	Kahle, PJ (corresponding author), Univ Clin Tubingen, Hertie Inst Clin Brain Res, Lab Funct Neurogenet, Dept Neurodegenerat, Otfried Muller Str 27, D-72076 Tubingen, Germany.	philipp.kahle@uni-tuebingen.de	Baekelandt, Veerle/ABB-9736-2020	Baekelandt, Veerle/0000-0001-8966-2921; Vogt Weisenhorn, Daniela/0000-0002-4566-6506; Wurst, Wolfgang/0000-0003-4422-7410	German Ministry of Education and Research National Genome Research Network; German Research Council Collaborative Research Center; Novartis; Helmholtz Alliance "Aging Brain,"; Hertie Foundation; Flemish Foundation for Scientific Research (FWO Vlaanderen)	German Ministry of Education and Research National Genome Research Network(Federal Ministry of Education & Research (BMBF)); German Research Council Collaborative Research Center(German Research Foundation (DFG)); Novartis(Novartis); Helmholtz Alliance "Aging Brain,"; Hertie Foundation; Flemish Foundation for Scientific Research (FWO Vlaanderen)(FWO)	This work was supported by grants from the German Ministry of Education and Research National Genome Research Network and the German Research Council Collaborative Research Center (SFB596 "Molecular Mechanisms of Neurodegeneration"), a Novartis collaborative research grant, the Helmholtz Alliance "Aging Brain," and the Hertie Foundation. V. R. was supported by a travel grant of the Flemish Foundation for Scientific Research (FWO Vlaanderen). We thank Lars Stolze [Hertie-Institut fur klinische Hirnforschung (HIH), Tubingen, Germany] for advice and donation of anti-CD11b, Ingo Autenrieth for helpful discussions, and Hidenori Ichijo and Thomas Gasser for support and critically reading the manuscript.	Abou-Sleiman PM, 2003, ANN NEUROL, V54, P283, DOI 10.1002/ana.10675; Badera V, 2005, BRAIN RES, V1041, P102, DOI 10.1016/j.brainres.2005.02.006; Bandopadhyay R, 2004, BRAIN, V127, P420, DOI 10.1093/brain/awh054; Batelli S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001884; Blackinton J, 2005, MOL BRAIN RES, V134, P76, DOI 10.1016/j.molbrainres.2004.09.004; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Calabrese V, 2007, NAT REV NEUROSCI, V8, P766, DOI 10.1038/nrn2214; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Chen LN, 2005, J BIOL CHEM, V280, P21418, DOI 10.1074/jbc.M413955200; Clements CM, 2006, P NATL ACAD SCI USA, V103, P15091, DOI 10.1073/pnas.0607260103; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Fan J, 2008, J BIOL CHEM, V283, P4022, DOI 10.1074/jbc.M707176200; GalveRoperh I, 1997, J NEUROSCI RES, V49, P569, DOI 10.1002/(SICI)1097-4547(19970901)49:5<569::AID-JNR7>3.0.CO;2-9; Geraerts M, 2005, J GENE MED, V7, P1299, DOI 10.1002/jgm.778; Gorner K, 2007, J BIOL CHEM, V282, P13680, DOI 10.1074/jbc.M609821200; Goldberg MS, 2005, NEURON, V45, P489, DOI 10.1016/j.neuron.2005.01.041; Gorner K, 2004, J BIOL CHEM, V279, P6943, DOI 10.1074/jbc.M309204200; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Guix FX, 2005, PROG NEUROBIOL, V76, P126, DOI 10.1016/j.pneurobio.2005.06.001; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P341; Hunot S, 2003, ANN NEUROL, V53, pS49, DOI 10.1002/ana.10481; Junn E, 2005, P NATL ACAD SCI USA, V102, P9691, DOI 10.1073/pnas.0409635102; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102; Krasowska-Zoladek A, 2007, J NEUROSCI RES, V85, P205, DOI 10.1002/jnr.21088; Manning-Bog AB, 2007, NEUROBIOL DIS, V27, P141, DOI 10.1016/j.nbd.2007.03.014; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; Miklossy J, 2006, EXP NEUROL, V197, P275, DOI 10.1016/j.expneurol.2005.10.034; Mitsumoto A, 2001, FREE RADICAL RES, V35, P885, DOI 10.1080/10715760100301381; Moore DJ, 2003, J NEUROCHEM, V87, P1558, DOI 10.1111/j.1471-4159.2003.02265.x; Mullett SJ, 2009, NEUROPATHOLOGY, V29, P125, DOI 10.1111/j.1440-1789.2008.00955.x; Mullett SJ, 2009, NEUROBIOL DIS, V33, P28, DOI 10.1016/j.nbd.2008.09.013; Nagashima R, 2008, NEUROSCI LETT, V440, P232, DOI 10.1016/j.neulet.2008.05.100; Neumann M, 2004, ACTA NEUROPATHOL, V107, P489, DOI 10.1007/s00401-004-0834-2; Nicholas C, 2007, J IMMUNOL, V179, P7121, DOI 10.4049/jimmunol.179.10.7121; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; Rizzu P, 2004, ANN NEUROL, V55, P113, DOI 10.1002/ana.10782; Shendelman S, 2004, PLOS BIOL, V2, P1764, DOI 10.1371/journal.pbio.0020362; Takahashi-Niki K, 2004, BIOCHEM BIOPH RES CO, V320, P389, DOI 10.1016/j.bbrc.2004.05.187; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Xu J, 2005, HUM MOL GENET, V14, P1231, DOI 10.1093/hmg/ddi134; Yamaguchi H, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-10; Yanagida T, 2006, J PHARMACOL SCI, V102, P243, DOI 10.1254/jphs.SC0060098; Yang YF, 2005, P NATL ACAD SCI USA, V102, P13670, DOI 10.1073/pnas.0504610102; Zhou WB, 2005, J BIOL CHEM, V280, P43150, DOI 10.1074/jbc.M507124200	45	135	139	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2478	2489		10.1096/fj.08-125153	http://dx.doi.org/10.1096/fj.08-125153			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19276172				2022-12-28	WOS:000268836700016
J	Dejima, K; Murata, D; Mizuguchi, S; Nomura, KH; Gengyo-Ando, K; Mitani, S; Kamiyama, S; Nishihara, S; Nomura, K				Dejima, Katsufumi; Murata, Daisuke; Mizuguchi, Souhei; Nomura, Kazuko H.; Gengyo-Ando, Keiko; Mitani, Shohei; Kamiyama, Shin; Nishihara, Shoko; Nomura, Kazuya			The ortholog of human solute carrier family 35 member B1 (UDP-galactose transporter-related protein 1) is involved in maintenance of ER homeostasis and essential for larval development in Caenorhabditis elegans	FASEB JOURNAL			English	Article						ER stress; RNAi; deletion mutant; glycosylation; model organism	NUCLEOTIDE-SUGAR TRANSPORTERS; ENDOPLASMIC-RETICULUM STRESS; FUNCTIONAL-CHARACTERIZATION; ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; SULFATE SYNTHESIS; GOLGI-APPARATUS; GENE-EXPRESSION; GLUCURONIC ACID; IDENTIFICATION	Although the solute carrier 35B1 (SLC35B1) is evolutionarily conserved, its functions in metazoans remain unknown. To elucidate its function, we examined developmental roles of an SLC35B1 family gene (HUT-1: homolog of UDP-Gal transporter) in Caenorhabditis elegans. We isolated a deletion mutant of the gene and characterized phenotypes of the mutant and hut-1 RNAi-treated worms. GFP-HUT-1 reporter analysis was performed to examine gene expression patterns. We also tested whether several nucleotide sugar transporters can compensate for hut-1 deficiency. The hut-1 deletion mutant and RNAi worms showed larval growth defect and lethality with disrupted intestinal morphology. Inactivation of hut-1 induced chronic endoplasmic reticulum ( ER) stress, and hut-1 showed genetic interactions with the atf-6, pek-1, and ire-1 genes involved in unfolded protein response signaling. ER ultrastructure and ER marker distribution in hut-1-deficient animals showed that HUT-1 is required for maintenance of ER structure. Reporter analysis revealed that HUT- 1 is an ER protein ubiquitously expressed in tissues, including the intestine. Lethality and the ER stress phenotype of the mutant were rescued with the human hut-1 ortholog UGTrel1. These results indicate important roles for hut-1 in development and maintenance of ER homeostasis in C. elegans.-Dejima, K., Murata, D., Mizuguchi, S., Nomura, K. H., Gengyo-Ando, K., Mitani, S., Kamiyama, S., Nishihara, S., Nomura, K. The ortholog of human solute carrier family 35 member B1 (UDP-galactose transporter- related protein 1) is involved in maintenance of ER homeostasis and essential for larval development in Caenorhabditis elegans. FASEB J. 23, 2215-2225 (2009)	[Dejima, Katsufumi; Murata, Daisuke; Mizuguchi, Souhei; Nomura, Kazuko H.; Nomura, Kazuya] Kyushu Univ, Dept Biol, Fac Sci, Fukuoka 8128581, Japan; [Dejima, Katsufumi; Murata, Daisuke; Mizuguchi, Souhei; Nomura, Kazuko H.; Gengyo-Ando, Keiko; Mitani, Shohei; Nishihara, Shoko; Nomura, Kazuya] Japan Sci & Technol Agcy, Saitama, Japan; [Gengyo-Ando, Keiko; Mitani, Shohei] Tokyo Womens Med Univ, Sch Med, Dept Physiol, Tokyo, Japan; [Kamiyama, Shin; Nishihara, Shoko] Soka Univ, Fac Engn, Cell Biol Lab, Dept Bioinformat, Tokyo, Japan	Kyushu University; Japan Science & Technology Agency (JST); Tokyo Women's Medical University; Soka University	Nomura, K (corresponding author), Kyushu Univ, Dept Biol, Fac Sci 33, Fukuoka 8128581, Japan.	knomuscb@mbox.kyushu-u.ac.jp	Gengyo-Ando, Keiko/B-2753-2012; Gengyo-Ando, Keiko/AAC-4504-2019	Nishihara, Shoko/0000-0002-1668-2603	Japan Science and Technology Corp; MEXT, Japan	Japan Science and Technology Corp(Japan Science & Technology Agency (JST)); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr. Yoshifumi Jigami and Dr. Takehiko Yoko-o ( National Institute of Advanced Industrial Science and Technology, Tokyo, Japan) for providing yeast hut1 genes; Dr. Roger Tsien ( University of California, San Diego, CA, USA) for providing the mCherry gene; and the Caenorhabditis Genetics Center ( University of Minnesota, Minneapolis, MN, USA; supported by the National Institutes of Health-National Center for Research Resources) for providing C. elegans strains. This work was supported by a grant-in-aid for JSPS fellows ( to K. D.) and a grant-in-aid for young scientists ( B) ( to S. M.) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Japan. The study is also supported by the Core Research for Evolutional Science and Technology Program of the Japan Science and Technology Corp. (to K.N.) and for Scientific Research on Priority Areas 14082207 (to K.N.) from MEXT, Japan.	Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P7276; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Berninsone P, 1997, J BIOL CHEM, V272, P12616, DOI 10.1074/jbc.272.19.12616; Berninsone Patricia M, 2006, WormBook, P1; BRENNER S, 1974, GENETICS, V77, P71; Caffaro CE, 2008, BIOCHEMISTRY-US, V47, P4337, DOI 10.1021/bi702468g; Caffaro CE, 2006, ACCOUNTS CHEM RES, V39, P805, DOI 10.1021/ar0400239; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Capul AA, 2007, J BIOL CHEM, V282, P14006, DOI 10.1074/jbc.M610869200; Dejima K, 2006, J BIOL CHEM, V281, P11431, DOI 10.1074/jbc.M601509200; Gengyo-Ando K, 2000, BIOCHEM BIOPH RES CO, V269, P64, DOI 10.1006/bbrc.2000.2260; Gengyo-Ando K, 2006, BIOCHEM BIOPH RES CO, V349, P1345, DOI 10.1016/j.bbrc.2006.08.183; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Guerardel Y, 2001, BIOCHEM J, V357, P167, DOI 10.1042/0264-6021:3570167; Handford M, 2006, BRAZ J MED BIOL RES, V39, P1149, DOI 10.1590/S0100-879X2006000900002; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hiraoka S, 2007, NAT MED, V13, P1363, DOI 10.1038/nm1655; Horton P, 2007, NUCLEIC ACIDS RES, V35, pW585, DOI 10.1093/nar/gkm259; Ishida N, 2005, GENOMICS, V85, P106, DOI 10.1016/j.ygeno.2004.09.010; Ishida N, 2004, PFLUG ARCH EUR J PHY, V447, P768, DOI 10.1007/s00424-003-1093-0; Kall L, 2007, NUCLEIC ACIDS RES, V35, pW429, DOI 10.1093/nar/gkm256; Kainuma M, 2001, YEAST, V18, P533, DOI 10.1002/yea.708; Kall L, 2005, BIOINFORMATICS, V21, pI251, DOI 10.1093/bioinformatics/bti1014; Kamauchi S, 2005, FEBS J, V272, P3461, DOI 10.1111/j.1742-4658.2005.04770.x; Kamiyama S, 2006, J BIOL CHEM, V281, P10945, DOI 10.1074/jbc.M508991200; Kamiyama S, 2003, J BIOL CHEM, V278, P25958, DOI 10.1074/jbc.M302439200; Karaskov E, 2006, ENDOCRINOLOGY, V147, P3398, DOI 10.1210/en.2005-1494; Kitagawa H, 2007, J BIOL CHEM, V282, P8533, DOI 10.1074/jbc.M611107200; Kobayashi T, 2006, BIOCHEM J, V400, P281, DOI 10.1042/BJ20060429; Lee W, 2005, BIOCHEM BIOPH RES CO, V338, P1018, DOI 10.1016/j.bbrc.2005.10.041; Lin JH, 2008, ANNU REV PATHOL-MECH, V3, P399, DOI 10.1146/annurev.pathmechdis.3.121806.151434; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/88299; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Martinez IM, 2003, PLANT CELL, V15, P561, DOI 10.1105/tpc.007609; Martinez-Duncker I, 2003, BIOCHIMIE, V85, P245, DOI 10.1016/S0300-9084(03)00046-4; Mello C, 1995, METHOD CELL BIOL, V48, P451; Mouysset J, 2006, J STRUCT BIOL, V156, P41, DOI 10.1016/j.jsb.2006.02.015; Muraoka M, 2007, J BIOL CHEM, V282, P24615, DOI 10.1074/jbc.M611358200; Murray JI, 2004, MOL BIOL CELL, V15, P2361, DOI 10.1091/mbc.E03-11-0799; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; Nakanishi H, 2001, YEAST, V18, P543, DOI 10.1002/yea.707; Norambuena L, 2002, J BIOL CHEM, V277, P32923, DOI 10.1074/jbc.M204081200; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Park BJ, 2001, MOL BIOL CELL, V12, P2835, DOI 10.1091/mbc.12.9.2835; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Reyes F, 2006, J BIOL CHEM, V281, P9145, DOI 10.1074/jbc.M512210200; Rolls MM, 2002, MOL BIOL CELL, V13, P1778, DOI 10.1091/mbc.01-10-0514; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Sasagawa Y, 2007, GENES CELLS, V12, P1063, DOI 10.1111/j.1365-2443.2007.01108.x; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shen XH, 2005, PLOS GENET, V1, P355, DOI 10.1371/journal.pgen.0010037; Shim J, 2004, MOL BIOL CELL, V15, P4818, DOI 10.1091/mbc.E04-02-0108; Thorpe GW, 2004, P NATL ACAD SCI USA, V101, P6564, DOI 10.1073/pnas.0305888101; Uccelletti D, 2008, MOL BIOL CELL, V19, P1337, DOI 10.1091/mbc.E07-06-0547; Uccelletti D, 2004, J BIOL CHEM, V279, P27390, DOI 10.1074/jbc.M402624200	58	17	21	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2215	2225		10.1096/fj.08-123737	http://dx.doi.org/10.1096/fj.08-123737			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19270184	Green Published			2022-12-28	WOS:000268836500021
J	Salmon, AB; Leonard, S; Masamsetti, V; Pierce, A; Podlutsky, AJ; Podlutskaya, N; Richardson, A; Austad, SN; Chaudhuri, AR				Salmon, Adam B.; Leonard, Shanique; Masamsetti, Venkata; Pierce, Anson; Podlutsky, Andrej J.; Podlutskaya, Natalia; Richardson, Arlan; Austad, Steven N.; Chaudhuri, Asish R.			The long lifespan of two bat species is correlated with resistance to protein oxidation and enhanced protein homeostasis	FASEB JOURNAL			English	Article						longevity; comparative biology; oxidative stress; ubiquitin-proteasome; Chiroptera	FREE-RADICAL PRODUCTION; NAKED MOLE-RATS; LIVING RODENT; ANTIOXIDANT DEFENSES; CELLULAR-RESISTANCE; HEART-MITOCHONDRIA; STRESS RESISTANCE; H2O2 PRODUCTION; MULTIPLE FORMS; METABOLIC-RATE	Altered structure, and hence function, of cellular macromolecules caused by oxidation can contribute to loss of physiological function with age. Here, we tested whether the lifespan of bats, which generally live far longer than predicted by their size, could be explained by reduced protein damage relative to short-lived mice. We show significantly lower protein oxidation (carbonylation) in Mexican free-tailed bats (Tadarida brasiliensis) relative to mice, and a trend for lower oxidation in samples from cave myotis bats (Myotis velifer) relative to mice. Both species of bat show in vivo and in vitro resistance to protein oxidation under conditions of acute oxidative stress. These bat species also show low levels of protein ubiquitination in total protein lysates along with reduced proteasome activity, suggesting diminished protein damage and removal in bats. Lastly, we show that bat-derived protein fractions are resistant to urea-induced protein unfolding relative to the level of unfolding detected in fractions from mice. Together, these data suggest that long lifespan in some bat species might be regulated by very efficient maintenance of protein homeostasis.-Salmon, A. B., Leonard, S., Masamsetti, V., Pierce, A., Podlutsky, A. J., Podlutskaya, N., Richardson, A., Austad, S. N., Chaudhuri, A. R. The long lifespan of two bat species is correlated with resistance to protein oxidation and enhanced protein homeostasis. FASEB J. 23, 2317-2326 (2009)	[Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA; [Pierce, Anson; Richardson, Arlan; Chaudhuri, Asish R.] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA; [Pierce, Anson; Richardson, Arlan; Austad, Steven N.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio	Chaudhuri, AR (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA.	chaudhuria@uthscsa.edu	Podlutsky, Andrej/F-5421-2015; Pierce, Anson/D-1079-2012	Pierce, Anson/0000-0002-1383-0180; Masamsetti, Venkata Sai Durga Pragathi/0000-0002-0251-1707	NIH [T32 AG021890-05, AG23843, R37 AG26557, AG022873];  [K07 AG025063 04]; NATIONAL INSTITUTE ON AGING [K07AG025063, R37AG026557, R01AG022873, R01AG023843, T32AG021890] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Bertran Friguet (Universite Paris, Paris, France) for providing 20S proteasome antibody. We also thank Tom Kunz and Louise Allen for help in obtaining our bat samples. This work was supported by K07 AG025063 04 (A. R. C., A. R., S.N.A.); NIH training grant T32 AG021890-05 (A. B. S.); and NIH grants AG23843, R37 AG26557 (A. R.), and AG022873 (S.N.A.).	Agarwal S, 1996, EXP GERONTOL, V31, P365, DOI 10.1016/0531-5565(95)02039-X; Andziak B, 2005, MECH AGEING DEV, V126, P1206, DOI 10.1016/j.mad.2005.06.009; Andziak B, 2006, AGING CELL, V5, P525, DOI 10.1111/j.1474-9726.2006.00246.x; Andziak B, 2006, AGING CELL, V5, P463, DOI 10.1111/j.1474-9726.2006.00237.x; AUSTAD SN, 1991, J GERONTOL, V46, pB47, DOI 10.1093/geronj/46.2.B47; Barja G, 2002, FREE RADICAL BIO MED, V33, P1167, DOI 10.1016/S0891-5849(02)00910-3; BARJA G, 1994, FREE RADICAL RES, V21, P317, DOI 10.3109/10715769409056584; BAUDRY M, 1986, NEUROBIOL AGING, V7, P255, DOI 10.1016/0197-4580(86)90004-7; Bokov A, 2004, MECH AGEING DEV, V125, P811, DOI 10.1016/j.mad.2004.07.009; Brunet-Rossinni AK, 2004, MECH AGEING DEV, V125, P11, DOI 10.1016/j.mad.2003.09.003; Brunet-Rossinni AK, 2004, BIOGERONTOLOGY, V5, P211, DOI 10.1023/B:BGEN.0000038022.65024.d8; Bulteau AL, 2002, ARCH BIOCHEM BIOPHYS, V397, P298, DOI 10.1006/abbi.2001.2663; Busuttil RA, 2003, AGING CELL, V2, P287, DOI 10.1046/j.1474-9728.2003.00066.x; Chaudhuri AR, 2006, MECH AGEING DEV, V127, P849, DOI 10.1016/j.mad.2006.08.006; Cohen AA, 2008, AM NAT, V172, P178, DOI 10.1086/589456; Csiszar A, 2007, AM J PHYSIOL-HEART C, V293, pH919, DOI 10.1152/ajpheart.01287.2006; Davies KJA, 2000, IUBMB LIFE, V50, P279, DOI 10.1080/15216540051081010; Finch CE, 1990, LONGEVITY SENESCENCE; Friedberg E. C., 2006, DNA REPAIR MUTAGENES; George JC, 1999, CAN J ZOOL, V77, P571, DOI 10.1139/cjz-77-4-571; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Harper JM, 2007, AGING CELL, V6, P1, DOI 10.1111/j.1474-9726.2006.00255.x; Herczenik E, 2008, FASEB J, V22, P2115, DOI 10.1096/fj.07-099671; Herrero A, 1998, MECH AGEING DEV, V103, P133, DOI 10.1016/S0047-6374(98)00035-9; Holmes DJ, 2003, EXP GERONTOL, V38, P1365, DOI 10.1016/j.exger.2003.10.018; JURGENS KD, 1987, COMP BIOCHEM PHYS A, V88, P361, DOI 10.1016/0300-9629(87)90498-1; Kapahi P, 1999, FREE RADICAL BIO MED, V26, P495, DOI 10.1016/S0891-5849(98)00323-2; Khidekel N, 2004, ORG BIOMOL CHEM, V2, P1, DOI 10.1039/b312466e; Labinskyy N, 2006, AM J PHYSIOL-HEART C, V291, pH2698, DOI 10.1152/ajpheart.00534.2006; Lambert AJ, 2007, AGING CELL, V6, P607, DOI 10.1111/j.1474-9726.2007.00312.x; Lorenzini A, 2005, MECH AGEING DEV, V126, P1130, DOI 10.1016/j.mad.2005.05.004; Miller RA, 2002, EXP BIOL MED, V227, P500, DOI 10.1177/153537020222700715; Murakami S, 2003, FASEB J, V17, P1565, DOI 10.1096/fj.02-1092fje; Ogburn CE, 2001, J GERONTOL A-BIOL, V56, pB468, DOI 10.1093/gerona/56.11.B468; Ogburn CE, 1998, J GERONTOL A-BIOL, V53, pB287, DOI 10.1093/gerona/53A.4.B287; Perez-Campo R, 1998, J COMP PHYSIOL B, V168, P149, DOI 10.1007/s003600050131; Pierce A, 2006, BIOCHEMISTRY-US, V45, P3077, DOI 10.1021/bi052031i; Podlutsky AJ, 2005, J GERONTOL A-BIOL, V60, P1366, DOI 10.1093/gerona/60.11.1366; Richardson A, 2004, BEST PRACT RES CL EN, V18, P393, DOI 10.1016/j.beem.2004.02.002; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; Salmon AB, 2005, AM J PHYSIOL-ENDOC M, V289, pE23, DOI 10.1152/ajpendo.00575.2004; Salmon AB, 2008, J GERONTOL A-BIOL, V63, P232, DOI 10.1093/gerona/63.3.232; SOHAL RS, 1990, MECH AGEING DEV, V53, P217, DOI 10.1016/0047-6374(90)90040-M; TOLMASOFF JM, 1980, P NATL ACAD SCI-BIOL, V77, P2777, DOI 10.1073/pnas.77.5.2777; Wilhelm D, 2007, COMP BIOCHEM PHYS C, V146, P214, DOI 10.1016/j.cbpc.2006.11.015; Wilkinson GS, 2002, AGING CELL, V1, P124, DOI 10.1046/j.1474-9728.2002.00020.x; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113	48	84	86	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2317	2326		10.1096/fj.08-122523	http://dx.doi.org/10.1096/fj.08-122523			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19244163	Green Published			2022-12-28	WOS:000268836500031
J	Wagner, C; Isermann, K; Roeder, T				Wagner, Christina; Isermann, Kerstin; Roeder, Thomas			Infection induces a survival program and local remodeling in the airway epithelium of the fly	FASEB JOURNAL			English	Article						Drosophila; trachea; inflammation; Foxo; Thor; asthma	JAK/STAT SIGNALING COMPONENTS; IMMUNE-RESPONSE; BRANCHING MORPHOGENESIS; CELL PROLIFERATION; GENE-EXPRESSION; INNATE IMMUNITY; TRACHEAL SYSTEM; DROSOPHILA; RNAI; IDENTIFICATION	Although the prevalence of inflammatory airway diseases is steadily growing, our knowledge regarding the underlying molecular and cellular mechanisms is fragmentary. The striking simplicity of the fruit fly's airway epithelium, which is composed of epithelial cells only, justifies its use as a model to study general features and response characteristics of airway epithelia in general. Infection with the gram-negative pathogen Erwinia carotovora induces an immune response in all epithelial cells via activation of the immune deficiency (IMD) pathway, but the transcriptional profile differs significantly from that observed after ectopic activation of this signaling pathway. After strong infections, genes controlling central aspects of tracheal development are reactivated, a response that is not seen after ectopic IMD pathway activation. Presumably to counteract infection-induced cell death-promoting signals, a survival response is launched, characterized by the concurrent expression and activation of the longevity genes dfoxo and dthor. Regions of the airways featuring the strongest immune reactions show substantial remodeling, which is characterized by a significant thickening of the epithelial cells. In conclusion, features related to those observed in inflammatory diseases of the human airways are apparently part of the normal response repertoire of airway epithelia to infection. -Wagner, C., Isermann, K., Roeder, T. Infection induces a survival program and local remodeling in the airway epithelium of the fly. FASEB J. 23, 2045-2054 (2009)	[Wagner, Christina; Isermann, Kerstin; Roeder, Thomas] Univ Kiel, Dept Zoophysiol, D-24098 Kiel, Germany; [Wagner, Christina; Roeder, Thomas] Forschungszentrum Borstel, Dept Immunol & Cell Biol, Borstel, Germany	University of Kiel; Forschungszentrum Borstel	Roeder, T (corresponding author), Univ Kiel, Dept Zoophysiol, Ohlshausenstr 40, D-24098 Kiel, Germany.	troeder@zoologie.uni-kiel.de	Wagner, Christina/M-7796-2018; Roeder, Thomas/B-9016-2011	Roeder, Thomas/0000-0002-3489-3834	Claussen-Simon-Stiftung; Stifterverb- and der deutschen Wirtschaft	Claussen-Simon-Stiftung; Stifterverb- and der deutschen Wirtschaft	This work is part of the Transregio 22 program of the Deutsche Forschungsgemeinschaft (TPA7). In addition, it was supported by the Claussen-Simon-Stiftung and the Stifterverb- and der deutschen Wirtschaft. We thank Bruno Lemaitre (Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland), Shigeo Hayashi (RIKEN Center for Developmental Biology, Kobe, Japan), Jean-Luc Imler (Institut de Biologie Moleculaire et Cellulaire, Strasbourg, France), Aya Takehana (Tohoku University, Sendai, Japan), Thomas Neufeld ( University of Minnesota, Minneapolis, MN, USA), Oscar Puig ( University of Helsinki, Helsinki, Finland), and the Bloomington Stock Center for fly stocks.	Affolter M, 2003, DEV CELL, V4, P11, DOI 10.1016/S1534-5807(02)00410-0; Baeg GH, 2005, GENE DEV, V19, P1861, DOI 10.1101/gad.1320705; Beckstead RB, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-12-r99; Bjorklund M, 2006, NATURE, V439, P1009, DOI 10.1038/nature04469; BRAND AH, 1993, DEVELOPMENT, V118, P401; Broide DH, 2005, P NATL ACAD SCI USA, V102, P17723, DOI 10.1073/pnas.0509235102; Cohen L, 2007, AM J RESP CRIT CARE, V176, P138, DOI 10.1164/rccm.200607-1062OC; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; Diamond G, 2000, INFECT IMMUN, V68, P113, DOI 10.1128/IAI.68.1.113-119.2000; Efron B, 2007, ANN APPL STAT, V1, P107, DOI 10.1214/07-AOAS101; Eynott PR, 2003, BRIT J PHARMACOL, V140, P1373, DOI 10.1038/sj.bjp.0705569; Ferrandon D, 1998, EMBO J, V17, P1217, DOI 10.1093/emboj/17.5.1217; Foley E, 2004, PLOS BIOL, V2, P1091, DOI 10.1371/journal.pbio.0020203; Franz O, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.11.e3; Friedman A, 2006, NATURE, V444, P230, DOI 10.1038/nature05280; Ghabrial A, 2003, ANNU REV CELL DEV BI, V19, P623, DOI 10.1146/annurev.cellbio.19.031403.160043; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Ha EM, 2005, SCIENCE, V310, P847, DOI 10.1126/science.1117311; Hay BA, 2006, ANNU REV CELL DEV BI, V22, P623, DOI 10.1146/annurev.cellbio.21.012804.093845; Hayashi S, 2002, GENESIS, V34, P58, DOI 10.1002/gene.10137; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Imboden M, 2008, THORAX, V63, P322, DOI 10.1136/thx.2007.085555; Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Liu L, 2003, P NATL ACAD SCI USA, V100, P2128, DOI 10.1073/pnas.252785099; Londhe VA, 2008, DEV DYNAM, V237, P328, DOI 10.1002/dvdy.21413; Lubarsky B, 2003, CELL, V112, P19, DOI 10.1016/S0092-8674(02)01283-7; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Machen TE, 2006, AM J PHYSIOL-CELL PH, V291, pC218, DOI 10.1152/ajpcell.00605.2005; Maillet F, 2008, CELL HOST MICROBE, V3, P293, DOI 10.1016/j.chom.2008.04.002; Miller LAD, 2004, DEV DYNAM, V231, P57, DOI 10.1002/dvdy.20105; Muller P, 2005, NATURE, V436, P871, DOI 10.1038/nature03869; Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Nybakken K, 2005, NAT GENET, V37, P1323, DOI 10.1038/ng1682; Pantano C, 2008, AM J RESP CRIT CARE, V177, P959, DOI 10.1164/rccm.200707-1096OC; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; Persson C, 2007, INSECT BIOCHEM MOLEC, V37, P1309, DOI 10.1016/j.ibmb.2007.08.003; Ruhle H, 1932, Z WISS ZOOL ABT A, V141, P159; Ryu JH, 2008, SCIENCE, V319, P777, DOI 10.1126/science.1149357; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; Schneider DS, 2007, PLOS BIOL, V5, P1847, DOI 10.1371/journal.pbio.0050247; Scott RC, 2007, CURR BIOL, V17, P1, DOI 10.1016/j.cub.2006.10.053; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Tingvall TO, 2001, EMBO REP, V2, P239; Tzou P, 2000, IMMUNITY, V13, P737, DOI 10.1016/S1074-7613(00)00072-8; Wagner C, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-446; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wehkamp J, 2005, P NATL ACAD SCI USA, V102, P18129, DOI 10.1073/pnas.0505256102; WHITTEN JM, 1957, Q J MICROSC SCI, V98, P123; Whitworth AJ, 2005, P NATL ACAD SCI USA, V102, P8024, DOI 10.1073/pnas.0501078102; Zaidman-Remy A, 2006, IMMUNITY, V24, P463, DOI 10.1016/j.immuni.2006.02.012	54	31	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2045	2054		10.1096/fj.08-114223	http://dx.doi.org/10.1096/fj.08-114223			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19237508				2022-12-28	WOS:000268836500005
J	Matsumura, N; Tsuji, T; Sumida, T; Kokubo, M; Onimaru, M; Doi, N; Takashima, H; Miyamoto-Sato, E; Yanagawa, H				Matsumura, Nobutaka; Tsuji, Toru; Sumida, Takeshi; Kokubo, Masahito; Onimaru, Michiko; Doi, Nobuhide; Takashima, Hideaki; Miyamoto-Sato, Etsuko; Yanagawa, Hiroshi			mRNA display selection of a high-affinity, Bcl-X-L-specific binding peptide	FASEB JOURNAL			English	Article						Bcl-2 family; BH3 domain; therapeutic peptide	IN-VITRO SELECTION; BH3-ONLY PROTEINS; INDUCE APOPTOSIS; BH3 PEPTIDES; FAMILY-MEMBERS; CELL-DEATH; BAX; ACTIVATION; BCL-X(L); DOMAINS	Bcl-X-L, an antiapoptotic member of the Bcl-2 family, is a mitochondrial protein that inhibits activation of Bax and Bak, which commit the cell to apoptosis, and it therefore represents a potential target for drug discovery. Peptides have potential as therapeutic molecules because they can be designed to engage a larger portion of the target protein with higher specificity. In the present study, we selected 16-mer peptides that interact with Bcl-X-L from random and degenerate peptide libraries using mRNA display. The selected peptides have sequence similarity with the Bcl-2 family BH3 domains, and one of them has higher affinity (IC50 = 0.9 mu M) than Bak BH3 (IC50 = 11.8 mu M) for Bcl-X-L in vitro. We also found that GFP fusions of the selected peptides specifically interact with Bcl-X-L, localize in mitochondria, and induce cell death. Further, a chimeric molecule, in which the BH3 domain of Bak protein was replaced with a selected peptide, retained the ability to bind specifically to Bcl-X-L. These results demonstrate that this selected peptide specifically antagonizes the function of Bcl-X-L and overcomes the effects of Bcl-X-L in intact cells. We suggest that mRNA display is a powerful technique to identify peptide inhibitors with high affinity and specificity for disease-related proteins.-Matsumura, N., Tsuji, T., Sumida, T., Kokubo, M., Onimaru, M., Doi, N., Takashima, H., Miyamoto-Sato, E., Yanagawa, H. mRNA display selection of a high-affinity, Bcl-X-L-specific binding peptide. FASEB J. 24, 2201-2210 (2010). www.fasebj.org	[Yanagawa, Hiroshi] Keio Univ, Dept Biosci & Informat, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan	Keio University	Yanagawa, H (corresponding author), Keio Univ, Dept Biosci & Informat, Kohoku Ku, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2238522, Japan.	hyana@bio.keio.ac.jp	Doi, Nobuhide/C-4481-2014	Doi, Nobuhide/0000-0002-2402-6390	Japan Ministry of Education, Culture, Sports, Science, and Technology (MEXT); New Energy and Industrial Technology Development Organization (NEDO) of Japan	Japan Ministry of Education, Culture, Sports, Science, and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); New Energy and Industrial Technology Development Organization (NEDO) of Japan(New Energy and Industrial Technology Development Organization (NEDO))	The authors thank Junko Shimizu for technical help in preparation of GFP-fusion plasmids. This work was supported, in part, by a grant-in-aid for scientific research, a Special Coordination Fund grant from the Japan Ministry of Education, Culture, Sports, Science, and Technology (MEXT), and a grant for practical application of university R&D results under the Matching Fund Method from the New Energy and Industrial Technology Development Organization (NEDO) of Japan.	Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Aouacheria A, 2001, ONCOGENE, V20, P5846, DOI 10.1038/sj.onc.1204740; Arai R, 2004, PROTEINS, V57, P829, DOI 10.1002/prot.20244; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Day CL, 2008, J MOL BIOL, V380, P958, DOI 10.1016/j.jmb.2008.05.071; Frankel A, 2003, CHEM BIOL, V10, P1043, DOI 10.1016/j.chembiol.2003.11.004; Geyer CR, 2000, METHOD ENZYMOL, V328, P171, DOI 10.1016/S0076-6879(00)28398-5; Hammond PW, 2001, J BIOL CHEM, V276, P20898, DOI 10.1074/jbc.M011641200; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Horisawa K, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh167; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Josephson K, 2005, J AM CHEM SOC, V127, P11727, DOI 10.1021/ja0515809; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Ke N, 2001, J BIOL CHEM, V276, P12481, DOI 10.1074/jbc.C000871200; Kim H, 2005, ONCOGENE, V24, P1252, DOI 10.1038/sj.onc.1208282; Kirkin V, 2004, BBA-MOL CELL RES, V1644, P229, DOI 10.1016/j.bbamcr.2003.08.009; Krajewska M, 1996, CANCER RES, V56, P2422; Lama D, 2008, PROTEINS, V73, P492, DOI 10.1002/prot.22075; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; Miyamoto-Sato E, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng078; Murakami H, 2006, NAT METHODS, V3, P357, DOI 10.1038/NMETH877; Nemoto N, 1997, FEBS LETT, V414, P405, DOI 10.1016/S0014-5793(97)01026-0; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297; Saito H, 2007, NUCLEIC ACIDS RES, V35, P6357, DOI 10.1093/nar/gkm692; Saito H, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm017; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schimmer AD, 2001, CELL DEATH DIFFER, V8, P725, DOI 10.1038/sj.cdd.4400870; Shangary S, 2004, MOL CANCER THER, V3, P1343; Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; Tateyama S, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj025; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001	40	9	9	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2010	24	7					2201	2210		10.1096/fj.09-143008	http://dx.doi.org/10.1096/fj.09-143008			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20181936				2022-12-28	WOS:000279343600007
J	Martina, E; Degen, M; Ruegg, C; Merlo, A; Lino, MM; Chiquet-Ehrismann, R; Brellier, F				Martina, Enrico; Degen, Martin; Rueegg, Curzio; Merlo, Adrian; Lino, Maddalena M.; Chiquet-Ehrismann, Ruth; Brellier, Florence			Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro	FASEB JOURNAL			English	Article						neovascularization; secreted glycoproteins	ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER; CELL-ADHESION; TUMOR; EXPRESSION; FIBRONECTIN; FIBROBLASTS; ANTIBODY; STROMA; RADIOIMMUNOTHERAPY	The microenvironment hosting a tumor actively participates in regulating tumor cell proliferation, migration, and invasion. Among the extracellular matrix proteins enriched in the stroma of carcinomas are the tenascin family members tenascin-C and tenascin-W. Whereas tenascin-C overexpression in gliomas is known to correlate with poor prognosis, the status of tenascin-W in brain tumors has not been investigated so far. In the present study, we analyzed protein levels of tenascin-W in 38 human gliomas and found expression of tenascin-W in 80% of the tumor samples, whereas no tenascin-W could be detected in control, nontumoral brain tissues. Double immunohistochemical staining of tenascin-W and von Willebrand factor revealed that tenascin-W is localized around blood vessels, exclusively in tumor samples. In vitro, the presence of tenascin-W increased the proportion of elongated human umbilical vein endothelial cells (HUVECs) and augmented the mean speed of cell migration. Furthermore, tenascin-W triggered sprouting of HUVEC spheroids to a similar extent as the proangio-genic factor tenascin-C. In conclusion, our study identifies tenascin-W as a candidate biomarker for brain tumor angiogenesis that could be used as a molecular target for therapy irrespective of the glioma subtype.-Martina, E., Degen, M., Ruegg, C., Merlo, A., Lino, M. M., Chiquet-Ehrismann, R., Brellier, F. Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro. FASEB J. 24, 778-787 (2010). www.fasebj.org	[Martina, Enrico; Degen, Martin; Chiquet-Ehrismann, Ruth; Brellier, Florence] Novartis Res Fdn, Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; [Rueegg, Curzio] Univ Lausanne, CHU Vaudois, Div Expt Oncol, Ctr Pluridisciplinaire Oncol, Lausanne, Switzerland; [Rueegg, Curzio] Swiss Inst Expt Canc Res, NCCR Mol Oncol, CH-1066 Epalinges, Switzerland; [Merlo, Adrian; Lino, Maddalena M.] Univ Basel Hosp, Dept Res, Mol Neurooncol Lab, CH-4031 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Institute Experimental Cancer Research; University of Basel	Brellier, F (corresponding author), Novartis Res Fdn, Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	florence.brellier@fmi.ch	Degen, Martin/H-5791-2013	Brellier, Florence/0000-0002-0143-472X; Degen, Martin/0000-0002-4356-3714	Schweizerische National-fonds (SNF); National Center for Competence in Research; Oncosuisse [01613-12-2004, SNF 3100A0-120235]; Krebsliga beider Basel [20-2008]	Schweizerische National-fonds (SNF)(Swiss National Science Foundation (SNSF)); National Center for Competence in Research; Oncosuisse; Krebsliga beider Basel	Grant support is provided by the Schweizerische National-fonds (SNF), National Center for Competence in Research (C. R.), Oncosuisse OCS-01613-12-2004 (A. M.), SNF 3100A0-120235 (R.C.-E.), and Krebsliga beider Basel 20-2008 (F. B.). We thank Gregory Bieler (Division of Experimental Oncology, University of Lausanne, Lausanne, Switzerland) for kindly providing us early passages of HUVECs, Natsuko Imaizumi and Eveline Faes for their technical expertise with angiogenesis assays, Catherine Schiltz and Sandrine Bichet for their help with immunohistochemistry, Daniela Kenzelmann (FMi, Basel, Switzerland) for the teneurin-4 constructs, Laurent Gelman for his help with microscopy, and Clare Isacke (Institute of Cancer Research, London, UK) for the culture medium of pericytes. We also thank Remi Terranova and Richard P. Tucker for critical reading of the manuscript.	Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bigner DD, 1998, J CLIN ONCOL, V16, P2202, DOI 10.1200/JCO.1998.16.6.2202; Brack SS, 2006, CLIN CANCER RES, V12, P3200, DOI 10.1158/1078-0432.CCR-05-2804; Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472.CAN-05-1204; Brellier F, 2009, SCAND J MED SCI SPOR, V19, P511, DOI 10.1111/j.1600-0838.2009.00916.x; Cairncross JG, 1998, J CLIN ONCOL, V16, P3210, DOI 10.1200/JCO.1998.16.9.3210; Calvo A, 2008, ONCOGENE, V27, P5373, DOI 10.1038/onc.2008.155; CANFIELD AE, 1995, J CELL SCI, V108, P797; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; De Santis R, 2003, BRIT J CANCER, V88, P996, DOI 10.1038/sj.bjc.6600818; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; Degen M, 2008, INT J CANCER, V122, P2454, DOI 10.1002/ijc.23417; Degen M, 2007, CANCER RES, V67, P9169, DOI 10.1158/0008-5472.CAN-07-0666; Fischer D, 1997, MOL BIOL CELL, V8, P2055, DOI 10.1091/mbc.8.10.2055; Giusti B, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2002; Herold-Mende C, 2002, INT J CANCER, V98, P362, DOI 10.1002/ijc.10233; Huang WT, 2001, CANCER RES, V61, P8586; Ishiwata T, 2005, ANTICANCER RES, V25, P489; Ivanov D, 2004, EXP CELL RES, V293, P207, DOI 10.1016/j.yexcr.2003.09.030; Kalas W, 2005, CANCER RES, V65, P8878, DOI 10.1158/0008-5472.CAN-05-1479; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kaspar M, 2006, INT J CANCER, V118, P1331, DOI 10.1002/IJC.21677; Kass L, 2007, INT J BIOCHEM CELL B, V39, P1987, DOI 10.1016/j.biocel.2007.06.025; Kimura H, 2007, BIOCHEM BIOPH RES CO, V356, P935, DOI 10.1016/j.bbrc.2007.03.071; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Korff T, 1999, J CELL SCI, V112, P3249; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Leins A, 2003, CANCER-AM CANCER SOC, V98, P2430, DOI 10.1002/cncr.11796; Lino M, 2009, CURR OPIN CELL BIOL, V21, P311, DOI 10.1016/j.ceb.2008.12.009; Lorusso G, 2008, HISTOCHEM CELL BIOL, V130, P1091, DOI 10.1007/s00418-008-0530-8; Marlind J, 2008, CLIN CANCER RES, V14, P6515, DOI 10.1158/1078-0432.CCR-07-5041; Orend G, 2003, ONCOGENE, V22, P3917, DOI 10.1038/sj.onc.1206618; Orend G, 2005, INT J BIOCHEM CELL B, V37, P1066, DOI 10.1016/j.biocel.2004.12.002; Orend G, 2006, CANCER LETT, V244, P143, DOI 10.1016/j.canlet.2006.02.017; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Reardon DA, 2007, EXPERT REV ANTICANC, V7, P675, DOI 10.1586/14737140.7.5.675; Ren RQ, 2007, BLOOD, V109, P2847, DOI 10.1182/blood-2006-08-039743; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; Rothhammer T, 2007, ONCOGENE, V26, P4158, DOI 10.1038/sj.onc.1210182; Saito Y, 2008, BIOL PHARM BULL, V31, P1003, DOI 10.1248/bpb.31.1003; Sauer S, 2009, BLOOD, V113, P2265, DOI 10.1182/blood-2008-06-160416; Schenk S, 1999, MOL BIOL CELL, V10, P2933, DOI 10.1091/mbc.10.9.2933; Scherberich A, 2004, J CELL SCI, V117, P571, DOI 10.1242/jcs.00867; Silacci M, 2006, PROTEIN ENG DES SEL, V19, P471, DOI 10.1093/protein/gzl033; Sivasankaran B, 2009, CANCER RES, V69, P458, DOI 10.1158/0008-5472.CAN-08-2610; Tanaka K, 2004, INT J CANCER, V108, P31, DOI 10.1002/ijc.11509; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tuxhorn JA, 2002, CANCER RES, V62, P6021; Zagzag D, 2002, CANCER RES, V62, P2660; Zamecnik J, 2005, ACTA NEUROPATHOL, V110, P435, DOI 10.1007/s00401-005-1078-5	50	42	46	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					778	787		10.1096/fj.09-140491	http://dx.doi.org/10.1096/fj.09-140491			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19884327	Green Published			2022-12-28	WOS:000274974600014
J	Thorgersen, EB; Hellerud, BC; Nielsen, EW; Barratt-Due, A; Fure, H; Lindstad, JK; Pharo, A; Fosse, E; Tonnessen, TI; Johansen, HT; Castellheim, A; Mollnes, TE				Thorgersen, Ebbe Billmann; Hellerud, Bernt Christian; Nielsen, Erik Waage; Barratt-Due, Andreas; Fure, Hilde; Lindstad, Julie Katrine; Pharo, Anne; Fosse, Erik; Tonnessen, Tor Inge; Johansen, Harald Thidemann; Castellheim, Albert; Mollnes, Tom Eirik			CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs	FASEB JOURNAL			English	Article						gram-negative bacteria; inflammation; innate immunity; lipopolysaccharide	TUMOR-NECROSIS-FACTOR; ANTI-CD14 ANTIBODY; OXIDATIVE BURST; C5A RECEPTOR; GELATINASE; COAGULATION; MODEL; INTERLEUKIN-10; COMPLEMENT; IC14	Sepsis is a severe infection-induced systemic inflammatory syndrome. Inhibition of downstream inflammatory mediators of sepsis, e.g., TNF-alpha, has failed in clinical trials. The aim of this study was to investigate the effects of inhibiting CD14, a key upstream innate immunity molecule, on the early inflammatory and hemostatic responses in a pig model of gram-negative sepsis. The study comprised two arms, whole live Escherichia coli bacteria and E. coli lipopolysaccharide (LPS) (n=25 and n=9 animals, respectively). The animals were allocated into treatment (anti-CD14) and control (IgG isotype or saline) groups. Inflammatory, hemostatic, physiological, and microbiological parameters were measured. The proinflammatory cytokines TNF-alpha, IL-1 beta, IL-6, and IL-8, but not the anti-inflammatory cytokine IL-10, were efficiently inhibited by anti-CD14. Furthermore, anti-CD14 preserved the leukocyte count and significantly reduced granulocyte enzyme matrix metalloproteinase-9 release and expression of the granulocyte membrane activation molecule wCD11R3 (pig CD11b). The hemostatic markers thrombin-antithrombin III complexes and plasminogen activator inhibitor-1 were significantly attenuated. Anti-CD14 did not affect LPS or E. coli DNA levels. This study documents that CD14 inhibition efficiently attenuates the proinflammatory cytokine response and granulocyte activation and reverses the procoagulant state but does not interfere with LPS levels or bacterial counts in E. coli-induced sepsis.-Thorgersen, E. B., Hellerud, B. C., Nielsen, E. W., Barratt-Due, A., Fure, H., Lindstad, J. K., Pharo, A., Fosse, E., Tonnessen, T. I., Johansen, H. T., Castell-heim, A., Mollnes, T. E. CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs. FASEB J. 24, 712-722 (2010). www.fasebj.org	[Thorgersen, Ebbe Billmann; Hellerud, Bernt Christian; Barratt-Due, Andreas; Lindstad, Julie Katrine; Pharo, Anne; Castellheim, Albert; Mollnes, Tom Eirik] Univ Hosp, Rikshosp, Inst Immunol, N-0027 Oslo, Norway; [Fosse, Erik; Tonnessen, Tor Inge] Univ Hosp, Rikshosp, Intervent Ctr, N-0027 Oslo, Norway; [Tonnessen, Tor Inge] Univ Hosp, Rikshosp, Dept Anesthesiol, N-0027 Oslo, Norway; [Nielsen, Erik Waage] Nordland Hosp, Dept Anesthesiol, Bodo, Norway; [Fure, Hilde] Nordland Hosp, Somat Res Lab, Bodo, Norway; [Nielsen, Erik Waage] Univ Tromso, Inst Clin Med, Tromso, Norway; [Johansen, Harald Thidemann] Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; UiT The Arctic University of Tromso; University of Oslo	Thorgersen, EB (corresponding author), Univ Hosp, Rikshosp, Inst Immunol, N-0027 Oslo, Norway.	ebbtho@rr-research.no	Mollnes, Tom/ABI-5183-2020; BARRATT-DUE, ANDREAS/AAG-9102-2019	Johansen, Harald Thidemann/0000-0001-6617-1732	U.S. National Institutes of Health [R01 EB003968-01A1]; Helse Sor-Ost [2008036]; Research Council of Norway; Norwegian Council on Cardiovascular Disease; Odd Fellows Foundation; Family Blix Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB003968] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Helse Sor-Ost; Research Council of Norway(Research Council of Norway); Norwegian Council on Cardiovascular Disease; Odd Fellows Foundation; Family Blix Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	The authors thank Kjersti Wendt, Hilde Nilsen, and Carmen Louwerens for excellent technical assistance and Dorte Christiansen for growing and preparing the bacteria. This work was supported by U.S. National Institutes of Health grant R01 EB003968-01A1, Helse Sor-Ost grant 2008036, the Research Council of Norway, the Norwegian Council on Cardiovascular Disease, the Odd Fellows Foundation, and the Family Blix Foundation.	Adib-Conquy M, 2003, AM J RESP CRIT CARE, V168, P158, DOI 10.1164/rccm.200209-1077OC; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8; Barboni B, 2000, BIOL REPROD, V63, P858, DOI 10.1095/biolreprod63.3.858; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Brekke OL, 2007, J LEUKOCYTE BIOL, V81, P1404, DOI 10.1189/jlb.0806538; Castellheim A, 2008, SCAND J IMMUNOL, V68, P75, DOI 10.1111/j.1365-3083.2008.02122.x; Cavaillon JM, 2005, J ENDOTOXIN RES, V11, P311, DOI 10.1179/096805105X58733; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Dubois B, 2002, EUR J IMMUNOL, V32, P2163, DOI 10.1002/1521-4141(200208)32:8<2163::AID-IMMU2163>3.0.CO;2-Q; Frevert CW, 2000, J IMMUNOL, V164, P5439, DOI 10.4049/jimmunol.164.10.5439; Goldfarb RD, 2005, SHOCK, V24, P75, DOI 10.1097/01.shk.0000191337.01036.b7; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Hu JL, 2005, BIOCHEM PHARMACOL, V70, P535, DOI 10.1016/j.bcp.2005.04.047; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; LEIBOVICI L, 1995, QJM-INT J MED, V88, P181; Leturcq DJ, 1996, J CLIN INVEST, V98, P1533, DOI 10.1172/JCI118945; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Levi M, 2006, CRIT CARE, V10, DOI 10.1186/cc4975; Makowski GS, 1996, ANAL BIOCHEM, V236, P353, DOI 10.1006/abio.1996.0179; Marshall JC, 2003, NAT REV DRUG DISCOV, V2, P391, DOI 10.1038/nrd1084; Marshall JC, 2008, J LEUKOCYTE BIOL, V83, P471, DOI 10.1189/jlb.0607380; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Michie HR, 1998, J ANTIMICROB CHEMOTH, V41, P47, DOI 10.1093/jac/41.suppl_1.47; Miyake K, 2006, J ENDOTOXIN RES, V12, P195, DOI 10.1179/096805106X118807; Mollnes TE, 2002, BLOOD, V100, P1869; Mollnes TE, 2008, ADV EXP MED BIOL, V632, P253, DOI 10.1007/978-0-387-78952-1_18; Oberholzer A, 2005, SHOCK, V23, P488, DOI 10.1097/01.shk.0000163802.46355.59; Olszyna DP, 2003, EUR CYTOKINE NETW, V14, P158; Opal SM, 2003, CRIT CARE MED, V31, P929, DOI 10.1097/01.CCM.0000054870.25767.EE; Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851; Panacek EA, 2004, CRIT CARE MED, V32, P2173, DOI 10.1097/01.CCM.0000145229.59014.6c; PATEL RT, 1994, BRIT J SURG, V81, P1306, DOI 10.1002/bjs.1800810914; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rahimi AAR, 2005, J IMMUNOL, V174, P7823, DOI 10.4049/jimmunol.174.12.7823; Renckens R, 2006, J IMMUNOL, V176, P3735, DOI 10.4049/jimmunol.176.6.3735; Roger T, 2009, P NATL ACAD SCI USA, V106, P2348, DOI 10.1073/pnas.0808146106; Saetre T, 2000, BLOOD COAGUL FIBRIN, V11, P433, DOI 10.1097/00001721-200007000-00006; Sandanger O, 2009, J IMMUNOL, V182, P588, DOI 10.4049/jimmunol.182.1.588; Schimke J, 1998, P NATL ACAD SCI USA, V95, P13875, DOI 10.1073/pnas.95.23.13875; Sriskandan S, 2008, J PATHOL, V214, P211, DOI 10.1002/path.2274; Stephens DS, 2007, LANCET, V369, P2196, DOI 10.1016/S0140-6736(07)61016-2; Tang AH, 2007, J LEUKOCYTE BIOL, V82, P282, DOI 10.1189/jlb.1206752; Thorgersen EB, 2009, INFECT IMMUN, V77, P725, DOI 10.1128/IAI.01305-08; Triantafilou M, 2004, BIOCHEM J, V381, P527, DOI 10.1042/BJ20040172; Ulevitch RJ, 2001, CRIT CARE MED, V29, pS8, DOI 10.1097/00003246-200107001-00004; van Furth AM, 1999, INFECT IMMUN, V67, P3714, DOI 10.1128/IAI.67.8.3714-3718.1999; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; Verbon A, 2003, J INFECT DIS, V187, P55, DOI 10.1086/346043; Verbon A, 2001, J IMMUNOL, V166, P3599, DOI 10.4049/jimmunol.166.5.3599; WAAGE A, 1987, LANCET, V1, P355; Wang E, 2000, J INFECT DIS, V182, P1255, DOI 10.1086/315811	55	51	56	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					712	722		10.1096/fj.09-140798	http://dx.doi.org/10.1096/fj.09-140798			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19841036	Green Published			2022-12-28	WOS:000274974600007
J	Blaauw, B; Canato, M; Agatea, L; Toniolo, L; Mammucari, C; Masiero, E; Abraham, R; Sandri, M; Schiaffino, S; Reggiani, C				Blaauw, Bert; Canato, Marta; Agatea, Lisa; Toniolo, Luana; Mammucari, Cristina; Masiero, Eva; Abraham, Reimar; Sandri, Marco; Schiaffino, Stefano; Reggiani, Carlo			Inducible activation of Akt increases skeletal muscle mass and force without satellite cell activation	FASEB JOURNAL			English	Article						BrdU; angiogenesis; skinned fibers; nuclear domain	MYONUCLEAR DOMAIN SIZE; ADDITION IS/IS; HYPERTROPHY; EXPRESSION; FIBERS; GROWTH; COUNTERPOINT; PREVENTS; PATHWAY; VELOCITY	A better understanding of the signaling pathways that control muscle growth is required to identify appropriate countermeasures to prevent or reverse the loss of muscle mass and force induced by aging, disuse, or neuromuscular diseases. However, two major issues in this field have not yet been fully addressed. The first concerns the pathways involved in leading to physiological changes in muscle size. Muscle hypertrophy based on perturbations of specific signaling pathways is either characterized by impaired force generation, e. g., myostatin knockout, or incompletely studied from the physiological point of view, e. g., IGF-1 overexpression. A second issue is whether satellite cell proliferation and incorporation into growing muscle fibers is required for a functional hypertrophy. To address these issues, we used an inducible transgenic model of muscle hypertrophy by short-term Akt activation in adult skeletal muscle. In this model, Akt activation for 3 wk was followed by marked hypertrophy (similar to 50% of muscle mass) and by increased force generation, as determined in vivo by ankle plantar flexor stimulation, ex vivo in intact isolated diaphragm strips, and in single-skinned muscle fibers. No changes in fiber-type distribution and resistance to fatigue were detectable. Bromodeoxyuridine incorporation experiments showed that Akt-dependent muscle hypertrophy was accompanied by proliferation of interstitial cells but not by satellite cell activation and new myonuclei incorporation, pointing to an increase in myonuclear domain size. We can conclude that during a fast hypertrophic growth myonuclear domain can increase without compromising muscle performance.-Blaauw, B., Canato, M., Agatea, L., Toniolo, L., Mammucari, C., Masiero, E., Abraham, R., Sandri, M., Schiaffino, S., Reggiani, C. Inducible activation of Akt increases skeletal muscle mass and force without satellite cell activation. FASEB J. 23, 3896-3905 (2009). www.fasebj.org	[Blaauw, Bert; Agatea, Lisa; Masiero, Eva; Abraham, Reimar; Sandri, Marco; Schiaffino, Stefano] Venetian Inst Mol Med, I-35126 Padua, Italy; [Canato, Marta; Toniolo, Luana; Reggiani, Carlo] Univ Padua, Dept Human Anat & Physiol, CNR, Inst Neurosci, Padua, Italy; [Agatea, Lisa; Mammucari, Cristina; Masiero, Eva; Sandri, Marco; Schiaffino, Stefano; Reggiani, Carlo] Univ Padua, Dept Biomed Sci, CNR, Inst Neurosci, Padua, Italy; [Sandri, Marco] Dulbecco Telethon Inst, Rome, Italy	Veneto Institute Molecular Medicine; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Fondazione Telethon; Dulbecco Telethon Institute (DTI)	Blaauw, B (corresponding author), Venetian Inst Mol Med, Via Orus 2, I-35126 Padua, Italy.	bertblaauw@yahoo.com	Toniolo, Luana/B-9647-2014; blaauw, bert/A-7614-2014; agatea, lisa/L-8267-2016	Toniolo, Luana/0000-0001-7160-5638; blaauw, bert/0000-0002-3893-1463; agatea, lisa/0000-0002-8380-9619; Schiaffino, Stefano/0000-0002-5607-6421; BLAAUW, BERT/0000-0002-4167-5106	Italian Ministry of University; Italian Space Agency; European Commission [LSHG-CT-2004-511978, LSHM-CT-2004-005272]; Fondazione Telethon Funding Source: Custom	Italian Ministry of University(Ministry of Education, Universities and Research (MIUR)); Italian Space Agency(Agenzia Spaziale Italiana (ASI)); European Commission(European CommissionEuropean Commission Joint Research Centre); Fondazione Telethon(Fondazione Telethon)	The authors thank Tom Sato (University of Texas, Houston, TX, USA) for the transgenic line expressing silent Akt and Steven Burden (University of New York, New York, NY, USA) for the transgenic line expressing Cre recombinase. The technical assistance of A. Picard, C. Argentini, T. Zaglia, and K. Dyar is gratefully acknowledged. This work was supported by grants from the Italian Ministry of University and the Italian Space Agency (OSMA project) to S. S. and C. R., and by grants from the European Commission to S. S. (Network of Excellence MYORES, contract LSHG-CT-2004-511978, and Integrated Project EXGENESIS, contract LSHM-CT-2004-005272). The authors declare no conflicts of interest.	Adams GR, 2002, AM J PHYSIOL-CELL PH, V283, pC1182, DOI 10.1152/ajpcell.00173.2002; Amthor H, 2007, P NATL ACAD SCI USA, V104, P1835, DOI 10.1073/pnas.0604893104; Amthor H, 2009, P NATL ACAD SCI USA, V106, P7479, DOI 10.1073/pnas.0811129106; Barton-Davis ER, 1999, ACTA PHYSIOL SCAND, V167, P301; Blaauw B, 2008, HUM MOL GENET, V17, P3686, DOI 10.1093/hmg/ddn264; Blough ER, 1996, ANAL BIOCHEM, V233, P31, DOI 10.1006/abio.1996.0003; Bothe GWM, 2000, GENESIS, V26, P165, DOI 10.1002/(SICI)1526-968X(200002)26:2<165::AID-GENE22>3.0.CO;2-F; Bottinelli R, 1996, J PHYSIOL-LONDON, V495, P573, DOI 10.1113/jphysiol.1996.sp021617; Bruusgaard JC, 2005, ACTA PHYSIOL SCAND, V185, P141, DOI 10.1111/j.1365-201X.2005.01462.x; D'Antona G, 2006, J PHYSIOL-LONDON, V570, P611, DOI 10.1113/jphysiol.2005.101642; Defranchi E, 2005, MICROSC RES TECHNIQ, V67, P27, DOI 10.1002/jemt.20177; Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542; GODT RE, 1977, BIOPHYS J, V19, P103, DOI 10.1016/S0006-3495(77)85573-2; Herbst KL, 2004, CURR OPIN CLIN NUTR, V7, P271, DOI 10.1097/00075197-200405000-00006; Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137; Hudon-David F, 2007, J MOL CELL CARDIOL, V42, P991, DOI 10.1016/j.yjmcc.2007.02.009; Izumiya Y, 2008, CELL METAB, V7, P159, DOI 10.1016/j.cmet.2007.11.003; Kadi F, 2004, J PHYSIOL-LONDON, V558, P1005, DOI 10.1113/jphysiol.2004.065904; Kim YK, 2003, J BIOL CHEM, V278, P47622, DOI 10.1074/jbc.M305909200; Kroll J, 2003, GENESIS, V35, P160, DOI 10.1002/gene.10180; Lai KMV, 2004, MOL CELL BIOL, V24, P9295, DOI 10.1128/MCB.24.21.9295-9304.2004; Liu JX, 2009, EXP PHYSIOL, V94, P117, DOI 10.1113/expphysiol.2008.043877; Lowe DA, 1999, CELL TISSUE RES, V296, P531, DOI 10.1007/s004410051314; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Mantilla CB, 2008, J APPL PHYSIOL, V104, P787, DOI 10.1152/japplphysiol.00347.2007; McCarthy JJ, 2007, J APPL PHYSIOL, V103, P1102; McCarthy JJ, 2007, J APPL PHYSIOL, V103, P1100, DOI 10.1152/japplphysiol.00101.2007a; METZGER JM, 1987, BIOPHYS J, V52, P127, DOI 10.1016/S0006-3495(87)83197-1; MOSS FP, 1971, ANAT REC, V170, P421, DOI 10.1002/ar.1091700405; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; NACHLAS MM, 1957, J HISTOCHEM CYTOCHEM, V5, P420, DOI 10.1177/5.4.420; Nader GA, 2005, INT J BIOCHEM CELL B, V37, P1985, DOI 10.1016/j.biocel.2005.02.026; O'Connor RS, 2007, J APPL PHYSIOL, V103, P1099, DOI 10.1152/japplphysiol.00101.2007; O'Connor RS, 2007, J APPL PHYSIOL, V103, P1107, DOI 10.1152/japplphysiol.00502.2007; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Paolini C, 2007, J PHYSIOL-LONDON, V583, P767, DOI 10.1113/jphysiol.2007.138024; PAVLATH GK, 1989, NATURE, V337, P570, DOI 10.1038/337570a0; Rehfeldt C, 2007, J APPL PHYSIOL, V103, P1104, DOI 10.1152/japplphysiol.00466.2007; ROSENBLATT JD, 1992, J APPL PHYSIOL, V73, P2538, DOI 10.1152/jappl.1992.73.6.2538; ROSENBLATT JD, 1994, MUSCLE NERVE, V17, P608, DOI 10.1002/mus.880170607; Rota M, 2005, CIRC RES, V97, P1332, DOI 10.1161/01.RES.0000196568.11624.ae; Roy RR, 1999, J APPL PHYSIOL, V87, P634, DOI 10.1152/jappl.1999.87.2.634; Sakamoto K, 2002, J BIOL CHEM, V277, P11910, DOI 10.1074/jbc.M112410200; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; SCHIAFFINO S, 1976, VIRCHOWS ARCH B, V21, P113; Sonnet C, 2006, J CELL SCI, V119, P2497, DOI 10.1242/jcs.02988; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Takahashi A, 2002, MOL CELL BIOL, V22, P4803, DOI 10.1128/MCB.22.13.4803-4814.2002; TSIKA RW, 1987, J APPL PHYSIOL, V63, P2111, DOI 10.1152/jappl.1987.63.5.2111	49	176	179	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3896	3905		10.1096/fj.09-131870	http://dx.doi.org/10.1096/fj.09-131870			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19661286				2022-12-28	WOS:000271272500025
J	McArthur, S; Yazid, S; Christian, H; Sirha, R; Flower, R; Buckingham, J; Solito, E				McArthur, Simon; Yazid, Samia; Christian, Helen; Sirha, Ravneet; Flower, Roderick; Buckingham, Julia; Solito, Egle			Annexin A1 regulates hormone exocytosis through a mechanism involving actin reorganization	FASEB JOURNAL			English	Article						FPR; ROCK; phosphorylation; siRNA	ANTERIOR-PITUITARY GLAND; FORMYL PEPTIDE RECEPTORS; PROTEIN-KINASE-C; HUMAN NEUTROPHIL; IN-VITRO; CHROMAFFIN CELLS; LIPOCORTIN-I; RHO GTPASES; INVOLVEMENT; RAT	The glucocorticoid-regulated protein annexin A1 is a potent inhibitor of hormone exocytosis in the neuroendocrine system, acting in a paracrine/juxtacrine manner. The signaling mechanism employed by annexin A1 in this process is uncertain, although we have recently presented evidence for a role of the formyl peptide receptor in vivo. We sought to characterize the mechanism of action of annexin A1 on exocytosis using the release of adrenocorticotrophin from the corticotroph-like cell line AtT20 as an in vitro model system. Through the comparison of adrenocorticotrophin release from cells expressing either wildtype annexin A1 or mutant forms, we show a critical involvement of phosphorylation on serine 27 and 45 in the translocation of the protein to the membrane and its inhibitory action on exocytosis. Moreover, we show, for the first time, that annexin A1-dependent inhibition of adrenocorticotrophin release involves the enhancement of actin polymerization to prevent exocytosis via formyl peptide receptor and Rho kinase signaling pathways. This finding has significant implications for the inhibitory actions of annexin A1 on exocytosis in other endocrine and immune contexts.-McArthur, S., Yazid, S., Christian, H., Sirha, R., Flower, R., Buckingham, J., Solito, E. Annexin A1 regulates hormone exocytosis through a mechanism involving actin reorganization. FASEB J. 23, 4000-4010 (2009). www.fasebj.org	[Solito, Egle] Univ London Imperial Coll Sci Technol & Med, Dept Cellular & Mol Neurosci, Fac Med, London W12 0NN, England; [Yazid, Samia; Flower, Roderick] Univ London St Bartholomews Hosp Med Coll, Coll Med, William Harvey Res Inst, London EC1M 6BQ, England; [Christian, Helen] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England	Imperial College London; University of London; Queen Mary University London; University of Oxford	Solito, E (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Cellular & Mol Neurosci, Fac Med, Hammersmith Campus,Burlington Danes Bldg,Rm 515,D, London W12 0NN, England.	e.solito@imperial.ac.uk	McArthur, Simon/V-6839-2019	McArthur, Simon/0000-0001-8521-1808; McArthur, Simon/0000-0002-9603-4381; Solito, Egle/0000-0001-5279-0049; Christian, Helen/0000-0002-4263-5499	Wellcome Trust	Wellcome Trust(Wellcome TrustEuropean Commission)	We are grateful to Prof. M. Perretti, for the help with qPCR experiments, and to our sponsor, Wellcome Trust. Many thanks to Dr. G. E. Gillies for helpful discussions during manuscript preparation.	AlvarezMartinez MT, 1997, BBA-PROTEIN STRUCT M, V1339, P331, DOI 10.1016/S0167-4838(97)00018-6; Bader MF, 2004, BBA-MOL CELL RES, V1742, P37, DOI 10.1016/j.bbamcr.2004.09.028; Bandeira-Melo C, 2005, J PHARMACOL EXP THER, V313, P1416, DOI 10.1124/jpet.104.080473; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buckingham JC, 2006, ANN NY ACAD SCI, V1088, P396, DOI 10.1196/annals.1366.002; Chapman LP, 2003, ENDOCRINOLOGY, V144, P1062, DOI 10.1210/en.2002-220650; Chodniewicz D, 2003, BLOOD, V102, P2251, DOI 10.1182/blood-2002-09-2936; Chodniewicz D, 2003, BLOOD, V101, P1181, DOI 10.1182/blood-2002-05-1435; Christian HC, 1999, J NEUROENDOCRINOL, V11, P707; Erlich R, 1998, MOL CELL ENDOCRINOL, V142, P87, DOI 10.1016/S0303-7207(98)00113-0; Gasman S, 1999, J CELL SCI, V112, P4763; Hayhoe RPG, 2006, BLOOD, V107, P2123, DOI 10.1182/blood-2005-08-3099; John C, 2002, ENDOCRINOLOGY, V143, P3060, DOI 10.1210/en.143.8.3060; John CD, 2007, FASEB J, V21, P1037, DOI 10.1096/fj.06-7299com; LLORET S, 1994, EUR J PHARMACOL, V264, P379, DOI 10.1016/0014-2999(94)00500-1; LLORET S, 1992, BIOCHEM PHARMACOL, V44, P1437, DOI 10.1016/0006-2952(92)90546-U; LOXLEY HD, 1993, J NEUROENDOCRINOL, V5, P51, DOI 10.1111/j.1365-2826.1993.tb00363.x; McArthur S, 2008, FUND CLIN PHARMACOL, V22, P23; Migeotte I, 2006, CYTOKINE GROWTH F R, V17, P501, DOI 10.1016/j.cytogfr.2006.09.009; MOSS SE, 1992, PORTLAND PRESS RES M, V2; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Perretti M, 2001, AM J PATHOL, V158, P1969, DOI 10.1016/S0002-9440(10)64667-6; Perretti M, 2000, CELL BIOL INT, V24, P163, DOI 10.1006/cbir.1999.0468; Ridley AJ, 2006, TRENDS CELL BIOL, V16, P522, DOI 10.1016/j.tcb.2006.08.006; Scannell M, 2007, J IMMUNOL, V178, P4595, DOI 10.4049/jimmunol.178.7.4595; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; Simoes RL, 2005, J IMMUNOL, V175, P1843, DOI 10.4049/jimmunol.175.3.1843; Solito E, 2006, FASEB J, V20, P1498, DOI 10.1096/fj.05-5319fje; Solito E, 2000, J IMMUNOL, V165, P1573, DOI 10.4049/jimmunol.165.3.1573; Solito E, 2003, ENDOCRINOLOGY, V144, P1164, DOI 10.1210/en.2002-220592; Solito E, 1998, CYTOKINE, V10, P514, DOI 10.1006/cyto.1997.0325; Solito E, 1998, CELL GROWTH DIFFER, V9, P327; Solito E, 1998, BRIT J PHARMACOL, V124, P1675, DOI 10.1038/sj.bjp.0701991; Solito E, 2008, TRENDS PHARMACOL SCI, V29, P135, DOI 10.1016/j.tips.2007.12.003; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Stenfeldt AL, 2007, INFLAMMATION, V30, P224, DOI 10.1007/s10753-007-9040-4; TASAKA K, 1994, AGENTS ACTIONS, V41, pC106, DOI 10.1007/BF02007788; TAYLOR AD, 1993, NEUROENDOCRINOLOGY, V58, P430, DOI 10.1159/000126572; Taylor AD, 1997, ENDOCRINOLOGY, V138, P2909, DOI 10.1210/en.138.7.2909; Tierney T, 2003, J NEUROENDOCRINOL, V15, P1134, DOI 10.1111/j.1365-2826.2003.01111.x; Trifaro JM, 2008, ACTA PHYSIOL, V192, P165, DOI 10.1111/j.1748-1716.2007.01808.x; WHITE MV, 1991, J IMMUNOL, V147, P667	43	28	30	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					4000	4010		10.1096/fj.09-131391	http://dx.doi.org/10.1096/fj.09-131391			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19625660				2022-12-28	WOS:000271272500035
J	Guillot, N; Caillet, E; Laville, M; Calzada, C; Lagarde, M; Vericel, E				Guillot, Nicolas; Caillet, Emilie; Laville, Martine; Calzada, Catherine; Lagarde, Michel; Vericel, Evelyne			Increasing intakes of the long-chain omega-3 docosahexaenoic acid: effects on platelet functions and redox status in healthy men	FASEB JOURNAL			English	Article						arachidonic acid; isoprostane; oxidative stress; vitamin E	POLYUNSATURATED FATTY-ACIDS; RICH FISH-OIL; LIPID-PEROXIDATION; EICOSAPENTAENOIC ACID; POSTMENOPAUSAL WOMEN; BLOOD-PLATELETS; HEART-DISEASE; SUPPLEMENTATION; PROSTAGLANDIN; CONSUMPTION	Docosahexaenoic acid (DHA) can prevent cardiovascular events. However, few studies have addressed the effects of DHA on both platelet reactivity and redox status in healthy subjects, and dose-related studies are scarce. The main objectives of the present study were to determine the effects of increasing doses of DHA on platelets and redox status in humans. Twelve healthy male volunteers (aged 53-65 yr) were assigned to consume an intake of successively 200, 400, 800, and 1600 mg/d DHA, as the only omega-3 fatty acid, for 2 wk each dose. Blood and urine samples were collected before and after each dose of DHA and at 8 wk after arrest of supplementation. DHA was incorporated in a dose-response fashion in platelet phospholipids. After supplementation with 400 and 800 mg/d DHA, platelet reactivity was significantly decreased. Platelet vitamin E concentration increased only after 200 mg/d DHA, while p38 MAP kinase phosphorylation decreased. Urinary isoprostane was also significantly lowered after 200 mg/d DHA but was increased after 1600 mg/d. Therefore, supplementation with only 200 mg/d DHA for 2 wk induced an antioxidant effect. It is concluded that low consumption of DHA could be an effective and nonpharmacological way to protect healthy men from platelet-related cardiovascular events.-Guillot, N., Caillet, E., Laville, M., Calzada, C., Lagarde, M., Vericel, E. Increasing intakes of the long-chain omega-3 docosahexaenoic acid: effects on platelet functions and redox status in healthy men. FASEB J. 23, 2909-2916 (2009). www.fasebj.org	[Vericel, Evelyne] INSA Lyon, INSERM U870, IMBL, F-69621 Villeurbanne, France; [Guillot, Nicolas; Caillet, Emilie; Laville, Martine; Calzada, Catherine; Lagarde, Michel; Vericel, Evelyne] Univ Lyon, Lyon, France; [Guillot, Nicolas; Caillet, Emilie; Laville, Martine; Calzada, Catherine; Lagarde, Michel; Vericel, Evelyne] INSA Lyon, RMND, F-69621 Villeurbanne, France; [Guillot, Nicolas; Caillet, Emilie; Laville, Martine; Calzada, Catherine; Lagarde, Michel; Vericel, Evelyne] INRA, U1235, Oullins, France; [Laville, Martine] Hosp Civils Lyon, CRNH RA, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; Institut National des Sciences Appliquees de Lyon - INSA Lyon; INRAE; CHU Lyon	Vericel, E (corresponding author), INSA Lyon, INSERM U870, IMBL, 20 Ave Albert Einstein, F-69621 Villeurbanne, France.	evelyne.vericel@insa-lyon.fr	Vericel, Evelyne/M-4187-2018	Guillot, Nicolas/0000-0003-1096-6960; Calzada, Catherine/0000-0001-8858-6752	Centre de Recherche en Nutrition Humaine (CRNH); INSERM; Groupe Lipides et Nutrition (Neuilly-sur-Seine, France); French Ministry of Education and Research	Centre de Recherche en Nutrition Humaine (CRNH); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Groupe Lipides et Nutrition (Neuilly-sur-Seine, France); French Ministry of Education and Research	We thank the participants for their contribution. We also thank the staff at the Centre de Recherche en Nutrition Humaine (CRNH) for help with data collection and some analyses. The authors gratefully thank Maud Tournoud for statistical advice and Martine Carreras for her technical assistance. This work was supported by INSERM and a grant from Groupe Lipides et Nutrition (Neuilly-sur-Seine, France). N.G. was a recipient of a grant from the French Ministry of Education and Research.	Allard JP, 1997, LIPIDS, V32, P535, DOI 10.1007/s11745-997-0068-2; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; BOUKHCHACHE D, 1982, BIOCHIM BIOPHYS ACTA, V713, P386, DOI 10.1016/0005-2760(82)90257-0; BOWYER DE, 1963, BIOCHIM BIOPHYS ACTA, V70, P423, DOI 10.1016/0926-6542(63)90061-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breslow JL, 2006, AM J CLIN NUTR, V83, p1477S, DOI 10.1093/ajcn/83.6.1477S; Brossard N, 1996, AM J CLIN NUTR, V64, P577, DOI 10.1093/ajcn/64.4.577; BRYANT RW, 1980, BIOCHEM BIOPH RES CO, V92, P268, DOI 10.1016/0006-291X(80)91548-X; Conquer JA, 1996, J NUTR, V126, P3032, DOI 10.1093/jn/126.12.3032; Conquer JA, 1997, LIPIDS, V32, P341, DOI 10.1007/s11745-997-0043-y; COREY EJ, 1983, P NATL ACAD SCI-BIOL, V80, P3581, DOI 10.1073/pnas.80.12.3581; Coulon L, 2003, FREE RADICAL BIO MED, V35, P616, DOI 10.1016/S0891-5849(03)00386-1; CROSET M, 1990, THROMB RES, V57, P1, DOI 10.1016/0049-3848(90)90190-N; Demaison L, 2002, CELL MOL LIFE SCI, V59, P463, DOI 10.1007/s00018-002-8439-1; DYERBERG J, 1979, LANCET, V2, P433, DOI 10.1016/S0140-6736(79)91490-9; Gresele P, 2008, J NUTR, V138, P1602, DOI 10.1093/jn/138.9.1602; Hamazaki T, 1996, J NUTR, V126, P2784; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; Higdon JV, 2001, J LIPID RES, V42, P407; Higdon JV, 2000, AM J CLIN NUTR, V72, P714; Hirafuji M, 2003, J PHARMACOL SCI, V92, P308; Hooper L, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003177.PUB2; International Society for the Study of Fatty Acids and Lipids, 2004, REC INT POL FATT AC; Kelley DS, 2007, AM J CLIN NUTR, V86, P324, DOI 10.1093/ajcn/86.2.324; Knapp HR, 1997, AM J CLIN NUTR, V65, P1687; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; LAGARDE M, 1980, THROMB RES, V17, P581, DOI 10.1016/0049-3848(80)90098-5; Larson MK, 2008, THROMB HAEMOSTASIS, V100, P634, DOI 10.1160/TH08-02-0084; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; MEYDANI M, 1991, J NUTR, V121, P484, DOI 10.1093/jn/121.4.484; Milte CM, 2008, BRIT J NUTR, V99, P1083, DOI 10.1017/S000711450785344X; Mori TA, 2003, FREE RADICAL BIO MED, V35, P772, DOI 10.1016/S0891-5849(03)00407-6; MORRIS MC, 1993, CIRCULATION, V88, P523, DOI 10.1161/01.CIR.88.2.523; Morrow JD, 2000, DRUG METAB REV, V32, P377, DOI 10.1081/DMR-100102340; Richard D, 2008, PHARMACOL RES, V57, P451, DOI 10.1016/j.phrs.2008.05.002; SACKS FM, 1995, J AM COLL CARDIOL, V25, P1492, DOI 10.1016/0735-1097(95)00095-L; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Veicel E, 1999, ATHEROSCLEROSIS, V147, P187, DOI 10.1016/S0021-9150(99)00171-9; Vericel E, 2004, DIABETES, V53, P1046, DOI 10.2337/diabetes.53.4.1046; Vericel E, 2003, J THROMB HAEMOST, V1, P566, DOI 10.1046/j.1538-7836.2003.00076.x; VONSCHACKY C, 1985, J CLIN INVEST, V76, P2446, DOI 10.1172/JCI112261; WAGNER BA, 1994, BIOCHEMISTRY-US, V33, P4449, DOI 10.1021/bi00181a003; Wright SA, 2008, ANN RHEUM DIS, V67, P841, DOI 10.1136/ard.2007.077156; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; Yavin E, 2006, PROSTAG LEUKOTR ESS, V75, P203, DOI 10.1016/j.plefa.2006.05.014	47	61	124	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					2909	2916		10.1096/fj.09-133421	http://dx.doi.org/10.1096/fj.09-133421			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19443612				2022-12-28	WOS:000270241000014
J	Berthelot, K; Immel, F; Gean, J; Lecomte, S; Oda, R; Kauffmann, B; Cullin, C				Berthelot, Karine; Immel, Francoise; Gean, Julie; Lecomte, Sophie; Oda, Reiko; Kauffmann, Brice; Cullin, Christophe			Driving amyloid toxicity in a yeast model by structural changes: a molecular approach	FASEB JOURNAL			English	Article						aggregation; FTIR; folding	HET-S PRION; FUNGUS PODOSPORA-ANSERINA; IN-VITRO; POLYGLUTAMINE OLIGOMERS; ESCHERICHIA-COLI; COMMON MECHANISM; FIBRIL FORMATION; ION CHANNELS; CONGO RED; PROTEIN	The amyloid aggregation pathway is a multistep process, and many in vitro studies have highlighted the role of particular intermediates in the cellular toxicity of various amyloid diseases. In a previous study, we generated a yeast toxic mutant (M8) of the harmless model amyloid protein Het-s(218-289). In this study, we compared the aggregation characteristics of the wild-type (WT) and the toxic mutant at the molecular level. Both proteins formed fibrillar amyloid aggregates but with different dye-binding properties and X-ray diffraction patterns. The toxic amyloid formed very unusual short (80 nm) unbranched fibers visible on transmission electron microscopy. Fourier transform infrared spectroscopy demonstrated that M8 beta-sheets were essentially organized into a mixed parallel and antiparallel structure, whereas the WT protein displayed a predominantly parallel organization. Cellular toxicity may therefore be related to assembly of the toxic amyloid in a new aggregation pathway.-Berthelot, K., Immel, F., Gean, J., Lecomte, S., Oda, R., Kauffmann, B., Cullin, C. Driving amyloid toxicity in a yeast model by structural changes: a molecular approach. FASEB J. 23, 2254-2263 (2009)	[Cullin, Christophe] Univ Bordeaux 2 Victor Segalen, Inst Biochim & Genet Cellulaires, CNRS, IBGC,UMR 5095, F-33077 Bordeaux, France; [Gean, Julie; Lecomte, Sophie; Oda, Reiko; Kauffmann, Brice] Univ Bordeaux 1, Pessac, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Cullin, C (corresponding author), Univ Bordeaux 2 Victor Segalen, Inst Biochim & Genet Cellulaires, CNRS, IBGC,UMR 5095, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	christophe.cullin@ibgc.u-bordeaux2.fr	Kauffmann, Brice/L-6029-2015; Immel, Françoise/N-7079-2019; Oda, Reiko/AAE-4185-2021; cullin, christophe/AAM-2179-2020; BERTHELOT, Karine V.J./A-5546-2011; Immel, Françoise/GNP-4167-2022; oda, reiko/B-2214-2013	Kauffmann, Brice/0000-0002-2932-3255; cullin, christophe/0000-0003-4110-4677; BERTHELOT, Karine V.J./0000-0003-0809-4921; Immel, Françoise/0000-0002-2028-902X; oda, reiko/0000-0003-3273-8635				Baglioni S, 2006, J NEUROSCI, V26, P8160, DOI 10.1523/JNEUROSCI.4809-05.2006; Balguerie A, 2003, EMBO J, V22, P2071, DOI 10.1093/emboj/cdg213; Boye-Harnasch M, 2006, J BIOTECHNOL, V125, P222, DOI 10.1016/j.jbiotec.2006.03.006; Brachmann A, 2005, EMBO J, V24, P3082, DOI 10.1038/sj.emboj.7600772; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; Claessen D, 2003, GENE DEV, V17, P1714, DOI 10.1101/gad.264303; Coustou V, 1997, P NATL ACAD SCI USA, V94, P9773, DOI 10.1073/pnas.94.18.9773; COUTHOUIS J, 2009, PLOS ONE IN PRESS; Dos Reis S, 2002, J BIOL CHEM, V277, P5703, DOI 10.1074/jbc.M110183200; Douglas PM, 2008, P NATL ACAD SCI USA, V105, P7206, DOI 10.1073/pnas.0802593105; Ehrnhoefer DE, 2008, NAT STRUCT MOL BIOL, V15, P558, DOI 10.1038/nsmb.1437; Elfrink K, 2008, P NATL ACAD SCI USA, V105, P10815, DOI 10.1073/pnas.0804721105; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Frid P, 2007, BRAIN RES REV, V53, P135, DOI 10.1016/j.brainresrev.2006.08.001; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; Hawe A, 2008, PHARM RES-DORDR, V25, P1487, DOI 10.1007/s11095-007-9516-9; Jang HB, 2008, TRENDS BIOCHEM SCI, V33, P91, DOI 10.1016/j.tibs.2007.10.007; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jeter C, 2005, MOL PLANT MICROBE IN, V18, P1235, DOI 10.1094/MPMI-18-1235; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; Kodali R, 2007, CURR OPIN STRUC BIOL, V17, P48, DOI 10.1016/j.sbi.2007.01.007; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Maddelein ML, 2002, P NATL ACAD SCI USA, V99, P7402, DOI 10.1073/pnas.072199199; Nagai Y, 2007, NAT STRUCT MOL BIOL, V14, P332, DOI 10.1038/nsmb1215; Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Patel BK, 2007, J MOL BIOL, V365, P773, DOI 10.1016/j.jmb.2006.10.069; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Quist A, 2005, P NATL ACAD SCI USA, V102, P10427, DOI 10.1073/pnas.0502066102; Ritter C, 2005, NATURE, V435, P844, DOI 10.1038/nature03793; Sabate R, 2007, J MOL BIOL, V370, P768, DOI 10.1016/j.jmb.2007.05.014; Sanbe A, 2004, P NATL ACAD SCI USA, V101, P10132, DOI 10.1073/pnas.0401900101; Sawaya MR, 2007, NATURE, V447, P453, DOI 10.1038/nature05695; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; Shorter J, 2008, NEUROSIGNALS, V16, P63, DOI 10.1159/000109760; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; Sreerama N., 2000, CIRCULAR DICHROISM P, P601; Takahashi T, 2008, HUM MOL GENET, V17, P345, DOI 10.1093/hmg/ddm311; Taneja V, 2007, MOL CELL, V27, P67, DOI 10.1016/j.molcel.2007.05.027; TURCQ B, 1991, MOL GEN GENET, V228, P265, DOI 10.1007/BF00282475; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wasmer C, 2008, SCIENCE, V319, P1523, DOI 10.1126/science.1151839	50	22	22	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2254	2263		10.1096/fj.08-125724	http://dx.doi.org/10.1096/fj.08-125724			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19228879				2022-12-28	WOS:000268836500025
J	Flitney, EW; Kuczmarski, ER; Adam, SA; Goldman, RD				Flitney, Eric W.; Kuczmarski, Edward R.; Adam, Stephen A.; Goldman, Robert D.			Insights into the mechanical properties of epithelial cells: the effects of shear stress on the assembly and remodeling of keratin intermediate filaments	FASEB JOURNAL			English	Article						phosphorylation; tonofibrils; cytoskeleton	LIVING ENDOTHELIAL-CELLS; DYNAMIC PROPERTIES; PROTEIN-KINASE; MULTIPLE SITES; CULTURED-CELLS; IN-VITRO; PHOSPHORYLATION; NETWORK; FLOW; CYTOKERATINS	The effects of shear stress on the keratin intermediate filament ( KIF) cytoskeleton of cultured human alveolar epithelial (A549) cells have been investigated. Under normal culture conditions, immunofluorescence revealed a delicate network of fine tonofibrils containing KIFs, together with many nonfilamentous, keratin-containing "particles," mostly containing either keratin 8 (K8) or 18 (K18), but not both. Triton X-100 extracted similar to 10% of the cellular keratin, and this was accompanied by a loss of the particles but not the KIFs. Shear stress dramatically reduced the soluble keratin component and transformed the fine bundles of KIFs into thicker," wavy" tonofibrils. Both effects were accompanied by the disappearance of most keratin particles and by increased phosphorylation of K8 and K18 on serine residues 73 and 33, respectively. The particles that remained after shearing were phosphorylated and were closely associated with KIFs. We suggest that keratin particles constitute a reservoir of protein that can be recruited into KIFs under flow, creating a more robust cytoskeleton able to withstand shear forces more effectively. -Flitney, E. W., Kuczmarski, E. R., Adam, S. A., Goldman, R. D. Insights into the mechanical properties of epithelial cells: the effects of shear stress on the assembly and remodeling of keratin intermediate filaments. FASEB J. 23, 2110-2119 (2009)	[Flitney, Eric W.; Kuczmarski, Edward R.; Adam, Stephen A.; Goldman, Robert D.] Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Goldman, RD (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.	r-goldman@northwestern.edu		Adam, Stephen/0000-0003-3444-7655	NIH [GM36806]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036806, R01GM036806] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work has been supported by a grant from the NIH (GM36806).	ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; BARBEE KA, 1995, AM J PHYSIOL-HEART C, V268, pH1765, DOI 10.1152/ajpheart.1995.268.4.H1765; BARBEE KA, 1994, CIRC RES, V74, P163, DOI 10.1161/01.RES.74.1.163; Chang L, 2006, J CELL BIOL, V172, P747, DOI 10.1083/jcb.200511033; CHOU CF, 1993, J CELL SCI, V105, P433; CHOU CF, 1994, J CELL SCI, V107, P1833; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; Chou YH, 2007, EXP CELL RES, V313, P2236, DOI 10.1016/j.yexcr.2007.04.008; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; Davies PF, 1995, J BIOMECH, V28, P1553, DOI 10.1016/0021-9290(95)00102-6; EICHNER R, 1985, ANN NY ACAD SCI, V455, P381, DOI 10.1111/j.1749-6632.1985.tb50424.x; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; Feng L, 1999, J CELL SCI, V112, P2081; Flitney EW, 2004, METHOD CELL BIOL, V78, P297; FRANKE WW, 1987, EXP CELL RES, V173, P17, DOI 10.1016/0014-4827(87)90328-4; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GALL L, 1987, BIOL CELL, V61, P33, DOI 10.1111/j.1768-322X.1987.tb00566.x; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Helfand BT, 2002, J CELL BIOL, V157, P795, DOI 10.1083/jcb.200202027; Helfand BT, 2003, J CELL SCI, V116, P2345, DOI 10.1242/jcs.00526; Helmke BP, 2001, BIOPHYS J, V80, P184, DOI 10.1016/S0006-3495(01)76006-7; Helmke BP, 2000, CIRC RES, V86, P745, DOI 10.1161/01.RES.86.7.745; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Herrmann H, 2002, J STRUCT BIOL, V137, P82, DOI 10.1006/jsbi.2002.4466; Ho CL, 1998, J CELL SCI, V111, P1767; HORWITZ B, 1981, EXP CELL RES, V134, P281, DOI 10.1016/0014-4827(81)90427-4; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LANE EB, 1982, EMBO J, V1, P1365, DOI 10.1002/j.1460-2075.1982.tb01324.x; Liao J, 1997, J BIOL CHEM, V272, P17565, DOI 10.1074/jbc.272.28.17565; Liovic M, 2003, J CELL SCI, V116, P1417, DOI 10.1242/jcs.00363; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; MILLER RK, 1991, J CELL BIOL, V113, P843, DOI 10.1083/jcb.113.4.843; MILLER RK, 1993, J CELL BIOL, V122, P123, DOI 10.1083/jcb.122.1.123; Omary MB, 2006, TRENDS BIOCHEM SCI, V31, P383, DOI 10.1016/j.tibs.2006.05.008; Oshima RG, 2002, CELL DEATH DIFFER, V9, P486, DOI 10.1038/sj.cdd.4400988; Owens DW, 2003, BIOESSAYS, V25, P748, DOI 10.1002/bies.10316; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; Ridge KM, 2005, J BIOL CHEM, V280, P30400, DOI 10.1074/jbc.M504239200; ROSEVEAR ER, 1990, CELL MOTIL CYTOSKEL, V17, P150, DOI 10.1002/cm.970170303; Russell D, 2004, J CELL SCI, V117, P5233, DOI 10.1242/jcs.01407; Schweizer J, 2006, J CELL BIOL, V174, P169, DOI 10.1083/jcb.200603161; Sivaramakrishnan S, 2008, P NATL ACAD SCI USA, V105, P889, DOI 10.1073/pnas.0710728105; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; Strnad P, 2002, J CELL SCI, V115, P4133, DOI 10.1242/jcs.00096; Stumptner C, 2000, AM J PATHOL, V156, P77, DOI 10.1016/S0002-9440(10)64708-6; Tao GZ, 2006, J CELL SCI, V119, P1425, DOI 10.1242/jcs.02861; Toivola DM, 1997, J CELL SCI, V110, P23; Windoffer R, 2006, J CELL BIOL, V173, P341, DOI 10.1083/jcb.200511124; Windoffer R, 2004, MOL BIOL CELL, V15, P2436, DOI 10.1091/mbc.E03-09-0707; Windoffer R, 1999, J CELL SCI, V112, P4521; Woll S, 2007, J CELL BIOL, V177, P795, DOI 10.1083/jcb.200703174; Woll S, 2005, EUR J CELL BIOL, V84, P311, DOI 10.1016/j.ejcb.2004.12.004; Yoon KH, 2001, J CELL BIOL, V153, P503, DOI 10.1083/jcb.153.3.503	54	66	69	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2110	2119		10.1096/fj.08-124453	http://dx.doi.org/10.1096/fj.08-124453			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19246484	Green Published			2022-12-28	WOS:000268836500011
J	Bromer, JG; Zhou, YP; Taylor, MB; Doherty, L; Taylor, HS				Bromer, Jason G.; Zhou, Yuping; Taylor, Melissa B.; Doherty, Leo; Taylor, Hugh S.			Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response	FASEB JOURNAL			English	Article						BPA; DNA methylation; HOXA10/Hoxa10; epigenetics; developmental programming	DNA METHYLATION; GENE-EXPRESSION; HOX GENES; DIETHYLSTILBESTROL DES; PROMOTER METHYLATION; ABERRANT EXPRESSION; HOMEOBOX GENE; CANCER; ENDOMETRIOSIS; IMPLANTATION	Bisphenol-A (BPA) is a nonsteroidal estrogen that is ubiquitous in the environment. The homeobox gene Hoxa10 controls uterine organogenesis, and its expression is affected by in utero BPA exposure. We hypothesized that an epigenetic mechanism underlies BPA-mediated alterations in Hoxa10 expression. We analyzed the expression pattern and methylation profile of Hoxa10 after in utero BPA exposure. Pregnant CD-1 mice were treated with BPA (5 mg/kg IP) or vehicle control on d 9-16 of pregnancy. Hoxa10 mRNA and protein expression were increased by 25% in the reproductive tract of mice exposed in utero. Bisulfite sequencing revealed that cytosine-guanine dinucleotide methylation was decreased from 67 to 14% in the promoter and from 71 to 3% in the intron of Hoxa10 after in utero BPA exposure. Decreased DNA methylation led to an increase in binding of ER-alpha to the Hoxa10 ERE both in vitro as and in vivo as determined by EMSA and chromatin immunoprecipitation, respectively. Diminished methylation of the ERE-containing promoter sequence resulted in an increase in ERE-driven gene expression in reporter assays. We identify altered methylation as a novel mechanism of BPA-induced altered developmental programming. Permanent epigenetic alteration of ERE sensitivity to estrogen may be a general mechanism through which endocrine disruptors exert their action.-Bromer, J. G., Zhou, Y., Taylor, M. B., Doherty, L., Taylor, H. S.. Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response. FASEB J. 24, 2273-2280 (2010). www.fasebj.org	[Bromer, Jason G.; Zhou, Yuping; Taylor, Melissa B.; Doherty, Leo; Taylor, Hugh S.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA	Yale University	Taylor, HS (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, 333 Cedar St,POB 208068, New Haven, CT 06520 USA.	hugh.taylor@yale.edu			U.S. National Institutes of Health [ES10610, HD052668]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD052668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010610] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Hongling Du for technical advice and assistance. This research was supported by U.S. National Institutes of Health grants ES10610 and HD052668.	Akbas GE, 2004, J MOL BIOL, V340, P1013, DOI 10.1016/j.jmb.2004.05.052; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Block K, 2000, FASEB J, V14, P1101, DOI 10.1096/fasebj.14.9.1101; Bromer JG, 2009, ENDOCRINOLOGY, V150, P3376, DOI 10.1210/en.2009-0071; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391, DOI 10.1289/ehp.7534; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; Chu MC, 2004, CANCER BIOL THER, V3, P568, DOI 10.4161/cbt.3.6.848; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Daftary GS, 2000, SEMIN REPROD MED, V18, P311, DOI 10.1055/s-2000-12568; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Du HL, 2004, ANN NY ACAD SCI, V1034, P152, DOI 10.1196/annals.1335.018; Enokida H, 2005, CLIN CANCER RES, V11, P6582, DOI 10.1158/1078-0432.CCR-05-0658; Greathouse KL, 2008, REPROD SCI, V15, P765, DOI 10.1177/1933719108322440; Howdeshell KL, 1999, NATURE, V401, P763, DOI 10.1038/44517; Issa JP, 2002, J NUTR, V132, p2388S, DOI 10.1093/jn/132.8.2388S; Kwon HE, 2004, ANN NY ACAD SCI, V1034, P1, DOI 10.1196/annals.1335.001; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lee B, 2009, BIOL REPROD, V80, P79, DOI 10.1095/biolreprod.108.070391; Lee TS, 2006, ANN NY ACAD SCI, V1091, P218, DOI 10.1196/annals.1378.068; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033; Markey CM, 2001, BIOL REPROD, V65, P1215, DOI 10.1093/biolreprod/65.4.1215; Martin R, 2007, J CLIN ENDOCR METAB, V92, P1920, DOI 10.1210/jc.2006-1694; Morrison AG, 2003, DOMEST ANIM ENDOCRIN, V25, P329, DOI 10.1016/j.domaniend.2003.06.004; Mountfort KA, 1997, FOOD ADDIT CONTAM, V14, P737, DOI 10.1080/02652039709374584; Newell-Price J, 2000, TRENDS ENDOCRIN MET, V11, P142, DOI 10.1016/S1043-2760(00)00248-4; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Sakuma M, 2007, CANCER SCI, V98, P380, DOI 10.1111/j.1349-7006.2007.00394.x; Sheehan DM, 2000, P SOC EXP BIOL MED, V224, P57, DOI 10.1046/j.1525-1373.2000.22401.x; Smith CC, 2007, FASEB J, V21, P239, DOI 10.1096/fj.06-6635com; Takahashi O, 2000, ENVIRON HEALTH PERSP, V108, P931, DOI 10.2307/3435050; Taylor HS, 1998, J CLIN INVEST, V101, P1379, DOI 10.1172/JCI1057; Whitcomb BP, 2003, CLIN CANCER RES, V9, P2277; Wu Y, 2005, AM J OBSTET GYNECOL, V193, P371, DOI 10.1016/j.ajog.2005.01.034; Wu Y, 2007, FERTIL STERIL, V87, P24, DOI 10.1016/j.fertnstert.2006.05.077; Yoshida HY, 2006, CANCER RES, V66, P889, DOI 10.1158/0008-5472.CAN-05-2828	39	196	213	0	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2273	2280		10.1096/fj.09-140533	http://dx.doi.org/10.1096/fj.09-140533			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20181937	Green Published			2022-12-28	WOS:000279343600014
J	Gitik, M; Reichert, F; Rotshenker, S				Gitik, Miri; Reichert, Fanny; Rotshenker, Shlomo			Cytoskeleton plays a dual role of activation and inhibition in myelin and zymosan phagocytosis by microglia	FASEB JOURNAL			English	Article						Wallerian degeneration; axonal injury; complement receptor-3; actin; myosin	PERIPHERAL-NERVE INJURY; FC-GAMMA-R; SCAVENGER-RECEPTOR; WALLERIAN DEGENERATION; MEDIATED PHAGOCYTOSIS; APOPTOTIC CELLS; DISTINCT ROLES; STRESS FIBERS; SPINAL-CORD; RHO GTPASES	A major innate immune function of microglia in the central nervous system is receptor-mediated phagocytosis of tissue debris and pathogens. We studied how phagocytosis of degenerated myelin (i.e., tissue debris) and zymosan (i.e., yeast pathogen) is regulated by the cytoskeleton through myosin light chain kinase (MLCK) and the small GTPase Rho and its effector Rho-kinase (ROCK) in primary mouse microglia. Our observations suggest a dual role of activation and inhibition of phagocytosis by MLCK and Rho/ROCK signaling. MLCK activated, whereas Rho/ROCK down-regulated complement receptor-3 (CR3) mediated, phagocytosis of C3bi-opsonized and nonopsonized myelin. These opposing roles of MLCK and Rho/ROCK depended on the preferential spatial localization of their distinctive functions. MLCK further activated, and Rho/ROCK down-regulated, phagocytosis of nonopsonized zymosan by nonopsonic receptors (e. g., Dectin-1). In contrast, MLCK down-regulated, but Rho/ROCK activated, CR3-mediated phagocytosis of C3bi-opsonized zymosan. Thus MLCK and Rho/ROCK can each activate or inhibit phagocytosis but always act in opposition. Whether activation or inhibition occurs depends on the nature of the phagocytosed particle (C3bi-opsonized or nonopsonized myelin or zymosan) and the receptors mediating each phagocytosis.-Gitik, M., Reichert, F., Rotshenker, S. Cytoskeleton plays a dual role of activation and inhibition in myelin and zymosan phagocytosis by microglia. FASEB J. 24, 2211-2221 (2010). www.fasebj.org	[Rotshenker, Shlomo] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Med Neurobiol, Inst Med Res Israel Canada, IL-91120 Jerusalem, Israel; Eric Roland Ctr Neurodegenerat Dis, Jerusalem, Israel	Hebrew University of Jerusalem	Rotshenker, S (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Med Neurobiol, Inst Med Res Israel Canada, POB 12272, IL-91120 Jerusalem, Israel.	shlomor@ekmd.huji.ac.il			Israel Science Foundation [11/06]	Israel Science Foundation(Israel Science Foundation)	This study was supported by the Israel Science Foundation (grant 11/06 to S. R.). The authors thank Dr. Carlo Laudana (University of Verona, Verona, Italy) for providing cell-permeable fusion protein P1(75-92).	Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; Be'eri M, 1998, EUR J NEUROSCI, V10, P2707; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Clark K, 2007, TRENDS CELL BIOL, V17, P178, DOI 10.1016/j.tcb.2007.02.002; Cohen G, 2006, GLIA, V53, P538, DOI 10.1002/glia.20304; da Costa CC, 1997, EUR J NEUROSCI, V9, P2650, DOI 10.1111/j.1460-9568.1997.tb01694.x; Dewitt S, 2006, J CELL SCI, V119, P443, DOI 10.1242/jcs.02756; Giagulli C, 2004, IMMUNITY, V20, P25, DOI 10.1016/S1074-7613(03)00350-9; GIAIMIS J, 1993, J LEUKOCYTE BIOL, V54, P564, DOI 10.1002/jlb.54.6.564; GRIFFIN JW, 1992, J NEUROIMMUNOL, V40, P153, DOI 10.1016/0165-5728(92)90129-9; Hall AB, 2006, IMMUNITY, V24, P305, DOI 10.1016/j.immuni.2006.02.005; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hannila SS, 2007, INT REV NEUROBIOL, V77, P57, DOI 10.1016/S0074-7742(06)77003-9; Humphries JD, 2006, J CELL SCI, V119, P3901, DOI 10.1242/jcs.03098; KAPLAN G, 1977, SCAND J IMMUNOL, V6, P797, DOI 10.1111/j.1365-3083.1977.tb02153.x; Kuhlmann T, 2002, J NEUROSCI RES, V67, P185, DOI 10.1002/jnr.10104; LE CV, 2002, J IMMUNOL, V169, P2003; Lukas TJ, 1999, J MED CHEM, V42, P910, DOI 10.1021/jm980573a; McKerracher L, 2006, J NEUROTRAUM, V23, P309, DOI 10.1089/neu.2006.23.309; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Nakaya M, 2006, J BIOL CHEM, V281, P8836, DOI 10.1074/jbc.M510972200; Olazabal IM, 2002, CURR BIOL, V12, P1413, DOI 10.1016/S0960-9822(02)01069-2; Pellegrin S, 2007, J CELL SCI, V120, P3491, DOI 10.1242/jcs.018473; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; REICHERT F, 1994, J NEUROSCI, V14, P3231; Reichert F, 2003, NEUROBIOL DIS, V12, P65, DOI 10.1016/S0969-9961(02)00008-6; Reichert F, 1996, J NEUROIMMUNOL, V70, P153, DOI 10.1016/S0165-5728(96)00112-9; Reichert F, 2001, NEUROBIOL DIS, V8, P504, DOI 10.1006/nbdi.2001.0383; Reichert F, 1999, EXP NEUROL, V160, P508, DOI 10.1006/exnr.1999.7229; RIOHORTEGA P, 1932, CYTOLOGY CELLULAR PA, P481; Rotshenker S, 2003, J MOL NEUROSCI, V21, P65, DOI 10.1385/JMN:21:1:65; Rotshenker S., 2007, ENCY PAIN, P2659; Rotshenker S, 2009, J MOL NEUROSCI, V39, P99, DOI 10.1007/s12031-009-9186-7; SCHENKEIN HA, 1981, J IMMUNOL, V126, P7; Slobodov U, 2001, EXP NEUROL, V167, P401, DOI 10.1006/exnr.2000.7559; SPEERT DP, 1985, J LEUKOCYTE BIOL, V38, P655, DOI 10.1002/jlb.38.5.655; Stoll G, 2002, J PERIPHER NERV SYST, V7, P13, DOI 10.1046/j.1529-8027.2002.02002.x; Swanson JA, 2008, NAT REV MOL CELL BIO, V9, P639, DOI 10.1038/nrm2447; Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-215; Tosello-Trampont AC, 2003, J BIOL CHEM, V278, P49911, DOI 10.1074/jbc.M306079200; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; vanderLaan LJW, 1996, J NEUROIMMUNOL, V70, P145, DOI 10.1016/S0165-5728(96)00110-5; VANGURI P, 1982, P NATL ACAD SCI-BIOL, V79, P3290, DOI 10.1073/pnas.79.10.3290; Xia Y, 1999, J IMMUNOL, V162, P2281	47	29	30	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2211	2221		10.1096/fj.09-146118	http://dx.doi.org/10.1096/fj.09-146118			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20179145				2022-12-28	WOS:000279343600008
J	Pochynyuk, O; Rieg, T; Bugaj, V; Schroth, J; Fridman, A; Boss, GR; Insel, PA; Stockand, JD; Vallon, V				Pochynyuk, Oleh; Rieg, Timo; Bugaj, Vladislav; Schroth, Jana; Fridman, Alla; Boss, Gerry R.; Insel, Paul A.; Stockand, James D.; Vallon, Volker			Dietary Na+ inhibits the open probability of the epithelial sodium channel in the kidney by enhancing apical P2Y(2)-receptor tone	FASEB JOURNAL			English	Article						ATP; aldosterone; distal nephron; blood pressure; nucleotide receptors	CORTICAL COLLECTING DUCT; RECEPTOR-MEDIATED INHIBITION; P2 RECEPTORS; ATP; TRANSPORT; RELEASE; CELLS; ABSORPTION; ACTIVATION; RETENTION	Apical release of ATP and UTP can activate P2Y(2) receptors in the aldosterone-sensitive distal nephron (ASDN) and inhibit the open probability (Po) of the epithelial sodium channel (ENaC). Little is known, however, about the regulation and physiological relevance of this system. Patch-clamp studies in freshly isolated ASDN provide evidence that increased dietary Na+ intake in wild-type mice lowers ENaC P-o, consistent with a contribution to Na+ homeostasis, and is associated with increased urinary concentrations of UTP and the ATP hydrolytic product, ADP. Genetic deletion of P2Y(2) receptors in mice (P2Y(2)(-/-); littermates to wild-type mice) or inhibition of apical P2Y-receptor activation in wild-type mice prevents dietary Na+-induced lowering of ENaC P-o. Although they lack suppression of ENaC P-o by dietary NaCl, P2Y(2)(-/-) mice do not exhibit NaCl-sensitive blood pressure, perhaps as a consequence of compensatory down-regulation of aldosterone levels. Consistent with this hypothesis, clamping mineralocorticoid activity at high levels unmasks greater ENaC activity and NaCl sensitivity of blood pressure in P2Y(2)(-/-) mice. The studies indicate a key role of the apical ATP/UTP-P2Y(2)-receptor system in the inhibition of ENaC Po in the ASDN in response to an increase in Na+ intake, thereby contributing to NaCl homeostasis and blood pressure regulation.Pochynyuk, O., Rieg, T., Bugaj, V., Schroth, J., Fridman, A., Boss, G. R., Insel, P. A., Stockand, J. D., Vallon, V. Dietary Na+ inhibits the open probability of the epithelial sodium channel in the kidney by enhancing apical P2Y(2)-receptor tone. FASEB J. 24, 2056-2065 (2010). www.fasebj.org	[Pochynyuk, Oleh; Bugaj, Vladislav; Stockand, James D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA; [Rieg, Timo; Fridman, Alla; Boss, Gerry R.; Insel, Paul A.; Vallon, Volker] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Insel, Paul A.; Vallon, Volker] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Rieg, Timo; Schroth, Jana; Vallon, Volker] Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Vallon, V (corresponding author), Univ Calif San Diego, Dept Med, 3350 La Jolla Village Dr 9151, San Diego, CA 92161 USA.	stockand@uthscsa.edu; vvallon@ucsd.edu	Rieg, Timo/W-7478-2019	Rieg, Timo/0000-0001-6082-662X; Stockand, James/0000-0002-3817-4319; Vallon, Volker/0000-0002-9211-2063; Boss, Gerry/0000-0002-9758-8714	U.S. National Institutes of Health [R01DK59594, R01GM66232, R01DK56248, R01DK28602, P30DK079337]; American Heart Association [064005N, 0825062F, 09SDG2230391]; Department of Veterans Affairs; National Kidney Foundation of Southern California; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594, R01DK056248, R01DK028602, P30DK079337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066232] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Department of Veterans Affairs(US Department of Veterans Affairs); National Kidney Foundation of Southern California; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Research was supported by the U.S. National Institutes of Health (R01DK59594 to J.D.S.; R01GM66232 to P.A.I.; and R01DK56248, R01DK28602 and P30DK079337 to V.V.), the American Heart Association (064005N to J.D.S. and 0825062F and 09SDG2230391 to O.P.), the Department of Veterans Affairs (to V.V.), and the National Kidney Foundation of Southern California (to T.R.). The authors thank B. Koller and W. Zinzow (University of North Carolina, Chapel Hill, NC, USA) for the P2Y<INF>2</INF><SUP>-/-</SUP> mouse.	BOSS GR, 1982, J BIOL CHEM, V257, P4242; Buscher R, 2006, PHARMACOGENET GENOM, V16, P199; Bugaj V, 2008, AM J PHYSIOL-RENAL, V295, pF1063, DOI 10.1152/ajprenal.90321.2008; Butterworth MB, 2009, AM J PHYSIOL-RENAL, V296, pF10, DOI 10.1152/ajprenal.90248.2008; Cuffe JE, 2000, J PHYSIOL-LONDON, V524, P77, DOI 10.1111/j.1469-7793.2000.00077.x; DUCHATELLE P, 1992, MOL CELL BIOCHEM, V114, P27; Geyti CS, 2008, PFLUG ARCH EUR J PHY, V455, P1105, DOI 10.1007/s00424-007-0366-4; Guyton AC, 1992, HYPERTENSION S1, V19, P12; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Homolya L, 1999, J BIOL CHEM, V274, P26454, DOI 10.1074/jbc.274.37.26454; Hovater MB, 2008, PURINERG SIGNAL, V4, P155, DOI 10.1007/s11302-007-9072-0; Hummler E, 2005, J AM SOC NEPHROL, V16, P3160, DOI 10.1681/ASN.2005040450; Jensen MEJ, 2007, J AM SOC NEPHROL, V18, P2062, DOI 10.1681/ASN.2006070700; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; Kunzelmann K, 2005, FASEB J, V19, P969, DOI 10.1096/fj.04-2469fje; Lehrmann H, 2002, J AM SOC NEPHROL, V13, P10, DOI 10.1681/ASN.V13110; Leipziger J, 2003, AM J PHYSIOL-RENAL, V284, pF419, DOI 10.1152/ajprenal.00075.2002; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; LING BN, 1990, MOL CELL BIOCHEM, V99, P141, DOI 10.1007/BF00230344; Lourdel S, 2005, J AM SOC NEPHROL, V16, P3642, DOI 10.1681/ASN.2005040363; Lu M, 2000, J GEN PHYSIOL, V116, P299, DOI 10.1085/jgp.116.2.299; Ma HP, 2005, J AM SOC NEPHROL, V16, P3182, DOI 10.1681/ASN.2005040434; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; PACHA J, 1993, J GEN PHYSIOL, V102, P25, DOI 10.1085/jgp.102.1.25; Pochynyuk O, 2007, J PHYSIOL-LONDON, V580, P365, DOI 10.1113/jphysiol.2006.127449; Pochynyuk O, 2008, J BIOL CHEM, V283, P36599, DOI 10.1074/jbc.M807129200; Rieg T, 2007, FASEB J, V21, P3717, DOI 10.1096/fj.07-8807com; Rieg T, 2007, EUR J PHARMACOL, V555, P174, DOI 10.1016/j.ejphar.2006.10.039; Rieg T, 2009, AM J PHYSIOL-REG I, V296, pR419, DOI 10.1152/ajpregu.90784.2008; Sackmann B., 1995, SINGLE CHANNEL RECOR, VSecond; Schwiebert EM, 2001, AM J PHYSIOL-RENAL, V280, pF945, DOI 10.1152/ajprenal.2001.280.6.F945; Shirley DG, 2005, AM J PHYSIOL-RENAL, V288, pF1243, DOI 10.1152/ajprenal.00152.2004; Staruschenko A, 2007, J AM SOC NEPHROL, V18, P1652, DOI 10.1681/ASN.2007010020; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; Thomas J, 2001, J MEMBRANE BIOL, V183, P115, DOI 10.1007/s00232-001-0059-4; Unwin RJ, 2003, NEWS PHYSIOL SCI, V18, P237, DOI 10.1152/nips.01436.2003; Vallon V, 2005, AM J PHYSIOL-REG I, V289, pR395, DOI 10.1152/ajpregu.00731.2004; Vallon V, 2008, AM J PHYSIOL-RENAL, V294, pF10, DOI 10.1152/ajprenal.00432.2007; Vallon V, 2009, J AM SOC NEPHROL, V20, P721, DOI 10.1681/ASN.2008040415; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Wildman SSP, 2008, J AM SOC NEPHROL, V19, P731, DOI 10.1681/ASN.2007040443	41	75	76	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					2056	2065		10.1096/fj.09-151506	http://dx.doi.org/10.1096/fj.09-151506			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20097874	Green Published			2022-12-28	WOS:000278200000039
J	Li, YY; Liu, L; Tollefsbol, TO				Li, Yuanyuan; Liu, Liang; Tollefsbol, Trygve O.			Glucose restriction can extend normal cell lifespan and impair precancerous cell growth through epigenetic control of hTERT and p16 expression	FASEB JOURNAL			English	Article						cancer; DNA methylation; histone modification; E2F-1; longevity	TELOMERASE ACTIVITY; CANCER-CELLS; TUMOR-CELLS; CALORIC RESTRICTION; GENETIC ELEMENTS; MECHANISMS; DISEASE; CARCINOMA; IMMORTALIZATION; INHIBITION	Cancer cells metabolize glucose at elevated rates and have a higher sensitivity to glucose reduction. However, the precise molecular mechanisms leading to different responses to glucose restriction between normal and cancer cells are not fully understood. We analyzed normal WI-38 and immortalized WI-38/S fetal lung fibroblasts and found that glucose restriction resulted in growth inhibition and apoptosis in WI-38/S cells, whereas it induced lifespan extension in WI-38 cells. Moreover, in WI-38/S cells glucose restriction decreased expression of hTERT (human telomerase reverse transcriptase) and increased expression of p16(INK4a). Opposite effects were found in the gene expression of hTERT and p16 in WI-38 cells in response to glucose restriction. The altered gene expression was partly due to glucose restriction-induced DNA methylation changes and chromatin remodeling of the hTERT and p16 promoters in normal and immortalized WI-38 cells. Furthermore, glucose restriction resulted in altered hTERT and p16 expression in response to epigenetic regulators in WI-38 rather than WI-38/S cells, suggesting that energy stress-induced differential epigenetic regulation may lead to different cellular fates in normal and precancerous cells. Collectively, these results provide new insights into the epigenetic mechanisms of a nutrient control strategy that may contribute to cancer therapy as well as antiaging approaches.-Li, Y., Liu, L., Tollefsbol, T. O. Glucose restriction can extend normal cell lifespan and impair precancerous cell growth through epigenetic control of hTERT and p16 expression. FASEB J. 24, 1442-1453 (2010). www.fasebj.org	[Li, Yuanyuan; Tollefsbol, Trygve O.] Univ Alabama, Dept Biol, Birmingham, AL 35294 USA; [Liu, Liang; Tollefsbol, Trygve O.] Univ Alabama, Ctr Aging, Birmingham, AL USA; [Liu, Liang] Univ Alabama, Dept Med, Birmingham, AL 35294 USA; [Tollefsbol, Trygve O.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA; [Tollefsbol, Trygve O.] Univ Alabama, Clin Nutr Res Ctr, Birmingham, AL USA; [Tollefsbol, Trygve O.] Univ Alabama, Comprehens Diabet Ctr, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Tollefsbol, TO (corresponding author), CH 175,1300 Univ Blvd, Birmingham, AL 35294 USA.	trygve@uab.edu		Tollefsbol, Trygve/0000-0002-0284-1511	Imperial Cancer Research Fund Laboratories, London, UK; NATIONAL CANCER INSTITUTE [R01CA129415] Funding Source: NIH RePORTER	Imperial Cancer Research Fund Laboratories, London, UK; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Gordon Peters (Imperial Cancer Research Fund Laboratories, London, UK) and Dr. Silvia Bacchetti (Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada) for kindly providing the luciferase constructs used in this investigation.	Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Berletch JB, 2008, J CELL BIOCHEM, V103, P509, DOI 10.1002/jcb.21417; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Casillas MA, 2003, GENE, V316, P57, DOI 10.1016/S0378-1119(03)00739-X; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Cuezva JM, 2002, CANCER RES, V62, P6674; Del Bufalo D, 2005, CELL DEATH DIFFER, V12, P1429, DOI 10.1038/sj.cdd.4401670; Dhahbi JM, 2004, P NATL ACAD SCI USA, V101, P5524, DOI 10.1073/pnas.0305300101; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Garber K, 2006, SCIENCE, V312, P1158, DOI 10.1126/science.312.5777.1158; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gupta AK, 1997, MOL CELL BIOCHEM, V170, P23, DOI 10.1023/A:1006890316102; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008; Hara E, 1996, MOL CELL BIOL, V16, P859; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Kanaya T, 1998, INT J CANCER, V78, P539, DOI 10.1002/(SICI)1097-0215(19981123)78:5<539::AID-IJC2>3.0.CO;2-I; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Leibiger IB, 2006, NAT MED, V12, P34, DOI 10.1038/nm0106-34; Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398; Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011; Lunt SJ, 2009, CLIN EXP METASTAS, V26, P19, DOI 10.1007/s10585-008-9182-2; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Munoz-Pinedo C, 2003, J BIOL CHEM, V278, P12759, DOI 10.1074/jbc.M212392200; RACKER E, AM SCI, V60, P56; Rohren EM, 2004, RADIOLOGY, V231, P305, DOI 10.1148/radiol.2312021185; Shin JY, 2000, CANCER RES, V60, P262; Thompson CB, 2005, COLD SH Q B, V70, P357, DOI 10.1101/sqb.2005.70.011; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Willcox BJ, 2007, ANN NY ACAD SCI, V1114, P434, DOI 10.1196/annals.1396.037; Zhu Z, 2007, CANCER RES, V67, P12018, DOI 10.1158/0008-5472.CAN-07-2834	36	89	95	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1442	1453		10.1096/fj.09-149328	http://dx.doi.org/10.1096/fj.09-149328			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20019239	Green Published			2022-12-28	WOS:000277158900017
J	Demonbreun, AR; Posey, AD; Heretis, K; Swaggart, KA; Earley, JU; Pytel, P; McNally, EM				Demonbreun, Alexis R.; Posey, Avery D.; Heretis, Konstantina; Swaggart, Kayleigh A.; Earley, Judy U.; Pytel, Peter; McNally, Elizabeth M.			Myoferlin is required for insulin-like growth factor response and muscle growth	FASEB JOURNAL			English	Article						myoblast fusion; receptor trafficking; lysosome; signaling	DEFECTIVE MEMBRANE REPAIR; ACTIVATED PROTEIN-KINASE; TYPE-1 IGF RECEPTOR; FACTOR-I; SKELETAL-MUSCLE; MUSCULAR-DYSTROPHY; MYOBLAST FUSION; DEAFNESS FORM; POMPE-DISEASE; STEM-CELLS	Insulin-like growth factor (IGF) is a potent stimulus of muscle growth. Myoferlin is a membrane-associated protein important for muscle development and regeneration. Myoferlin-null mice have smaller muscles and defective myoblast fusion. To understand the mechanism by which myoferlin loss retards muscle growth, we found that myoferlin-null muscle does not respond to IGF1. In vivo after IGF1 infusion, control muscle increased myofiber diameter by 25%, but myoferlin-null muscle was unresponsive. Myoblasts cultured from myoferlin-null muscle and treated with IGF1 also failed to show the expected increase in fusion to multinucleate myotubes. The IGF1 receptor colocalized with myoferlin at sites of myoblast fusion. The lack of IGF1 responsiveness in myoferlin-null myoblasts was linked directly to IGF1 receptor mistrafficking as well as decreased IGF1 signaling. In myoferlin-null myoblasts, the IGF1 receptor accumulated into large vesicular structures. These vesicles colocalized with a marker of late endosomes/lysosomes, LAMP2, specifying redirection from a recycling to a degradative pathway. Furthermore, ultrastructural analysis showed a marked increase in vacuoles in myoferlin-null muscle. These data demonstrate that IGF1 receptor recycling is required for normal myogenesis and that myoferlin is a critical mediator of postnatal muscle growth mediated by IGF1.-Demonbreun, A. R., Posey, A. D., Heretis, K., Swaggart, K. A., Earley, J. U., Pytel, P., McNally, E. M. Myoferlin is required for insulin-like growth factor response and muscle growth. FASEB J. 24, 1284-1295 (2010). www.fasebj.org	[Heretis, Konstantina; Earley, Judy U.; McNally, Elizabeth M.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Demonbreun, Alexis R.; McNally, Elizabeth M.] Univ Chicago, Comm Dev Biol, Chicago, IL 60637 USA; [Posey, Avery D.; McNally, Elizabeth M.] Univ Chicago, Comm Genet, Chicago, IL 60637 USA; [Swaggart, Kayleigh A.; McNally, Elizabeth M.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Pytel, Peter] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago	McNally, EM (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	emcnally@uchicago.edu	Posey, Avery D./P-4890-2019; McNally, Elizabeth/W-4909-2019	Posey, Avery D./0000-0001-8711-629X; Swaggart, Kayleigh/0000-0001-9856-1014; Demonbreun, Alexis/0000-0001-6823-125X; McNally, Elizabeth/0000-0002-1221-719X	U.S. National Institutes of Health (NIH) [NS047726]; Muscular Dystrophy Association; Jain Foundation; NIH [T32HL007381]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047726] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); Jain Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by U.S. National Institutes of Health (NIH) grant NS047726, the Muscular Dystrophy Association, and the Jain Foundation. A. R. D. was supported by NIH grant T32HL007381.	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Anderson LVB, 1999, HUM MOL GENET, V8, P855, DOI 10.1093/hmg/8.5.855; Bakker AC, 1997, J CELL SCI, V110, P2227; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Barton ER, 2006, APPL PHYSIOL NUTR ME, V31, P791, DOI 10.1139/h06-054; Barton-Davis ER, 1999, ACTA PHYSIOL SCAND, V167, P301; Cenacchi G, 2005, J CLIN PATHOL, V58, P190, DOI 10.1136/jcp.2004.018978; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Davis DB, 2000, HUM MOL GENET, V9, P217, DOI 10.1093/hmg/9.2.217; Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200; Doherty KR, 2008, J BIOL CHEM, V283, P20252, DOI 10.1074/jbc.M802306200; Doherty KR, 2005, DEVELOPMENT, V132, P5565, DOI 10.1242/dev.02155; Doherty KR, 2003, TRENDS MOL MED, V9, P327, DOI 10.1016/S1471-4914(03)00136-9; EDWALL D, 1989, ENDOCRINOLOGY, V124, P820, DOI 10.1210/endo-124-2-820; Eskelinen Eeva-Liisa, 2008, V445, P11, DOI 10.1007/978-1-59745-157-4_2; Eskelinen EL, 2002, MOL BIOL CELL, V13, P3355, DOI 10.1091/mbc.E02-02-0114; FURLANETTO RW, 1988, ENDOCRINOLOGY, V122, P2044, DOI 10.1210/endo-122-5-2044; George M, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-3; Giovannini S, 2008, MECH AGEING DEV, V129, P593, DOI 10.1016/j.mad.2008.08.001; Grant BD, 2008, TRAFFIC, V9, P2043, DOI 10.1111/j.1600-0854.2008.00834.x; Guilherme A, 2004, J BIOL CHEM, V279, P10593, DOI 10.1074/jbc.M307702200; Heidrych P, 2008, HUM MOL GENET, V17, P3814, DOI 10.1093/hmg/ddn279; Henry L, 2008, MOL BIOL CELL, V19, P2059, DOI 10.1091/mbc.E07-09-0902; Horsley V, 2003, CELL, V113, P483, DOI 10.1016/S0092-8674(03)00319-2; Jansen KM, 2006, J CELL BIOL, V174, P403, DOI 10.1083/jcb.200601102; KALDERON N, 1979, J CELL BIOL, V81, P411, DOI 10.1083/jcb.81.2.411; LEFAUCHEUR JP, 1995, J NEUROIMMUNOL, V57, P85, DOI 10.1016/0165-5728(94)00166-L; Liao L, 2006, ENDOCRINOLOGY, V147, P3877, DOI 10.1210/en.2005-1537; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Lynch GS, 2001, NEUROMUSCULAR DISORD, V11, P260, DOI 10.1016/S0960-8966(00)00192-9; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; McNally EM, 1996, HUM MOL GENET, V5, P1841, DOI 10.1093/hmg/5.11.1841; Meikle PJ, 1999, MOL GENET METAB, V66, P179, DOI 10.1006/mgme.1998.2800; Mourkioti F, 2005, TRENDS IMMUNOL, V26, P535, DOI 10.1016/j.it.2005.08.002; Mukherjee S, 2006, CIRC RES, V98, P743, DOI 10.1161/01.RES.0000214545.99387.e3; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Nguyen TT, 2007, REPRODUCTION, V134, P41, DOI 10.1530/REP-06-0087; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Raben N, 2008, HUM MOL GENET, V17, P3897, DOI 10.1093/hmg/ddn292; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Roux I, 2006, CELL, V127, P277, DOI 10.1016/j.cell.2006.08.040; SCHMID C, 1983, FEBS LETT, V161, P117, DOI 10.1016/0014-5793(83)80742-X; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; Yang SY, 2002, FEBS LETT, V522, P156, DOI 10.1016/S0014-5793(02)02918-6; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693; ZAPF A, 1994, ENDOCRINOLOGY, V134, P2445, DOI 10.1210/en.134.6.2445	49	44	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1284	1295		10.1096/fj.09-136309	http://dx.doi.org/10.1096/fj.09-136309			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	20008164	Green Published			2022-12-28	WOS:000276462300034
J	Evans, MD; Olinski, R; Loft, S; Cooke, MS				Evans, Mark D.; Olinski, Ryszard; Loft, Steffen; Cooke, Marcus S.		European Stand Comm Urinary DNA Le	Toward consensus in the analysis of urinary 8-oxo-7,8-dihydro-2 '-deoxyguanosine as a noninvasive biomarker of oxidative stress	FASEB JOURNAL			English	Article						DNA damage; DNA repair; immunoassay; mass spectrometry; electrochemical detection; disease	PERFORMANCE LIQUID-CHROMATOGRAPHY; TANDEM MASS-SPECTROMETRY; LINKED-IMMUNOSORBENT-ASSAY; DNA-DAMAGE; IN-VIVO; AUTOMATED-METHOD; HIGH-THROUGHPUT; 8-HYDROXY-2'-DEOXYGUANOSINE; EXCRETION; LESIONS	Of the DNA-derived biomarkers of oxidative stress, urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) is the most frequently measured. However, there is significant discrepancy between chromatographic and immunoassay approaches, and intratechnique agreement among all available chromatography-based assays and ELISAs is yet to be established. This is a significant obstacle to their use in large molecular epidemiological studies. To evaluate the accuracy of intra/intertechnique and interlaboratory measurements, samples of phosphate buffered saline and urine, spiked with different concentrations of 8-oxoG, together with a series of urine samples from healthy individuals were distributed to ESCULA members. All laboratories received identical samples, including 2 negative controls that contained no added 8-oxodG. Data were returned from 17 laboratories, representing 20 methods, broadly classified as mass spectrometric (MS), electrochemical detection (EC), or enzyme-linked immunosorbant assay (ELISA). Overall, there was good within-technique agreement, with the majority of laboratories' results lying within 1 SD of their consensus mean. However, ELISA showed more within-technique variation than did the chromatographic techniques and, for the urine samples, reported higher values. Bland-Altman plots revealed good agreement between MS and EC methods but concentration-dependent deviation for ELISA. All methods ranked urine samples according to concentration similarly. Creatinine levels are routinely used as a correction factor for urine concentration, and therefore we also conducted an interlaboratory comparison of methods for urinary creatinine determination, in which the vast majority of values lay within 1 SD of the consensus value, irrespective of the analysis procedure. This study reveals greater consensus than previously expected, although concern remains over ELISA.-ESCULA [European Standards Committee on Urinary (DNA) Lesion Analysis], Evans, M. D., Olinski, R., Loft, S., Cooke, M. S. Toward consensus in the analysis of urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine as a noninvasive biomarker of oxidative stress. FASEB J. 24, 1249-1260 (2010). www.fasebj.org	[Evans, Mark D.; Cooke, Marcus S.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester, Leics, England; [Cooke, Marcus S.] Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; [Olinski, Ryszard] Nicholas Copernicus Univ, Dept Clin Biochem, Coll Med, Bydgoszcz, Poland; [Loft, Steffen] Univ Copenhagen, Dept Publ Hlth, Environm Hlth Sect, Fac Hlth Sci, Copenhagen, Denmark	University of Leicester; University of Leicester; Nicolaus Copernicus University; Ludwik Rydygier Collegium Medicum; University of Copenhagen	Cooke, MS (corresponding author), Univ Leicester, Dept Canc Studies, Robert Kilpatrick Clin Sci Bldg, Leicester, Leics, England.	msc5@le.ac.uk	Cooke, Marcus S/D-4517-2013; Barbieri, Anna/I-1722-2015; Singh, Raj/A-5398-2011; Violante, Francesco S/A-6934-2009; Sram, Radim J/H-2455-2014; Siomek-Górecka, Agnieszka/C-6384-2015; Cooke, Marcus/ABI-1501-2020; jenner, andrew M/H-4791-2016; Rozalski, Rafal/E-3397-2014; Gackowski, Daniel/G-5693-2012; Evans, Mark/P-2305-2018; Rossner, Pavel/AAI-5789-2020; Rossner, Pavel/H-2569-2014; Olinski, Ryszard/E-9607-2014	Violante, Francesco S/0000-0003-4084-2782; Sram, Radim J/0000-0003-4256-3816; Siomek-Górecka, Agnieszka/0000-0002-2323-610X; Cooke, Marcus/0000-0003-0369-862X; jenner, andrew M/0000-0003-1767-2033; Gackowski, Daniel/0000-0002-7259-1511; Evans, Mark/0000-0003-3673-8501; Rossner, Pavel/0000-0001-6921-5446; Rossner, Pavel/0000-0001-6921-5446; Saez, Guillermo/0000-0002-8164-4048; Hu, Chiung-Wen/0000-0003-4821-7500; Halliwell, Barry/0000-0002-3560-7123; Chao, Mu-Rong/0000-0002-1894-6887; Olinski, Ryszard/0000-0001-9927-8755; Poulsen, Henrik Enghusen/0000-0003-4242-9924; ORHAN, HILMI/0000-0003-2464-1841; Rozalski, Rafal/0000-0003-2067-9981; Sram, Radim/0000-0002-2500-4572; WU, KUEN-YU/0000-0003-1388-475X; Loft, Steffen/0000-0001-9552-8518; Barbieri, Anna/0000-0001-8839-294X	European Union [513943]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089] Funding Source: NIH RePORTER; Medical Research Council [G0100873] Funding Source: researchfish; MRC [G0100873] Funding Source: UKRI	European Union(European Commission); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Some of the authors of this paper are partners in, and this work was partly supported by, ECNIS (Environmental Cancer Risk, Nutrition and Individual Susceptibility), a Network of Excellence operating within the European Union 6th Framework Program, Priority 5: Food Quality and Safety (contract 513943) More information about ESCULA is available online (http://escula. org). The authors thank the following members of the ESCULA steering committee that contributed to discussions related to these data: Andrew R. Collins and Jean Cadet. Members of ESCULA who participated in experimentation, along with commenting on, and approval of, data analysis and final manuscript, are the following: Pavel Rossner, Jr., and Radim Sram (Institute of Experimental Medicine AS CR, Prague, Czech Republic); Trine Henriksen, Henrik Enghusen Poulsen, and Allan Weimann (Laboratory for Clinical Pharmacology Q7642, Rigshospitalet, University Hospital Copenhagen, Copenhagen, Denmark); Anna Barbieri, Laura Sabatini, and Francesco Violante (Department of Internal Medicine, Geriatric Medicine and Nephrology, Section of Occupational Medicine, University of Bologna, Sant'Orsola Malpighi Hospital, Bologna, Italy); Satoko Kino, Tairin Ochi, Kazuo Sakai, and Masao Takeuchi (Japan Institute for the Control of Aging, Nikken SEIL Co., Shizuoka, Japan); Hiroshi Kasai (Department of Environmental Oncology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan); John H. N. Meerman (Leiden University, Leiden, The Netherlands); Daniel Gackowski, Rafal Rozalski, and Agnieszka Siomek (Department of Clinical Biochemistry, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland); Barry Halliwell, Andrew M. Jenner, and Huansong Wang (Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Centre for Life Science, Neurobiology and Ageing Program, Singapore); Concha Cerda and Guillermo Saez (Department of Biochemistry and Molecular Biology, Clinical Analysis Service, CDB, General University Hospital, University of Valencia, Valencia, Spain); Siamak Haghdoost (Centre for Radiation Protection Research, Department of Genetics, Microbiology and Toxicology, Stockholm University, Stockholm, Sweden); Peter Svoboda (Oxotox Co. Veddesta Centre, Jarfalla, Sweden); Chiung-Wen Hu and Mu-Rong Chao, (Departments of Public Health and Occupational Safety and Health, Chung Shan Medical University, Taichung, Taiwan); Kai-Yao Peng, Wei-Chung Shih, and Kuen-Yuh Wu (Institute of Occupational Medicine and Industrial Hygiene, College of Public Health, National Taiwan University, Taiwan); Hilmi Orhan and Nuriye Serra Istanbullu (Department of Toxicology, Faculty of Pharmacy, Ege University, Izmir, Turkey); Vilas Mistry (Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK); Peter B. Farmer, Jatinderpal Sandhu, and Rajinder Singh (Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK); Czarina Cortez and Yali Su (Kronos Science, Phoenix, AZ, USA); Regina M. Santella (Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA); and Pauline Lambert and Raymond Smith (ESA Laboratories, Inc., Chelmsford, MA, USA).	Baron K.E, 1989, NEW SHORT TXB CHEM P; BROWN RK, 1995, FREE RADICAL BIO MED, V18, P801, DOI 10.1016/0891-5849(94)00172-G; Cadet J, 2008, ACCOUNTS CHEM RES, V41, P1075, DOI 10.1021/ar700245e; CATHCART R, 1984, P NATL ACAD SCI-BIOL, V81, P5633, DOI 10.1073/pnas.81.18.5633; Collins A, 2002, CARCINOGENESIS, V23, P2129, DOI 10.1093/carcin/23.12.2129; Collins AR, 2000, FREE RADICAL RES, V32, P333, DOI 10.1080/10715760000300331; Cooke MS, 2006, FREE RADICAL BIO MED, V41, P1829, DOI 10.1016/j.freeradbiomed.2006.09.009; Cooke MS, 2008, CANCER EPIDEM BIOMAR, V17, P3, DOI 10.1158/1055-9965.EPI-07-0751; Cooke M, 2009, BIOMARKERS, V14, P103, DOI 10.1080/13547500802706012; Cooke MS, 2002, FREE RADICAL BIO MED, V33, P1601, DOI 10.1016/S0891-5849(02)01146-2; Cooke MS, 2006, CLIN CHIM ACTA, V365, P30, DOI 10.1016/j.cca.2005.09.009; Cooke MS, 2005, MUTAT RES-FUND MOL M, V574, P58, DOI 10.1016/j.mrfmmm.2005.01.022; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Crohns M, 2009, CLIN BIOCHEM, V42, P1082, DOI 10.1016/j.clinbiochem.2009.02.022; D'Errico M, 2008, MUTAT RES-REV MUTAT, V659, P4, DOI 10.1016/j.mrrev.2007.10.003; Dedon PC, 2008, CHEM RES TOXICOL, V21, P206, DOI 10.1021/tx700283c; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; Gackowski D, 2001, FREE RADICAL RES, V35, P825, DOI 10.1080/10715760100301321; Griffiths HR, 2002, MOL ASPECTS MED, V23, P101, DOI 10.1016/S0098-2997(02)00017-1; Haghdoost S, 2005, FREE RADICAL RES, V39, P153, DOI 10.1080/10715760500043132; Haghdoost S, 2001, INT J RADIAT ONCOL, V50, P405, DOI 10.1016/S0360-3016(00)01580-7; Haghdoost S, 2006, FREE RADICAL BIO MED, V41, P620, DOI 10.1016/j.freeradbiomed.2006.05.003; Harri M, 2007, J CHROMATOGR B, V853, P242, DOI 10.1016/j.jchromb.2007.03.016; Henriksen T, 2009, FREE RADICAL BIO MED, V47, P629, DOI 10.1016/j.freeradbiomed.2009.06.002; Hu CW, 2006, CLIN CHEM, V52, P1381, DOI 10.1373/clinchem.2005.063735; Hu CW, 2004, RAPID COMMUN MASS SP, V18, P505, DOI 10.1002/rcm.1367; Kasai H, 2003, J RADIAT RES, V44, P185, DOI 10.1269/jrr.44.185; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; Lin HS, 2004, BIOCHEM J, V380, P541, DOI 10.1042/BJ20040004; LOFT S, 1992, CARCINOGENESIS, V13, P2241, DOI 10.1093/carcin/13.12.2241; LOFT S, 2007, STATE VALIDATION BIO, P32; Loft S, 2006, CARCINOGENESIS, V27, P1245, DOI 10.1093/carcin/bgi313; Nia AB, 2001, CARCINOGENESIS, V22, P395, DOI 10.1093/carcin/22.3.395; Orhan H, 2004, FREE RADICAL RES, V38, P1269, DOI 10.1080/10715760400013763; PARK EM, 1992, P NATL ACAD SCI USA, V89, P3375, DOI 10.1073/pnas.89.8.3375; Poulsen HE, 1998, FREE RADICAL RES, V29, P565, DOI 10.1080/10715769800300601; Prieme H, 1998, CARCINOGENESIS, V19, P347, DOI 10.1093/carcin/19.2.347; Rossner P, 2007, MUTAT RES-FUND MOL M, V617, P23, DOI 10.1016/j.mrfmmm.2006.11.033; Sabatini L, 2005, RAPID COMMUN MASS SP, V19, P147, DOI 10.1002/rcm.1763; Salonen JT, 1996, NATURAL ANTIOXIDANTS, P78; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; Shimoi K, 2002, CANCER EPIDEM BIOMAR, V11, P767; Siomek A, 2007, ANTIOXID REDOX SIGN, V9, P143, DOI 10.1089/ars.2007.9.143; Song MF, 2009, FREE RADICAL BIO MED, V47, P41, DOI 10.1016/j.freeradbiomed.2009.02.017; Valavanidis A, 2009, J ENVIRON SCI HEAL C, V27, P120, DOI 10.1080/10590500902885684; VERHAGEN H, 1995, CARCINOGENESIS, V16, P969, DOI 10.1093/carcin/16.4.969; Yoshida R, 2002, CANCER EPIDEM BIOMAR, V11, P1076	47	120	120	1	41	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1249	1260		10.1096/fj.09-147124	http://dx.doi.org/10.1096/fj.09-147124			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19966135	Green Submitted, Green Published			2022-12-28	WOS:000276462300031
J	Pini, A; Falciani, C; Mantengoli, E; Bindi, S; Brunetti, J; Iozzi, S; Rossolini, GM; Bracci, L				Pini, Alessandro; Falciani, Chiara; Mantengoli, Elisabetta; Bindi, Stefano; Brunetti, Jlenia; Iozzi, Sara; Rossolini, Gian Maria; Bracci, Luisa			A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo	FASEB JOURNAL			English	Article						dendrimers; antibacterial; cystic fibrosis; gramnegative bacteria; LPS	BRANCHED PEPTIDES; SYNTHETIC PEPTIDES; POLYMYXIN-B; RESISTANCE; PATHOGENS; BINDING; DESIGN; LETHAL	We describe the nonnatural antimicrobial peptide KKIRVRLSA (M33) and its capacity to neutralize LPS-induced cytokine release, preventing septic shock in animals infected with bacterial species of clinical interest. M33 showed strong resistance to proteolytic degradation when synthesized in tetra-branched form with 4 peptides linked by a lysine core, making it suitable for use in vivo. HPLC and mass spectrometry demonstrated its stability in serum beyond 24 h. M33 was found to be very selective for gram-negative bacteria. Minimal inhibitory concentration (MIC) ranged from 0.3 to 3 mu M for multidrug resistant clinical isolates of several pathogenic species, including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. M33 neutralized LPS derived from P. aeruginosa and K. pneumoniae, and prevented TNF-alpha release from LPS-activated macrophages, with an EC50 of 3.8e-8 M and 2.8e-7 M, respectively, as detected by sandwich ELISA. M33 activity was also tested in sepsis animal models. It averted septic shock symptoms due to Escherichia coli and P. aeruginosa in doses compatible with clinical use (5-25 mg/kg). These properties make tetrabranched M33 peptide a good candidate for the development of a new antibacterial drug.-Pini, A., Falciani, C., Mantengoli, E., Bindi, S., Brunetti, J., Iozzi, S., Rossolini, G. M., Bracci, L. A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo. FASEB J. 24, 1015-1022 (2010). www.fasebj.org	[Pini, Alessandro; Falciani, Chiara; Bindi, Stefano; Brunetti, Jlenia; Iozzi, Sara; Bracci, Luisa] Univ Siena, Dept Mol Biol, Biochem Sect, I-53100 Siena, Italy; [Mantengoli, Elisabetta; Rossolini, Gian Maria] Univ Siena, Dept Mol Biol, Microbiol Sect, I-53100 Siena, Italy	University of Siena; University of Siena	Pini, A (corresponding author), Univ Siena, Dept Mol Biol, Biochem Sect, Via Fiorentina 1, I-53100 Siena, Italy.	pinia@unisi.it	Bracci, Luisa/V-9913-2018; Falciani, Chiara/R-1330-2018; Brunetti, Luisa/E-6464-2019; Pini, Alessandro/R-1359-2018	Bracci, Luisa/0000-0002-0738-5746; Falciani, Chiara/0000-0002-1027-8482; Brunetti, Luisa/0000-0001-8144-7186; Pini, Alessandro/0000-0002-3832-8349; ROSSOLINI, Gian Maria/0000-0002-9386-0434	Fondazione Italiana per la Ricerca sulla Fibrosi cistica [FFC 14/2009]	Fondazione Italiana per la Ricerca sulla Fibrosi cistica(Ministry of Health, ItalyItalian Cystic Fibrosis Research Foundation)	The authors thank Silvia Scali for technical help in peptide synthesis. Part of this work was financed by Fondazione Italiana per la Ricerca sulla Fibrosi cistica, grant FFC# 14/2009.	Arnold TM, 2007, AM J HEALTH-SYST PH, V64, P819, DOI 10.2146/ajhp060473; Bowdish DME, 2004, J IMMUNOL, V172, P3758, DOI 10.4049/jimmunol.172.6.3758; Bracci L, 2003, J BIOL CHEM, V278, P46590, DOI 10.1074/jbc.M308615200; Bracci L, 2002, BIOCHEMISTRY-US, V41, P10194, DOI 10.1021/bi0256025; Cirioni O, 2006, ANTIMICROB AGENTS CH, V50, P1672, DOI 10.1128/AAC.50.5.1672-1679.2006; Demitri MT, 1996, J ENDOTOXIN RES, V3, P445, DOI 10.1177/096805199600300602; Fabbrini M, 2009, ADV EXP MED BIOL, V611, P437, DOI 10.1007/978-0-387-73657-0_188; Falciani C, 2007, MOL CANCER THER, V6, P2441, DOI 10.1158/1535-7163.MCT-07-0164; Falciani C, 2007, CHEM BIOL DRUG DES, V69, P216, DOI 10.1111/j.1747-0285.2007.00487.x; Falciani C, 2009, EXPERT OPIN BIOL TH, V9, P171, DOI [10.1517/14712590802620501, 10.1517/14712590802620501 ]; Gordon YJ, 2005, CURR EYE RES, V30, P505, DOI 10.1080/02713680590968637; Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267; Lau YE, 2006, AM J RESP CELL MOL, V34, P399, DOI 10.1165/rcmb.2005-0170OC; Lozzi L, 2003, CHEM BIOL, V10, P411, DOI 10.1016/S1074-5521(03)00094-2; Marr AK, 2006, CURR OPIN PHARMACOL, V6, P468, DOI 10.1016/j.coph.2006.04.006; Michalopoulos A, 2008, CRIT CARE CLIN, V24, P377, DOI 10.1016/j.ccc.2007.12.003; Motzkus D, 2006, FASEB J, V20, P1701, DOI 10.1096/fj.05-4970fje; PECKMILLER KA, 1993, CANCER CHEMOTH PHARM, V32, P109, DOI 10.1007/BF00685612; Pini A, 2006, BIOCHEM J, V395, P157, DOI 10.1042/BJ20051747; Pini A, 2005, ANTIMICROB AGENTS CH, V49, P2665, DOI 10.1128/AAC.49.7.2665-2672.2005; Pini A, 2008, CURR PROTEIN PEPT SC, V9, P468, DOI 10.2174/138920308785915227; Pini A, 2008, PROTEIN PEPTIDE LETT, V15, P562, DOI 10.2174/092986608784966958; Pini A, 2007, J PEPT SCI, V13, P393, DOI 10.1002/psc.858; Prescott WA, 2005, PHARMACOTHERAPY, V25, P555, DOI 10.1592/phco.25.4.555.61025; Riccio ML, 2005, ANTIMICROB AGENTS CH, V49, P104, DOI 10.1128/AAC.49.1.104-110.2005; Rossetto G, 2007, NANOMED-NANOTECHNOL, V3, P198, DOI 10.1016/j.nano.2007.06.002; Rossolini GM, 2008, CLIN MICROBIOL INFEC, V14, P2, DOI 10.1111/j.1469-0691.2008.02126.x; Rossolini GM, 2008, ANTIMICROB AGENTS CH, V52, P4023, DOI 10.1128/AAC.00707-08; Rossolini GM, 2007, NEW MICROBIOL, V30, P332; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Walker John M., 1996, P525, DOI 10.1007/978-1-60327-259-9_88; Wong KF, 2009, PROTEIN PEPTIDE LETT, V16, P539, DOI 10.2174/092986609788167761; Yeaman MR, 2002, ANTIMICROB AGENTS CH, V46, P3883, DOI 10.1128/AAC.46.12.3883-3891.2002; Zavascki AP, 2007, J ANTIMICROB CHEMOTH, V60, P1206, DOI 10.1093/jac/dkm357; Zhang LJ, 2005, ANTIMICROB AGENTS CH, V49, P2921, DOI 10.1128/AAC.49.7.2921-2927.2005; Zhang LJ, 2006, EXPERT OPIN PHARMACO, V7, P653, DOI 10.1517/14656566.7.6.653	36	61	66	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1015	1022		10.1096/fj.09-145474	http://dx.doi.org/10.1096/fj.09-145474			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19917670				2022-12-28	WOS:000276462300009
J	Acin-Perez, R; Hoyos, B; Zhao, F; Vinogradov, V; Fischman, DA; Harris, RA; Leitges, M; Wongsiriroj, N; Blaner, WS; Manfredi, G; Hammerling, U				Acin-Perez, Rebeca; Hoyos, Beatrice; Zhao, Feng; Vinogradov, Valerie; Fischman, Donald A.; Harris, Robert A.; Leitges, Michael; Wongsiriroj, Nuttaporn; Blaner, William S.; Manfredi, Giovanni; Hammerling, Ulrich			Control of oxidative phosphorylation by vitamin A illuminates a fundamental role in mitochondrial energy homoeostasis	FASEB JOURNAL			English	Article						intermediary metabolism; pyruvate dehydrogenase complex; respiration; retinoid metabolism; signal transduction	PROTEIN-KINASE-C; RETRO-RETINOIDS; MOLECULAR-BASIS; CELL-GROWTH; ACTIVATION; ANHYDRORETINOL; DELTA; ABSORPTION; BIOLOGY; STRESS	The physiology of two metabolites of vitamin A is understood in substantial detail: retinaldehyde functions as the universal chromophore in the vertebrate and invertebrate eye; retinoic acid regulates a set of vertebrate transcription factors, the retinoic acid receptor superfamily. The third member of this retinoid triumvirate is retinol. While functioning as the precursor of retinaldehyde and retinoic acid, a growing body of evidence suggests a far more fundamental role for retinol in signal transduction. Here we show that retinol is essential for the metabolic fitness of mitochondria. When cells were deprived of retinol, respiration and ATP synthesis defaulted to basal levels. They recovered to significantly higher energy output as soon as retinol was restored to physiological concentration, without the need for metabolic conversion to other retinoids. Retinol emerged as an essential cofactor of protein kinase C delta (PKC delta), without which this enzyme failed to be activated in mitochondria. Furthermore, retinol needed to physically bind PKC delta, because mutation of the retinol binding site rendered PKC delta unresponsive to Rol, while retaining responsiveness to phorbol ester. The PKC delta/retinol complex signaled the pyruvate dehydrogenase complex for enhanced flux of pyruvate into the Krebs cycle. The baseline response was reduced in vitamin A-deficient lecithin: retinol acyl transferase-knockout mice, but this was corrected within 3 h by intraperitoneal injection of vitamin A; this suggests that vitamin A is physiologically important. These results illuminate a hitherto unsuspected role of vitamin A in mitochondrial bioenergetics of mammals, acting as a nutritional sensor. As such, retinol is of fundamental importance for energy homeostasis. The data provide a mechanistic explanation to the nearly 100-yr-old question of why vitamin A deficiency causes so many pathologies that are independent of retinoic acid action.-Acin-Perez, T., Hoyos, B., Zhao, F., Vinogradov, V., Fischman, D. A., Harris, R. A., Leitges, M., Wongsiriroj, N., Blaner, W. S., Manfredi, G., Hammerling, U. Control of oxidative phosphorylation by vitamin A illuminates a fundamental role in mitochondrial energy homoeostasis. FASEB J. 24, 627-636 (2010). www.fasebj.org	[Hoyos, Beatrice; Zhao, Feng; Vinogradov, Valerie; Hammerling, Ulrich] Sloan Kettering Inst Canc Res, Program Immunol, New York, NY 10065 USA; [Acin-Perez, Rebeca; Manfredi, Giovanni] Weill Cornell Med Sch, Dept Neurol & Neurobiol, New York, NY USA; [Fischman, Donald A.] Weill Cornell Med Sch, Dept Cell & Dev Biol, New York, NY USA; [Harris, Robert A.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN USA; [Leitges, Michael] Univ Oslo, Biotechnol Ctr Oslo, Oslo, Norway; [Wongsiriroj, Nuttaporn] Graz Univ, Inst Mol Biosci, Graz, Austria; [Blaner, William S.] Columbia Univ, Coll Phys & Surg, Dept Human Nutr, New York, NY USA; [Blaner, William S.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA	Memorial Sloan Kettering Cancer Center; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Indiana University System; Indiana University-Purdue University Indianapolis; University of Oslo; University of Graz; Columbia University; Columbia University	Hammerling, U (corresponding author), Sloan Kettering Inst Canc Res, Program Immunol, 1275 York Ave, New York, NY 10065 USA.	u-hammerling@ski.mskcc.org	Acin-Perez, Rebeca/H-6160-2015; Acin-Perez, Rebeca/AAU-4913-2020; Leitges, Michael/AAN-1953-2021	Acin-Perez, Rebeca/0000-0001-9553-8337; Acin-Perez, Rebeca/0000-0001-9553-8337; Leitges, Michael/0000-0003-4203-6995	National Institutes of Health [DK069384, CA089362, DK079221, K02NS047306]; NATIONAL CANCER INSTITUTE [R01CA089362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK079221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K02NS047306] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Anatoli Starkov and Gregg Duester for helpful discussions and Ouathek Ouerfelli and Alice Cao for their expertise in analytical chemistry. This work was supported by grants from the National Institutes of Health: DK069384 (to U. H.); CA089362 (to U. H.); DK079221 (to W. S. B.); and K02NS047306 (to G. M.). R. A.-P. thanks the Spanish Ministry of Education for a Fulbright fellowship.	Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; Chen YQ, 1999, CANCER RES, V59, P3985; Chiu HJ, 2008, FASEB J, V22, P3878, DOI 10.1096/fj.08-112375; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; EPPINGER TM, 1993, J EXP MED, V178, P1995, DOI 10.1084/jem.178.6.1995; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; Fernandez-Vizarra E, 2002, METHODS, V26, P292, DOI 10.1016/S1046-2023(02)00034-8; Galter D, 2003, EUR J BIOCHEM, V270, P1316, DOI 10.1046/j.1432-1033.2003.03502.x; GARBE A, 1992, J EXP MED, V176, P109, DOI 10.1084/jem.176.1.109; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155; Hoyos B, 2005, J BIOL CHEM, V280, P6872, DOI 10.1074/jbc.M412695200; Hoyos B, 2002, J BIOL CHEM, V277, P23949, DOI 10.1074/jbc.M110750200; Hoyos B, 2000, J EXP MED, V192, P835, DOI 10.1084/jem.192.6.835; Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680; Imam A, 2001, FASEB J, V15, P28; Kang HW, 2007, MOL CELL ENDOCRINOL, V271, P18, DOI 10.1016/j.mce.2007.03.002; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Kim HJ, 2006, ONCOGENE, V25, P2785, DOI 10.1038/sj.onc.1209303; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Korichneva I, 2003, J PHARMACOL EXP THER, V305, P426, DOI 10.1124/jpet.103.048900; Korichneva I, 1999, J CELL SCI, V112, P2521; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leitges M, 2002, MOL CELL BIOL, V22, P3970, DOI 10.1128/MCB.22.12.3970-3980.2002; Livera G, 2002, REPRODUCTION, V124, P173, DOI 10.1530/rep.0.1240173; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Mao GE, 2000, TOXICOL APPL PHARM, V163, P38, DOI 10.1006/taap.1999.8828; McCollum EV, 1913, J BIOL CHEM, V15, P167; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; O'Byrne SM, 2005, J BIOL CHEM, V280, P35647, DOI 10.1074/jbc.M507924200; OConnell MJ, 1996, J EXP MED, V184, P549, DOI 10.1084/jem.184.2.549; Osborne TB, 1913, J BIOL CHEM, V15, P311; Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PINTON P, 2004, J CELL BIOL, P1; Ross A. Catharine, 1994, P521; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; Vives-Bauza C, 2007, METHOD CELL BIOL, V80, P155, DOI 10.1016/S0091-679X(06)80007-5; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; Wongsiriroj N, 2008, J BIOL CHEM, V283, P13510, DOI 10.1074/jbc.M800777200; Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711	48	61	63	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					627	636		10.1096/fj.09-142281	http://dx.doi.org/10.1096/fj.09-142281			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19812372	Green Published			2022-12-28	WOS:000274045000030
J	Mata, J				Mata, Juan			Genome-wide mapping of myosin protein-RNA networks suggests the existence of specialized protein production sites	FASEB JOURNAL			English	Article						RIp-chip; fission yeast; posttranscriptional control	FISSION YEAST; MESSENGER-RNAS; ACTIN CYTOSKELETON; ARP2/3 COMPLEX; I MYOSINS; RIP-CHIP; IDENTIFICATION; TRANSPORT; FAMILY; RNG3P	Motor proteins can organize posttranscriptional processes by transporting ribonucleoprotein complexes to specific locations. To investigate a possible role of myosin proteins in gene expression control, I have identified mRNAs associated with five myosin heavy chains in the fission yeast Schizosaccharomyces pombe, by purifying the proteins and identifying bound transcripts using DNA microarrays. Each myosin coimmunoprecipitated with 5-13 different mRNAs (similar to 0.1-0.2% of all genes), including those encoding four different myosin heavy chains. Moreover, one of the myosins (Myo1) interacted with mRNAs encoding components of the cortical actin cytoskeleton. These interactions were not observed in control immunoprecipitates. A myosin-specific chaperone (Rng3) that interacts cotranslationally with myosin mRNAs was essential for the association between myosin proteins and transcripts but not between Myo1 and other mRNAs. Finally, proteins encoded by the Myo1-associated mRNAs immunoprecipitated each other's transcripts, but not myosin mRNAs. These interactions suggest the existence of two distinct myosin-containing ribonucleoprotein complexes: those containing myosin mRNAs and those associated with Myo1. They are distinguished by their mRNA composition, requirement for the Rng3 chaperone and the presence of nonmyosin cytoskeletal proteins. I propose that these complexes represent specialized sites for the production of myosin proteins and the assembly of cytoskeletal components, respectively.-Mata, J. Genome-wide mapping of myosin protein-RNA networks suggests the existence of specialized protein production sites. FASEB J. 24, 479-484 (2010). www.fasebj.org	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Cambridge	Mata, J (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	jm593@cam.ac.uk		Mata, Juan/0000-0002-5514-3653	Medical Research Council New Investigator Award [G0501168]; Medical Research Council [G0501168] Funding Source: researchfish; MRC [G0501168] Funding Source: UKRI	Medical Research Council New Investigator Award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The author thanks Jurg Bahler for support throughout this project. The author also thanks Jurg Bahler, Samuel Marguerat, and Maria Amorim for comments on the manuscript, and Stephen Watt for help with microarray experiments. Kathy Gould (Vanderbilt University Medical Center, Nashville, TN, USA) provided the rng3-65 mutant. This work was supported by a Medical Research Council New Investigator Award (G0501168) to J.M.	Amorim MJ, 2009, EMBO REP, V10, P186, DOI 10.1038/embor.2008.228; Barker SL, 2007, MOL BIOL CELL, V18, P2893, DOI 10.1091/mbc.E07-05-0436; Baroni Timothy E., 2008, V419, P93, DOI 10.1007/978-1-59745-033-1_6; Carnahan RH, 2003, J CELL BIOL, V162, P851, DOI 10.1083/jcb.200305012; Chang L, 2006, J CELL BIOL, V172, P747, DOI 10.1083/jcb.200511033; Chang W, 2008, RNA, V14, P491, DOI 10.1261/rna.665008; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; Gachet Y, 2003, MOLECULAR BIOLOGY OF SCHIZOSACCHAROMYCES POMBE, P225; Halbeisen RE, 2008, CELL MOL LIFE SCI, V65, P798, DOI 10.1007/s00018-007-7447-6; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Lee WL, 2000, J CELL BIOL, V151, P789, DOI 10.1083/jcb.151.4.789; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Lyne R, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-27; Mingle LA, 2005, J CELL SCI, V118, P2425, DOI 10.1242/jcs.02371; Mishra M, 2005, EUKARYOT CELL, V4, P567, DOI 10.1128/EC.4.3.567-576.2005; Moseley JB, 2006, MICROBIOL MOL BIOL R, V70, P605, DOI 10.1128/MMBR.00013-06; Parker R, 2007, MOL CELL, V25, P635, DOI 10.1016/j.molcel.2007.02.011; Shepard KA, 2003, P NATL ACAD SCI USA, V100, P11429, DOI 10.1073/pnas.2033246100; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Takizawa PA, 2000, SCIENCE, V290, P341, DOI 10.1126/science.290.5490.341; Tang HY, 2000, MOL CELL BIOL, V20, P12, DOI 10.1128/MCB.20.1.12-25.2000; Tasto JJ, 2001, YEAST, V18, P657, DOI 10.1002/yea.713; Wong KCY, 2000, J CELL SCI, V113, P2421	26	5	5	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					479	484		10.1096/fj.09-140335	http://dx.doi.org/10.1096/fj.09-140335			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19805578				2022-12-28	WOS:000274045000015
J	Pereira, RMS; Teixeira, KLD; Barreto-De-Souza, V; Calegari-Silva, TC; De-Melo, LDB; Soares, DC; Bou-Habib, DC; Silva, AM; Saraiva, EM; Lopes, UG				Pereira, Renata M. S.; Dias Teixeira, Karina Luiza; Barreto-de-Souza, Victor; Calegari-Silva, Teresa Cristina; De-Melo, Luiz D. B.; Soares, Deivid C.; Bou-Habib, Dumith C.; Silva, Aristobolo M.; Saraiva, Elvira M.; Lopes, Ulisses G.			Novel role for the double-stranded RNA-activated protein kinase PKR: modulation of macrophage infection by the protozoan parasite Leishmania	FASEB JOURNAL			English	Article						IL-10; Leishmania amazonensis; NF-kappa B; nitric oxide	NF-KAPPA-B; ARGINASE-I INDUCTION; NITRIC-OXIDE; MURINE MACROPHAGES; MAJOR INFECTION; INNATE IMMUNITY; L-ARGININE; INTERFERON; INTERLEUKIN-10; EXPRESSION	The evolution of Leishmania infection depends on the balance between microbicidal and suppressor macrophage functions. Double-stranded RNA (dsRNA)-activated protein kinase R (PKR), a classic antiviral protein, is able to regulate a number of signaling pathways and macrophage functions. We investigated the possible role of PKR in the modulation of Leishmania infection. Our data demonstrated that Leishmania amazonensis infection led to PKR activation and increased PKR levels. Consistently, in macrophages from PKR knockout 129Sv/Ev mice and RAW-264.7 cells stably expressing a dominant-negative (DN) construct of PKR (DN-PKR), L. amazonensis infection was strongly reduced. The treatment of infected macrophages with the synthetic double-stranded RNA poly(I: C), a potent PKR inductor, increased L. amazonensis intracellular proliferation. This effect was reversed by 2-aminopurine (2-AP), a pharmacological inhibitor of PKR, as well as by the expression of DN-PKR. NO release induced by dsRNA treatment was inhibited by L. amazonensis through NF-kappa B modulation. PKR activation induced by dsRNA also resulted in IL-10 production, whose neutralization with specific antibody completely abrogated L. amazonensis proliferation. Our data demonstrated a new role of PKR in protozoan parasitic infection through IL-10 modulation.-Pereira, R. M. S., Teixeira, K. L. D., Barreto-deSouza, V. Calegari-Silva, T. C., De-Melo, D. B., Soares, D. C., Bou-Habib, D. C., Silva, A. M., Saraiva, E. M., Lopes, U. G. Novel role for the double-stranded RNA-activated protein kinase PKR: modulation of macrophage infection by the protozoan parasite Leishmania. FASEB J. 24, 617-626 (2010). www.fasebj.org	[Pereira, Renata M. S.; Dias Teixeira, Karina Luiza; Calegari-Silva, Teresa Cristina; De-Melo, Luiz D. B.; Lopes, Ulisses G.] Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Mol Parasitol Lab, Inst Biofis Carlos Chagas Filho, BR-21949902 Rio De Janeiro, Brazil; [Soares, Deivid C.; Saraiva, Elvira M.] Univ Fed Rio de Janeiro, Lab Imunobiol Leishmanioses, Inst Microbiol Paulo Goes, BR-21949902 Rio De Janeiro, Brazil; [Barreto-de-Souza, Victor; Bou-Habib, Dumith C.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Pesquisas Timo, Rio De Janeiro, Brazil; [Silva, Aristobolo M.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Morfol, Belo Horizonte, MG, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; Universidade Federal de Minas Gerais	Lopes, UG (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Mol Parasitol Lab, Inst Biofis Carlos Chagas Filho, Av Carlos Chagas Filho S-N, BR-21949902 Rio De Janeiro, Brazil.	lopesu@biof.ufrj.br	Silva, Victor/AAL-3189-2021; Lopes, Ulisses Gazos/T-6634-2019; Dias Teixeira, Karina/J-4918-2017; Lopes, Ulisses/N-4416-2013; Silva, Aristóbolo/AAA-2239-2021; Pereira, Renata/V-6194-2019; Bou-Habib, Dumith/GPP-1624-2022; Silva, Aristobolo/CAF-4874-2022; Saraiva, Elvira M/L-2864-2017	Dias Teixeira, Karina/0000-0002-6115-6768; Silva, Aristóbolo/0000-0001-7473-7433; Bou-Habib, Dumith/0000-0003-0552-9045; Saraiva, Elvira M/0000-0002-6388-5286; Barreto S B Silva, Victor/0000-0002-7413-0735; Pereira, Renata/0000-0002-7719-8356; De Melo, Luiz Dione Barbosa/0000-0003-2445-9943; Calegari Silva, Teresa Cristina/0000-0002-1656-3460	Fundacao Carlos Chagas Filho de Amparo; Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico	Fundacao Carlos Chagas Filho de Amparo; Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	We thank Professor Marcela Lopes for revising the manuscript. We also thank Paulo Cordeiro for his technical expertise, Judy Grevan for editing the text in English, and the Hemotherapy Service of the Hospital Clementino Fraga Filho (Federal University of Rio de Janeiro) for providing buffy coats. This work was supported by the Brazilian research funding agencies Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico.	Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Barreto-De-Souza V, 2006, J INFECT DIS, V194, P846, DOI 10.1086/506618; Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497; Bogdan C, 1999, PARASITOL TODAY, V15, P22, DOI 10.1016/S0169-4758(98)01362-3; Bogdan CT, 2000, IMMUNOL REV, V173, P17, DOI 10.1034/j.1600-065X.2000.917307.x; Calegari-Silva TC, 2009, IMMUNOL LETT, V127, P19, DOI 10.1016/j.imlet.2009.08.009; Cameron P, 2004, J IMMUNOL, V173, P3297, DOI 10.4049/jimmunol.173.5.3297; Chakrabarti A, 2008, J BIOL CHEM, V283, P25132, DOI 10.1074/jbc.M804770200; Chatelain R, 1999, PARASITE IMMUNOL, V21, P211, DOI 10.1046/j.1365-3024.1999.00224.x; Cheung BKW, 2005, J IMMUNOL, V175, P7218, DOI 10.4049/jimmunol.175.11.7218; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Danelli MGM, 2009, PHYTOCHEMISTRY, V70, P608, DOI 10.1016/j.phytochem.2009.03.009; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Almeida MC, 2003, MEM I OSWALDO CRUZ, V98, P861, DOI 10.1590/S0074-02762003000700001; Domingo-Gil E, 2008, J VIROL, V82, P254, DOI 10.1128/JVI.01384-07; EVANS TG, 1993, J IMMUNOL, V151, P907; Garcia MA, 2007, BIOCHIMIE, V89, P799, DOI 10.1016/j.biochi.2007.03.001; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; GREEN SJ, 1990, IMMUNOL LETT, V25, P15, DOI 10.1016/0165-2478(90)90083-3; Gregory DJ, 2008, EUR J IMMUNOL, V38, P1071, DOI 10.1002/eji.200737586; GUSELLA GL, 1995, J IMMUNOL, V154, P345; Iniesta V, 2005, INFECT IMMUN, V73, P6085, DOI 10.1128/IAI.73.9.6085-6090.2005; Iniesta V, 2002, PARASITE IMMUNOL, V24, P113, DOI 10.1046/j.1365-3024.2002.00444.x; Iniesta V, 2001, J EXP MED, V193, P777, DOI 10.1084/jem.193.6.777; Jones DE, 2002, INFECT IMMUN, V70, P2151, DOI 10.1128/IAI.70.4.2151-2158.2002; Kane MM, 2001, J IMMUNOL, V166, P1141, DOI 10.4049/jimmunol.166.2.1141; KARP CL, 1993, J CLIN INVEST, V91, P1644, DOI 10.1172/JCI116372; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; Maggi LB, 2000, EMBO J, V19, P3630, DOI 10.1093/emboj/19.14.3630; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Munder M, 1999, J IMMUNOL, V163, P3771; Murray HW, 2003, J INFECT DIS, V188, P458, DOI 10.1086/376510; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; Padigel UM, 2003, J IMMUNOL, V171, P3705, DOI 10.4049/jimmunol.171.7.3705; Qi H, 2004, INFECT IMMUN, V72, P988, DOI 10.1128/IAI.72.2.988-995.2004; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Silva AM, 2004, J BIOL CHEM, V279, P37670, DOI 10.1074/jbc.M406554200; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; Vouldoukis I, 1997, EUR J IMMUNOL, V27, P860, DOI 10.1002/eji.1830270409; Ward SV, 2002, VIROLOGY, V296, P136, DOI 10.1006/viro.2002.1356; *WHO TROP DIS RES, 2009, LEISHM BURD DIS; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	48	42	43	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					617	626		10.1096/fj.09-140053	http://dx.doi.org/10.1096/fj.09-140053			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19812373	Bronze			2022-12-28	WOS:000274045000029
J	Armanet, M; Wojtusciszyn, A; Morel, P; Parnaud, G; Rousselle, P; Sinigaglia, C; Berney, T; Bosco, D				Armanet, Mathieu; Wojtusciszyn, Anne; Morel, Philippe; Parnaud, Geraldine; Rousselle, Patricia; Sinigaglia, Corinne; Berney, Thierry; Bosco, Domenico			Regulated laminin-332 expression in human islets of Langerhans	FASEB JOURNAL			English	Article						extracellular matrix; cytokines; PI3-K	NF-KAPPA-B; BASEMENT-MEMBRANE; IN-VITRO; PHOSPHATIDYLINOSITOL 3-KINASE; EXTRACELLULAR-MATRIX; CELL-PROLIFERATION; PANCREATIC-ISLETS; GAMMA-2 CHAIN; BETA-CELLS; INTERLEUKIN-1	Laminin-332 (LN-332) is a basement membrane component known to exert a beneficial effect on rat pancreatic beta cells in vitro. In this work, we analyzed the expression of LN-332 in human islets, its expression after inflammatory insults by cytokines, and the molecular mechanisms responsible for this effect. By Western blotting and RT-PCR, we showed that LN-332 was expressed in isolated human islets. By immunofluorescence on pancreas sections, we observed that labeling was confined to endocrine cells in islets. Confocal microscopy analysis on isolated islet cells revealed that labeling was granular but did not colocalize with hormone secretory granules. LN-332 was most abundant in cultured islets compared to freshly isolated islets and was found in culture medium, which suggests that it was secreted by islets. When islets were exposed to interleukin (IL)-1 beta, expression and secretion of LN-332 increased as compared to control. No effect was observed with tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma. LY294002, an inhibitor of phosphatidylinositol 3-kinase (PI3-K) activity, inhibited culture- and IL-1 beta-induced LN-332 expression in islets. These results show that LN-332, known to have some beneficial effect on beta cells in vitro, is produced and secreted by endocrine islet cells and is up-regulated by stressing conditions such as culture and IL-1 beta-exposure.-Armanet, M., Wojtusciszyn, A., Morel, P., Parnaud, G., Rousselle, P., Sinigaglia, C., Berney, T., Bosco, D. Regulated laminin-332 expression in human islets of Langerhans. FASEB J. 23, 4046-4055 (2009). www.fasebj.org	[Armanet, Mathieu; Wojtusciszyn, Anne; Morel, Philippe; Parnaud, Geraldine; Sinigaglia, Corinne; Berney, Thierry; Bosco, Domenico] Univ Hosp Geneva, Dept Surg, Cell Isolat & Transplantat Ctr, CH-1211 Geneva 4, Switzerland; [Armanet, Mathieu; Wojtusciszyn, Anne; Morel, Philippe; Parnaud, Geraldine; Sinigaglia, Corinne; Berney, Thierry; Bosco, Domenico] Univ Geneva, Geneva, Switzerland; [Rousselle, Patricia] CNRS, Inst Biol & Chim Prot, Lyon, France; [Rousselle, Patricia] Univ Lyon 1, F-69365 Lyon, France	University of Geneva; University of Geneva; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Bosco, D (corresponding author), Univ Hosp Geneva, Dept Surg, Cell Isolat & Transplantat Ctr, CH-1211 Geneva 4, Switzerland.	domenico.bosco@unige.ch	Berney, Thierry/ABE-9450-2021; Rousselle, Patricia/J-5290-2019; Rousselle, Patricia/CAF-3915-2022	Berney, Thierry/0000-0002-4230-9378; Rousselle, Patricia/0000-0003-0275-4562; Rousselle, Patricia/0000-0003-0275-4562; Wojtusciszyn, Anne/0000-0002-9410-9909; Bosco, Domenico/0000-0003-3453-9613	Swiss National Science Foundation [3200BO-116562]; Juvenile Diabetes Research Foundation [31-2008416]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation)	This work was supported by grants from the Swiss National Science Foundation (3200BO-116562 to P. M., D. B., and T. B.) and the Juvenile Diabetes Research Foundation (31-2008416). We thank Dr. Didier Cholet and Christelle Barraclough (Genomics Platform, National Centers of Competence in Research, University of Geneva School of Medicine) as well as Florentina Naville for their excellent technical assistance.	Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Amano S, 2004, BRIT J DERMATOL, V151, P961, DOI 10.1111/j.1365-2133.2004.06175.x; Baba Y, 2008, BRIT J CANCER, V98, P974, DOI 10.1038/sj.bjc.6604252; Bachy S, 2008, J CELL PHYSIOL, V214, P238, DOI 10.1002/jcp.21184; Bosco D, 2000, DIABETES, V49, P233, DOI 10.2337/diabetes.49.2.233; Brissova M, 2005, J HISTOCHEM CYTOCHEM, V53, P1087, DOI 10.1369/jhc.5C6684.2005; Bucher P, 2005, TRANSPLANTATION, V79, P91, DOI 10.1097/01.TP.0000147344.73915.C8; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Cahill CM, 2008, J BIOL CHEM, V283, P25900, DOI 10.1074/jbc.M707692200; Christiano AM, 1996, J INVEST DERMATOL, V106, P775, DOI 10.1111/1523-1747.ep12346246; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Diem R, 2003, MOL CELL NEUROSCI, V22, P487, DOI 10.1016/S1044-7431(02)00042-8; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; EIZIRIK DL, 1991, AUTOIMMUNITY, V10, P107, DOI 10.3109/08916939109004814; Ekblom P, 1996, CURR OPIN CELL BIOL, V8, P700, DOI 10.1016/S0955-0674(96)80112-8; Francoeur C, 2004, AM J PHYSIOL-GASTR L, V287, pG592, DOI 10.1152/ajpgi.00535.2003; Gentilini D, 2007, MOL HUM REPROD, V13, P317, DOI 10.1093/molehr/gam001; Ghosh S, 2000, MICROSC RES TECHNIQ, V51, P238, DOI 10.1002/1097-0029(20001101)51:3<238::AID-JEMT4>3.0.CO;2-3; Giannelli G, 2001, CLIN EXP METASTAS, V18, P439; Giannoukakis N, 2000, J BIOL CHEM, V275, P36509, DOI 10.1074/jbc.M005943200; Grassi M, 1999, J CELL SCI, V112, P2511; Hallmann R, 2005, PHYSIOL REV, V85, P979, DOI 10.1152/physrev.00014.2004; Hammar E, 2004, DIABETES, V53, P2034, DOI 10.2337/diabetes.53.8.2034; Henson ES, 2006, CELL SIGNAL, V18, P2089, DOI 10.1016/j.cellsig.2006.05.015; Hoorens A, 2001, DIABETES, V50, P551, DOI 10.2337/diabetes.50.3.551; Johansson M, 2006, ENDOCRINOLOGY, V147, P2315, DOI 10.1210/en.2005-0997; Kantengwa S, 1997, EXP CELL RES, V237, P394, DOI 10.1006/excr.1997.3803; Kariya Y, 2004, EXP CELL RES, V297, P508, DOI 10.1016/j.yexcr.2004.03.044; Kingsley K, 2002, BIOCHEM BIOPH RES CO, V294, P1017, DOI 10.1016/S0006-291X(02)00592-2; Kingsley K, 2002, BIOCHEM BIOPH RES CO, V293, P1000, DOI 10.1016/S0006-291X(02)00331-5; KORANG K, 1995, FEBS LETT, V368, P556, DOI 10.1016/0014-5793(95)00740-Z; Koshikawa N, 1999, CANCER RES, V59, P5596; Koshikawa N, 2008, CANCER RES, V68, P530, DOI 10.1158/0008-5472.CAN-07-5269; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Mandrup-Poulsen T R, 2001, Ugeskr Laeger, V163, P4176; Marinkovich MP, 2007, NAT REV CANCER, V7, P370, DOI 10.1038/nrc2089; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MATSUI C, 1995, J BIOL CHEM, V270, P23496, DOI 10.1074/jbc.270.40.23496; MATSUI C, 1995, J INVEST DERMATOL, V105, P648, DOI 10.1111/1523-1747.ep12324108; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; Miyazaki K, 2006, CANCER SCI, V97, P91, DOI 10.1111/j.1349-7006.2006.00150.x; Montolio M, 2007, J ENDOCRINOL, V192, P169, DOI 10.1677/joe.1.06968; MORITA A, 1985, BIOCHEM J, V229, P259, DOI 10.1042/bj2290259; Nikolova G, 2006, DEV CELL, V10, P397, DOI 10.1016/j.devcel.2006.01.015; Ogawa T, 2007, MOL BIOL CELL, V18, P1621, DOI 10.1091/mbc.E06-09-0806; Parnaud G, 2008, DIABETOLOGIA, V51, P91, DOI 10.1007/s00125-007-0855-1; Parnaud G, 2006, DIABETES, V55, P1413, DOI 10.2337/db05-1388; PETERS BP, 1985, J BIOL CHEM, V260, P4732; Pousset F, 2000, EUR CYTOKINE NETW, V11, P427; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Remy L, 2006, CANCER RES, V66, P11228, DOI 10.1158/0008-5472.CAN-06-1187; Ribaux P, 2007, ENDOCRINOLOGY, V148, P5582, DOI 10.1210/en.2007-0325; Roggia C, 2007, EXP CELL RES, V313, P921, DOI 10.1016/j.yexcr.2006.12.009; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Salo T, 1999, J ORAL PATHOL MED, V28, P337; Schenk S, 2003, TRENDS CELL BIOL, V13, P366, DOI 10.1016/S0962-8924(03)00129-6; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Steer SA, 2006, PLOS MED, V3, P253, DOI 10.1371/journal.pmed.0030017; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Virtanen I, 2008, DIABETOLOGIA, V51, P1181, DOI 10.1007/s00125-008-0997-9; Yamaoka T, 1999, INT J MOL MED, V3, P247; Yao K, 2008, OPHTHALMIC RES, V40, P69, DOI 10.1159/000113884	64	16	17	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4046	4055		10.1096/fj.08-127142	http://dx.doi.org/10.1096/fj.08-127142			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19667121				2022-12-28	WOS:000272193700002
J	Salem, MMAEL; Shalbaf, M; Gibbons, NCJ; Chavan, B; Thornton, JM; Schallreuter, KU				Salem, Mohamed M. A. E. L.; Shalbaf, Mohammad; Gibbons, Nicholas C. J.; Chavan, Bhaven; Thornton, J. M.; Schallreuter, Karin U.			Enhanced DNA binding capacity on up-regulated epidermal wild-type p53 in vitiligo by H2O2-mediated oxidation: a possible repair mechanism for DNA damage	FASEB JOURNAL			English	Review						peroxynitrite; catalase; 8-oxoG; p76(MDM2); cell cycle arrest; skin cancer; apoptosis	BASE-EXCISION-REPAIR; HYDROGEN-PEROXIDE H2O2; CELL-CYCLE CHECKPOINT; CATALASE GENE; INDUCED APOPTOSIS; ESCHERICHIA-COLI; COMPUTER-SIMULATION; REACTIVE OXYGEN; OGG1 GENE; IN-VIVO	Vitiligo is characterized by a patchy loss of inherited skin color affecting similar to 0.5% of individuals of all races. Despite the absence of the protecting pigment and the overwhelming evidence for hydrogen peroxide (H2O2)-induced oxidative stress in the entire epidermis of these patients, there is neither increased photodamage/skin aging nor a higher incidence for sun-induced nonmelanoma skin cancer. Here we demonstrate for the first time increased DNA damage via 8-oxoguanine in the skin and plasma in association with epidermal up-regulated phosphorylated/acetylated p53 and high levels of the p53 antagonist p76(MDM2). Short-patch base-excision repair via hOgg1, APE1, and polymerase beta DNA repair is up-regulated. Overexpression of Bcl-2 and low caspase 3 and cytochrome c levels argue against increased apoptosis in this disease. Moreover, we show the presence of high epidermal peroxynitrite (ONOO-) levels via nitrotyrosine together with high nitrated p53 levels. We demonstrate by EMSA that nitration of p53 by ONOO- (300 x 10(-6) M) abrogates DNA binding, while H2O2-oxidized p53 (10(-3) M) enhances DNA binding capacity and prevents ONOO--induced abrogation of DNA binding. Taken together, we add a novel reactive oxygen species to the list of oxidative stress inducers in vitiligo. Moreover, we propose up-regulated wild-type p53 together with p76(MDM2) as major players in the control of DNA damage/repair and prevention of photodamage and nonmelanoma skin cancer in vitiligo.-Salem, M. M. A. E. L., Shalbaf, M., Gibbons, N. C. J., Chavan, B., Thornton, J. M., Schallreuter, K. U. Enhanced DNA binding capacity on up-regulated epidermal wild-type p53 in vitiligo by H2O2-mediated oxidation: a possible repair mechanism for DNA damage. FASEB J. 23, 3790-3807 (2009). www.fasebj.org	[Salem, Mohamed M. A. E. L.; Shalbaf, Mohammad; Gibbons, Nicholas C. J.; Chavan, Bhaven; Thornton, J. M.; Schallreuter, Karin U.] Univ Bradford, Ctr Skin Sci, Sch Life Sci, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England; [Gibbons, Nicholas C. J.; Schallreuter, Karin U.] EM Arndt Univ, Inst Pigmentary Disorders, Greifswald, Germany	University of Bradford	Schallreuter, KU (corresponding author), Univ Bradford, Ctr Skin Sci, Sch Life Sci, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England.	k.schallreuter@bradford.ac.uk		Thornton, M Julie/0000-0002-3395-7066	Government of Egypt; Institute for Pigmentary Disorders; University of Bradford (Bradford, UK); Deutsche Vitiligo-Verein (Hamburg, Germany); American Vitiligo Research Foundation	Government of Egypt; Institute for Pigmentary Disorders; University of Bradford (Bradford, UK); Deutsche Vitiligo-Verein (Hamburg, Germany); American Vitiligo Research Foundation	This research is part of two Ph.D. theses (M. M. A. E. L. S. 2009; M. S. 2009). The work was supported by a stipend from the Government of Egypt and by the Institute for Pigmentary Disorders in association with E. M. Arndt University of Greifswald (Greifswald, Germany) and the University of Bradford (Bradford, UK). We are also very grateful for financial support by the Deutsche Vitiligo-Verein (Hamburg, Germany) and the American Vitiligo Research Foundation.	Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; ARONOFF S, 1965, SCIENCE, V150, P72, DOI 10.1126/science.150.3692.72; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BHAWAN J, 1983, J CUTAN PATHOL, V10, P207, DOI 10.1111/j.1600-0560.1983.tb00328.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Boissy RE, 1997, PIGM CELL RES, V10, P12, DOI 10.1111/j.1600-0749.1997.tb00461.x; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; BOITEUX S, 1993, J PHOTOCH PHOTOBIO B, V19, P87, DOI 10.1016/1011-1344(93)87101-R; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CALANCHINIPOSTIZZI E, 1987, DERMATOLOGICA, V174, P266, DOI 10.1159/000249197; Calmels S, 1997, CANCER RES, V57, P3365; Casp CB, 2002, PIGM CELL RES, V15, P62, DOI 10.1034/j.1600-0749.2002.00057.x; Chaudhry MA, 2007, CANCER CELL INT, V7, DOI 10.1186/1475-2867-7-15; Chazotte-Aubert L, 2000, BIOCHEM BIOPH RES CO, V267, P609, DOI 10.1006/bbrc.1999.2003; Cobbs CS, 2001, ARCH BIOCHEM BIOPHYS, V394, P167, DOI 10.1006/abbi.2001.2540; Cobbs CS, 2003, CANCER RES, V63, P8670; Crow JP, 1996, METHOD ENZYMOL, V269, P185; David SS, 2007, NATURE, V447, P941, DOI 10.1038/nature05978; Dell'Anna ML, 2003, PIGM CELL RES, V16, P553, DOI 10.1034/j.1600-0749.2003.00087.x; DELLANNA ML, 2006, J INVEST DERMATOL S3, V126; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elwary SMA, 2006, J INVEST DERMATOL, V126, P1879, DOI 10.1038/sj.jid.5700268; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Fortini P, 2003, MUTAT RES-FUND MOL M, V531, P127, DOI 10.1016/j.mrfmmm.2003.07.004; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Fromme JC, 2004, ADV PROTEIN CHEM, V69, P1; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gavalas NG, 2006, BIOCHEM BIOPH RES CO, V345, P1586, DOI 10.1016/j.bbrc.2006.05.063; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gibbons NQ, 2006, J INVEST DERMATOL, V126, P2576, DOI 10.1038/sj.jid.5700612; Gottifredi V, 2001, SCIENCE, V292, P1851, DOI 10.1126/science.1062238; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Halliwell B, 2002, ANN NY ACAD SCI, V962, P182, DOI 10.1111/j.1749-6632.2002.tb04067.x; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hasse S, 2004, J INVEST DERMATOL, V122, P307, DOI 10.1046/j.0022-202X.2004.22230.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HILLAR A, 1994, BIOCHEM J, V300, P531, DOI 10.1042/bj3000531; Huang Carol L, 2002, Am J Clin Dermatol, V3, P301, DOI 10.2165/00128071-200203050-00001; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito A, 2001, J BIOSCI BIOENG, V92, P598, DOI 10.1263/jbb.92.598; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Kasai H, 2002, FREE RADICAL BIO MED, V33, P450, DOI 10.1016/S0891-5849(02)00818-3; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Kemp EH, 2001, AUTOIMMUNITY, V34, P65, DOI 10.3109/08916930108994127; KIISTALA U, 1968, J INVEST DERMATOL, V50, P129, DOI 10.1038/jid.1968.15; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lee M, 2001, FREE RADICAL BIO MED, V31, P1550, DOI 10.1016/S0891-5849(01)00633-5; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; LIU JH, 1999, PROGR ASIAN SOCIAL P, V2, P9; LOFT S, 1993, J TOXICOL ENV HEALTH, V40, P391, DOI 10.1080/15287399309531806; Maeda T, 2002, J INVEST DERMATOL, V119, P22, DOI 10.1046/j.1523-1747.2002.01781.x; Maresca V, 1997, J INVEST DERMATOL, V109, P310, DOI 10.1111/1523-1747.ep12335801; Maresca V, 2006, J INVEST DERMATOL, V126, P182, DOI 10.1038/sj.jid.5700021; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; MESSMER UK, 1994, FEBS LETT, V355, P23; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MOELLMANN G, 1982, J INVEST DERMATOL, V79, P321, DOI 10.1111/1523-1747.ep12500086; Moretti S, 2002, PIGM CELL RES, V15, P87, DOI 10.1034/j.1600-0749.2002.1o049.x; OBERPRIELER NG, 2007, THESIS U BRADFORD BR; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Parikh SS, 1997, STRUCTURE, V5, P1543, DOI 10.1016/S0969-2126(97)00303-1; Park ES, 2007, J DERMATOL SCI, V47, P141, DOI 10.1016/j.jdermsci.2007.03.009; Park HH, 2006, EXP DERMATOL, V15, P377, DOI 10.1111/j.0906-6705.2006.00423.x; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Perra MT, 2006, MOL VIS, V12, P1136; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Ruiz-Argueelles A, 2007, J AUTOIMMUN, V29, P281, DOI 10.1016/j.jaut.2007.07.012; Saitoh T, 2001, MUTAT RES-DNA REPAIR, V486, P31, DOI 10.1016/S0921-8777(01)00078-7; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SALEM MMA, 2009, THESIS U BRADFORD BR; Schallreuter KU, 2008, EXP DERMATOL, V17, P139, DOI [10.1111/j.1600-0625.2007.00666_1.x, 10.1111/j.1600-0625.2007.00666.x]; Schallreuter KU, 2006, J INVEST DERMATOL, V126, P1036, DOI 10.1038/sj.jid.5700257; SCHALLREUTER KU, 1991, J INVEST DERMATOL, V97, P1081, DOI 10.1111/1523-1747.ep12492612; Schallreuter KU, 1999, J INVEST DERM SYMP P, V4, P91, DOI 10.1038/sj.jidsp.5640189; Schallreuter KU, 2004, BIOCHEM BIOPH RES CO, V315, P502, DOI 10.1016/j.bbrc.2004.01.082; Schallreuter KU, 2003, EXP DERMATOL, V12, P268, DOI 10.1034/j.1600-0625.2003.00084.x; Schallreuter KU, 2002, DERMATOLOGY, V204, P194, DOI 10.1159/000057881; Schallreuter KU, 2001, J INVEST DERMATOL, V116, P167, DOI 10.1046/j.1523-1747.2001.00220.x; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Shalbaf M, 2008, EXP DERMATOL, V17, P761, DOI 10.1111/j.1600-0625.2008.00697.x; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2008, TRENDS ENDOCRIN MET, V19, P17, DOI 10.1016/j.tem.2007.10.007; Song XZ, 2008, INT J MOL MED, V22, P9; Spencer JD, 2005, J ENDOCRINOL, V187, P293, DOI 10.1677/joe.1.06275; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tobin DJ, 2000, J PATHOL, V191, P407; Ullrich R, 2007, CELL MOL LIFE SCI, V64, P271, DOI 10.1007/s00018-007-6362-1; Van den Wijngaard RMJGJ, 2000, BRIT J DERMATOL, V143, P573, DOI 10.1046/j.1365-2133.2000.03712.x; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Vile GF, 1997, FEBS LETT, V412, P70, DOI 10.1016/S0014-5793(97)00748-5; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Westerhof W, 1997, CLIN EXP DERMATOL, V22, P54; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Wood JM, 2009, FASEB J, V23, P2065, DOI 10.1096/fj.08-125435; Wood JM, 2008, EXP DERMATOL, V17, P366, DOI 10.1111/j.1600-0625.2008.00699.x; Wood JM, 2006, J INVEST DERMATOL, V126, P13, DOI 10.1038/sj.jid.5700051; Wu LL, 2004, CLIN CHIM ACTA, V339, P1, DOI 10.1016/j.cccn.2003.09.010; Zhan QM, 2005, MUTAT RES-FUND MOL M, V569, P133, DOI 10.1016/j.mrfmmm.2004.06.055	115	59	62	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3790	3807		10.1096/fj.09-132621	http://dx.doi.org/10.1096/fj.09-132621			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19641144				2022-12-28	WOS:000271272500016
J	Xu, CF; Zhang, YHH; Thangavel, M; Richardson, MM; Liu, L; Zhou, B; Zheng, Y; Ostrom, RS; Zhang, XA				Xu, Congfeng; Zhang, Yanhui H.; Thangavel, Muthusamy; Richardson, Mekel M.; Liu, Li; Zhou, Bin; Zheng, Yi; Ostrom, Rennolds S.; Zhang, Xin A.			CD82 endocytosis and cholesterol-dependent reorganization of tetraspanin webs and lipid rafts	FASEB JOURNAL			English	Article						cell migration; membrane microdomain; protein trafficking; sterol lipid	CLATHRIN-INDEPENDENT ENDOCYTOSIS; METASTASIS SUPPRESSOR KAI1/CD82; MEDIATED ENDOCYTOSIS; EXTRACELLULAR DOMAIN; ORGANELLE IDENTITY; MEMBRANE DOMAINS; PROSTATE-CANCER; PROTEINS; RECEPTOR; SUPERFAMILY	Tetraspanin CD82 suppresses cell migration, tumor invasion, and tumor metastasis. To determine the mechanism by which CD82 inhibits motility, most studies have focused on the cell surface CD82, which forms tetraspanin-enriched microdomains (TEMs) with other transmembrane proteins, such as integrins. In this study, we found that CD82 undergoes endocytosis and traffics to endosomes and lysosomes. To determine the endocytic mechanism of CD82, we demonstrated that dynamin and clathrin are not essential for CD82 internalization. Depletion or sequestration of sterol in the plasma membrane markedly inhibited the endocytosis of CD82. Despite the demand on Cdc42 activity, CD82 endocytosis is distinct from macropinocytosis and the documented dynamin-independent pinocytosis. As a TEM component, CD82 reorganizes TEMs and lipid rafts by redistributing cholesterol into these membrane microdomains. CD82-containing TEMs are characterized by the cholesterol-containing microdomains in the extreme light- and intermediate-density fractions. Moreover, the endocytosis of CD82 appears to alleviate CD82-mediated inhibition of cell migration. Taken together, our studies demonstrate that lipid-dependent endocytosis drives CD82 trafficking to late endosomes and lysosomes, and CD82 reorganizes TEMs and lipid rafts through redistribution of cholesterol.-Xu, C., Zhang, Y. H., Thangavel, M., Richardson, M. M., Liu, L., Zhou, B., Zheng, Y., Ostrom, R. S., Zhang, X. A. CD82 endocytosis and cholesterol-dependent reorganization of tetraspanin webs and lipid rafts. FASEB J. 23, 3273-3288 (2009). www.fasebj.org	[Xu, Congfeng; Zhang, Yanhui H.; Richardson, Mekel M.; Liu, Li; Zhou, Bin; Zhang, Xin A.] Univ Tennessee, Hlth Sci Ctr, Vasc Biol Ctr, Memphis, TN 38163 USA; [Xu, Congfeng; Zhang, Yanhui H.; Richardson, Mekel M.; Liu, Li; Zhou, Bin; Zhang, Xin A.] Univ Tennessee, Hlth Sci Ctr, Ctr Canc, Memphis, TN 38163 USA; [Xu, Congfeng; Zhang, Yanhui H.; Richardson, Mekel M.; Liu, Li; Zhou, Bin; Zhang, Xin A.] Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38163 USA; [Xu, Congfeng; Zhang, Yanhui H.; Richardson, Mekel M.; Liu, Li; Zhou, Bin; Zhang, Xin A.] Univ Tennessee, Hlth Sci Ctr, Dept Mol Sci, Memphis, TN 38163 USA; [Thangavel, Muthusamy; Ostrom, Rennolds S.] Univ Tennessee, Hlth Sci Ctr, Dept Pharmacol, Memphis, TN 38163 USA; [Zheng, Yi] Cincinnati Childrens Hosp, Div Expt Hematol, Cincinnati, OH USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Zhang, XA (corresponding author), Univ Tennessee, Hlth Sci Ctr, Vasc Biol Ctr, Coleman Bldg,Room H300,956 Court Ave, Memphis, TN 38163 USA.	xazhang@utmem.edu	Ostrom, Rennolds/AAG-9694-2019; Zheng, Yi/J-7235-2015; Xu, Congfeng/E-4806-2013	Ostrom, Rennolds/0000-0002-7204-0357; Zheng, Yi/0000-0001-7089-6074; Xu, Congfeng/0000-0002-8009-4865; Zhang, Yanhui/0000-0001-8277-8008	National Institutes of Health [CA-96991]; Department of Defense [W81XWH-04-1-0156]; NATIONAL CANCER INSTITUTE [R01CA096991] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Drs. Lisa Jennings and David Armbruster for constructive suggestions and critical review of the manuscript. We especially thank all the colleagues who provided the antibodies and constructs used in this study. This work was supported by National Institutes of Health research grant CA-96991 and Department of Defense research grant W81XWH-04-1-0156 ( to X.A.Z.).	Arnaoutova I, 2003, MOL BIOL CELL, V14, P4448, DOI 10.1091/mbc.E02-11-0758; Behnia R, 2005, NATURE, V438, P597, DOI 10.1038/nature04397; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; Berditchevski F, 2001, J CELL SCI, V114, P4143; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Boesze-Battaglia K, 2002, J BIOL CHEM, V277, P41843, DOI 10.1074/jbc.M207111200; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Charrin S, 2003, EUR J IMMUNOL, V33, P2479, DOI 10.1002/eji.200323884; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Damm EM, 2005, J CELL BIOL, V168, P477, DOI 10.1083/jcb.200407113; Delaguillaumie A, 2004, J CELL SCI, V117, P5269, DOI 10.1242/jcs.01380; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Glebov OO, 2006, NAT CELL BIOL, V8, P46, DOI 10.1038/ncb1342; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Grassart A, 2008, EMBO REP, V9, P356, DOI 10.1038/embor.2008.28; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Guo QS, 2008, EUR J CELL BIOL, V87, P251, DOI 10.1016/j.ejcb.2007.11.004; Hammond C, 1998, J IMMUNOL, V161, P3282; He B, 2005, J BIOL CHEM, V280, P3346, DOI 10.1074/jbc.M406680200; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Jackson P, 2005, INT J BIOCHEM CELL B, V37, P530, DOI 10.1016/j.biocel.2004.08.009; Janvier K, 2005, MOL BIOL CELL, V16, P4231, DOI 10.1091/mbc.E05-03-0213; Kirkham M, 2005, BBA-MOL CELL RES, V1746, P349, DOI 10.1016/j.bbamcr.2005.11.005; Kirkham M, 2005, J CELL BIOL, V168, P465, DOI 10.1083/jcb.200407078; Kitadokoro K, 2001, EMBO J, V20, P12, DOI 10.1093/emboj/20.1.12; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548; Lewis CM, 2000, TRAFFIC, V1, P282, DOI 10.1034/j.1600-0854.2000.010310.x; Liu WM, 2006, CANCER LETT, V240, P183, DOI 10.1016/j.canlet.2005.08.018; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Martin F, 2005, J VIROL, V79, P10839, DOI 10.1128/JVI.79.17.10839-10851.2005; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mohrmann K, 1999, MOL MEMBR BIOL, V16, P81, DOI 10.1080/096876899294797; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367; Naslavsky N, 2004, MOL BIOL CELL, V15, P3542, DOI 10.1091/mbc.E04-02-0151; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Nydegger S, 2006, J CELL BIOL, V173, P795, DOI 10.1083/jcb.200508165; Odintsova E, 2000, CURR BIOL, V10, P1009, DOI 10.1016/S0960-9822(00)00652-7; Odintsova E, 2003, J CELL SCI, V116, P4557, DOI 10.1242/jcs.00793; Odintsova E, 2006, BIOCHEM J, V400, P315, DOI 10.1042/BJ20060259; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Pelkmans L, 2005, BBA-MOL CELL RES, V1746, P295, DOI 10.1016/j.bbamcr.2005.06.009; Pelkmans L, 2004, CELL, V118, P767, DOI 10.1016/j.cell.2004.09.003; Pelkmans L, 2003, CURR OPIN CELL BIOL, V15, P414, DOI 10.1016/S0955-0674(03)00081-4; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; Rous BA, 2002, MOL BIOL CELL, V13, P1071, DOI 10.1091/mbc.01-08-0409; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Seigneuret M, 2001, J BIOL CHEM, V276, P40055, DOI 10.1074/jbc.M105557200; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Slimane TA, 2003, MOL BIOL CELL, V14, P611, DOI 10.1091/mbc.E02-08-0528; Stipp CS, 2003, TRENDS BIOCHEM SCI, V28, P106, DOI 10.1016/S0968-0004(02)00014-2; Tarrant JM, 2003, TRENDS IMMUNOL, V24, P610, DOI 10.1016/j.it.2003.09.011; Tkachenko E, 2004, J CELL SCI, V117, P3189, DOI 10.1242/jcs.01190; Todeschini AR, 2007, J BIOL CHEM, V282, P8123, DOI 10.1074/jbc.M611407200; Tonoli H, 2005, TRENDS MOL MED, V11, P563, DOI 10.1016/j.molmed.2005.10.002; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; West MA, 2000, CURR BIOL, V10, P839, DOI 10.1016/S0960-9822(00)00595-9; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang XA, 2003, CANCER RES, V63, P2665; Zhang XA, 2003, J BIOL CHEM, V278, P27319, DOI 10.1074/jbc.M303039200; Zhou B, 2004, CANCER RES, V64, P7455, DOI 10.1158/0008-5472.CAN-04-1574	78	43	44	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3273	3288		10.1096/fj.08-123414	http://dx.doi.org/10.1096/fj.08-123414			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19497983	Green Published			2022-12-28	WOS:000270354300005
J	Bromberg, Y; Overton, J; Vaisse, C; Leibel, RL; Rost, B				Bromberg, Yana; Overton, John; Vaisse, Christian; Leibel, Rudolph L.; Rost, Burkhard			In silico mutagenesis: a case study of the melanocortin 4 receptor	FASEB JOURNAL			English	Article						MC4R; MC1R; SNAP; active functional site; obesity; diabetes	AGOUTI-RELATED PROTEIN; CELL-SURFACE EXPRESSION; STRUCTURE PREDICTION; STIMULATING-HORMONE; FUNCTIONAL ANALYSES; MOLECULAR-BASIS; MUTATIONS; OBESITY; POLYMORPHISMS; SUBSTITUTION	The melanocortin 4 receptor (MC4R) is a G-protein-coupled receptor ( GPCR) and a key molecule in the regulation of energy homeostasis. At least 159 substitutions in the coding region of human MC4R (hMC4R) have been described experimentally; over 80 of those occur naturally, and many have been implicated in obesity. However, assessment of the presumably functionally essential residues remains incomplete. Here we have performed a complete in silico mutagenesis analysis to assess the functional essentiality of all possible nonnative point mutants in the entire hMC4R protein ( 332 residues). We applied SNAP, which is a method for quantifying functional consequences of single amino acid ( AA) substitutions, to calculate the effects of all possible substitutions at each position in the hMC4R AA sequence. We compiled a mutability score that reflects the degree to which a particular residue is likely to be functionally important. We performed the same experiment for a paralogue human melanocortin receptor (hMC1R) and a mouse orthologue (mMC4R) in order to compare computational evaluations of highly related sequences. Three results are most salient: 1) our predictions largely agree with the available experimental annotations; 2) this analysis identified several AAs that are likely to be functionally critical, but have not yet been studied experimentally; and 3) the differential analysis of the receptors implicates a number of residues as specifically important to MC4Rs vs. other GPCRs, such as hMC1R.-Bromberg, Y., Overton, J., Vaisse, C., Leibel, R. L., Rost, B. In silico mutagenesis: a case study of the melanocortin 4 receptor. FASEB J. 23, 3059-3069 ( 2009). www.fasebj.org	[Bromberg, Yana; Rost, Burkhard] Columbia Univ, Ctr Computat Biol & Bioinformat, New York, NY 10032 USA; [Bromberg, Yana; Rost, Burkhard] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; [Overton, John; Leibel, Rudolph L.] Columbia Univ, Div Mol Genet, Naomi Berrie Diabet Ctr, New York, NY 10032 USA; [Rost, Burkhard] Columbia Univ, NE Struct Genom Consortium, New York, NY 10032 USA; [Rost, Burkhard] Columbia Univ, New York Consortium Membrane Prot Struct, New York, NY 10032 USA; [Vaisse, Christian] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; [Vaisse, Christian] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bromberg, Y (corresponding author), Columbia Univ, Ctr Computat Biol & Bioinformat, 1130 St Nicholas Ave,Room 802, New York, NY 10032 USA.	bromberg@rostlab.org	Bromberg, Yana/AAA-7801-2020; Rost, Burkhard/A-1908-2016; Vaisse, Christian/F-1067-2011	Bromberg, Yana/0000-0002-8351-0844; Rost, Burkhard/0000-0003-0179-8424; 	National Library of Medicine [R01-LM07329-01]; National Institutes of Health (NIH) [RO1-DK52431-15, RO1-DK60540, RO1-DK068152]; American Heart Association's Established Investigator Award; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060540, R01DK052431, R01DK068152] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM007329] Funding Source: NIH RePORTER	National Library of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association's Established Investigator Award(American Heart Association); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank Cedric Govaerts ( University of California, San Francisco) for providing us with an annotated data set of hMC4R variants and Guy Yachdav ( Columbia University) for help with maintenance of the SNAP web server. We also thank all those who deposit their experimental results into public databases. The work of Y.B. and B. R. was supported by grant R01-LM07329-01 from the National Library of Medicine; that of J.D.O. and R. L. L. by National Institutes of Health (NIH) grant RO1-DK52431-15; and that of C. V. by NIH grants RO1-DK60540 and RO1-DK068152 and by the American Heart Association's Established Investigator Award.	Adan RAH, 2003, TRENDS PHARMACOL SCI, V24, P315, DOI 10.1016/S0165-6147(03)00130-5; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Bromberg Y, 2008, BIOINFORMATICS, V24, P2397, DOI 10.1093/bioinformatics/btn435; Bromberg Y, 2008, BIOINFORMATICS, V24, pI207, DOI 10.1093/bioinformatics/btn268; Bromberg Y, 2007, NUCLEIC ACIDS RES, V35, P3823, DOI 10.1093/nar/gkm238; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; Calton MA, 2009, HUM MOL GENET, V18, P1140, DOI 10.1093/hmg/ddn431; Carroll L, 2005, PEPTIDES, V26, P1871, DOI 10.1016/j.peptides.2004.12.031; Chai BX, 2005, BIOCHEMISTRY-US, V44, P3418, DOI 10.1021/bi0478704; Chai BX, 2003, PEPTIDES, V24, P603, DOI 10.1016/S0196-9781(03)00104-9; Chen M, 2007, J BIOL CHEM, V282, P21712, DOI 10.1074/jbc.M702285200; Chen M, 2006, REGUL PEPTIDES, V136, P40, DOI 10.1016/j.regpep.2006.04.010; Dinulescu DM, 2000, J BIOL CHEM, V275, P6695, DOI 10.1074/jbc.275.10.6695; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; Farooqi IS, 2003, NEW ENGL J MED, V348, P1085, DOI 10.1056/NEJMoa022050; Frandberg PA, 2001, BIOCHEM BIOPH RES CO, V281, P851, DOI 10.1006/bbrc.2001.4429; Geller F, 2004, AM J HUM GENET, V74, P572, DOI 10.1086/382490; Govaerts C, 2005, PEPTIDES, V26, P1909, DOI 10.1016/j.peptides.2004.11.042; Haskell-Luevano C, 2001, BIOCHEMISTRY-US, V40, P6164, DOI 10.1021/bi010025q; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kawabata T, 1999, NUCLEIC ACIDS RES, V27, P355, DOI 10.1093/nar/27.1.355; Kim DH, 2008, BIOCHEM BIOPH RES CO, V365, P439, DOI 10.1016/j.bbrc.2007.10.170; Kishi T, 2003, J COMP NEUROL, V457, P213, DOI 10.1002/cne.10454; Kopp J, 2004, PHARMACOGENOMICS, V5, P405, DOI 10.1517/14622416.5.4.405; Larsen LH, 2005, J CLIN ENDOCR METAB, V90, P219, DOI 10.1210/jc.2004-0497; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Lubrano-Berthelier C, 2004, J CLIN ENDOCR METAB, V89, P2028, DOI 10.1210/jc.2003-031993; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Mossner R, 2007, ARCH DERMATOL RES, V298, P371, DOI 10.1007/s00403-006-0708-7; Mohammad S, 2007, J BIOL CHEM, V282, P4963, DOI [10.1074/jbc.m608283200, 10.1074/jbc.M608283200]; Moult J, 2007, PROTEINS, V69, P3, DOI 10.1002/prot.21767; Newman EA, 2006, J SURG RES, V132, P201, DOI 10.1016/j.jss.2006.02.003; Ng PC, 2000, BIOINFORMATICS, V16, P760, DOI 10.1093/bioinformatics/16.9.760; Nickolls SA, 2003, J PHARMACOL EXP THER, V304, P1217, DOI 10.1124/jpet.102.044974; Nijenhuis WAJ, 2003, J BIOL CHEM, V278, P22939, DOI 10.1074/jbc.M211326200; Ofran Y, 2005, DRUG DISCOV TODAY, V10, P1475, DOI 10.1016/S1359-6446(05)03621-4; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Patten CS, 2007, REGUL PEPTIDES, V142, P111, DOI 10.1016/j.regpep.2007.02.005; Punta M, 2007, METHODS, V41, P460, DOI 10.1016/j.ymeth.2006.07.026; Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325; Rost B, 1999, PROTEIN ENG, V12, P85, DOI 10.1093/protein/12.2.85; Schioth HB, 2005, ANN NY ACAD SCI, V1040, P460, DOI 10.1196/annals.1327.090; Srinivasan S, 2004, J CLIN INVEST, V114, P1158, DOI 10.1172/JCI200421927; Tan K, 2009, ENDOCRINOLOGY, V150, P114, DOI 10.1210/en.2008-0721; Tao YX, 2006, PHARMACOL THERAPEUT, V111, P949, DOI 10.1016/j.pharmthera.2006.02.008; Tao YX, 2005, J CLIN ENDOCR METAB, V90, P5632, DOI 10.1210/jc.2005-0519; Tao YX, 2005, MOL CELL ENDOCRINOL, V239, P1, DOI 10.1016/j.mce.2005.04.012; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VanLeeuwen D, 2003, J BIOL CHEM, V278, P15935, DOI 10.1074/jbc.M211546200; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wachira SJ, 2003, NEUROPEPTIDES, V37, P201, DOI 10.1016/S0143-4179(03)00026-X; Xiang ZM, 2006, BIOCHEMISTRY-US, V45, P7277, DOI 10.1021/bi0600300; Yamano Y, 2004, BIOSCI BIOTECH BIOCH, V68, P1369, DOI 10.1271/bbb.68.1369; Yang Y, 2003, MOL PHARMACOL, V64, P94, DOI 10.1124/mol.64.1.94; Yang YK, 1997, J BIOL CHEM, V272, P23000, DOI 10.1074/jbc.272.37.23000	57	32	34	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3059	3069		10.1096/fj.08-127530	http://dx.doi.org/10.1096/fj.08-127530			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19417090	Green Published			2022-12-28	WOS:000270241000028
J	Ortiz-Munoz, G; Houard, X; Martin-Ventura, JL; Ishida, BY; Loyau, S; Rossignol, P; Moreno, JA; Kane, JP; Chalkley, RJ; Burlingame, AL; Michel, JB; Meilhac, O				Ortiz-Munoz, Guadalupe; Houard, Xavier; Martin-Ventura, Jose-Luis; Ishida, Brian Y.; Loyau, Stephane; Rossignol, Patrick; Moreno, Juan-Antonio; Kane, John P.; Chalkley, Robert J.; Burlingame, Alma L.; Michel, Jean-Baptiste; Meilhac, Olivier			HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property	FASEB JOURNAL			English	Article							HIGH-DENSITY-LIPOPROTEINS; APOLIPOPROTEIN-A-I; 2-DIMENSIONAL GEL-ELECTROPHORESIS; ABDOMINAL AORTIC-ANEURYSMS; MASS-SPECTROMETRY; INTRAPLAQUE HEMORRHAGE; NEUTROPHIL ELASTASE; EDINBURGH ARTERY; MURAL THROMBUS; ACTIVATION	Various studies using proteomic approaches have shown that HDL can carry many proteins other than its constitutive apolipoprotein A-I (apoA-I). Using mass spectrometry and Western blotting, we showed the presence of alpha(1)-antitrypsin (AAT) (SERPINA1, serpin peptidase inhibitor, clade A, an elastase inhibitor) in HDL, isolated either by ultracentrifugation or by selected-affinity immunosorption using an anti-apoA-I column. Furthermore, we report that HDL possesses potent antielastase activity. We further showed that only HDL but not LDL is able to bind AAT. HDL-associated AAT was able to inhibit extracellular matrix degradation, cell detachment, and apoptosis induced by elastase in human vascular smooth muscle cells (VSMCs) and in mammary artery cultured ex vivo. Degradation of fibronectin by elastase used as a marker of pericellular proteolysis was prevented by addition of HDL. Elastase present in aortic abdominal aneurysm ( AAA) thrombus samples was also able to induce apoptosis of VSMCs in culture. This phenomenon was prevented by addition of HDL but not of LDL. Finally, we report that the proportion of AAT in HDL isolated from patients with an AAA is decreased relative to that from matched control subjects, suggesting a reduced capacity of HDL to inhibit elastase in these patients. In conclusion, our data provide evidence of a new potential antiatherogenic property of HDL attributable to AAT and its antielastase activity.-Ortiz-Munoz, G., Houard, X., Martin-Ventura, J.-L., Ishida, B. Y., Loyau, S., Rossignol, P., Moreno, J.-A., Kane, J. P., Chalkley, R. J., Burlingame, A. L., Michel, J.-B., Meilhac, O. High-density lipoprotein antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J. 23, 3129-3139 (2009). www.fasebj.org	[Ortiz-Munoz, Guadalupe; Houard, Xavier; Martin-Ventura, Jose-Luis; Loyau, Stephane; Moreno, Juan-Antonio; Michel, Jean-Baptiste; Meilhac, Olivier] Hop X Bichat, INSERM, U698, F-75877 Paris 18, France; [Ortiz-Munoz, Guadalupe; Houard, Xavier; Martin-Ventura, Jose-Luis; Loyau, Stephane; Moreno, Juan-Antonio; Michel, Jean-Baptiste; Meilhac, Olivier] Univ Paris 07, Paris, France; [Ortiz-Munoz, Guadalupe; Houard, Xavier; Martin-Ventura, Jose-Luis; Loyau, Stephane; Moreno, Juan-Antonio; Michel, Jean-Baptiste; Meilhac, Olivier] Ctr Hosp Univ X Bichat, Paris, France; [Ishida, Brian Y.; Kane, John P.; Chalkley, Robert J.; Burlingame, Alma L.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Rossignol, Patrick] Hop Jeanne Darc, Ctr Hosp Univ Nancy, Dommartin Les Toul, France; [Rossignol, Patrick] Ctr Invest Clin Nancy CIC P 9501, INSERM, Dommartin Les Toul, France; [Rossignol, Patrick] Nancy Univ, Fac Med, Vandoeuvre Les Nancy, France; [Rossignol, Patrick] INSERM, U961, F-54511 Vandoeuvre Les Nancy, France; [Rossignol, Patrick] Hop Europeen Georges Pompidou, Serv Med Vasc & Hypertens Arterielle, AP HP, Paris, France; [Rossignol, Patrick] Hop Europeen Georges Pompidou, Ctr Invest Clin, AP HP, Paris, France; [Rossignol, Patrick] Fac Med Rene Descartes Paris 5, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; University of California System; University of California San Francisco; CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Meilhac, O (corresponding author), Hop X Bichat, INSERM, U698, 46,Rue Henri Huchard, F-75877 Paris 18, France.	olivier.meilhac@inserm.fr	munoz, guadalupe ortiz/B-4969-2019; Michel, Jean-Baptiste/AAH-9336-2020; MARTIN-VENTURA, JOSE LUIS/Z-2386-2019; Meilhac, Olivier/N-4385-2017; Moreno, Juan Antonio/B-3487-2018	munoz, guadalupe ortiz/0000-0002-8928-0576; Moreno, Juan Antonio/0000-0002-7468-2871; MARTIN-VENTURA, JOSE LUIS/0000-0003-2090-8641; Loyau, stephane/0000-0001-8748-501X; Chalkley, Robert/0000-0002-9757-7302; Meilhac, Olivier/0000-0002-3740-7539	Leducq Foundation; European Community FAD [200647]; National Institutes of Health National Center for Research Resources [RR01614]; Fondation Lefoulon-Delalande; Fondation pour la Recherche Medicale; Fondation de France, Region Lorraine; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER	Leducq Foundation(Leducq Foundation); European Community FAD; National Institutes of Health National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Fondation Lefoulon-Delalande; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Fondation de France, Region Lorraine(Fondation de FranceRegion Grand-Est); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This research was supported by the Leducq Foundation, the European Community FAD project (FP-7, 200647), and National Institutes of Health National Center for Research Resources grant RR01614. X. H. was supported by a grant from the Fondation Lefoulon-Delalande. The RESAA study was promoted by Assistance Publique-Hopitaux de Paris, whereas the AMETHYST cohort is promoted by INSERM and supported by the Fondation pour la Recherche Medicale and the Fondation de France, Region Lorraine. We thank P. Julia, M. Sapoval, and D. Mouradian for help in recruiting patients for AMETHYST (Hopital Europeen Georges Pompidou, Paris, France), P. Julia for technical help ( RESAA operative samples), and Michel Azizi and D. Mouradian for enrollment of healthy volunteers (Hopital Europeen Georges Pompidou-INSERM Clinical Investigation Centre, Paris, France). We also thank Dr. Mary Osborne-Pellegrin for editing this article.	Aldonyte R, 2008, COPD, V5, P153, DOI 10.1080/15412550802092936; Asztalos BF, 2000, ARTERIOSCL THROM VAS, V20, P2670, DOI 10.1161/01.ATV.20.12.2670; Barter P, 2003, ATHEROSCLEROSIS, V168, P195, DOI 10.1016/S0021-9150(03)00006-6; BIHARIVARGA M, 1984, ATHEROSCLEROSIS, V50, P273, DOI 10.1016/0021-9150(84)90075-3; Bonnefoy A, 2000, THROMB RES, V98, P323, DOI 10.1016/S0049-3848(99)00242-X; Caligiuri G, 2006, ARTERIOSCL THROM VAS, V26, P618, DOI 10.1161/01.ATV.0000200380.73876.d9; CHEUNG MC, 1988, J LIPID RES, V29, P15; Cohen J R, 1991, J Invest Surg, V4, P423, DOI 10.3109/08941939109141172; Dollery CM, 2003, CIRCULATION, V107, P2829, DOI 10.1161/01.CIR.0000072792.65250.4A; Elias JE, 2007, NAT METHODS, V4, P207, DOI 10.1038/nmeth1019; Fontaine V, 2004, AM J PATHOL, V164, P2077, DOI 10.1016/S0002-9440(10)63766-2; Fontaine V, 2002, AM J PATHOL, V161, P1701, DOI 10.1016/S0002-9440(10)64447-1; Frankfurt OS, 2001, J HISTOCHEM CYTOCHEM, V49, P369, DOI 10.1177/002215540104900311; GALDSTON M, 1979, AM REV RESPIR DIS, V119, P435; Gechtman Z, 1997, BIOCHEM J, V325, P339, DOI 10.1042/bj3250339; Hobbs SD, 2003, EUR J VASC ENDOVASC, V26, P618, DOI 10.1016/S1078-5884(03)00412-X; Karlsson H, 2005, PROTEOMICS, V5, P1431, DOI 10.1002/pmic.200401010; Karlsson H, 2005, PROTEOMICS, V5, P551, DOI 10.1002/pmic.200300938; Katayama H, 2003, RAPID COMMUN MASS SP, V17, P1071, DOI 10.1002/rcm.1024; Kolodgie FD, 2003, NEW ENGL J MED, V349, P2316, DOI 10.1056/NEJMoa035655; Kovanen PT, 1997, HEART VESSELS, P125; KUNITAKE ST, 1992, P NATL ACAD SCI USA, V89, P6993, DOI 10.1073/pnas.89.15.6993; Leclercq A, 2007, J LEUKOCYTE BIOL, V82, P1420, DOI 10.1189/jlb.1106671; Lindstedt L, 2001, ATHEROSCLEROSIS, V155, P87, DOI 10.1016/S0021-9150(00)00544-X; Linsel-Nitschke P, 2005, NAT REV DRUG DISCOV, V4, P193, DOI 10.1038/nrd1658; LOWE GDO, 1993, CIRCULATION, V87, P1915, DOI 10.1161/01.CIR.87.6.1915; Martin-Ventura JL, 2007, ATHEROSCLEROSIS, V194, P334, DOI 10.1016/j.atherosclerosis.2006.10.030; MCVICAR JP, 1984, P NATL ACAD SCI-BIOL, V81, P1356, DOI 10.1073/pnas.81.5.1356; Meilhac O, 2003, FASEB J, V17, P1301, DOI 10.1096/fj.02-0687fje; Michel JB, 2003, ARTERIOSCL THROM VAS, V23, P2146, DOI 10.1161/01.ATV.0000099882.52647.E4; Mtairag EM, 2002, ARTERIOSCL THROM VAS, V22, P1824, DOI 10.1161/01.ATV.0000037102.31086.F4; NORRGARD O, 1985, BRIT J SURG, V72, P113, DOI 10.1002/bjs.1800720215; Petrache I, 2006, AM J PATHOL, V169, P1155, DOI 10.2353/ajpath.2006.060058; Rossignol P, 2004, EXP CELL RES, V299, P279, DOI 10.1016/j.yexcr.2004.05.034; Simoni G, 1996, Cardiovasc Surg, V4, P445, DOI 10.1016/0967-2109(95)00140-9; Sun J, 2007, J CLIN INVEST, V117, P3359, DOI 10.1172/JCI31311; Tall AR, 2008, J INTERN MED, V263, P256, DOI 10.1111/j.1365-2796.2007.01898.x; Tzoulaki I, 2007, CIRCULATION, V115, P2119, DOI 10.1161/CIRCULATIONAHA.106.635029; Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206	39	75	80	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3129	3139		10.1096/fj.08-127928	http://dx.doi.org/10.1096/fj.08-127928			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19417089	Green Published			2022-12-28	WOS:000270241000035
J	Schneider, M; Forster, H; Boersma, A; Seiler, A; Wehnes, H; Sinowatz, F; Neumuller, C; Deutsch, MJ; Walch, A; de Angelis, MH; Wurst, W; Ursini, F; Roveri, A; Maleszewski, M; Maiorino, M; Conrad, M				Schneider, Manuela; Foerster, Heidi; Boersma, Auke; Seiler, Alexander; Wehnes, Helga; Sinowatz, Fred; Neumueller, Christine; Deutsch, Manuel J.; Walch, Axel; de Angelis, Martin Hrabe; Wurst, Wolfgang; Ursini, Fulvio; Roveri, Antonella; Maleszewski, Marek; Maiorino, Matilde; Conrad, Marcus			Mitochondrial glutathione peroxidase 4 disruption causes male infertility	FASEB JOURNAL			English	Article						PHGPx; redox metabolism; selenoprotein; spermatogenesis	FUNCTIONAL INTERACTION; SELENOPROTEIN PHGPX; SPERM MATURATION; NUCLEAR FORM; VITAMIN-E; MOUSE; INJECTION; SELENIUM; CELLS; EXPRESSION	Selenium is linked to male fertility. Glutathione peroxidase 4 (GPx4), first described as an antioxidant enzyme, is the predominant selenoenzyme in testis and has been suspected of being vital for spermatogenesis. Cytosolic, mitochondrial, and nuclear isoforms are all encoded by the same gene. While disruption of entire GPx4 causes early embryonic lethality in mice, inactivation of nuclear GPx4 does not impair embryonic development or fertility. Here, we show that deletion of mitochondrial GPx4 (mGPx4) allows both normal embryogenesis and postnatal development, but causes male infertility. Infertility was associated with impaired sperm quality and severe structural abnormalities in the midpiece of spermatozoa. Knockout sperm display higher protein thiol content and recapitulate features typical of severe selenodeficiency. Interestingly, male infertility induced by mGPx4 depletion could be bypassed by intracytoplasmic sperm injection. We also show for the first time that mGPx4 is the prevailing GPx4 product in male germ cells and that mGPx4 disruption has no effect on proliferation or apoptosis of germinal or somatic tissue. Our study finally establishes that mitochondrial GPx4 confers the vital role of selenium in mammalian male fertility and identifies cytosolic GPx4 as the only GPx4 isoform being essential for embryonic development and apoptosis regulation.-Schneider, M., Forster, H., Boersma, A., Seiler, A., Wehnes, H., Sinowatz, F., Neumuller, C., Deutsch, M. J., Walch, A., Hrabe de Angelis, M., Wurst, W., Ursini, F., Roveri, A., Maleszewski, M., Maiorino, M. Conrad, M. Mitochondrial glutathione peroxidase 4 disruption causes male infertility. FASEB J. 23, 3233-3242 ( 2009). www.fasebj.org	[Schneider, Manuela; Foerster, Heidi; Seiler, Alexander; Conrad, Marcus] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Clin Mol Biol & Tumor Genet, Neuherberg, Germany; [Boersma, Auke; de Angelis, Martin Hrabe] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Expt Genet, Neuherberg, Germany; [Wehnes, Helga; Walch, Axel] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Pathol, Neuherberg, Germany; [Deutsch, Manuel J.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Dept Gene Vectors, Neuherberg, Germany; [Wurst, Wolfgang] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Dev Genet, Neuherberg, Germany; [Sinowatz, Fred; Neumueller, Christine] Univ Munich, Dept Vet Anat 2, Munich, Germany; [Ursini, Fulvio; Roveri, Antonella; Maiorino, Matilde] Univ Padua, Dept Biol Chem, Padua, Italy; [Maleszewski, Marek] Univ Warsaw, Inst Zool, Dept Embryol, Warsaw, Poland	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Padua; University of Warsaw	Conrad, M (corresponding author), German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Clin Mol Biol & Tumor Genet, Marchioninistr 25, D-81377 Munich, Germany.	marcus.conrad@helmholtz-muenchen.de	Sinowatz, Fred/V-1575-2019; de Angelis, Martin Hrabe/F-5531-2012; Walch, Axel/B-4554-2012; Conrad, Marcus/E-8792-2015; Roveri, Antonella/AAF-3669-2019	de Angelis, Martin Hrabe/0000-0002-7898-2353; Walch, Axel/0000-0001-5578-4023; Conrad, Marcus/0000-0003-1140-5612; Roveri, Antonella/0000-0002-3252-0559; Maleszewski, Marek/0000-0002-6699-0452; Wurst, Wolfgang/0000-0003-4422-7410	Deutsche Forschungsgemeinschaft (DFG) [CO 291/2-1]; DFG-Priority Programme [SPP1087]; Italian Ministry of University and Scientific Research	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); DFG-Priority Programme(German Research Foundation (DFG)); Italian Ministry of University and Scientific Research(Ministry of Education, Universities and Research (MIUR))	The authors are most grateful to Pierluigi Mauri and Louise Benazzi at the National Research Council (CNR), Milan, Italy, for the LC ESI MS/MS analysis. This work was supported by the Deutsche Forschungsgemeinschaft (DFG) ( CO 291/2-1) to M. C., the DFG-Priority Programme SPP1087 to M. C., and the Italian Ministry of University and Scientific Research.	Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; Arai M, 1996, BIOCHEM BIOPH RES CO, V227, P433, DOI 10.1006/bbrc.1996.1525; Borchert A, 2006, J BIOL CHEM, V281, P19655, DOI 10.1074/jbc.M601195200; Conrad M, 2005, MOL CELL BIOL, V25, P7637, DOI 10.1128/MCB.25.17.7637-7644.2005; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Conrad M, 2003, BIOTECHNIQUES, V34, P1136, DOI 10.2144/03346bm03; Conrad M, 2007, BIOL CHEM, V388, P1019, DOI 10.1515/BC.2007.130; FULTON BP, 1978, NATURE, V273, P149, DOI 10.1038/273149a0; GUNN SA, 1967, P SOC EXP BIOL MED, V124, P1260; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Hurst R, 2001, FREE RADICAL BIO MED, V31, P1051, DOI 10.1016/S0891-5849(01)00685-2; JACOBSSO.SO, 1965, ACTA VET SCAND, V6, P287; KIMURA Y, 1995, BIOL REPROD, V52, P709, DOI 10.1095/biolreprod52.4.709; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Maiorino M, 1998, FASEB J, V12, P1359, DOI 10.1096/fasebj.12.13.1359; Maiorino M, 2005, J BIOL CHEM, V280, P38395, DOI 10.1074/jbc.M505983200; Maiorino M, 2003, J BIOL CHEM, V278, P34286, DOI 10.1074/jbc.M305327200; MAIORINO M, 1989, LIPIDS, V24, P721, DOI 10.1007/BF02535211; Moreno SG, 2003, BIOL CHEM, V384, P635, DOI 10.1515/BC.2003.070; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Olson GE, 2005, BIOL REPROD, V73, P201, DOI 10.1095/biolreprod.105.040360; Pfeifer H, 2001, FASEB J, V15, P1236, DOI 10.1096/fj.00-0655fje; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; QUINN P, 1985, FERTIL STERIL, V44, P493; Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005; SHALGI R, 1989, BIOL REPROD, V40, P1037, DOI 10.1095/biolreprod40.5.1037; Ufer C, 2008, GENE DEV, V22, P1838, DOI 10.1101/gad.466308; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; URSINI F, 1982, BIOCHIM BIOPHYS ACTA, V710, P197, DOI 10.1016/0005-2760(82)90150-3; WALLACE E, 1983, GAMETE RES, V4, P389; Wang HP, 2001, FREE RADICAL BIO MED, V30, P825, DOI 10.1016/S0891-5849(01)00469-5; WU SH, 1973, BIOL REPROD, V8, P625, DOI 10.1093/biolreprod/8.5.625; Yagi K, 1998, BIOCHEM BIOPH RES CO, V245, P528, DOI 10.1006/bbrc.1998.8417; Yanagimachi R, 2005, REPROD BIOMED ONLINE, V10, P247, DOI 10.1016/S1472-6483(10)60947-9; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6	35	193	203	3	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3233	3242		10.1096/fj.09-132795	http://dx.doi.org/10.1096/fj.09-132795			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19417079				2022-12-28	WOS:000270241000045
J	Wright, JA; Wang, XY; Brown, DR				Wright, Josephine A.; Wang, Xiaoyan; Brown, David R.			Unique copper-induced oligomers mediate alpha-synuclein toxicity	FASEB JOURNAL			English	Article						Parkinson's disease; cell death; Lewy bodies; metal	RAPID CELLULAR DEGENERATION; DISEASE-LINKED MUTATIONS; TARGETING A-BETA; PARKINSONS-DISEASE; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; TRANSGENIC MICE; LEWY BODIES; HUMAN-BRAIN; NEURODEGENERATIVE DISEASE	Parkinson's disease and a number of other neurodegenerative diseases have been linked to either genetic mutations in the alpha-synuclein gene or show evidence of aggregates of the alpha-synuclein protein, sometimes in the form of Lewy bodies. There currently is no clear evidence of a distinct neurotoxic species of alpha-synuclein to explain the death of neurons in these diseases. We undertook to assess the toxicity of alpha-synuclein via exogenous application in cell culture. Initially, we showed that only aggregated alpha-synuclein is neurotoxic and requires the presence copper but not iron. Other members of the synuclein family showed no toxicity in any form and inherited point mutations did not alter the effective toxic concentration of alpha-synuclein. Through protein fractionation techniques, we were able to isolate an oligomeric species responsible for the toxicity of alpha-synuclein. This oligomeric species has a unique stellate appearance under EM and again, requires association with copper to induce cell death. The results allow us to suggest that the toxic species of alpha-synuclein in vivo could possibly be these stellate oligomers and not fibrils. Our data provide a link between the recently noted association of copper and alpha-synuclein and a potential role for the combination in causing neurodegeneration.-Wright, J. A., Wang, X., Brown, D. R. Unique copper-induced oligomers mediate alpha-synuclein toxicity. FASEB J. 23, 2384-2393 (2009)	[Wright, Josephine A.; Wang, Xiaoyan; Brown, David R.] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of Bath	Brown, DR (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.	bssdrb@bath.ac.uk		Wright, Josephine/0000-0003-4588-8827	Alzheimer's Research Trust UK [ART/PPG2005B/8]; Alzheimers Research UK [ART-PPG2005B-8] Funding Source: researchfish	Alzheimer's Research Trust UK; Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK))	The authors thank Ursula Potter for her expertise in electron microscopy imaging and the Alzheimer's Research Trust UK for funding (ART/PPG2005B/8).	Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Adlard PA, 2008, NEURON, V59, P43, DOI 10.1016/j.neuron.2008.06.018; Albani D, 2004, FASEB J, V18, P1713, DOI 10.1096/fj.04-1621fje; Bharathi, 2007, BIOCHEM BIOPH RES CO, V359, P115, DOI 10.1016/j.bbrc.2007.05.060; Bhatia R, 2000, FASEB J, V14, P1233, DOI 10.1096/fasebj.14.9.1233; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; Binolfi A, 2008, J AM CHEM SOC, V130, P11801, DOI 10.1021/ja803494v; Binolfi A, 2006, J AM CHEM SOC, V128, P9893, DOI 10.1021/ja0618649; Bodles AM, 2000, EUR J BIOCHEM, V267, P2186, DOI 10.1046/j.1432-1327.2000.01219.x; Borghi R, 2000, NEUROSCI LETT, V287, P65, DOI 10.1016/S0304-3940(00)01153-8; Cabin DE, 2002, J NEUROSCI, V22, P8797; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Danzer KM, 2007, J NEUROSCI, V27, P9220, DOI 10.1523/JNEUROSCI.2617-07.2007; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; DRAYER B, 1986, AM J ROENTGENOL, V147, P103, DOI 10.2214/ajr.147.1.103; Du HN, 2003, BIOCHEMISTRY-US, V42, P8870, DOI 10.1021/bi034028+; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; Dusa A, 2006, BIOCHEMISTRY-US, V45, P2752, DOI 10.1021/bi051426z; El-Agnaf OMA, 2000, J STRUCT BIOL, V130, P300, DOI 10.1006/jsbi.2000.4262; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; El-Agnaf OMA, 2006, FASEB J, V20, P419, DOI 10.1096/fj.03-1449com; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Forloni G, 2000, ANN NEUROL, V47, P632, DOI 10.1002/1531-8249(200005)47:5<632::AID-ANA11>3.3.CO;2-E; Fortin DL, 2005, J NEUROSCI, V25, P10913, DOI 10.1523/JNEUROSCI.2922-05.2005; Fredenburg RA, 2007, BIOCHEMISTRY-US, V46, P7107, DOI 10.1021/bi7000246; Furukawa K, 2006, J NEUROCHEM, V97, P1071, DOI 10.1111/j.1471-4159.2006.03803.x; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; GOLDBERG WJ, 1981, CLIN CHEM, V27, P562; Golts N, 2002, J BIOL CHEM, V277, P16116, DOI 10.1074/jbc.M107866200; Hayashita-Kinoh H, 2006, BIOCHEM BIOPH RES CO, V341, P1088, DOI 10.1016/j.bbrc.2006.01.057; Heise H, 2005, P NATL ACAD SCI USA, V102, P15871, DOI 10.1073/pnas.0506109102; Hoyer W, 2002, J MOL BIOL, V322, P383, DOI 10.1016/S0022-2836(02)00775-1; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lannfelt L, 2008, LANCET NEUROL, V7, P779, DOI 10.1016/S1474-4422(08)70167-4; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee EN, 2003, J NEUROCHEM, V84, P1128, DOI 10.1046/j.1471-4159.2003.01612.x; Lee EN, 2004, BIOCHEMISTRY-US, V43, P3704, DOI 10.1021/bi0356707; Lee HJ, 2008, INT J BIOCHEM CELL B, V40, P1835, DOI 10.1016/j.biocel.2008.01.017; Lee HJ, 2005, J NEUROSCI, V25, P6016, DOI 10.1523/JNEUROSCI.0692-05.2005; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Lee PH, 2006, J NEURAL TRANSM, V113, P1435, DOI 10.1007/s00702-005-0427-9; Lee SJ, 2008, J MOL NEUROSCI, V34, P17, DOI 10.1007/s12031-007-0012-9; Li J, 2001, BIOCHEMISTRY-US, V40, P11604, DOI 10.1021/bi010616g; Lo BC, 2002, P NATL ACAD SCI USA, V99, P10813; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Martin LJ, 2006, J NEUROSCI, V26, P41, DOI 10.1523/JNEUROSCI.4308-05.2006; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Ohtake H, 2004, NEUROLOGY, V63, P805, DOI 10.1212/01.WNL.0000139870.14385.3C; Outeiro TF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001867; PALL HS, 1987, LANCET, V2, P238; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rasia RM, 2005, P NATL ACAD SCI USA, V102, P4294, DOI 10.1073/pnas.0407881102; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Squitti R, 2006, NEUROLOGY, V67, P76, DOI 10.1212/01.wnl.0000223343.82809.cf; Sung JY, 2001, J BIOL CHEM, V276, P27441, DOI 10.1074/jbc.M101318200; Sung JY, 2005, J BIOL CHEM, V280, P25216, DOI 10.1074/jbc.M503341200; Tokuda T, 2006, BIOCHEM BIOPH RES CO, V349, P162, DOI 10.1016/j.bbrc.2006.08.024; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; van Raaij ME, 2006, BIOPHYS J, V91, pL96, DOI 10.1529/biophysj.106.090449; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; WARREN PJ, 1960, BRAIN, V83, P709, DOI 10.1093/brain/83.4.709; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Yamin G, 2005, BIOCHEMISTRY-US, V44, P9096, DOI 10.1021/bi048778a; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhang L, 2008, BRAIN RES, V1244, P40, DOI 10.1016/j.brainres.2008.08.067; Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244	84	117	117	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2384	2393		10.1096/fj.09-130039	http://dx.doi.org/10.1096/fj.09-130039			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19325037				2022-12-28	WOS:000268836700007
J	Evans, J; Catalano, RD; Brown, P; Sherwin, R; Critchley, HOD; Fazleabas, AT; Jabbour, HN				Evans, Jemma; Catalano, Rob D.; Brown, Pamela; Sherwin, Rob; Critchley, Hilary O. D.; Fazleabas, Asgerally T.; Jabbour, Henry N.			Prokineticin 1 mediates fetal-maternal dialogue regulating endometrial leukemia inhibitory factor	FASEB JOURNAL			English	Article						human chorionic gonadotropin; implantation; decidua; adhesion; laminin; fibronectin	HUMAN CHORIONIC-GONADOTROPIN; FACTOR LIF; TROPHOBLAST DIFFERENTIATION; UNEXPLAINED INFERTILITY; IMPLANTATION; EXPRESSION; BIOSYNTHESIS; STIMULATION; RECEPTORS; SECRETION	Implantation requires communication between a receptive endometrium and a healthy blastocyst. This maternal-embryonic crosstalk involves local mediators within the uterine microenvironment. We demonstrate that a secreted protein, prokineticin 1 (PROK1), is expressed in the receptive endometrium and during early pregnancy. PROK1 induces expression of leukemia inhibitory factor (LIF) in endometrial epithelial cells and first trimester decidua via a Gq-Ca2+-cSrc-mitogen-activated protein kinase kinase-mediated pathway. We show that human embryonic chorionic gonadotropin (hCG) induces sequential mRNA expression of PROK1 and LIF in an in vivo baboon model, in human endometrial epithelial cells, and in first-trimester decidua. We have used micro RNA constructs targeted to PROK1 to demonstrate that hCG-mediated LIF expression in the endometrium is dependent on prior induction of PROK1. Dual immunohistochemical analysis colocalized expression of the luteinizing hormone/chorionic gonadotropin receptor, PROK1, PROKR1, and LIF to the glandular epithelial cells of the first trimester decidual tissue. PROK1 enhances adhesion of trophoblast cells to fibronectin and laminin matrices, which are mediated predominantly via LIF induction. These data describe a novel signaling pathway mediating maternal-embryonic crosstalk, in which embryonic hCG via endometrial PROK1 may play a pivotal role in enhancing receptivity and maintaining early pregnancy.-Evans, J., Catalano, R. D., Brown, P., Sherwin, R., Critchley, H. O. D., Fazleabas, A. T., Jabbour, H. N. Prokineticin 1 mediates fetal-maternal dialogue regulating endometrial leukemia inhibitory factor. FASEB J. 23, 2165-2175 (2009)	[Evans, Jemma; Catalano, Rob D.; Brown, Pamela; Jabbour, Henry N.] Queens Med Res Inst, MRC, Human Reprod Sci Unit, Edinburgh EH16 4TJ, Midlothian, Scotland; [Sherwin, Rob] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; [Fazleabas, Asgerally T.] Univ Illinois, Coll Med, Dept Obstet & Gynecol, Chicago, IL 60612 USA	University of Edinburgh; University of Cambridge; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Jabbour, HN (corresponding author), Queens Med Res Inst, MRC, Human Reprod Sci Unit, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	h.jabbour@hrsu.mrc.ac.uk	CRITCHLEY, HILARY OD/C-7575-2013	evans, jemma/0000-0002-3300-8127; CRITCHLEY, HILARY/0000-0003-1913-4044	Medical Research Council [G9900991B] Funding Source: researchfish; MRC [MC_U127684438] Funding Source: UKRI; Medical Research Council [MC_U127684438, U.1276.00.004.00002.01/2(61014)] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ARICI A, 1995, J CLIN ENDOCR METAB, V80, P1908, DOI 10.1210/jc.80.6.1908; Bamberger AM, 1997, MOL HUM REPROD, V3, P789, DOI 10.1093/molehr/3.9.789; Battersby S, 2004, J CLIN ENDOCR METAB, V89, P2463, DOI 10.1210/jc.2003-032012; BHATT H, 1991, P NATL ACAD SCI USA, V88, P11408, DOI 10.1073/pnas.88.24.11408; BISCHOF P, 1995, AM J REPROD IMMUNOL, V34, P225, DOI 10.1111/j.1600-0897.1995.tb00945.x; Carlson CD, 1996, GLIA, V18, P141, DOI 10.1002/(SICI)1098-1136(199610)18:2<141::AID-GLIA6>3.3.CO;2-F; De Ziegler D, 2004, ANN NY ACAD SCI, V1034, P262, DOI 10.1196/annals.1335.028; DELAGE G, 1995, HUM REPROD, V10, P2483; Dockery P, 1998, HUM REPROD UPDATE, V4, P486, DOI 10.1093/humupd/4.5.486; ELIAS JA, 1994, AM J PHYSIOL, V266, pL426, DOI 10.1152/ajplung.1994.266.4.L426; Evans J, 2008, ENDOCRINOLOGY, V149, P2877, DOI 10.1210/en.2007-1633; FABER M, 1986, AM J PATHOL, V124, P384; Fan ZY, 2004, CYTOKINE, V28, P17, DOI 10.1016/j.cyto.2004.06.003; FERENCZY A, 1993, MICROSC RES TECHNIQ, V25, P91, DOI 10.1002/jemt.1070250203; FERNANDEZ PL, 1992, LAB INVEST, V66, P572; Filicori M, 2005, FERTIL STERIL, V84, P275, DOI 10.1016/j.fertnstert.2005.02.033; Fouladi-Nashta AA, 2005, DEV BIOL, V281, P1, DOI 10.1016/j.ydbio.2005.01.033; Goto S, 2007, FERTIL STERIL, V88, P1339, DOI 10.1016/j.fertnstert.2007.01.011; Hambartsoumian E, 1998, AM J REPROD IMMUNOL, V39, P137; Hoffmann P, 2006, ENDOCRINOLOGY, V147, P1675, DOI 10.1210/en.2005-0912; Ledee-Bataille N, 2002, HUM REPROD, V17, P213, DOI 10.1093/humrep/17.1.213; Licht P, 2007, MOL CELL ENDOCRINOL, V269, P85, DOI 10.1016/j.mce.2006.09.016; Licht P, 2001, Reprod Biol, V1, P10; Lunghi L, 2007, REPROD BIOL ENDOCRIN, V5, DOI 10.1186/1477-7827-5-6; Mikolajczyk Mateusz, 2003, Reprod Biol, V3, P259; Nachtigall MJ, 1996, J CLIN ENDOCR METAB, V81, P801, DOI 10.1210/jc.81.2.801; Norwitz ER, 2001, NEW ENGL J MED, V345, P1400, DOI 10.1056/NEJMra000763; Perrier d'Hauterive S, 2004, HUM REPROD, V19, P2633, DOI 10.1093/humrep/deh450; Psychoyos A, 1973, Vitam Horm, V31, P201; Red-Horse K, 2004, J CLIN INVEST, V114, P744, DOI 10.1172/JCI200422991; Ren S G, 1997, Early Pregnancy, V3, P102; Sawai K, 1997, BIOL REPROD, V56, P1274, DOI 10.1095/biolreprod56.5.1274; SAWAI K, 1995, J CLIN ENDOCR METAB, V80, P1449, DOI 10.1210/jc.80.4.1449; Sherwin JRA, 2007, ENDOCRINOLOGY, V148, P618, DOI 10.1210/en.2006-0832; Srisuparp S, 2001, ARCH MED RES, V32, P627, DOI 10.1016/S0188-4409(01)00330-7; Steck T, 2004, EUR J OBSTET GYN R B, V112, P69, DOI 10.1016/S0301-2115(03)00315-4; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Tabibzadeh S, 1998, HUM REPROD UPDATE, V4, P465, DOI 10.1093/humupd/4.5.465; Tapia A, 2008, HUM REPROD, V23, P1724, DOI 10.1093/humrep/den121; Vogiagis D, 1996, J ENDOCRINOL, V148, P95, DOI 10.1677/joe.0.1480095	40	65	67	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2165	2175		10.1096/fj.08-124495	http://dx.doi.org/10.1096/fj.08-124495			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19255255	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000268836500016
J	Chiang, HC; Iijima, K; Hakker, I; Zhong, Y				Chiang, Hsueh-Cheng; Iijima, Koichi; Hakker, Inessa; Zhong, Yi			Distinctive roles of different beta-amyloid 42 aggregates in modulation of synaptic functions	FASEB JOURNAL			English	Article						Alzheimer's disease; Drosophila; neuromuscular junction; endogenous	TRANSGENIC CAENORHABDITIS-ELEGANS; LONG-TERM POTENTIATION; SUPPRESSOR GENE DLG; ALZHEIMERS-DISEASE; NEUROMUSCULAR-JUNCTION; IN-VIVO; NEURODEGENERATIVE DISEASE; DROSOPHILA EMBRYOS; NEURONAL-ACTIVITY; MOUSE MODELS	To determine how endogenously secreted beta-amyloid 42 (A beta 42) aggregates regulate synaptic functions, we examined effects of A beta 42 at the neuromuscular junction of Drosophila larvae. Voltage-clamp recordings of synaptic transmission and optical analysis of vesicle recycling at presynaptic terminals show that expression of A beta 42 in neurons leads to a reduction of neurotransmitter release. However, expression of A beta 42 in postsynaptic muscle cells enhanced neurotransmitter release. Both effects are neutralized by A beta antibody, suggesting a role for secreted A beta 42 peptides. Application of exogenously prepared A beta 42 oligomers leads to a reduction in synaptic responses, whereas mixed A beta 42 aggregates with mainly fibrils elicit an opposite effect by increasing synaptic transmission. Further analysis of long-term depression (LTD) confirms differential effects of different A beta 42 aggregates. Taken together, our data suggest that A beta 42 is secreted from neurons primarily as oligomers that inhibit neurotransmitter release and exert no effect on LTD. Whereas larger-sized aggregates, possibly fibrils, are major components secreted from muscle cells, which enhance synaptic transmission and LTD. Thus, different types of cells may secrete distinct forms of A beta 42 aggregates, leading to different modulation of synaptic functions.-Chiang, H.-C., Iijima, K., Hakker, I., Zhong, Y. Distinctive roles of different beta-amyloid 42 aggregates in modulation of synaptic functions. FASEB J. 23, 1969-1977 (2009)	[Chiang, Hsueh-Cheng; Iijima, Koichi; Hakker, Inessa; Zhong, Yi] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Chiang, Hsueh-Cheng] SUNY Stony Brook, Dept Neurosci, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zhong, Y (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	zhongyi@cshl.edu		Zhong, Yi/0000-0002-7927-5976; Zhong, Yi/0000-0001-7810-9899	U.S. National Institutes of Health [2R01 NS34779-06]; U.S. Army Neurofibromatosis Research Program [DAMD17-99-1-9500]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034779] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Army Neurofibromatosis Research Program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr. Iijima-Ando Kanae (Thomas Jefferson University, Philadelphia, PA, USA) for providing G7 flies and Dr. Shouzhen Xia (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA) for providing C57 flies, and Dr. Jennifer Beshel for reading and correcting the manuscript. This work was supported by grants from the U.S. National Institutes of Health (2R01 NS34779-06), the U.S. Army Neurofibromatosis Research Program (DAMD17-99-1-9500), and Dart Neuroscience (San Diego, CA, USA) to Y. Z.	Abad MA, 2006, J NEUROSCI, V26, P12735, DOI 10.1523/JNEUROSCI.0575-06.2006; Almeida CG, 2005, NEUROBIOL DIS, V20, P187, DOI 10.1016/j.nbd.2005.02.008; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; Carmine-Simmen K, 2009, NEUROBIOL DIS, V33, P274, DOI 10.1016/j.nbd.2008.10.014; Chan HYE, 2000, CELL DEATH DIFFER, V7, P1075, DOI 10.1038/sj.cdd.4400757; Chin J, 2005, J NEUROSCI, V25, P9694, DOI 10.1523/JNEUROSCI.2980-05.2005; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Drake J, 2003, NEUROBIOL AGING, V24, P415, DOI 10.1016/S0197-4580(02)00225-7; Fay DS, 1998, J NEUROCHEM, V71, P1616; Fu HJ, 2006, J NEUROCHEM, V98, P1400, DOI 10.1111/j.1471-4159.2006.03960.x; Graf RA, 1998, BRAIN RES, V786, P115, DOI 10.1016/S0006-8993(97)01451-0; Greeve I, 2004, J NEUROSCI, V24, P3899, DOI 10.1523/JNEUROSCI.0283-04.2004; Guo HF, 2006, J NEUROSCI, V26, P4004, DOI 10.1523/JNEUROSCI.3616-05.2006; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Ho IS, 2007, J NEUROSCI, V27, P6852, DOI 10.1523/JNEUROSCI.0933-07.2007; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsieh H, 2006, NEURON, V52, P831, DOI 10.1016/j.neuron.2006.10.035; Iijima K, 2004, P NATL ACAD SCI USA, V101, P6623, DOI 10.1073/pnas.0400895101; Iijima K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001703; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; JOHANSEN J, 1989, J NEUROSCI, V9, P4318; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kuromi H, 1999, J NEUROSCI, V19, P1557; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lawrence PA, 1996, DEVELOPMENT, V122, P4095; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; LINK CD, 1995, P NATL ACAD SCI USA, V92, P9368, DOI 10.1073/pnas.92.20.9368; Liu YB, 1998, J NEUROCHEM, V71, P2322; Lozsadi DA, 2006, DEMENT GERIATR COGN, V22, P121, DOI 10.1159/000093664; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; Marsh JL, 2006, NEURON, V52, P169, DOI 10.1016/j.neuron.2006.09.025; Necula M, 2007, J BIOL CHEM, V282, P10311, DOI 10.1074/jbc.M608207200; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Palop JJ, 2006, NATURE, V443, P768, DOI 10.1038/nature05289; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Renden RB, 2003, J NEUROPHYSIOL, V89, P2620, DOI 10.1152/jn.01072.2002; ROMANELLI MF, 1990, ARCH NEUROL-CHICAGO, V47, P847, DOI 10.1001/archneur.1990.00530080029006; Torroja L, 1999, J NEUROSCI, V19, P7793; Tsai J, 2004, NAT NEUROSCI, V7, P1181, DOI 10.1038/nn1335; Urbanc B, 2002, P NATL ACAD SCI USA, V99, P13990, DOI 10.1073/pnas.222433299; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; Ye CP, 2004, NEUROSCI LETT, V366, P320, DOI 10.1016/j.neulet.2004.05.060	46	20	28	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1969	1977		10.1096/fj.08-121152	http://dx.doi.org/10.1096/fj.08-121152			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19255256	Green Published			2022-12-28	WOS:000266652400035
J	Martin, RM; Cardoso, MC				Martin, Robert M.; Cardoso, M. Cristina			Chromatin condensation modulates access and binding of nuclear proteins	FASEB JOURNAL			English	Article						fluorescence microscopy; GFP; mitosis; photoactivation; photobleaching	MAMMALIAN-CELLS; LIVING CELLS; IN-VIVO; DYNAMICS; HETEROCHROMATIN; HP1; DNA; DOMAINS; GFP; COMPARTMENTALIZATION	The condensation level of chromatin is controlled by epigenetic modifications and associated regulatory factors and changes throughout differentiation and cell cycle progression. To test whether changes of chromatin condensation levels per se affect access and binding of proteins, we used a hypertonic cell treatment. This shift to hyperosmolar medium increased nuclear calcium concentrations and induced a reversible chromatin condensation comparable to the levels in mitosis. However, this condensation was independent of mitotic histone H3 serine 10 phosphorylation. Photobleaching and photoactivation experiments with chromatin proteins- histone H2B-GFP and GFP-HP1 alpha-before and after induced chromatin condensation demonstrated that hypercondensation reduced their dissociation rate and stabilized their chromatin binding. Finally, measuring the distribution of nucleoplasmic proteins in the size range from 30 to 230 kDa, we found that even relatively small proteins like GFP were excluded from highly condensed chromatin in living cells. These results suggest that structural changes in condensed chromatin by themselves affect chromatin access and binding of chromatin proteins independent of regulatory histone modifications.-Martin, R. M., Cardoso, M. C. Chromatin condensation modulates access and binding of nuclear proteins. FASEB J. 24, 1066-1072 (2010). www.fasebj.org	[Cardoso, M. Cristina] Tech Univ Darmstadt, Dept Biol, D-64287 Darmstadt, Germany; [Martin, Robert M.; Cardoso, M. Cristina] Max Delbruck Ctr Mol Med, Berlin, Germany	Technical University of Darmstadt; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Cardoso, MC (corresponding author), Tech Univ Darmstadt, Dept Biol, Petersenstr 30, D-64287 Darmstadt, Germany.	cardoso@bio.tu-darmstadt.de	Cardoso, M. Cristina/F-5215-2011	Martin, Robert/0000-0001-5600-7525	German Research Council (DFG)	German Research Council (DFG)(German Research Foundation (DFG))	The authors thank Sabine M. Gorisch for many discussions, Jeffrey H. Stear for comments on the manuscript and Ulrike Ziebold [Max Delbruck Center for Molecular Medicine (MDC), Berlin, Germany] for the kind gift of anti-phospho H3 antibody. The authors are indebted to Heinrich Leonhardt for numerous discussions and helpful suggestions throughout the course of this project. This work was funded by grants of the German Research Council (DFG) to M.C.C.	Albiez H, 2006, CHROMOSOME RES, V14, P707, DOI 10.1007/s10577-006-1086-x; Belmont AS, 2006, CURR OPIN CELL BIOL, V18, P632, DOI 10.1016/j.ceb.2006.09.007; Belmont AS, 1999, CURR OPIN CELL BIOL, V11, P307, DOI 10.1016/S0955-0674(99)80041-6; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Cardoso MC, 1997, J CELL BIOL, V139, P579, DOI 10.1083/jcb.139.3.579; Chen DY, 2005, J CELL BIOL, V168, P41, DOI 10.1083/jcb.200407182; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Cremer T, 2000, CRIT REV EUKAR GENE, V10, P179; Cremer T, 2004, BIOL CELL, V96, P555, DOI 10.1016/j.biolcel.2004.07.002; Daban JR, 2003, BIOCHEM CELL BIOL, V81, P91, DOI 10.1139/o03-037; Dialynas GK, 2007, J CELL SCI, V120, P3415, DOI 10.1242/jcs.012914; Easwaran HP, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-42; Easwaran HP, 2004, EMBO REP, V5, P1181, DOI 10.1038/sj.embor.7400295; Ellenberg J, 1999, TRENDS CELL BIOL, V9, P52, DOI 10.1016/S0962-8924(98)01420-2; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Gorisch SM, 2005, J CELL SCI, V118, P5825, DOI 10.1242/jcs.02689; Gorisch SM, 2003, EXP CELL RES, V289, P282, DOI 10.1016/S0014-4827(03)00265-9; Grunwald D, 2008, BIOPHYS J, V94, P2847, DOI 10.1529/biophysj.107.115014; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Martin RM, 2007, CELL CYCLE, V6, P2422, DOI 10.4161/cc.6.19.4738; Mora-Bermudez F, 2007, METHODS, V41, P158, DOI 10.1016/j.ymeth.2006.07.035; Pack C, 2006, BIOPHYS J, V91, P3921, DOI 10.1529/biophysj.106.079467; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Phair RD, 2004, METHOD ENZYMOL, V375, P393; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Schmiedeberg L, 2004, MOL BIOL CELL, V15, P2819, DOI 10.1091/mbc.E03-11-0827; Verschure PJ, 2005, MOL CELL BIOL, V25, P4552, DOI 10.1128/MCB.25.11.4552-4564.2005; Verschure PJ, 2003, EMBO REP, V4, P861, DOI 10.1038/sj.embor.embor922	33	50	52	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1066	1072		10.1096/fj.08-128959	http://dx.doi.org/10.1096/fj.08-128959			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19897663	Green Published			2022-12-28	WOS:000276462300014
J	Schwirtlich, M; Emri, Z; Antal, K; Mate, Z; Katarova, Z; Szabo, G				Schwirtlich, Marija; Emri, Zsuzsa; Antal, Karoly; Mate, Zoltan; Katarova, Zoya; Szabo, Gabor			GABA(A) and GABA(B) receptors of distinct properties affect oppositely the proliferation of mouse embryonic stem cells through synergistic elevation of intracellular Ca2+	FASEB JOURNAL			English	Article						Ca2+ imaging; ES cell self-renewal/differentiation; connexin 43	GAMMA-AMINOBUTYRIC-ACID; SELF-RENEWAL; SIGNAL-TRANSDUCTION; DEVELOPING NEURONS; PROGENITOR CELLS; EPSILON-SUBUNIT; GAP-JUNCTIONS; IN-VITRO; CALCIUM; EXPRESSION	Gamma-amminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system of vertebrates, serves as an autocrine/paracrine signaling molecule during development, modulating a number of calcium (Ca2+)-dependent processes, including proliferation, migration, and differentiation, acting via 2 types of GABA receptors (GABARs): ionotropic GABA(A)Rs and metabotropic GABA(B)Rs. Here, we demonstrate that mouse embryonic stem cells (mESCs), which possess the capacity for virtually unlimited self-renewal and pluripotency, synthesize GABA and express functional GABA(A)Rs and GABA(B)Rs, as well as voltage-gated calcium channels (VGCCs), ryanodine receptors (RyRs), and inwardly rectifying potassium (GIRK) channels. On activation, both GABAR types triggered synergistically intracellular calcium rise. Muscimol (a GABA(A)R agonist) induced single Ca2+ transients involving both VGCC-mediated Ca2+ influx and intracellular stores, while baclofen (a GABA(B)R agonist) evoked Ca2+ transients followed by intercellular Ca2+ waves and oscillations that were resistant to antagonists and entirely dependent on Ca2+ release from intracellular stores. Prolonged treatment with muscimol slightly inhibited, while baclofen or SR95531 (a GABA(A)R antagonist) significantly facilitated, mESC proliferation. GABA(A)R-specific ligands also induced morphological and gene expression changes indicating a differentiation shift. Our data suggest that the interplay between GABARs and downstream (coupled) effectors differentially modulates mESC proliferation/differentiation through selective activation of second messenger signaling cascades.-Schwirtlich, M., Emri, Z., Antal, K., Mate, Z., Katarova, Z., Szabo, G. GABA(A) and GABA(B) receptors of distinct properties affect oppositely the proliferation of mouse embryonic stem cells through synergistic elevation of intracellular Ca2+. FASEB J. 24, 1218-1228 (2010). www.fasebj.org	[Schwirtlich, Marija; Mate, Zoltan; Katarova, Zoya; Szabo, Gabor] Hungarian Acad Sci, Inst Expt Med, Lab Mol Biol & Genet, H-1450 Budapest, Hungary; [Emri, Zsuzsa; Antal, Karoly] Hungarian Acad Sci, Dept Neurochem, Chem Res Ctr, H-1450 Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences	Szabo, G (corresponding author), Hungarian Acad Sci, Inst Expt Med, Lab Mol Biol & Genet, POB 67, H-1450 Budapest, Hungary.	szabog@koki.hu	Szabo, Gabor/A-5087-2008	Szabo, Gabor/0000-0001-5438-5151; Schwirtlich, Marija/0000-0002-2183-0164				BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BAIN G, 1993, MOL BRAIN RES, V17, P23, DOI 10.1016/0169-328X(93)90068-Z; Balakier H, 2002, HUM REPROD, V17, P2938, DOI 10.1093/humrep/17.11.2938; Balasubramanian S, 2004, J BIOL CHEM, V279, P18840, DOI 10.1074/jbc.M313470200; Barker JL, 1998, PERSPECT DEV NEUROBI, V5, P305; Ben-Ari Y, 2007, PHYSIOL REV, V87, P1215, DOI 10.1152/physrev.00017.2006; Bettler B, 2004, PHYSIOL REV, V84, P835, DOI 10.1152/physrev.00036.2003; Bettler B, 2006, PHARMACOL THERAPEUT, V110, P533, DOI 10.1016/j.pharmthera.2006.03.006; Bollan KA, 2008, MOL CELL NEUROSCI, V37, P610, DOI 10.1016/j.mcn.2007.12.011; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Collinson N, 2002, J NEUROSCI, V22, P5572; DEERAUSQUIN G, 1992, MOL PHARMACOL, V42, P407; Ducibella T, 2002, DEV BIOL, V250, P280, DOI 10.1006/dbio.2002.0788; Elias LAB, 2008, TRENDS NEUROSCI, V31, P243, DOI 10.1016/j.tins.2008.02.007; ERDO SL, 1990, J NEUROCHEM, V54, P363, DOI 10.1111/j.1471-4159.1990.tb01882.x; Fiszman ML, 1999, DEV BRAIN RES, V115, P1, DOI 10.1016/S0165-3806(99)00035-8; Fukui M, 2008, J CELL PHYSIOL, V216, P507, DOI 10.1002/jcp.21422; Glykys J, 2008, J NEUROSCI, V28, P1421, DOI 10.1523/JNEUROSCI.4751-07.2008; Goh G, 2005, THROMB HAEMOSTASIS, V94, P728, DOI 10.1160/TH05-04-0268; Haydar TF, 2000, J NEUROSCI, V20, P5764, DOI 10.1523/JNEUROSCI.20-15-05764.2000; Hirono M, 2001, NAT NEUROSCI, V4, P1207, DOI 10.1038/nn764; Hisatsune C, 2005, J BIOL CHEM, V280, P11723, DOI 10.1074/jbc.M409535200; Huang ZJ, 2006, NEURON, V50, P521, DOI 10.1016/j.neuron.2006.05.005; Jimenez-Gonzalez C, 2006, HUM REPROD UPDATE, V12, P253, DOI 10.1093/humupd/dmi050; Kanbara K, 2005, J ANDROL, V26, P485, DOI 10.2164/jandrol.04185; Kapur N, 2007, AM J PHYSIOL-CELL PH, V292, pC1510, DOI 10.1152/ajpcell.00181.2006; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Koyrakh L, 2005, J NEUROSCI, V25, P11468, DOI 10.1523/JNEUROSCI.3484-05.2005; Kwakowsky A, 2007, DEV DYNAM, V236, P3532, DOI 10.1002/dvdy.21361; Kwakowsky A, 2008, DEV DYNAM, V237, P3830, DOI 10.1002/dvdy.21768; Liu XX, 2005, NAT NEUROSCI, V8, P1179, DOI 10.1038/nn1522; Lomazzi M, 2008, TRENDS PHARMACOL SCI, V29, P544, DOI 10.1016/j.tips.2008.07.011; LoTurco JJ, 1995, NEURON, V15, P1287, DOI 10.1016/0896-6273(95)90008-X; Lu DP, 2003, BIOL REPROD, V69, P106, DOI 10.1095/biolreprod.102.014696; Luyt K, 2007, J NEUROCHEM, V100, P822, DOI 10.1111/j.1471-4159.2006.04255.x; Magnaghi V, 2004, EUR J NEUROSCI, V19, P2641, DOI 10.1111/j.0953-816X.2004.03368.x; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Meier SD, 2008, GLIA, V56, P1127, DOI 10.1002/glia.20684; Mody I, 2004, TRENDS NEUROSCI, V27, P569, DOI 10.1016/j.tins.2004.07.002; Mody I, 2008, NEUROCHEM INT, V52, P60, DOI 10.1016/j.neuint.2007.07.010; Mohler H, 2006, CELL TISSUE RES, V326, P505, DOI 10.1007/s00441-006-0284-3; Muller E, 2008, FRONT MOL NEUROSCI, V1, DOI 10.3389/neuro.02.003.2008; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Neelands TR, 1999, MOL PHARMACOL, V55, P168, DOI 10.1124/mol.55.1.168; NILSSON M, 1993, NEUROSCIENCE, V54, P605, DOI 10.1016/0306-4522(93)90232-5; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787; Obrietan K, 1998, J NEUROPHYSIOL, V79, P1360, DOI 10.1152/jn.1998.79.3.1360; Obrietan K, 1997, J NEUROSCI, V17, P4785; Obrietan K, 2002, J NEUROPHYSIOL, V88, P1005, DOI 10.1152/jn.2002.88.2.1005; Obrietan K, 1999, J NEUROPHYSIOL, V82, P94, DOI 10.1152/jn.1999.82.1.94; Orford KW, 2008, NAT REV GENET, V9, P115, DOI 10.1038/nrg2269; Owens DF, 2002, NAT REV NEUROSCI, V3, P715, DOI 10.1038/nrn919; PARRAMON M, 1995, J NEUROSCI RES, V41, P65, DOI 10.1002/jnr.490410108; Ritter B, 2005, CELL TISSUE RES, V319, P181, DOI 10.1007/s00441-004-0991-6; Rosemblit N, 1999, DEV BIOL, V206, P163, DOI 10.1006/dbio.1998.9120; Ross D, 2002, CELL CALCIUM, V32, P307, DOI 10.1016/S0143-4160(02)00198-7; Schuller HM, 2008, CARCINOGENESIS, V29, P1979, DOI 10.1093/carcin/bgn041; Shah BH, 2004, J BIOL CHEM, V279, P414, DOI 10.1074/jbc.M309083200; Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507; Silva J, 2008, CELL, V132, P532, DOI 10.1016/j.cell.2008.02.006; Stachecki JJ, 1996, DEVELOPMENT, V122, P2485; Tabata T, 2004, P NATL ACAD SCI USA, V101, P16952, DOI 10.1073/pnas.0405387101; Takehara A, 2007, CANCER RES, V67, P9704, DOI 10.1158/0008-5472.CAN-07-2099; Tamayama T, 2005, MOL CELL BIOCHEM, V273, P117, DOI 10.1007/s11010-005-8159-6; Thore S, 2005, J CELL SCI, V118, P4463, DOI 10.1242/jcs.02577; Tiao JY, 2008, J BIOL CHEM, V283, P31005, DOI 10.1074/jbc.M804464200; Tielens S, 2008, IN VITRO CELL DEV-AN, V44, P368, DOI 10.1007/s11626-008-9126-9; Todorova MG, 2008, J CELL PHYSIOL, V214, P354, DOI 10.1002/jcp.21203; Ulrich D, 2007, CURR OPIN NEUROBIOL, V17, P298, DOI 10.1016/j.conb.2007.04.001; Varju P, 2001, CELL TISSUE RES, V305, P239, DOI 10.1007/s004410100356; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99; Wang Doris D, 2008, Epilepsy Curr, V8, P137, DOI 10.1111/j.1535-7511.2008.00270.x; Wang HB, 2003, P NATL ACAD SCI USA, V100, P14914, DOI 10.1073/pnas.2436379100; Watanabe M, 2006, HISTOL HISTOPATHOL, V21, P1135, DOI 10.14670/HH-21.1135; Watanabe M, 2002, INT REV CYTOL, V213, P1; Webb SE, 2003, NAT REV MOL CELL BIO, V4, P539, DOI 10.1038/nrm1149; White J, 2005, STEM CELL REV, V1, P131, DOI 10.1385/SCR:1:2:131; Willoughby D, 2007, PHYSIOL REV, V87, P965, DOI 10.1152/physrev.00049.2006; WISDEN W, 1992, J NEUROSCI, V12, P1040; Worsdorfer P, 2008, STEM CELLS, V26, P431, DOI 10.1634/stemcells.2007-0482; Wong RCB, 2008, STEM CELL REV, V4, P283, DOI 10.1007/s12015-008-9038-9; Xiang YY, 2007, NAT MED, V13, P862, DOI 10.1038/nm1604; Yanagida E, 2004, CELL CALCIUM, V36, P135, DOI 10.1016/j.ceca.2004.01.022; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968	85	34	35	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2010	24	4					1218	1228		10.1096/fj.09-143586	http://dx.doi.org/10.1096/fj.09-143586			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19959723				2022-12-28	WOS:000276462300028
J	Gold, LI; Eggleton, P; Sweetwyne, MT; Van Duyn, LB; Greives, MR; Naylor, SM; Michalak, M; Murphy-Ullrich, JE				Gold, Leslie I.; Eggleton, Paul; Sweetwyne, Mariya T.; Van Duyn, Lauren B.; Greives, Matthew R.; Naylor, Sara-Megumi; Michalak, Marek; Murphy-Ullrich, Joanne E.			Calreticulin: non-endoplasmic reticulum functions in physiology and disease	FASEB JOURNAL			English	Review						phagocytosis; migration; extracellular matrix; wound healing; tumor recognition	CELL-SURFACE CALRETICULIN; HEAT-SHOCK PROTEINS; CLASS-I MOLECULES; RECEPTOR-RELATED PROTEIN; TUMOR-SPECIFIC IMMUNITY; GROWTH-FACTOR-BETA; APOPTOTIC CELLS; EXTRACELLULAR-MATRIX; TGF-BETA; HEAT-SHOCK-PROTEIN-70 HSP70	Calreticulin (CRT), when localized to the endoplasmic reticulum (ER), has important functions in directing proper conformation of proteins and glycoproteins, as well as in homeostatic control of cytosolic and ER calcium levels. There is also steadily accumulating evidence for diverse roles for CRT localized outside the ER, including data suggesting important roles for CRT localized to the outer cell surface of a variety of cell types, in the cytosol, and in the extracellular matrix (ECM). Furthermore, the addition of exogenous CRT rescues numerous CRT-driven functions, such as adhesion, migration, phagocytosis, and immunoregulatory functions of CRT-null cells. Recent studies show that topically applied CRT has diverse and profound biological effects that enhance cutaneous wound healing in animal models. This evidence for extracellular bioactivities of CRT has provided new insights into this classically ER-resident protein, despite a lack of knowledge of how CRT exits from the ER to the cell surface or how it is released into the extracellular milieu. Nonetheless, it has become clear that CRT is a multicompartmental protein that regulates a wide array of cellular responses important in physiological and pathological processes, such as wound healing, the immune response, fibrosis, and cancer.-Gold, L. I., Eggleton, P., Sweetwyne, M. T., Van Duyn, L. B., Greives, M. R., Naylor, S.-M., Michalak, M., Murphy-Ullrich, J. E. Calreticulin: non-endoplamic reticulum functions in physiology and disease. FASEB J. 24, 665-683 (2010). www.fasebj.org	[Gold, Leslie I.; Greives, Matthew R.; Naylor, Sara-Megumi] NYU, Dept Med, Sch Med, New York, NY 10016 USA; [Gold, Leslie I.; Greives, Matthew R.; Naylor, Sara-Megumi] NYU, Dept Pathol, Sch Med, New York, NY 10016 USA; [Van Duyn, Lauren B.; Murphy-Ullrich, Joanne E.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; [Sweetwyne, Mariya T.; Murphy-Ullrich, Joanne E.] Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; [Van Duyn, Lauren B.] Univ Alabama, Med Scientist Training Program, Birmingham, AL 35294 USA; [Eggleton, Paul] Univ Exeter, Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter, Devon, England; [Michalak, Marek] Univ Alberta, Dept Biochem, Edmonton, AB, Canada	New York University; New York University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Exeter; University of Alberta	Gold, LI (corresponding author), NYU, Dept Med, Sch Med, 550 1st Ave,NB16S13, New York, NY 10016 USA.	leslie.gold@nyumc.org	Sweetwyne, Mariya/GWR-2481-2022	Eggleton, Paul/0000-0001-8244-2125; Greives, Matthew/0000-0003-4602-5054	U.S. National Institutes of Health (NIH) [HL079644, T32 HL07918]; Medical Scientist Training Program [T32 GM008361]; American Red Cross [ARC17231, 16537]; European Union [FP7 215009]; Calretex, Inc., LLC; Canadian Institutes of Health Research [MOP-15291]; New York University Summer Fellowship in Internal Medicine; National Center for Research Resources [C06 RR 15490]; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015490] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007918, R01HL079644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008361] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Scientist Training Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Red Cross; European Union(European Commission); Calretex, Inc., LLC; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); New York University Summer Fellowship in Internal Medicine; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge the excellent technical help provided by Adrianne Chesser, Alexa Fredston-Hermann, and Fares Samra (Departments of Medicine and Pathology, New York University School of Medicine, New York, NY, USA). This study was supported by the following grants: U.S. National Institutes of Health (NIH) HL079644 (to J.E.M.U.); NIH T32 HL07918 (to M. T. S.); Medical Scientist Training Program T32 GM008361 (to L. B. V. D.); American Red Cross ARC17231, 16537, and European Union FP7 215009 (to P. E.), Calretex, Inc., LLC (to L. I. G.); and Canadian Institutes of Health Research MOP-15291 (to M. M.). S.M.N. was supported by the New York University Summer Fellowship in Internal Medicine. Original investigations (M. T. S., L. B. V., and J.E.M.U.) were conducted in a facility constructed with support from Research Facilities Improvement Program grant C06 RR 15490 from the National Center for Research Resources.	Afshar N, 2005, MOL CELL BIOL, V25, P8844, DOI 10.1128/MCB.25.20.8844-8853.2005; Agah A, 2004, MATRIX BIOL, V22, P539, DOI 10.1016/j.matbio.2003.09.004; Aguilar L, 2005, BIOL RES, V38, P187, DOI 10.4067/S0716-97602005000200008; Ahmed Zubair, 2009, V467, P3, DOI 10.1007/978-1-59745-241-0_1; Apetoh Lionel, 2007, Cancer Genomics & Proteomics, V4, P65; Arispe N, 2004, FASEB J, V18, P1636, DOI 10.1096/fj.04-2088com; Arosa FA, 1999, J BIOL CHEM, V274, P16917, DOI 10.1074/jbc.274.24.16917; Bandyopadhyay B, 2006, J CELL BIOL, V172, P1093, DOI 10.1083/jcb.200507111; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Bedard K, 2005, INT REV CYTOL, V245, P91, DOI 10.1016/S0074-7696(05)45004-4; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Brem H, 2007, J CLIN INVEST, V117, P1219, DOI 10.1172/JCI32169; Cai KX, 2008, CLIN CANCER RES, V14, P939, DOI 10.1158/1078-0432.CCR-07-1930; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Caramelo JJ, 2008, J BIOL CHEM, V283, P10221, DOI 10.1074/jbc.R700048200; Chaput N, 2007, J MOL MED, V85, P1069, DOI 10.1007/s00109-007-0214-1; Cheng CF, 2008, MOL CELL BIOL, V28, P3344, DOI 10.1128/MCB.01287-07; Cheng WF, 2006, CANCER GENE THER, V13, P873, DOI 10.1038/sj.cgt.7700956; Cheng WF, 2005, VACCINE, V23, P3864, DOI 10.1016/j.vaccine.2004.10.032; Chignard N, 2006, GASTROENTEROLOGY, V130, P2010, DOI 10.1053/j.gastro.2006.02.058; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; Coppolino MG, 2000, INT J BIOCHEM CELL B, V32, P171, DOI 10.1016/S1357-2725(99)00043-6; Coppolino MG, 1999, BIOCHEM J, V340, P41, DOI 10.1042/0264-6021:3400041; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; Corbett EF, 2000, J BIOL CHEM, V275, P27177; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Dai E, 1997, ARTERIOSCL THROM VAS, V17, P2359, DOI 10.1161/01.ATV.17.11.2359; Datta G, 2000, BIOCHEMISTRY-US, V39, P213, DOI 10.1021/bi991209w; Decca MB, 2007, J BIOL CHEM, V282, P8237, DOI 10.1074/jbc.M608559200; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; Denzer K, 2000, J CELL SCI, V113, P3365; Donnelly S, 2006, ARTHRITIS RHEUM-US, V54, P1543, DOI 10.1002/art.21783; Duus K, 2008, PROTEIN PEPTIDE LETT, V15, P103; Eggleton P, 1999, SCAND J IMMUNOL, V49, P466; EGGLETON P, 1994, CLIN IMMUNOL IMMUNOP, V72, P405, DOI 10.1006/clin.1994.1160; Elliott T, 2005, IMMUNOL REV, V207, P89, DOI 10.1111/j.0105-2896.2005.00311.x; Ellis IR, 1999, CELL BIOL INT, V23, P593, DOI 10.1006/cbir.1999.0423; Elton CM, 2002, THROMB HAEMOSTASIS, V88, P648, DOI 10.1055/s-0037-1613270; Ferguson MWJ, 2009, LANCET, V373, P1264, DOI 10.1016/S0140-6736(09)60322-6; Fevrier B, 2004, CURR OPIN CELL BIOL, V16, P415, DOI 10.1016/j.ceb.2004.06.003; Forslow A, 2007, CELL MOL LIFE SCI, V64, P66, DOI 10.1007/s00018-006-6255-8; Franz S, 2007, CELL DEATH DIFFER, V14, P733, DOI 10.1038/sj.cdd.4402066; Freikman I, 2009, ANAL BIOCHEM, V393, P111, DOI 10.1016/j.ab.2009.06.011; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; Gaipl US, 2006, CURR TOP MICROBIOL, V305, P161, DOI 10.1007/3-540-29714-6_8; Galiano RD, 2004, WOUND REPAIR REGEN, V12, P485, DOI 10.1111/j.1067-1927.2004.12404.x; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Gehrmann M, 2008, CELL STRESS CHAPERON, V13, P1, DOI 10.1007/s12192-007-0006-0; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Goeb V, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2644; Goicoechea S, 2002, J BIOL CHEM, V277, P37219, DOI 10.1074/jbc.M202200200; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; GRAY AJ, 1995, J BIOL CHEM, V270, P26602, DOI 10.1074/jbc.270.44.26602; Gu VY, 2008, MOL HUM REPROD, V14, P309, DOI 10.1093/molehr/gan017; Ribeiro CH, 2009, MOL IMMUNOL, V46, P1092, DOI 10.1016/j.molimm.2008.10.034; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; HEGMANS JP, 2008, EXOSOMES METHODS MOL, V484, P97; Honore C, 2007, ARTHRITIS RHEUM, V56, P1598, DOI 10.1002/art.22564; Horowitz JC, 2007, CELL SIGNAL, V19, P761, DOI 10.1016/j.cellsig.2006.10.001; Hsieh CJ, 2004, VACCINE, V22, P3993, DOI 10.1016/j.vaccine.2004.03.057; Ito M, 2007, NATURE, V447, P316, DOI 10.1038/nature05766; Jalali S, 2008, BBA-MOL CELL RES, V1783, P2344, DOI 10.1016/j.bbamcr.2008.08.014; Jazowiecka-Rakus J, 2007, ACTA BIOCHIM POL, V54, P125, DOI 10.18388/abp.2007_3278; Kageyama S, 2004, CLIN CHEM, V50, P857, DOI 10.1373/clinchem.2003.027425; Kageyama S, 2009, INT J UROL, V16, P481, DOI 10.1111/j.1442-2042.2009.02287.x; Keller M, 2008, CELL, V132, P818, DOI 10.1016/j.cell.2007.12.040; Kepp O, 2009, CELL CYCLE, V8, P860, DOI 10.4161/cc.8.6.7939; Kepp O, 2009, APOPTOSIS, V14, P364, DOI 10.1007/s10495-008-0303-9; Kepp O, 2009, CURR OPIN ONCOL, V21, P71, DOI 10.1097/CCO.0b013e32831bc375; Kreis S, 2005, EXP CELL RES, V305, P110, DOI 10.1016/j.yexcr.2004.12.023; Kreisel W, 1999, SCAND J GASTROENTERO, V34, P623; Kuraishi T, 2007, EXP CELL RES, V313, P500, DOI 10.1016/j.yexcr.2006.10.027; Kypreou KP, 2008, PROTEOMICS, V8, P2407, DOI 10.1002/pmic.200700831; Lange-Asschenfeldt B, 2001, J INVEST DERMATOL, V117, P1036, DOI 10.1046/j.0022-202x.2001.01519.x; LEONARD CM, 1991, DEV BIOL, V145, P99, DOI 10.1016/0012-1606(91)90216-P; Li WY, 2006, WOUND REPAIR REGEN, V14, P516, DOI 10.1111/j.1743-6109.2006.00158.x; Li W, 2007, EMBO J, V26, P1221, DOI 10.1038/sj.emboj.7601579; Li ZQ, 2001, J IMMUNOL, V166, P2427, DOI 10.4049/jimmunol.166.4.2427; Ling S, 2007, J IMMUNOL, V179, P6359, DOI 10.4049/jimmunol.179.9.6359; Macario AJL, 2007, ANN NY ACAD SCI, V1113, P178, DOI 10.1196/annals.1391.009; Madeo F, 2009, CELL CYCLE, V8, P639, DOI 10.4161/cc.8.4.7794; McDonnell JM, 1996, J BIOL CHEM, V271, P7891, DOI 10.1074/jbc.271.14.7891; Mesaeli N, 2004, MOL BIOL CELL, V15, P1862, DOI 10.1091/mbc.E03-04-0251; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 2009, BIOCHEM J, V417, P651, DOI 10.1042/BJ20081847; Michel JB, 2003, ARTERIOSCL THROM VAS, V23, P2146, DOI 10.1161/01.ATV.0000099882.52647.E4; Mirnikjoo B, 2009, J BIOL CHEM, V284, P22512, DOI 10.1074/jbc.C109.022913; Muller-Taubenberger A, 2001, EMBO J, V20, P6772, DOI 10.1093/emboj/20.23.6772; Multhoff G, 2007, METHODS, V43, P229, DOI 10.1016/j.ymeth.2007.06.006; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; Nanney LB, 2008, AM J PATHOL, V173, P610, DOI 10.2353/ajpath.2008.071027; Neckers L, 2006, HANDB EXP PHARM, V172, P259; Nishi H, 2004, ENDOCRINOLOGY, V145, P4113, DOI 10.1210/en.2003-1639; Obeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201; Obeid M, 2007, IMMUNOL REV, V220, P22, DOI 10.1111/j.1600-065X.2007.00567.x; Obeid M, 2007, CANCER RES, V67, P7941, DOI 10.1158/0008-5472.CAN-07-1622; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Obeid M, 2009, MOL CANCER THER, V8, P2693, DOI 10.1158/1535-7163.MCT-09-0228; Ochoa O, 2007, VASCULAR, V15, P350, DOI 10.2310/6670.2007.00056; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Orr AW, 2004, J BIOL CHEM, V279, P48983, DOI 10.1074/jbc.M404881200; Orr AW, 2003, J CELL SCI, V116, P2917, DOI 10.1242/jcs.00600; Orr AW, 2003, J CELL BIOL, V161, P1179, DOI 10.1083/jcb.200302069; Orr AW, 2002, J BIOL CHEM, V277, P20453, DOI 10.1074/jbc.M112091200; Ortiz-Munoz G, 2009, FASEB J, V23, P3129, DOI 10.1096/fj.08-127928; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Pallero MA, 2008, FASEB J, V22, P3968, DOI 10.1096/fj.07-104802; Panaretakis T, 2008, CELL DEATH DIFFER, V15, P1499, DOI 10.1038/cdd.2008.67; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Papp S, 2008, EXP CELL RES, V314, P1313, DOI 10.1016/j.yexcr.2008.01.008; Papp S, 2007, J BIOL CHEM, V282, P16585, DOI 10.1074/jbc.M701011200; Park YJ, 2008, P NATL ACAD SCI USA, V105, P11784, DOI 10.1073/pnas.0801394105; Patel JM, 1999, AM J PHYSIOL-LUNG C, V277, pL794, DOI 10.1152/ajplung.1999.277.4.L794; PEERSCHKE EIB, 1990, J IMMUNOL, V145, P2984; Petrovski G, 2007, CELL DEATH DIFFER, V14, P1117, DOI 10.1038/sj.cdd.4402112; Petrovski G, 2007, AUTOPHAGY, V3, P509; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Rabek JP, 2003, BIOCHEM BIOPH RES CO, V305, P566, DOI 10.1016/S0006-291X(03)00826-X; Raghavan M, 2008, TRENDS IMMUNOL, V29, P436, DOI 10.1016/j.it.2008.06.004; Rauch F, 2000, EXP CELL RES, V256, P105, DOI 10.1006/excr.2000.4818; RAUGI GJ, 1987, J INVEST DERMATOL, V89, P551, DOI 10.1111/1523-1747.ep12461198; Reilly D, 2004, PLATELETS, V15, P43, DOI 10.1080/09537100310001640055; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Sanchez D, 2008, CLIN EXP IMMUNOL, V153, P351, DOI 10.1111/j.1365-2249.2008.03701.x; Schmitt E, 2007, J LEUKOCYTE BIOL, V81, P15, DOI 10.1189/jlb.0306167; Schor SL, 2006, CELL MOTIL CYTOSKEL, V63, P287, DOI 10.1002/cm.20123; Sezestakowska D, 2006, CALCIUM BINDING PROT, V1, P135; Shaffer KL, 2005, DEV CELL, V9, P545, DOI 10.1016/j.devcel.2005.09.001; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Sipione S, 2005, J IMMUNOL, V174, P3212, DOI 10.4049/jimmunol.174.6.3212; Somogyi E, 2003, MATRIX BIOL, V22, P179, DOI 10.1016/S0945-053X(02)00117-8; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; Subramanian S, 2006, TRANSFUS CLIN BIOL, V13, P31, DOI 10.1016/j.tracli.2006.02.009; Taguchi J, 2000, ACTA NEUROPATHOL, V100, P153, DOI 10.1007/s004019900165; Tarr J, 2005, CRIT REV IMMUNOL, V25, P305, DOI 10.1615/CritRevImmunol.v25.i4.40; Tesniere A, 2008, CURR OPIN IMMUNOL, V20, P504, DOI 10.1016/j.coi.2008.05.007; Totary-Jain H, 2005, CIRC RES, V97, P1001, DOI 10.1161/01.RES.0000189260.46084.e5; Tran H, 2002, J CELL SCI, V115, P2031; Tsutsumi S, 2007, CANCER SCI, V98, P1536, DOI 10.1111/j.1349-7006.2007.00561.x; Tufi R, 2008, CELL DEATH DIFFER, V15, P274, DOI 10.1038/sj.cdd.4402275; Tutuncu L, 2004, DEV BIOL, V270, P246, DOI 10.1016/j.ydbio.2004.02.008; Valentijn AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421; Vance BA, 2005, ARCH BIOCHEM BIOPHYS, V438, P11, DOI 10.1016/j.abb.2005.04.009; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; Viaud S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004942; WATANABE L, 2006, FUKUSHIMA J MED SCI, V52, P1; Wearsch PA, 2008, CURR OPIN CELL BIOL, V20, P624, DOI 10.1016/j.ceb.2008.09.005; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; Wu LC, 1997, ARCH SURG-CHICAGO, V132, P753; Wu M, 2007, MATRIX BIOL, V26, P463, DOI 10.1016/j.matbio.2007.02.005; Xu Fei-Fei, 2008, Shengli Xuebao, V60, P29; Yao L, 2002, CANCER IMMUNOL IMMUN, V51, P358, DOI 10.1007/s00262-002-0294-2; Yao L, 2002, J LEUKOCYTE BIOL, V71, P47; Yoon GS, 2000, CANCER RES, V60, P1117; Yu X, 2006, CANCER RES, V66, P4795, DOI 10.1158/0008-5472.CAN-05-4579; Zeng G, 2006, J IMMUNOL, V177, P3582, DOI 10.4049/jimmunol.177.6.3582; Zhang KZ, 2008, METHOD ENZYMOL, V442, P395, DOI 10.1016/S0076-6879(08)01420-1; Zhang Y, 2009, J BIOL CHEM, V284, P10160, DOI 10.1074/jbc.M808356200; Zhu Q, 1997, BIOCHEM BIOPH RES CO, V232, P354, DOI 10.1006/bbrc.1997.6195; Zitvogel L, 2004, ADV IMMUNOL, V84, P131, DOI 10.1016/S0065-2776(04)84004-5; Zitvogel L, 2008, J CLIN INVEST, V118, P1991, DOI 10.1172/JCI35180; Zouq NK, 2009, J CELL SCI, V122, P357, DOI 10.1242/jcs.030478	167	286	321	2	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2010	24	3					665	683		10.1096/fj.09-145482	http://dx.doi.org/10.1096/fj.09-145482			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19940256	Green Published			2022-12-28	WOS:000274974600003
J	Nakao, S; Maruyama, K; Zandi, S; Melhorn, MI; Taher, M; Noda, K; Nusayr, E; Doetschman, T; Hafezi-Moghadam, A				Nakao, Shintaro; Maruyama, Kazuichi; Zandi, Souska; Melhorn, Mark I.; Taher, Mahdi; Noda, Kousuke; Nusayr, Eyad; Doetschman, Tom; Hafezi-Moghadam, Ali			Lymphangiogenesis and angiogenesis: concurrence and/or dependence? Studies in inbred mouse strains	FASEB JOURNAL			English	Article						cornea; conjunctiva; VEGF-A; FGF-2; VEGF-C; LYVE-1	FIBROBLAST-GROWTH-FACTOR; LYMPHATIC VESSELS; GENETIC-LOCI; FACTOR-C; NEOVASCULARIZATION; INFLAMMATION; HYPERPLASIA; MACROPHAGES; CORNEA; CELLS	Genetic background significantly affects angiogenesis in mice. However, lymphangiogenic response to growth factors (GFs) in different strains has not been studied. We report constitutive expression of corneal lymphatics that extends beyond the limits of normal limbal vessels. In untreated corneas, the total number (P = 0.006), the number above blood vessels (P = 10(-8)), and the area of preexisting lymphatics (P = 0.007) were significantly higher in C57BL/6 than in BALB/c mice. Normal corneas of three other strains, the nu/nu, 129E, and Black Swiss mice, showed in most parameters intermediate phenotypes. FGF-2(-/-) mice showed significantly less preexisting lymphatics than control (P = 0.009), which suggests a role for this GF in lymphatic development. VEGF-A-induced corneal lymphangiogenic response was significantly higher in BALB/c mice (P = 0.03), but it did not differ significantly in C57BL/6 mice, when compared to PBS-implanted control. FGFR-3 expression was higher in C57BL/6 than BALB/c mice, which suggests GF-receptor heterogeneity as a possible explanation for strain-dependent differences. The heterogeneity of preexisting lymphatic vessels in the limbal area significantly correlated with the extent of corneal lymphangiogenesis (VEGF-A: r = 0.7, P = 0.01; FGF-2: r = 0.96, P = 10(-5)) in BALB/c but not in C57BL/6 mice. Removal of conjunctival lymphatics did not affect GF-induced lymphangiogenesis. This work introduces physiological expression of lymphatics without blood vessels, which indicates that angiogenesis and lymphangiogenesis, even though intricately related, may occur independently. Furthermore, we show strain-dependence of normal and GF-induced lymphangiogenesis. These differences may affect disease development in various strains.-Nakao, S., Maruyama, K., Zandi, S., Melhorn, M. I., Taher, M., Noda, K., Nusayr, E., Doetschman, T., Hafezi-Moghadam, A. Lymphangiogenesis and angiogenesis: concurrence and/or dependence? Studies in inbred mouse strains. FASEB J. 24, 504-513 (2010). www.fasebj.org	[Nakao, Shintaro; Zandi, Souska; Melhorn, Mark I.; Taher, Mahdi; Noda, Kousuke; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA; [Nakao, Shintaro; Zandi, Souska; Melhorn, Mark I.; Taher, Mahdi; Noda, Kousuke; Hafezi-Moghadam, Ali] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA; [Maruyama, Kazuichi] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan; [Nusayr, Eyad; Doetschman, Tom] Univ Arizona, Dept Cell Biol & Anat, Tucson, AZ USA; [Nusayr, Eyad; Doetschman, Tom] Univ Arizona, Inst BIO5, Tucson, AZ USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary; Kyoto Prefectural University of Medicine; University of Arizona; University of Arizona	Hafezi-Moghadam, A (corresponding author), Angiogenesis Lab, 325 Cambridge St,3rd Floor, Boston, MA 02114 USA.	ali_hafezi-moghadam@meei.harvard.edu	Maruyama, Kazuichi/GRX-8129-2022	Maruyama, Kazuichi/0000-0001-6283-5466; Hafezi-Moghadam, Ali/0000-0002-5336-0697; Taher, Mahdi/0000-0001-8454-9751; Zandi, Souska/0000-0001-9351-4278	NIH [AI050775, HL086933, HL070174]; American Health Assistance Foundation; Japan Eye Bank Association and Tear Film and Ocular Surface Society; Young Investigator Fellowship; Massachusetts Lions Eye Research Fund; Research to Prevent Blindness; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070174, R01HL086933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050775] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Health Assistance Foundation(BrightFocus Foundation); Japan Eye Bank Association and Tear Film and Ocular Surface Society; Young Investigator Fellowship; Massachusetts Lions Eye Research Fund; Research to Prevent Blindness(Research to Prevent Blindness (RPB)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by NIH grants AI050775 (A.H.-M.), HL086933 (Alan Cross, University of Maryland, principal investigator, and A. H.-M.), and HL070174 (T. D.), the American Health Assistance Foundation (A. H.-M.), an overseas research fellowship award from Bausch & Lomb, a fellowship award from the Japan Eye Bank Association and Tear Film and Ocular Surface Society, a Young Investigator Fellowship (to S.N. under the mentorship of A. H.-M.), the Massachusetts Lions Eye Research Fund, and Research to Prevent Blindness. The authors thank Alexander Schering and Eiichi Sekiyama for their help with the preparation of the manuscript and Dr. Patricia D'Amore for her critical view of the work and helpful suggestions.	Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249; AOKI K, 1951, KAIBO GOKU ZASSHI, V24, P142; Baluk P, 2005, J CLIN INVEST, V115, P247, DOI 10.1172/JCI200522037; Bjorndahl MA, 2005, CANCER RES, V65, P9261, DOI 10.1158/0008-5472.CAN-04-2345; Cao RH, 2004, CIRC RES, V94, P664, DOI 10.1161/01.RES.0000118600.91698.BB; Chang LK, 2004, P NATL ACAD SCI USA, V101, P11658, DOI 10.1073/pnas.0404272101; Chen L, 2005, INVEST OPHTH VIS SCI, V46, P4536, DOI 10.1167/iovs.05-0975; Collin H B, 1966, Invest Ophthalmol, V5, P337; Cursiefen C, 2006, CORNEA, V25, P443, DOI 10.1097/01.ico.0000183485.85636.ff; Cursiefen C, 2004, INVEST OPHTH VIS SCI, V45, P2666, DOI 10.1167/iovs.03-1380; Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465; Cursiefen C, 2006, CORNEA, V25, P722, DOI 10.1097/01.ico.0000214230.21238.3d; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Karpanen T, 2008, ANNU REV PATHOL-MECH, V3, P367, DOI 10.1146/annurev.pathol.3.121806.151515; Kubo H, 2002, P NATL ACAD SCI USA, V99, P8868, DOI 10.1073/pnas.062040199; Lohela M, 2008, AM J PATHOL, V173, P1891, DOI 10.2353/ajpath.2008.080378; Maruyama K, 2005, J CLIN INVEST, V115, P2363, DOI 10.1172/JCI23874; Nakao S, 2003, J IMMUNOL, V170, P5704, DOI 10.4049/jimmunol.170.11.5704; Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298; Nakao S, 2007, AM J PATHOL, V171, P1058, DOI 10.2353/ajpath.2007.070172; Rogers MS, 2004, FASEB J, V18, P1050, DOI 10.1096/fj.03-1241com; Rogers MS, 2003, FASEB J, V17, P2112, DOI 10.1096/fj.03-0246fje; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Shin JW, 2006, MOL BIOL CELL, V17, P576, DOI 10.1091/mbc.E05-04-0368; Watari K, 2008, BIOCHEM BIOPH RES CO, V377, P826, DOI 10.1016/j.bbrc.2008.10.077; Yamada J, 1998, TRANSPL IMMUNOL, V6, P161, DOI 10.1016/S0966-3274(98)80041-5; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	29	39	41	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2010	24	2					504	513		10.1096/fj.09-134056	http://dx.doi.org/10.1096/fj.09-134056			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549JS	19858096	Green Published			2022-12-28	WOS:000274045000018
J	Nakatani, T; Ohnishi, M; Razzaque, MS				Nakatani, Teruyo; Ohnishi, Mutsuko; Razzaque, M. Shawkat			Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model	FASEB JOURNAL			English	Article						parathyroid hormone; vitamin D; calcification; survival; kidney; NaPi2a	X-LINKED HYPOPHOSPHATEMIA; SOFT-TISSUE CALCIFICATION; MINERAL ION METABOLISM; SHOCK-PROTEIN 47; VITAMIN-D; PHOSPHATE HOMEOSTASIS; PARATHYROID-HORMONE; TUMORAL CALCINOSIS; MISSENSE MUTATION; I COTRANSPORTER	Hyp mice possess a mutation that inactivates the phosphate-regulating gene, which is homologous to the endopeptidases of the X-chromosome (PHEX). The mutation is associated with severe hypophosphatemia due to excessive urinary phosphate wasting. Such urinary phosphate wasting in Hyp mice is associated with an increased serum accumulation of fibroblast growth factor (FGF) 23. We wanted to determine the biological significance of increased serum FGF23 levels and concomitant hypophosphatemia in Hyp mice and to evaluate whether FGF23 activity could be modified by manipulating klotho (a cofactor of FGF23 signaling). We generated Hyp and klotho double-mutant mice (Hyp/klotho(-/-)). Severe hypophosphatemia of Hyp mice was reversed to hyperphosphatemia in Hyp/klotho(-/-) double mutants, despite the fact that the double mutants showed significantly increased serum levels of FGF23. Hyperphosphatemia in Hyp/klotho(-/-) mice was associated with increased renal expression of sodium/phosphate cotransporter 2a (NaPi2a) protein. Exogenous injection of bioactive parathyroid hormone 1-34 down-regulated renal expression of NaPi2a and consequently reduced serum levels of phosphate in Hyp/klotho(-/-) mice. Moreover, in contrast to the Hyp mice, the Hyp/klotho(-/-) mice showed significantly higher serum levels of 1,25-dihydroxyvitamin D and developed extensive calcification in soft tissues and vascular walls. Furthermore, compared with the Hyp mice, Hyp/klotho(-/-) mice were smaller in size, showed features of generalized tissue atrophy, and generally died by 15-20 wk of age. Our in vivo studies provide genetic evidence for a pathological role of increased FGF23 activities in regulating abnormal phosphate homeostasis in Hyp mice. Moreover, these results suggest that even when serum levels of FGF23 are significantly high, in the absence of klotho, FGF23 is unable to regulate systemic phosphate homeostasis. Our in vivo observations have significant clinical implications in diseases associated with increased FGF23 activity and suggest that the functions of FGF23 can be therapeutically modulated by manipulating the effects of klotho.-Nakatani, Y., Ohnishi, M., Razzaque, M. S. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB J. 23, 3702-3711 (2009). www.fasebj.org	[Nakatani, Teruyo; Ohnishi, Mutsuko; Razzaque, M. Shawkat] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA	Harvard University; Harvard School of Dental Medicine	Razzaque, MS (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Room 304,188 Longwood Ave, Boston, MA 02115 USA.	mrazzaque@hms.harvard.edu	Razzaque, Mohammed S./K-4282-2019		National Institute of Diabetes and Digestive and Kidney Diseases, U.S. National Institutes of Health [R01-DK077276]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077276] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases, U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Parts of this research were supported by grant R01-DK077276 (to M. S. R.) from the National Institute of Diabetes and Digestive and Kidney Diseases, U.S. National Institutes of Health.	Bai XY, 2007, ENDOCRINOLOGY, V148, P4974, DOI 10.1210/en.2007-0243; Bai XY, 2002, MOL ENDOCRINOL, V16, P2913, DOI 10.1210/me.2002-0113; Benet-Pages A, 2005, HUM MOL GENET, V14, P385, DOI 10.1093/hmg/ddi034; Demer LL, 2008, CIRCULATION, V117, P2938, DOI 10.1161/CIRCULATIONAHA.107.743161; Doherty TM, 2004, ENDOCR REV, V25, P629, DOI 10.1210/er.2003-0015; ECAROT B, 1992, J BONE MINER RES, V7, P523; Fukumoto S, 2008, INTERNAL MED, V47, P337, DOI 10.2169/internalmedicine.47.0730; Gaasbeek A, 2005, AM J MED, V118, P1094, DOI 10.1016/j.amjmed.2005.02.014; Goetz R, 2007, MOL CELL BIOL, V27, P3417, DOI 10.1128/MCB.02249-06; Ichikawa S, 2007, J CLIN INVEST, V117, P2684, DOI 10.1172/JCI31330; Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881; Keusch I, 1998, KIDNEY INT, V54, P1224, DOI 10.1046/j.1523-1755.1998.00115.x; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Lanske B, 2007, AGEING RES REV, V6, P73, DOI 10.1016/j.arr.2007.02.002; Li SA, 2004, CELL STRUCT FUNCT, V29, P91, DOI 10.1247/csf.29.91; Liu D, 2008, AM J NEPHROL, V28, P555, DOI 10.1159/000115290; Liu SG, 2006, AM J PHYSIOL-ENDOC M, V291, pE38, DOI 10.1152/ajpendo.00008.2006; Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019; Memon F, 2008, KIDNEY INT, V74, P566, DOI 10.1038/ki.2008.218; Miyamoto KI, 2007, AM J NEPHROL, V27, P503, DOI 10.1159/000107069; Nakatani T, 2009, FASEB J, V23, P433, DOI 10.1096/fj.08-114397; Ohnishi M, 2009, KIDNEY INT, V75, P1166, DOI 10.1038/ki.2009.24; Pfister MF, 1998, P NATL ACAD SCI USA, V95, P1909, DOI 10.1073/pnas.95.4.1909; Razzaque MS, 2007, NAT CLIN PRACT ENDOC, V3, P788, DOI 10.1038/ncpendmet0667; Razzaque MS, 2009, AM J PHYSIOL-RENAL, V296, pF470, DOI 10.1152/ajprenal.90538.2008; Razzaque MS, 2007, J ENDOCRINOL, V194, P1, DOI 10.1677/JOE-07-0095; Razzaque MS, 2006, TRENDS MOL MED, V12, P298, DOI 10.1016/j.molmed.2006.05.002; Razzaque MS, 2009, NEPHROL DIAL TRANSPL, V24, P4, DOI 10.1093/ndt/gfn620; Razzaque MS, 1998, NEPHRON, V80, P434, DOI 10.1159/000045217; Razzaque MS, 2006, FASEB J, V20, P720, DOI 10.1096/fj.05-5432fje; Razzaque MS, 2005, J PATHOL, V207, P453, DOI 10.1002/path.1870; Razzaque MS, 2005, NEPHROL DIAL TRANSPL, V20, P2032, DOI 10.1093/ndt/gfh991; Razzaque MS, 1997, J PATHOL, V183, P24; Razzaque MS, 1998, MODERN PATHOL, V11, P1183; Segawa H, 2007, AM J PHYSIOL-RENAL, V292, pF769, DOI 10.1152/ajprenal.00248.2006; Sitara D, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000154; Tenenhouse HS, 1999, NEPHROL DIAL TRANSPL, V14, P333, DOI 10.1093/ndt/14.2.333; Tsujikawa H, 2003, MOL ENDOCRINOL, V17, P2393, DOI 10.1210/me.2003-0048; Wang H, 2008, J BONE MINER RES, V23, P939, DOI 10.1359/JBMR.080220; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Yu XJ, 2005, ENDOCRINOLOGY, V146, P4647, DOI 10.1210/en.2005-0670; Yu XJ, 2005, CYTOKINE GROWTH F R, V16, P221, DOI 10.1016/j.cytogfr.2005.01.002; Yuan B, 2008, J CLIN INVEST, V118, P722, DOI 10.1172/JCI32702; Yuan BZ, 2004, ENDOCRINOLOGY, V145, P3804, DOI 10.1210/en.2004-0192; Zha Y, 2008, AM J NEPHROL, V28, P755, DOI 10.1159/000128607; Zha Y, 2006, ENDOCRINOLOGY, V147, P5690, DOI 10.1210/en.2006-0302	46	86	88	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3702	3711		10.1096/fj.08-123992	http://dx.doi.org/10.1096/fj.08-123992			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19584304	Green Published			2022-12-28	WOS:000271272500008
J	Plouffe, BD; Kniazeva, T; Mayer, JE; Murthy, SK; Sales, VL				Plouffe, Brian D.; Kniazeva, Tatiana; Mayer, John E., Jr.; Murthy, Shashi K.; Sales, Virna L.			Development of microfluidics as endothelial progenitor cell capture technology for cardiovascular tissue engineering and diagnostic medicine	FASEB JOURNAL			English	Article						stem cell separation; immunophenotyping; cell adhesion; shear stress; device	SMOOTH-MUSCLE; SHEAR-STRESS; STEM-CELLS; ADHESION; FLOW; DIFFERENTIATION; CANCER	We have developed a unique microfluidic platform capable of capturing circulating endothelial progenitor cells (EPCs) by understanding surface chemistries and adhesion profiles. The surface of a variable-shear-stress microfluidic device was conjugated with 6 different antibodies [anti-CD34, -CD31, -vascular endothelial growth factor receptor-2 (VEGFR-2), -CD146, -CD45, and -von Willebrand factor (vWF)] designed to match the surface antigens on ovine peripheral blood-derived EPCs. Microfluidic analysis showed a shear-stress-dependent decrease in EPC adhesion on attached surface antigens. EPCs exhibited increased adhesion to antibodies against CD34, VEGFR-2, CD31, and CD146 compared to CD45, consistent with their endothelial cell-specific surface profile, when exposed to a minimum shear stress of 1.47 dyn/cm(2). Bone-marrow-derived mesenchymal stem cells and artery-derived endothelial and smooth muscle cells were used to demonstrate the specificity of the EPC microfluidic device. Coated hematopoietic specific-surface ( CD45) and granular vWF antibodies, as well as uncoated bare glass and substrate (1% BSA), were utilized as controls. Microfluidic devices have been developed as an EPC capture platform using immobilized antibodies targeted as EPC surface antigens. This EPC chip may provide a new and effective tool for addressing challenges in cardiovascular disease and tissue engineering.-Plouffe, B. D., Kniazeva, T., Mayer, J. E., Jr., Murthy, S. K., Sales, V. L. Development of microfluidics as endothelial progenitor cell capture technology for cardiovascular tissue engineering and diagnostic medicine. FASEB J. 23, 3309-3314 ( 2009). www.fasebj.org	[Plouffe, Brian D.; Kniazeva, Tatiana; Murthy, Shashi K.] Northeastern Univ, Dept Chem Engn, Boston, MA 02115 USA; [Mayer, John E., Jr.; Sales, Virna L.] Harvard Univ, Childrens Hosp, Sch Med, Dept Cardiac Surg, Boston, MA 02115 USA	Northeastern University; Harvard University; Boston Children's Hospital; Harvard Medical School	Murthy, SK (corresponding author), Northeastern Univ, Dept Chem Engn, 360 Huntington Ave,342 Snell Engn, Boston, MA 02115 USA.	smurthy@coe.neu.edu; virna.sales@childrens.harvard.edu	Plouffe, Brian/O-2520-2015; Plouffe, Brian/GON-3496-2022	Plouffe, Brian/0000-0002-1576-5714; 	American Health Assistance Foundation [H2007-017]; National Institutes of Health [HL-60463]; Center for Integration of Medicine and Innovative Technology (CIMIT); Gross Cardiovascular Fund and Center; American Heart Association Scientist Development [0635620T]; CIMIT [W81XWH-07-2-0011]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060463] Funding Source: NIH RePORTER	American Health Assistance Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Integration of Medicine and Innovative Technology (CIMIT); Gross Cardiovascular Fund and Center; American Heart Association Scientist Development(American Heart Association); CIMIT; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Michael Blaze, Ph.D. for editorial expertise. This work was supported by the National Heart Foundation, a program of the American Health Assistance Foundation, grant H2007-017 ( S. K. M.); the National Institutes of Health, grant HL-60463; the National Institute of Standards and Technology, grant NANB2H3053; the Center for Integration of Medicine and Innovative Technology (CIMIT); and the Gross Cardiovascular Fund and Center (J.E.M). V. L. S is the recipient of an American Heart Association Scientist Development grant (0635620T), a CIMIT Career Development grant, and a Miles and Eleanor Shore Fellowship. This work was supported by CIMIT under U. S. Army Medical Research Acquisition Activity Cooperative Agreement W81XWH-07-2-0011. The information contained herein does not necessarily reflect the position or policy of the U. S. government, and no official endorsement should be inferred. The authors report no conflicts of interest.	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006-0709; Bardin N, 2001, BLOOD, V98, P3677, DOI 10.1182/blood.V98.13.3677; Boos CJ, 2006, J AM COLL CARDIOL, V48, P1538, DOI 10.1016/j.jacc.2006.02.078; CLAUSEN J, 1981, LAB TECHNIQUES BIOCH, V1, P387; COZENSROBERTS C, 1990, BIOPHYS J, V58, P107, DOI 10.1016/S0006-3495(90)82357-2; CRAENENBROECK EMF, 2008, J IMMUNOL METHODS, V332, P31; Dvorin EL, 2003, TISSUE ENG, V9, P487, DOI 10.1089/107632703322066660; Dzau VJ, 2005, HYPERTENSION, V46, P7, DOI 10.1161/01.HYP.0000168923.92885.f7; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Lee S, 2007, P NATL ACAD SCI USA, V104, P9609, DOI 10.1073/pnas.0702668104; Leor J, 2006, J AM COLL CARDIOL, V48, P1588, DOI 10.1016/j.jacc.2006.07.032; Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035; Mettler BA, 2008, ANN THORAC SURG, V86, P132, DOI 10.1016/j.athoracsur.2008.02.074; Miwa J, 2008, J MICROELECTROMECH S, V17, P611, DOI 10.1109/JMEMS.2008.921706; Murthy SK, 2004, LANGMUIR, V20, P11649, DOI 10.1021/la048047b; Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385; Patel M, 2007, J FAM PRACTICE, V56, P64; Plouffe BD, 2008, LAB CHIP, V8, P462, DOI 10.1039/b715707j; Plouffe BD, 2007, LANGMUIR, V23, P5050, DOI 10.1021/la0700220; Rafii S, 2002, GENE THER, V9, P631, DOI 10.1038/sj.gt.3301723; Roncalli JG, 2008, TRENDS BIOTECHNOL, V26, P276, DOI 10.1016/j.tibtech.2008.01.005; Sales VL, 2007, CIRCULATION, V116, pI55, DOI 10.1161/CIRCULATIONAHA.106.6806637; Sales VL, 2007, TISSUE ENG, V13, P525, DOI 10.1089/ten.2006.0128; Timmermans F, 2009, J CELL MOL MED, V13, P87, DOI 10.1111/j.1582-4934.2008.00598.x; Toner M, 2005, ANNU REV BIOMED ENG, V7, P77, DOI 10.1146/annurev.bioeng.7.011205.135108; USAMI S, 1993, ANN BIOMED ENG, V21, P77, DOI 10.1007/BF02368167; Ward MR, 2007, CATHETER CARDIO INTE, V70, P983, DOI 10.1002/ccd.21302; Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471	30	75	77	0	44	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3309	3314		10.1096/fj.09-130260	http://dx.doi.org/10.1096/fj.09-130260			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19487310	Green Published			2022-12-28	WOS:000270354300008
J	Sani, MA; Keech, O; Gardestrom, P; Dufourc, EJ; Grobner, G				Sani, Marc-Antoine; Keech, Olivier; Gardestrom, Per; Dufourc, Erick J.; Grobner, Gerhard			Magic-angle phosphorus NMR of functional mitochondria: in situ monitoring of lipid response under apoptotic-like stress	FASEB JOURNAL			English	Article						respiration; oxidative stress; membrane integrity; cardiolipin; magnetic resonance; programmed cell death	CYTOCHROME-C RELEASE; POTATO-TUBER MITOCHONDRIA; RAT-LIVER MITOCHONDRIA; LOW-FREQUENCY MOTION; PERMEABILITY TRANSITION; P-31 NMR; SUBMITOCHONDRIAL PARTICLES; RESPIRATORY-CHAIN; CELL-DEATH; MEMBRANE	Using a noninvasive, solid-state magicangle spinning nuclear magnetic resonance (MAS NMR) approach, we track ex vivo the behavior of individual membrane components in isolated, active mitochondria (model system: potato tubers) during physiological processes. The individual phosphatidylcholine (PC), phosphatidylethanolamine (PE), and cardiolipin (CL) membrane constituents were identified as distinct lines by applying MAS (31)P NMR on extracted lipid membranes. However, the CL NMR signal appeared to be very broad in functional mitochondria, indicating a tight complex formation with membrane protein. Calcium stress induced severe membrane degradation without recovery of a single CL NMR resonance. This suggests that calcium overload destroys the outer mitochondrial membrane and does not modify strongly the CL protein complexes in the inner membrane; a conclusion confirmed by respiratory controls. Conversely, mitochondrial membrane disruption on time degradation or mechanical stress generates clearly visible identical CL NMR signals, similar to those observed in rehydrated lipid extracts. Similarly, noninvasive based NMR tracking of lipids in response to diverse physiological stimuli can easily be used for other organelles and whole living cells. Sani, M.-A., Keech, O., Gardestrom, P., Dufourc, E. J., Grobner, G. Magic-angle phosphorus NMR of functional mitochondria: in situ monitoring of lipid response under apoptotic-like stress. FASEB J. 23, 2872-2878 (2009). www.fasebj.org	[Sani, Marc-Antoine; Grobner, Gerhard] Umea Univ, Dept Chem, S-90187 Umea, Sweden; [Keech, Olivier; Gardestrom, Per] Umea Univ, Umea Plant Sci Ctr, Dept Plant Physiol, S-90187 Umea, Sweden; [Dufourc, Erick J.] Univ Bordeaux 1, UMR Chim & Biol Membranes & Nanoobjets 5248, CNRS, Pessac, France	Umea University; Umea University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Sani, MA (corresponding author), Umea Univ, Dept Chem, S-90187 Umea, Sweden.	marco.sani@chem.umu.se; gerhard.grobner@chem.umu.se	Sani, Marc-Antoine/B-7707-2013; DUFOURC, Erick Joel/AAA-4992-2020	Sani, Marc-Antoine/0000-0003-3284-2176; DUFOURC, Erick Joel/0000-0002-8221-9326	Knut and Alice Wallenberg Foundation; Kempe Foundation; Swedish Research Council; Umea University Insamlingsstiftelse; Centre National de la Recherche Scientifique (CNRS); Swedish Graduate Research School in Functional Genomics and Bioinformatics; Universities of Bordeaux 1 and Umea	Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Kempe Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Umea University Insamlingsstiftelse; Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Swedish Graduate Research School in Functional Genomics and Bioinformatics; Universities of Bordeaux 1 and Umea	This work was supported by the Knut and Alice Wallenberg Foundation, the Kempe Foundation, the Swedish Research Council, Umea University Insamlingsstiftelse, and the Centre National de la Recherche Scientifique (CNRS). Financial support was provided by the Swedish Graduate Research School in Functional Genomics and Bioinformatics. The Universities of Bordeaux 1 and Umea are acknowledged for setting up a cotutoring PhD program.	ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Arpagaus S, 2002, J BIOL CHEM, V277, P1780, DOI 10.1074/jbc.M109416200; Balk J, 1999, FEBS LETT, V463, P151, DOI 10.1016/S0014-5793(99)01611-7; Bayir H, 2006, BBA-BIOENERGETICS, V1757, P648, DOI 10.1016/j.bbabio.2006.03.002; Clayton R, 2005, J NEUROCHEM, V92, P840, DOI 10.1111/j.1471-4159.2004.02918.x; CORNELL BA, 1983, BIOCHIM BIOPHYS ACTA, V732, P473, DOI 10.1016/0005-2736(83)90065-2; CORNELL BA, 1982, BIOCHIM BIOPHYS ACTA, V689, P337, DOI 10.1016/0005-2736(82)90267-X; CULLIS PR, 1980, BIOCHIM BIOPHYS ACTA, V600, P625, DOI 10.1016/0005-2736(80)90466-6; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; DEKRUIJFF B, 1982, BIOCHIM BIOPHYS ACTA, V684, P47, DOI 10.1016/0005-2736(82)90047-5; DUFOURC EJ, 1993, PHOSPHORUS SULFUR, V77, P673; EDMAN K, 1987, BIOCHEM J, V243, P575, DOI 10.1042/bj2430575; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fortes F, 2001, J BIOENERG BIOMEMBR, V33, P43, DOI 10.1023/A:1005672623709; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grijalba MT, 1999, BIOCHEMISTRY-US, V38, P13279, DOI 10.1021/bi9828674; Grobner G, 1999, J MAGN RESON, V141, P335, DOI 10.1006/jmre.1999.1894; Jacotot E, 1999, ANN NY ACAD SCI, V887, P18, DOI 10.1111/j.1749-6632.1999.tb07919.x; Kagan VE, 2006, CHEM-BIOL INTERACT, V163, P15, DOI 10.1016/j.cbi.2006.04.019; Keech O, 2005, PHYSIOL PLANTARUM, V124, P403, DOI 10.1111/j.1399-3054.2005.00521.x; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lindstrom F, 2005, J AM CHEM SOC, V127, P6610, DOI 10.1021/ja042325b; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; MACDONALD PM, 1991, BIOCHEMISTRY-US, V30, P3558, DOI 10.1021/bi00228a029; Maciel EN, 2004, J NEUROCHEM, V90, P1025, DOI 10.1111/j.1471-4159.2004.02565.x; Malisan F, 2003, CURR MED CHEM, V10, P1573, DOI 10.2174/0929867033457188; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Mariano AB, 2005, PLANT PHYSIOL BIOCH, V43, P61, DOI 10.1016/j.plaphy.2004.12.008; PETIT PX, 1987, BIOCHIM BIOPHYS ACTA, V890, P377, DOI 10.1016/0005-2728(87)90166-6; Petrosillo G, 2004, J BIOL CHEM, V279, P53103, DOI 10.1074/jbc.M407500200; Petrosillo G, 2006, FEBS LETT, V580, P6311, DOI 10.1016/j.febslet.2006.10.036; PINHEIRO TJT, 1994, BIOCHEMISTRY-US, V33, P2451, DOI 10.1021/bi00175a013; SEELIG J, 1978, BIOCHIM BIOPHYS ACTA, V515, P105, DOI 10.1016/0304-4157(78)90001-1; SPOONER PJR, 1991, BIOCHEMISTRY-US, V30, P3880, DOI 10.1021/bi00230a011; SWAIRJO MA, 1994, BBA-BIOMEMBRANES, V1191, P354, DOI 10.1016/0005-2736(94)90186-4; TUPPER JOSEPH T., 1967, LIFE SCI, V6, P2021, DOI 10.1016/0024-3205(67)90220-2; Wenk MR, 2005, NAT REV DRUG DISCOV, V4, P594, DOI 10.1038/nrd1776; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zhang DW, 2008, J BIOL CHEM, V283, P3476, DOI 10.1074/jbc.M707528200	42	14	14	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2009	23	9					2872	2878		10.1096/fj.09-134114	http://dx.doi.org/10.1096/fj.09-134114			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19395474				2022-12-28	WOS:000270241000010
J	Serganova, I; Moroz, E; Vider, J; Gogiberidze, G; Moroz, M; Pillarsetty, N; Doubrovin, M; Minn, A; Thaler, HT; Massague, J; Gelovani, J; Blasberg, R				Serganova, Inna; Moroz, Ekaterina; Vider, Jelena; Gogiberidze, George; Moroz, Maxim; Pillarsetty, Nagavarakishore; Doubrovin, Michael; Minn, Andy; Thaler, Howard T.; Massague, Joan; Gelovani, Juri; Blasberg, Ronald			Multimodality imaging of TGF beta signaling in breast cancer metastases	FASEB JOURNAL			English	Article						Smads complex; herpes simplex virus type one thymidine kinase; green fluorescent protein; FEAU; positron emission tomography; bioluminescence; bone resorption	GROWTH-FACTOR-BETA; ANIMAL-MODELS; BONE METASTASIS; IN-VIVO; REPORTER GENE; CELLS; FLUORESCENT; EXPRESSION; BIOLUMINESCENT; INDUCTION	The skeleton is a preferred site for breast cancer metastasis. We have developed a multimodality imaging approach to monitor the transforming growth factor beta (TGF beta) signaling pathway in bone metastases, sequentially over time in the same animal. As model systems, two MDA-MB-231 breast cancer cells lines with different metastatic tropisms, SCP2 and SCP3, were transduced with constitutive and TGF beta-inducible reporter genes and were tested in vitro and in living animals. The sites and expansion of metastases were visualized by bioluminescence imaging using a constitutive firefly luciferase reporter, while TGF beta signaling in metastases was monitored by microPET imaging of HSV1-TK/GFP expression with [F-18] FEAU and by a more sensitive and cost-effective bioluminescence reporter, based on nonsecreted Gaussia luciferase. Concurrent and sequential imaging of metastases in the same animals provided insight into the location and progression of metastases, and the timing and course of TGF beta signaling. The anticipated and newly observed differences in the imaging of tumors from two related cell lines have demonstrated that TGF beta signal transduction pathway activity can be noninvasively imaged with high sensitivity and reproducibility, thereby providing the opportunity for an assessment of novel treatments that target TGF beta signaling.-Serganova, I., Moroz, E., Vider, J., Gogiberidze, G., Moroz, M., Pillarsetty, N., Doubrovin, M., Minn, A., Thaler, H. T., Massague, J., Gelovani, J., Blasberg, R. Multimodality imaging of TGF beta signaling in breast	[Blasberg, Ronald] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, Dept Neurol, SKI, New York, NY 10021 USA; [Pillarsetty, Nagavarakishore; Doubrovin, Michael; Blasberg, Ronald] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA; [Minn, Andy; Massague, Joan] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Blasberg, R (corresponding author), Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, Dept Neurol, SKI, MH Box 52,1275 York Ave, New York, NY 10021 USA.	blasberg@neurol.mskcc.org	Vider, Jelena/AAW-8577-2020; Vider, Jelena/B-9663-2011; Doubrovin, Mikhail/C-5859-2017	Vider, Jelena/0000-0003-1696-9812; Doubrovin, Mikhail/0000-0001-6607-2646; Serganova, Inna/0000-0003-3561-8663; Pillarsetty, Naga Vara Kishore/0000-0002-1750-7436; Minn, Andy/0000-0003-1418-0906; Massague, Joan/0000-0001-9324-8408	U. S. National Institutes of Health (NIH) [P50CA86438-01, P01CA094060, R24 CA83084, P30CA08748]; NATIONAL CANCER INSTITUTE [P01CA094060, P50CA086438, R24CA083084, P30CA008748] Funding Source: NIH RePORTER	U. S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Lyudmila Ageyeva and Katerina Dyomina for excellent technical assistance; Dr. R. J. Brentjens [Memorial Sloan-Kettering Cancer Center (MSKCC)] for providing a plasmid SFG-exGLuc-IRES-GFP; Dr. V. Ponomarev for valuable discussions; and Dr. S. Larson for help and generous support. This work was supported by U. S. National Institutes of Health (NIH) grant P50CA86438-01 and partly by NIH grant P01CA094060. Technical services were provided by the MSKCC Small-Animal Imaging Core Facility, supported in part by NIH Small Animal Imaging Resource Program grant R24 CA83084 and NIH center grant P30CA08748.	ARGUELLO F, 1990, CANCER, V65, P98, DOI 10.1002/1097-0142(19900101)65:1<98::AID-CNCR2820650121>3.0.CO;2-K; Arvanitis C, 2008, CANCER BIOL THER, V7, P1947, DOI 10.4161/cbt.7.12.6947; Berger F, 2002, EUR J NUCL MED MOL I, V29, P1225, DOI 10.1007/s00259-002-0850-1; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159; Cowey S, 2007, CLIN EXP METASTAS, V24, P389, DOI 10.1007/s10585-007-9076-8; Deroose CM, 2007, J NUCL MED, V48, P295; Doubrovin M, 2001, P NATL ACAD SCI USA, V98, P9300, DOI 10.1073/pnas.161091198; Edinger M, 2002, EUR J CANCER, V38, P2128, DOI 10.1016/S0959-8049(02)00410-0; EILON G, 1978, NATURE, V276, P726, DOI 10.1038/276726a0; Fritz V, 2007, BONE, V40, P1032, DOI 10.1016/j.bone.2006.11.026; Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078-0432.CCR-06-1007; HEALY AM, 1994, J BIOL CHEM, V269, P19095; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Kaijzel EL, 2007, CLIN CANCER RES, V13, P3490, DOI 10.1158/1078-0432.CCR-07-0402; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Katsuno Y, 2008, ONCOGENE, V27, P6322, DOI 10.1038/onc.2008.232; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Miyagawa T, 2008, J NUCL MED, V49, P637, DOI 10.2967/jnumed.107.046227; Phadke PA, 2006, CLIN CANCER RES, V12, P1431, DOI 10.1158/1078-0432.CCR-05-1806; Ponomarev V, 2001, NEOPLASIA, V3, P480, DOI 10.1038/sj.neo.7900204; Ponomarev V, 2004, EUR J NUCL MED MOL I, V31, P740, DOI 10.1007/s00259-003-1441-5; Rosol TJ, 2003, CANCER-AM CANCER SOC, V97, P748, DOI 10.1002/cncr.11150; Santos EB, 2009, NAT MED, V15, P338, DOI 10.1038/nm.1930; Schmidt-Weber CB, 2004, CURR OPIN IMMUNOL, V16, P709, DOI 10.1016/j.coi.2004.09.008; Serganova I, 2004, CANCER RES, V64, P6101, DOI 10.1158/0008-5472.CAN-04-0842; Sugano Y, 2003, ONCOGENE, V22, P2309, DOI 10.1038/sj.onc.1206305; TJUVAJEV JG, 1995, CANCER RES, V55, P6126; Tjuvajev JG, 1996, CANCER RES, V56, P4087; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Winkelmann CT, 2006, MOL IMAGING, V5, P105, DOI 10.2310/7290.2006.00011; Yang M, 2000, P NATL ACAD SCI USA, V97, P1206, DOI 10.1073/pnas.97.3.1206; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	39	44	46	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2662	2672		10.1096/fj.08-126920	http://dx.doi.org/10.1096/fj.08-126920			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19325038	Green Published			2022-12-28	WOS:000268836700034
J	Sun, XL; Salih, E; Oppenheim, FG; Helmerhorst, EJ				Sun, Xiuli; Salih, Erdjan; Oppenheim, Frank G.; Helmerhorst, Eva J.			Kinetics of histatin proteolysis in whole saliva and the effect on bioactive domains with metal-binding, antifungal, and wound-healing properties	FASEB JOURNAL			English	Article						oral; proteolytic; enzymes; proteins; proteomics	HISTIDINE-RICH-POLYPEPTIDES; HUMAN-PAROTID SECRETION; PERIODONTAL-DISEASE; IDENTIFICATION; PELLICLE; ZINC; PROTEASES; PEPTIDES; PROTEOMICS; ENZYMES	The present study was undertaken to investigate the rate and mode of degradation of individual histatin proteins in whole saliva to establish the impact on its functional domains. Pure synthetic histatins 1, 3, and 5 were incubated with whole saliva supernatant as the enzyme source, and peptides in the resultant digests were separated by reverse-phase-HPLC and structurally characterized by electrospray ionization-tandem mass spectrometry. The overall V-max/K-m ratios, a measure of proteolytic efficiency, were on the order of histatin-5 > histatin-3 > histatin-1. Mathematical models predict that histatins 1, 3, and 5 levels in whole saliva stabilize at 5.1, 1.9, and 1.2 mu M, representing 59, 27, and 11% of glandular histatins 1, 3, and 5 levels, respectively. Monitoring of the appearance and disappearance of histatin fragments yielded the identification of the first targeted enzymatic cleavage sites as K-13 and K-17 in histatin 1, R-22, Y-24, and R-25 in histatin 3, and Y-10, K-11, R-12, K-13, H-15, E-16, K-17, and H-18 in histatin 5. The data indicate that metal-binding, antifungal, and wound-healing domains are largely unaffected by the primary cleavage events in whole saliva, suggesting a sustained functional activity of these proteins in the proteolytic environment of the oral cavity.-Sun, X., Salih, E., Oppenheim, F. G., Helmerhorst, E. J. Kinetics of histatin proteolysis in whole saliva and the effect on bioactive domains with metal-binding, antifungal, and wound-healing properties. FASEB J. 23, 2691-2701 ( 2009)	[Sun, Xiuli; Salih, Erdjan; Oppenheim, Frank G.; Helmerhorst, Eva J.] Boston Univ, Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02118 USA	Boston University	Helmerhorst, EJ (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02118 USA.	helmer@bu.edu		Helmerhorst, Eva/0000-0002-4803-3018; Salih, Erdjan/0000-0003-3322-2323	National Institutes of Health/National Institute of Dental and Craniofacial Research [DE05672, DE07652, DE18448, DE18132, DE16699]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE007652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE018448, R01DE005672, R21DE018132, R03DE016699, R37DE005672] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This study was supported by National Institutes of Health/National Institute of Dental and Craniofacial Research grants DE05672, DE07652, DE18448, DE18132, and DE16699.	Amerongen AVN, 2002, ORAL DIS, V8, P12, DOI 10.1034/j.1601-0825.2002.1o816.x; ARMSTRONG WG, 1968, P ROY SOC MED, V61, P923, DOI 10.1177/003591576806100929; BAUM BJ, 1977, J DENT RES, V56, P1115, DOI 10.1177/00220345770560091801; BAUM BJ, 1976, ARCH BIOCHEM BIOPHYS, V177, P427, DOI 10.1016/0003-9861(76)90455-0; Brewer D, 1998, BIOCHEM CELL BIOL, V76, P247, DOI 10.1139/bcb-76-2-3-247; Bruno LS, 2005, BBA-MOL CELL RES, V1746, P65, DOI 10.1016/j.bbamcr.2005.08.007; CAMPESE M, 2009, ARCH ORAL BIOL, DOI DOI 10.1016/J.ARCHORAL-BIO.2008.11.010; Castagnola M, 2004, J BIOL CHEM, V279, P41436, DOI 10.1074/jbc.M404322200; Dawes C, 2004, CARIES RES, V38, P236, DOI 10.1159/000077760; Flora B, 2001, PROTEIN EXPRES PURIF, V23, P198, DOI 10.1006/prep.2001.1493; Freedman A, 1996, LANCET, V348, P1592, DOI 10.1016/S0140-6736(05)66216-2; Germaine G R, 1978, Adv Exp Med Biol, V107, P849; Grogan J, 2001, FEBS LETT, V491, P76, DOI 10.1016/S0014-5793(01)02157-3; Gusman H, 2001, BBA-PROTEIN STRUCT M, V1545, P86, DOI 10.1016/S0167-4838(00)00265-X; Gusman H, 2004, ARCH ORAL BIOL, V49, P11, DOI 10.1016/S0003-9969(03)00182-1; Gusman H, 2001, INFECT IMMUN, V69, P1402, DOI 10.1128/IAI.69.3.1402-1408.2001; Helmerhorst EJ, 2007, J DENT RES, V86, P680, DOI 10.1177/154405910708600802; Helmerhorst EJ, 2006, ARCH ORAL BIOL, V51, P1061, DOI 10.1016/j.archoralbio.2006.06.005; Helmerhorst EJ, 2008, J BIOL CHEM, V283, P19957, DOI 10.1074/jbc.M708282200; Iontcheva I, 2000, J DENT RES, V79, P732; Li J, 2004, J DENT RES, V83, P60, DOI 10.1177/154405910408300112; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Melino S, 1999, BIOCHEMISTRY-US, V38, P9626, DOI 10.1021/bi990212c; Melino S, 2006, BIOCHEMISTRY-US, V45, P15373, DOI 10.1021/bi0615137; Messana I, 2008, MOL CELL PROTEOMICS, V7, P911, DOI 10.1074/mcp.M700501-MCP200; NAKAMURA M, 1983, J PERIODONTAL RES, V18, P559, DOI 10.1111/j.1600-0765.1983.tb00393.x; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; OPPENHEIM FG, 1986, J BIOL CHEM, V261, P1177; Oudhoff MJ, 2008, FASEB J, V22, P3805, DOI 10.1096/fj.08-112003; Overall CM, 2007, NAT REV MOL CELL BIO, V8, P245, DOI 10.1038/nrm2120; PAYNE JB, 1991, ORAL MICROBIOL IMMUN, V6, P169, DOI 10.1111/j.1399-302X.1991.tb00472.x; Rothstein David M, 2002, Expert Opin Emerg Drugs, V7, P47, DOI 10.1517/14728214.7.1.47; Rothstein DM, 2001, ANTIMICROB AGENTS CH, V45, P1367, DOI 10.1128/AAC.45.5.1367-1373.2001; RUDNEY JD, 1995, CRIT REV ORAL BIOL M, V6, P343, DOI 10.1177/10454411950060040501; Sorsa T, 2004, ORAL DIS, V10, P311, DOI 10.1111/j.1601-0825.2004.01038.x; SUN X, 2009, PROTEOMICS IN PRESS; Vitorino R, 2004, BIOMED CHROMATOGR, V18, P570, DOI 10.1002/bmc.358; Vitorino R, 2004, PROTEOMICS, V4, P1109, DOI 10.1002/pmic.200300638; Vitorino R, 2007, BIOMED CHROMATOGR, V21, P1107, DOI 10.1002/bmc.830; WATANABE T, 1981, J DENT RES, V60, P1039, DOI 10.1177/00220345810600060601; XU T, 1991, INFECT IMMUN, V59, P2549, DOI 10.1128/IAI.59.8.2549-2554.1991; ZAHRADNIK RT, 1976, J DENT RES, V55, P664, DOI 10.1177/00220345760550042101	42	40	44	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2691	2701		10.1096/fj.09-131045	http://dx.doi.org/10.1096/fj.09-131045			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19339663	Green Published			2022-12-28	WOS:000268836700037
J	Nakai, K; Rogers, MS; Baba, T; Funakoshi, T; Birsner, AE; Luyindula, DS; D'Amato, RJ				Nakai, Kei; Rogers, Michael S.; Baba, Takashi; Funakoshi, Taisaku; Birsner, Amy E.; Luyindula, Dema S.; D'Amato, Robert J.			Genetic loci that control the size of laser-induced choroidal neovascularization	FASEB JOURNAL			English	Article						quantitative trait locus; QTL; recombinant inbred; BXD	ENDOTHELIAL GROWTH-FACTOR; QUANTITATIVE TRAIT LOCI; COMPLEMENT FACTOR-H; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; MOUSE STRAINS; GENOME SCAN; LABORATORY MOUSE; SUSCEPTIBILITY LOCI; MURINE MODEL	Angiogenesis is controlled by a balance between stimulators and inhibitors. We propose that the balance, as well as the general sensitivity of the endothelium to these factors, varies from individual to individual. Indeed, we have found that individual mouse strains have dramatically different responses to growth factor-induced neovascularization. Quantitative trait loci (QTLs), which influence the extent of corneal angiogenesis induced by vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF2), were previously identified by our laboratory. To investigate the genetic contribution to choroidal neovascularization (CNV), a leading cause of blindness, we have undertaken a similar mapping approach to identify QTLs that influence laser-induced CNV in the BXD series of recombinant inbred mouse strains. Composite interval mapping identified new angiogenic QTLs on chromosomes 2 and 19, in addition to confirming our previous corneal neovascularization QTLs of AngVq1 and AngFq2. The new QTLs are named AngCNVq1 and AngCNVq2. The newly mapped regions contain several candidate genes involved in the angiogenic process, including thrombospondin 1, delta-like 4, BclII modifying factor, phospholipase C, beta 2, adrenergic receptor, beta 1, actin-binding LIM protein 1 and colony stimulating factor 2 receptor, alpha. Differences in these regions may control individual susceptibility to CNV.-Nakai, K., Rogers, M. S., Baba, T., Funakoshi, T., Birsner, A. E., Luyindula, D. S., D'Amato, R. J. Genetic loci that control the size of laser-induced choroidal neovascularization. FASEB J. 23, 2235-2243 (2009)	[Nakai, Kei; Rogers, Michael S.; Birsner, Amy E.; Luyindula, Dema S.; D'Amato, Robert J.] Childrens Hosp, Dept Surg, Vasc Biol Program, Boston, MA 02115 USA; [Baba, Takashi; Funakoshi, Taisaku] Tottori Univ, Fac Med, Div Ophthalmol & Visual Sci, Tottori 680, Japan; [D'Amato, Robert J.] Harvard Univ, Sch Med, Dept Ophthalmol, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Tottori University; Harvard University	D'Amato, RJ (corresponding author), Childrens Hosp, Dept Surg, Vasc Biol Program, Karp 11-210,300 Longwood Ave, Boston, MA 02115 USA.	robert.damato@childrens.harvard.edu	Rogers, Michael/AAE-2217-2019; Rogers, Michael S/A-9814-2009	Rogers, Michael/0000-0002-5250-8434; Rogers, Michael S/0000-0002-5250-8434	National Eye Institute [RO1 EY12726]; NATIONAL EYE INSTITUTE [R01EY012726] Funding Source: NIH RePORTER	National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We thank Kristin Johnson for help in the preparation of digital art. Portions of this work were funded by a grant from the National Eye Institute (RO1 EY12726).	Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018; AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178; Balasubramanian SP, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-107; Barral S, 2006, INVEST OPHTH VIS SCI, V47, P5453, DOI 10.1167/iovs.06-0655; Blake JA, 2002, NUCLEIC ACIDS RES, V30, P113, DOI 10.1093/nar/30.1.113; Brannan CI, 2001, MAMM GENOME, V12, P882, DOI 10.1007/s00335-001-2084-0; Brown AC, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-12; Carroll S, 2004, J CELL SCI, V117, P105, DOI 10.1242/jcs.00847; Cherrington JM, 2000, ADV CANCER RES, V79, P1, DOI 10.1016/S0065-230X(00)79001-4; Cheverud JM, 1996, GENETICS, V142, P1305; Davis RC, 2005, GENOMICS, V86, P259, DOI 10.1016/j.ygeno.2005.05.010; DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3; Frazer KA, 2007, NATURE, V448, P1050, DOI 10.1038/nature06067; Ghazalpour A, 2006, PLOS GENET, V2, P1182, DOI 10.1371/journal.pgen.0020130; Gorin MB, 1999, MOL VIS, V5, pU31; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3; Higashi S, 1998, J CANCER RES CLIN, V124, P670, DOI 10.1007/s004320050230; Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723; Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807; Iughetti P, 2001, CANCER RES, V61, P7375; Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437; Kariyazono H, 2004, PEDIATR RES, V56, P953, DOI 10.1203/01.PDR.0000145280.26284.B9; Kenney-Hunt JP, 2006, MAMM GENOME, V17, P526, DOI 10.1007/s00335-005-0160-6; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kim AC, 1997, GENOMICS, V46, P291, DOI 10.1006/geno.1997.5029; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338; Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929; LANDER ES, 1989, GENETICS, V121, P185; Liu XB, 2000, CELL DEATH DIFFER, V7, P1119, DOI 10.1038/sj.cdd.4400745; Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104; Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y; Masinde Godfred L, 2002, Funct Integr Genomics, V2, P98, DOI 10.1007/s10142-002-0053-7; Masinde Godfred L, 2002, Funct Integr Genomics, V2, P120, DOI 10.1007/s10142-002-0067-1; McLaren J, 2000, HUM REPROD UPDATE, V6, P45, DOI 10.1093/humupd/6.1.45; Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4; Mountz JD, 2005, SCAND J IMMUNOL, V61, P128, DOI 10.1111/j.0300-9475.2005.01548.x; Nadeau JH, 2000, NAT GENET, V24, P221, DOI 10.1038/73427; Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891; Otto JM, 1999, ARTHRITIS RHEUM, V42, P2524, DOI 10.1002/1529-0131(199912)42:12<2524::AID-ANR4>3.0.CO;2-0; Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2; Reed DR, 2003, MAMM GENOME, V14, P302, DOI 10.1007/s00335-002-2170-y; Ren B, 2006, BBA-REV CANCER, V1765, P178, DOI 10.1016/j.bbcan.2005.11.002; Rogers MS, 2007, NAT PROTOC, V2, P2545, DOI 10.1038/nprot.2007.368; Rogers MS, 2004, FASEB J, V18, P1050, DOI 10.1096/fj.03-1241com; Rogers MS, 2003, FASEB J, V17, P2112, DOI 10.1096/fj.03-0246fje; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707; Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097; Schmidt S, 2000, MOL VIS, V6, P287; Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348; Shaked Y, 2005, CANCER CELL, V7, P101, DOI 10.1016/j.ccr.2004.11.023; Shiozawa Shunichi, 2002, Nihon Rinsho, V60, P2269; Smith JD, 2006, ARTERIOSCL THROM VAS, V26, P597, DOI 10.1161/01.ATV.0000201044.33220.5c; Smith SK, 2001, BRIT J OBSTET GYNAEC, V108, P777, DOI 10.1111/j.1471-0528.2001.00211.x; Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833; Stylianou IM, 2006, MAMM GENOME, V17, P22, DOI 10.1007/s00335-005-0091-2; Suh PG, 2001, BIOCHEM BIOPH RES CO, V288, P1, DOI 10.1006/bbrc.2001.5710; Symons RCA, 2002, P NATL ACAD SCI USA, V99, P11299, DOI 10.1073/pnas.162566999; Tanimoto K, 2003, CARCINOGENESIS, V24, P1779, DOI 10.1093/carcin/bgg132; Taylor BA, 1997, GENOMICS, V43, P249, DOI 10.1006/geno.1997.4835; Taylor BA, 2001, MAMM GENOME, V12, P95, DOI 10.1007/s003350010254; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje; Tripodis N, 2001, J NATL CANCER I, V93, P1484, DOI 10.1093/jnci/93.19.1484; Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436; Wade CM, 2002, NATURE, V420, P574, DOI 10.1038/nature01252; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476; Wong HPS, 2007, TOXICOL SCI, V97, P279, DOI 10.1093/toxsci/kfm060; Yang H, 2007, NAT GENET, V39, P1100, DOI 10.1038/ng2087; Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317; Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426; Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154; ZENG ZB, 1994, GENETICS, V136, P1457; ZENG ZB, 1993, P NATL ACAD SCI USA, V90, P10972, DOI 10.1073/pnas.90.23.10972; ZENG ZB, 1994, P 5 WORLD C GEN APPL, V22, P65; Zheng HR, 2003, DNA SEQUENCE, V14, P369, DOI 10.1080/10425170310001605491	84	14	14	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2235	2243		10.1096/fj.08-124321	http://dx.doi.org/10.1096/fj.08-124321			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19237505	Green Published			2022-12-28	WOS:000268836500023
J	Pederson, T				Pederson, Thoru			The discovery of eukaryotic genome design and its forgotten corollary - the postulate of gene regulation by nuclear RNA	FASEB JOURNAL			English	Article							CELLS; PROMOTERS; REVEALS	We now know that more of the DNA in eukaryotic cells is copied into RNA than previously had been thought. Many of these transcripts serve regulatory instead of template functions in gene readout. Some of these newly recognized RNAs come from regions of the genome that had heretofore been deemed "junk DNA," yet no one could answer the obvious question: if " junk," then why still around? Before memory fades, we should note that there were some reasonably well articulated ideas 30-40 years ago that anticipated these recent discoveries. It seems fitting to recall the prescience of those who first raised such unorthodoxy. They powerfully catalyzed progress. FASEB J. 23, 2019-2021 (2009)	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Program Cell & Dev Dynam, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Program Cell & Dev Dynam, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu			NIH [GM-21595, GM-21394]; National Science Foundation [MCB 0445841]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021595] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Work cited on nuclear RNA from my laboratory was supported by NIH grants GM-21595 and GM-21394. During the genesis of this essay my laboratory was supported by the National Science Foundation ( grant MCB 0445841). I thank Robert Haselkorn ( University of Chicago, Chicago, Illinois) for reading a rough draft and offering insightful comments.	ALLEN GE, 1978, TH MORGAN MAN HIS SC, pE0; BRITTEN RJ, 1968, SCIENCE, V161, P529, DOI 10.1126/science.161.3841.529; BRITTEN RJ, 1969, SCIENCE, V165, P349, DOI 10.1126/science.165.3891.349; CALVET JP, 1981, CELL, V26, P363, DOI 10.1016/0092-8674(81)90205-1; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; EBERT JD, 1994, THIS OUR GOLDEN AGE, pE0; FEDEROFF N, 1977, CELL, V10, P597; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; HALL BD, 1961, P NATL ACAD SCI USA, V47, P137, DOI 10.1073/pnas.47.2.137; He YP, 2008, SCIENCE, V322, P1855, DOI 10.1126/science.1163853; HOLLAND CA, 1980, J MOL BIOL, V138, P755, DOI 10.1016/0022-2836(80)90064-9; KAY LE, 1993, MOL VISION LIFE CALT, pE0; Pederson T, 2006, DEV BIOL, V300, P9, DOI 10.1016/j.ydbio.2006.10.006; Seila AC, 2008, SCIENCE, V322, P1849, DOI 10.1126/science.1162253	15	3	3	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2009	23	7					2019	2021		10.1096/fj.09-0702	http://dx.doi.org/10.1096/fj.09-0702			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19567373				2022-12-28	WOS:000268836500002
J	Chinopoulos, C; Gerencser, AA; Mandi, M; Mathe, K; Torocsik, B; Doczi, J; Turiak, L; Kiss, G; Konrad, C; Vajda, S; Vereczki, V; Oh, RJ; Adam-Vizi, V				Chinopoulos, Christos; Gerencser, Akos A.; Mandi, Miklos; Mathe, Katalin; Torocsik, Beata; Doczi, Judit; Turiak, Lilla; Kiss, Gergely; Konrad, Csaba; Vajda, Szilvia; Vereczki, Viktoria; Oh, Richard J.; Adam-Vizi, Vera			Forward operation of adenine nucleotide translocase during F0F1-ATPase reversal: critical role of matrix substrate-level phosphorylation	FASEB JOURNAL			English	Article						adenine nucleotide carrier; ATP synthasome; systems biology of mitochondria; SUCLA2; bioenergetics	HEART-RATE HEARTS; MITOCHONDRIAL ADENOSINE 5'-TRIPHOSPHATASE; CA-2&-INDUCED MEMBRANE TRANSITION; ALPHA-KETOGLUTARATE DEHYDROGENASE; CULTURED CORTICAL-NEURONS; SUCCINYL-COA SYNTHETASES; K-ATP CHANNELS; INTRACELLULAR ATP; IN-VITRO; CALCIUM DEREGULATION	In pathological conditions, F0F1-ATPase hydrolyzes ATP in an attempt to maintain mitochondrial membrane potential. Using thermodynamic assumptions and computer modeling, we established that mitochondrial membrane potential can be more negative than the reversal potential of the adenine nucleotide translocase (ANT) but more positive than that of the F0F1-ATPase. Experiments on isolated mitochondria demonstrated that, when the electron transport chain is compromised, the F0F1-ATPase reverses, and the membrane potential is maintained as long as matrix substrate-level phosphorylation is functional, without a concomitant reversal of the ANT. Consistently, no cytosolic ATP consumption was observed using plasmalemmal K-ATP channels as cytosolic ATP biosensors in cultured neurons, in which their in situ mitochondria were compromised by respiratory chain inhibitors. This finding was further corroborated by quantitative measurements of mitochondrial membrane potential, oxygen consumption, and extracellular acidification rates, indicating nonreversal of ANT of compromised in situ neuronal and astrocytic mitochondria; and by bioluminescence ATP measurements in COS-7 cells transfected with cytosolic- or nuclear-targeted luciferases and treated with mitochondrial respiratory chain inhibitors in the presence of glycolytic plus mitochondrial vs. only mitochondrial substrates. Our findings imply the possibility of a rescue mechanism that is protecting against cytosolic/nuclear ATP depletion under pathological conditions involving impaired respiration. This mechanism comes into play when mitochondria respire on substrates that support matrix substrate-level phosphorylation.-Chinopoulos, C., Gerencser, A.A., Mandi, M., Mathe, K., Torocsik, B., Doczi, J., Turiak, L., Kiss, G., Konrad, C., Vajda, S., Vereczki, V., Oh, R. J., Adam-Vizi, V. Forward operation of adenine nucleotide translocase during F0F1-ATPase reversal: critical role of matrix substrate-level phosphorylation. FASEB J. 24, 2405-2416 (2010). www.fasebj.org	[Chinopoulos, Christos; Mandi, Miklos; Mathe, Katalin; Torocsik, Beata; Doczi, Judit; Turiak, Lilla; Kiss, Gergely; Konrad, Csaba; Vajda, Szilvia; Adam-Vizi, Vera] Semmelweis Univ, Hungarian Acad Sci, Szentagothai Knowledge Ctr, Dept Med Biochem,Neurobiochem Grp, H-1094 Budapest, Hungary; [Vereczki, Viktoria] Semmelweis Univ, Fac Med, Dept Anat Histol & Embryol, H-1094 Budapest, Hungary; [Gerencser, Akos A.; Oh, Richard J.] Buck Inst Age Res, Novato, CA USA	Hungarian Academy of Sciences; Semmelweis University; Semmelweis University; Buck Institute for Research on Aging	Chinopoulos, C (corresponding author), Semmelweis Univ, Hungarian Acad Sci, Szentagothai Knowledge Ctr, Dept Med Biochem,Neurobiochem Grp, Tuzolto St 37-47,Room 4-521, H-1094 Budapest, Hungary.	chinopoulos.christos@eok.sote.hu; veronika.adam@eok.sote.hu	Mándi, Miklós/AGF-9798-2022	Torocsik, Beata/0000-0002-9838-3710; Adam-Vizi, Vera/0000-0002-8350-8701; Chinopoulos, Christos/0000-0003-0183-4149; Mandi, Miklos/0000-0002-0971-7695	Hungarian Scientific Research Fund (OTKA); Magyar Tudomanyos Akademia (MTA); National Office for Research and Technology (NKTH); Egeszsegugyi Tudomanyos Tanacs (ETT); Semmelweis University [63320]; OTKA-NKTH [NF68294, NNF78905]; U.S. National Institutes of Health [PL1-AG032118]; NATIONAL INSTITUTE ON AGING [PL1AG032118] Funding Source: NIH RePORTER	Hungarian Scientific Research Fund (OTKA)(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Magyar Tudomanyos Akademia (MTA); National Office for Research and Technology (NKTH)(National Office for Research and Technology); Egeszsegugyi Tudomanyos Tanacs (ETT); Semmelweis University; OTKA-NKTH(National Office for Research and TechnologyOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Pal Bauer (Semmelweis University) for providing the cytosolic and nuclear-targeted luciferase plasmids (originally made by the group of Dr. Giovanni Manfredi), Dr. James Remington (University of California-San Diego, La Jolla, CA, USA) for the mito-roGFP1 plasmid (67), Dr. Laszlo Buday (Semmelweis University) for providing the COS-7 cell line, Dr. Andras Szollosi and Professor Erzsebet Ligeti for helpful discussions, Dr. Laszlo Csanady for valuable theoretical advice, Andras Mathe for generating the Windows-based software, and Katalin Zolde for excellent technical assistance. This work was supported by grants from the Hungarian Scientific Research Fund (OTKA), Magyar Tudomanyos Akademia (MTA), National Office for Research and Technology (NKTH), and Egeszsegugyi Tudomanyos Tanacs (ETT) to V.A.V., Semmelweis University research grant 63320, OTKA-NKTH grant NF68294, and OTKA NNF78905 to C.C. A.A.G. was supported at the Buck Institute by U.S. National Institutes of Health grant PL1-AG032118.	AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; AKERMAN KEO, 1981, EUR J BIOCHEM, V115, P67; Allen TGJ, 2004, J PHYSIOL-LONDON, V554, P353, DOI 10.1113/jphysiol.2003.055889; APRILLE JR, 1993, J BIOENERG BIOMEMBR, V25, P473, DOI 10.1007/BF01108404; Bajic D, 2002, P NATL ACAD SCI USA, V99, P14494, DOI 10.1073/pnas.222379999; Ballanyi K, 1996, J PHYSIOL-LONDON, V495, P769, DOI 10.1113/jphysiol.1996.sp021632; Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x; Chinopoulos C, 2004, J NEUROCHEM, V91, P471, DOI 10.1111/j.1471-4159.2004.02732.x; Chinopoulos C, 1999, J NEUROCHEM, V73, P220, DOI 10.1046/j.1471-4159.1999.0730220.x; Chinopoulos C, 2010, BBA-MOL BASIS DIS, V1802, P221, DOI 10.1016/j.bbadis.2009.08.008; Chinopoulos C, 2009, BIOPHYS J, V96, P2490, DOI 10.1016/j.bpj.2008.12.3915; Choi SW, 2009, J NEUROCHEM, V109, P1179, DOI 10.1111/j.1471-4159.2009.06055.x; Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101; Cross RL, 2004, FEBS LETT, V576, P1, DOI 10.1016/j.febslet.2004.08.065; Dooley CT, 2004, J BIOL CHEM, V279, P22284, DOI 10.1074/jbc.M312847200; Dzeja PP, 2002, P NATL ACAD SCI USA, V99, P10156, DOI 10.1073/pnas.152259999; Gajewski CD, 2003, MOL BIOL CELL, V14, P3628, DOI 10.1091/mbc.E02-12-0796; Gerencser AA, 2005, BIOPHYS J, V88, P698, DOI 10.1529/biophysj.104.050062; Gerencser AA, 2009, J NEUROCHEM, V110, P990, DOI 10.1111/j.1471-4159.2009.06194.x; Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; Jiang C, 1997, J NEUROPHYSIOL, V77, P93, DOI 10.1152/jn.1997.77.1.93; Johnson JD, 1998, J BIOL CHEM, V273, P27580, DOI 10.1074/jbc.273.42.27580; Karschin A, 1998, J PHYSIOL-LONDON, V509, P339, DOI 10.1111/j.1469-7793.1998.339bn.x; Karschin C, 1997, FEBS LETT, V401, P59, DOI 10.1016/S0014-5793(96)01438-X; KAUFMAN S, 1953, J BIOL CHEM, V203, P869; LABBE RF, 1965, BIOCHIM BIOPHYS ACTA, V111, P403, DOI 10.1016/0304-4165(65)90050-4; Lambeth David O, 2002, IUBMB Life, V54, P143; Lambeth DO, 2004, J BIOL CHEM, V279, P36621, DOI 10.1074/jbc.M406884200; Mannella CA, 2001, IUBMB LIFE, V52, P93, DOI 10.1080/15216540152845885; MCMILLIN JB, 1988, MOL CELL BIOCHEM, V81, P121; Metelkin E, 2009, FEBS J, V276, P6942, DOI 10.1111/j.1742-4658.2009.07394.x; Nicholls DG, 2006, J BIOL CHEM, V281, P14864, DOI 10.1074/jbc.M510916200; O'Reilly CM, 2003, BIOPHYS J, V85, P3350, DOI 10.1016/S0006-3495(03)74754-7; OHNOSHOSAKU T, 1992, PFLUG ARCH EUR J PHY, V422, P260, DOI 10.1007/BF00376211; Ostergaard E, 2008, J INHERIT METAB DIS, V31, P226, DOI 10.1007/s10545-008-0828-7; OTTAWAY JH, 1981, INT J BIOCHEM, V13, P401, DOI 10.1016/0020-711X(81)90111-7; Pelletier MR, 2000, J NEUROPHYSIOL, V84, P2291, DOI 10.1152/jn.2000.84.5.2291; PETRONILLI V, 1988, BIOCHIM BIOPHYS ACTA, V932, P306, DOI 10.1016/0005-2728(88)90167-3; Phillips D, 2009, BIOCHEMISTRY-US, V48, P7140, DOI 10.1021/bi900725c; Porter RK, 2001, BBA-BIOENERGETICS, V1504, P120, DOI 10.1016/S0005-2728(00)00246-2; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; Rouslin W, 1996, J BIOL CHEM, V271, P23638, DOI 10.1074/jbc.271.39.23638; ROUSLIN W, 1987, AM J PHYSIOL, V252, pH622, DOI 10.1152/ajpheart.1987.252.3.H622; ROUSLIN W, 1990, AM J PHYSIOL, V259, pH1759, DOI 10.1152/ajpheart.1990.259.6.H1759; ROUSLIN W, 1995, J BIOENERG BIOMEMBR, V27, P117, DOI 10.1007/BF02110339; ROUSLIN W, 1990, ARCH BIOCHEM BIOPHYS, V280, P103, DOI 10.1016/0003-9861(90)90524-3; ROUSLIN W, 1986, AM J PHYSIOL, V250, P503; Sasaki N, 2001, AM J PHYSIOL-HEART C, V280, pH1882, DOI 10.1152/ajpheart.2001.280.4.H1882; Schnopp NM, 1996, CLIN NEUROPATHOL, V15, P348; Schwimmer C, 2005, J BIOL CHEM, V280, P30751, DOI 10.1074/jbc.M501831200; SCOTT ID, 1980, BIOCHEM J, V186, P21, DOI 10.1042/bj1860021; STUMPF DA, 1980, PEDIATR RES, V14, P1127, DOI 10.1203/00006450-198010000-00008; Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047; TANG XD, 1995, NEUROSCI LETT, V193, P93, DOI 10.1016/0304-3940(95)11675-M; Tomashek JJ, 2000, J BIOENERG BIOMEMBR, V32, P493, DOI 10.1023/A:1005617024904; TRAPP S, 1995, J PHYSIOL-LONDON, V487, P37, DOI 10.1113/jphysiol.1995.sp020859; Tretter L, 2000, J NEUROSCI, V20, P8972; Tyler D. D., 1967, METHOD ENZYMOL, V10, P75, DOI DOI 10.1016/0076-6879(67)10014-1; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; WILSON DF, 1983, J BIOL CHEM, V258, P464; WISNIEWSKI E, 1993, J BIOL CHEM, V268, P9343; Wu F, 2008, J PHYSIOL-LONDON, V586, P4193, DOI 10.1113/jphysiol.2008.154732; ZOLLNER H, 1990, HDB ENZYME INHIBITOR	65	73	74	2	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2010	24	7					2405	2416		10.1096/fj.09-149898	http://dx.doi.org/10.1096/fj.09-149898			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20207940	Green Published			2022-12-28	WOS:000279343600027
J	St-Onge, M; Lagarde, S; Laflamme, C; Rollet-Labelle, E; Marois, L; Naccache, PH; Pouliot, M				St-Onge, Mireille; Lagarde, Stephanie; Laflamme, Cynthia; Rollet-Labelle, Emmanuelle; Marois, Louis; Naccache, Paul H.; Pouliot, Marc			Proteinase-activated receptor-2 up-regulation by Fc gamma-receptor activation in human neutrophils	FASEB JOURNAL			English	Article						inflammation; polymorphonuclear leukocytes; PARs; primary granules	EPITHELIAL-CELLS; PROINFLAMMATORY CYTOKINES; MEDIATED PHAGOCYTOSIS; ADHESION MOLECULES; GENE-EXPRESSION; URATE CRYSTALS; IN-VIVO; INFLAMMATION; MIGRATION; THROMBIN	We shed new light on the expression and function of the proteinase-activated receptor (PAR) family, associated with inflammation and hyperalgesia, in human granulocytes. Resting cells expressed constitutive levels of PAR-2 and PAR-3 mRNA but not PAR-1 or PAR-4. Based on flow cytometry, stimulation with opsonized bacteria (Bop) specifically up-regulated cell surface expression of PAR-2 in a concentration-dependent and time-dependent manner, independent of transcription or de novo protein synthesis. Primary granules were identified as a source of preformed PAR-2 that can readily be mobilized at the surface on fusion with the plasma membrane. Cellular response to PAR-2 activation, measured as changes in intracellular calcium concentration, was enhanced in PAR-2 up-regulated cells. Increase of cell-surface PAR-2 and of cell responsiveness were dependent specifically on the engagement of immunoglobulin (Ig)-binding receptors. Together, our results reveal that mobilization of intracellular granules, in response to Ig-receptor activation, up-regulates PAR-2 surface expression and makes neutrophils more responsive to proteinase activity. This enhanced response to PAR-2 activation indicates that molecular communication between pain and inflammation may be more important than previously believed.-St-Onge, M., Lagarde, S., Laflamme, C., Rollet-Labelle, E., Marois, L., Naccache, P. H., Pouliot, M. Proteinase-activated receptor-2 upregulation by Fc gamma-receptor activation in human neutrophils. FASEB J. 24, 2116-2125 (2010). www.fasebj.org	[St-Onge, Mireille; Lagarde, Stephanie; Laflamme, Cynthia; Rollet-Labelle, Emmanuelle; Marois, Louis; Naccache, Paul H.; Pouliot, Marc] Univ Laval, Ctr Rech Rhumatol & Immunol, CHU Quebec, Dept Microbiol Infectiol & Immunol,Fac Med, Quebec City, PQ G1K 7P4, Canada	Laval University	Pouliot, M (corresponding author), CHUL, Ctr Rech Rhumatol & Immunol, 2705 Laurier Blvd,Off T1-49, Quebec City, PQ G1V 4G2, Canada.	marc.pouliot@crchul.ulaval.ca	Dufrechou, Stephanie/W-8547-2019; Pouliot, Marc/G-4103-2016	Pouliot, Marc/0000-0002-2466-5424; Marois, Louis/0000-0002-1567-5583	Canadian Institutes of Health Research (CIHR) [MOP-64315]; U.S. National Institutes of Health [R01 AR052614]; Fonds de la Recherche en Sante du Quebec (FRSQ); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052614] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fonds de la Recherche en Sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work is supported by grants from the Canadian Institutes of Health Research (CIHR, MOP-64315; M. P.) and the U.S. National Institutes of Health (R01 AR052614). M.P. is a Senior Investigator Scholar of the Fonds de la Recherche en Sante du Quebec (FRSQ). M.S.O. is the recipient of a studentship from the FRSQ. The authors declare no conflicting financial interests.	Barabe F, 2002, J IMMUNOL, V168, P4042, DOI 10.4049/jimmunol.168.8.4042; BEAULIEU AD, 1992, J BIOL CHEM, V267, P426; BERGER M, 1989, J CLIN INVEST, V84, P1302, DOI 10.1172/JCI114298; Borregaard N, 1995, Clin Exp Immunol, V101 Suppl 1, P6; Borregaard N, 2007, TRENDS IMMUNOL, V28, P340, DOI 10.1016/j.it.2007.06.002; Chin AC, 2008, J IMMUNOL, V181, P5702, DOI 10.4049/jimmunol.181.8.5702; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Coughlin SR, 2003, J CLIN INVEST, V111, P25, DOI 10.1172/JCI200317564; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; de Boer Willem I, 2007, Int J Chron Obstruct Pulmon Dis, V2, P205; Dulon S, 2005, AM J RESP CELL MOL, V32, P411, DOI 10.1165/rcmb.2004-0274OC; Dulon S, 2003, AM J RESP CELL MOL, V28, P339, DOI 10.1165/rcmb.4908; Dussault AA, 2006, BIOL PROCED ONLINE, V8, P1, DOI 10.1251/bpo114; Fernandes MJG, 2005, J LEUKOCYTE BIOL, V78, P524, DOI 10.1189/jlb.0804479; Ferrell WR, 2003, J CLIN INVEST, V111, P35, DOI 10.1172/JCI200316913; Foster PS, 2008, CURR MOL MED, V8, P585, DOI 10.2174/156652408785748013; FUJISHIMA S, 1993, J CELL PHYSIOL, V154, P478, DOI 10.1002/jcp.1041540305; GARCIA JGN, 1993, J CELL PHYSIOL, V156, P541, DOI 10.1002/jcp.1041560313; Gilbert C, 2003, ARTHRITIS RHEUM-US, V48, P1137, DOI 10.1002/art.10851; Gopinath R, 1997, CYTOMETRY, V30, P313; Houle S, 2005, BRIT J PHARMACOL, V146, P670, DOI 10.1038/sj.bjp.0706371; Howells GL, 1997, J CELL SCI, V110, P881; Hyun E, 2008, GUT, V57, P1222, DOI 10.1136/gut.2008.150722; INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389; Kato T, 2006, INT J HEMATOL, V84, P205, DOI 10.1532/IJH97.06141; Knecht W, 2007, J BIOL CHEM, V282, P26089, DOI 10.1074/jbc.M703840200; LYNCH JP, 1985, AM J MED, V78, P691, DOI 10.1016/0002-9343(85)90416-4; Monk PN, 2007, BRIT J PHARMACOL, V152, P429, DOI 10.1038/sj.bjp.0707332; MOVAT HZ, 1987, FASEB J, V46, P97; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; O'SHEA JJ, 1985, J IMMUNOL, V134, P2580; Oikonomopoulou K, 2006, J BIOL CHEM, V281, P32095, DOI 10.1074/jbc.M513138200; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Pham CTN, 2006, NAT REV IMMUNOL, V6, P541, DOI 10.1038/nri1841; POULIOT M, 1994, J EXP MED, V179, P1225, DOI 10.1084/jem.179.4.1225; Pouliot M, 2002, J IMMUNOL, V169, P5279, DOI 10.4049/jimmunol.169.9.5279; Roche N, 2003, RESP MED, V97, P228, DOI 10.1053/rmed.2003.1437; ROSALES C, 1991, J IMMUNOL, V146, P3937; Sawyer D W, 1989, Rev Infect Dis, V11 Suppl 7, pS1532; Seeliger S, 2003, FASEB J, V17, P1871, DOI 10.1096/fj.02-1112com; Sekiguchi F, 2005, YAKUGAKU ZASSHI, V125, P491, DOI 10.1248/yakushi.125.491; Selvatici R, 2006, EUR J PHARMACOL, V534, P1, DOI 10.1016/j.ejphar.2006.01.034; SHANLEY TP, 1995, MOL MED TODAY, V1, P40, DOI 10.1016/1357-4310(95)80019-0; Shpacovitch VM, 2007, EXP DERMATOL, V16, P799, DOI 10.1111/j.1600-0625.2007.00605.x; Shpacovitch VM, 2004, J LEUKOCYTE BIOL, V76, P388, DOI 10.1189/jlb.0503221; St-Onge M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004902; Steinhoff M, 2005, ENDOCR REV, V26, P1, DOI 10.1210/er.2003-0025; Suzuki T, 2006, CELL RES, V16, P887, DOI 10.1038/sj.cr.7310103; TERKELTAUB R, 1983, ARTHRITIS RHEUM, V26, P775, DOI 10.1002/art.1780260612; Uehara A, 2004, J IMMUNOL, V173, P4179, DOI 10.4049/jimmunol.173.6.4179; Vergnolle N, 2001, TRENDS PHARMACOL SCI, V22, P146, DOI 10.1016/S0165-6147(00)01634-5; Vergnolle N, 1999, J IMMUNOL, V163, P5064; Wang HY, 2006, CELL BIOL INT, V30, P688, DOI 10.1016/j.cellbi.2006.04.007; Williams C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004936	55	13	15	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					2116	2125		10.1096/fj.09-146167	http://dx.doi.org/10.1096/fj.09-146167			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20154268	Green Accepted, Green Published			2022-12-28	WOS:000278200000044
J	Sugawara, M; Resende, JM; Moraes, CM; Marquette, A; Chich, JF; Metz-Boutigue, MH; Bechinger, B				Sugawara, Masae; Resende, Jarbas M.; Moraes, Cleria Mendonca; Marquette, Arnaud; Chich, Jean-Francois; Metz-Boutigue, Marie-Helene; Bechinger, Burkhard			Membrane structure and interactions of human catestatin by multidimensional solution and solid-state NMR spectroscopy	FASEB JOURNAL			English	Article						cationic peptides; antimicrobial peptide; structure of membrane-associated peptide; oriented lipid bilayer; membrane topology; cell-penetrating peptide	CELL-PENETRATING PEPTIDES; CHROMOGRANIN-A FRAGMENT; O-GLYCOSYLATION SITES; ANTIMICROBIAL PEPTIDES; CATECHOLAMINE RELEASE; LIPID-MEMBRANES; PORE FORMATION; PROTEOLYTIC CLEAVAGE; ANTIBACTERIAL ACTION; SECONDARY STRUCTURE	Catestatin is a natural peptide of higher organisms including humans, with a wide variety of biological functions involved in catecholamine inhibition, cardiovascular regulation, control of blood pressure, inflammation, and innate immunity. It is derived from the natural processing of chromogranin A, induced in the skin after injury, and produced by chromaffin cells and neutrophils. With neutrophils, the peptide enters the cell by crossing the plasma membrane where it interacts with internal targets to induce calcium influx. Therefore, we investigated the membrane interactions and structure of several catestatin-derived peptides. Whereas fluorescence dye release experiments are indicative of membrane permeabilization, multidimensional solution NMR and circular dichroism spectroscopies show that catestatin adopts alpha-helical conformations between Ser-6 and Tyr-12 in the presence of dodecylphosphocholine micelles. Furthermore, proton-decoupled N-15 solid-state NMR spectroscopy of sequences labeled with N-15 and reconstituted into oriented lipid bilayers indicates that this domain is aligned in a strongly tilted to inplanar alignment. Proton-decoupled P-31 NMR spectra of the same samples are indicative of conformational and/or orientational heterogeneity at the level of the lipid bilayer head groups due to the presence of catestatin. The sequence and 3-dimensional structure of catestatin exhibit homologies with penetratin, which is suggestive that they both enter the cells by related mechanisms to target internal structures.-Sugawara, M., Resende, J. M., Moraes, C. M., Marquette, A., Chich, J.-F., Metz-Boutigue, M.-H., Bechinger, B. Membrane structure and interactions of human catestatin by multidimensional solution and solid-state NMR spectroscopy. FASEB J. 24, 1737-1146 (2010). www.fasebj.org	[Sugawara, Masae; Resende, Jarbas M.; Moraes, Cleria Mendonca; Marquette, Arnaud; Bechinger, Burkhard] Univ Strasbourg, CNRS, UMR 7177, Inst Chim, Strasbourg, France; [Resende, Jarbas M.] Univ Fed Minas Gerais, Dept Quim, Belo Horizonte, MG, Brazil; [Chich, Jean-Francois; Metz-Boutigue, Marie-Helene] Univ Strasbourg, INSERM, U575, Strasbourg, France; [Chich, Jean-Francois] INRA, Virol & Immunol Mol, Jouy En Josas, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universidade Federal de Minas Gerais; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Bechinger, B (corresponding author), Univ Strasbourg, Inst Le Bel, Fac Chim, 4 Rue Blaise Pascal, F-67070 Strasbourg, France.	bechinger@unistra.fr	Resende, Jarbas M/R-4519-2018	Resende, Jarbas/0000-0001-9827-7312; Mendonca de Moraes, Cleria/0000-0001-5602-9601	Institut National de la Sante et la Recherche Medicale (INSERM); Institut National de la Recherche Agronomique (INRA); University of Strasbourg; Centre National de la Recherche Scientifique (CNRS); Cordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Conselho Nacional de Desenvolvimeno Cientifico e Technologico (CNPq); Vaincre la Mucoviscidose [TG0602]; RMN Grand-Est Network of the Ministry of Recherche; European Commission [MCRTN-33439]	Institut National de la Sante et la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut National de la Recherche Agronomique (INRA); University of Strasbourg; Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Cordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Conselho Nacional de Desenvolvimeno Cientifico e Technologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Vaincre la Mucoviscidose; RMN Grand-Est Network of the Ministry of Recherche; European Commission(European CommissionEuropean Commission Joint Research Centre)	The authors thank Jesus Raya and Roland Graff for help with the solid-state and solution NMR spectrometers and Bernard Guerold (INSERM U575) for the peptide syntheses. This study was funded by the Institut National de la Sante et la Recherche Medicale (INSERM), Institut National de la Recherche Agronomique (INRA), the University of Strasbourg, and the Centre National de la Recherche Scientifique (CNRS). Furthermore, the CNRS, Cordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and Conselho Nacional de Desenvolvimeno Cientifico e Technologico (CNPq) are acknowledged for postdoctoral fellowships to M. S., C. M. M, and J.M.R., respectively. We thank Vaincre la Mucoviscidose (TG0602), the RMN Grand-Est Network of the Ministry of Recherche, and the European Commission under the 6th Framework Programme (Biocontrol, MCRTN-33439) for supporting the projects. We also thank the Brazilian-French program CAPES-COFECUB/EGIDE (487/05), which permitted several exchange visits to promote this work. The Institute for Supramolecular Chemistry of the University of Strasbourg (ISIS) is acknowledged for hosting the Bechinger Laboratory.	Alves ID, 2008, BBA-GEN SUBJECTS, V1780, P948, DOI 10.1016/j.bbagen.2008.04.004; Andronesi OC, 2004, J BIOMOL NMR, V30, P253, DOI 10.1007/s10858-004-3452-3; Angelone T, 2008, ENDOCRINOLOGY, V149, P4780, DOI 10.1210/en.2008-0318; Balayssac S, 2006, BIOCHEMISTRY-US, V45, P1408, DOI 10.1021/bi0518390; BANKS P, 1965, BIOCHEM J, V97, pC40, DOI 10.1042/bj0970040C; Barany-Wallje E, 2004, FEBS LETT, V567, P265, DOI 10.1016/j.febslet.2004.04.079; Bechinger B, 1999, BIOPOLYMERS, V51, P174, DOI 10.1002/(SICI)1097-0282(1999)51:3<174::AID-BIP2>3.0.CO;2-7; Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9; BECHINGER B, 1991, J MAGN RESON, V95, P585, DOI 10.1016/0022-2364(91)90173-Q; Bechinger B., 2003, CONCEPT MAGN RESON A, V18A, P130; Bechinger B, 2009, CURR OPIN COLLOID IN, V14, P349, DOI 10.1016/j.cocis.2009.02.004; Biswas N, 2008, ENDOCRINOLOGY, V149, P749, DOI 10.1210/en.2007-0838; Biswas N, 2009, ENDOCRINOLOGY, V150, P3547, DOI 10.1210/en.2008-1613; Blois A, 2006, REGUL PEPTIDES, V135, P78, DOI 10.1016/j.regpep.2006.04.007; Briolat J, 2005, CELL MOL LIFE SCI, V62, P377, DOI 10.1007/s00018-004-4461-9; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Davis JH, 1999, PROG NUCL MAG RES SP, V35, P1, DOI 10.1016/S0079-6565(99)00009-6; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Deshayes S, 2004, BIOCHEMISTRY-US, V43, P1449, DOI 10.1021/bi035682s; Egger M, 2008, EUR J PHARMACOL, V598, P104, DOI 10.1016/j.ejphar.2008.09.016; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Ferrero E, 2004, FASEB J, V18, P554, DOI 10.1096/fj.03-0922fje; Gadroy P, 1998, J BIOL CHEM, V273, P34087, DOI 10.1074/jbc.273.51.34087; Galanth C, 2009, BIOCHEMISTRY-US, V48, P313, DOI 10.1021/bi802025a; GALZI JL, 1995, NEUROPHARMACOLOGY, V34, P563, DOI 10.1016/0028-3908(95)00034-4; Hale JD, 2007, EXPERT REV ANTI-INFE, V5, P951, DOI 10.1586/14787210.5.6.951; Hallock KJ, 2003, BIOPHYS J, V84, P3052, DOI 10.1016/S0006-3495(03)70031-9; Hansen M, 2008, ADV DRUG DELIVER REV, V60, P572, DOI 10.1016/j.addr.2007.09.003; HEDIGER S, 1994, CHEM PHYS LETT, V223, P283, DOI 10.1016/0009-2614(94)00470-6; Helle KB, 2007, CELL MOL LIFE SCI, V64, P2863, DOI 10.1007/s00018-007-7254-0; Henriques ST, 2006, BIOCHEM J, V399, P1, DOI 10.1042/BJ20061100; Herbig ME, 2005, BIOPHYS J, V89, P4056, DOI 10.1529/biophysj.105.068692; Herrero CJ, 2002, J NEUROSCI, V22, P377, DOI 10.1523/JNEUROSCI.22-02-00377.2002; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; Jean-Francois F, 2008, BIOCHEMISTRY-US, V47, P6394, DOI 10.1021/bi800448h; Jean-Francois F, 2007, EUR BIOPHYS J BIOPHY, V36, P1019, DOI 10.1007/s00249-007-0169-8; Jean-Francois F, 2009, FASEB J, V23, P3692, DOI 10.1096/fj.09-135574; Jean-Francois F, 2008, BIOPHYS J, V95, P5748, DOI 10.1529/biophysj.108.136655; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jung HJ, 2008, J MICROBIOL BIOTECHN, V18, P990; Kennedy BP, 1998, PEPTIDES, V19, P1241, DOI 10.1016/S0196-9781(98)00086-2; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kruger PG, 2003, REGUL PEPTIDES, V114, P29, DOI 10.1016/S0167-0115(03)00069-7; Lamaziere A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001938; Lee JC, 2003, BIOCHEMISTRY-US, V42, P6938, DOI 10.1021/bi0300433; LENA C, 1993, TRENDS NEUROSCI, V16, P181, DOI 10.1016/0166-2236(93)90150-K; Lindberg M, 2001, FEBS LETT, V497, P39, DOI 10.1016/S0014-5793(01)02433-4; Lins L, 2008, BBA-BIOMEMBRANES, V1778, P1537, DOI 10.1016/j.bbamem.2008.04.006; Lugardon K, 2000, J BIOL CHEM, V275, P10745, DOI 10.1074/jbc.275.15.10745; Lugardon K, 2001, J BIOL CHEM, V276, P35875, DOI 10.1074/jbc.M104670200; Magzoub M, 2002, BBA-BIOMEMBRANES, V1563, P53, DOI 10.1016/S0005-2736(02)00373-5; Mahapatra NR, 2005, J CLIN INVEST, V115, P1942, DOI 10.1172/JCI24354; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; Mason AJ, 2006, FASEB J, V20, P320, DOI 10.1096/fj.05-4293fje; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; Park CB, 1998, BIOCHEM BIOPH RES CO, V244, P253, DOI 10.1006/bbrc.1998.8159; Preece NE, 2004, REGUL PEPTIDES, V118, P75, DOI 10.1016/j.regpep.2003.10.035; Radek KA, 2008, J INVEST DERMATOL, V128, P1525, DOI 10.1038/sj.jid.5701225; Ramamoorthy A, 2006, BBA-BIOMEMBRANES, V1758, P154, DOI 10.1016/j.bbamem.2006.02.014; Ramamoorthy A, 2010, BBA-BIOMEMBRANES, V1798, P223, DOI 10.1016/j.bbamem.2009.08.012; Ramamoorthy A, 2009, SOLID STATE NUCL MAG, V35, P201, DOI 10.1016/j.ssnmr.2009.03.003; RANCE M, 1983, J MAGN RESON, V52, P221, DOI 10.1016/0022-2364(83)90190-7; Luque-Ortega JR, 2008, FASEB J, V22, P1817, DOI 10.1096/fj.07-096081; Salnikov ES, 2009, BIOPHYS J, V96, P86, DOI 10.1529/biophysj.108.136242; Salnikov ES, 2009, BIOCHIMIE, V91, P734, DOI 10.1016/j.biochi.2009.01.002; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SIMON JP, 1989, BIOCHEM J, V262, P1; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; Strub JM, 1997, J BIOL CHEM, V272, P11928, DOI 10.1074/jbc.272.18.11928; Tang M, 2007, J AM CHEM SOC, V129, P11438, DOI 10.1021/ja072511s; Thennarasu S, 2005, CHEM PHYS LIPIDS, V137, P38, DOI 10.1016/j.chemphyslip.2005.06.003; Tsigelny I, 1998, REGUL PEPTIDES, V77, P43, DOI 10.1016/S0167-0115(98)00040-8; Verly RM, 2009, BIOPHYS J, V96, P2194, DOI 10.1016/j.bpj.2008.11.063; Watts Anthony, 2004, Methods Mol Biol, V278, P403; Wenk MR, 1998, BIOCHEMISTRY-US, V37, P3909, DOI 10.1021/bi972615n; Wi S, 2008, J PHYS CHEM B, V112, P11402, DOI 10.1021/jp801825k; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004501; Ziegler A, 2008, ADV DRUG DELIVER REV, V60, P580, DOI 10.1016/j.addr.2007.10.005	82	37	39	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1737	1746		10.1096/fj.09-142554	http://dx.doi.org/10.1096/fj.09-142554			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20103720	Green Submitted			2022-12-28	WOS:000278200000011
J	Fang, F; Lue, LF; Yan, SQ; Xu, HW; Luddy, JS; Chen, D; Walker, DG; Stern, DM; Yan, SF; Schmidt, AM; Chen, JX; Yan, SS				Fang, Fang; Lue, Lih-Fen; Yan, Shiqiang; Xu, Hongwei; Luddy, John S.; Chen, Doris; Walker, Douglas G.; Stern, David M.; Yan, Shifang; Schmidt, Ann Marie; Chen, John X.; Yan, Shirley Shidu			RAGE-dependent signaling in microglia contributes to neuroinflammation, A beta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						A beta-binding protein; microglia/neuron interaction; cytokine; animal model	AMYLOID PRECURSOR PROTEIN; GLYCATION END-PRODUCTS; CYTOKINE UP-REGULATION; NECROSIS-FACTOR-ALPHA; APP TRANSGENIC MICE; P38 MAP KINASE; NEURODEGENERATIVE DISEASES; MITOCHONDRIAL DYSFUNCTION; SYNAPTIC DYSFUNCTION; TAU PHOSPHORYLATION	Microglia are critical for amyloid-beta peptide (A beta)-mediated neuronal perturbation relevant to Alzheimer's disease (AD) pathogenesis. We demonstrate that overexpression of receptor for advanced glycation end products (RAGE) in imbroglio exaggerates neuroinflammation, as evidenced by increased proinflammatory mediator production, A beta accumulation, impaired learning/ memory, and neurotoxicity in an A beta rich environment. Transgenic (Tg) mice expressing human mutant APP (mAPP) in neurons and RAGE in microglia displayed enhanced IL-1 beta and TNF-alpha production, increased infiltration of microglia and astrocytes, accumulation of A beta, reduced acetylcholine esterase (AChE) activity, and accelerated deterioration of spatial learning/ memory. Notably, introduction of a signal transduction- defective mutant RAGE (DN-RAGE) to microglia attenuates deterioration induced by A beta. These findings indicate that RAGE signaling in microglia contributes to the pathogenesis of an inflammatory response that ultimately impairs neuronal function and directly affects amyloid accumulation. We conclude that blockade of microglial RAGE may have a beneficial effect on A beta-mediated neuronal perturbation relevant to AD pathogenesis.-Fang, F., Lue, L.-F., Yan, S., Xu, H., Luddy, J. S., Chen, D., Walker, D. G., Stern, D. M., Yan, S., Schmidt, A. M., Chen, J. X., Yan, S. S. RAGE-dependent signaling in microglia contributes to neuroinflammation, A beta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J. 24, 1043-1055 (2010). www.fasebj.org	[Yan, Shirley Shidu] Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; [Fang, Fang; Yan, Shiqiang; Xu, Hongwei; Luddy, John S.; Chen, Doris; Yan, Shifang; Schmidt, Ann Marie; Yan, Shirley Shidu] Columbia Univ, Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; [Yan, Shirley Shidu] Columbia Univ, Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; [Lue, Lih-Fen; Walker, Douglas G.] Sun Hlth Res Inst, Lab Neuroinflammat, Sun City, AZ USA; [Yan, Shiqiang] Langzhou Univ, Coll Chem & Chem Engn, Langzhou, Peoples R China; [Stern, David M.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Chen, John X.] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA	Columbia University; Columbia University; Columbia University; Banner Research; Banner Health; Banner Sun Health Research Institute; Lanzhou University; University System of Ohio; University of Cincinnati; Memorial Sloan Kettering Cancer Center	Yan, SS (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.	sdy1@columbia.edu	xu, hong/GSD-8903-2022		U.S. Public Health Service [PO1AG17490]; Arizona Alzheimer's Consortium; NATIONAL INSTITUTE ON AGING [P01AG017490] Funding Source: NIH RePORTER	U.S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Arizona Alzheimer's Consortium; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grants from the U.S. Public Health Service (PO1AG17490). L-F. L. and D.G.W. were supported by a grant from the Arizona Alzheimer's Consortium. D.S. is a consultant of TransTech Pharma.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; ANDERSEN K, 1995, NEUROLOGY, V45, P1441, DOI 10.1212/WNL.45.8.1441; Arancio O, 2004, EMBO J, V23, P4096, DOI 10.1038/sj.emboj.7600415; Blalock EM, 2005, AGEING RES REV, V4, P481, DOI 10.1016/j.arr.2005.06.006; Britschgi M, 2007, NAT MED, V13, P408, DOI 10.1038/nm0407-408; Chen X, 2007, CURR MOL MED, V7, P735; Cho HJ, 2009, FASEB J, V23, P2639, DOI 10.1096/fj.08-126383; Craft JM, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-15; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868; Du H, 2011, NEUROBIOL AGING, V32, P398, DOI 10.1016/j.neurobiolaging.2009.03.003; DU Y.S., 1997, P NATL ACAD SCI USA, V94, P5296; Dudal S, 2004, NEUROBIOL AGING, V25, P861, DOI 10.1016/j.neurobiolaging.2003.08.008; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Ferrer I, 2004, NEUROTOX RES, V6, P469, DOI 10.1007/BF03033283; Floden AM, 2007, J NEUROSCI METH, V164, P218, DOI 10.1016/j.jneumeth.2007.04.018; Floden AM, 2005, J NEUROSCI, V25, P2566, DOI 10.1523/JNEUROSCI.4998-04.2005; Frautschy SA, 1998, AM J PATHOL, V152, P307; Giovannini MG, 2002, NEUROBIOL DIS, V11, P257, DOI 10.1006/nbdi.2002.0538; Giri R, 2002, AM J PHYSIOL-CELL PH, V283, pC895, DOI 10.1152/ajpcell.00293.2001; Giri R, 2000, AM J PHYSIOL-CELL PH, V279, pC1772, DOI 10.1152/ajpcell.2000.279.6.C1772; GIULIAN D, 1994, NEUROCHEM INT, V25, P227, DOI 10.1016/0197-0186(94)90066-3; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; Griffin WST, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-5; Hadding A, 2004, BBA-MOL CELL RES, V1691, P67, DOI 10.1016/j.bbamcr.2004.01.003; Haq S, 2001, CIRCULATION, V103, P670; Heneka MT, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-22; Heneka MT, 2005, BRAIN, V128, P1442, DOI 10.1093/brain/awh452; Hensley K, 1999, J NEUROCHEM, V72, P2053, DOI 10.1046/j.1471-4159.1999.0722053.x; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Javadov SA, 2000, CARDIOVASC RES, V45, P360, DOI 10.1016/S0008-6363(99)00365-X; Johnson GVW, 2003, EXP NEUROL, V183, P263, DOI 10.1016/S0014-4886(03)00268-1; Li YK, 2003, J NEUROSCI, V23, P1605; Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200; Lue LF, 2005, CNS NEUROL DISORD-DR, V4, P249, DOI 10.2174/1568007054038210; Lue LF, 2002, J NEUROSCI RES, V70, P599, DOI 10.1002/jnr.10422; Lue LF, 2001, NEUROBIOL AGING, V22, P945, DOI 10.1016/S0197-4580(01)00311-6; Lue LF, 2001, EXP NEUROL, V171, P29, DOI 10.1006/exnr.2001.7732; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; McGeer PL, 2006, J ALZHEIMERS DIS, V9, P271; Miller MC, 2008, BRAIN RES, V1230, P273, DOI 10.1016/j.brainres.2008.06.124; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; Morgan D, 2005, J NEUROPATH EXP NEUR, V64, P743, DOI 10.1097/01.jnen.0000178444.33972.e0; Mruthinti S, 2006, NEUROSCIENCE, V142, P463, DOI 10.1016/j.neuroscience.2006.06.010; Mruthinti S, 2004, NEUROBIOL AGING, V25, P1023, DOI 10.1016/j.neurobiolaging.2003.11.001; Mruthinti S, 2003, J MOL NEUROSCI, V20, P223, DOI 10.1385/JMN:20:3:223; Mruthinti S, 2007, CURR ALZHEIMER RES, V4, P581, DOI 10.2174/156720507783018325; Mruthinti Shyamala, 2006, Current Alzheimer Research, V3, P229, DOI 10.2174/156720506777632899; Munoz L, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-21; Origlia N, 2008, J NEUROSCI, V28, P3521, DOI 10.1523/JNEUROSCI.0204-08.2008; Origlia N, 2009, J ALZHEIMERS DIS, V17, P59, DOI 10.3233/JAD-2009-1045; Pei JJ, 2001, J ALZHEIMERS DIS, V3, P41, DOI 10.3233/JAD-2001-3107; Ranaivo HR, 2006, J NEUROSCI, V26, P662, DOI 10.1523/JNEUROSCI.4652-05.2006; Rong LL, 2005, RESTOR NEUROL NEUROS, V23, P355; Rong LL, 2004, FASEB J, V18, P1818, DOI 10.1096/fj.04-1900com; Sasaki N, 2001, BRAIN RES, V888, P256, DOI 10.1016/S0006-8993(00)03075-4; Savage MJ, 2002, J NEUROSCI, V22, P3376; Schieven GL, 2005, CURR TOP MED CHEM, V5, P921, DOI 10.2174/1568026054985902; Stalder M, 1999, AM J PATHOL, V154, P1673, DOI 10.1016/S0002-9440(10)65423-5; Sturchler E, 2008, J NEUROSCI, V28, P5149, DOI 10.1523/JNEUROSCI.4878-07.2008; Sun AY, 2003, EXP NEUROL, V183, P394, DOI 10.1016/S0014-4886(03)00180-8; Swatton JE, 2004, EUR J NEUROSCI, V19, P2711, DOI 10.1111/j.0953-816X.2004.03365.x; Takuma K, 2005, FASEB J, V19, P597, DOI 10.1096/fj.04-2582fje; Tarkowski E, 2003, J NEUROL NEUROSUR PS, V74, P1200, DOI 10.1136/jnnp.74.9.1200; Tesseur I, 2006, J CLIN INVEST, V116, P3060, DOI 10.1172/JCI27341; Uchihara T, 1997, STROKE, V28, P1948, DOI 10.1161/01.STR.28.10.1948; Van Eldik LJ, 2007, INT REV NEUROBIOL, V82, P277, DOI 10.1016/S0074-7742(07)82015-0; van Groen T, 2005, BRAIN RES REV, V48, P370, DOI 10.1016/j.brainresrev.2004.12.026; Vehmas AK, 2003, NEUROBIOL AGING, V24, P321, DOI 10.1016/S0197-4580(02)00090-8; Walker DG, 2005, J NEUROSCI RES, V81, P412, DOI 10.1002/jnr.20484; Weninger SC, 2001, NAT MED, V7, P527, DOI 10.1038/87839; Wilson JS, 2009, J GERONTOL A-BIOL, V64, P264, DOI 10.1093/gerona/gln002; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Yamamoto M, 2005, AM J PATHOL, V166, P1475, DOI 10.1016/S0002-9440(10)62364-4; Yamamoto M, 2007, AM J PATHOL, V170, P680, DOI 10.2353/ajpath.2007.060378; Yan SD, 2005, INT J EXP PATHOL, V86, P161, DOI 10.1111/j.0959-9673.2005.00427.x; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Zhu XW, 2005, NEUROCHEM RES, V30, P791, DOI 10.1007/s11064-005-6872-x; Zhu XW, 2001, J NEUROCHEM, V79, P311, DOI 10.1046/j.1471-4159.2001.00597.x	81	223	245	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1043	1055		10.1096/fj.09-139634	http://dx.doi.org/10.1096/fj.09-139634			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19906677	Green Published			2022-12-28	WOS:000276462300012
J	Dosch, DD; Ballmer-Hofer, K				Dosch, Debora Dell'Era; Ballmer-Hofer, Kurt			Transmembrane domain-mediated orientation of receptor monomers in active VEGFR-2 dimers	FASEB JOURNAL			English	Article						angiogenesis; receptor tyrosine kinase	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE DOMAIN; PAPILLOMAVIRUS E5 PROTEIN; STEM-CELL FACTOR; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; EGF RECEPTOR; ACTIVATION; ANGIOGENESIS; COMPLEX	Vascular endothelial growth factors (VEGFs) activate cellular receptor tyrosine kinases (RTKs) such as VEGFR-1, -2, and -3. These receptors are activated upon ligand binding to the extracellular receptor domain (ECD), resulting in receptor dimerization and activation of the intracellular kinase domain. Here we investigated the molecular mechanism of activation of the human VEGFR-2 expressed in human HEK293, monkey COS-1, and porcine aortic endothelial cells. To study the role of dimerization in receptor activation we created a series of dimerization- promoting transmembrane domain (TMD) mutants lacking the extracellular domain. The TMDs consisted of 23 valine and 2 glutamic acid residues spaced 7 aa apart in different positions of the transmembrane helix. All TMDs dimerized VEGFR-2, each in a specific orientation, giving rise to a series of either active or inactive receptor dimers. One particular TMD, V6/13E, gave rise to highly active kinase dimers, while all the other dimerizing TMD mutant receptors had 6- to 10-fold lower activity. When the V6/13E TMD was introduced into the full-length receptor in place of the native TMD, it promoted ligand-independent activation. Nonactivating TMDs, on the other hand, gave rise to inactive receptor mutants, both in the absence and in the presence of VEGF. These data demonstrate that dimerization is necessary, but not sufficient, for receptor activation, and that ligand-mediated receptor activation requires specific orientation of receptor monomers. Our study also shows that dimerization is mimicked by distinct dimerization- promoting TMDs that position the intracellular kinase domain either in an active or inactive conformation.-Dell'Era Dosch, D., Ballmer-Hofer, K. Transmembrane domain-mediated orientation of receptor monomers in active VEGFR-2 dimers. FASEB J. 24, 32-38 (2010). www.fasebj.org	[Dosch, Debora Dell'Era; Ballmer-Hofer, Kurt] Paul Scherrer Inst, CH-5232 Villigen, AG, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Ballmer-Hofer, K (corresponding author), Paul Scherrer Inst, OFLC 102, CH-5232 Villigen, AG, Switzerland.	kurt.ballmer@psi.ch		Ballmer-Hofer, Kurt/0000-0002-3800-9129	Swiss National Science Foundation [3100B-103545]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	We thank Dr. R. Jaussi for his technical support in plasmid construction and Dr. P. Berger and A. Giese for critically reading this manuscript. This project was supported in part by Swiss National Science Foundation grant 3100B-103545 issued to K.B.-H.	ASLANIDIS C, 1990, NUCLEIC ACIDS RES, V18, P6069, DOI 10.1093/nar/18.20.6069; Barton WA, 2006, NAT STRUCT MOL BIOL, V13, P524, DOI 10.1038/nsmb1101; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; Bennasroune A, 2004, MOL BIOL CELL, V15, P3464, DOI 10.1091/mbc.E03-10-0753; Brown RJ, 2005, NAT STRUCT MOL BIOL, V12, P814, DOI 10.1038/nsmb977; Cebe-Suarez S, 2006, CELL MOL LIFE SCI, V63, P601, DOI 10.1007/s00018-005-5426-3; Chen LI, 1997, J CELL BIOL, V137, P619, DOI 10.1083/jcb.137.3.619; Crooks D, 2000, MOL BIOL CELL, V11, P3559, DOI 10.1091/mbc.11.10.3559; DiMaio D, 2000, CYTOKINE GROWTH F R, V11, P283, DOI 10.1016/S1359-6101(00)00012-5; Drevs J, 2000, CANCER RES, V60, P4819; Geiser M, 2001, BIOTECHNIQUES, V31, P88, DOI 10.2144/01311st05; GULLICK WJ, 1992, EMBO J, V11, P43, DOI 10.1002/j.1460-2075.1992.tb05025.x; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Lemmon MA, 2007, CELL, V130, P213, DOI 10.1016/j.cell.2007.07.006; Liu HL, 2007, EMBO J, V26, P891, DOI 10.1038/sj.emboj.7601545; LOFTS FJ, 1993, ONCOGENE, V8, P2813; Mattoon D, 2001, ONCOGENE, V20, P3824, DOI 10.1038/sj.onc.1204523; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; MEYER AN, 1994, P NATL ACAD SCI USA, V91, P4634, DOI 10.1073/pnas.91.11.4634; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Ruch C, 2007, NAT STRUCT MOL BIOL, V14, P249, DOI 10.1038/nsmb1202; Schlessinger J, 2003, SCIENCE, V300, P750, DOI 10.1126/science.1082024; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Schubert C, 2007, J BIOL CHEM, V282, P4094, DOI 10.1074/jbc.M608183200; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Smith BC, 1996, REAL-TIME IMAGING, V2, P3, DOI 10.1006/rtim.1996.0002; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; Tao Q, 2001, J BIOL CHEM, V276, P21916, DOI 10.1074/jbc.M100763200; TESSLER S, 1994, J BIOL CHEM, V269, P12456; Thiel KW, 2007, P NATL ACAD SCI USA, V104, P19238, DOI 10.1073/pnas.0703854104; Walter M, 2007, J MOL BIOL, V367, P839, DOI 10.1016/j.jmb.2007.01.036; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Yang Y, 2008, P NATL ACAD SCI USA, V105, P7681, DOI 10.1073/pnas.0802896105; Yuzawa S, 2007, CELL, V130, P323, DOI 10.1016/j.cell.2007.05.055; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	40	41	42	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					32	38		10.1096/fj.09-132670	http://dx.doi.org/10.1096/fj.09-132670			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19726758				2022-12-28	WOS:000273233600006
J	Evangelisti, C; Florian, MC; Massimi, I; Dominici, C; Giannini, G; Galardi, S; Bue, MC; Massalini, S; McDowell, HP; Messi, E; Gulino, A; Farace, MG; Ciafre, SA				Evangelisti, Cristina; Florian, Maria Carolina; Massimi, Isabella; Dominici, Carlo; Giannini, Giuseppe; Galardi, Silvia; Bue, Maria Cristina; Massalini, Simone; McDowell, Heather P.; Messi, Elio; Gulino, Alberto; Farace, Maria Giulia; Ciafre, Silvia Anna			MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness	FASEB JOURNAL			English	Article						MicroRNA; tumor; neuronal; retinoic acid	MICRORNA EXPRESSION; RETINOIC ACID; DOUBLECORTIN; GENE; MIGRATION; DIFFERENTIATION; SPECIFICITY; DIAGNOSIS; SUGGESTS; CRITERIA	MicroRNAs are a class of sophisticated regulators of gene expression, acting as post-transcriptional inhibitors that recognize their target mRNAs through base pairing with short regions along the 3'UTRs. Several microRNAs are tissue specific, suggesting a specialized role in tissue differentiation or maintenance, and quite a few are critically involved in tumorigenesis. We studied miR-128, a brain-enriched microRNA, in retinoic acid-differentiated neuroblastoma cells, and we found that this microRNA is up-regulated in treated cells, where it down-modulates the expression of two proteins involved in the migratory potential of neural cells: Reelin and DCX. Consistently, miR-128 ectopic overexpression suppressed Reelin and DCX, whereas the LNA antisense-mediated miR-128 knockdown caused the two proteins to increase. Ectopic miR-128 overexpression reduced neuroblastoma cell motility and invasiveness, and impaired cell growth. Finally, the analysis of a small series of primary human neuroblastomas showed an association between high levels of miR-128 expression and favorable features, such as favorable Shimada category or very young age at diagnosis. Thus, we provide evidence for a role for miR-128 in the molecular events modulating neuroblastoma progression and aggressiveness.-Evangelisti, C., Florian, M. C., Massimi, I., Dominici, C., Giannini, G., Galardi, S., Bue, M. C., Massalini, S., McDowell, H. P., Messi, E., Gulino, A., Farace, M. G., Ciafre, S. A. MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB J. 23, 4276-4287 (2009). www.fasebj.org	[Evangelisti, Cristina; Galardi, Silvia; Bue, Maria Cristina; Massalini, Simone; Farace, Maria Giulia; Ciafre, Silvia Anna] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; [Florian, Maria Carolina; Messi, Elio] Univ Milan, Fac Farm, Dipartimento Endocrinol Fisiopatol & Biol Applica, Milan, Italy; [Massimi, Isabella; Giannini, Giuseppe; Gulino, Alberto] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy; [Dominici, Carlo; McDowell, Heather P.] Univ Roma La Sapienza, Dept Pediat, I-00185 Rome, Italy; [Dominici, Carlo] Bambino Gesu Pediat Hosp, Lab Oncol, Rome, Italy; [Dominici, Carlo] Univ Liverpool, Div Child Hlth, Sch Reprod & Dev Med, Liverpool L69 3BX, Merseyside, England; [McDowell, Heather P.] Royal Liverpool Childrens Natl Hlth Serv Trust Al, Div Oncol, Liverpool, Merseyside, England; [Gulino, Alberto] Neuromed Inst, Pozzilli, Italy	University of Rome Tor Vergata; University of Milan; Sapienza University Rome; Sapienza University Rome; IRCCS Bambino Gesu; University of Liverpool; IRCCS Neuromed	Ciafre, SA (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Montpellier 1, I-00133 Rome, Italy.	ciafre@uniroma2.it	ciafrè, silvia anna/G-1783-2012; Giannini, Giuseppe/B-5672-2013; Florian, M. Carolina/AAH-5309-2019	ciafrè, silvia anna/0000-0001-6467-8396; Giannini, Giuseppe/0000-0003-0299-4056; Florian, M. Carolina/0000-0002-5791-1310; Messi, Elio/0000-0002-9515-1463; GALARDI, SILVIA/0000-0002-3646-4064	Italian Ministry of Instruction; University and Scientific Research; FIRB [RBNE01H3K5, RBNE01MBEC]; Italy-USA Collaborative Programme; Ministry of Health; Associazione Italiana per la Ricerca sul Cancro; National Research Council; Ministry of University and Research; Telethon [GGP07118]	Italian Ministry of Instruction(Ministry of Education, Universities and Research (MIUR)); University and Scientific Research; FIRB; Italy-USA Collaborative Programme; Ministry of Health; Associazione Italiana per la Ricerca sul Cancro; National Research Council; Ministry of University and Research; Telethon	The authors are grateful to Dr. Pierluigi Altavista (Section of Toxicology and Biomedical Sciences, ENEA Research Center Casaccia, Rome) for performing the statistical analysis. This study was funded in part by grants from the Italian Ministry of Instruction, University and Scientific Research, FIRB RBNE01H3K5 to S. A. C., FIRB RBNE01MBEC and Italy-USA Collaborative Programme, Ministry of Health to MGF, and from Associazione Italiana per la Ricerca sul Cancro, Ministry of Health, the National Research Council, the Ministry of University and Research, Telethon grant GGP07118 to G. G.	Baetge E E, 1992, Perspect Dev Neurobiol, V1, P21; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernreuther C, 2006, ACTA NEUROPATHOL, V111, P247, DOI 10.1007/s00401-006-0038-z; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Castel V, 2007, CLIN TRANSL ONCOL, V9, P478, DOI 10.1007/s12094-007-0091-7; Chen Y, 2007, J NEUROCHEM, V103, P650, DOI 10.1111/j.1471-4159.2007.04797.x; Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Daou MC, 2005, ACTA NEUROPATHOL, V110, P472, DOI 10.1007/s00401-005-1070-0; De Bernardi B, 2003, J CLIN ONCOL, V21, P1592, DOI 10.1200/JCO.2003.05.191; des Portes V, 1998, CELL, V92, P51; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Encinas M, 1999, J NEUROCHEM, V73, P1409, DOI 10.1046/j.1471-4159.1999.0731409.x; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gao FB, 2008, TRENDS NEUROSCI, V31, P20, DOI 10.1016/j.tins.2007.10.004; Hoebeeck J, 2007, INT J CANCER, V120, P533, DOI 10.1002/ijc.22326; Kato M, 2008, BIOL CELL, V100, P71, DOI 10.1042/BC20070078; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Masui K, 2008, BRAIN TUMOR PATHOL, V25, P1, DOI 10.1007/s10014-007-0225-1; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Messi E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-30; Mi SL, 2007, P NATL ACAD SCI USA, V104, P19971, DOI 10.1073/pnas.0709313104; Mizuguchi M, 1999, AM J PATHOL, V155, P1713, DOI 10.1016/S0002-9440(10)65486-7; Mosse YP, 2007, GENE CHROMOSOME CANC, V46, P936, DOI 10.1002/gcc.20477; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Oltra S, 2005, DIAGN MOL PATHOL, V14, P53, DOI 10.1097/01.pas.0000149876.32376.c0; Perrone G, 2007, MODERN PATHOL, V20, P344, DOI 10.1038/modpathol.3800743; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Sato N, 2006, GASTROENTEROLOGY, V130, P548, DOI 10.1053/j.gastro.2005.11.008; Seigel GM, 2007, MOL VIS, V13, P823; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Tissir F, 2003, NAT REV NEUROSCI, V4, P496, DOI 10.1038/nrn1113; Voigt A, 2003, MED PEDIATR ONCOL, V40, P205, DOI 10.1002/mpo.10250; Wang Q, 2002, CANCER LETT, V179, P71, DOI 10.1016/S0304-3835(01)00846-1; Watanabe Y, 2007, METHOD ENZYMOL, V427, P65, DOI 10.1016/S0076-6879(07)27004-1; Yang HKC, 2004, J NEUROSCI RES, V76, P282, DOI 10.1002/jnr.20071; Yarrow JC, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-21; Zhang Y, 2009, J MOL MED, V87, P43, DOI 10.1007/s00109-008-0403-6	45	124	127	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4276	4287		10.1096/fj.09-134965	http://dx.doi.org/10.1096/fj.09-134965			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19713529	Green Submitted			2022-12-28	WOS:000272193700022
J	Barbi, J; Snider, HM; Bhardwaj, N; Lezama-Davila, CM; Durbin, JE; Satoskar, AR				Barbi, Joseph; Snider, Heidi M.; Bhardwaj, Neeti; Lezama-Davila, Claudio M.; Durbin, Joan E.; Satoskar, Abhay R.			Signal transducer and activator of transcription 1 in T cells plays an indispensable role in immunity to Leishmania major by mediating Th1 cell homing to the site of infection	FASEB JOURNAL			English	Article						CXCR3; protozoa	MURINE LEISHMANIASIS; IFN-GAMMA; CUTANEOUS LEISHMANIASIS; CUTTING EDGE; STAT1; EXPRESSION; BET; INDUCTION; CD4(+); MICE	The signal transducer and activator of transcription 1 (STAT1) signaling pathway mediates the biological functions of IFN-gamma. We have previously shown that the STAT1 pathway is indispensable for host resistance against Leishmania major infection. In this study, we examined the role of STAT1 in lymphocytes and specifically CD4(+) and CD8(+) T cells in mediating immunity against L. major by transferring T cells from wild-type (WT) and STAT1(-/-) C57BL/6 mice into Rag2(-/-) C57BL/6 mice. Rag2(-/-) mice reconstituted with unfractionated STAT1(-/-) splenocytes (B cells and T cells) failed to mount an efficient Th1 response after L. major infection, produced more IL-4, and developed large lesions full of parasites. In contrast, Rag2(-/-) mice reconstituted with WT (STAT1(+/+)) splenocytes mounted a Th1 response and developed self-resolving lesions. Studies using Rag2(-/-) recipients that received a combination of purified CD4(+) and CD8(+) T cells from WT or STAT1(-/-) mice revealed that STAT1 deficiency in CD4(+) T cells, but not in CD8(+) T cells, leads to development of chronic, nonhealing lesions and systemic dissemination of parasites into the spleen after L. major infection. Further studies using Rag2(-/-) recipients of WT Thy1.1(+) and STAT1(-/-) Thy1.2(+) T cells showed that STAT1 in CD4(+) T cells was not required for Th1 differentiation during L. major infection. However, it was critical for up-regulation of CXCR3 on CD4(+) T cells and their migration to the regional lymph node and the cutaneous site of infection. Together, these studies indicate that the STAT1 pathway in CD4(+) T cells plays a critical role in immunity against L. major by controlling the migration of Th1 cells to the site of infection rather than their generation. Further, they reveal an essential role for CD4(+) T cell STAT1 in preventing systemic dissemination of L. major infection.-Barbi, J., Snider, H. M., Bhardwaj, N., Lezama-Davila, C. M., Durbin, J. E., Satoskar, A. R. Signal transducer and activator of transcription 1 in T cells plays an indispensable role in immunity to Leishmania major by mediating Th1 cell homing to the site of infection. FASEB J. 23, 3990-3999 (2009). www.fasebj.org	[Barbi, Joseph; Snider, Heidi M.; Bhardwaj, Neeti; Lezama-Davila, Claudio M.; Satoskar, Abhay R.] Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; [Satoskar, Abhay R.] Ohio State Univ, Ctr Microbial Interface Biol, Columbus, OH 43210 USA; [Durbin, Joan E.] Childrens Hosp, Dept Pathol, Columbus, OH 43205 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Satoskar, AR (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.	satoskar.2@osu.edu	Satoskar, Abhay/AAB-7748-2019		U. S. National Institutes of Health/National Institute of Allergy and Infectious Diseases [R56 AI 068829]; National Institute of Dental and Craniofacial Research [F30 DE020001-0109]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051823, R56AI068829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F30DE020001] Funding Source: NIH RePORTER	U. S. National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	N. B. was an M. Sc. student at Ohio State University; C. M. L. D. is an international scholar supported by Fundacion Pablo Garcia of the government of Campeche. This work received financial aid from a U. S. National Institutes of Health/National Institute of Allergy and Infectious Diseases grant (R56 AI 068829) to A. R. S. and a National Institute of Dental and Craniofacial Research fellowship (F30 DE020001-0109) to H. M. S. The authors declare no conflicts of interest.	Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Barbi J, 2007, BLOOD, V110, P2215, DOI 10.1182/blood-2007-03-081307; Belkaid Y, 2002, J IMMUNOL, V168, P3992, DOI 10.4049/jimmunol.168.8.3992; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; Heinzel FP, 1995, RES IMMUNOL, V146, P575, DOI 10.1016/0923-2494(96)83034-3; HOERAUF A, 1994, INT IMMUNOL, V6, P1117, DOI 10.1093/intimm/6.8.1117; Johnson LM, 2007, J IMMUNOL, V178, P7259, DOI 10.4049/jimmunol.178.11.7259; Kane MM, 2001, J IMMUNOL, V166, P1141, DOI 10.4049/jimmunol.166.2.1141; Lieberman LA, 2004, J IMMUNOL, V172, P457, DOI 10.4049/jimmunol.172.1.457; LIEW FY, 1993, ADV PARASIT, V32, P161, DOI 10.1016/S0065-308X(08)60208-0; LOCKSLEY RM, 1991, RES IMMUNOL, V142, P28, DOI 10.1016/0923-2494(91)90007-6; Lord GM, 2005, BLOOD, V106, P3432, DOI 10.1182/blood-2005-04-1393; Mikhak Z, 2006, J IMMUNOL, V176, P4959, DOI 10.4049/jimmunol.176.8.4959; Morishima N, 2005, J IMMUNOL, V175, P1686, DOI 10.4049/jimmunol.175.3.1686; MUNDER M, 1998, J EXP MED, V179, P1731; Murray HW, 2005, LANCET, V366, P1561, DOI 10.1016/S0140-6736(05)67629-5; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Rosas LE, 2005, EUR J IMMUNOL, V35, P515, DOI 10.1002/eji.200425422; Rosas LE, 2003, EUR J IMMUNOL, V33, P1799, DOI 10.1002/eji.200323163; Rosas LE, 2006, J IMMUNOL, V177, P22, DOI 10.4049/jimmunol.177.1.22; SHER A, 1983, CIBA F SYMP, V99, P174; SOBER D, 2001, J IMMUNOL, V167, P957; Suzue K, 2003, EUR J IMMUNOL, V33, P2666, DOI 10.1002/eji.200323292; Takeda A, 2003, J IMMUNOL, V170, P4886, DOI 10.4049/jimmunol.170.10.4886	27	11	11	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3990	3999		10.1096/fj.09-138057	http://dx.doi.org/10.1096/fj.09-138057			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19641143	Green Published			2022-12-28	WOS:000271272500034
J	Drake, PMW; Barbi, T; Sexton, A; McGowan, E; Stadlmann, J; Navarre, C; Paul, MJ; Ma, JKC				Drake, Pascal M. W.; Barbi, Tommaso; Sexton, Amy; McGowan, Edward; Stadlmann, Johannes; Navarre, Catherine; Paul, Matthew J.; Ma, Julian K. -C.			Development of rhizosecretion as a production system for recombinant proteins from hydroponic cultivated tobacco	FASEB JOURNAL			English	Article						transgenic plants; molecular farming; plant growth regulators; proteases; glycosylation	MONOCLONAL-ANTIBODIES; HAIRY ROOTS; PLANT-CELLS; PHARMACEUTICALS; GLYCOSYLATION	Rhizosecretion is an attractive technology for the production of recombinant proteins from transgenic plants. However, to date, yields of plant-derived recombinant pharmaceuticals by this method have been too low for commercial viability. Studies conducted focused on three transgenic plant lines grown in hydroponic culture medium, two expressing monoclonal antibodies Guy's 13 and 4E10 and one expressing a small microbicide polypeptide cyanovirin-N. Rhizosecretion rates increased significantly by the addition of the plant growth regulator alpha-naphthalene acetic acid. The maximum rhizosecretion rates achieved were 58 mu g/g root dry weight/24 h for Guy's 13, 10.43 mu g/g root dry weight/24 h for 4E10, and 766 mu g/g root dry weight/24 h for cyanovirin-N, the highest figures so far reported for a full-length antibody and a recombinant protein, respectively. The plant growth regulators indolebutyric acid, 6-benzylaminopurine, and kinetin were also demonstrated to increase rhizosecretion of Guy's 13. The effect of the growth regulators differed, as alpha-naphthalene acetic acid and indole-butyric acid increased the root dry weight of hydroponic plants, whereas the cytokinins benzylaminopurine and kinetin increased rhizosecretion without affecting root mass. A comparative glycosylation analysis between MAb Guy's 13 purified from either hydroponic culture medium or from leaf extracts demonstrated a similar pattern of glycosylation comprising high mannose to complex glycoforms. Analysis of the hydroponic culture medium at harvest revealed significantly lower and less complex levels of proteolytic enzymes, in comparison with leaf extracts, which translated to a higher proportion of intact Guy's 13 IgG in relation to other IgG products. Hydroponic medium could be added directly to a chromatography column for affinity purification, allowing simple and rapid production of high purity Guy's 13 antibody. In addition to the attractiveness of controlled cultivation within a contained environment for pharmaceutical-producing plants, this study demonstrates advantages with respect to the quality and downstream purification of recombinant proteins.-Drake, P. M. W., Barbi, T., Sexton, A., McGowan, E., Stadlmann, J., Navarre, C., Paul, M. J., Ma, J. K.- C. Development of rhizosecretion as a production system for recombinant proteins	[Drake, Pascal M. W.; Barbi, Tommaso; Sexton, Amy; McGowan, Edward; Paul, Matthew J.; Ma, Julian K. -C.] Univ London, Sch Med, St Georges Hosp, Dept Cellular & Mol Med,Mol Immunol Unit, London SW17 0RE, England; [Stadlmann, Johannes] Univ Nat Resources & Appl Life Sci Vienna, Inst Chem, A-1180 Vienna, Austria; [Navarre, Catherine] Univ Catholique Louvain, Inst Sci Vie, B-1348 Louvain, Belgium	St Georges University London; University of London; University College London; UCL Medical School; University of Natural Resources & Life Sciences, Vienna; Universite Catholique Louvain	Drake, PMW (corresponding author), Univ London, Sch Med, St Georges Hosp, Dept Cellular & Mol Med,Mol Immunol Unit, Cranmer Terrace, London SW17 0RE, England.	pdrake@sgul.ac.uk	Stadlmann, Johannes/AAC-3157-2021	Stadlmann, Johannes/0000-0001-5693-6690; Drake, Pascal/0000-0002-6181-0600; Ma, Julian/0000-0003-0767-0042; Paul, Mathew/0000-0002-0852-8788	St. George's University of London/Royal Holloway University of London	St. George's University of London/Royal Holloway University of London	We thank Sir Joseph Hotung for funding P. M. W. D. and J.K.-C.M. We are grateful to Dr. Dietmar Katinger (Polymun Scientific GmbH, Vienna, Austria) for providing the 4E10 peptide and to Dr. Barry O'Keefe (National Cancer Institute, Frederick, MD, USA) for providing the rabbit anti-CV-N antiserum. T. B. is funded by a joint St. George's University of London/Royal Holloway University of London Ph. D. studentship.	Boehm R, 2007, ANN NY ACAD SCI, V1102, P121, DOI 10.1196/annals.1408.009; Borisjuk NV, 1999, NAT BIOTECHNOL, V17, P466, DOI 10.1038/8643; Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521, DOI 10.1128/AAC.41.7.1521; Cabanes-Macheteau M, 1999, GLYCOBIOLOGY, V9, P365, DOI 10.1093/glycob/9.4.365; CARPITA N, 1979, SCIENCE, V205, P1144, DOI 10.1126/science.205.4411.1144; Delannoy M, 2008, PROTEOMICS, V8, P2285, DOI 10.1002/pmic.200700507; Drake PMW, 2003, PLANT MOL BIOL, V52, P233, DOI 10.1023/A:1023909331482; FIREK S, 1994, PLANT MOL BIOL, V24, P833; Gaume A, 2003, PLANT CELL REP, V21, P1188, DOI 10.1007/s00299-003-0660-3; Gleba D, 1999, P NATL ACAD SCI USA, V96, P5973, DOI 10.1073/pnas.96.11.5973; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Johri MM, 2001, CURR SCI INDIA, V80, P199; Kneer R, 1999, J EXP BOT, V50, P1553, DOI 10.1093/jexbot/50.339.1553; Komarnytsky S, 2006, PLANT PHYSIOL, V141, P1185, DOI 10.1104/pp.105.074419; Ma JKC, 2005, EMBO REP, V6, P593, DOI 10.1038/sj.embor.7400470; MA JKC, 1994, EUR J IMMUNOL, V24, P131, DOI 10.1002/eji.1830240120; Magnuson NS, 1996, PROTEIN EXPRES PURIF, V7, P220, DOI 10.1006/prep.1996.0030; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; SEXTON A, 2005, FASEB J, V19; Sexton A, 2006, FASEB J, V20, P356, DOI 10.1096/fj.05-4742fje; Sparrow PAC, 2007, TRANSGENIC RES, V16, P147, DOI 10.1007/s11248-007-9074-2; Stadlmann J, 2008, PROTEOMICS, V8, P2858, DOI 10.1002/pmic.200700968; van Dolleweerd CJ, 2003, INFECT IMMUN, V71, P754, DOI 10.1128/IAI.71.2.754-765.2003; Wongsamuth R, 1997, BIOTECHNOL BIOENG, V54, P401, DOI 10.1002/(SICI)1097-0290(19970605)54:5&lt;401::AID-BIT1&gt;3.0.CO;2-I	24	56	57	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2009	23	10					3581	3589		10.1096/fj.09-131771	http://dx.doi.org/10.1096/fj.09-131771			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19470800				2022-12-28	WOS:000270354300034
J	Kan, NG; Junghans, D; Belmonte, JCI				Kan, Natalia G.; Junghans, Dirk; Izpisua Belmonte, Juan Carlos			Compensatory growth mechanisms regulated by BMP and FGF signaling mediate liver regeneration in zebrafish after partial hepatectomy	FASEB JOURNAL			English	Article						hepatocyte proliferation; liver-to-body weight ratio; liver mass restoration; Danio rerio	RAT-LIVER; FIN REGENERATION; IN-VIVO; EXPRESSION; SPECIFICATION; ENDODERM; INJURY; REQUIRES; PATHWAY; MUTANT	Here, we describe the zebrafish (Danio rerio) as a vertebrate model system to study liver regeneration with the added benefit of its powerful genetics and screening possibilities to uncover the molecular pathways underlying liver regeneration. We developed a partial hepatectomy (PH) protocol in zebrafish and investigated in detail the cellular and morphological changes during the process of liver regeneration. We show that the type of regenerative response is dependent on the size of the injury sustained by the zebrafish liver. Furthermore, we demonstrate for the first time that the mechanisms of liver regeneration in zebrafish after PH are strikingly similar to those of rodents and humans, with 100% recovery of the liver mass after 6-7 d postsurgery. This occurs via compensatory growth mediated by proliferation of hepatocytes throughout the entire liver remnant. By analyzing transgenic fish expressing dominant-negative forms of either bone morphogenetic protein (BMP) receptor or fibroblast growth factor (FGF) receptor 1, we demonstrate that the BMP and FGF signaling pathways are crucial regulators of the early events during liver regeneration after PH. Our study demonstrates that the mechanisms of liver regeneration in zebrafish are highly similar to the processes ongoing during mammalian liver regeneration and make the adult zebrafish a suitable model system to study the mechanisms of liver regeneration.-Kan, N. G., Junghans, D., Belmonte, J. C. I. Compensatory growth mechanisms regulated by BMP and FGF signaling mediate liver regeneration in zebrafish after partial hepatectomy. FASEB J. 23, 3516-3525 (2009). www.fasebj.org	[Kan, Natalia G.; Junghans, Dirk; Izpisua Belmonte, Juan Carlos] Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; [Junghans, Dirk; Izpisua Belmonte, Juan Carlos] Ctr Regenerat Med Barcelona, Barcelona, Spain	Salk Institute; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Centro de Medicina Regenerativa de Barcelona; University of Barcelona	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu			G. Harold and Leila Y. Mathers Charitable Foundation; U. S. National Institutes of Health; Marato; Fundacion Cellex	G. Harold and Leila Y. Mathers Charitable Foundation; U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Marato; Fundacion Cellex	The authors greatly appreciate the generous gift of BMP2 and Noggin recombinant proteins from Dr. Senyon Choe ( Salk Institute, La Jolla, CA, USA). We thank Verdon Taylor, Gerald Pao and Karl-Dimiter Bissig for helpful discussions and constructive comments on the manuscript, Michael Schorpp (Max-Planck Institute of Immunobiology, Freiburg, Germany) for providing zebrafish; and May Schwarz for proofreading the manuscript. This work was supported by grants from the G. Harold and Leila Y. Mathers Charitable Foundation, the U. S. National Institutes of Health, the Marato, and Fundacion Cellex. N.G.K., D.J., and J.C.I.B. designed the research; N.G.K. and D.J. performed the research; N.G.K., D.J., and J.C.I.B analyzed the data; and N.G.K., D.J., and J.C.I.B. wrote the paper.	AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BARUCH Y, 1995, J HEPATOL, V23, P328, DOI 10.1016/0168-8278(95)80477-3; Burke ZD, 2006, CURR BIOL, V16, pR688, DOI 10.1016/j.cub.2006.08.011; Calmont A, 2006, DEV CELL, V11, P339, DOI 10.1016/j.devcel.2006.06.015; Driever W, 1996, DEVELOPMENT, V123, P37; Fausto N, 2006, HEPATOLOGY, V43, pS45, DOI 10.1002/hep.20969; GHOSH C, 1994, CELL BIOL TOXICOL, V10, P167, DOI 10.1007/BF00757560; Goessling W, 2008, DEV BIOL, V320, P161, DOI 10.1016/j.ydbio.2008.05.526; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GRISHAM JW, 1962, CANCER RES, V22, P842; Haffter P, 1996, DEVELOPMENT, V123, P1; Hioki O, 1996, J HEPATOL, V24, P217, DOI 10.1016/S0168-8278(96)80032-8; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Junghans D, 2005, DEV DYNAM, V233, P528, DOI 10.1002/dvdy.20365; Lam SH, 2006, NAT BIOTECHNOL, V24, P73, DOI 10.1038/nbt1169; Lee Y, 2005, DEVELOPMENT, V132, P5173, DOI 10.1242/dev.02101; Lepilina A, 2006, CELL, V127, P607, DOI 10.1016/j.cell.2006.08.052; Michalopoulos GK, 2007, J CELL PHYSIOL, V213, P286, DOI 10.1002/jcp.21172; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Monga SPS, 2001, HEPATOLOGY, V33, P1098, DOI 10.1053/jhep.2001.23786; Nakatsuka R, 2007, J BIOCHEM, V141, P113, DOI 10.1093/jb/mvm012; Ober EA, 2006, NATURE, V442, P688, DOI 10.1038/nature04888; Poss FD, 2000, DEV BIOL, V222, P347, DOI 10.1006/dbio.2000.9722; Poss KD, 2003, DEV DYNAM, V226, P202, DOI 10.1002/dvdy.10220; Pyati UJ, 2005, DEVELOPMENT, V132, P2333, DOI 10.1242/dev.01806; Rossi JM, 2001, GENE DEV, V15, P1998, DOI 10.1101/gad.904601; Sadler KC, 2007, P NATL ACAD SCI USA, V104, P1570, DOI 10.1073/pnas.0610774104; Shin D, 2007, DEVELOPMENT, V134, P2041, DOI 10.1242/dev.000281; Sosa-Pineda B, 2000, NAT GENET, V25, P254, DOI 10.1038/76996; Steiling H, 2003, ONCOGENE, V22, P4380, DOI 10.1038/sj.onc.1206499; Sturm J, 2004, LIVER INT, V24, P161, DOI 10.1111/j.1478-3231.2004.0896.x; Sugimoto H, 2007, FASEB J, V21, P256, DOI 10.1096/fj.06-6837com; Tan XP, 2006, GASTROENTEROLOGY, V131, P1561, DOI 10.1053/j.gastro.2006.08.042; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Thummel R, 2006, DEV DYNAM, V235, P336, DOI 10.1002/dvdy.20630; Weglarz TC, 2000, P NATL ACAD SCI USA, V97, P12595, DOI 10.1073/pnas.220430497; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Whitehead GG, 2005, SCIENCE, V310, P1957, DOI 10.1126/science.1117637; Yin VP, 2008, GENE DEV, V22, P728, DOI 10.1101/gad.1641808; Zaret KS, 2002, NAT REV GENET, V3, P499, DOI 10.1038/nrg837	41	65	70	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3516	3525		10.1096/fj.09-131730	http://dx.doi.org/10.1096/fj.09-131730			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19546304	Green Published			2022-12-28	WOS:000270354300028
J	Martin, HL; Teismann, P				Martin, Heather L.; Teismann, Peter			Glutathione-a review on its role and significance in Parkinson's disease	FASEB JOURNAL			English	Review						oxidative stress; complex I; ubiquitin-proteasome; inflammation; incidental Lewy body disease	MITOCHONDRIAL COMPLEX-I; NITRIC-OXIDE SYNTHASE; OXIDATIVE STRESS; SUBSTANTIA-NIGRA; CELL-DEATH; DOPAMINERGIC NEURODEGENERATION; MPTP MODEL; LIPID-PEROXIDATION; N-ACETYLCYSTEINE; DEPLETION	Parkinson's disease (PD) is the second most common neurodegenerative disease, affecting over a million people in the United States alone, and is characterized by rigidity, bradykinesia, resting tremor, and postural instability. Its main neuropathological feature is the loss of dopaminergic neurons of the substantia nigra pars compacta. However, the pathogenesis of this loss is not understood fully. One of the earliest biochemical changes seen in PD is a reduction in the levels of total glutathione, a key cellular antioxidant. Traditionally, it has been thought that this decrease in GSH levels is the consequence of increased oxidative stress, a process heavily implicated in PD pathogenesis. However, emerging evidence suggests that GSH depletion may itself play an active role in PD pathogenesis. This review aims to explore the contribution of GSH depletion to PD pathogenesis.-Martin, H. L., Teismann, P. Glutathione-a review on its role and significance in Parkinson's disease. FASEB J. 23, 3263-3272 (2009). www.fasebj.org	[Martin, Heather L.; Teismann, Peter] Univ Aberdeen, Coll Life Sci & Med, Sch Med Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Teismann, P (corresponding author), Univ Aberdeen, Coll Life Sci & Med, Sch Med Sci, Aberdeen AB25 2ZD, Scotland.	p.teismann@abdn.ac.uk						Alam ZI, 1997, J NEUROCHEM, V69, P1326; Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Anantharam V, 2007, NEUROTOXICOLOGY, V28, P988, DOI 10.1016/j.neuro.2007.08.008; Aoyama K, 2008, EUR J NEUROSCI, V27, P20, DOI 10.1111/j.1460-9568.2007.05979.x; Bahat-Stroomza M, 2005, EUR J NEUROSCI, V21, P637, DOI 10.1111/j.1460-9568.2005.03889.x; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Bharath S, 2005, ANTIOXID REDOX SIGN, V7, P900, DOI 10.1089/ars.2005.7.900; BlumDegen D, 1995, NEUROSCI LETT, V202, P17, DOI 10.1016/0304-3940(95)12192-7; Brigelius-Flohe R, 2004, ARCH BIOCHEM BIOPHYS, V423, P66, DOI 10.1016/j.abb.2003.12.008; Brodacki B, 2008, NEUROSCI LETT, V441, P158, DOI 10.1016/j.neulet.2008.06.040; Caneda-Ferron B, 2008, J NEUROCHEM, V105, P225, DOI 10.1111/j.1471-4159.2007.05130.x; Chinta SJ, 2008, BBA-GEN SUBJECTS, V1780, P1362, DOI 10.1016/j.bbagen.2008.02.005; Chinta SJ, 2006, FREE RADICAL BIO MED, V41, P1442, DOI 10.1016/j.freeradbiomed.2006.08.002; Chinta SJ, 2006, NEUROSCI LETT, V402, P137, DOI 10.1016/j.neulet.2006.03.056; Chinta SJ, 2006, FREE RADICAL BIO MED, V40, P1557, DOI 10.1016/j.freeradbiomed.2005.12.023; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Czlonkowska A, 1996, NEURODEGENERATION, V5, P137, DOI 10.1006/neur.1996.0020; Dahm CC, 2006, J BIOL CHEM, V281, P10056, DOI 10.1074/jbc.M512203200; Danielson SR, 2008, FREE RADICAL BIO MED, V44, P1787, DOI 10.1016/j.freeradbiomed.2008.03.005; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dickinson DA, 2002, BIOCHEM PHARMACOL, V64, P1019, DOI 10.1016/S0006-2952(02)01172-3; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Drechsel DA, 2007, TOXICOL APPL PHARM, V220, P341, DOI 10.1016/j.taap.2007.02.002; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; Droge W, 2007, AGING CELL, V6, P361, DOI 10.1111/j.1474-9726.2007.00294.x; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Esposito E, 2007, EXP NEUROL, V205, P295, DOI 10.1016/j.expneurol.2007.02.008; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Genestra M, 2007, CELL SIGNAL, V19, P1807, DOI 10.1016/j.cellsig.2007.04.009; Glinka Y, 1998, EUR J PHARMACOL, V351, P121, DOI 10.1016/S0014-2999(98)00279-9; Greenamyre JT, 2001, IUBMB LIFE, V52, P135, DOI 10.1080/15216540152845939; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Haddad JJ, 2005, MOL IMMUNOL, V42, P987, DOI 10.1016/j.molimm.2004.09.029; Haddad JJ, 2002, BIOCHEM PHARMACOL, V63, P305, DOI 10.1016/S0006-2952(01)00870-X; Hald A, 2005, EXP NEUROL, V193, P279, DOI 10.1016/j.expneurol.2005.01.013; HASTINGS TG, 1995, J NEUROCHEM, V64, P919; Hirsch EC, 2005, PARKINSONISM RELAT D, V11, pS9, DOI 10.1016/j.parkreldis.2004.10.013; Hoglinger GU, 2003, J NEUROCHEM, V86, P1297, DOI 10.1046/j.1471-4159.2003.01952.x; Hsu M, 2005, J NEUROCHEM, V92, P1091, DOI 10.1111/j.1471-4159.2004.02929.x; Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101; Ilic TV, 1999, FUNCT NEUROL, V14, P141; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jha N, 2002, J NEUROCHEM, V80, P555, DOI 10.1046/j.0022-3042.2001.00009.x; Jha N, 2000, J BIOL CHEM, V275, P26096, DOI 10.1074/jbc.M000120200; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; KISH SJ, 1985, NEUROSCI LETT, V58, P343, DOI 10.1016/0304-3940(85)90078-3; Komatsu H, 2003, FREE RADICAL RES, V37, P293, DOI 10.1080/1071576021000046613; Kramer BC, 2002, NEUROSCIENCE, V114, P361, DOI 10.1016/S0306-4522(02)00310-X; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Lee I, 2008, CELL, V134, P268, DOI 10.1016/j.cell.2008.05.046; Liberatore GT, 1999, NAT MED, V5, P1403; MATTAMMAL MB, 1995, J NEUROCHEM, V64, P1645; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MCLELLAN LI, 1995, CARCINOGENESIS, V16, P2099, DOI 10.1093/carcin/16.9.2099; MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Nikulina MA, 2000, CYTOKINE, V12, P1391, DOI 10.1006/cyto.2000.0712; Offen D, 2004, J NEUROCHEM, V89, P1241, DOI 10.1111/j.1471-4159.2004.02428.x; Olanow CW, 2007, MOVEMENT DISORD, V22, pS335, DOI 10.1002/mds.21675; PERISTERIS P, 1992, CELL IMMUNOL, V140, P390, DOI 10.1016/0008-8749(92)90205-4; Pocernich CB, 2001, NEUROCHEM INT, V39, P141, DOI 10.1016/S0197-0186(01)00012-2; Pocernich CB, 2000, NEUROCHEM INT, V36, P185, DOI 10.1016/S0197-0186(99)00126-6; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Przedborski S, 2005, PARKINSONISM RELAT D, V11, pS3, DOI 10.1016/j.parkreldis.2004.10.012; ROBINSON MK, 1993, ARCH SURG-CHICAGO, V128, P29; Saravanan KS, 2006, NEUROCHEM INT, V49, P28, DOI 10.1016/j.neuint.2005.12.016; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; Seaton TA, 1996, BIOCHEM PHARMACOL, V52, P1657, DOI 10.1016/S0006-2952(96)00452-2; Sechi G, 1996, PROG NEURO-PSYCHOPH, V20, P1159, DOI 10.1016/S0278-5846(96)00103-0; Shamoto-Nagai M, 2007, J NEURAL TRANSM, V114, P1559, DOI 10.1007/s00702-007-0789-2; Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056; SIAN J, 1994, ANN NEUROL, V36, P356, DOI 10.1002/ana.410360306; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; SOFIC E, 1988, J NEURAL TRANSM, V74, P199, DOI 10.1007/BF01244786; SOFIC E, 1992, NEUROSCI LETT, V142, P128, DOI 10.1016/0304-3940(92)90355-B; Tarohda T, 2005, ANAL BIOANAL CHEM, V383, P224, DOI 10.1007/s00216-005-3423-x; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Vasquez OL, 2001, J NEUROCHEM, V76, P1593, DOI 10.1046/j.1471-4159.2001.00223.x; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; ZEEVALK G, 2008, SOC NEUR ABSTR; Zeevalk GD, 2007, EXP NEUROL, V203, P512, DOI 10.1016/j.expneurol.2006.09.004; Zeevalk GD, 2008, BIOMED PHARMACOTHER, V62, P236, DOI 10.1016/j.biopha.2008.01.017; ZHANG F, 1994, J MED CHEM, V37, P1084, DOI 10.1021/jm00034a006; Zhou C, 2008, ANN NY ACAD SCI, V1147, P93, DOI 10.1196/annals.1427.023; Zhu YG, 2006, BRAIN RES, V1090, P35, DOI 10.1016/j.brainres.2006.03.063	93	205	217	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3263	3272		10.1096/fj.08-125443	http://dx.doi.org/10.1096/fj.08-125443			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19542204				2022-12-28	WOS:000270354300004
J	Riccio, G; Esposito, G; Leoncini, E; Contu, R; Condorelli, G; Chiariello, M; Laccetti, P; Hrelia, S; D'Alessio, G; De Lorenzo, C				Riccio, Gennaro; Esposito, Giovanni; Leoncini, Emanuela; Contu, Riccardo; Condorelli, Gianluigi; Chiariello, Massimo; Laccetti, Paolo; Hrelia, Silvana; D'Alessio, Giuseppe; De Lorenzo, Claudia			Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents	FASEB JOURNAL			English	Article						immunotherapy; immunoRNase; Herceptin; trastuzumab; Her2; heart failure	BREAST-CANCER; MONOCLONAL-ANTIBODIES; TRASTUZUMAB HERCEPTIN; CARDIAC DEVELOPMENT; ERBB2; RECEPTOR; CARDIOMYOPATHY; CARCINOMAS; SURVIVAL; COMPACT	This study investigated potential cardiotoxicity as exerted by Erbicin-derived-immunoagents (EDIAs), novel human anti-ErbB2 immunoagents engineered by fusion of a human anti-ErbB2 scFv, Erbicin, with either a human RNase or the Fc region of a human IgG1. EDIAs are strongly cytotoxic on ErbB2-positive cells in vitro and in vivo and bind to an epitope different from that of Herceptin, a humanized anti-ErbB2 mAb effective in the therapy of breast carcinoma, but cardiotoxic in a high percentage of cases. Toxicity and apoptosis were tested in vitro by 3-(4,5-dimethyl-2-thizolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), DNA fragmentation, and immunoblotting analyses. Echocardiography was measured in mice after treatment with each immunoagent. Cardiac fibrosis and detection of apoptosis were examined by Sirius red staining of collagen and TUNEL assay, respectively. EDIAs were found in vitro to have no adverse effects on cardiac cells for which Herceptin is severely toxic. In vivo studies on a mouse model showed that the EDIAs did not alter cardiac function, whereas Herceptin and doxorubicin, used as positive controls, significantly reduced the fractional shortening parameter. Cardiac fibrosis and apoptosis were not significantly affected in mice treated with EDIAs. Thus, EDIAs could fulfill the therapeutic need of patients ineligible for Herceptin treatment due to cardiac dysfunction.-Riccio, G., Esposito, G., Leoncini, E., Contu, R., Condorelli, G., Chiariello, M., Laccetti, P., Hrelia, S., D'Alessio, G., De Lorenzo, C. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J. 23, 3171-3178 ( 2009). www.fasebj.org	[Riccio, Gennaro; Laccetti, Paolo; D'Alessio, Giuseppe; De Lorenzo, Claudia] Univ Naples Federico II, Dipartimento Biol Strutturale & Funz, I-80126 Naples, Italy; [Esposito, Giovanni; Chiariello, Massimo] Univ Naples Federico II, Dipartimento Med Clin Sci Cardiovasc & Immunol, I-80126 Naples, Italy; [Leoncini, Emanuela; Hrelia, Silvana] Univ Bologna, Dipartimento Biochim G Moruzzi, Bologna, Italy; [Contu, Riccardo; Condorelli, Gianluigi] Multimedica, Ist Ricovero & Cura Carattere Sci, Milan, Italy	University of Naples Federico II; University of Naples Federico II; University of Bologna; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Multimedica	De Lorenzo, C (corresponding author), Univ Naples Federico II, Dipartimento Biol Strutturale & Funz, Via Cinthia, I-80126 Naples, Italy.	cladelor@unina.it	Riccio, Gennaro/AAH-6275-2020; Hrelia, Silvana/P-2864-2015; Esposito, Giovanni/F-2880-2010; Condorelli, Gianluigi/Q-6736-2017	Hrelia, Silvana/0000-0001-7857-4512; Esposito, Giovanni/0000-0003-0565-7127; Condorelli, Gianluigi/0000-0003-0481-6843; Riccio, Gennaro/0000-0003-2541-5790; De Lorenzo, Claudia/0000-0002-6195-5631	Associazione Italiana per la Ricerca sul Cancro, Milan, Italy; Ministero dell'Universita e della Ricerca, Rome, Italy; Biotecnol, S. A., Lisbon, Portugal	Associazione Italiana per la Ricerca sul Cancro, Milan, Italy(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Universita e della Ricerca, Rome, Italy(Ministry of Education, Universities and Research (MIUR)); Biotecnol, S. A., Lisbon, Portugal	This work was financially supported by the Associazione Italiana per la Ricerca sul Cancro, Milan, Italy; the Ministero dell'Universita e della Ricerca, Rome, Italy; and Biotecnol, S. A., Lisbon, Portugal. We thank Dr. Rosanna Cozzolino for skilled assistance.	Angeloni C, 2008, AM J PHYSIOL-HEART C, V294, pH1233, DOI 10.1152/ajpheart.01091.2007; Baselga J, 2000, SEMIN ONCOL, V27, P27; Baselga J, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.28544; BORDONI A, 1991, BIOCHEM BIOPH RES CO, V174, P869, DOI 10.1016/0006-291X(91)91498-2; Burris HA, 2005, J CLIN ONCOL, V23, P5305, DOI 10.1200/JCO.2005.16.584; Chien KR, 2000, SEMIN ONCOL, V27, P9, DOI 10.1053/sonc.2000.19892; Crone SA, 2002, NAT MED, V8, P459, DOI 10.1038/nm0502-459; De Lorenzo C, 2007, BRIT J CANCER, V97, P1354, DOI 10.1038/sj.bjc.6604022; De Lorenzo C, 2005, CARCINOGENESIS, V26, P1890, DOI 10.1093/carcin/bgi146; De Lorenzo C, 2004, BRIT J CANCER, V91, P1200, DOI 10.1038/sj.bjc.6602110; De Lorenzo C, 2004, CANCER RES, V64, P4870; De Lorenzo C, 2002, CLIN CANCER RES, V8, P1710; Erickson SL, 1997, DEVELOPMENT, V124, P4999; Force T, 2007, NAT REV CANCER, V7, P332, DOI 10.1038/nrc2106; Kauraniemi P, 2004, ONCOGENE, V23, P1010, DOI 10.1038/sj.onc.1207200; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Perez EA, 2006, J CLIN ONCOL, V24, P3032, DOI 10.1200/JCO.2005.03.4744; Schneider JW, 2001, SEMIN ONCOL, V28, P18, DOI 10.1053/sonc.2001.28546; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sparano JA, 2001, SEMIN ONCOL, V28, P20, DOI 10.1053/sonc.2001.22813; SRINIVAS U, 1993, CANCER IMMUNOL IMMUN, V36, P397, DOI 10.1007/BF01742256; Stebbing J, 2000, CANCER TREAT REV, V26, P287, DOI 10.1053/ctrv.2000.0182; Troise F, 2008, FEBS J, V275, P4967, DOI 10.1111/j.1742-4658.2008.06625.x; Vander Heiden MG, 1999, MOL CELL, V3, P159; Zhang HT, 1999, EXP MOL PATHOL, V67, P15, DOI 10.1006/exmp.1999.2266	28	59	59	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3171	3178		10.1096/fj.09-131383	http://dx.doi.org/10.1096/fj.09-131383			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19417081				2022-12-28	WOS:000270241000039
J	Sohrab, S; Petrusca, DN; Lockett, AD; Schweitzer, KS; Rush, NI; Gu, Y; Kamocki, K; Garrison, J; Petrache, I				Sohrab, Sadaf; Petrusca, Daniela N.; Lockett, Angelia D.; Schweitzer, Kelly S.; Rush, Natalia I.; Gu, Yuan; Kamocki, Krzysztof; Garrison, Jana; Petrache, Irina			Mechanism of alpha-1 antitrypsin endocytosis by lung endothelium	FASEB JOURNAL			English	Article						vascular; serpin; cigarette smoke; caveolin; COPD; apoptosis	CIGARETTE-SMOKE; GOLGI-APPARATUS; ALPHA(1)-ANTITRYPSIN; INTERNALIZATION; APOPTOSIS; RECEPTOR; DEFICIENCY; GLYCOSPHINGOLIPIDS; DEGRADATION; EXPRESSION	The integrity of lung alveoli is maintained by proper circulating levels of alpha-1 antitrypsin (A1AT). Next to cigarette smoking, A1AT deficiency is a major risk factor for lung emphysema development. We recently reported that in addition to neutralizing neutrophil elastases in the extracellular compartment, A1AT is internalized by lung endothelial cells and inhibits apoptosis. We hypothesized that the intracellular uptake of A1AT by endothelial cells may be required for its protective function; therefore, we studied the mechanisms of A1AT internalization by primary rat lung microvascular endothelial cells and the effect of cigarette smoke on this process both in vitro and in vivo ( in mice). Purified A1AT was taken up intracellularly by endothelial cells in a time-dependent, dose-dependent, and conformer-specific manner and was detected in the cytoplasm of endothelial cells of nondiseased human lung sections. Despite a critical role for caveoli in endothelial cell endocytosis in general, specific inhibition of clathrin-mediated, but not caveoli-mediated, endocytosis profoundly decreased A1AT internalization and reversed the A1AT's antiapoptotic action. Further more, A1AT associated with clathrin heavy chains, but not with caveolin-1 in the plasma membrane fraction of endothelial cells. Interestingly, cigarette smoke exposure significantly inhibited A1AT uptake both in endothelial cells and in the mouse lung and altered the intracellular distribution of clathrin heavy chains. Our results suggest that clathrin-mediated endocytosis regulates A1AT intracellular function in the lung endothelium and may be an important determinant of the serpin's protection against developing cigarette smoke-induced emphysema. Sohrab, S., Petrusca, D. N., Lockett, A. D., Schweitzer, K. S., Rush, N. I., Gu, Y., Kamocki, K., Garrison, J., Petrache, I. Mechanism of alpha-1 antitrypsin endocytosis by lung endothelium. FASEB J. 23, 3149-3158 (2009). www.fasebj.org	[Sohrab, Sadaf; Petrusca, Daniela N.; Lockett, Angelia D.; Schweitzer, Kelly S.; Rush, Natalia I.; Gu, Yuan; Kamocki, Krzysztof; Garrison, Jana; Petrache, Irina] Indiana Univ, Div Pulm Allergy Crit Care & Occupat Med, Dept Med, Indianapolis, IN 46202 USA; [Lockett, Angelia D.] Indiana Univ, Dept Microbiol & Immunol, Indianapolis, IN 46204 USA; [Kamocki, Krzysztof; Petrache, Irina] Indiana Univ, Dept Biochem & Mol Biol, Indianapolis, IN 46204 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Petrache, I (corresponding author), Indiana Univ, Div Pulm Allergy Crit Care & Occupat Med, Dept Med, Walther Hall R3,C400,980 W Walnut St, Indianapolis, IN 46202 USA.	ipetrach@iupui.edu	Petrache, Irina/AAZ-9648-2020		Flight Attendent Medical Research Institute (FAMRI); National Institutes of Health, National Heart, Lung, and Blood Institute [1P50 HL084945]; VA Merit Award; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060519] Funding Source: NIH RePORTER	Flight Attendent Medical Research Institute (FAMRI); National Institutes of Health, National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); VA Merit Award(US Department of Veterans Affairs); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Mary Van Demark and Jeremy Adamowicz for superb technical assistance with caspase-3 and elastase activity assays and mouse tail-vein injection, respectively. This study was supported by the Flight Attendent Medical Research Institute (FAMRI); the National Institutes of Health, National Heart, Lung, and Blood Institute grant 1P50 HL084945; and a VA Merit Award.	Aldonyte R, 2008, COPD, V5, P153, DOI 10.1080/15412550802092936; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Campos MA, 2005, CHEST, V128, P1179, DOI 10.1378/chest.128.3.1179; CARLSON JA, 1988, J CLIN INVEST, V82, P26, DOI 10.1172/JCI113580; CARP H, 1980, EXP LUNG RES, V1, P225, DOI 10.3109/01902148009065462; CARRELL RW, 1986, J CLIN INVEST, V78, P1427, DOI 10.1172/JCI112731; Dabbagh K, 2001, J CELL PHYSIOL, V186, P73, DOI 10.1002/1097-4652(200101)186:1<73::AID-JCP1002>3.0.CO;2-Q; GADEK JE, 1981, J CLIN INVEST, V68, P1158, DOI 10.1172/JCI110360; HANOVER JA, 1984, CELL, V39, P283, DOI 10.1016/0092-8674(84)90006-0; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Huang HH, 2004, INT J CANCER, V112, P1042, DOI 10.1002/ijc.20494; HUBBARD RC, 1990, LUNG, V168, P565, DOI 10.1007/BF02718179; JANOFF A, 1979, SCIENCE, V206, P1313, DOI 10.1126/science.316187; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Miller SDW, 2007, HEPATOLOGY, V46, P496, DOI 10.1002/hep.21689; MOLMENTI EP, 1993, J CLIN INVEST, V92, P2022, DOI 10.1172/JCI116797; Mulgrew AT, 2004, CHEST, V125, P1952, DOI 10.1378/chest.125.5.1952; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; Petrache I, 2008, AM J PHYSIOL-LUNG C, V295, pL44, DOI 10.1152/ajplung.00448.2007; Petrache I, 2006, AM J PATHOL, V169, P1155, DOI 10.2353/ajpath.2006.060058; Petrache L, 2006, AM J RESP CRIT CARE, V173, P1222, DOI 10.1164/rccm.200512-1842OC; PREDESCU D, 1993, AM J PHYSIOL, V265, pH725, DOI 10.1152/ajpheart.1993.265.2.H725; Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Simone E, 2009, CELL TISSUE RES, V335, P283, DOI 10.1007/s00441-008-0676-7; Singh RD, 2003, MOL BIOL CELL, V14, P3254, DOI 10.1091/mbc.E02-12-0809; SMITH KF, 1990, BIOCHEM J, V267, P203, DOI 10.1042/bj2670203; SOFER A, 1995, J BIOL CHEM, V270, P12117, DOI 10.1074/jbc.270.20.12117; Subramaniyam D, 2008, INT J BIOCHEM CELL B, V40, P258, DOI 10.1016/j.biocel.2007.07.016; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Taggart C, 2000, J BIOL CHEM, V275, P27258; Talmud PJ, 2003, ARTERIOSCL THROM VAS, V23, P644, DOI 10.1161/01.ATV.0000065196.61663.8D; Tuder RM, 2007, AM J RESP CELL MOL, V37, P130, DOI 10.1165/rcmb.2007-0163TR; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107	38	43	44	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3149	3158		10.1096/fj.09-129304	http://dx.doi.org/10.1096/fj.09-129304			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19423638	Green Published			2022-12-28	WOS:000270241000037
J	De, A; Ray, P; Loening, AM; Gambhir, SS				De, Abhijit; Ray, Pritha; Loening, Andreas Markus; Gambhir, Sanjiv Sam			BRET3: a red-shifted bioluminescence resonance energy transfer (BRET)-based integrated platform for imaging protein-protein interactions from single live cells and living animals	FASEB JOURNAL			English	Article						Renilla luciferase; red fluorescent protein; self-illuminating fluorescent protein; cooled charge-coupled device camera	IN-VIVO; LIGHT; ACTIVATION; RECEPTORS	Taking advantage of the bioluminescence resonance energy transfer (BRET) phenomenon, we report the development of a highly photon-efficient, self-illuminating fusion protein combining a mutant red fluorescent protein (mOrange) and a mutant Renilla reniformis luciferase (RLuc8). This new BRET fusion protein (BRET3) exhibits severalfold improvement in light intensity in comparison with existing BRET fusion proteins. BRET3 also exhibits the most red-shifted light output (564-nm peak wavelength) of any reported bioluminescent protein that utilizes its natural substrate coelenterazine, a benefit of which is demonstrated at various tissue depths in small animals. The imaging utility of BRET3 at the single-cell level is demonstrated using an intramolecular sensor incorporating two mammalian target of rapamycin pathway proteins (FKBP12 and FRB) that dimerize only in the presence of rapamycin. With its increased photon intensity, red-shifted light output, and good spectral resolution (similar to 85 nm), BRET3 shows improved spatial and temporal resolution for measuring intracellular events in single cells and in living small animal models. The development of further BRET3-based assays will allow imaging of protein-protein interactions using a single assay directly scalable from intact living cells to small living subjects, allowing accelerated drug discovery.-De, A., Ray, P., Loening, A. M., Gambhir, S. S. BRET3: a red-shifted bioluminescence resonance energy transfer ( BRET) based integrated platform for imaging protein-protein interactions from single live cells and living animals. FASEB J. 23, 2702-2709 ( 2009)	[Gambhir, Sanjiv Sam] Stanford Univ, Dept Radiol, Bio X Program, James H Clark Ctr,Sch Med, Stanford, CA 94305 USA; [De, Abhijit; Ray, Pritha; Loening, Andreas Markus; Gambhir, Sanjiv Sam] Stanford Univ, Sch Med, Mol Imaging Program Stanford, Stanford, CA 94305 USA; [Loening, Andreas Markus; Gambhir, Sanjiv Sam] Stanford Univ, Sch Med, Dept Bioengn, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Gambhir, SS (corresponding author), Stanford Univ, Dept Radiol, Bio X Program, James H Clark Ctr,Sch Med, 318 Campus Dr,E150, Stanford, CA 94305 USA.	sgambhir@stanford.edu	DE, ABHIJIT/AAR-5631-2021; Loening, Andreas/GPP-3949-2022	DE, ABHIJIT/0000-0002-5818-0206; Loening, Andreas/0000-0003-3316-7467	National Institutes of Health [5RO1 CA82214]; NCI ICMIC [P50 CA114747]; CCNE [U54 CA119367]; NCI SAIRP; NATIONAL CANCER INSTITUTE [U54CA119367, R01CA082214, P50CA114747] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI ICMIC; CCNE; NCI SAIRP; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by National Institutes of Health grants 5RO1 CA82214 ( to S. S. G.), NCI ICMIC P50 CA114747 ( to S. S. G.), CCNE U54 CA119367 ( to S. S. G.), and NCI SAIRP. We thank Yiwei ( Kevin) Jia ( Olympus), Kenya Okazaki ( Olympus), and Tim Doyle ( Stanford Small Animal Imaging Facility) for technical help with cell imaging.	CHRISTENSON MA, 2002, LUMINESCENCE BIOTECH, P469; Coulon V, 2008, BIOPHYS J, V94, P1001, DOI 10.1529/biophysj.107.117275; De A, 2005, FASEB J, V19, P2017, DOI 10.1096/fj.05-4628fje; De A, 2007, CANCER RES, V67, P7175, DOI 10.1158/0008-5472.CAN-06-4623; DIONNE P, 2002, LUMINESCENCE BIOTECH, P539; Hamdan FF, 2005, J BIOMOL SCREEN, V10, P463, DOI 10.1177/1087057105275344; Hebert TE, 2006, CELL BIOCHEM BIOPHYS, V45, P85, DOI 10.1385/CBB:45:1:85; Hoshino H, 2007, NAT METHODS, V4, P637, DOI 10.1038/NMETH1069; Issad T, 2007, EXPERT OPIN THER TAR, V11, P541, DOI 10.1517/14728222.11.4.541; Levi J, 2007, J AM CHEM SOC, V129, P11900, DOI 10.1021/ja073936h; Loening AM, 2007, NAT METHODS, V4, P641, DOI 10.1038/NMETH1070; Loening AM, 2006, PROTEIN ENG DES SEL, V19, P391, DOI 10.1093/protein/gzl023; Massoud TF, 2007, CURR OPIN BIOTECH, V18, P31, DOI 10.1016/j.copbio.2007.01.007; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; Milligan G, 2004, EUR J PHARM SCI, V21, P397, DOI 10.1016/j.ejps.2003.11.010; Molinari P, 2008, BIOCHEM J, V409, P251, DOI 10.1042/BJ20070803; Ohmiya Y, 2005, JPN J APPL PHYS 1, V44, P6368, DOI 10.1143/JJAP.44.6368; Paulmurugan R, 2005, TRAC-TREND ANAL CHEM, V24, P446, DOI 10.1016/j.trac.2005.02.005; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Pfleger KDG, 2006, NAT METHODS, V3, P165, DOI 10.1038/nmeth841; Pfleger KDG, 2006, CELL SIGNAL, V18, P1664, DOI 10.1016/j.cellsig.2006.01.004; Piehler J, 2005, CURR OPIN STRUC BIOL, V15, P4, DOI 10.1016/j.sbi.2005.01.008; Rosenfeldt G, 2008, MOL PLANT, V1, P4, DOI 10.1093/mp/ssm002; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; SIEGEL RM, 2000, SCI STKE, pPL1; Welsh DK, 2005, CURR OPIN BIOTECH, V16, P73, DOI 10.1016/j.copbio.2004.12.006; Welsh DK, 2004, CURR BIOL, V14, P2289, DOI 10.1016/j.cub.2004.11.057; Xu XD, 2007, P NATL ACAD SCI USA, V104, P10264, DOI 10.1073/pnas.0701987104; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Zal T, 2004, CURR OPIN IMMUNOL, V16, P418, DOI 10.1016/j.coi.2004.05.019	31	69	73	2	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2702	2709		10.1096/fj.08-118919	http://dx.doi.org/10.1096/fj.08-118919			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19351700	Green Published			2022-12-28	WOS:000268836700038
J	Gorlovoy, P; Larionov, S; Pham, TTH; Neumann, H				Gorlovoy, Philipp; Larionov, Sergey; Pham, Thao Thi Hien; Neumann, Harald			Accumulation of tau induced in neurites by microglial proinflammatory mediators	FASEB JOURNAL			English	Article						neuroinflammation; neurodegeneration; cytokines; tumor necrosis factor-alpha; Alzheimer disease	LIFETIME IMAGING MICROSCOPY; PAIRED HELICAL FILAMENTS; ACTIVATED PROTEIN-KINASE; AMYLOID-BETA PROTEIN; N-TERMINAL KINASE; ALZHEIMERS-DISEASE; MOUSE MODEL; TNF-ALPHA; NEURODEGENERATIVE DISEASE; FLUORESCENT PROTEINS	Aggregated fibrillary microtubule-associated protein tau is the major component of neurofibrillary tangles in Alzheimer's disease. The exact molecular mechanism of tau aggregation is unknown. Microglial cell activation and migration toward amyloid-beta plaques precede the appearance of dysmorphic neurites and formation of neurofibrillary tangles. Here, we analyzed the accumulation of tau at a distance range of expected spontaneous aggregation by fluorescence lifetime-based Forster resonance energy transfer in cultured primary murine neurons cotransfected with the human tau gene tagged to the green fluorescent protein variants Citrine (tau-Citrine) and Cerulean (tau-Cerulean). No spontaneous accumulation of cotransfected tau-Citrine and tau-Cerulean was detected in untreated neurons. Coculture of neurons with activated microglia induced aggregation of tau in neurites. Treatment of neurons with tumor necrosis factor-alpha (TNF-alpha) stimulated reactive oxygen species generation and resulted in the accumulation of tau-Citrine and tau-Cerulean in neurites, which was inhibited by neutralization of TNF and the free radical inhibitor 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox). These data demonstrate that activated microglia and the microglial-derived proinflammatory cytokine TNF can induce accumulation of the aggregation-prone tau molecules in neurites via reactive oxygen species.-Gorlovoy, P., Larionov, S., Pham, T. T. H., Neumann, H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J. 23, 2502-2513 (2009)	[Neumann, Harald] Univ Bonn, Neural Regenerat Unit, Inst Reconstruct Neurobiol, D-53127 Bonn, Germany; Hertie Fdn, Bonn, Germany	University of Bonn	Neumann, H (corresponding author), Univ Bonn, Neural Regenerat Unit, Inst Reconstruct Neurobiol, Sigmund Freud Str 25, D-53127 Bonn, Germany.	hneuman1@uni-bonn.de	Neumann, Harald/A-9718-2010	Neumann, Harald/0000-0002-5071-5202	Hertie-Foundation; Walter-und-Ilse-Rose-Foundation; Deutsche Forschungsgemeinschaft [SFB704, KFO177]; European Union (NeuroproMiSe)	Hertie-Foundation; Walter-und-Ilse-Rose-Foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Union (NeuroproMiSe)(European Commission)	We thank O. Brustle for general support. We thank Dr. A. Moussif for technical advice and C. Frank, J. Schumacher, and R. Hass for excellent technical support of cell cultures and molecular biology. We also thank Dr. D. Piston (Vanderbilt University Medical Center, Nashville, TN, USA) for Cerulean, Dr. O. Griesbeck (Max Planck Institute of Neurobiology, Munich, Germany) for Citrine, and Dr. E. Ponimaskin (University Gottingen, Gottingen, Germany) for N1E-115 neuroblastoma cell line. The Neural Regeneration Group at the University Bonn is supported by the Hertie-Foundation and Walter-und-Ilse-Rose-Foundation. This project was supported by the Deutsche Forschungsgemeinschaft (SFB704, KFO177) and the European Union (NeuroproMiSe).	Alkam T, 2008, BEHAV BRAIN RES, V189, P100, DOI 10.1016/j.bbr.2007.12.014; Bacskai BJ, 2003, J BIOMED OPT, V8, P368, DOI 10.1117/1.1584442; Bastiaens PIH, 1999, TRENDS CELL BIOL, V9, P48, DOI 10.1016/S0962-8924(98)01410-X; Behl C, 1999, PROG NEUROBIOL, V57, P301, DOI 10.1016/S0301-0082(98)00055-0; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Ciruela F, 2008, CURR OPIN BIOTECH, V19, P338, DOI 10.1016/j.copbio.2008.06.003; Combs CK, 2001, J NEUROSCI, V21, P1179; Dawson HN, 2001, J CELL SCI, V114, P1179; FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Heikal AA, 2000, P NATL ACAD SCI USA, V97, P11996, DOI 10.1073/pnas.97.22.11996; Hoffmann B, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2937829; Horiguchi T, 2003, AM J PATHOL, V163, P1021, DOI 10.1016/S0002-9440(10)63462-1; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ibi M, 2006, FREE RADICAL BIO MED, V40, P1785, DOI 10.1016/j.freeradbiomed.2006.01.009; Kim YS, 2007, MOL CELL, V26, P675, DOI 10.1016/j.molcel.2007.04.021; Leckband D, 2000, ANNU REV BIOPH BIOM, V29, P1, DOI 10.1146/annurev.biophys.29.1.1; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Li R, 2004, J NEUROSCI, V24, P1760, DOI 10.1523/JNEUROSCI.4580-03.2004; Malo GD, 2007, BIOCHEMISTRY-US, V46, P9865, DOI 10.1021/bi602664c; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Medeiros R, 2007, J NEUROSCI, V27, P5394, DOI 10.1523/JNEUROSCI.5047-06.2007; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010; Mrak RE, 2007, J NEUROPATH EXP NEUR, V66, P683, DOI 10.1097/nen.0b013e31812503e1; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Periasamy A, 2001, J BIOMED OPT, V6, P287, DOI 10.1117/1.1383063; Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032; PERRY VH, 1995, CURR OPIN NEUROBIOL, V5, P636, DOI 10.1016/0959-4388(95)80069-7; Piston DW, 2007, TRENDS BIOCHEM SCI, V32, P407, DOI 10.1016/j.tibs.2007.08.003; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945; Schwab C, 2008, J ALZHEIMERS DIS, V13, P359; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; Shaner NC, 2005, NAT METHODS, V2, P905, DOI 10.1038/NMETH819; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Stagi M, 2006, FASEB J, V20, P2573, DOI 10.1096/fj.06-6679fje; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Suhling K, 2005, PHOTOCH PHOTOBIO SCI, V4, P13, DOI 10.1039/b412924p; Takei Y, 2000, J CELL BIOL, V150, P989, DOI 10.1083/jcb.150.5.989; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; Wallrabe H, 2005, CURR OPIN BIOTECH, V16, P19, DOI 10.1016/j.copbio.2004.12.002; Walsh DT, 2005, NEUROPATH APPL NEURO, V31, P491, DOI 10.1111/j.1365-2990.2005.00666.x; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x; Zhu XW, 2004, LANCET NEUROL, V3, P219, DOI 10.1016/S1474-4422(04)00707-0	53	102	108	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2502	2513		10.1096/fj.08-123877	http://dx.doi.org/10.1096/fj.08-123877			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19289607				2022-12-28	WOS:000268836700018
J	Colussi, C; Gurtner, A; Rosati, J; Illi, B; Ragone, G; Piaggio, G; Moggio, M; Lamperti, C; D'Angelo, G; Clementi, E; Minetti, G; Mozzetta, C; Antonini, A; Capogrossi, MC; Puri, PL; Gaetano, C				Colussi, Claudia; Gurtner, Aymone; Rosati, Jessica; Illi, Barbara; Ragone, Gianluca; Piaggio, Giulia; Moggio, Maurizio; Lamperti, Costanza; D'Angelo, Grazia; Clementi, Emilio; Minetti, Giulia; Mozzetta, Chiara; Antonini, Annalisa; Capogrossi, Maurizio C.; Puri, Pier Lorenzo; Gaetano, Carlo			Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy	FASEB JOURNAL			English	Article						histone deacetylase; protein phosphatase; differentiation; myoblast; histone	HISTONE DEACETYLASE INHIBITORS; MUSCLE SATELLITE CELLS; C-FOS PROMOTER; SKELETAL-MUSCLE; GENE-EXPRESSION; GLYCOPROTEIN COMPLEX; ENDOTHELIAL-CELLS; MDX MOUSE; ACETYLATION; SYNTHASE	The present study provides evidence that abnormal patterns of global histone modification are present in the skeletal muscle nuclei of mdx mice and Duchenne muscular dystrophy (DMD) patients. A combination of specific histone H3 modifications, including Ser-10 phosphorylation, acetylation of Lys 9 and 14, and Lys 79 methylation, were found enriched in muscle biopsies from human patients affected by DMD and in late-term fetuses, early postnatal pups, or adult mdx mice. In this context, chromatin immunoprecipitation experiments showed an enrichment of these modifications at the loci of genes involved in proliferation or inflammation, suggesting a regulatory effect on gene expression. Remarkably, the reexpression of dystrophin induced by gentamicin treatment or the administration of nitric oxide (NO) donors reversed the abnormal pattern of H3 histone modifications. These findings suggest an unanticipated link between the dystrophin-activated NO signaling and the remodeling of chromatin. In this context, the regulation of class IIa histone deacetylases (HDACs) 4 and 5 was found altered as a consequence of the reduced NO-dependent protein phosphatase 2A activity, indicating that both NO and class IIa HDACs are important for satellite cell differentiation and gene expression in mdx mice. In conclusion, this work provides the first evidence of a role for NO as an epigenetic regulator in DMD.-Colussi, C., Gurtner, A., Rosati, J., Illi, B., Ragone, G., Piaggio, G., Moggio, M., Lamperti, C., D'Angelo, G., Clementi, E., Minetti, G., Mozzetta, C., Antonini, A., Capogrossi, M. C., Puri, P. L., Gaetano, C. Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy. FASEB J. 23, 2131-2141 (2009)	[Rosati, Jessica; Antonini, Annalisa; Capogrossi, Maurizio C.; Gaetano, Carlo] Ist Dermopat Immacolata, Lab Patol Vasc, I-00167 Rome, Italy; [Colussi, Claudia; Illi, Barbara] Ist Cardiol Monzino, Lab Terapia Gen & Biol Vasc, Milan, Italy; [Gurtner, Aymone; Piaggio, Giulia] Ist Regina Elena, Lab Oncogenesi Mol, I-00161 Rome, Italy; [Gurtner, Aymone; Piaggio, Giulia] Ist Regina Elena, Rome Oncogenom Ctr, I-00161 Rome, Italy; [Ragone, Gianluca] Ist Dermopat Immacolata, Mol Oncol Lab, I-00167 Rome, Italy; [Moggio, Maurizio; Lamperti, Costanza] Univ Milan, Fdn Osped Maggiore Mangiagalli & Regina Elena, Ctr Dino Ferrari, Milan, Italy; [Clementi, Emilio] Univ Milan, Dipartimento Sci Preclin, Milan, Italy; [D'Angelo, Grazia; Clementi, Emilio] Ist Sci E Medea, Bosisio Parini, Italy; [Minetti, Giulia; Mozzetta, Chiara; Puri, Pier Lorenzo] Santa Lucia Fdn, Ist Dulbecco Telethon, Ist Ricovero & Cura Carattere Sci, Rome, Italy; [Minetti, Giulia; Mozzetta, Chiara; Puri, Pier Lorenzo] European Brain Res Inst, Rome, Italy; [Puri, Pier Lorenzo] Burnham Inst Med Res, San Diego, CA USA	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Centro Cardiologico Monzino; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milan; IRCCS Eugenio Medea; IRCCS Santa Lucia	Gaetano, C (corresponding author), Ist Dermopat Immacolata, Lab Patol Vasc, Via Monti Creta 104, I-00167 Rome, Italy.	gaetano@idi.it	Mozzetta, Chiara/K-9947-2018; Piaggio, Giulia/J-7214-2018; Mozzetta, Chiara/Q-2786-2019; Illi, Barbara/AAY-8650-2020; Rosati, Jessica Diana/AAK-6084-2020; lamperti, costanza/J-8801-2016; Colussi, Claudia/H-8609-2019; gurtner, aymone/AAB-8843-2020; Rosati, Jessica Diana/H-2867-2016; Mittal, Ashwani/J-2124-2012; Piaggio, Giulia/AAD-7336-2022; Gaetano, Carlo/P-9997-2019; Gurtner, Aymone/J-7217-2018; D'Angelo, Maria Grazia/K-4685-2016	Mozzetta, Chiara/0000-0002-7147-7266; Piaggio, Giulia/0000-0003-2114-1892; Mozzetta, Chiara/0000-0002-7147-7266; Rosati, Jessica Diana/0000-0002-4483-386X; lamperti, costanza/0000-0002-2280-2253; gurtner, aymone/0000-0002-7661-9059; Rosati, Jessica Diana/0000-0002-4483-386X; Mittal, Ashwani/0000-0002-6588-6194; Gaetano, Carlo/0000-0002-5238-1832; Gurtner, Aymone/0000-0002-7661-9059; Colussi, Claudia/0000-0002-7727-8911; D'Angelo, Maria Grazia/0000-0003-1241-4350; Puri, Pier Lorenzo/0000-0003-4964-0095	Fondo per gli Investimenti della Ricerca di Base [RBLA035A4X-1-FIRB]; UE FP6 [UE-LHSB-CT-04-502988]; Association Francaise contre les Myopathies (AFM) [MNM2-06, DdT2-06]; MDA [88202]; Telethon [GGP07006, GTB07001E]; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Fondo per gli Investimenti della Ricerca di Base(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); UE FP6(European Commission); Association Francaise contre les Myopathies (AFM)(Association Francaise contre les Myopathies); MDA(Muscular Dystrophy Association); Telethon(Fondazione Telethon); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	This work has been partially supported by Fondo per gli Investimenti della Ricerca di Base grant RBLA035A4X-1-FIRB to M. C. C.; UE FP6 grant UE-LHSB-CT-04-502988 to M. C. C.; Association Francaise contre les Myopathies (AFM) grants MNM2-06 to C. G and DdT2-06 to M. C. C.; MDA grant 88202 to C. G.; Telethon grant GGP07006 and an AFM grant to E. C; and Telethon project GTB07001E and Eurobiobank project QLTR-2001-02769 to M. M. G. P. was supported by Associazione Italiana per la Ricerca sul Cancro, ISS-ACC, and Ministero della Sanita grant ICS-120.4/RA00-90-R.F.02/184. P. L. P was supported by a Telethon special grant, the Muscular Dystrophy Association, Parent Project Onlus, and Compagnia San Paolo di Torino. C. M. is a recipient of an AFM fellowship, and G. M. is a recipient of a Parent Project Onlus fellowship. P. L. P. is an Associate Telethon scientist at the Dulbecco Telethon Institute. C. C. is a Ph. D. student at the "Scienze Endocrino-Metaboliche e Endocrino-Chirurgiche" School of the Chair of Endocrinology, Catholic University, Rome 00165, Italy.	Anderson JE, 2000, MOL BIOL CELL, V11, P1859, DOI 10.1091/mbc.11.5.1859; Barnes PJ, 2005, EUR RESPIR J, V25, P552, DOI 10.1183/09031936.05.00117504; Barton-Davis ER, 1999, J CLIN INVEST, V104, P375, DOI 10.1172/JCI7866; BISCHOFF R, 1986, DEV BIOL, V115, P129, DOI 10.1016/0012-1606(86)90234-4; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Brunelli S, 2007, P NATL ACAD SCI USA, V104, P264, DOI 10.1073/pnas.0608277104; Butler R, 2006, NAT REV NEUROSCI, V7, P784, DOI 10.1038/nrn1989; Chen ML, 2008, J MOL NEUROSCI, V34, P89, DOI 10.1007/s12031-007-9005-y; Cohen TJ, 2007, J BIOL CHEM, V282, P33752, DOI 10.1074/jbc.M706268200; Colussi C, 2008, P NATL ACAD SCI USA, V105, P19183, DOI 10.1073/pnas.0805514105; Crosbie RH, 2001, NAT MED, V7, P27, DOI 10.1038/83309; Dennis C, 2003, NATURE, V421, P686, DOI 10.1038/421686a; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dogra C, 2006, J CELL PHYSIOL, V208, P575, DOI 10.1002/jcp.20696; Eberharter A, 2005, BIOL CHEM, V386, P745, DOI 10.1515/BC.2005.087; Engel A.G., 1994, DYSTROPHINOPATHIES, VVolume 2; Glenisson W, 2007, BBA-MOL CELL RES, V1773, P1572, DOI 10.1016/j.bbamcr.2007.05.016; Grozdanovic Z, 1999, HISTOL HISTOPATHOL, V14, P243, DOI 10.14670/HH-14.243; Gucuyener K, 2000, BRAIN DEV-JPN, V22, P181, DOI 10.1016/S0387-7604(00)00106-6; Henke N, 2007, CIRC RES, V101, P268, DOI 10.1161/CIRCRESAHA.107.150474; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Houben F, 2007, BBA-MOL CELL RES, V1773, P675, DOI 10.1016/j.bbamcr.2006.09.018; Illi B, 2008, CIRC RES, V102, P51, DOI 10.1161/CIRCRESAHA.107.157305; Judge LM, 2006, J CELL SCI, V119, P1537, DOI 10.1242/jcs.02857; Kasai T, 2004, J BIOMED SCI, V11, P534, DOI 10.1159/000077905; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Liu T, 2006, CANCER TREAT REV, V32, P157, DOI 10.1016/j.ctrv.2005.12.006; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Mai A, 2005, J MED CHEM, V48, P3344, DOI 10.1021/jm049002a; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Martin M, 2008, P NATL ACAD SCI USA, V105, P4727, DOI 10.1073/pnas.0708455105; McArdle A, 1998, CLIN SCI, V95, P83, DOI 10.1042/CS19980029; McKinsey TA, 2004, NOVART FDN SYMP, V259, P163; Mejat A, 2005, NAT NEUROSCI, V8, P313, DOI 10.1038/nn1408; Minetti GC, 2006, NAT MED, V12, P1147, DOI 10.1038/nm1479; Nott A, 2008, NATURE, V455, P411, DOI 10.1038/nature07238; Paroni G, 2008, MOL BIOL CELL, V19, P655, DOI 10.1091/mbc.E07-06-0623; Pescatori M, 2007, FASEB J, V21, P1210, DOI 10.1096/fj.06-7285com; Peter AK, 2006, EXP CELL RES, V312, P2580, DOI 10.1016/j.yexcr.2006.04.024; Phatnani HP, 2006, GENE DEV, V20, P2922, DOI 10.1101/gad.1477006; Pisconti A, 2006, J CELL BIOL, V172, P233, DOI 10.1083/jcb.200507083; Porter JD, 2004, HUM MOL GENET, V13, P257, DOI 10.1093/hmg/ddh033; Punkt K, 2006, BIOCHEM BIOPH RES CO, V348, P259, DOI 10.1016/j.bbrc.2006.07.056; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Ragno R, 2008, EUR J MED CHEM, V43, P621, DOI 10.1016/j.ejmech.2007.05.004; RAHM M, 1989, J CELL PHYSIOL, V139, P237, DOI 10.1002/jcp.1041390204; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Taddei A, 2005, EMBO REP, V6, P520, DOI 10.1038/sj.embor.7400441; Tidball JG, 2007, J APPL PHYSIOL, V102, P1677, DOI 10.1152/japplphysiol.01145.2006; Tidball JG, 2004, MOL GENET METAB, V82, P312, DOI 10.1016/j.ymgme.2004.06.006; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; TROUCHE D, 1995, FEBS LETT, V361, P140, DOI 10.1016/0014-5793(95)00140-5; Wehling M, 2001, J CELL BIOL, V155, P123, DOI 10.1083/jcb.200105110; YABLONKAREUVENI Z, 1994, DEV BIOL, V164, P588, DOI 10.1006/dbio.1994.1226; Yahi H, 2006, EXPERT OPIN THER TAR, V10, P923, DOI 10.1517/14728222.10.6.923; Zaccagnini G, 2005, J BIOL CHEM, V280, P14790, DOI 10.1074/jbc.M414644200; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	62	58	59	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2131	2141		10.1096/fj.08-115618	http://dx.doi.org/10.1096/fj.08-115618			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19264835				2022-12-28	WOS:000268836500013
J	Wood, JM; Decker, H; Hartmann, H; Chavan, B; Rokos, H; Spencer, JD; Hasse, S; Thornton, MJ; Shalbaf, M; Paus, R; Schallreuter, KU				Wood, J. M.; Decker, H.; Hartmann, H.; Chavan, B.; Rokos, H.; Spencer, J. D.; Hasse, S.; Thornton, M. J.; Shalbaf, M.; Paus, R.; Schallreuter, K. U.			Senile hair graying: H2O2-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair	FASEB JOURNAL			English	Article						MSRA&B; tyrosinase; catalase; follicle cells	HYDROGEN-PEROXIDE H2O2; HUMAN EPIDERMAL MELANOCYTES; HUMAN SKIN; IN-VIVO; OCULOCUTANEOUS ALBINISM; FOLLICLE PIGMENTATION; VITILIGO PATHOGENESIS; AUTOIMMUNE-DISEASE; RAMAN-SPECTROSCOPY; CALCIUM IMBALANCE	Senile graying of human hair has been the subject of intense research since ancient times. Reactive oxygen species have been implicated in hair follicle melanocyte apoptosis and DNA damage. Here we show for the first time by FT-Raman spectroscopy in vivo that human gray/white scalp hair shafts accumulate hydrogen peroxide (H2O2) in millimolar concentrations. Moreover, we demonstrate almost absent catalase and methionine sulfoxide reductase A and B protein expression via immunofluorescence and Western blot in association with a functional loss of methionine sulfoxide (Met-S=O) repair in the entire gray hair follicle. Accordingly, Met-S=O formation of Met residues, including Met 374 in the active site of tyrosinase, the key enzyme in melanogenesis, limits enzyme functionality, as evidenced by FT-Raman spectroscopy, computer simulation, and enzyme kinetics, which leads to gradual loss of hair color. Notably, under in vitro conditions, Met oxidation can be prevented by L-methionine. In summary, our data feed the long-voiced, but insufficiently proven, concept of H2O2-induced oxidative damage in the entire human hair follicle, inclusive of the hair shaft, as a key element in senile hair graying, which does not exclusively affect follicle melanocytes. This new insight could open new strategies for intervention and reversal of the hair graying process.-Wood, J. M., Decker, H., Hartmann, H., Chavan, B., Rokos, H., Spencer, J. D., Hasse, S., Thornton, M. J., Shalbaf, M., Paus, R., Schallreuter, K. U. Senile hair graying: H2O2-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair. FASEB J. 23, 2065-2075 (2009)	[Wood, J. M.; Chavan, B.; Rokos, H.; Spencer, J. D.; Hasse, S.; Thornton, M. J.; Shalbaf, M.; Schallreuter, K. U.] Univ Bradford, Dept Biomed Sci Clin & Expt Dermatol, Bradford BD7 1DP, W Yorkshire, England; [Wood, J. M.; Rokos, H.; Spencer, J. D.; Hasse, S.] Univ Bradford, Inst Pigmentary Disorders, Bradford BD7 1DP, W Yorkshire, England; [Decker, H.; Hartmann, H.] Johannes Gutenberg Univ Mainz, Inst Mol Biophys, Mainz, Germany; [Paus, R.] Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany; [Paus, R.] Univ Manchester, Manchester, Lancs, England	University of Bradford; University of Bradford; Johannes Gutenberg University of Mainz; University of Lubeck; University of Manchester	Schallreuter, KU (corresponding author), Univ Bradford, Dept Biomed Sci Clin & Expt Dermatol, Bradford BD7 1DP, W Yorkshire, England.	k.schallreuter@bradford.ac.uk	Paus, Ralf/F-6243-2011	Thornton, M Julie/0000-0002-3395-7066	Deutsche Forschungsgemeinschaft, Germany; Research Centre for Medicine and Science, Mainz, Germany	Deutsche Forschungsgemeinschaft, Germany(German Research Foundation (DFG)); Research Centre for Medicine and Science, Mainz, Germany	We dedicate this paper to the first author, who lost the battle against cancer during the preparation of this manuscript in February 2008. A manuscript is a fitting final word for this renowned, enthusiastic scientist. This research has been supported by the University of Bradford, by a grant to K. U. S. from Stiefel International, and by private donations. H. D. is grateful for financial support from Deutsche Forschungsgemeinschaft, Germany, and the Research Centre for Medicine and Science, Mainz, Germany. Primary human HFMs were a generous gift from Professor D. J. Tobin ( University of Bradford).	Ancans J, 2001, EXP CELL RES, V268, P26, DOI 10.1006/excr.2001.5251; Arck PC, 2006, FASEB J, V20, P1567, DOI 10.1096/fj.05-4039fje; ARONOFF S, 1965, SCIENCE, V150, P72, DOI 10.1126/science.150.3692.72; Borovansky J, 2006, PIGM CELL RES, V19, P170, DOI 10.1111/j.1600-0749.2006.00295.x; Botchkarev VA, 2001, AM J PATHOL, V158, P1913, DOI 10.1016/S0002-9440(10)64659-7; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; Commo S, 2004, BRIT J DERMATOL, V150, P435, DOI 10.1046/j.1365-2133.2004.05787.x; Cooksey CJ, 1998, BIOCHEM J, V333, P685, DOI 10.1042/bj3330685; Decker H, 2000, TRENDS BIOCHEM SCI, V25, P392, DOI 10.1016/S0968-0004(00)01602-9; Decker H, 2007, GENE, V398, P183, DOI 10.1016/j.gene.2007.02.051; Decker H, 2006, ANGEW CHEM INT EDIT, V45, P4546, DOI 10.1002/anie.200601255; Garcia-Borron JC, 2002, PIGM CELL RES, V15, P162, DOI 10.1034/j.1600-0749.2002.02012.x; Gibbons NQ, 2006, J INVEST DERMATOL, V126, P2576, DOI 10.1038/sj.jid.5700612; Hasse S, 2004, J INVEST DERMATOL, V122, P307, DOI 10.1046/j.0022-202X.2004.22230.x; Kauser S, 2003, J INVEST DERMATOL, V120, P1073, DOI 10.1046/j.1523-1747.2003.12242.x; KAUSER S, 2007, PIGMENT CELL RES, V20, P432; Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104; Land EJ, 2007, TOHOKU J EXP MED, V212, P341, DOI 10.1620/tjem.212.341; Lee JW, 2005, MECH AGEING DEV, V126, P79, DOI 10.1016/j.mad.2004.09.011; Magerl M, 2002, EXP DERMATOL, V11, P381, DOI 10.1034/j.1600-0625.2002.110414.x; Maresca V, 2006, J INVEST DERMATOL, V126, P182, DOI 10.1038/sj.jid.5700021; Moskovitz J, 2003, P NATL ACAD SCI USA, V100, P7486, DOI 10.1073/pnas.1332607100; Muller-Rover S, 1999, J INVEST DERM SYMP P, V4, P272, DOI 10.1038/sj.jidsp.5640228; NANNINGA PB, 1991, PIGM CELL RES, V4, P193, DOI 10.1111/j.1600-0749.1991.tb00438.x; Nishimura EK, 2005, SCIENCE, V307, P720, DOI 10.1126/science.1099593; Ogawa F, 2006, J INVEST DERMATOL, V126, P1128, DOI 10.1038/sj.jid.5700116; PITTELKOW MR, 1989, J CELL PHYSIOL, V140, P565, DOI 10.1002/jcp.1041400323; Rokos H, 2004, J RAMAN SPECTROSC, V35, P125, DOI 10.1002/jrs.1114; Rokos H, 2008, J RAMAN SPECTROSC, V39, P1214, DOI 10.1002/jrs.1968; Sarin KY, 2007, STEM CELL REV, V3, P212, DOI 10.1007/s12015-007-0028-0; Schallreuter KU, 2008, EXP DERMATOL, V17, P139, DOI [10.1111/j.1600-0625.2007.00666_1.x, 10.1111/j.1600-0625.2007.00666.x]; Schallreuter KU, 2008, EXP DERMATOL, V17, P141, DOI 10.1111/j.1600-0625.2007.00666_2.x; Schallreuter KU, 2008, J INVEST DERMATOL, V128, P808, DOI 10.1038/sj.jid.5701100; Schallreuter KU, 2007, LIFE SCI, V80, P2221, DOI 10.1016/j.lfs.2007.01.028; Schallreuter KU, 2006, J INVEST DERMATOL, V126, P947, DOI 10.1038/sj.jid.5700086; Schallreuter KU, 2006, BIOCHEM BIOPH RES CO, V349, P931, DOI 10.1016/j.bbrc.2006.08.138; Schallreuter KU, 1999, BIOCHEM BIOPH RES CO, V262, P423, DOI 10.1006/bbrc.1999.1241; SCHALLREUTER KU, 1991, J INVEST DERMATOL, V97, P1081, DOI 10.1111/1523-1747.ep12492612; Schallreuter KU, 1999, J INVEST DERM SYMP P, V4, P91, DOI 10.1038/sj.jidsp.5640189; Schallreuter KU, 2006, BIOCHEM BIOPH RES CO, V342, P145, DOI 10.1016/j.bbrc.2006.01.124; SCHALLREUTER KU, 1994, SCIENCE, V263, P1444, DOI 10.1126/science.8128228; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Schweikardt T, 2007, PIGM CELL RES, V20, P394, DOI 10.1111/j.1600-0749.2007.00405.x; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2005, J INVEST DERMATOL, V124, P13, DOI 10.1111/j.0022-202X.2004.23528.x; Slominski A, 1996, J INVEST DERMATOL, V106, P1203, DOI 10.1111/1523-1747.ep12348479; SLOMINSKI A, 1994, J INVEST DERMATOL, V102, P862, DOI 10.1111/1523-1747.ep12382606; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; Spatz KR, 2008, EXP DERMATOL, V17, P632, DOI 10.1111/j.1600-0625.2008.00742_18.x; Spencer JD, 2008, ENDOCRINOLOGY, V149, P1638, DOI 10.1210/en.2007-1317; Spencer JD, 2007, J INVEST DERMATOL, V127, P411, DOI 10.1038/sj.jid.5700538; SPRITZ RA, 1993, SEMIN DERMATOL, V12, P167; Spritz RA, 1997, HUM MUTAT, V10, P171, DOI 10.1002/(SICI)1098-1004(1997)10:2<171::AID-HUMU11>3.3.CO;2-9; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Tobin DJ, 1999, J INVEST DERM SYMP P, V4, P323, DOI 10.1038/sj.jidsp.5640239; Tripathi RK, 1999, PIGM CELL RES, V12, P187, DOI 10.1111/j.1600-0749.1999.tb00512.x; Trueb Ralph M, 2005, J Cosmet Dermatol, V4, P60, DOI 10.1111/j.1473-2165.2005.40203.x; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wood JM, 2004, BIOCHEM BIOPH RES CO, V325, P1412, DOI 10.1016/j.bbrc.2004.10.185; WOOD JM, 1991, BIOCHIM BIOPHYS ACTA, V1074, P378, DOI 10.1016/0304-4165(91)90088-X; WOOD JM, 1995, BIOCHEM BIOPH RES CO, V206, P480, DOI 10.1006/bbrc.1995.1068; Wood JM, 2006, J INVEST DERMATOL, V126, P13, DOI 10.1038/sj.jid.5700051	62	142	148	3	63	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2065	2075		10.1096/fj.08-125435	http://dx.doi.org/10.1096/fj.08-125435			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19237503				2022-12-28	WOS:000268836500007
J	Chung, B; Verdier, F; Matak, P; Deschemin, JC; Mayeux, P; Vaulont, S				Chung, Bomee; Verdier, Frederique; Matak, Pavle; Deschemin, Jean-Christophe; Mayeux, Patrick; Vaulont, Sophie			Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone	FASEB JOURNAL			English	Article						hepatocyte; erythroblasts; inflammation	HEREDITARY HEMOCHROMATOSIS PROTEIN; TRANSFERRIN RECEPTOR 2; GENE-EXPRESSION; MICE; INFLAMMATION; ANEMIA; HFE; CYTOKINE; CELLS; BMP6	Erythropoietic activity is known to affect iron homeostasis through regulation of the liver iron regulatory hormone hepcidin. To identify new factors secreted by the erythroblasts that could influence hepcidin synthesis, we set up a coculture model. HuH7 hepatoma cells cocultured with primary human erythroblasts or erythroleukemic UT7 cells presented a 20-to 35-fold increase of hepcidin gene expression. This induction was fully blunted in the presence of a neutralizing oncostatin M antibody, demonstrating that this cytokine, belonging to the IL-6 family of cytokines, was responsible for increased levels of hepcidin expression. We further demonstrated that recombinant oncostatin M induced a dramatic transcriptional increase of hepcidin in HuH7 cells through specific activation of the STAT pathway. Hepcidin induction by oncostatin M was also observed in hepatocytes in primary culture and is believed to be cell specific since no induction was found in isolated bone marrow cells, macrophagic, stromal, and lymphoma-derived cell lines, nor in erythroblasts. Finally, we show that oncostatin M administration in vivo increases hepcidin expression and leads to significantly decreased serum iron levels. This work identifies a new potent inducer of hepcidin expression in the liver and supports a role for modulators of oncostatin M signaling pathway in treating iron disorders.-Chung, B., Verdier, F., Matak, P., Deschemin, J.-C., Mayeux, P., Vaulont, S. Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone. FASEB J. 24, 2093-2103 (2010). www.fasebj.org	[Vaulont, Sophie] Univ Paris 05, Inst Cochin, Fac Med Cochin Port Royal, CNRS,UMR 8104, F-75014 Paris, France; [Chung, Bomee; Verdier, Frederique; Matak, Pavle; Deschemin, Jean-Christophe; Mayeux, Patrick; Vaulont, Sophie] INSERM, U567, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Vaulont, S (corresponding author), Univ Paris 05, Inst Cochin, Fac Med Cochin Port Royal, CNRS,UMR 8104, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	sophie.vaulont@inserm.fr	Verdier, Frédérique/P-1512-2017; Vaulont, Sophie/O-6732-2017	Deschemin, Jean-Christophe/0000-0002-1256-8459	Agence Nationale de la Recherche, EU [LSHM-CT-2006-037296]; Association pour la Recherche sur le Cancer [1145]	Agence Nationale de la Recherche, EU(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	The authors greatly thank Yael Zermati, all the members of the hepcidin team, and Hugues Gascan for fruitful discussions. This work was supported by funding from the Agence Nationale de la Recherche, EU contract LSHM-CT-2006-037296, and Association pour la Recherche sur le Cancer grant 1145.	Andrews NC, 2007, ANNU REV PHYSIOL, V69, P69, DOI 10.1146/annurev.physiol.69.031905.164337; Andrews NC, 2004, J CLIN INVEST, V113, P1251, DOI 10.1172/JCI200421441; Andriopoulos B, 2009, NAT GENET, V41, P482, DOI 10.1038/ng.335; Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777; Babitt JL, 2007, J CLIN INVEST, V117, P1933, DOI 10.1172/JCI31342; Bothwell, 1980, METHODS HEMATOLOGY, V1, P90; Chen SH, 2004, CYTOKINE GROWTH F R, V15, P379, DOI 10.1016/j.cytogfr.2004.06.002; De Domenico I, 2008, NAT REV MOL CELL BIO, V9, P72, DOI 10.1038/nrm2295; Demirag MD, 2009, INTERNAL MED, V48, P421, DOI 10.2169/internalmedicine.48.1578; Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003; Falzacappa MVV, 2007, BLOOD, V109, P353, DOI 10.1182/blood-2006-07-033969; Freyssinier JM, 1999, BRIT J HAEMATOL, V106, P912; Gao JW, 2009, CELL METAB, V9, P217, DOI 10.1016/j.cmet.2009.01.010; Goswami T, 2006, J BIOL CHEM, V281, P28494, DOI 10.1074/jbc.C600197200; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Huang H, 2009, BLOOD, V113, P3593, DOI 10.1182/blood-2008-08-173641; Ichihara M, 1997, BLOOD, V90, P165; Inamura J, 2005, HEPATOL RES, V33, P198, DOI 10.1016/j.hepres.2005.08.005; Johnson MB, 2004, BLOOD, V104, P4287, DOI 10.1182/blood-2004-06-2477; Kamiya A, 2001, FEBS LETT, V492, P90, DOI 10.1016/S0014-5793(01)02140-8; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; Kanda J, 2009, INT J HEMATOL, V90, P545, DOI 10.1007/s12185-009-0443-x; Kautz L, 2008, BLOOD, V112, P1503, DOI 10.1182/blood-2008-03-143354; Kautz L, 2009, BLOOD, V114, P2515, DOI 10.1182/blood-2009-02-206771; Kinoshita T, 1999, P NATL ACAD SCI USA, V96, P7265, DOI 10.1073/pnas.96.13.7265; Koening CL, 2009, BLOOD, V114, P1913, DOI 10.1182/blood-2009-03-209577; Lee MS, 2005, HUM VACCINES, V1, P6, DOI 10.4161/hv.1.1.1424; Liu HY, 2009, INT J MOL MED, V23, P161, DOI 10.3892/ijmm_00000113; Lou DQ, 2005, HEPATOLOGY, V41, P1056, DOI 10.1002/hep.20663; Matak P, 2009, HAEMATOL-HEMATOL J, V94, P773, DOI 10.3324/haematol.2008.003400; Menon MP, 2006, J CLIN INVEST, V116, P683, DOI 10.1172/JCI25227; Meynard D, 2009, NAT GENET, V41, P478, DOI 10.1038/ng.320; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499; Pak M, 2006, BLOOD, V108, P3730, DOI 10.1182/blood-2006-06-028787; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Peyssonnaux C, 2006, BLOOD, V107, P3727, DOI 10.1182/blood-2005-06-2259; Pietrangelo A, 2007, GASTROENTEROLOGY, V132, P294, DOI 10.1053/j.gastro.2006.10.018; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Plater-Zyberk C, 2001, ARTHRITIS RHEUM, V44, P2697, DOI 10.1002/1529-0131(200111)44:11<2697::AID-ART450>3.0.CO;2-#; Ramey G, 2007, FEBS LETT, V581, P1053, DOI 10.1016/j.febslet.2007.02.002; Ramey G, 2009, HAEMATOL-HEMATOL J, V94, P765, DOI 10.3324/haematol.2008.003541; Ramsay AJ, 2009, HAEMATOL-HEMATOL J, V94, P840, DOI 10.3324/haematol.2008.001867; Robb A, 2004, BLOOD, V104, P4294, DOI 10.1182/blood-2004-06-2481; Schmidt PJ, 2008, CELL METAB, V7, P205, DOI 10.1016/j.cmet.2007.11.016; Sow FB, 2007, J LEUKOCYTE BIOL, V82, P934, DOI 10.1189/jlb.0407216; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tanaka M, 2004, REV PHYSIOL BIOCH P, V149, P39, DOI 10.1007/s10254-003-0013-1; Tanno T, 2007, NAT MED, V13, P1096, DOI 10.1038/nm1629; Tanno T, 2009, BLOOD, V114, P181, DOI 10.1182/blood-2008-12-195503; Theurl I, 2008, BLOOD, V111, P2392, DOI 10.1182/blood-2007-05-090019; Vaulont S, 2005, J CLIN INVEST, V115, P2079, DOI 10.1172/JCI25642; Verdier F, 2000, J BIOL CHEM, V275, P18375, DOI 10.1074/jbc.275.24.18375; Viatte L, 2009, BIOCHIMIE, V91, P1223, DOI 10.1016/j.biochi.2009.06.012; Vokurka M, 2006, PHYSIOL RES, V55, P667, DOI 10.33549/physiolres.930841; Wallace DF, 2009, HEPATOLOGY, V50, P1992, DOI 10.1002/hep.23198; Wang RH, 2005, CELL METAB, V2, P399, DOI 10.1016/j.cmet.2005.10.010; Wrighting DM, 2008, CURR TOP DEV BIOL, V82, P141, DOI 10.1016/S0070-2153(07)00006-3; WRIGHTING DM, 2006, BLOOD, V103, P10289; Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54; Zhang DL, 2009, CELL METAB, V9, P461, DOI 10.1016/j.cmet.2009.03.006	61	35	36	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					2093	2103		10.1096/fj.09-152561	http://dx.doi.org/10.1096/fj.09-152561			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20124431	Bronze			2022-12-28	WOS:000278200000042
J	Jarmalavicius, S; Trefzer, U; Walden, P				Jarmalavicius, Saulius; Trefzer, Uwe; Walden, Peter			Differential arginine methylation of the G-protein pathway suppressor GPS-2 recognized by tumor-specific T cells in melanoma	FASEB JOURNAL			English	Article						cancer; immunology; major histocompatibility complex; mass spectrometry; post-translational modification; protein arginine methylation; T lymphocytes	MASS-SPECTROMETRY; POSTTRANSLATIONAL MODIFICATIONS; SYMMETRIC DIMETHYLARGININE; CANCER-IMMUNOTHERAPY; PEPTIDE; METHYLTRANSFERASE; RESIDUES; IDENTIFICATION; EPITOPES; COMPLEX	The aim of the study was to identify as potential therapeutic targets specific molecular alterations in tumor cells recognized by the immune system. To identify such targets, we analyzed the human leukocyte antigen (HLA) peptidomes of human melanoma cells by 2-dimensional nano-HPLC/mass spectrometry and tested the immunological significance of the peptides by ex vivo ELISpot assays with lymphocytes from melanoma patients. The peptide SQNPRFYHK was identified as derived from the regulator of the nuclear corepressor complex (NCoR) G-protein pathway suppressor 2 (GPS-2) and to be differentially unmethylated, monomethylated or asymmetrically dimethylated at the arginine. The methylation state was specifically recognized by the immune system in that only the monomethylated variant induced T-cell responses and significantly stronger responses in patients than in healthy controls. The methylations were confirmed with synthetic analogues and in vitro radiolabeling assays with recombinant GPS-2 and synthetic peptides. The immunity of the 3 variants of GPS-2 was tested in T-cell assays with T lymphocytes of melanoma patients compared with healthy donors. The results show for the first time that GPS-2 is differentially methylated at a site that lacks known methylation motifs and that the methylation state is detected by the immune system.-Jarmalavicius, S., Trefzer, U., Walden, P. Differential arginine methylation of the G-protein pathway suppressor GPS-2 recognized by tumor-specific T cells in melanoma. FASEB J. 24, 937-946 (2010). www.fasebj.org	[Walden, Peter] Humboldt Univ, Dept Dermatol, Charite Univ Med Berlin, Clin Res Grp Tumor Immunol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Walden, P (corresponding author), Humboldt Univ, Dept Dermatol, Charite Univ Med Berlin, Clin Res Grp Tumor Immunol, Charitepl 1, D-10117 Berlin, Germany.	peter.walden@charite.de			German Research Council (DFG) [KFO50, FOR299/2-1,2]; EU [10132690]	German Research Council (DFG)(German Research Foundation (DFG)); EU(European Commission)	We thank Stefanie Gross (Charite-Universitatsmedizin Berlin) for providing the melanoma cell lines, Anne Bredenbeck for her help in establishing the T-cell analysis, Arthur O'Connor for technical assistance, and Patricia Zambon for help in preparing this manuscript. The work was supported in part with funds of the German Research Council (DFG; KFO50 and FOR299/2-1,2) and the EU Regional Fund for Berlin ProFit (10132690). The protocol for the use of human materials had been reviewed and approved by the institutional ethics committee of the Charite-Universitatsmedizin Berlin (EA1/206/05).	BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Boulanger MC, 2005, J VIROL, V79, P124, DOI 10.1128/JVI.79.1.124-131.2005; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Bredenbeck A, 2005, J IMMUNOL, V174, P6716, DOI 10.4049/jimmunol.174.11.6716; Cheng DH, 2007, MOL CELL, V25, P71, DOI 10.1016/j.molcel.2006.11.019; Cook JR, 2006, BIOCHEM BIOPH RES CO, V342, P472, DOI 10.1016/j.bbrc.2006.01.167; Degenhardt YY, 2001, J VIROL, V75, P151, DOI 10.1128/JVI.75.1.151-160.2001; Demine R, 2005, J BIOL CHEM, V280, P17573, DOI 10.1074/jbc.M501233200; Demine R, 2004, RAPID COMMUN MASS SP, V18, P907, DOI 10.1002/rcm.1420; Demine R, 2003, MOL BIOTECHNOL, V25, P71, DOI 10.1385/MB:25:1:71; Diederichs S, 2004, J BIOL CHEM, V279, P33727, DOI 10.1074/jbc.M401708200; Engelhard VH, 2006, CURR OPIN IMMUNOL, V18, P92, DOI 10.1016/j.coi.2005.11.015; Fuchs SY, 2005, CANCER METAST REV, V24, P329, DOI 10.1007/s10555-005-1581-0; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gehrig PM, 2004, J AM SOC MASS SPECTR, V15, P142, DOI 10.1016/j.jasms.2003.10.002; Hughes RM, 2006, J AM CHEM SOC, V128, P12735, DOI 10.1021/ja061656g; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Kessler Jan H, 2004, Curr Protoc Immunol, VChapter 18, DOI 10.1002/0471142735.im1812s61; Kessler JH, 2003, HUM IMMUNOL, V64, P245, DOI 10.1016/S0198-8859(02)00787-5; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Lee J, 2005, J BIOL CHEM, V280, P32890, DOI 10.1074/jbc.M506944200; Lee JH, 2005, J BIOL CHEM, V280, P3656, DOI 10.1074/jbc.M405295200; Lee TH, 2006, DNA REPAIR, V5, P32, DOI 10.1016/j.dnarep.2005.07.004; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Milner E, 2006, MOL CELL PROTEOMICS, V5, P357, DOI 10.1074/mcp.M500241-MCP200; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Pahlich S, 2006, BBA-PROTEINS PROTEOM, V1764, P1890, DOI 10.1016/j.bbapap.2006.08.008; Peng YC, 2000, J VIROL, V74, P5872, DOI 10.1128/JVI.74.13.5872-5879.2000; Peng YC, 2001, MOL CELL BIOL, V21, P5913, DOI 10.1128/MCB.21.17.5913-5924.2001; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Rappsilber J, 2003, ANAL CHEM, V75, P3107, DOI 10.1021/ac026283q; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Swiercz R, 2005, BIOCHEM J, V386, P85, DOI 10.1042/BJ20041466; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Yague J, 2000, PROTEIN SCI, V9, P2210, DOI 10.1110/ps.9.11.2210; Yewdell JW, 1996, J IMMUNOL, V157, P1823; Zarling AL, 2006, P NATL ACAD SCI USA, V103, P14889, DOI 10.1073/pnas.0604045103; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zobel-Thropp P, 1998, J BIOL CHEM, V273, P29283, DOI 10.1074/jbc.273.45.29283; Zou Y, 2005, BIOCHEMISTRY-US, V44, P6293, DOI 10.1021/bi0475525	44	11	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					937	946		10.1096/fj.09-136283	http://dx.doi.org/10.1096/fj.09-136283			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19917673				2022-12-28	WOS:000274974600029
J	Goren, A; Dahan, N; Goren, E; Baruch, L; Machluf, M				Goren, Amit; Dahan, Nitsan; Goren, Efrat; Baruch, Limor; Machluf, Marcelle			Encapsulated human mesenchymal stem cells: a unique hypoimmunogenic platform for long-term cellular therapy	FASEB JOURNAL			English	Article						bone marrow-derived stem cells; cell-based therapy; cell immunogenicity; tumor angiogenesis; cell encapsulation	ENDOGENOUS INHIBITORS; DIFFERENTIATION; ANGIOGENESIS; BIOCOMPATIBILITY; IMMUNOGENICITY; ENDOSTATIN; CHALLENGES; FRAGMENT; DELIVERY; RELEASE	Cell encapsulation is a promising approach for long-term delivery of therapeutic agents. Nonetheless, this system has failed to reach clinical settings, as the entrapped cells provoke a host immune reaction. Mesenchymal stem cells (MSCs), however, potentially may overcome this impediment and serve as a promising platform for cell-based microencapsulation. They are known to be hypoimmunogenic and can be genetically modified to express a variety of therapeutic factors. We have designed alginate-PLL microcapsules that can encapsulate human MSCs (hMSCs) for extended periods, as demonstrated by fluorescence and H-3-thymidine assays. The encapsulated hMSCs maintained their mesenchymal surface markers and differentiated to all the typical mesoderm lineages. In vitro and in vivo immunogenicity studies revealed that encapsulated hMSCs were significantly hypoimmunogenic, leading to a 3-fold decrease in cytokine expression compared to entrapped cell lines. The efficacy of such systems was demonstrated by genetically modifying the cells to express the hemopexin-like protein (PEX), an inhibitor of angiogenesis. Live imaging and tumor measurements showed that encapsulated hMSC-PEX injected adjacent to glioblastoma tumors in nude mice led to a significant reduction in tumor volume (87%) and weight (83%). We clearly demonstrate that hMSCs are the cell of choice for microencapsulation cell based-therapy, thus bringing this technology closer to clinical application.-Goren, A., Dahan, N., Goren, E., Baruch, L., Machluf, M. Encapsulated human mesenchymal stem cells: a unique hypoimmunogenic platform for long-term cellular therapy. FASEB J. 24, 22-31 (2010). www.fasebj.org	[Machluf, Marcelle] Technion Israel Inst Technol, Fac Biotechnol & Food Engn, Lab Canc Drug Delivery & Mammalian Cell Technol, Haifa, Israel	Technion Israel Institute of Technology	Machluf, M (corresponding author), Technion Israel Inst Technol, Fac Biotechnol & Food Engn, Lab Canc Drug Delivery & Mammalian Cell Technol, Haifa, Israel.	machlufm@tx.technion.ac.il	Baruch, Limor/AAC-7019-2022		Edward Satell Fellowship	Edward Satell Fellowship	We thank Prof. Rona S. Carroll ( Harvard Medical School, Boston, MA, USA) for the lentiviral vectors and Dr. Tendler Mark for his assistance with the animal studies. This work was financially supported by a grant from the Edward Satell Fellowship.	Alhadlaq A, 2004, STEM CELLS DEV, V13, P436, DOI 10.1089/1547328041797552; Aslan H, 2006, STEM CELLS, V24, P1728, DOI 10.1634/stemcells.2005-0546; Barry FP, 2005, STEM CELLS DEV, V14, P252, DOI 10.1089/scd.2005.14.252; Baruch L, 2006, BIOPOLYMERS, V82, P570, DOI 10.1002/bip.20509; Bello L, 2002, CLIN CANCER RES, V8, P3539; Bello L, 2001, CANCER RES, V61, P8730; Benny O, 2005, CLIN CANCER RES, V11, P768; Benoit DSW, 2008, NAT MATER, V7, P816, DOI 10.1038/nmat2269; Benoit DSW, 2007, ADV FUNCT MATER, V17, P2085, DOI 10.1002/adfm.200700012; Beyth S, 2005, BLOOD, V105, P2214, DOI 10.1182/blood-2004-07-2921; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Bunger CM, 2005, BIOMATERIALS, V26, P2353, DOI 10.1016/j.biomaterials.2004.07.017; Compte M, 2009, STEM CELLS, V27, P753, DOI 10.1634/stemcells.2008-0831; de Groot M, 2004, J SURG RES, V121, P141, DOI 10.1016/j.jss.2004.02.018; de Vos P, 2002, DIABETOLOGIA, V45, P159, DOI 10.1007/s00125-001-0729-x; Ding HF, 2007, BIOCHEM BIOPH RES CO, V362, P923, DOI 10.1016/j.bbrc.2007.08.094; Duvshani-Eshet M, 2007, MOL CANCER THER, V6, P2371, DOI 10.1158/1535-7163.MCT-07-0019; Figliuzzi M, 2006, ACTA BIOMATER, V2, P221, DOI 10.1016/j.actbio.2005.12.002; Ghidoni I, 2008, CYTOTECHNOLOGY, V58, P49, DOI 10.1007/s10616-008-9161-0; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; Hoelters J, 2005, J GENE MED, V7, P718, DOI 10.1002/jgm.731; Jackson L, 2007, J POSTGRAD MED, V53, P121; JARVIS AP, 1986, IN VITRO CELL DEV B, V22, P589, DOI 10.1007/BF02623518; Joki T, 2001, NAT BIOTECHNOL, V19, P35, DOI 10.1038/83481; Kim SK, 2005, CLIN CANCER RES, V11, P5965, DOI 10.1158/1078-0432.CCR-05-0371; Klyushnenkova E, 2005, J BIOMED SCI, V12, P47, DOI 10.1007/s11373-004-8183-7; Le Blanc K, 2007, J INTERN MED, V262, P509, DOI 10.1111/j.1365-2796.2007.01844.x; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; Liu Y, 2009, J MICROENCAPSUL, V26, P130, DOI [10.1080/02652040802193014, 10.1080/02652040802193014 ]; McMahon JM, 2006, STEM CELLS DEV, V15, P87, DOI 10.1089/scd.2006.15.87; Mosca JD, 2000, CLIN ORTHOP RELAT R, pS71; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Orive G, 2006, BIOMATERIALS, V27, P3691, DOI 10.1016/j.biomaterials.2006.02.048; Orive G, 2004, TRENDS BIOTECHNOL, V22, P87, DOI 10.1016/j.tibtech.2003.11.004; Perrot P, 2007, ANN PLAS SURG, V59, P201, DOI 10.1097/SAP.0b013e31802c1ff2; Read TA, 2001, NAT BIOTECHNOL, V19, P29, DOI 10.1038/83471; Rege TA, 2005, NEURO-ONCOLOGY, V7, P106, DOI 10.1215/S115285170400119X; Ren C, 2008, GENE THER, V15, P1446, DOI 10.1038/gt.2008.101; Ren CC, 2008, STEM CELLS, V26, P2332, DOI 10.1634/stemcells.2008-0084; SOONSHIONG P, 1994, LANCET, V343, P950, DOI 10.1016/S0140-6736(94)90067-1; Steinert A, 2003, J ORTHOP RES, V21, P1090, DOI 10.1016/S0736-0266(03)00100-1; Sun SK, 2003, STEM CELLS, V21, P527, DOI 10.1634/stemcells.21-5-527; Tropel P, 2004, EXP CELL RES, V295, P395, DOI 10.1016/j.yexcr.2003.12.030; Uccelli A, 2007, TRENDS IMMUNOL, V28, P219, DOI 10.1016/j.it.2007.03.001; Uccelli A, 2006, EUR J IMMUNOL, V36, P2566, DOI 10.1002/eji.200636416; Van Damme A, 2006, STEM CELLS, V24, P896, DOI 10.1634/stemcells.2003-0106; Visted T, 2003, EXPERT OPIN BIOL TH, V3, P551; Weber M, 2002, BIOMATERIALS, V23, P2003, DOI 10.1016/S0142-9612(01)00329-5; Weir C, 2008, HEART LUNG CIRC, V17, P395, DOI 10.1016/j.hlc.2008.01.006; Zilberman Y, 2002, POLYM ADVAN TECHNOL, V13, P863, DOI 10.1002/pat.231	50	110	118	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					22	31		10.1096/fj.09-131888	http://dx.doi.org/10.1096/fj.09-131888			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19726759				2022-12-28	WOS:000273233600005
J	Jean, L; Lee, CF; Lee, C; Shaw, M; Vaux, DJ				Jean, Letitia; Lee, Chiu Fan; Lee, Chongsoo; Shaw, Michael; Vaux, David J.			Competing discrete interfacial effects are critical for amyloidogenesis	FASEB JOURNAL			English	Article						islet amyloid polypeptide; surface tension; hydrophobic-hydrophilic interfaces	ISLET AMYLOID POLYPEPTIDE; PHOSPHOLIPID MONOLAYERS; BETA-PROTEIN; FIBRILLOGENESIS; AGGREGATION; MEMBRANE; DISEASE; FIBRIL; MECHANISM; PEPTIDES	Amyloid accumulation is associated with pathological conditions, including type II diabetes and Alzheimer's disease. Lipids influence amyloidogenesis and are themselves targets for amyloid-mediated cell membrane disruption. Amyloid precursors are surface-active, accumulating at hydrophobic-hydrophilic interfaces (e. g., air-water), where their biophysical and kinetic behaviors differ from those in the bulk solution with significant and underappreciated consequences. Biophysical modeling predicted the probability and rate of beta-sheet amyloid dimer formation to be higher and faster at the air-water interface (AWI) than in the bulk (by 14 and similar to 1500 times, respectively). Time-course staining experiments with a typical amyloid dye verified our predictions by demonstrating that without AWI, islet amyloid polypeptide (IAPP) fibrilization was abolished or slowed, depending on the conditions. Our controls included undisturbed IAPP reactions, and we ascertained that the AWI removal process (technical or material) did not itself affect the reaction. Furthermore, we showed that the role of membranes in amyloidogenesis has been previously underestimated; in an in vivo-like situation (with no AWI), anionic liposomes (containing dioleoylphosphatidylglycerol) enhanced IAPP fibrilogenesis far more than described previously in conventional assay conditions (in the presence of an AWI). These findings have implications for the protein misfolding field and in assay design to target toxic protein aggregation.-Jean, L., Lee, C. F., Lee, C., Shaw, M., Vaux, D. J. Competing discrete interfacial effects are critical for amyloidogenesis. FASEB J. 24, 309-317 (2010). www.fasebj.org	[Jean, Letitia; Shaw, Michael; Vaux, David J.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Lee, Chiu Fan; Lee, Chongsoo] Univ Oxford, Dept Phys, Clarendon Lab, Oxford OX1 3RE, England	University of Oxford; University of Oxford	Vaux, DJ (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	david.vaux@path.ox.ac.uk		Lee, Chiu Fan/0000-0003-4363-9050; Jean, Letitia/0000-0002-6450-7148; Vaux, David/0000-0002-4901-9795	Synaptica Ltd. (Didcot, Oxfordshire, UK); Glasstone Trust (Oxford, UK); MRC [G0801917] Funding Source: UKRI; Medical Research Council [G0801917] Funding Source: researchfish	Synaptica Ltd. (Didcot, Oxfordshire, UK); Glasstone Trust (Oxford, UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Helen Mather for technical contribution. This work was supported by a research grant from Synaptica Ltd. (Didcot, Oxfordshire, UK). C. F. L. was supported by the Glasstone Trust (Oxford, UK).	Chi EY, 2008, PROTEINS, V72, P1, DOI 10.1002/prot.21887; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Dubay KF, 2004, J MOL BIOL, V341, P1317, DOI 10.1016/j.jmb.2004.06.043; Engel MFM, 2008, P NATL ACAD SCI USA, V105, P6033, DOI 10.1073/pnas.0708354105; Engel MFM, 2006, J MOL BIOL, V356, P783, DOI 10.1016/j.jmb.2005.12.020; Fernandez-Escamilla AM, 2004, NAT BIOTECHNOL, V22, P1302, DOI 10.1038/nbt1012; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Jackson M. B., 2006, MOL CELLULAR BIOPHYS; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Knight JD, 2004, J MOL BIOL, V341, P1175, DOI 10.1016/j.jmb.2004.06.086; Knight JD, 2006, BIOCHEMISTRY-US, V45, P9496, DOI 10.1021/bi060579z; Larson JL, 2000, PROTEIN SCI, V9, P427; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; Lopes DHJ, 2007, BIOPHYS J, V93, P3132, DOI 10.1529/biophysj.107.110635; Maltseva E, 2005, CHEMBIOCHEM, V6, P1817, DOI 10.1002/cbic.200500116; MATSUYAMA A, 1995, MACROMOLECULES, V28, P131, DOI 10.1021/ma00105a017; O'Nuallain B, 2005, BIOCHEMISTRY-US, V44, P12709, DOI 10.1021/bi050927h; Quist A, 2005, P NATL ACAD SCI USA, V102, P10427, DOI 10.1073/pnas.0502066102; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Ruschak AM, 2007, P NATL ACAD SCI USA, V104, P12341, DOI 10.1073/pnas.0703306104; RUSTENBECK I, 1994, LIPIDS, V29, P685, DOI 10.1007/BF02538912; Sabate R, 2005, J PHYS CHEM B, V109, P11027, DOI 10.1021/jp050716m; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; Szymczyk K, 2006, J COLLOID INTERF SCI, V293, P172, DOI 10.1016/j.jcis.2005.06.038; Terzi E, 1997, BIOCHEMISTRY-US, V36, P14845, DOI 10.1021/bi971843e; Yoon S, 2004, PROTEIN SCI, V13, P2149, DOI 10.1110/ps.04790604	30	43	44	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2010	24	1					309	317		10.1096/fj.09-137653	http://dx.doi.org/10.1096/fj.09-137653			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	539DL	19741169				2022-12-28	WOS:000273233600031
J	Bang, ML; Caremani, M; Brunello, E; Littlefield, R; Lieber, RL; Chen, J; Lombardi, V; Linari, M				Bang, Marie-Louise; Caremani, Marco; Brunello, Elisabetta; Littlefield, Ryan; Lieber, Richard L.; Chen, Ju; Lombardi, Vincenzo; Linari, Marco			Nebulin plays a direct role in promoting strong actin-myosin interactions	FASEB JOURNAL			English	Article						muscle performance; muscle force generation; cytoskeletal proteins	THIN FILAMENT LENGTHS; RABBIT PSOAS MUSCLE; SKELETAL-MUSCLE; STRIATED-MUSCLE; NEMALINE MYOPATHY; FORCE DEVELOPMENT; ATP HYDROLYSIS; POINTED ENDS; FIBERS; PHOSPHATE	The role of the actin filament-associated protein nebulin on mechanical and kinetic properties of the actomyosin motor was investigated in skeletal muscle of wild-type (wt) and nebulin-deficient (nebulin(-/-)) mice that were 1 d old, an age at which sarcomeric structure is still well preserved. In Ca(2+)-activated skinned fibers from psoas muscle, we determined the Ca(2+) dependence of isometric force and stiffness, the rate of force redevelopment after unloaded shortening (k(TR)), the power during isotonic shortening, and the unloaded shortening velocity (V(0)). Our results show a 65% reduction in isometric force in nebulin(-/-) fibers at saturating [Ca(2+)], whereas neither thin-filament length nor the Ca(2+) sensitivity of the contractile system is affected. Stiffness measurements indicate that the reduction in isometric force is due to a reduction in the number of actin-attached myosin motors, whereas the force of the motor is unchanged. Furthermore, in nebulin(-/-) fibers, kTR is decreased by 57%, V(0) is increased by 63%, and the maximum power is decreased by 80%. These results indicate that, in the absence of nebulin, the attachment probability of the myosin motors to actin is decreased, revealing a direct role for nebulin in promoting strong actomyosin interactions responsible for force and power production.-Bang, M.-L., Caremani, M., Brunello, E., Littlefield, R., Lieber, R. L., Chen, J., Lombardi, V., Linari, M. Nebulin plays a direct role in promoting strong actin-myosin interactions. FASEB J. 23, 4117-4125 (2009). www.fasebj.org	[Bang, Marie-Louise] CNR, ITB, Dulbecco Telethon Inst, I-20090 Milan, Italy; [Bang, Marie-Louise] Ist Ricovero & Cura Carattere Sci Multimed, Milan, Italy; [Caremani, Marco; Brunello, Elisabetta; Lombardi, Vincenzo; Linari, Marco] Univ Florence, Dipartimento Biol Evoluzionist, Lab Fisiol, Florence, Italy; [Caremani, Marco; Linari, Marco] Univ Florence, Consorzio Nazl Interuniv Sci Fis Mat, Florence, Italy; [Littlefield, Ryan] Univ Washington, Friday Harbor Labs, Ctr Cell Dynam, Friday Harbor, WA 98250 USA; [Lieber, Richard L.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; [Lieber, Richard L.] Univ Calif San Diego, Dept Orthopaed Surg, La Jolla, CA 92093 USA; [Chen, Ju] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Lieber, Richard L.] Vet Affairs Med Ctr, La Jolla, CA USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Fondazione Telethon; Dulbecco Telethon Institute (DTI); University of Florence; University of Florence; University of Washington; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bang, ML (corresponding author), CNR, ITB, Dulbecco Telethon Inst, Via Fratelli Cervi 93, I-20090 Milan, Italy.	m.bang@itb.cnr.it; marco.linari@unifi.it	Bang, Marie-Louise/B-5683-2015; Chen, Ju/E-5579-2011	Bang, Marie-Louise/0000-0001-8859-5034; Brunello, Elisabetta/0000-0003-3167-4828; Lieber, Richard/0000-0002-7203-4520; Caremani, Marco/0000-0001-9128-7227; LINARI, MARCO/0000-0001-6512-4897	U. S. National Institutes of Health [R01 AR49033]; Ministero dell'Universitae della Ricerca [MiUR-Cofin 2006]; Ministero del Lavoro, della Salute e delle Politiche Sociali [RF-MUL-2007-666195]; Telethon-Italy [TCP07006]; Fondazione Cariplo [2007.5812]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049033] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministero dell'Universitae della Ricerca(Ministry of Education, Universities and Research (MIUR)); Ministero del Lavoro, della Salute e delle Politiche Sociali; Telethon-Italy(Fondazione Telethon); Fondazione Cariplo(Fondazione Cariplo); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors acknowledge the Telethon Electron Microscopy core facility (directed by R. S. Polishchuk) for the preparation and analysis of electron microscopic specimens and thank Mario Dolfi for skilled technical assistance. This research was supported by the U. S. National Institutes of Health (grant R01 AR49033), Ministero dell'Universitae della Ricerca (MiUR-Cofin 2006), and Ministero del Lavoro, della Salute e delle Politiche Sociali (grant RF-MUL-2007-666195). M.-L. B. is an Assistant Telethon Scientist supported by Telethon-Italy (grant TCP07006) and Fondazione Cariplo (grant 2007.5812).	Bang ML, 2006, J CELL BIOL, V173, P905, DOI 10.1083/jcb.200603119; Bang ML, 2002, J STRUCT BIOL, V137, P119, DOI 10.1006/jsbi.2002.4457; Bang ML, 2001, J CELL BIOL, V153, P413, DOI 10.1083/jcb.153.2.413; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; Brunello E, 2006, J PHYSIOL-LONDON, V577, P971, DOI 10.1113/jphysiol.2006.115394; CASELLA JF, 1987, J CELL BIOL, V105, P371, DOI 10.1083/jcb.105.1.371; Castillo A, 2009, BIOPHYS J, V96, P1856, DOI 10.1016/j.bpj.2008.10.053; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; EDMAN KAP, 1979, J PHYSIOL-LONDON, V291, P143, DOI 10.1113/jphysiol.1979.sp012804; FINK RHA, 1986, J PHYSIOL-LONDON, V373, P513, DOI 10.1113/jphysiol.1986.sp016060; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P577, DOI 10.1113/jphysiol.1984.sp015394; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; Hill AV, 1913, BIOCHEM J, V7, P471, DOI 10.1042/bj0070471; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; Huxley AF, 1980, J PHYSL, V305, P15; JIN JP, 1991, FEBS LETT, V281, P93, DOI 10.1016/0014-5793(91)80366-B; KAWAI M, 1987, PFLUG ARCH EUR J PHY, V408, P1, DOI 10.1007/BF00581833; Kohler J, 2002, P NATL ACAD SCI USA, V99, P3557, DOI 10.1073/pnas.062415899; LABEIT S, 1995, J MOL BIOL, V248, P308, DOI 10.1016/S0022-2836(95)80052-2; Linari M, 2004, J PHYSIOL-LONDON, V554, P335, DOI 10.1113/jphysiol.2003.051748; Linari M, 2007, BIOPHYS J, V92, P2476, DOI 10.1529/biophysj.106.099549; Littlefield R, 2002, BIOPHYS J, V82, P2548, DOI 10.1016/S0006-3495(02)75598-7; Littlefield R, 2001, NAT CELL BIOL, V3, P544, DOI 10.1038/35078517; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; Ma K, 2002, FEBS LETT, V532, P273, DOI 10.1016/S0014-5793(02)03655-4; McElhinny AS, 2001, J BIOL CHEM, V276, P583, DOI 10.1074/jbc.M005693200; MILLAR NC, 1990, J BIOL CHEM, V265, P20234; Ottenheijm CAC, 2008, FASEB J, V22, P2912, DOI 10.1096/fj.07-104372; PFUHL M, 1994, EMBO J, V13, P1782, DOI 10.1002/j.1460-2075.1994.tb06446.x; Piazzesi G, 2007, CELL, V131, P784, DOI 10.1016/j.cell.2007.09.045; Regnier M, 1995, AM J PHYSIOL-CELL PH, V269, pC1532, DOI 10.1152/ajpcell.1995.269.6.C1532; ROOT DD, 1994, BIOCHEMISTRY-US, V33, P12581, DOI 10.1021/bi00208a008; Root DD, 2001, BIOCHEMISTRY-US, V40, P1171, DOI 10.1021/bi0015010; SCHAFER DA, 1995, J CELL BIOL, V128, P61, DOI 10.1083/jcb.128.1.61; Simmons RM, 1974, RECENT ADV PHYSIOL, V31, P87; Sleep J, 2005, J PHYSIOL-LONDON, V563, P671, DOI 10.1113/jphysiol.2004.078873; Stehle R, 2000, BIOPHYS J, V78, P1458, DOI 10.1016/S0006-3495(00)76699-9; Wallgren-Pettersson C, 1999, NEUROMUSCULAR DISORD, V9, P564, DOI 10.1016/S0960-8966(99)00061-9; Wallgren-Pettersson C, 2002, NEUROMUSCULAR DISORD, V12, P674, DOI 10.1016/S0960-8966(02)00065-2; Wang K, 1996, J BIOL CHEM, V271, P4304; Witt CC, 2006, EMBO J, V25, P3843, DOI 10.1038/sj.emboj.7601242	43	54	54	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2009	23	12					4117	4125		10.1096/fj.09-137729	http://dx.doi.org/10.1096/fj.09-137729			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19679637	Green Published			2022-12-28	WOS:000272193700008
J	Kuzmenkin, A; Liang, HM; Xu, GX; Pfannkuche, K; Eichhorn, H; Fatima, A; Luo, HY; Saric, T; Wernig, M; Jaenisch, R; Hescheler, J				Kuzmenkin, Alexey; Liang, Huamin; Xu, Guoxing; Pfannkuche, Kurt; Eichhorn, Hardy; Fatima, Azra; Luo, Hongyan; Saric, Tomo; Wernig, Marius; Jaenisch, Rudolf; Hescheler, Juergen			Functional characterization of cardiomyocytes derived from murine induced pluripotent stem cells in vitro	FASEB JOURNAL			English	Article						iPS cells; cardiac differentiation; electrophysiology; patch-clamp; reprogramming	RECTIFIER K+-CURRENT; ION-CHANNEL EXPRESSION; CARDIAC MYOCYTES; SODIUM-CHANNELS; SOMATIC-CELLS; CALCIUM-CHANNEL; 2 COMPONENTS; GENERATION; MOUSE; FIBROBLASTS	Several types of terminally differentiated somatic cells can be reprogrammed into a pluripotent state by ectopic expression of Klf4, Oct3/4, Sox2, and c-Myc. Such induced pluripotent stem (iPS) cells have great potential to serve as an autologous source of cells for tissue repair. In the process of developing iPS-cell-based therapies, the major goal is to determine whether differentiated cells derived from iPS cells, such as cardiomyocytes (CMs), have the same functional properties as their physiological in vivo counterparts. Therefore, we differentiated murine iPS cells to CMs in vitro and characterized them by RTPCR, immunocytochemistry, and electrophysiology. As key markers of cardiac lineages, transcripts for Nkx2.5, alpha MHC, Mlc2v, and cTnT could be identified. Immunocytochemical stainings revealed the presence of organized sarcomeric actinin but the absence of mature atrial natriuretic factor. We examined characteristics and developmental changes of action potentials, as well as functional hormonal regulation and sensitivity to channel blockers. In addition, we determined expression patterns and functionality of cardiac-specific voltage-gated Na+, Ca2+, and K+ channels at early and late differentiation stages and compared them with CMs derived from murine embryonic stem cells (ESCs) as well as with fetal CMs. We conclude that iPS cells give rise to functional CMs in vitro, with established hormonal regulation pathways and functionally expressed cardiac ion channels; CMs generated from iPS cells have a ventricular phenotype; and cardiac development of iPS cells is delayed compared with maturation of native fetal CMs and of ESC-derived CMs. This difference may reflect the incomplete reprogramming of iPS cells and should be critically considered in further studies to clarify the suitability of the iPS model for regenerative medicine of heart disorders.-Kuzmenkin, A., Liang, H., Xu, G., Pfannkuche, K., Eichhorn, H., Fatima, A., Luo, H., S. aric, T., Wernig, M., Jaenisch, R., Hescheler, J. Functional characterization of cardiomyocytes derived from murine induced pluripotent stem cells in vitro. FASEB J. 23, 4168-4180 (2009). www.fasebj.org	[Kuzmenkin, Alexey; Liang, Huamin; Xu, Guoxing; Pfannkuche, Kurt; Eichhorn, Hardy; Fatima, Azra; Luo, Hongyan; Saric, Tomo; Hescheler, Juergen] Univ Cologne, Inst Neurophysiol, Med Ctr, D-50931 Cologne, Germany; [Saric, Tomo; Hescheler, Juergen] Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany; [Liang, Huamin; Xu, Guoxing; Luo, Hongyan] Huazhong Univ Sci & Technol, Dept Physiol, Wuhan 430074, Peoples R China; [Liang, Huamin; Xu, Guoxing; Luo, Hongyan] Huazhong Univ Sci & Technol, Tongji Med Coll, Chinese German Stem Cell Ctr, Wuhan 430074, Peoples R China; [Wernig, Marius; Jaenisch, Rudolf] MIT, Whitehead Inst Biomed Res, Cambridge, MA USA; [Jaenisch, Rudolf] MIT, Dept Biol, Cambridge, MA USA	University of Cologne; University of Cologne; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Hescheler, J (corresponding author), Univ Cologne, Inst Neurophysiol, Med Ctr, Robert Koch Str 39, D-50931 Cologne, Germany.	j.hescheler@uni-koeln.de	Saric, Tomo/B-3415-2015	Saric, Tomo/0000-0001-8344-1095; Pfannkuche, Kurt Paul/0000-0002-4284-774X	Koln Fortune [102/2007]; German Federal Ministry for Education and Research [01 GN 0541]	Koln Fortune; German Federal Ministry for Education and Research(Federal Ministry of Education & Research (BMBF))	We thank Cornelia Bottinger and Rebecca Dieterich for technical assistance and Matthias Matzkies for fruitful discussion. This work was supported by a Koln Fortune grant to A. K. (102/2007) and by a German Federal Ministry for Education and Research grant to J. H. and T. S.. ( BMBF, grant 01 GN 0541).	Aasen T, 2008, NAT BIOTECHNOL, V26, P1276, DOI 10.1038/nbt.1503; Aoi T, 2008, SCIENCE, V321, P699, DOI 10.1126/science.1154884; Banach K, 2003, AM J PHYSIOL-HEART C, V284, pH2114, DOI 10.1152/ajpheart.01106.2001; Bony C, 2001, J CELL BIOL, V152, P717, DOI 10.1083/jcb.152.4.717; Chin MH, 2009, CELL STEM CELL, V5, P111, DOI 10.1016/j.stem.2009.06.008; Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447; Davies MP, 1996, CIRC RES, V78, P15, DOI 10.1161/01.RES.78.1.15; Doevendans PA, 2000, J MOL CELL CARDIOL, V32, P839, DOI 10.1006/jmcc.2000.1128; Ehrlich JR, 2003, J PHYSIOL-LONDON, V551, P801, DOI 10.1113/jphysiol.2003.046417; Eminli S, 2008, STEM CELLS, V26, P2467, DOI 10.1634/stemcells.2008-0317; Feron O, 1999, LIFE SCI, V64, P471, DOI 10.1016/S0024-3205(98)00590-6; Fiset C, 1997, J PHYSIOL-LONDON, V504, P557, DOI 10.1111/j.1469-7793.1997.557bd.x; Fleischmann BK, 2004, J CLIN INVEST, V114, P994, DOI 10.1172/JCI200415925; Fleischmann M, 1998, FEBS LETT, V440, P370, DOI 10.1016/S0014-5793(98)01476-8; GRANT AO, 1989, CIRC RES, V65, P1247, DOI 10.1161/01.RES.65.5.1247; Gryshchenko O, 2000, PFLUG ARCH EUR J PHY, V439, P798, DOI 10.1007/s004240051007; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanna J, 2008, CELL, V133, P250, DOI 10.1016/j.cell.2008.03.028; Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Hochedlinger K, 2006, NATURE, V441, P1061, DOI 10.1038/nature04955; INSEL PA, 1983, NEW ENGL J MED, V308, P1361; Jaenisch R, 2004, NEW ENGL J MED, V351, P2787, DOI 10.1056/NEJMp048304; Ji GJ, 1999, FASEB J, V13, P313, DOI 10.1096/fasebj.13.2.313; JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75; Kamiya K, 2001, MOL PHARMACOL, V60, P244, DOI 10.1124/mol.60.2.244; Kim JB, 2008, NATURE, V454, P646, DOI 10.1038/nature07061; Kodama I, 1999, AM J PHYSIOL-HEART C, V276, pH793, DOI 10.1152/ajpheart.1999.276.3.H793; Kolossov E, 2005, FASEB J, V19, P577, DOI 10.1096/fj.03-1451fje; Kolossov E, 1998, J CELL BIOL, V143, P2045, DOI 10.1083/jcb.143.7.2045; Kolossov E, 2006, J EXP MED, V203, P2315, DOI 10.1084/jem.20061469; LEFKOWITZ RJ, 1976, LIFE SCI, V18, P461, DOI 10.1016/0024-3205(76)90323-4; Lei M, 2004, J PHYSIOL-LONDON, V559, P835, DOI 10.1113/jphysiol.2004.068643; Lei M, 1996, EXP PHYSIOL, V81, P725, DOI 10.1113/expphysiol.1996.sp003972; Lowry WE, 2008, P NATL ACAD SCI USA, V105, P2883, DOI 10.1073/pnas.0711983105; Maherali N, 2008, CELL STEM CELL, V3, P340, DOI 10.1016/j.stem.2008.08.003; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Maingret F, 2002, BIOCHEM BIOPH RES CO, V292, P339, DOI 10.1006/bbrc.2002.6674; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; Marionneau C, 2005, J PHYSIOL-LONDON, V562, P223, DOI 10.1113/jphysiol.2004.074047; Matsumura H, 2007, NAT METHODS, V4, P23, DOI 10.1038/NMETH973; Mauritz C, 2008, CIRCULATION, V118, P507, DOI 10.1161/CIRCULATIONAHA.108.778795; MCDONALD TV, 1989, BIOPHYS J, V55, P1261, DOI 10.1016/S0006-3495(89)82921-2; Narazaki G, 2008, CIRCULATION, V118, P498, DOI 10.1161/CIRCULATIONAHA.108.769562; NAYLER WG, 1983, MED J AUSTRALIA, V2, P506, DOI 10.5694/j.1326-5377.1983.tb122621.x; Odorico JS, 2001, STEM CELLS, V19, P193, DOI 10.1634/stemcells.19-3-193; ONO K, 1995, AM J PHYSIOL-HEART C, V269, pH453, DOI 10.1152/ajpheart.1995.269.2.H453; Oyamada Y, 1996, EXP CELL RES, V229, P318, DOI 10.1006/excr.1996.0377; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Pfannkuche K, 2009, CELL PHYSIOL BIOCHEM, V24, P73, DOI 10.1159/000227815; Pond AL, 2000, J BIOL CHEM, V275, P5997, DOI 10.1074/jbc.275.8.5997; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1992, HYPERTENSION, V19, P228, DOI 10.1161/01.HYP.19.3.228; Schenke-Layland K, 2008, STEM CELLS, V26, P1537, DOI 10.1634/stemcells.2008-0033; SCHOUTEN VJA, 1984, EUR HEART J, V5, P984, DOI 10.1093/oxfordjournals.eurheartj.a061618; Schram G, 2002, CIRC RES, V90, P939, DOI 10.1161/01.RES.0000018627.89528.6F; Sensch O, 2000, BRIT J PHARMACOL, V131, P1089, DOI 10.1038/sj.bjp.0703673; Shi Y, 2008, CELL STEM CELL, V2, P525, DOI 10.1016/j.stem.2008.05.011; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; SPEDDING M, 1992, BIOCHEM SOC T, V20, P147, DOI 10.1042/bst0200147; Stadtfeld M, 2008, CURR BIOL, V18, P890, DOI 10.1016/j.cub.2008.05.010; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; VERHEIJCK EE, 1995, CIRC RES, V76, P607, DOI 10.1161/01.RES.76.4.607; Wernig M, 2008, NAT BIOTECHNOL, V26, P916, DOI 10.1038/nbt1483; Wernig M, 2008, P NATL ACAD SCI USA, V105, P5856, DOI 10.1073/pnas.0801677105; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Yamanaka S, 2007, CELL STEM CELL, V1, P39, DOI 10.1016/j.stem.2007.05.012; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhang JH, 2009, CIRC RES, V104, pE30, DOI 10.1161/CIRCRESAHA.108.192237; Zhang Z, 2002, CIRC RES, V90, P981, DOI 10.1161/01.RES.0000018003.14304.E2	72	99	113	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4168	4180		10.1096/fj.08-128546	http://dx.doi.org/10.1096/fj.08-128546			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19703934				2022-12-28	WOS:000272193700013
J	Shein, NA; Grigoriadis, N; Alexandrovich, AG; Simeonidou, C; Lourbopoulos, A; Polyzoidou, E; Trembovler, V; Mascagni, P; Dinarello, CA; Shohami, E				Shein, Na'ama A.; Grigoriadis, Nikolaos; Alexandrovich, Alexander G.; Simeonidou, Constantina; Lourbopoulos, Athanasios; Polyzoidou, Eleni; Trembovler, Victoria; Mascagni, Paolo; Dinarello, Charles A.; Shohami, Esther			Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury	FASEB JOURNAL			English	Article						epigenetic; closed head injury; regeneration	FOCAL CEREBRAL-ISCHEMIA; CLOSED-HEAD INJURY; SUBEROYLANILIDE HYDROXAMIC ACID; AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MOUSE MODEL; BINDING-PROTEIN CBP; HUNTINGTONS-DISEASE; ANTILEUKEMIC ACTIVITY; NERVOUS-SYSTEM; VALPROIC ACID	Despite efforts aimed at developing novel therapeutics for traumatic brain injury (TBI), no specific pharmacological agent is currently clinically available. Here, we show that the pan-histone deacetylase (HDAC) inhibitor ITF2357, a compound shown to be safe and effective in humans, improves functional recovery and attenuates tissue damage when administered as late as 24 h postinjury. Using a well-characterized, clinically relevant mouse model of closed head injury (CHI), we demonstrate that a single dose of ITF2357 administered 24 h postinjury improves neurobehavioral recovery from d 6 up to 14 d postinjury (improved neurological score vs. vehicle; P <= 0.05), and that this functional benefit is accompanied by decreased neuronal degeneration, reduced lesion volume (22% reduction vs. vehicle; P <= 0.01), and is preceded by increased acetylated histone H3 levels and attenuation of injury-induced decreases in cytoprotective heat-shock protein 70 kDa and phosphorylated Akt. Moreover, reduced glial accumulation and activation were observed 3 d postinjury, and total p53 levels at the area of injury and caspase-3 immunoreactivity within microglia/macrophages at the trauma area were elevated, suggesting enhanced clearance of these cells via apoptosis following treatment. Hence, our findings underscore the relevance of HDAC inhibitors for ameliorating trauma-induced functional deficits and warrant consideration of applying ITF2357 for this indication.-Shein, N. A., Grigoriadis, N., Alexandrovich, A. G., Simeonidou, C., Lourbopoulos, A., Polyzoidou, E., Trembovler, V., Mascagni, P., Dinarello, C. A., Shohami, E. Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J. 23, 4266-4275 (2009). www.fasebj.org	[Shein, Na'ama A.; Alexandrovich, Alexander G.; Trembovler, Victoria; Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Grigoriadis, Nikolaos; Lourbopoulos, Athanasios; Polyzoidou, Eleni] AHEPA Univ Hosp, Dept Neurol, Thessaloniki, Greece; [Simeonidou, Constantina] Aristotle Univ Thessaloniki, Dept Physiol, GR-54006 Thessaloniki, Greece; [Mascagni, Paolo] Res Ctr, Balsamo, Italy; [Dinarello, Charles A.] Univ Colorado Denver, Dept Med, Aurora, CO USA	Hebrew University of Jerusalem; Aristotle University of Thessaloniki; Ahepa University Hospital; Aristotle University of Thessaloniki; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il	Dinarello, Charles/C-8524-2013		U. S. National Institutes of Health [AI-15614]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015614, R01AI015614] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	E. S. is the incumbent of the Dr. Leon and Mina Deutch Chair in psychopharmacology at the Hebrew University. This work was supported by U. S. National Institutes of Health grant AI-15614 (to C. A. D.). P. M. is an employee of Italfarmaco, S. p. A., Italy. The authors thank Prof. A. Rubinstein (Hebrew University) for his assistance in obtaining antibodies used in this series of experiments.	Albert MS, 2007, NEW ENGL J MED, V357, P502, DOI 10.1056/NEJMcibr073273; Armeanu S, 2005, J HEPATOL, V42, P210, DOI 10.1016/j.jhep.2004.10.020; Atweh GF, 1999, BLOOD, V93, P1790; Barbetti V, 2008, ONCOGENE, V27, P1767, DOI 10.1038/sj.onc.1210820; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Brown IR, 2007, ANN NY ACAD SCI, V1113, P147, DOI 10.1196/annals.1391.032; Camelo S, 2005, J NEUROIMMUNOL, V164, P10, DOI 10.1016/j.jneuroim.2005.02.022; Carlisi D, 2008, INT J ONCOL, V32, P177; Carta S, 2006, BLOOD, V108, P1618, DOI 10.1182/blood-2006-03-014126; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Delgado-Esteban M, 2007, J NEUROCHEM, V102, P194, DOI 10.1111/j.1471-4159.2007.04450.x; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Gardian G, 2005, J BIOL CHEM, V280, P556, DOI 10.1074/jbc.M410210200; Gerstner T, 2008, EXPERT OPIN PHARMACO, V9, P285, DOI 10.1517/14656566.9.2.285 ; Glauben R, 2008, GUT, V57, P613, DOI 10.1136/gut.2007.134650; Glauben R, 2006, J IMMUNOL, V176, P5015, DOI 10.4049/jimmunol.176.8.5015; Golay J, 2007, LEUKEMIA, V21, P1892, DOI 10.1038/sj.leu.2404860; Grosjean MB, 2007, HISTOL HISTOPATHOL, V22, P235, DOI 10.14670/HH-22.235; Hahnen E, 2008, EXPERT OPIN INV DRUG, V17, P169, DOI 10.1517/13543784.17.2.169; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin KL, 2001, J MOL NEUROSCI, V16, P49, DOI 10.1385/JMN:16:1:49; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Khan O, 2008, NAT CLIN PRACT ONCOL, V5, P714, DOI 10.1038/ncponc1238; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; Langley B, 2005, CNS NEUROL DISORD-DR, V4, P41, DOI 10.2174/1568007053005091; Leoni F, 2005, MOL MED, V11, P1, DOI 10.2119/2006-00005.Dinarello; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Moussaieff A, 2008, J CEREBR BLOOD F MET, V28, P1341, DOI 10.1038/jcbfm.2008.28; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; OSBORNE KA, 1987, J NEUROL NEUROSUR PS, V50, P402, DOI 10.1136/jnnp.50.4.402; Perrine SP, 2005, ANN NY ACAD SCI, V1054, P257, DOI 10.1196/annals.1345.033; Petri S, 2006, NEUROBIOL DIS, V22, P40, DOI 10.1016/j.nbd.2005.09.013; Qi X, 2004, MOL PHARMACOL, V66, P899, DOI 10.1124/mol.104.001339; Rouaux C, 2004, BIOCHEM PHARMACOL, V68, P1157, DOI 10.1016/j.bcp.2004.05.035; Rouaux C, 2003, EMBO J, V22, P6537, DOI 10.1093/emboj/cdg615; Ryu H, 2005, J NEUROCHEM, V93, P1087, DOI 10.1111/j.1471-4159.2005.03077.x; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Saha RN, 2006, CELL DEATH DIFFER, V13, P539, DOI 10.1038/sj.cdd.4401769; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006; Thomas EA, 2008, P NATL ACAD SCI USA, V105, P15564, DOI 10.1073/pnas.0804249105; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Vojinovic J, 2008, ARTHRITIS RHEUM-US, V58, pS943; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Ying MY, 2006, J BIOL CHEM, V281, P12580, DOI 10.1074/jbc.M511677200; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085	51	81	82	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4266	4275		10.1096/fj.09-134700	http://dx.doi.org/10.1096/fj.09-134700			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	19723705	Green Published			2022-12-28	WOS:000272193700021
J	Melzer, N; Meuth, SG; Wiendl, H				Melzer, Nico; Meuth, Sven G.; Wiendl, Heinz			CD8(+) T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability	FASEB JOURNAL			English	Review						CNS inflammation; oligodendrocyte death; neuronal degeneration; demyelination; axonal damage; immunological synapse	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; PARANEOPLASTIC CEREBELLAR DEGENERATION; MULTIPLE-SCLEROSIS LESIONS; AMYOTROPHIC-LATERAL-SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PIG VENTRICULAR MYOCYTES; INFLAMMATORY DEMYELINATING DISEASES; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RESTRICTED CROSS-PRESENTATION	Cytotoxic CD8(+) T cells are increasingly recognized as key players in various inflammatory and degenerative central nervous system (CNS) disorders. CD8(+) T cells are believed to actively contribute to neural damage in these CNS conditions. Conceptually, one can separate two possible ways that CD8(+) T cells harm neuronal function or integrity: CD8(+) T cells either directly target neurons and their neurites in an antigen-or contact-dependent fashion, or exert their action via "collateral" mechanisms of neuronal damage that might follow destruction of the myelin sheath or glial cells in both the CNS gray and white matter. After introducing clinical examples, in which the putative relevance CD8(+) T cells has been demonstrated, we summarize knowledge on the sequence of initiation and execution of CD8(+) T-cell responses in the CNS. This includes the initial antigen cross-presentation and priming of naive CD8(+) T cells, followed by the invasion, migration, and target-cell recognition of CD8(+) effector T cells in the CNS parenchyma. Moreover, we discuss mechanisms of impaired electrical signaling and cell death of neurons as direct and collateral targets of CD8(+) T cells in the CNS.-Melzer, N., Meuth, S. G., and Wiendl, H. CD8(+) T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. FASEB J. 23, 3659-3673 (2009). www.fasebj.org	[Melzer, Nico; Meuth, Sven G.; Wiendl, Heinz] Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany	University of Wurzburg	Melzer, N (corresponding author), Univ Wurzburg, Dept Neurol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.	melzer_n1@klinik.uni-wuerzburg.de; heinz.wiendl@klinik.uni-wuerzburg.de	Wiendl, Heinz/AAX-6041-2021; Meuth, Sven G/HHM-8941-2022; Melzer, Nico/HGE-2991-2022	Meuth, Sven G/0000-0003-2571-3501; Melzer, Nico/0000-0002-2420-701X; Wiendl, Heinz/0000-0003-4310-3432	Interdisciplinary Center for Clinical Research Wurzburg [IZKF Z-3/4, IZKF A54-1]; German Research Foundation [SFB581, TP A8]	Interdisciplinary Center for Clinical Research Wurzburg; German Research Foundation(German Research Foundation (DFG))	Research of the authors is supported by the Interdisciplinary Center for Clinical Research Wurzburg (IZKF Z-3/4 to N.M. and H. W.; IZKF A54-1 to S. G. M. and H. W.), and the German Research Foundation (SFB581, TP A8, to H. W).	ACHIM CL, 1992, J NEUROPATH EXP NEUR, V51, P257, DOI 10.1097/00005072-199205000-00003; Ackerman AL, 2004, NAT IMMUNOL, V5, P678, DOI 10.1038/ni1082; Ahmed Z, 2002, AM J PATHOL, V161, P1577, DOI 10.1016/S0002-9440(10)64436-7; Albert ML, 2004, NAT REV CANCER, V4, P36, DOI 10.1038/nrc1255; Albert ML, 1998, NAT MED, V4, P1321, DOI 10.1038/3315; Albert ML, 2000, ANN NEUROL, V47, P9; Anderton SM, 2008, CURR OPIN NEUROL, V21, P248, DOI 10.1097/WCO.0b013e3282febf58; Appay V, 2007, J IMMUNOL, V179, P7406, DOI 10.4049/jimmunol.179.11.7406; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Bacso Z, 1996, IMMUNOL LETT, V51, P175, DOI 10.1016/0165-2478(96)02573-4; Baldwin RL, 1996, P NATL ACAD SCI USA, V93, P1021, DOI 10.1073/pnas.93.3.1021; Bauer J, 1998, AM J PATHOL, V153, P715, DOI 10.1016/S0002-9440(10)65615-5; Bauer J, 2007, ANN NEUROL, V62, P67, DOI 10.1002/ana.21148; Beauvillain C, 2008, GLIA, V56, P69, DOI 10.1002/glia.20565; Becher B, 2006, J MOL MED, V84, P532, DOI 10.1007/s00109-006-0065-1; Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S; Bene L, 1997, CYTOMETRY, V27, P353, DOI 10.1002/(SICI)1097-0320(19970401)27:4<353::AID-CYTO6>3.0.CO;2-D; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Bien CG, 2002, ANN NEUROL, V51, P311, DOI 10.1002/ana.10100; Binah O, 2002, J MOL CELL CARDIOL, V34, P1147, DOI 10.1006/jmcc.2002.2056; BINAH O, 1994, J PHARMACOL EXP THER, V268, P1581; Binah O, 2001, J CARDIOVASC PHARM, V38, P298, DOI 10.1097/00005344-200108000-00016; BINAH O, 1992, PFLUG ARCH EUR J PHY, V420, P172, DOI 10.1007/BF00374987; Bitsch A, 2000, BRAIN, V123, P1174, DOI 10.1093/brain/123.6.1174; Bo L, 2003, MULT SCLER, V9, P323, DOI 10.1191/1352458503ms917oa; BOOSS J, 1983, J NEUROL SCI, V62, P219, DOI 10.1016/0022-510X(83)90201-0; Boulanger LM, 2004, NAT REV NEUROSCI, V5, P521, DOI 10.1038/nrn1428; Boulanger LM, 2001, CURR OPIN NEUROBIOL, V11, P568, DOI 10.1016/S0959-4388(00)00251-8; Breart B, 2008, J CLIN INVEST, V118, P1390, DOI 10.1172/JCI34388; Brisebois M, 2006, J IMMUNOL, V177, P2403, DOI 10.4049/jimmunol.177.4.2403; Brochard V, 2009, J CLIN INVEST, V119, P182, DOI 10.1172/JCI36470; Buzza MS, 2006, BIOL CHEM, V387, P827, DOI 10.1515/BC.2006.106; Calzascia T, 2005, IMMUNITY, V22, P175, DOI 10.1016/j.immuni.2004.12.008; Calzascia T, 2003, J IMMUNOL, V171, P2187, DOI 10.4049/jimmunol.171.5.2187; Carbone FR, 1998, IMMUNOL TODAY, V19, P368, DOI 10.1016/S0167-5699(98)01301-2; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Carpenter EL, 2008, J NEUROIMMUNOL, V193, P173, DOI 10.1016/j.jneuroim.2007.10.014; Choi C, 2004, BRAIN RES REV, V44, P65, DOI 10.1016/j.brainresrev.2003.08.007; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; Das A, 2008, J NEUROSCI RES, V86, P2992, DOI 10.1002/jnr.21737; de Berg PJV, 2008, CURR OPIN IMMUNOL, V20, P339, DOI 10.1016/j.coi.2008.03.007; Dustin ML, 1997, P NATL ACAD SCI USA, V94, P3909, DOI 10.1073/pnas.94.8.3909; Esser MT, 1998, J EXP MED, V187, P1057, DOI 10.1084/jem.187.7.1057; Evans CF, 1996, J EXP MED, V184, P2371, DOI 10.1084/jem.184.6.2371; Felzen B, 1998, CIRC RES, V82, P438, DOI 10.1161/01.RES.82.4.438; FELZEN B, 1994, CARDIOVASC RES, V28, P643, DOI 10.1093/cvr/28.5.643; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Flugel A, 2007, J NEUROIMMUNOL, V191, P86, DOI 10.1016/j.jneuroim.2007.09.017; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; Ford ML, 2005, EUR J IMMUNOL, V35, P76, DOI 10.1002/eji.200425660; FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909; Friese MA, 2005, BRAIN, V128, P1747, DOI 10.1093/brain/awh578; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; Galea I, 2007, J EXP MED, V204, P2023, DOI 10.1084/jem.20070064; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; Garg SK, 2008, J IMMUNOL, V180, P3866, DOI 10.4049/jimmunol.180.6.3866; Giometto B, 1997, NEUROPATH APPL NEURO, V23, P468, DOI 10.1046/j.1365-2990.1997.00078.x; Giuliani F, 2003, J IMMUNOL, V171, P368, DOI 10.4049/jimmunol.171.1.368; GOBEL K, 2009, 8 M GERM NEUR SOC 20; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; Guyton MK, 2005, J NEUROSCI RES, V81, P53, DOI 10.1002/jnr.20470; HAHN S, 1995, IMMUNOL REV, V146, P57, DOI 10.1111/j.1600-065X.1995.tb00684.x; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; HAUSER SL, 1986, ANN NEUROL, V19, P578, DOI 10.1002/ana.410190610; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; Hobom M, 2004, BRAIN PATHOL, V14, P148, DOI 10.1111/j.1750-3639.2004.tb00047.x; Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768; Hoftberger R, 2004, BRAIN PATHOL, V14, P43; Holmoy T, 2008, EUR J NEUROL, V15, P360, DOI 10.1111/j.1468-1331.2008.02065.x; Howe CL, 2007, NEUROBIOL DIS, V25, P354, DOI 10.1016/j.nbd.2006.10.001; Huse M, 2008, NAT IMMUNOL, V9, P1105, DOI 10.1038/ni.f.215; Huseby ES, 2001, J EXP MED, V194, P669, DOI 10.1084/jem.194.5.669; Ip CW, 2006, J NEUROSCI, V26, P8206, DOI 10.1523/JNEUROSCI.1921-06.2006; ISAAZ S, 1995, EUR J IMMUNOL, V25, P1071, DOI 10.1002/eji.1830250432; ITAGAKI S, 1988, NEUROSCI LETT, V91, P259, DOI 10.1016/0304-3940(88)90690-8; Johnson AJ, 2001, FASEB J, V15, P2760, DOI 10.1096/fj.01-0373fje; KAGAN BL, 1992, SCIENCE, V255, P1427, DOI 10.1126/science.1371890; KAGAN BL, 1993, ANN NY ACAD SCI, V707, P317, DOI 10.1111/j.1749-6632.1993.tb38062.x; KAGEYAMA S, 1995, J IMMUNOL, V154, P567; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; Kataoka T, 1997, IMMUNOLOGY, V91, P493, DOI 10.1046/j.1365-2567.1997.00257.x; KATAOKA T, 1994, J IMMUNOL, V153, P3938; Kataoka T, 1996, J IMMUNOL, V156, P3678; Kawakami N, 2005, J EXP MED, V201, P1805, DOI 10.1084/jem.20050011; KAWAMATA T, 1992, AM J PATHOL, V140, P691; Kessler B, 1998, J IMMUNOL, V161, P6939; Koller H, 1997, PROG NEUROBIOL, V52, P1, DOI 10.1016/S0301-0082(96)00065-2; Koning N, 2007, ANN NEUROL, V62, P504, DOI 10.1002/ana.21220; Kuhlmann T, 2002, BRAIN, V125, P2202, DOI 10.1093/brain/awf235; Kuhn JR, 2002, IMMUNITY, V16, P111, DOI 10.1016/S1074-7613(02)00262-5; Kurts C, 1997, J EXP MED, V186, P2057, DOI 10.1084/jem.186.12.2057; Kurts C, 1998, J EXP MED, V188, P409, DOI 10.1084/jem.188.2.409; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; Kwidzinski E, 2005, FASEB J, V19, P1347, DOI 10.1096/fj.04-3228fje; Lafon M, 2008, J IMMUNOL, V180, P7506, DOI 10.4049/jimmunol.180.11.7506; Li G, 2005, TRENDS MOL MED, V11, P350, DOI 10.1016/j.molmed.2005.06.009; Li Y, 1997, J IMMUNOL, V158, P1428; Liu YW, 2006, NAT MED, V12, P518, DOI 10.1038/nm1402; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Magnus T, 2005, J NEUROSCI, V25, P2537, DOI 10.1523/JNEUROSCI.4794-04.2005; Malipiero U, 1999, EUR J IMMUNOL, V29, P3053, DOI 10.1002/(SICI)1521-4141(199910)29:10<3053::AID-IMMU3053>3.0.CO;2-I; Malmestrom C, 2008, J NEUROIMMUNOL, V196, P159, DOI 10.1016/j.jneuroim.2008.03.001; MANNING PT, 1987, AM J PATHOL, V128, P395; MATTER A, 1979, IMMUNOLOGY, V36, P179; McGavern DB, 2002, NAT IMMUNOL, V3, P918, DOI 10.1038/ni843; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; McLaughlin KA, 2008, ADV IMMUNOL, V98, P121, DOI 10.1016/S0065-2776(08)00404-5; McPherson SW, 2006, GLIA, V53, P457, DOI 10.1002/glia.20298; Medana I, 2001, AM J PATHOL, V159, P809, DOI 10.1016/S0002-9440(10)61755-5; Medana I, 2001, J IMMUNOL, V167, P674, DOI 10.4049/jimmunol.167.2.674; Medana IM, 2000, EUR J IMMUNOL, V30, P3623, DOI 10.1002/1521-4141(200012)30:12<3623::AID-IMMU3623>3.0.CO;2-F; Merkler D, 2006, J CLIN INVEST, V116, P1254, DOI 10.1172/JCI27372; MEUTH SG, 2008, 6 FENS FOR EUR NEUR; Meuth SG, 2008, J NEUROIMMUNOL, V194, P62, DOI 10.1016/j.jneuroim.2007.11.013; Meyer R, 2001, J NEUROSCI, V21, P6214, DOI 10.1523/JNEUROSCI.21-16-06214.2001; Mizuno T, 2008, FASEB J, V22, P1797, DOI 10.1096/fj.07-099499; Moll NM, 2008, NEUROLOGY, V70, P336, DOI 10.1212/01.wnl.0000284601.54436.e4; Mott RT, 2004, GLIA, V46, P369, DOI 10.1002/glia.20009; Mrass P, 2006, J EXP MED, V203, P2749, DOI 10.1084/jem.20060710; Murray PD, 1998, J NEUROSCI, V18, P7306; Na SY, 2008, BRAIN, V131, P2353, DOI 10.1093/brain/awn148; Neijssen J, 2005, NATURE, V434, P83, DOI 10.1038/nature03290; Neumann H, 1998, P NATL ACAD SCI USA, V95, P5779, DOI 10.1073/pnas.95.10.5779; Neumann H, 1997, J EXP MED, V185, P305, DOI 10.1084/jem.185.2.305; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; Ng LG, 2008, IMMUNOL REV, V221, P147, DOI 10.1111/j.1600-065X.2008.00596.x; Nitsch R, 2004, J NEUROSCI, V24, P2458, DOI 10.1523/JNEUROSCI.4703-03.2004; Ortler S, 2008, EUR J IMMUNOL, V38, P1734, DOI 10.1002/eji.200738071; Panzara MA, 1999, NEUROBIOL DIS, V6, P392, DOI 10.1006/nbdi.1999.0252; Perez-Liz G, 2008, ANN NEUROL, V64, P379, DOI 10.1002/ana.21443; PERSECHINI PM, 1990, J CELL BIOL, V110, P2109, DOI 10.1083/jcb.110.6.2109; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Petito CK, 2006, J NEUROVIROL, V12, P272, DOI 10.1080/13550280600879204; Petito CK, 2003, J NEUROVIROL, V9, P36, DOI 10.1080/13550280390173391; Pipkin ME, 2007, CURR OPIN IMMUNOL, V19, P301, DOI 10.1016/j.coi.2007.04.011; POENIE M, 1987, EMBO J, V6, P2223, DOI 10.1002/j.1460-2075.1987.tb02494.x; Purbhoo MA, 2004, NAT IMMUNOL, V5, P524, DOI 10.1038/ni1058; Ransohoff RM, 2003, NAT REV IMMUNOL, V3, P569, DOI 10.1038/nri1130; RensingEhl A, 1996, EUR J IMMUNOL, V26, P2271, DOI 10.1002/eji.1830260945; Rivera-Quinones C, 1998, NAT MED, V4, P187, DOI 10.1038/nm0298-187; ROTHSTEIN TL, 1978, J IMMUNOL, V121, P1652; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; Sanchez-Ruiz M, 2008, J IMMUNOL, V180, P8421, DOI 10.4049/jimmunol.180.12.8421; Saxena A, 2008, J IMMUNOL, V181, P1617, DOI 10.4049/jimmunol.181.3.1617; SCHMIED M, 1993, AM J PATHOL, V143, P446; Schwab N, 2009, BRAIN, V132, P1236, DOI 10.1093/brain/awp003; Seder RA, 2003, NAT IMMUNOL, V4, P835, DOI 10.1038/ni969; Shilkrut M, 2001, J CARDIOVASC ELECTR, V12, P185, DOI 10.1046/j.1540-8167.2001.00185.x; Shriver LP, 2006, AM J PATHOL, V169, P999, DOI 10.2353/ajpath.2006.050791; Spaeny-Dekking EHA, 1998, J IMMUNOL, V160, P3610; Stadelmann C, 2008, CURR OPIN NEUROL, V21, P229, DOI 10.1097/01.wco.0000318863.65635.9a; Stinchcombe JC, 2007, ANNU REV CELL DEV BI, V23, P495, DOI 10.1146/annurev.cellbio.23.090506.123521; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Sun DM, 2001, J IMMUNOL, V166, P7579, DOI 10.4049/jimmunol.166.12.7579; Sutton IJ, 2004, J NEUROIMMUNOL, V150, P98, DOI 10.1016/j.jneuroim.2003.12.026; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; TAKAHASHI K, 1991, EUR J IMMUNOL, V21, P1559, DOI 10.1002/eji.1830210634; TAKAHASHI Y, 2009, EPILEPSIA, DOI DOI 10.1111/J.1528-1167.2008.01977; Tanaka M, 1999, J NEUROL SCI, V168, P28, DOI 10.1016/S0022-510X(99)00163-X; Tanaka M, 1998, J NEUROL SCI, V161, P88, DOI 10.1016/S0022-510X(98)00257-3; Town T, 2005, NEUROMOL MED, V7, P255, DOI 10.1385/NMM:7:3:255; Trajkovic V, 2004, GLIA, V47, P168, DOI 10.1002/glia.20046; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538; TROOST D, 1990, NEUROPATH APPL NEURO, V16, P401, DOI 10.1111/j.1365-2990.1990.tb01276.x; Vanderlugt CL, 2002, NAT REV IMMUNOL, V2, P85, DOI 10.1038/nri724; VASS K, 1990, AM J PATHOL, V137, P789; Verschuuren J, 1996, ACTA NEUROPATHOL, V91, P519, DOI 10.1007/s004010050460; Walter L, 2007, J IMMUNOL, V178, P6038, DOI 10.4049/jimmunol.178.10.6038; Wang WW, 2008, GLIA, V56, P241, DOI 10.1002/glia.20609; Waterhouse NJ, 2006, J CELL BIOL, V173, P133, DOI 10.1083/jcb.200510072; WHITE FA, 1992, J VIROL, V66, P5726, DOI 10.1128/JVI.66.10.5726-5734.1992; Wiedemann A, 2006, P NATL ACAD SCI USA, V103, P10985, DOI 10.1073/pnas.0600651103; Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6; Wuthrich C, 2006, J NEUROVIROL, V12, P116, DOI 10.1080/13550280600716604; YOUNG JDE, 1986, P NATL ACAD SCI USA, V83, P150, DOI 10.1073/pnas.83.1.150; Zhu B, 2003, AM J PATHOL, V162, P1639, DOI 10.1016/S0002-9440(10)64298-8; Zozulya AL, 2008, HUM IMMUNOL, V69, P797, DOI 10.1016/j.humimm.2008.07.014	181	63	65	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2009	23	11					3659	3673		10.1096/fj.09-136200	http://dx.doi.org/10.1096/fj.09-136200			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19567369	Bronze			2022-12-28	WOS:000271272500004
J	Filtz, TM; Grubb, DR; McLeod-Dryden, TJ; Luo, JT; Woodcock, EA				Filtz, Theresa M.; Grubb, David R.; McLeod-Dryden, Tiffany J.; Luo, Jieting; Woodcock, Elizabeth A.			Gq-initiated cardiomyocyte hypertrophy is mediated by phospholipase C beta 1b	FASEB JOURNAL			English	Article						adenovirus; inhibitory minigene; splice variant; alpha(1)-adrenergci receptor; sarcolemmal localization	NEONATAL-RAT CARDIOMYOCYTES; CARDIAC-HYPERTROPHY; PRESSURE-OVERLOAD; MYOCARDIAL HYPERTROPHY; MYOCYTE HYPERTROPHY; SIGNALING PATHWAYS; HEART-FAILURE; G-PROTEINS; RECEPTOR; GROWTH	Activation of the heterotrimeric G protein Gq causes cardiomyocyte hypertrophy in vivo and in cell culture models. Hypertrophic responses induced by pressure or volume overload are exacerbated by increased Gq activity and ameliorated by Gq inhibition. Gq activates phospholipase C beta (PLC beta) subtypes, resulting in generation of the intracellular messengers inositol(1,4,5)tris-phosphate [Ins(1,4,5)P-3] and sn-1,2-diacylglycerol (DAG), which regulate intracellular Ca2+ and conventional protein kinase C subtypes, respectively. Gq can also signal independently of PLC beta, and the involvement of either Ins(1,4,5)P-3 or DAG in cardiomyocyte hypertrophy has not been unequivocally established. Overexpression of one splice variant of PLC beta 1, specifically PLC beta 1b, in neonatal rat cardiomyocytes causes increased cell size, elevated protein/DNA ratio, and heightened expression of the hypertrophy-related marker gene, atrial natriuretic peptide. The other splice variant, PLC beta 1a, had no effect. Expression of a 32-aa C-terminal PLC beta 1b peptide, which competes with PLC beta 1b for sarcolemmal association, prevented PLC activation and eliminated hypertrophic responses initiated by Gq or Gq-coupled alpha(1)-adrenergic receptors. In contrast, a PLC beta(1)a C-terminal peptide altered neither PLC activity nor cellular hypertrophy. We conclude that hypertrophic responses initiated by Gq are mediated specifically by PLC beta 1b. Preventing PLC beta 1b association with the sarcolemma may provide a useful therapeutic target to limit hypertrophy.-Filtz, T. M., Grubb, D. R., McLeod-Dryden, T. J., Luo, J., Woodcock, E. A. Gq-initiated cardiomyocyte hypertrophy is mediated by phospholipase C beta 1b. FASEB J. 23, 3564-3570 (2009). www.fasebj.org	[Filtz, Theresa M.; Grubb, David R.; McLeod-Dryden, Tiffany J.; Luo, Jieting; Woodcock, Elizabeth A.] Baker IDI Heart & Diabet Inst, Mol Cardiol Lab, Melbourne, Vic 8008, Australia	Baker Heart and Diabetes Institute	Woodcock, EA (corresponding author), Baker IDI Heart & Diabet Inst, Mol Cardiol Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	woodcock@bakeridi.edu.au		Filtz, Theresa/0000-0002-5348-1114	Australian National Health and Medical Research Council [526623, 418935]; Australian National Heart Foundation [G 08M 3695];  [417803]	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian National Heart Foundation(National Heart Foundation of Australia); 	This work was supported by grants from the Australian National Health and Medical Research Council (526623 and 418935) and the Australian National Heart Foundation (G 08M 3695), as well as a research fellowship (417803) to E. A. W.	Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Arthur JF, 2001, J BIOL CHEM, V276, P37341, DOI 10.1074/jbc.M106572200; BAHK YY, 1994, J BIOL CHEM, V269, P8240; Bare DJ, 2005, J BIOL CHEM, V280, P15912, DOI 10.1074/jbc.M414212200; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Bush EW, 2006, J BIOL CHEM, V281, P33487, DOI 10.1074/jbc.M605536200; CannonCarlson S, 1997, ANAL BIOCHEM, V246, P146, DOI 10.1006/abio.1997.2002; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Esposito G., 2001, CARDIOVASC RES, V50, P65; Estacion M, 2004, J BIOL CHEM, V279, P22047, DOI 10.1074/jbc.M402320200; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Fan GF, 2005, J BIOL CHEM, V280, P40337, DOI 10.1074/jbc.M506810200; Fielitz J, 2008, P NATL ACAD SCI USA, V105, P3059, DOI 10.1073/pnas.0712265105; Grubb DR, 2008, FASEB J, V22, P2768, DOI 10.1096/fj.07-102558; Hardie RC, 2003, ANNU REV PHYSIOL, V65, P735, DOI 10.1146/annurev.physiol.65.092101.142505; Hines WA, 1998, J MOL CELL CARDIOL, V30, P485, DOI 10.1006/jmcc.1997.0613; Kovarova M, 2001, MOL CELL BIOL, V21, P8318, DOI 10.1128/MCB.21.24.8318-8328.2001; Kuwahara K, 2006, J CLIN INVEST, V116, P3114, DOI 10.1172/JCI27702; Lorell BH, 1997, CIRCULATION, V96, P3824; Lutz S, 2005, J BIOL CHEM, V280, P11134, DOI 10.1074/jbc.M411322200; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Morris JB, 2006, J MOL CELL CARDIOL, V41, P17, DOI 10.1016/j.yjmcc.2006.03.011; Morris JB, 2004, J BIOL CHEM, V279, P8740, DOI 10.1074/jbc.M310012200; Niizeki T, 2008, AM J PHYSIOL-HEART C, V295, pH245, DOI 10.1152/ajpheart.00066.2008; Niizeki T, 2008, CIRC J, V72, P309, DOI 10.1253/circj.72.309; Nishimaru K, 2008, J MOL CELL CARDIOL, V44, P520, DOI 10.1016/j.yjmcc.2007.12.007; Onohara N, 2006, EMBO J, V25, P5305, DOI 10.1038/sj.emboj.7601417; Paradis P, 2000, P NATL ACAD SCI USA, V97, P931, DOI 10.1073/pnas.97.2.931; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pham TM, 2003, J MOL CELL CARDIOL, V35, P287, DOI 10.1016/S0022-2828(03)00009-9; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rojas RJ, 2007, J BIOL CHEM, V282, P29201, DOI 10.1074/jbc.M703458200; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; Thomas WG, 2002, CIRC RES, V90, P135, DOI 10.1161/hh0202.104109; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Wang H, 2005, CIRC RES, V97, P1305, DOI 10.1161/01.RES.0000196578.15385.bb; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Woodcock EA, 1997, MOL CELL BIOCHEM, V172, P121, DOI 10.1023/A:1006871722652; WU D, 1992, J BIOL CHEM, V25, P1811; Wu X, 2006, J CLIN INVEST, V116, P675, DOI 10.1172/JCI27374; Xu AM, 2001, MOL CELL BIOL, V21, P2981, DOI 10.1128/MCB.21.9.2981-2990.2001	49	61	62	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3564	3570		10.1096/fj.09-133983	http://dx.doi.org/10.1096/fj.09-133983			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19564249				2022-12-28	WOS:000270354300032
J	Pant, K; Watt, J; Greenberg, M; Jones, M; Szczesna-Cordary, D; Moore, JR				Pant, Kiran; Watt, James; Greenberg, Michael; Jones, Michelle; Szczesna-Cordary, Danuta; Moore, Jeffrey R.			Removal of the cardiac myosin regulatory light chain increases isometric force production	FASEB JOURNAL			English	Article						lever arm; in vitro motility assay; optical trapping; flexibility	COILED-COIL; LEVER ARM; CONFORMATIONAL-CHANGES; MOLECULAR MOTOR; SCALLOP MYOSIN; CROSS-BRIDGE; NECK REGION; DOMAIN; ACTIN; GENERATION	The myosin neck, which is supported by the interactions between light chains and the underlying alpha-helical heavy chain, is thought to act as a lever arm to amplify movements originating in the globular motor domain. Here, we studied the role of the cardiac myosin regulatory light chains (RLCs) in the capacity of myosin to produce force using a novel optical-trap-based isometric force in vitro motility assay. We measured the isometric force and actin filament velocity for native porcine cardiac (PC) myosin, RLC-depleted PC (PCdepl) myosin, and PC myosin reconstituted with recombinant bacterially expressed human cardiac RLC (PCrecon). RLC depletion reduced unloaded actin filament velocity by 58% and enhanced the myosin-based isometric force similar to 2-fold. No significant change between PC and PCdepl preparations was observed in the maximal rate of actin-activated myosin ATPase activity. Reconstitution of PCdepl myosin with human RLC partially restored the velocity and force levels to near untreated values. The reduction in unloaded velocity after RLC extraction is consistent with the myosin neck acting as a lever, while the enhancement in isometric force can be directly related to enhancement of unitary force. The force data are consistent with a model in which the neck region behaves as a cantilevered beam.-Pant, K., Watt, J., Greenberg, M., Jones, M., Szczesna-Cordary, D., Moore, J. R. Removal of the cardiac myosin regulatory light chain increases isometric force production. FASEB J. 23, 3571-3580 (2009). www.fasebj.org	[Pant, Kiran; Watt, James; Greenberg, Michael; Moore, Jeffrey R.] Boston Univ, Dept Physiol & Biophys, Sch Med, Boston, MA 02118 USA; [Jones, Michelle; Szczesna-Cordary, Danuta] Univ Miami, L Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL USA	Boston University; University of Miami	Moore, JR (corresponding author), Boston Univ, Dept Physiol & Biophys, Sch Med, L-720,72 E Concord St, Boston, MA 02118 USA.	jxmoore@bu.edu		Moore, Jeffrey/0000-0001-7190-9332; Greenberg, Michael/0000-0003-1320-3547	National Institute of Health (NIH); American Heart Association (AHA) [NIH-HL077280, AHA-0435434T, AHA-0815704D, NIH-HL071778]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077280, R01HL071778] Funding Source: NIH RePORTER	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association (AHA)(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Tanya Mealy for help with the estimation of myosin on the bead surface. We also thank Dr. Katarzyna Kazmierczak for the contribution to actin-activated myosin ATPase assays. This work was supported by National Institute of Health (NIH) and American Heart Association (AHA) grants NIH-HL077280 and AHA-0435434T (to J.M.), AHA-0815704D (to M. G.), and NIH-HL071778 ( to D.S.-C.).	Baker JE, 1998, P NATL ACAD SCI USA, V95, P2944, DOI 10.1073/pnas.95.6.2944; Bing W, 2000, BIOCHEM J, V350, P693, DOI 10.1042/0264-6021:3500693; Corrie JET, 1999, NATURE, V400, P425, DOI 10.1038/22704; Dobbie I, 1998, NATURE, V396, P383, DOI 10.1038/24647; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Drabikowski W, 1964, BIOCH MUSCLE CONTRAC, P125; Fiske CH, 1925, J BIOL CHEM, V66, P375; Greenberg MJ, 2009, J MOL CELL CARDIOL, V46, P108, DOI 10.1016/j.yjmcc.2008.09.126; Hao YD, 2006, BIOPHYS J, V91, P4500, DOI 10.1529/biophysj.106.088492; HOFMANN PA, 1990, J GEN PHYSIOL, V95, P477, DOI 10.1085/jgp.95.3.477; Howard J, 1996, Proc Natl Acad Sci U S A, V93, P4462; Howard J., 2001, MECH MOTOR PROTEINS; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; Irving M, 2000, NAT STRUCT BIOL, V7, P482, DOI 10.1038/75890; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; JANSON LW, 1992, CELL MOTIL CYTOSKEL, V22, P274, DOI 10.1002/cm.970220407; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Jontes JD, 1997, J CELL BIOL, V139, P683, DOI 10.1083/jcb.139.3.683; KIMURA M, 1984, BIOPHYS J, V45, P603, DOI 10.1016/S0006-3495(84)84198-3; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; Kohler J, 2002, P NATL ACAD SCI USA, V99, P3557, DOI 10.1073/pnas.062415899; Li Y, 2003, NATURE, V424, P341, DOI 10.1038/nature01801; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MARGOSSIAN SS, 1987, J MUSCLE RES CELL M, V8, P437, DOI 10.1007/BF01578433; Moore JR, 2004, J MUSCLE RES CELL M, V25, P29, DOI 10.1023/B:JURE.0000021394.48560.71; Moore JR, 2001, J CELL BIOL, V155, P625, DOI 10.1083/jcb.200103128; MOSS RL, 1982, J BIOL CHEM, V257, P8588; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; Root DD, 2006, BIOPHYS J, V90, P2852, DOI 10.1529/biophysj.105.071597; Sakamoto T, 2003, J BIOL CHEM, V278, P29201, DOI 10.1074/jbc.M303662200; Schwaiger I, 2002, NAT MATER, V1, P232, DOI 10.1038/nmat776; Shih WM, 2000, CELL, V102, P683, DOI 10.1016/S0092-8674(00)00090-8; Spink BJ, 2008, NAT STRUCT MOL BIOL, V15, P591, DOI 10.1038/nsmb.1429; Straub F.B., 1942, STUDIES I MED CHEM U, P3; Straussman R, 2007, J MOL BIOL, V366, P1232, DOI 10.1016/j.jmb.2006.11.083; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; Swank DM, 2002, NAT CELL BIOL, V4, P312, DOI 10.1038/ncb776; Szczesna D, 1996, J BIOL CHEM, V271, P5246; Szczesna-Cordary D, 2007, FASEB J, V21, P3974, DOI 10.1096/fj.07-8630com; Taylor J.R., 1997, INTRO ERROR ANAL STU, P181; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; VANBUREN P, 1994, P NATL ACAD SCI USA, V91, P12403, DOI 10.1073/pnas.91.26.12403; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Wang EZ, 1996, ARCH BIOCHEM BIOPHYS, V329, P156, DOI 10.1006/abbi.1996.0204; Warshaw DM, 2000, J BIOL CHEM, V275, P37167, DOI 10.1074/jbc.M006438200; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	52	36	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3571	3580		10.1096/fj.08-126672	http://dx.doi.org/10.1096/fj.08-126672			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19470801	Green Published			2022-12-28	WOS:000270354300033
J	Price, MM; Kapitonov, D; Allegood, J; Milstien, S; Oskeritzian, CA; Spiegel, S				Price, Megan M.; Kapitonov, Dmitri; Allegood, Jeremy; Milstien, Sheldon; Oskeritzian, Carole A.; Spiegel, Sarah			Sphingosine-1-phosphate induces development of functionally mature chymase-expressing human mast cells from hematopoietic progenitors	FASEB JOURNAL			English	Article						tryptase; anaphylatoxin; CCL2; S1P receptors; degranulation; IL-6	FC-EPSILON-RI; CYTOKINE PRODUCTION; SPHINGOSINE 1-PHOSPHATE; RECOMBINANT HUMAN; SERUM-FREE; LYSOPHOSPHATIDIC ACID; HUMAN MACROPHAGES; CA2+ SIGNALS; IN-VITRO; MCT TYPE	Mast cells (MCs) play a critical role in both acute and chronic inflammation and mature in peripheral tissues from bone marrow-derived progenitors that circulate in the blood as immature precursors. MCs developed from cord blood-derived progenitors cultured with stem cell factor (SCF) alone express intragranular tryptase (MC(T)s), the phenotype predominant in the lung. MC progenitors are likely to encounter the serum-borne bioactive sphingolipid metabolite, sphingosine-1-phosphate (S1P), during migration to target tissues. S1P accelerated the development of cord blood-derived MCs (CB-MCs) and strikingly increased the numbers of MC-expressing chymase. These MCs have functional Fc epsilon RIs, and similar to skin MC(TC)s that express both tryptase and chymase, also express CD88 and are activated by anaphylatoxin C5a and the secretagogue compound 48/80. S1P induced release of IL-6, a cytokine known to promote development of functionally mature MC(TC)s, from cord blood cultures containing adherent macrophages, and from highly purified macrophages, but not from macrophage-depleted CB-MCs. In contrast, S1P stimulated secretion of the chemokine, monocyte chemoattractant protein 1 (MCP-1/CCL2), from these macrophage-depleted and purified CB-MCs. These results suggest crucial roles for S1P in regulating development of human MCs and their functions and reveal a complex interplay between macrophages and MC progenitors in the development of mature human MCs.-Price, M. M., Kapitonov, D., Allegood, J., Milstien, S., Oskeritzian, C. A., Spiegel, S. Sphingosine-1-phosphate induces development of functionally mature chymase-expressing human mast cells from hematopoietic progenitors. FASEB J. 23, 3506-3515 (2009). www.fasebj.org	[Price, Megan M.; Kapitonov, Dmitri; Allegood, Jeremy; Milstien, Sheldon; Oskeritzian, Carole A.; Spiegel, Sarah] Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Richmond, VA 23298 USA	Virginia Commonwealth University	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, 1101 E Marshall St,2011 Sanger Hall, Richmond, VA 23298 USA.	sspiegel@vcu.edu		Kapitonov, Dmitri/0000-0001-9177-5239	National Institutes of Health [RO1AI500941, U19AI077435-018690, K01AR053186]; National Institute of Mental Health; NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050094, U19AI077435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR053186] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank the Labor and Delivery team at the VCU Health System for kindly providing us with human umbilical cord blood samples and Amgen (Thousand Oaks, CA, USA) for stem cell factor. We also acknowledge the helpful discussions with Drs. Lawrence Schwartz, Daniel Conrad, and John Ryan. This work was supported by National Institutes of Health grants RO1AI500941 and U19AI077435-018690 (S.S.) and K01AR053186 (C.A.O.), and the Intramural Research Program of the National Institute of Mental Health (S.M.).	Ahn K, 2000, J ALLERGY CLIN IMMUN, V106, P321, DOI 10.1067/mai.2000.108107; Andersen HB, 2008, J IMMUNOL METHODS, V336, P166, DOI 10.1016/j.jim.2008.04.016; Bagga S, 2004, BLOOD, V104, P4080, DOI 10.1182/blood-2004-03-1166; BEAVEN MA, 1983, J PHARMACOL EXP THER, V224, P620; Berdyshev EV, 2005, ANAL BIOCHEM, V339, P129, DOI 10.1016/j.ab.2004.12.006; Caughey GH, 2007, IMMUNOL REV, V217, P141, DOI 10.1111/j.1600-065X.2007.00509.x; Chen CC, 2005, P NATL ACAD SCI USA, V102, P11408, DOI 10.1073/pnas.0504197102; Choi OH, 1996, NATURE, V380, P634; Clair JMS, 2004, J CLIN INVEST, V113, P628, DOI 10.1172/JCI200419062; Conti P, 2002, ALLERGY ASTHMA PROC, V23, P103; CRAIG SS, 1988, LAB INVEST, V58, P682; Dahl C, 2002, J IMMUNOL METHODS, V262, P137, DOI 10.1016/S0022-1759(02)00011-X; Duong CQ, 2004, BBA-MOL CELL BIOL L, V1682, P112; Edsall LC, 1999, ANAL BIOCHEM, V272, P80, DOI 10.1006/abio.1999.4157; Fueller M, 2003, CELL SIGNAL, V15, P367, DOI 10.1016/S0898-6568(02)00117-1; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Hornuss C, 2001, EUR J PHARMACOL, V429, P303, DOI 10.1016/S0014-2999(01)01329-2; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kambe M, 2001, CLIN EXP ALLERGY, V31, P1077, DOI 10.1046/j.1365-2222.2001.01126.x; Kirshenbaum AS, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-45; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; LOWMAN MA, 1988, J ALLERGY CLIN IMMUN, V81, P574, DOI 10.1016/0091-6749(88)90199-6; Maurer M, 2004, NATURE, V432, P512, DOI 10.1038/nature03085; Melendez AJ, 2004, J IMMUNOL, V173, P1596, DOI 10.4049/jimmunol.173.3.1596; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; MITSUI H, 1993, P NATL ACAD SCI USA, V90, P735, DOI 10.1073/pnas.90.2.735; Moon TC, 2003, MOL CELLS, V16, P154; Nishio H, 2005, INT J LEGAL MED, V119, P331, DOI 10.1007/s00414-005-0524-1; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Olivera A, 2006, J BIOL CHEM, V281, P2515, DOI 10.1074/jbc.M508931200; Olivera A, 2008, PROSTAG OTH LIPID M, V86, P1, DOI 10.1016/j.prostaglandins.2008.02.005; Olivera A, 2007, IMMUNITY, V26, P287, DOI 10.1016/j.immuni.2007.02.008; Orinska Z, 2007, NAT MED, V13, P927, DOI 10.1038/nm1615; Oskeritzian CA, 1999, J IMMUNOL, V163, P5105; Oskeritzian CA, 2005, J ALLERGY CLIN IMMUN, V115, P1162, DOI 10.1016/j.jaci.2005.02.022; Oskeritzian CA, 2004, J IMMUNOL, V172, P593, DOI 10.4049/jimmunol.172.1.593; Oskeritzian CA, 2008, BLOOD, V111, P4193, DOI 10.1182/blood-2007-09-115451; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Rivera J, 2008, NAT REV IMMUNOL, V8, P753, DOI 10.1038/nri2400; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Rosen H, 2008, IMMUNOL REV, V223, P221, DOI 10.1111/j.1600-065X.2008.00645.x; Roviezzo F, 2004, P NATL ACAD SCI USA, V101, P11170, DOI 10.1073/pnas.0401439101; Saito H, 1996, J IMMUNOL, V157, P343; Schwartz LB, 2002, CL ALLER IM, V16, P3; Shimizu Y, 2004, CLIN EXP ALLERGY, V34, P917, DOI 10.1111/j.1365-2222.2004.01971.x; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Skeritzian CA, 2007, PHARMACOL THERAPEUT, V115, P390, DOI 10.1016/j.pharmthera.2007.05.011; Sullards MC, 2007, METHOD ENZYMOL, V432, P83, DOI 10.1016/S0076-6879(07)32004-1; Urtz N, 2004, MOL CELL BIOL, V24, P8765, DOI 10.1128/MCB.24.19.8765-8777.2004; Vlasenko LP, 2005, J IMMUNOL, V174, P6456, DOI 10.4049/jimmunol.174.10.6456; Yamaguchi M, 2007, SCAND J IMMUNOL, V65, P581, DOI 10.1111/j.1365-3083.2007.01937.x; Zhao W, 2005, J IMMUNOL, V175, P2635, DOI 10.4049/jimmunol.175.4.2635	54	19	20	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3506	3515		10.1096/fj.08-128900	http://dx.doi.org/10.1096/fj.08-128900			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19535686	Green Published			2022-12-28	WOS:000270354300027
J	Sviderskaya, EV; Easty, DJ; Lawrence, MA; Sanchez, DP; Negulyaev, YA; Patel, RH; Anand, P; Korchev, YE; Bennett, DC				Sviderskaya, Elena V.; Easty, David J.; Lawrence, Mark A.; Sanchez, Daniel P.; Negulyaev, Yuri A.; Patel, Ricken H.; Anand, Praveen; Korchev, Yuri E.; Bennett, Dorothy C.			Functional neurons and melanocytes induced from immortal lines of postnatal neural crest-like stem cells	FASEB JOURNAL			English	Article						determination; differentiation; melanoma; chondrocyte; Schwann cell	FIBROBLAST-GROWTH-FACTOR; ROOT GANGLION NEURONS; MALIGNANT-MELANOMA; MOUSE MELANOCYTES; SENSORY NEURONS; PIGMENT-CELLS; SCHWANN-CELLS; ION-CHANNEL; ADULT SKIN; DIFFERENTIATION	Stem cells, that is, cells that can both reproduce themselves and differentiate into functional cell types, attract much interest as potential aids to healing and disease therapy. Embryonic neural crest is pluripotent and generates the peripheral nervous system, melanocytes, and some connective tissues. Neuralcrest-related stem cells have been reported previously in postnatal skin: committed melanocytic stem cells in the hair follicle, and pluripotent cell types from the hair follicle and papilla that can produce various sets of lineages. Here we describe novel pluripotent neural crest-like stem cells from neonatal mouse epidermis, with different potencies, isolated as 3 independent immortal lines. Using alternative regulatory factors, they could be converted to large numbers of either Schwann precursor cells, pigmented melanocytes, chondrocytes, or functional sensory neurons showing voltage-gated sodium channels. Some of the neurons displayed abundant active TRPV1 and TRPA1 receptors. Such functional neurons have previously been obtained in culture only with difficulty, by explantation. The system was also used to generate comparative gene expression data for the stem cells, melanocytes, and melanoblasts that sufficiently explain the lack of pigment in melanoblasts and provide a rationale for some genes expressed apparently ectopically in melanomas, such as ephrin receptors.-Sviderskaya, E. V., Easty, D. J., Lawrence, M. A., Sanchez, D. P., Negulyaev, Y. A., Patel, R. H., Anand, P., Korchev, Y. E., Bennett, D. C. Functional neurons and melanocytes induced from immortal lines of postnatal neural crest-like stem cells. FASEB J. 23, 3179-3192 ( 2009). www.fasebj.org	[Sviderskaya, Elena V.; Easty, David J.; Lawrence, Mark A.; Patel, Ricken H.; Bennett, Dorothy C.] St Georges Univ London, Div Basic Med Sci, Ctr Mol & Metab Signalling, London SW17 0RE, England; [Sanchez, Daniel P.; Korchev, Yuri E.] Univ London Imperial Coll Sci Technol & Med, Div Med, London Ctr Nanotechnol, London, England; [Negulyaev, Yuri A.] Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia; [Anand, Praveen] Univ London Imperial Coll Sci Technol & Med, Fac Med, Peripheral Neuropathy Unit, London, England	St Georges University London; Imperial College London; University of London; University College London; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; Imperial College London	Sviderskaya, EV (corresponding author), St Georges Univ London, Div Basic Med Sci, Ctr Mol & Metab Signalling, London SW17 0RE, England.	esviders@sgul.ac.uk	Negulyaev, Yuri/N-6531-2015; Bennett, Dorothy C/C-2418-2008; Sviderskaya, Elena V/D-2419-2009; babakinejad, babak/G-2674-2012; Herrera, Daniel P Sanchez/B-5141-2009	Negulyaev, Yuri/0000-0002-1773-9798; Bennett, Dorothy C/0000-0002-3639-7527; Herrera, Daniel P Sanchez/0000-0002-8556-562X; Korchev, Yuri/0000-0002-4872-8696	Wellcome Trust [064583, 078327, 081118]; Centre for Molecular and Metabolic Signaling; Russian Academy of Sciences; BBSRC [BB/D018595/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D018595/1] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Centre for Molecular and Metabolic Signaling; Russian Academy of Sciences(Russian Academy of Sciences); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We are grateful to Simon Hill and Yvette Bland for skilled technical assistance; to many colleagues for cDNA probes ( see Materials and Methods); Vince Hearing ( U. S. National Institutes of Health, Bethesda, MD, USA) for antibodies; Kris Jessen and Rhona Mirsky for valuable discussions; Marcio Hagel-Franco, Matt Todd, Sara Dexter, Rebecca Singleton, Natalie Atherton, Ming Fung, and Angela Brennan for preliminary experiments on NCLSCs; and Lynn Plowright for her contribution to Fig. 2. E. V. S. was supported by Wellcome Trust grants 064583 and 078327 ( Wellcome Trust University Award), M. A. L. by Wellcome Trust grant 081118 ( Student Elective Prize), D. P. S by the Imperial College London/GlaxoSmithKline collaborative program, and Y.A.N. by a grant from the Centre for Molecular and Metabolic Signaling, St. George's, and the Molecular and Cell Biology Program of the Russian Academy of Sciences.	BADER CR, 1983, NATURE, V305, P808, DOI 10.1038/305808a0; Baker MD, 2002, PROG BIOPHYS MOL BIO, V78, P83, DOI 10.1016/S0079-6107(02)00007-X; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Bassi MT, 1996, GENOME RES, V6, P880, DOI 10.1101/gr.6.9.880; Bennett DC, 2003, PIGM CELL RES, V16, P333, DOI 10.1034/j.1600-0749.2003.00067.x; BENNETT DC, 1989, DEVELOPMENT, V105, P379; Carreira S, 1998, MOL CELL BIOL, V18, P5099, DOI 10.1128/MCB.18.9.5099; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cheung M, 2005, DEV CELL, V8, P179, DOI 10.1016/j.devcel.2004.12.010; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; Cook AL, 2003, J INVEST DERMATOL, V121, P1150, DOI 10.1046/j.1523-1747.2003.12562.x; Coste B, 2004, MOL CELL NEUROSCI, V26, P123, DOI 10.1016/j.mcn.2004.01.015; Cummins TR, 1999, J NEUROSCI, V19, DOI 10.1523/JNEUROSCI.19-24-j0001.1999; Dhaka A, 2006, ANNU REV NEUROSCI, V29, P135, DOI 10.1146/annurev.neuro.29.051605.112958; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; Dunn KJ, 2000, P NATL ACAD SCI USA, V97, P10050, DOI 10.1073/pnas.97.18.10050; Easty DJ, 2000, MELANOMA RES, V10, P401, DOI 10.1097/00008390-200010000-00001; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; EISEN T, 1995, ONCOGENE, V11, P2157; Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181; Hagedorn L, 1999, DEVELOPMENT, V126, P3781; HALABAN R, 1984, IN VITRO CELL DEV B, V20, P447; HIROBE T, 1992, DEVELOPMENT, V114, P435; Hornyak TJ, 2000, J INVEST DERMATOL, V115, P106, DOI 10.1046/j.1523-1747.2000.00030.x; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HUSZAR D, 1991, DEVELOPMENT, V112, P131; ITO K, 1984, J EMBRYOL EXP MORPH, V84, P49; Jessen KR, 2002, J ANAT, V200, P367, DOI 10.1046/j.1469-7580.2002.00046.x; Joseph NM, 2004, DEVELOPMENT, V131, P5599, DOI 10.1242/dev.01429; Kawa Y, 2000, PIGM CELL RES, V13, P73, DOI 10.1034/j.1600-0749.13.s8.14.x; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; Kruger GM, 2002, NEURON, V35, P657, DOI 10.1016/S0896-6273(02)00827-9; Le Douarin NM, 2004, DEVELOPMENT, V131, P4637, DOI 10.1242/dev.01350; Le Douarin NM, 1999, NEURAL CREST, V2; LeMaster AM, 1999, J NEUROSCI, V19, P5919, DOI 10.1523/JNEUROSCI.19-14-05919.1999; Lentz SI, 1999, J NEUROSCI, V19, P1038; Maruyama H, 2004, PFLUG ARCH EUR J PHY, V449, P76, DOI 10.1007/s00424-004-1315-0; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; Ono H, 1998, PIGM CELL RES, V11, P291, DOI 10.1111/j.1600-0749.1998.tb00738.x; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Real C, 2006, DEV BIOL, V300, P656, DOI 10.1016/j.ydbio.2006.09.032; RHEINWALD JG, 1975, CELL, V6, P317, DOI 10.1016/0092-8674(75)90183-X; Rush AM, 2007, J PHYSIOL-LONDON, V579, P1, DOI 10.1113/jphysiol.2006.121483; Sanchez-Martin MS, 2003, AM J MED GENET A, V122A, P125, DOI 10.1002/ajmg.a.20345; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Sieber-Blum M, 2004, DEV DYNAM, V231, P258, DOI 10.1002/dvdy.20129; Sieber-Blum M, 2000, INT REV CYTOL, V197, P1, DOI 10.1016/S0074-7696(00)97001-3; SIEBERBLUM M, 1980, DEV BIOL, V80, P96, DOI 10.1016/0012-1606(80)90501-1; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Soriano P, 1997, DEVELOPMENT, V124, P2691; SPANAKIS E, 1992, DEVELOPMENT, V114, P675; Sviderskaya EV, 1998, DEV DYNAM, V213, P452, DOI 10.1002/(SICI)1097-0177(199812)213:4<452::AID-AJA10>3.0.CO;2-6; Sviderskaya EV, 1997, J INVEST DERMATOL, V108, P30, DOI 10.1111/1523-1747.ep12285621; SVIDERSKAYA EV, 1995, DEVELOPMENT, V121, P1547; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; Sviderskaya EV, 2001, DEV DYNAM, V221, P373, DOI 10.1002/dvdy.1153; Sviderskaya EV, 1998, GENETICS, V148, P381; SWOPE VB, 1995, EXP CELL RES, V217, P453, DOI 10.1006/excr.1995.1109; Teng L, 2006, ADV EXP MED BIOL, V589, P206; Vance KW, 2004, PIGM CELL RES, V17, P318, DOI 10.1111/j.1600-0749.2004.00164.x; Weerda HG, 1998, ACTA OTO-LARYNGOL, V118, P337; Wong CE, 2006, J CELL BIOL, V175, P1005, DOI 10.1083/jcb.200606062; Yu H, 2006, AM J PATHOL, V168, P1879, DOI 10.2353/ajpath.2006.051170; Zhang JM, 1997, DEV DYNAM, V208, P375	69	24	24	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3179	3192		10.1096/fj.08-123596	http://dx.doi.org/10.1096/fj.08-123596			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19447881	Green Published, Green Accepted			2022-12-28	WOS:000270241000040
J	Huang, YH; Chin, CC; Ho, HN; Chou, CK; Shen, CN; Kuo, HC; Wu, TJ; Wu, YC; Hung, YC; Chang, CC; Ling, TY				Huang, Yen-Hua; Chin, Cheng-Chieh; Ho, Hong-Nerng; Chou, Chuan-Kai; Shen, Chia-Ning; Kuo, Hung-Chih; Wu, Tsai-Jung; Wu, Yu-Chih; Hung, Yu-Ching; Chang, Chih-Cheng; Ling, Thai-Yen			Pluripotency of mouse spermatogonial stem cells maintained by IGF-1-dependent pathway	FASEB JOURNAL			English	Article						germline stem cells; stem cell-microenvironment interaction; Leydig cells; serum-free culture; cell signaling	PRIMORDIAL GERM-CELLS; IN-VITRO; SELF-RENEWAL; SERUM-FREE; CULTURE; GROWTH; PROLIFERATION; TESTIS; FATE; MICE	Recent studies indicate that neonatal spermatogonial stem cells (SSCs) possess pluripotency. However, the mechanisms that regulate the pluripotent differentiation capacity of SSCs remain unclear. Here, we describe a new method to clonally derive pluripotent SSCs from neonatal mouse testis. By coculturing with testicular stromal cells, SSCs can be maintained and expanded in serum-free conditions. Unlike endogenous SSCs, these in vitro expanded SSCs showed strong alkaline phosphatase (AP) activity and displayed characteristics of embryonic stem cells and primordial germ cells, which were therefore designated as AP(+) germline stem cells (AP(+) GSCs). The pluripotency of AP(+) GSCs was confirmed by in vitro differentiation toward hepatic and neuronal lineages and formation of embryonic chimeras after injection into blastocysts. Further investigation revealed that insulin-like growth factor-1 (IGF-1) secreted from Leydig cells was a key factor involved in maintaining the pluripotency of AP(+) GSCs. The blockage of IGF-1 receptor phosphorylation and its downstream PI3K pathway by PPP or LY294002 dramatically reduced their AP activity and expression of pluripotent genes, such as Oct-4, Blimp1, and Nanog. In conclusion, the present study demonstrated that IGF-1 secreted by testicular Leydig cells plays an important role in maintaining the pluripotency of SSCs in culture, which provides an insight into the molecular mechanism underlying germ cell pluripotency. -Huang, Y.-H., Chin, C.-C., Ho, H.-N., Chou, C.-K., Shen, C.-N., Kuo, H.-C., Wu, T.-J., Wu, Y.-C., Hung, Y.-C., Chang, C.-C., Ling, T.-Y. Pluripotency of mouse spermatogonial stem cells maintained by IGF-1-dependent pathway. FASEB J. 23, 2076-2087 (2009)	[Huang, Yen-Hua; Chin, Cheng-Chieh; Wu, Tsai-Jung; Wu, Yu-Chih; Chang, Chih-Cheng] Taipei Med Univ, Taipei Med Univ Hosp, Dept Biochem, Taipei, Taiwan; [Huang, Yen-Hua; Chin, Cheng-Chieh; Wu, Tsai-Jung; Wu, Yu-Chih; Chang, Chih-Cheng] Taipei Med Univ, Taipei Med Univ Hosp, Sch Med, Grad Inst Med Sci, Taipei, Taiwan; [Huang, Yen-Hua] Taipei Med Univ, Taipei Med Univ Hosp, Ctr Reprod Med, Taipei, Taiwan; [Ho, Hong-Nerng] Natl Taiwan Univ, Coll Med & Hosp, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Taipei 10764, Taiwan; [Ho, Hong-Nerng] Natl Taiwan Univ, Coll Med, Grad Inst Immunol, Taipei 10764, Taiwan; [Ling, Thai-Yen] Natl Taiwan Univ, Coll Med, Inst Pharmacol, Taipei, Taiwan; [Chou, Chuan-Kai; Hung, Yu-Ching] Natl Appl Res Labs, Natl Lab Anim Ctr, Taipei, Taiwan; [Shen, Chia-Ning; Kuo, Hung-Chih] Acad Sinica, Stem Cell Program, Genom Res Ctr, Taipei 115, Taiwan; [Kuo, Hung-Chih] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan; [Shen, Chia-Ning; Wu, Yu-Chih] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan	Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Applied Research Laboratories - Taiwan; Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Defense Medical Center	Huang, YH (corresponding author), Taipei Med Univ, Sch Med, Grad Inst Med Sci, Dept Biochem, Taipei, Taiwan.	rita1204@tmu.edu.tw; tyling@ntu.edu.tw	SHEN, CHIA-NING/C-6878-2011; NTU, Ref07/AAX-7890-2021; Kuo, Hung-Chih/H-7810-2014	SHEN, CHIA-NING/0000-0002-0747-217X; Kuo, Hung-Chih/0000-0003-1336-1203; Wu, Tsai-Jung/0000-0002-4136-7218; Ling, Thai-Yen/0000-0002-3992-883X; Wu, Yu-Chih/0000-0001-5781-2665	National Science Council, Taiwan [NSC93-2311-B-038-006, NSC95-2311B-038-002-MY2, NSC96-3111-B-038-001]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	We thank Professor John Yu at the Stem Cell Program, the Genomics Research Center, Academia Sinica for encouragement and support. We also thank Ping Wu and Shu-Fen Cheng at the Department of Biochemistry and Dr. Chien-Jui Cheng at the Department of Pathology, Graduate Institute of Medical Sciences, Taipei Medical University, for excellent technical support. This work was supported by grants from the National Science Council, Taiwan, NSC93-2311-B-038-006, NSC95-2311B-038-002-MY2, and NSC96-3111-B-038-001.	Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; de Rooij DG, 1998, CURR OPIN CELL BIOL, V10, P694, DOI 10.1016/S0955-0674(98)80109-9; GarciaCastro MI, 1997, J CELL BIOL, V138, P471, DOI 10.1083/jcb.138.2.471; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Guan K, 2006, NATURE, V440, P1199, DOI 10.1038/nature04697; Horii T, 2003, THERIOGENOLOGY, V59, P1257, DOI 10.1016/S0093-691X(02)01166-4; Kanatsu-Shinohara M, 2004, CELL, V119, P1001, DOI 10.1016/j.cell.2004.11.011; Kanatsu-Shinohara M, 2003, BIOL REPROD, V69, P612, DOI 10.1095/biolreprod.103.017012; Kanatsu-Shinohara M, 2005, BIOL REPROD, V72, P985, DOI 10.1095/biolreprod.104.036400; Hamra FK, 2007, J BIOL CHEM, V282, P721, DOI 10.1074/jbc.M608398200; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; KOSHIMIZU U, 1995, DEV BIOL, V168, P683, DOI 10.1006/dbio.1995.1113; Kubota H, 2004, P NATL ACAD SCI USA, V101, P16489, DOI 10.1073/pnas.0407063101; Kubota H, 2004, BIOL REPROD, V71, P722, DOI 10.1095/biolreprod.104.029207; Ling TY, 2006, P NATL ACAD SCI USA, V103, P9530, DOI 10.1073/pnas.0510232103; McLean AB, 2007, STEM CELLS, V25, P29, DOI 10.1634/stemcells.2006-0219; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Moe-Behrens GHG, 2003, MOL ENDOCRINOL, V17, P2630, DOI 10.1210/me.2003-0006; Nagano M, 2003, BIOL REPROD, V68, P2207, DOI 10.1095/biolreprod.102.014050; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Oatley JA, 2008, ANNU REV CELL DEV BI, V24, P263, DOI 10.1146/annurev.cellbio.24.110707.175355; Oatley JM, 2007, J BIOL CHEM, V282, P25842, DOI 10.1074/jbc.M703474200; Oatley JM, 2006, P NATL ACAD SCI USA, V103, P9524, DOI 10.1073/pnas.0603332103; Ohinata Y, 2005, NATURE, V436, P207, DOI 10.1038/nature03813; Pan GJ, 2007, CELL RES, V17, P42, DOI 10.1038/sj.cr.7310125; Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STEVENS LC, 1984, CELL DIFFER DEV, V15, P69, DOI 10.1016/0045-6039(84)90054-X; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Villalpando I, 2008, EXP BIOL MED, V233, P419, DOI 10.3181/0708-RM-212; Watanabe S, 2006, ONCOGENE, V25, P2697, DOI 10.1038/sj.onc.1209307	37	82	86	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2076	2087		10.1096/fj.08-121939	http://dx.doi.org/10.1096/fj.08-121939			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19246485				2022-12-28	WOS:000268836500008
J	Messaoudi, S; Milliez, P; Samuel, JL; Delcayre, C				Messaoudi, Smail; Milliez, Paul; Samuel, Jane-Lise; Delcayre, Claude			Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density	FASEB JOURNAL			English	Article						hormone; VEGFa; oxidative stress; streptozotocin; transgenic animal	ENDOTHELIAL GROWTH-FACTOR; LEFT-VENTRICULAR DYSFUNCTION; MINERALOCORTICOID RECEPTOR; CORONARY DYSFUNCTION; PLASMA-ALDOSTERONE; OXIDATIVE STRESS; SPIRONOLACTONE; FAILURE; CARDIOMYOPATHY; FIBROSIS	Recent reports showed an unexpected worsening of endothelial function by aldosterone antagonism in diabetic patients, suggesting that aldosterone could interfere with the detrimental consequences of diabetes on microvasculature and thus on cardiac function. To test this hypothesis, diabetes (D) was induced using streptozotocin in transgenic (Tg) male mice overexpressing aldosterone-synthase in the heart and in wild-type (Wt) mice. Eight weeks after streptozotocin injection, impairment of left ventricular systolic function, measured by echocardiography (fractional shortening), was accompanied by a decrease in capillaries/ cardiomyocyte ratio (-20%) and VEGFa expression (-40%) in Wt-D mice compared with normoglycemic littermates. Furthermore, Wt-D mice demonstrated an increase in superoxide production (+100%) and protein carbonylation (+33%), hallmarks of oxidative stress. Except for a slight increase in protein carbonylation, all of these diabetes-associated cardiac alterations were undetectable in Tg-D mice. Fibrosis was induced similarly in both diabetic groups. Eplerenone (an aldosterone antagonist) abolished all of the effects of aldosterone-synthase overexpression but had no effect in Wt-D mice. Thus, aldosterone prevents systolic dysfunction through a mineralocorticoid receptor-dependent mechanism that may include preventing VEGFa down-regulation and maintaining capillary density. Understanding how aldosterone prevents VEGFa down-regulation in experimental diabetes could be important to define new strategies targeting the prevention of a decrease in capillary density.-Messaoudi, S., Milliez, P., Samuel, J.-L., Delcayre, C. Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density. FASEB J. 23, 2176-2185 (2009)	[Messaoudi, Smail; Milliez, Paul; Samuel, Jane-Lise; Delcayre, Claude] Hop Lariboisiere, INSERM, U942, F-75010 Paris, France; [Messaoudi, Smail; Samuel, Jane-Lise; Delcayre, Claude] Paris Diderot Univ, Paris, France; [Milliez, Paul] Cote Nacre Univ Hosp, Dept Cardiol, Caen, France; [Samuel, Jane-Lise] Lariboisiere Hosp, Assistance Publ Hop Paris, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CHU de Caen NORMANDIE; Universite de Caen Normandie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite	Delcayre, C (corresponding author), Hop Lariboisiere, INSERM, U942, 41 Blvd Chapelle, F-75010 Paris, France.	claude.delcayre@inserm.fr		Samuel, Jane-Lise/0000-0002-7346-2404	Groupe de Reflexion pour la Recherche Cardiovasculaire; European Section of Aldosterone Council; Groupe Paris Nord Circulation; Fondation de France; CNRS; INSERM	Groupe de Reflexion pour la Recherche Cardiovasculaire; European Section of Aldosterone Council; Groupe Paris Nord Circulation; Fondation de France(Fondation de France); CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	The authors thank Dr Annabel Chen-Tournoux for editorial assistance. This work was supported by the Groupe de Reflexion pour la Recherche Cardiovasculaire, the European Section of Aldosterone Council, The Groupe Paris Nord Circulation, the Fondation de France, the CNRS, and INSERM.	Ambroisine ML, 2007, CIRCULATION, V116, P2435, DOI 10.1161/CIRCULATIONAHA.107.722009; Asbun J, 2006, J AM COLL CARDIOL, V47, P693, DOI 10.1016/j.jacc.2005.09.050; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Beggah AT, 2002, P NATL ACAD SCI USA, V99, P7160, DOI 10.1073/pnas.102673599; Breyer MD, 2005, J AM SOC NEPHROL, V16, P27, DOI [10.1681/ASN.2009070721, 10.1681/ASN.2004080648]; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; CRONIN CC, 1995, DIABETIC MED, V12, P809, DOI 10.1111/j.1464-5491.1995.tb02084.x; Dalle-Donne I, 2006, J CELL MOL MED, V10, P389, DOI 10.1111/j.1582-4934.2006.tb00407.x; Davies JI, 2004, DIABETOLOGIA, V47, P1687, DOI 10.1007/s00125-004-1510-8; DEAZEVEDO MJ, 1995, DIABETES RES CLIN PR, V27, P205, DOI 10.1016/0168-8227(95)01047-H; Delcayre C, 2002, J MOL CELL CARDIOL, V34, P1577, DOI 10.1006/jmcc.2002.2088; Dhalla NS, 1998, CARDIOVASC RES, V40, P239, DOI 10.1016/S0008-6363(98)00186-2; Fang ZY, 2004, ENDOCR REV, V25, P543, DOI 10.1210/er.2003-0012; Fiordaliso F, 2006, LIFE SCI, V79, P121, DOI 10.1016/j.lfs.2005.12.036; Fraccarollo D, 2003, J AM COLL CARDIOL, V42, P1666, DOI 10.1016/j.jacc.2003.05.003; Garnier A, 2004, CIRCULATION, V110, P1819, DOI 10.1161/01.CIR.0000142858.44680.27; Hsueh W, 2007, CIRC RES, V100, P1415, DOI 10.1161/01.RES.0000266449.37396.1f; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; Lai LY, 2007, LIFE SCI, V81, P570, DOI 10.1016/j.lfs.2007.06.025; McQueen AP, 2005, J MOL CELL CARDIOL, V39, P882, DOI 10.1016/j.yjmcc.2005.07.017; Michel F, 2004, CIRCULATION, V109, P1933, DOI 10.1161/01.CIR.0000127112.36796.9B; MICHEL JB, 1988, CIRC RES, V62, P641, DOI 10.1161/01.RES.62.4.641; Milliez P, 2005, EUR HEART J, V26, P2193, DOI 10.1093/eurheartj/ehi478; Miric G, 2001, BRIT J PHARMACOL, V133, P687, DOI 10.1038/sj.bjp.0704131; Nagata K, 2006, HYPERTENSION, V47, P656, DOI 10.1161/01.HYP.0000203772.78696.67; PINTO YM, 1993, CARDIOVASC RES, V27, P1933, DOI 10.1093/cvr/27.11.1933; PITT B, 1995, CARDIOVASC DRUG THER, V9, P145, DOI 10.1007/BF00877755; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Poornima IG, 2006, CIRC RES, V98, P596, DOI 10.1161/01.RES.0000207406.94146.c2; Ratajczak P, 2005, J APPL PHYSIOL, V99, P244, DOI 10.1152/japplphysiol.01292.2004; Reaven GM, 1996, NEW ENGL J MED, V334, P374, DOI 10.1056/NEJM199602083340607; Rocha R, 2002, AM J PHYSIOL-HEART C, V283, pH1802, DOI 10.1152/ajpheart.01096.2001; RUBLER S, 1972, AM J CARDIOL, V30, P595, DOI 10.1016/0002-9149(72)90595-4; Schiffrin EL, 2006, HYPERTENSION, V47, P312, DOI 10.1161/01.HYP.0000201443.63240.a7; SCHUNKERT H, 1993, CARDIOVASC RES, V27, P731, DOI 10.1093/cvr/27.5.731; STAESSEN J, 1981, NEW ENGL J MED, V304, P1110; Stewart RAH, 2008, AM HEART J, V156, P348, DOI 10.1016/j.ahj.2008.03.012; Strauer BE, 1997, DIABETES, V46, pS119, DOI 10.2337/diab.46.2.S119; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Sun Y, 2006, CARDIOVASC RES, V71, P300, DOI 10.1016/j.cardiores.2006.03.007; Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002; Uhrenholt TR, 2004, ACTA PHYSIOL SCAND, V181, P415, DOI 10.1111/j.1365-201X.2004.01313.x; Verma S, 2003, CAN J PHYSIOL PHARM, V81, P493, DOI 10.1139/Y03-041; Virdis A, 2002, HYPERTENSION, V40, P504, DOI 10.1161/01.HYP.0000034738.79310.06; Yoon YS, 2005, CIRCULATION, V111, P2073, DOI 10.1161/01.CIR.0000162472.52990.36; Young M, 2004, ENDOCRINOLOGY, V145, P3153, DOI 10.1210/en.2004-0005	47	25	27	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2009	23	7					2176	2185		10.1096/fj.08-125302	http://dx.doi.org/10.1096/fj.08-125302			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UC	19255254				2022-12-28	WOS:000268836500017
J	West, NP; Chow, FME; Randall, EJ; Wu, J; Chen, J; Ribeiro, JMC; Britton, WJ				West, Nicholas P.; Chow, Frances M. E.; Randall, Elizabeth J.; Wu, Jing; Chen, Jian; Ribeiro, Jose M. C.; Britton, Warwick J.			Cutinase-like proteins of Mycobacterium tuberculosis: characterization of their variable enzymatic functions and active site identification	FASEB JOURNAL			English	Article						secreted enzymes; activity	PATHOGENIC MYCOBACTERIA; EXTRACELLULAR LIPASE; SEQUENCE ALIGNMENT; LIPOLYTIC ENZYMES; CULTURE FILTRATE; BOVIS BCG; PURIFICATION; MACROPHAGES; ESTERASE; DATABASE	Discovery and characterization of novel secreted enzymes of Mycobacterium tuberculosis are important for understanding the pathogenesis of one of the most important human bacterial pathogens. The proteome of M. tuberculosis contains over 400 potentially secreted proteins, the majority of which are uncharacterized. A family of seven cutinase-like proteins (CULPs) was identified by bioinformatic analysis, expressed and purified from Escherichia coli, and characterized in terms of their enzymatic activities. These studies revealed a functional diversity of enzyme classes based on differential preferences for substrate chain length. One member, Culp1, exhibited strong esterase activity, 40-fold higher than that of Culp6, which had strong activity as a lipase. Another, Culp4, performed moderately as an esterase and weakly as a lipase. Culp6 lipase activity was optimal above pH 7.0, and fully maintained to pH 8.5. None of the CULP members exhibited cutinase activity. Site-directed mutagenesis of each residue of the putative catalytic triad in Culp6 confirmed that each was essential for activity toward all fatty acid chain lengths of nitrophenyl esters and lipolytic function. Culp1 and Culp2 were present only in culture supernatants of M. tuberculosis, while Culp6, which is putatively essential for mycobacterial growth, was retained in the cell wall, suggesting the proteins play distinct roles in mycobacterial biology.-West, N. P., Chow, F. M. E., Randall, E. J., Wu, J., Chen, J., Ribeiro, J. M. C., Britton, W. J. Cutinase-like proteins of Mycobacterium tuberculosis: characterization of their variable enzymatic functions and active site identification. FASEB J. 23, 1694-1704 (2009)	[West, Nicholas P.; Chow, Frances M. E.; Randall, Elizabeth J.; Britton, Warwick J.] Centenary Inst Canc Med & Cell Biol, Mycobacterial Res Program, Newtown, NSW 2042, Australia; [Wu, Jing; Chen, Jian] Jiangnan Univ, State Key Lab Food Sci & Technol, Wuxi, Jiangsu, Peoples R China; [Wu, Jing; Chen, Jian] Jiangnan Univ, Sch Biotechnol, Wuxi, Jiangsu, Peoples R China; [Wu, Jing; Chen, Jian] Jiangnan Univ, Key Lab Ind Biotechnol, Wuxi, Jiangsu, Peoples R China; [Ribeiro, Jose M. C.] NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; [Britton, Warwick J.] Univ Sydney, Dept Med, Sydney, NSW 2006, Australia	University of Sydney; Centenary Institute; Jiangnan University; Jiangnan University; Jiangnan University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Sydney	West, NP (corresponding author), Centenary Inst Canc Med & Cell Biol, Mycobacterial Res Program, Locked Bag 6, Newtown, NSW 2042, Australia.	n.west@centenary.org.au	Wu, Jing/GZK-5063-2022; West, Nicholas P/C-3119-2008	West, Nicholas P/0000-0003-0955-9890; Ribeiro, Jose/0000-0002-9107-0818; Britton, Warwick/0000-0001-6721-9646	Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [HHSN266200400091C] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARMSTRONG JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713; Arpigny JL, 1999, BIOCHEM J, V343, P177, DOI 10.1042/0264-6021:3430177; Bach H, 2008, CELL HOST MICROBE, V3, P316, DOI 10.1016/j.chom.2008.03.008; Beatty WL, 2000, INFECT IMMUN, V68, P6997, DOI 10.1128/IAI.68.12.6997-7002.2000; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; Canaan S, 2004, EUR J BIOCHEM, V271, P3953, DOI 10.1111/j.1432-1033.2004.04335.x; Chen S, 2008, J BIOL CHEM, V283, P25854, DOI 10.1074/jbc.M800848200; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Deb C, 2006, J BIOL CHEM, V281, P3866, DOI 10.1074/jbc.M505556200; Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0; Egmond MR, 2000, BIOCHIMIE, V82, P1015, DOI 10.1016/S0300-9084(00)01183-4; FETT WF, 1992, APPL ENVIRON MICROB, V58, P2123, DOI 10.1128/AEM.58.7.2123-2130.1992; Fett WF, 2000, LETT APPL MICROBIOL, V31, P25, DOI 10.1046/j.1472-765X.2000.00752.x; Gupta R, 2003, BIOTECHNOL APPL BIOC, V37, P63, DOI 10.1042/BA20020059; Hovav AH, 2005, INFECT IMMUN, V73, P250, DOI 10.1128/IAI.73.1.250-257.2005; HUGHES AL, 1994, P ROY SOC B-BIOL SCI, V256, P119, DOI 10.1098/rspb.1994.0058; HUYGEN K, 1994, INFECT IMMUN, V62, P363, DOI 10.1128/IAI.62.2.363-370.1994; KORDEL M, 1991, J BACTERIOL, V173, P4836, DOI 10.1128/jb.173.15.4836-4841.1991; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; LAUNOIS P, 1994, INFECT IMMUN, V62, P3679, DOI 10.1128/IAI.62.9.3679-3687.1994; LESUISSE E, 1993, EUR J BIOCHEM, V216, P155, DOI 10.1111/j.1432-1033.1993.tb18127.x; Lun SC, 2007, J BIOL CHEM, V282, P18348, DOI 10.1074/jbc.M700035200; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Marchler-Bauer A, 2002, NUCLEIC ACIDS RES, V30, P281, DOI 10.1093/nar/30.1.281; MARTINEZ C, 1994, BIOCHEMISTRY-US, V33, P83, DOI 10.1021/bi00167a011; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ohno S., 1970, EVOLUTION GENE DUPLI; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Parker SK, 2007, J BACTERIOL, V189, P4153, DOI 10.1128/JB.01909-06; Pernas MA, 2001, FEBS LETT, V501, P87, DOI 10.1016/S0014-5793(01)02630-8; Pratt J, 2000, CURR MICROBIOL, V40, P306, DOI 10.1007/s002849910061; PURDY RE, 1975, BIOCHEMISTRY-US, V14, P2824, DOI 10.1021/bi00684a006; Quistad GB, 2000, J BIOCHEM MOL TOXIC, V14, P51, DOI 10.1002/(SICI)1099-0461(2000)14:1<51::AID-JBT7>3.0.CO;2-W; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Sable SB, 2005, INFECT IMMUN, V73, P3547, DOI 10.1128/IAI.73.6.3547-3558.2005; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schaefer Wilhelm, 1993, Trends in Microbiology, V1, P69, DOI 10.1016/0966-842X(93)90037-R; Stewart GR, 2005, PLOS PATHOG, V1, P269, DOI 10.1371/journal.ppat.0010033; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vergne I, 2005, P NATL ACAD SCI USA, V102, P4033, DOI 10.1073/pnas.0409716102; VONTIGERSTROM RG, 1989, CAN J MICROBIOL, V35, P511, DOI 10.1139/m89-079; Walburger A, 2004, SCIENCE, V304, P1800, DOI 10.1126/science.1099384; WALTON TJ, 1972, BIOCHEMISTRY-US, V11, P1885, DOI 10.1021/bi00760a025; Walz I, 2007, EUR FOOD RES TECHNOL, V225, P593, DOI 10.1007/s00217-006-0435-5; Weldingh K, 1999, FEMS IMMUNOL MED MIC, V23, P159, DOI 10.1111/j.1574-695X.1999.tb01235.x; Weldingh K, 1998, INFECT IMMUN, V66, P3492, DOI 10.1128/IAI.66.8.3492-3500.1998; West NP, 2008, VACCINE, V26, P3853, DOI 10.1016/j.vaccine.2008.05.007; WHEELER PR, 1988, J GEN MICROBIOL, V134, P2111; WHEELER PR, 1990, J GEN MICROBIOL, V136, P211, DOI 10.1099/00221287-136-1-211; WINKLER UK, 1979, J BACTERIOL, V138, P663, DOI 10.1128/JB.138.3.663-670.1979	52	57	61	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1694	1704		10.1096/fj.08-114421	http://dx.doi.org/10.1096/fj.08-114421			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19225166	Green Published			2022-12-28	WOS:000266652400009
